<SEC-DOCUMENT>0001140361-26-028868.txt : 20260720
<SEC-HEADER>0001140361-26-028868.hdr.sgml : 20260720
<ACCEPTANCE-DATETIME>20260720064519
ACCESSION NUMBER:		0001140361-26-028868
CONFORMED SUBMISSION TYPE:	S-4
PUBLIC DOCUMENT COUNT:		47
FILED AS OF DATE:		20260720
DATE AS OF CHANGE:		20260720

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			STANDARD BIOTOOLS INC.
		CENTRAL INDEX KEY:			0001162194
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				770513190
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-4
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-297560
		FILM NUMBER:		261185124

	BUSINESS ADDRESS:	
		STREET 1:		50 MILK STREET
		STREET 2:		10TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02109
		BUSINESS PHONE:		6502666000

	MAIL ADDRESS:	
		STREET 1:		50 MILK STREET
		STREET 2:		10TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02109

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FLUIDIGM CORP
		DATE OF NAME CHANGE:	20011113
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-4
<SEQUENCE>1
<FILENAME>ny20077604x1_s4.htm
<DESCRIPTION>S-4
<TEXT>
<html><head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 26.3.2.5342
         Copyright 1995 - 2026 Broadridge -->
  </head><body style="color: #000000;" bgcolor="#ffffff">
<!--Begin Page 1-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 540pt;"><a name="ny20077604x1_s4_100-regcov_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 540pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 25pt; text-align: center;">As filed with the Securities and Exchange Commission on July 20, 2026 </div><div class="BRDSX_regno" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 1pt; text-align: right;">Registration No. 333-&#8195;&#8195;&#8195; </div></div></div><div class="BRDSX_block-frill" style="width: 540pt; margin-left: 0pt;"><div><div class="BRDSX_rule-full" style="height: 0pt; width: 100%; border-bottom: 2pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div><div class="BRDSX_rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-left: auto; margin-right: auto; margin-top: 4pt;"> </div></div></div><div class="BRDSX_block-main" style="width: 540pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold; margin-top: 9.5pt; text-align: center;">UNITED STATES <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold; margin-top: 0pt; text-align: center;">SECURITIES AND EXCHANGE COMMISSION <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-weight: bold; margin-top: 0pt; text-align: center; font-size: 12pt;"><font style="font-size: 12pt;">Washington, D.C. 20549</font></div><div><div class="BRDSX_rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 3.75pt;"> </div></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 16pt; font-weight: bold; margin-top: 6.5pt; text-align: center;">FORM S-4 <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-weight: bold; margin-top: 0pt; text-align: center; font-size: 12pt;"><font style="font-size: 12pt;">REGISTRATION STATEMENT </font><br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-weight: bold; margin-top: 0pt; text-align: center; font-size: 12pt;"><font style="font-size: 12pt; font-style: italic;">UNDER </font><br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-weight: bold; margin-top: 0pt; text-align: center; font-size: 12pt;"><font style="font-size: 12pt; font-style: italic;">THE SECURITIES ACT OF 1933</font></div><div><div class="BRDSX_rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 3.75pt;"> </div></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 18pt; font-weight: bold; margin-top: 6.5pt; text-align: center;">STANDARD BIOTOOLS INC. <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-weight: bold; margin-top: 0pt; text-align: center; font-size: 9pt;"><font style="font-size: 9pt; font-weight: normal;">(Exact Name of Registrant as Specified in Its Charter)</font></div><div><div class="BRDSX_rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 3.75pt;"> </div></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 2pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="margin-top: 0pt; width: 540pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 172pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 172pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 172pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr><td style="width: 172pt; padding-bottom: 0.5pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">Delaware</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 172pt; padding-bottom: 0.5pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">3826</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 172pt; padding-bottom: 0.5pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">77-0513190 </div></td></tr><tr><td style="width: 172pt; padding-top: 0.17pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: center;">(State or other jurisdiction of <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: center;">incorporation or organization)</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 172pt; padding-top: 0.17pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: center;">(Primary Standard Industrial <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: center;">Classification Code Number)</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 172pt; padding-top: 0.17pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: center;">(I.R.S. Employer <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: center;">Identification No.)</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 3pt; width: 172pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 172pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 172pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 2pt; text-align: center;">50 Milk Street, 10th Floor <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">Boston, MA 02109 <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">(650) 266-6000 <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-weight: normal;">(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant&#8217;s Principal Executive Offices) </font></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 2pt; text-align: center;">Michael Egholm, Ph.D. <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">President and Chief Executive Officer <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">50 Milk Street, 10th Floor <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">Boston, MA 02109 <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">(650) 266-6000 <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-weight: normal;">(Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent For Service)</font></div><div><div class="BRDSX_rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 3.75pt;"> </div></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-style: italic; font-weight: bold; margin-top: 4pt; text-align: center;">Copies to:<font style="font-style: normal; font-weight: normal;"> </font></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="margin-top: 0pt; width: 540pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 264pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 264pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr><td style="width: 264pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">Damien Zoubek, Esq. <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">Jenny Hochenberg, Esq. <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">Abigail Hathaway, Esq. <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">Michael Levitt, Esq. <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">Freshfields US LLP<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">3 World Trade Center <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">175 Greenwich Street<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">New York, NY 10007 <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">(212) 277-4000</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 264pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">Effie Toshav, Esq. <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">David Michaels, Esq.<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">Robert Freedman, Esq.<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">Amanda Rose, Esq.<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">Ryan Mitteness, Esq. <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">Fenwick &amp; West LLP <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">One Front Street <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">Floors 31-33<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">San Francisco, CA 94111 <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">(415) 875-2300</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 3pt; width: 264pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 264pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div><div class="BRDSX_rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 3.75pt;"> </div></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 4pt; text-align: center;">Approximate date of commencement of proposed sale of the securities to the public:<font style="font-weight: normal;"> </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 2pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As soon as practicable&#160;after the effective date of this registration statement and consummation of the merger of Siri Merger Sub, Inc. (&#8220;Merger Sub&#8221;), a Delaware corporation and wholly owned subsidiary of Standard BioTools Inc., a Delaware corporation (&#8220;Standard BioTools&#8221;), with and into Treeline Biosciences, Inc., a Delaware corporation (&#8220;Treeline&#8221;), as described in the Agreement and Plan of Merger and Reorganization, dated as of June&#160;6, 2026, among Standard BioTools, Treeline and Merger Sub.<font style="font-weight: normal;"> </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 2pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If the securities being registered on this Form&#160;are being offered in connection with the formation of a holding company and there is compliance with General Instruction G, check the following box. <font style="font-size: 1pt;">&#8201;</font><font style="font-family: Arial, Helvetica, sans-serif;">&#x2610;</font> </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 2pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If this Form&#160;is filed to register additional securities for an offering pursuant to Rule&#160;462(b) under the Securities Act check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. <font style="font-size: 1pt;">&#8201;</font><font style="font-family: Arial, Helvetica, sans-serif;">&#x2610;</font> </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 2pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If this Form&#160;is a post-effective amendment filed pursuant to Rule&#160;462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. <font style="font-size: 1pt;">&#8201;</font><font style="font-family: Arial, Helvetica, sans-serif;">&#x2610;</font> </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 2pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="margin-top: 0pt; width: 540pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 240pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 12pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 240pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 12pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr><td style="width: 240pt; padding-bottom: 0.5pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Large accelerated filer</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 12pt; padding-bottom: 0.5pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 1pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;<font style="font-size: 9pt; font-family: Arial, Helvetica, sans-serif;">&#x2610;</font></div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 240pt; padding-bottom: 0.5pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Accelerated filer</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 12pt; padding-bottom: 0.5pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#x2612; </div></td></tr><tr><td style="width: 240pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Non-accelerated filer</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 12pt; padding-top: 0.46pt; padding-bottom: 0.5pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 1pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;<font style="font-size: 9pt; font-family: Arial, Helvetica, sans-serif;">&#x2610;</font></div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 240pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Smaller reporting company</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 12pt; padding-top: 0.46pt; padding-bottom: 0.5pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 1pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;<font style="font-size: 9pt; font-family: Arial, Helvetica, sans-serif;">&#x2610;</font><font style="font-size: 9pt;"> </font></div></td></tr><tr><td style="width: 240pt; padding-top: 0.17pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 12pt; padding-top: 0.17pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 240pt; padding-top: 0.17pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Emerging growth company</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 12pt; padding-top: 0.46pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 1pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;<font style="font-size: 9pt; font-family: Arial, Helvetica, sans-serif;">&#x2610;</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 3pt; width: 240pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 12pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 240pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 12pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 2pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;7(a)(2)(B) of the Securities Act. <font style="font-size: 1pt;">&#8201;</font><font style="font-family: Arial, Helvetica, sans-serif;">&#x2610;</font> </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 2pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If applicable, place an X in the box to designate the appropriate rule provision relied upon in conducting this transaction: </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 2pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Exchange Act Rule&#160;13e-4(i) (Cross-Border Issuer Tender Offer) <font style="font-size: 1pt;">&#8201;</font><font style="font-family: Arial, Helvetica, sans-serif;">&#x2610;</font> </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 2pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Exchange Act Rule&#160;14d-1(d) (Cross-Border Third-Party Tender Offer) <font style="font-size: 1pt;">&#8201;</font><font style="font-family: Arial, Helvetica, sans-serif;">&#x2610;</font> </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 2pt; margin-left: 0pt; text-align: left;">The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section&#160;8(a) of the Securities Act or until the registration statement shall become effective on such date as the United States Securities and Exchange Commission, acting pursuant to said Section&#160;8(a), may determine.<font style="font-weight: normal;"> </font></div></div><div class="BRDSX_block-frill" style="width: 540pt; margin-top: 12pt; margin-left: 0pt;"><div><div class="BRDSX_rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div><div class="BRDSX_rule-full" style="height: 0pt; width: 100%; border-bottom: 2pt solid #000000; margin-bottom: 1pt; margin-left: auto; margin-right: auto; margin-top: 4pt;"> </div></div></div></div>
<!--End Page 1-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 2-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_101-note_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">EXPLANATORY NOTE </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This registration statement on Form&#160;S-4 contains two prospectuses, as set forth below. </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-style: italic;">Primary Offering Prospectus</font>. A primary offering proxy statement/prospectus of Standard BioTools Inc. (&#8220;Standard BioTools&#8221;) with respect to the issuance of shares of Standard BioTools common stock to the stockholders of Treeline Biosciences, Inc. (&#8220;Treeline&#8221;) in connection with the Merger described herein, and the solicitation of proxies from Standard BioTools stockholders in connection therewith. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-style: italic;">Resale Prospectus</font>. A resale prospectus with respect to the resale, from time to time, by the selling securityholders named in the section entitled &#8220;Selling Securityholders&#8221; of shares of Standard BioTools common stock issued to them in connection with the Merger. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The resale prospectus is substantively identical to the primary offering prospectus, except for the following: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the resale prospectus contains a different cover page; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a &#8220;Selling Securityholders&#8221; section is included in the resale prospectus;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">an alternate &#8220;Plan of Distribution&#8221; is included in the resale prospectus; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a &#8220;Use of Proceeds&#8221; section is included in the resale prospectus. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This registration statement includes a set of alternate pages after the end of the primary offering prospectus (the &#8220;Alternate Pages&#8221;) that form a part of the resale prospectus and not the primary offering prospectus. The primary offering prospectus excludes the Alternate Pages and will be used for the primary offering by Standard BioTools. The resale prospectus adds and substitutes the Alternate Pages and will be used for the resale offering by the selling securityholders named therein. </div></div></div></div>
<!--End Page 2-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 3-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 504pt;"><a name="ny20077604x1_s4_102-cov_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 504pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><div style="color: #FC0014; font-size: 9.5pt; font-family: Arial, Helvetica, sans-serif; text-align: left; margin-bottom: 12pt;">Information contained herein is subject to completion or amendment. A registration statement relating to these securities has been filed with the United States Securities and Exchange Commission. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This proxy statement/prospectus shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.</div>PRELIMINARY - SUBJECT TO COMPLETION - DATED JULY 20, 2026</div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 13.75pt; text-align: center;"><img style="height: 101px; width: 142px;" src="logo_standardbiov2.jpg"><br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201; <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19pt; text-align: center;">MERGER PROPOSAL - YOUR VOTE IS VERY IMPORTANT</div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 4pt; text-align: center;"><div class="BRDSX_rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-top: 3pt; display: inline-block; margin-left: auto; margin-right: auto;"> </div> <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.3pt; margin-top: 8pt; text-align: right;">&#8195;&#8195;&#8195;&#8195;, 2026 </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.3pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Dear Stockholders of Standard BioTools Inc.: </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.3pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As previously announced, on June&#160;6, 2026, Standard BioTools Inc., a Delaware corporation (&#8220;Standard BioTools&#8221;), entered into an Agreement and Plan of Merger and Reorganization (the &#8220;Merger Agreement&#8221;) with Treeline Biosciences, Inc., a Delaware corporation (&#8220;Treeline&#8221;), and Siri Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Standard BioTools (&#8220;Merger Sub&#8221;), pursuant to which Standard BioTools and Treeline will combine in an all-stock merger upon the terms and conditions set forth in the Merger Agreement. In accordance with the Merger Agreement, (i) Merger Sub will merge with and into Treeline, with Treeline surviving as a wholly owned subsidiary of Standard BioTools (the &#8220;Merger&#8221; and, together with the other transactions contemplated by the Merger Agreement, the &#8220;Transactions&#8221;), and (ii) at the effective time of the Merger (the &#8220;Effective Time&#8221;), Standard BioTools will file an amendment to its certificate of incorporation (the &#8220;Charter Amendment&#8221;) to (a)&#160;change its name to Treeline Biosciences Holdings, Inc. and (b) effect a reverse stock split (the &#8220;Reverse Stock Split&#8221;) of all outstanding shares of common stock, par value $0.001 per share, of Standard BioTools (the &#8220;Standard BioTools Common Stock&#8221;), if the Reverse Stock Split has not been effected prior to the Effective Time as permitted by the Merger Agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.3pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As a result of the Merger, each share of Treeline common stock, par value $0.00001 per share (the &#8220;Treeline Common Stock&#8221;), issued and outstanding immediately prior to the Effective Time and each share of Treeline preferred stock, par value $0.00001 per share (the &#8220;Treeline Preferred Stock&#8221; and, together with the Treeline Common Stock, the &#8220;Treeline Capital Stock&#8221;), issued and outstanding immediately prior to the Effective Time (in each case, other than shares held in treasury and dissenting shares) will be converted into the right to receive a number of shares of Standard BioTools Common Stock based on an exchange ratio calculated in accordance with the Merger Agreement (described in more detail in the section titled &#8220;<font style="font-style: italic;">The Merger Agreement &#8212; Exchange Ratio</font>&#8221; beginning on page&#160;<a href="#tEXR">202</a> of the accompanying proxy statement/prospectus) (the &#8220;Exchange Ratio&#8221;), with the number of shares of Standard BioTools Common Stock that each holder of Treeline Capital Stock is entitled to receive being rounded down to the nearest whole share and computed after aggregating all shares of Treeline Capital Stock held by such holder. The Exchange Ratio is based on the relative capitalization of each of Treeline and Standard BioTools and assumes (i) an equity value for Treeline of $2.5&#160;billion and (ii)&#160;an equity value for Standard BioTools equal to $460&#160;million, reduced by the amount by which the Parent Net Cash (as defined in the Merger Agreement) is less than $449&#160;million at the closing of the Merger (the &#8220;Closing&#8221;) or increased by the amount by which Parent Net Cash is more than $451&#160;million at the Closing. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.3pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Following the Closing, former Standard BioTools stockholders are expected to hold approximately 16% of the combined company on a fully diluted basis, and former Treeline stockholders are expected to hold approximately 84% of the combined company on a fully diluted basis. Under certain circumstances further described in the Merger Agreement, the pro forma ownership percentages may be adjusted based on the amount of Parent Net Cash at Closing as finally determined in accordance with the Merger Agreement (described in more detail in the sections titled &#8220;<font style="font-style: italic;">The Merger Agreement &#8212; Exchange Ratio</font>&#8221; and &#8220;<font style="font-style: italic;">The Merger Agreement &#8212; Calculation of Parent Net Cash</font>&#8221; beginning on pages <a href="#tEXR">202</a> and <a href="#tCOPN">203</a>, respectively, of the accompanying proxy statement/prospectus). Based on Standard BioTools&#8217; and Treeline&#8217;s capitalization as of June&#160;3, 2026 and May&#160;28, 2026, respectively, and taking into account Standard BioTools&#8217; estimate of Parent Net Cash as of the Closing, and before giving effect to the proposed Reverse Stock Split, each share of Treeline Capital Stock is currently estimated to be entitled to receive approximately 11.6997&#160;shares of Standard BioTools Common Stock. This ratio may increase or decrease as of the Closing based on the companies&#8217; respective actual capitalizations as of the Closing and the actual amount of Parent Net Cash as of the Closing. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.3pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, as of the Effective Time, Standard BioTools will assume Treeline&#8217;s 2021 Equity Incentive Plan and each outstanding option to purchase shares of Treeline Common Stock (each, a &#8220;Treeline Option&#8221;), whether vested or unvested. Each such Treeline Option so assumed by Standard BioTools will continue to have, and be subject to, the same terms and conditions applicable to such Treeline Option immediately prior to the Effective Time, except that (i) such Treeline Option will be exercisable for that number of shares of Standard BioTools Common Stock equal to the number of shares of Treeline Common Stock subject to such Treeline Option immediately prior to the Effective Time multiplied by the Exchange Ratio and rounded down to the next nearest share of Standard BioTools Common Stock, and (ii)&#160;the exercise price per share of each such Treeline Option will be the exercise price per share in effect for that Treeline Option immediately prior to the Effective Time divided by the Exchange Ratio and rounded up to the next nearest cent. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.3pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, as of the Effective Time, (i) each warrant to purchase shares of Treeline Capital Stock (each, a &#8220;Treeline Warrant&#8221;) that has been amended to require net-exercise in connection with the Merger (the &#8220;Treeline Converting Warrants&#8221;) and that is outstanding immediately prior to the Effective Time will, by virtue of the Merger, be cancelled and extinguished and converted into the right to receive, for each share of Treeline Common Stock that would be received upon the net-exercise of such Treeline Converting Warrant in accordance with its terms, a number of shares of Standard BioTools Common Stock equal to the Exchange Ratio and (ii)&#160;each Treeline Warrant that is not a Treeline Converting Warrant and that is outstanding immediately prior to the Effective Time will, by virtue of the Merger, be assumed by Standard BioTools. Each such Treeline Warrant so assumed by Standard BioTools will continue to have, and be subject to, the same terms and conditions applicable to such Treeline Warrant immediately prior to the Effective Time, except that (a) such Treeline Warrant will be exercisable for that number of shares of Standard BioTools Common Stock equal to the number of shares of Treeline Common Stock subject to such Treeline Warrant immediately prior to the Effective Time multiplied by the Exchange Ratio and rounded down to the next nearest share of Standard BioTools Common Stock and (b) the warrant price per share will be the warrant price per share in effect for such Treeline Warrant immediately prior to the Effective Time divided by the Exchange Ratio and rounded up to the nearest thousandth of a cent. </div></div></div></div>
<!--End Page 3-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 4-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 504pt;"><a name="ny20077604x1_s4_102-cov_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 504pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.3pt; margin-top: 6.25pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Each share of Standard BioTools Common Stock issued and outstanding at the time of the Merger will remain issued and outstanding and, subject to the Reverse Stock Split, will be unaffected by the Merger. In addition, prior to the Effective Time, Standard BioTools expects to declare a dividend to Standard BioTools stockholders as of the close of business on the last business day prior to the day on which the Effective Time occurs in the form of one contingent value right (each, a &#8220;CVR&#8221;) for each outstanding share of Standard BioTools Common Stock held by such stockholder on such date. The payment date for such dividend will be three business days after the Effective Time. The CVRs will be issued pursuant to the terms of a Contingent Value Rights Agreement to be entered into between Standard BioTools and a rights agent (the &#8220;CVR Agreement&#8221;) (described in more detail in the section titled &#8220;<font style="font-style: italic;">The Merger&#160;&#8212; CVR Agreement</font>&#8221; beginning on page <a href="#tCVR">194</a> of the accompanying proxy statement/prospectus). Pursuant to the CVR Agreement, the holder of each CVR will be entitled to receive a payment for each 12-month CVR payment period during the five-year term of the CVR Agreement, consisting of a number of shares of the combined company&#8217;s common stock (with fractional shares settled in cash) equal to such holder&#8217;s pro rata portion of the aggregate net proceeds received by the combined company during such 12-month CVR payment period from the following sources, in each case less certain permitted deductions: (i) proceeds from any sale, disposition, or other monetization of Standard BioTools&#8217; mass cytometry and microfluidics businesses (the &#8220;Legacy Business&#8221;); (ii)&#160;proceeds from convertible notes or other investments held by Standard BioTools as of the date of the Closing (the &#8220;Closing Date&#8221;); (iii) earnout, milestone, royalty or other similar contingent payments due to Standard BioTools under contracts in effect as of the Closing Date, including payments from Illumina, Inc. pursuant to the Stock Purchase Agreement dated June&#160;22, 2025; and (iv) any surplus in Parent Net Cash delivered at Closing as finally determined under the Merger Agreement. The maximum number of shares of common stock of the combined company which may be issued pursuant to the CVR Agreement is 76,000,000. There can be no assurance that any payments will be made on the CVRs. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.3pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under the Merger Agreement, Standard BioTools must use its commercially reasonable efforts to effect the sale, license, transfer, disposition, divestiture or other monetization of the Legacy Business. If Standard BioTools has not entered into a definitive agreement for the disposition of any portion of the Legacy Business on or before the date the registration statement on Form&#160;S-4 of which the accompanying proxy statement/prospectus forms a part is declared effective under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), Standard BioTools is required to commence mutually agreed wind-down activities with respect to that portion of the Legacy Business. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.3pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The accompanying proxy statement/prospectus also relates to the offer and sale, from time to time, of shares of Standard BioTools Common Stock by certain stockholders of Treeline who will receive shares of Standard BioTools Common Stock in the Merger (the &#8220;Selling Securityholders&#8221;). Standard BioTools will not receive any of the proceeds from any sale of shares of Standard BioTools Common Stock by the Selling Securityholders. See &#8220;<font style="font-style: italic;">Selling Securityholders</font>&#8221; and &#8220;<font style="font-style: italic;">Plan of Distribution</font>&#8221; in the resale prospectus also included in the registration statement on Form&#160;S-4 of which the accompanying proxy statement/prospectus forms a part. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.3pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Standard BioTools and Treeline expect the board of directors of the combined company will consist of 12&#160;members, with ten members designated by Treeline and two members designated by Standard BioTools. The parties also expect that, immediately after the Effective Time, Dr.&#160;Josh Bilenker, currently the chief executive officer and co-founder of Treeline, will be appointed as Chief Executive Officer of the combined company, Dr.&#160;Jeff Engelman, currently the chief scientific officer and co-founder of Treeline, will be appointed as Chief Scientific Officer of the combined company, and Spencer Smith, currently the chief financial officer of Treeline, will be appointed as Chief Financial Officer of the combined company. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.3pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Standard BioTools Common Stock is currently listed on The Nasdaq Global Select Market under the symbol &#8220;LAB&#8221;. After completion of the Merger, Standard BioTools will be renamed &#8220;Treeline Biosciences Holdings, Inc.&#8221;, and it is expected that the common stock of the combined company will trade on The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) under the symbol &#8220;TRLN.&#8221; It is a condition to the consummation of the Merger that existing shares of Standard BioTools Common Stock are listed on Nasdaq as of the Closing Date and that the shares of Standard BioTools Common Stock issuable in connection with the Merger have been approved for listing on Nasdaq, subject to official notice of issuance, but there can be no assurance that such listing condition will be met. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.3pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We have scheduled a special meeting of the stockholders of Standard BioTools (the &#8220;Special Meeting&#8221;), to be held entirely virtually on &#8195;&#8195;&#8195;&#8195;, 2026, at which the stockholders of Standard BioTools will be asked to vote on the Share Issuance Proposal, the Charter Amendment Proposal, the Post-Closing Equity Incentive Plan Proposal, the Post-Closing ESPP Proposal, the Advisory Compensation Proposal and the Adjournment Proposal (each as defined herein). We cannot consummate the Merger and the other Transactions unless the stockholders of Standard BioTools approve the Share Issuance Proposal and the Charter Amendment Proposal as described herein. Approval of the Post-Closing Equity Incentive Plan Proposal, the Post-Closing ESPP Proposal, the Advisory Compensation Proposal and the Adjournment Proposal are not conditions to completion of the Merger. Your vote is very important, regardless of the number of shares of Standard BioTools Common Stock that you own. <font style="font-weight: bold;">Whether or not you expect to attend the Special Meeting, please submit a proxy to vote your shares as promptly as possible so that your shares may be represented and voted at the Special Meeting.</font> </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.3pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As described in the accompanying proxy statement/prospectus, concurrently with the execution of the Merger Agreement, certain stockholders of Standard BioTools (including its directors and certain officers), collectively holding approximately 39% of the outstanding shares of Standard BioTools Common Stock, entered into voting agreements with Standard BioTools, Treeline and Merger Sub (the &#8220;Voting Agreements&#8221;) (described in more detail in the section titled &#8220;<font style="font-style: italic;">The Special Meeting &#8212; Voting Agreements</font>&#8221; beginning on page <a href="#tVOA">107</a> of the accompanying proxy statement/prospectus) pursuant to which they have agreed to vote all of their shares of Standard BioTools Common Stock in favor of the Share Issuance Proposal, the Charter Amendment Proposal, the Post-Closing Equity Incentive Plan Proposal and the Post-Closing ESPP Proposal, subject to the terms of the Voting Agreements, including a reduction in the number of shares subject to the voting requirements for certain stockholders in the event of a change in the recommendation of the Special Committee (as defined below) in favor of the Transactions such that the aggregate number of outstanding shares of Standard BioTools Common Stock subject to the voting requirements in the Voting Agreements is reduced to approximately 30% of the outstanding shares of Standard BioTools Common Stock. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.3pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Standard BioTools Board of Directors (the &#8220;Standard BioTools Board&#8221;) established a special committee of the Standard BioTools Board consisting solely of &#8220;disinterested directors&#8221; (as defined in Section&#160;144(e)(4) of the Delaware General Corporation Law (the &#8220;DGCL&#8221;)) (the &#8220;Special Committee&#8221;) and delegated to the Special Committee the full power and authority of the Standard BioTools Board, to the maximum extent permitted by applicable law, to (i) explore, consider, evaluate, review, negotiate and approve or reject the Transactions and, if Standard BioTools Board approval of the Transactions is required under the DGCL, recommend to the Standard BioTools Board for approval or rejection of the Transactions and (ii) determine whether the Transactions are advisable, fair to and in the best interests of Standard BioTools and its stockholders. After due consideration and discussion of the factors that the Special Committee deemed relevant, the Special Committee unanimously (i) determined that the Transactions are advisable, fair to and in the best interests of Standard BioTools and its stockholders, (ii) approved and declared advisable the Merger Agreement and the </div></div></div></div>
<!--End Page 4-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 5-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 504pt;"><a name="ny20077604x1_s4_102-cov_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 504pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.3pt; margin-top: 6.25pt; margin-left: 0pt; text-align: left;">Transactions and recommended that the Standard BioTools Board approve and declare advisable the Transactions and (iii)&#160;recommended that the Standard BioTools Board resolve to recommend the approval of the issuance of Standard BioTools Common Stock pursuant to the Merger Agreement (the &#8220;Share Issuance&#8221;) and the Charter Amendment by Standard BioTools&#8217; stockholders. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.3pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Acting upon the recommendation of the Special Committee, the Standard BioTools Board has (i) determined that the Transactions are advisable, fair to and in the best interests of Standard BioTools and its stockholders, (ii) approved and declared advisable the Merger Agreement and the Transactions and (iii) resolved to recommend the approval of the Share Issuance and the Charter Amendment by Standard BioTools&#8217; stockholders. In addition, the Standard BioTools Board resolved to recommend the approval of the Post-Closing Equity Incentive Plan, the Post-Closing ESPP, on a nonbinding, advisory basis, the Merger-Related Compensation by Standard BioTools&#8217; stockholders and the adjournment of the Special Meeting, if necessary or appropriate to solicit additional proxies. The Standard BioTools Board recommends that Standard BioTools stockholders vote &#8220;<font style="font-weight: bold;">FOR</font>&#8221; each of the proposals to be considered at the Special Meeting and described in the accompanying proxy statement/prospectus. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.3pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Merger Agreement and the Transactions have also been approved by Treeline&#8217;s board of directors. In addition, after execution of the Merger Agreement, on June&#160;6, 2026, Treeline stockholders comprising the required majorities under Treeline&#8217;s organizational documents delivered their written consent adopting the Merger Agreement and approving the Transactions.</div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.49pt; text-align: center;"><div class="BRDSX_rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-top: 6pt; display: inline-block; margin-left: auto; margin-right: auto;"> </div> <br></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.3pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The obligations of Treeline and Standard BioTools to consummate the Merger are subject to the satisfaction or waiver (to the extent permitted by applicable law) of several conditions set forth in the Merger Agreement, including receipt of Standard BioTools stockholder approval for the required proposals described in the accompanying proxy statement/prospectus. The accompanying proxy statement/prospectus contains detailed information about Treeline, Standard BioTools, the Special Meeting, the Merger Agreement, the Transactions (including the Merger) and the other business to be considered by the Standard BioTools stockholders at the Special Meeting. <font style="font-weight: bold;">Standard BioTools encourages you to read the accompanying proxy statement/prospectus carefully. In particular, you should read the &#8220;Risk Factors&#8221; section beginning on page <a href="#tRF">33</a> of the accompanying proxy statement/prospectus for a discussion of the risks you should consider in evaluating the Transactions and how they will affect you.</font> </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.3pt; margin-top: 6.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On behalf of the Standard BioTools Board, thank you for your consideration and continued support. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.3pt; margin-top: 6.5pt; text-align: center;">Thomas Carey <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.3pt; margin-top: 0pt; text-align: center;"><font style="font-style: italic;">Chairperson of the Board</font><br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.3pt; margin-top: 0pt; text-align: center;">Standard BioTools Inc. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.3pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Neither the United States Securities and Exchange Commission (the &#8220;SEC&#8221;) nor any state securities commission has approved or disapproved of the Merger, the securities to be issued in connection with the Merger or any other transaction described in the accompanying proxy statement/prospectus or passed upon the adequacy or accuracy of the disclosure in the accompanying proxy statement/prospectus. Any representation to the contrary is a criminal offense.<font style="font-weight: normal;"> </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.3pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The accompanying proxy statement/prospectus is dated &#8195;&#8195;&#8195;&#8195;&#8195;&#8194;, 2026 and is first being mailed to the Standard BioTools stockholders on or about &#8195;&#8195;&#8195;&#8195;&#8195;&#8194;, 2026. </div></div></div></div>
<!--End Page 5-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 6-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_103-info_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">ADDITIONAL INFORMATION </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The accompanying proxy statement/prospectus incorporates by reference important business and financial information about Standard BioTools from other documents that are not included in or delivered with the accompanying proxy statement/prospectus. This information is available to you without charge upon your request. You can obtain the documents incorporated by reference into the accompanying proxy statement/prospectus by requesting them in writing or by telephone from Standard BioTools at the following addresses and telephone numbers: </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; text-align: center;">Standard BioTools Inc. <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">50 Milk Street, 10th Floor <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Boston, MA 02109<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Attention: Corporate Secretary <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Telephone: (650) 266-6000 <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">or<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8195; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Standard BioTools stockholders may also consult the website of Standard BioTools for more information concerning the Merger and the other transactions described in the accompanying proxy statement/prospectus. The website of Standard BioTools is <font style="font-style: italic;">www.standardbio.com</font>. Information included on the website of Standard BioTools is not incorporated by reference into the accompanying proxy statement/prospectus. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If you would like to request any documents, you must do so by &#8195;&#8195;&#8195;, 2026, in order to receive them before the Special Meeting. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For a more detailed description of the information incorporated by reference in the accompanying proxy statement/prospectus and how you may obtain it, see &#8220;<font style="font-style: italic;">Where You Can Find More Information</font>&#8221; beginning on page&#160;<a href="#tWYC">335</a> of the accompanying proxy statement/prospectus. </div></div></div></div>
<!--End Page 6-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 7-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_104-notice_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><img style="height: 127px; width: 177px;" src="logo_standardbiov2x1.jpg"><br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; text-align: center;">STANDARD BIOTOOLS INC. <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-weight: normal;">50 Milk Street, 10th Floor </font><br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-weight: normal;">Boston, MA 02109 </font></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; text-align: center;">NOTICE OF SPECIAL MEETING OF STOCKHOLDERS <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">TO BE HELD ON </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">To the Stockholders of Standard BioTools Inc.: </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We cordially invite you to attend a special meeting of the stockholders of Standard BioTools Inc., a Delaware corporation (&#8220;Standard BioTools&#8221;), being held in connection with a proposed all-stock business combination with Treeline Biosciences, Inc., a Delaware corporation (&#8220;Treeline&#8221;). On June&#160;6, 2026, Standard BioTools, Treeline and Siri Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Standard BioTools (&#8220;Merger Sub&#8221;), entered into an Agreement and Plan of Merger and Reorganization (the &#8220;Merger Agreement&#8221;), pursuant to which Merger Sub will merge with and into Treeline, with Treeline surviving as a wholly owned subsidiary of Standard BioTools (the &#8220;Merger&#8221; and, together with the other transactions contemplated by the Merger Agreement, the &#8220;Transactions&#8221;), and Standard BioTools will be renamed &#8220;Treeline Biosciences Holdings, Inc.&#8221; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The special meeting will take place exclusively online via webcast on &#8195;&#8195;&#8195; , 2026, at &#8195;&#8195;&#8195; (the &#8220;Special Meeting&#8221;). The Special Meeting can be accessed by visiting www.virtualshareholdermeeting.com/LAB2026SM, where you will be able to listen to the meeting live, submit questions, and vote online. At the Special Meeting, you will be asked to consider and vote upon the following proposals: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-style: italic;">Share Issuance Proposal. </font>To approve the issuance of shares of common stock, par value $0.001 per share, of Standard BioTools (&#8220;Standard BioTools Common Stock&#8221;) in connection with the Merger and in accordance with Nasdaq Listing Rules 5635(a) and 5635(b) (the &#8220;Share Issuance Proposal&#8221;); </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-style: italic;">Charter Amendment Proposal. </font>To approve an amendment to the Standard BioTools Eighth Amended and Restated Certificate of Incorporation, as amended (the &#8220;Standard BioTools Charter&#8221;), to effect a reverse stock split (the &#8220;Reverse Stock Split&#8221;) of Standard BioTools&#8217; issued and outstanding common stock at a ratio in the range from 1-for-&#8195; to 1-for-&#8195;, inclusive, with the final ratio to be mutually agreed to by Standard BioTools and Treeline and an amendment to the Standard BioTools Charter (together with the amendment to the Standard BioTools Charter to effect the Reverse Stock Split, the &#8220;Charter Amendment&#8221;) to change the name of Standard BioTools to &#8220;Treeline Biosciences Holdings, Inc.&#8221; (the &#8220;Charter Amendment Proposal&#8221;); </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-style: italic;">Post-Closing Equity Incentive Plan Proposal. </font>To approve the Post-Closing Equity Incentive Plan (as defined in the accompanying proxy statement/prospectus) in the form attached as Annex&#160;I to the accompanying proxy statement/prospectus, which will become effective at the effective time of the Merger and is contingent on the closing of the Merger (the &#8220;Closing&#8221;) (the &#8220;Post-Closing Equity Incentive Plan Proposal&#8221;); </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-style: italic;">Post-Closing ESPP Proposal. </font>To approve the Post-Closing Employee Stock Purchase Plan (as defined in the accompanying proxy statement/prospectus) in the form attached as Annex&#160;J to the accompanying proxy statement/prospectus, which will become effective at the effective time of the Merger and is contingent on the Closing (the &#8220;Post-Closing ESPP Proposal&#8221;); </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-style: italic;">Advisory Compensation Proposal</font>. To approve, on a nonbinding, advisory basis, the Merger-Related Compensation (as defined in the accompanying proxy statement/prospectus) (the &#8220;Advisory Compensation Proposal&#8221;); and </div></td></tr></table></div></div></div>
<!--End Page 7-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 8-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_104-notice_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-style: italic;">Adjournment Proposal. </font>To approve adjournments of the Special Meeting from time to time, if necessary or appropriate, to solicit additional proxies in favor of the Share Issuance Proposal and the Charter Amendment Proposal if there are insufficient votes at the time of such adjournment to approve such proposals or to ensure that any supplement or amendment to the accompanying proxy statement/prospectus is timely provided to Standard BioTools stockholders (the &#8220;Adjournment Proposal&#8221; and, together with the Share Issuance Proposal, the Charter Amendment Proposal, the Post-Closing Equity Incentive Plan Proposal, the Post-Closing ESPP Proposal and the Advisory Compensation Proposal, the &#8220;Proposals&#8221;). </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">You can vote &#8220;<font style="font-weight: bold;">FOR</font>,&#8221; &#8220;<font style="font-weight: bold;">AGAINST</font>&#8221; or &#8220;<font style="font-weight: bold;">ABSTAIN</font>&#8221; on each of the Proposals. The approval by Standard BioTools stockholders of the Share Issuance Proposal and the Charter Amendment Proposal is a condition to the consummation of the Merger and the other Transactions. If the Share Issuance Proposal and the Charter Amendment Proposal are not approved, the Merger and the other Transactions will not be consummated. Approval of the Post-Closing Equity Incentive Plan Proposal, the Post-Closing ESPP Proposal, the Advisory Compensation Proposal and the Adjournment Proposal is not required for the consummation of the Merger and the other Transactions. The Standard BioTools Board of Directors (the &#8220;Standard BioTools Board&#8221;) is not aware of any other business to be acted upon at the Special Meeting. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Proposals are described in more detail in the accompanying proxy statement/prospectus, which you should read carefully in its entirety. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Standard BioTools Board has set &#8195;&#8195;&#8195;&#8195;, 2026 as the record date for the Special Meeting. Only holders of record of Standard BioTools Common Stock as of 5:00 p.m. U.S. Eastern Time on &#8195;&#8195;&#8195;&#8195;, 2026 will be entitled to notice of and to vote at the Special Meeting and any adjournments thereof. Any stockholder entitled to attend and vote at the Special Meeting is entitled to appoint a proxy to attend and vote on such stockholder&#8217;s behalf. Such proxy need not be a holder of Standard BioTools Common Stock. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">To be approved, (1) the Share Issuance Proposal, the Post-Closing Equity Incentive Plan Proposal, the Post-Closing ESPP Proposal, the Advisory Compensation Proposal and the Adjournment Proposal require the affirmative vote of a majority of the voting power of the shares of Standard BioTools&#8217; capital stock present in person or represented by proxy at the Special Meeting and entitled to vote on such Proposal at the Special Meeting and (2)&#160;the Charter Amendment Proposal requires the affirmative vote of the holders of Standard BioTools&#8217; capital stock entitled to vote thereon, voting as a single class, by a majority of the votes cast for or against such Proposal at the Special Meeting. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The failure of any stockholder of record of Standard BioTools to submit a signed proxy card, grant a proxy electronically over the Internet or by telephone or to vote virtually by ballot at the Special Meeting will have no effect on the outcome of the vote for the Proposals. Abstentions will have the same effect as a vote &#8220;<font style="font-weight: bold;">AGAINST</font>&#8221; the Proposals (other than the Charter Amendment Proposal) and will have no effect on the outcome of the vote for the Charter Amendment Proposal. If you hold your shares of Standard BioTools&#8217; capital stock in &#8220;street name&#8221; through a bank, broker or other nominee and you do not instruct your bank, broker or other nominee on how to vote your shares, your bank, broker or other nominee will not be permitted to vote your shares on any of the Proposals, which will have no effect on the outcome of the vote for the Proposals. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Your vote is very important. Whether or not you expect to attend the Special Meeting, we urge you to submit your proxy with respect to your shares of Standard BioTools Common Stock as promptly as possible by: (1)&#160;accessing the Internet website specified on your proxy card; (2) calling the toll-free number specified on your proxy card; or (3) signing and returning the enclosed proxy card in the postage-paid envelope provided, to ensure that your shares of Standard BioTools Common Stock are represented and voted at the Special Meeting. <font style="font-weight: normal;">Submitting a proxy now will not prevent you from being able to vote in person at the Special Meeting. If your shares of Standard BioTools Common Stock are held in &#8220;street name&#8221; in the name of a bank, broker or other nominee, please follow the instructions on the voting instruction card furnished by such bank, broker or other nominee. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Special Committee of the Standard BioTools Board has unanimously (i) determined that the Transactions are advisable, fair to and in the best interests of Standard BioTools and its stockholders, (ii)&#160;approved and declared advisable the Merger Agreement and the Transactions and recommended that the </div></div></div></div>
<!--End Page 8-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 9-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_104-notice_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Standard BioTools Board approve and declare advisable the Transactions and (iii) recommended that the Standard BioTools Board resolve to recommend the approval of the Share Issuance and the Charter Amendment (in each case, as defined in the accompanying proxy statement/prospectus) by Standard BioTools&#8217; stockholders.<font style="font-weight: normal;"> </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, the Standard BioTools Board has (i) determined that the Transactions are advisable, fair to and in the best interests of Standard BioTools and its stockholders, (ii) approved and declared advisable the Merger Agreement and the Transactions and (iii) resolved to recommend the approval of the Share Issuance, the Charter Amendment,<font style="font-weight: normal;"> </font>the Post-Closing Equity Incentive Plan, the Post-Closing ESPP, on a nonbinding, advisory basis, the Merger-Related Compensation and the adjournment of the Special Meeting, if necessary or appropriate to solicit additional proxies (in each case, as defined in the accompanying proxy statement/prospectus) by Standard BioTools&#8217; stockholders. The Standard BioTools Board recommends that you vote &#8220;FOR&#8221; each Proposal.<font style="font-weight: normal;"> </font></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; text-align: right;">By Order of the Board of Directors, <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">&#8195;<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">Michael Egholm, Ph.D. <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;"><font style="font-style: italic;">President and Chief Executive Officer</font> <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">&#8195;<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">Boston, MA <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">&#8195;&#8195;&#8195;&#8195;, 2026 </div></div></div></div>
<!--End Page 9-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 10-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_105-vote_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">YOUR VOTE IS IMPORTANT! </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">WHETHER OR NOT YOU EXPECT TO ATTEND THE SPECIAL MEETING, WE URGE YOU TO SUBMIT YOUR PROXY AS PROMPTLY AS POSSIBLE (1) VIA THE INTERNET, (2) BY TELEPHONE OR (3) BY MARKING, SIGNING AND DATING THE ENCLOSED STANDARD BIOTOOLS PROXY CARD AND RETURNING IT IN THE POSTAGE-PAID ENVELOPE PROVIDED. IF YOU ATTEND THE SPECIAL MEETING AND WISH TO VOTE YOUR SHARES OF STANDARD BIOTOOLS COMMON STOCK, YOU MAY DO SO AT ANY TIME PRIOR TO THE CLOSING OF THE POLLS AT THE SPECIAL MEETING. <font style="font-weight: normal;">You may revoke your proxy or change your vote at any time before the polls close at the Special Meeting. If your shares of Standard BioTools Common Stock are held in &#8220;street name&#8221; in the name of a bank, broker or other nominee holder of record, please follow the instructions on the voting instruction card furnished to you by such record holder. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We urge you to read the accompanying proxy statement/prospectus, including all documents incorporated by reference into the accompanying proxy statement/prospectus, and its annexes and exhibits carefully and in their entirety. If you have any questions concerning the Merger Agreement, the Transactions, the Proposals, the Special Meeting or the accompanying proxy statement/prospectus, would like additional copies of the accompanying proxy statement/prospectus or need help voting your shares of Standard BioTools, please contact: </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 74.5pt; text-align: center;">or<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;"><img style="height: 127px; width: 177px;" src="logo_standardbiov2x1.jpg"><br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201; <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">50 Milk Street, 10th Floor <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Boston, MA 02109<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Attention: Investor Relations <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Telephone: (650) 266-6000 <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Email: investors@standardbio.com <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">https://investors.standardbio.com </div></div></div></div>
<!--End Page 10-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 11-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_106-toc_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">TABLE OF CONTENTS<font style="font-weight: normal;"> </font></div><a name="TOC"><!--Anchor--></a><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="margin-top: 4pt; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 425pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 13.72pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 13.72pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 15.55pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr><td style="width: 425pt; padding-bottom: 0.83pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tQA">QUESTIONS AND ANSWERS ABOUT THE MERGER<font style="padding-left: 1.5pt;"></font></a></div></td><td style="width: 13.72pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.72pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 15.55pt; padding-bottom: 0.83pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tQA"><font style="padding-left: 10.55pt;">1</font> </a></div></td></tr><tr><td style="width: 425pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tPOS">PROSPECTUS SUMMARY<font style="padding-left: 1.67pt;"></font></a></div></td><td style="width: 13.72pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.72pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 15.55pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tPOS"><font style="padding-left: 5.55pt;">14</font> </a></div></td></tr><tr><td style="width: 425pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tSHF">SELECTED HISTORICAL FINANCIAL DATA FOR TREELINE<font style="padding-left: 0.28pt;"></font></a></div></td><td style="width: 13.72pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.72pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 15.55pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tSHF"><font style="padding-left: 5.55pt;">29</font> </a></div></td></tr><tr><td style="width: 425pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tSPF">SELECTED PRO FORMA FINANCIAL INFORMATION<font style="padding-left: 0.69pt;"></font></a></div></td><td style="width: 13.72pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.72pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 15.55pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tSPF"><font style="padding-left: 5.55pt;">30</font> </a></div></td></tr><tr><td style="width: 425pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tCPS">COMPARATIVE PER SHARE MARKET PRICE AND DIVIDEND INFORMATION<font style="padding-left: 4.51pt;"></font></a></div></td><td style="width: 13.72pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.72pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 15.55pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tCPS"><font style="padding-left: 5.55pt;">32</font> </a></div></td></tr><tr><td style="width: 425pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tRF">RISK FACTORS<font style="padding-left: 3.15pt;"></font></a></div></td><td style="width: 13.72pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.72pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 15.55pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tRF"><font style="padding-left: 5.55pt;">33</font> </a></div></td></tr><tr><td style="width: 425pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tFLS">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS<font style="padding-left: 0.83pt;"></font></a></div></td><td style="width: 13.72pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.72pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 15.55pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tFLS"><font style="padding-left: 0.55pt;">104</font> </a></div></td></tr><tr><td style="width: 425pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tSPE">THE SPECIAL MEETING<font style="padding-left: 2.89pt;"></font></a></div></td><td style="width: 13.72pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.72pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 15.55pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tSPE"><font style="padding-left: 0.55pt;">105</font> </a></div></td></tr><tr><td style="width: 425pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tSBP">STANDARD BIOTOOLS PROPOSALS<font style="padding-left: 2.95pt;"></font></a></div></td><td style="width: 13.72pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.72pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 15.55pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tSBP"><font style="padding-left: 1.29pt;">111</font> </a></div></td></tr><tr><td style="width: 425pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tPAR">THE PARTIES TO THE MERGER<font style="padding-left: 0.13pt;"></font></a></div></td><td style="width: 13.72pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.72pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 15.55pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tPAR"><font style="padding-left: 0.55pt;">134</font> </a></div></td></tr><tr><td style="width: 425pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tMER">THE MERGER<font style="padding-left: 3.9pt;"></font></a></div></td><td style="width: 13.72pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.72pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 15.55pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tMER"><font style="padding-left: 0.55pt;">135</font> </a></div></td></tr><tr><td style="width: 425pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tMEA">THE MERGER AGREEMENT<font style="padding-left: 0.29pt;"></font></a></div></td><td style="width: 13.72pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.72pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 15.55pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tMEA"><font style="padding-left: 0.55pt;">201</font> </a></div></td></tr><tr><td style="width: 425pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tTBD">TREELINE BUSINESS DESCRIPTION<font style="padding-left: 2.53pt;"></font></a></div></td><td style="width: 13.72pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.72pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 15.55pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tTBD"><font style="padding-left: 0.55pt;">228</font> </a></div></td></tr><tr><td style="width: 425pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;"><a href="#tMDA">TREELINE MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND&#160;RESULTS OF OPERATIONS<font style="padding-left: 2.05pt;"></font></a></div></td><td style="width: 13.72pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.72pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 15.55pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tMDA"><font style="padding-left: 0.55pt;">263</font> </a></div></td></tr><tr><td style="width: 425pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tBOD">BOARD OF DIRECTORS AND MANAGEMENT FOLLOWING THE MERGER<font style="padding-left: 3.39pt;"></font></a></div></td><td style="width: 13.72pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.72pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 15.55pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tBOD"><font style="padding-left: 0.55pt;">276</font> </a></div></td></tr><tr><td style="width: 425pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tECT">EXECUTIVE COMPENSATION OF TREELINE<font style="padding-left: 1.33pt;"></font></a></div></td><td style="width: 13.72pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.72pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 15.55pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tECT"><font style="padding-left: 0.55pt;">283</font> </a></div></td></tr><tr><td style="width: 425pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;"><a href="#tCER">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS OF THE COMBINED COMPANY<font style="padding-left: 3.43pt;"></font></a></div></td><td style="width: 13.72pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.72pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 15.55pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tCER"><font style="padding-left: 0.55pt;">288</font> </a></div></td></tr><tr><td style="width: 425pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tUNA">UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION<font style="padding-left: 2.97pt;"></font></a></div></td><td style="width: 13.72pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.72pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 15.55pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tUNA"><font style="padding-left: 0.55pt;">292</font> </a></div></td></tr><tr><td style="width: 425pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;"><a href="#tMUS">MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS WITH RESPECT TO THE MERGER<font style="padding-left: 0.84pt;"></font></a></div></td><td style="width: 13.72pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.72pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 15.55pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tMUS"><font style="padding-left: 0.55pt;">305</font> </a></div></td></tr><tr><td style="width: 425pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tDCS">DESCRIPTION OF CAPITAL STOCK<font style="padding-left: 3.6pt;"></font></a></div></td><td style="width: 13.72pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.72pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 15.55pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tDCS"><font style="padding-left: 0.55pt;">308</font> </a></div></td></tr><tr><td style="width: 425pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tCSR">COMPARISON OF STOCKHOLDER RIGHTS<font style="padding-left: 3.36pt;"></font></a></div></td><td style="width: 13.72pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.72pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 15.55pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tCSR"><font style="padding-left: 0.55pt;">312</font> </a></div></td></tr><tr><td style="width: 425pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;"><a href="#tSEC">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT OF STANDARD BIOTOOLS<font style="padding-left: 2.12pt;"></font></a></div></td><td style="width: 13.72pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.72pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 15.55pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tSEC"><font style="padding-left: 0.55pt;">320</font> </a></div></td></tr><tr><td style="width: 425pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;"><a href="#tSEO">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT OF TREELINE<font style="padding-left: 4.73pt;"></font></a></div></td><td style="width: 13.72pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.72pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 15.55pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tSEO"><font style="padding-left: 0.55pt;">322</font> </a></div></td></tr><tr><td style="width: 425pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;"><a href="#tPRO">PRO FORMA SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT OF THE COMBINED COMPANY<font style="padding-left: 1.06pt;"></font></a></div></td><td style="width: 13.72pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.72pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 15.55pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tPRO"><font style="padding-left: 0.55pt;">326</font> </a></div></td></tr><tr><td style="width: 425pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tOTM">OTHER MATTERS<font style="padding-left: 1.12pt;"></font></a></div></td><td style="width: 13.72pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.72pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 15.55pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tOTM"><font style="padding-left: 0.55pt;">327</font> </a></div></td></tr><tr><td style="width: 425pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tHOU">HOUSEHOLDING OF PROXY MATERIALS<font style="padding-left: 3.75pt;"></font></a></div></td><td style="width: 13.72pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.72pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 15.55pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tHOU"><font style="padding-left: 0.55pt;">328</font> </a></div></td></tr><tr><td style="width: 425pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tTAR">TRANSFER AGENT AND REGISTRAR<font style="padding-left: 4.09pt;"></font></a></div></td><td style="width: 13.72pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.72pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 15.55pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tTAR"><font style="padding-left: 0.55pt;">329</font> </a></div></td></tr><tr><td style="width: 425pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tSSP">SUBMISSION OF STOCKHOLDER PROPOSALS<font style="padding-left: 1.88pt;"></font></a></div></td><td style="width: 13.72pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.72pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 15.55pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tSSP"><font style="padding-left: 0.55pt;">330</font> </a></div></td></tr><tr><td style="width: 425pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tCSB">COMMUNICATIONS FROM STANDARD BIOTOOLS STOCKHOLDERS<font style="padding-left: 0.95pt;"></font></a></div></td><td style="width: 13.72pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.72pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 15.55pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tCSB"><font style="padding-left: 0.55pt;">332</font> </a></div></td></tr><tr><td style="width: 425pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tLEG">LEGAL MATTERS<font style="padding-left: 2.05pt;"></font></a></div></td><td style="width: 13.72pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.72pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 15.55pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tLEG"><font style="padding-left: 0.55pt;">333</font> </a></div></td></tr><tr><td style="width: 425pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tEXP">EXPERTS<font style="padding-left: 4.77pt;"></font></a></div></td><td style="width: 13.72pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.72pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 15.55pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tEXP"><font style="padding-left: 0.55pt;">333</font> </a></div></td></tr><tr><td style="width: 425pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tIBR">INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE<font style="padding-left: 1.82pt;"></font></a></div></td><td style="width: 13.72pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.72pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 15.55pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tIBR"><font style="padding-left: 0.55pt;">334</font> </a></div></td></tr><tr><td style="width: 425pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tWYC">WHERE YOU CAN FIND MORE INFORMATION<font style="padding-left: 0.99pt;"></font></a></div></td><td style="width: 13.72pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.72pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 15.55pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tWYC"><font style="padding-left: 0.55pt;">335</font> </a></div></td></tr><tr><td style="width: 425pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;"><a href="#tICF">TREELINE BIOSCIENCES, INC. AND SUBSIDIARY INDEX TO CONSOLIDATED FINANCIAL STATEMENTS<font style="padding-left: 4.41pt;"></font></a></div></td><td style="width: 13.72pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.72pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 15.55pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tICF"><font style="padding-left: 1.66pt;">F-1 </font></a></div></td></tr><tr><td style="width: 425pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANA">ANNEX A: MERGER AGREEMENT<font style="padding-left: 2.8pt;"></font></a></div></td><td style="width: 13.72pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.72pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 15.55pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tANA">A-1 </a></div></td></tr><tr><td style="width: 425pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANB">ANNEX B: OPINION OF CENTERVIEW<font style="padding-left: 0.01pt;"></font></a></div></td><td style="width: 13.72pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.72pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 15.55pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tANB"><font style="padding-left: 0.55pt;">B-1 </font></a></div></td></tr><tr><td style="width: 425pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANC">ANNEX C: OPINION OF UBS<font style="padding-left: 4.76pt;"></font></a></div></td><td style="width: 13.72pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.72pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 15.55pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tANC"><font style="padding-left: 0.55pt;">C-1 </font></a></div></td></tr><tr><td style="width: 425pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tAND">ANNEX D: FORM OF VOTING AGREEMENT<font style="padding-left: 4.67pt;"></font></a></div></td><td style="width: 13.72pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.72pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 15.55pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tAND">D-1 </a></div></td></tr><tr><td style="width: 425pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANE">ANNEX E: FORM OF LOCK-UP AGREEMENT<font style="padding-left: 0.96pt;"></font></a></div></td><td style="width: 13.72pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.72pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 15.55pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tANE"><font style="padding-left: 1.11pt;">E-1 </font></a></div></td></tr><tr><td style="width: 425pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANF">ANNEX F: FORM OF CVR AGREEMENT<font style="padding-left: 3.91pt;"></font></a></div></td><td style="width: 13.72pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.72pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 15.55pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tANF"><font style="padding-left: 1.66pt;">F-1 </font></a></div></td></tr><tr><td style="width: 425pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANG">ANNEX G: AMENDMENT TO CERTIFICATE OF INCORPORATION (REVERSE STOCK SPLIT)<font style="padding-left: 1.95pt;"></font></a></div></td><td style="width: 13.72pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.72pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 15.55pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tANG">G-1 </a></div></td></tr><tr><td style="width: 425pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANH">ANNEX H: AMENDMENT TO CERTIFICATE OF INCORPORATION (NAME CHANGE)<font style="padding-left: 2.06pt;"></font></a></div></td><td style="width: 13.72pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.72pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 15.55pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tANH">H-1 </a></div></td></tr><tr><td style="width: 425pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANI">ANNEX I: FORM OF POST-CLOSING EQUITY INCENTIVE PLAN<font style="padding-left: 1.37pt;"></font></a></div></td><td style="width: 13.72pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.72pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 15.55pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tANI"><font style="padding-left: 3.89pt;">I-1 </font></a></div></td></tr><tr><td style="width: 425pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANJ">ANNEX J: FORM OF POST-CLOSING EMPLOYEE STOCK PURCHASE PLAN<font style="padding-left: 0.33pt;"></font></a></div></td><td style="width: 13.72pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.72pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 15.55pt; padding-top: 0.46pt; padding-bottom: 0.83pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tANJ"><font style="padding-left: 3.33pt;">J-1 </font></a></div></td></tr><tr><td style="width: 425pt; padding-top: 0.46pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANK">ANNEX K: FORM OF PROXY CARD<font style="padding-left: 2.63pt;"></font></a></div></td><td style="width: 13.72pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.72pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 15.55pt; padding-top: 0.46pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tANK">K-1</a></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 425pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 13.72pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 13.72pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 15.55pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">i<br></div></div></div>
<!--End Page 11-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 12-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_107-qa_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tQA"><!--Anchor--></a>QUESTIONS AND ANSWERS ABOUT THE MERGER </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following are answers to some questions that you, as a stockholder of Standard BioTools Inc., a Delaware corporation (&#8220;Standard BioTools,&#8221; &#8220;we&#8221; or &#8220;our&#8221;), may have regarding the proposed business combination (the &#8220;Merger&#8221; and, together with the other transactions contemplated by the Merger Agreement, as defined below, the &#8220;Transactions&#8221;) between Standard BioTools and Treeline Biosciences, Inc., a Delaware corporation (&#8220;Treeline&#8221;) and the proposals to be considered at the special meeting of Standard BioTools stockholders (the &#8220;Special Meeting&#8221;). This section does not provide all the information that might be important to you with respect to the proposed Merger. Standard BioTools urges you to carefully read the remainder of this proxy statement/prospectus, including the annexes. The information in this proxy statement/prospectus, including the information contained in this &#8220;<font style="font-style: italic;">Questions and Answers About the Merger</font>,&#8221; does not give effect to any reverse stock split that may be effected prior to or concurrently with the Closing. </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Why am I receiving this proxy statement/prospectus? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;"><font style="font-weight: normal;">On June&#160;6, 2026, Standard BioTools entered into an Agreement and Plan of Merger and Reorganization (the &#8220;Merger Agreement&#8221;) with Treeline and Siri Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Standard BioTools (&#8220;Merger Sub&#8221;), pursuant to which Standard BioTools and Treeline will combine in an all-stock merger upon the terms and conditions set forth in the Merger Agreement. The Merger Agreement provides, among other things, that Merger Sub will merge with and into Treeline, with Treeline surviving the Merger as a wholly owned subsidiary of Standard BioTools. In connection with the Merger, Standard BioTools will change its name to Treeline Biosciences Holdings, Inc. A copy of the Merger Agreement is included in this proxy statement/prospectus as Annex&#160;A. </font></div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The Merger cannot be completed unless Standard BioTools stockholders approve, among other matters, (1) the issuance of shares of Standard BioTools&#8217; common stock, par value $0.001 per share (&#8220;Standard BioTools Common Stock&#8221;) (the &#8220;Share Issuance&#8221;), to Treeline stockholders in exchange for their shares of Treeline&#8217;s common stock, par value $0.00001 per share (&#8220;Treeline Common Stock&#8221;), and their shares of Treeline&#8217;s preferred stock, par value $0.00001 per share (&#8220;Treeline Preferred Stock&#8221; and together with the Treeline Common Stock, the &#8220;Treeline Capital Stock&#8221;), in connection with the Merger, (2) an amendment to the Standard BioTools Eighth Amended and Restated Certificate of Incorporation, as amended (the &#8220;Standard BioTools Charter&#8221;) to effect a reverse stock split of the issued and outstanding Standard BioTools Common Stock at a ratio in the range from 1-for-&#8195; to 1-for-&#8195;, inclusive, with the final ratio to be mutually agreed to by Standard BioTools and Treeline (the &#8220;Reverse Stock Split&#8221;) and (3)&#160;an amendment to the Standard BioTools Charter to change the name of Standard BioTools to &#8220;Treeline Biosciences Holdings, Inc.&#8221; (together with the amendment to the Standard BioTools Charter to effect the Reverse Stock Split, the &#8220;Charter Amendment&#8221;). </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Standard BioTools is using this document as a proxy statement to solicit proxies from Standard BioTools stockholders in connection with proposals relating to the Merger at the Special Meeting. Standard BioTools is also using this document as a prospectus by which Standard BioTools will offer and issue shares of Standard BioTools Common Stock in connection with the Merger, and as a resale prospectus by which certain selling securityholders named herein (the &#8220;Selling Securityholders&#8221;) will offer and sell, from time to time, shares of Standard BioTools Common Stock that they will receive as Merger consideration in their capacity as Treeline stockholders. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-align: left;">This proxy statement/prospectus contains important information about the Merger and the proposals being voted on at the Special Meeting. You should read it carefully and in its entirety. The enclosed materials allow Standard BioTools stockholders to have their shares voted by proxy without attending the Special Meeting, which will be held virtually. Your vote is important. We encourage you to submit your proxy as soon as possible.<font style="font-weight: normal;"> </font></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Who is Treeline? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;"><font style="font-weight: normal;">Treeline is a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and other serious diseases. Treeline&#8217;s approach is built on a differentiated, repeatable discovery platform that identifies compelling molecular targets and matches them with the most appropriate drug modality. Treeline seeks to prove it can pick good targets, nominate highly-vetted development candidates, and make thoughtful development decisions across a diverse and ambitious pipeline, with the goal of redefining the treatment of serious diseases. Treeline wants its platform story to be repeatability. Treeline currently has three Phase 1 </font></div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">1<br></div></div></div>
<!--End Page 12-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 13-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_107-qa_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: left;">programs, TLN-121, TLN-254, and TLN-372, and a fourth program, TLN-499, nearing clinical entry, all in oncology. Treeline&#8217;s preclinical pipeline includes programs in neurology and immunology, in addition to oncology. </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Why is Standard BioTools proposing the Merger with Treeline? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;"><font style="font-weight: normal;">The board of directors of Standard BioTools (the &#8220;Standard BioTools Board&#8221;) and a special committee of the Standard BioTools Board consisting of disinterested directors (as defined in Section&#160;144(e)(4) of the Delaware General Corporation Law (the &#8220;DGCL&#8221;)) (the &#8220;Special Committee&#8221;) have approved the Merger and the other Transactions. To review the reasons for the Merger in more detail, see &#8220;</font><font style="font-style: italic; font-weight: normal;">The Merger &#8212; Standard BioTools&#8217; Reasons for the Merger</font><font style="font-weight: normal;">&#8221; and &#8220;</font><font style="font-style: italic; font-weight: normal;">The Merger &#8212; Treeline&#8217;s Reasons for the Merger</font><font style="font-weight: normal;">&#8221; for more information. </font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">What am I being asked to vote on? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;"><font style="font-weight: normal;">At the Special Meeting, Standard BioTools stockholders will be asked to consider and vote on the following proposals: </font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">To approve the issuance of shares of Standard BioTools Common Stock to stockholders of Treeline pursuant to the terms of the Merger Agreement and in accordance with Nasdaq Listing Rules 5635(a) and 5635(b) (the &#8220;Share Issuance Proposal&#8221;); </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">To approve an amendment to the Standard BioTools Charter to effect a reverse stock split of Standard BioTools&#8217; issued and outstanding common stock at a ratio in the range from 1-for-&#8195; to 1-for-&#8195;, inclusive, with the final ratio to be mutually agreed to by Standard BioTools and Treeline and an amendment to the Standard BioTools Charter to change the name of Standard BioTools to &#8220;Treeline Biosciences Holdings, Inc.&#8221; (the &#8220;Charter Amendment Proposal&#8221;); </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">To approve the Post-Closing Equity Incentive Plan in the form attached as Annex&#160;I to this proxy statement/prospectus (the &#8220;Post-Closing Equity Incentive Plan&#8221;), which will become effective at the effective time of the Merger and is contingent on the closing of the Merger (the &#8220;Closing&#8221;) (the &#8220;Post-Closing Equity Incentive Plan Proposal&#8221;); </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">To approve the Post-Closing Employee Stock Purchase Plan in the form attached as Annex&#160;J to this proxy statement/prospectus (the &#8220;Post-Closing ESPP&#8221;), which will become effective at the effective time of the Merger and is contingent on the Closing (the &#8220;Post-Closing ESPP Proposal&#8221;); </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">To approve, on a nonbinding, advisory basis, the compensation and benefits that will or may become payable by Standard BioTools to its named executive officers in connection with the Merger (the &#8220;Merger-Related Compensation,&#8221; and such proposal, the &#8220;Advisory Compensation Proposal&#8221;); and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">To approve adjournments of the Special Meeting from time to time, if necessary or appropriate, to solicit additional proxies in favor of the Share Issuance Proposal and the Charter Amendment Proposal, if there are insufficient votes at the time of such adjournment to approve such proposals or to ensure that any supplement or amendment to this proxy statement/prospectus is timely provided to Standard BioTools stockholders (the &#8220;Adjournment Proposal&#8221; and, together with the Share Issuance Proposal, the Charter Amendment Proposal, the Post-Closing Equity Incentive Plan Proposal, the Post-Closing ESPP Proposal and the Advisory Compensation Proposal, the &#8220;Proposals&#8221;). </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">What will Treeline stockholders receive in the Merger? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;"><font style="font-weight: normal;">As a result of the Merger, each share of Treeline common stock, par value $0.00001 per share (the &#8220;Treeline Common Stock&#8221;), issued and outstanding immediately prior to the Effective Time and each share of Treeline preferred stock, par value $0.00001 per share (the &#8220;Treeline Preferred Stock&#8221; and, together with the Treeline Common Stock, the &#8220;Treeline Capital Stock&#8221;), issued and outstanding immediately prior to the Effective Time (in each case, other than shares held in treasury and dissenting shares) will be converted into the right to receive a number of shares of Standard BioTools Common Stock based on an exchange ratio calculated in accordance with the Merger Agreement (described in more detail in the section titled &#8220;</font><font style="font-style: italic; font-weight: normal;">The Merger Agreement&#8201;&#8212;&#8201;Exchange Ratio</font><font style="font-weight: normal;">&#8221; beginning on page <a href="#tEXR">202</a> of this proxy statement/prospectus) (the &#8220;Exchange Ratio&#8221;), with the number of shares of Standard BioTools Common Stock that each holder of Treeline Capital Stock is entitled to receive being rounded down to the nearest whole share and computed after aggregating all shares of Treeline Capital </font></div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">2<br></div></div></div>
<!--End Page 13-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 14-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_107-qa_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: left;">Stock held by such holder. The Exchange Ratio is based on the relative capitalization of each of Treeline and Standard BioTools and assumes (i) an equity value for Treeline of $2.5&#160;billion and (ii) an equity value for Standard BioTools equal to $460&#160;million, reduced by the amount by which the Parent Net Cash (as defined in the Merger Agreement) is less than $449&#160;million at the Closing or increased by the amount by which Parent Net Cash is more than $451&#160;million at the Closing. For a more complete description of the treatment of Treeline Capital Stock in the Merger, please see the section titled &#8220;<font style="font-style: italic;">The Merger Agreement &#8212; Merger Consideration</font>&#8221; beginning on page <a href="#tMGC">201</a> of this proxy statement/prospectus. </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">What will holders of Treeline stock options receive in the Merger? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;"><font style="font-weight: normal;">As of the Effective Time, Standard BioTools will assume Treeline&#8217;s 2021 Equity Incentive Plan and each outstanding option to purchase shares of Treeline Common Stock (each, a &#8220;Treeline Option&#8221;), whether vested or unvested. Each such Treeline Option so assumed by Standard BioTools will continue to have, and be subject to, the same terms and conditions applicable to such Treeline Option immediately prior to the Effective Time, except that (i) such Treeline Option will be exercisable for that number of shares of Standard BioTools Common Stock equal to the number of shares of Treeline Common Stock subject to such Treeline Option immediately prior to the Effective Time multiplied by the Exchange Ratio and rounded down to the next nearest share of Standard BioTools Common Stock, and (ii) the exercise price per share of each such Treeline Option will be the exercise price per share in effect for that Treeline Option immediately prior to the Effective Time divided by the Exchange Ratio and rounded up to the next nearest cent. For a more complete description of the treatment of Treeline Options in the Merger, please see the section titled &#8220;</font><font style="font-style: italic; font-weight: normal;">The Merger Agreement &#8212; Treatment of Treeline Stock Options</font><font style="font-weight: normal;">&#8221; beginning on page <a href="#tTOTS">205</a> of this proxy statement/prospectus. </font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">What will holders of Treeline warrants receive in the Merger? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;"><font style="font-weight: normal;">As of the Effective Time, (i) each warrant to purchase shares of Treeline Capital Stock (each, a &#8220;Treeline Warrant&#8221;) that has been amended to require net-exercise in connection with the Merger (the &#8220;Treeline Converting Warrants&#8221;) and that is outstanding immediately prior to the Effective Time will, by virtue of the Merger, be cancelled and extinguished and converted into the right to receive, for each share of Treeline Common Stock that would be received upon the net-exercise of such Treeline Converting Warrant in accordance with its terms, a number of shares of Standard BioTools Common Stock equal to the Exchange Ratio and (ii) each Treeline Warrant that is not a Treeline Converting Warrant and that is outstanding immediately prior to the Effective Time will, by virtue of the Merger, be assumed by Standard BioTools. Each such Treeline Warrant so assumed by Standard BioTools will continue to have, and be subject to, the same terms and conditions applicable to such Treeline Warrant immediately prior to the Effective Time, except that (a) such Treeline Warrant will be exercisable for that number of shares of Standard BioTools Common Stock equal to the number of shares of Treeline Common Stock subject to such Treeline Warrant immediately prior to the Effective Time multiplied by the Exchange Ratio and rounded down to the next nearest share of Standard BioTools Common Stock and (b) the warrant price per share will be the warrant price per share in effect for such Treeline Warrant immediately prior to the Effective Time divided by the Exchange Ratio and rounded up to the nearest thousandth of a cent.</font> <font style="font-weight: normal;">For a more complete description of the treatment of Treeline Warrants in the Merger, please see the section titled &#8220;</font><font style="font-style: italic; font-weight: normal;">The Merger Agreement&#8201;&#8212;&#8201;Treatment of Treeline Warrants</font><font style="font-weight: normal;">&#8221; beginning on page <a href="#tTOTW">205</a> of this proxy statement/prospectus. </font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">What will Standard BioTools stockholders receive in the Merger? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;"><font style="font-weight: normal;">Standard BioTools stockholders will continue to own and hold their existing shares of Standard BioTools Common Stock. Each share of Standard BioTools Common Stock issued and outstanding at the time of the Merger will remain issued and outstanding and, subject to the Reverse Stock Split, will be unaffected by the Merger. </font></div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">In addition, prior to the Effective Time, Standard BioTools expects to declare a dividend to Standard BioTools stockholders as of the close of business on the last business day prior to the day on which the Effective Time occurs in the form of one contingent value right (each, a &#8220;CVR&#8221;) for each outstanding share of Standard BioTools Common Stock held by such stockholder on such date. The payment date for such dividend will be three business days after the Effective Time. The CVRs will be issued pursuant to the terms of a Contingent Value Rights Agreement to be entered into between Standard BioTools and a rights agent (the &#8220;CVR Agreement&#8221;). </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">3<br></div></div></div>
<!--End Page 14-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 15-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_107-qa_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: left;">Pursuant to the CVR Agreement, the holder of each CVR will be entitled to receive a payment for each 12-month CVR payment period during the five-year term of the CVR Agreement, consisting of a number of shares of the combined company&#8217;s common stock (with fractional shares settled in cash) equal to such holder&#8217;s pro rata portion of the aggregate net proceeds received by the combined company during such 12-month CVR payment period from the following sources, in each case less certain permitted deductions: (i) proceeds from any sale, disposition, or other monetization of the Legacy Business; (ii) proceeds from convertible notes or other investments held by Standard BioTools as of the date of the Closing (the &#8220;Closing Date&#8221;); (iii) earnout, milestone, royalty or other similar contingent payments due to Standard BioTools under contracts in effect as of the Closing Date, including payments from Illumina, Inc. pursuant to the Stock Purchase Agreement dated June&#160;22, 2025; and (iv) any surplus in Parent Net Cash delivered at Closing as finally determined under the Merger Agreement. The maximum number of shares of common stock of the combined company which may be issued pursuant to the CVR Agreement is 76,000,000. There can be no assurance that any payments will be made on the CVRs. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The right to the contingent payments contemplated by the CVR Agreement is a contractual right only and is not transferable, except in the limited circumstances specified in the CVR Agreement. The CVRs will not be evidenced by a certificate or any other instrument and will not be registered with the SEC. The CVRs will not have any voting or dividend rights and will not represent any equity or ownership interest in Standard BioTools or any of its respective affiliates. No interest will accrue on any amounts payable in respect of the CVRs. Shares of Standard BioTools Common Stock underlying the CVRs have been registered on the Form&#160;S-4 of which this proxy statement/prospectus forms a part. </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">What will Standard BioTools optionholders and RSU holders and participants in the Standard BioTools 2017 Employee Stock Purchase Plan receive in the Merger? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;"><font style="font-weight: normal;">Standard BioTools optionholders and RSU holders will continue to own and hold their Standard BioTools equity awards outstanding as of the Closing in accordance with their existing terms, subject to adjustment as required under Standard BioTools&#8217; equity plans, including for the Reverse Stock Split. Standard BioTools expects that any outstanding and unvested equity awards (other than those held by members of the executive leadership team) will accelerate vesting at the consummation of the transactions contemplated by the Merger Agreement subject to continued employment or service through such date or upon an earlier qualifying termination. Outstanding and unvested equity awards held by members of the executive leadership team (including the Standard BioTools executive officers) will accelerate vesting in connection with a qualifying termination that occurs during the period beginning three months before and ending 12 months after a change of control of Standard BioTools (which includes the Merger) in accordance with the applicable Standard BioTools CIC Severance Plans (as defined below), and, pursuant to their terms, outstanding and unvested equity awards held by non-employee directors will accelerate vesting upon the Closing.</font></div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">In addition, the current offering period under the Standard BioTools 2017 Employee Stock Purchase Plan will be terminated and all accumulated contributions made by participants will be refunded as soon as practicable and, in any event, at least 15 business days prior to the Closing. The Standard BioTools 2017 Employee Stock Purchase Plan will be terminated contingent on and effective at the Closing. </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">What equity stake will existing Standard BioTools stockholders hold in Standard BioTools immediately following the Merger? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;"><font style="font-weight: normal;">Upon the Closing, based upon the number of shares of Standard BioTools Common Stock expected to be issued in the Merger, pre-Merger Standard BioTools stockholders will own approximately 16% of the outstanding equity of the combined company on a fully diluted basis and pre-Merger Treeline stockholders will own approximately 84% of the outstanding equity of the combined company on a fully diluted basis. Under certain circumstances further described in the Merger Agreement, the pro forma ownership percentages may be adjusted based on the amount of Parent Net Cash at Closing as finally determined in accordance with the Merger Agreement. </font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">What will happen to Standard BioTools&#8217; Legacy Business in connection with the Merger? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;"><font style="font-weight: normal;">Under the Merger Agreement, Standard BioTools must use its commercially reasonable efforts to effect the sale, license, transfer, disposition, divestiture or other monetization of the Legacy Business. If Standard </font></div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">4<br></div></div></div>
<!--End Page 15-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 16-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_107-qa_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: left;">BioTools has not entered into a definitive agreement for the disposition of any portion of the Legacy Business on or before the date the registration statement on Form&#160;S-4 of which this proxy statement/prospectus forms a part is declared effective under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), Standard BioTools is required to commence mutually agreed wind-down activities with respect to that portion of the Legacy Business. </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Why is Standard BioTools seeking stockholder approval to issue shares of Standard BioTools Common Stock to existing stockholders of Treeline in the Merger? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;"><font style="font-weight: normal;">Because the Standard BioTools Common Stock is listed on The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;), Standard BioTools is subject to Nasdaq&#8217;s rules and regulations. Nasdaq Listing Rule&#160;5635(a) requires stockholder approval with respect to the issuance of Standard BioTools Common Stock when, among other instances, the shares to be issued are being issued in connection with the acquisition of the stock or assets of another company and are equal to 20% or more of the outstanding shares of Standard BioTools Common Stock before the issuance. In addition, Nasdaq Listing Rule&#160;5635(b) requires stockholder approval when any issuance or potential issuance will result in a &#8220;change of control&#8221; of the issuer. Although Nasdaq has not adopted any rule on what constitutes a &#8220;change of control&#8221; for purposes of Rule&#160;5635(b), Nasdaq has previously indicated that the acquisition of, or right to acquire, by a single investor or affiliated investor group, as little as 20% of the common stock (or securities convertible into or exercisable for common stock) or voting power of an issuer could constitute a change of control. Nasdaq will consider all facts and circumstances concerning a transaction, including whether there are any other relationships or agreements between the company and the investor or group. Nasdaq Listing Rule&#160;5635(d) also requires stockholder approval for a transaction other than a public offering involving the sale, issuance or potential issuance by an issuer of common equity securities (or securities convertible into or exercisable for common equity securities) at a price that is less than the market value of the stock if the number of equity securities to be issued is or may be equal to 20% or more of the common equity securities, or 20% or more of the voting power, outstanding before the issuance. </font></div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">In connection with the Merger, Standard BioTools expects to issue shares of Standard BioTools Common Stock that will represent greater than 20% of its voting stock outstanding before the issuance. Accordingly, Standard BioTools is seeking stockholder approval of the issuance of Standard BioTools Common Stock pursuant to the Merger Agreement under the Nasdaq listing rules. </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Will the common stock of the combined company trade on an exchange? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;"><font style="font-weight: normal;">Shares of Standard BioTools Common Stock are currently listed on The Nasdaq Global Select Market under the symbol &#8220;LAB.&#8221; After completion of the Merger, Standard BioTools will be renamed &#8220;Treeline Biosciences Holdings, Inc.&#8221; and it is expected that the common stock of the combined company will trade on The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) under the symbol &#8220;TRLN.&#8221; It is a condition to the consummation of the Merger that existing shares of Standard BioTools Common Stock are listed on Nasdaq as of the Closing Date and that the shares of Standard BioTools Common Stock issuable in connection with the Merger have been approved for listing on Nasdaq, subject to official notice of issuance, but there can be no assurance such listing condition will be met. If such listing condition is not met, the Merger will not be consummated unless such condition is waived. Accordingly, you are advised that Standard BioTools stockholders will not have certainty regarding the listing of the combined company&#8217;s shares at the time you are asked to vote at the Special Meeting. </font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Who will be the directors of the combined company following the Merger? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;"><font style="font-weight: normal;">Immediately following the Merger, the combined company&#8217;s board of directors is expected to be composed of 12&#160;members. Treeline is expected to appoint ten directors and Standard BioTools is expected to appoint two&#160;directors to the initial board of the combined company. Treeline&#8217;s initial appointees to the combined company board are expected to be Joshua Bilenker, Jeffrey Engelman, Kristina Burow, David Bonita, David Schenkein, Steven Elms, Aftab Kherani, Avi Naider, Ali Satvat and Susan Desmond-Hellmann, and Standard BioTools&#8217; initial appointees to the combined company board are expected to be &#8195;&#8195;&#8195; and &#8195;&#8195;&#8195; . The other current members of the Standard BioTools Board are expected to resign from the Standard BioTools Board at the Closing. Joshua Bilenker is expected to be appointed as chair of the board of directors of the combined company. For additional information, please see the section titled &#8220;</font><font style="font-style: italic; font-weight: normal;">Board of Directors and Management Following the Merger</font><font style="font-weight: normal;">&#8221; beginning on page <a href="#tBOD">276</a> of this proxy statement/prospectus. </font></div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">5<br></div></div></div>
<!--End Page 16-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 17-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_107-qa_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Who will be the executive officers of the combined company immediately following the Merger? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;"><font style="font-weight: normal;">Immediately following the Merger, the executive management team of the combined company is expected to consist of members of the Treeline executive management team prior to the Merger, including: </font></div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="width: 448pt; margin-left: 20pt;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 218pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 218pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 218pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 218pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Title </div></td></tr><tr><td style="width: 218pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Dr.&#160;Joshua Bilenker<font style="padding-left: 1.35pt;"></font></div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 218pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chief Executive Officer </div></td></tr><tr><td style="width: 218pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Dr.&#160;Jeffrey Engelman<font style="padding-left: 4.88pt;"></font></div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 218pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chief Scientific Officer </div></td></tr><tr><td style="width: 218pt; padding-top: 1.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Spencer Smith<font style="padding-left: 1.9pt;"></font></div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 218pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chief Financial Officer</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 218pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 218pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Did the Standard BioTools Board form a Special Committee to consider the Merger, and did the Special Committee approve the Merger? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;"><font style="font-weight: normal;">The Standard BioTools Board established a special committee consisting solely of &#8220;disinterested directors&#8221; (as&#160;defined in Section&#160;144(e)(4) of the DGCL) (the &#8220;Special Committee&#8221;) and delegated to the Special Committee the full power and authority of the Standard BioTools Board, to the maximum extent permitted by applicable law, to (i) explore, consider, evaluate, review, negotiate and approve or reject the Transactions and, if approval of the Standard BioTools Board is required under the DGCL, recommend to the Standard BioTools Board for approval or rejection the Transactions and (ii) determine whether the Transactions are advisable, fair to and in the best interests of Standard BioTools and its stockholders. </font></div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The Special Committee retained (i) UBS Securities LLC to serve as its independent financial advisor and (ii)&#160;Freshfields US LLP to serve as its legal advisor, in each case to assist the Special Committee in connection with fulfilling and discharging its duties as delegated by the Standard BioTools Board. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">After due consideration and discussion of the factors that the Special Committee deemed relevant, the Special Committee unanimously (i) determined that the Transactions are advisable, fair to and in the best interests of Standard BioTools and its stockholders, (ii) approved and declared advisable the Merger Agreement and the Transactions and recommended that the Standard BioTools Board approve and declare advisable the Transactions and (iii) recommended that the Standard BioTools Board resolve to recommend the approval of the Share Issuance and the Charter Amendment (in each case, as defined in the section titled &#8220;<font style="font-style: italic;">The Special Meeting&#8201;&#8212;&#8201;Purpose of the Special Meeting</font>&#8221; beginning on page&#160;<a href="#tPOTS">105</a> of this proxy statement/prospectus) by the Standard BioTools stockholders. </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">As a Standard BioTools stockholder, how does the Standard BioTools Board recommend that I vote? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;"><font style="font-weight: normal;">The Standard BioTools Board, in consultation with financial and legal advisors and management, has (i)&#160;determined that the Transactions are advisable, fair to and in the best interests of Standard BioTools and its stockholders; (ii) approved and declared advisable the Merger Agreement and the Transactions; and (iii)&#160;resolved to recommend the approval of the Share Issuance, the Charter Amendment, the Post-Closing Equity Incentive Plan, the Post-Closing ESPP, on a nonbinding, advisory basis, the Merger-Related Compensation by the Standard BioTools stockholders and the adjournment of the Special Meeting, if necessary or appropriate to solicit additional proxies. </font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Has Treeline approved the Merger and the other Transactions? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;"><font style="font-weight: normal;">Yes. The Transactions were approved by the Treeline Board. In addition, after execution of the Merger Agreement, on June&#160;6, 2026, Treeline stockholders comprising the required majorities under Treeline&#8217;s organizational documents delivered their written consent adopting the Merger Agreement and approving the Transactions. </font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">When do you expect to complete the Merger? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;"><font style="font-weight: normal;">Standard BioTools and Treeline expect to complete the Merger in the second half of 2026, subject to the satisfaction of customary closing conditions contained in the Merger Agreement including Standard BioTools stockholder approval and regulatory approval. However, Standard BioTools cannot assure you when or if the Merger will be completed. If the Merger is not consummated prior to the outside date of March&#160;31, 2027, either party may elect to terminate the Merger Agreement. See &#8220;</font><font style="font-style: italic; font-weight: normal;">The Merger Agreement &#8212; Conditions to the Completion of the Merger</font><font style="font-weight: normal;">&#8221; for more information regarding conditions to the completion of the Merger. </font></div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">6<br></div></div></div>
<!--End Page 17-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 18-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_107-qa_pg7"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">What are the key conditions to Closing? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;"><font style="font-weight: normal;">The consummation of the Transactions is subject to the satisfaction or waiver (to the extent permitted by applicable law) of certain customary closing conditions, including, among other things, (i) approval by the Standard BioTools stockholders of the Share Issuance Proposal and the Charter Amendment Proposal, (ii) the effectiveness of the registration statement on Form&#160;S-4 of which this proxy statement/prospectus forms a part to register certain of the shares of Standard BioTools Common Stock to be issued pursuant to the Merger Agreement, (iii) the listing of existing shares of Standard BioTools Common Stock on Nasdaq as of the Closing Date and the approval for listing on Nasdaq of the shares of Standard BioTools Common Stock issuable in connection with the Merger, subject to official notice of issuance, and (iv) expiration or termination of the waiting period applicable to the Transactions under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. </font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">What happens if the Merger is not completed? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;"><font style="font-weight: normal;">If the Merger is not completed, Standard BioTools will not issue any Standard BioTools Common Stock to the Treeline stockholders and Standard BioTools stockholders will not receive CVRs. Instead, Standard BioTools will remain an independent, public company and, assuming that Standard BioTools continues to comply with the required Nasdaq listing standards, Standard BioTools Common Stock will continue to be traded on The Nasdaq Global Select Market. </font></div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">In addition, if the Merger Agreement is terminated in certain circumstances, Standard BioTools may be required to pay a termination fee or expense reimbursement to Treeline. Upon termination of the Merger Agreement under specified circumstances, including if Treeline terminates the Merger Agreement due to a change in the Standard BioTools Board recommendation in favor of the Transactions, Standard BioTools will be required to make a payment to Treeline equal to $16.1&#160;million in cash. Standard BioTools also will be required to reimburse Treeline&#8217;s reasonable out-of-pocket fees in connection with the Transactions up to a maximum of $5&#160;million if the Merger Agreement is terminated due to a failure to obtain the required approval of Standard BioTools stockholders. See &#8220;<font style="font-style: italic;">The Merger Agreement &#8212; Termination Fee and Expense Reimbursement</font>&#8221; for a complete discussion of the circumstances under which a termination fee or expense reimbursement will be required to be paid. </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Is the completion of the Merger subject to a financing condition? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;"><font style="font-weight: normal;">No, the completion of the Merger is not subject to any financing condition. </font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Is Standard BioTools permitted to seek alternative business combinations prior to the Closing? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;"><font style="font-weight: normal;">From the date of the Merger Agreement to the effective time of the Merger or, if earlier, the termination of the Merger Agreement in accordance with its terms, Standard BioTools will be subject to customary restrictions on its ability to, among other things, (i) solicit, initiate or knowingly facilitate certain competing acquisition proposals from third parties, (ii) participate in discussions and engage in negotiations with, and provide non-public information to, third parties regarding competing acquisition proposals, (iii) enter into any binding or nonbinding agreement for a competing acquisition proposal and (iv) withdraw, modify or fail to publicly affirm (in certain circumstances) the Standard BioTools Board recommendation in favor of the Transactions. However, under certain specified circumstances, Standard BioTools is permitted to participate in discussions and engage in negotiations with, and provide non-public information to, third parties with respect to a competing acquisition proposal that did not result from a breach of the foregoing restrictions, if the Standard BioTools Board determines in good faith after consultation with its outside legal and financial advisors that such competing acquisition proposal constitutes a Parent Superior Proposal (as defined in the Merger Agreement) or could reasonably be expected to result in a Parent Superior Proposal and that the failure to take such actions would reasonably be expected to be inconsistent with the Standard BioTools Board&#8217;s fiduciary duties. Standard BioTools is required to notify Treeline of certain competing acquisition proposals, provide copies of written documentation related to such competing acquisition proposals and give Treeline a customary match period before effecting a change in the Standard BioTools Board recommendation in favor of the Transactions. </font></div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">7<br></div></div></div>
<!--End Page 18-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 19-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_107-qa_pg8"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">What are the material U.S. federal income tax considerations with respect to the Merger to holders of Standard BioTools Common Stock? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;"><font style="font-weight: normal;">Standard BioTools stockholders will not sell, exchange or dispose of any shares of Standard BioTools Common Stock as a result of the Merger, so the Merger should not result in recognition of gain or loss by the Standard BioTools stockholders for U.S. federal income tax purposes in respect of their Standard BioTools Common Stock. </font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">What are the material U.S. federal income tax considerations with respect to the issuance of the CVRs, including any distributions of Standard BioTools Common Stock under the CVRs? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;"><font style="font-weight: normal;">Although the U.S. federal income tax treatment of the CVRs is uncertain and the matter is not free from doubt, Standard BioTools intends to treat (i) a holder&#8217;s receipt of the CVRs as a non-taxable distribution of a right to acquire stock with respect to the holder&#8217;s existing shares of Standard BioTools Common Stock governed by Section&#160;305 of the United States Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;) and (ii) a holder&#8217;s receipt of Standard BioTools Common Stock in respect of the CVRs as a non-taxable exercise of the right to receive stock under the CVRs for U.S. federal income tax purposes. This position may be challenged by the Internal Revenue Service (&#8220;IRS&#8221;), in which case it is possible that holders of Standard BioTools Common Stock could be required to recognize taxable income in respect of the receipt of the CVRs or the receipt of Standard BioTools Common Stock under the CVRs, in each case, without a corresponding receipt of cash. It is also possible that the distribution of the right to acquire stock could be taxable as a constructive distribution, as discussed below. Please review the information in the section titled &#8220;</font><font style="font-style: italic; font-weight: normal;">The Merger &#8212; CVR Agreement</font><font style="font-weight: normal;">&#8221; for a discussion of the material U.S. federal income tax consequences of the CVRs to holders of Standard BioTools Common Stock. </font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">What are the material U.S. federal income tax considerations with respect to the reverse stock split to holders of Standard BioTools Common Stock? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;"><font style="font-weight: normal;">A holder of Standard BioTools Common Stock should not recognize gain or loss upon the reverse stock split, except to the extent such holder receives cash in lieu of a fractional share of Standard BioTools Common Stock, and subject to the discussion in the section titled &#8220;</font><font style="font-style: italic; font-weight: normal;">Standard BioTools Proposals &#8212; Proposal #2: The Charter Amendment Proposal</font><font style="font-weight: normal;">.&#8221; Please review the information in the section titled &#8220;</font><font style="font-style: italic; font-weight: normal;">Standard BioTools Proposals &#8212; Proposal #2: The Charter Amendment Proposal &#8212; Material U.S. Federal Income Tax Considerations with Respect to the Reverse Stock Split</font><font style="font-weight: normal;">&#8221; for a more complete description of the material U.S.&#160;federal income tax considerations with respect to the reverse stock split to holders of Standard BioTools Common Stock. </font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">When and where is the Special Meeting? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;"><font style="font-weight: normal;">The Special Meeting will be held on &#8195;&#8195;&#8195;, at &#8195;&#8195;&#8195; unless postponed or adjourned to a later date. The Special Meeting will be held entirely online at www.virtualshareholdermeeting.com/LAB2026SM, where you will be able to listen to the meeting live, submit questions and vote online. </font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">What do I need to do now? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;"><font style="font-weight: normal;">After you have carefully read this proxy statement/prospectus and have decided how you wish to vote your shares, please vote your shares promptly so that your shares are represented and voted at the Special Meeting, as applicable, even if you plan on attending. If you hold your shares in your name as a stockholder of record, you must complete, sign and mail your proxy card in the enclosed postage-paid return envelope as soon as possible or submit a proxy to vote by Internet or phone, following the instructions on your proxy card. If you hold your shares in &#8220;street name&#8221; through a bank, broker or other nominee, you must direct that organization how to vote in accordance with the instructions you have received from it. If you hold your shares of Standard BioTools&#8217; capital stock in &#8220;street name&#8221; through a bank, broker or other nominee and you do not instruct your bank, broker or other nominee on how to vote your shares, your bank, broker or other nominee will not be permitted to vote your shares on any of the Proposals. </font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">What constitutes a quorum for the Special Meeting? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;"><font style="font-weight: normal;">A quorum will be present at the Special Meeting if the holders of a majority in voting power of the shares of Standard BioTools&#8217; capital stock issued and outstanding and entitled to vote as of the close of business on &#8195;&#8195;&#8195; , which is the record date of the Special Meeting (the &#8220;Record Date&#8221;), are present virtually at the </font></div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">8<br></div></div></div>
<!--End Page 19-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 20-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_107-qa_pg9"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: left;">Special Meeting or represented by proxy. As of the close of business on the Record Date, there were &#8195;&#8195;&#8195; shares of Standard BioTools Common Stock issued and outstanding and entitled to vote. This means that at least &#8195;&#8195;&#8195; shares of Standard BioTools Common Stock must be represented by stockholders present virtually at the Special Meeting or represented by proxy to have a quorum. Your shares will be counted towards the quorum if you submit a valid proxy or attend the Special Meeting. Abstentions, if any, will be included in determining the number of shares present at the meeting for the purpose of determining the presence of a quorum. A failure to instruct your bank, broker or other nominee will result in your shares not being included in the calculation of the number of shares of Standard BioTools Common Stock represented at the Special Meeting for purposes of determining whether a quorum has been achieved. However, your shares of Standard BioTools Common Stock will be counted toward determining whether a quorum is present if you instruct your bank, broker or other nominee on how to vote your shares with respect to one or more of the Proposals. </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">What is the vote required to approve each proposal? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;"><font style="font-weight: normal;">Approval of the Share Issuance Proposal, the Post-Closing Equity Incentive Plan Proposal, the Post-Closing ESPP Proposal, the Advisory Compensation Proposal and the Adjournment Proposal requires the affirmative vote of a majority of the voting power of the shares of Standard BioTools&#8217; capital stock present virtually or represented by proxy at the Special Meeting and entitled to vote on such Proposals. Assuming a quorum is present, if you mark &#8220;</font>ABSTAIN<font style="font-weight: normal;">&#8221; on your proxy card or when voting by Internet or phone with respect to these Proposals, it will have the same effect as a vote &#8220;</font>AGAINST<font style="font-weight: normal;">&#8221; the proposal. If you fail to submit a proxy or fail to vote at the Special Meeting it will have no effect on the outcome of the vote for such Proposals. </font></div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Approval of the Charter Amendment Proposal requires the affirmative vote of the holders of Standard BioTools&#8217; capital stock entitled to vote thereon, voting as a single class, by a majority of the votes cast for or against such Proposal at the Special Meeting. Assuming a quorum is present, if you mark &#8220;<font style="font-weight: bold;">ABSTAIN</font>&#8221; on your proxy card or when submitting a proxy to vote your shares by Internet or phone with respect to the Charter Amendment Proposal, it will have no effect on the outcome of the vote for the proposal. If you fail to submit a proxy or fail to vote at the Special Meeting it will have no effect on the outcome of the vote for the Charter Amendment Proposal. The Standard BioTools Board has approved the Standard BioTools Charter amendment to change the name of Standard BioTools to &#8220;Treeline Biosciences Holdings, Inc.&#8221; and no vote of the Standard BioTools stockholders is required to approve such Standard BioTools Charter amendment under the DGCL. Standard BioTools is voluntarily seeking the approval of Standard BioTools stockholders for such Standard BioTools Charter amendment pursuant to the Merger Agreement. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">If you hold your shares of Standard BioTools&#8217; capital stock in &#8220;street name&#8221; through a bank, broker or other nominee and you do not instruct your bank, broker or other nominee on how to vote your shares, your bank, broker or other nominee will not be permitted to vote your shares on any of the Proposals, which will have no effect on the outcome of the vote for the Proposals. </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">How does the Standard BioTools Board recommend that I vote at the Special Meeting? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;"><font style="font-weight: normal;">The Standard BioTools Board recommends that Standard BioTools stockholders vote &#8220;</font>FOR<font style="font-weight: normal;">&#8221; the Share Issuance Proposal, &#8220;</font>FOR<font style="font-weight: normal;">&#8221; the Charter Amendment Proposal, &#8220;</font>FOR<font style="font-weight: normal;">&#8221; the Post-Closing Equity Incentive Plan Proposal, &#8220;</font>FOR<font style="font-weight: normal;">&#8221; the Post-Closing ESPP Proposal, &#8220;</font>FOR<font style="font-weight: normal;">&#8221; the Advisory Compensation Proposal and &#8220;</font>FOR<font style="font-weight: normal;">&#8221; the Adjournment Proposal. </font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">How does the Special Committee recommend that I vote at the Special Meeting? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;"><font style="font-weight: normal;">The Special Committee has recommended to the Board that the Board recommend that Standard BioTools stockholders vote &#8220;</font>FOR<font style="font-weight: normal;">&#8221; the Share Issuance Proposal and &#8220;</font>FOR<font style="font-weight: normal;">&#8221; the Charter Amendment Proposal. </font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">As a Standard BioTools stockholder, why is my vote important? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;"><font style="font-weight: normal;">The Merger cannot be completed unless Standard BioTools stockholders approve the Share Issuance Proposal and the Charter Amendment Proposal. Your vote is important no matter how many shares you own. Please take the time to vote. Take a moment to read the instructions below. Choose the way to vote that is easiest and most convenient for you and cast your vote as soon as possible. Any abstention will have the same effect as a vote &#8220;AGAINST&#8221; the Share Issuance Proposal, the Post-Closing Equity Incentive Plan Proposal, the Post-Closing ESPP Proposal, the Advisory Compensation Proposal and the Adjournment Proposal (but will have no effect on </font></div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">9<br></div></div></div>
<!--End Page 20-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 21-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_107-qa_pg10"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: left;">the outcome of the vote for the Charter Amendment Proposal). If you hold your shares of Standard BioTools&#8217; capital stock in &#8220;street name&#8221; through a bank, broker or other nominee, failure to instruct your bank, broker or other nominee on how to vote your shares will have no effect on the outcome of the vote for any of the Proposals. </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Who can vote at the Special Meeting? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;"><font style="font-weight: normal;">Holders of outstanding shares of Standard BioTools Common Stock as of the close of business on the Record Date are eligible to vote at the Special Meeting. </font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Am I a Standard BioTools stockholder of record or a beneficial owner? Why does this matter? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;"><font style="font-weight: normal;">If, on the Record Date, your shares were registered directly in your name with Standard BioTools&#8217; transfer agent, Computershare Trust Company, N.A., then you are a stockholder of record with respect to those shares. </font></div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">If, on the Record Date, your shares were held in an account at a bank, broker or other nominee, then you are the beneficial owner of shares held in &#8220;street name&#8221; and these proxy materials are being forwarded to you by that organization. The organization holding your account is considered the stockholder of record for purposes of voting at the Special Meeting. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-align: left;">The form in which you own your shares affects how you vote your shares and how you can change your vote. </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">How do I attend the Special Meeting and how can I vote my shares? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;"><font style="font-weight: normal;">We are conducting a virtual special meeting so our stockholders can participate from any geographic location with Internet connectivity. We have designed the format of the virtual online special meeting to provide stockholders the same ability to participate that they would have at an in-person meeting. </font></div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">To attend the Special Meeting, you must go to the meeting website at www.virtualshareholdermeeting.com/LAB2026SM and enter the 16-digit control number found on your proxy card or voting instruction card sent to you by your bank, broker or other nominee. Once admitted, during the Special Meeting, you may vote and submit questions by following the instructions available on the meeting website. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Access to the meeting platform will begin at &#8195;&#8195;&#8195; on &#8195;&#8195;&#8195;. If you encounter any difficulties accessing the virtual meeting during check-in or during the meeting, please call the technical support number that will be posted on the meeting website login page at www.virtualshareholdermeeting.com/LAB2026SM. Technical support will be available beginning at &#8195;&#8195;&#8195; on &#8195;&#8195;&#8195; and will remain available until the meeting has ended. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Rules for the conduct of the Special Meeting will be available on the applicable meeting website. To obtain a copy of the rules of conduct for the Special Meeting in advance of the Special Meeting, please submit an email to ir@standardbio.com. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Regardless of whether you plan to participate in the Special Meeting, it is important that your shares be represented and voted at the Special Meeting. Accordingly, we encourage you to vote in advance of the Special Meeting. </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">How can I vote my shares of Standard BioTools? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;"><font style="font-weight: normal;">For each proposal, you may vote &#8220;</font>FOR<font style="font-weight: normal;">&#8221; or &#8220;</font>AGAINST<font style="font-weight: normal;">&#8221; each proposal, or &#8220;</font>ABSTAIN<font style="font-weight: normal;">&#8221; from voting on such proposal. </font></div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">If you are the &#8220;record holder&#8221; of your shares, meaning that you own your shares in your own name and not through a bank or brokerage firm, you may submit a proxy to vote in one of four ways: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-style: italic; font-weight: bold;">You may submit a proxy to vote over the Internet.</font> If you have Internet access, you may submit a proxy to vote your shares at &#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195; by following the instructions on that site or on the &#8220;Vote by Internet&#8221; instructions on the enclosed proxy card. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-style: italic; font-weight: bold;">You may vote by telephone.</font> You may submit a proxy to vote your shares by calling &#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195; and following the instructions provided or following the &#8220;Vote by Phone&#8221; instructions on the enclosed proxy card. </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">10<br></div></div></div>
<!--End Page 21-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 22-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_107-qa_pg11"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-style: italic; font-weight: bold;">You may submit a proxy to vote by mail.</font> You may submit a proxy to vote by completing and signing the proxy card enclosed with this proxy&#160;statement/prospectus and promptly mailing it in the enclosed postage-prepaid envelope. You do not need to put a stamp on the enclosed envelope if you mail it from the United States. The shares you own will be voted according to your completed proxy card. If you are a holder of record and you sign and return the proxy card, but do not give any instructions on a particular matter described in this proxy statement/prospectus, the shares of Standard BioTools Common Stock you own will be voted in accordance with the recommendations of the Standard BioTools Board. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-style: italic; font-weight: bold;">You may vote online during the Special Meeting.</font> To attend the meeting virtually, you must go to the meeting website at www.virtualshareholdermeeting.com/LAB2026SM. Once admitted, during the Special Meeting, you may vote by following the instructions available on the meeting website. </div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The deadline for receipt of a completed proxy card returned by mail at the address stated on the proxy card for the Special Meeting is &#8195;&#8195;&#8195; on &#8195;&#8195;&#8195;. The deadline for submitting a proxy to vote via the Internet or by telephone is on &#8195;&#8195;&#8195;. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">If you are a beneficial owner, you may vote your shares by directing the bank, broker or other nominee on how to vote the shares in your account. Please refer to the voting instructions provided by your bank, broker or other nominee. Many organizations allow beneficial owners to give voting instructions via telephone or the Internet, as well as in writing. If you are a beneficial owner and would like to vote your shares at the Special Meeting, please contact your bank, broker or other nominee for instructions and documents that may be required in order to do so. </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">What if I return a Standard BioTools proxy card but do not make specific choices? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;"><font style="font-weight: normal;">You will only receive a proxy card if you are the record holder of your shares of Standard BioTools Common Stock. If you are a record holder and return a signed proxy card without marking any voting selections, your shares will be voted &#8220;</font>FOR<font style="font-weight: normal;">&#8221; the Share Issuance Proposal, &#8220;</font>FOR<font style="font-weight: normal;">&#8221; the Charter Amendment Proposal, &#8220;</font>FOR<font style="font-weight: normal;">&#8221; the Post-Closing Equity Incentive Plan Proposal, &#8220;</font>FOR<font style="font-weight: normal;">&#8221; the Post-Closing ESPP Proposal, &#8220;</font>FOR<font style="font-weight: normal;">&#8221; the Advisory Compensation Proposal and &#8220;</font>FOR<font style="font-weight: normal;">&#8221; the Adjournment Proposal in accordance with the recommendation of the Standard BioTools Board. If any other matter is properly presented at the meeting, your proxy (one of the individuals named on your proxy card) will vote your shares using his or her best judgment. </font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">If my shares of Standard BioTools are held in &#8220;street name&#8221; by my bank, broker or other nominee, will my bank, broker or other nominee automatically vote my shares for me? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;"><font style="font-weight: normal;">No. If the shares you own are held in the name of a bank, broker or other nominee, also known as &#8220;street name,&#8221; such bank, broker or other nominee, as the record holder of your shares, is required to vote your shares according to your instructions. In order to vote your shares held in &#8220;street name,&#8221; you will need to follow the directions your bank, broker or other nominee provides you. Many banks, brokers or nominees also offer the option of voting over the Internet or by telephone, instructions for which would be provided by your bank, broker or nominee on your voting instruction card. </font></div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Under applicable stock exchange rules, banks, brokers and other nominees may use their discretion to vote &#8220;uninstructed&#8221; shares (i.e., shares of record held by banks, brokers or other nominees, but with respect to which the beneficial owner of such shares has not provided instructions on how to vote on a particular proposal) with respect to matters that are considered to be &#8220;discretionary.&#8221; Your bank, broker or other nominee will not be allowed to vote your shares with respect to &#8220;non-discretionary&#8221; items. A &#8220;broker non-vote&#8221; occurs when shares held by a bank, broker or other nominee in &#8220;street name&#8221; for a beneficial owner are voted on at least one proposal but not voted with respect to a particular proposal because that organization (i) has not received voting instructions from the beneficial owner for that proposal and (ii) lacks discretionary voting power to vote those shares for that proposal. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The Share Issuance Proposal, the Charter Amendment Proposal, the Post-Closing Equity Incentive Plan Proposal, the Post-Closing ESPP Proposal, the Advisory Compensation Proposal and the Adjournment Proposal are each expected to be treated as non-discretionary items. Therefore, your bank, broker or other nominee </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">11<br></div></div></div>
<!--End Page 22-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 23-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_107-qa_pg12"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: left;">cannot vote your shares of Standard BioTools without your specific voting instructions. Because the only proposals for consideration at the Special Meeting are non-discretionary proposals, it is not expected that there will be any broker non-votes at the Special Meeting. However, if there are any broker non-votes, they will have no effect on the outcome of the vote for the Proposals. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">If you hold your shares of Standard BioTools&#8217; capital stock in &#8220;street name&#8221; through a bank, broker or other nominee and you do not instruct your bank, broker or other nominee on how to vote your shares, your bank, broker or other nominee will not be permitted to vote your shares on any of the Proposals, which will have no effect on the outcome of the vote for the Proposals. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">If you are a beneficial owner and would like to vote your shares at the Special Meeting, please contact your bank, broker or other nominee for instructions and documents that may be required in order to do so. </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Can I change my vote? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;"><font style="font-weight: normal;">Yes. If you are a record holder of shares of Standard BioTools Common Stock, you can revoke your proxy and change your vote at any time before the final vote at the Special Meeting. To do so, you must do one of the following: </font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">You may return by mail another properly completed proxy card with a later date, which must be received at the address stated on the proxy card no later than &#8195;&#8195;&#8195; on &#8195;&#8195;&#8195;; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">You may submit another properly completed proxy with a later date via the Internet or by telephone before the closing of those voting facilities at &#8195;&#8195;&#8195; on &#8195;&#8195;&#8195;; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">You may attend the virtual online Special Meeting and vote at the meeting (but simply attending the virtual online meeting will not, by itself, revoke your proxy); or </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">You may send a written notice that you are revoking your proxy to Standard BioTools&#8217; Corporate Secretary at Standard BioTools Inc., 50 Milk Street, 10th Floor, Boston, MA 02109, Attn: Corporate Secretary. </div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-align: left;">A revocation or later-dated proxy received by Standard BioTools after the vote will not affect the vote. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">If you are a beneficial holder (and hold your shares in &#8220;street name&#8221; through a bank, broker or other nominee), you should contact that organization to revoke your proxy or change your vote in accordance with its instructions. </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">What happens if I fail to submit a proxy or I abstain from voting? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;"><font style="font-weight: normal;">If you are a holder of record and you fail to submit a proxy, or if you are a beneficial owner and fail to instruct your bank, broker or other nominee to vote, it will have no effect on the outcome of the vote for any of the Proposals. </font></div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">An abstention occurs when a Standard BioTools stockholder returns a proxy with an &#8220;<font style="font-weight: bold;">ABSTAIN</font>&#8221; instruction or virtually attends the Special Meeting and abstains from voting. Abstentions will count toward the establishment of a quorum. Abstentions (i)&#160;will have the same effect as a vote &#8220;<font style="font-weight: bold;">AGAINST</font>&#8221; the Proposals (other than the Charter Amendment Proposal) and (ii)&#160;will have no effect on the outcome of the vote for the Charter Amendment Proposal. </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Who will solicit and pay the cost of soliciting proxies? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;"><font style="font-weight: normal;">Standard BioTools has engaged &#8195;&#8195;&#8195; to assist in the solicitation of proxies for the Special Meeting. Standard BioTools estimates that it will pay &#8195;&#8195;&#8195; a fee of approximately $&#8195;&#8195;&#8195;, plus reimbursement of reasonable expenses. Standard BioTools has agreed to indemnify &#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195; against various liabilities and expenses that relate to or arise out of its solicitation of proxies (subject to certain exceptions). </font></div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Standard BioTools and Treeline will share equally the cost of printing and filing of this proxy statement/prospectus and the proxy card. Arrangements will also be made with brokerage firms and other custodians, nominees and fiduciaries who are record holders of Standard BioTools Common Stock for the forwarding of solicitation materials to the beneficial owners of Standard BioTools Common Stock. Standard BioTools will reimburse these brokers, custodians, nominees and fiduciaries for the reasonable out-of-pocket expenses they incur in connection with the forwarding of solicitation materials. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">12<br></div></div></div>
<!--End Page 23-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 24-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_107-qa_pg13"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Who counts the votes? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;"><font style="font-weight: normal;">&#8195;&#8195;&#8195; has been engaged as Standard BioTools&#8217; independent agent to tabulate stockholder votes. If you are a stockholder of record, your executed proxy card will be returned directly to &#8195;&#8195;&#8195; for tabulation. If you hold your shares through a broker, your broker will return one proxy card to &#8195;&#8195;&#8195; on behalf of all of its clients. </font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">If I am not in favor of the Merger, what are my rights? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;"><font style="font-weight: normal;">Standard BioTools stockholders are not entitled to appraisal rights under the DGCL in connection with the Merger or the other Transactions. If you are not in favor of the Merger, you may vote against the Share Issuance Proposal, the Charter Amendment Proposal, the Post-Closing Equity Incentive Plan Proposal, the Post-Closing ESPP Proposal and the Advisory Compensation Proposal. The approval by Standard BioTools stockholders of the Share Issuance Proposal and the Charter Amendment Proposal is a condition to the consummation of the Merger and the other Transactions. If the Share Issuance Proposal and the Charter Amendment Proposal are not approved, the Merger and the other Transactions will not be consummated. Information about how Standard BioTools stockholders may vote on the proposals being considered in connection with the Merger can be found under the section entitled &#8220;</font><font style="font-style: italic; font-weight: normal;">The Special Meeting</font><font style="font-weight: normal;">&#8221; beginning on page <a href="#tSPE">105</a> of this proxy statement/prospectus. </font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">What should I do if I receive more than one set of voting materials? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;"><font style="font-weight: normal;">Standard BioTools stockholders may receive more than one set of voting materials, including multiple copies of this proxy statement/prospectus and multiple proxy cards. For example, if you hold shares of Standard BioTools Common Stock in more than one brokerage account, you will receive a separate voting instruction card for each brokerage account in which you hold such shares. If you are a holder of record of Standard BioTools Common Stock and your shares are registered in more than one name, you will receive more than one proxy card. Please complete, sign, date and return each proxy card and voting instruction card that you receive or otherwise follow the voting instructions set forth in this proxy statement/prospectus to ensure that you vote every share of Standard BioTools Common Stock that you own. </font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Where can I find the voting results of the Special Meeting? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;"><font style="font-weight: normal;">The preliminary voting results will be announced at the Special Meeting. In addition, within four business days following the Special Meeting, Standard BioTools will disclose the preliminary or, if available, final voting results of the Special Meeting on a Current Report on Form&#160;8-K filed with the SEC. If preliminary voting results are disclosed, Standard BioTools will file an amended Current Report on Form&#160;8-K with the SEC to disclose final voting results within four business days following certification of the final voting results. </font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">How will I know when the other conditions to completion of the Merger have been satisfied or waived? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;"><font style="font-weight: normal;">As of the date of this proxy statement/prospectus, the parties have not satisfied the closing conditions to the Merger. If the closing conditions are satisfied or waived (to the extent permitted by applicable law), Standard BioTools will announce the Closing via the filing of a Current Report on Form&#160;8-K with the SEC. There is also a possibility that the closing conditions to the Merger will not be satisfied or waived prior to the outside date of March&#160;31, 2027, after which date either party may elect to terminate the Merger Agreement. As a result, it is possible that factors outside the control of both companies could result in the Merger being completed at a different time or not at all. </font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Are there any risks that I should consider in deciding whether to vote for the adoption of the Proposals? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;"><font style="font-weight: normal;">Yes. You should read and carefully consider the risk factors set forth in the &#8220;</font><font style="font-style: italic; font-weight: normal;">Risk Factors</font><font style="font-weight: normal;">&#8221; section of this proxy statement/prospectus beginning on page <a href="#tRF">33</a>. </font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Who can answer any questions I may have about the Merger or the transactions contemplated by the Merger Agreement? </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">A:<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;"><font style="font-weight: normal;">If you have any questions about the Merger or the transactions contemplated by the Merger Agreement, or if you need additional copies of this proxy statement/prospectus, you should contact: </font></div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">13<br></div></div></div>
<!--End Page 24-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 25-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 492pt;"><a name="ny20077604x1_s4_108-summary_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="BRDSX_page-content" style="margin-left: 12pt;"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tPOS"><!--Anchor--></a>PROSPECTUS SUMMARY </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This summary highlights selected information from this proxy statement/prospectus and may not contain all of the information that is important to you. To better understand the Merger and the proposals being considered at the Special Meeting, you should read this entire proxy statement/prospectus carefully, including the Merger Agreement and the other annexes to which you are referred in this proxy statement/prospectus. For more information, please see the section entitled &#8220;Where You Can Find More Information&#8221; beginning on page <a href="#tWYC">335</a> of this proxy statement/prospectus. Except where specifically noted, the following information and all other information contained in the proxy statement/prospectus does not give effect to any reverse stock split that may be effected prior to or concurrently with the Closing.<font style="font-style: normal;"> </font></div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Overview of the Companies </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Standard BioTools Inc.</div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">50 Milk Street, 10th Floor <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Boston, MA 02109<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Telephone: (650) 266-6000 </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Standard BioTools Inc. (&#8220;Standard BioTools&#8221;) is committed to setting the new standard in the life science tools industry through strategic consolidation, best-in-class operations and a world-class management team. Standard BioTools&#8217; established portfolio includes essential, standardized next-generation solutions designed to help biomedical researchers develop better therapeutics faster. Standard BioTools offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. With advanced technologies in proteomics and genomics, Standard BioTools empowers scientists to gain deeper biological insights, accelerate discoveries, and drive improved health outcomes across diverse therapeutic areas including immunology, oncology, neuroscience, cardiometabolic diseases and more. Standard BioTools Common Stock is listed on The Nasdaq Global Select Market under the symbol &#8220;LAB.&#8221; </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Treeline Biosciences, Inc. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">500 Arsenal Street <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Watertown, MA 02472 <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Telephone: (857) 228-0050 </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline Biosciences, Inc. (&#8220;Treeline&#8221;) is a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and other serious diseases. Treeline&#8217;s approach is built on a differentiated, repeatable discovery platform that identifies compelling molecular targets and matches them with the most appropriate drug modality. Treeline seeks to prove it can pick good targets, nominate highly-vetted development candidates, and make thoughtful development decisions across a diverse and ambitious pipeline, with the goal of redefining the treatment of serious diseases. Treeline wants its platform story to be repeatability. Treeline currently has three Phase&#160;1 programs, TLN-121, TLN-254, and TLN-372, and a fourth program, TLN-499, nearing clinical entry, all in oncology. Treeline&#8217;s preclinical pipeline includes programs in neurology and immunology, in addition to oncology. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">Siri Merger Sub, Inc. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">50 Milk Street, 10th Floor <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Boston, MA 02109<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Telephone: (650) 266-6000 </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Siri Merger Sub, Inc.&#160;(&#8220;Merger Sub&#8221;) is a direct, wholly owned subsidiary of Standard BioTools. Merger Sub was incorporated in the State of Delaware on May&#160;27, 2026, solely for the purpose of carrying out the Merger. Merger Sub has not carried on any activities to date, except for activities incidental to its formation and activities undertaken in connection with the Merger. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">The Merger (see page <a href="#tMER">135</a>) </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On June&#160;6, 2026, Standard BioTools entered into the Merger Agreement with Treeline and Merger Sub, pursuant to which Standard BioTools and Treeline will combine in an all-stock merger upon the terms and conditions set forth in the Merger Agreement. In accordance with the Merger Agreement, Merger Sub will merge </div></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">14<br></div></div></div>
<!--End Page 25-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 26-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 492pt;"><a name="ny20077604x1_s4_108-summary_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="BRDSX_page-content" style="margin-left: 12pt;"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">with and into Treeline, with Treeline surviving as a wholly owned subsidiary of Standard BioTools (the &#8220;Merger&#8221; and, together with the other transactions contemplated by the Merger Agreement, the &#8220;Transactions&#8221;), and at the effective time of the Merger (the &#8220;Effective Time&#8221;), Standard BioTools will file an amendment to its certificate of incorporation (the &#8220;Charter Amendment&#8221;) to (i) change its name to Treeline Biosciences Holdings, Inc. and (ii)&#160;effect a reverse stock split (the &#8220;Reverse Stock Split&#8221;) of all outstanding shares of common stock, par value $0.001 per share, of Standard BioTools (the &#8220;Standard BioTools Common Stock&#8221;), if the Reverse Stock Split has not been effected prior to the Effective Time as permitted by the Merger Agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As a result of the Merger, each share of Treeline Common Stock issued and outstanding immediately prior to the Effective Time and each share of Treeline Preferred Stock issued and outstanding immediately prior to the Effective Time (in each case, other than shares held in treasury and dissenting shares) will be converted into the right to receive a number of shares of Standard BioTools Common Stock based on an exchange ratio calculated in accordance with the Merger Agreement (described in more detail in the section titled &#8220;<font style="font-style: italic;">The Merger Agreement &#8212; Exchange Ratio</font>&#8221; beginning on page <a href="#tEXR">202</a> of this proxy statement/prospectus) (the &#8220;Exchange Ratio&#8221;), with the number of shares of Standard BioTools Common Stock that each holder of Treeline Capital Stock is entitled to receive being rounded down to the nearest whole share and computed after aggregating all shares of Treeline Capital Stock held by such holder. The Exchange Ratio is based on the relative capitalization of each of Treeline and Standard BioTools and assumes (i) an equity value for Treeline of $2.5&#160;billion and (ii) an equity value for Standard BioTools equal to $460&#160;million, reduced by the amount by which the Parent Net Cash (as defined in the Merger Agreement) is less than $449&#160;million at the closing of the Merger (the &#8220;Closing&#8221;) or increased by the amount by which Parent Net Cash is more than $451&#160;million at the Closing. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Following the Closing, former Standard BioTools stockholders are expected to hold approximately 16% of the combined company on a fully diluted basis, and former Treeline stockholders are expected to hold approximately 84% of the combined company on a fully diluted basis. Under certain circumstances further described in the Merger Agreement, the pro forma ownership percentages may be adjusted based on the amount of Parent Net Cash at Closing as finally determined in accordance with the Merger Agreement (described in more detail in the sections titled &#8220;<font style="font-style: italic;">The Merger Agreement &#8212; Exchange Ratio</font>&#8221; and &#8220;<font style="font-style: italic;">The Merger Agreement &#8212; Calculation of Parent Net Cash</font>&#8221; beginning on pages <a href="#tEXR">202</a> and <a href="#tCOPN">203</a>, respectively, of this proxy statement/prospectus). Based on Standard BioTools&#8217; and Treeline&#8217;s capitalization as of June&#160;3, 2026 and May&#160;28, 2026, respectively, and taking into account Standard BioTools&#8217; estimate of Parent Net Cash as of the Closing, and before giving effect to the proposed Reverse Stock Split, each share of Treeline Capital Stock is currently estimated to be entitled to receive approximately 11.6997&#160;shares of Standard BioTools Common Stock. This ratio may increase or decrease as of the Closing based on the companies&#8217; respective actual capitalizations as of the Closing and the actual amount of Parent Net Cash as of the Closing. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, as of the Effective Time, Standard BioTools will assume Treeline&#8217;s 2021 Equity Incentive Plan and each outstanding option to purchase shares of Treeline Common Stock (each, a &#8220;Treeline Option&#8221;), whether vested or unvested. Each such Treeline Option so assumed by Standard BioTools will continue to have, and be subject to, the same terms and conditions applicable to such Treeline Option immediately prior to the Effective Time, except that (i) such Treeline Option will be exercisable for that number of shares of Standard BioTools Common Stock equal to the number of shares of Treeline Common Stock subject to such Treeline Option immediately prior to the Effective Time multiplied by the Exchange Ratio and rounded down to the next nearest share of Standard BioTools Common Stock, and (ii) the exercise price per share of each such Treeline Option will be the exercise price per share in effect for that Treeline Option immediately prior to the Effective Time divided by the Exchange Ratio and rounded up to the next nearest cent. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, as of the Effective Time, (i) each warrant to purchase shares of Treeline Capital Stock (each, a &#8220;Treeline Warrant&#8221;) that has been amended to require net-exercise in connection with the Merger (the &#8220;Treeline Converting Warrants&#8221;) and that is outstanding immediately prior to the Effective Time will, by virtue of the Merger, be cancelled and extinguished and converted into the right to receive, for each share of Treeline Common Stock that would be received upon the net-exercise of such Treeline Converting Warrant in accordance with its terms, a number of shares of Standard BioTools Common Stock equal to the Exchange Ratio and (ii) each Treeline Warrant that is not a Treeline Converting Warrant and that is outstanding immediately prior to the Effective Time will, by virtue of the Merger, be assumed by Standard BioTools. Each such Treeline Warrant so assumed by Standard BioTools will continue to have, and be subject to, the same terms and conditions applicable to such Treeline Warrant immediately prior to the Effective Time, except that (a) such Treeline Warrant will be exercisable for that number of shares of Standard BioTools Common Stock equal to the number of shares of Treeline Common Stock subject to such </div></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">15<br></div></div></div>
<!--End Page 26-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 27-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 492pt;"><a name="ny20077604x1_s4_108-summary_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="BRDSX_page-content" style="margin-left: 12pt;"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Treeline Warrant immediately prior to the Effective Time multiplied by the Exchange Ratio and rounded down to the next nearest share of Standard BioTools Common Stock and (b) the warrant price per share will be the warrant price per share in effect for such Treeline Warrant immediately prior to the Effective Time divided by the Exchange Ratio and rounded up to the nearest thousandth of a cent. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Merger is intended to qualify as a reorganization within the meaning of Section&#160;368(a) of the United States Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;). For a more complete description of the Merger and the Exchange Ratio, please see the section entitled &#8220;<font style="font-style: italic;">The Merger Agreement</font>&#8221; in this proxy statement/prospectus. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Merger will be completed (i) as soon as reasonably practicable, and in no event later than three business days following the day on which the last to be satisfied or waived of each of the conditions to consummation of the Merger set forth in the Merger Agreement (other than those conditions that by their nature are to be satisfied at the Closing, but subject to the satisfaction or waiver of those conditions) have been satisfied or waived in accordance with the Merger Agreement, including approval by the Standard BioTools stockholders of the issuance of Standard BioTools Common Stock in the Merger (the &#8220;Share Issuance&#8221;) and the Charter Amendment, or (ii) at such other place and time and/or on such other date as Standard BioTools and Treeline may otherwise agree in writing. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Merger is anticipated to close promptly after the Special Meeting scheduled to be held on &#8195;&#8195;&#8195;, 2026. However, Standard BioTools cannot predict the exact timing of the completion of the Merger because it is subject to the satisfaction or waiver (to the extent permitted by applicable law) of various conditions. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Standard BioTools&#8217; Legacy Business </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under the Merger Agreement, Standard BioTools must use its commercially reasonable efforts to effect the sale, license, transfer, disposition, divestiture or other monetization of its mass cytometry and microfluidics businesses (the &#8220;Legacy Business&#8221; and each such transaction, a &#8220;Legacy Transaction&#8221;). If Standard BioTools has not entered into a definitive agreement for the disposition of any portion of the Legacy Business on or before the date the registration statement on Form&#160;S-4 of which this proxy statement/prospectus forms a part is declared effective under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), Standard BioTools is required to commence mutually agreed wind-down activities with respect to that portion of the Legacy Business. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">The Special Committee </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Entities affiliated with Casdin Capital, LLC (&#8220;Casdin Capital&#8221;) currently own approximately 23% of the issued and outstanding Standard BioTools Common Stock, and Eli Casdin, the Founder and Chief Investment Officer of Casdin Capital, is a director of Standard BioTools. Entities affiliated with Casdin Capital are also equity investors in Treeline and currently own approximately 5.28% of Treeline. In light of these positions, the Standard BioTools Board of Directors (the &#8220;Standard BioTools Board&#8221;) formed a special committee as described below to evaluate the Merger and the other Transactions. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Standard BioTools Board established a special committee consisting solely of &#8220;disinterested directors&#8221; (as&#160;defined in Section&#160;144(e)(4) of the Delaware General Corporation Law (the &#8220;DGCL&#8221;)) (the &#8220;Special Committee&#8221;) and delegated to the Special Committee the full power and authority of the Standard BioTools Board, to the maximum extent permitted by applicable law, to (i) explore, consider, evaluate, review, negotiate and approve or reject the Transactions and, if approval of the Standard BioTools Board is required under the DGCL, recommend to the Standard BioTools Board for approval or rejection the Transactions and (ii) determine whether the Transactions are advisable, fair to and in the best interests of Standard BioTools and its stockholders. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Special Committee, consisting of directors Fenel Eloi and Frank Witney, retained (i) UBS Securities LLC (&#8220;UBS&#8221;) to serve as its independent financial advisor and (ii) Freshfields US LLP (&#8220;Freshfields&#8221;) to serve as its legal advisor, in each case to assist the Special Committee in connection with fulfilling and discharging its duties as delegated by the Standard BioTools Board. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Special Committee, with the assistance of its legal and financial advisors, has since its formation, among other things, (i) met regularly to explore, consider, evaluate, review and negotiate the Merger and the other Transactions and the potential terms and conditions thereof and (ii) solicited the views of the Special Committee&#8217;s advisors and members of Standard BioTools management regarding the Merger and the other Transactions, including as to the strategic rationale for, the potential risks and benefits of, and the potential terms and conditions of the Merger and the other Transactions. The Special Committee reviewed financial analysis prepared by UBS and received a fairness opinion from UBS in connection with the Merger and the other Transactions. The Special Committee also reviewed the material terms and conditions of the Merger Agreement and related documents with representatives of Freshfields. </div></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">16<br></div></div></div>
<!--End Page 27-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 28-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 492pt;"><a name="ny20077604x1_s4_108-summary_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="BRDSX_page-content" style="margin-left: 12pt;"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">After due consideration and discussion of the factors that the Special Committee deemed relevant, the Special Committee unanimously (i) determined that the Transactions are advisable, fair to and in the best interests of Standard BioTools and its stockholders, (ii) approved and declared advisable the Merger Agreement and the Transactions and recommended that the Standard BioTools Board approve and declare advisable the Transactions and (iii) recommended that the Standard BioTools Board resolve to recommend the approval of the Share Issuance and the Charter Amendment by Standard BioTools&#8217; stockholders. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Reasons for the Merger (see page <a href="#tSBIO1">163</a>) </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Standard BioTools&#8217; Reasons for the Merger </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">During the course of its evaluation of the Merger Agreement and the Transactions, each of the Special Committee and the Standard BioTools Board held numerous meetings, consulted with Standard BioTools&#8217; management, its legal counsel and financial advisor, reviewed and assessed a significant amount of information and considered the business, assets, liabilities, results of operations, financial performance, capital needs, strategic direction and prospects of each of Standard BioTools and Treeline. In reaching its decision to approve the Merger Agreement and Transactions, the Special Committee, in connection with its determination and recommendation to the Standard BioTools Board, and the Standard BioTools Board, following such recommendation by the Special Committee, considered a number of factors that it viewed as supporting its decision to approve the Merger Agreement and the Transactions. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For a full description of the factors considered by each of the Special Committee and the Standard BioTools Board in reaching its decision to approve the Merger Agreement and the Transactions, see &#8220;<font style="font-style: italic;">The Merger &#8212; Standard BioTools&#8217; Reasons for the Merger</font>&#8221; beginning on page <a href="#tSBIO1">163</a> of this proxy statement/prospectus. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Treeline&#8217;s Reasons for the Merger </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Treeline Board has approved the Merger Agreement and the Transactions. The Treeline Board reviewed several factors in reaching its decision and believes that the Merger Agreement and the Transactions are in the best interests of, and fair to, Treeline and its stockholders. For a full description of the factors considered by the Treeline Board in reaching its decision to approve the Merger Agreement and the Transactions, including the Merger, see &#8220;<font style="font-style: italic;">The Merger &#8212; Treeline&#8217;s Reasons for the Merger</font>&#8221; beginning on page <a href="#tTRE1">168</a> of this proxy statement/prospectus. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Opinion of Standard BioTools&#8217; Financial Advisor (see page <a href="#tOPIS1">171</a>) </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Standard BioTools retained Centerview Partners LLC (&#8220;Centerview&#8221;) as financial advisor to the Standard BioTools Board in connection with the proposed Merger and the other transactions contemplated by the Merger Agreement, which are collectively referred to as the &#8220;Transactions&#8221; throughout this section and the summary of Centerview&#8217;s opinion below under the caption &#8220;<font style="font-style: italic;">The Merger &#8212; Opinion of Standard BioTools&#8217; Financial Advisor</font>.&#8221; In connection with this engagement, the Standard BioTools Board requested that Centerview evaluate the fairness, from a financial point of view, to Standard BioTools of the Exchange Ratio provided for pursuant to the Merger Agreement. On June&#160;5, 2026, Centerview rendered to the Standard BioTools Board its oral opinion, which was subsequently confirmed by delivery of a written opinion dated June&#160;6, 2026 that, as of such date and based upon and subject to the assumptions made, procedures followed, matters considered, and qualifications and limitations upon the review undertaken by Centerview in preparing its opinion, the Exchange Ratio provided for pursuant to the Merger Agreement was fair, from a financial point of view, to Standard BioTools. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The full text of Centerview&#8217;s written opinion, dated June&#160;6, 2026, which describes the assumptions made, procedures followed, matters considered, and qualifications and limitations upon the review undertaken by Centerview in preparing its opinion, is attached as Annex&#160;B and is incorporated herein by reference. <font style="font-weight: bold;">Centerview&#8217;s financial advisory services and opinion were provided for the information and assistance of the Standard BioTools Board (in their capacity as directors and not in any other capacity) in connection with and for purposes of its consideration of the Transactions and Centerview&#8217;s opinion addressed only the fairness, from a financial point of view, as of the date thereof, to Standard BioTools of the Exchange Ratio provided for pursuant to the Merger Agreement. Centerview&#8217;s opinion did not address any other term or aspect of the Merger Agreement or the Transactions and does not constitute a recommendation to any stockholder of Standard BioTools or any other person as to how such stockholder or other person should vote with respect to the Merger or otherwise act with respect to the Transactions or any other matter.</font> </div></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">17<br></div></div></div>
<!--End Page 28-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 29-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 492pt;"><a name="ny20077604x1_s4_108-summary_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="BRDSX_page-content" style="margin-left: 12pt;"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The full text of Centerview&#8217;s written opinion should be read carefully in its entirety for a description of the assumptions made, procedures followed, matters considered, and qualifications and limitations upon the review undertaken by Centerview in preparing its opinion.<font style="font-weight: normal;"> </font></div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">Opinion of Standard BioTools Special Committee&#8217;s Financial Advisor (see page <a href="#tOPISB1">176</a>) </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">UBS Securities LLC (&#8220;UBS&#8221;) was retained by the Special Committee to act as financial advisor in connection with the Transactions. As part of that engagement, the Special Committee requested that UBS render an opinion as to the fairness, from a financial point of view, to Standard BioTools of the Exchange Ratio provided for in the Merger. On June&#160;5, 2026, at a meeting of the Special Committee held to evaluate the Merger Agreement and the transactions contemplated thereby, including the Merger, UBS delivered to the Special Committee an oral opinion, which opinion was confirmed by delivery of a written opinion dated as of June&#160;5, 2026, to the effect that, as of that date and based upon, and subject to, among other things, the assumptions made, procedures followed, matters considered and qualifications and limitations on the review undertaken by UBS in connection with its opinion, the Exchange Ratio provided for in the Merger was fair, from a financial point of view, to Standard BioTools. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The full text of UBS&#8217;s opinion describes the assumptions made, procedures followed, matters considered and qualifications and limitations on the review undertaken by UBS. UBS&#8217;s opinion is attached to this proxy statement/prospectus as Annex&#160;C and is incorporated herein by reference. <font style="font-weight: bold;">UBS&#8217;s opinion was provided for the benefit of the Special Committee in connection with, and for the purpose of, its evaluation of the Exchange Ratio and addresses only the fairness, from a financial point of view, to Standard BioTools of the Exchange Ratio provided for in the Merger. UBS&#8217;s opinion does not address the relative merits of the Transactions as compared to other business strategies or transactions that might be available to Standard BioTools, or Standard BioTools&#8217; underlying business decision to effect the Transactions. UBS&#8217;s opinion does not constitute a recommendation to any stockholder as to how such stockholder should vote or act with respect to the Transactions. Holders of Standard BioTools Common Stock are encouraged to read UBS&#8217;s opinion carefully and in its entirety.</font> </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">Recommendation of the Standard BioTools Board </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">After consultation with Standard BioTools management and its financial and legal advisors, and consideration of the recommendation of the Special Committee, the Standard BioTools Board (i) determined that the Transactions are advisable, fair to and in the best interests of Standard BioTools and its stockholders, (ii) approved and declared advisable the Merger Agreement and the Transactions and (iii) resolved to recommend the approval of the Share Issuance and the Charter Amendment by Standard BioTools&#8217; stockholders. In addition, after consultation with Standard BioTools management and its financial and legal advisors, the Standard BioTools Board resolved to recommend the approval of the Post-Closing Equity Incentive Plan, the Post-Closing ESPP, on a nonbinding, advisory basis, the Merger-Related Compensation by Standard BioTools&#8217; stockholders and the adjournment of the Special Meeting, if necessary or appropriate to solicit additional proxies. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Accordingly, the Standard BioTools Board recommends by vote of all participating directors that Standard BioTools stockholders vote &#8220;<font style="font-weight: bold;">FOR</font>&#8221; the Share Issuance Proposal, &#8220;<font style="font-weight: bold;">FOR</font>&#8221; the Charter Amendment Proposal, &#8220;<font style="font-weight: bold;">FOR</font>&#8221; the Post-Closing Equity Incentive Plan Proposal, &#8220;<font style="font-weight: bold;">FOR</font>&#8221; the Post-Closing ESPP Proposal, &#8220;<font style="font-weight: bold;">FOR</font>&#8221; the Advisory Compensation Proposal and &#8220;<font style="font-weight: bold;">FOR</font>&#8221; the Adjournment Proposal. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">Interests of Certain Directors, Officers and Affiliates of Standard BioTools and Treeline (see page <a href="#tIOSB">185</a>) </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Interests of Standard BioTools Directors and Executive Officers in the Merger </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In considering the recommendation of the Standard BioTools Board with respect to issuing shares of Standard BioTools Common Stock pursuant to the Merger Agreement and the other matters to be acted upon by Standard BioTools stockholders at the Special Meeting, Standard BioTools stockholders should be aware that certain members of the Standard BioTools Board and executive officers of Standard BioTools have interests in the Merger that may be different from, or in addition to, interests they have as Standard BioTools stockholders. Interests of the directors and executive officers of Standard BioTools may be different from, or in addition to, the interests of the Standard BioTools stockholders for the following reasons, among others: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">&#8195;&#8195;&#8195; and &#8195;&#8195;&#8195;, members of the Standard BioTools Board, will continue as directors of the combined company after the Merger and will be eligible to be compensated as directors of the combined company following the Closing in accordance with the combined company&#8217;s outside director compensation policy. </div></td></tr></table></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">18<br></div></div></div>
<!--End Page 29-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 30-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 492pt;"><a name="ny20077604x1_s4_108-summary_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="BRDSX_page-content" style="margin-left: 12pt;"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">All outstanding equity awards issued by Standard BioTools and held by non-employee directors of Standard BioTools will become fully vested at Closing and it is anticipated that the cash retainers payable to such directors for the calendar quarter in which the Closing occurs will be paid without proration. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Affiliates of Casdin Capital, LLC own approximately 5.28% of Treeline and will receive a pro rata portion of the Merger consideration. Eli Casdin, a director of Standard BioTools, is the Founder and Chief Investment Officer of Casdin Capital, LLC. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The Standard BioTools CIC Severance Plans (as defined below) provide that, in the event of a termination of employment without cause (as defined in the CIC Severance Plans) or an executive officer&#8217;s resignation for good reason (as defined in the CIC Severance Plans), in each case, during the period beginning three months before and ending 12 months after a change of control of Standard BioTools, the executive officers of Standard BioTools are entitled to severance benefits, which include, among other things, a lump sum payment of cash severance and pro-rated annual target bonus and accelerated vesting of any outstanding and unvested equity awards held by the executive officer. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Stock options to purchase shares of Standard BioTools Common Stock (the &#8220;Standard BioTools Options&#8221;) that were granted to Standard BioTools executive officers between 2024 and 2026 will be amended to extend the post-employment exercise period to a date that is 30 months following the executive&#8217;s separation date. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Treeline and Sean Mackay, Standard BioTools&#8217; Chief Business Officer, have commenced discussions regarding a possible transition consulting arrangement pursuant to which, following the Closing, Mr.&#160;Mackay would provide transition consulting services to the combined company for a period of approximately six months. The terms of any such arrangement have not been finalized and there is no assurance that such an agreement will be entered into. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Under the Merger Agreement, Standard BioTools&#8217; directors and executive officers are entitled to continued indemnification, expense reimbursement and insurance coverage. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">These interests and others are discussed in more detail in the section entitled &#8220;<font style="font-style: italic;">The Merger &#8212; Interests of Standard BioTools Directors and Executive Officers in the Merger</font>&#8221; beginning on page <a href="#tIOSB">185</a> of this proxy statement/prospectus. The Standard BioTools Board members were aware of and considered these interests, among other matters, in reaching their decision to approve the Merger Agreement, to approve the transactions contemplated by the Merger Agreement and to recommend the approval of the Proposals to Standard BioTools stockholders. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Interests of Treeline Directors and Executive Officers in the Merger </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In connection with their approval of the Merger Agreement, the Treeline Board was aware that certain directors and executive officers of Treeline have interests in the Merger that may be different from, or in addition to, interests they have as Treeline stockholders. These interests include the following: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">As of June&#160;1, 2026, each of Joshua Bilenker, Jeffrey Engelman, and Spencer Smith beneficially own Treeline Options to purchase shares of Treeline Common Stock, which will be assumed by Standard BioTools. Each such assumed Treeline Option will continue to have, and be subject to the same terms and conditions that applied to such Treeline Option immediately prior to the Effective Time, except that such Treeline Option will be exercisable for that number of shares of Standard BioTools Common Stock equal to the number of shares of Treeline Common Stock subject to such Treeline Option immediately prior to the Effective Time multiplied by the Exchange Ratio and rounded down to the next nearest share of Standard BioTools Common Stock, and the exercise price per share of each such Treeline Option will be the exercise price per share in effect for that Treeline Option immediately prior to the Effective Time divided by the Exchange Ratio and rounded up to the next nearest cent. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Treeline&#8217;s directors and executive officers are currently expected to become directors and executive officers of the combined company following the Closing. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Under the Merger Agreement, Treeline&#8217;s directors and executive officers are entitled to continued indemnification, expense reimbursement and insurance coverage. </div></td></tr></table></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">19<br></div></div></div>
<!--End Page 30-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 31-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 492pt;"><a name="ny20077604x1_s4_108-summary_pg7"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="BRDSX_page-content" style="margin-left: 12pt;"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">These interests and others are discussed in more detail in the section entitled &#8220;<font style="font-style: italic;">The Merger &#8212; Interests of Treeline Directors and Executive Officers in the Merger</font>&#8221; beginning on page <a href="#tINTER1">189</a> of this proxy statement/prospectus. The Treeline Board members were aware of and considered these interests, among other matters, in reaching their decisions to approve the Merger Agreement and to approve the transactions contemplated by the Merger Agreement. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16pt; margin-left: 0pt; text-align: left;">Board of Directors and Management Following the Merger (see page <a href="#tBOD">276</a>) </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Following the Closing, the board of directors of the combined company is expected to be composed of 12&#160;members, including ten directors who are currently directors of Treeline and two directors who are currently directors of Standard BioTools. Treeline&#8217;s initial appointees to the combined company board are expected to be Dr.&#160;Joshua Bilenker, Dr.&#160;Jeffrey Engelman, Kristina Burow, David Bonita, David Schenkein, Steven Elms, Aftab Kherani, Avi Naider, Ali Satvat and Susan Desmond-Hellmann, and Standard BioTools&#8217; initial appointees to the combined company board are expected to be &#8195;&#8195;&#8195; and &#8195;&#8195;&#8195;. Dr.&#160;Joshua Bilenker is expected to become chair of the board of directors of the combined company at and after the Closing. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, effective as of the Closing, Treeline&#8217;s management team is expected to become the management team of the combined company, and the following Treeline officers are expected to become the executive officers of the combined company: </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 231pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 231pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 231pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name</div></td><td style="width: 3pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 231pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Title </div></td></tr><tr><td style="width: 231pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Dr.&#160;Joshua Bilenker<font style="padding-left: 4.35pt;"></font></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 231pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chief Executive Officer </div></td></tr><tr><td style="width: 231pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Dr.&#160;Jeffrey Engelman<font style="padding-left: 2.88pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 231pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chief Scientific Officer </div></td></tr><tr><td style="width: 231pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Spencer Smith<font style="padding-left: 4.9pt;"></font></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 231pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chief Financial Officer</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 231pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 231pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">The Merger Agreement (see page <a href="#tMEA">201</a>) </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Overview </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On June&#160;6, 2026, Standard BioTools, Treeline and Merger Sub entered into the Merger Agreement. The Merger Agreement provides, among other things, that on the terms and subject to the conditions set forth therein, Merger Sub will merge with and into Treeline, with Treeline surviving as a wholly owned subsidiary of Standard BioTools (the &#8220;Merger&#8221; and, collectively with the other transactions contemplated by the Merger Agreement, the &#8220;Transactions&#8221;). Upon the consummation of the Merger, Standard BioTools will change its name to Treeline Biosciences Holdings, Inc. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Following the Closing, and in accordance with an Exchange Ratio calculated in accordance with the Merger Agreement, former Standard BioTools stockholders are expected to own approximately 16% of the combined company on a fully diluted basis and the former Treeline stockholders are expected to own approximately 84% of the combined company on a fully diluted basis. The Exchange Ratio is based on the relative capitalization of each of Treeline and Standard BioTools and assumes (i) an equity value for Treeline of $2.5&#160;billion and (ii) an equity value for Standard BioTools equal to $460&#160;million, reduced by the amount by which the Parent Net Cash (as defined in the Merger Agreement) is less than $449&#160;million at the Closing or increased by the amount by which Parent Net Cash is more than $451&#160;million at the Closing. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16pt; margin-left: 0pt; text-align: left;">Treatment of Treeline Capital Stock </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In accordance with the Merger Agreement, each issued and outstanding share of Treeline Capital Stock (other than treasury shares and dissenting shares) will be converted into the right to receive a number of shares of Standard BioTools Common Stock based on the Exchange Ratio (described in more detail in the section titled &#8220;<font style="font-style: italic;">The Merger Agreement&#8201;&#8212;&#8201;Exchange Ratio</font>&#8221; beginning on page <a href="#tEXR">202</a> of this proxy statement/prospectus), provided that the number of shares of Standard BioTools Common Stock which each holder of Treeline Capital Stock is entitled to receive will be rounded down to the nearest whole share and computed after aggregating all shares of Treeline Capital Stock held by such holder. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16pt; margin-left: 0pt; text-align: left;">Treatment of Treeline Stock Options </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">At the Effective Time, Treeline&#8217;s 2021 Equity Incentive Plan and each outstanding Treeline Option, whether vested or unvested, without any action on the part of the holder thereof, will be assumed by Standard BioTools. Each such Treeline Option so assumed will continue to have, and be subject to, the same terms and conditions applicable </div></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">20<br></div></div></div>
<!--End Page 31-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 32-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 492pt;"><a name="ny20077604x1_s4_108-summary_pg8"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="BRDSX_page-content" style="margin-left: 12pt;"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">to such Treeline Option immediately prior to the Effective Time, including vesting terms and provisions, except that (i) such Treeline Option will be exercisable for that number of shares of Standard BioTools Common Stock equal to the number of shares of Treeline Common Stock subject to such Treeline Option immediately prior to the Effective Time multiplied by the Exchange Ratio and rounded down to the next nearest share of Standard BioTools Common Stock, and (ii) the exercise price per share of such Treeline Option will be the exercise price per share in effect for such Treeline Option immediately prior to the Effective Time divided by the Exchange Ratio and rounded up to the next nearest cent. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In accordance with the Merger Agreement, as soon as reasonably practicable following the Closing Date, Standard BioTools will file a registration statement on Form&#160;S-8 (or such other appropriate form, if required) with respect to the offering of the shares of Standard BioTools Common Stock issuable upon the exercise of the assumed Treeline Options and will use reasonable best efforts to maintain the effectiveness of such registration statement thereafter for so long as any of such Treeline Options remain outstanding. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Treatment of Treeline Warrants </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">At the Effective Time, each Treeline Warrant that has been amended to require net-exercise in connection with the Merger and that is outstanding immediately prior to the Effective Time will, by virtue of the Merger and without any action on the part of Treeline or the holder thereof, be cancelled and extinguished and converted into the right to receive, for each share of Treeline Common Stock that would be received upon the net-exercise of such warrant in accordance with its terms, a number of shares of Standard BioTools Common Stock equal to the Exchange Ratio. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, at the Effective Time, each Treeline Warrant that is not a Treeline Converting Warrant and that is outstanding immediately prior to the Effective Time will, by virtue of the Merger and without any action on the part of Treeline or the holder thereof, be assumed by Standard BioTools. Each Treeline Warrant so assumed will continue to have, and be subject to, the same terms and conditions applicable to such Treeline Warrant immediately prior to the Effective Time, except that (i) such Treeline Warrant will be exercisable for that number of shares of Standard BioTools Common Stock equal to the number of shares of Treeline Common Stock subject to such Treeline Warrant immediately prior to the Effective Time multiplied by the Exchange Ratio and rounded down to the next nearest share of Standard BioTools Common Stock and (ii) the warrant price per share will be the warrant price per share in effect for such Treeline Warrant immediately prior to the Effective Time divided by the Exchange Ratio and rounded up to the nearest thousandth of a cent. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Conditions to the Completion of the Merger (see page <a href="#tCONCOMMER">207</a>) </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under the Merger Agreement, the Closing is subject to, and will take place following the satisfaction or waiver (to the extent permitted by applicable law) by Standard BioTools or Treeline, as applicable, of certain customary closing conditions, including, without limitation: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Standard BioTools must obtain approval of its stockholders of the Share Issuance Proposal and the Charter Amendment Proposal; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the absence of any law, judgment (preliminary, temporary or permanent) or other legal restraint or binding order or determination by any governmental entity that is in effect and restrains, enjoins, makes illegal or otherwise prohibits the consummation of the Merger; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the registration statement on Form&#160;S-4 of which this proxy statement/prospectus forms a part, which is being filed by Standard BioTools with the SEC to register certain of the shares of Standard BioTools Common Stock to be issued to the holders of shares of Treeline Common Stock in connection with the Merger, must become effective and not subject to any stop order or proceeding seeking a stop order; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the shares of Standard BioTools Common Stock issuable pursuant to the Merger Agreement must be approved for listing on Nasdaq; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the waiting period (and any extension thereof) applicable to the Merger or any other transactions contemplated by the Merger Agreement under the Hart-Scott-Rodino Act must have expired or been terminated. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, each party&#8217;s obligation to complete the Merger and the other transactions contemplated by the Merger Agreement is further subject to the satisfaction or waiver (to the extent permitted by applicable law) by that party of the following additional conditions: </div></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">21<br></div></div></div>
<!--End Page 32-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 33-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 492pt;"><a name="ny20077604x1_s4_108-summary_pg9"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="BRDSX_page-content" style="margin-left: 12pt;"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the accuracy of the other party&#8217;s representations and warranties, subject to specified materiality qualifications; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the performance, in all material respects, by the other party, of such party&#8217;s obligations pursuant to the Merger Agreement; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the absence of a continuing &#8220;material adverse effect&#8221; with respect to the other party, as such term is defined in the Merger Agreement; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the other party must have delivered a customary closing certificate certifying that the closing conditions related to the accuracy of representations and warranties, performance of obligations and absence of a material adverse effect have been satisfied. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Standard BioTools&#8217; obligation to effect the Merger is subject to the following additional conditions: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Standard BioTools must have received a certification that the shares of Treeline Capital Stock are not &#8220;United States real property interests&#8221;; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Treeline must have delivered to Standard BioTools evidence that all of the obligations of Treeline under certain agreements have been terminated. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline&#8217;s obligation to complete the Merger is subject to the following additional conditions: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Standard BioTools must effect the amendments to the Standard BioTools Charter pursuant to the Charter Amendment Proposal; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Treeline must receive resignations of each director and officer of Standard BioTools and its subsidiaries, other than the Standard BioTools directors who will continue as directors of the combined company following the Effective Time. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">There is no assurance that these conditions will be satisfied or the timing within which these conditions will be satisfied. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">No Solicitation (see page <a href="#tNOSOL">211</a>) </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Each of Standard BioTools and Treeline has agreed that, subject to limited exceptions, Standard BioTools and Treeline will not, and will cause their subsidiaries and their subsidiaries&#8217; directors, officers and employees not to, and will cause their respective investment bankers, attorneys, accountants and other advisors, agents and representatives of Treeline and Standard BioTools, not to, directly or indirectly: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">solicit, initiate, induce, knowingly encourage or knowingly facilitate any inquiries or the making of any proposal or offer that constitutes, or could reasonably be expected to lead to, a Company Acquisition Proposal (as defined in the Merger Agreement) or a Parent Acquisition Proposal (as defined in the Merger Agreement); </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">participate in any discussions or negotiations or cooperate in any way with any person regarding any Company Acquisition Proposal or Parent Acquisition Proposal or any inquiry, proposal or offer that could reasonably be expected to lead to a Company Acquisition Proposal or a Parent Acquisition Proposal; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">provide any non-public information or data concerning Standard BioTools, Treeline or any of their subsidiaries to any person in connection with, or for the purpose of soliciting, initiating, inducing, encouraging or facilitating any Company Acquisition Proposal or Parent Acquisition Proposal or any inquiry, proposal or offer that could reasonably be expected to lead to a Company Acquisition Proposal or a Parent Acquisition Proposal; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">enter into any binding or nonbinding letter of intent, term sheet, memorandum of understanding, merger agreement, acquisition agreement, agreement in principle, option agreement, joint venture agreement, partnership agreement, lease agreement or other similar agreement with respect to, or that could reasonably be expected to lead to, a Company Acquisition Proposal or a Parent Acquisition Proposal (other than, with respect to Standard BioTools, a confidentiality agreement entered into in accordance with the applicable provisions of the Merger Agreement); </div></td></tr></table></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">22<br></div></div></div>
<!--End Page 33-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 34-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 492pt;"><a name="ny20077604x1_s4_108-summary_pg10"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="BRDSX_page-content" style="margin-left: 12pt;"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">adopt, approve, declare advisable or recommend or make any public statement approving or recommending any inquiry, proposal or offer that constitutes, or could reasonably be expected to lead to, a Company Acquisition Proposal or a Parent Acquisition Proposal (including by approving any transaction, or approving any person becoming an &#8220;interested stockholder,&#8221; for purposes of Section&#160;203 of the DGCL); </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">take any action or exempt any person (other than the other party and its subsidiaries) from the restriction on &#8220;business combinations&#8221; or any similar provision contained in applicable takeover laws or its organizational or other governing documents; or </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">resolve, publicly propose or agree to do any of the foregoing actions. </div></td></tr></table><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Board Recommendation Change (see page <a href="#tSBIOCIR">215</a>) </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The board of directors of each of Standard BioTools and Treeline may not change its recommendation in favor of the Merger, except that prior to receipt of Standard BioTools stockholder approval of the Merger, the Standard BioTools Board may effect a change in recommendation as a result of a material development or change in circumstances (an &#8220;Intervening Event&#8221;), or with respect to a superior offer that did not result from a material breach of the Merger Agreement, if: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Standard BioTools provided Treeline with four business days&#8217; prior written notice that it intends to make a change in recommendation; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">prior to making such a change in recommendation, Standard BioTools engaged in good faith negotiations with Treeline to consider adjustments to the terms and conditions of the Merger Agreement so that the acquisition proposal ceases to be a superior offer or the failure to make a change in recommendation in response to the Intervening Event would no longer be inconsistent with Standard BioTools Board&#8217;s fiduciary duties; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The Standard BioTools Board determined in good faith after consultation with outside financial advisors and outside legal counsel that the failure to make such change in recommendation would reasonably be expected to be inconsistent with its fiduciary duties to its stockholders under applicable law. </div></td></tr></table><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Termination (see page <a href="#tTERM">224</a>) </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Merger Agreement may be terminated under certain customary and limited circumstances at any time prior to the Closing, including without limitation: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">by mutual written consent of Standard BioTools and Treeline; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">by either Standard BioTools or Treeline, if (i) the Merger has not been consummated by 11:59 p.m. (Eastern Time) on March&#160;31, 2027 (the &#8220;Termination Date&#8221;), where the terminating party&#8217;s material breach of the Merger Agreement is not the cause of, and has not resulted in, the failure of such condition, (ii) the Share Issuance Proposal and the Charter Amendment Proposal have not been approved by the requisite vote of the holders of Standard BioTools&#8217; capital stock at the Special Meeting (the &#8220;Standard BioTools Stockholder Approval&#8221;), or (iii) if any applicable law, judgment or other legal restraint or binding order or determination by any governmental entity restrains, enjoins, makes illegal or otherwise prohibits the consummation of the Merger and such restraint will have become final and non-appealable, where the terminating party complied with its obligations with respect to regulatory matters under the Merger Agreement; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">by Treeline if: (i) prior to obtaining the Standard BioTools Stockholder Approval, (A) a &#8220;Parent Change of Recommendation&#8221; (as such term is defined in the Merger Agreement) has occurred, (B) the Standard BioTools Board fails to publicly reaffirm its recommendation within 10 business days after Treeline so requests in writing, (C) the Standard BioTools Board fails to publicly recommend against any tender offer or exchange offer subject to Regulation 14D under the Exchange Act within 10 business days of the commencement of such offer or (D) Standard BioTools intentionally and materially breaches its no solicitation or negotiation and notice obligations as set forth in the Merger Agreement; or (ii) Standard BioTools or Merger Sub has materially breached or failed to perform any of its representations, warranties, covenants or agreements under the Merger Agreement, such that the Standard BioTools&#8217; conditions to the Closing in the Merger Agreement with respect to the accuracy of its representations or compliance with its </div></td></tr></table></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">23<br></div></div></div>
<!--End Page 34-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 35-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 492pt;"><a name="ny20077604x1_s4_108-summary_pg11"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="BRDSX_page-content" style="margin-left: 12pt;"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_bl" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: left;">agreements in the Merger Agreement would not be satisfied, provided that Treeline cannot terminate the Merger Agreement pursuant to this clause (ii) if Treeline is then in material breach of any of its representations, warranties, covenants or agreements under the Merger Agreement; or </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">by Standard BioTools if Treeline has materially breached or failed to perform any of its representations, warranties, covenants or agreements under the Merger Agreement, such that Treeline&#8217;s conditions to the Closing in the Merger Agreement with respect to the accuracy of its representations or compliance with its agreements in the Merger Agreement would not be satisfied, provided that Standard BioTools cannot terminate the Merger Agreement pursuant to this provision if Standard BioTools is then in material breach of any of its representations, warranties, covenants or agreements under the Merger Agreement. </div></td></tr></table><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13pt; margin-left: 0pt; text-align: left;">Termination Fee (see page <a href="#tTFER">225</a>) </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Merger Agreement provides that a termination fee in the amount of $16.1&#160;million will be payable by Standard BioTools if the Merger Agreement is terminated under certain circumstances, including if Treeline terminates the Merger Agreement due to a change in the Standard BioTools Board recommendation in favor of the Transactions. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Merger Agreement also provides that, under certain circumstances, Standard BioTools will reimburse Treeline for all reasonable out of pocket fees and expenses incurred by Treeline in connection with the Merger Agreement and the other Transactions, up to a maximum of $5&#160;million, if the Merger Agreement is terminated under certain circumstances, including if Treeline terminates the Merger Agreement due to a failure to obtain the required approval of Standard BioTools stockholders. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13pt; margin-left: 0pt; text-align: left;">Contingent Value Rights Agreement (see page <a href="#tCVRA1">300</a>) </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Prior to the Effective Time, Standard BioTools expects to declare a dividend to Standard BioTools stockholders as of the close of business on the last business day prior to the day on which the Effective Time occurs in the form of one contingent value right (each, a &#8220;CVR&#8221;) for each outstanding share of Standard BioTools Common Stock held by such stockholder on such date. The payment date for such dividend will be three business days after the Effective Time. The CVRs will be issued pursuant to the terms of a Contingent Value Rights Agreement to be entered into between Standard BioTools and a rights agent substantially in the form attached as Annex&#160;F to this proxy statement/prospectus (the &#8220;CVR Agreement&#8221;). </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Pursuant to the CVR Agreement, the holder of each CVR will be entitled to receive a payment for each 12-month CVR payment period during the five-year term of the CVR Agreement, consisting of a number of shares of the combined company&#8217;s common stock (with fractional shares settled in cash) equal to such holder&#8217;s pro rata portion of the aggregate net proceeds received by the combined company during such 12-month CVR payment period from the following sources, in each case less certain permitted deductions: (i) proceeds from any sale, disposition, or other monetization of the Legacy Business; (ii) proceeds from convertible notes or other investments held by Standard BioTools as of the Closing Date; (iii) earnout, milestone, royalty or other similar contingent payments due to Standard BioTools under contracts in effect as of the Closing Date, including payments from Illumina, Inc. pursuant to the Stock Purchase Agreement dated June&#160;22, 2025; and (iv) any surplus in Parent Net Cash delivered at Closing as finally determined under the Merger Agreement. The maximum number of shares of common stock of the combined company which may be issued pursuant to the CVR Agreement is 76,000,000. There can be no assurance that any payments will be made on the CVRs. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The right to the contingent payments contemplated by the CVR Agreement is a contractual right only and is not transferable, except in the limited circumstances specified in the CVR Agreement. The CVRs will not be evidenced by a certificate or any other instrument and will not be registered with the SEC. The CVRs will not have any voting or dividend rights and will not represent any equity or ownership interest in Standard BioTools or any of its respective affiliates. No interest will accrue on any amounts payable in respect of the CVRs. The shares of Standard BioTools Common Stock which may be issued in connection with the CVRs have been registered on the registration statement on Form&#160;S-4 of which this proxy statement/prospectus forms a part. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12.5pt; margin-left: 0pt; text-align: left;">Voting Agreements </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Concurrently with the execution of the Merger Agreement, certain stockholders of Standard BioTools (including its directors and certain officers), collectively holding approximately 39% of the outstanding shares of Standard BioTools Common Stock, entered into voting agreements with Standard BioTools, Treeline and Merger </div></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">24<br></div></div></div>
<!--End Page 35-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 36-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 492pt;"><a name="ny20077604x1_s4_108-summary_pg12"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="BRDSX_page-content" style="margin-left: 12pt;"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Sub (the &#8220;Voting Agreements&#8221;) pursuant to which they have agreed to vote all of their shares of Standard BioTools Common Stock in favor of the Share Issuance Proposal, the Charter Amendment Proposal, the Post-Closing Equity Incentive Plan Proposal and the Post-Closing ESPP Proposal, subject to the terms of the Voting Agreements, including a reduction in the number of shares subject to the voting requirements for certain stockholders in the event of a change in the recommendation of the Special Committee in favor of the Transactions such that the aggregate number of outstanding shares of Standard BioTools Common Stock subject to the voting requirements in the Voting Agreements is reduced to approximately 30% of the outstanding shares of Standard BioTools Common Stock. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13.5pt; margin-left: 0pt; text-align: left;">Lock-Up Agreements (see page <a href="#tLOCK1">194</a>) </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Concurrently with the execution of the Merger Agreement, certain stockholders of Treeline holding approximately 70% of the outstanding shares of Treeline Capital Stock as of June&#160;6, 2026, and the directors of Standard BioTools, who together beneficially own approximately 4% of Standard BioTools Common Stock as of June&#160;3, 2026, including each individual who will serve as a director or executive officer of the combined company following the Closing, entered into lock-up agreements, pursuant to which, subject to specified exceptions, such persons agreed that they would not offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Standard BioTools Common Stock or any securities convertible into or exercisable or exchangeable for shares of Standard BioTools Common Stock (including securities that may be issued upon exercise of an option to purchase shares of Standard BioTools Common Stock or a warrant to purchase shares of Standard BioTools Common Stock), for 180 days following the Effective Time. The shares of Standard BioTools Common Stock held by the Selling Securityholders are subject to these lock-up agreements and may not be sold until the applicable lock-up period expires (subject to certain exceptions set forth in the applicable lock-up agreements), notwithstanding that such shares are registered for resale pursuant to the resale prospectus also included in the registration statement on Form&#160;S-4 of which this proxy statement/prospectus forms a part. See &#8220;<font style="font-style: italic;">Selling Securityholders</font>&#8221; and &#8220;<font style="font-style: italic;">Plan of Distribution</font>&#8221; in the resale prospectus. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13.5pt; margin-left: 0pt; text-align: left;">Nasdaq Stock Market Listing </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Shares of Standard BioTools Common Stock are currently listed on The Nasdaq Global Select Market under the symbol &#8220;LAB.&#8221; Standard BioTools anticipates that the common stock of the combined company will be listed on The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) following the Closing under the trading symbol &#8220;TRLN.&#8221; It is a condition to the consummation of the Merger that existing shares of Standard BioTools Common Stock are listed on Nasdaq as of the Closing Date and that the shares of Standard BioTools Common Stock issuable in connection with the Merger have been approved for listing on Nasdaq, subject to official notice of issuance, but there can be no assurance such listing condition will be met. If such listing condition is not met, the Merger will not be consummated unless the condition is waived.</div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13.5pt; margin-left: 0pt; text-align: left;">Regulatory Approvals Required for the Merger (see page <a href="#tREG1">199</a>) </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">To consummate the Merger, Treeline and Standard BioTools must obtain approvals or consents from, or make filings with, the Federal Trade Commission (the &#8220;FTC&#8221;) and the Antitrust Division of the U.S. Department of Justice (the &#8220;DOJ&#8221;). Under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the &#8220;HSR Act&#8221;), the Merger cannot be consummated until, among other things, notifications have been given and certain information has been provided to the FTC and the Antitrust Division of the DOJ and all applicable waiting periods (and any extensions thereof) have expired or been terminated. On June&#160;29, 2026, Treeline and Standard BioTools made submissions in accordance with the HSR Act to the FTC and the DOJ. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The HSR approval condition is discussed under &#8220;<font style="font-style: italic;">The Merger &#8212; Regulatory Approvals Required for the Merger</font>&#8221; beginning on page <a href="#tREG1">199</a> of this proxy statement/prospectus. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13pt; margin-left: 0pt; text-align: left;">Anticipated Accounting Treatment (see page <a href="#tAAT1">200</a>) </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Merger is expected to be accounted for as a reverse recapitalization in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). For accounting purposes, Treeline is considered to be the accounting acquirer in this transaction. The treatment as an in-substance reverse recapitalization is based on the assessment that as a result of, and following, Standard BioTools&#8217; discontinuation of its Legacy Business, and settlement of its other remaining operating assets and liabilities, prior to or concurrently with the closing of the Merger, Standard BioTools will not meet the definition of a &#8220;business&#8221; under ASC 805. </div></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">25<br></div></div></div>
<!--End Page 36-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 37-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 492pt;"><a name="ny20077604x1_s4_108-summary_pg13"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="BRDSX_page-content" style="margin-left: 12pt;"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Appraisal Rights (see page <a href="#tAPR1">200</a>) </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Standard BioTools stockholders are not entitled to appraisal rights under the DGCL. However, Treeline&#8217;s stockholders will be entitled to appraisal rights under the DGCL with respect to the Merger. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Material U.S. Federal Income Tax Considerations (see page <a href="#tMUS">305</a>) </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Standard BioTools and Treeline intend to treat the Merger as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a) of the Code, and the Merger as a &#8220;plan of reorganization&#8221; within the meaning of Treasury Regulations Section&#160;1.368-2(g). Assuming it so qualifies, and subject to the limitations and qualifications described herein under &#8220;<font style="font-style: italic;">Material U.S. Federal Income Tax Considerations with Respect to the Merger</font>&#8221; beginning on page&#160;<a href="#tMUS">305</a> of this proxy statement/prospectus, a U.S. holder of Treeline Common Stock will generally not recognize gain or loss upon the exchange of its Treeline Common Stock for Standard BioTools Common Stock. Because the Standard BioTools stockholders will not sell, exchange or dispose of any shares of Standard BioTools Common Stock in the Merger, the Merger should not result in recognition of gain or loss by the Standard BioTools stockholders. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Please review the information set forth in the section entitled &#8220;<font style="font-style: italic;">Material U.S. Federal Income Tax Considerations with Respect to the Merger</font>&#8221; for a more complete description of the material U.S. federal income tax considerations with respect to the Merger. Each holder should consult their own tax advisors as to the specific tax consequences of the Merger. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Comparison of Stockholder Rights (see page <a href="#tCSR">312</a>) </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As a result of the Merger, the holders of Treeline Capital Stock will become holders of Standard BioTools Common Stock, and their rights will be governed by the DGCL, the Standard BioTools Charter and the Standard BioTools Amended and Restated Bylaws (the &#8220;Standard BioTools Bylaws&#8221;), rather than the Treeline Certificate of Incorporation (the &#8220;Treeline Charter&#8221;) and the Treeline Bylaws (the &#8220;Treeline Bylaws&#8221;). Following the Merger, former Treeline stockholders will have different rights as Standard BioTools stockholders than they had as Treeline stockholders. For additional information on stockholder rights, see &#8220;<font style="font-style: italic;">Comparison of Stockholder Rights</font>&#8221; beginning on page <a href="#tCSR">312</a> of this proxy statement/prospectus. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Risk Factors (see page <a href="#tRF">33</a>) </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Merger, including the possibility that the Merger may not be completed, poses a number of risks to Standard BioTools and its securityholders. In addition, Treeline is subject to various risks as a clinical stage biosciences company. You are encouraged to read a detailed description of these risks which is contained under &#8220;<font style="font-style: italic;">Risk Factors</font>&#8221; beginning on page <a href="#tRF">33</a> of this proxy statement/prospectus. Some of these risks include the following: </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Risks Related to the Merger </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Standard BioTools and Treeline may not be successful in consummating the Merger. The consummation of the Merger is subject to various conditions, including approval by the Standard BioTools stockholders, regulatory approval, and obtaining approval by Nasdaq to the listing of the Standard BioTools Common Stock. Failure to satisfy these conditions would prevent the Closing. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The Merger consideration paid at Closing may have a greater or lesser value than at the time the Merger Agreement was signed or at the time of the Special Meeting. The value of the Merger consideration will be impacted by fluctuations in the market price of Standard BioTools Common Stock. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The Exchange Ratio, which determines the number of shares to be issued to the Treeline stockholders, will vary to the extent that Parent Net Cash at Closing is more than $451&#160;million or less than $449&#160;million. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The Merger Agreement contains provisions that could discourage a potential competing acquirer of Standard BioTools or Treeline. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The pendency of the Merger could materially adversely affect the business, financial condition, results of operations or cash flows of Standard BioTools or Treeline. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Standard BioTools and Treeline directors and executive officers have interests in the Merger that may be different from, or in addition to, the interests of Standard BioTools and Treeline stockholders. </div></td></tr></table></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">26<br></div></div></div>
<!--End Page 37-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 38-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 492pt;"><a name="ny20077604x1_s4_108-summary_pg14"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="BRDSX_page-content" style="margin-left: 12pt;"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Even if the Merger is consummated, there is no assurance that Standard BioTools stockholders will realize the anticipated benefits from the Merger. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Standard BioTools stockholders will experience significant dilution as a result of the Merger. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Sales of a significant number of shares in the public market following the Closing, or the perception that such sales could occur, would have an adverse impact on the Standard BioTools stock price. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">If the Merger is not completed, Standard BioTools&#8217; stock price may decline significantly. </div></td></tr></table><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Risks Related to the Proposed Reverse Stock Split </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The reverse stock split may not increase the combined company&#8217;s stock price over the long-term. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The reverse stock split may decrease the liquidity of the combined company&#8217;s common stock. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The reverse stock split may lead to a decrease in the combined company&#8217;s overall market capitalization. </div></td></tr></table><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Risks Related to Treeline </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Treeline is an early clinical-stage biopharmaceutical company with a limited operating history, has not completed clinical development and has no products approved for commercial sale, which may make it difficult for investors to evaluate Treeline&#8217;s business, likelihood of success and viability. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Treeline has incurred significant net losses in each period since its inception and has not generated any product revenue. It expects to continue to incur significant net losses for the foreseeable future and may never achieve or maintain profitability. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Treeline may require additional capital to finance its operations. If Treeline is unable to raise such capital when needed, or on acceptable terms, Treeline may be forced to delay, reduce or eliminate one or more of its R&amp;D programs, future commercialization efforts, product development or other operations. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Treeline is substantially dependent on the advancement of TLN-121, TLN-254, TLN-372 and TLN-499 and its other potential or future product candidates. If Treeline is unable to advance its product candidates through development, obtain regulatory approval and ultimately commercialize such product candidates, or experiences significant delays in doing so, Treeline&#8217;s business will be materially harmed. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Drug development is a lengthy and expensive process, the outcome of clinical testing is inherently uncertain, and results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results. Treeline may incur additional costs or experience delays in completing, or be unable to complete, the development and commercialization of TLN-121, TLN-254, TLN-372, TLN-499 and/or other potential or future product candidates for many reasons, including a failure to replicate positive results from earlier preclinical studies or clinical trials in ongoing or future preclinical studies or clinical trials. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">A marketed inhibitor (tazemetostat) in the same class as TLN-254 was withdrawn from the market due to safety concerns, and adverse developments affecting the EZH2 inhibitor class could delay, limit or prevent the development and approval of TLN-254 (including for use in combination with TLN-121). </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Treeline relies, and expects to continue to rely, on third parties to conduct its discovery, preclinical studies, manufacturing and clinical trials, and if these third parties do not satisfactorily carry out their contractual duties, fail to comply with applicable regulatory requirements or do not meet expected deadlines, Treeline&#8217;s development programs may be delayed or subject to increased costs or Treeline may be unable to obtain marketing authorization, each of which may have an adverse effect on Treeline&#8217;s business, financial condition, results of operations and prospects. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Adverse side effects or other safety risks associated with TLN-121, TLN-254, TLN-372 and TLN-499 or other product candidates Treeline may develop could delay or preclude approval, cause Treeline to suspend or discontinue clinical trials or abandon further development, limit the commercial profile of an approved product, or result in significant negative consequences following regulatory approval, if any. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Preliminary, topline or interim data from Treeline&#8217;s clinical trials that it announces or publishes from time to time may change as more patient data become available and/or are subject to audit and verification procedures that could result in material changes in the final data. </div></td></tr></table></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">27<br></div></div></div>
<!--End Page 38-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 39-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 492pt;"><a name="ny20077604x1_s4_108-summary_pg15"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="BRDSX_page-content" style="margin-left: 12pt;"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The breadth and diversity of Treeline&#8217;s pipeline may strain its limited resources, and Treeline may be unable to advance all of its programs or to prioritize among them effectively. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Treeline&#8217;s ability to identify new product candidates depends on its integrated drug discovery organization, including its wet-lab and computational capabilities, which may not perform as expected. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Treeline&#8217;s product candidates include targeted protein degraders and other modalities that have limited clinical and regulatory precedent. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Treeline is conducting, and may in the future conduct, clinical trials for its current or future product candidates outside the United States, and the FDA and comparable foreign regulatory authorities may not accept data from such trials. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The regulatory approval process is highly uncertain, and Treeline may be unable to obtain, or may be delayed in obtaining, U.S. or foreign regulatory approval and, as a result, unable to commercialize Treeline&#8217;s current product candidates and any future product candidates. Even if Treeline believes its current, or planned, clinical trials are successful, regulatory authorities may not agree that they provide adequate data on safety or efficacy. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">If Treeline is unable to obtain and maintain patent protection or other necessary rights for any of Treeline&#8217;s product candidates and technology, or if the scope of the patent protection obtained is not sufficiently broad or Treeline&#8217;s rights under Treeline&#8217;s patents are not sufficiently broad, Treeline&#8217;s competitors could develop and commercialize products and technology similar or identical to Treeline&#8217;s, and Treeline&#8217;s ability to successfully commercialize Treeline&#8217;s products and technology may be adversely affected. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">If Treeline breaches any of its license agreements, including its license agreement with Jiangsu Hengrui Pharmaceuticals Co., Ltd. or the CRT Pioneer Fund LP, or any other agreements with third parties, or if there are disputes over the intellectual property that Treeline licenses, it could have a material adverse effect on Treeline&#8217;s commercialization efforts for Treeline&#8217;s current or future product candidates. </div></td></tr></table><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Risks Related to the Ownership of the Common Stock of the Combined Company </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The market price of the combined company&#8217;s common stock is expected to be volatile, and the market price of the common stock may drop following the Merger. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The combined company may incur losses for the foreseeable future and may never achieve profitability. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The combined company will have broad discretion in how to use the cash and cash equivalents of the combined company and may invest or spend the company&#8217;s cash in ways with which you do not agree. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">These risks and other risks are discussed in greater detail under the section titled &#8220;<font style="font-style: italic;">Risk Factors</font>&#8221; beginning on page&#160;<a href="#tRF">33</a> of this proxy statement/prospectus. You are encouraged to read and consider all of these risks carefully. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Resale of Standard BioTools Common Stock (see page Alt-<a href="#tRESALE">2</a>) </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This proxy statement/prospectus also relates to the possible resale of shares of Standard BioTools Common Stock by certain Treeline stockholders, who are referred to in this proxy statement/prospectus as the &#8220;Selling&#160;Securityholders.&#8221; The Selling Securityholders may offer and sell, from time to time, any or all of the shares of Standard BioTools Common Stock which they acquired in a private placement in connection with the Merger, which consists of approximately 1.5 billion shares of Standard BioTools Common Stock issued to the Selling Securityholders. See &#8220;<font style="font-style: italic;">Selling Securityholders</font>&#8221; and &#8220;<font style="font-style: italic;">Plan of Distribution</font>&#8221; in the resale prospectus also included in the registration statement on Form&#160;S-4 of which this proxy statement/prospectus forms a part. </div></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">28<br></div></div></div>
<!--End Page 39-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 40-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_109-selected_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tSHF"><!--Anchor--></a>SELECTED HISTORICAL FINANCIAL DATA FOR TREELINE </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The selected historical condensed consolidated statements of operations data of Treeline for the three months ended March&#160;31, 2026 and 2025 and the condensed consolidated balance sheet data as of March&#160;31, 2026 are derived from Treeline&#8217;s unaudited condensed consolidated interim financial statements included elsewhere in this proxy statement/prospectus. The selected historical consolidated statements of operations data of Treeline for the years ended December&#160;31, 2025 and 2024 and the selected historical consolidated balance sheet data as of December&#160;31, 2025 and 2024 are derived from Treeline&#8217;s audited consolidated financial statements included elsewhere in this proxy statement/prospectus. The unaudited condensed consolidated interim financial data set forth below have been prepared on the same basis as Treeline&#8217;s audited consolidated financial statements and, in the opinion of Treeline&#8217;s management, include all normal and recurring adjustments, that are necessary for the fair statement of such data. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline&#8217;s historical results are not necessarily indicative of the results that may be expected in the future and Treeline&#8217;s results for the three months ended March&#160;31, 2026 are not necessarily indicative of the results that may be expected for the full year ending December&#160;31, 2026 or any other period. You should read the following selected historical consolidated financial data together with the sections entitled &#8220;<font style="font-style: italic;">Treeline Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font>&#8221; and Treeline&#8217;s audited consolidated financial statements and accompanying notes and unaudited condensed consolidated interim financial statements and accompanying notes included elsewhere in this proxy statement/prospectus. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 228pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 110.1pt;" colspan="4"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 109.73pt;" colspan="4"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 228pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 5.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.05pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td colspan="4" style="width: 110.1pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31,</div></td><td style="width: 5.05pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.05pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td colspan="4" style="width: 109.73pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, </div></td></tr><tr class="BRDSX_header"><td style="width: 228pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 5.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.05pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2026</div></td><td style="width: 5.05pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.05pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div></td><td style="width: 5.05pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.05pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.63pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div></td><td style="width: 5.05pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.05pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div></td></tr><tr class="BRDSX_header"><td style="width: 228pt; padding-top: 2.08pt; padding-bottom: 2.88pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 5.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td colspan="4" style="width: 110.1pt; padding-top: 2.08pt; padding-bottom: 2.88pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(unaudited)</div></td><td style="width: 5.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.63pt; padding-top: 2.08pt; padding-bottom: 2.88pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 5.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 2.08pt; padding-bottom: 2.88pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td></tr><tr class="BRDSX_header"><td style="width: 228pt; padding-top: 2.58pt; padding-bottom: 2.88pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 5.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td colspan="10" style="width: 229.93pt; padding-top: 2.58pt; padding-bottom: 2.88pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(in thousands, except for share data and per share amounts) </div></td></tr><tr><td style="width: 228pt; padding-top: 2.51pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating expenses:<br></div></td><td style="width: 5.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 2.51pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 5.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 2.51pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 5.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.63pt; padding-top: 2.51pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 5.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 2.51pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 228pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research and development<font style="padding-left: 2.76pt;"></font></div></td><td style="width: 5.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<font style="padding-left: 17.5pt;">49,098</font></div></td><td style="width: 5.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">$<font style="padding-left: 17.5pt;">39,213</font></div></td><td style="width: 5.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.63pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">$<font style="padding-left: 12.13pt;">160,009</font></div></td><td style="width: 5.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">$<font style="padding-left: 12.5pt;">151,706 </font></div></td></tr><tr><td style="width: 228pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">General and administrative<font style="padding-left: 2.2pt;"></font></div></td><td style="width: 5.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 27.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">6,959</font></div></td><td style="width: 5.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 27.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">5,789</font></div></td><td style="width: 5.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.63pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 22.13pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">23,256</font></div></td><td style="width: 5.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">23,558 </font></div></td></tr><tr><td style="width: 228pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total operating expenses<font style="padding-left: 1.23pt;"></font></div></td><td style="width: 5.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">56,057</font></div></td><td style="width: 5.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">45,002</font></div></td><td style="width: 5.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.63pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 17.13pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">183,265</font></div></td><td style="width: 5.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">175,264 </font></div></td></tr><tr><td style="width: 228pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss from operations<font style="padding-left: 0.53pt;"></font></div></td><td style="width: 5.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 19.17pt;">(56,057)</font></div></td><td style="width: 5.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 19.17pt;">(45,002)</font></div></td><td style="width: 5.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.63pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 13.8pt;">(183,265)</font></div></td><td style="width: 5.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 14.17pt;">(175,264) </font></div></td></tr><tr><td style="width: 228pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other income<font style="padding-left: 0.8pt;"></font></div></td><td style="width: 5.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 27.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">5,516</font></div></td><td style="width: 5.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 27.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">5,202</font></div></td><td style="width: 5.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.63pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 22.13pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">20,726</font></div></td><td style="width: 5.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">12,777 </font></div></td></tr><tr><td style="width: 228pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net loss<font style="padding-left: 3.01pt;"></font></div></td><td style="width: 5.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 14.17pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(50,541</font><font style="padding-bottom: 0.5pt;">)</font></div></td><td style="width: 5.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 14.17pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(39,800</font><font style="padding-bottom: 0.5pt;">)</font></div></td><td style="width: 5.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.63pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 8.8pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(162,539</font><font style="padding-bottom: 0.5pt;">)</font></div></td><td style="width: 5.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 9.17pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(162,487</font><font style="padding-bottom: 0.5pt;">) </font></div></td></tr><tr><td style="width: 228pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Share Information:<br></div></td><td style="width: 5.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 5.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 5.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.63pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 5.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 228pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net loss per share of common stock, basic and diluted<font style="padding-left: 4.45pt;"></font></div></td><td style="width: 5.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">$</font><font style="padding-left: 24.17pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(1.93</font><font style="padding-bottom: 1.5pt;">)</font></div></td><td style="width: 5.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">$</font><font style="padding-left: 24.17pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(2.02</font><font style="padding-bottom: 1.5pt;">)</font></div></td><td style="width: 5.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.63pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">$</font><font style="padding-left: 23.8pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(7.42</font><font style="padding-bottom: 1.5pt;">)</font></div></td><td style="width: 5.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">$</font><font style="padding-left: 24.17pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(8.47</font><font style="padding-bottom: 1.5pt;">) </font></div></td></tr><tr><td style="width: 228pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Weighted-average shares of common stock outstanding, basic and diluted<font style="padding-left: 2.74pt;"></font></div></td><td style="width: 5.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">26,212,247</font></div></td><td style="width: 5.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">19,747,963</font></div></td><td style="width: 5.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.63pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">21,911,034</font></div></td><td style="width: 5.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">19,187,080</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 228pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 50pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 50pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 49.63pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 50pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 276pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 10.2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 10.2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 45pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 10.19pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 10.19pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 106.21pt;" colspan="4"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 276pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 10.2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.2pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31,</div></td><td style="width: 10.19pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.19pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td colspan="4" style="width: 106.21pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, </div></td></tr><tr class="BRDSX_header"><td style="width: 276pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Balance Sheet Data</div></td><td style="width: 10.2pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.2pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2026</div></td><td style="width: 10.19pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.19pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div></td><td style="width: 10.19pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.19pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div></td></tr><tr class="BRDSX_header"><td style="width: 276pt; padding-top: 2.08pt; padding-bottom: 2.88pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 10.2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 2.08pt; padding-bottom: 2.88pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(unaudited)</div></td><td style="width: 10.19pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.19pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 2.08pt; padding-bottom: 2.88pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 10.19pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.19pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 2.08pt; padding-bottom: 2.88pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td></tr><tr class="BRDSX_header"><td style="width: 276pt; padding-top: 2.58pt; padding-bottom: 2.88pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 10.2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td colspan="7" style="width: 171.59pt; padding-top: 2.58pt; padding-bottom: 2.88pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(in thousands) </div></td></tr><tr><td style="width: 276pt; padding-top: 2.51pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash, cash equivalents, restricted cash, and marketable securities<font style="padding-left: 3.6pt;"></font></div></td><td style="width: 10.2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 2.51pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<font style="padding-left: 7.5pt;">554,206</font></div></td><td style="width: 10.19pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.19pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 2.51pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<font style="padding-left: 7.5pt;">605,944</font></div></td><td style="width: 10.19pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.19pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 2.51pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<font style="padding-left: 3.33pt;">504,214 </font></div></td></tr><tr><td style="width: 276pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total assets<font style="padding-left: 2.27pt;"></font></div></td><td style="width: 10.2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<font style="padding-left: 7.5pt;">603,375</font></div></td><td style="width: 10.19pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.19pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<font style="padding-left: 7.5pt;">655,055</font></div></td><td style="width: 10.19pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.19pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<font style="padding-left: 3.33pt;">544,843 </font></div></td></tr><tr><td style="width: 276pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total liabilities<font style="padding-left: 3.38pt;"></font></div></td><td style="width: 10.2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<font style="padding-left: 12.5pt;">40,208</font></div></td><td style="width: 10.19pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.19pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<font style="padding-left: 12.5pt;">42,558</font></div></td><td style="width: 10.19pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.19pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<font style="padding-left: 8.33pt;">33,478 </font></div></td></tr><tr><td style="width: 276pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Working capital<font style="padding-left: 4.59pt;"></font></div></td><td style="width: 10.2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<font style="padding-left: 7.5pt;">541,343</font></div></td><td style="width: 10.19pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.19pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<font style="padding-left: 7.5pt;">589,361</font></div></td><td style="width: 10.19pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.19pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<font style="padding-left: 3.33pt;">486,755 </font></div></td></tr><tr><td style="width: 276pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total redeemable convertible preferred stock<font style="padding-left: 4.27pt;"></font></div></td><td style="width: 10.2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$1,181,061</div></td><td style="width: 10.19pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.19pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$1,181,061</div></td><td style="width: 10.19pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.19pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<font style="padding-left: 3.33pt;">939,275 </font></div></td></tr><tr><td style="width: 276pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total stockholders&#8217; deficit<font style="padding-left: 4.41pt;"></font></div></td><td style="width: 10.2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<font style="padding-left: 4.17pt;">(617,894)</font></div></td><td style="width: 10.19pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.19pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<font style="padding-left: 4.17pt;">(568,564)</font></div></td><td style="width: 10.19pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.19pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$(427,910)</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 276pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 10.2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 10.2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 45pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 10.19pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 10.19pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 45pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 10.19pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 10.19pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 40.83pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">29<br></div></div></div>
<!--End Page 40-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 41-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_109-selected_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tSPF"><!--Anchor--></a>SELECTED PRO FORMA FINANCIAL INFORMATION </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following selected unaudited pro forma condensed combined financial data (the &#8220;selected pro forma data&#8221;) give effect to the Merger. The selected unaudited pro forma condensed combined statements of operations for the year ended December&#160;31, 2025 and the three months ended March&#160;31, 2026 give effect to the Merger as if the Merger had occurred on January&#160;1, 2025. The selected unaudited pro forma condensed combined balance sheet as of March&#160;31, 2026 gives effect to the Merger as if the Merger had occurred on March&#160;31, 2026, assuming that each outstanding share of Treeline Capital Stock, each Treeline Option and each outstanding warrant to purchase Treeline Common Stock that is not a Treeline Converting Warrant had become Standard BioTools Common Stock, Standard BioTools Options or a warrant to purchase Standard BioTools Common Stock, respectively, based on an estimated Exchange Ratio of 11.6997 (based on Standard BioTools&#8217; and Treeline&#8217;s capitalization as of June&#160;3, 2026 and May&#160;28, 2026, respectively, and taking into account Standard BioTools&#8217; estimated cash position as of the Closing and excluding the effect of the proposed Standard BioTools reverse stock split). In addition, each Treeline Converting Warrant will be converted into a number of shares of Standard BioTools Common Stock calculated by applying the estimated Exchange Ratio to each share of Treeline Common Stock that would have been received upon net-exercise of such warrant. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The selected pro forma data have been derived from, and should be read in conjunction with, the more detailed unaudited pro forma condensed combined financial information of Standard BioTools following the Merger appearing elsewhere in this proxy statement/prospectus and the accompanying notes to the unaudited pro forma condensed combined financial information. See &#8220;<font style="font-style: italic;">Unaudited Pro Forma Condensed Combined Financial Information</font>&#8221; beginning on page <a href="#tUNA">292</a> of this proxy statement/prospectus. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, the selected pro forma data were based on, and should be read in conjunction with, the following historical consolidated financial statements and accompanying notes: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">separate historical consolidated financial statements of Standard BioTools as of, and for the year ended December&#160;31, 2025 and historical unaudited condensed consolidated financial statements of Standard BioTools as of, and for the three months ended March&#160;31, 2026, and the related notes included in Standard BioTools&#8217; Quarterly Report on Form&#160;10-Q for the quarterly period ended March&#160;31, 2026 and Standard BioTools&#8217; Annual Report on Form&#160;10-K for the year ended December&#160;31, 2025, in each case, incorporated by reference into this proxy statement/prospectus; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">separate historical consolidated financial statements of Treeline as of, and for the year ended and three months ended, December&#160;31, 2025 and March&#160;31, 2026, respectively, included elsewhere in this proxy statement/prospectus. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The pro forma financial information does not include any adjustments for the disposition of SomaLogic, Inc. by Standard BioTools. On January&#160;30, 2026, Standard BioTools completed the sale of all of the equity interests of SomaLogic, Inc., Sengenics Corporation LLC, and Sengenics Corporation Pte Ltd (collectively, the &#8220;SomaLogic Entities&#8221;) to Illumina, Inc. (&#8220;Illumina&#8221;) pursuant to the Stock Purchase Agreement (the &#8220;Purchase Agreement&#8221;), dated June&#160;22, 2025, by and between Standard BioTools and Illumina. The SomaLogic Entities comprised Standard BioTools&#8217; SomaScan&#174; Business, including its SomaScan assay platform and related products and services. Standard BioTools determined that the SomaLogic Entities met the held-for-sale criteria under ASC 360, Property, Plant, and Equipment, and the discontinued operations criteria under ASC 205, Presentation of Financial Statements, during the second quarter of 2025. Accordingly, during the year ended December&#160;31, 2025, Standard BioTools presented the SomaLogic Entities as held-for-sale and as discontinued operations for all periods presented. No pro forma adjustments to the statement of operations for the year ended December&#160;31, 2025 or the three months ended March&#160;31, 2026 are necessary, as those periods already reflect the full effect of removing the SomaLogic Entities from the continued operations presentation. Similarly, no pro forma adjustments to the balance sheet as of March&#160;31, 2026 are necessary, as the balance sheet as of such date already gives effect to the disposition of the SomaLogic Entities.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As of the filing of the registration statement on Form S-4 of which this proxy statement/prospectus forms a part, one or more definitive asset purchase agreements for the sale of the Legacy Business have not yet been executed. Both parties expect the sale of the Legacy Business to be completed prior to or concurrently with the closing of the Merger, and the selected pro forma data have been prepared on that basis. Although asset purchase agreements have not yet been executed and wind-down activities have not been completed, all existing business activities of Standard BioTools are expected to be disposed prior to the closing of the Merger. Therefore, the pro forma adjustments give effect to the disposition of the Legacy Business and the related assets and activities, which </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">30<br></div></div></div>
<!--End Page 41-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 42-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_109-selected_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">are considered probable, as if it had occurred. Any proceeds obtained from the sale of the Legacy Business is subject to the CVR. Net proceeds from the sale of the Legacy Business would be fully offset by a CVR liability, which has not been reflected within the selected pro forma data due to the uncertainty of expected net proceeds. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The selected pro forma data have been presented for informational purposes only. The selected pro forma data do not purport to represent the actual results of operations that Standard BioTools and Treeline would have achieved had the companies been combined during the periods presented in the selected financial data and is not intended to project the future results of operations that Standard BioTools may achieve after the Merger is consummated. The selected pro forma data do not reflect any cost savings that may be realized as a result of the Merger and also do not reflect any restructuring or integration-related costs to achieve those potential cost savings. Amounts below are presented in thousands, except per share amounts. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 264pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 3.21pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 3.21pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 111.99pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 3.21pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 3.21pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 79.17pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 264pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 3.21pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.21pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 111.99pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Pro Forma Three Months Ended <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31,</div></td><td style="width: 3.21pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.21pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 79.17pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Pro Forma Year Ended <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, </div></td></tr><tr class="BRDSX_header"><td style="width: 264pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Income Statement Data</div></td><td style="width: 3.21pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.21pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 111.99pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2026</div></td><td style="width: 3.21pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.21pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 79.17pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025 </div></td></tr><tr class="BRDSX_header"><td style="width: 264pt; padding-top: 2.08pt; padding-bottom: 2.88pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 3.21pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.21pt;"><div style="font-size: 1pt;">&#8194;</div></td><td colspan="4" style="width: 197.58pt; padding-top: 2.08pt; padding-bottom: 2.88pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(unaudited)<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(in thousands, except for share data and <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">per share amounts) </div></td></tr><tr><td style="width: 264pt; padding-top: 2.51pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating expenses:<br></div></td><td style="width: 3.21pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.21pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 111.99pt; padding-top: 2.51pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 3.21pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.21pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 79.17pt; padding-top: 2.51pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 264pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research and development<font style="padding-left: 3.76pt;"></font></div></td><td style="width: 3.21pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.21pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 111.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 24.74pt; text-align: left;">$<font style="padding-left: 30pt;">49,098</font></div></td><td style="width: 3.21pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.21pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 79.17pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.33pt; text-align: left;">$<font style="padding-left: 25pt;">160,009 </font></div></td></tr><tr><td style="width: 264pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Selling, general and administrative<font style="padding-left: 2.09pt;"></font></div></td><td style="width: 3.21pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.21pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 111.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 24.74pt; text-align: left;"><font style="padding-left: 35pt;">20,073</font></div></td><td style="width: 3.21pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.21pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 79.17pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.33pt; text-align: left;"><font style="padding-left: 30pt;">100,868 </font></div></td></tr><tr><td style="width: 264pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Restructuring and related charges<font style="padding-left: 2.57pt;"></font></div></td><td style="width: 3.21pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.21pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 111.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 24.74pt; text-align: left;"><font style="padding-left: 40pt;">3,080</font></div></td><td style="width: 3.21pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.21pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 79.17pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.33pt; text-align: left;"><font style="padding-left: 35pt;">50,566</font> </div></td></tr><tr><td style="width: 264pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Transaction and integration expenses<font style="padding-left: 3.29pt;"></font></div></td><td style="width: 3.21pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.21pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 111.99pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 24.74pt; text-align: left;"><font style="padding-left: 52.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 3.21pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.21pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 79.17pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.33pt; text-align: left;"><font style="padding-left: 40pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">2,162 </font></div></td></tr><tr><td style="width: 264pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total operating expenses<font style="padding-left: 2.23pt;"></font></div></td><td style="width: 3.21pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.21pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 111.99pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 24.74pt; text-align: left;"><font style="padding-left: 35pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">72,</font><font style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">251</font></div></td><td style="width: 3.21pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.21pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 79.17pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.33pt; text-align: left;"><font style="padding-left: 30pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">3</font><font style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">13,605 </font></div></td></tr><tr><td style="width: 264pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss from continuing operations<font style="padding-left: 1.25pt;"></font></div></td><td style="width: 3.21pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.21pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 111.99pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 24.74pt; text-align: left;"><font style="padding-left: 31.67pt;">(72,251)</font></div></td><td style="width: 3.21pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.21pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 79.17pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.33pt; text-align: left;"><font style="padding-left: 26.67pt;">(313,605) </font></div></td></tr><tr><td style="width: 264pt; padding-top: 1.01pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net loss from continuing operations<font style="padding-left: 2.64pt;"></font></div></td><td style="width: 3.21pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.21pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 111.99pt; padding-top: 1.01pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 24.74pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 26.67pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(6</font><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">8,865</font><font style="padding-bottom: 0.5pt;">)</font></div></td><td style="width: 3.21pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.21pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 79.17pt; padding-top: 1.01pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.33pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 21.67pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(</font><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">241,633</font><font style="padding-bottom: 0.5pt;">) </font></div></td></tr><tr><td style="width: 264pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Share Information:<br></div></td><td style="width: 3.21pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.21pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 111.99pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 3.21pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.21pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 79.17pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 264pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net loss per share from continuing operations, basic and diluted<font style="padding-left: 1.02pt;"></font></div></td><td style="width: 3.21pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.21pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 111.99pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 24.74pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">$</font><font style="padding-left: 36.67pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(0.0</font><font style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">3</font><font style="padding-bottom: 1.5pt;">)</font></div></td><td style="width: 3.21pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.21pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 79.17pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.33pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">$</font><font style="padding-left: 36.67pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(0.</font><font style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">10</font><font style="padding-bottom: 1.5pt;">) </font></div></td></tr><tr><td style="width: 264pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Shares used in computing net loss per share attributable to common stockholders, basic and diluted<font style="padding-left: 0.7pt;"></font></div></td><td style="width: 3.21pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.21pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 111.99pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 24.74pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">2,</font><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">407,631,800</font></div></td><td style="width: 3.21pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.21pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 79.17pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.33pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">2,3</font><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">50,729,463</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 264pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 3.21pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 3.21pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 111.99pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 3.21pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 3.21pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 79.17pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 360pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 7.82pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 7.82pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 92.35pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 360pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Balance Sheet Data</div></td><td style="width: 7.82pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.82pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 92.35pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Pro Forma March&#160;31, 2026 </div></td></tr><tr class="BRDSX_header"><td style="width: 360pt; padding-top: 2.08pt; padding-bottom: 2.88pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 7.82pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.82pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 92.35pt; padding-top: 2.08pt; padding-bottom: 2.88pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(in thousands) </div></td></tr><tr class="BRDSX_header"><td style="width: 360pt; padding-top: 2.58pt; padding-bottom: 2.88pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 7.82pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.82pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 92.35pt; padding-top: 2.58pt; padding-bottom: 2.88pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(unaudited) </div></td></tr><tr><td style="width: 360pt; padding-top: 2.51pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash, cash equivalents, restricted cash, and marketable securities<font style="padding-left: 2.6pt;"></font></div></td><td style="width: 7.82pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.82pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 92.35pt; padding-top: 2.51pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 23.68pt; text-align: left;">$1,060,159 </div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total assets<font style="padding-left: 1.27pt;"></font></div></td><td style="width: 7.82pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.82pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 92.35pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 23.68pt; text-align: left;">$1,180,445 </div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total liabilities<font style="padding-left: 2.38pt;"></font></div></td><td style="width: 7.82pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.82pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 92.35pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 23.68pt; text-align: left;">$<font style="padding-left: 7.87pt;">&#8203;113,767 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total stockholders&#180; equity<font style="padding-left: 3.22pt;"></font></div></td><td style="width: 7.82pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.82pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 92.35pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 23.68pt; text-align: left;">$1,066,678 </div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total liabilities and stockholders&#180; equity<font style="padding-left: 1.57pt;"></font></div></td><td style="width: 7.82pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.82pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 92.35pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 23.68pt; text-align: left;">$1,180,445</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 360pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 7.82pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 7.82pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 92.35pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0.5pt; margin-left: 0pt; text-align: justify;"> </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">31<br></div></div></div>
<!--End Page 42-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 43-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_109-selected_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tCPS"><!--Anchor--></a>COMPARATIVE PER SHARE MARKET PRICE AND DIVIDEND INFORMATION </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Market Prices </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Standard BioTools Common Stock is currently listed on The Nasdaq Global Select Market under the symbol &#8220;LAB.&#8221; The closing price of the Standard BioTools Common Stock on June&#160;5, 2026, the last day of trading prior to the announcement of the Merger, as reported on Nasdaq, was $1.15 per share. The closing price of the Standard BioTools Common Stock on &#8195;&#8195;&#8195;, 2026, the last practicable date before the date of this proxy statement/prospectus, as reported on Nasdaq, was $&#8195;&#8195; per share. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Because the market price of the Standard BioTools Common Stock is subject to fluctuation, the market value of the shares of the Standard BioTools Common Stock that the Treeline stockholders will be entitled to receive in the Merger may increase or decrease. The market price of Standard BioTools Common Stock has fluctuated since the date of the announcement of the Merger Agreement and will continue to fluctuate from the date of this proxy statement/prospectus to the date of the Special Meeting and the date the Merger is consummated and thereafter. No assurance can be given concerning the market price of Standard BioTools Common Stock before consummation of the Merger or the market price of Standard BioTools Common Stock after consummation of the Merger. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Shares of Standard BioTools Common Stock are currently listed on The Nasdaq Global Select Market under the symbol &#8220;LAB.&#8221; Standard BioTools anticipates that the common stock of the combined company will be listed on The Nasdaq Stock Market LLC following the Closing under the trading symbol &#8220;TRLN.&#8221; It is a condition to the consummation of the Merger that existing shares of Standard BioTools Common Stock are listed on Nasdaq as of the Closing Date and that the shares of Standard BioTools Common Stock issuable in connection with the Merger have been approved for listing on Nasdaq, subject to official notice of issuance, but there can be no assurance such listing condition will be met. If such listing condition is not met, the Merger will not be consummated unless the condition is waived. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline is a private company and shares of Treeline Capital Stock are not publicly traded. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Holders </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As of 5:00 p.m. U.S. Eastern Time on the Record Date, &#8195;&#8195; shares of Standard BioTools Common Stock, held by &#8195;&#8195; holders of record, were outstanding and entitled to vote at the Special Meeting. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Dividends </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Standard BioTools has never declared or paid any cash dividends on Standard BioTools Common Stock. Any determination to pay cash dividends subsequent to the Merger will be at the discretion of the combined company&#8217;s then-current board of directors and will depend upon a number of factors, including the combined company&#8217;s results of operations, financial condition, future prospects, contractual restrictions, restrictions imposed by applicable law and other factors the then-current board of directors deems relevant. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Prior to the Effective Time, Standard BioTools expects to declare a dividend to Standard BioTools stockholders as of the close of business on the last business day prior to the day on which the Effective Time occurs in the form of one CVR for each outstanding share of Standard BioTools Common Stock held by such stockholder on such date. The payment date for such dividend will be three business days after the Effective Time. The CVRs will be issued pursuant to the terms of the CVR Agreement. See &#8220;<font style="font-style: italic;">The Merger &#8212; CVR Agreement</font>.&#8221; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline has never paid or declared any cash dividends on Treeline Capital Stock and does not anticipate paying any cash dividends on the Treeline Capital Stock in the foreseeable future. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">32<br></div></div></div>
<!--End Page 43-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 44-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tRF"><!--Anchor--></a>RISK FACTORS </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition to the other information contained in or incorporated by reference into this proxy statement/prospectus, including the matters addressed under &#8220;Cautionary Statement Regarding Forward-Looking Statements&#8221; in this proxy statement/prospectus, Standard BioTools stockholders should carefully consider the following risks in deciding whether to vote for the approval of the Standard BioTools Proposals. Descriptions of other risks can be found in the Annual Report for Standard BioTools on Form&#160;10-K for the year ended December&#160;31, 2025, the Quarterly Report for Standard BioTools on Form&#160;10-Q for the quarter ended March&#160;31, 2026, and any amendments thereto, as such risks may be updated or supplemented in Standard BioTools&#8217; subsequently filed Quarterly Reports on Form&#160;10-Q or Current Reports on Form&#160;8-K, and other filings with the SEC from time to time, which are incorporated by reference into this proxy statement/prospectus. You should read carefully this entire proxy statement/prospectus and its annexes and exhibits and the other documents incorporated by reference into this proxy statement/prospectus. See also &#8220;Incorporation of Certain Documents by Reference&#8221; and &#8220;Where You Can Find More Information&#8221; beginning on pages <a href="#tIBR">334</a> and <a href="#tWYC">335</a>, respectively, of this proxy statement/prospectus.<font style="font-style: normal;"> </font></div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Risks Related to the Merger </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Standard BioTools and Treeline may not be successful in consummating the Merger. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">There can be no assurance that the Merger will be successfully consummated or lead to increased stockholder value. The completion of the Merger is dependent on a number of factors that may be beyond the control of Standard BioTools and Treeline, including, among other things, market conditions, regulatory approval and stockholder approval. Any failure to consummate the Merger would have a material adverse effect on Standard BioTools&#8217; and Treeline&#8217;s businesses and could significantly impair Standard BioTools&#8217; and Treeline&#8217;s ability to enter into alternative strategic transactions. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The process of completing the Merger is costly, time-consuming and complex. Standard BioTools and Treeline have incurred, and may in the future incur, significant costs related to the Merger, including legal and accounting fees and expenses and other related charges, which have been and will be incurred regardless of whether the Merger is completed. Standard BioTools and Treeline may also incur additional unanticipated expenses in connection with the Merger. These expenses will decrease the remaining cash available for use in Standard BioTools&#8217; and Treeline&#8217;s businesses. Also, the Merger could have a variety of negative consequences, or yield unexpected results, that adversely affect Standard BioTools&#8217; and Treeline&#8217;s businesses and decrease the remaining cash available for use in the combined company&#8217;s future business. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If the Merger is not completed in a timely fashion, Standard BioTools and Treeline may experience reputational harm and the value of the Standard BioTools Common Stock and the Treeline Common Stock may be adversely impacted. In addition, speculation regarding the completion of the Merger and perceived uncertainties related to the future of Standard BioTools could cause Standard BioTools&#8217; stock price to fluctuate significantly. Also, if the Merger Agreement is terminated and the board of directors of Standard BioTools determines to seek another business combination, there can be no assurance that Standard BioTools will be able to find another third party to transact a business combination with, yielding comparable or greater benefits. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">The consummation of the Merger is subject to various conditions, including approval by the Standard BioTools stockholders, regulatory approval, and obtaining approval by Nasdaq to the listing of the Standard BioTools Common Stock. Failure to satisfy these conditions would prevent the Closing. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Merger Agreement contains a number of conditions that must be satisfied or waived (to the extent permitted by applicable law) in order to consummate the Merger, some of which are not within Standard BioTools&#8217; control. These conditions include, among others: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">approval of the Share Issuance Proposal and the Charter Amendment Proposal by the Standard BioTools stockholders; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">approval for listing on Nasdaq of the Standard BioTools Common Stock to be issued to Treeline stockholders in connection with the Merger, subject to official notice of issuance; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">expiration or termination of the waiting period relating to the Merger under applicable antitrust laws; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the absence of any law, judgment, order or other legal restraint prohibiting the Merger; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the effectiveness of the registration statement on Form&#160;S-4 of which this proxy statement/prospectus is a part. </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">33<br></div></div></div>
<!--End Page 44-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 45-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Any failure to satisfy or, to the extent permitted by applicable law, waive these required closing conditions may prevent, delay or otherwise materially adversely affect the consummation of the Merger. Standard BioTools cannot predict with certainty whether or when any of the required conditions will be satisfied or, to the extent permitted by applicable law, waived, and cannot assure you that Standard BioTools will be able to successfully consummate the Merger as currently contemplated under the Merger Agreement or at all. For additional information regarding the conditions to the Merger, see &#8220;<font style="font-style: italic;">The Merger Agreement &#8212; Conditions to the Completion of the Merger</font>&#8221; beginning on page <a href="#tCONCOMMER">207</a> of this proxy statement/prospectus. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, the Merger might not be consummated because Treeline or Standard BioTools may elect to terminate the Merger Agreement in certain circumstances. Upon termination of the Merger Agreement under specified circumstances, including if Treeline terminates the Merger Agreement due to a change in the Standard BioTools Board recommendation in favor of the Transactions, Standard BioTools will be required to make a payment to Treeline equal to $16.1&#160;million in cash. In addition, Standard BioTools will be required to reimburse Treeline&#8217;s reasonable out-of-pocket fees in connection with the Transactions up to a maximum of $5&#160;million if the Merger Agreement is terminated due to a failure to obtain the required approval of Standard BioTools stockholders. See &#8220;<font style="font-style: italic;">The Merger Agreement &#8212; Termination</font>&#8221; beginning on page <a href="#tTERM">224</a> of this proxy statement/prospectus. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">The Merger consideration paid at closing may have a greater or lesser value than at the time the Merger Agreement was signed or at the time of the Special Meeting. The value of the Merger consideration will be impacted by fluctuations in the market price of Standard BioTools Common Stock. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In connection with the closing of the Merger (the &#8220;Closing&#8221;), each share of Treeline Common Stock and Treeline Preferred Stock issued and outstanding immediately prior to the Effective Time will be converted into the right to receive a number of shares of Standard BioTools Common Stock equal to the Exchange Ratio, provided that the number of shares of Standard BioTools Common Stock which each holder of Treeline Capital Stock is entitled to receive will be rounded down to the nearest whole share and computed after aggregating all shares of Treeline Capital Stock held by such holder, with no cash payable in lieu of fractional shares. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Exchange Ratio will not be adjusted in the event of any change in the market price of Standard BioTools Common Stock and, as a result, prior to the Effective Time, Standard BioTools stockholders and Treeline stockholders cannot be sure of the value of the Standard BioTools Common Stock to be issued in connection with the Merger. Changes in the Standard BioTools stock price can result from a variety of factors, including general market, industry and economic conditions, changes in the respective businesses, operations and prospects of Treeline and Standard BioTools, regulatory considerations, results of the Special Meeting, announcements with respect to the Merger or any of the foregoing, and other factors beyond the control of Treeline or Standard BioTools. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The exact dollar value of the Standard BioTools Common Stock that the Standard BioTools stockholders and the Treeline stockholders will hold upon consummation of the Merger will not be known at the time of the Special Meeting and may be greater than, the same as or less than the current market price of the Standard BioTools Common Stock at the time of the Special Meeting. The market price of Standard BioTools Common Stock is subject to general price fluctuations in the market for publicly traded equity securities and has experienced volatility in the past and may vary significantly after the date of the Special Meeting. As a result of these fluctuations, the value of the Merger consideration will also vary. For example, based on the range of closing prices of Standard BioTools Common Stock during the period from June&#160;5, 2026, the last trading day before public announcement of the Merger, through &#8195;&#8195;&#8195; , the latest practicable trading date before the filing of this proxy statement/prospectus and in each case, taking into account Standard BioTools&#8217; current cash position and excluding the effect of any proposed Standard BioTools reverse stock split, the Exchange Ratio represented a value ranging from a low of $&#8195;&#8195; to a high of $&#8195;&#8195; for each share of Treeline Common Stock. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">The Exchange Ratio, which determines the number of shares to be issued to the Treeline stockholders, will vary based on the extent to which Parent Net Cash at Closing is more than $451&#160;million or less than $449&#160;million. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The value of the Merger consideration will also be impacted by the amount of Parent Net Cash (as defined in the Merger Agreement) that Standard BioTools has at Closing. The Exchange Ratio, which determines the number of shares of Standard BioTools Common Stock to be issued to former Treeline stockholders, will vary in part based on the amount of Parent Net Cash that Standard BioTools has at Closing. To the extent that Parent Net Cash is more than $451&#160;million, the Exchange Ratio will be lower and Treeline stockholders will receive fewer shares of Standard BioTools Common Stock; to the extent that Parent Net Cash is less than $449&#160;million, the Exchange Ratio will be </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">34<br></div></div></div>
<!--End Page 45-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 46-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">higher and Treeline stockholders will receive more shares of Standard BioTools Common Stock, resulting in incremental dilution to the Standard BioTools stockholders. The term &#8220;Parent Net Cash,&#8221; as defined in the Merger Agreement, will be reduced by the amount of certain liabilities of Standard BioTools at Closing. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">The Merger Agreement contains provisions that could discourage a potential competing acquirer of Standard BioTools or Treeline. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Merger Agreement contains &#8220;no shop&#8221; provisions that restrict each of Standard BioTools&#8217; and Treeline&#8217;s ability to solicit, initiate, induce, knowingly encourage or knowingly facilitate, or take any other action designed to facilitate, competing third-party proposals relating to a merger, reorganization or consolidation of the respective company or an acquisition of the respective company&#8217;s stock or assets. In addition, Standard BioTools generally has an opportunity to offer to modify the terms of the Merger Agreement in response to any competing acquisition proposals before the Standard BioTools Board may withdraw or qualify its recommendation with respect to the Merger. If the Merger Agreement is terminated in connection with the pursuit of a third-party transaction by Standard BioTools, Standard BioTools will be required to pay a termination fee of $16.1&#160;million to Treeline and/or reimburse up to a maximum of $5&#160;million of Treeline&#8217;s expenses. See &#8220;<font style="font-style: italic;">The Merger Agreement &#8212; Termination</font>&#8221; and &#8220;<font style="font-style: italic;">The Merger Agreement &#8212; Termination Fee and Expense Reimbursement</font>&#8221; beginning on pages <a href="#tTERM">224</a> and <a href="#tTFER">225</a>, respectively, of this proxy statement/prospectus. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">These provisions could discourage a potential third-party acquirer that might have an interest in acquiring all or a significant portion of Standard BioTools from considering or proposing an acquisition, even if it were prepared to pay consideration with a higher per share cash or market value than the market value proposed in the Merger. A&#160;potential third-party acquirer maintaining interest in the face of these provisions might propose to pay a lower price to Standard BioTools stockholders than it might otherwise have proposed to pay because of the added expense of the termination fee and expense reimbursement described above. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If the Merger Agreement is terminated and Standard BioTools determines to seek another business combination, it may not be able to negotiate a transaction with another party on terms comparable to, or better than, the terms of the Merger. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">The pendency of the Merger could materially adversely affect the business, financial condition, results of operations or cash flows of Standard BioTools or Treeline. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The announcement and pendency of the Merger could disrupt Standard BioTools&#8217; and Treeline&#8217;s businesses, in any of the following ways, among others: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Standard BioTools&#8217; or Treeline&#8217;s employees may experience uncertainty about their future roles with the combined company, which might adversely affect each company&#8217;s ability to retain and hire key managers and other employees; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the attention of Standard BioTools management or Treeline management may be directed toward completion of the Merger and transaction-related considerations and may be diverted from each company&#8217;s day-to-day business operations and, following the completion of the Merger, the attention of the combined company&#8217;s management may also be diverted to such matters; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">vendors, suppliers, business partners or others may seek to modify or terminate their business relationship with Standard BioTools, Treeline or the combined company following completion of the Merger; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Standard BioTools, Treeline or the combined company following completion of the Merger, and their respective officers and directors, could become subject to lawsuits relating to the Merger; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Standard BioTools or Treeline may experience negative reactions from their stockholders, among others. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">These disruptions could be exacerbated by a delay in the completion of the Merger or termination of the Merger Agreement. Additionally, if the Merger is not consummated, each company will have incurred significant costs and diverted the time and attention of management. A failure to consummate the Merger may also result in negative publicity, reputational harm, litigation against Standard BioTools, Treeline and/or their respective directors and officers, and a negative impression of the companies in the financial markets. The occurrence of any of these events individually or in combination could have a material adverse effect on either or both companies&#8217; financial performance and stock price. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">35<br></div></div></div>
<!--End Page 46-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 47-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">The interim operating covenants contained in the Merger Agreement may prevent Standard BioTools or Treeline from pursuing opportunities that would be beneficial to stockholders of the combined company. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Merger Agreement restricts Standard BioTools and Treeline from taking certain actions until the Effective Time without the consent of the other party, including, among others: the payment of dividends; the issuance of equity (including certain equity incentive awards); certain increases to employee compensation and benefits; capital expenditures; the incurrence of indebtedness; acquisitions and divestitures; and the entry into or amending certain material contracts. Standard BioTools and Treeline are required to conduct their business in the ordinary course of business in all material respects. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The restrictive covenants, which are subject to various specific exceptions, may prevent Standard BioTools or Treeline from pursuing attractive business opportunities that may arise prior to the consummation of the Merger. Although Standard BioTools and Treeline may be able to pursue such activities with the other company&#8217;s consent, the other company may not be willing to provide its consent. For a description of the restrictive covenants applicable to Standard BioTools and Treeline, see &#8220;<font style="font-style: italic;">The Merger Agreement &#8212; Covenants; Conduct of Business Pending the Merger</font>&#8221; beginning on page <a href="#tCCBPM">217</a> of this proxy statement/prospectus. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">The Merger may be completed even though a material adverse effect may result from the announcement of the Merger, industry-wide changes or other causes. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In general, neither Standard BioTools nor Treeline is obligated to complete the Merger if there is a continuing material adverse effect affecting the other party between June&#160;6, 2026, the date of the Merger Agreement, and the Closing. However, certain types of changes are excluded from the concept of a &#8220;material adverse effect.&#8221; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Such exclusions include, but are not limited to, general business or economic conditions generally affecting the industry in which the applicable party operates; political conditions, acts of war, the outbreak or escalation of armed hostilities, acts of terrorism, earthquakes, wildfires, hurricanes, tsunamis, floods, mudslides, weather conditions, other natural disasters, man-made disasters, health and other emergencies, calamities, epidemics, pandemics (including COVID-19 and any evolutions or mutations thereof), disease outbreaks, other acts of God or force majeure events; changes in financial, banking or securities markets, including changes in interest rates in the United States or any other country or region in the world; any change in law or GAAP; any change in the stock price or trading volume of Standard BioTools Common Stock; a failure to meet internal or analysts&#8217; expectations or projections; and the execution or announcement of the Merger Agreement or the pendency of the Merger. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Therefore, if any of these events were to occur, impacting Standard BioTools or Treeline, the other party would still be obliged to consummate the Closing. If any such adverse changes occur and Standard BioTools and Treeline consummate the Closing, the stock price of the combined company may suffer. This in turn may reduce the value of the Merger to the stockholders of Standard BioTools, Treeline or both. For a more complete discussion of what constitutes a material adverse effect on Standard BioTools or Treeline, see the section entitled &#8220;<font style="font-style: italic;">The Merger Agreement &#8212; Conditions to the Completion of the Merger</font>&#8221; beginning on page <a href="#tCONCOMMER">207</a> of this proxy statement/prospectus. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">If Standard BioTools and Treeline complete the Merger, the combined company may need to raise additional capital in the future by issuing equity securities or additional debt or through licensing arrangements, which may cause significant dilution to the combined company&#8217;s stockholders or restrict the combined company&#8217;s operations. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Additional financing may not be available to the combined company when it is needed or may not be available on favorable terms. To the extent that the combined company raises additional capital by issuing equity securities, or debt securities convertible into equity securities, such financing will cause additional dilution to all of the securityholders of the combined company, including Standard BioTools&#8217; pre-Merger stockholders and Treeline&#8217;s former stockholders, and could have an adverse impact on the combined company&#8217;s stock price. It is also possible that the terms of any new equity securities may have preferences over the combined company&#8217;s common stock. Any debt financing the combined company enters into may include covenants that restrict its operations. These restrictive covenants may include limitations on additional borrowing and specific restrictions on the use of the combined company&#8217;s assets, as well as prohibitions on its ability to create liens, pay dividends, redeem its stock or make investments. In addition, if the combined company raises additional funds through licensing arrangements, it may be necessary to grant licenses on terms that are not favorable to the combined company. Any such financings could have a material adverse effect on the combined company. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">36<br></div></div></div>
<!--End Page 47-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 48-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Litigation that may be filed against Standard BioTools, Treeline, Merger Sub and/or their officers and directors could prevent or delay the consummation of the Merger. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The outcome of any lawsuit that may be filed challenging the Merger is uncertain. One of the conditions to the Closing is that no applicable law, judgment (whether temporary, preliminary or permanent) or other legal restraint or binding order or determination by any governmental entity of competent jurisdiction shall be in effect that prevents, restrains, enjoins, makes illegal or otherwise prohibits the consummation of the Merger or any of the other transactions contemplated by the Merger Agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Accordingly, if any future lawsuit is successful in obtaining an order enjoining consummation of the Merger, then such order may prevent the Merger from being consummated, or from being consummated within the expected time frame, and could result in substantial costs to Standard BioTools and Treeline, including but not limited to, legal fees and costs associated with the indemnification of directors and officers. Any such injunction or delay in the Merger being completed may adversely affect Standard BioTools&#8217; or Treeline&#8217;s business, financial condition, results of operations, and cash flows. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Standard BioTools and Treeline directors and executive officers have interests in the Merger that may be different from, or in addition to, the interests of Standard BioTools and Treeline stockholders. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Certain of the directors and executive officers of Standard BioTools and Treeline have interests in the Merger that may be different from, or in addition to, those of Standard BioTools and Treeline stockholders. These interests include, but are not limited to, the continued service of certain Standard BioTools and Treeline directors as directors and of Treeline executive officers as executive officers of the combined company after the date of consummation of the Merger (the &#8220;Closing Date&#8221;), in respect of the Treeline executive officers, assumption of their Treeline Options by Standard BioTools in accordance with the Merger Agreement, and in respect of the Standard BioTools directors and executive officers, accelerated vesting of Standard BioTools equity awards held by Standard BioTools non-employee directors on the Closing Date, receipt of a pro rata portion of the Merger consideration by affiliates of Casdin Capital, LLC (which owns 5.28% of Treeline and of which Eli Casdin, a director of Standard BioTools, is the Founder and Chief Investment Officer), certain severance payments and benefits (including acceleration of equity awards) for Standard BioTools executive officers in the event of a qualifying termination in connection with the consummation of the transactions contemplated by the Merger Agreement pursuant to the Standard BioTools CIC Severance Plans, extension of the post-employment exercise period for 30 months for certain Standard BioTools Options held by Standard BioTools executive officers, a possible transitional consulting agreement between Treeline and Sean Mackay, and provisions in the Merger Agreement regarding continued indemnification of and advancement of expenses of the directors and executive officers of Standard BioTools and Treeline. Standard BioTools stockholders should be aware of these interests when they consider the recommendation of the Standard BioTools Board that they vote in favor of the Merger-related proposals. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The members of the Standard BioTools Board and the Treeline Board were aware of and considered these interests relating to Standard BioTools and Treeline, among other matters, in evaluating the Merger Agreement and the Merger, and in recommending that Standard BioTools stockholders approve the Proposals. The interests of Standard BioTools and Treeline directors and executive officers are described in more detail under &#8220;<font style="font-style: italic;">The Merger &#8212; Interests of Standard BioTools Directors and Executive Officers in the Merger</font>&#8221; beginning on page <a href="#tIOSB">185</a> and &#8220;<font style="font-style: italic;">The Merger &#8212; Interests of Treeline&#8217;s Directors and Executive Officers in the Merger</font>&#8221; beginning on page <a href="#tINTER1">189</a> of this proxy statement/prospectus. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">The business of the combined company following the Merger will be different than the business of Standard BioTools prior to the Merger. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Standard BioTools currently develops, manufactures and sells a diversified range of instrumentation, consumables, and services that help scientists and biomedical researchers develop better therapeutics faster. Its proprietary multi-omics tools are used in a broad range of applications, including proteomics and genomics, and other areas of translational and clinical research. Its instruments and consumables are sold to leading academic research institutions, translational research and medicine centers, cancer centers, clinical research laboratories, and biopharmaceutical, biotechnology, and plant and animal research companies. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In connection with the Merger, Standard BioTools expects to sell or otherwise monetize its Legacy Business, and the business of the combined company will consist of Treeline&#8217;s business. Treeline is a clinical-stage biopharmaceutical company that matches compelling biological targets with proven drug approaches, including </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">37<br></div></div></div>
<!--End Page 48-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 49-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">small molecule inhibitors, protein degraders, and targeted therapy antibody-drug conjugates, by integrating in-house R&amp;D with leading-edge computational tools. Treeline&#8217;s pipeline spans oncology, neurology and immunology. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This change in the business of Standard BioTools from manufacturing and selling instruments to being a clinical-stage biopharmaceutical company could have a significant impact on the trading and market price of the common stock of the combined company following the Merger. The change in business may attract different investors and analysts and could result in the combined company&#8217;s common stock being more volatile than it was prior to the Merger. We cannot predict with certainty how the change in business will impact the combined company&#8217;s common stock following the consummation of the Merger. There can be no assurance that the change in business will not have a material adverse impact on the trading price and liquidity of the combined company&#8217;s common stock.</div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Following the consummation of the Merger, the composition of the board of directors and management of the combined company will be different from the composition of the current board of directors and management of Standard BioTools. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Following the consummation of the Merger, the board of directors of the combined company is expected to consist of 12 members, including ten director designees of Treeline and two director designees of Standard BioTools. In addition, the management team of Treeline will become the management team of Standard BioTools. In particular, Dr.&#160;Joshua Bilenker, currently the chief executive officer and co-founder of Treeline, will serve as Chief&#160;Executive Officer of the combined company, Dr.&#160;Jeffrey Engelman, currently the chief scientific officer and co-founder of Treeline, will serve as Chief Scientific Officer of the combined company, and Spencer Smith, currently the chief financial officer of Treeline, will serve as Chief Financial Officer of the combined company. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This change in board membership and management of the combined company may affect the combined company&#8217;s business strategy and operating decisions following the consummation of the Merger, as compared to those of Standard BioTools prior to the Merger. In addition, there can be no assurances that the board of directors of the combined company will function effectively as a team and that any differences or difficulties, should they arise, will not have an adverse effect on the combined company&#8217;s business or results after the Closing Date. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Following consummation of the Merger, the former Standard BioTools stockholders will own less than a majority of the outstanding common stock of the combined company and will therefore have less influence over the combined company than they do now. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Immediately following completion of the Merger and the issuance of the Standard BioTools Common Stock to the Treeline stockholders at the Effective Time, Standard BioTools&#8217; current stockholders in the aggregate will not have a majority ownership and voting interest in the combined company, which will result in Standard BioTools stockholders having less influence on the combined company&#8217;s management and policies. Immediately following completion of the Merger and using an estimated Exchange Ratio based on Standard BioTools&#8217; and Treeline&#8217;s capitalization as of June&#160;3, 2026 and May&#160;28, 2026, respectively, and taking into account Standard BioTools&#8217; estimated cash position as of the Closing but excluding any effect of the proposed Standard BioTools reverse stock split, Treeline stockholders and Standard BioTools stockholders are expected to own approximately 84% and 16%, respectively, of the combined company&#8217;s outstanding shares on a fully diluted basis. As a result, current Standard BioTools stockholders will have significantly less influence on the combined company&#8217;s management and policies than they currently have. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Because the lack of a public market for the shares of Treeline Capital Stock makes it difficult to evaluate the fairness of the Merger, Standard BioTools may pay more to the Treeline stockholders than the fair market value of the Treeline Capital Stock. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The outstanding shares of Treeline Capital Stock are privately held and are not traded in any public market. The lack of a public market makes it extremely difficult to determine the fair market value of the shares of Treeline Capital Stock. Because the Exchange Ratio that will be used to calculate the number of shares of Standard BioTools Common Stock to be issued to Treeline stockholders was determined based on negotiations between the parties, it is possible that Standard BioTools may pay more than the aggregate fair market value for the shares of Treeline Capital Stock. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">38<br></div></div></div>
<!--End Page 49-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 50-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg7"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">The opinions of Standard BioTools&#8217; financial advisors do not reflect changes in circumstances that may have occurred or that may occur between the signing of the Merger Agreement and the consummation of the Merger. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The opinion rendered to the Standard BioTools Board by Centerview and the opinion rendered to the Standard BioTools Special Committee by UBS were provided in connection with, and at the time of, the Standard BioTools Board&#8217;s and Standard BioTools Special Committee&#8217;s respective evaluations of the Merger. These opinions were based on the respective financial analyses performed, which considered market and other conditions then in effect, and financial forecasts and other information made available to Centerview and UBS, as of the date of their respective opinions, which may have changed, or may change, after the date of the opinions. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Neither the Standard BioTools Board nor the Standard BioTools Special Committee has obtained updated opinions from their respective financial advisors as of the date of this proxy statement/prospectus or as of any other date, nor does either expect to receive updated, revised or reaffirmed opinions prior to the consummation of the Merger. Changes in the operations and prospects of Treeline or Standard BioTools, general market and economic conditions and other factors that may be beyond the control of Treeline or Standard BioTools, and which changes were not taken into account by Standard BioTools&#8217; financial advisors in rendering their respective opinions, may significantly alter the value of Treeline or Standard BioTools or the prices of Treeline Common Stock or Standard BioTools Common Stock by the time the Merger is consummated. The opinions do not speak as of the time the Merger will be consummated or as of any date other than the date of such opinions. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Because there are no plans for Standard BioTools&#8217; financial advisors to update their opinions, the opinions do not address the fairness of the Exchange Ratio or the Merger consideration, as applicable, from a financial point of view, at any time other than the time such opinions were rendered, even though the Standard BioTools Board&#8217;s recommendation that Standard BioTools stockholders vote &#8220;<font style="font-weight: bold;">FOR</font>&#8221; the Standard BioTools Proposals is made as of the date of this proxy statement/prospectus. For a description of the opinions that the Standard BioTools Board and the Standard BioTools Special Committee received from their respective financial advisors, see &#8220;<font style="font-style: italic;">The Merger &#8212; Opinion of Standard BioTools&#8217; Financial Advisor</font>&#8221; beginning on page <a href="#tOPIS1">171</a> of this proxy statement/prospectus and &#8220;<font style="font-style: italic;">The Merger &#8212; Opinion of Standard BioTools Special Committee&#8217;s Financial Advisor</font>&#8221; beginning on page <a href="#tOPISB1">176</a> of this proxy statement/prospectus. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Failure to consummate the Merger could negatively impact future stock prices, operations and financial results of Standard BioTools. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If the Merger is not consummated for any reason, Standard BioTools may be subject to a number of material risks, including the following: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a decline in the market price of Standard BioTools Common Stock to the extent that its current market price reflects a market assumption that the Merger will be consummated and will be beneficial to the value of the common stock after the Closing Date; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">having to pay certain costs related to the proposed Merger, such as legal, accounting, financial advisory, printing and mailing fees, which must be paid regardless of whether the Merger is consummated; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">addressing the consequences of operational decisions made since the signing of the Merger Agreement, including decisions made as a result of restrictions on Standard BioTools&#8217; operations imposed by the terms of the Merger Agreement and decisions to delay or defer capital expenditures; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">returning the focus of management and personnel to operating Standard BioTools on a standalone basis, without any of the benefits expected to have been provided by the consummation of the Merger; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">negative reactions from stockholders, customers, suppliers and employees. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition to the above risks, Standard BioTools may be required, under certain circumstances, to pay a termination fee of $16.1&#160;million to Treeline, including if Treeline terminates the Merger Agreement due to a change in the Standard BioTools Board recommendation in favor of the Transactions, or in some cases reimburse Treeline&#8217;s reasonable out-of-pocket transaction-related expenses (up to a maximum of $5&#160;million), including if Treeline terminates the Merger Agreement due to a failure to obtain the required approval of Standard BioTools stockholders, which may adversely affect Standard BioTools&#8217; financial condition. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The business of Standard BioTools may be adversely impacted by the failure to pursue other beneficial opportunities due to the focus of Standard BioTools management on the Merger. A failure to consummate the Merger may also result in negative publicity, reputational harm, potential litigation against Standard BioTools or its </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">39<br></div></div></div>
<!--End Page 50-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 51-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg8"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">directors and officers, and a negative impression of the companies in the financial markets. If the Merger is not consummated, we cannot assure the Standard BioTools stockholders that these risks will not materialize and will not materially adversely affect the business, financial results and stock price of Standard BioTools. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">If the Merger is not completed, and there is no superior alternative transaction available, the Standard BioTools Board may decide to pursue a dissolution and liquidation of the Standard BioTools business. In such an event, the amount of cash available for distribution to Standard BioTools&#8217; stockholders will depend heavily on the timing of such liquidation as well as the amount of cash that will need to be reserved for commitments and contingent liabilities. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If the Merger is not completed, and there is no superior alternative transaction available, the Standard BioTools Board may decide to pursue a dissolution and liquidation of the Standard BioTools business if it concludes that such strategy is in the best interests of the Standard BioTools stockholders. In such an event, the amount of cash available for distribution to Standard BioTools&#8217; stockholders will depend heavily on the timing of such decision and, with the passage of time, the amount of cash available for distribution will be reduced as Standard BioTools continues to fund its operations. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, if the Standard BioTools Board were to approve and recommend, and Standard BioTools stockholders were to approve, a dissolution and liquidation, Standard BioTools would be required under Delaware corporate law to pay its outstanding obligations, as well as to make reasonable provision for contingent and unknown obligations, prior to making any distributions in liquidation to Standard BioTools&#8217; stockholders. As a result of this requirement, a portion of Standard BioTools&#8217; assets may need to be reserved pending the resolution of such obligations and the timing of any such resolution is uncertain. In addition, Standard BioTools may be subject to litigation or other claims related to a dissolution and liquidation. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If a dissolution and liquidation were pursued, the Standard BioTools Board, in consultation with its advisors, would need to evaluate these matters and make a determination about a reasonable amount to reserve. Accordingly, holders of Standard BioTools Common Stock could lose all or a significant portion of their investment in the event of a liquidation, dissolution or winding up. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13pt; margin-left: 0pt; text-align: left;">Standard BioTools stockholders will not be entitled to appraisal rights in the Merger. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Appraisal rights are statutory rights that, if applicable under law, enable stockholders to dissent from an extraordinary transaction, such as a merger, and to demand that the corporation pay the fair value for their shares as determined by a court in a judicial proceeding instead of receiving the consideration offered to stockholders in connection with the extraordinary transaction. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under &#167; 262(b) of the Delaware General Corporation Law, stockholders do not have appraisal rights if the shares of stock they hold, as of the record date for determination of stockholders entitled to vote at the meeting of stockholders to act upon a merger, are either (i) listed on a national securities exchange or (ii) held of record by more than 2,000&#160;holders. Notwithstanding the foregoing, appraisal rights are available if stockholders are required by the terms of the Merger Agreement to accept for their shares anything other than (a) shares of stock of the surviving corporation, (b)&#160;shares of stock of another corporation that will either be listed on a national securities exchange or held of record by more than 2,000 holders, (c) cash instead of fractional shares or (d) any combination of clauses&#160;(a)&#160;through (c). </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Because the Standard BioTools Common Stock is listed on The Nasdaq Global Select Market, a national securities exchange, and is expected to continue to be so listed on the Record Date, Standard BioTools stockholders will not be entitled to appraisal rights in the Merger with respect to their Standard BioTools Common Stock. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">The unaudited forecasted financial information included in this proxy statement/prospectus is for illustrative purposes only and the actual financial condition and results of operations of the combined company after the Merger may differ materially. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The unaudited forecasted financial information included in this proxy statement/prospectus is presented for illustrative purposes only and is not necessarily indicative of what the combined company&#8217;s actual financial condition or results of operations would have been had the Merger been completed on the dates indicated, nor is it indicative of the future financial condition or results of operations of the combined company. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The forecasted financial information included in this proxy statement/prospectus was not prepared with a view toward public disclosure, and such unaudited forecasted financial information was not prepared with a view toward </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">40<br></div></div></div>
<!--End Page 51-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 52-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg9"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">compliance with published guidelines of any regulatory or professional body for the preparation or presentation of prospective financial information, including the published guidelines of the Securities and Exchange Commission and the guidelines established by the American Institute of Certified Public Accountants. Neither the independent accountants of Standard BioTools or Treeline, nor any other independent accountants, have audited, reviewed, compiled or applied agreed upon procedures, examined or performed any procedures with respect to the forecasted financial information contained herein, nor have they expressed any opinion or any other form of assurance on such information or the achievability thereof, and, accordingly, such independent accountants assume no responsibility for, and disclaim any association with, Standard BioTools&#8217; and Treeline&#8217;s forecasted financial information. The reports of the auditors of Standard BioTools and Treeline included or incorporated by reference in this proxy statement/prospectus relate to previously issued financial statements and do not extend to the forecasted financial information, and should not be read to do so, and, accordingly, such independent accountants assume no responsibility for, and disclaim any association with, the forecasted financial information. Further, no other independent accountants have compiled, examined or performed any procedures with respect to the forecasted financial information contained herein, nor have they expressed any opinion or any other form of assurance on such information or the achievability thereof. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The forecasted financial information included in this proxy statement/prospectus speaks only as of the date on which such information was prepared, and neither Standard BioTools nor Treeline undertakes any obligation, other than as required by applicable law, to update the forecasted financial information included herein to reflect events or circumstances after the date the forecasted financial information was prepared or to reflect the occurrence of anticipated or unanticipated events or circumstances. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">The market price for Standard BioTools Common Stock following completion of the Merger may fluctuate. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The market price of the Standard BioTools Common Stock could fall following the consummation of the Merger. At the Closing, we expect that Standard BioTools will issue approximately 2 billion shares of Standard BioTools Common Stock (excluding the effect of any proposed Standard BioTools reverse stock split) as merger consideration to the Treeline stockholders. Treeline stockholders may decide not to hold the Standard BioTools Common Stock they receive in the Merger. Other Treeline stockholders, such as funds with limitations on the amount of stock they are permitted to hold in individual issuers, may be required to sell Standard BioTools Common Stock that they receive in the Merger. Such sales, or market perception of such sales, of Standard BioTools Common Stock could result in a higher-than-average trading volume following the Closing and may cause the market price for Standard BioTools Common Stock to decline. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Standard BioTools or Treeline may waive one or more of the conditions to the Merger and may do so without re-soliciting stockholder approval. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Standard BioTools or Treeline may agree to waive (to the extent permitted by applicable law), in whole or in part, some of the conditions to each party&#8217;s obligations to complete the Merger, to the extent permitted by applicable law. For example, it is a condition to Standard BioTools&#8217; and Treeline&#8217;s respective obligations to close the Merger that certain of the representations and warranties of the other party are true and correct in all respects as of the Closing Date, except where the failure of such representations and warranties to be true and correct would not have a material adverse effect. However, if the board of directors of either party determines that it is in the best interests of the stockholders of that company to waive any breach of representation by the other party, then such board of directors may elect to waive that condition (to the extent permitted by applicable law). </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In the event of a waiver of a condition (to the extent permitted by applicable law), the board of directors of Standard BioTools will evaluate the materiality of any such waiver to determine whether amendment of this proxy statement/prospectus and re-solicitation of proxies is necessary. In the event that the board of directors of Standard BioTools, in its own reasonable discretion, determines any such waiver is not significant enough to require re-solicitation of its stockholders, it will have the discretion to cause the Merger to be completed without seeking further stockholder approval, which decision may have a material adverse effect on the stockholders of the combined company following the Merger. For example, the market could react negatively to such information, which may cause a substantial decline in the price of the common stock of the combined company following the Merger. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Notwithstanding the foregoing, certain closing conditions may not be waived due to applicable law or otherwise. The following closing conditions may not be waived: receipt of the requisite stockholder approvals; the </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">41<br></div></div></div>
<!--End Page 52-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 53-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg10"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">effectiveness of the registration statement on Form&#160;S-4 of which this proxy statement/prospectus forms a part; and the absence of any order or injunction that has the effect of prohibiting the consummation of the Merger. The foregoing closing conditions are the only closing conditions to the Merger that may not be waived. All other closing conditions to the Merger may be waived (to the extent permitted by applicable law) by Standard BioTools and/or Treeline, as applicable. See the section &#8220;<font style="font-style: italic;">The Merger Agreement &#8212; Conditions to the Completion of the Merger</font>&#8221; for further information. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Standard BioTools might not be able to utilize a significant portion of its net operating loss carryforwards and research and development tax credit carryforwards. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Standard BioTools has incurred significant net losses since its inception and cannot guarantee when, if ever, it will become profitable. Unused net operating loss (&#8220;NOL&#8221;) and tax credit carryforwards will generally carry forward to offset future taxable income, subject to applicable limitations on the use of those losses. Federal NOLs incurred in taxable years ending on or before December&#160;31, 2017 are eligible to be carried forward for up to 20&#160;years, and to be deducted in full against income for the years to which they may be carried. Federal NOLs incurred in taxable years ending after December&#160;31, 2017 are eligible to be carried forward indefinitely, but may offset no more than 80% of the taxable income for the years to which they are carried (computed without regard to the deduction for carryovers of NOLs). To the extent they expire unused, these NOLs and tax credit carryforwards will not be available to offset future income tax liabilities. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, under Sections 382 and 383 of the Code, and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change,&#8221; which is generally defined as a greater than 50% change, by value, in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change NOLs and tax credit carryovers to reduce its tax liability for post-change periods may be limited. Standard BioTools has experienced ownership changes in the past, will experience an ownership change as a result of the Merger, and may experience future ownership changes as a result of subsequent shifts in its stock ownership, some of which may be outside of its control. As a result, Standard BioTools&#8217; ability to use its historical NOLs and tax credit carryovers to offset future income tax liabilities is limited by prior ownership changes and may become limited by additional ownership changes in the future (including any ownership change resulting from the Merger). </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Standard BioTools stockholders may not receive any payment on the CVRs, and the CVRs may otherwise expire valueless. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The right of Standard BioTools stockholders to receive any future payment for or derive any value from the CVRs will be contingent in part upon the combined company&#8217;s receipt of (i) proceeds from any sale, disposition, or other monetization of the Legacy Business; (ii) proceeds from convertible notes or other investments held by Standard BioTools as of the Closing Date; (iii) earnout, milestone, royalty or other similar contingent payments due to Standard BioTools under contracts in effect as of the Closing Date, including payments from Illumina, Inc. pursuant to the Stock Purchase Agreement dated June&#160;22, 2025; and (iv) any surplus in Parent Net Cash delivered at Closing as finally determined under the Merger Agreement, and the timing and amount of the consideration received thereunder. If the combined company is not successful in entering into disposition agreements related to the Legacy Business or receiving payments thereunder within the time period specified in the CVR Agreement, there are no proceeds from convertible notes or other investments, there are no earnout, milestone, royalty or other similar payments under existing Standard BioTools contracts, and there is no Parent Net Cash surplus, no payments will be made in respect of the CVRs. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Following the Effective Time, the combined company will have sole authority over whether and how to monetize the Legacy Business (if at all), and the combined company&#8217;s only obligations will be to carry out the obligations set forth in the CVR Agreement. Furthermore, the CVRs will be unsecured obligations of the combined company and all payments under the CVRs and all other obligations under the CVR Agreement and the CVRs and any rights or claims relating thereto will be subordinated in right of payment to the prior payment in full of all current or future senior obligations of the combined company. Accordingly, there can be no assurance that holders of CVRs will receive any payments with respect to the CVRs. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Any payments under the CVRs will be made in shares of the combined company&#8217;s common stock, subject to the maximum cap of 76,000,000 shares. If substantial payments are made under the CVRs, the issuance of such shares will dilute the ownership percentage of all stockholders of the combined company who are not CVR holders, including former Treeline stockholders. This dilution could be material if the Legacy Business is sold or monetized </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">42<br></div></div></div>
<!--End Page 53-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 54-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg11"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">at a significant value during the CVR payment period. Additionally, any such shares paid in respect of the CVRs will be subject to market conditions and may decline in value following payment. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, CVR holders will have limited ability to transfer their CVRs, which are not registered with the SEC&#160;and will not trade on any securities exchange. The CVRs are illiquid instruments with no established market, and CVR holders may be unable to sell, assign or otherwise dispose of their CVRs except in the limited circumstances specified in the CVR Agreement. The illiquidity of the CVRs may make it difficult for CVR holders to realize any value from their CVRs prior to the expiration of the CVR Agreement. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">The tax treatment of the CVRs is uncertain. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Standard BioTools intends to treat a holder&#8217;s receipt of the CVRs as a non-taxable distribution with respect to the holder&#8217;s existing shares of Standard BioTools Common Stock for U.S. federal income tax purposes. However, the U.S.&#160;federal income tax treatment of the CVRs is uncertain. There is no legal authority directly addressing the U.S.&#160;federal income tax treatment of the receipt of, and payments under, the CVRs, and there can be no assurance that the IRS would not assert, or that a court would not sustain, a position that could result in adverse U.S. federal income tax consequences to holders of the CVRs. For example, the IRS may assert that the distribution of the CVRs is a taxable distribution of property, which would be taxable as a dividend to the extent of the holder&#8217;s pro rata share of Standard BioTools&#8217; current and accumulated earnings and profits, if any, with any excess being treated as a return of capital to the extent thereof and then as capital gain. For more information regarding the U.S. federal income tax considerations with respect to the CVRs, see the section titled &#8220;<font style="font-style: italic;">The Merger &#8212; CVR Agreement</font>&#8221; and &#8220;<font style="font-style: italic;">The Merger&#160;&#8212; Material U.S. Federal Income Tax Considerations with Respect to the CVRs to Holders of Standard BioTools Common Stock</font>.&#8221; </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13.5pt; margin-left: 0pt; text-align: left;">Risks Related to the Proposed Reverse Stock Split </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">The reverse stock split may not increase the combined company&#8217;s stock price over the long-term. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">A principal purpose of the reverse stock split is to increase the per-share market price of Standard BioTools&#8217; Common Stock above the minimum bid price requirement under the Nasdaq listing rules in order to facilitate the listing of the shares of Standard BioTools Common Stock being issued in the Merger on Nasdaq. It cannot be assured, however, that the reverse stock split will accomplish this objective for any meaningful period of time. While it is expected that the reduction in the number of outstanding shares of Standard BioTools Common Stock will proportionally increase the market price of the Standard BioTools Common Stock, it cannot be assured that the reverse stock split will increase the market price of the Standard BioTools Common Stock by a multiple of the reverse stock split ratio mutually agreed by Standard BioTools and Treeline, or result in any permanent or sustained increase in the market price of the Standard BioTools Common Stock, which is dependent upon many factors, including Standard BioTools&#8217; business and financial performance, general market conditions and prospects for future success. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Thus, there is no assurance that the reverse stock split will sufficiently increase the per-share market price of the Standard BioTools Common Stock in order to facilitate the listing of the shares of Standard BioTools Common Stock being issued in the Merger on Nasdaq. In addition, even if the stock price of the Standard BioTools Common Stock meets the listing requirements for Nasdaq initially, it cannot be assured that the stock price will continue to do so. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13.5pt; margin-left: 0pt; text-align: left;">The reverse stock split may decrease the liquidity of the combined company&#8217;s common stock. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Although the Standard BioTools Board believes that the anticipated increase in the market price of the combined company&#8217;s common stock resulting from the proposed reverse stock split could encourage interest in the combined company&#8217;s common stock and possibly promote greater liquidity for its stockholders, such liquidity could also be adversely affected by the reduced number of shares outstanding after the reverse stock split. The reduction in the number of outstanding shares may lead to reduced trading and a smaller number of market makers for the combined company&#8217;s common stock. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13.5pt; margin-left: 0pt; text-align: left;">The reverse stock split may lead to a decrease in the combined company&#8217;s overall market capitalization. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Should the market price of the combined company&#8217;s common stock decline after the reverse stock split, the percentage decline may be greater, due to the smaller number of shares outstanding, than it would have been prior to the reverse stock split. A reverse stock split is often viewed negatively by the market and, consequently, can lead to a </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">43<br></div></div></div>
<!--End Page 54-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 55-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg12"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">decrease in the combined company&#8217;s overall market capitalization. If the per share market price does not increase in proportion to the reverse stock split ratio, then the value of the combined company, as measured by its stock capitalization, will be reduced. In some cases, the per-share stock price of companies that have effected reverse stock splits subsequently declined back to pre-reverse split levels, and accordingly, it cannot be assured that the total market value of the combined company&#8217;s common stock will remain the same after the reverse stock split is effected, or that the reverse stock split will not have an adverse effect on the combined company&#8217;s stock price due to the reduced number of shares outstanding after the reverse stock split. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Risks Related to the Business of the Combined Company After the Merger </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">The combined company may not realize all of the anticipated benefits of the Merger and may incur greater than expected expenses in connection with the consummation of the Merger. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The negotiation and consummation of the Merger may require more time or greater cash resources than anticipated and expose the combined company to other operational and financial risks, including: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">increased near-term and long-term expenditures; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the diversion of management attention; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">exposure to unknown liabilities; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">higher than expected acquisition costs; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">write-down of assets or goodwill or incurrence of non-recurring, impairment or other charges; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">increased amortization expenses; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">inability to retain key employees; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">inability to recruit additional employees; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the possibility of future litigation; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a decline in the combined company&#8217;s results of operations, financial condition or cash flows; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a decline in the market price of the combined company&#8217;s common stock; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">contingent liabilities that are larger than expected; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">potential unknown liabilities, adverse consequences and unforeseen increased expenses associated with the Merger; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">tax effects of the Merger, including the ability to realize the benefits of any deferred tax assets or liabilities; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">disruption of existing relationships with business partners, and other constituencies; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the disruption of, or the loss of momentum in, ongoing research and development activities. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Many of these factors are outside the control of Standard BioTools and Treeline, and any one of them could result in increased costs, decreased expected revenues and diversion of management time and energy, which could materially impact the business, financial condition, results of operations and cash flows of the combined company. These factors could cause dilution to the earnings per share of the combined company, decrease or delay the expected benefits expected from the Merger and negatively impact the price of Standard BioTools Common Stock. As a result, it cannot be assured that the combined company will realize the full benefits anticipated from the Merger within the anticipated time frames, or at all. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, following the Merger, it is possible that there may be unknown, contingent or other liabilities or problems that may arise in the future, the existence and/or magnitude of which Standard BioTools was previously unaware. Any such liabilities or problems could have an adverse effect on the combined company&#8217;s business, financial condition, results of operations or cash flows. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Even if the Merger is successfully consummated, there can be no assurance that the Merger will result in the realization of the full benefit for the combined company&#8217;s stockholders or that these benefits will be realized within </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">44<br></div></div></div>
<!--End Page 55-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 56-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg13"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">the expected time frames or at all. Difficulties in achieving these benefits could harm the reputation of the combined company. In addition, by engaging in the Merger, Standard BioTools may forego or delay pursuit of other opportunities that may have proven to have greater commercial potential. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Standard BioTools and Treeline will incur substantial direct and indirect costs as a result of the Merger and the combined company will incur substantial direct and indirect expenses following the Merger. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Standard BioTools and Treeline will incur substantial expenses in connection with and as a result of consummating the Merger, and over a period of time following the consummation of the Merger, the combined company will incur substantial expenses in connection with coordinating and operating the businesses of Treeline and, to the extent not sold or otherwise monetized prior to consummation of the Merger, Standard BioTools. A&#160;portion of the transaction costs related to the Merger will be incurred regardless of whether the Merger is consummated. While Standard BioTools and Treeline have assumed that a certain level of transaction expenses will be incurred, factors beyond Standard BioTools&#8217; and Treeline&#8217;s control could affect the total amount or the timing of these expenses. Although many of the expenses that will be incurred, by their nature, are difficult to estimate accurately, the current estimate of the aggregate expenses that will be incurred by Standard BioTools and Treeline is approximately &#8195;&#8195;&#8195; , which is subject to change. These expenses may exceed the costs historically borne by Standard BioTools and Treeline. These expenses could adversely affect the financial condition, results of operations and cash flows of the combined company following the consummation of the Merger. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">The actual financial position and results of operations of the combined company after the Merger may differ materially from the unaudited pro forma financial information included in this proxy statement/prospectus. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The unaudited pro forma financial information included in this proxy statement/prospectus is presented for informational purposes only and may not be an indication of what Standard BioTools&#8217; financial position or results of operations would have been had the Merger been consummated on the dates indicated. The unaudited pro forma financial information has been derived from the audited and unaudited historical financial statements of Standard BioTools and Treeline and certain adjustments and assumptions regarding Standard BioTools after giving effect to the Merger. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The information upon which these adjustments and assumptions have been made is preliminary, and such adjustments and assumptions are difficult to make with accuracy. Moreover, the unaudited pro forma financial information do not reflect all costs that are expected to be incurred by the combined company in connection with the Merger. For example, the impact of any incremental costs incurred in integrating the two companies is not reflected in the unaudited pro forma financial information. As a result, the actual financial condition of the combined company following the Merger may not be consistent with, or evident from, these unaudited pro forma condensed combined financial statements.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, the assumptions used in preparing the unaudited pro forma financial information may not prove to be accurate, and other factors may affect the combined company&#8217;s financial condition or results of operations following the consummation of the Merger. Any material variance from the pro forma financial information may cause significant variations in the market price of the Standard BioTools Common Stock. See &#8220;<font style="font-style: italic;">Unaudited Pro Forma Condensed Combined Financial Information</font>&#8221; beginning on page <a href="#tUNA">292</a> of this proxy statement/prospectus. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13pt; margin-left: 0pt; text-align: left;">The Merger will be dilutive to Standard BioTools&#8217; earnings per share. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Because Standard BioTools Common Stock will be issued in connection with the Merger, the Merger will be dilutive to Standard BioTools&#8217; earnings per share. Future events and conditions could increase the dilution that is currently projected, including adverse changes in market conditions, additional transaction and integration-related costs and other factors such as the failure to realize some or all of the benefits anticipated in the Merger. Any dilution of, or delay of any accretion to, Standard BioTools&#8217; earnings per share could cause the price of Standard BioTools&#8217; Shares to decline or grow at a reduced rate. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">The combined company may require additional capital to finance its operations, which may not be available on acceptable terms, or at all. If the combined company is unable to raise capital when needed, it would be forced to delay, reduce or terminate its product development or commercialization efforts. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The combined company may require additional capital to finance its operations, which may not be available on acceptable terms or at all. The combined company&#8217;s future capital requirements will depend upon a number of factors, including: the number and timing of future product candidates in the pipeline; progress with and results from </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">45<br></div></div></div>
<!--End Page 56-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 57-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg14"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">preclinical testing and clinical trials; the ability to manufacture sufficient drug supplies to complete preclinical and clinical trials; the costs involved in preparing, filing, acquiring, prosecuting, maintaining and enforcing patent and other intellectual property claims; and the time and costs involved in obtaining regulatory approvals and favorable reimbursement or formulary acceptance. If the combined company is required to seek additional funding in the future, it may seek to do so through public or private equity offerings or debt financings, credit or loan facilities or a combination of one or more of these funding sources. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If the combined company raises additional funds by issuing equity securities, its stockholders will suffer dilution and the terms of any financing may adversely affect the rights of its stockholders. In addition, as a condition to providing additional funds, future investors may demand, and may be granted, rights superior to those of existing stockholders. Debt financing, if available, would subject the combined company to fixed payment obligations and is likely to involve restrictive covenants limiting the combined company&#8217;s flexibility in conducting future business activities, and, in the event of insolvency, debt holders would be repaid before holders of the combined company&#8217;s equity securities would receive any distribution of corporate assets. Additionally, global economic instability, higher interest rates and diminished credit availability may limit the combined company&#8217;s ability to obtain debt financing on favorable terms. If the combined company raises additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, the combined company may have to relinquish certain valuable intellectual property or other rights to its product candidates, technologies, future revenue streams or research programs or grant licenses on terms that may not be favorable to it. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The ability to raise additional funds will depend on financial, economic and other factors, many of which are beyond the combined company&#8217;s control. Fundraising efforts may divert management from their day-to-day activities, which may adversely affect the combined company&#8217;s ability to develop and commercialize its product candidates. Disruptions in the financial markets in general, and due to public health crises, geopolitical conflicts and economic instability, may make equity and debt financing more difficult to obtain, and may have a material adverse effect on the combined company&#8217;s ability to meet its fundraising needs. We cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">The combined company may become involved in litigation, including securities class action litigation, that could divert management&#8217;s attention and harm the combined company&#8217;s business, and insurance coverage may not be sufficient to cover all costs and damages. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In the past, litigation, including securities class action litigation, has often followed certain significant business transactions, such as a merger, or the announcement of negative events, such as negative results from clinical trials. These events may also result in investigations by the SEC. The combined company may be exposed to such litigation in connection with the Merger even if no wrongdoing occurred. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Furthermore, the stock market in general, and Nasdaq and biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. In the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. The market price of the combined company&#8217;s stock may be volatile, and the combined company may be the target of this type of litigation in the future. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Litigation is usually expensive and diverts management&#8217;s attention and resources from other business concerns, which could adversely affect the combined company&#8217;s business and cash resources and its ability to achieve the benefits of the Merger or the ultimate value Standard BioTools and Treeline stockholders receive in the Merger. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">The combined company may not pay any cash dividends on its capital stock in the foreseeable future, and capital appreciation, if any, will be its stockholders&#8217; sole source of gain. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The combined company may not pay any cash dividends on its capital stock in the foreseeable future, and may choose to retain all of its future earnings, if any, to finance the growth and development of its business. In addition, the terms of any future debt agreements may preclude the combined company from paying dividends. As a result, capital appreciation, if any, of the combined company&#8217;s common stock will be the sole source of gain for stockholders for the foreseeable future. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">46<br></div></div></div>
<!--End Page 57-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 58-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg15"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">The combined company&#8217;s management team will be required to devote substantial time to complying with public company responsibilities. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The combined company will incur significant legal, accounting and other expenses as a public company that Treeline did not incur as a private company, including costs associated with public company reporting obligations under the Exchange Act. The combined company&#8217;s management team will consist of the executive officers of Treeline prior to the Merger. These executive officers and other personnel will need to devote substantial time to gaining expertise related to public company reporting requirements and compliance with applicable laws and regulations to ensure that the combined company complies with all of these requirements. Operating the combined company as a public company will divert a substantial amount of management&#8217;s time from running the business to complying with SEC and Nasdaq requirements. Any changes the combined company makes to comply with these obligations may not be sufficient to allow it to satisfy its obligations as a public company on a timely basis, or at all. These reporting requirements, rules and regulations, coupled with the increase in potential litigation exposure associated with being a public company, could also make it more difficult for the combined company to attract and retain qualified persons to serve on the board of directors or on board committees or to serve as executive officers, or to obtain certain types of insurance, including directors&#8217; and officers&#8217; insurance, on acceptable terms. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As a public company, the combined company will incur significant legal, accounting and other expenses that Treeline did not incur as a private company. The Sarbanes-Oxley Act of 2002 and rules subsequently implemented by the SEC and Nasdaq have imposed various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. The combined company&#8217;s management and other personnel will need to devote a substantial amount of time to these compliance initiatives which they have not had to do previously while Treeline was a private company. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Pursuant to Section&#160;404 of the Sarbanes-Oxley Act, the combined company is required to furnish a report by management on its internal control over financial reporting and, depending on the combined company&#8217;s status as a &#8220;smaller reporting company&#8221; or &#8220;accelerated filer&#8221; following the consummation of the Merger, and depending on the extent to which newly proposed SEC rules are adopted and become applicable to the combined company, an attestation report on internal control over financial reporting may need to be issued by the combined company&#8217;s independent registered public accounting firm. Compliance with Section&#160;404 requires companies to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If the combined company or, if required, its independent registered public accounting firm is not able to conclude within the prescribed timeframe that the company&#8217;s internal control over financial reporting is effective as required by Section&#160;404, this could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of the combined company&#8217;s financial statements. In addition, if the combined company is not able to continue to meet these requirements, it may not be able to remain listed on Nasdaq. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The SEC proposed a series of rules in May&#160;2026 which, if adopted, could significantly reduce the compliance burden imposed on U.S. reporting companies, including potentially requiring fewer companies to obtain auditor attestations of their internal control over financial reporting pursuant to Section&#160;404 of the Sarbanes-Oxley Act. However, there is no assurance that any of the SEC&#8217;s rule proposals will be adopted, or will be adopted as proposed, or that they would apply to the combined company in whole or in part, if at all. Accordingly, until the SEC adopts final rules, if any, and their applicability to the combined company is analyzed and confirmed, investors should not assume that SEC rulemaking will alleviate any of the compliance burden imposed on the combined company by virtue of being a U.S. reporting company. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">If the combined company fails to establish and maintain proper and effective internal control over financial reporting, its operating results and ability to operate its business could be harmed. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Ensuring that the combined company has adequate internal financial and accounting controls and procedures in place so that it can produce accurate financial statements on a timely basis is a costly and time-consuming effort that needs to be re-evaluated frequently. Creation of adequate internal control over financial reporting is a process </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">47<br></div></div></div>
<!--End Page 58-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 59-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg16"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with generally accepted accounting principles. Section&#160;404 of the Sarbanes-Oxley Act will require annual management assessment of the effectiveness of the combined company&#8217;s internal control over financial reporting. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Implementing any appropriate changes to Treeline&#8217;s internal controls may distract the combined company&#8217;s officers and employees, entail substantial costs to modify Treeline&#8217;s existing processes, and take significant time to complete. These changes may not, however, be effective in maintaining the adequacy of the combined company&#8217;s internal controls, and any failure to maintain that adequacy, or consequent inability to produce accurate financial statements on a timely basis, could increase the combined company&#8217;s operating costs and harm its business. In addition, investors&#8217; perceptions that the combined company&#8217;s internal controls are inadequate or that the combined company is unable to produce accurate financial statements on a timely basis may harm the combined company&#8217;s stock price. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">The combined company&#8217;s disclosure controls and procedures may not prevent or detect all errors or acts of fraud. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition to the requirement to maintain adequate internal control over financial reporting, the combined company will also be required by the Exchange Act to design its disclosure controls and procedures to reasonably assure that information which the combined company discloses in reports it files or submits under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. Any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in the control system, misstatements due to error or fraud may occur and not be detected. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about the combined company, its business or its market, its stock price and trading volume could decline. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The trading market for the combined company&#8217;s common stock will be influenced by the research and reports that equity research analysts publish about it and its business. Equity research analysts may elect not to provide research coverage of the combined company&#8217;s common stock after the completion of the Merger, and such lack of research coverage may adversely affect the market price of its common stock. In the event it does have equity research analyst coverage, the price of the combined company&#8217;s common stock could decline if one or more equity research analysts downgrade its stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of the combined company or fails to publish reports on it regularly, demand for its common stock could decrease, which in turn could cause its stock price or trading volume to decline. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">The combined company will have broad discretion in the use of the cash and cash equivalents of the combined company and may invest or spend such resources in ways with which you do not agree and in ways that may not increase the value of your investment. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The combined company will have broad discretion over the use of the cash and cash equivalents of the combined company. You may not agree with the combined company&#8217;s decisions, and its use of these resources may not yield any return on your investment. The combined company&#8217;s failure to apply these resources effectively could compromise its ability to pursue its growth strategy and the combined company might not be able to yield a significant return, if any, on its investment of these resources. You will not have the opportunity to influence its decisions on how to use the combined company&#8217;s cash resources. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">If any of the events described in the sections describing the risks related to Treeline in these &#8220;Risk Factors&#8221; occur, those events could cause potential benefits of the Merger not to be realized. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Following completion of the Merger, the combined company will be susceptible to many of the risks described in the sections herein entitled &#8220;<font style="font-style: italic;">Risks Related to Treeline&#8217;s Financial Position, Limited Operating History and Need for Additional Capital</font>,&#8221; &#8220;<font style="font-style: italic;">Risks Related to Treeline&#8217;s Product Development, Regulatory Approval, Commercialization and Manufacturing</font>,&#8221; &#8220;<font style="font-style: italic;">Risks Related to Government Regulation</font>,&#8221; &#8220;<font style="font-style: italic;">Risks Related to Treeline&#8217;s Intellectual Property</font>&#8221; and &#8220;<font style="font-style: italic;">Risks Related to Treeline&#8217;s Business and Operations</font>.&#8221; To the extent any of the events in </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">48<br></div></div></div>
<!--End Page 59-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 60-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg17"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">the risks described in these sections occur, the potential benefits of the Merger may not be realized and the results of operations and financial condition of the combined company could be adversely affected in a material way. This could cause the market price of the combined company&#8217;s common stock to decline. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">The market price of the combined company&#8217;s common stock is expected to be volatile, and the market price of the combined company&#8217;s common stock may drop following the Merger. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The market price of the combined company&#8217;s common stock following the Merger could be subject to significant fluctuations. Some of the factors that may cause the market price of the combined company&#8217;s common stock to fluctuate include: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">results of clinical trials and preclinical studies of the combined company&#8217;s product candidates, or those of the combined company&#8217;s competitors or the combined company&#8217;s existing or future collaborators; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the ability of the combined company to obtain regulatory approvals for its product candidates, and delays or failures to obtain such approvals; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">failure of any of the combined company&#8217;s product candidates, if approved, to achieve commercial success; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">failure to meet or exceed financial and development projections the combined company may provide to the public; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">failure to meet or exceed the financial and development projections of the investment community; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">if the combined company does not achieve the perceived benefits of the Merger as rapidly or to the extent anticipated by financial or industry analysts; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">failure by the combined company to maintain its existing third-party license and supply agreements; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">announcements of significant acquisitions, strategic collaborations, joint ventures or capital commitments by the combined company or its competitors; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">actions taken by regulatory agencies with respect to the combined company&#8217;s product candidates, clinical studies, manufacturing process or sales and marketing terms; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">disputes or other developments relating to proprietary rights, including patents, litigation matters, and the combined company&#8217;s ability to obtain patent protection for its technologies; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">additions or departures of key personnel; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">significant lawsuits, including patent or stockholder litigation; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">if securities or industry analysts do not publish research or reports about the combined company&#8217;s business, or if they issue adverse or misleading opinions regarding its business and stock; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">changes in the market valuations of similar companies; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">general market or macroeconomic conditions or market conditions in the pharmaceutical and biotechnology sectors; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">changes in laws or regulations applicable to the combined company&#8217;s product candidates; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">adverse publicity generally, including with respect to other products and potential products in such market; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">sales of securities by the combined company or its securityholders in the future; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">if the combined company fails to raise an adequate amount of capital to fund its operations or continued development of its product candidates; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">trading volume of the combined company&#8217;s common stock; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">failure to maintain compliance with the listing requirements of Nasdaq; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">announcements by competitors of new commercial products, clinical progress or lack thereof, significant contracts, commercial relationships or capital commitments; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the introduction of technological innovations or new therapies that compete with the products and services of the combined company; and </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">49<br></div></div></div>
<!--End Page 60-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 61-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg18"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">period-to-period fluctuations in the combined company&#8217;s financial results. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies. These broad market fluctuations may also adversely affect the trading price of the combined company&#8217;s common stock. In addition, a recession, depression or other sustained adverse market event could materially and adversely affect the combined company&#8217;s business and the value of its common stock. In the past, following periods of volatility in the market price of a company&#8217;s securities, stockholders have often instituted class action securities litigation against such companies. Furthermore, market volatility may lead to increased stockholder activism if the combined company experiences a market valuation that activists believe is not reflective of its intrinsic value. Activist campaigns that contest or conflict with the combined company&#8217;s strategic direction or seek changes in the composition of its board of directors could have an adverse effect on its operating results, financial condition and cash flows. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Upon completion of the Merger, failure by the combined company to comply with the initial listing standards of Nasdaq will prevent its stock from being listed on Nasdaq. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Upon completion of the Merger, Standard BioTools, under the new name &#8220;Treeline Biosciences Holdings, Inc.,&#8221; will be required to meet the initial listing requirements to maintain the listing and continued trading of its shares on Nasdaq. These initial listing requirements are more difficult to achieve than the continued listing requirements, and include a $4.00 minimum bid price requirement at the time of initial listing. Pursuant to the Merger Agreement, Standard BioTools agreed to use its commercially reasonable efforts to cause the shares of Standard BioTools Common Stock being issued in the Merger to be approved for listing on Nasdaq at or prior to the effective time of the Merger. In order to meet the $4.00 minimum bid price initial listing requirement at the Closing, the Standard BioTools Board intends to effect a reverse stock split of the shares of Standard BioTools Common Stock, which must be approved by the Standard BioTools stockholders before it can be implemented. However, often a reverse stock split will not result in a trading price for the affected common stock that is proportional to the ratio of the split. Following the Merger, if the combined company is unable to continue to satisfy Nasdaq listing requirements, Nasdaq may notify the combined company that its shares of common stock will not be listed on Nasdaq. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Upon a potential delisting from Nasdaq, if the common stock of the combined company is not then eligible for quotation on another market or exchange, trading of the shares could be conducted in the over-the-counter market or on an electronic bulletin board established for unlisted securities such as the Pink Sheets or the OTC Bulletin Board. In such event, it is likely that there would be significantly less liquidity in the trading of the common stock of the combined company; decreases in institutional and other investor demand for the shares, coverage by securities analysts, market making activity and information available concerning trading prices and volume; and fewer broker dealers willing to execute trades in the common stock of the combined company. Also, it may be difficult for the combined company to raise additional capital if the combined company&#8217;s common stock is not listed on a major exchange. The occurrence of any of these events could result in a further decline in the market price of the common stock of the combined company and could have a material adverse effect on the combined company. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">An active trading market for the combined company&#8217;s common stock may not develop and its stockholders may not be able to resell their shares of common stock for a profit, if at all. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Prior to the Merger, there had been no public market for shares of Treeline capital stock. An active trading market for the combined company&#8217;s shares of common stock may never develop or be sustained. If an active market for the combined company&#8217;s common stock does not develop or is not sustained, it may be difficult for the combined company&#8217;s stockholders to sell their shares at an attractive price or at all. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Future sales of shares by existing stockholders could cause the combined company&#8217;s stock price to decline. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If existing securityholders of Standard BioTools and Treeline sell, or indicate an intention to sell, substantial amounts of the combined company&#8217;s common stock in the public market after legal restrictions on resale discussed in this proxy statement/prospectus lapse, the trading price of the common stock of the combined company could decline. The combined company is expected to have outstanding a total of approximately &#8195;&#8195;&#8195; million shares of common stock immediately following the completion of the Merger. Approximately &#8195;&#8195;&#8195; % of combined company common stock will be freely tradeable upon completion of the Merger and approximately &#8195;&#8195;&#8195; % of combined company common stock will become available for sale in the public market beginning 180 days after the </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">50<br></div></div></div>
<!--End Page 61-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 62-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg19"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Closing as a result of the expiration of lock-up agreements between Standard BioTools on the one hand and certain securityholders of Standard BioTools and Treeline on the other hand (and without giving effect to any restrictions on resale under securities laws). In addition, as soon as reasonably practicable following the Closing Date, Standard BioTools will file a registration statement on Form&#160;S-8 (or such other appropriate form, if required) with respect to the offering of the shares of Standard BioTools Common Stock issuable upon the exercise of the assumed Treeline Options. The shares of common stock that are subject to outstanding Treeline Options will become eligible for sale in the public market upon the automatic effectiveness of the Form&#160;S-8 upon filing. If these shares are sold, the trading price of the combined company&#8217;s common stock could decline. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The expiration of lock-up agreements 180 days after the Closing could result in a significant increase in selling pressure on the combined company&#8217;s common stock. The market&#8217;s anticipation of such sales, even if the sales do not occur, could depress the trading price of the combined company&#8217;s common stock prior to the expiration of the lock-up period. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This proxy statement/prospectus also registers for resale approximately 1.5 billion shares of Standard BioTools Common Stock held by the Selling Securityholders. These shares remain subject to the lock-up agreements described above and may not be sold until those agreements expire (subject to certain exceptions set forth in the applicable lock-up agreements). However, because the shares will be registered for resale pursuant to the registration statement on Form&#160;S-4 of which this proxy statement/prospectus and the resale prospectus form a part, once the lock-up period expires, the Selling Securityholders will be able to sell such shares immediately, without any further registration or compliance with the volume and other limitations of Rule&#160;144 under the Securities Act that would otherwise apply to restricted securities. As a result, expiration of the lock-up period could produce a more sudden increase in the supply of shares available for sale than would otherwise be the case, which could cause the market price of the combined company&#8217;s common stock to decline. We have no control over whether or when the Selling Securityholders will sell their shares following expiration of the lock-up period. See &#8220;<font style="font-style: italic;">Selling Securityholders</font>&#8221; and &#8220;<font style="font-style: italic;">Plan of Distribution</font>&#8221; in the resale prospectus also included in the registration statement on Form&#160;S-4 of which this proxy statement/prospectus forms a part. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">We have a limited ability to control the timing and manner of sales by the Selling Securityholders, which could have an adverse impact on the market price of Standard BioTools Common Stock. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This proxy statement/prospectus also registers for resale shares of Standard BioTools Common Stock held by the Selling Securityholders. Subject to the lock-up agreements described herein, we have no control over when or whether the Selling Securityholders will sell their shares or the prices at which they choose to sell. The Selling Securityholders may sell their shares at any time or from time to time in one or more types of transactions (which may include block transactions) at then-prevailing market prices, at prices related to prevailing market prices, in negotiated transactions, or otherwise as described in the &#8220;Plan of Distribution&#8221; in the resale prospectus also included in the registration statement on Form&#160;S-4 of which this proxy statement/prospectus forms a part. Sales by the Selling Securityholders may occur at times when, in our judgment, it would not be advisable for us or our stockholders for such sales to be made, such as during periods of lower trading volume, during periods when we may be in possession of material nonpublic information (which the Selling Securityholders would not be required to delay sales for), or when market conditions may otherwise be unfavorable. Sales by the Selling Securityholders, or the perception that such sales may occur, could depress the market price of Standard BioTools Common Stock and impair our ability to raise capital through the sale of additional equity securities. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Former Treeline stockholders will control the combined company, and their interests may conflict with the interests of the former Standard BioTools stockholders. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Upon completion of the Merger, former Treeline stockholders are expected to own approximately 84% of the outstanding common stock of the combined company on a fully diluted basis, and former Standard BioTools stockholders are expected to own approximately 16% of the outstanding common stock of the combined company on a fully diluted basis. In addition, the board of directors of the combined company is expected to consist of 12&#160;members, with ten members designated by Treeline and two members designated by Standard BioTools. As a result, former Treeline stockholders and the directors designated by Treeline will have the ability to control the outcome of matters submitted to the stockholders of the combined company for approval, including the election of directors and the approval of significant corporate transactions. The interests of former Treeline stockholders may </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">51<br></div></div></div>
<!--End Page 62-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 63-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg20"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">not always coincide with the interests of former Standard BioTools stockholders. This concentration of ownership could delay, defer, or prevent a change in control of the combined company, deprive stockholders of an opportunity to receive a premium for their shares as part of a sale of the combined company, and could ultimately affect the market price of the combined company&#8217;s common stock. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">If Standard BioTools is classified as a &#8220;shell company&#8221; under SEC rules as of the closing of the Merger, the combined company could be subject to more stringent reporting requirements, offering limitations and resale restrictions. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We believe that based on Standard BioTools&#8217; assets and operations on an actual and pro forma basis after giving effect to the Merger, Standard BioTools is not a &#8220;shell company&#8221; under SEC rules and will not be a &#8220;shell company&#8221; at Closing. However, if Standard BioTools were to be classified as a &#8220;shell company&#8221; under SEC rules, such status could affect the combined company in several ways, including that: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the combined company would need to file a Current Report on Form&#160;8-K to report the Form&#160;10 type information (&#8220;Super 8-K&#8221;) after the Closing reflecting its status as an entity that is no longer a shell company; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the combined company would not be eligible to use a registration statement on Form&#160;S-3 until 12 full calendar months after the Closing; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the combined company would need to wait at least 60 calendar days after the filing of the Super 8-K to file a Form&#160;S-8 for any equity plans or awards, such as the Post-Closing Equity Incentive Plan and the Post-Closing ESPP; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the combined company would be an &#8220;ineligible issuer&#8221; for three years following the Closing, which would prevent the combined company from (i) incorporating by reference in its Form&#160;S-1 filings, (ii)&#160;using&#160;a free writing prospectus or (iii) taking advantage of the well-known seasoned issuer status, even if otherwise eligible based on its public float; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">investors who (i) were affiliates of Treeline at the time the Merger was submitted for the consent of Treeline&#8217;s stockholders, (ii) receive securities of the combined company in the Merger and (iii)&#160;publicly&#160;offer or sell such securities would be deemed to be engaged in a distribution of such securities, and therefore would be underwriters with respect to resales of those securities; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Rule&#160;144(i)(2) would limit the ability of holders of restricted securities, and any affiliates of the public company, to publicly resell Rule&#160;145(c) securities per Rule&#160;145(d), as well as any other &#8220;restricted&#8221; or &#8220;control&#8221; securities of the combined company per Rule&#160;144, until one year after the Form&#160;10 information is filed with the SEC. As a result, Selling Securityholders who are affiliates of the combined company would not be able to rely on Rule&#160;144 to resell shares during such period, and will be subject to restrictions on their ability to sell shares registered for resale under the registration statement on Form&#160;S-4 of which this proxy statement/prospectus and the resale prospectus form a part. Non-affiliate Selling Securityholders may resell their registered shares pursuant to the resale prospectus, but may face additional restrictions if they seek to resell any shares not covered by the registration statement on Form&#160;S-4 of which this proxy statement/prospectus and the resale prospectus form a part. Any affiliate of the public company would not be able to sell their shares under Rule 144 until one year after the Form 10 information is filed with the SEC. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The foregoing SEC requirements will increase the combined company&#8217;s time and cost of raising capital and complying with securities laws. These limitations could also adversely affect the liquidity of the combined company&#8217;s securities and could limit the combined company&#8217;s ability to offer equity compensation to attract and retain employees. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">The combined company&#8217;s business will change significantly following the Merger, which may result in a loss of existing investor interest and analyst coverage. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Prior to the Merger, Standard BioTools was a life sciences tools company focused on mass cytometry and microfluidics technologies. Following the Merger, the combined company&#8217;s primary focus will be on Treeline&#8217;s clinical-stage biopharmaceutical programs in oncology, neurology and immunology. This significant change in business focus may result in a loss of interest from investors who invested in Standard BioTools for exposure to the </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">52<br></div></div></div>
<!--End Page 63-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 64-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg21"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">life sciences tools industry. In addition, equity research analysts who currently cover Standard BioTools&#8217; stock may elect to discontinue coverage following the Merger, and the combined company may need to establish relationships with new analysts who cover the biopharmaceutical industry. The lack of continuity in analyst coverage could adversely affect trading volume and the market price of the combined company&#8217;s common stock. Furthermore, existing stockholders of Standard BioTools, including certain institutional investors, may have investment mandates or portfolio guidelines that do not permit investment in clinical-stage biopharmaceutical companies, which could result in selling pressure following the Merger. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">Risks Related to Treeline&#8217;s Financial Position, Limited Operating History and Need for Additional Capital </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">Treeline is an early clinical-stage biopharmaceutical company with a limited operating history, has not completed clinical development and has no products approved for commercial sale, which may make it difficult for investors to evaluate Treeline&#8217;s business, likelihood of success and viability. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline is an early clinical-stage biopharmaceutical company with a limited operating history. Treeline commenced operations in 2021, has no products approved for commercial sale and has never generated any revenue. Drug development is a highly speculative undertaking and involves a substantial degree of risk. It entails substantial upfront capital expenditures and significant risk that any product candidate will fail to demonstrate adequate efficacy or an acceptable safety profile, gain regulatory approval or become commercially viable. To date, Treeline has devoted substantially all of its resources to identifying, acquiring and developing its product candidates and technologies, including TLN-121, TLN-254, TLN-372 and TLN-499, building its pipeline, conducting preclinical studies and early-stage clinical trials, organizing and staffing its company, business planning, establishing and maintaining its intellectual property portfolio, establishing arrangements with third parties for the manufacture of its product candidates, raising capital and providing general and administrative support for these operations. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">To date, Treeline has funded its operations primarily with proceeds from sales of its convertible preferred stock. From inception through March&#160;31, 2026, it received an aggregate of $1.2&#160;billion in net proceeds from sales of its convertible preferred stock. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline has not yet demonstrated an ability to successfully complete any clinical trials, including for TLN-121, TLN-254, TLN-372 and TLN-499, obtain regulatory approvals, manufacture a commercial-scale product or arrange for a third party to do so on its behalf, or conduct sales and marketing activities necessary for successful product commercialization. As a result, it may be more difficult for investors to accurately predict its likelihood of success and viability than it could be if it had a longer operating history. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, Treeline may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors and risks frequently experienced by clinical-stage biopharmaceutical companies developing therapies for oncology and other serious diseases. Treeline also may need to transition from a company with a research and development focus to a company capable of supporting commercial activities. Treeline has not yet demonstrated an ability to successfully overcome such risks and difficulties, or to make such a transition. If Treeline does not adequately address these risks and difficulties or successfully make such a transition, its business will suffer. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Treeline has incurred significant net losses in each period since its inception and has not generated any product revenue. It expects to continue to incur significant net losses for the foreseeable future and may never achieve or maintain profitability. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline has incurred significant operating losses since its inception, has not generated any product revenue to date and has financed its operations primarily through private placements of its convertible preferred stock. For the three months ended March&#160;31, 2026 and for the years ended December&#160;31, 2025 and 2024, it reported a net loss of $50.5&#160;million, $162.5&#160;million and $162.5&#160;million, respectively. It had an accumulated deficit of $651.8&#160;million as of March&#160;31, 2026. There is no assurance that Treeline will obtain financing from other sources, or that it will be able to obtain such financing on favorable terms, if at all. Substantially all of Treeline&#8217;s losses have resulted from expenses incurred in connection with operations identifying, acquiring and developing its product candidates and technologies, including TLN-121, TLN-254, TLN-372 and TLN-499, and other potential or future product candidates, building its pipeline, conducting preclinical studies and early-stage clinical trials, organizing and staffing its company, business planning, establishing and maintaining its intellectual property portfolio, establishing arrangements with third parties for the manufacture of its product candidates, raising capital and providing general and administrative support for these operations. Treeline expects to incur increasing levels of operating losses for the </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">53<br></div></div></div>
<!--End Page 64-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 65-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg22"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">foreseeable future as it continues its research and development activities, continues its ongoing clinical trials, initiates additional clinical trials, seeks to expand its product pipeline and clinical applications, seeks regulatory approval for its current and future product candidates, and invests in its organization. Treeline&#8217;s prior losses have had, and combined with expected future losses will continue to have, an adverse effect on its stockholders&#8217; equity and working capital. Treeline expects its research and development expenses to significantly increase as it advances TLN-121, TLN-254, TLN-372 and TLN-499 through clinical trials, advances other earlier-stage product candidates and identifies new product candidates. In addition, if Treeline obtains regulatory approval for TLN-121, TLN-254, TLN-372 and TLN-499 or other product candidates, it will incur significant sales, marketing, manufacturing and distribution expenses in connection with the commercialization of TLN-121, TLN-254, TLN-372 and TLN-499 or any other product candidates. Furthermore, upon the completion of the Merger, Treeline expects to incur additional costs associated with operating as a public company that it did not incur as a private company. Treeline may never succeed in these activities and, even if it does, it may never generate any revenue or revenue that is significant enough to achieve profitability. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As a result, Treeline expects to continue to incur significant and increasing net losses for the foreseeable future. Because of the numerous risks and uncertainties associated with developing therapeutic products, Treeline is unable to predict the extent of any future losses or when it will become profitable, if at all. To become and remain profitable, Treeline must succeed in discovering, developing, obtaining regulatory approvals for, and eventually commercializing products that generate significant revenue. Treeline is only in the preliminary stages of these activities. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Even if Treeline does become profitable, it may not be able to sustain or increase its profitability on a quarterly or annual basis. In addition, Treeline expects its financial condition and operating results to fluctuate significantly from quarter-to-quarter and year-to-year due to a variety of factors, many of which are beyond its control. Accordingly, you should not rely on the results of any quarterly or annual periods as indications of future operating performance. If Treeline fails to become and remain profitable, there may be an adverse effect on the value of Treeline which could impair its ability to raise capital, expand its business, maintain its research and development efforts, diversify its product candidate pipeline, achieve its strategic objectives or even continue its operations. A&#160;decline in the value of Treeline could also cause you to lose all or part of your investment. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Treeline may require additional capital to finance its operations. If Treeline is unable to raise such capital when needed, or on acceptable terms, Treeline may be forced to delay, reduce or eliminate one or more of its research and drug development programs, future commercialization efforts, product development or other operations. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Developing product candidates, including conducting preclinical studies and clinical trials, is a very time-consuming, expensive and uncertain process that takes years to complete. Treeline&#8217;s operations have consumed substantial amounts of cash since inception, and Treeline expects its expenses to increase substantially in connection with its ongoing activities, particularly as Treeline advances TLN-121, TLN-254, TLN-372 and TLN-499 and other potential or future product candidates through preclinical and clinical development. Treeline expects increased expenses as it continues its research and development, continues its ongoing clinical trials, initiates additional clinical trials, seeks to expand its product pipeline and clinical applications, seeks regulatory approval for its current and future product candidates, and invests in its organization. In addition, if Treeline obtains regulatory approval for any of its product candidates, it expects to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution. Furthermore, upon the completion of the Merger, Treeline expects to incur additional costs associated with operating as a public company that it did not incur as a private company. Accordingly, it will need to obtain substantial additional funding in connection with its continuing operations. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Based on Treeline&#8217;s current operating plan, it believes its existing cash and cash equivalents as of March&#160;31, 2026, along with the net cash held by Standard BioTools upon consummation of the Merger, will enable Treeline to fund Treeline&#8217;s operations into 2029. Treeline has based this estimate on assumptions that may prove to be wrong, and Treeline could use its capital resources sooner than it currently expects. Changes beyond Treeline&#8217;s control may occur that would cause it to use its available capital before that time, including changes in and progress of its drug development activities and changes in regulations. Treeline&#8217;s future capital requirements will be dependent on many factors, including: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the progress, timing and results of preclinical studies and clinical trials for TLN-121, TLN-254, TLN-372 and TLN-499 or other potential or future product candidates; </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">54<br></div></div></div>
<!--End Page 65-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 66-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg23"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the extent to which Treeline develops, in-licenses, out-licenses or acquires any future product candidates or technologies; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the number and development requirements of any future product candidates that Treeline may pursue, and other indications for Treeline&#8217;s current product candidates that it may pursue; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the costs, timing and outcome of obtaining regulatory approvals of Treeline&#8217;s current or future product candidates; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the scope and costs of making arrangements with third-party manufacturers, or establishing manufacturing capabilities, for both clinical and commercial supplies of Treeline&#8217;s current or future product candidates; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the costs involved in growing Treeline&#8217;s organization to the size needed to allow for the research, development and potential commercialization of its current or future product candidates; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the costs associated with commercializing any approved product candidates, including establishing sales, marketing, market access and distribution capabilities; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the costs associated with operating as a growing public company that it did not incur as a private company; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">to the extent Treeline pursues strategic collaborations, including collaborations to commercialize TLN-121, TLN-254, TLN-372 and TLN-499 or any of its other potential or future product candidates, its ability to establish and maintain collaborations on favorable terms, if at all, as well as the timing and amount of any milestone or royalty payments it is required to make or are eligible to receive under such collaborations or its current licenses; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the costs associated with completing any post-marketing studies or trials required by the U.S. Food and Drug Administration (&#8220;FDA&#8221;), or other comparable foreign regulatory authorities; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the revenue, if any, received from commercial sales of TLN-121, TLN-254, TLN-372 and TLN-499 or any of Treeline&#8217;s other potential or future product candidates, if any are approved; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing Treeline&#8217;s intellectual property rights and defending intellectual property-related claims that it may become subject to, including any litigation costs and the outcome of such litigation; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the costs associated with potential product liability claims, including the costs associated with obtaining insurance against such claims and with defending against such claims. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Even if the Merger is successful, Treeline will require additional capital to complete its planned preclinical studies and clinical trials for its current and other potential or future product candidates to obtain regulatory approval, and Treeline anticipates needing to raise additional capital to complete the development of, and eventually commercialize, its product candidates, if approved. Adequate additional financing may not be available to Treeline on favorable terms, or at all. Treeline&#8217;s ability to raise additional funds will be dependent on financial, economic and market conditions, geopolitical issues and other factors, over which Treeline may have limited or no control. In addition, Treeline may seek additional capital due to favorable market conditions or strategic considerations even if it believes it has sufficient funds for its current or future operating plans. If adequate funds are not available on commercially acceptable terms when needed, Treeline may be forced to delay, reduce or terminate the development or commercialization, if approved, of all or part of its research programs or product candidates or it may be unable to take advantage of future business opportunities, including pursuing new in-licenses and acquisitions. Furthermore, any additional capital-raising efforts may divert Treeline&#8217;s management from their day-to-day activities, which may adversely affect Treeline&#8217;s ability to develop and commercialize its current and other product candidates, if approved. Changing circumstances, some of which may be beyond its control, could cause it to consume capital significantly faster than it currently anticipates, and it may need to seek additional funds sooner than planned. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline&#8217;s failure to raise capital as and when needed or on acceptable terms could significantly harm its business, financial condition, results of operations and prospects, and Treeline may have to delay, reduce the scope of, suspend or eliminate one or more of its research or drug development programs, preclinical studies, clinical trials or future commercialization efforts. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">55<br></div></div></div>
<!--End Page 66-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 67-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg24"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Risks Related to Treeline&#8217;s Product Development, Regulatory Approval, Commercialization and Manufacturing </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">Treeline is substantially dependent on the advancement of TLN-121, TLN-254, TLN-372 and TLN-499 and its other potential or future product candidates. If Treeline is unable to advance its product candidates through development, obtain regulatory approval and ultimately commercialize such product candidates, or experiences significant delays in doing so, Treeline&#8217;s business will be materially harmed. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline&#8217;s future success is highly dependent on Treeline&#8217;s ability to timely complete successful preclinical studies and clinical trials, obtain regulatory approval for, and then successfully commercialize, its product candidates. Treeline&#8217;s most advanced product candidates, TLN-121, TLN-254 and TLN-372, are in Phase 1 clinical development. Treeline currently has no products that are approved for sale in any jurisdiction. Treeline has invested substantially all of its efforts and financial resources in TLN-121, TLN-254, TLN-372 and TLN-499 and its other potential or future product candidates, and in conducting preclinical studies and clinical trials. There can be no assurance that TLN-121, TLN-254, TLN-372 and TLN-499 or any other product candidates Treeline develops will achieve success in their clinical trials or obtain regulatory approval. In the future, Treeline may also become dependent on other product candidates that it may develop or acquire; however, given Treeline&#8217;s early stage of development, it may be several years, if at all, before it has demonstrated the safety and efficacy of a treatment sufficient to warrant approval for commercialization. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline&#8217;s ability to generate product revenue, which it does not expect will occur for many years, if ever, will be heavily dependent on the successful development and eventual commercialization of its current product candidates, and the development of potential or future product candidates. The success of TLN-121, TLN-254, TLN-372 and TLN-499 and other potential or future product candidates will be dependent on several factors, including the following: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">timely completion of successful current and future preclinical studies and clinical trials resulting in attractive, competitive target product profiles; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">clearance of Investigational New Drug applications (&#8220;INDs&#8221;) by the FDA or other similar clinical trial applications by comparable foreign regulatory authorities for Treeline&#8217;s future clinical trials for Treeline&#8217;s pipeline product candidates; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">timely and successful enrollment and completion of clinical trials, including in compliance with the FDA&#8217;s good clinical practices (&#8220;GCPs&#8221;) and any additional regulatory requirements from comparable foreign regulatory authorities, with favorable results; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Treeline&#8217;s ability to enroll adequate subjects to allow the results to be generalizable to the U.S. population; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the frequency and severity of adverse events in clinical trials; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">approval of New Drug Applications (&#8220;NDAs&#8221;) by the FDA or other comparable foreign regulatory authorities, including Treeline&#8217;s ability to complete any post-marketing commitments or requirements; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">raising additional funds necessary to complete clinical development of and commercialize Treeline&#8217;s current or future product candidates; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">obtaining, maintaining, expanding and protecting Treeline&#8217;s patent, trade secret and other intellectual property and regulatory exclusivity for Treeline&#8217;s current and future product candidates; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">making arrangements with third-party manufacturers, or establishing manufacturing capabilities, for both clinical and commercial supplies of Treeline&#8217;s current and future product candidates and ensuring a resilient, effective supply chain that produces supply that outpaces demand; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">developing and implementing marketing and reimbursement strategies, and creating adequate demand forecasts for supply and sales planning; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">establishing sales, marketing and distribution capabilities and launching commercial sales of Treeline&#8217;s products, if and when approved, whether alone or in collaboration with others; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">demonstration of safety and efficacy and acceptable risk-benefit profiles of Treeline&#8217;s product candidates to the satisfaction of the FDA and comparable foreign regulatory authorities and attractive to physicians, patients, advocates, payors and caregivers; </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">56<br></div></div></div>
<!--End Page 67-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 68-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg25"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">acceptance of Treeline&#8217;s products, if and when approved, by patients, the medical community and third-party payors underpinned by adequate health economic data and a meaningful value proposition; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">effectively competing with existing and future therapies, including timing of market entry and the authorized label of Treeline&#8217;s products, if approved, relative to competing products; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">obtaining and maintaining third-party payor coverage and adequate reimbursement in both public and private payor spaces; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">obtaining appropriate support from patient advocacy organizations; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">addressing any delays in Treeline&#8217;s clinical trials resulting from any major natural disasters, regional and global geopolitical conflicts, supply chain issues, health pandemics or significant political events; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">maintaining a continued acceptable safety profile of Treeline&#8217;s products following approval, if and when approved. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Many of these factors are beyond Treeline&#8217;s control, and it is possible that none of Treeline&#8217;s product candidates will ever obtain regulatory approval even if it expends substantial time and resources seeking such approval. If Treeline does not achieve one or more of these factors in a timely manner or at all, it could experience significant delays or an inability to successfully commercialize its product candidates, which would materially harm its business. For example, Treeline&#8217;s business could be harmed if results of its ongoing clinical trials of TLN-121, TLN-254 and TLN-372 show unexpected adverse events or a lack of efficacy in the indications Treeline intends to treat, do not meet the clinical endpoints or if Treeline experiences other regulatory or developmental issues. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Drug development is a lengthy and expensive process, the outcome of clinical testing is inherently uncertain, and results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results. Treeline may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of TLN-121, TLN-254, TLN-372, TLN-499 and/or other potential or future product candidates for many reasons, including a failure to replicate positive results from earlier preclinical studies or clinical trials in ongoing or future preclinical studies or clinical trials. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">TLN-121, TLN-254 and TLN-372 are in Phase 1 clinical development and represent Treeline&#8217;s clinical-stage product candidates. Treeline&#8217;s pipeline also includes TLN-499 and potential or future product candidates in preclinical and discovery-stage development. The risk of failure is high for early clinical-stage product candidates. It is impossible to predict when or if Treeline&#8217;s product candidates or any future product candidates will receive regulatory approval. To obtain the requisite regulatory approvals to commercialize any product candidate, Treeline must demonstrate through extensive preclinical studies and lengthy, complex and expensive clinical trials that Treeline&#8217;s product candidates are safe and effective. Clinical testing can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the preclinical study and clinical trial processes. The results of preclinical studies and early clinical trials of Treeline&#8217;s product candidates or any future product candidates, or a competitor&#8217;s product candidate in the same class, may not be predictive of the results of later-stage clinical trials. Interim, topline or preliminary results of a clinical trial are not necessarily indicative of final results. Treeline may be unable to establish benefit on clinical endpoints that applicable regulatory authorities would consider clinically meaningful, and a clinical trial can fail at any stage of testing. Differences in trial design between early-stage clinical trials and later-stage clinical trials make it difficult to extrapolate the results of earlier clinical trials to later clinical trials. Moreover, clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in clinical trials have nonetheless failed to obtain regulatory approval of their products. A&#160;number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or to unfavorable safety profiles, notwithstanding promising results in earlier trials. Most product candidates that commence clinical trials are never approved as products and there can be no assurance that any of Treeline&#8217;s future clinical trials will ultimately be successful or support clinical development of Treeline&#8217;s product candidates or any future product candidates. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Additionally, Treeline&#8217;s current clinical trials utilize, and future clinical trials may utilize, an open-label trial design. An open-label clinical trial is one where both the patient and investigator know whether the patient is receiving the investigational product candidate or either an existing approved drug or placebo. Most typically, open-label clinical trials test only the investigational product candidate and sometimes may do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">57<br></div></div></div>
<!--End Page 68-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 69-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg26"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">patients in open-label clinical trials are aware when they are receiving treatment. Open-label clinical trials may be subject to a patient bias where patients perceive their symptoms to have improved merely due to their awareness of receiving an experimental treatment. In addition, open-label clinical trials may be subject to an investigator bias where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more favorably given this knowledge. The results from an open-label trial of Treeline&#8217;s product candidates may not be predictive of future clinical trial results when studied in a controlled environment with a placebo or active control. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline may experience delays in initiating or completing clinical trials. Treeline also may experience numerous unforeseen events during, or as a result of, any future clinical trials that could delay or prevent Treeline&#8217;s ability to receive regulatory approval or commercialize Treeline&#8217;s product candidates or any future product candidates, including: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">reports from clinical testing of other therapies may raise safety or efficacy concerns about Treeline&#8217;s current or future product candidates; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">regulatory authorities, institutional review boards (&#8220;IRBs&#8221;) or ethics committees may not authorize Treeline or Treeline&#8217;s investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site, or may halt or suspend an ongoing clinical trial; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Treeline may experience delays in reaching or fail to reach agreement on acceptable terms with prospective trial sites and prospective contract research organizations (&#8220;CROs&#8221;), the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">clinical trial sites may deviate from the trial protocol or drop out of a trial; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">clinical trials of any of Treeline&#8217;s product candidates may fail to show safety or efficacy or produce negative or inconclusive results and Treeline may decide, or regulatory authorities may require Treeline, to conduct additional preclinical studies or clinical trials or Treeline may decide to abandon product development programs; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the number of subjects required for clinical trials of any product candidates may be larger than Treeline anticipates, enrollment in these clinical trials may be slower than Treeline anticipates or subjects may discontinue their participation in these clinical trials or fail to return for post-treatment follow-up at a higher rate than Treeline anticipates; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Treeline&#8217;s third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to Treeline in a timely manner, or at all, or may deviate from the clinical trial protocol or drop out of the trial, which may require that Treeline add new clinical trial sites or investigators; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Treeline may elect, or regulatory authorities, IRBs, or ethics committees may require, that Treeline or Treeline&#8217;s investigators, suspend or terminate clinical research or trials for various reasons, including noncompliance with regulatory requirements or a finding that the participants in Treeline&#8217;s trials are being exposed to unacceptable health risks; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the cost of clinical trials of any of Treeline&#8217;s product candidates or any future product candidates may be greater than Treeline anticipates, and Treeline may not have sufficient funds to complete such trials; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the quality of Treeline&#8217;s product candidates or any future product candidates or other materials necessary to conduct clinical trials of Treeline&#8217;s product candidates or any future product candidates may be inadequate to initiate or complete a given clinical trial; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Treeline may be unable to manufacture sufficient quantities or quality of Treeline&#8217;s current or future product candidates for use in preclinical studies or clinical trials; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Treeline may be unable to meet drug specifications suitable for use in clinical trials and commercial applications; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Treeline may receive feedback from regulatory authorities that requires Treeline to modify the design of Treeline&#8217;s clinical trials; </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">58<br></div></div></div>
<!--End Page 69-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 70-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg27"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Treeline may fail to establish an appropriate safety profile for a product candidate based on clinical or preclinical data for such product candidate as well as data emerging from other therapies in the same class as Treeline&#8217;s product candidates or any future product candidates; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the FDA or other comparable foreign regulatory authorities may require Treeline to submit additional data such as long-term toxicology studies, conduct additional dose optimization or dose-ranging studies, evaluate multiple doses or dosing regimens, or satisfy other requirements before permitting Treeline to initiate a clinical trial, including a pivotal clinical trial; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">global health crises or regional or global geopolitical conflicts may increase the likelihood that Treeline encounters such difficulties or delays in initiating, enrolling, conducting, or completing Treeline&#8217;s planned clinical trials. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline could also encounter delays if a clinical trial is suspended or terminated by Treeline, the IRBs overseeing the institutions in which such trials are being conducted, or the FDA or other comparable regulatory authorities, or if a clinical trial is recommended for suspension or termination by the Data Safety Monitoring Board (&#8220;DSMB&#8221;) for such trial. A suspension or termination may be imposed due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements, including the FDA&#8217;s GCP regulations, or Treeline&#8217;s clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other comparable foreign regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product or treatment, failure to establish or achieve clinically meaningful trial endpoints, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. For example, in June&#160;2026, the FDA placed a partial clinical hold on Treeline&#8217;s clinical trials evaluating treatment with TLN-254. This hold has impacted the Phase 1 TLN-254 monotherapy trial in patients with relapsed or refractory peripheral T-cell lymphoma, and a separate Phase 1 trial that includes a treatment arm of TLN-254 in combination with TLN-121 in patients with non-Hodgkin&#8217;s lymphoma. This hold was initiated following FDA&#8217;s May&#160;2026 announcement of an increased rate of hematologic second primary malignancies in patients receiving tazemetostat for relapsed or refractory follicular lymphoma in a clinical trial. Following this announcement, the sponsor of tazemetostat discontinued its clinical trials of tazemetostat and withdrew the product from the market for its approved indications. Tazemetostat is in the same drug class as TLN-254. Adverse safety findings involving similar product candidates or approved products to Treeline&#8217;s product candidates that are developed or commercialized by third parties could likewise result in clinical holds, delays or additional regulatory requirements for Treeline&#8217;s product candidates, even where Treeline&#8217;s own trials have not raised the same or similar level of concerns. The partial clinical hold on TLN-254 could delay Treeline&#8217;s development of TLN-254 and, if Treeline is unable to resolve it, could result in termination of the TLN-254 program. Clinical studies may also be delayed or terminated as a result of ambiguous or negative interim results. Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of Treeline&#8217;s product candidates or any future product candidates. Further, the FDA or other comparable foreign regulatory authorities may disagree with Treeline&#8217;s clinical trial design and Treeline&#8217;s interpretation of data from clinical trials, or may change the requirements for approval even after they have reviewed and commented on the design for Treeline&#8217;s clinical trials. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline cannot predict with any certainty the schedule for commencement and completion of future clinical trials. Further, conducting clinical trials in foreign countries, as Treeline is currently doing and may do in the future for Treeline&#8217;s product candidates, presents additional risks that may delay completion of Treeline&#8217;s clinical trials. These risks include the failure of enrolled patients in foreign countries to adhere to clinical protocol as a result of differences in healthcare services or cultural customs, managing additional administrative burdens associated with foreign regulatory schemes, as well as political and economic risks relevant to such foreign countries. If Treeline is required to conduct additional clinical trials or other testing of Treeline&#8217;s current or future product candidates beyond those that Treeline currently contemplates, if Treeline is unable to successfully complete clinical trials of Treeline&#8217;s current or future product candidates or other testing in a timely manner, if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, Treeline may incur unplanned costs, or be delayed in seeking and obtaining regulatory approval. Additionally, if Treeline receives such approval at all, or receives more limited or restrictive regulatory approval, or if Treeline becomes subject to additional post-marketing testing requirements or has the product removed from the market after obtaining regulatory approval, Treeline could incur significant costs and limitations which may adversely affect Treeline&#8217;s financial condition and operating results. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">59<br></div></div></div>
<!--End Page 70-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 71-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg28"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Additionally, if the results of Treeline&#8217;s clinical trials are inconclusive or if there are safety concerns or serious adverse events (&#8220;SAEs&#8221;) associated with Treeline&#8217;s product candidates, Treeline may: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">be delayed in obtaining regulatory approval, if at all; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">obtain approval for indications or patient populations that are not as broad as intended or desired or may have restricted duration expectations or guidance; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">be required to perform additional clinical trials to support approval or be subject to additional post-marketing testing requirements; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">have regulatory authorities withdraw or suspend their approval of the product or impose restrictions on its distribution in the form of a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;); </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">be subject to the addition of labeling statements, such as warnings or contraindications; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">be sued; or </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">experience damage to Treeline&#8217;s reputation. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline&#8217;s drug development costs may also increase if Treeline experiences delays in testing or obtaining regulatory approvals. Also, delays in obtaining regulatory approval may increase commercialization costs if the competitive environment becomes more intense prior to market entry. Treeline does not know whether any of Treeline&#8217;s preclinical studies or clinical trials will begin as planned, need to be restructured or be completed on schedule, if at all. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Moreover, principal investigators for Treeline&#8217;s clinical trials may serve as scientific advisors or consultants to Treeline from time to time and receive compensation in connection with such services. Under certain circumstances, Treeline may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authority may conclude that a financial relationship between Treeline and a principal investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA or comparable foreign regulatory authority may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of Treeline&#8217;s marketing applications by the FDA or comparable foreign regulatory authority, as the case may be, and may ultimately lead to the denial of regulatory approval of one or more of Treeline&#8217;s product candidates. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline may make formulation or manufacturing changes to Treeline&#8217;s product candidates, in which case Treeline may need to conduct additional preclinical or clinical studies to bridge Treeline&#8217;s modified product candidates to earlier versions. If Treeline experiences delays in the commencement or completion of Treeline&#8217;s clinical trials, or if Treeline terminates a clinical trial prior to completion, the commercial prospects of Treeline&#8217;s current or any future product candidates could be negatively impacted, and Treeline&#8217;s ability to generate revenues from Treeline&#8217;s current or future product candidates may be delayed or eliminated entirely. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">A marketed inhibitor (tazemetostat) in the same class as TLN-254 was withdrawn from the market due to safety concerns, and adverse developments affecting the EZH2 inhibitor class could delay, limit or prevent the development and approval of TLN-254 (including for use in combination with TLN-121). </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">TLN-254, one of Treeline&#8217;s clinical-stage product candidates, is an oral inhibitor of EZH2 that Treeline in-licensed from Jiangsu Hengrui Pharmaceuticals Co., Ltd. (&#8220;Hengrui&#8221;). In March&#160;2026, another EZH2 inhibitor, tazemetostat (formerly marketed as Tazverik), was voluntarily withdrawn from all markets, including the United States, after an independent data monitoring committee identified cases of secondary hematologic malignancies in a clinical trial combining tazemetostat with lenalidomide and rituximab (18 cases, 5.7% hematologic secondary malignancy) compared to lenalidomide and rituximab alone (0 cases of hematologic second primary malignancy) in patients with relapsed or refractory follicular lymphoma, leading its sponsor to also discontinue clinical development. In June&#160;2026, the FDA placed a partial clinical hold on Treeline&#8217;s clinical trials evaluating treatment with TLN-254. This hold has impacted the Phase 1 TLN-254 monotherapy trial in patients with relapsed or refractory peripheral T-cell lymphoma, and a separate Phase 1 trial that includes a treatment arm of TLN-254 in combination with TLN-121 in patients with non-Hodgkin&#8217;s lymphoma. As a result of these developments, the FDA&#160;and comparable foreign regulatory authorities may apply heightened scrutiny to product candidates that inhibit </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">60<br></div></div></div>
<!--End Page 71-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 72-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg29"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">EZH2, including TLN-254, and may require additional preclinical or clinical data, impose additional clinical holds, labeling restrictions or monitoring requirements, narrow the patient populations that may be studied or treated, or decline to approve TLN-254 (including for use in combination with TLN-121). Any of these outcomes, or any actual or perceived safety concerns associated with the EZH2 inhibitor class generally, could delay, limit or prevent the development, regulatory approval or commercialization of TLN-254, could reduce its commercial potential if approved, and could require Treeline to commit additional resources, any of which could materially and adversely affect Treeline&#8217;s business, financial condition, results of operations and prospects. Because Treeline in-licensed TLN-254 from Hengrui, Treeline may also have limited control over certain development, regulatory and manufacturing decisions for the program and depends on Hengrui&#8217;s continued performance under Treeline&#8217;s license agreement with Hengrui (the &#8220;Hengrui License Agreement&#8221;). </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Treeline relies, and expects to continue to rely, on third parties to conduct its discovery, preclinical studies, manufacturing and clinical trials, and if these third parties do not satisfactorily carry out their contractual duties, fail to comply with applicable regulatory requirements or do not meet expected deadlines, Treeline&#8217;s development programs may be delayed or subject to increased costs or Treeline may be unable to obtain marketing authorization, each of which may have an adverse effect on Treeline&#8217;s business, financial condition, results of operations and prospects. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline does not independently conduct all aspects of its discovery and preclinical studies, manufacturing, and clinical trials. It relies, and expects to continue to rely, on third parties such as CROs, contract development and manufacturing organizations (&#8220;CDMOs&#8221;), consultants, clinical investigators, clinical trial sites, collaborators and other independent contractors to conduct, supervise or monitor its preclinical studies and clinical trials, and to conduct manufacturing and it has limited control over their activities. The timing of the initiation and completion of these activities will therefore be partially controlled by such third parties and may result in delays to Treeline&#8217;s development programs. Specifically, Treeline expects CROs, independent clinical investigators and consultants to play a significant role in the conduct of these studies and trials and the subsequent collection and analysis of data. However, these third parties are not Treeline&#8217;s employees, may have competing priorities and commitments to other entities, and may not devote sufficient time or resources to Treeline&#8217;s programs or meet expected deadlines. In addition, Treeline has less control over the timing, quality and other aspects of discovery and preclinical studies, manufacturing and clinical trials than it would if it were to conduct these activities on its own. Nevertheless, Treeline is responsible for ensuring that these third parties comply with current Good Manufacturing Practices (&#8220;cGMPs&#8221;), GCP and Good Laboratory Practice requirements and other applicable regulations, and if they fail to do so, or fail to conduct a study or trial in accordance with the applicable protocol, or fail to be diligent, careful or timely, the data generated may be deemed unreliable and Treeline may be required to repeat, extend or delay its studies or trials or conduct additional ones. Treeline cannot make any assurances that, upon inspection, the FDA will determine that its clinical trials comply with GCPs. Treeline&#8217;s failure or the failure of third parties on whom Treeline relies to comply with these regulations may require Treeline to stop and/or repeat clinical trials, which would delay the marketing authorization process or prevent marketing authorization. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">There is no guarantee that any such CROs, clinical trial investigators, clinical trial sites or other third parties on which Treeline relies will devote adequate time and resources to Treeline&#8217;s development activities or perform as contractually required. In addition, these third parties may be subject to macroeconomic conditions, such as staffing shortages and supply chain or inflationary pressures that limit their ability to achieve anticipated timelines or result in a greater cost to Treeline. For example, Treeline is aware of recurrent shortages of non-human primates available for preclinical studies and although that is not expected to impact Treeline&#8217;s current business, if Treeline begins new product development programs Treeline could be subject to longer development times or difficulty completing necessary research. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Furthermore, these third parties may also have relationships with other entities, some of which may be Treeline&#8217;s competitors for whom they may also be conducting clinical trials or other therapeutic candidate development activities that could harm Treeline&#8217;s competitive position. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If any of these third parties terminate their engagement with Treeline, perform inadequately, experience their own regulatory, financial or operational difficulties, or fail to meet applicable standards, Treeline&#8217;s business could be adversely affected, research and development programs may be delayed or impaired, its costs may increase, and its ability to obtain regulatory approval for and to commercialize its product candidates may be impaired. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">From time to time, Treeline may support investigator-initiated or investigator-sponsored clinical trials of its product candidates that are conducted by third-party investigators or institutions over whose design, conduct, data </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">61<br></div></div></div>
<!--End Page 72-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 73-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg30"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">collection and regulatory compliance Treeline has limited control. Adverse events, protocol deviations, non-compliance with applicable regulatory requirements or unfavorable or inconsistent results arising in any such trial could delay, limit or otherwise harm the clinical development or regulatory approval of Treeline&#8217;s product candidates, even though Treeline would not control these trials. Treeline may also have obligations to collect, evaluate and report to the FDA or comparable foreign regulatory authorities safety information arising from any such trials. Serious adverse events or other safety findings in any such trial could be attributed to Treeline&#8217;s product candidates, could result in a clinical hold or other regulatory action affecting Treeline&#8217;s own clinical trials, and could harm the reputation of, or market perception regarding, the affected product candidate. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">If Treeline experiences delays or difficulties in the enrollment of patients in clinical trials, Treeline&#8217;s receipt of necessary regulatory approvals could be delayed or prevented. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Patient enrollment, a significant factor in the timing and completion of clinical trials, is affected by many factors including the size and nature of the patient population, the number and location of enrolling clinical sites engaged by Treeline, the proximity of patients to clinical sites, the eligibility and exclusion criteria for the trial, the design of the clinical trial, the inability to obtain and maintain patient consents, the risk that enrolled participants will drop out before completion, competing clinical trials, and clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new drugs or therapeutic biologics, including those being developed by Treeline&#8217;s competitors, that may be approved for the indications being investigated by Treeline, and patients&#8217; inability to complete treatment due to illness or other events. The patient populations for Treeline&#8217;s product candidates are limited to those with non-Hodgkin&#8217;s lymphomas, T-cell lymphoma, and KRAS mutant solid tumors, which are substantially smaller than the general treated cancer population, and certain of these cancers may have limited prevalence. Clinical sites participating in Treeline-sponsored clinical trials will need to screen and identify these patients, including through the evaluation of patient biopsies and blood samples that may require the use of companion diagnostic tests, and it may be difficult to identify and enroll a sufficient number of eligible patients. In addition, some of Treeline&#8217;s competitors currently have ongoing clinical trials for product candidates that would seek to enroll the same patients as Treeline&#8217;s product candidates, and patients who would otherwise be eligible for Treeline&#8217;s clinical trials may instead enroll in clinical trials of Treeline&#8217;s competitors&#8217; product candidates. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Furthermore, Treeline expects to rely on its collaborators, CROs and clinical trial sites to ensure the proper and timely conduct of its future clinical trials, including the patient enrollment process, and Treeline has limited influence over their performance. Additionally, Treeline could encounter delays if treating physicians face unresolved ethical issues associated with enrolling patients in current or planned clinical trials of Treeline&#8217;s current or any future product candidates in lieu of prescribing existing treatments that have established safety and efficacy profiles. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline may not be able to initiate or continue its ongoing or planned clinical trials for its current or future product candidates if it is unable to enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or comparable foreign regulatory authorities. Treeline cannot be certain (i) how many patients will meet its criteria for inclusion in its clinical trials, (ii) that the number of patients enrolled in each program will suffice for marketing authorization or (iii) whether the indication targeted will be included in the approved product labeling. If Treeline&#8217;s strategies for patient identification and enrollment prove unsuccessful, it may have difficulty enrolling or maintaining patients appropriate for Treeline&#8217;s product candidates. Patient enrollment is also affected by other factors, including: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">severity of the disease under investigation; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the incidence and prevalence of Treeline&#8217;s target indications; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Treeline&#8217;s ability to recruit clinical trial investigators of appropriate competencies and experience; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">clinicians&#8217; and patients&#8217; awareness of, and perceptions as to, the potential advantages and risks of Treeline&#8217;s product candidates in relation to other available therapies, including any new products that may be approved for the indications it is investigating; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the availability, expertise, dedication and selection of CROs, to manage operations related to clinical trial enrollment; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">competing studies or trials with similar eligibility criteria; </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">62<br></div></div></div>
<!--End Page 73-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 74-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg31"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">invasive procedures required to enroll patients and to obtain evidence of the product candidate&#8217;s performance during the clinical trial; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">availability and efficacy of approved medications for the disease under investigation; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">eligibility criteria defined in the protocol for the trial in question; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the size and nature of the patient population required for analysis of the trial&#8217;s primary endpoints; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">efforts to facilitate timely enrollment in clinical trials; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">whether Treeline is subject to a partial or full clinical hold on any of its clinical trials; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">reluctance of physicians or patient advocacy organizations to encourage patient participation in clinical trials; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the ability to monitor patients adequately during and after treatment; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Treeline&#8217;s ability to obtain and maintain patient consents; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">proximity and availability of clinical trial sites for prospective patients. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If Treeline is unable to enroll a sufficient number of patients for its clinical trials, it would result in significant delays or might require it to abandon one or more clinical trials altogether. Even if Treeline is able to enroll a sufficient number of patients for its clinical trials, it may have difficulty retaining patients in its clinical trials. For example, if patients are receiving placebo in a clinical trial, those patients may perceive that they are not receiving the product candidate being tested, and they may decide to withdraw from that clinical trial to pursue other alternative therapies rather than continue the trial with the perception that they are receiving placebo. Enrollment delays in Treeline&#8217;s clinical trials may result in increased development costs for TLN-121, TLN-254, TLN-372 and TLN-499, or other potential or future product candidates, slow down or halt Treeline&#8217;s product candidate development and approval process and jeopardize its ability to seek and obtain the regulatory approval required to commence product sales and to generate revenue, if needed. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Adverse side effects or other safety risks associated with TLN-121, TLN-254, TLN-372 and TLN-499 or other potential or future product candidates Treeline may develop could delay or preclude approval, cause Treeline to suspend or discontinue clinical trials or abandon further development, limit the commercial profile of an approved product, or result in significant negative consequences following regulatory approval, if any. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">There may be treatment-related SAEs or unexpected serious adverse reactions suspected to be associated with the use of TLN-121, TLN-254, TLN-372 and TLN-499 or other potential or future product candidates. Treeline&#8217;s clinical trials may reveal significant adverse events not seen in its preclinical studies or prior clinical trials and may result in a safety or tolerability profile that could delay or prevent regulatory approval or market acceptance of TLN-121, TLN-254, TLN-372 and TLN-499 or other product candidates. Undesirable or clinically unmanageable side effects observed in Treeline&#8217;s clinical trials for its product candidates or of a competitor developing similar product candidates could occur and cause it or regulatory authorities to interrupt, delay or halt Treeline&#8217;s clinical trials (such as the partial clinical hold of Treeline&#8217;s TLN-254 clinical trials with respect to the cohorts receiving TLN-254 as a monotherapy or in combination with TLN-121) and could result in more restrictive labeling than anticipated or the delay or denial of regulatory approval by the FDA or comparable foreign regulatory authorities. The partial clinical hold on TLN-254 could delay Treeline&#8217;s development of TLN-254 and, if Treeline is unable to resolve it, could result in termination of the TLN-254 program. If additional adverse events, SAEs or other side effects are observed in any of Treeline&#8217;s or its competitor&#8217;s clinical trials that are atypical of, or more severe than, the known side effects of the respective class of agents that each of Treeline&#8217;s product candidates is a part of, or other products in development for the same indications, or the current standard of care, Treeline may have difficulty recruiting participants to its clinical trials, participants may drop out of its trials, or Treeline may be required to abandon those trials or its development efforts of one or more product candidates altogether. Furthermore, clinical trials by their nature utilize a sample of the potential patient population. With a limited number of subjects and limited duration of exposure, rare and severe side effects of Treeline&#8217;s product candidates or those of its competitors may only be uncovered with a significantly larger number of patients exposed to the drug. Undesirable or clinically unmanageable side effects observed in Treeline&#8217;s clinical trials for its product candidates could also occur following discontinuation of TLN-121, TLN-254, TLN-372 and TLN-499, or other product candidates with sufficient recovery periods, and Treeline will need to monitor the severity and duration of side effects in its clinical trials. If such effects are more severe, less reversible than Treeline expects or not reversible at all, it may decide or be required to perform </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">63<br></div></div></div>
<!--End Page 74-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 75-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg32"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">additional studies or to halt or delay further clinical or preclinical development of TLN-121, TLN-254, TLN-372 or TLN-499, as applicable, or other product candidates, which could result in the delay or denial of regulatory approval by the FDA or other comparable foreign regulatory authorities. Adverse events and SAEs that emerge during clinical investigation of or treatment with TLN-121, TLN-254, TLN-372 and TLN-499&#160;or other product candidates may be deemed to be related to Treeline&#8217;s product candidates. Moreover, if Treeline&#8217;s product candidates are associated with undesirable side effects in clinical trials or have characteristics that are unexpected, Treeline may elect to abandon or limit its development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective, which may limit the commercial expectations for Treeline&#8217;s product candidates, if approved. This may require longer and more extensive clinical development, or regulatory authorities may increase the amount of data and information required to approve, market or maintain approval for TLN-121, TLN-254, TLN-372 and TLN-499 or future product candidates and could result in warnings and precautions in Treeline&#8217;s product labeling or a restrictive REMS. This may also result in an inability to obtain approval of TLN-121, TLN-254, TLN-372 and TLN-499 or future product candidates. Treeline, the FDA or other comparable foreign regulatory authorities or an IRB or ethics committee may suspend clinical trials of a product candidate at any time for various reasons, including a belief that participants in such trials are being exposed to unacceptable health risks or adverse side effects. Even if the side effects do not preclude a product candidate from obtaining or maintaining regulatory approval, undesirable side effects may inhibit market acceptance of such approved product due to its safety or tolerability versus other therapies. Further, it is possible that, as Treeline tests its product candidates in larger, longer and more extensive clinical trials, including with different dosing regimens, or as the use of its drug candidates becomes more widespread following any regulatory approval, illnesses, injuries, discomforts and other adverse events that were observed in earlier trials, as well as conditions that did not occur or went undetected in previous trials, will be reported by patients. Any of these developments could materially harm Treeline&#8217;s business, financial condition, results of operations and prospects. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Preliminary, topline or interim data from Treeline&#8217;s clinical trials that it announces or publishes from time to time may change as more patient data become available and/or are subject to audit and verification procedures that could result in material changes in the final data. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">From time to time, Treeline may publicly disclose preliminary, topline or interim data from its clinical trials, such as preliminary, topline or interim data analysis from its ongoing Phase 1 clinical trials for TLN-121, TLN-254 and TLN-372. These data and related findings and conclusions may only reflect certain endpoints rather than all endpoints and are subject to change. Treeline also makes assumptions, estimations, calculations and conclusions as part of its analyses of data, and it may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the preliminary or topline results that Treeline reports may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Preliminary or topline data also remain subject to review and verification procedures that may result in the final data being materially different from the preliminary or topline data Treeline previously published. As a result, preliminary and topline data should be viewed with caution until the final data are available. In addition, Treeline may report preliminary data or interim analyses of the clinical trials it may conduct and complete, which are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse changes between preliminary or interim data and final data could significantly harm Treeline&#8217;s business and prospects. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Further, the information Treeline chooses to publicly disclose regarding a particular study or clinical trial is typically selected from a more extensive amount of available information. You or others may not agree with what Treeline determines is the material or otherwise appropriate information to include in its disclosure, and any information Treeline determines not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product, product candidate or its business. If the preliminary, topline or interim data that Treeline reports differ from later, final or actual results, or if others, including regulatory authorities, disagree with the conclusions reached, its ability to obtain approval for, and commercialize, its product candidates may be harmed, which could harm its business, financial condition, results of operations and prospects. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">64<br></div></div></div>
<!--End Page 75-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 76-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg33"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Treeline may seek to develop and commercialize its product candidates in combination with other therapies, which exposes Treeline to additional risks. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline may seek to develop or commercialize its product candidates in combination with one or more currently approved therapies or therapies in development. The availability, pricing, supply, regulatory status and clinical performance of any such combination agent are outside Treeline&#8217;s control. If Treeline&#8217;s product candidates are used in combination with therapies that are supplied by third parties, Treeline will depend on those third parties to supply, in sufficient quantities and on a timely basis, the combination therapies on terms acceptable to Treeline, if at all. If Treeline is unable to obtain a sufficient supply of those combination therapies on commercially reasonable terms, or at all, Treeline&#8217;s clinical development or commercialization activities involving such combination therapies could be delayed, limited or prevented. Additionally, if a combination agent is withdrawn from the market, becomes the subject of a safety signal, is not supplied on commercially reasonable terms, or fails to demonstrate efficacy in the relevant indication, the development or commercialization of Treeline&#8217;s product candidate in combination with that agent could be delayed or abandoned, and any approval Treeline obtains may be limited to use in combination with a specific agent. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Even if any product candidate Treeline develops were to receive marketing approval or be commercialized for use in combination with other existing therapies, Treeline would continue to be subject to the risks that the FDA or comparable foreign regulatory authorities could revoke approval of the combination therapy, or that a third-party therapy that Treeline&#8217;s product candidates are used in combination with could be withdrawn from the market, or that safety, efficacy, manufacturing or supply issues could arise with respect to any of the combination therapies. This could result in Treeline&#8217;s products, if approved, being removed from the market or being less successful commercially. Treeline may also evaluate its product candidates in combination with one or more other therapies that have not yet been approved for marketing by the FDA or comparable foreign regulatory authorities. Treeline will not be able to market and sell any product candidate in combination with any such unapproved therapies that do not ultimately obtain marketing approval. In addition, unapproved therapies face the same regulatory, development and commercial risks as Treeline&#8217;s own product candidates. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Although Treeline intends to explore other therapeutic opportunities in addition to the product candidates that it is currently developing, Treeline may fail to identify viable new product candidates for clinical development for a number of reasons. If Treeline fails to identify additional potential product candidates, its business could be materially harmed. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline may expend its limited resources to pursue a particular product candidate in specific indications and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success. Because Treeline has limited financial and managerial resources, it focuses its development efforts on certain selected product candidates in certain selected indications. As a result, Treeline may forgo or delay pursuit of opportunities with other potential or future product candidates, or other indications for its current or any future product candidates that later prove to have greater commercial potential. Treeline&#8217;s resource allocation decisions may cause it to fail to capitalize on viable commercial products or profitable market opportunities. Treeline&#8217;s spending on current and future development programs and product candidates for specific indications may not yield any commercially viable product candidates. If Treeline does not accurately evaluate the commercial potential or target market for a particular product candidate, Treeline may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for it to retain sole development and commercialization rights to such product candidate. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">The breadth and diversity of Treeline&#8217;s pipeline may strain its limited resources, and Treeline may be unable to advance all of its programs or to prioritize among them effectively. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline&#8217;s pipeline is broad and diverse, comprising multiple product candidates and programs that span different modalities, biological targets, therapeutic areas and indications and that range across stages of development from discovery and preclinical research through Phase 1 clinical trials. Advancing a large number of programs in parallel requires substantial financial, managerial, scientific, clinical, regulatory, manufacturing and operational resources, as well as significant management attention, and Treeline has limited resources. As a result, Treeline must continually decide which product candidates, modalities and indications to prioritize, and it may be unable to advance all of its programs simultaneously or on its anticipated timelines. Treeline&#8217;s prioritization and resource-allocation decisions may prove to be incorrect, and constraints on its resources or management attention could delay one or more programs, cause Treeline to narrow, partner, deprioritize or discontinue programs that later </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">65<br></div></div></div>
<!--End Page 76-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 77-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg34"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">prove to have greater scientific or commercial potential, or otherwise impair Treeline&#8217;s ability to execute across its pipeline. These challenges may be heightened as Treeline integrates its operations with Standard BioTools and operates as part of a combined public company, and any failure to manage the breadth and complexity of its pipeline effectively could materially and adversely affect Treeline&#8217;s business, financial condition, results of operations and prospects. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Treeline&#8217;s ability to identify new product candidates depends on its integrated drug discovery organization, including its wet-lab and computational capabilities, which may not perform as expected. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline&#8217;s ability to identify, evaluate and advance new product candidates depends on its integrated drug discovery organization, which combines in-house wet-lab research &#8212; including custom assay development, structural and biophysical characterization of targets, and medicinal chemistry across small molecule inhibitors, protein degraders and targeted therapy antibody-drug conjugates (&#8220;TT-ADCs&#8221;) &#8212; with computational capabilities, including physics-based modeling and artificial intelligence and machine learning (&#8220;AI/ML&#8221;). Treeline uses these computational tools to accelerate and sharpen its experimental work and to prioritize experiments and compounds for synthesis and testing, rather than as a substitute for its wet-lab research or the judgment of its scientific personnel. The success of these efforts depends on the quality and completeness of the underlying biological and chemical data, the validity of Treeline&#8217;s models and assumptions, the integration of its experimental and computational work, and the expertise and continued service of its scientists. These methods are complex and rapidly evolving, and they may produce inaccurate predictions, may fail to identify viable product candidates, or may yield candidates that do not translate from preclinical models into clinical efficacy or an acceptable safety profile. Treeline&#8217;s discovery efforts may also be rendered less competitive by advances in computational chemistry, structural biology or AI/ML-based drug discovery achieved by others. Any of these outcomes could impair Treeline&#8217;s ability to replenish its pipeline and could materially harm Treeline&#8217;s business. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline&#8217;s use of AI/ML and other computational methods is also subject to evolving legal, regulatory and ethical considerations, including with respect to data rights, the intellectual property protection of its computational methods and their outputs, and regulatory expectations regarding the evidence supporting computational claims. The legal and regulatory framework governing AI/ML continues to develop and remains uncertain, and compliance may be costly and time-consuming. Any failure by Treeline, or by the third parties on whose data, models or computing infrastructure it relies, to comply with these requirements, or any actual or perceived misuse of these tools, could expose Treeline to regulatory or legal liability or reputational harm, or could delay or limit its discovery and development activities. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Treeline&#8217;s product candidates include targeted protein degraders and other modalities that have limited clinical and regulatory precedent. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline&#8217;s product candidates span multiple modalities, including targeted protein degraders, such as TLN-121 and TLN-499, and small-molecule inhibitors, such as TLN-254 and TLN-372, and Treeline is pursuing additional modalities in its preclinical and discovery programs. Certain of these modalities, in particular targeted protein degradation and TT-ADCs, have limited clinical and regulatory precedent. The number of approved therapies based on these modalities remains limited, and the FDA and comparable foreign regulatory authorities have limited experience reviewing them. As a result, the regulatory pathway for Treeline&#8217;s product candidates may be longer, more uncertain, more complex or more costly than for therapies based on more established modalities, and regulators may apply novel or evolving standards or require additional preclinical or clinical data. These modalities may also present development and manufacturing challenges and may be associated with unexpected safety, efficacy, pharmacokinetic or immunogenicity findings that are not yet fully understood. Any of these factors could delay or prevent the development, regulatory approval or commercialization of Treeline&#8217;s product candidates, and adverse developments affecting one product candidate or program based on a given modality could negatively affect Treeline&#8217;s other potential or future product candidates or programs that rely on the same or similar approaches. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Treeline is conducting, and may in the future conduct, clinical trials of its product candidates outside the United States, and the FDA and comparable foreign regulatory authorities may not accept data from such trials. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline is conducting, and may in the future conduct, clinical trials of its product candidates outside the United&#160;States, and the FDA and comparable foreign regulatory authorities may not accept data from such trials. For example, Treeline&#8217;s ongoing Phase 1 study of TLN-372 is being conducted in the United States, Canada, Australia and Spain. The acceptance of data from clinical trials conducted outside the United States by the FDA or other </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">66<br></div></div></div>
<!--End Page 77-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 78-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg35"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">comparable foreign regulatory authorities may be subject to certain conditions or may not be accepted at all. In cases where data from foreign clinical trials are intended to serve as the sole basis for regulatory approval in the United States, the FDA&#160;will generally not approve the application unless (i) the data are applicable to the U.S. population and U.S. medical practice; (ii) the trials were performed by clinical investigators of recognized competence and pursuant to GCP&#160;regulations; and (iii) the data may be considered valid without the need for an on-site inspection by the FDA or, if the FDA considers such an inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. In addition, even where the foreign study data are not intended to serve as the sole basis for approval, the FDA will not accept the data from a foreign clinical study not conducted under an IND as support for an application for marketing approval unless the study is well-designed and well-conducted in accordance with GCPs and the FDA is able to validate the data from the study through an on-site inspection if deemed necessary. Additionally, the FDA&#8217;s clinical trial requirements, including sufficient size of patient populations and statistical powering, must be met. Many foreign regulatory authorities have similar approval requirements. In addition, such foreign trials are subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. Conducting clinical trials outside the United States also exposes Treeline to additional risks, including risks associated with foreign exchange fluctuations, compliance with foreign manufacturing, customs, shipment and storage requirements, and cultural differences in medical practice and clinical research, and diminished protection of intellectual property in some countries. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">There can be no assurance that the FDA or any comparable foreign regulatory authority will accept data from trials conducted outside of the United States or the applicable jurisdiction. For example, for FDA acceptance, Treeline will have to demonstrate that the foreign data are applicable to the U.S. population and U.S. medical practice. If the FDA or other comparable foreign regulatory authorities do not accept such data, it would result in the need for additional trials, which could be costly and time-consuming, and which may result in current or future product candidates that Treeline may develop being delayed or not receiving approval for commercialization in the applicable jurisdiction. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">If, in the future, Treeline is unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market any product it may develop, Treeline may not be successful in commercializing those products if they are approved. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline does not have a sales or marketing infrastructure and has no experience in the sales, marketing or distribution of any current or future product candidates. To achieve commercial success for any approved product, Treeline must either develop a sales and marketing organization or outsource these functions to third parties. In the future and if any of Treeline&#8217;s product candidates are approved, it may choose to build a focused sales, marketing and commercial support infrastructure to sell, or participate in sales activities with collaborators for some of Treeline&#8217;s current or future product candidates. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">There are risks involved with both establishing Treeline&#8217;s own commercial capabilities and entering into arrangements with third parties to perform these services. For example, factors that may inhibit Treeline&#8217;s efforts to commercialize any approved product candidates include: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the inability to recruit and retain adequate numbers of effective sales, marketing, coverage or reimbursement, customer service, medical affairs and other support personnel; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the inability of sales personnel to obtain access to or persuade adequate numbers of decision makers of the utility of future approved product candidates; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the inability of reimbursement professionals to negotiate arrangements for formulary access, reimbursement and other acceptance by payors; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the inability to price any of Treeline&#8217;s current or future product candidates at a sufficient price point to ensure an adequate and attractive level of profitability; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">restricted or closed distribution channels that make it difficult to distribute Treeline&#8217;s current or future product candidates to segments of the patient population; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the lack of complementary product candidates to be offered by sales personnel, which may put Treeline at a competitive disadvantage relative to companies with more extensive product candidate lines; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">unforeseen costs and expenses associated with creating an independent commercialization organization. </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">67<br></div></div></div>
<!--End Page 78-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 79-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg36"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If the commercial launch of a product candidate, if approved, for which Treeline recruits a sales force and establishes marketing and other commercialization capabilities is delayed or does not occur for any reason, Treeline would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and Treeline&#8217;s investment would be lost if Treeline cannot retain or reposition its commercialization personnel. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If Treeline were to enter into arrangements with third parties to perform sales, marketing, commercial support and distribution services, Treeline&#8217;s sales revenue or the profitability of sales revenue may be lower than if Treeline were to do so itself. In addition, Treeline may not be successful in entering into arrangements with third parties to commercialize its product candidates or may be unable to do so on terms that are favorable to it. Treeline may have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market Treeline&#8217;s product candidates effectively. If Treeline does not establish commercialization capabilities successfully, either on its own or in collaboration with third parties, it will not be successful in commercializing its product candidates, if approved. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Treeline&#8217;s current or future product candidates may not achieve adequate market acceptance among physicians, patients or their families, healthcare payors and others in the medical community necessary for commercial success. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Even if Treeline&#8217;s current or future product candidates receive regulatory approval, they may not gain adequate market acceptance among physicians, patients or their families, third-party payors and others in the medical community. The degree of market acceptance of any of Treeline&#8217;s approved product candidates will be dependent on a number of factors, including: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the efficacy, durability and safety profile as demonstrated in clinical trials compared to alternative treatments; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the timing of market introduction of the product candidate as well as competitive products; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the clinical indications for which a product candidate is approved; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">restrictions on the use of product candidates in the labeling approved by regulatory authorities, such as boxed warnings or contraindications in labeling, or a REMS, if any, which may not be required of alternative treatments and competitor products; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the terms of any approvals and the countries in which approvals are obtained; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the potential and perceived advantages of Treeline&#8217;s current or future product candidates over alternative treatments; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the cost of treatment in relation to alternative treatments and the cost/benefit ratios of each; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the availability of coverage and adequate reimbursement by third-party payors, including government authorities, and timing of relevant formulary decision-making resulting in this coverage and reimbursement; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the availability of an approved product candidate for use as a combination therapy; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">relative convenience and ease of administration in relation to competition; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the effectiveness of sales, marketing efforts and market access; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">publicity relating to Treeline&#8217;s product candidates or those of Treeline&#8217;s competitors; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">potential product liability claims; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the approval of new therapies for the same indications. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If any of Treeline&#8217;s current or future product candidates are approved but do not achieve an adequate level of acceptance by physicians, hospitals, healthcare payors and patients, it may not generate or derive sufficient revenue from that product candidate and its financial results could be negatively impacted. Treeline&#8217;s efforts to educate the medical community and third-party payors regarding the benefits of its products may require significant resources and may never be successful. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">68<br></div></div></div>
<!--End Page 79-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 80-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg37"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">If Treeline&#8217;s product candidates do not achieve projected development milestones or commercialization in the announced or expected timeframes, the further development or commercialization of such product candidates may be delayed, and its business will be harmed. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline has estimated, and may in the future estimate, the timing of the accomplishment of various scientific, clinical, manufacturing, regulatory and other product development objectives. These milestones have and may include Treeline&#8217;s expectations regarding the commencement or completion of preclinical studies and clinical trials, data readouts, the submission of regulatory filings, the receipt of marketing approval or the realization of other commercialization objectives. The achievement of many of these milestones may be outside of Treeline&#8217;s control. All of these milestones are based on a variety of assumptions, including assumptions regarding capital resources, constraints and priorities, progress of and results from development activities and the receipt of key regulatory approvals or actions, any of which may cause the timing of achievement of the milestones to vary considerably from Treeline&#8217;s estimates. If Treeline or its collaborators fail to achieve announced milestones in the expected timeframes, the commercialization of the product candidates may be delayed, its credibility may be undermined and its business and results of operations may be harmed. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Even if Treeline completes the necessary preclinical studies and clinical trials, Treeline cannot predict when, or if, Treeline will obtain regulatory approval to commercialize a product candidate and the approval may be for a narrower indication than Treeline seeks. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Prior to commercialization, Treeline&#8217;s product candidates must be approved by the FDA pursuant to an NDA in the United States and pursuant to similar marketing applications by comparable foreign regulatory authorities. The process of obtaining marketing approvals, both in the United States and abroad, is expensive and takes many years, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Failure to obtain marketing approval for a product candidate will prevent Treeline from commercializing the product candidate. Treeline has not received approval to market Treeline&#8217;s product candidates from regulatory authorities in any jurisdiction. Treeline has no experience in submitting and supporting the applications necessary to gain marketing approvals, and, in the event regulatory authorities indicate that Treeline may submit such applications, Treeline may be unable to do so as quickly and efficiently as desired. Securing marketing approval requires the submission of extensive preclinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish the product candidate&#8217;s safety and efficacy. Securing marketing approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the regulatory authorities. Treeline&#8217;s product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude Treeline&#8217;s obtaining marketing approval or prevent or limit commercial use. Regulatory authorities have substantial discretion in the approval process and may refuse to accept or file any application or may decide that Treeline&#8217;s data are insufficient for approval and require additional preclinical, clinical or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of a product candidate. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Approval of Treeline&#8217;s product candidates may be delayed or refused for many reasons, including: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of Treeline&#8217;s clinical trials; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Treeline may be unable to demonstrate, to the satisfaction of the FDA or comparable foreign regulatory authorities, that Treeline&#8217;s product candidates are safe and effective for any of their proposed indications; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the populations studied in clinical trials may not be sufficiently broad or representative to assure efficacy and safety in the populations for which Treeline seeks approval; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Treeline may be unable to demonstrate that Treeline&#8217;s product candidates&#8217; clinical and other benefits outweigh their safety risks; or </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the data collected from clinical trials of Treeline&#8217;s product candidates may not be sufficient to support the submission of an NDA or other comparable submission in foreign jurisdictions or to obtain regulatory approval in the United States or elsewhere. </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">69<br></div></div></div>
<!--End Page 80-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 81-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg38"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Even if Treeline&#8217;s product candidates meet their pre-specified safety and efficacy endpoints in clinical trials, the regulatory authorities may not complete their review processes in a timely manner and may not consider such clinical trial results sufficient to grant, or Treeline may not be able to obtain regulatory approval. Additional delays may result if an FDA Advisory Committee or other regulatory authority recommends non-approval or restrictions on approval. In addition, Treeline may experience delays or rejections based upon additional government regulation from future legislation or administrative action, or changes in regulatory authority policy during the period of product development, clinical trials and the review process. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Regulatory authorities also may approve a product candidate for more limited indications than requested or they may impose significant limitations in the form of narrow indications, warnings, contraindications or a REMS. These regulatory authorities may also grant approval subject to the performance of costly post-marketing clinical trials. In addition, regulatory authorities may not approve the labeling claims that are necessary or desirable for the successful commercialization of Treeline&#8217;s product candidates. Any of the foregoing scenarios could materially harm the commercial prospects for Treeline&#8217;s product candidates and adversely affect Treeline&#8217;s business, financial condition, results of operations and prospects. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Adverse events in the therapeutic fields being pursued by Treeline, including oncology, neurology or immunology, or in the biopharmaceutical and biotechnology industries, could damage public perception of Treeline&#8217;s current or future product candidates and negatively affect Treeline&#8217;s business. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline&#8217;s approach includes the use of targeted protein degraders and other modalities with limited clinical and regulatory precedent. Adverse events in clinical trials of Treeline&#8217;s product candidates, or post-marketing activities, or in clinical trials of others developing similar products or that are related to approved therapies with similar modalities to Treeline&#8217;s product candidates, and the resulting publicity, as well as any other adverse events that may occur in the future in any of the therapeutic fields or modalities being pursued by Treeline, could result in a decrease in demand for any product that Treeline may develop. If public perception is influenced by claims that the use of therapies in any of the therapeutic fields or modalities being pursued by Treeline is unsafe, whether related to Treeline&#8217;s therapies or those of its competitors, Treeline&#8217;s product candidates or products, if approved, may not be accepted by the general public or the medical community. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Future adverse events in any of the therapeutic fields or modalities being pursued by Treeline or the biopharmaceutical and biotechnology industries could also result in greater government regulation, stricter labeling requirements and potential regulatory delays in the testing or approvals of Treeline&#8217;s products. Any increased scrutiny could delay or increase the costs of obtaining marketing approval for Treeline&#8217;s current or future product candidates. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Treeline may need to use existing commercial diagnostic tests or develop, or enter into a collaboration or partnership to develop, novel complementary diagnostics and/or novel companion diagnostics for some of its current or future product candidates. If Treeline or its partners are unable to successfully develop these companion diagnostics or complementary diagnostics, or experience significant delays in doing so, Treeline may not realize the full commercial potential of its future product candidates. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In some cases, a predictive biomarker may be used to identify the right patients for Treeline&#8217;s programs and its current or future product candidates. Accordingly, Treeline believes that its success may depend, in part, on its ability to use existing diagnostic tests from third parties or develop novel complementary diagnostics and/or novel companion diagnostics in collaboration with partners. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In the event that novel tests will need to be developed, Treeline has little experience in the development of diagnostics. Treeline expects to rely on partners in developing appropriate diagnostics to pair with its current or future product candidates. Treeline may be unsuccessful in entering into or maintaining collaborations for the development of companion diagnostics for use with its current or future product candidates in its markets of interest. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Complementary diagnostics and companion diagnostics are subject to regulation by the FDA and comparable foreign regulatory authorities as medical devices and require separate regulatory approval, clearance or certification prior to commercialization. In addition, if the FDA determines that a companion diagnostic device is essential to the safe and effective use of a novel therapeutic product or indication, the FDA generally will not approve the therapeutic product or new therapeutic product indication if the companion diagnostic is not also approved or cleared for that indication. Companion diagnostics are developed in conjunction with clinical programs for the associated therapeutic product, and the FDA has generally required premarket approval of companion diagnostics </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">70<br></div></div></div>
<!--End Page 81-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 82-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg39"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">for certain therapies. The approval or clearance of a companion diagnostic as part of the therapeutic product&#8217;s further labeling limits the use of the therapeutic product to only those patients who express the specific characteristic, such as a biomarker, that the companion diagnostic was developed to detect. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If Treeline, its partners, or any third parties that Treeline engages to assist it, are unable to successfully develop complementary diagnostics and/or companion diagnostics for its product candidates and any future product candidates, or Treeline experiences delays in doing so: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the development of Treeline&#8217;s product candidates and any other future product candidates may be adversely affected if Treeline is unable to appropriately select patients for enrollment in Treeline&#8217;s clinical trials; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Treeline may be unable to obtain approval for any of its product candidates for which the FDA or foreign regulatory authority has determined a companion diagnostic is required; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Treeline may not realize the full commercial potential of its product candidates and any other future product candidates that receive marketing approval if, among other reasons, Treeline is unable to appropriately identify, or it takes Treeline longer to identify, patients who are likely to benefit from therapy with its products, if approved. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Even if Treeline or its current or future partners are successful in the development of diagnostics for use with its current or future product candidates, there are also risks associated with the commercial supply of these diagnostics. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Treeline&#8217;s future growth may be dependent, in part, on its ability to operate in foreign markets, where it would be subject to additional regulatory burdens and other risks and uncertainties. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline&#8217;s future growth may be dependent, in part, on its ability to develop and commercialize TLN-121, TLN-254, TLN-372 and TLN-499, if approved, and other potential or future product candidates in foreign markets for which it may rely on collaboration with third parties. Treeline is not permitted to market or promote TLN-121, TLN-254, TLN-372 and TLN-499 or other product candidates before it receives regulatory approval from the applicable regulatory authority in that foreign market and may never receive such regulatory approval for TLN-121, TLN-254, TLN-372 and TLN-499 or other product candidates. To obtain separate regulatory approval in many other countries, Treeline must comply with numerous and varying regulatory requirements of such countries regarding safety and efficacy and governing, among other things, manufacturing, clinical trials and commercial sales, pricing and distribution of TLN-121, TLN-254, TLN-372 and TLN-499 or other product candidates, and it cannot predict success in these jurisdictions. If Treeline fails to comply with the regulatory requirements in international markets and receive applicable regulatory approvals, its target market will be reduced and its ability to realize the full market potential of TLN-121, TLN-254, TLN-372 and TLN-499 or other product candidates will be harmed and its business will be adversely affected. Treeline may not obtain foreign regulatory approvals on a timely basis, if at all. Its failure to obtain approval of any of TLN-121, TLN-254, TLN-372 and TLN-499 or other product candidates by regulatory authorities in another country may significantly diminish the commercial prospects of that product candidate and its business, financial condition, results of operations and prospects could be materially and adversely affected. Moreover, even if Treeline obtains approval of TLN-121, TLN-254, TLN-372 and TLN-499 or other product candidates and ultimately commercializes TLN-121, TLN-254, TLN-372 and TLN-499 or other product candidates in foreign markets, it would be subject to the risks and uncertainties, including the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements and reduced protection of intellectual property rights in some foreign countries. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">The manufacture of drugs is complex, and Treeline&#8217;s third-party manufacturers may encounter difficulties in production. If any of Treeline&#8217;s third-party manufacturers encounter such difficulties, Treeline&#8217;s ability to provide supply of Treeline&#8217;s current or future product candidates for clinical trials, Treeline&#8217;s ability to obtain marketing approval, or Treeline&#8217;s ability to provide supply of Treeline&#8217;s product candidates for patients, if approved, could be delayed or stopped. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline does not own or operate facilities for the manufacture of its product candidates and instead relies, and expects to continue to rely, on third-party manufacturers and supply partners to manufacture its current and future product candidates and the components thereof. Treeline intends to establish manufacturing relationships with a limited number of suppliers to manufacture raw materials, the drug substance and finished product of any product candidate for which Treeline is responsible for preclinical or clinical development. As part of any marketing approval, a manufacturer and its processes are required to be qualified by the FDA (or comparable regulatory </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">71<br></div></div></div>
<!--End Page 82-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 83-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg40"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">authorities outside of the United States) prior to regulatory approval. If supply from an approved vendor is interrupted, there could be a significant disruption in commercial supply. An alternative vendor would need to be qualified through appropriate regulatory filings which could result in further delay. The FDA or other regulatory agencies outside of the United States may also require additional studies if a new supplier is relied upon for commercial production. Switching vendors may involve substantial costs and is likely to result in a delay in Treeline&#8217;s desired clinical and commercial timelines. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The process of manufacturing drugs is complex, highly regulated and subject to multiple risks. Manufacturing drugs is highly susceptible to product loss due to contamination, equipment failure, improper installation or operation of equipment, vendor or operator error, inconsistency in yields, variability in product characteristics and difficulties in scaling the production process. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered at the facilities of Treeline&#8217;s manufacturers, such facilities may need to be closed for an extended period of time to investigate and remedy the contamination, which could delay clinical trials and adversely harm Treeline&#8217;s business. Moreover, if the FDA determines that Treeline&#8217;s CDMOs are not in compliance with applicable laws and FDA&#160;regulations, including those governing cGMPs, the FDA may deny NDA approval until the deficiencies are corrected or Treeline replaces the manufacturer in Treeline&#8217;s NDA with a manufacturer that is in compliance. In addition, approved products and the facilities at which they are manufactured are required to maintain ongoing compliance with extensive FDA requirements and the requirements of other similar agencies, including ensuring that quality control and manufacturing procedures conform to cGMP requirements. As such, Treeline&#8217;s CDMOs are subject to continual review and periodic inspections to assess compliance with cGMPs. Furthermore, although Treeline does not have day-to-day control over the operations of its CDMOs, it is responsible for ensuring compliance with applicable laws and regulations, including cGMPs. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, Treeline relies on third parties located in China for some of its contract manufacturing, and Treeline expects to continue to use such third-party manufacturers for such purposes. For any activities conducted in China, Treeline is exposed to the possibility of product supply disruption and increased costs in the event of changes in the policies of the United States or Chinese governments, political unrest or unstable economic conditions in China. In addition, certain Chinese biotechnology companies may become subject to trade restrictions, sanctions, other regulatory requirements, or proposed legislation by the U.S. government, which could restrict or even prohibit Treeline&#8217;s ability to work with such entities, thereby potentially disrupting the supply of material to Treeline. For example, the BIOSECURE Act, which was signed into law in December&#160;2025 as part of the National Defense Authorization Act for Fiscal Year 2026, prohibits U.S. federal agencies from entering into or renewing any contract, loan, or grant with any entity that uses biotechnology equipment or services produced or provided by a &#8220;biotechnology company of concern&#8221; to perform that contract. The BIOSECURE Act also prohibits U.S.&#160;government loan and grant recipients from using federal loan or grant money to enter into contracts with entities that use equipment from &#8220;biotechnology companies of concern&#8221; in the performance of any federal prime contract or subcontract. The Office of Management and Budget (&#8220;OMB&#8221;) of the U.S. Government will issue a list of &#8220;biotechnology companies of concern,&#8221; which will include certain companies that are identified on the U.S.&#160;Department of Defense&#8217;s annual List of Chinese Military Companies, also known as the 1260H List, other entities which the U.S. Government has deemed as such pursuant to a separate designation process, and certain subsidiary, parent, and successor entities of the foregoing. Treeline is currently party to agreements with WuXi&#160;Apptec Co., Ltd. (&#8220;WuXi Apptec&#8221;) and WuXi Biologics for certain development and manufacturing services. WuXi Apptec was designated on the 1260H List on June&#160;8, 2026. WuXi&#160;Biologics is not currently designated on the 1260H List; however, WuXi Biologics was previously explicitly named as a &#8220;biotechnology company of concern&#8221; in pre-enactment draft versions of the BIOSECURE Act. The BIOSECURE Act includes a safe harbor provision providing that the restrictions do not apply to equipment or services that were formerly but are no longer provided by a &#8220;biotechnology company of concern.&#8221; The BIOSECURE Act also includes a grandfathering provision providing that the prohibitions shall not apply for a five-year period to biotechnology equipment or services produced or provided under a contract or agreement entered into before the applicable effective date. It is unclear whether the grandfathering provision would apply to entities designated as &#8220;biotechnology companies of concern&#8221; due to their inclusion on the 1260H List. The guidance to be issued by OMB&#160;regarding implementation of the BIOSECURE Act may provide further clarity on this point. If WuXi Apptec and/or WuXi Biologics are designated as &#8220;biotechnology companies of concern&#8221; by OMB, Treeline may be restricted in its ability to work with such companies to the extent Treeline would contract with, or otherwise receive funding from, the U.S. government. As a result, Treeline may need to seek alternative CDMO relationships. While Treeline believes it will be able to identify </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">72<br></div></div></div>
<!--End Page 83-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 84-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg41"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">and contract with such alternative CDMOs, Treeline cannot guarantee that alternative CDMOs with the necessary capabilities and capacity would be available on a timeline that would not materially delay the development of its product candidates and cannot predict the terms of any such alternative arrangement nor what actions may ultimately be taken with respect to trade relations between the United States and China or other countries, what products and services may be subject to such actions or what actions may be taken by China or the other countries in retaliation. In addition, any unfavorable government policies on international trade, such as export controls, capital controls or tariffs, new legislation or regulations, renegotiation of existing trade agreements, or any retaliatory trade actions due to recent or future trade tension, may impede, delay, limit, or increase the cost of manufacturing Treeline&#8217;s product candidates. Such events could result in Treeline&#8217;s clinical or commercial supply of drug, packaging and other services being interrupted or limited, which would have an adverse effect on Treeline&#8217;s business, financial condition, results of operations and prospects. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, there are risks associated with large scale manufacturing for clinical trials or commercial scale including, among others, cost overruns, potential problems with process scale-up, process reproducibility, stability issues, compliance with cGMPs, lot consistency and timely availability of raw materials. Even if Treeline obtains regulatory approval for any of Treeline&#8217;s product candidates, there is no assurance that manufacturers will be able to manufacture the approved product to specifications acceptable to the FDA or other regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential launch of the product or to meet potential future demand. If Treeline&#8217;s manufacturers are unable to produce sufficient quantities for clinical trials or for commercialization, commercialization efforts would be impaired, which would have an adverse effect on Treeline&#8217;s business, financial condition, results of operations and prospects. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline believes that it will rely on a limited number of manufacturers for its product candidates for which it has identified single-source suppliers for the various steps of manufacture. This reliance on a limited number of manufacturers and the complexity of drug manufacturing and the difficulty of scaling up a manufacturing process could cause the delay of clinical trials, regulatory submissions, required approvals or commercialization of Treeline&#8217;s product candidates, cause Treeline to incur higher costs and prevent Treeline from commercializing Treeline&#8217;s product candidates successfully. Furthermore, if Treeline&#8217;s suppliers fail to deliver the required clinical or commercial quantities of materials on a timely basis and at commercially reasonable prices, and Treeline is unable to secure one or more replacement suppliers capable of production in a timely manner at a substantially equivalent cost, Treeline&#8217;s clinical trials may be delayed or Treeline could lose potential revenue. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Treeline may not be successful in finding strategic collaborators for development of existing or future product candidates or successfully commercializing or competing in the market for certain indications. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In the future, Treeline may decide to collaborate with other pharmaceutical and biotechnology companies for the development and potential commercialization of existing and future product candidates. It faces significant competition in seeking appropriate collaborators. Whether Treeline reaches a definitive agreement for a collaboration will depend, among other things, upon its assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or comparable foreign regulatory authorities, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing drugs, the existence of uncertainty with respect to its ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that may result in a reduced number of potential future collaborators. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If Treeline is unable to do so, it may have to curtail the development of the product candidate for which it is seeking to collaborate, reduce or delay its development program or one or more of its other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase its expenditures and undertake development or commercialization activities at its own expense. If Treeline elects to increase its expenditures to fund development or commercialization activities on its own, it may need to obtain additional capital, which may not be available to Treeline on acceptable terms or at all. If it does not have sufficient funds, it may not be able to further develop its product candidates or bring them to market and generate product revenue. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">73<br></div></div></div>
<!--End Page 84-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 85-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg42"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The success of any potential collaboration arrangements will depend heavily on the efforts and activities of its collaborators. Collaborators generally have significant discretion in determining the efforts and resources that they will apply to these collaborations. Disagreements between parties to a collaboration arrangement regarding clinical development and commercialization matters can lead to delays in the development process or commercializing the applicable product candidate and, in some cases, termination of such collaboration arrangements. These disagreements can be difficult to resolve if neither of the parties has final decision-making authority. Collaborations with pharmaceutical or biotechnology companies and other third parties often are terminated or allowed to expire by the other party. Any such termination or expiration would adversely affect Treeline financially and could harm its business reputation. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Risks Related to Government Regulation </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">The regulatory approval process is highly uncertain, and Treeline may be unable to obtain, or may be delayed in obtaining, U.S. or foreign regulatory approval and, as a result, unable to commercialize Treeline&#8217;s current product candidates and any future product candidates. Even if Treeline believes its current, or planned, clinical trials are successful, regulatory authorities may not agree that they provide adequate data on safety or efficacy. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline&#8217;s current and any future product candidates are subject to extensive governmental regulations relating to, among other things, research, testing, development, manufacturing, approval, recordkeeping, reporting, labeling, storage, packaging, advertising and promotion, pricing, post-approval monitoring, marketing and distribution of products. Rigorous preclinical testing and clinical trials and an extensive regulatory approval process are required to be completed successfully in the United States and in many foreign jurisdictions before a new biopharmaceutical product can be marketed. Satisfaction of these and other regulatory requirements is costly, time-consuming, uncertain and subject to unanticipated delays. It is possible that none of the product candidates Treeline may develop will obtain the regulatory approvals necessary for it to begin marketing and selling them. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">While Treeline has clinical trials currently ongoing, it has limited experience as a company in conducting and managing clinical trials and has no experience completing the later-stage clinical trials necessary to obtain regulatory approvals, including approval by the FDA, or obtaining marketing approval for any product candidate. The time required to obtain FDA and other approvals is unpredictable but typically takes many years following the commencement of clinical trials, depending on the type, complexity and novelty of the product candidate. The standards that the FDA and its foreign counterparts use when regulating Treeline require judgment and can change, which makes it difficult to predict with certainty their application. Any analysis Treeline performs of data from preclinical and clinical activities is subject to confirmation and interpretation by regulatory authorities, which could delay, limit or prevent regulatory approval. Treeline may also encounter unexpected delays or increased costs due to new government regulations, for example, from future legislation or administrative action, or from changes in FDA&#160;policy during the period of product development, clinical trials and FDA regulatory review. It is not possible to predict whether additional legislative changes will be enacted, or whether FDA or foreign regulations, guidance or interpretations will be changed, or the impact of such changes, if any. Any elongation or de-prioritization of preclinical studies or clinical trials or delay in regulatory review resulting from such disruptions could adversely affect the development and study of Treeline&#8217;s current or other future product candidates. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Further, the FDA and other comparable foreign regulatory authorities may respond to any IND or NDA (and their foreign equivalents) that Treeline may submit by defining requirements that Treeline does not anticipate. Such responses could delay clinical development of Treeline&#8217;s current or any future product candidates. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, the approval policies or regulations of the FDA and other comparable regulatory authorities in other jurisdictions may change in a manner rendering Treeline&#8217;s clinical or manufacturing data insufficient for approval. Any delay or failure in obtaining required approvals could have a material and adverse effect on Treeline&#8217;s ability to generate revenues from the particular product candidate for which it is seeking approval. Furthermore, any regulatory approval to market a product may be subject to limitations on the approved uses for which Treeline may market the product or on the labeling or other restrictions. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline is also subject to or may in the future become subject to numerous foreign regulatory requirements governing, among other things, the conduct of clinical trials, manufacturing and marketing authorization, pricing and third-party reimbursement. The foreign regulatory approval process varies among countries and may include all of the risks associated with the FDA approval process described above, as well as risks attributable to the satisfaction of local regulations in foreign jurisdictions. Moreover, the time required to obtain approval may differ from that required to obtain FDA approval. FDA approval does not ensure approval by regulatory authorities outside </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">74<br></div></div></div>
<!--End Page 85-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 86-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg43"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">the United States and vice versa. Any delay or failure to obtain United States or foreign regulatory approval for a product candidate could have a material and adverse effect on Treeline&#8217;s business, financial condition, results of operations and prospects. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">From time to time during the development and regulatory approval process for Treeline&#8217;s product candidates, Treeline engages in discussions with the FDA and other regulatory authorities regarding its development programs, including discussions about the regulatory requirements for approval. Sometimes different regulatory authorities provide different or conflicting advice. While Treeline will attempt to harmonize the advice it receives from multiple regulatory authorities, it is not always practical to do so. Also, Treeline may choose not to harmonize conflicting advice when harmonization would significantly delay clinical trial data or when it believes it is otherwise inappropriate. In addition, regulatory authorities may change their views on aspects of the clinical programs, including study designs, or the ability of the studies as designed to support approval of a product. If Treeline is unable to effectively and efficiently resolve and comply with the inquiries and requests of the FDA and other regulatory authorities, the approval of its product candidates may be delayed or denied, and their value may be reduced. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">The designation of any of Treeline&#8217;s product candidates for an expedited program by the FDA or any comparable foreign regulatory authority, even if granted, may not lead to a faster development or regulatory review or approval process, and does not increase the likelihood that Treeline&#8217;s product candidates will receive regulatory approval. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Where an expedited program is available in a particular country, Treeline may seek to utilize such program for some or all of Treeline&#8217;s product candidates. For example, various regulatory programs in the United States, such as Breakthrough Therapy Designation, Fast Track Designation or Priority Review Designation, are designed to expedite the development and review of therapies to treat certain diseases. Treeline may seek such designations, and comparable designations by foreign regulatory authorities, for one or more of its product candidates for the treatment of certain indications, as applicable. However, regulatory authorities have broad discretion as to whether or not to grant such designations. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Even if Treeline receives such a designation for any product candidates in the future, Treeline may not experience a faster development process, review or approval compared to drugs considered for approval under conventional regulatory procedures and such a designation does not assure ultimate approval by the applicable regulatory authority. Even if one or more of Treeline&#8217;s product candidates qualify for such a designation, the applicable regulatory authority may later decide that such product candidates no longer meet the conditions for qualification. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Obtaining and maintaining regulatory approval of Treeline&#8217;s product candidates in one jurisdiction does not mean that Treeline will be successful in obtaining regulatory approval of Treeline&#8217;s product candidates in other jurisdictions. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Obtaining and maintaining regulatory approval of Treeline&#8217;s product candidates in one jurisdiction does not guarantee that Treeline will be able to obtain or maintain regulatory approval in any other jurisdiction. For example, even if the FDA grants regulatory approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion of the product candidate in those countries. Moreover, the receipt of regulatory approval in another jurisdiction, such as the conditional approval of TLN-254 in China, does not expedite or result in approval in the United States or other jurisdictions. However, a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from those in the United States, including additional preclinical studies or clinical trials as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that Treeline intends to charge for Treeline&#8217;s products is also subject to approval. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for Treeline and could delay or prevent the introduction of Treeline&#8217;s products in certain countries. If Treeline or any partner Treeline works with fails to comply with the regulatory requirements in international markets or fails to receive applicable regulatory approvals, Treeline&#8217;s target market will be reduced and Treeline&#8217;s ability to realize the full market potential of Treeline&#8217;s product candidates will be harmed. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">75<br></div></div></div>
<!--End Page 86-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 87-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg44"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Even if Treeline receives regulatory approval for Treeline&#8217;s current product candidates and any future product candidates, Treeline will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense. Additionally, Treeline&#8217;s current product candidates and any future product candidates, if approved, could be subject to labeling and other restrictions and market withdrawal. Treeline may also be subject to penalties if Treeline fails to comply with regulatory requirements or experiences unanticipated problems with Treeline&#8217;s products. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Any regulatory approvals that Treeline obtains for Treeline&#8217;s current or any future product candidates may also be subject to limitations on the approved indicated uses for which a product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing and surveillance to monitor the safety and efficacy of the product candidate. In addition, if the FDA or other comparable foreign regulatory authorities approve any of Treeline&#8217;s product candidates, the manufacturing processes, labeling, packaging, distribution, post-approval monitoring and adverse event reporting, storage, import, export, advertising, promotion and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. The FDA has significant post-market authority, including the authority to require labeling changes based on new safety information and to require post-market studies or clinical trials to evaluate safety risks related to the use of a product or to require withdrawal of the product from the market. The FDA also has the authority to require a REMS after approval, which may impose further requirements or restrictions on the distribution or use of an approved drug. The manufacturing facilities Treeline uses to make future product candidates, if any, will also be subject to periodic review and inspection by the FDA or other comparable foreign regulatory authorities, including for continued compliance with cGMP requirements. The discovery of any new or previously unknown problems with Treeline&#8217;s CDMOs, manufacturing processes or facilities may result in restrictions on the product, manufacturer or facility, including withdrawal of the product from the market. If Treeline relies on CDMOs, Treeline will not have control over compliance with applicable rules and regulations by such manufacturers. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Moreover, any product promotion and advertising will also be subject to regulatory requirements and continuing regulatory review. The FDA imposes stringent restrictions on manufacturers&#8217; communications regarding use of their products. If Treeline promotes Treeline&#8217;s product candidates or any of Treeline&#8217;s future product candidates in a manner inconsistent with FDA-approved labeling or otherwise not in compliance with FDA&#160;regulations, Treeline may be subject to enforcement action. Moreover, while Treeline believes that Treeline&#8217;s current product candidates or any future product candidates may provide better safety or effectiveness as compared to approved products, if Treeline does not study Treeline&#8217;s current product candidates or any future product candidates in head-to-head trials with those products, Treeline will not be able to make comparative claims for Treeline&#8217;s products, if approved. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If Treeline or Treeline&#8217;s CDMOs or other service providers fail to comply with applicable continuing regulatory requirements in the United States or foreign jurisdictions in which Treeline seeks to market Treeline&#8217;s products, Treeline or they may be subject to, among other things: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Form&#160;483s, restrictions on the manufacturing of the product, product recalls or withdrawal of the product from the market; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">warning or untitled letters or holds on clinical trials; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">refusal of the FDA or comparable foreign regulatory authorities to accept new marketing applications or approve pending applications or supplements to approved applications, or suspension or revocation of product approvals; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">product seizure or detention, or refusal to permit the import or export of products; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">mandated modification of promotional materials and labeling and the issuance of corrective information; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a requirement to implement a REMS, which may result in additional requirements or restrictions on the distribution or use of a product; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing warnings or other safety information about the product; or </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">injunctions or the imposition of fines or civil or criminal penalties. </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">76<br></div></div></div>
<!--End Page 87-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 88-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg45"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Any government investigation of alleged violations of law could require Treeline to expend significant time and resources in response and could generate adverse publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect Treeline&#8217;s ability to commercialize and generate revenue from Treeline&#8217;s products, if approved. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of Treeline and Treeline&#8217;s operating results will be adversely affected. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Subsequent discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with Treeline&#8217;s CDMOs or manufacturing processes, or failure to comply with regulatory requirements, may result in these same consequences. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">The policies of the FDA or other regulatory authorities may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of any of Treeline&#8217;s product candidates or Treeline&#8217;s future product candidates. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If Treeline is slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if Treeline is not able to maintain regulatory compliance, Treeline may lose any regulatory approval that Treeline may have obtained and Treeline may not achieve or sustain profitability, which would adversely affect Treeline&#8217;s business. Treeline also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, three decisions from the U.S. Supreme Court in July&#160;2024 may lead to an increase in litigation against regulatory agencies that could create uncertainty and thus negatively impact Treeline&#8217;s business. The first decision overturned established precedent that required courts to defer to regulatory agencies&#8217; interpretations of ambiguous statutory language. The second decision overturned regulatory agencies&#8217; ability to impose civil penalties in administrative proceedings. The third decision extended the statute of limitations within which entities may challenge agency actions. These cases may result in increased litigation by industry against regulatory agencies and impact how such agencies choose to pursue enforcement and compliance actions. However, the specific, lasting effects of these decisions, which may vary within different judicial districts and circuits, are unknown. Treeline also cannot predict the extent to which regulations, policies, and decisions of the FDA or other regulatory authorities, such as the SEC, may become subject to increasing legal challenges, delays, and changes. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Disruptions at the FDA and other government agencies caused by, among other factors, funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel, slow the time necessary for new products to be reviewed and/or approved, or otherwise prevent those agencies from performing normal business functions on which the operation of Treeline&#8217;s business may rely, which would adversely affect Treeline&#8217;s business. In addition, there is substantial uncertainty regarding new initiatives and how these might impact the FDA and other government agencies, which could prevent, limit or delay development and regulatory approval of Treeline&#8217;s product candidates and adversely affect Treeline&#8217;s business. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, government shutdowns, statutory, regulatory, and policy changes, the FDA&#8217;s ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#8217;s ability to perform routine functions. In addition, government funding of other government agencies on which Treeline&#8217;s operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Disruptions at the FDA and other government agencies or comparable foreign regulatory authorities may also slow the time necessary for the review and/or approval of clinical trial or marketing applications, which would adversely affect Treeline&#8217;s business. For example, the U.S. government has reduced the number of federal employees, including at FDA, by establishing voluntary termination programs, by position eliminations or by involuntary terminations, and the FDA has experienced turnover at senior levels. Changes in FDA staffing could result in delays in the FDA&#8217;s responsiveness or in its ability to review submissions or applications, issue regulations or guidance, or implement or enforce regulatory requirements in a timely fashion or at all. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Similar consequences would also result in the event of a significant shutdown of the federal government. For example, over the last several years, and most recently in late 2025, the U.S. government has shut down several times, and certain regulatory agencies, such as the FDA, had to furlough critical employees and stop critical activities. If a prolonged government shutdown occurs, or if geopolitical or global health concerns prevent the FDA&#160;from conducting their regular inspections, reviews, or other regulatory activities, or if the volume of </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">77<br></div></div></div>
<!--End Page 88-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 89-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg46"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">applications to the FDA for new product candidates increases materially, it could significantly impact the ability of the FDA to timely review and process Treeline&#8217;s regulatory submissions, which could have a material adverse effect on Treeline&#8217;s business. Further, future government shutdowns or delays could impact Treeline&#8217;s ability to access the public markets and obtain necessary capital in order to properly capitalize and continue Treeline&#8217;s operations. If any legislation, executive orders, or lapses in agency funding impose constraints on the FDA&#8217;s ability to engage in oversight and implementation activities in the normal course, Treeline&#8217;s business may be negatively impacted. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">FDA-regulated industries, such as Treeline&#8217;s, face uncertainty with regard to the regulatory environment Treeline will face as Treeline proceeds with research and development, and possibly in the future, commercialization. Some of these efforts have manifested to date in the form of personnel measures that could impact the FDA&#8217;s ability to hire and retain key personnel, which could result in delays or limitations on Treeline&#8217;s ability to obtain guidance from the FDA&#160;on Treeline&#8217;s product candidates in development and obtain the requisite regulatory approvals in the future. Moreover, the U.S. government paused payments by, reduced the budget of, and terminated grants provided by the National Institutes of Health (&#8220;NIH&#8221;) related to its funding for medical research, which has decreased, and may continue to decrease, the ability of facilities that rely on NIH funding to enroll and conduct clinical trials or increase the costs to Treeline of conducting clinical trials. Some of these actions have been challenged in court and there remains general uncertainty regarding future activities. New executive orders, regulations, policies or guidance could be issued or promulgated that adversely affect Treeline or create a more challenging or costly environment to pursue the development of new therapeutic products. Alternatively, state governments may attempt to address or react to changes at the federal level with changes to their own regulatory frameworks in a manner that is adverse to Treeline&#8217;s operations. If Treeline becomes negatively impacted by future governmental orders, regulations, policies or guidance, there could be a material adverse effect on Treeline and Treeline&#8217;s business. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Treeline&#8217;s operations and relationships with healthcare providers, healthcare organizations, customers and third-party payors will be subject to applicable anti-bribery, anti-kickback, fraud and abuse, transparency and other healthcare laws and regulations, which could expose Treeline to, among other things, enforcement actions, criminal sanctions, civil penalties, contractual damages, reputational harm, administrative burdens and diminished profits and future earnings. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline&#8217;s current and future arrangements with healthcare providers, healthcare organizations, third-party payors and customers expose Treeline to broadly applicable anti-bribery, fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which Treeline researches, markets, sells and distributes any of Treeline&#8217;s product candidates, if approved. Restrictions under applicable federal and state anti-bribery and healthcare laws and regulations, include the following: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the federal Anti-Kickback Statute, which prohibits, among other things, individuals and entities from knowingly and willfully soliciting, receiving, offering, or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual, or the purchase, order or recommendation of, any good or service for which payment may be made under a federal and state healthcare program such as Medicare and Medicaid. The term remuneration has been broadly interpreted to include anything of value. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the federal criminal and civil false claims and civil monetary penalties laws, including the federal False Claims Act, which can be enforced through civil whistleblower or qui tam actions against individuals or entities, and the Federal Civil Monetary Penalties Law, which prohibit, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. In addition, certain marketing practices, including off-label promotion, may also violate false claims laws. Moreover, the government may assert that a claim including items and services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) and its implementing regulations, which imposes criminal and civil liability, prohibits, among other things, knowingly and willfully executing, or attempting to execute a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">78<br></div></div></div>
<!--End Page 89-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 90-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg47"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_bl" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: left;">false statement in connection with the delivery of or payment for healthcare benefits, items or services; similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (&#8220;HITECH&#8221;), and their respective implementing regulations, which impose obligations on certain healthcare providers, health plans, and healthcare clearinghouses, known as covered entities, as well as their business associates and covered subcontractors that perform certain services involving the storage, use or disclosure of individually identifiable health information for or on behalf of a covered entity and their business associates, including mandatory contractual terms, with respect to safeguarding the privacy, security, and transmission of individually identifiable health information, and require notification to affected individuals and regulatory authorities of certain breaches of security of individually identifiable health information; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the federal Physician Payments Sunshine Act, which requires certain manufacturers of covered drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program, with certain exceptions, to report annually to the Centers for Medicare&#160;&amp;&#160;Medicaid Services (&#8220;CMS&#8221;) information related to certain payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain other health care professionals (such as physician assistants and certain advanced practice nurses), and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members, with the information made publicly available on a searchable website; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Foreign Corrupt Practices Act (&#8220;FCPA&#8221;), which prohibits U.S. businesses and their representatives from directly or indirectly offering to pay, paying, promising to pay or authorizing the payment of money or anything of value to a foreign official in order to influence any act or decision of the foreign official in his or her official capacity or to secure any other improper advantage in order to obtain or retain business; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, that may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">certain state laws that require biopharmaceutical companies to comply with the biopharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug manufacturers to report information related to payments to physicians and other healthcare providers or marketing expenditures and drug pricing information, and state and local laws that require the registration of biopharmaceutical sales representatives; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">state and non-U.S. laws governing the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Efforts to ensure that Treeline&#8217;s current and future business arrangements with third parties comply with applicable healthcare laws and regulations could involve substantial costs. It is possible that governmental authorities will conclude that Treeline&#8217;s business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If Treeline&#8217;s operations are found to be in violation of any such requirements, Treeline may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, the curtailment or restructuring of Treeline&#8217;s operations, loss of eligibility to obtain approvals from the FDA, exclusion from participation in government contracting, healthcare reimbursement or other government programs, including Medicare and Medicaid, integrity oversight and reporting obligations, or reputational harm, any of which could adversely affect Treeline&#8217;s financial results. These risks cannot be entirely eliminated. Any action against Treeline for an alleged or suspected violation could cause Treeline to incur significant legal expenses and could divert Treeline&#8217;s management&#8217;s attention from the operation of Treeline&#8217;s business, even if Treeline&#8217;s defense is successful. In addition, achieving and sustaining compliance with applicable laws and regulations may be costly to Treeline in terms of money, time and resources. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">79<br></div></div></div>
<!--End Page 90-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 91-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg48"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Treeline may face difficulties from healthcare legislative and regulatory reform measures. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In the United States and some foreign jurisdictions, there have been, and Treeline expects there will continue to be, a number of legislative and regulatory changes to the healthcare system, including cost containment measures that may reduce or limit coverage and reimbursement for newly approved drugs and affect Treeline&#8217;s ability to profitably sell any product candidates for which Treeline obtains marketing approval. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of care. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For example, the Patient Protection and Affordable Care Act, as amended (the &#8220;ACA&#8221;), made significant changes to the healthcare system, including an increase to manufacturers&#8217; rebate liability under the Medicaid Drug Rebate Program, the imposition of a significant annual fee on companies that manufacture or import branded prescription drug products, and other health policy reforms that substantially changed the way healthcare is financed by both governmental and private insurers. In addition, legislative changes adopted since the ACA include aggregate reductions to Medicare payments to providers of 2% per fiscal year, which began in 2013 and, as a result of subsequent legislation, will remain in effect through 2032 unless additional Congressional action is taken. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Since that time, there has continued to be heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several presidential executive orders, Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, reduce the costs of drugs under Medicare, and reform government program reimbursement methodologies for drug products. Several of these initiatives culminated in the enactment of the Inflation Reduction Act (&#8220;IRA&#8221;) in August&#160;2022, which, among other things, requires the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) to directly negotiate the selling price of a statutorily specified number of drugs and biologics each year that CMS reimburses under Medicare Part&#160;B and Part&#160;D. The negotiated price may not exceed a statutory ceiling price. Only high-expenditure single-source drugs that have been approved for at least 7&#160;years (11 years for single-source biologics) are eligible to be selected by CMS for negotiation, with the negotiated price taking effect two years after the selection year. For 2026, the first year in which negotiated prices become effective, CMS&#160;selected&#160;10&#160;high-cost Medicare Part&#160;D products in 2023, negotiations began in 2024, and the negotiated maximum fair price for each product has been announced. In addition, CMS selected and announced the negotiated maximum fair price for 15 additional Medicare Part&#160;D drugs, which will become effective in 2027. For 2028, CMS has selected an additional 15 drugs, comprised of drugs covered under Medicare Part&#160;D and, for the first time, drugs payable under Medicare Part&#160;B. For 2029 and subsequent years, 20 Part&#160;B or Part&#160;D drugs will be selected. Due to a statutory amendment in July&#160;2025, a drug or biological product that has one or more orphan drug designations will be excluded from the IRA&#8217;s price negotiation requirements, but will lose that exclusion if it is approved for an indication that is not one of the designated rare diseases or conditions, unless such disqualifying approvals are withdrawn by the time CMS&#160;evaluates the drug for selection for negotiation. The law also imposes rebates on Medicare Part&#160;B and Part&#160;D drugs whose prices have increased at a rate greater than the rate of inflation, and in November&#160;2024, CMS finalized regulations for these inflation rebates. In addition, the law eliminated the &#8220;donut hole&#8221; under Medicare Part&#160;D&#160;beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and requiring manufacturers to subsidize, through a newly established manufacturer discount program, 10% of Part&#160;D enrollees&#8217; prescription costs for brand drugs below the out-of-pocket limit, and 20% once the out-of-pocket limit has been reached. The IRA permits the Secretary of HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. Manufacturers that fail to comply with the IRA may be subject to various penalties, including civil monetary penalties. The provisions related to the negotiation of selling prices of high-expenditure single-source drugs and biologics have been challenged in numerous lawsuits, but to date those challenges have been unsuccessful, and in May&#160;2026 the U.S. Supreme Court declined to review the first wave of manufacturer challenges, leaving in place lower court decisions that upheld the program. Additional challenges to later negotiation cycles remain pending and further challenges may be brought, but CMS is continuing to implement the program, which is expected to have a significant impact on the biopharmaceutical industry. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Further, in July&#160;2025, the One Big Beautiful Bill Act (the &#8220;OBBBA&#8221;) was enacted, which, among other things, narrowed access to ACA marketplace enrollment, and is anticipated to reduce Medicaid spending and enrollment through measures such as work requirements and other eligibility conditions for certain beneficiaries, caps on state-directed payments in Medicaid managed care, and limits on states&#8217; ability to use provider taxes to finance their Medicaid programs. The current federal administration is pursuing policies to reduce regulations and expenditures across government including at HHS, which include the FDA and CMS, and related agencies. These actions </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">80<br></div></div></div>
<!--End Page 91-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 92-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg49"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">included, for example, directives to reduce agency workforce, rescind a Biden administration executive order tasking the Center for Medicare and Medicaid Innovation to consider new payment and healthcare models to limit drug spending, and promote most-favored-nation (&#8220;MFN&#8221;) drug pricing, among other directives. For example, on May&#160;12, 2025, President Trump issued an Executive Order that, among other things, required HHS, within 30 days, to establish and communicate to drug manufacturers MFN price targets designed to bring drug prices for American patients in line with those in comparably developed nations. If significant progress towards MFN pricing is not achieved, the Executive Order requires HHS to propose a rulemaking to implement MFN pricing. On December&#160;19, 2025, CMS released two proposed rules that would incorporate MFN pricing principles into federal reimbursement for prescription drugs. The first proposal, the Global Benchmark for Efficient Drug Pricing Model (&#8220;GLOBE&#8221;) for Medicare Part&#160;B, would require manufacturers of specified single source drugs and sole source biologics to pay incremental rebates based on international benchmark prices, with participation triggered for products meeting CMS&#8217;s spending and eligibility criteria. The second proposal, the Guarding U.S. Medicare Against Rising Drug Costs (&#8220;GUARD&#8221;) model for Medicare Part&#160;D, would similarly mandate manufacturer rebates for qualifying sole source drugs where the Medicare net price exceeds an MFN benchmark derived from international reference pricing methodologies. As proposed, GLOBE would begin a five-year performance period on October&#160;1, 2026 and GUARD&#160;would begin its performance period in 2027. These proposals will likely be subject to legal challenges that could delay their implementation or modify their impact on manufacturer pricing and revenue. Additionally, in November&#160;2025, CMS introduced the GENErating cost Reductions for U.S. Medicaid (&#8220;GENEROUS&#8221;) Model, a voluntary MFN framework for manufacturers participating in the Medicaid Drug Rebate Program. Although it is voluntary, the GENEROUS model could also impact the drug pricing landscape for manufacturers. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If the proposed GLOBE and GUARD model rules or other MFN pricing rules are finalized, they are likely to mandate reduced prices of at least some drugs in the United States, if they are also sold in comparator countries. Even if Treeline does not market drugs in such countries, Treeline will be indirectly affected if Treeline&#8217;s drugs compete with drugs that were reduced by MFN pricing. Further, as part of the Make America Healthy Again Commission&#8217;s recent Strategy Report, the administration is working across government agencies to increase enforcement on direct-to-consumer pharmaceutical advertising. These actions and policies may significantly reduce U.S. drug prices, potentially impacting manufacturers&#8217; global pricing strategies and profitability, while increasing their operational costs and compliance risks. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access, restrictions or prohibitions on certain marketing practices, reporting of specified categories of remuneration provided to health care practitioners, marketing cost disclosure and transparency measures, including reporting and justification of launch prices or price increases above specified thresholds, and, in some cases, measures designed to encourage importation from other countries and bulk purchasing. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline expects that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for pharmaceuticals and other healthcare products and services, lead to more rigorous coverage criteria, or result in reduced demand for Treeline&#8217;s product candidates or any future product candidates or additional pricing pressures. The implementation of cost containment measures or other healthcare reforms may prevent Treeline from being able to generate revenue, attain profitability, or commercialize Treeline&#8217;s products, if approved. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Even if Treeline is able to commercialize Treeline&#8217;s current product candidates and any future product candidates, if approved, such product candidate may become subject to unfavorable pricing regulations or third-party coverage and reimbursement policies, which would harm Treeline&#8217;s business. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The availability of coverage and the adequacy of reimbursement by governmental healthcare programs, such as Medicare and Medicaid, private health insurers and other third-party payors are essential for most patients to be able to afford prescription medications such as Treeline&#8217;s product candidates, if approved. Sales of any of Treeline&#8217;s product candidates that receive regulatory approval will be dependent substantially, both in the United States and internationally, on the extent to which the costs of Treeline&#8217;s product candidates will be paid by health maintenance, managed care, pharmacy benefit, and similar healthcare management organizations or reimbursed by government health administration authorities, private health coverage insurers and other third-party payors. If reimbursement is not available, or is available only to limited levels, Treeline may not be able to successfully commercialize Treeline&#8217;s product candidates. Even if coverage is provided, the approved reimbursement amount may not be high </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">81<br></div></div></div>
<!--End Page 92-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 93-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg50"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">enough to allow Treeline to establish or maintain pricing sufficient to realize an adequate return on Treeline&#8217;s investment. Coverage and reimbursement may impact the demand for, or the price of, any product candidate for which Treeline obtains regulatory approval. If coverage and reimbursement are not available or reimbursement is available only to limited levels, Treeline may not successfully commercialize any product candidate for which Treeline obtains regulatory approval. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">There is significant uncertainty related to insurance coverage and reimbursement of newly approved products. In the United States, principal decisions about reimbursement for new products are typically made by CMS. CMS&#160;decides whether and to what extent a new product will be covered and reimbursed under Medicare, and private payors often follow CMS&#8217;s decisions regarding coverage and reimbursement to a substantial degree. However, one payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product. As a result, the coverage determination process is often time-consuming and costly. This process will require Treeline to provide scientific and clinical support for the use of Treeline&#8217;s products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Further, such payors are increasingly challenging the price, examining the medical necessity and reviewing the cost effectiveness of medical products. There may be especially significant delays in obtaining coverage and reimbursement for newly approved products. Third-party payors may limit coverage to specific products on an approved list, known as a formulary, which might not include all FDA-approved products for a particular indication. Treeline may need to conduct expensive pharmaco-economic studies to demonstrate the medical necessity and cost effectiveness of Treeline&#8217;s products. Nonetheless, Treeline&#8217;s product candidates may not be considered medically necessary or cost effective. Treeline cannot be sure that coverage and reimbursement will be available for any product that Treeline commercializes and, if reimbursement is available, what the level of reimbursement will be. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Moreover, increasing efforts by governmental and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for Treeline&#8217;s product candidates, if approved. Treeline expects to experience pricing pressures in connection with the sale of Treeline&#8217;s product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Treeline is subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws and anti-money laundering laws and regulations. Compliance with these legal standards could impair Treeline&#8217;s ability to compete in domestic and international markets. Treeline can face criminal liability and other serious consequences for violations, which can harm Treeline&#8217;s business. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions and other trade laws and regulations prohibit, among other things, companies and their employees, agents, CROs, CDMOs, legal counsel, accountants, consultants, contractors and other partners from authorizing, promising, offering, providing, soliciting, or receiving directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector. Violations of these laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences. Treeline has direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. Treeline also expects Treeline&#8217;s non-U.S. activities to increase over time. Treeline expects to rely on third parties for research, preclinical studies and clinical trials and/or to obtain necessary permits, licenses, patent registrations and other regulatory approvals. Treeline can be held liable for the corrupt or other illegal activities of Treeline&#8217;s personnel, agents, or partners, even if Treeline does not explicitly authorize or have prior knowledge of such activities. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline is also subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations and various economic and trade sanctions regulations administered by the U.S.&#160;Treasury Department&#8217;s Office of Foreign Assets Control. Compliance with applicable regulatory requirements regarding the export of Treeline&#8217;s products may create delays in the introduction of </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">82<br></div></div></div>
<!--End Page 93-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 94-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg51"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Treeline&#8217;s products in international markets or, in some cases, prevent the export of Treeline&#8217;s products to some countries altogether. Furthermore, U.S.&#160;export control laws and economic sanctions prohibit the provision of certain products and services to countries, governments and persons targeted by U.S. sanctions. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Governments outside the United States tend to impose strict price controls, which may adversely affect Treeline&#8217;s revenue, if any. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In some countries, particularly member states of the EU, the pricing of therapeutic products is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after receipt of regulatory approval for a product. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU member states and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices. Reduced prices in EU member states could also result in reduced prices in the U.S. if the U.S. finalizes the proposed GLOBE or GUARD models or other MFN pricing rules (see &#8220;Risks Related to Government Regulation &#8212; Treeline may face difficulties from healthcare legislative and regulatory reform measures.&#8221;). In addition, to obtain coverage and reimbursement or pricing approvals in some countries, Treeline may be required to conduct a clinical trial or other studies that compare the cost-effectiveness of Treeline&#8217;s current or any future product candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If reimbursement of any product candidate approved for marketing is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, Treeline&#8217;s business, financial condition, results of operations or prospects could be materially and adversely affected. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Risks Related to Treeline&#8217;s Intellectual Property </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">If Treeline is unable to obtain and maintain patent protection or other necessary rights for any of Treeline&#8217;s current or future product candidates and technology, or if the scope of the patent protection obtained is not sufficiently broad or Treeline&#8217;s rights under Treeline&#8217;s patents are not sufficiently broad, Treeline&#8217;s competitors could develop and commercialize products and technology similar or identical to Treeline&#8217;s, and Treeline&#8217;s ability to successfully commercialize Treeline&#8217;s products and technology may be adversely affected. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline&#8217;s success is dependent in part on Treeline&#8217;s ability to obtain and maintain proprietary or intellectual property protection in the United States and other countries for Treeline&#8217;s current product candidates or any future product candidates, as well as Treeline&#8217;s core technologies, including Treeline&#8217;s manufacturing know-how. Treeline strives to protect and enhance the proprietary technology, inventions and improvements that are commercially important to the development of Treeline&#8217;s business by seeking, maintaining and defending Treeline&#8217;s intellectual property, whether developed internally or licensed from third parties. Treeline also relies on trade secrets, know-how, continuing technological innovation and in-licensing opportunities to develop, strengthen and maintain Treeline&#8217;s proprietary position in the therapeutic fields being pursued by Treeline. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The patent position of biotechnology and biopharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has in recent years been the subject of much litigation. The degree of patent protection Treeline requires to successfully compete in the marketplace may be unavailable or severely limited in some cases and may not adequately protect Treeline&#8217;s rights or permit Treeline to gain or keep any competitive advantage. Treeline cannot provide any assurances that any of Treeline&#8217;s owned or licensed patent applications will mature into issued patents, and cannot provide any assurances that any such patents, if issued, will include claims with a scope sufficient to protect Treeline&#8217;s current and future product candidates or otherwise provide any competitive advantage. Additionally, patents can be enforced only in those jurisdictions in which the patent has issued. Furthermore, patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after its first nonprovisional U.S. filing. The natural expiration of a patent outside of the United&#160;States varies in accordance with provisions of applicable local law, but is generally 20 years from the earliest </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">83<br></div></div></div>
<!--End Page 94-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 95-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg52"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">local filing date. Various extensions may be available; however, the life of a patent, and the protection it affords, is limited. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline&#8217;s licensed patent portfolio may not provide Treeline with adequate and continuing patent protection sufficient to exclude others from commercializing products similar to Treeline&#8217;s product candidates, including biosimilar and interchangeable versions of such products. In addition, the patent portfolio licensed to Treeline is, or may be, licensed to third parties outside Treeline&#8217;s licensed field, and such third parties may have certain enforcement rights. Thus, patents licensed to Treeline could be put at risk of being invalidated or interpreted narrowly in litigation filed by or against another licensee or in administrative proceedings brought by or against another licensee in response to such litigation or for other reasons. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Other parties have developed technologies that may be related or competitive to Treeline&#8217;s own and such parties may have filed or may file patent applications, or may have received or may receive patents, claiming inventions that may overlap or conflict with those claimed in Treeline&#8217;s own patent applications or issued patents. Publication of discoveries in the scientific literature lags behind the actual discoveries, and patent applications in the United States and in other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, Treeline cannot know with certainty whether the inventors of Treeline&#8217;s patents and applications were the first to make the inventions claimed in those patents or pending patent applications, or that they were the first to file for patent protection of such inventions. Further, Treeline cannot assure that all of the potentially relevant prior art relating to Treeline&#8217;s patents and patent applications has been found. If such prior art exists, it can invalidate a patent or prevent a patent from issuing from a pending patent application. As a result, the issuance, scope, validity and commercial value of Treeline&#8217;s patent rights cannot be predicted with any certainty. Further, if the breadth or strength of protection provided by Treeline&#8217;s patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with Treeline to license, develop or commercialize current or future product candidates. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, the patent prosecution process is expensive and time-consuming, and Treeline or Treeline&#8217;s licensors may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. In addition, the scope of the claims initially submitted for examination may be significantly narrowed by the time they issue, if at all. It is also possible that Treeline or Treeline&#8217;s licensors will fail to identify patentable aspects of Treeline&#8217;s research and development output before it is too late to obtain patent protection. Treeline cannot provide any assurances that Treeline will be able to pursue or obtain additional patent protection based on Treeline&#8217;s research and development efforts, or that any such patents or other intellectual property Treeline generates will provide any competitive advantage. Moreover, Treeline may not have the right to control the preparation, filing and prosecution of patent applications, or to control the maintenance of the patents, covering technology that Treeline licenses from third parties. Therefore, these patents and applications may not be filed, prosecuted or maintained in a manner consistent with the best interests of Treeline&#8217;s business. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Even if Treeline acquires patent protection that Treeline expects should enable Treeline to maintain competitive advantage, the issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability. Third&#160;parties, including former employees, consultants, collaborators and competitors, may challenge the inventorship, scope, validity, or enforceability thereof, which may result in such patents being narrowed, invalidated or held unenforceable. If issued, Treeline&#8217;s patents may be challenged in patent offices in the United States and abroad, or in court. For example, Treeline may be subject to Post Grant Review or Inter Partes Review proceedings to the U.S. Patent Trial and Appeal Board challenging the validity of one or more claims of Treeline&#8217;s patents, once issued. Such submissions may also be made prior to a patent&#8217;s issuance, precluding the granting of a patent based on one of Treeline&#8217;s patent applications. Treeline may become involved in opposition, reexamination, inter partes review, post-grant review, derivation, or similar proceedings in the United States or abroad challenging the claims of Treeline&#8217;s patents, once issued. Furthermore, patents may be challenged in court, once issued. Competitors may have filed patent applications before the inventors of Treeline&#8217;s patents did. A competitor may also claim that Treeline is infringing its patents and that Treeline therefore cannot practice Treeline&#8217;s technology as claimed under Treeline&#8217;s patent applications and patents, if issued. As a result, one or more claims of Treeline&#8217;s patents may be narrowed or invalidated. In litigation, a competitor could claim that Treeline&#8217;s patents, if issued, are not valid for a number of reasons. If a court agrees, Treeline would lose Treeline&#8217;s rights to those challenged patents. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">84<br></div></div></div>
<!--End Page 95-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 96-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg53"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Even if they are unchallenged, Treeline&#8217;s patents and pending patent applications, if issued, may not provide Treeline with any meaningful protection or prevent competitors from designing around Treeline&#8217;s patent claims to circumvent Treeline&#8217;s patents by developing similar or alternative technologies or therapeutics in a non-infringing manner. For example, even if Treeline has a valid and enforceable patent, Treeline may not be able to exclude others from practicing Treeline&#8217;s invention if the other party can show that they used the invention in commerce before Treeline&#8217;s filing date or the other party benefits from an ex-U.S. compulsory license. If the patent protection provided by the patents and patent applications Treeline holds or pursues with respect to Treeline&#8217;s product candidates is not sufficiently broad to impede such competition, Treeline&#8217;s ability to successfully commercialize Treeline&#8217;s product candidates could be negatively affected, which would harm Treeline&#8217;s business. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Certain regulatory exclusivities may be available. However, the scope of such regulatory exclusivities is subject to change, and may not provide Treeline with adequate and continuing protection sufficient to exclude others from commercializing products similar to Treeline&#8217;s product candidates. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">If Treeline is unable to protect the confidentiality of Treeline&#8217;s trade secrets, Treeline&#8217;s business and competitive position could be harmed. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition to patent protection, Treeline relies on the protection of Treeline&#8217;s trade secrets, unpatented know-how, technology and other proprietary information to maintain Treeline&#8217;s competitive position. Although Treeline has taken steps to protect Treeline&#8217;s trade secrets and unpatented know-how, including entering into confidentiality agreements with third parties, and confidential information and inventions agreements with employees, consultants and advisors, Treeline cannot provide any assurances that any party thereto will not breach the agreement and disclose Treeline&#8217;s proprietary information, including Treeline&#8217;s trade secrets, and Treeline may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Moreover, third parties may still obtain this information or may come upon this or similar information independently, and Treeline would have no right to prevent them from using that technology or information to compete with Treeline. If any of these events occurs or if Treeline otherwise loses protection for Treeline&#8217;s trade secrets, the value of this information may be greatly reduced, and Treeline&#8217;s competitive position could be harmed. If Treeline does not apply for patent protection prior to such publication or if Treeline cannot otherwise maintain the confidentiality of Treeline&#8217;s proprietary technology and other confidential information, then Treeline&#8217;s ability to obtain patent protection or to protect Treeline&#8217;s trade secret information may be jeopardized. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">If Treeline breaches any of its license agreements, including its license agreement with Jiangsu Hengrui Pharmaceuticals Co., Ltd. or the CRT Pioneer Fund LP, or any other agreements with third parties, or if there are disputes over the intellectual property that Treeline licenses, it could have a material adverse effect on Treeline&#8217;s commercialization efforts for Treeline&#8217;s current or future product candidates. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline is party to license agreements with third parties, including the Hengrui License Agreement and its license agreement with the CRT Pioneer Fund LP (the &#8220;CRT License Agreement&#8221;) that enables Treeline to utilize third-party intellectual property for the development and commercialization of certain of Treeline&#8217;s product candidates, and Treeline may in the future enter into more such license agreements with third parties under which Treeline licenses the use, development and commercialization rights to current or future product candidates or technology from third parties. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">These intellectual property license agreements may require Treeline to comply with various obligations, including diligence obligations such as development and commercialization obligations, as well as potential royalty and milestone payments and other obligations. If Treeline fails to comply with its obligations under any of these license agreements, uses the licensed intellectual property in an unauthorized manner, becomes subject to bankruptcy-related proceedings or otherwise materially breaches any of these license agreements, the terms of the license granted may be materially modified, such as by rendering currently exclusive licenses non-exclusive, or it may give Treeline&#8217;s licensors the right to terminate the applicable license agreement, in whole or in part. Generally, the loss of or termination of Treeline&#8217;s rights under the license agreement, or any other licenses Treeline may acquire in the future, could harm Treeline&#8217;s business, financial condition, results of operations and prospects. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline may also, in the future, enter into license agreements with third parties under which Treeline is a sublicensee. If Treeline&#8217;s sublicensor fails to comply with its obligations under its upstream license agreement with </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">85<br></div></div></div>
<!--End Page 96-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 97-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg54"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">its licensor, the licensor may have the right to terminate the upstream license, which may result in termination of Treeline&#8217;s sublicense. If this were to occur, Treeline would no longer have rights to the applicable intellectual property unless Treeline is able to secure Treeline&#8217;s own direct license with the owner of the relevant rights, which Treeline may not be able to do on reasonable terms, or at all, which may impact Treeline&#8217;s ability to continue to develop and commercialize product candidates incorporating the relevant intellectual property. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Licensing of intellectual property is important to Treeline&#8217;s business and involves complex legal, business and scientific issues. Disputes may arise between Treeline and Treeline&#8217;s licensors regarding intellectual property subject to a license agreement, including: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the scope of rights granted under the license agreement and other interpretation-related issues; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">whether and the extent to which Treeline&#8217;s technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Treeline&#8217;s right to sublicense patent and other intellectual property rights to third parties under collaborative development relationships; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Treeline&#8217;s diligence obligations with respect to the use of the licensed technology in relation to Treeline&#8217;s development and commercialization product candidates, and what activities satisfy those diligence obligations; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Treeline&#8217;s right to transfer or assign the license; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by Treeline&#8217;s licensors and Treeline and Treeline&#8217;s partners; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">whether and the extent to which inventors are able to contest the assignment of their rights to Treeline&#8217;s licensors. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If disputes over intellectual property that Treeline has licensed or licenses in the future prevent or impair Treeline&#8217;s ability to maintain Treeline&#8217;s current licensing arrangements on acceptable terms or at all, Treeline may be unable to successfully develop and commercialize the affected product candidates, which could have a material adverse effect on Treeline&#8217;s business. In addition, if disputes arise as to ownership of licensed intellectual property, Treeline&#8217;s ability to pursue or enforce the licensed patent rights may be jeopardized. If Treeline or Treeline&#8217;s licensors fail to adequately protect this intellectual property, Treeline&#8217;s ability to commercialize Treeline&#8217;s products could suffer. Further, certain of Treeline&#8217;s future license agreements with third parties may limit or delay Treeline&#8217;s ability to consummate certain transactions, may impact the value of those transactions or may limit Treeline&#8217;s ability to pursue certain activities (e.g., Treeline may in the future enter into license agreements that are not assignable or transferable, or that require the licensor&#8217;s express consent in order for an assignment or transfer to take place). </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Treeline may not be able to protect Treeline&#8217;s intellectual property rights throughout the world. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline&#8217;s patent applications are being processed by national patent offices around the world. There is uncertainty about which patents will issue and, if they do, as to when, to whom, and with what scope of claims. In addition, third parties may attempt to invalidate Treeline&#8217;s intellectual property rights. Even if Treeline&#8217;s rights are not directly challenged, disputes could lead to the weakening of Treeline&#8217;s intellectual property rights. Treeline&#8217;s defense against any attempt by third parties to circumvent or invalidate Treeline&#8217;s intellectual property rights could be costly to Treeline, could require significant time and attention of Treeline&#8217;s management and could have a material and adverse effect on Treeline&#8217;s business, financial condition, results of operations and prospects or Treeline&#8217;s ability to successfully compete. If Treeline is found to infringe a third-party&#8217;s intellectual property rights, Treeline could be forced, including by court order, to cease developing, manufacturing or commercializing the infringing product candidate or product. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Although Treeline has pending patent applications in the United States and other countries, filing, prosecuting, maintaining, enforcing and defending patents in all countries throughout the world would be prohibitively expensive, and Treeline&#8217;s intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, Treeline may not be able to prevent third parties from practicing Treeline&#8217;s inventions in all countries outside the United States or from selling or importing products made using Treeline&#8217;s inventions in and into the United States or other jurisdictions. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">86<br></div></div></div>
<!--End Page 97-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 98-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg55"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Competitors may use Treeline&#8217;s technologies in jurisdictions where Treeline has not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where Treeline has patent protection, but enforcement is not as strong as that in the United States. These products may compete with Treeline&#8217;s product candidates, and Treeline&#8217;s patents, the patents of Treeline&#8217;s licensors, or other intellectual property rights may not be effective or sufficient to prevent them from competing. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of many foreign countries do not favor the enforcement of patents and other intellectual property protection, which could make it difficult for Treeline to stop the infringement of Treeline&#8217;s patents or Treeline&#8217;s licensors&#8217; patents or marketing of competing products in violation of Treeline&#8217;s proprietary rights. Proceedings to enforce Treeline&#8217;s patent rights in foreign jurisdictions could result in substantial costs and divert Treeline&#8217;s efforts and attention from other aspects of Treeline&#8217;s business, could put Treeline&#8217;s patents or the patents of Treeline&#8217;s licensors at risk of being invalidated or interpreted narrowly and Treeline&#8217;s patent applications or the patent applications of Treeline&#8217;s licensors at risk of not issuing and could provoke third parties to assert claims against Treeline. Treeline may not prevail in any lawsuits that Treeline initiates, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, Treeline&#8217;s efforts to enforce Treeline&#8217;s intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that Treeline develops or licenses. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If Treeline is forced to grant a license to third parties with respect to any patents relevant to Treeline&#8217;s business, Treeline&#8217;s competitive position may be impaired, and Treeline&#8217;s business, financial condition, results of operations and prospects may be adversely affected. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Treeline, Treeline&#8217;s licensors, or any future collaborators and strategic partners may need to resort to litigation to protect or enforce Treeline&#8217;s patents, if and when granted, or other proprietary rights, all of which could be costly, time consuming, delay or prevent the development and commercialization of product candidates and any future product candidates, or put Treeline&#8217;s patents, if and when granted, and other proprietary rights at risk. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Competitors may infringe Treeline&#8217;s patents, if and when granted, or other intellectual property. If Treeline were to initiate legal proceedings against a third party to enforce a patent covering one of Treeline&#8217;s products or Treeline&#8217;s technology, the defendant could counterclaim that Treeline&#8217;s patent is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, for example, lack of utility, lack of novelty, lack of adequate written description, obviousness, including obviousness-type double patenting, or non-enablement. Grounds for an unenforceability assertion could be an allegation that an individual connected with prosecution of the patent withheld relevant information from the United&#160;States Patent and Trademark Office (&#8220;USPTO&#8221;), or made a misleading statement, during prosecution. The outcome following legal assertions of invalidity or unenforceability during patent litigation is unpredictable. With respect to the validity question, for example, Treeline cannot be certain that there is no invalidating prior art, of which Treeline and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, Treeline would lose at least part, and perhaps all, of the patent protection on one or more of Treeline&#8217;s products or certain aspects of Treeline&#8217;s technology. Such a loss of patent protection could have a material and adverse effect on Treeline&#8217;s business, financial condition, results of operations and prospects. Derivation proceedings provoked by third parties or brought by Treeline may be necessary to determine the inventorship of inventions with respect to Treeline&#8217;s patents or patent applications. An unfavorable outcome could require Treeline to cease using the related technology or to attempt to license rights to it from the prevailing party. Treeline&#8217;s business could be harmed if the prevailing party does not offer Treeline a license on commercially reasonable terms or at all, or if a non-exclusive license is offered and Treeline&#8217;s competitors gain access to the same technology. In addition, the uncertainties associated with litigation could have a material adverse effect on Treeline&#8217;s ability to raise the funds necessary to continue Treeline&#8217;s clinical trials, continue Treeline&#8217;s research programs, license necessary technology from third parties, or enter into development partnerships that would help Treeline bring Treeline&#8217;s product candidates or any future product candidates to market. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of Treeline&#8217;s confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions, or other interim proceedings or developments. If </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">87<br></div></div></div>
<!--End Page 98-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 99-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg56"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of Treeline&#8217;s common stock. Patents and other intellectual property rights will not protect Treeline&#8217;s technology if competitors design around Treeline&#8217;s protected technology without legally infringing Treeline&#8217;s patents or other intellectual property rights. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Intellectual property rights of third parties could adversely affect Treeline&#8217;s ability to commercialize Treeline&#8217;s product candidates and any future product candidates, and Treeline, Treeline&#8217;s licensors or collaborators, or any future strategic partners may become subject to third-party claims or litigation alleging infringement of patents or other proprietary rights or seeking to invalidate patents or other proprietary rights. Treeline might be required to litigate or obtain licenses from third parties in order to develop or market Treeline&#8217;s product candidates and any future product candidates. Such litigation or licenses could be costly or not available on commercially reasonable terms. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline, Treeline&#8217;s licensors or collaborators, or any future strategic partners, may be subject to third-party claims for infringement or misappropriation of patent or other proprietary rights. There are a substantial number of forums available for challenging intellectual property rights, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and biopharmaceutical industries, including patent infringement lawsuits, interferences, derivations, post-grant reviews, oppositions and inter partes review proceedings before the USPTO, and corresponding foreign patent offices. There may be issued patents and pending patent applications that claim aspects of Treeline&#8217;s targets or Treeline&#8217;s product candidates or any future product candidates and modifications that Treeline may need to apply to Treeline&#8217;s product candidates or any future product candidates. There may be issued patents that claim methods which may be relevant to the products Treeline wishes to develop. Thus, it is possible that one or more entities will hold patent rights to which Treeline will need a license. If those entities refuse to grant Treeline a license to such patent rights on reasonable terms, Treeline may not be able to market products or perform research and development or other activities covered by these patents, which could have a material and adverse effect on Treeline&#8217;s business, financial condition, results of operations and prospects. If Treeline, Treeline&#8217;s licensors or collaborators, or any future strategic partners are found to infringe a third-party patent or other intellectual property rights, Treeline could be required to pay damages, potentially including treble damages and attorneys&#8217; fees if Treeline or they are found to have infringed willfully. In addition, Treeline, Treeline&#8217;s licensors or collaborators, or any future strategic partners may choose to seek, or be required to seek, a license from a third party, which may not be available on acceptable terms, if at all. Even if a license can be obtained on acceptable terms, the rights may be non-exclusive, which could give Treeline&#8217;s competitors access to the same technology or intellectual property rights licensed to Treeline. If Treeline fails to obtain a required license, Treeline or Treeline&#8217;s existing or future collaborators, or any future strategic partners, may be unable to effectively market product candidates based on Treeline&#8217;s technology, which could limit Treeline&#8217;s ability to generate revenue or achieve profitability and possibly prevent Treeline from generating revenue sufficient to sustain Treeline&#8217;s operations. In addition, Treeline may find it necessary to pursue claims or initiate lawsuits to protect or enforce Treeline&#8217;s patent or other intellectual property rights. The cost to Treeline in defending or initiating any litigation or other proceeding relating to patent or other proprietary rights, even if resolved in Treeline&#8217;s favor, could be substantial, and litigation could divert Treeline&#8217;s management&#8217;s attention. Some of Treeline&#8217;s competitors may be able to sustain the costs of complex patent litigation more effectively than Treeline can because they have substantially greater resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could delay Treeline&#8217;s research and development efforts and limit Treeline&#8217;s ability to continue Treeline&#8217;s operations. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline&#8217;s competitive position may suffer if patents issued to third parties or other third-party intellectual property rights cover Treeline&#8217;s products or product candidates or elements thereof, or Treeline&#8217;s manufacture or uses relevant to Treeline&#8217;s development plans. In such cases, Treeline may not be in a position to develop or commercialize products or product candidates until such patents expire or unless Treeline successfully pursues litigation to nullify or invalidate the third-party intellectual property right concerned, or enters into a license agreement with the intellectual property right holder, if available on commercially reasonable terms. There may be pending patent applications or issued patents held by third parties of which Treeline is aware but does not believe are valid or enforceable or does not believe Treeline infringes, or of which Treeline is not aware, which applications or patents, if found to be valid and enforceable, could be alleged to be infringed by Treeline&#8217;s product candidates or any future product candidates. If such an infringement claim should be brought and be successful, Treeline may be </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">88<br></div></div></div>
<!--End Page 99-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 100-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg57"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">required to pay substantial damages, including potentially treble damages and attorneys&#8217; fees for willful infringement, and Treeline may be forced to abandon Treeline&#8217;s product candidates or any future product candidates or seek a license from any patent holders. No assurances can be given that a license will be available on commercially reasonable terms, if at all. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">It is also possible that Treeline has failed to identify relevant third-party patents or applications. Patent applications covering Treeline&#8217;s products could have been filed by others without Treeline&#8217;s knowledge. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover Treeline&#8217;s products or the use of Treeline&#8217;s products. Third-party intellectual property right holders may also actively bring infringement claims against Treeline. Treeline cannot guarantee that Treeline will be able to successfully settle or otherwise resolve such infringement claims. If Treeline is unable to successfully settle future claims on terms acceptable to Treeline, Treeline may be required to engage in or continue costly, unpredictable and time-consuming litigation and may be prevented from or experience substantial delays in marketing Treeline&#8217;s products. Parties making claims against Treeline may be able to sustain the costs of complex patent litigation more effectively than Treeline can because they have substantially greater resources. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk that some of Treeline&#8217;s confidential information could be compromised by disclosure. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have material adverse effect on Treeline&#8217;s ability to raise additional funds or otherwise have a material adverse effect on Treeline&#8217;s business, financial condition, results of operations and prospects. If Treeline fails in any such dispute, in addition to being forced to pay damages, Treeline may be temporarily or permanently prohibited from commercializing any of Treeline&#8217;s product candidates or any future product candidates that are held to be infringing. Treeline might, if possible, also be forced to redesign product candidates so that Treeline no longer infringes the third-party intellectual property rights. Any of these events, even if Treeline were ultimately to prevail, could require Treeline to divert substantial financial and management resources that Treeline would otherwise be able to devote to Treeline&#8217;s business and could have a material and adverse effect on Treeline&#8217;s business, financial condition, results of operations and prospects. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Intellectual property litigation could cause Treeline to spend substantial resources and distract Treeline&#8217;s personnel from their normal responsibilities. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Litigation and other legal proceedings relating to intellectual property claims, with or without merit, are unpredictable and generally expensive and time consuming and are likely to divert significant resources from Treeline&#8217;s core business, including distracting Treeline&#8217;s technical and management personnel from their normal responsibilities. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of Treeline&#8217;s confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of Treeline&#8217;s Common Stock. Moreover, such litigation or proceedings could substantially increase Treeline&#8217;s operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of Treeline&#8217;s competitors may be able to sustain the costs of such litigation or proceedings more effectively than Treeline can because of their greater financial resources and more mature and developed intellectual property portfolios. Accordingly, despite Treeline&#8217;s efforts, Treeline may not be able to prevent third parties from infringing upon or misappropriating or from successfully challenging Treeline&#8217;s intellectual property rights. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on Treeline&#8217;s ability to compete in the marketplace. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Treeline may be subject to claims that Treeline or Treeline&#8217;s employees or consultants have wrongfully used or disclosed alleged intellectual property of Treeline&#8217;s employees&#8217; or consultants&#8217; former employers or their clients. These claims may be costly to defend and if Treeline does not successfully do so, Treeline may be required to pay monetary damages and may lose valuable intellectual property rights or personnel. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Many of Treeline&#8217;s employees, including Treeline&#8217;s management, were previously employed at biotechnology or biopharmaceutical companies, including Treeline&#8217;s competitors or potential competitors. Some of these employees executed proprietary rights, non-disclosure and non-competition agreements in connection with such </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">89<br></div></div></div>
<!--End Page 100-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 101-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg58"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">previous employment. From time to time, Treeline has been, and in the future may be, subject to claims that these employees or Treeline has inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend against these claims. If Treeline fails in defending such claims, in addition to paying monetary damages, Treeline may lose valuable intellectual property rights or personnel. A loss of key research personnel or their work product could hamper Treeline&#8217;s ability to develop and ultimately commercialize, or prevent Treeline from developing and commercializing, Treeline&#8217;s product candidates or any future product candidates, which could severely harm Treeline&#8217;s business, financial condition, results of operations and prospects. Even if Treeline is successful in defending against these claims, litigation could result in substantial costs and be a distraction to management. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Patent terms may be insufficient to protect Treeline&#8217;s competitive position on Treeline&#8217;s product candidates and any future product candidates for an adequate amount of time. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various patent term adjustments or extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering Treeline&#8217;s product candidates or any future product candidates are obtained, once the patent life has expired, Treeline may be open to competition from competitive products, including biosimilars or interchangeables. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, Treeline&#8217;s owned and licensed patent portfolio may not provide Treeline with sufficient rights to exclude others from commercializing products similar or identical to Treeline&#8217;s. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">If Treeline does not obtain patent term extension for any product candidates Treeline may develop, Treeline&#8217;s business may be harmed. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Depending upon the timing, duration and specifics of any FDA regulatory approval of any product candidates Treeline may develop and Treeline&#8217;s technology, Treeline&#8217;s U.S. patent or one or more U.S. patents that may issue in the future based on a patent application that Treeline licenses or owns may be eligible for limited patent term extension under the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent extension term of up to five&#160;years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent may be extended and only those claims covering the approved product, a method for using it or a method for manufacturing it may be extended. The application for the extension must be submitted prior to the expiration of the patent for which extension is sought and within 60 days of FDA approval. A patent that covers multiple products for which approval is sought can only be extended in connection with one of the approvals. However, Treeline may not be granted an extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than Treeline requests. In addition, to the extent Treeline wishes to pursue patent term extension based on a patent that Treeline in-licenses from a third party, Treeline would need the cooperation of that third party. If Treeline is unable to obtain patent term extension or the term of any such extension is less than Treeline requests, Treeline&#8217;s competitors may obtain approval of competing products following Treeline&#8217;s patent expiration, and Treeline&#8217;s revenue could be reduced. Any of the foregoing could have a material adverse effect on Treeline&#8217;s business, financial condition, results of operations and prospects. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Obtaining and maintaining Treeline&#8217;s patent protection is dependent on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and Treeline&#8217;s patent protection could be reduced or eliminated for non-compliance with these requirements. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to be paid to the USPTO and various governmental patent agencies outside of the United&#160;States in several stages over the lifetime of the patents and/or applications. Treeline has systems in place to remind Treeline to pay these fees, and Treeline employs an outside firm and/or relies on Treeline&#8217;s outside counsel to pay these fees due to the USPTO and non-U.S. governmental patent agencies. The USPTO and various non-U.S. governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. Treeline employs reputable law firms and other professionals to help Treeline comply, and in many cases an inadvertent lapse can be cured by payment of a late fee </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">90<br></div></div></div>
<!--End Page 101-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 102-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg59"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">or by other means in accordance with the applicable rules. However, there are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, Treeline&#8217;s competitors might be able to enter the market and this circumstance would have a material adverse effect on Treeline&#8217;s business. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Changes in U.S. patent and ex-U.S. patent laws could diminish the value of patents in general, thereby impairing Treeline&#8217;s ability to protect Treeline&#8217;s current or future product candidates. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Changes in either the patent laws or interpretation of the patent laws in the United States or in other jurisdictions could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. In the United States, numerous recent changes to the patent laws and proposed changes to the rules of the USPTO may have a significant impact on Treeline&#8217;s ability to protect Treeline&#8217;s technology and enforce Treeline&#8217;s intellectual property rights. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, the patent positions of companies in the development and commercialization of pharmaceuticals and biologics are particularly uncertain. U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the validity and enforceability of patents once obtained. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on Treeline&#8217;s patent rights and Treeline&#8217;s ability to protect, defend and enforce Treeline&#8217;s patent rights in the future. For example, in Amgen Inc. v. Sanofi, 598 U.S. 594 (2023), the Supreme Court held that claims with functional language may face high hurdles in fulfilling the enablement requirement. Recent Federal Circuit decisions raise questions regarding the award of patent term adjustment (&#8220;PTA&#8221;) for patents where related patents have been issued without a PTA. Thus, it cannot be said with certainty how PTA will or will not be viewed in the future and whether patent expiration dates may be impacted. Treeline cannot predict how this and future decisions by the courts, the U.S. Congress or the USPTO may impact the value of Treeline&#8217;s patents. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Similarly, changes in patent law and regulations in other countries or jurisdictions or changes in the governmental bodies that enforce them or changes in how the relevant governmental authority enforces patent laws or regulations may weaken Treeline&#8217;s ability to obtain new patents or to enforce patents that Treeline has licensed or that Treeline may obtain in the future. For example, the complexity and uncertainty of European patent laws have also increased in recent years. In certain member states of the European Union, a new unitary patent system took effect June&#160;1, 2023, which will significantly impact European patents, including those granted before the introduction of such a system. Under the unitary patent system, European applications have the option, upon grant of a patent, of becoming a Unitary Patent which will be subject to the jurisdiction of the Unitary Patent Court (&#8220;UPC&#8221;). As the UPC is a new court system, there is no precedent for the court, increasing the uncertainty of any litigation. Patents granted before the implementation of the UPC will have the option of opting out of the jurisdiction of the UPC and remaining as national patents in the UPC&#160;countries. Patents that remain under the jurisdiction of the UPC will be potentially vulnerable to a single UPC-based revocation challenge that, if successful, could invalidate the patent in all countries who are signatories to the UPC. Treeline cannot predict with certainty the long-term effects of any potential changes. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">If Treeline&#8217;s trademarks and trade names are not adequately protected, then Treeline may not be able to build name recognition in Treeline&#8217;s markets of interest and Treeline&#8217;s business may be adversely affected. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline&#8217;s current or future trademarks or trade names may be challenged, infringed, circumvented or declared generic or descriptive or determined to be infringing on other marks. Treeline may not be able to protect Treeline&#8217;s rights to these trademarks and trade names or may be forced to stop using these names, which Treeline needs for name recognition by potential partners or customers in Treeline&#8217;s markets of interest. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">During trademark registration proceedings, Treeline may receive rejections of Treeline&#8217;s applications by the USPTO or by the comparable agencies in other foreign jurisdictions. Although Treeline would be given an opportunity to respond to those rejections, Treeline may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against Treeline&#8217;s trademarks, and Treeline&#8217;s trademarks may not survive such proceedings. If Treeline is unable to establish name recognition based on Treeline&#8217;s trademarks and trade names, Treeline may not be able to </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">91<br></div></div></div>
<!--End Page 102-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 103-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg60"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">compete effectively and Treeline&#8217;s business may be adversely affected. Treeline may license Treeline&#8217;s trademarks and trade names to third parties, such as distributors. Although these license agreements may provide guidelines for how Treeline&#8217;s trademarks and trade names may be used, a breach of these agreements or misuse of Treeline&#8217;s trademarks and trade names by Treeline&#8217;s licensees may jeopardize Treeline&#8217;s rights in or diminish the goodwill associated with Treeline&#8217;s trademarks and trade names. Moreover, any name Treeline has proposed to use with Treeline&#8217;s therapeutic candidate in the United States must be approved by the FDA, regardless of whether Treeline has registered it, or applied to register it, as a trademark. Similar requirements exist in the European Union and in other countries. The FDA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. If the FDA (or an equivalent administrative body in a foreign jurisdiction) objects to any of Treeline&#8217;s proposed proprietary product names, it may be required to expend significant additional resources in an effort to identify a suitable substitute name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. Furthermore, in many countries, owning and maintaining a trademark registration may not provide an adequate defense against a subsequent infringement claim asserted by the owner of a senior trademark. At times, competitors or other third parties may adopt trade names or trademarks similar to Treeline&#8217;s, thereby impeding Treeline&#8217;s ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of Treeline&#8217;s registered or unregistered trademarks or trade names. If Treeline asserts trademark infringement claims, a court may determine that the marks Treeline has asserted are invalid or unenforceable, or that the party against whom Treeline has asserted trademark infringement has superior rights to the marks in question. In this case, Treeline could ultimately be forced to cease use of such trademarks. In addition, geo-political actions in the United States and in foreign countries could increase the uncertainties and costs surrounding the prosecution or maintenance of Treeline&#8217;s patent applications or those of any current or future licensors and the maintenance, enforcement or defense of Treeline&#8217;s issued patents or those of any current or future licensors. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Intellectual property rights do not necessarily address all potential threats to Treeline&#8217;s business. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The degree of future protection afforded by Treeline&#8217;s intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect Treeline&#8217;s business or permit Treeline to maintain Treeline&#8217;s competitive advantage. For example: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">others may be able to develop products that are similar to Treeline&#8217;s product candidates but that are not covered by the claims of the patents that Treeline owns or licenses; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Treeline or Treeline&#8217;s licensors or collaborators might not have been the first to make the inventions covered by the issued patents or patent application that Treeline owns or licenses; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Treeline or Treeline&#8217;s licensors or collaborators might not have been the first to file patent applications covering certain of Treeline&#8217;s inventions; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">others may independently develop similar or alternative technologies or duplicate any of Treeline&#8217;s technologies without infringing Treeline&#8217;s intellectual property rights; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">it is possible that the pending patent applications Treeline owns or licenses will not lead to issued patents; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">issued patents that Treeline owns or licenses may be held invalid or unenforceable, as a result of legal challenges by Treeline&#8217;s competitors; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Treeline&#8217;s competitors might conduct research and development activities in countries where Treeline does not have patent rights and then use the information learned from such activities to develop competitive products for sale in Treeline&#8217;s major commercial markets; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Treeline may not develop additional proprietary technologies that are patentable; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the patents of others may have an adverse effect on Treeline&#8217;s business; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Treeline may fail to adequately protect and police Treeline&#8217;s trademarks and trade secrets; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Treeline may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Should any of these events occur, it could significantly harm Treeline&#8217;s business, financial condition, results of operations and prospects. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">92<br></div></div></div>
<!--End Page 103-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 104-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg61"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Risks Related to Treeline&#8217;s Business and Operations </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">Treeline&#8217;s future performance is dependent on its ability to retain key employees and to attract, retain and motivate qualified personnel and manage its human capital. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline&#8217;s ability to compete in the highly competitive biopharmaceutical industry is largely dependent on its ability to attract, motivate and retain highly qualified clinical, quality control, scientific, medical and managerial personnel. Treeline is highly dependent on the development and management expertise of its executive officer team, including its co-founders Joshua Bilenker and Jeffrey Engelman. Treeline currently does not maintain &#8220;key person&#8221; life insurance on these individuals or any of its employees. This lack of insurance means that Treeline may not have adequate compensation for the loss of the services of these individuals. The loss of one or more members of Treeline&#8217;s management team or other key employees or advisors could delay its research and development programs and have a material and adverse effect on its business, financial condition, results of operations and prospects. Treeline is dependent on the continued service of its technical personnel, because of the highly technical nature of Treeline&#8217;s product candidates, and the specialized nature of the regulatory approval process. Because Treeline&#8217;s management team and key employees are not obligated to provide it with continued service, they could terminate their employment with Treeline at any time without penalty. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline conducts its operations at its corporate headquarters in Watertown, Massachusetts, and has labs in San&#160;Diego, California and Basel, Switzerland, and an office in Stamford, Connecticut, as well as remote employees across the United States. Competition for skilled personnel in Treeline&#8217;s market, and nationally, is intense and may limit Treeline&#8217;s ability to hire and retain highly qualified personnel on acceptable terms or at all. Treeline also faces competition for personnel from other companies, universities, public and private research institutions, government entities and other organizations. Treeline&#8217;s future performance will be dependent in large part on its continued ability to attract and retain highly qualified scientific, technical and management personnel, as well as personnel with expertise in clinical testing, manufacturing, governmental regulation and commercialization. If Treeline is unable to continue to attract and retain high-quality personnel, the rate and success at which it can discover and develop product candidates will be limited, which could have a material and adverse effect on its business, financial condition, results of operations and prospects. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Treeline expects to expand its development and regulatory capabilities, and as a result, Treeline may encounter difficulties in managing its growth, which could disrupt Treeline&#8217;s operations. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As of March&#160;31, 2026, Treeline had 163 full-time employees. Treeline expects to increase the number of its employees and the scope of its operations, particularly in the areas of clinical development, clinical operations, manufacturing, late-stage regulatory affairs, finance, accounting, management information systems, business operations, public company compliance, communications and other corporate development functions, and, if TLN-121, TLN-254, TLN-372 and TLN-499 or any of its other potential or future product candidates receive regulatory approval, sales, marketing and distribution capabilities. If Treeline acquires additional product candidates or enters into future collaborations, it may have to further expand its employee base beyond its current projections, which may include further preclinical research and development or later-stage regulatory operations. To manage Treeline&#8217;s anticipated future growth and operations as a public company, it must continue to implement and improve its managerial, operational and financial systems, expand its facilities and continue to recruit and train additional qualified personnel. Due to Treeline&#8217;s limited financial resources and the limited experience of its management team in managing a company with such anticipated growth and with developing sales, marketing and distribution infrastructure, it may not be able to effectively manage the expansion of its operations or recruit and train additional qualified personnel. As Treeline&#8217;s operations expand, it also expects that it will need to manage additional relationships with various strategic partners, suppliers and other third parties. The expansion of Treeline&#8217;s operations may lead to significant costs and may divert its management and business development resources. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If Treeline is not able to effectively manage growth and expand its operations, it may not be able to successfully implement the tasks necessary to further develop and commercialize, if approved, TLN-121, TLN-254, TLN-372 and TLN-499 or other potential or future product candidates and, accordingly, it may not achieve its research, development and commercialization goals. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Treeline faces substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than Treeline does. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The pharmaceutical and biotechnology industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary and novel products and product candidates. Treeline&#8217;s competitors </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">93<br></div></div></div>
<!--End Page 104-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 105-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg62"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">have developed, are developing or may develop products, product candidates and processes competitive with Treeline&#8217;s product candidates. Any product candidates that Treeline successfully develops and commercializes will compete with existing therapies and new therapies that may become available in the future. Treeline believes that a significant number of product candidates are currently under development, and may become commercially available in the future, for the treatment of conditions for which Treeline is currently attempting and may in the future attempt to develop product candidates. In addition, Treeline&#8217;s product candidates may need to compete with drugs physicians use off-label to treat the indications for which Treeline seeks approval. This may make it difficult for Treeline to replace existing therapies with Treeline&#8217;s product candidates. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In particular, there is intense competition in the pharmaceutical and biotechnology industries. Treeline has competitors both in the U.S. and internationally, including major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies, emerging and start-up companies, universities and other research institutions. Treeline also competes with these organizations to recruit and retain qualified scientific and management personnel, which could negatively affect Treeline&#8217;s level of expertise and Treeline&#8217;s ability to execute its business plan. Treeline will also face competition in establishing clinical trial sites and patient enrollment in clinical trials, as well as in acquiring technologies complementary to, or necessary for, Treeline&#8217;s programs. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Many of Treeline&#8217;s competitors, either alone or with their collaborators, have significantly greater financial resources, established presence in the market, and expertise in research and development, manufacturing, preclinical and clinical testing, obtaining regulatory approvals and reimbursement and marketing approved products than Treeline. Large pharmaceutical and biotechnology companies, in particular, have extensive experience in clinical testing, obtaining regulatory approvals, recruiting patients and manufacturing biotechnology product candidates. These companies also have significantly greater research and marketing capabilities than Treeline and may also have product candidates that have been approved or are in late stages of development, and collaborative arrangements in Treeline&#8217;s target markets with leading companies and research institutions. Established pharmaceutical and biotechnology companies may also invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make the product candidates that Treeline develops obsolete. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies, as well as in acquiring technologies complementary to, or necessary for, Treeline&#8217;s programs. As a result of all of these factors, Treeline&#8217;s competitors may succeed in obtaining approval from the FDA or other comparable foreign regulatory authorities or in discovering, developing and commercializing product candidates in Treeline&#8217;s field before Treeline does. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline&#8217;s potential commercial opportunity could be reduced or eliminated if competitors develop and commercialize products that are safer, more effective, have fewer or less severe adverse events, are more convenient, have a broader label, are marketed more effectively, are more widely reimbursed or are less expensive than any products that Treeline may develop. Physicians may be more willing to prescribe competitors&#8217; products for various reasons, and may rely on guidelines related to treatment of patients issued by medical societies, industry groups or other organizations, which may not include, and may never include, Treeline&#8217;s products. Treeline&#8217;s competitors also may obtain marketing approval from the FDA or other comparable foreign regulatory authorities for their products more rapidly than Treeline may obtain approval for its product candidates, which could result in competitors establishing a strong market position before Treeline is able to enter the market, or make Treeline&#8217;s development and marketing more complicated. Even if the product candidates Treeline develops achieve marketing approval, they may be priced at a significant premium over competitive products if any have been approved by then, resulting in reduced competitiveness. Technological advances or products developed by Treeline&#8217;s competitors may render Treeline&#8217;s technologies or product candidates obsolete, less competitive or not economical. If Treeline is unable to compete effectively, Treeline&#8217;s opportunity to generate revenue from the sale of products Treeline may develop, if approved, could be adversely affected. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Treeline depends on its information technology systems and data, and those of the third parties with whom it works, and any disruption to, or security incident affecting, those systems or data could result in material adverse consequences to Treeline&#8217;s business. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline is increasingly dependent on information technology systems, infrastructure and data to operate Treeline&#8217;s business. In the ordinary course of business, Treeline, and the third parties with whom Treeline works, collect, process, store, generate, transfer, and transmit (collectively, process) a significant amount of personal information and other sensitive information, including Treeline&#8217;s proprietary and confidential business data, trade </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">94<br></div></div></div>
<!--End Page 105-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 106-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg63"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">secrets, employee data, intellectual property, data Treeline collects about trial participants in connection with clinical trials, and other sensitive third-party data (collectively, sensitive data). It is important that Treeline does so in a manner designed to maintain the availability, confidentiality, and integrity of such data. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline and the third parties with whom Treeline works may experience security incidents caused by Treeline&#8217;s personnel, vendors, or other external actors, including cyber-attacks, malicious internet-based activity, online and offline fraud, and other activities that could threaten the confidentiality, integrity, and availability of Treeline&#8217;s sensitive data and information technology systems and those of the third parties with whom Treeline works. Such threats are prevalent, continue to rise, are increasingly difficult to detect, and come from a variety of sources, including criminals, &#8220;hacktivists,&#8221; insiders, and sophisticated nation state or state-supported actors. Treeline and the third parties with whom Treeline works are subject to evolving threats such as social engineering attacks (including deep fakes and phishing), malicious code (such as viruses and worms), malware (including advanced persistent threat intrusions), denial-of-service attacks, credential stuffing, credential harvesting, personnel misconduct or error, ransomware attacks, supply-chain attacks, software bugs, server malfunctions, software or hardware failures, loss of data, adware, telecommunications failures, earthquakes, fires, floods, attacks enhanced or facilitated by artificial intelligence, and other similar threats. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">It may be difficult or costly to detect, investigate, mitigate, contain, and remediate a security incident. Treeline&#8217;s efforts to do so may not be successful. Actions taken by Treeline or the third parties with whom Treeline works to detect, investigate, mitigate, contain, and remediate a security incident could result in outages, data losses, and disruptions of Treeline&#8217;s business. Threat actors may also gain access to the same or other networks and systems after a compromise of Treeline&#8217;s networks and systems or those of the third parties with whom Treeline works. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Remote work has increased risks to Treeline&#8217;s information technology systems and data, as Treeline&#8217;s employees utilize network connections, computers and devices outside Treeline&#8217;s premises or network, including working at home, while in transit and in public locations. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Future business transactions (such as acquisitions) could expose Treeline to additional cybersecurity risks and vulnerabilities as Treeline&#8217;s systems could be negatively affected by vulnerabilities present in acquired or integrated entities&#8217; systems and technologies. Furthermore, Treeline may discover security issues not found during due diligence of such acquired or integrated entities or it may be difficult to integrate companies into Treeline&#8217;s information technology environment and security program. In particular, in connection with the Merger, Treeline (and, following the closing, the combined company) expects to integrate, continue to operate, or wind down certain information technology systems and data of Standard BioTools and any undetected vulnerabilities or prior security incidents in those systems could expose the combined company to additional cybersecurity risks. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline also outsources certain elements of Treeline&#8217;s information technology systems and operations to various third parties. Treeline&#8217;s ability to monitor these third parties&#8217; information security practices is limited, and these third&#160;parties may not have adequate information security measures in place despite any applicable contractual representations and warranties to do so. If the third parties with whom Treeline works experience a security incident or other interruption, Treeline could experience adverse consequences. While Treeline may be entitled to damages if such third parties fail to satisfy their privacy or security related obligations to Treeline, any award may be insufficient to cover Treeline&#8217;s damages, or Treeline may be unable to recover any such award. In addition, supply chain attacks have increased in frequency and severity, and Treeline cannot guarantee that third parties&#8217; infrastructure in Treeline&#8217;s supply chain or that of the third parties with whom Treeline works have not been or will not be compromised. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline, and the third parties with whom Treeline works, take steps designed to detect, mitigate, and remediate vulnerabilities in Treeline&#8217;s information systems; however, Treeline may not detect and remediate all such vulnerabilities on a timely basis. Further, Treeline may experience delays in developing and deploying remedial measures and patches designed to address identified vulnerabilities. Vulnerabilities could be exploited and result in a security incident. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Despite the implementation of these security measures, any of the previously identified or similar threats could cause a security incident or other interruption that could result in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure of, or access to Treeline&#8217;s sensitive data, or Treeline&#8217;s information technology systems, or those of the third parties with whom Treeline works. A security incident or other interruption could disrupt the ability of Treeline, or the third parties with whom Treeline works, to provide Treeline&#8217;s services. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">95<br></div></div></div>
<!--End Page 106-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 107-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg64"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">To try to protect Treeline&#8217;s information technology systems and sensitive data, Treeline has expended and may expend significant resources to implement and maintain specific security measures, industry standards, and reasonable security measures. Applicable data privacy and security obligations may require Treeline, or Treeline may voluntarily choose, to notify relevant stakeholders, including affected individuals, customers, regulatory authorities, and investors, of security incidents, or to take other actions, such as providing credit monitoring and identity theft protection services. Such disclosures and related actions can be costly, and the disclosure or the failure to comply with such applicable requirements could lead to adverse consequences. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The risk of a security incident or other disruption has generally increased as the number, intensity, and the sophistication of attempted and successful attacks and intrusions from around the world have increased. Treeline may not be able to anticipate all types of security threats, nor implement effective preventive measures against all such security threats. If Treeline (or a third party with whom Treeline works) experiences or is perceived to have experienced a security incident involving sensitive data or information technology systems, Treeline may experience material adverse consequences, such as government enforcement actions (for example, investigations, fines, penalties, audits, or inspections); additional reporting requirements or oversight; restrictions on processing sensitive data; litigation (including possible class action claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; diversion of management attention; interruptions in Treeline&#8217;s operations (including availability of data); financial loss; and other similar harms. Security incidents and attendant material consequences may cause existing customers to stop enrolling patients in Treeline&#8217;s sponsored clinical trials or prescribing Treeline&#8217;s products, deter new customers from doing so, and negatively impact Treeline&#8217;s ability to grow and operate Treeline&#8217;s business. Furthermore, if the information technology systems of a third party with whom Treeline works become subject to a security incident or other disruption, Treeline may have insufficient recourse against such third parties and Treeline may have to expend significant resources to mitigate the impact of such an event, and to develop and implement protections to prevent future events of this nature from occurring. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Significant disruptions of Treeline&#8217;s information technology systems or those of the third parties with whom Treeline works, or security breaches could result in the loss, misappropriation or unauthorized access, use, or disclosure of, or the prevention of access to, confidential information (including trade secrets or other intellectual property or proprietary business information) and claims by Treeline&#8217;s counterparties that Treeline has failed to comply with legal or contractual obligations, which could result in financial, legal, business, and reputational harm to Treeline. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">There can be no assurance that the limitations of liability in Treeline&#8217;s contracts would be enforceable or adequate to protect Treeline from liabilities and damage, and Treeline may not have adequate insurance coverage to cover all types of costs, expenses and losses Treeline could incur with respect to security breaches or disruptions. The successful assertion of one or more large claims against Treeline that exceed any available insurance coverage, or results in changes to Treeline&#8217;s insurance policies (including premium increases or the imposition of large deductible or co-insurance requirements), could have an adverse effect on Treeline&#8217;s business. In addition, Treeline cannot be sure that Treeline&#8217;s existing insurance coverage will continue to be available on acceptable terms or that Treeline&#8217;s insurers will not deny coverage as to any future claim. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Treeline and the third parties with whom it works are, or may in the future become, subject to stringent and changing obligations related to data privacy and security. Treeline&#8217;s (or their) actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation (including class action claims) or mass arbitration demands; fines or penalties; disruptions to Treeline&#8217;s business operations; reputational harm; loss of revenue or profits; loss of customers or sales; and other adverse business consequences. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The global data protection landscape is rapidly evolving and Treeline&#8217;s data processing activities subject Treeline to numerous data privacy and security obligations, such as various state, federal and foreign laws, regulations, guidance, industry standards, external and internal privacy and security policies, contractual requirements and other obligations that govern the processing of sensitive data by Treeline and on Treeline&#8217;s behalf, and Treeline may be subject to new or additional obligations related to data privacy and security and face increased scrutiny from regulatory authorities as Treeline&#8217;s business grows. The legislative and regulatory landscape for data privacy and security continues to evolve worldwide, and there has been an increasing focus on these issues with the potential to adversely affect Treeline&#8217;s business. Various global legislative and regulatory bodies, or self-regulatory organizations, may expand current laws, rules or regulations, enact new ones or issue guidance regarding data privacy and security that could impact Treeline&#8217;s business. As implementation standards and enforcement practices </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">96<br></div></div></div>
<!--End Page 107-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 108-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg65"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">are likely to remain uncertain for the foreseeable future, Treeline cannot yet determine the impact that future privacy and security obligations may have on Treeline&#8217;s business. This evolution creates uncertainty in Treeline&#8217;s business and may affect Treeline&#8217;s ability to operate in certain jurisdictions or to process sensitive data, necessitate the acceptance of more onerous obligations in Treeline&#8217;s contracts, result in liability, or impose additional costs on Treeline. The cost of compliance with these obligations is high and is likely to increase in the future. Any failure or perceived failure by Treeline to comply with federal, state or foreign laws or regulations, Treeline&#8217;s internal policies and procedures or Treeline&#8217;s contracts governing Treeline&#8217;s processing of sensitive data could result in negative publicity, government investigations or actions, claims by third parties or damage to Treeline&#8217;s reputation, any of which could have a material adverse effect on Treeline&#8217;s business, financial condition, results of operations and prospects. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In the United States, federal, state, and local governments have enacted numerous data privacy and security laws, including consumer protection laws (e.g., Section&#160;5 of the Federal Trade Commission Act), comprehensive consumer privacy laws, sector-specific privacy laws, data breach notification laws, laws regarding marketing, and other similar laws governing the processing of sensitive data that Treeline is or may in the future be required to comply with. In addition, Treeline obtains health information from third parties (including research institutions from which Treeline obtains clinical trial data) that is subject to privacy and security requirements under HIPAA, which imposes among other things, certain requirements relating to the privacy, security, transmission, and breach of individually identifiable health information. If Treeline violates HIPAA, depending on the specific facts and circumstances, Treeline could be subject to significant fines, penalties or regulatory inquiries or actions. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Over a third of U.S. states have enacted comprehensive consumer privacy laws that impose certain obligations on covered businesses, including providing specific disclosures in privacy notices and affording residents with certain rights concerning their personal information. Similar laws are being considered in several other states, as well as at the federal and local levels, and Treeline expects more states to pass similar laws in the future. While these states exempt some data processed in the context of clinical trials, these developments may further complicate compliance efforts and increase legal risk and compliance costs for Treeline and the third parties with whom Treeline works. Certain states have also adopted specific privacy and security laws and regulations which govern the privacy, processing and protection of health-related personal information. Such laws and regulations will likely be subject to interpretation by various courts and other governmental authorities, creating potentially complex compliance issues for Treeline and Treeline&#8217;s future customers and strategic partners. In addition to government activity, privacy advocacy groups and technology and other industries continue to consider new or revised self-regulatory standards related to privacy and security that may place additional burdens on Treeline. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Outside the United States, an increasing number of laws, regulations, and industry standards govern data privacy and security. For example, in Canada, the Personal Information Protection and Electronic Documents Act and various related provincial laws apply to Treeline&#8217;s operations. In the European Union, the General Data Protection Regulation (the &#8220;GDPR&#8221;) imposes stringent requirements on the processing of personal data, including health data collected in connection with clinical trials, and restricts transfers of personal data outside the European Economic Area; non-compliance can result in fines of up to the greater of &#8364;20&#160;million or 4% of total worldwide annual turnover. In the United Kingdom, the UK GDPR and the Data Protection Act 2018 impose comparable obligations and potential penalties. In Australia, the Privacy Act 1988 (Cth) and the Australian Privacy Principles govern the handling of personal information, and in Singapore, the Personal Data Protection Act 2012 imposes obligations relating to the collection, use, and disclosure of personal data, in each case including in connection with the clinical trials Treeline conducts in those jurisdictions. These and other non-U.S. data protection regimes may impose obligations that differ from, or are more onerous than, those applicable in the United States, and may increase Treeline&#8217;s compliance costs and legal risk. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Additionally, the U.S. Department of Justice issued a final rule, effective April&#160;8, 2025 (with the Department of Justice&#8217;s limited enforcement period having ended on July&#160;8, 2025 and certain affirmative compliance obligations subject to a later compliance date of October&#160;6, 2025), entitled &#8220;Preventing Access to U.S. Sensitive Personal Data and Government-Related Data by Countries of Concern or Covered Persons,&#8221; which places additional restrictions on certain data transactions involving &#8220;countries of concern&#8221; (currently, China (including Hong Kong and Macau), Russia, Iran, North Korea, Cuba, and Venezuela) and &#8220;covered persons&#8221; (entities owned by, organized under the laws of, or operating in such countries, as well as certain individuals affiliated with those countries). The rule restricts or prohibits a range of business activities, such as vendor engagements, data brokerage transactions, employment of certain individuals, and certain investor agreements, if they involve the transfer or access to </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">97<br></div></div></div>
<!--End Page 108-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 109-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg66"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">&#8220;sensitive personal data&#8221; (such as precise geolocation data, biometric identifiers, personal health data, and personal financial data) above specific thresholds. Certain transactions may be permitted if specific security requirements are met or exemptions apply, but others may be outright prohibited. Violations of the rule could result in significant civil and criminal fines and penalties. Aside from certain narrow exemptions, the rule applies regardless of whether data is anonymized, key-coded, pseudonymized, de-identified or encrypted, which may present challenges for companies like Treeline and may impact Treeline&#8217;s ability to transfer data in connection with certain transactions or agreements. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition to data privacy and security laws, Treeline is also bound by other contractual obligations related to data privacy and security. For example, Treeline may be contractually required to indemnify and hold harmless third&#160;parties with whom Treeline works from the costs or consequences of non-compliance with applicable laws, rules and regulations or other legal obligations relating to privacy or security or any inadvertent or unauthorized processing of sensitive data that Treeline stores or handles as part of operating Treeline&#8217;s business. Any of these events could adversely affect Treeline&#8217;s reputation, business, or financial condition, including but not limited to: loss of customers; interruptions or stoppages in Treeline&#8217;s business operations (including clinical trials); inability to process personal information or to operate in certain jurisdictions; limited ability to develop or commercialize Treeline&#8217;s products; expenditure of time and resources to defend any claim or inquiry; adverse publicity; or substantial changes to Treeline&#8217;s business model or operations. Treeline also publishes privacy policies, marketing materials, and other statements concerning data privacy and security. Regulatory authorities in the United States and other jurisdictions are increasingly scrutinizing these statements, and if these policies, materials or statements are found to be deficient, deceptive, unfair, or misleading, Treeline would be subject to investigation or enforcement actions by regulatory authorities. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline cannot assure you that Treeline&#8217;s CROs, CDMOs or other third parties with whom Treeline works will not breach contractual obligations imposed by Treeline, or that they will not experience data security incidents or other interruptions, which could have a corresponding effect on Treeline&#8217;s business, including under privacy laws and regulations or which could in turn adversely affect Treeline&#8217;s business, financial condition, results of operations and prospects. Treeline&#8217;s contractual measures and Treeline&#8217;s own privacy and security-related safeguards may not be sufficient to completely protect Treeline from the risks associated with the third-party processing of such information. Any of the foregoing could adversely affect Treeline&#8217;s business, financial condition, results of operations and prospects. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Complying with these complex and often evolving privacy and security related obligations can be expensive, difficult, time consuming, and subject to inconsistent application and interpretation. Any actual or perceived failure to comply with any such obligations, whether by Treeline, or by Treeline&#8217;s CROs, CDMOs, partners or other third parties with whom Treeline works, could result in significant adverse consequences, including: investigation costs; material fines and penalties; compensatory, special, punitive, or statutory damages; litigation (including class action claims) and mass arbitration demands; government enforcement actions; requirements to provide notices, credit monitoring or other services to impacted individuals; adverse actions against Treeline&#8217;s licenses; bans or restrictions on processing personal information; required changes to Treeline&#8217;s services, technologies, systems, or practices (or those of Treeline&#8217;s partners); reputational damage; imprisonment of company officials; and injunctive relief. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, any actual, perceived or suspected failure to comply with applicable privacy and security obligations &#8212; regardless of whether it results in unauthorized or unlawful processing of sensitive data &#8212; may lead to enforcement actions, private litigation, significant fines and penalties, regulatory investigations, adverse publicity, loss of customer trust, and other consequences that could adversely affect Treeline&#8217;s business, financial condition, results of operations and prospects. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">If Treeline, or any contract manufacturers or suppliers it engages, fail to comply with environmental, health and safety laws and regulations, Treeline could become subject to fines or penalties or incur costs that could harm its business. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline and Treeline&#8217;s third-party contractors are subject to numerous federal, state, local and foreign environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Treeline&#8217;s operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Treeline&#8217;s operations also produce hazardous waste products. Treeline generally contracts with third parties for the disposal of these materials and wastes. Treeline cannot eliminate the risk of contamination or injury from these materials. In the event of </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">98<br></div></div></div>
<!--End Page 109-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 110-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg67"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">contamination or injury resulting from Treeline&#8217;s use of hazardous materials, Treeline could be held liable for any resulting damages, and any liability could exceed Treeline&#8217;s resources, including any available insurance. Treeline could also be held liable for unexpected safety events that could happen in its business offices. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, Treeline&#8217;s leasing and operation of real property may subject it to liability pursuant to certain of these laws or regulations. Under existing United States environmental laws and regulations, current or previous owners or operators of real property and entities that disposed or arranged for the disposal of hazardous substances may be held strictly, jointly and severally liable for the cost of investigating or remediating contamination caused by hazardous substance releases, even if they did not know of and were not responsible for the releases. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline could incur significant costs and liabilities which may adversely affect its financial condition and operating results for failure to comply with such laws and regulations, including, among other things, civil or criminal fines and penalties, property damage and personal injury claims, costs associated with upgrades to Treeline&#8217;s facilities or changes to its operating procedures, or injunctions limiting or altering its operations. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Although Treeline maintains liability insurance to cover it for costs and expenses that it may incur due to injuries to its employees, this insurance may not provide adequate coverage against potential liabilities. Treeline does not maintain insurance for environmental liability or toxic tort claims that may be asserted against it in connection with its storage or disposal of biological, hazardous or radioactive materials. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, Treeline may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations, which are becoming increasingly more stringent, may impair its research, development or production efforts. Treeline&#8217;s failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Treeline&#8217;s business entails a significant risk of product liability and its ability to obtain sufficient insurance coverage could have a material and adverse effect on its business, financial condition, results of operations and prospects. If product liability lawsuits are brought against Treeline, it may incur substantial liabilities and may be required to limit, delay or cease commercialization of its products. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">When Treeline conducts clinical trials of its current and any future product candidates, it may be exposed to significant product liability risks inherent in the development, testing, manufacturing and marketing of therapeutic treatments. Product liability claims could delay or prevent completion of Treeline&#8217;s development programs. If Treeline succeeds in marketing products, if approved, Treeline will continue to face the risk of product liability claims. Such claims could result in an FDA investigation of the safety and effectiveness of its products, its manufacturing processes and facilities or its marketing programs and potentially a recall of its products or more serious enforcement action by U.S. or foreign regulatory authorities, limitations on the approved indications for which they may be used or suspension or withdrawal of approvals. If Treeline cannot successfully defend itself against product liability claims, it may incur substantial liabilities or be required to limit, delay or cease the commercialization of its products. Regardless of the merits or eventual outcome, liability claims may also result in decreased demand for its products, termination of clinical trial sites or entire trial programs, withdrawal of clinical trial participants, injury to its reputation and significant negative media attention, significant costs to defend the related litigation, a diversion of management&#8217;s time and its resources from its business operations, substantial monetary awards to trial participants or patients, loss of revenue, and the inability to commercialize any products that Treeline may develop. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline currently maintains general liability insurance and product liability insurance that it believes is sufficient. It may, however, need to obtain higher levels of insurance coverage for later stages of clinical development or marketing any of its product candidates. Any insurance Treeline has or may obtain may not provide sufficient coverage against potential liabilities. Furthermore, clinical trial and product liability insurance is becoming increasingly expensive. As a result, Treeline may be unable to obtain sufficient insurance at a reasonable cost to protect it against losses caused by product liability claims that could have a material and adverse effect on its business, financial condition, results of operations and prospects. Treeline&#8217;s inability to obtain and retain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of its product candidates. Although Treeline will maintain such insurance, any claim that may be brought against it could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by its insurance or that is in excess of the limits of its insurance coverage. Treeline&#8217;s insurance </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">99<br></div></div></div>
<!--End Page 110-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 111-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg68"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">policies will also have various exclusions, and it may be subject to a product liability claim for which it has no coverage. Treeline may have to pay any amounts awarded by a court or negotiated in a settlement that exceed its coverage limitations or that are not covered by its insurance, and it may not have, or be able to obtain, sufficient capital to pay such amounts. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Treeline&#8217;s employees, independent contractors, principal investigators, CROs, CDMOs, consultants and vendors may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline is exposed to the risk of fraud or other misconduct by Treeline&#8217;s employees, independent contractors, principal investigators, consultants and commercial partners. Misconduct by these parties could include intentional failures to comply with the regulations of FDA and non-U.S. regulators, provide accurate information to the FDA&#160;and non-U.S. regulators, comply with healthcare fraud and abuse laws and regulations in the United States and abroad, report financial information or data accurately or disclose unauthorized activities to Treeline. If Treeline obtains FDA&#160;approval of any of its current or future product candidates and begins commercializing those products in the United States, Treeline&#8217;s potential exposure under these laws will increase significantly, and the costs associated with compliance with these laws will likely increase. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct could also involve the improper use of information obtained in the course of clinical studies, which could result in regulatory sanctions and cause serious harm to Treeline&#8217;s reputation. It is not always possible to identify and deter employee misconduct, and the precautions Treeline takes to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting Treeline from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against Treeline, and Treeline is not successful in defending or asserting Treeline&#8217;s rights, those actions could have a significant impact on Treeline&#8217;s business, including the imposition of significant fines or other sanctions. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Changes in tax laws or regulations that are applied adversely to Treeline may have a material adverse effect on Treeline&#8217;s business, cash flows, financial condition or results of operations. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">New income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could adversely affect Treeline&#8217;s business operations and financial performance. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For example, legislation enacted in 2017, informally titled the Tax Cuts and Jobs Act (&#8220;TCJA&#8221;), enacted many significant changes to the U.S. tax laws. For Treeline&#8217;s 2022 through 2024 tax years, the TCJA eliminated the option to immediately deduct research and development expenditures and required taxpayers to amortize domestic expenditures over five years and foreign expenditures over fifteen years. Beginning with Treeline&#8217;s 2025 tax year, the OBBBA&#160;restored immediate deductibility of domestic expenditures, while foreign expenditures will continue to be capitalized and amortized over fifteen years. Future changes in corporate tax rates, the realization of net deferred tax assets relating to Treeline&#8217;s operations, the taxation of foreign earnings, and the deductibility of expenses could have a material impact on the value of its deferred tax assets, could result in significant one-time charges, and could increase its future tax expense. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to it. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Further, Treeline is subject to U.S. federal, state, and local income taxes and other taxes in the United States and will be subject to income taxes, withholding taxes, transaction taxes, and other taxes in any foreign jurisdictions in which it currently does business or may do business in the future. Due to the expanding scale of Treeline&#8217;s international business activities, it may become subject to taxation in additional foreign jurisdictions. Moreover, changes to Treeline&#8217;s corporate structure, including increased headcount and expanded functions outside of the United States, as well as changes to the tax laws in the jurisdictions in which it does business, could impact its worldwide effective tax rate and adversely affect its operating results and financial condition. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Treeline&#8217;s ability to use Treeline&#8217;s net operating loss carryforwards and certain other tax attributes may be limited. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline has incurred substantial losses during Treeline&#8217;s history and does not expect to become profitable in the near future, and Treeline may never achieve profitability. Under current law, unused U.S. federal net operating </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">100<br></div></div></div>
<!--End Page 111-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 112-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg69"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">losses generated in tax years beginning after December&#160;31, 2017 will not expire and may be carried forward indefinitely, but the deductibility of such federal net operating losses for any year is limited to no more than 80% of current year taxable income (without regard to certain deductions). Treeline&#8217;s U.S. federal research tax credits have a carryforward of 20 years. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, both Treeline&#8217;s current and Treeline&#8217;s future unused losses and other tax attributes may be subject to limitation under Sections 382 and 383 of the U.S. Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), if Treeline undergoes, or has undergone, an &#8220;ownership change,&#8221; generally defined as a greater than 50 percentage point change (by value) in Treeline&#8217;s equity ownership by certain stockholders or groups of stockholders over a three-year period. It is possible that Treeline has undergone one or more &#8220;ownership changes&#8221; in the past. Treeline may also undergo an ownership change as a result of the Merger or other shifts in the ownership of Treeline&#8217;s capital stock in the future, which may further limit Treeline&#8217;s ability to use Treeline&#8217;s pre-change net operating loss carryforwards and other pre-change tax attributes (such as research tax credits) to offset Treeline&#8217;s post-change income or taxes. Similar provisions of state tax law may also apply to limit Treeline&#8217;s use of accumulated state tax attributes. In addition, at the state level, there may be periods during which the use of net operating losses is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. As a result, even if Treeline attains profitability, Treeline may be unable to use all or a material portion of Treeline&#8217;s net operating losses and other tax attributes, which could adversely affect Treeline&#8217;s future cash flows. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Treeline&#8217;s estimates of market opportunity, including the prevalence and incidence of disease in its target indications, and forecasts of market growth may prove to be inaccurate, and even if the markets in which it competes achieve the forecasted growth, its business may not grow at similar rates, or at all. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline&#8217;s estimates and forecasts relating to size and expected growth of its target market, including the prevalence and incidence of disease in its target indications, may prove to be inaccurate. These estimates and forecasts are based on and derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations and market research, which may not accurately identify the size of the market for Treeline&#8217;s product candidates. The total addressable market opportunity for TLN-121, TLN-254, TLN-372 and TLN-499 and Treeline&#8217;s other potential or future product candidates will ultimately depend upon, among other things, the final labeling for Treeline&#8217;s product candidates, if Treeline&#8217;s product candidates are approved for sale in Treeline&#8217;s target indications, acceptance by the medical community and patient access, drug pricing and reimbursement. The number of patients nationally or globally may turn out to be lower than expected, patients may not be otherwise amenable to treatment with Treeline&#8217;s product candidates, or new patients may become increasingly difficult to identify or gain access to, all of which would adversely affect Treeline&#8217;s results of operations and Treeline&#8217;s business. Even if the markets in which Treeline competes meet its size estimates and growth forecasts, Treeline&#8217;s business may not grow at similar rates, or at all. Treeline&#8217;s growth is subject to many factors, including its success in implementing its business strategy, which is subject to many risks and uncertainties. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline&#8217;s revenue will be dependent, in part, upon the size of the markets in the territories for which it gains regulatory approval, the accepted price for the product, the ability to obtain coverage and reimbursement and whether it owns the commercial rights for that territory. If the number of Treeline&#8217;s addressable patients is not as significant as it estimates, the indication approved by regulatory authorities is narrower than it expects or the treatment population is narrowed by competition, physician choice or treatment guidelines, Treeline may not generate significant revenue from sales of such products, even if approved. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Unfavorable global economic conditions could adversely affect Treeline&#8217;s business, financial condition and results of operations. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline&#8217;s results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. A severe or prolonged economic downturn could result in a variety of risks to Treeline&#8217;s business, including weakened demand for Treeline&#8217;s product candidates and Treeline&#8217;s ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain Treeline&#8217;s suppliers, possibly resulting in supply disruption, or cause Treeline&#8217;s customers to delay making payments for Treeline&#8217;s services. If the current equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly, and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on Treeline&#8217;s growth strategy and financial performance and could require Treeline to delay or abandon clinical development plans. In addition, there is a risk that one or more of Treeline&#8217;s current service providers, manufacturers and other partners may not survive such </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">101<br></div></div></div>
<!--End Page 112-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 113-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg70"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">difficult economic times, which could directly affect Treeline&#8217;s ability to attain Treeline&#8217;s operating goals on schedule and on budget. Any of the foregoing could harm Treeline&#8217;s business and Treeline cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact Treeline&#8217;s business. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In particular, inflation, rising or volatile interest rates, instability in the global banking system or the failure of financial institutions, armed conflicts and geopolitical instability, including in Europe and the Middle East, and the actual and threatened imposition of tariffs, the possibility of a recession or further economic downturn, trade restrictions, sanctions or other trade barriers could increase Treeline&#8217;s operating costs, disrupt its supply chain and the operations of the third parties on which it depends, limit its access to capital, and otherwise adversely affect Treeline&#8217;s business, financial condition and results of operations. Supply chain disruptions and delays as a result of any new tariff policies or trade restrictions could also negatively impact Treeline&#8217;s cost of materials and production processes. For example, on February&#160;24, 2026, the U.S. imposed a temporary import surcharge of 10% ad valorem on most articles imported into the U.S. Additionally, following a Section&#160;232 national security investigation into pharmaceutical imports that concluded that imported pharmaceuticals and active pharmaceutical ingredients threaten U.S. national security, the President issued a proclamation imposing new tariffs on certain patented pharmaceuticals and associated pharmaceutical ingredients on April&#160;2, 2026. While there are some exclusions, the proclamation established a default tariff rate of 100% on covered patented pharmaceuticals and ingredients, with reduced rates for companies that have entered into approved onshoring plans and/or qualifying most-favored-nation pricing agreements, and the tariffs are scheduled to take effect for certain named companies on July&#160;31, 2026 and for all other companies on September&#160;29, 2026. These rules are subject to future changes, which may impact Treeline&#8217;s supply chain and create uncertainty in the broader pharmaceutical industry. </div><div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Treeline, or the third parties upon whom Treeline depends, may be adversely affected by natural disasters and other calamities, including pandemics, and Treeline&#8217;s business continuity and disaster recovery plans may not adequately protect Treeline from a serious disaster. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Natural disasters could severely disrupt Treeline&#8217;s operations and have a material adverse effect on Treeline&#8217;s business, results of operations, financial condition and prospects. If a natural disaster, fire, hurricane, power outage or other event occurred that prevented Treeline from using all or a significant portion of Treeline&#8217;s headquarters, that damaged critical infrastructure, such as Treeline&#8217;s suppliers&#8217; manufacturing facilities, or that otherwise disrupted operations, such as data storage, it may be difficult or, in certain cases, impossible for Treeline to continue Treeline&#8217;s business for a substantial period of time. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Occurrences of epidemics or pandemics, depending on their scale, may cause different degrees of damage to the national and local economies within Treeline&#8217;s geographic focus. Global economic conditions may be disrupted by widespread outbreaks of infectious or contagious diseases, and such disruption may adversely affect clinical development plans. Pandemics or similar events could have an adverse effect on the coordination of research and development, Treeline&#8217;s capital raising efforts, and the financial condition of Treeline&#8217;s business, as well as the ability of Treeline to retain key personnel and continue to expand product candidate development and conduct clinical trials. Extraordinary actions taken by international, federal, state and local public health and governmental authorities to contain and combat the outbreak and spread of infectious diseases, including travel bans, quarantines and similar mandates for many individuals and businesses to substantially restrict daily activities could have an adverse effect on Treeline&#8217;s financial condition and ability to raise financing. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The disaster recovery and business continuity plans Treeline has in place may prove inadequate in the event of a serious disaster or similar event. Treeline may incur substantial expenses as a result of the limited nature of Treeline&#8217;s disaster recovery and business continuity plans, which could have a material adverse effect on Treeline&#8217;s business. The extent and duration of the economic slowdown attributable to any public health crisis or other adverse event remains uncertain. A continued significant economic slowdown could have a substantial adverse effect on Treeline&#8217;s financial condition, liquidity, and results of operations. If these conditions persist for an extended term, it could have a material adverse effect on Treeline&#8217;s future revenue and sales. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">102<br></div></div></div>
<!--End Page 113-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 114-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_110-risk_pg71"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Risks Related to Standard BioTools&#8217; Business </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">You should also read and consider the risk factors specific to Standard BioTools&#8217; business. These risks are described in Part&#160;I, Item&#160;1A of Standard BioTools&#8217; Annual Report on Form&#160;10-K for the year ended December&#160;31, 2025, and any amendments thereto, as such risks have been or may be updated or supplemented in Standard BioTools&#8217; subsequently filed Quarterly Reports on Form&#160;10-Q or Current Reports on Form&#160;8-K, and in other documents that are incorporated by reference into this proxy statement/prospectus. See &#8220;<font style="font-style: italic;">Incorporation of Certain Documents by Reference</font>&#8221; and &#8220;<font style="font-style: italic;">Where You Can Find More Information</font>&#8221; beginning on pages <a href="#tIBR">334</a> and <a href="#tWYC">335</a>, respectively, of this proxy statement/prospectus. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">103<br></div></div></div>
<!--End Page 114-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 115-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_111-fls_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tFLS"><!--Anchor--></a>CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This proxy statement/prospectus contains forward-looking statements. All statements contained herein, other than statements of historical fact, including statements regarding Standard BioTools&#8217; future results of operations and financial position, Standard BioTools&#8217; business strategy and plans, and Standard BioTools&#8217; objectives for future operations, and forecasts of Treeline&#8217;s, Standard BioTools&#8217; and the combined company&#8217;s future performance, are forward-looking statements. The words &#8220;anticipate,&#8221; &#8220;expect,&#8221; &#8220;project,&#8221; &#8220;intend,&#8221; &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;plan,&#8221; &#8220;could,&#8221; &#8220;target,&#8221; &#8220;contemplate,&#8221; &#8220;estimate,&#8221; &#8220;position,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;opportunity&#8221; and similar expressions and the negatives of those terms are intended to identify forward-looking statements. Forward-looking statements include statements regarding the expected timing of the closing of the Transactions; the potential benefits of the proposed Transactions; the prospective performance and outlook of the combined company&#8217;s business, performance and opportunities; the ability of the parties to complete the proposed Transactions; the competitive position of the combined company; the expected post-closing ownership of the combined company; the expected management team and board of directors of the combined company; the combined company&#8217;s expected cash at Closing and cash runway after the Closing; Treeline&#8217;s product candidates and the potential benefits thereof and potential new indications; Treeline&#8217;s expectations with regard to the timing and availability of data from its current and planned clinical trials and preclinical studies; the timing of IND filings and planned clinical entries for Treeline&#8217;s preclinical programs; the expected development activities and related timing of such activities of the combined company&#8217;s product candidates; the timing of the announcement of trial results of the combined company&#8217;s product candidates; the potential market size and size of the potential patient populations for Treeline&#8217;s product candidates and any future product candidates; as well as any assumptions underlying any of the foregoing. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks include, but are not limited to, risks and uncertainties related to: (i) the ability to obtain the requisite approval from stockholders of Standard BioTools; (ii)&#160;the risk that the proposed Transactions may not be completed in a timely manner or at all; (iii)&#160;the&#160;possibility that competing offers or acquisition proposals will be made; (iv) the possibility that any or all of the various conditions to the consummation of the proposed Transactions may not be satisfied or waived, including the failure to receive any required regulatory approvals from any applicable governmental entities; (v)&#160;the&#160;occurrence of any event, change or other circumstance that could give rise to the termination of the Merger Agreement, including in circumstances that would require Standard BioTools to pay a termination fee or other expenses; (vi) the effect of the pendency of the proposed Transactions on the parties&#8217; ability to retain and hire key personnel, their ability to maintain relationships with customers, suppliers and others with whom they do business, their business generally or their stock price; (vii) risks related to diverting management&#8217;s attention from ongoing business operations or the loss of one or more members of the management team; (viii) the risk that stockholder litigation in connection with the proposed Transactions may result in significant costs of defense, indemnification and liability; (ix) the parties&#8217; ability to realize the anticipated benefits of the proposed Transactions; (x) the risk that the parties may assume unexpected liabilities and expenses as a result of the proposed Transactions; (xi) the risk that the potential dispositions of Standard BioTools&#8217; mass cytometry and microfluidics businesses may not be completed on favorable terms or at all; (xii) the risk that Standard BioTools could fail to maintain the listing of its common stock on Nasdaq; (xiii)&#160;uncertainties as to the potential for development, commercialization and other benefits of any of Treeline&#8217;s product candidates; and (xiv) uncertainties as to Treeline&#8217;s anticipated preclinical and clinical drug development activities and related timelines, including the expected timing for commencing clinical trials and announcing data and other clinical results. For information regarding other related risks, see the &#8220;<font style="font-style: italic;">Risk Factors</font>&#8221; section contained in this proxy statement/prospectus, as well as the &#8220;<font style="font-style: italic;">Risk Factors</font>&#8221; section contained in Standard BioTools&#8217; Annual Report on Form&#160;10-K for the year ended December&#160;31, 2025, filed with the SEC on March&#160;16, 2026, and in Standard BioTools&#8217; most recent Quarterly Report on Form&#160;10-Q and in Standard BioTools&#8217; other filings with the SEC. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Should one or more of these risks or uncertainties materialize, or should any of Standard BioTools or Treeline&#8217;s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. There may also be additional risks that Standard BioTools considers immaterial or which are unknown. It is not possible to predict or identify all such risks. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, Standard BioTools assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">104<br></div></div></div>
<!--End Page 115-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 116-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_112-special_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tSPE"><!--Anchor--></a>THE SPECIAL MEETING </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Date, Time, and Place of the Special Meeting </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Special Meeting will be held on &#8195;&#8195;&#8195;, 2026, commencing at &#8195;&#8195;&#8195;, Eastern Time, unless postponed or adjourned to a later date. The Special Meeting will be held entirely online and can be accessed at www.virtualshareholdermeeting.com/LAB2026SM. Standard BioTools is sending this proxy statement/prospectus to its stockholders in connection with the solicitation of proxies by the Standard BioTools Board for use at the Special Meeting and any adjournments or postponements of the Special Meeting. On or about &#8195;&#8195;&#8195;, 2026, Standard BioTools commenced mailing this proxy statement/prospectus and the enclosed form of proxy card to its stockholders entitled to vote at the Special Meeting. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;"><a name="tPOTS"><!--Anchor--></a>Purpose of the Special Meeting </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">At the Standard BioTools Special Meeting, Standard BioTools stockholders will be asked to consider and vote upon the following proposals: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Proposal #1: Share Issuance Proposal. To approve the issuance of Standard BioTools Common Stock in connection with the Merger and in accordance with Nasdaq Listing Rules 5635(a) and 5635(b) (the &#8220;Share Issuance&#8221; and such proposal, the &#8220;Share Issuance Proposal&#8221;); </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Proposal #2: Charter Amendment Proposal. To approve an amendment to the Standard BioTools Charter to effect a reverse stock split of Standard BioTools&#8217; issued and outstanding common stock at a ratio in the range from 1-for-&#8195;&#8195; to 1-for-&#8195;&#8195;, inclusive, with the final ratio to be mutually agreed to by Standard BioTools and Treeline and an amendment to the Standard BioTools Charter to change the name of Standard BioTools to &#8220;Treeline Biosciences Holdings, Inc.&#8221; (the &#8220;Charter Amendment Proposal&#8221;); </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Proposal #3: Post-Closing Equity Incentive Plan Proposal. To approve the Post-Closing Equity Incentive Plan in the form attached as Annex&#160;I to this proxy statement/prospectus, which will become effective at the effective time of the Merger and is contingent on the closing of the Merger (the &#8220;Closing&#8221;) (the &#8220;Post-Closing Equity Incentive Plan&#8221; and such proposal, the &#8220;Post-Closing Equity Incentive Plan Proposal&#8221;); </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Proposal #4: Post-Closing ESPP Proposal. To approve the Post-Closing Employee Stock Purchase Plan in the form attached as Annex&#160;J to this proxy statement/prospectus, which will become effective at the effective time of the Merger and is contingent on the Closing (the &#8220;Post-Closing ESPP&#8221; and such proposal, the &#8220;Post-Closing ESPP Proposal&#8221;); </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Proposal #5: Advisory Compensation Proposal. To approve, on a nonbinding, advisory basis, the compensation and benefits that will or may become payable by Standard BioTools to its named executive officers in connection with the Merger (the &#8220;Merger-Related Compensation&#8221;, and such proposal, the &#8220;Advisory Compensation Proposal&#8221;); and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Proposal #6: Adjournment Proposal. To approve adjournments of the Special Meeting from time to time, if necessary or appropriate, to solicit additional proxies in favor of the Share Issuance Proposal and the Charter Amendment Proposal, if there are insufficient votes at the time of such adjournment to approve such proposals or to ensure that any supplement or amendment to this proxy statement/prospectus is timely provided to Standard BioTools stockholders (the &#8220;Adjournment Proposal&#8221; and, together with the Share Issuance Proposal, the Charter Amendment Proposal, the Post-Closing Equity Incentive Plan Proposal, the Post-Closing ESPP Proposal and the Advisory Compensation Proposal, the &#8220;Proposals&#8221;). </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Each of the Share Issuance Proposal and the Charter Amendment Proposal is a condition to completion of the Merger. The issuance of Standard BioTools Common Stock in connection with the Merger, the amendment to the Standard BioTools Charter to effect a reverse stock split of Standard BioTools&#8217; issued and outstanding common stock and the amendment to the Standard BioTools Charter to change the name of the company will not take place unless approved by the requisite Standard BioTools stockholders. The Standard BioTools Board has approved the Standard BioTools Charter amendment to change the name of Standard BioTools to &#8220;Treeline Biosciences Holdings, Inc.&#8221; and no vote of the Standard BioTools stockholders is required to approve such Standard BioTools Charter </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">105<br></div></div></div>
<!--End Page 116-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 117-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_112-special_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">amendment under the DGCL. Standard BioTools is voluntarily seeking the approval of Standard BioTools stockholders for such Standard BioTools Charter amendment pursuant to the Merger Agreement. Therefore, the Merger cannot be consummated without the approval of the Share Issuance Proposal and the Charter Amendment Proposal. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Recommendation of the Standard BioTools Board </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">After due consideration and discussion of the factors that the Special Committee deemed relevant, the Special Committee unanimously (i) determined that the Merger and the other Transactions are advisable, fair to and in the best interests of Standard BioTools and its stockholders, (ii) approved and declared advisable the Merger Agreement and the Transactions and recommended that the Standard BioTools Board approve and declare advisable the Transactions and (iii) recommended that the Standard BioTools Board resolve to recommend the approval of the Share Issuance and the Charter Amendment by the Standard BioTools stockholders. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Upon the recommendation of the Special Committee, the Standard BioTools Board has determined and believes that the Share Issuance Proposal and the Charter Amendment Proposal are advisable, fair to and in the best interests of Standard BioTools and its stockholders. The Standard BioTools Board has also determined and believes that each of the Post-Closing Equity Incentive Plan Proposal, the Post-Closing ESPP Proposal and the Advisory Compensation Proposal are advisable, fair to and in the best interests of Standard BioTools and its stockholders.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Accordingly, the Standard BioTools Board recommends that the Standard BioTools stockholders vote &#8220;<font style="font-weight: bold;">FOR</font>&#8221; the Share Issuance Proposal, &#8220;<font style="font-weight: bold;">FOR</font>&#8221; the Charter Amendment Proposal, &#8220;<font style="font-weight: bold;">FOR</font>&#8221; the Post-Closing Equity Incentive Plan Proposal, &#8220;<font style="font-weight: bold;">FOR</font>&#8221; the Post-Closing ESPP Proposal, &#8220;<font style="font-weight: bold;">FOR</font>&#8221; the Advisory Compensation Proposal and &#8220;<font style="font-weight: bold;">FOR</font>&#8221; the Adjournment Proposal. See &#8220;<font style="font-style: italic;">The Merger &#8212; Standard BioTools&#8217; Reasons for the Merger</font>&#8221; beginning on page <a href="#tSBIO1">163</a> of this proxy statement/prospectus. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Consummation of the Merger is conditioned on approval of the Share Issuance Proposal and the Charter Amendment Proposal. Consummation of the Merger is not conditioned on the approval of the Post-Closing Equity Incentive Plan Proposal, the Post-Closing ESPP Proposal, the Advisory Compensation Proposal and/or the Adjournment Proposal. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Record Date for the Special Meeting and Quorum </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Record Date </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Only holders of record of Standard BioTools Common Stock at 5:00 p.m. U.S. Eastern Time on &#8195;&#8195;&#8195; , 2026, the Record Date for the Special Meeting, will be entitled to notice of, and to vote at, the Special Meeting or any postponements or adjournments thereof. Each share of Standard BioTools Common Stock entitles the holder thereof to cast one vote on each matter that comes before the Special Meeting. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As of the Record Date, there were &#8195;&#8195; shares of Standard BioTools Common Stock outstanding and entitled to vote at the Special Meeting. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Quorum </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In order for business to be conducted at the Special Meeting, a quorum must be present. A quorum will be present at the Special Meeting if the holders of a majority in voting power of the shares of Standard BioTools&#8217; capital stock issued and outstanding and entitled to vote as of the close of business on the Record Date are present virtually or represented by proxy at the Special Meeting. Abstentions (shares of Standard BioTools Common Stock for which proxies have been received but for which the holders have abstained from voting or as to which the holder attends the Special Meeting but does not vote) will be counted toward the establishment of a quorum. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">A failure to instruct your bank, broker or other nominee will result in your shares not being included in the calculation of the number of shares of Standard BioTools Common Stock represented at the Special Meeting for purposes of determining whether a quorum has been achieved. However, your shares of Standard BioTools Common Stock will be counted toward determining whether a quorum is present if you instruct your bank, broker or other nominee on how to vote your shares of Standard BioTools Common Stock with respect to one or more of the Proposals. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Required Vote </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Approval by Standard BioTools stockholders of the Share Issuance Proposal and the Charter Amendment Proposal is a condition to the consummation of the Merger. If the Share Issuance Proposal and the Charter </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">106<br></div></div></div>
<!--End Page 117-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 118-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_112-special_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Amendment Proposal are not approved, the Merger will not be consummated. Approval by the Standard BioTools stockholders of the Post-Closing Equity Incentive Plan Proposal, the Post-Closing ESPP Proposal and/or Adjournment Proposal is not a condition to the consummation of the Merger. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The voting standards required for each of the Proposals to be adopted by the Standard BioTools stockholders are as follows: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Proposal #1: Share Issuance Proposal. Approval of the Share Issuance Proposal requires the affirmative vote of a majority of the voting power of the shares of Standard BioTools&#8217; capital stock present virtually or represented by proxy at the Special Meeting and entitled to vote on such Proposal at the Special Meeting. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Proposal #2: Charter Amendment Proposal. Approval of the Charter Amendment Proposal requires the affirmative vote of the holders of Standard BioTools&#8217; capital stock entitled to vote thereon, voting as a single class, by a majority of the votes cast for or against such Proposal at the Special Meeting. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Proposal #3: Post-Closing Equity Incentive Plan Proposal. Approval of the Post-Closing Equity Incentive Plan Proposal requires the affirmative vote of a majority of the voting power of the shares of Standard BioTools&#8217; capital stock present virtually or represented by proxy at the Special Meeting and entitled to vote on such Proposal at the Special Meeting. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Proposal #4: Post-Closing ESPP Proposal. Approval of the Post-Closing ESPP Proposal requires the affirmative vote of a majority of the voting power of the shares of Standard BioTools&#8217; capital stock present virtually or represented by proxy at the Special Meeting and entitled to vote on such Proposal at the Special Meeting. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Proposal #5: Advisory Compensation Proposal. Approval of the Advisory Compensation Proposal requires the affirmative vote of a majority of the voting power of the shares of Standard BioTools&#8217; capital stock present virtually or represented by proxy at the Special Meeting and entitled to vote on such Proposal at the Special Meeting. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Proposal #6: Adjournment Proposal. Approval of the Adjournment Proposal requires the affirmative vote of a majority of the voting power of the shares of Standard BioTools&#8217; capital stock present virtually or represented by proxy at the Special Meeting and entitled to vote on such Proposal at the Special Meeting. </div></td></tr></table><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;"><a name="tVOA"><!--Anchor--></a>Voting Agreements </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Concurrently with the execution of the Merger Agreement, certain stockholders of Standard BioTools (including its directors and certain officers), collectively holding approximately 39% of the outstanding shares of Standard BioTools Common Stock, entered into voting agreements with Standard BioTools, Treeline and Merger Sub (the &#8220;Voting Agreements&#8221;) pursuant to which they have agreed to vote all of their shares of Standard BioTools Common Stock in favor of the Share Issuance Proposal, the Charter Amendment Proposal, the Post-Closing Equity Incentive Plan Proposal and the Post-Closing ESPP Proposal, subject to the terms of the Voting Agreements, including a reduction in the number of shares subject to the voting requirements for certain stockholders in the event of a change in the recommendation of the Special Committee in favor of the Transactions such that the aggregate number of outstanding shares of Standard BioTools Common Stock subject to the voting requirements in the Voting Agreements is reduced to approximately 30% of the outstanding shares of Standard BioTools Common Stock. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Voting by Standard BioTools&#8217; Directors and Executive Officers </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As of the Record Date, directors and executive officers of Standard BioTools and their affiliates beneficially owned shares of Standard BioTools Common Stock, representing approximately &#8195;&#8195;% of the Standard BioTools Common Stock outstanding on that date. See &#8220;<font style="font-style: italic;">&#8212; Voting Agreements</font>&#8221; above, for a description of voting agreements entered into by Standard BioTools&#8217; directors and executive officers and entities affiliated with Viking Global Investors LP, in their capacity as stockholders of Standard BioTools. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Voting of Proxies </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If, as of the Record Date for the Special Meeting, your shares were registered directly in your name with the transfer agent for Standard BioTools Common Stock, Computershare Trust Company, N.A., then you are a stockholder of record. Whether or not you plan to attend the Special Meeting, Standard BioTools urges you to fill out and return the proxy card or submit a proxy to vote your shares over the telephone or on the internet as described below to ensure that your vote is counted. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">107<br></div></div></div>
<!--End Page 118-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 119-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_112-special_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If you are a stockholder of record of Standard BioTools Common Stock as of the Record Date, a proxy card has been delivered to you together with this proxy statement/prospectus. Standard BioTools requests that Standard BioTools stockholders sign the accompanying proxy card and return it promptly in the enclosed postage-paid envelope. Standard BioTools stockholders may also authorize a proxy to vote their Standard BioTools Common Stock by telephone or through the Internet. Information and applicable deadlines for authorizing a proxy to vote by telephone or through the Internet are set forth on the enclosed proxy card. When the accompanying proxy is returned properly executed, the Standard BioTools Common Stock represented by it will be voted at the Special Meeting or any adjournment or postponement thereof in accordance with the instructions contained in the proxy. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Accordingly, if you are a stockholder of record: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">To vote at the Special Meeting, please attend the Special Meeting and vote in person. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">To submit a proxy to vote using the proxy card, simply complete, sign and date the accompanying proxy card and return it promptly in the envelope provided. If you return your signed proxy card before the Special Meeting, Standard BioTools will vote your shares in accordance with the proxy card. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">To submit a proxy to vote over the internet, please follow the instructions provided on the proxy card. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">To submit a proxy to vote by telephone, you may vote by proxy by calling the toll-free number found on the proxy card. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If you are a beneficial owner of shares registered in the name of your bank, broker or other nominee, you should have received voting instructions from that organization rather than from Standard BioTools. Simply follow the voting instructions provided to ensure that your vote is counted. You may vote by telephone or over the internet as instructed by your bank, broker or other nominee. To vote at the Special Meeting, you must contact your bank, broker or other nominee and obtain a valid legal proxy in order to vote at the Special Meeting. Follow the voting instructions from your bank, broker or other nominee, or contact your bank, broker or other nominee for instructions. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Your vote is important. Accordingly, whether or not you plan to attend the Special Meeting, please submit a proxy as soon as possible by telephone, over the Internet, or by signing and returning the enclosed proxy card, if you are a stockholder of record, or by following the voting instructions from your bank, broker or other nominee, if you are a beneficial owner of shares. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Incomplete Proxies </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If you are a stockholder of record of Standard BioTools and a proxy is signed and returned without an indication as to how the shares of Standard BioTools Common Stock represented by the proxy are to be voted with regard to a particular proposal, the Standard BioTools Common Stock represented by the proxy will be voted in favor of each such proposal, as applicable, in accordance with the recommendation of the Standard BioTools Board. In accordance with the Standard BioTools Bylaws and the DGCL, except as otherwise required by law, business transacted at the Special Meeting will be limited to those matters set forth in the notice of the meeting. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Failures to Vote, Broker Non-Votes, and Abstentions </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If you hold your shares of Standard BioTools Common Stock in a stock brokerage account or if your shares of Standard BioTools Common Stock are held by a bank, broker, or other nominee (that is, in &#8220;street name&#8221;), you must provide the record holder of your shares with instructions on how to vote your shares of Standard BioTools Common Stock. Please follow the voting instructions provided by your bank, broker, or other nominee. Please note that you are not permitted to vote shares of Standard BioTools Common Stock held in &#8220;street name&#8221; by returning a proxy card directly to Standard BioTools or by voting virtually at the Special Meeting unless you provide a &#8220;legal proxy,&#8221; which you must obtain from your bank, broker, or other nominee. Obtaining a legal proxy may take several days. Further, brokers who hold shares of Standard BioTools Common Stock on behalf of their customers may not give a proxy to Standard BioTools to vote those shares without specific instructions from their customers. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Accordingly, if your bank, broker, or other nominee holds your shares of Standard BioTools Common Stock in &#8220;street name&#8221; as of the Record Date and you fail to instruct your bank, broker, or other nominee to vote your shares of Standard BioTools Common Stock, your bank, broker or other nominee will not be permitted to vote on your behalf on the Proposals and your shares of Standard BioTools Common Stock will not be counted towards determining whether a quorum is present. Your shares of Standard BioTools Common Stock will, however, be </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">108<br></div></div></div>
<!--End Page 119-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 120-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_112-special_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">counted toward determining whether a quorum is present if you instruct your bank, broker or other nominee on how to vote your shares of Standard BioTools Common Stock with respect to each of the Proposals. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Even if your shares of Standard BioTools Common Stock are held in &#8220;street name,&#8221; you are welcome to attend the Special Meeting. If your shares of Standard BioTools Common Stock are held in &#8220;street name,&#8221; you may not vote your shares of Standard BioTools Common Stock virtually at the Special Meeting unless you obtain a proxy, executed in your favor, from the holder of record (i.e., your bank, broker, or other nominee). If you hold your shares of Standard BioTools Common Stock in &#8220;street name&#8221; and wish to vote virtually at the Special Meeting, please contact your bank, broker or other nominee before the Special Meeting to obtain the necessary proxy from the holder of record. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under the Nasdaq listing rules, brokers do not have discretionary authority to vote on non-routine matters. A &#8220;broker non-vote&#8221; occurs when a broker submits a proxy that states that the broker votes for at least one proposal but does not vote for proposals on non-routine matters because the broker has not received instructions from the beneficial owners on how to vote and thus does not have discretionary authority to vote on those proposals. Because all of the matters to be considered at the Special Meeting are non-routine and brokers will not have discretionary authority to vote on any of the Proposals, Standard BioTools does not expect to receive any broker non-votes. If broker non-votes were received, they would not have any impact on the outcome of the Proposals. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Abstentions (virtually or by proxy) will have the same effect as a vote &#8220;<font style="font-weight: bold;">AGAINST</font>&#8221; the Proposals (other than the Charter Amendment Proposal) and will have no effect on the outcome of the vote for the Charter Amendment Proposal. If you fail to submit a proxy or fail to vote at the Special Meeting it will have no effect on the outcome of the vote for the Proposals. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Revocability of Proxies and Changes to a Standard BioTools Stockholder&#8217;s Vote </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If you are a holder of record of shares of Standard BioTools Common Stock on the Record Date, you have the power to revoke your proxy at any time before your proxy is exercised at the Special Meeting. You can revoke your proxy in one of three ways: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">sending a written notice of revocation that is received by Standard BioTools prior to 11:59 p.m., U.S.&#160;Eastern Time, on the day preceding the Special Meeting, stating that you would like to revoke your proxy, to Standard BioTools&#8217; Corporate Secretary at Standard BioTools Inc., 50 Milk Street, 10th Floor, Boston, MA 02109, Attn: Corporate Secretary; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">submitting a new proxy bearing a later date (by Internet, telephone or mail) that is received by Standard BioTools prior to 11:59 p.m., U.S. Eastern Time, on the day preceding the Special Meeting; or </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">attending the Special Meeting and voting virtually or bringing a written notice of revocation to the Secretary of the Special Meeting prior to the voting at the Special Meeting (your attendance at the meeting will not, by itself, revoke your proxy; you must vote virtually by ballot at the meeting to change your vote or submit a written notice of revocation to revoke your proxy). Attending the Special Meeting will not automatically revoke a proxy that was submitted through the Internet or by telephone or mail. If you wish to change your vote at the Special Meeting, you must vote by ballot at such meeting to change your vote, or if you wish to revoke your vote at the Special Meeting you must bring a written notice of revocation to the Secretary of the Special Meeting prior to the voting of the Special Meeting. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If you are a Standard BioTools stockholder whose shares are held in &#8220;street name&#8221; by a bank, broker, or other nominee, you may revoke your proxy and vote your shares of Standard BioTools Common Stock virtually at the Special Meeting only in accordance with applicable rules and procedures as employed by such bank, broker, or other nominee. If your shares are held in an account at a bank, broker, or other nominee, you should contact your bank, broker, or other nominee to change your vote. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Solicitation of Proxies </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The cost of the solicitation of proxies from Standard BioTools stockholders will be borne by Standard BioTools. In addition to solicitations by mail, Standard BioTools&#8217; directors, officers, employees and other agents may solicit proxies personally, by telephone, by facsimile or otherwise, without additional compensation. Standard BioTools and Treeline will share equally the costs of printing and filing this proxy statement/prospectus and proxy card. Standard BioTools will also request brokerage firms, nominees, custodians and fiduciaries to forward proxy </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">109<br></div></div></div>
<!--End Page 120-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 121-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_112-special_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">materials to the beneficial owners of shares of Standard BioTools Common Stock held of record on the Record Date and will provide customary reimbursement to such firms for the cost of forwarding these materials. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Standard BioTools has retained &#8195;&#8195;&#8195; to assist in the solicitation of proxies and has agreed to pay them a fee of approximately &#8195;&#8195;&#8195;, plus reasonable and documented expenses, for these services. Standard BioTools has also agreed to indemnify &#8195;&#8195;&#8195; and related parties against certain liabilities and expenses arising out of its services in connection with the Special Meeting. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Adjournments </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Although it is not currently expected, the Merger Agreement provides that (A) if on or before the date on which the Special Meeting is scheduled, Standard BioTools reasonably believes that (1) it will not receive sufficient proxies for approval of the Share Issuance Proposal or the Charter Amendment Proposal, whether or not a quorum is present or (2)&#160;it&#160;will not have enough shares of Standard BioTools Common Stock represented to constitute a quorum necessary to conduct the business of the Special Meeting, Standard BioTools may (and, if requested by Treeline, Standard BioTools will) postpone or adjourn, or make one or more successive postponements or adjournments of, the Special Meeting and (B) Standard BioTools may postpone or adjourn the Special Meeting to allow reasonable additional time for the filing or mailing of any supplemental or amended disclosure that Standard BioTools has determined, after consultation with outside legal counsel, is reasonably likely to be required under applicable law and for such supplemental or amended disclosure to be disseminated and reviewed by stockholders of Standard BioTools prior to the Special Meeting, as long as the date of the Special Meeting is not postponed or adjourned more than an aggregate of 30&#160;days in connection with all such postponements or adjournments pursuant to either or both of the preceding clauses (A) and (B). Pursuant to the Standard BioTools Bylaws, notice need not be given of any such adjourned meeting if the time and place thereof are announced at the meeting at which adjournment is taken. If the Special Meeting is adjourned for the purpose of soliciting additional proxies, stockholders who have already sent in their proxies will be allowed to revoke them at any time prior to their use. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Postponements </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">At any time prior to convening the Special Meeting, the Standard BioTools Board may postpone the meeting without the approval of the Standard BioTools stockholders. Although it is not currently expected, the Merger Agreement provides that the Standard BioTools Board may postpone the Special Meeting for the purpose of soliciting additional proxies if Standard BioTools has not received sufficient proxies to constitute a quorum or sufficient votes for approval of the Share Issuance Proposal and the Charter Amendment Proposal or to allow reasonable additional time for the filing or mailing of any supplemental or amended disclosure that Standard BioTools has determined, after consultation with outside legal counsel, is reasonably likely to be required under applicable law and for such supplemental or amended disclosure to be disseminated and reviewed by stockholders of Standard BioTools prior to the Special Meeting. The Merger Agreement provides that the Special Meeting will not be adjourned or postponed to a date that is more than an aggregate of 30 days after the date for which the Special Meeting was originally scheduled. If the Special Meeting is postponed for the purpose of soliciting additional proxies, stockholders who have already sent in their proxies will be allowed to revoke them at any time prior to their use. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Stockholder List </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">A list of Standard BioTools stockholders entitled to vote at the Special Meeting will be available for inspection by any stockholder for any purpose germane to the Special Meeting for a period of at least 10 days prior to the Special Meeting during ordinary business hours, at Standard BioTools&#8217; corporate office, located at 50 Milk Street, 10th Floor, Boston, MA 02109. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Other Matters </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As of the date of this proxy statement/prospectus, the Standard BioTools Board does not know of any business to be presented at the Special Meeting other than as set forth in the notice accompanying this proxy statement/prospectus. If any other matters should properly come before the Special Meeting, it is intended that the shares represented by proxies will be voted with respect to such matters in accordance with the judgment of the persons voting the proxies. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Assistance </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If you need assistance in completing your proxy card or have questions regarding the Special Meeting, please contact &#8195;&#8195;&#8195;, the proxy solicitor for Standard BioTools, by telephone toll-free at &#8195;&#8195;&#8195;. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">110<br></div></div></div>
<!--End Page 121-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 122-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_113-proposals_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tSBP"><!--Anchor--></a>STANDARD BIOTOOLS PROPOSALS </div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; text-align: center;">Proposal #1: The Share Issuance Proposal </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Overview </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Standard BioTools stockholders are asked to approve the issuance of Standard BioTools Common Stock to Treeline stockholders in connection with the Merger in accordance with Nasdaq Listing Rules 5635(a) and 5635(b). Standard BioTools stockholders should carefully read this proxy statement/prospectus in its entirety, including the documents incorporated by reference, and the Merger Agreement, for more detailed information concerning the Merger Agreement and the Share Issuance Proposal. For a detailed discussion of the terms of the Merger Agreement and the Merger, including the proposed share issuance, see the information about the Merger and the Merger Agreement throughout this proxy statement/prospectus, including the information set forth in the sections entitled &#8220;<font style="font-style: italic;">The Merger</font>&#8221; and &#8220;<font style="font-style: italic;">The Merger Agreement</font>&#8221; beginning on pages <a href="#tMER">135</a> and <a href="#tMEA">201</a>, respectively, of this proxy statement/prospectus. A copy of the Merger Agreement is attached as Annex&#160;A to this proxy statement/prospectus. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Standard BioTools Board formed the Special Committee, composed solely of &#8220;disinterested directors&#8221;, pursuant to Section&#160;144(e)(4) of the DGCL, and delegated to the Special Committee the full power and authority of the Standard BioTools Board to explore, consider, evaluate, review, negotiate, and approve or reject the Merger and the other Transactions as further described in &#8220;<font style="font-style: italic;">The Merger &#8212; Background of the Merger</font>&#8221; beginning on page <a href="#tBACK1">138</a> of this proxy statement/prospectus. The Standard BioTools Board, upon the unanimous recommendation of the Special Committee, determined by vote of all participating directors that the Merger Agreement and the Merger are advisable, fair to and in the best interests of Standard BioTools and its stockholders, adopted and approved the Merger Agreement and the transactions contemplated thereby, and recommended that Standard BioTools stockholders approve the Share Issuance Proposal. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Approval of the Share Issuance Proposal is a condition to the consummation of the Merger. <font style="font-weight: normal;">If the Share Issuance Proposal is not approved, the Merger will not occur. For a detailed discussion of the conditions of the Merger, see &#8220;</font><font style="font-style: italic; font-weight: normal;">The Merger Agreement &#8212; Conditions to the Completion of the Merger</font><font style="font-weight: normal;">&#8221; beginning on page <a href="#tCONCOMMER">207</a> of this proxy statement/prospectus. </font></div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Reason for the Proposal </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under Nasdaq Listing Rule&#160;5635(a)(1), a company listed on Nasdaq is required to obtain stockholder approval prior to the issuance of common stock in connection with the acquisition of another company&#8217;s stock, if the number of shares of common stock to be issued is in excess of 20% of the number of shares of common stock then outstanding. The potential issuance of the shares of Standard BioTools Common Stock in the Merger exceeds the 20% threshold under the Nasdaq listing rules and is expected to represent approximately &#8195;&#8195;% of Standard BioTools Common Stock expected to be outstanding immediately following the Closing. Accordingly, in order to ensure compliance with Nasdaq Listing Rule&#160;5635(a)(1), Standard BioTools must obtain the approval of Standard BioTools stockholders for the issuance of these shares in the Merger. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, under Nasdaq Listing Rule&#160;5635(b), a company listed on Nasdaq is required to obtain stockholder approval prior to an issuance of stock that will result in a &#8220;change of control&#8221; of the listed company. Standard BioTools believes that Nasdaq may take the position that the Merger constitutes a &#8220;change of control&#8221; of the listed company within the meaning of the Nasdaq listing rules. Accordingly, in order to ensure compliance with Nasdaq Listing Rule&#160;5635(b), Standard BioTools must obtain the approval of Standard BioTools stockholders of the change of control resulting from the Merger. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Vote Required for Approval </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The approval of the Share Issuance Proposal requires the affirmative vote of a majority of the voting power of the shares of Standard BioTools&#8217; capital stock present virtually or represented by proxy at the Special Meeting and entitled to vote on such Proposal at the Special Meeting. Abstentions will have the same effect as a vote &#8220;<font style="font-weight: bold;">AGAINST</font>&#8221; the Share Issuance Proposal. If you fail to cast your vote, in person or by proxy, or fail to give voting instructions to your brokerage firm, bank, trust or other nominee, it will have no effect on the outcome of the vote for the Share Issuance Proposal. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Merger is conditioned upon the approval of the Share Issuance Proposal. Notwithstanding the approval of the Share Issuance Proposal, if the Merger is not consummated for any reason, the actions contemplated by the Share Issuance Proposal will not be effected. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">111<br></div></div></div>
<!--End Page 122-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 123-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_113-proposals_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Share Issuance Proposal is conditioned on the approval of the Charter Amendment Proposal. Notwithstanding the approval of the Share Issuance Proposal, if the Charter Amendment Proposal is not approved, the actions contemplated by the Share Issuance Proposal will not be effected and the Merger will not be consummated. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Certain Standard BioTools stockholders have agreed to vote any shares of Standard BioTools Common Stock owned by them in favor of the Share Issuance Proposal. Please see the section titled &#8220;<font style="font-style: italic;">The Special Meeting &#8212; Voting Agreements</font>&#8221; beginning on page <a href="#tVOA">107</a> of this proxy statement/prospectus for more information. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<font style="font-weight: bold;">FOR</font>&#8221; the approval of the Share Issuance Proposal. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Board Recommendation </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Standard BioTools Board recommends that Standard BioTools stockholders vote &#8220;FOR&#8221; the Share Issuance Proposal.<font style="font-weight: normal;"> </font></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">112<br></div></div></div>
<!--End Page 123-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 124-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_113-proposals_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Proposal #2: The Charter Amendment Proposal </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">Overview </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Standard BioTools stockholders are asked to approve (1) an amendment to the Standard BioTools Charter that will implement a reverse stock split of the issued and outstanding shares of Standard BioTools Common Stock at a ratio in the range of one new share for every &#8195;&#8195; shares and one new share for every &#8195;&#8195; shares outstanding (or any number in between), with the final ratio to be mutually agreed to by Standard BioTools and Treeline and (2) an amendment to the Standard BioTools Charter to effect the name change of &#8220;Standard BioTools Inc.&#8221; to &#8220;Treeline Biosciences Holdings, Inc.&#8221; effective only upon the completion of the Merger. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Standard BioTools Board has approved the Standard BioTools Charter amendment to change the name of Standard BioTools to &#8220;Treeline Biosciences Holdings, Inc.&#8221; and no vote of the Standard BioTools stockholders is required to approve such Standard BioTools Charter amendment under the DGCL. Standard BioTools is voluntarily seeking the approval of Standard BioTools stockholders for such Standard BioTools Charter amendment pursuant to the Merger Agreement.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">A copy of the proposed form of certificate of amendment to the Standard BioTools Charter to effect the reverse stock split is attached as Annex&#160;G to this proxy statement/prospectus and a copy of the proposed form of certificate of amendment to the Standard BioTools Charter to effect the name change is attached as Annex&#160;H to this proxy statement/prospectus. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Reverse Stock Split </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Upon the effectiveness of the amendment to the Standard BioTools Charter to effect the reverse stock split (the &#8220;reverse stock split effective time&#8221;), the issued and outstanding shares of Standard BioTools Common Stock immediately prior to the reverse stock split effective time will be reclassified into a smaller number of shares such that a Standard BioTools stockholder will own a number of shares ranging from one new share of Standard BioTools Common Stock for every &#8195;&#8195; to &#8195;&#8195; shares of Standard BioTools Common Stock held by such stockholder immediately prior to the reverse stock split effective time. By approving the Charter Amendment Proposal, stockholders will be deemed to approve multiple amendments providing for a Reverse Stock Split at each number within the identified range and authorize Standard BioTools to file the amendment effecting the Reverse Stock Split at the agreed upon range and to abandon all other amendments. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Based upon the reverse stock split ratio selected by Standard BioTools and Treeline, proportionate adjustments will be made to the per share exercise price, and/or the number of shares issuable upon the exercise or vesting of all then outstanding Standard BioTools Options or RSUs, which will result in a proportional decrease in the number of shares of Standard BioTools Common Stock reserved for issuance upon exercise or vesting of such stock options or RSUs, and a proportional increase in the exercise price of all stock options. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Standard BioTools Board may determine to effect the reverse stock split, if it is approved by the stockholders, even if the other proposals to be acted upon at the meeting are not approved, including the Share Issuance Proposal. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">By approving the Reverse Stock Split Proposal, Standard BioTools stockholders will approve multiple amendments to the Standard BioTools Charter pursuant to which any whole number of issued and outstanding shares of Standard BioTools Common Stock, between and including &#8195;&#8195; to &#8195;&#8195;, would be combined into one share of Standard BioTools Common Stock and will authorize the Standard BioTools Board to file such certificate of amendment, as mutually agreed by the Standard BioTools Board and the Treeline Board. As of the Record Date, &#8195;&#8195; shares of Standard BioTools Common Stock were authorized, &#8195;&#8195; shares of Standard BioTools Common Stock were outstanding and no shares of Standard BioTools Common Stock were held in treasury. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">All holders of Standard BioTools Common Stock will be affected proportionately by the reverse stock split. No fractional shares of Standard BioTools Common Stock will be issued as a result of the reverse stock split. Instead, Standard BioTools stockholders who otherwise would be entitled to receive fractional shares will be entitled to receive cash as set forth below under the caption &#8220;<font style="font-style: italic;">No Fractional Shares</font>&#8221; in exchange for any fractional share that would otherwise be issued. Each Standard BioTools stockholder will hold the same percentage of the outstanding shares of Standard BioTools Common Stock immediately following the reverse stock split as that Standard BioTools stockholder did immediately prior to the reverse stock split, except to the extent that the reverse stock split results in Standard BioTools stockholders receiving cash in lieu of fractional shares. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">113<br></div></div></div>
<!--End Page 124-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 125-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_113-proposals_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Should Standard BioTools receive the required stockholder approval for this Reverse Stock Split Proposal, and following such stockholder approval, the Standard BioTools Board, subject to agreement by Treeline, determines that effecting the reverse stock split is in the best interests of Standard BioTools and its stockholders, the reverse stock split will become effective as specified in the amendment filed with the Secretary of State of the State of Delaware. The amendment filed thereby will contain the number of shares selected by the Standard BioTools Board and the Treeline Board within the limits set forth in this proposal to be combined into one share of Standard BioTools Common Stock. Accordingly, upon the effectiveness of the amendment to the Standard BioTools Charter, at the reverse stock split effective time, every &#8195;&#8195; to &#8195;&#8195; shares (or any number in between) of Standard BioTools Common Stock outstanding immediately prior to the split effective time will be combined and reclassified into one share of Standard BioTools Common Stock. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The proposed form of certificate of amendment to the Standard BioTools Charter to effect the reverse stock split, will affect the reverse stock split but <font style="font-style: italic; font-weight: bold;">will not</font> change the number of authorized shares of Standard BioTools Common Stock or preferred stock, or the par value of Standard BioTools Common Stock or preferred stock. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Notwithstanding approval of this proposal by Standard BioTools stockholders, the Standard BioTools Board may, in its sole discretion, abandon the proposed amendment and determine prior to the effectiveness of any filing with the Secretary of State of the State of Delaware not to effect the reverse stock split, as permitted under Section&#160;242(c) of the DGCL. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Reasons for the Reverse Stock Split </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Standard BioTools Board approved the proposal approving the amendment to the Standard BioTools Charter effecting the reverse stock split for the following reasons: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Standard BioTools Board believes effecting the reverse stock split will result in an increase in the minimum bid price of Standard BioTools Common Stock, thereby increasing the ability of the combined company to satisfy the Nasdaq listing requirements for the combined company common stock and reducing the risk of a delisting of Standard BioTools Common Stock from Nasdaq in the future; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Standard BioTools Board believes a higher stock price may help generate investor interest in Standard BioTools and ultimately the combined company and help Standard BioTools attract and retain employees; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Standard BioTools Board believes a higher stock price may increase trading volume in Standard BioTools Common Stock and facilitate future financings by the combined company; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Standard BioTools Board believes that a range of reverse stock split ratios provides it with the most flexibility to achieve the desired results of the reverse stock split. </div></td></tr></table><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Requirements for Listing on Nasdaq </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Standard BioTools Common Stock is listed on Nasdaq under the symbol &#8220;LAB.&#8221; Standard BioTools has filed a listing application pursuant to the terms of the Merger Agreement for the combined company to list the securities of the combined company on Nasdaq. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">According to the Nasdaq listing rules, an issuer must, in a case such as this, apply for initial inclusion following a transaction whereby the issuer combines with a non-Nasdaq entity, resulting in a change of control of the issuer and potentially allowing the non-Nasdaq entity to obtain a Nasdaq listing. Accordingly, the listing standards of Nasdaq will require Standard BioTools to have, among other things, a $4.00 per share minimum bid price as of the Closing, which would necessitate effecting a reverse stock split in order to increase the price of the Standard BioTools Common Stock to above $4.00 per share. In addition, it is a condition to the Closing that the shares of Standard BioTools common stock to be issued in the Merger pursuant to the Merger Agreement have been approved for listing on Nasdaq. Therefore, unless the trading price of the Standard BioTools Common Stock otherwise increases to more than $4.00 per share prior to the consummation of the Merger, the reverse stock split would be necessary in order to satisfy Nasdaq requirements and consummate the Merger. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">One of the effects of the reverse stock split will be to effectively increase the proportion of authorized shares which are unissued relative to those which are issued. This could result in Standard BioTools&#8217; management being able to issue more shares without further stockholder approval. The reverse stock split will not affect the number of authorized shares of Standard BioTools&#8217; capital stock, which will continue to be authorized pursuant to the Standard BioTools Charter. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">114<br></div></div></div>
<!--End Page 125-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 126-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_113-proposals_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Potential Increased Investor Interest </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The closing price of the Standard BioTools Common Stock on &#8195;&#8195; , 2026, the last business day prior to the date of this proxy statement/prospectus, as reported on Nasdaq, was $&#8195;&#8195; per share. An investment in Standard BioTools Common Stock may not appeal to brokerage firms that are reluctant to recommend lower priced securities to their clients. Investors may also be dissuaded from purchasing lower priced stocks because the brokerage commissions, as a percentage of the total transaction, tend to be higher for such stocks. Moreover, the analysts at many brokerage firms do not monitor the trading activity or otherwise provide research coverage of lower priced stocks. Also, the Standard BioTools Board believes that most investment funds are reluctant to invest in lower priced stocks. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">There are risks associated with the reverse stock split, including that the reverse stock split may not result in an increase in the per share price of Standard BioTools Common Stock at the levels expected or at all. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Standard BioTools cannot predict whether the reverse stock split will increase the market price for Standard BioTools Common Stock. The history of similar reverse stock splits for companies in like circumstances is varied. There is no assurance that: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the market price per share of Standard BioTools Common Stock after the reverse stock split will rise in proportion to the reduction in the number of shares of Standard BioTools Common Stock outstanding before the reverse stock split; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the reverse stock split will result in a per share price that will attract brokers and investors who do not trade in lower priced stocks; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the reverse stock split will result in a per share price that will increase the ability of Standard BioTools to attract and retain employees; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the market price per share will either exceed or remain in excess of the $1.00 minimum bid price as required by Nasdaq for continued listing; or </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the reverse stock split will increase the trading volume in Standard BioTools Common Stock and facilitate future financings by the combined company. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The market price of Standard BioTools Common Stock will also be based on the performance of Standard BioTools, and after the Merger, on the performance of the combined company, and other factors, some of which are unrelated to the number of shares outstanding. If the reverse stock split is effected and the market price of Standard BioTools Common Stock declines, the percentage decline as an absolute number and as a percentage of the overall market capitalization of Standard BioTools may be greater than would occur in the absence of a reverse stock split. Furthermore, the liquidity of Standard BioTools Common Stock could be adversely affected by the reduced number of shares that would be outstanding after the reverse stock split. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Principal Effects of the Reverse Stock Split </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The reverse stock split will be realized simultaneously for all shares of Standard BioTools Common Stock and Standard BioTools Options and RSUs outstanding immediately prior to the reverse stock split effective time. The reverse stock split will affect all holders of shares of Standard BioTools Common Stock outstanding immediately prior to the reverse stock split effective time uniformly and each such stockholder will hold the same percentage of Standard BioTools Common Stock outstanding immediately following the reverse stock split as that stockholder held immediately prior to the reverse stock split, except for immaterial adjustments that may result from the treatment of fractional shares as described below. The reverse stock split will not change the par value of Standard BioTools Common Stock or preferred stock and will not reduce the number of authorized shares of Standard BioTools Common Stock or preferred stock. Standard BioTools Common Stock issued pursuant to the reverse stock split will remain fully paid and nonassessable. Proportionate adjustments will be made to the per share exercise price, the number of shares issuable upon the exercise, vesting or settlement of all outstanding options to purchase shares of Standard BioTools Common Stock, and the number of shares reserved for issuance pursuant to Standard BioTools&#8217; existing equity incentive and employee stock purchase plans will be reduced proportionately based on the split ratio. The reverse stock split will not affect Standard BioTools continuing to be subject to the periodic reporting requirements of the Exchange Act. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">115<br></div></div></div>
<!--End Page 126-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 127-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_113-proposals_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Procedure for Effecting Reverse Stock Split and Exchange of Stock Certificates </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If the Standard BioTools stockholders approve the amendment to the Standard BioTools Charter effecting the reverse stock split, the Standard BioTools Board and the Treeline Board mutually agree that a reverse stock split is necessary, and the Standard BioTools Board still believes that a reverse stock split is in the best interests of Standard BioTools and its stockholders, Standard BioTools will file the certificate of amendment to the Standard BioTools Charter with the Secretary of State of the State of Delaware at such time as the Standard BioTools Board has determined to be the appropriate reverse stock split effective time. The Standard BioTools Board and Treeline Board may agree to delay effecting the reverse stock split without resoliciting stockholder approval. Beginning at the reverse stock split effective time, each stock certificate representing pre-split shares will be deemed for all corporate purposes to evidence ownership of post-split shares. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Beneficial Owners of Standard BioTools Common Stock<font style="font-style: normal;">. Upon the implementation of the reverse stock split, Standard BioTools intends to treat shares held by stockholders in &#8220;street name&#8221; (i.e., through a bank, broker, custodian or other nominee), in the same manner as registered stockholders whose shares are registered in their names. Banks, brokers, custodians or other nominees will be instructed to effect the reverse stock split for their beneficial holders holding Standard BioTools Common Stock in &#8220;street name.&#8221; However, these banks, brokers, custodians or other nominees may have different procedures than registered stockholders for processing the reverse stock split and making payment for fractional shares. If a stockholder holds shares of Standard BioTools Common Stock with a bank, broker, custodian or other nominee and has any questions in this regard, stockholders are encouraged to contact their bank, broker, custodian or other nominee. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Registered Holders of Standard BioTools Common Stock in Book-Entry Form<font style="font-style: normal;">. Standard BioTools&#8217; registered holders of common stock hold their shares electronically in book-entry form with Standard BioTools&#8217; transfer agent, Computershare Trust Company, N.A. These stockholders do not hold physical stock certificates evidencing their ownership of Standard BioTools Common Stock. However, they are provided with a statement reflecting the number of shares of Standard BioTools Common Stock registered in their accounts. No action needs to be taken to receive post-reverse stock split shares or payment in lieu of fractional shares, if applicable. If a stockholder is entitled to post-reverse stock split shares, a transaction statement will automatically be sent to the stockholder&#8217;s address of record indicating the number of shares of Standard BioTools Common Stock held following the reverse stock split. </font></div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">No Fractional Shares </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">No fractional shares will be issued in connection with the reverse stock split. Stockholders of record who otherwise would be entitled to receive fractional shares because they hold a number of pre-split shares not evenly divisible by the number of pre-split shares for which each post-split share is to be reclassified, will be entitled to a cash payment in lieu thereof at a price equal to the fraction to which the stockholder would otherwise be entitled multiplied by the closing price of the Standard BioTools Common Stock on Nasdaq on the date of the filing of the certificate of amendment to the Standard BioTools Charter effecting the reverse stock split. For the foregoing purposes, all shares of Standard BioTools Common Stock held by a holder will be aggregated (thus resulting in no more than one fractional share per holder). The ownership of a fractional interest will not give the holder thereof any voting, dividend or other rights except to receive payment therefor as described herein. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Standard BioTools stockholders should be aware that, under the escheat laws of the various jurisdictions where stockholders reside, where Standard BioTools is domiciled and where the funds will be deposited, sums due for fractional interests that are not timely claimed after the effective date of the split may be required to be paid to the designated agent for each such jurisdiction, unless correspondence has been received by Standard BioTools or the exchange agent concerning ownership of such funds within the time permitted in such jurisdiction. Thereafter, stockholders otherwise entitled to receive such funds will have to seek to obtain them directly from the state to which they were paid. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Potential Anti-Takeover Effect </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Although the increased proportion of unissued authorized shares to issued shares could, under certain circumstances, have an anti-takeover effect, for example, by permitting issuances that would dilute the stock ownership of a person seeking to effect a change in the composition of the Standard BioTools Board or contemplating a tender offer or other transaction for the combination of Standard BioTools with another company, the Reverse Stock Split Proposal is not being proposed in response to any effort of which Standard BioTools is aware to accumulate shares of Standard BioTools Common Stock or obtain control of Standard BioTools, other than </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">116<br></div></div></div>
<!--End Page 127-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 128-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_113-proposals_pg7"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">in connection with the Merger, nor is it part of a plan by management to recommend a similar amendment to the Standard BioTools Board and stockholders. Other than the proposals being submitted to the Standard BioTools stockholders for their consideration at the Special Meeting, the Standard BioTools Board does not currently contemplate recommending the adoption of any other actions that could be construed to affect the ability of third parties to take over or change control of Standard BioTools. For more information, please see the section titled &#8220;<font style="font-style: italic;">Risk&#160;Factors &#8212; Risks Related to the Business of the Combined Company After the Merger</font>&#8221; of this proxy statement/prospectus. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">Material U.S. Federal Income Tax Considerations with Respect to the Reverse Stock Split </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following is a discussion of the material U.S. federal income tax considerations with respect to the reverse stock split that are applicable to U.S. holders (which, for purposes of this discussion, has the same meaning as in &#8220;<font style="font-style: italic;">The&#160;Merger &#8212; Material U.S. Federal Income Tax Considerations with Respect to the CVRs to Holders of Standard BioTools Common Stock</font>&#8221;) of Standard BioTools Common Stock. This discussion does not purport to be a complete analysis of all potential tax considerations and is based upon current provisions of the Code, existing Treasury regulations, judicial decisions and published rulings and administrative pronouncements of the IRS, all in effect as of the date hereof and all of which are subject to differing interpretations or change. Any such change or differing interpretation, which may be retroactive, could alter the tax consequences to holders of Standard BioTools Common Stock as described in this summary. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Additionally, this discussion does not address all U.S. federal income tax consequences relevant to holders of Standard BioTools Common Stock. In addition, it does not address consequences relevant to holders of Standard BioTools Common Stock that are subject to particular U.S. or non-U.S. tax rules, including, without limitation, to holders of Standard BioTools Common Stock that are: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">persons who do not hold their Standard BioTools Common Stock as a &#8220;capital asset&#8221; within the meaning of Section&#160;1221 of the Code; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">brokers, dealers or traders in securities, banks, insurance companies, other financial institutions or mutual funds; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">real estate investment trusts; regulated investment companies; tax-exempt organizations or governmental organizations; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">pass-through entities such as partnerships, S corporations, disregarded entities for federal income tax purposes and limited liability companies (and investors therein); </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">subject to the alternative minimum tax provisions of the Code; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">persons who hold their shares as part of a hedge, wash sale, synthetic security, conversion transaction or other integrated transaction; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">persons that have a functional currency other than the U.S. dollar; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">traders in securities who elect to apply a mark-to-market method of accounting; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">persons who hold shares of Standard BioTools Common Stock that may constitute &#8220;qualified small business stock&#8221; under Section&#160;1202 of the Code or as &#8220;Section&#160;1244 stock&#8221; for purposes of Section&#160;1244 of the Code; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">persons who acquired their shares of Standard BioTools Common Stock in a transaction subject to the gain rollover provisions of Section&#160;1045 of the Code; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">persons subject to special tax accounting rules as a result of any item of gross income with respect to Standard BioTools Common Stock being taken into account in an &#8220;applicable financial statement&#8221; (as defined in the Code); </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">persons deemed to sell Standard BioTools Common Stock under the constructive sale provisions of the Code; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">persons who acquired their shares of Standard BioTools Common Stock pursuant to the exercise of options or otherwise as compensation or through a tax-qualified retirement plan or through the exercise of a warrant or conversion rights under convertible instruments; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">expatriates or former citizens or long-term residents of the United States. </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">117<br></div></div></div>
<!--End Page 128-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 129-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_113-proposals_pg8"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Holders of Standard BioTools Common Stock subject to particular U.S. or non-U.S. tax rules, including those that are described in the preceding paragraph, are urged to consult their own tax advisors regarding the consequences to them of the reverse stock split. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If an entity that is treated as a partnership for U.S. federal income tax purposes (or any other pass-through entity) holds Standard BioTools Common Stock, the U.S. federal income tax treatment of a partner in the partnership or other pass-through entity will generally depend upon the status of the partner, the activities of the partnership or other pass-through entity and certain determinations made at the partner level. Partners of a partnership or other pass-through entity holding Standard BioTools Common Stock should consult their tax advisors regarding the tax consequences of the Merger. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, the following discussion does not address (a) any tax consequences of transactions effectuated before, after or at the same time as the reverse stock split, whether or not they are in connection with the reverse stock split, except as specifically provided below; (b) the tax consequences of the reverse stock split under state, local and foreign tax laws; (c) any U.S. federal non-income tax consequences of the reverse stock split, including estate, gift or other tax consequences; or (d) the Medicare contribution tax on net investment income. No ruling from the IRS has been or will be requested in connection with the reverse stock split. Standard BioTools stockholders should be aware that the IRS could adopt a position contrary to that set forth in this discussion and which could be sustained by a court. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">STOCKHOLDERS SHOULD CONSULT THEIR TAX ADVISORS WITH RESPECT TO THE APPLICATION OF THE U.S. FEDERAL INCOME TAX LAWS TO THEIR PARTICULAR SITUATIONS AS WELL AS ANY TAX CONSEQUENCES OF THE REVERSE STOCK SPLIT ARISING UNDER THE U.S. FEDERAL ESTATE OR GIFT TAX LAWS OR UNDER THE LAWS OF ANY STATE, LOCAL OR NON-U.S. TAXING JURISDICTION OR UNDER ANY APPLICABLE INCOME TAX TREATY.<font style="font-weight: normal;"> </font></div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Tax Considerations with Respect to the Reverse Stock Split </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The proposed reverse stock split is intended to constitute a &#8220;recapitalization&#8221; for U.S. federal income tax purposes pursuant to Section&#160;368(a)(1)(E) of the Code. As a result, a U.S. holder is not expected to recognize gain or loss upon the proposed reverse stock split, except with respect to cash received in lieu of a fractional share of Standard BioTools Common Stock, as discussed below. A U.S. holder&#8217;s aggregate adjusted tax basis in the shares of Standard BioTools Common Stock received pursuant to the proposed reverse stock split is expected to equal the aggregate adjusted tax basis of the shares of Standard BioTools Common Stock surrendered (excluding any portion of such basis that is allocated to any fractional share of Standard BioTools Common Stock), and such U.S. holder&#8217;s holding period in the shares of Standard BioTools Common Stock received is expected to include the holding period in the shares of Standard BioTools Common Stock surrendered. U.S. Treasury Regulations provide detailed rules for allocating the tax basis and holding period of the shares of Standard BioTools Common Stock surrendered to the shares of Standard BioTools Common Stock received in a recapitalization pursuant to the proposed reverse stock split. U.S. holders of shares of Standard BioTools Common Stock acquired on different dates and at different prices should consult their tax advisors regarding the allocation of the tax basis and holding period of such shares. </div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Cash in Lieu of Fractional Shares </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">A U.S. holder that receives cash in lieu of a fractional share of Standard BioTools Common Stock pursuant to the proposed reverse stock split is expected to recognize capital gain or loss in an amount equal to the difference between the amount of cash received and the U.S. holder&#8217;s tax basis in the shares of Standard BioTools Common Stock surrendered that is allocated to such fractional share of Standard BioTools Common Stock. Such capital gain or loss is expected to be long-term capital gain or loss if the U.S. holder&#8217;s holding period for Standard BioTools Common Stock surrendered exceeded one year at the reverse stock split effective time. </div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 15pt; margin-left: 0pt; text-align: left;">Tax Reporting Regarding the Reverse Stock Split </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Assuming the reverse stock split qualifies as a recapitalization within the meaning of Section&#160;368(a) of the Code, each U.S. holder who receives shares of Standard BioTools Common Stock in the reverse stock split is required to retain permanent records pertaining to the reverse stock split and make such records available to any authorized IRS officers and employees. Such records should specifically include information regarding the amount, basis, and fair market value of all transferred property and relevant facts regarding any liabilities assumed or extinguished as part of such reorganization. Each U.S. holder who owned at least five percent (by vote or value) of </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">118<br></div></div></div>
<!--End Page 129-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 130-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_113-proposals_pg9"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">the total outstanding stock of Standard BioTools or who owned securities in Standard BioTools with a basis of $1,000,000 or more are required to attach a statement to their tax returns for the year in which the reverse stock split is consummated that contains the information listed in Treasury Regulations Section&#160;1.368-3(b). Such statement must include the holder&#8217;s tax basis in the U.S. holder&#8217;s Standard BioTools Common Stock and the fair market value of such stock. Each U.S. holder is urged to consult with its tax advisor to comply with these rules. </div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 19pt; margin-left: 0pt; text-align: left;">Information Reporting and Backup Withholding </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Payments of cash made in lieu of a fractional share of Standard BioTools Common Stock may, under certain circumstances, be subject to information reporting and backup withholding. To prevent backup withholding, each holder of Standard BioTools Common Stock that does not otherwise establish an exemption should furnish its taxpayer identification number and comply with the applicable certification procedures. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Backup withholding is not an additional tax. Any amounts withheld will be allowed as a credit against the holder&#8217;s U.S. federal income tax liability and may entitle such holder to a refund, provided the required information is timely furnished to the IRS. Holders of Standard BioTools Common Stock should consult their tax advisors regarding their qualification for an exemption from backup withholding and the procedures for obtaining such an exemption. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Effects of the Name Change </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If the Standard BioTools stockholders approve the amendment to the Standard BioTools Charter effecting the name change, Standard BioTools will file the certificate of amendment to the Standard BioTools Charter with the Secretary of State of the State of Delaware upon the completion of the Merger. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Following the change of the Standard BioTools&#8217; corporate name, it is expected that the common stock of the combined company will trade on Nasdaq under the symbol &#8220;TRLN.&#8221; Stockholders will not experience any change in their rights as a stockholder as a result of this amendment to the Standard BioTools Charter. Stockholders will not be required to submit their stock certificates for exchange as a result of this proposed name change. Following the effective date of the name change, all new stock certificates issued will use the new name for the combined company. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Vote Required for Approval </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The approval of the Charter Amendment Proposal requires the affirmative vote of the holders of Standard BioTools&#8217; capital stock entitled to vote thereon, voting as a single class, by a majority of the votes cast for or against such Proposal at the Special Meeting. Abstentions will have no effect on the outcome of the vote for the Charter Amendment Proposal. If you fail to cast your vote, in person or by proxy, or fail to give voting instructions to your brokerage firm, bank, trust or other nominee, it will have no effect on the outcome of the vote for the Charter Amendment Proposal. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Merger is conditioned upon the approval of the Charter Amendment Proposal. If the Charter Amendment Proposal is not approved, the Merger will not occur. However, the Standard BioTools Board, without Treeline&#8217;s input, may determine to effect the reverse stock split, if it is approved by the Standard BioTools stockholders, even if the other proposals to be acted upon at the meeting are not approved, including the Share Issuance Proposal. For a detailed discussion of the conditions of the Merger, see &#8220;<font style="font-style: italic;">The Merger Agreement &#8212; Conditions to the Completion of the Merger</font>&#8221; beginning on page <a href="#tCONCOMMER">207</a> of this proxy statement/prospectus. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Certain Standard BioTools stockholders have agreed to vote any shares of Standard BioTools Common Stock owned by them in favor of the Charter Amendment Proposal. Please see the section titled &#8220;<font style="font-style: italic;">The Special Meeting &#8212; Voting Agreements</font>&#8221; beginning on page <a href="#tVOA">107</a> of this proxy statement/prospectus for more information. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<font style="font-weight: bold;">FOR</font>&#8221; the approval of the Charter Amendment Proposal. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Board Recommendation </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Standard BioTools Board recommends that Standard BioTools stockholders vote &#8220;FOR&#8221; the Charter Amendment Proposal.<font style="font-weight: normal;"> </font></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">119<br></div></div></div>
<!--End Page 130-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 131-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_113-proposals_pg10"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Proposal #3: The Post-Closing Equity Incentive Plan Proposal </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13pt; margin-left: 0pt; text-align: left;">Overview </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Standard BioTools stockholders are being asked to approve the Post-Closing Equity Incentive Plan of the combined company in the form attached as Annex&#160;I to this proxy statement/prospectus (the &#8220;Post-Closing Equity Incentive Plan&#8221;). The Standard BioTools Board initially approved the Post-Closing Equity Incentive Plan on July&#160;14, 2026, subject to Standard BioTools stockholder approval and the consummation of the Merger. If the Standard BioTools stockholders approve the Post-Closing Equity Incentive Plan and the Merger is consummated, the Post-Closing Equity Incentive Plan will become effective upon the later of (i) the Closing and (ii) the date this plan is approved by the Standard BioTools stockholders (the &#8220;Effective Date&#8221;). If the Post-Closing Equity Incentive Plan is not approved by the Standard BioTools stockholders, it will not become effective and no awards will be granted thereunder. The Post-Closing Equity Incentive Plan is described in more detail below. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13.5pt; margin-left: 0pt; text-align: left;">Reasons for the Proposal </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">At the Standard BioTools 2026 annual meeting held on June&#160;17, 2026, Standard BioTools stockholders approved the Standard BioTools 2026 Equity Incentive Plan (the &#8220;2026 EIP&#8221;), which replaced the Standard BioTools 2011&#160;Equity Incentive Plan (the &#8220;2011 EIP&#8221; and collectively with the 2026 EIP and the Treeline 2021&#160;Equity Incentive Plan, the &#8220;Prior Plans&#8221;). Although the 2026 EIP was approved only shortly before the date of this Proposal, the Standard BioTools Board has determined to adopt the Post-Closing Equity Incentive Plan in connection with the Merger in order to establish a single equity-compensation program sized and structured for the combined company, including to right-size the share pool available for future awards and to align award terms across the combined company following the Merger. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The purpose of the Post-Closing Equity Incentive Plan is to promote and closely align the interests of employees, officers, directors and other service providers of the combined company and its stockholders by providing stock-based compensation and other performance-based compensation. The objectives of the Post-Closing Equity Incentive Plan are to attract and retain the best available employees, officers, directors and other service providers for positions of substantial responsibility and to motivate participants to optimize the profitability and growth of the combined company through incentives that link the personal interests of participants to those of the combined company&#8217;s stockholders. The Post-Closing Equity Incentive Plan allows for the grant of stock options, stock appreciation rights, restricted stock, restricted stock units and other stock-based awards. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13.5pt; margin-left: 0pt; text-align: left;">Treatment of Existing Equity Plans </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If the Post-Closing Equity Incentive Plan becomes effective at the Effective Date: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">no further awards will be granted under the 2026 EIP on or after the effective date of the Post-Closing Equity Incentive Plan; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">all awards outstanding under the Prior Plans as of the Closing will remain outstanding and continue to be governed by the terms of the applicable plan and award agreement under which they were granted (as adjusted pursuant to the exchange ratio for the awards under the Treeline 2021 Equity Incentive Plan);</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any shares that, as of the Effective Date of the Post-Closing Equity Incentive Plan, remain available for issuance and are not subject to outstanding awards under the 2026 EIP and the Treeline 2021 Equity Incentive Plan (as adjusted pursuant to the exchange ratio) will be available for issuance under the Post-Closing Equity Incentive Plan; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any shares that, after the Effective Date of the Post-Closing Equity Incentive Plan, are subject to outstanding awards under the Prior Plans (as adjusted pursuant to the exchange ratio for the awards under the Treeline 2021 Equity Incentive Plan) that are forfeited, expire or are cancelled, or are withheld or reacquired by combined company to pay an exercise price or satisfy a tax-withholding obligation, will be recycled and again become available for issuance under the Post-Closing Equity Incentive Plan. </div></td></tr></table><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13.5pt; margin-left: 0pt; text-align: left;">Summary of the Post-Closing Equity Incentive Plan </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following summary of the material terms of the Post-Closing Equity Incentive Plan is qualified in its entirety by reference to the full text of the plan attached as Annex&#160;I. Capitalized terms used but not defined in this summary have the meanings given in the Post-Closing Equity Incentive Plan. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">120<br></div></div></div>
<!--End Page 131-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 132-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_113-proposals_pg11"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Eligibility </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Employees, non-employee directors and consultants of the combined company and its parents, subsidiaries and affiliates are eligible to receive awards, except that incentive stock options (&#8220;ISOs&#8221;) may be granted only to employees of the combined company and its parent and subsidiary corporations. As of June&#160;30, 2026, approximately 129 employees, six non-employee directors and one consultant would be eligible to participate. Because the combined company&#8217;s workforce following the Merger will differ from Standard BioTools&#8217; current workforce, following the closing of the Merger, approximately 175 employees, 10 non-employee directors and 20 consultants of the combined company are expected to be eligible to participate in the Post-Closing Equity Incentive Plan. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Administration </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Post-Closing Equity Incentive Plan will be administered by the compensation committee of the board of the combined company or by the board of the combined company acting in place of the compensation committee. Subject to the terms and conditions of the Post-Closing Equity Incentive Plan, the administrator will have the authority, among other things, to select the persons to whom awards may be granted, construe and interpret the Post-Closing Equity Incentive Plan, determine the terms of awards and prescribe, amend, and rescind the rules and regulations relating to the Post Closing Equity Incentive Plan or any award granted thereunder. The Post-Closing Equity Incentive Plan provides that the administrator may delegate its authority, including the authority to grant awards, to one or more executive officers to the extent permitted by applicable law, provided that awards granted to non-employee directors may only be determined by the board of the combined company. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Shares Subject to the Plan; Automatic Annual Increase; Dilutive Impact </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Standard BioTools has initially reserved 200,000,000 shares of the combined company&#8217;s common stock for issuance pursuant to awards granted under the Post-Closing Equity Incentive Plan, plus (a) the shares that, as of the Effective Date, remain available for issuance and are not subject to outstanding awards under the 2026 EIP; (b) the shares that, as of the Effective Date, remain available for issuance and are not subject to outstanding awards under the Treeline 2021&#160;Equity Incentive Plan (as adjusted pursuant to the exchange ratio, which is currently anticipated to be approximately 1:11.6997); (c) shares subject to awards outstanding under the Prior Plans that, after the effective date, cease to be subject to such awards by forfeiture, termination or otherwise; (d) shares issued under the Prior Plans that are repurchased by the combined company or are otherwise forfeited; and (e) shares subject to awards under the Prior Plans that are used to pay the exercise price of a stock option or withheld to satisfy tax-withholding obligations. Any shares added to the reserve as described in clauses (a) through (e) will be issuable as the combined company&#8217;s common stock. All numbers set forth in this section are on a pre-reverse stock split basis. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The number of shares available for grant and issuance under the Post-Closing Equity Incentive Plan will increase automatically on January&#160;1 of each of the first ten (10) calendar years during the term of the plan by the lesser of (a)&#160;5%&#160;of the sum of the total number of shares of all classes of the combined company&#8217;s common stock, the total number of shares of the combined company&#8217;s common stock subject to pre-funded warrants (if any), and the total number of shares of the combined company&#8217;s common stock issuable upon the conversion of any preferred stock (if any), in each case outstanding on the immediately preceding December&#160;31, and (b) such smaller number of shares as may be determined by the board of the combined company or the compensation committee. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, the following shares will again become available for issuance under the Post-Closing Equity Incentive Plan: (i) shares subject to options or stock appreciation rights granted under the Post-Closing Equity Incentive Plan that cease to be subject to the option or stock appreciation right for any reason other than exercise of the option or stock appreciation right; (ii) shares subject to awards granted under the Post-Closing Equity Incentive Plan that are forfeited or repurchased by the combined company at the original purchase price; (iii) shares subject to awards granted under the Post-Closing Equity Incentive Plan that otherwise terminate without such shares being issued; and (iv) shares subject to awards granted under the Post-Closing Equity Incentive Plan that are surrendered pursuant to an Exchange Program. To the extent an award is paid out in cash or other property rather than shares, the cash payment will not reduce the number of shares available for issuance under the Post-Closing Equity Incentive Plan, and shares used to pay the exercise price of an award or withheld to satisfy the tax-withholding obligations related to an award will become available for future grant under the Post-Closing Equity Incentive Plan. Awards substituted or assumed in an acquisition do not reduce the share reserve. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As of June&#160;30, 2026, approximately 391,462,923 shares of Standard BioTools Common Stock were outstanding, and the closing price of a share of Standard BioTools Common Stock on that date was $0.82. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">121<br></div></div></div>
<!--End Page 132-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 133-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_113-proposals_pg12"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As of June&#160;30, 2026, awards covering an aggregate of approximately 34,888,779 shares of Standard BioTools Common Stock were outstanding under the 2011 EIP, consisting of (i) options to purchase approximately 15,904,085 shares, with a weighted-average exercise price of $1.59 per share and a weighted-average remaining term of approximately 8.7 years, and (ii) approximately 18,984,694 shares subject to outstanding restricted stock units. In addition, approximately 22,722,747 shares remained available for future grant under the 2026 EIP as of that date. As of June 30, 2026, no awards were outstanding under the 2026 EIP. For additional information regarding Standard BioTools&#8217; equity compensation plans, see &#8220;<font style="font-style: italic;">Proposal #3: The Post-Closing Equity Incentive Plan Proposal &#8212; Summary of the Post-Closing Equity Incentive Plan &#8212; Equity Compensation Plan Information as of December&#160;31, 2025</font>&#8221;.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As of June 30, 2026, awards covering an aggregate of approximately 22,260,755 shares of Treeline Common Stock (which, based on the currently estimated exchange ratio of 1:11.6997 would be 260,444,155 shares of Standard BioTools Common Stock) were outstanding under the Treeline 2021 Equity Incentive Plan, consisting of (i) options to purchase approximately 260,444,155 shares (on an as-converted basis, based on the currently estimated exchange ratio), with a weighted-average exercise price of $1.885 per share (on an as-converted basis, based on the currently estimated exchange ratio) and a weighted-average remaining term of approximately 7.76 years, and (ii) approximately zero shares subject to outstanding restricted stock units (on an as-converted basis, based on the currently estimated exchange ratio). In addition, approximately 95,236,997 shares (on an as-converted basis, based on the currently estimated exchange ratio) remained available for future grant under the Treeline 2021 Equity Incentive Plan as of that date. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Standard BioTools has initially reserved 200,000,000 shares of the combined company common stock for issuance under the Post-Closing Equity Incentive Plan. In addition to the initial share reserve, as of June 30, 2026, approximately 22,722,747 shares of Standard BioTools Common Stock remained available for future grant under the 2026 EIP, which was approved by Standard BioTools stockholders at its 2026&#160;annual meeting, and approximately 95,236,997 shares represent shares that remained available for future grant under the Treeline 2021 Equity Incentive Plan (on an as-converted basis, based on the currently estimated exchange ratio). The shares reserved under the Post-Closing Equity Incentive Plan (including the shares available for future grant under the 2026 EIP as of June 30, 2026 and the shares available for future grant under the Treeline 2021 Equity Incentive Plan (on an as-converted basis, based on the currently estimated exchange ratio)) are estimated to represent approximately 12% of the shares of combined company&#8217;s common stock anticipated to be outstanding immediately following the Effective Time. This share reserve is subject to the automatic annual increase described above. In light of the combined company&#8217;s need to attract, retain and motivate employees, officers, directors and other service providers following the Merger, the Standard BioTools Board believes that the size of the share reserve, and the resulting potential dilution to Standard BioTools&#8217; stockholders, is reasonable. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">ISO Limit </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The maximum number of shares of the combined company that may be issued on the exercise of ISOs is 1,000,000,000. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Types of Awards </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Post-Closing Equity Incentive Plan provides for the grant of stock options (including ISOs and nonqualified stock options), stock appreciation rights, restricted stock awards, restricted stock units, performance awards, and stock bonus awards. ISOs may be granted only to employees of the combined company and its parent and subsidiary corporations; all other awards may be granted to employees, non-employee directors and consultants. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Options<font style="font-style: normal;">. The Post-Closing Equity Incentive Plan provides for the grant of both ISOs intended to qualify under Section&#160;422 of the Code, and non-statutory stock options to purchase shares of the combined company&#8217;s common stock at a stated exercise price. ISOs may only be granted to employees, including officers and directors who are also employees. The exercise price of stock options granted under the Post-Closing Equity Incentive Plan must be at least equal to the fair market value of the combined company&#8217;s common stock on the date of grant. ISOs granted to an individual who holds, directly or by attribution, more than ten percent of the total combined voting power of all classes of the combined company&#8217;s capital stock must have an exercise price of at least 110% the fair market value of the combined company&#8217;s common stock on the date of grant. Options may vest based on service and/or achievement of performance conditions, as determined by the administrator. The administrator may provide for options to be exercised only as they vest or to be immediately exercisable, with any shares issued on exercise </font></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">122<br></div></div></div>
<!--End Page 133-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 134-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_113-proposals_pg13"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">generally being subject to the combined company&#8217;s right of repurchase that lapses as the shares vest. The maximum term of options granted under the Post-Closing Equity Incentive Plan is ten years from the date of grant, except that the maximum permitted term of ISOs granted to an individual who holds, directly or by attribution, more than ten percent of the total combined voting power of all classes of the combined company&#8217;s capital stock is five years from the date of grant. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Stock Appreciation Rights<font style="font-style: normal;">. A stock appreciation right provides for a payment, in cash or shares of the combined company&#8217;s common stock up to a specified maximum of shares, if determined by the administrator, to the participant based upon the difference between the fair market value of the combined company&#8217;s common stock on the date of exercise and a predetermined exercise price, multiplied by the number of shares. Stock appreciation rights may vest based on service and/or achievement of performance conditions. No stock appreciation right may have a term that is longer than ten years from the date of grant. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Restricted Stock Awards<font style="font-style: normal;">. A restricted stock award is an offer by the combined company to grant or sell shares of the combined company&#8217;s common stock subject to restrictions, which may lapse based on the satisfaction of service and/or achievement of performance conditions. The price, if any, of a restricted stock award will be determined by the administrator. Holders of restricted stock awards, unlike holders of options, will have the right to vote and any dividends or distributions paid with respect to such shares will be subject to the same vesting terms and other restrictions as the restricted stock award and will be accrued and paid when the vesting terms on such shares lapse. Unless otherwise determined by the administrator, vesting will cease on the date the participant no longer provides services to the combined company and unvested shares may be forfeited to or repurchased by the combined company. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Restricted Stock Units<font style="font-style: normal;">. Restricted stock units represent the right to receive shares of the combined company&#8217;s common stock at a specified date in the future and may be subject to vesting based on service and/or achievement of performance conditions. Restricted stock units may be settled in cash, shares of the combined company&#8217;s common stock, or a combination of both as soon as practicable following vesting or on a later date subject to the terms of the Post-Closing Equity Incentive Plan and any applicable award agreement, which may provide for settlement only in shares. No restricted stock unit may have a term that is longer than ten years from the date of grant. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Performance Awards<font style="font-style: normal;">. Performance awards granted pursuant to the Post-Closing Equity Incentive Plan may be in the form of a cash bonus, or an award of performance shares or performance units denominated in shares of the combined company&#8217;s common stock that may be settled in cash, property, or by issuance of those shares, subject to the satisfaction or achievement of specified performance conditions. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Stock Bonus Awards<font style="font-style: normal;">. A stock bonus award provides for payment in the form of cash, shares of the combined company&#8217;s common stock or a combination thereof, based on the fair market value of shares subject to such award as determined by the administrator. The awards may be granted as consideration for services already rendered, or at the discretion of the administrator, may be subject to vesting restrictions based on continued service and/or performance conditions. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Dividend Equivalent Rights<font style="font-style: normal;">. Dividend equivalent rights may be granted at the discretion of the administrator and represent the right to receive the value of dividends, if any, paid by the combined company in respect of the number of shares of the combined company&#8217;s common stock underlying an award. Dividend equivalent rights will be subject to the same vesting or performance conditions as the underlying award and will be paid only when the underlying award becomes vested or may be deemed to have been reinvested by the combined company. </font></div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Non-Employee Director Compensation Limit </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The aggregate value of awards granted under the plan to any non-employee director, together with cash compensation paid for service as a non-employee director, may not exceed $1,000,000 in the calendar year in which the director first joins the combined company board of directors and $750,000 in each subsequent calendar year (with equity valued at grant-date fair value). </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Adjustments </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In the event of a change in the number or class of outstanding shares of the combined company&#8217;s common stock by reason of a stock dividend, extraordinary dividend or distribution (other than a regular cash dividend), recapitalization, stock split, reverse stock split, subdivision, combination, consolidation, reclassification, spin-off, or similar change in the combined company&#8217;s capital structure, proportional adjustments will be made to (i) the number </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">123<br></div></div></div>
<!--End Page 134-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 135-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_113-proposals_pg14"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">and class of shares reserved for issuance under the Post-Closing Equity Incentive Plan, (ii) the exercise prices, number and class of shares subject to outstanding options or stock appreciation rights, (iii) the number and class of shares subject to other outstanding awards, and (iv) the maximum number of shares that may be issued as ISOs under the Post-Closing Equity Incentive Plan, subject to any required action by the combined company&#8217;s board of directors or its stockholders and compliance with applicable laws. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Corporate Transactions / Change in Control </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Post-Closing Equity Incentive Plan provides that, in the event of a Corporate Transaction, outstanding awards will be subject to the agreement evidencing the Corporate Transaction, which need not treat all outstanding awards in an identical manner, and may include one or more of the following: (i) the continuation of the outstanding awards, (ii) the assumption of the outstanding awards by the surviving corporation, acquiring company or its parents, (iii) the substitution by the surviving corporation, acquiring company or its parents of equivalent equity awards for the outstanding awards, (iv) the full or partial acceleration of exercisability or vesting or lapse of the combined company&#8217;s right to repurchase or other terms of forfeiture and accelerated expiration of the award, (v) the settlement of the full value of the outstanding awards, whether or not then vested or exercisable, in cash, cash equivalents, or securities of the successor entity (or its parent) with a fair market value equal to the required amount, as determined in accordance with the Post-Closing Equity Incentive Plan, which payments may be deferred until the date or dates the award would have become exercisable or vested, or (vi) the cancellation of outstanding awards for no consideration.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In the event the successor or the acquiring company refuses to assume, convert, replace, or substitute awards as provided above pursuant to a Corporate Transaction, the administrator will notify each participant that such award will, if exercisable, be exercisable or vested for a period of time determined by the administrator and expire after such period. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Notwithstanding the foregoing, upon the occurrence of a Corporate Transaction, the vesting of all awards granted to non-employee directors will accelerate and such awards will become exercisable, to the extent applicable, and vested in full immediately prior to the consummation of the Corporate Transaction. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Exchange, Repricing and Buy-Out of Awards </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The administrator may, without prior stockholder approval, (i) reduce the exercise price of outstanding options or stock appreciation rights without the consent of any participant (provided that the exercise price may not be reduced below the fair market value on the date of the reduction) and (ii) pay cash or issue new awards in exchange for the surrender and cancellation of any, or all, outstanding awards, subject to the consent of any affected participant to the extent required by the terms of the Post-Closing Equity Incentive Plan. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Transferability </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Except in limited circumstances, awards granted under the Post-Closing Equity Incentive Plan may generally not be transferred in any manner other than by will or by the laws of descent and distribution. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Amendment and Termination </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The combined company&#8217;s Board or the compensation committee may amend the Post-Closing Equity Incentive Plan at any time, subject to stockholder approval as may be required by applicable law or listing standards; no amendment or termination may adversely affect any then-outstanding award without the consent of the affected participant, except as necessary to comply with applicable law or as otherwise provided by the plan. Unless earlier terminated, the plan will terminate ten years after the date the combined company&#8217;s Board adopts the plan.</div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Sub-Plans </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Subject to the terms of the Post-Closing Equity Incentive Plan, the administrator may establish a sub-plan under the Post-Closing Equity Incentive Plan and/or modify the terms of awards granted to participants outside of the United States to comply with any laws or regulations applicable to any such jurisdiction. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Clawback </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">All awards are subject to clawback or recoupment under any compensation recovery policy adopted by the Standard BioTools Board or the board of the combined company required by applicable law, as well as the company&#8217;s insider-trading policy. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">124<br></div></div></div>
<!--End Page 135-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 136-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_113-proposals_pg15"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Material U.S. Federal Income Tax Consequences </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following is a summary of the U.S. federal income tax treatment applicable to the combined company and the participants who receive awards under the Post-Closing Equity Incentive Plan based on the federal income tax laws in effect on the date of this proxy statement/prospectus. This summary is not intended to be exhaustive and does not address all matters relevant to a particular participant based on their specific circumstances. The summary expressly does not discuss the income tax laws of any state, municipality, or non-U.S. taxing jurisdiction, or the gift, estate, excise (including the rules applicable to deferred compensation under Section&#160;409A of the Code), or tax laws other than U.S. federal income tax law. Because individual circumstances may vary, each participant is urged to consult their own tax advisor concerning the tax implications of awards granted under the Post-Closing Equity Incentive Plan. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Incentive Stock Options </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Options granted under the Post-Closing Equity Incentive Plan may be either ISOs, which are intended to satisfy the requirements of Section&#160;422 of the Code, or non-qualified stock options, which are not intended to meet such requirements. No taxable income is recognized by the optionee at the time of the ISO grant, and no taxable income is recognized for ordinary income tax purposes at the time the option is exercised, although taxable income may arise at that time for alternative minimum tax purposes. Unless there is a &#8220;disqualifying disposition&#8221;, as described below, the ISO optionee will recognize long-term capital gain in an amount equal to the excess of (i) the amount realized upon the sale or other disposition of the purchased shares over (ii) the exercise price paid for the shares. A disqualifying disposition occurs if the disposition is less than two years after the date of grant or less than one year after the exercise date. If there is a disqualifying disposition of the shares, then the excess of (i)&#160;the fair market value of those shares on the exercise date or (if less) the amount realized upon such sale or disposition over (ii) the exercise price paid for the shares will be taxable as ordinary income to the optionee. Any additional gain or loss recognized upon the disposition will be a capital gain or loss. If the ISO optionee makes a disqualifying disposition of the purchased shares, then the combined company will be entitled to an income tax deduction for the taxable year in which such disposition occurs equal to the amount of ordinary income recognized by the optionee as a result of the disposition. The combined company will not be entitled to any income tax deduction if the optionee makes a qualifying disposition of the shares. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Nonqualified Stock Options </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">No taxable income is recognized by an optionee upon the grant of a non-qualified stock option. The optionee in general will recognize ordinary income, in the year in which the option is exercised, equal to the excess of the fair market value of the purchased shares on the exercise date over the exercise price paid for the shares, and the optionee will be required to satisfy the tax withholding requirements applicable to such income. The combined company will be entitled to an income tax deduction equal to the amount of ordinary income recognized by the optionee with respect to the exercised non-qualified stock option. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Stock Appreciation Rights </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">No taxable income is recognized upon receipt of a stock appreciation right. The participant will recognize ordinary income in the year in which the SAR is exercised, in an amount equal to the excess of the fair market value of the underlying shares of common stock on the exercise date over the exercise price in effect for the exercised right, and the participant will be required to satisfy the tax withholding requirements applicable to such income. The combined company will be entitled to an income tax deduction equal to the amount of ordinary income recognized by the participant in connection with the exercise of the stock appreciation right. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Restricted Stock Awards </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">A participant who receives unvested shares of combined company common stock will not recognize any taxable income at the time those shares are granted but will have to report as ordinary income, as and when those shares subsequently vest, an amount equal to the excess of (i) the fair market value of the shares on the vesting date over (ii) the cash consideration (if any) paid for the shares. The participant may, however, elect under Section&#160;83(b) of the Code to include as ordinary income in the year the unvested shares are issued an amount equal to the excess of (a) the fair market value of those shares on the issue date over (b) the cash consideration (if any) paid for such </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">125<br></div></div></div>
<!--End Page 136-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 137-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_113-proposals_pg16"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">shares. If the Section&#160;83(b) election is made, the participant will not recognize any additional income as and when the shares subsequently vest. The combined company will be entitled to an income tax deduction equal to the amount of ordinary income recognized by the participant at the time such ordinary income is recognized by the participant. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Restricted Stock Units and Other Stock-Based Awards </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Generally, no taxable income is recognized upon the grant of RSUs or other stock-based awards. The participant will recognize ordinary income in the year in which the award is settled in shares or cash. The amount of that income will be equal to the fair market value of the shares on the date of issuance or the amount of the cash paid in settlement of the award, and the participant will be required to satisfy the tax withholding requirements applicable to the income. The combined company will be entitled to an income tax deduction equal to the amount of ordinary income recognized by the participant at the time the shares are issued or the cash amount is paid. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Deductibility of Executive Compensation </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Section&#160;162(m) of the Code limits the deductibility for federal income tax purposes of certain compensation paid to any &#8220;covered employee&#8221; in excess of $1&#160;million. It is expected that compensation deductions for any covered employee with respect to awards granted under the Post-Closing Equity Incentive Plan will be subject to the $1&#160;million annual deduction limitation. The administrator of the Post-Closing Equity Incentive Plan may grant awards under the Post-Closing Equity Incentive Plan or otherwise that are or may become non-deductible when it believes doing so is in the best interests of the combined company and its stockholders. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">New Plan Benefits </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Because awards are granted at the compensation committee&#8217;s discretion, the benefits or amounts that will be received under the Post-Closing Equity Incentive Plan are not determinable at this time. Accordingly, a New Plan Benefits table is not provided.</div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Equity Compensation Plan Information as of December 31, 2025 </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="margin-top: 4pt; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 204pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.17pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.17pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 79.18pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.16pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.16pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 67.98pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.16pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.16pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 79.85pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 204pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Plan Category</div></td><td style="width: 6.17pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.17pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 79.18pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of securities <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">to <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">be issued upon exercise <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">of outstanding options, <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">warrants and rights</div></td><td style="width: 6.16pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.16pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 67.98pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Weighted average <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">exercise price of <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">outstanding <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">options, <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">warrants and rights</div></td><td style="width: 6.16pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.16pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 79.85pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of securities <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">remaining available for <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">future issuance under <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">equity compensation <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">plans <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(excluding securities <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">reflected in column (a)) </div></td></tr><tr class="BRDSX_header"><td style="width: 204pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 6.17pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.17pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 79.18pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(a)</div></td><td style="width: 6.16pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.16pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 67.98pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(b)</div></td><td style="width: 6.16pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.16pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 79.85pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(c)</div></td></tr><tr><td style="width: 204pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Equity compensation plans approved by security holders<br></div></td><td style="width: 6.17pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.17pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 79.18pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6.16pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.16pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 67.98pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6.16pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.16pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 79.85pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 204pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2011 Equity Incentive Plan<font style="padding-left: 2.72pt;"></font></div></td><td style="width: 6.17pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.17pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 79.18pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.08pt; text-align: left;">29,231,388</div></td><td style="width: 6.16pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.16pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 67.98pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.74pt; text-align: left;">$1.97</div></td><td style="width: 6.16pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.16pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 79.85pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.43pt; text-align: left;">23,633,056 </div></td></tr><tr><td style="width: 204pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2017 Employee Stock Purchase Plan<font style="padding-left: 4.31pt;"></font></div></td><td style="width: 6.17pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.17pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 79.18pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.08pt; text-align: left;"><font style="padding-left: 35pt;">&#8212;</font></div></td><td style="width: 6.16pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.16pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 67.98pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.74pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td style="width: 6.16pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.16pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 79.85pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.43pt; text-align: left;"><font style="padding-left: 12.5pt;">465,087</font> </div></td></tr><tr><td style="width: 204pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Equity compensation plans not approved by security holders<br></div></td><td style="width: 6.17pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.17pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 79.18pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6.16pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.16pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 67.98pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6.16pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.16pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 79.85pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 204pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2022 Inducement Equity Incentive Plan<font style="padding-left: 2.64pt;"></font></div></td><td style="width: 6.17pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.17pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 79.18pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.08pt; text-align: left;"><font style="padding-left: 5pt;">7,262,607</font></div></td><td style="width: 6.16pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.16pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 67.98pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.74pt; text-align: left;">$3.99</div></td><td style="width: 6.16pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.16pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 79.85pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.43pt; text-align: left;"><font style="padding-left: 12.5pt;">964,839</font> </div></td></tr><tr><td style="width: 204pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2017 Inducement Incentive Plan<font style="padding-left: 1.81pt;"></font></div></td><td style="width: 6.17pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.17pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 79.18pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.08pt; text-align: left;"><font style="padding-left: 35pt;">&#8212;</font></div></td><td style="width: 6.16pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.16pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 67.98pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.74pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td style="width: 6.16pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.16pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 79.85pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.43pt; text-align: left;"><font style="padding-left: 17.5pt;">60,616</font> </div></td></tr><tr><td style="width: 204pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">SomaLogic Equity Incentive Plans<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup><font style="padding-left: 3.61pt;"></font></div></td><td style="width: 6.17pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.17pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 79.18pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.08pt; text-align: left;">15,531,391</div></td><td style="width: 6.16pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.16pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 67.98pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.74pt; text-align: left;">$4.70</div></td><td style="width: 6.16pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.16pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 79.85pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.43pt; text-align: left;"><font style="padding-left: 35pt;">&#8212;</font></div></td></tr><tr><td style="width: 204pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total<font style="padding-left: 1.09pt;"></font></div></td><td style="width: 6.17pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.17pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 79.18pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.08pt; text-align: left;">52,025,386</div></td><td style="width: 6.16pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.16pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 67.98pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.74pt; text-align: left;">$3.68</div></td><td style="width: 6.16pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.16pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 79.85pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.43pt; text-align: left;">25,123,598</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 204pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.17pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.17pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 79.18pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.16pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.16pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 67.98pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.16pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.16pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 79.85pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div><div class="BRDSX_rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 12.75pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Consists of the SomaLogic 2009 Equity Incentive Plan, the SomaLogic 2017 Equity Incentive Plan, and the SomaLogic 2021 Omnibus Incentive Plan. </div></td></tr></table><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13.5pt; margin-left: 0pt; text-align: left;">Registration with the SEC </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If the Post-Closing Equity Incentive Plan is approved by Standard BioTools&#8217; stockholders and becomes effective, subject to the Closing, the combined company intends to file a registration statement on Form&#160;S-8, as soon as reasonably practicable after the Closing, registering the shares reserved for issuance under the Post-Closing Equity Incentive Plan. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">126<br></div></div></div>
<!--End Page 137-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 138-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_113-proposals_pg17"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Vote Required for Approval </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The approval of the Post-Closing Equity Incentive Plan Proposal requires the affirmative vote of a majority of the voting power of the shares of Standard BioTools&#8217; capital stock present virtually or represented by proxy at the Special Meeting and entitled to vote on such Proposal at the Special Meeting. Abstentions will have the same effect as a vote &#8220;<font style="font-weight: bold;">AGAINST</font>&#8221; the Post-Closing Equity Incentive Plan Proposal. If you fail to cast your vote, in person or by proxy, or fail to give voting instructions to your brokerage firm, bank, trust or other nominee, it will have no effect on the outcome of the vote for the Post-Closing Equity Incentive Plan Proposal. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Certain Standard BioTools stockholders have agreed to vote any shares of Standard BioTools Common Stock owned by them in favor of the Post-Closing Equity Incentive Plan Proposal. Please see the section titled &#8220;<font style="font-style: italic;">The&#160;Special Meeting &#8211;Voting Agreements</font>&#8221; beginning on page <a href="#tVOA">107</a> of this proxy statement/prospectus for more information. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<font style="font-weight: bold;">FOR</font>&#8221; the approval of the Post-Closing Equity Incentive Plan Proposal. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Merger is not conditioned on the approval of the Post-Closing Equity Incentive Plan Proposal. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Board Recommendation </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Standard BioTools Board recommends that Standard BioTools stockholders vote &#8220;FOR&#8221; the Post-Closing Equity Incentive Plan Proposal.<font style="font-weight: normal;"> </font></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">127<br></div></div></div>
<!--End Page 138-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 139-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_113-proposals_pg18"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Proposal #4: The Post-Closing ESPP Proposal </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13pt; margin-left: 0pt; text-align: left;">Overview </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Standard BioTools stockholders are being asked to approve the Post-Closing Employee Stock Purchase Plan of the combined company in the form attached as Annex&#160;J to this proxy statement/prospectus (the &#8220;Post-Closing ESPP&#8221;). The Standard BioTools Board initially approved the Post-Closing ESPP on July 14, 2026, subject to Standard BioTools stockholder approval and the consummation of the Merger. If the Standard BioTools stockholders approve the Post-Closing ESPP, and the Merger is consummated, the Post-Closing ESPP will become effective upon the later of (i) the Closing and (ii) the date this plan is approved by the Standard BioTools stockholders. If the Post-Closing ESPP is not approved by the Standard BioTools stockholders, it will not become effective. The Post-Closing ESPP is described in more detail below. Capitalized terms used but not defined in this summary have the meanings given in the Post-Closing ESPP. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The purpose of the Post-Closing ESPP is to provide employees of the combined company and its designated subsidiaries with an opportunity to purchase shares of the combined company common stock through accumulated contributions. The Post-Closing ESPP, and the rights of participants to make purchases thereunder, is intended to qualify under Section&#160;423 of the Code; however, sub-plans that do not meet the requirements of Section&#160;423 of the Code may be established for the benefit of eligible employees of non-U.S. subsidiaries of the combined company. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13.5pt; margin-left: 0pt; text-align: left;">Post-Closing Employee Stock Purchase Plan </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following summary is qualified in its entirety by reference to the text of the Post-Closing ESPP, a copy of which is attached as Annex&#160;J to this proxy statement/prospectus. Standard BioTools stockholders should refer to the Post-Closing ESPP for more complete and detailed information about the terms and conditions of the Post-Closing ESPP. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13.5pt; margin-left: 0pt; text-align: left;">Eligibility </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Employees eligible to participate in any offering pursuant to the Post-Closing ESPP generally include any employee that is employed by the combined company or certain of its designated subsidiaries or affiliates at the beginning of the offering period. However, the administrator may exclude employees who have been employed for less than two&#160;years, are customarily employed for 20 hours or less per week, are customarily employed for five months or less in a calendar year, certain highly compensated employees as determined in accordance with applicable tax laws, and certain employees who are citizens or residents of a foreign jurisdiction if such participation is prohibited under applicable local laws or would violate the requirements of Section&#160;423 of the Code (with respect to an offering under the Section&#160;423 Component). In addition, any employee who owns, or is deemed to own because of attribution rules, 5% or more of the total combined voting power or value of all classes of the combined company&#8217;s capital stock, or the capital stock of one of its qualifying subsidiaries, or who will own such amount because of participation in the Post-Closing ESPP, will not be eligible to participate in the Post-Closing ESPP. The administrator may impose additional restrictions on eligibility from time to time. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As of June&#160;30, 2026, approximately 120 employees would be eligible to participate in the Post-Closing ESPP. Because the combined company&#8217;s workforce following the Merger will differ from Standard BioTools&#8217; current workforce, following the closing of the Merger, approximately 175 employees of the combined company are expected to be eligible to participate in the Post-Closing ESPP. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13.5pt; margin-left: 0pt; text-align: left;">Shares Subject to the Plan; Automatic Annual Increase </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Standard BioTools has initially reserved 26,865,998 shares of the combined company&#8217;s common stock for issuance pursuant to awards granted under the Post-Closing ESPP. All numbers set forth in this section are on a pre-reverse stock split basis. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The ESPP Share Pool will increase automatically on January&#160;1 of each of the first ten (10) calendar years during the term of the plan by the lesser of (a) 1% of the sum of the total number of shares of all classes of the combined company&#8217;s common stock, the total number of shares of the combined company&#8217;s common stock subject to pre-funded warrants (if any), and the total number of shares of the combined company&#8217;s common stock issuable upon the conversion of any preferred stock (if any), in each case outstanding on the immediately preceding December&#160;31, and (b) such smaller number of shares as may be determined by the board of the combined company or the compensation committee. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">128<br></div></div></div>
<!--End Page 139-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 140-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_113-proposals_pg19"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Share Limit </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The maximum number of shares of the combined company&#8217;s common stock that may be issued pursuant to the Post-Closing ESPP is 270,000,000. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Offering and Purchase Periods </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under the Post-Closing ESPP, eligible employees will be offered the option to purchase shares of the combined company&#8217;s common stock at a discount over a series of offering periods through accumulated payroll deductions over the period. Each offering period may itself consist of one or more purchase periods. No offering period may be longer than 27 months. Unless the administrator determines otherwise, offering periods will be approximately six&#160;months with a single six-month purchase period. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Contributions; Purchase Price </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">A participant may contribute, through payroll deductions, from 1% up to 15% of his or her eligible compensation (generally, base salary or regular hourly wages), subject to the limits below. The purchase price for shares purchased under the Post-Closing ESPP during any given purchase period will be 85% of the lesser of the fair market value of the combined company&#8217;s common stock on (1) the first trading day of the applicable offering period or (2) the last trading day of the applicable purchase period. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Limitations </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">No participant may purchase more than 5,000 shares of the combined company&#8217;s common stock on any one purchase date and may not subscribe for more than $25,000 in fair market value of shares of the combined company&#8217;s common stock, determined as of the date the offering period commences, in any calendar year in which the offering is in effect. The administrator in its discretion may set a higher or lower maximum number of shares which may be purchased for a subsequent purchase period. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Withdrawal </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">A participant may withdraw from an offering before the purchase date, in which case the participant&#8217;s accumulated payroll deductions will be refunded without interest; termination of employment ends participation, with accumulated contributions refunded without interest. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Adjustments Upon Recapitalization </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If the number or class of outstanding shares of the combined company&#8217;s common stock is changed by stock dividend, recapitalization, stock split, reverse stock split, subdivision, combination, reclassification or similar change in the combined company&#8217;s capital structure without consideration, then the administrator will proportionately adjust the number or class of shares of the combined company&#8217;s common stock that are available under the Post-Closing ESPP, the purchase price and number or class of shares any participant has elected to purchase as well as the maximum number of shares which may be purchased by participants. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Corporate Transaction </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If the combined company is subject to a Corporate Transaction (as defined in the Post-Closing ESPP), the offering period then in effect will be shortened by setting a new purchase date and will end on that new purchase date. The new purchase date will occur on or prior to the consummation of the Corporate Transaction, as determined by the board of the combined company Board or the compensation committee, and the Post-Closing ESPP will terminate on the consummation of the Corporate Transaction. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Transferability </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Participants may generally not assign, transfer, pledge, or otherwise dispose of payroll deductions credited to their account or any rights regarding an election to purchase shares pursuant to the Post-Closing ESPP other than by will or the laws of descent or distribution. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Amendment; Termination </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The board of the combined company or the compensation committee may amend, suspend, or terminate the Post-Closing ESPP at any time without stockholder consent, except as required by law. Unless earlier terminated, the Post-Closing ESPP will terminate upon the earlier to occur of the issuance of all shares of the combined </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">129<br></div></div></div>
<!--End Page 140-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 141-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_113-proposals_pg20"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">company&#8217;s common stock reserved for issuance under the Post-Closing ESPP, or the tenth anniversary of the effective date of the Post-Closing ESPP. The combined company expects to register the shares issuable under the Post-Closing ESPP on a Form&#160;S-8 after the Closing and stockholder approval. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Material U.S. Federal Income Tax Consequences </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following is a brief description of the federal income tax treatment that will generally apply to the grant and exercise of rights under the Post-Closing ESPP, based on federal income tax laws in effect on the date of this proxy statement/prospectus. The exact federal income tax treatment of options under the Post-Closing ESPP will depend on the specific nature of any such option and the individual tax attributes of the participant. The following summary is not intended to be exhaustive and, among other considerations, does not describe gift, estate, social security, state, local or international tax consequences. In addition, if one or more sub-plans are established for employees of non-U.S. subsidiaries, the tax rules may be different than discussed below. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Post-Closing ESPP is intended to qualify as an &#8220;employee stock purchase plan&#8221; under Section&#160;423 of the Code and, as a result, employees who participate in the Post-Closing ESPP will be afforded favorable tax treatment subject to meeting certain requirements specified by the Code. In general, there are no federal income tax consequences to a participant upon the grant of the option to purchase shares under the Post-Closing ESPP at the beginning of an offering period or upon its exercise on the exercise date at the end of an offering period. Upon the disposition of shares of common stock acquired upon exercise of an option, the participant will generally be subject to tax and the nature and amount of the tax will depend on whether the employee has satisfied the statutory holding period. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If the employee holds shares acquired under the Post-Closing ESPP for at least two years from the grant date of his or her option and at least one year from the date he or she acquired the shares (referred to as the &#8220;statutory holding period&#8221;), any gain on the sale of the shares will be taxed as ordinary income to the extent of the lesser of (i)&#160;the amount by which the fair market value of the shares on the grant date (i.e., the first day of the option period) exceeded the exercise price for the option, or (ii) the amount by which the fair market value of the shares on the date of sale exceeds the exercise price of the option. Any additional gain or loss will be taxed as long-term capital gain or loss. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If the participant sells or otherwise disposes of the shares before the expiration of the statutory holding period, then in the year of such &#8220;disqualifying&#8221; disposition, the participant will be required to recognize ordinary income equal to the difference between the fair market value of the shares on the date of the exercise of the option and the exercise price of the option. Any additional gain or loss will be short-term or long-term capital gain or loss depending on the length of time the employee has held the shares. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The combined company is not entitled to any deduction with respect to the difference between the fair market value of the common stock and the option exercise price if the participant satisfies the statutory holding period described above. If shares are sold before the statutory holding period is satisfied, the combined company receives a tax deduction for any ordinary income recognized by the participant. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">New Plan Benefits </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Because participation is voluntary and depends on each eligible employee&#8217;s election and on the future fair market value of the combined company common stock, the benefits or amounts that will be received under the Post-Closing ESPP are not determinable at this time, and a New Plan Benefits table is not provided. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Registration with the SEC </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If the Post-Closing ESPP is approved by Standard BioTools&#8217; stockholders and becomes effective, the combined company intends to file a registration statement on Form&#160;S-8, as soon as reasonably practicable following the consummation of the Merger, registering the shares reserved for issuance under the Post-Closing ESPP. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Vote Required for Approval </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The approval of the Post-Closing ESPP Proposal requires the affirmative vote of a majority of the voting power of the shares of Standard BioTools&#8217; capital stock present virtually or represented by proxy at the Special Meeting and entitled to vote on such Proposal at the Special Meeting. Abstentions will have the same effect as a vote &#8220;<font style="font-weight: bold;">AGAINST</font>&#8221; the Post-Closing ESPP Proposal. If you fail to cast your vote, in person or by proxy, or fail to give voting instructions to your brokerage firm, bank, trust or other nominee, it will have no effect on the outcome of the vote for the Post-Closing ESPP Proposal. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">130<br></div></div></div>
<!--End Page 141-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 142-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_113-proposals_pg21"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Certain Standard BioTools stockholders have agreed to vote any shares of Standard BioTools Common Stock owned by them in favor of the Post-Closing ESPP Proposal. Please see the section titled &#8220;<font style="font-style: italic;">The Special Meeting &#8211; Voting Agreements</font>&#8221; beginning on page <a href="#tVOA">107</a> of this proxy statement/prospectus for more information. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<font style="font-weight: bold;">FOR</font>&#8221; the approval of the Post-Closing ESPP Proposal. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Merger is not conditioned upon the approval of the Post-Closing ESPP Proposal. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Board Recommendation </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Standard BioTools Board recommends that Standard BioTools stockholders vote &#8220;FOR&#8221; the Post-Closing ESPP Proposal.<font style="font-weight: normal;"> </font></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">131<br></div></div></div>
<!--End Page 142-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 143-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_113-proposals_pg22"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Proposal #5: The Advisory Compensation Proposal </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Overview </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Standard BioTools stockholders are being asked to approve, pursuant to Section&#160;14A of the Exchange Act and Rule&#160;14a-21 thereunder, on a nonbinding, advisory basis, the compensation and benefits that will or may be payable to Standard BioTools&#8217; named executive officers in connection with the Merger as disclosed in the section entitled &#8220;<font style="font-style: italic;">Interests of Standard BioTools Directors and Executive Officers in the Merger &#8212; Quantification of Potential Payments to Standard BioTools Named Executive Officers in Connection with the Merger</font>&#8221; beginning on page <a href="#tQUA1">188</a> of this proxy statement/prospectus. The Advisory Compensation Proposal gives Standard BioTools stockholders the opportunity to express their views on the Merger-related compensation and benefits of Standard BioTools&#8217; named executive officers. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Accordingly, Standard BioTools is asking its stockholders to vote &#8220;<font style="font-weight: bold;">FOR</font>&#8221; the adoption of the following resolution, on a nonbinding, advisory basis: </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">&#8220;RESOLVED, that the compensation and benefits that will or may be paid or become payable to Standard BioTools&#8217; named executive officers in connection with the Merger, and the agreements or understandings pursuant to which such compensation and benefits will or may be paid or become payable, in each case as disclosed pursuant to Item&#160;402(t) of Regulation S-K in the section entitled &#8220;<font style="font-style: italic;">Interests of Standard BioTools Directors and Executive Officers in the Merger &#8212; Quantification of Potential Payments to Standard BioTools Named Executive Officers in Connection with the Merger</font>&#8221; of the proxy statement/prospectus for this meeting is hereby APPROVED.&#8221; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Because the vote on the Advisory Compensation Proposal is advisory only, it will not be binding on Standard BioTools. If the Merger is completed, the Merger-related compensation and benefits may be paid to Standard BioTools&#8217; named executive officers to the extent payable in accordance with the terms of the compensation agreements and arrangements even if stockholders fail to approve the Advisory Compensation Proposal. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Vote Required for Approval </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The approval of the Advisory Compensation Proposal requires the affirmative vote of a majority of the voting power of the shares of Standard BioTools&#8217; capital stock present virtually or represented by proxy at the Special Meeting and entitled to vote on such Proposal at the Special Meeting. Abstentions will have the same effect as a vote &#8220;<font style="font-weight: bold;">AGAINST</font>&#8221; the Advisory Compensation Proposal. If you fail to cast your vote, in person or by proxy, or fail to give voting instructions to your brokerage firm, bank, trust or other nominee, it will have no effect on the outcome of the vote for the Advisory Compensation Proposal. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Merger is not conditioned upon the approval of the Advisory Compensation Proposal. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares &#8220;<font style="font-weight: bold;">FOR</font>&#8221; the Advisory Compensation Proposal. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Board Recommendation </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Standard BioTools Board recommends that Standard BioTools stockholders vote &#8220;FOR&#8221; the Advisory Compensation Proposal.<font style="font-weight: normal;"> </font></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">132<br></div></div></div>
<!--End Page 143-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 144-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_113-proposals_pg23"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Proposal #6: The Adjournment Proposal </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Overview </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Standard BioTools stockholders are being asked to approve adjournments of the Special Meeting from time to time, if necessary or appropriate, to solicit additional affirmative votes in favor of the Share Issuance Proposal and the Charter Amendment Proposal if there are insufficient votes at the time of such adjournment to approve such proposals or to ensure that any supplement or amendment to this proxy statement/prospectus is timely provided to Standard BioTools stockholders. The Merger Agreement provides that the Special Meeting may not be postponed or adjourned more than an aggregate of 30 days in connection with all postponements or adjournments, whether to solicit additional proxies or to allow reasonable additional time for the filing or mailing of any supplemental or amended disclosure. Consummation of the Merger is not conditioned on the approval of this Adjournment Proposal. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If the Standard BioTools stockholders approve this Adjournment Proposal, Standard BioTools could adjourn or postpone the Special Meeting, and any adjourned or postponed session of the Special Meeting, and use the additional time to solicit additional proxies for the approval of the Share Issuance Proposal and the Charter Amendment Proposal. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If, at the Special Meeting, the number of shares of Standard BioTools Common Stock present or represented and voting in favor of the Share Issuance Proposal and the Charter Amendment Proposal is insufficient to approve such proposals, Standard BioTools may move to adjourn the Special Meeting in order to enable the Standard BioTools Board to solicit additional proxies for approval of the Share Issuance Proposal and the Charter Amendment Proposal. In that event, the Standard BioTools stockholders will be asked to vote only upon the Adjournment Proposal, and not the Share Issuance Proposal, the Charter Amendment Proposal, the Post-Closing Equity Incentive Plan Proposal and the Post-Closing ESPP Proposal. Standard BioTools may also adjourn the Special Meeting to ensure that any supplement or amendment to this proxy statement/prospectus is timely provided to Standard BioTools stockholders. Additionally, pursuant to the Standard BioTools Bylaws, the chairperson of the meeting may adjourn the meeting without the approval of the Standard BioTools stockholders. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Adjournment Proposal relates only to adjournments of the Special Meeting occurring for purposes of soliciting additional proxies for approval of the Share Issuance Proposal and the Charter Amendment Proposal in the event that there are insufficient votes to approve those proposals or ensure that any supplement or amendment to this proxy statement/prospectus is timely provided to stockholders. Standard BioTools retains full authority to the extent set forth in its bylaws and Delaware law (subject to the terms of the Merger Agreement) to adjourn the Special Meeting for any other purpose, or to postpone the Special Meeting before it is convened, without the consent of any Standard BioTools stockholders. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Vote Required for Approval </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The approval of the Adjournment Proposal requires the affirmative vote of a majority of the voting power of the shares of Standard BioTools&#8217; capital stock present virtually or represented by proxy at the Special Meeting and entitled to vote on such Proposal at the Special Meeting. Abstentions will have the same effect as a vote &#8220;<font style="font-weight: bold;">AGAINST</font>&#8221; the Adjournment Proposal. If you fail to cast your vote, in person or by proxy, or fail to give voting instructions to your brokerage firm, bank, trust or other nominee, it will have no effect on the outcome of the vote for the Adjournment Proposal. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Merger is not conditioned upon the approval of the Adjournment Proposal. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares &#8220;<font style="font-weight: bold;">FOR</font>&#8221; the Adjournment Proposal. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Board Recommendation </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Standard BioTools Board recommends that Standard BioTools stockholders vote &#8220;FOR&#8221; the Adjournment Proposal.</div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">133<br></div></div></div>
<!--End Page 144-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 145-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_114-parties_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tPAR"><!--Anchor--></a>THE PARTIES TO THE MERGER </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Standard BioTools Inc.</div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">50 Milk Street, 10th Floor <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Boston, MA 02109 <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Telephone: (650) 266-6000 </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Standard BioTools is committed to setting the new standard in the life science tools industry through strategic consolidation, best-in-class operations and a world-class management team. Standard BioTools&#8217; established portfolio includes essential, standardized next-generation solutions designed to help biomedical researchers develop better therapeutics faster. Standard BioTools offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. With advanced technologies in proteomics and genomics, Standard BioTools empowers scientists to gain deeper biological insights, accelerate discoveries, and drive improved health outcomes across diverse therapeutic areas including immunology, oncology, neuroscience, cardiometabolic diseases and more. Standard BioTools Common Stock is listed on The Nasdaq Global Select Market under the symbol &#8220;LAB.&#8221; </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Treeline Biosciences, Inc. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">500 Arsenal Street <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Watertown, MA 02472 <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Telephone: (857) 228-0050 </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline Biosciences is a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and other serious diseases. Treeline&#8217;s approach is built on a differentiated, repeatable discovery platform that identifies compelling molecular targets and matches them with the most appropriate drug modality. Treeline seeks to prove it can pick good targets, nominate highly-vetted development candidates, and make thoughtful development decisions across a diverse and ambitious pipeline, with the goal of redefining the treatment of serious diseases. Treeline wants its platform story to be repeatability. Treeline currently has three Phase 1 programs, TLN-121, TLN-254, and TLN-372, and a fourth program, TLN-499, nearing clinical entry, all in oncology. Treeline&#8217;s preclinical pipeline includes programs in neurology and immunology, in addition to oncology. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Siri Merger Sub, Inc. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">50 Milk Street, 10th Floor <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Boston, MA 02109 <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Telephone: (650) 266-6000 </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Merger Sub is a direct, wholly owned subsidiary of Standard BioTools. Merger Sub was incorporated in the State of Delaware on May&#160;27, 2026, solely for the purpose of carrying out the Merger. Merger Sub has not carried on any activities to date, except for activities incidental to its formation and activities undertaken in connection with the Merger. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">134<br></div></div></div>
<!--End Page 145-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 146-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_115-merger_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tMER"><!--Anchor--></a>THE MERGER </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This section of the proxy statement/prospectus describes certain material aspects of the proposed Merger. This section may not contain all of the information that is important to you. You should carefully read this entire proxy statement/prospectus and the documents incorporated herein by reference, including the full text of the Merger Agreement, which is attached as Annex&#160;A, for a more complete understanding of the Merger. In addition, important business and financial information about Standard BioTools is incorporated into this proxy statement/prospectus by reference. See also &#8220;Where You Can Find More Information&#8221; beginning on page <a href="#tWYC">335</a> of this proxy statement/prospectus.<font style="font-style: normal;"> </font></div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">General Description of the Merger </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Standard BioTools, Treeline and Merger Sub, a wholly owned subsidiary of Standard BioTools, have entered into the Merger Agreement, dated as of June&#160;6, 2026, which provides for the merger of Merger Sub with and into Treeline. As a result of the Merger, the separate existence of Merger Sub will cease and Treeline will continue its existence under the laws of the State of Delaware as the surviving corporation of the Merger and as a wholly owned subsidiary of Standard BioTools. It is expected that in connection with the Merger, Standard BioTools will change its name to &#8220;Treeline Biosciences Holdings, Inc.&#8221; </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Consideration to be Received by the Treeline Stockholders </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As a result of the Merger, each share of Treeline Common Stock issued and outstanding immediately prior to the Effective Time and each share of Treeline Preferred Stock issued and outstanding immediately prior to the Effective Time (in each case, other than shares held in treasury and dissenting shares) will be converted into the right to receive a number of shares of Standard BioTools Common Stock based on an exchange ratio calculated in accordance with the Merger Agreement (described in more detail in the section titled &#8220;<font style="font-style: italic;">The Merger Agreement &#8212; Exchange Ratio</font>&#8221; beginning on page <a href="#tEXR">202</a> of this proxy statement/prospectus) (the &#8220;Exchange Ratio&#8221;), with the number of shares of Standard BioTools Common Stock that each holder of Treeline Capital Stock is entitled to receive being rounded down to the nearest whole share and computed after aggregating all shares of Treeline Capital Stock held by such holder. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Exchange Ratio is based on the relative capitalization of each of Treeline and Standard BioTools and assumes (i) an equity value for Treeline of $2.5&#160;billion and (ii) an equity value for Standard BioTools equal to $460&#160;million, reduced by the amount by which the Parent Net Cash (as defined in the Merger Agreement) is less than $449&#160;million at the Closing or increased by the amount by which Parent Net Cash is more than $451&#160;million at the Closing. Based on Standard BioTools&#8217; and Treeline&#8217;s capitalization as of June&#160;3, 2026 and May&#160;28, 2026, respectively, and taking into account Standard BioTools&#8217; estimate of Parent Net Cash as of the Closing, and before giving effect to the proposed Reverse Stock Split, each share of Treeline Capital Stock is currently estimated to be entitled to receive approximately 11.6997 shares of Standard BioTools Common Stock. This ratio may increase or decrease as of the Closing based on the companies&#8217; respective actual capitalizations as of the Closing and the actual amount of Parent Net Cash as of the Closing. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Following the Closing, former Standard BioTools stockholders are expected to hold approximately 16% of the combined company on a fully diluted basis, and former Treeline stockholders are expected to hold approximately 84% of the combined company on a fully diluted basis. Under certain circumstances further described in the Merger Agreement, the pro forma ownership percentages may be adjusted based on the amount of Parent Net Cash at Closing as finally determined in accordance with the Merger Agreement as described in more detail in the sections titled &#8220;<font style="font-style: italic;">The Merger Agreement &#8212; Exchange Ratio</font>&#8221; and &#8220;<font style="font-style: italic;">The Merger Agreement &#8212; Calculation of Parent Net Cash</font>&#8221; beginning on pages <a href="#tEXR">202</a> and <a href="#tCOPN">203</a>, respectively, of this proxy statement/prospectus. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, as of the Effective Time, Standard BioTools will assume Treeline&#8217;s 2021 Equity Incentive Plan and each outstanding Treeline Option, whether vested or unvested. Each such Treeline Option so assumed by Standard BioTools will continue to have, and be subject to, the same terms and conditions applicable to such Treeline Option immediately prior to the Effective Time, except that (i) such Treeline Option will be exercisable for that number of shares of Standard BioTools Common Stock equal to the number of shares of Treeline Common Stock subject to such Treeline Option immediately prior to the Effective Time multiplied by the Exchange Ratio and rounded down to the next nearest share of Standard BioTools Common Stock, and (ii) the exercise price per share of each such Treeline Option will be the exercise price per share in effect for that Treeline Option immediately prior to the Effective Time divided by the Exchange Ratio and rounded up to the next nearest cent. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">135<br></div></div></div>
<!--End Page 146-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 147-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_115-merger_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, as of the Effective Time, (i) each Treeline Warrant that has been amended to require net-exercise in connection with the Merger (the &#8220;Treeline Converting Warrants&#8221;) and that is outstanding immediately prior to the Effective Time will, by virtue of the Merger, be cancelled and extinguished and converted into the right to receive, for each share of Treeline Common Stock that would be received upon the net-exercise of such Treeline Converting Warrant in accordance with its terms, a number of shares of Standard BioTools Common Stock equal to the Exchange Ratio and (ii) each Treeline Warrant that is not a Treeline Converting Warrant and that is outstanding immediately prior to the Effective Time will, by virtue of the Merger, be assumed by Standard BioTools. Each such Treeline Warrant so assumed by Standard BioTools will continue to have, and be subject to, the same terms and conditions applicable to such Treeline Warrant immediately prior to the Effective Time, except that (a) such Treeline Warrant will be exercisable for that number of shares of Standard BioTools Common Stock equal to the number of shares of Treeline Common Stock subject to such Treeline Warrant immediately prior to the Effective Time multiplied by the Exchange Ratio and rounded down to the next nearest share of Standard BioTools Common Stock and (b) the warrant price per share will be the warrant price per share in effect for such Treeline Warrant immediately prior to the Effective Time divided by the Exchange Ratio and rounded up to the nearest thousandth of a cent. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For a more complete description of the treatment of Treeline securities in the Merger, please see the sections titled &#8220;<font style="font-style: italic;">The Merger Agreement &#8212; Treatment of Treeline Stock Options</font>&#8221; and &#8220;<font style="font-style: italic;">The Merger Agreement &#8212; Treatment of Treeline Warrants</font>&#8221; both beginning on page <a href="#tTOTW">205</a> of this proxy statement/prospectus. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Consideration to be Received by the Standard BioTools Stockholders </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Prior to the Effective Time, Standard BioTools expects to declare a dividend to Standard BioTools stockholders as of the close of business on the last business day prior to the day on which the Effective Time occurs in the form of one CVR for each outstanding share of Standard BioTools Common Stock held by such stockholder on such date. The payment date for such dividend will be three business days after the Effective Time. The CVRs will be issued pursuant to the terms of a CVR Agreement to be entered into between Standard BioTools and a rights agent. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Pursuant to the CVR Agreement, the holder of each CVR will be entitled to receive a payment for each 12-month CVR payment period during the five-year term of the CVR Agreement, consisting of a number of shares of the combined company&#8217;s common stock (with fractional shares settled in cash) equal to such holder&#8217;s pro rata portion of the aggregate net proceeds received by the combined company during such 12-month CVR payment period from the following sources: (i) proceeds from any sale, disposition, or other monetization of the Legacy Business; (ii) proceeds from convertible notes or other investments held by Standard BioTools as of the Closing Date; (iii) earnout, milestone, royalty or other similar contingent payments due to Standard BioTools under contracts in effect as of the Closing Date, including payments from Illumina, Inc. pursuant to the Stock Purchase Agreement dated June&#160;22, 2025; and (iv) any surplus in Parent Net Cash delivered at Closing as finally determined under the Merger Agreement. The maximum number of shares of common stock of the combined company which may be issued pursuant to the CVR Agreement is 76,000,000. There can be no assurance that any payments will be made on the CVRs. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The right to the contingent payments contemplated by the CVR Agreement is a contractual right only and is not transferable, except in the limited circumstances specified in the CVR Agreement. The CVRs will not be evidenced by a certificate or any other instrument and will not be registered with the SEC. The CVRs will not have any voting or dividend rights and will not represent any equity or ownership interest in Standard BioTools or any of its respective affiliates. No interest will accrue on any amounts payable in respect of the CVRs. The shares of Standard BioTools Common Stock which may be issued in connection with the CVRs have been registered on the Form&#160;S-4 of which this proxy statement/prospectus forms a part. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Exchange Ratio </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Exchange Ratio is calculated using a formula intended to allocate existing Standard BioTools and Treeline securityholders a percentage of the combined company. Based on the capitalization of Standard BioTools and Treeline as of June&#160;3, 2026 and May&#160;28, 2026, respectively, and taking into account Standard BioTools&#8217; estimate of Parent Net Cash as of the Closing, the Exchange Ratio was estimated to be equal to approximately 11.6997 shares of Standard BioTools Common Stock for each share of Treeline Capital Stock. However, this estimate is subject to adjustment prior to the closing of the Merger (the &#8220;Closing&#8221;) based on the extent to which the Parent Net Cash of Standard BioTools as of 12:01 a.m. Eastern Time on the Closing Date is more than $451&#160;million or less than </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">136<br></div></div></div>
<!--End Page 147-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 148-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_115-merger_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">$449&#160;million (and, as a result, Standard BioTools securityholders could own less, and Treeline securityholders could own more, or vice versa, of the combined company). Standard BioTools currently anticipates that its Parent Net Cash as of Closing will be approximately $450&#160;million. There can be no assurance that any of these assumptions will be accurate at Closing when the final Exchange Ratio is determined. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Exchange Ratio formula is the quotient obtained (rounded to four decimal places) by dividing (x) the Treeline Value Per Share by (y) the Standard BioTools Value Per Share, in which: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">&#8220;Treeline Value Per Share&#8221; means the quotient of (A) the Treeline Valuation, divided by (B) the number of Treeline Outstanding Shares. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">&#8220;Treeline Valuation&#8221; means (A) $2,500,000,000, plus (B) the sum of the exercise prices of all in-the-money Treeline stock options that are unexpired, unexercised, and outstanding as of immediately prior to the Effective Time and that are included in the calculation of Treeline Outstanding Shares. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">&#8220;Treeline Outstanding Shares&#8221; means the sum, without duplication, of the aggregate number of shares of Treeline Capital Stock that are issued and outstanding immediately prior to the Effective Time (on an as-converted to Treeline Common Stock basis) or issuable upon the exercise of, or pursuant to, any in-the-money Treeline stock options, Treeline warrants or other direct or indirect rights to acquire shares of Treeline Capital Stock, in each case that are issued and outstanding immediately prior to the Effective Time (whether or not then vested or exercisable). </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">&#8220;Standard BioTools Value Per Share&#8221; means the quotient of (A) the Standard BioTools Valuation, divided by (B) the number of Standard BioTools Outstanding Shares. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">&#8220;Standard BioTools Valuation&#8221; means (A) $460,000,000, plus (B) the amount by which the Parent Net Cash of Standard BioTools exceeds $451&#160;million, if any, minus (C) the amount by which the Parent Net Cash of Standard BioTools is less than $449&#160;million, if any, plus (D) the sum of the exercise prices of all in-the-money Standard BioTools Options that are unexpired, unexercised, and outstanding as of immediately prior to the Effective Time and that are included in the calculation of Standard BioTools Outstanding Shares. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">&#8220;Standard BioTools Outstanding Shares&#8221; means the sum, without duplication, of the aggregate number of shares of Standard BioTools Common Stock that are issued and outstanding immediately prior to the Effective Time or issuable upon the settlement of any Standard BioTools restricted stock units (&#8220;Standard BioTools RSUs&#8221;) or the exercise of any in-the-money Standard BioTools Options, in-the-money Standard BioTools warrants or other in-the-money direct or indirect rights to acquire shares of Standard BioTools Common Stock (other than the Indenture, dated as of February&#160;4, 2014, between Standard BioTools and U.S.&#160;Bank), in each case that are issued and outstanding immediately prior to the Effective Time (whether or not then vested or exercisable). </div></td></tr></table><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">The Special Committee </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Standard BioTools Board previously established a Special Committee consisting solely of &#8220;disinterested directors&#8221; (as defined in Section&#160;144(e)(4) of the Delaware General Corporation Law) and delegated to the Special Committee the full power and authority of the Standard BioTools Board, to the maximum extent permitted by applicable law, to, among other things, (i) explore, consider, evaluate, review, negotiate and approve or reject the Merger and the other Transactions and, if approval of the Standard BioTools Board is required under the Delaware General Corporation Law, recommend whether the Standard BioTools Board should approve or reject the Merger and the other Transactions and (ii) determine whether the Merger and the other Transactions are advisable, fair to and in the best interests of Standard BioTools and its stockholders. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Special Committee retained (i) UBS to serve as its independent financial advisor and (ii) Freshfields to serve as its legal advisor, in each case to assist the Special Committee in connection with fulfilling and discharging its duties as delegated by the Standard BioTools Board. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Special Committee, with the assistance of its independent legal and financial advisors, has since its formation, among other things, (i) met regularly to explore, consider, evaluate, review and negotiate the Merger and the other Transactions and the potential terms and conditions thereof and (ii) solicited the views of the Special Committee&#8217;s advisors and members of Standard BioTools management regarding the Merger and the other Transactions, including as to the strategic rationale for, the potential risks and benefits of, and the potential terms </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">137<br></div></div></div>
<!--End Page 148-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 149-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_115-merger_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">and conditions of the Merger and the other Transactions. The Special Committee reviewed financial analysis prepared by UBS and received a fairness opinion from UBS in connection with the Merger and the other Transactions. The Special Committee also reviewed the material terms and conditions of the Merger Agreement and related documents with representatives of Freshfields. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">After due consideration and discussion of the factors that the Special Committee deemed relevant, the Special Committee unanimously (i) determined that the Merger and the other Transactions are advisable, fair to and in the best interests of Standard BioTools and its stockholders, (ii) approved and declared advisable the Merger Agreement and the other Transactions and recommended that the Standard BioTools Board approve and declare advisable the Transactions and (iii) recommended that the Standard BioTools Board resolve to recommend the approval of the Share Issuance and the Charter Amendment by Standard BioTools stockholders. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;"><a name="tBACK1"><!--Anchor--></a>Background of the Merger </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following chronology summarizes the key meetings and events that led to the signing of the Merger Agreement. This chronology does not purport to catalogue every conversation or event among members of the Board of Directors (the &#8220;Board&#8221;) of Standard BioTools Inc. (&#8220;Standard BioTools&#8221;), the Special Committee of the Board (the &#8220;Special Committee&#8221;) or any other committee of the Board, Standard BioTools management, Standard BioTools&#8217; or Treeline Biosciences, Inc.&#8217;s (&#8220;Treeline&#8221;) financial or legal advisors or any other person.<font style="font-style: normal;"> </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As part of its ongoing review and evaluation of Standard BioTools&#8217; long-term strategic goals and plans, the Board, together with Standard BioTools management, periodically reviews and evaluates Standard BioTools&#8217; historical performance, competitive position, future growth prospects, business plans, overall strategic direction and opportunities to enhance stockholder value. These reviews have included discussions as to whether Standard BioTools should continue to execute its strategy as a standalone company, in which it would operate its existing life sciences tools businesses and deploy cash on hand to acquire additional life sciences tools assets, or pursue various other strategic alternatives, including other potential acquisitions, business combinations and transformative transactions. As part of its ongoing review of its portfolio, Standard BioTools has also periodically evaluated the potential divestiture of one or more of its business lines and engaged in discussions with various potential acquirors for such business lines. As part of these reviews, the Board and Standard BioTools management have considered the benefits and risks of such potential strategic alternatives and have periodically discussed such strategic alternatives with Standard BioTools&#8217; financial and legal advisors. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In 2022, the Board formed a Transaction Committee of the Board (the &#8220;Transaction Committee&#8221;), which held its first meeting on October&#160;14, 2022, for efficiency purposes to provide oversight and guidance with respect to Standard BioTools&#8217; evaluation of potential strategic transaction alternatives. The Transaction Committee was not established on account of any actual or perceived conflicts of interest, has included various Board members since its inception and is currently comprised of three members of the Board, Eli Casdin, Troy Cox and Dr.&#160;Frank Witney, PhD, each of whom was appointed to the Transaction Committee by the Board based on their financial and industry sophistication, familiarity with Standard BioTools&#8217; businesses and operations and experience evaluating strategic transactions involving life sciences companies. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In the course of renegotiation of existing commercial arrangements between Standard BioTools and Illumina,&#160;Inc. (&#8220;Illumina&#8221;), discussions developed regarding a potential sale of Standard BioTools&#8217; SomaLogic business to Illumina (the &#8220;SomaLogic Transaction&#8221;). In connection with the process leading to the SomaLogic Transaction, the Board formed a special committee of independent and disinterested directors comprised of Fenel Eloi and Dr.&#160;Witney (the &#8220;SomaLogic Special Committee&#8221;) to oversee and approve or reject the SomaLogic Transaction given that Casdin Capital, LLC (together with its affiliates, &#8220;Casdin Capital&#8221;) held a small ownership stake in Illumina at that time. The SomaLogic Special Committee unanimously approved the SomaLogic Transaction and recommended it to the Board for approval, and the Board unanimously approved the SomaLogic Transaction. On June&#160;22, 2025, Standard BioTools signed a definitive agreement for the sale of the SomaLogic business to Illumina for aggregate cash consideration of up to $425&#160;million, comprising (i) an upfront payment of $350&#160;million in cash, payable at the closing of the SomaLogic Transaction, subject to a customary purchase price adjustment, and (ii) up to $75&#160;million in earnout payments, payable upon the achievement of specified targets for net revenue generated from SomaScan assay services or any other SOMAmer-based assay services and sales of SOMAmer-based array kits and SOMAmer-based next-generation sequencing library preparation kits in fiscal years 2025 and 2026. The SomaLogic Special Committee and the Board believed that the attractive purchase price being offered by Illumina for the SomaLogic business was the result of, among other factors, (i) the improvements and </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">138<br></div></div></div>
<!--End Page 149-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 150-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_115-merger_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">value creation during Standard BioTools&#8217; ownership of the SomaLogic business, (ii) the fact that Illumina was the most logical and interested buyer for the SomaLogic business and well positioned to take the SomaLogic business into its next phase of growth, the benefits of which would be shared with Standard BioTools through the earnout, and (iii) vigorous negotiations with Illumina during which Illumina increased its proposed price multiple times. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">During the discussions for the SomaLogic Transaction, Illumina stated that it would not be interested in pursuing an acquisition of all of Standard BioTools and was only interested in acquiring the SomaLogic business. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Throughout the summer and fall of 2025, Standard BioTools management, with periodic assistance from representatives of Centerview Partners LLC (&#8220;Centerview&#8221;) and in anticipation of receipt of the upfront cash proceeds from the closing of the SomaLogic Transaction, conducted a review of potential strategic alternatives for the deployment of that capital with the objective of maximizing stockholder value. This review focused on opportunities in the life sciences tools and bioprocessing industries, and Standard BioTools management held meetings with numerous strategic parties to discuss potential strategic transactions involving Standard BioTools. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On July&#160;15, 2025, representatives of Company A, a privately held company pursuing next generation life science research reagents, presented a business update to representatives of Standard BioTools management. Standard BioTools and Company A had previously executed a mutual confidentiality agreement on June&#160;24, 2024, which agreement did not include any standstill provisions, and representatives of Standard BioTools had participated in various discussions with representatives of Company A, leading to the submission of non-binding letters of intent on July&#160;11, 2024 and on January&#160;29, 2025 for the acquisition of Company A by Standard BioTools. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On July&#160;25, 2025, Sean Mackay, Chief Business Officer of Standard BioTools, met by videoconference with the Chief Financial Officer and Chief Operating Officer of Company B, a publicly traded company pursuing a bioprocessing growth strategy, for preliminary strategic discussions between Standard BioTools and Company B. Standard BioTools and Company B had previously executed a mutual confidentiality agreement on March&#160;19, 2025, which agreement did not include any standstill provisions, and Mr.&#160;Mackay had participated in preliminary strategic discussions with representatives of Company B following execution of that confidentiality agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On July&#160;29, 2025, the Board held a meeting, with representatives of Standard BioTools management in attendance, to discuss continuing to build on Standard BioTools&#8217; life sciences tools strategy by way of bolt-on acquisitions in that space. The Board discussed that Standard BioTools should spend time reviewing a broader range of strategic alternatives across other industries as well, including in bioprocessing. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On August&#160;2, 2025, Dr.&#160;Michael Egholm, PhD, Chief Executive Officer of Standard BioTools, met in person with a representative of Company C, a publicly traded life science tools company, to discuss a potential acquisition of Company C by Standard BioTools. Subsequent to that meeting, the representative of Company C contacted Dr.&#160;Egholm to explain that Company C was not ready at that time to engage in bilateral negotiations solely with Standard BioTools and that Company C was considering initiating a sale process for itself. Standard BioTools and Company C had previously executed a mutual confidentiality agreement on March&#160;31, 2025, which agreement contained customary standstill provisions in favor of Standard BioTools, which standstill provisions provided for an automatic fall-away upon a transaction of the type contemplated by the Merger Agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On August&#160;14, 2025, representatives of Standard BioTools management met in person with representatives of Company C for diligence meetings and facilities tours. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On August&#160;19, 2025, Dr.&#160;Egholm, Mr.&#160;Mackay and other representatives of Standard BioTools met with the Chief Executive Officer and Chief Operating Officer of Company B for an overview of Company B&#8217;s business operations and plans. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On September&#160;2, 2025, representatives of Company C&#8217;s financial advisor spoke with representatives of Centerview and sent a process letter to Centerview soliciting bids for a potential acquisition of Company C. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On September&#160;5, 2025, Standard BioTools and Company D, a privately held bioprocessing company, executed a mutual confidentiality agreement, which did not contain any standstill provisions. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On September&#160;8, 2025 and September&#160;12, 2025, Mr.&#160;Mackay met with the Chief Operating Officer of Company B to discuss a potential merger of Standard BioTools and Company B. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">139<br></div></div></div>
<!--End Page 150-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 151-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_115-merger_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Also on September&#160;8, 2025, Dr.&#160;Egholm and another representative of Standard BioTools met by videoconference with the Chief Executive Officer and Chief Operating Officer of Company D to discuss the business of Company D. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On September&#160;10, 2025, representatives of Standard BioTools management again met in person with representatives of Company C for diligence meetings and facilities tours. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">After consideration, Standard BioTools management determined not to pursue an acquisition of Company C due to a variety of factors, including lack of strategic fit and synergies with Standard BioTools&#8217; existing businesses, the unattractive business outlook for Company C and concerns regarding Company C&#8217;s competitive positioning in this market. In September&#160;2025, Dr.&#160;Egholm communicated to a representative of Company C that Standard BioTools would not be submitting a bid for the acquisition of Company C. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On September&#160;11, 2025, Dr.&#160;Egholm and other representatives of Standard BioTools met in person with representatives of Company D, which meeting included a site visit of Company D. Mr.&#160;Mackay and other representatives of Standard BioTools had subsequent conversations with a key investor in Company D to discuss potential terms of an acquisition of Company D by Standard BioTools. Ultimately, the Board decided not to pursue an acquisition of Company D due to lack of synergies with Standard BioTools&#8217; existing business and lack of scale as an independent acquisition target. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On September&#160;15, 2025, the Board held a meeting to discuss a variety of potential acquisition strategies in the life sciences tools industry, including high growth tools transformation, life science research tools, bioprocessing reinvention and diagnostics, as well as a potential strategic pivot into healthcare information technology or biotechnology. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On September&#160;16, 2025, Dr.&#160;Egholm, Mr.&#160;Mackay and other representatives of Standard BioTools met in person with representatives of Company A for an on-site diligence session in preparation for the potential submission of a non-binding letter of intent for the acquisition of Company A by Standard BioTools. From October&#160;2025 through December&#160;2025, Mr.&#160;Mackay had multiple conversations with the representatives of Company A to discuss potential partnerships or strategic transactions. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On September&#160;23, 2025, Dr.&#160;Egholm met for dinner with the Chief Executive Officer of Company E, a publicly traded life sciences tools company, to discuss a potential merger between Standard BioTools and Company E. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On September&#160;24, 2025, Dr.&#160;Egholm met with the Chief Executive Officer of Company B for dinner to discuss a potential merger of Standard BioTools and Company B. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Also on September&#160;24, 2025, Standard BioTools and Company E executed a mutual confidentiality agreement, which did not contain any standstill provisions. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On October&#160;2, 2025, Dr.&#160;Egholm, Mr.&#160;Mackay and other representatives of Standard BioTools met in person with representatives of Company B to conduct on-site due diligence in preparation for submitting a non-binding letter of intent for a potential merger of Standard BioTools and Company B. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On October&#160;3, 2025, Dr.&#160;Egholm, Mr.&#160;Mackay and other representatives of Standard BioTools met in person with representatives of Company F, a privately held next generation bioprocessing reagents company, for a diligence session. Standard BioTools and Company F had executed a confidentiality agreement on June&#160;18, 2025, which agreement did not include any standstill provisions. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On October&#160;10, 2025, the Transaction Committee held a meeting, with representatives of Standard BioTools management in attendance, to discuss (i) potential strategic transactions with each of Company A, Company B, Company F and Company G, a publicly traded life sciences tools company, as part of a holistic bioprocessing strategy for Standard BioTools and (ii) the terms of a proposed non-binding letter of intent for a potential merger of Standard BioTools and Company B (the &#8220;Company B Letter of Intent&#8221;), which the Transaction Committee authorized Standard BioTools management to submit to Company B on that basis. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On October&#160;15, 2025, Dr.&#160;Egholm spoke by telephone with the Chief Executive Officer of Company B and, following that discussion, submitted the Company B Letter of Intent to Company B. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On October&#160;23, 2025, the Chief Executive Officer of Company B contacted Dr.&#160;Egholm by telephone and stated that Company B was not interested in proceeding with a transaction on the terms set forth in the Company B Letter of Intent, and discussions between Standard BioTools and Company B ceased at that time. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">140<br></div></div></div>
<!--End Page 151-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 152-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_115-merger_pg7"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On October&#160;28, 2025, the Board held a meeting, with representatives of Standard BioTools management in attendance, to discuss management&#8217;s proposed bioprocessing strategy for Standard BioTools, including potential next steps in respect of potential acquisition targets in the bioprocessing space. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On November&#160;11, 2025 and November&#160;13, 2025, Mr.&#160;Mackay and another representative of Standard BioTools met by videoconference with the Chief Executive Officer of Company F to discuss the business of Company F. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On November&#160;14, 2025, the Transaction Committee held a meeting, with representatives of Standard BioTools management in attendance. The Transaction Committee determined not to pursue further discussions with Company B given Company B&#8217;s October&#160;23, 2025 response to the Company B Letter of Intent. The Transaction Committee also discussed potential roll-up acquisitions of Company A, Company F and Company G. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On December&#160;16, 2025, the Board held a meeting, with representatives of Standard BioTools management in attendance, to discuss, among other things, potential roll-up acquisitions of Company F and Company G. Ultimately, the Board decided not to pursue an acquisition of Company F due to lack of synergies with Standard BioTools&#8217; existing business and lack of scale as an independent acquisition target. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On January&#160;13, 2026, the management teams of Standard BioTools and Company A met in person at the 44<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> Annual J.P. Morgan Healthcare Conference in San Francisco, California (the &#8220;JPM Healthcare Conference&#8221;). Ultimately, Standard BioTools management determined not to make an updated offer for an acquisition of Company A due to a lack of strategic fit with the larger M&amp;A transactions being considered by Standard BioTools. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On January&#160;14, 2026, Dr.&#160;Egholm, Alex Kim, Chief Financial Officer of Standard BioTools, and Mr.&#160;Mackay met with the Chief Executive Officer, Chief Financial Officer and Chief Operating Officer of Company E at the JPM Healthcare Conference, during which meeting they shared overviews of each other&#8217;s businesses and agreed to meet again following the conference.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In the course of Standard BioTools&#8217; exploration of a broader scope of potential strategic alternatives, Mr.&#160;Casdin, a member of the Board and the Transaction Committee, in November&#160;2025 informed Company H, a privately held healthcare company, and on January&#160;27, 2026 informed Treeline, which were companies he believed to have promising businesses and capital raising needs, that Standard BioTools was looking for potential counterparties for a strategic business combination. In the context of this outreach, Mr.&#160;Casdin notified Thomas Carey, Chairman of the Board, that he had made these contacts and that Casdin Capital held a small ownership position in each of Company H and Treeline.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On January&#160;29, 2026, the management teams of Standard BioTools and Company E met for management presentations, during which meeting they discussed a potential merger. Ultimately, Standard BioTools and Company E did not pursue a transaction due to a variety of factors, including the dilution impact to Company E of the potential merger as well as Standard BioTools&#8217; management&#8217;s view of the complexity of Company E&#8217;s capital structure. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On January&#160;30, 2026, Standard BioTools completed the SomaLogic Transaction, resulting in approximately $550&#160;million in cash and cash equivalents on Standard BioTools&#8217; balance sheet at closing. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On February&#160;2, 2026, Mr.&#160;Mackay and the Chief Executive Officer of Company I, a privately held life sciences tools company, met by videoconference for an introductory call to discuss strategic interest of Standard BioTools in Company I. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On February&#160;17, 2026, the Board held an in-person meeting, with representatives of Standard BioTools management in attendance, to discuss, among other things, (i) the challenges that Standard BioTools had faced to that point in identifying a life sciences tools growth asset to acquire that also had strategic linkages with its microfluidics and mass cytometry businesses (the &#8220;legacy businesses&#8221;), (ii) the potential to broaden Standard BioTools&#8217; strategic alternatives review to cover transformative repositioning opportunities involving counterparties in other industries, such as bioprocessing, healthcare information technology, pharmaceutical software and AI and biotechnology, in light of the lack of success that Standard BioTools had seen in identifying suitable transaction candidates in the life sciences tools space despite its efforts over many months to do so, (iii) potential avenues for the divestitures of the legacy businesses and (iv) business overviews of multiple potential counterparties to strategic transactions involving Standard BioTools, including Company G as a potential entry point into the bioprocessing space. The Board also determined that it should have biweekly meetings going forward to support the momentum of Standard BioTools&#8217; ongoing strategic alternatives review. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">141<br></div></div></div>
<!--End Page 152-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 153-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_115-merger_pg8"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On February&#160;19, 2026, Dr.&#160;Joshua Bilenker, MD, Chief Executive Officer of Treeline, other members of the Board of Directors of Treeline (the &#8220;Treeline Board&#8221;) and Spencer Smith, Chief Financial Officer of Treeline, met by videoconference to discuss a potential reverse merger opportunity with Standard BioTools. Mr.&#160;Smith presented an overview of Standard BioTools, including its cash balance following the closing of the SomaLogic Transaction, its market capitalization and its major stockholders. The members of the Treeline Board and Mr.&#160;Smith discussed several considerations with respect to a potential transaction, including (i) the valuation of Treeline at various valuation step-ups from the valuation of Treeline in its most recent equity financing and the resulting post-merger ownership for pre-merger Standard BioTools stockholders, (ii) a proposed disposal or spin-off of Standard BioTools&#8217; legacy businesses and (iii) a preliminary path and timeline to a potential transaction. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On February&#160;22, 2026, Dr.&#160;Bilenker reached out to Mr.&#160;Carey by email requesting an introductory call. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On February&#160;25, 2026, Mr.&#160;Carey contacted a representative of Freshfields US LLP (&#8220;Freshfields&#8221;), outside legal counsel to Standard BioTools, to let him know of the outreach from Dr.&#160;Bilenker and to update Freshfields on Standard BioTools activities in its evaluation of strategic transaction alternatives. In that discussion, Mr.&#160;Carey informed the representative of Freshfields that Casdin Capital held a small ownership position in Treeline as well as in Company H. Following that conversation and on that day, the representative of Freshfields spoke by telephone with a representative of outside legal counsel to Casdin Capital and Mr.&#160;Casdin (together with Casdin Capital, &#8220;Casdin&#8221;), to discuss the fact that Casdin Capital held ownership positions in each of Treeline and Company H. The representative of Freshfields stated that he would be discussing with the Standard BioTools Board the appropriate procedural steps to implement as a result. The representative of Casdin&#8217;s outside counsel provided the representative of Freshfields the information he had with respect to Casdin Capital&#8217;s ownership positions in Treeline and Company H, noting that those positions were less than 5% and 2% of the total equity of those companies, respectively, as of that time. The representatives of Freshfields and Casdin&#8217;s outside counsel discussed the recommendation that the Board form a special committee comprised exclusively of directors independent from Casdin for the consideration of any potential strategic transaction with Treeline, Company H or any other counterparty in which Casdin Capital held an economic interest. The representative of Casdin&#8217;s outside counsel said that Casdin would support such a construct as being in the best interests of Standard BioTools&#8217; stockholders. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Also on February&#160;25, 2026, the Board held a meeting, with a representative of Freshfields in attendance, to discuss process protocols for Standard BioTools&#8217; evaluation of potential strategic transactions in which the counterparties were entities in which Casdin Capital held an economic interest. Neither Mr.&#160;Casdin nor Shaun Rodriguez of Casdin Capital, in his capacity as a Board observer, was in attendance at the meeting. The representative of Freshfields reviewed with the Board the directors&#8217; fiduciary duties generally, as well as in the context of potential strategic transactions in which the counterparties were entities in which Casdin Capital held an economic interest. The Board discussed the potential formation of a special committee, comprised solely of directors independent of Casdin, to explore, consider, evaluate, review, negotiate and approve or reject any potential transaction with such a counterparty in which Casdin Capital held an economic interest, to determine whether such a transaction is advisable, fair to and in the best interests of Standard BioTools and its stockholders and to recommend to the Board what action, if any, should be taken by Standard BioTools with respect to such a transaction. The Board discussed that such a special committee could consist of directors Fenel Eloi and Dr.&#160;Witney, each of whom had served on the SomaLogic Special Committee and had been deemed independent from Casdin and Illumina at that time. Mr.&#160;Eloi and Dr.&#160;Witney confirmed that they would be willing to serve in this capacity again, that it was still the case that they had no personal or professional relationships with Casdin that would undermine their independence and that they would decline any additional Board compensation for serving in those roles were a special committee to be reconstituted. The Board also affirmed that a special committee, if formed, would be empowered to retain its own independent financial advisor. The Board determined that Mr.&#160;Carey and Dr.&#160;Egholm should have an introductory call with Dr.&#160;Bilenker, and that the Board would then determine whether to form a special committee if a potential transaction with either of Treeline or Company H seemed worth pursuing. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On February&#160;26, 2026, the Chief Executive Officer of Company H reached out to Mr.&#160;Carey by email to request an introductory meeting. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On March&#160;2, 2026, Mr.&#160;Carey and Dr.&#160;Egholm met by videoconference with the Chief Executive Officer of Company H to discuss a potential strategic transaction between Standard BioTools and Company H. The Chief Executive Officer of Company H stated during that meeting that he would follow up with an indication of interest in respect of such a transaction. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">142<br></div></div></div>
<!--End Page 153-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 154-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_115-merger_pg9"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On March&#160;3, 2026, Mr.&#160;Mackay and the Chief Executive Officer of Company I met by videoconference to discuss a potential acquisition of Company I by Standard BioTools. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Also on March&#160;3, 2026, the Chief Executive Officer of Company H sent Mr.&#160;Carey and Dr.&#160;Egholm a non-binding indication of interest for a potential strategic transaction (the &#8220;March&#160;3 Company H Proposal&#8221;), providing for (i) a stock-for-stock reverse merger transaction with a specified equity value for Company H and an ascribed equity value for Standard BioTools based on a 5-day volume-weighted average price (VWAP) of its common stock, resulting in an implied ownership interest in the combined company of approximately 16% for pre-merger Standard BioTools stockholders, (ii) the delivery of a contingent value right (CVR) to pre-merger Standard BioTools stockholders representing the right to receive net proceeds from the monetization of the legacy businesses and contingent receivables, including any earnout payment from Illumina in respect of the SomaLogic Transaction, (iii) a combined company board comprising directors designated by each party in proportion to their equity ownership at closing, with a chairperson designated by Company H, and (iv) the combined company to be led by Company H&#8217;s existing management team. The March&#160;3 Company H Proposal also included a request for 90 days of exclusivity to negotiate a potential transaction. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On March&#160;4, 2026, the Board held a meeting, with representatives of Standard BioTools management and Freshfields and Mr.&#160;Rodriguez in attendance. Mr.&#160;Mackay updated the Board on Standard BioTools&#8217; strategic alternatives review, including the potential divestitures of the legacy businesses and the status of discussions with Company G, Company H and Company I. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In executive session without the representatives of Standard BioTools management present, the Board then discussed several considerations with the representatives of Freshfields in connection with the March&#160;3 Company H Proposal, including, among other things, that (i) Standard BioTools would need to undertake a diligence process on Company H, including a valuation analysis, in order to form a view on the merits of the March&#160;3 Company H Proposal and (ii) the Special Committee should be formed if Standard BioTools&#8217; exploration of the March&#160;3 Company H Proposal were to go forward and in any event before Standard BioTools management expressed any view to Company H on the value aspects of the March&#160;3 Company H Proposal. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In a further executive session without Mr.&#160;Casdin or Mr.&#160;Rodriguez present, the Board determined that it would retain a financial advisor to consider all reasonable strategic transactions and alternatives in order to maximize stockholder value. In addition, in light of Casdin Capital&#8217;s ownership stake in each of Treeline and Company H, the Board determined that it was appropriate for the Board to establish the Special Committee, comprised of Mr.&#160;Eloi and Dr.&#160;Witney, in the near term and to empower and authorize the Special Committee to, among other things, retain its own independent financial advisor. The representatives of Freshfields said that they would circulate a unanimous written consent to form the Special Committee, with the authority of the Special Committee to be consistent with what had been discussed previously with the Board. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Also on March&#160;4, 2026, Messrs. Carey and Cox and Dr.&#160;Egholm met by videoconference with Dr.&#160;Bilenker and Mr.&#160;Smith, regarding the business of Treeline. During that call, Dr.&#160;Bilenker proposed a reverse merger between Standard BioTools and Treeline, with Standard BioTools to be valued at its net cash and its legacy businesses to be divested in connection with the potential transaction. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On March&#160;5, 2026, Dr.&#160;Egholm spoke by telephone with the Chief Executive Officer of Company H to state that the Board and Standard BioTools management were continuing to review the March&#160;3 Company H Proposal and that Standard BioTools would be interested in further engagement with Company H. Dr.&#160;Egholm did not express a view on the substance of the March&#160;3 Company H Proposal, including any of the value aspects of the proposal. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Also on March&#160;5, 2026 and on numerous occasions thereafter, Dr.&#160;Bilenker and Mr.&#160;Smith met by videoconference with members of the Treeline Board to provide updates and discuss the potential transaction with Standard BioTools and to obtain feedback from the Treeline Board members on the potential transaction and on transaction terms and process. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On March&#160;6, 2026, representatives of Freshfields met via videoconference with Mr.&#160;Eloi and Dr.&#160;Witney to confirm again their independence with respect to each of Company H, Treeline and Casdin and their disinterestedness with respect to the potential transactions with each of Company H and Treeline. During this discussion, Mr.&#160;Eloi and Dr.&#160;Witney confirmed that they had no financial, professional, social or other relationships that would impair their independence or disinterestedness as a member of the Special Committee. Mr.&#160;Eloi and Dr.&#160;Witney also began discussions with each other and with the representatives of Freshfields regarding which </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">143<br></div></div></div>
<!--End Page 154-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 155-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_115-merger_pg10"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">financial advisor to retain on behalf of the Special Committee once it was formally constituted, including that the Special Committee when it had been constituted in connection with the SomaLogic Transaction had evaluated a number of financial advisors and had ultimately selected UBS Securities LLC (&#8220;UBS&#8221;) for that transaction and had been pleased with UBS&#8217;s work on that mandate. The representatives of Freshfields also discussed the Special Committee retaining legal counsel, and Mr.&#160;Eloi and Dr.&#160;Witney expressed a preference for Freshfields to also represent the Special Committee, as had been the case during the SomaLogic Transaction. The representatives of Freshfields stated that they believed they could do so, as Freshfields continued to have no prior relationship with Casdin, and since the Special Committee was formed to address the potential conflict with Casdin, which was not a controlling shareholder.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Also in that meeting, Mr. Eloi and Dr. Witney discussed with the representatives of Freshfields the process to be followed by the Special Committee in its anticipated evaluation of potential transactions within its purview, including the process for interviewing and selecting an independent financial advisor for the Special Committee. The prospective members of the Special Committee expressed their view to the representatives of Freshfields that, because a reverse merger transaction with either Treeline or Company H would represent a transformative and strategic pivot from the life sciences tools industry to another industry and because Standard BioTools would be considering potential transactions with Treeline or Company H at the same time Standard BioTools was conducting a broad review of strategic alternatives, many of which would not fall within the purview of the Special Committee, it was important to them that the process be structured such that the full Board, including Mr. Casdin at certain times, had the opportunity to meet regularly and deliberate the merits of the various potential transactions under consideration, and which would also allow the Special Committee to take into account as it saw fit the perspectives of the other members of the Board. The prospective members of the Special Committee also noted that a number of members of the Board had more experience in the biotechnology space, and so it would be important to benefit from that experience in evaluating potential transactions in that industry. The prospective members of the Special Committee were also of the view that Centerview, were it to be formally retained as Standard BioTools&#8217; financial advisor in connection with the potential transactions, should continue to manage the interactions with and due diligence review of the potential counterparties for efficiency purposes and to avoid having multiple financial advisors managing different interactions across multiple parties, some of which may not be within the purview of the Special Committee. They also discussed that the Special Committee and its independent financial advisor could leverage Standard BioTools management&#8217;s due diligence efforts given that management was best placed to undertake such an exercise. In making these determinations, the prospective members of the Special Committee noted that the Special Committee would have full authority to approve or reject any transaction in which the counterparty was an entity in which Casdin Capital held an economic interest, and that they would exercise that authority and their ability to oversee the transaction process in the manner they saw fit based upon how those potential transactions developed. The prospective Special Committee members also discussed the key areas of due diligence that they would want to see with respect to each of Company H and Treeline, were either transaction to be pursued. The representatives of Freshfields shared those diligence focus area requests with Standard BioTools management as they formulated their diligence plan. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On March&#160;9, 2026, Standard BioTools and Company H executed a mutual confidentiality agreement, which contained customary standstill provisions in favor of Standard BioTools, which standstill provisions provided for an automatic fall-away upon a transaction of the type contemplated by the Merger Agreement.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Also on March&#160;9, 2026, Dr.&#160;Egholm and the Chief Executive Officer of Company G met by videoconference to discuss a potential strategic transaction between Standard BioTools and Company G. Dr.&#160;Egholm informed the Chief Executive Officer of Company G that Standard BioTools was conducting preliminary diligence on Company G based on publicly available information. The Chief Executive Officer of Company G told Dr.&#160;Egholm that he would inform the Board of Directors of Company G of this development. The Chief Executive Officer of Company G never contacted Dr.&#160;Egholm after that call, and Company G never executed a confidentiality agreement with Standard BioTools. Standard BioTools management determined not to follow up with Company G due to management&#8217;s determination that Company G lacked strategic fit, as it was a smaller scale company and Standard BioTools was pursuing a larger, more transformational acquisition strategy.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On March&#160;11, 2026, Dr.&#160;Egholm, Dr.&#160;Bilenker and Mr.&#160;Smith met for dinner to discuss a potential reverse merger between Standard BioTools and Treeline. At the dinner, the representatives of Treeline expressed their view that Standard BioTools should be valued at its balance sheet cash as of closing of such a transaction and should divest its legacy businesses in connection with any such transaction.</div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">144<br></div></div></div>
<!--End Page 155-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 156-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_115-merger_pg11"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On March&#160;12, 2026, representatives of Company H delivered a management presentation by videoconference to Dr.&#160;Egholm and Messrs. Kim and Mackay. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On March&#160;13, 2026, Mr.&#160;Mackay met by videoconference with the Chief Executive Officer of Company I and representatives of the largest stockholder of Company I for a follow-up call to discuss a potential acquisition of Company I by Standard BioTools. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On March&#160;17, 2026, Mr.&#160;Smith spoke with a representative of Centerview about a potential transaction between Treeline and Standard BioTools, including the treatment of Standard BioTools&#8217; legacy businesses and anticipated future payments from Illumina. Later that day, Dr.&#160;Bilenker sent a letter to Messrs. Carey and Cox and Dr.&#160;Egholm expressing the view that Standard BioTools should be valued at its balance sheet cash at closing of such a transaction. The letter also stated that disposal of the legacy businesses (including potential future milestone and royalty payments) in connection with a reverse merger with Treeline would simplify the valuation of Standard BioTools and permit Treeline management to focus on its core business and that Treeline was not intending to operate the legacy businesses. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On March&#160;18, 2026, the Transaction Committee held a meeting, with all of the members of the Board, representatives of Standard BioTools management and Freshfields and Mr.&#160;Rodriguez in attendance. The directors discussed with the representatives of Freshfields the status of the potential divestitures of the legacy businesses, the status of the preliminary discussions with each of Company G, Company H, Company I and Treeline and the need to engage a financial advisor for the strategic alternatives review underway by Standard BioTools. The Board, all members of which were present at the meeting, discussed the engagement of Centerview as Standard BioTools&#8217; financial advisor in connection with its review of potential strategic alternatives, including Centerview&#8217;s expertise and reputation in advising healthcare and healthcare technology companies in strategic transactions and Centerview&#8217;s historical representation of and familiarity with Standard BioTools, including the assistance that had been provided to date by Centerview, and instructed the representatives of Standard BioTools management to discuss terms of engagement with representatives of Centerview. Representatives of Freshfields again reviewed with the Board the directors&#8217; fiduciary duties generally, as well as in the context of a potential strategic transaction with a counterparty in which Casdin Capital held an economic interest, and the pending formation of the Special Committee. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The unanimous written consent forming the Special Committee, comprised of Mr.&#160;Eloi and Dr.&#160;Witney, became effective on March&#160;20, 2026, as that was the date of the last signature of the members of the Board executing the unanimous written consent, which written consent authorized and empowered the Special Committee to, among other things, (i) explore, consider, evaluate, review, negotiate and approve or reject any potential transaction in which the counterparty was an entity in which Casdin Capital held an economic interest (any such transaction, a &#8220;Committee Transaction&#8221;) and, if Board approval of any Committee Transaction is required under the Delaware General Corporation Law (the &#8220;DGCL&#8221;), recommend to the Board for approval or rejection such Committee Transaction, (ii)&#160;determine whether any Committee Transaction is advisable, fair to and in the best interests of Standard BioTools and its stockholders and (iii) direct, oversee and receive advice and cooperation from any officers, employees, advisors, consultants and agents of Standard BioTools and to retain, at Standard BioTools&#8217; expense, legal counsel, financial advisors and any additional third parties or advisors that the Special Committee may deem necessary, useful or advisable to assist the Special Committee in performing its duties and responsibilities. The unanimous written consent also provided that the Board would not authorize and approve any Committee Transaction and, if Standard BioTools stockholder approval or adoption of any Committee Transaction is required under the DGCL, would not recommend such Committee Transaction to Standard BioTools stockholders, in each case unless such Committee Transaction has first been approved or recommended for approval by the Special Committee. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On March&#160;23, 2026, Mr.&#160;Mackay and another representative of Standard BioTools met by videoconference with the Chief Executive Officer of Company I and representatives of the largest stockholder of Company I for a follow-up call to discuss a potential acquisition of Company I by Standard BioTools. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On March&#160;24, 2026, Standard BioTools and Company I executed a mutual confidentiality agreement, which contained customary standstill provisions in favor of Standard BioTools, which standstill provisions provided for an automatic fall-away upon a transaction of the type contemplated by the Merger Agreement. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">145<br></div></div></div>
<!--End Page 156-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 157-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_115-merger_pg12"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Beginning on March&#160;25, 2026, the representatives of UBS, as prospective independent financial advisor to the Special Committee, were onboarded and began their review of the potential transactions within the purview of the Special Committee, including discussions with Standard BioTools management and the representatives of Centerview and Freshfields. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Also on March&#160;25, 2026, a representative of Centerview had a telephone conversation with the Chief Executive Officer of Company J, a publicly traded biotechnology company, in which he expressed interest in a potential reverse merger with Standard BioTools. The Chief Executive Officer of Company J expressed hesitation as to whether Company J needed the amount of cash that Standard BioTools would bring to the combined company and whether Company J would be willing to take on the resulting amount of dilution. The Chief Executive Officer of Company J never contacted the representative of Centerview after that telephone call, and Company J never executed a confidentiality agreement with Standard BioTools. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Also on March&#160;25, 2026, the Treeline Board held a meeting, with representatives of Treeline management and Fenwick &amp; West LLP (&#8220;Fenwick&#8221;), outside legal counsel to Treeline, in attendance. Mr.&#160;Casdin had the right to attend meetings of the Treeline Board as an observer, but did not join this meeting, the February&#160;19, 2026 or March&#160;5, 2026 discussions among Treeline Board members or any subsequent meetings of the Treeline Board. At this meeting, the Treeline Board reviewed the discussions that had occurred with representatives of Standard BioTools and Centerview, and discussed perspectives on a potential reverse merger transaction with Standard BioTools (as well as other potential strategies for raising capital to finance Treeline&#8217;s clinical trials and product development activities, including a possible initial public offering or a private equity financing of Treeline). The Treeline Board then discussed the terms and structure for a potential reverse merger transaction with Standard BioTools, the potential benefits and risks of such a transaction, and the valuation to be assigned to Treeline in any such transaction. Following this discussion, the Treeline Board authorized Treeline&#8217;s senior management to deliver a written proposal to Standard BioTools for a reverse merger transaction. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On March&#160;26, 2026, Standard BioTools and Treeline executed a mutual confidentiality agreement, which contained customary standstill provisions in favor of Standard BioTools, which standstill provisions provided for an automatic fall-away upon a transaction of the type contemplated by the Merger Agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On March&#160;27, 2026, Mr.&#160;Smith sent Dr.&#160;Egholm a non-binding indication of interest and term sheet for a potential strategic transaction (the &#8220;March&#160;27 Treeline Proposal&#8221;), a copy of which had been previously provided to the Treeline Board. The March&#160;27 Treeline Proposal provided for (i) a stock-for-stock reverse merger ascribing an equity value of $2.5 to $3&#160;billion to Treeline and an equity value of $585&#160;million to Standard BioTools (assuming closing net cash of $575&#160;million), as well as a potential private financing, (ii) a CVR to pre-merger Standard BioTools stockholders for proceeds from post-closing third-party milestone payments and royalties, net of legacy business wind-down costs, (iii) Standard BioTools to endeavor to sell its legacy businesses prior to closing, with any wind-down costs remaining at closing deducted from its net cash balance for purposes of the exchange ratio, (iv) a combined company board selected by Treeline with one or two Standard BioTools designees and (v) the combined company to be led by Treeline&#8217;s existing management team. The March&#160;27 Treeline Proposal also included a request for 30 days of exclusivity to negotiate a potential transaction. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On March&#160;31, 2026, representatives of Company K, a privately held biotechnology company, delivered a management presentation by videoconference to representatives of Standard BioTools management. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Also on March&#160;31, 2026, Standard BioTools and Company K executed a mutual confidentiality agreement, which contained customary standstill provisions in favor of Standard BioTools, which standstill provisions provided for an automatic fall-away upon a transaction of the type contemplated by the Merger Agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On April&#160;1, 2026, the Transaction Committee held a meeting, with all of the members of the Board, representatives of Standard BioTools management, Centerview and Freshfields and Mr.&#160;Rodriguez in attendance, to discuss the status of the potential transactions with each of Company H, Company I and Treeline. The representatives of Centerview provided the directors with business overviews of each of those three potential counterparties, but did not present any fundamental valuation work at the meeting, and noted that preliminary discussions were underway with Company K. The directors discussed several considerations in connection with the March&#160;3 Company H Proposal and the March&#160;27 Treeline Proposal, principally that due diligence reviews would need to be conducted in order to form a view on the valuations ascribed to each of Company H and Treeline and whether a transaction with either party would be something the Board would support from a strategic standpoint. The directors also noted that the March&#160;27 Treeline Proposal gave Standard BioTools credit for its full cash balance </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">146<br></div></div></div>
<!--End Page 157-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 158-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_115-merger_pg13"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">while the March&#160;3 Company H Proposal valued Standard BioTools at its stock price, which was trading at a discount to its cash balance. The representatives of Centerview also reviewed for the directors the preliminary discussions that had taken place between Standard BioTools management and representatives of Company I, including Standard BioTools management&#8217;s view that the valuation proposed by representatives of Company I appeared difficult to support based on the diligence information made available by Company I to date. The representatives of Centerview also noted that Company I&#8217;s expectations with respect to value and mix of cash and stock proceeds would result in Standard BioTools utilizing $400&#160;million of its cash balance to pay a portion of the cash purchase price, and the remainder would be paid through the issuance of stock worth $200&#160;million that would result in Company I&#8217;s shareholders holding a majority of the outstanding shares of the combined company. The representatives of Centerview noted that Standard BioTools&#8217; review of and outreach to potential counterparties for a number of different types of transactions had been wide-ranging and conducted over a significant period of time and that, with respect to reverse merger candidates, the universe of attractive counterparties that would be willing and able to support the dilution that would be caused by Standard BioTools&#8217; substantial cash balance in a business combination was relatively limited. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On April&#160;2, 2026, Standard BioTools and Company L, a privately held diagnostics company and potential acquisition target, executed a mutual confidentiality agreement, which contained customary standstill provisions in favor of Standard BioTools, which standstill provisions provided for an automatic fall-away upon a transaction of the type contemplated by the Merger Agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On April&#160;2, 2026, Dr.&#160;Egholm spoke by telephone with a representative of the largest stockholder of Company I to discuss a potential acquisition of Company I by Standard BioTools. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On April&#160;3, 2026, the Special Committee held a meeting, with representatives of UBS and Freshfields in attendance, to review engaging UBS as the Special Committee&#8217;s independent financial advisor and Freshfields as its legal advisor, in each case in connection with the Special Committee&#8217;s consideration of any Committee Transaction, topics which had been previously discussed by the members of the Special Committee in the period leading up to the Special Committee being formally established. Representatives of UBS made a presentation to the Special Committee regarding UBS&#8217; capabilities in the various industries being evaluated by Standard BioTools for potential transactions. The Special Committee again reviewed UBS&#8217;s experience in acting as financial advisor to the Special Committee in the SomaLogic Transaction, UBS&#8217;s familiarity with Standard BioTools, UBS&#8217;s ability to cover the industries of both Company H and Treeline, the fact that the Special Committee had interviewed and considered various other investment banks in connection with the SomaLogic Transaction, each of which had not been selected for various reasons, and UBS&#8217;s independence with respect to any Committee Transaction based upon preliminary relationship disclosure made by UBS to the Special Committee at the meeting with respect to Company H, Treeline and Casdin. The Special Committee also reviewed Freshfields&#8217; representation of Standard BioTools and the Special Committee in the SomaLogic Transaction and Freshfields&#8217; independence with respect to any Committee Transaction based upon preliminary relationship disclosure made by Freshfields to the Special Committee at the meeting with respect to Company H, Treeline and Casdin. After discussion, the Special Committee concluded that none of the information provided in the relationship disclosure provided orally by the representatives of UBS or Freshfields to the Special Committee at the meeting raised any concerns regarding either UBS&#8217;s or Freshfields&#8217; independence or ability to advise the Special Committee. The Special Committee confirmed and approved the selection of UBS as its financial advisor and Freshfields as its legal advisor, subject to receipt from each of them of a complete written relationship disclosure and the Special Committee&#8217;s review of that information. The Special Committee also reviewed again the independence of the members of the Special Committee, and concluded that neither Mr.&#160;Eloi nor Dr.&#160;Witney had any financial, professional, social or other relationships with Company H, Treeline or Casdin or any potential conflicting interest in any Committee Transaction that would impair their independence or disinterestedness as members of the Special Committee. Representatives of Freshfields then led the Special Committee through a discussion of its fiduciary duties. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Also on April&#160;3, 2026, Company K sent Dr.&#160;Egholm and a representative of Centerview a non-binding proposal for a stock-for-stock merger in which Standard BioTools would issue 19.9% of its outstanding shares to Company K stockholders, and Company K stockholders would also receive a CVR entitling them to up to $150&#160;million based on the achievement of specified milestones, payable in cash or Standard BioTools stock priced when the applicable milestone is achieved. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">147<br></div></div></div>
<!--End Page 158-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 159-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_115-merger_pg14"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On April&#160;7, 2026, Mr.&#160;Carey, Dr.&#160;Egholm, Mr.&#160;Mackay and Christopher Leidel, Vice President of Business Development at Standard BioTools, and representatives of Centerview met in person with the Treeline management team for an in-depth presentation by Treeline management on Treeline&#8217;s multiple pipeline opportunities and Treeline&#8217;s available clinical and pre-clinical data. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Later on April&#160;7, 2026, Dr.&#160;Egholm, Mr.&#160;Mackay and another representative of Standard BioTools met for dinner with representatives of Company K to discuss a potential strategic transaction between Standard BioTools and Company K. After consideration, Standard BioTools management determined that while the business of Company K was compelling, it was very early stage, and the proposal from Company K did not represent the type of transformative transaction for which Standard BioTools was looking, and informed representatives of Company K of the same. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On April&#160;9, 2026, representatives of Treeline provided Treeline management&#8217;s financial projections to Standard BioTools, and the parties held a series of follow-up diligence calls throughout that week, including a call on April&#160;10, 2026, with representatives of Centerview in attendance, to review Treeline management&#8217;s financial projections. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Also on April&#160;9, 2026, Dr.&#160;Bilenker and Mr.&#160;Carey spoke by telephone to discuss the potential transaction. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Also on April&#160;9, 2026, representatives of Company H and Standard BioTools management met by videoconference for a financial diligence call, but no detailed financial projections were provided by Company H at that time. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On April&#160;13, 2026, the Transaction Committee held a meeting, with all of the members of the Board, representatives of Standard BioTools management, Centerview, UBS and Freshfields and Mr.&#160;Rodriguez in attendance. The directors discussed the ongoing strategic alternatives review with the members of Standard BioTools management and the advisors, including that (i) Standard BioTools management and advisors had engaged in substantive discussions with a significant number of potential strategic counterparties, and preliminary discussions with many more, across the life sciences tools, healthcare information technology and biotechnology industries, ultimately identifying Company H, Company I and Treeline as attractive potential counterparties, (ii) only a small number of biotechnology companies could absorb the dilution a reverse merger with Standard BioTools would entail given its substantial cash balance, making Treeline uniquely positioned, and (iii) Treeline&#8217;s pipeline of multiple drug candidates in development across different modalities made it a more compelling biotechnology transaction partner than a single-molecule company. The representatives of Centerview then presented to the directors preliminary perspectives on valuation for each of Company H, Company I and Treeline based on the information received to date, and indicated that they would present their preliminary financial analyses at an upcoming meeting. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On April&#160;14, 2026, representatives of Treeline and representatives of Standard BioTools management and Centerview met by videoconference for a follow-up call to review Treeline management&#8217;s financial projections. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Also on April&#160;14, 2026, Dr.&#160;Egholm and Mr.&#160;Mackay met with representatives of a key investor in Company M, a publicly traded life sciences tools company, regarding a potential merger of Standard BioTools and Company M. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On April&#160;15, 2026, Mr.&#160;Mackay, another representative of Standard BioTools and representatives of Centerview met by videoconference with the Chief Executive Officer of Company I for a due diligence session covering Company I. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On April&#160;16, 2026, the Special Committee held a meeting, with representatives of Freshfields in attendance. The Special Committee discussed with the representatives of Freshfields, among other things, (i) the fee arrangement proposed by UBS in connection with its engagement as financial advisor to the Special Committee, (ii) the scope of work being undertaken by UBS to assist the Special Committee in evaluating any Committee Transaction, (iii) that the Special Committee would look to UBS to provide financial analyses of the potential transactions with each of Company H and Treeline, Standard BioTools&#8217; status quo operating plan and a liquidation or wind-down of Standard BioTools, which the Special Committee viewed as realistic potential alternatives to a reverse merger in light of the lack of attractive acquisition targets identified in Standard BioTools&#8217; strategic alternatives review to date, and (iv) the importance of conducting scientific and commercial due diligence on Treeline, for which Standard BioTools management was in the process of engaging a third-party advisor to assist in that effort.</div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">148<br></div></div></div>
<!--End Page 159-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 160-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_115-merger_pg15"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Also on April&#160;16, 2026, representatives of Company L delivered a management presentation by videoconference to representatives of Standard BioTools management. After consideration, Standard BioTools management determined that a transaction with Company L would not represent the type of transformative transaction for which Standard BioTools was looking. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Also on April&#160;16, 2026, Dr.&#160;Egholm met with representatives of another key investor in Company M regarding a potential merger of Standard BioTools and Company M. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On April&#160;17, 2026, a representative of Company M contacted Dr.&#160;Egholm to state that Company M was not interested in further discussions with Standard BioTools regarding a potential merger, and Company M never executed a confidentiality agreement with Standard BioTools. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Also on April&#160;17, 2026, representatives of Standard BioTools management and Centerview met with representatives of Company H to discuss Company H&#8217;s long-range estimates and forward assumptions. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Also on April&#160;17, 2026, the Board held a meeting, with representatives of Standard BioTools management, Centerview, UBS and Freshfields and Mr.&#160;Rodriguez in attendance, to discuss an illustrative counterproposal to the March&#160;27 Treeline Proposal. Representatives of Centerview presented Standard BioTools management&#8217;s preliminary financial projections for Treeline, which reflected risk adjustments made by Standard BioTools management to Treeline management&#8217;s financial projections (the &#8220;April&#160;17 Treeline Projections&#8221;), as well as the key underlying assumptions for such projections. The representatives of Centerview then presented preliminary financial information and analyses of Treeline on a standalone basis, utilizing the April&#160;17 Treeline Projections. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Board discussed the terms of an illustrative counterproposal to the March&#160;27 Treeline Proposal providing for (i) a Treeline equity value of $2.35 to $2.5&#160;billion, compared to $2.5 to $3&#160;billion in the March&#160;27 Treeline Proposal, (ii)&#160;an adjustment to Treeline&#8217;s valuation for deviation from an agreed cash target at closing and (iii) two members of the combined company board to be designated by Standard BioTools (rather than one or two). A representative of Standard BioTools&#8217; management noted that Standard BioTools&#8217; cash balance at the closing of a transaction with Treeline would likely be approximately $500&#160;million given the cost of ongoing operations and certain known liabilities as well as estimated transaction expenses and that this updated cash estimate should be communicated to Treeline along with the potential counterproposal. The Board noted that a transaction with Treeline would require a vote of Standard BioTools stockholders and that Treeline would likely require voting agreements from significant Standard BioTools stockholders. Mr.&#160;Eloi stated that the Special Committee had not yet formed a view on the illustrative counterproposal to Treeline. A representative of Freshfields stated that the Special Committee would be meeting when UBS was sufficiently advanced in its review of the March&#160;27 Treeline Proposal and that the Special Committee would then make a determination as to what counterproposal, if any, to make to Treeline.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Also at the meeting, in executive session without the financial advisors present, members of Standard BioTools management reviewed with the Board the proposed economic terms for the engagement of Centerview as Standard BioTools&#8217; financial advisor, and the Board authorized Standard BioTools management to negotiate an engagement letter with Centerview on the basis of the economic terms discussed at the meeting. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">By separate communications with representatives of Freshfields on April&#160;17, 2026, the members of the Special Committee discussed and approved economic terms for the engagement of UBS as financial advisor to the Special Committee and instructed the representatives of Freshfields to negotiate an engagement letter with UBS on that basis. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On April&#160;19, 2026, a representative of Treeline called a representative of Centerview to inquire as to the status of Standard BioTools&#8217; review of the March&#160;27 Treeline Proposal and when Treeline could expect a response. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On April&#160;21, 2026, the Board held a meeting, with representatives of Standard BioTools management, Centerview, UBS and Freshfields and Mr.&#160;Rodriguez in attendance. The Board discussed several considerations with respect to the legacy businesses with the advisors, including the (i) potential divestitures of the legacy businesses, (ii) various structural options for the dispositions of those businesses in connection with a potential strategic transaction and (iii) the corresponding impact of those options on Standard BioTools&#8217; cash balance. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Also at the meeting, representatives of Centerview presented Standard BioTools management&#8217;s preliminary financial projections for each of Company H and Company I, as well as the key underlying assumptions for such projections, and Centerview&#8217;s preliminary financial analysis of each of Company H and Company I. The Board </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">149<br></div></div></div>
<!--End Page 160-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 161-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_115-merger_pg16"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">discussed with the representatives of Centerview the wide valuation gap for Company H between Centerview&#8217;s preliminary financial analysis and the March&#160;3 Company H Proposal. The Board expressed the view that the representatives of Centerview should respond to Company H expressing a willingness to continue work, but highlighting the valuation gap and noting that Standard BioTools should be valued based on its cash balance rather than its current share price, as it was in the March&#160;3 Company H Proposal. The members of the Special Committee stated that they would be meeting with the representatives of UBS and Freshfields later that evening to discuss and determine a course of action with respect to the March&#160;3 Company H Proposal. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Regarding Company I, the Board discussed that Company I&#8217;s financial progress, growth profile and business prospects indicated it was not the right time for Company I to serve as the anchor asset of a publicly traded company. The Board determined that the representatives of Standard BioTools management or the representatives of Centerview should inform Company I that Standard BioTools was not interested in pursuing a transaction at this time on the basis of the framework and structure discussed, and Mr.&#160;Mackay did so shortly after the meeting. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The representatives of Centerview then reviewed with the Board an updated illustrative counterproposal to Treeline, providing for a Treeline equity value of $2.25 to $2.5&#160;billion and a $500&#160;million net cash target for Standard BioTools. The Board expressed the view that the representatives of Centerview could deliver the potential counterproposal and indicate willingness to grant Treeline&#8217;s request for 30 days of exclusivity, provided that the parties reached alignment on the key economic terms. The members of the Special Committee again noted that they would be meeting with representatives of UBS and Freshfields later that evening to discuss and determine a course of action with respect to Treeline. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Board then held an executive session without Mr.&#160;Casdin, Mr.&#160;Rodriguez or the representatives of Standard BioTools management, Centerview or UBS in attendance, so that the Board could discuss the topics covered at the meeting without Mr.&#160;Casdin or Mr.&#160;Rodriguez present.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Later on April&#160;21, 2026, the Special Committee held a meeting, with representatives of UBS and Freshfields in attendance, to discuss how to respond to Treeline, including the substance of the illustrative counterproposal to Treeline discussed at the meetings of the Board earlier that evening and on April&#160;17. The Special Committee discussed its views of the key distinguishing factors making Treeline an attractive counterparty for a reverse merger with Standard BioTools, including (i) its impressive management team, including Dr.&#160;Bilenker, who had already founded and had a successful exit from a company called Loxo Oncology, which had been purchased by Eli Lilly for $8&#160;billion, (ii) the fact that Treeline&#8217;s investor base was comprised of top tier biotech investors with discerning investment criteria and (iii)&#160;Treeline&#8217;s four separate product candidates, which gave Treeline multiple opportunities for a successful launch and would derisk Standard BioTools&#8217; investment in Treeline as compared to a biotech company that only focused on a single lead molecule. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Representatives of UBS reviewed UBS&#8217;s preliminary financial analysis of Treeline, based on the April&#160;17 Treeline Projections. Representatives of UBS reviewed the potential counterproposal to Treeline that had been discussed at the Board meeting held earlier that evening, and stated such potential counterproposal reflected input from the representatives of UBS that had been provided to the representatives of Centerview prior to that Board meeting. The potential counterproposal provided (i) a Treeline equity value of $2.25 to $2.5&#160;billion (representing a decrease in the lower end of the valuation range from the potential counterproposal presented at the April&#160;17, 2026 meeting of the Board), (ii) that Treeline&#8217;s valuation be adjusted for its cash balance at closing, (iii) that one or two Standard BioTools directors be retained on the combined company board and (iv)&#160;that the requested 30-day exclusivity period would be granted if the parties reached alignment on economic terms. The Special Committee discussed the potential counterproposal with its advisors, and discussed whether there were any further modifications that should be made to the potential counterproposal, but determined that was not necessary, in particular because the potential counterproposal already reflected UBS&#8217;s prior input (including with respect to the reduction in the lower end of the Treeline equity valuation range from $2.35 billion to $2.25 billion, improvements to the net cash calculation for Standard BioTools and ways to obtain assurances regarding Treeline&#8217;s uses of cash prior to closing of a transaction). After this discussion, the Special Committee supported the counterproposal and instructed the representatives of Freshfields to authorize the representatives of Centerview to deliver the counterproposal on that basis, but with flexibility to drop the proposal to adjust Treeline&#8217;s valuation for its cash balance at closing if necessary, given that Treeline&#8217;s business depended on its ability to spend cash as needed, including to fund clinical trials. The Special Committee also discussed and approved the proposed response to Company H discussed at the Board meeting earlier that evening, noting that the value gap between the parties </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">150<br></div></div></div>
<!--End Page 161-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 162-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_115-merger_pg17"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">seemed insurmountable and that, in any event, Company H did not seem like an ideal counterparty for a reverse merger. After the meeting, representatives of Freshfields informed representatives of Centerview and Standard BioTools management of the Special Committee&#8217;s determinations.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On April&#160;22, 2026, a representative of Centerview called Dr.&#160;Bilenker and Mr.&#160;Smith to preview the counterproposal to Treeline, and later that day, the representatives of Freshfields sent a revised draft of the term sheet to the representatives of Fenwick that reflected the changes discussed with the Board and the Special Committee, as well as certain modifications in the term sheet to the definition of net cash that would impact Standard BioTools&#8217; valuation. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On April&#160;23, 2026, Treeline&#8217;s management, members of the Treeline Board and representatives of Fenwick met by videoconference to discuss Standard BioTools&#8217; response to the March&#160;27 Treeline Proposal. During the meeting, Mr.&#160;Smith reviewed Standard BioTools&#8217; counterproposal, including Standard BioTools&#8217; proposed Treeline valuation range of $2.25 to $2.5&#160;billion, Standard BioTools&#8217; revised net cash estimate of $500&#160;million and an updated path and timeline to signing and closing of the potential transaction. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Also on April&#160;23, 2026, Mr.&#160;Smith called a representative of Centerview to ask whether Standard BioTools management had informed Viking Global Investors (&#8220;Viking&#8221;), Standard BioTools&#8217; second largest stockholder after Casdin Capital, about the potential strategic transaction with Treeline, indicating that Treeline would require voting agreements from both Casdin and Viking in support of the potential transaction. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Also on April&#160;23, 2026, the representatives of Centerview communicated the message to Company H&#8217;s financial advisor regarding the valuation gap between the parties, and the representatives of Company H&#8217;s financial advisor stated that they would discuss with their client and revert. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On April&#160;24, 2026, a representative of Fenwick called a representative of Freshfields to discuss certain open points in the revised term sheet.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On April&#160;26, 2026, a representative of Treeline called a representative of Centerview to preview that a revised draft of the term sheet would be forthcoming and stated that Treeline would not be willing to transact with Standard BioTools at a valuation for Treeline of less than $2.5&#160;billion and that Treeline would like to defer discussion of a potential private financing. The following day, Mr.&#160;Smith sent the revised term sheet to a representative of Centerview (the &#8220;April&#160;27 Treeline Proposal&#8221;), providing for, among other things, (i) no adjustment to Treeline&#8217;s valuation for its cash balance at closing, (ii) an equity value for Treeline of $2.5&#160;billion and (iii) revisions to the definition of net cash that would impact Standard BioTools&#8217; valuation.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Also on April&#160;27, 2026, a representative of Company H&#8217;s financial advisor called a representative of Centerview and expressed disappointment on the valuation gap between the parties. The representative of Company H&#8217;s financial advisor offered to have a call with Standard BioTools management that week for a more detailed discussion on Company H management&#8217;s forecasts. The representative of Centerview stated that he would report this to Standard BioTools. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On April&#160;28, 2026, representatives of Freshfields spoke by phone with internal and external counsel to Casdin regarding Standard BioTools&#8217; expectation that Casdin would be required to provide a voting agreement in support of the potential strategic transaction with Treeline. Counsel to Casdin stated that they had concerns with Casdin&#8217;s signing a voting agreement to support a transaction where Mr.&#160;Casdin was a member of the Board and Casdin Capital was a stockholder of Standard BioTools and also a stockholder of Treeline, but that they would evaluate this request if and when it came formally from Treeline. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Also on April&#160;28, 2026, the Board held an in-person meeting, with representatives of Standard BioTools management, Centerview, UBS and Freshfields in attendance, to discuss, among other things, the April&#160;27 Treeline Proposal, in which the only substantive issue remaining was the $2.5&#160;billion equity value ascribed to Treeline, as compared to Standard BioTools&#8217; proposed range of $2.25 to $2.5&#160;billion. Mr.&#160;Rodriguez was not in attendance at the meeting. The Board discussed several considerations with the representatives of Centerview and Freshfields, including, among other things, (i) that an expert consultant had been engaged to conduct scientific and commercial due diligence on Treeline, (ii) Treeline&#8217;s desire to defer discussion of a potential private financing and (iii) that the $2.5&#160;billion valuation was supported by Centerview&#8217;s preliminary financial analysis, IPO valuation step-ups for select comparable biotechnology companies (relative to their last round of private financing) and Treeline&#8217;s most recent private financing valuation, and the fact that Treeline had indicated it would not transact at any lower valuation. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">151<br></div></div></div>
<!--End Page 162-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 163-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_115-merger_pg18"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Mr.&#160;Casdin then left the meeting so that the Board could deliberate without him present. The remaining members of the Board discussed, among other things, the key factors making Treeline an attractive counterparty for a reverse merger and their view that an adjustment to Treeline&#8217;s valuation for its cash balance was neither necessary nor beneficial. The Board expressed the view that any determination as to the $2.5&#160;billion valuation would need to be made by the Special Committee, but that the Board was supportive of accepting the $2.5&#160;billion valuation and entering into 30 days of exclusivity with Treeline. The Board also expressed the view that the substantial valuation gap with Company H seemed insurmountable and that Standard BioTools should decline an additional meeting with Company H, subject to any differing views of the Special Committee. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Later on April&#160;28, 2026, the Special Committee held an in-person meeting, with representatives of UBS and Freshfields in attendance, to discuss the response to the April&#160;27 Treeline Proposal discussed at the Board meeting earlier that afternoon. Following discussion among the members of the Special Committee and representatives of UBS and Freshfields, the Special Committee determined (i) to accept the $2.5&#160;billion valuation for Treeline, (ii) to accept the absence of an adjustment to Treeline&#8217;s valuation for its cash balance at closing, provided that Treeline would be subject to appropriate interim operating restrictions on the use of its cash, (iii) to make certain modifications in the term sheet to the definition of net cash that would impact Standard BioTools&#8217; valuation in a manner favorable to Standard BioTools stockholders, (iv) to enter into 30 days of exclusivity with Treeline and (v) to decline an additional meeting with Company H. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Later on April&#160;28, 2026, a representative of Centerview spoke with Dr.&#160;Bilenker and Mr.&#160;Smith by telephone to preview that a revised draft of the term sheet was forthcoming and to discuss next steps in the parties&#8217; mutual due diligence review.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On April&#160;29, 2026, the representatives of Freshfields sent a revised draft of the term sheet to Fenwick that reflected the changes that had been discussed with the Special Committee, and the representatives of Centerview reached out to the representatives of the financial advisor to Company H to decline an additional meeting. Later on April&#160;29, 2026, Standard BioTools and Treeline executed the non-binding term sheet, including a binding obligation on each party not to negotiate an acquisition for the majority of such party&#8217;s capital stock with any other parties for 30 days. The exclusivity obligation in the term sheet did not prevent Standard BioTools from entering into disposition agreements in respect of the legacy businesses during the exclusivity period. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In April&#160;2026, the $25&#160;million earnout payment from the SomaLogic Transaction in respect of fiscal year 2025 was paid in full to Standard BioTools by Illumina. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On May&#160;4, 2026, Fenwick sent an initial draft of the Merger Agreement to Freshfields. The initial draft of the Merger Agreement, among other things, (i) stated that voting agreements would be required of significant Standard BioTools stockholders, as well as its directors and officers, (ii) included a &#8220;force the vote&#8221; provision requiring Standard BioTools to put the potential transaction to a vote of its stockholders even in the event of a change in recommendation by the Special Committee (or the Board acting at the recommendation of the Special Committee) (an &#8220;Adverse Recommendation Change&#8221;), (iii) contemplated that significant Treeline stockholders would provide voting agreements but that Treeline stockholder approval would not be obtained until after effectiveness of the Standard BioTools registration statement and (iv) provided that post-closing proceeds from any sale of the legacy businesses would be delivered to pre-merger Standard BioTools stockholders by way of a CVR. The draft Merger Agreement did not provide for a concurrent private financing, as Treeline management believed that the combined company would be adequately capitalized in view of the anticipated cash balances of Treeline and Standard BioTools at closing. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">During the week of May&#160;4, 2026, each of Treeline and Standard BioTools granted the other party access to a virtual data room so that each party could commence its due diligence review. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On May&#160;5, 2026, representatives of Centerview delivered to the Board a customary relationship disclosure letter with respect to Company H, Company I, Treeline and Casdin, which letter disclosed Centerview&#8217;s existing relationships with Casdin arising by virtue of financial advisory services provided by Centerview to companies in which Casdin Capital was a significant minority stockholder, as more fully described below under the caption &#8220;<font style="font-style: italic;">The Merger &#8211; Opinion of Standard BioTools&#8217; Financial Advisor</font>&#8221;, the substance of which had been previously disclosed to the Board and known during the pendency of the evaluation of the potential transaction with Treeline and Company H. The fact that Centerview had relationships with Casdin had also been previously disclosed to the Board </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">152<br></div></div></div>
<!--End Page 163-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 164-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_115-merger_pg19"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">and known since the outset of the process leading to the SomaLogic Transaction. The letter did not disclose any financial advisory engagements with any of Company H, Company I or Treeline in the past two years or the receipt of any investment banking, financial advisory or financing fees from Company H, Company I or Treeline in the past two years. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Also on May&#160;5, 2026, representatives of UBS delivered to the Special Committee a customary relationship disclosure letter with respect to Company H, Treeline and Casdin. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Also on May&#160;5, 2026, representatives of Freshfields delivered to the Special Committee a customary relationship disclosure letter with respect to Company H, Treeline and Casdin, which letter did not disclose any mandates for or fees received from any of Company H, Treeline or Casdin since January&#160;1, 2024. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Also on May&#160;5, 2026, Treeline engaged Wedbush Securities Inc. (&#8220;Wedbush&#8221;) as its strategic financial advisor for the potential transaction with Standard BioTools based on Wedbush&#8217;s experience advising life sciences companies in reverse merger transactions. In the course of Treeline&#8217;s discussions with Standard BioTools, representatives of Wedbush met with and provided input to members of Treeline&#8217;s management. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Also on May&#160;5, 2026, representatives of Centerview informed representatives of each of Company K and Company L that Standard BioTools had decided to move forward with another alternative. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On May&#160;6, 2026, the Board held a meeting, with representatives of Standard BioTools management, Centerview, UBS and Freshfields and Mr.&#160;Rodriguez in attendance. The representatives of Centerview updated the Board on the status of discussions with Treeline, the status of the potential divestitures of the legacy businesses and a progress update on the scientific and commercial due diligence review of Treeline by the outside consultant that had been retained by Standard BioTools. The representatives of Freshfields provided the Board with an overview of the key terms in the initial draft of the Merger Agreement received from Fenwick, noting that the Special Committee and the Board would reconvene to review proposed positions to be taken in the draft Merger Agreement that would ultimately be sent back to Fenwick. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On May&#160;8, 2026, a representative of Vinson &amp; Elkins (&#8220;V&amp;E&#8221;), outside legal counsel to Casdin, informed a representative of Freshfields that the request for Casdin to provide a voting agreement in support of the potential transaction with Treeline was still being discussed internally with Casdin, while noting Casdin&#8217;s previously expressed concerns with signing such an agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Also on May&#160;8, 2026, Mr.&#160;Smith called a representative of Centerview to inquire about Standard BioTools&#8217; intended timing for informing Viking of the potential transaction and requesting a voting agreement and to express that Treeline would like to have signed the Merger Agreement by the end of the initial 30-day exclusivity period. On the same day, a representative of Fenwick discussed the same matters with a representative of Freshfields. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Also on May&#160;8, 2026, the Special Committee held a meeting, with representatives of UBS and Freshfields in attendance, to discuss the use of a private financing in the potential transaction. The Special Committee concluded that, while a private financing could be a helpful tool to support the valuation of the combined company, it was ultimately not necessary because the combined company was expected to be sufficiently capitalized by the parties&#8217; existing cash balances. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Also on May&#160;8, 2026, the UBS engagement letter was executed. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Also on May&#160;8, 2026, the representatives of Fenwick sent a draft of the voting agreement and a draft of the CVR agreement to Freshfields. Representatives of Freshfields shared Fenwick&#8217;s draft voting agreement with representatives of V&amp;E. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">During the weeks of May&#160;11, May&#160;18 and May&#160;25, 2026, each of Standard BioTools and Treeline continued to conduct due diligence with respect to the other party and engaged in several due diligence calls with representatives of the other party. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On May&#160;13, 2026, representatives of Standard BioTools management met in person in New York City with representatives of Treeline for a technical due diligence session on Treeline. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Later on May&#160;13, 2026, the Board held a meeting, with representatives of Standard BioTools management, Centerview, UBS and Freshfields and Mr.&#160;Rodriguez in attendance. Mr.&#160;Casdin was not in attendance at the meeting. The representatives of Freshfields reviewed the material points in the draft Merger Agreement received from Fenwick, and the representatives of Freshfields recommended positions on those points. The Board discussed </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">153<br></div></div></div>
<!--End Page 164-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 165-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_115-merger_pg20"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">several considerations with the representatives of Centerview, UBS and Freshfields, including, among other things, (i) that Standard BioTools management had explored a &#8220;CVR trust&#8221; structure as an alternative to divesting the legacy businesses, but that such a structure would likely result in a lower valuation for Standard BioTools because it would require a cash infusion potentially larger than the deduction to net cash for wind-down costs remaining at closing, among other complications, and (ii) whether a private financing should be raised in connection with the potential transaction, noting that while a private financing could support the combined company&#8217;s initial trading value after the merger, the fact patterns for reverse mergers using private financings were not analogous to Standard BioTools&#8217; situation given the combined company&#8217;s significant expected cash balance. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In an executive session without the representatives of Standard BioTools management, Mr.&#160;Casdin or Mr.&#160;Rodriguez present, the Board discussed that voting agreements from Casdin and Viking had been requested firmly by Treeline. The Board also discussed with the representatives of Freshfields the importance of negotiating for a locked-up deal in which Treeline was not able to pursue alternative transactions in order to maximize transaction certainty, and that the representatives of Freshfields had proposed to Fenwick that Treeline stockholders approve the potential transaction by written consent immediately following signing of the Merger Agreement, which would remove any interloper risk on the Treeline side that would otherwise exist after public announcement of the potential transaction. The Board further discussed that it would be reasonable to accept the &#8220;force the vote&#8221; construct for the Standard BioTools stockholder vote in light of the proposal regarding Treeline stockholder approval. In this discussion, the members of the Board discussed that there was significantly more interloper risk with respect to a potential acquisition of Treeline, which was a promising biotechnology company with a number of product candidates, than there was the possibility of an attractive third party proposal for Standard BioTools, which was trading below its cash balance and which had been in discussions with a large number of potential transaction counterparties for a significant period of time. Both members of the Special Committee, who were present in the executive session without any representative of Casdin present, concurred with the positions to be taken and authorized returning a responsive markup of the Merger Agreement to the representatives of Fenwick, indicating that the Standard BioTools voting agreements and private financing were open issues and otherwise reflecting the positions discussed at the meeting. The members of the Special Committee stated that they would not require a separate meeting to discuss the positions to be taken in the draft Merger Agreement as they supported those positions. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On May&#160;14, 2026, Mr.&#160;Carey and a representative of Freshfields spoke with a representative of V&amp;E regarding the request for Casdin to sign a voting agreement in support of the potential transaction with Treeline. Mr.&#160;Carey and a representative of Freshfields indicated that closing certainty and a public expression of Casdin&#8217;s support for the potential transaction were of critical importance to Treeline. The representative of V&amp;E stated that while Casdin was supportive of the potential transaction, Casdin did not want to sign such a voting agreement, and that he did not anticipate that Casdin would ultimately agree to do so without also conditioning the closing of the potential transaction on the approval of a majority of the stockholders of Standard BioTools unaffiliated with Casdin (such requirement, the &#8220;Majority of the Unaffiliated Approval&#8221;). That same day, Mr.&#160;Casdin contacted Dr.&#160;Bilenker by telephone to inform Dr.&#160;Bilenker that Casdin did not want to sign a voting agreement.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Also on May&#160;14, 2026, Treeline management and members of the Treeline Board held a meeting to provide the Treeline Board with an update on the status of the potential transaction, including a review of open issues. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">A representative of Freshfields contacted each of Mr.&#160;Eloi and Dr.&#160;Witney after the discussion with V&amp;E to alert them to that discussion, and they discussed the Majority of the Unaffiliated Approval concept. In those discussions, each member of the Special Committee noted that Treeline had insisted it would not proceed with the potential transaction without an unqualified voting commitment from Casdin, and expressed concerns about whether the potential transaction would proceed were Casdin to remain unwilling to do so. In that regard and after the discussion of the pros and cons of the Majority of the Unaffiliated Approval, each of Mr.&#160;Eloi and Dr.&#160;Witney expressed their views to the representatives of Freshfields that while they would support the inclusion of such a condition, they would be comfortable proceeding without it.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On May&#160;15, 2026, representatives of Freshfields and Fenwick spoke by telephone. The representatives of Freshfields relayed the position of Casdin as articulated in the discussion that they had with Casdin&#8217;s outside counsel. The representatives of Fenwick reaffirmed that Treeline would require a voting agreement from Casdin in support of the potential transaction and that they did not foresee the Treeline Board authorizing the potential transaction without one.</div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">154<br></div></div></div>
<!--End Page 165-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 166-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_115-merger_pg21"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Also on May&#160;15, 2026, Freshfields sent a revised draft of the Merger Agreement to Fenwick. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Also on May&#160;15, 2026, representatives of Treeline, Standard BioTools management and Centerview met by videoconference to discuss Standard BioTools&#8217; financial position and anticipated net cash balance. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On May&#160;19, 2026, representatives of Freshfields and Fenwick spoke by telephone. The representatives of Fenwick requested to speak directly with a representative of V&amp;E regarding the Casdin voting agreement, and the representatives of Freshfields stated that they would arrange that conversation.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On May&#160;20, 2026, Fenwick sent a revised draft of the Merger Agreement to Freshfields, which, among other things, (i) reverted to Treeline&#8217;s prior position that Treeline stockholder approval would be provided only after effectiveness of the Standard BioTools registration statement, (ii) proposed that each party reimburse the other&#8217;s expenses if its stockholders voted down the potential transaction, up to a cap to be determined, (iii) provided that each party pay the other party a fiduciary out termination fee in certain circumstances, in an amount to be determined, (iv) did not contemplate a private financing and (v) required Standard BioTools to use commercially reasonable efforts to effect enumerated wind-down activities related to the legacy businesses and permitted the divestiture of the legacy businesses in the interim period with Treeline&#8217;s consent. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Also on May&#160;20, 2026, representatives of Treeline, Standard BioTools, Fenwick, Brown Rudnick LLP, intellectual property counsel to Standard BioTools, Freshfields and Centerview met by videoconference for an intellectual property due diligence session on Treeline&#8217;s intellectual property. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On May&#160;21, 2026, Standard BioTools executed a wall-cross confidentiality agreement with Viking. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Also on May&#160;21, 2026, Dr.&#160;Bilenker and Mr.&#160;Carey spoke by telephone to discuss the potential transaction. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Also on May&#160;21, 2026, representatives of Freshfields, Fenwick and V&amp;E met by videoconference. A representative of V&amp;E requested, on behalf of Casdin, that given Casdin Capital&#8217;s investment in Treeline, in order for Casdin to consider entering into a voting agreement, Standard BioTools and Treeline would need to condition the closing of the potential transaction on the Majority of the Unaffiliated Approval. The representatives of Freshfields stated that they believed the Board and Special Committee would support such a condition, and articulated reasoning to the representatives of Fenwick as to why they believed such a condition would not cause undue uncertainty to the potential transaction. The representatives of Fenwick noted that such a condition was not necessary as the Board had created the Special Committee to address any potential conflicts of interest from Casdin having a small ownership stake in Treeline. The representatives of Fenwick nonetheless said that they would discuss this proposal with Treeline.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Later on May&#160;21, 2026, the Treeline Board held a meeting, with Mr.&#160;Smith and representatives of Fenwick in attendance. At this meeting, Mr.&#160;Smith reviewed the potential transaction with Standard BioTools and the related timeline. A representative of Fenwick then discussed the potential transaction terms and open issues, and reviewed the fiduciary duties of the Treeline Board in evaluating the potential transaction. The Treeline Board and representatives of Fenwick discussed the request by V&amp;E for a Majority of the Unaffiliated Approval, and the Treeline Board directed the representatives of Fenwick to respond that Treeline would not be willing to proceed with a transaction that was subject to a Majority of the Unaffiliated Approval. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Later on May&#160;21, 2026, the Board held a meeting, with representatives of Standard BioTools management, Centerview, UBS and Freshfields and Mr.&#160;Rodriguez in attendance. The representatives of Standard BioTools management and Centerview provided an update on discussions with prospective buyers for legacy businesses. A representative of Centerview then presented to the directors the findings of the scientific and commercial due diligence review conducted by the outside consultant retained by Standard BioTools, which were fundamentally aligned with Standard BioTools management&#8217;s view of the Treeline pipeline and opportunity. The Board then discussed several considerations with the representatives of Freshfields regarding the Merger Agreement, including the Board&#8217;s view that Standard BioTools (i) should continue to insist that Treeline deliver stockholder approval immediately following signing of the Merger Agreement, (ii) could agree to Treeline&#8217;s proposed expense reimbursement construct, up to a cap of approximately 1% of Standard BioTools&#8217; equity value at the transaction price, (iii) should add a restriction on the combined company raising a private financing below the transaction price for a period post-closing, which Treeline had verbally indicated it would be willing to accept, and (iv) propose that Standard BioTools use commercially reasonable efforts to divest the legacy businesses prior to closing with Treeline consent, and, if divestiture agreements had not been signed by the time of effectiveness of the Standard BioTools registration statement, Standard BioTools would be required to commence certain agreed wind-down activities. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">155<br></div></div></div>
<!--End Page 166-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 167-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_115-merger_pg22"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In executive session, without Mr.&#160;Casdin or Mr.&#160;Rodriguez present, a representative of Freshfields informed the Board that Casdin had indicated it would only be willing to sign a voting agreement if the potential transaction were subject to a Majority of the Unaffiliated Approval as an additional procedural safeguard, in addition to the Special Committee, in light of Casdin Capital&#8217;s ownership stake in Treeline. The representative of Freshfields explained the pros and cons of a Majority of the Unaffiliated Approval condition, and, following that discussion, the Board expressed its view that, while a Majority of the Unaffiliated Approval condition could provide an additional procedural safeguard in view of Casdin Capital&#8217;s investment in Treeline, the Board could make the judgment to support the potential transaction without a Majority of the Unaffiliated Approval condition. The members of the Special Committee noted that they had already had discussions with Freshfields regarding the Majority of the Unaffiliated Approval concept after it was first raised and that they had come to that judgment as well.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On the evening of May&#160;21, 2026, a representative of Fenwick called a representative of Freshfields to state that, after consideration, Treeline would not be willing to proceed with a transaction that was subject to a Majority of the Unaffiliated Approval. A representative of Freshfields subsequently relayed this position to a representative of V&amp;E.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On May&#160;22, 2026, the Special Committee held a meeting, with representatives of UBS and Freshfields in attendance, to discuss the proposed responses to open issues in the draft Merger Agreement that had been covered at the May&#160;21, 2026 meeting of the Board. After discussion among the members of the Special Committee and the representatives of UBS and Freshfields, the Special Committee determined that the draft Merger Agreement should be returned to Fenwick on that basis. The representatives of Freshfields informed the Special Committee of Treeline&#8217;s rejection of Casdin&#8217;s request to subject the potential transaction to a Majority of the Unaffiliated Approval. The Special Committee stated again that it would not require the Majority of the Unaffiliated Approval condition in order to move forward with the potential transaction in light of Treeline&#8217;s firm position on the topic. The Special Committee also discussed its view that Standard BioTools&#8217; standalone strategy was no longer viable in light of the fact that Standard BioTools&#8217; strategic alternatives review had not yielded any suitable life sciences tools acquisition targets, and that its decision whether to approve the potential transaction with Treeline would be informed by a comparison of the value creation from the potential transaction with a liquidation scenario in which the liquidation proceeds would be distributed to stockholders. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Also on May&#160;22, 2026, representatives of Treeline, Standard BioTools, Fenwick, KPMG and Centerview met by videoconference for a due diligence discussion of Treeline&#8217;s finance and accounting. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On May&#160;23, 2026, the representatives of Freshfields sent a revised draft of the Merger Agreement to Fenwick. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Also on May&#160;23, 2026, at the request of Mr. Carey and Standard BioTools management, a representative of Centerview contacted Mr.&#160;Casdin by telephone to discuss the fact that conditioning that the closing of the potential transaction on a Majority of the Unaffiliated Approval would not be acceptable to Treeline, as had been communicated by the representatives of Fenwick on May&#160;21, 2026. Mr.&#160;Casdin responded by noting his concerns in view of Casdin Capital&#8217;s investment in Treeline, while agreeing that he would no longer insist on a Majority of the Unaffiliated Approval. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On May&#160;24, 2026, the representatives of Freshfields delivered a revised draft voting agreement to the representatives of V&amp;E in the form required by Treeline but with modifications to make the voting agreement potentially more palatable to Casdin and more beneficial to Standard BioTools. In particular, the draft voting agreement provided that no more than 35% of the outstanding Standard BioTools shares entitled to vote would be subject to voting commitments across all voting agreement signatories in the aggregate. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On May&#160;25, 2026, the representatives of Fenwick sent a revised draft of the Merger Agreement to Freshfields, which, among other things, (i) rejected the 12-month post-closing restriction on equity issuances (including any private financing) at a lower valuation than the transaction price and (ii) proposed a fiduciary out termination fee, payable by Standard BioTools in certain circumstances, of $27.5&#160;million, or approximately 5.4% of Standard BioTools&#8217; equity value at the transaction price. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On May&#160;26, 2026, the Special Committee held a meeting, with representatives of Freshfields, in attendance, to discuss the process leading to a signing of the potential transaction with Treeline and an update on the negotiations regarding definitive transaction documents. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Also on May&#160;26, 2026, Mr.&#160;Carey, Dr.&#160;Egholm and Mr.&#160;Mackay met with representatives of Viking to discuss the potential transaction with Treeline and the request for a voting agreement from Viking. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">156<br></div></div></div>
<!--End Page 167-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 168-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_115-merger_pg23"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On May&#160;27, 2026, Dr.&#160;Bilenker and Mr.&#160;Smith delivered a management presentation by videoconference to representatives of Viking. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Also on May 27, 2026, the representatives of Freshfields sent a revised draft of the CVR agreement to Fenwick. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Also on May&#160;27, 2026, a representative of V&amp;E sent a revised draft of the voting agreement to Freshfields, that included, among other things, (i) a fall-away of Casdin&#8217;s voting commitments upon an Adverse Recommendation Change, so that Casdin would not have to vote in favor of the potential transaction in the event of an Adverse Recommendation Change, and (ii) an indemnity pursuant to which Standard BioTools would indemnify Casdin for losses suffered as a result of litigation arising out of or related to the voting agreement or the Merger Agreement and payment by Standard BioTools of Casdin&#8217;s out-of-pocket costs and expenses in connection with the voting agreement, which positions the representative of V&amp;E stated that Casdin had requested after, and in response to, Treeline&#8217;s position on Casdin&#8217;s requests for the Majority of the Unaffiliated Approval, and the Board and Special Committee being willing to proceed without a Majority of the Unaffiliated Approval condition in light of Treeline&#8217;s firm position. Later that day, representatives of Fenwick communicated to representatives of Freshfields that they believed that the Treeline Board would be of the view that a voting agreement without a fall-away upon an Adverse Recommendation Change was the sole basis on which Treeline would be willing to transact, but that it believed that Treeline Board would accept the 35% cap across all voting agreements. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Also on May&#160;27, 2026, the Board held a meeting, with representatives of Standard BioTools management, Centerview, UBS and Freshfields and Mr.&#160;Rodriguez in attendance. The Board discussed several considerations with the representatives of Freshfields regarding the draft Merger Agreement and draft CVR agreement, including, among other things, that (i) the methodology for determining the deductions to Standard BioTools&#8217; net cash at closing and post-closing CVR proceeds would be the subject of further negotiation between the parties, (ii) the restriction on a post-closing private financing should be reinstated with a duration of six months, (iii) the expense reimbursement cap should be filled in as $5&#160;million and (iv) the fiduciary out termination fee should be 3.5% of Standard BioTools&#8217; equity value at the transaction price. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Also at the meeting, the representatives of Centerview presented their financial analysis of Standard BioTools on a standalone basis based on Standard BioTools management&#8217;s projections. Standard BioTools management had also provided Centerview with a liquidation value for Standard BioTools, which implied greater value to Standard BioTools stockholders than the standalone forecasts. The Board directed Centerview to use liquidation value as the metric against which to compare the value creation offered by the potential transaction as a result. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In executive session, without the representatives of Standard BioTools management, Mr.&#160;Casdin or Mr.&#160;Rodriguez present, the Board discussed the ongoing negotiations around the Casdin voting agreement. The representatives of Freshfields reported that the representatives of Fenwick had made it clear earlier that day that Treeline insisted on removing the fall-away provision from the voting agreement. The Board discussed with the representatives of Freshfields Casdin&#8217;s requests for indemnity and expense reimbursement, and the Board determined that it was not willing to agree to those provisions. The members of the Special Committee stated that they agreed with these positions, and the Board and the Special Committee directed that a revised draft of the voting agreement be returned to V&amp;E removing the fall-away upon an Adverse Recommendation Change, as insisted upon by Treeline, and rejecting Casdin&#8217;s other requests. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Also on May&#160;27, 2026, the representatives of Freshfields sent a revised draft of the voting agreement to V&amp;E. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On May&#160;27 and May&#160;28, 2026, the representatives of Fenwick sent revised drafts of the CVR agreement and Merger Agreement to Freshfields. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On May&#160;28, 2026, Mr.&#160;Smith called a representative of Centerview to inquire as to the status of the request that Viking sign a voting agreement in support of the potential transaction. Following that meeting, the representatives of Freshfields sent a draft voting agreement to Cleary, Gottlieb, Steen &amp; Hamilton LLP (&#8220;Cleary&#8221;), outside legal counsel to Viking. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Also on May&#160;28, 2026, a representative of V&amp;E sent a revised draft of the voting agreement to Freshfields that reinstated the fall-away, indemnity and expense reimbursement provisions. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Also on May&#160;28, 2026, Mr.&#160;Mackay and Mr.&#160;Smith spoke by telephone to discuss that Standard BioTools management&#8217;s estimated net cash balance at closing, after further refinement by Standard BioTools management, was expected to be approximately $450&#160;million and to discuss certain terms of the CVR agreement. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">157<br></div></div></div>
<!--End Page 168-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 169-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_115-merger_pg24"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Also on May&#160;28, 2026, the Treeline Board held a meeting, with Mr.&#160;Smith and representatives of Fenwick in attendance. Mr.&#160;Smith presented to the Treeline Board updates on the potential transaction, including regarding the discussions related to divestitures of Standard BioTools&#8217; legacy businesses. Representatives of Fenwick then reviewed with the Treeline Board the status of the voting agreements from certain Standard BioTools stockholders, including a proposed 35% cap on shares subject to voting commitments and Casdin&#8217;s requests with respect to its voting agreement. Following discussion, the Treeline Board determined that Casdin&#8217;s participation in the voting agreements, without a fall-away provision, was necessary in order to proceed with the potential transaction, but that Treeline could accept the 35% cap, as had been communicated by representatives of Fenwick to representatives of Freshfields. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Also on May&#160;28, 2026, Mr.&#160;Carey and Dr.&#160;Bilenker spoke by telephone and discussed the potential transaction and Treeline&#8217;s requirements for Casdin and Viking to enter into voting agreements. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Also on May&#160;28, 2026, Standard BioTools and Treeline executed an amendment to the term sheet that extended the earliest time at which either party could terminate exclusivity from 11:59 p.m. Eastern Time on May&#160;29, 2026 to 11:59&#160;p.m. Eastern Time on June&#160;1, 2026. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On May&#160;29, 2026, Dr.&#160;Bilenker, Mr.&#160;Smith and Dr.&#160;Jeffrey Engelman, Chief Scientific Officer of Treeline, had a follow-up call with representatives of Viking to further review Treeline&#8217;s management presentation. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Also on May&#160;29, 2026, the Special Committee held a meeting, with representatives of UBS and Freshfields in attendance. Representatives of UBS reviewed Standard BioTools management&#8217;s updated financial projections for Treeline (the &#8220;May&#160;27 Treeline Projections&#8221;), which had been updated from the April&#160;17 Treeline Projections based on the results of Standard BioTools&#8217; scientific and commercial due diligence review, as well as the key underlying revenue and cost assumptions for such projections. Representatives of UBS noted that the updated assumptions reflected Standard BioTools management&#8217;s views regarding increased probability of success for each of Treeline&#8217;s programs. Representatives of UBS reviewed UBS&#8217; preliminary financial analysis of Treeline and the exchange ratio provided for in the Merger Agreement (the &#8220;Exchange Ratio&#8221;), based on the May&#160;27 Treeline Projections and the wind-down value of Standard BioTools provided by Standard BioTools management. The members of the Special Committee discussed their view that, taking into account the financial analyses reviewed by representatives of UBS, the potential value creation from the potential transaction was higher than the wind-down value of Standard BioTools. The Special Committee directed UBS to use the wind-down value of Standard BioTools for its financial analysis and fairness opinion. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Special Committee discussed with the representatives of Freshfields that the parties remained at an impasse on the open points in the Casdin voting agreement. The Special Committee reaffirmed its determinations (i) to support Standard BioTools&#8217; rejection of the indemnity and expense reimbursement provisions requested by Casdin and (ii) that a fall-away upon an Adverse Recommendation Change was not necessary, including in light of the fact that the fall-away was not acceptable to Treeline.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Also on May&#160;29, 2026, representatives of UBS delivered to the Special Committee an updated relationship disclosure letter with respect to Treeline and Casdin. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Also on May&#160;29, 2026, Mr.&#160;Carey and Dr.&#160;Bilenker spoke again by telephone and discussed the potential transaction and Treeline&#8217;s requirements for voting agreements. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On May&#160;29 and May&#160;30, 2026, the representatives of Freshfields and Fenwick continued to negotiate and exchange drafts of the Merger Agreement and the related disclosure letters, CVR agreement and other ancillary transaction documents. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Also on May&#160;30, 2026, Dr.&#160;Egholm and Mr.&#160;Mackay met by videoconference with representatives of Viking to further discuss the potential transaction and the request that Viking sign a voting agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Also on May&#160;30, 2026, the representatives of Cleary sent a revised draft of the Viking voting agreement to Freshfields, which the representatives of Freshfields discussed with representatives of Fenwick, and then confirmed to Cleary was in agreed form. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Also on May&#160;30, 2026, at the request of Mr. Carey and Standard BioTools management, a representative of Centerview contacted Mr.&#160;Casdin by telephone to see if Mr.&#160;Casdin would be willing to change his position regarding the voting agreement. Mr.&#160;Casdin responded by telling the representative of Centerview that he believed that the Treeline transaction was the best outcome for Standard BioTools stockholders and that, notwithstanding his </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">158<br></div></div></div>
<!--End Page 169-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 170-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_115-merger_pg25"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">concerns regarding Casdin Capital&#8217;s investment in Treeline, if Treeline would not proceed without a voting commitment in the form they had originally sought from Casdin, Casdin would drop the requests for the fall-away provision, indemnity and expense reimbursement and sign a voting agreement in the form required by Treeline. Later that day, a representative of V&amp;E corroborated what Mr.&#160;Casdin had told the representative of Centerview. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Also on May&#160;30, 2026, Dr.&#160;Bilenker and Mr.&#160;Carey spoke by telephone regarding the anticipated upcoming announcement of the potential transaction. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Also on May&#160;30, 2026, the Centerview engagement letter was executed. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On the morning of May&#160;31, 2026, a representative of V&amp;E informed the representatives of Freshfields that Mr.&#160;Casdin was reconsidering his position on the voting agreement in light of his and his advisors&#8217; previously stated concerns with respect to the voting agreement and had requested that the meeting of the Board scheduled for that day be delayed. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Later that morning, the Special Committee held a meeting, with representatives of UBS and Freshfields in attendance. Representatives of Freshfields provided the update on transaction discussions, reporting that transaction documentation had been finalized, but noting the communication that had been received from V&amp;E shortly before the Special Committee meeting. The Special Committee determined that it should proceed with the meeting as planned and requested that UBS deliver its fairness opinion at the meeting so that Standard BioTools could proceed to enter into the transaction later that day if the issue around the Casdin voting agreement was successfully resolved. The representatives of Freshfields again provided the Special Committee with a presentation on the fiduciary duties and standards of review with respect to the potential transaction under Delaware law. Mr.&#160;Eloi and Dr.&#160;Witney reaffirmed their independence from each of Treeline and Casdin and their disinterestedness regarding the potential transaction and re-confirmed that they did not have financial, professional, social or other relationships that would impair their independence or disinterestedness. The representatives of Freshfields then reviewed with the Special Committee the independence of each of UBS (including with respect to the updated relationship disclosure letter previously made available to the Special Committee) and Freshfields, noting that Freshfields had not had any mandates for or received any fees from Treeline or Casdin. Following that review, the Special Committee affirmed that it had no concerns regarding the independence of UBS or Freshfields or their ability to have advised the Special Committee. The representatives of Freshfields presented to the Special Committee the key terms of the Transaction Documents, and, after discussion, the Special Committee determined that it had no further questions regarding their terms. Representatives of UBS reviewed UBS&#8217; financial analyses of the Exchange Ratio, and then delivered the oral opinion of UBS to the effect that, as of such date and based upon, and subject to, among other things, the assumptions made, procedures followed, matters considered and qualifications and limitations on the review undertaken by UBS in connection with its opinion, the Exchange Ratio provided for in the Merger was fair, from a financial point of view, to Standard BioTools. After discussion, the Special Committee (i) determined that the potential transaction was advisable, fair to and in the best interests of Standard BioTools and its stockholders, (ii) approved and declared advisable the Transaction Documents and the Transactions, (iii) recommended that the Board approve and authorize the execution and delivery by Standard BioTools of, and performance by Standard BioTools of its obligations under the Transaction Documents, and the consummation by Standard BioTools of the Transactions, and (iv) recommended that the Board resolve to recommend approval of the Stock Issuance and the Charter Amendment by Standard BioTools stockholders. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Following the meeting of the Special Committee and still on the morning of May&#160;31, 2026, the Board held a meeting, with representatives of Standard BioTools management, Centerview, UBS and Freshfields in attendance, from which Mr.&#160;Casdin recused himself. Mr.&#160;Rodriguez was not present at the meeting. A representative of Freshfields provided the Board with an update on the status of the negotiations around the Casdin voting agreement and informed the Board that the Special Committee had approved the potential transaction and recommended that the Board approve the potential transaction, in each case on the basis that the issue around the Casdin voting agreement was successfully resolved. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Representatives of Freshfields again provided the Board with a presentation on the fiduciary duties and standards of review with respect to the potential transaction under Delaware law. Mr.&#160;Cox also recalled that Dr.&#160;Bilenker, in his past role at Loxo Oncology had been a customer of Foundation Medicine when Mr.&#160;Cox was Chief Executive Officer of Foundation Medicine many years ago. The Board and the representatives of Freshfields noted Mr.&#160;Cox&#8217;s disclosure and concluded that it did not raise any concerns. The representatives of Freshfields then reviewed with the Board the updated relationship disclosure letter previously made available to the Board by </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">159<br></div></div></div>
<!--End Page 170-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 171-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_115-merger_pg26"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Centerview, noting that Centerview had existing relationships with Casdin, which had been previously disclosed and known during the pendency of the evaluation of the potential transaction, and had no mandates for, and did not receive any fees from, Treeline in the past two years. The representatives of Freshfields noted that Freshfields had not had any mandates for or received any fees from Treeline or Casdin. The representatives of Freshfields presented to the Board the key terms of the Transaction Documents, and, after discussion, the Board determined that it had no further questions regarding their terms. The representatives of Centerview then reviewed with the Board Centerview&#8217;s financial analysis of the Exchange Ratio and a comparison of the value creation for Standard BioTools stockholders in the potential transaction against the liquidation value for Standard BioTools, which comparison showed that the value creation from the potential transaction was higher than the liquidation value. The Board then agreed to reconvene when there was a further update on the Casdin voting agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">During the remainder of the day, the representatives of Freshfields had conversations with representatives of V&amp;E and Fenwick to see if there was a way to reach agreement on the voting agreement from Casdin. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On the evening of May&#160;31, 2026, the Treeline Board held a meeting, with Mr.&#160;Smith and representatives of Fenwick in attendance. Dr.&#160;Bilenker reviewed with the Treeline Board the status of the potential transaction with Standard BioTools and the voting agreement from Casdin. Following discussion, the Treeline Board determined not to proceed with the potential transaction with Standard BioTools without a voting agreement from Casdin in the form they were seeking, and directed that a notice be sent to Standard BioTools to return or destroy all Treeline confidential information in Standard BioTools&#8217; possession. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On the evening of May&#160;31, 2026, a representative of Fenwick emailed Freshfields stating that the Treeline Board had met and was not willing to proceed without a signed voting agreement from Casdin in the form they were seeking. Later that evening, a representative of Fenwick sent Freshfields a formal letter requesting Standard BioTools return or destroy all Treeline confidential information. Representatives of Freshfields subsequently notified representatives of V&amp;E of this development.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Also on the evening of May&#160;31, 2026, the representatives of Freshfields informed the Special Committee of the decision of the Treeline Board. The oral opinion delivered by UBS to the Special Committee earlier that day was of no further force or effect. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On June&#160;1, 2026, Mr.&#160;Mackay contacted Mr.&#160;Smith by telephone to inform him that Standard BioTools was considering potential next steps to find a path forward to signing the Merger Agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Also on June&#160;1, 2026, the Special Committee held a meeting, with the representatives of Freshfields and a representative of Richards, Layton &amp; Finger, P.A. (&#8220;RLF&#8221;), Delaware counsel to Standard BioTools, in attendance. The Special Committee discussed with representatives of Freshfields and RLF V&amp;E&#8217;s concerns that the voting agreement, in the form required by Treeline, would not fall away in the event of an Adverse Recommendation Change. The Special Committee discussed with the representatives of Freshfields and RLF that the aggregate 35% cap on the number of Standard BioTools shares subject to the voting agreements was specifically introduced by Freshfields and RLF to address these types of concerns. The Special Committee and the representatives of Freshfields discussed potential solutions to the impasse, including whether there were changes that could be made to the voting agreement to make it more palatable to Casdin in light of the concerns expressed by Casdin. The Special Committee determined to reconvene the next morning to discuss the matter further. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On the morning of June&#160;2, 2026, the Special Committee held a meeting, with representatives of Standard BioTools management, UBS, Freshfields and RLF in attendance. The representatives of Standard BioTools management presented their view of the options available to Standard BioTools: (i) the potential transaction with Treeline, which appeared to provide the highest potential return to Standard BioTools and its stockholders, (ii) the divestiture of the legacy businesses and liquidation of the remainder of Standard BioTools, (iii) the full wind-down of the legacy businesses and liquidation of Standard BioTools and (iv) continuing to operate the legacy businesses, implement significant restructuring measures and continue to explore M&amp;A opportunities. The representatives of Standard BioTools management expressed their view that the standalone operating path was the most challenging, and that, in the absence of the transaction with Treeline, a wind-down of the legacy businesses would preserve the most value for its stockholders. In an executive session without the representatives of Standard BioTools management or UBS present, the Special Committee restated its belief in the merits of the potential transaction, including its view that it was financially superior for Standard BioTools stockholders than the other alternatives, </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">160<br></div></div></div>
<!--End Page 171-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 172-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_115-merger_pg27"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">including liquidation. The Special Committee also discussed further potential changes to the voting agreement that could make it more palatable to Casdin. The Special Committee decided to invite the other Board members (excluding Mr.&#160;Casdin) before the Special Committee determined a course of action. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On the afternoon of June&#160;2, 2026, the Special Committee held a meeting, with the other members of the Board (excluding Mr.&#160;Casdin) and representatives of Standard BioTools management, UBS, Freshfields and RLF in attendance. The representatives of Standard BioTools management repeated the presentation they had given to the Special Committee that morning. In executive session without the representatives of Standard BioTools management or UBS present, the directors discussed a potential solution suggested by Freshfields, which was for the Standard BioTools shares held by Casdin Capital to be cut back upon an Adverse Recommendation Change such that the total shares subject to voting commitments would not exceed 30% of Standard BioTools shares entitled to vote (the &#8220;Cutback Proposal&#8221;). The representatives of Freshfields further explained that, following an Adverse Recommendation Change, the shares committed to be voted pursuant to Casdin&#8217;s voting agreement (and the voting agreements of the other directors and officers) would be cut back such that the total shares that would remain subject to voting commitments would be capped at 30% of the shares entitled to vote. The representatives of Freshfields explained that, because Casdin collectively owned approximately 23.4% of Standard BioTools&#8217; shares, Standard BioTools&#8217; directors and officers (other than Mr.&#160;Casdin) collectively owned approximately 0.7% and Viking owned approximately 15%, the Cutback Proposal would ensure that, in the event of an Adverse Recommendation Change, Casdin would not be committed to vote any more shares in favor of the potential transaction than Viking, an unaffiliated sophisticated third party investor. The Special Committee discussed with the representatives of Freshfields and RLF their view that the Cutback Proposal was better than the 35% cap, with which the Special Committee had already been comfortable. Following discussion with its legal advisors, the Special Committee directed the representatives of Freshfields to convey it to V&amp;E and to instruct a representative of Centerview to convey it to Casdin directly to see if that could constitute a basis on which Casdin would be comfortable delivering a voting agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On June&#160;3, 2026, a representative of Centerview called Mr.&#160;Casdin to communicate the Cutback Proposal, and a representative of Freshfields called a representative of V&amp;E to do the same. The representative of V&amp;E stated that he would take the proposal back to Casdin for consideration. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On June&#160;4, 2026, a representative of V&amp;E informed Freshfields that Casdin was aligned with the Cutback Proposal in concept and would be willing to proceed to sign a voting agreement on that basis, subject to review of the proposed language. The representative of V&amp;E also stated that it was important that the cutback mechanism would apply on a pro rata basis among Casdin and the other Standard BioTools directors and officers based on their respective shareholdings such that Mr.&#160;Casdin would effectively be situated in the same manner as the other directors and officers. The representatives of Freshfields then sent a draft voting agreement to V&amp;E reflecting the Cutback Proposal. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Also on June&#160;4, 2026, the Special Committee held a meeting, with representatives of Freshfields and RLF in attendance, to receive an update from Freshfields regarding the discussions that had occurred with V&amp;E and to discuss next steps. After discussion, the Special Committee directed that the Cutback Proposal be communicated to the representatives of Fenwick to determine whether Treeline would be willing to proceed on that basis. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Throughout the rest of June&#160;4 and June&#160;5, 2026, the representatives of Centerview and Freshfields communicated with the representatives of Treeline and Fenwick regarding the Cutback Proposal. The representatives of Treeline and Fenwick indicated that they believed that the Treeline Board would be willing to approve the execution of the Merger Agreement on that basis. Throughout June&#160;5, 2026 and June&#160;6, 2026, the representatives of Freshfields and Fenwick exchanged successive revised drafts of the Merger Agreement and related disclosure schedules, and of the CVR Agreement, and finalized the forms of these documents. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On June&#160;5, 2026, Dr.&#160;Egholm and Mr.&#160;Mackay met by videoconference with representatives of Viking to provide them with an update on the status of the potential transaction, including that the Merger Agreement could be signed later that day or the following day. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On the evening of June&#160;5, 2026, the Special Committee held a meeting, with representatives of UBS and Freshfields in attendance, to consider the potential transaction and to review the final form of the Merger Agreement. Mr.&#160;Mackay informed the Special Committee that late the previous evening, the U.S. Food &amp; Drug Administration had placed a partial clinical hold on studies involving TLN-254, a program licensed from China intended for co-development with Treeline&#8217;s proprietary program TLN-121, including Treeline&#8217;s TLN-254 </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">161<br></div></div></div>
<!--End Page 172-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 173-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_115-merger_pg28"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">monotherapy Phase 1 study and the TLN-254 combination cohort of the TLN-121 Phase 1 study. Mr.&#160;Mackay explained that Standard BioTools management had reviewed this development with its advisors and, taking into account the advice of its advisors, determined that it had no effect on the valuation of Treeline or the desirability of the potential transaction. Representatives of Freshfields again provided the Special Committee with a presentation on the fiduciary duties and standards of review with respect to the potential transaction under Delaware law. Representatives of UBS confirmed that there had been no changes to UBS&#8217; relationship disclosure since the meeting of the Special Committee on May&#160;31, 2026. Mr.&#160;Eloi and Dr.&#160;Witney reaffirmed their independence from each of Treeline and Casdin and their disinterestedness regarding the potential transaction and re-confirmed that they did not have financial, professional, social or other relationships that would impair their independence or disinterestedness. The Special Committee then discussed the revisions to the Transaction Documents since May&#160;31, 2026 with Freshfields and determined that it had no further questions regarding their terms. Representatives of UBS reviewed UBS&#8217; financial analyses of the Exchange Ratio, and then delivered the oral opinion of UBS, which was subsequently confirmed by delivery of a written opinion dated as of June&#160;5, 2026, to the effect that, as of that date and based upon, and subject to, among other things, the assumptions made, procedures followed, matters considered and qualifications and limitations on the review undertaken by UBS in connection with its opinion, the Exchange Ratio provided for in the Merger was fair, from a financial point of view, to Standard BioTools, as more fully described below under the caption &#8220;<font style="font-style: italic;">The Merger &#8211; Opinion of the Special Committee&#8217;s Financial Advisor</font>&#8221;. After discussion, the Special Committee unanimously (i) determined that the potential transaction was advisable, fair to and in the best interests of Standard BioTools and its stockholders, (ii) approved and declared advisable the Transaction Documents and the Transactions, (iii) recommended that the Board approve and authorize the execution and delivery by Standard BioTools of, and performance by Standard BioTools of its obligations under the Transaction Documents, and the consummation by Standard BioTools of the Transactions, and (iv) recommended that the Board resolve to recommend approval of the Stock Issuance and the Charter Amendment by Standard BioTools stockholders.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Following the meeting of the Special Committee and still on June&#160;5, 2026, the Board held a meeting, with representatives of Standard BioTools management, Centerview, UBS and Freshfields in attendance, to consider the potential transaction and to review the final form of the Merger Agreement. Mr.&#160;Rodriguez was not present at the meeting. The representatives of Freshfields informed the Board that the Special Committee had met earlier that evening and approved the potential transaction and recommended that the Board approve the potential transaction. Mr.&#160;Mackay provided the Board with the same update he had provided the Special Committee regarding the partial clinical hold that had been put in place the prior evening. Mr.&#160;Casdin then left the meeting, recusing himself from the deliberations and the vote on the potential transaction. Representatives of Freshfields again provided the Board with a presentation on the fiduciary duties and standards of review with respect to the potential transaction under Delaware law. The representatives of Centerview confirmed that there had been no changes to its relationship disclosure since the meeting of the Board on May&#160;31, 2026. The Board then discussed the revisions to the Transaction Documents since May&#160;31, 2026 with Freshfields and determined that it had no further questions regarding their terms. Representatives of Centerview confirmed that the financial analysis presented to the Board on May&#160;31, 2026 had not materially changed, and then rendered an oral opinion, which was subsequently confirmed by delivery of a written opinion dated June&#160;6, 2026, that, as of such date and based upon and subject to various assumptions made, procedures followed, matters considered, and qualifications and limitations upon the review undertaken in preparing its opinion, the Exchange Ratio was fair, from a financial point of view, to Standard BioTools, as more fully described below under the caption &#8220;<font style="font-style: italic;">The Merger &#8211; Opinion of Standard BioTools&#8217; Financial Advisor</font>&#8221;. After discussion, the Board (i) determined that the potential transaction was advisable, fair to and in the best interests of Standard BioTools and its stockholders, (ii) approved and declared advisable the Transaction Documents and the Transactions, (iii) approved and authorized the execution and delivery by Standard BioTools of, and performance by Standard BioTools of its obligations under the Transaction Documents, and the consummation by Standard BioTools of the Transactions, and (iv) resolved to recommend approval of the Stock Issuance and the Charter Amendment by Standard BioTools stockholders. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On the morning of June&#160;6, 2026, the Treeline Board held a meeting by videoconference, with Mr.&#160;Smith and representatives of Fenwick in attendance. Mr.&#160;Smith provided the Treeline Board with an update on the potential transaction, including the Cutback Proposal, and the willingness of Casdin and Treeline to proceed with voting agreements that reflected this proposal but were otherwise in the form that had been previously agreed by the parties. Representatives of Fenwick then reviewed with the Treeline Board the terms and conditions of the proposed Merger Agreement and the transactions contemplated thereby. Following discussion, the Treeline Board </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">162<br></div></div></div>
<!--End Page 173-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 174-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_115-merger_pg29"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">(i)&#160;determined that the transactions contemplated by the Merger Agreement, including the Merger, were advisable, fair to and in the best interests of Treeline and its stockholders, (ii) approved and declared advisable the Merger Agreement and the contemplated transactions and (iii) resolved to recommend the adoption of the Merger Agreement by Treeline stockholders. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Later on June&#160;6, 2026, Standard BioTools and Treeline executed the Merger Agreement and the Voting Agreements, and each of Casdin and Viking also executed a Voting Agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On the morning of June&#160;8, 2026, before the opening of trading on Nasdaq, Standard BioTools and Treeline issued a joint press release announcing the execution of the Merger Agreement. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;"><a name="tSBIO1"><!--Anchor--></a>Standard BioTools&#8217; Reasons for the Merger </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In the course of reaching the recommendations described in the section of this proxy statement/prospectus captioned &#8220;&#8212;<font style="font-style: italic;">Recommendation of the Special Committee and the Standard BioTools Board</font>&#8221;, the Special Committee considered, in consultation with UBS, acting as financial advisor to the Special Committee, and Freshfields, acting as legal counsel to the Special Committee and Standard BioTools, and having discussed certain matters with Standard BioTools management, the following material factors that weighed in favor of the Merger Agreement and the Transactions, which are not intended to be exhaustive and are not presented in any relative order of importance: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the fact that Standard BioTools conducted an extensive, open and durationally significant strategic alternatives review process, initially focusing on potential acquisition targets and merger partners in the life sciences tools industry but not resulting in a transaction with any of them, and later broadening the strategic alternatives review process to include potential counterparties in the healthcare information technology and biotechnology industries; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the fact that Standard BioTools&#8217; strategic alternatives review process described above involved substantive discussions with more than 15 parties and preliminary discussions with numerous additional parties over the course of many months prior to focusing on discussions with Company G, Company I and Treeline as potential counterparties for a strategic transaction involving Standard BioTools; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the fact that Standard BioTools publicly disclosed in connection with the announcements of the signing of a definitive agreement for the SomaLogic Transaction on June&#160;23, 2025 and the completion of the SomaLogic Transaction on January&#160;30, 2026 that Standard BioTools intended to use its substantial cash balance to pursue strategic M&amp;A transactions, and anyone willing to propose a strategic transaction involving Standard BioTools had ample opportunity to do so; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Standard BioTools management&#8217;s feedback that Standard BioTools&#8217; standalone operating plan was no longer viable in light of the fact that Standard BioTools&#8217; strategic alternatives review had not yielded any suitable life sciences tools acquisition targets; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the financial condition and prospects of Standard BioTools and the risks associated with continuing to operate Standard BioTools on a standalone basis, particularly in light of the historical and projected financial performance of Standard BioTools&#8217; microfluidics and mass cytometry businesses as well as financial market conditions and the historical stock price performance of Standard BioTools Common Stock, which had traded at a discount to Standard BioTools&#8217; cash balance for an extended period; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Special Committee&#8217;s understanding of Standard BioTools&#8217; industry, business, strategy, technology, financial condition and prospects (including the prospects of Standard BioTools as a standalone company absent the potential transaction with Treeline and the risks involved in achieving such prospects), as well as Standard BioTools&#8217; historical and projected financial performance; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Special Committee&#8217;s belief, that absent the potential transaction with Treeline, Standard BioTools&#8217; prospects as a standalone company were limited; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the fact that Treeline was uniquely positioned as a viable candidate for a reverse merger transaction with Standard BioTools given the limited universe of attractive biotechnology companies that would be willing and able to support the dilution that would be caused by Standard BioTools&#8217; substantial cash balance in a business combination; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Special Committee&#8217;s belief in the key distinguishing factors making Treeline an attractive counterparty for a reverse merger with Standard BioTools, including the fact that its investor base was comprised of top </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">163<br></div></div></div>
<!--End Page 174-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 175-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_115-merger_pg30"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_bl" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: left;">tier biotech investors with discerning investment criteria and its four separate product candidates, which gave Treeline multiple opportunities for a successful launch and would derisk Standard BioTools&#8217; investment in Treeline as compared to a single-molecule biotech company; </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Special Committee&#8217;s positive view, based in part on the scientific and commercial due diligence conducted by Standard BioTools&#8217; management and advisors, that Treeline&#8217;s current development and clinical trial plans for its product candidates present a market opportunity with the potential to create meaningful value for the stockholders of the combined company and an opportunity for Standard BioTools&#8217; stockholders to participate in the future potential growth of the combined company; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Special Committee&#8217;s view that the combined company will be led by an experienced board of directors, comprising 10 current Treeline directors and two current Standard BioTools directors, and an impressive and experienced senior management team from Treeline; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Special Committee&#8217;s view that the exchange ratio provided pursuant to the Merger Agreement (the &#8220;Exchange Ratio&#8221;) was the result of extensive negotiation and a belief that the Exchange Ratio was the most favorable exchange ratio that could reasonably be obtained and the terms set forth in the Merger Agreement were the most favorable terms to Standard BioTools to which Treeline was willing to agree; <br></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Special Committee&#8217;s consideration of the expected cash balance of the combined company of more than $900&#160;million at Closing, including the approximately $450&#160;million of net cash expected to be contributed by Standard BioTools; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Special Committee&#8217;s view, following a review with Standard BioTools&#8217; management and its advisors of Treeline&#8217;s current development and clinical trial plans, of the likelihood that the combined company would possess sufficient cash resources at Closing to fund Treeline&#8217;s operations into the year 2029; <br></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the potential for legacy Standard BioTools&#8217; stockholders to receive additional value following the Closing pursuant to the CVR Agreement, which preserves for legacy Standard BioTools stockholders the potential value from the following sources, in each case less any deductions permitted under the CVR Agreement: (i) the proceeds of any sale, disposition or other monetization of Standard BioTools&#8217; legacy businesses; (ii) proceeds from convertible notes or other investments held by Standard BioTools as of the Closing Date; (iii) earnout, milestone, royalty or other similar contingent payments due to Standard BioTools under contracts in effect as of the Closing Date, including any payments from Illumina in respect of the SomaLogic Transaction; and (iv) any surplus in Standard BioTools&#8217; net cash delivered at Closing as finally determined under the Merger Agreement; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">that Standard BioTools&#8217; stockholders will continue to have ongoing equity participation in Standard BioTools following the Transactions and will be able to participate in the combined company&#8217;s potential future earnings and growth and to benefit from increases, if any, in the value of the shares of combined company common stock; <br></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Special Committee&#8217;s belief, which was reinforced by the limited interest from potential counterparties resulting from a thorough review of strategic alternatives by Standard BioTools, that the potential transaction with Treeline was the most favorable transaction available to Standard BioTools; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Special Committee&#8217;s belief, after extensive discussions with Standard BioTools management, financial advisors and legal counsel, that the potential transaction with Treeline is more favorable to Standard BioTools stockholders than the potential value that might have resulted from other strategic alternatives available to Standard BioTools, including the standalone operating plan or a liquidation or dissolution of Standard BioTools and the distribution of any available cash to its stockholders; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the financial analysis reviewed by UBS with the Special Committee as well as the oral opinion of UBS rendered to the Special Committee on June&#160;5, 2026, which was subsequently confirmed by delivery of a written opinion dated June 5, 2026, to the effect that, as of that date and based upon, and subject to, among other things, the assumptions made, procedures followed, matters considered and qualifications and limitations upon the review undertaken by UBS in connection with its opinion, the Exchange Ratio provided for in the Merger was fair, from a financial point of view, to Standard BioTools, as more fully described below under the caption &#8220;<font style="font-style: italic;">The Merger &#8211; Opinion of Standard BioTools Special Committee&#8217;s Financial Advisor</font>&#8221;; and </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">164<br></div></div></div>
<!--End Page 175-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 176-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_115-merger_pg31"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the terms and conditions of the Merger Agreement, as discussed in more detail in the section of this proxy statement/prospectus captioned &#8220;<font style="font-style: italic;">Merger Agreement</font>.&#8221; </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Special Committee also considered the factors discussed below, relating to the procedural safeguards that it believes were and are present to ensure the fairness of the Transactions to Standard BioTools stockholders. The Special Committee believes such factors support its determinations and recommendations and provide assurance of the procedural fairness of the Transactions: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the authority granted to the Special Committee by the Standard BioTools Board to negotiate the terms and conditions of the definitive agreement with respect to the Transactions, or to determine not to pursue the Transactions, and the fact that the Standard BioTools Board delegated to the Special Committee the full power and authority of the Standard BioTools Board to, among other things, explore, consider, evaluate, review, negotiate and approve or reject any potential transaction in which the counterparty was an entity in which Casdin Capital, LLC (together with its affiliates, &#8220;Casdin Capital&#8221;) held an economic interest; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">that the Merger Agreement provides that for all purposes under the Merger Agreement and the other agreements contemplated by the Merger Agreement, Standard BioTools and the Standard BioTools Board will act only as authorized and approved by, or in accordance with the recommendation of, as applicable, the Special Committee; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">that the Closing is conditioned upon (i) the approval of the Share Issuance, by the affirmative vote of a majority of the voting power of the shares of Standard BioTools&#8217; capital stock present in person or represented by proxy at the Special Meeting and entitled to vote on such matter and (ii) the approval of the Charter Amendment by the affirmative vote of the holders of Standard BioTools&#8217; capital stock entitled to vote thereon, voting as a single class, by a majority of the votes cast for or against such matter; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the ability of the Standard BioTools Board or the Special Committee, under certain circumstances, to effect a Parent Change in Recommendation in response to a Parent Superior Proposal, subject to Standard BioTools paying Treeline the Parent Termination Fee if Treeline terminates the Merger Agreement as a result of such Parent Change in Recommendation; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the ability of the Standard BioTools Board or the Special Committee, under certain circumstances, to make a Parent Board Recommendation Change in response to a Parent Intervening Event if the Standard BioTools Board or the Special Committee, as applicable, determines in good faith, after consultation with outside financial advisors and outside legal counsel, that the failure to make a Parent Change in Recommendation would be inconsistent with the fiduciary duties of the Standard BioTools Board to holders of Standard BioTools&#8217; capital stock under applicable law, subject to Standard BioTools paying Treeline the Parent Termination Fee if Treeline terminates the Merger Agreement as a result of such Parent Change in Recommendation; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">that the Parent Termination Fee is $16.1 million, which is equal to 3.5% of the equity value of Standard BioTools at the transaction price; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Special Committee&#8217;s belief that the Parent Termination Fee payable to Treeline in certain circumstances was reasonable in the context of termination fees payable in comparable transactions and in light of the overall terms of the Merger Agreement; <br></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the fact that, in the event of a Parent Change in Recommendation, the total shares subject to voting commitments under the Voting Agreements would not exceed 30% of Standard BioTools shares entitled to vote; <br></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">that the members of the Special Committee will not personally benefit from the consummation of the Transactions, in a manner different from Standard BioTools stockholders, except for indemnification and continuing directors and officers liability insurance coverage; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">that the Special Committee held 14 formal meetings to discuss and evaluate the potential transaction with Treeline and that each member of the Special Committee was actively engaged in the process; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">that the Special Committee retained and received the advice of (i) UBS as its financial advisor and (ii) Freshfields as its legal advisor; and </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">165<br></div></div></div>
<!--End Page 176-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 177-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_115-merger_pg32"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">that the financial and other terms and conditions of the Transactions were the product of extensive negotiations between the Special Committee, with the assistance of its financial and legal advisors, on the one hand, and Treeline and its representatives, on the other hand. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In the course of reaching the determination described in the section of this proxy statement/prospectus captioned &#8220;&#8212;<font style="font-style: italic;">Recommendation of the Special Committee and the Standard BioTools Board</font>&#8221;, the Special Committee also considered and balanced, in consultation with its own financial and legal advisors, the factors that weighed in favor of the Transactions against a variety of potentially negative factors, uncertainties and risks in its deliberations concerning the Merger Agreement and the Transactions, which are not intended to be exhaustive and are not presented in any relative order of importance: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the early-stage nature of Treeline&#8217;s clinical trials and the risks and uncertainties associated with the development and commercialization of Treeline&#8217;s products, as well as other scientific, technical and regulatory risks and uncertainties, and the risk that Treeline may not achieve its financial forecasts and prospects; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the scientific, technical, regulatory and other risks and uncertainties associated with Treeline&#8217;s business; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the risks and costs to Standard BioTools of the pendency of the Transactions or if the Transactions do not close in a timely manner or at all, including negative effects on the trading price of the shares of Standard BioTools Common Stock or on the reputation of Standard BioTools, the potential effect of the diversion of management and employee attention from Standard BioTools&#8217; business, the substantial expenses which Standard BioTools will have incurred, and the potential adverse effect on the relationship of Standard BioTools with its employees, agents, customers and other business contacts; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the restrictions on the conduct of Standard BioTools&#8217; business prior to the consummation of the Transactions, requiring Standard BioTools to conduct its business in the ordinary course, which may delay or prevent Standard BioTools from undertaking certain business opportunities or strategic transactions that may arise or any other actions Standard BioTools would otherwise take with respect to its operations pending consummation of the Transactions; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">that the Exchange Ratio is determined based upon Standard BioTools&#8217; net cash position at the closing of the Transactions, which could result in a less favorable Exchange Ratio in the event Standard BioTools&#8217; net cash position decreases; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the risk that the conditions to the parties&#8217; obligations to complete the Transactions may not be satisfied, and as a result, the possibility that the Transactions may not be consummated; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the risk that Standard BioTools stockholders may not approve the Proposals at the Special Meeting; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the fact that completion of the Transactions is conditioned on certain closing conditions, including that no material adverse effect on Standard BioTools has occurred that is continuing, that are not entirely within Standard BioTools&#8217; control; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the prohibition on Standard BioTools to solicit alternative acquisition proposals during the pendency of the Transactions; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the fact that, if Treeline terminates the Merger Agreement as a result of a Parent Change in Recommendation, Standard BioTools would be required to pay Treeline the Parent Termination Fee of $16.1&#160;million; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the fact that, if the Merger Agreement is terminated due to failure to obtain the Parent Stockholder Approval, Standard BioTools would be required to reimburse certain expenses of Treeline up to a cap of $5&#160;million; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the fact that Standard BioTools does not have a right to terminate the Merger Agreement in connection with a Parent Change in Recommendation; <br></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the fact that the representations and warranties of Treeline in the Merger Agreement do not survive the Closing and the potential risk of liabilities that may arise post-Closing; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the risk that the anticipated benefits of the Transactions might not be realized; </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">166<br></div></div></div>
<!--End Page 177-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 178-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_115-merger_pg33"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the risk of litigation arising from stockholders in respect of the Merger Agreement or the Transactions and the associated costs, burden and inconvenience involved in defending those proceedings; <br></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the possibility that the Standard BioTools&#8217; legacy businesses may not be sold or monetized prior to the Closing; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the possibility that legacy Standard BioTools stockholders will not receive any consideration under the CVRs and the CVRs may otherwise expire valueless; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the lack of availability of appraisal rights under the DGCL to holders of Standard BioTools Common Stock which would not allow holders to seek appraisal of the fair value of their shares of Standard BioTools Common Stock; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the various other risks associated with the combined company and the potential transaction with Treeline, including those described in the sections titled &#8220;<font style="font-style: italic;">Risk Factors</font>&#8221; and &#8220;<font style="font-style: italic;">Cautionary Note&#160;Regarding Forward-Looking Statements</font>&#8221; in this proxy statement/prospectus. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The above discussion of the information and factors considered by the Special Committee is not intended to be exhaustive but indicates the material matters considered. In reaching its determination and recommendation, the Special Committee did not quantify, rank or assign any relative or specific weight to any of the foregoing factors, and individual members of the Special Committee may have considered various factors differently. The Special Committee did not undertake to make any specific determination as to whether any specific factor, or any particular aspect of any factor, supported or did not support its ultimate recommendation. The Special Committee based its unanimous recommendation on the totality of the information presented to, and factors considered by, it. In addition, individual members of the Special Committee may have given differing weights to different factors. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In reaching the determination described in the section of this proxy statement/prospectus captioned &#8220;&#8212;<font style="font-style: italic;">Recommendation of the Special Committee and the Standard BioTools Board</font>&#8221;, the Standard BioTools Board (excluding Mr.&#160;Casdin who recused himself from the vote on the Transactions) considered a number of factors, including the factors considered by the Special Committee summarized above and the following material factors, which are not intended to be exhaustive and are not presented in any relative order of importance: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the fact that the Special Committee unanimously (i) determined that the potential transaction was advisable, fair to and in the best interests of Standard BioTools and its stockholders, (ii) approved and declared advisable the transaction documents and the Transactions, (iii) recommended that the Standard BioTools Board approve and authorize the execution and delivery by Standard BioTools of, and performance by Standard BioTools of its obligations under the transaction documents, and the consummation by Standard BioTools of the Transactions, and (iv) recommended that the Standard BioTools Board resolve to recommend approval of the Share Issuance and the Charter Amendment by Standard BioTools stockholders; <br></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the procedural fairness of the Transactions, including that the Transactions were extensively negotiated by the Special Committee comprised solely of directors that are independent from Mr.&#160;Casdin and Casdin Capital and disinterested with respect to the Transactions, and who are best positioned and able to evaluate and negotiate the potential transaction with Treeline, and that the Special Committee was advised by its own financial and legal advisors; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the opinion of Centerview rendered to the Standard BioTools Board on June&#160;5, 2026, which was subsequently confirmed by delivery of a written opinion dated June&#160;6, 2026, that, as of such date and based upon and subject to the assumptions made, procedures followed, matters considered, and qualifications and limitations upon the review undertaken by Centerview in preparing its opinion, the Exchange Ratio provided for pursuant to the Merger Agreement was fair, from a financial point of view, to Standard BioTools, as more fully described below under the caption &#8220;<font style="font-style: italic;">The Merger &#8211; Opinion of Standard BioTools&#8217; Financial Advisor</font>.&#8221; </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The above discussion of the information and factors considered by the Standard BioTools Board (excluding Mr.&#160;Casdin who recused himself from the vote on the Transactions) is not intended to be exhaustive but indicates the material matters considered. In reaching its determination and recommendation, the Standard BioTools Board (excluding Mr.&#160;Casdin who recused himself from the vote on the Transactions) did not quantify, rank or assign any relative or specific weight to any of the foregoing factors, and individual members of the Standard BioTools Board </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">167<br></div></div></div>
<!--End Page 178-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 179-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_115-merger_pg34"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">may have considered various factors differently. The Standard BioTools Board (excluding Mr.&#160;Casdin who recused himself from the vote on the Transactions) did not undertake to make any specific determination as to whether any specific factor, or any particular aspect of any factor, supported or did not support its ultimate recommendation. The Standard BioTools Board (excluding Mr.&#160;Casdin who recused himself from the vote on the Transactions) based its recommendation on the totality of the information presented to, and factors considered by, it. In addition, individual members of the Standard BioTools Board may have given differing weights to different factors. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Recommendation of the Special Committee and the Standard BioTools Board</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">After due consideration and discussion of the factors that the Special Committee deemed relevant, the Special Committee unanimously (i)&#160;determined that the Transactions are advisable, fair to and in the best interests of Standard BioTools and its stockholders, (ii)&#160;approved and declared advisable the Merger Agreement and the Transactions and recommended that the Standard BioTools Board approve and declare advisable the Transactions and (iii)&#160;recommended that the Standard BioTools Board resolve to recommend the approval of the Share Issuance and the Charter Amendment by Standard BioTools&#8217; stockholders. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">At a meeting held on June&#160;5, 2026, among other things, the Standard BioTools Board (i) determined that the Merger Agreement and all other agreements, instruments, certificates and documents required to be delivered in connection therewith (collectively, the &#8220;Transaction Documents&#8221;), the Merger and the other Transactions contemplated by the Merger Agreement (together with the Merger, the &#8220;Transactions&#8221;), including (A) the issuance of shares of Standard BioTools Common Stock pursuant to the terms of the Merger Agreement (the &#8220;Share Issuance&#8221;), and (B) amendments to the Eighth Amended and Restated Certificate of Incorporation of Standard BioTools, as amended (the &#8220;Charter Amendment&#8221;) to (1) effect a reverse stock split of Standard BioTools&#8217; issued and outstanding common stock at a ratio in the range from 1-for-&#8195;&#8195;&#8195;&#8195; to 1-for-&#8195;&#8195;&#8195;&#8195;, inclusive, with the final ratio to be mutually agreed to by Standard BioTools and Treeline (the &#8220;Reverse Stock Split&#8221;) and (2) change the name of Standard BioTools to &#8220;Treeline Biosciences Holdings, Inc.&#8221;, were advisable, fair to and in the best interests of Standard BioTools and its stockholders, (ii)&#160;authorized, approved, adopted, ratified and confirmed the Merger Agreement and the other Transaction Documents, in each case substantially in the form presented to the Standard BioTools Board, and the consummation of the Merger and the other Transactions, including the Share Issuance, the Reverse Stock Split, and the Charter Amendment and (iii)&#160;resolved to recommend the approval of the Share Issuance, the Reverse Stock Split, the Charter Amendment and the adjournment of the Special Meeting, if necessary or appropriate to solicit additional proxies by Standard BioTools stockholders. In addition, at a meeting held on July 14, 2026, among other things, the Standard BioTools Board (i) determined that (A) the Post-Closing Equity Incentive Plan, (B) the Post-Closing ESPP and (C) the Merger-Related Compensation were advisable, fair to and in the best interests of Standard BioTools and its stockholders, (ii) adopted the Post-Closing Equity Incentive Plan and the Post-Closing ESPP, in each case substantially in the form presented to the Standard BioTools Board and subject to the Closing and approval by Standard BioTools stockholders, and (iii) resolved to recommend the approval of the Post-Closing Equity Incentive Plan, the Post-Closing ESPP and, on a nonbinding, advisory basis, the Merger-Related Compensation by Standard BioTools stockholders. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">ACCORDINGLY, THE STANDARD BIOTOOLS BOARD RECOMMENDS THAT STANDARD BIOTOOLS STOCKHOLDERS VOTE (1) &#8220;FOR&#8221; THE SHARE ISSUANCE PROPOSAL, (2) &#8220;FOR&#8221; THE CHARTER AMENDMENT PROPOSAL, (3) &#8220;FOR&#8221; THE POST-CLOSING EQUITY INCENTIVE PLAN PROPOSAL, (4) &#8220;FOR&#8221; THE POST-CLOSING ESPP PROPOSAL, (5) &#8220;FOR&#8221; THE ADVISORY COMPENSATION PROPOSAL AND (6) &#8220;FOR&#8221; THE STANDARD BIOTOOLS ADJOURNMENT PROPOSAL.<font style="font-weight: normal;"> </font></div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;"><a name="tTRE1"><!--Anchor--></a>Treeline&#8217;s Reasons for the Merger </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In the course of reaching its decision to approve the Merger, the Treeline Board consulted with Treeline&#8217;s senior management, legal counsel and financial advisors, and considered a wide variety of factors. Ultimately, the Treeline Board concluded that a merger with Standard BioTools was the best option to generate capital resources to support the advancement of Treeline&#8217;s pipeline, fund the combined company and provide Treeline&#8217;s stockholders with access to the public capital markets, and that the merger with Standard BioTools offered a superior pathway for doing so as compared to the alternatives considered by the Treeline Board, including an initial public offering. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">168<br></div></div></div>
<!--End Page 179-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 180-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_115-merger_pg35"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Additional factors the Treeline Board considered included the following (which factors are not necessarily presented in any order of relative importance): </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Merger will potentially expand the access to capital and the range of investors available as a public company to support the preclinical and clinical development of Treeline&#8217;s pipeline, compared to the capital and investors Treeline could otherwise gain access to if it continued to operate as a privately-held company; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the potential benefits from increased public market awareness of Treeline and its pipeline; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the historical and current information concerning Treeline&#8217;s business, including its financial performance and condition, operations, management and preclinical and clinical data; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the current economic, industry, financial, and market conditions affecting Treeline, and the highly competitive and rapidly evolving nature of the biotechnology and biopharmaceutical industries in which Treeline operates, including the competitive environment for private capital formation; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Treeline Board&#8217;s fiduciary duties to Treeline stockholders; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Treeline Board&#8217;s belief that no alternatives to the Merger were reasonably likely to create greater value for Treeline stockholders, after considering the various financing and other strategic options to enhance stockholder value that were considered by the Treeline Board; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Treeline Board&#8217;s expectation that the Merger would be a higher probability and more cost-effective means to access capital than other options considered, including an initial public offering; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the expectation that substantially all of Treeline&#8217;s employees, including its management, will serve in similar roles at the combined company; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the expected operations, management structure and operating plans of the combined company (including the ability to support the combined company&#8217;s current and planned preclinical studies and clinical trials); </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the financial resources, assets and liabilities of Standard BioTools; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the availability of appraisal rights under the Delaware General Corporation Law (&#8220;DGCL&#8221;) to holders of Treeline capital stock who comply with the required procedures under the DGCL, which allow such holders to seek appraisal of the fair value of their shares of Treeline capital stock as determined by the Delaware Court of Chancery; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the terms and conditions of the Merger Agreement, including the following: </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the determination that the expected relative percentage ownership of Standard BioTools stockholders and Treeline stockholders in the combined company was appropriate, based on the Treeline Board&#8217;s judgment and assessment of the approximate valuations of Standard BioTools (including the value of the expected Parent Net Cash) and Treeline; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the expectation that the Merger will be treated as a reorganization for U.S. federal income tax purposes, with the result that the Treeline stockholders will generally not recognize taxable gain or loss for U.S.&#160;federal income tax purposes with respect to the Merger; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the limited number and nature of the conditions of Standard BioTools&#8217; obligation to consummate the Merger; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the rights of Treeline under the Merger Agreement to consider certain unsolicited acquisition proposals under certain circumstances should Treeline receive a superior offer and to effect a change in recommendation in favor of the Merger as a result of a superior offer; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the rights of Treeline under the Merger Agreement to effect a change in recommendation in favor of the Merger as a result of a material development or change in circumstances (i.e., applicable Intervening Events, as defined in the Merger Agreement); </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the conclusion of the Treeline Board that the potential termination fees payable by Standard BioTools or Treeline to the other party, and the circumstances when such fee may be payable, were reasonable; and </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">169<br></div></div></div>
<!--End Page 180-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 181-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_115-merger_pg36"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the belief that the other terms of the Merger Agreement, including the parties&#8217; representations, warranties and covenants, and the conditions to their respective obligations, were reasonable in light of the entire transaction; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the shares of Standard BioTools Common Stock issued to Treeline stockholders, including shares of Standard BioTools Common Stock issued in exchange for shares of Treeline Common Stock, will be registered on a Form&#160;S-4 registration statement and will become freely tradable for Treeline stockholders who are not affiliates of Treeline and who are not parties to lock-up agreements; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Voting Agreements, pursuant to which certain directors, officers and stockholders of Treeline and Standard BioTools, respectively, have agreed, solely in their capacity as stockholders of Treeline and Standard BioTools, respectively, to vote all of their shares of Treeline capital stock or Standard BioTools Common Stock (subject to reduction in the case of Voting Agreements on the part of certain Standard BioTools stockholders, as described in more detail in the section titled &#8220;The Special Meeting &#8212; Voting Agreements&#8221; in this proxy statement/prospectus) in favor of the adoption or approval, respectively, of the Merger Agreement; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the ability to obtain a Nasdaq listing and the change of the combined company&#8217;s name to Treeline Biosciences Holdings, Inc. prior to or upon the closing of the Merger; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the likelihood that the Merger will be consummated on a timely basis. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Treeline Board also considered a number of uncertainties and risks in its deliberations concerning the Merger and the other transactions contemplated by the Merger Agreement, including the following: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the possibility that the Merger might not be completed and the potential adverse effect of the public announcement of the Merger on the reputation of Treeline and the ability of Treeline to obtain financing in the future in the event the Merger is not completed; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Exchange Ratio used to establish the number of shares of Standard BioTools Common Stock to be issued to Treeline stockholders in the Merger is fixed, except for adjustments due to Parent Net Cash, and thus the relative percentage ownership of Standard BioTools stockholders and Treeline stockholders in the combined company immediately following the completion of the Merger is similarly fixed; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the potential reduction of Parent Net Cash prior to the Closing; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">potential complications in the wind-down of Standard BioTools&#8217; legacy businesses, if such businesses are not sold prior to the closing of the Merger; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the possibility that Standard BioTools could, under certain circumstances, consider unsolicited acquisition proposals if superior to the Merger or change its recommendation to approve the Merger upon certain events; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the risk that the Merger might not be completed in a timely manner or at all, for a variety of reasons, such as the failure of Standard BioTools to obtain the required stockholder vote, and the potential adverse effect on the reputation of Treeline and the ability of Treeline to obtain financing in the future in the event the Merger is not completed; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the costs involved in connection with completing the Merger, the time and effort of Treeline senior management required to complete the Merger, the related disruptions or potential disruptions to Treeline&#8217;s business operations and future prospects, including its relationships with its employees, suppliers and partners and others that do business or may do business in the future with Treeline, and related administrative challenges associated with combining the companies; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the additional expenses and obligations to which Treeline&#8217;s business will be subject to following the Merger that Treeline has not previously been subject to, and the operational changes to Treeline&#8217;s business, in each case, that may result from being a public company; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the fact that the representations and warranties in the Merger Agreement do not survive the closing of the Merger and the potential risk of liabilities that may arise post-closing; </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">170<br></div></div></div>
<!--End Page 181-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 182-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_115-merger_pg37"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the risk that future sales of common stock by existing Standard BioTools stockholders may cause the price of Standard BioTools Common Stock to fall, thus reducing the potential value of Standard BioTools Common Stock received by Treeline stockholders following the Merger; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">various other risks associated with the combined company and the Merger, including the risks described in the section titled &#8220;Risk Factors&#8221; in this proxy statement/prospectus. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The foregoing information is not intended to be exhaustive, but is believed to include a summary of all of the material factors considered by the Treeline Board in its consideration of the Merger Agreement and the transactions contemplated thereby. After conducting an overall analysis of these and other factors, including thorough discussions with, and questioning of, Treeline&#8217;s senior management and legal counsel, the Treeline Board concluded that the benefits, advantages and opportunities of a potential transaction outweighed the uncertainties and risks described above. Based on this overall analysis of the factors described above, the Treeline Board approved the Merger Agreement, the Merger and the other transactions contemplated by the Merger Agreement. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;"><a name="tOPIS1"><!--Anchor--></a>Opinion of Standard BioTools&#8217; Financial Advisor </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On June&#160;5, 2026, Centerview rendered to the Standard BioTools Board its oral opinion, subsequently confirmed in a written opinion dated June&#160;6, 2026, that, as of such date and based upon and subject to various assumptions made, procedures followed, matters considered, and qualifications and limitations upon the review undertaken by Centerview in preparing its opinion, the Exchange Ratio provided for pursuant to the Merger Agreement was fair, from a financial point of view, to Standard BioTools. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The full text of Centerview&#8217;s written opinion, dated June&#160;6, 2026, which describes the assumptions made, procedures followed, matters considered, and qualifications and limitations upon the review undertaken by Centerview in preparing its opinion, is attached as Annex&#160;B and is incorporated herein by reference. <font style="font-weight: bold;">The summary of the written opinion of Centerview set forth below is qualified in its entirety to the full text of Centerview&#8217;s written opinion attached as Annex&#160;B. Centerview&#8217;s financial advisory services and opinion were provided for the information and assistance of the Standard BioTools Board (in their capacity as directors and not in any other capacity) in connection with and for purposes of its consideration of the Transactions and Centerview&#8217;s opinion only addressed the fairness, from a financial point of view, as of the date thereof, to Standard BioTools of the Exchange Ratio provided for pursuant to the Merger Agreement. Centerview&#8217;s opinion did not address any other term or aspect of the Merger Agreement or the Transactions and does not constitute a recommendation to any stockholder of Standard BioTools or any other person as to how such stockholder or other person should vote with respect to the Merger or otherwise act with respect to the Transactions or any other matter.</font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The full text of Centerview&#8217;s written opinion should be read carefully in its entirety for a description of the assumptions made, procedures followed, matters considered, and qualifications and limitations upon the review undertaken by Centerview in preparing its opinion.<font style="font-weight: normal;"> </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In connection with rendering the opinion described above and performing its related financial analyses, Centerview reviewed, among other things: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Merger Agreement dated June&#160;6, 2026; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Form&#160;of CVR Agreement; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Annual Report on Form&#160;10-K of Standard BioTools for the fiscal year ended December&#160;31, 2025; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">certain Quarterly Reports on Form&#160;10-Q of Standard BioTools; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">audited consolidated balance sheets for Treeline for the fiscal years ended 2024 and 2025 and related audited consolidated statements of income and cash flows for the fiscal years ended 2023, 2024 and 2025; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">unaudited consolidated balance sheets and related consolidated statements of income and cash flows of Treeline for the fiscal quarters ended March&#160;31, 2025 and March&#160;31, 2026; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">certain internal information relating to the capitalization, business, operations, earnings, cash flow, assets, liabilities and prospects of Treeline provided by management of Treeline, which is referred to in this summary of Centerview&#8217;s opinion as the &#8220;Treeline Internal Data&#8221;; </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">171<br></div></div></div>
<!--End Page 182-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 183-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_115-merger_pg38"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">certain financial forecasts, analyses and projections relating to Treeline prepared by management of Treeline as adjusted by management of Standard BioTools, which as so adjusted is referred to in this summary of Centerview&#8217;s opinion as the &#8220;Treeline Forecasts&#8221;;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">certain internal information relating to the business, operations, earnings, cash flow, assets, liabilities and prospects of Standard BioTools, including (a) certain financial forecasts, analyses and projections relating to Standard BioTools prepared by management of Standard BioTools, which are referred to in this summary of Centerview&#8217;s opinion as the &#8220;Standard BioTools Forecasts&#8221; and (b) a liquidation analysis of Standard BioTools prepared by the management of Standard BioTools, which is referred to in this summary of Centerview&#8217;s opinion as the &#8220;Standard BioTools Liquidation Analysis&#8221; and collectively, the &#8220;Standard BioTools Internal Data&#8221;; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">certain cost savings projected by the management of Standard BioTools to result from the Transactions, which are referred to in this summary of Centerview&#8217;s opinion as &#8220;Synergies.&#8221; </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Centerview also participated in discussions with members of the senior management and representatives of Standard BioTools regarding their assessment of the Treeline Internal Data, the Standard BioTools Internal Data and the Synergies, as appropriate. In addition, Centerview conducted such other financial studies and analyses and took into account such other information as Centerview deemed appropriate. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Centerview assumed, without independent verification or any responsibility therefor, the accuracy and completeness of the financial, legal, regulatory, tax, accounting and other information supplied to, discussed with, or reviewed by Centerview for purposes of its opinion and, with Standard BioTools&#8217; consent, Centerview relied upon such information as being complete and accurate. In that regard, Centerview assumed, at Standard BioTools&#8217; direction, that the Treeline Internal Data and Standard BioTools Internal Data (including, without limitation, the Treeline Forecasts and Standard BioTools Forecasts) and the Synergies were reasonably prepared on bases reflecting the best currently available estimates and judgments of the management of Treeline or Standard BioTools, as applicable, as to the matters covered thereby and Centerview relied, at Standard BioTools&#8217; direction, on the Treeline Internal Data, the Treeline Forecasts and Standard BioTools Internal Data (including without limitation the Standard BioTools Liquidation Analysis, but excluding the Standard BioTools Forecasts) and the Synergies for purposes of Centerview&#8217;s analysis and opinion. Further, Centerview assumed, at Standard BioTools&#8217; direction that the Standard BioTools Liquidation Analysis had been reasonably prepared on bases reflecting the best currently available estimates and judgments of the management of Standard BioTools as to the expected realizable value of Standard BioTools&#8217; assets, assuming an orderly liquidation of such assets and the remaining amounts estimated to be available upon completion of such liquidation for distribution to holders of Standard BioTools&#8217; shares and Centerview relied, at Standard BioTools&#8217; direction, on the Standard BioTools Liquidation Analysis for purposes of Centerview&#8217;s analysis and opinion. Centerview expressed no view or opinion as to the Treeline Internal Data, the Treeline Forecasts, the Standard BioTools Internal Data (including, without limitation, the Standard BioTools Forecasts and the Standard BioTools Liquidation Analysis) or the Synergies or the assumptions on which they were based. In addition, at Standard BioTools&#8217; direction, Centerview assumed that there will be no Parent Net Cash Shortfall or Parent Net Cash Surplus (each, as defined in the Merger Agreement) and that the adjustment to the valuation of Standard BioTools for purposes of the Exchange Ratio in the Merger Agreement will result in a valuation of Standard BioTools of $465,700,000. In addition, at Standard BioTools&#8217; direction, Centerview did not make any independent evaluation or appraisal of any of the assets or liabilities (contingent, derivative, off-balance-sheet or otherwise) of Standard BioTools or Treeline, nor was Centerview furnished with any such evaluation or appraisal (other than the Standard BioTools Liquidation Analysis), and was not asked to conduct, and did not conduct, a physical inspection of the properties or assets of Standard BioTools or Treeline. Centerview assumed, at Standard BioTools&#8217; direction, that (i) the final executed Merger Agreement would not differ in any respect material to Centerview&#8217;s analysis or opinion from the Merger Agreement reviewed by Centerview, (ii) the representations and warranties made by Standard BioTools and Treeline in the Merger Agreement and related agreements were and will be true and correct in all respects material to Centerview&#8217;s analysis, and (iii) there would be no adjustments to the consideration that would be material to Centerview&#8217;s analysis or its opinion. Centerview also assumed, at Standard BioTools&#8217; direction, that the Transactions will be consummated on the terms set forth in the Merger Agreement and in accordance with all applicable laws and other relevant documents or requirements, without delay or the waiver, modification or amendment of any term, condition or agreement, the effect of which would be material to Centerview&#8217;s analysis or Centerview&#8217;s opinion and that, in the course of obtaining the necessary governmental, regulatory and other approvals, consents, releases and waivers for the Transactions, no delay, limitation, restriction, </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">172<br></div></div></div>
<!--End Page 183-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 184-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_115-merger_pg39"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">condition or other change, including any divestiture requirements or amendments or modifications, will be imposed, the effect of which would be material to Centerview&#8217;s analysis or Centerview&#8217;s opinion. Centerview also assumed, at Standard BioTools&#8217; direction, that the Merger will qualify for U.S. federal income tax purposes as a reorganization within the meaning of Section&#160;368(a) of the Internal Revenue Code of 1986, as amended. Centerview did not evaluate and did not express any opinion as to the solvency or fair value of Standard BioTools, Treeline or any other person, or the ability of Standard BioTools or such other person to pay its obligations when they come due, or as to the impact of the Transactions on such matters, under any state, federal or other laws relating to bankruptcy, insolvency or similar matters. Centerview is not a legal, regulatory, tax or accounting advisor, and Centerview expressed no opinion as to any legal, regulatory, tax or accounting matters. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Centerview&#8217;s opinion expressed no view as to, and did not address, Standard BioTools&#8217; underlying business decision to proceed with or effect the Transactions, or the relative merits of the Transactions as compared to any alternative business strategies or transactions that might be available to Standard BioTools or in which Standard BioTools might engage. Centerview&#8217;s opinion was limited to and addressed only the fairness, from a financial point of view, as of the date of Centerview&#8217;s written opinion, to Standard BioTools of the Exchange Ratio provided for pursuant to the Merger Agreement. For purposes of its opinion, Centerview was not asked to, and Centerview did not, express any view on, and its opinion did not address, any other term or aspect of the Merger Agreement or the Transactions, including, without limitation, the structure or form of the Transactions, the CVRs, the CVR Agreement, the form or terms of the CVR with respect to transferability, illiquidity or otherwise, or any other agreements or arrangements contemplated by the Merger Agreement or entered into in connection with or otherwise contemplated by the Transactions, including, without limitation, the fairness of the Transactions or any other term or aspect of the Transactions to, or any consideration to be received in connection therewith by, or the impact of the Transactions on, the holders of any other class of securities, creditors or other constituencies of Standard BioTools or any other party. In addition, Centerview expressed no view or opinion as to the fairness (financial or otherwise) of the amount, nature or any other aspect of any compensation to be paid or payable to any of the officers, directors or employees of Standard BioTools, Treeline or any party, or class of such persons in connection with the Transactions, whether relative to the Exchange Ratio provided for pursuant to the Merger Agreement or otherwise. Centerview&#8217;s opinion was necessarily based on financial, economic, monetary, currency, market and other conditions and circumstances as in effect on, and the information made available to Centerview as of, the date of Centerview&#8217;s written opinion, and Centerview does not have any obligation or responsibility to update, revise or reaffirm its opinion based on circumstances, developments or events occurring after the date of Centerview&#8217;s written opinion. Centerview expressed no view or opinion as to any consequence that may result from the Transactions, including as to the price at which Standard BioTools&#8217; shares will trade at any time, including following the announcement or consummation of the Transactions. Centerview&#8217;s opinion does not constitute a recommendation to any stockholder of Standard BioTools or any other person as to how such stockholder or other person should vote or otherwise act with respect to the Transactions or any other matter. Centerview&#8217;s financial advisory services and its written opinion were provided for the information and assistance of the Standard BioTools Board (in their capacity as directors and not in any other capacity) in connection with and for purposes of its consideration of the Transactions. The issuance of Centerview&#8217;s opinion was approved by the Centerview Partners LLC Fairness Opinion Committee. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">Summary of Centerview Financial Analysis </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following is a summary of the material financial analyses prepared and reviewed with the Standard BioTools Board in connection with Centerview&#8217;s opinion, dated June&#160;6, 2026. <font style="font-weight: bold;">The summary set forth below does not purport to be a complete description of the financial analyses performed or factors considered by, and underlying the opinion of, Centerview, nor does the order of the financial analyses described represent the relative importance or weight given to those financial analyses by Centerview. Centerview may have deemed various assumptions more or less probable than other assumptions, so the reference ranges resulting from any particular portion of the analyses summarized below should not be taken to be Centerview&#8217;s view of the actual value of Standard BioTools or Treeline or a combination thereof. Some of the summaries of the financial analyses set forth below include information presented in tabular format. In order to fully understand the financial analyses, the tables must be read together with the text of each summary, as the tables alone do not constitute a complete description of the financial analyses performed by Centerview. Considering the data in the tables below without considering all financial analyses or factors or the full narrative description of such analyses or factors, including the methodologies and assumptions underlying such analyses or factors, could create a misleading or incomplete view of the processes underlying Centerview&#8217;s financial analyses and its opinion.</font> In performing its analyses, Centerview made numerous </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">173<br></div></div></div>
<!--End Page 184-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 185-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_115-merger_pg40"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">assumptions with respect to industry performance, general business and economic conditions and other matters, many of which are beyond the control of Standard BioTools or any other parties to the Transactions. None of Treeline, Standard BioTools, Merger Sub or Centerview or any other person assumes responsibility if future results are materially different from those discussed. Any estimates contained in these analyses are not necessarily indicative of actual values or predictive of future results or values, which may be significantly more or less favorable than as set forth below. In addition, analyses relating to the value of Treeline do not purport to be appraisals or reflect the prices at which Treeline may actually be sold. Accordingly, the assumptions and estimates used in, and the results derived from, the financial analyses are inherently subject to substantial uncertainty. Except as otherwise noted, the following quantitative information, to the extent that it is based on market data, is based on market data as it existed on or before June&#160;5, 2026 (the last trading day before the public announcement of the Transaction) and is not necessarily indicative of current market conditions. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">At the direction of the Standard BioTools Board, Centerview assumed for purposes of its financial analyses and opinion to the Standard BioTools Board, that the Exchange Ratio provided for in the Merger pursuant to the Merger Agreement would be equal to 11.6997 shares of Standard BioTools common stock for each share of Treeline capital stock, which assumed, among other things, that the valuation of Standard BioTools for purposes of the Exchange Ratio in the Merger Agreement will result in a valuation of Standard BioTools of approximately $465,700,000 and the valuation of Treeline for purposes of the Exchange Ratio in the Merger Agreement will result in a valuation of Treeline of approximately $2,542,600,000. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Standard BioTools Liquidation Analysis </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Centerview reviewed and considered the Standard BioTools Liquidation Analysis prepared by management of Standard BioTools and noted that the estimates of future cash distributable to Standard BioTools&#8217; stockholders therein resulted in an aggregate implied equity value for Standard BioTools at the time of such distribution of approximately $468,000,000. Centerview divided the foregoing equity value by the number of fully diluted outstanding shares of Standard BioTools common stock (determined using the treasury stock method), based on information provided by management of Standard BioTools as set forth in the Standard BioTools Internal Data. This analysis resulted in an implied equity value of Standard BioTools common stock of $1.14 per share. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Treeline Discounted Cash Flow Analysis </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Centerview performed a discounted cash flow analysis of Treeline based on the Treeline Forecasts. A discounted cash flow analysis is a traditional valuation methodology used to derive a valuation of an asset or set of assets by calculating the &#8220;present value&#8221; of estimated future cash flows of the asset or set of assets. &#8220;Present value&#8221; refers to the current value of future cash flows or amounts and is obtained by discounting those future cash flows or amounts by a discount rate that takes into account macroeconomic assumptions and estimates of risk, the opportunity cost of capital, expected returns and other appropriate factors. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In performing this analysis, Centerview calculated a range of equity values for shares of Treeline common stock by (a) discounting to present value as of June&#160;30, 2026 using discount rates ranging from 12.0% to 15.0% (reflecting Centerview&#8217;s analysis of Treeline&#8217;s weighted average cost of capital): (i) the forecasted risk-adjusted, after-tax unlevered free cash flows of Treeline over the period beginning on July&#160;1, 2026 and ending on December&#160;31, 2050, utilized by Centerview based on the Treeline Forecasts and (ii) an implied terminal value of Treeline, and (b) adding to the foregoing results (i) Treeline&#8217;s estimated cash balance as of June&#160;30, 2026, (ii)&#160;estimated tax savings from usage of Treeline&#8217;s estimated federal net operating losses and (iii) the estimated net impact on Treeline of future capital raising transactions (net of dilution), as set forth in the Treeline Forecasts. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This analysis resulted in a range of implied equity values of Treeline of $3,040&#160;million to $4,205&#160;million. Centerview divided the foregoing equity values by the number of fully diluted outstanding shares of Treeline common stock (determined using the treasury stock method), based on information provided by management of Treeline as set forth in the Treeline Internal Data. This analysis resulted in a range of implied equity values of Treeline common stock of $15.88 to $21.89 per share. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Relative Valuation Analysis </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Based upon a comparison of the implied equity value of Standard BioTools pursuant to the liquidation analysis described above and the range of implied equity values for Treeline pursuant to the discounted cash flow analysis described above , Centerview calculated a range of implied exchange ratios for the Merger. With respect to the range </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">174<br></div></div></div>
<!--End Page 185-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 186-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_115-merger_pg41"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">of exchange ratios, the higher ratio assumes the higher implied value per share of Treeline common stock divided by the implied value per share of Standard BioTools common stock, and the lower ratio assumes the lowest implied value per share of Treeline common stock divided by the implied value per share of Standard BioTools common stock.</div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 288pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 8.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 8.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 85pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 8.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 8.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 60pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 288pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 8.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.75pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 85pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Implied Equity Value/<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Exchange Ratio</div></td><td style="width: 8.75pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.75pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 60pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Price Per Share </div></td></tr><tr><td style="width: 288pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Discounted Cash Flow Analysis of Treeline<font style="padding-left: 1.35pt;"></font></div></td><td style="width: 8.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 85pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">$3,040.00 &#8211; 4,205.00</div></td><td style="width: 8.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 60pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">$15.88 &#8211; 21.89 </div></td></tr><tr><td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Liquidation Value of Standard BioTools<font style="padding-left: 0.85pt;"></font></div></td><td style="width: 8.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 85pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">$468.00</div></td><td style="width: 8.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 60pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">$1.14 </div></td></tr><tr><td style="width: 288pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Implied Exchange Ratio<font style="padding-left: 3.3pt;"></font></div></td><td style="width: 8.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 85pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">13.9676x &#8211; 19.2152x</div></td><td style="width: 8.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 60pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 288pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 8.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 8.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 85pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 8.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 8.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 60pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Centerview then compared the implied range of exchange ratios set forth above to the Exchange Ratio pursuant to the Merger Agreement of 11.6997x. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Value Creation Analysis </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Centerview compared the estimated liquidation value of the stand-alone Standard BioTools to the pro forma value of the surviving entity after giving effect to the Transactions, including the pro forma ownership of Standard BioTools equityholders of 15.5% as a result of the Exchange Ratio pursuant to the Merger. Centerview determined the pro forma surviving entity equity value by calculating the sum of (i) the estimated liquidation value for Standard BioTools, (ii) the equity value of Treeline using the midpoint value determined in Centerview&#8217;s discounted cash flow analysis and (iii) the net present value of the Synergies (consisting of financing costs avoided, net of transaction fees). The value creation analysis, at the Exchange Ratio, yielded accretion to the Standard BioTools stockholders of 33% (not taking into account the Synergies) and 40% (taking into account the Synergies) as compared to Standard BioTools&#8217; stand-alone value. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">General </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The preparation of a financial opinion is a complex analytical process involving various determinations as to the most appropriate and relevant methods of financial analysis and the application of those methods to the particular circumstances and, therefore, a financial opinion is not readily susceptible to summary description. In arriving at its opinion, Centerview did not draw, in isolation, conclusions from or with regard to any factor or analysis that it considered. Rather, Centerview made its determination as to fairness on the basis of its experience and professional judgment after considering the results of all of the analyses. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Centerview&#8217;s financial analyses and opinion were only one of many factors taken into consideration by the Standard BioTools Board in its evaluation of the Transactions. Consequently, the analyses described above should not be viewed as determinative of the views of the Board of Directors or management of Standard BioTools with respect to the Exchange Ratio or as to whether the Standard BioTools Board would have been willing to determine that a different consideration was fair. The consideration for the transaction was determined through arm&#8217;s-length negotiations between Standard BioTools and Treeline and was approved by the Standard BioTools Board and Treeline. Centerview provided advice to Standard BioTools during these negotiations. Centerview did not, however, recommend any specific amount of consideration to Standard BioTools or its Board or that any specific amount of consideration constituted the only appropriate consideration for the transaction. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Centerview is a securities firm engaged directly and through affiliates and related persons in a number of investment banking, financial advisory and merchant banking activities. In the two years prior to the date of its written opinion, Centerview had been engaged to provide financial advisory services to Standard BioTools, including in connection with Standard BioTools&#8217; sale of its SomaLogic business to Illumina, Inc. in 2025, and Centerview received between $10&#160;million and $15&#160;million in compensation from Standard BioTools for such services during such period. In the two years prior to the date of its written opinion, Centerview had been engaged to provide financial advisory services unrelated to Standard BioTools to two companies in which affiliates of Casdin Capital, LLC (&#8220;Casdin Capital&#8221;), a significant minority stockholder of Standard BioTools, held a significant minority equity interest, and Centerview received between $20&#160;million and $25&#160;million in compensation from one&#160;such company, and expects that it could receive between $20&#160;million and $25&#160;million in compensation from the other such company in the future. In the two years prior to the date of its written opinion, Centerview had been engaged to provide financial advisory services unrelated to Standard BioTools to Inhibrx, Inc. (&#8220;Inhibrx&#8221;) in connection with Inhibrx&#8217;s sale to Sanofi in 2024 and to RayzeBio, Inc. (&#8220;RayzeBio&#8221;) in connection with RayzeBio&#8217;s </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">175<br></div></div></div>
<!--End Page 186-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 187-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_115-merger_pg42"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">sale to Bristol-Myers Squibb in 2024, both companies in which affiliates of Viking Global Investors LP (&#8220;Viking Global&#8221;), a significant minority stockholder of Standard BioTools, held a significant minority equity interest, and Centerview received between $40&#160;million and $50&#160;million in compensation from Inhibrx and received between $80&#160;million and $90&#160;million in compensation from RayzeBio in connection with such engagements. In the two years prior to the date of its written opinion, Centerview had not been engaged to provide financial advisory or other services to Treeline, and Centerview did not receive any compensation from Treeline during such period. Centerview may provide financial advisory and other services to or with respect to Standard BioTools, Treeline, Casdin Capital, Viking Global, or their respective affiliates, including portfolio companies of Casdin Capital and Viking Global in the future, for which Centerview may receive compensation. Certain (i) of Centerview and its affiliates&#8217; directors, officers, members and employees, or family members of such persons, (ii) of Centerview&#8217;s affiliates or related investment funds and (iii) investment funds or other persons in which any of the foregoing may have financial interests or with which they may co-invest, may at any time acquire, hold, sell or trade, in debt, equity and other securities or financial instruments (including derivatives, bank loans or other obligations) of, or investments in, Standard BioTools, Treeline, Casdin Capital, or Viking Global, or any of their respective affiliates, including portfolio companies of Casdin Capital and Viking Global, or any other party that may be involved in the Transactions. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Standard BioTools Board selected Centerview as its financial advisor in connection with the Transactions based on Centerview&#8217;s expertise and reputation in advising healthcare and healthcare technology companies in strategic transactions and Centerview&#8217;s historical representation of and familiarity with Standard BioTools.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In connection with Centerview&#8217;s services as the financial advisor to the Standard BioTools Board, Standard BioTools has agreed to pay Centerview (i) a fee of $3 million in connection with the rendering of Centerview&#8217;s opinion (the &#8220;Opinion Fee&#8221;), (ii) a transaction fee of $11 million against which the Opinion Fee can be credited and (iii)&#160;a discretionary fee of up to $1.5 million, to be determined solely by Standard BioTools. In addition, Standard BioTools has agreed to reimburse certain of Centerview&#8217;s expenses arising, and to indemnify Centerview against certain liabilities that may arise, out of Centerview&#8217;s engagement. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;"><a name="tOPISB1"><!--Anchor--></a>Opinion of Standard BioTools Special Committee&#8217;s Financial Advisor </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">UBS was retained by the Special Committee to act as financial advisor in connection with the Transactions. As part of that engagement, the Special Committee requested that UBS render an opinion as to the fairness, from a financial point of view, to Standard BioTools of the Exchange Ratio provided for in the Merger. On June&#160;5, 2026, at a meeting of the Special Committee held to evaluate the Merger Agreement and the transactions contemplated thereby, including the Merger, UBS delivered to the Special Committee an oral opinion, which opinion was confirmed by delivery of a written opinion dated as of June&#160;5, 2026, to the effect that, as of that date and based upon, and subject to, among other things, the assumptions made, procedures followed, matters considered and qualifications and limitations on the review undertaken by UBS in connection with its opinion, the Exchange Ratio provided for in the Merger was fair, from a financial point of view, to Standard BioTools. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The full text of UBS&#8217;s opinion describes the assumptions made, procedures followed, matters considered and qualifications and limitations on the review undertaken by UBS. UBS&#8217;s opinion is attached to this proxy statement/prospectus as Annex&#160;C and is incorporated herein by reference. <font style="font-weight: bold;">UBS&#8217;s opinion was provided for the benefit of the Special Committee in connection with, and for the purpose of, its evaluation of the Exchange Ratio and addresses only the fairness, from a financial point of view, to Standard BioTools of the Exchange Ratio provided for in the Merger. UBS&#8217;s opinion does not address the relative merits of the Transactions as compared to other business strategies or transactions that might be available to Standard BioTools, or Standard BioTools&#8217; underlying business decision to effect the Transactions. UBS&#8217;s opinion does not constitute a recommendation to any stockholder as to how such stockholder should vote or act with respect to the Transactions. Holders of Standard BioTools Common Stock are encouraged to read UBS&#8217;s opinion carefully and in its entirety. </font>The following summary of UBS&#8217;s opinion is qualified in its entirety by reference to, and should be read in conjunction with, the full text of UBS&#8217;s opinion. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">176<br></div></div></div>
<!--End Page 187-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 188-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_115-merger_pg43"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In arriving at its opinion, UBS, among other things: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">reviewed certain publicly available business and financial information relating to Treeline and Standard BioTools; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">reviewed certain internal financial information and other data relating to the business and financial prospects of Treeline that were provided to UBS by the management of Standard BioTools that were not publicly available, including financial forecasts and estimates prepared by the management of Treeline as adjusted by the management of Standard BioTools that Standard BioTools directed UBS to utilize for purposes of its analysis (the &#8220;Treeline Projections&#8221;); </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">reviewed certain internal financial information and other data relating to the business and financial prospects of Standard BioTools that were provided to UBS by the management of Standard BioTools that were not publicly available, including financial forecasts and estimates with respect to Standard BioTools on a standalone basis as a going concern prepared by the management of Standard BioTools (the &#8220;Going Concern Projections&#8221;) and a wind-down analysis of Standard BioTools prepared by the management of Standard BioTools (&#8220;Standard BioTools wind-down analysis&#8221; (as defined below)); </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">reviewed certain estimates as to the amount of the Parent Net Cash Surplus, if any, and the Parent Net Cash Shortfall, if any, in each case, prepared by the management of Standard BioTools and that Standard BioTools directed UBS to utilize for purposes of its analysis (&#8220;Standard BioTools Net Cash Estimates&#8221;); </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">conducted discussions with members of the senior management of Standard BioTools concerning the businesses and financial prospects of Standard BioTools and Treeline; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">performed a discounted cash flow analysis of Treeline in which UBS analyzed the future cash flows of Treeline using the Treeline Projections; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">reviewed publicly available financial and stock market data with respect to certain other companies UBS&#160;believed to be generally relevant; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">reviewed a draft, dated June&#160;5, 2026, of the Merger Agreement; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">conducted such other financial studies, analyses and investigations, and considered such other information, as UBS deemed necessary or appropriate. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In connection with its review, with the consent of the Special Committee, UBS assumed and relied upon, without independent verification, the accuracy and completeness in all material respects of the information provided to or reviewed by UBS for the purpose of its opinion. In addition, with the consent of the Special Committee, UBS did not make any independent evaluation or appraisal of any of the assets or liabilities (contingent or otherwise) of Standard BioTools or Treeline, nor was UBS furnished with any such evaluation or appraisal (other than the Standard BioTools wind-down analysis). With respect to Treeline Projections and Standard BioTools Net Cash Estimates, UBS assumed, at the direction of the Special Committee, that they had been reasonably prepared on a basis reflecting the best currently available estimates and judgments of the Special Committee and the management of Standard BioTools as to the future financial performance or status of Standard BioTools and Treeline and the other matters covered thereby. In addition, UBS assumed, with the approval of the Special Committee, that Treeline Projections and Standard BioTools Net Cash Estimates will be achieved at the times and in the amounts projected. Further, UBS expressed no view or opinion with respect to Treeline Projections, the Going Concern Projections, the Standard BioTools wind-down analysis or Standard BioTools Net Cash Estimates or the assumptions on which they are based. UBS relied on the assessments of the management of Standard BioTools as to, among other things, the product pipeline, future products, technology and intellectual property of Treeline, including the viability of and risks associated with such product pipeline, future products, technology and intellectual property. The Special Committee advised UBS, and at the direction of the Special Committee UBS relied upon and assumed that (a)&#160;Standard BioTools&#8217; assets and liabilities are comprised solely of cash and certain operating assets and related liabilities; and (b) (i) Standard BioTools had suffered significant recurring losses from operations, (ii) Standard BioTools&#8217; management prepared the Going Concern Projections and the Standard BioTools wind-down analysis and (iii) the Board and the Special Committee determined that the Standard BioTools wind-down analysis reflects the best currently available estimates and judgments as to the future financial performance of Standard BioTools on a standalone basis and that the Going Concern Projections do not reflect the best currently available estimates and judgments as to the future financial performance of Standard BioTools on a standalone basis. UBS also assumed, with </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">177<br></div></div></div>
<!--End Page 188-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 189-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_115-merger_pg44"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">the consent of the Special Committee, that the Transactions will qualify for U.S. federal income tax purposes as a reorganization within the meaning of Section&#160;368(a) of the Internal Revenue Code of 1986, as amended. UBS&#8217;s opinion was necessarily based on economic, monetary, market and other conditions as in effect on, and the information available to UBS as of, the date of its opinion. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">At the direction of the Special Committee, UBS was not asked to, and UBS did not, offer any opinion as to the terms, other than the Exchange Ratio to the extent expressly specified in UBS&#8217;s opinion, of the Merger Agreement or any related documents or the form of the Transactions, including, but not limited to, any of the Closing Dividend (as defined below), Legacy Transaction or Reverse Stock Split, the CVRs, the CVR Agreement, the Voting Agreements or the Lock-Up Agreements. In addition, UBS expressed no opinion as to the fairness of the amount or nature of any compensation to be received by any officers, directors or employees of any parties to the Transactions, or any class of such persons, relative to the Exchange Ratio. UBS expressed no opinion as to what the value of Standard BioTools Common Stock or CVRs will be when issued pursuant to the Transactions or the price at which Standard BioTools Common Stock will trade at any time. In rendering its opinion, UBS assumed, with the consent of the Special Committee, that (i) the final executed form of the Merger Agreement would not differ in any material respect from the draft that UBS reviewed, (ii) the parties to the Merger Agreement will comply with all material terms of the Merger Agreement and the CVR Agreement, as applicable, and (iii) the Transactions will be consummated in accordance with the terms of the Merger Agreement and the CVR Agreement without any adverse waiver or amendment of any material term or condition thereof. UBS also assumed that all governmental, regulatory or other consents and approvals necessary for the consummation of the Transactions will be obtained without any material adverse effect on Standard BioTools, Treeline or the Transactions. The issuance of UBS&#8217;s opinion was approved by an authorized committee of UBS. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In connection with rendering its opinion to the Special Committee, UBS performed a variety of financial and comparative analyses which are summarized below. The following summary is not a complete description of all analyses performed and factors considered by UBS in connection with its opinion. The preparation of a fairness opinion is a complex process involving subjective judgments and is not necessarily susceptible to partial analysis or summary description. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">UBS believes that its analysis and the summary below must be considered as a whole and that selecting portions of its analysis and factors, or focusing on information presented in tabular format, without considering all analyses and factors or the full narrative description of the analyses, could create a misleading or incomplete view of the processes underlying UBS&#8217;s analyses and opinion. UBS did not draw, in isolation, conclusions from or with regard to any one factor or method of analysis for purposes of its opinion, but rather arrived at its ultimate opinion based on results of all analyses undertaken by it and assessed as a whole. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Treeline Projections, Standard BioTools Net Cash Estimates and Standard BioTools wind-down analysis, and the estimates of the future financial performances reflecting such estimates, in or underlying UBS&#8217;s analyses are not necessarily indicative of future results or values, which may be significantly more or less favorable than those estimates. In performing its analyses, UBS considered industry performance, general business and economic conditions and other matters, many of which are beyond the control of Standard BioTools and Treeline. Estimates of the financial value of companies do not purport to be appraisals or necessarily reflect the prices at which companies may actually be sold. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Exchange Ratio was determined through negotiation between Standard BioTools and Treeline, and the decision by the Special Committee to approve the Merger Agreement was solely that of the Special Committee. UBS&#8217;s&#160;opinion and financial analyses were only one of many factors considered by the Special Committee in its evaluation of the Merger Agreement and the transactions contemplated thereby, including the Merger, and should not be viewed as determinative of the views of the Special Committee with respect to the Merger Agreement, the transactions contemplated thereby, including the Merger, or the Exchange Ratio. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following is a brief summary of the material financial analyses performed by UBS and reviewed with the Special Committee on June&#160;5, 2026, in connection with UBS&#8217;s opinion. <font style="font-weight: bold;">The financial analyses summarized below include information presented in tabular format. In order to fully understand UBS&#8217;s financial analyses, the tables must be read together with the text of each summary. The tables alone do not constitute a complete description of the financial analyses. Considering the data below without considering the full narrative description of the financial analyses, including the methodologies and assumptions underlying the analyses, could create a misleading or incomplete view of UBS&#8217;s financial analyses.</font> </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">178<br></div></div></div>
<!--End Page 189-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 190-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_115-merger_pg45"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following summary does not purport to be a complete description of the financial analyses performed by UBS. The following quantitative information, to the extent that it is based on market data, is based on market data as it existed on or before June&#160;4, 2026, and is not necessarily indicative of current or future market conditions. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For purposes of its financial analyses, UBS calculated the projected exchange ratio at closing of the Transactions (&#8220;Projected Exchange Ratio&#8221;) of 11.6997x by (a) calculating the fully diluted equity value of Treeline by adding the Aggregate Treeline Exercise Price (as defined in the Merger Agreement) of approximately $43&#160;million, per Standard BioTools&#8217; management, to $2,500&#160;million, per the Merger Agreement and Standard BioTools&#8217; management, (b)&#160;calculating the fully diluted equity value of Standard BioTools by adding the Aggregate Standard BioTools Exercise Price (as defined in the Merger Agreement) of approximately $6&#160;million, per Standard BioTools&#8217; management, to $460&#160;million, per the Merger Agreement and Standard BioTools&#8217; management (assuming a Standard BioTools Net Cash Surplus and Standard BioTools Net Cash Shortfall each of $0 per the Standard BioTools Net Cash Estimates), (c)&#160;dividing the fully diluted equity value of Treeline and the fully diluted equity value of Standard BioTools, respectively, by the fully diluted shares outstanding of Treeline Capital Stock of approximately 194.1&#160;million and the fully diluted shares outstanding of Standard BioTools Common Stock of approximately 415.9&#160;million, respectively, in each case per Standard BioTools&#8217; management, to derive an implied value per share of Treeline Capital Stock of $13.10 and an implied value per share of Standard BioTools Common Stock of $1.12 and (d) dividing the implied value per share of Treeline Capital Stock by the implied value per share of Standard BioTools Common Stock. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Discounted Cash Flow Analysis </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">UBS performed a discounted cash flow analysis (&#8220;DCF Analysis&#8221;) of Treeline on a standalone basis using Treeline Projections. UBS calculated a range of implied present values, as of June&#160;30, 2026, of the standalone after-tax unlevered free cash flows that Treeline is forecasted to generate from July&#160;1, 2026, through December&#160;31, 2050, as set forth in Treeline Projections, using discount rates ranging between 15.0% and 17.0%, based on UBS&#8217; estimate of Treeline&#8217;s weighted average cost of capital, which is referred to as &#8220;WACC&#8221;. UBS also calculated estimated terminal values for Treeline by applying perpetuity growth rates ranging from (30)% to 0% to Treeline&#8217;s terminal year after-tax unlevered free cash flow. The estimated terminal values were then discounted to present value as of June&#160;30, 2026 using discount rates ranging from 15.0% to 17.0%, based on UBS&#8217; estimate of Treeline&#8217;s WACC. UBS then derived a reference range of implied equity values for Treeline of $2,595&#160;million to $3,270&#160;million from the implied enterprise value reference range resulting from the sum of such present values, by adding Treeline&#8217;s projected cash of approximately $510&#160;million, as of June&#160;30, 2026 and per Standard BioTools&#8217; management, and the Aggregate Treeline Exercise Price of approximately $43&#160;million, per Standard BioTools&#8217; management, to derive a range of implied fully diluted equity values for Treeline of $2,638&#160;million to $3,313&#160;million. UBS then divided the range of implied fully diluted equity values of Treeline by the number of fully diluted shares outstanding of Treeline Capital Stock of approximately 194.1&#160;million, as provided by Standard BioTools&#8217; management. This analysis indicated a range of implied values per share of Treeline of $13.59 to $17.07. </div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 20pt; text-align: left;">Exchange Ratio Implied by DCF Analysis </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Using the range of implied values per share of Treeline Capital Stock derived from the DCF Analysis and the implied value per share of Standard BioTools Common Stock calculated as described above, UBS calculated the ratio of the lowest implied value per share of Treeline Capital Stock to the implied value per share of Standard BioTools Common Stock and the ratio of the highest implied value per share of Treeline Capital Stock to the implied value per share of Standard BioTools Common Stock, which indicated a range of implied exchange ratios of 12.1378x to 15.2438x, as compared to the Projected Exchange Ratio of 11.6997x. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Comparable Company Analysis </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">UBS reviewed publicly available Wall Street research analysts&#8217; estimates, public filings and other publicly available financial and stock market information of the below early-stage oncology companies with multiple assets that UBS in its professional judgment considered generally relevant to Treeline for purposes of its financial analyses, which companies are referred to as the &#8220;Selected Companies&#8221; and which analysis is referred to as the &#8220;Comparable Company Analysis&#8221;. The data reviewed included each Selected Company&#8217;s enterprise value or &#8220;EV&#8221; (defined as equity market value less cash, cash equivalents and equity investments, plus total debt (as applicable)). </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">179<br></div></div></div>
<!--End Page 190-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 191-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_115-merger_pg46"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 384pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 3.79pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 3.79pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 76.42pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 384pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Selected Companies</div></td><td style="width: 3.79pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.79pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 76.42pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Enterprise Value ($M) </div></td></tr><tr><td style="width: 384pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Erasca, Inc.<font style="padding-left: 4.58pt;"></font></div></td><td style="width: 3.79pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.79pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 76.42pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 24.46pt; text-align: left;">$4,221 </div></td></tr><tr><td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Tango Therapeutics, Inc.<font style="padding-left: 2.41pt;"></font></div></td><td style="width: 3.79pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.79pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 76.42pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 24.46pt; text-align: left;">$3,280 </div></td></tr><tr><td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Monte Rosa Therapeutics, Inc.<font style="padding-left: 3.66pt;"></font></div></td><td style="width: 3.79pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.79pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 76.42pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 24.46pt; text-align: left;">$1,249 </div></td></tr><tr><td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Nurix Therapeutics, Inc.<font style="padding-left: 3.94pt;"></font></div></td><td style="width: 3.79pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.79pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 76.42pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 24.46pt; text-align: left;">$1,207 </div></td></tr><tr><td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">ORIC Pharmaceuticals, Inc.<font style="padding-left: 4.32pt;"></font></div></td><td style="width: 3.79pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.79pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 76.42pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 24.46pt; text-align: left;">$<font style="padding-left: 7.5pt;">474 </font></div></td></tr><tr><td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">BridgeBio Oncology Therapeutics, Inc.<font style="padding-left: 3.66pt;"></font></div></td><td style="width: 3.79pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.79pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 76.42pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 24.46pt; text-align: left;">$<font style="padding-left: 7.5pt;">273 </font></div></td></tr><tr><td style="width: 384pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">C4 Therapeutics, Inc.<font style="padding-left: 0.6pt;"></font></div></td><td style="width: 3.79pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.79pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 76.42pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 24.46pt; text-align: left;">$<font style="padding-left: 7.5pt;">509</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 384pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 3.79pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 3.79pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 76.42pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Using its professional judgment and experience, UBS selected an implied EV range for Treeline of $474&#160;million to $3,280&#160;million, which represents the 25th percentile and 75th percentile of the Selected Companies&#8217; EVs, respectively, and added to the implied range of EVs Treeline&#8217;s projected cash of approximately $510&#160;million, as of June&#160;30, 2026 and per Standard BioTools&#8217; management, to derive a range of implied equity values of Treeline of $985&#160;million to $3,791&#160;million. UBS then added the Aggregate Treeline Exercise Price of approximately $43&#160;million, per Standard BioTools&#8217; management, to the range of implied equity values of Treeline to derive an implied fully diluted equity value range of $1,028&#160;million to $3,834&#160;million. UBS then divided the range of implied fully diluted equity values of Treeline by the number of fully diluted shares outstanding of Treeline Capital Stock of 194.1&#160;million. This analysis indicated a range of implied values per share of Treeline Capital Stock of $5.29 to $19.75. </div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 20pt; text-align: left;">Exchange Ratio Implied by Comparable Company Analysis </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Using the range of implied values per share of Treeline Capital Stock derived from the Comparable Company Analysis and the implied value per share of Standard BioTools Common Stock calculated as described above, UBS calculated the ratio of the lowest implied value per share of Treeline Capital Stock to the implied value per share of Standard BioTools Common Stock and the ratio of the highest implied value per share of Treeline Capital Stock to the implied value per share of Standard BioTools Common Stock, which indicated a range of implied exchange ratios of 4.7285x to 17.6402x, as compared to the Projected Exchange Ratio of 11.6997x. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">No Selected Company is identical to Treeline. In evaluating the Selected Companies, UBS made numerous judgments and assumptions with regard to industry performance, general business, economic, market and financial conditions and other matters, many of which are beyond the control of Standard BioTools, Treeline and UBS. Mathematical analysis, such as determining the 25th percentile and 75th percentile, is not in itself a meaningful method of using the Selected Companies&#8217; data. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Standard BioTools Wind-Down Analysis </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition to performing the foregoing DCF Analysis and Comparable Company Analysis for the purposes of its financial analysis and opinion, for informational purposes, UBS also reviewed with the Special Committee a comparison, from the perspective of the value received by stockholders of Standard BioTools, of the illustrative value indicated by the Standard BioTools wind-down analysis of $468&#160;million, provided by management of Standard BioTools and assuming no Transactions, to the illustrative value to stockholders of Standard BioTools at 15.5% ownership of such stockholders in the pro forma Treeline resulting from the Transactions. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">To derive implied equity values of the pro forma company resulting from the Transactions, UBS added to the implied equity value ranges from the DCF Analysis and Comparable Company Analysis of $2,595&#160;million to $3,270&#160;million and $985&#160;million to $3,791&#160;million, respectively, as described above, Standard BioTools&#8217; projected net cash at closing of the Merger of $450&#160;million, per Standard BioTools&#8217; management and the Standard BioTools Net Cash Estimates, which resulted in implied equity values of the pro forma Treeline resulting from the Transactions of $3,045&#160;million to $3,720&#160;million, based on the DCF Analysis, and $1,435&#160;million to $4,241&#160;million, based on the Comparable Company Analysis. UBS then multiplied each range of implied equity values by 15.5% to derive a range of implied equity value to stockholders of Standard BioTools of $471&#160;million to $576&#160;million, based on the DCF Analysis, and $222&#160;million to $657&#160;million, based on the Comparable Company Analysis, in each case as compared to the $468&#160;million of illustrative value indicated by the Standard BioTools wind-down analysis. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Miscellaneous </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under the terms of UBS&#8217;s engagement by the Special Committee, Standard BioTools has agreed to pay UBS for its financial advisory services in connection with the proposed transaction an aggregate fee of $5.0 million, </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">180<br></div></div></div>
<!--End Page 191-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 192-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_115-merger_pg47"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">$1.5&#160;million of which became payable upon delivery of UBS&#8217;s opinion, $750,000 of which became payable upon execution of the Merger Agreement and the remainder of which is contingent upon consummation of the Transactions. In addition, Standard BioTools has agreed to reimburse certain of UBS&#8217;s expenses arising, and indemnify UBS against certain liabilities that may arise, out of UBS&#8217;s engagement. UBS Group AG (the indirect parent of UBS) and its subsidiaries, branches and affiliates provide a wide range of commercial banking, investment banking and other activities (including wealth and investment management, corporate finance, subscription lines, asset management, securities issuing, trading and brokerage activities, research and other investment and financial businesses and services). During the period from April&#160;1, 2024 through May&#160;28, 2026, UBS or one of its affiliates acted as financial advisor to a special committee of the Board in connection with the sale of the SomaScan business for which UBS or its affiliates received compensation not in excess of $5.0&#160;million. During the period from April&#160;1, 2024 through May&#160;28, 2026, UBS and/or its affiliates have not provided services to Casdin Capital LLC, a significant shareholder of Standard BioTools (&#8220;Casdin&#8221;), and/or its affiliates or Treeline and/or its affiliates and have not received compensation therefrom. In the future, UBS and/or its affiliates may provide services to Standard BioTools, Casdin and their respective affiliates and/or Treeline and its affiliates for which UBS and/or its affiliates may receive compensation. In addition, in the ordinary course of business, UBS, its affiliates and their respective employees may currently own or trade or otherwise originate, hedge or enforce interests in loans, debt and/or equity securities of Standard BioTools (including its affiliates), Casdin (including its affiliates) and/or Treeline (including its affiliates) for its own account or for the accounts of customers, and may at any time hold a long or short position in, or security interests over, such securities. As of May&#160;28, 2026, UBS held shares of Standard BioTools Common Stock (including shares of Standard BioTools Common Stock held by UBS Asset Management in discretionary accounts and held on behalf of a client, related to client facilitation or as security) having a market value of approximately $729&#160;thousand as of such date and constituting less than 1% of the outstanding shares of Standard BioTools Common Stock. As of May&#160;28, 2026, UBS did not hold any of the outstanding shares of Treeline Capital Stock or shares of Casdin common stock. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Special Committee selected UBS as its financial advisor in connection with the Transactions because UBS is an internationally recognized investment banking firm with substantial experience in similar transactions. UBS is continually engaged in the valuation of businesses and their securities in connection with mergers and acquisitions, leveraged buyouts, negotiated underwritings, competitive bids, secondary distributions of listed and unlisted securities and private placements. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Summary of Certain Unaudited Prospective Financial Information </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Standard BioTools does not as a matter of course publicly disclose financial projections or forecasts as to future performance, revenues, earnings or other results given, among other things, the unpredictability, uncertainty and subjectivity of the underlying assumptions and estimates inherent in preparing financial projections and forecasts. However, in connection with the transactions contemplated by the Merger Agreement, Standard BioTools&#8217; management prepared and made available to the Special Committee and the Standard BioTools Board in connection with their evaluations of the Merger as described herein, and to Centerview and UBS in connection with their financial analyses and opinions, certain unaudited prospective financial information concerning Treeline (the &#8220;Standard BioTools management Treeline projections&#8221;) and Standard BioTools (the &#8220;Standard BioTools management Standard BioTools projections&#8221; and together with the Standard BioTools management Treeline projections, the &#8220;Standard BioTools management projections&#8221;) on a standalone basis, without giving effect to the Merger, set forth in this section. The Standard BioTools management Treeline projections were prepared by Standard BioTools&#8217; management based on discussions with and materials provided by Treeline to Standard BioTools management; the Standard BioTools management Treeline projections were originally prepared by Treeline&#8217;s management and then adjusted by Standard BioTools&#8217; management. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, in connection with the evaluation of the proposed transaction with Treeline, Standard BioTools management prepared an analysis with respect to Standard BioTools&#8217; estimated value to its stockholders in a liquidation scenario, including an estimate of the net cash that would be available for distribution to Standard BioTools shareholders in connection with any such potential future liquidation or dissolution. This wind-down or liquidation analysis was based on certain assumptions and estimates of Standard BioTools regarding asset values, liabilities, wind-down costs and expenses, reserves for contingent liabilities, taxes, estimates for timing and quantum of distributions to stockholders, and other relevant factors relating to the potential winddown of Standard BioTools&#8217; operations (the &#8220;Standard BioTools wind-down analysis&#8221; and, together with the Standard BioTools management projections, the &#8220;unaudited prospective financial information&#8221;). </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">181<br></div></div></div>
<!--End Page 192-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 193-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_115-merger_pg48"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The summaries of the unaudited prospective financial information are not being included in this proxy statement/prospectus to influence any Standard BioTools stockholder&#8217;s decision whether to vote for any of the Proposals or for any other related purpose. The summaries of the unaudited prospective financial information are being included in this proxy statement/prospectus because the unaudited prospective financial information was provided to the Special Committee and the Standard BioTools Board in order to evaluate strategic alternatives considered by the Special Committee and the Standard BioTools Board, including the Transactions, and to Centerview and UBS in connection with their evaluation of the Transactions. The unaudited prospective financial information may differ from publicized analyst estimates and forecasts and, in each instance, do not take into account any events or circumstances after the date they were prepared, including the announcement of the Merger and the other Transactions. This unaudited prospective financial information was not prepared with a view toward compliance with published guidelines of the SEC or the guidelines established by the American Institute of Certified Public Accountants for preparation or presentation of prospective financial information. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The unaudited prospective financial information, although presented with numerical specificity, is necessarily based on numerous variables, estimates and assumptions that are inherently uncertain, and many of which are beyond Standard BioTools&#8217; control. Modeling and forecasting the future development and commercialization of drug candidates by an emerging biotechnology company is a highly speculative endeavor. Because the unaudited prospective financial information spans multiple years, by their nature they will become subject to greater uncertainty with each successive year and are unlikely to anticipate each circumstance that will have an effect on the combined company&#8217;s business and its results of operations. The unaudited prospective financial information was prepared by Standard BioTools&#8217; management based on certain estimates and assumptions with respect to general business, economic, competitive, regulatory, reimbursement and other market and financial conditions and other future events, all of which are difficult to predict and many of which are beyond Standard BioTools&#8217; control. Although Standard BioTools believes its assumptions about Treeline to be reasonable, all financial projections are inherently uncertain, and Standard BioTools expects that differences will exist between actual and projected results. As a result, there can be no assurance that any of the unaudited prospective financial information accurately reflects future trends or, in the case of the Standard BioTools management Treeline projections, accurately estimate the future market for Treeline&#8217;s product candidates or future product candidates it may develop. There also can be no assurance that Treeline will obtain the regulatory approvals necessary for the commercialization of any product candidate, or that Treeline&#8217;s competitors will not commercialize products that are safer, more effective, or more successfully marketed and sold than any product that Treeline may market or commercialize. The unaudited prospective financial information is subject to many risks and uncertainties, and you are urged to review the section titled &#8220;<font style="font-style: italic;">Risk Factors</font>&#8221; beginning on page <a href="#tRF">33</a> of this proxy statement/prospectus for a description of risk factors relating to the Transactions and Treeline&#8217;s business. You should also read the section titled &#8220;<font style="font-style: italic;">Cautionary Statement Regarding Forward-Looking Statements</font>&#8221; beginning on page <a href="#tFLS">104</a> of this proxy statement/prospectus for additional information regarding the risks inherent in forward-looking information such as the unaudited prospective financial information. The unaudited prospective financial information was not reviewed or approved by Treeline&#8217;s management, its board of directors or its advisors. In addition, the unaudited prospective financial information will be affected by Treeline&#8217;s ability to achieve strategic goals, objectives and targets over the applicable period. Accordingly, there can be no assurance that any of the forecasts shown herein will be realized, and actual results may vary materially from those shown. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The unaudited prospective financial information included in this proxy statement/prospectus has been prepared by, and is the responsibility of, Standard BioTools management. Standard BioTools&#8217; independent registered public accountant has not audited, reviewed, examined, compiled nor applied agreed-upon procedures with respect to the accompanying prospective financial information and, accordingly, does not express an opinion or any other form of assurance with respect thereto. The independent registered public accountant&#8217;s report incorporated by reference relates to Standard BioTools&#8217; previously issued financial statements. It does not extend to the prospective financial information and should not be read to do so. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline&#8217;s independent registered public accountant has not audited, reviewed, examined, compiled or applied agreed-upon procedures with respect to the accompanying prospective financial information, and accordingly does not express any opinion or any other form of assurance with respect thereto. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The unaudited prospective financial information concerning Treeline and Standard BioTools set forth below was developed under the assumption of continued standalone operation and did not give effect to any changes or expenses as a result of the Merger or any other effects of the Merger or any impact should the Merger fail to be </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">182<br></div></div></div>
<!--End Page 193-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 194-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_115-merger_pg49"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">consummated. The inclusion of such unaudited prospective financial information does not constitute an admission or representation that the information is material. The inclusion of such unaudited prospective financial information should not be regarded as an indication that Standard BioTools and/or its affiliates, officers, directors, advisors or other representatives or Treeline and/or its affiliates, officers, directors, advisors or other representatives consider such information to be necessarily predictive of actual future events and such information should not be relied upon as such. None of Standard BioTools and/or its affiliates, officers, directors, advisors or other representatives or Treeline and/or its affiliates, officers, directors, advisors or other representatives makes any representation or warranty or gives any stockholder of Standard BioTools, Treeline or any other person any assurance regarding the ultimate performance of Standard BioTools or Treeline compared to the information in any forecasts, the likelihood that actual results will not differ materially from the unaudited prospective financial information, the results of Treeline&#8217;s ongoing and planned clinical trials, the potential timing and approval of commercial launch of any future product of Treeline, the effectiveness or marketability of Treeline&#8217;s product candidates, or the overall future performance of Standard BioTools or Treeline. <font style="font-weight: bold;">In particular, the unaudited prospective financial information set forth below should not be relied upon as public guidance</font>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">You should also note that the unaudited prospective financial information was not prepared with a view toward public disclosure or with a view toward complying with GAAP, the published guidelines of the SEC or the guidelines established by the American Institute of Certified Public Accountants for preparation and presentation of prospective financial information. The information set forth in this section entitled &#8220;<font style="font-style: italic;">&#8212; Summary of Certain Unaudited Prospective Financial Information</font>&#8221; was prepared utilizing Standard BioTools&#8217; historical internal accounting policies and forecast approach and does not give effect to the adoption of any new accounting pronouncements. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Certain of the measures included in the unaudited prospective financial information set forth below may be considered non-GAAP financial measures. Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information presented in compliance with GAAP, and non-GAAP financial measures as used by Standard BioTools and Treeline may not be comparable to similarly titled amounts used by other companies. Furthermore, there are limitations inherent in non-GAAP financial measures because they exclude charges and credits that are required to be included in a GAAP presentation. Because non-GAAP financial measures do not reflect a comprehensive system of accounting, differ from GAAP measures with the same captions, and may differ from non-GAAP financial measures with the same or similar captions that are used by other companies, non-GAAP measures should be considered as a supplement to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Financial measures provided to a financial advisor are excluded from the definition of non-GAAP financial measures and, therefore, are not subject to SEC rules regarding disclosures of non-GAAP financial measures, which would otherwise require a reconciliation of a non-GAAP financial measure to a GAAP financial measure. Reconciliations of non-GAAP financial measures were not provided to Centerview for purposes of its financial analysis as described above in &#8220;<font style="font-style: italic;">The Merger &#8212; Opinion of Standard BioTools&#8217; Financial Advisor,</font>&#8221; to UBS for purposes of its financial analysis described above in &#8220;<font style="font-style: italic;">The Merger &#8212; Opinion of Standard BioTools Special Committee&#8217;s Financial Advisor</font>&#8221; or to the Special Committee or Standard BioTools Board in connection with their consideration of the Merger. Accordingly, Standard BioTools has not provided a reconciliation of the non-GAAP financial measures included in the unaudited prospective financial information set forth below. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Standard BioTools&#8217; internally prepared unaudited prospective financial information set forth below was based on estimates, assumptions and judgments made by Standard BioTools management at the time of its preparation and speaks only as of such times. Such unaudited prospective financial information does not take into account any circumstances, transactions or events occurring after the date on which it was prepared. Some or all of the assumptions underlying such information may have changed since the date such information was prepared. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">STANDARD BIOTOOLS HAS NOT UPDATED AND DOES NOT INTEND TO UPDATE OR OTHERWISE REVISE THE UNAUDITED PROSPECTIVE FINANCIAL INFORMATION SET FORTH BELOW TO REFLECT CIRCUMSTANCES EXISTING AFTER THE DATE WHEN MADE OR TO REFLECT THE OCCURRENCE OF FUTURE EVENTS, EVEN IN THE EVENT THAT ANY OR ALL OF THE ASSUMPTIONS UNDERLYING SUCH INFORMATION ARE NO LONGER APPROPRIATE. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The unaudited prospective financial information set forth below should not be relied upon as necessarily indicative of actual future results, and readers of this proxy statement/prospectus are cautioned not to place undue reliance on such unaudited prospective financial information.<font style="font-weight: normal;"> </font></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">183<br></div></div></div>
<!--End Page 194-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 195-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; position: relative; width: 528pt;"><a name="ny20077604x1_s4_115-merger_pg50"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 30pt;"><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Standard BioTools Management Treeline Projections </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Set forth below is a summary of the Standard BioTools management Treeline risk-adjusted projections, which are select projected financial information for Treeline for fiscal years 2026 through 2050 based on information as prepared by Standard BioTools management in connection with Standard BioTools&#8217; evaluation of the Merger and each of Treeline&#8217;s product candidates (in millions): </div></div><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 528pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 484.18pt;" colspan="73"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 41pt; padding-bottom: 2.7pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold;">&#160;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td colspan="73" style="width: 484.18pt; padding-bottom: 2.7pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: center;">Calendar Year Ending Dec 31, </div></td></tr><tr class="BRDSX_header"><td style="width: 41pt; padding-top: 2.47pt; padding-bottom: 2.7pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">($ in millions)</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 2.47pt; padding-bottom: 2.7pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: center;">2026E</div></td><td style="width: 1.46pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 2.47pt; padding-bottom: 2.7pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: center;">2027E</div></td><td style="width: 1.46pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 2.47pt; padding-bottom: 2.7pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: center;">2028E</div></td><td style="width: 1.46pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 2.47pt; padding-bottom: 2.7pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: center;">2029E</div></td><td style="width: 1.46pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 2.47pt; padding-bottom: 2.7pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: center;">2030E</div></td><td style="width: 1.46pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 2.47pt; padding-bottom: 2.7pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: center;">2031E</div></td><td style="width: 1.46pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 2.47pt; padding-bottom: 2.7pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: center;">2032E</div></td><td style="width: 1.46pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 2.47pt; padding-bottom: 2.7pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: center;">2033E</div></td><td style="width: 1.46pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 2.47pt; padding-bottom: 2.7pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: center;">2034E</div></td><td style="width: 1.46pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 2.47pt; padding-bottom: 2.7pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: center;">2035E</div></td><td style="width: 1.46pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 2.47pt; padding-bottom: 2.7pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: center;">2036E</div></td><td style="width: 1.46pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 2.47pt; padding-bottom: 2.7pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: center;">2037E</div></td><td style="width: 1.46pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 2.47pt; padding-bottom: 2.7pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: center;">2038E</div></td><td style="width: 1.46pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 2.47pt; padding-bottom: 2.7pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: center;">2039E</div></td><td style="width: 1.46pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 2.47pt; padding-bottom: 2.7pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: center;">2040E</div></td><td style="width: 1.46pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 2.47pt; padding-bottom: 2.7pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: center;">2041E</div></td><td style="width: 1.46pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 2.47pt; padding-bottom: 2.7pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: center;">2042E</div></td><td style="width: 1.46pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 2.47pt; padding-bottom: 2.7pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: center;">2043E</div></td><td style="width: 1.46pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.76pt; padding-top: 2.47pt; padding-bottom: 2.7pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: center;">2044E</div></td><td style="width: 1.46pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.76pt; padding-top: 2.47pt; padding-bottom: 2.7pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: center;">2045E</div></td><td style="width: 1.46pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.76pt; padding-top: 2.47pt; padding-bottom: 2.7pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: center;">2046E</div></td><td style="width: 1.46pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.76pt; padding-top: 2.47pt; padding-bottom: 2.7pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: center;">2047E</div></td><td style="width: 1.46pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.76pt; padding-top: 2.47pt; padding-bottom: 2.7pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: center;">2048E</div></td><td style="width: 1.46pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 2.47pt; padding-bottom: 2.7pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: center;">2049E</div></td><td style="width: 1.46pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 2.47pt; padding-bottom: 2.7pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: center;">2050E </div></td></tr><tr><td style="width: 41pt; padding-top: 2.47pt; padding-bottom: 1.95pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; margin-left: 6.1pt; text-indent: -6.1pt; text-align: left;">Global Net Revenue<font style="font-size: 4.5pt; position: relative; top: -2.5pt;">(1)</font><font style="font-weight: normal; padding-left: 0.78pt;"></font></div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 2.47pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold;">&#160;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 2.47pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$120</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 2.47pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$40</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 2.47pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$13</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 2.47pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$16</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 2.47pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$95</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 2.47pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$353</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 2.47pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$886</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 2.47pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$1,549</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 2.47pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$2,223</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 2.47pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$2,719</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 2.47pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$3,068</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 2.47pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$3,321</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 2.47pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$3,525</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 2.47pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$3,695</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 2.47pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$3,833</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 2.47pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$3,963</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 2.47pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$3,007</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.76pt; padding-top: 2.47pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$1,720</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.76pt; padding-top: 2.47pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$1,506</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.76pt; padding-top: 2.47pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$1,266</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.76pt; padding-top: 2.47pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$1,203</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.76pt; padding-top: 2.47pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$1,156</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 2.47pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$492</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 2.47pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$422 </div></td></tr><tr><td style="width: 41pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">% Growth<font style="font-style: normal; padding-left: 4.47pt;"></font></div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic;">&#160;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">n.m.</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">(67%)</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">(68%)</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">29%</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">477%</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">273%</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">151%</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">75%</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">44%</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">22%</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">13%</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">8%</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">6%</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">5%</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">4%</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">3%</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">(24%)</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.76pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">(43%)</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.76pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">(12%)</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.76pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">(16%)</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.76pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">(5%)</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.76pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">(4%)</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">(57%)</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">(14%) </div></td></tr><tr><td style="width: 41pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">EBIT<font style="font-size: 4.5pt; position: relative; top: -2.5pt;">(2)</font><font style="font-weight: normal; padding-left: 4.66pt;"></font></div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">($226)</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">($153)</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">($265)</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">($338)</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">($274)</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">($241)</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$62</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$538</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$1,120</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$1,778</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$2,144</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$2,506</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$2,730</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$2,905</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$3,047</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$3,195</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$3,334</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$2,435</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.76pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$1,195</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.76pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$986</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.76pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$865</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.76pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$814</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.76pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$778</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$142</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$84 </div></td></tr><tr><td style="width: 41pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">% Margin<font style="font-style: normal; padding-left: 4.81pt;"></font></div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">n.m.</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">n.m.</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">n.m.</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">n.m.</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">n.m.</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">n.m.</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">18%</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">61%</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">72%</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">80%</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">79%</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">82%</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">82%</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">82%</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">82%</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">83%</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">84%</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">81%</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.76pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">69%</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.76pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">65%</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.76pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">68%</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.76pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">68%</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.76pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">67%</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">29%</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">20% </div></td></tr><tr><td style="width: 41pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">NOPAT<font style="font-size: 4.5pt; position: relative; top: -2.5pt;">(3)</font><font style="font-weight: normal; padding-left: 3.79pt;"></font></div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">($226)</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">($153)</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">($265)</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">($338)</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">($274)</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">($241)</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$59</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$510</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$1,062</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$1,378</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$1,587</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$1,855</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$2,020</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$2,150</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$2,255</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$2,364</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$2,467</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$1,802</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.76pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$884</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.76pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$730</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.76pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$640</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.76pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$603</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.76pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$576</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$105</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$62 </div></td></tr><tr><td style="width: 41pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">% Margin<font style="font-style: normal; padding-left: 4.81pt;"></font></div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">n.m.</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">n.m.</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">n.m.</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">n.m.</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">n.m.</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">n.m.</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">17%</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">58%</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">69%</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">62%</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">58%</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">60%</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">61%</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">61%</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">61%</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">62%</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">62%</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">60%</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.76pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">51%</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.76pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">48%</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.76pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">51%</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.76pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">50%</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.76pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">50%</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">21%</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">15% </div></td></tr><tr><td style="width: 41pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; margin-left: 6.1pt; text-indent: -6.1pt; text-align: left;">Unlevered FCF<font style="font-size: 4.5pt; position: relative; top: -2.5pt;">(3)</font><font style="font-weight: normal; padding-left: 1.28pt;"></font></div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">($226)</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">($153)</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">($265)</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">($338)</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">($275)</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">($245)</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$46</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$481</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$1,021</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$1,331</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$1,544</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$1,822</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$1,996</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$2,132</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$2,241</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$2,353</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$2,457</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$1,846</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.76pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$946</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.76pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$766</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.76pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$687</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.76pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$608</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.76pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$580</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$140</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; padding-bottom: 1.95pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-weight: bold; margin-top: 0pt; text-align: right;">$67 </div></td></tr><tr><td style="width: 41pt; padding-top: 1.72pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">% Margin<font style="font-style: normal; padding-left: 4.81pt;"></font></div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">n.m.</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">n.m.</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">n.m.</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">n.m.</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">n.m.</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">n.m.</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">13%</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">54%</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">66%</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">60%</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">57%</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">59%</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">60%</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">60%</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">61%</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">61%</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">62%</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.77pt; padding-top: 1.72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">61%</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.76pt; padding-top: 1.72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">55%</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.76pt; padding-top: 1.72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">51%</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.76pt; padding-top: 1.72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">54%</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.76pt; padding-top: 1.72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">51%</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.76pt; padding-top: 1.72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">50%</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">28%</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 16.26pt; padding-top: 1.72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6.1pt; font-style: italic; margin-top: 0pt; text-align: right;">16%</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 3.9pt; width: 41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 16.26pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 16.26pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 16.26pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 16.26pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 16.26pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 16.26pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 16.26pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 16.26pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 16.77pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 16.77pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 16.77pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 16.77pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 16.77pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 16.77pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 16.77pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 16.77pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 16.77pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 16.77pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 16.76pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 16.76pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 16.76pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 16.76pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 16.76pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 16.26pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 1.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.9pt; width: 16.26pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table></div><div class="BRDSX_block-main" style="width: 468pt; margin-left: 30pt;"><div><div class="BRDSX_rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-top: 3pt; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt;"> </div></div><div class="BRDSX_ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 4pt; margin-left: 0pt; text-align: left;">Note: &#8220;n.m.&#8221; indicates negative margin </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Global net revenue includes probability-of-success-adjusted product sales, royalties to Treeline and milestones to Treeline including upfront payments. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(2)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Earnings before interest and taxes (EBIT) gives effect to milestones and royalty payments to partners, research &amp; development expenses, sales &amp; marketing expenses, and general &amp; administrative expenses; burdened by stock based compensation. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(3)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Net operating profit after taxes (NOPAT) and unlevered free cash flow (FCF) include benefit from NOLs. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Standard BioTools management Treeline risk-adjusted projections included, among other things, key assumptions regarding the risks of clinical trials and regulatory approval, timing of commercial launch, peak sales, pricing, the length of exclusivity of products, costs and expenses, partnering and licensing arrangements and other relevant factors relating to Treeline&#8217;s product candidates. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13pt; margin-left: 0pt; text-align: left;">Standard BioTools Management Standard BioTools Projections </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Set forth below is a summary of the Standard BioTools management Standard BioTools projections, which are select projected financial information for Standard BioTools, inclusive of the Legacy Business, for fiscal years 2026 through 2030 based on a base case scenario (in millions): </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 168pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 14.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 14.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 271.11pt;" colspan="16"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 168pt; padding-bottom: 2.6pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7.3pt; font-weight: bold;">&#160;</div></td><td style="width: 14.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 14.41pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td colspan="16" style="width: 271.11pt; padding-bottom: 2.6pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7.3pt; font-weight: bold; margin-top: 0pt; text-align: center;">Base Case Scenario </div></td></tr><tr class="BRDSX_header"><td style="width: 168pt; padding-top: 2.33pt; padding-bottom: 2.6pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7.3pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">($ in millions)</div></td><td style="width: 14.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 14.41pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 23.7pt; padding-top: 2.33pt; padding-bottom: 2.6pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7.3pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025A</div></td><td style="width: 14.41pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 14.41pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 23.7pt; padding-top: 2.33pt; padding-bottom: 2.6pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7.3pt; font-weight: bold; margin-top: 0pt; text-align: center;">2026E</div></td><td style="width: 14.41pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 14.41pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 19.46pt; padding-top: 2.33pt; padding-bottom: 2.6pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7.3pt; font-weight: bold; margin-top: 0pt; text-align: center;">2027E</div></td><td style="width: 14.41pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 14.41pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 20.05pt; padding-top: 2.33pt; padding-bottom: 2.6pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7.3pt; font-weight: bold; margin-top: 0pt; text-align: center;">2028E</div></td><td style="width: 14.41pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 14.41pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 20.05pt; padding-top: 2.33pt; padding-bottom: 2.6pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7.3pt; font-weight: bold; margin-top: 0pt; text-align: center;">2029E</div></td><td style="width: 14.41pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 14.41pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 20.05pt; padding-top: 2.33pt; padding-bottom: 2.6pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7.3pt; font-weight: bold; margin-top: 0pt; text-align: center;">2030E</div></td></tr><tr><td style="width: 168pt; padding-top: 2.33pt; padding-bottom: 1.85pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7.3pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Revenue<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup><font style="font-weight: normal; padding-left: 3.02pt;"></font></div></td><td style="width: 14.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 14.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 23.7pt; padding-top: 2.33pt; padding-bottom: 1.85pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7.3pt; font-weight: bold; margin-top: 0pt; text-align: right;">$85.3</div></td><td style="width: 14.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 14.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 23.7pt; padding-top: 2.33pt; padding-bottom: 1.85pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7.3pt; font-weight: bold; margin-top: 0pt; text-align: right;">$85.3</div></td><td style="width: 14.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 14.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 19.46pt; padding-top: 2.33pt; padding-bottom: 1.85pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7.3pt; font-weight: bold; margin-top: 0pt; text-align: right;">$85.4</div></td><td style="width: 14.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 14.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 20.05pt; padding-top: 2.33pt; padding-bottom: 1.85pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7.3pt; font-weight: bold; margin-top: 0pt; text-align: right;">$85.6</div></td><td style="width: 14.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 14.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 20.05pt; padding-top: 2.33pt; padding-bottom: 1.85pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7.3pt; font-weight: bold; margin-top: 0pt; text-align: right;">$84.7</div></td><td style="width: 14.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 14.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 20.05pt; padding-top: 2.33pt; padding-bottom: 1.85pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7.3pt; font-weight: bold; margin-top: 0pt; text-align: right;">$84.2 </div></td></tr><tr><td style="width: 168pt; padding-top: 1.58pt; padding-bottom: 1.85pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7.3pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">Revenue Growth<font style="font-style: normal; padding-left: 2.62pt;"></font></div></td><td style="width: 14.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 14.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 23.7pt; padding-top: 1.58pt; padding-bottom: 1.85pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7.3pt; margin-top: 0pt; text-align: right;">&#8212;</div></td><td style="width: 14.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 14.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 23.7pt; padding-top: 1.58pt; padding-bottom: 1.85pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7.3pt; margin-top: 0pt; text-align: right;">0.0%</div></td><td style="width: 14.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 14.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 19.46pt; padding-top: 1.58pt; padding-bottom: 1.85pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7.3pt; margin-top: 0pt; text-align: right;">0.1%</div></td><td style="width: 14.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 14.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 20.05pt; padding-top: 1.58pt; padding-bottom: 1.85pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7.3pt; margin-top: 0pt; text-align: right;">0.2%</div></td><td style="width: 14.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 14.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 20.05pt; padding-top: 1.58pt; padding-bottom: 1.85pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7.3pt; margin-top: 0pt; text-align: right;">(1.0%)</div></td><td style="width: 14.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 14.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 20.05pt; padding-top: 1.58pt; padding-bottom: 1.85pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7.3pt; margin-top: 0pt; text-align: right;">(0.6)%</div></td></tr><tr><td style="width: 168pt; padding-top: 1.58pt; padding-bottom: 1.85pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7.3pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Adjusted EBITDA (excl. SBC<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup>)<font style="font-weight: normal; padding-left: 0.33pt;"></font></div></td><td style="width: 14.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 14.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 23.7pt; padding-top: 1.58pt; padding-bottom: 1.85pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7.3pt; font-weight: bold; margin-top: 0pt; text-align: right;">$(62.6)</div></td><td style="width: 14.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 14.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 23.7pt; padding-top: 1.58pt; padding-bottom: 1.85pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7.3pt; font-weight: bold; margin-top: 0pt; text-align: right;">$(10.6)</div></td><td style="width: 14.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 14.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 19.46pt; padding-top: 1.58pt; padding-bottom: 1.85pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7.3pt; font-weight: bold; margin-top: 0pt; text-align: right;">$0.2</div></td><td style="width: 14.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 14.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 20.05pt; padding-top: 1.58pt; padding-bottom: 1.85pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7.3pt; font-weight: bold; margin-top: 0pt; text-align: right;">$(0.6)</div></td><td style="width: 14.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 14.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 20.05pt; padding-top: 1.58pt; padding-bottom: 1.85pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7.3pt; font-weight: bold; margin-top: 0pt; text-align: right;">$(1.5)</div></td><td style="width: 14.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 14.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 20.05pt; padding-top: 1.58pt; padding-bottom: 1.85pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7.3pt; font-weight: bold; margin-top: 0pt; text-align: right;">$(2.6) </div></td></tr><tr><td style="width: 168pt; padding-top: 1.58pt; padding-bottom: 1.85pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7.3pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">Adjusted EBITDA (excluding SBC<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup>) Margin<font style="font-style: normal; padding-left: 4.13pt;"></font></div></td><td style="width: 14.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 14.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 23.7pt; padding-top: 1.58pt; padding-bottom: 1.85pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7.3pt; margin-top: 0pt; text-align: right;">(73.3)%</div></td><td style="width: 14.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 14.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 23.7pt; padding-top: 1.58pt; padding-bottom: 1.85pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7.3pt; margin-top: 0pt; text-align: right;">(12.4)%</div></td><td style="width: 14.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 14.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 19.46pt; padding-top: 1.58pt; padding-bottom: 1.85pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7.3pt; margin-top: 0pt; text-align: right;">0.2%</div></td><td style="width: 14.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 14.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 20.05pt; padding-top: 1.58pt; padding-bottom: 1.85pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7.3pt; margin-top: 0pt; text-align: right;">(0.7)%</div></td><td style="width: 14.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 14.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 20.05pt; padding-top: 1.58pt; padding-bottom: 1.85pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7.3pt; margin-top: 0pt; text-align: right;">(1.7)%</div></td><td style="width: 14.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 14.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 20.05pt; padding-top: 1.58pt; padding-bottom: 1.85pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7.3pt; margin-top: 0pt; text-align: right;">(3.1)% </div></td></tr><tr><td style="width: 168pt; padding-top: 1.58pt; padding-bottom: 1.85pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7.3pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">uFCF (excl. SBC)<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup><font style="font-weight: normal; padding-left: 0.13pt;"></font></div></td><td style="width: 14.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 14.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 23.7pt; padding-top: 1.58pt; padding-bottom: 1.85pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7.3pt; font-weight: bold; margin-top: 0pt; text-align: right;">$(72)</div></td><td style="width: 14.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 14.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 23.7pt; padding-top: 1.58pt; padding-bottom: 1.85pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7.3pt; font-weight: bold; margin-top: 0pt; text-align: right;">$(13)</div></td><td style="width: 14.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 14.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 19.46pt; padding-top: 1.58pt; padding-bottom: 1.85pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7.3pt; font-weight: bold; margin-top: 0pt; text-align: right;">$(3)</div></td><td style="width: 14.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 14.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 20.05pt; padding-top: 1.58pt; padding-bottom: 1.85pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7.3pt; font-weight: bold; margin-top: 0pt; text-align: right;">$(3)</div></td><td style="width: 14.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 14.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 20.05pt; padding-top: 1.58pt; padding-bottom: 1.85pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7.3pt; font-weight: bold; margin-top: 0pt; text-align: right;">$(3)</div></td><td style="width: 14.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 14.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 20.05pt; padding-top: 1.58pt; padding-bottom: 1.85pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7.3pt; font-weight: bold; margin-top: 0pt; text-align: right;">$(5) </div></td></tr><tr><td style="width: 168pt; padding-top: 1.58pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7.3pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">SBC<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup><font style="font-style: normal; padding-left: 1.8pt;"></font></div></td><td style="width: 14.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 14.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 23.7pt; padding-top: 1.58pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7.3pt; margin-top: 0pt; text-align: right;">$26</div></td><td style="width: 14.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 14.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 23.7pt; padding-top: 1.58pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7.3pt; margin-top: 0pt; text-align: right;">$17</div></td><td style="width: 14.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 14.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 19.46pt; padding-top: 1.58pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7.3pt; margin-top: 0pt; text-align: right;">$16</div></td><td style="width: 14.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 14.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 20.05pt; padding-top: 1.58pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7.3pt; margin-top: 0pt; text-align: right;">$16</div></td><td style="width: 14.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 14.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 20.05pt; padding-top: 1.58pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7.3pt; margin-top: 0pt; text-align: right;">$15</div></td><td style="width: 14.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 14.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 20.05pt; padding-top: 1.58pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7.3pt; margin-top: 0pt; text-align: right;">$15</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 3.7pt; width: 168pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.7pt; width: 14.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.7pt; width: 14.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.7pt; width: 23.7pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.7pt; width: 14.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.7pt; width: 14.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.7pt; width: 23.7pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.7pt; width: 14.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.7pt; width: 14.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.7pt; width: 19.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.7pt; width: 14.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.7pt; width: 14.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.7pt; width: 20.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.7pt; width: 14.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.7pt; width: 14.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.7pt; width: 20.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.7pt; width: 14.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.7pt; width: 14.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.7pt; width: 20.05pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div><div class="BRDSX_rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 8.25pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Total revenue growth from 2025 to 2030 is 0%. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(2)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Represents stock-based compensation. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(3)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Unlevered free cash flow (excluding stock-based compensation) reflects adjusted EBIT, tax-effected at 21% plus depreciation and amortization, changes in net working capital and other cash adjustments and excludes the impact of the estimated 2026 Illumina earn-out and royalties. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Standard BioTools management Standard BioTools projections included, among other things, key assumptions regarding Standard BioTools&#8217; revenue growth, costs and expenses and other relevant factors relating to Standard BioTools&#8217; current operating business. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13pt; margin-left: 0pt; text-align: left;">Standard BioTools Wind-Down Analysis </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Standard BioTools management also prepared a wind-down analysis estimating the amount of aggregate net cash which could be available for distribution to Standard BioTools stockholders which was shared with the Special Committee, the Standard BioTools Board, Centerview and UBS. The Standard BioTools wind-down analysis estimated </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">184<br></div></div></div>
<!--End Page 195-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 196-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_115-merger_pg51"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">the future cash distributable to Standard BioTools stockholders after giving effect to wind-down activities, which resulted in an aggregate implied equity value for Standard BioTools at the time of such distribution of approximately $468&#160;million. Key assumptions in this calculation are that the amount of estimated cash and marketable securities distributable to Standard BioTools stockholders would be reduced by, among other things, net lease liabilities, executive severance related fees and asset sale transaction fees, long-term contracts, accrued liabilities and long-term contract obligations, non-executive severance related fees, and wind-down / restructuring fees. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In light of the foregoing factors and the uncertainties inherent in the unaudited prospective financial information, stockholders are cautioned not to place undue reliance on the unaudited prospective financial information contained herein.<font style="font-weight: normal;"> </font></div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 4pt; margin-left: 0pt; text-align: left;"><a name="tIOSB"><!--Anchor--></a>Interests of Standard BioTools Directors and Executive Officers in the Merger </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In considering the recommendation of the Standard BioTools Board with respect to the Proposals, Standard BioTools stockholders should be aware that certain members of the Standard BioTools Board and certain executive officers of Standard BioTools may have interests in the Merger that are different from, or in addition to, interests of Standard BioTools stockholders generally. These interests may present them with actual or perceived conflicts of interest and these interests, to the extent material, are described below.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Standard BioTools Board was aware of these potential conflicts of interest and considered them, among other matters, in reaching its decision to approve the Merger Agreement and the Merger, and to recommend that the Standard BioTools stockholders approve the Merger as contemplated by this proxy statement/prospectus. The interests of Standard BioTools&#8217; directors and executive officers include, but are not limited to, the following: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">&#8195;&#8195;&#8195;&#8195;&#8195; and &#8195;&#8195;&#8195;&#8195;&#8195;, members of the Standard BioTools Board, will continue as directors of the combined company after the Merger and will be eligible to be compensated as directors of the combined company following the Closing in accordance with the combined company&#8217;s outside director compensation policy. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">All outstanding and unvested equity awards issued by Standard BioTools and held by non-employee directors of Standard BioTools will become fully vested at Closing and it is anticipated that the cash retainers payable to such directors for the calendar quarter in which the Closing occurs will be paid without proration. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Affiliates of Casdin Capital, LLC own 5.28% of Treeline and will receive a pro rata portion of the Merger consideration. Eli Casdin, a director of Standard BioTools, is the Founder and Chief Investment Officer of Casdin Capital, LLC. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The Standard BioTools CIC Severance Plans (as defined below) provide that, in the event of a termination of employment without cause (as defined in the CIC Severance Plans) or a resignation for good reason (as defined in the CIC Severance Plans), in each case, during the period beginning three months before and ending 12 months after a change of control of Standard BioTools, the executive officers of Standard BioTools are entitled to severance benefits, which include, among other things, a lump sum payment of cash severance and pro-rated annual target bonus and accelerated vesting of any outstanding and unvested equity awards held by the executive officer. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The Standard BioTools Options that were granted to Standard BioTools executive officers between 2024 and 2026 will be amended to extend the post-employment exercise period to a date that is 30 months following the executive&#8217;s separation date. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Treeline and Sean Mackay, Standard BioTools&#8217; Chief Business Officer, have commenced discussions regarding a possible transition consulting arrangement pursuant to which, following the Closing, Mr.&#160;Mackay would provide transition consulting services to the combined company for a period of approximately six months. The terms of any such arrangement have not been finalized and there is no assurance that such an agreement will be entered into. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Under the Merger Agreement, Standard BioTools&#8217; directors and executive officers are entitled to continued indemnification, expense reimbursement and insurance coverage. </div></td></tr></table><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Continuing Directors </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As of the Effective Time, &#8195;&#8195;&#8195;&#8195;&#8195; and &#8195;&#8195;&#8195;&#8195;&#8195;, members of the Standard BioTools Board, will continue as directors after the Merger, and, following the Closing, &#8195;&#8195;&#8195;&#8195;&#8195; and &#8195;&#8195;&#8195;&#8195;&#8195; will be eligible to be compensated as directors of the post-Closing combined company pursuant to the combined company director compensation policy that is expected to remain in place following the Merger. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">185<br></div></div></div>
<!--End Page 196-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 197-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_115-merger_pg52"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Ownership Interests </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As of June&#160;3, 2026, Standard BioTools&#8217; current directors and executive officers beneficially owned, in the aggregate, approximately 28.02% of the outstanding shares of Standard BioTools Common Stock, as described in &#8220;<font style="font-style: italic;">Security Ownership of Certain Beneficial Owners and Management of Standard BioTools</font>.&#8221; </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">Treatment of Equity Awards Held by Directors and Executive Officers </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following table sets forth, for each Standard BioTools director and executive officer, the number of vested and unvested Standard BioTools Options and unvested Standard BioTools RSUs held by the director or executive officer as of June&#160;3, 2026 (including any such Standard BioTools RSUs approved but not yet effective as of such date). Depending on when the Closing Date occurs, certain Standard BioTools Options or Standard BioTools RSUs shown in the table may vest in accordance with their terms prior to the Closing Date, or may be exercised or forfeited (upon a termination of service) and additional Standard BioTools Options and Standard BioTools RSUs may be granted prior to the Closing Date. The values of the Standard BioTools RSUs are calculated based on a per share value of $0.876, the average closing market price of Standard BioTools Common Stock over the first five trading days following the first public announcement of the transactions contemplated by the Merger Agreement, without giving effect to the proposed Reverse Stock Split. Standard BioTools Options held by the non-employee directors and named executive officers of Standard BioTools have exercise prices that are higher than $0.876 per share and, accordingly, no value is ascribed to such Standard BioTools Options. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 240pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 62.72pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 52.64pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 40pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 40pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 240pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Name </div></td><td style="width: 4.08pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 62.72pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Vested but<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Unexercised Stock <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Options (#)</div></td><td style="width: 4.08pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.64pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Unvested Stock <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Options (#)</div></td><td style="width: 4.08pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Unvested <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">RSUs (#)</div></td><td style="width: 4.08pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Value of<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">unvested <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">RSUs ($) </div></td></tr><tr><td style="width: 240pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Non-Employee Directors<br></div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 62.72pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.64pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Thomas Carey<font style="padding-left: 3.91pt;"></font></div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 62.72pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.36pt; text-align: left;"><font style="padding-left: 7.5pt;">435,425</font></div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.64pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.32pt; text-align: left;"><font style="padding-left: 12.5pt;">67,178</font></div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 7.5pt;">133,053 </font></div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 7.87pt;">116,554 </font></div></td></tr><tr><td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Eli Casdin<font style="padding-left: 0.56pt;"></font></div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 62.72pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.36pt; text-align: left;"><font style="padding-left: 7.5pt;">432,841</font></div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.64pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.32pt; text-align: left;"><font style="padding-left: 12.5pt;">10,472</font></div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 7.5pt;">134,335 </font></div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 7.87pt;">117,677 </font></div></td></tr><tr><td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Troy Cox<font style="padding-left: 4.24pt;"></font></div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 62.72pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.36pt; text-align: left;">1,399,587</div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.64pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.32pt; text-align: left;"><font style="padding-left: 12.5pt;">46,170</font></div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 7.5pt;">145,448 </font></div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 7.5pt;">127,412 </font></div></td></tr><tr><td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Fenel Eloi<font style="padding-left: 1.12pt;"></font></div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 62.72pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.36pt; text-align: left;"><font style="padding-left: 7.5pt;">222,781</font></div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.64pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.32pt; text-align: left;"><font style="padding-left: 12.5pt;">10,472</font></div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 7.87pt;">112,614 </font></div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt;">98,650 </font></div></td></tr><tr><td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Kathy Hibbs<font style="padding-left: 1.68pt;"></font></div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 62.72pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.36pt; text-align: left;"><font style="padding-left: 7.5pt;">341,725</font></div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.64pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.32pt; text-align: left;"><font style="padding-left: 12.5pt;">61,942</font></div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt;">94,592 </font></div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt;">82,863 </font></div></td></tr><tr><td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Franklin Witney, Ph.D.<font style="padding-left: 0.13pt;"></font></div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 62.72pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.36pt; text-align: left;"><font style="padding-left: 7.5pt;">288,753</font></div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.64pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.32pt; text-align: left;"><font style="padding-left: 12.5pt;">10,472</font></div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt;">94,592 </font></div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt;">82,863 </font></div></td></tr><tr><td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Executive Officers<br></div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 62.72pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.64pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Michael Egholm, Ph.D.<font style="padding-left: 2.79pt;"></font></div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 62.72pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.36pt; text-align: left;">6,358,387</div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.64pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.32pt; text-align: left;">4,549,226</div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5,294,204 </div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">4,637,723 </div></td></tr><tr><td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Hanjoon Alex Kim<font style="padding-left: 1.4pt;"></font></div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 62.72pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.36pt; text-align: left;">2,196,814</div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.64pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.32pt; text-align: left;">1,405,601</div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2,202,246 </div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">1,929,167 </div></td></tr><tr><td style="width: 240pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Sean Mackay<font style="padding-left: 3.36pt;"></font></div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 62.72pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.36pt; text-align: left;"><font style="padding-left: 7.5pt;">470,296</font></div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.64pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.32pt; text-align: left;">1,164,444</div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">1,248,748 </div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">1,093,903</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 240pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 62.72pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 52.64pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 40pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 40pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Standard BioTools outside director compensation policy, which applies to non-employee directors of Standard BioTools, provides that in the event of a change in control as defined in the Amended &amp; Restated Standard BioTools 2011 Equity Incentive Plan, which includes the Merger, all unvested equity awards then held by non-employee directors will vest fully and become exercisable as to all Standard BioTools Common Stock thereunder regardless of performance goals, vesting criteria or other conditions. Accordingly, all unvested Standard BioTools RSUs and all unvested Standard BioTools Options held by the non-employee directors will vest at the Closing, subject to the continued service of the non-employee directors through the Closing. Standard BioTools Options and Standard BioTools RSUs held by the Standard BioTools&#8217; executive officers will continue in accordance with their existing terms, subject to adjustment as required under the Standard BioTools&#8217; equity plans, including for the Reverse Stock Split, and subject to acceleration provided for in the CIC Severance Plans (as described below). </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Certain Standard BioTools executive officers participate in the Standard BioTools 2017 Employee Stock Purchase Plan. As of June&#160;3, 2026, there were no accumulated payroll deductions by Standard BioTools executive officers that may be used to purchase Standard BioTools Common Stock under the Standard BioTools 2017 Employee Stock Purchase Plan. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;"><a name="tSBS2026"><!--Anchor--></a>2026 Standard BioTools Severance Plan </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In May&#160;2026, Standard BioTools entered into participation agreements under the 2026 Change of Control and Severance Plan (the 2026 Change of Control and Severance Plan and the participation agreements thereunder, collectively, the &#8220;2026 CIC Severance Plan&#8221;), with each of Alex Kim (Standard BioTools&#8217; Chief Financial Officer) and Sean Mackay (Standard BioTools&#8217; Chief Business Officer) (each, a &#8220;Standard BioTools Non-CEO Executive&#8221;). </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">186<br></div></div></div>
<!--End Page 197-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 198-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_115-merger_pg53"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under the 2026 CIC Severance Plan, if the Standard BioTools Non-CEO Executive&#8217;s employment is terminated during the period beginning three months before a change of control (which includes the Merger) and ending 12&#160;months after a change of control of Standard BioTools (such period, the &#8220;Change of Control Period&#8221;), either (i)&#160;by Standard BioTools for a reason other than cause (as defined in the 2026 CIC Severance Plan) or due to the Standard BioTools Non-CEO Executive&#8217;s death or disability (as defined in the 2026 CIC Severance Plan), or (ii)&#160;by the Standard BioTools Non-CEO Executive for good reason (as defined in the 2026 CIC Severance Plan), then, subject to the Standard BioTools Non-CEO Executive&#8217;s execution and non-revocation of a release of claims in favor of Standard BioTools and continued compliance with the applicable confidentiality, proprietary information and invention assignment agreement (the &#8220;Severance Conditions&#8221;), the Standard BioTools Non-CEO Executive will be entitled to receive the following severance benefits: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">A lump-sum payment totaling 150% of the sum of (x) his annual base salary (as in effect immediately before the change of control or the termination, whichever is greater) plus (y) the greater of (A) his annual target bonus (as in effect immediately before termination or immediately before the change of control, whichever is higher) or (B) the average of the annual cash incentives actually paid to him for the three fiscal years preceding the year in which his termination occurs; provided, however, that if the annual bonus with respect to the most recently preceding fiscal year has not yet been paid, his annual target bonus will be used as the bonus for that year in calculating the average; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">A pro-rated lump-sum payment of the Standard BioTools Non-CEO Executive&#8217;s annual target bonus in effect immediately prior to the change of control or the termination, whichever is greater. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Payment by Standard BioTools of costs for continued health coverage for the Standard BioTools Non-CEO Executive, his spouse, and/or his dependents, as applicable, for a period of 18 months; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">100% vesting acceleration of his then-outstanding and unvested equity awards; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Reasonable outplacement services in accordance with any applicable policy of Standard BioTools that is in effect as of the termination (or if no such policy is in effect, as determined by Standard BioTools in its sole discretion); and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Reimbursement of the reasonable attorneys&#8217; fees incurred in connection with the review of the separation agreement and release of claims up to $5,000. </div></td></tr></table><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;"><a name="t2SBSP"><!--Anchor--></a>2023 Standard BioTools Severance Plan </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In May&#160;2026, Standard BioTools entered into a participation agreement with Dr.&#160;Michael Egholm (Standard BioTools&#8217; Chief Executive Officer) under the 2023 Change of Control and Severance Plan, as amended and restated (the 2023 Change of Control and Severance Plan and the participation agreement thereunder, collectively, the &#8220;2023 CIC Severance Plan&#8221;, and together with the 2026 CIC Severance Plan, the &#8220;CIC Severance Plans&#8221;). </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under the 2023 CIC Severance Plan, if Dr.&#160;Egholm&#8217;s employment is terminated within the Change of Control Period either (i) by Standard BioTools for a reason other than cause (as defined in the 2023 CIC Severance Plan) or due to Dr.&#160;Egholm&#8217;s death or disability (as defined in the 2023 CIC Severance Plan) or (ii) by Dr.&#160;Egholm for good reason (as defined in the 2023 CIC Severance Plan), then, subject to Dr.&#160;Egholm&#8217;s compliance with the Severance Conditions, Dr.&#160;Egholm will be entitled to receive the following severance benefits: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">A lump-sum payment totaling 250% of the sum of (x) Dr.&#160;Egholm&#8217;s annual base salary (as in effect immediately before the change of control or the termination, whichever is greater) plus (y) the greater of (A) Dr.&#160;Egholm&#8217;s annual target bonus (as in effect immediately before termination or immediately before the change of control, whichever is higher) or (B) the average of the annual bonuses actually paid to Dr.&#160;Egholm for the three fiscal years preceding the year in which termination occurs; provided, however, that if the annual bonus with respect to the most recently preceding fiscal year has not yet been paid, Dr.&#160;Egholm&#8217;s annual target bonus will be used as the bonus for that year in calculating the average; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">A pro-rated lump-sum payment of Dr.&#160;Egholm&#8217;s annual target bonus in effect immediately prior to the change of control or the termination, whichever is greater; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Payment by Standard BioTools of costs for continued health coverage for Dr.&#160;Egholm, his spouse, and/or his dependents, as applicable, for a period of 30 months; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">100% vesting acceleration of Dr.&#160;Egholm&#8217;s then-outstanding and unvested equity awards; </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">187<br></div></div></div>
<!--End Page 198-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 199-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_115-merger_pg54"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Reasonable outplacement services in accordance with any applicable policy of Standard BioTools that is in effect as of the termination (or if no such policy is in effect, as determined by Standard BioTools in its sole discretion); and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Reimbursement of the reasonable attorneys&#8217; fees incurred in connection with the review of the separation agreement and release of claims up to $8,000. </div></td></tr></table><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">280G Cutback </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, pursuant to the CIC Severance Plans, in the event that any payment or benefit payable to a named executive officer of Standard BioTools would constitute a parachute payment within the meaning of Section&#160;280G of the Code, then the named executive officer would either receive all such payments and benefits in full or such payments and benefits would be reduced to the greatest amount that does not trigger the excise tax pursuant to Section&#160;4999 of the Code, whichever results in the greater after-tax amount for the named executive officer. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Extension of the Post-Employment Exercise Period of Standard BioTools Options </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In connection with the Merger, the Standard BioTools Options that were granted to each of Dr.&#160;Egholm, Mr.&#160;Alex Kim and Mr.&#160;Sean Mackay, in each case, between 2024 and 2026 will be amended to extend the post-employment exercise period to a date that is 30 months following the executive&#8217;s separation date. As of June&#160;3, 2026, Dr.&#160;Egholm holds 6,377,840 Standard BioTools Options; Mr.&#160;Alex Kim holds 1,984,640 Standard BioTools Options; and Mr.&#160;Sean Mackay holds 1,634,740&#160;Standard BioTools Options, in each case, granted within the relevant time period with an exercise price ranging from $0.985 to $2.580. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Transition Consulting Arrangement </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline and Sean Mackay, Standard BioTools&#8217; Chief Business Officer, have commenced discussions regarding a transition consulting arrangement pursuant to which, following the Closing, Mr.&#160;Mackay would provide transition consulting services to the combined company for a period of approximately six months to assist with the integration of the businesses and the transition of his responsibilities. As of the date of this proxy statement/prospectus, the principal terms of any such arrangement, including the scope of services and the compensation payable to Mr.&#160;Mackay, have not been determined, the parties have not entered into any definitive agreement, and there can be no assurance that they will do so. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;"><a name="tQUA1"><!--Anchor--></a>Quantification of Potential Payments to Standard BioTools Named Executive Officers in Connection with the Merger </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In accordance with Item&#160;402(t) of Regulation S-K, the table below sets forth the estimated amounts of compensation and benefits that are based on or otherwise relate to the Merger that may become payable to each of Standard BioTools&#8217; named executive officers, as determined for purposes of Standard BioTools&#8217; most recent annual proxy statement, assuming the Merger is completed as of October&#160;30, 2026 (which is an assumed date solely for the purposes of the calculations in this section) and, with respect to severance amounts, assuming the named executive officer experienced a qualifying termination of employment on such date. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The estimated amounts below are based on multiple assumptions, including (i) the named executive officer&#8217;s base salary and target bonus opportunity as in effect as of June&#160;3, 2026, (ii) the number of such Standard BioTools Options and Standard BioTools RSUs held by the named executive officers as of June&#160;3, 2026 (including any such equity awards approved but not yet effective as of such date), and assuming that no additional grants, vesting, exercise or forfeiture of such equity awards will occur following June&#160;3, 2026, and (iii) other assumptions described in this proxy statement/prospectus. These assumptions may or may not actually occur. In addition, certain amounts payable will vary depending on the actual date the Merger is completed and the actual date, if any, of a qualifying termination of employment. As a result, the actual amounts, if any, to be received by a named executive officer may differ in material respects from the amounts set forth below. The disclosures in the table below and the accompanying footnotes should be read in conjunction with the narrative description of the compensation arrangements set forth above. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">188<br></div></div></div>
<!--End Page 199-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 200-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_115-merger_pg55"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Golden Parachute Compensation </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following table sets forth all golden parachute compensation that will or may be payable to Standard BioTools&#8217; named executive officers. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 264pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.52pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.52pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 40pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.52pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.52pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 40pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.52pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.52pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 39.85pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.52pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.52pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 40pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 264pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Name</div></td><td style="width: 5.52pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.52pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Cash<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup> <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">($)</div></td><td style="width: 5.52pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.52pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Equity<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup> <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">($)</div></td><td style="width: 5.52pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.52pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 39.85pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Perquisites/<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Benefits<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup><br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">($)</div></td><td style="width: 5.52pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.52pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">($) </div></td></tr><tr><td style="width: 264pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Michael Egholm, Ph.D.<font style="padding-left: 1.79pt;"></font></div></td><td style="width: 5.52pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.52pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 0.37pt;">4,411,008 </font></div></td><td style="width: 5.52pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.52pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">4,637,723 </div></td><td style="width: 5.52pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.52pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 39.85pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.67pt; text-align: left;">126,324 </div></td><td style="width: 5.52pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.52pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">9,175,055 </div></td></tr><tr><td style="width: 264pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Hanjoon Alex Kim<font style="padding-left: 0.4pt;"></font></div></td><td style="width: 5.52pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.52pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">1,784,492 </div></td><td style="width: 5.52pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.52pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">1,929,167 </div></td><td style="width: 5.52pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.52pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 39.85pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.67pt; text-align: left;"><font style="padding-left: 5pt;">69,748 </font></div></td><td style="width: 5.52pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.52pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3,783,407 </div></td></tr><tr><td style="width: 264pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Sean Mackay<font style="padding-left: 2.36pt;"></font></div></td><td style="width: 5.52pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.52pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">1,460,422 </div></td><td style="width: 5.52pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.52pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">1,093,903 </div></td><td style="width: 5.52pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.52pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 39.85pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.67pt; text-align: left;"><font style="padding-left: 5pt;">77,382 </font></div></td><td style="width: 5.52pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.52pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2,631,707</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 264pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.52pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.52pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 40pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.52pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.52pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 40pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.52pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.52pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 39.85pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.52pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.52pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 40pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div><div class="BRDSX_rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 13.25pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">The amounts in this column represent the estimated cash amounts to which Standard BioTools&#8217; named executive officers would be entitled as severance payments under the CIC Severance Plans, comprised of estimated cash severance of $3,806,668, $1,432,215, and $1,209,425 for Dr.&#160;Egholm, Mr.&#160;Kim and Mr.&#160;Mackay, respectively, and estimated pro-rated annual target bonuses of $604,340, $352,277 and $250,997 for Dr.&#160;Egholm, Mr.&#160;Kim and Mr.&#160;Mackay, respectively, as further described in the sections entitled &#8220;<font style="font-style: italic;">2026 Standard BioTools Severance Plan</font>&#8221; and &#8220;<font style="font-style: italic;">2023 Standard BioTools Severance Plan</font>&#8221; beginning on pages <a href="#tSBS2026">186</a> and <a href="#t2SBSP">187</a>, respectively, of this proxy statement/prospectus. The cash payment is &#8220;double trigger&#8221; and would be payable in a lump sum upon a termination of the named executive officer&#8217;s employment without cause (as defined in the CIC Severance Plans) or a resignation by the named executive officer for good reason (as defined in the CIC Severance Plans), in each case during a Change of Control Period. The cash payment is conditioned on the named executive officer&#8217;s compliance with the Severance Conditions. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(2)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">The amounts listed in this column represent the estimated aggregate value of outstanding and unvested Standard BioTools RSUs. The vesting of equity awards held by the named executive officers is subject to &#8220;double trigger&#8221; acceleration pursuant to the terms of the CIC Severance Plans and will be fully accelerated upon a termination of the named executive officer&#8217;s employment without cause or a resignation by the named executive officer for good reason, in each case during a Change of Control Period. The acceleration of outstanding and unvested Standard BioTools RSUs is conditioned on the satisfaction of the Severance Conditions in accordance with the CIC Severance Plans. The amounts reported in this column were calculated based on a per share value of $0.876, the average closing market price of Standard BioTools Common Stock over the first five trading days following the first public announcement of the transactions contemplated by the Merger Agreement, without giving effect to the proposed Reverse Stock Split. The following table shows the number of shares subject to unvested Standard BioTools RSUs and quantifies the value of the unvested Standard BioTools RSUs held by the named executive officers that would accelerate upon a qualifying termination of employment in connection with the Merger based on the assumptions described above. Standard BioTools Options held by the named executive officers have exercise prices that are higher than $0.876 per share and, accordingly, no value is ascribed to such Standard BioTools Options in this table. These numbers do not forecast any grants, additional issuances, dividends or additional deferrals of equity-based awards following the date of this proxy statement/prospectus. Depending on when the Closing Date occurs, certain equity-based awards shown in the table may vest in accordance with their terms prior to the Closing Date or may be exercised or forfeited (upon a termination of service). </div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 448pt; margin-left: 20pt;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 228pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 11.47pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 11.47pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 87.07pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 11.47pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 11.47pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 87.07pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 228pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Name</div></td><td style="width: 11.47pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 11.47pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 87.07pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of Standard <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">BioTools RSUs <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Subject to Double-trigger<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Acceleration (#)</div></td><td style="width: 11.47pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 11.47pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 87.07pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Value of Standard <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">BioTools RSUs <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Subject to Double-trigger <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Acceleration ($) </div></td></tr><tr><td style="width: 228pt; padding-top: 2.08pt; padding-bottom: 1.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Michael Egholm, Ph.D.<font style="padding-left: 0.23pt;"></font></div></td><td style="width: 11.47pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 11.47pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 87.07pt; padding-top: 2.08pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 27.54pt; text-align: left;">5,294,204 </div></td><td style="width: 11.47pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 11.47pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 87.07pt; padding-top: 2.08pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 27.54pt; text-align: left;">4,637,723 </div></td></tr><tr><td style="width: 228pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Hanjoon Alex Kim<font style="padding-left: 0.12pt;"></font></div></td><td style="width: 11.47pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 11.47pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 87.07pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 27.54pt; text-align: left;">2,202,246 </div></td><td style="width: 11.47pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 11.47pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 87.07pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 27.54pt; text-align: left;">1,929,167 </div></td></tr><tr><td style="width: 228pt; padding-top: 1.33pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Sean Mackay<font style="padding-left: 2.69pt;"></font></div></td><td style="width: 11.47pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 11.47pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 87.07pt; padding-top: 1.33pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 27.54pt; text-align: left;">1,248,748 </div></td><td style="width: 11.47pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 11.47pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 87.07pt; padding-top: 1.33pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 27.54pt; text-align: left;">1,093,903</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 3.25pt; width: 228pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 11.47pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 11.47pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 87.07pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 11.47pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 11.47pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 87.07pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(3)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">The amounts listed in this column represent the aggregate amount of (A) estimated value of the monthly premium (both the employer and employee portions of the premium) under Standard BioTools&#8217; current group health care plan multiplied by 30 in the case of Dr.&#160;Egholm and multiplied by 18 in the case of the other named executive officers, taking inflation into account (estimated to be $107,324, $53,748 and $61,328 for Dr.&#160;Egholm, Mr.&#160;Kim and Mr.&#160;Mackay, respectively), (B) the reimbursement of attorney fees in connection with reviewing the separation agreement and release of claims (in the amount of $8,000 for Dr.&#160;Egholm and $5,000 for other named executive officers) and (C)&#160;the estimated value of the outplacement service in accordance with Standard BioTools&#8217; policy ($11,000 for each named executive officer). The health care premium payment, the reimbursement of attorney fees and the outplacement services are &#8220;double trigger&#8221; and would be due upon a termination of the named executive officer&#8217;s employment by Standard BioTools without cause or a resignation by the named executive officer for good reason, in each case during the Change of Control Period, subject to the satisfaction of the Severance Conditions in accordance with the CIC Severance Plans. Payment of the health care premiums will be made by Standard BioTools during the 30-month or 18-month period, as applicable, following the named executive&#8217;s qualifying terminations. </div></td></tr></table><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;"><a name="tINTER1"><!--Anchor--></a>Interests of Treeline Directors and Executive Officers in the Merger </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In considering the recommendation of the Treeline Board with respect to approving the Merger, Standard BioTools stockholders should be aware that Treeline&#8217;s directors and executive officers have interests in the Merger that are different from, or in addition to, the interests of Treeline stockholders generally. These interests may present them with actual or potential conflicts of interest, and these interests, to the extent material, are described below. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">189<br></div></div></div>
<!--End Page 200-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 201-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_115-merger_pg56"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Treeline Board was aware of these potential conflicts of interest and considered them, among other matters, in reaching its decision to approve the Merger Agreement and the Merger, and to recommend that the Treeline stockholders approve the Merger as contemplated by this proxy statement/prospectus. The interests of Treeline&#8217;s directors and executive officers include, but are not limited to, the following: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">As of June&#160;1, 2026, each of Dr.&#160;Joshua Bilenker, Dr.&#160;Jeffrey Engelman, and Mr.&#160;Spencer Smith beneficially own Treeline Options to purchase shares of Treeline Common Stock, which will be assumed by Standard BioTools. Each such assumed Treeline Option will continue to have, and be subject to the same terms and conditions that applied to such Treeline Option immediately prior to the Effective Time, except that such Treeline Option will be exercisable for that number of shares of Standard BioTools Common Stock equal to the number of shares of Treeline Common Stock subject to such Treeline Option immediately prior to the Effective Time multiplied by the Exchange Ratio and rounded down to the next nearest share of Standard BioTools Common Stock, and the exercise price per share of each such Treeline Option will be the exercise price per share in effect for that Treeline Option immediately prior to the Effective Time divided by the Exchange Ratio and rounded up to the next nearest cent. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Treeline&#8217;s directors and executive officers are currently expected to become directors and executive officers of the combined company following the Closing. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Under the Merger Agreement, Treeline&#8217;s directors and executive officers are entitled to continued indemnification, expense reimbursement and insurance coverage. </div></td></tr></table><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Ownership Interests </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As of June&#160;1, 2026, Treeline&#8217;s current directors and executive officers beneficially owned, in the aggregate, approximately 48.54% of the outstanding shares of Treeline Common Stock, as described in &#8220;<font style="font-style: italic;">Security Ownership of Certain Beneficial Owners and Management of Treeline</font>.&#8221; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Certain Treeline stockholders affiliated with Treeline&#8217;s directors also currently beneficially own shares of Treeline Common Stock. The table below sets forth the shares of Treeline Common Stock beneficially owned by affiliates of Treeline&#8217;s directors as of June&#160;1, 2026, assuming the conversion of all outstanding shares of Treeline convertible preferred stock into an equal number of shares of Treeline Common Stock as of June&#160;1, 2026. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 2pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="margin-top: 0pt; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 324pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.16pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.16pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 133.68pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 324pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Stockholder</div></td><td style="width: 5.16pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.16pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 133.68pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of Shares of Treeline Common <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Stock Beneficially Owned </div></td></tr><tr><td style="width: 324pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">OrbiMed Private Investments VIII, LP<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup><font style="padding-left: 3.26pt;"></font></div></td><td style="width: 5.16pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.16pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 133.68pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 44.34pt; text-align: left;">18,954,101 </div></td></tr><tr><td style="width: 324pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Entities Affiliated with ARCH Venture Partners<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup><font style="padding-left: 2.88pt;"></font></div></td><td style="width: 5.16pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.16pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 133.68pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 44.34pt; text-align: left;">18,954,100 </div></td></tr><tr><td style="width: 324pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Entities Affiliated with GV<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup><font style="padding-left: 4.35pt;"></font></div></td><td style="width: 5.16pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.16pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 133.68pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 44.34pt; text-align: left;">18,652,137 </div></td></tr><tr><td style="width: 324pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Aisling Capital Partners V, LP<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(4)</sup><font style="padding-left: 1.75pt;"></font></div></td><td style="width: 5.16pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.16pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 133.68pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 44.34pt; text-align: left;"><font style="padding-left: 5pt;">2,373,137</font> </div></td></tr><tr><td style="width: 324pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Entities Affiliated with KKR &amp; Co., Inc.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(5)(8)</sup><font style="padding-left: 1.72pt;"></font></div></td><td style="width: 5.16pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.16pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 133.68pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 44.34pt; text-align: left;">19,674,722 </div></td></tr><tr><td style="width: 324pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Entities Affiliated with Access Industries<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(6)</sup><font style="padding-left: 4.09pt;"></font></div></td><td style="width: 5.16pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.16pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 133.68pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 44.34pt; text-align: left;">21,646,973 </div></td></tr><tr><td style="width: 324pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Entities Affiliated with Ajax Health<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(7)(8)</sup><font style="padding-left: 1.99pt;"></font></div></td><td style="width: 5.16pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.16pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 133.68pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 44.34pt; text-align: left;"><font style="padding-left: 5pt;">9,755,587</font> </div></td></tr><tr><td style="width: 324pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Entities Affiliated with Avi Naider<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(9)</sup><font style="padding-left: 0.37pt;"></font></div></td><td style="width: 5.16pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.16pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 133.68pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 44.34pt; text-align: left;"><font style="padding-left: 5pt;">2,138,523</font></div></td></tr><tr><td style="width: 324pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Entities Affiliated with Joshua Bilenker, M.D.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(10)</sup><font style="padding-left: 0.18pt;"></font></div></td><td style="width: 5.16pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.16pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 133.68pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 44.34pt; text-align: left;"><font style="padding-left: 5pt;">7,225,929</font> </div></td></tr><tr><td style="width: 324pt; padding-top: 0.51pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Entities Affiliated with Jeffrey Engelman, M.D., Ph.D.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(11)</sup><font style="padding-left: 0.8pt;"></font></div></td><td style="width: 5.16pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.16pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 133.68pt; padding-top: 0.51pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 44.34pt; text-align: left;"><font style="padding-left: 5pt;">3,333,333</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 324pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.16pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.16pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 133.68pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div><div class="BRDSX_rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 12.75pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Represents 18,954,101 shares of Treeline Common Stock held of record by OrbiMed Private Investments VIII, LP. (&#8220;OPI VIII&#8221;). OrbiMed Capital GP VIII LLC (&#8220;GP VIII&#8221;) is the general partner of OPI VIII and OrbiMed Advisors LLC (&#8220;OrbiMed Advisors&#8221;) is the managing member of GP VIII. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VIII. Dr.&#160;Bonita, a member of the Treeline Board, is a member of OrbiMed Advisors. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(2)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Represents (i) 15,446,674 shares of Treeline Common Stock directly held of record by ARCH Venture Fund XI, L.P. (&#8220;ARCH Fund XI&#8221;), and (ii) 3,507,426 shares of Treeline Common Stock directly held of record by ARCH Venture Fund XII, L.P. (&#8220;ARCH Fund XII,&#8221; with ARCH Fund XI, the &#8220;ARCH Venture Funds&#8221;). ARCH Venture Partners XI, L.P. (&#8220;AVP XI LP&#8221;) is the sole general partner of ARCH Fund&#160;XI, and ARCH Venture Partners XI, LLC (&#8220;AVP XI LLC&#8221;) is the sole general partner of AVP XI LP, and each of them may be deemed to beneficially own securities directly held of record by ARCH Fund XI. ARCH Venture Partners XII, L.P. (&#8220;AVP XII LP&#8221;) is the sole general partner of ARCH Fund XII, and ARCH Venture Partners XII, LLC (&#8220;AVP XII LLC&#8221;) is the sole general partner of AVP XII LP, and each of them may be deemed to beneficially own securities directly held of record by ARCH Fund XII. Each of AVP XI LLC and AVP XII LLC exercises voting and investment power through an investment committee comprised of Kristina M. Burow, a member of the Treeline Board, Keith Crandell, Steven Gillis, and Robert Nelsen. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(3)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Represents 16,050,603 shares held of record by GV 2021, L.P. (&#8220;GV 2021 LP&#8221;) and 2,601,534 shares held of record by GV 2025, L.P. (&#8220;GV 2025 LP&#8221; and together with GV 2021 LP, the &#8220;GV Funds&#8221;). GV 2021 GP, L.P. (&#8220;GV 2021 GP&#8221;) is the general partner of GV 2021 </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">190<br></div></div></div>
<!--End Page 201-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 202-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_115-merger_pg57"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 5.25pt; margin-left: 20pt; text-align: left;">LP and GV 2021 GP, L.L.C. (&#8220;GV 2021 LLC&#8221;) is the general partner of GV 2021 GP. GV 2025 GP, L.P. (&#8220;GV 2025 GP&#8221;) is the general partner of GV 2025 LP and GV 2025 GP, L.L.C. (&#8220;GV 2025 LLC&#8221;) is the general partner of GV 2025 GP. Alphabet Holdings LLC is the sole member of GV 2021 LLC and GV 2025 LLC. XXVI Holdings Inc. (&#8220;XXVI&#8221;) is the sole member of Alphabet Holdings LLC. Alphabet Inc. is the controlling stockholder of XXVI. As such, GV 2021 GP and GV 2021 LLC may be deemed to indirectly beneficially own securities held by GV 2021 LP, and GV 2025 GP and GV 2025 LLC may be deemed to indirectly beneficially own securities held by GV 2025 LP. Further, Alphabet Holdings LLC, XXVI, and Alphabet Inc. may be deemed to indirectly beneficially own the securities directly held by the GV Funds. </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(4)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Represents 2,373,137 shares of Treeline Common Stock under held by Aisling Capital V, LP. (&#8220;Aisling V&#8221;). Aisling Capital Partners V, LP (&#8220;Aisling GP V&#8221;) serves as general partner of Aisling V, and Aisling Capital Partners V LLC (&#8220;Aisling V LLC&#8221;) serves as general partner of Aisling GP V. The individual managing members (collectively, the &#8220;Aisling Managers&#8221;) of Aisling V LLC are Dr.&#160;Andrew Schiff and Steven Elms, a member of the Treeline Board. As such, each of Aisling GP V, Aisling V LLC, and the Aisling Managers may be deemed to share voting and investment discretion with respect to securities directly held by Aisling V. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(5)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Represents (i) 4,471,402 shares of Treeline Common Stock held by KKR Forest LLC, (ii) 9,291,197 shares of Treeline Common Stock held by KKR Forest Aggregator L.P. (together with KKR Forest LLC, the &#8220;KKR Entities&#8221;), and (iii) 5,912,123 shares of Treeline Common Stock held by Ajax Zeus TL LLC (&#8220;AZTL&#8221;). </div></td></tr></table><div class="BRDSX_ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 3pt; margin-left: 20pt; text-align: left;">KKR Forest Aggregator L.P., as the managing member of KKR Forest LLC, KKR Forest Aggregator GP LLC, as the general partner of KKR Forest Aggregator L.P., KKR Health Care Strategic Growth Fund II SCSp, as the sole member of KKR Forest Aggregator GP LLC, KKR Associates HCSG II SCSp, as the general partner of KKR Health Care Strategic Growth Fund II SCSp, KKR HCSG II S.&#224; r.l., as the general partner of KKR Associates HCSG II SCSp, KKR HCSG II Holdings Limited, as the sole shareholder of KKR HCSG II S.&#224; r.l., KKR Group Partnership L.P., as the sole shareholder of KKR HCSG II Holdings Limited, KKR Group Holdings Corp., as the general partner of KKR Group Partnership L.P., KKR Group Co. Inc., as the sole shareholder of KKR Group Holdings Corp., KKR &amp; Co. Inc. (&#8220;KKR&#8221;), as the sole shareholder of KKR Group Co. Inc., KKR Management LLP, as the Series&#160;I preferred stockholder of KKR, and Messrs. Henry R. Kravis and George R. Roberts, as the founding partners of KKR Management LLP, may be deemed to be the beneficial owners having shared voting and investment power with respect to the shares held by the KKR Entities.</div><div class="BRDSX_ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 3pt; margin-left: 20pt; text-align: left;">Neptune Medical Technology LLC (&#8220;Neptune&#8221;), as the managing member of AZTL, Zeus Health LLC, as a member of Neptune, KKR Zeus Aggregator LLC, as the managing member of Zeus Health LLC, KKR Health Care Strategic Growth Fund L.P., as the managing member of KKR Zeus Aggregator LLC, KKR Associates HCSG L.P., as the general partner of KKR Health Care Strategic Growth Fund L.P., KKR HCSG GP LLC, as the general partner of KKR Associates HCSG L.P., KKR Group Partnership L.P., as the sole member of KKR HCSG GP LLC, KKR Group Holdings Corp., as the general partner of KKR Group Partnership L.P., KKR Group Co. Inc., as the sole shareholder of KKR Group Holdings Corp., KKR, as the sole shareholder of KKR Group Co. Inc., KKR Management LLP, as the Series&#160;I preferred stockholder of KKR, and Messrs. Henry R. Kravis and George R. Roberts, as the founding partners of KKR Management LLP, may be deemed to be beneficial owners having shared voting and investment power with respect to the shares held by AZTL. </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(6)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Represents (i) 11,078,236 shares of Treeline Common Stock directly held by AI Life Sciences Investments LLC (&#8220;AI Life&#8221;) and (ii)&#160;10,568,737 shares of Treeline Common Stock directly held by AI Treeline Holdings LLC (&#8220;AI Treeline&#8221;). Such securities may be deemed to be beneficially owned by Access Industries Holdings LLC (&#8220;AIH&#8221;), Access Industries, LLC (&#8220;AI&#8221;), Access Industries Management, LLC (&#8220;AIM&#8221;), AI LSI Management LLC (&#8220;LSI Management&#8221;) and Len Blavatnik. AI Life controls a majority of the outstanding voting interests in AI Treeline, AIH controls a majority of the outstanding voting interests in AI Life, AI controls a majority of the outstanding voting interests in AIH, LSI Management is the management member of AI Life, AIM controls AI and AIH is the management of LSI Management. Len Blavatnik is the controlling person of AIM and controls a majority of the outstanding voting interests in AI and may be deemed to exercise voting and investment discretion over securities held directly or indirectly by each of the aforementioned entities. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(7)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Represents (i) 1,715,779 shares of Treeline Common Stock held by Ajax Health III LLC, (ii) 2,127,685 shares of Treeline Common Stock held by Ajax HQ Treeline 2022 SPV, LLC, and (iii) 5,912,123 shares of Treeline Common Stock held by AZTL. </div></td></tr></table><div class="BRDSX_ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 3pt; margin-left: 20pt; text-align: left;">Ajax Health III LLC is governed by a board of managers comprised of five voting managers, a majority of which are appointed by HealthQuest Partners III, L.P. HealthQuest Venture Management III, L.L.C. is the general partner of HealthQuest Partners III, L.P. Garheng Kong is the managing member of HealthQuest Venture Management III, L.L.C. and has sole voting and investment power over the shares held by Ajax Health III LLC. </div><div class="BRDSX_ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 3pt; margin-left: 20pt; text-align: left;">Ajax HQ Treeline 2022 SPV, LLC is governed by a board of managers comprised of three voting managers, a majority of which are appointed by HealthQuest Ajax III-A SPV, L.P. HealthQuest Ajax III-A Management, L.L.C. is the general partner of HealthQuest Ajax III-A SPV, L.P. Garheng Kong is the managing member of HealthQuest Ajax III-A Management, L.L.C. and has sole voting and investment power over the shares held by Ajax HQ Treeline 2022 SPV, LLC. </div><div class="BRDSX_ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 3pt; margin-left: 20pt; text-align: left;">Dr.&#160;Kong, HealthQuest Partners III, L.P., HealthQuest Venture Management III, L.L.C., HealthQuest Ajax III-A SPV, L.P. and HealthQuest Ajax III-A Management, L.L.C. disclaim beneficial ownership over all of the shares owned by Ajax Health III LLC, Ajax HQ Treeline 2022 SPV, LLC and AZTL except to the extent of their pecuniary interest therein.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(8)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">AZTL is directly owned by entities affiliated with KKR and Ajax Health III LLC. Neptune is the managing member of AZTL. Neptune is governed by a board of managers comprised of two voting managers, one non-voting CEO manager. Each of Zeus Health LLC, which is indirectly controlled by KKR through certain intermediary funds and entities, and Ajax Health III LLC (more specifically discussed in footnote 17, above) has the right to designate a voting manager. Board action generally requires approval of each voting manager. Thus, KKR and Ajax Health III LLC ultimately share voting power and investment power over the Treeline Common Stock held by AZTL. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(9)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Represents (i) 473,850 shares of Treeline Common Stock directly held by AZN TL LLC, (ii) 1,045,259 shares of Treeline Common Stock directly held by AZN TLII LLC (together with AZN TL LLC, the &#8220;Naider LLCs&#8221;), and (iii) 619,414 shares of Treeline Common Stock directly held by the Debra Klein 2019 Irrevocable Trust (the &#8220;Klein Trust&#8221;). Mr.&#160;Naider serves as manager of the Naider LLCs and as trustee of the Klein Trust and may be deemed to exercise voting and investment discretion over the securities held by them in such capacities.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(10)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Represents (i) 1,000,000 shares of Treeline Common Stock directly held by Dr. Bilenker&#8217;s spouse and (ii) an aggregate 6,225,929 shares of Treeline Common Stock held directly by trusts. Dr. Bilenker may be deemed to exercise voting and/or investment discretion over the securities held by each of the trusts noted in subclause (ii) of the preceding sentence.</div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">191<br></div></div></div>
<!--End Page 202-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 203-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_115-merger_pg58"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5.25pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(11)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Represents (i) 2,333,333 shares of Treeline Common Stock directly held by The Jeffrey A. Engelman Trust&#8211; 2023, (ii) 500,000 shares of Treeline Common Stock directly held by The Engelman Irrevocable Trust fbo Alexis, and (iii) 500,000 shares of Treeline Common Stock directly held by The Engelman Irrevocable Trust fbo Charles (together with The Jeffrey A. Engelman Trust &#8211; 2023 and The Engelman Irrevocable Trust fbo Alexis, the &#8220;Engelman Trusts&#8221;). Dr. Engelman serves as trustee of the Engelman Trusts and may be deemed to exercise voting and investment discretion in such capacity.</div></td></tr></table><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Treatment of Treeline Warrants </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under the terms of the Merger Agreement, each warrant to purchase shares of Treeline Common Stock that is outstanding immediately prior to the effective time of the merger will have been amended prior to the effective time to provide for the treatment described below. At the effective time, each such warrant will, by virtue of the merger and without any action on the part of Treeline or the holder thereof, be cancelled and converted into the right to receive, for each share of Treeline Common Stock that would be received upon the net exercise of such warrant in accordance with its terms (with each share of Treeline Common Stock valued at the Company Value Per Share (as defined in the Merger Agreement) for such purpose), a number of shares of Standard BioTools Common Stock equal to the Exchange Ratio. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Certain Treeline stockholders affiliated with Treeline&#8217;s directors also currently hold warrants to purchase shares of Treeline Common Stock. The table below sets forth the shares of Treeline Common Stock underlying the warrants beneficially owned by affiliates of Treeline&#8217;s directors that are exercisable within 60 days of June&#160;1, 2026. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 2pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="margin-top: 0pt; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 324pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 7.97pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 7.97pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 128.05pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 324pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Stockholder</div></td><td style="width: 7.97pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.97pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 128.05pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of Shares of Treeline <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Common Stock Underlying Warrants <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Beneficially Owned </div></td></tr><tr><td style="width: 324pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">OrbiMed Private Investments VIII, LP<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup><font style="padding-left: 3.26pt;"></font></div></td><td style="width: 7.97pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.97pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 128.05pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 44.03pt; text-align: left;"><font style="padding-left: 7.5pt;">435,525 </font></div></td></tr><tr><td style="width: 324pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Entities Affiliated with ARCH Venture Partners<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup><font style="padding-left: 2.88pt;"></font></div></td><td style="width: 7.97pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.97pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 128.05pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 44.03pt; text-align: left;"><font style="padding-left: 7.5pt;">435,525 </font></div></td></tr><tr><td style="width: 324pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Entities Affiliated with GV<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup><font style="padding-left: 4.35pt;"></font></div></td><td style="width: 7.97pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.97pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 128.05pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 44.03pt; text-align: left;"><font style="padding-left: 7.5pt;">390,230 </font></div></td></tr><tr><td style="width: 324pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Aisling Capital Partners V, LP<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(4)</sup><font style="padding-left: 1.75pt;"></font></div></td><td style="width: 7.97pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.97pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 128.05pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 44.03pt; text-align: left;"><font style="padding-left: 12.5pt;">36,584</font> </div></td></tr><tr><td style="width: 324pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Entities Affiliated with KKR &amp; Co., Inc.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(5)(8)</sup><font style="padding-left: 1.72pt;"></font></div></td><td style="width: 7.97pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.97pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 128.05pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 44.03pt; text-align: left;"><font style="padding-left: 7.5pt;">402,163 </font></div></td></tr><tr><td style="width: 324pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Entities Affiliated with Access Industries<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(6)</sup><font style="padding-left: 4.09pt;"></font></div></td><td style="width: 7.97pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.97pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 128.05pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 44.03pt; text-align: left;">2,418,623 </div></td></tr><tr><td style="width: 324pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Entities Affiliated with Ajax Health<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(7)(8)</sup><font style="padding-left: 1.99pt;"></font></div></td><td style="width: 7.97pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.97pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 128.05pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 44.03pt; text-align: left;"><font style="padding-left: 7.5pt;">149,559 </font></div></td></tr><tr><td style="width: 324pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">AZN TLII LLC<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(9)</sup><font style="padding-left: 4.62pt;"></font></div></td><td style="width: 7.97pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.97pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 128.05pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 44.03pt; text-align: left;"><font style="padding-left: 7.5pt;">239,252</font> </div></td></tr><tr><td style="width: 324pt; padding-top: 0.51pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Entities Affiliated with Joshua Bilenker, M.D.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(10)</sup><font style="padding-left: 0.18pt;"></font></div></td><td style="width: 7.97pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.97pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 128.05pt; padding-top: 0.51pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 44.03pt; text-align: left;"><font style="padding-left: 12.5pt;">36,403</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 324pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 7.97pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 7.97pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 128.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div><div class="BRDSX_rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 12.75pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Represents 435,525 shares of Treeline Common Stock underlying warrants that are exercisable within 60 days of June&#160;1, 2026 held by OPI&#160;VIII. GP VIII is the general partner of OPI VIII and OrbiMed Advisors is the managing member of GP VIII. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VIII. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(2)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Represents (i) 87,105 shares of Treeline Common Stock underlying warrants held of record by ARCH Fund XI, and (ii) 348,420 shares of Treeline Common Stock underlying warrants held of record by ARCH Fund XII, with all such warrants exercisable within 60 days of June&#160;1, 2026. AVP XI LP is the sole general partner of ARCH Fund XI, and AVP XI LLC is the sole general partner of AVP XI LP, and each of them may be deemed to beneficially own securities directly held of record by ARCH Fund XI. AVP XII LP is the sole general partner of ARCH Fund XII, and AVP XII LLC is the sole general partner of AVP XII LP, and each of them may be deemed to beneficially own securities directly held of record by ARCH Fund XII. Each of AVP XI LLC and AVP XII LLC exercises voting and investment power through an investment committee comprised of Kristina M. Burow, a member of the Treeline Board, Keith Crandell, Steven Gillis, and Robert Nelsen. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(3)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Represents 390,230 shares of Treeline Common Stock underlying warrants that are exercisable within 60 days of June&#160;1, 2026 held of record by GV 2025 LP. GV 2025 GP is the general partner of GV 2025 LP and GV 2025 LLC is the general partner of GV 2025 GP. Alphabet Holdings LLC is the sole member of GV 2025 LLC. XXVI is the sole member of Alphabet Holdings LLC. Alphabet Inc. is the controlling stockholder of XXVI. As such, GV 2025 GP and GV 2025 LLC may be deemed to indirectly beneficially own securities held by GV 2025 LP. Further, Alphabet Holdings LLC, XXVI, and Alphabet Inc. may be deemed to indirectly beneficially own the securities directly held by the GV Funds. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(4)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Represents 36,584 shares of Treeline Common Stock underlying warrants that are exercisable within 60 days of June&#160;1, 2026 held by Aisling V. Aisling GP V serves as general partner of Aisling V, and Aisling V LLC serves as general partner of Aisling GP V. The Aisling Managers of Aisling V LLC are Dr.&#160;Andrew Schiff and Steven Elms, a member of the Treeline Board. As such, each of Aisling GP V, Aisling V LLC, and the Aisling Managers may be deemed to share voting and investment discretion with respect to securities directly held by Aisling V. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(5)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Represents (i) 287,446 shares of Treeline Common Stock underlying warrants held by KKR Forest LLC and (ii) 114,717 shares of Treeline Common Stock underlying warrants held by AZTL, with all such warrants exercisable within 60 days of June&#160;1, 2026. </div></td></tr></table><div class="BRDSX_ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 3pt; margin-left: 20pt; text-align: left;">KKR Forest Aggregator L.P., as the managing member of KKR Forest LLC, KKR Forest Aggregator GP LLC, as the general partner of KKR Forest Aggregator L.P., KKR Health Care Strategic Growth Fund II SCSp, as the sole member of KKR Forest Aggregator GP LLC, KKR Associates HCSG II SCSp, as the general partner of KKR Health Care Strategic Growth Fund II SCSp, KKR HCSG II S.&#224; r.l., as the general partner of KKR Associates HCSG II SCSp, KKR HCSG II Holdings Limited, as the sole shareholder of KKR HCSG II S.&#224; r.l., KKR Group Partnership L.P., as the sole shareholder of KKR HCSG II Holdings Limited, KKR Group Holdings Corp., as the general partner of KKR Group Partnership L.P., KKR Group Co. Inc., as the sole shareholder of KKR Group Holdings Corp., KKR, as the sole shareholder of KKR Group Co. Inc., KKR Management LLP, as the Series&#160;I preferred stockholder of KKR &amp; Co. Inc., and Messrs. Henry </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">192<br></div></div></div>
<!--End Page 203-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 204-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_115-merger_pg59"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 5.25pt; margin-left: 20pt; text-align: left;">R. Kravis and George R. Roberts, as the founding partners of KKR Management LLP, may be deemed to be the beneficial owners having shared voting and investment power with respect to the shares held by the KKR Entities.</div><div class="BRDSX_ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 3pt; margin-left: 20pt; text-align: left;">Neptune, as the managing member of AZTL, Zeus Health LLC, as a member of Neptune, KKR Zeus Aggregator LLC, as the managing member of Zeus Health LLC, KKR Health Care Strategic Growth Fund L.P., as the managing member of KKR Zeus Aggregator LLC, KKR Associates HCSG L.P., as the general partner of KKR Health Care Strategic Growth Fund L.P., KKR HCSG GP LLC, as the general partner of KKR Associates HCSG L.P., KKR Group Partnership L.P., as the sole member of KKR HCSG GP LLC, KKR Group Holdings Corp., as the general partner of KKR Group Partnership L.P., KKR Group Co. Inc., as the sole shareholder of KKR Group Holdings Corp., KKR, as the sole shareholder of KKR Group Co. Inc., KKR Management LLP, as the Series&#160;I preferred stockholder of KKR, and Messrs. Henry R. Kravis and George R. Roberts, as the founding partners of KKR Management LLP, may be deemed to be beneficial owners having shared voting and investment power with respect to the shares held by AZTL. </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(6)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Represents 2,418,623 shares of Treeline Common Stock underlying warrants that are exercisable within 60 days of June&#160;1, 2026 held by AI Treeline. Such securities may be deemed to be beneficially owned by AIH, AI, AIM, LSI Management and Len Blavatnik. AI Life controls a majority of the outstanding voting interests in AI Treeline, AIH controls a majority of the outstanding voting interests in AI Life, AI controls a majority of the outstanding voting interests in AIH, LSI Management is the management member of AI Life, AIM controls AI and AIH is the management of LSI Management. Len Blavatnik is the controlling person of AIM and controls a majority of the outstanding voting interests in AI and may be deemed to exercise voting and investment discretion over securities held directly or indirectly by each of the aforementioned entities. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(7)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Represents (i) 34,842 shares of Treeline Common Stock underlying warrants held by Ajax HQ Treeline 2022 SPV, LLC, and (ii)&#160;114,717&#160;shares of Treeline Common Stock underlying warrants held by AZTL. </div></td></tr></table><div class="BRDSX_ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 3pt; margin-left: 20pt; text-align: left;">Ajax Health III LLC is governed by a board of managers comprised of five voting managers, a majority of which are appointed by HealthQuest Partners III, L.P. HealthQuest Venture Management III, L.L.C. is the general partner of HealthQuest Partners III, L.P. Garheng Kong is the managing member of HealthQuest Venture Management III, L.L.C. and has sole voting and investment power over the shares held by Ajax Health III LLC. </div><div class="BRDSX_ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 3pt; margin-left: 20pt; text-align: left;">Ajax HQ Treeline 2022 SPV, LLC is governed by a board of managers comprised of three voting managers, a majority of which are appointed by HealthQuest Ajax III-A SPV, L.P. HealthQuest Ajax III-A Management, L.L.C. is the general partner of HealthQuest Ajax III-A SPV, L.P. Garheng Kong is the managing member of HealthQuest Ajax III-A Management, L.L.C. and has sole voting and investment power over the shares held by Ajax HQ Treeline 2022 SPV, LLC. </div><div class="BRDSX_ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 3pt; margin-left: 20pt; text-align: left;">Dr.&#160;Kong, HealthQuest Partners III, L.P., HealthQuest Venture Management III, L.L.C., HealthQuest Ajax III-A SPV, L.P. and HealthQuest Ajax III-A Management, L.L.C. disclaim beneficial ownership over all of the shares owned by Ajax Health III LLC, Ajax HQ Treeline 2022 SPV, LLC and AZTL except to the extent of their pecuniary interest therein. </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(8)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">AZTL is directly owned by entities affiliated with KKR and Ajax Health III LLC. Neptune is the managing member of AZTL. Neptune is governed by a board of managers comprised of two voting managers, and one non-voting CEO manager. Each of Zeus Health LLC, which is indirectly controlled by KKR &amp; Co. Inc. (&#8220;KKR&#8221;) through certain intermediary funds and entities, and Ajax Health III LLC (more specifically discussed in footnote 8, above) has the right to designate a voting manager. Board action generally requires approval of each voting manager. Thus, KKR and Ajax Health III LLC ultimately share voting power and investment power over the AZTL shares. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(9)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Represents 239,252 shares of Treeline Common Stock directly held by AZN TLII LLC. Mr.&#160;Naider serves as manager of AZN TLII LLC and may be deemed to exercise voting and investment discretion over the securities held by them in such capacities. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(10)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Represents an aggregate 36,403 shares of Treeline Common Stock held directly by trusts. Dr. Bilenker may be deemed to exercise voting and/or investment discretion over the securities held by each of the trusts.</div></td></tr></table><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Treatment of Treeline Options Held by Executive Officers </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under the Merger Agreement, as of the Effective Time, Standard BioTools will assume Treeline&#8217;s 2021 Equity Incentive Plan and each outstanding Treeline Option, whether vested or unvested. Each such Treeline Option so assumed by Standard BioTools will continue to have, and be subject to, the same terms and conditions applicable to such Treeline Option immediately prior to the Effective Time, except that (i) such Treeline Option will be exercisable for that number of shares of Standard BioTools Common Stock equal to the number of shares of Treeline Common Stock subject to such Treeline Option immediately prior to the Effective Time multiplied by the Exchange Ratio and rounded down to the next nearest share of Standard BioTools Common Stock, and (ii) the exercise price per share of each such Treeline Option will be the exercise price per share in effect for that Treeline Option immediately prior to the Effective Time divided by the Exchange Ratio and rounded up to the next nearest cent. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The table below presents information concerning outstanding Treeline Options held by Treeline&#8217;s current executive officers as of June&#160;1, 2026, broken down between vested and unvested options. The number of shares underlying each Treeline Option and the applicable per-share exercise price do not reflect the Exchange Ratio or the Reverse Stock Split. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 2pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="margin-top: 0pt; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 240pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 10.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 10.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 45.56pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 10.07pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 10.07pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 32.45pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 10.07pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 10.07pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 36.95pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 10.07pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 10.07pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 32.44pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 240pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Name</div></td><td style="width: 10.08pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.08pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45.56pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Vested<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Options Held</div></td><td style="width: 10.07pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.07pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.45pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Weighted<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Average<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Exercise<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Price of<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Vested<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Options</div></td><td style="width: 10.07pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.07pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36.95pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Unvested<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Options<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Held</div></td><td style="width: 10.07pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.07pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.44pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Weighted<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Average<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Exercise<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Price of<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Unvested<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Options </div></td></tr><tr><td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Joshua Bilenker<font style="padding-left: 3.35pt;"></font></div></td><td style="width: 10.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45.56pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.53pt; text-align: left;"><font style="padding-left: 5pt;">16,668</font></div></td><td style="width: 10.07pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.07pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.45pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.98pt; text-align: left;">$2.41</div></td><td style="width: 10.07pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.07pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36.95pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.23pt; text-align: left;">650,000</div></td><td style="width: 10.07pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.07pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.44pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.98pt; text-align: left;">$2.43 </div></td></tr><tr><td style="width: 240pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Jeffrey Engelman<font style="padding-left: 1.88pt;"></font></div></td><td style="width: 10.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45.56pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.53pt; text-align: left;">269,158</div></td><td style="width: 10.07pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.07pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.45pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.98pt; text-align: left;">$1.68</div></td><td style="width: 10.07pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.07pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36.95pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.23pt; text-align: left;">650,000</div></td><td style="width: 10.07pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.07pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.44pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.98pt; text-align: left;">$2.43 </div></td></tr><tr><td style="width: 240pt; padding-top: 0.01pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Spencer Smith<font style="padding-left: 3.9pt;"></font></div></td><td style="width: 10.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45.56pt; padding-top: 0.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.53pt; text-align: left;">134,397</div></td><td style="width: 10.07pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.07pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.45pt; padding-top: 0.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.98pt; text-align: left;">$2.09</div></td><td style="width: 10.07pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.07pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36.95pt; padding-top: 0.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.23pt; text-align: left;">398,334</div></td><td style="width: 10.07pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.07pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.44pt; padding-top: 0.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.98pt; text-align: left;">$2.41</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 240pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 10.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 10.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 45.56pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 10.07pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 10.07pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 32.45pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 10.07pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 10.07pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 36.95pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 10.07pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 10.07pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 32.44pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">193<br></div></div></div>
<!--End Page 204-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 205-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_115-merger_pg60"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Management Following the Merger </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As described in the section titled &#8220;<font style="font-style: italic;">Board of Directors and Management Following the Merger</font>,&#8221; Treeline&#8217;s directors and executive officers are currently expected to become the directors and executive officers of the combined company upon the closing of the Merger. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Indemnification and Insurance </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For a discussion of the indemnification and insurance provisions related to the Treeline directors and officers under the Merger Agreement, please see the sections titled &#8220;<font style="font-style: italic;">The Merger Agreement-Indemnification; Directors&#8217; and Officers&#8217; Insurance</font>&#8221; and &#8220;<font style="font-style: italic;">Certain Relationships and Related Party Transactions of the Combined Company-Treeline&#8217;s Transactions</font>.&#8221; </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;"><a name="tLOCK1"><!--Anchor--></a>Lock-Up Agreements </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Concurrently with the execution of the Merger Agreement, certain stockholders of Treeline holding approximately 70% of the outstanding shares of Treeline Capital Stock as of June&#160;6, 2026, and the directors of Standard BioTools, who together beneficially own approximately 4% of Standard BioTools Common Stock as of June 3, 2026, including each individual who will serve as a director or executive officer of the combined company following the Closing, entered into lock-up agreements, pursuant to which, subject to specified exceptions, such persons agreed that they would not offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Standard BioTools Common Stock or any securities convertible into or exercisable or exchangeable for shares of Standard BioTools Common Stock (including securities that may be issued upon exercise of an option to purchase shares of Standard BioTools Common Stock or a warrant to purchase shares of Standard BioTools Common Stock), for 180 days following the Effective Time. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;"><a name="tCVR"><!--Anchor--></a>CVR Agreement </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Prior to the Effective Time, Standard BioTools expects to declare a dividend to Standard BioTools stockholders as of the close of business on the last business day prior to the day on which the Effective Time occurs in the form of one CVR for each outstanding share of Standard BioTools Common Stock held by such stockholder on such date. The payment date for such dividend will be three business days after the Effective Time. The CVRs will be issued pursuant to the terms of a CVR Agreement to be entered into between Standard BioTools and a rights agent. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Pursuant to the CVR Agreement, the holder of each CVR will be entitled to receive a payment for each 12-month CVR payment period during the five-year term of the CVR Agreement, consisting of a number of shares of the combined company&#8217;s common stock (with fractional shares settled in cash) equal to such holder&#8217;s pro rata portion of the aggregate net proceeds received by the combined company during such 12-month CVR payment period from the following sources, in each case less certain permitted deductions: (i) proceeds from any sale, disposition, or other monetization of the Legacy Business; (ii) proceeds from convertible notes or other investments held by Standard BioTools as of the Closing Date; (iii) earnout, milestone, royalty or other similar contingent payments due to Standard BioTools under contracts in effect as of the Closing Date, including payments from Illumina, Inc. pursuant to the Stock Purchase Agreement dated June&#160;22, 2025; and (iv) any surplus in Parent Net Cash delivered at Closing as finally determined under the Merger Agreement. The maximum number of shares of common stock of the combined company which may be issued pursuant to the CVR Agreement is 76,000,000. There can be no assurance that any payments will be made on the CVRs. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The right to the contingent payments contemplated by the CVR Agreement is a contractual right only and is not transferable, except in the limited circumstances specified in the CVR Agreement. The CVRs will not be evidenced by a certificate or any other instrument and will not be registered with the SEC. The CVRs will not have any voting or dividend rights and will not represent any equity or ownership interest in Standard BioTools or any of its respective affiliates. No interest will accrue on any amounts payable in respect of the CVRs. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The foregoing description of the CVR Agreement does not purport to be complete and is qualified in its entirety by reference to the CVR Agreement, a form of which is filed as Annex&#160;F to this proxy statement/prospectus. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Withholding </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The CVR Agreement provides that the issuer and the rights agent will be entitled to deduct and withhold, or cause to be deducted and withheld, from any payment payable to CVR holders pursuant to the CVR Agreement, such amounts as it is required to deduct and withhold with respect to the making of such payment under any </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">194<br></div></div></div>
<!--End Page 205-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 206-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_115-merger_pg61"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">provision of applicable law relating to taxes. To the extent that amounts are so deducted and withheld, such deducted and withheld amounts will be treated for all purposes of the CVR Agreement as having been paid to the CVR holder in respect of which such deduction and withholding was made. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Material U.S. Federal Income Tax Considerations with Respect to the CVRs to Holders of Standard BioTools Common Stock </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following is a discussion of the material U.S. federal income tax considerations relating to the receipt of the CVRs by Standard BioTools stockholders pursuant to the Contingent Value Rights Agreement and distributions of Standard BioTools Common Stock pursuant to the CVRs to holders of Standard BioTools Common Stock. This discussion does not purport to be a complete analysis of all potential tax considerations and is based upon current provisions of the Code, existing Treasury regulations, judicial decisions and published rulings and administrative pronouncements of the IRS, all in effect as of the date hereof and all of which are subject to differing interpretations or change. Any such change or differing interpretation, which may be retroactive, could alter the tax consequences to holders of Standard BioTools Common Stock as described in this summary. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This discussion does not address all U.S. federal income tax considerations relevant to a Standard BioTools stockholder, including the alternative minimum tax. In addition, it does not address consequences relevant to Standard BioTools stockholders that are subject to particular U.S. or non-U.S. tax rules, including, without limitation, to Standard BioTools stockholders that are: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">persons who do not hold their Standard BioTools Common Stock as a &#8220;capital asset&#8221; within the meaning of Section&#160;1221 of the Code; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">brokers, dealers or traders in securities, banks, insurance companies, other financial institutions or mutual funds; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">real estate investment trusts; regulated investment companies; tax-exempt organizations or governmental organizations; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">pass-through entities such as partnerships, S corporations, disregarded entities for federal income tax purposes and limited liability companies (and investors therein); </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">persons who hold their shares as part of a hedge, wash sale, synthetic security, conversion transaction or other integrated transaction; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">persons that have a functional currency other than the U.S. dollar; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">traders in securities who elect to apply a mark-to-market method of accounting; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">persons who hold shares of Standard BioTools Common Stock that may constitute &#8220;qualified small business stock&#8221; under Section&#160;1202 of the Code or as &#8220;Section&#160;1244 stock&#8221; for purposes of Section&#160;1244 of the Code; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">persons who acquired their shares of Standard BioTools Common Stock in a transaction subject to the gain rollover provisions of Section&#160;1045 of the Code; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">persons subject to special tax accounting rules as a result of any item of gross income with respect to Standard BioTools common stock being taken into account in an &#8220;applicable financial statement&#8221; (as defined in the Code); </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">persons deemed to sell Standard BioTools Common Stock under the constructive sale provisions of the Code; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">persons holding Standard BioTools Common Stock who exercise dissenters&#8217; rights; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">persons who acquired their shares of Standard BioTools Common Stock pursuant to the exercise of options or otherwise as compensation or through a tax-qualified retirement plan or through the exercise of a warrant or conversion rights under convertible instruments; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">certain expatriates or former citizens or long-term residents of the United States. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If an entity that is treated as a partnership for U.S. federal income tax purposes holds Standard BioTools Common Stock, the U.S. federal income tax treatment of a partner in the partnership or other pass-through entity will generally depend upon the status of the partner, the activities of the partnership or other pass-through entity and </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">195<br></div></div></div>
<!--End Page 206-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 207-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_115-merger_pg62"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">certain determinations made at the partner level. Partners of a partnership or other pass-through entity holding Standard BioTools Common Stock should consult their tax advisors regarding the tax consequences of the receipt of the CVRs and distributions of Standard BioTools Common Stock pursuant to the CVRs. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, the following discussion does not address: (a) the tax consequences of transactions effectuated before, after or at the same time as the distribution of the CVRs, whether or not they are in connection with the distribution of the CVRs, including, without limitation, the Merger and the reverse stock split, except as specifically provided below; (b) the tax consequences of the ownership of shares of Standard BioTools Common Stock distributed with respect to the CVRs; (c) any U.S. federal non-income tax consequences of the receipt of the CVRs and distributions of Standard BioTools Common Stock pursuant to the CVRs, including estate, gift or other tax consequences; (d) any state, local or non-U.S. tax consequences; or (e) the Medicare contribution tax on net investment income. The CVRs generally may not be transferred or assigned except for certain permitted transfers; accordingly, this discussion assumes the CVRs will not be transferable or assignable and will not address any consequences of transferring, assigning or otherwise disposing of the CVRs or any interest therein. No ruling from the IRS has been or will be requested in connection with the distribution of the CVRs or distributions of Standard BioTools Common Stock pursuant to the CVRs. Standard BioTools stockholders should be aware that the IRS could adopt a position which could be sustained by a court contrary to that set forth in this discussion. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">STOCKHOLDERS SHOULD CONSULT THEIR TAX ADVISORS WITH RESPECT TO THE APPLICATION OF THE U.S. FEDERAL INCOME TAX LAWS TO THEIR PARTICULAR SITUATIONS AS WELL AS ANY TAX CONSEQUENCES OF THE RECEIPT OF THE CVRS AND DISTRIBUTIONS OF STANDARD BIOTOOLS COMMON STOCK PURSUANT TO THE CVRS ARISING UNDER THE U.S. FEDERAL ESTATE OR GIFT TAX LAWS OR UNDER THE LAWS OF ANY STATE, LOCAL OR NON-U.S. TAXING JURISDICTION OR UNDER ANY APPLICABLE INCOME TAX TREATY.<font style="font-weight: normal;"> </font></div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Tax Treatment of Receipt of CVRs for U.S. Holders </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For purposes of this discussion, a &#8220;U.S. holder&#8221; is a beneficial owner of Standard BioTools Common Stock that is, for U.S. federal income tax purposes: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">an individual who is a citizen or resident of the United States; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a corporation or any other entity taxable as a corporation created or organized in or under the laws of the United States, any state thereof, or the District of Columbia; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a trust if either (i) a court within the United States is able to exercise primary supervision over the administration of such trust, and one or more United States persons (within the meaning of Section&#160;7701(a)(30) of the Code) is authorized or has the authority to control all substantial decisions of such trust, or (ii) the trust was in existence on August&#160;20, 1996 and has a valid election in effect under applicable Treasury Regulations to be treated as a United States person for U.S. federal income tax purposes; or </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">an estate, the income of which is subject to U.S. federal income tax regardless of its source. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">There is substantial uncertainty as to the tax treatment of CVRs. Specifically, there is no authority directly addressing whether contingent value rights with characteristics similar to the CVRs are treated as a distribution of property, a distribution of rights to acquire equity, or an &#8220;open transaction&#8221; for U.S. federal income tax purposes. Under applicable U.S. tax principles, such questions are inherently factual in nature. As a result, it is not possible to express a definitive conclusion as to the U.S. federal income tax treatment of the receipt of CVRs or receipt of payment (if any) in respect of the CVRs. U.S. holders of Standard BioTools Common Stock are urged to consult their tax advisors regarding the tax consequences to them of the receipt of CVRs and receipt of payment (if any) in respect of the CVRs. </div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Non-Taxable Distribution of Stock Rights under Section&#160;305 of the Code </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As discussed under the section above titled &#8220;<font style="font-style: italic;">The Merger&#8201;&#8212;&#8201;CVR Agreement</font>,&#8221; the CVRs represent the right to receive, under the conditions stated therein, shares of Standard BioTools Common Stock, and payments (if any) made under the CVRs solely in Standard BioTools Common Stock. Accordingly, Standard BioTools intends to take the position that the distribution of the CVRs is treated as a distribution of rights to acquire stock for U.S. federal income tax purposes to which Section&#160;305(a) of the Code applies. Under such treatment, then subject to the </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">196<br></div></div></div>
<!--End Page 207-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 208-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_115-merger_pg63"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">discussion under &#8220;&#8212; Constructive Distributions&#8221; below, U.S. holders of Standard BioTools Common Stock should not recognize gain or loss or include any amount in income as a result of the distribution of the CVRs. If the fair market value of the CVRs a U.S. holder receives is less than 15% of the fair market value of the holder&#8217;s existing shares of Common Stock with respect to which the CVRs are distributed on the date the holder receives the CVRs, the CVRs will be allocated a zero dollar basis for U.S. federal income tax purposes, unless the holder elects to allocate the holder&#8217;s basis in the holder&#8217;s existing shares of Standard BioTools Common Stock with respect to which the CVRs are distributed between the holder&#8217;s existing shares of Standard BioTools Common Stock and the CVRs in proportion to the relative fair market values thereof, determined on the date of receipt of the CVRs. Although the fair market value of the CVRs is uncertain, Standard BioTools intends to take the position that, on the distribution date of the CVRs, the fair market value of a CVR will be less than 15% of the fair market value of the share of Standard BioTools Common Stock with respect to which such CVR is distributed, so that allocation of basis to the CVRs is not required. Further, the holding period of the CVRs should include the holding period of such holder&#8217;s Standard BioTools Common Stock. Standard BioTools has not obtained, and does not intend to obtain, an appraisal of the fair market value of the CVRs. In determining the fair market value of the CVRs, U.S. holders should consider all relevant facts and circumstances, including the length of the period during which the CVRs will remain outstanding and the fact that the CVRs are generally non-transferable. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Pursuant to Section&#160;305(a) of the Code, in general, the receipt by a stockholder of a stock dividend should not be included in the taxable income of the recipient. Although the matter is not free from doubt, Standard BioTools intends to take the position that a U.S. holder&#8217;s receipt of shares of Standard BioTools Common Stock under the CVRs is a non-taxable exercise of the right to acquire stock under the CVRs for U.S. federal income tax purposes. If such treatment is correct, a U.S. holder should not recognize gain or loss or include any amount in income upon receipt of Common Stock pursuant to the CVR. In such case, a U.S. holder&#8217;s tax basis in Common Stock received as payment pursuant to the CVR should equal the portion of the U.S. holder&#8217;s basis in its Common Stock that the U.S. holder allocated to the CVR under the paragraph above. The holding period of any Common Stock received pursuant to the CVRs should begin on the date on which the Common Stock was received. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If a U.S. holder&#8217;s CVRs expire without any distribution of shares of Standard BioTools Common Stock with respect thereto, the U.S. holder should not recognize any gain or loss for U.S. federal income tax purposes, and the U.S. holder should re-allocate any portion of the tax basis in the holder&#8217;s existing Standard BioTools Common Stock previously allocated to the CVRs that have expired to the existing Standard BioTools Common Stock with respect to which such CVRs were received. If a U.S. holder&#8217;s CVRs expire after the holder has disposed of the shares of Standard BioTools Common Stock with respect to which the CVRs were received, the U.S. holder should consult with the holder&#8217;s own tax advisor regarding the tax treatment of the expiration of the CVRs. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Standard BioTools&#8217; reporting position with respect to the treatment of the distribution of the CVRs is not binding on the IRS or the courts. This position may be challenged by the IRS, in which case holders of Standard BioTools Common Stock could be required to recognize taxable income in respect of the receipt of the CVRs without a corresponding receipt of cash. </div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Taxable Distribution </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Alternative characterizations are also possible. If Section&#160;305(a) does not apply to the distribution of CVRs, then such distribution would generally be treated for U.S. federal income tax purposes as a distribution of property. In this case, there is uncertainty as to whether such distribution of property should be treated as an &#8220;open transaction&#8221; or a &#8220;closed transaction.&#8221; Whether &#8220;open transaction&#8221; or &#8220;closed transaction&#8221; treatment applies is inherently factual in nature. Pursuant to U.S. Treasury Regulations addressing contingent payment obligations analogous to the CVRs, if the fair market value of the CVRs is &#8220;reasonably ascertainable,&#8221; a U.S. holder receiving CVRs in a taxable distribution should generally treat the transaction as a &#8220;closed transaction.&#8221; If the value of the CVRs on the date of distribution cannot be &#8220;reasonably ascertained,&#8221; then &#8220;open transaction&#8221; treatment may apply. The U.S. Treasury Regulations state that only in &#8220;rare and extraordinary&#8221; cases would the value of contingent payment obligations not be reasonably ascertainable. </div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Open Transaction </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If the issuance of the CVRs is treated as a taxable distribution of property that qualifies as an open transaction, (because, for example, the value of the CVRs on the distribution date cannot be &#8220;reasonably ascertained&#8221;), a U.S. holder should not immediately take the CVRs into account in determining whether such holder must recognize </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">197<br></div></div></div>
<!--End Page 208-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 209-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_115-merger_pg64"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">income or gain, if any, on the receipt of the CVRs and such holder would take no tax basis in the CVRs. Rather, the U.S. holder&#8217;s U.S. federal income tax treatment would be determined at the time future payments, if any, with respect to the CVRs are received or deemed received in accordance with the U.S. holder&#8217;s regular method of accounting. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Where the issuance of the CVRs is characterized as an open transaction, a U.S. holder is generally expected to recognize taxable income upon the distribution of Standard BioTools Common Stock pursuant to the CVR occurs in an amount equal to the fair market value of the newly received shares of Common Stock as of that date. This distribution would generally be treated first as a taxable dividend to the extent of Standard BioTools&#8217; current or accumulated earnings and profits (as determined for U.S. federal income tax purposes) in the year that shares are issued under the CVR, then as a non-taxable return of capital to the extent of the U.S. holder&#8217;s basis in its Standard BioTools Common Stock, and finally as capital gain from the sale or exchange of Standard BioTools Common Stock with respect to any remaining value. A U.S. holder&#8217;s tax basis in Common Stock received as payment pursuant to the CVR would generally equal the fair market value of the Standard BioTools Common Stock upon receipt and the holding period of such shares would generally begin with and include the date of receipt. </div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Closed Transaction </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If the issuance of the CVRs is treated as a taxable distribution of property that qualifies as a closed transaction, each U.S. holder would generally be treated as receiving a distribution in an amount equal to the fair market value of the CVR issued to such U.S. holder on the date of the issuance. This distribution would generally be treated first as a taxable dividend to the extent of Standard BioTools&#8217; current or accumulated earnings and profits (as determined for U.S. federal income tax purposes), then as a non-taxable return of capital to the extent of the U.S. holder&#8217;s basis in its Standard BioTools Common Stock, and finally as capital gain from the sale or exchange of Standard BioTools Common Stock with respect to any remaining value. A U.S. holder&#8217;s initial tax basis in such holder&#8217;s CVR would generally equal the fair market value of such CVR on the date of their issuance. The holding period of such CVR would generally begin on the date of issuance. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">It is possible that payments received with respect to a CVR up to the amount of the U.S. holder&#8217;s adjusted tax basis in the CVR may first be treated as a non-taxable return of a U.S. holder&#8217;s adjusted tax basis in the CVR, with any amount received in excess of such basis treated as gain from the disposition of the CVR. Payments with respect to a CVR could alternatively be treated as ordinary income. U.S. holders are urged to consult their tax advisors regarding the characterization of payments received with respect to the CVRs. </div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Constructive Distributions </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Even if the distribution of the CVRs or of Standard BioTools Common Stock with respect to the CVRs is treated as a distribution of stock for purposes of section 305(a), the distribution of CVRs may nonetheless be treated as a taxable stock dividend under section 305(b) if, as part of a plan or series of related transactions, Standard BioTools pays a dividend in money or other property with respect to its stock or any outstanding stock rights (including in respect of interest under convertible notes). Under Section&#160;305(b) of the Code, a distribution of stock will be treated as a distribution of property if it has the result of the receipt of property by some shareholders and an increase in the proportionate interests of other shareholders in the corporation&#8217;s earnings and profits or assets. It is possible that Standard BioTools&#8217; payment of interest on its convertible notes may cause the distribution of the CVRs to be taxable as a constructive distribution of property. Under this treatment, the distribution of the CVRs or of Standard BioTools Common Stock with respect to the CVRs to be taxed as a constructive distribution would be treated as a dividend to the U.S. holder to the extent of Standard BioTools&#8217; current and accumulated earnings and profits as of the year of the distribution, then as a recovery of the U.S. holder&#8217;s basis in its existing shares of Standard BioTools Common Stock, and then as capital gain. U.S. holders are encouraged to consult with their own tax advisors on this issue. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Due to the substantial uncertainty regarding the tax treatment of the CVRs (and any future distributions of Standard BioTools Common Stock pursuant to the CVRs), U.S. holders are urged to consult their tax advisors concerning the recognition of gain and/or loss in connection with the CVRs and the applicability of information reporting and backup withholding.<font style="font-weight: normal;"> </font></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">198<br></div></div></div>
<!--End Page 209-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 210-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_115-merger_pg65"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Tax Treatment of Receipt of CVRs for Non-U.S. Holders </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For purposes of this discussion, a &#8220;non-U.S. holder&#8221; means a beneficial owner of Standard BioTools Common Stock that is neither a U.S. holder nor a partnership (or other pass-through entity) for U.S. federal income tax purposes. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As discussed above, Standard BioTools intends to take the position that the distribution of the CVRs is treated as a distribution of rights to acquire equity for U.S. federal income tax purposes to which Section&#160;305(a) of the Code applies. If such treatment is correct, then subject to the discussion under &#8220;&#8212; <font style="font-style: italic;">Constructive Distributions</font>&#8221; above, non-U.S. holders generally should not be subject to U.S. federal income tax as a result of the distribution of the CVRs. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Notwithstanding the foregoing, or if the distribution of the CVRs is taxable as a constructive distribution, it is possible that the receipt of the CVRs could be a taxable event and taxable as a distribution or other income as described above. Generally, if any portion of the distribution of CVRs to non-U.S. holders is treated as a dividend for U.S. federal income tax purposes (as described above), such dividend will be subject to withholding at a rate of 30% (or at a lower rate under an applicable income tax treaty) on the fair market value of the CVR. Further, under the terms of the CVR Agreement, the issuer and the rights agent are permitted to deduct all applicable withholding taxes upon the delivery, if any, of Standard BioTools Common Stock in respect of a CVR. If the receipt of the CVRs is effectively connected with a non-U.S. holder&#8217;s conduct of a trade or business within the United States (and, if required, by an applicable income tax treaty, the non-U.S. holder maintains a permanent establishment in the United States to which the distribution of the CVRs (or delivery of Standard BioTools Common Stock) is attributable), the non-U.S. holder will be exempt from the 30% withholding tax and the distribution of the CVRs (or delivery of Standard BioTools Common Stock) will be subject to taxation in the same manner as if such non-U.S. holder were a U.S. holder. To claim the exemption, the non-U.S. holder must furnish to the applicable withholding agent a valid IRS Form&#160;W-8ECI (or applicable successor form), certifying that the distribution (or delivery, as applicable) is effectively connected with such non-U.S. holder&#8217;s conduct of a trade or business in the United States. A non-U.S. holder that is a corporation also may be subject to a branch profits tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty) of all or a portion of its effectively connected earnings and profits. A non-U.S. holder that is an entity may also be subject to U.S. federal withholding tax at a rate of 30% if the holder has failed to comply with the requirements under the Foreign Account Tax Compliance Act or establish an exemption therefrom. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This discussion does not discuss all of the tax considerations that may be applicable to a non-U.S. holder. Non-U.S. holders are urged to consult their tax advisors to determine the U.S. federal, state, local and non-U.S. income and other tax considerations that may be relevant to them in light of their particular circumstances. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Due to the legal and factual uncertainty regarding the tax treatment of the CVRs (and any future distributions of Standard BioTools Common Stock pursuant to the CVRs), non-U.S. holders are urged to consult their tax advisors concerning the recognition of gain and/or loss or withholding that may apply in connection with the CVRs. Non-U.S. holders should consult their tax advisors regarding the applicability of information reporting and backup withholding and/or withholding under the Foreign Account Tax Compliance Act with respect to the CVRs and any future distributions of Standard BioTools Common Stock pursuant to the CVRs, particularly in light of the uncertainty under U.S. federal income tax law relating to the tax treatment of the CVRs.<font style="font-weight: normal;"> </font></div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;"><a name="tREG1"><!--Anchor--></a>Regulatory Approvals Required for the Merger </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The obligations of Standard BioTools and Treeline to effect the Merger are conditioned upon, among other things, the expiration or termination of the waiting period relating to the Merger under the HSR Act, as more fully described below under the caption &#8220;<font style="font-style: italic;">The Merger Agreement &#8212; Conditions to the Completion of the Merger,&#8221;</font> beginning on page <a href="#tCONCOMMER">207</a> in this proxy statement/prospectus. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under the HSR Act, certain transactions, including the Merger, may not be completed unless certain waiting period requirements have expired or been terminated. The HSR Act provides that the parties must file a pre-Merger notification with the FTC and the Antitrust Division of the DOJ. A transaction notifiable under the HSR Act may not be completed until the expiration of a 30-calendar-day waiting period following the parties&#8217; filings of their respective HSR Act notification forms or the early termination of that waiting period. At any time before the expiration of the initial waiting period, the FTC or DOJ may issue a Request for Additional Information and </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">199<br></div></div></div>
<!--End Page 210-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 211-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_115-merger_pg66"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Documentary Material, which is referred to in this proxy statement/prospectus as a &#8220;second request.&#8221; If a second&#160;request is issued, the parties may not complete the merger until they each substantially comply with the second request and observe a second 30-calendar-day waiting period, unless the waiting period is terminated earlier. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Each of Standard BioTools and Treeline filed its respective HSR Act notification and report with respect to the Merger on June&#160;29, 2026. As such, the 30-calendar-day waiting period will expire on July&#160;29, 2026, subject to the issuance of a second request by the FTC or DOJ. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Standard BioTools and Treeline have agreed to use their respective reasonable best efforts to take, or cause to be taken, all actions and to do, or cause to be done, all things necessary, proper or advisable under applicable laws in connection with the Merger or any of the other Transactions, including to obtain, as promptly as possible, all consents required to be obtained from any governmental entity that are necessary, proper or advisable to consummate the Merger, in each case subject to certain exceptions, as more fully described below under the caption &#8220;<font style="font-style: italic;">The Merger Agreement &#8212; Regulatory Approvals Required for the Merger</font>&#8221; beginning on page <a href="#tREG1A">220</a> in this proxy statement/prospectus. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;"><a name="tAAT1"><!--Anchor--></a>Anticipated Accounting Treatment </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Merger is expected to be accounted for as a reverse recapitalization in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). For accounting purposes, Treeline is considered to be the accounting acquirer in this transaction. The treatment as an in-substance reverse recapitalization is based on the assessment that as a result of, and following, Standard BioTools&#8217; discontinuation of its Legacy Business, and settlement of its other remaining operating assets and liabilities, prior to or concurrently with the closing of the Merger, Standard BioTools will not meet the definition of a &#8220;business&#8221; under ASC&#160;805 </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;"><a name="tAPR1"><!--Anchor--></a>Appraisal Rights </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under the DGCL, Standard BioTools stockholders are not entitled to appraisal rights in connection with the Merger or other Transactions, but Treeline stockholders are entitled to appraisal rights in connection with the Merger under Section&#160;262 of the DGCL. Appraisal rights are statutory rights that, if applicable under law, enable stockholders to dissent from an extraordinary transaction, such as a merger, and to demand that the corporation pay the fair value for their shares as determined by a court in a judicial proceeding instead of receiving the consideration offered to the stockholders in connection with the transaction. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Nasdaq Stock Market Listing </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Shares of Standard BioTools Common Stock are currently listed on The Nasdaq Global Select Market under the symbol &#8220;LAB.&#8221; In the Merger Agreement, Standard BioTools has agreed to use reasonable best efforts to cause the shares of Standard BioTools Common Stock to be issued in the Merger to be approved for listing on Nasdaq, subject to official notice of issuance, prior to the Effective Time. Standard BioTools anticipates that the common stock of the combined company will be listed on The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) following the Closing under the trading symbol &#8220;TRLN.&#8221; It is a condition to closing that existing shares of Standard BioTools Common Stock be listed on Nasdaq as of the Closing Date, and the shares of Standard BioTools Common Stock issuable in connection with the Merger must be approved for listing on Nasdaq, subject to official notice of issuance, but there can be no assurance such listing condition will be met. If such listing condition is not met, the Merger will not be consummated unless the condition is waived. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">200<br></div></div></div>
<!--End Page 211-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 212-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_116-agreement_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tMEA"><!--Anchor--></a>THE MERGER AGREEMENT </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following is a summary of the material terms of the Merger Agreement. A copy of the Merger Agreement is attached to this proxy statement/prospectus as Annex&#160;A and is incorporated by reference into this proxy statement/prospectus. The Merger Agreement has been attached to this proxy statement/prospectus to provide you with information regarding its terms. It is not intended to provide any other factual information about Treeline, Standard BioTools or Merger Sub. The following description does not purport to be complete and is qualified in its entirety by reference to the Merger Agreement. You should refer to the full text of the Merger Agreement for details of the Merger and the terms and conditions of the Merger Agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Merger Agreement contains representations and warranties that Standard BioTools and Merger Sub, on the one hand, and Treeline, on the other hand, have made to one another as of specific dates. These representations and warranties have been made for the benefit of the other parties to the Merger Agreement and may be intended not as statements of fact but rather as a way of allocating the risk to one of the parties if those statements prove to be incorrect. In addition, the assertions embodied in the representations and warranties are qualified by information in confidential disclosure schedules exchanged by the parties in connection with signing the Merger Agreement. While Treeline and Standard BioTools do not believe that these disclosure schedules contain information required to be publicly disclosed under the applicable securities laws, other than information that has already been so disclosed, the disclosure schedules do contain information that modifies, qualifies and creates exceptions to the representations and warranties set forth in the attached Merger Agreement. Accordingly, you should not rely on the representations and warranties as current characterizations of factual information about Standard BioTools or Treeline because they were made as of specific dates, may be intended merely as a risk allocation mechanism between Standard BioTools and Merger Sub, on the one hand, and Treeline, on the other hand, and are modified by the disclosure schedules. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For purposes of this summary, each of Standard BioTools and Treeline are referred to as &#8220;a party&#8221; and collectively as &#8220;the parties.&#8221; </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">General </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under the Merger Agreement, Merger Sub, a wholly owned subsidiary of Standard BioTools formed by Standard BioTools in connection with the Merger under the laws of the State of Delaware, will merge with and into Treeline, with Treeline surviving as a wholly owned subsidiary of Standard BioTools (the &#8220;Surviving Company&#8221;). </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Closing and Effectiveness of the Merger </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The closing of the Merger (the &#8220;Closing&#8221;) will take place as soon as reasonably practicable and in no event later than three business days following the day on which the last to be satisfied or waived of each of the closing conditions contained in the Merger Agreement (other than those conditions that by their nature are to be satisfied at the Closing but subject to the satisfaction or waiver of those conditions) must have been satisfied or waived in accordance with the Merger Agreement, or at such other place and time and/or on such other date as Standard BioTools and Treeline may otherwise agree in writing (the date on which the Closing occurs, the &#8220;Closing Date&#8221;). </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Upon the Closing, Standard BioTools and Treeline will cause the certificate of merger with respect to the Merger to be executed, acknowledged and filed with the Secretary of State of the State of Delaware. The Merger will become effective at the time when the certificate of merger has been duly filed with the Secretary of State of the State of Delaware or at such later time as may be agreed upon by the parties in writing (the &#8220;Effective Time&#8221;). Neither Standard BioTools nor Treeline can predict the exact timing of the consummation of the Merger. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;"><a name="tMGC"><!--Anchor--></a>Merger Consideration </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">At the Effective Time: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">each share of Treeline Common Stock and Treeline Preferred Stock issued and outstanding immediately prior to the Effective Time (excluding any shares of Treeline Common Stock and Treeline Preferred Stock held in treasury (the &#8220;Excluded Shares&#8221;) and excluding any share of Treeline Capital Stock the holders of which have exercised appraisal rights in accordance with the DGCL (&#8220;Dissenting Shares&#8221;)) will, as a result of the Merger and without any action on the part of the holder thereof, be automatically converted into the right to receive a number of shares of Standard BioTools Common Stock, equal to the Exchange Ratio, provided that the number of shares of Standard BioTools Common Stock which each holder of Treeline Capital Stock is entitled to receive will be rounded down to the nearest whole share and </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">201<br></div></div></div>
<!--End Page 212-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 213-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_116-agreement_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_bl" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: left;">computed after aggregating all shares of Treeline Capital Stock held by such holder (the &#8220;Per Share Merger Consideration&#8221; and the aggregate shares of Standard BioTools Common Stock issued by applying the Exchange Ratio in accordance with the Merger Agreement, the &#8220;Merger Consideration&#8221;); </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">all of the shares of Treeline Common Stock and Treeline Preferred Stock (other than Excluded Shares and Dissenting Shares) will cease to be outstanding, be cancelled and cease to exist, and (A) each certificate formerly representing any of the shares of Treeline Common Stock and Treeline Preferred Stock (other than Excluded Shares and Dissenting Shares) and (B) each book-entry account formerly representing any uncertificated shares of Treeline Common Stock and Treeline Preferred Stock (other than Excluded Shares and Dissenting Shares) will thereafter represent only the right to receive the Per Share Merger Consideration and any distributions or dividends payable on shares of Standard BioTools Common Stock in accordance with the Merger Agreement; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">each Excluded Share, by virtue of the Merger and without any action on the part of any person, will cease to be outstanding, will be cancelled without payment of any consideration therefor and will cease to exist; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">each share of common stock, par value $0.001 per share, of Merger Sub issued and outstanding immediately prior to the Effective Time will be converted into and become one validly issued, fully paid and non-assessable share of common stock, par value $0.001 per share, of the Surviving Company, and such converted shares will constitute the only outstanding shares of capital stock of the Surviving Company immediately following the Effective Time. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">No fractional shares of Standard BioTools Common Stock will be issued in connection with the Merger, and no certificates or scrip for any such fractional shares will be issued. Each share of Treeline Common Stock and Treeline Preferred Stock (other than Excluded Shares and Dissenting Shares) will be automatically converted into the right to receive a number of shares of Standard BioTools Common Stock equal to the Exchange Ratio, with the number of shares of Standard BioTools Common Stock which each holder of Treeline Capital Stock is entitled to receive being rounded down to the nearest whole share and computed after aggregating all shares of Treeline Capital Stock held by such holder. </div></td></tr></table><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;"><a name="tEXR"><!--Anchor--></a>Exchange Ratio </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Exchange Ratio is calculated using a formula intended to allocate existing Standard BioTools and Treeline securityholders a percentage of the combined company. Based on the capitalization of Standard BioTools and Treeline as of June&#160;3, 2026 and May&#160;28, 2026, respectively, and taking into account Standard BioTools&#8217; estimate of Parent Net Cash as of the Closing, the Exchange Ratio was estimated to be equal to approximately 11.6997 shares of Standard BioTools Common Stock for each share of Treeline Capital Stock. However, this estimate is subject to adjustment prior to the Closing based on the extent to which the Parent Net Cash of Standard BioTools as of 12:01&#160;a.m. Eastern Time on the Closing Date is more than $451&#160;million or less than $449&#160;million (and, as a result, Standard BioTools securityholders could own less, and Treeline securityholders could own more, or vice versa, of the combined company). </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Based on the estimates set forth above, immediately following the completion of the Merger, Standard BioTools securityholders would own approximately 16% of the capital stock of the combined company post-Merger on a fully-diluted basis, and Treeline securityholders would own approximately 84% of the capital stock of the combined company post-Merger on a fully-diluted basis. These ownership percentages may be adjusted up or down to the extent that Parent Net Cash is more than $451&#160;million or less than $449&#160;million. Standard BioTools currently anticipates that its Parent Net Cash as of Closing will be approximately $450&#160;million, and the currently estimated ownership percentages reflect this projection. There can be no assurance that any of these assumptions will be accurate at Closing when the final Exchange Ratio is determined. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Exchange Ratio formula is the quotient obtained (rounded to four decimal places) by dividing (x) the Treeline Value Per Share by (y) the Standard BioTools Value Per Share, in which: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">&#8220;Treeline Value Per Share&#8221; means the quotient of (A) the Treeline Valuation, divided by (B) the number of Treeline Outstanding Shares. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">&#8220;Treeline Valuation&#8221; means (A) $2,500,000,000, plus (B) the sum of the exercise prices of all in-the-money Treeline stock options that are unexpired, unexercised, and outstanding as of immediately prior to the Effective Time and that are included in the calculation of Treeline Outstanding Shares. </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">202<br></div></div></div>
<!--End Page 213-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 214-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_116-agreement_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">&#8220;Treeline Outstanding Shares&#8221; means the sum, without duplication, of the aggregate number of shares of Treeline Capital Stock that are issued and outstanding immediately prior to the Effective Time (on an as-converted to Treeline Common Stock basis) or issuable upon the exercise of or pursuant to, any in-the-money Treeline stock options, Treeline warrants or other direct or indirect rights to acquire shares of Treeline Capital Stock, in each case that are issued and outstanding immediately prior to the Effective Time (whether or not then vested or exercisable). </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">&#8220;Standard BioTools Value Per Share&#8221; means the quotient of (A) the Standard BioTools Valuation, divided by (B) the number of Standard BioTools Outstanding Shares. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">&#8220;Standard BioTools Valuation&#8221; means (A) $460,000,000, plus (B) the amount by which the Parent Net Cash of Standard BioTools exceeds $451&#160;million, if any, minus (C) the amount by which the Parent Net Cash of Standard BioTools is less than $449&#160;million, if any, plus (D) the sum of the exercise prices of all in-the-money Standard BioTools Options that are unexpired, unexercised, and outstanding as of immediately prior to the Effective Time and that are included in the calculation of Standard BioTools Outstanding Shares. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">&#8220;Standard BioTools Outstanding Shares&#8221; means the sum, without duplication, of the aggregate number of shares of Standard BioTools Common Stock that are issued and outstanding immediately prior to the Effective Time or issuable upon the settlement of any Standard BioTools RSUs or the exercise of any in-the-money Standard BioTools Options, in-the-money Standard BioTools warrants or other in-the-money direct or indirect rights to acquire shares of Standard BioTools Common Stock (other than the Indenture, dated as of February&#160;4, 2014, between Standard BioTools and U.S. Bank N.A.), in each case that are issued and outstanding immediately prior to the Effective Time (whether or not then vested or exercisable). </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Merger Agreement provides that if, between the time of calculating the Exchange Ratio and the Effective Time, the outstanding shares of Treeline Capital Stock or Standard BioTools Common Stock have been changed into, or exchanged for, a different number of shares or a different class or series of shares, by reason of any stock dividend, subdivision, reclassification, recapitalization, split, reverse split, combination or exchange of shares or other like change (any of the foregoing, a &#8220;capitalization change&#8221;), the Exchange Ratio will, to the extent necessary, be equitably adjusted (including as a result of the reverse stock split contemplated by the Merger Agreement to the extent such split has not previously been taken into account in calculating the Exchange Ratio and occurs prior to the Effective Time) to reflect such change to the extent necessary to provide the holders of Treeline Capital Stock and holders of Standard BioTools Common Stock with the same economic effect as contemplated by the Merger Agreement prior to such stock dividend, subdivision, reclassification, recapitalization, split, reverse split, combination or exchange of shares or other like change. In addition, the Merger Agreement provides that if a capitalization change occurs prior to the Effective Time, the terms of any other agreement contemplated to be entered into in connection with transactions contemplated by the Merger Agreement will, to the extent necessary, be equitably adjusted to reflect such change to the extent necessary to provide the applicable parties or holders with the same economic effect as contemplated by such agreement prior thereto. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;"><a name="tCOPN"><!--Anchor--></a>Calculation of Parent Net Cash </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Pursuant to the terms of the Merger Agreement, &#8220;Parent Net Cash&#8221; means, as of 12:01 a.m. Eastern Time on the Closing Date and without duplication, the sum of: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the cash, cash equivalents and marketable securities of Standard BioTools and its subsidiaries other than Restricted Cash (as defined below), </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any prepaid expenses or deposits paid or made by Standard BioTools or its subsidiaries, and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the sum of (i) Standard BioTools&#8217; accounts receivable minus its accounts payable and accrued expenses, in each case related to the Legacy Business (which may be a negative number) and (ii) 20% of the book value of any inventory of the Legacy Business, in each case as of the Closing and determined in accordance with GAAP, </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">minus<font style="font-style: normal;"> the sum of the following, in each case to the extent unpaid as of 12:01 a.m. Eastern Time on the Closing&#160;Date: </font></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any transaction expenses of Standard BioTools or its subsidiaries, </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">203<br></div></div></div>
<!--End Page 214-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 215-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_116-agreement_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any outstanding indebtedness of Standard BioTools and its subsidiaries, </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any Parent Termination Costs (as defined in the Merger Agreement), </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">all premiums, underwriting costs, brokerage commissions, costs, expenses and other amounts in respect of the D&amp;O tail policy, </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any out-of-pocket expenses incurred by Standard BioTools prior to the Closing (whether or not payable prior to the Closing) associated with the disposition of the Legacy Business, </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">solely in the event the Wind-Down Activities (as defined herein under &#8220;<font style="font-style: italic;">The Merger Agreement &#8212; Treatment of Legacy Business</font>&#8221;) with respect to any portion of the Legacy Business have been commenced, or are required to be commenced, pursuant to the Merger Agreement, any Wind-Down Costs as set forth in the Wind-Down Schedule (as defined herein under &#8220;<font style="font-style: italic;">The Merger Agreement &#8212; Treatment of Legacy Business</font>&#8221;) with respect to such portion of the Legacy Business, </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">actual costs arising under or in connection with certain matters set forth in Standard BioTools&#8217; disclosure schedule to the Merger Agreement, </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">solely to the extent not provided for in the Wind-Down Schedule, any Specified Cash-Walk Items (as defined herein under &#8220;<font style="font-style: italic;">The Merger Agreement &#8212; Treatment of Legacy Business</font>&#8221;) (it being understood that if Specified Cash-Walk Items are provided for in the Wind-Down Schedule, the treatment thereof in the Wind-Down Schedule will govern in the event of any conflict) and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any unpaid taxes incurred or to be incurred, in a taxable period (or portion thereof) ending on or prior to the Closing Date or otherwise in connection with the Closing, by Standard BioTools and its affiliates, including in connection with the above. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For purposes of the definition of &#8220;Parent Net Cash&#8221; as used in the Merger Agreement, &#8220;Restricted Cash&#8221; means, without duplication, (i) cash of Standard BioTools that has been historically classified as restricted cash by Standard BioTools or that is otherwise required to be classified as restricted cash in accordance with the accounting principles specified in the Merger Agreement, (ii) cash held outside of the United States that is subject to restrictions or penalties, or otherwise cannot be readily repatriated to the United States (by dividend or similar distribution if held by a subsidiary), (iii) cash that is represented by real estate lease deposits, (iv) cash that is held in reserve accounts or third-party escrow accounts, and (v) cash collateralizing any obligation, but excluding restricted cash securing corporate credit card obligations; provided that if any cash would be treated as Restricted Cash pursuant to the foregoing clauses (i) through (v) on account of any of lease, escrow, obligation or other liability reflected as a deduct in the calculation of Parent Net Cash, then such cash will not be treated as Restricted Cash. For purposes of determining the amount of cash to be considered Restricted Cash solely as a result of taxes on repatriation, only the amount of any net taxes payable to repatriate such cash to the United States will be treated as Restricted Cash. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">At least 10 business days before the anticipated Closing Date, Treeline must deliver to Standard BioTools capitalization information required to calculate the Exchange Ratio. At least five business days before the anticipated Closing Date, Standard BioTools must deliver to Treeline a schedule setting forth, in reasonable detail, Standard BioTools&#8217; good faith estimated calculation of its Parent Net Cash and the Exchange Ratio, prepared and certified by Standard BioTools&#8217; chief financial officer. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Within 30 days after the Closing Date, Treeline may dispute any part of the calculations set forth in the schedule by delivering a written notice to that effect to Standard BioTools (referred to herein as a &#8220;dispute notice&#8221;). Any dispute notice must identify in reasonable detail the nature and amounts of any proposed revisions to the schedule. If Treeline delivers a dispute notice, then Standard BioTools and Treeline will attempt in good faith to resolve the disputed items and negotiate an agreed-upon determination of Parent Net Cash.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If Standard BioTools and Treeline are unable to negotiate an agreed-upon determination of Parent Net Cash within 30 calendar days after delivery of the dispute notice, then any remaining disagreements will be referred to an independent auditor of recognized national standing mutually agreed upon by Standard BioTools and Treeline. The determination of the amount of Parent Net Cash made by the independent auditor will be final and binding on Standard BioTools and Treeline and will be deemed to have been finally determined for purposes of the Merger Agreement and to represent the final Parent Net Cash for purposes of the Merger Agreement. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">204<br></div></div></div>
<!--End Page 215-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 216-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_116-agreement_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If the final Parent Net Cash as determined pursuant to the foregoing procedure is less than Parent Net Cash as set forth in Standard BioTools&#8217; schedule, the Exchange Ratio will be recalculated adjusting only such final Parent Net Cash and with no other changes to the components thereof. In such event, each former holder of Treeline Common Stock that was issued and outstanding (other than Excluded Shares and Dissenting Shares) and Treeline Converting Warrants that were outstanding, in each case immediately prior to the Effective Time, will be entitled to receive, without duplication, in respect of each such share of Treeline Common Stock or each share of Treeline Common Stock that would have been received upon the net-exercise of such Treeline Converting Warrants, a number of additional shares of Standard BioTools Common Stock equal to the modified Exchange Ratio minus the original Exchange Ratio. The number of shares of Standard BioTools Common Stock each former holder of Treeline Capital Stock and Treeline Converting Warrants is entitled to receive will be rounded down to the nearest whole share and computed after aggregating all Treeline Capital Stock held by such holder of Treeline Capital Stock. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If the final Parent Net Cash is greater than or equal to Parent Net Cash as set forth in Standard BioTools&#8217; schedule, the Parent Net Cash surplus will be added to the proceeds to be distributed to holders of CVRs pursuant to the terms of the CVR Agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Parent Net Cash balance of Standard BioTools is subject to numerous factors, some of which are outside of the control of Standard BioTools. The actual amount of Parent Net Cash of Standard BioTools will depend significantly on the timing of the Closing. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;"><a name="tTOTS"><!--Anchor--></a>Treatment of Treeline Stock Options </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">At the Effective Time, Treeline&#8217;s 2021 Equity Incentive Plan and each outstanding Treeline Option, whether vested or unvested, without any action on the part of the holder thereof, will be assumed by Standard BioTools. Each such Treeline Option so assumed will continue to have, and be subject to, the same terms and conditions applicable to such Treeline Option immediately prior to the Effective Time, including vesting terms and provisions, except that (1) such Treeline Option will be exercisable for that number of shares of Standard BioTools Common Stock equal to the number of shares of Treeline Common Stock subject to such stock option immediately prior to the Effective Time multiplied by the Exchange Ratio and rounded down to the next nearest share of Standard BioTools Common Stock, and (2) the exercise price per share will be the exercise price per share in effect for such stock option immediately prior to the Effective Time divided by the Exchange Ratio and rounded up to the next nearest cent. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As soon as reasonably practicable following the Closing Date, Standard BioTools will file a registration statement on Form&#160;S-8 (or such other appropriate form, if required) with respect to the offering of the shares of Standard BioTools Common Stock issuable upon the exercise of the assumed Treeline Options and will use reasonable best efforts to maintain the effectiveness of such registration statement thereafter for so long as any of such Treeline Options remain outstanding. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;"><a name="tTOTW"><!--Anchor--></a>Treatment of Treeline Warrants </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">At the Effective Time, each Treeline warrant that has been amended to require net-exercise in connection with the Merger that is outstanding immediately prior to the Effective Time will, by virtue of the Merger and without any action on the part of Treeline or the holder thereof, be cancelled and extinguished and converted into the right to receive, for each share of Treeline Common Stock that would be received upon the net-exercise of such warrant in accordance with its terms (with each share of Treeline Common Stock valued at the Treeline Value Per Share for such purposes), a number of shares of Standard BioTools Common Stock equal to the Exchange Ratio. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, at the Effective Time, each Treeline Warrant that is not a Treeline Converting Warrant and that is outstanding immediately prior to the Effective Time will, by virtue of the Merger and without any action on the part of Treeline or the holder thereof, be assumed by Standard BioTools. Each such warrant so assumed will continue to have and be subject to the same terms and conditions applicable to such warrant immediately prior to the Effective Time, except that (1) such warrant will be exercisable for that number of shares of Standard BioTools Common Stock equal to the number of shares of Treeline Common Stock subject to such warrant immediately prior to the Effective Time multiplied by the Exchange Ratio and rounded down to the next nearest share of Standard BioTools Common Stock and (2) the warrant price per share will be the warrant price per share in effect for such warrant immediately prior to the Effective Time divided by the Exchange Ratio and rounded up to the nearest thousandth of a cent. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">205<br></div></div></div>
<!--End Page 216-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 217-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_116-agreement_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Treatment of Standard BioTools Common Stock </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Except as contemplated by the proposed reverse stock split of issued and outstanding Standard BioTools Common Stock as described in this proxy statement/prospectus, and except for the issuance of one CVR for each share of Standard BioTools Common Stock outstanding, Standard BioTools Common Stock will remain unaffected by the Merger. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Procedures for Exchanging Treeline Common Stock </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Merger Agreement provides that, at the Closing, Standard BioTools will issue and cause to be deposited with Computershare Trust Company, N.A. (the &#8220;Exchange Agent&#8221;) evidence of book entry shares representing the non-certificated shares of Standard BioTools Common Stock issuable in connection with the Merger. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Merger Agreement provides that, promptly (and in any event within two business days) after the Effective Time, the Exchange Agent will mail to (i) each record holder of shares of Treeline Common Stock represented by a certificate (a &#8220;Certificate&#8221;) (other than holders of Excluded Shares or Dissenting Shares) or (ii) each book-entry account representing any uncertificated shares of Treeline Common Stock (&#8220;Uncertificated Shares&#8221;) who is entitled to any payment in respect of Treeline Common Stock held by such holder immediately prior to the Effective Time, a letter of transmittal in customary form specifying that delivery will be effected only upon delivery of the Certificates (or affidavits of loss in lieu thereof) or Uncertificated Shares to the Exchange Agent and instructions for surrendering the Certificates (or affidavits of loss in lieu thereof) or Uncertificated Shares to the Exchange Agent. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Upon surrender of a Certificate (or affidavit of loss in lieu thereof) or an Uncertificated Share to the Exchange Agent in accordance with the terms of such letter of transmittal, the holder will be entitled to receive in exchange therefor the Per Share Merger Consideration and any dividends or other distributions with a record date after the Effective Time which is required to be paid pursuant to the Merger Agreement (in each case less any required tax withholdings). At the Effective Time, all holders of shares of Treeline Common Stock (other than any Excluded Shares) that were issued and outstanding immediately prior to the Effective Time will cease to have any rights as stockholders of Treeline. In addition, from and after the Effective Time, no transfer of shares of Treeline Common Stock will be registered on the stock transfer books of Treeline. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If any Certificate has been lost, stolen or destroyed, in order for the person claiming such Certificate to be lost, stolen or destroyed to receive the shares of Standard BioTools Common Stock and/or dividends or other distributions with a record date after the Effective Time to which such person would otherwise be entitled pursuant to the terms of the Merger Agreement, such person will have to (i) make an affidavit of that fact, and (ii) if required by the Exchange Agent&#8217;s customary practices, enter into an indemnification agreement in customary form providing an indemnity against any claim that may be made against the Exchange Agent with respect to such Certificate. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">From and after the Effective Time, until it is surrendered, each Certificate or Uncertificated Share will represent only the right to receive the Per Share Merger Consideration. Standard BioTools will not pay dividends or other distributions on any shares of Standard BioTools Common Stock to be issued in exchange for any unsurrendered Certificate or Uncertificated Share until such Certificate (or affidavit of loss in lieu thereof) or Uncertificated Share is surrendered as provided in the Merger Agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">HOLDERS OF TREELINE COMMON STOCK SHOULD NOT SEND IN THEIR TREELINE STOCK CERTIFICATES UNTIL THEY RECEIVE A LETTER OF TRANSMITTAL FROM THE EXCHANGE AGENT WITH INSTRUCTIONS FOR THE SURRENDER OF TREELINE STOCK CERTIFICATES. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;"><a name="tBODA"><!--Anchor--></a>Board of Directors and Management Following the Merger </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Pursuant to the Merger Agreement, the combined company&#8217;s board of directors will consist of at least nine members, with between seven and ten such members designated by Treeline in its discretion and two such members designated by Standard BioTools. The composition of the combined company&#8217;s board of directors following the Effective Time in the aggregate is expected to satisfy the requisite independence requirements and SEC rules, as well as the sophistication and independence requirements for the required committees, pursuant to Nasdaq listing requirements. It is anticipated that after the Effective Time, the combined company&#8217;s board of directors will consist of Dr.&#160;Joshua Bilenker, Dr.&#160;Jeffrey Engelman, Kristina Burow, David Bonita, David Schenkein, Steven Elms, Aftab&#160;Kherani, Avi Naider, Ali Satvat and Susan Desmond-Hellmann, each appointed by Treeline, and &#8195;&#8195;&#8195;&#8195; and &#8195;&#8195;&#8195;&#8195;&#8195;, each appointed by Standard BioTools.</div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">206<br></div></div></div>
<!--End Page 217-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 218-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_116-agreement_pg7"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">It is anticipated that the management team of the combined company upon the consummation of the Merger will consist of Treeline&#8217;s management team. In particular, the parties have agreed that Dr.&#160;Joshua Bilenker, currently the chief executive officer and co-founder of Treeline, will serve as Chief Executive Officer of the combined company, Dr.&#160;Jeffrey Engelman, currently the chief scientific officer of Treeline, will serve as Chief Scientific Officer of the combined company, and Spencer Smith, currently the chief financial officer of Treeline, will serve as Chief Financial Officer of the combined company. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Amendment of the Certificate of Incorporation of Standard BioTools </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In the Merger Agreement Standard BioTools agreed to amend its certificate of incorporation to (i) change its name to &#8220;Treeline Biosciences Holdings, Inc.&#8221; or such other name as designated in writing by Treeline no later than five business days prior to the Closing Date and (ii) effect the Reverse Stock Split, if needed. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;"><a name="tCONCOMMER"><!--Anchor--></a>Conditions to the Completion of the Merger </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Each party&#8217;s obligation to complete the Merger and the other transactions contemplated by the Merger Agreement is subject to the satisfaction or waiver (to the extent permitted by applicable law) by each of the parties, as of immediately prior to the Closing, of various conditions, which include the following: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Share Issuance Proposal and the Charter Amendment Proposal must have been approved by the affirmative vote of a majority of the voting power of the shares of Standard BioTools&#8217; capital stock present virtually or represented by proxy at a meeting of Standard BioTools stockholders and entitled to vote on such Proposal at the Special Meeting or the affirmative vote of the holders of Standard BioTools&#8217; capital stock entitled to vote thereon, voting as a single class, by a majority of the votes cast for or against such Proposal at the Special Meeting, as applicable (the &#8220;Standard BioTools Stockholder Approval&#8221;); </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Merger Agreement must have been adopted by the affirmative written consent of the holders of a majority of the outstanding Treeline capital stock entitled to vote thereon and the affirmative written consent of the holders of a majority of Treeline preferred stock entitled to vote thereon (the &#8220;Treeline Stockholder Approval&#8221;); </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">no applicable law, judgment (whether temporary, preliminary or permanent) or other legal restraint or binding order or determination by any governmental entity of competent jurisdiction is in effect that prevents, restrains, enjoins, makes illegal or otherwise prohibits the consummation of the Merger or any of the other transactions contemplated by the Merger Agreement; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the registration statement on Form&#160;S-4 of which this proxy statement/prospectus forms a part, which is being filed by Standard BioTools with the SEC to register certain of the shares of Standard BioTools Common Stock to be issued to the holders of the shares of Treeline Common Stock in connection with the Merger, must have been declared effective by the SEC under the Securities Act of 1933 (as amended, the &#8220;Securities Act&#8221;) and no stop order suspending the effectiveness of such registration statement has been issued and remains in effect and no legal proceedings for that purpose have been initiated or threatened in writing by the SEC unless subsequently withdrawn; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the existing shares of Standard BioTools Common Stock must be listed on Nasdaq as of the Closing Date, and the shares of Standard BioTools Common Stock issuable in connection with the Merger must have been approved for listing on Nasdaq, subject to official notice of issuance; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the waiting period (and any extension thereof) applicable to the Merger or any of the transactions contemplated by the Merger Agreement under the HSR Act shall have expired or been terminated, and any consents, authorizations, clearances and approvals required to be obtained with respect to the Merger or any of the transactions contemplated by the Merger Agreement under the foreign antitrust laws specified in the Merger Agreement shall have been obtained. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, each party&#8217;s obligation to complete the Merger and the other transactions contemplated by the Merger Agreement is further subject to the satisfaction or waiver (to the extent permitted by applicable law) by that party of the following additional conditions: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">(i) each of the representations and warranties of the other party other than the Standard BioTools Fundamental Representations and the Treeline Fundamental Representations (as such terms are defined below), as applicable, must be true and correct (without giving effect to any limitation as to &#8220;materiality&#8221; </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">207<br></div></div></div>
<!--End Page 218-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 219-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_116-agreement_pg8"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_bl" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: left;">or &#8220;material adverse effect&#8221; set forth in the Merger Agreement) at and as of the date of the Merger Agreement and at and as of the Closing Date as if made on and as of the Closing Date (except to the extent in either case expressly made as of an earlier date, in which case as of such earlier date), except where the failure of such representations and warranties to be true and correct (without giving effect to any limitation as to &#8220;materiality&#8221; or &#8220;material adverse effect&#8221; set forth in the Merger Agreement), would not have a material adverse effect on the other party, (ii) the representations and warranties of the other party related to organizational documents, due organization, subsidiaries, capitalization, authority to enter into the Merger Agreement, non-contravention and consents, application of takeover laws, and brokers/finders and, with respect to Standard BioTools only, financial statements and opinion of financial advisor, must be true and correct (A) in all respects, in the case of any such representations and warranties to the extent they are qualified within the text thereof by any &#8220;materiality&#8221; or &#8220;material adverse effect&#8221; qualifications, or (B) in all material respects, in the case of any such representations and warranties to the extent they are not so qualified within the text thereof by any such &#8220;materiality&#8221; or &#8220;material adverse effect&#8221; qualifications, in each case at and as of the date of the Merger Agreement and at and as of the Closing Date as if made on and as of the Closing Date (except to the extent in either case expressly made as of an earlier date, in which case as of such earlier date), (iii) the representations and warranties related to authorized capital stock, warrants, equity plans, absence of certain securities, and, with respect to Treeline, preferred stock, must be true and correct in all respects, except for de minimis inaccuracies, at and as of the date of the Merger Agreement and at and as of the Closing Date as if made at and as of such time (except to the extent expressly made as of an earlier date, in which case as of such earlier date) and (iv) the representations and warranties of the other party related to the existence of a material adverse effect on the other party must be true and correct in all respects at and as of the date of the Merger Agreement and as of the Closing Date as if made on and as of the Closing Date (such representations and warranties referenced in clauses (ii), (iii) and (iv) by Standard BioTools, the &#8220;Standard BioTools Fundamental Representations&#8221; and such representations and warranties referenced in clauses (ii), (iii) and (iv) by Treeline, the &#8220;Treeline Fundamental Representations&#8221;); </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the other party must have performed in all material respects all obligations in the Merger Agreement required to be performed by it at or prior to the Closing; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">there must not have occurred any material adverse effect on the other party after the date of the Merger Agreement; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the other party to the Merger Agreement must have delivered a customary closing certificate to such party certifying that the closing conditions related to the accuracy of representations and warranties, lack of material adverse effect and performance in all material respects of all obligations required to be performed by the other party under the Merger Agreement have been satisfied. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, Standard BioTools&#8217; obligation to effect the Merger and the other transactions contemplated by the Merger Agreement is further subject to the satisfaction or waiver (to the extent permitted by applicable law) by Standard BioTools of the following additional conditions: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Standard BioTools must have received the Treeline Stockholder Written Consent; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Standard BioTools must have received at the Closing a properly executed certification that the Treeline shares are not &#8220;United States real property interests&#8221; in accordance with the Internal Revenue Code; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Treeline must have delivered to Standard BioTools evidence reasonably satisfactory to Standard BioTools that, as of the Effective Time, all of the obligations of Treeline under certain agreements have been terminated without any liability being imposed on the part of Standard BioTools or the Surviving Company. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, Treeline&#8217;s obligation to complete the Merger is further subject to the satisfaction of the following conditions or waiver by Treeline of such additional conditions (to the extent permitted by applicable law): </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Standard BioTools effecting the Standard BioTools Charter Amendment and delivering to Treeline a file-stamped copy of the Standard BioTools Charter Amendment; and </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">208<br></div></div></div>
<!--End Page 219-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 220-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_116-agreement_pg9"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Treeline having received copies of the resignations, effective as of the Effective Time, of each director and officer of Standard BioTools and its subsidiaries other than the Standard BioTools directors who will continue as directors following the Effective Time. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Merger Agreement provides that the following events shall not be considered a material adverse effect to Standard BioTools or Treeline, as applicable: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">general business or economic conditions generally affecting the industry in which such party and its subsidiaries operate; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">political conditions, acts of war, the outbreak or escalation of armed hostilities, acts of terrorism, earthquakes, wildfires, hurricanes, tsunamis, floods, mudslides, weather conditions, other natural disasters, man-made disasters, health and other emergencies, calamities, epidemics, pandemics (including COVID-19 and any evolutions or mutations thereof), disease outbreaks, other acts of God or force majeure events; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">changes in financial, banking or securities markets, including changes in interest rates in the United States or any other country or region in the world and changes in exchange rates for the currencies of any countries and any suspension of trading in securities (whether equity, debt, derivative or hybrid securities) generally on any securities exchange or over-the-counter market operating in the United States or any other country or region in the world; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any change in, or any compliance with or action taken for the purpose of complying with, any law or generally accepted accounting principles (or interpretations thereof); </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any change in the stock price or trading volume of such party&#8217;s common stock (it being understood, however, that any effect causing or contributing to any change in stock price or trading volume may be taken into account in determining whether a material adverse effect has occurred, unless such effects are otherwise excepted from this definition); </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any failure by such party to meet internal or analysts&#8217; expectations or projections or the results of operations of such party (it being understood, however, that any effect causing or contributing to the failure to meet internal or analysts&#8217; expectations or projections or the results of operations of such party may be taken into account in determining whether a material adverse effect has occurred, unless such effects are otherwise excepted from this definition); </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the execution or announcement of the Merger Agreement or the pendency of the Merger and the other transactions contemplated by the Merger Agreement (the &#8220;Transactions&#8221;), including (A) the identity of the other party, (B) the loss or departure of officers or other employees of such party or any of its subsidiaries directly or indirectly resulting from, arising out of, attributable to, or related to the Transactions, and (C) any other negative development (or potential negative development) in the relationships of such party or any of its subsidiaries with business partners, whether as a direct or indirect result of the loss or departure of officers or employees of such party or any of its subsidiaries or otherwise, directly or indirectly resulting from, arising out of, attributable to, or related to the Transactions; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any actions taken or failure to take action, in each case, to which such party has provided its prior written consent; or compliance with the terms of, or the taking of any action required or contemplated by, the Merger Agreement; or the failure to take any action prohibited by the Merger Agreement; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any fees or expenses incurred in connection with the Transactions; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">with respect to Treeline, (A) any results, outcomes, data, adverse events or side effects arising from any clinical trials being conducted by or on behalf of Treeline or any of its subsidiaries or any competitor of Treeline or any of its subsidiaries (or the announcements thereof), (B) results of meetings with the FDA or other governmental entity (including any minutes of, or communications from, any governmental entity in connection with such meetings) with respect to Treeline products, (C) the determination by, or the delay of a determination by, the FDA or any other applicable governmental entity, or any panel or advisory body empowered or appointed thereby, with respect to a clinical hold, acceptance, filing, designation (including de-designation for the accelerated approval pathway), approval, clearance, non-acceptance, hold, refusal to file, refusal to designate, non-approval, disapproval or non-clearance, or requirement to conduct additional clinical studies or trials, with respect to the Treeline products or&#160;(D) FDA approval (or other clinical or </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">209<br></div></div></div>
<!--End Page 220-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 221-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_116-agreement_pg10"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_bl" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: left;">regulatory developments), market entry or pending market entry of any product competitive with or related to any of the Treeline products, or any guidance, announcement or publication by the FDA or other applicable governmental entity relating to Treeline products; or </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any legal proceedings made or brought by any of the current or former stockholders of such party (on their own behalf or on behalf of such party) against Standard BioTools, Merger Sub, Treeline or any of their directors or officers, including legal proceedings arising out of the Merger or in connection with any other Transactions; </div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">provided that, any event referred to in the first, second, third and fourth bullets above may be considered a material adverse effect to such party to the extent disproportionately affecting such party and its subsidiaries, taken as a whole, relative to other similarly situated companies in the industries in which such party and its subsidiaries operate. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Representations and Warranties </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Merger Agreement contains customary representations and warranties of Standard BioTools, Merger Sub and Treeline for a transaction of this type relating to, among other things: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">organizational documents; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">due organization; subsidiaries; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">capitalization; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">authority; binding nature of the Merger Agreement; required votes; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">non-contravention; consents; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">SEC documents (with respect to Standard BioTools and Merger Sub only); </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">financial statements; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">absence of changes; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">absence of undisclosed liabilities; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">title to assets; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">legal proceedings; orders; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">contracts; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">employee and labor matters; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">benefit plans; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">environmental matters; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">taxes; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">intellectual property; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">privacy and data security; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">compliance with laws; permits; regulatory matters; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">insurance; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">real estate; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">registration statement and proxy statement/prospectus; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">transactions with affiliates; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">brokers and finders; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">opinion of financial advisor (with respect to Standard BioTools and Merger Sub only); </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">certain business practices; </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">210<br></div></div></div>
<!--End Page 221-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 222-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_116-agreement_pg11"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">customers and suppliers (with respect to Standard BioTools and Merger Sub only); </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">ownership of common stock; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">ownership and operations of Merger Sub (with respect to Standard BioTools and Merger Sub only). </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The representations and warranties are, in many respects, qualified by materiality and knowledge, and will not survive the Merger, but their accuracy forms the basis of certain of the conditions to the obligations of Standard BioTools and Treeline to complete the Merger, subject to materiality thresholds. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;"><a name="tNOSOL"><!--Anchor--></a>No Solicitation by Treeline </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Merger Agreement provides that, except as described below, Treeline will not, and will cause its and its subsidiaries&#8217; directors, officers, employees, investment bankers, attorneys, accountants and other advisors, agents and representatives not to, directly or indirectly: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">solicit, initiate, induce, knowingly encourage or knowingly facilitate any inquiries or the making of any proposal or offer that constitutes, or could reasonably be expected to lead to, a Treeline Acquisition Proposal (as defined below); </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">participate in any discussions or negotiations or cooperate in any way with any person regarding any Treeline Acquisition Proposal or any inquiry, proposal or offer that could reasonably be expected to lead to a Treeline Acquisition Proposal; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">provide any non-public information or data concerning it or any of its subsidiaries to any person in connection with any Treeline Acquisition Proposal or for the purpose of soliciting, initiating, inducing, encouraging or facilitating a Treeline Acquisition Proposal or any inquiry, proposal or offer that could reasonably be expected to lead to a Treeline Acquisition Proposal; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">enter into any binding or nonbinding letter of intent, term sheet, memorandum of understanding, merger agreement, acquisition agreement, agreement in principle, option agreement, joint venture agreement, partnership agreement, lease agreement or other similar agreement with respect to a Treeline Acquisition Proposal or that could reasonably be expected to lead to a Treeline Acquisition Proposal; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">adopt, approve, declare advisable or recommend or make any public statement approving or recommending any inquiry, proposal or offer that constitutes, or could reasonably be expected to lead to, a Treeline Acquisition Proposal (including by approving any transaction, or approving any person becoming an &#8220;interested stockholder,&#8221; for purposes of Section&#160;203 of the DGCL); </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">take any action or exempt any person (other than Standard BioTools and its subsidiaries) from the restriction on &#8220;business combinations&#8221; or any similar provision contained in applicable takeover laws or its organizational or other governing documents; or </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">resolve, publicly propose or agree to do any of the foregoing actions. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline also agreed that it will, and will cause its subsidiaries and representatives to, immediately cease and cause to be terminated any solicitation, encouragement, discussions and negotiations with any person conducted prior to the date of the Merger Agreement with respect to any Treeline Acquisition Proposal, or inquiry, proposal, or offer that could reasonably be expected to lead to a Treeline Acquisition Proposal, and will promptly terminate access by any such person to any physical or electronic data rooms relating to any such Treeline Acquisition Proposal. Treeline also agreed to, as soon as reasonably practicable after the date of the Merger Agreement and in all events no later than three business days after the date of the Merger Agreement, deliver a written notice to any person it entered into a confidentiality agreement with in anticipation of a Treeline Acquisition Proposal within the last 12 months, to the effect that it will end all discussions and negotiations with such person with respect to any such Treeline Acquisition Proposal and requesting the prompt return or destruction of any confidential information furnished to such person relating to any Treeline Acquisition Proposal. Treeline will also (i) use its reasonable best efforts to have such confidential information returned to it or destroyed, (ii) immediately terminate all physical and electronic data room access provided to any such person or its representatives, and (iii) prohibit any third party (other than Standard BioTools and its representatives) from having access to any physical or electronic data room relating to any possible Treeline Acquisition Proposal. Treeline further agreed to use reasonable best efforts to </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">211<br></div></div></div>
<!--End Page 222-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 223-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_116-agreement_pg12"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">enforce the terms of each confidentiality agreement entered into with any other person. Treeline agreed to not grant any waiver of, or agree to any amendment or modification to, or release any such person from, any such agreement, to permit such person to submit a Treeline Acquisition Proposal. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline also agreed that it will promptly (and, in any event, within 24 hours) notify Standard BioTools (orally and in writing) if (i) any written or other inquiries, proposals or offers with respect to a Treeline Acquisition Proposal or any inquiries, proposals, offers or requests for information relating to or that could reasonably be expected to lead to a Treeline Acquisition Proposal are received by Treeline or any of its representatives, (ii) any person requests non-public information from Treeline or any of its representatives in connection with any Treeline Acquisition Proposal (provided that Treeline will only be required to provide notice once per person under this clause (ii)) or (iii) any discussions or negotiations with respect to or that could reasonably be expected to lead to a Treeline Acquisition Proposal are sought to be initiated with Treeline, indicating, in connection with such notice, the name of such Person and the material terms and conditions of any proposals or offers (including, if applicable, copies of any written requests, proposals or offers, including proposed agreements and other material written communications or, if oral, a summary of the material terms and conditions of such proposal or offer), and thereafter will keep Standard BioTools reasonably informed, on a current basis (and in any event within 24 hours), of any material developments with respect to any such proposals or offers (including any amendments thereto), including by promptly providing copies of any additional requests, proposals or offers, including any drafts of proposed agreements and any amendments thereto and other information set forth above and copies of any written materials provided to such person by Treeline or any of its representatives. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline agreed that it and its subsidiaries will not enter into a confidentiality agreement with any person that would prohibit it from providing any information to Standard BioTools pursuant to the terms of, or otherwise complying with its obligations under the no solicitation or negotiation and notice provisions of, the Merger Agreement; and that it would not provide any information to any other person pursuant to any confidentiality agreement entered into prior to the date of the Merger Agreement unless such person agreed prior to receipt of such information to waive any provision that would prohibit Treeline from providing any information to Standard BioTools pursuant to the terms of the Merger Agreement or otherwise prohibit Treeline from complying with its obligations under the no solicitation or negotiation and notice provisions of the Merger Agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">A &#8220;Treeline Acquisition Proposal&#8221; means any transaction or series of related transactions (other than the Transactions) for: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any acquisition or purchase from Treeline by any person or &#8220;group&#8221; (as defined in or under Section&#160;13(d) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)), directly or indirectly, of more than a 25% interest in the total outstanding securities (or instruments convertible into or exercisable or exchangeable for 25% or more of such securities) of Treeline, including pursuant to a stock purchase, merger, consolidation, tender offer, share exchange or other transaction involving Treeline or any of its subsidiaries; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any merger, consolidation, business combination, share exchange, issuance of securities, acquisition of securities, reorganization, recapitalization or other similar transaction involving Treeline, pursuant to which the stockholders of Treeline immediately preceding such transaction hold less than 75% of the equity interests in the surviving or resulting entity of such transaction or any parent entity thereof; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any sale, lease, exchange, transfer or disposition (in each case, other than in the ordinary course of business) of more than 25% of the assets of Treeline or its subsidiaries (taken as a whole) (measured by the fair market value thereof); or </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any combination of the foregoing. </div></td></tr></table><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">No Solicitation by Standard BioTools </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Merger Agreement provides that, except as described below, and other than a sale, license, transfer or other winding down of Standard BioTools&#8217; Legacy Business, Standard BioTools will not, and will cause its and its subsidiaries&#8217; directors, officers, employees, investment bankers, attorneys, accountants and other advisors, agents and representatives not to, directly or indirectly: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">solicit, initiate, induce, knowingly encourage or knowingly facilitate any inquiries or the making of any proposal or offer that constitutes, or could reasonably be expected to lead to, a Standard BioTools Acquisition Proposal (as defined below); </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">212<br></div></div></div>
<!--End Page 223-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 224-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_116-agreement_pg13"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">participate in any discussions or negotiations or cooperate in any way with any person regarding any Standard BioTools Acquisition Proposal or any inquiry, proposal or offer that could reasonably be expected to lead to a Standard BioTools Acquisition Proposal; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">provide any non-public information or data concerning it or any of its subsidiaries to any person in connection with any Standard BioTools Acquisition Proposal or for the purpose of soliciting, initiating, inducing, encouraging or facilitating a Standard BioTools Acquisition Proposal or any inquiry, proposal or offer that could reasonably be expected to lead to a Standard BioTools Acquisition Proposal; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">enter into any binding or nonbinding letter of intent, term sheet, memorandum of understanding, merger agreement, acquisition agreement, agreement in principle, option agreement, joint venture agreement, partnership agreement, lease agreement or other similar agreement with respect to a Standard BioTools Acquisition Proposal or that could reasonably be expected to lead to a Standard BioTools Acquisition Proposal (other than an Acceptable Confidentiality Agreement (as defined below)); </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">adopt, approve, declare advisable or recommend or make any public statement approving or recommending any inquiry, proposal or offer that constitutes, or could reasonably be expected to lead to, a Standard BioTools Acquisition Proposal (including by approving any transaction, or approving any person becoming an &#8220;interested stockholder,&#8221; for purposes of Section&#160;203 of the DGCL); </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">take any action or exempt any person (other than Treeline and its subsidiaries) from the restriction on &#8220;business combinations&#8221; or any similar provision contained in applicable takeover laws or its organizational or other governing documents; or </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">resolve, publicly propose or agree to do any of the foregoing actions. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Standard BioTools also agreed that it will, and will cause its subsidiaries and representatives to, immediately cease and cause to be terminated any solicitation, encouragement, discussions and negotiations with any person conducted prior to the date of the Merger Agreement with respect to any Standard BioTools Acquisition Proposal, or inquiry, proposal, or offer that could reasonably be expected to lead to a Standard BioTools Acquisition Proposal, and will promptly terminate access by any such person to any physical or electronic data rooms relating to any such Standard BioTools Acquisition Proposal. Standard BioTools also agreed to, as soon as reasonably practicable after the date of the Merger Agreement and in all events no later than three business days after the date of the Merger Agreement, deliver a written notice to any person it entered into a confidentiality agreement with in anticipation of a Standard BioTools Acquisition Proposal within the last 12 months, to the effect that it will end all discussions and negotiations with such person with respect to any such Standard BioTools Acquisition Proposal and requesting the prompt return or destruction of any confidential information furnished to such person relating to any Standard BioTools Acquisition Proposal. Standard BioTools will also (i) use its reasonable best efforts to have such confidential information returned to it or destroyed, (ii) immediately terminate all physical and electronic data room access provided to any such person or its representatives, and (iii) prohibit any third party (other than Treeline and its representatives) from having access to any physical or electronic data room relating to any possible Standard BioTools Acquisition Proposal. Standard BioTools further agreed to use reasonable best efforts to enforce the terms of each confidentiality agreement entered into with any other person. Standard BioTools agreed to not grant any waiver of, or agree to any amendment or modification to, or release any such person from, any such agreement, to permit such person to submit a Standard BioTools Acquisition Proposal, unless in any such case the Standard BioTools Board shall have determined, in good faith, after consultation with outside legal counsel, that the failure to take such actions would be inconsistent with the fiduciary duties of the Standard BioTools board of directors to the holders of Standard BioTools&#8217; capital stock under applicable law. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Notwithstanding the foregoing, prior to the time, but not after, the Standard BioTools Stockholder Approval is obtained, Standard BioTools may, in response to a bona fide written Standard BioTools Acquisition Proposal (which proposal was made after the date of the Merger Agreement and has not been withdrawn) which did not result from a breach of solicitation and negotiation provisions of the Merger Agreement and so long as it has provided written notice to Treeline of the identity of such person or group making the Standard BioTools Acquisition Proposal, the material terms and conditions of such proposal (including, if applicable, copies of any material written communications) and its intention to engage or participate in any discussions or negotiations with any such person or group, (i) provide access to non-public information regarding Standard BioTools or any of its subsidiaries to the person or group making the proposal (provided that such information has previously been made available to Treeline or is provided to Treeline substantially concurrently with the making of such information available to such person or </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">213<br></div></div></div>
<!--End Page 224-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 225-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_116-agreement_pg14"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">group and that, prior to furnishing any such non-public information, Standard BioTools receives from the person or group making such Standard BioTools Acquisition Proposal an executed confidentiality agreement with terms at least as restrictive in all material respects (including with respect to confidentiality and restrictions on use) on such person(s) as the confidentiality agreement with Treeline (an &#8220;Acceptable Confidentiality Agreement&#8221;)) (it being understood that such confidentiality agreement need not include a &#8220;standstill&#8221; agreement or prohibit the making or amending of a Standard BioTools Acquisition Proposal), and (ii) engage or participate in any discussions or negotiations with any such person or group regarding such proposal if, and only if, prior to taking any action described in clause (i) or (ii) above, the Standard BioTools Board determines in good faith after consultation with outside financial advisors and outside legal counsel that (x) such Standard BioTools Acquisition Proposal either constitutes a Standard BioTools Superior Proposal or could reasonably be expected to result in a Standard BioTools Superior Proposal and (y) the failure to take such action would reasonably be expected to be inconsistent with the fiduciary duties of the Standard BioTools board of directors to the holders of Standard BioTools&#8217; capital stock under applicable law. Standard BioTools is required to provide Treeline with an accurate and complete copy of the Acceptable Confidentiality Agreement promptly (and in any event within 24 hours) after the execution thereof. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Standard BioTools also agreed that it will promptly (and, in any event, within 24 hours) notify Treeline (orally and in writing) if (i) any written or other inquiries, proposals or offers with respect to a Standard BioTools Acquisition Proposal or any inquiries, proposals, offers or requests for information relating to or that could reasonably be expected to lead to a Standard BioTools Acquisition Proposal are received by Standard BioTools or any of its representatives, (ii)&#160;any person requests non-public information from Standard BioTools or any of its representatives in connection with any Standard BioTools Acquisition Proposal (provided that Standard BioTools will only be required to provide notice once per person under this clause (ii)) or (iii) any discussions or negotiations with respect to or that could reasonably be expected to lead to a Standard BioTools Acquisition Proposal are sought to be initiated with Standard BioTools, indicating, in connection with such notice, the name of such person and the material terms and conditions of any proposals or offers (including, if applicable, copies of any written requests, proposals or offers, including proposed agreements and other material written communications or, if oral, a summary of the material terms and conditions of such proposal or offer), and thereafter shall keep Treeline reasonably informed, on a current basis (and in any event within 24 hours), of any material developments with respect to any such proposals or offers (including any amendments thereto), including by promptly providing copies of any additional requests, proposals or offers, including any drafts of proposed agreements and any amendments thereto and other information set forth above and copies of any written materials provided to such person by Standard BioTools or any of its representatives. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Standard BioTools agreed that it and its subsidiaries will not enter into a confidentiality agreement with any person that would prohibit it from providing any information to Treeline pursuant to the terms of, or otherwise complying with its obligations under the no solicitation or negotiation and notice provisions of, the Merger Agreement; and that it would not provide any information to any other person pursuant to any confidentiality agreement entered into prior to the date of the Merger Agreement unless such person agreed prior to receipt of such information to waive any provision that would prohibit Standard BioTools from providing any information to Treeline pursuant to the terms of the Merger Agreement or otherwise prohibit Standard BioTools from complying with its obligations under the no solicitation or negotiation and notice provisions of the Merger Agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">A &#8220;Standard BioTools Acquisition Proposal&#8221; means any transaction or series of related transactions (other than the Transactions) for: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any acquisition or purchase from Standard BioTools by any person or &#8220;group&#8221; (as defined in or under Section&#160;13(d) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)), directly or indirectly, of more than a 15% interest in the total outstanding securities (or instruments convertible into or exercisable or exchangeable for 15% or more of such securities) of Standard BioTools, including pursuant to a stock purchase, merger, consolidation, tender offer, share exchange or other transaction involving Standard BioTools or any of its subsidiaries; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any tender offer (including self-tender) or exchange offer that if consummated would result in any person or &#8220;group&#8221; (as defined in or under Section&#160;13(d) of the Exchange Act) beneficially owning 15% or more of the total outstanding securities (or instruments convertible into or exercisable or exchangeable for 15% or more of such securities) of Standard BioTools; </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">214<br></div></div></div>
<!--End Page 225-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 226-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_116-agreement_pg15"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any merger, consolidation, business combination, share exchange, issuance of securities, acquisition of securities, reorganization, recapitalization or other similar transaction involving Standard BioTools, pursuant to which the stockholders of Standard BioTools immediately preceding such transaction hold less than 85% of the equity interests in the surviving or resulting entity of such transaction or any parent entity thereof; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any sale, lease, exchange, transfer or disposition (in each case, other than in the ordinary course of business) of more than 15% of the assets of Standard BioTools or its subsidiaries (taken as a whole) (measured by the fair market value thereof); or </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any combination of the foregoing. </div></td></tr></table><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;"><a name="tSBIOCIR"><!--Anchor--></a>No Standard BioTools Change in Recommendation or Standard BioTools Alternative Acquisition Agreement </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Except as provided below, the Standard BioTools Board and each committee thereof may not (i)(A) withhold, withdraw, qualify or modify (or propose or resolve to withhold, withdraw, qualify or modify), in a manner adverse to Treeline, its recommendation to Standard BioTools&#8217; stockholders to approve the Share Issuance and the Charter Amendment (the &#8220;Standard BioTools Board Recommendation&#8221;), (B) approve, recommend or otherwise declare advisable (or propose or resolve to approve, recommend or otherwise declare advisable) any Standard BioTools Acquisition Proposal or (C) remove the Standard BioTools Board Recommendation from or fail to include the Standard BioTools Board Recommendation in the proxy statement/prospectus (each, a &#8220;Standard BioTools Change in Recommendation&#8221;) or (ii) approve, recommend or declare advisable, or propose to approve, recommend or declare advisable, or cause or permit Standard BioTools or any of its subsidiaries to enter into any letter of intent, term sheet, memorandum of understanding, agreement in principle, acquisition agreement, merger agreement, option agreement, joint venture agreement, partnership agreement, lease agreement or other similar agreement (other than an Acceptable Confidentiality Agreement) relating to or that could reasonably be expected to lead to any Standard BioTools Acquisition Proposal or any agreement requiring Standard BioTools (or that would require or could reasonably be expected to require Standard BioTools) to abandon, terminate, delay or fail to consummate the Merger or any other transaction contemplated by the Merger Agreement or that would otherwise materially impede, interfere with or be inconsistent with, the Transactions (a &#8220;Standard BioTools Alternative Acquisition Agreement&#8221;). </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Notwithstanding the foregoing, following receipt of a bona fide written Standard BioTools Acquisition Proposal by Standard BioTools after the date of the Merger Agreement that did not result from a breach of the no solicitation provisions of the Merger Agreement and with respect to which Standard BioTools has received a written, definitive form of Standard BioTools Alternative Acquisition Agreement that has not been withdrawn and has been determined by the Standard BioTools Board in good faith, after consultation with outside financial advisors and outside legal counsel, to constitute a Standard BioTools Superior Proposal, the Standard BioTools board of directors may, at any time prior to the time the Standard BioTools Stockholder Approval is obtained, make a Standard BioTools Change in Recommendation, if all of the following conditions are met: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Standard BioTools provided Treeline with four business days&#8217; prior written notice, which notice shall contain certain required information as further specified in the Merger Agreement; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">prior to making such Standard BioTools Change in Recommendation, Standard BioTools engaged, and used its reasonable best efforts to cause its representatives to engage, in good faith negotiations with Treeline, during such four-business day notice period to consider adjustments to the terms and conditions of the Merger Agreement or other proposals that may be proposed in writing by Treeline during such notice period such that the Standard BioTools Alternative Acquisition Agreement would cease to constitute a Standard BioTools Superior Proposal; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Standard BioTools Board determined in good faith, after consultation with outside financial advisors and outside legal counsel, that, in light of such Standard BioTools Acquisition Proposal and taking into account any revised terms proposed in writing by Treeline and the results of the negotiations contemplated by the preceding bullet, such Standard BioTools Acquisition Proposal continues to constitute a Standard BioTools Superior Proposal and, after consultation with outside legal counsel, that the failure to make such Standard BioTools Change in Recommendation would reasonably be expected to be inconsistent with the fiduciary duties of the Standard BioTools Board to its stockholders under applicable law. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">A &#8220;Standard BioTools Superior Proposal&#8221; means any bona fide, written Standard BioTools Acquisition Proposal on terms which the Standard BioTools Board determines in its good faith judgment, after consultation with outside financial </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">215<br></div></div></div>
<!--End Page 226-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 227-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_116-agreement_pg16"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">advisors and outside legal counsel, would reasonably be expected to be consummated in accordance with its terms, taking into account all legal, financial and regulatory aspects of the proposal and the person or group of persons making the proposal, and, if consummated, would result in a transaction more favorable to Standard BioTools&#8217; stockholders from a financial point of view than the Merger (after taking into account any revisions to the terms of the Transactions and the time likely to be required to consummate such Standard BioTools Acquisition Proposal); provided that for purposes of the definition of &#8220;Standard BioTools Superior Proposal&#8221;, the references to &#8220;15%&#8221; in the definition of Standard BioTools Acquisition Proposal shall be deemed to be references to &#8220;50%.&#8221; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, notwithstanding the foregoing, the Standard BioTools Board may make a Standard BioTools Change in Recommendation upon the occurrence of a Standard BioTools Intervening Event (as defined below) prior to receipt of the Standard BioTools Stockholder Approval if: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Standard BioTools provided Treeline with four business days&#8217; prior written notice, which notice shall contain certain required information as further specified in the Merger Agreement; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Standard BioTools engaged in good faith negotiations with Treeline during such four business day notice period to consider adjustments to the terms and conditions of the Merger Agreement or other proposals that may be proposed in writing by Treeline during such notice period such that the failure of the Standard BioTools Board to make a Standard BioTools Change in Recommendation in response to the Standard BioTools Intervening Event would no longer be inconsistent with the fiduciary duties of the Standard BioTools Board to its stockholders under applicable law; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Standard BioTools Board determined in good faith, after consultation with outside financial advisors and outside legal counsel, that, in light of such Standard BioTools Intervening Event and taking into account any revised terms proposed in writing by Treeline and the results of the negotiations contemplated by the preceding bullet, that the failure of the Standard BioTools Board to make a Standard BioTools Change in Recommendation would be inconsistent with the fiduciary duties of the Standard BioTools Board to its stockholders under applicable law; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Standard BioTools&#8217; obligation to call, give notice of and hold the special meeting of stockholders shall not be limited or otherwise affected by the commencement, disclosure, announcement or submission of any Standard BioTools Superior Proposal or Standard BioTools Acquisition Proposal or by any Standard BioTools Change in Recommendation. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;Standard BioTools Intervening Event&#8221; means any effect that is material to Standard BioTools and its subsidiaries taken as a whole, occurring or arising after the date of the Merger Agreement that (i) was not known to, or reasonably foreseeable by, the Standard BioTools Board (or, if known, the magnitude or effect of which was not known to, or reasonably foreseeable) prior to the execution of the Merger Agreement, which effect (or the magnitude or effect thereof) becomes known to, or reasonably foreseeable by, the Standard BioTools Board prior to the receipt of Standard BioTools Stockholder Approval and (ii) does not relate to (A) a Standard BioTools Acquisition Proposal or (B) (1) any changes in the market price or trading volume of Standard BioTools, (2) the mere fact Treeline or Standard BioTools meets or exceeds any internal or analysts&#8217; published projections, forecasts, estimates or predictions of revenue, earnings or other financial or operating metrics for any period ending on or after the date of the Merger Agreement, or changes after the date of the Merger Agreement in the market price or trading volume of the Standard BioTools Common Stock or the credit rating of Standard BioTools (provided, that any facts or occurrences giving rise or contributing to such change or event may be taken into account when determining a Standard BioTools Intervening Event), (3) any events or developments relating to Treeline or any of its affiliates, (4)&#160;any event or development generally affecting the industries in which Standard BioTools or Treeline operate or in the economy generally or other general business, financial, market or political conditions, including changes in interest rates in the United States or any other country or region in the world and changes in exchange rates for the currencies of any countries and any suspension of trading in securities (whether equity, debt, derivative or hybrid securities) generally on any securities exchange or over-the-counter market operating in the United States or any other country or region in the world, (5) any change in any applicable law or other legal or regulatory conditions or changes in GAAP or other accounting standards, (6) any event or development to the extent directly resulting from the announcement or pendency of, or any actions required to be taken by Standard BioTools or Treeline (or refrained to be taken by Standard BioTools or Treeline) pursuant to the Merger Agreement or the consummation of the Transactions, including expiration or termination of waiting periods or the receipt of approvals, consents or clearances applicable to the Merger under antitrust laws, (7) earthquakes, hurricanes, tsunamis, tornadoes, floods, </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">216<br></div></div></div>
<!--End Page 227-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 228-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_116-agreement_pg17"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">mudslides, wildfires or other natural disasters, weather conditions and other force majeure events or (8) any legal proceedings made or brought by any of the current or former stockholders of Standard BioTools or Treeline (on their own behalf or on behalf of Standard BioTools or Treeline) against Standard BioTools or Treeline, including legal proceedings arising out of the Transactions. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Stockholder Approvals </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Unless the Merger Agreement is terminated in accordance with the terms of the Merger Agreement, Standard BioTools is obligated under the Merger Agreement to establish the record date for, duly call, give notice of and use its reasonable best efforts to convene and hold the Special Meeting to consider and vote upon the Share Issuance, the Charter Amendment, and any Legacy Transaction that requires the approval of Standard BioTools stockholders, which meeting will take place within 45 days after the declaration of the effectiveness of the Registration Statement. Standard BioTools agreed in the Merger Agreement to use its reasonable best efforts to hold the Special Meeting as soon as practicable after the date on which the Registration Statement becomes effective. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Immediately after the execution of the Merger Agreement, Treeline agreed to take all action necessary to obtain the Treeline Stockholder Written Consent constituting the Treeline Stockholder Approval. On June&#160;6, 2026, Treeline obtained the Treeline Stockholder Written Consent. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Promptly following receipt of the Treeline Stockholder Approval, Treeline agreed to prepare and mail a notice to every stockholder of Treeline that did not execute a written consent substantially concurrently with the execution and delivery of the Merger Agreement. The notice will be a statement to the effect that the Treeline Board determined that the Merger is advisable in accordance with the DGCL and in the best interests of the stockholders of Treeline, will provide the stockholders of Treeline to whom it is sent with notice of the actions taken in the Treeline Stockholder Written Consent, including the adoption and approval of the Merger Agreement, the Merger and the other Transactions, and will include a description of the appraisal rights of Treeline&#8217;s stockholders available under the DGCL. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;"><a name="tCCBPM"><!--Anchor--></a>Covenants; Conduct of Business Pending the Merger </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Each of Standard BioTools and Treeline agreed that during the period from the date of the Merger Agreement to the earlier of the termination of the Merger Agreement in accordance with its terms and the Effective Time (the &#8220;Pre-Closing Period&#8221;), it will, and cause each of its subsidiaries to, (A) in the case of Treeline, (i) conduct its business in all material respects in the ordinary course of its normal operations and consistent in all material respects with past practices (the &#8220;Ordinary Course of Business&#8221;) and (ii) use commercially reasonable efforts to preserve intact the material components of its present business organization, keep available the services of its present officers and key employees in all material respects, preserve its relationships with manufacturers, suppliers, vendors, distributors, governmental entities, customers, licensors, licensees and others with which it has material business dealings, comply in all material respects with all applicable laws and maintain in effect all permits necessary to the conduct of such party&#8217;s business in accordance with their terms and renew any such permits that would otherwise expire pursuant to their terms, and (B) in the case of Standard BioTools, (i) conduct its business in all material respects in the Ordinary Course of Business and (ii) use commercially reasonable efforts to comply in all material respects with all applicable laws, in each case, except (a) as set forth in the disclosure schedules (the &#8220;Disclosure Schedules&#8221;) delivered by Standard BioTools or Treeline, as applicable, pursuant to the Merger Agreement, (b) as expressly permitted or required by the Merger Agreement (including Wind-Down Activities and any Legacy Transaction conducted in accordance with the Merger Agreement), (c) as required by applicable law or (d) as may be consented to in writing by the other party, which consent shall not be unreasonably withheld, delayed or conditioned. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Each of Standard BioTools and Treeline also agreed that, subject to certain limited exceptions, without the consent of the other party, it will not, and will not permit any of its subsidiaries to, during the Pre-Closing Period (except as set forth in such party&#8217;s Disclosure Schedules, expressly permitted by or required in accordance with the Merger Agreement (including Wind-Down Activities and any Legacy Transaction conducted in accordance with the Merger Agreement) or as required by applicable laws): </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">establish a record date for, declare, accrue, set aside or pay any dividend or make any other distribution (whether in cash, stock or property) in respect of any shares of its capital stock or other equity interests or securities or repurchase (other than in the case of Standard BioTools the issuance of the Closing Dividend and the completion of the Reverse Stock Split in accordance with the Merger Agreement), redeem or </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">217<br></div></div></div>
<!--End Page 228-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 229-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_116-agreement_pg18"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_bl" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: left;">otherwise reacquire any shares of its capital stock or other equity interests or securities (except repurchases from terminated employees, directors or consultants of such party or in connection with the payment of the exercise price and/or withholding taxes incurred upon the exercise, settlement or vesting of any award or purchase rights granted under such party&#8217;s equity compensation plans in accordance with the terms of such award in effect on the date of the Merger Agreement); </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">sell, issue, grant, modify, reprice, amend, pledge or otherwise dispose of or encumber or authorize: (1) any capital stock or other equity interests or security of such party or any of its subsidiaries (except for shares of such party&#8217;s common stock issued upon the valid exercise or conversion of outstanding options or warrants or settlement of outstanding RSUs) (other than the amendment of any Treeline warrant to become a Treeline Converting Warrant); (2) any option, warrant or right to acquire any capital stock or any other equity interests or security (other than Treeline options granted to (A) new employees who were offered a specific number of Treeline options as part of their offer letters entered into prior to the date of the Merger Agreement or, in the Ordinary Course of Business, after the date of the Merger Agreement and (B)&#160;existing employees in the Ordinary Course of Business as annual incentive compensation) or (3) any instrument convertible into or exchangeable for any capital stock or other equity interests or security of such party or any of its subsidiaries (or, in the case of Standard BioTools, Merger Sub); </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">except as required by the terms of the Merger Agreement, adopt, amend, terminate or waive or propose to adopt, amend, terminate or waive such party&#8217;s or its subsidiaries&#8217; organizational documents, or effect or be a party to any merger, consolidation, share exchange, business combination, recapitalization, reclassification of shares, stock split, reverse stock split or similar transaction except for the Transactions; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">except as required by the terms of the Merger Agreement, amend, terminate or waive or propose to amend, terminate or waive any of such party&#8217;s equity plans, any provision of any agreement regarding any of such party&#8217;s outstanding stock options, restricted stock unit grant, or performance-based vesting restricted stock unit grant, or otherwise modify any of the terms of any outstanding option, restricted stock unit, warrant or other equity interest or security or any related contract; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">adopt or implement any stockholder rights plan or similar arrangement; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">form any subsidiary or acquire or propose to acquire any equity interest or other interest in, or business of, any other entity or enter into a joint venture with any other entity; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">lend money to any person (except for the advancement of expenses to employees, directors and consultants in the Ordinary Course of Business), (2) incur or guarantee any indebtedness for borrowed money, (3)&#160;guarantee any debt securities of others, (4) other than the incurrence or payment of transaction expenses, make any capital expenditure (in the case of Treeline, in excess of $3&#160;million in the aggregate), or (5) make any investment in, including by way of capital contribution or acquisition of equity interests or debt securities of, any person; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">in the case of Treeline, other than in the Ordinary Course of Business and, in the case of Standard BioTools, other than as required by applicable law or the terms of any employee benefit plan as in effect on the date of the Merger Agreement: (1) adopt, terminate, establish or enter into any employee benefit plan; (2) cause or permit any employee benefit plan to be amended in any material respect; or (3) increase or modify the amount or form of the wages, salary, commissions, or bonus compensation payable to any of its directors, officers or employees; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">recognize any labor union or labor organization, or enter into any collective bargaining agreement, or take any similar actions with respect to any employee, group of employees, or representative of any employees; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">in the case of Standard BioTools, hire any employee or contractor, other than to fill vacancies caused by the termination of employees and contractors whose employment or engagement is terminated after the date of the Merger Agreement; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">acquire any material asset (other than intellectual property rights); </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">in the case of Treeline, (A) sell, lease or otherwise irrevocably dispose of any of its material assets or properties (other than intellectual property rights), or (B) grant any lien with respect to such assets or properties, except in the Ordinary Course of Business; </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">218<br></div></div></div>
<!--End Page 229-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 230-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_116-agreement_pg19"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">in the case of Treeline, (A) sell, assign, transfer, license, sublicense, grant any lien (other than certain permitted liens) with respect to or otherwise dispose of any material intellectual property (in each case, other than pursuant to non-exclusive licenses granted in the ordinary course of business or pursuant to a collaboration agreement) or (B) cancel, fail to refile a provisional application after abandonment, fail to renew or extend, or fail to diligently prosecute (including making any filing, pay any fee, or take any other action necessary to prosecute and maintain) any intellectual property (in the case of licensed intellectual property, solely to the extent that Treeline or any of its subsidiaries has rights to control, prosecution and maintenance thereof), except, for each of the foregoing, in the ordinary course of prosecution upon exercise of reasonable business judgment by Treeline or the lapse or expiry of intellectual property at the end of its statutory term; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">in the case of Standard BioTools, (A) sell, assign, transfer, license, sublicense or grant any lien (other than certain permitted liens) with respect to or otherwise dispose of any material intellectual property (in each case, other than pursuant to non-exclusive licenses granted in the Ordinary Course of Business) or otherwise dispose of any intellectual property, or (B) cancel, fail to refile a provisional application after abandonment, fail to renew or extend or fail to diligently prosecute (including making any filing, pay any fee, or take any other action necessary to prosecute and maintain) any material intellectual property (in the case of any licensed intellectual property, solely to the extent that Standard BioTools or any of its subsidiaries has rights to control the prosecution and maintenance thereof), except, for each of the foregoing, in the ordinary course of prosecution upon exercise of reasonable business judgment by Standard BioTools or the lapse or expiry of intellectual property at the end of its statutory term; provided that the prior written consent of Treeline (not to be unreasonably withheld, conditioned or delayed) will be required prior to Standard BioTools&#8217; entry into any definitive agreement, or binding term sheet or letter of intent, relating to any Legacy Transaction involving the actions described in this provision; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">disclose to any third party (other than pursuant to written confidentiality obligations, as required by applicable law, or, in the case of Treeline, in the ordinary course of conducting clinical trials or other clinical research activities subject to contractual or statutory confidentiality obligations) or otherwise fail to preserve and maintain, any material trade secrets, know-how, methods, protocols, specifications, techniques, data or other confidential information or ideas; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">make, change or revoke any material tax election, fail to pay any income or other material tax as such tax becomes due and payable, file any amendment making any material change to any tax return, settle or compromise any income tax or other material tax liability or submit any voluntary disclosure application, enter into any tax allocation, sharing, indemnification or other similar agreement or arrangement (other than commercial contracts entered into in the Ordinary Course of Business the principal subject matter of which is not the allocation of taxes), request or consent to any extension or waiver of any limitation period with respect to any claim or assessment for any income tax or other material taxes (other than pursuant to an extension of time to file any tax return granted in the Ordinary Course of Business of not more than seven months), or adopt or change any material accounting method in respect of taxes; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">materially amend, terminate or expressly release any material rights under any material contract, or enter into (and, in the case of Standard BioTools, renew or extend the term of) any contract that is or would be considered a material contract under specified clauses of the definition of &#8220;material contract&#8221; if in effect on the date hereof; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">in the case of Standard BioTools, fail to pay accounts payable and other obligations when due (or, if earlier, the date that such account payable or other obligation would typically be paid by Standard BioTools in the Ordinary Course of Business), or accelerate the collection of accounts receivable; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">in the case of Standard BioTools, make any expenditures, incur any liabilities or discharge or satisfy any liabilities greater than $100,000 in each case, other than those expenditures or liabilities that will not survive the Closing, are discharged or satisfied prior to the Closing, and/or are taken into account in the calculation of Parent Net Cash; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">in the case of Standard BioTools, following the delivery to Treeline of the schedule of Parent Net Cash as required by the Merger Agreement, incur any liability, obligation or commitment that would result in a reduction of Parent Net Cash as of the Closing by more than $50,000 in the aggregate; </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">219<br></div></div></div>
<!--End Page 230-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 231-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_116-agreement_pg20"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">other than as required by law or GAAP, take any action to change accounting policies or procedures; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">settle or compromise any legal proceeding other than solely for monetary damages (net of insurance proceeds received) not in excess of $200,000 individually or $1,000,000 in the aggregate; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">enter into or amend any contract if such contract or amendment would reasonably be expected to prevent or materially impede, interfere with, hinder or delay the consummation of the Transactions; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">fail to maintain in full force and effect the existing insurance policies or to renew or replace such insurance policies with comparable insurance policies; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">dissolve or liquidate such party or any of its subsidiaries; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">in the case of Standard BioTools, enter into any new line of business outside Standard BioTools&#8217; existing business; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">make any payment or loan to, or enter into any agreement, arrangement or understanding with, any of its stockholders, directors, managers, officers or other affiliates; or </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">agree, resolve or commit to do any of the foregoing. </div></td></tr></table><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;"><a name="tREG1A"><!--Anchor--></a>Regulatory Approvals Required for the Merger </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Each of Standard BioTools and Treeline agreed: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">that each party will, and will cause each of its subsidiaries and affiliates to, use its reasonable best efforts to take, or cause to be taken, all actions and to do, or cause to be done, all things necessary, proper or advisable under applicable laws in connection with the Merger and the Transactions; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">that each party will use reasonable best efforts to (i) prepare and file, as promptly as possible, but not later than 15 business days after the date of the Merger Agreement as it relates to the HSR Act, any and all documentation to effect all necessary filings required by applicable antitrust laws with respect to the Merger, (ii) deliver as promptly as practicable to the appropriate governmental entities any additional information and documentary material that may be requested by any governmental entity in connection with the Merger, and (iii) obtain, as promptly as practicable, all consents, clearances and approvals required to be obtained from any governmental entity that are necessary, proper or advisable to consummate the Merger, including by advocating for antitrust clearance; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">to the extent permitted by applicable law, each party will promptly advise the other party of any material communication between it or its affiliates and any governmental entity regarding the Merger or otherwise materially affecting its ability to timely consummate the Merger; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">each party will consult and cooperate with the other party, and consider in good faith the views of the other party, in connection with, and provide to the other in advance (to the extent legally permissible), any analyses, presentations, memoranda, briefs, arguments, opinions and proposals made or submitted by or on behalf of any party to the Merger Agreement in connection with proceedings under or relating to antitrust laws; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">each party will (i) promptly notify the other party of all meetings or substantive communications with any governmental entity relating to any antitrust laws, and give the other party an opportunity to participate in each of such meetings, (ii) promptly notify the other party of all substantive oral and written communications with any governmental entity related to any antitrust laws, (iii) provide the other party with a reasonable advance opportunity to review and comment upon all written communications with a governmental entity regarding antitrust laws and (iv) provide the other party with copies of all written communications from any governmental entity relating to any antitrust laws; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">each party will, and will cause each of its subsidiaries and affiliates to, take reasonable actions necessary to obtain any consents, clearances or approvals required under or in connection with antitrust laws to expeditiously close the Merger or the other transactions contemplated by the Merger Agreement (and in any event by or prior to the termination date of the Merger Agreement); provided that, notwithstanding the </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">220<br></div></div></div>
<!--End Page 231-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 232-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_116-agreement_pg21"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_bl" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: left;">foregoing, neither party will be required to take, or agree or commit to take any actions that would reasonably be expected to have, individually or in the aggregate, a material and adverse effect on Standard BioTools and its subsidiaries (including Treeline after giving effect to the Closing), taken as a whole, after the Closing; </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">each party will bear its own expenses and costs incurred by such party in connection with any filings and submissions pursuant to antitrust laws; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">each party will use reasonable best efforts to obtain any consents, approvals or waivers of third parties requested by the other party to the Merger Agreement with respect to any contracts to which such party is a party as may be necessary for consummation of the Transactions or required by the terms of such contract as a result of the Merger or the other Transactions; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">each party will not, and will cause each of its subsidiaries and affiliates not to, acquire or agree to acquire any rights, interests, assets, business, person or division thereof (through acquisition, license, joint venture, collaboration or otherwise) or take any other actions, if such acquisition or action would reasonably be expected to (i) prevent, materially delay, or adversely affect in any material respect the ability of Standard BioTools and its affiliates or Treeline to consummate the Merger or any of the Transactions, or (ii) cause any party to be required to obtain any clearances, consents, approvals, waivers, waiting period expirations or terminations, non-actions or other authorizations under any laws with respect to the Merger or the other transactions contemplated by the Merger Agreement. </div></td></tr></table><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Indemnification; Directors&#8217; and Officers&#8217; Insurance </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Each of Standard BioTools and the Surviving Company have agreed in the Merger Agreement, jointly and severally, from the Effective Time through the sixth anniversary of the date on which the Effective Time occurs, to indemnify and hold harmless each person who is now, or has been at any time prior to the date hereof, or who becomes prior to the Effective Time, a director or officer of Standard BioTools or Treeline or any of their respective subsidiaries (each, an &#8220;indemnified person&#8221;) against all claims, losses, liabilities, damages, judgments, fines and reasonable fees, costs and expenses, including attorneys&#8217; fees and disbursements, incurred in connection with any claim, action, suit, proceeding or investigation, whether civil, criminal, administrative or investigative, arising out of or pertaining to the fact that the indemnified person is or was a director or officer of Standard BioTools or Treeline or any of their respective subsidiaries, whether asserted or claimed prior to, at or after the Effective Time, to the fullest extent permitted under applicable law (including the DGCL).</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Merger Agreement provides that each indemnified person will be entitled to advancement of expenses (including attorneys&#8217; fees) incurred in the defense of any such claim, action, suit, proceeding or investigation from each of Standard BioTools and the Surviving Company, jointly and severally, upon receipt by Standard BioTools or the Surviving Company from the indemnified person of a request therefor; provided that any person to whom expenses are advanced provides an undertaking, to the extent then required by the DGCL, to repay such advances if it is ultimately determined that such person is not entitled to indemnification. From the Effective Time through the sixth anniversary of the date on which the Effective Time occurs, the Treeline certificate of incorporation and the Surviving Company bylaws will contain provisions no less favorable than the provisions relating to indemnification, advancement of expenses and elimination of liability for monetary damages set forth in the organizational documents of Treeline and Standard BioTools immediately prior to the Effective Time, and such provisions shall not be amended, repealed, abrogated or otherwise modified in any manner that would adversely affect any indemnified person. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Prior to the Effective Time, Standard BioTools is required to purchase a six-year prepaid &#8220;tail policy&#8221; (the &#8220;D&amp;O Tail Policy&#8221;) for the non-cancellable extension of the directors&#8217; and officers&#8217; liability coverage of Standard BioTools&#8217; existing directors&#8217; and officers&#8217; insurance policies for a claims reporting or discovery period of at least six years from and after the Effective Time with respect to any claim related to any period of time at or prior to the Effective Time, with terms, conditions, retentions and limits of liability that are no less favorable than the coverage provided Standard BioTools&#8217; existing policies as of the date of the Merger Agreement with respect to any actual or alleged error, misstatement, misleading statement, act, omission, neglect, breach of duty or any matter claimed against a director or officer of Standard BioTools by reason of him or her serving in such capacity that existed or occurred at or prior to the Effective Time (including in connection with the Merger Agreement or the Transactions). </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">221<br></div></div></div>
<!--End Page 232-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 233-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_116-agreement_pg22"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Other Agreements </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Each of Standard BioTools and Treeline has agreed to: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">during the Pre-Closing Period, promptly notify the other party in writing upon becoming aware of any event, condition, fact or circumstance that would reasonably be expected to make the timely satisfaction of any condition to Closing impossible; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">during the Pre-Closing Period, promptly advise the other party in writing upon becoming aware of (i) any claim asserted or legal proceeding commenced, or, to the party&#8217;s knowledge, either: (A) with respect to a governmental entity, overtly threatened; or (B) with respect to any other person, threatened in writing, in each case against, relating to, involving or otherwise affecting any of the Transactions; (ii) any knowledge of any notice from any person alleging that the consent of such person is or may be required in connection with the Merger or any of the other Transactions; and (iii) any other material legal proceeding or material claim threatened in writing, commenced or asserted against any party or its respective subsidiaries; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">subject to certain conditions, afford the other party&#8217;s representatives reasonable access (at the requesting party&#8217;s cost) under the supervision of appropriate personnel of the other party, during normal business hours during the period prior to the Effective Time, to the other party&#8217;s, and each of its subsidiaries&#8217; employees, properties, assets, books, records and contracts and, during such period, each of Standard BioTools and Treeline will, and will cause each of its subsidiaries to, furnish promptly to the other all information concerning its or any of its subsidiaries&#8217; capital stock, business and personnel as may reasonably be requested by the other, as and when reasonably requested by the other party; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">use its reasonable best efforts to, and cause its subsidiaries to, cause the Merger to qualify as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a) of the Code, as amended, and, if requested by the SEC, use their respective reasonable best efforts to cause its respective counsel to deliver a tax opinion; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">during the Pre-Closing Period, consult with each other prior to issuing or making, and provide each other the reasonable opportunity to review and comment on, any press releases or other public announcements with respect to the Transactions and any filings with any governmental entity (including any national securities exchange) with respect thereto, subject to certain exceptions; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">use its reasonable best efforts to (i) take all action reasonably appropriate to ensure that no state takeover statute or similar statute or regulation is or becomes applicable to the Merger Agreement or the Transactions and (ii) if any state takeover statute or similar statute or regulation becomes applicable to the Merger Agreement or the Transactions, take all action reasonably appropriate to ensure that the Transactions may be consummated as promptly as practicable on the terms contemplated by the Merger Agreement and otherwise to eliminate or minimize the effect of such statute or regulation on the Transactions; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">use reasonable best efforts to cause each individual who will serve as a director or executive officer of Standard BioTools following the Closing, and such other stockholders to be agreed by the parties, to execute and deliver a lock-up agreement no later than the Closing, pursuant to which each signatory shall agree not to offer, pledge, sell or otherwise transfer or dispose of any shares of Standard BioTools Common Stock (or any securities convertible into or exercisable or exchangeable for shares of Standard BioTools Common Stock) held by such signatory for a period of 180 days following the Closing, subject to customary exceptions. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Standard BioTools has agreed to: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">use its reasonable best efforts to cause the shares of Standard BioTools Common Stock to be issued in the Merger to be approved for listing on Nasdaq, subject to official notice of issuance, prior to the Effective Time; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">obtain and deliver to Treeline at or prior to the Effective Time (or, at the option of Treeline, at a later date) the resignation of each officer and director of Standard BioTools and each of its subsidiaries, effective as of the Effective Time (it being understood that such resignation shall not constitute a voluntary termination of employment under any employment agreement or employee benefit plan applicable to such individual&#8217;s status as an officer or director of Standard BioTools or a subsidiary thereof); </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">222<br></div></div></div>
<!--End Page 233-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 234-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_116-agreement_pg23"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">enter into customary indemnification agreements reasonably satisfactory to Treeline with each individual to be appointed to, or serving on, the board of directors of Standard BioTools at Closing, which indemnification agreements shall continue to be effective following the Closing; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">take all necessary actions to terminate its 401(k) plan, effective as of no later than the date immediately preceding the Closing Date, unless otherwise directed by Treeline; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">take actions necessary to fully vest any and all unvested amounts of the accounts of all participants in its 401(k) Plan with respect to any employees who are to be transferred in connection with a Legacy Transaction (as defined below), or who are affected by the termination of the 401(k) plan, prior to and conditioned upon termination of the 401(k) plan;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">prior to the Effective Time, terminate each then-current offering period under its employee stock purchase plan and refund all accumulated contributions made by participants in such plan, and, terminate the employee stock purchase plan at Treeline&#8217;s request; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">prior to the Effective Time, adopt the Post-Closing Equity Incentive Plan, subject to the Closing and effective as of the Effective Time; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">prior to the Effective Time, adopt the Post-Closing Employee Stock Purchase Plan, subject to the Closing and effective as of the Effective Time; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">subject to the approval of the Post-Closing Equity Incentive Plan and the Post-Closing Employee Stock Purchase Plan at the Special Meeting, file with the SEC, as soon as reasonably practicable after the Effective Time, a registration statement on Form&#160;S-8 relating to the shares of Standard BioTools Common Stock issuable with respect to the Post-Closing Equity Incentive Plan and the Post-Closing Employee Stock Purchase Plan. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline has agreed to </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">cause any stockholder agreements, voting agreements, registration rights agreements, co-sale agreements and any other similar contracts between Treeline and any holders of Treeline capital stock, including any such contract granting any person investor rights, rights of first refusal, registration rights or director designation rights, to be terminated immediately prior to the Effective Time without any material liability being imposed on the part of Standard BioTools or Treeline; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">cooperate with Standard BioTools as reasonably requested by Standard BioTools with respect to any Nasdaq listing application filed by Standard BioTools and promptly furnish all information concerning Treeline and its stockholders that may be required or reasonably requested in connection with any Nasdaq listing; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">from the date of the Merger Agreement until the earlier of the Effective Time and the termination of the Merger Agreement in accordance with its terms, not to, and not permit any of its subsidiaries to, take, authorize, approve or permit any action that results in, or would reasonably be expected to result in, a material adjustment to the Conversion Price (as defined in the certificate of incorporation of Treeline) or the conversion rate of any series of the Treeline Preferred Stock. </div></td></tr></table><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">Closing Dividend; CVR Agreement </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Prior to the Effective Time, Standard BioTools expects to declare a dividend to Standard BioTools stockholders as of the close of business on the last business day prior to the day on which the Effective Time occurs (the &#8220;Closing Dividend&#8221;) in the form of one CVR for each outstanding share of Standard BioTools Common Stock held by such stockholder on such date. The payment date for such dividend will be three business days after the Effective Time. The CVRs will be issued pursuant to the terms of a Contingent Value Rights Agreement to be entered into between Standard BioTools and a rights agent. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Pursuant to the CVR Agreement, the holder of each CVR will be entitled to receive a payment for each 12-month CVR payment period during the five-year term of the CVR Agreement, consisting of a number of shares of the combined company&#8217;s common stock (with fractional shares settled in cash) equal to such holder&#8217;s pro rata portion of the aggregate net proceeds received by the combined company during such 12-month CVR payment period from the following sources: (i) proceeds from any sale, disposition, or other monetization of the Legacy Business; (ii) proceeds from convertible notes or other investments held by Standard BioTools as of the Closing </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">223<br></div></div></div>
<!--End Page 234-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 235-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_116-agreement_pg24"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Date; (iii) earnout, milestone, royalty or other similar contingent payments due to Standard BioTools under contracts in effect as of the Closing Date, including payments from Illumina, Inc. pursuant to the Stock Purchase Agreement dated June&#160;22, 2025; and (iv) any surplus in Parent Net Cash delivered at Closing as finally determined under the Merger Agreement. The maximum number of shares of common stock of the combined company which may be issued pursuant to the CVR Agreement is 76,000,000. There can be no assurance that any payments will be made on the CVRs. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The payment of the Closing Dividend will be expressly conditioned upon the occurrence of the Effective Time, and if the Effective Time does not occur for any reason following the setting of the record date for the Closing Dividend, (i)&#160;the Closing Dividend shall be deemed not to have been declared, (ii) no CVRs shall be issued or distributed to any holder of Standard BioTools Common Stock, (iii) the CVR Agreement shall be of no force or effect and (iv) Standard BioTools shall have no obligation to any holder of Standard BioTools Common Stock with respect to any CVR or the Closing Dividend. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Treatment of Legacy Business </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In the Merger Agreement, Standard BioTools has agreed to use its commercially reasonable efforts to effect the sale, license, transfer, disposition, divestiture or other monetization transaction with respect to its Legacy Business (such transaction, a &#8220;Legacy Transaction&#8221;); provided that (i) the prior written consent of Treeline (not to be unreasonably withheld, conditioned or delayed) shall be required prior to Standard BioTools&#8217; entry into any definitive agreement, or binding term sheet or letter of intent, relating to any Legacy Transaction and (ii) Standard BioTools will not be required to enter into any specific Legacy Transaction. Standard BioTools has agreed to keep Treeline reasonably informed of the status of any Legacy Transaction. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Merger Agreement provides that Standard BioTools and Treeline will work together in good faith (and in consultation with one or more nationally recognized wind-down consultants) to reach agreement within 30 days of the date of the Merger Agreement on a mutually acceptable written schedule (the &#8220;Wind-Down Schedule&#8221;) that sets forth the actions that would be required in order to wind down the Legacy Business (the &#8220;Wind-Down Activities&#8221;) and the costs to effect such Wind-Down Activities (the &#8220;Wind-Down Costs&#8221;) or a methodology to determine such costs, with the goals of (i) minimizing and eliminating remaining obligations and liabilities of Standard BioTools while at the same time maximizing the amount of Parent Net Cash and (ii) preserving cash. Standard BioTools and Treeline agreed that they would work together in good faith to ensure that the Wind-Down Schedule addresses, among other matters, current and non-current accrued liabilities, long-term contract obligations of Standard BioTools (including deferred revenue) and liabilities arising under service contracts in effect prior to the Closing (the &#8220;Specified Cash-Walk Items&#8221;). </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In lieu of pursuing a Legacy Transaction with respect to all or any portion of the Legacy Business, Standard BioTools may elect at any time to commence the Wind-Down Activities. In the event that Standard BioTools has not entered into a definitive agreement for the disposition of any portion of the Legacy Business on or prior to the date that the registration statement on Form&#160;S-4 of which this proxy statement/prospectus forms a part is declared effective under the Securities Act, Standard BioTools will be required to undertake, and to cause its subsidiaries to undertake, the Wind-Down Activities, together with such modifications as may be mutually agreed by Standard BioTools and Treeline, acting reasonably, with respect to such portion of the Legacy Business. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;"><a name="tTERM"><!--Anchor--></a>Termination </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Merger Agreement may be terminated at any time before the Effective Time, whether before or after the Standard BioTools Stockholder Approval and the Treeline Stockholder Approval have been obtained, as set forth below: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">by mutual written consent of Standard BioTools and Treeline; or </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">by either Standard BioTools or Treeline, if the Merger has not been consummated by 11:59 p.m. Eastern Time on March&#160;31, 2027 (the &#8220;Termination Date&#8221;), provided that the right to terminate the Merger Agreement is not available to any party if its material breach of the Merger Agreement has been the cause of, or resulted in, the failure of the Merger to be consummated by the Termination Date; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">by either Standard BioTools or Treeline, if the Standard BioTools Stockholder Approval was not obtained at the Special Meeting duly convened therefor or at any adjournment or postponement thereof at which a vote upon the Share Issuance and Charter Amendment was taken; </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">224<br></div></div></div>
<!--End Page 235-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 236-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_116-agreement_pg25"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">by either Standard BioTools or Treeline, if any applicable law, judgment or other legal restraint or binding order or determination by any governmental entity prevents, restrains, enjoins, makes illegal or otherwise prohibits the consummation of the Merger or any of the Transactions and such restraint shall have become final and non-appealable, provided that the terminating party shall have complied with its obligations with respect to regulatory matters under the Merger Agreement; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">by Treeline, if: </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">prior to obtaining the Standard BioTools Stockholder Approval, (i) a Standard BioTools Change in Recommendation has occurred, (ii) the Standard BioTools Board has failed to publicly reaffirm its recommendation to approve the Standard BioTools Board Recommendation within 10 business days after Treeline so requests in writing following the public disclosure of any Standard BioTools Acquisition Proposal with any person other than Treeline (or if the Special Meeting is scheduled to be held within 10 business days of the written request of Treeline, promptly and in any event prior to the date of which the Special Meeting is scheduled to be held), (iii) the Standard BioTools board of directors has failed to publicly recommend against any tender offer or exchange offer subject to Regulation 14D under the Exchange Act that constitutes a Standard BioTools Acquisition Proposal (including by taking no position with respect to the acceptance of such tender offer or exchange offer by Standard BioTools&#8217; stockholders) within 10 business days of the commencement of such tender offer or exchange offer or (iv) Standard BioTools has intentionally and materially breached its no solicitation or negotiation and notice obligations under the Merger Agreement, provided, that Treeline&#8217;s right to terminate the Merger Agreement pursuant to this provision shall expire upon receipt of the Standard BioTools Stockholder Approval; or </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">prior to the Effective Time, Standard BioTools or Merger Sub breaches any of its representations, warranties, covenants or agreements contained in the Merger Agreement, or any such representation and warranty shall have become untrue after the date of the Merger Agreement, such that any of the conditions to closing the Merger related to the accuracy of Standard BioTools&#8217; representations in the Merger Agreement or compliance by Standard BioTools with its agreements in the Merger Agreement would not be satisfied, and such breach or failure to be true is not curable, or, if curable, is not cured in accordance with the terms of the Merger Agreement; provided, that Treeline shall not have the right to terminate the Merger Agreement pursuant to this provision if Treeline is then in material breach of any of its representations, warranties, covenants or agreements under the Merger Agreement; or </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">by Standard BioTools, if: </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">prior to the Effective Time, Treeline breaches or fails to perform any of its representations, warranties or covenants contained in the Merger Agreement, or any such representation and warranty has become untrue after the date of the Merger Agreement, such that any of Treeline&#8217;s conditions to closing the Merger related to the accuracy of Treeline&#8217;s representations in the Merger Agreement or compliance by Treeline with its agreements in the Merger Agreement would not be satisfied, and such breach or failure to be true is not curable, or, if curable, is not cured in accordance with the terms of the Merger Agreement; provided, that Standard BioTools shall not have the right to terminate the Merger Agreement pursuant to this provision if Standard BioTools is then in material breach of any of its representations, warranties, covenants or agreements under the Merger Agreement. </div></td></tr></table><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;"><a name="tTFER"><!--Anchor--></a>Termination Fee and Expense Reimbursement </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Merger Agreement provides that Standard BioTools will be required to pay a termination fee to Treeline in the amount of $16.1&#160;million (the &#8220;Standard BioTools Termination Fee&#8221;) under the following circumstances: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">In the event that (i) after the date of the Merger Agreement, a Standard BioTools Acquisition Proposal has been made to Standard BioTools and such Standard BioTools Acquisition Proposal becomes publicly known prior to the Special Meeting and, in either case, such Standard BioTools Acquisition Proposal has not been withdrawn at the time of the Special Meeting, or a third party has publicly announced an intention to make a Standard BioTools Acquisition Proposal and such intention has not been withdrawn at the time of the Special Meeting, (ii) the Merger Agreement is terminated (A) by either party due to the </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">225<br></div></div></div>
<!--End Page 236-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 237-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_116-agreement_pg26"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_bl" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: left;">Merger not being consummated by the Termination Date, (B) by either party because applicable law, judgment or other legal restraint or binding order or determination by a government entity is in effect that prevents, restrains, enjoins, makes illegal or otherwise prohibits the consummation of the Merger or any of the Transactions or (C) by Treeline due to Standard BioTools breaching any of its representations, warranties, covenants or agreements contained in the Merger Agreement, or any such representation and warranty having become untrue after the date of the Merger Agreement, such that any of the conditions to closing the Merger related to the accuracy of Standard BioTools&#8217; representations or compliance by Standard BioTools with its agreements in the Merger Agreement would not be satisfied, and such breach or failure, if curable, is not cured in accordance with the terms of the Merger Agreement (provided, that Treeline will not have the right to terminate the Merger Agreement pursuant to this provision if Treeline is then in material breach of any of its representations, warranties, covenants or agreements contained in the Merger Agreement), and (iii) within 12 months after such termination, Standard BioTools enters into a Standard BioTools Alternative Acquisition Agreement with respect to a Standard BioTools Acquisition Proposal or consummates a Standard BioTools Acquisition Proposal (solely for purposes of this provision, the references to &#8220;15%&#8221; in the definition of Standard BioTools Acquisition Proposal shall be deemed to be references to &#8220;50%&#8221;); or </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">In the event that the Merger Agreement is terminated by Treeline if, prior to obtaining the Standard BioTools Stockholder Approval, (i) a Standard BioTools Change in Recommendation has occurred, (ii) the Standard BioTools Board has failed to publicly reaffirm its recommendation to approve the Standard BioTools Board Recommendation within 10 business days after Treeline so requests in writing following the public disclosure of any Standard BioTools Acquisition Proposal with any person other than Treeline (or if the Special Meeting is scheduled to be held within 10 business days of the written request of Treeline, promptly and in any event prior to the date of which the Special Meeting is scheduled to be held), (iii) the Standard BioTools Board has failed to publicly recommend against any tender offer or exchange offer subject to Regulation 14D under the Exchange Act that constitutes a Standard BioTools Acquisition Proposal (including by taking no position with respect to the acceptance of such tender offer or exchange offer by Standard BioTools&#8217; stockholders) within 10 business days of the commencement of such tender offer or exchange offer or (iv) Standard BioTools has intentionally and materially breached its no solicitation or negotiation and notice obligations under the Merger Agreement, provided, that Treeline&#8217;s right to terminate the Merger Agreement pursuant to this provision shall expire upon receipt of the Standard BioTools Stockholder Approval. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Standard BioTools Termination Fee will be payable pursuant to the first bullet above within one business day of the consummation of a Standard BioTools Acquisition Proposal or pursuant to the second bullet above within two business days after termination. If the Merger Agreement is validly terminated by either party because there is a legal restraint which restricts or prohibits the Merger or by Treeline due to a breach of warranty or agreement by Standard BioTools, then the Standard BioTools Termination Fee will be reduced by an amount equal to the Fee Reimbursement (as defined below) actually paid to Treeline. Standard BioTools will not be required to pay the Standard BioTools Termination Fee more than once. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Merger Agreement provides that Standard BioTools will reimburse Treeline for all reasonable out-of-pocket fees and expenses incurred by Treeline in connection with the Merger Agreement and the Transactions, up to a maximum of $5&#160;million (the &#8220;Fee Reimbursement&#8221;), if the Merger Agreement is terminated by Treeline due to the Standard BioTools Stockholder Approval not being obtained (provided that the right to terminate the Merger Agreement pursuant to this provision will not be available to Treeline if its material breach of the Merger Agreement has been the cause of, or resulted in, the failure to obtain the Standard BioTools Stockholder Approval).</div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">Specific Performance </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The parties to the Merger Agreement acknowledged and agreed that irreparable damage would occur and that the parties would not have any adequate remedy at law if any provision of the Merger Agreement were not performed in accordance with its specific terms or were otherwise breached, and that monetary damages, even if available, would not be an adequate remedy therefor. The parties accordingly agreed that each party shall be entitled to an injunction or injunctions, specific performance and other equitable relief to prevent breaches of the Merger Agreement and to enforce specifically the performance of the terms and provisions hereof, without proof of actual damages (and each party waived any requirement for the security or posting of any bond in connection with such remedy), in addition to any other remedy to which they are entitled at law or in equity. The parties further agreed not </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">226<br></div></div></div>
<!--End Page 237-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 238-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_116-agreement_pg27"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">to assert that a remedy of specific enforcement is unenforceable, invalid, contrary to applicable law or inequitable for any reason, and not to assert that a remedy of monetary damages would provide an adequate remedy for any such breach or that Standard BioTools or Treeline otherwise have an adequate remedy at law. The parties acknowledged that the agreements described in this paragraph are an integral part of the transactions contemplated by the Merger Agreement, and that, without these agreements, the parties would not have entered into the Merger Agreement. Treeline will not be entitled to both (i)&#160;specific performance to cause the other party to consummate the Closing and (ii) payment of the Standard BioTools Termination Fee. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Expenses </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Except as described under the heading &#8220;<font style="font-style: italic;">Termination Fee and Expense Reimbursement</font>&#8221; above, whether or not the Merger is consummated, all costs and expenses incurred in connection with the Merger Agreement and the Transactions will be paid by the party incurring such expense. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Amendment </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Merger Agreement may be amended by an instrument in writing signed by the parties at any time, except that after the Merger Agreement has been approved by the stockholders of a party, no amendment which by law requires further approval by the stockholders of such party will be made without such further approval, provided that after the Closing no amendment to the Merger Agreement may be made by Standard BioTools without the consent of the legacy Standard BioTools directors that would reasonably be expected to adversely impact the rights of the holders of Standard BioTools equity interests immediately prior to the Effective Time or adversely impact in any material respect the amount or timing of any payments to such stockholders (or the inputs into such payments) under the Merger Agreement or the CVR Agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Following the Closing and prior to the later of (x) the valid termination of the CVR Agreement and (y) the final determination of Parent Net Cash pursuant to the Merger Agreement (such period, the &#8220;Post-Closing Period&#8221; ), any amendment of, or waiver under, the Merger Agreement that would reasonably be expected to adversely impact the rights of the holders of Standard BioTools equity interests as of immediately prior to the Effective Time or adversely impact in any material respect the amount or timing of any payments to such stockholders (or the inputs into such payments) under the Merger Agreement or the CVR Agreement will require and be subject to the consent of the legacy Standard BioTools directors. If at any time during the Post-Closing Period, either legacy Standard BioTools director ceases to serve on the combined company board for any reason, any decisions vested in the legacy Standard BioTools directors under the Merger Agreement will be vested solely in the remaining legacy Standard BioTools director. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Governing Law </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Merger Agreement is governed by the laws of the State of Delaware. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">227<br></div></div></div>
<!--End Page 238-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 239-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_117-bus_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tTBD"><!--Anchor--></a>TREELINE BUSINESS DESCRIPTION </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Unless otherwise indicated or the context otherwise requires, references in this section to &#8220;Treeline,&#8221; the &#8220;Company&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and other similar terms refer to Treeline Biosciences, Inc.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline was created to invent, develop, and commercialize innovative medicines in oncology and other serious diseases.<font style="font-style: normal;"> </font>We focus on hard-but-solvable problems and aspire to build a sustainable biopharmaceutical company by making medicines at the highest level, reliably and repeatedly.<font style="font-style: normal;"> </font></div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Overview </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline is a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and other serious diseases. Our approach is built on a differentiated, repeatable discovery platform that identifies compelling molecular targets and matches them with the most appropriate drug modality. We seek to prove we can pick good targets, nominate highly-vetted development candidates (&#8220;DCs&#8221;), and make thoughtful development decisions across a diverse and ambitious pipeline, with the goal of redefining the treatment of serious diseases. We want our platform story to be repeatability. We currently have three Phase 1 programs, TLN-121, TLN-254, and TLN-372, and a fourth program, TLN-499, nearing clinical entry, all in oncology. Our preclinical pipeline includes programs in neurology and immunology, in addition to oncology. We expect three additional programs to enter clinical testing in 2027 and 2028. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We believe the depth of our pipeline reflects the talents, expertise, and flexibility of our team. There are a finite number of molecular targets that we find compelling enough to pursue. We focus on targets with the potential to deliver meaningful clinical benefit that meet four criteria: disease dependency, therapeutic index, path to druggability, and patient need. We believe the specific features of a molecular target should determine the drug modality, i.e., whether a small molecule inhibitor, protein degrader, or targeted therapy antibody-drug conjugate (&#8220;TT-ADC&#8221;) approach is employed. In other words, we believe the ultimate DC should reflect the therapeutic solution with the best chance of delivering the target product profile (&#8220;TPP&#8221;).</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If pipeline attrition must occur, we hope to realize it before the start of a human clinical trial. Thus, we have strict criteria, which include internal data and external factors, for nominating DCs. We seek not only to prove a hypothesis but also work hard to generate data that could disqualify compounds under consideration prior to a clinical start. We aim to advance a compound into human clinical trials only when it satisfies these stringent criteria. We require in vivo efficacy and safety profiles that can be realistically achieved through conservative dosing assumptions. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In just five years, we have generated a diversified pipeline of more than 10 programs, with all but one discovered by our in-house team. Our current Phase 1 clinical programs include TLN-121, an oral protein degrader targeting the transcription factor B-cell lymphoma 6 (&#8220;BCL6&#8221;); TLN-254 (in-licensed), an oral inhibitor of enhancer of zeste homolog 2 (&#8220;EZH2&#8221;); and TLN-372, a selective, orally bioavailable inhibitor of the commonly mutated oncogene Kirsten Rat Sarcoma Viral Oncogene Homolog (&#8220;KRAS&#8221;). We intend to provide guidance for TLN-121 and TLN-372 in the first quarter of 2027 and expect to disclose data for these programs in 2027. TLN-499, an oral targeted protein degrader of B-cell lymphoma-X long (&#8220;BCL-XL&#8221;), is near clinical entry, and we expect to begin a first-in-human trial in the second half of 2026. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Both TLN-121 and TLN-254 are in development for the treatment of lymphoma. Non-Hodgkin Lymphoma (&#8220;NHL&#8221;) is the most common hematological malignancy worldwide, accounting for approximately 90% of lymphomas and up to 3% of all cancer diagnoses and deaths. There are over 40 major subtypes of NHL, including two of the most common subtypes, diffuse large B-cell lymphoma (&#8220;DLBCL&#8221;, 30-58% of cases) and follicular lymphoma (&#8220;FL&#8221;, up to 30% of cases), and rarer subtypes like peripheral T-cell lymphoma (&#8220;PTCL&#8221;, 6% of cases). While current standard of care treatments for NHL can be initially effective, many patients relapse or are refractory to available therapies. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In preclinical studies, TLN-121 was shown to potently and selectively degrade BCL6. It was designed to minimize off-target protein degradation so that it would have a greater ability to combine with cytotoxic chemotherapy, CD19- and CD20-targeted therapies, and other drug classes with anti-lymphoma activity. We are currently enrolling patients with DLBCL, FL, and the T follicular helper (&#8220;TFH&#8221;) subtype of PTCL in a Phase 1 clinical trial. As of a March&#160;6, 2026 data cutoff date, TLN-121 monotherapy delivered an overall response rate (&#8220;ORR&#8221;) of 84% and a complete response (&#8220;CR&#8221;) rate of 32%, by Lugano criteria, across all disease types. As of the data cutoff date, no dose-limiting toxicities (&#8220;DLTs&#8221;) were reported and most treatment-emergent adverse events </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">228<br></div></div></div>
<!--End Page 239-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 240-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_117-bus_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">(&#8220;TEAEs&#8221;) and treatment-related adverse events (&#8220;TRAEs&#8221;) were Grade 1. To date, we believe TLN-121 has shown compelling single-agent activity and a potentially favorable safety profile in heavily pretreated patients. We intend for future cohorts in this trial to explore TLN-121 monotherapy and combinations of TLN-121 with other anti-lymphoma agents, which could enable development in earlier lines of therapy. We plan to provide guidance on the expected timing of data from this trial in the first quarter of 2027, with data anticipated later in 2027. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We identified EZH2 as a promising molecular target, believing it could complement the mechanism of action of TLN-121. We licensed TLN-254 (marketed as Airuijing&#8482; in China) from Jiangsu Hengrui Pharmaceuticals Co., Ltd. (&#8220;Hengrui&#8221;). TLN-254 is currently being tested as a single-agent in a Phase 1 clinical trial and also in combination with TLN-121 in another Phase 1 clinical trial, described above. The first trial is designed to assess pharmacokinetics (&#8220;PK&#8221;) in Western patients with PTCL, as well as in an exploratory cohort of patients with cutaneous T-cell lymphoma (&#8220;CTCL&#8221;). As of a March&#160;6, 2026 data cutoff date from the TLN-254 monotherapy trial in PTCL, TLN-254 monotherapy delivered an ORR of 62% and CR of 33%, by Lugano criteria. TEAEs and TRAEs were primarily Grade 1 and 2. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">There is regulatory uncertainty surrounding the TLN-254 program based in part on a safety signal observed for another medicine in this drug class (tazemetostat, Tazverik&#174;) when combined with lenalidomide (Revlimid&#174;) and rituximab (Rituxan&#174;), which resulted in the withdrawal of tazemetostat from the market in March&#160;2026. On June&#160;2, 2026, the United States Food and Drug Administration (&#8220;FDA&#8221;) placed a partial clinical hold on our TLN-254 monotherapy Phase 1 clinical trial and the TLN-254 combination arm of the TLN-121 Phase 1 trial. Patients in these trials may continue receiving TLN-254 if they are deriving a clinical benefit, but further enrollment to receive TLN-254 in these studies has been paused. We believe there could still be a compelling risk-benefit proposition for TLN-254 in the setting of aggressive lymphomas, such as DLBCL and PTCL. We are working with the FDA to address the partial hold. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">TLN-372 is our third program in the clinic. In the United States, a new KRAS-altered malignancy is diagnosed in approximately 150,000 patients each year and KRAS mutations are associated with a poor prognosis across indications. KRAS represents a compelling but challenging target, and therefore an opportunity to redefine the treatment landscape. TLN-372 was intentionally designed to have activity against wild type (&#8220;WT&#8221;) and most of the common mutations of KRAS. We believe TLN-372 has the potential to differentiate from the crowded KRAS landscape by achieving therapeutically relevant free-drug exposures throughout the dosing period and avoiding DLTs that are due to concomitant inhibition of HRAS and NRAS. These features should allow for deep target inhibition associated with single-agent response rates and dose-intense combinability with anti-epidermal growth factor receptor (&#8220;EGFR&#8221;) antibodies, immunotherapy, cytotoxics, and other drug classes. We believe&#8212;because of the biology of RAS-mutated cancer&#8212;that dose-intense combination regimens are the future of the field, especially in earlier lines of therapy. TLN-372 was built for this purpose. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are currently enrolling a Phase 1 clinical trial designed to assess the safety, PK, and anti-tumor activity of TLN-372 in patients with locally advanced or metastatic solid tumors harboring common KRAS mutations and KRAS WT amplified solid tumors. The trial is also designed to explore the efficacy and safety of TLN-372 when given in combination with other anticancer agents. As of May&#160;2026, dose-dependent increases in PK were observed, and no DLTs have been reported. Measured free-drug exposures are consistent with exposures predicted by preclinical in vitro and in vivo modeling. We plan to provide guidance on the expected timing of data from this trial in the first quarter of 2027, with data anticipated later in 2027. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our fourth program, TLN-499, is expected to enter clinical testing in the second half of 2026. In healthy cells, BCL-XL plays a protective role in preventing cell death. Extensive third-party literature suggests that the inhibition of BCL-XL potentiates the effects of many other classes of therapy. We believe that the co-development of TLN-499 with the right partner drug(s) could generate meaningful anti-tumor activity in high unmet need cancers. Our Phase 1 clinical trial is designed to test the combination of TLN-499 with the BCL-2 inhibitor venetoclax in patients with small cell lung cancer (&#8220;SCLC&#8221;), neuroendocrine cancer (&#8220;NEC&#8221;), Merkel cell carcinoma (&#8220;MCC&#8221;), malignant pleural mesothelioma, and synovial sarcoma. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our preclinical pipeline currently includes programs in neurology, immunology, and oncology. We expect three additional internally discovered programs to enter clinical testing in 2027 and 2028. We plan to provide additional </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">229<br></div></div></div>
<!--End Page 240-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 241-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_117-bus_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">guidance on these programs in the first quarter of 2027. We are also working on additional discovery-stage programs, a subset of which we hope will enter lead optimization and ultimately clinical testing. We are unlikely to comment on these earlier-stage programs until they have entered human clinical testing, given the high bar we have established for advancing candidates to this stage. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In summary, we have combined the technology and scale advantages of a large pharmaceutical company with the entrepreneurial culture of a biotechnology company. Our goal is to create and replenish one of the most exciting and diversified pipelines in the biopharma industry and produce meaningful clinical results across multiple programs. A belief in Treeline is a belief that our team has the target judgment, DC nomination standards, and clinical-regulatory expertise necessary to achieve this goal. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Our Pipeline </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We have established a diversified pipeline of more than 10 programs in development, with three in clinical trials. We believe our pipeline reflects the strategic priorities and scientific judgment of our management team more than a thematic commitment to a particular therapeutic area or drug class.</div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 15.25pt; text-align: center;"><img style="height: 162px; width: 618px;" src="ny20077604x1_figure01x1.jpg"><br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201; <br></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Figure 1: Our pipeline of investigational product candidates.<font style="font-style: normal;"> </font></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-weight: bold;">TLN-121</font> is an oral protein degrader targeting BCL6. BCL6 is a transcriptional repressor essential to the formation and function of germinal centers in secondary lymphoid tissues. BCL6 staining by immunohistochemistry is routinely used in the cell of origin diagnosis of B-cell and T-cell lymphoma. Most patients with DLBCL, FL, and TFH lymphoma (a subset of PTCL) express BCL6. Our TLN-121 development program will explore TLN-121 alone and in combination with other active classes of therapy. DLBCL and FL are sensitive to CD19- and CD20-directed therapies, be they monoclonal antibodies, bispecific antibodies, or chimeric antigen receptor T-cell (&#8220;CAR-T&#8221;) therapies. Cytotoxic chemotherapy and certain targeted therapies are also important for the treatment of DLBCL and FL, as well as PTCL. Thus, compatibility with these modalities was a key design feature of TLN-121. TLN-121 is currently in Phase 1 development for patients with B-cell and T-cell lymphoma, where single-agent activity has been observed to date in patients with DLBCL, FL, and TFH PTCL. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-weight: bold;">TLN-254</font> is an oral inhibitor of EZH2, a master regulator of cell proliferation, apoptosis, and senescence. Its increased expression and mutations have been implicated in the development of lymphoma. In laboratory models, EZH2 potentiates the repression of BCL6 target genes, suggesting synergistic potential with BCL6-directed therapies. TLN-254 was licensed from Hengrui, which markets the agent as Airuijing&#8482; (zeprumetostat or SHR2554) in relapsed/refractory PTCL in China. TLN-254 is currently in Phase 1 development for patients with PTCL, where it has generated safety and efficacy data generally consistent with those reported for SHR2554 by cross-study comparison. It is also in Phase 1 development in combination with TLN-121. However, in March&#160;2026, an approved drug in the same class as TLN-254, tazemetostat (Tazverik), was withdrawn from the market because of a safety signal (increased rate of myeloid malignancy) in a randomized trial when it was combined with lenalidomide (Revlimid) and rituximab (Rituxan). On June&#160;2, 2026, the FDA placed a partial clinical hold on the TLN-254 monotherapy Phase 1 clinical trial and on the TLN-254 combination arm of the TLN-121 Phase 1 trial due to concerns regarding the potential for secondary malignancies in patients treated with the EZH2 inhibitor class of drug. Patients in these trials may continue receiving TLN-254 if they are deriving a clinical benefit, but </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">230<br></div></div></div>
<!--End Page 241-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 242-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_117-bus_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_bl" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: left;">enrollment to receive TLN-254 in these studies has been paused. We believe there could still be a compelling risk-benefit proposition for TLN-254 in the setting of aggressive lymphoma, namely DLBCL and PTCL, which have high unmet need, and are actively engaging with the FDA to address the clinical hold. </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-weight: bold;">TLN-372</font> is an oral inhibitor of KRAS. The KRAS oncogene is among the most frequently mutated in human cancers, especially pancreatic ductal adenocarcinoma (&#8220;PDAC&#8221;), colorectal cancer (&#8220;CRC&#8221;), non-small cell lung cancer (&#8220;NSCLC&#8221;), cholangiocarcinoma, uterine endometrial carcinoma, and low grade serous ovarian carcinoma (&#8220;LGSOC&#8221;). KRAS is an unforgiving oncogenic molecular target because it requires deep levels of inhibition throughout the 24-hour dosing period to effect tumor regression. Additionally, we believe combination drug development will be required to address co-mutated pathways and mechanisms of resistance. Currently there are three classes of anti-KRAS drugs in use and/or in development: mutant-selective drugs targeting G12C and G12D; tri-complex inhibitor (&#8220;TCI&#8221;) molecular glues that bind KRAS/HRAS/NRAS; and pan-KRAS inhibitors that bind both mutated and unmutated KRAS, but spare HRAS/NRAS. TLN-372 belongs in this third, pan-KRAS, category. We believe our carefully engineered pan-KRAS inhibitor could be differentiated in the clinic from other programs based on its potential to achieve high systemic exposures, avoid mechanisms of resistance unique to mutant-selective inhibitors, avoid certain dose-limiting toxicities of TCI molecular glues, and combine well&#8212;as measured by dose intensity&#8212;with anti-EGFR antibodies, immunotherapy, cytotoxic chemotherapy, and other drug classes. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-weight: bold;">TLN-499</font> is an oral protein degrader targeting BCL-XL. Certain cancer cells overexpress BCL-XL, as well as other pro-survival proteins to prevent<font style="font-style: italic;"> </font>the initiation of apoptosis as they experience diverse stresses. Extensive third-party literature suggests that an anti-BCL-XL therapy could meaningfully potentiate other classes of medicines. However, several factors have complicated drug development efforts against BCL-XL. First, BCL-XL is an essential mediator of platelet survival, and thrombocytopenia has been dose limiting. Second, choosing the right partner drug(s) and disease settings creates combinatorial complexity that requires careful prioritization. TLN-499 was designed for potent degradation of BCL-XL in a way that may mitigate, but not eliminate, platelet toxicity. TLN-499 is expected to enter Phase 1 testing in the second half of 2026.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-weight: bold;">Lead optimization pipeline.</font> In addition to TLN-121, TLN-372, and TLN-499, three internally discovered programs are expected to enter clinical testing in 2027 and 2028. For each program, there is a presumptive DC worthy of Phase 1 testing, though ongoing or planned experiments or external factors may cause us to consider an alternate DC choice, which would impact timelines and/or program feasibility. We plan to provide additional guidance on these programs in the first quarter of 2027. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-weight: bold;">Discovery pipeline.</font> We are working on multiple additional discovery-stage programs, a subset of which we hope enter lead optimization and ultimately clinical testing. Each program has at least one significant risk gate that may not be cleared, resulting in a pause or termination of the program. These include: i) an inability to engineer a compelling drug against the target; ii) pending experimental data that weaken the biologic or therapeutic window hypothesis; and iii) unforeseen data external to the company that question the TPP hypothesis or viability of the program. Our discovery pipeline is built around the expectation of attrition, and we are unlikely to comment on these early-stage, higher risk programs until they have entered human clinical testing. </div></td></tr></table><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Our Team </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We built our team from the ground-up to utilize leading-edge technologies and maximize the abilities of a fully-integrated in-house discovery team. </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Joshua Bilenker, M.D., is our co-founder and CEO. Prior to Treeline, Dr.&#160;Bilenker founded and served as the CEO of Loxo Oncology until its acquisition by Eli Lilly and Company for $8&#160;billion. Under his leadership at Loxo, the team developed and commercialized three FDA-approved medicines. Prior to Loxo, Dr.&#160;Bilenker was Operating Partner at Aisling Capital and a Medical Officer at the FDA. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Jeffrey Engelman, M.D., Ph.D., is our co-founder and Chief Scientific Officer. Prior to Treeline, Dr.&#160;Engelman served as Global Head of Oncology at Novartis Institutes for BioMedical Research where </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">231<br></div></div></div>
<!--End Page 242-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 243-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_117-bus_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_bl" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: left;">he ran oncology R&amp;D. Previously, Dr.&#160;Engelman led an academic research lab and served as Director, Molecular Therapeutics and Director, Thoracic Oncology at Massachusetts General Hospital, where his research focused on ways to disrupt signal transduction in cancers. </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Spencer Smith, M.B.A., joined Treeline as our Senior Vice President of Corporate Development in 2021 and has served as our CFO since January&#160;2025. Prior to Treeline, Mr.&#160;Smith was Senior Vice President and CFO at Sentio Investments and CFO at Sentio Healthcare Properties, a public, non-traded REIT. Mr.&#160;Smith was previously Associate at Aisling Capital, and he began his career as a Business Analyst at McKinsey &amp; Company. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our board of directors is composed of well-respected leaders and investors in the life sciences industry. It consists of Joshua Bilenker, CEO and co-founder of Treeline; David Bonita, General Partner of OrbiMed; Kristina Burow, Managing Director at ARCH Venture Partners; Susan Desmond-Hellmann, Independent Director, former CEO of the Bill &amp; Melinda Gates Foundation; Steven Elms, Managing Partner of Aisling; Jeffrey Engelman, CSO and co-founder of Treeline; Aftab Kherani, Managing Partner of Ajax Health; Avi Naider, President of AI Life Sciences, an affiliate of Access Industries; Ali Satvat, Partner of KKR; and David Schenkein, General Partner of GV. Additionally, two Standard BioTools directors will join the combined company&#8217;s Board. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Our Strategy </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We aspire to build a sustainable biopharmaceutical company by making medicines reliably and repeatedly, at the highest level. We focus on hard-but-solvable problems. We match compelling disease targets to the best drug modality for product candidates capable of delivering in the clinic. For us to deliver on this mission, we must execute against several strategic imperatives: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-weight: bold;">Advancing our clinical-stage programs. </font>We currently have three ongoing clinical development programs and one about to enter the clinic, all in oncology. We believe the programs that have entered clinical development have the potential to deliver differentiated clinical results and improve standards of care. As therapeutic options change, however, our clinical development decisions must contend with combination regimens, line of therapy choices and enriched population opportunities. We have invested significant time and resources in the design of our clinical programs, including dose and schedule selection, the prioritization of disease subsets, and endpoint selection, which we believe will support productive global regulatory conversations that could lead to commercialization. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-weight: bold;">Curating our preclinical programs for high probability clinical starts. </font>We have built<font style="font-weight: bold;"> </font>and continue to cultivate a diversified preclinical pipeline that includes programs from discovery through lead optimization. Our internal R&amp;D team has a long collective track record of bringing product candidates into the clinic and obtaining drug approvals. We have insourced critical R&amp;D functions so that we can encourage cross-functional collaboration and support quality control. Our pipeline is built around three ideas: i) targets that meet the criteria of disease dependency, therapeutic index, path to druggability, and patient need; ii) multiple drug modalities (small molecule inhibitors, protein degraders, or targeted therapy ADCs), which provide a broader range of potential solutions to the specific challenges of a given target; and iii) a DC selection process with intensive and conservative vetting standards. This approach is intended to advance our most promising preclinical candidates into clinical development, while deprioritizing others. We also believe our financing model, which avoids single asset concentration, aligns investors and management incentives, and has enabled us to hold out for higher-probability clinical entries. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-weight: bold;">Empowering our team of experts. </font>We have a deeply experienced team of discovery, computational, translational, clinical, regulatory, operational, and financial professionals who position our programs for success. Our team is united by a shared attention to detail and dedication to answering key scientific questions so that we can allocate resources to the highest quality opportunities. We believe our model combines the technology and scale advantages of a large pharmaceutical company with the entrepreneurial culture of a biotechnology company. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-weight: bold;">Maximizing the commercial potential of any future medicines. </font>Our pipeline is sufficiently deep for us to consider partnering with collaborators, selling an asset or launching any given product ourselves. At a program level, this decision will be made based on the complexity and cost of registration enabling trials, the scale of the commercial opportunity, the opportunity cost relative to other programs in the pipeline, our cost of capital, and the quality of inbound interest. </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">232<br></div></div></div>
<!--End Page 243-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 244-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_117-bus_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Our Approach </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our ambition is to build a biopharmaceutical company capable of repeatedly inventing therapies that redefine the treatment of serious diseases. To do so, we have built and financed the company around a small number of first principle R&amp;D beliefs. First, we believe there are a finite number of innovative, compelling molecular target ideas. Targeted protein degradation, antibody drug conjugates, and continued advances in small molecule chemistry have substantially expanded the range of proteins that can be addressed pharmacologically. Our discovery model is built around multiple internal teams of domain experts who have a track record of identifying targets and delivering clinical candidates against them. Second, we believe the specific features of a molecular target should determine which drug modality can yield the most compelling TPP. Third, we believe thorough and critical vetting of a presumptive DC can increase the probability of clinical success. We have avoided time-based program objectives and contingent funding structures because they impair rather than enhance these behaviors. Fourth, we believe innovation against difficult targets cannot be outsourced and requires cross-functional teams of experts working together under the same roof. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Target Selection Strategy: Four Criteria </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We focus on targets that we believe have the potential to deliver meaningful clinical benefit. We evaluate each prospective target against four criteria: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-weight: bold;">Disease dependency.</font> We look for targets where strong evidence indicates that the target drives the underlying pathology of the disease. That evidence may come from human genetics, validated preclinical models, or clinical trial data. We prioritize causal targets even when they have historically been considered difficult to drug. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-weight: bold;">Therapeutic index.</font> We consider the expected gap between the target engagement needed for clinical benefit and the level associated with toxicity. At the start of each program, we assess expected on-target and off-target toxicities. Sometimes a protein degrader or TT-ADC can meaningfully expand what would have been a narrow therapeutic index for a small molecule inhibitor. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-weight: bold;">Path to druggability.</font> We consider the potential ligandability of a prospective target, defined as the ability to modulate the target sufficiently for the desired functional effect. We use orthogonal biochemical, biophysical, structure-based, and computational approaches to uncover and exploit structure-activity relationship (SAR) insights that can move a project forward. For previously unliganded targets, this workflow has required sustained upfront investment in protein science, assay development, and screening. Protein degraders provide additional optionality when small molecule binders against novel pockets are discovered because they can be extremely potent and work even when the binding pocket is not critical to protein function. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-weight: bold;">Patient need.</font> We prioritize targets where a successfully approved therapeutic would meaningfully improve the standard of care for patients with the disease. </div></td></tr></table><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Matchmaking: Pairing Targets and Drug Modalities </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">A target of interest should be matched to the drug modality best suited to address it&#8211;one that maximizes the intended biologic effect, minimizes toxicities that could affect dose intensity, and provides the best overall outcome for the patient. We believe that the unique challenges (e.g., resynthesis rate, binding surface, etc.) posed by a given molecular target should determine how it is drugged, not the technology biases of the biopharma company. By being open-minded to many technology solutions, we are able to consider a wider berth of targets. Currently, we have three modalities in-house: small molecule inhibitors, protein degraders, and TT-ADCs. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Small Molecule Inhibitors.<font style="font-weight: normal;"> Small molecules remain the modality of choice for many intracellular targets where high-affinity, selective binding to a defined site can drive the desired pharmacology. To be clinically effective, an oral small molecule must dissolve in the gastrointestinal tract (&#8220;GI&#8221;), traverse cellular membranes, avoid rapid metabolic clearance, and bind its intended target with sufficient potency to achieve target engagement at well-tolerated doses. The molecule must also avoid off-target activities likely to produce dose-limiting toxicities in order to maintain a wide therapeutic index. Our medicinal chemistry teams build these properties into the lead identification and optimization screening cascades from the earliest stages of a small molecule design. Depending on the structure and biology of a given target, we design inhibitors with distinct binding modes. These include orthosteric inhibitors that compete directly at the substrate or ligand binding site, allosteric inhibitors that bind a </font></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">233<br></div></div></div>
<!--End Page 244-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 245-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_117-bus_pg7"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">separate regulatory site to modulate target activity, and covalent inhibitors that form a durable chemical bond with a specific residue on the target to achieve sustained inhibition. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Protein Degraders.<font style="font-weight: normal;"> Targeted protein degradation is a newer therapeutic modality. Unlike inhibitors, which block an active site, degraders bind the target protein and tag it for destruction by the cell&#8217;s own housekeeping machinery. This mechanism of action has put into play drug targets that have historically been considered undruggable, such as scaffolding proteins and transcription factors which may lack easily liganded and/or functional protein pockets. A single degrader molecule only needs to bind the protein long enough to induce degradation; it can then cycle from one target protein to the next, producing a catalytic effect. In this way, protein degraders can sometimes drive deeper and more durable target reduction than occupancy-based inhibition. The modality carries trade-offs, however, as degraders lack the physiochemical properties outlined in Lipinski&#8217;s Rule&#160;of Five (a set of physicochemical properties believed to be necessary for an active oral drug), which can make oral dosing difficult. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Targeted Therapy Antibody Drug Conjugates.<font style="font-weight: normal;"> Conventional ADCs use a monoclonal antibody to deliver a cytotoxic chemotherapy payload preferentially to tumor cells. Our TT-ADCs apply the idea of antibody-mediated delivery to a different problem: an otherwise promising targeted therapy that is dose limited by toxicity in a specific healthy tissue. By attaching the targeted therapy to a monoclonal antibody, it is sometimes possible to direct the medicine away from the problematic healthy tissue, to reduce toxicity, while maximizing efficacy. Each TT-ADC program requires coordinated design of the payload, linker, antibody, and release mechanism. The payload must be potent and stable enough to inhibit its target after intracellular release; the linker-payload must remain intact in circulation and release appropriately after internalization; and the antibody must direct delivery to the intended tumor lineage while sparing relevant healthy tissues. </font></div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Intensive Vetting of Development Candidate </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We believe the decision to advance a clinical DC should be based on an extensive preclinical package that pressure tests all knowable risks for the program. We try to generate data that could disqualify a molecule. In oncology, we ensure that a DC demonstrates in vivo efficacy in many cell line-derived xenograft (&#8220;CDX&#8221;) and when possible, a diverse set of patient-derived xenografts (&#8220;PDX&#8221;) models. A well conducted PDX mouse clinical trial can be a robust predictor of response rate in human trials, as well as validate co-development opportunities with other therapies. We prioritize absorption, distribution, metabolism, and excretion (&#8220;ADME&#8221;) in the up-front design of our lead chemical series for more predictable human dose and exposure estimates in humans. Additionally, we try to ascertain preliminary preclinical safety for the DC, using conservative assumptions, before advancing it into clinical development. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">In-House Invention: Integrated Wet Lab and Computational Science </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We believe that drugging difficult targets requires hand-built solutions and that true innovation cannot be outsourced. Each program is supported by custom assay development, structural and biophysical characterization of the target, and a screening and lead-optimization strategy tailored to the underlying biology. From hit identification through development candidate selection, our medicinal chemists iteratively optimize potency, selectivity, and the drug-like properties required for a given small molecule inhibitor, protein degrader, or TT-ADC linker and payload. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our computational platform is built to accelerate and sharpen wet-lab work, not replace it. Our computational capability consists of a proprietary infrastructure that seamlessly connects lab notebook data to leading-edge physics-based modeling and artificial intelligence and machine learning (&#8220;AI/ML&#8221;) approaches. In turn, computationally enabled predictions are integrated directly into the drug discovery workflow. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Examples of how we use computation to make our programs better include: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-weight: bold;">Computationally guided chemical space exploration.</font> In one of our programs, this approach enabled us to identify and rapidly progress a new chemical scaffold with advantaged ADME properties. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-weight: bold;">Virtual high-throughput screening. </font>We screen libraries in silico, which include trillions of compounds, with a focus on diversity, synthesizability and drug-like properties. It is also reassuring when a subset of these ideas matches results from real-world high-throughput screens. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-weight: bold;">Scalable molecular dynamics.</font> Cloud-based GPU infrastructure allows us to run molecular dynamics simulations at the scale and frequency our medicinal chemistry programs require, without reliance on dedicated supercomputing resources. </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">234<br></div></div></div>
<!--End Page 245-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 246-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_117-bus_pg8"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-weight: bold;">Real-time predictive workflows. </font>Model predictions are generated automatically when a compound is entered into the electronic lab notebook, so they are available as design decisions are being made. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Leading-edge computational methods are layered onto our wet lab efforts to sharpen decisions, prioritize experiments, and accelerate the work: experimental results can inform better models, which can produce better predictions, which can guide better experiments. Yet, the foundation of our discovery organization is our people. Our biologists, chemists, protein scientists, and computational scientists work together in integrated program teams. We are resourced to perform all critical research activities in-house, and we use external CROs and FTEs as extenders of internal capacity rather than substitutes for it. We believe this model enables faster iteration across disciplines, tighter integration of experimental and computational work, and accumulation of proprietary know-how that compounds across programs. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Clinical Programs </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Lymphoma: Disease Overview and Treatment Landscape </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">NHL represents a heterogeneous group of malignancies originating from B cells, T cells, or natural killer cells. NHL is the most common hematological malignancy worldwide, accounting for approximately 90% of lymphomas and 3% of all cancer diagnoses and deaths, based on data from 2019-2024. There are over 40 major subtypes of NHL, including two of the most common subtypes, DLBCL (30-58% of cases) and FL (up to 30% of cases), and rarer subtypes like PTCL (6% of cases). While initial treatments for NHL can be effective, many patients relapse or are refractory to available therapies. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">DLBCL<font style="font-weight: normal;"> is the most common large B-cell lymphoma and is also among the most aggressive. Based on an analysis of data from 2019-2023, the annual incidence of DLBCL in the United States is approximately 5.5 per 100,000 persons and the death rate is 1.7 per 100,000 persons. With combination chemotherapy/immunotherapy treatments, outright cures are achievable in the majority of patients. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">First-line therapy for DLBCL is combination chemotherapy with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) or R-CHP (rituximab, cyclophosphamide, doxorubicin, and prednisone) in combination with polatuzumab vedotin. While these therapies are associated with prolonged remissions and/or cure in greater than 60% of patients, 10% to 15% of patients do not respond and 20% to 25% relapse. Patients who are refractory or who relapse have a poor prognosis. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">FL<font style="font-weight: normal;"> is the second most common NHL with an incidence rate of 2.4 cases per 100,000 persons and a death rate of 0.4 per 100,000, based on an analysis of data from 2019-2023. FL exhibits a wide range of clinical behaviors due to its significant mutational heterogeneity. Asymptomatic patients with low disease burden may be managed through a watch and wait approach. Treatment is typically initiated when patients exhibit constitutional symptoms, evidence of organ compromise or rapid disease progression. The goal of therapy is a long-term remission or durable disease control with well-tolerated treatment regimens. FL is generally considered incurable. FL can transform into DLBCL at an annualized risk of 2 to 3%, an outcome that is associated with diminished survival.</font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Standard first-line therapies for FL include immunotherapy with an anti-CD20 antibody with or without chemotherapy (e.g., bendamustine, CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), or CVP (cyclophosphamide, vincristine sulfate, and prednisone)). No single treatment option is considered standard of care in the second-line setting. Options include anti-CD20 antibodies (e.g., rituximab or obinutuzumab) as a single agent or in combination with chemotherapy agents such as bendamustine. Lenalidomide is also approved for the treatment of relapsed/refractory FL in the United States. In later lines, zanubrutinib, bispecific antibodies, and CAR-T therapies are approved. As patients progress through successive lines of therapy, they typically exhibit diminishing response rates and shorter disease-free intervals. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">PTCL<font style="font-weight: normal;"> is a rare and heterogeneous subgroup of T-cell NHL comprising two dozen subtypes. The TFH cell lymphomas are subtypes of PTCL and include angioimmunoblastic T-cell lymphoma (&#8220;AITL&#8221;), follicular type, and TFH NOS. AITL is the most common of these with an incidence of 0.05 cases per 100,000 persons in the United States based on an analysis of data from 1992-2001. The prognosis after a PTCL diagnosis remains poor, with a 70% relapse rate after initial therapy and 2- and 5-year overall survival (&#8220;OS&#8221;) rates of 45% and 35%, respectively. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">First-line therapy typically consists of a combination chemotherapy regimen, such as CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), CHOEP (cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone) or other multidrug regimens. For patients with CD30+ PTCL, brentuximab vedotin in combination with chemotherapy was shown to confer a survival benefit compared to chemotherapy alone. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">235<br></div></div></div>
<!--End Page 246-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 247-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_117-bus_pg9"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">In relapsed/refractory disease, second-line chemotherapy regimens and hematopoietic stem cell transplantation may also be considered. Other therapies for TFH PTCL subtypes include belinostat and pralatrexate. However, these agents carry modest response rates of approximately 25% with durations of response less than one year. National Comprehensive Cancer Network (&#8220;NCCN&#8221;) guidelines recommend a clinical trial as the preferred option for relapsed/refractory T-cell lymphoma, indicating a significant need for new treatment options. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">TLN-121 </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">TLN-121 is an oral protein degrader of BCL6. BCL6 is part of a protein complex that enables B cells to undergo affinity maturation, a normal lymph node response to invasive pathogens whereby antibodies are fine tuned for an optimal immune response. BCL6 is a transcriptional repressor that turns off genes important to cell differentiation, cell cycle arrest, DNA damage response, and T-cell engagement. BCL6 thus allows immune cells to undergo simultaneous somatic hypermutation and cell proliferation, processes important for creating antibody diversity but dangerous for malignant transformation. Most DLBCLs and FLs arise from B cells exiting the germinal center reaction and are dependent on BCL6 to maintain their growth and survival. BCL6 has also been implicated as a key dependency for TFH-like PTCLs such as AITL. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In preclinical studies, TLN-121 was shown to potently and selectively degrade BCL6. It was designed to minimize off-target protein degradation so that it would have the best chance of combinability with cytotoxic chemotherapy, CD19- and CD20- targeted therapies and other drug classes with anti-lymphoma activity. The volcano plot in Figure 2 below demonstrates the selectivity of TLN-121 for BCL6. TLN-121 shows no in vitro activity against classical immunomodulatory drug targets such as Ikaros and Aiolos, transcription factors that play critical roles in lymphocyte development, differentiation, and homeostasis.</div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 15.25pt; text-align: center;"><img style="height: 303px; width: 268px;" src="ny20077604x1_figure02.jpg"><br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201; <br></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Figure 2: In vitro<font style="font-style: normal;"> </font>data show TLN-121 has high selectivity for BCL6.<font style="font-style: normal;"> </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">T-cell immunotherapies, including CD20/CD3 bispecific T-cell engagers and CD19 CAR-T therapies, are approved in the management of DLBCL and FL. T-cell engagers form a pseudo-immune synapse between cytotoxic T-cells and tumor cells with their two antibody &#8220;arms&#8221;: one binds a T-cell antigen, CD3, and the other binds a B-cell lymphoma-associated antigen, CD20. In the case of CAR-T cell therapies, the CAR-T cells themselves seek out lymphoma cells via their CD19 binding moiety. For all T-cell immunotherapies, bringing T-cells in proximity to a lymphoma cell then increases T-cell activation and B-cell lymphoma-directed cell killing. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">BCL6 degradation promotes expression of many synapse proteins required for effective T-B cell interactions. We hypothesized that a BCL6 degrader could potentiate the activity of T-cell immunotherapies through its effects on the tumor immune microenvironment. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">236<br></div></div></div>
<!--End Page 247-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 248-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_117-bus_pg10"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The activity of TLN-121 in combination with CD19 CAR-T cells was assessed in mice engrafted with the DLBCL cell line OCI-Ly1 to establish a xenograft tumor model. Both TLN-121 and CD19 CAR-T cells alone demonstrated modest tumor growth inhibition. Untransduced T-cells performed similarly to vehicle, as expected, and the efficacy of TLN-121 and untransduced T-cells combined appeared similar to that of TLN-121 alone. None of these treatments decreased tumor volume relative to baseline. Strikingly, the combination of TLN-121 and CD19 CAR-T cells shrank tumors in four out of six mice and led to CR in two out of six mice.</div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 15.25pt; text-align: center;"><img style="height: 192px; width: 617px;" src="ny20077604x1_figure03x2.jpg"><br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201; <br></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Figure 3: Anti-tumor activity of TLN-121, untransduced T-cells and CD19 CAR-T cells as single agents and in combination<font style="font-style: normal;"> </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The activity of TLN-121 was also tested in combination with CD20/CD3 bispecific T cell-engaging antibodies using an OCI-Ly1 xenograft model supplemented with human T cells. In this setting, TLN-121 alone demonstrated tumor growth inhibition. The bispecific T cell&#8211;engaging antibody epcoritamab, administered at doses approximating clinical exposures, induced tumor stasis as a single agent. Combining TLN-121 with epcoritamab enhanced anti-tumor activity relative to either single agent, achieving a 66.7% CR rate versus 0% with TLN-121 alone and 20% with epcoritamab alone.</div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 14.75pt; text-align: center;"><img style="height: 204px; width: 616px;" src="ny20077604x1_figure04x2.jpg"><br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201; <br></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Figure 4: Anti-tumor activity of TLN-121 and epcoritamab as single agents and in combination<font style="font-style: normal;"> </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We believe these findings support the clinical evaluation of TLN-121 in combination with bispecific T cell-engaging agents and other T-cell immunotherapies. </div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20pt; margin-left: 20pt; text-align: left;">Ongoing Clinical Trials for TLN-121 </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Phase 1 clinical trial of TLN-121 initiated in July&#160;2025. It is designed to characterize TLN-121 as a monotherapy, and in combination with other anti-lymphoma agents, in DLBCL, FL, and TFH PTCL. Adult patients with relapsed/refractory DLBCL, FL, high-grade B-cell lymphoma (&#8220;HGBCL&#8221;) and TFH PTCL are eligible. The trial design is summarized in Figure 3, below. We are investigating TLN-121 in multiple escalating doses as a monotherapy and in combination with TLN-254. The trial also includes a dose-expansion portion; we plan to evaluate TLN-121 monotherapy and combinations with TLN-254, bispecific antibodies, and other agents with anti-lymphoma activity. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">237<br></div></div></div>
<!--End Page 248-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 249-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_117-bus_pg11"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Patients in the dose escalation portion of the trial must have BCL6-positive disease as reported by local pathology reports. We expect the trial to enroll 60-100 patients across the dose escalation portion of the trial and approximately 140 patients in the dose expansion portion. We expect to initiate combination dosing for these expansion cohorts in the second half of 2026. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 14.75pt; text-align: center;"><img style="height: 256px; width: 619px;" src="ny20077604x1_figure05.jpg"><br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 8pt; margin-left: 0pt; text-align: left;">Figure 5: Design of Phase 1 Clinical Trial of TLN-121. Schema includes current and planned future combinations.</div><div class="BRDSX_ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 5pt; margin-left: 0pt; text-align: left;">* <font style="font-style: italic;">subject to partial clinical hold</font> </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The primary endpoints of the dose escalation portion of the clinical trial are the safety and tolerability of TLN-121, and the determination of the maximum tolerated dose (&#8220;MTD&#8221;) of TLN-121 as a monotherapy and in combination. Secondary endpoints include PK measures, ORR, CR rate and duration of response (&#8220;DOR&#8221;). For the dose expansion portion, the primary endpoint is ORR of TLN-121 as a monotherapy and in combination. Secondary endpoints include safety and tolerability, measures of anti-tumor activity (CR rate, DOR, progression free survival, and OS) as a monotherapy and in combination, and measures of PK as a monotherapy and in combination. Measures of anti-tumor activity (ORR, CR, and partial response (&#8220;PR&#8221;)) in this trial are assessed by the Lugano Criteria, which is standard in lymphoma. In contrast to the Response Evaluation Criteria in Solid Tumors (&#8220;RECIST&#8221;) framework, Lugano incorporates FDG-PET/CT scans for DLBCL, FL, HGBCL, and PTCL. Under the Lugano criteria for these lymphomas, a CR (also called a complete metabolic response) is defined as lymphoma activity at or below background levels, and a partial response (also called a partial metabolic response) is defined as a significant reduction in avidity with residual tumor masses. </div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 20pt; text-align: left;">Initial Results for TLN-121 </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As of a March&#160;6, 2026 data cutoff date, 38 patients had been enrolled in the single-agent dose escalation portion of the study and 19 were evaluable for efficacy because they had undergone at least one response assessment or they had progressed prior to the first scan. Across patients with DLBCL, FL, and PTCL, the blended ORR was 84% (n=16/19). The CR rate was 32% (n=6/19) and the PR rate was 53% (n=10/19). Complete responses were observed in each histology studied. Patients were heavily pre-treated, with prior lines of therapy ranging from two to eight. Of the patients with DLBCL and FL, 50% of patients had received a prior T-/immune-cell engager and 33% of patients had received prior CAR-T therapy.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As of a March&#160;3, 2026 data cutoff date, the safety data set included 34 patients. No DLTs were reported. The majority of TEAEs and TRAEs were Grade 1. The TRAEs occurring in 10% or greater of patients were nausea, arthralgia, myalgia, heart rate-corrected QTc interval (&#8220;QTc&#8221;) prolongation and fatigue. The three cases of asymptomatic Grade 3 QTc prolongation were reported in patients with impaired clearance and outlier exposures, or concomitant medications. </div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 20pt; text-align: left;">Next Steps for TLN-121 </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We believe TLN-121 has shown compelling preliminary efficacy and safety data across lymphoma types in heavily pretreated patients as a single agent. We plan to provide guidance on the expected timing of data from this trial in the first quarter of 2027, with data anticipated later in 2027. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">238<br></div></div></div>
<!--End Page 249-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 250-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_117-bus_pg12"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">TLN-254 </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">TLN-254 is an oral inhibitor of enhancer of EZH2, which functions as a master regulator of cell proliferation, apoptosis and senescence. Its increased expression and gain-of-function mutations have been implicated in the development of solid tumors and lymphoid neoplasms. As part of Polycomb Repressive Complex 2 (PRC2), EZH2 potentiates the repression of BCL6 target genes by adding methylation marks to chromatin at lysine 27 of histone H3 (H3K27me3). These methylation marks recruit CBX8, which in turn cooperates with BCL6 in assembling the BCOR-PRC1 complex. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Encouraged by the potential mechanistic complementarity to BCL6, we licensed TLN-254 from Hengrui as a potential combination partner for TLN-121. We have the rights to TLN-254 worldwide, excluding Greater China. Hengrui markets TLN-254 as Airuijing&#8482; (zeprumetostat or SHR2554) in China for patients with relapsed or refractory PTCL who have received at least one prior systemic therapy. Importantly, a drug in the same drug class as TLN-254, tazemetostat (Tazverik), was voluntarily withdrawn from the market in March&#160;2026. At the time of its accelerated approval, Tazverik was associated with a second primary malignancy risk of 1.7%. But in a confirmatory trial when combined with lenalidomide (Revlimid) and rituximab (Rituxan) in the first-line FL setting, the rate was found to exceed 5% over a median treatment duration of 15.8 months (range: 6.9 &#8211; 33 months). Despite these data for Tazverik, we believe there could still be a compelling risk-benefit proposition for TLN-254 in the setting of aggressive lymphomas like DLBCL and PTCL. Patients with these diseases have high unmet need and face a high risk of imminent death, especially in later lines of therapy. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On June&#160;2, 2026, the FDA placed a partial clinical hold on the TLN-254 monotherapy Phase 1 study and the TLN-254 combination arm within the TLN-121 Phase 1 study due to concerns regarding the potential for secondary malignancies. Enrollment in the TLN-254 monotherapy study and the combination arm of the TLN-121 study have been paused. Patients currently deriving clinical benefit from TLN-254 may continue treatment, and investigators are in the process of ensuring all patients treated with TLN-254 are aware of the potential risks. We are working with the FDA to address the partial hold. </div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 20pt; text-align: left;">Clinical Trials for TLN-254 </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are evaluating TLN-254 in two clinical trials: TLN-254-2401, a &#8220;Phase 1b, Randomized, Dose Optimization Study to Assess the Anti-Tumor Activity, Safety, and Pharmacokinetics of TLN-254 in Patients With Relapsed or Refractory T-cell Lymphoma,&#8221; and the TLN-121 Phase 1 trial described above that includes a combination arm with TLN-254. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We initiated the Phase 1b clinical trial of TLN-254 in December&#160;2024. The trial design is summarized in Figure 4. The trial was designed to enroll 40 patients with PTCL who had at least one prior systemic therapy. The patients with PTCL were randomized 1:1 to receive one of two dose levels of TLN-254, twice daily. An additional 10 patients with CTCL who had had two prior systemic therapies were enrolled in an exploratory cohort; they received the higher dose level of TLN-254 twice daily. Efficacy for the patients with PTCL is assessed by the Lugano Criteria and by the Global Assessment for CTCL for the patients with CTCL. Secondary endpoints include safety and tolerability and measures of PK. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 15.25pt; text-align: center;"><img style="height: 161px; width: 618px;" src="ny20077604x1_figure06.jpg"><br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Figure 6: Design of Phase 1 Clinical Trial of TLN-254<font style="font-style: normal;"> </font></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">239<br></div></div></div>
<!--End Page 250-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 251-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_117-bus_pg13"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6.75pt; margin-left: 20pt; text-align: left;">Initial Results for TLN-254 </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As of a March&#160;6, 2026 data cutoff date, 41 patients had been enrolled (31 patients with PTCL and 10 patients with CTCL). In patients with PTCL, 21 were efficacy-evaluable and the overall response rate (ORR) was 62% (n=13/21). The CR rate was 33% (n=7/21) and the PR rate was 29% (n=6/21). These response rates are inclusive of dose levels tested. Patients were heavily pre-treated, with prior lines of therapy ranging from one to six. As of a March&#160;6, 2026 data cutoff date, the safety dataset included 37 patients. The majority of TEAEs and TRAEs were Grade 1 or 2. TRAEs occurring in 10% or greater of patients were dysgeusia, fatigue, anemia, alopecia, platelet count decrease, diarrhea, and nausea. TRAEs of Grade 3 or higher were reported in 16.2% of patients. One patient with PTCL developed AML while in PR and receiving study treatment. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">TLN-372: Our Approach to KRAS Driven Cancers </div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 20pt; text-align: left;">KRAS in Cancer </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In the United States, a new KRAS altered malignancy is diagnosed in approximately 150,000 patients each year. Mutations in the KRAS oncogene are common across a broad spectrum of human cancers, most notably pancreatic, colorectal, non-small cell lung, and uterine cancer. The three most commonly occurring KRAS mutations, G12D, G12V, and G12C, represent more than half of all KRAS-driven cancers. A meaningful subset of KRAS driven tumors show regression when treated with single-agent RAS directed therapies. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 14.75pt; text-align: center;"><img style="height: 209px; width: 613px;" src="ny20077604x1_figure07x1.jpg"><br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Figure 7: Estimated newly diagnosed patients per year in the United States for distinct KRAS mutant alleles/KRAS WT amplification in several cancer types. Adapted from Hofmann et al. Cancer Discov (2022) 12 (4): 924&#8211;937.<font style="font-style: normal;"> </font></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-style: italic;">*<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-style: italic; text-align: left;">Other solid tumors include invasive ductal carcinoma, stomach adenocarcinoma, esophageal adenocarcinoma and gastroesophageal junction cancer. Patient numbers approximated to nearest hundred.<font style="font-style: normal;"> </font></div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">KRAS has been a historically difficult oncology target to drug, though recent clinical trial results from mutant-selective and pan-RAS approaches are important steps forward. We believe that the next advances for KRAS-directed therapies will address two outstanding problems. First, many KRAS-mutated tumors engage compensatory feedback signaling when KRAS is inhibited, suggesting combination therapy is important. Second, KRAS requires deep target inhibition, which can be difficult to achieve because of inherent pharmacologic limitations imposed by the chemical space in which most known KRAS pharmacophores reside. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">While in some cancer-types, such as KRAS-mutant low-grade serous ovarian carcinoma, KRAS blockade alone may produce meaningful single-agent activity, most KRAS-driven tumors will likely require combination therapy to realize the full potential of KRAS inhibition. One well-characterized mechanism that we believe can be countered with combination therapy is adaptive resistance through EGFR feedback. For example, in CRC, inhibiting KRAS or downstream pathway nodes has been shown to trigger compensatory EGFR signaling that enables tumor cells to bypass direct KRAS blockade. Similar biology may be relevant in pancreatic cancer as well. In these settings, adding an anti-EGFR antibody may meaningfully deepen clinical benefit. The ability of a KRAS inhibitor to participate in these combination regimens depends heavily on its tolerability, since toxicity that overlaps with a partner agent can limit the dose intensity of both drugs. This is one reason the breadth of RAS inhibition matters. A pan-RAS approach that inhibits HRAS and NRAS in addition to KRAS may introduce toxicities not attributable to KRAS inhibition alone, which could reduce the safety window in combination with other agents. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">240<br></div></div></div>
<!--End Page 251-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 252-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_117-bus_pg14"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Achieving deep and sustained target coverage poses a separate challenge. Experience with other oncogenic drivers suggests that maximal target suppression is often associated with improved efficacy, and KRAS may similarly require near-complete inhibition. This requires both high potency and favorable drug-like properties: an oral inhibitor must be sufficiently soluble and permeable to support absorption from the GI tract into the circulation, and it must be cleared at a moderate rate to sustain target inhibition even at the trough of the dosing cycle. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">These requirements have proven difficult to satisfy with many of the KRAS-directed chemotypes studied clinically to date, including agents designed to bind the switch II pocket. Among these agents, pan-KRAS inhibitors have often been limited by poor solubility, while many G12D-directed inhibitors have been limited by poor permeability. Either limitation can reduce systemic exposure and work against the continuous inhibition KRAS appears to require. These liabilities may also affect tolerability, since low bioavailability can necessitate higher doses, potentially increasing nonspecific toxicity, especially in the GI tract. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We integrated these two principles &#8212; the complex biology of KRAS cancer and the chemistry challenges of achieving deep and sustained pathway inhibition &#8212; into our TPP for TLN-372. We believe a KRAS-directed therapy needs to be combinable with other drug classes, such as anti-EGFR antibodies, immunotherapy, cytotoxic chemotherapy, and anti-PD1/PDL1 antibodies. For this reason, we have pursued a KRAS, instead of a pan-RAS, profile. We also recognized the importance of balancing the need for extreme potency with a favorable ADME/PK profile. For this reason, we have explored differentiated chemistry space from the published switch II pocket binders and have identified a DC that should not require high dose levels to potently and durably suppress the target. </div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 20pt; text-align: left;">Rationale for TLN-372 </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">TLN-372 is a selective, orally bioavailable pan-KRAS inhibitor with activity against both WT and G12D, G12V, G12C, G12S, G12A, G13C, G12F, and G13D mutant KRAS proteins. Trial TLN-372-2501 is designed to describe the safety, PK, and anti-tumor activity of TLN-372 in locally advanced or metastatic solid tumors harboring these mutations, as well as KRAS WT amplified solid tumors. This study is also designed to accelerate the development of TLN-372 in combination with other anticancer agents. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our TPP for TLN-372 &#8212; combinability with other drug classes and deep target inhibition following oral dosing &#8212; provides a useful roadmap for tracking our progress. We should be followed according to the following milestones: i) identifying a recommended Phase 2 dose and schedule associated with exposures that cause tumor regressions even in the more recalcitrant preclinical models, ii) demonstrating that human beings can withstand chronic KRAS inhibition at these levels with acceptable toxicity, iii) demonstrating single-agent response rate data consistent with effective target inhibition, and iv) demonstrating combinability with anti-EGFR antibodies, anti-PD1 therapies, immunotherapy, and cytotoxic chemotherapy. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We believe the design choices that led to TLN-372 position it well to demonstrate clinical utility across KRAS cancer. Below, we briefly compare our approach for TLN-372 with alternate approaches being pursued across the global biopharma pipeline, with a focus on mutant selective inhibitors and pan-RAS molecular glues. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><u>Mutant Selective Inhibitors.</u> In 2013, Shokat and colleagues provided a structural rationale for the development of covalent switch II inhibitors that exploit the cysteine residue of KRAS G12C. As of this writing, two such inhibitors, sotorasib and adagrasib, have received FDA approval for the second-line treatment of KRAS G12C-mutant NSCLC and in combination with anti-EGFR antibodies in CRC, with newer G12C inhibitors in late stage clinical trials. The aspartic acid residue&#8211;the &#8220;D&#8221; in G12D&#8211;is also amenable to a mutant selective approach. Many preclinical and clinical programs have adapted chemical scaffolds inspired by the G12C inhibitors. The addition of a piperidine motif, defined by a nitrogen bridge, allows these drugs to form a critical hydrogen bond and salt bridge with the aspartic acid (G12D). However, these published switch II binder G12D compounds often have low permeability, features that predict limited free drug exposure. More recently, encouraging data were presented for a covalent TCI molecular glue (defined below) called zoldonrasib, with selectivity for G12D, which uses a different chemistry approach. The conceptual appeal of mutant selective approaches is the opportunity for a wide therapeutic index, since healthy cells do not<font style="font-style: italic;"> </font>express the mutant G12C or G12D protein. The two principal downsides are: 1) the chemistry feasibility of mutant-selective inhibitors beyond C and D has not been established, such that the patients with other common KRAS mutations (G12V, etc.) require other approaches, and 2) published data suggest mutant selective drugs may apply selective pressure on the cancer to mutate and depend on other non-C/non-D KRAS mutations. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><u>Pan-RAS Molecular Glues.</u> Tri-complex molecular glues inhibit KRAS, HRAS and NRAS with similar potency. Derived from the natural product sanglifehrin A, these drugs bind cyclophilin A (&#8220;CypA&#8221;), a cellular </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">241<br></div></div></div>
<!--End Page 252-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 253-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_117-bus_pg15"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">protein. The drug-CypA complex has a high affinity for KRAS, HRAS, and NRAS when bound to GTP, preventing interactions with downstream effector proteins such as RAF or PI3K. The most advanced drug utilizing this approach, daraxonrasib (RMC-6236), has shown single-agent activity in Phase 1 and 2 trials across cancer histologies, and an OS advantage in a randomized Phase 3 trial in second-line PDAC. The conceptual appeal of pan-RAS molecular glues is their preferential potency for KRAS in its GTP bound &#8220;on&#8221; state, since rapidly dividing cancer cells depend on activated KRAS. The principal downside, however, is their simultaneous inhibition of HRAS and NRAS may contribute to the AEs of skin rash, diarrhea, nausea, vomiting and mucositis. We believe the severity of some of these AEs may prevent these agents from achieving exposures associated with maximal efficacy in humans. In addition, these toxicities overlap with those caused by chemotherapy drugs and anti-EGFR antibodies, leading to dose reductions for both the pan-RAS inhibitor and the partner drug(s) in published combination regimens. </div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 20pt; text-align: left;">Preclinical Data for TLN-372 </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The anti-tumor activity of TLN-372 was evaluated in vivo using CDX and/or PDX models of NSCLC, pancreatic, colorectal and gastric cancer. TLN-372 was active against tumor xenografts driven by KRAS G12C, KRAS G12D, KRAS G12V or KRAS WT amplification. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Single-agent oral dosing of TLN-372 at 100 mg/kg or greater BID strongly regressed the NCI-H727 NSCLC CDX model (KRAS G12V mutant) and the LU11568 NSCLC PDX model (KRAS G12D mutant) shown below.</div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 15.25pt; margin-left: 0pt; text-align: left;"><img style="height: 293px; width: 618px;" src="ny20077604x1_figure08x2.jpg"><br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Figure 8: Anti-tumor activity of TLN-372 in NSCLC<font style="font-style: normal;"> </font></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">242<br></div></div></div>
<!--End Page 253-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 254-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_117-bus_pg16"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">TLN-372 also demonstrated single-agent activity in pancreatic cancer CDX and PDX models (HPAC CDX model (KRAS G12D mutant) and PA1457 PDX model (KRAS G12D mutant) shown below). The combination of TLN-372 with the anti-EGFR antibody cetuximab demonstrated improved efficacy in some PDAC PDX models.</div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 15.25pt; text-align: center;"><img style="height: 284px; width: 618px;" src="ny20077604x1_figure09x1.jpg"><br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Figure 9: Anti-tumor activity of TLN-372 in PDAC as a single agent and in combination<font style="font-style: normal;"> </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 19.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">TLN-372 also demonstrated anti-tumor activity in colorectal and KRAS-amplified gastric cancer models. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 15.25pt; text-align: center;"><img style="height: 269px; width: 624px;" src="ny20077604x1_figure10x1.jpg"><br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Figure 10: Anti-tumor activity of TLN-372 in CRC and gastric cancer models<font style="font-style: normal;"> </font></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">243<br></div></div></div>
<!--End Page 254-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 255-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_117-bus_pg17"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6.75pt; margin-left: 20pt; text-align: left;">Ongoing Clinical Trials for TLN-372 </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In September&#160;2025, we initiated a Phase 1 clinical trial of TLN-372. The trial is open to patients with locally advanced or metastatic solid tumors with a KRAS mutation, including G12X, G13X, or WT amplification. Patients with G12R mutations are excluded from the trial. The trial design is summarized in Figure 11 below and consists of a dose escalation portion and a dose expansion portion. Combination regimens planned in dose escalation include the combination of an anti-EGFR antibody with TLN-372. Planned combinations in dose expansion that include an anti-EGFR antibody, an anti-PD-1/PD-L1 or PD-(L)1/VEGF antibody, and chemotherapy. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 14.75pt; text-align: center;"><img style="height: 245px; width: 607px;" src="ny20077604x1_figure11.jpg"><br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Figure 11: Design of Phase 1 Clinical Trial of TLN-372. Schema includes current and planned future combinations.<font style="font-style: normal;"> </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The primary endpoints of the dose escalation portion are safety and the identification of a MTD of TLN-372 as a monotherapy. Secondary endpoints include measures of PK, ORR according to RECIST, DOR, and additional safety measures. In the dose expansion and combination portion of the trial, the primary endpoints are to evaluate the anti-tumor activity ORR of TLN-372 as a monotherapy and in combination with other treatments in patients with advanced or metastatic KRAS mutant colon and pancreatic cancer, and measures of safety of TLN-372 in combination with PD-1/PD-L1 immunotherapy in patients with advanced or metastatic KRAS mutant NSCLC cancer. Secondary endpoints include additional measures of safety and tolerability of TLN-372 as a monotherapy and in combination with an anti-EGFR antibody, evaluation of the anti-tumor activity of TLN-372 in combination with anti-EGFR antibody or a PD-1/PD-L1 antibody, and measures of PK. </div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 19.5pt; margin-left: 20pt; text-align: left;">Initial Results for TLN-372 </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As of May&#160;2026, the Phase 1 dose escalation study of TLN-372 has progressed into dose-level 4. As of May&#160;2026, dose-dependent increases in PK were observed and no DLTs have been reported. Measured free-drug exposures are in line with exposures predicted by preclinical in vitro and in vivo modeling. We plan to provide guidance on the expected timing of data from this trial in the first quarter of 2027, with data anticipated later in 2027. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">TLN-499 </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">TLN-499 is an oral targeted protein degrader of BCL-XL. In healthy cells, BCL-XL plays a protective role in preventing cell death. BCL-XL acts by sequestering pro-death proteins like BIM, BAX, and BAK, thereby preventing them from aggregating, disrupting the mitochondrial membrane and causing apoptosis. Extensive third-party literature suggests that antagonizing BCL-XL could meaningfully potentiate other drug classes such as chemotherapeutics and targeted agents, including EGFR, KRAS, BRAF, MEK and BCL-2 inhibitors. To figure out which, if any, of these doublet hypotheses had the potential for the most impressive clinical results, we leveraged over 200 unique PDX models across eight cancer types, testing 19 different combinations. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our choice of a targeted protein degrader strategy for BCL-XL was in part driven by the knowledge that BCL-XL directly regulates the programmed life span of circulating platelets. Dose-limiting thrombocytopenia has been an issue for drugs that inhibit BCL-XL, such as navitoclax. TLN-499 was designed to potently degrade </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">244<br></div></div></div>
<!--End Page 255-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 256-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_117-bus_pg18"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">BCL-XL in a way that may mitigate platelet toxicity as compared to direct inhibitors. We believe that careful dosing of TLN-499 could simultaneously lead to acceptable levels of thrombocytopenia and deep knockdown of BCL-XL. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Based on our own CDX and PDX studies, we believe that the co-development of TLN-499 with the right partner drug(s) could generate meaningful anti-tumor activity in high unmet need cancers. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The combination of TLN-499 and the BCL-2 inhibitor venetoclax led to CR and durable cures in a large panel of PDX models, from which examples are shown below. The activity of this combination is qualitatively distinct from that of navitoclax, an inhibitor of both BCL-2 and BCL-XL. Navitoclax only demonstrates modest tumor growth inhibition, while the combination of a BCL-XL degrader and venetoclax effectively cures certain xenograft models, with tumors not growing back in the observation period after withdrawing treatment.</div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 14.75pt; text-align: center;"><img style="height: 223px; width: 617px;" src="ny20077604x1_figure12x1.jpg"><br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201; <br></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Figure 12: Anti-tumor activity of Treeline BCL-XL tool degrader, venetoclax, and BCL-2/BCL-XL dual inhibitor navitoclax in SCLC models; anti-tumor activity of TLN-499 and venetoclax in gastric NEC cancer model<font style="font-style: normal;"> </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Based on these data, the first hypothesis we plan to test in the clinic is the combination of TLN-499 with the BCL-2 inhibitor venetoclax in SCLC, NEC, MCC, malignant pleural mesothelioma, and synovial sarcoma.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">TLN-499 has completed IND-enabling activities, and we plan to initiate a first-in-human clinical trial in the second half of 2026. The proposed Phase 1 trial design for TLN-499 represents the co-development of a novel-novel combination. We designed the trial to minimize the exposure of clinical trial patients to single-agent therapies with very low expectations for clinical benefit, since neither TLN-499 nor venetoclax is expected to have single-agent activity in the cancers eligible for enrollment. Although there is precedent for novel-novel Phase 1 designs, the approach will require global regulatory support. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Pipeline/Future Opportunities </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The research and discovery engine that produced our clinical programs &#8212; TLN-121, TLN-372 and soon TLN-499 &#8212; is a resource that is being rapidly deployed against new high conviction targets. Whether addressing unliganded pockets and proteins, seemingly intractable medicinal chemistry challenges, or finding new solutions to therapeutic window challenges, our internal R&amp;D team continues to produce promising DCs. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our diversified preclinical pipeline currently includes programs in neurology, immunology, and oncology. We expect three new homegrown programs to enter clinical testing in 2027 and 2028. We plan to provide additional guidance on these programs in the first quarter of 2027. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">Intellectual Property </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our success depends in large part on our ability to obtain and maintain proprietary protection for our product candidates, technologies, and know-how, to operate without infringing on the proprietary rights of others, and to prevent others from infringing our proprietary rights. We actively monitor the intellectual property landscape to identify potential competitive threats, opportunities, and relevant third-party intellectual property. Our strategy is to protect and enhance our proprietary technology, inventions, and improvements that are commercially important to the development of our business by seeking, maintaining, and defending our intellectual property, whether developed internally or licensed from third parties. We will also seek to rely on protections and advantages afforded </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">245<br></div></div></div>
<!--End Page 256-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 257-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_117-bus_pg19"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">through expedited development and review, data exclusivity, market exclusivity and patent term extensions where available. We also rely on trade secrets and confidential information, know-how and continuing technological innovation to develop and maintain our proprietary and intellectual property position. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We have sought and intend to continue seeking patent protection in the United States and internationally related to the proprietary programs and technologies that we believe are important to our business, including compositions of matter of our programs, their methods of use, related technologies, diagnostics, and other inventions and improvements that are central to our research and development efforts, such as combination therapies. In addition, we intend to seek additional patent protection which may enhance commercial success to the extent warranted by future developments. We also intend to seek patent protection for manufacturing processes, formulations, and other aspects of production related to our product candidates where such protection is available and strategically warranted. We carefully manage the timing and content of our scientific publications, presentations, and other public disclosures to ensure that such disclosures do not prejudice our ability to obtain patent protection for our inventions. As of May&#160;22, 2026, our intellectual property portfolio contained owned, co-owned, and in-licensed cases and contained multiple issued and pending U.S. and foreign national applications, including provisional and national applications issued and pending in the United States, Europe, China, Japan, and additional foreign jurisdictions. As of May&#160;22, 2026, we owned, co-owned, or in-licensed ten issued U.S. patents, 161 issued foreign patents, 372&#160;pending patent applications in the U.S. and worldwide, 24 PCT applications, and 82 U.S. provisional patent applications. These patents and patent applications are expected to expire, when granted after examination in the case of pending patent applications or filed as PCT and/or U.S. non-provisional applications, between 2036 and 2047, excluding any patent term adjustments or extensions and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">TLN-121 Program </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As of May&#160;22, 2026, we own or in-license 22 patent families covering various aspects of TLN-121 and related compounds, including five issued U.S. patents, 88 issued foreign patents, 222 pending U.S. and foreign patent applications, nine PCT applications, and 22 U.S. provisional applications. These patent applications are expected to expire, when granted after examination or filed as PCT and/or U.S. non-provisional applications, between 2043 and 2047, excluding any patent term adjustments or extensions and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">TLN-254 Program </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As of May&#160;22, 2026, we own or license eight patent families covering various aspects of TLN-254, including five issued U.S. patents, 73 issued foreign patents, 52 pending U.S. and foreign patent applications, and two PCT applications. These patents and patent applications are expected to expire, when granted after examination in the case of pending patent applications or filed as PCT and/or U.S. non-provisional applications, between 2036 and 2046, excluding any patent term adjustments or extensions and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">TLN-372 Program </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As of May&#160;22, 2026, Treeline owns 12 patent families covering various aspects of TLN-372, including 83&#160;pending U.S. and foreign patent applications, three PCT applications, and seven U.S. provisional applications. These patent applications are expected to expire, when granted after examination or filed as PCT and/or U.S. non-provisional applications, between 2044 and 2047, excluding any patent term adjustments or extensions and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We expect to file additional patent applications in support of current and future product candidates as well as new platform and core technologies. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our commercial success will depend in part on obtaining and maintaining patent protection on our current and future product candidates and their related methods of use, as well as successfully defending any such patents against third-party challenges and operating without infringing on the proprietary rights of others. Our ability to stop third parties from making, using, selling, offering to sell or importing our product candidates will depend, in part, on the extent to which we have rights under valid and enforceable patents that cover these activities. The development of our product candidates is at a relatively early stage, and as a consequence, our patent portfolio is also at an early stage, and prosecution has yet to commence on some of the pending patent applications. Prosecution is a lengthy </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">246<br></div></div></div>
<!--End Page 257-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 258-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_117-bus_pg20"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">process, during which the scope of the claims initially submitted for examination by the USPTO may be narrowed (sometimes significantly) by the time they issue, if they issue at all. We expect this to be the case with respect to our pending patent applications. We cannot be sure that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications filed by us in the future, nor can we be sure that any patents that may be granted to us in the future will be commercially useful in protecting our product candidates, discovery programs and processes. For this and more comprehensive risks related to intellectual property, please see the section titled &#8220;<font style="font-style: italic;">Risk Factors &#8212; Risks Related to Treeline&#8217;s Intellectual Property</font>.&#8221; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The terms of individual patents depend upon the legal term of the patents in the countries in which they are obtained. In most countries in which we file, including the United States, the patent term is generally 20 years from the earliest date of filing a non-provisional patent application. In the United States, a patent&#8217;s term may be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the USPTO in examining and granting a patent, or may be shortened if a patent is terminally disclaimed over an earlier filed patent. In the United States, the term of a patent that covers a drug approved by the FDA may also be eligible for extension, which permits patent term restoration as compensation for the patent term lost during the FDA regulatory review process. The Hatch-Waxman Act permits a patent term extension of up to five years beyond the expiration of the patent. The length of the patent term extension is related to the length of time the subject drug candidate is under regulatory review. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval; only one patent may be extended; and only those claims covering the approved product, a method for using it, or a method for manufacturing it may be extended. Similar provisions to extend the term of a patent that covers an approved drug are available in Europe and certain foreign jurisdictions. In the future, if and when our products receive FDA approval, we expect to apply for patent term extensions on patents covering those products. We plan to seek patent term extensions to any issued patents we may obtain in any jurisdiction where such patent term extensions are available; however, there is no guarantee that the applicable authorities, including the FDA in the United States, will agree with our assessment that such extensions should be granted, and if granted, the length of such extensions. For more information regarding the risks related to intellectual property, see the section titled &#8220;<font style="font-style: italic;">Risk Factors &#8212; Risks Related to Treeline&#8217;s Intellectual Property</font>.&#8221; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In most instances, we have submitted and expect to submit patent applications directly to the USPTO as provisional patent applications. Corresponding non-provisional patent applications and/or PCT applications must be filed not later than 12 months after the provisional application filing date. While we intend to timely file non-provisional patent applications and/or PCT applications relating to our provisional patent applications, we cannot predict whether any such patent applications will result in the issuance of patents that provide us with any competitive advantage. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We file U.S. non-provisional applications and PCT applications that claim the benefit of the priority date of earlier filed provisional applications, when applicable. The PCT system allows an international patent application to be filed within 12 months of the filing date of each provisional application, and to designate all of the PCT member states in which national patent applications can later be pursued based on the international patent application filed under the PCT. The PCT searching authority performs a patentability search and issues a non-binding patentability opinion which can be used to evaluate the chances of success for the national applications in foreign countries prior to having to incur the filing fees. Although a PCT application does not issue as a patent, it allows the applicant to seek protection in any of the member states through national-phase applications. Before the end of the period of approximately two and a half years from the first priority date of the patent application, separate patent applications can be pursued in any of the PCT member states either by direct national filing or, in some cases, by filing through a regional patent organization, such as the European Patent Office. The PCT system delays expenses, allows a limited evaluation of the chances of success for national/regional patent applications, and enables substantial savings where applications are abandoned within the first two and a half years of filing. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For all patent applications, we determine claiming strategy on a case-by-case basis. Advice of counsel and our business model and needs are always considered. We seek to file patents containing claims for protection of all useful applications of our proprietary technologies and any product candidates, as well as all new applications and/or uses we discover for existing technologies and product candidates, assuming these are strategically valuable. We continuously reassess the number and type of patent applications, as well as the pending and issued patent claims to pursue maximum coverage and value for our processes and compositions, given existing patent office rules and regulations. Further, claims may be modified during patent prosecution to meet our intellectual property and business needs. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">247<br></div></div></div>
<!--End Page 258-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 259-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_117-bus_pg21"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We recognize that the ability to obtain patent protection and the degree of such protection depend on a number of factors, including the extent of the prior art, the novelty and non-obviousness of the invention, and the ability to satisfy the enablement requirement of the patent laws. In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted or further altered even after patent issuance. Consequently, we may not obtain or maintain adequate patent protection for any of our future product candidates or for our technology platform. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from competitors. Any patents that we hold may be challenged, circumvented or invalidated by third parties. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition to patent protection, we rely on the protection of our trade secrets, unpatented know-how, technology and other proprietary information to maintain our competitive position. We seek to protect and maintain the confidentiality of proprietary information to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection. Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees, consultants, vendors, collaborators and advisors, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology. Thus, we may not be able to meaningfully protect our trade secrets. It is our policy to require our employees, consultants, vendors, outside scientific collaborators, sponsored researchers and other advisors to execute confidentiality agreements upon the commencement of employment or consulting or other relationships with us. These agreements provide that all confidential information concerning our business or financial affairs developed or made known to the individual during the course of the individual&#8217;s or entity&#8217;s relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances. Our agreements with employees also provide that all inventions conceived by the employee in the course of employment with us or from the employee&#8217;s use of our confidential information are our exclusive property. However, such confidentiality agreements and invention assignment agreements can be breached and we may not have adequate remedies for any such breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. If our employees, consultants, vendors, collaborators or advisors use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting trade secrets, know-how and inventions. For more information regarding the risks related to our intellectual property, see the section titled &#8220;<font style="font-style: italic;">Risk Factors &#8212; Risks Related to Treeline&#8217;s Intellectual Property</font>.&#8221; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The patent positions of biotechnology and biopharmaceutical companies like us are generally uncertain and involve complex legal, scientific and factual questions. Our commercial success will also depend in part on not infringing upon the proprietary rights of third parties. Third-party patents could require us to alter our development or commercial strategies, or our product candidates, products or processes, obtain licenses or cease certain activities. Our breach of any license agreements or our failure to obtain a license to proprietary rights required to develop or commercialize our future products may have a material adverse impact on us. If third parties prepare and file patent applications in the United States that also claim technology to which we have rights, we may have to participate in interference or derivation proceedings in the USPTO to determine priority of invention. For more information, see the section titled &#8220;<font style="font-style: italic;">Risk Factors &#8212; Risks Related to Treeline&#8217;s Intellectual Property</font>.&#8221; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">When available to expand market exclusivity, our strategy is to obtain or license additional intellectual property related to current or contemplated development platforms, core elements of technology and/or clinical candidates. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">Manufacturing </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We rely on, oversee, and manage third-party CDMOs to support development and manufacture of product candidates for our clinical trials, including with respect to the manufacture and supply of starting materials, intermediates, drug substance (&#8220;DS&#8221;) and drug product (&#8220;DP&#8221;), and packaged and labeled clinical trial materials for our product candidates for use in clinical trials. We expect our strategy of using CDMOs will enable us to maintain a more efficient infrastructure, avoiding the necessity to acquire our own manufacturing facilities and equipment, while simultaneously enabling us to focus our expertise on the clinical development and the potential future commercialization of our products. We believe our use of well-understood modalities, small molecules (inhibitors and degraders) and antibody drug conjugates, along with our use of established dosage forms (tablets, gelcaps, lyophilized products for reconstitution), will allow us to continue to use CDMOs to manufacture our product candidates using reliable and reproducible processes. In the event we advance any of our product candidates to Phase 3 clinical trials, we intend to qualify, enter into manufacturing and supply agreements with, and potentially </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">248<br></div></div></div>
<!--End Page 259-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 260-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_117-bus_pg22"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">transfer DS and DP manufacture and commercial packaging to one or more additional third-party CDMOs with whom we may also enter into commercial supply agreements prior to any potential regulatory approval if any of our product candidates are approved and commercialized. We expect to continue developing product candidates that can be produced cost-effectively using CDMOs. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Government Regulation </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Government authorities in the United States, at the federal, state and local level, and in other countries and jurisdictions, extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, post-approval monitoring and reporting, and import and export of pharmaceutical products. The processes for obtaining regulatory approvals in the United States and in foreign countries and jurisdictions, along with subsequent compliance with applicable statutes and regulations and other regulatory authorities, require the expenditure of substantial time and financial resources. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">FDA Review and Approval Process </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In the United States, pharmaceutical products are subject to extensive regulation by the FDA. The Federal Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;) and other federal and state statutes and regulations govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of pharmaceutical products. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Pharmaceutical products used for the prevention, treatment, diagnosis, mitigation, or cure of a disease or condition of a human being are subject to regulation under the FDCA and are approved for marketing under the New Drug Application (&#8220;NDA&#8221;) pathway. Failure to comply with applicable United States requirements may subject a company to a variety of administrative or judicial sanctions, such as a clinical hold, FDA refusal to approve pending NDAs, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties, and criminal prosecution. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Pharmaceutical product development for a new product or certain changes to an approved product in the United States typically involves preclinical laboratory and animal tests, the submission to the FDA of an Investigational New Drug application (&#8220;IND&#8221;) which must become effective before clinical testing may commence, and adequate and well-controlled clinical trials to establish the safety and effectiveness of the drug for each indication for which FDA approval is sought. Satisfaction of FDA pre-market approval requirements typically takes many years, and the actual time required may vary substantially based upon the type, complexity, and novelty of the product or disease. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Preclinical tests include laboratory evaluation of product chemistry, formulation, and toxicity, as well as animal trials to assess pharmacological and toxicological characteristics of the active ingredient to identify potential safety concerns of the product. The conduct of the preclinical tests must comply with federal regulations and requirements, including Good Laboratory Practices (&#8220;GLP&#8221;). The results of preclinical testing are submitted to the FDA as part of an IND along with other information, including information about product chemistry, manufacturing, and controls (&#8220;CMC&#8221;) and a proposed clinical trial protocol. Long-term preclinical tests, such as animal tests of reproductive toxicity and carcinogenicity, may continue after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA may impose a partial or full clinical hold. A partial clinical hold is a delay or suspension of fewer than all clinical trials subject to the IND, or certain parts of a clinical trial. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Clinical trials involve the administration of the investigational drug to healthy volunteers or patients under the supervision of a qualified investigator. Clinical trials must be conducted: (i) in compliance with federal regulations; (ii)&#160;in compliance with Good Clinical Practices (&#8220;GCPs&#8221;), an international standard meant to protect the rights, safety and welfare of research participants and to define the roles of clinical trial sponsors, administrators, and monitors; as well as (iii) under protocols detailing the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. Each protocol involving testing on U.S. participants and subsequent protocol amendments must be submitted to the FDA as part of the IND. While the IND is active, progress reports summarizing the results, if known, of the clinical trials and preclinical studies performed since the </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">249<br></div></div></div>
<!--End Page 260-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 261-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_117-bus_pg23"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">last progress report, among other information, must be submitted at least annually to the FDA, and written IND safety reports must be submitted to the FDA and investigators in certain circumstances. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The FDA may order the temporary or permanent discontinuation of a clinical trial at any time, or impose other sanctions, if it believes that the clinical trial either is not being conducted in accordance with FDA regulations or presents an unacceptable risk to the clinical trial participants. The study protocol and informed consent information for participants in clinical trials must also be submitted to an Institutional Review Board (&#8220;IRB&#8221;) for approval. The IRB will also monitor the clinical trial until it is completed. The IRB may also require the clinical trial at the site to be halted, either temporarily or permanently, for failure to comply with the IRB&#8217;s requirements, or may impose other conditions. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether a trial may move forward at designated checkpoints based on access to certain data from the trial. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Clinical trials to support NDAs for marketing approval are typically conducted in three sequential phases, but the phases may be combined or overlap. In Phase 1, the initial introduction of the drug into healthy human subjects or patients, the product is tested to assess safety, dosage tolerance, metabolism, pharmacokinetics (&#8220;PK&#8221;), pharmacological actions, side effects associated with drug exposure, and to obtain early evidence of a treatment effect if possible. Phase 2 usually involves trials in a limited patient population to determine the effectiveness of the drug for a particular indication, determine optimal dose and regimen, and to identify common adverse effects and safety risks. If a compound demonstrates evidence of effectiveness and an acceptable safety profile in Phase 2 evaluations, Phase 3 trials are undertaken to obtain additional information about clinical effects and confirm efficacy and safety in a larger number of patients, typically at geographically dispersed clinical trial sites, to permit the FDA to evaluate the overall benefit-risk relationship of the drug and to provide adequate information for the labeling of the product. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The FDA requires that a sponsor demonstrates that the drug is safe for its intended use, there is substantial evidence of the drug&#8217;s effectiveness, and the drug&#8217;s benefits outweigh its risks. Substantial evidence of effectiveness may be demonstrated by a single adequate and well-controlled trial, typically Phase 3, plus confirmatory evidence or by more than one adequate and well-controlled clinical trial. In the case of a single adequate and well-controlled clinical trial plus confirmatory evidence, the strength of the design, conduct, analysis, and results of the single trial will affect the strength of confirmatory evidence needed to establish substantial evidence of effectiveness, with a general expectation for either a highly persuasive trial or a source of strong confirmatory evidence. FDA may exercise flexibility regarding the application of these standards based on clinical considerations such as disease severity, unmet need, and disease rarity. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, the sponsor of an investigational drug in a Phase 2 or Phase 3 clinical trial for a serious or life-threatening disease is required to make available, such as by posting on its website, its policy on evaluating and responding to requests for expanded access to such investigational drug. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">FDA Review Process </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, an NDA is prepared and submitted to the FDA. FDA approval of the NDA is required before marketing and distribution of the product may begin in the United States. The NDA must include the results of all preclinical, clinical and other testing, as well as a compilation of data relating to the product&#8217;s pharmacology and CMC. The cost of preparing and submitting an NDA is substantial. The submission of most NDAs is additionally subject to a substantial application user fee. Under an approved NDA, the applicant is also subject to an annual program fee. These fees typically increase annually. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The FDA has 60 days from its receipt of an NDA to conduct a preliminary review and determine whether the application will be filed based on the FDA&#8217;s threshold determination that it is adequately organized and sufficiently complete to permit substantive review. If the FDA determines the application is incomplete because it does not on its face contain required information, the FDA may refuse to file the application and request additional information rather than file an NDA. In this event, the NDA must be resubmitted with the additional information. The resubmitted application also is subject to preliminary review before the FDA files it. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Once the submission is filed, the FDA begins an in-depth review. The FDA has agreed to certain performance goals to complete the review of NDAs. Most applications are classified as Standard Review products that have a goal of being reviewed within ten months of the date the FDA files the NDA; applications classified as Priority </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">250<br></div></div></div>
<!--End Page 261-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 262-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_117-bus_pg24"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Review have a goal of being reviewed within six months of the date the FDA files the NDA. An NDA can be classified for Priority Review when the FDA determines the drug has the potential to treat a serious or life-threatening condition and, if approved, would be a significant improvement in safety or effectiveness compared to available therapies. The FDA does not always meet its PDUFA goal dates for standard and priority NDAs, and the review process for both standard and priority reviews may be extended by the FDA for three months to consider information the FDA considers to be a major amendment to the NDA. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The FDA may also refer applications for novel drugs, as well as drugs that present difficult questions of safety or efficacy, to an advisory committee &#8212; typically a panel that includes clinicians, statisticians, and other experts &#8212; for review, evaluation, and a recommendation as to whether the NDA should be approved. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCPs. Additionally, the FDA will generally inspect the facility or the facilities at which the drug product is manufactured. The FDA will not approve the product unless compliance with current Good Manufacturing Practices (&#8220;cGMP&#8221;) is satisfactory and adequate to assure consistent production of the product within required specifications, and the NDA contains data that provide substantial evidence that the drug is safe and effective in the claimed indication. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">After the FDA evaluates the NDA and completes any clinical and manufacturing site inspections, it issues either an approval letter or a complete response letter. A complete response letter generally outlines the deficiencies in the NDA submission and may require substantial additional testing, or information, in order for the FDA to reconsider the application for approval. If, or when, those deficiencies have been addressed to the FDA&#8217;s satisfaction in a resubmission of the NDA, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in two or six months depending on the type of information included. Even if such data and information are submitted, the FDA may decide that the NDA does not satisfy the criteria for approval. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">An approval letter authorizes commercial marketing and distribution of the drug with specific prescribing information for specific indications. As a condition of NDA approval, the FDA may require a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;) to help ensure that the benefits of the drug outweigh the potential risks to patients. A REMS can include medication guides, communication plans for healthcare professionals, and elements to assure safe use (&#8220;ETASU&#8221;). ETASU can include, but are not limited to, special training or certification for prescribing or dispensing the drug, dispensing the drug only under certain circumstances, special monitoring, and the use of patient-specific registries. The requirement for a REMS can materially affect the potential market and profitability of the product. Moreover, the FDA may require substantial post-approval testing and surveillance to monitor the product&#8217;s safety or efficacy. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Once granted, product approvals may be withdrawn if compliance with regulatory standards is not maintained, or problems are identified following initial marketing. Changes to some of the conditions established in an approved NDA, including changes in indications, labeling, or manufacturing processes or facilities, require submission and FDA approval of a new NDA, or NDA supplement before the change can be implemented. An NDA supplement for a new indication typically requires clinical data similar to that in the original application, and the FDA uses the same procedures and actions in reviewing NDA supplements as it does in reviewing original NDAs. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Expedited Programs </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The FDA is authorized to facilitate the development, and expedite the review, of drugs that are intended for the treatment of a serious or life-threatening disease or condition for which there is no effective treatment and which demonstrate the potential to address unmet medical needs for the condition. These programs include fast track designation and breakthrough therapy designation. These designations are not mutually exclusive, and product candidates may qualify for one or more of these programs. Although these programs are intended to expedite product development and review, they do not alter the standards for FDA approval. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Fast track designation may be granted for products that are intended to treat a serious or life-threatening disease or condition and preclinical or clinical data demonstrate the potential to address unmet medical needs for the condition. Fast track designation applies to both the product and the specific indication for which it is being studied. The sponsor of a new product candidate can request the FDA to designate the candidate for a specific indication for fast track status concurrent with, or after, submission of the IND for the candidate. The FDA must determine if the product candidate qualifies for fast track designation within 60 days of receipt of the sponsor&#8217;s request. Sponsors of </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">251<br></div></div></div>
<!--End Page 262-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 263-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_117-bus_pg25"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">product candidates designated as fast track products may have greater interactions with the FDA, and the FDA may initiate review of sections of the fast track product candidate&#8217;s NDA before the application is complete. This &#8220;rolling review&#8221; is available if the FDA determines, after preliminary evaluation of clinical data submitted by the sponsor, that a fast track product candidate may be effective. The sponsor must also provide, and the FDA must approve, a schedule for the submission of the remaining information, and the sponsor must pay applicable user fees. However, the FDA&#8217;s goal timeline for reviewing a rolling submission does not begin until the last section of the application is submitted. In addition, the fast track designation may be withdrawn by the FDA if the FDA believes that the designation is no longer supported by data emerging in the clinical trial process, or if the designated product candidate development program is no longer being pursued. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Breakthrough therapy designation may be granted for products that are intended, alone or in combination with one or more other products, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that product candidates may demonstrate substantial improvement over currently approved therapies on one or more clinically significant endpoints. Under the breakthrough therapy program, the sponsor of a new product candidate may request that the FDA designate the candidate for a specific indication as a breakthrough therapy concurrent with, or after, the submission of the IND for the drug product. The FDA must determine if the drug product qualifies for breakthrough therapy designation within 60 days of receipt of the sponsor&#8217;s request. The FDA may take certain actions with respect to breakthrough therapies, including holding meetings with the sponsor throughout the development process, providing timely advice to the product sponsor regarding development and approval, involving more senior staff in the review process, assigning a cross-disciplinary project lead for the review team, and taking other steps to design the clinical studies in an efficient manner. Breakthrough therapy designation may be rescinded if a product candidate no longer meets the qualifying criteria. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Accelerated Approval Pathway </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Accelerated approval may be granted for a product that is intended to treat a serious or life-threatening condition that provides a meaningful therapeutic advantage to patients over existing treatments. A product eligible for accelerated approval may be approved on the basis of either a surrogate endpoint that is reasonably likely to predict clinical benefit, or on an intermediate clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality (&#8220;IMM&#8221;) and that is reasonably likely to predict an effect on IMM or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition, and the availability or lack of alternative treatments. Product candidates granted accelerated approval must meet the same statutory standards for safety and efficacy as those granted traditional approval. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit but is not itself a measure of clinical benefit. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. An intermediate clinical endpoint is a measurement of a therapeutic effect that is considered reasonably likely to predict the clinical benefit of a product candidate, such as an effect on IMM. The FDA has limited experience with accelerated approvals based on intermediate clinical endpoints but has indicated that such endpoints generally could support accelerated approval where a clinical trial demonstrates a relatively short-term clinical benefit in a chronic disease setting in which assessing long-term clinical benefit is essential for traditional approval, but the short-term benefit is considered reasonably likely to predict long-term benefit. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The accelerated approval pathway is most often used in settings in which the course of a disease is long, and an extended period of time is required to measure the intended clinical benefit of a product candidate, even if the effect on the surrogate or intermediate clinical endpoint occurs rapidly. Thus, accelerated approval has been used extensively in the development and approval of products for treatment of a variety of cancers in which the goal of therapy is generally to improve survival or decrease morbidity and the duration of the typical disease course requires lengthy and sometimes large studies to demonstrate a clinical or survival benefit. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The accelerated approval pathway is usually contingent on a sponsor&#8217;s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the product candidate&#8217;s clinical benefit, and, in most cases, the FDA may require that the trial be designed, initiated, and/or fully enrolled prior to approval. As a result, a product candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion of post-approval clinical trials to confirm the effect on the clinical endpoint. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">252<br></div></div></div>
<!--End Page 263-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 264-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_117-bus_pg26"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Failure to conduct required post-approval studies, or confirm a clinical benefit during post-marketing studies, would allow the FDA to withdraw the product from the market on an expedited basis. All promotional materials for product candidates approved under accelerated approval are subject to prior review by the FDA unless the FDA informs the sponsor otherwise. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The FDA is authorized to require a post-approval study to be underway prior to approval or within a specified time period following approval and is required to specify conditions of any required post-approval study, which may include milestones such as a target date of study completion. Sponsors are required to submit progress reports for required post-approval studies and any conditions required by the FDA not later than 180 calendar days following approval and not less frequently than every 180 days thereafter until completion or termination of the study. The FDA may initiate enforcement action for the failure to conduct with due diligence a required post-approval study, including a failure to meet any required conditions specified by the FDA or to submit timely reports. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Disclosure of Clinical Trial Information </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Sponsors of clinical trials of FDA-regulated products, including drugs, are required to register and disclose certain clinical trial information on the website www.ClinicalTrials.gov. Information related to the product, patient population, phase of investigation, trial sites and investigators, and other aspects of the clinical trial is then made public as part of the registration. Sponsors are also obligated to disclose the results of their clinical trials after completion. Disclosure of the results of clinical trials can be delayed in certain circumstances for up to two years after the date of completion of the trial. Competitors may use this publicly available information to gain knowledge regarding the progress of development programs as well as clinical trial design. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">U.S. Patent Term Restoration and Marketing Exclusivity </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Amendments, NDA applicants are required to identify to FDA each patent whose claims cover the applicant&#8217;s drug or approved method of using the drug. Upon approval of a drug, the applicant must update its listing of patents to the FDA in a timely fashion, and each of the patents listed in the application for the drug is then published in the FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Drugs listed in the Orange Book can, in turn, be cited by potential generic competitors in support of approval of an abbreviated NDA (&#8220;ANDA&#8221;). An ANDA provides for marketing of a drug product that has the same active ingredient(s), strength, route of administration, and dosage form as the listed drug and has been shown through bioequivalence testing to be therapeutically equivalent to the listed drug. An approved ANDA product is considered to be therapeutically equivalent to the listed drug. Other than the requirement for bioequivalence testing, ANDA applicants are not required to conduct, or submit results of, preclinical or clinical tests to prove the safety or effectiveness of their drug product. Drugs approved under the ANDA pathway are commonly referred to as &#8220;generic equivalents&#8221; to the listed drug and can often be substituted by pharmacists under prescriptions written for the original listed drug pursuant to each state&#8217;s laws on drug substitution. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The ANDA applicant is required to certify to the FDA concerning any patents identified for the reference listed drug in the Orange Book. Specifically, the applicant must certify to each patent in one of the following ways: (i) the required patent information has not been filed; (ii) the listed patent has expired; (iii) the listed patent has not expired but will expire on a particular date and approval is sought after patent expiration; or (iv) the listed patent is invalid, unenforceable or will not be infringed by the new product. A certification that the new product will not infringe the already approved product&#8217;s listed patents, or that such patents are invalid or unenforceable, is called a Paragraph IV certification. For patents listed that claim an approved method of use, under certain circumstances the ANDA applicant may also elect to submit a statement certifying that its proposed ANDA label does not contain (or carves out) any language regarding the patented method-of-use rather than certify to a listed method-of-use patent, which is called a Section&#160;VIII statement. If the applicant does not challenge the listed patents through a Paragraph IV certification, the ANDA application will not be approved until all the listed patents claiming the referenced product have expired. If the ANDA applicant has provided a Paragraph IV certification to the FDA, the applicant must also send notice of the Paragraph IV certification to the NDA-holder and patentee(s) once the ANDA has been accepted for filing by the FDA (referred to as the &#8220;notice letter&#8221;). The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice letter. The filing of a patent infringement lawsuit within 45 days of the receipt of a Paragraph IV certification automatically prevents the FDA from approving the ANDA until the earlier of </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">253<br></div></div></div>
<!--End Page 264-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 265-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_117-bus_pg27"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">30 months from the date the notice letter is received, expiration of the patent, the date of a settlement order or consent decree signed and entered by the court stating that the patent that is the subject of the certification is invalid or not infringed, or a decision in the patent case that is favorable to the ANDA applicant. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The ANDA application also will not be approved until any applicable non-patent exclusivity listed in the Orange Book for the referenced product has expired. In some instances, an ANDA applicant may receive approval prior to expiration of certain non-patent exclusivity if the applicant seeks, and FDA permits, the omission of such exclusivity-protected information from the ANDA prescribing information. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Upon NDA approval of a new chemical entity (&#8220;NCE&#8221;), which is a drug that contains no active moiety that has been approved by FDA in any other NDA, that drug receives five years of marketing exclusivity during which FDA cannot receive any ANDA seeking approval of a generic version of that drug unless the application contains a Paragraph IV certification, in which case the application may be submitted one year prior to expiration of the NCE exclusivity. If there is no listed patent in the Orange Book, there may not be a Paragraph IV certification, and, thus, no ANDA for a generic version of the drug may be filed before the expiration of the exclusivity period. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Certain changes to an approved drug, such as the approval of a new indication, the approval of a new strength, and the approval of a new condition of use, are associated with a three-year period of exclusivity from the date of approval during which FDA cannot approve an ANDA for a generic drug that includes the change. In some instances, an ANDA applicant may receive approval prior to expiration of the three-year exclusivity if the applicant seeks, and FDA permits, the omission of such exclusivity-protected information from the ANDA package insert. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Hatch-Waxman Amendments permit a patent term extension as compensation for patent term lost during the FDA regulatory review process. Patent term extension, however, cannot extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date. After NDA approval, owners of relevant drug patents may apply for the extension. The allowable patent term extension depends on a number of factors and is on a case-by-case basis, generally calculated as half of the drug&#8217;s testing phase (the time between IND application and NDA submission) and all of the review phase (the time between NDA submission and approval) that occurs after patent issuance up to a maximum of five years and subject to the 14-year cap. The time can be reduced for any time FDA determines that the applicant did not pursue approval with due diligence. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The United States Patent and Trademark Office (&#8220;USPTO&#8221;), in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. However, the USPTO may not grant an extension because of, for example, an applicant failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than requested. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The total patent term after the extension may not extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be enforced during the extension period. The application for the extension must be submitted prior to the expiration of the patent, and for patents that might expire during the application phase, the patent owner may request an interim patent extension. An interim patent extension increases the patent term by up to one year and may be renewed up to four times. For each interim patent extension granted, the post-approval patent extension is reduced by one year. The director of the USPTO must determine that approval of the drug covered by the patent for which a patent extension is being sought is likely. Interim patent extensions are not available for a drug for which an NDA has not been submitted. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Pediatric Information </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under the Pediatric Research Equity Act (&#8220;PREA&#8221;), NDAs or supplements to NDAs must contain data to assess the safety and effectiveness of the drug product for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the drug product is safe and effective. The FDA may grant full or partial waivers or deferrals for submission of data.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Best Pharmaceuticals for Children Act (&#8220;BPCA&#8221;) provides a six-month extension of exclusivity&#8212;patent or non-patent&#8212;for a drug if certain conditions are met. Conditions for exclusivity include the FDA&#8217;s determination that information relating to the use of a new drug in the pediatric population may produce health benefits in that </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">254<br></div></div></div>
<!--End Page 265-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 266-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_117-bus_pg28"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">population, the FDA making a written request for pediatric studies, and the applicant agreeing to perform, and reporting on, the requested studies within the statutory time frame. Applications under the BPCA are treated as priority applications, with all of the benefits that designation confers. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Post-Approval Requirements </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Once an NDA is approved, a product will be subject to certain post-approval requirements. For instance, the FDA closely regulates the post-approval marketing and promotion of drugs, including standards and regulations for direct-to-consumer advertising, off-label promotion, industry-sponsored scientific and educational activities and promotional activities involving the internet. Drugs may be marketed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability, including investigation by federal and state authorities. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Adverse event reporting and submission of periodic reports is required following FDA approval of an NDA. The FDA also may require post-marketing testing, REMS, and surveillance to monitor the effects of an approved product, or the FDA may place conditions on an approval that could restrict the distribution or use of the product. In addition, quality control, drug manufacture, packaging, and labeling procedures must continue to conform to cGMPs after approval. Drug manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies. Registration with the FDA subjects entities to periodic unannounced inspections by the FDA, during which the agency inspects a drug&#8217;s manufacturing facilities to assess compliance with cGMP. Accordingly, manufacturers must continue to expend time, money, and effort in the areas of production and quality-control to maintain compliance with cGMP. Regulatory authorities may withdraw product approvals or request product recalls if a company fails to comply with regulatory standards, if it encounters problems following initial marketing, or if previously unrecognized problems are subsequently discovered. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Other potential consequences include, among other things: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Form&#160;483s, restrictions on the manufacturing of the product, product recalls or withdrawal of the product from the market; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">warning or untitled letters or holds on clinical trials; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">refusal of the FDA or comparable foreign regulatory authorities to accept new marketing applications or approve pending applications or supplements to approved applications, or suspension or revocation of product approvals; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">product seizure or detention, or refusal to permit the import or export of products; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">mandated modification of promotional materials and labeling and the issuance of corrective information; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing warnings or other safety information about the product; or </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">injunctions or the imposition of fines or civil or criminal penalties. </div></td></tr></table><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Regulation Outside of the United States </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition to regulations in the United States, pharmaceutical companies may also be subject to a variety of regulations in other jurisdictions governing clinical studies, commercial sales, and distribution of pharmaceutical products. Most countries outside of the United States require that clinical trial applications be submitted to and approved by the local regulatory authority for each clinical study. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In Canada, for example, the manufacture and sale of new drugs are controlled by Health Canada. New drugs must pass through a number of testing stages, including preclinical testing and human clinical trials. Preclinical testing involves testing the new drug&#8217;s chemistry, pharmacology and toxicology in vitro and in vivo. Successful results (that is, potentially valuable pharmacological activity combined with an acceptable low level of toxicity) enable the developer of the new drug to file a clinical trial application to begin clinical trials involving humans. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">To study a drug in Canadian patients, a clinical trial application submission must be filed with Health Canada. The clinical trial application submission must contain specified information, including the results of the pre-clinical </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">255<br></div></div></div>
<!--End Page 266-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 267-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_117-bus_pg29"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">tests completed at the time of the submission and any available information regarding use of the drug in humans. In addition, since the method of manufacture may affect the efficacy and safety of a new drug, information on manufacturing methods and standards and the stability of the drug substance and dosage form must be presented. Production methods and quality control procedures must be in place to ensure an acceptably pure product, essentially free of contamination, and to ensure uniformity with respect to all quality aspects. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, all federally regulated trials must be approved and monitored by an independent committee of doctors, scientists, advocates and others to ensure safety and ethical standards, known as IRBs or Ethics Review Boards (&#8220;ERBs&#8221;). The review boards study and approve all study-related documents before a clinical trial begins and also carefully monitor data to detect benefit or harm, and validity of results. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Provided Health Canada does not reject a clinical trial application submission and IRB or ERB approval has been obtained, clinical trials can begin. Clinical trials for product candidates in Canada, as in the United States, are generally carried out in three phases. Phase 1 involves studies to evaluate toxicity and ideal dose levels in healthy humans. The new drug is administered to human patients who have met the clinical trial entry criteria to determine pharmacokinetics, human tolerance and prevalence of any adverse side effects. Phases 2 and 3 involve therapeutic studies. In Phase 2, efficacy, dosage, side effects and safety are established in a small number of patients who have the disease or disorder that the new drug is intended to treat. In Phase 3, there are controlled clinical trials in which the new drug is administered to a large number of patients who are likely to receive benefit from the new drug. In Phase 3, the effectiveness of the new drug in patients is compared to that of standard accepted methods of treatment in order to provide sufficient data for the statistical proof of safety and efficacy for the new drug. If clinical studies establish that a new drug has value, the manufacturer submits a new drug submission application to Health Canada for marketing approval. The new drug submission contains all known information about the new drug, including the results of preclinical testing and clinical trials. Information about a substance contained in a new drug submission includes its proper name, its chemical name, and details on its method of manufacturing and purification, and its biological, pharmacological and toxicological properties. The new drug submission also provides information about the dosage form of the new drug, including a quantitative listing of all ingredients used in its formulation, its method of manufacture, manufacturing facility information, packaging and labeling, the results of stability tests, and its diagnostic or therapeutic claims and side effects, as well as details of the clinical trials to support the safety and efficacy of the new drug. Furthermore, for biological products, an on-site evaluation is completed to assess the production process and manufacturing facility. It is required prior to the issuance of a notice of compliance. All aspects of the new drug submission are critically reviewed by Health Canada. If a new drug submission is found satisfactory, a notice of compliance is issued permitting the new drug to be sold for the approved use. In addition to obtaining a Notice of Compliance, Canadian law generally requires any establishment that fabricates, packages/labels, imports, distributes, wholesales or tests a drug to hold a Drug Establishment Licence (DEL) under the Food and Drug Regulations. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Health Canada has a policy of priority evaluation of new drug submissions for all drugs intended for serious or life-threatening diseases for which no drug product has received regulatory approval in Canada and for which there is reasonable scientific evidence to indicate that the proposed new drug is safe and may provide effective treatment. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">An exception to the foregoing requirements relating to the manufacture and sale of a new drug is the limited authorization that may be available in respect of the sale of new drugs for emergency treatment. Under the special access program, Health Canada may authorize the sale of a quantity of a new drug for human use to a specific practitioner for the emergency treatment of a patient under the practitioner&#8217;s care. Prior to authorization, the practitioner must supply Health Canada with information concerning the medical emergency for which the new drug is required, such data as is in the possession of the practitioner with respect to the use, safety and efficacy of the new drug, the names of the institutions at which the new drug is to be used and such other information as may be requested by Health Canada. In addition, the practitioner must agree to report to both the drug manufacturer and Health Canada the results of the new drug&#8217;s use in the medical emergency, including information concerning adverse reactions, and must account to Health Canada for all quantities of the new drug made available. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Canadian regulatory approval requirements for new drugs outlined above are similar to those of other major pharmaceutical markets. While the testing carried out in Canada is often acceptable for the purposes of regulatory submissions in other countries, individual regulatory authorities may request supplementary testing during their assessment of any submission. Therefore, the clinical testing conducted under Health Canada authorization or the approval of regulatory authorities of other countries may not be accepted by regulatory authorities outside Canada or other countries. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">256<br></div></div></div>
<!--End Page 267-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 268-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_117-bus_pg30"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The monitoring of a new drug does not cease once it is on the market. For example, a manufacturer of a new drug must report any new information received concerning serious side effects, as well as the failure of the new drug to produce desired effects. If Health Canada determines it to be in the interest of public health, a notice of compliance for a new drug may be suspended and the new drug may be removed from the market. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">A post-marketing surveillance program involves clinical trials conducted after a drug is marketed (referred to as Phase 4 studies in the United States) and is an important source of information on as yet undetected adverse outcomes, especially in populations that may not have been involved in the premarketing trials (e.g., children, the elderly, pregnant women) and the drug&#8217;s long-term morbidity and mortality profile. Regulatory authorities may require companies to conduct Phase 4 studies as a condition of market approval. Companies often conduct post-marketing studies in the absence of a regulatory mandate. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">Healthcare Laws and Regulations </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Sales of pharmaceutical products and related activities, such as arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers, are subject to fraud and abuse and other healthcare laws and regulations, which are enforced by the federal government and the states and foreign governments in which the business is conducted. Applicable healthcare laws and regulations that may affect a company&#8217;s ability to operate if and when marketing approval is granted for a product candidate include the following: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the federal Anti-Kickback Statute, which prohibits, among other things, individuals and entities from knowingly and willfully soliciting, receiving, offering or providing remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order, or recommendation of, any good or service for which payment may be made, in whole or in part, under a federal or state healthcare program, such as Medicare or Medicaid. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Rather, if &#8220;one purpose&#8221; of the remuneration is to induce referrals, the federal Anti-Kickback Statute is violated. Violations are subject to civil and criminal fines and penalties for each violation, plus up to three times the remuneration involved, imprisonment, and exclusion from federal programs; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the federal criminal and civil false claims and civil monetary penalties laws, including the federal False Claims Act (&#8220;FCA&#8221;), which can be enforced through civil whistleblower or &#8220;qui tam&#8221; actions against individuals or entities, and prohibits, among other things, knowingly presenting, or causing to be presented to the federal government claims for payment that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. Manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims. In addition, certain marketing practices, including off-label promotion, may also violate false claims laws. Moreover, the government may assert that a claim including items and services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA. The FCA also permits a private individual acting as a &#8220;whistleblower&#8221; to bring actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Health Insurance Portability and Accountability Act (&#8220;HIPAA&#8221;), which prohibits, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of payor (e.g., public or private), or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (&#8220;HITECH&#8221;) and their respective implementing regulations, which impose obligations on certain covered </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">257<br></div></div></div>
<!--End Page 268-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 269-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_117-bus_pg31"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_bl" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: left;">healthcare providers, health plans, and healthcare clearinghouses, as well as their respective business associates and subcontractors that perform certain services involving the storage, use or disclosure of individually identifiable health information for or on behalf of a covered entity and their business associates, including mandatory contractual terms, with respect to safeguarding the privacy, security, and transmission of individually identifiable health information, and require notification to affected individuals and regulatory authorities of certain breaches of security of individually identifiable health information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions; </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">even when HIPAA/HITECH do not apply, according to the Federal Trade Commission (&#8220;FTC&#8221;), failing to take appropriate steps to keep consumers&#8217; personal information secure constitutes unfair acts or practices in or affecting commerce in violation of Section&#160;5(a) of the Federal Trade Commission Act, 15 U.S.C.&#160;&#167; 45(a). The FTC expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable information is considered sensitive data that merits stronger safeguards; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with certain exceptions, to report annually to the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain other health care professionals (such as physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists and certain nurse midwives) and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members, with the information made publicly available on a searchable website; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Foreign Corrupt Practices Act (&#8220;FCPA&#8221;), which prohibits U.S. businesses and their representatives from offering to pay, paying, promising to pay or authorizing the payment of money or anything of value to a foreign official in order to influence any act or decision of the foreign official in his or her official capacity or to secure any other improper advantage in order to obtain or retain business; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">analogous state laws and regulations, such as state anti-kickback and false claims laws, that may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed under Medicaid and other state programs, or in several states, apply regardless of payor, including private insurers and cash-pay patients; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">state laws that require the registration of manufacturers and wholesale distributors of drug and biological products who ship into a state, including in certain states that require registration even if such manufacturers or distributors have no place of business within the state. Some states also impose requirements on manufacturers and distributors to establish the pedigree of product in the chain of distribution, including some states that require manufacturers and others to adopt new technology capable of tracking and tracing product as it moves through the distribution chain; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">certain state laws that require pharmaceutical and biotechnology companies to establish marketing compliance programs and comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug manufacturers to report information related to payments to physicians and other healthcare providers or marketing expenditures and drug pricing information, and state and local laws that require the registration of pharmaceutical sales representatives, as well as prohibit pharmacies and other healthcare entities from providing certain physician prescribing data to pharmaceutical and biotechnology companies for use in sales and marketing, and to prohibit certain other sales and marketing practices. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Additionally, we are subject to state and foreign laws governing the collection, use, access, confidentiality, privacy and security of health-related and other personal information, many of which differ from each other in significant ways and are often not preempted by HIPAA. Failure to comply with these laws, where applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation. For example, the </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">258<br></div></div></div>
<!--End Page 269-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 270-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_117-bus_pg32"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">California Consumer Privacy Act (&#8220;CCPA&#8221;), as amended by the California Privacy Rights Act (CPRA), authorizes administrative fines and civil penalties of up to several thousand dollars per violation &#8212; with higher amounts for intentional violations and violations involving minors &#8212; and provides a limited private right of action (with statutory damages) for certain data-breach-related security failures. These per-violation penalties can result in significant aggregate exposure in the event of widespread non-compliance or a large-scale data breach. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Pharmaceutical Coverage, Pricing and Reimbursement </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Significant uncertainty exists as to the coverage and reimbursement status of any product candidates that receive regulatory approval. In the United States and markets in other countries, sales of any products for which a company receives regulatory approval for commercial sale will depend, in part, on the extent to which third-party payors provide coverage, and establish adequate reimbursement levels for such products. In the United States, third-party payors include federal and state healthcare programs, government authorities, private managed care providers, private health insurers and other organizations, where there is no uniform policy for coverage and reimbursement, and policies can differ significantly from payor to payor. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Third-party payors are increasingly challenging the price, examining the medical necessity and reviewing the cost-effectiveness of medical drug products and medical services, in addition to questioning their safety and efficacy. Such payors may limit coverage to specific drug products on an approved list, also known as a formulary, which might not include all of the FDA-approved drugs for a particular indication. Companies may need to conduct expensive pharmaco-economic studies in order to demonstrate the medical necessity and cost-effectiveness of their products, in addition to the costs required to obtain the FDA approvals. Nonetheless, a product candidate may not be considered medically necessary or cost-effective. Moreover, the process for determining whether a third-party payor will provide coverage for a drug product may be separate from the process for setting the price of a drug product or for establishing the reimbursement rate that such a payor will pay for the drug product. A payor&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Further, one payor&#8217;s determination to provide coverage for a drug product does not assure that other payors will also provide coverage for the drug product. Adequate third-party reimbursement may not be available to enable a company to maintain price levels sufficient to realize an appropriate return on its investment in product development. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The marketability of any product candidates for which regulatory approval is granted for commercial sale may suffer if the government and third-party payors fail to provide adequate coverage and reimbursement. In addition, emphasis on managed care in the United States has increased and could increase the pressure on pharmaceutical pricing. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which regulatory approval is granted, less favorable coverage policies and reimbursement rates may be implemented in the future. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Healthcare Reform </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The United States and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system. In the United States, there have been, and continue to be, significant judicial, administrative, executive and legislative efforts by the federal government, state governments, regulators and third-party payors to control or manage the increased costs of healthcare and, more generally, to reform the U.S. healthcare system. The pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. For example, in March&#160;2010, the Patient Protection and Affordable Care Act (&#8220;ACA&#8221;) was enacted, which was intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms. The ACA substantially changed the way healthcare is financed by both governmental and private insurers and significantly impacts the U.S. pharmaceutical industry. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On August&#160;16, 2022, the Inflation Reduction Act (&#8220;IRA&#8221;) was signed into law, which, among other things, requires the Department of Health and Human Services (&#8220;HHS&#8221;) to directly negotiate the selling price of a statutorily specified number of drugs and biologics each year that CMS reimburses under Medicare Part&#160;B and Part&#160;D. The negotiated price may not exceed a statutory ceiling price. Only high-expenditure single-source drugs that have been approved for at least seven years (11 years for single-source biologics) are eligible to be selected for negotiation, with the negotiated price taking effect two years after the selection year. For 2026, the first year in which negotiated prices become effective, CMS selected 10 high-cost Medicare Part&#160;D products in 2023, </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">259<br></div></div></div>
<!--End Page 270-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 271-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_117-bus_pg33"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">negotiations began in 2024, and the negotiated maximum fair price for each product has been announced. In addition, CMS selected and announced the negotiated maximum fair price for 15 additional Medicare Part&#160;D drugs, which will become effective in 2027. For 2028, CMS has selected an additional 15 drugs, comprised of drugs covered under Medicare Part&#160;D and, for the first time, drugs payable under Medicare Part&#160;B. For 2029 and subsequent years, 20 Part&#160;B or Part&#160;D drugs will be selected. The IRA also imposes rebates on Medicare Part&#160;B and Part&#160;D drugs whose prices have increased at a rate greater than the rate of inflation, and in November&#160;2024, CMS finalized regulations for these inflation rebates. In addition, the law eliminated the &#8220;donut hole&#8221; under Medicare Part&#160;D beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and requiring manufacturers to subsidize, through a newly established manufacturer discount program, 10% of Part&#160;D enrollees&#8217; prescription costs for brand drugs below the out-of-pocket limit, and 20% once the out-of-pocket limit has been reached. The IRA permits the Secretary of HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. Manufacturers that fail to comply with the IRA may be subject to various penalties, some significant, including civil monetary penalties. These provisions may be subject to legal challenges. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Further, the federal administration is pursuing policies to reduce regulations and expenditures across government, including at HHS, which include the FDA and CMS, and related agencies. These actions included, for example, directives to reduce agency workforce, rescind a prior administration Executive Order tasking the Center for Medicare and Medicaid Innovation to consider new payment and healthcare models to limit drug spending, and promote most-favored-nation (&#8220;MFN&#8221;) drug pricing, among other directives. For example, on May&#160;12, 2025, the federal administration issued an Executive Order that, among other things, required HHS, within 30 days, to establish and communicate to drug manufacturers MFN price targets designed to bring drug prices for American patients in line with those in comparably developed nations. If significant progress towards MFN pricing is not achieved, the Executive Order requires HHS to propose a rulemaking to implement MFN pricing. Recently, on December&#160;19, 2025, CMS issued proposed regulations to establish, under the Center for Medicare and Medicaid Innovation, two mandatory MFN pricing demonstration models under Medicare Part&#160;B and Part&#160;D, respectively. The first proposal, the Global Benchmark for Efficient Drug Pricing Model (&#8220;GLOBE&#8221;) for Medicare Part&#160;B, would require manufacturers of specified single source drugs and sole source biologics to pay incremental rebates based on international benchmark prices, with participation triggered for products meeting CMS&#8217;s spending and eligibility criteria. The second proposal, the Guarding U.S. Medicare Against Rising Drug Costs (&#8220;GUARD&#8221;) model for Medicare Part&#160;D, would similarly mandate manufacturer rebates for qualifying sole source drugs where the Medicare net price exceeds an MFN benchmark derived from international reference pricing methodologies. As proposed, GLOBE would begin a five-year performance period on October&#160;1, 2026, and GUARD would begin its performance period in 2027. These proposals will likely be subject to legal challenges that could delay their implementation or modify their impact on manufacturer pricing and revenue. If these rules or other MFN pricing rules are finalized, they are likely to mandate reduced prices of at least some drugs in the United States, if they are also sold in comparator countries. Further, as part of the Make America Healthy Again (&#8220;MAHA&#8221;) Commission&#8217;s recent Strategy Report, the administration is working across government agencies to increase enforcement on direct-to-consumer pharmaceutical advertising. These actions and policies may significantly reduce U.S. drug prices, potentially impacting manufacturers&#8217; global pricing strategies and profitability, while increasing their operational costs and compliance risks. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access, and marketing cost disclosure and transparency measures, including reporting and justification of launch prices or price increases above specified thresholds, and in some cases, measures designed to encourage importation from other countries and bulk purchasing. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Additional federal, state, and foreign healthcare reform measures may be adopted in the future, particularly given the recent change of administration, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in limited coverage and reimbursement and reduced demand for pharmaceutical products or additional pricing pressures. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Material Agreements </div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 0pt; text-align: left;">CRT Pioneer Fund License Agreement </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In May&#160;2022, Treeline entered into an exclusive worldwide License Agreement (the &#8220;CRT License Agreement&#8221;) with CRT Pioneer Fund LP (&#8220;CPF&#8221;) to research, develop, manufacture, and commercialize products targeting BCL6 (B-cell lymphoma 6 protein) (&#8220;BCL6 Products&#8221;), with the right to grant sublicenses (other than to </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">260<br></div></div></div>
<!--End Page 271-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 272-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_117-bus_pg34"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">parties engaged in certain tobacco-related business activities) under certain specified intellectual property. Under the CRT License Agreement, Treeline is obligated to use commercially reasonable efforts to develop at least one BCL6 Product in the United States and at least two additional major markets in an oncology indication. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline paid an up-front fee of $2.0&#160;million in 2022, and may owe future development milestone payments totaling up to $22.5&#160;million, commercial milestone payments totaling up to $53.0&#160;million, and low-single-digit royalties on net sales of any product containing a compound that is directed against and modulates the activity of BCL6, payable until generic competition commences with respect to such product on a country-by-country basis. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The CRT License Agreement will continue on a country-by-country basis until commencement of generic competition of such BCL6 Product in such country, subject to earlier termination by either party for the other&#8217;s uncured material breach or insolvency, by Treeline for convenience on a country-by-country basis upon prior written notice, or by CPF upon certain specified breaches by Treeline. </div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20pt; margin-left: 0pt; text-align: left;">Jiangsu Hengrui Pharmaceuticals License Agreement </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In February&#160;2023, we entered into an Exclusive License Agreement (the &#8220;Hengrui License Agreement&#8221;) with Jiangsu Hengrui Pharmaceuticals Co., Ltd. (&#8220;Hengrui&#8221;) with the right to grant sublicenses (subject to certain exceptions), pursuant to which we obtained exclusive rights under certain specified intellectual property to develop, manufacture, commercialize and exploit products containing SHR2554 (TLN-254) or certain related compounds outside of mainland China, Hong Kong, Macau, and Taiwan (&#8220;Greater China&#8221;) and pursuant to which we granted to Hengrui exclusive rights under certain specified intellectual property to develop, manufacture, commercialize and exploit products containing SHR2554 (TLN-254) or certain related compounds in Greater China. Under the Hengrui License Agreement, we are obligated to use commercially reasonable efforts to develop at least one licensed product in the United States and another five major markets. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We paid an up-front fee of $11.0&#160;million in 2023, and may owe additional development milestone payments totaling up to $45.0&#160;million, commercial milestone payments totaling up to $650.0&#160;million, and tiered royalties ranging in the lower teens based on future net sales of licensed products, subject to customary step-downs and a royalty floor. Royalties are payable on a product-by-product and country-by-country basis until the later of (i) ten years following the date of first commercial sale with respect to such product, and (ii) the expiration of the last valid claim in such country covering such product. The Hengrui License Agreement will continue until expiration of the last-to-expire royalty term, subject to earlier termination by either party for the other&#8217;s uncured material breach or insolvency, by us for convenience upon prior written notice, or by Hengrui upon certain specified breaches by us. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Competition </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We face substantial competition from multiple sources, including large and specialty pharmaceutical and biotechnology companies, academic research institutions and governmental agencies and public and private research institutions. Our competitors compete with us on the level of the technologies employed, or on the level of development of product candidates. In addition, many small biotechnology companies have formed collaborations with large, established companies to obtain support for their research, development and commercialization of products or combine several treatment approaches to develop longer lasting or more efficacious treatments that may potentially directly compete with our current or future product candidates. We anticipate that we will continue to face increasing competition as new therapies and combinations thereof, technologies, and data emerge for the treatment of oncological, autoimmune, neurological, and other serious diseases. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our current product candidates, initially under development for treatment of oncological, autoimmune, and neurological diseases, if approved, would face competition from approved treatments, some of which have achieved commercial success. To compete successfully, we need to differentiate our product candidates from these currently marketed drugs, meaning that we will have to demonstrate that the relative cost, method of administration, dosing frequency, safety, tolerability or efficacy of our product candidates provides a better alternative to existing and new products. Our commercial opportunity and likelihood of success will be reduced or eliminated if our product candidates, if approved, are not ultimately demonstrated to be safer, more effective, more conveniently administered, or less expensive than the current standards of care. Furthermore, even if our product candidates are able to achieve these attributes, acceptance of our products, if approved, may be inhibited by the reluctance of physicians to switch from existing products to our products, or if physicians choose to reserve our products for use in limited circumstances. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">261<br></div></div></div>
<!--End Page 272-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 273-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_117-bus_pg35"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Many of our competitors, either alone or in combination with their respective strategic partners, have significantly greater financial resources and expertise in research and development, manufacturing, the regulatory approval process and marketing than we do. Mergers and acquisition activity in the pharmaceutical, biopharmaceutical and biotechnology sector is likely to result in greater resource concentration among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through sizeable collaborative arrangements with established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our commercial opportunity could be reduced or eliminated if one or more of our competitors develop and commercialize products that are safer, more effective, better tolerated, or of greater convenience or economic benefit than our proposed product offering. Our competitors also may be in a position to obtain FDA or other regulatory approval for their products more rapidly, resulting in a stronger or dominant market position before we are able to enter the market. The key competitive factors affecting the success of all of our programs are likely to be product safety, efficacy, convenience and treatment cost. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Employees and Human Capital Resources </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As of March&#160;31, 2026, we had 163 employees, 133 of whom were engaged in research and development activities. Seventy-three percent of our employees hold Ph.D., M.D. or other advanced degrees. None of our employees are represented by a labor union or covered under a collective bargaining agreement. We consider our relationship with our employees to be positive. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and new employees, advisors and consultants. It is important that we not only attract and retain the best and brightest diverse talent, but also ensure they remain engaged and can thrive in an environment that is committed to helping them grow, succeed and contribute directly to achieving our purpose. The principal purposes of our equity and cash incentive plans are to attract, retain and reward personnel through the granting of stock-based and cash-based compensation awards, in order to increase our success by motivating such individuals to perform to the best of their abilities and achieve our objectives. We also strive to foster career growth and internal mobility by providing a broad range of training, mentoring and other development opportunities. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Facilities </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our headquarters are located in Watertown, Massachusetts, where we lease 45,000 square feet of office and laboratory space pursuant to a lease agreement that expires in December&#160;2027. We also lease 3,147 square feet of office space in Stamford, Connecticut, pursuant to a lease agreement that expires in October&#160;2029, and 35,117 square feet of office and laboratory space in San Diego, California, pursuant to a lease agreement that expires in April&#160;2034. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We believe our existing facilities are sufficient to meet our near-term needs and that suitable additional space will be available as and when needed. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">262<br></div></div></div>
<!--End Page 273-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 274-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_118-mda_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tMDA"><!--Anchor--></a>TREELINE MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following discussion and analysis of Treeline&#8217;s financial condition and results of operations should be read in conjunction with Treeline&#8217;s consolidated financial statements as of and for the years ended December&#160;31, 2025 and 2024, Treeline&#8217;s unaudited condensed consolidated interim financial statements as of March&#160;31, 2026 and for the three months ended March&#160;31, 2026 and 2025, and the related notes included elsewhere in this proxy statement/prospectus. Some of the information contained in this discussion and analysis or set forth elsewhere in this proxy statement/prospectus, including information with respect to Treeline&#8217;s plans and strategy for its business, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set out under the section entitled &#8220;Risk Factors&#8221; in this proxy statement/prospectus, Treeline&#8217;s actual results could differ materially from the results described in or implied by these forward-looking statements. See also the section entitled &#8220;Cautionary Statement Regarding Forward-Looking Statements&#8221; in this proxy statement/prospectus.<font style="font-style: normal;"> </font></div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16pt; margin-left: 0pt; text-align: left;">Overview </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline Biosciences is a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and other serious diseases. Treeline&#8217;s approach is built on a differentiated, repeatable discovery platform that identifies compelling molecular targets and matches them with the most appropriate drug modality. Treeline seeks to prove it can pick good targets, nominate highly-vetted development candidates (&#8220;DCs&#8221;), and make thoughtful development decisions across a diverse and ambitious pipeline, with the goal of redefining the treatment of serious diseases. Treeline wants its platform story to be repeatability. Treeline currently has three Phase 1 programs, TLN-121, TLN-254, and TLN-372, and a fourth program, TLN-499, nearing clinical entry, all in oncology. Treeline&#8217;s preclinical pipeline includes programs in neurology and immunology, in addition to oncology. Treeline expects three additional programs to enter clinical testing in 2027 and 2028. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline believes the depth of its pipeline reflects the talents, expertise and flexibility of its team. There are a finite number of molecular targets that Treeline finds compelling enough to pursue. Treeline focuses on targets with the potential to deliver meaningful clinical benefit that meet four criteria: disease dependency, therapeutic index, path to druggability, and patient need. Treeline believes the specific features of a molecular target should determine the drug modality, i.e., whether a small molecule inhibitor, protein degrader, or targeted therapy antibody-drug conjugate (&#8220;TT-ADC&#8221;) approach is employed. In other words, Treeline believes the ultimate DC should reflect the therapeutic solution with the best chance of delivering the target product profile (&#8220;TPP&#8221;).</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If pipeline attrition must occur, Treeline hopes to realize it before the start of a human clinical trial. Thus, Treeline has strict criteria, which include internal data and external factors, for nominating DCs. Treeline seeks not only to prove a hypothesis but also works hard to generate data that could disqualify compounds under consideration prior to a clinical start. Treeline aims to advance a compound into human clinical trials only when it satisfies these stringent criteria. Treeline requires in vivo efficacy and safety profiles that can be realistically achieved through conservative dosing assumptions. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In just five years, Treeline has generated a diversified pipeline of more than 10 programs, with all but one discovered by Treeline&#8217;s in-house team. Treeline&#8217;s current Phase 1 clinical programs include TLN-121, an oral protein degrader targeting the transcription factor B-cell lymphoma 6 (&#8220;BCL6&#8221;); TLN-254 (in-licensed), an oral inhibitor of enhancer of zeste homolog 2 (&#8220;EZH2&#8221;); and TLN-372, a selective, orally bioavailable inhibitor of the commonly mutated oncogene Kirsten Rat Sarcoma Viral Oncogene Homolog (&#8220;KRAS&#8221;). Treeline intends to provide guidance for TLN-121 and TLN-372 in the first quarter of 2027 and expects to disclose data for these programs in 2027. TLN-499, an oral targeted protein degrader of B-cell lymphoma-X long (&#8220;BCL-XL&#8221;), is near clinical entry, and Treeline expects to begin a first-in-human trial in the second half of 2026. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Since its inception, Treeline has devoted substantially all of its efforts and financial resources to organizing and staffing its company, business planning, raising capital, research and development activities, conducting preclinical studies and clinical trials, establishing and maintaining its intellectual property portfolio, establishing arrangements with third parties for drug manufacturing and providing general and administrative support for these operations. Treeline has funded its operations to date primarily through sales of its convertible preferred stock. As of March&#160;31, 2026, Treeline had received aggregate net proceeds of $1.2&#160;billion from issuances of its convertible preferred stock and had cash, cash equivalents and marketable securities of $553.1 million. Treeline has not generated any revenue from product sales and incurred significant operating losses since inception. Treeline&#8217;s net losses were $162.5&#160;million for each of the years ended December&#160;31, 2025 and 2024, and $50.5&#160;million and $39.8&#160;million for the </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">263<br></div></div></div>
<!--End Page 274-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 275-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_118-mda_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">three months ended March&#160;31, 2026 and 2025, respectively. As of March&#160;31, 2026, Treeline had an accumulated deficit of $651.8&#160;million. Treeline&#8217;s net losses may fluctuate significantly from quarter-to-quarter and year-to-year, depending on the timing of its clinical trials and its expenditures on research and development activities. Treeline expects to continue to incur significant expenses and operating losses for the foreseeable future as Treeline continues to develop its pipeline and expand its corporate infrastructure. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline does not expect to generate any revenues from product sales unless and until it has successfully completed development and obtained regulatory approval for one or more of its product candidates, which will not be for at least the next several years, if ever. As a result, Treeline will require substantial additional funding to further develop its product candidates and support continuing operations. Until such time that Treeline can generate substantial product revenue, if ever, it expects to finance its operations through equity offerings, debt financings or other capital sources, which could include income from collaborations, strategic partnerships, licensing arrangements with third parties or other similar arrangements. However, Treeline may be unable to raise additional funds or enter into such other arrangements when needed or on commercially acceptable terms, if at all. Any failure to raise capital as and when needed could have a material adverse effect on Treeline&#8217;s financial condition and on its ability to pursue its business plans and strategies, including its research and development activities. If Treeline is unable to raise capital, it could delay, reduce or terminate planned activities to reduce costs. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Recent Developments </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On June&#160;6, 2026, Treeline entered into an Agreement and Plan of Merger with Standard BioTools Inc. (&#8220;Standard BioTools&#8221;) and Siri Merger Sub, Inc. (&#8220;Merger Sub&#8221;), a wholly owned subsidiary of Standard BioTools, pursuant to which the Merger Sub will merge with and into Treeline, with Treeline surviving as a wholly owned subsidiary of Standard BioTools (the &#8220;Merger&#8221;). At the effective time of the Merger, each outstanding share of Treeline&#8217;s capital stock, including each share of convertible preferred stock (which will convert into common stock immediately prior to the Merger), will be converted into the right to receive shares of Standard BioTools common stock based on an exchange ratio determined in accordance with the Merger Agreement. Each outstanding option to purchase Treeline common stock, whether vested or unvested, will be assumed by Standard BioTools and converted into an option to purchase Standard BioTools common stock, with the number of shares and exercise price adjusted by the exchange ratio. Each outstanding warrant that is amended prior to the effective time to provide for net-exercise treatment will be cancelled and converted into the right to receive Standard BioTools common stock based on the exchange ratio. Any warrant that is not amended for such treatment will be assumed by Standard BioTools and become exercisable for Standard BioTools common stock, with the number of shares and warrant price adjusted by the exchange ratio. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In connection with the Merger, Standard BioTools has agreed to use commercially reasonable efforts to dispose of its legacy mass cytometry and microfluidics businesses and, to the extent no disposition is completed, to wind down those businesses, such that the combined company is not expected to retain those operations. Completion of the Merger is subject to customary closing conditions, including approval by the stockholders of both the Company (which has been obtained) and Standard BioTools and the effectiveness of a registration statement on Form&#160;S-4. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">License Agreements </div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">CRT Pioneer Fund License Agreement </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In May&#160;2022, Treeline entered into an exclusive worldwide License Agreement (the &#8220;CRT License Agreement&#8221;) with CRT Pioneer Fund LP (&#8220;CPF&#8221;) to research, develop, manufacture, and commercialize products targeting BCL6 (B-cell lymphoma 6 protein) (&#8220;BCL6 Products&#8221;), with the right to grant sublicenses (other than to parties engaged in certain tobacco-related business activities) under certain specified intellectual property. Under the CRT License Agreement, Treeline is obligated to use commercially reasonable efforts to develop at least one BCL6 Product in the United States and at least two additional major markets in an oncology indication. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline paid an up-front fee of $2.0&#160;million in 2022, and may owe future development milestone payments totaling up to $22.5&#160;million, commercial milestone payments totaling up to $53.0&#160;million, and low-single-digit royalties on net sales of any product containing a compound that is directed against and modulates the activity of BCL6, payable until generic competition commences with respect to such product on a country-by-country basis. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">264<br></div></div></div>
<!--End Page 275-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 276-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_118-mda_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The CRT License Agreement will continue on a country-by-country basis until commencement of generic competition of such BCL6 Product in such country, subject to earlier termination by either party for the other&#8217;s uncured material breach or insolvency, by Treeline for convenience on a country-by-country basis upon prior written notice, or by CPF upon certain specified breaches by Treeline. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline incurred and paid $2.5&#160;million and $0 in milestone payments during the years ended December&#160;31, 2025 and 2024, respectively. Treeline did not incur expense related to the CRT License Agreement during the three months ended March&#160;31, 2026 or 2025. As of March&#160;31, 2026, Treeline paid $4.5&#160;million to CPF under the CRT License Agreement. </div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 15pt; margin-left: 0pt; text-align: left;">Jiangsu Hengrui Pharmaceuticals License Agreement </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In February&#160;2023, Treeline entered into an Exclusive License Agreement (the &#8220;Hengrui License Agreement&#8221;) with Jiangsu Hengrui Pharmaceuticals Co., Ltd. (&#8220;Hengrui&#8221;) with the right to grant sublicenses (subject to certain exceptions), pursuant to which Treeline obtained exclusive rights under certain specified intellectual property to develop, manufacture, commercialize and exploit products containing SHR2554 (TLN-254) or certain related compounds outside of mainland China, Hong Kong, Macau, and Taiwan (&#8220;Greater China&#8221;) and pursuant to which Treeline granted to Hengrui exclusive rights under certain specified intellectual property to develop, manufacture, commercialize and exploit products containing SHR2554 (TLN-254) or certain related compounds in Greater China. Under the Hengrui License Agreement, Treeline is obligated to use commercially reasonable efforts to develop at least one licensed product in the United States and another five major markets. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline paid an up-front fee of $11.0&#160;million in 2023, and may owe additional development milestone payments totaling up to $45.0&#160;million, commercial milestone payments totaling up to $650.0&#160;million, and tiered royalties ranging in the lower teens based on future net sales of licensed products, subject to customary step-downs and a royalty floor. Royalties are payable on a product-by-product and country-by-country basis until the later of (i)&#160;ten years following the date of first commercial sale with respect to such product, and (ii) the expiration of the last valid claim in such country covering such product. The Hengrui License Agreement will continue until expiration of the last-to-expire royalty term, subject to earlier termination by either party for the other&#8217;s uncured material breach or insolvency, by Treeline for convenience upon prior written notice, or by Hengrui upon certain specified breaches by Treeline. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">To date, Treeline has not incurred fees under the Hengrui License Agreement other than the up-front fee of $11.0&#160;million. Treeline has incurred operating expenses of $0.1&#160;million to Hengrui related to the Hengrui License Agreement during the three months ended March&#160;31, 2026 and 2025, and $0.1&#160;million and $0.2&#160;million during the years ended December&#160;31, 2025 and 2024, respectively, related to research and development activities. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Components of Results of Operations </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Operating Expenses </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">Research and Development Expenses </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Research and development expenses consist primarily of costs incurred for Treeline&#8217;s discovery efforts and the preclinical and clinical development of product candidates. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">External costs include: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">costs of funding research performed by third parties that conduct research and development and preclinical and clinical activities on Treeline&#8217;s behalf, including contract research organizations (&#8220;CROs&#8221;), contract development and manufacturing organizations (&#8220;CDMOs&#8221;), and academic research collaborators; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">costs of chemistry, manufacturing and controls (&#8220;CMC&#8221;) activities, including manufacture of clinical trial materials; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">costs of laboratory supplies and acquiring, developing and manufacturing preclinical study and clinical trial materials; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">license fees and milestone payments related to in-licensed products and technologies; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">facilities, depreciation and other expenses, which include allocated expenses for rent and maintenance of facilities, insurance and other operating costs. </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">265<br></div></div></div>
<!--End Page 276-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 277-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_118-mda_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Internal costs include: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">personnel-related costs, including salaries, benefits and stock-based compensation expense, for employees engaged in research and development functions; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">costs related to compliance with regulatory requirements; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">facilities, depreciation and other expenses, which include allocated expenses for rent and maintenance of facilities, insurance and other operating costs; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">software and computational chemistry costs. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline expenses research and development costs as incurred. Costs for certain development activities are recognized based on an evaluation of the progress to completion of specific tasks using information and data provided to Treeline by its vendors and clinical sites. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and are reflected in Treeline&#8217;s consolidated financial statements as other assets (prepaid research and development) or accrued expenses (accrued research and development). </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline classifies and evaluates its external research and development expenses between clinical and preclinical. Treeline does not classify or evaluate its internal research and development expenses by program as these expenses primarily relate to compensation, depreciation, materials and supplies, and other costs which are deployed across multiple potential therapeutic modalities, programs, and therapeutic areas under development. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Once a product candidate has received clearance from the FDA of its Investigational New Drug (&#8220;IND&#8221;) application or equivalent application or filing filed with any equivalent authority outside the United States, Treeline considers it a clinical program. For each of its clinical programs, Treeline reports or will report external research and development costs attributable to such clinical programs. These external development costs include: fees paid to CROs, CDMOs, consultants and clinical development activities. Any internal research and development expenses, consisting of personnel costs associated with clinical programs, are categorized as personnel costs, including stock-based compensation. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Until such time as a product candidate receives clearance of its IND application or equivalent, Treeline considers it a preclinical program. For Treeline&#8217;s preclinical programs, it reports external development costs and other external research and development costs collectively. These external development costs include: fees paid to CROs and CDMOs and consultants. Preclinical research and development activities often benefit more than one preclinical program and so disaggregating the data would be neither practical nor meaningful. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline plans to substantially increase its research and development expenses for the foreseeable future as it continues the research and development of its current and any potential future product candidates it may determine to pursue. The process of conducting the necessary developmental and clinical research to obtain regulatory approval is costly and time-consuming, and the successful development of Treeline&#8217;s product candidates is highly uncertain. Treeline may never succeed in achieving regulatory approval for any of its product candidates. Further, a number of factors, including those outside of Treeline&#8217;s control, could adversely impact the timing and duration of its product candidates&#8217; development, which could increase its research and development expenses. Such factors include: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the timing, cost and progress of preclinical and clinical development activities; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the number and scope of preclinical and clinical programs Treeline decides to pursue; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the progress of the development efforts of parties with whom Treeline may, in the future, enter into collaborations and/or research and development agreements; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Treeline&#8217;s ability to maintain, and the costs and fees associated with, its current licenses and research and development programs and its ability to establish new collaboration arrangements; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Treeline&#8217;s ability to establish manufacturing capabilities or engage third parties to manufacture its product candidates; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the timing and cost of regulatory submissions and timing of regulatory approvals; </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">266<br></div></div></div>
<!--End Page 277-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 278-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_118-mda_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Treeline&#8217;s efforts to enhance operational systems and hire additional personnel, including personnel to support development of its product candidates; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the impact of any business interruptions to Treeline&#8217;s operations or to those of the third parties with whom it works. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As a result of these and other factors, Treeline is unable to determine the duration and completion costs of its research and development projects, the costs of related clinical development or when and to what extent Treeline will generate revenue from the commercialization of its product candidates. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">General and Administrative Expenses </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">General and administrative expenses consist primarily of personnel costs, including salaries, benefits and stock-based compensation expense for employees in executive, finance, accounting, information technology, legal and human resource functions. General and administrative expenses also include corporate facility costs, including rent, utilities, depreciation and maintenance, legal fees related to intellectual property and corporate matters as well as fees for accounting and consulting services. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline expects that its general and administrative expenses will increase in the future as it expands its operations to support its continued research and development activities, potential commercialization efforts, and protection of its intellectual property. Treeline also expects that it will incur increased costs as a result of operating as a public company. These increases will likely include increased costs related to the hiring of additional personnel and fees to outside consultants, lawyers and accountants, among other expenses. Increased costs associated with being a public company will also include expenses related to services associated with maintaining compliance with the requirements of The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) and the Securities and Exchange Commission (&#8220;SEC&#8221;), insurance and investor relations costs. If any of Treeline&#8217;s current or future product candidates obtain marketing approval, Treeline expects that it will incur significantly increased expenses associated with sales and marketing efforts. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Other Income </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Other income consists primarily of interest earned and net amortization of premium and discount on Treeline&#8217;s marketable securities. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Results of Operations </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Comparison of the Three months ended March&#160;31, 2026 and 2025 </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following table summarizes Treeline&#8217;s results of operations for the periods indicated (in thousands): </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 288pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 80.74pt;" colspan="4"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 35.83pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 36.22pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 288pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 4.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.54pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td colspan="4" style="width: 80.74pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31,</div></td><td style="width: 4.54pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 4.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36.22pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td></tr><tr class="BRDSX_header"><td style="width: 288pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 4.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.54pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2026</div></td><td style="width: 4.54pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.54pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div></td><td style="width: 4.54pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.54pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">$ Change</div></td><td style="width: 4.54pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.54pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36.22pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">% Change </div></td></tr><tr><td style="width: 288pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating expenses:<br></div></td><td style="width: 4.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 4.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 4.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 4.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36.22pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research and development<font style="padding-left: 2.76pt;"></font></div></td><td style="width: 4.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<font style="padding-left: 3.33pt;">49,098</font></div></td><td style="width: 4.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">$<font style="padding-left: 3.33pt;">39,213</font></div></td><td style="width: 4.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">$<font style="padding-left: 8.33pt;">9,885</font></div></td><td style="width: 4.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36.22pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.7pt; text-align: left;"><font style="padding-left: 3.33pt;">25.2% </font></div></td></tr><tr><td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">General and administrative<font style="padding-left: 2.2pt;"></font></div></td><td style="width: 4.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">6,959</font></div></td><td style="width: 4.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">5,789</font></div></td><td style="width: 4.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">1,170</font></div></td><td style="width: 4.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36.22pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.7pt; text-align: left;"><font style="padding-left: 3.33pt;">20.2% </font></div></td></tr><tr><td style="width: 288pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total operating expenses<font style="padding-left: 1.23pt;"></font></div></td><td style="width: 4.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">56,057</font></div></td><td style="width: 4.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">45,002</font></div></td><td style="width: 4.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 8.7pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">11,055</font></div></td><td style="width: 4.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36.22pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.7pt; text-align: left;"><font style="padding-left: 3.33pt;">24.6% </font></div></td></tr><tr><td style="width: 288pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss from operations<font style="padding-left: 0.53pt;"></font></div></td><td style="width: 4.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">(56,057)</font></div></td><td style="width: 4.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 5pt;">(45,002)</font></div></td><td style="width: 4.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 5.37pt;">(11,055)</font></div></td><td style="width: 4.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36.22pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.7pt; text-align: left;">(24.6)% </div></td></tr><tr><td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other income<font style="padding-left: 0.8pt;"></font></div></td><td style="width: 4.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">5,516</font></div></td><td style="width: 4.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">5,202</font></div></td><td style="width: 4.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">314</font></div></td><td style="width: 4.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36.22pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.7pt; text-align: left;"><font style="padding-left: 8.33pt;">6.0% </font></div></td></tr><tr><td style="width: 288pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net loss<font style="padding-left: 3.01pt;"></font></div></td><td style="width: 4.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$(50,541</font><font style="padding-bottom: 0.5pt;">)</font></div></td><td style="width: 4.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$(39,800</font><font style="padding-bottom: 0.5pt;">)</font></div></td><td style="width: 4.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$(10,741</font><font style="padding-bottom: 0.5pt;">)</font></div></td><td style="width: 4.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36.22pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.7pt; text-align: left;">(27.0)%</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 288pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 4.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 4.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 35.83pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 4.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 4.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 35.83pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 4.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 4.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 35.83pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 4.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 4.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 36.22pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Research and Development Expenses </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Research and development expenses increased by $9.9 million from $39.2 million for the three months ended March&#160;31, 2025 to $49.1 million for the three months ended March&#160;31, 2026. The increase was due to a $14.7&#160;million increase in Treeline&#8217;s clinical programs driven by the initiation of its Phase 1 trials for TLN-121 and TLN-372, a $0.6 million increase in personnel costs due to increased salaries and benefits, and an increase in stock-based compensation, partially offset by a $5.4 million decrease in its preclinical programs and other research and development as a portion of activity that was previously preclinical advanced into clinical development due to IND acceptance of the TLN-121 and TLN-372 programs. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">267<br></div></div></div>
<!--End Page 278-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 279-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_118-mda_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Research and development expenses disaggregated and classified by clinical program, preclinical program expenses and personnel costs are summarized in the table below: </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 288pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.61pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.61pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 77.96pt;" colspan="4"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 32.22pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 36.22pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 288pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 5.61pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.61pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td colspan="4" style="width: 77.96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31,</div></td><td style="width: 5.6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.22pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 5.6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36.22pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td></tr><tr class="BRDSX_header"><td style="width: 288pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 5.61pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.61pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 33.37pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2026</div></td><td style="width: 5.61pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.61pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 33.37pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div></td><td style="width: 5.6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.22pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">$ Change</div></td><td style="width: 5.6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36.22pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">% Change </div></td></tr><tr><td style="width: 288pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Clinical programs:<br></div></td><td style="width: 5.61pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.61pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 33.37pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 5.61pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.61pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 33.37pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 5.6pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.6pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.22pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 5.6pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.6pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36.22pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">TLN-121<font style="padding-left: 2.73pt;"></font></div></td><td style="width: 5.61pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.61pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 33.37pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.43pt; text-align: left;">$<font style="padding-left: 5pt;">9,536</font></div></td><td style="width: 5.61pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.61pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 33.37pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.44pt; text-align: left;">$<font style="padding-left: 17.5pt;">&#8212;</font></div></td><td style="width: 5.6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.22pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.69pt; text-align: left;">$<font style="padding-left: 3.33pt;">9,536</font></div></td><td style="width: 5.6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36.22pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.7pt; text-align: left;"><font style="padding-left: 10.83pt;">&#8212;% </font></div></td></tr><tr><td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">TLN-372<font style="padding-left: 2.73pt;"></font></div></td><td style="width: 5.61pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.61pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 33.37pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.43pt; text-align: left;"><font style="padding-left: 10pt;">4,593</font></div></td><td style="width: 5.61pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.61pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 33.37pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.44pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td style="width: 5.6pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.6pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.22pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.69pt; text-align: left;"><font style="padding-left: 8.33pt;">4,593</font></div></td><td style="width: 5.6pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.6pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36.22pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.7pt; text-align: left;"><font style="padding-left: 10.83pt;">&#8212;% </font></div></td></tr><tr><td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">TLN-254<font style="padding-left: 2.73pt;"></font></div></td><td style="width: 5.61pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.61pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 33.37pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.43pt; text-align: left;"><font style="padding-left: 10pt;">1,820</font></div></td><td style="width: 5.61pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.61pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 33.37pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.44pt; text-align: left;"><font style="padding-left: 10pt;">1,223</font></div></td><td style="width: 5.6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.22pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.69pt; text-align: left;"><font style="padding-left: 15.83pt;">597</font></div></td><td style="width: 5.6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36.22pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.7pt; text-align: left;"><font style="padding-left: 3.33pt;">48.8% </font></div></td></tr><tr><td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Preclinical programs and other<font style="padding-left: 2.49pt;"></font></div></td><td style="width: 5.61pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.61pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 33.37pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.43pt; text-align: left;"><font style="padding-left: 5pt;">20,035</font></div></td><td style="width: 5.61pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.61pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 33.37pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.44pt; text-align: left;"><font style="padding-left: 5pt;">25,477</font></div></td><td style="width: 5.6pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.6pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.22pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.69pt; text-align: left;"><font style="padding-left: 5pt;">(5,442)</font></div></td><td style="width: 5.6pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.6pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36.22pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.7pt; text-align: left;">(21.4)% </div></td></tr><tr><td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Personnel costs, including stock-based compensation<font style="padding-left: 3.06pt;"></font></div></td><td style="width: 5.61pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.61pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 33.37pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.43pt; text-align: left;"><font style="padding-left: 5.37pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">13,114</font></div></td><td style="width: 5.61pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.61pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 33.37pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.44pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">12,513</font></div></td><td style="width: 5.6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.22pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.69pt; text-align: left;"><font style="padding-left: 15.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">601</font></div></td><td style="width: 5.6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36.22pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.7pt; text-align: left;"><font style="padding-left: 8.33pt;">4.8% </font></div></td></tr><tr><td style="width: 288pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total research and development expenses<font style="padding-left: 4.59pt;"></font></div></td><td style="width: 5.61pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.61pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 33.37pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.43pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$49,098</font></div></td><td style="width: 5.61pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.61pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 33.37pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.44pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$39,213</font></div></td><td style="width: 5.6pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.6pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.22pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.69pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">9,885</font></div></td><td style="width: 5.6pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.6pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36.22pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.7pt; text-align: left;"><font style="padding-left: 3.33pt;">25.2%</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 288pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.61pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.61pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 33.37pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.61pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.61pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 33.37pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.6pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.6pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 32.22pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.6pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.6pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 36.22pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">General and Administrative Expenses </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">General and administrative expenses for the three months ended March&#160;31, 2026 were $7.0 million, compared to $5.8 million for the three months ended March&#160;31, 2025. The increase of $1.2 million was primarily attributable to a $0.9 million increase in professional fees and corporate and intellectual property legal fees and a $0.3 million increase in personnel costs, due to increased salaries and benefits and stock-based compensation. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Other Income </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Other income for the three months ended March&#160;31, 2026 was $5.5 million, compared to $5.2 million for the three months ended March&#160;31, 2025. The increase was primarily attributable to the increase in interest income resulting from the increase in Treeline&#8217;s cash, cash equivalents and marketable securities. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Comparison of the Years Ended December 31, 2025 and 2024 </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following table summarizes Treeline&#8217;s results of operations for the periods indicated (in thousands): </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 276pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 92.82pt;" colspan="4"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 32.22pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 36.22pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 276pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 5.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.13pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td colspan="4" style="width: 92.82pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended December&#160;31,</div></td><td style="width: 5.13pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.22pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 5.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36.22pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td></tr><tr class="BRDSX_header"><td style="width: 276pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 5.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.13pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.28pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div></td><td style="width: 5.13pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.13pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.28pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024</div></td><td style="width: 5.13pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.13pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.22pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">$ Change</div></td><td style="width: 5.13pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.13pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36.22pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">% Change </div></td></tr><tr><td style="width: 276pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating expenses:<br></div></td><td style="width: 5.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 5.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 5.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.22pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 5.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36.22pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 276pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research and development<font style="padding-left: 0.76pt;"></font></div></td><td style="width: 5.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.23pt; text-align: left;">$<font style="padding-left: 3.33pt;">160,009</font></div></td><td style="width: 5.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.23pt; text-align: left;">$<font style="padding-left: 3.33pt;">151,706</font></div></td><td style="width: 5.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.22pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.7pt; text-align: left;">$<font style="padding-left: 3.33pt;">8,303</font></div></td><td style="width: 5.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36.22pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.36pt; text-align: left;"><font style="padding-left: 5pt;">5.5% </font></div></td></tr><tr><td style="width: 276pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">General and administrative<font style="padding-left: 0.2pt;"></font></div></td><td style="width: 5.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.23pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">23,256</font></div></td><td style="width: 5.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.23pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">23,558</font></div></td><td style="width: 5.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.22pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.7pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(302</font><font style="padding-bottom: 1.5pt;">)</font></div></td><td style="width: 5.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36.22pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.36pt; text-align: left;"><font style="padding-left: 1.67pt;">(1.3)% </font></div></td></tr><tr><td style="width: 276pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total operating expenses<font style="padding-left: 4.23pt;"></font></div></td><td style="width: 5.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.23pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">183,265</font></div></td><td style="width: 5.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.23pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">175,264</font></div></td><td style="width: 5.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.22pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.7pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">8,001</font></div></td><td style="width: 5.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36.22pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.36pt; text-align: left;"><font style="padding-left: 5pt;">4.6% </font></div></td></tr><tr><td style="width: 276pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss from operations<font style="padding-left: 3.53pt;"></font></div></td><td style="width: 5.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.23pt; text-align: left;"><font style="padding-left: 5pt;">(183,265)</font></div></td><td style="width: 5.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.23pt; text-align: left;"><font style="padding-left: 5pt;">(175,264)</font></div></td><td style="width: 5.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.22pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.7pt; text-align: left;"><font style="padding-left: 5pt;">(8,001)</font></div></td><td style="width: 5.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36.22pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.36pt; text-align: left;"><font style="padding-left: 1.67pt;">(4.6)% </font></div></td></tr><tr><td style="width: 276pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other income<font style="padding-left: 3.8pt;"></font></div></td><td style="width: 5.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.23pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">20,726</font></div></td><td style="width: 5.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.23pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">12,777</font></div></td><td style="width: 5.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.22pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.7pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">7,949</font></div></td><td style="width: 5.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36.22pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.36pt; text-align: left;">62.2% </div></td></tr><tr><td style="width: 276pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net loss<font style="padding-left: 1.01pt;"></font></div></td><td style="width: 5.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.28pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.23pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$(162,539</font><font style="padding-bottom: 0.5pt;">)</font></div></td><td style="width: 5.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.28pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.23pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$(162,487</font><font style="padding-bottom: 0.5pt;">)</font></div></td><td style="width: 5.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.22pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.7pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 12.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(52</font><font style="padding-bottom: 0.5pt;">)</font></div></td><td style="width: 5.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36.22pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.36pt; text-align: left;"><font style="padding-left: 7.5pt;">&#8212;%</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 276pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 41.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 41.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 32.22pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 36.22pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">Research and Development Expenses </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Research and development expenses increased by $8.3 million from $151.7 million for the year ended December&#160;31, 2024 to $160.0 million for the year ended December&#160;31, 2025. The increase was due to a $16.4&#160;million increase in Treeline&#8217;s clinical programs driven by the initiation of its Phase 1 trials for TLN-121 and TLN-372 and a $2.5 million increase in personnel costs, due to increased salaries and benefits and stock-based compensation, partially offset by a $10.6 million decrease in its preclinical programs and other research and development as a portion of activity that was previously preclinical advanced into clinical development due to IND&#160;acceptance of the TLN-121 and TLN-372 programs. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">268<br></div></div></div>
<!--End Page 279-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 280-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_118-mda_pg7"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Research and development expenses disaggregated and classified by clinical program, preclinical program expenses and personnel costs are summarized in the table below: </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 288pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 3.17pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 3.17pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 88.9pt;" colspan="4"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 3.17pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 3.17pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 35.83pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 3.17pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 3.17pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 36.22pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 288pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 3.17pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.17pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td colspan="4" style="width: 88.9pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended December&#160;31,</div></td><td style="width: 3.17pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.17pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 3.17pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.17pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36.22pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td></tr><tr class="BRDSX_header"><td style="width: 288pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 3.17pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.17pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.28pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div></td><td style="width: 3.17pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.17pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.28pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024</div></td><td style="width: 3.17pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.17pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">$ Change</div></td><td style="width: 3.17pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.17pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36.22pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">% Change </div></td></tr><tr><td style="width: 288pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Clinical programs:<br></div></td><td style="width: 3.17pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.17pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 3.17pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.17pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 3.17pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.17pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 3.17pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.17pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36.22pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">TLN-121<font style="padding-left: 2.73pt;"></font></div></td><td style="width: 3.17pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.17pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.89pt; text-align: left;">$<font style="padding-left: 10pt;">8,687</font></div></td><td style="width: 3.17pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.17pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.89pt; text-align: left;">$<font style="padding-left: 22.5pt;">&#8212;</font></div></td><td style="width: 3.17pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.17pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">$<font style="padding-left: 8.33pt;">8,687</font></div></td><td style="width: 3.17pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.17pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36.22pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.7pt; text-align: left;"><font style="padding-left: 10.83pt;">&#8212;% </font></div></td></tr><tr><td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">TLN-372<font style="padding-left: 2.73pt;"></font></div></td><td style="width: 3.17pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.17pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.89pt; text-align: left;"><font style="padding-left: 15pt;">7,601</font></div></td><td style="width: 3.17pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.17pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.89pt; text-align: left;"><font style="padding-left: 27.5pt;">&#8212;</font></div></td><td style="width: 3.17pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.17pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 13.33pt;">7,601</font></div></td><td style="width: 3.17pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.17pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36.22pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.7pt; text-align: left;"><font style="padding-left: 10.83pt;">&#8212;% </font></div></td></tr><tr><td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">TLN-254<font style="padding-left: 2.73pt;"></font></div></td><td style="width: 3.17pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.17pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.89pt; text-align: left;"><font style="padding-left: 15pt;">6,245</font></div></td><td style="width: 3.17pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.17pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.89pt; text-align: left;"><font style="padding-left: 15pt;">6,091</font></div></td><td style="width: 3.17pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.17pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 20.83pt;">154</font></div></td><td style="width: 3.17pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.17pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36.22pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.7pt; text-align: left;"><font style="padding-left: 8.33pt;">2.5% </font></div></td></tr><tr><td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Preclinical programs and other<font style="padding-left: 2.49pt;"></font></div></td><td style="width: 3.17pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.17pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.89pt; text-align: left;"><font style="padding-left: 10pt;">87,994</font></div></td><td style="width: 3.17pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.17pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.89pt; text-align: left;"><font style="padding-left: 10pt;">98,635</font></div></td><td style="width: 3.17pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.17pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 5pt;">(10,641)</font></div></td><td style="width: 3.17pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.17pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36.22pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.7pt; text-align: left;">(10.8)% </div></td></tr><tr><td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Personnel costs, including stock-based compensation<font style="padding-left: 3.06pt;"></font></div></td><td style="width: 3.17pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.17pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.89pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">49,482</font></div></td><td style="width: 3.17pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.17pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.89pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">46,980</font></div></td><td style="width: 3.17pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.17pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">2,502</font></div></td><td style="width: 3.17pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.17pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36.22pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.7pt; text-align: left;"><font style="padding-left: 8.33pt;">5.3% </font></div></td></tr><tr><td style="width: 288pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total research and development expenses<font style="padding-left: 4.59pt;"></font></div></td><td style="width: 3.17pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.17pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.28pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.89pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$160,009</font></div></td><td style="width: 3.17pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.17pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.28pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.89pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$151,706</font></div></td><td style="width: 3.17pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.17pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 8.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">8,303</font></div></td><td style="width: 3.17pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.17pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36.22pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.7pt; text-align: left;"><font style="padding-left: 8.33pt;">5.5%</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 288pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 3.17pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 3.17pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 41.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 3.17pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 3.17pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 41.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 3.17pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 3.17pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 35.83pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 3.17pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 3.17pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 36.22pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">General and Administrative Expenses </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">General and administrative expenses for the year ended December&#160;31, 2025 were $23.3&#160;million, compared to $23.6&#160;million for the year ended December&#160;31, 2024. The decrease of $0.3&#160;million was primarily attributable to a $1.0&#160;million decrease in professional fees and corporate and intellectual property legal fees, partially offset by a $0.7&#160;million increase in personnel costs, due to increased salaries and benefits and stock-based compensation expense. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Other Income </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Other income for the year ended December&#160;31, 2025 was $20.7&#160;million, compared to $12.8&#160;million for the year ended December&#160;31, 2024. The increase was primarily attributable to the increase in interest income resulting from the increase in Treeline&#8217;s cash, cash equivalents and marketable securities. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Liquidity and Capital Resources </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">Liquidity </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Since its inception through March&#160;31, 2026, Treeline has not generated any revenue from product sales and it does not expect to generate any revenue from commercial sales for the foreseeable future, if at all. To date, Treeline has been financed primarily by aggregate net proceeds of $1.2&#160;billion from the issuance of convertible preferred stock. As of March&#160;31, 2026, Treeline had cash, cash equivalents and marketable securities of $553.1&#160;million. Based upon Treeline&#8217;s current operating plan, Treeline estimates that its cash, cash equivalents and marketable securities as of March&#160;31, 2026, together with the estimated cash expected upon the closing of the Merger, will be sufficient to fund its operations and capital expenditure requirements into 2029. Treeline has based this estimate on assumptions that may prove to be wrong and could exhaust its available capital resources sooner than expected. Treeline&#8217;s primary use of cash is to fund operating expenses, which consist of research and development expenses and general and administrative expenses. Cash used to fund operating expenses is impacted by the timing of when Treeline pays these expenses, as reflected in the change in its outstanding accounts payable and accrued expenses. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In 2025, Treeline entered into a Series&#160;A-2 Preferred Stock (&#8220;Series&#160;A-2&#8221;) and Warrant Purchase Agreement with new and existing investors for the sale of 29,731,819 shares of Series&#160;A-2 at $8.6103 per share for proceeds of $255.5&#160;million, net of issuance costs. Each purchaser also received a warrant to purchase nonredeemable common stock at an exercise price of $0.00001 per share, which expire ten years from issuance, exercisable for a total of 5,377,111 shares of common stock. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In 2024, Treeline issued 48,985,495 shares of Series&#160;A-1 Preferred Stock (&#8220;Series&#160;A-1&#8221;) at a purchase price of $8.6103 per share for proceeds of $421.6&#160;million, net of issuance costs. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">269<br></div></div></div>
<!--End Page 280-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 281-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_118-mda_pg8"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Future Funding Requirements </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline expects that its expenses and capital requirements will increase substantially in connection with its ongoing activities, particularly as it: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">advances clinical-stage product candidates, TLN-121, TLN-254 and TLN-372, through ongoing and planned clinical trials; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">initiates clinical development of TLN-499 and any other product candidates Treeline may identify; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">continues to discover and develop additional product candidates; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">seeks regulatory approvals for product candidates that successfully complete clinical trials; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">establishes sales, marketing, distribution and other commercial infrastructure in the future to commercialize any product candidates for which Treeline may obtain regulatory approval, whether independently or with a collaborator; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">hires additional research and development, clinical and regulatory personnel and, if any product candidates are approved, sales and marketing personnel; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">expands, maintains and protects Treeline&#8217;s intellectual property portfolio; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">acquires or in-licenses other product candidates, technologies and intellectual property rights; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">incurs additional costs associated with operating as a public company following the consummation of the Merger; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">adds operational, financial, legal, compliance and management information systems and personnel to support research and development and commercialization efforts. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical products, Treeline is unable to estimate the exact amount of its working capital requirements. Treeline&#8217;s future funding requirements will depend on, and could increase significantly as a result of, many factors, including the scope, progress, results and costs of preclinical development, laboratory testing and clinical trials for its product candidates; the number and development requirements of other product candidates that Treeline may pursue; the costs, timing and outcome of regulatory review of product candidates; the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing its intellectual property rights and defending intellectual property-related claims; and its ability to establish and maintain collaborations or license agreements on favorable terms, if at all. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Until such time, if ever, that Treeline can generate substantial revenue from product sales, it expects to finance its operations through some combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. To the extent that Treeline raises additional capital through the sale of equity or convertible debt securities, the ownership interest of its stockholders may be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of its stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting Treeline&#8217;s ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If Treeline raises additional funds through collaborations, strategic alliances or licensing arrangements with third parties, it may have to relinquish valuable rights to its technologies, future revenue streams, research programs or product candidates, or grant licenses on terms that may not be favorable to Treeline. If Treeline is unable to raise additional funds through equity or debt financings when needed or at all, it may be required to delay, limit, reduce or terminate its research or drug development programs, product development, future commercialization efforts or other operations or grant rights to develop and market product candidates that it would otherwise prefer to develop and market itself. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">270<br></div></div></div>
<!--End Page 281-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 282-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_118-mda_pg9"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Cash Flows </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following table shows a summary of Treeline&#8217;s cash flows for the periods indicated (in thousands): </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 240pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 9.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 9.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 90.34pt;" colspan="4"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 9.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 9.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 100.34pt;" colspan="4"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 240pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 9.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.34pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td colspan="4" style="width: 90.34pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31,</div></td><td style="width: 9.34pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.34pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td colspan="4" style="width: 100.34pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Years Ended <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, </div></td></tr><tr class="BRDSX_header"><td style="width: 240pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 9.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.34pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2026</div></td><td style="width: 9.34pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.34pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div></td><td style="width: 9.34pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.34pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div></td><td style="width: 9.34pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.34pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div></td></tr><tr><td style="width: 240pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net cash (used in) provided by:<br></div></td><td style="width: 9.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 9.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 9.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 9.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating activities<font style="padding-left: 3.91pt;"></font></div></td><td style="width: 9.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$(53,096)</div></td><td style="width: 9.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$(45,841)</div></td><td style="width: 9.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$(164,418)</div></td><td style="width: 9.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$(160,243) </div></td></tr><tr><td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Investing activities<font style="padding-left: 1.69pt;"></font></div></td><td style="width: 9.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 8.33pt;">39,046</font></div></td><td style="width: 9.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 8.33pt;">29,209</font></div></td><td style="width: 9.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10pt;">(85,815)</font></div></td><td style="width: 9.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">(256,349) </font></div></td></tr><tr><td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Financing activities<font style="padding-left: 3.91pt;"></font></div></td><td style="width: 9.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">241</font></div></td><td style="width: 9.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">165</font></div></td><td style="width: 9.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">257,014</font></div></td><td style="width: 9.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">422,422 </font></div></td></tr><tr><td style="width: 240pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Net (decrease) increase in cash, cash equivalents and restricted cash<font style="padding-left: 0.03pt;"></font></div></td><td style="width: 9.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$(13,809</font><font style="padding-bottom: 0.5pt;">)</font></div></td><td style="width: 9.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$(16,467</font><font style="padding-bottom: 0.5pt;">)</font></div></td><td style="width: 9.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 13.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">6,781</font></div></td><td style="width: 9.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 13.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">5,830</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 240pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 9.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 9.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 35.83pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 9.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 9.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 35.83pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 9.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 9.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 40.83pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 9.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 9.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 40.83pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Cash Flows from Operating Activities </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Net cash used in operating activities of $53.1 million during the three months ended March&#160;31, 2026 was attributable to Treeline&#8217;s net loss of $50.5 million and a $3.8 million net decrease in working capital, partially offset by $1.2 million of non-cash charges primarily related to stock-based compensation and depreciation and amortization expense, partially offset by the amortization of premiums and discounts on marketable securities. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Net cash used in operating activities of $45.8 million during the three months ended March&#160;31, 2025 was attributable to Treeline&#8217;s net loss of $39.8 million, a $6.0 million net decrease in working capital, and $0.1 million of non-cash adjustments related to the amortization of premiums and discounts on marketable securities, partially offset by depreciation and amortization expense and stock-based compensation expense. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Net cash used in operating activities of $164.4&#160;million during the year ended December&#160;31, 2025 was attributable to Treeline&#8217;s net loss of $162.5&#160;million and a $4.4&#160;million net decrease in working capital, partially offset by $2.5&#160;million of non-cash charges primarily related to depreciation and amortization expense and stock-based compensation expense, partially offset by the amortization of premiums and discounts on marketable securities. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Net cash used in operating activities of $160.2&#160;million during the year ended December&#160;31, 2024 was attributable to Treeline&#8217;s net loss of $162.5&#160;million and a $1.2&#160;million net decrease in working capital, partially offset by $3.5&#160;million of non-cash charges primarily related to depreciation and amortization expense and stock-based compensation expense, partially offset by the amortization of premiums and discounts on marketable securities. </div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Cash Flows from Investing Activities </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">During the three months ended March&#160;31, 2026, net cash provided by investing activities was $39.0&#160;million primarily as a result of $94.3&#160;million of marketable securities maturing in the period, partially offset by $55.1&#160;million of marketable security purchases. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">During the three months ended March&#160;31, 2025, net cash provided by investing activities was $29.2&#160;million primarily as a result of $97.5&#160;million of marketable securities maturing in the period, partially offset by $68.1&#160;million of marketable security purchases. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">During the year ended December&#160;31, 2025, net cash used in investing activities was $85.8&#160;million primarily as a result of $522.2&#160;million of marketable security purchases and $1.3&#160;million of purchases of fixed assets, partially offset by $437.7&#160;million of marketable securities maturing in the period. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">During the year ended December&#160;31, 2024, net cash used in investing activities was $256.3&#160;million primarily as a result of $445.9&#160;million of marketable security purchases and $5.1&#160;million of purchases of fixed assets, partially offset by $194.7&#160;million of marketable securities maturing in the period. </div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 17pt; margin-left: 0pt; text-align: left;">Cash Flows from Financing Activities </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">During the three months ended March&#160;31, 2026 and 2025, net cash provided by financing activities was $0.2&#160;million due to proceeds received from the exercise of stock options. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">271<br></div></div></div>
<!--End Page 282-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 283-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_118-mda_pg10"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">During the years ended December&#160;31, 2025 and 2024, net cash provided by financing activities was $257.0&#160;million and $422.4&#160;million, respectively, primarily due to proceeds from the issuance of preferred stock and prefunded warrants, net of issuance costs. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">Contractual Obligations and Commitments </div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 0pt; text-align: left;">Leases </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline leases office and laboratory space in Watertown, Massachusetts; San Diego, California; and Stamford, Connecticut under operating leases that expire at various dates from 2027 to 2034. Refer to Note&#160;7 to Treeline&#8217;s audited financial statements appearing elsewhere in this proxy statement/prospectus for additional details on Treeline&#8217;s leases. </div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 17pt; margin-left: 0pt; text-align: left;">License Agreements </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under Treeline&#8217;s license agreements, Treeline is required to make payments upon successful completion and achievement of certain milestones as well as royalty payments upon sales of products covered by such licenses. The payment obligations under the license agreements are contingent upon future events such as Treeline&#8217;s achievement of specified development, clinical, regulatory, and commercial milestones. To the extent that the timing of these future milestone payments are not known, Treeline has not included these fees in its balance sheets for the periods presented. Refer to Note&#160;8 to Treeline&#8217;s audited financial statements appearing elsewhere in this proxy statement/prospectus for additional details on Treeline&#8217;s license agreements. </div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 17pt; margin-left: 0pt; text-align: left;">Other </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline enters into contracts in the normal course of business with third-party service providers for clinical trials, preclinical research studies and testing, manufacturing and other services and products for operating purposes. Treeline may also enter into additional research, manufacturing, supplier and other agreements in the future, which may require up-front payments and long-term commitments of cash. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">Recent Accounting Pronouncements </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">See Note 2 to Treeline&#8217;s audited consolidated financial statements included elsewhere in this proxy statement/prospectus for a description of recent accounting pronouncements applicable to its consolidated financial statements. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">Critical Accounting Policies and Estimates </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline&#8217;s management&#8217;s discussion and analysis of its financial condition and results of operations are based on its consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States (&#8220;U.S. GAAP&#8221;). The preparation of the consolidated financial statements requires Treeline to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in its consolidated financial statements. On an ongoing basis, Treeline evaluates its estimates and judgments, including those related to accrued research and development, fair value of its common stock and stock-based compensation. Treeline bases its estimates on historical experience, known trends and events, and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions and any such differences may be material. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">While Treeline&#8217;s significant accounting policies are described in more detail in Note&#160;2 to its audited consolidated financial statements included elsewhere in this proxy statement/prospectus, Treeline believes the following accounting policies are the most critical to the judgments and estimates used in the preparation of its consolidated financial statements. </div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 17pt; margin-left: 0pt; text-align: left;">Research and Development Expenses </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Research and development expenses consist primarily of costs incurred in connection with the development of Treeline&#8217;s programs. Research and development costs are expensed as incurred. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">272<br></div></div></div>
<!--End Page 283-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 284-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_118-mda_pg11"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline accrues research and development expenses for activities performed by third parties based upon estimates of progress of studies, including the phase or completion of events, invoices received, and contracted costs. Treeline determines the estimates by reviewing contracts, vendor agreements and purchase orders, and through discussions with its internal personnel and external service providers as to the progress or stage of completion of activities or services and the agreed-upon fee to be paid for such services. However, actual costs and timing of clinical trials are highly uncertain, subject to risks and may change depending upon a number of factors, including Treeline&#8217;s development plans. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline makes estimates of its accrued expenses as of each balance sheet date in its consolidated financial statements based on facts and circumstances known at that time. If the actual timing of the performance of services or the level of effort varies from the estimate, Treeline will adjust the accrual accordingly. Advance payments for services, including fees for CROs and CDMOs that will be used in future research and development activities, are deferred and recognized as expense in the period that the related goods are consumed or services are performed. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Costs incurred in obtaining technology licenses, which include up-front cash payments and liabilities for costs to perform certain research activities on behalf of the licensor that are deemed probable and estimable, are immediately recognized as acquired in-process R&amp;D expense provided that the technology licensed has not reached feasibility and has no alternative future use. </div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Stock-Based Compensation </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline measures compensation expense for all stock-based awards based on the estimated fair value of the award on the grant date. Treeline uses the Black-Scholes option pricing model to value its stock option awards and recognizes forfeitures as they occur. Compensation expense is recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the award. Treeline has not issued awards where vesting is subject to a market or performance condition. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Black-Scholes option pricing model requires the use of subjective assumptions that include the expected stock price volatility, the risk-free interest rate, the expected term of stock options, the expected dividend yield and the fair value of the underlying common stock on the date of grant. See Note&#160;10 to Treeline&#8217;s audited consolidated financial statements and Note&#160;9 to its unaudited condensed consolidated interim financial statements included elsewhere in this proxy statement/prospectus for information concerning certain of the specific assumptions Treeline used in applying the Black-Scholes option pricing model to determine the estimated fair value of its stock options granted during the years ended December 31, 2025 and 2024 and for the three months ended March&#160;31, 2026 and 2025. </div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Determination of fair value of common stock </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline is required to estimate the fair value of its common stock underlying its stock-based awards. Because its common stock is not currently publicly traded, its board of directors determined the fair value of its common stock on each grant date, with input from its management, considering its most recently available third-party valuation of its common stock. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">These independent third-party valuations were performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants&#8217; Auditing and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation (the &#8220;Guide&#8221;). The methodology to determine the fair value of Treeline&#8217;s common stock included estimating the fair value of the enterprise using a market approach, which estimates the fair value of a company by including an estimation of the value of the business based on guideline public companies under a number of different scenarios. The Guide identifies various available methods for allocating enterprise value across classes and series of capital stock to determine the estimated fair value of common stock at each valuation date. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">273<br></div></div></div>
<!--End Page 284-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 285-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_118-mda_pg12"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In accordance with the Guide, Treeline considered the following methods: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Option Pricing Method (OPM). Under the OPM, shares are valued by creating a series of call options with exercise prices based on the liquidation preferences and conversion terms of each equity class. The estimated fair values of the convertible preferred stock and common stock are inferred by analyzing these options. This method is appropriate to use when the range of possible future outcomes is so difficult to predict that estimates would be highly speculative, and dissolution or liquidation is not imminent. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Probability-Weighted Expected Return Method (PWERM). The PWERM is a scenario-based analysis that estimates value per share based on the probability-weighted present value of expected future investment returns, considering each of the possible outcomes available to Treeline, as well as the economic and control rights of each share class. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Hybrid Method. The Hybrid Method is a hybrid between PWERM and OPM, where the equity value is estimated based on probability-weighted value across multiple scenarios where the OPM is used to estimate the allocation of value within one or more of those scenarios. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Based on Treeline&#8217;s early stage as a company, the difficulty in predicting the range of specific outcomes (and their likelihood), and other relevant factors, Treeline determined the OPM scenario was most appropriate for valuations through September&#160;2024. Given Treeline&#8217;s subsequent financing transactions, including the issuance of Series&#160;A-1 in October&#160;2024 and Series&#160;A-2 in 2025, and its early discussions on a public liquidity event, Treeline utilized a Hybrid Method approach to value its equity on October&#160;2, 2024 and August&#160;21, 2025. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline&#8217;s board of directors considered various objective and subjective factors to determine the fair value of Treeline&#8217;s common stock as of each grant date, including: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the prices at which Treeline sold shares of convertible preferred stock and the superior rights and preferences of the convertible preferred stock relative to Treeline&#8217;s common stock at the time of each grant; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the progress of Treeline&#8217;s research and development programs; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Treeline&#8217;s stage of development and business strategy; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">external market conditions affecting the biotechnology industry and trends within the biotechnology industry; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Treeline&#8217;s financial position, including cash on hand, and its historical and forecasted performance and operating results; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the lack of an active public market for Treeline&#8217;s common stock and its convertible preferred stock; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the likelihood of achieving a liquidity event, such as an initial public offering, or sale of the company in light of prevailing market conditions; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the analysis of initial public offerings and the market performance of similar companies in the biotechnology and biopharmaceutical industries. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The assumptions underlying these valuations were complex and subjective and represented management&#8217;s best estimates, which involved inherent uncertainties and the application of management&#8217;s judgment. As a result, if Treeline had used significantly different assumptions or estimates, the fair value of its common stock and its stock-based compensation expense could be materially different. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Following the consummation of the Merger and listing of Treeline&#8217;s common stock on Nasdaq, the fair value of Treeline&#8217;s common stock will be determined based on the quoted market price. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">274<br></div></div></div>
<!--End Page 285-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 286-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_118-mda_pg13"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following table summarizes by grant date the number of shares of common stock subject to stock options granted from January&#160;1, 2024 through the date of this proxy statement/prospectus, as well as the associated per share exercise price and the estimated fair value per share of Treeline&#8217;s common stock as of the grant date: </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 88.8pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 88.8pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 88.8pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 88.8pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 88.8pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 88.8pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Grant Date</div></td><td style="width: 3pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 88.8pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Type of Award</div></td><td style="width: 3pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 88.8pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of Awards <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Grants</div></td><td style="width: 3pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 88.8pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Exercise Price Per <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Share of Common <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Stock</div></td><td style="width: 3pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 88.8pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Estimated Fair Value <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Per Share of <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Common Stock </div></td></tr><tr><td style="width: 88.8pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">October&#160;2, 2024<font style="padding-left: 1.59pt;"></font></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 88.8pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 30.51pt; text-align: left;">Option</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 88.8pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 24.4pt; text-align: left;">5,214,182</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 88.8pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 33.15pt; text-align: left;">$2.25</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 88.8pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 33.15pt; text-align: left;">$2.25 </div></td></tr><tr><td style="width: 88.8pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">August&#160;21, 2025<font style="padding-left: 4.92pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 88.8pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 30.51pt; text-align: left;">Option</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 88.8pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 24.4pt; text-align: left;">5,868,250</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 88.8pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 33.15pt; text-align: left;">$2.56</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 88.8pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 33.15pt; text-align: left;">$2.56</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 88.8pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 88.8pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 88.8pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 88.8pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 88.8pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">Quantitative and Qualitative Disclosures about Market Risk </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline is a smaller reporting company as defined by Item&#160;10 of Regulation S-K and is not required to provide the information otherwise required under this item. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Smaller Reporting Company Status </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline is a &#8220;smaller reporting company&#8221; as defined in the Securities Exchange Act of 1934, as amended. Following closing of the Merger, it may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as the market value of the shares of common stock of the combined company held by non-affiliates is less than $250.0&#160;million measured on the last business day of its second fiscal quarter, or its annual revenue is less than $100.0&#160;million during the most recently completed fiscal year and the market value of its shares of common stock held by non-affiliates is less than $700.0&#160;million measured on the last business day of its second fiscal quarter. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">275<br></div></div></div>
<!--End Page 286-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 287-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_119-director_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tBOD"><!--Anchor--></a>BOARD OF DIRECTORS AND MANAGEMENT FOLLOWING THE MERGER </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">Executive Officers and Directors </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Upon the completion of the Merger, the business and affairs of the combined company will be managed under the direction of the combined company&#8217;s board of directors. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following table sets forth, as of June&#160;1, 2026, the names, ages, and positions of each of the individuals who are expected to serve as executive officers and directors of the combined company following the completion of the Merger: </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 216pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 204pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 216pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name</div></td><td style="width: 3pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Age</div></td><td style="width: 3pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 204pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Position </div></td></tr><tr><td style="width: 216pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Executive Officers:<br></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 204pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 216pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Joshua Bilenker, M.D.<font style="padding-left: 3.64pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13pt; text-align: left;">54</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 204pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chief Executive Officer, President and Director </div></td></tr><tr><td style="width: 216pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Jeffrey Engelman, M.D., Ph.D.<font style="padding-left: 3.99pt;"></font></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13pt; text-align: left;">55</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 204pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chief Scientific Officer and Director </div></td></tr><tr><td style="width: 216pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Spencer Smith<font style="padding-left: 4.9pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13pt; text-align: left;">43</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 204pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chief Financial Officer </div></td></tr><tr><td style="width: 216pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 204pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 216pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Non-Employee Directors:<br></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 204pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 216pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Kristina Burow<font style="padding-left: 1.57pt;"></font></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13pt; text-align: left;">52</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 204pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director </div></td></tr><tr><td style="width: 216pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">David Bonita, M.D.<font style="padding-left: 3.79pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13pt; text-align: left;">50</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 204pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director </div></td></tr><tr><td style="width: 216pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">David Schenkein, M.D., Ph.D.<font style="padding-left: 1.03pt;"></font></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13pt; text-align: left;">69</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 204pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director </div></td></tr><tr><td style="width: 216pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Steven Elms<font style="padding-left: 3.23pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13pt; text-align: left;">62</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 204pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director </div></td></tr><tr><td style="width: 216pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Aftab Kherani, M.D.<font style="padding-left: 4.92pt;"></font></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13pt; text-align: left;">52</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 204pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director </div></td></tr><tr><td style="width: 216pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Avi Naider<font style="padding-left: 4.53pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13pt; text-align: left;">54</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 204pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director </div></td></tr><tr><td style="width: 216pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Ali Satvat<font style="padding-left: 3.23pt;"></font></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13pt; text-align: left;">48</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 204pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director </div></td></tr><tr><td style="width: 216pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Susan Desmond-Hellmann, M.D., M.P.H.<font style="padding-left: 1.87pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13pt; text-align: left;">68</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 204pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director </div></td></tr><tr><td style="width: 216pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 204pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director </div></td></tr><tr><td style="width: 216pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 204pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 216pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 204pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Executive Officers </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Joshua Bilenker, M.D.<font style="font-weight: normal;"> is Treeline&#8217;s Co-Founder and has served as the Chief Executive Officer, President, and a member of the board of directors of Treeline since April&#160;2021. Previously, he was chief executive officer of Loxo Oncology, Inc., or Loxo Oncology, a cancer-focused biotechnology company, from July&#160;2013 through its acquisition by Eli Lilly and Company in 2019, after which he continued leading Loxo Oncology at Lilly until January&#160;2021. Dr.&#160;Bilenker co-founded and was the chief executive officer of Loxo Oncology from 2013 to 2019. From 2006 to 2013, Dr.&#160;Bilenker worked as a life sciences venture capital investor at Aisling Capital LLC. From 2004 to 2006, he served as a medical officer at the U.S. Food and Drug Administration in the Office of Oncology. Dr.&#160;Bilenker trained at the University of Pennsylvania in internal medicine and medical oncology, earning board certification in these specialties. He received his M.D. from The Johns Hopkins University School of Medicine and his A.B. degree in English from Princeton University. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Jeffrey Engelman, M.D., Ph.D.<font style="font-weight: normal;"> is Treeline&#8217;s Co-Founder and has served as the Chief Scientific Officer and as a member of the board of directors of Treeline since April&#160;2021. Prior to Treeline, Dr.&#160;Engelman served as Global Head of Oncology at the Novartis Institutes for BioMedical Research (a research arm of Novartis AG) from June&#160;2016 to April&#160;2021. Earlier in his career, he held positions of increasing responsibility at Massachusetts General Hospital, including Director of Thoracic Oncology and Director of Molecular Therapeutics, from 2007 to 2016. Dr.&#160;Engelman received a B.S. in Chemistry from Northwestern University and an M.D. and a Ph.D. in Molecular Pharmacology from Albert Einstein College of Medicine. We believe Dr.&#160;Engelman is qualified to serve on the combined company&#8217;s board of directors due to his expertise in oncology drug discovery and development and his experience leading global research organizations. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Spencer Smith<font style="font-weight: normal;"> has served as Treeline&#8217;s Chief Financial Officer since January&#160;2025 and previously served as Senior Vice President of Corporate Development from April&#160;2021 to January&#160;2025. Prior to joining Treeline, Mr.&#160;Smith served as the Senior Vice President and Chief Financial Officer of Sentio Investments, LLC, a healthcare real estate investment firm, from November&#160;2013 to January&#160;2017 and January&#160;2017 to March&#160;2021, respectively. Earlier in his career, Mr.&#160;Smith worked as an Analyst and Associate at Aisling Capital, a venture capital firm focused </font></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">276<br></div></div></div>
<!--End Page 287-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 288-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_119-director_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">on investing in biotechnology companies, from May&#160;2006 to November&#160;2013. Mr.&#160;Smith also worked as a Business Analyst at McKinsey &amp; Company, a global management and strategy consulting firm. Mr.&#160;Smith earned a B.A. in Economics from Princeton University and an M.B.A. from The Wharton School of the University of Pennsylvania. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Non-Employee Directors </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Kristina Burow<font style="font-weight: normal;"> has served as a member of the Treeline Board since April&#160;2021. Ms.&#160;Burow is a Managing Director of ARCH Venture Partners and has played a central role in shaping the firm&#8217;s life sciences strategy since joining in 2002. She is a co-founder and director of Neumora Therapeutics, Inc. since 2020 and currently serves on the board of Scholar Rock Holding Corporation and several other private companies. Ms.&#160;Burow served on the boards of Unity Biotechnology, Inc. from July&#160;2013 to March&#160;2022, Beam Therapeutics from June&#160;2017 to June&#160;2024, Gossamer Bio, Inc. from January 2018 to August 2023 and Metsera, Inc. (acquired by Pfizer Inc.) from July 2023 to November 2025. Ms.&#160;Burow previously was a co-founder and director of Receptos, Inc. (acquired by Celgene Corporation) from 2010 to September&#160;2015. Prior to ARCH Venture Partners, Ms.&#160;Burow was an associate with the Novartis BioVenture Fund (an affiliate of Novartis AG). Ms.&#160;Burow holds a B.S. in Chemistry from the University of California, Berkeley, an M.A. in Chemistry from Columbia University, and an M.B.A. from the University of Chicago Booth School of Business. We believe Ms.&#160;Burow is qualified to serve on the combined company&#8217;s board of directors due to her venture capital experience in life sciences, her expertise in co-founding successful biotechnology companies, and her extensive board governance experience. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">David Bonita, M.D.<font style="font-weight: normal;"> has served as a member of the Treeline Board since April&#160;2021. Dr.&#160;Bonita is a member of OrbiMed Advisors LLC, a leading healthcare-dedicated investment firm. He currently serves on the boards of Acutus Medical, Inc., ImageneBio, Inc. and Prelude Therapeutics, Inc., as well as several other private companies. Dr.&#160;Bonita also previously served on the boards of IMARA Inc. from March&#160;2019 to February&#160;2023, Tricida, Inc. from January&#160;2014 to January&#160;2023 and Repare Therapeutics Inc. from September&#160;2019 to February&#160;2026. Prior to OrbiMed, Dr.&#160;Bonita worked in healthcare investment banking at Morgan Stanley and UBS Group AG. He received his B.A. in Biology from Harvard University and his joint M.D. and M.B.A. from Columbia University. We believe Dr.&#160;Bonita is qualified to serve on the combined company&#8217;s board of directors based on his extensive experience evaluating and investing in healthcare companies and his service on multiple public and private boards. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">David Schenkein, M.D., Ph.D.<font style="font-weight: normal;"> has served as a member of the Treeline Board since April&#160;2021. Dr.&#160;Schenkein is a General Partner and Co-lead of the Life Sciences team at GV (formerly Google Ventures). Prior to joining GV in 2019, he served as Chief Executive Officer of Agios Pharmaceuticals, Inc. for ten years. He previously held senior clinical leadership roles at Genentech, Inc. (a member of the Roche Group) and Millennium Pharmaceuticals, Inc. (now a wholly owned subsidiary of Takeda Pharmaceutical Company Limited). Dr.&#160;Schenkein currently serves on the boards of Prime Medicine, Inc., Denali Therapeutics Inc., and Regeneron Pharmaceuticals, Inc., and has served as Adjunct Clinical Professor at Tufts Medical Center since 2009. Dr.&#160;Schenkein earned his M.D. at the State University of New York Upstate Medical University and completed his training at Tufts University School of Medicine. We believe Dr.&#160;Schenkein is qualified to serve on the combined company&#8217;s board of directors due to his experience leading a publicly traded oncology-focused company, his clinical expertise in hematology and oncology, and his venture investing experience in life sciences. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Steven Elms<font style="font-weight: normal;"> has served as a member of the Treeline Board since April&#160;2021. Mr.&#160;Elms currently serves as Managing Partner at Aisling Capital, where he has been working since 2000. Prior to joining Aisling, Mr.&#160;Elms was a Principal in the Life Sciences Investment Banking Group of Chase H&amp;Q (formerly Hambrecht &amp; Quist). Mr.&#160;Elms currently serves as Chairman of the board of ADMA Biologics, Inc. and is on the boards of Marker Therapeutics, Inc. and Elevation Oncology, Inc., and several private companies. Mr.&#160;Elms previously served on the boards of Elevation Oncology, Inc. from July&#160;2019 to July&#160;2025 and Zosano Pharma Corporation from May&#160;2018 to May&#160;2022. He also serves on the INVO Board at Northwestern University. Mr.&#160;Elms received his B.S. in Human Biology from Stanford University and his M.B.A. from the Kellogg School of Management at Northwestern University. We believe Mr.&#160;Elms is qualified to serve on the combined company&#8217;s board of directors due to his decades of healthcare-focused investment experience and his breadth of board governance experience. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Aftab Kherani, M.D.<font style="font-weight: normal;"> has served as a member of the Treeline Board since April&#160;2021. Dr. Kherani is a Managing Partner at Ajax Health, where he has worked since 2020. He previously was a Partner at Aisling Capital. Prior to joining Aisling Capital, he served as an Engagement Manager at McKinsey &amp; Company in the Pharmaceutical, Medical Product, and Private Equity practices. Dr.&#160;Kherani currently serves on the boards of several private companies. Earlier in his career, Dr.&#160;Kherani completed his residency in general surgery and served as Chief </font></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">277<br></div></div></div>
<!--End Page 288-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 289-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_119-director_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Resident at Duke University Medical Center, and completed a post-doctoral research fellowship at Columbia University. Dr.&#160;Kherani received a B.S. in Biology, a B.A. in Economics from Duke University, and his M.D. from Duke University School of Medicine. We believe Dr.&#160;Kherani is qualified to serve on the combined company&#8217;s board of directors due to his medical training and broad healthcare investing and governance experience. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Avi Naider<font style="font-weight: normal;"> has served as a member of the Treeline Board since April&#160;2021. Mr.&#160;Naider is President of AI Life Sciences, a life sciences and medical technology investment group affiliated with Access Industries. Mr.&#160;Naider served on the board of Loxo Oncology from its founding until its acquisition by Eli Lilly and Company in 2019. He currently serves on the boards of several private companies and has operational and entrepreneurial experience in several industries, including financial software, real estate development and medical products and services. Mr.&#160;Naider started his career at the Boston Consulting Group. He earned his B.A. from Princeton University&#8217;s Woodrow Wilson School of Public and International Affairs. We believe Mr.&#160;Naider is qualified to serve on the combined company&#8217;s board of directors due to his life sciences investment expertise and his broad governance experience. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Ali Satvat<font style="font-weight: normal;"> has served as a member of the Treeline Board since 2022. Mr.&#160;Satvat currently co-leads the Health Care industry team at KKR &amp; Co. Inc. and serves as Global Head of KKR&#8217;s Health Care Strategic Growth platform, where he has been working since 2012. Prior to joining KKR, Mr.&#160;Satvat was a Principal at Apax Partners and previously held positions with Johnson &amp; Johnson Development Corporation, Audax Group, and The Blackstone Group. Mr.&#160;Satvat currently serves on the boards of BridgeBio Pharma, Inc., Coherus Oncology, Inc., PRA Health Sciences, Inc., and several private companies. Mr.&#160;Satvat previously served on the boards of Impel Pharmaceuticals, Inc. from December&#160;2018 to April&#160;2024 and Eidos Therapeutics, Inc. (acquired by BridgeBio Pharma, Inc.) from June&#160;2018 to January&#160;2021. Mr.&#160;Satvat holds an A.B. in History and Science from Harvard College and an M.B.A. in Health Care Management and Entrepreneurial Management from The Wharton School of the University of Pennsylvania. We believe Mr.&#160;Satvat is qualified to serve on the combined company&#8217;s board of directors due to his extensive healthcare private equity experience and his broad governance experience across numerous public and private healthcare companies. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Susan Desmond-Hellmann, M.D., M.P.H.<font style="font-weight: normal;"> has served as a member of the Treeline Board since May&#160;2026. She currently serves as a Senior Advisor at Lazard, Inc. and a Senior Advisor at GV (formerly Google Ventures). Dr.&#160;Desmond-Hellmann previously served as Chief Executive Officer of the Bill &amp; Melinda Gates Foundation from 2014 to 2020. Earlier in her career, Dr.&#160;Desmond-Hellmann served as the Chancellor of the University of California, San&#160;Francisco, and spent fourteen years at Genentech, Inc., serving multiple roles including President of Product Development. Dr.&#160;Desmond-Hellmann currently serves on the board of Pfizer, Inc. Dr.&#160;Desmond-Hellmann holds a B.S. in Pre-Medical Studies from the University of Nevada, Reno, an M.D. from the University of Nevada, Reno, and an M.P.H. from the University of California, Berkeley. We believe Dr.&#160;Desmond-Hellmann is qualified to serve on the combined company&#8217;s board of directors due to her extensive experience in the medical industry and her experience in oncological research. </font></div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Election of Officers </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Each executive officer of the combined company will serve at the discretion of the board of directors and holds office until his or her successor is duly elected and qualified or until his or her earlier resignation or removal. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Board of Directors </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Standard BioTools&#8217; board of directors currently consists of seven members divided into three staggered classes, with one class to be elected at each annual meeting to serve for a three-year term. The staggered structure of the board of directors will remain in place for the combined company following the completion of the Merger. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">It is anticipated that these directors will be appointed to the three staggered director classes of the combined company&#8217;s board of directors as follows: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Class&#160;I directors (term ending 2027): </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Class&#160;II directors (term ending 2028): </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Class&#160;III directors (term ending 2029): </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">There are no family relationships among any of the combined company&#8217;s proposed directors and executive officers. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">278<br></div></div></div>
<!--End Page 289-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 290-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_119-director_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Pursuant to the Merger Agreement, each of Standard BioTools&#8217; directors (other than &#8195;&#8195;&#8195; and &#8195;&#8195;&#8195; and officers shall resign immediately prior to the Effective Time. Following the completion of the Merger, the combined company&#8217;s board of directors will consist of twelve directors, with ten designated by Treeline and two designated by Standard BioTools. Treeline expects that all of its current directors will continue to serve as directors on the combined company&#8217;s board of directors following the Merger. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Director Independence </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Nasdaq Rule&#160;5605 requires a majority of a listed company&#8217;s board of directors to be comprised of independent directors. In addition, Nasdaq requires that, subject to specified exceptions, each member of a listed company&#8217;s audit, compensation and nominating and corporate governance committees be independent and that audit committee members also satisfy independence criteria set forth in Rule&#160;10A-3 under the Exchange Act. Under Rule&#160;5605(a)(2), a director will only qualify as an &#8220;independent director&#8221; if, in the opinion of the company, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. In order to be considered independent for purposes of Rule&#160;10A-3, a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee, the board of directors, or any other board committee, accept, directly or indirectly, any consulting, advisory, or other compensatory fee from the listed company or any of its subsidiaries or otherwise be an affiliated person of the listed company or any of its subsidiaries. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Each individual expected to serve on the combined company&#8217;s board of directors upon the completion of the Merger, other than Drs. Bilenker and Engelman, will qualify as an independent director under the Nasdaq listing standards. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Board Leadership Structure </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline expects that the combined company&#8217;s board of directors will maintain the flexibility to determine whether the roles of Chair of the combined company&#8217;s board of directors and Chief Executive Officer should be combined or separated, based on what it believes is in the best interests of the combined company at a given point in time. Treeline believes that this flexibility is in the best interest of the combined company and that a one-size-fits-all approach to corporate governance, with a mandated independent Chair, would not result in better governance or oversight. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">At this time, Treeline believes that Dr.&#160;Bilenker, Treeline&#8217;s current Chief Executive Officer and President and the expected Chief Executive Officer and President of the combined company, is best situated to serve as Chair of the combined company&#8217;s board of directors. Dr.&#160;Bilenker is highly knowledgeable and has longstanding experience with respect to Treeline&#8217;s business, operations and industry and is expected to have an ongoing executive responsibility for the combined company. Dr.&#160;Bilenker is well positioned to identify strategic priorities and lead the combined company&#8217;s consideration and analysis of such priorities. In addition, Dr.&#160;Bilenker offers a robust understanding of risks facing Treeline and risks that the combined company will face. In Treeline&#8217;s view, this enables the combined company&#8217;s board of directors to better understand the combined company and work with management to enhance stockholder value. In addition, Treeline believes that this structure will enable the combined company to better fulfill its risk oversight responsibilities and enhance the ability of the Chief Executive Officer to effectively communicate the combined company&#8217;s board of directors&#8217; view to management. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline expects that &#8195;&#8195;&#8195;&#8195;&#8195; will be appointed as the lead independent director of the combined company to help reinforce the independence of the combined company&#8217;s board of directors as a whole. The position of lead independent director is expected to be structured to serve as an effective balance to a combined Chief Executive Officer/Chair of the combined company&#8217;s board of directors: the lead independent director will be empowered to, among other duties and responsibilities, preside over board meetings in the absence of the Chair, act as liaison between the Chair and the independent directors, preside over meetings of the independent directors, and consult with the Chair in planning and setting schedules and agendas for board meetings to be held during the year. As a result, Treeline believes that the lead independent director will help ensure the effective independent functioning of the combined company&#8217;s board of directors in its oversight responsibilities. In addition, Treeline believes that the lead independent director will be better positioned to build a consensus among directors and to serve as a conduit between the other independent directors and the Chair of the combined company&#8217;s board of directors, for example, by facilitating the inclusion on meeting agendas of matters of concern to the independent directors. In light of Dr.&#160;Bilenker&#8217;s extensive history with and knowledge of Treeline, and because the combined company&#8217;s board of directors&#8217; lead independent director will be empowered to play a significant role in the combined company&#8217;s board </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">279<br></div></div></div>
<!--End Page 290-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 291-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_119-director_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">of directors&#8217; leadership and in reinforcing the independence of the combined company&#8217;s board of directors, Treeline believes that it will be advantageous for the combined company to combine the positions of Chief Executive Officer and Chair of the combined company&#8217;s board of directors. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Role of the Board in Risk Oversight </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The audit committee of the combined company&#8217;s board of directors is expected to be primarily responsible for overseeing the risk management processes on behalf of its board of directors. Treeline expects that the audit committee of the combined company&#8217;s board of directors will receive reports from management periodically regarding the assessment of risks of the combined company. In addition, the audit committee will be expected to report regularly to the combined company&#8217;s board of directors, which will also consider its risk profile. The audit committee and the combined company&#8217;s board of directors will focus on the most significant risks the combined company faces and its general risk management strategies. While the combined company&#8217;s board of directors will oversee the combined company&#8217;s risk management, management will be responsible for day-to-day risk management processes. The combined company&#8217;s board of directors will expect management to consider risk and risk management in each business decision, to proactively develop and monitor risk management strategies and processes for day-to-day activities and to effectively implement risk management strategies adopted by the audit committee and the combined company&#8217;s board of directors. Treeline believes this division of responsibilities will be the most effective approach for addressing the risks the combined company faces and that the combined company&#8217;s board of directors&#8217; leadership structure, which also emphasizes the independence of the combined company&#8217;s board of directors in its oversight of its business and affairs, supports this approach. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Committees of the Board of Directors </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Standard BioTools&#8217; board of directors currently has the following standing committees: audit committee, compensation (human capital) committee, and nominating and corporate governance committee. Following the completion of the Merger, the combined company will continue to have the following standing committees: audit committee, compensation committee, and nominating and corporate governance committee. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">Audit Committee </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Following the completion of the Merger, the members of the combined company&#8217;s audit committee are expected to be &#8195;&#8195;, &#8195;&#8195;&#8195; and &#8195;&#8195; . &#8195;&#8195;&#8195; is expected to serve as the chair of the combined company&#8217;s audit committee. All members of the audit committee will meet the requirements for financial literacy under the applicable rules and regulations of the SEC and Nasdaq and &#8195;&#8195;&#8195; will qualify as an &#8220;audit committee financial expert&#8221; as defined under the applicable rules of the SEC and have the requisite financial sophistication as defined under the applicable rules and regulations of Nasdaq. Under the rules of the SEC, members of the audit committee must also meet heightened independence standards. Each proposed member of the audit committee will be independent under the applicable rules of the SEC and Nasdaq. The audit committee will operate under a written charter that will satisfy the applicable standards of the SEC and Nasdaq. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Standard BioTools&#8217; audit committee&#8217;s responsibilities include, among other things: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">overseeing the work of Standard BioTools&#8217; independent registered public accounting firm; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">approving the hiring, discharge, and compensation of Standard BioTools&#8217; independent registered public accounting firm; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">approving engagements of Standard BioTools&#8217; independent registered public accounting firm to render any audit or permissible non-audit services; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">evaluating the qualifications, independence, and performance of Standard BioTools&#8217; independent registered public accounting firm; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">discussing and, as appropriate, reviewing with management and Standard BioTools&#8217; independent registered public accounting firm its annual and quarterly financial statements and its major critical accounting policies and practices; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">reviewing management&#8217;s assessment of Standard BioTools&#8217; internal controls; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">reviewing the adequacy and effectiveness of Standard BioTools&#8217; internal control policies and procedures. </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">280<br></div></div></div>
<!--End Page 291-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 292-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_119-director_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The audit committee of the combined company is generally expected to retain these duties and responsibilities following the completion of the Merger. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Compensation Committee </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Following the completion of the Merger, the members of the combined company&#8217;s compensation committee are expected to be &#8195;&#8195;, &#8195;&#8195;&#8195; and &#8195;&#8195;&#8195;. &#8195;&#8195; is expected to serve as the chair of the combined company&#8217;s compensation committee. Each proposed member of the combined company&#8217;s compensation committee will be independent under the listing standards of Nasdaq, a &#8220;non-employee director&#8221; as defined in Rule&#160;16b-3 promulgated under the Exchange Act. The composition of the compensation committee will comply with the applicable requirements of the rules and regulations of Nasdaq and the SEC. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Standard BioTools&#8217; compensation (human capital) committee&#8217;s responsibilities include, among other things: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">reviewing and approving, or making recommendations to Standard BioTools&#8217; board of directors to approve, the compensation and benefits of its CEO and other executive officers; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">reviewing and approving, or making recommendations to its board of directors to approve, its corporate goals and objectives relevant to the compensation of Standard BioTools&#8217; CEO; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">providing oversight of Standard BioTools&#8217; overall compensation plans and benefits program; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">administering Standard BioTools&#8217; equity incentive plans. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The compensation committee of the combined company is expected to retain these duties and responsibilities following completion of the Merger. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Nominating and Corporate Governance Committee </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Following the completion of the Merger, the members of the combined company&#8217;s nominating and corporate governance committee are expected to be &#8195;&#8195;, &#8195;&#8195; and &#8195;&#8195;&#8195;. &#8195;&#8195;&#8195; is expected to serve as the chair of the combined company&#8217;s nominating and corporate governance committee. The composition of the nominating and corporate governance committee will meet the requirements for independence under, and the functioning of such nominating and corporate governance committee will comply with, any applicable requirements of the rules and regulations of Nasdaq and the SEC. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Standard BioTools&#8217; nominating and corporate governance committee&#8217;s responsibilities include, among other things: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">evaluating and making recommendations regarding the composition, organization, and governance of Standard BioTools&#8217; board of directors and its committees; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">evaluating the performance of members of Standard BioTools&#8217; board of directors and making recommendations regarding committee and Chair assignments; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">recommending desired qualifications for Standard BioTools&#8217; board membership and conducting searches for potential members of the board; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">reviewing and recommending Standard BioTools&#8217; board compensation programs for outside directors; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">reviewing and making recommendations concerning management succession planning; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">developing and making recommendations with regard to Standard BioTools&#8217; corporate governance guidelines. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The nominating and corporate governance committee of the combined company is generally expected to retain these duties and responsibilities following the completion of the Merger. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">Compensation Committee Interlocks and Insider Participation </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Following the completion of the Merger, each member of the combined company&#8217;s compensation committee will be a &#8220;non-employee&#8221; director within the meaning of Rule&#160;16b-3 promulgated under the Exchange Act and independent within the meaning of the independent director guidelines of Nasdaq. None of the combined company&#8217;s proposed executive officers currently serves, or in the past year has served, as a member of the compensation </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">281<br></div></div></div>
<!--End Page 292-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 293-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_119-director_pg7"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">committee (or other board committee performing equivalent functions or, in the absence of any such committee, the board of directors) of any entity that has one or more of its executive officers who is proposed to serve on the combined company&#8217;s board of directors or compensation committee following the completion of the Merger. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Code of Business Conduct and Ethics </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The combined company will maintain a code of business conduct and ethics that applies to all directors, officers and employees, including the combined company&#8217;s principal executive officer, principal financial officer, principal accounting officer or controller, or person performing similar functions. A copy of the code will be available on the Corporate Governance section of the combined company&#8217;s website, &#8195;&#8195;&#8195;&#8195;&#8195;, upon the completion of the Merger. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Non-Employee Director Compensation </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Standard BioTools and Treeline expect to terminate Standard BioTools&#8217; non-employee director compensation policy immediately prior to the closing of the Merger. The combined company&#8217;s board of directors expects to adopt a new non-employee director compensation policy to be effective following the closing. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">282<br></div></div></div>
<!--End Page 293-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 294-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_120-executive_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tECT"><!--Anchor--></a>EXECUTIVE COMPENSATION OF TREELINE </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline&#8217;s named executive officers, who are its principal executive officer and the two most highly compensated executive officers (other than its principal executive officer) serving as executive officers as of December&#160;31, 2025, were: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Joshua Bilenker, M.D., Chief Executive Officer and President; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Jeffrey Engelman, M.D., Ph.D., Chief Scientific Officer; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Spencer Smith, Chief Financial Officer. </div></td></tr></table><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Summary Compensation Table </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following table presents summary information regarding the total compensation for services rendered in all capacities that was awarded to and earned by Treeline&#8217;s named executive officers during the years ended December&#160;31, 2025 and December&#160;31, 2024. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 168pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 20pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 32.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 32.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 49.32pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 49.32pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 40pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 168pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name and Principal Position</div></td><td style="width: 6.36pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.36pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 20pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year</div></td><td style="width: 6.36pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.36pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Salary<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">($)</div></td><td style="width: 6.36pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.36pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Option<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Award<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">($)<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div></td><td style="width: 6.36pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.36pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.32pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Non-Equity<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Incentive Plan<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Compensation<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">($)</div></td><td style="width: 6.36pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.36pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.32pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">All Other<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Compensation</div></td><td style="width: 6.36pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.36pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">($) </div></td></tr><tr><td rowspan="2" style="width: 168pt; height: 14pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Joshua Bilenker, M.D. <font style="padding-left: 3.14pt;"></font> <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><font style="font-style: italic;">Chief Executive Officer and President</font><br></div></td><td style="width: 6.36pt; background-color: #CCEEFF;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 20pt; height: 14pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">2025</div></td><td style="width: 6.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; height: 14pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">541,203</div></td><td style="width: 6.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; height: 14pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">735,800</div></td><td style="width: 6.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.32pt; height: 14pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.41pt; text-align: left;">357,194<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup></div></td><td style="width: 6.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.32pt; height: 14pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.91pt; text-align: left;">52,255<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup></div></td><td style="width: 6.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; height: 14pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">1,686,452 </div></td></tr><tr><td style="width: 6.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 20pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">2024</div></td><td style="width: 6.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">533,205</div></td><td style="width: 6.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td style="width: 6.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.32pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.41pt; text-align: left;">361,513<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(4)</sup> </div></td><td style="width: 6.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.32pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.91pt; text-align: left;">49,360<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup></div></td><td style="width: 6.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 7.5pt;">944,078 </font></div></td></tr><tr><td rowspan="2" style="width: 168pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Jeffrey Engelman, M.D., Ph.D. <font style="padding-left: 3.49pt;"></font> <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><font style="font-style: italic;">Chief Scientific Officer</font><br></div></td><td style="width: 6.36pt;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 20pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">2025</div></td><td style="width: 6.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">541,203</div></td><td style="width: 6.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">735,800</div></td><td style="width: 6.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.32pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.41pt; text-align: left;">297,662<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup></div></td><td style="width: 6.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.32pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.91pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td style="width: 6.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">1,574,665 </div></td></tr><tr><td style="width: 6.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 20pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">2024</div></td><td style="width: 6.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">533,205</div></td><td style="width: 6.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td style="width: 6.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.32pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.41pt; text-align: left;">551,261<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(5)</sup></div></td><td style="width: 6.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.32pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.91pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td style="width: 6.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">1,084,466 </div></td></tr><tr><td rowspan="2" style="width: 168pt; height: 12.75pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Spencer Smith<font style="padding-left: 1.9pt;"></font> <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><font style="font-style: italic;">Chief Financial Officer</font><br></div></td><td style="width: 6.36pt; background-color: #CCEEFF;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 20pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">2025</div></td><td style="width: 6.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">425,000</div></td><td style="width: 6.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">441,480</div></td><td style="width: 6.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.32pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.41pt; text-align: left;">187,000<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup></div></td><td style="width: 6.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.32pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.91pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td style="width: 6.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">1,053,480 </div></td></tr><tr><td style="width: 6.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 20pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">2024</div></td><td style="width: 6.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">373,427</div></td><td style="width: 6.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td style="width: 6.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.32pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.41pt; text-align: left;">126,592<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(4)</sup></div></td><td style="width: 6.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.32pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.91pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td style="width: 6.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 7.5pt;">500,019</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 168pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 20pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 32.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 32.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 49.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 49.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 40pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div><div class="BRDSX_rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 12.75pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Treeline&#8217;s named executive officers did not receive stock option grants in 2024. The amounts reported in the Option Awards column represent the aggregate grant date fair value of stock options granted under Treeline&#8217;s 2021 Equity Incentive Plan (the &#8220;2021 Plan&#8221;) to Treeline&#8217;s named executive officers during the year ended December&#160;31, 2025 computed in accordance with FASB ASC Topic 718. The assumptions used in calculating the grant date fair value of the stock options reported in the Option Awards column are set forth in Note&#160;10 to Treeline&#8217;s audited financial statements included elsewhere in this proxy statement/prospectus. Note&#160;that the amounts reported in this column reflect the aggregate accounting cost for these stock options, and do not necessarily correspond to the actual economic value that may be received by the named executive officers from the stock options. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(2)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Represents the bonus paid to the named executive officers in cash in 2026 for 2025 performance pursuant to Treeline&#8217;s annual incentive program. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(3)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Represents the costs related to housing expenses for Dr.&#160;Bilenker in 2025 and 2024 for use of a corporate apartment made available to him while traveling to our headquarters for business purposes. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(4)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Represents the bonus paid to the named executive officer in cash in 2025 for 2024 performance pursuant to Treeline&#8217;s annual incentive program. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(5)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Represents the aggregate of (i) an annual bonus of $301,261 paid to Dr.&#160;Engelman in cash in 2025 for 2024 performance pursuant to Treeline&#8217;s annual incentive program and (ii) a retention bonus of $250,000 paid in cash in 2025 to Dr.&#160;Engelman pursuant to Dr.&#160;Engelman&#8217;s offer letter that was subject to continued employment with Treeline through December&#160;31, 2024. </div></td></tr></table><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Narrative to the Summary Compensation Table </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Annual Base Salary </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The base salary of Treeline&#8217;s named executive officers is generally determined and approved by the Treeline Board in connection with the commencement of employment of the named executive officer and may be adjusted from time to time thereafter as the Treeline Board determines appropriate. The base salaries for our named executive officers for fiscal years 2025 and 2024 are included in the Summary Compensation Table above. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">Annual Incentive Bonus </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition to base salaries, each of Treeline&#8217;s named executive officers is eligible to earn annual cash bonuses, which are designed to provide appropriate incentives to Treeline&#8217;s named executive officers to achieve defined annual corporate goals and to reward Treeline&#8217;s named executive officers for individual achievements towards these goals. The annual bonus awarded to each named executive officer may be based in part on the extent to which Treeline achieves corporate goals. At the end of the year, the Treeline Board reviews Treeline&#8217;s performance against </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">283<br></div></div></div>
<!--End Page 294-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 295-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_120-executive_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">each corporate goal and considers the extent to which Treeline achieved each of its corporate goals. The Treeline Board also generally considers each named executive officer&#8217;s individual contributions toward reaching these goals. The bonus amounts vary from year to year based on corporate performance. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For 2024, each of Dr.&#160;Bilenker, Dr.&#160;Engelman, and Mr.&#160;Smith was eligible for a target bonus equal to 60%, 50%, and 30% of their base salary, respectively. Based on the achievement of corporate and individual performance objectives, the Treeline Board approved 2024 annual bonuses with a bonus multiplier of 1.13x the bonus target, which were paid in 2025 and are included in the Summary Compensation Table above. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For 2025, each of Dr.&#160;Bilenker, Dr.&#160;Engelman, and Mr.&#160;Smith was eligible for a target bonus equal to 60%, 50%, and 40% of their base salary, respectively. Based on the achievement of corporate and individual performance objectives, the Treeline Board approved 2025 annual bonuses with a bonus multiplier of 1.1x the bonus target, which were paid in 2026 and are included in the Summary Compensation Table above. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Retention Bonus </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In fiscal 2024, Dr.&#160;Engelman was eligible to receive a retention bonus of $250,000, subject to continued employment with Treeline through December&#160;31, 2024 and to be paid in the first payroll period following December&#160;31, 2024, pursuant to Dr.&#160;Engelman&#8217;s offer letter. The retention bonus was paid in 2025 and is included in the Summary Compensation Table above. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Equity-Based Incentive Awards </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline&#8217;s equity-based incentive awards are designed to align Treeline&#8217;s named executive officers&#8217; interests with those of its stockholders and to retain and incentivize Treeline&#8217;s named executive officers over the long term. To date, Treeline has used stock option grants for this purpose because it believes they are an effective means by which to align the long-term interests of its executive officers with those of its stockholders. Each stock option award was granted under the 2021 Plan. There are currently no other types of equity awards outstanding. The terms of the 2021 Plan are described below under the subsection titled &#8220;<font style="font-style: italic;">-Treeline 2021 Equity Incentive Plan</font>.&#8221; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Treeline Board or an authorized committee thereof is responsible for approving equity grants. Vesting of equity awards is generally tied to continuous service with Treeline and serves as an additional retention measure. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Employment Arrangements with Treeline&#8217;s Named Executive Officers </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Each of Treeline&#8217;s named executive officers&#8217; employment is &#8220;at will&#8221; and may be terminated at any time. Each of Treeline&#8217;s named executive officers has entered into offer letters with Treeline, which include each officer&#8217;s base salary, a discretionary annual incentive bonus opportunity, severance entitlements and standard employee benefit plan participation. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Potential Payments Upon Termination or Change in Control </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Regardless of the manner in which a named executive officer&#8217;s service terminates, each named executive officer is entitled to receive amounts earned during his term of service, including unpaid salary and unused vacation. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, each of Treeline&#8217;s named executive officers&#8217; equity awards is subject to the terms of the 2021 Plan and award agreement thereunder. A description of the termination and change in control provisions in the 2021 Plan and awards granted thereunder is provided in the subsection titled &#8220;<font style="font-style: italic;">- Treeline 2021 Equity Incentive Plan</font>&#8221; below, and a description of the vesting provisions of each equity award held by Treeline&#8217;s named executive officers which is outstanding and unvested as of December&#160;31, 2025 is provided in the Outstanding Equity Awards at Fiscal Year End table below. The Merger will not constitute a change in control under the 2021 Plan. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Following the Merger, Treeline anticipates that the combined company&#8217;s board of directors will adopt a Severance and Change in Control Plan (the &#8220;Severance Plan&#8221;), under which each of Treeline&#8217;s named executive officers will become eligible to receive certain benefits. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">284<br></div></div></div>
<!--End Page 295-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 296-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_120-executive_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Outstanding Equity Awards at December&#160;31, 2025 </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following table provides information regarding each unexercised Treeline Option granted pursuant to the 2021 Plan held by Treeline&#8217;s named executive officers as of December&#160;31, 2025: </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 144pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.65pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.65pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 45.87pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.65pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.65pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 55.52pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.65pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.65pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 194.68pt;" colspan="10"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 144pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 4.65pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.65pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45.87pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 4.65pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.65pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.52pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 4.65pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.65pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td colspan="10" style="width: 194.68pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Option Award </div></td></tr><tr class="BRDSX_header"><td style="width: 144pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name</div></td><td style="width: 4.65pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.65pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45.87pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Grant Date<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div></td><td style="width: 4.65pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.65pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.52pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Vesting <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Commencement <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Date</div></td><td style="width: 4.65pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.65pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.62pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Securities<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Underlying<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Unexercised<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Options<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Exercisable</div></td><td style="width: 4.65pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.65pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 47.84pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Securities<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Underlying<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Unexercised<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Options<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Unexercisable</div></td><td style="width: 4.65pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.65pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 31.76pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Option<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Exercise<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Price Per <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Share ($)</div></td><td style="width: 4.65pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.65pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45.56pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Option<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Expiration<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Date </div></td></tr><tr><td style="width: 144pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Joshua Bilenker, M.D.<font style="padding-left: 1.64pt;"></font><br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><font style="font-style: italic;">Chief Executive Officer and President</font><br></div></td><td style="width: 4.65pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.65pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45.87pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.15pt; text-align: left;"><font style="padding-left: 0.37pt;">02/11/2025</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup></div></td><td style="width: 4.65pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.65pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.52pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.98pt; text-align: left;"><font style="padding-left: 0.37pt;">02/11/2025</font></div></td><td style="width: 4.65pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.65pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.62pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.74pt; text-align: left;"><font style="padding-left: 4.63pt;">33,333</font></div></td><td style="width: 4.65pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.65pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 47.84pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.67pt; text-align: left;">316,667</div></td><td style="width: 4.65pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.65pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 31.76pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.13pt; text-align: left;">2.25</div></td><td style="width: 4.65pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.65pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45.56pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">02/10/2035 </div></td></tr><tr><td rowspan="2" style="width: 144pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Jeffrey Engelman, M.D. Ph.D.<font style="padding-left: 4.49pt;"></font> <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><font style="font-style: italic;">Chief Scientific Officer</font><br></div></td><td style="width: 4.65pt;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.65pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45.87pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.15pt; text-align: left;"><font style="padding-left: 0.37pt;">02/11/2025</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup></div></td><td style="width: 4.65pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.65pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.52pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.98pt; text-align: left;"><font style="padding-left: 0.37pt;">02/11/2025</font></div></td><td style="width: 4.65pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.65pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.62pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.74pt; text-align: left;"><font style="padding-left: 4.63pt;">83,333</font></div></td><td style="width: 4.65pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.65pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 47.84pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.67pt; text-align: left;">316,667</div></td><td style="width: 4.65pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.65pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 31.76pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.13pt; text-align: left;">2.25</div></td><td style="width: 4.65pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.65pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45.56pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">02/10/2035 </div></td></tr><tr><td style="width: 4.65pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45.87pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.15pt; text-align: left;">06/30/2021<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(4)</sup></div></td><td style="width: 4.65pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.65pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.52pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.98pt; text-align: left;">04/05/2021</div></td><td style="width: 4.65pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.65pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.62pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.74pt; text-align: left;">119,158</div></td><td style="width: 4.65pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.65pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 47.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.67pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td style="width: 4.65pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.65pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 31.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.13pt; text-align: left;">0.90</div></td><td style="width: 4.65pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.65pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45.56pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">06/29/2031 </div></td></tr><tr><td rowspan="3" style="width: 144pt; height: 12.75pt; padding-top: 1.01pt; text-align: left; vertical-align: top; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Spencer Smith<font style="padding-left: 2.9pt;"></font><br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><font style="font-style: italic;">Chief Financial Officer</font><br></div></td><td style="width: 4.65pt; background-color: #CCEEFF;" rowspan="3"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.65pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45.87pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.15pt; text-align: left;"><font style="padding-left: 0.37pt;">02/11/2025</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup></div></td><td style="width: 4.65pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.65pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.52pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.98pt; text-align: left;"><font style="padding-left: 0.37pt;">02/11/2025</font></div></td><td style="width: 4.65pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.65pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.62pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.74pt; text-align: left;"><font style="padding-left: 4.64pt;">50,000</font></div></td><td style="width: 4.65pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.65pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 47.84pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.67pt; text-align: left;">190,000</div></td><td style="width: 4.65pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.65pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 31.76pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.13pt; text-align: left;">2.25</div></td><td style="width: 4.65pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.65pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45.56pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">02/10/2035 </div></td></tr><tr><td style="width: 4.65pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45.87pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.15pt; text-align: left;">01/17/2023<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup></div></td><td style="width: 4.65pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.65pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.52pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.98pt; text-align: left;">01/17/2023</div></td><td style="width: 4.65pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.65pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.62pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.74pt; text-align: left;"><font style="padding-left: 4.63pt;">36,458</font></div></td><td style="width: 4.65pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.65pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 47.84pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.67pt; text-align: left;"><font style="padding-left: 5pt;">13,542</font></div></td><td style="width: 4.65pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.65pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 31.76pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.13pt; text-align: left;">1.70</div></td><td style="width: 4.65pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.65pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45.56pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">01/16/2033 </div></td></tr><tr><td style="width: 4.65pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45.87pt; padding-top: 1.01pt; text-align: center; vertical-align: top; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.15pt; text-align: left;">06/30/2021<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(4)</sup></div></td><td style="width: 4.65pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.65pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.52pt; padding-top: 1.01pt; text-align: center; vertical-align: top; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.98pt; text-align: left;">04/01/2021</div></td><td style="width: 4.65pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.65pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.62pt; padding-top: 1.01pt; text-align: center; vertical-align: top; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.74pt; text-align: left;"><font style="padding-left: 9.64pt;">2,731</font></div></td><td style="width: 4.65pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.65pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 47.84pt; padding-top: 1.01pt; text-align: center; vertical-align: top; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.67pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td style="width: 4.65pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.65pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 31.76pt; padding-top: 1.01pt; text-align: center; vertical-align: top; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.13pt; text-align: left;">0.90</div></td><td style="width: 4.65pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.65pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45.56pt; padding-top: 1.01pt; text-align: center; vertical-align: top; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">06/29/2031</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 144pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 4.65pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 4.65pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 45.87pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 4.65pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 4.65pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 55.52pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 4.65pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 4.65pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 41.62pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 4.65pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 4.65pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 47.84pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 4.65pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 4.65pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 31.76pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 4.65pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 4.65pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 45.56pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div><div class="BRDSX_rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 12.75pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">All outstanding Treeline Options were granted under the 2021 Plan. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(2)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Vests in equal monthly installments over the four-year period starting on the Vesting Commencement Date, in each case subject to continuous service with Treeline through each such vesting date. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(3)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Vests as to a quarter of the shares on the one-year anniversary of the Vesting Commencement Date, and thereafter vests monthly over three&#160;years, in each case subject to continuous service with Treeline through each such vesting date. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(4)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">This option award was fully vested as of December&#160;31, 2025. </div></td></tr></table><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">Other Benefits </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline&#8217;s named executive officers are eligible to participate in employee benefit plans on the same basis as Treeline&#8217;s other employees, including a 401(k) plan and health and welfare plans. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Treeline 2021 Equity Incentive Plan </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline maintains the 2021 Plan, which was adopted by the Treeline Board in February&#160;2021, and subsequently amended from time to time and most recently in November&#160;2025. The purpose of the 2021 Plan is to provide incentives to attract, retain and motivate eligible persons whose present and potential contributions are important to the success of Treeline by offering eligible persons an opportunity to participate in Treeline&#8217;s future performance through the grant of awards. The material terms of the 2021 Plan are summarized below: </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Share Reserve<font style="font-style: normal;">. Subject to adjustment as provided in the 2021 Plan, the total number of shares of Treeline Common Stock reserved and available for grant and issuance under the 2021 Plan is 38,152,270 shares, or the Share Reserve. In the event that shares previously issued under the 2021 Plan are reacquired by Treeline pursuant to a forfeiture provision, right of first refusal, or repurchase, such shares shall be added to the number of shares then available for issuance. Shares withheld in payment of exercise price or withholding obligations shall remain available for issuance. If an outstanding option, restricted stock unit (&#8220;RSU&#8221;) or stock appreciation rights (&#8220;SARs&#8221;) expires, is cancelled, forfeited or terminated, the shares allocable to the unexercised or unsettled portion shall remain available for issuance. Cash settlements in respect of an award do not reduce the Share Reserve. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Administration<font style="font-style: normal;">. The 2021 Plan is administered by a committee appointed by the Treeline Board or the Treeline Board (if no committee is appointed) (the &#8220;Committee&#8221;). Subject to the terms of the 2021 Plan, the Committee has the authority to, among other things, construe and interpret the plan, select the persons to whom awards will be granted, determine the form and terms of awards, prescribe, amend, expand, modify and rescind rules and regulations relating to the 2021 Plan, and make all other determinations necessary or advisable in connection with the administration of the 2021 Plan. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Eligibility<font style="font-style: normal;">. Pursuant to the 2021 Plan, Treeline may grant incentive stock options (&#8220;ISOs&#8221;) only to employees (including officers and directors who are also employees) of Treeline or of a parent or subsidiary of Treeline. Non-qualified stock options (&#8220;NQSOs&#8221;) and all other types of awards may be granted to employees, officers, </font></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">285<br></div></div></div>
<!--End Page 296-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 297-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_120-executive_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">directors and consultants of Treeline or any parent or subsidiary of Treeline, provided such consultants render bona fide services not in connection with the offer and sale of securities in a capital-raising transaction. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Options<font style="font-style: normal;">. The 2021 Plan provides for the grant of both (i) ISOs, which are intended to qualify for tax treatment as set forth under Section&#160;422 of the Code and (ii) NQSOs to purchase shares of Treeline Common Stock, each at a stated exercise price. The exercise price of each stock option shall not be less than the fair market value of Treeline Common Stock on the date of grant unless expressly determined in writing by the Treeline Board; provided that the exercise price of any ISO granted to a ten percent stockholder will not be less than 110% of the fair market value of Treeline Common Stock on the date of grant. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The maximum permitted term of options granted under the 2021 Plan is ten years from the date of grant, except that the maximum permitted term of ISOs granted to a ten percent stockholder is five years from the date of grant. Options may be awarded as immediately exercisable but subject to repurchase or may be exercisable within the times or upon the events determined by the Treeline Board. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Restricted Stock Awards<font style="font-style: normal;">. The 2021 Plan provides for the issuance of restricted stock awards, which are offers by Treeline to sell to an eligible person shares that are subject to certain specified restrictions. Among other terms and conditions, Treeline may retain a right to repurchase unvested restricted stock following the holder&#8217;s termination of service. The purchase price and other terms of each restricted stock award are generally determined by the Committee. As of the date hereof, no restricted stock awards are outstanding under the 2021 Plan. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Restricted Stock Units<font style="font-style: normal;">. The 2021 Plan provides for the issuance of RSUs covering a number of shares that may be settled in cash, by issuance of Treeline Common Stock at a date in the future, or by a combination of cash and shares. No RSU will have a term longer than ten years from the date the RSU is granted. The terms, including the number of shares, timing of settlement, consideration to be distributed, and effect of termination, will be generally determined by the Treeline Board and set forth in an award agreement. As of the date hereof, no RSUs have been granted under the 2021 Plan. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Stock Appreciation Rights<font style="font-style: normal;">. The 2021 Plan provides for the issuance of SARs that may be settled in cash or shares (which may consist of restricted stock or RSUs) or a combination thereof, having a value equal to the value determined by multiplying the difference between the fair market value on the date of exercise over the exercise price and the number of shares with respect to which the SAR is being exercised. No SAR will be exercisable after the expiration of ten years from the date the SAR is granted. The exercise price of a SAR may not be less than the fair market value on the date of grant. No SARs have been granted under the 2021 Plan, and no SARs are expected to be granted under the 2021 Plan prior to the closing of the Merger. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Limited Transferability<font style="font-style: normal;">. Except as permitted by the Committee, awards granted under the 2021 Plan, and any interest therein, will not be transferable or assignable by the participant, other than by will or by the laws of descent and distribution, and, with respect to NQSOs for participants in the U.S., by instrument to an inter vivos or testamentary trust or by gift to a &#8220;family member&#8221; as defined in Rule&#160;701. Awards may not be made subject to execution, attachment or similar process. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Corporate Transaction<font style="font-style: normal;">. In the event of an Acquisition or Other Combination (as defined in the 2021 Plan), outstanding awards under the 2021 Plan shall be subject to the agreement evidencing such transaction, which need not treat all outstanding awards in an identical manner. Such agreement, without the participant&#8217;s consent, may provide for one or more of the following with respect to outstanding awards: (a) continuation of such awards if Treeline is the successor entity, (b) assumption of outstanding awards by the successor or acquiring entity, (c)&#160;substitution of equivalent awards by the successor or acquiring entity, (d) full or partial exercisability or vesting and accelerated expiration, (e) settlement of the fair market value in cash, cash equivalents or securities of the successor entity followed by cancellation, or (f) termination of any outstanding award not exercised prior to consummation of the transaction. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Adjustments<font style="font-style: normal;">. In the event of a stock dividend, recapitalization, stock split, reverse stock split, subdivision, combination, reclassification or other change in the capital structure of Treeline affecting shares without consideration, then in order to prevent diminution or enlargement of the benefits or potential benefits intended to be made available under the 2021 Plan, (a) the number and class of shares reserved for issuance under the 2021 Plan, (b) the exercise prices of and number and class of shares subject to outstanding options and SARs, and (c) the purchase prices of and/or number and class of shares subject to other outstanding awards will be proportionately adjusted, subject to any required action by the Treeline Board or the stockholders and compliance with applicable securities or other laws. </font></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">286<br></div></div></div>
<!--End Page 297-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 298-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_120-executive_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">TREELINE DIRECTOR COMPENSATION </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Non-Employee Director Compensation Policy </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Historically, Treeline has not paid cash compensation to any of its non-employee directors for service on the Treeline Board. Following the Merger, Treeline anticipates that the combined company&#8217;s board of directors will adopt a new non-employee director compensation policy, under which the non-employee members of the board of directors of the combined company will participate. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">287<br></div></div></div>
<!--End Page 298-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 299-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_121-certain_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tCER"><!--Anchor--></a>CERTAIN RELATIONSHIPS AND RELATED PARTY <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">TRANSACTIONS OF THE COMBINED COMPANY </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition to the compensation arrangements, including employment, termination of employment and change in control arrangements, with Standard BioTools&#8217; and Treeline&#8217;s directors and executive officers, the following is a description of each transaction involving Standard BioTools since January&#160;1, 2025, each transaction involving Treeline since January&#160;1, 2023 and each currently proposed transaction in which: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">(i) in respect of Standard BioTools, the amounts involved exceeded or will exceed $120,000 and (ii) in respect of Treeline, the amounts involved exceeded or will exceed the lesser of $120,000 and 1% of the average of Treeline&#8217;s total assets at year-end for the last two completed fiscal years, as applicable; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any of Standard BioTools&#8217; or Treeline&#8217;s directors, executive officers or holders of more than 5% of Standard BioTools&#8217; or Treeline&#8217;s capital stock, or an affiliate or immediate family member of the foregoing persons, had or will have a direct or indirect material interest. </div></td></tr></table><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Standard BioTools&#8217; Transactions </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On December&#160;9, 2025, Standard BioTools invested $5.0&#160;million in unsecured convertible loan notes issued by a privately-held life sciences company. The notes bear interest at 8% per annum, mature in December&#160;2027, and are subordinated to the issuer&#8217;s senior indebtedness. The notes automatically convert into equity upon a qualified financing of at least $20&#160;million or an initial public offering with gross proceeds of at least $100&#160;million, in each case at a 20% discount to the applicable offering price. At maturity, any outstanding principal and accrued interest automatically convert into preferred shares at a conversion price based on a valuation cap of eight times the issuer&#8217;s trailing 12-month revenue. Standard BioTools invested in the notes alongside a fund associated with Mr.&#160;Casdin, a member of the Standard BioTools Board. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Policy Concerning Audit Committee Approval of Related Person Transactions </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Standard BioTools Board and audit committee have adopted a formal written policy that Standard BioTools&#8217; executive officers, directors, holders of more than 5% of any class of Standard BioTools&#8217; voting securities, and any member of the immediate family of any of the foregoing persons are not permitted to enter into any transaction with Standard BioTools for which disclosure would be required under Item&#160;404 of Regulation S-K, referred to as a related person transaction, without the review and approval or ratification of Standard BioTools&#8217; audit committee, or other independent members of the Standard BioTools Board if it is inappropriate for Standard BioTools&#8217; audit committee to review such transaction due to a conflict of interest. Any related person transaction must be presented to the audit committee for review, consideration, and approval or ratification. In approving or rejecting any such related person transaction, the audit committee is to consider the relevant facts and circumstances available and deemed relevant to the audit committee, including, but not limited to, whether the transaction is on terms no less favorable than terms generally available to an unaffiliated third party under the same or similar circumstances and the extent of the related person&#8217;s interest in the transaction. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Treeline Related Party Transactions </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">Agreements Related to the Merger </div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">Lock-Up Agreements </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Concurrently with the execution of the Merger Agreement, certain officers, directors and stockholders of Treeline holding approximately 70.41% of the outstanding shares of Treeline Capital Stock as of June&#160;6, 2026 entered into lock-up agreements, pursuant to which, subject to specified exceptions, such persons agreed to certain restrictions on transfers of shares of Standard BioTools common stock beneficially held by such persons or such persons&#8217; family members for the 180-day period following the Effective Time. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">288<br></div></div></div>
<!--End Page 299-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 300-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_121-certain_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Equity Financings </div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 0pt; text-align: left;">Series&#160;A-1 Preferred Stock Financing </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In October&#160;2024, Treeline issued and sold an aggregate of 48,985,495 shares of its Series&#160;A-1 Preferred Stock at a purchase price of $8.6103 for an aggregate purchase price of approximately $422.0&#160;million to investors that included certain existing 5% holders and their affiliates of Treeline. The participation of such 5% holders in the Series&#160;A-1 Financing is summarized below: </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 2pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="margin-top: 0pt; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 288pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.48pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.48pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 89.26pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.48pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.48pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 72.82pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 288pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">NAME OF STOCKHOLDER</div></td><td style="width: 4.48pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.48pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 89.26pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">SHARES OF SERIES A-1<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">PREFERRED STOCK</div></td><td style="width: 4.48pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.48pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72.82pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">TOTAL PURCHASE <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">PRICE ($) </div></td></tr><tr><td style="width: 288pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">OrbiMed Private Investments VIII, LP<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup><font style="padding-left: 2.26pt;"></font></div></td><td style="width: 4.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 89.26pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 24.63pt; text-align: left;">5,574,718</div></td><td style="width: 4.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72.82pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.41pt; text-align: left;">$47,999,994 </div></td></tr><tr><td style="width: 288pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Entities Affiliated with ARCH Venture Partners<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup><font style="padding-left: 1.88pt;"></font></div></td><td style="width: 4.48pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.48pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 89.26pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 24.63pt; text-align: left;">5,574,717</div></td><td style="width: 4.48pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.48pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72.82pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.41pt; text-align: left;">$47,999,986 </div></td></tr><tr><td style="width: 288pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Entities Affiliated with GV<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup><font style="padding-left: 3.35pt;"></font></div></td><td style="width: 4.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 89.26pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 24.63pt; text-align: left;">5,574,718</div></td><td style="width: 4.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72.82pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.41pt; text-align: left;">$47,999,994 </div></td></tr><tr><td style="width: 288pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Funds and Accounts Managed by T. Rowe Price Associates, Inc.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(4)</sup><font style="padding-left: 4.41pt;"></font></div></td><td style="width: 4.48pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.48pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 89.26pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 24.63pt; text-align: left;">6,039,273</div></td><td style="width: 4.48pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.48pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72.82pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.41pt; text-align: left;">$51,999,952 </div></td></tr><tr><td style="width: 288pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Entities Affiliated with KKR &amp; Co., Inc.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(5)</sup><font style="padding-left: 4.46pt;"></font></div></td><td style="width: 4.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 89.26pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 24.63pt; text-align: left;">9,291,197</div></td><td style="width: 4.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72.82pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.41pt; text-align: left;">$79,999,994 </div></td></tr><tr><td style="width: 288pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Entities Affiliated with Access Industries<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(6)</sup><font style="padding-left: 3.09pt;"></font></div></td><td style="width: 4.48pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.48pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 89.26pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 24.63pt; text-align: left;">6,039,277</div></td><td style="width: 4.48pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.48pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72.82pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.41pt; text-align: left;">$51,999,987 </div></td></tr><tr><td style="width: 288pt; padding-top: 0.51pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Entities Affiliated with Casdin Capital LLC<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(7)</sup><font style="padding-left: 2.24pt;"></font></div></td><td style="width: 4.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 89.26pt; padding-top: 0.51pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 24.63pt; text-align: left;">3,019,638</div></td><td style="width: 4.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72.82pt; padding-top: 0.51pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.41pt; text-align: left;">$25,999,989</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 288pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 4.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 4.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 89.26pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 4.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 4.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 72.82pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div><div class="BRDSX_rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 12.75pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Consists of shares held by an entity affiliated with OrbiMed, which beneficially owns more than 5% of outstanding Treeline Capital Stock. David Bonita, a member of the Treeline Board, is a general partner of OrbiMed. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(2)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Consists of shares held by entities affiliated with ARCH Venture, which beneficially owns more than 5% of outstanding Treeline Capital Stock. Kristina Burow, a member of the Treeline Board, is a managing director at the ARCH Venture entities. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(3)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Consists of shares held by entities affiliated with GV, which beneficially owns more than 5% of outstanding Treeline Capital Stock. David&#160;Schenkein, a member of the Treeline Board, is a general partner at GV. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(4)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Consists of shares held by entities affiliated with T. Rowe Price, which beneficially owns more than 5% of outstanding Treeline Capital Stock. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(5)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Consists of shares held by entities affiliated with KKR, which beneficially owns more than 5% of outstanding Treeline Capital Stock. Ali&#160;Satvat, a member of the Treeline Board, is a partner at KKR. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(6)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Consists of shares held by an entity affiliated with Access Industries, which beneficially owns more than 5% of outstanding Treeline Capital Stock. Avi Naider, a member of the Treeline Board, is president at AI Life Sciences, an entity affiliated with Access Industries. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(7)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Consists of shares held by entities affiliated with Casdin, which beneficially owns more than 5% of outstanding Treeline Capital Stock. </div></td></tr></table><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 17pt; margin-left: 0pt; text-align: left;">Series&#160;A-2 Preferred Stock and Warrant Financing </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On August&#160;21, 2025, Treeline entered into a Series&#160;A-2 Preferred Stock and Warrant Purchase Agreement (the &#8220;Series&#160;A-2 Purchase Agreement&#8221;) with the investors listed therein, pursuant to which Treeline agreed to issue and sell shares of its Series&#160;A-2 Preferred Stock, together with warrants to purchase additional shares of common stock of Treeline (the &#8220;Common Stock Warrants&#8221;) (the &#8220;Series&#160;A-2 Financing&#8221;). At the closing of the Series&#160;A-2 Financing, Treeline issued and sold an aggregate of 29,731,819 shares of Series&#160;A-2 Preferred Stock at a purchase price of $8.6103 per share, together with Common Stock Warrants to purchase up to an aggregate of 5,377,111&#160;shares, for an aggregate purchase price of approximately $256&#160;million. Investors in the Series&#160;A-2 Financing included holders of more than 5% of the outstanding shares of Treeline Capital Stock. The participation of 5% holders and director-affiliated entities in the Series&#160;A-2 Financing is summarized below: </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 2pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="margin-top: 0pt; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 288pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.48pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.48pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 89.26pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.48pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.48pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 72.82pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 288pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">NAME OF STOCKHOLDER</div></td><td style="width: 4.48pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.48pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 89.26pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">SHARES OF SERIES A-2<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">PREFERRED STOCK</div></td><td style="width: 4.48pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.48pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72.82pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">TOTAL PURCHASE <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">PRICE ($) </div></td></tr><tr><td style="width: 288pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">OrbiMed Private Investments VIII, LP<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup><font style="padding-left: 2.26pt;"></font></div></td><td style="width: 4.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 89.26pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.13pt; text-align: left;"><font style="padding-left: 5pt;">2,903,498</font></div></td><td style="width: 4.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72.82pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.41pt; text-align: left;">$24,999,989 </div></td></tr><tr><td style="width: 288pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Entities Affiliated with ARCH Venture Partners<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup><font style="padding-left: 1.88pt;"></font></div></td><td style="width: 4.48pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.48pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 89.26pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.13pt; text-align: left;"><font style="padding-left: 5pt;">2,903,498</font></div></td><td style="width: 4.48pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.48pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72.82pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.41pt; text-align: left;">$24,999,989 </div></td></tr><tr><td style="width: 288pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Entities Affiliated with GV<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup><font style="padding-left: 3.35pt;"></font></div></td><td style="width: 4.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 89.26pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.13pt; text-align: left;"><font style="padding-left: 5pt;">2,601,534</font></div></td><td style="width: 4.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72.82pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.41pt; text-align: left;">$22,399,988 </div></td></tr><tr><td style="width: 288pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Funds and Accounts Managed by T. Rowe Price Associates, Inc.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(4)</sup><font style="padding-left: 4.41pt;"></font></div></td><td style="width: 4.48pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.48pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 89.26pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.13pt; text-align: left;"><font style="padding-left: 5pt;">3,472,584</font></div></td><td style="width: 4.48pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.48pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72.82pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.41pt; text-align: left;">$29,899,990 </div></td></tr><tr><td style="width: 288pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Entities Affiliated with KKR &amp; Co., Inc.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(5)</sup><font style="padding-left: 4.46pt;"></font></div></td><td style="width: 4.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 89.26pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.13pt; text-align: left;"><font style="padding-left: 5pt;">1,916,308</font></div></td><td style="width: 4.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72.82pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.41pt; text-align: left;">$16,499,987 </div></td></tr><tr><td style="width: 288pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Entities Affiliated with Access Industries<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(6)</sup><font style="padding-left: 3.09pt;"></font></div></td><td style="width: 4.48pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.48pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 89.26pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.13pt; text-align: left;">10,568,737</div></td><td style="width: 4.48pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.48pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72.82pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.41pt; text-align: left;">$90,999,996 </div></td></tr><tr><td style="width: 288pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Entities Affiliated with Ajax Health<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(7)</sup><font style="padding-left: 4.74pt;"></font></div></td><td style="width: 4.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 89.26pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.13pt; text-align: left;"><font style="padding-left: 5pt;">1,056,872</font></div></td><td style="width: 4.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72.82pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.41pt; text-align: left;">$<font style="padding-left: 5pt;">9,099,985 </font></div></td></tr><tr><td style="width: 288pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Entities Affiliated with Casdin Capital LLC<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(8)</sup><font style="padding-left: 2.24pt;"></font></div></td><td style="width: 4.48pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.48pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 89.26pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.13pt; text-align: left;"><font style="padding-left: 12.5pt;">464,558</font></div></td><td style="width: 4.48pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.48pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72.82pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.41pt; text-align: left;">$<font style="padding-left: 5pt;">3,999,984 </font></div></td></tr><tr><td style="width: 288pt; padding-top: 0.51pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Aisling Capital V, LP<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(9)</sup><font style="padding-left: 1.01pt;"></font></div></td><td style="width: 4.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 89.26pt; padding-top: 0.51pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.13pt; text-align: left;"><font style="padding-left: 12.5pt;">243,893</font></div></td><td style="width: 4.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72.82pt; padding-top: 0.51pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.41pt; text-align: left;">$<font style="padding-left: 5pt;">2,099,992</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 288pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 4.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 4.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 89.26pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 4.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 4.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 72.82pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div><div class="BRDSX_rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 12.75pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Consists of shares held by an entity affiliated with OrbiMed, which beneficially owns more than 5% of outstanding Treeline Capital Stock. David Bonita, a member of the Treeline Board, is a general partner of OrbiMed. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(2)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Consists of shares held by entities affiliated with ARCH Venture, which beneficially owns more than 5% of outstanding Treeline Capital Stock. Kristina Burow, a member of the Treeline Board, is a managing director at ARCH Venture. </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">289<br></div></div></div>
<!--End Page 300-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 301-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_121-certain_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5.25pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(3)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Consists of shares held by entities affiliated with GV, which beneficially owns more than 5% of outstanding Treeline Capital Stock. David Schenkein, a member of the Treeline Board, is a general partner at GV. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(4)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Consists of shares held by entities affiliated with T. Rowe Price, which beneficially owns more than 5% of outstanding Treeline Capital Stock. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(5)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Consists of shares held by entities affiliated with KKR, which beneficially owns more than 5% of outstanding Treeline Capital Stock. Ali&#160;Satvat, a member of the Treeline Board, is a partner at KKR. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(6)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Consists of shares held by an entity affiliated with AI Treeline, which beneficially owns more than 5% of outstanding Treeline Capital Stock. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(7)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Consists of shares held by entities affiliated with Ajax, which beneficially owns more than 5% of outstanding Treeline Capital Stock. Aftab&#160;Kherani, a member of the Treeline Board, is a managing partner at Ajax. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(8)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Consists of shares held by entities affiliated with Casdin, which beneficially owns more than 5% of outstanding Treeline Capital Stock. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(9)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Steven Elms, a member of the Treeline Board, is a managing partner at Aisling Capital V, LP. </div></td></tr></table><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Other Transactions </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Since October&#160;2022, Jennifer Kherani, the spouse of Aftab Kherani, a member of the Treeline Board, is employed by Treeline in a non-executive officer role as Vice President, Clinical Safety. During fiscal 2023, fiscal 2024 and fiscal 2025, Dr.&#160;J. Kherani&#8217;s annual base salary was $291,667, $358,750 and $364,131, respectively, in addition to bonus payments for fiscal 2023, fiscal 2024, and fiscal 2025 of $115,500, $121,616, and $120,163, respectively. For each fiscal period, Dr.&#160;J. Kherani&#8217;s compensation was based on reference to external market practice of similar positions or internal pay equity when compared to the compensation paid to employees in similar positions who were not related to a member of the Treeline Board. Dr.&#160;J. Kherani was also eligible for equity awards on the same general terms and conditions as applicable to employees in similar positions who were not related to a member of the Treeline Board. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Investor Agreements </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline is party to an investors&#8217; rights agreement, voting agreement and right of first refusal and co-sale agreement containing registration rights, information rights, voting rights and rights of first refusal and co-sale, among other things, with certain of its stockholders, including holders of more than 5% of the outstanding shares of Treeline Capital Stock, and entities with which certain of Treeline&#8217;s officers and directors are affiliated. The foregoing agreements will terminate at or prior to the closing of the Merger. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Indemnification Agreements </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline&#8217;s restated certificate of incorporation contains provisions limiting the liability of directors and officers of Treeline, and Treeline&#8217;s bylaws, as amended, provide that Treeline will indemnify each of its directors and executive officers (as defined in Rule&#160;3b-7 promulgated under the Exchange Act) to the fullest extent not prohibited by the DGCL or any other applicable law. Treeline&#8217;s restated certificate of incorporation also provides the Treeline Board with discretion to indemnify its directors, officers and agents (and any other persons to which the DGCL permits Treeline to provide indemnification) pursuant to Treeline&#8217;s bylaws, as amended, agreements, vote of Treeline&#8217;s stockholders or disinterested directors or otherwise, in excess of the indemnification and advancement otherwise permitted by Section&#160;145 of the DGCL. In addition, Treeline&#8217;s bylaws, as amended, provide that Treeline has the power to indemnify its other officers, employees and other agents as set forth in the DGCL or any other applicable law. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treeline has entered, and the combined company will enter, into separate indemnification agreements with each of its directors and executive officers. Treeline&#8217;s indemnification agreements provide, and the combined company&#8217;s indemnification agreements will provide, that Treeline, or the combined company, as applicable, will indemnify each of their respective directors and officers against any and all expenses incurred by that director or officer because of his or her status as one of Treeline&#8217;s or the combined company&#8217;s, as applicable, directors and/or officers or while serving in such capacity, is or was serving or has agreed to serve as a director, officer, employee or agent of another entity, to the fullest extent permitted by the DGCL, Treeline&#8217;s or the combined company&#8217;s amended and restated certificate of incorporation and amended and restated bylaws. In addition, Treeline&#8217;s indemnification agreements provide, and the combined company&#8217;s indemnification agreements will provide, that, to the fullest extent permitted by the DGCL, Treeline or the combined company, as applicable, will advance all expenses incurred by their respective directors and officers in connection with a legal proceeding involving his or her status as a director or executive officer or while serving in such capacity, is or was serving or has agreed to serve as a director, officer, employee or agent of another entity. The terms of the combined company&#8217;s indemnification agreements are qualified in their entirety by reference to the actual text of the indemnification agreement, a form of which is filed as an exhibit to this proxy statement/prospectus. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">290<br></div></div></div>
<!--End Page 301-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 302-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_121-certain_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Policies and Procedures for Transactions with Related Persons </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Following the closing of the Merger, the combined company plans to adopt a new written related-person transactions policy that sets forth its policies and procedures regarding the identification, review, consideration and oversight of &#8220;related-person transactions.&#8221; For purposes of the combined company&#8217;s policy only, a &#8220;related-person transaction&#8221; will be a transaction, arrangement or relationship (or any series of similar transactions, arrangements or relationships) in which the combined company and any &#8220;related person&#8221; are participants involving an amount that exceeds $120,000 in any fiscal year and a related person had, has or will have a direct or indirect material interest. Transactions involving compensation for services provided to the combined company as an employee, consultant or director will not be considered related-person transactions under this policy. A related person will be any executive officer, director, nominee to become a director or a holder of more than five percent of the combined company&#8217;s common stock, including any of their immediate family members and affiliates, including entities owned or controlled by such persons. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">291<br></div></div></div>
<!--End Page 302-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 303-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_122-unaudited_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tUNA"><!--Anchor--></a>UNAUDITED PRO FORMA CONDENSED COMBINED <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">FINANCIAL INFORMATION </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Defined terms included below shall have the same meaning as terms defined and included elsewhere in this proxy statement/prospectus.<font style="font-style: normal;"> </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On June&#160;6, 2026, Standard BioTools, Merger Sub, and Treeline entered into the Merger Agreement, pursuant to which, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into Treeline (the &#8220;Merger&#8221;), with Treeline surviving the Merger as a wholly owned subsidiary of Standard BioTools. The Merger is expected to close in the second half of 2026 following the effectiveness of the registration statement on Form&#160;S-4 of which this proxy statement/prospectus forms a part, receipt of approval by the stockholders of Standard BioTools, approval of the listing of the Standard BioTools Common Stock on Nasdaq and the satisfaction of the other customary closing conditions set forth in the Merger Agreement. In connection with the Merger, each holder of Treeline Capital Stock will receive shares of Standard BioTools Common Stock. Standard BioTools following the Merger is referred to herein as the Combined Company. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Prior to the effective time, Standard BioTools will enter into the CVR Agreement with a rights agent pursuant to which Standard BioTools stockholders of record as of a date agreed to by Standard BioTools and Treeline prior to the effective time will receive one CVR for each outstanding share of Standard BioTools Common Stock held by such stockholders on such date. Pursuant to the CVR Agreement, the holder of each CVR will be entitled to receive a payment for each 12-month CVR payment period during the five-year term of the CVR Agreement, consisting of a number of shares of the Combined Company&#8217;s common stock (with fractional shares settled in cash) equal to such holder&#8217;s pro rata portion of the aggregate net proceeds received by the Combined Company during such 12-month CVR payment period from the following sources, in each case less certain permitted deductions: (i) proceeds from any sale, disposition, or other monetization of Standard BioTools&#8217; mass cytometry and microfluidics businesses; (ii)&#160;proceeds from convertible notes or other investments held by Standard BioTools as of the Closing Date; (iii)&#160;earnout, milestone, royalty or other similar contingent payments due to Standard BioTools under contracts in effect as of the Closing Date, including payments from Illumina, Inc. pursuant to the Stock Purchase Agreement dated June&#160;22, 2025; and (iv) any surplus in Parent Net Cash delivered at Closing as finally determined under the Merger Agreement. The maximum number of shares of Combined Company common stock which may be issued pursuant to the CVR Agreement is 76,000,000. There can be no assurance that any payments will be made on the CVRs. The CVRs will not have any voting or dividend rights, will not represent any equity or ownership interest in Standard BioTools or its subsidiaries, and interest will not accrue on any amounts payable on the CVRs. Prior to the effective time, Standard BioTools will declare a pre-closing dividend to its common stockholders of record consisting of one CVR for each outstanding share of Standard BioTools Common Stock held by such stockholder as of such date, representing the right to receive contingent share-based settlement upon the occurrence of certain events set forth in the CVR Agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">At the Effective Time, upon the terms and subject to the conditions set forth in the Merger Agreement, each share of capital stock of Treeline (including each share of Treeline redeemable convertible preferred stock) issued and outstanding immediately prior to the Effective Time shall be automatically converted into the right to receive a number of shares of Standard BioTools Common Stock, rounded down to the nearest whole share, equal to the Exchange Ratio, calculated pursuant to a formula set forth in the Merger Agreement that is based on (i) an equity value for Treeline of $2.5&#160;billion and (ii) an equity value for Standard BioTools equal to $460&#160;million, reduced by the amount by which the Parent Net Cash (as defined in the Merger Agreement) is less than $449&#160;million at the Closing or increased by the amount by which Parent Net Cash is more than $451&#160;million at the Closing. Because Standard BioTools&#8217; final Net Cash, calculated in accordance with the Merger Agreement and generally consisting of Standard BioTools unrestricted cash, cash equivalents and short-term and long-term investments, less Standard BioTools outstanding indebtedness, accrued and unpaid transaction expenses, severance and retention obligations, and certain other agreed liabilities, in each case as of the determination time, will not be determined until the Closing, and because the number of shares of Standard BioTools Common Stock issuable to Treeline stockholders is determined based on, among other things, Standard BioTools final Net Cash, Standard BioTools stockholders cannot be certain of the exact number of shares that will be issued to Treeline stockholders when Standard BioTools stockholders vote on the Proposals at the Special Meeting. Standard BioTools will assume outstanding and unexercised options to purchase shares of Treeline Common Stock, and in connection with the Merger, they will be converted into options to purchase shares of Standard BioTools Common Stock based on the Exchange Ratio. Each Treeline Converting Warrant will be cancelled and converted into the right to receive Standard BioTools Common Stock equal to the net-exercise shares (valued at the Company Value Per Share (as defined in the Merger Agreement)) multiplied by the Exchange Ratio. Each Treeline Warrant that is not a Treeline Converting Warrant will be assumed by Standard </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">292<br></div></div></div>
<!--End Page 303-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 304-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_122-unaudited_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">BioTools and converted into a warrant to purchase Standard BioTools Common Stock, with the number of shares multiplied by, and the warrant price divided by, the Exchange Ratio. As of the Effective Time, Standard BioTools stockholders will continue to own and hold their then existing shares of Standard BioTools Common Stock, after giving effect to the proposed Reverse Stock Split at an assumed ratio of &#8195;&#8195;&#8195;. The Exchange Ratio referenced above is an estimate only and the final Exchange Ratio will be determined pursuant to a formula described in more detail in the section entitled &#8220;<font style="font-style: italic;">The Merger Agreement&#8201;&#8212;&#8201;Exchange Ratio</font>&#8221; in this proxy statement/prospectus. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The pro forma Exchange Ratio of 11.6997-to-1 has been calculated assuming Standard BioTools Net Cash at Closing is approximately $450&#160;million. If the final Parent Net Cash determined after Closing is lower than the amount set forth on the Parent Net Cash Schedule (as defined in the Merger Agreement), a modified Exchange Ratio will be calculated and each former holder of Treeline Capital Stock and Treeline Converting Warrants will receive additional shares of Standard BioTools Common Stock equal to the difference. If final Parent Net Cash equals or exceeds the scheduled amount, the surplus will be added to the proceeds distributable to CVR holders. Accordingly, the unaudited pro forma adjustments described herein are sensitive to the final Parent Net Cash determination, and the actual Combined Company share count and per-share amounts could differ materially from the pro forma presentation. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following unaudited pro forma condensed combined financial information gives effect to (i)&#160;the Merger, which is expected to be accounted for as a reverse recapitalization under U.S. GAAP, (ii) the probable wind-down and / or sale of Standard BioTools&#8217; Legacy Business, including the transfer of certain of Standard BioTools operating assets and liabilities to one or more third-parties, and other wind-down activities for Standard BioTools remaining operating assets and liabilities, (iii) the automatic conversion of Treeline redeemable convertible preferred stock, (iv) the Reverse Stock Split, and (v) other Merger related items. For further details related to the accounting for the Merger, please see Note&#160;1 below. All share amounts have been adjusted to reflect the estimated Exchange Ratio described above, unless otherwise stated. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The unaudited pro forma condensed combined balance sheet combines the historical consolidated balance sheets of Treeline and Standard BioTools as of March&#160;31, 2026, and depicts the accounting of the transactions prepared pursuant to Article&#160;11 of Regulation S-X (the pro forma balance sheet transaction accounting adjustments), as if the transactions occurred on March 31, 2026. The unaudited pro forma condensed combined statements of operations for the three months ended March 31, 2026 and for the year ended December 31, 2025 combine the historical results of Treeline and Standard BioTools for those periods and depict the pro forma statements of operations transaction accounting adjustments assuming that the transactions occurred on January 1, 2025. All transaction accounting adjustments on the pro forma balance sheet and pro forma statements of operations are collectively referred to as the transaction accounting adjustments or pro forma adjustments. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This unaudited pro forma condensed combined financial information and related notes have been derived from and should be read in conjunction with: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the historical audited consolidated financial statements of Treeline for the year ended December&#160;31, 2025, and the related notes included elsewhere in this proxy statement/prospectus; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the historical audited consolidated financial statements of Standard BioTools for the year ended December&#160;31, 2025, and the related notes incorporated by reference into this proxy statement/prospectus from Standard BioTools Annual Report on Form&#160;10-K for the year ended December&#160;31, 2025; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the historical unaudited condensed consolidated financial statements of Treeline as of and for the three months ended March&#160;31, 2026, and the related notes included elsewhere in this proxy statement/prospectus; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the historical unaudited condensed consolidated financial statements of Standard BioTools as of and for the three months ended March&#160;31, 2026, and the related notes incorporated by reference into this proxy statement/prospectus from Standard BioTools Quarterly Report on Form&#160;10-Q for the quarter ended March&#160;31, 2026; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the section titled &#8220;<font style="font-style: italic;">Treeline Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font>&#8221; which is included elsewhere in this proxy statement/prospectus, the Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations with respect to Standard BioTools contained in its annual report on Form&#160;10-K for the year ended December&#160;31, 2025 and in its </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">293<br></div></div></div>
<!--End Page 304-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 305-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_122-unaudited_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_bl" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: left;">quarterly report on Form&#160;10-Q for the quarter ended March&#160;31, 2026, which are incorporated by reference herein, and other financial information relating to Treeline and Standard BioTools included elsewhere in (or incorporated by reference into) this proxy statement/prospectus. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The unaudited pro forma condensed combined financial information is based on the assumptions and pro forma adjustments that are described in the accompanying notes. The pro forma adjustments are preliminary and subject to further revision as additional information becomes available and additional analyses are performed, including but not limited to finalization of the Exchange Ratio at Closing, finalization of net cash, the ultimate disposition status of the Legacy Business at Closing, additional direct and incremental offering costs, and the Reverse Stock Split. Adjustments have been made solely for the purpose of providing unaudited pro forma condensed combined financial information. Differences between these preliminary estimates and the final accounting, expected to be completed after the Closing of the Merger, may occur and could have a material impact on the accompanying unaudited pro forma condensed combined financial information. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The unaudited pro forma condensed combined financial information does not give effect to the potential impact of current financial conditions, regulatory matters, operating efficiencies or other savings or expenses that may be associated with the integration of the two companies. The unaudited pro forma condensed combined financial information is not necessarily indicative of the financial position or results of operations in future periods or the result that actually would have been realized had Standard BioTools and Treeline been a combined organization during the specified periods. The actual results reported in periods following the Merger may differ significantly from those reflected in the unaudited pro forma condensed combined financial information presented herein for a number of reasons, including, but not limited to, differences in the assumptions used to prepare this unaudited pro forma condensed combined financial information. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">294<br></div></div></div>
<!--End Page 305-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 306-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_122-unaudited_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEET <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">AS OF MARCH 31, 2026 <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">(in thousands, except per share amounts) </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 127pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 46.61pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 55.78pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.86pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 46.6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 55.76pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 46.19pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.86pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 42.75pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 127pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.61pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Historical</div></td><td style="width: 2.1pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.78pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">As Adjusted</div></td><td style="width: 2.1pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Historical</div></td><td style="width: 2.1pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.19pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 42.75pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td></tr><tr class="BRDSX_header"><td style="width: 127pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.61pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Standard <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">BioTools, Inc.</div></td><td style="width: 2.1pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.78pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Transaction <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Accounting <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Adjustments-<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Legacy Business <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Disposition <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">and Other <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Adjustments</div></td><td style="width: 2.1pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Standard <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">BioTools, Inc.</div></td><td style="width: 2.1pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Treeline <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Biosciences, Inc.</div></td><td style="width: 2.1pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.19pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Transaction <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Accounting <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Adjustments-<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Reverse <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Merger</div></td><td style="width: 2.1pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 42.75pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Pro Forma <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Combined </div></td></tr><tr><td style="width: 127pt; padding-top: 2.02pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">ASSETS<br></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.61pt; padding-top: 2.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.78pt; padding-top: 2.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 2.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 2.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 2.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.19pt; padding-top: 2.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 2.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 42.75pt; padding-top: 2.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td></tr><tr><td style="width: 127pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Current assets:<br></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.61pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.78pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.19pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 42.75pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td></tr><tr><td style="width: 127pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash and cash equivalents<font style="padding-left: 4.64pt;"></font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.61pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.49pt; text-align: left;">$265,772</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.78pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10.86pt; text-align: left;">$<font style="padding-left: 3.16pt;">25,000</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">A</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.49pt; text-align: left;">$290,772</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10.07pt; text-align: left;">$<font style="padding-left: 4.75pt;">32,561</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.19pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 6.08pt; text-align: left;">$<font style="padding-left: 4.75pt;">(9,900)</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 0.52pt;">C</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 42.75pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<font style="padding-left: 7.13pt;">277,753 </font></div></td></tr><tr><td style="width: 127pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.61pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.78pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.19pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 6.08pt; text-align: left;"><font style="padding-left: 4.75pt;">(25,179)</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">D</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 42.75pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td></tr><tr><td style="width: 127pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.61pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.78pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.19pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 6.08pt; text-align: left;"><font style="padding-left: 4.75pt;">(10,501)</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 1.05pt;">E</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 42.75pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td></tr><tr><td style="width: 127pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Short-term investments<font style="padding-left: 0.72pt;"></font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.61pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.49pt; text-align: left;"><font style="padding-left: 4.75pt;">189,404</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.78pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10.86pt; text-align: left;"><font style="padding-left: 24.54pt;">&#8212;</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.49pt; text-align: left;"><font style="padding-left: 4.75pt;">189,404</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10.07pt; text-align: left;"><font style="padding-left: 4.75pt;">520,540</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.19pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 6.08pt; text-align: left;"><font style="padding-left: 24.54pt;">&#8212;</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 42.75pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 11.88pt;">709,944 </font></div></td></tr><tr><td style="width: 127pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Accounts receivable, net<font style="padding-left: 0.98pt;"></font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.61pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.49pt; text-align: left;"><font style="padding-left: 9.5pt;">16,637</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.78pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10.86pt; text-align: left;"><font style="padding-left: 4.75pt;">(16,637)</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 0.52pt;">B</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.49pt; text-align: left;"><font style="padding-left: 26.13pt;">&#8212;</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10.07pt; text-align: left;"><font style="padding-left: 26.13pt;">&#8212;</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.19pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 6.08pt; text-align: left;"><font style="padding-left: 24.54pt;">&#8212;</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 42.75pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 33.25pt;">&#8212; </font></div></td></tr><tr><td style="width: 127pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Inventory<font style="padding-left: 2.69pt;"></font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.61pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.49pt; text-align: left;"><font style="padding-left: 9.5pt;">18,594</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.78pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10.86pt; text-align: left;"><font style="padding-left: 4.75pt;">(18,594)</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 0.52pt;">B</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.49pt; text-align: left;"><font style="padding-left: 26.13pt;">&#8212;</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10.07pt; text-align: left;"><font style="padding-left: 26.13pt;">&#8212;</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.19pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 6.08pt; text-align: left;"><font style="padding-left: 24.54pt;">&#8212;</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 42.75pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 33.25pt;">&#8212; </font></div></td></tr><tr><td style="width: 127pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Prepaid expenses and other current assets<font style="padding-left: 3.19pt;"></font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.61pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.49pt; text-align: left;"><font style="padding-left: 14.25pt;">6,046</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.78pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10.86pt; text-align: left;"><font style="padding-left: 9.5pt;">(4,796)</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 0.52pt;">B</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.49pt; text-align: left;"><font style="padding-left: 14.25pt;">1,250</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10.07pt; text-align: left;"><font style="padding-left: 9.85pt;">13,411</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.19pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 6.08pt; text-align: left;"><font style="padding-left: 24.54pt;">&#8212;</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 42.75pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 16.63pt;">14,661 </font></div></td></tr><tr><td style="width: 127pt; padding-top: 1.02pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Contingent consideration receivable<font style="padding-left: 0.59pt;"></font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.61pt; padding-top: 1.02pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.49pt; text-align: left;"><font style="padding-left: 9.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">25,000</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.78pt; padding-top: 1.02pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10.86pt; text-align: left;"><font style="padding-left: 4.75pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(25,000</font><font style="padding-bottom: 1.5pt;">)</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 1.02pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">A</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 1.02pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.49pt; text-align: left;"><font style="padding-left: 26.13pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 1.02pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10.07pt; text-align: left;"><font style="padding-left: 26.13pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.19pt; padding-top: 1.02pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 6.08pt; text-align: left;"><font style="padding-left: 7.91pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">50,000</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 1.02pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 1.58pt;">F</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 42.75pt; padding-top: 1.02pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 16.63pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">50,000 </font></div></td></tr><tr><td style="width: 127pt; padding-top: 2.27pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total current assets<font style="padding-left: 1.43pt;"></font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.61pt; padding-top: 2.27pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.49pt; text-align: left;"><font style="padding-left: 4.75pt;">521,453</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.78pt; padding-top: 2.27pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10.86pt; text-align: left;"><font style="padding-left: 4.75pt;">(40,027)</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 2.27pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 2.27pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.49pt; text-align: left;"><font style="padding-left: 4.75pt;">481,426</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 2.27pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10.07pt; text-align: left;"><font style="padding-left: 4.75pt;">566,512</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.19pt; padding-top: 2.27pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 6.08pt; text-align: left;"><font style="padding-left: 12.66pt;">4,420</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 2.27pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 42.75pt; padding-top: 2.27pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 4.75pt;">1,052,358 </font></div></td></tr><tr><td style="width: 127pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Property and equipment, net<font style="padding-left: 1.98pt;"></font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.61pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.49pt; text-align: left;"><font style="padding-left: 9.5pt;">17,103</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.78pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10.86pt; text-align: left;"><font style="padding-left: 4.75pt;">(17,103)</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 0.52pt;">B</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.49pt; text-align: left;"><font style="padding-left: 26.13pt;">&#8212;</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10.07pt; text-align: left;"><font style="padding-left: 9.5pt;">10,502</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.19pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 6.08pt; text-align: left;"><font style="padding-left: 24.54pt;">&#8212;</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 42.75pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 16.63pt;">10,502 </font></div></td></tr><tr><td style="width: 127pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 9.5pt; text-indent: -9.5pt; text-align: left;">Operating lease right-of-use asset, net<font style="padding-left: 0.3pt;"></font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.61pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.49pt; text-align: left;"><font style="padding-left: 9.5pt;">25,545</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.78pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10.86pt; text-align: left;"><font style="padding-left: 9.5pt;">(5,849)</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 0.52pt;">B</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.49pt; text-align: left;"><font style="padding-left: 9.5pt;">19,696</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10.07pt; text-align: left;"><font style="padding-left: 9.5pt;">17,987</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.19pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 6.08pt; text-align: left;"><font style="padding-left: 24.54pt;">&#8212;</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 42.75pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 16.63pt;">37,683 </font></div></td></tr><tr><td style="width: 127pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Long-term investments<font style="padding-left: 1.24pt;"></font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.61pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.49pt; text-align: left;"><font style="padding-left: 9.5pt;">71,357</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.78pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10.86pt; text-align: left;"><font style="padding-left: 24.54pt;">&#8212;</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.49pt; text-align: left;"><font style="padding-left: 9.5pt;">71,357</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10.07pt; text-align: left;"><font style="padding-left: 26.13pt;">&#8212;</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.19pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 6.08pt; text-align: left;"><font style="padding-left: 24.54pt;">&#8212;</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 42.75pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 16.63pt;">71,357 </font></div></td></tr><tr><td style="width: 127pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Deferred tax asset, non-current<font style="padding-left: 1.99pt;"></font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.61pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.49pt; text-align: left;"><font style="padding-left: 21.38pt;">270</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.78pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10.86pt; text-align: left;"><font style="padding-left: 24.54pt;">&#8212;</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.49pt; text-align: left;"><font style="padding-left: 21.38pt;">270</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10.07pt; text-align: left;"><font style="padding-left: 26.13pt;">&#8212;</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.19pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 6.08pt; text-align: left;"><font style="padding-left: 24.54pt;">&#8212;</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 42.75pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 28.5pt;">270 </font></div></td></tr><tr><td style="width: 127pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Restricted cash<font style="padding-left: 1.86pt;"></font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.61pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.49pt; text-align: left;"><font style="padding-left: 26.13pt;">&#8212;</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.78pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10.86pt; text-align: left;"><font style="padding-left: 24.54pt;">&#8212;</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.49pt; text-align: left;"><font style="padding-left: 26.13pt;">&#8212;</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10.07pt; text-align: left;"><font style="padding-left: 14.25pt;">1,105</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.19pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 6.08pt; text-align: left;"><font style="padding-left: 24.54pt;">&#8212;</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 42.75pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 21.38pt;">1,105 </font></div></td></tr><tr><td style="width: 127pt; padding-top: 1.02pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other non-current assets<font style="padding-left: 1.78pt;"></font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.61pt; padding-top: 1.02pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.49pt; text-align: left;"><font style="padding-left: 14.25pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">3,386</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.78pt; padding-top: 1.02pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10.86pt; text-align: left;"><font style="padding-left: 9.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(3,386</font><font style="padding-bottom: 1.5pt;">)</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 1.02pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 0.52pt;">B</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 1.02pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.49pt; text-align: left;"><font style="padding-left: 26.13pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 1.02pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10.07pt; text-align: left;"><font style="padding-left: 14.25pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">7,269</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.19pt; padding-top: 1.02pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 6.08pt; text-align: left;"><font style="padding-left: 21.38pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(99</font><font style="padding-bottom: 1.5pt;">)</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 1.02pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 1.05pt;">E</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 42.75pt; padding-top: 1.02pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 21.38pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">7,170 </font></div></td></tr><tr><td style="width: 127pt; padding-top: 2.27pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total assets<font style="padding-left: 0.71pt;"></font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.61pt; padding-top: 2.27pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.49pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 0.35pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">639,114</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.78pt; padding-top: 2.27pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10.86pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$(66,365</font><font style="padding-bottom: 0.5pt;">)</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 2.27pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 2.27pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.49pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$572,749</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 2.27pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10.07pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$603,375</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.19pt; padding-top: 2.27pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 6.08pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 7.91pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">&#8203;</font><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">4,321</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 2.27pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 42.75pt; padding-top: 2.27pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$1,180,445 </font></div></td></tr><tr><td style="width: 127pt; padding-top: 3.27pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.61pt; padding-top: 3.27pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.78pt; padding-top: 3.27pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 3.27pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 3.27pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 3.27pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.19pt; padding-top: 3.27pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 3.27pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 42.75pt; padding-top: 3.27pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td></tr><tr><td style="width: 127pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 9.5pt; text-indent: -9.5pt; text-align: left;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY<br></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.61pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.78pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.19pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 42.75pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td></tr><tr><td style="width: 127pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Accounts payable<font style="padding-left: 1.83pt;"></font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.61pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.49pt; text-align: left;">$<font style="padding-left: 9.5pt;">8,007</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.78pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10.86pt; text-align: left;">$<font style="padding-left: 4.75pt;">(8,007)</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 0.52pt;">B</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.49pt; text-align: left;">$<font style="padding-left: 21.38pt;">&#8212;</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10.07pt; text-align: left;">$<font style="padding-left: 9.5pt;">5,738</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.19pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 6.08pt; text-align: left;">$<font style="padding-left: 19.79pt;">&#8212;</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 42.75pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<font style="padding-left: 16.63pt;">5,738 </font></div></td></tr><tr><td style="width: 127pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Accrued liabilities<font style="padding-left: 4.72pt;"></font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.61pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.49pt; text-align: left;"><font style="padding-left: 9.5pt;">15,684</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.78pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10.86pt; text-align: left;"><font style="padding-left: 4.75pt;">(15,684)</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 0.52pt;">B</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.49pt; text-align: left;"><font style="padding-left: 26.13pt;">&#8212;</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10.07pt; text-align: left;"><font style="padding-left: 9.5pt;">15,581</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.19pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 6.08pt; text-align: left;"><font style="padding-left: 24.54pt;">&#8212;</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 42.75pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 16.63pt;">15,581</font> </div></td></tr><tr><td style="width: 127pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Operating lease liabilities, current<font style="padding-left: 2.72pt;"></font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.61pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.49pt; text-align: left;"><font style="padding-left: 14.25pt;">5,540</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.78pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10.86pt; text-align: left;"><font style="padding-left: 9.5pt;">(1,169)</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 0.52pt;">B</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.49pt; text-align: left;"><font style="padding-left: 14.25pt;">4,371</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10.07pt; text-align: left;"><font style="padding-left: 14.25pt;">3,850</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.19pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 6.08pt; text-align: left;"><font style="padding-left: 24.54pt;">&#8212;</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 42.75pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 21.38pt;">8,221 </font></div></td></tr><tr><td style="width: 127pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Deferred revenue, current<font style="padding-left: 1.78pt;"></font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.61pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.49pt; text-align: left;"><font style="padding-left: 14.25pt;">9,981</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.78pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10.86pt; text-align: left;"><font style="padding-left: 9.5pt;">(9,981)</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 0.52pt;">B</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.49pt; text-align: left;"><font style="padding-left: 26.13pt;">&#8212;</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10.07pt; text-align: left;"><font style="padding-left: 26.13pt;">&#8212;</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.19pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 6.08pt; text-align: left;"><font style="padding-left: 24.54pt;">&#8212;</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 42.75pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 33.25pt;">&#8212; </font></div></td></tr><tr><td style="width: 127pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Deferred grant income, current<font style="padding-left: 2.72pt;"></font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.61pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.49pt; text-align: left;"><font style="padding-left: 14.25pt;">2,991</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.78pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10.86pt; text-align: left;"><font style="padding-left: 9.5pt;">(2,991)</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 0.52pt;">B</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.49pt; text-align: left;"><font style="padding-left: 26.13pt;">&#8212;</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10.07pt; text-align: left;"><font style="padding-left: 26.13pt;">&#8212;</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.19pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 6.08pt; text-align: left;"><font style="padding-left: 24.54pt;">&#8212;</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 42.75pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 33.25pt;">&#8212; </font></div></td></tr><tr><td style="width: 127pt; padding-top: 1.02pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">CVR liability, current<font style="padding-left: 2.13pt;"></font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.61pt; padding-top: 1.02pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.49pt; text-align: left;"><font style="padding-left: 26.13pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.78pt; padding-top: 1.02pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10.86pt; text-align: left;"><font style="padding-left: 24.54pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 1.02pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 1.02pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.49pt; text-align: left;"><font style="padding-left: 26.13pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 1.02pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10.07pt; text-align: left;"><font style="padding-left: 26.13pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.19pt; padding-top: 1.02pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 6.08pt; text-align: left;"><font style="padding-left: 7.91pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">50,000</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 1.02pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 1.58pt;">F</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 42.75pt; padding-top: 1.02pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 16.63pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">50,000 </font></div></td></tr><tr><td style="width: 127pt; padding-top: 2.27pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total current liabilities<font style="padding-left: 3.23pt;"></font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.61pt; padding-top: 2.27pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.49pt; text-align: left;"><font style="padding-left: 9.5pt;">42,203</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.78pt; padding-top: 2.27pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10.86pt; text-align: left;"><font style="padding-left: 4.75pt;">(37,832)</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 2.27pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 2.27pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.49pt; text-align: left;"><font style="padding-left: 14.25pt;">4,371</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 2.27pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10.07pt; text-align: left;"><font style="padding-left: 9.5pt;">25,169</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.19pt; padding-top: 2.27pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 6.08pt; text-align: left;"><font style="padding-left: 7.91pt;">50,000</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 2.27pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 42.75pt; padding-top: 2.27pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 16.63pt;">79,540 </font></div></td></tr><tr><td style="width: 127pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Convertible notes, non-current<font style="padding-left: 3.28pt;"></font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.61pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.49pt; text-align: left;"><font style="padding-left: 21.38pt;">299</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.78pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10.86pt; text-align: left;"><font style="padding-left: 24.54pt;">&#8212;</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.49pt; text-align: left;"><font style="padding-left: 21.38pt;">299</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10.07pt; text-align: left;"><font style="padding-left: 26.13pt;">&#8212;</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.19pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 6.08pt; text-align: left;"><font style="padding-left: 24.54pt;">&#8212;</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 42.75pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 28.5pt;">299 </font></div></td></tr><tr><td style="width: 127pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 9.5pt; text-indent: -9.5pt; text-align: left;">Operating lease liabilities, non-current<font style="padding-left: 0.81pt;"></font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.61pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.49pt; text-align: left;"><font style="padding-left: 9.5pt;">23,652</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.78pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10.86pt; text-align: left;"><font style="padding-left: 9.5pt;">(4,990)</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 0.52pt;">B</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.49pt; text-align: left;"><font style="padding-left: 9.5pt;">18,662</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10.07pt; text-align: left;"><font style="padding-left: 9.5pt;">15,039</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.19pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 6.08pt; text-align: left;"><font style="padding-left: 24.54pt;">&#8212;</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 42.75pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 16.63pt;">33,701 </font></div></td></tr><tr><td style="width: 127pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Deferred revenue, non-current<font style="padding-left: 4.37pt;"></font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.61pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.49pt; text-align: left;"><font style="padding-left: 14.25pt;">3,013</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.78pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10.86pt; text-align: left;"><font style="padding-left: 9.5pt;">(3,013)</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 0.52pt;">B</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.49pt; text-align: left;"><font style="padding-left: 26.13pt;">&#8212;</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10.07pt; text-align: left;"><font style="padding-left: 26.13pt;">&#8212;</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.19pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 6.08pt; text-align: left;"><font style="padding-left: 24.54pt;">&#8212;</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 42.75pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 33.25pt;">&#8212; </font></div></td></tr><tr><td style="width: 127pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 9.5pt; text-indent: -9.5pt; text-align: left;">Deferred grant income, non-current<font style="padding-left: 0.81pt;"></font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.61pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.49pt; text-align: left;"><font style="padding-left: 14.25pt;">3,557</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.78pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10.86pt; text-align: left;"><font style="padding-left: 9.5pt;">(3,557)</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 0.52pt;">B</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.49pt; text-align: left;"><font style="padding-left: 26.13pt;">&#8212;</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10.07pt; text-align: left;"><font style="padding-left: 26.13pt;">&#8212;</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.19pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 6.08pt; text-align: left;"><font style="padding-left: 24.54pt;">&#8212;</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 42.75pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 33.25pt;">&#8212; </font></div></td></tr><tr><td style="width: 127pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Deferred tax liability<font style="padding-left: 4.96pt;"></font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.61pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.49pt; text-align: left;"><font style="padding-left: 21.38pt;">823</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.78pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10.86pt; text-align: left;"><font style="padding-left: 16.63pt;">(810)</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 0.52pt;">B</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.49pt; text-align: left;"><font style="padding-left: 26.13pt;">13</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10.07pt; text-align: left;"><font style="padding-left: 26.13pt;">&#8212;</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.19pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 6.08pt; text-align: left;"><font style="padding-left: 24.54pt;">&#8212;</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 42.75pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 33.25pt;">13 </font></div></td></tr><tr><td style="width: 127pt; padding-top: 1.02pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other non-current liabilities<font style="padding-left: 3.58pt;"></font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.61pt; padding-top: 1.02pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.49pt; text-align: left;"><font style="padding-left: 14.25pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">4,444</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.78pt; padding-top: 1.02pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10.86pt; text-align: left;"><font style="padding-left: 9.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(4,230</font><font style="padding-bottom: 1.5pt;">)</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 1.02pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 0.52pt;">B</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 1.02pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.49pt; text-align: left;"><font style="padding-left: 21.38pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">214</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 1.02pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10.07pt; text-align: left;"><font style="padding-left: 26.13pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.19pt; padding-top: 1.02pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 6.08pt; text-align: left;"><font style="padding-left: 24.54pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 1.02pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 42.75pt; padding-top: 1.02pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 28.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">214 </font></div></td></tr><tr><td style="width: 127pt; padding-top: 2.27pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total liabilities<font style="padding-left: 2.51pt;"></font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.61pt; padding-top: 2.27pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.49pt; text-align: left;"><font style="padding-left: 9.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">77,991</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.78pt; padding-top: 2.27pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10.86pt; text-align: left;"><font style="padding-left: 4.75pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(54,432</font><font style="padding-bottom: 1.5pt;">)</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 2.27pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 2.27pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.49pt; text-align: left;"><font style="padding-left: 9.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">23,559</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 2.27pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10.07pt; text-align: left;"><font style="padding-left: 9.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">40,208</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.19pt; padding-top: 2.27pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 6.08pt; text-align: left;"><font style="padding-left: 7.91pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">50,000</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 2.27pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 42.75pt; padding-top: 2.27pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.22pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">1</font><font style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">13,767 </font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 127pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 46.61pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 55.78pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.86pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 46.6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 55.76pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 46.19pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.86pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 42.75pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">See accompanying notes to the unaudited pro forma condensed combined financial statements<br></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">295<br></div></div></div>
<!--End Page 306-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 307-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_122-unaudited_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="margin-top: 4pt; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 127pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 46.61pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 55.78pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.86pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 46.6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 55.76pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 46.19pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.86pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 42.75pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 127pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.61pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Historical</div></td><td style="width: 2.1pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.78pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">As Adjusted</div></td><td style="width: 2.1pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Historical</div></td><td style="width: 2.1pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.19pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 42.75pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td></tr><tr class="BRDSX_header"><td style="width: 127pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.61pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Standard <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">BioTools, Inc.</div></td><td style="width: 2.1pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.78pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Transaction <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Accounting <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Adjustments-<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Legacy Business <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Disposition <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">and Other <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Adjustments</div></td><td style="width: 2.1pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Standard <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">BioTools, Inc.</div></td><td style="width: 2.1pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Treeline <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Biosciences, Inc.</div></td><td style="width: 2.1pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.19pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Transaction <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Accounting <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Adjustments-<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Reverse <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Merger</div></td><td style="width: 2.1pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 42.75pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Pro Forma <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Combined </div></td></tr><tr><td style="width: 127pt; padding-top: 2.02pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 9.5pt; text-indent: -9.5pt; text-align: left;">Redeemable convertible preferred stock<font style="padding-left: 2.89pt;"></font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.61pt; padding-top: 2.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0.35pt; text-align: left;"><font style="padding-left: 36.41pt;">&#8212;</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.78pt; padding-top: 2.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10.86pt; text-align: left;"><font style="padding-left: 24.54pt;">&#8212;</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 2.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 2.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0.34pt; text-align: left;"><font style="padding-left: 36.41pt;">&#8212;</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 2.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 6.5pt; text-align: left;"><font style="padding-left: 4.75pt;">1,181,061</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.19pt; padding-top: 2.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0.14pt; text-align: left;"><font style="padding-left: 4.75pt;">(1,181,061)</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 2.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;">G</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 42.75pt; padding-top: 2.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 33.25pt;">&#8212; </font></div></td></tr><tr><td style="width: 127pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Common stock<font style="padding-left: 1.84pt;"></font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.61pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0.35pt; text-align: left;"><font style="padding-left: 31.66pt;">408</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.78pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10.86pt; text-align: left;"><font style="padding-left: 24.54pt;">&#8212;</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0.34pt; text-align: left;"><font style="padding-left: 31.66pt;">408</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 6.5pt; text-align: left;"><font style="padding-left: 33.25pt;">&#8212;</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.19pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0.14pt; text-align: left;"><font style="padding-left: 24.54pt;">1,612</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;">H</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 42.75pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 21.38pt;">2,020 </font></div></td></tr><tr><td style="width: 127pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Additional paid-in capital<font style="padding-left: 2.01pt;"></font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.61pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0.35pt; text-align: left;"><font style="padding-left: 7.91pt;">1,741,172</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.78pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10.86pt; text-align: left;"><font style="padding-left: 24.54pt;">&#8212;</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0.34pt; text-align: left;"><font style="padding-left: 7.91pt;">1,741,172</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 6.5pt; text-align: left;"><font style="padding-left: 16.63pt;">34,370</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.19pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0.14pt; text-align: left;"><font style="padding-left: 16.63pt;">(24,436)</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;">H</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 42.75pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 4.75pt;">1,751,106 </font></div></td></tr><tr><td style="width: 127pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 9.5pt; text-indent: -9.5pt; text-align: left;">Accumulated other comprehensive loss<font style="padding-left: 0.47pt;"></font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.61pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0.35pt; text-align: left;"><font style="padding-left: 28.85pt;">(511)</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.78pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10.86pt; text-align: left;"><font style="padding-left: 24.54pt;">&#8212;</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0.34pt; text-align: left;"><font style="padding-left: 28.85pt;">(511)</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 6.5pt; text-align: left;"><font style="padding-left: 25.34pt;">(441)</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.19pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0.14pt; text-align: left;"><font style="padding-left: 32.01pt;">511</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;">H</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 42.75pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 25.34pt;">(441) </font></div></td></tr><tr><td style="width: 127pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Accumulated deficit<font style="padding-left: 2.33pt;"></font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.61pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0.35pt; text-align: left;"><font style="padding-left: 4.75pt;">(1,133,479)</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.78pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10.86pt; text-align: left;"><font style="padding-left: 5.1pt;">(11,933)</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0.26pt; text-align: left;">B</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0.34pt; text-align: left;"><font style="padding-left: 4.75pt;">(1,145,412)</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 6.5pt; text-align: left;"><font style="padding-left: 8.71pt;">(651,823)</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.19pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0.14pt; text-align: left;"><font style="padding-left: 8.61pt;">1,111,228</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;">H</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 42.75pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 8.71pt;">(686,007) </font></div></td></tr><tr><td style="width: 127pt; padding-top: 1.02pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Treasury stock at cost<font style="padding-left: 1.86pt;"></font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.61pt; padding-top: 1.02pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0.35pt; text-align: left;"><font style="padding-left: 16.63pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(46,467</font><font style="padding-bottom: 1.5pt;">)</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.78pt; padding-top: 1.02pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10.86pt; text-align: left;"><font style="padding-left: 24.54pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 1.02pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 1.02pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0.34pt; text-align: left;"><font style="padding-left: 16.63pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(46,467</font><font style="padding-bottom: 1.5pt;">)</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 1.02pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 6.5pt; text-align: left;"><font style="padding-left: 33.25pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.19pt; padding-top: 1.02pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0.14pt; text-align: left;"><font style="padding-left: 19.79pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">46,467</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 1.02pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;">H</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 42.75pt; padding-top: 1.02pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 33.25pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </font></div></td></tr><tr><td style="width: 127pt; padding-top: 2.27pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 9.5pt; text-indent: -9.5pt; text-align: left;">Total stockholders&#8217; equity (deficit)<font style="padding-left: 4.53pt;"></font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.61pt; padding-top: 2.27pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0.35pt; text-align: left;"><font style="padding-left: 15.04pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">561,123</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.78pt; padding-top: 2.27pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10.86pt; text-align: left;"><font style="padding-left: 5.1pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(11,933</font><font style="padding-bottom: 1.5pt;">)</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 2.27pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 2.27pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0.34pt; text-align: left;"><font style="padding-left: 15.04pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">549,190</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 2.27pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 6.5pt; text-align: left;"><font style="padding-left: 8.71pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(617,894</font><font style="padding-bottom: 1.5pt;">)</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.19pt; padding-top: 2.27pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0.14pt; text-align: left;"><font style="padding-left: 7.91pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">1,13</font><font style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">5,382</font></div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 2.27pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 42.75pt; padding-top: 2.27pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 4.75pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">1,06</font><font style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">6,678 </font></div></td></tr><tr><td style="width: 127pt; padding-top: 2.27pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 9.5pt; text-indent: -9.5pt; text-align: left;">Total liabilities and stockholders&#8217; equity<font style="padding-left: 1.38pt;"></font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.61pt; padding-top: 2.27pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0.35pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 10.64pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">639,114</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.78pt; padding-top: 2.27pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10.86pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$(66,365</font><font style="padding-bottom: 0.5pt;">)</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 2.27pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 2.27pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0.34pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 10.29pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">572,749</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 2.27pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 6.5pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 7.13pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">603,375</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.19pt; padding-top: 2.27pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0.14pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 19.79pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">&#8203;</font><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">4,321</font></div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; padding-top: 2.27pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 42.75pt; padding-top: 2.27pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$1,180,445</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 127pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 46.61pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 55.78pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.86pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 46.6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 55.76pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 46.19pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.86pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 2.1pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 42.75pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">See accompanying notes to the unaudited pro forma condensed combined financial statements<br></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">296<br></div></div></div>
<!--End Page 307-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 308-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_122-unaudited_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">UNAUDITED PRO FORMA CONDENSED COMBINED <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">STATEMENT OF OPERATIONS FOR THE YEAR ENDED DECEMBER 31, 2025 <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">(in thousands, except share and per share amounts) </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 108pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 49.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 55.77pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 2.99pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 46.6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 55.76pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 56.25pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 56.25pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 108pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.5pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Historical</div></td><td style="width: 1.9pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.77pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.99pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">As Adjusted</div></td><td style="width: 1.9pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Historical</div></td><td style="width: 1.9pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.25pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.5pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.25pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td></tr><tr class="BRDSX_header"><td style="width: 108pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.5pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Standard <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">BioTools, Inc.</div></td><td style="width: 1.9pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.77pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Transaction <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Accounting <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Adjustments - <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Legacy Business <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Disposition <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">and Other <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Adjustments</div></td><td style="width: 1.9pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.99pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Standard <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">BioTools, Inc.</div></td><td style="width: 1.9pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Treeline <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Biosciences, Inc.</div></td><td style="width: 1.9pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.25pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Transaction <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Accounting <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Adjustments - <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Reverse <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Merger</div></td><td style="width: 1.9pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.5pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.25pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Pro Forma <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Combined </div></td></tr><tr><td style="width: 108pt; padding-top: 2.04pt; padding-bottom: 1.5pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Revenue:<br></div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.5pt; padding-top: 2.04pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.77pt; padding-top: 2.04pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.99pt; padding-top: 2.04pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 2.04pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 2.04pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.25pt; padding-top: 2.04pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.5pt; padding-top: 2.04pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.25pt; padding-top: 2.04pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 108pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Product revenue<font style="padding-left: 2.03pt;"></font></div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.5pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<font style="padding-left: 20.25pt;">61,659</font></div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.77pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 11.76pt; text-align: left;">$(61,659)</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.99pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">I</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 7.17pt; text-align: left;">$<font style="padding-left: 18.74pt;">&#8212;</font></div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 5.55pt; text-align: left;">$<font style="padding-left: 31.17pt;">&#8212;</font></div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.25pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<font style="padding-left: 42.75pt;">&#8212;</font></div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.5pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.25pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<font style="padding-left: 42.75pt;">&#8212; </font></div></td></tr><tr><td style="width: 108pt; padding-top: 1.17pt; padding-bottom: 2.75pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Services and other revenue<font style="padding-left: 2.27pt;"></font></div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.5pt; padding-top: 1.17pt; padding-bottom: 2.75pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 24.75pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">23,672</font></div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.77pt; padding-top: 1.17pt; padding-bottom: 2.75pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 11.76pt; text-align: left;"><font style="padding-left: 4.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(23,672</font><font style="padding-bottom: 1.5pt;">)</font></div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.99pt; padding-top: 1.17pt; padding-bottom: 2.75pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">I</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 1.17pt; padding-bottom: 2.75pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 7.17pt; text-align: left;"><font style="padding-left: 23.24pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 1.17pt; padding-bottom: 2.75pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 5.55pt; text-align: left;"><font style="padding-left: 35.67pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.25pt; padding-top: 1.17pt; padding-bottom: 2.75pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 47.25pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.5pt; padding-top: 1.17pt; padding-bottom: 2.75pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.25pt; padding-top: 1.17pt; padding-bottom: 2.75pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 47.25pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </font></div></td></tr><tr><td style="width: 108pt; padding-top: 2.42pt; padding-bottom: 2.75pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total revenue<font style="padding-left: 1.66pt;"></font></div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.5pt; padding-top: 2.42pt; padding-bottom: 2.75pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 24.75pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">85,331</font></div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.77pt; padding-top: 2.42pt; padding-bottom: 2.75pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 11.76pt; text-align: left;"><font style="padding-left: 4.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(85,331</font><font style="padding-bottom: 1.5pt;">)</font></div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.99pt; padding-top: 2.42pt; padding-bottom: 2.75pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 2.42pt; padding-bottom: 2.75pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 7.17pt; text-align: left;"><font style="padding-left: 23.24pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 2.42pt; padding-bottom: 2.75pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 5.55pt; text-align: left;"><font style="padding-left: 35.67pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.25pt; padding-top: 2.42pt; padding-bottom: 2.75pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 47.25pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.5pt; padding-top: 2.42pt; padding-bottom: 2.75pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.25pt; padding-top: 2.42pt; padding-bottom: 2.75pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 47.25pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </font></div></td></tr><tr><td style="width: 108pt; padding-top: 2.42pt; padding-bottom: 1.5pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cost of revenue:<br></div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.5pt; padding-top: 2.42pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.77pt; padding-top: 2.42pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.99pt; padding-top: 2.42pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 2.42pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 2.42pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.25pt; padding-top: 2.42pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.5pt; padding-top: 2.42pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.25pt; padding-top: 2.42pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 108pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Cost of product revenue<font style="padding-left: 4.04pt;"></font></div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.5pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 24.75pt;">29,553</font></div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.77pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 11.76pt; text-align: left;"><font style="padding-left: 4.5pt;">(29,553)</font></div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.99pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">I</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 7.17pt; text-align: left;"><font style="padding-left: 23.24pt;">&#8212;</font></div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 5.55pt; text-align: left;"><font style="padding-left: 35.67pt;">&#8212;</font></div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.25pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 47.25pt;">&#8212;</font></div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.5pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.25pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 47.25pt;">&#8212; </font></div></td></tr><tr><td style="width: 108pt; padding-top: 1.17pt; padding-bottom: 2.75pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Cost of services and other revenue<font style="padding-left: 2.27pt;"></font></div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.5pt; padding-top: 1.17pt; padding-bottom: 2.75pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 24.75pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">13,235</font></div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.77pt; padding-top: 1.17pt; padding-bottom: 2.75pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 11.76pt; text-align: left;"><font style="padding-left: 4.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(13,235</font><font style="padding-bottom: 1.5pt;">)</font></div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.99pt; padding-top: 1.17pt; padding-bottom: 2.75pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">I</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 1.17pt; padding-bottom: 2.75pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 7.17pt; text-align: left;"><font style="padding-left: 23.24pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 1.17pt; padding-bottom: 2.75pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 5.55pt; text-align: left;"><font style="padding-left: 35.67pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.25pt; padding-top: 1.17pt; padding-bottom: 2.75pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 47.25pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.5pt; padding-top: 1.17pt; padding-bottom: 2.75pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.25pt; padding-top: 1.17pt; padding-bottom: 2.75pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 47.25pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </font></div></td></tr><tr><td style="width: 108pt; padding-top: 2.42pt; padding-bottom: 2.75pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total cost of revenue<font style="padding-left: 0.17pt;"></font></div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.5pt; padding-top: 2.42pt; padding-bottom: 2.75pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 24.75pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">42,788</font></div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.77pt; padding-top: 2.42pt; padding-bottom: 2.75pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 11.76pt; text-align: left;"><font style="padding-left: 4.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(42,788</font><font style="padding-bottom: 1.5pt;">)</font></div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.99pt; padding-top: 2.42pt; padding-bottom: 2.75pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 2.42pt; padding-bottom: 2.75pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 7.17pt; text-align: left;"><font style="padding-left: 23.24pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 2.42pt; padding-bottom: 2.75pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 5.55pt; text-align: left;"><font style="padding-left: 35.67pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.25pt; padding-top: 2.42pt; padding-bottom: 2.75pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 47.25pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.5pt; padding-top: 2.42pt; padding-bottom: 2.75pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.25pt; padding-top: 2.42pt; padding-bottom: 2.75pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 47.25pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </font></div></td></tr><tr><td style="width: 108pt; padding-top: 2.42pt; padding-bottom: 1.5pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Gross profit<font style="padding-left: 2.52pt;"></font></div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.5pt; padding-top: 2.42pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 24.75pt;">42,543</font></div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.77pt; padding-top: 2.42pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 11.76pt; text-align: left;"><font style="padding-left: 4.5pt;">(42,543)</font></div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.99pt; padding-top: 2.42pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 2.42pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 7.17pt; text-align: left;"><font style="padding-left: 23.24pt;">&#8212;</font></div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 2.42pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 5.55pt; text-align: left;"><font style="padding-left: 35.67pt;">&#8212;</font></div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.25pt; padding-top: 2.42pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 47.25pt;">&#8212;</font></div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.5pt; padding-top: 2.42pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.25pt; padding-top: 2.42pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 47.25pt;">&#8212; </font></div></td></tr><tr><td style="width: 108pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating expenses:<br></div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.5pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.77pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.99pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.25pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.5pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.25pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 108pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Research and development<font style="padding-left: 4.27pt;"></font></div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.5pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 24.75pt;">25,987</font></div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.77pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 11.76pt; text-align: left;"><font style="padding-left: 4.5pt;">(25,987)</font></div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.99pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">I</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 7.17pt; text-align: left;"><font style="padding-left: 23.24pt;">&#8212;</font></div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 5.55pt; text-align: left;"><font style="padding-left: 15.42pt;">160,009</font></div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.25pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 47.25pt;">&#8212;</font></div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.5pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.25pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 27pt;">160,009 </font></div></td></tr><tr><td style="width: 108pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Selling, general and administrative<font style="padding-left: 4.27pt;"></font></div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.5pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 20.25pt;">109,861</font></div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.77pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 11.76pt; text-align: left;"><font style="padding-left: 4.5pt;">(32,249)</font></div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.99pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">I</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 7.17pt; text-align: left;"><font style="padding-left: 7.49pt;">77,612</font></div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 5.55pt; text-align: left;"><font style="padding-left: 19.92pt;">23,256</font></div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.25pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 47.25pt;">&#8212;</font></div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.5pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.25pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 27pt;">100,868 </font></div></td></tr><tr><td style="width: 108pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Restructuring and related charges<font style="padding-left: 3.43pt;"></font></div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.5pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 24.75pt;">14,782</font></div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.77pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 11.76pt; text-align: left;"><font style="padding-left: 23.24pt;">&#8212;</font></div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.99pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 7.17pt; text-align: left;"><font style="padding-left: 7.49pt;">14,782</font></div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 5.55pt; text-align: left;"><font style="padding-left: 35.67pt;">&#8212;</font></div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.25pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 31.5pt;">35,784</font></div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.5pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 3pt;">J</font></div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.25pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 31.5pt;">50,566</font> </div></td></tr><tr><td style="width: 108pt; padding-top: 1.17pt; padding-bottom: 2.75pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Transaction and integration expenses<font style="padding-left: 2.03pt;"></font></div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.5pt; padding-top: 1.17pt; padding-bottom: 2.75pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 29.25pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">2,162</font></div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.77pt; padding-top: 1.17pt; padding-bottom: 2.75pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 11.76pt; text-align: left;"><font style="padding-left: 23.24pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.99pt; padding-top: 1.17pt; padding-bottom: 2.75pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 1.17pt; padding-bottom: 2.75pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 7.17pt; text-align: left;"><font style="padding-left: 11.99pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">2,162</font></div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 1.17pt; padding-bottom: 2.75pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 5.55pt; text-align: left;"><font style="padding-left: 35.67pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.25pt; padding-top: 1.17pt; padding-bottom: 2.75pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 47.25pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.5pt; padding-top: 1.17pt; padding-bottom: 2.75pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.25pt; padding-top: 1.17pt; padding-bottom: 2.75pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 36pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">2,162 </font></div></td></tr><tr><td style="width: 108pt; padding-top: 2.42pt; padding-bottom: 2.75pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total operating expenses<font style="padding-left: 1.42pt;"></font></div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.5pt; padding-top: 2.42pt; padding-bottom: 2.75pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 20.25pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">152,792</font></div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.77pt; padding-top: 2.42pt; padding-bottom: 2.75pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 11.76pt; text-align: left;"><font style="padding-left: 4.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(5</font><font style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">8,236</font><font style="padding-bottom: 1.5pt;">)</font></div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.99pt; padding-top: 2.42pt; padding-bottom: 2.75pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 2.42pt; padding-bottom: 2.75pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 7.17pt; text-align: left;"><font style="padding-left: 7.49pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">94,556</font></div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 2.42pt; padding-bottom: 2.75pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 5.55pt; text-align: left;"><font style="padding-left: 15.42pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">183,265</font></div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.25pt; padding-top: 2.42pt; padding-bottom: 2.75pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 31.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">35,784</font></div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.5pt; padding-top: 2.42pt; padding-bottom: 2.75pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.25pt; padding-top: 2.42pt; padding-bottom: 2.75pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 27pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">3</font><font style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">13,605 </font></div></td></tr><tr><td style="width: 108pt; padding-top: 2.42pt; padding-bottom: 1.5pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 9pt; text-indent: -9pt; text-align: left;">Loss from continuing operations<font style="padding-left: 4.27pt;"></font></div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.5pt; padding-top: 2.42pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 17.59pt;">(110,249)</font></div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.77pt; padding-top: 2.42pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 11.76pt; text-align: left;"><font style="padding-left: 7.49pt;">15,693</font></div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.99pt; padding-top: 2.42pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 2.42pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 7.17pt; text-align: left;"><font style="padding-left: 4.5pt;">(94,556)</font></div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 2.42pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 5.55pt; text-align: left;"><font style="padding-left: 12.42pt;">(183,265)</font></div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.25pt; padding-top: 2.42pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 28.51pt;">(35,784)</font></div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.5pt; padding-top: 2.42pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.25pt; padding-top: 2.42pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 24.01pt;">(313,605) </font></div></td></tr><tr><td style="width: 108pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Interest income<font style="padding-left: 0.03pt;"></font></div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.5pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 29.25pt;">9,179</font></div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.77pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 11.76pt; text-align: left;"><font style="padding-left: 23.24pt;">&#8212;</font></div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.99pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 7.17pt; text-align: left;"><font style="padding-left: 11.99pt;">9,179</font></div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 5.55pt; text-align: left;"><font style="padding-left: 35.67pt;">&#8212;</font></div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.25pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 47.25pt;">&#8212;</font></div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.5pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.25pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 36pt;">9,179 </font></div></td></tr><tr><td style="width: 108pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Interest expense<font style="padding-left: 2.54pt;"></font></div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.5pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 37.51pt;">(26)</font></div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.77pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 11.76pt; text-align: left;"><font style="padding-left: 23.24pt;">&#8212;</font></div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.99pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 7.17pt; text-align: left;"><font style="padding-left: 20.25pt;">(26)</font></div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 5.55pt; text-align: left;"><font style="padding-left: 35.67pt;">&#8212;</font></div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.25pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 47.25pt;">&#8212;</font></div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.5pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.25pt; padding-top: 1.17pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 44.26pt;">(26) </font></div></td></tr><tr><td style="width: 108pt; padding-top: 1.17pt; padding-bottom: 2.75pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other income, net<font style="padding-left: 1.03pt;"></font></div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.5pt; padding-top: 1.17pt; padding-bottom: 2.75pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 29.25pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">4,394</font></div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.77pt; padding-top: 1.17pt; padding-bottom: 2.75pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 11.76pt; text-align: left;"><font style="padding-left: 23.24pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.99pt; padding-top: 1.17pt; padding-bottom: 2.75pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 1.17pt; padding-bottom: 2.75pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 7.17pt; text-align: left;"><font style="padding-left: 11.99pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">4,394</font></div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 1.17pt; padding-bottom: 2.75pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 5.55pt; text-align: left;"><font style="padding-left: 19.92pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">20,726</font></div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.25pt; padding-top: 1.17pt; padding-bottom: 2.75pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 47.25pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.5pt; padding-top: 1.17pt; padding-bottom: 2.75pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.25pt; padding-top: 1.17pt; padding-bottom: 2.75pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 31.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">25,120 </font></div></td></tr><tr><td style="width: 108pt; padding-top: 2.42pt; padding-bottom: 1.5pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 9pt; text-indent: -9pt; text-align: left;">Loss from continuing operations before income taxes<font style="padding-left: 3.26pt;"></font></div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.5pt; padding-top: 2.42pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 21.76pt;">(96,702)</font></div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.77pt; padding-top: 2.42pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 11.76pt; text-align: left;"><font style="padding-left: 7.49pt;">15,693</font></div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.99pt; padding-top: 2.42pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 2.42pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 7.17pt; text-align: left;"><font style="padding-left: 4.5pt;">(81,009)</font></div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 2.42pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 5.55pt; text-align: left;"><font style="padding-left: 12.42pt;">(162,539)</font></div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.25pt; padding-top: 2.42pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 28.51pt;">(35,784)</font></div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.5pt; padding-top: 2.42pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.25pt; padding-top: 2.42pt; padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 24.01pt;">(279,332) </font></div></td></tr><tr><td style="width: 108pt; padding-top: 1.17pt; padding-bottom: 2.75pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Income tax benefit<font style="padding-left: 3.29pt;"></font></div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.5pt; padding-top: 1.17pt; padding-bottom: 2.75pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 24.75pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">37,876</font></div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.77pt; padding-top: 1.17pt; padding-bottom: 2.75pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 11.76pt; text-align: left;"><font style="padding-left: 15.75pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(177</font><font style="padding-bottom: 1.5pt;">)</font></div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.99pt; padding-top: 1.17pt; padding-bottom: 2.75pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">I</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 1.17pt; padding-bottom: 2.75pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 7.17pt; text-align: left;"><font style="padding-left: 7.49pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">37,699</font></div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 1.17pt; padding-bottom: 2.75pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 5.55pt; text-align: left;"><font style="padding-left: 35.67pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.25pt; padding-top: 1.17pt; padding-bottom: 2.75pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 47.25pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.5pt; padding-top: 1.17pt; padding-bottom: 2.75pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.25pt; padding-top: 1.17pt; padding-bottom: 2.75pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 31.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">37,699 </font></div></td></tr><tr><td style="width: 108pt; padding-top: 2.42pt; padding-bottom: 3.75pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 9pt; text-indent: -9pt; text-align: left;">Net (loss) income from continuing operations<font style="padding-left: 3.52pt;"></font></div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.5pt; padding-top: 2.42pt; padding-bottom: 3.75pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 17.26pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(58,826</font><font style="padding-bottom: 0.5pt;">)</font></div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.77pt; padding-top: 2.42pt; padding-bottom: 3.75pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 11.76pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 2.99pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">&#8203;</font><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">15,516</font></div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.99pt; padding-top: 2.42pt; padding-bottom: 3.75pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 2.42pt; padding-bottom: 3.75pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 7.17pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$(43,310</font><font style="padding-bottom: 0.5pt;">)</font></div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 2.42pt; padding-bottom: 3.75pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 5.55pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 7.92pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(162,539</font><font style="padding-bottom: 0.5pt;">)</font></div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.25pt; padding-top: 2.42pt; padding-bottom: 3.75pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 24.01pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">&#8203;</font><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(35,784</font><font style="padding-bottom: 0.5pt;">)</font></div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.5pt; padding-top: 2.42pt; padding-bottom: 3.75pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.25pt; padding-top: 2.42pt; padding-bottom: 3.75pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 19.51pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(2</font><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">41,633</font><font style="padding-bottom: 0.5pt;">) </font></div></td></tr><tr><td style="width: 108pt; padding-top: 3.42pt; padding-bottom: 3.75pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 9pt; text-indent: -9pt; text-align: left;">Net loss per share from continuing operations, basic and diluted<font style="padding-left: 0.77pt;"></font></div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.5pt; padding-top: 3.42pt; padding-bottom: 3.75pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 26.26pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(0.15</font><font style="padding-bottom: 0.5pt;">)</font></div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.77pt; padding-top: 3.42pt; padding-bottom: 3.75pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.99pt; padding-top: 3.42pt; padding-bottom: 3.75pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 3.42pt; padding-bottom: 3.75pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 3.42pt; padding-bottom: 3.75pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 5.55pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 21.42pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(7.42</font><font style="padding-bottom: 0.5pt;">)</font></div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.25pt; padding-top: 3.42pt; padding-bottom: 3.75pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 33.01pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(0.02</font><font style="padding-bottom: 0.5pt;">)</font></div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.5pt; padding-top: 3.42pt; padding-bottom: 3.75pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.25pt; padding-top: 3.42pt; padding-bottom: 3.75pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 33.01pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(0.</font><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">10</font><font style="padding-bottom: 0.5pt;">) </font></div></td></tr><tr><td style="width: 108pt; padding-top: 3.42pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 9pt; text-indent: -9pt; text-align: left;">Shares used in computing net loss per share attributable to common stockholders, basic and diluted<font style="padding-left: 0.77pt;"></font></div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.5pt; padding-top: 3.42pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 4.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">381,622,547</font></div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.77pt; padding-top: 3.42pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2.99pt; padding-top: 3.42pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 3.42pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 3.42pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 5.55pt; text-align: left;"><font style="padding-left: 4.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">21,911,034</font></div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.25pt; padding-top: 3.42pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 4.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">1,9</font><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">47,195,882</font></div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.5pt; padding-top: 3.42pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">K</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.25pt; padding-top: 3.42pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 4.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">2,3</font><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">50,729,463</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 3pt; width: 108pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 49.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 55.77pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 2.99pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 46.6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 55.76pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 56.25pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 1.9pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 56.25pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">See accompanying notes to the unaudited pro forma condensed combined financial statements<br></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">297<br></div></div></div>
<!--End Page 308-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 309-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_122-unaudited_pg7"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">UNAUDITED PRO FORMA CONDENSED COMBINED <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">STATEMENT OF OPERATIONS FOR THE THREE MONTHS ENDED MARCH 31, 2026 <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">(in thousands, except share and per share amounts) </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 469.21pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 108pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 51.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 55.77pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 3.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 46.6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 55.76pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 58.74pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.78pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 58.74pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 108pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.69pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Historical</div></td><td style="width: 1.5pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.77pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.13pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">As Adjusted</div></td><td style="width: 1.5pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Historical</div></td><td style="width: 1.5pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 58.74pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.78pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 58.74pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td></tr><tr class="BRDSX_header"><td style="width: 108pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.69pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Standard <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">BioTools, Inc.</div></td><td style="width: 1.5pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.77pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Transaction <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Accounting <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Adjustments - <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Legacy Business <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Disposition <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">and Other <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Adjustments</div></td><td style="width: 1.5pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.13pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Standard <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">BioTools, Inc.</div></td><td style="width: 1.5pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Treeline <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Biosciences, Inc.</div></td><td style="width: 1.5pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 58.74pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Transaction <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Accounting <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Adjustments - <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Reverse <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Merger</div></td><td style="width: 1.5pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.78pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 58.74pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Pro Forma <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Combined </div></td></tr><tr><td style="width: 108pt; padding-top: 2.03pt; padding-bottom: 1.43pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Revenue:<br></div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.69pt; padding-top: 2.03pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt;">&#160;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.77pt; padding-top: 2.03pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt;">&#160;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.13pt; padding-top: 2.03pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt;">&#160;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 2.03pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt;">&#160;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 2.03pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt;">&#160;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 58.74pt; padding-top: 2.03pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt;">&#160;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.78pt; padding-top: 2.03pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt;">&#160;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 58.74pt; padding-top: 2.03pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt;">&#160;</div></td></tr><tr><td style="width: 108pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Product revenue<font style="padding-left: 4.33pt;"></font></div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.69pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<font style="padding-left: 21.14pt;">15,454</font></div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.77pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 11.05pt; text-align: left;">$(15,454)</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.13pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">I</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 6.46pt; text-align: left;">$<font style="padding-left: 19.57pt;">&#8212;</font></div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;">$<font style="padding-left: 32.89pt;">&#8212;</font></div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 58.74pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<font style="padding-left: 44.64pt;">&#8212;</font></div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.78pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt;">&#160;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 58.74pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<font style="padding-left: 44.64pt;">&#8212; </font></div></td></tr><tr><td style="width: 108pt; padding-top: 1.08pt; padding-bottom: 2.68pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Services and other revenue<font style="padding-left: 0.91pt;"></font></div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.69pt; padding-top: 1.08pt; padding-bottom: 2.68pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 30.54pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">5,692</font></div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.77pt; padding-top: 1.08pt; padding-bottom: 2.68pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 11.05pt; text-align: left;"><font style="padding-left: 9.4pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(5,692</font><font style="padding-bottom: 1.5pt;">)</font></div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.13pt; padding-top: 1.08pt; padding-bottom: 2.68pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">I</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 1.08pt; padding-bottom: 2.68pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 6.46pt; text-align: left;"><font style="padding-left: 24.27pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 1.08pt; padding-bottom: 2.68pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><font style="padding-left: 37.59pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 58.74pt; padding-top: 1.08pt; padding-bottom: 2.68pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 49.34pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.78pt; padding-top: 1.08pt; padding-bottom: 2.68pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt;">&#160;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 58.74pt; padding-top: 1.08pt; padding-bottom: 2.68pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 49.34pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </font></div></td></tr><tr><td style="width: 108pt; padding-top: 2.33pt; padding-bottom: 2.68pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total revenue<font style="padding-left: 4.38pt;"></font></div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.69pt; padding-top: 2.33pt; padding-bottom: 2.68pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 25.84pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">21,146</font></div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.77pt; padding-top: 2.33pt; padding-bottom: 2.68pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 11.05pt; text-align: left;"><font style="padding-left: 4.7pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(21,146</font><font style="padding-bottom: 1.5pt;">)</font></div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.13pt; padding-top: 2.33pt; padding-bottom: 2.68pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt;">&#160;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 2.33pt; padding-bottom: 2.68pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 6.46pt; text-align: left;"><font style="padding-left: 24.27pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 2.33pt; padding-bottom: 2.68pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><font style="padding-left: 37.59pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 58.74pt; padding-top: 2.33pt; padding-bottom: 2.68pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 49.34pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.78pt; padding-top: 2.33pt; padding-bottom: 2.68pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt;">&#160;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 58.74pt; padding-top: 2.33pt; padding-bottom: 2.68pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 49.34pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </font></div></td></tr><tr><td style="width: 108pt; padding-top: 2.33pt; padding-bottom: 1.43pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cost of revenue:<br></div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.69pt; padding-top: 2.33pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt;">&#160;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.77pt; padding-top: 2.33pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt;">&#160;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.13pt; padding-top: 2.33pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt;">&#160;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 2.33pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt;">&#160;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 2.33pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt;">&#160;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 58.74pt; padding-top: 2.33pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt;">&#160;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.78pt; padding-top: 2.33pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt;">&#160;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 58.74pt; padding-top: 2.33pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt;">&#160;</div></td></tr><tr><td style="width: 108pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Cost of product revenue<font style="padding-left: 0.09pt;"></font></div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.69pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 30.54pt;">7,706</font></div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.77pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 11.05pt; text-align: left;"><font style="padding-left: 9.4pt;">(7,706)</font></div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.13pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">I</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 6.46pt; text-align: left;"><font style="padding-left: 24.27pt;">&#8212;</font></div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><font style="padding-left: 37.59pt;">&#8212;</font></div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 58.74pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 49.34pt;">&#8212;</font></div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.78pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt;">&#160;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 58.74pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 49.34pt;">&#8212; </font></div></td></tr><tr><td style="width: 108pt; padding-top: 1.08pt; padding-bottom: 2.68pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Cost of services and other revenue<font style="padding-left: 0.91pt;"></font></div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.69pt; padding-top: 1.08pt; padding-bottom: 2.68pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 30.54pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">2,132</font></div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.77pt; padding-top: 1.08pt; padding-bottom: 2.68pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 11.05pt; text-align: left;"><font style="padding-left: 9.4pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(2,132</font><font style="padding-bottom: 1.5pt;">)</font></div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.13pt; padding-top: 1.08pt; padding-bottom: 2.68pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">I</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 1.08pt; padding-bottom: 2.68pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 6.46pt; text-align: left;"><font style="padding-left: 24.27pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 1.08pt; padding-bottom: 2.68pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><font style="padding-left: 37.59pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 58.74pt; padding-top: 1.08pt; padding-bottom: 2.68pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 49.34pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.78pt; padding-top: 1.08pt; padding-bottom: 2.68pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt;">&#160;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 58.74pt; padding-top: 1.08pt; padding-bottom: 2.68pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 49.34pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </font></div></td></tr><tr><td style="width: 108pt; padding-top: 2.33pt; padding-bottom: 2.68pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total cost of revenue<font style="padding-left: 1.72pt;"></font></div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.69pt; padding-top: 2.33pt; padding-bottom: 2.68pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 30.54pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">9,838</font></div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.77pt; padding-top: 2.33pt; padding-bottom: 2.68pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 11.05pt; text-align: left;"><font style="padding-left: 9.4pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(9,838</font><font style="padding-bottom: 1.5pt;">)</font></div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.13pt; padding-top: 2.33pt; padding-bottom: 2.68pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt;">&#160;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 2.33pt; padding-bottom: 2.68pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 6.46pt; text-align: left;"><font style="padding-left: 24.27pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 2.33pt; padding-bottom: 2.68pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><font style="padding-left: 37.59pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 58.74pt; padding-top: 2.33pt; padding-bottom: 2.68pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 49.34pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.78pt; padding-top: 2.33pt; padding-bottom: 2.68pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt;">&#160;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 58.74pt; padding-top: 2.33pt; padding-bottom: 2.68pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 49.34pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </font></div></td></tr><tr><td style="width: 108pt; padding-top: 2.33pt; padding-bottom: 1.43pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Gross profit<font style="padding-left: 0.51pt;"></font></div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.69pt; padding-top: 2.33pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 26.19pt;">11,308</font></div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.77pt; padding-top: 2.33pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 11.05pt; text-align: left;"><font style="padding-left: 5.05pt;">(11,308)</font></div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.13pt; padding-top: 2.33pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt;">&#160;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 2.33pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 6.46pt; text-align: left;"><font style="padding-left: 24.27pt;">&#8212;</font></div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 2.33pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><font style="padding-left: 37.59pt;">&#8212;</font></div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 58.74pt; padding-top: 2.33pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 49.34pt;">&#8212;</font></div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.78pt; padding-top: 2.33pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt;">&#160;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 58.74pt; padding-top: 2.33pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 49.34pt;">&#8212; </font></div></td></tr><tr><td style="width: 108pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating expenses:<br></div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.69pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt;">&#160;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.77pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt;">&#160;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.13pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt;">&#160;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt;">&#160;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt;">&#160;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 58.74pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt;">&#160;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.78pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt;">&#160;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 58.74pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt;">&#160;</div></td></tr><tr><td style="width: 108pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Research and development<font style="padding-left: 2.11pt;"></font></div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.69pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 30.89pt;">2,117</font></div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.77pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 11.05pt; text-align: left;"><font style="padding-left: 9.74pt;">(2,117)</font></div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.13pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">I</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 6.46pt; text-align: left;"><font style="padding-left: 24.27pt;">&#8212;</font></div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><font style="padding-left: 21.14pt;">49,098</font></div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 58.74pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 49.34pt;">&#8212;</font></div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.78pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt;">&#160;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 58.74pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 32.89pt;">49,098 </font></div></td></tr><tr><td style="width: 108pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Selling, general and administrative<font style="padding-left: 1.89pt;"></font></div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.69pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 25.84pt;">18,607</font></div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.77pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 11.05pt; text-align: left;"><font style="padding-left: 9.4pt;">(5,493)</font></div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.13pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">I</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 6.46pt; text-align: left;"><font style="padding-left: 8.17pt;">13,114</font></div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><font style="padding-left: 25.84pt;">6,959</font></div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 58.74pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 49.34pt;">&#8212;</font></div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.78pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt;">&#160;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 58.74pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 32.89pt;">20,073 </font></div></td></tr><tr><td style="width: 108pt; padding-top: 1.08pt; padding-bottom: 2.68pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Restructuring and related charges<font style="padding-left: 2.12pt;"></font></div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.69pt; padding-top: 1.08pt; padding-bottom: 2.68pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 30.54pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">3,080</font></div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.77pt; padding-top: 1.08pt; padding-bottom: 2.68pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 11.05pt; text-align: left;"><font style="padding-left: 24.27pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.13pt; padding-top: 1.08pt; padding-bottom: 2.68pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt;">&#160;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 1.08pt; padding-bottom: 2.68pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 6.46pt; text-align: left;"><font style="padding-left: 12.53pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">3,080</font></div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 1.08pt; padding-bottom: 2.68pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><font style="padding-left: 37.59pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 58.74pt; padding-top: 1.08pt; padding-bottom: 2.68pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 49.34pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.78pt; padding-top: 1.08pt; padding-bottom: 2.68pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt;">&#160;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 58.74pt; padding-top: 1.08pt; padding-bottom: 2.68pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 37.59pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">3,080 </font></div></td></tr><tr><td style="width: 108pt; padding-top: 2.33pt; padding-bottom: 2.68pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total operating expenses<font style="padding-left: 2.36pt;"></font></div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.69pt; padding-top: 2.33pt; padding-bottom: 2.68pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 25.84pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">23,804</font></div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.77pt; padding-top: 2.33pt; padding-bottom: 2.68pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 11.05pt; text-align: left;"><font style="padding-left: 9.4pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(7,</font><font style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">610</font><font style="padding-bottom: 1.5pt;">)</font></div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.13pt; padding-top: 2.33pt; padding-bottom: 2.68pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt;">&#160;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 2.33pt; padding-bottom: 2.68pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 6.46pt; text-align: left;"><font style="padding-left: 7.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">16,</font><font style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">194</font></div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 2.33pt; padding-bottom: 2.68pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><font style="padding-left: 21.14pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">56,057</font></div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 58.74pt; padding-top: 2.33pt; padding-bottom: 2.68pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 49.34pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.78pt; padding-top: 2.33pt; padding-bottom: 2.68pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt;">&#160;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 58.74pt; padding-top: 2.33pt; padding-bottom: 2.68pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 32.89pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">72,</font><font style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">251 </font></div></td></tr><tr><td style="width: 108pt; padding-top: 2.33pt; padding-bottom: 1.43pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 9.4pt; text-indent: -9.4pt; text-align: left;">Loss from continuing operations<font style="padding-left: 2.11pt;"></font></div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.69pt; padding-top: 2.33pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.72pt;">(12,496)</font></div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.77pt; padding-top: 2.33pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 11.05pt; text-align: left;"><font style="padding-left: 9.4pt;">(3,698)</font></div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.13pt; padding-top: 2.33pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt;">&#160;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 2.33pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 6.46pt; text-align: left;"><font style="padding-left: 4.7pt;">(16,194)</font></div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 2.33pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><font style="padding-left: 18.02pt;">(56,057)</font></div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 58.74pt; padding-top: 2.33pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 49.34pt;">&#8212;</font></div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.78pt; padding-top: 2.33pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt;">&#160;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 58.74pt; padding-top: 2.33pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 29.76pt;">(72,251) </font></div></td></tr><tr><td style="width: 108pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Interest income, net<font style="padding-left: 1.28pt;"></font></div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.69pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 30.89pt;">3,511</font></div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.77pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 11.05pt; text-align: left;"><font style="padding-left: 24.27pt;">&#8212;</font></div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.13pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt;">&#160;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 6.46pt; text-align: left;"><font style="padding-left: 12.87pt;">3,511</font></div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><font style="padding-left: 37.59pt;">&#8212;</font></div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 58.74pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 49.34pt;">&#8212;</font></div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.78pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt;">&#160;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 58.74pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 37.94pt;">3,511 </font></div></td></tr><tr><td style="width: 108pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 9.4pt; text-indent: -9.4pt; text-align: left;">Other (expense) income, net<font style="padding-left: 4.77pt;"></font></div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.69pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 27.41pt;">(5,630)</font></div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.77pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 11.05pt; text-align: left;"><font style="padding-left: 24.27pt;">&#8212;</font></div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.13pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt;">&#160;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 6.46pt; text-align: left;"><font style="padding-left: 9.4pt;">(5,630)</font></div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><font style="padding-left: 25.84pt;">5,516</font></div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 58.74pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 49.34pt;">&#8212;</font></div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.78pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt;">&#160;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 58.74pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 41.86pt;">(114) </font></div></td></tr><tr><td style="width: 108pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 9.4pt; text-indent: -9.4pt; text-align: left;">Loss from continuing operations before income taxes<font style="padding-left: 1.94pt;"></font></div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.69pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.72pt;">(14,615)</font></div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.77pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 11.05pt; text-align: left;"><font style="padding-left: 9.4pt;">(3,698)</font></div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.13pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt;">&#160;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 6.46pt; text-align: left;"><font style="padding-left: 4.7pt;">(18,313)</font></div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><font style="padding-left: 18.02pt;">(50,541)</font></div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 58.74pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 49.34pt;">&#8212;</font></div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.78pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt;">&#160;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 58.74pt; padding-top: 1.08pt; padding-bottom: 1.43pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 29.76pt;">(68,854) </font></div></td></tr><tr><td style="width: 108pt; padding-top: 1.08pt; padding-bottom: 2.68pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Income tax expense<font style="padding-left: 1.02pt;"></font></div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.69pt; padding-top: 1.08pt; padding-bottom: 2.68pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 39.51pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(11</font><font style="padding-bottom: 1.5pt;">)</font></div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.77pt; padding-top: 1.08pt; padding-bottom: 2.68pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 11.05pt; text-align: left;"><font style="padding-left: 24.27pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.13pt; padding-top: 1.08pt; padding-bottom: 2.68pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt;">&#160;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 1.08pt; padding-bottom: 2.68pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 6.46pt; text-align: left;"><font style="padding-left: 21.49pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(11</font><font style="padding-bottom: 1.5pt;">)</font></div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 1.08pt; padding-bottom: 2.68pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><font style="padding-left: 37.59pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 58.74pt; padding-top: 1.08pt; padding-bottom: 2.68pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 49.34pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.78pt; padding-top: 1.08pt; padding-bottom: 2.68pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt;">&#160;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 58.74pt; padding-top: 1.08pt; padding-bottom: 2.68pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 46.56pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(11</font><font style="padding-bottom: 1.5pt;">) </font></div></td></tr><tr><td style="width: 108pt; padding-top: 2.33pt; padding-bottom: 3.68pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 9.4pt; text-indent: -9.4pt; text-align: left;">Net loss from continuing operations<font style="padding-left: 2.11pt;"></font></div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.69pt; padding-top: 2.33pt; padding-bottom: 3.68pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 18.02pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(14,626</font><font style="padding-bottom: 0.5pt;">)</font></div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.77pt; padding-top: 2.33pt; padding-bottom: 3.68pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 11.05pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 4.7pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(3,</font><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">698</font><font style="padding-bottom: 0.5pt;">)</font></div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.13pt; padding-top: 2.33pt; padding-bottom: 3.68pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt;">&#160;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 2.33pt; padding-bottom: 3.68pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 6.46pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$(18,324</font><font style="padding-bottom: 0.5pt;">)</font></div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 2.33pt; padding-bottom: 3.68pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 13.32pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(50,541</font><font style="padding-bottom: 0.5pt;">)</font></div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 58.74pt; padding-top: 2.33pt; padding-bottom: 3.68pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 44.64pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">&#8212;</font></div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.78pt; padding-top: 2.33pt; padding-bottom: 3.68pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt;">&#160;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 58.74pt; padding-top: 2.33pt; padding-bottom: 3.68pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 25.07pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(6</font><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">8,865</font><font style="padding-bottom: 0.5pt;">) </font></div></td></tr><tr><td style="width: 108pt; padding-top: 3.33pt; padding-bottom: 3.68pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 9.4pt; text-indent: -9.4pt; text-align: left;">Net loss per share from continuing operations, basic and diluted<font style="padding-left: 2.57pt;"></font></div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.69pt; padding-top: 3.33pt; padding-bottom: 3.68pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 27.41pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(0.04</font><font style="padding-bottom: 0.5pt;">)</font></div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.77pt; padding-top: 3.33pt; padding-bottom: 3.68pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt;">&#160;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.13pt; padding-top: 3.33pt; padding-bottom: 3.68pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt;">&#160;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 3.33pt; padding-bottom: 3.68pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt;">&#160;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 3.33pt; padding-bottom: 3.68pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 22.72pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(1.93</font><font style="padding-bottom: 0.5pt;">)</font></div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 58.74pt; padding-top: 3.33pt; padding-bottom: 3.68pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt;">&#160;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.78pt; padding-top: 3.33pt; padding-bottom: 3.68pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt;">&#160;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 58.74pt; padding-top: 3.33pt; padding-bottom: 3.68pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 34.46pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(0.0</font><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">3</font><font style="padding-bottom: 0.5pt;">) </font></div></td></tr><tr><td style="width: 108pt; padding-top: 3.33pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 9.4pt; text-indent: -9.4pt; text-align: left;">Shares used in computing net loss per share attributable to common stockholders, basic and diluted<font style="padding-left: 0.15pt;"></font></div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.69pt; padding-top: 3.33pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 4.7pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">388,20</font><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">1,770</font></div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.77pt; padding-top: 3.33pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt;">&#160;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.13pt; padding-top: 3.33pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt;">&#160;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.6pt; padding-top: 3.33pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt;">&#160;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 55.76pt; padding-top: 3.33pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><font style="padding-left: 4.7pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">26,212,247</font></div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 58.74pt; padding-top: 3.33pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 4.7pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">1,9</font><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">93,217,782</font></div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.78pt; padding-top: 3.33pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">K</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 58.74pt; padding-top: 3.33pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 4.7pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">2,</font><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">407,631,800</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.85pt; width: 108pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.85pt; width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.85pt; width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.85pt; width: 51.69pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.85pt; width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.85pt; width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.85pt; width: 55.77pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.85pt; width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.85pt; width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.85pt; width: 3.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.85pt; width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.85pt; width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.85pt; width: 46.6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.85pt; width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.85pt; width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.85pt; width: 55.76pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.85pt; width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.85pt; width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.85pt; width: 58.74pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.85pt; width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.85pt; width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.85pt; width: 6.78pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.85pt; width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.85pt; width: 1.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.85pt; width: 58.74pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.4pt; margin-top: 0.5pt; margin-left: 0pt; text-align: left;"> </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">See accompanying notes to the unaudited pro forma condensed combined financial statements<br></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">298<br></div></div></div>
<!--End Page 309-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 310-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_123-unaudited01_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">1.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Description of the Merger </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On June&#160;6, 2026, Standard BioTools, Merger Sub, and Treeline entered into the Merger Agreement, pursuant to which, Merger Sub will merge with and into Treeline, with Treeline surviving the Merger as a wholly owned subsidiary of Standard BioTools. Subject to the terms and conditions of the Merger Agreement, at the Closing: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">each outstanding share of Treeline Common Stock, including shares of Treeline Common Stock issued in connection with the conversion of Treeline redeemable convertible preferred stock, shall be automatically converted into the right to receive a number of shares of Standard BioTools Common Stock, rounded down to the nearest whole share, equal to the Exchange Ratio; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">each outstanding and unexercised Treeline Option immediately prior to the Closing will be assumed by Standard BioTools and will be converted to an option to purchase shares of Standard BioTools Common Stock, with necessary adjustments to the number of shares and exercise price to reflect the Exchange Ratio; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">each outstanding and unexercised warrant, each of which are pre-funded, to purchase shares of Treeline Common Stock (&#8220;Treeline Warrants&#8221;) immediately prior to the Closing will be either (i) if a Treeline Converting Warrant, cancelled and converted into the right to receive Standard BioTools Common Stock equal to the net-exercise shares (valued at the Company Value Per Share (as defined in the Merger Agreement)) multiplied by the Exchange Ratio, or (ii) if not a Treeline Converting Warrant, assumed by Standard BioTools and converted into a warrant to purchase Standard BioTools Common Stock, with the number of shares multiplied by, and the warrant price divided by, the Exchange Ratio. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Immediately following the Merger, Standard BioTools stockholders as of immediately prior to the Merger are expected to own approximately 16% of the outstanding capital stock of the Combined Company on a fully diluted basis, and former Treeline stockholders are expected to own approximately 84% of the outstanding capital stock of the Combined Company on a fully diluted basis. Treeline stockholders are expected to receive approximately 2,006,187,515 shares of Standard BioTools Common Stock in connection with the Merger, based on the number of shares of Treeline Common Stock outstanding immediately prior to the Merger, the number of shares of Treeline Preferred Stock outstanding as of March&#160;31, 2026, which will be converted into shares of Treeline Common Stock on a one-for-one basis immediately prior to the closing of the Merger, and number of Treeline Converting Warrants outstanding as of March 31, 2026, which will be converted into shares of Treeline Common Stock equal to the net-exercise shares multiplied by the Exchange Ratio. These estimates are subject to certain inputs, which includes, but is not limited to, the assumption that Parent Net Cash at the Closing will be approximately $450&#160;million and the proposed Reverse Stock Split at an assumed ratio of &#8195;&#8195;&#8195;&#8195;. A $10.0 million increase from the Parent Net Cash target would result in an approximately 47,728,248 decrease in the number of shares of Standard BioTools Common Stock issued to Treeline stockholders, calculated pursuant to the Exchange Ratio. A $10.0 million decrease from the Parent Net Cash target would result in an approximately 49,822,746 increase in the number of shares of Standard BioTools Common Stock issued to Treeline stockholders, calculated pursuant to the Exchange Ratio. Both examples result in less than a 1% change in ownership on a fully diluted basis. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Legacy Business Disposition </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As of the filing of the registration statement on Form&#160;S-4 of which this proxy statement/prospectus forms a part, one or more definitive asset purchase agreements for the sale of the Legacy Business have not yet been executed. Both parties expect the sale of the Legacy Business to be completed prior to or concurrently with the closing of the Merger, and these pro forma financial statements have been prepared on that basis. Although asset purchase agreements have not yet been executed and wind-down activities have not been completed, all existing business activities of Standard BioTools are expected to be disposed prior to the closing of the Merger. Therefore, the pro forma adjustments give effect to the disposition of the Legacy Business and the related assets and activities, which are considered probable, as if it had occurred. Any proceeds obtained from the sale of the Legacy Business is subject to the CVR. Net proceeds from the sale of the Legacy Business would be fully offset by a CVR liability, which has not been reflected within the pro forma financial statements due to the uncertainty of expected net proceeds. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">299<br></div></div></div>
<!--End Page 310-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 311-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_123-unaudited01_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Contingent Consideration Receivable </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On January&#160;30, 2026, Standard BioTools completed the sale of its SomaScan business to Illumina. Pursuant to the sale, Standard BioTools was entitled to contingent earnout payments based on the achievement of specified revenue thresholds. Standard BioTools recognized a $25.0&#160;million contingent consideration receivable in Standard BioTools unaudited condensed consolidated balance sheets as of March&#160;31, 2026 related to the realized earnout payments based on fiscal year 2025 revenues. Standard BioTools received the $25.0&#160;million contingent consideration receivable in May&#160;2026 and therefore a pro forma adjustment is reflected for the payment. In addition, Standard BioTools is eligible to receive additional contingent earnout payments of up to $50.0&#160;million based on the achievement of specified revenue thresholds for SomaScan assay services and related products during the year ended December&#160;31, 2026. The 2026 earnout payments, when received, are subject to the CVR. As of the filing date, management&#8217;s fair value estimate of the fiscal year 2026 SomaScan earnout receivable is $50.0&#160;million as the current assessment is that the payments are probable, and accordingly the pro forma financial statements reflect a $50.0&#160;million consideration receivable and a corresponding $50.0&#160;million current CVR liability. This amount is subject to finalization of a fair value analysis and additional facts and circumstances that may change prior to the Merger, and therefore the actual payments may differ than the current estimate. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;"><a name="tCVRA1"><!--Anchor--></a>Contingent Value Rights Agreement </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Prior to the effective date, Standard BioTools will enter into the CVR Agreement with a rights agent pursuant to which Standard BioTools stockholders will receive one CVR for each share of Standard BioTools common stock held. Pursuant to the CVR Agreement, the holder of each CVR will be entitled to receive a payment for each 12-month CVR payment period during the five-year term of the CVR Agreement, consisting of a number of shares of the combined company&#8217;s common stock (with fractional shares settled in cash) equal to such holder&#8217;s pro rata portion of the aggregate net proceeds received by the combined company during such 12-month CVR payment period from the following sources, in each case less certain permitted deductions: (i) proceeds from any sale, disposition, or other monetization of the Legacy Business; (ii) proceeds from convertible notes or other investments held by Standard BioTools as of the Closing Date; (iii) earnout, milestone, royalty or other similar contingent payments due to Standard BioTools under contracts in effect as of the Closing Date, including payments from Illumina, Inc. pursuant to the Stock Purchase Agreement dated June&#160;22, 2025; and (iv) any surplus in Parent Net Cash delivered at Closing as finally determined under the Merger Agreement. The maximum number of shares of common stock of the combined company which may be issued pursuant to the CVR Agreement is 76,000,000. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The CVR is a freestanding financial instrument that meets the definition of a derivative under ASC 815 and does not qualify for any scope exception. The own-equity scope exception is not available because the number of shares deliverable is determined by reference to the net proceeds realized, which derive principally from a right to earnout and similar payments (a financial asset), rather than being fixed by reference to Standard BioTools own equity, so the instrument is not considered indexed to Standard BioTools own stock. Accordingly, the CVR is classified as a derivative liability, measured at fair value at the Effective Time, with subsequent changes in fair value recognized in earnings. The CVRs will not have any voting or dividend rights and will not represent any equity or ownership interest in Standard BioTools. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For pro forma purposes, management&#8217;s best estimate of fair value is $50.0&#160;million which is the maximum fiscal&#160;year 2026 Illumina earnout. The fair value of the other potential CVR proceeds, including any net proceeds from the sale of the Legacy Business, cannot be reasonably estimated as of the filing date, and no asset or CVR liability has been recorded in respect of those amounts.</div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">SomaLogic Disposition </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The unaudited pro forma condensed combined financial statements do not include any adjustments for the disposition of SomaLogic, Inc. by Standard BioTools. On January 30, 2026, Standard BioTools completed the sale of all of the equity interests of the SomaLogic Entities to Illumina pursuant to the Purchase Agreement, dated June 22, 2025, by and between Standard BioTools and Illumina. The SomaLogic Entities comprised Standard BioTools&#8217; SomaScan&#174; Business, including its SomaScan assay platform and related products and services. Standard BioTools determined that the SomaLogic Entities met the held-for-sale criteria under ASC 360, Property, Plant, and Equipment, and the discontinued operations criteria under ASC 205, Presentation of Financial Statements, during the second quarter of 2025. Accordingly, during the year ended December 31, 2025, Standard BioTools presented the SomaLogic Entities as held-for-sale and as discontinued operations for all periods presented. No pro forma </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">300<br></div></div></div>
<!--End Page 311-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 312-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_123-unaudited01_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">adjustments to the statement of operations for the year ended December 31, 2025 or the three months ended March 31, 2026 are necessary, as those periods already reflect the full effect of removing the SomaLogic Entities from the continued operations presentation. Similarly, no pro forma adjustments to the balance sheet as of March 31, 2026 are necessary, as the balance sheet as of such date already gives effect to the disposition of the SomaLogic Entities. </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Basis of Presentation </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For accounting purposes, Treeline is considered to be the acquiring company and the Merger will be accounted for as a reverse recapitalization of Standard BioTools by Treeline because at the closing of the Merger, after divesting the Legacy Business, Standard BioTools is expected to have nominal operations and its assets are expected to primarily be cash, cash equivalents, and investments. In addition, Treeline stockholders will own a substantial majority of the voting rights of the combined company, Treeline will designate a majority of the initial members of the board of directors of the combined company, and Treeline&#8217;s executive management team will become the management team of the combined company. Both parties currently expect the sale of the Legacy Business to be completed prior to or concurrently with the closing of the Merger, and these pro formas have been prepared on that basis. The remaining assets are non-operational in nature and are not significant, including right-of-use assets for leased space that were not used for operations at closing of the Merger and any potential contingent earnout receivables described above. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under reverse recapitalization accounting, the assets and liabilities of Standard BioTools will be recorded, as of the completion of the Merger, at their fair values which are expected to approximate book values because of the nature of the assets and liabilities. No goodwill or intangible assets are expected to be recognized. The unaudited pro forma condensed combined balance sheet as of March&#160;31, 2026 gives effect to the Merger as if it had occurred on March&#160;31, 2026, and the unaudited pro forma condensed combined statements of operations for the year ended December&#160;31, 2025 and the three months ended March&#160;31, 2026 give effect to the Merger as if it had occurred on January&#160;1, 2025. The pro forma financial information reflects transaction accounting adjustments that depict the accounting for the Merger. The historical financial statements of Standard BioTools and Treeline have been adjusted in the accompanying pro forma financial information to give effect to pro forma events that are directly related to the Merger and are described in the accompanying notes. The accompanying pro forma financial information also gives effect to the disposition of the Legacy Business which is not directly attributable to the Merger but is deemed relevant to the pro forma financial position and operations of the combined companies. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">To the extent there are significant changes to the business following completion of the Merger, the assumptions and estimates set forth in the unaudited pro forma condensed combined financial statements could change significantly. Accordingly, the pro forma adjustments are subject to further adjustments as additional information becomes available and as additional analyses are conducted following the completion of the merger. There can be no assurances that these additional analyses will not result in material changes to the estimates of fair value. </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">3.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Pro Forma Adjustments </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The pro forma adjustments were based on the preliminary information available at the time of the preparation of the unaudited pro forma condensed combined financial information. </div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 18pt; margin-left: 0pt; text-align: left;"><u>3a. Adjustments to Unaudited Pro Forma Condensed Combined </u><u>Balance Sheet as of March&#160;31, 2026</u> </div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 17pt; margin-left: 0pt; text-align: left;">Transaction Accounting Adjustments &#8211; Legacy Business Disposition </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">A<font style="font-weight: normal;"> &#8211; Reflects the collection of the contingent consideration receivable of $25.0&#160;million, which was collected by Standard BioTools in May&#160;2026. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">B &#8211; <font style="font-weight: normal;">Reflects the derecognition of the Legacy Business assets and liabilities, all of which are assumed to be disposed of either via a sale or winddown of the related activities. As any proceeds from a sale are subject to a CVR liability and such proceeds cannot be reasonably estimated as of the filing date, a pro forma adjustment is not reflected for additional cash. The operating lease right-of-use asset and related lease liabilities that survive the transaction do not relate to space used in the Combined Company&#8217;s operations. Standard BioTools was unable to exit this lease under its terms and instead subleases the space to a third party. Treeline does not anticipate using the space following the Merger. Management believes the contractual rental terms are materially consistent with current </font></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">301<br></div></div></div>
<!--End Page 312-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 313-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_123-unaudited01_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">market rental rates and concluded there are no favorable or unfavorable lease terms. Management will revisit this conclusion upon the Closing. The historical carrying value of all remaining working capital assets and liabilities approximate fair value due to their short term nature and includes $1.3&#160;million of prepaid D&amp;O tail insurance. </div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Transaction Accounting Adjustments &#8211; Reverse Merger </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">C <font style="font-weight: normal;">&#8211; Reflects the preliminary estimated incremental compensation expense of $9.9 million related to severance and change-in-control payments resulting from pre-existing employment agreements for executives that were agreed upon prior to the Merger. The $9.9 million had not yet been paid or fully accrued for as of March&#160;31, 2026 and, because such costs are expected to be paid prior to the Closing, the $9.9 million is recorded as a decrease to cash and cash equivalents and an increase to accumulated deficit. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">D<font style="font-weight: normal;"> &#8211; Reflects the preliminary estimated transaction costs of $25.2 million, not yet reflected in the historical financial statements of Standard BioTools, which are expected to be incurred by Standard BioTools in connection with the Merger, such as advisory, legal, accounting, auditing, and other professional fees. Because these are Standard BioTools' pre-Closing expenses, they are recognized in Standard BioTools' accumulated deficit and, upon elimination of Standard BioTools' historical equity in the reverse recapitalization, are reflected in the additional paid-in capital of the combined company. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">E &#8211; <font style="font-weight: normal;">Reflects the preliminary estimated transaction costs of $10.6 million incurred by Treeline in connection with the Merger, such as advisory, legal, and auditor fees as (i) a decrease in cash of $10.5 million, (ii) the derecognition of deferred offering costs of $0.1 million included in the historical financial statements, and (iii) a reduction to additional paid-in capital of $10.6 million. As the Merger is accounted for as a reverse recapitalization, equivalent to the issuance of equity for the net assets of Standard BioTools, these direct and incremental costs are treated as a reduction of the net proceeds received within additional paid-in capital. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">F<font style="font-weight: normal;"> &#8211; Reflects the gross recognition of the fiscal year 2026 SomaScan/Illumina earnout, which represents management&#8217;s best estimate of fair value. The adjustment records a $50.0 million current contingent consideration receivable and a corresponding $50.0 million current CVR liability. The $50.0 million represents management&#8217;s best estimate of the fair value of the earnout based on the information available as of the filing date. The estimate of the amount expected to be realized and distributable to CVR holders is classified as current consistent with the expected timing of realization. Management measured the earnout at fair value, which is intended to be consistent with the manner in which the corresponding CVR liability is measured since substantially all of the economic benefit of these rights is passed through to CVR holders. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">G <font style="font-weight: normal;">&#8211; Conversion of Treeline&#8217;s redeemable convertible preferred stock into common stock of the Combined Company upon completion of the Merger. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">H <font style="font-weight: normal;">&#8211; To record the (i) Exchange Ratio adjustment to Treeline&#8217;s common stock outstanding, (ii) issuance of common stock upon conversion of Treeline redeemable convertible preferred shares, (iii)&#160;issuance of common stock upon conversion of Treeline Converting Warrants, (iv) elimination of Standard BioTools historical equity carrying value, (v) Standard BioTools transaction costs of $25.2 million and severance costs of $9.9 million, (vi) the increase in compensation expense related accelerated vesting of Standard BioTool options and RSUs of certain executives related to the pre-existing employment agreements discussed in C and for certain employees upon approval from Standard BioTools&#8217; board of directors, and (vii) Treeline transaction costs: </font></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 96pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 88.24pt;" colspan="4"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 41.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 50.95pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 45.32pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 41.76pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 45.76pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 6.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.57pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td colspan="4" style="width: 88.24pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Common stock</div></td><td style="width: 4.57pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt; border-bottom: none;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td rowspan="2" style="width: 41.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Additional <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">paid-in <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">capital</div></td><td style="width: 4.57pt; border-bottom: none;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt; border-bottom: none;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td rowspan="2" style="width: 50.95pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Accumulated <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">other <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">comprehensive <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">loss</div></td><td style="width: 4.57pt; border-bottom: none;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt; border-bottom: none;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td rowspan="2" style="width: 45.32pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Accumulated <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">deficit</div></td><td style="width: 4.57pt; border-bottom: none;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt; border-bottom: none;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td rowspan="2" style="width: 41.76pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Treasury <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">stock at cost</div></td><td style="width: 4.57pt; border-bottom: none;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt; border-bottom: none;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td rowspan="2" style="width: 45.76pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">stockholders&#8217; <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">equity <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(deficit) </div></td></tr><tr class="BRDSX_header"><td style="width: 96pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(amounts in thousands)</div></td><td style="width: 6.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.57pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 48.88pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">shares</div></td><td style="width: 6.57pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.57pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 26.22pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">amount</div></td><td style="width: 4.57pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr><td style="width: 96pt; padding-top: 2.06pt; padding-bottom: 1.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 8.5pt; text-indent: -8.5pt; text-align: left;">Adjustment to Treeline common stock outstanding in connection with the Exchange Ratio<font style="padding-left: 1.32pt;"></font></div></td><td style="width: 6.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 48.88pt; padding-top: 2.06pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 6.38pt;">244,853,914</font></div></td><td style="width: 6.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 26.22pt; padding-top: 2.06pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 1.43pt; text-align: left;">$<font style="padding-left: 6.38pt;">245</font></div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.08pt; padding-top: 2.06pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 1.42pt; text-align: left;">$<font style="padding-left: 18.42pt;">(245)</font></div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.95pt; padding-top: 2.06pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 19.1pt; text-align: left;">$&#8212;</div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45.32pt; padding-top: 2.06pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 16.28pt; text-align: left;">$&#8212;</div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.76pt; padding-top: 2.06pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 14.51pt; text-align: left;">$&#8212;</div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45.76pt; padding-top: 2.06pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 3.76pt; text-align: left;">$<font style="padding-left: 25.5pt;">&#8212; </font></div></td></tr><tr><td style="width: 96pt; padding-top: 1.31pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 8.5pt; text-indent: -8.5pt; text-align: left;">Issuance of common stock upon conversion of Treeline redeemable convertible preferred shares<font style="padding-left: 4.14pt;"></font></div></td><td style="width: 6.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 48.88pt; padding-top: 1.31pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">1,694,528,033</div></td><td style="width: 6.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 26.22pt; padding-top: 1.31pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 1.43pt; text-align: left;"><font style="padding-left: 4.25pt;">1,695</font></div></td><td style="width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.08pt; padding-top: 1.31pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 1.42pt; text-align: left;"><font style="padding-left: 4.25pt;">1,179,366</font></div></td><td style="width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.95pt; padding-top: 1.31pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 19.1pt; text-align: left;"><font style="padding-left: 4.25pt;">&#8212;</font></div></td><td style="width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45.32pt; padding-top: 1.31pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 16.28pt; text-align: left;"><font style="padding-left: 4.25pt;">&#8212;</font></div></td><td style="width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.76pt; padding-top: 1.31pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 14.51pt; text-align: left;"><font style="padding-left: 4.25pt;">&#8212;</font></div></td><td style="width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45.76pt; padding-top: 1.31pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 3.76pt; text-align: left;"><font style="padding-left: 4.25pt;">1,181,061 </font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 3.25pt; width: 96pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 6.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 6.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 48.88pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 6.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 6.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 26.22pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 41.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 50.95pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 45.32pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 41.76pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 45.76pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">302<br></div></div></div>
<!--End Page 313-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 314-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_123-unaudited01_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="margin-top: 4pt; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 96pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 88.24pt;" colspan="4"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 41.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 50.95pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 45.32pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 41.76pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 45.76pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 6.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.57pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td colspan="4" style="width: 88.24pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Common stock</div></td><td style="width: 4.57pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt; border-bottom: none;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td rowspan="2" style="width: 41.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Additional <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">paid-in <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">capital</div></td><td style="width: 4.57pt; border-bottom: none;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt; border-bottom: none;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td rowspan="2" style="width: 50.95pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Accumulated <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">other <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">comprehensive <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">loss</div></td><td style="width: 4.57pt; border-bottom: none;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt; border-bottom: none;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td rowspan="2" style="width: 45.32pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Accumulated <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">deficit</div></td><td style="width: 4.57pt; border-bottom: none;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt; border-bottom: none;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td rowspan="2" style="width: 41.76pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Treasury <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">stock at cost</div></td><td style="width: 4.57pt; border-bottom: none;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt; border-bottom: none;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td rowspan="2" style="width: 45.76pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">stockholders&#8217; <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">equity <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(deficit) </div></td></tr><tr class="BRDSX_header"><td style="width: 96pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(amounts in thousands)</div></td><td style="width: 6.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.57pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 48.88pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">shares</div></td><td style="width: 6.57pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.57pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 26.22pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">amount</div></td><td style="width: 4.57pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr><td style="width: 96pt; padding-top: 2.06pt; padding-bottom: 1.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 8.5pt; text-indent: -8.5pt; text-align: left;">Issuance of common stock upon conversion of Treeline Converting Warrants<font style="padding-left: 4.91pt;"></font></div></td><td style="width: 6.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 48.88pt; padding-top: 2.06pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 1.01pt; text-align: left;"><font style="padding-left: 8.45pt;">62,095,143 </font></div></td><td style="width: 6.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 26.22pt; padding-top: 2.06pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 1.84pt; text-align: left;"><font style="padding-left: 13.87pt;">62 </font></div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.08pt; padding-top: 2.06pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 0.09pt; text-align: left;"><font style="padding-left: 29.58pt;">(62)</font></div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.95pt; padding-top: 2.06pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 17.13pt; text-align: left;"><font style="padding-left: 8.02pt;">&#8212;</font></div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45.32pt; padding-top: 2.06pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 3.53pt; text-align: left;"><font style="padding-left: 29.58pt;">&#8212;</font></div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.76pt; padding-top: 2.06pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 7.07pt; text-align: left;"><font style="padding-left: 18.96pt;">&#8212;</font></div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45.76pt; padding-top: 2.06pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 4.52pt; text-align: left;"><font style="padding-left: 28.07pt;">&#8212;</font></div></td></tr><tr><td style="width: 96pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 8.5pt; text-indent: -8.5pt; text-align: left;">Elimination of Standard BioTools&#8217; historical carrying values<font style="padding-left: 3.22pt;"></font></div></td><td style="width: 6.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 48.88pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 1.01pt; text-align: left;"><font style="padding-left: 38.2pt;">&#8212;</font></div></td><td style="width: 6.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 26.22pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 1.84pt; text-align: left;"><font style="padding-left: 6.79pt;">(408</font><font style="padding-left: 0.17pt;">)</font></div></td><td style="width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.08pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 0.09pt; text-align: left;"><font style="padding-left: 4.08pt;">(1,191,982)</font></div></td><td style="width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.95pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 17.13pt; text-align: left;"><font style="padding-left: 4.08pt;">511</font></div></td><td style="width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45.32pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 3.53pt; text-align: left;"><font style="padding-left: 4.08pt;">1,145,412</font></div></td><td style="width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.76pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 7.07pt; text-align: left;"><font style="padding-left: 4.08pt;">46,467</font></div></td><td style="width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45.76pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 4.52pt; text-align: left;"><font style="padding-left: 28.07pt;">&#8212; </font></div></td></tr><tr><td style="width: 96pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 8.5pt; text-indent: -8.5pt; text-align: left;">Standard BioTools&#8217; transaction costs and severance expenses<font style="padding-left: 4.08pt;"></font></div></td><td style="width: 6.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 48.88pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 1.01pt; text-align: left;"><font style="padding-left: 38.2pt;">&#8212;</font></div></td><td style="width: 6.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 26.22pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 1.84pt; text-align: left;"><font style="padding-left: 13.87pt;">&#8212;</font></div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.08pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 0.09pt; text-align: left;"><font style="padding-left: 14.71pt;">(25,179)</font></div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.95pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 17.13pt; text-align: left;"><font style="padding-left: 8.02pt;">&#8212;</font></div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45.32pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 3.53pt; text-align: left;"><font style="padding-left: 16.13pt;">(9,900</font><font style="padding-left: 0.17pt;">)</font></div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.76pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 7.07pt; text-align: left;"><font style="padding-left: 18.96pt;">&#8212;</font></div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45.76pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 4.52pt; text-align: left;"><font style="padding-left: 10.37pt;">(35,079</font><font style="padding-left: 0.17pt;">) </font></div></td></tr><tr><td style="width: 96pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 8.5pt; text-indent: -8.5pt; text-align: left;">Standard BioTools&#8217; accelerated vesting of certain employees and executive awards<font style="padding-left: 1.62pt;"></font></div></td><td style="width: 6.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 48.88pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 1.01pt; text-align: left;"><font style="padding-left: 8.45pt;">18,225,281</font></div></td><td style="width: 6.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 26.22pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 1.84pt; text-align: left;"><font style="padding-left: 13.87pt;">18</font></div></td><td style="width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.08pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 0.09pt; text-align: left;"><font style="padding-left: 17.54pt;">24,266</font></div></td><td style="width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.95pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 17.13pt; text-align: left;"><font style="padding-left: 8.02pt;">&#8212;</font></div></td><td style="width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45.32pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 3.53pt; text-align: left;"><font style="padding-left: 11.88pt;">(24,284</font><font style="padding-left: 0.17pt;">)</font></div></td><td style="width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.76pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 7.07pt; text-align: left;"><font style="padding-left: 18.96pt;">&#8212;</font></div></td><td style="width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45.76pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 4.52pt; text-align: left;"><font style="padding-left: 28.07pt;">&#8212; </font></div></td></tr><tr><td style="width: 96pt; padding-top: 1.31pt; padding-bottom: 2.88pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Treeline&#8217;s transaction costs<font style="padding-left: 1.34pt;"></font></div></td><td style="width: 6.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 48.88pt; padding-top: 1.31pt; padding-bottom: 2.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 1.01pt; text-align: left;"><font style="padding-left: 38.36pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 6.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 26.22pt; padding-top: 1.31pt; padding-bottom: 2.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 1.84pt; text-align: left;"><font style="padding-left: 14.04pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.08pt; padding-top: 1.31pt; padding-bottom: 2.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 0.09pt; text-align: left;"><font style="padding-left: 15.88pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(</font><font style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">10,600</font><font style="padding-bottom: 1.5pt;">)</font></div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.95pt; padding-top: 1.31pt; padding-bottom: 2.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 17.13pt; text-align: left;"><font style="padding-left: 8.19pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45.32pt; padding-top: 1.31pt; padding-bottom: 2.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 3.53pt; text-align: left;"><font style="padding-left: 29.75pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.76pt; padding-top: 1.31pt; padding-bottom: 2.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 7.07pt; text-align: left;"><font style="padding-left: 19.13pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45.76pt; padding-top: 1.31pt; padding-bottom: 2.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 4.52pt; text-align: left;"><font style="padding-left: 11.54pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(</font><font style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">10,600</font><font style="padding-left: 0.17pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"></font><font style="padding-bottom: 1.5pt;">) </font></div></td></tr><tr><td style="width: 96pt; padding-top: 2.56pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Pro forma adjustment<font style="padding-left: 3.57pt;"></font></div></td><td style="width: 6.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 48.88pt; padding-top: 2.56pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 1.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">2,019,702,371</font></div></td><td style="width: 6.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 26.22pt; padding-top: 2.56pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 1.84pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$1,612</font></div></td><td style="width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.08pt; padding-top: 2.56pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 0.09pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 11.8pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(</font><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">24,436</font><font style="padding-bottom: 0.5pt;">)</font></div></td><td style="width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.95pt; padding-top: 2.56pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 17.13pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 0.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">511</font></div></td><td style="width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45.32pt; padding-top: 2.56pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 3.53pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 2.13pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">&#8203;</font><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">1,111,228</font></div></td><td style="width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.76pt; padding-top: 2.56pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 7.07pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 1.01pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">46,467</font></div></td><td style="width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45.76pt; padding-top: 2.56pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 4.52pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$1,135,382</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 3.25pt; width: 96pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 6.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 6.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 48.88pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 6.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 6.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 26.22pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 41.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 50.95pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 45.32pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 41.76pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 45.76pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 23.25pt; margin-left: 0pt; text-align: left;"><u>3b. Adjustments to Unaudited Pro Forma Condensed </u><u>C</u><u>ombined </u><u>Statement of Operations for the Three&#160;Months </u><u>Ended March&#160;31, 2026 and for Year Ended December&#160;31, 2025</u> </div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Transaction Accounting Adjustments &#8211; Asset Disposition and Other </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">I <font style="font-weight: normal;">&#8211; Reflects the derecognition of all Legacy Business statement of operations activity, assuming that such businesses were sold on January&#160;1, 2025, as Standard BioTools&#8217; operating losses are directly related to the Legacy Business operating assets and liabilities. </font></div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 18pt; margin-left: 0pt; text-align: left;">Transaction Accounting Adjustments &#8211; Reverse Merger </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">J <font style="font-weight: normal;">&#8211; Reflects a post-combination compensation charge consisting of $24.3 million of stock-based compensation expense from the accelerated vesting of unvested equity awards of certain executives related to pre-existing employment agreements discussed in C and for certain employees upon approval from Standard BioTools&#8217; board of directors and $9.9 million of cash severance arising under preexisting employment agreements for executives that were agreed upon prior to the Merger. In addition, this adjustment includes $1.6 million of retention bonuses for non-executive employees who will provide transition services following the Closing. These amounts are nonrecurring and are not expected to affect the combined company's results beyond 12 months following the Merger.</font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">K<font style="font-weight: normal;"> &#8211; The pro forma combined basic and diluted earnings per share have been adjusted to reflect the pro forma net loss for the three months ended March&#160;31, 2026 and the year ended December&#160;31, 2025. In addition, the number of shares used in calculating the pro forma combined basic and diluted net loss per share has been adjusted to reflect the estimated total number of shares of common stock of the Combined Company that would be outstanding as of the closing. Consistent with ASC 260-10-45-13, the Treeline Warrants are included in historical weighted-average number of Treeline common stock outstanding for the year ended December&#160;31, 2025 since the underlying common shares are issuable for little to no consideration and there are no vesting conditions or contingencies associated with the warrants. Therefore, there is no separate pro forma weighted average number of common shares adjustment related to the Treeline Warrants. The following table sets forth the calculation of the pro forma weighted average number of common shares outstanding &#8211; basic and diluted. </font></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 312pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 70.06pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 64.49pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 312pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(amounts in thousands)</div></td><td style="width: 5.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.36pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 70.06pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three months ended <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31, 2026</div></td><td style="width: 5.36pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.36pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 64.49pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year ended <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2025 </div></td></tr><tr><td style="width: 312pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Historical weighted-average number of Treeline common stock outstanding<font style="padding-left: 2.06pt;"></font></div></td><td style="width: 5.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 70.06pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.03pt; text-align: left;"><font style="padding-left: 5pt;">26,212,247</font></div></td><td style="width: 5.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.25pt; text-align: left;"><font style="padding-left: 5.37pt;">21,911,034 </font></div></td></tr><tr><td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Impact of Treeline redeemable convertible preferred stock assuming conversion as of January&#160;1, 2025<font style="padding-left: 2.87pt;"></font></div></td><td style="width: 5.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 70.06pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.03pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">144,834,563</font></div></td><td style="width: 5.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.25pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">144,834,563 </font></div></td></tr><tr><td style="width: 312pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Application of Exchange Ratio to Treeline&#8217;s pro forma weighted-average shares outstanding<font style="padding-left: 0.36pt;"></font></div></td><td style="width: 5.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 70.06pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.03pt; text-align: left;"><font style="padding-left: 17.87pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">11.6997</font></div></td><td style="width: 5.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 64.49pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.25pt; text-align: left;"><font style="padding-left: 17.87pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">11.6997 </font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 312pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 70.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 64.49pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">303<br></div></div></div>
<!--End Page 314-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 315-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_123-unaudited01_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="margin-top: 4pt; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 312pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 70.06pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 64.49pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 312pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(amounts in thousands)</div></td><td style="width: 5.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.36pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 70.06pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three months ended <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31, 2026</div></td><td style="width: 5.36pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.36pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 64.49pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year ended <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2025 </div></td></tr><tr><td style="width: 312pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Adjusted Treeline weighted-average number of common stock outstanding<font style="padding-left: 0.39pt;"></font></div></td><td style="width: 5.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 70.06pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.28pt; text-align: left;">2,001,204,749</div></td><td style="width: 5.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.5pt; text-align: left;">1,950,881,635 </div></td></tr><tr><td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Historical weighted-average number of Standard BioTools common stock outstanding<font style="padding-left: 2.84pt;"></font></div></td><td style="width: 5.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 70.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.28pt; text-align: left;"><font style="padding-left: 7.5pt;">388,201,770</font></div></td><td style="width: 5.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.5pt; text-align: left;"><font style="padding-left: 7.5pt;">381,622,547</font> </div></td></tr><tr><td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Impact of accelerated vesting of Standard BioTools RSUs <font style="padding-left: 0.82pt;"></font></div></td><td style="width: 5.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 70.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.28pt; text-align: left;"><font style="padding-left: 12.5pt;">18,225,281</font> </div></td><td style="width: 5.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.5pt; text-align: left;"><font style="padding-left: 12.5pt;">18,225,281</font></div></td></tr><tr><td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Application of the proposed Reverse Stock Split at an assumed ratio of&#160;<font style="padding-left: 3.46pt;"></font></div></td><td style="width: 5.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 70.06pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="border-bottom: 1pt solid #000000; padding-left: 57.5pt; margin-left: 1.84pt;"></font></div></td><td style="width: 5.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="border-bottom: 1pt solid #000000; padding-left: 57.5pt; margin-left: 3.5pt;"></font></div></td></tr><tr><td style="width: 312pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Pro forma combined weighted-average number of common stock outstanding<font style="padding-left: 2.84pt;"></font></div></td><td style="width: 5.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 70.06pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.28pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">2,407,631,800</font></div></td><td style="width: 5.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 64.49pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.5pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">2,350,729,463</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 312pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 70.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 64.49pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">304<br></div></div></div>
<!--End Page 315-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 316-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_124-tax_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tMUS"><!--Anchor--></a>MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS WITH RESPECT TO THE MERGER </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following discussion summarizes and describes the U.S. federal income tax considerations with respect to the Merger for U.S. holders (as defined below) of Treeline Common Stock that exchange their Treeline Common Stock for Standard BioTools Common Stock in the Merger. This discussion is based on the Code, U.S. Treasury regulations promulgated thereunder, judicial decisions and published rulings and administrative pronouncements of the IRS, in each case in effect as of the date hereof. These authorities may change or be subject to differing interpretations. Any such change or differing interpretation may be applied retroactively in a manner that could adversely affect a U.S. holder. Neither Standard BioTools nor Treeline has sought, and neither party intends to seek, any rulings from the IRS regarding the matters discussed below. Accordingly, there can be no assurance the IRS or a court will not take a contrary position to that discussed below regarding the tax consequences of the Merger. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This discussion assumes that the Merger will be consummated in accordance with the Merger Agreement and as further described in this proxy statement/prospectus. This discussion addresses the material U.S. federal income tax considerations with respect to the Merger; however, it does not address any tax consequences arising under the Medicare contribution tax on net investment income, nor does it address any tax consequences arising under the laws of any state, local or non-U.S. jurisdiction, or under any U.S. federal laws other than those pertaining to the income tax. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This discussion applies only to U.S. holders of Treeline Common Stock who hold such shares as a capital asset within the meaning of Section&#160;1221 of the Code (generally, property held for investment). Further, this discussion does not purport to address aspects of U.S. federal income taxation that may be relevant to U.S. holders of Treeline Common Stock in light of their particular circumstances and does not apply to U.S. holders of Treeline Common Stock subject to special treatment under the U.S. federal income tax laws including, without limitation: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">banks, insurance companies and other financial institutions; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">tax-exempt and governmental organizations; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">partnerships, S corporations and other pass-through entities (and investors in partnerships, S corporations and other pass-through entities); </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">regulated investment companies and real estate investment trusts; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">controlled foreign corporations and passive foreign investment companies; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">brokers and dealers in stocks, securities, commodities or currencies; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">persons who hold their Treeline Common Stock as &#8220;qualified small business stock&#8221; under Section&#160;1202 of the Code or as &#8220;Section&#160;1244 stock&#8221; under Section&#160;1244 of the Code or who acquired their Treeline Common Stock in a transaction subject to the gain rollover provisions of Section&#160;1045 of the Code; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">traders in securities that elect to apply a mark-to-market method of accounting; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">persons subject to the alternative minimum tax; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">persons who acquired Treeline Common Stock pursuant to the exercise of employee stock options, through a tax qualified retirement plan or otherwise as compensation; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">persons whose functional currency is not the U.S. dollar; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">persons who hold Treeline Common Stock as part of a hedge, straddle, constructive sale, conversion or other integrated transaction; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">persons who acquired their Treeline Common Stock pursuant to the exercise of warrants or conversion rights under convertible instruments; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">persons who are subject to special tax accounting rules under Section&#160;451(b) of the Code; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">U.S. expatriates. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, this summary does not address (i) the tax consequences of the Merger under U.S. federal non-income tax law (including estate, gift or other non-income taxes), (ii) the tax consequences of the Merger under state, local or non-U.S. tax laws, (iii) the impact of the alternative minimum tax provisions of the Code (including the 15% minimum tax applicable to the adjusted financial statement income of certain corporations), (iv) the tax </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">305<br></div></div></div>
<!--End Page 316-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 317-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_124-tax_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">consequences of transactions effectuated before, subsequent to or concurrently with the Merger (whether or not any such transactions are consummated in connection with the Merger), including, without limitation, any transaction in which Treeline Common Stock shares are acquired, or (v) the tax consequences of the Merger to Treeline stockholders who exercise appraisal or dissenters&#8217; rights. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For purposes of this discussion, the term &#8220;U.S. holder&#8221; means a beneficial owner of Treeline Common Stock that is, for U.S. federal income tax purposes, </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">an individual citizen or resident of the United States; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a corporation, or entity treated as a corporation for U.S. federal income tax purposes, organized under the laws of the United States, any state thereof or the District of Columbia; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a trust that (i) is subject to the primary supervision of a U.S. court and the control of one or more &#8220;United States persons&#8221; (within the meaning of Section&#160;7701(a)(30) of the Code) or (ii) has made a valid election to be treated as a United States person for U.S. federal income tax purposes; or </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">an estate, the income of which is subject to U.S. federal income tax regardless of its source. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If an entity or arrangement treated as a partnership for U.S. federal income tax purposes holds Treeline Common Stock, the tax treatment of a partner in such partnership will depend on the status of the partner and the activities of the partnership. Any entity treated as a partnership for U.S. federal income tax purposes that holds Treeline Common Stock and any partners in such partnership should consult their tax advisors regarding the tax consequences of the Merger to them. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">THE FOLLOWING DISCUSSION ONLY ADDRESSES THE MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS WITH RESPECT TO THE MERGER. ALL HOLDERS OF TREELINE COMMON STOCK SHOULD CONSULT THEIR TAX ADVISORS AS TO THE PARTICULAR TAX CONSEQUENCES TO THEM OF THE MERGER, INCLUDING THE APPLICABILITY AND EFFECT OF ANY U.S. FEDERAL, STATE, LOCAL, NON-U.S., AND OTHER TAX LAWS.<font style="font-weight: normal;"> </font></div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Effects of the Merger </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Merger is intended to qualify as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a) of the Code and will be so reported by Standard BioTools, Treeline and Merger Sub. However, it is not a condition to Standard BioTools&#8217;, Treeline&#8217;s or Merger Sub&#8217;s obligations to complete the Merger that the Merger so qualify. If the Merger does not so qualify, the tax treatment will differ from that described in this discussion, and U.S. holders would be required to recognize gain or loss on their exchange of Treeline common stock for Standard BioTools common stock. No ruling has been or will be sought from the IRS with respect to the tax consequences of the Merger. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Provided that the Merger qualifies as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a) of the Code, the material U.S. federal income tax considerations of the Merger will generally be as follows. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">U.S. Federal Income Tax Consequences of the Merger to U.S. Holders of Treeline Common Stock </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">A U.S. holder of Treeline Common Stock that exchanges their Treeline Common Stock for Standard BioTools Common Stock in the Merger: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">will not recognize any gain or loss upon the exchange of Treeline Common Stock for Standard BioTools Common Stock in the Merger; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">will have an aggregate tax basis in the Standard BioTools Common Stock received in the Merger equal to the holder&#8217;s aggregate adjusted tax basis of the Treeline Common Stock surrendered in exchange therefor, reduced by the basis allocable to any fractional share of Standard BioTools Common Stock for which cash is received; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">will have a holding period for the Standard BioTools Common Stock received in the Merger that includes its holding period for its Treeline Common Stock surrendered in exchange therefor. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treasury Regulations provide detailed rules for allocating the tax basis and holding period of the shares of Treeline Common Stock surrendered to the shares of Standard BioTools Common Stock received. U.S. holders of shares of Treeline Common Stock acquired on different dates and at different prices should consult their tax advisors regarding the allocation of the tax basis and holding period of such shares. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">306<br></div></div></div>
<!--End Page 317-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 318-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_124-tax_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This discussion of U.S. federal income tax considerations of the Merger is for general information purposes only and is not intended to be, and should not be construed as, tax advice. U.S. holders are urged to consult their tax advisors regarding the U.S. federal income tax consequences of the Merger in light of their personal circumstances and the consequences to them under state, local and non-U.S. tax laws and other federal tax laws.<font style="font-weight: normal;"> </font></div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Reorganization Reporting </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Each U.S. holder who receives shares of Standard BioTools Common Stock in the Merger is required to retain permanent records pertaining to the Merger and make such records available to any authorized IRS officers and employees. Such records should specifically include information regarding the amount, basis and fair market value of all transferred property, and relevant facts regarding any liabilities assumed or extinguished as part of such reorganization. U.S. holders who owned immediately before the Merger at least five percent (by vote or value) of the total outstanding Treeline Common Stock are required to attach a statement to their tax returns for the year in which the Merger is consummated that contains the information listed in Treasury Regulation Section&#160;1.368-3(b). Such statement must include the U.S. holder&#8217;s tax basis in such U.S. holder&#8217;s Treeline Common Stock surrendered in the Merger, the fair market value of such Treeline Common Stock, the date of the Merger and the name and employer identification number of each of Treeline and Standard BioTools. U.S. holders are urged to consult with their tax advisors to comply with these rules. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This summary does not take into account any U.S. holder&#8217;s particular circumstances and does not address consequences that may be particular to such U.S. holder. Therefore, each U.S. holder should consult their own tax advisor regarding the particular consequences of the Merger to such U.S. holder.<font style="font-weight: normal;"> </font></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">307<br></div></div></div>
<!--End Page 318-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 319-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_125-description_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tDCS"><!--Anchor--></a>DESCRIPTION OF CAPITAL STOCK </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As a result of the Merger and the other transactions described in this proxy statement/prospectus, Treeline stockholders will become stockholders of Standard BioTools, which will continue as the combined company under the name &#8220;Treeline Biosciences Holdings, Inc.&#8221; This proxy statement/prospectus also relates to the resale, from time to time, by the Selling Securityholders of shares of Standard BioTools Common Stock acquired in the Merger. See &#8220;Selling Securityholders,&#8221; &#8220;Use of Proceeds,&#8221; &#8220;Determination of Offering Price&#8221; and &#8220;Plan of Distribution&#8221; in the resale prospectus included in the registration statement on Form&#160;S-4 of which this proxy statement/prospectus forms a part. The rights of former Treeline stockholders and the rights of Standard BioTools stockholders following the consummation of the Merger will be governed by the Standard BioTools Charter, as amended, and the Standard BioTools Bylaws. The following description of Standard BioTools&#8217; capital stock is a summary, does not purport to be complete and is qualified in its entirety by reference to the latest Standard BioTools SEC filings on Form&#160;10-K and 10-Q, the Standard BioTools Charter, the Standard BioTools Bylaws, and the applicable provisions of the DGCL. The discussion in this section does not give effect to any reverse stock split that may be adopted prior to the Closing. See also &#8220;Comparison of Stockholder Rights&#8221; beginning on page <a href="#tCSR">312</a> of this proxy statement/prospectus.<font style="font-style: normal;"> </font></div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Authorized Capital Shares </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Standard BioTools authorized capital stock consists of 600,000,000 shares of Standard BioTools Common Stock, par value $0.001 per share, and 10,000,000 shares of preferred stock, par value $0.001 per share (the &#8220;Standard BioTools Preferred Stock&#8221;). As of the Record Date, there were &#8195;&#8195;&#8195;&#8195; shares of Standard BioTools Common Stock outstanding and no shares of Standard BioTools Preferred Stock issued or outstanding. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Common Stock </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The holders of Standard BioTools Common Stock are entitled to one vote per share on all matters to be voted on by the Standard BioTools stockholders. Subject to preferences that may be applicable to any outstanding shares of Standard BioTools Preferred Stock, if any, holders of Standard BioTools Common Stock are entitled to receive ratably such dividends as may be declared by the Standard BioTools Board out of funds legally available for that purpose. In the event of the liquidation, dissolution or winding up of Standard BioTools, the holders of Standard BioTools Common Stock are entitled to share ratably in all assets remaining after the payment of liabilities, subject to the prior distribution rights of Standard BioTools Preferred Stock then outstanding, if any. Holders of Standard BioTools Common Stock have no preemptive, conversion or subscription rights. There are no redemption or sinking fund provisions applicable to the Standard BioTools Common Stock. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, the Standard BioTools Charter provides that certain corporate actions require the approval of the Standard BioTools stockholders. These actions, and the vote required, are as follows: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the removal of a director requires the vote of a majority of the voting power of the issued and outstanding capital stock entitled to vote in the election of directors; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the amendment of provisions of the Standard BioTools Charter relating to blank check preferred stock, the classification of the Standard BioTools Board, the removal of directors, the filling of vacancies on the Standard BioTools Board, cumulative voting, procedures for annual and special meetings of the stockholders, action by written consent of stockholders and procedures for the amendment of the Standard BioTools Charter require the vote of 66 2/3% of the Standard BioTools&#8217; then outstanding voting securities. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">When Standard BioTools issues shares of Standard BioTools Common Stock registered under the registration statement on Form&#160;S-4 of which this proxy statement/prospectus forms a part, such shares of Standard BioTools Common Stock will be fully paid and nonassessable, and will not have, or be subject to, any preemptive or similar rights. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Preferred Stock </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Standard BioTools Charter provides for 10,000,000 authorized shares of preferred stock. The Standard BioTools Board has the authority, without further action by the Standard BioTools stockholders, to designate and issue the Standard BioTools Preferred Stock in one or more series. The Standard BioTools Board may also fix by resolution or resolutions the designations, powers, preferences and rights, and the qualifications, limitations or restrictions, of each such series of Standard BioTools Preferred Stock, any or all of which may be greater than or senior to those of the Standard BioTools Common Stock. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">308<br></div></div></div>
<!--End Page 319-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 320-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_125-description_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Though the actual effect of any such issuance on the rights of the holders of Standard BioTools Common Stock will not be known until the Standard BioTools Board determines the specific rights of the holders of Preferred Stock, the potential effects of such an issuance include: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">diluting the voting power of the holders of Standard BioTools Common Stock; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">reducing the likelihood that holders of Standard BioTools Common Stock will receive dividend payments; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">reducing the likelihood that holders of Standard BioTools Common Stock will receive payments in the event of a liquidation, dissolution, or winding up; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">delaying, deterring or preventing a change-in-control or other corporate takeover. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The purpose of authorizing the Standard BioTools Board to issue preferred stock in one or more series and to determine the number of shares in the series and the rights and preferences associated with such series is to eliminate delays associated with stockholder votes on specific issuances. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change in control of Standard BioTools or other corporate action. As of the date of this proxy statement/prospectus, there are no shares of preferred stock outstanding, and Standard BioTools has no present plans to issue any shares of preferred stock. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Registration Rights Agreements </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On January&#160;23, 2022, Standard BioTools entered into a Registration Rights Agreement, as amended by that certain Exchange Agreement, dated March&#160;18, 2024 (the &#8220;Exchange Agreement&#8221;), with Casdin Private Growth Equity Fund II, L.P. and Casdin Partners Master Fund, L.P. (together, &#8220;Casdin&#8221;), and Viking Global Opportunities Illiquid Investments Sub-Master LP and Viking Global Opportunities Drawdown (Aggregator) LP (together, &#8220;Viking&#8221; and, collectively with Casdin, the &#8220;Purchasers&#8221;), pursuant to which the Purchasers have certain customary registration rights with respect to any shares of Standard BioTools Common Stock or other securities issued or issuable with respect to such shares (i) held by a Purchaser as of the date of the Exchange Agreement and (ii) acquired by the Purchasers pursuant to the Exchange Agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Following the closing of the merger with SomaLogic, Inc. (&#8220;SomaLogic&#8221;) on January&#160;5, 2024, Standard BioTools assumed certain registration rights previously granted by SomaLogic, including (i) those certain resale registration and piggyback registration obligations under that certain Amended and Restated Registration Rights Agreement, dated as of September&#160;1, 2021 and (ii) those certain registration obligations under that certain Agreement and Plan of Merger, dated as of July&#160;25, 2022, by and among SomaLogic, Panther Merger Subsidiary I, LLC, Panther Merger Subsidiary II, LLC, Palamedrix Inc., and Shareholders Representative Services, LLC, as the securityholder representative. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Anti-Takeover Effects of Delaware Law and the Standard BioTools Certificate of Incorporation and Bylaws </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Certain provisions of Delaware law and the Standard BioTools Charter and Standard BioTools Bylaws contain provisions that could have the effect of delaying, deferring or discouraging another party from acquiring control of Standard BioTools. These provisions, which are summarized below, are expected to discourage certain types of coercive takeover practices and inadequate takeover bids. These provisions are also designed in part to encourage anyone seeking to acquire control of Standard BioTools to first negotiate with the Standard BioTools Board. We believe that the advantages gained by protecting the ability to negotiate with any unsolicited and potentially unfriendly acquirer outweigh the disadvantages of discouraging such proposals, including those priced above the then-current market value of the Standard BioTools Common Stock, because, among other reasons, the negotiation of such proposals could improve their terms. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Certificate of Incorporation and Bylaws </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Standard BioTools Charter and Bylaws include provisions that: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">authorize the Standard BioTools Board to issue, without further action by the stockholders, additional shares of undesignated preferred stock; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">require that any action to be taken by the stockholders be effected at a duly called annual or special meeting and not by written consent; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">specify that special meetings of the stockholders can be called only by the Standard BioTools Board, the Chairperson of the Standard BioTools Board, the Secretary, the Chief Executive Officer or the President; </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">309<br></div></div></div>
<!--End Page 320-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 321-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_125-description_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">establish an advance notice procedure for stockholder proposals to be brought before an annual meeting of the stockholders and an advance notice procedure for nominations of persons for election to the Standard BioTools Board at any stockholder meeting; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">provide that directors may be removed only for cause; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">provide that (i) vacancies on the Standard BioTools Board resulting from one or more director resignations from the Standard BioTools Board may be filled by a majority of directors then in office, including those who have so resigned, and (ii) vacancies on the Standard BioTools Board resulting from any increase in the authorized number of directors elected by all of the stockholders having the right to vote as a single class may be filled only by a majority of the directors then in office, even though less than a quorum, or by a sole remaining director; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">subject to the rights of holders of any outstanding Preferred Stock, establish that the Standard BioTools Board is divided into three classes, Class&#160;I, Class&#160;II, and Class&#160;III, with each class serving staggered terms; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">specify that no stockholder is permitted to cumulate votes at any election of the Standard BioTools Board; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">require the affirmative vote of a majority of the Standard BioTools Board and at least 66 2&#8725;3% of the total voting power of outstanding voting securities, voting together as a single class, to amend the above-mentioned provisions. </div></td></tr></table><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Delaware Anti-Takeover Statute </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Standard BioTools is subject to the provisions of Section&#160;203 of the Delaware General Corporation Law regulating corporate takeovers (&#8220;Section&#160;203&#8221;). In general, Section&#160;203 prohibits a publicly-held Delaware corporation from engaging, under certain circumstances, in a business combination with an interested stockholder for a period of three years following the date the person became an interested stockholder unless: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, but not for determining the outstanding voting stock owned by the interested stockholder, (i) voting stock owned by persons who are directors and also officers, and (ii) voting stock owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">at or subsequent to the date of the transaction, the business combination is approved by the board of directors of the corporation and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 2&#8725;3% of the outstanding voting stock which is not owned by the interested stockholder. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Generally, a business combination includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. An interested stockholder is a person who, together with its affiliates and associates, owns, or is an affiliate or associate of the corporation and within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation&#8217;s outstanding voting stock. We expect the existence of this provision to have an anti-takeover effect with respect to transactions the Standard BioTools Board does not approve in advance. We also anticipate that Section&#160;203 may discourage business combinations or other attempts that might result in a premium over the market price for the shares of Standard BioTools Common Stock held by the stockholders. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The provisions of Delaware law and the Standard BioTools Charter and Bylaws could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of the Standard BioTools Common Stock that often result from actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing changes in the Standard BioTools management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interests. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">310<br></div></div></div>
<!--End Page 321-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 322-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_125-description_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Choice of Forum </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Standard BioTools Bylaws provide that, unless Standard BioTools consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, another State court in Delaware or the federal district court for the District of Delaware) shall, to the fullest extent permitted by law, be the sole and exclusive forum for (a) any derivative action or proceeding brought on behalf of the corporation, (b) any action asserting a claim of breach of a fiduciary duty owed by any director, stockholder, officer or other employee of the corporation to the corporation or the corporation&#8217;s stockholders, (c) any action arising pursuant to any provision of the DGCL or the certificate of incorporation or these bylaws (as either may be amended from time to time) or (d) any action asserting a claim governed by the internal affairs doctrine, except for, as to each of (a) through (d) above, any claim as to which such court determines that there is an indispensable party not subject to the jurisdiction of such court (and the indispensable party does not consent to the personal jurisdiction of such court within 10 days following such determination), which is vested in the exclusive jurisdiction of a court or forum other than such court or for which such court does not have subject matter jurisdiction. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Standard BioTools Bylaws also provide that unless Standard BioTools consents in writing to the selection of an alternative forum, the federal district courts of the United States of America shall be the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act, against any person in connection with any offering of the corporation&#8217;s securities, including, without limitation and for the avoidance of doubt, any auditor, underwriter, expert, control person or other defendant. For the avoidance of doubt, the choice of forum provision does not apply to any action brought to enforce a duty or liability created by the Exchange Act or any successor thereto. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For the avoidance of doubt, this provision is intended to benefit and may be enforced by Standard BioTools, its officers and directors, the underwriters to any offering giving rise to such complaint, and any other professional entity whose profession gives authority to a statement made by that person or entity and who has prepared or certified any part of the documents underlying the offering. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions, and there can be no assurance that such provisions will be enforced by a court in those other jurisdictions. Any person or entity purchasing or otherwise acquiring any interest in Standard BioTools&#8217; securities shall be deemed to have notice of and consented to these forum provisions. These forum provisions may impose additional costs on stockholders, may limit Standard BioTools&#8217; stockholders&#8217; ability to bring a claim in a forum they find favorable, and the designated courts may reach different judgments or results than other courts. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Transfer Agent and Registrar </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The transfer agent and registrar for the Standard BioTools Common Stock is Computershare Trust Company, N.A. The transfer agent&#8217;s address is 462 South 4th Street, Suite 1600, Louisville, KY 40202, and its telephone number is (800) 662-7232 or (781) 575&#173;2879. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Nasdaq Global Select Market Listing </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Standard BioTools Common Stock is traded on The Nasdaq Global Select Market under the trading symbol &#8220;LAB.&#8221; Upon the consummation of the Merger, it is expected that the Standard BioTools Common Stock will be traded on Nasdaq under the trading symbol &#8220;TRLN,&#8221; subject to official notice of issuance. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">311<br></div></div></div>
<!--End Page 322-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 323-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_126-comparison_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tCSR"><!--Anchor--></a>COMPARISON OF STOCKHOLDER RIGHTS </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The rights of Standard BioTools stockholders are governed by the Standard BioTools Charter, the Standard BioTools Bylaws, and the DGCL. The rights of Treeline stockholders are governed by the Treeline Charter and the Treeline Bylaws, as well as the DGCL. Upon consummation of the Merger, the rights of the Treeline stockholders will be governed by the Standard BioTools Charter, as amended, and the Standard BioTools Bylaws, each of which are filed as exhibits to the registration statement to which this proxy statement/prospectus relates, as well as the DGCL. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following is a summary discussion of the material differences, as of the date of this proxy statement/prospectus, between the current rights of Treeline stockholders and the current rights of Standard BioTools stockholders. The following description does not purport to be a complete statement of all the differences, or a complete description of the specific provisions referred to in this summary. The identification of specific differences is not intended to indicate that other equally or more significant differences do not exist. Stockholders should read carefully the relevant provisions of the DGCL, the Standard BioTools Charter, the Standard BioTools Bylaws, the Treeline Charter and the Treeline Bylaws. Standard BioTools has filed with the SEC its governing documents referenced in this summary of stockholder rights and will send copies to you without charge, upon your request. See <font style="font-style: italic;">&#8220;Where You Can Find More Information&#8221; </font>beginning on page <a href="#tWYC">335</a> of this proxy statement/prospectus. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 108pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 168pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 168pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 108pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Rights of Standard BioTools Stockholders</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Rights of Treeline Stockholders </div></td></tr><tr><td style="width: 108pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Authorized Capital</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The authorized capital stock of Standard BioTools consists of 600,000,000 shares of common stock, $0.001 par value per share, and 10,000,000 shares of preferred stock, $0.001 par value per share.</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The authorized capital stock of Treeline consists of 222,260,000 shares of common stock, $0.00001 par value per share, and 174,566,382 shares of preferred stock, $0.00001 par value per share. The preferred stock is designated as 64,723,570 shares of Series&#160;A Preferred Stock, 80,110,993 shares of Series&#160;A-1 Preferred Stock and 29,731,819 shares of Series&#160;A-2 Preferred Stock.</div></td></tr><tr><td style="width: 108pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 108pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Outstanding Capital Stock</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">As of the Record Date, Standard BioTools had &#8195;&#8195;&#8195;&#8195; shares of Standard BioTools Common Stock issued and outstanding and no shares of Standard BioTools Preferred Stock issued and outstanding.</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">As of the Record Date, Treeline had &#8195;&#8195;&#8195;&#8195; shares of Treeline Common Stock issued and outstanding, &#8195;&#8195;&#8195;&#8195;&#8194; shares of Series&#160;A Preferred Stock issued and outstanding,&#8195;&#8195;&#8195;&#8195;&#8194; shares of Series&#160;A-1 Preferred Stock issued and outstanding and &#8195;&#8195;&#8195;&#8195; shares of Series&#160;A-2 Preferred Stock issued and outstanding.</div></td></tr><tr><td style="width: 108pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 108pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Rights of Common Stock</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Each holder of a share of Standard BioTools Common Stock is entitled to one vote for each such share held of record on the applicable record date on each matter voted on at a meeting of stockholders.</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Each holder of shares of Treeline Common Stock is entitled to one vote for each share of Treeline Common Stock held at all meetings of stockholders.</div></td></tr><tr><td style="width: 108pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 108pt; padding-top: 0.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Rights of Preferred Stock</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 0.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Under the Standard BioTools Charter, the Standard BioTools Board, subject to limitations prescribed by law, may fix by resolution the designations, powers, preferences and rights, and the qualifications, limitations or restrictions thereof, of any wholly unissued series of Standard BioTools Preferred Stock, including, without limitation, authority to</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 0.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The Treeline Charter sets forth the rights, preferences and privileges of Treeline Preferred Stock, including, without limitation, the dividend rights, conversion rights, voting rights, liquidation preferences and protective rights of Treeline Preferred Stock. Treeline Preferred Stock is not redeemable at the option of the preferred holders. </div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 108pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 168pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 168pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">312<br></div></div></div>
<!--End Page 323-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 324-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_126-comparison_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="margin-top: 4pt; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 108pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 168pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 168pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 108pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Rights of Standard BioTools Stockholders</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Rights of Treeline Stockholders </div></td></tr><tr><td style="width: 108pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">fix by resolution the dividend rights, dividend rate, conversion rights, voting rights, rights and terms of redemption (including sinking fund provisions), redemption price or prices, and liquidation preferences of any such series of Preferred Stock, and the number of shares constituting any such series and the designation thereof, or any of the foregoing.</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 108pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 108pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Preferred Voting</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">N/A</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The Treeline Charter provides that, on matters presented to Treeline stockholders, each holder of Treeline Preferred Stock is entitled to cast the number of votes equal to the number of whole shares of Treeline Common Stock into which the holder&#8217;s Treeline Preferred Stock is convertible as of the record date, voting together with the Treeline Common Stock as a single class on an as-converted basis, except as provided by law or the Treeline Charter. </div></td></tr><tr><td style="width: 108pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 108pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Number of Directors</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The Standard BioTools Charter provides that the number of directors that constitutes the entire Standard BioTools Board shall be determined in the manner set forth in the Standard BioTools Bylaws. The Standard BioTools Bylaws provide that the Standard BioTools Board shall consist of one or more members, and unless the Standard BioTools Charter fixes the number of directors, the total number of directors constituting the Standard BioTools Board is to be determined by resolution of the Standard BioTools Board and no reduction of the authorized number of directors should have the effect of removing any director before that director&#8217;s term of office expires. The Standard BioTools Board currently has seven directors.</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The Treeline Charter provides that, subject to any additional vote required by the Treeline Charter, the number of directors of Treeline shall be determined in the manner set forth in the Treeline Bylaws. The Treeline Bylaws provide that the Treeline Board shall consist of one or more members and that, after the initial number of one director, unless otherwise required by law or the Treeline Charter, the number of directors shall be fixed from time to time by resolution of a majority of the total number of authorized directors or by stockholders holding at least a majority of the voting power of Treeline&#8217;s outstanding stock then entitled to vote at an election of directors.<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195;<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The Treeline Bylaws provide that no decrease in the authorized number of directors constituting the Treeline Board shall shorten the term of any incumbent director. The Treeline Charter also provides that each director is entitled to one vote on each matter presented to the Treeline Board. The Treeline Board currently has ten directors. </div></td></tr><tr><td style="width: 108pt; padding-top: 0.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 0.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 0.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 108pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 168pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 168pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">313<br></div></div></div>
<!--End Page 324-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 325-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_126-comparison_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="margin-top: 4pt; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 108pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 168pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 168pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 108pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Rights of Standard BioTools Stockholders</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Rights of Treeline Stockholders </div></td></tr><tr><td style="width: 108pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Election of Directors</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The Standard BioTools Charter provides that, other than any directors who may be elected by holders of Standard BioTools Preferred Stock under specified circumstances, Standard BioTools directors shall be divided into three classes as nearly equal in size as is practicable. At each annual meeting of stockholders, directors of the Standard BioTools Board shall be elected for a full term of three years to succeed the directors of the class whose terms expire at such annual meeting. If the number of directors is changed, any newly created directorships or decrease in directorships shall be apportioned among the classes as to make all classes as nearly equal in number as is practicable, provided that no decrease in the number of directors constituting the Standard BioTools Board shall shorten the term of any incumbent director.</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The Treeline Charter provides that, for so long as at least 28,783,593 shares of Treeline Preferred Stock remain outstanding, the holders of Series&#160;A Preferred Stock and Series&#160;A-1 Preferred Stock, exclusively and as a separate class, are entitled to elect seven Preferred Directors (as defined in the Treeline Charter); the holders of Treeline Common Stock, exclusively and as a separate class, are entitled to elect two Common Directors; and the holders of Treeline Common Stock, Series&#160;A Preferred Stock and Series&#160;A-1 Preferred Stock, voting together as a single class on an as-converted basis, are entitled to elect any remaining directors.<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195;<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Holders of Series&#160;A-2 Preferred Stock have no right to vote those shares, separately or together with any other class or series, for the election or removal of Treeline directors. </div></td></tr><tr><td style="width: 108pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 108pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Removal of Directors</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The Standard BioTools Charter provides that any director or the entire Standard BioTools Board may be removed from office at any time, but only for cause, and only by the affirmative vote of the holders of at least a majority of the voting power of the issued and outstanding capital stock of Standard BioTools entitled to vote in the election of directors.</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The Treeline Bylaws provide that, except as provided by the Treeline Charter or applicable law, any director or the entire Treeline Board may be removed, with or without cause, by the holders of a majority of the shares then entitled to vote at an election of directors.<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195;<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Holders of Series&#160;A-2 Preferred Stock have no right to vote those shares, separately or together with any other class or series, for the election or removal of Treeline directors.</div></td></tr><tr><td style="width: 108pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 108pt; padding-top: 0.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Vacancies on the Board</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 0.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The Standard BioTools Charter provides that vacancies and newly created directorships on the Standard BioTools Board shall be filled only by the affirmative vote of a majority of the remaining directors then in office, even though less than a quorum, or by a sole remaining director, and not by the stockholders. A person so elected by the Standard BioTools Board to fill a vacancy or newly created directorship shall hold office until the next election of the class for which that director shall have been chosen until his or her successor shall have been duly elected and qualified, or until such director&#8217;s</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 0.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The Treeline Charter provides that a vacancy in the office of a Remaining Director may be filled by the stockholders entitled to elect that director or by a majority of the Board then in office, although less than a quorum, or by a sole remaining director. A vacancy in the office of a Common Director may be filled by the stockholders entitled to elect that director or by at least a majority of the Common Directors then in office, although less than a quorum, or by a sole Common Director. If the holders of Series&#160;A Preferred Stock and Series&#160;A-1 Preferred Stock fail to elect a sufficient number of Preferred Directors, the </div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 108pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 168pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 168pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">314<br></div></div></div>
<!--End Page 325-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 326-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_126-comparison_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="margin-top: 4pt; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 108pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 168pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 168pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 108pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Rights of Standard BioTools Stockholders</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Rights of Treeline Stockholders </div></td></tr><tr><td style="width: 108pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">earlier death, resignation, or removal. No decrease in the number of directors constituting the Standard BioTools Board shall shorten the term of any incumbent director.</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">unfilled Preferred Director positions remain vacant until filled by those holders, and no other stockholders may fill them.<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195;<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The Treeline Bylaws provide that, unless otherwise provided by the Treeline Charter, each director holds office until the next annual meeting of stockholders and until such director&#8217;s successor is duly elected and qualified, or until such director&#8217;s earlier death, resignation or removal. </div></td></tr><tr><td style="width: 108pt; padding-top: 0.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Advance Notice Requirements for Stockholder Nominations and Other&#160;Proposals</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 0.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The Standard BioTools Charter provides that advance notice of stockholder nominations for the election of directors and of business to be brought by stockholders before any meeting of the stockholders shall be given in the manner and to the extent provided in the Standard BioTools Bylaws.<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195;<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The Standard BioTools Bylaws provide that nominations and other proposals shall be made at an annual meeting of stockholders only (A) by or at the direction of the Standard BioTools Board or (B) by a stockholder of Standard BioTools who (1) was a stockholder of record at the time of the giving of the notice required and entitled to vote at the annual meeting and (2) has complied with the notice procedures. In addition to any other applicable requirements, the stockholder must have given timely notice of the nomination thereof in proper written form to Standard BioTools&#8217; Secretary containing certain information and must be received by the Secretary at the principal executive offices of Standard BioTools not later than the 45th day nor earlier than the 75th day before the one-year anniversary of the date on which Standard BioTools first mailed its proxy materials or a notice of availability of proxy materials (whichever is earlier) for the preceding year&#8217;s annual meeting; <font style="font-style: italic;">provided, however</font>, that in the event that no annual meeting was held in the previous year or if the date of the annual meeting is advanced by more than 30 days prior to or delayed by more than 60 days after the one-year anniversary of the date of the previous year&#8217;s annual</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 0.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 108pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 168pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 168pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">315<br></div></div></div>
<!--End Page 326-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 327-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_126-comparison_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="margin-top: 4pt; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 108pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 168pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 168pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 108pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Rights of Standard BioTools Stockholders</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Rights of Treeline Stockholders </div></td></tr><tr><td style="width: 108pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">meeting, then, for notice by the stockholder to be timely, it must be so received by the Secretary not earlier than the close of business on the 120th day prior to such annual meeting and not later than the close of business on the later of (i) the 90th day prior to such annual meeting, or (ii) the tenth day following the day on which public announcement of the date of such annual meeting is first made.</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 108pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 108pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Notice of Special Meeting</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The Standard BioTools Bylaws provide that whenever stockholders are required or permitted to take any action at a meeting, a written notice of the meeting shall be given which shall state the place, if any, date and hour of the meeting, the means of remote communications, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at such meeting, the record date for determining the stockholders entitled to vote at the meeting, if such date is different from the record date for determining stockholders entitled to notice of the meeting, and, in the case of a special meeting, the purpose or purposes for which the meeting is called. The written notice of any meeting of stockholders shall be given not less than 10 days nor more than 60 days before the date of the meeting to each stockholder entitled to vote at such meeting as of the record date for determining the stockholders entitled to notice of the meeting.</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The Treeline Bylaws provide that notice of all stockholder meetings shall be given in writing or by electronic transmission in the manner provided by law, stating the date, time and place, if any, of the meeting and, in the case of a special meeting, the purpose or purposes for which the meeting is called. Unless otherwise required by applicable law or the Treeline Charter, the notice must be given not less than 10 nor more than 60&#160;days before the meeting to each stockholder of record entitled to vote at the meeting.</div></td></tr><tr><td style="width: 108pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 108pt; padding-top: 0.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amendments to the Charter</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 0.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Under the DGCL, an amendment to the certificate of incorporation generally requires (1) the approval of the board of directors, (2) the approval of a majority of the outstanding stock entitled to vote upon the proposed amendment and (3)&#160;the approval of the holders of a majority of the outstanding stock of each class entitled to vote thereon as a class, provided that, in the case of an amendment to effect a reverse stock split or subdivision of shares or to otherwise increase or decrease the number of authorized shares of a class, such amendment may (except to the extent provided otherwise by the certificate of</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 0.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Under the DGCL, an amendment to the certificate of incorporation generally requires (1) the approval of the board of directors, (2) the approval of a majority of the outstanding stock entitled to vote upon the proposed amendment and (3)&#160;the approval of the holders of a majority of the outstanding stock of each class entitled to vote thereon as a class, provided that, in the case of an amendment to effect a reverse stock split or subdivision of shares or to otherwise increase or decrease the number of authorized shares of a class, such amendment may (except to the extent provided otherwise by the certificate of </div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 108pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 168pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 168pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">316<br></div></div></div>
<!--End Page 327-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 328-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_126-comparison_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="margin-top: 4pt; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 108pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 168pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 168pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 108pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Rights of Standard BioTools Stockholders</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Rights of Treeline Stockholders </div></td></tr><tr><td style="width: 108pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">incorporation) be approved by a majority of the votes cast, subject to certain exceptions. The Standard BioTools Charter provides that, except as otherwise required by law, holders of Standard BioTools Common Stock shall not be entitled to vote on any amendment to the Standard BioTools Charter (including any certificate of designation filed with respect to any series of preferred stock) that relates solely to the terms of one or more outstanding series of preferred stock if the holders of such affected series are entitled, either separately or together as a class with the holders of one or more other such series, to vote thereon by law or pursuant to the Standard BioTools Charter (including any certificate of designation filed with respect to any series of preferred stock).<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195;<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Standard BioTools reserves the right to amend or repeal any provision contained in the Standard BioTools Charter in the manner prescribed by the laws of the State of Delaware and all rights conferred upon stockholders are granted subject to this reservation; <font style="font-style: italic;">provided, however</font>, that notwithstanding any other provision of the Standard BioTools Charter or any provision of law that might otherwise permit a lesser vote or no vote, the Standard BioTools Board acting pursuant to a resolution adopted by a majority of the Standard BioTools Board and the affirmative vote of sixty-six and two-thirds percent (66 2&#8725;3%) of the then outstanding voting securities of Standard BioTools, voting together as a single class, shall be required for the amendment, repeal or modification of certain provisions.</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">incorporation) be approved by a majority of the votes cast, subject to certain exceptions. The Treeline Charter provides that the number of authorized shares of Treeline Common Stock may be increased or decreased, but not below the number of shares then outstanding, by the affirmative vote of the holders of a majority of the votes represented by all outstanding shares of Treeline capital stock entitled to vote, without a separate class vote of the holders of Treeline Common Stock, in addition to any vote of the holders of one or more series of Treeline Preferred Stock that may be required by the Treeline Charter.<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195;<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">At any time when at least 34,585,587 shares of Treeline Preferred Stock are outstanding, Treeline may not amend, alter or repeal any provision of the Treeline Charter or Treeline Bylaws in a manner that adversely affects the powers, preferences or rights of Treeline Preferred Stock or any series thereof without the written consent or affirmative vote of the Requisite Holders (as defined in the Treeline Charter), in addition to any other vote required by law or the Treeline Charter. The Treeline Charter also requires the affirmative vote of the holders of a majority of the shares of Treeline Preferred Stock then outstanding to amend or repeal, or adopt any provision inconsistent with, Treeline&#8217;s corporate opportunity provision in Article&#160;XII of the Treeline Charter. </div></td></tr><tr><td style="width: 108pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 108pt; padding-top: 0.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amendments to Bylaws</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 0.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The Standard BioTools Charter provides that the Standard BioTools Board is expressly authorized to adopt, alter, amend or repeal the Standard BioTools Bylaws. The affirmative vote of at least a majority of the Standard BioTools Board then in office shall be required to adopt, amend, alter or repeal the Standard BioTools Bylaws. The Standard BioTools Bylaws may also be adopted, amended, altered or repealed by the stockholders of</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 0.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The Treeline Charter provides that, subject to any additional vote required by the Treeline Charter or the Treeline Bylaws, the Treeline Board is expressly authorized to make, repeal, alter, amend and rescind any or all of the Treeline Bylaws. The Treeline Bylaws provide that, unless otherwise required by the Treeline Charter, Treeline stockholders holding at least a majority of the voting power of Treeline&#8217;s outstanding voting stock then entitled to vote at an </div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 108pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 168pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 168pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">317<br></div></div></div>
<!--End Page 328-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 329-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_126-comparison_pg7"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="margin-top: 4pt; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 108pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 168pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 168pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 108pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Rights of Standard BioTools Stockholders</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Rights of Treeline Stockholders </div></td></tr><tr><td style="width: 108pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Standard BioTools. Notwithstanding any provisions of the Standard BioTools Bylaws, the Standard BioTools Bylaws may not be amended, altered or repealed except in accordance with related provisions in the Standard BioTools Bylaws.<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195;<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The Standard BioTools Bylaws provide that the Standard BioTools Bylaws may be adopted, amended or repealed by the stockholders entitled to vote; <font style="font-style: italic;">provided, however</font>, that the affirmative vote of the holders of at least 66 2&#8725;3% of the total voting power of outstanding voting securities, voting together as a single class, shall be required for the stockholders of Standard BioTools to alter, amend or repeal, or adopt any bylaw inconsistent with certain provisions of the Standard BioTools Bylaws. The Standard BioTools Board shall also have the power to adopt, amend or repeal the Standard BioTools Bylaws; <font style="font-style: italic;">provided, however</font>, that a bylaw amendment adopted by stockholders which specifies the votes that shall be necessary for the election of directors shall not be further amended or repealed by the Standard BioTools Board.</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">election of directors have the power to adopt, amend or repeal the Treeline Bylaws, and that, to the extent provided in the Treeline Charter, the Treeline Board also has the power to adopt, amend or repeal the Treeline Bylaws. </div></td></tr><tr><td style="width: 108pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 108pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Special Meeting of Stockholders</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The Standard BioTools Charter provides that special meetings of stockholders may be called only by the Standard BioTools Board, the Chairperson of the Standard BioTools Board, the Chief Executive Officer or the President (in the absence of a chief executive officer), and any power of stockholders to call a special meeting of stockholders is specifically denied.</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The Treeline Bylaws provide that special meetings of stockholders for any purpose or purposes may be called at any time by the Chairperson of the Board, the Chief Executive Officer, the President, the holders of shares of Treeline entitled to cast not less than 10% of the total number of votes entitled to be cast by all stockholders at the meeting, or by a majority of the Whole Board, and may not be called by any other person or persons. If a special meeting is called by any person or persons other than a majority of the Board, those persons must deliver a written request to call the meeting to each Board member, and the Board then determines a time and date for the meeting that is not more than 120 days nor less than 35 days after the request is delivered to each Board member. </div></td></tr><tr><td style="width: 108pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 108pt; padding-top: 0.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Forum Selection</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 0.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The Standard BioTools Bylaws provide that, unless Standard BioTools consents in writing to the selection of an alternative forum, the Court of Chancery of the State</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 0.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The Treeline Charter provides that, unless Treeline consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall, to </div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 108pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 168pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 168pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">318<br></div></div></div>
<!--End Page 329-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 330-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_126-comparison_pg8"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="margin-top: 4pt; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 108pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 168pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 168pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 108pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Rights of Standard BioTools Stockholders</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Rights of Treeline Stockholders </div></td></tr><tr><td style="width: 108pt; padding-top: 1.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 1.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">of Delaware (or, if the Court of Chancery does not have jurisdiction, another State court in Delaware or the federal district court for the District of Delaware) shall, to the fullest extent permitted by law, be the sole and exclusive forum for (a) any derivative action or proceeding brought on behalf of Standard BioTools, (b) any action asserting a claim of breach of a fiduciary duty owed by any director, stockholder, officer or other employee of Standard BioTools to the stockholders of Standard BioTools, (c) any action arising pursuant to any provision of the DGCL or the Standard BioTools charter or bylaws (as either may be amended from time to time) or (d) any action asserting a claim governed by the internal affairs doctrine, except for, as to each of (a) through (d) above, any claim as to which such court determines that there is an indispensable party not subject to the jurisdiction of such court (and the indispensable party does not consent to the personal jurisdiction of such court within 10 days following such determination), which is vested in the exclusive jurisdiction of a court or forum other than such court or for which such court does not have subject matter jurisdiction.<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195;<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Unless Standard BioTools consents in writing to the selection of an alternative forum, the federal district courts of the United States of America shall be the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933, as amended, against any person in connection with any offering of the corporation&#8217;s securities, including, without limitation and for the avoidance of doubt, any auditor, underwriter, expert, control person or other defendant.</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 168pt; padding-top: 1.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">the fullest extent permitted by law, be the sole and exclusive forum for derivative actions brought on behalf of Treeline, fiduciary duty claims owed by current or former directors, officers, employees or stockholders to Treeline or its stockholders, claims arising under the DGCL, the Treeline Charter or Treeline Bylaws, claims as to which the DGCL confers jurisdiction on the Court of Chancery, claims to interpret, apply, enforce or determine the validity of the Treeline Charter or Treeline Bylaws, and claims governed by the internal affairs doctrine. The Treeline Bylaws separately provide that, unless Treeline consents in writing to the selection of an alternative forum, to the fullest extent permitted by law, the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause of action under the Securities Act of 1933, as amended, and related SEC rules and regulations.</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 108pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 168pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 168pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">319<br></div></div></div>
<!--End Page 330-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 331-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_127-security_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tSEC"><!--Anchor--></a>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">AND MANAGEMENT OF STANDARD BIOTOOLS </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following table sets forth information known to Standard BioTools regarding the beneficial ownership of Standard BioTools Common Stock as of June&#160;3, 2026 by each person known to Standard BioTools to be: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the beneficial owner of more than 5% of the outstanding Standard BioTools Common Stock; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">each of Standard BioTools&#8217; named executive officers and directors; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">all of Standard BioTools&#8217; executive officers and directors as a group. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Beneficial ownership is determined according to the rules of the SEC, which generally provide that a person has beneficial ownership of a security if he, she, or it possesses sole or shared voting or investment power over that security, including options and warrants that are currently exercisable or exercisable within 60 days and RSUs that vest within 60 days. Shares of common stock issuable upon exercise of options and warrants currently exercisable within 60 days and RSUs that vest within 60 days are deemed outstanding solely for purposes of calculating the percentage of total ownership and total voting power of the beneficial owner thereof. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The beneficial ownership of Standard BioTools Common Stock is based on 391,462,923 shares of Standard BioTools Common Stock issued and outstanding as of June&#160;3, 2026, and the percentages of Standard BioTools Common Stock beneficially owned were calculated using these respective numbers as the denominators and as specified in this paragraph and in the footnotes below. Unless otherwise indicated, Standard BioTools believes that each person named in the table below has sole voting and investment power with respect to all shares of the Standard BioTools Common Stock beneficially owned by them. Unless otherwise indicated, the business address of each of the following entities or individuals is c/o Standard BioTools Inc., 50 Milk Street, 10th Floor, Boston, MA&#160;02109. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 312pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 8.77pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 8.77pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 52.65pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 8.77pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 8.77pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 68.26pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 312pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name of Beneficial Owner</div></td><td style="width: 8.77pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.77pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.65pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Common Stock <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Beneficially <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Owned</div></td><td style="width: 8.77pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.77pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 68.26pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Percent of Common <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Stock Beneficially <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Owned </div></td></tr><tr><td style="width: 312pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">5% Stockholders<br></div></td><td style="width: 8.77pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.77pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.65pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 8.77pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.77pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 68.26pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Entities affiliated with Casdin Capital, LLC<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup><font style="padding-left: 0.97pt;"></font></div></td><td style="width: 8.77pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.77pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.65pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.51pt; text-align: left;"><font style="padding-left: 4.63pt;">88,783,856</font></div></td><td style="width: 8.77pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.77pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 68.26pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.88pt; text-align: left;">22.68% </div></td></tr><tr><td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Entities affiliated with Viking Global Investors LP<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup><font style="padding-left: 3.98pt;"></font></div></td><td style="width: 8.77pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.77pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.65pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.51pt; text-align: left;"><font style="padding-left: 4.63pt;">58,651,170</font></div></td><td style="width: 8.77pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.77pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 68.26pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.88pt; text-align: left;">14.98% </div></td></tr><tr><td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">BlackRock, Inc.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup><font style="padding-left: 1.05pt;"></font></div></td><td style="width: 8.77pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.77pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.65pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.51pt; text-align: left;"><font style="padding-left: 5pt;">22,452,115</font></div></td><td style="width: 8.77pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.77pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 68.26pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.88pt; text-align: left;"><font style="padding-left: 5pt;">5.74% </font></div></td></tr><tr><td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Entities affiliated with MAK Capital Fund LP<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(4)</sup><font style="padding-left: 2.08pt;"></font></div></td><td style="width: 8.77pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.77pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.65pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.51pt; text-align: left;"><font style="padding-left: 4.63pt;">26,172,626</font></div></td><td style="width: 8.77pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.77pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 68.26pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.88pt; text-align: left;"><font style="padding-left: 5pt;">6.69% </font></div></td></tr><tr><td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Directors and Named Executive Officers<br></div></td><td style="width: 8.77pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.77pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.65pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 8.77pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.77pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 68.26pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Thomas Carey<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(5)</sup><font style="padding-left: 2.16pt;"></font></div></td><td style="width: 8.77pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.77pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.65pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.51pt; text-align: left;"><font style="padding-left: 17.13pt;">679,404</font></div></td><td style="width: 8.77pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.77pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 68.26pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.88pt; text-align: left;"><font style="padding-left: 22.5pt;">* </font></div></td></tr><tr><td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Eli Casdin<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(6)</sup><font style="padding-left: 3.82pt;"></font></div></td><td style="width: 8.77pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.77pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.65pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.51pt; text-align: left;"><font style="padding-left: 4.63pt;">93,819,283</font></div></td><td style="width: 8.77pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.77pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 68.26pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.88pt; text-align: left;">23.97% </div></td></tr><tr><td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Troy Cox<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(7)</sup><font style="padding-left: 2.5pt;"></font></div></td><td style="width: 8.77pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.77pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.65pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.51pt; text-align: left;"><font style="padding-left: 9.63pt;">1,943,036</font></div></td><td style="width: 8.77pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.77pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 68.26pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.88pt; text-align: left;"><font style="padding-left: 22.5pt;">* </font></div></td></tr><tr><td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Michael Egholm, Ph.D.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(8)</sup><font style="padding-left: 1.05pt;"></font></div></td><td style="width: 8.77pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.77pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.65pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.51pt; text-align: left;"><font style="padding-left: 9.63pt;">8,407,139</font></div></td><td style="width: 8.77pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.77pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 68.26pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.88pt; text-align: left;"><font style="padding-left: 5pt;">2.15% </font></div></td></tr><tr><td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Fenel M. Eloi<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(9)</sup><font style="padding-left: 0.49pt;"></font></div></td><td style="width: 8.77pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.77pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.65pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.51pt; text-align: left;"><font style="padding-left: 17.13pt;">451,414</font></div></td><td style="width: 8.77pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.77pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 68.26pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.88pt; text-align: left;"><font style="padding-left: 22.5pt;">* </font></div></td></tr><tr><td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Kathy Hibbs<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(10)</sup><font style="padding-left: 1.18pt;"></font></div></td><td style="width: 8.77pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.77pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.65pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.51pt; text-align: left;"><font style="padding-left: 17.13pt;">498,490</font></div></td><td style="width: 8.77pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.77pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 68.26pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.88pt; text-align: left;"><font style="padding-left: 22.5pt;">* </font></div></td></tr><tr><td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Alex Kim<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(11)</sup><font style="padding-left: 2.57pt;"></font></div></td><td style="width: 8.77pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.77pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.65pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.51pt; text-align: left;"><font style="padding-left: 9.63pt;">3,355,098</font></div></td><td style="width: 8.77pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.77pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 68.26pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.88pt; text-align: left;"><font style="padding-left: 22.5pt;">* </font></div></td></tr><tr><td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Sean Mackay<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(12)</sup><font style="padding-left: 2.86pt;"></font></div></td><td style="width: 8.77pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.77pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.65pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.51pt; text-align: left;"><font style="padding-left: 17.13pt;">728,100</font></div></td><td style="width: 8.77pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.77pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 68.26pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.88pt; text-align: left;"><font style="padding-left: 22.5pt;">* </font></div></td></tr><tr><td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Frank Witney, Ph.D.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(13)</sup><font style="padding-left: 0.19pt;"></font></div></td><td style="width: 8.77pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.77pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.65pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.51pt; text-align: left;"><font style="padding-left: 17.13pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">514,312</font></div></td><td style="width: 8.77pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.77pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 68.26pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.88pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"></font><font style="padding-bottom: 1.5pt;">* </font></div></td></tr><tr><td style="width: 312pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">All current directors and executive officers as a group (9 persons)<font style="font-weight: normal;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(14)</sup></font><font style="font-weight: normal; padding-left: 3.2pt;"></font></div></td><td style="width: 8.77pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.77pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.65pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.51pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">110,396,276</font></div></td><td style="width: 8.77pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.77pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 68.26pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.88pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">28.02</font><font style="padding-bottom: 0.5pt;">%</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 312pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 8.77pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 8.77pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 52.65pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 8.77pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 8.77pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 68.26pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div><div class="BRDSX_rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 13.25pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(*)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Less than one percent </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Consists of securities held by Casdin Partners Master Fund, L.P. (&#8220;Casdin Master Fund&#8221;), Casdin Private Growth Equity Fund II, L.P. (&#8220;Casdin Private Growth Fund II&#8221;), and Casdin Private Growth Equity Fund, L.P. (&#8220;Casdin Private Growth Fund&#8221;). Casdin Capital, LLC (&#8220;Casdin Capital&#8221;) is the investment adviser to Casdin Master Fund, Casdin Private Growth Fund II and Casdin Private Growth Fund, Casdin Partners GP, LLC (&#8220;Casdin Partners GP&#8221;) is the general partner of Casdin Master Fund, Casdin Private Growth Equity Fund II GP, LLC (&#8220;Casdin Private Growth GP II&#8221;) is the general partner of Casdin Private Growth Fund II, Casdin Private Growth Equity Fund GP, LLC (&#8220;Casdin Private Growth GP&#8221;) is the general partner of Casdin Private Growth Fund, and Eli Casdin is the managing member of Casdin Capital, Casdin Partners GP, Casdin Private Growth II GP and Casdin Private Growth GP. Represents shared voting and dispositive power held with respect to 72,100,000 shares of common stock held by Casdin Master Fund, 13,939,637 shares of common stock held by Casdin Private Growth Fund II, and 2,744,219 shares of common stock held by Casdin Private Growth Fund. Casdin Capital&#8217;s address is 1350 Avenue of the Americas, Suite 2600, New York, New York 10019. </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">320<br></div></div></div>
<!--End Page 331-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 332-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_127-security_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5.25pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(2)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">This information is based solely on a Schedule 13G/A filed jointly by Viking Global Investors LP (&#8220;VGI&#8221;), Viking Global Opportunities Parent GP LLC (&#8220;Opportunities Parent&#8221;), Viking Global Opportunities GP LLC (&#8220;Opportunities GP&#8221;), Viking Global Opportunities Portfolio GP LLC (&#8220;Opportunities Portfolio GP&#8221;), Viking Global Opportunities Illiquid Investments Sub-Master LP (the &#8220;Viking Hybrid Fund&#8221;), Viking Global Opportunities Drawdown GP LLC (&#8220;Drawdown GP&#8221;), Viking Global Opportunities Drawdown Portfolio GP LLC (&#8220;Drawdown Portfolio GP&#8221;), Viking Global Opportunities Drawdown (Aggregator) LP (the &#8220;Viking Drawdown Fund&#8221;), O. Andreas Halvorsen and Rose S. Shabet (collectively, &#8220;Viking Global Investors&#8221;), filed with the SEC on May&#160;15, 2026, which reported ownership as of March&#160;31, 2026. Represents (i) 39,296,310 shares of common stock held by Viking Hybrid Fund and (ii) 19,354,860 shares of common stock held by Viking Drawdown Fund. The Viking Hybrid Fund has the authority to dispose of and vote the shares directly owned by it, which power may be exercised by its general partner, Opportunities Portfolio GP, and by VGI, which provides managerial services to the Viking Hybrid Fund. O. Andreas Halvorsen and Rose Shabet, as Executive Committee members of Viking Global Partners LLC (the general partner of VGI) and Opportunities Parent (the sole member of Opportunities GP, which is the sole member of Opportunities Portfolio GP), have shared authority to direct the voting and disposition of investments beneficially owned by VGI and Opportunities Portfolio GP. The Viking Drawdown Fund has the authority to dispose of and vote the shares directly owned by it, which power may be exercised by its general partner, Drawdown Portfolio GP, and by VGI, which provides managerial services to the Viking Drawdown Fund. O. Andreas Halvorsen and Rose Shabet, as Executive Committee members of Viking Global Partners LLC (the general partner of VGI) and Opportunities Parent (the sole member of Drawdown GP, which is the sole member of Drawdown Portfolio GP), have shared authority to direct the voting and disposition of investments beneficially owned by VGI and Drawdown Portfolio GP. Viking Global Investors&#8217; address is c/o Viking Global Investors LP, 600 Washington Boulevard, Floor 11, Stamford, Connecticut 06901. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(3)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Based on information reported by BlackRock, Inc. on a Schedule 13G filed with the SEC on November&#160;8, 2024. Consists of shares of common stock held of record by BlackRock, Inc. The address of BlackRock, Inc. is 50 Hudson Yards, New York, New York 10001. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(4)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Based on information reported jointly by MAK Capital Fund LP (&#8220;MAK Fund&#8221;), MAK Capital One L.L.C. (&#8220;MAK Capital&#8221;), and Michael A. Kaufman on a Schedule 13G/A filed with the SEC on May&#160;15, 2026. The address of (i) MAK Fund is c/o Wakefield Quin, Victoria Place, 31 Victoria Street, Bermuda; and (ii) MAK Capital and Mr.&#160;Kaufman is 590 Madison Avenue, 31st Floor, New York, NY&#160;10022. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(5)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Consists of (i) 112,287 shares of common stock held by Mr.&#160;Carey, (ii) 459,705 shares of common stock underlying options that are exercisable as of June 3, 2026 or will become exercisable within 60 days after such date held by Mr.&#160;Carey, and (iii) 107,412 shares of common stock issuable upon vesting of RSUs within 60 days of June 3, 2026 held by Mr. Carey. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(6)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Includes (i) 72,100,000 shares of common stock held of record by Casdin Master Fund, (ii) 13,939,637 shares of common stock held by Casdin Private Growth Fund II, and (iii) 2,744,219 shares of common stock held of record by Casdin Private Growth Fund (see Footnote &#8206;(1) above). Mr.&#160;Casdin is the managing member of the general partners of Casdin Master Fund, Casdin Private Growth Fund II, and Casdin Private Growth Fund, and, as such, is deemed to have indirect beneficial ownership of such shares. Also includes (i) 2,819,718 shares of common stock held by Mr.&#160;Casdin, (ii) 443,313 shares of common stock underlying options that are exercisable as of June 3, 2026 or will become exercisable within 60 days after such date held by Mr.&#160;Casdin, (iii) 107,840 shares of common stock issuable upon vesting of RSUs within 60 days of June 3, 2026 held by Mr. Casdin and (iv) 1,664,556 shares of common stock issuable upon exercise of warrants which may be deemed to be beneficially owned by Mr.&#160;Casdin. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(7)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Consists of (i) 231,138 shares of common stock held by Mr.&#160;Cox, (ii) 1,417,991 shares of common stock underlying options that are exercisable as of June 3, 2026 or will become exercisable within 60 days after such date held by Mr.&#160;Cox, (iii) 108,908 shares of common stock issuable upon vesting of RSUs within 60 days of June 3, 2026 held by Mr. Cox and (iv) 184,999 shares of common stock issuable upon exercise of warrants held by Mr.&#160;Cox. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(8)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Consists of (i) 1,298,752 shares of common stock held by Dr.&#160;Egholm, (ii) 6,358,387 shares of common stock underlying options that are exercisable as of June 3, 2026 or will become exercisable within 60 days after such date held by Dr.&#160;Egholm, and (iii) 750,000 shares of common stock issuable upon vesting of RSUs within 60 days of June 3, 2026 held by Dr.&#160;Egholm. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(9)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Consists of (i) 123,569 shares of common stock held by Mr.&#160;Eloi, (ii) 233,253 shares of common stock underlying options that are exercisable as of June 3, 2026 or will become exercisable within 60 days after such date held by Mr.&#160;Eloi, and (iii) 94,592 shares of common stock issuable upon vesting of RSUs within 60 days of June 3, 2026 held by Mr. Eloi. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(10)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Consists of (i) 43,128 shares of common stock held by Ms.&#160;Hibbs, (ii) 360,770 shares of common stock underlying options that are exercisable as of June 3, 2026 or will become exercisable within 60 days after such date held by Ms.&#160;Hibbs, and (iii) 94,592 shares of common stock issuable upon vesting of RSUs within 60 days of June 3, 2026 held by Ms. Hibbs. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(11)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Consists of (i) 558,284 shares of common stock held by Mr.&#160;Kim, (ii) 2,196,814 shares of common stock underlying options that are exercisable as of June 3, 2026 or will become exercisable within 60 days after such date held by Mr.&#160;Kim, and (iii) 600,000 shares of common stock issuable upon vesting of RSUs within 60 days of June 3, 2026 held by Mr.&#160;Kim. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(12)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Consists of (i) 257,804 shares of common stock held by Mr.&#160;Mackay, and (ii) 470,296 shares of common stock underlying options that are exercisable as of June 3, 2026 or will become exercisable within 60 days after such date held by Mr.&#160;Mackay. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(13)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Consists of (i) 4,225 shares of common stock held by First Amended and Restated Revocable Trust Agreement For the Franklin R. Witney and Catherine J. Caulfield-Witney Trust Agreement Dated September 25, 2009 (dated July&#160;31, 2018), of which Dr.&#160;Witney is the trustee, (ii)&#160;116,270 shares of common stock held by Dr.&#160;Witney, (iii) 299,225 shares of common stock underlying options that are exercisable as of June 3, 2026 or will become exercisable within 60 days after such date held by Dr.&#160;Witney, and (iv) 94,592 shares of common stock issuable upon vesting of RSUs within 60 days of June 3, 2026 held by Dr. Witney. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(14)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">See footnotes (5) through (13) above. </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">321<br></div></div></div>
<!--End Page 332-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 333-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_127-security_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tSEO"><!--Anchor--></a>SECURITY OWNERSHIP OF CERTAIN <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">BENEFICIAL OWNERS AND MANAGEMENT OF TREELINE </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following table sets forth information with respect to the beneficial ownership of Treeline Capital Stock as of June&#160;1, 2026 for: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Each person, or group of affiliated persons, who beneficially owned more than 5% of Treeline&#8217;s outstanding shares of common stock; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Each current director of Treeline; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Each named executive officer of Treeline; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">All current executive officers and directors of Treeline as a group. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The number of shares beneficially owned by each stockholder is determined under rules of the SEC and includes voting or investment power with respect to securities. Under these rules, beneficial ownership includes any shares as to which the individual or entity has sole or shared voting power or investment power. In computing the number of shares beneficially owned by an individual or entity and the percentage ownership of that person, shares of Treeline Common Stock subject to options, warrants or other rights held by such person that are currently exercisable or will become exercisable within 60 days are considered outstanding, although these shares are not considered outstanding for purposes of computing the percentage ownership of any other person. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Beneficial ownership prior to the completion of the merger, as shown in the table below, is based on 171,472,795 shares of Treeline Common Stock outstanding as of June&#160;1, 2026, assuming the conversion of all outstanding shares of Treeline convertible preferred stock into an equal number of shares of Treeline Common Stock as of June&#160;1, 2026 and including an aggregate 5,377,111 shares of common stock underlying 5,377,111 common stock warrants. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Each of the stockholders listed has sole voting and investment power with respect to the shares beneficially owned by the stockholder unless noted otherwise, subject to community property laws where applicable. Unless otherwise indicated, the address of each beneficial owner listed in the table below is c/o Treeline Biosciences, Inc., 500 Arsenal St., Watertown, MA 02472. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: -2pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="margin-top: -2pt; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 312pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 10.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 10.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 61.91pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 10.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 10.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 52.65pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 312pt; padding-bottom: 1.63pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name of Beneficial Owner</div></td><td style="width: 10.36pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.36pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 61.91pt; padding-bottom: 1.63pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of Shares <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">of Treeline <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Common Stock <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Beneficially <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Owned</div></td><td style="width: 10.36pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.36pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.65pt; padding-bottom: 1.63pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">% of Treeline <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Common Stock <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Beneficially <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Owned </div></td></tr><tr><td style="width: 312pt; padding-top: 1.26pt; padding-bottom: 0.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Directors and Named Executive Officers:<br></div></td><td style="width: 10.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 61.91pt; padding-top: 1.26pt; padding-bottom: 0.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 10.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.65pt; padding-top: 1.26pt; padding-bottom: 0.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 312pt; padding-top: 0.26pt; padding-bottom: 0.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Joshua Bilenker, M.D.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup><font style="padding-left: 0.9pt;"></font></div></td><td style="width: 10.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 61.91pt; padding-top: 0.26pt; padding-bottom: 0.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.46pt; text-align: left;"><font style="padding-left: 0.37pt;">11,873,437 </font></div></td><td style="width: 10.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.65pt; padding-top: 0.26pt; padding-bottom: 0.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.08pt; text-align: left;"><font style="padding-left: 5pt;">6.92% </font></div></td></tr><tr><td style="width: 312pt; padding-top: 0.26pt; padding-bottom: 0.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Jeffrey Engelman, M.D., Ph.D.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup><font style="padding-left: 1.25pt;"></font></div></td><td style="width: 10.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 61.91pt; padding-top: 0.26pt; padding-bottom: 0.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.46pt; text-align: left;"><font style="padding-left: 5pt;">3,635,823</font></div></td><td style="width: 10.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.65pt; padding-top: 0.26pt; padding-bottom: 0.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.08pt; text-align: left;"><font style="padding-left: 5pt;">2.12% </font></div></td></tr><tr><td style="width: 312pt; padding-top: 0.26pt; padding-bottom: 0.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Spencer Smith<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup><font style="padding-left: 2.16pt;"></font></div></td><td style="width: 10.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 61.91pt; padding-top: 0.26pt; padding-bottom: 0.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.46pt; text-align: left;"><font style="padding-left: 12.5pt;">628,468 </font></div></td><td style="width: 10.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.65pt; padding-top: 0.26pt; padding-bottom: 0.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.08pt; text-align: left;"><font style="padding-left: 22.5pt;">* </font></div></td></tr><tr><td style="width: 312pt; padding-top: 0.26pt; padding-bottom: 0.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Kristina Burow<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(4)</sup><font style="padding-left: 3.83pt;"></font></div></td><td style="width: 10.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 61.91pt; padding-top: 0.26pt; padding-bottom: 0.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.46pt; text-align: left;">19,389,625</div></td><td style="width: 10.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.65pt; padding-top: 0.26pt; padding-bottom: 0.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.08pt; text-align: left;"><font style="padding-left: 0.37pt;">11.31% </font></div></td></tr><tr><td style="width: 312pt; padding-top: 0.26pt; padding-bottom: 0.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">David Bonita, M.D.<font style="padding-left: 4.79pt;"></font></div></td><td style="width: 10.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 61.91pt; padding-top: 0.26pt; padding-bottom: 0.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.46pt; text-align: left;"><font style="padding-left: 35pt;">&#8212;</font></div></td><td style="width: 10.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.65pt; padding-top: 0.26pt; padding-bottom: 0.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.08pt; text-align: left;"><font style="padding-left: 22.5pt;">* </font></div></td></tr><tr><td style="width: 312pt; padding-top: 0.26pt; padding-bottom: 0.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">David Schenkein, M.D., Ph.D.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(5)</sup><font style="padding-left: 3.28pt;"></font></div></td><td style="width: 10.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 61.91pt; padding-top: 0.26pt; padding-bottom: 0.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.46pt; text-align: left;">19,042,367</div></td><td style="width: 10.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.65pt; padding-top: 0.26pt; padding-bottom: 0.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.08pt; text-align: left;"><font style="padding-left: 0.37pt;">11.11% </font></div></td></tr><tr><td style="width: 312pt; padding-top: 0.26pt; padding-bottom: 0.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Steven Elms<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(6)</sup><font style="padding-left: 0.49pt;"></font></div></td><td style="width: 10.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 61.91pt; padding-top: 0.26pt; padding-bottom: 0.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.46pt; text-align: left;"><font style="padding-left: 5pt;">2,409,721</font></div></td><td style="width: 10.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.65pt; padding-top: 0.26pt; padding-bottom: 0.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.08pt; text-align: left;"><font style="padding-left: 5pt;">1.41% </font></div></td></tr><tr><td style="width: 312pt; padding-top: 0.26pt; padding-bottom: 0.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Aftab Kherani, M.D.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(7)</sup><font style="padding-left: 2.18pt;"></font></div></td><td style="width: 10.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 61.91pt; padding-top: 0.26pt; padding-bottom: 0.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.46pt; text-align: left;">10,231,781</div></td><td style="width: 10.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.65pt; padding-top: 0.26pt; padding-bottom: 0.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.08pt; text-align: left;"><font style="padding-left: 5pt;">5.96% </font></div></td></tr><tr><td style="width: 312pt; padding-top: 0.26pt; padding-bottom: 0.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Avi Naider<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(8)</sup><font style="padding-left: 1.79pt;"></font></div></td><td style="width: 10.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 61.91pt; padding-top: 0.26pt; padding-bottom: 0.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.46pt; text-align: left;"><font style="padding-left: 5pt;">2,377,775</font></div></td><td style="width: 10.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.65pt; padding-top: 0.26pt; padding-bottom: 0.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.08pt; text-align: left;"><font style="padding-left: 5pt;">1.39% </font></div></td></tr><tr><td style="width: 312pt; padding-top: 0.26pt; padding-bottom: 0.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Ali Satvat<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(9)</sup><font style="padding-left: 0.49pt;"></font></div></td><td style="width: 10.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 61.91pt; padding-top: 0.26pt; padding-bottom: 0.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.46pt; text-align: left;">20,076,885</div></td><td style="width: 10.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.65pt; padding-top: 0.26pt; padding-bottom: 0.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.08pt; text-align: left;"><font style="padding-left: 0.37pt;">11.71% </font></div></td></tr><tr><td style="width: 312pt; padding-top: 0.26pt; padding-bottom: 0.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Susan Desmond-Hellmann<font style="padding-left: 2.03pt;"></font></div></td><td style="width: 10.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 61.91pt; padding-top: 0.26pt; padding-bottom: 0.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.46pt; text-align: left;"><font style="padding-left: 35pt;">&#8212;</font></div></td><td style="width: 10.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.65pt; padding-top: 0.26pt; padding-bottom: 0.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.08pt; text-align: left;"><font style="padding-left: 22.5pt;">* </font></div></td></tr><tr><td style="width: 312pt; padding-top: 0.26pt; padding-bottom: 0.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">All executive officers and directors as a group (11 persons)<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(10)</sup><font style="padding-left: 0.7pt;"></font></div></td><td style="width: 10.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 61.91pt; padding-top: 0.26pt; padding-bottom: 0.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.46pt; text-align: left;">83,639,042</div></td><td style="width: 10.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.65pt; padding-top: 0.26pt; padding-bottom: 0.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.08pt; text-align: left;">48.54% </div></td></tr><tr><td style="width: 312pt; padding-top: 0.26pt; padding-bottom: 0.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">5% or Greater Stockholders:<br></div></td><td style="width: 10.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 61.91pt; padding-top: 0.26pt; padding-bottom: 0.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 10.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.65pt; padding-top: 0.26pt; padding-bottom: 0.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 312pt; padding-top: 0.26pt; padding-bottom: 0.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">OrbiMed Private Investments VIII, LP<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(11)</sup><font style="padding-left: 2.79pt;"></font></div></td><td style="width: 10.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 61.91pt; padding-top: 0.26pt; padding-bottom: 0.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.46pt; text-align: left;">19,389,626</div></td><td style="width: 10.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.65pt; padding-top: 0.26pt; padding-bottom: 0.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.08pt; text-align: left;"><font style="padding-left: 0.37pt;">11.31% </font></div></td></tr><tr><td style="width: 312pt; padding-top: 0.26pt; padding-bottom: 0.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Entities Affiliated with ARCH Venture Partners<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(12)</sup><font style="padding-left: 2.13pt;"></font></div></td><td style="width: 10.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 61.91pt; padding-top: 0.26pt; padding-bottom: 0.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.46pt; text-align: left;">19,389,625</div></td><td style="width: 10.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.65pt; padding-top: 0.26pt; padding-bottom: 0.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.08pt; text-align: left;"><font style="padding-left: 0.37pt;">11.31% </font></div></td></tr><tr><td style="width: 312pt; padding-top: 0.26pt; padding-bottom: 0.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Entities Affiliated with GV<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(13)</sup><font style="padding-left: 3.6pt;"></font></div></td><td style="width: 10.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 61.91pt; padding-top: 0.26pt; padding-bottom: 0.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.46pt; text-align: left;">19,042,367</div></td><td style="width: 10.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.65pt; padding-top: 0.26pt; padding-bottom: 0.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.08pt; text-align: left;"><font style="padding-left: 0.37pt;">11.11% </font></div></td></tr><tr><td style="width: 312pt; padding-top: 0.26pt; padding-bottom: 0.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Funds and Accounts Managed by T. Rowe Price Associates, Inc.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(14)</sup><font style="padding-left: 4.66pt;"></font></div></td><td style="width: 10.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 61.91pt; padding-top: 0.26pt; padding-bottom: 0.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.46pt; text-align: left;">16,159,778</div></td><td style="width: 10.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.65pt; padding-top: 0.26pt; padding-bottom: 0.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.08pt; text-align: left;"><font style="padding-left: 5pt;">9.42% </font></div></td></tr><tr><td style="width: 312pt; padding-top: 0.26pt; padding-bottom: 0.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Entities Affiliated with KKR &amp; Co., Inc.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(15)(18)</sup><font style="padding-left: 2.22pt;"></font></div></td><td style="width: 10.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 61.91pt; padding-top: 0.26pt; padding-bottom: 0.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.46pt; text-align: left;">20,076,885</div></td><td style="width: 10.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.65pt; padding-top: 0.26pt; padding-bottom: 0.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.08pt; text-align: left;"><font style="padding-left: 0.37pt;">11.71% </font></div></td></tr><tr><td style="width: 312pt; padding-top: 0.26pt; padding-bottom: 0.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Entities Affiliated with Access Industries<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(16)</sup><font style="padding-left: 3.34pt;"></font></div></td><td style="width: 10.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 61.91pt; padding-top: 0.26pt; padding-bottom: 0.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.46pt; text-align: left;">24,065,596</div></td><td style="width: 10.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.65pt; padding-top: 0.26pt; padding-bottom: 0.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.08pt; text-align: left;">14.03% </div></td></tr><tr><td style="width: 312pt; padding-top: 0.26pt; padding-bottom: 0.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Entities Affiliated with Ajax Health<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(17)(18)</sup><font style="padding-left: 2.49pt;"></font></div></td><td style="width: 10.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 61.91pt; padding-top: 0.26pt; padding-bottom: 0.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.46pt; text-align: left;"><font style="padding-left: 5pt;">9,905,146</font></div></td><td style="width: 10.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.65pt; padding-top: 0.26pt; padding-bottom: 0.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.08pt; text-align: left;"><font style="padding-left: 5pt;">5.78% </font></div></td></tr><tr><td style="width: 312pt; padding-top: 0.26pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Entities Affiliated with Casdin Capital LLC<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(19)</sup><font style="padding-left: 2.49pt;"></font></div></td><td style="width: 10.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 61.91pt; padding-top: 0.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.46pt; text-align: left;"><font style="padding-left: 5pt;">8,855,698</font></div></td><td style="width: 10.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.65pt; padding-top: 0.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.08pt; text-align: left;"><font style="padding-left: 5pt;">5.16%</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 312pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 10.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 10.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 61.91pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 10.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 10.36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 52.65pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div><div class="BRDSX_rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 8.25pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">*<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Represents beneficial ownership of less than one percent. </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">322<br></div></div></div>
<!--End Page 333-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 334-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_127-security_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5.25pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Represents (i) 4,561,105 shares of Treeline Common Stock directly held by Dr.&#160;Bilenker, (ii) 1,000,000 shares of Treeline Common Stock directly held by Dr.&#160;Bilenker&#8217;s spouse, (iii) an aggregate 6,262,332 shares of Treeline Common Stock held directly by trusts, and (iv)&#160;50,000 shares of Treeline Common Stock subject to options that are exercisable within 60 days of June&#160;1, 2026. Dr.&#160;Bilenker may be deemed to exercise voting and/or investment discretion over the securities held by each of the trusts noted in subclause (iii) of the preceding sentence. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(2)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Represents (i) 2,333,333 shares of Treeline Common Stock directly held by The Jeffrey A. Engelman Trust &#8211; 2023, (ii) 500,000 shares of Treeline Common Stock directly held by The Engelman Irrevocable Trust fbo Alexis, (iii) 500,000 shares of Treeline Common Stock directly held by The Engelman Irrevocable Trust fbo Charles (together with The Jeffrey A. Engelman Trust &#8211; 2023 and The Engelman Irrevocable Trust fbo Alexis, the &#8220;Engelman Trusts&#8221;), and (iv) 302,490 shares of Treeline Common Stock subject to options that are exercisable within 60 days of June&#160;1, 2026. Dr.&#160;Engelman serves as trustee of the Engelman Trusts and may be deemed to exercise voting and investment discretion in such capacity. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(3)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Represents (i) 471,987 shares of Treeline Common Stock held by Mr.&#160;Smith and (ii) 156,481 shares of Treeline Common Stock subject to options that are exercisable within 60 days of June&#160;1, 2026. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(4)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Consists entirely of securities held by the ARCH Venture Funds. Ms.&#160;Burow, a member of the Treeline Board, is a managing director of ARCH Venture Partners and a member of the investment committee of AVP XI LLC and AVP XII LLC and may be deemed to share voting and investment discretion with respect to securities held by the ARCH Venture Funds. See footnote 12 below for more information relating to the ARCH Venture Funds. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(5)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Consists entirely of securities held by the GV Funds. Dr.&#160;Schenkein, a member of the Treeline Board, is a general partner of Google Ventures and may be deemed to share voting and investment discretion with respect to securities held by the GV Affiliates. See footnote 13&#160;below for more information relating to the GV Affiliates. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(6)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Consists entirely of securities directly held by Aisling V. Aisling GP V serves as general partner of Aisling V, and Aisling V LLC serves as general partner of Aisling GP V. The Aisling Managers of Aisling V LLC are Dr.&#160;Andrew Schiff and Steven Elms, a member of the Treeline Board. As such, each of Aisling GP V, Aisling V LLC, and the Aisling Managers may be deemed to share voting and investment discretion with respect to securities directly held by Aisling V. The principal business address of each of the aforementioned parties is 489&#160;Fifth&#160;Avenue, 10th Floor, New York, NY 10017. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(7)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Consists of (i) securities held by the Ajax Affiliates and (ii) 326,635 shares of Treeline Common Stock subject to options that are exercisable within 60 days of June&#160;1, 2026 held by Jennifer Kherani, Dr.&#160;Kherani&#8217;s spouse. Dr.&#160;Kherani, a member of the Treeline Board, is a partner of Ajax Health III, LLC and may be deemed to share voting and investment discretion with respect to securities held by the Ajax Affiliates. See footnotes 17 and 18 below for more information relating to the Ajax Affiliates. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(8)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Represents (i) 473,850 shares of Treeline Common Stock directly held by AZN TL LLC, (ii) 1,284,511 shares of Treeline Common Stock directly held by AZN TLII LLC (together with AZN TL LLC, the &#8220;Naider LLCs&#8221;), and (iii) 619,414 shares of Treeline Common Stock directly held by the Debra Klein 2019 Irrevocable Trust (the &#8220;Klein Trust&#8221;). Mr.&#160;Naider serves as manager of the Naider LLCs and as trustee of the Klein Trust and may be deemed to exercise voting and investment discretion over the securities held by them in such capacities. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(9)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Consists entirely of securities held by the investment funds and entities described in footnote 15, below (the &#8220;KKR Funds&#8221;), which are affiliated with Kohlberg Kravis Roberts &amp; Co. L.P. Mr.&#160;Satvat, a member of the Treeline Board, is a partner of Kohlberg Kravis Roberts &amp; Co. L.P. and may be deemed to share voting and investment discretion with respect to securities directly held by the KKR Funds. See footnotes 15 and 18 below for more information relating to the KKR Funds. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(10)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Represents the total of all securities beneficially owned by our directors and officers, consisting of an aggregate (i) 82,803,436 shares of our Treeline Common Stock and (ii) 835,606 shares underlying options to purchase Treeline Common Stock, which are vested and exercisable within 60 days of June&#160;1, 2026. The total amount only accounts for the AZTL Shares once and does not double count these shares. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(11)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Represents 19,389,626 shares of Treeline Common Stock held of record by OPI VIII. GP VIII is the general partner of OPI VIII and OrbiMed Advisors is the managing member of GP VIII. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VIII. Dr.&#160;Bonita, a member of the Treeline Board, is a member of OrbiMed Advisors. The principal business address for the aforementioned parties is c/o OrbiMed Advisors LLC, 601 Lexington Avenue 54th Floor, New York, NY 10022. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(12)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Represents (i) 15,533,779 shares of Treeline Common Stock directly held of record by ARCH Fund XI, and (ii) 3,855,846 shares of Treeline Common Stock directly held of record by ARCH Fund XII. AVP XI LP is the sole general partner of ARCH Fund XI, and AVP XI LLC is the sole general partner of AVP XI LP, and each of them may be deemed to beneficially own securities directly held of record by ARCH Fund XI. AVP XII LP is the sole general partner of ARCH Fund XII, and AVP XII LLC is the sole general partner of AVP XII LP, and each of them may be deemed to beneficially own securities directly held of record by ARCH Fund XII. Each of AVP XI LLC and AVP XII LLC exercises voting and investment power through an investment committee comprised of Kristina M. Burow, a member of the Treeline Board, Keith Crandell, Steven Gillis, and Robert Nelsen. The address of each of the aforementioned parties is c/o ARCH Venture Partners, 8755 West Higgins Road, Suite 1025, Chicago, IL 60631. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(13)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Represents 16,050,603 shares held of record by GV 2021 LP and 2,991,764 shares held of record by GV 2025 LP. GV 2021 GP is the general partner of GV 2021 LP and GV 2021 LLC is the general partner of GV 2021 GP. GV 2025 GP is the general partner of GV 2025 LP and GV 2025 LLC is the general partner of GV 2025 GP. Alphabet Holdings LLC is the sole member of GV 2021 LLC and GV 2025 LLC. XXVI is the sole member of Alphabet Holdings LLC. Alphabet Inc. is the controlling stockholder of XXVI. As such, GV 2021 GP and GV 2021 LLC may be deemed to indirectly beneficially own securities held by GV 2021 LP, and GV 2025 GP and GV 2025 LLC may be deemed to indirectly beneficially own securities held by GV 2025 LP. Further, Alphabet Holdings LLC, XXVI, and Alphabet Inc. may be deemed to indirectly beneficially own the securities directly held by the GV Funds. The principal business address of each of the aforementioned parties is 1600 Amphitheatre Parkway, Mountain View, CA 94043. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(14)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Represents (i) 75,165 shares of Treeline Common Stock directly held by Costco 401(k) Retirement Plan, (ii) 1,300,069 shares of Treeline Common Stock directly held by T. Rowe Price All-Cap Opportunities Fund, (iii) 53,538 shares of Treeline Common Stock directly held by T. Rowe Price All-Cap Opportunities Portfolio, (iv) 8,223 shares of Treeline Common Stock directly held by T. Rowe Price Global Allocation Fund, Inc., (v) 5,458,806 shares of Treeline Common Stock directly held by T. Rowe Price Health Sciences Fund, Inc., (vi)&#160;249,086 shares of Treeline Common Stock directly held by T. Rowe Price Health Sciences Portfolio, (vii) 596,089 shares of Treeline Common Stock directly held by T. Rowe Price Institutional Small-Cap Stock Fund, (viii) 1,153 shares of Treeline Common Stock directly held by T. Rowe Price Moderate Allocation Portfolio, (ix) 88 shares of Treeline Common Stock directly held by T. Rowe Price </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">323<br></div></div></div>
<!--End Page 334-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 335-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_127-security_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 5.25pt; margin-left: 20pt; text-align: left;">Multi-Strategy Total Return Fund, Inc., (x) 5,392,138 shares of Treeline Common Stock directly held by T. Rowe Price New Horizons Fund, Inc., (xi) 782,004 shares of Treeline Common Stock directly held by T. Rowe Price New Horizons Trust, (xii) 1,096,399 shares of Treeline Common Stock directly held by T. Rowe Price Small-Cap Stock Fund, Inc., (xiii) 6,382 shares of Treeline Common Stock directly held by T. Rowe Price Small-Cap Stock Trust, (xiv) 8,103 shares of Treeline Common Stock directly held by T. Rowe Price Spectrum Conservative Allocation Fund, (xv) 12,620 shares of Treeline Common Stock directly held by T. Rowe Price Spectrum Moderate Allocation Fund, (xvi) 173 shares of Treeline Common Stock directly held by T. Rowe Price Spectrum Moderate Allocation Portfolio, (xvii) 30,705 shares of Treeline Common Stock directly held by T. Rowe Price Spectrum Moderate Growth Allocation Fund, (xviii)&#160;37,160&#160;shares of Treeline Common Stock directly held by T. Rowe Price U.S. Equities Trust, (xix) 506,532 shares of Treeline Common Stock directly held by T. Rowe Price U.S. Small-Cap Core Equity Trust, (xx) 461,213 shares of Treeline Common Stock directly held by TD Mutual Funds - TD Health Sciences Fund, (xxi) 41,583 shares of Treeline Common Stock directly held by TD Mutual Funds - TD U.S. Small-Cap Equity Fund, and (xxii) 42,549 shares of Treeline Common Stock directly held by U.S. Small-Cap Stock Trust. TRPA serves as investment adviser to each of T. Rowe Price All-Cap Opportunities Fund, T. Rowe Price All-Cap Opportunities Portfolio, T. Rowe Price Global Allocation Fund, Inc., T. Rowe Price Health Sciences Fund, Inc., T. Rowe Price Health Sciences Portfolio, T. Rowe Price Multi-Strategy Total Return Fund, Inc., T. Rowe Price New Horizons Fund, Inc., T. Rowe Price New Horizons Trust, T. Rowe Price U.S. Equities Trust, and TD Mutual Funds &#8211; TD Health Sciences Fund. TRPA may be deemed to exercise voting and investment discretion with respect to the securities held by these funds and accounts. TRPIM serves as investment advisor to each of Costco 401(k) Retirement Plan, T. Rowe Price Institutional Small-Cap Stock Fund, T. Rowe Price Moderate Allocation Portfolio, T. Rowe Price Small-Cap Stock Fund, Inc., T. Rowe Price Small-Cap Stock Trust, T. Rowe Price Spectrum Conservative Allocation Fund, T. Rowe Price Spectrum Moderate Allocation Fund, T. Rowe Price Spectrum Moderate Allocation Portfolio, T. Rowe Price Spectrum Moderate Growth Allocation Fund, T.&#160;Rowe Price U.S. Small-Cap Core Equity Trust, TD Mutual Funds &#8211; TD U.S. Small-Cap Equity Fund, and U.S. Small-Cap Stock Trust. TRPIM may be deemed to exercise voting and investment discretion with respect to the securities held by these funds and accounts. TRPA and TRPIM are wholly owned subsidiaries of T. Rowe Price Group, Inc., which is a publicly traded financial services holding company. The principal business address of each of the aforementioned parties is 1307 Point Street, Baltimore, MD 21231. </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(15)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Represents (i) 4,758,848 shares of Treeline Common Stock held by KKR Forest LLC, (ii) 9,291,197 shares of Treeline Common Stock held by KKR Forest Aggregator L.P., and (iii) 6,026,840 shares of Treeline Common Stock held by Ajax Zeus TL LLC (such shares the &#8220;AZTL Shares&#8221;). </div></td></tr></table><div class="BRDSX_ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 3pt; margin-left: 20pt; text-align: left;">KKR Forest Aggregator L.P., as the managing member of KKR Forest LLC, KKR Forest Aggregator GP LLC, as the general partner of KKR Forest Aggregator L.P., KKR Health Care Strategic Growth Fund II SCSp, as the sole member of KKR Forest Aggregator GP LLC, KKR Associates HCSG II SCSp, as the general partner of KKR Health Care Strategic Growth Fund II SCSp, KKR HCSG II S.&#224; r.l., as the general partner of KKR Associates HCSG II SCSp, KKR HCSG II Holdings Limited, as the sole shareholder of KKR HCSG II S.&#224; r.l., KKR Group Partnership L.P., as the sole shareholder of KKR HCSG II Holdings Limited, KKR Group Holdings Corp., as the general partner of KKR Group Partnership L.P., KKR Group Co. Inc., as the sole shareholder of KKR Group Holdings Corp., KKR, as the sole shareholder of KKR Group Co. Inc., KKR Management LLP, as the Series&#160;I preferred stockholder of KKR, and Messrs. Henry R. Kravis and George R. Roberts, as the founding partners of KKR Management LLP, may be deemed to be the beneficial owners having shared voting and investment power with respect to the shares held by the KKR Entities.</div><div class="BRDSX_ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 3pt; margin-left: 20pt; text-align: left;">Neptune, as the managing member of AZTL, Zeus Health LLC, as a member of Neptune, KKR Zeus Aggregator LLC, as the managing member of Zeus Health LLC, KKR Health Care Strategic Growth Fund L.P., as the managing member of KKR Zeus Aggregator LLC, KKR Associates HCSG L.P., as the general partner of KKR Health Care Strategic Growth Fund L.P., KKR HCSG GP LLC, as the general partner of KKR Associates HCSG L.P., KKR Group Partnership L.P., as the sole member of KKR HCSG GP LLC, KKR Group Holdings Corp., as the general partner of KKR Group Partnership L.P., KKR Group Co. Inc., as the sole shareholder of KKR Group Holdings Corp., KKR, as the sole shareholder of KKR Group Co. Inc., KKR Management LLP, as the Series&#160;I preferred stockholder of KKR, and Messrs. Henry R. Kravis and George R. Roberts, as the founding partners of KKR Management LLP, may be deemed to be beneficial owners having shared voting and investment power with respect to the shares held by AZTL. </div><div class="BRDSX_ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 3pt; margin-left: 20pt; text-align: left;">The principal business address of AZTL and Neptune is 650 Live Oak, Suite 200, Menlo Park, CA 94025. The principal business address of KKR Forest LLC and Zeus Health LLC is c/o Kohlberg Kravis Roberts &amp; Co. L.P., 2800 Sand Hill Road, Suite 200, Menlo Park, CA&#160;94025.The principal business address of each of the other entities identified in this footnote is 30 Hudson Yards, New York, NY 10001. The principal business address for Mr.&#160;Kravis is c/o Kohlberg Kravis Roberts &amp; Co. L.P., 30 Hudson Yards, New York, NY 10001. The principal business address of Mr.&#160;Roberts is c/o Kohlberg Kravis Roberts &amp; Co. L.P., 2800 Sand Hill Road, Suite 200, Menlo Park, CA&#160;94025. </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(16)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Represents (i) 11,078,236 shares of Treeline Common Stock directly held by AI Life and (ii) 12,987,360 shares of Treeline Common Stock directly held by AI Treeline. Such securities may be deemed to be beneficially owned by AIH, AI, AIM, LSI Management, and Len Blavatnik. AI Life controls a majority of the outstanding voting interests in AI Treeline, AIH controls a majority of the outstanding voting interests in AI Life, AI controls a majority of the outstanding voting interests in AIH, LSI Management is the management member of AI Life, AIM controls AI and AIH is the management of LSI Management. Len Blavatnik is the controlling person of AIM and controls a majority of the outstanding voting interests in AI and may be deemed to exercise voting and investment discretion over securities held directly or indirectly by each of the aforementioned entities. The principal business address for each of the aforementioned parties is 40&#160;West 57<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> Street, 28<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> Floor, New York, NY 10019. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(17)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Represents (i) 1,715,779 shares of Treeline Common Stock held by Ajax Health III LLC, (ii) 2,162,527 shares of Treeline Common Stock held by Ajax HQ Treeline 2022 SPV, LLC, and (iii) the AZTL Shares. </div></td></tr></table><div class="BRDSX_ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 3pt; margin-left: 20pt; text-align: left;">Ajax Health III LLC is governed by a board of managers comprised of five voting managers, a majority of which are appointed by HealthQuest Partners III, L.P. HealthQuest Venture Management III, L.L.C. is the general partner of HealthQuest Partners III, L.P. Garheng Kong is the managing member of HealthQuest Venture Management III, L.L.C. and has sole voting and investment power over the shares held by Ajax Health III LLC. </div><div class="BRDSX_ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 3pt; margin-left: 20pt; text-align: left;">Ajax HQ Treeline 2022 SPV, LLC is governed by a board of managers comprised of three voting managers, a majority of which are appointed by HealthQuest Ajax III-A SPV, L.P. HealthQuest Ajax III-A Management, L.L.C. is the general partner of HealthQuest Ajax III-A SPV, L.P. Garheng Kong is the managing member of HealthQuest Ajax III-A Management, L.L.C. and has sole voting and investment power over the shares held by Ajax HQ Treeline 2022 SPV, LLC. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">324<br></div></div></div>
<!--End Page 335-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 336-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_127-security_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 5.25pt; margin-left: 20pt; text-align: left;">Dr.&#160;Kong, HealthQuest Partners III, L.P., HealthQuest Venture Management III, L.L.C., HealthQuest Ajax III-A SPV, L.P. and HealthQuest Ajax III-A Management, L.L.C. disclaim beneficial ownership over all of the shares owned by Ajax Health III LLC, Ajax HQ Treeline 2022 SPV, LLC and AZTL except to the extent of their pecuniary interest therein. The principal business address of Ajax Health III LLC and Ajax HQ Treeline 2022 SPV, LLC is 650 Live Oak, Suite 200, Menlo Park, CA 94025. The principal business address for Dr.&#160;Kong is 805 Las Cimas Parkway, Suite 245, Austin, TX 78746. </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(18)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">AZTL is directly owned by entities affiliated with KKR and Ajax Health III LLC. Neptune is the managing member of AZTL. Neptune is governed by a board of managers comprised of two voting managers, and one non-voting CEO manager. Each of Zeus Health LLC, which is indirectly controlled by KKR through certain intermediary funds and entities, and Ajax Health III LLC (more specifically discussed in footnote 17, above) has the right to designate a voting manager. Board action generally requires approval of each voting manager. Thus, KKR and Ajax Health III LLC ultimately share voting power and investment power over the AZTL shares. The principal business address of AZTL and Neptune is 650 Live Oak, Suite 200, Menlo Park, CA 94025. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(19)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Represents (i) 5,574,739 shares of Treeline Common Stock directly held by Casdin Partners Master Fund, L.P. (&#8220;Casdin Master Fund&#8221;), (ii) 1,277,546 shares of Treeline Common Stock held by Casdin Private Growth Equity Fund, L.P. (&#8220;Casdin PGE Fund I&#8221;), and (iii)&#160;2,003,413 shares of Treeline Common Stock held by Casdin Private Growth Equity Fund II, L.P. (&#8220;Casdin PGE Fund II&#8221; and, together with Casdin Master Fund and Casdin PGE Fund I, the &#8220;Casdin Funds&#8221;). The general partners of Casdin Partners Master Fund, L.P., Casdin Private Growth Equity Fund, L.P., and Casdin Private Growth Equity Fund II, L.P. are Casdin Partners GP, LLC, Casdin Private Growth Equity Fund GP, LLC, and Casdin Private Growth Equity Fund II GP, LLC, respectively, each a Delaware limited liability company. Eli Casdin is the Managing Member of each of Casdin Partners GP, LLC, Casdin Private Growth Equity Fund GP, LLC and Casdin Private Growth Equity Fund II GP, LLC, and controls Casdin Capital, LLC. In each case, the general partner and Casdin Capital, LLC are ultimately controlled by Eli Casdin. The principal business address of each of the aforementioned parties is 1350 Avenue of the Americas, Suite 2600, New York, NY 10019. </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">325<br></div></div></div>
<!--End Page 336-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 337-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_127-security_pg7"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tPRO"><!--Anchor--></a>PRO FORMA SECURITY OWNERSHIP OF CERTAIN <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">BENEFICIAL OWNERS AND MANAGEMENT OF THE COMBINED COMPANY </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following table provides an illustration, after giving pro forma effect to the Merger, of the amount of Standard BioTools Common Stock that is expected to be beneficially owned immediately following the effective time of the Merger by the following persons: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the beneficial owners of more than 5% of the outstanding Standard BioTools Common Stock; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">each of Standard BioTools&#8217; executive officers and directors (including the ten directors appointed by Treeline who will join the Standard BioTools Board upon the completion of the Merger); and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">all of Standard BioTools&#8217; executive officers and directors as a group (including the ten directors appointed by Treeline who will join the Standard BioTools Board upon the completion of the Merger). </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following table assumes the following: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Merger resulted in the issuance of approximately 2 billion shares of Standard BioTools Common Stock based on an estimated Exchange Ratio of 11.6997 (based on Standard BioTools&#8217; and Treeline&#8217;s capitalization as of June&#160;3, 2026 and May&#160;28, 2026 and taking into account Standard BioTools&#8217; estimated cash position as of the Closing and excluding the effect of the proposed Standard BioTools reverse stock split); </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the number of outstanding shares of Standard BioTools Common Stock at the Effective Time of the Merger was substantially the same as the number of shares outstanding on June&#160;3, 2026; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the total number of shares of Standard BioTools Common Stock that will be outstanding upon consummation of the Merger will be &#8195;&#8195;&#8195;&#8195; shares; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the number of shares and securities convertible into shares of Standard BioTools Common Stock held by the individuals and entities below at the Effective Time of the Merger was substantially the same as the holdings of these individuals and entities on June&#160;3, 2026, except for shares issued and conversions of convertible securities pursuant to the Merger. </div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 360pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 7pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 7pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 39.99pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 7pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 7pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 39.99pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 360pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name of Beneficial Owner</div></td><td style="width: 7pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 39.99pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Common <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Stock <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Beneficially <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Owned</div></td><td style="width: 7pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 39.99pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Percent of <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Common <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Stock <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Beneficially <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Owned </div></td></tr><tr><td style="width: 360pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">5% Stockholders<font style="font-weight: normal; padding-left: 4.46pt;"></font></div></td><td style="width: 7pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 39.99pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 7pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 39.99pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 7pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 39.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 7pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 39.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 7pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 39.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 7pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 39.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Directors and Executive Officers<font style="font-weight: normal; padding-left: 3.01pt;"></font></div></td><td style="width: 7pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 39.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 7pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 39.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 7pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 39.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 7pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 39.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 7pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 39.99pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="border-bottom: 1pt solid #000000; padding-left: 30pt; margin-left: 5pt;"></font></div></td><td style="width: 7pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 39.99pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="border-bottom: 1pt solid #000000; padding-left: 30pt; margin-left: 5pt;"></font></div></td></tr><tr><td style="width: 360pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">All current directors and executive officers as a group (&#8195;&#8195; persons)<font style="font-weight: normal; padding-left: 3.69pt;"></font></div></td><td style="width: 7pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 39.99pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">&#8195;&#8195;&#8195;</font></div></td><td style="width: 7pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 39.99pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">&#8195;&#8195;&#8195;</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 360pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 7pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 7pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 39.99pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 7pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 7pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 39.99pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">326<br></div></div></div>
<!--End Page 337-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 338-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_128-other_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tOTM"><!--Anchor--></a>OTHER MATTERS </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">As of the date of this proxy statement/prospectus, the Standard BioTools Board does not intend to present any matters other than those described herein at the Special Meeting and is unaware of any matters to be presented by other parties. If other matters are properly brought before the meeting for action by the stockholders, proxies will be voted in accordance with the recommendation of the Standard BioTools Board or, in the absence of such a recommendation, in accordance with the judgment of the proxy holder. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">327<br></div></div></div>
<!--End Page 338-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 339-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_128-other_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tHOU"><!--Anchor--></a>HOUSEHOLDING OF PROXY MATERIALS </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The SEC has adopted rules that permit companies and intermediaries (e.g., brokers) to satisfy the delivery requirements for proxy statements, notices or other meeting materials with respect to two or more stockholders sharing the same address by delivering a single set of proxy materials or other meeting materials addressed to those stockholders. This process, which is commonly referred to as &#8220;householding,&#8221; potentially means extra convenience for stockholders and cost savings for companies. Some brokers household proxy materials, delivering a single proxy statement or notice to multiple stockholders sharing an address unless contrary instructions have been received from the affected stockholders. Once you have received notice from your broker that they will be householding materials to your address, householding will continue until you are notified otherwise or until you revoke your consent. If, at any time, you no longer wish to participate in householding and would prefer to receive a separate proxy statement or notice, or if your household is receiving multiple copies of these documents and you wish to request that future deliveries be limited to a single copy, please notify your broker. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Requests for additional copies of this proxy statement/prospectus should be directed to: </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; text-align: center;">Standard BioTools Inc. <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">50 Milk Street, 10th Floor <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Boston, MA 02109 <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Attention: Corporate Secretary <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Telephone: (650) 266-6000 </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">328<br></div></div></div>
<!--End Page 339-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 340-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_128-other_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tTAR"><!--Anchor--></a>TRANSFER AGENT AND REGISTRAR </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The transfer agent and registrar for Standard BioTools is Computershare Trust Company, N.A. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">329<br></div></div></div>
<!--End Page 340-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 341-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_129-stockholder_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tSSP"><!--Anchor--></a>SUBMISSION OF STOCKHOLDER PROPOSALS </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Stockholders may present proper proposals for inclusion in the Standard BioTools proxy statement and for consideration at the next annual meeting of stockholders by submitting their proposals in writing to Standard BioTools&#8217; Corporate Secretary in a timely manner. For a stockholder proposal to be considered for inclusion in Standard BioTools&#8217; proxy statement for Standard BioTools&#8217; next annual meeting of stockholders (the &#8220;2027 Annual Meeting&#8221;), Standard BioTools&#8217; Corporate Secretary must receive the written proposal at Standard BioTools&#8217; principal executive offices not later than December&#160;28, 2026, the date that is 120 calendar days before the date that is one year after the date of Standard BioTools&#8217; proxy statement released to stockholders in connection with the 2026 Annual Meeting; provided, however, that in the event that Standard BioTools holds its 2027 Annual Meeting more than 30 days before or after the one-year anniversary date of the 2026 Annual Meeting, Standard BioTools will disclose the new deadline by which stockholder proposals must be received under Item&#160;5 of Standard BioTools&#8217; earliest possible Quarterly Report on Form&#160;10-Q or, if impracticable, by any means reasonably calculated to inform stockholders. In addition, stockholder proposals must otherwise comply with the requirements of Rule&#160;14a-8 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). Such proposals also must comply with SEC regulations under Rule&#160;14a-8 regarding the inclusion of stockholder proposals in company-sponsored proxy materials. Proposals should be addressed to: </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; text-align: center;">Standard BioTools Inc. <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Attn: Corporate Secretary <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">50 Milk Street, 10th Floor <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Boston, MA 02109 </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Other Proposals, Including Director Nominations, Not for Inclusion in Standard BioTools&#8217; Proxy Statement </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Standard BioTools Bylaws also establish an advance notice procedure for stockholders who wish to present a proposal, including director nominations, before an annual meeting of stockholders, but do not intend for the proposal to be included in Standard BioTools&#8217; proxy statement. The Standard BioTools Bylaws provide that the only business that may be conducted at an annual meeting is business that is (i) specified in the Standard BioTools proxy materials with respect to such meeting, (ii) otherwise properly brought before the meeting by or at the direction of the Standard BioTools Board, or (iii) properly brought before the meeting by a stockholder of record entitled to vote at the annual meeting who has delivered timely written notice to Standard BioTools&#8217; Corporate Secretary, which notice must contain the information specified in the Standard BioTools Bylaws. To be timely under the Standard BioTools Bylaws for Standard BioTools&#8217; 2027 Annual Meeting, Standard BioTools&#8217; Corporate Secretary must receive the written notice at Standard BioTools&#8217; principal executive offices not earlier than the date that is 75 days before (February&#160;11, 2027), or later than the date that is 45 days before (March&#160;13, 2027), the one-year anniversary of the date on which Standard BioTools first mailed its proxy materials or a notice of availability of proxy materials (whichever is earlier) for the 2026 Annual Meeting. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In the event that Standard BioTools holds its 2027 Annual Meeting more than 30 days before or more than 60&#160;days after the one-year anniversary date of the 2026 Annual Meeting, then notice of a stockholder proposal that is not intended to be included in Standard BioTools&#8217; proxy statement must be received no earlier than the close of business on the 120<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th </sup>day before the 2027 Annual Meeting and no later than the close of business on the later of the following two dates: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the 90th day prior to the 2027 Annual Meeting, or </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the 10th day following the day on which public announcement of the date of such meeting is first made. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If a stockholder who has notified us of his, her or its intention to present a proposal at an annual meeting does not appear to present such proposal at such meeting, Standard BioTools is not required to present the proposal for a vote at the meeting. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition to satisfying the requirements under the advance notice procedures of the Standard BioTools Bylaws described above, to comply with the universal proxy rules under the Exchange Act, any stockholder who intends to solicit proxies in support of director nominees other than Standard BioTools&#8217; nominees must provide written notice that sets forth the information required by Rule&#160;14a-19 under the Exchange Act no later than April&#160;18, 2027 and otherwise comply with the requirements of Rule&#160;14a-19. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">330<br></div></div></div>
<!--End Page 341-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 342-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_129-stockholder_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Submitting Recommendations for Director Candidates to Standard BioTools&#8217; Nominating and Corporate Governance Committee </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition to the above, a stockholder may make a recommendation to Standard BioTools&#8217; nominating and corporate governance committee relating to director candidates. It is the policy of the nominating and corporate governance committee of the Standard BioTools Board (the &#8220;Nominating and Corporate Governance Committee&#8221;) to consider recommendations for candidates to the Standard BioTools Board from stockholders holding not less than one percent (1%) of the outstanding shares of the Standard BioTools Common Stock continuously for at least twelve&#160;months prior to the date of submission of the recommendation. For additional information regarding stockholder recommendations for director candidates, please see the section entitled &#8220;<font style="font-style: italic;">Corporate Governance and Board of Directors &#8212; Process for Recommending Candidates to the Board of Directors</font>&#8221; of Standard BioTools&#8217; definitive proxy statement filed on Schedule 14A with the SEC on April&#160;27, 2026. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Availability of Bylaws </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Standard BioTools Bylaws are available on the Standard BioTools website at https://investors.StandardBio.com/corporate-governance/governance-overview. You may also contact the Standard BioTools Corporate Secretary at Standard BioTools&#8217; principal executive offices for a copy of the relevant bylaw provisions regarding the requirements for making stockholder proposals and nominating director candidates. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">331<br></div></div></div>
<!--End Page 342-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 343-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_129-stockholder_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tCSB"><!--Anchor--></a>COMMUNICATIONS FROM STANDARD BIOTOOLS STOCKHOLDERS </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Standard BioTools Board will give appropriate attention to written communications that are submitted by stockholders and will respond if and as appropriate. Standard BioTools&#8217; Secretary is primarily responsible for monitoring communications from stockholders and for providing copies or summaries to Standard BioTools&#8217; directors as he or she considers appropriate. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Communications are distributed to the Standard BioTools Board, or to any individual directors as appropriate, depending on the facts and circumstances outlined in the communication. Stockholders who wish to send communications on any topic to the Standard BioTools Board should address such communications to the Standard BioTools Board (i) in writing: c/o Corporate Secretary, Standard BioTools Inc., 50 Milk Street, 10th Floor Boston, MA 02109 or (ii) by going online to: <font style="font-style: italic;">https://investors.standardbio.com</font> and clicking on &#8220;Governance&#8201;&#8212;&#8201;Contact the Board.&#8221; </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">332<br></div></div></div>
<!--End Page 343-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 344-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_130-legal_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tLEG"><!--Anchor--></a>LEGAL MATTERS </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Freshfields US LLP, New York, New York, will pass upon the validity of the Standard BioTools Common Stock to be issued pursuant to the Merger. </div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; text-align: center;"><a name="tEXP"><!--Anchor--></a>EXPERTS </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The financial statements of Standard BioTools Inc. and management&#8217;s assessment of the effectiveness of internal control over financial reporting (which is included in Management&#8217;s Report on Internal Control over Financial Reporting) incorporated in this proxy statement/prospectus by reference to Standard BioTools Inc.&#8217;s Annual Report on Form&#160;10-K for the year ended December&#160;31, 2025 have been so incorporated in reliance on the report of PricewaterhouseCoopers LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The consolidated financial statements of Treeline Biosciences, Inc. and subsidiary at December 31, 2025 and 2024, and for each of the two years in the period ended December&#160;31, 2025, included in the proxy statement of Standard BioTools Inc., which is referred to and made a part of this prospectus and registration statement, have been audited by Ernst &amp; Young LLP, independent registered public accounting firm, as set forth in their report appearing elsewhere herein, and included in reliance upon such report given on the authority of such firm as experts in accounting and auditing. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">333<br></div></div></div>
<!--End Page 344-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 345-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_131-incorp_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tIBR"><!--Anchor--></a>INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The SEC allows Standard BioTools to incorporate certain information into this proxy statement/prospectus by reference to other information that has been filed with the SEC. The information incorporated by reference is deemed to be part of this proxy statement/prospectus (including the resale prospectus also included in the registration statement on Form&#160;S-4 of which this proxy statement/prospectus forms a part), except as set forth below and except for any information superseded by information in this proxy statement/prospectus or in later filed documents incorporated by reference into this proxy statement/prospectus. The documents that are incorporated by reference contain important information about Standard BioTools and you should read this document together with any other documents incorporated by reference in this proxy statement/prospectus. Copies of all or any part of this proxy statement/prospectus, including the documents incorporated by reference or the exhibits, are available at the SEC&#8217;s website at <font style="font-style: italic;">www.sec.gov</font>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This proxy statement/prospectus incorporates by reference the following documents that have previously been filed with the SEC by Standard BioTools (File No. 001-34180), in each case excluding any information furnished but not filed pursuant to the rules promulgated under the Exchange Act: </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 228pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 228pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 228pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Standard BioTools SEC Filings (File No. 001-34180)</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 228pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Period </div></td></tr><tr><td style="width: 228pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Annual Report on Form&#160;10-K</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 228pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Fiscal year ended <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1162194/000119312526108326/lab-20251231.htm">December&#160;31, 2025</a>, filed on March 16, 2026 </div></td></tr><tr><td style="width: 228pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Portions of the Proxy Statement on Schedule 14A incorporated by reference in the Annual Report on Form&#160;10-K for the fiscal year ended December&#160;31, 2025</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 228pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Filed <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1162194/000114036126017100/ny20061287x1_def14a.htm">April&#160;27, 2026</a> </div></td></tr><tr><td style="width: 228pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Quarterly Reports on Form&#160;10-Q</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 228pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Quarterly period ended <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1162194/000119312526208967/lab-20260331.htm">March&#160;31, 2026</a>, filed on May 6, 2026 </div></td></tr><tr><td style="width: 228pt; padding-top: 1.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Current Reports on Form&#160;8-K, excluding any information furnished but not filed pursuant to the rules promulgated under the Exchange Act.</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 228pt; padding-top: 1.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Filed on <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1162194/000110465926008375/tm264472d1_8k.htm">January&#160;30, 2026</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1162194/000110465926010965/tm265294d1_8ka.htm">February&#160;5, 2026</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1162194/000119312526177290/lab-20250913.htm">April&#160;24, 2026</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1162194/000119312526245181/lab-20260521.htm">May&#160;28, 2026</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1162194/000119312526255403/lab-20260529.htm">June&#160;3, 2026</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1162194/000119312526259877/d309595d8k.htm">June&#160;5, 2026</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1162194/000110465926071195/tm2617100d1_8k.htm">June&#160;8, 2026</a> and <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1162194/000119312526275946/lab-20260617.htm">June&#160;18, 2026</a>.</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 228pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 228pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, Standard BioTools is incorporating by reference any documents it may file under Section&#160;13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this proxy statement/prospectus and prior to the date of the Special Meeting. Such documents are considered to be part of this proxy statement/prospectus, effective as of the date such documents are filed with the SEC. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Standard BioTools files annual, quarterly and current reports, proxy statements and other information with the SEC. You may obtain the information incorporated by reference and any other materials Standard BioTools files with the SEC without charge by following the instructions in the section entitled &#8220;<font style="font-style: italic;">Where You Can Find More Information</font>&#8221; beginning on page <a href="#tWYC">335</a> of this proxy statement/prospectus. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Standard BioTools has not authorized anyone to give any information or make any representation about the Merger, the Merger Agreement or the transactions contemplated thereby, including any of the proposals set forth herein, that is different from, or in addition to, that contained in this proxy statement/prospectus or in any of the materials that have been incorporated into this proxy statement/prospectus. Therefore, if anyone does give you information of this sort, you should not rely on it. If you are in a jurisdiction where offers to exchange or sell, or solicitations of offers to exchange or purchase, the securities offered by this proxy statement/prospectus or the solicitation of proxies is unlawful, or if you are a person to whom it is unlawful to direct these types of activities, then the offer presented in this proxy statement/prospectus does not extend to you. The information contained in this proxy statement/prospectus speaks only as of the date of this proxy statement/prospectus unless the information specifically indicates that another date applies.<font style="font-weight: normal;"> </font></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">334<br></div></div></div>
<!--End Page 345-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 346-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_131-incorp_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tWYC"><!--Anchor--></a>WHERE YOU CAN FIND MORE INFORMATION </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Standard BioTools files annual, quarterly and current reports, proxy statements and other information with the SEC. The SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC, including Standard BioTools, which you can access at <font style="font-style: italic;">www.sec.gov</font>. Standard BioTools&#8217; SEC filings are also available on Standard BioTools&#8217; corporate website at <font style="font-style: italic;">www.standardbio.com</font> under the heading &#8220;Investor Relations.&#8221; By referring to Standard BioTools&#8217; website and the SEC&#8217;s website, Standard BioTools does not incorporate any such website or its contents into this proxy statement/prospectus. Standard BioTools Common Stock is listed on The Nasdaq Global Select Market under the trading symbol &#8220;LAB.&#8221; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Standard BioTools has filed with the SEC a registration statement on Form&#160;S-4, of which this proxy statement/prospectus is a part, under the Securities Act to register certain of the shares of Standard BioTools Common Stock to be issued to Treeline stockholders in the Merger. The registration statement, including the attached annexes, exhibits and schedules, contains additional relevant information about Standard BioTools and Standard BioTools Common Stock. This proxy statement/prospectus does not contain all of the information set forth in the registration statement because certain parts of the registration statement are omitted in accordance with the rules and regulations of the SEC. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Standard BioTools has supplied all of the information contained in or incorporated by reference into this proxy statement/prospectus relating to Standard BioTools, and Treeline has supplied all information contained in this proxy statement/prospectus relating to Treeline. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Standard BioTools has engaged &#8195;&#8195;&#8195; as its proxy solicitor for the Special Meeting. Any questions about the Merger, requests for additional copies of documents or assistance submitting a proxy or voting your shares of Standard BioTools&#8217; capital stock may be directed to &#8195;&#8195;&#8195; by mail at &#8195;&#8195;&#8195; or via email at &#8195;&#8195;&#8195;. Standard BioTools stockholders may call &#8195;&#8195;&#8195; toll-free at &#8195;&#8195;&#8195;. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">335<br></div></div></div>
<!--End Page 346-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 347-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_200-fintoc_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tICF"><!--Anchor--></a>TREELINE BIOSCIENCES, INC. AND SUBSIDIARY <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 432pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 8.56pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 8.56pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 18.89pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 432pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 8.56pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.56pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 18.89pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Page </div></td></tr><tr><td style="width: 432pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Audited Consolidated Financial Statements<br></div></td><td style="width: 8.56pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.56pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 18.89pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tROI">Report of Independent Registered Public Accounting Firm<font style="padding-left: 0.66pt;"></font></a></div></td><td style="width: 8.56pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.56pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 18.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tROI"><font style="padding-left: 5pt;">F-2 </font></a></div></td></tr><tr><td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tCBSD">Consolidated Balance Sheets, December&#160;31, 2025 and 2024<font style="padding-left: 0.39pt;"></font></a></div></td><td style="width: 8.56pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.56pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 18.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tCBSD"><font style="padding-left: 5pt;">F-3 </font></a></div></td></tr><tr><td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;"><a href="#tCSOOA">Consolidated Statements of Operations and Comprehensive Loss, Years Ended December&#160;31, 2025 and&#160;2024<font style="padding-left: 2.56pt;"></font></a></div></td><td style="width: 8.56pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.56pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 18.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tCSOOA"><font style="padding-left: 5pt;">F-4 </font></a></div></td></tr><tr><td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;"><a href="#tCSORP">Consolidated Statements of Redeemable Preferred Stock and Stockholders&#8217; Deficit, Years Ended December&#160;31, 2025 and 2024<font style="padding-left: 1.47pt;"></font></a></div></td><td style="width: 8.56pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.56pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 18.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tCSORP"><font style="padding-left: 5pt;">F-5 </font></a></div></td></tr><tr><td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tCSOCF">Consolidated Statements of Cash Flows, Years Ended December&#160;31, 2025 and 2024<font style="padding-left: 4.56pt;"></font></a></div></td><td style="width: 8.56pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.56pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 18.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tCSOCF"><font style="padding-left: 5pt;">F-6 </font></a></div></td></tr><tr><td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tNTCF">Notes to Consolidated Financial Statements<font style="padding-left: 4.54pt;"></font></a></div></td><td style="width: 8.56pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.56pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 18.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tNTCF"><font style="padding-left: 5pt;">F-7 </font></a></div></td></tr><tr><td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Unaudited Interim Consolidated Financial Statements<br></div></td><td style="width: 8.56pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.56pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 18.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tCBSM">Consolidated Balance Sheets, March&#160;31, 2026 and December&#160;31, 2025<font style="padding-left: 1.8pt;"></font></a></div></td><td style="width: 8.56pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.56pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 18.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tCBSM">F-23 </a></div></td></tr><tr><td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;"><a href="#tCSOO">Consolidated Statements of Operations and Comprehensive Loss, Three Months Ended March&#160;31, 2026 and 2025<font style="padding-left: 2.56pt;"></font></a></div></td><td style="width: 8.56pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.56pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 18.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tCSOO">F-24 </a></div></td></tr><tr><td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;"><a href="#tCSOR">Consolidated Statements of Redeemable Preferred Stock and Stockholders&#8217; Deficit, Three Months Ended March&#160;31, 2026 and 2025<font style="padding-left: 1.46pt;"></font></a></div></td><td style="width: 8.56pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.56pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 18.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tCSOR">F-25 </a></div></td></tr><tr><td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tCSOC">Consolidated Statements of Cash Flows, Three Months Ended March&#160;31, 2026 and 2025<font style="padding-left: 0.31pt;"></font></a></div></td><td style="width: 8.56pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.56pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 18.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tCSOC">F-26 </a></div></td></tr><tr><td style="width: 432pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tNTIC">Notes to Interim Consolidated Financial Statements<font style="padding-left: 2.6pt;"></font></a></div></td><td style="width: 8.56pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.56pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 18.89pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tNTIC">F-27</a></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 432pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 8.56pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 8.56pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 18.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-1<br></div></div></div>
<!--End Page 347-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 348-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_201-fintab_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tROI"><!--Anchor--></a>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </div><div class="BRDSX_h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">To the Stockholders and the Board of Directors of Treeline Biosciences, Inc. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Opinion on the Financial Statements </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We have audited the accompanying consolidated balance sheets of Treeline Biosciences, Inc. and subsidiary (the Company) as of December&#160;31, 2025 and 2024, the related consolidated statements of operations and comprehensive loss, redeemable preferred stock and stockholders&#8217; deficit and cash flows for the years then ended December&#160;31, 2025, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December&#160;31, 2025 and 2024, and the results of its operations and its cash flows for the years then ended December&#160;31, 2025, in conformity with U.S. generally accepted accounting principles. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Basis for Opinion </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States) and in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </div><div class="BRDSX_h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">/s/ Ernst &amp; Young LLP </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">We have served as the Company&#8217;s auditor since 2021. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">Iselin, New Jersey </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">June&#160;16, 2026 </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-2<br></div></div></div>
<!--End Page 348-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 349-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_201-fintab_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tCBSD"><!--Anchor--></a>TREELINE BIOSCIENCES, INC. AND SUBSIDIARY <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">CONSOLIDATED BALANCE SHEETS <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">(In thousands, except share and per share data)<font style="font-weight: normal;"> </font></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 360pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 96.91pt;" colspan="4"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 360pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.54pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td colspan="4" style="width: 96.91pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31 </div></td></tr><tr class="BRDSX_header"><td style="width: 360pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.54pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div></td><td style="width: 5.54pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.54pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div></td></tr><tr><td style="width: 360pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Assets<br></div></td><td style="width: 5.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 5.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Current assets:<br></div></td><td style="width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Cash and cash equivalents<font style="padding-left: 2.26pt;"></font></div></td><td style="width: 5.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">$<font style="padding-left: 12.5pt;">46,331</font></div></td><td style="width: 5.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<font style="padding-left: 8.33pt;">39,534 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Marketable securities<font style="padding-left: 1.71pt;"></font></div></td><td style="width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 12.5pt;">558,469</font></div></td><td style="width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 8.33pt;">463,520 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Other current assets<font style="padding-left: 3.1pt;"></font></div></td><td style="width: 5.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 17.87pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">11,502</font></div></td><td style="width: 5.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 13.7pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">11,006 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total current assets<font style="padding-left: 0.45pt;"></font></div></td><td style="width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 12.5pt;">616,302</font></div></td><td style="width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 8.33pt;">514,060 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 5.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 5.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Property and equipment, net<font style="padding-left: 4.19pt;"></font></div></td><td style="width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 17.87pt;">11,896</font></div></td><td style="width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 13.33pt;">16,885 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Right-of-use asset<font style="padding-left: 0.03pt;"></font></div></td><td style="width: 5.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">18,971</font></div></td><td style="width: 5.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 13.33pt;">10,845 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Restricted cash<font style="padding-left: 1.69pt;"></font></div></td><td style="width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">1,144</font></div></td><td style="width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 18.33pt;">1,160 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other assets<font style="padding-left: 3.91pt;"></font></div></td><td style="width: 5.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">6,742</font></div></td><td style="width: 5.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 18.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">1,893 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total assets<font style="padding-left: 1.27pt;"></font></div></td><td style="width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 7.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">655,055</font></div></td><td style="width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">544,843 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 5.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 5.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Liabilities, convertible preferred stock and stockholders&#8217; deficit<br></div></td><td style="width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Current liabilities:<br></div></td><td style="width: 5.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 5.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Accounts payable<font style="padding-left: 1.14pt;"></font></div></td><td style="width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">$<font style="padding-left: 17.5pt;">5,297</font></div></td><td style="width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<font style="padding-left: 13.33pt;">7,332 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Accrued expenses<font style="padding-left: 0.04pt;"></font></div></td><td style="width: 5.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">17,671</font></div></td><td style="width: 5.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 13.33pt;">15,665 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Current lease liability<font style="padding-left: 0.86pt;"></font></div></td><td style="width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">3,973</font></div></td><td style="width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 18.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">4,308 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total current liabilities<font style="padding-left: 1.56pt;"></font></div></td><td style="width: 5.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">26,941</font></div></td><td style="width: 5.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 13.33pt;">27,305 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Noncurrent lease liability<font style="padding-left: 0.87pt;"></font></div></td><td style="width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">15,617</font></div></td><td style="width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 18.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">6,173 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total liabilities<font style="padding-left: 2.38pt;"></font></div></td><td style="width: 5.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">42,558</font></div></td><td style="width: 5.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">33,478 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Redeemable convertible preferred stock:<br></div></td><td style="width: 5.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 5.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Series&#160;A, Series&#160;A-1, Series&#160;A-2 Convertible Preferred Stock, par value $0.00001: 174,566,382 shares authorized, 144,834,563 shares issued and outstanding as of December&#160;31, 2025; 115,102,744 shares issued and outstanding as of December&#160;31, 2024 (Liquidation value $1,196,404 at December&#160;31, 2025)<font style="padding-left: 4.21pt;"></font></div></td><td style="width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 5pt;">1,181,061</font></div></td><td style="width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 8.33pt;">939,275 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Commitments and contingencies (Note&#160;7)<br></div></td><td style="width: 5.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 5.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Stockholders&#8217; deficit:<br></div></td><td style="width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Common stock, par value $0.00001: 222,260,000 shares authorized, 20,765,754 shares issued and outstanding as of December&#160;31, 2025; 19,657,900 shares issued and outstanding as of December&#160;31, 2024<font style="padding-left: 3.09pt;"></font></div></td><td style="width: 5.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 35pt;">&#8212;</font></div></td><td style="width: 5.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 30.83pt;">&#8212; </font></div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Additional paid-in-capital<font style="padding-left: 3.91pt;"></font></div></td><td style="width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">32,242</font></div></td><td style="width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 13.7pt;">11,168 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Accumulated other comprehensive income (loss)<font style="padding-left: 1.45pt;"></font></div></td><td style="width: 5.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 30pt;">476</font></div></td><td style="width: 5.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">(335) </font></div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Accumulated deficit<font style="padding-left: 1.14pt;"></font></div></td><td style="width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 9.17pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(601,282</font><font style="padding-bottom: 1.5pt;">)</font></div></td><td style="width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(438,743</font><font style="padding-bottom: 1.5pt;">) </font></div></td></tr><tr><td style="width: 360pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total stockholders&#8217; deficit<font style="padding-left: 3.41pt;"></font></div></td><td style="width: 5.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 9.17pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(568,564</font><font style="padding-bottom: 1.5pt;">)</font></div></td><td style="width: 5.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(427,910</font><font style="padding-bottom: 1.5pt;">) </font></div></td></tr><tr><td style="width: 360pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total liabilities, redeemable preferred stock and stockholders&#8217; deficit<font style="padding-left: 2.93pt;"></font></div></td><td style="width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 7.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">655,055</font></div></td><td style="width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">544,843</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 360pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 45pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.54pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 40.83pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_footer" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.5pt; text-align: center;"></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 9.47pt; text-align: center;">The accompanying notes are an integral part of these consolidated financial statements.<br></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-3<br></div></div></div>
<!--End Page 349-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 350-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_201-fintab_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tCSOOA"><!--Anchor--></a>TREELINE BIOSCIENCES, INC. AND SUBSIDIARY <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">(IN THOUSANDS) </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 336pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 8.09pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 8.09pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 115.81pt;" colspan="4"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 8.09pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.09pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td colspan="4" style="width: 115.81pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended December&#160;31 </div></td></tr><tr class="BRDSX_header"><td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 8.09pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.09pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.63pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div></td><td style="width: 8.09pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.09pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div></td></tr><tr><td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating expenses:<br></div></td><td style="width: 8.09pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.09pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.63pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 8.09pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.09pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Research and development<font style="padding-left: 0.76pt;"></font></div></td><td style="width: 8.09pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.09pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.63pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<font style="padding-left: 12.13pt;">160,009</font></div></td><td style="width: 8.09pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.09pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<font style="padding-left: 12.5pt;">151,706 </font></div></td></tr><tr><td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">General and administrative<font style="padding-left: 0.2pt;"></font></div></td><td style="width: 8.09pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.09pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.63pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.13pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">23,256</font></div></td><td style="width: 8.09pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.09pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">23,558 </font></div></td></tr><tr><td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total operating expenses<font style="padding-left: 4.23pt;"></font></div></td><td style="width: 8.09pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.09pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.63pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 17.13pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">183,265</font></div></td><td style="width: 8.09pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.09pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">175,264 </font></div></td></tr><tr><td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 8.09pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.09pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.63pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 8.09pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.09pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss from operations<font style="padding-left: 3.53pt;"></font></div></td><td style="width: 8.09pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.09pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.63pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 13.8pt;">(183,265)</font></div></td><td style="width: 8.09pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.09pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 14.17pt;">(175,264) </font></div></td></tr><tr><td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other income<font style="padding-left: 3.8pt;"></font></div></td><td style="width: 8.09pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.09pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.63pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.13pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">20,726</font></div></td><td style="width: 8.09pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.09pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">12,777 </font></div></td></tr><tr><td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net loss<font style="padding-left: 1.01pt;"></font></div></td><td style="width: 8.09pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.09pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.63pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 13.8pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(162,539</font><font style="padding-bottom: 1.5pt;">)</font></div></td><td style="width: 8.09pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.09pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 14.17pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(162,487</font><font style="padding-bottom: 1.5pt;">) </font></div></td></tr><tr><td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 8.09pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.09pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.63pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 8.09pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.09pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Share information:<br></div></td><td style="width: 8.09pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.09pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.63pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 8.09pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.09pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net loss per share of common stock, basic and diluted<font style="padding-left: 2.45pt;"></font></div></td><td style="width: 8.09pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.09pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.63pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">$</font><font style="padding-left: 23.8pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(7.42</font><font style="padding-bottom: 1.5pt;">) </font></div></td><td style="width: 8.09pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.09pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">$</font><font style="padding-left: 24.17pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(8.47</font><font style="padding-bottom: 1.5pt;">) </font></div></td></tr><tr><td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Weighted-average shares of common stock outstanding, basic and diluted<font style="padding-left: 4.66pt;"></font></div></td><td style="width: 8.09pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.09pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.63pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">21,911,034</font></div></td><td style="width: 8.09pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.09pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">19,187,080 </font></div></td></tr><tr><td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 8.09pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.09pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.63pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 8.09pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.09pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Comprehensive loss:<br></div></td><td style="width: 8.09pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.09pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.63pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 8.09pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.09pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Net loss<font style="padding-left: 1.01pt;"></font></div></td><td style="width: 8.09pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.09pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.63pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 13.8pt;">(162,539)</font></div></td><td style="width: 8.09pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.09pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 14.17pt;">(162,487) </font></div></td></tr><tr><td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Unrealized gain (loss) on marketable securities, net of tax<font style="padding-left: 2.75pt;"></font></div></td><td style="width: 8.09pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.09pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.63pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 35pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">811</font></div></td><td style="width: 8.09pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.09pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 31.67pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(524</font><font style="padding-bottom: 1.5pt;">) </font></div></td></tr><tr><td style="width: 336pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Comprehensive loss<font style="padding-left: 2.69pt;"></font></div></td><td style="width: 8.09pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.09pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.63pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 8.8pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(161,728</font><font style="padding-bottom: 0.5pt;">)</font></div></td><td style="width: 8.09pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.09pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 9.54pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(163,011</font><font style="padding-bottom: 0.5pt;">)</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 336pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 8.09pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 8.09pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 49.63pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 8.09pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 8.09pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 50pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 9.47pt; text-align: center;">The accompanying notes are an integral part of these consolidated financial statements.<br></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-4<br></div></div></div>
<!--End Page 350-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 351-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_201-fintab_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tCSORP"><!--Anchor--></a>TREELINE BIOSCIENCES, INC. AND SUBSIDIARY <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; DEFICIT <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">(IN THOUSANDS, EXCEPT SHARE DATA) </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 469.01pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 108pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 84.75pt;" colspan="4"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 1.75pt; border-right: 1pt solid #000000;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 1.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 70.24pt;" colspan="4"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 36.45pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 53.17pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 45.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 47.1pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 108pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td colspan="4" style="width: 84.75pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Series&#160;A, Series&#160;A-1, <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Series&#160;A-2 <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Preferred Stock</div></td><td style="width: 1.75pt; border-right: 1pt solid #000000; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.75pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td colspan="4" style="width: 70.24pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Common Stock</div></td><td style="width: 2pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt; border-bottom: none;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td rowspan="2" style="width: 36.45pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Additional<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Paid-In <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Capital</div></td><td style="width: 2pt; border-bottom: none;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt; border-bottom: none;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td rowspan="2" style="width: 53.17pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Accumulated<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Other<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Comprehensive<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Loss) <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Income</div></td><td style="width: 2pt; border-bottom: none;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt; border-bottom: none;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td rowspan="2" style="width: 45.31pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Accumulated<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Deficit</div></td><td style="width: 2pt; border-bottom: none;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt; border-bottom: none;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td rowspan="2" style="width: 47.1pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Stockholders&#8217;<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Deficit </div></td></tr><tr class="BRDSX_header"><td style="width: 108pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 42.5pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares</div></td><td style="width: 2pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 38.25pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Amount</div></td><td style="width: 1.75pt; border-right: 1pt solid #000000; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.75pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 38.25pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares</div></td><td style="width: 2pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 27.99pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Amount </div></td><td style="width: 2pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr><td style="width: 108pt; padding-top: 2.06pt; padding-bottom: 1.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Balance at January&#160;1, 2024<font style="padding-left: 4.06pt;"></font></div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 42.5pt; padding-top: 2.06pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 4.56pt;">66,117,249</font></div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 38.25pt; padding-top: 2.06pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<font style="padding-left: 6.38pt;">517,663</font></div></td><td style="width: 1.75pt; border-right: 1pt solid #000000; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 38.25pt; padding-top: 2.06pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">18,871,370</div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 27.99pt; padding-top: 2.06pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 7.62pt; text-align: left;">$&#8212;</div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36.45pt; padding-top: 2.06pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 4.41pt; text-align: left;">$<font style="padding-left: 4.25pt;">6,228</font></div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 53.17pt; padding-top: 2.06pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 16.68pt; text-align: left;">$<font style="padding-left: 2.83pt;">189</font></div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45.31pt; padding-top: 2.06pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 5.3pt; text-align: left;">$(276,256)</div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 47.1pt; padding-top: 2.06pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 6.19pt; text-align: left;">$(269,839) </div></td></tr><tr><td style="width: 108pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Exercise of stock options<font style="padding-left: 0.19pt;"></font></div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 42.5pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 34pt;">&#8212;</font></div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 38.25pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 29.75pt;">&#8212;</font></div></td><td style="width: 1.75pt; border-right: 1pt solid #000000;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 38.25pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10.63pt;">786,530</font></div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 27.99pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 7.62pt; text-align: left;"><font style="padding-left: 4.25pt;">&#8212;</font></div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36.45pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 4.41pt; text-align: left;"><font style="padding-left: 14.88pt;">810</font></div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 53.17pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 16.68pt; text-align: left;"><font style="padding-left: 11.33pt;">&#8212;</font></div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45.31pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 5.3pt; text-align: left;"><font style="padding-left: 26.2pt;">&#8212;</font></div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 47.1pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 6.19pt; text-align: left;"><font style="padding-left: 21.95pt;">810 </font></div></td></tr><tr><td style="width: 108pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Stock-based compensation</div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 42.5pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 34pt;">&#8212;</font></div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 38.25pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 29.75pt;">&#8212;</font></div></td><td style="width: 1.75pt; border-right: 1pt solid #000000; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 38.25pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 29.75pt;">&#8212;</font></div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 27.99pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 7.62pt; text-align: left;"><font style="padding-left: 4.25pt;">&#8212;</font></div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36.45pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 4.41pt; text-align: left;"><font style="padding-left: 8.5pt;">4,130</font></div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 53.17pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 16.68pt; text-align: left;"><font style="padding-left: 11.33pt;">&#8212;</font></div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45.31pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 5.3pt; text-align: left;"><font style="padding-left: 26.2pt;">&#8212;</font></div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 47.1pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 6.19pt; text-align: left;"><font style="padding-left: 15.58pt;">4,130 </font></div></td></tr><tr><td style="width: 108pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Unrealized loss on marketable securities<font style="padding-left: 3.89pt;"></font></div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 42.5pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 34pt;">&#8212;</font></div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 38.25pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 29.75pt;">&#8212;</font></div></td><td style="width: 1.75pt; border-right: 1pt solid #000000;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 38.25pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 29.75pt;">&#8212;</font></div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 27.99pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 7.62pt; text-align: left;"><font style="padding-left: 4.25pt;">&#8212;</font></div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36.45pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 4.41pt; text-align: left;"><font style="padding-left: 19.13pt;">&#8212;</font></div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 53.17pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 16.68pt; text-align: left;"><font style="padding-left: 4.25pt;">(524)</font></div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45.31pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 5.3pt; text-align: left;"><font style="padding-left: 26.2pt;">&#8212;</font></div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 47.1pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 6.19pt; text-align: left;"><font style="padding-left: 19.13pt;">(524) </font></div></td></tr><tr><td style="width: 108pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Sale of Series&#160;A-1 convertible Preferred Stock, net of issuance cost of $168<font style="padding-left: 3.86pt;"></font></div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 42.5pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 4.25pt;">48,985,495</font></div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 38.25pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10.63pt;">421,612</font></div></td><td style="width: 1.75pt; border-right: 1pt solid #000000; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 38.25pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 29.75pt;">&#8212;</font></div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 27.99pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 7.62pt; text-align: left;"><font style="padding-left: 4.25pt;">&#8212;</font></div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36.45pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 4.41pt; text-align: left;"><font style="padding-left: 19.13pt;">&#8212;</font></div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 53.17pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 16.68pt; text-align: left;"><font style="padding-left: 11.33pt;">&#8212;</font></div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45.31pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 5.3pt; text-align: left;"><font style="padding-left: 26.2pt;">&#8212;</font></div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 47.1pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 6.19pt; text-align: left;"><font style="padding-left: 26.2pt;">&#8212; </font></div></td></tr><tr><td style="width: 108pt; padding-top: 1.31pt; padding-bottom: 2.88pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Net loss<font style="padding-left: 3.26pt;"></font></div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 42.5pt; padding-top: 1.31pt; padding-bottom: 2.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 34pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 38.25pt; padding-top: 1.31pt; padding-bottom: 2.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 29.75pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 1.75pt; border-right: 1pt solid #000000;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 38.25pt; padding-top: 1.31pt; padding-bottom: 2.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 29.75pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 27.99pt; padding-top: 1.31pt; padding-bottom: 2.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 7.62pt; text-align: left;"><font style="padding-left: 4.25pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36.45pt; padding-top: 1.31pt; padding-bottom: 2.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 4.41pt; text-align: left;"><font style="padding-left: 19.13pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 53.17pt; padding-top: 1.31pt; padding-bottom: 2.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 16.68pt; text-align: left;"><font style="padding-left: 11.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45.31pt; padding-top: 1.31pt; padding-bottom: 2.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 5.3pt; text-align: left;"><font style="padding-left: 4.25pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(162,487</font><font style="padding-bottom: 1.5pt;">)</font></div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 47.1pt; padding-top: 1.31pt; padding-bottom: 2.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 6.19pt; text-align: left;"><font style="padding-left: 4.25pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(162,487</font><font style="padding-bottom: 1.5pt;">) </font></div></td></tr><tr><td style="width: 108pt; padding-top: 2.56pt; padding-bottom: 1.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Balance at December&#160;31, 2024</div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 42.5pt; padding-top: 2.56pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 0.31pt;">115,102,744</font></div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 38.25pt; padding-top: 2.56pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10.63pt;">939,275</font></div></td><td style="width: 1.75pt; border-right: 1pt solid #000000; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 38.25pt; padding-top: 2.56pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">19,657,900</div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 27.99pt; padding-top: 2.56pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 7.62pt; text-align: left;"><font style="padding-left: 4.25pt;">&#8212;</font></div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36.45pt; padding-top: 2.56pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 4.41pt; text-align: left;"><font style="padding-left: 4.56pt;">11,168</font></div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 53.17pt; padding-top: 2.56pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 16.68pt; text-align: left;"><font style="padding-left: 4.25pt;">(335)</font></div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45.31pt; padding-top: 2.56pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 5.3pt; text-align: left;"><font style="padding-left: 4.25pt;">(438,743)</font></div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 47.1pt; padding-top: 2.56pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 6.19pt; text-align: left;"><font style="padding-left: 4.25pt;">(427,910) </font></div></td></tr><tr><td style="width: 108pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Sale of Series&#160;A-2 convertible preferred stock and pre-funded warrants, net of issuance costs of $521<font style="padding-left: 0.55pt;"></font></div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 42.5pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 4.25pt;">29,731,819</font></div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 38.25pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10.63pt;">241,786</font></div></td><td style="width: 1.75pt; border-right: 1pt solid #000000;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 38.25pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 29.75pt;">&#8212;</font></div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 27.99pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 7.62pt; text-align: left;"><font style="padding-left: 4.25pt;">&#8212;</font></div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36.45pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 4.41pt; text-align: left;"><font style="padding-left: 4.25pt;">13,739</font></div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 53.17pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 16.68pt; text-align: left;"><font style="padding-left: 11.33pt;">&#8212;</font></div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45.31pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 5.3pt; text-align: left;"><font style="padding-left: 26.2pt;">&#8212;</font></div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 47.1pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 6.19pt; text-align: left;"><font style="padding-left: 11.33pt;">13,739 </font></div></td></tr><tr><td style="width: 108pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Exercise of stock options<font style="padding-left: 0.19pt;"></font></div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 42.5pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 34pt;">&#8212;</font></div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 38.25pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 29.75pt;">&#8212;</font></div></td><td style="width: 1.75pt; border-right: 1pt solid #000000; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 38.25pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 4.25pt;">1,107,854</font></div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 27.99pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 7.62pt; text-align: left;"><font style="padding-left: 4.25pt;">&#8212;</font></div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36.45pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 4.41pt; text-align: left;"><font style="padding-left: 8.5pt;">1,489</font></div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 53.17pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 16.68pt; text-align: left;"><font style="padding-left: 11.33pt;">&#8212;</font></div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45.31pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 5.3pt; text-align: left;"><font style="padding-left: 26.2pt;">&#8212;</font></div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 47.1pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 6.19pt; text-align: left;"><font style="padding-left: 15.58pt;">1,489 </font></div></td></tr><tr><td style="width: 108pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Stock-based compensation</div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 42.5pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 34pt;">&#8212;</font></div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 38.25pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 29.75pt;">&#8212;</font></div></td><td style="width: 1.75pt; border-right: 1pt solid #000000;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 38.25pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 29.75pt;">&#8212;</font></div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 27.99pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 7.62pt; text-align: left;"><font style="padding-left: 4.25pt;">&#8212;</font></div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36.45pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 4.41pt; text-align: left;"><font style="padding-left: 8.5pt;">5,846</font></div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 53.17pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 16.68pt; text-align: left;"><font style="padding-left: 11.33pt;">&#8212;</font></div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45.31pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 5.3pt; text-align: left;"><font style="padding-left: 26.2pt;">&#8212;</font></div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 47.1pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 6.19pt; text-align: left;"><font style="padding-left: 15.58pt;">5,846 </font></div></td></tr><tr><td style="width: 108pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Unrealized gain on marketable securities<font style="padding-left: 3.89pt;"></font></div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 42.5pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 34pt;">&#8212;</font></div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 38.25pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 29.75pt;">&#8212;</font></div></td><td style="width: 1.75pt; border-right: 1pt solid #000000; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 38.25pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 29.75pt;">&#8212;</font></div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 27.99pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 7.62pt; text-align: left;"><font style="padding-left: 4.25pt;">&#8212;</font></div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36.45pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 4.41pt; text-align: left;"><font style="padding-left: 19.13pt;">&#8212;</font></div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 53.17pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 16.68pt; text-align: left;"><font style="padding-left: 7.39pt;">811</font></div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45.31pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 5.3pt; text-align: left;"><font style="padding-left: 26.2pt;">&#8212;</font></div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 47.1pt; padding-top: 1.31pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 6.19pt; text-align: left;"><font style="padding-left: 22.27pt;">811 </font></div></td></tr><tr><td style="width: 108pt; padding-top: 1.31pt; padding-bottom: 2.88pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Net loss<font style="padding-left: 3.26pt;"></font></div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 42.5pt; padding-top: 1.31pt; padding-bottom: 2.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 34pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 38.25pt; padding-top: 1.31pt; padding-bottom: 2.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 29.75pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 1.75pt; border-right: 1pt solid #000000;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 38.25pt; padding-top: 1.31pt; padding-bottom: 2.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 29.75pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 27.99pt; padding-top: 1.31pt; padding-bottom: 2.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 7.62pt; text-align: left;"><font style="padding-left: 4.25pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36.45pt; padding-top: 1.31pt; padding-bottom: 2.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 4.41pt; text-align: left;"><font style="padding-left: 19.13pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 53.17pt; padding-top: 1.31pt; padding-bottom: 2.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 16.68pt; text-align: left;"><font style="padding-left: 11.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45.31pt; padding-top: 1.31pt; padding-bottom: 2.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 5.3pt; text-align: left;"><font style="padding-left: 4.25pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(162,539</font><font style="padding-bottom: 1.5pt;">)</font></div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 47.1pt; padding-top: 1.31pt; padding-bottom: 2.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 6.19pt; text-align: left;"><font style="padding-left: 4.25pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(162,539</font><font style="padding-bottom: 1.5pt;">) </font></div></td></tr><tr><td style="width: 108pt; padding-top: 2.56pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Balance at December&#160;31, 2025</div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 42.5pt; padding-top: 2.56pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">144,834,563</font></div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 38.25pt; padding-top: 2.56pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$1,181,061</font></div></td><td style="width: 1.75pt; border-right: 1pt solid #000000; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 1.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 38.25pt; padding-top: 2.56pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">20,765,754</font></div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 27.99pt; padding-top: 2.56pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 7.62pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$&#8212;</font></div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36.45pt; padding-top: 2.56pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 4.41pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$32,242</font></div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 53.17pt; padding-top: 2.56pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 16.68pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 2.83pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">476</font></div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45.31pt; padding-top: 2.56pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 5.3pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$(601,282</font><font style="padding-bottom: 0.5pt;">)</font></div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 47.1pt; padding-top: 2.56pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 0pt; margin-left: 6.19pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$(568,564</font><font style="padding-bottom: 0.5pt;">)</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 3.25pt; width: 108pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 42.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 38.25pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 1.75pt; border-right: 1pt solid #000000; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 1.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 38.25pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 27.99pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 36.45pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 53.17pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 45.31pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 2pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 47.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 9.47pt; text-align: center;">The accompanying notes are an integral part of these consolidated financial statements.<br></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-5<br></div></div></div>
<!--End Page 351-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 352-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_201-fintab_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tCSOCF"><!--Anchor--></a>TREELINE BIOSCIENCES, INC. AND SUBSIDIARY <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">CONSOLIDATED STATEMENTS OF CASH FLOWS <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">(IN THOUSANDS) </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 348pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 9.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 9.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 100.84pt;" colspan="4"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 348pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 9.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.59pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td colspan="4" style="width: 100.84pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended December&#160;31 </div></td></tr><tr class="BRDSX_header"><td style="width: 348pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 9.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.59pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div></td><td style="width: 9.59pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.59pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div></td></tr><tr><td style="width: 348pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating activities<br></div></td><td style="width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net loss<font style="padding-left: 3.01pt;"></font></div></td><td style="width: 9.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$(162,539)</div></td><td style="width: 9.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$(162,487) </div></td></tr><tr><td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Adjustments to reconcile net loss from operations to net cash used in operating activities:<br></div></td><td style="width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Stock-based compensation<font style="padding-left: 3.59pt;"></font></div></td><td style="width: 9.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 18.33pt;">5,846</font></div></td><td style="width: 9.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 18.33pt;">4,130 </font></div></td></tr><tr><td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Depreciation and amortization<font style="padding-left: 3.87pt;"></font></div></td><td style="width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 18.33pt;">6,061</font></div></td><td style="width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 18.33pt;">5,566 </font></div></td></tr><tr><td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Amortization of premium and discount on marketable securities, net<font style="padding-left: 2.52pt;"></font></div></td><td style="width: 9.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 15.37pt;">(9,611)</font></div></td><td style="width: 9.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 15pt;">(6,559) </font></div></td></tr><tr><td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Disposals of fixed assets<font style="padding-left: 1.93pt;"></font></div></td><td style="width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 25.83pt;">201</font></div></td><td style="width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 25.83pt;">325 </font></div></td></tr><tr><td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Changes in operating assets and liabilities:<br></div></td><td style="width: 9.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 9.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Prepaid expenses and other assets<font style="padding-left: 0.55pt;"></font></div></td><td style="width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 15pt;">(5,345)</font></div></td><td style="width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 15pt;">(3,935) </font></div></td></tr><tr><td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Accounts payable<font style="padding-left: 4.14pt;"></font></div></td><td style="width: 9.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 15pt;">(2,020)</font></div></td><td style="width: 9.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 18.33pt;">2,849 </font></div></td></tr><tr><td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Accrued expenses<font style="padding-left: 3.04pt;"></font></div></td><td style="width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 18.33pt;">2,006</font></div></td><td style="width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 30.83pt;">80 </font></div></td></tr><tr><td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Right of use assets and operating lease liabilities, net<font style="padding-left: 4.17pt;"></font></div></td><td style="width: 9.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">983</font></div></td><td style="width: 9.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(212</font><font style="padding-bottom: 1.5pt;">) </font></div></td></tr><tr><td style="width: 348pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net cash used in operating activities<font style="padding-left: 0.82pt;"></font></div></td><td style="width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">(164,418)</font></div></td><td style="width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">(160,243) </font></div></td></tr><tr><td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 9.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 9.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Investing activities<br></div></td><td style="width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Purchases of marketable securities<font style="padding-left: 2.51pt;"></font></div></td><td style="width: 9.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">(522,195)</font></div></td><td style="width: 9.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">(445,949) </font></div></td></tr><tr><td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Maturities of marketable securities<font style="padding-left: 1.39pt;"></font></div></td><td style="width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 8.33pt;">437,668</font></div></td><td style="width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 8.33pt;">194,730 </font></div></td></tr><tr><td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Purchases of fixed assets<font style="padding-left: 0.82pt;"></font></div></td><td style="width: 9.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 15pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(1,288</font><font style="padding-bottom: 1.5pt;">)</font></div></td><td style="width: 9.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 15pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(5,130</font><font style="padding-bottom: 1.5pt;">) </font></div></td></tr><tr><td style="width: 348pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net cash used in investing activities<font style="padding-left: 1.93pt;"></font></div></td><td style="width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10pt;">(85,815)</font></div></td><td style="width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">(256,349) </font></div></td></tr><tr><td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 9.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 9.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Financing activities<br></div></td><td style="width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Proceeds from exercise of options<font style="padding-left: 4.44pt;"></font></div></td><td style="width: 9.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 18.33pt;">1,489</font></div></td><td style="width: 9.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 25.83pt;">810 </font></div></td></tr><tr><td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Proceeds from issuance of preferred stock and prefunded warrants, net of issuance costs<font style="padding-left: 0.51pt;"></font></div></td><td style="width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">255,525</font></div></td><td style="width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">421,612 </font></div></td></tr><tr><td style="width: 348pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net cash provided by financing activities<font style="padding-left: 1.38pt;"></font></div></td><td style="width: 9.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">257,014</font></div></td><td style="width: 9.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">422,422 </font></div></td></tr><tr><td style="width: 348pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net increase in cash, cash equivalents, and restricted cash<font style="padding-left: 0.04pt;"></font></div></td><td style="width: 9.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 18.33pt;">6,781</font></div></td><td style="width: 9.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 18.33pt;">5,830 </font></div></td></tr><tr><td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash, cash equivalents, and restricted cash, beginning of year<font style="padding-left: 4.75pt;"></font></div></td><td style="width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">40,694</font></div></td><td style="width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">34,864 </font></div></td></tr><tr><td style="width: 348pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash, cash equivalents, and restricted cash, end of year<font style="padding-left: 0.31pt;"></font></div></td><td style="width: 9.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 8.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">47,475</font></div></td><td style="width: 9.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 8.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">40,694 </font></div></td></tr><tr><td style="width: 348pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Supplemental noncash investing information<br></div></td><td style="width: 9.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 9.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Unrealized gain (loss) on marketable securities<font style="padding-left: 2.52pt;"></font></div></td><td style="width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 21.2pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">811</font></div></td><td style="width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 17.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(524</font><font style="padding-bottom: 0.5pt;">) </font></div></td></tr><tr><td style="width: 348pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Property and equipment in accounts payable<font style="padding-left: 3.05pt;"></font></div></td><td style="width: 9.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 25.83pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">15</font></div></td><td style="width: 9.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 20.83pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">153 </font></div></td></tr><tr><td style="width: 348pt; padding-top: 3.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Initial recognition of operating lease right-of-use asset<font style="padding-left: 3.36pt;"></font></div></td><td style="width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 3.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 8.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">12,500</font></div></td><td style="width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 3.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 13.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">4,401</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 348pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 40.83pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 9.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 40.83pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 9.47pt; text-align: center;">The accompanying notes are an integral part of these consolidated financial statements.<br></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-6<br></div></div></div>
<!--End Page 352-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 353-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_202-finnotes_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;"><a name="tNTCF"><!--Anchor--></a>1. Organization and Description of Business </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Treeline Biosciences, Inc. and Subsidiary (the Company) is a biotechnology company focused on building transformative precision medicines for patients with cancer and other serious conditions. In 2023, the Company created a wholly owned Swiss subsidiary, Treeline Biosciences GmbH, for the purposes of conducting research and development (R&amp;D). The Company&#8217;s reporting currency is the U.S. dollar. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Liquidity </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company has incurred losses and negative cash flows from operations since inception and has an accumulated deficit of $601.3&#160;million as of December&#160;31, 2025. The Company anticipates incurring additional losses until such time, if ever, as it can generate significant sales of its product candidates. Substantial additional financing will be needed by the Company to fund its operations and to commercially develop its product candidates. No assurance can be given that any such financing will be available when needed or that the Company&#8217;s R&amp;D efforts will be successful. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company follows the provisions of the Financial Accounting Standards Board (the FASB) Accounting Standards Codification (ASC) Topic 205-40, <font style="font-style: italic;">Presentation of Financial Statements &#8212; Going Concern</font>, which requires management to assess the Company&#8217;s ability to continue as a going concern within one year after the date the consolidated financial statements are issued. As of December&#160;31, 2025, the Company had cash, cash equivalents, and marketable securities of $604.8 million, which the Company expects to be sufficient to fund its operating expenses and capital expenditure requirements for at least the next 12 months from the issuance date of these consolidated financial statements. To fund its operating expenses and capital expenditure requirements after that date, the Company plans to seek additional funding through public or private equity offerings, debt financings, collaborations, strategic alliances, and/or licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into strategic alliances or other arrangements on favorable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company&#8217;s stockholders. If the Company is unable to obtain funding, the Company could be required to delay, reduce, or eliminate R&amp;D programs, product portfolio expansion, or future commercialization efforts, which could adversely affect its business prospects. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Risks and Uncertainties </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company faces risks associated with biotechnology companies. Product candidates currently being researched will require significant additional R&amp;D efforts, including extensive preclinical studies and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital for the Company to complete its R&amp;D, defend its intellectual property rights, and recruit and retain skilled personnel and key members of management. Even if the Company&#8217;s efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">2. Basis of Presentation and Significant Accounting Policies </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Basis of Presentation </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The accompanying consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (GAAP). Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the ASC and Accounting Standards Updates (ASUs) of the FASB. The accompanying consolidated financial statements include all adjustments necessary for the fair presentation of the Company&#8217;s financial position for the period presented. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">Principles of Consolidation </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company&#8217;s consolidated financial statements include the accounts of Treeline Biosciences, Inc. and its wholly owned subsidiary, Treeline Biosciences GmbH. All intercompany transactions between and among the Company and its subsidiary have been eliminated in consolidation. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">Use of Estimates </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and expenses reported in the consolidated financial statements and the accompanying notes. Due to the uncertainty of factors regarding the estimates or judgments used in the preparation of the consolidated financial statements, actual results may vary materially from these estimates. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-7<br></div></div></div>
<!--End Page 353-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 354-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_202-finnotes_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">Estimates and assumptions are periodically reviewed, and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Areas that require management&#8217;s estimates include fair value of the Company&#8217;s common stock and stock-based compensation (Note&#160;10). </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">Fair Value of Financial Instruments </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Management believes that the carrying amounts of the Company&#8217;s cash and cash equivalents and accounts payable, accrued expenses, and other liabilities approximate fair value due to the short-term nature of those instruments. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">Concentration of Credit Risk </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, and marketable securities. Substantially all of the Company&#8217;s cash deposits are maintained at a large, creditworthy financial institution. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash and cash equivalents beyond the normal credit risk associated with commercial banking relationships. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Foreign Currency </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Monetary assets and liabilities resulting from transactions denominated in currencies other than the functional currency are remeasured into the functional currency at exchange rates prevailing at the balance sheet date. Non-monetary assets and liabilities denominated in foreign currencies are measured using historical exchange rates prevailing at the date of the transaction and are not subsequently remeasured. Foreign currency remeasurement gains and losses are recognized within other income in the consolidated statements of operations and comprehensive loss. Foreign currency remeasurement gains and losses for the years ended December&#160;31, 2025 and 2024 were not material. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Cash, Cash Equivalents, and Restricted Cash </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company considers all highly liquid investments purchased with original maturities of three months or less from the purchase date to be cash equivalents. Cash equivalents consist primarily of amounts invested in a money market account. The Company held cash as of December&#160;31, 2025 and 2024, of approximately $1.1 million and $1.2&#160;million, respectively, in separate restricted bank accounts for lease security deposits. The Company has classified these amounts as long-term restricted cash on the accompanying consolidated balance sheets as these leases expire after December&#160;31, 2026. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Marketable Securities </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company&#8217;s marketable securities consist of investments in corporate debt securities, commercial paper, and government bonds that are classified as available for sale. These securities are carried at fair value with the unrealized gains and losses included, net of tax, in accumulated other comprehensive income (loss), a component of stockholders&#8217; equity. Realized gains and losses and declines in value determined to be other than temporary are included on the Company&#8217;s statements of operations and comprehensive loss. All marketable securities are available for use, as needed, to fund operations and therefore, the Company classifies all marketable securities as current assets on the consolidated balance sheets. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Property and Equipment </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Property and equipment (Note&#160;5) are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight-line method over the estimated useful lives of the assets, ranging from three to seven years, as follows: </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 372pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 12pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 12pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 72pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 372pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Fixed Asset Type</div></td><td style="width: 12pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 12pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Estimated <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Useful Life </div></td></tr><tr><td style="width: 372pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Computer equipment</div></td><td style="width: 12pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 12pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">3 years </div></td></tr><tr><td style="width: 372pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lab equipment </div></td><td style="width: 12pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 12pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">5 years </div></td></tr><tr><td style="width: 372pt; padding-top: 1.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Furniture and fixtures</div></td><td style="width: 12pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 12pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">7 years</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 372pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 12pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 12pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 72pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-8<br></div></div></div>
<!--End Page 354-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 355-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_202-finnotes_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">Expenditures for repairs and maintenance of assets are charged to expense as incurred, while major betterments are capitalized. Upon retirement or sale, the cost and related accumulated depreciation of assets disposed of are removed from the accounts and any resulting gain or loss is included on the statements of operations and comprehensive loss. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company reviews long-lived assets, such as property and equipment, for impairment when events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. If indicators of impairment are present, the assets are tested for recoverability by comparing the carrying amount of the assets with the related estimated future undiscounted cash flows that the assets are expected to generate. If the expected cash flows are less than the carrying value of the asset, then the asset is considered to be impaired and its carrying value is written down to fair value, based on the related estimated discounted future cash flows. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16pt; margin-left: 0pt; text-align: left;">Leases </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Contractual arrangements that meet the definition of a lease are classified as operating or finance leases and are recorded on the consolidated balance sheets as both a right-of-use asset (ROU asset) and lease liability, calculated by discounting fixed lease payments over the lease term at the Company&#8217;s incremental borrowing rate (IBR). Lease ROU assets and lease obligations are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. ROU assets are adjusted for payments made at or before the commencement date. The Company currently has operating leases for office and lab space. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company considers a lease term to be the noncancelable period that it has the right to use the underlying asset, including any periods where it is reasonably certain the Company will exercise any option to extend the contract. Lease costs for minimum lease payments for operating leases are recognized on a straight-line basis over the lease term. Lease liabilities are increased by interest and reduced by payments each period, and the ROU asset is reduced over the lease term. Variable lease payments that do not depend on an index or rate are recognized as lease costs when incurred. In measuring the ROU assets and lease liabilities, the Company has elected to combine lease and non-lease components. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company does not recognize ROU assets or lease liabilities for short-term leases, if any, having initial terms of 12&#160;months or less at lease commencement as an accounting policy election, and recognizes rent expense on a straight-line basis over the lease term for these types of leases. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16pt; margin-left: 0pt; text-align: left;">Patent-Related Costs </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Patent-related costs incurred in connection with patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses in the accompanying consolidated statement of operations and comprehensive loss. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Research and Development Costs </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">R&amp;D costs are expensed as incurred. R&amp;D expenses are composed of costs incurred in performing R&amp;D activities and consist primarily of personnel costs, facilities costs, depreciation, lab expenses, software expenses, third-party license fees, costs related to third parties engaged to conduct clinical trials and preclinical R&amp;D activities, and stock-based compensation expenses. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company has entered into various R&amp;D contracts with third parties to conduct research on its behalf. These agreements are generally cancelable. The Company records accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies, including the phase or completion of events, invoices received, and contracted costs. Significant judgments and estimates may be required in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates. The Company&#8217;s historical accrual estimates have not been materially different from the actual costs. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Costs incurred in obtaining technology licenses, which include up-front cash payments, common stock issuances, and liabilities for costs to perform certain research activities on behalf of the licensor that are deemed probable and estimable, are immediately recognized as acquired in-process R&amp;D expense provided that the technology licensed has not reached feasibility and has no alternative future use. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Segment Information </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-9<br></div></div></div>
<!--End Page 355-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 356-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_202-finnotes_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">assessing performance. The Company views its operations and manages its business in one operating segment. The Company&#8217;s chief operating decision-maker (CODM), its chief executive officer, manages the Company&#8217;s operations on a consolidated basis for the purpose of allocating resources. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The accounting policies of the segment are the same as those described in the summary of significant accounting policies. The CODM assesses performance, makes operating decisions, and allocates resources for its segment based on net loss, which is reported on the statements of operations. The measure of segment assets is reported on the balance sheet as total assets. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">The table below summarizes the significant expense categories regularly reviewed by the CODM: </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 360pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 95.92pt;" colspan="4"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 360pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 6.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.05pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td colspan="4" style="width: 95.92pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Years Ended December&#160;31 </div></td></tr><tr class="BRDSX_header"><td style="width: 360pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 6.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.05pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.91pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div></td><td style="width: 6.05pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.05pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.91pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div></td></tr><tr><td style="width: 360pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Clinical programs<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(a)</sup>:<br></div></td><td style="width: 6.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.91pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.91pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">TLN-121<font style="padding-left: 4.73pt;"></font></div></td><td style="width: 6.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.91pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.54pt; text-align: left;">$<font style="padding-left: 13.33pt;">8,687</font></div></td><td style="width: 6.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.91pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.54pt; text-align: left;">$<font style="padding-left: 25.83pt;">&#8212; </font></div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">TLN-254<font style="padding-left: 4.73pt;"></font></div></td><td style="width: 6.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.91pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.54pt; text-align: left;"><font style="padding-left: 18.33pt;">6,245</font></div></td><td style="width: 6.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.91pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.54pt; text-align: left;"><font style="padding-left: 18.33pt;">6,091 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">TLN-372<font style="padding-left: 4.73pt;"></font></div></td><td style="width: 6.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.91pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.54pt; text-align: left;"><font style="padding-left: 18.33pt;">7,601</font></div></td><td style="width: 6.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.91pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.54pt; text-align: left;"><font style="padding-left: 30.83pt;">&#8212; </font></div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Preclinical programs and other<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(b)</sup><font style="padding-left: 0.74pt;"></font></div></td><td style="width: 6.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.91pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.54pt; text-align: left;"><font style="padding-left: 13.33pt;">87,994</font></div></td><td style="width: 6.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.91pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.54pt; text-align: left;"><font style="padding-left: 13.33pt;">98,635 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Personnel costs, including stock-based compensation<font style="padding-left: 0.06pt;"></font></div></td><td style="width: 6.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.91pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.54pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">49,482</font></div></td><td style="width: 6.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.91pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.54pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">46,980 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total research and development expenses<font style="padding-left: 1.59pt;"></font></div></td><td style="width: 6.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.91pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.54pt; text-align: left;"><font style="padding-left: 8.33pt;">160,009</font></div></td><td style="width: 6.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.91pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.54pt; text-align: left;"><font style="padding-left: 8.33pt;">151,706 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">General and administrative<br></div></td><td style="width: 6.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.91pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.91pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Personnel costs, including stock-based compensation<font style="padding-left: 0.06pt;"></font></div></td><td style="width: 6.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.91pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.54pt; text-align: left;"><font style="padding-left: 13.7pt;">11,162</font></div></td><td style="width: 6.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.91pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.54pt; text-align: left;"><font style="padding-left: 13.33pt;">10,465 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Professional fees and other<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(c)</sup><font style="padding-left: 1.16pt;"></font></div></td><td style="width: 6.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.91pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.54pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">12,094</font></div></td><td style="width: 6.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.91pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.54pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">13,093 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total general and administrative expenses<font style="padding-left: 4.92pt;"></font></div></td><td style="width: 6.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.91pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.54pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">23,256</font></div></td><td style="width: 6.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.91pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.54pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">23,558 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total operating expenses<font style="padding-left: 3.23pt;"></font></div></td><td style="width: 6.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.91pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.54pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">183,265</font></div></td><td style="width: 6.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.91pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.54pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">175,264 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss from operations<font style="padding-left: 2.53pt;"></font></div></td><td style="width: 6.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.91pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.54pt; text-align: left;"><font style="padding-left: 5pt;">(183,265)</font></div></td><td style="width: 6.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.91pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.54pt; text-align: left;"><font style="padding-left: 5pt;">(175,264) </font></div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other income<font style="padding-left: 2.8pt;"></font></div></td><td style="width: 6.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.91pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.54pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">20,726</font></div></td><td style="width: 6.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.05pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.91pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.54pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">12,777 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net loss<font style="padding-left: 0.01pt;"></font></div></td><td style="width: 6.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.91pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.54pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(162,539</font><font style="padding-bottom: 1.5pt;">)</font></div></td><td style="width: 6.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 41.91pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.54pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(162,487</font><font style="padding-bottom: 1.5pt;">)</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 360pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 41.91pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.05pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 41.91pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div><div class="BRDSX_rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 13.25pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(a)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Once a program has received approval from the FDA of its investigational new drug (IND) application, the Company classifies the program as a clinical program. Until a program has received approval of its IND application, the Company considers it a preclinical program. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(b)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Preclinical programs and other includes expenses related to the Company&#8217;s preclinical programs, rent expense, and lab supplies. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(c)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Professional fees and other includes legal, accounting, and audit fees, rent expense, software licenses, and insurance costs. </div></td></tr></table><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Stock-Based Compensation </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company measures employee and nonemployee share-based awards at their grant-date fair values and records compensation expense on a straight-line basis over the vesting periods of the awards. The Company accounts for forfeitures in the periods in which they occur. Estimating the fair value of share-based awards requires the input of subjective assumptions, including the estimated fair value of the Company&#8217;s common stock and, for stock options, the expected term of the options and stock price volatility. The Company uses the Black-Scholes option-pricing model to value its stock option awards. The assumptions used in estimating the fair value of share-based awards represent management&#8217;s estimates and involve inherent uncertainties and the application of management&#8217;s judgment. As a result, if factors change and management uses different assumptions, share-based compensation expense could be materially different for future awards. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The expected term of the stock options is estimated using the &#8220;simplified method&#8221; as the Company has limited historical information from which to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. The simplified method is the midpoint between the vesting period and the contractual term of the option. For stock price volatility, the Company uses comparable public companies as a basis for its expected volatility to calculate the fair value of option grants. The risk-free rate is based on the U.S. Treasury yield curve commensurate with the expected term of the option. The dividend rate is zero as the Company has not planned, nor does it plan in the foreseeable future, to declare dividends. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-10<br></div></div></div>
<!--End Page 356-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 357-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_202-finnotes_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Income Taxes </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Income taxes are accounted for under the asset and liability method. The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company&#8217;s assets and liabilities, and the expected benefits of net operating losses and income tax credit carryforwards. The impact of changes in tax rates and laws on deferred taxes, if any, applied during the period in which temporary differences are expected to be settled is reflected in the Company&#8217;s consolidated financial statements in the period of enactment. The measurement of deferred tax assets is reduced, if necessary, if, based on weight of the evidence, it is more likely than not that some, or all, of the deferred tax assets will not be realized. As of December&#160;31, 2025 and 2024, the Company has concluded that a full valuation allowance is necessary for all of its net deferred tax assets. The Company had no amounts recorded for uncertain tax positions, interest, or penalties in the accompanying consolidated financial statements. Although there are no unrecognized income tax benefits, when applicable, the Company&#8217;s policy is to report interest and penalties related to unrecognized income tax benefits as a component of income tax expense or benefit. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16pt; margin-left: 0pt; text-align: left;">Net Loss Per Share </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. Common shares issuable upon exercise of the pre-funded warrants that were sold in connection with the 2025 Series&#160;A-2 Preferred Stock and Warrant Purchase Agreement are included in the calculation of weighted-average number of shares outstanding for the year ended December&#160;31, 2025. Consistent with the guidance in ASC 260-10-45-13, the underlying common shares are issuable for little to no consideration and there are no vesting conditions or contingencies associated with the warrants. Accordingly, the aggregate number of common shares underlying the pre-funded warrants have been considered outstanding for purposes of the calculation of net loss per share from the date of issuance. Diluted net loss per share of common stock includes the effect, if any, from the potential exercise of securities, such as stock options, unvested restricted stock units, and convertible preferred stock which would result in the issuance of incremental shares of common stock. Basic and diluted net loss per share is presented in conformity with the two-class method required for participating securities as the convertible preferred stock is considered a participating security. The Company&#8217;s participating securities do not have a contractual obligation to share in the Company&#8217;s losses. As such, the net loss is attributed entirely to common stockholders. Because the Company has reported a net loss for the reporting periods presented, the diluted net loss per common share is the same as basic net loss per common share for those periods. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive: </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 348pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 110pt;" colspan="4"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 348pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td colspan="4" style="width: 110pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">As of December&#160;31, </div></td></tr><tr class="BRDSX_header"><td style="width: 348pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div></td><td style="width: 5pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div></td></tr><tr><td style="width: 348pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Convertible preferred stock<font style="padding-left: 0.54pt;"></font></div></td><td style="width: 5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">144,834,563</div></td><td style="width: 5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 0.37pt;">115,102,744 </font></div></td></tr><tr><td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Stock options<font style="padding-left: 0.78pt;"></font></div></td><td style="width: 5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">18,441,432</font></div></td><td style="width: 5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5.37pt;">14,879,112 </font></div></td></tr><tr><td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Unvested restricted stock awards<font style="padding-left: 3.61pt;"></font></div></td><td style="width: 5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 40pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">866,301 </font></div></td></tr><tr><td style="width: 348pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total<font style="padding-left: 0.09pt;"></font></div></td><td style="width: 5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">163,275,995</font></div></td><td style="width: 5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">130,848,157</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 348pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 50pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 50pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Amounts in the above table reflect the common stock equivalents. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Recently Adopted Accounting Standards </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">From time to time, new accounting pronouncements are issued by the FASB and are early adopted by the Company or adopted as of the specified effective date. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In November&#160;2023, the FASB issued ASU 2023-07, <font style="font-style: italic;">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</font> (ASU-2023-07), which expands segment disclosures including, among other matters, significant segment expenses regularly provided to the chief operating decision-maker and the title and position of the chief operating decision-maker. The amendments included in this ASU apply to all public entities that are required to report segment information in accordance with Topic 280, including those with a single reportable segment. The amendments are effective for fiscal years beginning after December&#160;15, 2023 and interim periods within fiscal years beginning after December&#160;15, 2024. The Company adopted ASU 2023-07 effective for the year ended December&#160;31, 2024 on a retrospective basis. The additional disclosures required by ASU 2023-07 are reflected in the segment information presented in Note&#160;2. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-11<br></div></div></div>
<!--End Page 357-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 358-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_202-finnotes_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">In December&#160;2023, the FASB issued ASU 2023-09, <font style="font-style: italic;">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</font>. The amendments in this update apply to all entities that are subject to Topic 740, Income Taxes. The standard requires disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation as well as information on income taxes paid. For public entities, the amendments in this update are effective for annual periods beginning after December&#160;15, 2024 and may be applied prospectively or retrospectively. The amendments were applied retrospectively and are reflected in Note&#160;11. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Recently Issued Accounting Pronouncements Not Yet Adopted </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In November&#160;2024, the FASB issued ASU 2024-03, <font style="font-style: italic;">Income Statement &#8212; Reporting Comprehensive Income &#8212; Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</font>, which requires public entities to disclose additional information about specific expense categories in the notes to the financial statements on an interim and annual basis. In January&#160;2025, the FASB issued ASU 2025-01, <font style="font-style: italic;">Income Statement &#8212; Reporting Comprehensive Income &#8212; Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date</font>. The amendments are effective for annual periods beginning after December&#160;15, 2026 and interim periods within annual periods beginning after December&#160;15, 2027. As an emerging growth company that has elected the extended transition period, the Company expects to adopt this standard for the annual period beginning January&#160;1, 2028. Early adoption is permitted. The Company is currently evaluating the impact this standard will have on its consolidated financial statements. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In May&#160;2025, the FASB issued ASU 2025-03,<font style="font-style: italic;"> Business Combinations (Topic 805) and Consolidation (Topic 810): Determining the Accounting Acquirer in the Acquisition of a Variable Interest Entity</font>, which requires entities to consider the factors in ASC 805-10-55-12 through 55-15 when identifying the accounting acquirer in a business combination effected primarily through an exchange of equity interests in which the legal acquiree is a variable interest entity that meets the definition of a business (ASU 2025-03). The amendments are effective for all entities for annual periods beginning after December&#160;15, 2026 and interim periods within those periods, with early adoption permitted. The Company has elected to early adopt ASU 2025-03 effective January&#160;1, 2026. Because the standard is applied prospectively, adoption has no effect on the Company&#8217;s consolidated financial statements as of and for the year ended December&#160;31, 2025 and 2024. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">3. Marketable Securities </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">The following is a summary of the Company&#8217;s marketable securities (amounts in thousands): </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 240pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.28pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.28pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 37.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 56.07pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 54.74pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 37.5pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 240pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 5.28pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.28pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Amortized <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Cost</div></td><td style="width: 5.27pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.27pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.07pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Gross <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Unrealized Gain</div></td><td style="width: 5.27pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.27pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 54.74pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Gross <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Unrealized Loss</div></td><td style="width: 5.27pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.27pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Fair<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Value </div></td></tr><tr><td style="width: 240pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">As of December&#160;31, 2025<br></div></td><td style="width: 5.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 5.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.07pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 5.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 54.74pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 5.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Marketable securities:<br></div></td><td style="width: 5.28pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.28pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 5.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.07pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 5.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 54.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 5.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Commercial paper<font style="padding-left: 3.36pt;"></font></div></td><td style="width: 5.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$228,361</div></td><td style="width: 5.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.07pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.03pt; text-align: left;">$<font style="padding-left: 5pt;">85</font></div></td><td style="width: 5.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 54.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.2pt; text-align: left;">$(14)</div></td><td style="width: 5.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$228,432 </div></td></tr><tr><td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Corporate debt securities<font style="padding-left: 2.54pt;"></font></div></td><td style="width: 5.28pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.28pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10pt;">86,174</font></div></td><td style="width: 5.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.07pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.03pt; text-align: left;"><font style="padding-left: 10pt;">63</font></div></td><td style="width: 5.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 54.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.2pt; text-align: left;"><font style="padding-left: 8.33pt;">&#8212;</font></div></td><td style="width: 5.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10pt;">86,237 </font></div></td></tr><tr><td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">U.S. Treasury bonds<font style="padding-left: 0.83pt;"></font></div></td><td style="width: 5.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">220,885</font></div></td><td style="width: 5.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.07pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.03pt; text-align: left;"><font style="padding-left: 5pt;">292</font></div></td><td style="width: 5.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 54.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.2pt; text-align: left;"><font style="padding-left: 8.33pt;">&#8212;</font></div></td><td style="width: 5.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">221,177 </font></div></td></tr><tr><td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">U.S. government agency<font style="padding-left: 3.64pt;"></font></div></td><td style="width: 5.28pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.28pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">22,572</font></div></td><td style="width: 5.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.07pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.03pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">51</font></div></td><td style="width: 5.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 54.74pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.2pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 5.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">22,623 </font></div></td></tr><tr><td style="width: 240pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total assets measured at fair value<font style="padding-left: 0.2pt;"></font></div></td><td style="width: 5.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$557,992</font></div></td><td style="width: 5.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.07pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.03pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$491</font></div></td><td style="width: 5.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 54.74pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.2pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$(14</font><font style="padding-bottom: 0.5pt;">)</font></div></td><td style="width: 5.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$558,469</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 240pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 37.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 56.07pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 54.74pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 37.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 240pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.28pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.28pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 37.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 56.07pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 54.74pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 37.5pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 240pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 5.28pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.28pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Amortized <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Cost</div></td><td style="width: 5.27pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.27pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.07pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Gross <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Unrealized Gain</div></td><td style="width: 5.27pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.27pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 54.74pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Gross <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Unrealized Loss</div></td><td style="width: 5.27pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.27pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Fair<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Value </div></td></tr><tr><td style="width: 240pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">As of December&#160;31, 2024<br></div></td><td style="width: 5.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 5.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.07pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 5.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 54.74pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 5.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Marketable securities:<br></div></td><td style="width: 5.28pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.28pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 5.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.07pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 5.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 54.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 5.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Commercial paper<font style="padding-left: 3.36pt;"></font></div></td><td style="width: 5.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$270,535</div></td><td style="width: 5.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.07pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.03pt; text-align: left;">$<font style="padding-left: 5pt;">78</font></div></td><td style="width: 5.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 54.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.7pt; text-align: left;">$<font style="padding-left: 5pt;">(80)</font></div></td><td style="width: 5.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$270,533 </div></td></tr><tr><td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Corporate debt securities<font style="padding-left: 2.54pt;"></font></div></td><td style="width: 5.28pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.28pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10pt;">25,005</font></div></td><td style="width: 5.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.07pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.03pt; text-align: left;"><font style="padding-left: 15pt;">8</font></div></td><td style="width: 5.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 54.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.7pt; text-align: left;"><font style="padding-left: 10pt;">(28)</font></div></td><td style="width: 5.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10pt;">24,985 </font></div></td></tr><tr><td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">U.S. Treasury bonds<font style="padding-left: 0.83pt;"></font></div></td><td style="width: 5.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">142,528</font></div></td><td style="width: 5.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.07pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.03pt; text-align: left;"><font style="padding-left: 10pt;">46</font></div></td><td style="width: 5.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 54.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.7pt; text-align: left;"><font style="padding-left: 5pt;">(421)</font></div></td><td style="width: 5.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">142,153 </font></div></td></tr><tr><td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">U.S. government agency<font style="padding-left: 3.64pt;"></font></div></td><td style="width: 5.28pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.28pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">25,787</font></div></td><td style="width: 5.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.07pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.03pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">73</font></div></td><td style="width: 5.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 54.74pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.7pt; text-align: left;"><font style="padding-left: 10.37pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(11</font><font style="padding-bottom: 1.5pt;">)</font></div></td><td style="width: 5.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">25,849 </font></div></td></tr><tr><td style="width: 240pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total assets measured at fair value<font style="padding-left: 0.2pt;"></font></div></td><td style="width: 5.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$463,855</font></div></td><td style="width: 5.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.07pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.03pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$205</font></div></td><td style="width: 5.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 54.74pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.7pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$(540</font><font style="padding-bottom: 0.5pt;">)</font></div></td><td style="width: 5.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$463,520</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 240pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 37.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 56.07pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 54.74pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 37.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company&#8217;s marketable securities generally have contractual maturity dates of between 3 and 24 months as of December&#160;31, 2025. Net unrealized gain on marketable securities as of December&#160;31, 2025, was $0.5 million. Net </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-12<br></div></div></div>
<!--End Page 358-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 359-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_202-finnotes_pg7"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">unrealized loss on marketable securities as of December&#160;31, 2024, was $0.3&#160;million. As of December&#160;31, 2025, the Company had 8 securities with a total fair market value of $54.3&#160;million in an unrealized loss position. The gains and losses in the table above were primarily due to changes in interest rates, and not due to increased credit risks associated with specific securities, and the Company believes that it is not more likely than not that the Company will be required to sell its marketable securities before recovery of their amortized cost bases, which may be at maturity. Accordingly, no other-than-temporary impairment was recorded for the years ended December&#160;31, 2025 or 2024, and there were no realized gains or losses recorded during the year ended December&#160;31, 2025 or 2024. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following is a summary of the Company&#8217;s marketable debt securities by contractual maturity (amounts in thousands): </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 2pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="margin-top: 0pt; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 360pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 8.25pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 8.25pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 91.5pt;" colspan="4"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 360pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 8.25pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.25pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td colspan="4" style="width: 91.5pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">As of December&#160;31 </div></td></tr><tr class="BRDSX_header"><td style="width: 360pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 8.25pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.25pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div></td><td style="width: 8.25pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.25pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div></td></tr><tr><td style="width: 360pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Due in one year or less<font style="padding-left: 0.59pt;"></font></div></td><td style="width: 8.25pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.25pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$464,332</div></td><td style="width: 8.25pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.25pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$329,017 </div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Due after one year through five years<font style="padding-left: 3.12pt;"></font></div></td><td style="width: 8.25pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.25pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">94,137</font></div></td><td style="width: 8.25pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.25pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">134,503 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total<font style="padding-left: 2.09pt;"></font></div></td><td style="width: 8.25pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.25pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$558,469</font></div></td><td style="width: 8.25pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.25pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$463,520</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 360pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 8.25pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 8.25pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 37.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 8.25pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 8.25pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 37.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Actual maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12.5pt; margin-left: 0pt; text-align: left;">4. Fair Value Measurements </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or a liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Level&#160;1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Level&#160;2 Inputs: Other than quoted prices included in Level&#160;1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Level&#160;3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date. </div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: justify;">The following tables present the Company&#8217;s assets that are measured at fair value on a recurring basis (amounts in thousands): </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 336pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 32.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 37.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 29.99pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Level&#160;1)</div></td><td style="width: 5.34pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Level&#160;2)</div></td><td style="width: 5.34pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 29.99pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Level&#160;3) </div></td></tr><tr><td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Assets as of December&#160;31, 2025<br></div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 29.99pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash equivalents (money market accounts), including restricted cash<font style="padding-left: 3.59pt;"></font></div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$47,475</div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<font style="padding-left: 22.5pt;">&#8212;</font></div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 29.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.5pt; text-align: left;">$&#8212; </div></td></tr><tr><td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Marketable securities:<br></div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 29.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Commercial paper<font style="padding-left: 4.36pt;"></font></div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">228,432</font></div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 29.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.5pt; text-align: left;"><font style="padding-left: 5pt;">&#8212; </font></div></td></tr><tr><td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Corporate debt securities<font style="padding-left: 3.54pt;"></font></div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10pt;">86,237</font></div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 29.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.5pt; text-align: left;"><font style="padding-left: 5pt;">&#8212; </font></div></td></tr><tr><td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">U.S. government and agency securities<font style="padding-left: 2.44pt;"></font></div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">243,800</font></div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 29.99pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.5pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </font></div></td></tr><tr><td style="width: 336pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total assets measured at fair value<font style="padding-left: 1.2pt;"></font></div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$47,475</font></div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$558,469</font></div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 29.99pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.5pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$&#8212;</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 336pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 32.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 37.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 29.99pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 336pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 32.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 37.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 29.99pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Level&#160;1)</div></td><td style="width: 5.34pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Level&#160;2)</div></td><td style="width: 5.34pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 29.99pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Level&#160;3) </div></td></tr><tr><td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Assets as of December&#160;31, 2024<br></div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 29.99pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash equivalents (money market accounts), including restricted cash<font style="padding-left: 3.59pt;"></font></div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$40,694</div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<font style="padding-left: 22.5pt;">&#8212;</font></div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 29.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.5pt; text-align: left;">$&#8212; </div></td></tr><tr><td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Marketable securities:<br></div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 29.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Commercial paper<font style="padding-left: 4.36pt;"></font></div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">270,533</font></div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 29.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.5pt; text-align: left;"><font style="padding-left: 5pt;">&#8212; </font></div></td></tr><tr><td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Corporate debt securities<font style="padding-left: 3.54pt;"></font></div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10pt;">24,985</font></div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 29.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.5pt; text-align: left;"><font style="padding-left: 5pt;">&#8212; </font></div></td></tr><tr><td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">U.S. government and agency securities<font style="padding-left: 2.44pt;"></font></div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">168,002</font></div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 29.99pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.5pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </font></div></td></tr><tr><td style="width: 336pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total assets measured at fair value<font style="padding-left: 1.2pt;"></font></div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$40,694</font></div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$463,520</font></div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 29.99pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.5pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$&#8212;</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 336pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 32.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 37.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 29.99pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-13<br></div></div></div>
<!--End Page 359-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 360-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_202-finnotes_pg8"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">The fair values of the Company&#8217;s Level&#160;2 marketable securities are estimated primarily based on benchmark yields, reported trades, market-based quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers, and reference data, including market research publications, which represent a market approach. In general, a market approach is utilized if there is readily available and relevant market activity for an individual security. This valuation technique may change from period to period, based on the relevance and availability of market data. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">5. Property and Equipment, Net </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">Property and equipment consist of the following (amounts in thousands): </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 360pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 9.09pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 9.09pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 89.84pt;" colspan="4"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 360pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 9.09pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.09pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td colspan="4" style="width: 89.84pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31 </div></td></tr><tr class="BRDSX_header"><td style="width: 360pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 9.09pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.09pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div></td><td style="width: 9.09pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.09pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div></td></tr><tr><td style="width: 360pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lab equipment<font style="padding-left: 2.23pt;"></font></div></td><td style="width: 9.09pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.09pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<font style="padding-left: 3.33pt;">29,392</font></div></td><td style="width: 9.09pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.09pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<font style="padding-left: 3.33pt;">28,545 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Furniture and fixtures<font style="padding-left: 0.3pt;"></font></div></td><td style="width: 9.09pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.09pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 20.83pt;">733</font></div></td><td style="width: 9.09pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.09pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 13.33pt;">1,028 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Computer equipment<font style="padding-left: 2.79pt;"></font></div></td><td style="width: 9.09pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.09pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">979</font></div></td><td style="width: 9.09pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.09pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">768 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total property and equipment<font style="padding-left: 4.06pt;"></font></div></td><td style="width: 9.09pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.09pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 8.33pt;">31,104</font></div></td><td style="width: 9.09pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.09pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 8.33pt;">30,341 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Less accumulated depreciation<font style="padding-left: 4.21pt;"></font></div></td><td style="width: 9.09pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.09pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(19,208</font><font style="padding-bottom: 1.5pt;">)</font></div></td><td style="width: 9.09pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.09pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(13,456</font><font style="padding-bottom: 1.5pt;">) </font></div></td></tr><tr><td style="width: 360pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Property and equipment, net<font style="padding-left: 4.19pt;"></font></div></td><td style="width: 9.09pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.09pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 3.7pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">11,896</font></div></td><td style="width: 9.09pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.09pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">16,885</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 360pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 9.09pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 9.09pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 35.83pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 9.09pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 9.09pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 35.83pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Depreciation expense was $6.1 million and $5.6&#160;million for the years ended December&#160;31, 2025 and 2024, respectively. Of the total property and equipment, net, $0.3&#160;million were located in Switzerland as of December&#160;31, 2025 and 2024, with the remaining property and equipment, net located in the United States. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">6. Accrued Expenses </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">Accrued expenses consist of the following (amounts in thousands): </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 360pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 10.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 10.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 86.5pt;" colspan="4"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 360pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 10.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.75pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td colspan="4" style="width: 86.5pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31 </div></td></tr><tr class="BRDSX_header"><td style="width: 360pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 10.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.75pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div></td><td style="width: 10.75pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.75pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div></td></tr><tr><td style="width: 360pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Employee compensation<font style="padding-left: 3.91pt;"></font></div></td><td style="width: 10.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<font style="padding-left: 5pt;">8,309</font></div></td><td style="width: 10.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<font style="padding-left: 5pt;">8,533 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Professional services<font style="padding-left: 3.37pt;"></font></div></td><td style="width: 10.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 17.5pt;">585</font></div></td><td style="width: 10.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt;">1,737 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Clinical trials<font style="padding-left: 3.35pt;"></font></div></td><td style="width: 10.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt;">2,809</font></div></td><td style="width: 10.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 17.5pt;">287 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other research and development<font style="padding-left: 2.83pt;"></font></div></td><td style="width: 10.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt;">5,529</font></div></td><td style="width: 10.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10.37pt;">4,711 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other<font style="padding-left: 4.73pt;"></font></div></td><td style="width: 10.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">439</font></div></td><td style="width: 10.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">397 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total accrued expenses<font style="padding-left: 4.91pt;"></font></div></td><td style="width: 10.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$17,671</font></div></td><td style="width: 10.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$15,665</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 360pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 10.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 10.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 32.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 10.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 10.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 32.5pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">7. Commitments and Contingencies </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">Operating Leases </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company has operating leases in San Diego, California; Stamford, Connecticut; and Watertown, Massachusetts, none of which provide for a bargain purchase option or transfer of ownership at any point during the leases. The Company evaluates renewal options at lease inception and on an ongoing basis and includes renewal options that it is reasonably certain to exercise in its expected lease terms when classifying leases and measuring lease liabilities. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company&#8217;s leases generally do not provide an implicit rate, and therefore, the Company uses its incremental borrowing rate (9%&#8211;13%) as the discount rate when measuring operating lease liabilities. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of the lease. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-14<br></div></div></div>
<!--End Page 360-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 361-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_202-finnotes_pg9"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">Future undiscounted minimum annual lease payments under the Company&#8217;s leases as of December&#160;31, 2025 are as follows (amounts in thousands): </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 408pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 12.09pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 12.09pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 35.83pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr><td style="width: 408pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Future undiscounted minimum annual lease payments<br></div></td><td style="width: 12.09pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 12.09pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2026<font style="padding-left: 0.5pt;"></font></div></td><td style="width: 12.09pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 12.09pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<font style="padding-left: 8.33pt;">4,236 </font></div></td></tr><tr><td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2027<font style="padding-left: 0.5pt;"></font></div></td><td style="width: 12.09pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 12.09pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 13.33pt;">5,462 </font></div></td></tr><tr><td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2028<font style="padding-left: 0.5pt;"></font></div></td><td style="width: 12.09pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 12.09pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 13.33pt;">2,914 </font></div></td></tr><tr><td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2029<font style="padding-left: 0.5pt;"></font></div></td><td style="width: 12.09pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 12.09pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 13.33pt;">2,983 </font></div></td></tr><tr><td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2030<font style="padding-left: 0.5pt;"></font></div></td><td style="width: 12.09pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 12.09pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 13.33pt;">2,979 </font></div></td></tr><tr><td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Thereafter<font style="padding-left: 3.86pt;"></font></div></td><td style="width: 12.09pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 12.09pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">10,597 </font></div></td></tr><tr><td style="width: 408pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total lease payments<font style="padding-left: 1.78pt;"></font></div></td><td style="width: 12.09pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 12.09pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 8.33pt;">29,171 </font></div></td></tr><tr><td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Less imputed interest<font style="padding-left: 4.97pt;"></font></div></td><td style="width: 12.09pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 12.09pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(10,216</font><font style="padding-bottom: 1.5pt;">) </font></div></td></tr><tr><td style="width: 408pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total lease liabilities<font style="padding-left: 2.89pt;"></font></div></td><td style="width: 12.09pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 12.09pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">18,955</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 408pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 12.09pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 12.09pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 35.83pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">During the years ended December&#160;31, 2025 and 2024, operating lease costs were $5.5&#160;million and $4.1&#160;million, respectively. During the years ended December&#160;31, 2025 and 2024, variable lease expense was $3.6&#160;million and $3.3&#160;million, respectively. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In addition, the Company is party to short-term leases having a term of 12 months or less at the commencement date. The Company recognizes short-term lease expense on a straight-line basis and does not record a related right-of-use asset or lease liability for such leases. The costs related to short-term leases were $0.4 million and $0.6&#160;million for the years ended December&#160;31, 2025 and 2024, respectively. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">During the years ended December&#160;31, 2025 and 2024, the following other information associated with the leases is as follows (amounts in thousands): </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 360pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 13.25pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 13.25pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 27.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 13.25pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 13.25pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 27.5pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 360pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 13.25pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.25pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 27.5pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div></td><td style="width: 13.25pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.25pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 27.5pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div></td></tr><tr><td style="width: 360pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating cash flows from operating leases<font style="padding-left: 3.96pt;"></font></div></td><td style="width: 13.25pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.25pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 27.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$5,075</div></td><td style="width: 13.25pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.25pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 27.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<font style="padding-left: 0.37pt;">3,911 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Weighted average remaining lease term &#8211; operating leases (years)<font style="padding-left: 0.08pt;"></font></div></td><td style="width: 13.25pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.25pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 27.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt;">6.00</font></div></td><td style="width: 13.25pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.25pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 27.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt;">3.00 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Weighted average discount rate &#8211; operating leases<font style="padding-left: 2.82pt;"></font></div></td><td style="width: 13.25pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.25pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 27.5pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">12.30%</font></div></td><td style="width: 13.25pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.25pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 27.5pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">12.50%</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 360pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 13.25pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 13.25pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 27.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 13.25pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 13.25pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 27.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">Litigation </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Liabilities for loss contingencies arising from claims, assessments, litigation, fines, penalties, and other sources (collectively, Contingency Matters) are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. For Contingency Matters in which the likelihood of material loss is at least reasonably possible, the Company provides disclosure of the possible loss or range of loss. If a reasonable estimate cannot be made, however, the Company will provide disclosure to that effect. At December&#160;31, 2025 and 2024, there are no Contingency Matters currently outstanding. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">8. License Agreements </div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">CRT Pioneer Fund License Agreement </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In May&#160;2022, the Company entered into an exclusive worldwide license agreement (the CRT License Agreement) with CRT Pioneer Fund LP (CPF) to research, develop, manufacture, and commercialize products targeting BCL6 (B-cell lymphoma 6 protein) (BCL6 Products). As consideration for the license, the Company paid an up-front license fee of $2.0&#160;million in 2022, and may owe future development milestone payments totaling up to $22.5&#160;million, commercial milestone payments totaling up to $53.0&#160;million, and low-single-digit royalties on net sales of any product covered by the CRT License Agreement, payable until generic competition commences with respect to such product on a country-by-country basis. The Company incurred and paid $2.5&#160;million and $0 in milestone payments during the years ended December&#160;31, 2025 and 2024, respectively. As of December&#160;31, 2025, the Company paid $4.5&#160;million to CPF under the CRT License Agreement. The CRT License Agreement will continue on a country-by-country basis until expiration of the royalty term, subject to earlier termination by either party for the other&#8217;s uncured material breach or by the Company for convenience upon prior written notice. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-15<br></div></div></div>
<!--End Page 361-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 362-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_202-finnotes_pg10"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Jiangsu Hengrui Pharmaceuticals License Agreement </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In February&#160;2023, the Company entered into an exclusive license agreement (the Jiangsu License) with Jiangsu Hengrui Pharmaceuticals (Jiangsu), pursuant to which the Company obtained exclusive rights to develop and commercialize SHR2554 (TLN-254) and related products outside of mainland China, Hong Kong, Macau, and Taiwan. As consideration for the Exclusive License, the Company paid an up-front fee of $11.0&#160;million in 2023, and may owe additional development milestone payments totaling up to $45.0&#160;million, commercial milestone payments totaling up to $650.0&#160;million, and tiered royalties ranging in the lower teens based on future net sales of licensed products, subject to customary step-downs and a royalty floor. Royalties are payable on a product-by-product and country-by-country basis until expiration of the applicable royalty term. To date, the Company has not incurred expenses related to the Jiangsu License other than the up-front fee of $11.0&#160;million. The Company has incurred operating expenses of $0.1&#160;million and $0.2&#160;million to Jiangsu during the years ended December&#160;31, 2025 and 2024, respectively, related to research and development activities. The Jiangsu License will continue until expiration of the last-to-expire royalty term, subject to earlier termination by either party for the other&#8217;s uncured material breach or by the Company for convenience upon prior written notice. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">9. Convertible Preferred Stock and Stockholders&#8217; Deficit </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">Convertible Preferred Stock </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Prior to 2023, the Company issued 64,382,377 shares of Series&#160;A Preferred Stock (Series&#160;A) at a purchase price of $7.8275 per share and also sold 1,393,679 shares of Series&#160;A-1 Preferred Stock (Series&#160;A-1) at a purchase price of $8.6103 per share for net proceeds of $515.4&#160;million. A total of 341,193 shares of Series&#160;A were issued upon conversion of the principal and accrued interest of a convertible promissory note. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In October&#160;2024, the Company issued 48,985,495 shares of Series&#160;A-1 at a purchase price of $8.6103 per share for net proceeds of $421.6&#160;million. This issuance represented the Future Series&#160;A-1 Rights that were initially described in the Series&#160;A and A-1 Preferred Stock purchase agreement. The Company determined that the Future Series&#160;A-1 Rights did not meet the definition of a freestanding financial instrument as they were not legally detachable. The Future Series&#160;A-1 Rights were also evaluated as an embedded derivative and the Company determined they did not meet the definition of a derivative instrument for which bifurcation would be required. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In 2025, the Company entered into a Series&#160;A-2 Preferred Stock (Series&#160;A-2) and Warrant Purchase Agreement with new and existing investors for the sale of 29,731,819 shares of Series&#160;A-2 at $8.6103 (Original Issue Price) per share for net proceeds of $255.5&#160;million. Each purchaser also received a warrant to purchase nonredeemable common stock at an exercise price of $0.00001 per share (Warrants or pre-funded warrants), which expire ten years from issuance, exercisable for a total of 5,377,111 shares of common stock. In connection with the filing of the restated certificate of incorporation in August&#160;2025, the Company reduced the number of authorized shares of Series&#160;A from 64,730,402 to 64,723,570 to eliminate previously authorized but unissued Series&#160;A shares. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Warrant holders have no voting rights. The Warrants were classified as a component of stockholders&#8217; equity within additional paid-in capital. The Warrants are equity classified because they (i) are freestanding financial instruments that are legally detachable and separately exercisable from Series&#160;A-2, (ii) are immediately exercisable, (iii) do not embody an obligation for the Company to repurchase its shares, (iv) permit the holders to receive a fixed number of shares of common stock upon exercise, (v) are indexed to the Company&#8217;s common stock, and (vi) meet the equity classification criteria. As of December&#160;31, 2025, there were Warrants to purchase 5,377,111 shares of common stock outstanding. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The authorized, issued, and outstanding shares of the Company&#8217;s convertible preferred and liquidation values as of December&#160;31, 2025 were as follows (in thousands, except for share amounts): </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 216pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 7.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 7.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 50pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 7.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 7.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 50pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 7.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 7.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 45pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 7.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 7.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 45pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 216pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 7.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.75pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Authorized <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares</div></td><td style="width: 7.75pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.75pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Outstanding <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares</div></td><td style="width: 7.75pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.75pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Liquidation <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Value</div></td><td style="width: 7.75pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.75pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Carrying <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Value </div></td></tr><tr><td style="width: 216pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Series&#160;A<font style="padding-left: 4.9pt;"></font></div></td><td style="width: 7.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">64,723,570</font></div></td><td style="width: 7.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">64,723,570</font></div></td><td style="width: 7.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<font style="padding-left: 7.5pt;">506,624</font></div></td><td style="width: 7.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<font style="padding-left: 7.5pt;">505,692 </font></div></td></tr><tr><td style="width: 216pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Series&#160;A-1<font style="padding-left: 1.57pt;"></font></div></td><td style="width: 7.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5.37pt;">80,110,993</font></div></td><td style="width: 7.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">50,379,174</font></div></td><td style="width: 7.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt;">433,780</font></div></td><td style="width: 7.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt;">433,583 </font></div></td></tr><tr><td style="width: 216pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Series&#160;A-2 <font style="padding-left: 4.07pt;"></font></div></td><td style="width: 7.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">29,731,819</font></div></td><td style="width: 7.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">29,731,819</font></div></td><td style="width: 7.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">256,000</font></div></td><td style="width: 7.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">241,786 </font></div></td></tr><tr><td style="width: 216pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total<font style="padding-left: 3.09pt;"></font></div></td><td style="width: 7.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">174,566,382</font></div></td><td style="width: 7.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">144,834,563</font></div></td><td style="width: 7.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$ 1,196,404</font></div></td><td style="width: 7.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$ 1,181,061</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 216pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 7.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 7.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 50pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 7.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 7.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 50pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 7.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 7.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 45pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 7.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 7.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 45pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-16<br></div></div></div>
<!--End Page 362-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 363-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_202-finnotes_pg11"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">The authorized, issued, and outstanding shares of the Company&#8217;s convertible preferred and liquidation values as of December&#160;31, 2024 were as follows (in thousands, except for share amounts): </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 204pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 10.85pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 10.85pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 49.63pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 10.85pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 10.85pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 49.63pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 10.85pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 10.85pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 40.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 10.85pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 10.85pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 37.5pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 204pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 10.85pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.85pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.63pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Authorized <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares</div></td><td style="width: 10.85pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.85pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.63pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Outstanding <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares</div></td><td style="width: 10.85pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.85pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.46pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Liquidation <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Value</div></td><td style="width: 10.85pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.85pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Carrying <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Value </div></td></tr><tr><td style="width: 204pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Series&#160;A<font style="padding-left: 2.9pt;"></font></div></td><td style="width: 10.85pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.85pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.63pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 4.63pt;">64,730,402</font></div></td><td style="width: 10.85pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.85pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.63pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 4.63pt;">64,723,570</font></div></td><td style="width: 10.85pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.85pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.46pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.48pt; text-align: left;">$ 506,624</div></td><td style="width: 10.85pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.85pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$ 505,692 </div></td></tr><tr><td style="width: 204pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Series&#160;A-1<font style="padding-left: 4.57pt;"></font></div></td><td style="width: 10.85pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.85pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.63pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 4.63pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">50,403,973</font></div></td><td style="width: 10.85pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.85pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.63pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 4.63pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">50,379,174</font></div></td><td style="width: 10.85pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.85pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.46pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.48pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">433,780</font></div></td><td style="width: 10.85pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.85pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">433,583 </font></div></td></tr><tr><td style="width: 204pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total<font style="padding-left: 1.09pt;"></font></div></td><td style="width: 10.85pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.85pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.63pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">115,134,375</font></div></td><td style="width: 10.85pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.85pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 49.63pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">115,102,744</font></div></td><td style="width: 10.85pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.85pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.46pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.48pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$ 940,404</font></div></td><td style="width: 10.85pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10.85pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$ 939,275</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 204pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 10.85pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 10.85pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 49.63pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 10.85pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 10.85pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 49.63pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 10.85pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 10.85pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 40.46pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 10.85pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 10.85pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 37.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The following is a summary of the rights, preferences, and terms of the Series&#160;A, Series&#160;A-1, and Series&#160;A-2: </div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Dividends </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">Series&#160;A, Series&#160;A-1, and Series&#160;A-2 have no stated dividends. </div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Voting and Board Representation </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Series&#160;A, Series&#160;A-1, and Series&#160;A-2 holders are entitled to one vote per share of Series&#160;A, Series&#160;A-1, and Series&#160;A-2 (i.e., Series&#160;A, Series&#160;A-1, and Series&#160;A-2 holders vote with common stockholders on an as-converted basis). The board of directors consists of nine members. The Series&#160;A and Series&#160;A-1 holders may designate seven members as long as at least 28,783,593 shares of Series&#160;A, Series&#160;A-1, and Series&#160;A-2 remain outstanding. The holders of a majority of the outstanding shares of common stock may designate two members. The remaining independent members, if any, may be elected by holders of common stock, Series&#160;A, and Series&#160;A-1, voting together as a single class on an as-converted-to-common stock basis. Holders of Series&#160;A-2 have no right to vote for or remove any directors. </div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 17pt; margin-left: 0pt; text-align: left;">Liquidation </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In the event of any liquidation, dissolution, or winding up of the Company or a Deemed Liquidation Event as defined in the Company&#8217;s Restated Certificate of Incorporation, the holders of Series&#160;A, Series&#160;A-1, and Series&#160;A-2 are treated as a single class and are entitled to be paid out of the assets of the Company before any distribution or payment is made to holders of common stock. The liquidation value per share of Series&#160;A, Series&#160;A-1, and Series&#160;A-2 is equal to the greater of (a) the Original Issue Price plus any dividends declared but unpaid or (b) the amount per share as would have been payable had all shares of Series&#160;A, Series&#160;A-1, or Series&#160;A-2 been converted into common stock. The Original Issuance Price is $7.8275 per share for Series&#160;A and $8.6103 for Series&#160;A-1 and Series&#160;A-2. To the extent the funds and assets of the Company available for distribution to its stockholders are insufficient to fully repay the liquidation value due to Series&#160;A, Series&#160;A-1, and Series&#160;A-2 holders, the Series&#160;A, Series&#160;A-1, and Series&#160;A-2 holders shall share ratably in any distribution of funds. </div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 17pt; margin-left: 0pt; text-align: left;">Conversion Ratio </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The initial conversion price equals the Original Issue Price of $7.8275 per share for Series&#160;A, and $8.6103 per share for Series&#160;A-1 and Series&#160;A-2 shares. Therefore, each Series&#160;A, Series&#160;A-1, and Series&#160;A-2 share converts into an equal number of shares of common stock (1 for 1). </div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 17pt; margin-left: 0pt; text-align: left;">Optional Conversion </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Each share of Series&#160;A, Series&#160;A-1, and Series&#160;A-2 is convertible at the holder&#8217;s option at any time into common stock at the Original Issue Price. Each share of Series&#160;A-2 may be converted into one share of Series&#160;A-1 upon at least ten days&#8217; written notice to the Company. </div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 17pt; margin-left: 0pt; text-align: left;">Mandatory Conversion </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Series&#160;A, Series&#160;A-1, and Series&#160;A-2 shares will automatically convert into common stock immediately prior to (i)&#160;a Qualified IPO; (ii) a Direct Listing; (iii) a merger, acquisition, or other business combination involving a special purpose acquisition company or similar entity that does not constitute a Deemed Liquidation Event and that results in each Series&#160;A, Series&#160;A-1, and Series&#160;A-2 holder receiving consideration per share of at least 1.25 times the Original Issue Price of Series&#160;A-1; or (iv) the occurrence of an event, date, or time specified by vote or written consent of the holders of a majority of the outstanding Preferred Stock. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-17<br></div></div></div>
<!--End Page 363-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 364-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_202-finnotes_pg12"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Redemption </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Preferred Stock is subject to redemption under certain deemed liquidation events not solely within the control of the Company, as defined, and as such is considered contingently redeemable for accounting purposes and is classified as temporary equity in the Company&#8217;s consolidated balance sheets. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">Common Stock and Restricted Common Stock </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The holders of the common stock are entitled to one vote per share of common stock held at all meetings of stockholders. Unless required by law, there shall be no cumulative voting. In the event of any voluntary or involuntary liquidation, dissolution, or winding up of the Company, after the payment of all preferential amounts required to be paid to the holders of shares of Series&#160;A, Series&#160;A-1, and Series&#160;A-2, the remaining funds and assets available for distribution to the stockholders of the Company will be distributed among the holders of shares of common stock, pro rata based on the number of shares of common stock held by each such holder. </div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">Restricted Stock Awards (RSAs) Under The Plan </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">After inception, the Company granted 4,282,916 shares of RSAs to employees and other service providers that generally vested over a four-year period with 25% of awards vesting after one year and then monthly thereafter. The fair value of an RSA is equal to the fair value of the Company&#8217;s common stock on the date of grant. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following table summarizes the activity related to the unvested restricted stock grants to employees and nonemployees: </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 384pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 20.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 20.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 43.33pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 384pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 20.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 20.34pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 43.33pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares </div></td></tr><tr><td style="width: 384pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Unvested as of January&#160;1, 2024<font style="padding-left: 0.98pt;"></font></div></td><td style="width: 20.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 20.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 43.33pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 3.33pt;">1,401,001 </font></div></td></tr><tr><td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Granted<font style="padding-left: 4.29pt;"></font></div></td><td style="width: 20.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 20.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 43.33pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 33.33pt;">&#8212; </font></div></td></tr><tr><td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Vested<font style="padding-left: 4.84pt;"></font></div></td><td style="width: 20.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 20.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 43.33pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">(1,063,786) </div></td></tr><tr><td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Forfeited<font style="padding-left: 4.85pt;"></font></div></td><td style="width: 20.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 20.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 43.33pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 33.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </font></div></td></tr><tr><td style="width: 384pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Unvested at December&#160;31, 2024<font style="padding-left: 2.93pt;"></font></div></td><td style="width: 20.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 20.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 43.33pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10.83pt;">337,215 </font></div></td></tr><tr><td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Granted<font style="padding-left: 4.29pt;"></font></div></td><td style="width: 20.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 20.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 43.33pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 33.33pt;">&#8212; </font></div></td></tr><tr><td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Vested<font style="padding-left: 4.84pt;"></font></div></td><td style="width: 20.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 20.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 43.33pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 7.5pt;">(337,215) </font></div></td></tr><tr><td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Forfeited<font style="padding-left: 4.85pt;"></font></div></td><td style="width: 20.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 20.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 43.33pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 33.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </font></div></td></tr><tr><td style="width: 384pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Unvested at December&#160;31, 2025<font style="padding-left: 2.93pt;"></font></div></td><td style="width: 20.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 20.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 43.33pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 33.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">&#8212;</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 384pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 20.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 20.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 43.33pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 17pt; margin-left: 0pt; text-align: left;">Restricted Stock Awards Outside the Plan </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">At and shortly after inception, the Company issued an aggregate of 13,690,972 shares of common stock to its founders, a collaboration and research partner in connection with a collaboration and sponsored research agreement and an advisor outside of the Plan. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The estimated fair value of the shares on the date of each issuance to such grantees was $0.0001 per share. As of December&#160;31, 2025, 13,570,139 of such shares of common stock issued to the founders, commercial partner, and advisor outside of the Plan are fully vested. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 384pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 20.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 20.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 43.33pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 384pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 20.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 20.34pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 43.33pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares </div></td></tr><tr><td style="width: 384pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Unvested as of January&#160;1, 2024<font style="padding-left: 0.98pt;"></font></div></td><td style="width: 20.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 20.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 43.33pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 3.33pt;">3,948,357 </font></div></td></tr><tr><td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Granted<font style="padding-left: 4.29pt;"></font></div></td><td style="width: 20.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 20.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 43.33pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 33.33pt;">&#8212; </font></div></td></tr><tr><td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Vested<font style="padding-left: 4.84pt;"></font></div></td><td style="width: 20.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 20.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 43.33pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">(3,419,271) </div></td></tr><tr><td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Forfeited<font style="padding-left: 4.85pt;"></font></div></td><td style="width: 20.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 20.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 43.33pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 33.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </font></div></td></tr><tr><td style="width: 384pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Unvested at December&#160;31, 2024<font style="padding-left: 2.93pt;"></font></div></td><td style="width: 20.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 20.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 43.33pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10.83pt;">529,086 </font></div></td></tr><tr><td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Granted<font style="padding-left: 4.29pt;"></font></div></td><td style="width: 20.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 20.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 43.33pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 33.33pt;">&#8212; </font></div></td></tr><tr><td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Vested<font style="padding-left: 4.84pt;"></font></div></td><td style="width: 20.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 20.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 43.33pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 7.5pt;">(529,086) </font></div></td></tr><tr><td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Forfeited<font style="padding-left: 4.85pt;"></font></div></td><td style="width: 20.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 20.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 43.33pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 33.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </font></div></td></tr><tr><td style="width: 384pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Unvested at December&#160;31, 2025<font style="padding-left: 2.93pt;"></font></div></td><td style="width: 20.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 20.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 43.33pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 33.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">&#8212;</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 384pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 20.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 20.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 43.33pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-18<br></div></div></div>
<!--End Page 364-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 365-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_202-finnotes_pg13"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">10. Stock-Based Compensation </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In 2021, the Company adopted the 2021 Equity Incentive Plan (as amended from time to time, the Plan) which provides for the granting of incentive stock options (ISOs) and nonqualified stock options (NQSOs). ISOs may be granted only to employees (including officers and directors who are also employees). NQSOs may be granted to employees, officers, directors, consultants, advisors, and other service providers of the Company. As of December&#160;31, 2025, 38,152,270&#160;shares were reserved for issuance under the Plan, of which 12,636,056 shares were available for future issuance. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The amount, terms of grants, and exercisability provisions are determined and set by the Company&#8217;s board of directors. The Company measures employee and nonemployee stock-based awards at grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the award. The Company recorded stock-based compensation expense in the following expense categories of its statements of operations and comprehensive loss (amounts in thousands): </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 2pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="margin-top: 0pt; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 360pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.86pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.86pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 94.28pt;" colspan="4"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 360pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 6.86pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td colspan="4" style="width: 94.28pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended December&#160;31 </div></td></tr><tr class="BRDSX_header"><td style="width: 360pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 6.86pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.28pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div></td><td style="width: 6.86pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.28pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div></td></tr><tr><td style="width: 360pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research and development<font style="padding-left: 4.76pt;"></font></div></td><td style="width: 6.86pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.39pt; text-align: left;">$4,873</div></td><td style="width: 6.86pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.39pt; text-align: left;">$3,479 </div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">General and administrative<font style="padding-left: 4.2pt;"></font></div></td><td style="width: 6.86pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.39pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">973</font></div></td><td style="width: 6.86pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.39pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">651 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total stock-based compensation expense<font style="padding-left: 4.64pt;"></font></div></td><td style="width: 6.86pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.28pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.39pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$5,846</font></div></td><td style="width: 6.86pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.28pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.39pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$4,130</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 360pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.86pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.86pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 40.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.86pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.86pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 40.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Stock Options </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company has issued service-based stock options that generally have a contractual term of up to ten years and may be exercisable in cash or as otherwise determined by the board of directors. Vesting generally occurs over a period of four years with 25% of awards vesting after one year and then monthly thereafter. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">The following table summarizes the activity related to stock options: </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 2pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="margin-top: 0pt; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 228pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 45pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 48.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 44.79pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 50.44pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 228pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 6.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.41pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares</div></td><td style="width: 6.41pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.41pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 48.5pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Weighted <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Average <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Exercise Price <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Per Share</div></td><td style="width: 6.41pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.41pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 44.79pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Weighted <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Average <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Remaining <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Contractual <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Term (Years)</div></td><td style="width: 6.41pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.41pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.44pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Aggregate <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Intrinsic Value <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(in thousands) </div></td></tr><tr><td style="width: 228pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Outstanding as of December&#160;31, 2023<font style="padding-left: 3.88pt;"></font></div></td><td style="width: 6.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">12,379,406</div></td><td style="width: 6.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 48.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.99pt; text-align: left;">$1.27</div></td><td style="width: 6.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 44.79pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.14pt; text-align: left;">8.4</div></td><td style="width: 6.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.44pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 228pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Granted<font style="padding-left: 3.29pt;"></font></div></td><td style="width: 6.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">4,191,589</font></div></td><td style="width: 6.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 48.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.99pt; text-align: left;"><font style="padding-left: 5pt;">1.79</font></div></td><td style="width: 6.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 44.79pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.44pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 228pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Exercised<font style="padding-left: 1.07pt;"></font></div></td><td style="width: 6.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 9.17pt;">(786,530)</font></div></td><td style="width: 6.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 48.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.99pt; text-align: left;"><font style="padding-left: 5pt;">1.03</font></div></td><td style="width: 6.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 44.79pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.44pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.97pt; text-align: left;">$<font style="padding-left: 12.5pt;">628</font></div></td></tr><tr><td style="width: 228pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Forfeited or expired<font style="padding-left: 0.53pt;"></font></div></td><td style="width: 6.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 9.17pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(905,353</font><font style="padding-bottom: 1.5pt;">)</font></div></td><td style="width: 6.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 48.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.99pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">1.52</font></div></td><td style="width: 6.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 44.79pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="border-bottom: 1pt solid #000000; padding-left: 12.5pt; margin-left: 19.47pt;"></font></div></td><td style="width: 6.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.44pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="border-bottom: 1pt solid #000000; padding-left: 32.5pt; margin-left: 5.12pt;"></font></div></td></tr><tr><td style="width: 228pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Outstanding as of December&#160;31, 2024<font style="padding-left: 3.88pt;"></font></div></td><td style="width: 6.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 0.37pt;">14,879,112</font></div></td><td style="width: 6.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 48.5pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.99pt; text-align: left;"><font style="padding-left: 5pt;">1.42</font></div></td><td style="width: 6.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 44.79pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.14pt; text-align: left;">8.0</div></td><td style="width: 6.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.44pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.97pt; text-align: left;">$ 12,391 </div></td></tr><tr><td style="width: 228pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Granted<font style="padding-left: 3.29pt;"></font></div></td><td style="width: 6.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">5,803,750</font></div></td><td style="width: 6.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 48.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.99pt; text-align: left;"><font style="padding-left: 5pt;">2.32</font></div></td><td style="width: 6.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 44.79pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.44pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 228pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Exercised<font style="padding-left: 1.07pt;"></font></div></td><td style="width: 6.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 1.67pt;">(1,107,854)</font></div></td><td style="width: 6.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 48.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.99pt; text-align: left;"><font style="padding-left: 5pt;">1.34</font></div></td><td style="width: 6.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 44.79pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.44pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.97pt; text-align: left;">$<font style="padding-left: 5pt;">1,090</font></div></td></tr><tr><td style="width: 228pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Forfeited or expired<font style="padding-left: 0.53pt;"></font></div></td><td style="width: 6.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 1.67pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(1,133,576</font><font style="padding-bottom: 1.5pt;">)</font></div></td><td style="width: 6.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 48.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.99pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">1.75</font></div></td><td style="width: 6.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 44.79pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="border-bottom: 1pt solid #000000; padding-left: 12.5pt; margin-left: 19.47pt;"></font></div></td><td style="width: 6.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.44pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="border-bottom: 1pt solid #000000; padding-left: 32.5pt; margin-left: 5.12pt;"></font></div></td></tr><tr><td style="width: 228pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Outstanding as of December&#160;31, 2025<font style="padding-left: 3.88pt;"></font></div></td><td style="width: 6.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">18,441,432</font></div></td><td style="width: 6.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 48.5pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.99pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">1.68</font></div></td><td style="width: 6.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 44.79pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.14pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">7.6</font></div></td><td style="width: 6.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.44pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.97pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$ 16,150 </font></div></td></tr><tr><td style="width: 228pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exercisable as of December&#160;31, 2025<font style="padding-left: 1.11pt;"></font></div></td><td style="width: 6.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">10,007,903</font></div></td><td style="width: 6.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 48.5pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.99pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">1.36</font></div></td><td style="width: 6.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 44.79pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.14pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">6.6</font></div></td><td style="width: 6.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.41pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.44pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.97pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 0.37pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">11,997 </font></div></td></tr><tr><td style="width: 228pt; padding-top: 3.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Vested and expected to vest as of December&#160;31, 2025<font style="padding-left: 2.24pt;"></font></div></td><td style="width: 6.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 3.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">18,441,432</font></div></td><td style="width: 6.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 48.5pt; padding-top: 3.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.99pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">1.68</font></div></td><td style="width: 6.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 44.79pt; padding-top: 3.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.14pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">7.6</font></div></td><td style="width: 6.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.44pt; padding-top: 3.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.97pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$ 16,150</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 228pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 45pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 48.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 44.79pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 50.44pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Options granted to employees during the years ended December&#160;31, 2025 and 2024, had a weighted average grant-date fair value of $1.89 and $1.40 per share, respectively. As of December&#160;31, 2025, the unrecognized compensation cost was $13.5 million and will be recognized over an estimated weighted average amortization period of 2.7 years. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The fair value of options is estimated using the Black-Scholes option-pricing model, which takes into account inputs such as the exercise price, the estimated fair value of the underlying common stock at the grant date, expected term, estimated stock price volatility, risk-free interest rate, and dividend yield. The fair value of stock options granted during the years ended December&#160;31, 2025 and 2024, were determined using the methods and assumptions discussed below. </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The expected term of stock options with service-based vesting is determined using the &#8220;simplified&#8221; method, as prescribed in the Securities and Exchange Commission&#8217;s Staff Accounting Bulletin (SAB) No. 107, whereby the expected life equals the arithmetic midpoint of the vesting term and the original contractual term of the option due to the Company&#8217;s lack of sufficient historical data. </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-19<br></div></div></div>
<!--End Page 365-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 366-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_202-finnotes_pg14"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The expected stock price volatility is based on historical volatility of comparable public entities within the Company&#8217;s industry, which were commensurate with the expected term assumption as described in SAB No. 107. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The risk-free interest rate is based on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period that is commensurate with the expected term. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The expected dividend yield is 0% because the Company has not historically paid and does not expect, for the foreseeable future, to pay a dividend on its common stock. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">As the Company&#8217;s common stock has not been publicly traded, the Company periodically estimates the fair value of the Company&#8217;s common stock considering, among other things, contemporaneous valuations of its common stock in accordance with the guidance provided by the American Institute of Certified Public Accountants, <font style="font-style: italic;">Valuation of Privately-Held-Company Equity Securities Issued as Compensation &#8212; Accounting and Valuation Guide.</font> </div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The grant-date fair value of each option grant was estimated using the Black-Scholes option-pricing model using the following weighted average assumptions: </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 360pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.86pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.86pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 94.28pt;" colspan="4"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 360pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 6.86pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td colspan="4" style="width: 94.28pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended December&#160;31 </div></td></tr><tr class="BRDSX_header"><td style="width: 360pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 6.86pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 42.78pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div></td><td style="width: 6.86pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.78pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div></td></tr><tr><td style="width: 360pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected term (in years)<font style="padding-left: 3.93pt;"></font></div></td><td style="width: 6.86pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 42.78pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.14pt; text-align: left;"><font style="padding-left: 27.5pt;">6</font></div></td><td style="width: 6.86pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.78pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.14pt; text-align: left;"><font style="padding-left: 22.5pt;">6 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected stock price volatility<font style="padding-left: 0.59pt;"></font></div></td><td style="width: 6.86pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 42.78pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.14pt; text-align: left;"><font style="padding-left: 5pt;">102.09%</font></div></td><td style="width: 6.86pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.78pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.14pt; text-align: left;"><font style="padding-left: 5pt;">93.96% </font></div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Risk-free interest rate<font style="padding-left: 0.88pt;"></font></div></td><td style="width: 6.86pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 42.78pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.14pt; text-align: left;"><font style="padding-left: 15pt;">4.21%</font></div></td><td style="width: 6.86pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.78pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.14pt; text-align: left;"><font style="padding-left: 10pt;">4.10% </font></div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected dividend yield<font style="padding-left: 0.3pt;"></font></div></td><td style="width: 6.86pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 42.78pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.14pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;%</font></div></td><td style="width: 6.86pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.78pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.14pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;% </font></div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Fair value of option grant<font style="padding-left: 0.3pt;"></font></div></td><td style="width: 6.86pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 42.78pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.14pt; text-align: left;">$<font style="padding-left: 10pt;">1.89</font></div></td><td style="width: 6.86pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.86pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.78pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.14pt; text-align: left;">$<font style="padding-left: 5pt;">1.40</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 360pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.86pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.86pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 42.78pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.86pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.86pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 37.78pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">11. Income Taxes </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company provides for income taxes under ASC 740. Under ASC 740, the liability method is used. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company has not recorded a current or deferred income tax expense or benefit. The Company&#8217;s loss before income taxes was $162.5&#160;million for the year ended December&#160;31, 2025, which represents a U.S. loss of $162.6&#160;million partially offset by non-U.S. income, compared with $162.5&#160;million and $162.5&#160;million, respectively, for the year ended December&#160;31, 2024. As of December&#160;31, 2025 and 2024, the Company does not have any uncertain tax positions. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The components of the Company&#8217;s deferred taxes as of December&#160;31 are composed of the following (amounts in thousands): </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 360pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 40.83pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 40.83pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 360pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 6.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.59pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div></td><td style="width: 6.59pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.59pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div></td></tr><tr><td style="width: 360pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Deferred tax assets<br></div></td><td style="width: 6.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net operating losses<font style="padding-left: 1.42pt;"></font></div></td><td style="width: 6.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<font style="padding-left: 3.33pt;">121,143</font></div></td><td style="width: 6.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<font style="padding-left: 8.33pt;">53,478 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">R&amp;D credits<font style="padding-left: 1.68pt;"></font></div></td><td style="width: 6.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 13.33pt;">25,983</font></div></td><td style="width: 6.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 13.33pt;">19,479 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other<font style="padding-left: 4.73pt;"></font></div></td><td style="width: 6.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 25.83pt;">759</font></div></td><td style="width: 6.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 25.83pt;">476 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lease liabilities<font style="padding-left: 4.47pt;"></font></div></td><td style="width: 6.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 18.33pt;">4,745</font></div></td><td style="width: 6.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 18.33pt;">2,620 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amortization<font style="padding-left: 4.18pt;"></font></div></td><td style="width: 6.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">31,379</font></div></td><td style="width: 6.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">57,825 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Gross deferred tax assets<font style="padding-left: 2.83pt;"></font></div></td><td style="width: 6.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 8.33pt;">184,009</font></div></td><td style="width: 6.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 8.33pt;">133,878 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Less valuation allowance<font style="padding-left: 1.42pt;"></font></div></td><td style="width: 6.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(179,023</font><font style="padding-bottom: 1.5pt;">)</font></div></td><td style="width: 6.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(130,376</font><font style="padding-bottom: 1.5pt;">) </font></div></td></tr><tr><td style="width: 360pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total deferred tax assets<font style="padding-left: 0.74pt;"></font></div></td><td style="width: 6.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 18.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">4,986</font></div></td><td style="width: 6.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 18.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">3,502 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Deferred tax liabilities<br></div></td><td style="width: 6.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lease assets<font style="padding-left: 3.36pt;"></font></div></td><td style="width: 6.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 15pt;">(4,595)</font></div></td><td style="width: 6.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 15pt;">(2,607) </font></div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Fixed assets<font style="padding-left: 3.91pt;"></font></div></td><td style="width: 6.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(391</font><font style="padding-bottom: 1.5pt;">)</font></div></td><td style="width: 6.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(895</font><font style="padding-bottom: 1.5pt;">) </font></div></td></tr><tr><td style="width: 360pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total deferred tax liabilities<font style="padding-left: 1.85pt;"></font></div></td><td style="width: 6.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 15pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(4,986</font><font style="padding-bottom: 0.5pt;">)</font></div></td><td style="width: 6.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.59pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 15pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(3,502</font><font style="padding-bottom: 0.5pt;">) </font></div></td></tr><tr><td style="width: 360pt; padding-top: 3.26pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net deferred tax assets<font style="padding-left: 1.72pt;"></font></div></td><td style="width: 6.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 3.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 25.83pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">&#8212;</font></div></td><td style="width: 6.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 3.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 25.83pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">&#8212;</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 360pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 40.83pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.59pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 40.83pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-20<br></div></div></div>
<!--End Page 366-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 367-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_202-finnotes_pg15"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">The reconciliation tax bill, commonly known as the &#8220;One Big Beautiful Bill Act&#8221; (OBBBA), was signed into law July&#160;4, 2025, which is considered the enactment date under GAAP. Based on the OBBBA, the Company will make a method change to accelerate unamortized domestic R&amp;D amounts in the 2025 taxable year. As a result of this implementation, the Company&#8217;s deferred tax assets as of December&#160;31, 2025, reflects the change in tax treatment for these expenditures. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets. Based on the Company&#8217;s operating losses, the Company has concluded that it is more likely than not that the benefit of its deferred tax assets will not be realized. Accordingly, the Company has recorded a valuation allowance against its net&#160;deferred tax asset as of December&#160;31, 2025 and 2024. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">A reconciliation of income tax benefit computed at the statutory federal income tax rate to income taxes as reflected in the financial statements is as follows (amounts outside of percentages in thousands): </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 264pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 40.83pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 22.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 35.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 48.18pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 264pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.13pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Gross</div></td><td style="width: 7.13pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.13pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 22.5pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Rate</div></td><td style="width: 7.13pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.13pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.46pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Tax</div></td><td style="width: 7.13pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.13pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 48.18pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Effective Rate </div></td></tr><tr><td style="width: 264pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">December&#160;31, 2025<br></div></td><td style="width: 7.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 7.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 22.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 7.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.46pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 7.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 48.18pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 264pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">U.S. federal statutory tax rate<font style="padding-left: 3.77pt;"></font></div></td><td style="width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$(162,465)</div></td><td style="width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 22.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">21.0%</font></div></td><td style="width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.46pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$(34,118)</div></td><td style="width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 48.18pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.67pt; text-align: left;"><font style="padding-left: 3.33pt;">21.0% </font></div></td></tr><tr><td style="width: 264pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">State and local income taxes, net of federal income tax effect<font style="padding-left: 2.6pt;"></font></div></td><td style="width: 7.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 30.83pt;">&#8212;</font></div></td><td style="width: 7.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 22.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">100.0</div></td><td style="width: 7.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.46pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 25.46pt;">&#8212;</font></div></td><td style="width: 7.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 48.18pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.67pt; text-align: left;"><font style="padding-left: 10.83pt;">&#8212; </font></div></td></tr><tr><td style="width: 264pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Foreign tax effects:<br></div></td><td style="width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 22.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.46pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 48.18pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 264pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Other foreign jurisdictions<font style="padding-left: 0.42pt;"></font></div></td><td style="width: 7.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 27.5pt;">(32)</font></div></td><td style="width: 7.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 22.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">100.0</div></td><td style="width: 7.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.46pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.13pt;">(32)</font></div></td><td style="width: 7.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 48.18pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.67pt; text-align: left;"><font style="padding-left: 10.83pt;">&#8212; </font></div></td></tr><tr><td style="width: 264pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Effect of cross-border tax laws:<br></div></td><td style="width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 22.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.46pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 48.18pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 264pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Global intangible low-taxed income<font style="padding-left: 2.37pt;"></font></div></td><td style="width: 7.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 30.83pt;">19</font></div></td><td style="width: 7.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 22.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">21.0</font></div></td><td style="width: 7.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.46pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 30.46pt;">4</font></div></td><td style="width: 7.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 48.18pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.67pt; text-align: left;"><font style="padding-left: 10.83pt;">&#8212; </font></div></td></tr><tr><td style="width: 264pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Tax credits:<br></div></td><td style="width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 22.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.46pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 48.18pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 264pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Research and development tax credits<font style="padding-left: 4.89pt;"></font></div></td><td style="width: 7.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 15pt;">(5,493)</font></div></td><td style="width: 7.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 22.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 7.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.46pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 9.63pt;">(5,493)</font></div></td><td style="width: 7.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 48.18pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.67pt; text-align: left;"><font style="padding-left: 8.33pt;">3.4 </font></div></td></tr><tr><td style="width: 264pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Changes in valuation allowance<font style="padding-left: 4.03pt;"></font></div></td><td style="width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 8.33pt;">161,831</font></div></td><td style="width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 22.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.46pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 7.96pt;">38,326</font></div></td><td style="width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 48.18pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.67pt; text-align: left;">(23.6) </div></td></tr><tr><td style="width: 264pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Nontaxable or nondeductible items:<br></div></td><td style="width: 7.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 7.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 22.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 7.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.46pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 7.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 48.18pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 264pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Other (all permanent)<font style="padding-left: 4.87pt;"></font></div></td><td style="width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 18.33pt;">4,638</font></div></td><td style="width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 22.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">21.0</font></div></td><td style="width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.46pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 20.46pt;">974</font></div></td><td style="width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 48.18pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.67pt; text-align: left;"><font style="padding-left: 5pt;">(0.6) </font></div></td></tr><tr><td style="width: 264pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other<font style="padding-left: 3.73pt;"></font></div></td><td style="width: 7.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 18.33pt;">1,620</font></div></td><td style="width: 7.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 22.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">21.0</font></div></td><td style="width: 7.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.46pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 20.46pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">339</font></div></td><td style="width: 7.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 48.18pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.67pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(0.2</font><font style="padding-bottom: 1.5pt;">) </font></div></td></tr><tr><td style="width: 264pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Effective tax rate<font style="padding-left: 2.82pt;"></font></div></td><td style="width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 22.5pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.46pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 25.46pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">&#8212;</font></div></td><td style="width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 48.18pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.67pt; text-align: left;"><font style="padding-left: 10.83pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">&#8212;</font><font style="padding-bottom: 0.5pt;">%</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 264pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 40.83pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 22.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 35.46pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 7.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 48.18pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 264pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 40.83pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 22.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 35.83pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 48.18pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 264pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Gross</div></td><td style="width: 7.08pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 22.5pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Rate</div></td><td style="width: 7.08pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Tax</div></td><td style="width: 7.08pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 48.18pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Effective Rate </div></td></tr><tr><td style="width: 264pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">December&#160;31, 2024<br></div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 22.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 48.18pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 264pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">U.S. federal statutory tax rate<font style="padding-left: 3.77pt;"></font></div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$(162,487)</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 22.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">21.0%</font></div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$(34,122)</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 48.18pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.67pt; text-align: left;"><font style="padding-left: 3.33pt;">21.0% </font></div></td></tr><tr><td style="width: 264pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">State and local income taxes, net of federal income tax effect<font style="padding-left: 2.6pt;"></font></div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 30.83pt;">&#8212;</font></div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 22.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">100.0</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 48.18pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.67pt; text-align: left;"><font style="padding-left: 10.83pt;">&#8212; </font></div></td></tr><tr><td style="width: 264pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Foreign tax effects:<br></div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 22.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 48.18pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 264pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Other foreign jurisdictions<font style="padding-left: 0.42pt;"></font></div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 27.5pt;">(13)</font></div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 22.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">100.0</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.5pt;">(13)</font></div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 48.18pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.67pt; text-align: left;"><font style="padding-left: 10.83pt;">&#8212; </font></div></td></tr><tr><td style="width: 264pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Effect of cross-border tax laws:<br></div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 22.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 48.18pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 264pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Global intangible low-taxed income<font style="padding-left: 2.37pt;"></font></div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 30.83pt;">&#8212;</font></div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 22.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">21.0</font></div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 48.18pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.67pt; text-align: left;"><font style="padding-left: 10.83pt;">&#8212; </font></div></td></tr><tr><td style="width: 264pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Tax credits:<br></div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 22.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 48.18pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 264pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Research and development tax credits<font style="padding-left: 4.89pt;"></font></div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 15pt;">(7,803)</font></div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 22.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt;">(7,803)</font></div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 48.18pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.67pt; text-align: left;"><font style="padding-left: 8.33pt;">4.8 </font></div></td></tr><tr><td style="width: 264pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Changes in valuation allowance<font style="padding-left: 4.03pt;"></font></div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 8.33pt;">167,302</font></div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 22.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 8.33pt;">41,298</font></div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 48.18pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.67pt; text-align: left;">(25.4) </div></td></tr><tr><td style="width: 264pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Nontaxable or nondeductible items:<br></div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 22.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 48.18pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 264pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Other (all permanent)<font style="padding-left: 4.87pt;"></font></div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 18.33pt;">2,909</font></div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 22.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">21.0</font></div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 21.2pt;">611</font></div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 48.18pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.67pt; text-align: left;"><font style="padding-left: 5pt;">(0.4) </font></div></td></tr><tr><td style="width: 264pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other<font style="padding-left: 3.73pt;"></font></div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 25.83pt;">139</font></div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 22.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">21.0</font></div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">29</font></div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 48.18pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.67pt; text-align: left;"><font style="padding-left: 10.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </font></div></td></tr><tr><td style="width: 264pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Effective tax rate<font style="padding-left: 2.82pt;"></font></div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40.83pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 22.5pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 35.83pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 25.83pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">&#8212;</font></div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 48.18pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.67pt; text-align: left;"><font style="padding-left: 10.83pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">&#8212;</font><font style="padding-bottom: 0.5pt;">%</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 264pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 40.83pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 22.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 35.83pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 48.18pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As of December&#160;31, 2025 and 2024, the Company had U.S. federal net operating loss carryforwards of $459.2&#160;million and $195.6&#160;million, respectively, which may be available to offset future income tax liabilities. As of December&#160;31, 2025 and 2024, the Company also had U.S. state net operating loss carryforwards of $403.8&#160;million and $204.0&#160;million, respectively, which may be available to offset future income tax liabilities. The federal net operating loss carryforwards and state net operating losses relating to Florida and New Mexico may be carried forward indefinitely, while the state net operating losses relating to Connecticut and Massachusetts may be carried forward for 20 years. As of December&#160;31, 2025, the Company also had U.S. federal R&amp;D of $19.6&#160;million, and California R&amp;D, and Massachusetts R&amp;D credit </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-21<br></div></div></div>
<!--End Page 367-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 368-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_202-finnotes_pg16"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">carryforwards of $8.0&#160;million. The federal R&amp;D credits have a carryforward of 20 years, while the California and Massachusetts R&amp;D credits may be carried forward indefinitely. For the years ended December&#160;31, 2025 and 2024, the majority of the Company&#8217;s income and expense is generated in the state of Massachusetts. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Under the provisions of the Internal Revenue Code, the net operating loss carryforward is subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. The net operating loss carryforward may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code of 1986, respectively, as well as similar state tax provisions. This could limit the amount of tax attributes that the Company can utilize annually to offset future taxable income or tax liabilities. The amount of the annual limitation will be determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company files income tax returns in the U.S. and various state jurisdictions. The federal and state income tax returns filed to date remain subject to tax examination. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service or state tax authorities to the extent utilized in a future period. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Consistent with the Company&#8217;s practice in historical periods, the Company does maintain an assertion that the accumulated earnings of its foreign subsidiaries are considered to be permanently reinvested. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company has elected to recognize the tax on global intangible low-taxed income (GILTI) as a period expense in the period the tax is incurred. As such, the Company has included its GILTI provision associated with current year operations solely within the estimated annual effective tax rate and has not provided additional GILTI on deferred items. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">12. Subsequent Events </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company has evaluated subsequent events through June&#160;16, 2026, the date on which the accompanying consolidated financial statements were issued, and has determined that the following matters required disclosure. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On June&#160;6, 2026, the Company entered into an Agreement and Plan of Merger and Reorganization (the Merger Agreement) with Standard BioTools Inc. (Nasdaq: LAB) (Standard) and Siri Merger Sub, Inc. (Merger Sub), a wholly owned subsidiary of Standard. Under the Merger Agreement, Merger Sub will merge with and into the Company, and the Company will survive as a wholly owned subsidiary of Standard (the Merger). Upon completion of the Merger, the business of Treeline will continue as the business of the surviving corporation. At the effective time of the Merger, each outstanding share of the Company&#8217;s common stock, including each share of Series&#160;A, Series&#160;A-1, and Series&#160;A-2 convertible preferred stock (which will convert into common stock immediately prior to the Merger), will be converted into the right to receive shares of Standard common stock based on an exchange ratio determined in accordance with the Merger Agreement. Each outstanding option to purchase the Company&#8217;s common stock, whether vested or unvested, will be assumed by Standard and converted into an option to purchase Standard common stock, with the number of shares and exercise price adjusted by the exchange ratio and otherwise subject to its existing terms. Each outstanding warrant that is amended prior to the effective time to provide for net-exercise treatment will be cancelled and converted into the right to receive Standard common stock based on the exchange ratio. Any warrant that is not amended for such treatment will be assumed by Standard and become exercisable for Standard common stock, with the number of shares and warrant price adjusted by the exchange ratio. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In connection with the Merger, Standard has agreed to use commercially reasonable efforts to dispose of its legacy mass cytometry and microfluidics businesses and, to the extent no disposition is completed, to wind down those businesses, such that the combined company is not expected to retain those operations. Completion of the Merger is subject to customary closing conditions, including approval by the stockholders of both the Company and Standard and the effectiveness of a registration statement on Form&#160;S-4. The Merger had no effect on the Company&#8217;s consolidated financial statements as of and for the year ended December&#160;31, 2025. The Company is currently evaluating the accounting and financial reporting effects of the transaction. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-22<br></div></div></div>
<!--End Page 368-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 369-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_203-fintab01_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tCBSM"><!--Anchor--></a>TREELINE BIOSCIENCES, INC. AND SUBSIDIARY <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">(In thousands, except share and per share data)<font style="font-weight: normal;"> </font></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 360pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 45pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 46.49pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 360pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 4.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.13pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-style: italic; font-weight: bold; margin-top: 0pt; text-align: center;">Unaudited<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-style: italic; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-style: normal;">March&#160;31,</font><br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-style: italic; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-style: normal;">2026</font></div></td><td style="width: 4.13pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.13pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.49pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-style: italic; font-weight: bold; margin-top: 0pt; text-align: center;">Audited<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-style: italic; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-style: normal;">December&#160;31,</font><br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-style: italic; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-style: normal;">2025 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Assets<br></div></td><td style="width: 4.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 4.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Current assets:<br></div></td><td style="width: 4.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 4.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Cash and cash equivalents<font style="padding-left: 2.26pt;"></font></div></td><td style="width: 4.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<font style="padding-left: 12.5pt;">32,561 </font></div></td><td style="width: 4.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.75pt; text-align: left;">$<font style="padding-left: 12.5pt;">46,331 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Marketable securities<font style="padding-left: 1.71pt;"></font></div></td><td style="width: 4.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 12.5pt;">520,540 </font></div></td><td style="width: 4.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.75pt; text-align: left;"><font style="padding-left: 12.5pt;">558,469 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Other current assets<font style="padding-left: 3.1pt;"></font></div></td><td style="width: 4.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 17.87pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">13,411 </font></div></td><td style="width: 4.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.75pt; text-align: left;"><font style="padding-left: 17.87pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">11,502 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total current assets<font style="padding-left: 0.45pt;"></font></div></td><td style="width: 4.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 12.5pt;">566,512 </font></div></td><td style="width: 4.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.49pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.75pt; text-align: left;"><font style="padding-left: 12.5pt;">616,302 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Property and equipment, net<font style="padding-left: 4.19pt;"></font></div></td><td style="width: 4.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">10,502 </font></div></td><td style="width: 4.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.75pt; text-align: left;"><font style="padding-left: 17.87pt;">11,896 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Right of use asset<font style="padding-left: 1.69pt;"></font></div></td><td style="width: 4.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">17,987 </font></div></td><td style="width: 4.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.75pt; text-align: left;"><font style="padding-left: 17.5pt;">18,971 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Restricted cash<font style="padding-left: 1.69pt;"></font></div></td><td style="width: 4.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">1,105 </font></div></td><td style="width: 4.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.75pt; text-align: left;"><font style="padding-left: 22.5pt;">1,144 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other assets<font style="padding-left: 3.91pt;"></font></div></td><td style="width: 4.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">7,269 </font></div></td><td style="width: 4.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.75pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">6,742 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total assets<font style="padding-left: 1.27pt;"></font></div></td><td style="width: 4.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 7.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">603,375 </font></div></td><td style="width: 4.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.49pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.75pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 7.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">655,055 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Liabilities, redeemable convertible preferred stock and stockholders&#8217; deficit<br></div></td><td style="width: 4.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 4.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.49pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Current liabilities:<br></div></td><td style="width: 4.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 4.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Accounts payable<font style="padding-left: 1.14pt;"></font></div></td><td style="width: 4.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<font style="padding-left: 17.5pt;">5,738 </font></div></td><td style="width: 4.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.75pt; text-align: left;">$<font style="padding-left: 17.5pt;">5,297 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Accrued expenses<font style="padding-left: 0.04pt;"></font></div></td><td style="width: 4.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">15,581 </font></div></td><td style="width: 4.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.75pt; text-align: left;"><font style="padding-left: 17.5pt;">17,671 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Current lease liability<font style="padding-left: 0.86pt;"></font></div></td><td style="width: 4.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">3,850 </font></div></td><td style="width: 4.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.75pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">3,973 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total current liabilities<font style="padding-left: 1.56pt;"></font></div></td><td style="width: 4.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">25,169 </font></div></td><td style="width: 4.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.49pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.75pt; text-align: left;"><font style="padding-left: 17.5pt;">26,941 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Noncurrent lease liability<font style="padding-left: 0.87pt;"></font></div></td><td style="width: 4.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">15,039 </font></div></td><td style="width: 4.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.75pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">15,617 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total liabilities<font style="padding-left: 2.38pt;"></font></div></td><td style="width: 4.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">40,208 </font></div></td><td style="width: 4.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.49pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.75pt; text-align: left;"><font style="padding-left: 17.5pt;">42,558</font></div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 4.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 4.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Redeemable convertible preferred stock:<br></div></td><td style="width: 4.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 4.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Series&#160;A, Series&#160;A-1, Series&#160;A-2 Convertible Preferred Stock, par value $0.00001: 174,566,382 shares authorized, 144,834,563 shares issued and outstanding as of March&#160;31, 2026 and December&#160;31, 2025 (Liquidation value $1,196,404 at March&#160;31, 2026)<font style="padding-left: 4.17pt;"></font></div></td><td style="width: 4.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">1,181,061 </font></div></td><td style="width: 4.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.75pt; text-align: left;"><font style="padding-left: 5pt;">1,181,061 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Commitments and Contingencies (Note&#160;6)<br></div></td><td style="width: 4.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 4.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Stockholders' deficit:<br></div></td><td style="width: 4.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 4.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Common stock, par value $0.00001: 222,260,000 shares authorized, 20,928,134 shares issued and outstanding as of March&#160;31, 2026; 20,765,754 shares issued and outstanding as of December&#160;31, 2025<font style="padding-left: 3.09pt;"></font></div></td><td style="width: 4.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 35pt;">&#8212; </font></div></td><td style="width: 4.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.75pt; text-align: left;"><font style="padding-left: 35pt;">&#8212; </font></div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Additional paid-in-capital<font style="padding-left: 3.91pt;"></font></div></td><td style="width: 4.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">34,370 </font></div></td><td style="width: 4.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.75pt; text-align: left;"><font style="padding-left: 17.5pt;">32,242 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Accumulated other comprehensive (loss) income<font style="padding-left: 1.45pt;"></font></div></td><td style="width: 4.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 26.67pt;">(441)</font></div></td><td style="width: 4.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.75pt; text-align: left;"><font style="padding-left: 30pt;">476 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Accumulated deficit<font style="padding-left: 1.14pt;"></font></div></td><td style="width: 4.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 9.17pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(651,823</font><font style="padding-bottom: 1.5pt;">)</font></div></td><td style="width: 4.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.75pt; text-align: left;"><font style="padding-left: 9.17pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(601,282</font><font style="padding-bottom: 1.5pt;">) </font></div></td></tr><tr><td style="width: 360pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total stockholders&#8217; deficit<font style="padding-left: 3.41pt;"></font></div></td><td style="width: 4.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 9.17pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(617,894</font><font style="padding-bottom: 1.5pt;">)</font></div></td><td style="width: 4.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.49pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.75pt; text-align: left;"><font style="padding-left: 9.17pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(568,564</font><font style="padding-bottom: 1.5pt;">) </font></div></td></tr><tr><td style="width: 360pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total liabilities, redeemable convertible preferred stock and stockholders&#8217; deficit<font style="padding-left: 0.44pt;"></font></div></td><td style="width: 4.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 7.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">603,375 </font></div></td><td style="width: 4.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.49pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.75pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 7.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">655,055</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 360pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 4.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 4.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 45pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 4.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 4.13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 46.49pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 9.47pt; text-align: center;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.<br></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-23<br></div></div></div>
<!--End Page 369-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 370-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_203-fintab01_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tCSOO"><!--Anchor--></a>TREELINE BIOSCIENCES, INC. AND SUBSIDIARY <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">(In thousands) </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 336pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 117.85pt;" colspan="4"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td colspan="4" style="width: 117.85pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended March&#160;31, </div></td></tr><tr class="BRDSX_header"><td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.85pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2026</div></td><td style="width: 7.08pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.84pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025 </div></td></tr><tr><td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating expenses:<br></div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.85pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.84pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Research and development<font style="padding-left: 0.76pt;"></font></div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.92pt; text-align: left;">$<font style="padding-left: 17.5pt;">49,098 </font></div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.92pt; text-align: left;">$<font style="padding-left: 17.5pt;">39,213 </font></div></td></tr><tr><td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">General and administrative<font style="padding-left: 0.2pt;"></font></div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.92pt; text-align: left;"><font style="padding-left: 27.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">6,959 </font></div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.92pt; text-align: left;"><font style="padding-left: 27.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">5,789 </font></div></td></tr><tr><td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total operating expenses<font style="padding-left: 4.23pt;"></font></div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.85pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.92pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">56,057 </font></div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.84pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.92pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">45,002</font></div></td></tr><tr><td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.85pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.84pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss from operations<font style="padding-left: 3.53pt;"></font></div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.92pt; text-align: left;"><font style="padding-left: 19.17pt;">(56,057)</font></div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.92pt; text-align: left;"><font style="padding-left: 19.17pt;">(45,002) </font></div></td></tr><tr><td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Other income <font style="padding-left: 1.3pt;"></font></div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.92pt; text-align: left;"><font style="padding-left: 27.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">5,516 </font></div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.92pt; text-align: left;"><font style="padding-left: 27.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">5,202 </font></div></td></tr><tr><td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net loss<font style="padding-left: 1.01pt;"></font></div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.85pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.92pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 14.17pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(50,541</font><font style="padding-bottom: 0.5pt;">)</font></div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.84pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.92pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 14.17pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(39,800</font><font style="padding-bottom: 0.5pt;">)</font></div></td></tr><tr><td style="width: 336pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.85pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.84pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Share Information:<br></div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net loss per share of common stock, basic and diluted<font style="padding-left: 2.45pt;"></font></div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.92pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 24.17pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(1.93</font><font style="padding-bottom: 0.5pt;">)</font></div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.92pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 24.17pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(2.02</font><font style="padding-bottom: 0.5pt;">) </font></div></td></tr><tr><td style="width: 336pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Weighted-average shares of common stock outstanding, basic and diluted<font style="padding-left: 4.66pt;"></font></div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.85pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.92pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">26,212,247 </font></div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.84pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.92pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">19,747,963</font></div></td></tr><tr><td style="width: 336pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.85pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.84pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Comprehensive loss<br></div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Net loss<font style="padding-left: 1.01pt;"></font></div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.92pt; text-align: left;">$<font style="padding-left: 14.17pt;">(50,541)</font></div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.92pt; text-align: left;">$<font style="padding-left: 14.17pt;">(39,800) </font></div></td></tr><tr><td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Unrealized (loss) gain on marketable securities, net of tax<font style="padding-left: 2.75pt;"></font></div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.92pt; text-align: left;"><font style="padding-left: 31.67pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(917</font><font style="padding-bottom: 1.5pt;">)</font></div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.92pt; text-align: left;"><font style="padding-left: 35pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">421 </font></div></td></tr><tr><td style="width: 336pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Comprehensive loss<font style="padding-left: 2.69pt;"></font></div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.85pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.92pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 14.17pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(51,458</font><font style="padding-bottom: 0.5pt;">)</font></div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.84pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.92pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 14.17pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(39,379</font><font style="padding-bottom: 0.5pt;">)</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 336pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 51.85pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 51.84pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 9.47pt; text-align: center;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.<br></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-24<br></div></div></div>
<!--End Page 370-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 371-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_203-fintab01_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tCSOR"><!--Anchor--></a>TREELINE BIOSCIENCES, INC. AND SUBSIDIARY <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE PREFERRED STOCK AND STOCKHOLDERS&#8217; DEFICIT <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">(IN THOUSANDS, EXCEPT SHARE DATA) </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 66pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 3.92pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 3.92pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 83.84pt;" colspan="4"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 3.66pt; border-right: 1pt solid #000000;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 3.66pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 71.81pt;" colspan="4"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 3.91pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 3.91pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 53.77pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 3.91pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 3.91pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 53.17pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 3.91pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 3.91pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 45.32pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 3.91pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 3.91pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 47.1pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 66pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 3.92pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.92pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td colspan="4" style="width: 83.84pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Series&#160;A, Series&#160;A-1, <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Series&#160;A-2 <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Preferred Stock</div></td><td style="width: 3.66pt; border-right: 1pt solid #000000; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.66pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td colspan="4" style="width: 71.81pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Common Stock</div></td><td style="width: 3.91pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.91pt; border-bottom: none;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td rowspan="2" style="width: 53.77pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Additional <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Paid-In-Capital</div></td><td style="width: 3.91pt; border-bottom: none;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.91pt; border-bottom: none;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td rowspan="2" style="width: 53.17pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Accumulated <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">other <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Comprehensive <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Income (Loss)</div></td><td style="width: 3.91pt; border-bottom: none;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.91pt; border-bottom: none;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td rowspan="2" style="width: 45.32pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Accumulated <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Deficit</div></td><td style="width: 3.91pt; border-bottom: none;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.91pt; border-bottom: none;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td rowspan="2" style="width: 47.1pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Stockholders&#8217; <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Deficit </div></td></tr><tr class="BRDSX_header"><td style="width: 66pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 3.92pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.92pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares</div></td><td style="width: 3.92pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.92pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Amount</div></td><td style="width: 3.66pt; border-right: 1pt solid #000000; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.66pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares</div></td><td style="width: 3.91pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.91pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 27.99pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Amount </div></td><td style="width: 3.91pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr><td style="width: 66pt; padding-top: 2.08pt; padding-bottom: 1.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 8pt; text-indent: -8pt; text-align: left;">Balance at January&#160;1, 2026<font style="padding-left: 0.13pt;"></font></div></td><td style="width: 3.92pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.92pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 2.08pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">144,834,563 </div></td><td style="width: 3.92pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.92pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; padding-top: 2.08pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$1,181,061 </div></td><td style="width: 3.66pt; border-right: 1pt solid #000000; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.66pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; padding-top: 2.08pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">20,765,754 </div></td><td style="width: 3.91pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.91pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 27.99pt; padding-top: 2.08pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 8pt; text-align: left;">$&#8212; </div></td><td style="width: 3.91pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.91pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 53.77pt; padding-top: 2.08pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 13.89pt; text-align: left;">$32,242 </div></td><td style="width: 3.91pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.91pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 53.17pt; padding-top: 2.08pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 17.26pt; text-align: left;">$<font style="padding-left: 2.66pt;">476 </font></div></td><td style="width: 3.91pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.91pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45.32pt; padding-top: 2.08pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 6.33pt; text-align: left;">$(601,282)</div></td><td style="width: 3.91pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.91pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 47.1pt; padding-top: 2.08pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 7.22pt; text-align: left;">$(568,564) </div></td></tr><tr><td style="width: 66pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 8pt; text-indent: -8pt; text-align: left;">Exercise of stock options<font style="padding-left: 2.44pt;"></font></div></td><td style="width: 3.92pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.92pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 32pt;">&#8212; </font></div></td><td style="width: 3.92pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.92pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 28pt;">&#8212; </font></div></td><td style="width: 3.66pt; border-right: 1pt solid #000000;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.66pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10pt;">162,380 </font></div></td><td style="width: 3.91pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.91pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 27.99pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 8pt; text-align: left;"><font style="padding-left: 4pt;">&#8212; </font></div></td><td style="width: 3.91pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.91pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 53.77pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 13.89pt; text-align: left;"><font style="padding-left: 14pt;">241 </font></div></td><td style="width: 3.91pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.91pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 53.17pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 17.26pt; text-align: left;"><font style="padding-left: 10.66pt;">&#8212; </font></div></td><td style="width: 3.91pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.91pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45.32pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 6.33pt; text-align: left;"><font style="padding-left: 24.66pt;">&#8212; </font></div></td><td style="width: 3.91pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.91pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 47.1pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 7.22pt; text-align: left;"><font style="padding-left: 20.66pt;">241 </font></div></td></tr><tr><td style="width: 66pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 8pt; text-indent: -8pt; text-align: left;">Stock-based compensation<font style="padding-left: 1.56pt;"></font></div></td><td style="width: 3.92pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.92pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 32pt;">&#8212; </font></div></td><td style="width: 3.92pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.92pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 28pt;">&#8212; </font></div></td><td style="width: 3.66pt; border-right: 1pt solid #000000; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.66pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 28pt;">&#8212; </font></div></td><td style="width: 3.91pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.91pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 27.99pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 8pt; text-align: left;"><font style="padding-left: 4pt;">&#8212; </font></div></td><td style="width: 3.91pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.91pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 53.77pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 13.89pt; text-align: left;"><font style="padding-left: 8pt;">1,887 </font></div></td><td style="width: 3.91pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.91pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 53.17pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 17.26pt; text-align: left;"><font style="padding-left: 10.66pt;">&#8212; </font></div></td><td style="width: 3.91pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.91pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45.32pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 6.33pt; text-align: left;"><font style="padding-left: 24.66pt;">&#8212; </font></div></td><td style="width: 3.91pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.91pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 47.1pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 7.22pt; text-align: left;"><font style="padding-left: 14.66pt;">1,887 </font></div></td></tr><tr><td style="width: 66pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 8pt; text-indent: -8pt; text-align: left;">Unrealized loss on marketable securities<font style="padding-left: 0.79pt;"></font></div></td><td style="width: 3.92pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.92pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 32pt;">&#8212; </font></div></td><td style="width: 3.92pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.92pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 28pt;">&#8212; </font></div></td><td style="width: 3.66pt; border-right: 1pt solid #000000;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.66pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 28pt;">&#8212; </font></div></td><td style="width: 3.91pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.91pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 27.99pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 8pt; text-align: left;"><font style="padding-left: 4pt;">&#8212; </font></div></td><td style="width: 3.91pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.91pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 53.77pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 13.89pt; text-align: left;"><font style="padding-left: 18pt;">&#8212; </font></div></td><td style="width: 3.91pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.91pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 53.17pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 17.26pt; text-align: left;"><font style="padding-left: 4pt;">(917)</font></div></td><td style="width: 3.91pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.91pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45.32pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 6.33pt; text-align: left;"><font style="padding-left: 24.66pt;">&#8212; </font></div></td><td style="width: 3.91pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.91pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 47.1pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 7.22pt; text-align: left;"><font style="padding-left: 18pt;">(917) </font></div></td></tr><tr><td style="width: 66pt; padding-top: 1.33pt; padding-bottom: 2.88pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net Loss<font style="padding-left: 0.34pt;"></font></div></td><td style="width: 3.92pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.92pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 1.33pt; padding-bottom: 2.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 32pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </font></div></td><td style="width: 3.92pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.92pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; padding-top: 1.33pt; padding-bottom: 2.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 28pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </font></div></td><td style="width: 3.66pt; border-right: 1pt solid #000000; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.66pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; padding-top: 1.33pt; padding-bottom: 2.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 28pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </font></div></td><td style="width: 3.91pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.91pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 27.99pt; padding-top: 1.33pt; padding-bottom: 2.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 8pt; text-align: left;"><font style="padding-left: 4pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </font></div></td><td style="width: 3.91pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.91pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 53.77pt; padding-top: 1.33pt; padding-bottom: 2.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 13.89pt; text-align: left;"><font style="padding-left: 18pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </font></div></td><td style="width: 3.91pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.91pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 53.17pt; padding-top: 1.33pt; padding-bottom: 2.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 17.26pt; text-align: left;"><font style="padding-left: 10.66pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </font></div></td><td style="width: 3.91pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.91pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45.32pt; padding-top: 1.33pt; padding-bottom: 2.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 6.33pt; text-align: left;"><font style="padding-left: 8pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(50,541</font><font style="padding-bottom: 1.5pt;">)</font></div></td><td style="width: 3.91pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.91pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 47.1pt; padding-top: 1.33pt; padding-bottom: 2.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 7.22pt; text-align: left;"><font style="padding-left: 8pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(50,541</font><font style="padding-bottom: 1.5pt;">) </font></div></td></tr><tr><td style="width: 66pt; padding-top: 2.58pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 8pt; text-indent: -8pt; text-align: left;">Balance at March&#160;31, 2026<font style="padding-left: 0.13pt;"></font></div></td><td style="width: 3.92pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.92pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 40pt; padding-top: 2.58pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">144,834,563 </font></div></td><td style="width: 3.92pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.92pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; padding-top: 2.58pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$1,181,061 </font></div></td><td style="width: 3.66pt; border-right: 1pt solid #000000;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.66pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; padding-top: 2.58pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">20,928,134 </font></div></td><td style="width: 3.91pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.91pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 27.99pt; padding-top: 2.58pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 8pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$&#8212; </font></div></td><td style="width: 3.91pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.91pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 53.77pt; padding-top: 2.58pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 13.89pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$34,370 </font></div></td><td style="width: 3.91pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.91pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 53.17pt; padding-top: 2.58pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 17.26pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$(441</font><font style="padding-bottom: 0.5pt;">)</font></div></td><td style="width: 3.91pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.91pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45.32pt; padding-top: 2.58pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 6.33pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$(651,823</font><font style="padding-bottom: 0.5pt;">)</font></div></td><td style="width: 3.91pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.91pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 47.1pt; padding-top: 2.58pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 7.22pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$(617,894</font><font style="padding-bottom: 0.5pt;">)</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 3.25pt; width: 66pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 3.92pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 3.92pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 40pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 3.92pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 3.92pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 3.66pt; border-right: 1pt solid #000000;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 3.66pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 3.91pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 3.91pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 27.99pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 3.91pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 3.91pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 53.77pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 3.91pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 3.91pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 53.17pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 3.91pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 3.91pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 45.32pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 3.91pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 3.91pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 47.1pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="margin-top: 4pt; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 66pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 78.33pt;" colspan="4"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.06pt; border-right: 1pt solid #000000;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.06pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 72.61pt;" colspan="4"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 53.77pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 53.17pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 45.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 47.1pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 66pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 4.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.31pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td colspan="4" style="width: 78.33pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Series&#160;A, Series&#160;A-1 <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Preferred Stock</div></td><td style="width: 4.06pt; border-right: 1pt solid #000000; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.06pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td colspan="4" style="width: 72.61pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Common Stock</div></td><td style="width: 4.31pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.31pt; border-bottom: none;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td rowspan="2" style="width: 53.77pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Additional <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Paid-In-Capital</div></td><td style="width: 4.31pt; border-bottom: none;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.31pt; border-bottom: none;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td rowspan="2" style="width: 53.17pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Accumulated <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">other <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Comprehensive <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Loss) Income</div></td><td style="width: 4.31pt; border-bottom: none;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.31pt; border-bottom: none;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td rowspan="2" style="width: 45.31pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Accumulated <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Deficit</div></td><td style="width: 4.31pt; border-bottom: none;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.31pt; border-bottom: none;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td rowspan="2" style="width: 47.1pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Stockholders&#8217; <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Deficit </div></td></tr><tr class="BRDSX_header"><td style="width: 66pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 4.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.31pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 39.71pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares</div></td><td style="width: 4.31pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.31pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 30pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Amount</div></td><td style="width: 4.06pt; border-right: 1pt solid #000000; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.06pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares</div></td><td style="width: 4.31pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.31pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 27.99pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Amount </div></td><td style="width: 4.31pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr><td style="width: 66pt; padding-top: 2.08pt; padding-bottom: 1.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 8pt; text-indent: -8pt; text-align: left;">Balance at January&#160;1, 2025<font style="padding-left: 0.13pt;"></font></div></td><td style="width: 4.31pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.31pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 39.71pt; padding-top: 2.08pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">115,102,744 </div></td><td style="width: 4.31pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.31pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 30pt; padding-top: 2.08pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$939,275 </div></td><td style="width: 4.06pt; border-right: 1pt solid #000000; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; padding-top: 2.08pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">19,657,900 </div></td><td style="width: 4.31pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.31pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 27.99pt; padding-top: 2.08pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 7.99pt; text-align: left;">$&#8212; </div></td><td style="width: 4.31pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.31pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 53.77pt; padding-top: 2.08pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 13.88pt; text-align: left;">$<font style="padding-left: 0.3pt;">11,168 </font></div></td><td style="width: 4.31pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.31pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 53.17pt; padding-top: 2.08pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 17.25pt; text-align: left;">$(335)</div></td><td style="width: 4.31pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.31pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45.31pt; padding-top: 2.08pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 6.33pt; text-align: left;">$(438,743)</div></td><td style="width: 4.31pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.31pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 47.1pt; padding-top: 2.08pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 7.22pt; text-align: left;">$(427,910) </div></td></tr><tr><td style="width: 66pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 8pt; text-indent: -8pt; text-align: left;">Exercise of stock options<font style="padding-left: 2.44pt;"></font></div></td><td style="width: 4.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 39.71pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 31.7pt;">&#8212; </font></div></td><td style="width: 4.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 30pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22pt;">&#8212; </font></div></td><td style="width: 4.06pt; border-right: 1pt solid #000000;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.06pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt;">170,399 </font></div></td><td style="width: 4.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 27.99pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 7.99pt; text-align: left;"><font style="padding-left: 4pt;">&#8212; </font></div></td><td style="width: 4.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 53.77pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 13.88pt; text-align: left;"><font style="padding-left: 14pt;">165 </font></div></td><td style="width: 4.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 53.17pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 17.25pt; text-align: left;"><font style="padding-left: 10.66pt;">&#8212; </font></div></td><td style="width: 4.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45.31pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 6.33pt; text-align: left;"><font style="padding-left: 24.66pt;">&#8212; </font></div></td><td style="width: 4.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 47.1pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 7.22pt; text-align: left;"><font style="padding-left: 20.66pt;">165 </font></div></td></tr><tr><td style="width: 66pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 8pt; text-indent: -8pt; text-align: left;">Stock-based compensation<font style="padding-left: 1.56pt;"></font></div></td><td style="width: 4.31pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.31pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 39.71pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 31.7pt;">&#8212; </font></div></td><td style="width: 4.31pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.31pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 30pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22pt;">&#8212; </font></div></td><td style="width: 4.06pt; border-right: 1pt solid #000000; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 28pt;">&#8212; </font></div></td><td style="width: 4.31pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.31pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 27.99pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 7.99pt; text-align: left;"><font style="padding-left: 4pt;">&#8212; </font></div></td><td style="width: 4.31pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.31pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 53.77pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 13.88pt; text-align: left;"><font style="padding-left: 8pt;">1,349 </font></div></td><td style="width: 4.31pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.31pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 53.17pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 17.25pt; text-align: left;"><font style="padding-left: 10.66pt;">&#8212; </font></div></td><td style="width: 4.31pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.31pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45.31pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 6.33pt; text-align: left;"><font style="padding-left: 24.66pt;">&#8212; </font></div></td><td style="width: 4.31pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.31pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 47.1pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 7.22pt; text-align: left;"><font style="padding-left: 14.66pt;">1,349 </font></div></td></tr><tr><td style="width: 66pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 8pt; text-indent: -8pt; text-align: left;">Unrealized gain on marketable securities<font style="padding-left: 0.79pt;"></font></div></td><td style="width: 4.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 39.71pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 31.7pt;">&#8212; </font></div></td><td style="width: 4.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 30pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22pt;">&#8212; </font></div></td><td style="width: 4.06pt; border-right: 1pt solid #000000;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.06pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 28pt;">&#8212; </font></div></td><td style="width: 4.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 27.99pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 7.99pt; text-align: left;"><font style="padding-left: 4pt;">&#8212; </font></div></td><td style="width: 4.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 53.77pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 13.88pt; text-align: left;"><font style="padding-left: 18pt;">&#8212; </font></div></td><td style="width: 4.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 53.17pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 17.25pt; text-align: left;"><font style="padding-left: 6.66pt;">421 </font></div></td><td style="width: 4.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45.31pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 6.33pt; text-align: left;"><font style="padding-left: 24.66pt;">&#8212; </font></div></td><td style="width: 4.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 47.1pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 7.22pt; text-align: left;"><font style="padding-left: 20.66pt;">421 </font></div></td></tr><tr><td style="width: 66pt; padding-top: 1.33pt; padding-bottom: 2.88pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net Loss<font style="padding-left: 0.34pt;"></font></div></td><td style="width: 4.31pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.31pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 39.71pt; padding-top: 1.33pt; padding-bottom: 2.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 31.7pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </font></div></td><td style="width: 4.31pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.31pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 30pt; padding-top: 1.33pt; padding-bottom: 2.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </font></div></td><td style="width: 4.06pt; border-right: 1pt solid #000000; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; padding-top: 1.33pt; padding-bottom: 2.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 28pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </font></div></td><td style="width: 4.31pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.31pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 27.99pt; padding-top: 1.33pt; padding-bottom: 2.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 7.99pt; text-align: left;"><font style="padding-left: 4pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </font></div></td><td style="width: 4.31pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.31pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 53.77pt; padding-top: 1.33pt; padding-bottom: 2.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 13.88pt; text-align: left;"><font style="padding-left: 18pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </font></div></td><td style="width: 4.31pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.31pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 53.17pt; padding-top: 1.33pt; padding-bottom: 2.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 17.25pt; text-align: left;"><font style="padding-left: 10.66pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </font></div></td><td style="width: 4.31pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.31pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45.31pt; padding-top: 1.33pt; padding-bottom: 2.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 6.33pt; text-align: left;"><font style="padding-left: 8pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(39,800</font><font style="padding-bottom: 1.5pt;">)</font></div></td><td style="width: 4.31pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.31pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 47.1pt; padding-top: 1.33pt; padding-bottom: 2.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 7.22pt; text-align: left;"><font style="padding-left: 8pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(39,800</font><font style="padding-bottom: 1.5pt;">) </font></div></td></tr><tr><td style="width: 66pt; padding-top: 2.58pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 8pt; text-indent: -8pt; text-align: left;">Balance at March&#160;31, 2025<font style="padding-left: 0.13pt;"></font></div></td><td style="width: 4.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 39.71pt; padding-top: 2.58pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">115,102,744 </font></div></td><td style="width: 4.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 30pt; padding-top: 2.58pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$939,275 </font></div></td><td style="width: 4.06pt; border-right: 1pt solid #000000;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.06pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; padding-top: 2.58pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">19,828,299 </font></div></td><td style="width: 4.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 27.99pt; padding-top: 2.58pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 7.99pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$&#8212; </font></div></td><td style="width: 4.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 53.77pt; padding-top: 2.58pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 13.88pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$ 12,682 </font></div></td><td style="width: 4.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 53.17pt; padding-top: 2.58pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 17.25pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 6.66pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">86 </font></div></td><td style="width: 4.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45.31pt; padding-top: 2.58pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 6.33pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$(478,543</font><font style="padding-bottom: 0.5pt;">)</font></div></td><td style="width: 4.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 47.1pt; padding-top: 2.58pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 7.22pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$(465,775</font><font style="padding-bottom: 0.5pt;">)</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 3.25pt; width: 66pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 4.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 4.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 39.71pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 4.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 4.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 30pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 4.06pt; border-right: 1pt solid #000000;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 4.06pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 4.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 4.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 27.99pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 4.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 4.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 53.77pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 4.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 4.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 53.17pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 4.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 4.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 45.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 4.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 4.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3.25pt; width: 47.1pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 9.47pt; text-align: center;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.<br></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-25<br></div></div></div>
<!--End Page 371-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 372-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_203-fintab01_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tCSOC"><!--Anchor--></a>TREELINE BIOSCIENCES, INC. AND SUBSIDIARY <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">(IN THOUSANDS) </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 348pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 111.85pt;" colspan="4"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 348pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td colspan="4" style="width: 111.85pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended March&#160;31, </div></td></tr><tr class="BRDSX_header"><td style="width: 348pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.85pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2026</div></td><td style="width: 4.08pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.84pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025 </div></td></tr><tr><td style="width: 348pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating activities<br></div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.85pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.84pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net loss<font style="padding-left: 3.01pt;"></font></div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8pt; text-align: left;">$(50,541)</div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8pt; text-align: left;">$(39,800) </div></td></tr><tr><td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Adjustments to reconcile net loss to net cash used in operations:<br></div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Stock-based compensation<font style="padding-left: 3.59pt;"></font></div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8pt; text-align: left;"><font style="padding-left: 13.33pt;">1,887 </font></div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8pt; text-align: left;"><font style="padding-left: 13.33pt;">1,349 </font></div></td></tr><tr><td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Depreciation and amortization<font style="padding-left: 3.87pt;"></font></div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8pt; text-align: left;"><font style="padding-left: 13.33pt;">1,541 </font></div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8pt; text-align: left;"><font style="padding-left: 13.33pt;">1,498 </font></div></td></tr><tr><td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Amortization of premium and discount on marketable securities, net<font style="padding-left: 2.52pt;"></font></div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8pt; text-align: left;"><font style="padding-left: 10pt;">(2,196)</font></div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8pt; text-align: left;"><font style="padding-left: 10pt;">(2,923) </font></div></td></tr><tr><td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Changes in operating assets and liabilities:<br></div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Prepaid expenses and other assets<font style="padding-left: 0.55pt;"></font></div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8pt; text-align: left;"><font style="padding-left: 10pt;">(2,436)</font></div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8pt; text-align: left;"><font style="padding-left: 13.33pt;">1,914 </font></div></td></tr><tr><td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Accounts payable<font style="padding-left: 4.14pt;"></font></div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8pt; text-align: left;"><font style="padding-left: 20.83pt;">456 </font></div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8pt; text-align: left;"><font style="padding-left: 17.5pt;">(734) </font></div></td></tr><tr><td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Accrued expenses<font style="padding-left: 3.04pt;"></font></div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8pt; text-align: left;"><font style="padding-left: 10pt;">(2,090)</font></div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8pt; text-align: left;"><font style="padding-left: 10pt;">(7,539) </font></div></td></tr><tr><td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Operating right of use assets and liabilities, net<font style="padding-left: 2.78pt;"></font></div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8pt; text-align: left;"><font style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">283 </font></div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8pt; text-align: left;"><font style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">394 </font></div></td></tr><tr><td style="width: 348pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net cash used in operating activities<font style="padding-left: 0.82pt;"></font></div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.85pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8pt; text-align: left;"><font style="padding-left: 5pt;">(53,096)</font></div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.84pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8pt; text-align: left;"><font style="padding-left: 5pt;">(45,841)</font></div></td></tr><tr><td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Investing activities<br></div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Purchases of marketable securities<font style="padding-left: 2.51pt;"></font></div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8pt; text-align: left;"><font style="padding-left: 5pt;">(55,071)</font></div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8pt; text-align: left;"><font style="padding-left: 5pt;">(68,099) </font></div></td></tr><tr><td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Maturities of marketable securities<font style="padding-left: 1.39pt;"></font></div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8pt; text-align: left;"><font style="padding-left: 8.33pt;">94,279 </font></div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8pt; text-align: left;"><font style="padding-left: 8.33pt;">97,500 </font></div></td></tr><tr><td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Purchases of fixed assets<font style="padding-left: 0.82pt;"></font></div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(162</font><font style="padding-bottom: 1.5pt;">)</font></div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(192</font><font style="padding-bottom: 1.5pt;">) </font></div></td></tr><tr><td style="width: 348pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net cash provided by investing activities<font style="padding-left: 2.49pt;"></font></div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.85pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8pt; text-align: left;"><font style="padding-left: 8.33pt;">39,046 </font></div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.84pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8pt; text-align: left;"><font style="padding-left: 8.33pt;">29,209</font></div></td></tr><tr><td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Financing Activities<br></div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Proceeds from exercise of options<font style="padding-left: 4.44pt;"></font></div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8pt; text-align: left;"><font style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">241 </font></div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8pt; text-align: left;"><font style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">165 </font></div></td></tr><tr><td style="width: 348pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net cash provided by financing activities<font style="padding-left: 1.38pt;"></font></div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.85pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8pt; text-align: left;"><font style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">241 </font></div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.84pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8pt; text-align: left;"><font style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">165 </font></div></td></tr><tr><td style="width: 348pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net decrease in cash, cash equivalents and restricted cash<font style="padding-left: 0.88pt;"></font></div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.85pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8pt; text-align: left;"><font style="padding-left: 5pt;">(13,809)</font></div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.84pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8pt; text-align: left;"><font style="padding-left: 5pt;">(16,467) </font></div></td></tr><tr><td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash, cash equivalents and restricted cash at beginning of period<font style="padding-left: 1.69pt;"></font></div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">47,475 </font></div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">40,694 </font></div></td></tr><tr><td style="width: 348pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash, cash equivalents and restricted cash at end of period<font style="padding-left: 2.25pt;"></font></div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.85pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">33,666 </font></div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.84pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">24,227</font></div></td></tr><tr><td style="width: 348pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.85pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.84pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Supplemental noncash investing information<br></div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 348pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Unrealized (loss) gain on marketable securities<font style="padding-left: 2.52pt;"></font></div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.85pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 12.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(917</font><font style="padding-bottom: 0.5pt;">)</font></div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.84pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</font><font style="padding-left: 15.83pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">421</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 348pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 51.85pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 4.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 51.84pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 9.47pt; text-align: center;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.<br></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-26<br></div></div></div>
<!--End Page 372-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 373-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_204-finnotes01_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;"><a name="tNTIC"><!--Anchor--></a>1. Organization and Description of Business </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Treeline Biosciences, Inc. and Subsidiary (the Company) is a biotechnology company focused on building transformative precision medicines for patients with cancer and other serious conditions. In 2023, the Company created a wholly owned Swiss subsidiary, Treeline Biosciences GmbH, for the purposes of conducting research and development (R&amp;D). The Company&#8217;s reporting currency is the U.S. dollar. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Liquidity </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company has incurred losses and negative cash flows from operations since inception and has an accumulated deficit of $651.8 million as of March&#160;31, 2026. The Company anticipates incurring additional losses until such time, if ever, as it can generate significant sales of its product candidates. Substantial additional financing will be needed by the Company to fund its operations and to commercially develop its product candidates. No assurance can be given that any such financing will be available when needed or that the Company&#8217;s R&amp;D efforts will be successful. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company follows the provisions of the Financial Accounting Standards Board (the FASB) Accounting Standards Codification (ASC) Topic 205-40, <font style="font-style: italic;">Presentation of Financial Statements &#8212; Going Concern</font>, which requires management to assess the Company&#8217;s ability to continue as a going concern within one year after the date the condensed consolidated financial statements are issued. As of March 31, 2026, the Company had cash, cash equivalents, and marketable securities of $553.1 million, which the Company expects to be sufficient to fund its operating expenses and capital expenditure requirements for at least the next 12 months from the issuance date of these condensed consolidated financial statements. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Risks and Uncertainties </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company faces risks associated with biotechnology companies. Product candidates currently being researched will require significant additional R&amp;D efforts, including extensive preclinical studies and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital for the Company to complete its R&amp;D, defend its intellectual property rights, and recruit and retain skilled personnel and key members of management. Even if the Company&#8217;s efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">2. Summary of Significant Accounting Policies </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Basis of Presentation </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The accompanying condensed consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (GAAP) for interim financial information. Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the ASC and Accounting Standards Updates (ASUs) of the FASB. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Unaudited Interim Condensed Consolidated Financial Information </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The accompanying condensed consolidated balance sheet as of March&#160;31, 2026, the condensed consolidated statements of operations and comprehensive loss for the three months ended March&#160;31, 2026 and 2025, the condensed consolidated statements of cash flows for the three months ended March&#160;31, 2026 and 2025 and the condensed consolidated statements of stockholders&#8217; deficit for the three months ended March&#160;31, 2026 and 2025 are unaudited. The unaudited interim consolidated financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the unaudited interim condensed consolidated financial statements) considered necessary to present fairly the Company&#8217;s financial position as of March&#160;31, 2026 and its results of operations for the three months ended March&#160;31, 2026 and 2025. Operating results for the three months ended March&#160;31, 2026 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2026, or any future year or period. The interim condensed consolidated financial statements, presented herein, do not contain the required disclosures under U.S. GAAP for annual financial statements. The accompanying unaudited interim condensed consolidated financial statements should be read in conjunction with the annual audited consolidated financial statements and related notes as of and for the year ended December&#160;31, 2025. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Cash, Cash Equivalents, and Restricted Cash </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company considers all highly liquid investments purchased with original maturities of three months or less from the purchase date to be cash equivalents. Cash equivalents consist primarily of amounts invested in a money market account. The Company held cash as of March&#160;31, 2026 and December 31, 2025, of approximately $1.1&#160;million in separate restricted bank accounts for lease security deposits. The Company has classified these amounts as long-term restricted cash on the accompanying condensed consolidated balance sheets as these leases expire after March 31, 2027. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-27<br></div></div></div>
<!--End Page 373-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 374-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_204-finnotes01_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Marketable Securities </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company&#8217;s marketable securities consist of investments in corporate debt securities, commercial paper, and government bonds that are classified as available for sale. These securities are carried at fair value with the unrealized gains and losses included, net of tax, in accumulated other comprehensive income (loss), a component of stockholders&#8217; equity. Realized gains and losses and declines in value determined to be other than temporary are included on the Company&#8217;s statements of operations and comprehensive loss. All marketable securities are available for use, as needed, to fund operations and therefore, the Company classifies all marketable securities as current assets on the condensed consolidated balance sheets. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">Foreign Currency </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Monetary assets and liabilities resulting from transactions denominated in currencies other than the functional currency are remeasured into the functional currency at exchange rates prevailing at the balance sheet date. Non-monetary assets and liabilities denominated in foreign currencies are measured using historical exchange rates prevailing at the date of the transaction and are not subsequently remeasured. Foreign currency remeasurement gains and losses are recognized within other income in the consolidated statements of operations and comprehensive loss. There were no material foreign currency remeasurement gains or losses for the three months ended March&#160;31, 2026 and 2025. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">Deferred Financing Costs </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company capitalizes costs that are directly associated with in-process equity financings until such financings are consummated, at which time such costs are recorded against the gross proceeds from the applicable financing. If a financing is abandoned, deferred financing costs are expensed immediately. As of March 31, 2026, the Company incurred $0.1&#160;million in deferred financing costs which are included within other assets in the accompanying condensed consolidated balance sheet. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">Segment Information </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment. The Company&#8217;s chief operating decision-maker (CODM), its chief executive officer, manages the Company&#8217;s operations on a consolidated basis for the purpose of allocating resources. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The accounting policies of the segment are the same as those described in the summary of significant accounting policies. The CODM assesses performance, makes operating decisions, and allocates resources for its segment based on net loss, which is reported on the statements of operations. The measure of segment assets is reported on the balance sheet as total assets. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">The table below summarizes the significant expense categories regularly reviewed by the CODM: </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 348pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.62pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.62pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 110.78pt;" colspan="4"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 348pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 4.62pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.62pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td colspan="4" style="width: 110.78pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended March&#160;31, </div></td></tr><tr class="BRDSX_header"><td style="width: 348pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 4.62pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.62pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.77pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2026</div></td><td style="width: 4.62pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.62pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.77pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025 </div></td></tr><tr><td style="width: 348pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Clinical programs<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(a)</sup>:<br></div></td><td style="width: 4.62pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.62pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.77pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 4.62pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.62pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.77pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">TLN-121<font style="padding-left: 2.73pt;"></font></div></td><td style="width: 4.62pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.62pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.14pt; text-align: left;">$<font style="padding-left: 5pt;">9,536 </font></div></td><td style="width: 4.62pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.62pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.14pt; text-align: left;">$<font style="padding-left: 17.5pt;">&#8212; </font></div></td></tr><tr><td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">TLN-254<font style="padding-left: 2.73pt;"></font></div></td><td style="width: 4.62pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.62pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.14pt; text-align: left;"><font style="padding-left: 10pt;">1,820 </font></div></td><td style="width: 4.62pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.62pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.14pt; text-align: left;"><font style="padding-left: 10pt;">1,223 </font></div></td></tr><tr><td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">TLN-372<font style="padding-left: 2.73pt;"></font></div></td><td style="width: 4.62pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.62pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.14pt; text-align: left;"><font style="padding-left: 10pt;">4,593 </font></div></td><td style="width: 4.62pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.62pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.14pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212; </font></div></td></tr><tr><td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Preclinical programs and other<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(b)</sup><font style="padding-left: 3.74pt;"></font></div></td><td style="width: 4.62pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.62pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.14pt; text-align: left;"><font style="padding-left: 5pt;">20,035 </font></div></td><td style="width: 4.62pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.62pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.14pt; text-align: left;"><font style="padding-left: 5pt;">25,477 </font></div></td></tr><tr><td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Personnel costs, including stock-based compensation<font style="padding-left: 3.06pt;"></font></div></td><td style="width: 4.62pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.62pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.77pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.14pt; text-align: left;"><font style="padding-left: 5.37pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">13,114 </font></div></td><td style="width: 4.62pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.62pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.77pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.14pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">12,513 </font></div></td></tr><tr><td style="width: 348pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total research and development expenses<font style="padding-left: 4.59pt;"></font></div></td><td style="width: 4.62pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.62pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.77pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.14pt; text-align: left;"><font style="padding-left: 5pt;">49,098 </font></div></td><td style="width: 4.62pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.62pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.77pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.14pt; text-align: left;"><font style="padding-left: 5pt;">39,213 </font></div></td></tr><tr><td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">General and administrative<br></div></td><td style="width: 4.62pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.62pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 4.62pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.62pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Personnel costs, including stock-based compensation<font style="padding-left: 3.06pt;"></font></div></td><td style="width: 4.62pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.62pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.14pt; text-align: left;"><font style="padding-left: 10pt;">2,983 </font></div></td><td style="width: 4.62pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.62pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.14pt; text-align: left;"><font style="padding-left: 10pt;">2,692 </font></div></td></tr><tr><td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Professional fees and other<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(c)</sup><font style="padding-left: 4.16pt;"></font></div></td><td style="width: 4.62pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.62pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.77pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.14pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">3,976 </font></div></td><td style="width: 4.62pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.62pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.77pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.14pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">3,097 </font></div></td></tr><tr><td style="width: 348pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total general and administrative expenses<font style="padding-left: 2.92pt;"></font></div></td><td style="width: 4.62pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.62pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.77pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.14pt; text-align: left;"><font style="padding-left: 10pt;">6,959 </font></div></td><td style="width: 4.62pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.62pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.77pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.14pt; text-align: left;"><font style="padding-left: 10pt;">5,789 </font></div></td></tr><tr><td style="width: 348pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total operating expenses<font style="padding-left: 1.23pt;"></font></div></td><td style="width: 4.62pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.62pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.77pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.14pt; text-align: left;"><font style="padding-left: 5pt;">56,057 </font></div></td><td style="width: 4.62pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.62pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.77pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.14pt; text-align: left;"><font style="padding-left: 5pt;">45,002 </font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 348pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 4.62pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 4.62pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 50.77pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 4.62pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 4.62pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 50.77pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-28<br></div></div></div>
<!--End Page 374-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 375-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_204-finnotes01_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="margin-top: 4pt; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 348pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.62pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.62pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 110.78pt;" colspan="4"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 348pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 4.62pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.62pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td colspan="4" style="width: 110.78pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended March&#160;31, </div></td></tr><tr class="BRDSX_header"><td style="width: 348pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 4.62pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.62pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.77pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2026</div></td><td style="width: 4.62pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.62pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.77pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025 </div></td></tr><tr><td style="width: 348pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss from operations<font style="padding-left: 0.53pt;"></font></div></td><td style="width: 4.62pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.62pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.77pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.47pt; text-align: left;"><font style="padding-left: 5pt;">(56,057)</font></div></td><td style="width: 4.62pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.62pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.77pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.47pt; text-align: left;"><font style="padding-left: 5pt;">(45,002) </font></div></td></tr><tr><td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other income<font style="padding-left: 0.8pt;"></font></div></td><td style="width: 4.62pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.62pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.77pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.47pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">5,516 </font></div></td><td style="width: 4.62pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.62pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.77pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.47pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">5,202 </font></div></td></tr><tr><td style="width: 348pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net loss<font style="padding-left: 3.01pt;"></font></div></td><td style="width: 4.62pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.62pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.77pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.47pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$(50,541</font><font style="padding-bottom: 0.5pt;">)</font></div></td><td style="width: 4.62pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.62pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.77pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.47pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$(39,800</font><font style="padding-bottom: 0.5pt;">)</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 348pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 4.62pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 4.62pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 50.77pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 4.62pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 4.62pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 50.77pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div><div class="BRDSX_rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 20.5pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(a)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Once a program has received approval from the FDA of its investigational new drug (IND) application, the Company classifies the program as a clinical program. Until a program has received approval of its IND application, the Company considers it a preclinical program. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(b)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Preclinical programs and other includes expenses related to the Company&#8217;s preclinical programs, rent expense, and lab supplies. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(c)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Professional fees and other includes legal, accounting, and audit fees, rent expense, software licenses, and insurance costs. </div></td></tr></table><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Net Loss Per Share </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. Common shares issuable upon exercise of the pre-funded warrants that were sold in connection with the 2025 Series&#160;A-2 Preferred Stock and Warrant Purchase Agreement are included in the calculation of weighted-average number of shares outstanding for the year ended December&#160;31, 2025. Consistent with the guidance in ASC 260-10-45-13, the underlying common shares are issuable for little to no consideration and there are no vesting conditions or contingencies associated with the warrants. Accordingly, the aggregate number of common shares underlying the pre-funded warrants have been considered outstanding for purposes of the calculation of net loss per share from the date of issuance. Diluted net loss per share of common stock includes the effect, if any, from the potential exercise of securities, such as stock options, unvested restricted stock units, and convertible preferred stock which would result in the issuance of incremental shares of common stock. Basic and diluted net loss per share is presented in conformity with the two-class method required for participating securities as the convertible preferred stock is considered a participating security. The Company&#8217;s participating securities do not have a contractual obligation to share in the Company&#8217;s losses. As such, the net loss is attributed entirely to common stockholders. Because the Company has reported a net loss for the reporting periods presented, the diluted net loss per common share is the same as basic net loss per common share for those periods. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive: </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 348pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 110pt;" colspan="4"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 348pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td colspan="4" style="width: 110pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">As of March&#160;31, </div></td></tr><tr class="BRDSX_header"><td style="width: 348pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2026</div></td><td style="width: 5pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025 </div></td></tr><tr><td style="width: 348pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Convertible preferred stock<font style="padding-left: 0.54pt;"></font></div></td><td style="width: 5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">144,834,563 </div></td><td style="width: 5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 0.37pt;">115,102,744 </font></div></td></tr><tr><td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Stock options<font style="padding-left: 0.78pt;"></font></div></td><td style="width: 5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5.37pt;">22,571,711 </font></div></td><td style="width: 5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">18,285,076 </font></div></td></tr><tr><td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Unvested restricted stock awards<font style="padding-left: 3.61pt;"></font></div></td><td style="width: 5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 40pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</font></div></td><td style="width: 5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">90,052 </font></div></td></tr><tr><td style="width: 348pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total<font style="padding-left: 0.09pt;"></font></div></td><td style="width: 5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">167,406,274 </font></div></td><td style="width: 5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">133,477,872</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 348pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 50pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 50pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.5pt; margin-left: 0pt; text-align: left;">Amounts in the above table reflect the common stock equivalents. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Recently Adopted Accounting Standards </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">From time to time, new accounting pronouncements are issued by the FASB and are early adopted by the Company or adopted as of the specified effective date. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In May&#160;2025, the FASB issued ASU 2025-03, <font style="font-style: italic;">Business Combinations (Topic 805) </font>and <font style="font-style: italic;">Consolidation (Topic 810)</font>: <font style="font-style: italic;">Determining the Accounting Acquirer in the Acquisition of a Variable Interest Entity</font>, which requires entities to consider the factors in ASC 805-10-55-12 through 55-15 when identifying the accounting acquirer in a business combination effected primarily through an exchange of equity interests in which the legal acquiree is a variable interest entity that meets the definition of a business. The Company early adopted ASU 2025-03 effective January&#160;1, 2026 on a prospective basis. The adoption did not have an impact on the Company&#8217;s condensed consolidated financial statements for the three&#160;months ended March&#160;31, 2026. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-29<br></div></div></div>
<!--End Page 375-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 376-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_204-finnotes01_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">3. Marketable Securities </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">The following is a summary of the Company&#8217;s marketable securities (amounts in thousands): </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 240pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 37.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 52.52pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 50.3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 37.5pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 240pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 6.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.27pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Amortized <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Cost</div></td><td style="width: 6.27pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.27pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.52pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Gross <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">unrealized gain</div></td><td style="width: 6.27pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.27pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.3pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Gross <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">unrealized loss</div></td><td style="width: 6.27pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.27pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Fair <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Value </div></td></tr><tr><td style="width: 240pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">As of March&#160;31, 2026<br></div></td><td style="width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.52pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.3pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Marketable securities<br></div></td><td style="width: 6.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.52pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.3pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Commercial paper<font style="padding-left: 3.36pt;"></font></div></td><td style="width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$222,737 </div></td><td style="width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.52pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.76pt; text-align: left;">$<font style="padding-left: 5pt;">6 </font></div></td><td style="width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.3pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.48pt; text-align: left;">$(194)</div></td><td style="width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$222,549 </div></td></tr><tr><td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Corporate debt securities<font style="padding-left: 2.54pt;"></font></div></td><td style="width: 6.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10pt;">94,867 </font></div></td><td style="width: 6.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.52pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.76pt; text-align: left;"><font style="padding-left: 10pt;">1 </font></div></td><td style="width: 6.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.3pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.48pt; text-align: left;"><font style="padding-left: 5pt;">(142)</font></div></td><td style="width: 6.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10pt;">94,726 </font></div></td></tr><tr><td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">US Treasury Bonds<font style="padding-left: 4.16pt;"></font></div></td><td style="width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">187,784 </font></div></td><td style="width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.52pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.76pt; text-align: left;"><font style="padding-left: 5pt;">57 </font></div></td><td style="width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.3pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.48pt; text-align: left;"><font style="padding-left: 5pt;">(172)</font></div></td><td style="width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">187,669 </font></div></td></tr><tr><td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">US Government Agency<font style="padding-left: 4.19pt;"></font></div></td><td style="width: 6.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">15,593 </font></div></td><td style="width: 6.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.52pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.76pt; text-align: left;"><font style="padding-left: 5.37pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">11 </font></div></td><td style="width: 6.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.3pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.48pt; text-align: left;"><font style="padding-left: 15pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(8</font><font style="padding-bottom: 1.5pt;">)</font></div></td><td style="width: 6.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">15,596 </font></div></td></tr><tr><td style="width: 240pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total assets measured at fair value<font style="padding-left: 0.2pt;"></font></div></td><td style="width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$520,981 </font></div></td><td style="width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.52pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.76pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$75 </font></div></td><td style="width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.3pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.48pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$(516</font><font style="padding-bottom: 0.5pt;">)</font></div></td><td style="width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$520,540</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 240pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 37.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 52.52pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 50.3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 37.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 240pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 37.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 52.52pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 50.3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 37.5pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 240pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 6.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.27pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Amortized <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Cost</div></td><td style="width: 6.27pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.27pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.52pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Gross <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">unrealized gain</div></td><td style="width: 6.27pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.27pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.3pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Gross <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">unrealized loss</div></td><td style="width: 6.27pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.27pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Fair <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Value </div></td></tr><tr><td style="width: 240pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">As of December&#160;31, 2025<br></div></td><td style="width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.52pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.3pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Marketable securities<br></div></td><td style="width: 6.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.52pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.3pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Commercial paper<font style="padding-left: 3.36pt;"></font></div></td><td style="width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$228,361 </div></td><td style="width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.52pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.26pt; text-align: left;">$<font style="padding-left: 5pt;">85 </font></div></td><td style="width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.3pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.98pt; text-align: left;">$(14)</div></td><td style="width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$228,432 </div></td></tr><tr><td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Corporate debt securities<font style="padding-left: 2.54pt;"></font></div></td><td style="width: 6.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10pt;">86,174 </font></div></td><td style="width: 6.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.52pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.26pt; text-align: left;"><font style="padding-left: 10pt;">63 </font></div></td><td style="width: 6.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.3pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.98pt; text-align: left;"><font style="padding-left: 8.33pt;">&#8212; </font></div></td><td style="width: 6.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10pt;">86,237 </font></div></td></tr><tr><td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">US Treasury Bonds<font style="padding-left: 4.16pt;"></font></div></td><td style="width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">220,885 </font></div></td><td style="width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.52pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.26pt; text-align: left;"><font style="padding-left: 5pt;">292 </font></div></td><td style="width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.3pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.98pt; text-align: left;"><font style="padding-left: 8.33pt;">&#8212; </font></div></td><td style="width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">221,177 </font></div></td></tr><tr><td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">US Government Agency<font style="padding-left: 4.19pt;"></font></div></td><td style="width: 6.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">22,572 </font></div></td><td style="width: 6.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.52pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.26pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">51 </font></div></td><td style="width: 6.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.3pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.98pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </font></div></td><td style="width: 6.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">22,623 </font></div></td></tr><tr><td style="width: 240pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total assets measured at fair value<font style="padding-left: 0.2pt;"></font></div></td><td style="width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$557,992 </font></div></td><td style="width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.52pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.26pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$491 </font></div></td><td style="width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.3pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.98pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$(14</font><font style="padding-bottom: 0.5pt;">)</font></div></td><td style="width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$558,469</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 240pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 37.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 52.52pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 50.3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 37.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company&#8217;s marketable securities generally have contractual maturity dates of between 6 and 24 months as of March 31, 2026. Net unrealized loss on marketable securities as of March 31, 2026, was $0.4&#160;million. Net unrealized gain on marketable securities as of December&#160;31, 2025, was $0.5&#160;million. As of March&#160;31, 2026, the Company had 64&#160;securities with a total fair market value of $345.9&#160;million in an unrealized loss position. The gains and losses in the table above were primarily due to changes in interest rates, and not due to increased credit risks associated with specific securities, and the Company believes that it is not more likely than not that the Company will be required to sell its marketable securities before recovery of their amortized cost bases, which may be at maturity. Accordingly, no other-than-temporary impairment was recorded for the three months ended March 31, 2026 or 2025, and there were no realized gains or losses recorded during the three months ended March&#160;31, 2026. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following is a summary of the Company&#8217;s marketable debt securities by contractual maturity (amounts in thousands): </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 2pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="margin-top: 0pt; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 336pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 3.64pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 3.64pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 124.73pt;" colspan="4"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 3.64pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.64pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td colspan="4" style="width: 124.73pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">As of </div></td></tr><tr class="BRDSX_header"><td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 3.64pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.64pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.96pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31, 2026</div></td><td style="width: 3.64pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.64pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 64.49pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2025 </div></td></tr><tr><td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Due in one year or less<font style="padding-left: 1.59pt;"></font></div></td><td style="width: 3.64pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.64pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.72pt; text-align: left;">$462,587 </div></td><td style="width: 3.64pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.64pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.5pt; text-align: left;">$464,332 </div></td></tr><tr><td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Due after one year through two years<font style="padding-left: 4.67pt;"></font></div></td><td style="width: 3.64pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.64pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.72pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">57,953 </font></div></td><td style="width: 3.64pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.64pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.5pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">94,137 </font></div></td></tr><tr><td style="width: 336pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total<font style="padding-left: 3.09pt;"></font></div></td><td style="width: 3.64pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.64pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 52.96pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.72pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$520,540 </font></div></td><td style="width: 3.64pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3.64pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 64.49pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.5pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$558,469</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 336pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 3.64pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 3.64pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 52.96pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 3.64pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 3.64pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 64.49pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Actual maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">4. Fair Value Measurements </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or a liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date. </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-30<br></div></div></div>
<!--End Page 376-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 377-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_204-finnotes01_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date. </div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following tables present the Company&#8217;s assets that are measured at fair value on a recurring basis (amounts in thousands): </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 336pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 32.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 37.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 29.99pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Level&#160;1) </div></td><td style="width: 5.34pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Level&#160;2) </div></td><td style="width: 5.34pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 29.99pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Level&#160;3) </div></td></tr><tr><td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Assets as of March&#160;31, 2026<br></div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 29.99pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash equivalents (money market accounts), including restricted cash <font style="padding-left: 1.09pt;"></font></div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$33,666 </div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<font style="padding-left: 22.5pt;">&#8212; </font></div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 29.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.5pt; text-align: left;">$&#8212; </div></td></tr><tr><td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Marketable securities<br></div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 29.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Commercial paper<font style="padding-left: 4.36pt;"></font></div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212; </font></div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">222,549 </font></div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 29.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.5pt; text-align: left;"><font style="padding-left: 5pt;">&#8212; </font></div></td></tr><tr><td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Corporate debt securities<font style="padding-left: 3.54pt;"></font></div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212; </font></div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10pt;">94,726 </font></div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 29.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.5pt; text-align: left;"><font style="padding-left: 5pt;">&#8212; </font></div></td></tr><tr><td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">U.S. government and agency securities<font style="padding-left: 2.44pt;"></font></div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </font></div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">203,265 </font></div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 29.99pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.5pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </font></div></td></tr><tr><td style="width: 336pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total assets measured at fair value<font style="padding-left: 1.2pt;"></font></div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$33,666 </font></div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$520,540 </font></div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 29.99pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.5pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$&#8212;</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 336pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 32.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 37.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 29.99pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 336pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 32.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 37.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 29.99pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Level&#160;1) </div></td><td style="width: 5.34pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Level&#160;2) </div></td><td style="width: 5.34pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 29.99pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Level&#160;3) </div></td></tr><tr><td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Assets as of December&#160;31, 2025<br></div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 29.99pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash equivalents (money market accounts), including restricted cash <font style="padding-left: 1.09pt;"></font></div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$47,475 </div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<font style="padding-left: 22.5pt;">&#8212; </font></div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 29.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.5pt; text-align: left;">$&#8212; </div></td></tr><tr><td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Marketable securities<br></div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 29.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Commercial paper<font style="padding-left: 4.36pt;"></font></div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212; </font></div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">228,432 </font></div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 29.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.5pt; text-align: left;"><font style="padding-left: 5pt;">&#8212; </font></div></td></tr><tr><td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Corporate debt securities<font style="padding-left: 3.54pt;"></font></div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212; </font></div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10pt;">86,237 </font></div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 29.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.5pt; text-align: left;"><font style="padding-left: 5pt;">&#8212; </font></div></td></tr><tr><td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">U.S. government and agency securities<font style="padding-left: 2.44pt;"></font></div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </font></div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">243,800 </font></div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 29.99pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.5pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </font></div></td></tr><tr><td style="width: 336pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total assets measured at fair value<font style="padding-left: 1.2pt;"></font></div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$47,475 </font></div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 37.5pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$558,469 </font></div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 29.99pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.5pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$&#8212;</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 336pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 32.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 37.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 5.34pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 29.99pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The fair values of the Company&#8217;s Level 2 marketable securities are estimated primarily based on benchmark yields, reported trades, market-based quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers, and reference data, including market research publications, which represent a market approach. In general, a market approach is utilized if there is readily available and relevant market activity for an individual security. This valuation technique may change from period to period, based on the relevance and availability of market data. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">5. Accrued Expenses </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">Accrued expenses consist of the following (amounts in thousands): </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 360pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.64pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.64pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 34.96pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.64pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.64pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 46.49pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 360pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 6.64pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.64pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 34.96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31, <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2026</div></td><td style="width: 6.64pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.64pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.49pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025 </div></td></tr><tr><td style="width: 360pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Employee compensation<font style="padding-left: 3.91pt;"></font></div></td><td style="width: 6.64pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.64pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 34.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.22pt; text-align: left;">$<font style="padding-left: 5pt;">2,258 </font></div></td><td style="width: 6.64pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.64pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7pt; text-align: left;">$<font style="padding-left: 5pt;">8,309 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Professional services<font style="padding-left: 3.37pt;"></font></div></td><td style="width: 6.64pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.64pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 34.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.22pt; text-align: left;"><font style="padding-left: 10pt;">1,332 </font></div></td><td style="width: 6.64pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.64pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7pt; text-align: left;"><font style="padding-left: 17.5pt;">585 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research and development<font style="padding-left: 4.76pt;"></font></div></td><td style="width: 6.64pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.64pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 34.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.22pt; text-align: left;"><font style="padding-left: 5.37pt;">11,658 </font></div></td><td style="width: 6.64pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.64pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7pt; text-align: left;"><font style="padding-left: 10pt;">8,338 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other<font style="padding-left: 4.73pt;"></font></div></td><td style="width: 6.64pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.64pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 34.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.22pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">333 </font></div></td><td style="width: 6.64pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.64pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">439 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total accrued expenses<font style="padding-left: 4.91pt;"></font></div></td><td style="width: 6.64pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.64pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 34.96pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.22pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$15,581 </font></div></td><td style="width: 6.64pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.64pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.49pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$17,671</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 360pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.64pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.64pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 34.96pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.64pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.64pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 46.49pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13.5pt; margin-left: 0pt; text-align: left;">6. Commitments and Contingencies </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Operating Leases </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company has operating leases in San Diego, California; Stamford, Connecticut; and Watertown, Massachusetts, none of which provide for a bargain purchase option or transfer of ownership at any point during the leases. The Company evaluates renewal options at lease inception and on an ongoing basis and includes renewal options that it is reasonably certain to exercise in its expected lease terms when classifying leases and measuring lease liabilities. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company&#8217;s leases generally do not provide an implicit rate, and therefore, the Company uses its incremental borrowing rate (9%&#8211;13%) as the discount rate when measuring operating lease liabilities. The incremental borrowing </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-31<br></div></div></div>
<!--End Page 377-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 378-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_204-finnotes01_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of the lease. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Future undiscounted minimum annual lease payments under the Company&#8217;s leases as of March 31, 2026 are as follows (amounts in thousands): </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 408pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 13.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 13.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 32.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr><td style="width: 408pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Future undiscounted minimum annual lease payments:<br></div></td><td style="width: 13.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2026 (remaining nine months)<font style="padding-left: 4.13pt;"></font></div></td><td style="width: 13.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<font style="padding-left: 5pt;">2,940 </font></div></td></tr><tr><td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2027<font style="padding-left: 0.5pt;"></font></div></td><td style="width: 13.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt;">6,097 </font></div></td></tr><tr><td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2028<font style="padding-left: 0.5pt;"></font></div></td><td style="width: 13.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt;">2,914 </font></div></td></tr><tr><td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2029<font style="padding-left: 0.5pt;"></font></div></td><td style="width: 13.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt;">2,983 </font></div></td></tr><tr><td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2030<font style="padding-left: 0.5pt;"></font></div></td><td style="width: 13.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt;">2,979 </font></div></td></tr><tr><td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Thereafter<font style="padding-left: 3.86pt;"></font></div></td><td style="width: 13.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">10,597 </font></div></td></tr><tr><td style="width: 408pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total lease payments<font style="padding-left: 1.78pt;"></font></div></td><td style="width: 13.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$28,510 </div></td></tr><tr><td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Less: imputed interest<font style="padding-left: 2.19pt;"></font></div></td><td style="width: 13.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 6.67pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(9,621</font><font style="padding-bottom: 1.5pt;">) </font></div></td></tr><tr><td style="width: 408pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total lease liabilities<font style="padding-left: 2.89pt;"></font></div></td><td style="width: 13.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 32.5pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$18,889</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 408pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 13.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 13.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 32.5pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">During the three months ended March&#160;31, 2026 and 2025, operating lease costs were $1.6&#160;million and $1.3&#160;million, respectively. During the three months ended March&#160;31, 2026 and 2025, variable lease expense was $1.1&#160;million and $0.8&#160;million, respectively. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In addition, the Company is party to short-term leases having a term of 12 months or less at the commencement date. The Company recognizes short-term lease expense on a straight-line basis and does not record a related right-of-use asset or lease liability for such leases. The costs related to short-term leases were immaterial for the three months ended March&#160;31, 2026 and 2025. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">During the three months ended March&#160;31, 2026 and 2025, the following other information associated with the leases is as follows (amounts in thousands): </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 360pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 13.25pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 13.25pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 27.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 13.25pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 13.25pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 27.5pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 360pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 13.25pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.25pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 27.5pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2026 </div></td><td style="width: 13.25pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.25pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 27.5pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025 </div></td></tr><tr><td style="width: 360pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating Cash flows from operating leases<font style="padding-left: 1.73pt;"></font></div></td><td style="width: 13.25pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.25pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 27.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$1,296 </div></td><td style="width: 13.25pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.25pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 27.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$1,303 </div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Weighted-average remaining lease term - operating leases (years)<font style="padding-left: 0.92pt;"></font></div></td><td style="width: 13.25pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.25pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 27.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt;">6.10</font></div></td><td style="width: 13.25pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.25pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 27.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt;">2.60 </font></div></td></tr><tr><td style="width: 360pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Weighted-average discount rate - operating leases<font style="padding-left: 3.66pt;"></font></div></td><td style="width: 13.25pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.25pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 27.5pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt;">12.2%</font></div></td><td style="width: 13.25pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13.25pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 27.5pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt;">12.6%</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 360pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 13.25pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 13.25pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 27.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 13.25pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 13.25pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 27.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12.5pt; margin-left: 0pt; text-align: left;">Litigation </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Liabilities for loss contingencies arising from claims, assessments, litigation, fines, penalties, and other sources (collectively, Contingency Matters) are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. For Contingency Matters in which the likelihood of material loss is at least reasonably possible, the Company provides disclosure of the possible loss or range of loss. If a reasonable estimate cannot be made, however, the Company will provide disclosure to that effect. At March&#160;31, 2026 and December&#160;31, 2025, there are no Contingency Matters currently outstanding. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">7. License Agreements </div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 0pt; text-align: left;">CRT Pioneer Fund License Agreement </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In May 2022, the Company entered into an exclusive worldwide license agreement (the CRT License Agreement) with CRT Pioneer Fund LP (CPF) to research, develop, manufacture, and commercialize products targeting BCL6 (B-cell lymphoma 6 protein) (BCL6 Products). As consideration for the license, the Company paid an up-front license fee of $2.0 million in 2022, and may owe future development milestone payments totaling up to $22.5 million, commercial milestone payments totaling up to $53.0 million, and low-single-digit royalties on net sales of any product covered by the CRT License Agreement, payable until generic competition commences with respect to such product on a country-by-country basis. As of March&#160;31, 2026, the Company paid $4.5&#160;million to CPF under the CRT License Agreement. The CRT License Agreement will continue on a country-by-country basis until expiration of the royalty term, subject to earlier termination by either party for the other&#8217;s uncured material breach or by the Company for convenience upon prior written notice. The Company did not incur expense related to the License Agreement during the three months ended March&#160;31, 2026 and 2025. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-32<br></div></div></div>
<!--End Page 378-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 379-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_204-finnotes01_pg7"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Jiangsu Hengrui Pharmaceuticals License Agreement </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In February 2023, the Company entered into an exclusive license agreement (the Jiangsu License) with Jiangsu Hengrui Pharmaceuticals (Jiangsu), pursuant to which the Company obtained exclusive rights to develop and commercialize SHR2554 (TLN-254) and related products outside of mainland China, Hong Kong, Macau, and Taiwan. As consideration for the Exclusive License, the Company paid an up-front fee of $11.0 million in 2023, and may owe additional development milestone payments totaling up to $45.0 million, commercial milestone payments totaling up to $650.0 million, and tiered royalties ranging in the lower teens based on future net sales of licensed products, subject to customary step-downs and a royalty floor. Royalties are payable on a product-by-product and country-by-country basis until expiration of the applicable royalty term. To date, the Company has not incurred expenses related to the Jiangsu License other than the up-front fee of $11.0&#160;million. The Company has incurred operating expenses of $0.1&#160;million to Jiangsu during the three months ended March&#160;31, 2026 and 2025, related to research and development activities. The Jiangsu License will continue until expiration of the last-to-expire royalty term, subject to earlier termination by either party for the other&#8217;s uncured material breach or by the Company for convenience upon prior written notice. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">8. Convertible Preferred Stock and Stockholders&#8217; Deficit </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">Convertible Preferred Stock </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company&#8217;s Series&#160;A Preferred Stock (Series&#160;A), Series&#160;A-1 Preferred Stock (Series&#160;A-1), and Series&#160;A-2 Preferred Stock (Series&#160;A-2) (collectively, Convertible Preferred Stock) are disclosed in the financial statements included in &#8220;Note&#160;9. Convertible Preferred Stock and Stockholders&#8217; Deficit&#8221; for the year ended December 31, 2025. Since the date of such consolidated financial statements, there have been no significant changes to the Company&#8217;s redeemable convertible preferred stock. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The authorized, issued, and outstanding shares of the Company&#8217;s convertible preferred and liquidation values as of March 31, 2026 and December&#160;31, 2025 were as follows (in thousands, except for share amounts): </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 216pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 7.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 7.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 50pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 7.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 7.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 50pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 7.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 7.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 45pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 7.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 7.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 45pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 216pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 7.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.75pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Authorized <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares</div></td><td style="width: 7.75pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.75pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Outstanding <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares</div></td><td style="width: 7.75pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.75pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Liquidation <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Value</div></td><td style="width: 7.75pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.75pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Carrying <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Value </div></td></tr><tr><td style="width: 216pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Series&#160;A<font style="padding-left: 4.9pt;"></font></div></td><td style="width: 7.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">64,723,570 </font></div></td><td style="width: 7.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">64,723,570 </font></div></td><td style="width: 7.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<font style="padding-left: 7.5pt;">506,624 </font></div></td><td style="width: 7.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<font style="padding-left: 7.5pt;">505,692 </font></div></td></tr><tr><td style="width: 216pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Series&#160;A-1<font style="padding-left: 1.57pt;"></font></div></td><td style="width: 7.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5.37pt;">80,110,993 </font></div></td><td style="width: 7.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">50,379,174 </font></div></td><td style="width: 7.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt;">433,780 </font></div></td><td style="width: 7.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt;">433,583 </font></div></td></tr><tr><td style="width: 216pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Series&#160;A-2<font style="padding-left: 1.57pt;"></font></div></td><td style="width: 7.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">29,731,819 </font></div></td><td style="width: 7.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">29,731,819 </font></div></td><td style="width: 7.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">256,000 </font></div></td><td style="width: 7.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">241,786 </font></div></td></tr><tr><td style="width: 216pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 7.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">174,566,382 </font></div></td><td style="width: 7.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">144,834,563 </font></div></td><td style="width: 7.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$1,196,404 </font></div></td><td style="width: 7.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$1,181,061</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 216pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 7.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 7.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 50pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 7.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 7.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 50pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 7.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 7.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 45pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 7.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 7.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 45pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The significant rights and obligations of the Company&#8217;s Convertible Preferred Stock are disclosed in the Company&#8217;s annual consolidated financial statements for the year ended December&#160;31, 2025. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Common Stock and Restricted Common Stock </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The holders of the common stock are entitled to one vote per share of common stock held at all meetings of stockholders. Unless required by law, there shall be no cumulative voting. In the event of any voluntary or involuntary liquidation, dissolution, or winding up of the Company, after the payment of all preferential amounts required to be paid to the holders of shares of Convertible Preferred Stock, the remaining funds and assets available for distribution to the stockholders of the Company will be distributed among the holders of shares of common stock, pro rata based on the number of shares of common stock held by each such holder. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">9. Stock-Based Compensation </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In 2021, the Company adopted the 2021 Equity Incentive Plan (as amended from time to time, the Plan) which provides for the granting of incentive stock options (ISOs) and nonqualified stock options (NQSOs). ISOs may be granted only to employees (including officers and directors who are also employees). NQSOs may be granted to employees, officers, directors, consultants, advisors, and other service providers of the Company. As of March 31, 2026, 38,152,270 shares were reserved for issuance under the Plan, of which 8,343,397 shares were available for future issuance. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-33<br></div></div></div>
<!--End Page 379-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 380-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_204-finnotes01_pg8"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">The amount, terms of grants, and exercisability provisions are determined and set by the Company&#8217;s board of directors. The Company measures employee and nonemployee stock-based awards at grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the award. The Company recorded stock-based compensation expense in the following expense categories of its statements of operations and comprehensive loss (amounts in thousands): </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 336pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 117.85pt;" colspan="4"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td colspan="4" style="width: 117.85pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended March&#160;31, </div></td></tr><tr class="BRDSX_header"><td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.85pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2026</div></td><td style="width: 7.08pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.84pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025 </div></td></tr><tr><td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research and development<font style="padding-left: 0.76pt;"></font></div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.85pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.17pt; text-align: left;">$1,550 </div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.84pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.17pt; text-align: left;">$1,124 </div></td></tr><tr><td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">General and administrative<font style="padding-left: 0.2pt;"></font></div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.17pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">337 </font></div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.17pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">225 </font></div></td></tr><tr><td style="width: 336pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total stock-based compensation expense<font style="padding-left: 0.64pt;"></font></div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.85pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.17pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$1,887 </font></div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.84pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.17pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$1,349</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 336pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 51.85pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 51.84pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">Stock Options </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company has issued service-based stock options that generally have a contractual term of up to ten years and may be exercisable in cash or as otherwise determined by the board of directors. Vesting generally occurs over a period of four years with 25% of awards vesting after one year and then monthly thereafter. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">The following table summarizes the activity related to stock options: </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 228pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 45pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 46.27pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 61.76pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 50.44pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 228pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares</div></td><td style="width: 4.57pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.27pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Weighted <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">average <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">exercise price <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">per share </div></td><td style="width: 4.57pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 61.76pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Weighted-average <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">remaining <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">contractual term <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(years) </div></td><td style="width: 4.57pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.44pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Aggregate <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Intrinsic Value <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(in thousands) </div></td></tr><tr><td style="width: 228pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Outstanding as of January&#160;1, 2026<font style="padding-left: 3.87pt;"></font></div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">18,441,432 </div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.27pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.89pt; text-align: left;">$1.68 </div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 61.76pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.14pt; text-align: left;"><font style="padding-left: 5pt;">7.6</font></div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.44pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.98pt; text-align: left;">$16,150 </div></td></tr><tr><td style="width: 228pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Granted<font style="padding-left: 3.29pt;"></font></div></td><td style="width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">4,625,600 </font></div></td><td style="width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.27pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.89pt; text-align: left;"><font style="padding-left: 5pt;">2.56 </font></div></td><td style="width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 61.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.44pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 228pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Exercised<font style="padding-left: 1.07pt;"></font></div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 9.17pt;">(162,380)</font></div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.27pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.89pt; text-align: left;"><font style="padding-left: 5pt;">1.48 </font></div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 61.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.44pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.98pt; text-align: left;">$<font style="padding-left: 12.5pt;">175 </font></div></td></tr><tr><td style="width: 228pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Forfeited or expired<font style="padding-left: 0.53pt;"></font></div></td><td style="width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 9.17pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(332,941</font><font style="padding-bottom: 1.5pt;">)</font></div></td><td style="width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.27pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.89pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">1.73 </font></div></td><td style="width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 61.76pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.14pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt; padding-right: 7.5pt;">&#8195;</font></div></td><td style="width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.44pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="border-bottom: 1pt solid #000000; padding-left: 32.5pt; margin-left: 8.81pt;"></font></div></td></tr><tr><td style="width: 228pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Outstanding as of March&#160;31, 2026<font style="padding-left: 3.87pt;"></font></div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 0.37pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">22,571,711 </font></div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.27pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.89pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$1.86 </font></div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 61.76pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.14pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">7.8</font></div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.44pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.98pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$15,698 </font></div></td></tr><tr><td style="width: 228pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exercisable as of March&#160;31, 2026<font style="padding-left: 1.1pt;"></font></div></td><td style="width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">10,781,870 </font></div></td><td style="width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.27pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.89pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$1.42 </font></div></td><td style="width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 61.76pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.14pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">6.4</font></div></td><td style="width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.44pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.98pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$12,334 </font></div></td></tr><tr><td style="width: 228pt; padding-top: 3.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Vested and expected to vest as of March&#160;31, 2026<font style="padding-left: 2.23pt;"></font></div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 3.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 0.37pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">22,571,711 </font></div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 46.27pt; padding-top: 3.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.89pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$1.86 </font></div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 61.76pt; padding-top: 3.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.14pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">7.8</font></div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 50.44pt; padding-top: 3.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.98pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$15,698</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 228pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 45pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 46.27pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 61.76pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 4.57pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 50.44pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Options granted to employees during the three months ended March&#160;31, 2026 and 2025, had a weighted average grant-date fair value of $2.08 and $1.84 per share, respectively. As of March&#160;31, 2026, the unrecognized compensation cost was $20.8 million and will be recognized over an estimated weighted average amortization period of 3.0 years. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">The fair value of the stock options granted was estimated using the following assumptions: </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 336pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 117.85pt;" colspan="4"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td colspan="4" style="width: 117.85pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended March&#160;31, </div></td></tr><tr class="BRDSX_header"><td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.85pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2026</div></td><td style="width: 7.08pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.84pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025 </div></td></tr><tr><td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected term (in years)<font style="padding-left: 4.93pt;"></font></div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.85pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"><font style="padding-left: 27.5pt;">6</font></div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.84pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"><font style="padding-left: 27.5pt;">6 </font></div></td></tr><tr><td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected stock price volatility<font style="padding-left: 1.59pt;"></font></div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"><font style="padding-left: 5pt;">102.43%</font></div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"><font style="padding-left: 5pt;">102.43% </font></div></td></tr><tr><td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Risk-free interest rate<font style="padding-left: 1.88pt;"></font></div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"><font style="padding-left: 15pt;">3.88%</font></div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"><font style="padding-left: 15pt;">4.41% </font></div></td></tr><tr><td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected dividend yield<font style="padding-left: 1.3pt;"></font></div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;%</font></div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;% </font></div></td></tr><tr><td style="width: 336pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Fair value of option grant<font style="padding-left: 1.3pt;"></font></div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.85pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;">$<font style="padding-left: 10pt;">2.08 </font></div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 51.84pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;">$<font style="padding-left: 10pt;">1.84</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 336pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 51.85pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 51.84pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">10. Subsequent Events </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company has evaluated subsequent events through June&#160;16, 2026, the date on which the accompanying condensed consolidated financial statements were issued, and has determined that the following matters required disclosure. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Merger with Standard BioTools Inc. and the related transactions are described in Note&#160;12 to the Company&#8217;s audited financial statements as of and for the year ended December&#160;31, 2025. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-34<br></div></div></div>
<!--End Page 380-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 381-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: right;"><a name="tANA"><!--Anchor--></a>Annex&#160;A<br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: right;">&#8195;<br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: right;">Execution Version </div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 19.5pt; text-align: center;">AGREEMENT AND PLAN OF MERGER AND REORGANIZATION <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-weight: normal;">among </font><br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-weight: normal;">&#8195;</font><br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">TREELINE BIOSCIENCES, INC., <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">STANDARD BIOTOOLS INC., <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-weight: normal;">and </font><br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-weight: normal;">&#8195;</font><br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">SIRI MERGER SUB, INC.</div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 7.5pt; text-align: center;"><div class="BRDSX_rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-top: 6pt; display: inline-block; margin-left: auto; margin-right: auto;"> </div> <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; text-align: center;">Dated as of June&#160;6, 2026 </div></div></div></div>
<!--End Page 381-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 382-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">TABLE OF CONTENTS<font style="font-weight: normal;"> </font></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 7pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 528pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 486pt;" colspan="7"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 36pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td colspan="7" style="width: 486pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Page </div></td></tr><tr><td colspan="7" style="width: 486pt; padding-top: 0.54pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAA1">Article&#160;I THE MERGER; CLOSING; SURVIVING COMPANY<font style="padding-left: 0.53pt;"></font></a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; padding-top: 0.54pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAA1"><font style="padding-left: 4.5pt;">A-2</font></a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS11">1.1</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS11">The Merger<font style="padding-left: 1.19pt;"></font></a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS11"><font style="padding-left: 4.5pt;">A-2 </font></a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS12">1.2</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS12">Closing<font style="padding-left: 0.75pt;"></font></a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS12"><font style="padding-left: 4.5pt;">A-2 </font></a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS13">1.3</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS13">Effective Time<font style="padding-left: 0.18pt;"></font></a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS13"><font style="padding-left: 4.5pt;">A-2 </font></a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS14">1.4</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS14">Parent Charter Amendment; Surviving Company Certificate of Incorporation<font style="padding-left: 1.61pt;"></font></a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS14"><font style="padding-left: 4.5pt;">A-2 </font></a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS15">1.5</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS15">Surviving Company Bylaws<font style="padding-left: 1.76pt;"></font></a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS15"><font style="padding-left: 4.5pt;">A-2 </font></a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS16">1.6</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS16">Directors and Officers of Parent<font style="padding-left: 3.49pt;"></font></a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS16"><font style="padding-left: 4.5pt;">A-2 </font></a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS17">1.7</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS17">Directors and Officers of the Surviving Company<font style="padding-left: 0.49pt;"></font></a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS17"><font style="padding-left: 4.5pt;">A-2 </font></a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td colspan="7" style="width: 486pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAA2">Article&#160;II EFFECT OF THE MERGER ON SECURITIES; EXCHANGE<font style="padding-left: 0.15pt;"></font></a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAA2"><font style="padding-left: 4.5pt;">A-2</font></a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS21">2.1</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS21">Effect on Capital Stock<font style="padding-left: 4.7pt;"></font></a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS21"><font style="padding-left: 4.5pt;">A-2 </font></a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS22">2.2</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS22">Exchange of Certificates<font style="padding-left: 4.81pt;"></font></a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS22"><font style="padding-left: 4.5pt;">A-3 </font></a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS23">2.3</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS23">Treatment of Company Options and Warrants<font style="padding-left: 4.76pt;"></font></a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS23"><font style="padding-left: 4.5pt;">A-4 </font></a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS24">2.4</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS24">Withholding Rights<font style="padding-left: 2.86pt;"></font></a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS24"><font style="padding-left: 4.5pt;">A-5 </font></a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS25">2.5</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS25">Appraisal Rights.<font style="padding-left: 0.77pt;"></font></a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS25"><font style="padding-left: 4.5pt;">A-5 </font></a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS26">2.6</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS26">Calculation of Parent Net Cash.<font style="padding-left: 4.55pt;"></font></a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS26"><font style="padding-left: 4.5pt;">A-6 </font></a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS27">2.7</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS27">Post-Closing Adjustment of Parent Net Cash.<font style="padding-left: 0.78pt;"></font></a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS27"><font style="padding-left: 4.5pt;">A-6 </font></a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td colspan="7" style="width: 486pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAA3">Article&#160;III REPRESENTATIONS AND WARRANTIES OF THE COMPANY<font style="padding-left: 2.45pt;"></font></a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAA3"><font style="padding-left: 4.5pt;">A-7</font></a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS31">3.1</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS31">Organizational Documents<font style="padding-left: 2.21pt;"></font></a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS31"><font style="padding-left: 4.5pt;">A-7 </font></a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS32">3.2</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS32">Due Organization; Subsidiaries<font style="padding-left: 0.96pt;"></font></a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS32"><font style="padding-left: 4.5pt;">A-7 </font></a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS33">3.3</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS33">Capitalization<font style="padding-left: 3.27pt;"></font></a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS33"><font style="padding-left: 4.5pt;">A-8 </font></a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS34">3.4</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS34">Authority; Binding Nature of Agreement; Required Vote<font style="padding-left: 0.64pt;"></font></a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS34"><font style="padding-left: 4.5pt;">A-9 </font></a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS35">3.5</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS35">Non-Contravention; Consents<font style="padding-left: 1.03pt;"></font></a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS35"><font style="padding-left: 4.5pt;">A-9 </font></a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS36">3.6</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS36">Financial Statements<font style="padding-left: 3.53pt;"></font></a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS36">A-10 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS37">3.7</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS37">Absence of Changes<font style="padding-left: 4.78pt;"></font></a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS37">A-10 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS38">3.8</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS38">Absence of Undisclosed Liabilities<font style="padding-left: 2.55pt;"></font></a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS38">A-10 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS39">3.9</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS39">Title to Assets<font style="padding-left: 2.57pt;"></font></a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS39">A-10 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS310">3.10</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS310">Legal Proceedings; Orders<font style="padding-left: 2.8pt;"></font></a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS310">A-10 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS311">3.11</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS311">Contracts<font style="padding-left: 4.26pt;"></font></a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS311"><font style="padding-left: 0.33pt;">A-11 </font></a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS312">3.12</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS312">Employee and Labor Matters; Benefits Plans<font style="padding-left: 2.07pt;"></font></a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS312">A-12 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS313">3.13</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS313">Environmental Matters<font style="padding-left: 0.54pt;"></font></a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS313">A-14 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS314">3.14</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS314">Taxes<font style="padding-left: 2.89pt;"></font></a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS314">A-15 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS315">3.15</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS315">Intellectual Property<font style="padding-left: 0.04pt;"></font></a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS315">A-16 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS316">3.16</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS316">Privacy and Data Security<font style="padding-left: 4.55pt;"></font></a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS316">A-17 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS317">3.17</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS317">Compliance with Laws; Permits; Regulatory Matters<font style="padding-left: 3.57pt;"></font></a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS317">A-18 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS318">3.18</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS318">Insurance<font style="padding-left: 3.78pt;"></font></a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS318">A-19 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS319">3.19</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS319">Real Estate<font style="padding-left: 3.02pt;"></font></a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS319">A-19 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS320">3.20</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS320">Registration Statement and Proxy Statement/Prospectus<font style="padding-left: 2.82pt;"></font></a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS320">A-20 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS321">3.21</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS321">Transactions with Affiliates<font style="padding-left: 4.27pt;"></font></a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS321">A-20 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS322">3.22</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS322">Brokers and Finders<font style="padding-left: 0.78pt;"></font></a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS322">A-20 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS323">3.23</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS323">Certain Business Practices<font style="padding-left: 3.29pt;"></font></a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS323">A-20 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS324">3.24</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS324">Ownership of Parent Common Stock<font style="padding-left: 0.79pt;"></font></a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS324">A-20 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td colspan="7" style="width: 486pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAA4">Article&#160;IV REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB<font style="padding-left: 1.1pt;"></font></a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAA4">A-21</a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS41">4.1</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS41">Organizational Documents<font style="padding-left: 2.21pt;"></font></a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS41">A-21 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS42">4.2</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS42">Due Organization; Subsidiaries<font style="padding-left: 0.96pt;"></font></a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS42">A-21 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS43">4.3</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS43">Capitalization<font style="padding-left: 3.27pt;"></font></a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS43">A-21 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS44">4.4</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS44">Authority; Binding Nature of Agreement; Required Vote<font style="padding-left: 0.64pt;"></font></a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS44">A-22 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS45">4.5</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS45">Non-Contravention; Consents<font style="padding-left: 1.03pt;"></font></a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS45">A-23 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS46">4.6</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS46">SEC Documents; Financial Statements<font style="padding-left: 4.04pt;"></font></a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS46">A-23 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS47">4.7</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS47">Absence of Changes<font style="padding-left: 4.78pt;"></font></a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS47">A-24 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS48">4.8</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS48">Absence of Undisclosed Liabilities<font style="padding-left: 2.55pt;"></font></a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS48">A-25 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS49">4.9</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS49">Title to Assets<font style="padding-left: 2.57pt;"></font></a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS49">A-25 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS410">4.10</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS410">Legal Proceedings; Orders<font style="padding-left: 2.8pt;"></font></a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS410">A-25 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS411">4.11</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS411">Contracts<font style="padding-left: 4.26pt;"></font></a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS411">A-25 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS412">4.12</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS412">Employee and Labor Matters; Benefits Plans<font style="padding-left: 2.07pt;"></font></a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS412">A-26 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS413">4.13</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS413">Environmental Matters<font style="padding-left: 0.54pt;"></font></a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS413">A-29 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS414">4.14</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS414">Taxes<font style="padding-left: 2.89pt;"></font></a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS414">A-29 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS415">4.15</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS415">Intellectual Property<font style="padding-left: 0.04pt;"></font></a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS415">A-31 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS416">4.16</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS416">Privacy and Data Security<font style="padding-left: 4.55pt;"></font></a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS416">A-32 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS417">4.17</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS417">Compliance with Laws; Permits; Regulatory Matters<font style="padding-left: 3.57pt;"></font></a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS417">A-32 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS418">4.18</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS418">Insurance<font style="padding-left: 3.78pt;"></font></a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS418">A-34 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS419">4.19</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS419">Real Estate<font style="padding-left: 3.02pt;"></font></a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS419">A-34 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS420">4.20</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS420">Registration Statement and Proxy Statement/Prospectus<font style="padding-left: 2.82pt;"></font></a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS420">A-34 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS421">4.21</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS421">Transactions with Affiliates<font style="padding-left: 4.27pt;"></font></a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS421">A-35 </a></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 3pt; width: 24pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 24pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 426pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 36pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-i<br></div></div></div>
<!--End Page 382-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 383-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="margin-top: 4pt; width: 528pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 486pt;" colspan="7"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 36pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td colspan="7" style="width: 486pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Page </div></td></tr><tr><td style="width: 24pt; padding-top: 0.54pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; padding-top: 0.54pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS422">4.22</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; padding-top: 0.54pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS422">Brokers and Finders<font style="padding-left: 0.78pt;"></font></a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; padding-top: 0.54pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS422">A-35 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS423">4.23</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS423">Opinion of Financial Advisor<font style="padding-left: 3.03pt;"></font></a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS423">A-35 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS424">4.24</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS424">Certain Business Practices<font style="padding-left: 3.29pt;"></font></a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS424">A-35 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS425">4.25</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS425">Ownership and Operations of Merger Sub<font style="padding-left: 2.73pt;"></font></a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS425">A-35 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS426">4.26</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS426">Customers and Suppliers.<font style="padding-left: 1.52pt;"></font></a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS426">A-35 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS427">4.27</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS427">Ownership of the Company Common Stock<font style="padding-left: 0.53pt;"></font></a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS427">A-35 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td colspan="7" style="width: 486pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAA5">Article&#160;V COVENANTS<font style="padding-left: 3.61pt;"></font></a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAA5">A-36</a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS51">5.1</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS51">Interim Operations<font style="padding-left: 0.54pt;"></font></a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS51">A-36 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS52">5.2</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS52">Company Acquisition Proposals; Company Change in Recommendation<font style="padding-left: 3.3pt;"></font></a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS52">A-39 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS53">5.3</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS53">Parent Acquisition Proposals; Parent Change in Recommendation<font style="padding-left: 2.32pt;"></font></a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS53">A-42 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS54">5.4</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS54">Information Supplied<font style="padding-left: 1.53pt;"></font></a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS54">A-45 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS55">5.5</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS55">Stockholder Approvals<font style="padding-left: 1.02pt;"></font></a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS55">A-46 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS56">5.6</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS56">Regulatory Approvals; Reasonable Best Efforts<font style="padding-left: 2.98pt;"></font></a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS56">A-47 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS57">5.7</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS57">Access; Consultation<font style="padding-left: 2.52pt;"></font></a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS57">A-48 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS58">5.8</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS58">Stock Exchange Listing<font style="padding-left: 2.78pt;"></font></a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS58">A-48 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS59">5.9</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS59">Publicity<font style="padding-left: 1.25pt;"></font></a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS59">A-48 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS510">5.10</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS510">Expenses<font style="padding-left: 4.76pt;"></font></a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS510">A-48 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS511">5.11</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS511">Indemnification; Directors&#8217; and Officers&#8217; Insurance<font style="padding-left: 4.37pt;"></font></a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS511">A-49 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS512">5.12</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS512">Takeover Statute<font style="padding-left: 3.16pt;"></font></a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS512">A-49 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS513">5.13</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS513">Control of Company&#8217;s or Parent&#8217;s Operations<font style="padding-left: 0.55pt;"></font></a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS513">A-49 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS514">5.14</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS514">Directors and Officers<font style="padding-left: 3.47pt;"></font></a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS514">A-49 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS515">5.15</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS515">Lock-Up Agreements<font style="padding-left: 1.04pt;"></font></a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS515">A-50 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS516">5.16</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS516">Approval by Sole Stockholder of Merger Sub<font style="padding-left: 4.97pt;"></font></a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS516">A-50 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS517">5.17</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS517">Stockholder Litigation<font style="padding-left: 2.52pt;"></font></a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS517">A-50 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS518">5.18</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS518">Tax Treatment<font style="padding-left: 1.64pt;"></font></a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS518">A-50 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS519">5.19</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS519">Parent Resignations<font style="padding-left: 2.02pt;"></font></a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS519">A-51 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS520">5.20</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS520">Obligations of Merger Sub and Surviving Company<font style="padding-left: 1.96pt;"></font></a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS520">A-51 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS521">5.21</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS521">Closing Dividend; CVR Agreement<font style="padding-left: 0.02pt;"></font></a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS521">A-51 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS522">5.22</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS522">Parent Reverse Stock Split<font style="padding-left: 2.53pt;"></font></a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS522">A-51 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS523">5.23</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS523">Wind-Down Activities and Legacy Transactions; Parent Employees<font style="padding-left: 0.69pt;"></font></a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS523">A-51 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS524">5.24</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS524">Termination of Company Investor Agreements<font style="padding-left: 0.94pt;"></font></a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS524">A-52 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS525">5.25</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS525">Parent Equity Plans.<font style="padding-left: 0.52pt;"></font></a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS525">A-52 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS526">5.26</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS526">Termination of the Parent&#8217;s 401(k) Plan<font style="padding-left: 1.19pt;"></font></a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS526">A-52 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS527">5.27</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS527">Company Preferred Stock<font style="padding-left: 0.29pt;"></font></a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS527">A-52 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td colspan="7" style="width: 486pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAA6">Article&#160;VI CONDITIONS<font style="padding-left: 4.96pt;"></font></a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAA6">A-53</a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS61">6.1</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS61">Conditions to Each Party&#8217;s Obligation to Effect the Contemplated Transactions<font style="padding-left: 4.74pt;"></font></a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS61">A-53 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS62">6.2</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS62">Conditions to Obligations of Parent and Merger Sub<font style="padding-left: 0.71pt;"></font></a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS62">A-53 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS63">6.3</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS63">Conditions to Obligation of Company<font style="padding-left: 2.26pt;"></font></a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS63">A-54 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS64">6.4</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS64">Frustration of Conditions<font style="padding-left: 2.77pt;"></font></a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS64">A-54 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td colspan="7" style="width: 486pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAA7">Article&#160;VII TERMINATION<font style="padding-left: 0.63pt;"></font></a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAA7">A-54</a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS71">7.1</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS71">Termination by Mutual Consent<font style="padding-left: 3.66pt;"></font></a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS71">A-54 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS72">7.2</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS72">Termination by Either Parent or Company<font style="padding-left: 2.18pt;"></font></a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS72">A-54 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS73">7.3</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS73">Termination by Company<font style="padding-left: 1.4pt;"></font></a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS73">A-55 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS74">7.4</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS74">Termination by Parent<font style="padding-left: 3.41pt;"></font></a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS74">A-55 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS75">7.5</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS75">Company Termination Fee and Expense Reimbursement.<font style="padding-left: 3.11pt;"></font></a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS75">A-55 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS76">7.6</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS76">Parent Termination Fee and Expense Reimbursement<font style="padding-left: 2.37pt;"></font></a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS76">A-56 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS77">7.7</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS77">Notice of Termination<font style="padding-left: 4.08pt;"></font></a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS77">A-56 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS78">7.8</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS78">Effect of Termination and Abandonment<font style="padding-left: 3.27pt;"></font></a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS78">A-56 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS79">7.9</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS79">Remedies<font style="padding-left: 3.26pt;"></font></a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS79">A-56 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td colspan="7" style="width: 486pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAA8">Article&#160;VIII MISCELLANEOUS AND GENERAL<font style="padding-left: 3.49pt;"></font></a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAA8">A-57</a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS81">8.1</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS81">Survival<font style="padding-left: 3.26pt;"></font></a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS81">A-57 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS82">8.2</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS82">Amendment<font style="padding-left: 4.26pt;"></font></a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS82">A-57 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS83">8.3</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS83">Assignability<font style="padding-left: 0.76pt;"></font></a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS83">A-57 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS84">8.4</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS84">Waiver<font style="padding-left: 2.99pt;"></font></a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS84">A-57 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS85">8.5</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS85">Entire Agreement; Counterparts; Exchanges by Electronic Transmission<font style="padding-left: 4.34pt;"></font></a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS85">A-57 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS86">8.6</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS86">Governing Law and Venue; Waiver of Jury Trial<font style="padding-left: 0.11pt;"></font></a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS86">A-57 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS87">8.7</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS87">Notices<font style="padding-left: 1.26pt;"></font></a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS87">A-58 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS88">8.8</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS88">No Third Party Beneficiaries<font style="padding-left: 4.72pt;"></font></a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS88">A-58 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS89">8.9</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS89">Severability<font style="padding-left: 0.27pt;"></font></a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS89">A-58 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS810">8.10</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS810">No Other Representations and Warranties<font style="padding-left: 4.21pt;"></font></a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS810">A-59 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS811">8.11</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS811">Construction<font style="padding-left: 2.26pt;"></font></a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS811">A-59 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS812">8.12</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS812">Specific Performance<font style="padding-left: 1.06pt;"></font></a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS812">A-60 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS813">8.13</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS813">Actions by Parent After the Closing<font style="padding-left: 0.04pt;"></font></a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS813">A-60 </a></div></td></tr><tr><td style="width: 24pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 4.13pt; text-align: left;"><a href="#tANXAS814">8.14</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS814">Special Committee Approval<font style="padding-left: 4.28pt;"></font></a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 36pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 8.75pt; text-align: left;"><a href="#tANXAS814">A-60</a></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 3pt; width: 24pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 24pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 426pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 36pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-ii<br></div></div></div>
<!--End Page 383-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 384-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-align: left;"><u>Exhibits</u> </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_txtann" style="width: 528pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 60pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 456pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr><td style="width: 60pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exhibit&#160;A</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 456pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Definitions </div></td></tr><tr><td style="width: 60pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exhibit&#160;B</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 456pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Form&#160;of Company Stockholder Written Consent </div></td></tr><tr><td style="width: 60pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exhibit&#160;C</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 456pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Form&#160;of Certificate of Merger </div></td></tr><tr><td style="width: 60pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exhibit&#160;D</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 456pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Form of Surviving Company Certificate of Incorporation </div></td></tr><tr><td style="width: 60pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exhibit&#160;E</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 456pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Form&#160;of Surviving Company Bylaws </div></td></tr><tr><td style="width: 60pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exhibit&#160;F</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 456pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Form&#160;of Parent Net Cash Schedule </div></td></tr><tr><td style="width: 60pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exhibit&#160;G</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 456pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Directors and Officers of Parent </div></td></tr><tr><td style="width: 60pt; padding-top: 0.67pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exhibit&#160;H</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 456pt; padding-top: 0.67pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Form of CVR Agreement</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 3pt; width: 60pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 456pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6.5pt; margin-left: 0pt; text-align: left;"><u>Schedules</u> </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_txtann" style="width: 528pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 60pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 456pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr><td style="width: 60pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Schedule A</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 456pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consenting Company Stockholders </div></td></tr><tr><td style="width: 60pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Schedule B</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 456pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Accounting Principles </div></td></tr><tr><td style="width: 60pt; padding-top: 0.67pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Schedule C</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 456pt; padding-top: 0.67pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Investor Agreements</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 3pt; width: 60pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 456pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-iii<br></div></div></div>
<!--End Page 384-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 385-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><table cellspacing="0" cellpadding="0" class="BRDSX_txtann" style="margin-top: 4pt; width: 528pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 258pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 258pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr><td style="width: 258pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-variant: small-caps; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Defined Terms Index<font style="font-variant: normal;"> </font></div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 258pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-variant: small-caps; font-weight: bold; margin-top: 0pt; text-align: right;">Section</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 3pt; width: 258pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 258pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table></div><div class="BRDSX_columns" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_BRDSX_block-main-columns" style="width: 258pt; float: left;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_finann" style="width: 258pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 4pt; width: 180pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 4pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 4pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 4pt; width: 72pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Acceptable Parent Confidentiality Agreement<font style="padding-left: 3.58pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;5.3(b) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Accounting Firm<font style="padding-left: 1.02pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;2.7(d) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Agreement<font style="padding-left: 2.78pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Preamble </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Anticipated Closing Date<font style="padding-left: 1.28pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;2.6(b) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">capitalization change<font style="padding-left: 1.55pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;2.1(c) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Carta<font style="padding-left: 3.26pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;2.2(g) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Certificate<font style="padding-left: 4.78pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;2.1(a)(ii) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Certificate of Merger<font style="padding-left: 1.47pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;1.3 </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Closing<font style="padding-left: 4.75pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;1.2 </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Closing Date<font style="padding-left: 0.51pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;1.2 </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Closing Dividend<font style="padding-left: 4.01pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;5.21(a) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Code<font style="padding-left: 3.75pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Recitals </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Company<font style="padding-left: 2.75pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Preamble, Preamble </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Company Alternative Acquisition Agreement<font style="padding-left: 0.05pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;5.2(e) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Company Audited Financial Statements<font style="padding-left: 4.53pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;3.6(a) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Company Balance Sheet<font style="padding-left: 4.28pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;3.7(a) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Company Board<font style="padding-left: 3.51pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Recitals </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Company Board Recommendation<font style="padding-left: 2.78pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Recitals </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Company Change in Recommendation<font style="padding-left: 3.03pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;5.2(e) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Company Common Stock<font style="padding-left: 4.25pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;3.3(a) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Company Disclosure Schedule<font style="padding-left: 1.79pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Article&#160;III </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Company Equity Plan<font style="padding-left: 3.26pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;3.3(d) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Company Fee Reimbursement<font style="padding-left: 3.28pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;7.6(b) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Company Financial Statements<font style="padding-left: 0.28pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;3.6(a) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Company In-bound License<font style="padding-left: 2.28pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;3.15(d) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Company Leased Real Property<font style="padding-left: 3.05pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;3.19 </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Company Lock-Up Agreement<font style="padding-left: 1.29pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Recitals </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Company Material Contract<font style="padding-left: 1.79pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;3.11(a) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Company Out-bound License<font style="padding-left: 1.28pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;3.15(d) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Company Partner Permits<font style="padding-left: 4.78pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;3.17(c) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Company Permits<font style="padding-left: 3.01pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;3.17(c) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Company Preferred Stock<font style="padding-left: 4.29pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;3.3(a) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Company Real Estate Leases<font style="padding-left: 3.05pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;3.19 </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Company Sensitive Data<font style="padding-left: 3.28pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;3.16(a) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Company Series&#160;A Preferred Stock<font style="padding-left: 2.3pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;3.3(a) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Company Series&#160;A-1 Preferred Stock<font style="padding-left: 4.31pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;3.3(a) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Company Series&#160;A-2 Preferred Stock<font style="padding-left: 4.31pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;3.3(a) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Company Shares<font style="padding-left: 1.52pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Recitals </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Company Stockholder Approval<font style="padding-left: 1.28pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;3.4(b) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Company Stockholder Written Consent<font style="padding-left: 1.06pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Recitals </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Company Unaudited Financial Statements<font style="padding-left: 0.55pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;3.6(a) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consenting Company Stockholders<font style="padding-left: 0.27pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Recitals </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">CVR<font style="padding-left: 4.25pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;5.21(a) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">CVR Agreement<font style="padding-left: 2.52pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;5.21(a) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">CVR Record Date<font style="padding-left: 1.78pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;5.21(a) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">D&amp;O Tail Policy<font style="padding-left: 1.56pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;5.11(b) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">DGCL<font style="padding-left: 3.26pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Recitals </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Dispute Notice<font style="padding-left: 3.52pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;2.7(a) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Dissenting Shares<font style="padding-left: 3.02pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;2.5(a) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Divested Business<font style="padding-left: 1.52pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;4.11(c) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Divested Business Employees<font style="padding-left: 4.28pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;4.12(k) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">DOL<font style="padding-left: 4.26pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;3.12(b) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Effective Time<font style="padding-left: 4.18pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;1.3 </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Electronic Certificates<font style="padding-left: 2.06pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;2.2(g) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Enforceability Exceptions<font style="padding-left: 4.05pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;3.4(a) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exchange Agent<font style="padding-left: 3.52pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;2.2(a) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exchange Fund<font style="padding-left: 1.52pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;2.2(a) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Excluded Shares<font style="padding-left: 2.53pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;2.1(a)(i) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Final Parent Net Cash Surplus<font style="padding-left: 3.78pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;2.7(g) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Indemnified Person<font style="padding-left: 2.03pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;5.11(a) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Intended Tax Treatment<font style="padding-left: 2.07pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Recitals </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Interim Net Cash Schedule<font style="padding-left: 0.54pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;2.6(a) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Investor Agreements<font style="padding-left: 3.04pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;5.24 </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">IRS<font style="padding-left: 3.75pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;3.12(b) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Legacy Parent Directors<font style="padding-left: 0.31pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;5.14(a) </div></td></tr></table></div><div class="BRDSX_BRDSX_block-main-columns" style="margin-left: 12pt; width: 258pt; float: left;"><table cellspacing="0" cellpadding="0" class="BRDSX_finann" style="margin-top: 4pt; width: 258pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 4pt; width: 180pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 4pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 4pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 4pt; width: 72pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Legal Restraints<font style="padding-left: 4.03pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;6.1(b) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lock-Up Agreements<font style="padding-left: 0.04pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Recitals </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Merger<font style="padding-left: 1.43pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Recitals </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Merger Consideration<font style="padding-left: 3.7pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;2.1(a)(i) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Merger Sub<font style="padding-left: 0.18pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Preamble </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Modified Exchange Ratio<font style="padding-left: 4.78pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;2.7(e) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Parent<font style="padding-left: 4.76pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Preamble </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Parent Alternative Acquisition Agreement<font style="padding-left: 2.06pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;5.3(e) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Parent Balance Sheet<font style="padding-left: 1.29pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;4.7 </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Parent Board<font style="padding-left: 0.52pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Recitals </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Parent Board Recommendation<font style="padding-left: 4.79pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Recitals </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Parent Certifications<font style="padding-left: 3.54pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;4.6(a) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Parent Change in Recommendation<font style="padding-left: 0.04pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;5.3(e) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Parent Charter Amendment<font style="padding-left: 4.29pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;1.4(a) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Parent Common Stock<font style="padding-left: 1.26pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;4.3(a) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Parent Disclosure Schedule<font style="padding-left: 3.8pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Article&#160;IV </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Parent Equity Plans<font style="padding-left: 1.77pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;4.3(d) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Parent ESPP<font style="padding-left: 2.01pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;4.3(d) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Parent Fee Reimbursement<font style="padding-left: 0.29pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;7.5(b) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Parent In-bound License<font style="padding-left: 4.3pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;4.15(d) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Parent Leased Real Property<font style="padding-left: 0.06pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;4.19 </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Parent Legacy Transaction<font style="padding-left: 1.78pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;5.23(a) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Parent Lock-Up Agreement<font style="padding-left: 3.3pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Recitals </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Parent Material Contract<font style="padding-left: 3.8pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;4.11(a) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Parent Net Cash Schedule<font style="padding-left: 4.04pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;2.6(b) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Parent Out-bound License<font style="padding-left: 3.29pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;4.15(d) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Parent Partner Permits<font style="padding-left: 1.79pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;4.17(c) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Parent Permits<font style="padding-left: 0.02pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;4.17(c) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Parent Real Estate Leases<font style="padding-left: 0.06pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;4.19 </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Parent Reverse Stock Split<font style="padding-left: 1.53pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;5.22 </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Parent SEC Documents<font style="padding-left: 2.78pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;4.6(a) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Parent Sensitive Data<font style="padding-left: 0.29pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;4.16(a) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Parent Share Issuance<font style="padding-left: 3.8pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Recitals </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Parent Stockholder Approval<font style="padding-left: 3.29pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;4.4(c) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Parent Stockholders Meeting<font style="padding-left: 3.29pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;5.5(b)(i) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Parent Voting Agreement<font style="padding-left: 2.11pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Recitals </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Parties<font style="padding-left: 3.26pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Preamble </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Party<font style="padding-left: 3.76pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Preamble </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Per Share Merger Consideration<font style="padding-left: 1.72pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;2.1(a)(i) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Post-Closing Period<font style="padding-left: 0.51pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;8.13 </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">PPACA<font style="padding-left: 4.57pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;3.12(i) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Pre-Closing Period<font style="padding-left: 4.02pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;5.1(a) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Proxy Statement/Prospectus<font style="padding-left: 1.53pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;5.4(a) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Recall<font style="padding-left: 4.76pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;3.17(e) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Recipient<font style="padding-left: 3.26pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;7.9(a) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Registration Statement<font style="padding-left: 0.53pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;5.4(a) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Representatives<font style="padding-left: 0.78pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;5.2(a) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Response Date<font style="padding-left: 4.02pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;2.7(a) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Rights Agent<font style="padding-left: 0.5pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;5.21(a) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Special Committee<font style="padding-left: 4.02pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Recitals </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Specified Cash-Walk Items<font style="padding-left: 4.52pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;5.23(b) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Stockholder Notice<font style="padding-left: 3.03pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;5.5(a)(iii) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Surviving Company<font style="padding-left: 0.01pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;1.1 </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Surviving Company Bylaws<font style="padding-left: 0.76pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;1.5 </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Surviving Company Certificate of Incorporation</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;1.4(b) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Tax Opinion<font style="padding-left: 2.64pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;5.18(d) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Termination Date<font style="padding-left: 4.66pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;7.2(a) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Termination Fee<font style="padding-left: 3.66pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;7.9(a) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Trade Control Laws<font style="padding-left: 0.6pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;3.23(b) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Transaction Litigation<font style="padding-left: 2.85pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;5.17 </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Uncertificated Shares<font style="padding-left: 0.06pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;2.1(a)(ii) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">WARN Act<font style="padding-left: 1.51pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;3.12(s) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Willful Breach<font style="padding-left: 4.39pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;7.8 </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Wind-Down Activities<font style="padding-left: 1.38pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;5.23(b) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Wind-Down Costs<font style="padding-left: 0.87pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;5.23(b) </div></td></tr><tr><td style="width: 180pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Wind-Down Schedule<font style="padding-left: 2.89pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 72pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">Section&#160;5.23(b)</div></td></tr></table></div><div style="clear: both;"> </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-iv<br></div></div></div>
<!--End Page 385-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 386-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">AGREEMENT AND PLAN OF MERGER AND REORGANIZATION </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">This<font style="font-weight: bold;"> AGREEMENT AND PLAN OF MERGER AND REORGANIZATION </font>(hereinafter referred to as this &#8220;<font style="font-weight: bold;">Agreement</font>&#8221;), dated as of June&#160;6, 2026, among Treeline Biosciences, Inc., a Delaware corporation (the &#8220;<font style="font-weight: bold;">Company</font>&#8221;), Standard BioTools Inc., a Delaware corporation (&#8220;<font style="font-weight: bold;">Parent</font>&#8221;), and Siri Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (&#8220;<font style="font-weight: bold;">Merger Sub</font>&#8221;). Parent, Merger Sub and the Company are each sometimes referred to herein as a &#8220;<font style="font-weight: bold;">Party</font>&#8221; and collectively as the &#8220;<font style="font-weight: bold;">Parties</font>&#8221;. Defined terms used in this Agreement have the respective meanings ascribed to them by the definitions in this Agreement or in <u>Exhibit&#160;A</u>. </div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 20.5pt; text-align: center;">RECITALS </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">A.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; text-align: justify;">The Parties wish to effect a business combination through the merger of Merger Sub with and into the Company, with the Company being the surviving corporation (the &#8220;<font style="font-weight: bold;">Merger</font>&#8221;). </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">B.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; text-align: justify;">In connection with the Merger, each outstanding share of the Company Capital Stock (&#8220;<font style="font-weight: bold;">Company Shares</font>&#8221;) issued and outstanding immediately prior to the Effective Time shall be cancelled and each holder of Company Shares shall have the right to receive the Per Share Merger Consideration upon the terms and subject to the conditions set forth in this Agreement and in accordance with the General Corporation Law of the State of Delaware (the &#8220;<font style="font-weight: bold;">DGCL</font>&#8221;) (other than Company Shares to be cancelled in accordance with <u>Section&#160;2.1(a)(iii)</u>). </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">C.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; text-align: justify;">The board of directors of the Company (the &#8220;<font style="font-weight: bold;">Company Board</font>&#8221;) has (i) determined that the Contemplated Transactions, including the Merger, are advisable, fair to and in the best interests of the Company and its stockholders, (ii) approved and declared advisable this Agreement and the Contemplated Transactions, and (iii) resolved to recommend the adoption of this Agreement by the Company&#8217;s stockholders (such recommendation, the &#8220;<font style="font-weight: bold;">Company Board Recommendation</font>&#8221;). </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">D.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; text-align: justify;">The board of directors of Parent (the &#8220;<font style="font-weight: bold;">Parent Board</font>&#8221;) has established a special committee of the Parent Board consisting solely of &#8220;disinterested directors&#8221; (as defined in Section&#160;144(e)(4) of the DGCL) (the &#8220;<font style="font-weight: bold;">Special Committee</font>&#8221;) and has delegated to the Special Committee the full power and authority of the Parent Board, to the maximum extent permitted by applicable law, to (i) explore, consider, evaluate, review, negotiate, approve or reject the Contemplated Transactions and, if Parent Board approval of the Contemplated Transactions is required under the DGCL, recommend to the Parent Board for approval or rejection the Contemplated Transactions and (ii) determine whether the Contemplated Transactions are advisable, fair to and in the best interests of Parent and its stockholders. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">E.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; text-align: justify;">The Special Committee has unanimously (i) determined that the Contemplated Transactions are advisable, fair to and in the best interests of Parent and its stockholders, (ii) approved and declared advisable this Agreement and the Contemplated Transactions and recommended that the Parent Board approve and declare advisable the Contemplated Transactions and (iii) recommended that the Parent Board resolve to recommend the approval of the issuance of shares of Parent Common Stock pursuant to this Agreement (the &#8220;<font style="font-weight: bold;">Parent Share Issuance</font>&#8221;), the Parent Charter Amendment and the Parent Reverse Stock Split by Parent&#8217;s stockholders (such recommendation, the &#8220;<font style="font-weight: bold;">Parent Board Recommendation</font>&#8221;). </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">F.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; text-align: justify;">The Parent Board has (i) determined that the Contemplated Transactions are advisable, fair to and in the best interests of Parent and its stockholders, (ii) approved and declared advisable this Agreement and the Contemplated Transactions, and (iii) resolved to make the Parent Board Recommendation. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">G.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; text-align: justify;">The board of directors of Merger Sub, by resolutions duly adopted, has (i) determined that the Contemplated Transactions, including the Merger, are advisable, fair to and in the best interests of Merger Sub and its sole stockholder, (ii) approved and declared advisable this Agreement and the Contemplated Transactions and (iii) resolved to recommend the adoption of this Agreement by Parent as its sole stockholder. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">H.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; text-align: justify;">Immediately (and in any event within 24 hours) following the execution and delivery of this Agreement, the Company shall seek to obtain and deliver to Parent a written consent in substantially the form attached hereto as <u>Exhibit&#160;B</u> (the &#8220;<font style="font-weight: bold;">Company Stockholder Written Consent</font>&#8221;) executed by the stockholders identified on <u>Schedule A</u> (the &#8220;<font style="font-weight: bold;">Consenting Company Stockholders</font>&#8221;), evidencing, among other things, the obtainment of the Company Stockholder Approval. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">I.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; text-align: justify;">Concurrently with the execution and delivery of this Agreement, and as a condition and inducement to the Company&#8217;s willingness to enter into this Agreement, certain stockholders of Parent have entered into an agreement with Parent and the Company (each, a &#8220;<font style="font-weight: bold;">Parent Voting Agreement</font>&#8221;) pursuant to which each such stockholder has agreed, among other things, to vote the shares of capital stock of Parent held by such stockholder in favor of the Parent Share Issuance, the Parent Charter Amendment and the Parent Reverse Stock Split. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">J.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; text-align: justify;">Concurrently with the execution and delivery of this Agreement, and as a condition and inducement to Parent&#8217;s willingness to enter into this Agreement, certain stockholders of the Company (including each individual who will serve as a director or executive officer of Parent following the Closing) have entered into a lock-up agreement (each, a &#8220;<font style="font-weight: bold;">Company Lock-Up Agreement</font>&#8221;). </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">K.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; text-align: justify;">Concurrently with the execution and delivery of this Agreement, and as a condition and inducement to the Company&#8217;s willingness to enter into this Agreement, certain stockholders of Parent (including each individual who will serve as a director or executive officer of Parent following the Closing) have entered into a lock-up agreement (each, a &#8220;<font style="font-weight: bold;">Parent Lock-Up Agreement</font>&#8221; and together with the Company Lock-Up Agreements, the &#8220;<font style="font-weight: bold;">Lock-Up Agreements</font>&#8221;). </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">L.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; text-align: justify;">For U.S. federal income Tax purposes, it is intended that (i) the Merger will qualify as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a) of the Internal Revenue Code of 1986, as amended (the &#8220;<font style="font-weight: bold;">Code</font>&#8221;) (such treatment, the &#8220;<font style="font-weight: bold;">Intended Tax Treatment</font>&#8221;) and (ii) this Agreement be, and it is hereby adopted as a &#8220;plan of reorganization&#8221; within the meaning of Treasury Regulations Sections 1.368-2(g) and 1.368-3(a). </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-1<br></div></div></div>
<!--End Page 386-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 387-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg7"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">NOW, THEREFORE<font style="font-weight: normal;">, in consideration of the premises, and of the representations, warranties, covenants and agreements contained herein, the Parties hereby agree as follows: </font></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 17.5pt; text-align: center;"><a name="tANXAA1"><!--Anchor--></a>ARTICLE&#160;I <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">THE MERGER; CLOSING; SURVIVING COMPANY </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS11"><!--Anchor--></a>1.1&#8195;<u>The Merger</u>. Upon the terms and subject to the conditions set forth in this Agreement, at the Effective Time, Merger Sub shall be merged with and into the Company and the separate corporate existence of Merger Sub shall thereupon cease. The Company shall be the surviving company in the Merger (sometimes hereinafter referred to as the &#8220;<font style="font-weight: bold;">Surviving Company</font>&#8221;), and the separate corporate existence of the Company with all its rights, privileges, immunities, powers and franchises shall continue unaffected by the Merger, except as set forth in <u>Article&#160;II</u>. The Merger shall have the effects specified in this Agreement and the DGCL. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS12"><!--Anchor--></a>1.2&#8195;<u>Closing</u>. The closing of the Merger (the &#8220;<font style="font-weight: bold;">Closing</font>&#8221;) shall take place (a) via electronic exchange of the required Closing documentation set forth in <u>Section&#160;1.3</u> and <u>Article&#160;VI</u>, as soon as reasonably practicable, and in no event later than three Business Days following the day on which the last to be satisfied or waived of each of the conditions set forth in <u>Article&#160;VI</u> (other than those conditions that by their nature are to be satisfied at the Closing, but subject to the satisfaction or waiver of those conditions) shall have been satisfied or waived in accordance with this Agreement or (b) at such other place and time and/or on such other date as the Company and Parent may otherwise agree in writing (the date on which the Closing occurs, the &#8220;<font style="font-weight: bold;">Closing Date</font>&#8221;). </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS13"><!--Anchor--></a>1.3&#8195;<u>Effective Time</u>. Upon the Closing, the Company and Parent will cause the certificate of merger with respect to the Merger in the form attached hereto as <u>Exhibit&#160;C</u> (the &#8220;<font style="font-weight: bold;">Certificate of Merger</font>&#8221;) to be executed, acknowledged and filed with the Secretary of State of the State of Delaware as provided in the DGCL. The Merger shall become effective at the time when the Certificate of Merger has been duly filed with the Secretary of State of the State of Delaware or at such later time as may be agreed upon by the Parties in writing and set forth in the Certificate of Merger in accordance with the DGCL (the &#8220;<font style="font-weight: bold;">Effective Time</font>&#8221;). </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS14"><!--Anchor--></a>1.4&#8195;<u>Parent Charter Amendment; Surviving Company Certificate of Incorporation</u>.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;The certificate of incorporation of Parent immediately following the Effective Time shall be identical to the certificate of incorporation of Parent immediately prior to the Effective Time, until thereafter amended as provided therein or by applicable Law; <u>provided</u> that at the Effective Time, Parent shall file an amendment to its certificate of incorporation to (i) change the name of Parent to &#8220;Treeline Biosciences Holdings, Inc.&#8221; or such other name as designated in writing by the Company no later than five Business Days prior to the Closing Date and (ii) effect the Parent Reverse Stock Split if not previously effected prior to the Effective Time as permitted by <u>Section&#160;5.22</u> (the &#8220;<font style="font-weight: bold;">Parent Charter Amendment</font>&#8221;). </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;At the Effective Time, by the filing of the Certificate of Merger, the certificate of incorporation of the Company shall be amended and restated in its entirety to read as set forth in <u>Exhibit&#160;E</u> and as so amended and restated shall be the certificate of incorporation of the Surviving Company (the &#8220;<font style="font-weight: bold;">Surviving Company Certificate of Incorporation</font>&#8221;), until thereafter amended as provided therein or by applicable Law, subject to <u>Section&#160;5.11(b)</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS15"><!--Anchor--></a>1.5&#8195;<u>Surviving Company Bylaws</u>. At the Effective Time, the bylaws of the Company shall be amended and restated in their entirety to read as set forth in <u>Exhibit&#160;E</u> and as so amended and restated shall be the bylaws of the Surviving Company (the &#8220;<font style="font-weight: bold;">Surviving Company Bylaws</font>&#8221;), until thereafter amended as provided therein, in the Surviving Company Certificate of Incorporation or by applicable Law, subject to <u>Section&#160;5.11(a)</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS16"><!--Anchor--></a>1.6&#8195;<u>Directors and Officers of Parent</u>. The Parties shall take all actions necessary so that the directors and officers of Parent immediately following the Effective Time, each to hold office in accordance with Parent&#8217;s Organizational Documents, shall be as set forth in <u>Section&#160;5.14</u> after giving effect to the provisions of <u>Section&#160;5.14(a)</u>, or such other Persons as shall be mutually agreed upon by Parent and the Company in writing prior to the Effective Time until their successors have been duly elected or appointed and qualified or until their earlier death, resignation or removal in accordance with Parent&#8217;s Organizational Documents and applicable Law, subject to <u>Section&#160;5.11(a)</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS17"><!--Anchor--></a>1.7&#8195;<u>Directors and Officers of the Surviving Company</u>. The Parties shall take all actions necessary so that the directors and officers of the Surviving Company immediately following the Effective Time, each to hold office in accordance with the Surviving Company&#8217;s Organizational Documents, shall be as set forth in <u>Section&#160;5.14</u> after giving effect to the provisions of <u>Section&#160;5.14(a)</u>, or such other Persons as shall be mutually agreed upon by Parent and the Company in writing prior to the Effective Time until their successors have been duly elected or appointed and qualified or until their earlier death, resignation or removal in accordance with the Surviving Company&#8217;s Organizational Documents and applicable Law, subject to <u>Section&#160;5.11(a)</u>. </div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 17.5pt; text-align: center;"><a name="tANXAA2"><!--Anchor--></a>ARTICLE&#160;II <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">EFFECT OF THE MERGER ON SECURITIES; EXCHANGE </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 7pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS21"><!--Anchor--></a>2.1&#8195;<u>Effect on Capital Stock</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;At the Effective Time, as a result of the Merger and without any action on the part of the holder of any capital stock of the Company, Parent or Merger Sub or any other Person: </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(i)&#8195;<u>Merger Consideration</u>. Each Company Share issued and outstanding immediately prior to the Effective Time (other than Company Shares held in treasury (the &#8220;<font style="font-weight: bold;">Excluded Shares</font>&#8221;) and Dissenting Shares) shall be automatically converted into the right to receive a </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-2<br></div></div></div>
<!--End Page 387-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 388-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg8"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">number of shares of Parent Common Stock equal to the Exchange Ratio (the &#8220;<font style="font-weight: bold;">Per Share Merger Consideration</font>&#8221; and the aggregate shares of Parent Common Stock issued by applying the Exchange Ratio in accordance with this <u>Section&#160;2.1(a)</u> and <u>Section&#160;2.3</u>, the &#8220;<font style="font-weight: bold;">Merger Consideration</font>&#8221;). The number of shares of Parent Common Stock each holder of Company Shares is entitled to receive pursuant to this <u>Section&#160;2.1(a)</u> shall be rounded down to the nearest whole share and computed after aggregating all Company Shares held by such holder of Company Shares. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(ii)&#8195;At the Effective Time, all of the Company Shares (other than Excluded Shares and Dissenting Shares) shall cease to be outstanding, shall be cancelled and shall cease to exist, and (A) each certificate (a &#8220;<font style="font-weight: bold;">Certificate</font>&#8221;) formerly representing any of the Company Shares (other than Excluded Shares and Dissenting Shares) and (B) each book-entry account formerly representing any uncertificated Company Shares (&#8220;<font style="font-weight: bold;">Uncertificated Shares</font>&#8221;) (other than Excluded Shares and Dissenting Shares) shall thereafter represent only the right to receive the Per Share Merger Consideration and any distributions or dividends payable pursuant to <u>Section&#160;2.2(c)</u>, without interest, in each case to be issued or paid in consideration therefor upon surrender of such Certificates or Uncertificated Shares in accordance with <u>Section&#160;2.2</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(iii)&#8195;<u>Cancellation of Excluded Shares</u>. Each Excluded Share shall, by virtue of the Merger and without any action on the part of the Company, Parent, Merger Sub or any other Person, cease to be outstanding, shall be cancelled without payment of any consideration therefor and shall cease to exist. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;<u>Merger Sub</u>. Each share of common stock, par value $0.001 per share, of Merger Sub issued and outstanding immediately prior to the Effective Time shall be converted into and become (on a one-for-one basis) one validly issued, fully paid and nonassessable share of common stock, $0.001 par value per share, of the Surviving Company, and such converted shares shall constitute the only outstanding shares of capital stock of the Surviving Company immediately following the Effective Time. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(c)&#8195;<u>Adjustments to Exchange Ratio</u>. If, between the time of calculating the Exchange Ratio and the Effective Time, the outstanding shares of Company Capital Stock or Parent Common Stock shall have been changed into, or exchanged for, a different number of shares or a different class or series of shares, by reason of any stock dividend, subdivision, reclassification, recapitalization, split, reverse split, combination or exchange of shares or other like change (any of the foregoing, a &#8220;<font style="font-weight: bold;">capitalization change</font>&#8221;), the Exchange Ratio shall, to the extent necessary, be equitably adjusted (including as a result of the Parent Reverse Stock Split to the extent such split has not previously been taken into account in calculating the Exchange Ratio and occurs prior to the Effective Time) to reflect such change to the extent necessary to provide the holders of Company Capital Stock and holders of Parent Common Stock with the same economic effect as contemplated by this Agreement prior to such stock dividend, subdivision, reclassification, recapitalization, split, reverse split, combination or exchange of shares or other like change; <u>provided</u> that nothing herein will be construed to permit the Company or Parent to take any action with respect to Company Capital Stock or Parent Common Stock, respectively, that is prohibited or not expressly permitted by the terms of this Agreement. Likewise, if a capitalization change occurs prior to the Effective Time, the terms of any other agreement contemplated to be entered into in connection with transactions contemplated hereby shall, to the extent necessary, be equitably adjusted to reflect such change to the extent necessary to provide the applicable parties or holders with the same economic effect as contemplated by such agreement prior thereto. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS22"><!--Anchor--></a>2.2&#8195;<u>Exchange of Certificates</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;<u>Exchange Agent and Exchange Fund</u>. Prior to the Effective Time, Parent shall designate Computershare Trust Company, N.A., its transfer agent, as the exchange agent in connection with the Merger (the &#8220;<font style="font-weight: bold;">Exchange Agent</font>&#8221;). The Exchange Agent shall also act as the agent for the Company&#8217;s stockholders for the purpose of receiving their surrendered Certificates and Uncertificated Shares and shall obtain no rights or interests in the Company Shares represented thereby. At the Closing, Parent shall issue and cause to be deposited with the Exchange Agent evidence of book-entry shares representing non-certificated shares of Parent Common Stock issuable pursuant to <u>Section&#160;2.1(a)</u> and <u>Section&#160;2.3</u>. The shares of Parent Common Stock so deposited with the Exchange Agent (which shall be non-certificated shares of Parent Common Stock in book-entry form), together with any dividends or distributions received by the Exchange Agent with respect to such shares of Parent Common Stock, are referred to collectively as the &#8220;<font style="font-weight: bold;">Exchange Fund</font>.&#8221; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;<u>Exchange Procedures</u>. Promptly after the Effective Time (and in any event within two Business Days thereafter), the Exchange Agent shall mail to each holder of record of Company Shares represented by a Certificate (other than holders of Excluded Shares or Dissenting Shares) or Uncertificated Shares who is entitled to any payment in respect of Company Shares held by such holder immediately prior to the Effective Time (i) a letter of transmittal in customary form specifying that delivery shall be effected, and risk of loss and title to the Certificates shall pass, only upon delivery of the Certificates (or affidavits of loss in lieu of the Certificates as provided in <u>Section&#160;2.2(f)</u>) or Uncertificated Shares to the Exchange Agent, such letter of transmittal to be in such form and have such other provisions as Parent and the Company may reasonably agree, and (ii) instructions for surrendering the Certificates (or affidavits of loss in lieu of the Certificates as provided in <u>Section&#160;2.2(f)</u>) or Uncertificated Shares to the Exchange Agent. Prior to the Closing, the Company may (and at the request of the Company, Parent shall use reasonable best efforts to) cause the Exchange Agent to collect letters of transmittal in advance of the Closing (it being understood that such letters of transmittal shall be contingent on, and shall be effective on, the occurrence of the Effective Time). Upon surrender of a Certificate (or affidavit of loss in lieu of the Certificate as provided in <u>Section&#160;2.2(f)</u>) or an Uncertificated Share to the Exchange Agent in accordance with the terms of such letter of transmittal, the holder of such surrendered Certificate or Uncertificated Share shall be entitled to receive in exchange therefor the Per Share Merger Consideration and any dividends or other distributions pursuant to <u>Section&#160;2.2(c)</u>, less in each case any required Tax withholdings as provided in <u>Section&#160;2.4</u>. The Certificate or Uncertificated Share so surrendered shall forthwith be cancelled. Until due surrender of the Certificates or Uncertificated Shares, each Certificate and Uncertificated Share that immediately prior to the Effective Time represented Company Shares shall be deemed, from and after the Effective Time, to represent only the right to receive the Per Share Merger Consideration (and any distributions or dividends payable pursuant to <u>Section&#160;2.2(c)</u>). In the event of a transfer of ownership of Company Shares that is not registered in the transfer records of the Company, the applicable portion of Merger </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-3<br></div></div></div>
<!--End Page 388-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 389-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg9"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Consideration to be exchanged upon due surrender of the Certificate or Uncertificated Share, as applicable, pursuant to <u>Section&#160;2.1(a)</u> may be issued and paid to such transferee if (x) in the case of a Certificate, such Certificate formerly representing such Company Shares is surrendered to the Exchange Agent, (y) in the case of an Uncertificated Share, written instructions authorizing the transfer of such Uncertificated Share are presented to the Exchange Agent, and (z) the Certificate, in the case of clause (x), and the written instructions, in the case of clause (y), are accompanied by all documents required to evidence and effect such transfer and to evidence that any applicable stock transfer Taxes have been paid or are not applicable, in each case, in form and substance, reasonably satisfactory to Parent and the Exchange Agent. If any shares of Parent Common Stock representing Merger Consideration are to be delivered to a Person other than the holder in whose name any Company Shares are registered, it shall be a condition of such exchange that the Person requesting such delivery shall pay any transfer or other similar Taxes required by reason of the transfer of such shares of Parent Common Stock to a Person other than the registered holder of any Company Shares, or shall establish to the satisfaction of Parent and the Exchange Agent that such Tax has been paid or is not applicable. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(c)&#8195;<u>Distributions with Respect to Unexchanged Shares</u>. All shares of Parent Common Stock to be issued pursuant to the Merger shall be deemed issued and outstanding as of the Effective Time and whenever a dividend or other distribution is declared by Parent in respect of the Parent Common Stock, the record date for which is after the Effective Time, that declaration shall include dividends or other distributions in respect of all shares of Parent Common Stock issuable in the Merger. No dividends or other distributions in respect of the Parent Common Stock issued pursuant to the Merger shall be paid to any holder of any un-surrendered Certificate or Uncertificated Share that was issued and outstanding immediately prior to the Effective Time until such Certificate (or affidavit of loss in lieu thereof as provided in <u>Section&#160;2.2(f)</u>) or Uncertificated Share is surrendered for exchange in accordance with this <u>Article II</u>. Subject to the effect of applicable Laws, following surrender of any such Certificate (or affidavit of loss in lieu thereof as provided in <u>Section&#160;2.2(f)</u>) or Uncertificated Share, there shall be issued and/or paid to the holder of the whole shares of Parent Common Stock issued in exchange therefor, without interest thereon, (a) at the time of such surrender, the dividends or other distributions with a record date after the Effective Time theretofore payable with respect to such whole shares of Parent Common Stock and not paid and (b) at the appropriate payment date, the dividends or other distributions payable with respect to such whole shares of Parent Common Stock with a record date after the Effective Time, but with a payment date subsequent to surrender. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(d)&#8195;<u>Transfer</u>. From and after the Effective Time, there shall be no transfers on the stock transfer books of the Company of the Company Shares that were outstanding immediately prior to the Effective Time. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(e)&#8195;<u>Termination of Exchange Fund</u>. Any portion of the Exchange Fund (including the proceeds of any investments of the Exchange Fund) that remains unclaimed by the holders of Company Shares that were issued and outstanding immediately prior to the Effective Time for 180 days after the Effective Time shall be delivered, at Parent&#8217;s option, to Parent. Any former holder of Company Shares (other than Excluded Shares and Dissenting Shares) who has not theretofore complied with <u>Section 2.2(b)</u> shall thereafter look only to Parent for delivery of any shares of Parent Common Stock and any dividends and other distributions in respect of the Parent Common Stock to be issued or paid pursuant to the provisions of this <u>Article&#160;II</u> (after giving effect to any required Tax withholdings as provided in <u>Section&#160;2.4</u>) upon due surrender of its Certificates (or affidavits of loss in lieu of the Certificates as provided in <u>Section 2.2(f)</u>) or Uncertificated Shares that were issued and outstanding immediately prior to the Effective Time, without any interest thereon. Notwithstanding the foregoing, none of the Surviving Company, Parent, the Exchange Agent or any other Person shall be liable to any former holder of Company Shares for any amount properly delivered to a public official pursuant to applicable abandoned property, escheat or similar Laws. To the fullest extent permitted by Law, immediately prior to the date any Merger Consideration would otherwise escheat to or become the property of any Governmental Entity, such Merger Consideration shall become the property of Parent, free and clear of all claims or interest of any Person previously entitled thereto. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(f)&#8195;<u>Lost, Stolen or Destroyed Certificates</u>. In the event any Certificate representing Company Shares (other than Excluded Shares and Dissenting Shares) that were issued and outstanding immediately prior to the Effective Time shall have been lost, stolen or destroyed, upon the making of an affidavit of that fact by the Person claiming such Certificate to be lost, stolen or destroyed, and, if required by the Exchange Agent&#8217;s customary practices, the entry by such Person into an indemnification agreement in customary form providing an indemnity against any claim that may be made against it with respect to such Certificate, the Exchange Agent will issue in exchange for such lost, stolen or destroyed Certificate, shares of Parent Common Stock and any dividends and other distributions in respect of the Parent Common Stock that would have been issuable or payable pursuant to the provisions of this <u>Article&#160;II</u> (after giving effect to any required Tax withholdings as provided in <u>Section&#160;2.4</u>) had such lost, stolen or destroyed Certificate been surrendered. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(g)&#8195;<u>Cancellation of Electronic Certificates</u>. On the Closing Date, the Company will deliver written instructions to its transfer agent, eShares, Inc. d/b/a Carta, Inc. (&#8220;<font style="font-weight: bold;">Carta</font>&#8221;), with a copy to Parent, directing Carta to cancel all book-entry entitlements in the form of electronic stock certificates (&#8220;<font style="font-weight: bold;">Electronic Certificates</font>&#8221;) on the Carta electronic capitalization management system existing immediately prior to the Effective Time representing Company Capital Stock effective as of the Effective Time and deliver to Parent, as promptly as practicable, written confirmation of such cancellation of all such Electronic Certificates. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS23"><!--Anchor--></a>2.3&#8195;<u>Treatment of Company Options and Warrants</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;At the Effective Time, the Company Equity Plan and each outstanding Company Option, whether vested or unvested, without any action on the part of the holder thereof, will be assumed by Parent. Each such Company Option so assumed by Parent under this Agreement shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions, except that (i) such Company Option will be exercisable for that number of shares of Parent Common Stock </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-4<br></div></div></div>
<!--End Page 389-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 390-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg10"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">equal to the number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time multiplied by the Exchange Ratio and rounded down to the next nearest share of Parent Common Stock, and (ii) the exercise price per share shall be the exercise price per share in effect for such Company Option immediately prior to the Effective Time divided by the Exchange Ratio and rounded up to the next nearest cent. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;Prior to the Effective Time, the Company and the Company Board shall take all actions necessary or appropriate, including adopting any resolutions or amendments and providing any notices to participants (which resolutions, amendments and notices shall be provided to Parent in advance of adoption and for which the Company shall consider in good faith any comments provided by Parent), which are necessary to effectuate the treatment of the Company Options set forth in <u>Section&#160;2.3(a)</u> prior to the Effective Time. At or prior to the Effective Time, Parent shall take all corporate actions necessary or appropriate, including adopting any resolutions (which resolutions shall be reasonably satisfactory to the Company) to effectuate the treatment of the Company Options set forth in <u>Section&#160;2.3(a)</u> and, if necessary, reserve for issuance a sufficient number of shares of Parent Common Stock for delivery upon exercise of Company Options assumed by it in accordance with <u>Section&#160;2.3(a)</u>, subject to approval of the requisite stockholders of Parent. Notwithstanding anything to the contrary in the foregoing, in all cases, the exercise price of, and the number of shares of Parent Common Stock subject to, each assumed Company Option shall be determined as necessary to comply with Sections 424 and 409A of the Code. Following the Effective Time, references to the Company in the Company Equity Plan and award agreements for the Company Options that are not terminated at or prior to the Effective Time shall thereupon be deemed references to Parent and references to Company Common Stock therein shall be deemed references to Parent Common Stock with appropriate equitable adjustments in accordance with the terms of the Company Equity Plan to reflect the Contemplated Transactions. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(c)&#8195;At the Effective Time, each Company Converting Warrant that is outstanding immediately prior to the Effective Time shall, by virtue of the Merger and without any action on the part of the Company or the holder thereof, be cancelled and extinguished and converted into the right to receive, for each share of Company Common Stock that would be received upon the net-exercise of such Company Converting Warrant in accordance with its terms (with each share of Company Common Stock valued at the Company Value Per Share for such purposes), a number of shares of Parent Common Stock equal to the Exchange Ratio.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(d)&#8195;At the Effective Time, each Assumed Company Warrant that is outstanding immediately prior to the Effective Time shall, by virtue of the Merger and without any action on the part of the Company or the holder thereof, be assumed by Parent. Each such Assumed Company Warrant so assumed by Parent under this Agreement shall continue to have, and be subject to, the same terms and conditions applicable to such Assumed Company Warrant immediately prior to the Effective Time, except that (i) such Assumed Company Warrant will be exercisable for that number of shares of Parent Common Stock equal to the number of shares of Company Common Stock subject to such Assumed Company Warrant immediately prior to the Effective Time multiplied by the Exchange Ratio and rounded down to the next nearest share of Parent Common Stock, and (ii) the warrant price per share shall be the warrant price per share in effect for such Assumed Company Warrant immediately prior to the Effective Time divided by the Exchange Ratio and rounded up to the nearest thousandth of a cent. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(e)&#8195;As soon as reasonably practicable following the Closing Date (but in no event later than 10 Business Days after the Closing Date), Parent will file an appropriate registration statement on Form&#160;S-8 (or such other appropriate form, if required) with respect to the offering of the shares of Parent Common Stock issuable upon the exercise of the assumed Company Options and will use reasonable best efforts to maintain the effectiveness of registration statement thereafter for so long as any of such Company Options remain outstanding. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS24"><!--Anchor--></a>2.4&#8195;<u>Withholding Rights</u>. Each of Parent, Merger Sub, the Company, the Surviving Company and the Exchange Agent shall be entitled to deduct and withhold from the consideration otherwise payable to Persons pursuant to this Agreement any amounts it is required to deduct and withhold with respect to the making of such payment under the Code or any other applicable state, local or foreign Tax Law. To the extent that amounts are so withheld and timely remitted by Parent, Merger Sub, the Company, the Surviving Company or the Exchange Agent, as the case may be, to the applicable Governmental Entity, such amounts shall be treated for all purposes of this Agreement as having been paid to such Person in respect of which such deduction and withholding was made. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS25"><!--Anchor--></a>2.5&#8195;<u>Appraisal Rights</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;Notwithstanding any provision of this Agreement to the contrary, Company Shares that are outstanding immediately prior to the Effective Time and which are held by stockholders who have exercised and perfected appraisal rights for such Company Shares in accordance with Section&#160;262 of the DGCL (collectively, the &#8220;<font style="font-weight: bold;">Dissenting Shares</font>&#8221;) shall not be converted into or represent the right to receive the Merger Consideration described in <u>Section&#160;2.1</u> attributable to such Dissenting Shares. Such stockholders shall be entitled to receive payment of the appraised value of such Company Shares held by them in accordance with Section&#160;262 of the DGCL, unless and until such stockholders fail to perfect or effectively withdraw or otherwise lose their appraisal rights under the DGCL. All Dissenting Shares held by stockholders who shall have failed to perfect or who effectively shall have withdrawn or lost their right to appraisal of such Company Shares under the DGCL shall thereupon be deemed to be converted into and to have become exchangeable for, as of the Effective Time, the right to receive the Merger Consideration attributable to such Dissenting Shares upon their surrender in the manner provided in <u>Section&#160;2.2</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;The Company shall give Parent prompt written notice of any demands by dissenting stockholders received by the Company, withdrawals of such demands and any other instruments served on the Company and any material correspondence received by the Company in connection with such demands. The Company shall not, without Parent&#8217;s prior written consent, make any payment with respect to, or settle or offer to settle, any such demands, or agree to do any of the foregoing. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-5<br></div></div></div>
<!--End Page 390-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 391-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg11"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS26"><!--Anchor--></a>2.6&#8195;<u>Calculation of Parent Net Cash</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;Parent shall deliver to the Company a schedule, substantially in the form attached hereto as <u>Exhibit&#160;F </u>(each, an &#8220;<font style="font-weight: bold;">Interim Net Cash Schedule</font>&#8221;), promptly (and in no event more than 10 days) following the end of each calendar month between the date of this Agreement and the Closing Date, setting forth its good faith estimated calculation of Parent Net Cash, including each component thereof, as if the Closing had occurred on the last day of such calendar month, and its good faith estimated calculation of Parent Net Cash, including each component thereof, if the Closing were to occur on the last day of the then current calendar month, in reasonable detail, together with reasonable supporting documentation; <u>provided</u> that each Interim Net Cash Schedule shall be delivered for information purposes only and shall not be considered the Parent Net Cash Schedule for any purposes hereunder. Following delivery of each Interim Net Cash Schedule, Parent and the Company shall attempt in good faith to resolve any disagreements regarding the calculation of Parent Net Cash set forth in such Interim Net Cash Schedule, and Parent shall consider in good faith any appropriate changes to be reflected in subsequent Interim Net Cash Schedules; <u>provided</u>, <u>however</u>, that nothing in this <u>Section&#160;2.6(a)</u> shall require Parent to revise or redeliver any previously delivered Interim Net Cash Schedule or shall limit Parent&#8217;s discretion in preparing any subsequent Interim Net Cash Schedule in a manner consistent with the definitions of the applicable terms set forth in this Agreement; <u>provided</u>, <u>further</u>, that in no event will any disagreement regarding the calculation of Parent Net Cash in any Interim Net Cash Schedule or the Parent Net Cash Schedule that has been prepared in good faith be a basis to delay or prevent the Closing (it being understood that all disputes with respect thereto are to be resolved pursuant to <u>Section&#160;2.7</u>). For the avoidance of doubt, no Interim Net Cash Schedule shall be binding on either Party with respect to the final determination of Parent Net Cash as of the Closing. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;No less than 10 Business Days prior to the anticipated date for Closing (as mutually agreed in good faith by Parent and the Company) (the &#8220;<font style="font-weight: bold;">Anticipated Closing Date</font>&#8221;), the Company shall deliver to Parent the Company capitalization information required to calculate the Exchange Ratio. No less than five Business Days prior to the Anticipated Closing Date, Parent shall deliver to the Company a schedule, substantially in the form attached hereto as <u>Exhibit&#160;F</u> (the &#8220;<font style="font-weight: bold;">Parent Net Cash Schedule</font>&#8221;), setting forth, in reasonable detail, Parent&#8217;s good faith estimated calculation of (i)&#160;Parent Net Cash and (ii) the Exchange Ratio (<u>provided</u> that the Company shall have timely delivered to Parent the Company capitalization information required to calculate the Exchange Ratio), in each case as of 12:01 a.m. Eastern Time on the Anticipated Closing Date, prepared and certified by Parent&#8217;s chief financial officer (or if there is no chief financial officer at such time, the principal financial and accounting officer of Parent). </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(c)&#8195;During the Pre-Closing Period, Parent shall make available to the Company, its accountants and/or counsel, the work papers (subject to the execution of customary work paper access letters if requested by Parent&#8217;s accountants) and back-up materials (including relevant invoices and similar evidence of outstanding obligations) used or useful in preparing any Interim Net Cash Schedule or the Parent Net Cash Schedule, as reasonably requested by the Company, and, if reasonably requested by the Company, Parent&#8217;s internal finance personnel, accountants and counsel at reasonable times and upon reasonable notice to discuss the most recent Interim Net Cash Schedule and the Parent Net Cash Schedule and the information and transactions reflected therein. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS27"><!--Anchor--></a>2.7&#8195;<u>Post-Closing Adjustment of Parent Net Cash</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;Within 30 days after the Closing Date (the last day of such period, the &#8220;<font style="font-weight: bold;">Response Date</font>&#8221;), the Company may dispute any part of the calculations set forth in the Parent Net Cash Schedule by delivering a written notice to that effect to Parent (a &#8220;<font style="font-weight: bold;">Dispute Notice</font>&#8221;). Any Dispute Notice shall (i) identify in reasonable detail, to the extent then known, the nature and amounts of any proposed revisions to the Parent Net Cash Schedule and (ii) only include disagreements based on mathematical errors or based on the Parent Net Cash not being calculated in accordance with the definitions of the applicable terms set forth in this Agreement or properly accounting for the components thereof in accordance with such definitions. Any action or decision of Parent (but not the Company) with respect to the matters set forth in this <u>Section&#160;2.7</u> shall require and be subject to the consent of the Legacy Parent Directors (with disputes arising therefrom to be resolved in accordance with procedures set forth in <u>Section&#160;2.7(d))</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;If, on or prior to the Response Date, the Company notifies Parent in writing that it has no objections to the calculations set forth in the Parent Net Cash Schedule or, if prior to 11:59 p.m. Eastern Time on the Response Date, the Company has failed to deliver a Dispute Notice to Parent, then the calculation of Parent Net Cash set forth in the Parent Net Cash Schedule shall be deemed to have been finally determined by the Parties for purposes of this Agreement and to represent the final Parent Net Cash for purposes of the determination of the Exchange Ratio pursuant to this Agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(c)&#8195;If the Company delivers a Dispute Notice on or prior to 11:59 p.m. Eastern Time on the Response Date, then Parent and the Company shall attempt in good faith to resolve the disputed item(s) and negotiate an agreed-upon determination of Parent Net Cash, which agreed-upon Parent Net Cash amount shall be deemed finally determined, binding and non-appealable for purposes of this Agreement and to represent the final Parent Net Cash for purposes of this Agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(d)&#8195;If Parent and the Company are unable to negotiate an agreed-upon determination of Parent Net Cash pursuant to <u>Section&#160;2.7(c)</u> within 30&#160;calendar days after delivery of the Dispute Notice (or such other period as Parent and the Company may mutually agree upon in writing), then any remaining disagreements as to the calculation of Parent Net Cash shall be referred to an independent auditor of recognized national standing mutually agreed upon by Parent and the Company (the &#8220;<font style="font-weight: bold;">Accounting Firm</font>&#8221;). Parent shall promptly deliver to the Accounting Firm all work papers and back-up materials used in preparing the Parent Net Cash Schedule, and Parent and the Company shall use reasonable best efforts to cause the Accounting Firm to make its determination within 30 calendar days of accepting its selection; <u>provided</u> that any failure of the Accounting Firm to strictly conform to any deadline or time period contained within this <u>Section&#160;2.7(d)</u> shall not render the determination of the Accounting Firm invalid and shall not be a basis for seeking to overturn any determination rendered by the Accounting Firm. Parent and the Company shall be afforded the opportunity to present to the Accounting Firm any material related to the unresolved disputes and to discuss the issues with the Accounting Firm; <u>provided</u> that no such presentation or discussion shall occur without the presence of a representative of each of Parent and the Company. The Accounting Firm shall act as an expert and not as arbitrator. The determination of the </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-6<br></div></div></div>
<!--End Page 391-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 392-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg12"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Accounting Firm shall be limited to the disagreements submitted to the Accounting Firm and based solely on the written submissions made by or on behalf of Parent and the Company (and not by independent review). The Accounting Firm may not assign a value to any item in dispute greater than the greatest value for such item assigned by Parent or the Company in the Parent Net Cash Schedule or a Dispute Notice or less than the smallest value for such item assigned by Parent or the Company in the Parent Net Cash Schedule or a Dispute Notice. The determination of the amount of Parent Net Cash made by the Accounting Firm shall be made in writing delivered to each of Parent and the Company, shall be final, binding and non-appealable on Parent and the Company and shall be deemed to have been finally determined for purposes of this Agreement and to represent the final Parent Net Cash for purposes of this Agreement, absent a showing of manifest error. The fees and expenses of the Accounting Firm shall be allocated between Parent and the Company in the same proportion that the disputed amount of the Parent Net Cash that was unsuccessfully disputed by such Party (as finally determined by the Accounting Firm) bears to the total disputed amount of the Parent Net Cash, and such portion of the costs and expenses of the Accounting Firm borne by Parent shall be deducted from the final determination of the amount of Parent Net&#160;Cash. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(e)&#8195;If the final Parent Net Cash as determined pursuant to this <u>Section&#160;2.7</u> is less than Parent Net Cash as set forth in the Parent Net Cash Schedule, the Exchange Ratio shall be recalculated adjusting only such final Parent Net Cash and with no other changes to the components thereof (such recalculation, the &#8220;<font style="font-weight: bold;">Modified Exchange Ratio</font>&#8221;).</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(f)&#8195;Each former holder of (x) any Company Shares that were issued and outstanding (other than Excluded Shares and Dissenting Shares) and (y) Company Converting Warrants that were outstanding, in each case immediately prior to the Effective Time, shall be entitled to receive, without duplication, in respect of (i) each such Company Share or (ii) each Company Share that would have been received upon the net-exercise of such Company Converting Warrant, a number of additional shares of Parent Common Stock equal to the Modified Exchange Ratio <u>minus</u> the Exchange Ratio. The number of shares of Parent Common Stock each former holder of Company Shares and Company Warrants is entitled to receive pursuant to this <u>Section&#160;2.7(f)</u> shall be rounded down to the nearest whole share and computed after aggregating all Company Shares held by such holder of Company Shares. Parent shall promptly issue and cause to be deposited with the Exchange Agent evidence of book-entry shares representing non-certificated shares of Parent Common Stock issuable pursuant to this <u>Section 2.7(f)</u> for further distribution to such former holders of Company Shares and Company Converting Warrants in accordance with <u>Section&#160;2.2</u>, <font style="font-style: italic;">mutatis mutandis</font>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(g)&#8195;If the final Parent Net Cash is greater than or equal to Parent Net Cash as set forth in the Parent Net Cash Schedule (such excess, the &#8220;<font style="font-weight: bold;">Final Parent Net Cash Surplus</font>&#8221;), the Final Parent Net Cash Surplus shall be added to the proceeds to be distributed to holders of CVRs pursuant to the terms of the CVR Agreement. </div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 20pt; text-align: center;"><a name="tANXAA3"><!--Anchor--></a>ARTICLE&#160;III <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">REPRESENTATIONS AND WARRANTIES OF THE COMPANY </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The Company represents and warrants to Parent as set forth in the statements contained in this <u>Article&#160;III</u> except as set forth in the disclosure letter delivered by the Company to Parent at or before the execution and delivery by the Company of this Agreement (the &#8220;<font style="font-weight: bold;">Company Disclosure Schedule</font>&#8221;). The Company Disclosure Schedule shall be arranged in numbered and lettered sections corresponding to the numbered and lettered sections contained in this <u>Article&#160;III</u>, and the disclosure in any section of the Company Disclosure Schedule shall be deemed to qualify other sections in this <u>Article&#160;III</u> to the extent that it is reasonably apparent on the face of such disclosure that such disclosure also qualifies or applies to such other sections. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS31"><!--Anchor--></a>3.1&#8195;<u>Organizational Documents</u>. The Company has made available to Parent accurate copies of the Organizational Documents of the Company and each of its Subsidiaries in effect as of the date of this Agreement. Neither the Company nor any of its Subsidiaries is in material breach or violation of its respective Organizational Documents. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS32"><!--Anchor--></a>3.2&#8195;<u>Due Organization; Subsidiaries</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;The Company is a corporation duly incorporated, validly existing and in good standing under the Laws of the State of Delaware, and has all necessary corporate power and authority: (i) to conduct its business in the manner in which its business is currently being conducted; (ii)&#160;to own or lease and use its property and assets in the manner in which its property and assets are currently owned or leased and used; and (iii) to perform its obligations under all Contracts by which it is bound, except where the failure to have such power or authority would not have a Company Material Adverse Effect. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;The Company is duly licensed and qualified to do business and is in good standing (to the extent applicable in such jurisdiction), under the Laws of all jurisdictions where the nature of its business requires such licensing or qualification other than in jurisdictions where the failure to be so qualified would not have a Company Material Adverse Effect. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(c)&#8195;Each of the Company&#8217;s Subsidiaries is identified in <u>Section&#160;3.2(c)</u> of the Company Disclosure Schedule; and neither the Company nor any of the entities identified in <u>Section&#160;3.2(c)</u> of the Company Disclosure Schedule owns any capital stock of, or any equity, ownership or profit sharing interest of any nature in, or controls directly or indirectly, any other entity other than the entities identified in <u>Section&#160;3.2(c)</u> of the Company Disclosure Schedule.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(d)&#8195;Each of the Company&#8217;s Subsidiaries is a corporation or other legal entity duly organized, validly existing and, if applicable, in good standing under the Laws of the jurisdiction of its organization and has all necessary corporate or other power and authority to conduct its business in the manner in which its business is currently being conducted and to own or lease and use its property and assets in the manner in which its property and assets are currently owned or leased and used, except where the failure to have such power or authority would not have a Company Material Adverse Effect. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-7<br></div></div></div>
<!--End Page 392-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 393-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg13"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(e)&#8195;Neither the Company nor any of its Subsidiaries is or has otherwise been, directly or indirectly, a party to, member of or participant in any partnership, joint venture or similar business entity. Neither the Company nor any of its Subsidiaries has agreed or is obligated to make or is bound by any Contract under which it may become obligated to make, any future investment in or capital contribution to any other entity. Neither the Company nor any of its Subsidiaries has, at any time, been a general partner of, or has otherwise been liable for any of the debts or other obligations of, any general partnership, limited partnership or other entity. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(f)&#8195;All of the outstanding shares of capital stock or equivalent equity interests of each Subsidiary of the Company are owned of record and beneficially, directly or indirectly, by the Company free and clear of all material liens, pledges, security interests or other encumbrances. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS33"><!--Anchor--></a>3.3&#8195;<u>Capitalization</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;The authorized capital stock of the Company as of the date of this Agreement consists of (i) 222,260,000 shares of common stock, par value $0.00001 per share (&#8220;<font style="font-weight: bold;">Company Common Stock</font>&#8221;), and (ii) 174,566,382 shares of preferred stock, par value $0.00001 per share (&#8220;<font style="font-weight: bold;">Company Preferred Stock</font>&#8221;), 64,723,570 shares of which have been designated Series&#160;A Preferred Stock (the &#8220;<font style="font-weight: bold;">Company Series&#160;A Preferred Stock</font>&#8221;), 80,110,993 shares of which have been designated Series&#160;A-1 Preferred Stock (the &#8220;<font style="font-weight: bold;">Company Series&#160;A-1 Preferred Stock</font>&#8221;) and 29,731,819 shares of which have been designated Series&#160;A-2 Preferred Stock (the &#8220;<font style="font-weight: bold;">Company Series&#160;A-2 Preferred Stock</font>&#8221;). As of the close of business on the Reference Date, (w) 21,261,061 shares of Company Common Stock, (x) 64,723,570 shares of Series&#160;A Preferred Stock, (y) 50,379,174 shares of Series&#160;A-1 Preferred Stock and (z) 29,731,819 shares of Series&#160;A-2 Preferred Stock are issued and outstanding. The Company does not hold any shares of its capital stock in its treasury. From the close of business on the Reference Date to the date of this Agreement, the Company has not issued any shares of its capital stock other than the issuance of shares of Company Common Stock upon the exercise of Company Options or Company Warrants, in each case, that were outstanding as of the close of business on the Reference Date in accordance with the terms thereof. There are no accrued and unpaid dividends with respect to any outstanding shares of capital stock of the Company or any of its Subsidiaries. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;<u>Section&#160;3.3(b)</u> of the Company Disclosure Schedule lists, as of the Reference Date, (i) each holder of issued and outstanding Company Warrants, (ii) the number and type of shares subject to each Company Warrant, (iii) the exercise price of each Company Warrant, and (iv)&#160;the termination date of each Company Warrant. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(c)&#8195;All of the outstanding shares of Company Capital Stock have been duly authorized and validly issued and are fully paid and nonassessable. None of the outstanding shares of Company Capital Stock is entitled or subject to any preemptive right, right of participation, right of maintenance or any similar right and none of the outstanding shares of Company Capital Stock is subject to any right of first refusal in favor of the Company. Except as contemplated herein, there is no Company Contract relating to the voting or registration of, or restricting any Person from purchasing, selling, pledging or otherwise disposing of (or granting any option or similar right with respect to), any shares of Company Capital Stock. There is no Company Contract pursuant to which the Company or any of its Subsidiaries may become obligated to repurchase, redeem or otherwise acquire any outstanding shares of Company Capital Stock or other securities. The Company has made available to Parent a complete and accurate copy of each Investor Agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(d)&#8195;Except for the 2021 Equity Incentive Plan (the &#8220;<font style="font-weight: bold;">Company Equity Plan</font>&#8221;) and the award agreements thereunder, the Company does not have any stock option plan or any other plan, program, agreement or arrangement providing for any equity-based compensation for any Person. As of the close of business on the Reference Date, 38,152,270 shares of Company Common Stock were authorized for issuance under the Company Equity Plan, of which 22,450,360 shares of Company Common Stock were subject to issuance upon the exercise of Company Options and 8,131,821&#160;shares of Company Common Stock remained available for future issuance pursuant to the Company Equity Plan. <u>Section&#160;3.3(d)</u> of the Company Disclosure Schedule sets forth a true, correct and complete list, as of the Reference Date, with respect to each Company Option of (i) the name of the holder of such Company Option (or if not permitted under applicable Data Protection Regulations, the grant ID); (ii) the number of shares of Company Common Stock subject to such outstanding Company Option; (iii) the grant or issuance date of such Company Option; (iv) the applicable vesting schedule of such Company Option; (v) the exercise price of such Company Option; (vi) the expiration date of such Company Option; and (vii)&#160;whether such Company Option is intended to be an &#8220;incentive stock option&#8221; as defined in Section&#160;422 of the Code. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(e)&#8195;Except for the Company Options and the Company Warrants, there is no (i) outstanding subscription, option, call, warrant or right (whether or not currently exercisable) to acquire any shares of the capital stock or other securities of the Company or any of its Subsidiaries, (ii)&#160;outstanding security, instrument or obligation that is or may become convertible into or exchangeable for any shares of the capital stock or other securities of the Company or any of its Subsidiaries or (iii) condition or circumstance that would be reasonably likely to give rise to or provide a basis for the assertion of a claim by any Person to the effect that such Person is entitled to acquire or receive any shares of capital stock or other securities of the Company or any of its Subsidiaries. There are no outstanding or authorized stock appreciation, phantom stock, profit participation or other similar rights (including any rights that are linked in any way to the price or value of the capital stock or other securities) with respect to the Company or any of its Subsidiaries. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(f)&#8195;All outstanding shares of Company Capital Stock, Company Options, Company Warrants and other securities of the Company have been issued and granted in material compliance with (i) all applicable securities Laws and other applicable Laws, (ii) the Organizational Documents of the Company and the Investor Agreements and (iii) all requirements set forth in applicable Contracts. No Company Options have an exercise price that has been less than the fair market value of the underlying stock as of the date such Company Option was granted or has any feature for the deferral of compensation that could render the grant subject to Section 409A of the Code. Each Company Option characterized by the Company as an &#8220;incentive stock option&#8221; within the meaning of Section&#160;422 of the Code was granted in compliance with all of the applicable requirements of Section&#160;422 of the Code. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-8<br></div></div></div>
<!--End Page 393-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 394-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg14"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(g)&#8195;As of the date of this Agreement, (i) the Original Issue Price (as defined in the certificate of incorporation of the Company) is $7.8275 for the Company Series&#160;A Preferred Stock, $8.6103 for the Company Series&#160;A-1 Preferred Stock and $8.6103 for the Company Series&#160;A-2 Preferred Stock, (ii) the Conversion Price (as defined in the certificate of incorporation of the Company) is $7.8275 for the Company Series&#160;A Preferred Stock, $8.6103 for the Company Series&#160;A-1 Preferred Stock and $8.6103 for the Company Series&#160;A-2 Preferred Stock and (iii) the Company Preferred Stock is convertible on a one-share-for-one-share basis into Company Common Stock. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(h)&#8195;The treatment of Company Capital Stock, Company Options and Company Warrants under this Agreement is consistent with and in accordance with the Organizational Documents of the Company, the Investor Agreements, any other applicable Contract and applicable Law. In connection with the Contemplated Transactions, no holder of any Company Options or Company Warrants is (after taking into account the amendment of any Company Warrant to become a Company Converting Warrant) entitled to any consideration for such Company Options or Company Warrants in excess of the consideration provided in this Agreement, and, as of immediately after the Effective Time, no holder or former holder of Company Options or Company Warrants shall have the right to acquire any shares of Company Capital Stock. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS34"><!--Anchor--></a>3.4&#8195;<u>Authority; Binding Nature of Agreement; Required Vote</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;The Company has all requisite corporate power and authority to execute and deliver this Agreement, to perform its obligations hereunder and, subject to receipt of the Company Stockholder Approval, to consummate the Contemplated Transactions. The Company Board (at a meeting duly called and held or by written consent in lieu of a meeting) has (i) determined that the Contemplated Transactions, including the Merger, are advisable, fair to and in the best interests of the Company and its stockholders, (ii) approved and declared advisable this Agreement and the Contemplated Transactions, and (iii) resolved to make the Company Board Recommendation. As of the date of this Agreement, such resolutions have not been amended or withdrawn. This Agreement has been duly executed and delivered by the Company and, assuming the due authorization, execution and delivery by Parent and Merger Sub, constitutes the legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, except, in each case, as enforcement may be limited by bankruptcy, insolvency, reorganization or similar Laws affecting creditors&#8217; rights generally and by general principles of equity (the &#8220;<font style="font-weight: bold;">Enforceability Exceptions</font>&#8221;). </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;Except for the adoption of this Agreement by (i) the affirmative written consent of the holders of a majority of the outstanding Company Capital Stock entitled to vote thereon and (ii) the affirmative written consent of the holders of a majority of Company Preferred Stock entitled to vote thereon (such approval, the &#8220;<font style="font-weight: bold;">Company Stockholder Approval</font>&#8221;), no other corporate proceedings on the part of the Company stockholders are necessary to authorize, adopt or approve, as applicable, this Agreement or the Contemplated Transactions. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS35"><!--Anchor--></a>3.5&#8195;<u>Non-Contravention; Consents</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;Subject to (i) obtaining the Company Stockholder Approval, (ii) the filing of the Certificate of Merger required by the DGCL and (iii)&#160;any applicable requirements of the HSR Act or any foreign Antitrust Laws, neither (x) the execution, delivery or performance of this Agreement by the Company, nor (y) the consummation by the Company of the Contemplated Transactions, will (with or without notice or lapse of time): </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(i)&#8195;result in a violation or breach of any of the provisions of the Organizational Documents of the Company or any of its Subsidiaries; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(ii)&#8195;result in a violation or breach of, or give any Governmental Entity the right to exercise any remedy or obtain any relief under, any Law or any order, writ, injunction, judgment or decree to which the Company or any of its Subsidiaries, or any of the assets owned by the Company or any of its Subsidiaries, is subject; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(iii)&#8195;result in a violation or breach of any of the terms or requirements of, or give any Governmental Entity the right to revoke, withdraw, suspend, cancel, terminate or modify, any Governmental Authorization that is held by the Company or any of its Subsidiaries; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(iv)&#8195;result in a violation or breach of, or result in a default under, any provision of any Company Material Contract, or give any Person the right to: (A) declare a default or exercise any remedy under any Company Material Contract; (B) any material payment, rebate, chargeback, penalty or change in delivery schedule under any Company Material Contract; (C) accelerate the maturity or performance of any Company Material Contract; or (D) cancel, terminate or modify any term of any Company Material Contract; or </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(v)&#8195;result in the imposition or creation of any Lien upon or with respect to any asset owned or used by the Company or any of its Subsidiaries (except for Permitted Liens). </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;Except for (i) the filing of the Certificate of Merger with the Secretary of State of the State of Delaware pursuant to the DGCL and (ii) any applicable requirements of the HSR Act or any foreign Antitrust Laws, neither the Company nor any of its Subsidiaries is or will be required to make any filing with or give any notice to, or to obtain any Consent from, any Governmental Entity in connection with (x) the execution, delivery or performance by the Company of this Agreement, or (y) the consummation by the Company of the Contemplated Transactions, which if individually or in the aggregate were not given or obtained, would reasonably be expected to prevent or materially delay the ability of the Company to consummate the Contemplated Transactions or that would have a Company Material Adverse Effect. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(c)&#8195;The Company Board has taken and will take all actions necessary to ensure that the restrictions applicable to business combinations contained in Section&#160;203 of the DGCL are, and will be, inapplicable to the execution, delivery and performance of this Agreement and the Company Voting Agreement and to the consummation of the Contemplated Transactions. To the Company&#8217;s Knowledge, no other takeover statute or similar Law applies or purports to apply to the Merger, this Agreement, the Company Voting Agreement or any of the Contemplated Transactions. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-9<br></div></div></div>
<!--End Page 394-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 395-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg15"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS36"><!--Anchor--></a>3.6&#8195;<u>Financial Statements</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;The Company has made available to Parent accurate copies of the audited consolidated balance sheets of the Company and its Subsidiaries as of December&#160;31, 2024 and December&#160;31, 2025, and the related audited consolidated statements of income and cash flows for the fiscal years ended December&#160;31, 2023, 2024 and 2025, together with all related notes and schedules thereto and including a signed unqualified audit report in connection therewith from the auditing firm which audited such consolidated financial statements (the &#8220;<font style="font-weight: bold;">Company Audited Financial Statements</font>&#8221;), and the unaudited consolidated balance sheet and related consolidated statements of income and cash flows for the three-month period ended March&#160;31, 2025 and March&#160;31, 2026 (the &#8220;<font style="font-weight: bold;">Company Unaudited Financial Statements</font>&#8221; and, together with the Company Audited Financial Statements, collectively, the &#8220;<font style="font-weight: bold;">Company Financial Statements</font>&#8221;). </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;The Company Financial Statements (i) were prepared in accordance with GAAP applied on a consistent basis unless otherwise noted therein throughout the periods indicated and (ii) fairly present, in all material respects, the financial position of the Company and its consolidated Subsidiaries as of the respective dates thereof and the results of operations and cash flows of the Company and its consolidated Subsidiaries for the periods covered thereby. There has been no material change in the Company&#8217;s accounting methods or principles that would be required to be disclosed in the Company&#8217;s financial statements in accordance with GAAP. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(c)&#8195;The Company maintains a system of internal control over financial reporting that is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP and to provide reasonable assurance (i) that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, (ii) that receipts and expenditures are made only in accordance with authorizations of management and the Company Board and (iii)&#160;regarding prevention or timely detection of the unauthorized acquisition, use or disposition of the Company&#8217;s assets that could have a material effect on the Company&#8217;s financial statements. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(d)&#8195;The Company has not identified and has not received written notice from an independent auditor of (i) any significant deficiency or material weakness in the system of internal controls utilized by the Company, (ii) any fraud that involves the Company&#8217;s management or other employees who have a significant role in the preparation of financial statements or the internal controls over financial reporting utilized by the Company or (iii) any claim or allegation regarding any of the foregoing. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS37"><!--Anchor--></a>3.7&#8195;<u>Absence of Changes</u>.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;Except as expressly contemplated or permitted by or in connection with the execution and delivery of this Agreement, between the date of the Company&#8217;s latest consolidated unaudited balance sheet (the &#8220;<font style="font-weight: bold;">Company Balance Sheet</font>&#8221;) and the date of this Agreement, (i) the Company has conducted its business in the Ordinary Course of Business in all material respects (except for the execution and performance of this Agreement and the discussions, negotiations and transactions related thereto, including the Contemplated Transactions) and (ii) there has not occurred any action, event or occurrence that would have required the consent of Parent pursuant to <u>Sections</u> <u>5.1(a)(vii)</u>, <u>5.1(a)(ix)</u>, <u>5.1(a)(x)</u>, <u>5.1(a)(xi)</u>, <u>5.1(a)(xiii</u>), <u>5.1(a)(xiv)</u>, <u>5.1(a)(xv</u>), <u>5.1(a)(xix)</u> and, to the extent relating to the foregoing, <u>Section&#160;5.1(a)(xxi)</u>, had such action, event or occurrence taken place after the execution and delivery of this Agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;Since December&#160;31, 2025, there has not been any Company Material Adverse Effect (disregarding for purposes of this <u>Section&#160;3.7(b)</u> clause (2) of the definition thereof). </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS38"><!--Anchor--></a>3.8&#8195;<u>Absence of Undisclosed Liabilities</u>. Neither the Company nor any of its Subsidiaries has any liability, debt or obligation, individually or in the aggregate, of a type required to be recorded or reflected on the Company&#8217;s balance sheet or disclosed in the footnotes thereto under GAAP except for liabilities, debts or obligations (a) disclosed, reflected or reserved against in Company Balance Sheet or disclosed in the notes thereto included in the Company Financial Statements as so required by GAAP, (b) that have been incurred by the Company or any of its Subsidiaries since the date of the Company Balance Sheet in the Ordinary Course of Business (none of which are liabilities or obligations directly or indirectly related to a breach of Contract, breach of warranty, tort, infringement, Legal Proceeding or violation of, or non-compliance with, Law), (c) for performance of obligations of the Company or any of its Subsidiaries under the Contracts which have not resulted from a breach of such Contracts, breach of warranty, tort, infringement or violation of Law, or (d) incurred in connection with the Contemplated Transactions. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS39"><!--Anchor--></a>3.9&#8195;<u>Title to Assets</u>. The Company and each of its Subsidiaries owns, and has good and valid title to, or, in the case of leased properties and assets, valid leasehold interests in, all material tangible properties or material tangible assets and material equipment used or held for use in its business or operations or purported to be owned by it, including: (a) all material tangible assets reflected on the Company Balance Sheet; and (b) all other material tangible assets reflected in the books and records of the Company or any of its Subsidiaries as being owned by the Company or such Subsidiary. All of such assets are owned or, in the case of leased assets, leased by the Company or its applicable Subsidiary free and clear of any Liens, other than Permitted Liens. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS310"><!--Anchor--></a>3.10&#8194;<u>Legal Proceedings; Orders</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;As of the date of this Agreement, there is no pending Legal Proceeding and no Person has threatened in writing to commence any Legal Proceeding: (i) that involves (A) the Company, (B) any of its Subsidiaries, (C) any Company Associate (in his or her capacity as such) or (D)&#160;any of the material assets owned or used by the Company or any of its Subsidiaries; and (ii) that challenges, or that may have the effect of preventing, delaying, making illegal or otherwise interfering with, the Contemplated Transactions. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;Since January&#160;1, 2025, no Legal Proceeding has been pending against the Company or any of its Subsidiaries that resulted, or could reasonably be expected to result, in any liability that is material to the Company and its Subsidiaries, taken as a whole. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-10<br></div></div></div>
<!--End Page 395-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 396-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg16"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(c)&#8195;There is no material order, writ, injunction, judgment or decree to which the Company or any of its Subsidiaries, or any of the material assets owned or used by the Company or any of its Subsidiaries, is subject; <u>provided</u> that to the extent any such representations or warranties in this sentence pertain to any order, writ, injunction, judgment or decree that relates to the execution, delivery, performance or consummation of this Agreement or any of the Contemplated Transactions, such representations and warranties are made only as of the date of this Agreement. To the Company&#8217;s Knowledge, no officer or employee of the Company or any of its Subsidiaries is subject to any unsatisfied order, writ, injunction, judgment or decree that prohibits such officer or employee from engaging in or continuing any conduct, activity or practice relating to the business of the Company or any of its Subsidiaries or to any material assets owned or used by the Company or any of its Subsidiaries. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS311"><!--Anchor--></a>3.11&#8194;<u>Contracts</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;<u>Section&#160;3.11(a)</u> of the Company Disclosure Schedule sets forth a true, correct and complete list, as of the date of this Agreement, of all Company Contracts, entered into prior to or on the date of this Agreement, in the following categories (other than any Company Benefit Plan, any purchase order or work order issued pursuant to the terms of a Company Contract disclosed on <u>Section&#160;3.11(a)</u> of the Company Disclosure Schedule, any quality agreement, any business associate agreement, any data processing addenda and any confidentiality agreement) (each such Company Contract, whether or not set forth on <u>Section&#160;3.11(a)</u> of the Company Disclosure Schedule and including, for purposes of <u>Section&#160;3.11(b)</u> and <u>Section&#160;5.1(a)(xiv)</u>, those entered into after the date of this Agreement, a &#8220;<font style="font-weight: bold;">Company Material Contract</font>&#8221;): </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(i)&#8195;each Contract containing (A) any provision limiting the freedom of the Company or any of its Subsidiaries or, at or after the Effective Time, Parent or any of its Affiliates, to engage in any line of business, development program, therapeutic area or geographic area or with any Person or compete with any Person, other than any covenant not to solicit any employee, customer, or consultant entered into in the Ordinary Course of Business, (B) any &#8220;most-favored nations&#8221; obligation or similar provision (including with respect to pricing) restricting the Company or any of its Subsidiaries or, at or after the Effective Time, Parent or any of its Affiliates, (C) any exclusivity obligation on the Company, any of its Subsidiaries or, at or after the Effective Time, Parent or any of its Affiliates or (D) an obligation for Company or any of its Subsidiaries to purchase a minimum quantity of goods or services or to purchase all or substantially all of a certain type of good or service from a single vendor and its Affiliates in any geographic area or contains a &#8220;take or pay&#8221; provision, other than, in the cases of clauses (A) and (C) above, any confidentiality or non-use provisions in Contracts entered into in the Ordinary Course of Business, which are not material to the business of or operations of the Company and its Subsidiaries, taken as a whole; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(ii)&#8195;each Contract that governs the formation, creation, governance, economics or control of any joint venture, legal partnership or other similar arrangement, other than with respect to any Contract solely between or among the Company and any of its Subsidiaries; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(iii)&#8195;each Contract relating to capital expenditures and requiring payments after the date of this Agreement in excess of $500,000&#160;pursuant to its express terms and not cancelable without penalty; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(iv)&#8195;each Contract relating to the disposition or acquisition of material assets or any ownership interest in any entity (whether by merger, sale of stock, sale of assets or otherwise); </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(v)&#8195;each Contract providing for the creation of any mortgages, indentures, loans, notes or credit agreements, security agreements or other agreements or instruments providing for the creation of material Indebtedness of the Company or any of its Subsidiaries or creating any material Liens, other than Permitted Liens or Contracts required to be disclosed on <u>Section&#160;3.11(a)(vii)</u> of the Company Disclosure Schedule, with respect to any material assets of the Company or any of its Subsidiaries; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 30pt; text-indent: 30pt; text-align: left;">(vi)&#8195;each Company Real Estate Lease; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(vii)&#8195;each (A) Company Out-bound License, (B) Company In-bound License, (C) settlement, co-existence or other similar Contract that (I) involves the settlement of any pending or threatened Legal Proceeding and (II) either involves a payment obligation after the date of this Agreement in excess of $500,000 or grants a third party a license or right to use or restricts any Person from filing, registering, enforcing, disposing of or otherwise exploiting any Company Owned IP or (D) Contract that includes any covenant, agreement, undertaking or commitment by the Company or its Subsidiaries not to sue any other Person for infringement, misappropriation or other violation of Company IP or otherwise assert any Company IP against any other Person; <u>provided</u> that the foregoing in this subclause (D) shall not be construed to include license grants; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(viii)&#8195;each Contract pursuant to which the Company or any of its Subsidiaries has continuing milestone, royalty or similar contingent payment obligations, but not including any payments due upon completion of contracted services, including upon the achievement of development, regulatory or commercial milestones or obligation to pay any royalty, dividend, profit-sharing or similar payment based on the revenues or profits of the Company or any of its Subsidiaries, in each case, excluding indemnification and performance guarantee obligations provided for in the Ordinary Course of Business and any Contracts required to be disclosed on <u>Section&#160;3.11(a)(vii)</u> of the Company Disclosure Schedule; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(ix)&#8195;each Contract that is not terminable at will with no more than 90 days&#8217; prior notice (with no penalty or payment) by the Company or its Subsidiaries, as applicable, and which expressly provides for payment or receipt by the Company or any of its Subsidiaries after the date of this Agreement under any such Contract of more than $1,000,000 in the aggregate; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(x)&#8195;each collective bargaining agreement or other similar Contract with any labor organization, union, group or association covering employees of the Company or its Subsidiaries; </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-11<br></div></div></div>
<!--End Page 396-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 397-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg17"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(xi)&#8195;each Contract with any Company Affiliate providing for severance or similar termination payments, retention or change in control payments, or for the acceleration of vesting or grant of any incentive equity or similar compensation, in connection with the Contemplated Transactions; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(xii)&#8195;each Contract pursuant to which any material research or development activities are conducted by the Company or any of its Subsidiaries for a third party, including each master clinical trial agreement or similar framework agreement, but excluding individual clinical site agreements, clinical trial agreements with individual investigators or institutions, and work orders, task orders or statements of work issued under such master clinical trial agreement or similar framework agreement; or </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(xiii)&#8195;each stockholders&#8217;, investors rights&#8217;, registration rights or similar Contract to which the Company or any of its Subsidiaries is a party, including the Investor Agreements. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;The Company has made available to Parent true, correct and complete copies of all Company Material Contracts, including all material amendments thereto, in each case in effect on the date of this Agreement but excluding any purchase orders, work orders, quality agreements, business associate agreements and data processing addenda incorporated therein. There are no Company Material Contracts that are not in written form. None of the Company, any of its Subsidiaries or, to the Company&#8217;s Knowledge, any other party to a Company Material Contract, has breached, violated or defaulted under, or received written notice that it breached, violated or defaulted under, any of the terms or conditions of, or Laws applicable to, any Company Material Contract in such manner as would permit any other party to cancel or terminate any such Company Material Contract, or would permit any other party to seek damages or pursue other legal remedies which would reasonably be expected to be material to the Company and its Subsidiaries, taken as a whole. As to the Company and its Subsidiaries, each Company Material Contract is valid, binding, enforceable and in full force and effect, subject to the Enforceability Exceptions. No counterparty to a Company Material Contract has notified the Company in writing (or, to the Company&#8217;s Knowledge, otherwise) that it intends to terminate or not renew a Company Material Contract. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS312"><!--Anchor--></a>3.12&#8194;<u>Employee and Labor Matters; Benefits Plans</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;<u>Section&#160;3.12(a)</u> of the Company Disclosure Schedule sets forth a true, correct and complete list of all material Company Benefit Plans in effect on the date of this Agreement, including each such Company Benefit Plan that provides for retirement, change in control, stay or retention deferred compensation, incentive compensation, severance or retiree medical or life insurance benefits, but excluding (i) any employment agreement, offer letter, employment contract or consultancy agreement with a natural person that is in all material respects consistent with the standard form made available to Parent prior to the date of this Agreement and listed on <u>Section&#160;3.12(a)</u> of the Company Disclosure Schedule, (ii) any individual equity award agreement that is in all material respects consistent with the standard form made available to Parent prior to the date of this Agreement and listed on <u>Section&#160;3.12(a)</u> of the Company Disclosure Schedule and (iii) any Company Benefit Plans required to be maintained pursuant to applicable Laws that do not provide compensation or benefits in excess of those required by applicable Laws. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;As applicable with respect to each Company Benefit Plan required to be listed on <u>Section&#160;3.12(a)</u> of the Company Disclosure Schedule, the Company has made available to Parent true, correct and complete copies of (i) each Company Benefit Plan, including all material amendments thereto, and in the case of an unwritten Company Benefit Plan, a written description thereof, (ii) the current summary plan description and each summary of material modifications thereto, (iii) the most recently filed annual report with any Governmental Entity (e.g., Form&#160;5500 and all schedules thereto), (iv) the most recent determination, opinion or advisory letter from the Internal Revenue Service (&#8220;<font style="font-weight: bold;">IRS</font>&#8221;) with respect to each Company Benefit Plan intended to qualify under Section&#160;401(a) of the Code, (v) the most recent nondiscrimination testing report, (vi) all non-routine correspondence received from or provided to the United States Department of Labor (&#8220;<font style="font-weight: bold;">DOL</font>&#8221;), the Pension Benefit Guaranty Corporation, the IRS or any other Governmental Entity between January&#160;1, 2025 and the date of this Agreement and (vii) all notices and filings concerning IRS or DOL or other Governmental Entity audits or investigations, including with respect to &#8220;prohibited transactions&#8221; within the meaning of Section&#160;406 of ERISA or Section&#160;4975 of the Code, between January&#160;1, 2025 and the date of this Agreement.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(c)&#8195;Each Company Benefit Plan has been established, maintained, funded, operated and administered in compliance in all material respects with its terms and any related documents or agreements and the applicable provisions of ERISA, the Code and all other applicable Laws. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(d)&#8195;The Company Benefit Plans that are &#8220;employee pension benefit plans&#8221; within the meaning of Section&#160;3(2) of ERISA and that are intended to meet the qualification requirements of Section&#160;401(a) of the Code have received determination or opinion letters from the IRS<font style="font-weight: bold;"> </font>on which they may currently rely to the effect that such plans are qualified under Section 401(a) of the Code and the related trusts are exempt from federal income Taxes under Section&#160;501(a) of the Code, respectively, or are covered by advisory or opinion letters with respect to a volume submitter or prototype plan, and, to the Company&#8217;s Knowledge, nothing has occurred that would reasonably be expected to materially adversely affect the qualification of such Company Benefit Plan or the tax exempt status of the related trust. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(e)&#8195;None of the Company, any of its Subsidiaries or any Company ERISA Affiliate has maintained, contributed to, been required to contribute to, or had any actual or contingent liability with respect to, (i) any &#8220;employee pension benefit plan&#8221; (within the meaning of Section&#160;3(2) of ERISA) that is subject to Title IV or Section&#160;302 of ERISA or Section&#160;412 of the Code, (ii) any &#8220;multiemployer plan&#8221; (within the meaning of Section&#160;3(37) of ERISA), (iii) any &#8220;multiple employer plan&#8221; (within the meaning of Section&#160;413 of the Code), (iv) any &#8220;multiple employer welfare arrangement&#8221; (within the meaning of Section&#160;3(40) of ERISA) or (v) any &#8220;voluntary employees beneficiary association&#8221; within the meaning of Section&#160;501(c)(9) of the Code. The obligations of all Company Benefit Plans that provide health, welfare or similar insurance are fully insured by bona fide third-party insurers. No Company Benefit Plan is maintained through a human resources or benefit outsourcing entity, professional employer organization or other similar provider. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-12<br></div></div></div>
<!--End Page 397-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 398-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg18"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(f)&#8195;As of the date of this Agreement, there are no pending audits or investigations by any Governmental Entity involving any Company Benefit Plan, and no pending or, to the Company&#8217;s Knowledge, threatened claims (except for individual claims for benefits payable in the normal operation of the Company Benefit Plans), suits or proceedings involving any Company Benefit Plan, any fiduciary thereof or service provider thereto. Since January&#160;1, 2025, all material contributions and premium payments required to have been timely made under any of the Company Benefit Plans or by applicable Law (without regard to any waivers granted under Section&#160;412 of the Code), have been timely made and neither the Company nor any of its Subsidiaries has any liability for any such unpaid contributions with respect to any Company Benefit Plan, all benefits accrued under any unfunded Company Benefit Plan have been paid, accrued or otherwise adequately reserved in accordance with GAAP, and all reports, returns and similar documents required to be filed with any Governmental Entity or distributed to any plan participant have been timely filed or distributed. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(g)&#8195;None of the Company or any of its Subsidiaries, or, to the Company&#8217;s Knowledge, any fiduciary, trustee or administrator of any Company Benefit Plan, has engaged in, or in connection with the Contemplated Transactions will engage in, any transaction with respect to any Company Benefit Plan which would subject any such Company Benefit Plan, the Company or any of its Subsidiaries to a material Tax, penalty or liability for a &#8220;prohibited transaction&#8221; under Section&#160;406 of ERISA or Section&#160;4975 of the Code. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(h)&#8195;No Company Benefit Plan provides death, medical, dental, vision, life insurance or other welfare benefits beyond termination of service or retirement, other than coverage mandated by Part&#160;B of Subtitle B of Title I of ERISA, Section&#160;4980B of the Code or any other Law at the participant or beneficiary&#8217;s sole expense or, as described in <u>Section&#160;3.12(h)</u> of the Company Disclosure Schedule, as provided with respect to continuation health coverage as part of severance, and none of the Company or any of its Subsidiaries has any obligation to provide such insurance or benefits (whether under a Company Benefit Plan or otherwise) nor has made a written or oral representation promising to provide such insurance or benefits. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(i)&#8195;For each Company Benefit Plan that is a group health plan under Section&#160;733(a)(1) of ERISA, the Company has complied in all material respects with the Patient Protection and Affordable Care Act, including the Health Care and Education Reconciliation Act of 2010, as amended and including any guidance issued thereunder (&#8220;<font style="font-weight: bold;">PPACA</font>&#8221;), and COBRA. Neither the Company nor any of its Subsidiaries has failed to comply in all material respects with ERISA Sections 601 to 608 and Code Section&#160;4980B and the Company has, for any relevant period, offered the requisite number of &#8220;full-time employees&#8221; group health coverage that is &#8220;affordable&#8221; and of &#8220;minimum value&#8221; (as such terms are defined by the employer shared responsibility provisions of PPACA). The Company has not incurred (whether or not assessed), or is not reasonably expected to incur or to be subject to, any Tax, penalty or other liability that may be imposed under PPACA or Sections 4980B, 4980D, 4980H, 6721 or 6722 of the Code or with respect to any requirement to timely file PPACA information returns with the IRS or provide statements to participants under Section&#160;6056 or 6055 of the Code or state law requirements as applicable, or pursuant to Sections 4976 through 4980 of the Code or Title I of ERISA with respect to any of Company Benefit Plans. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(j)&#8195;Except as otherwise contemplated under this Agreement or as set forth on <u>Section&#160;3.12(j)</u> of the Company Disclosure Schedule, neither the execution of this Agreement nor the consummation of the Contemplated Transactions will either alone or in connection with any other event(s) (i) result in any payment (whether of severance pay or otherwise) becoming due to or forgiveness of indebtedness for any Company Associate, (ii) increase any amount of compensation or benefits otherwise payable to any Company Associate, (iii) result in the acceleration of the time of payment, funding or vesting of any benefits under any Company Benefit Plan, (iv) require any contribution or payment to fund any obligation under any Company Benefit Plan or (v) limit the right to merge, amend or terminate any Company Benefit Plan (or result in adverse consequences for so doing). </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(k)&#8195;Neither the execution of this Agreement nor the consummation of the Contemplated Transactions (either alone or when combined with the occurrence of any other event, including a termination of employment) will result in the receipt or retention (i) by any person who is a &#8220;disqualified individual&#8221; (within the meaning of Section&#160;280G of the Code) with respect to the Company and its Subsidiaries of any payment or benefit that is characterized as a &#8220;parachute payment&#8221; (within the meaning of Section&#160;280G of the Code), determined without regard to the application of Section&#160;280G(b)(5) of the Code or (ii) any amount the deduction for which would be disallowed under Section&#160;162(m) of the Code. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(l)&#8195;Each Company Benefit Plan providing for deferred compensation that constitutes a &#8220;nonqualified deferred compensation plan&#8221; (as defined in Section&#160;409A(d)(1) of the Code and the regulations promulgated thereunder) is, and has been, established, administered and maintained in material compliance in both form and operation with the requirements of Section&#160;409A of the Code and the regulations promulgated thereunder. The Company does not have any liability for nonreporting or underreporting of income subject to Section&#160;409A of the Code. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(m)&#8195;No Person has any &#8220;gross up&#8221; agreements with the Company or any of its Subsidiaries or other assurance of reimbursement by the Company or any of its Subsidiaries for any Taxes imposed under Section&#160;409A or Section&#160;4999 of the Code. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(n)&#8195;There are, and since January&#160;1, 2025 there have been, no actual, threatened or pending negotiations, strikes, labor disputes, work stoppages, requests for representation, pickets, work slow-downs due to labor disagreements or any proceedings or arbitrations that involve the labor or employment relations of the Company or any of its Subsidiaries. Neither the Company nor any of its Subsidiaries is a party to or bound by, or has a duty to bargain under, any collective bargaining agreement or other Contract with a labor union or labor organization representing any of its employees, and there is no labor union or labor organization representing or, to the Company&#8217;s Knowledge, purporting to represent or seeking to represent any employees of the Company or its Subsidiaries, including through the filing of a petition for representation election. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(o)&#8195;The Company and each of its Subsidiaries is, and since January&#160;1, 2025 has been, in material compliance with all applicable Laws respecting labor, employment, employment practices, and terms and conditions of employment, including worker classification, discrimination, wrongful termination, harassment and retaliation, equal employment opportunities, fair employment practices, meal and rest periods, immigration and I-9, reasonable accommodation, disability rights or benefits, child labor, working conditions, privacy, employee safety and health, wages </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-13<br></div></div></div>
<!--End Page 398-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 399-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg19"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">(including overtime wages), unemployment and workers&#8217; compensation, leaves of absence, hours of work and orders, regulations, ordinances and guidelines by any Governmental Entity regarding COVID-19 (including any &#8220;stay at home&#8221; orders or other similar orders, regulations or guidelines). Except as would not be reasonably likely to result in a liability that is material to the Company and its Subsidiaries, taken as a whole, with respect to employees of the Company or any of its Subsidiaries, each of the Company and its Subsidiaries, since January&#160;1, 2025 (i) has withheld and reported all amounts required by Law or by agreement to be withheld and reported with respect to wages, salaries and other payments, benefits, or compensation to employees, (ii) is not liable for any arrears of wages (including overtime wages), premiums, commissions, paid time off, on-call payments, bonus, benefits, severance pay or any Taxes or any penalty for failure to comply with any of the foregoing, and (iii) is not liable for any payment to any trust or other fund governed by or maintained by or on behalf of any Governmental Entity, with respect to unemployment compensation benefits, disability, social security or other benefits or obligations for employees (other than routine payments to be made in the Ordinary Course of Business). As of the date of this Agreement, there are no actions, suits, claims, charges, demands, lawsuits, investigations, audits or administrative matters pending or, to the Company&#8217;s Knowledge, threatened or reasonably anticipated against the Company or any of its Subsidiaries or Company Associates (in his or her capacity as such) relating to any current or former employee, applicant for employment, independent contractor, employment agreement or Company Benefit Plan (other than routine claims for benefits). All U.S.-based employees of the Company and its Subsidiaries are employed &#8220;at-will&#8221; and their employment can be terminated without advance notice or payment of severance. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(p)&#8195;Except as would not be reasonably likely to result in a liability that is material to the Company and its Subsidiaries, taken as a whole, with respect to each individual since January&#160;1, 2025 who rendered services to the Company or any of its Subsidiaries, the Company and each of its Subsidiaries has accurately classified each such individual as an employee, independent contractor, or otherwise under all applicable Laws and, for each individual classified as an employee, the Company has accurately classified him or her as overtime eligible or overtime ineligible under all applicable Laws. Neither the Company nor any of its Subsidiaries has any material liability with respect to any misclassification of (i)&#160;any Person as an independent contractor rather than as an employee, (ii) any employee leased from another employer or (iii) any employee currently or formerly classified as exempt from overtime wages. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(q)&#8195;There is not and has not been since January&#160;1, 2025, nor, to the Company&#8217;s Knowledge, is there or has there been since January&#160;1, 2025, any threat of, any strike, slowdown, work stoppage, lockout, union election petition, demand for recognition, or any similar activity or dispute, or, to the Company&#8217;s Knowledge, any union organizing activity, against the Company or any of its Subsidiaries. No event has occurred, and, to the Company&#8217;s Knowledge, no condition or circumstance exists, that would reasonably be expected directly or indirectly to give rise to or provide a basis for the commencement of any such strike, slowdown, work stoppage, lockout, union election petition, demand for recognition, or any similar activity or dispute. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(r)&#8195;No Company Benefit Plan is or has been maintained outside the jurisdiction of the United States, or covers or covered any employee permanently residing or working outside the United States. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(s)&#8195;Since January&#160;1, 2025, neither the Company nor its Subsidiaries has caused (i) a plant closing as defined in the Worker Adjustment and Retraining Notification Act (the &#8220;<font style="font-weight: bold;">WARN Act</font>&#8221;) affecting any single site of employment of the Company or any of its Subsidiaries or one or more operating units within any site of employment of the Company or any of its Subsidiaries or (ii) a mass layoff as defined in the WARN Act, nor has the Company or any of its Subsidiaries been affected by any transaction or engaged in layoffs or employment terminations sufficient in number to trigger application of any similar foreign, state or local Law. No employee of the Company or any of its Subsidiaries has suffered an employment loss, as defined in the WARN Act, within the 90-day period ending on the Closing Date.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(t)&#8195;No Legal Proceedings are as of the date of this Agreement open and pending (or between January&#160;1, 2025 and the date of this Agreement have been settled or otherwise closed) against the Company or any of its Subsidiaries with respect to the employment of, or failure to employ, any individual, including any brought with or by the Equal Employment Opportunity Commission, the Office of Federal Contract Compliance Programs, or other Governmental Entity regulating the employment or compensation of individuals (or, with respect to discrimination, unlawful harassment, retaliation, or similar wrongdoing, pursuant to internal complaint procedures), and no employee of the Company or any of its Subsidiaries has made, between January&#160;1, 2025 and the date of this Agreement, a written complaint of discrimination, unlawful harassment, retaliation, or other similar wrongdoing or, to the Company&#8217;s Knowledge, between January&#160;1, 2025 and the date of this Agreement, an oral complaint. Between January&#160;1, 2025 and the date of this Agreement, neither the Company nor any of its Subsidiaries has received any requests for, or conducted, an internal investigation of any Company Associate with respect to any claims with respect to discrimination, unlawful harassment, retaliation, or other similar wrongdoing. Neither the Company nor any of its Subsidiaries is a party to any settlement agreement with a Company Associate resolving allegations of sexual or other unlawful harassment, discrimination, or retaliation by any Company Associate. The Company and its Subsidiaries have used reasonable best efforts to promptly, thoroughly and impartially investigate all employment discrimination, sexual or other unlawful harassment, and retaliation allegations of, or against, any employee in accordance with applicable Law. With respect to each such allegation with potential merit, the applicable employer has taken prompt corrective action reasonably calculated to prevent further discrimination and harassment or retaliation, and neither the Company nor any of its Subsidiaries reasonably expects to incur any material liability with respect to any such allegation. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS313"><!--Anchor--></a>3.13&#8194;<u>Environmental Matters</u>. The Company and each of its Subsidiaries are, and have been since January&#160;1, 2025, in compliance in all material respects with all applicable Environmental Laws. The Company and each of its Subsidiaries have and maintain, in full force and effect, all Governmental Authorizations required under applicable Environmental Laws for the operation of their respective businesses or use of the Company Leased Real Property and the Company and each of its Subsidiaries are in compliance in all material respects with the terms and conditions thereof. Neither the Company nor any of its Subsidiaries has received any written notice or other communication (in writing or otherwise), whether from a Governmental Entity or other Person, that alleges that the Company or any of its Subsidiaries (a) is not in material compliance with, or has material liability pursuant to, any Environmental Law, (b) has been identified as a potentially responsible party with respect to any contaminated site under any </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-14<br></div></div></div>
<!--End Page 399-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 400-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg20"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Environmental Law or (c) has generated, stored, treated, transported, disposed of or arranged for any other Person to transport or dispose of Hazardous Materials that have been found at any site at which a Governmental Entity or other Person has conducted or has been ordered to conduct a remedial investigation, removal or other response actions pursuant to Environmental Law. To the Company&#8217;s Knowledge, there are no underground storage tanks or other underground storage receptacles for Hazardous Materials present on any Company Leased Real Property. To the Company&#8217;s Knowledge, there has been no release of or exposure to any Hazardous Materials at, on or under the Company Leased Real Property. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS314"><!--Anchor--></a>3.14&#8194;<u>Taxes</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;The Company and each of its Subsidiaries have timely filed (taking into account all extensions of time to file that have been granted) all income Tax Returns and other material Tax Returns that they were required to file under applicable Law. All such Tax Returns are correct and complete in all material respects and have been prepared in substantial compliance with all applicable Law. No written claim has ever been made prior to the date of this Agreement by any Governmental Entity in any jurisdiction where the Company or any of its Subsidiaries does not file a particular Tax Return or pay a particular Tax that the Company or such Subsidiary is subject to taxation by that jurisdiction. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;All income Taxes and any other material Taxes due and owing by the Company or any of its Subsidiaries on or before the date of this Agreement (whether or not shown on any Tax Return) have been fully paid. The unpaid Taxes of the Company and its Subsidiaries did not, as of the date of the Company Balance Sheet, materially exceed the reserve for Tax liability (excluding any reserve for deferred Taxes established to reflect timing differences between book and Tax items) set forth on the face of the Company Balance Sheet. Since the date of the Company Balance Sheet, neither the Company nor any of its Subsidiaries has incurred any material Tax liability outside the Ordinary Course of Business or otherwise inconsistent with past custom and practice. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(c)&#8195;All material Taxes that the Company or any of its Subsidiaries are or were required by Law to withhold or collect have been duly and timely withheld or collected in all material respects on behalf of its respective employees, independent contractors, stockholders, lenders, customers or other third parties and have been timely paid to the proper Governmental Entity or other Person or properly set aside in accounts for this purpose. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(d)&#8195;There are no Liens for material Taxes (other than Permitted Liens) upon any of the assets of the Company or any of its Subsidiaries. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(e)&#8195;No outstanding deficiencies for income Taxes or any other material Taxes with respect to the Company or any of its Subsidiaries have been claimed, proposed or assessed by any Governmental Entity in writing. There are no pending or ongoing, nor, to the Company&#8217;s Knowledge, threatened audits, assessments or other actions for or relating to any liability in respect of a material amount of Taxes of the Company or any of its Subsidiaries. Neither the Company nor any of its Subsidiaries (nor any of their predecessors) has waived any statute of limitations in respect of any income Taxes or other material Taxes or agreed to any extension of time with respect to any income Tax or other material Tax assessment or deficiency, which waiver or extension is still in effect. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(f)&#8195;Neither the Company nor any of its Subsidiaries has been a United States real property holding corporation within the meaning of Section&#160;897(c)(2) of the Code during the applicable period specified in Section&#160;897(c)(1)(A)(ii) of the Code. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(g)&#8195;Neither the Company nor any of its Subsidiaries is a party to any material Tax allocation agreement, Tax sharing agreement, Tax indemnity agreement, or similar agreement or arrangement, other than commercial agreements entered into in the Ordinary Course of Business the principal subject matter of which is not the allocation of Taxes. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(h)&#8195;Neither the Company nor any of its Subsidiaries will be required to include any material item of income in, or exclude any material item of deduction from, taxable income for any Tax period (or portion thereof) ending after the Closing Date as a result of any (i) change in method of accounting for Tax purposes made on or prior to the Closing Date, (ii) use of an improper method of accounting for a Tax period (or portion thereof) ending on or prior to the Closing Date, (iii) &#8220;closing agreement&#8221; as described in Section&#160;7121 of the Code (or any similar provision of state, local or foreign Law) executed on or prior to the Closing Date, (iv) installment sale or open transaction disposition made on or prior to the Closing Date, (v) prepaid amount received or deferred revenue accrued on or prior to the Closing Date or (vi) application of Section&#160;367(d) of the Code to any transfer of intangible property on or prior to the Closing Date. The Company has not made any election under Section&#160;965(h) of the Code. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(i)&#8195;Neither the Company nor any of its Subsidiaries has ever been (i) a member of a consolidated, combined or unitary Tax group (other than such a group the common parent of which is the Company) or (ii) a party to any joint venture, partnership, or other arrangement that is treated as a partnership for U.S. federal income Tax purposes. Neither the Company nor any of its Subsidiaries has any liability for any material Taxes of any Person (other than the Company and any of its Subsidiaries) under Treasury Regulations Section&#160;1.1502-6 (or any similar provision of state, local, or foreign Law), as a transferee or successor, or otherwise. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(j)&#8195;Neither the Company nor any of its Subsidiaries (i) is a &#8220;passive foreign investment company&#8221; within the meaning of Section&#160;1297&#160;of the Code or (ii) has a permanent establishment (within the meaning of an applicable Tax treaty) or other office or fixed place of business in a country other than the country in which it is organized. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(k)&#8195;Neither the Company nor any of its Subsidiaries has participated in or been a party to a transaction that, as of the date of this Agreement, constitutes a &#8220;listed transaction&#8221; that is required to be reported to the IRS pursuant to Section&#160;6011 of the Code and applicable Treasury Regulations thereunder. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(l)&#8195;Neither the Company nor any of its Subsidiaries has taken or agreed to take any action or knows of any fact that could reasonably be expected to prevent the Merger from qualifying for the Intended Tax Treatment. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-15<br></div></div></div>
<!--End Page 400-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 401-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg21"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(m)&#8195;Neither the Company nor any of its Subsidiaries has availed itself of any Tax relief pursuant to any pandemic response laws that could reasonably be expected to materially impact the Tax payment and/or Tax reporting obligations of the Company and its Affiliates (including Parent and its Subsidiaries) after the Closing Date. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(n)&#8195;Neither the Company nor any of its Subsidiaries has constituted either a &#8220;distributing corporation&#8221; or a &#8220;controlled corporation&#8221; (within the meaning of Section&#160;355(a)(1)(A) of the Code) in a transaction that was purported or intended to be governed in whole or in part by Sections 355 or 361 of the Code (A) within the two-year period ending on the date of this Agreement or (B) in a distribution which could otherwise constitute part of a &#8220;plan&#8221; or &#8220;series of related transactions&#8221; (within the meaning of Section&#160;355(e) of the Code) in conjunction with the Contemplated Transactions. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(o)&#8195;For purposes of this <u>Section&#160;3.14</u>, each reference to the Company or any of its Subsidiaries shall be deemed to include any Person that was liquidated into, merged with, or is otherwise a predecessor to, the Company of any of its Subsidiaries. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS315"><!--Anchor--></a>3.15&#8194;<u>Intellectual Property</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;<u>Section&#160;3.15(a)</u> of the Company Disclosure Schedule sets forth, to the Company&#8217;s Knowledge, a true, correct and complete list of all of the following Company IP as of the date of this Agreement: (A) issued Patents and pending applications for Patents, (B) registered Trademarks and applications for registration of Trademarks, (C) Internet domain names and (D) registered Copyrights, indicating as to each item, as applicable: (i) the current legal and record owner(s), (ii) the jurisdictions in which such item is issued or registered or in which any application for issuance or registration has been filed, (iii) the respective issuance, registration or application number of the item, (iv) the dates of application, issuance or registration of the item and (v) the current status of the item (e.g., registered or pending). As of the date of this Agreement, no interference, opposition, reissue, reexamination or other proceeding of any nature (other than ex parte initial or continuing examination proceedings in front of a government agency) is pending or threatened in writing, in which the scope, validity, enforceability or ownership of any Company Owned IP, or, to the Company&#8217;s Knowledge, any Company Licensed IP, is being or has been contested or challenged. To the Company&#8217;s Knowledge, all Company IP is in effect, valid, subsisting and enforceable and has not been abandoned or dedicated to the public domain or adjudged invalid or unenforceable. With respect to Company Owned IP: (x) the Company has taken reasonable steps to avoid revocation, cancellation, or unintentional lapse or otherwise materially adversely affecting its enforceability, use, or priority, (y) to the Company&#8217;s Knowledge, all duties of disclosure, candor and good faith have been complied with, and (z) all other material procedural requirements have been complied with, or can be complied with, without materially and adversely affecting such Company Owned IP&#8217;s enforceability, use or priority, including, with respect to such Company Owned IP, (1) inventors having been properly identified on all Patents, (2) all necessary affidavits of inventorship, ownership, use and continuing use and other filings having been timely made, and (3) all necessary maintenance fees and other fees timely paid to file, prosecute, obtain and maintain in effect all such rights in all material respects. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;The Company or its Subsidiaries solely and exclusively owns or has rights to all right, title and interest in and to all material Company Owned IP, free and clear of all Liens other than Permitted Liens, and has the right to use all other Intellectual Property Rights necessary for, or used in or held for use by, the Company or its Subsidiaries in their businesses as currently conducted. Except as set forth on <u>Section&#160;3.15(b)</u> of the Company Disclosure Schedule, to the Company&#8217;s Knowledge, the applicable third-party licensor solely owns the Intellectual Property Rights that are exclusively licensed or sublicensed to Company or any of its Subsidiaries under a Company In-bound License. Each Company Associate materially involved in the creation or development of any material Company Owned IP has signed a valid, enforceable written agreement containing a present assignment of all such Person&#8217;s rights in such material Company Owned IP to the Company or its Subsidiaries (without further payment being owed to any such Person and without any restrictions or obligations on the Company&#8217;s or its Subsidiaries&#8217; ownership or use thereof). Each Person with access to any material Trade Secrets owned or purported to be owned by the Company or any of its Subsidiaries has signed a valid, enforceable written agreement containing confidentiality provisions protecting such Trade Secrets, which, to the Company&#8217;s Knowledge, has not been materially breached by any such Person. The Company and its Subsidiaries have taken commercially reasonable measures to protect against unauthorized disclosure of any Trade Secret that is material to the business of the Company and its Subsidiaries, taken as a whole, as currently conducted. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(c)&#8195;No funding, facilities or personnel of any Governmental Entity, university, college, research institute, other educational, academic or not-for-profit institution has been used, in whole or in part, to create any material Company Owned IP or, to the Company&#8217;s Knowledge, any material Company Licensed IP, except for any such funding or use of facilities or personnel that does not result in such Person obtaining ownership of, a statutory license to, &#8220;march-in&#8221; rights or a right to direct the location of manufacturing of products with respect to such Company Owned IP. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(d)&#8195;<u>Section&#160;3.15(d)</u> of the Company Disclosure Schedule sets forth a true, correct and complete list of each license agreement pursuant to which the Company or any of its Subsidiaries (i) is granted a license or sublicense under any material Intellectual Property Right owned by any third party that is used by the Company or any of its Subsidiaries in its business as conducted as of the date of this Agreement (each a &#8220;<font style="font-weight: bold;">Company In-bound License</font>&#8221;) or (ii) grants to any third party a license or sublicense under any material Company IP or any material Intellectual Property Right licensed to the Company or any of its Subsidiaries under a Company In-bound License (each a &#8220;<font style="font-weight: bold;">Company Out-bound License</font>&#8221;); <u>provided</u> that neither &#8220;Company In-bound Licenses&#8221; nor &#8220;Company Out-bound Licenses&#8221; shall include any Standard IP Contracts. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(e)&#8195;To the Company&#8217;s Knowledge, since January&#160;1, 2025, the operation of the businesses of the Company and its Subsidiaries has not infringed or misappropriated or otherwise violated any valid Intellectual Property Rights owned by any other Person. As of the date of this Agreement, no Legal Proceeding (i) is pending (or is threatened in writing) against the Company or any of its Subsidiaries alleging that the operation of the businesses of the Company or any of its Subsidiaries is infringing, misappropriating or otherwise violating or has infringed, misappropriated or otherwise violated any Intellectual Property Rights owned by any other Person or (ii) has been commenced (or threatened in writing) by the Company or any of its Subsidiaries against any other Person alleging that the operation of the businesses of such Person is infringing, misappropriating or </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-16<br></div></div></div>
<!--End Page 401-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 402-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg22"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">otherwise violating or has infringed, misappropriated or otherwise violated any Company Owned IP. Since January&#160;1, 2025, neither the Company nor any of its Subsidiaries has received any written notice or other written communication alleging that the operation of the businesses of the Company or any of its Subsidiaries is infringing, misappropriating or otherwise violating, or has infringed, misappropriated or otherwise violated Intellectual Property Rights of another Person nor has the Company or any of its Subsidiaries made any written notice or other written communication alleging any other Person is infringing, misappropriating or otherwise violating, or has infringed, misappropriated or otherwise violated, any Company Owned IP. To the Company&#8217;s Knowledge, no third party is infringing, misappropriating or otherwise violating any Company IP. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(f)&#8195;None of the Company Owned IP or, to the Company&#8217;s Knowledge, any Company Licensed IP, is subject to any pending or outstanding injunction, directive, order, judgment or other disposition of dispute that adversely and materially restricts the use, transfer, registration or licensing by the Company or any of its Subsidiaries of any such Company Owned IP or Company Licensed IP. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(g)&#8195;None of the Company or its Subsidiaries is now or has ever been a member or promoter of, or a contributor to, any industry standards body or any similar organization that would reasonably be expected to require or obligate the Company or any of its Subsidiaries to grant or offer to any other Person any license or right to any Company IP. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS316"><!--Anchor--></a>3.16&#8194;<u>Privacy and Data Security</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;The operation of the Company&#8217;s and its Subsidiaries&#8217; business is in compliance in all material respects with applicable Data Protection Regulations. Neither the execution, delivery or performance of this Agreement, nor the consummation of the Contemplated Transactions will result in any material violation of applicable Data Protection Regulations. Since January&#160;1, 2023, there have been (i) no Security Incidents materially impacting Personal Data (including any clinical trial data or other data obtained from or about clinical trial subjects, research participants, investigators, or investigator personnel) or any confidential data or Trade Secrets used in the business of the Company or its Subsidiaries as currently conducted (collectively, &#8220;<font style="font-weight: bold;">Company Sensitive Data</font>&#8221;) (and the Company and its Subsidiaries have not provided or been required under applicable Data Protection Regulations to provide notification of any breach of privacy or data security), (ii) no material violations of any security policy of the Company or its Subsidiaries regarding any such Company Sensitive Data and (iii) no material unintended or improper disclosure of any Company Sensitive Data in the possession, custody or control of the Company or its Subsidiaries or a contractor or agent acting on behalf of the Company or its Subsidiaries. Since January&#160;1, 2023, none of the Company or its Subsidiaries has received any written notice (x) from a vendor or data processor that processes Company Sensitive Data on behalf of the Company or any of its Subsidiaries with respect to a Security Incident materially impacting Company Sensitive Data or (y) from any other Person, including from any supervisory authority or Governmental Entity of any complaint, investigation, inquiry or enforcement action regarding its Company Sensitive Data processing. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;Each of the Company and its Subsidiaries has materially complied, and continues to materially comply, with applicable Data Protection Regulations, including with (i) requirements to process Personal Data lawfully, (ii) contractual requirements applicable to the engagement of data processors processing Personal Data on behalf of the Company and its Subsidiaries, (iii) requirements to provide adequate security measures to protect Company Sensitive Data, (iv) conduct of appropriate data privacy impact assessments to the extent required by applicable Data Protection Regulations, (v) provisions related to lawful cross-border data transfers of Personal Data and (vi) applicable requirements for the collection, use, storage and security of clinical trial data under ICH Guidelines for Good Clinical Practice and applicable regulations. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(c)&#8195;Each of the Company and its Subsidiaries has implemented commercially reasonable physical, technical and organizational measures designed to protect Company Sensitive Data against loss, destruction and damage, unauthorized access, use, modification, disclosure or other misuse. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(d)&#8195;To the Company&#8217;s Knowledge, (i) the Company and its Subsidiaries have implemented commercially reasonable safeguards for transfers of Personal Data outside of a country of origin in compliance in all material respects with applicable Data Protection Regulations, and (ii)&#160;none of the Company or its Subsidiaries has suspended or terminated a transfer of Personal Data due to violation of applicable Data Protection Regulations or received any written notice from a supervisory authority regarding any concerns about a transfer of Personal Data, except, in each case, as would not have a Company Material Adverse Effect. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(e)&#8195;With respect to any clinical trial or other clinical research study conducted by or on behalf of the Company or any of its Subsidiaries, to the Company&#8217;s Knowledge, the Company and its Subsidiaries have obtained all required informed consents from clinical trial subjects and research participants and all required approvals from institutional review boards or independent ethics committees, in each case in compliance in all material respects with applicable Data Protection Regulations, 21 C.F.R. Parts 50 and 56 and ICH Guidelines for Good Clinical Practice. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(f)&#8195;The Company and its Subsidiaries have deployed and used AI in material compliance with all applicable Laws and Data Protection Regulations, as well as in all material respects with Contract terms applicable to the Company and its Subsidiaries&#8217; processing of Training Data. The Company and its Subsidiaries do not use any data that is subject to an obligation of confidentiality by the Company or its Subsidiaries under all applicable Laws and Contracts to which the Company or any of its Subsidiaries is subject or a party, in any prompts or inputs to any AI tools by Company or its Subsidiaries, except in cases where such AI tools do not use such data, prompts or inputs to train the machine learning or algorithm of such tools or to improve the services related to such AI tools other than solely for use by the Company or its Subsidiaries as permitted by all applicable Laws and Contracts to which the Company or any of its Subsidiaries is subject or a party. The Company has implemented and maintains commercially reasonable policies relating to governance or implementation of AI, including its policies relating to (A) management oversight and approval of employees&#8217; and contractors&#8217; use and implementation of AI, and (B) use and implementation of AI in a manner that is designed to avoid violation, infringement or misappropriation of any third Person&#8217;s Intellectual Property Rights and violation of applicable Laws. The Company and its Subsidiaries have not used or employed any AI tools in a manner that would materially limit the Company&#8217;s or any of its Subsidiaries&#8217; ownership of, </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-17<br></div></div></div>
<!--End Page 402-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 403-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg23"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">or otherwise materially impair the Company&#8217;s or any of its Subsidiaries&#8217; ability to use, commercialize, or otherwise exploit, the Intellectual Property Rights in or pertaining to any output generated by the use of AI tools by or for the Company and its Subsidiaries. The Company does not use AI for any activity that is banned or prohibited under any applicable Law, including activities designated as &#8220;high risk&#8221; or otherwise subject to heightened requirements or restrictions under any applicable Law. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS317"><!--Anchor--></a>3.17&#8194;<u>Compliance with Laws; Permits; Regulatory Matters</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;The Company and each of its Subsidiaries are and, to the Company&#8217;s Knowledge, each Company Partner is, and since January&#160;1, 2025 have been, in compliance in all material respects with all applicable Laws, including Health Care Laws. Since January&#160;1, 2025, neither the Company, any of its Subsidiaries nor, to the Company&#8217;s Knowledge, any Company Partner has received any pending or threatened claim, complaint, suit, proceeding, hearing, enforcement audit, investigation, arbitration, or other adverse action from any Person, including any Governmental Entity or customer, alleging product liability, material non-compliance or material violation of any applicable Laws, including Health Care Laws. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;There is no judgment, injunction, order or decree by a Governmental Entity binding upon the Company, any of its Subsidiaries or, to the Company&#8217;s Knowledge, any Company Partner, which (i) has or would reasonably be expected to have the effect of prohibiting or materially impairing any current material business practice of the Company, any of its Subsidiaries or, to the Company&#8217;s Knowledge, any Company Partner, any acquisition of material property by the Company, any of its Subsidiaries or, to the Company&#8217;s Knowledge, any Company Partner, or the conduct of any material portion of the business by the Company, any of its Subsidiaries or, to the Company&#8217;s Knowledge, any Company Partner, as currently conducted, (ii) is reasonably likely to have a material adverse effect on the Company&#8217;s ability to comply with or perform any covenant or obligation under this Agreement, or (iii) is reasonably likely to have the effect of preventing, materially delaying, making illegal or otherwise materially interfering with the Contemplated Transactions; <u>provided</u> that the representations and warranties in the foregoing clauses (ii) and (iii) are made only as of the date of this Agreement. The Company is not and, since January&#160;1, 2025, has not been a party to any corporate integrity agreements, monitoring agreements, consent decrees, deferred prosecution agreements, settlement orders, or similar agreements with or imposed by any Governmental Entity. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(c)&#8195;The Company, its Subsidiaries and, to the Company&#8217;s Knowledge, each Company Partner currently hold and operate in compliance in all material respects with, and, at all times since January&#160;1, 2025, have held and operated in compliance in all material respects with, all Governmental Authorizations that are or have been necessary for the conduct of the business of the Company and its Subsidiaries as previously conducted and as currently being conducted. All such permits that are necessary for the conduct of the business of the Company and its Subsidiaries as currently conducted (the &#8220;<font style="font-weight: bold;">Company Permits</font>&#8221;) and necessary for the conduct of the business of the Company Partners as currently conducted (the &#8220;<font style="font-weight: bold;">Company Partner Permits</font>&#8221;) are valid and are in full force and effect (in the case of the Company Partner Permits, to the Company&#8217;s Knowledge), and, assuming the notices, filings or other Consents listed on <u>Section&#160;3.17(c)</u> of the Company Disclosure Schedule have been made or obtained, will continue to be so upon consummation of the Contemplated Transactions, except as would not have a Company Material Adverse Effect. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(d)&#8195;The Company, its Subsidiaries and, to the Company&#8217;s Knowledge, the Company Partners, hold all right, title and interest in and to all Company Permits and Company Partner Permits free and clear of any Lien. All fees and charges with respect to such Company Permits and Company Partner Permits, as of the date of this Agreement, have been paid in full and all filing, reporting and maintenance obligations have been completely and timely satisfied (in the case of the Company Partner Permits, to the Company&#8217;s Knowledge), except as would not have a Company Material Adverse Effect. The Company and each of its Subsidiaries are in material compliance with the terms of the Company Permits and the Company Partner Permits. To the Company&#8217;s Knowledge, as of the date of this Agreement, no Legal Proceeding is pending or threatened, which seeks to revoke, limit, suspend, or materially modify any Company Permit or any Company Partner Permit. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(e)&#8195;None of the Company Products have been or have been requested by a Governmental Entity or other Person to be recalled, withdrawn, removed, suspended, seized, the subject of a corrective action, or discontinued (whether voluntarily or otherwise) (collectively &#8220;<font style="font-weight: bold;">Recall</font>&#8221;). Neither the Company or any of its Subsidiaries, nor, to the Company&#8217;s Knowledge, any Governmental Entity or other Person, has sought, is seeking, or, to the Company&#8217;s Knowledge, has or is currently threatening or contemplating any Recall of a Company Product. The Company Products have been manufactured, packaged, labeled, tested, stored, shipped, handled, warehoused and distributed in material compliance with all applicable Health Care Laws and are not and have not been prohibited from introduction into interstate commerce under applicable Health Care Laws. Except as would not have a material impact on the Company and its Subsidiaries, taken as a whole, since January&#160;1, 2025, neither the Company nor any of its Subsidiaries has either voluntarily or involuntarily issued, or caused to be issued, any notice or communication due to an alleged lack of safety, efficacy or material noncompliance with any applicable Health Care Laws for any Company Product. To the Company&#8217;s Knowledge, as of the date of this Agreement, there are no facts that would reasonably be expected to result in (x) such a notice or communication or (y) the termination or suspension of marketing of any Company Product. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(f)&#8195;As of the date of this Agreement, none of the Company, its Subsidiaries, or any of their respective officers, directors, employees, independent contractors or, to the Company&#8217;s Knowledge, agents or the Company Partners and their respective officers, directors, employees, independent contractors or agents have been or are currently: </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 30pt; text-indent: 30pt; text-align: left;">(i)&#8195;subject to mandatory or permissive debarment or suspension pursuant to 21 U.S.C. &#167; 335a; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 30pt; text-indent: 30pt; text-align: left;">(ii)&#8195;excluded under 42 U.S.C. &#167; 1320a-7 or any similar law, rule or regulation of any Governmental Entity; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(iii)&#8195;excluded, debarred, suspended or deemed ineligible to participate in federal procurement and non-procurement programs, including those produced by the U.S. General Services Administration; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(iv)&#8195;charged, named in a complaint, convicted, or otherwise found liable in any Legal Proceeding that falls within the ambit of 21&#160;U.S.C. &#167; 331, 21 U.S.C. &#167; 333, 21 U.S.C. &#167; 334, 21 U.S.C. &#167; 335a, 21 U.S.C. &#167; 335b, 42 U.S.C. &#167; 1320a &#8211; 7, 31 U.S.C. &#167;&#167; 3729 &#8211; 3733, </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-18<br></div></div></div>
<!--End Page 403-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 404-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg24"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">42&#160;U.S.C. &#167; 1320a-7a, or any other applicable Health Care Laws or, to the Company&#8217;s Knowledge, threatened with prosecution by a Governmental Entity, including the Centers for Medicare and Medicaid Services, the U.S. Department of Health and Human Services, state attorney general, or the U.S. Department of Justice, for any violation of any of the foregoing; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(v)&#8195;disqualified or deemed ineligible pursuant to 21 C.F.R. Parts 312, 511, or 812, or otherwise restricted, in whole or in part, or subject to an assurance; or </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(vi)&#8195;had a pending Legal Proceeding, or otherwise received any written notice from any Governmental Entity or any Person threatening, investigating, or pursuing (i)-(v) above or, to the Company&#8217;s Knowledge, committed any violation of any applicable Health Care Law, that could reasonably be expected to serve as the basis for any such exclusion, suspension, debarment or other ineligibility. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(g)&#8195;The Company has not been restrained in any material respect by a Governmental Entity in its ability to conduct or have conducted the manufacturing; non-clinical, clinical or other testing; distribution; promotion or marketing of the Company Products. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(h)&#8195;All studies and tests conducted by or on behalf of, or sponsored by, the Company or any of its Subsidiaries, or in which the Company or any of its Subsidiaries or the Company Products has participated, were and, if still pending, are being conducted in compliance in all material respects with all applicable Health Care Laws. To the Company&#8217;s Knowledge, the study reports, protocols, and statistical analysis plans for all such studies and tests accurately, completely, and fairly reflect the results from such studies and tests. As of the date of this Agreement, the Company has not received written notice of any complaints, information, or adverse experience reports related to a Company Product that would reasonably be expected to be material to the Company and its Subsidiaries, taken as a whole. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(i)&#8195;Since January&#160;1, 2025, neither the Company nor any of its Subsidiaries nor, to the Company&#8217;s Knowledge, any of the Company Partners has received any written notice from FDA or any other Governmental Entity that it has (i) commenced, or threatened to initiate, any Legal Proceeding to implement a partial or full clinical hold or withdraw any approvals granted to the Company for any clinical investigation of any Company Product, or (ii) commenced, or threatened to initiate, any Legal Proceeding to enjoin manufacture or distribution of any Company Product. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(j)&#8195;To the Knowledge of the Company, there are no material Legal Proceedings or governmental, regulatory or administrative investigations, audits, inquiries or actions, or any facts, circumstances or conditions that would reasonably be expected to form the basis for any material Legal Proceeding or governmental, regulatory or administrative investigation, audit, inquiry or action, against or affecting the Company, any of its Subsidiaries or any of the Company Partners arising under (i) the FDCA and the regulations of FDA promulgated thereunder or similar Law, (ii)&#160;the Public Health Service Act of 1944, (iii) the Social Security Act or regulations of the Office of the Inspector General of the Department of Health and Human Services or similar Laws, (iv) applicable Laws relating to government health care programs, private health care plans, or the privacy and confidentiality of patient health information, including United States federal and state Laws pertaining to the Medicare and Medicaid programs, United States federal and state Laws applicable to health care fraud and abuse, kickbacks, physician self-referral, false claims made to a Governmental Entity or government or private health care program, and United States federal or state Laws pertaining to contracting with the government and similar Laws or (v) ICH Guidelines for Good Clinical Practice, 21 C.F.R. Parts 11, 50, 54, 56, 312, 812 and 814 or any comparable foreign Laws relating to the conduct of clinical trials. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(k)&#8195;The Company, its Subsidiaries and, to the Company&#8217;s Knowledge, the Company Partners have not made any false, misleading, or untrue statement of material fact, or failed to disclose a material fact required to be disclosed, to any Governmental Entity, nor committed any act, made any statement, or failed to make any statement that would reasonably be likely to provide a basis for the FDA to invoke its policy with respect to &#8220;Fraud, Untrue Statements of Material Facts, Bribery and Illegal Gratuities,&#8221; or for any other Governmental Entity to invoke any similar policy. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS318"><!--Anchor--></a>3.18&#8194;<u>Insurance</u>. The Company has made available to Parent true, correct and complete copies of all material insurance policies and all material self-insurance programs and arrangements relating to the business, assets, liabilities and operations of the Company and each of its Subsidiaries in effect on the date of this Agreement. Each insurance policy of the Company and each of its Subsidiaries is in full force and effect and the Company and each of its Subsidiaries are in compliance in all material respects with the terms thereof. Other than customary end of policy notifications from insurance carriers, between January&#160;1, 2025 and the date of this Agreement, neither the Company nor any of its Subsidiaries has received any written notice or other written communication regarding any actual or possible (a) cancellation or invalidation of any insurance policy or (b) refusal or denial of any coverage, reservation of rights or rejection of any material claim under any insurance policy. The Company and each of its Subsidiaries have provided timely written notice to the appropriate insurance carrier(s) of each Legal Proceeding that is currently pending against the Company or any of its Subsidiaries for which the Company or such Subsidiary has insurance coverage, and no such carrier has issued a denial of coverage or a reservation of rights with respect to any such Legal Proceeding or informed the Company or any of its Subsidiaries of its intent to do so. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS319"><!--Anchor--></a>3.19&#8194;<u>Real Estate</u>. Neither the Company nor any of its Subsidiaries owns, or has ever owned, any real property. <u>Section&#160;3.19</u> of the Company Disclosure Schedule sets forth a true, correct and complete list as of the date of this Agreement of all real properties with respect to which the Company or any of its Subsidiaries directly or indirectly holds a valid leasehold interest (including any subleases, licenses or sublicenses) as well as any other real estate that is in the possession of or leased, subleased or licensed by the Company or any of its Subsidiaries (the &#8220;<font style="font-weight: bold;">Company Leased Real Property</font>&#8221;), and a true, correct and complete list of all of the Company Leased Real Property under which any such real property is leased, subleased, licensed or otherwise possessed (the &#8220;<font style="font-weight: bold;">Company Real Estate Leases</font>&#8221;), each of which is in full force and effect, with no existing material default by the Company thereunder (or any act which, with notice or the passage of time, or both, could result in a material default under the Company Real Estate Leases). The Company&#8217;s or its applicable Subsidiary&#8217;s use, occupancy and operation of each such Company Leased Real Property conforms to all applicable Laws, and the Company or its applicable Subsidiary has exclusive possession of each such Company Leased Real Property and has not granted any use or occupancy rights to tenants, subtenants or licensees with respect to such Company Leased Real Property. Neither the Company nor any of its Subsidiaries has assigned, transferred, mortgaged, subleased or pledged (directly or indirectly) any interest in any of the Company Real </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-19<br></div></div></div>
<!--End Page 404-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 405-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg25"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Estate Leases. In addition, each of the Company and its applicable Subsidiary has a valid leasehold interest in (or a valid right to use and occupy) the Company Leased Real Property, free and clear of all Liens other than Permitted Liens. To the Company&#8217;s Knowledge, neither the whole nor any part of the Company Leased Real Property is subject to any pending suit for condemnation or other taking by any Governmental Entity, and no such condemnation or other taking is threatened or contemplated. The Company Leased Real Property comprises all of the real property used in, and is necessary for, the operation of the business of the Company and its Subsidiaries as currently conducted. Neither the Company nor any of its Subsidiaries has ever leased or operated at any real property other than the Company Leased Real Property. All structures and buildings on the Company Leased Real Property are adequately maintained and are in good operating condition and repair for the requirements of the business of the Company and its Subsidiaries as currently conducted. To the Company&#8217;s Knowledge, there is no pending or contemplated special assessment or reassessment of any parcel included in the Company Leased Real Property that would result in a material increase in the rent, additional rent or other sums and charges payable by the Company or its Subsidiaries. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS320"><!--Anchor--></a>3.20&#8194;<u>Registration Statement and Proxy Statement/Prospectus</u> . None of the information supplied or to be supplied by the Company in writing for inclusion or incorporation by reference in (a) the Registration Statement will, at the time the Registration Statement or any amendment or supplement thereto is declared effective under the Securities Act or at the time of the Parent Stockholders Meeting, contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading or (b) the Proxy Statement/Prospectus will, at the date the Proxy Statement/Prospectus or any amendment or supplement thereto is first mailed to Parent&#8217;s stockholders or at the time of the Parent Stockholders Meeting, contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they are made, not misleading in any material respect. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS321"><!--Anchor--></a>3.21&#8194;<u>Transactions with Affiliates</u>. Since January&#160;1, 2025, no event has occurred that would constitute a transaction between the Company and any of its Affiliates, directors, executive officers or beneficial owners of more than five percent of the outstanding equity securities of the Company that would be required to be disclosed pursuant to Item&#160;404 of Regulation S-K promulgated under the Securities Act if the Company were subject to such reporting requirements. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS322"><!--Anchor--></a>3.22&#8194;<u>Brokers and Finders</u>. Except for Wedbush Securities Inc., no broker, finder or investment banker is entitled to any brokerage fee, finder&#8217;s fee, opinion fee, success fee, transaction fee or other fee or commission in connection with the Contemplated Transactions based upon arrangements made by or on behalf of the Company or any of its Subsidiaries. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS323"><!--Anchor--></a>3.23&#8194;<u>Certain Business Practices</u>.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;None of the Company, any of its Subsidiaries or any of their respective directors, officers, employees or, to the Company&#8217;s Knowledge, agents or any other Person acting on their behalf has directly or indirectly made any bribes, rebates, payoffs, influence payments, kickbacks, or other unlawful payment, in the form of cash, gifts, or anything of value, or taken any other action or made or failed to make any other statement, in violation of Anti-Bribery Laws. Neither the Company nor any of its Subsidiaries nor any of their respective officers, employees or agents is or has been, in any capacity relating to the Company or such Subsidiary, the subject of any debarment or exclusionary claims, actions, proceedings, or, to the Company&#8217;s Knowledge, investigation by any Governmental Entity with respect to potential violations of Anti-Bribery Laws. None of the Company, any of its Subsidiaries or any of their respective principals (as defined at 48 C.F.R. 52.209-5(a)(2)) would be required to certify affirmatively to any element of the certification at 48 C.F.R. 52.209-5. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;None of the Company nor any of its Subsidiaries, nor any of their respective officers, directors or employees acting on their behalf, is currently, or has in the past five years been (i) a Sanctioned Person, (ii) organized or ordinarily resident in a Sanctioned Country, (iii) engaged in any unlawful dealings or transactions or entered into any agreement with or for the benefit of any Sanctioned Person or in any Sanctioned Country, (iv)&#160;engaging in any export, reexport, transfer or provision of any goods, software, technology, data or service without, or exceeding the scope of any licenses or authorizations under all applicable Ex-Im Laws or (v) otherwise in violation of applicable Sanctions Laws, Ex-Im Laws, or the anti-boycott laws administered by the U.S. Department of Commerce and the U.S. Department of Treasury&#8217;s Internal Revenue Service (collectively, &#8220;<font style="font-weight: bold;">Trade Control Laws</font>&#8221;). </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(c)&#8195;Neither the Company nor any of its Subsidiaries is, or is owned or controlled by, a Sanctioned Person, and to the Company&#8217;s Knowledge, no officer, manager, director or holder of shares, stocks, securities or other interest in the Company or its Subsidiaries is a Sanctioned Person. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(d)&#8195;Each of the Company and its Subsidiaries has obtained all authorizations, licenses, and other permits, consents, notices, waivers, and approvals as required by Trade Control Laws and is in compliance with the terms of all such authorizations, licenses, and other permits, consents, notices, waivers, and approvals. There are no active or pending internal or third-party (including Governmental Entity) investigations related to the Company&#8217;s or any of its Subsidiaries&#8217; compliance with Trade Control Laws. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS324"><!--Anchor--></a>3.24&#8194;<u>Ownership of Parent Common Stock</u>. Since January&#160;1, 2025, neither the Company nor any of its Subsidiaries has &#8220;owned&#8221; (as such term is defined in Section&#160;203(c) of the DGCL), directly or indirectly, any shares of Parent Common Stock or other securities convertible into, exchangeable into or exercisable for shares of Parent Common Stock. There are no voting trusts or other agreements or understandings to which the Company or any its Subsidiaries is a party with respect to the voting of the capital stock or other equity interest of Parent or any of its Subsidiaries. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-20<br></div></div></div>
<!--End Page 405-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 406-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg26"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;"><a name="tANXAA4"><!--Anchor--></a>ARTICLE&#160;IV <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Parent represents and warrants to the Company as set forth in the statements contained in this <u>Article&#160;IV</u> except as set forth (a) in the Parent SEC Documents filed with, or furnished to, the SEC on or after January&#160;1, 2025 and publicly available on the SEC&#8217;s Electronic Data Gathering Analysis and Retrieval system prior to the date of this Agreement (but (i) without giving effect to any amendment thereof filed with, or furnished to, the SEC on or after the date hereof and (ii) excluding any disclosures contained under the heading &#8220;Risk Factors&#8221; and any disclosure of risks included in any &#8220;forward-looking statements&#8221; disclaimer or in any other section to the extent they are forward-looking statements or cautionary, predictive or forward-looking in nature) or (b) in the disclosure letter delivered by Parent to the Company at or before the execution and delivery by Parent of this Agreement (the &#8220;<font style="font-weight: bold;">Parent Disclosure Schedule</font>&#8221;). The Parent Disclosure Schedule shall be arranged in numbered and lettered sections corresponding to the numbered and lettered sections contained in this <u>Article&#160;IV</u>, and the disclosure in any section of the Parent Disclosure Schedule shall be deemed to qualify other sections in this <u>Article&#160;IV</u> to the extent that it is reasonably apparent on the face of such disclosure that such disclosure also qualifies or applies to such other sections. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS41"><!--Anchor--></a>4.1&#8195;<u>Organizational Documents</u>. Parent has made available to the Company accurate and complete copies of the Organizational Documents of Parent, Merger Sub and each of Parent&#8217;s other Subsidiaries in effect as of the date of this Agreement. Neither Parent, nor Merger Sub nor any of Parent&#8217;s other Subsidiaries is in material breach or violation of its respective Organizational Documents. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS42"><!--Anchor--></a>4.2&#8195;<u>Due Organization; Subsidiaries</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;Parent is a corporation duly incorporated, validly existing and in good standing under the Laws of the State of Delaware, and has all necessary corporate power and authority: (i) to conduct its business in the manner in which its business is currently being conducted; (ii) to own or lease and use its property and assets in the manner in which its property and assets are currently owned or leased and used; and (iii) to perform its obligations under all Contracts by which it is bound, except where the failure to have such power or authority would not have a Parent Material Adverse Effect. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;Parent is duly licensed and qualified to do business and is in good standing (to the extent applicable in such jurisdiction), under the Laws of all jurisdictions where the nature of its business requires such licensing or qualification other than in jurisdictions where the failure to be so qualified would not have a Parent Material Adverse Effect. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(c)&#8195;Each of Parent&#8217;s Subsidiaries is identified in <u>Section&#160;4.2(c)</u> of the Parent Disclosure Schedule; and neither Parent nor any of the entities identified in <u>Section&#160;4.2(c)</u> of the Parent Disclosure Schedule owns any capital stock of, or any equity, ownership or profit sharing interest of any nature in, or controls directly or indirectly, any other entity other than the entities identified in <u>Section&#160;4.2(c)</u> of the Parent Disclosure Schedule.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(d)&#8195;Each of Parent&#8217;s Subsidiaries is a corporation or other legal entity duly organized, validly existing and, if applicable, in good standing under the Laws of the jurisdiction of its organization and has all necessary corporate or other power and authority to conduct its business in the manner in which its business is currently being conducted and to own or lease and use its property and assets in the manner in which its property and assets are currently owned or leased and used, except where the failure to have such power or authority would not have a Parent Material Adverse Effect. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(e)&#8195;Neither Parent nor any of its Subsidiaries is or has otherwise been, directly or indirectly, a party to, member of or participant in any partnership, joint venture or similar business entity. Neither Parent nor any of its Subsidiaries has agreed or is obligated to make or is bound by any Contract under which it may become obligated to make, any future investment in or capital contribution to any other entity. Neither Parent nor any of its Subsidiaries has, at any time, been a general partner of, or has otherwise been liable for any of the debts or other obligations of, any general partnership, limited partnership or other entity. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(f)&#8195;All of the outstanding shares of capital stock or equivalent equity interests of each Subsidiary of Parent are owned of record and beneficially, directly or indirectly, by Parent free and clear of all material liens, pledges, security interests or other encumbrances. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS43"><!--Anchor--></a>4.3&#8195;<u>Capitalization</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;The authorized capital stock of Parent as of the date of this Agreement consists of (i) 600,000,000 shares of common stock, par value $0.001 per share (the &#8220;<font style="font-weight: bold;">Parent Common Stock</font>&#8221;), of which 391,462,923 shares have been issued and are outstanding as of the close of business on the Reference Date and (ii) 10,000,000 shares of preferred stock, par value $0.001 per share, of which no shares have been issued and are outstanding as of the close of business on the Reference Date. After giving effect to the Parent Charter Amendment, Parent has authorized a sufficient number of shares of Parent Common Stock to issue the Merger Consideration. Parent does not hold any shares of its capital stock in its treasury. From the close of business on the Reference Date to the date of this Agreement, Parent has not issued any shares of its capital stock other than the issuance of shares of Parent Common Stock upon the exercise of Parent Equity Awards, Parent ESPP Options or Parent Warrants, in each case that were outstanding as of the close of business on the Reference Date in accordance with the terms thereof. There are no accrued and unpaid dividends with respect to any outstanding shares of capital stock of Parent or any of its Subsidiaries. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;<u>Section&#160;4.3(b)</u> of the Parent Disclosure Schedule lists, as of the Reference Date, (i) each holder of issued and outstanding Parent Warrants, (ii) the number and type of shares subject to each Parent Warrant, (iii) the exercise price of each Parent Warrant, and (iv) the termination date of each Parent Warrant. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(c)&#8195;All of the outstanding shares of Parent Common Stock have been duly authorized and validly issued and are fully paid and nonassessable. None of the outstanding shares of Parent Common Stock is entitled or subject to any preemptive right, right of participation, right of maintenance or any similar right and none of the outstanding shares of Parent Common Stock is subject to any right of first refusal in favor of Parent. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-21<br></div></div></div>
<!--End Page 406-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 407-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg27"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The shares of Parent Common Stock issuable as Merger Consideration will be, when issued, duly authorized and validly issued and fully paid and nonassessable, and not subject to, or issued in violation of, any preemptive right, right of participation, right of maintenance, right of first refusal or any similar right. Except as contemplated herein, there is no Parent Contract relating to the voting or registration of, or restricting any Person from purchasing, selling, pledging or otherwise disposing of (or granting any option or similar right with respect to), any shares of Parent Common Stock. There is no Parent Contract pursuant to which Parent or any of its Subsidiaries may become obligated to repurchase, redeem or otherwise acquire any outstanding shares of Parent Common Stock or other securities. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(d)&#8195;Except for (i) Parent&#8217;s 2011 Equity Incentive Plan, Parent&#8217;s 2022 Inducement Incentive Plan, Parent&#8217;s 2017 Inducement Incentive Plan, and the SomaLogic Equity Plans, in each case, as amended (collectively, the &#8220;<font style="font-weight: bold;">Parent Equity Plans</font>&#8221;) and the award agreements thereunder, and (ii) Parent&#8217;s 2017 Employee Stock Purchase Plan, as amended (the &#8220;<font style="font-weight: bold;">Parent ESPP</font>&#8221;), Parent does not have any stock option plan or any other plan, program, agreement or arrangement providing for any equity-based compensation for any Person. As of the close of business on the Reference Date, (A) 66,598,611 shares of Parent Common Stock were authorized for issuance under the Parent Equity Plans, of which 32,020,617 shares of Parent Common Stock were subject to issuance upon the exercise of Parent Options, 18,687,069 shares of Parent Common Stock were issuable upon settlement of Parent RSUs, and 15,890,925 shares of Parent Common Stock remained available for future issuance pursuant to the Parent Equity Plans, and (B) 285,087 shares of Parent Common Stock remained available for future issuance pursuant to the Parent ESPP. <u>Section&#160;4.3(d)</u> of the Parent Disclosure Schedule sets forth a true, correct and complete list, as of the Reference Date, with respect to each Parent Equity Award of (i) the name of the holder of such Parent Equity Award (or if not permitted under applicable Data Protection Regulations, the grant ID); (ii) the number of shares of Parent Common Stock subject to such Parent Equity Award; (iii) the Parent Equity Plan under which such Parent Equity Award was granted; (iv) the grant or issuance date of such Parent Equity Award; (v) the applicable vesting schedule of such Parent Equity Award; and (vi) if such Parent Equity Award is a Parent Option, the exercise price and the expiration date of such Parent Option and whether such Parent Option is intended to be an &#8220;incentive stock option&#8221; as defined in Section&#160;422 of the Code. After giving effect to the Parent Charter Amendment, Parent has authorized, subject to approval by Parent&#8217;s stockholders, a sufficient number of shares of Parent Common Stock issuable upon the exercise of Company Options to be assumed by Parent pursuant to <u>Section&#160;2.3(a)</u> as of the Effective Time. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(e)&#8195;Except for the Parent Equity Awards, Parent ESPP Options, and the Parent Warrants, there is no (i) outstanding subscription, option, call, warrant or right (whether or not currently exercisable) to acquire any shares of the capital stock or other securities of Parent or any of its Subsidiaries, (ii) outstanding security, instrument or obligation that is or may become convertible into or exchangeable for any shares of the capital stock or other securities of Parent or any of its Subsidiaries or (iii) condition or circumstance that would be reasonably likely to give rise to or provide a basis for the assertion of a claim by any Person to the effect that such Person is entitled to acquire or receive any shares of capital stock or other securities of Parent or any of its Subsidiaries. There are no outstanding or authorized stock appreciation, phantom stock, profit participation or other similar rights (including any rights that are linked in any way to the price or value of the capital stock or other securities) with respect to Parent or any of its Subsidiaries. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(f)&#8195;All outstanding shares of Parent Common Stock, the Parent Equity Awards, the Parent Warrants and other securities of Parent have been issued and granted in material compliance with (i) all applicable securities Laws and other applicable Laws, (ii) the Organizational Documents of Parent and (iii) all requirements set forth in applicable Contracts. No Parent Options have an exercise price that has been less than the fair market value of the underlying stock as of the date such Parent Option was granted or has any feature for the deferral of compensation that could render the grant subject to Section 409A of the Code. Each Parent Option characterized by Parent as an &#8220;incentive stock option&#8221; within the meaning of Section&#160;422 of the Code was granted in compliance with all of the applicable requirements of Section&#160;422 of the Code. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS44"><!--Anchor--></a>4.4&#8195;<u>Authority; Binding Nature of Agreement; Required Vote</u> </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;Each of Parent and Merger Sub has all requisite corporate power and authority to execute and deliver this Agreement, to perform its obligations hereunder and, subject, with respect to Parent, to receipt of the Parent Stockholder Approval, and with respect to Merger Sub, the adoption of this Agreement by Parent in its capacity as sole stockholder of Merger Sub, to consummate the Contemplated Transactions.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;At a meeting duly called and held, the Special Committee has unanimously (i) determined that the Contemplated Transactions are advisable, fair to and in the best interests of Parent and its stockholders, (ii) approved and declared advisable this Agreement, the Contemplated Transactions and recommend that the Parent Board approve and declare advisable the Contemplated Transactions and (iii) recommended that the Parent Board resolve to make the Parent Board Recommendation. The Parent Board, acting upon the recommendation of the Special Committee at a meeting duly called, has (i) determined that the Contemplated Transactions are advisable, fair to and in the best interests of Parent and its stockholders, (ii) approved and declared advisable this Agreement and the Contemplated Transactions and (iii) resolved to make the Parent Board Recommendation. As of the date of this Agreement, such resolutions have not been amended or withdrawn. This Agreement has been duly executed and delivered by Parent and Merger Sub and, assuming the due authorization, execution and delivery by the Company, constitutes the legal, valid and binding obligation of Parent and Merger Sub, enforceable against each of Parent and Merger Sub in accordance with its terms, except, in each case, as enforcement may be limited by the Enforceability Exceptions. Prior to the execution of the Parent Voting Agreement, the Parent Board approved the Parent Voting Agreement and the transactions contemplated thereby. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(c)&#8195;Except for (i) the approval of the Parent Share Issuance, by the affirmative vote of a majority of the voting power of the shares of Parent&#8217;s capital stock present in person or represented by proxy at the Parent Stockholder Meeting and entitled to vote on such matter, (ii) the approval of the Parent Charter Amendment and the Parent Reverse Stock Split by the affirmative vote of the holders of Parent&#8217;s capital stock entitled to vote thereon, voting as a single class, by a majority of the votes cast for or against such matter (such approvals set forth in (i) and (ii), collectively, the </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-22<br></div></div></div>
<!--End Page 407-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 408-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg28"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Parent Stockholder Approval</font>&#8221;) and (iii) the approval of the Post-Closing Equity Incentive Plan and Post-Closing ESPP by the affirmative vote of a majority of the voting power of the shares of Parent&#8217;s capital stock present in person or represented by proxy at the Parent Stockholders Meeting and entitled to vote thereon, no other corporate proceedings on the part of the Parent stockholders are necessary to authorize, adopt or approve, as applicable, this Agreement or the Contemplated Transactions. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS45"><!--Anchor--></a>4.5&#8195;<u>Non-Contravention; Consents</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;Subject to (i) obtaining the Parent Stockholder Approval, (ii) the filing of the Certificate of Merger required by the DGCL, (iii) (A)&#160;the filing with the SEC of the Proxy Statement/Prospectus in definitive form, (B) the filing with the SEC, and declaration of effectiveness under the Securities Act of the Registration Statement and (C) the filing with the SEC of such reports and other filings under, and such other compliance with, the Exchange Act and the Securities Act, and the rules and regulations thereunder, as may be required in connection with this Agreement, and the Contemplated Transactions, (iv) such Consents, registrations, declarations, notices or filings as are required to be made or obtained under the securities or &#8220;blue sky&#8221; laws of various states in connection with the issuance of the shares of Parent Common Stock to be issued as the Merger Consideration, (v) such filings with and approvals of Nasdaq as are required to permit the consummation of the Merger and the listing of the shares of Parent Common Stock to be issued as the Merger Consideration and (vi) any applicable requirements of the HSR Act or any foreign Antitrust Laws, neither (x) the execution, delivery or performance of this Agreement by Parent nor (y) the consummation by Parent of the Contemplated Transactions, will (with or without notice or lapse of time): </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 30pt; text-indent: 30pt; text-align: left;">(i)&#8195;result in a violation or breach of any of the provisions of the Organizational Documents of Parent or any of its Subsidiaries; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(ii)&#8195;result in a violation or breach of, or give any Governmental Entity the right to exercise any remedy or obtain any relief under, any Law or any order, writ, injunction, judgment or decree to which Parent or any of its Subsidiaries, or any of the assets owned by Parent or any of its Subsidiaries, is subject; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(iii)&#8195;result in a violation or breach of any of the terms or requirements of, or give any Governmental Entity the right to revoke, withdraw, suspend, cancel, terminate or modify, any Governmental Authorization that is held by Parent or any of its Subsidiaries; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(iv)&#8195;result in a violation or breach of, or result in a default under, any provision of any Parent Material Contract, or give any Person the right to: (A) declare a default or exercise any remedy under any Parent Material Contract; (B) any material payment, rebate, chargeback, penalty or change in delivery schedule under any Parent Material Contract; (C) accelerate the maturity or performance of any Parent Material Contract; or (D) cancel, terminate or modify any term of any Parent Material Contract; or </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(v)&#8195;result in the imposition or creation of any Lien upon or with respect to any asset owned or used by Parent or any of its Subsidiaries (except for Permitted Liens); </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;Except for (i) the filing of the Certificate of Merger with the Secretary of State of the State of Delaware pursuant to the DGCL, (ii)&#160;(A)&#160;the filing with the SEC of the Proxy Statement/Prospectus in definitive form, (B) the filing with the SEC, and declaration of effectiveness under the Securities Act of the Registration Statement, and (C) the filing with the SEC of such reports and other filings under, and such other compliance with, the Exchange Act and the Securities Act, and the rules and regulations thereunder, as may be required in connection with this Agreement, and the Contemplated Transactions, (iii) such Consents, registrations, declarations, notices or filings as are required to be made or obtained under the securities or &#8220;blue sky&#8221; laws of various states in connection with the issuance of the shares of Parent Common Stock to be issued as the Merger Consideration, (iv) such filings with and approvals of Nasdaq as are required to permit the consummation of the Merger and the listing of the shares of Parent Common Stock to be issued as the Merger Consideration, (v) any applicable requirements of the HSR Act or any foreign Antitrust Laws, and (vi) such consents, waivers, approvals, orders, authorizations, registrations, declarations and filings as may be required under applicable federal and state securities Laws, neither Parent nor any of its Subsidiaries is or will be required to make any filing with or give any notice to, or to obtain any Consent from, any Governmental Entity in connection with (x) the execution, delivery or performance by Parent of this Agreement, or (y) the consummation by Parent of the Contemplated Transactions, which if individually or in the aggregate were not given or obtained, would reasonably be expected to prevent or materially delay the ability of Parent to consummate the Contemplated Transactions or that would have a Parent Material Adverse Effect.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(c)&#8195;The Parent Board and the board of directors of Merger Sub have taken and will take all actions necessary to ensure that the restrictions applicable to business combinations contained in Section&#160;203 of the DGCL are, and will be, inapplicable to the execution, delivery and performance of this Agreement and the Parent Voting Agreement and to the consummation of the Contemplated Transactions. To Parent&#8217;s Knowledge, no other takeover statute or similar Law applies or purports to apply to the Merger, this Agreement, the Parent Voting Agreement or any of the Contemplated Transactions. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS46"><!--Anchor--></a>4.6&#8195;<u>SEC Documents; Financial Statements</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;Other than such documents that can be obtained on the SEC&#8217;s website at www.sec.gov, Parent has made available to the Company accurate copies of all registration statements, proxy statements, Parent Certifications (as defined below) and other statements, reports, schedules, forms and other documents filed by Parent with the SEC after the date that is 12 months prior to the date hereof (the &#8220;<font style="font-weight: bold;">Parent SEC Documents</font>&#8221;). Since the date 12 months prior to the date hereof, all material statements, reports, schedules, forms and other documents required to have been filed by Parent with the SEC have been so filed on a timely basis. As of the time it was filed with the SEC (or, if amended or superseded by a filing prior to the date of this Agreement, then on the date of such filing), each of the Parent SEC Documents complied in all material respects with the applicable requirements of the Securities Act or the Exchange Act (as the case may be) and, as of the time they were filed, none of the Parent SEC Documents contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-23<br></div></div></div>
<!--End Page 408-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 409-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg29"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">statements therein, in light of the circumstances under which they were made, not misleading (or, in the case of a Parent SEC Document that is a registration statement, as amended or supplemented, if applicable, filed pursuant to the Securities Act, as of the date such registration statement or amendment became effective, contained any untrue statement of a material fact or omitted to state any material fact required to be stated therein or necessary to make the statements made therein not misleading); <u>provided</u> that no representation is made as to the accuracy of any financial projections or forward-looking statements or the completeness of any information furnished by Parent to the SEC solely for the purposes of complying with Regulation FD promulgated under the Exchange Act. The certifications and statements required by Rule&#160;13a-14 under the Exchange Act and 18 U.S.C. &#167;1350 (Section&#160;906 of the Sarbanes-Oxley Act) relating to the Parent SEC Documents (collectively, the &#8220;<font style="font-weight: bold;">Parent Certifications</font>&#8221;) are accurate and complete in all material respects and comply as to form and content in all material respects with all applicable Laws. As used in this <u>Section&#160;4.6</u>, the term &#8220;file&#8221; and variations thereof shall be broadly construed to include any manner in which a document or information is furnished, supplied or otherwise made available to the SEC. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;The financial statements (including any related notes) contained or incorporated by reference in the Parent SEC Documents (i)&#160;complied as to form in all material respects with the published rules and regulations of the SEC applicable thereto, (ii) were prepared in accordance with GAAP (except as may be indicated in the notes to such financial statements or, in the case of unaudited financial statements, except as permitted by the SEC on Form&#160;10-Q under the Exchange Act, and except that the unaudited financial statements may not contain footnotes and are subject to normal and recurring year-end adjustments) applied on a consistent basis unless otherwise noted therein throughout the periods indicated and (iii)&#160;fairly present, in all material respects, the financial position of Parent and its consolidated Subsidiaries as of the respective dates thereof and the results of operations and cash flows of Parent and its consolidated Subsidiaries for the periods covered thereby. Other than as expressly disclosed in the Parent SEC Documents filed between January&#160;1, 2025 and the date of this Agreement there has been no material change in Parent&#8217;s accounting methods or principles that would be required to be disclosed in Parent&#8217;s financial statements in accordance with GAAP. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(c)&#8195;As of the date of this Agreement, Parent is in compliance in all material respects with the applicable current listing and governance rules and regulations of Nasdaq. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(d)&#8195;Parent maintains a system of internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP and to provide reasonable assurance (i) that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, (ii) that receipts and expenditures are made only in accordance with authorizations of management and the Parent Board and (iii) regarding prevention or timely detection of the unauthorized acquisition, use or disposition of Parent&#8217;s assets that could have a material effect on Parent&#8217;s financial statements. Parent has evaluated the effectiveness of Parent&#8217;s system of internal control over financial reporting as of March&#160;31, 2026, and, to the extent required by applicable Law, presented in any applicable Parent SEC Document that is a report on Form&#160;10-K or Form&#160;10-Q (or any amendment thereto) its conclusions about the effectiveness of the internal control over financial reporting as of the end of the period covered by such report or amendment based on such evaluation. Parent has disclosed, based on its most recent evaluation of internal control over financial reporting, to Parent&#8217;s auditors and audit committee (and made available to the Company a summary of the significant aspects of such disclosure) (A) all significant deficiencies, if any, in the design or operation of internal control over financial reporting that are reasonably likely to adversely affect Parent&#8217;s ability to record, process, summarize and report financial information and (B) any known fraud that involves management or other employees who have a significant role in Parent&#8217;s internal control over financial reporting. Parent has not identified, based on its most recent evaluation of internal control over financial reporting, any material weaknesses in the design or operation of Parent&#8217;s internal control over financial reporting. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(e)&#8195;Parent maintains &#8220;disclosure controls and procedures&#8221; (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) that are reasonably designed to ensure that information required to be disclosed by Parent in the periodic reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the required time periods, and that all such information is accumulated and communicated to Parent&#8217;s management as appropriate to allow timely decisions regarding required disclosure and to make the Parent Certifications. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(f)&#8195;As of May&#160;29, 2026, Parent&#8217;s cash, cash equivalents and marketable securities, as determined in accordance with GAAP and in a manner consistent with the preparation of the Parent Balance Sheet, are not less than $543,793,566. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(g)&#8195;<u>Section&#160;4.6(g)</u> of the Parent Disclosure Schedule sets forth, as of April&#160;30, 2026, an aging schedule of all accounts payable and accounts receivable of Parent and its Subsidiaries, which schedule is, to the Knowledge of Parent, complete and accurate. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(h)&#8195;A good faith estimate of Parent Net Cash, including each component thereof, as of the date of this Agreement, is set forth in <u>Section&#160;4.6(h)</u> of the Parent Disclosure Schedule. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS47"><!--Anchor--></a>4.7&#8195;<u>Absence of Changes</u>.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;Except as expressly contemplated or permitted by or in connection with the execution and delivery of this Agreement, between the date of Parent&#8217;s latest consolidated unaudited balance sheet (the &#8220;<font style="font-weight: bold;">Parent Balance Sheet</font>&#8221;) and the date of this Agreement, (i) Parent has conducted its business in the Ordinary Course of Business in all material respects (except for the execution and performance of this Agreement and the discussions, negotiations and transactions related thereto, including the Contemplated Transactions) and (ii) there has not occurred any action, event or occurrence that would have required the consent of the Company pursuant to <u>Sections 5.1(b)(vii)</u>, <u>5.1(b)(ix)</u>, <u>5.1(b)(xi)</u>, <u>5.1(b)(xii)</u>, <u>5.1(b)(xiv)</u>, <u>5.1(b)(xv)</u>, <u>5.1(b)(xix)</u>, <u>5.1(b)(xxiii)</u>, <u>5.1(b)(xxiv)</u> and, to the extent relating to the foregoing, <u>Section&#160;</u><u>5.1(b)(xxvi</u>), had such action, event or occurrence taken place after the execution and delivery of this Agreement.</div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-24<br></div></div></div>
<!--End Page 409-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 410-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg30"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;Since December&#160;31, 2025, there has not been any Parent Material Adverse Effect (disregarding for purposes of this <u>Section&#160;4.7(b)</u> clause (2) of the definition thereof). </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS48"><!--Anchor--></a>4.8&#8195;<u>Absence of Undisclosed Liabilities</u>. Neither Parent nor any of its Subsidiaries has any liability, debt or obligation, individually or in the aggregate, of a type required to be recorded or reflected on Parent&#8217;s balance sheet or disclosed in the footnotes thereto under GAAP except for liabilities, debts or obligations (a) disclosed, reflected or reserved against in the Parent Balance Sheet or disclosed in the notes thereto included in the Parent SEC Documents as so required by GAAP, (b) that have been incurred by Parent or any of its Subsidiaries since the date of the Parent Balance Sheet in the Ordinary Course of Business (none of which are liabilities or obligations directly or indirectly related to a breach of Contract, breach of warranty, tort, infringement, Legal Proceeding or violation of, or non-compliance with, Law), (c) for performance of obligations of Parent or any of its Subsidiaries under the Contracts which have not resulted from a breach of such Contracts, breach of warranty, tort, infringement or violation of Law, or (d) incurred in connection with the Contemplated Transactions. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS49"><!--Anchor--></a>4.9&#8195;<u>Title to Assets</u>. Parent and each of its Subsidiaries owns, and has good and valid title to, or, in the case of leased properties and assets, valid leasehold interests in, all material tangible properties or material tangible assets and material equipment used or held for use in its business or operations or purported to be owned by it, including: (a) all material tangible assets reflected on the Parent Balance Sheet; and (b) all other material tangible assets reflected in the books and records of Parent or any of its Subsidiaries as being owned by Parent or such Subsidiary. All of such assets are owned or, in the case of leased assets, leased by Parent or its applicable Subsidiary free and clear of any Liens, other than Permitted Liens. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS410"><!--Anchor--></a>4.10&#8194;<u>Legal Proceedings; Orders</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;As of the date of this Agreement, there is no pending material Legal Proceeding and no Person has threatened in writing to commence any material Legal Proceeding: (i) that involves (A) Parent, (B) any of its Subsidiaries, (C) any Parent Associate (in his or her capacity as such) or (D) any of the material assets owned or used by Parent or any of its Subsidiaries; and (ii) that challenges, or that may have the effect of preventing, delaying, making illegal or otherwise interfering with, the Contemplated Transactions. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;Between January&#160;1, 2025 and the date of this Agreement, no Legal Proceeding has been pending against Parent or any of its Subsidiaries that resulted, or could reasonably be expected to result, in any liability that is material to Parent and its Subsidiaries, taken as a whole. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(c)&#8195;As of the date of this Agreement, there is no material order, writ, injunction, judgment or decree to which Parent or any of its Subsidiaries, or any of the material assets owned or used by Parent or any of its Subsidiaries, is subject; <u>provided</u> that to the extent any such representations or warranties in this sentence pertain to any order, writ, injunction, judgment or decree that relates to the execution, delivery, performance or consummation of this Agreement or any of the Contemplated Transactions, such representations and warranties are made only as of the date of this Agreement. To Parent&#8217;s Knowledge, no officer or employee of Parent or any of its Subsidiaries is subject to any unsatisfied order, writ, injunction, judgment or decree that prohibits such officer or employee from engaging in or continuing any conduct, activity or practice relating to the business of Parent or any of its Subsidiaries or to any material assets owned or used by Parent or any of its Subsidiaries. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS411"><!--Anchor--></a>4.11&#8194;<u>Contracts</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;<u>Section&#160;4.11(a)</u> of the Parent Disclosure Schedule sets forth a true, correct and complete list, as of the date of this Agreement, of all Parent Contracts, entered into prior to or on the date of this Agreement, in the following categories (other than any Parent Benefit Plan, any purchase order or work order issued pursuant to the terms of a Parent Contract disclosed on <u>Section&#160;4.11(a)</u> of the Parent Disclosure Schedule, any quality agreement, any business associate agreement, any data processing addenda and any confidentiality agreement) (each such Parent Contract, whether or not set forth on <u>Section&#160;4.11(a)</u> of the Parent Disclosure Schedule and including, for purposes of <u>Section&#160;4.11(b)</u> and <u>Section&#160;5.1(b)(xv)</u>, those entered into after the date of this Agreement, a &#8220;<font style="font-weight: bold;">Parent Material Contract</font>&#8221;): </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 30pt; text-indent: 30pt; text-align: left;">(i)&#8195;each material contract as defined in Item&#160;601(b)(10) of Regulation S-K as promulgated under the Securities Act; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(ii)&#8195;each Contract containing (A) any provision limiting the freedom of Parent or any of its Subsidiaries or, at or after the Effective Time, the Company or any of its Affiliates, to engage in any line of business, development program, therapeutic area or geographic area or with any Person or compete with any Person, other than any covenant not to solicit any employee, customer, or consultant entered into in the Ordinary Course of Business, (B) any &#8220;most-favored nations&#8221; obligation or similar provision (including with respect to pricing) restricting Parent or any of its Subsidiaries or, at or after the Effective Time, the Company or any of its Affiliates, (C) any exclusivity obligation on Parent or any of its Subsidiaries or, at or after the Effective Time, the Company or any of its Affiliates or (D) an obligation for Parent or any of its Subsidiaries to purchase a minimum quantity of goods or services or to purchase all or substantially all of a certain type of good or service from a single vendor and its Affiliates in any geographic area or contains a &#8220;take or pay&#8221; provision, other than, in the cases of clauses (A) and (C) above, any confidentiality or non-use provisions in Contracts entered into in the Ordinary Course of Business, which are not material to the business of or operations of Parent and its Subsidiaries, taken as a whole; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(iii)&#8195;each Contract that governs the formation, creation, governance, economics or control of any joint venture, legal partnership or other similar arrangement, other than with respect to any Contract solely between or among Parent and any of its Subsidiaries; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(iv)&#8195;each Contract relating to capital expenditures and requiring payments after the date of this Agreement in excess of $150,000&#160;pursuant to its express terms and not cancelable without penalty; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(v)&#8195;each Contract relating to the disposition or acquisition of material assets or any ownership interest in any entity (whether by merger, sale of stock, sale of assets or otherwise); </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-25<br></div></div></div>
<!--End Page 410-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 411-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg31"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(vi)&#8195;each Contract providing for the creation of any mortgages, indentures, loans, notes or credit agreements, security agreements or other agreements or instruments providing for the creation of material Indebtedness of Parent or any of its Subsidiaries or creating any Liens, other than Permitted Liens or Contracts required to be disclosed on <u>Section&#160;4.11(a)(vii)</u> of the Parent Disclosure Schedule, with respect to any material assets of Parent or any of its Subsidiaries; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 30pt; text-indent: 30pt; text-align: left;">(vii)&#8195;each Parent Real Estate Lease; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(viii)&#8195;each (A) to Parent&#8217;s Knowledge, Parent Out-bound License, (B) to Parent&#8217;s Knowledge, Parent In-bound License, (C)&#160;settlement, co-existence or other similar Contract that (I) involves the settlement of any pending or threatened Legal Proceeding and (II)&#160;either involves a payment obligation after the date of this Agreement in excess of $250,000 or grants a third party a license or right to use or restricts any Person from filing, registering, enforcing, disposing of or otherwise exploiting any Parent Owned IP or (D) Contract that includes any covenant, agreement, undertaking or commitment by the Parent or its Subsidiaries not to sue any other Person for infringement, misappropriation or other violation of any Parent IP or otherwise assert any Parent IP against any other Person; <u>provided</u> that the foregoing this subclause (D) shall not be construed to include license grants; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(ix)&#8195;each Contract pursuant to which Parent or any of its Subsidiaries has continuing milestone, royalty or similar contingent payment obligations, but not including any payments due for or upon completion of contracted services, including upon the achievement of development, regulatory or commercial milestones or obligation to pay any royalty, dividend, profit-sharing or similar payment based on the revenues or profits of Parent or any of its Subsidiaries, in each case, excluding indemnification and performance guarantee obligations provided for in the Ordinary Course of Business, any Contracts required to be disclosed on <u>Section&#160;4.11(a)(viii)</u> of the Parent Disclosure Schedule and any Parent In-bound Licenses that are terminable at will (with no penalty or payment); </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(x)&#8195;each Contract that is not terminable at will with no more than 90 days&#8217; prior notice (with no penalty or payment) by Parent or its Subsidiaries, as applicable, and which expressly provides for payment or receipt by Parent or any of its Subsidiaries after the date of this Agreement under any such Contract of more than $250,000; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(xi)&#8195;each collective bargaining agreement or other similar Contract with any labor organization, union, group or association covering employees of Parent or its Subsidiaries; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(xii)&#8195;the Illumina Agreement, and any other Contracts with Illumina or any of its Affiliates in connection with the transactions contemplated by the Illumina Agreement and any Contracts between Parent and any Subsidiaries sold as part of the Divested Business; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(xiii)&#8195;each Contract (A) providing for the payment of cash or any other compensation or benefits upon the consummation of the Merger, (B) restricting Parent&#8217;s ability to terminate the employment of any employee, thereof at any time for any lawful reason or for no reason without penalty, other than as required by applicable Law, (C) restricting Parent&#8217;s ability to terminate the services of any individual consultant or any individual independent contractor thereof at any time for any lawful reason or for no reason without penalty, other than any such Contract that is terminable upon no more than thirty (30) days&#8217; prior notice or (D) providing for severance or similar termination payments, retention or change in control payments, or for the acceleration of vesting or grant of any incentive equity or similar compensation; or </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(xiv)&#8195;each Contract pursuant to which any material research or development activities are conducted by the Parent or any of its Subsidiaries for a third party. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;Parent has made available to the Company true, correct and complete copies of all Parent Material Contracts, including all material amendments thereto, in each case in effect on the date of this Agreement but excluding any purchase orders, work orders, quality agreements, business associate agreements and data processing addenda incorporated therein. There are no Parent Material Contracts that are not in written form. None of Parent, any of its Subsidiaries or, to Parent&#8217;s Knowledge, any other party to a Parent Material Contract, has breached, violated or defaulted under, or received written notice that it breached, violated or defaulted under, any of the terms or conditions of, or Laws applicable to, any Parent Material Contract in such manner as would permit any other party to cancel or terminate any such Parent Material Contract, or would permit any other party to seek damages or pursue other legal remedies which would reasonably be expected to be material to Parent and its Subsidiaries, taken as a whole. As to Parent and its Subsidiaries, each Parent Material Contract is valid, binding, enforceable and in full force and effect, subject to the Enforceability Exceptions. No counterparty to a Parent Material Contract has notified Parent in writing (or, to Parent&#8217;s Knowledge, otherwise) that it intends to terminate or not renew a Parent Material Contract. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(c)&#8195;All Contracts relating to the &#8220;Business&#8221; as defined in the Illumina Agreement (herein referred to as the &#8220;<font style="font-weight: bold;">Divested Business</font>&#8221;) have been fully transferred to Illumina, Inc., an Affiliate thereof or an entity acquired by Illumina, Inc. or an Affiliate thereof pursuant to the Illumina Agreement or otherwise constitute liabilities or obligations related to the Business for which Parent is entitled to seek indemnification under Section&#160;9.2(b)(ii) of the Illumina Agreement. Except as set forth on <u>Section&#160;4.12(c)</u> of the Parent Disclosure Schedule, neither Parent nor any of its Subsidiaries has any obligations or liabilities to Illumina, Inc. or any of its Affiliates under the Illumina Agreement (including for a breach thereof). </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS412"><!--Anchor--></a>4.12&#8194;<u>Employee and Labor Matters; Benefits Plans</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;<u>Section&#160;4.12(a)</u> of Parent Disclosure Schedule sets forth a true, correct and complete list of all material Parent Benefit Plans in effect on the date of this Agreement, including each such Parent Benefit Plan that provides for retirement, change in control, stay or retention deferred compensation, incentive compensation, severance or retiree medical or life insurance benefits, but excluding (i) any employment agreement, offer letter, employment contract or consultancy agreement with a natural person that is in all material respects consistent with the standard form made available to the Company prior to the date of this Agreement and listed on <u>Section&#160;4.12(a)</u> of the Parent Disclosure Schedule, (ii) any individual equity </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-26<br></div></div></div>
<!--End Page 411-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 412-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg32"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">award agreement that is in all material respects consistent with the standard form made available to the Company prior to the date of this Agreement and listed on <u>Section&#160;4.12(a)</u> of the Parent Disclosure Schedule and (iii) any Parent Benefit Plans required to be maintained pursuant to applicable Laws that do not provide compensation or benefits in excess of those required by applicable Laws. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;As applicable with respect to each Parent Benefit Plan required to be listed on <u>Section&#160;4.12(a)</u> of the Parent Disclosure Schedule, Parent has made available to the Company true, correct and complete copies of (i) each Parent Benefit Plan, including all material amendments thereto, and in the case of an unwritten Parent Benefit Plan, a written description thereof, (ii) the current summary plan description and each summary of material modifications thereto, (iii) the most recently filed annual report with any Governmental Entity (e.g., Form&#160;5500 and all schedules thereto), (iv) the most recent determination, opinion or advisory letter from the IRS with respect to each Parent Benefit Plan intended to qualify under Section&#160;401(a) of the Code, (v) the most recent nondiscrimination testing report, (vi) all non-routine correspondence received from or provided to the DOL, the Pension Benefit Guaranty Corporation, the IRS or any other Governmental Entity between January&#160;1, 2025 and the date of this Agreement and (vii) all notices and filings concerning IRS or DOL or other Governmental Entity audits or investigations, including with respect to &#8220;prohibited transactions&#8221; within the meaning of Section&#160;406 of ERISA or Section 4975 of the Code, between January&#160;1, 2025 and the date of this Agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(c)&#8195;Each Parent Benefit Plan has been established, maintained, funded, operated and administered in compliance in all material respects with its terms and any related documents or agreements and the applicable provisions of ERISA, the Code and all other applicable Laws. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(d)&#8195;The Parent Benefit Plans that are &#8220;employee pension benefit plans&#8221; within the meaning of Section&#160;3(2) of ERISA and that are intended to meet the qualification requirements of Section&#160;401(a) of the Code have received determination or opinion letters from the IRS on which they may currently rely to the effect that such plans are qualified under Section&#160;401(a) of the Code and the related trusts are exempt from federal income Taxes under Section&#160;501(a) of the Code, respectively, or are covered by advisory or opinion letters with respect to a volume submitter or prototype plan, and, to Parent&#8217;s Knowledge, nothing has occurred that would reasonably be expected to materially adversely affect the qualification of such Parent Benefit Plan or the tax exempt status of the related trust. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(e)&#8195;None of Parent, any of its Subsidiaries or any Parent ERISA Affiliate has maintained, contributed to, been required to contribute to, or had any actual or contingent liability with respect to, (i) any &#8220;employee pension benefit plan&#8221; (within the meaning of Section&#160;3(2) of ERISA) that is subject to Title IV or Section&#160;302 of ERISA or Section&#160;412 of the Code, (ii) any &#8220;multiemployer plan&#8221; (within the meaning of Section&#160;3(37) of ERISA), (iii) any &#8220;multiple employer plan&#8221; (within the meaning of Section&#160;413 of the Code), (iv) any &#8220;multiple employer welfare arrangement&#8221; (within the meaning of Section&#160;3(40) of ERISA) or (v) any &#8220;voluntary employees beneficiary association&#8221; within the meaning of Section&#160;501(c)(9) of the Code. The obligations of all Parent Benefit Plans that provide health, welfare or similar insurance are fully insured by bona fide third-party insurers. No Parent Benefit Plan is maintained through a human resources or benefit outsourcing entity, professional employer organization or other similar provider. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(f)&#8195;As of the date of this Agreement, there are no pending audits or investigations by any Governmental Entity involving any Parent Benefit Plan, and no pending or, to Parent&#8217;s Knowledge, threatened claims (except for individual claims for benefits payable in the normal operation of the Parent Benefit Plans), suits or proceedings involving any Parent Benefit Plan, any fiduciary thereof or service provider thereto. Since January&#160;1, 2025, all material contributions and premium payments required to have been timely made under any of the Parent Benefit Plans or by applicable Law (without regard to any waivers granted under Section&#160;412 of the Code), have been timely made and neither Parent nor any of its Subsidiaries has any liability for any such unpaid contributions with respect to any Parent Benefit Plan, all benefits accrued under any unfunded Parent Benefit Plan have been paid, accrued or otherwise adequately reserved in accordance with GAAP, and all reports, returns and similar documents required to be filed with any Governmental Entity or distributed to any plan participant have been timely filed or distributed. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(g)&#8195;None of Parent or any of its Subsidiaries, or, to Parent&#8217;s Knowledge, any fiduciary, trustee or administrator of any Parent Benefit Plan, has engaged in, or in connection with the Contemplated Transactions will engage in, any transaction with respect to any Parent Benefit Plan which would subject any such Parent Benefit Plan, Parent or any of its Subsidiaries to a material Tax, penalty or liability for a &#8220;prohibited transaction&#8221; under Section&#160;406 of ERISA or Section&#160;4975 of the Code. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(h)&#8195;No Parent Benefit Plan provides death, medical, dental, vision, life insurance or other welfare benefits beyond termination of service or retirement, other than coverage mandated by Part&#160;B of Subtitle B of Title I of ERISA, Section&#160;4980B of the Code or any other Law at the participant or beneficiary&#8217;s sole expense or, as described in <u>Section&#160;4.12(h)</u> of the Parent Disclosure Schedule, as provided with respect to continuation health coverage as part of severance, and none of Parent or any of its Subsidiaries has any obligation to provide such insurance or benefits (whether under a Parent Benefit Plan or otherwise) nor has made a written or oral representation promising to provide such insurance or benefits. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(i)&#8195;For each Parent Benefit Plan that is a group health plan under Section&#160;733(a)(1) of ERISA, Parent has complied in all material respects with the Patient Protection and Affordable Care Act, including PPACA, and COBRA. Neither Parent nor any of its Subsidiaries has failed to comply in all material respects with ERISA Sections 601 to 608 and Code Section&#160;4980B and Parent has, for any relevant period, offered the requisite number of &#8220;full-time employees&#8221; group health coverage that is &#8220;affordable&#8221; and of &#8220;minimum value&#8221; (as such terms are defined by the employer shared responsibility provisions of PPACA). Parent has not incurred (whether or not assessed), or is not reasonably expected to incur or to be subject to, any Tax, penalty or other liability that may be imposed under PPACA or Sections 4980B, 4980D, 4980H, 6721 or 6722&#160;of the Code or with respect to any requirement to timely file PPACA information returns with the IRS or provide statements to participants under Section&#160;6056 or 6055 of the Code or state law requirements as applicable, or pursuant to Sections 4976 through 4980 of the Code or Title I of ERISA with respect to any of Parent Benefit Plans. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(j)&#8195;Except as otherwise contemplated under this Agreement or as set forth on <u>Section&#160;4.12(j)</u> of the Parent Disclosure Schedule, neither the execution of this Agreement nor the consummation of the Contemplated Transactions will either alone or in connection with any other event(s) </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-27<br></div></div></div>
<!--End Page 412-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 413-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg33"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">(i)&#160;result in any payment (whether of severance pay or otherwise) becoming due to or forgiveness of indebtedness for any Parent Associate, (ii)&#160;increase any amount of compensation or benefits otherwise payable to any Parent Associate, (iii) result in the acceleration of the time of payment, funding or vesting of any benefits under any Parent Benefit Plan, (iv) require any contribution or payment to fund any obligation under any Parent Benefit Plan or (v) limit the right to merge, amend or terminate any Parent Benefit Plan (or result in adverse consequences for so doing). </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(k)&#8195;All severance, retention or other payments required to be made by Parent or any of its Affiliates to any former Parent Associates providing services to the Divested Business (the &#8220;<font style="font-weight: bold;">Divested Business Employees</font>&#8221;) as of the date of and in connection with the transactions contemplated by the Illumina Agreement have been paid in full and Parent has no outstanding liabilities to or obligations to the Divested Business Employees. Parent has obtained valid and binding releases from all Divested Business Employees who received severance or other payments in connection with the transactions contemplated by the Illumina Agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(l)&#8195;Neither the execution of this Agreement nor the consummation of the Contemplated Transactions (either alone or when combined with the occurrence of any other event, including a termination of employment) will result in the receipt or retention (i) by any person who is a &#8220;disqualified individual&#8221; (within the meaning of Section&#160;280G of the Code) with respect to Parent and its Subsidiaries of any payment or benefit that is characterized as a &#8220;parachute payment&#8221; (within the meaning of Section&#160;280G of the Code), determined without regard to the application of Section&#160;280G(b)(5) of the Code or (ii) any amount the deduction for which would be disallowed under Section&#160;162(m) of the Code. All Parent Benefit Plans and other arrangements of the Parent or any Subsidiary are in material compliance with Section&#160;457A of the Code and no payments thereunder are subject to the penalties of Section&#160;457A of the Code. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(m)&#8195;Each Parent Benefit Plan providing for deferred compensation that constitutes a &#8220;nonqualified deferred compensation plan&#8221; (as defined in Section&#160;409A(d)(1) of the Code and the regulations promulgated thereunder) is, and has been, established, administered and maintained in material compliance in both form and operation with the requirements of Section&#160;409A of the Code and the regulations promulgated thereunder. Parent does not have any liability for nonreporting or underreporting of income subject to Section&#160;409A of the Code. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(n)&#8195;No Person has any &#8220;gross up&#8221; agreements with Parent or any of its Subsidiaries or other assurance of reimbursement by Parent or any of its Subsidiaries for any Taxes. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(o)&#8195;There are, and since January&#160;1, 2025 there have been, no actual, threatened or pending negotiations, strikes, labor disputes, work stoppages, requests for representation, pickets, work slow-downs due to labor disagreements or any proceedings or arbitrations that involve the labor or employment relations of Parent or any of its Subsidiaries. Neither Parent nor any of its Subsidiaries is a party to or bound by, or has a duty to bargain under, any collective bargaining agreement or other Contract with a labor union or labor organization representing any of its employees, and there is no labor union or labor organization representing or, to Parent&#8217;s Knowledge, purporting to represent or seeking to represent any employees of Parent or its Subsidiaries, including through the filing of a petition for representation election. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(p)&#8195;Parent and each of its Subsidiaries is, and since January&#160;1, 2025 has been, in material compliance with all applicable Laws respecting labor, employment, employment practices, and terms and conditions of employment, including worker classification, discrimination, wrongful termination, harassment and retaliation, equal employment opportunities, fair employment practices, meal and rest periods, immigration and I-9, reasonable accommodation, disability rights or benefits, child labor, working conditions, privacy, employee safety and health, wages (including overtime wages), unemployment and workers&#8217; compensation, leaves of absence, hours of work and orders, regulations, ordinances and guidelines by any Governmental Entity regarding COVID-19 (including any &#8220;stay at home&#8221; orders or other similar orders, regulations or guidelines). Except as would not be reasonably likely to result in a liability that is material to Parent and its Subsidiaries, taken as a whole, with respect to employees of Parent or any of its Subsidiaries, each of Parent and its Subsidiaries, since January&#160;1, 2025 (i) has withheld and reported all amounts required by Law or by agreement to be withheld and reported with respect to wages, salaries and other payments, benefits, or compensation to employees, (ii) is not liable for any arrears of wages (including overtime wages), premiums, commissions, paid time off, on-call payments, bonus, benefits, severance pay or any Taxes or any penalty for failure to comply with any of the foregoing, and (iii) is not liable for any payment to any trust or other fund governed by or maintained by or on behalf of any Governmental Entity, with respect to unemployment compensation benefits, disability, social security or other benefits or obligations for employees (other than routine payments to be made in the Ordinary Course of Business). As of the date of this Agreement, there are no actions, suits, claims, charges, demands, lawsuits, investigations, audits or administrative matters pending or, to Parent&#8217;s Knowledge, threatened or reasonably anticipated against Parent or any of its Subsidiaries or Parent Associates (in his or her capacity as such) relating to any current or former employee, applicant for employment, independent contractor, employment agreement or Parent Benefit Plan (other than routine claims for benefits). All U.S.-based employees of Parent and its Subsidiaries are employed &#8220;at-will&#8221; and their employment can be terminated without advance notice or payment of severance. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(q)&#8195;Except as would not be reasonably likely to result in a liability that is material to Parent and its Subsidiaries, taken as a whole, with respect to each individual since January&#160;1, 2025 who rendered services to Parent or any of its Subsidiaries, Parent and each of its Subsidiaries has accurately classified each such individual as an employee, independent contractor, or otherwise under all applicable Laws and, for each individual classified as an employee, Parent has accurately classified him or her as overtime eligible or overtime ineligible under all applicable Laws. Neither Parent nor any of its Subsidiaries has any material liability with respect to any misclassification of (i) any Person as an independent contractor rather than as an employee, (ii) any employee leased from another employer or (iii) any employee currently or formerly classified as exempt from overtime wages. No employees of Parent or any of its Subsidiaries are employed on a work visa or work permit. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(r)&#8195;There is not and has not been since January&#160;1, 2025, nor, to Parent&#8217;s Knowledge, is there or has there been since January&#160;1, 2025, any threat of, any strike, slowdown, work stoppage, lockout, union election petition, demand for recognition, or any similar activity or dispute, or, to </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-28<br></div></div></div>
<!--End Page 413-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 414-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg34"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Parent&#8217;s Knowledge, any union organizing activity, against Parent or any of its Subsidiaries. No event has occurred, and, to Parent&#8217;s Knowledge, no condition or circumstance exists, that would reasonably be expected directly or indirectly to give rise to or provide a basis for the commencement of any such strike, slowdown, work stoppage, lockout, union election petition, demand for recognition, or any similar activity or dispute. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(s)&#8195;No Parent Benefit Plan is or has been maintained outside the jurisdiction of the United States, or covers or covered any employee permanently residing or working outside the United States. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(t)&#8195;Since January&#160;1, 2025, neither Parent nor its Subsidiaries has caused (i) a plant closing as defined in the WARN Act affecting any single site of employment of Parent or any of its Subsidiaries or one or more operating units within any site of employment of Parent or any of its Subsidiaries or (ii) a mass layoff as defined in the WARN Act, nor has Parent or any of its Subsidiaries been affected by any transaction or engaged in layoffs or employment terminations sufficient in number to trigger application of any similar foreign, state or local Law. No employee of Parent or any of its Subsidiaries has suffered an employment loss, as defined in the WARN Act, within the 90-day period ending on the date of this Agreement. Since January&#160;1, 2025, neither Parent nor its Subsidiaries has implemented any material workplace changes such as layoffs, furloughs or permanent office closures. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(u)&#8195;No Legal Proceedings are as of the date of this Agreement open and pending (or between January&#160;1, 2025 and the date of this Agreement have been settled or otherwise closed) against Parent or any of its Subsidiaries with respect to the employment of, or failure to employ, any individual, including any brought with or by the Equal Employment Opportunity Commission, the Office of Federal Contract Compliance Programs, or other Governmental Entity regulating the employment or compensation of individuals (or, with respect to discrimination, unlawful harassment, retaliation, or similar wrongdoing, pursuant to internal complaint procedures), and no employee of Parent or any of its Subsidiaries has made, between January&#160;1, 2025 and the date of this Agreement, a written complaint of discrimination, unlawful harassment, retaliation, or other similar wrongdoing or, to Parent&#8217;s Knowledge, between January&#160;1, 2025 and the date of this Agreement, an oral complaint. Between January&#160;1, 2025 and the date of this Agreement, neither Parent nor any of its Subsidiaries has received any requests for, or conducted, an internal investigation of any Parent Associate with respect to any claims with respect to discrimination, unlawful harassment, retaliation, or other similar wrongdoing. Neither Parent nor any of its Subsidiaries is a party to any settlement agreement with a Parent Associate resolving allegations of sexual or other unlawful harassment, discrimination, or retaliation by any Parent Associate. Parent and its Subsidiaries have used reasonable best efforts to promptly, thoroughly and impartially investigate all employment discrimination, sexual or other unlawful harassment, and retaliation allegations of, or against, any employee in accordance with applicable Law. With respect to each such allegation with potential merit, the applicable employer has taken prompt corrective action reasonably calculated to prevent further discrimination and harassment or retaliation, and neither Parent nor any of its Subsidiaries reasonably expects to incur any material liability with respect to any such allegation. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(v)&#8195;<u>Section&#160;4.12(v)</u> of the Parent Disclosure Schedule sets forth a true, correct and complete list of all persons who are employees of Parent or any of its Subsidiaries as of the date of this Agreement, including any employee who is on a leave of absence of any nature, paid or unpaid, authorized or unauthorized, and sets forth for each such individual the following: (i) name (unless not permitted under applicable Data Protection Regulations), (ii) title or position (unless not permitted under applicable Data Protection Regulations) (including whether full or part time), (iii) hire date, (iv) annual base salary or hourly rate of pay, (v) commission, bonus or other incentive-based compensation opportunity for the current year, (vi)&#160;leave or layoff status, if applicable, (vii) classification as either exempt or non-exempt under the Fair Labor Standards Act and state and local wage and hour laws and (viii) city, state, and country of service. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(w)&#8195;<u>Section&#160;4.12(w)</u> of the Parent Disclosure Schedule sets forth a true, correct and complete list of each Person retained by Parent (and any Subsidiary thereof) as of the date of this Agreement as a consultant or independent contractor and further sets forth the following information with respect to each: (i) name (unless not permitted under applicable Data Protection Regulations), (ii) services provided, (iii) date of engagement, (iv) the entity or entities to which the individual provides services, (v) fees paid or payable to the individual, (vi) service location (including city, state and country), and (vii) any applicable termination fee provisions or notice provisions that require more than thirty (30) days&#8217; prior notice. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS413"><!--Anchor--></a>4.13&#8194;<u>Environmental Matters</u>. Parent and each of its Subsidiaries are, and have been since January&#160;1, 2025, in compliance in all material respects with all applicable Environmental Laws. Parent and each of its Subsidiaries have and maintain, in full force and effect, all Governmental Authorizations required under applicable Environmental Laws for the operation of their respective businesses or use of the Parent Leased Real Property and Parent and each of its Subsidiaries are in compliance in all material respects with the terms and conditions thereof. Neither Parent nor any of its Subsidiaries has received any written notice or other communication (in writing or otherwise), whether from a Governmental Entity or other Person, that alleges that Parent or any of its Subsidiaries (a) is not in material compliance with, or has material liability pursuant to, any Environmental Law, (b) has been identified as a potentially responsible party with respect to any contaminated site under any Environmental Law or (c) has generated, stored, treated, transported, disposed of or arranged for any other Person to transport or dispose of Hazardous Materials that have been found at any site at which a Governmental Entity or other Person has conducted or has been ordered to conduct a remedial investigation, removal or other response actions pursuant to Environmental Law. To Parent&#8217;s Knowledge, there are no underground storage tanks or other underground storage receptacles for Hazardous Materials present on any Parent Leased Real Property. To Parent&#8217;s Knowledge, there has been no release of or exposure to any Hazardous Materials at, on or under the Parent Leased Real Property. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS414"><!--Anchor--></a>4.14&#8194;<u>Taxes</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;Parent and each of its Subsidiaries have timely filed (taking into account all extensions of time to file that have been granted) all income Tax Returns and other material Tax Returns that they were required to file under applicable Law. All such Tax Returns are correct and complete </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-29<br></div></div></div>
<!--End Page 414-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 415-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg35"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">in all material respects and have been prepared in substantial compliance with all applicable Law. No written claim has ever been made prior to the date of this Agreement by any Governmental Entity in any jurisdiction where Parent or any of its Subsidiaries does not file a particular Tax Return or pay a particular Tax that Parent or such Subsidiary is subject to taxation by that jurisdiction. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;All income Taxes and any other material Taxes due and owing by Parent or any of its Subsidiaries on or before the date of this Agreement (whether or not shown on any Tax Return) have been fully paid. The unpaid Taxes of Parent and its Subsidiaries did not, as of the date of the Parent Balance Sheet, materially exceed the reserve for Tax liability (excluding any reserve for deferred Taxes established to reflect timing differences between book and Tax items) set forth on the face of the Parent Balance Sheet. Since the date of the Parent Balance Sheet, neither Parent nor any of its Subsidiaries has incurred any material Tax liability outside the Ordinary Course of Business or otherwise inconsistent with past custom and practice. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(c)&#8195;All material Taxes that Parent or any of its Subsidiaries are or were required by Law to withhold or collect have been duly and timely withheld or collected in all material respects on behalf of its respective employees, independent contractors, stockholders, lenders, customers or other third parties and have been timely paid to the proper Governmental Entity or other Person or properly set aside in accounts for this purpose. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-indent: 40pt; text-align: left;">(d)&#8195;There are no Liens for material Taxes (other than Permitted Liens) upon any of the assets of Parent or any of its Subsidiaries. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(e)&#8195;No outstanding deficiencies for income Taxes or any other material Taxes with respect to Parent or any of its Subsidiaries have been claimed, proposed or assessed by any Governmental Entity in writing. There are no pending or ongoing, nor, to Parent&#8217;s Knowledge, threatened audits, assessments or other actions for or relating to any liability in respect of a material amount of Taxes of Parent or any of its Subsidiaries. Neither Parent nor any of its Subsidiaries (nor any of their predecessors) has waived any statute of limitations in respect of any income Taxes or other material Taxes or agreed to any extension of time with respect to any income Tax or other material Tax assessment or deficiency, which waiver or extension is still in effect. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(f)&#8195;Neither Parent nor any of its Subsidiaries has been a United States real property holding corporation within the meaning of Section&#160;897(c)(2) of the Code during the applicable period specified in Section&#160;897(c)(1)(A)(ii) of the Code. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(g)&#8195;Neither Parent nor any of its Subsidiaries is a party to any material Tax allocation agreement, Tax sharing agreement, Tax indemnity agreement, or similar agreement or arrangement, other than commercial agreements entered into in the Ordinary Course of Business the principal subject matter of which is not the allocation of Taxes. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(h)&#8195;Neither Parent nor any of its Subsidiaries will be required to include any material item of income in, or exclude any material item of deduction from, taxable income for any Tax period (or portion thereof) ending after the Closing Date as a result of any (i) change in method of accounting for Tax purposes made on or prior to the Closing Date, (ii) use of an improper method of accounting for a Tax period (or portion thereof) ending on or prior to the Closing Date, (iii) &#8220;closing agreement&#8221; as described in Section&#160;7121 of the Code (or any similar provision of state, local or foreign Law) executed on or prior to the Closing Date, (iv) installment sale or open transaction disposition made on or prior to the Closing Date, (v)&#160;prepaid amount received or deferred revenue accrued on or prior to the Closing Date or (vi) application of Section&#160;367(d) of the Code to any transfer of intangible property on or prior to the Closing Date. Parent has not made any election under Section&#160;965(h) of the Code. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(i)&#8195;Neither Parent nor any of its Subsidiaries has ever been (i) a member of a consolidated, combined or unitary Tax group (other than such a group the common parent of which is Parent) or (ii) a party to any joint venture, partnership, or other arrangement that is treated as a partnership for U.S. federal income Tax purposes. Neither Parent nor any of its Subsidiaries has any liability for any material Taxes of any Person (other than Parent and any of its Subsidiaries) under Treasury Regulations Section&#160;1.1502-6 (or any similar provision of state, local, or foreign Law), as a transferee or successor, or otherwise. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(j)&#8195;Neither Parent nor any of its Subsidiaries (i) is a &#8220;passive foreign investment company&#8221; within the meaning of Section&#160;1297 of the Code or (ii) has ever had a permanent establishment (within the meaning of an applicable Tax treaty) or otherwise had an office or fixed place of business in a country other than the country in which it is organized. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(k)&#8195;Neither Parent nor any of its Subsidiaries has participated in or been a party to a transaction that, as of the date of this Agreement, constitutes a &#8220;listed transaction&#8221; that is required to be reported to the IRS pursuant to Section&#160;6011 of the Code and applicable Treasury Regulations thereunder. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(l)&#8195;Neither Parent nor any of its Subsidiaries has taken or agreed to take any action or knows of any fact that could reasonably be expected to prevent the Merger from qualifying for the Intended Tax Treatment. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(m)&#8195;Neither Parent nor any of its Subsidiaries has availed itself of any Tax relief pursuant to any pandemic response laws that could reasonably be expected to materially impact the Tax payment and/or Tax reporting obligations of Parent and its Affiliates (including the Company and its Subsidiaries) after the Closing Date. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(n)&#8195;Neither Parent nor any of its Subsidiaries has constituted either a &#8220;distributing corporation&#8221; or a &#8220;controlled corporation&#8221; (within the meaning of Section&#160;355(a)(1)(A) of the Code) in a transaction that was purported or intended to be governed in whole or in part by Sections&#160;355&#160;or 361 of the Code (A) within the two-year period ending on the date of this Agreement or (B) in a distribution which could otherwise constitute part of a &#8220;plan&#8221; or &#8220;series of related transactions&#8221; (within the meaning of Section&#160;355(e) of the Code) in conjunction with the Contemplated Transactions. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(o)&#8195;For purposes of this <u>Section 4.14</u>, each reference to Parent or any of its Subsidiaries shall be deemed to include any Person that was liquidated into, merged with, or is otherwise a predecessor to, Parent or any of its Subsidiaries. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-30<br></div></div></div>
<!--End Page 415-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 416-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg36"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS415"><!--Anchor--></a>4.15&#8194;<u>Intellectual Property</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;<u>Section&#160;4.15(a)</u> of the Parent Disclosure Schedule sets forth, to Parent&#8217;s Knowledge, a true, correct and complete list of all of the following Parent IP as of the date of this Agreement: (A) issued Patents and pending applications for Patents, (B) registered Trademarks and applications for registration of Trademarks, (C) Internet domain names and (D) registered Copyrights, indicating as to each item, as applicable: (i) the current legal and record owner(s), (ii) the jurisdictions in which such item is issued or registered or in which any application for issuance or registration has been filed, (iii) the respective issuance, registration or application number of the item, (iv) the dates of application, issuance or registration of the item and (v) the current status of the item (e.g., registered or pending). As of the date of this Agreement, no interference, opposition, reissue, reexamination or other proceeding of any nature (other than <font style="font-style: italic;">ex parte</font> initial or continuing examination proceedings in front of a government agency) is pending or threatened in writing, in which the scope, validity, enforceability or ownership of any Parent Owned IP, or, to the Parent&#8217;s Knowledge, any Parent Licensed IP, is being or has been contested or challenged. To Parent&#8217;s Knowledge, all Parent IP is in effect, valid, subsisting and enforceable and has not been abandoned or dedicated to the public domain or adjudged invalid or unenforceable. With respect to Parent Owned IP, to Parent&#8217;s Knowledge: (x) Parent has taken reasonable steps consistent with ordinary course intellectual property management practices to avoid revocation, cancellation, or unintentional lapse or otherwise materially adversely affecting its enforceability, use, or priority, (y) all duties of disclosure, candor and good faith have been complied with, and (z) all other material procedural requirements have been complied with, or can be complied with, without materially and adversely affecting such Parent Owned IP&#8217;s enforceability, use or priority, including, with respect to such Parent Owned IP, (1)&#160;inventors having been properly identified on all Patents, (2)&#160;all necessary affidavits of inventorship, ownership, use and continuing use and other filings having been timely made, and (3) all necessary maintenance fees and other fees timely paid to file, prosecute, obtain and maintain in effect all such rights in all material respects. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;To Parent&#8217;s Knowledge, Parent or its Subsidiaries solely and exclusively owns or has rights to all right, title and interest in and to all material Parent Owned IP, free and clear of all Liens other than Permitted Liens, and has the right to use all other Intellectual Property Rights necessary for, or used in or held for use by, Parent or its Subsidiaries in their businesses as currently conducted. Except as set forth on <u>Section&#160;4.15(b)</u> of the Parent Disclosure Schedule, to the Parent&#8217;s Knowledge, the applicable third-party licensor solely owns the Intellectual Property Rights that are exclusively licensed or sublicensed to Parent or any of its Subsidiaries under a Parent In-bound License. Each Parent Associate materially involved in the creation or development of any material Parent Owned IP has signed a valid, enforceable written agreement containing a present assignment of all such Person&#8217;s rights in such material Parent Owned IP to Parent or its Subsidiaries (without further payment being owed to any such Person and without any restrictions or obligations on Parent&#8217;s or its Subsidiaries&#8217; ownership or use thereof). Each Person with access to any material Trade Secrets owned or purported to be owned by Parent or any of its Subsidiaries has signed a valid, enforceable written agreement containing confidentiality provisions protecting such Trade Secrets, which, to Parent&#8217;s Knowledge, has not been materially breached by any such Person. Parent and its Subsidiaries have taken commercially reasonable measures to protect against unauthorized disclosure of any Trade Secret that is material to the business of Parent and its Subsidiaries, taken as a whole, as currently conducted. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(c)&#8195;No funding, facilities or personnel of any Governmental Entity, university, college, research institute, other educational, academic or not-for-profit institution has been used, in whole or in part, to create any material Parent Owned IP or, to Parent&#8217;s Knowledge, any material Parent Licensed IP, except for any such funding or use of facilities or personnel that does not result in such Person obtaining ownership of, a statutory license to, or &#8220;march-in&#8221; rights or a right to direct the location of manufacturing of products with respect to such Parent Owned IP. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(d)&#8195;<u>Section&#160;4.15(d)</u> of the Parent Disclosure Schedule, to Parent&#8217;s Knowledge, sets forth a true, correct and complete list of each license agreement pursuant to which Parent or any of its Subsidiaries (i) is granted a license or sublicense under any material Intellectual Property Right owned by any third party that is used by Parent or any of its Subsidiaries in its business as conducted as of the date of this Agreement (each a &#8220;<font style="font-weight: bold;">Parent In-bound License</font>&#8221;) or (ii) grants to any third party a license or sublicense under any material Parent IP or any material Intellectual Property Right licensed to Parent or any of its Subsidiaries under a Parent In-bound License (each a &#8220;<font style="font-weight: bold;">Parent Out-bound License</font>&#8221;); provided that neither &#8220;Parent In-bound Licenses&#8221; nor &#8220;Parent Out-bound Licenses&#8221; shall include any Standard IP Contracts. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(e)&#8195;To Parent&#8217;s Knowledge, since January&#160;1, 2025, the operation of the businesses of Parent and its Subsidiaries has not infringed or misappropriated or otherwise violated any valid Intellectual Property Rights owned by any other Person. As of the date of this Agreement, no Legal Proceeding (i) is pending (or is threatened in writing) against Parent or any of its Subsidiaries alleging that the operation of the businesses of Parent or any of its Subsidiaries is infringing, misappropriating or otherwise violating or has infringed, misappropriated or otherwise violated any Intellectual Property Rights owned by any other Person or (ii) has been commenced (or threatened in writing) by Parent or any of its Subsidiaries against any other Person alleging that the operation of the businesses of such Person is infringing, misappropriating or otherwise violating or has infringed, misappropriated or otherwise violated any Parent Owned IP. Since January&#160;1, 2025, neither Parent nor any of its Subsidiaries has received any written notice or other written communication alleging that the operation of the businesses of Parent or any of its Subsidiaries is infringing, misappropriating or otherwise violating, or has infringed, misappropriated or otherwise violated Intellectual Property Rights of another Person nor has Parent or any of its Subsidiaries made any written notice or other written communication alleging any other Person is infringing, misappropriating or otherwise violating, or has infringed, misappropriated or otherwise violated, any Parent Owned IP. To the Parent&#8217;s Knowledge, no third party is infringing, misappropriating or otherwise violating any Parent IP. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(f)&#8195;None of the Parent Owned IP or, to Parent&#8217;s Knowledge, any Parent Licensed IP, is subject to any pending or outstanding injunction, directive, order, judgment or other disposition of dispute that adversely and materially restricts the use, transfer, registration or licensing by Parent or any of its Subsidiaries of any such Parent Owned IP or Parent Licensed IP. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-31<br></div></div></div>
<!--End Page 416-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 417-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg37"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(g)&#8195;None of Parent or its Subsidiaries is now or has ever been a member or promoter of, or a contributor to, any industry standards body or any similar organization that would reasonably be expected to require or obligate Parent or any of its Subsidiaries to grant or offer to any other Person any license or right to any Parent IP. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS416"><!--Anchor--></a>4.16&#8194;<u>Privacy and Data Security</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;The operation of Parent&#8217;s and its Subsidiaries&#8217; business is in compliance in all material respects with applicable Data Protection Regulations. Neither the execution, delivery or performance of this Agreement, nor the consummation of the Contemplated Transactions will result in any material violation of applicable Data Protection Regulations. Since January&#160;1, 2023, there have been (i) no Security Incidents materially impacting Personal Data (including any clinical trial data or other data obtained from or about clinical trial subjects, research participants, investigators, or investigator personnel) or any confidential data or Trade Secrets used in the business of Parent or its Subsidiaries as currently conducted (collectively, &#8220;<font style="font-weight: bold;">Parent Sensitive Data</font>&#8221;) (and Parent and its Subsidiaries have not provided or been required under applicable Data Protection Regulations to provide notification of any breach of privacy or data security), (ii) no material violations of any security policy of Parent or its Subsidiaries regarding any such Parent Sensitive Data and (iii) no material unintended or improper disclosure of any Parent Sensitive Data in the possession, custody or control of Parent or its Subsidiaries or a contractor or agent acting on behalf of Parent or its Subsidiaries. Since January&#160;1, 2023, none of Parent or its Subsidiaries has received any written notice (x) from a vendor or data processor that processes Parent Sensitive Data on behalf of Parent or any of its Subsidiaries with respect to a Security Incident materially impacting Parent Sensitive Data or (y) from any other Person, including from any supervisory authority or Governmental Entity of any complaint, investigation, inquiry or enforcement action regarding its Parent Sensitive Data processing. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;Each of Parent and its Subsidiaries has materially complied, and continues to materially comply, with applicable Data Protection Regulations, including with (i) requirements to process Personal Data lawfully, (ii) contractual requirements applicable to the engagement of data processors processing Personal Data on behalf of Parent and its Subsidiaries, (iii) requirements to provide adequate security measures to protect Parent Sensitive Data, (iv) conduct of appropriate data privacy impact assessments to the extent required by applicable Data Protection Regulations, (v)&#160;provisions related to lawful cross-border data transfers of Personal Data and (vi) applicable requirements for the collection, use, storage and security of clinical trial data under ICH Guidelines for Good Clinical Practice and applicable regulations. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(c)&#8195;Each of Parent and its Subsidiaries has implemented commercially reasonable physical, technical and organizational measures designed to protect Parent Sensitive Data against loss, destruction and damage, unauthorized access, use, modification, disclosure or other misuse. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(d)&#8195;To Parent&#8217;s Knowledge, (i) Parent and its Subsidiaries have implemented commercially reasonable safeguards for transfers of Personal Data outside of a country of origin in compliance in all material respects with applicable Data Protection Regulations, and (ii) none of Parent or its Subsidiaries has suspended or terminated a transfer of Personal Data due to violation of applicable Data Protection Regulations or received any written notice from a supervisory authority regarding any concerns about a transfer of Personal Data, except, in each case, as would not have a Parent Material Adverse Effect. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(e)&#8195;With respect to any clinical trial or other clinical research study conducted by or on behalf of Parent or any of its Subsidiaries, to Parent&#8217;s Knowledge, Parent and its Subsidiaries have obtained all required informed consents from clinical trial subjects and research participants and all required approvals from institutional review boards or independent ethics committees, in each case in compliance in all material respects with Data Protection Regulations, 21 C.F.R. Parts 50 and 56 and ICH Guidelines for Good Clinical Practice. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(f)&#8195;Parent and its Subsidiaries have deployed and used AI in material compliance with all applicable Laws and Data Protection Regulations, as well as in all material respects with Contract terms applicable to Parent and its Subsidiaries&#8217; processing of Training Data. Parent and its Subsidiaries do not use any data that is subject to an obligation of confidentiality by Parent or its Subsidiaries under all applicable Laws and Contracts to which Parent or any of its Subsidiaries is subject or a party, in any prompts or input to any AI tools by Parent or its Subsidiaries, except in cases where such AI tools do not use such data, prompts or inputs to train the machine learning or algorithm of such tools or to improve the services related to such AI tools other than solely for use by the Parent or its Subsidiaries as permitted by all applicable Laws and Contracts to which Parent or any of its Subsidiaries is subject or a party. Parent has implemented and maintains commercially reasonable policies relating to governance or implementation of AI, including its policies relating to (A) management oversight and approval of employees&#8217; and contractors&#8217; use and implementation of AI, and (B) use and implementation of AI in a manner that is designed to avoid violation, infringement or misappropriation of any third Person&#8217;s Intellectual Property Rights and violation of applicable Laws. Parent and its Subsidiaries have not used or employed any AI tools in a manner that would materially limit Parent&#8217;s or any of its Subsidiaries&#8217; ownership of, or otherwise materially impair Parent&#8217;s or any of its Subsidiaries&#8217; ability to use, commercialize, or otherwise exploit, the Intellectual Property Rights in or pertaining to any output generated by the use of AI tools by or for Parent and its Subsidiaries. Parent does not use AI for any activity that is banned or prohibited under any applicable Law, including activities designated as &#8220;high risk&#8221; or otherwise subject to heightened requirements or restrictions under any applicable Law. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS417"><!--Anchor--></a>4.17&#8194;<u>Compliance with Laws; Permits; Regulatory Matters</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;Parent and each of its Subsidiaries, and the operation of the business of Parent and its Subsidiaries, are and, to Parent&#8217;s Knowledge, each Parent Partner is, and since January&#160;1, 2025 have been, in compliance in all material respects with all applicable Laws, including Health Care Laws. Since January&#160;1, 2025, neither Parent, any of its Subsidiaries nor, to Parent&#8217;s Knowledge, any Parent Partner has received any pending or threatened claim, complaint, suit, proceeding, hearing, enforcement audit, investigation, arbitration, or other adverse action from any Person, including any Governmental Entity or customer, alleging product liability, material non-compliance or material violation of any applicable Laws, including Health Care Laws. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-32<br></div></div></div>
<!--End Page 417-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 418-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg38"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;There is no judgment, injunction, order or decree by a Governmental Entity binding upon Parent, any of its Subsidiaries or, to Parent&#8217;s Knowledge, any Parent Partner, which (i) has or would reasonably be expected to have the effect of prohibiting or materially impairing any current material business practice of Parent, any of its Subsidiaries or, to Parent&#8217;s Knowledge, any Parent Partner, any acquisition of material property by Parent, any of its Subsidiaries or, to Parent&#8217;s Knowledge, any Parent Partner, or the conduct of any material portion of the business by Parent, any of its Subsidiaries or, to Parent&#8217;s Knowledge, any Parent Partner, as currently conducted, (ii) is reasonably likely to have a material adverse effect on Parent&#8217;s ability to comply with or perform any covenant or obligation under this Agreement, or (iii) is reasonably likely to have the effect of preventing, materially delaying, making illegal or otherwise materially interfering with the Contemplated Transactions; <u>provided</u> that the representations and warranties in the foregoing clauses (ii) and (iii) are made only as of the date of this Agreement. Parent is not and, since January&#160;1, 2025, has not been a party to any corporate integrity agreements, monitoring agreements, consent decrees, deferred prosecution agreements, settlement orders, or similar agreements with or imposed by any Governmental Entity. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(c)&#8195;Parent, its Subsidiaries and, to Parent&#8217;s Knowledge, each Parent Partner currently hold and operate in compliance in all material respects with, and, at all times since January&#160;1, 2025, have held and operated in compliance in all material respects with, all Governmental Authorizations that are or have been necessary for the conduct of the business of Parent and its Subsidiaries as previously conducted and as currently being conducted. All such permits that are necessary for the conduct of the business of Parent and its Subsidiaries as currently conducted (the &#8220;<font style="font-weight: bold;">Parent Permits</font>&#8221;) and necessary for the conduct of the business of the Parent Partners as currently conducted (the &#8220;<font style="font-weight: bold;">Parent Partner Permits</font>&#8221;) are valid and are in full force and effect (in the case of the Parent Partner Permits, to Parent&#8217;s Knowledge), and, assuming the notices, filings or other Consents listed on <u>Section&#160;4.17(c)</u> of the Parent Disclosure Schedule have been made or obtained, will continue to be so upon consummation of the Contemplated Transactions, except as would not have a Parent Material Adverse Effect. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(d)&#8195;Parent, its Subsidiaries and, to Parent&#8217;s Knowledge, the Parent Partners hold all right, title and interest in and to all Parent Permits and Parent Partner Permits free and clear of any Lien. All fees and charges with respect to such Parent Permits and Parent Partner Permits, as of the date of this Agreement, have been paid in full and all filing, reporting and maintenance obligations have been completely and timely satisfied (in the case of the Parent Partner Permits, to Parent&#8217;s Knowledge), except as would not have a Parent Material Adverse Effect. Parent and each of its Subsidiaries are in material compliance with the terms of the Parent Permits and the Parent Partner Permits. To Parent&#8217;s Knowledge, as of the date of this Agreement, no Legal Proceeding is pending or threatened, which seeks to revoke, limit, suspend, or materially modify any Parent Permit or any Parent Partner Permit. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(e)&#8195; None of the Parent Products have been or have been requested by a Governmental Entity or other Person to be Recalled. Neither Parent nor any of its Subsidiaries, nor, to Parent&#8217;s Knowledge, any Governmental Entity or other Person, has sought, is seeking, or, to Parent&#8217;s Knowledge, has or is currently threatening or contemplating any Recall of a Parent Product. The Parent Products have been manufactured, packaged, labeled, tested, stored, shipped, handled, warehoused and distributed in material compliance with all applicable Health Care Laws and are not and have not been prohibited from introduction into interstate commerce under applicable Health Care Laws. All products marketed by Parent or any of its Subsidiaries are, and have been, labeled, promoted and advertised in material compliance with applicable Health Care Laws. Except as would not have a material impact on Parent and its Subsidiaries, taken as a whole, since January&#160;1, 2025, neither Parent nor any of its Subsidiaries has either voluntarily or involuntarily issued, or caused to be issued, any notice or communication due to an alleged lack of safety, efficacy or material noncompliance with any applicable Health Care Laws for any Parent Product. To Parent&#8217;s Knowledge, as of the date of this Agreement, there are no facts that would reasonably be expected to result in (x) such a notice or communication or (y) the termination or suspension of marketing of any Parent Product. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(f)&#8195;As of the date of this Agreement, none of Parent, its Subsidiaries, or any of their respective officers, directors, employees, independent contractors or, to Parent&#8217;s Knowledge, agents or the Parent Partners and their respective officers, directors, employees, independent contractors or agents have been or are currently: </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 30pt; text-indent: 30pt; text-align: left;">(i)&#8195;subject to mandatory or permissive debarment or suspension pursuant to 21 U.S.C. &#167; 335a; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 30pt; text-indent: 30pt; text-align: left;">(ii)&#8195;excluded under 42 U.S.C. &#167; 1320a-7 or any similar law, rule or regulation of any Governmental Entity; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(iii)&#8195;excluded, debarred, suspended or deemed ineligible to participate in federal procurement and non-procurement programs, including those produced by the U.S. General Services Administration; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(iv)&#8195;charged, named in a complaint, convicted, or otherwise found liable in any Legal Proceeding that falls within the ambit of 21&#160;U.S.C. &#167; 331, 21 U.S.C. &#167; 333, 21 U.S.C. &#167; 334, 21 U.S.C. &#167; 335a, 21 U.S.C. &#167; 335b, 42 U.S.C. &#167; 1320a - 7, 31 U.S.C. &#167;&#167; 3729 - 3733, 42&#160;U.S.C. &#167; 1320a-7a, or any other applicable Health Care Laws or, to Parent&#8217;s Knowledge, threatened with prosecution by a Governmental Entity, including the Centers for Medicare and Medicaid Services, the U.S. Department of Health and Human Services, state attorney general, or the U.S. Department of Justice, for any violation of any of the foregoing; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(v)&#8195;disqualified or deemed ineligible pursuant to 21 C.F.R. Parts 312, 511, or 812, or otherwise restricted, in whole or in part, or subject to an assurance; or </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(vi)&#8195;had a pending Legal Proceeding, or otherwise received any written notice from any Governmental Entity or any Person threatening, investigating, or pursuing (i)-(v) above or, to Parent&#8217;s Knowledge, committed any violation of any applicable Health Care Law, that could reasonably be expected to serve as the basis for any such exclusion, suspension, debarment or other ineligibility. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(g)&#8195;Parent has not been restrained in any material respect by a Governmental Entity in its ability to conduct or have conducted the manufacturing; non-clinical, clinical or other testing; distribution; promotion or marketing of the Parent Products. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-33<br></div></div></div>
<!--End Page 418-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 419-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg39"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(h)&#8195;All studies and tests conducted by or on behalf of, or sponsored by, the Parent or any of its Subsidiaries, or in which the Parent or any of its Subsidiaries or the Parent Products has participated, were and, if still pending, are being conducted in compliance in all material respects with all applicable Health Care Laws. To the Parent&#8217;s Knowledge, the study reports, protocols, and statistical analysis plans for all such studies and tests accurately, completely, and fairly reflect the results from such studies and tests. As of the date of this Agreement, the Parent has not received written notice of any complaints, information, or adverse experience reports related to a Parent Product that would reasonably be expected to be material to the Parent and its Subsidiaries, taken as a whole. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(i)&#8195;Since January&#160;1, 2025, neither Parent nor any of its Subsidiaries nor, to Parent&#8217;s Knowledge, any of the Parent Partners has received any written notice from FDA or any other Governmental Entity that it has (i) commenced, or threatened to initiate, any Legal Proceeding to implement a partial or full clinical hold or withdraw any approvals granted to Parent for any clinical investigation of any Parent Product, or (ii)&#160;commenced, or threatened to initiate, any Legal Proceeding to enjoin manufacture or distribution of any Parent Product. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(j)&#8195;To the Knowledge of Parent, there are no material Legal Proceedings or governmental, regulatory or administrative investigations, audits, inquiries or actions, or any facts, circumstances or conditions that would reasonably be expected to form the basis for any material Legal Proceeding or governmental, regulatory or administrative investigation, audit, inquiry or action, against or affecting Parent, any of its Subsidiaries or any of the Parent Partners arising under the FDCA and the regulations of FDA promulgated thereunder or similar Law and other applicable Health Care Laws. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(k)&#8195;The Parent, its Subsidiaries and, to Parent&#8217;s Knowledge, the Parent Partners have not made any false, misleading, or untrue statement of material fact, or failed to disclose a material fact required to be disclosed, to any Governmental Entity, nor committed any act, made any statement, or failed to make any statement that would reasonably be likely to provide a basis for the FDA to invoke its policy with respect to &#8220;Fraud, Untrue Statements of Material Facts, Bribery and Illegal Gratuities,&#8221; or for any other Governmental Entity to invoke any similar policy. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS418"><!--Anchor--></a>4.18&#8194;<u>Insurance</u>. Parent has made available to the Company true, correct and complete copies of all material insurance policies and all material self-insurance programs and arrangements relating to the business, assets, liabilities and operations of Parent and each of its Subsidiaries in effect on the date of this Agreement. Each insurance policy of Parent and each of its Subsidiaries is in full force and effect and Parent and each of its Subsidiaries are in compliance in all material respects with the terms thereof. Other than customary end of policy notifications from insurance carriers, between January&#160;1, 2025 and the date of this Agreement, neither Parent nor any of its Subsidiaries has received any written notice or other written communication regarding any actual or possible (a) cancellation or invalidation of any insurance policy or (b) refusal or denial of any coverage, reservation of rights or rejection of any material claim under any insurance policy. Parent and each of its Subsidiaries have provided timely written notice to the appropriate insurance carrier(s) of each Legal Proceeding that is currently pending against Parent or any of its Subsidiaries for which Parent or such Subsidiary has insurance coverage, and no such carrier has issued a denial of coverage or a reservation of rights with respect to any such Legal Proceeding or informed Parent or any of its Subsidiaries of its intent to do so. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS419"><!--Anchor--></a>4.19&#8194;<u>Real Estate</u>. Neither Parent nor any of its Subsidiaries owns, or has ever owned, any real property. <u>Section&#160;4.19</u> of the Parent Disclosure Schedule sets forth a true, correct and complete list as of the date of this Agreement of all real properties with respect to which Parent or any of its Subsidiaries directly or indirectly holds a valid leasehold interest (including any subleases, licenses or sublicenses) as well as any other real estate that is in the possession of or leased, subleased or licensed by Parent or any of its Subsidiaries (the &#8220;<font style="font-weight: bold;">Parent Leased Real Property</font>&#8221;), and a true, correct and complete list of all of the Parent Leased Real Property under which any such real property is leased, subleased, licensed or otherwise possessed (the &#8220;<font style="font-weight: bold;">Parent Real Estate Leases</font>&#8221;), each of which is in full force and effect, with no existing material default by Parent thereunder (or any act which, with notice or the passage of time, or both, could result in a material default under the Parent Real Estate Leases). Parent&#8217;s or its applicable Subsidiary&#8217;s use, occupancy and operation of each such Parent Leased Real Property conforms to all applicable Laws, and Parent or its applicable Subsidiary has exclusive possession of each such Parent Leased Real Property and has not granted any use or occupancy rights to tenants, subtenants or licensees with respect to such Parent Leased Real Property. Neither Parent nor any of its Subsidiaries has assigned, transferred, mortgaged, subleased or pledged (directly or indirectly) any interest in any of the Parent Real Estate Leases. In addition, each of Parent and its applicable Subsidiary has a valid leasehold interest in (or a valid right to use and occupy) the Parent Leased Real Property, free and clear of all Liens other than Permitted Liens. To Parent&#8217;s Knowledge, neither the whole nor any part of the Parent Leased Real Property is subject to any pending suit for condemnation or other taking by any Governmental Entity, and no such condemnation or other taking is threatened or contemplated. The Parent Leased Real Property comprises all of the real property used in, and is necessary for, the operation of the business of Parent and its Subsidiaries as currently conducted. Neither Parent nor any of its Subsidiaries has ever leased or operated at any real property other than the Parent Leased Real Property. All structures and buildings on the Parent Leased Real Property are adequately maintained and are in good operating condition and repair for the requirements of the business of Parent and its Subsidiaries as currently conducted. To Parent&#8217;s Knowledge, there is no pending or contemplated special assessment or reassessment of any parcel included in the Parent Leased Real Property that would result in a material increase in the rent, additional rent or other sums and charges payable by Parent or its Subsidiaries. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS420"><!--Anchor--></a>4.20&#8194;<u>Registration Statement and Proxy Statement/Prospectus</u>. None of the information supplied or to be supplied by Parent in writing for inclusion or incorporation by reference in (a) the Registration Statement will, at the time the Registration Statement or any amendment or supplement thereto is declared effective under the Securities Act, contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading or (b) the Proxy Statement/Prospectus will, at the date it is first mailed to Parent&#8217;s stockholders or at the time of the Parent Stockholders Meeting, contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they are made, not </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-34<br></div></div></div>
<!--End Page 419-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 420-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg40"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">misleading in any material respect. The Proxy Statement/Prospectus will comply as to form with the requirements of the Exchange Act and the rules and regulations thereunder, except that no representation is made by Parent with respect to statements made or incorporated by reference therein based on information supplied by the Company for inclusion or incorporation by reference therein. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS421"><!--Anchor--></a>4.21&#8194;<u>Transactions with Affiliates</u>. Since March&#160;31, 2026, no event has occurred that would be required to be reported by Parent pursuant to Item&#160;404 of Regulation S-K as promulgated under the Securities Act. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS422"><!--Anchor--></a>4.22&#8194;<u>Brokers and Finders</u>. Except for Centerview Partners LLC and UBS Securities LLC, no broker, finder or investment banker is entitled to any brokerage fee, finder&#8217;s fee, opinion fee, success fee, transaction fee or other fee or commission in connection with the Contemplated Transactions based upon arrangements made by or on behalf of Parent or any of its Subsidiaries, including Merger Sub. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS423"><!--Anchor--></a>4.23&#8194;<u>Opinion of Financial Advisor</u>. As of the date of this Agreement, (a) the Parent Board has received the oral opinion, that will subsequently be provided in writing, of Centerview Partners LLC that, as of the date of such opinion and based upon and subject to the various qualifications, assumptions, limitations and other matters set forth therein, the Exchange Ratio is fair, from a financial point of view, to Parent and (b) the Special Committee (in such capacity) has received the oral opinion (to be subsequently confirmed in writing) of UBS Securities LLC, as financial advisor to the Special Committee, that, as of the date of such opinion and based upon and subject to the various qualifications, assumptions, limitations and other matters set forth therein, the Exchange Ratio provided for in the Merger is fair, from a financial point of view, to Parent. Parent shall, promptly following the execution of this Agreement by all Parties, furnish a copy of each such written opinion to the Company solely for informational purposes (it being agreed that none of the Company, nor any of its Affiliates or Representatives, shall have the right to rely on such opinion). </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS424"><!--Anchor--></a>4.24&#8194;<u>Certain Business Practices</u>.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;None of Parent, any of its Subsidiaries or any of their respective directors, officers, employees or, to Parent&#8217;s Knowledge, agents or any other Person acting on their behalf has directly or indirectly made any bribes, rebates, payoffs, influence payments, kickbacks, or other unlawful payment, in the form of cash, gifts, or anything of value, or taken any other action or made or failed to make any other statement, in violation of Anti-Bribery Laws except, in each case, as would not be material to Parent&#8217;s business or operations. Neither Parent nor any of its Subsidiaries nor any of their respective officers, employees or agents is or has been, in any capacity relating to Parent or such Subsidiary, the subject of any debarment or exclusionary claims, actions, proceedings, or, to Parent&#8217;s Knowledge, investigation by any Governmental Entity with respect to potential violations of Anti-Bribery Laws except, in each case, as would not be material to Parent&#8217;s business or operations. None of Parent, any of its Subsidiaries or any of their respective principals (as defined at 48 C.F.R. 52.209-5(a)(2)) would be required to certify affirmatively to any element of the certification at 48 C.F.R. 52.209-5. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;None of Parent nor any of its Subsidiaries, nor to Parent&#8217;s Knowledge, any of their respective officers, directors or employees acting on their behalf, is currently, or has since January&#160;1, 2025 been (i) a Sanctioned Person, (ii) organized or ordinarily resident in a Sanctioned Country, (iii) engaged in any material unlawful dealings or transactions with or for the benefit of any Sanctioned Person or in any Sanctioned Country, (iv)&#160;engaged in any export, reexport, transfer or provision of any goods, software, technology, data or service without, or exceeding the scope of, any licenses or authorizations under all applicable Ex-Im Laws or (v) otherwise in material violation of applicable Trade Control Laws. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(c)&#8195;Each of Parent and its Subsidiaries has obtained all authorizations, licenses, and other permits, consents, notices, waivers, and approvals as required by Trade Control Laws and is in compliance with the terms of all such authorizations, licenses, and other permits, consents, notices, waivers, and approvals. There are no active or pending internal or third-party (including Governmental Entity) investigations related to Parent&#8217;s or any of its Subsidiaries&#8217; compliance with Trade Control Laws. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS425"><!--Anchor--></a>4.25&#8194;<u>Ownership and Operations of Merger Sub</u>. Parent directly owns beneficially all of the outstanding shares of common stock of Merger Sub. Merger Sub was formed solely for the purpose of engaging in the Merger, has engaged in no other business activities, and has incurred no liabilities or obligations other than as expressly contemplated hereby or as otherwise required or incidental to negotiate, execute, deliver and effect the Contemplated Transactions. The authorized shares of common stock of Merger Sub consist of 1,000 shares, all of which are validly issued and outstanding. All of the issued and outstanding shares of Merger Sub are directly owned by Parent, free and clear of any Liens other than Liens imposed under any federal or state securities Laws. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS426"><!--Anchor--></a>4.26&#8194;<u>Customers and Suppliers</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;<u>Section&#160;4.26(a)</u> of the Parent Disclosure Schedule sets forth a correct and complete list of the 10 largest customers of Parent and its Subsidiaries based on the aggregate revenue received or accrued by Parent and its Subsidiaries, taken as a whole, for the twelve-month period ended December&#160;31, 2025. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;<u>Section&#160;4.26(b)</u> of the Parent Disclosure Schedule sets forth a correct and complete list of the 10 largest suppliers of Parent and its Subsidiaries based on the aggregate payments made or accrued by Parent and its Subsidiaries, taken as a whole, for the three-month period ended December&#160;31, 2025. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS427"><!--Anchor--></a>4.27&#8194;<u>Ownership of the Company Common Stock</u>. Since January&#160;1, 2025, neither Parent nor any of its Subsidiaries has &#8220;owned&#8221; (as such term is defined in Section&#160;203(c) of the DGCL), directly or indirectly, any shares of Company Common Stock or other securities convertible into, exchangeable into or exercisable for shares of Company Common Stock. There are no voting trusts or other agreements or understandings to which Parent or any its Subsidiaries is a party with respect to the voting of the capital stock or other equity interest of the Company or any of its Subsidiaries. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-35<br></div></div></div>
<!--End Page 420-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 421-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg41"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;"><a name="tANXAA5"><!--Anchor--></a>ARTICLE&#160;V <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">COVENANTS </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 7.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS51"><!--Anchor--></a>5.1&#8195;<u>Interim Operations</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;<u>Conduct of Business by the Company</u>. Except (i) for matters set forth in <u>Section&#160;5.1(a)</u> of the Company Disclosure Schedule, (ii) as expressly permitted by or required in accordance with this Agreement, (iii) as required by applicable Law or (iv) as may be consented to in writing by Parent (which consent shall not be unreasonably withheld, delayed or conditioned), from the date of this Agreement to the Effective Time, or, if earlier, the termination of this Agreement in accordance with its terms (such time, the &#8220;<font style="font-weight: bold;">Pre-Closing Period</font>&#8221;), the Company shall, and shall cause each of its Subsidiaries to, (x) conduct its business in all material respects in the Ordinary Course of Business and (y) use commercially reasonable efforts to (1)&#160;preserve intact the material components of its present business organization, (2) keep available the services of its present officers and key employees in all material respects, (3) preserve its relationships with manufacturers, suppliers, vendors, distributors, Governmental Entities with jurisdiction over the Company&#8217;s operations, customers, licensors, licensees and others with which it has material business dealings, (4) comply in all material respects with all applicable Laws and (5) maintain in effect all Company Permits in accordance with their terms and renew any Company Permit that would otherwise expire pursuant to their terms (it being agreed that matters addressed by the specific provisions of the next sentence shall be governed by such provisions rather than the general provisions of this sentence). In addition, and without limiting the generality of the foregoing, except for matters set forth in the Company Disclosure Schedule or otherwise expressly permitted or expressly contemplated by this Agreement or required by applicable Law or with the prior written consent of Parent (which shall not be unreasonably withheld, conditioned or delayed), during the Pre-Closing Period, the Company shall not, and shall not permit any of its Subsidiaries to, do any of the following: </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(i)&#8195;establish a record date for, declare, accrue, set aside or pay any dividend or make any other distribution (whether in cash, stock or property) in respect of any shares of its capital stock or other equity interests or securities or repurchase, redeem or otherwise reacquire any shares of its capital stock or other equity interests or securities (except repurchases from terminated employees, directors or consultants of the Company or in connection with the payment of the exercise price and/or withholding Taxes incurred upon the exercise, settlement or vesting of any award or purchase rights granted under the Company Equity Plan in accordance with the terms of such award in effect on the date of this Agreement); </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(ii)&#8195;sell, issue, grant, modify, amend, reprice, pledge or otherwise dispose of or encumber or authorize: (A) any capital stock or other equity interests or security of the Company or any of its Subsidiaries (except for shares of Company Common Stock issued upon the valid exercise or conversion of outstanding Company Options or Company Warrants (other than the amendment of any Company Warrant to become a Company Converting Warrant)); (B) any option, warrant or right to acquire any capital stock or any other equity interests or security, other than Company Options granted to (1) new employees who were offered a specific number of Company Options as part of offer letters entered into prior to the date of this Agreement or, in Ordinary Course of Business, after the date of this Agreement and (2)&#160;existing employees in the Ordinary Course of Business as annual incentive compensation or (C) any instrument convertible into or exchangeable for any capital stock or other equity interests or security of the Company or any of its Subsidiaries; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(iii)&#8195;except as required by the terms of this Agreement, adopt, amend, terminate or waive or propose to adopt, amend, terminate or waive any of the Company&#8217;s or its Subsidiaries&#8217; Organizational Documents, or effect or be a party to any merger, consolidation, share exchange, business combination, recapitalization, reclassification of shares, stock split, reverse stock split or similar transaction except for the Contemplated Transactions; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(iv)&#8195;except as required by the terms of this Agreement, amend, terminate or waive or propose to amend, terminate or waive the Company Equity Plan, any provision of any agreement evidencing any outstanding stock option, any restricted stock unit grant, or performance-based vesting restricted stock unit grant, or otherwise modify any of the terms of any outstanding option, restricted stock unit, warrant or other equity interest or security or any related Contract; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 30pt; text-indent: 30pt; text-align: left;">(v)&#8195;adopt or implement any stockholder rights plan or similar arrangement; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(vi)&#8195;form any Subsidiary or acquire or propose to acquire any equity interest or other interest in, or business of, any other entity or enter into a joint venture with any other entity; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(vii)&#8195;(A) lend money to any Person (except for the advancement of expenses to employees, directors and consultants in the Ordinary Course of Business), (B)&#160;incur or guarantee any indebtedness for borrowed money, (C)&#160;guarantee any debt securities of others, (D)&#160;other than the incurrence or payment of Transaction Expenses, make any capital expenditure in excess of $3,000,000 in the aggregate, or (E)&#160;make any investment in, including by way of capital contribution or acquisition of equity interests or debt securities of, any Person; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(viii)&#8195;other than in the Ordinary Course of Business: (A) adopt, terminate, establish or enter into any Company Benefit Plan; (B)&#160;cause or permit any Company Benefit Plan to be amended in any material respect, or (C) increase or modify the amount or form of the wages, salary, commissions, or bonus compensation payable to any of its directors, officers or employees; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(ix)&#8195;recognize any labor union or labor organization, or enter into any collective bargaining agreement, or take any similar actions with respect to any employee, group of employees, or representative of any employees; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(x)&#8195;acquire any material asset (other than Intellectual Property Rights) or sell, lease or otherwise irrevocably dispose of any of its material assets or properties (other than Intellectual Property Rights), or grant any Lien with respect to such assets or properties, except in the Ordinary Course of Business; </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-36<br></div></div></div>
<!--End Page 421-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 422-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg42"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(xi)&#8195;(A) sell, assign, transfer, license, sublicense, grant any Lien (other than Permitted Liens) with respect to or otherwise dispose of any material Company IP (in each case, other than pursuant to non-exclusive licenses granted in the Ordinary Course of Business or pursuant to a Company Collaboration Agreement) or (B) cancel, fail to refile a provisional application after abandonment, fail to renew or extend, or fail to diligently prosecute (including making any filing, pay any fee, or take any other action necessary to prosecute and maintain) any Company IP (in the case of Company Licensed IP, solely to the extent that the Company or any of its Subsidiaries has rights to control, prosecution and maintenance thereof), except, for each of the foregoing, in the ordinary course of prosecution upon exercise of reasonable business judgment by the Company or the lapse or expiry of Company IP at the end of its statutory term; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(xii)&#8195;disclose to any third party (other than (A) pursuant to written confidentiality obligations, (B) as required by applicable Law, including applicable Data Protection Regulations, or (C) in the ordinary course of conducting clinical trials or other clinical research activities subject to contractual or statutory confidentiality obligations) or otherwise fail to preserve and maintain, any material Trade Secrets of the Company; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(xiii)&#8195;make (other than on an originally filed income Tax Return), change or revoke any material Tax election, fail to pay any income Tax or other material Tax as such Tax becomes due and payable, file any amendment making any material change to any Tax Return, settle or compromise any income Tax or other material Tax liability or submit any voluntary disclosure application, enter into any Tax allocation, sharing, indemnification or other similar agreement or arrangement (other than commercial agreements entered into in the Ordinary Course of Business the principal subject matter of which is not the allocation of Taxes), request or consent to any extension or waiver of any limitation period with respect to any claim or assessment for any income Tax or other material Taxes (other than pursuant to an extension of time to file any Tax Return granted in the Ordinary Course of Business of not more than seven months), or change any material accounting method in respect of Taxes; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(xiv)&#8195;(A) materially amend, terminate (other than automatic terminations) or expressly release any material rights under any Company Material Contract, or (B) enter into any Contract that is or would be considered a Company Material Contract under any of clauses <u>(i)</u>, <u>(vi)</u> or <u>(ix</u>) of <u>Section&#160;3.11(a)</u> (it being understood that the renewal or extension of any such Contract in the Ordinary Course of Business shall be permitted) if in effect on the date hereof, in each case other than Company Collaboration Agreements; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 30pt; text-indent: 30pt; text-align: left;">(xv)&#8195;other than as required by Law or GAAP, take any action to change accounting policies or procedures; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(xvi)&#8195;settle or compromise any Legal Proceeding other than solely for monetary damages (net of insurance proceeds received) not in excess of $200,000 individually or $1,000,000 in the aggregate; <u>provided</u> that such settlement or compromise does not impose any non-monetary obligations on the Company or its Subsidiaries (other than customary confidentiality and de minimis contractual obligations in the applicable compromise or settlement agreement that are incidental to an award of monetary damages thereunder) and does not involve the admission of wrongdoing by the Company, any of its Subsidiaries or any of their respective directors or officers; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(xvii)&#8195;enter into or amend any Contract if such Contract or amendment would reasonably be expected to prevent or materially impede, interfere with, hinder or delay the consummation of the Contemplated Transactions; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(xviii)&#8195;fail to maintain in full force and effect the existing insurance policies of the Company or to renew or replace such insurance policies with comparable insurance policies; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 30pt; text-indent: 30pt; text-align: left;">(xix)&#8195;dissolve or liquidate the Company or any Subsidiary thereof; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(xx)&#8195;make any payment or loan to, or enter into any agreement, arrangement or understanding with, any of its stockholders, directors, managers, officers or other Affiliates; or </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 30pt; text-indent: 30pt; text-align: left;">(xxi)&#8195;agree, resolve or commit to do any of the foregoing. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;<u>Conduct of Business by Parent</u>. Except (i) for matters set forth in <u>Section 5.1(b)</u> of the Parent Disclosure Schedule, (ii) as expressly permitted by or required in accordance with this Agreement (including Wind-Down Activities and any Parent Legacy Transaction conducted in accordance with <u>Section&#160;5.23</u>), (iii) as required by applicable Law or (iv) as may be consented to in writing by the Company (which consent shall not be unreasonably withheld, delayed or conditioned), during the Pre-Closing Period, Parent shall, and shall cause each of its Subsidiaries to, (x) conduct its business in all material respects in the Ordinary Course of Business and (y) use commercially reasonable efforts to comply in all material respects with all applicable Laws. In addition, and without limiting the generality of the foregoing, except for matters set forth in the Parent Disclosure Schedule or otherwise expressly permitted or expressly contemplated by this Agreement (including Wind-Down Activities and any Parent Legacy Transaction conducted in accordance with <u>Section&#160;5.23</u>) or required by applicable Law or with the prior written consent of the Company (which shall not be unreasonably withheld, conditioned or delayed), during the Pre-Closing Period, Parent shall not, and shall not permit any of its Subsidiaries to, do any of the following: </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(i)&#8195;establish a record date for, declare, accrue, set aside or pay any dividend or make any other distribution (whether in cash, stock or property) in respect of any shares of its capital stock or other equity interests or securities or repurchase (other than the issuance of the Closing Dividend in accordance with <u>Section&#160;5.21 </u>and the completion of the Parent Reverse Stock Split in accordance with <u>Section&#160;5.22</u>), redeem or otherwise reacquire any shares of its capital stock or other equity interests or securities (except repurchases from terminated employees, directors or consultants of Parent or in connection with the payment of the exercise price and/or withholding Taxes incurred upon the exercise, settlement or vesting of any award or purchase rights granted under the Parent Equity Plans in accordance with the terms of such award in effect on the date of this Agreement); </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-37<br></div></div></div>
<!--End Page 422-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 423-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg43"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(ii)&#8195;sell, issue, grant, modify, reprice, amend, pledge or otherwise dispose of or encumber or authorize: (A) any capital stock or other equity interests or security of Parent, any of its Subsidiaries or Merger Sub (except for shares of Parent Common Stock issued upon the valid exercise of Parent Options or Parent ESPP Options, settlement of Parent RSUs or conversion of Parent Warrants); (B) any option, warrant or right to acquire any capital stock or any other equity interests or security; or (C) any instrument convertible into or exchangeable for any capital stock or other equity interests or security of Parent, any of its Subsidiaries or Merger Sub; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(iii)&#8195;except as required by the terms of this Agreement, adopt, amend, terminate or waive or propose to adopt, amend, terminate or waive any of Parent&#8217;s or its Subsidiaries&#8217; Organizational Documents, or effect or be a party to any merger, consolidation, share exchange, business combination, recapitalization, reclassification of shares, stock split, reverse stock split or similar transaction except for the Contemplated Transactions; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(iv)&#8195;except as required by the terms of this Agreement, amend, terminate or waive or propose to amend, terminate or waive any of Parent Equity Plans, any provision of any agreement evidencing any outstanding stock option, any restricted stock unit grant, or performance-based vesting restricted stock unit grant, or otherwise modify any of the terms of any outstanding option, restricted stock unit, warrant or other equity interest or security or any related Contract; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 30pt; text-indent: 30pt; text-align: left;">(v)&#8195;adopt or implement any stockholder rights plan or similar arrangement; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(vi)&#8195;form any Subsidiary or acquire or propose to acquire any equity interest or other interest in, or business of, any other entity or enter into a joint venture with any other entity; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(vii)&#8195;(A) lend money to any Person (except for the advancement of expenses to employees, directors and consultants in the Ordinary Course of Business), (B) incur or guarantee any indebtedness for borrowed money, (C) guarantee any debt securities of others, (D)&#160;other than the incurrence or payment of Transaction Expenses, make any capital expenditures, or (E) make any investment in, including by way of capital contribution or acquisition of equity interests or debt securities of, any Person; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(viii)&#8195;other than as required by applicable Law or the terms of any Parent Benefit Plan as in effect on the date of this Agreement: (A) adopt, terminate, establish or enter into any Parent Benefit Plan; (B) cause or permit any Parent Benefit Plan to be amended in any material respect, or (C) increase or modify the amount or form of the wages, salary, commissions, or bonus compensation payable to any of its directors, officers or employees; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(ix)&#8195;recognize any labor union or labor organization, or enter into any collective bargaining agreement, or take any similar actions with respect to any employee, group of employees, or representative of any employees; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(x)&#8195;hire any employee or contractor, other than to fill vacancies caused by the termination of employees and contractors whose employment or engagement is terminated after the date of this Agreement; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 30pt; text-indent: 30pt; text-align: left;">(xi)&#8195;acquire any material asset (other than Intellectual Property Rights); </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(xii)&#8195;(A) sell, assign, transfer, license, sublicense, grant any Lien (other than any Permitted Lien) with respect to or otherwise dispose of any material Parent IP (in each case, other than pursuant to non-exclusive licenses granted in the Ordinary Course of Business) or (B)&#160;cancel, fail to refile a provisional application after abandonment, fail to renew or extend or fail to diligently prosecute (including making any filing, pay any fee, or take any other action necessary to prosecute and maintain) and material Parent IP (in the case of any Parent Licensed IP, solely to the extent that Parent or any of its Subsidiaries has rights to control the prosecution and maintenance thereof), except, for each of the foregoing, in the ordinary course of prosecution upon exercise of reasonable business judgment by Parent or the lapse or expiry of Parent IP at the end of its statutory term; <u>provided</u> that the prior written consent of the Company (not to be unreasonably withheld, conditioned or delayed) shall be required prior to Parent&#8217;s entry into any definitive agreement, or binding term sheet or letter of intent, relating to any Parent Legacy Transaction involving the actions described in this <u>Section&#160;5.1(b)(xii)</u>; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(xiii)&#8195;disclose to any third party (other than (A) pursuant to written confidentiality obligations or (B) as required by applicable Law) or otherwise fail to preserve and maintain, any material Trade Secrets of Parent; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(xiv)&#8195;make (other than on an originally filed income Tax Return), change or revoke any material Tax election, fail to pay any income Tax or other material Tax as such Tax becomes due and payable, file any amendment making any material change to any Tax Return, settle or compromise any income Tax or other material Tax liability or submit any voluntary disclosure application, enter into any Tax allocation, sharing, indemnification or other similar agreement or arrangement (other than commercial agreements entered into in the Ordinary Course of Business the principal subject matter of which is not the allocation of Taxes), request or consent to any extension or waiver of any limitation period with respect to any claim or assessment for any income Tax or other material Taxes (other than pursuant to an extension of time to file any Tax Return granted in the Ordinary Course of Business of not more than seven months), or change any material accounting method in respect of Taxes; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(xv)&#8195;(A) materially amend, terminate (other than automatic terminations) or expressly release any material rights under any Parent Material Contract, or (B) enter into, renew or extend the term of (other than automatic renewals or extensions) any Contract that is or would be considered a Parent Material Contract under any of clauses <u>(ii)</u>, <u>(vii</u>) or <u>(x</u>) of Section&#160;<u>4.11(a)</u> (it being understood that the renewal or extension of any such Contract in the Ordinary Course of Business shall be permitted so long as the renewed or extended Contract contains terms of the type described in clauses <u>(ii)</u>, <u>(vii</u>) or <u>(x</u>) of Section&#160;<u>4.11(a)</u> that are no less favorable to Parent or its Subsidiaries as the relevant terms in the existing Contract) if in effect on the date hereof; </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-38<br></div></div></div>
<!--End Page 423-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 424-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg44"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(xvi)&#8195;fail to pay accounts payable and other obligations when due (or, if earlier, the date that such account payable or other obligation would typically be paid by Parent in the Ordinary Course of Business), or accelerate the collection of accounts receivable; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(xvii)&#8195;make any expenditures, incur any liabilities or discharge or satisfy any liabilities greater than $100,000, in each case, other than those expenditures or liabilities that (A) will not survive the Closing, (B) are discharged or satisfied prior to the Closing, and/or (C)&#160;are taken into account in the calculation of Parent Net Cash; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(xviii)&#8195;following the delivery by Parent to the Company of the Parent Net Cash Schedule pursuant to <u>Section&#160;2.6(a)</u>, incur or pay any liability, obligation or commitment (including any Transaction Expense) that would result in a reduction of Parent Net Cash as of the Closing by more than $50,000 in the aggregate; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 30pt; text-indent: 30pt; text-align: left;">(xix)&#8195;other than as required by Law or GAAP, take any action to change accounting policies or procedures; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(xx)&#8195;(A) settle or compromise any Legal Proceeding other than solely for monetary damages (net of insurance proceeds received) not in excess of $200,000 individually or $1,000,000 in the aggregate; <u>provided</u> that such settlement or compromise does not impose any non-monetary obligations on Parent or its Subsidiaries (other than customary confidentiality and de minimis contractual obligations in the applicable compromise or settlement agreement that are incidental to an award of monetary damages thereunder) and does not involve the admission of wrongdoing by Parent, any of its Subsidiaries or any of their respective directors or officers or (B) initiate any Legal Proceeding; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(xxi)&#8195;enter into or amend any Contract if such Contract or amendment would reasonably be expected to prevent or materially impede, interfere with, hinder or delay the consummation of the Contemplated Transactions; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(xxii)&#8195;fail to maintain in full force and effect the existing insurance policies of Parent or to renew or replace such insurance policies with comparable insurance policies; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 30pt; text-indent: 30pt; text-align: left;">(xxiii)&#8195;dissolve or liquidate Parent or any Subsidiary thereof; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 30pt; text-indent: 30pt; text-align: left;">(xxiv)&#8195;enter into any new line of business outside Parent&#8217;s existing business; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(xxv)&#8195;make any payment or loan to, or enter into any agreement, arrangement or understanding with, any of its directors, managers, officers or other Affiliates; or </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 30pt; text-indent: 30pt; text-align: left;">(xxvi)&#8195;agree, resolve or commit to do any of the foregoing. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(c)&#8195;<u>Notice of Material Events</u>. During the Pre-Closing Period, each Party shall promptly notify the other Party in writing upon becoming aware of any event, condition, fact or circumstance that would reasonably be expected to make the satisfaction of any of the conditions set forth&#160;in <u>Article&#160;VI</u> impossible. Without limiting the generality of the foregoing, a Party shall promptly advise the other Party in writing upon becoming aware of (i) any claim asserted or Legal Proceeding commenced, or, to the Party&#8217;s knowledge, either: (A) with respect to a Governmental Entity, overtly threatened; or (B) with respect to any other Person, threatened in writing, in each case against, relating to, involving or otherwise affecting any of the Contemplated Transactions; (ii) any knowledge of any notice from any Person alleging that the consent of such Person is or may be required in connection with the Merger or any of the other Contemplated Transactions; and (iii) any other material Legal Proceeding or material claim threatened in writing, commenced or asserted against such Party or its respective Subsidiaries. No notification given pursuant to this <u>Section&#160;5.1(c)</u> shall limit or otherwise affect any of the representations, warranties, covenants, obligations, rights or remedies of the Parties contained in this Agreement or the conditions to the obligations of the Parties under this Agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(d)&#8195;All notices, requests, instructions, communications or other documents to be given in connection with any consultation or approval required pursuant to this <u>Section&#160;5.1</u> shall be in writing and shall be deemed given as provided for in <u>Section&#160;8.7</u>, and, in each case, shall be addressed to such individuals as the Parties shall designate in writing from time to time. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS52"><!--Anchor--></a>5.2&#8195;<u>Company Acquisition Proposals; Company Change in Recommendation</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;<u>No Solicitation or Negotiation</u>. During the Pre-Closing Period, except as expressly permitted by this <u>Section&#160;5.2</u>, the Company shall not, and the Company shall cause its and its Subsidiaries&#8217; directors, officers and employees not to, and shall cause its and their respective investment bankers, attorneys, accountants and other advisors, agents and representatives (collectively, along with such directors, officers and employees, &#8220;<font style="font-weight: bold;">Representatives</font>&#8221;) not to, directly or indirectly: </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(i)&#8195;solicit, initiate, induce, knowingly encourage or knowingly facilitate (including by way of granting a waiver under Section&#160;203&#160;of the DGCL) any inquiries or the making of any proposal or offer that constitutes, or could reasonably be expected to lead to, a Company Acquisition Proposal; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(ii)&#8195;participate in any discussions or negotiations or cooperate in any way with any Person regarding any Company Acquisition Proposal or any inquiry, proposal or offer that could reasonably be expected to lead to a Company Acquisition Proposal; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(iii)&#8195;provide any non-public information or data concerning the Company or any of its Subsidiaries to any Person in connection with, or for the purpose of soliciting, initiating, inducing, encouraging or facilitating, any Company Acquisition Proposal or any inquiry, proposal or offer that could reasonably be expected to lead to a Company Acquisition Proposal; </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-39<br></div></div></div>
<!--End Page 424-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 425-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg45"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(iv)&#8195;enter into any binding or nonbinding letter of intent, term sheet, memorandum of understanding, merger agreement, acquisition agreement, agreement in principle, option agreement, joint venture agreement, partnership agreement, lease agreement or other similar agreement with respect to, or that could reasonably be expected to lead to, a Company Acquisition Proposal; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(v)&#8195;adopt, approve, declare advisable or recommend or make any public statement approving or recommending any inquiry, proposal or offer that constitutes, or could reasonably be expected to lead to, a Company Acquisition Proposal (including by approving any transaction, or approving any Person becoming an &#8220;interested stockholder,&#8221; for purposes of Section&#160;203 of the DGCL); </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(vi)&#8195;take any action or exempt any Person (other than Parent and its Subsidiaries) from the restriction on &#8220;business combinations&#8221; or any similar provision contained in applicable takeover laws or the Company&#8217;s organizational or other governing documents; or </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 30pt; text-indent: 30pt; text-align: left;">(vii)&#8195;resolve, publicly propose or agree to do any of the foregoing. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company shall, and shall cause its Subsidiaries and Representatives to, immediately cease and cause to be terminated any solicitation, encouragement, discussions and negotiations with any Person conducted heretofore with respect to any Company Acquisition Proposal, or inquiry, proposal or offer that could reasonably be expected to lead to a Company Acquisition Proposal and shall promptly terminate access by any such Person to any physical or electronic data rooms relating to any such Company Acquisition Proposal. The Company shall (i) as soon as reasonably practicable after the date of this Agreement (and in all events no later than three Business Days), deliver a written notice to each Person that entered into a confidentiality agreement in anticipation of potentially making a Company Acquisition Proposal within the last 12 months, to the effect that the Company is ending all discussions and negotiations with such Person with respect to any such Company Acquisition Proposal effective as of the date hereof and requesting the prompt return or destruction of all confidential information previously furnished to such Person by or on behalf of the Company relating to any Company Acquisition Proposal (and the Company shall use its reasonable best efforts to have such information returned or destroyed) and immediately terminate all physical and electronic data room access previously granted to any such party or its Representatives and (ii)&#160;commencing on the date of this Agreement, prohibit any third party (other than Parent and its Representatives) from having access to any physical or electronic data room relating to any possible Company Acquisition Proposal. The Company shall use its reasonable best efforts to enforce the terms of each confidentiality agreement with any such Person. The Company shall not grant any waiver of, or agree to any amendment or modification to, or release any such Person from, any such agreement, to permit such Person to submit a Company Acquisition Proposal. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;<u>Notice</u>. The Company shall promptly (and, in any event, within 24 hours) notify Parent (orally and in writing) if (i) any written or other inquiries, proposals or offers with respect to a Company Acquisition Proposal or any inquiries, proposals, offers or requests for information relating to or that could reasonably be expected to lead to a Company Acquisition Proposal are received by the Company or any of its Representatives, (ii) any Person requests non-public information from the Company or any of its Representatives in connection with any Company Acquisition Proposal (<u>provided</u> that the Company shall only be required to provide notice once per Person under this clause (ii)) or (iii) any discussions or negotiations with respect to or that could reasonably be expected to lead to a Company Acquisition Proposal are sought to be initiated with the Company, indicating, in connection with such notice, the name of such Person and the material terms and conditions of any proposals or offers (including, if applicable, copies of any written requests, proposals or offers, including proposed agreements and other material written communications or, if oral, a summary of the material terms and conditions of such proposal or offer), and thereafter shall keep Parent reasonably informed, on a current basis (and in any event within 24 hours), of any material developments with respect to any such proposals or offers (including any amendments thereto), including by promptly providing copies of any additional requests, proposals or offers, including any drafts of proposed agreements and any amendments thereto and other information set forth above and copies of any written materials provided to such Person by the Company or any of its Representatives. The Company agrees that it and its Subsidiaries will not enter into any confidentiality agreement with any Person subsequent to the date of this Agreement which prohibits the Company from providing any information to Parent in accordance with this <u>Section 5.2</u> or otherwise prohibits the Company from complying with its obligations under this <u>Section&#160;5.2</u>. The Company further agrees that it will not provide information to any Person pursuant to any confidentiality agreement entered into prior to the date of this Agreement unless such Person agrees prior to receipt of such information to waive any provision that would prohibit the Company from providing any information to Parent in accordance with this <u>Section&#160;5.2</u> or otherwise prohibit the Company from complying with its obligations under this <u>Section&#160;5.2</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(c)&#8195;For purposes of this Agreement, &#8220;<font style="font-weight: bold;">Company Acquisition Proposal</font>&#8221; means any transaction or series of related transactions (other than the Contemplated Transactions) involving: (i) any acquisition or purchase from the Company by any Person or &#8220;group&#8221; (as defined in or under Section&#160;13(d) of the Exchange Act), directly or indirectly, of more than a 25% interest in the total outstanding securities (or instruments convertible into or exercisable or exchangeable for 25% or more of such securities) of the Company, including pursuant to a stock purchase, merger, consolidation, tender offer, share exchange or other transaction involving the Company or any of its Subsidiaries; (ii) any merger, consolidation, business combination, share exchange, issuance of securities, acquisition of securities, reorganization, recapitalization or other similar transaction involving the Company, pursuant to which the stockholders of the Company immediately preceding such transaction hold less than 75% of the equity interests in the surviving or resulting entity of such transaction or any parent entity thereof; (iii) any sale, lease, exchange, transfer or disposition (in each case, other than in the ordinary course of business) of more than 25% of the assets of the Company and its Subsidiaries (taken as a whole) (measured by the fair market value thereof); or (iv) any combination of the foregoing; <u>provided</u> that the negotiation of and entry into a Company Collaboration Agreement shall not constitute a Company Acquisition Proposal. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(d)&#8195;The Company agrees that in the event that the Company or any Representative of the Company takes any action which, if taken by the Company, would constitute a breach of this <u>Section&#160;5.2</u>, the Company shall be deemed to be in breach of this <u>Section&#160;5.2</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(e)&#8195;<u>No Company Change in Recommendation or Company Alternative Acquisition Agreement</u>. Except as provided in <u>Section&#160;5.2(f)</u>, the Company Board and each committee of the Company Board shall not (i)(A) withhold, withdraw, qualify or modify (or propose or resolve to withhold, </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-40<br></div></div></div>
<!--End Page 425-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 426-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg46"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">withdraw, qualify or modify), in a manner adverse to Parent, the Company Board Recommendation or (B) approve, recommend or otherwise declare advisable (or propose or resolve to approve, recommend or otherwise declare advisable) any Company Acquisition Proposal (any such action referred to in this clause (i), a &#8220;<font style="font-weight: bold;">Company Change in Recommendation</font>&#8221;) or (ii) approve, recommend or declare advisable, or propose to approve, recommend or declare advisable, or cause or permit the Company or any of its Subsidiaries to enter into any letter of intent, term sheet, memorandum of understanding, agreement in principle, acquisition agreement, merger agreement, option agreement, joint venture agreement, partnership agreement, lease agreement or other similar agreement relating to or that could reasonably be expected to lead to any Company Acquisition Proposal or any agreement requiring the Company (or that would require or could reasonably be expected to require the Company) to abandon, terminate, delay or fail to consummate the Merger or any other transaction contemplated by this Agreement or that would otherwise materially impede, interfere with or be inconsistent with, the Contemplated Transactions (a &#8220;<font style="font-weight: bold;">Company Alternative Acquisition Agreement</font>&#8221;). </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(f)&#8195;<u>Company Change in Recommendation Due to Superior Proposal</u>. Notwithstanding anything to the contrary set forth in <u>Section&#160;5.2(d)</u>, following receipt of a bona fide written Company Acquisition Proposal by the Company after the date of this Agreement that did not result from a breach of this <u>Section&#160;5.2</u> and with respect to which the Company has received a written, definitive form of Company Alternative Acquisition Agreement that has not been withdrawn, and the Company Board determining in good faith, after consultation with outside financial advisors and outside legal counsel, that such Company Acquisition Proposal constitutes a Company Superior Proposal, the Company Board may, at any time prior to the time the Company Stockholder Approval is obtained, make a Company Change in Recommendation, if all of the following conditions are met: </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(i)&#8195;the Company shall have complied in all material respects with the provisions of this <u>Section&#160;5.2</u> with respect to such Company Acquisition Proposal and shall have (A) provided to Parent four Business Days&#8217; prior written notice, which shall state expressly (1) that it has received a written Company Acquisition Proposal that constitutes a Company Superior Proposal, (2) the material terms and conditions of the Company Acquisition Proposal (including the consideration offered therein and the identity of the Person or group making the Company Acquisition Proposal), including an unredacted copy of the Company Alternative Acquisition Agreement and all other written documents and a summary of the material terms of oral communications related to the Company Superior Proposal (it being understood and agreed that any material amendment to any Company Acquisition Proposal (including the financial terms or any other material term or condition of such Company Acquisition Proposal) shall require a new notice to Parent and an additional two Business Day notice period) and (3) that, subject to clause (ii) below, the Company Board has determined to effect a Company Change in Recommendation, and (B) prior to making such a Company Change in Recommendation, (x) engaged, and used its reasonable best efforts to cause its Representatives to engage, in good faith negotiations with Parent (to the extent Parent wishes to engage) during such four&#160;Business Day period to consider adjustments to the terms and conditions of this Agreement or other proposals that may be proposed in writing by Parent during such notice period such that such Company Acquisition Proposal ceases to constitute a Company Superior Proposal, and (y) in determining whether to make a Company Change in Recommendation, the Company Board shall take into account any changes to the terms of this Agreement, and any other proposals, proposed in writing by Parent; and </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(ii)&#8195;the Company Board shall have determined, in good faith, after consultation with outside financial advisors and outside legal counsel, that, in light of such Company Acquisition Proposal and taking into account any revised terms proposed in writing by Parent and the results of negotiations with Parent pursuant to clause (i) above, such Company Acquisition Proposal continues to constitute a Company Superior Proposal and, after consultation with outside legal counsel, that the failure to make such Company Change in Recommendation would reasonably be expected to be inconsistent with the fiduciary duties of the Company Board to the holders of Company Shares under applicable Law. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(g)&#8195;<u>Company Change in Recommendation Due to Company Intervening Event</u>. Notwithstanding anything to the contrary set forth in <u>Section&#160;5.2(e)</u>, upon the occurrence of any Company Intervening Event, the Company Board may, at any time prior to the time the Company Stockholder Approval is obtained, make a Company Change in Recommendation, if all of the following conditions are met: </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(i)&#8195;the Company shall have (A) provided to Parent four Business Days&#8217; prior written notice, which shall (1) set forth in reasonable detail information describing the Company Intervening Event and the rationale for the Company Change in Recommendation (it being understood and agreed that any amendment to the facts and circumstances relating to the Company Intervening Event shall require a new notice to Parent and an additional two Business Day notice period), and (2) state expressly that, subject to clause (ii) below, the Company Board has determined to effect a Company Change in Recommendation and (B) prior to making such a Company Change in Recommendation, engaged in good faith negotiations with Parent (to the extent Parent wishes to engage) during such four Business Day period to consider adjustments to the terms and conditions of this Agreement or other proposals that may be proposed in writing by Parent during such notice period in such a manner that the failure of the Company Board to make a Company Change in Recommendation in response to the Company Intervening Event in accordance with clause (ii) below would no longer be inconsistent with the fiduciary duties of the Company Board to the holders of Company Shares under applicable Law; and </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(ii)&#8195;the Company Board shall have determined in good faith, after consultation with outside financial advisors and outside legal counsel, that in light of such Company Intervening Event and taking into account any revised terms proposed in writing by Parent and the results of negotiations with Parent pursuant to clause (i) above, the failure to make a Company Change in Recommendation, would be inconsistent with the fiduciary duties of the Company Board to the holders of Company Shares under applicable Law. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(h)&#8195;<u>Certain Permitted Disclosure</u>. Nothing contained in this <u>Section&#160;5.2</u> shall be deemed to prohibit the Company from complying with its disclosure obligations under applicable U.S. federal or state Law (as determined in good faith by the Company) with regard to a Company </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-41<br></div></div></div>
<!--End Page 426-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 427-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg47"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Acquisition Proposal; <u>provided</u>, that this <u>Section&#160;5.2(h)</u> shall not be deemed to permit the Company or the Company Board to effect a Company Change in Recommendation except in accordance with <u>Sections 5.2(f)</u> or <u>5.2(g)</u>. The Company shall not submit to its stockholders for approval any Company Acquisition Proposal prior to the valid termination of this Agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS53"><!--Anchor--></a>5.3&#8195;<u>Parent</u><u> Acquisition</u><u> Proposals; Parent Change in Recommendation</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;<u>No Solicitation or Negotiation</u>. During the Pre-Closing Period, except as expressly permitted by this <u>Section&#160;5.3</u> or in connection with any Parent Legacy Transaction conducted in accordance with <u>Section&#160;5.23</u>, Parent shall not, and Parent shall cause its and its Subsidiaries&#8217; directors, officers and employees not to, and shall cause its and their respective Representatives not to, directly or indirectly: </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(i)&#8195;solicit, initiate, induce, knowingly encourage or knowingly facilitate (including by way of granting a waiver under Section&#160;203&#160;of the DGCL) any inquiries or the making of any proposal or offer that constitutes, or could reasonably be expected to lead to, a Parent Acquisition Proposal; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(ii)&#8195;participate in any discussions or negotiations or cooperate in any way with any Person regarding any Parent Acquisition Proposal or any inquiry, proposal or offer that could reasonably be expected to lead to a Parent Acquisition Proposal; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(iii)&#8195;provide any non-public information or data concerning Parent or any of its Subsidiaries to any Person in connection with, or for the purpose of soliciting, initiating, inducing, encouraging or facilitating, any Parent Acquisition Proposal or any inquiry, proposal or offer that could reasonably be expected to lead to a Parent Acquisition Proposal; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(iv)&#8195;enter into any binding or nonbinding letter of intent, term sheet, memorandum of understanding, merger agreement, acquisition agreement, agreement in principle, option agreement, joint venture agreement, partnership agreement, lease agreement or other similar agreement with respect to, or that could reasonably be expected to lead to, a Parent Acquisition Proposal (other than an Acceptable Parent Confidentiality Agreement entered into in accordance with <u>Section&#160;5.3(b)</u>); </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(v)&#8195;adopt, approve, declare advisable or recommend or make any public statement approving or recommending any inquiry, proposal or offer that constitutes, or could reasonably be expected to lead to, a Parent Acquisition Proposal (including by approving any transaction, or approving any Person becoming an &#8220;interested stockholder,&#8221; for purposes of Section&#160;203 of the DGCL); </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(vi)&#8195;take any action or exempt any Person (other than the Company and its Subsidiaries) from the restriction on &#8220;business combinations&#8221; or any similar provision contained in applicable takeover laws or Parent&#8217;s organizational or other governing documents; or </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 30pt; text-indent: 30pt; text-align: left;">(vii)&#8195;resolve, publicly propose or agree to do any of the foregoing. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Parent shall, and shall cause its Subsidiaries and Representatives to, immediately cease and cause to be terminated any solicitation, encouragement, discussions and negotiations with any Person conducted heretofore with respect to any Parent Acquisition Proposal, or inquiry, proposal or offer that could reasonably be expected to lead to a Parent Acquisition Proposal and shall promptly terminate access by any such Person to any physical or electronic data rooms relating to any such Parent Acquisition Proposal. Parent shall (i) as soon as reasonably practicable after the date of this Agreement (and in all events no later than three Business Days), deliver a written notice to each Person that entered into a confidentiality agreement in anticipation of potentially making a Parent Acquisition Proposal within the last 12 months, to the effect that Parent is ending all discussions and negotiations with such Person with respect to any such Parent Acquisition Proposal effective as of the date hereof and requesting the prompt return or destruction of all confidential information previously furnished to such Person by or on behalf of Parent relating to any Parent Acquisition Proposal (and Parent shall use its reasonable best efforts to have such information returned or destroyed) and immediately terminate all physical and electronic data room access previously granted to any such party or its Representatives and (ii) commencing on the date of this Agreement, prohibit any third&#160;party (other than the Company and its Representatives) from having access to any physical or electronic data room relating to any possible Parent Acquisition Proposal. Parent shall use its reasonable best efforts to enforce the terms of each confidentiality agreement with any such Person. Parent shall not grant any waiver of, or agree to any amendment or modification to, or release any such Person from, any such agreement, to permit such Person to submit a Parent Acquisition Proposal, unless in any such case the Parent Board shall have determined, in good faith, after consultation with outside legal counsel, that the failure to take such actions would be inconsistent with the fiduciary duties of the Parent Board to the holders of Parent capital stock under applicable Law. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;<u>Fiduciary Exception to No Solicitation Provision</u>. Notwithstanding anything to the contrary in <u>Section&#160;5.3(a)</u>, prior to the time, but not after, the Parent Stockholder Approval is obtained, Parent may, in response to a <font style="font-style: italic;">bona fide</font> written Parent Acquisition Proposal (which Parent Acquisition Proposal was made after the date of this Agreement and has not been withdrawn) which did not result from a breach of this <u>Section&#160;5.3</u> and so long as it has provided written notice to the Company of the identity of such Person or group making the Parent Acquisition Proposal, the material terms and conditions of such Parent Acquisition Proposal (including, if applicable, copies of any material written communications) and its intention to engage or participate in any discussions or negotiations with any such Person or group, (i) provide access to non-public information regarding Parent or any of its Subsidiaries to the Person or group making the Parent Acquisition Proposal (<u>provided</u><font style="font-style: italic;"> </font>that such information has previously been made available to the Company or is provided to the Company substantially concurrently with the making of such information available to such Person or group and that, prior to furnishing any such non-public information, Parent receives from the Person or group making such Parent Acquisition Proposal an executed confidentiality agreement with terms at least as restrictive in all material respects (including with respect to confidentiality and restrictions on use) on such Person(s) as the Confidentiality Agreement&#8217;s terms are on with the Company (an &#8220;<font style="font-weight: bold;">Acceptable Parent Confidentiality Agreement</font>&#8221;)) (it being understood that such confidentiality agreement need not include a &#8220;standstill&#8221; agreement or prohibit the making or amending of a Parent Acquisition Proposal), and (ii) engage or participate in any discussions or negotiations with any such Person or group regarding such Parent Acquisition Proposal if, and only if, prior to taking any action described in clause (i) or (ii) above, the Parent Board determines </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-42<br></div></div></div>
<!--End Page 427-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 428-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg48"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">in good faith after consultation with outside financial advisors and outside legal counsel that (x) such Parent Acquisition Proposal either constitutes a Parent Superior Proposal or could reasonably be expected to result in a Parent Superior Proposal and (y) the failure to take such action would reasonably be expected to be inconsistent with the fiduciary duties of the Parent Board to the holders of Parent capital stock under applicable Law. Parent shall provide the Company with an accurate and complete copy of the Acceptable Parent Confidentiality Agreement entered into as contemplated by this <u>Section&#160;5.3(b)</u> promptly (and in any event within 24 hours) after the execution thereof. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(c)&#8195;<u>Notice</u>. Parent shall promptly (and, in any event, within 24 hours) notify the Company (orally and in writing) if (i) any written or other inquiries, proposals or offers with respect to a Parent Acquisition Proposal or any inquiries, proposals, offers or requests for information relating to or that could reasonably be expected to lead to a Parent Acquisition Proposal are received by Parent or any of its Representatives, (ii) any Person requests non-public information from Parent or any of its Representatives in connection with any Parent Acquisition Proposal (<u>provided</u> that Parent shall only be required to provide notice once per Person under this clause (ii)) or (iii) any discussions or negotiations with respect to or that could reasonably be expected to lead to a Parent Acquisition Proposal are sought to be initiated with Parent, indicating, in connection with such notice, the name of such Person and the material terms and conditions of any proposals or offers (including, if applicable, copies of any written requests, proposals or offers, including proposed agreements and other material written communications or, if oral, a summary of the material terms and conditions of such proposal or offer), and thereafter shall keep the Company reasonably informed, on a current basis (and in any event within 24&#160;hours), of any material developments with respect to any such proposals or offers (including any amendments thereto), including by promptly providing copies of any additional requests, proposals or offers, including any drafts of proposed agreements and any amendments thereto and other information set forth above and copies of any written materials provided to such Person by Parent or any of its Representatives. Parent agrees that it and its Subsidiaries will not enter into any confidentiality agreement with any Person subsequent to the date of this Agreement which prohibits Parent from providing any information to the Company in accordance with this <u>Section&#160;5.3</u> or otherwise prohibits Parent from complying with its obligations under this <u>Section&#160;5.3</u>. Parent further agrees that it will not provide information to any Person pursuant to any confidentiality agreement entered into prior to the date of this Agreement unless such Person agrees prior to receipt of such information to waive any provision that would prohibit Parent from providing any information to the Company in accordance with this <u>Section&#160;5.3</u> or otherwise prohibit Parent from complying with its obligations under this <u>Section 5.3</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 40pt; text-align: left;">(d)&#8195;<u>Definitions</u>. For purposes of this Agreement: </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Parent Acquisition Proposal</font>&#8221; means any transaction or series of related transactions (other than the Contemplated Transactions) involving: (i) any acquisition or purchase from Parent by any Person or &#8220;group&#8221; (as defined in or under Section&#160;13(d) of the Exchange Act), directly or indirectly, of more than a 15% interest in the total outstanding securities (or instruments convertible into or exercisable or exchangeable for 15% or more of such securities) of Parent, including pursuant to a stock purchase, merger, consolidation, tender offer, share exchange or other transaction involving Parent or any of its Subsidiaries; (ii) any tender offer (including self-tender) or exchange offer that if consummated would result in any Person or &#8220;group&#8221; (as defined in or under Section&#160;13(d) of the Exchange Act) beneficially owning 15% or more of the total outstanding securities (or instruments convertible into or exercisable or exchangeable for 15% or more of such securities) of Parent; (iii) any merger, consolidation, business combination, share exchange, issuance of securities, acquisition of securities, reorganization, recapitalization or other similar transaction involving Parent, pursuant to which the stockholders of Parent immediately preceding such transaction hold less than 85% of the equity interests in the surviving or resulting entity of such transaction or any parent entity thereof; (iv) any sale, lease, exchange, transfer or disposition (in each case, other than in the ordinary course of business) of more than 15% of the assets of Parent and its Subsidiaries (taken as a whole) (measured by the fair market value thereof); or (v) any combination of the foregoing. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Parent Intervening Event</font>&#8221; means any Effect that is material to Parent and its Subsidiaries taken as a whole, occurring or arising after the date of this Agreement that (i) was not known to, or reasonably foreseeable by, the Parent Board (or if known, the magnitude or effect of which was not known to, or reasonably foreseeable) prior to the execution of this Agreement, which Effect (or the magnitude or effect thereof) becomes known to, or reasonably foreseeable by, the Parent Board prior to the receipt of the Parent Stockholder Approval and (ii) does not relate to (A) a Parent Acquisition Proposal or (B) (1) any changes in the market price or trading volume of Parent, (2) the mere fact the Company or Parent meets or exceeds any internal or analysts&#8217; published projections, forecasts, estimates or predictions of revenue, earnings or other financial or operating metrics for any period ending on or after the date of this Agreement, or changes after the date of this Agreement in the market price or trading volume of the Parent Common Stock or the credit rating of Parent (it being understood that, with respect to clause (2), the facts or occurrences giving rise or contributing to such change or event may be taken into account when determining a Parent Intervening Event), (3) any events or developments relating to the Company or any of its Affiliates, (4) any event or development generally affecting the industries in which Parent or the Company operate or in the economy generally or other general business, financial, market or political conditions, including changes in interest rates in the United States or any other country or region in the world and changes in exchange rates for the currencies of any countries and any suspension of trading in securities (whether equity, debt, derivative or hybrid securities) generally on any securities exchange or over-the-counter market operating in the United States or any other country or region in the world, (5) any change in any applicable Law or other legal or regulatory conditions or changes in GAAP or other accounting standards, (6) any event or development to the extent directly resulting from the announcement or pendency of, or any actions required to be taken by Parent or the Company (or refrained to be taken by Parent or the Company) pursuant to the Agreement or the consummation of the Contemplated Transactions, including expiration or termination of waiting periods or the receipt of approvals, consents or clearances applicable to the Merger under the Antitrust Laws, (7)&#160;earthquakes, hurricanes, tsunamis, tornadoes, floods, mudslides, wildfires or other natural disasters, weather conditions and other force majeure events or (8)&#160;any Legal Proceedings made or brought by any of the current or former stockholders of Parent or the Company (on their own behalf or on behalf of Parent or the Company) against Parent or the Company, including Legal Proceedings arising out of the Contemplated Transactions. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-43<br></div></div></div>
<!--End Page 428-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 429-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg49"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Parent Superior Proposal</font>&#8221; means any bona fide, written Parent Acquisition Proposal on terms which the Parent Board determines in its good faith judgment, after consultation with outside financial advisors and outside legal counsel, would reasonably be expected to be consummated in accordance with its terms, taking into account all legal, financial and regulatory aspects of the proposal and the Person or group of Persons making the proposal, and, if consummated, would result in a transaction more favorable to Parent&#8217;s stockholders from a financial point of view than the Merger (after taking into account any revisions to the terms of the Contemplated Transactions pursuant to <u>Section&#160;5.3(f)</u> of this Agreement and the time likely to be required to consummate such Parent Acquisition Proposal); <u>provided</u> that for purposes of the definition of &#8220;Parent Superior Proposal&#8221;, the references to &#8220;15%&#8221; in the definition of Parent Acquisition Proposal shall be deemed to be references to &#8220;50%&#8221;. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(e)&#8195;<u>No Parent Change in Recommendation or Parent Alternative Acquisition Agreement</u>. Except as provided in <u>Section&#160;5.3(f)</u>, the Parent Board and each committee of the Parent Board shall not (and the Special Committee shall not recommend that the Parent Board) (i)(A) withhold, withdraw, qualify or modify (or publicly propose or resolve to withhold, withdraw, qualify or modify), in a manner adverse to the Company, the Parent Board Recommendation or (B) approve, recommend or otherwise declare advisable (or publicly propose or resolve to approve, recommend or otherwise declare advisable) any Parent Acquisition Proposal or make or authorize the making of any public statement (oral or written), (C) remove the Parent Board Recommendation from or fail to include the Parent Board Recommendation in the Proxy Statement/Prospectus (any such action referred to in this clause (i), a &#8220;<font style="font-weight: bold;">Parent Change in Recommendation</font>&#8221;) or (ii) approve, recommend or declare advisable, or propose to approve, recommend or declare advisable, or cause or permit Parent or any of its Subsidiaries to enter into any letter of intent, term sheet, memorandum of understanding, agreement in principle, acquisition agreement, merger agreement, option agreement, joint venture agreement, partnership agreement, lease agreement or other similar agreement (other than an Acceptable Parent Confidentiality Agreement entered into in compliance with <u>Section&#160;5.3(b)</u>) relating to or that could reasonably be expected to lead to any Parent Acquisition Proposal or any agreement requiring Parent (or that would require or could reasonably be expected to require Parent) to abandon, terminate, delay or fail to consummate the Merger or any other transaction contemplated by this Agreement or that would otherwise materially impede, interfere with or be inconsistent with, the Contemplated Transactions (a &#8220;<font style="font-weight: bold;">Parent Alternative Acquisition Agreement</font>&#8221;). </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(f)&#8195;<u>Parent Change in Recommendation Due to Superior Proposal</u>. Notwithstanding anything to the contrary set forth in <u>Section&#160;5.3(e)</u>, following receipt of a <font style="font-style: italic;">bona fide</font> written Parent Acquisition Proposal by Parent after the date of this Agreement that did not result from a breach of this <u>Section&#160;5.3</u> and with respect to which Parent has received a written, definitive form of a Parent Alternative Acquisition Agreement that has not been withdrawn, and the Parent Board determining in good faith, after consultation with outside financial advisors and outside legal counsel, that such Parent Acquisition Proposal constitutes a Parent Superior Proposal, the Parent Board may, at any time prior to the time the Parent Stockholder Approval is obtained, make a Parent Change in Recommendation, if all of the following conditions are met: </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(i)&#8195;Parent shall have complied in all material respects with the provisions of this <u>Section&#160;5.3</u> with respect to such Parent Acquisition Proposal and shall have (A) provided to the Company four Business Days&#8217; prior written notice, which shall state expressly (1) that it has received a written Parent Acquisition Proposal that constitutes a Parent Superior Proposal, (2) the material terms and conditions of the Parent Acquisition Proposal (including the consideration offered therein and the identity of the Person or group making the Parent Acquisition Proposal), including an unredacted copy of the Parent Alternative Acquisition Agreement and all other written documents and a summary of the material terms of oral communications related to the Parent Superior Proposal (it being understood and agreed that any material amendment to any Parent Acquisition Proposal (including the financial terms or any other material term or condition of such Parent Acquisition Proposal) shall require a new notice to the Company and an additional two Business Day notice period) and (3) that, subject to clause (ii) below, the Parent Board has determined to effect a Parent Change in Recommendation, and (B) prior to making such a Parent Change in Recommendation, (x) engaged, and used its reasonable best efforts to cause its Representatives to engage, in good faith negotiations with the Company (to the extent the Company wishes to engage) during such four Business Day period to consider adjustments to the terms and conditions of this Agreement or other proposals that may be proposed in writing by the Company during such notice period such that the Parent Acquisition Proposal ceases to constitute a Parent Superior Proposal, and (y) in determining whether to make a Parent Change in Recommendation, the Parent Board shall take into account any changes to the terms of this Agreement, and any other proposals, proposed in writing by the Company; and </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(ii)&#8195;the Parent Board shall have determined, in good faith, after consultation with outside financial advisors and outside legal counsel, that, in light of such Parent Acquisition Proposal and taking into account any revised terms proposed in writing by the Company and the results of negotiations with Parent pursuant to clause (i) above, such Parent Acquisition Proposal continues to constitute a Parent Superior Proposal and, after consultation with outside legal counsel, that the failure to make such Parent Change in Recommendation would reasonably be expected to be inconsistent with the fiduciary duties of the Parent Board to the holders of Parent capital stock under applicable Law. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(g)&#8195;<u>Parent Change in Recommendation Due to Parent Intervening Event</u>. Notwithstanding anything to the contrary set forth in <u>Section&#160;5.3(e)</u>, upon the occurrence of any Parent Intervening Event, the Parent Board may, at any time prior to the time the Parent Stockholder Approval is obtained, make a Parent Change in Recommendation, if all of the following conditions are met: </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(i)&#8195;Parent shall have (A) provided to the Company four Business Days&#8217; prior written notice, which shall (1) set forth in reasonable detail information describing the Parent Intervening Event and the rationale for the Parent Change in Recommendation (it being understood and agreed that any amendment to the facts and circumstances relating to the Parent Intervening Event shall require a new notice to the Company and an additional two Business Day notice period), and (2) state expressly that, subject to clause (ii) below, the Parent Board has determined to effect a Parent Change in Recommendation and (B) prior to making such a Parent Change in Recommendation, engaged in good faith negotiations with the Company (to the extent the Company wishes to engage) during such four&#160;Business Day period to consider adjustments to </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-44<br></div></div></div>
<!--End Page 429-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 430-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg50"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">the terms and conditions of this Agreement or other proposals that may be proposed in writing by the Company during such notice period in such a manner that the failure of the Parent Board to make a Parent Change in Recommendation in response to the Parent Intervening Event in accordance with clause (ii) below would no longer be inconsistent with the fiduciary duties of the Parent Board to the holders of Parent capital stock under applicable Law; and </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(ii)&#8195;the Parent Board shall have determined in good faith, after consultation with outside financial advisors and outside legal counsel, that in light of such Parent Intervening Event and taking into account any revised terms proposed in writing by the Company and the results of negotiations with the Company pursuant to clause (i) above, the failure to make a Parent Change in Recommendation, would be inconsistent with the fiduciary duties of Parent Board to the holders of Parent&#8217;s capital stock under applicable Law. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(iii)&#8195;Parent&#8217;s obligation to call, give notice of and hold the Parent Stockholder Meeting in accordance with <u>Section&#160;5.5(b)</u> shall not be limited or otherwise affected by the commencement, disclosure, announcement or submission of any Parent Superior Proposal or Parent Acquisition Proposal or by any Parent Change in Recommendation. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(h)&#8195;<u>Certain Permitted Disclosure</u>. Nothing contained in this <u>Section&#160;5.3</u> shall be deemed to prohibit Parent from complying with its disclosure obligations under applicable U.S. federal or state Law (as determined in good faith by Parent) with regard to a Parent Acquisition Proposal; <u>provided</u> that any &#8220;stop look and listen&#8221; communication to its stockholders of the nature contemplated by Rule&#160;14d-9 under the Exchange Act shall include an affirmative statement to the effect that the recommendation of the Parent Board is affirmed or remains unchanged; <u>provided</u>, <u>further</u>, that this <u>Section&#160;5.3(h)</u> shall not be deemed to permit the Parent Board to effect a Parent Change in Recommendation except in accordance with <u>Sections&#160;5.3(f)</u> or <u>5.3(g)</u>. Parent shall not submit to the vote of its stockholders any Parent Acquisition Proposal or Parent Superior Proposal prior to the valid termination of this Agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(i)&#8195;Parent agrees that in the event that Parent or any Representative of Parent takes any action which, if taken by Parent, would constitute a breach of this <u>Section&#160;5.3</u>, Parent shall be deemed to be in breach of this <u>Section&#160;5.3</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS54"><!--Anchor--></a>5.4&#8195;<u>Information Supplied</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;Parent shall prepare and cause to be filed with the SEC a proxy statement (as amended or supplemented from time to time, the &#8220;<font style="font-weight: bold;">Proxy Statement/Prospectus</font>&#8221;) with respect to the Parent Stockholders Meeting. As promptly as practicable (and in any event within 60 days) following the date of this Agreement, Parent shall prepare and file with the SEC a registration statement on Form&#160;S-4 (as amended or supplemented from time to time, the &#8220;<font style="font-weight: bold;">Registration Statement</font>&#8221;), in which the Proxy Statement/Prospectus will be included as a prospectus, in connection with the registration under the Securities Act of the shares of Parent Common Stock to be issued in the Merger (it being understood that Parent shall use its reasonable best efforts to prepare and file the Registration Statement with the SEC within 45 days of the date of this Agreement). Parent shall use its reasonable best efforts to have the Registration Statement declared effective under the Securities Act as promptly as practicable after such filing and to keep the Registration Statement effective as long as is necessary to consummate the Merger and the other Contemplated Transactions. Parent shall also take any action (other than qualifying to do business in any jurisdiction in which it is not now so qualified or filing a general consent to service of process) required to be taken under any applicable state securities or &#8220;blue sky&#8221; laws in connection with the issuance of shares of Parent Common Stock in the Merger. Each of the Company and Parent shall furnish or cause to be furnished all information about the such Party and its officers, directors and shareholders requested by the other Party that is required to be disclosed in the Proxy Statement/Prospectus or the Registration Statement, including without limitation all requisite information about each individual designated by the Parent pursuant to <u>Section&#160;5.14</u> to be appointed to the board of directors of Parent upon the Closing. Parent shall use reasonable best efforts to cause the Proxy Statement/Prospectus to be mailed to Parent&#8217;s stockholders as promptly as practicable after the Registration Statement is declared effective under the Securities Act. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;No filing of, or amendment or supplement to, the Registration Statement or the Proxy Statement/Prospectus will be made by Parent without providing the Company a reasonable opportunity to review and comment thereon (other than any filing, amendment or supplement in connection with a Parent Change in Recommendation or a Parent Alternative Acquisition Agreement), and Parent shall consider in good faith and reflect all comments reasonably proposed by the Company. Parent shall promptly provide the Company with copies of all such filings, amendments or supplements to the extent not publicly available. Each of the Company and Parent shall furnish all information concerning such Person and its Affiliates to the other and provide such other assistance as may be reasonably requested by such other Party to be included therein and shall otherwise reasonably assist and cooperate with the other in the preparation of the Registration Statement or Proxy Statement/Prospectus, as applicable, and the resolution of any comments to either received from the SEC. If at any time prior to the receipt of the Parent Stockholder Approval, any information relating to the Company or Parent, or any of their respective Affiliates, directors or officers, should be discovered by the Company or Parent which is required to be set forth in an amendment or supplement to either the Registration Statement or the Proxy Statement/Prospectus, so that either such document would not include any misstatement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading, the Party which discovers such information shall promptly notify the other Party and an appropriate amendment or supplement describing such information shall be promptly filed with the SEC and, to the extent required by applicable Law, disseminated to the stockholders of Parent. The Parties shall notify each other promptly of the receipt of any comments from the SEC or the staff of the SEC and of any request by the SEC or the staff of the SEC for amendments or supplements to the Registration Statement or the Proxy Statement/Prospectus, or for additional information, and shall supply each other with copies of (i) all correspondence between it or any of its Representatives, on the one hand, and the SEC or the staff of the SEC, on the other hand, with respect to the Registration Statement, Proxy Statement/Prospectus or the Merger and (ii) all orders of the SEC relating to the Registration Statement. No response to any comments from the SEC or the staff of the SEC relating to the Proxy Statement/Prospectus will be made by Parent without providing the </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-45<br></div></div></div>
<!--End Page 430-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 431-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg51"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Company a reasonable opportunity to review and comment thereon unless pursuant to a telephone call initiated by the SEC, and Parent shall consider in good faith and reflect all comments reasonably proposed by the Company. Parent will cause the Registration Statement and Proxy Statement/Prospectus to comply as to form in all material respects with the applicable provisions of the Securities Act and the Exchange Act and the rules and regulations thereunder. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(c)&#8195;Prior to the Effective Time, the Company shall, and shall cause its Subsidiaries to, use commercially reasonable efforts to (A)&#160;cooperate in connection with Parent&#8217;s compliance with its obligations under the Exchange Act and the Securities Act and the rules and regulations promulgated thereunder as may be reasonably requested by Parent, including with respect to preparation of the Proxy Statement/Prospectus and the Registration Statement, (B) provide on a timely basis all audited and unaudited consolidated financial statements of the Company and its Subsidiaries required by applicable Law to be included in any filing with the SEC of Parent or any of its affiliates, including the Proxy Statement/Prospectus, the Registration Statement and any Form&#160;8-K related to the transactions contemplated by this Agreement, (C) provide such financial records and information regarding the Company and its Subsidiaries as may be reasonably necessary for Parent to prepare any pro forma financial statements required by applicable Law to be included in any statements, forms, schedules, reports or other documents filed or furnished by Parent or its affiliates with the SEC, including the Proxy Statement/Prospectus, the Registration Statement and any Form&#160;8-K relating to the transactions contemplated by this Agreement and (D) in connection with the provision of audited and unaudited consolidated financial statements of the Company and its Subsidiaries to be included in the Proxy Statement/Prospectus and the Registration Statement, provide a customary &#8220;management&#8217;s discussion and analysis of financial condition and results of operations&#8221; for each period included in such audited and unaudited consolidated financial statements; <u>provided</u> that, upon delivery of any financial statements pursuant to (B) and (C) above, such financial statements shall be deemed Company Financial Statements, as applicable, for purposes of this Agreement and the representations and warranties set forth in Section&#160;3.6 shall be deemed to apply to such financial statements with the same force and effect as if made as of the date of this Agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(d)&#8195;Notwithstanding anything to the contrary contained in this <u>Section&#160;5.4</u>, Parent shall not be in breach of any of the foregoing provisions of this <u>Section&#160;5.4</u> to the extent the failure by the Company or any of its Subsidiaries to deliver any required information to Parent in connection with the Proxy Statement/Prospectus and Registration Statement (including the Company Financial Statements) resulted in the Parent&#8217;s failure to meet its obligations under the foregoing provisions of this <u>Section&#160;5.4</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(e)&#8195;During the period from the date of this Agreement to the earlier of the Effective Time and the time, if any, at which this Agreement is terminated pursuant to Article&#160;VII, the Company shall request its auditors to (i) cooperate with respect to any filing with the SEC of Parent or any of its affiliates, including the Proxy Statement/Prospectus, the Registration Statement and any Form&#160;8-K relating to the transactions contemplated by this Agreement, including in connection with the preparation of any required pro forma financial statements or the delivery of any auditor consents and (ii) provide access to the Parent and its Representatives to the work papers of the Company&#8217;s auditors. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS55"><!--Anchor--></a>5.5&#8195;<u>Stockholder Approvals</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 40pt; text-align: left;">(a)&#8195;<u>Company Stockholder Written Consent</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(i)&#8195;Immediately after the execution of this Agreement, the Company shall solicit, and take all action necessary to obtain, in accordance with this Agreement, the DGCL, the Organizational Documents of the Company and the Investor Agreements, the Company Stockholder Written Consent from the Consenting Company Stockholders constituting the Company Stockholder Approval. Under no circumstances shall the Company assert that any other approval or consent is necessary by its stockholders to approve this Agreement and the Contemplated Transactions. Upon obtaining the Company Stockholder Approval, the Company shall promptly deliver copies of the executed Company Stockholder Written Consent to Parent. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(ii)&#8195;All materials (including any amendments thereto) submitted to the stockholders of the Company in accordance with this <u>Section&#160;5.5(a)</u> shall be subject to Parent&#8217;s advance review and reasonable approval. The Parties shall reasonably cooperate with each other and provide, and require their respective Representatives to provide, the other Party and its Representatives with all true, correct and complete information regarding such Party or its Subsidiaries that is required by applicable Law to be included in any information statement or other materials distributed to the Company&#8217;s stockholders in connection with the Contemplated Transactions or reasonably requested by the other Party to be included therein. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(iii)&#8195;Promptly following receipt of the Company Stockholder Approval, the Company shall prepare and mail a notice (the &#8220;<font style="font-weight: bold;">Stockholder Notice</font>&#8221;) to every stockholder of the Company that did not execute the Company Stockholder Written Consent substantially concurrently with the execution and delivery of this Agreement. The Stockholder Notice shall (A) be a statement to the effect that the Company Board determined that the Merger is advisable in accordance with Section&#160;251(b) of the DGCL and in the best interests of the stockholders of the Company and authorized, approved and adopted this Agreement, the Merger and the other Contemplated Transactions, (B) provide the stockholders of the Company to whom it is sent with notice of the actions taken in the Company Stockholder Written Consent, including the adoption and approval of this Agreement, the Merger and the other Contemplated Transactions in accordance with Section&#160;228(e) of the DGCL and the Organizational Documents of the Company, and (C) include a description of the appraisal rights of the Company&#8217;s stockholders available under the DGCL, along with such other information as is required thereunder and pursuant to applicable Law. All materials (including any amendments thereto) submitted to the stockholders of the Company in accordance with this <u>Section&#160;5.5(a)(iii)</u> shall be subject to Parent&#8217;s advance review and reasonable approval. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-46<br></div></div></div>
<!--End Page 431-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 432-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg52"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: left;">(b)&#8195;<u>Parent Stockholders Meeting</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(i)&#8195;Parent will, as promptly as practicable in accordance with applicable Law and its certificate of incorporation and bylaws, establish a record date for, duly call and give notice of, and use its reasonable best efforts to convene a meeting of holders of Parent Common Stock to consider and vote upon the Parent Share Issuance, the Parent Charter Amendment, the Parent Reverse Stock Split, and any Parent Legacy Transaction that requires the approval of the Parent Stockholders, which meeting shall in any event take place within 45 days after the declaration of the effectiveness of the Registration Statement (the &#8220;<font style="font-weight: bold;">Parent Stockholders Meeting</font>&#8221;). Parent shall use its reasonable best efforts to hold the Parent Stockholders Meeting as soon as practicable after the date on which the Registration Statement becomes effective. Subject to the provisions of <u>Section&#160;5.3</u>, the Parent Board shall (and the Special Committee shall, if applicable, recommend that the Parent Board) include the Parent Board Recommendation in the Proxy Statement/Prospectus and recommend at the Parent Stockholders Meeting that the holders of capital stock of Parent approve the Parent Share Issuance, the Parent Charter Amendment and the Parent Reverse Stock Split, and shall use its reasonable best efforts to obtain and solicit such approval. Notwithstanding the foregoing, (A) if on or before the date on which the Parent Stockholders Meeting is scheduled, Parent reasonably believes that (1) it will not receive proxies representing the Parent Stockholder Approval, whether or not a quorum is present or (2) it will not have enough shares of Parent Common Stock represented to constitute a quorum necessary to conduct the business of the Parent Stockholders Meeting, Parent may (and, if requested by the Company, Parent shall) postpone or adjourn, or make one or more successive postponements or adjournments of, the Parent Stockholders Meeting and (B) Parent may postpone or adjourn the Parent Stockholders Meeting to allow reasonable additional time for the filing or mailing of any supplemental or amended disclosure that Parent has determined, after consultation with outside legal counsel, is reasonably likely to be required under applicable Law and for such supplemental or amended disclosure to be disseminated and reviewed by stockholders of Parent prior to the Parent Stockholders Meeting, as long as the date of the Parent Stockholders Meeting is not postponed or adjourned more than an aggregate of 30 days in connection with all such postponements or adjournments pursuant to either or both of the preceding clauses (A) and (B). </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(ii)&#8195;Notwithstanding any Parent Change in Recommendation, Parent shall comply with its obligations under <u>Section&#160;5.5(b)(i)</u> unless this Agreement is terminated in accordance with <u>Article&#160;VII</u> prior to the Parent Stockholders Meeting. Without the prior written consent of the Company, the Parent Share Issuance, the Parent Charter Amendment and the Parent Reverse Stock Split shall be the only matters (other than matters of procedure and matters required by Law to be voted on by Parent&#8217;s stockholders in connection with the Contemplated Transactions) that Parent shall propose to be acted on by the stockholders of Parent at the Parent Stockholders Meeting. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS56"><!--Anchor--></a>5.6&#8195;<u>Regulatory Approvals; Reasonable Best Efforts</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;Subject to the terms and conditions of this Agreement, each Party shall, and shall cause each of its Subsidiaries and Affiliates to, use its reasonable best efforts to take, or cause to be taken, all actions and to do, or cause to be done, all things necessary, proper or advisable under applicable Laws in connection with the Merger or any of the Contemplated Transactions. Notwithstanding anything in this Agreement to the contrary, Parent and the Company each agree to, and the Company shall cause each Additional Filing Party to, use reasonable best efforts to (i)&#160;prepare and file, as promptly as practicable, but in any event no later than 15 Business Days after the date of this Agreement as it relates to the HSR Act, any and all documentation to effect all necessary filings required by applicable Antitrust Laws with respect to the Merger, (ii)&#160;deliver as promptly as practicable to the appropriate Governmental Entities any additional information and documentary material that may be requested by any Governmental Entities in connection with the Merger, and (iii) obtain, as promptly as practicable, all Consents required to be obtained from any Governmental Entity that are necessary, proper or advisable to consummate the Merger, including by advocating for antitrust clearance. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;To the extent permitted by applicable Law, each of the Company and Parent shall promptly advise the other Party of any material communication between it or its Affiliates and any Governmental Entity (and if in writing, furnish the other party with a copy of such communication) regarding the Merger contemplated by this Agreement or otherwise materially affecting its ability to timely consummate the Merger contemplated by this Agreement pursuant to the terms hereof. In furtherance and not in limitation of <u>Section&#160;5.6(a)</u>, Parent and the Company shall consult and cooperate with one another, and consider in good faith the views of one another, in connection with, and provide to the other in advance (to the extent legally permissible), any analyses, presentations, memoranda, briefs, arguments, opinions and proposals made or submitted by or on behalf of any party hereto in connection with proceedings under or relating to the Antitrust Laws. Without limiting the foregoing, the Parties hereto agree to (i) promptly notify each other of all meetings or substantive communications with any Governmental Entity relating to any Antitrust Laws, and give each other an opportunity to participate in each of such meetings, (ii) promptly notify each other of all substantive oral and written communications with any Governmental Entity relating to any Antitrust Laws, (iii) provide each other with a reasonable advance opportunity to review and comment upon all written communications (including any analyses, presentations, memoranda, briefs, arguments, opinions and proposals) with a Governmental Entity regarding any Antitrust Laws and (iv) provide each other with copies of all written communications from any Governmental Entity relating to any Antitrust Laws. Any such disclosures or provision of competitively sensitive materials provided under this <u>Section&#160;5.6(b)</u> may be provided on an outside counsel only basis if deemed advisable by the Parties. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(c)&#8195;Notwithstanding anything in this Agreement to the contrary, each Party shall, and shall cause each of its subsidiaries and Affiliates to, take reasonable actions necessary to obtain any consents, clearances or approvals required under or in connection with the Antitrust Laws to expeditiously close the Merger or the other transactions contemplated by this Agreement (and in any event by or before the Termination Date); <u>provided</u> that, notwithstanding anything to the contrary contained in this Agreement, neither Party shall be required to take, or agree or commit to take (and without the consent of the other Party, shall not be permitted to take, or agree or commit to take), any actions that would reasonably be expected to have, individually or in the aggregate, a material and adverse effect on Parent and its Subsidiaries (including the Company after giving effect to the Closing), taken as a whole, following the Closing; <u>provided</u>, <u>further</u>, that no Party shall take or agree to take or commit to take any such action unless such action is conditioned upon the Closing. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-47<br></div></div></div>
<!--End Page 432-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 433-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg53"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(d)&#8195;Each Party shall bear its own expenses and costs incurred by such Party in connection with any filings and submissions pursuant to Antitrust Laws. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(e)&#8195;Prior to the Effective Time, each Party shall use reasonable best efforts to obtain any consents, approvals or waivers of third parties requested by the other Party hereto with respect to any Contracts to which it is a party as may be necessary for the consummation of the Contemplated Transactions or required by the terms of any Contract as a result of the execution, performance or consummation of the Merger or the other transactions contemplated by this Agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(f)&#8195;The Company, Parent and Merger Sub shall not, and shall cause their respective Subsidiaries and Affiliates not to, acquire or agree to acquire any rights, interests, assets, business, Person or division thereof (through acquisition, license, joint venture, collaboration or otherwise) or take any other actions, if such acquisition or action would reasonably be expected to (i) prevent, materially delay, or adversely affect in any material respect the ability of Parent and its Affiliates or the Company to consummate the Merger or any of the Contemplated Transactions, or (ii) cause Parent, Merger Sub or the Company to be required to obtain any clearances, consents, approvals, waivers, waiting period expirations or terminations, non-actions or other authorizations under any Laws with respect to the Merger or the other transactions contemplated by this Agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS57"><!--Anchor--></a>5.7&#8195;<u>Access; Consultation</u>. Upon reasonable notice, and except as may otherwise be required by applicable Law, each of the Company and Parent shall, and shall cause each of its Subsidiaries and their respective Representatives to, afford the other Party&#8217;s Representatives reasonable access (at the requesting Party&#8217;s cost) under the supervision of appropriate personnel of the other Party, during normal business hours during the period prior to the Effective Time, to the other Party&#8217;s, and each of its Subsidiaries&#8217; employees, properties, assets, books, records and contracts and, during such period, each of the Company and Parent shall, and shall cause each of its Subsidiaries to, furnish promptly to the other all information concerning its or any of its Subsidiaries&#8217; capital stock, business and personnel as may reasonably be requested by the other, as and when reasonably requested by the requesting Party; <u>provided</u> that no investigation pursuant to this <u>Section&#160;5.7</u> shall affect or be deemed to modify any representation or warranty made by the Company or Parent; <u>provided</u>, <u>further</u> that the foregoing shall require neither the Company nor Parent to permit any invasive sampling or testing or to disclose any information pursuant to this <u>Section&#160;5.7</u> to the extent that (i) in the reasonable good faith judgment of such Party, any applicable Law requires such Party or its Subsidiaries to restrict or prohibit access to any such properties or information, (ii) in the reasonable good faith judgment of such Party, the information is subject to confidentiality obligations to a third party, (iii) disclosure of any such information or document would result in the loss of attorney-client privilege or (iv) information is not reasonably available or accessible to such Party; <u>provided</u>, <u>further</u> that with respect to clauses (i)&#160;through (iii) of this <u>Section&#160;5.7</u>, Parent or the Company, as applicable, shall use its reasonable best efforts to (x) obtain the required consent of any such third party to provide such inspection or disclosure, (y) develop an alternative to providing such information so as to address such matters that is reasonably acceptable to Parent and the Company and (z) in the case of clauses (i) and (iii), implement appropriate and mutually agreeable measures to permit the disclosure of such information in a manner to remove the basis for the objection, including by arrangement of appropriate clean room procedures, redaction or entry into a customary joint defense agreement with respect to any information to be so provided, if the Parties determine that doing so would reasonably permit the disclosure of such information without violating applicable Law or jeopardizing such privilege. Any investigation pursuant to this <u>Section&#160;5.7</u> shall be conducted in such a manner as not to interfere unreasonably with the conduct of the business of the other Party. All requests for information made pursuant to this <u>Section&#160;5.7</u> shall be directed in writing to an executive officer of the Company or Parent, as applicable, or such Person as may be designated by any such executive officer. Each Party shall take reasonable steps to ensure that any information it obtains regarding the other Party pursuant to this <u>Section&#160;5.7</u> shall be used solely in connection with, and in furtherance of effecting, the Contemplated Transactions. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS58"><!--Anchor--></a>5.8&#8195;<u>Stock Exchange Listing</u>. Parent shall use reasonable best efforts to cause the shares of Parent Common Stock to be issued in the Merger to be approved for listing on Nasdaq, subject to official notice of issuance, prior to the Effective Time. The Company will cooperate with Parent as reasonably requested by Parent with respect to any Nasdaq listing application filed by Parent and promptly furnish to Parent all information concerning the Company and its stockholders that may be required or reasonably requested in connection with any action contemplated by this <u>Section&#160;5.8</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS59"><!--Anchor--></a>5.9&#8195;<u>Publicity</u>. The initial press release with respect to the Merger and the other Contemplated Transactions shall be a joint press release approved by both Parties and thereafter the Company and Parent shall consult with each other prior to issuing or making, and provide each other the reasonable opportunity to review and comment on, any press releases or other public announcements with respect to the Contemplated Transactions and any filings with any Governmental Entity (including any national securities exchange) with respect thereto, except (a) as may be required by applicable Law or by obligations pursuant to any listing agreement with or rules of any national securities exchange, (b) any press release or public statement that consists solely of information previously disclosed in all material respects in prior press releases issued or public statements made by a Party in compliance with this <u>Section&#160;5.9</u>, (c) any internal announcements to employees regarding the Merger so long as such statements consist solely of information previously disclosed in all material respects in previous press releases issued or public disclosures or public statements made jointly by the Parties (or individually, if approved by the other Party) or (d) with respect to any Company Change in Recommendation or Parent Change in Recommendation, or with respect to any Company Superior Proposal or Parent Superior Proposal or Parent&#8217;s or the Company&#8217;s response thereto. Notwithstanding the foregoing, Parent shall provide the Company with a reasonable opportunity to review and comment on any broad-based employee communications by Parent to employees of the Company or its Subsidiaries regarding the Merger or the other Contemplated Transactions prior to distribution thereof. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS510"><!--Anchor--></a>5.10&#8194;<u>Expenses</u>. Except as otherwise provided in <u>Section&#160;7.5</u> and <u>Section&#160;7.6</u>, whether or not the Merger is consummated, all costs and expenses incurred in connection with this Agreement and the Contemplated Transactions shall be paid by the Party incurring such expense. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-48<br></div></div></div>
<!--End Page 433-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 434-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg54"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS511"><!--Anchor--></a>5.11&#8194;<u>Indemnification; Directors&#8217; and Officers&#8217; Insurance</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;From the Effective Time through the sixth anniversary of the date on which the Effective Time occurs, each of Parent and the Surviving Company shall, jointly and severally, indemnify and hold harmless each person who is now, or has been at any time prior to the date hereof, or who becomes prior to the Effective Time, a director or officer of Parent or the Company or any of their respective Subsidiaries (each, an &#8220;<font style="font-weight: bold;">Indemnified Person</font>&#8221;) against all claims, losses, liabilities, damages, judgments, fines and reasonable fees, costs and expenses, including attorneys&#8217; fees and disbursements, incurred in connection with any claim, action, suit, proceeding or investigation, whether civil, criminal, administrative or investigative, arising out of or pertaining to the fact that the Indemnified Person is or was a director or officer of Parent or the Company or any of their respective Subsidiaries, whether asserted or claimed prior to, at or after the Effective Time, to the fullest extent permitted under applicable Law (including the DGCL). Each Indemnified Person will be entitled to advancement of expenses (including attorneys&#8217; fees) incurred in the defense of any such claim, action, suit, proceeding or investigation from each of Parent and the Surviving Company, jointly and severally, upon receipt by Parent or the Surviving Company from the Indemnified Person of a request therefor; <u>provided</u> that any person to whom expenses are advanced provides an undertaking, to the extent then required by the DGCL, to repay such advances if it is ultimately determined that such person is not entitled to indemnification. From the Effective Time through the sixth anniversary of the date on which the Effective Time occurs, the Company Certificate of Incorporation and the Surviving Company Bylaws shall contain provisions no less favorable than the provisions relating to indemnification, advancement of expenses and elimination of liability for monetary damages set forth in the Organizational Documents of the Company and Parent immediately prior to the Effective Time, and such provisions shall not be amended, repealed, abrogated or otherwise modified in any manner that would adversely affect any Indemnified Person. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;Prior to the Effective Time, Parent shall purchase a six-year prepaid &#8220;tail policy&#8221; (the &#8220;<font style="font-weight: bold;">D&amp;O Tail Policy</font>&#8221;) for the non-cancellable extension of the directors&#8217; and officers&#8217; liability coverage of Parent&#8217;s existing directors&#8217; and officers&#8217; insurance policies for a claims reporting or discovery period of at least six years from and after the Effective Time with respect to any claim related to any period of time at or prior to the Effective Time, with terms, conditions, retentions and limits of liability that are no less favorable than the coverage provided Parent&#8217;s existing policies as of the date of this Agreement with respect to any actual or alleged error, misstatement, misleading statement, act, omission, neglect, breach of duty or any matter claimed against a director or officer of Parent by reason of him or her serving in such capacity that existed or occurred at or prior to the Effective Time (including in connection with this Agreement or the Contemplated Transactions). </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(c)&#8195;In the event Parent or the Surviving Company or any of their respective successors or assigns (i) consolidates with or merges into any other Person and shall not be the continuing or surviving corporation or entity of such consolidation or merger, (ii) transfers all or substantially all of its properties and assets to any Person or (iii) engages in any similar transaction, then, and in each such case, proper provision shall be made so that the successors and assigns of Parent or the Surviving Company, as the case may be, shall assume all of the obligations set forth in this <u>Section&#160;5.11</u>. Parent shall cause the Surviving Company to perform all of the obligations of the Surviving Company under this <u>Section&#160;5.11</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(d)&#8195;The provisions of this <u>Section&#160;5.11</u> are intended to be in addition to the rights otherwise available to the current and former officers and directors of Parent and the Company by Law, charter, bylaw or agreement, and shall operate for the benefit of, and shall be enforceable by, each of the Indemnified Persons, their heirs and their representatives. The obligations set forth in this <u>Section&#160;5.11</u> shall not be terminated, amended or otherwise modified in any manner that adversely affects any Indemnified Person, or any person who is a beneficiary under the policies referred to in this <u>Section&#160;5.11</u> and their heirs and representatives, without the prior written consent of such affected Indemnified Person or other person. Parent shall pay all expenses, including reasonable attorneys&#8217; fees, that may be incurred by any Indemnified Person in successfully enforcing the rights provided in this <u>Section&#160;5.11</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(e)&#8195;Notwithstanding anything herein to the contrary, if any claim (whether arising before, at or after the Effective Time) is made against any of the Indemnified Persons on or prior to the sixth anniversary of the Effective Time, the provisions of this <u>Section&#160;5.11</u> shall continue in effect until the final disposition of such claim. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS512"><!--Anchor--></a>5.12&#8194;<u>Takeover Statute</u>. The Company and the Company Board and Parent and the Parent Board shall use their respective reasonable best efforts to (a) take all action reasonably appropriate to ensure that no state takeover statute or similar statute or regulation is or becomes applicable to this Agreement or the Contemplated Transactions and (b) if any state takeover statute or similar statute or regulation becomes applicable to this Agreement or the Contemplated Transactions, take all action reasonably appropriate to ensure that the Contemplated Transactions may be consummated as promptly as practicable on the terms contemplated by this Agreement and otherwise to eliminate or minimize the effect of such statute or regulation on the Contemplated Transactions. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS513"><!--Anchor--></a>5.13&#8194;<u>Control of Company&#8217;s or Parent&#8217;s Operations</u>. Nothing contained in this Agreement shall give Parent or the Company, directly or indirectly, rights to control or direct the operations of the other prior to the Effective Time. Prior to the Effective Time, each of Parent and the Company shall exercise, consistent with the terms and conditions of this Agreement, complete control and supervision of its operations. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS514"><!--Anchor--></a>5.14&#8194;<u>Directors and Officers</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;The Parties shall use reasonable best efforts and take all necessary action so that immediately after the Effective Time, (i) the Parent Board is comprised of at least nine members, with between seven and ten such members designated by the Company in its discretion, two such members designated by Parent, subject to the reasonable approval of the Company (the &#8220;<font style="font-weight: bold;">Legacy Parent Directors</font>&#8221;) (with the Person listed as chair of the Parent Board in <u>Exhibit G</u> designated by the Company as the chair of the Parent Board), with each such designee set forth in <u>Exhibit&#160;G</u> as added or modified from time to time in accordance with this <u>Section&#160;5.14(a)</u>, (ii) the Persons listed in <u>Exhibit&#160;G</u> under the heading &#8220;Officers&#8221; are elected or appointed, as applicable, to the positions of officers of Parent, as set forth therein, to serve in such positions effective as of the Effective Time until successors are duly appointed and qualified in accordance with applicable Law and (iii) the board of directors and officers of the Surviving Company </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-49<br></div></div></div>
<!--End Page 434-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 435-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg55"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">are as set forth in <u>Exhibit&#160;G</u>. If any Person listed in <u>Exhibit&#160;G</u> is unable or unwilling to serve as an officer of Parent, as set forth therein, as of the Effective Time, the Parties shall mutually agree upon a successor. The Persons listed in <u>Exhibit&#160;G</u> under the heading &#8220;Board Designees &#8211; Company&#8221; shall be the Company&#8217;s designees pursuant to clause (i) of this <u>Section&#160;5.14(a)</u> (which list may be changed by the Company at any time prior to the Closing by written notice to Parent to include different board designees). Each Person listed in <u>Exhibit&#160;G</u> under the heading &#8220;Committee Members&#8221; shall be a member of the committee of the Parent Board set forth opposite such Person&#8217;s name, in each case effective as of immediately after the Effective Time (which list may be added or changed by the Company at any time prior to the Closing by written notice to Parent to include different Committee Members). Prior to the Closing, the Company may, in its discretion, determine that the Parent Board will be a classified board following the Closing and designate a class to each designee set forth in <u>Exhibit&#160;G</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;The Company Board and the Parent Board (or, in each case, a duly authorized committee thereof) shall, prior to the Effective Time, take all such actions within its control as may be necessary or appropriate to cause the Contemplated Transactions and any other dispositions of equity securities of the Company and acquisitions of equity securities of Parent (including derivative securities) in connection with the Contemplated Transactions by each individual who is a director or executive officer of the Company or is or may become a director or executive officer of Parent in connection with the Contemplated Transactions to be exempt under Rule&#160;16b-3 promulgated under the Exchange Act. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(c)&#8195;On the Closing Date, Parent shall enter into customary indemnification agreements reasonably satisfactory to the Company with each individual to be appointed to, or serving on, the board of directors of Parent upon the Closing, which indemnification agreements shall continue to be effective following the Closing. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS515"><!--Anchor--></a>5.15&#8194;<u>Lock-Up Agreements</u>. Parent and the Company shall use reasonable best efforts to cause each individual who will serve as a director or executive officer of Parent following the Closing to execute and deliver a Company Lock-Up Agreement or Parent Lock-Up Agreement, as applicable, and such other stockholders of the Parties as may be otherwise agreed by the Parties to execute and deliver a Company Lock-Up Agreement or Parent Lock-Up Agreement, as applicable, in each case no later than the Closing. Pursuant to each Lock-Up Agreement, the signatory shall agree not to sell, transfer, pledge, hypothecate or otherwise dispose of any shares of Parent Common Stock held by such signatory for a period of 180 days following the Closing, subject to customary exceptions. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS516"><!--Anchor--></a>5.16&#8194;<u>Approval by Sole Stockholder of Merger Sub</u>. Immediately (and in any event within 24 hours) following the execution and delivery of this Agreement by the Parties, Parent, as sole stockholder of Merger Sub, shall adopt this Agreement and approve the Merger, in accordance with Delaware Law, by written consent. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS517"><!--Anchor--></a>5.17&#8194;<u>Stockholder Litigation</u>. Each Party shall notify the other Party, in writing and promptly after acquiring knowledge thereof, of any Legal Proceedings related to this Agreement, the Merger or the other Contemplated Transactions that is brought against or, to the Knowledge of the Company or Parent, threatened against, either Party, either Party&#8217;s Subsidiaries and/or any of their respective directors or officers (collectively, &#8220;<font style="font-weight: bold;">Transaction Litigation</font>&#8221;) and shall keep the other Party informed on a reasonably current basis with respect to the status thereof. Each Party shall control any Transaction Litigation brought against such Party or such Party&#8217;s Subsidiaries and/or any of their respective directors or officers. Each Party shall provide the other Party (a)&#160;the opportunity to participate in the defense of any such Transaction Litigation and (b) the right to review and comment in advance on all material filings or responses to be made by the Parties in connection with any such Transaction Litigation (and the Parties shall in good faith take such comments and other advice into consideration). The Parties agree to cooperate in the defense and settlement of any such Transaction Litigation, and neither Party shall settle any such Transaction Litigation without the prior written consent of the other Party (not to be unreasonably withheld, conditioned or delayed), except that such other Party will not be obligated to consent to any settlement that does not include a full release of the said Party and such Party&#8217;s Affiliates or that imposes an injunction or other equitable relief upon the said Party or any of its Affiliates. Without limiting in any way the Parties&#8217; obligations under <u>Section&#160;5.6</u>, each of the Company and Parent shall, and shall cause their respective Subsidiaries to, cooperate in the defense or settlement of any Transaction Litigation contemplated by this <u>Section&#160;5.17</u>. For purposes of this <u>Section&#160;5.17</u>, with respect to a Party not controlling a Transaction Litigation, &#8220;participate&#8221; means that such Party will be kept reasonably apprised by the Party controlling such Transaction Litigation of proposed strategy and other significant decisions with respect to such Transaction Litigation (to the extent that the attorney-client privilege between such controlling Party and its counsel is not undermined or otherwise adversely affected), and such non-controlling Party may offer comments or suggestions with respect to such Transaction Litigation but will not be afforded any decision-making power or other authority over such Transaction Litigation except for the settlement or compromise consent set forth above. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS518"><!--Anchor--></a>5.18&#8194;<u>Tax Treatment</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;Each of Parent and Merger Sub shall use its respective reasonable best efforts to, and cause each of their respective Subsidiaries to, cause the Merger to qualify for the Intended Tax Treatment. Neither Parent nor Merger Sub shall take any action (or fail to take any action, including failing to use its reasonable best efforts to proscribe any of its respective Subsidiaries from taking any action) that could reasonably be expected to prevent or impede such qualification. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;The Company shall use its reasonable best efforts to, and cause its Subsidiaries to, cause the Merger to qualify for the Intended Tax Treatment. The Company shall not take any action (or fail to take any action, including failing to use its reasonable best efforts to proscribe any of its Subsidiaries from taking any action) that could reasonably be expected to prevent or impede such qualification. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(c)&#8195;Unless otherwise required pursuant to a final &#8220;determination&#8221; within the meaning of Section&#160;1313(a) of the Code or any analogous provision of applicable state, local or foreign Law, (i) each of the Parties shall report the Merger for U.S. federal income tax purposes as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a) of the Code in all Tax Returns, and (ii) none of the Parties shall take any Tax reporting position inconsistent with the characterization of the Contemplated Transactions as a &#8220;reorganization&#8221; under Section&#160;368(a) of the Code. The Parties to this Agreement adopt this Agreement as a &#8220;plan of reorganization&#8221; within the meaning of Treasury Regulations Sections 1.368-2(g)&#160;and 1.368-3(a), to </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-50<br></div></div></div>
<!--End Page 435-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 436-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg56"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">which Parent, Merger Sub and the Company are parties under Section&#160;368(b) of the Code. In the event that the Merger would be reasonably likely to fail to qualify as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a) of the Code, each of the Parties agrees to use reasonable best efforts to adopt an alternative structure, including a &#8220;two-step merger&#8221; described in Revenue Ruling 2001-46, if applicable, that would permit the Contemplated Transactions to qualify for tax-deferred treatment under the Code. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(d)&#8195;If, in connection with the preparation and filing of the Proxy Statement/Prospectus, the Registration Statement or any other filing required by applicable Law or the SEC&#8217;s review thereof, the SEC requests or requires that a tax opinion with respect to the U.S. federal income tax consequences of the Merger and the Intended Tax Treatment be prepared and submitted (a &#8220;<font style="font-weight: bold;">Tax Opinion</font>&#8221;), (i) Parent and the Company shall each use their respective reasonable best efforts to deliver to Fenwick &amp; West LLP, counsel to the Company, and to Freshfields US LLP, counsel to Parent, customary Tax representation letters satisfactory to each such counsel, dated and executed as of such date(s) as determined to be reasonably necessary by each such counsel in connection with the preparation and filing of such Registration Statement or any other filing required by applicable Law, (ii)&#160;the Company shall use its reasonable best efforts to cause Fenwick &amp; West LLP to furnish a Tax Opinion addressed to the Company, subject to customary assumptions and limitations, satisfactory to the SEC and (iii) Parent shall use its reasonable best efforts to cause Freshfields US LLP to furnish a Tax Opinion addressed to Parent, subject to customary assumptions and limitations, satisfactory to the SEC. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(e)&#8195;Notwithstanding anything to the contrary contained herein, Parent and the Company each shall pay 50% of all transfer, documentary, sales, use, stamp, registration, value added or other similar Taxes incurred in connection with the Merger, and the portion paid for by Parent will be treated as a Transaction Expense of Parent hereunder. The party responsible under applicable Law shall file any necessary Tax Returns with respect to all such Taxes, and, if required by applicable Law, each of Parent, the Company and their respective Affiliates shall join in the execution of any such Tax Returns. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS519"><!--Anchor--></a>5.19&#8194;<u>Parent Resignations</u>. Parent shall obtain and deliver to the Company at or prior to the Effective Time (or, at the option of the Company, at a later date) the resignation of each officer and director of Parent and each of its Subsidiaries, effective as of the Effective Time (it being understood that such resignation shall not constitute a voluntary termination of employment under any employment agreement or Parent Benefit Plan applicable to such individual&#8217;s status as an officer or director of Parent or a Subsidiary thereof). </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS520"><!--Anchor--></a>5.20&#8194;<u>Obligations of Merger Sub and Surviving Company</u>. Parent will take all action necessary to cause each of Merger Sub and the Surviving Company to perform their respective obligations under this Agreement before and after the Effective Time. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS521"><!--Anchor--></a>5.21&#8194;<u>Closing Dividend; CVR Agreement</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;Prior to the Effective Time, Parent may declare a dividend (the &#8220;<font style="font-weight: bold;">Closing Dividend</font>&#8221;) to its stockholders of record of one contingent value right (each, a &#8220;<font style="font-weight: bold;">CVR</font>&#8221;) for each outstanding share of Parent Common Stock held by such stockholder as of the close of business on the last Business Day prior to the day on which the Effective Time occurs (the &#8220;<font style="font-weight: bold;">CVR Record Date</font>&#8221;), each CVR representing the right to receive contingent payments upon the occurrence of certain events set forth in, and subject to and in accordance with the terms and conditions of, a Contingent Value Rights Agreement to be entered into by Parent and a rights agent (the &#8220;<font style="font-weight: bold;">Rights Agent</font>&#8221;) selected by Parent with the Company&#8217;s prior written approval (such approval not to be unreasonably withheld, delayed or conditioned) (the &#8220;<font style="font-weight: bold;">CVR Agreement</font>&#8221;), in substantially the form attached hereto as <u>Exhibit&#160;H</u>, with such customary or reasonable revisions to the CVR Agreement that are requested by the Rights Agent. The payment date for the Closing Dividend shall be three Business Days after the Effective Time; <u>provided</u> that the payment of such dividend shall be expressly conditioned upon the occurrence of the Effective Time, and if the Effective Time does not occur for any reason following the setting of the CVR Record Date, (i)&#160;the Closing Dividend shall be deemed not to have been declared, (ii) no CVRs shall be issued or distributed to any holder of Parent Common Stock, (iii)&#160;the CVR Agreement shall be of no force or effect and (iv) Parent shall have no obligation to any holder of Parent Common Stock with respect to any CVR or the Closing Dividend. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;In the event Parent declares the Closing Dividend, prior to the Effective Time, Parent shall authorize and duly adopt, execute and deliver the CVR Agreement, and shall instruct the Rights Agent selected by Parent pursuant to <u>Section&#160;5.21(a)</u> to execute and deliver the CVR Agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS522"><!--Anchor--></a>5.22&#8194;<u>Parent Reverse Stock Split</u>. Unless otherwise agreed by the Parties, Parent shall submit to Parent&#8217;s stockholders at the Parent Stockholders Meeting a proposal to approve and adopt an amendment to Parent&#8217;s certificate of incorporation to authorize the Parent Board to effect a reverse stock split of all outstanding shares of Parent Common Stock at a reverse stock split ratio mutually agreed to by the Company and Parent (the &#8220;<font style="font-weight: bold;">Parent Reverse Stock Split</font>&#8221;), and shall take such other actions as shall be reasonably necessary to effectuate the Parent Reverse Stock Split. The Parent Reverse Stock Split may take effect prior to the Effective Time to the extent Parent determines that would be necessary or advisable to comply with Nasdaq Rule&#160;5110(a) or any other Nasdaq rule or regulation. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS523"><!--Anchor--></a>5.23&#8194;<u>Wind-Down Activities and Legacy Transactions; Parent Employees</u>.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;Parent shall use its commercially reasonable efforts to effect the sale, license, transfer, disposition, divestiture or other monetization transaction with respect to the Parent Legacy Business (each, a &#8220;<font style="font-weight: bold;">Parent Legacy Transaction</font>&#8221;); <u>provided</u> that (i) the prior written consent of the Company (not to be unreasonably withheld, conditioned or delayed) shall be required prior to Parent&#8217;s entry into any definitive agreement, or binding term sheet or letter of intent, relating to any Parent Legacy Transaction and (ii) Parent shall not be required to enter into any specific Parent Legacy Transaction. Parent shall keep the Company reasonably informed of the status of any Parent Legacy Transaction. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;Parent and the Company shall work together in good faith (and in consultation with one or more nationally recognized wind-down consultants) to reach agreement within 30 days of the date of this Agreement on a mutually acceptable written schedule (the &#8220;<font style="font-weight: bold;">Wind-Down Schedule</font>&#8221;) that sets forth the actions that would be required in order to wind down the Parent Legacy Business (the &#8220;<font style="font-weight: bold;">Wind-Down Activities</font>&#8221;) and </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-51<br></div></div></div>
<!--End Page 436-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 437-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg57"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">the costs to effect such Wind-Down Activities (the &#8220;<font style="font-weight: bold;">Wind-Down Costs</font>&#8221;) or a methodology to determine such costs, with the goals of (i)&#160;minimizing and eliminating remaining obligations and Liabilities of Parent while at the same time maximizing the amount of Parent Net Cash and (ii) preserving cash. Parent and the Company shall work together in good faith to ensure that the Wind-Down Schedule addresses, among other matters, current and non-current accrued liabilities, long-term contract obligations of Parent (including deferred revenue) and liabilities arising under service contracts in effect prior to the Closing (the &#8220;<font style="font-weight: bold;">Specified Cash-Walk Items</font>&#8221;).</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(c)&#8195;In lieu of pursuing a Parent Legacy Transaction with respect to all or any portion of the Parent Legacy Business, Parent may elect at any time to commence the Wind-Down Activities. In the event that Parent has not entered into a definitive agreement for the disposition of a particular portion of the Parent Legacy Business on or prior to the date that the Registration Statement is declared effective under the Securities Act, Parent shall be required to undertake, and to cause its Subsidiaries to undertake, the Wind-Down Activities, together with such modifications as may be mutually agreed by Parent and the Company, acting reasonably, with respect to such portion of the Parent Legacy Business. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 40pt; text-align: left;">(d)&#8195;Parent agrees to take the actions set forth on Section&#160;5.23(d) of the Parent Disclosure Schedule. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS524"><!--Anchor--></a>5.24&#8194;<u>Termination of Company Investor Agreements</u>. The Company shall cause any stockholder agreements, voting agreements, registration rights agreements, co-sale agreements and any other similar Contracts between the Company and any holders of Company Capital Stock, including any such Contract granting any Person investor rights, rights of first refusal, registration rights or director designation rights, including the Contracts set forth on <u>Schedule C</u> except as noted in such schedule (collectively, the &#8220;<font style="font-weight: bold;">Investor Agreements</font>&#8221;), to be terminated immediately prior to the Effective Time, without any material liability being imposed on the part of Parent or the Surviving Company; <u>provided</u> that any liabilities remaining under any Investor Agreement shall not be included in the definition of Parent Net Cash or as a &#8220;Permitted Deduction&#8221; under the CVR Agreement; <u>provided</u>, <u>further</u>, that no action by the Company or any party to an Investor Agreement shall be required under this <u>Section&#160;5.24</u> for any Investor Agreements that automatically terminate at the Effective Time by operation of the express terms of such Investor Agreements. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS525"><!--Anchor--></a>5.25&#8194;<u>Parent Equity Plans</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;Prior to the Effective Time, the Parent Board shall adopt the Post-Closing Equity Incentive Plan, subject to the Closing and effective as of the Effective Time, and shall include a proposal in the Proxy Statement/Prospectus for the stockholders of Parent to approve the Post-Closing Equity Incentive Plan. Subject to the approval of the Post-Closing Equity Incentive Plan by the stockholders of Parent prior to the Effective Time, Parent shall file with the SEC, promptly after the Effective Time and at the Company&#8217;s expense, a registration statement on Form&#160;S-8 (or any successor form), if available for use by Parent, relating to the shares of Parent Common Stock issuable with respect to the Post-Closing Equity Incentive Plan. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;Prior to the Effective Time, the Parent Board shall adopt the Post-Closing ESPP, subject to the Closing and effective as of the Effective Time, and shall include a proposal in the Proxy Statement/Prospectus for the stockholders of Parent to approve the Post-Closing ESPP. Subject to the approval of the Post-Closing ESPP by the stockholders of Parent prior to the Effective Time, Parent shall file with the SEC, promptly after the Effective Time and at the Company&#8217;s expense, a registration statement on Form&#160;S-8 (or any successor form), if available for use by Parent, relating to the shares of Parent Common Stock issuable with respect to the Post-Closing ESPP. For the avoidance of doubt, approval of the Post-Closing Equity Incentive Plan and Post-Closing ESPP by the stockholders of Parent shall not be a condition to Closing. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(c)&#8195;At least 15 Business Days prior to the Effective Time, the Parent Board (or the Human Capital Committee of the Parent Board) shall terminate each then-current offering period under the Parent ESPP and shall refund all contributions made by participants in the Parent ESPP, in each case, in accordance with applicable Laws and the terms of the Parent ESPP. Following such termination, no new offering period will commence prior to the Effective Time. If requested by the Company in writing at least five Business Days prior to the Closing, the Parent Board shall also terminate the Parent ESPP, subject to the Closing and effective as of the Effective Time. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(d)&#8195;Parent shall provide the Company with a copy of any resolutions, proposals, or other corporate actions (the form and substance of which shall be subject to reasonable review and approval by the Company; <u>provided</u> that such approval shall not be unreasonably withheld, conditioned or delayed) required by this <u>Section&#160;5.25</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS526"><!--Anchor--></a>5.26&#8194;<u>Termination of the Parent&#8217;s 401(k) Plan</u>. Unless otherwise directed by the Company in writing at least five Business Days before the Effective Time, Parent shall take all necessary actions to terminate each Parent Benefit Plan intended to be qualified under Section 401(a) of the Code (each, a &#8220;<font style="font-weight: bold;">Parent 401(k) Plan</font>&#8221;), with such termination effective as of no later than the date immediately preceding the Closing Date. Parent shall provide the Company with a copy of any resolutions or other corporate action (the form and substance of which shall be subject to reasonable review and approval by the Company; <u>provided</u> that such approval shall not be unreasonably withheld, conditioned or delayed) evidencing that the Parent 401(k) Plans will be terminated effective as of no later than the date immediately preceding the Closing Date, contingent upon the Effective Time, and will adopt any necessary amendments to the Parent 401(k) Plans to effect such termination. Prior to and conditioned upon termination of the Parent 401(k) Plans or, with respect to any employees who are to be transferred pursuant to any Parent Legacy Transaction, the consummation of a Parent Legacy Transaction, Parent shall take any action necessary to fully vest any and all unvested amounts of the accounts of all participants in the Parent 401(k) Plans that are impacted by such termination or by a Parent Legacy Transaction, as applicable. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS527"><!--Anchor--></a>5.27&#8194;<u>Company Preferred Stock</u>. From the date of this Agreement until the earlier of the Effective Time and the termination of this Agreement in accordance with its terms, the Company shall not, and shall not permit any of its Subsidiaries to, take, authorize, approve or permit any action that results in, or would reasonably be expected to result in, a material adjustment to the Conversion Price (as defined in the certificate of incorporation of the Company) or the conversion rate of any series of the Company Preferred Stock. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-52<br></div></div></div>
<!--End Page 437-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 438-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg58"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;"><a name="tANXAA6"><!--Anchor--></a>ARTICLE&#160;VI <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">CONDITIONS </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS61"><!--Anchor--></a>6.1&#8195;<u>Conditions to Each Party&#8217;s Obligation to Effect the Contemplated Transactions</u>. The respective obligation of each Party to effect the Merger and the other Contemplated Transactions is subject to the satisfaction or waiver as of immediately prior to the Closing of each of the following conditions: </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;<u>Stockholder Approvals</u>. (i) The Company Stockholder Approval shall have been obtained in accordance with applicable Law and the Company&#8217;s Organizational Documents and (ii) the Parent Stockholder Approval shall have been obtained in accordance with applicable Law and Parent&#8217;s Organizational Documents. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;<u>Legal Restraint</u>. No applicable Law and no Judgment, preliminary, temporary or permanent, or other legal restraint and no binding order or determination by any Governmental Entity of competent jurisdiction (collectively, the &#8220;<font style="font-weight: bold;">Legal Restraints</font>&#8221;) shall be in effect that prevents, restrains, enjoins, makes illegal or otherwise prohibits the consummation of the Merger or any of the Contemplated Transactions. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(c)&#8195;<u>Registration Statement</u>. The Registration Statement shall have been declared effective by the SEC under the Securities Act and no stop order suspending the effectiveness of the Registration Statement shall have been issued and remain in effect, and no Legal Proceedings for that purpose shall have been initiated or threatened in writing by the SEC, unless subsequently withdrawn. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(d)&#8195;<u>Nasdaq Listing</u>. The existing shares of Parent Common Stock shall be listed on Nasdaq as of the Closing Date, and the shares of Parent Common Stock issuable in connection with the Merger shall have been approved for listing on Nasdaq, subject to official notice of issuance. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(e)&#8195;<u>Competition Clearances</u>. The waiting period (and any extension thereof) applicable to the Merger or any of the Contemplated Transactions under the HSR Act shall have expired or been terminated, and any consents, authorizations, clearances and approvals required to be obtained with respect to the Merger or any of the Contemplated Transactions under the foreign Antitrust Laws forth in <u>Section&#160;6.1(e)</u> of the Company Disclosure Schedules shall have been obtained. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS62"><!--Anchor--></a>6.2&#8195;<u>Conditions to Obligations of Parent and Merger Sub</u>. The obligations of Parent and Merger Sub to effect the Merger and the other Contemplated Transactions are also subject to the satisfaction or waiver by Parent as of immediately prior to the Closing of the following conditions: </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;<u>Representations and Warranties</u>. (i) The representations and warranties of the Company contained in this Agreement (except for the representations and warranties contained in <u>Sections 3.1</u> (Organizational Documents), <u>3.2(a)</u> (Due Organization), <u>3.2(c)</u> (Subsidiaries), <u>3.3</u> (Capitalization), <u>3.4</u> (Authority; Binding Nature of Agreement; Required Vote), <u>3.5(a)(i)</u> (Non-Contravention; Consents), <u>3.5(c)</u> (Takeover Laws), <u>3.7(b)</u> (Absence of Changes), and <u>3.22</u> (Brokers and Finders)) shall be true and correct (without giving effect to any limitation as to &#8220;materiality&#8221; or &#8220;Company Material Adverse Effect&#8221; set forth therein) at and as of the date of this Agreement and at and as of the Closing Date as if made at and as of such time (except to the extent expressly made as of an earlier date, in which case as of such earlier date), except where the failure of such representations and warranties to be true and correct (without giving effect to any limitation as to &#8220;materiality&#8221; or &#8220;Company Material Adverse Effect&#8221; set forth therein) would not have a Company Material Adverse Effect (disregarding for purposes of this <u>Section&#160;6.2(a)</u> clause (2) of the definition thereof); (ii) the representations and warranties of the Company contained in <u>Sections 3.1</u> (Organizational Documents), <u>3.2(a)</u> (Due Organization), <u>3.2(c)</u> (Subsidiaries), <u>3.3</u> (Capitalization) (other than <u>Section&#160;3.3(a)</u>, <u>Section&#160;3.3(b)</u>, the first and second sentences of <u>Section&#160;3.3(d)</u>, <u>Section&#160;3.3(e)</u> and <u>Section&#160;3.3(g)</u>), <u>3.4</u> (Authority; Binding Nature of Agreement; Required Vote), <u>3.5(a)(i)</u> (Non-Contravention; Consents), <u>3.5(c)</u> (Takeover Laws) and <u>3.22</u> (Brokers and Finders) shall be true and correct (A) in all respects, in the case of any such representations and warranties to the extent they are qualified within the text thereof by any &#8220;materiality&#8221; or &#8220;Company Material Adverse Effect&#8221; qualifications or (B) in all material respects, in the case of any such representations and warranties to the extent they are not so qualified within the text thereof by any such &#8220;materiality&#8221; or &#8220;Company Material Adverse Effect&#8221; qualifications, in each case at and as of the date of this Agreement and at and as of the Closing Date as if made at and as of such time (except to the extent expressly made as of an earlier date, in which case as of such earlier date); (iii) the representations and warranties of the Company contained in <u>Section&#160;3.3(a)</u>, <u>Section&#160;3.3(b)</u>, the first and second sentences of <u>Section&#160;3.3(d)</u>, the first sentence of <u>Section&#160;3.3(e)</u> and <u>Section&#160;3.3(g)</u> (Capitalization) shall be true and correct in all respects, except for <font style="font-style: italic;">de minimis</font> inaccuracies, at and as of the date of this Agreement and at and as of the Closing Date as if made at and as of such time (except to the extent expressly made as of an earlier date, in which case as of such earlier date); and (iv) the representations and warranties of the Company contained in <u>Section&#160;3.7(b)</u> (Absence of Changes) shall be true and correct in all respects at and as of the date of this Agreement and at and as of the Closing Date as if made at and as of such time. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;<u>Performance of Obligations of the Company</u>. The Company shall have performed in all material respects all obligations required to be performed by it under this Agreement at or prior to the Closing. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(c)&#8195;<u>No Company Material Adverse Effect</u>. After the date of this Agreement, there shall not have occurred and be continuing a Company Material Adverse Effect. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-indent: 40pt; text-align: left;">(d)&#8195;<u>Company Closing Deliverables</u>.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(i)&#8195;Parent shall have received at the Closing a certificate signed on behalf of the Company by a senior executive officer of the Company to the effect that the conditions set forth in <u>Sections 6.2(a)</u>, <u>(b)</u> and <u>(c)</u> have been satisfied. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(ii)&#8195;Parent shall have received at the Closing a properly executed certification that the Company Shares are not &#8220;United States real property interests&#8221; in accordance with the Treasury Regulations under Sections 897 and 1445 of the Code, together with a notice to the IRS (which shall be filed by Parent with the IRS following the Closing) in accordance with the provisions of Treasury Regulations Section&#160;1.897-2(h)(2). </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-53<br></div></div></div>
<!--End Page 438-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 439-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg59"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(iii)&#8195;<u>Company Stockholder Written Consent</u>. The Company shall have delivered to Parent the Company Stockholder Written Consent. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(iv)&#8195;<u>Termination of Obligations under the Investor Agreements</u>. The Company shall have delivered to Parent evidence reasonably satisfactory to Parent that, as of the Effective Time, all of the obligations of the Company under each of the Investor Agreements have been terminated without any material liability being imposed on the part of Parent or the Surviving Company (other than such Investor Agreements that automatically terminate at the Effective Time by operation of the express terms of such Investor Agreements), except as provided in <u>Schedule C</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS63"><!--Anchor--></a>6.3&#8195;<u>Conditions to Obligation of Company</u>. The obligations of the Company to effect the Merger and the other Contemplated Transactions are also subject to the satisfaction or waiver by the Company as of immediately prior to the Closing of the following conditions: </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;<u>Representations and Warranties</u>. (i) The representations and warranties of Parent contained in this Agreement (except for the representations and warranties contained in <u>Sections 4.1</u> (Organizational Documents), <u>4.2(a)</u> (Due Organization), <u>4.2(c)</u> (Subsidiaries), <u>4.3</u> (Capitalization), <u>4.4</u> (Authority; Binding Nature of Agreement; Required Vote), <u>4.5(a)(i)</u> (Non-Contravention; Consents), <u>4.5(c)</u> (Takeover Laws), <u>4.6(f)</u> (Financial Statements), <u>4.7(b)</u> (Absence of Changes), <u>4.22</u> (Brokers and Finders) and <u>4.24</u> (first sentence only) (Opinion of Financial Advisor)) shall be true and correct (without giving effect to any limitation as to &#8220;materiality&#8221; or &#8220;Parent Material Adverse Effect&#8221; set forth therein) at and as of the date of this Agreement and at and as of the Closing Date as if made at and as of such time (except to the extent expressly made as of an earlier date, in which case as of such earlier date), except where the failure of such representations and warranties to be true and correct (without giving effect to any limitation as to &#8220;materiality&#8221; or &#8220;Parent Material Adverse Effect&#8221; set forth therein) would have a Parent Material Adverse Effect; (ii) the representations and warranties of Parent contained in <u>Sections 4.1</u> (Organizational Documents), <u>4.2(a</u>) (Due Organization), <u>4.2(c)</u> (Subsidiaries), <u>4.3</u> (Capitalization) (other than <u>Section&#160;4.3(a)</u>, <u>Section&#160;4.3(b)</u>, the first and second sentences of <u>Section&#160;4.3(d)</u> and <u>Section&#160;4.3(e)</u>), <u>4.4</u> (Authority; Binding Nature of Agreement; Required Vote), <u>4.5(a)(i)</u> (Non-Contravention; Consents), <u>4.5(c)</u> (Takeover Laws), <u>4.6(f)</u> (Financial Statements), <u>4.22</u> (Brokers and Finders) and <u>4.24</u> (first sentence only) (Opinion of Financial Advisor) shall be true and correct (A) in all respects, in the case of any such representations and warranties to the extent they are qualified within the text thereof by any &#8220;materiality&#8221; or &#8220;Parent Material Adverse Effect&#8221; qualifications or (B) in all material respects, in the case of any such representations and warranties to the extent they are not so qualified within the text thereof by any such &#8220;materiality&#8221; or &#8220;Parent Material Adverse Effect&#8221; qualifications, in each case at and as of the date of this Agreement and at and as of the Closing Date as if made at and as of such time (except to the extent expressly made as of an earlier date, in which case as of such earlier date); (iii) the representations and warranties of Parent contained in <u>Section&#160;4.3(a)</u>, <u>Section&#160;4.3(b)</u>, the first and second sentences of <u>Section&#160;4.3(d)</u> and the first sentence of <u>Section&#160;4.3(e)</u> (Capitalization) shall be true and correct in all respects, except for <font style="font-style: italic;">de minimis</font> inaccuracies, at and as of the date of this Agreement and at and as of the Closing Date as if made at and as of such time (except to the extent expressly made as of an earlier date, in which case as of such earlier date); and (iv) the representations and warranties of Parent contained in <u>Section&#160;4.7(b)</u> (Absence of Changes) shall be true and correct in all respects at and as of the date of this Agreement and at and as of the Closing Date as if made at and as of such time. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;<u>Performance of Obligations of Parent and Merger Sub</u>. Each of Parent and Merger Sub shall have performed in all material respects all obligations required to be performed by it under this Agreement at or prior to the Closing. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(c)&#8195;<u>No Parent Material Adverse Effect</u>. After the date of this Agreement, there shall not have occurred and be continuing a Parent Material Adverse Effect. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(d)&#8195;<u>Parent Charter Amendment</u>. Parent shall have effected the Parent Charter Amendment and delivered to the Company a file-stamped copy of the amendment to Parent&#8217;s certificate of incorporation effecting the Parent Charter Amendment. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(e)&#8195;<u>Parent Certificate</u>. The Company shall have received at the Closing a certificate signed on behalf of Parent by a senior executive officer of Parent to the effect that the conditions set forth in <u>Sections 6.3(a)</u>, <u>(b)</u> and <u>(c)</u> have been satisfied. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(f)&#8195;<u>Resignations</u>. The Company shall have received copies of the resignations, effective as of the Effective Time, of each director and officer (for such officers, limited to the offices held by such officers and not to such officer&#8217;s employment) of Parent and its Subsidiaries, other than a resignation from the individuals designated directors to the Parent Board by Parent in accordance with <u>Section&#160;5.14(a)</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS64"><!--Anchor--></a>6.4&#8195;<u>Frustration of Conditions</u>. None of the Company, Parent or Merger Sub may rely, either as a basis for not consummating the Merger or the other transactions or terminating this Agreement and abandoning the Merger, on the failure of any condition set forth in <u>Sections 6.1</u>, <u>6.2</u> or <u>6.3</u>, as the case may be, to be satisfied if such failure was caused by such Party&#8217;s material breach of any provision of this Agreement. </div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 20pt; text-align: center;"><a name="tANXAA7"><!--Anchor--></a>ARTICLE&#160;VII <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">TERMINATION </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS71"><!--Anchor--></a>7.1&#8195;<u>Termination by Mutual Consent</u>. This Agreement may be terminated and the Merger may be abandoned at any time prior to the Effective Time, whether before or after satisfaction of the condition referred to in <u>Section&#160;6.1(a)</u>, by mutual written consent of the Company and Parent. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS72"><!--Anchor--></a>7.2&#8195;<u>Termination by Either Parent or Company</u>. This Agreement may be terminated and the Merger may be abandoned at any time prior to the Effective Time by either Parent or the Company if: </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;the Merger shall not have been consummated by 11:59 p.m. (Eastern Time) on March&#160;31, 2027, (the &#8220;<font style="font-weight: bold;">Termination Date</font>&#8221;): <u>provided</u> that the right to terminate this Agreement under this <u>Section&#160;7.2(a)</u> shall not be available to any Party if its material breach of any provision of this Agreement has been the cause of, or resulted in, the failure of the Merger to be consummated by the Termination Date; </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-54<br></div></div></div>
<!--End Page 439-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 440-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg60"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;the Parent Stockholder Approval shall not have been obtained at a meeting duly convened therefor or at any adjournment or postponement thereof, in each case at which a vote upon the Parent Stockholder Approval was taken; or </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(c)&#8195;if the condition set forth in <u>Section&#160;6.1(b)</u> is not satisfied and the Legal Restraint giving rise to such non-satisfaction shall have become final and non-appealable; <u>provided</u> that the terminating Party shall have complied with its obligations pursuant to <u>Section 5.6</u> in respect of any such Legal Restraint. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS73"><!--Anchor--></a>7.3&#8195;<u>Termination by Company</u>. This Agreement may be terminated and the Merger may be abandoned at any time prior to the Effective Time by the Company if: </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;at any time prior to the Parent Stockholder Approval having been obtained, (i) a Parent Change in Recommendation shall have occurred, (ii) the Parent Board shall have failed to publicly reaffirm the Parent Board Recommendation within 10 Business Days after the Company so requests in writing (<font style="font-style: italic;"><u>provided</u></font> that the Company shall be limited to one such request with respect to any Parent Acquisition Proposal unless such Parent Acquisition Proposal has been modified, and then one such request with respect to any such modification) following the public disclosure of any Parent Acquisition Proposal with any Person other than the Company (or if the Parent Stockholders Meeting is scheduled to be held within 10&#160;Business Days of the written request of the Company, promptly and in any event prior to the date on which the Parent Stockholders Meeting is scheduled to be held), (iii) the Parent Board shall have failed to publicly recommend against any tender offer or exchange offer subject to Regulation 14D under the Exchange Act that constitutes a Parent Acquisition Proposal (including, for these purposes, by taking no position with respect to the acceptance of such tender offer or exchange offer by Parent&#8217;s stockholders) within 10 Business Days of the commencement of such tender offer or exchange offer or (iv) Parent shall have intentionally and materially breached its obligations set forth in <u>Section&#160;5.3(a)</u>; <u>provided</u> that the Company&#8217;s right to terminate this Agreement pursuant to this <u>Section&#160;7.3(a)</u> shall expire upon receipt of the Parent Stockholder Approval; or </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;at any time prior to the Effective Time, whether before or after satisfaction of the condition referred to in <u>Section&#160;6.1(a)</u> is obtained, if there has been a breach of any representation, warranty, covenant or agreement made by Parent or Merger Sub in this Agreement, or any such representation and warranty shall have become untrue after the date of this Agreement, such that any condition set forth in <u>Section&#160;6.3(a)</u> or <u>Section&#160;6.3(b)</u>, as the case may be, would not be satisfied and such breach or failure to be true is not curable or, if curable, is not cured prior to the earlier of (i) 30 days following notice to Parent from the Company of such breach or failure and (ii) the date that is one Business Day prior to the Termination Date; <u>provided</u> that the Company shall not have the right to terminate this Agreement pursuant to this <u>Section&#160;7.3(b)</u> if the Company is then in material breach of any of its representations, warranties, covenants or agreements under this Agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS74"><!--Anchor--></a>7.4&#8195;<u>Termination by Parent</u>. This Agreement may be terminated and the Merger may be abandoned at any time prior to the Effective Time by Parent if: </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;at any time prior to the Company Stockholder Approval having been obtained, (i) a Company Change in Recommendation shall have occurred or (ii) the Company shall have intentionally and materially breached its obligations set forth in <u>Section&#160;5.2(a)</u>; <u>provided</u> that Parent&#8217;s right to terminate this Agreement pursuant to this <u>Section&#160;7.4(a)</u> shall expire upon receipt of the Company Stockholder Approval; or </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;at any time prior to the Effective Time, whether before or after satisfaction of the condition referred to in <u>Section&#160;6.1(a)</u> is obtained, if there has been a breach of any representation, warranty, covenant or agreement made by the Company in this Agreement, or any such representation and warranty shall have become untrue after the date of this Agreement, such that any condition set forth in <u>Section&#160;6.2(a)</u> or <u>Section&#160;6.2(b)</u>, as the case may be, would not be satisfied and such breach or failure to be true is not curable or, if curable, is not cured prior to the earlier of (i) 30 days following notice to the Company from Parent of such breach or failure and (ii) the date that is one Business Day prior to the Termination Date; <u>provided</u> that Parent shall not have the right to terminate this Agreement pursuant to this <u>Section&#160;7.4(b)</u> if Parent is then in material breach of any of its representations, warranties, covenants or agreements under this Agreement; or </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(c)&#8195;if the Company does not deliver to Parent the Company Stockholder Written Consent constituting the Company Stockholder Approval within 24 hours following execution and delivery of this Agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS75"><!--Anchor--></a>7.5&#8195;<u>Company Termination Fee and Expense Reimbursement</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;In the event that (i) (A) after the date of this Agreement, a Company Acquisition Proposal shall have been made to the Company and such Company Acquisition Proposal shall not have been withdrawn at the time the Company Stockholder Approval is obtained, or a third party has announced an intention to make a Company Acquisition Proposal and such intention shall not have been withdrawn at the time the Company Stockholder Approval is obtained, (B) this Agreement is terminated by the Company or Parent pursuant to <u>Section&#160;7.2(a)</u> or <u>Section&#160;7.2(b)</u>, or by Parent pursuant to <u>Section&#160;7.4(b)</u>, and (C) within 12 months after such termination, the Company enters into a Company Alternative Acquisition Agreement with respect to a Company Acquisition Proposal or consummates a Company Acquisition Proposal (solely for purposes of this <u>Section&#160;7.5(a)(i)</u>, the references to &#8220;25%&#8221; in the definition of Company Acquisition Proposal shall be deemed to be references to &#8220;50%&#8221;); or (ii) this Agreement is terminated by Parent pursuant to <u>Section&#160;7.4(a)</u>; then the Company shall, within two Business Days after such termination in the case of clause (ii) or within one Business Day after the consummation of a Company Acquisition Proposal, in the case of clause (i), pay (or cause to be paid) to Parent the Company Termination Fee by wire transfer of same day funds (<u>provided</u> that if either the Company or Parent terminates this Agreement pursuant to <u>Section&#160;7.2(a)</u> or <u>Section&#160;7.2(b)</u> at any time when Parent would then be been permitted to terminate this Agreement pursuant to <u>Section&#160;7.4(a)</u>, this Agreement shall be deemed terminated pursuant to <u>Section&#160;7.4(a)</u> for purposes of this <u>Section&#160;7.5(a)</u>); <u>provided</u>, <u>further</u>, that if this Agreement was validly terminated pursuant to <u>Section&#160;7.2(b)</u> or <u>Section&#160;7.4(b)</u>, the Company Termination Fee shall be reduced by an amount equal to the Parent Fee Reimbursement actually paid to Parent pursuant to <u>Section&#160;7.5(b)</u>. In no event shall the Company be required to pay the Company Termination Fee on more than one occasion. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-55<br></div></div></div>
<!--End Page 440-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 441-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg61"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;If this Agreement is terminated by Parent pursuant to <u>Section&#160;7.4(c)</u>, the Company shall reimburse Parent for all reasonable out of pocket fees and expenses incurred by Parent in connection with this Agreement and the Contemplated Transactions (which shall not include any fees and expenses incurred by Parent in connection with any Parent Legacy Transaction), up to a maximum of $5,000,000 (the &#8220;<font style="font-weight: bold;">Parent Fee Reimbursement</font>&#8221;), by wire transfer of same day funds within five Business Days following the date on which Parent submits to the Company true and correct copies of reasonable documentation supporting such expenses. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS76"><!--Anchor--></a>7.6&#8195;<u>Parent Termination Fee and Expense Reimbursement</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;In the event that (i) (A) after the date of this Agreement, a Parent Acquisition Proposal shall have been made to Parent and such Parent Acquisition Proposal becomes publicly known prior to the Parent Stockholders Meeting and, in either case, such Parent Acquisition Proposal shall not have been withdrawn at the time of the Parent Stockholders Meeting, or a third party has publicly announced an intention to make a Parent Acquisition Proposal and such intention shall not have been withdrawn at the time of the Parent Stockholders Meeting, (B) this Agreement is terminated by Parent or the Company pursuant to <u>Section&#160;7.2(a)</u> or <u>Section&#160;7.2(c)</u>, or by the Company pursuant to <u>Section&#160;7.3(b)</u>, and (C) within 12 months after such termination, Parent enters into a Parent Alternative Acquisition Agreement with respect to a Parent Acquisition Proposal or consummates a Parent Acquisition Proposal (solely for purposes of this <u>Section&#160;7.6(a)(i)</u>, the references to &#8220;15%&#8221; in the definition of Parent Acquisition Proposal shall be deemed to be references to &#8220;50%&#8221;); or (ii) this Agreement is terminated by the Company pursuant to <u>Section&#160;7.3(a)</u>; then Parent shall, within two Business Days after such termination in the case of clause (ii) or within one Business Day after the consummation of a Parent Acquisition Proposal, in the case of clause (i), pay (or cause to be paid) to the Company the Parent Termination Fee by wire transfer of same day funds (<u>provided</u> that if either the Company or Parent terminates this Agreement pursuant to <u>Section&#160;7.2(a)</u> or <u>Section&#160;7.2(c)</u> at any time after the Company would have been permitted to terminate this Agreement pursuant to <u>Section&#160;7.3(a)</u>, this Agreement shall be deemed terminated pursuant to <u>Section&#160;7.3(a)</u> for purposes of this <u>Section&#160;7.6(a)</u>); <u>provided</u>, <u>further</u>, that if this Agreement was validly terminated pursuant to <u>Section&#160;7.2(c)</u> or <u>Section&#160;7.3(b)</u>, the Parent Termination Fee shall be reduced by an amount equal to the Company Fee Reimbursement actually paid to the Company pursuant to <u>Section&#160;7.6(b)</u>. In no event shall Parent be required to pay the Parent Termination Fee on more than one occasion. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;If this Agreement is terminated pursuant to <u>Section&#160;7.2(b)</u>, Parent shall reimburse the Company for all reasonable out of pocket fees and expenses incurred by the Company in connection with this Agreement and the Contemplated Transactions, up to a maximum of $5,000,000&#160;(the &#8220;<font style="font-weight: bold;">Company Fee Reimbursement</font>&#8221;<font style="font-weight: bold;"> </font>), by wire transfer of same day funds within five Business Days following the date on which the Company submits to Parent true and correct copies of reasonable documentation supporting such expenses. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS77"><!--Anchor--></a>7.7&#8195;<u>Notice of Termination</u>. The Party desiring to terminate this Agreement pursuant to <u>Section 7.1</u>, <u>Section&#160;7.2</u>, <u>Section&#160;7.3</u> or <u>Section&#160;7.4</u> shall give written notice of such termination to the other Parties in accordance with <u>Section&#160;8.7</u>, specifying the provision of this Agreement pursuant to which such termination is effected. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS78"><!--Anchor--></a>7.8&#8195;<u>Effect of Termination and Abandonment</u>. In the event of termination of this Agreement and the abandonment of the Merger pursuant to this <u>Article&#160;VII</u>, this Agreement (other than as set forth in this <u>Section&#160;7.8</u> and in <u>Section&#160;8.1</u>) shall become void and of no effect with no liability on the part of any Party (or of any of its respective Representatives); <u>provided</u> that no such termination shall relieve any Party (a) from any liability for Fraud or Willful Breach of this Agreement prior to such termination and (b) from any obligation to pay, if applicable, the Company Termination Fee pursuant to <u>Section&#160;7.5</u> or the Parent Termination Fee pursuant to <u>Section&#160;7.6</u>, as applicable. For purposes of this Agreement, the term &#8220;<font style="font-weight: bold;">Willful Breach</font>&#8221; means a deliberate act or a deliberate failure to act, taken or not taken with the actual knowledge that such act or failure to act would, or would reasonably be expected to, result in or constitute a material breach of this Agreement, regardless of whether breaching was the object of the act or failure to act. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS79"><!--Anchor--></a>7.9&#8195;<u>Remedies</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;Each Party acknowledges that the agreements contained in <u>Sections 7.5</u> and <u>7.6</u> are an integral part of the Contemplated Transactions, and that, without these agreements, no Party would have entered into this Agreement; accordingly, if the Company fails to pay promptly the Company Termination Fee pursuant to <u>Section&#160;7.5</u> or Parent fails to pay promptly the Parent Termination Fee pursuant to <u>Section&#160;7.6</u> (each, a &#8220;<font style="font-weight: bold;">Termination Fee</font>&#8221;), and, in order to obtain such Termination Fee, the Party entitled to receive such Termination Fee (the &#8220;<font style="font-weight: bold;">Recipient</font>&#8221;) commences a suit which results in a judgment against the Party obligated to pay such Termination Fee (the &#8220;<font style="font-weight: bold;">Payor</font>&#8221;), the Payor shall pay to the Recipient its costs and expenses (including attorneys&#8217; fees) in connection with such suit, together with interest on such Termination Fee at the prime rate in effect on the date such Termination Fee was required to be paid through the date of full payment thereof. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;The Parties agree that the monetary remedies set forth in this <u>Article&#160;VII</u> and the specific performance remedies set forth in <u>Section&#160;8.12</u> shall be the sole and exclusive remedies of (i) the Company and its Subsidiaries against Parent, Merger Sub and any of their respective former, current or future general or limited partners, stockholders, managers, members, Representatives or Affiliates, on the one hand, and of Parent, Merger Sub and any of their respective former, current or future general or limited partners, stockholders, managers, members, Representatives or Affiliates against the Company and its Subsidiaries, on the other hand, for any loss suffered as a result of the failure of the Merger to be consummated except in the case of Fraud or a Willful Breach of this Agreement (in which case only the breaching Party (and not the stockholders of such Party) shall be liable for damages for such Fraud or Willful Breach, and such liability shall not be limited to the amount of the applicable Termination Fee), and upon payment of such amount, none of the Parties or any of their respective former, current or future general or limited partners, stockholders, managers, members, Representatives or Affiliates shall have any further liability or obligation relating to or arising out of this Agreement or the Contemplated Transactions, except for the liability of a Party in the case of Fraud or a Willful Breach of this Agreement by such Party and (ii) Parent and Merger Sub against the Company and its Subsidiaries and any of their respective former, current or future general or limited partners, stockholders, managers, members, Representatives or Affiliates for any loss suffered as a result of the failure of the Contemplated Transactions to be consummated except in the case of Fraud or a Willful Breach of this Agreement (in which case the Company shall be liable for damages for such Fraud </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-56<br></div></div></div>
<!--End Page 441-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 442-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg62"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">or Willful Breach, and such liability shall not be limited to the amount of any termination fee or expense reimbursement), and upon payment of such amount, none of the Company and its Subsidiaries or any of their respective former, current or future general or limited partners, stockholders, managers, members, Representatives or Affiliates shall have any further liability or obligation relating to or arising out of this Agreement or the Contemplated Transactions, except for the liability of the Company in the case of Fraud or a Willful Breach of this Agreement. </div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 12pt; text-align: center;"><a name="tANXAA8"><!--Anchor--></a>ARTICLE&#160;VIII <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">MISCELLANEOUS AND GENERAL </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS81"><!--Anchor--></a>8.1&#8195;<u>Survival</u>. This <u>Article&#160;</u>VIII and the agreements of the Company, Parent and Merger Sub contained in <u>Section&#160;5.10</u>, <u>Section&#160;5.11</u> and <u>Section&#160;5.18</u> shall survive the consummation of the Merger. This <u>Article</u> VIII (other than <u>Section&#160;8.2</u>, <u>Section&#160;8.3</u> and <u>Section&#160;8.4</u>) and the agreements of the Company, Parent and Merger Sub contained in <u>Section&#160;5.10</u>, <u>Section&#160;7.5</u>, <u>Section&#160;7.6</u>, <u>Section&#160;7.8</u> and <u>Section&#160;7.9</u> and the Confidentiality Agreement shall survive the termination of this Agreement. All other representations, warranties, covenants and agreements in this Agreement and in any certificate or other writing delivered pursuant hereto shall not survive the consummation of the Merger or the termination of this Agreement. This <u>Section&#160;8.1</u> shall not limit any covenant or agreement of the Parties which by its terms contemplates performance after the Effective Time. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS82"><!--Anchor--></a>8.2&#8195;<u>Amendment</u>. This Agreement may be amended with the approval of the Company, Merger Sub and Parent at any time (whether before or after obtaining the Company Stockholder Approval or before or after obtaining the Parent Stockholder Approval); <u>provided</u> that after any such approval of this Agreement by a Party&#8217;s stockholders, no amendment shall be made which by Law requires further approval of such stockholders without the further approval of such stockholders; <u>provided</u>, <u>further</u> that after the Closing, no amendment to this Agreement shall be made by Parent without the consent of the Legacy Parent Directors that would reasonably be expected to adversely impact the rights of the holders of Parent equity interests immediately prior to the Effective Time (the &#8220;<font style="font-weight: bold;">Legacy Parent Stockholders</font>&#8221;) or adversely impact in any material respect the amount or timing of any payments to the Legacy Parent Stockholders (or the inputs into such payments) under this Agreement or the CVR Agreement, including any payments under the Illumina Agreement. This Agreement may not be amended except by an instrument in writing signed on behalf of each of the Company, Merger Sub and Parent.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS83"><!--Anchor--></a>8.3&#8195;<u>Assignability</u>. This Agreement shall be binding upon, and shall be enforceable by and inure solely to the benefit of, the Parties and their respective successors and permitted assigns; <u>provided</u> that neither this Agreement nor any of a Party&#8217;s rights or obligations hereunder may be assigned or delegated by such Party without the prior written consent of the other Party, and any attempted assignment or delegation of this Agreement or any of such rights or obligations by such Party without the other Party&#8217;s prior written consent shall be void and of no effect. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS84"><!--Anchor--></a>8.4&#8195;<u>Waiver</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;No failure on the part of any Party to exercise any power, right, privilege or remedy under this Agreement, and no delay on the part of any Party in exercising any power, right, privilege or remedy under this Agreement, shall operate as a waiver of such power, right, privilege or remedy; and no single or partial exercise of any such power, right, privilege or remedy shall preclude any other or further exercise thereof or of any other power, right, privilege or remedy. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;No Party shall be deemed to have waived any claim arising out of this Agreement, or any power, right, privilege or remedy under this Agreement, unless the waiver of such claim, power, right, privilege or remedy is expressly set forth in a written instrument duly executed and delivered on behalf of such Party and any such waiver shall not be applicable or have any effect except in the specific instance in which it is given; <u>provided</u> that after the Closing, no waiver shall be made by Parent without the consent of the Legacy Parent Directors that would reasonably be expected to adversely impact the rights of the Legacy Parent Stockholders or adversely impact in any material respect the amount or timing of any payments to the Legacy Parent Stockholders (or the inputs into such payments) under this Agreement or the CVR Agreement, including any payments under the Illumina Agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS85"><!--Anchor--></a>8.5&#8195;<u>Entire Agreement; Counterparts; Exchanges by Electronic Transmission</u>. This Agreement, the Company Disclosure Schedule, the Parent Disclosure Schedule and the other agreements referred to in this Agreement constitute the entire agreement and supersede all prior agreements and understandings, both written and oral, among or between any of the Parties with respect to the subject matter hereof and thereof; <u>provided</u> that the Confidentiality Agreement shall not be superseded and shall remain in full force and effect in accordance with its terms. Notwithstanding any other provision of this Agreement to the contrary, the information set forth in the Company Disclosure Schedule and the Parent Disclosure Schedule constitutes &#8220;facts ascertainable&#8221; as that term is used in Section&#160;251(b) of the DGCL, and the Company Disclosure Schedule and the Parent Disclosure Schedule do not form part of this Agreement but instead operate upon the terms of this Agreement as provided herein. This Agreement may be executed in several counterparts, each of which shall be deemed an original and all of which shall constitute one and the same instrument. The exchange of a fully executed Agreement (in counterparts or otherwise) by all Parties by electronic transmission in. PDF format shall be sufficient to bind the Parties to the terms and conditions of this Agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS86"><!--Anchor--></a>8.6&#8195;<u>Governing Law and Venue; Waiver of Jury Trial</u>. This Agreement shall be governed by, and construed in accordance with, the Laws of the State of Delaware, regardless of the Laws that might otherwise govern under applicable principles of conflicts of laws. In any action or proceeding between any of the Parties arising out of or relating to this Agreement or any of the Contemplated Transactions, each of the Parties: (a) irrevocably and unconditionally consents and submits to the exclusive jurisdiction and venue of the Court of Chancery of the State of Delaware located in New Castle County or, to the extent such court does not have subject matter jurisdiction, the United States District Court for the District of Delaware or, to the extent that neither of the foregoing courts has jurisdiction, the Superior Court of the State of Delaware; (b) agrees that all claims in respect of such action or proceeding shall be heard and determined exclusively in accordance with clause (a) of this <u>Section&#160;8.6</u>; (c) waives any objection to laying venue in any such action or proceeding in such courts; (d) waives any objection that such courts are an inconvenient forum or do not have jurisdiction over any Party; and (e) agrees that service of process upon such Party in any such action or proceeding shall be effective if notice is given </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-57<br></div></div></div>
<!--End Page 442-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 443-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg63"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">in accordance with <u>Section 8.7</u> of this Agreement. EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY ACTION OR PROCEEDING WHICH MAY ARISE UNDER THIS AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE IT HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY ACTION OR PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT AND ANY OF THE AGREEMENTS DELIVERED IN CONNECTION HEREWITH, OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY. EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT (I) NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF ANY ACTION OR PROCEEDING, SEEK TO ENFORCE EITHER OF SUCH WAIVERS, (II) IT UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF SUCH WAIVERS, (III) IT MAKES SUCH WAIVERS VOLUNTARILY AND (IV) IT HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS <u>SECTION 8.6</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS87"><!--Anchor--></a>8.7&#8195;<u>Notices</u>. All notices, requests, instructions, demands and other communications under this Agreement shall be in writing and shall be deemed given (a) when delivered personally by hand (with written confirmation of receipt), (b) delivered by e-mail (provided that no &#8220;bounceback&#8221; or similar notification of non-delivery is received by the sender with respect thereto) or (c) when received by the addressee if sent by nationally recognized overnight delivery service or prepaid first class certified mail (with written confirmation of receipt), in each case, at the following addresses: </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_txtann" style="width: 528pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 29pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 487pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr><td style="width: 29pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 487pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">if to Parent or Merger Sub:</div></td></tr><tr><td style="width: 29pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 487pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 29pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 487pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Standard BioTools Inc. </div></td></tr><tr><td style="width: 29pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 487pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">50 Milk Street, 10th Floor </div></td></tr><tr><td style="width: 29pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 487pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Boston, MA 02109 </div></td></tr><tr><td style="width: 29pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 487pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Attention: [***] </div></td></tr><tr><td style="width: 29pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 487pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Email: [***] </div></td></tr><tr><td style="width: 29pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 487pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 29pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 487pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">with copies to (which shall not constitute notice):</div></td></tr><tr><td style="width: 29pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 487pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 29pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 487pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Freshfields US LLP </div></td></tr><tr><td style="width: 29pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 487pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3 World Trade Center </div></td></tr><tr><td style="width: 29pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 487pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">175 Greenwich Street </div></td></tr><tr><td style="width: 29pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 487pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">New York, NY 10007 </div></td></tr><tr><td style="width: 29pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 487pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Attn: Damien R. Zoubek; Jenny Hochenberg; Abigail G. Hathaway </div></td></tr><tr><td style="width: 29pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 487pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Email: damien.zoubek@freshfields.com; jenny.hochenberg@freshfields.com; <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">abigail.hathaway@freshfields.com </div></td></tr><tr><td style="width: 29pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 487pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 29pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 487pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">if to the Company: </div></td></tr><tr><td style="width: 29pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 487pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 29pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 487pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Treeline Biosciences, Inc. </div></td></tr><tr><td style="width: 29pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 487pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">[***] </div></td></tr><tr><td style="width: 29pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 487pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Attention: [***] </div></td></tr><tr><td style="width: 29pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 487pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Email: [***] </div></td></tr><tr><td style="width: 29pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 487pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 29pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 487pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">with copies to (which shall not constitute notice): </div></td></tr><tr><td style="width: 29pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 487pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 29pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 487pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Fenwick &amp; West LLP </div></td></tr><tr><td style="width: 29pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 487pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">902 Broadway, 18th Floor </div></td></tr><tr><td style="width: 29pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 487pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">New York, NY 10010 </div></td></tr><tr><td style="width: 29pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 487pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Attn: Effie Toshav; David Michaels </div></td></tr><tr><td style="width: 29pt; padding-top: 0.67pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 487pt; padding-top: 0.67pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Email: EToshav@fenwick.com; DMichaels@fenwick.com</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 3pt; width: 29pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 487pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">or to such other persons or addresses as may be designated in writing by the Party to receive such notice as provided above. Unless a different deadline for the delivery of notices, requests, instructions, demands and other communications is expressly provided for in this Agreement, all such notices, requests instructions, demands and other communications will be deemed given on the day delivered pursuant to the means set forth above if delivered before 5:00 p.m. Eastern Time, and otherwise on the next following day. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS88"><!--Anchor--></a>8.8&#8195;<u>No Third Party Beneficiaries</u>. This Agreement is not intended to, and does not, confer upon any Person other than Parties any rights or remedies hereunder, other than (a) the Indemnified Persons as provided in <u>Section&#160;5.11</u>, (b) the right of the Company&#8217;s stockholders to receive the Merger Consideration after the Closing and (c) the rights of the Company&#8217;s other equityholders pursuant to <u>Section 2.3 after the Closing</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS89"><!--Anchor--></a>8.9&#8195;<u>Severability</u>. Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions of this Agreement or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction. If a final judgment of a court of competent jurisdiction declares that any term or provision </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-58<br></div></div></div>
<!--End Page 443-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 444-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg64"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">of this Agreement is invalid or unenforceable, the Parties agree that the court making such determination shall have the power to limit such term or provision, to delete specific words or phrases or to replace such term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this Agreement shall be valid and enforceable as so modified. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS810"><!--Anchor--></a>8.10&#8194;<u>No Other Representations and Warranties</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;Except for the representations and warranties of the Company contained in <u>Article III</u>, Parent and Merger Sub acknowledge that neither the Company nor any of its Subsidiaries is making and has not made, and no other Person is making or has made on behalf of the Company or any of its Subsidiaries, any express or implied representation or warranty in connection with this Agreement or the Contemplated Transactions. Neither Parent nor Merger Sub is relying and neither Parent nor Merger Sub has relied on any representations or warranties whatsoever regarding the subject matter of this Agreement, express or implied, except for the representations and warranties in <u>Article III</u>, including the Company Disclosure Schedule. Such representations and warranties by the Company constitute the sole and exclusive representations and warranties of the Company and its Subsidiaries in connection with the Contemplated Transactions and each of Parent and Merger Sub understands, acknowledges and agrees that all other representations and warranties of any kind or nature whether express, implied or statutory are specifically disclaimed by the Company and its Subsidiaries. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;Except for the representations and warranties of Parent and Merger Sub contained in <u>Article&#160;IV</u>, the Company acknowledges that neither Parent nor Merger Sub is making or has made, and no other Person is making or has made on behalf of Parent or Merger Sub, any express or implied representation or warranty in connection with this Agreement or the Contemplated Transactions. The Company is not relying and it has not relied on any representations or warranties whatsoever regarding the subject matter of this Agreement, express or implied, except for the representations and warranties in <u>Article IV</u>, including the Parent Disclosure Schedule. Such representations and warranties by Parent and Merger Sub constitute the sole and exclusive representations and warranties of Parent and Merger Sub in connection with the Contemplated Transactions and the Company understands, acknowledges and agrees that all other representations and warranties of any kind or nature whether express, implied or statutory are specifically disclaimed by Parent. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;"><a name="tANXAS811"><!--Anchor--></a>8.11&#8194;<u>Construction</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-indent: 40pt; text-align: left;">(a)&#8195;References to &#8220;cash,&#8221; &#8220;dollars&#8221; or &#8220;$&#8221; are to U.S. dollars. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;For purposes of this Agreement, whenever the context requires: the singular shall include the plural, and vice versa; the masculine gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter gender shall include masculine and feminine genders. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(c)&#8195;The Parties have participated jointly in the negotiating and drafting of this Agreement and agree that any rule of construction to the effect that ambiguities are to be resolved against the drafting Party shall not be applied in the construction or interpretation of this Agreement, and no presumption or burden of proof shall arise favoring or disfavoring any Party by virtue of the authorship of any provision of this Agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(d)&#8195;As used in this Agreement, the words &#8220;include&#8221; and &#8220;including,&#8221; and variations thereof, shall not be deemed to be terms of limitation, but rather shall be deemed to be followed by the words &#8220;without limitation.&#8221; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(e)&#8195;The words &#8220;hereof,&#8221; &#8220;herein&#8221; and &#8220;hereunder&#8221; and words of similar import, when used in this Agreement, refer to this Agreement as a whole and not to any particular provision of this Agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-indent: 40pt; text-align: left;">(f)&#8195;References herein to a Person are also to such Person&#8217;s successors and permitted assigns. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-indent: 40pt; text-align: left;">(g)&#8195;Unless otherwise specifically provided for herein, the term &#8220;or&#8221; will not be deemed to be exclusive. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(h)&#8195;Except as otherwise indicated, all references in this Agreement to &#8220;Sections,&#8221; &#8220;Exhibits&#8221; and &#8220;Schedules&#8221; are intended to refer to Sections of this Agreement and Exhibits and Schedules to this Agreement, respectively. Any capitalized terms used in any Exhibits or Schedules but not otherwise defined therein have the meanings ascribed to such terms as in this Agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(i)&#8195;Any reference to (A) any Contract (including this Agreement) are to the Contract as amended, modified, supplemented, restated or replaced from time to time (in the case of Contract, to the extent permitted by the terms thereof and, if applicable, by the terms of this Agreement) and (B) any Law refers to such Law as amended, modified, supplemented or replaced from time to time (and, in the case of statutes, include any rules and regulations promulgated under such statute) and references to any section of any Law include any successor to such section. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(j)&#8195;The headings and table of contents contained in this Agreement are for convenience of reference only, shall not be deemed to be a part of this Agreement and shall not be referred to in connection with the construction or interpretation of this Agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(k)&#8195;The Parties agree that each of the Company Disclosure Schedule and the Parent Disclosure Schedule shall be arranged in sections and subsections corresponding to the numbered and lettered sections and subsections contained in this Agreement. The disclosures in any section or subsection of the Company Disclosure Schedule or the Parent Disclosure Schedule shall qualify other sections and subsections in this Agreement to the extent it is readily apparent on its face from a reading of the disclosure that such disclosure is applicable to such other sections and subsections. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(l)&#8195;The phrases &#8220;provided to,&#8221; &#8220;made available,&#8221; &#8220;furnished to,&#8221; and phrases of similar import when used herein, unless the context otherwise requires, shall mean, with respect to any statement in <u>Article&#160;III</u> or <u>Article&#160;IV</u> to the effect that any information, document or other material has been &#8220;delivered&#8221; or &#8220;provided&#8221; to a Party or its representatives, that such information, document, or material was (i) made available for review in the virtual data room set up by the Parties in connection with this Agreement at least one Business Day prior to the date of this Agreement, </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-59<br></div></div></div>
<!--End Page 444-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 445-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg65"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">(ii)&#160;actually delivered (whether by physical or electronic delivery) upon request to the other Party or its representatives at least one Business Day prior to the date of this Agreement or (iii) with respect to Parent, such material is disclosed in the Parent SEC Documents filed with the SEC prior to the date hereof and publicly made available on the SEC&#8217;s Electronic Data Gathering Analysis and Retrieval system. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(m)&#8195;Unless indicated otherwise, (i) any action required to be taken by or on a day or Business Day may be taken until 11:59 PM Eastern Time on such day or Business Day, (ii) all references to &#8220;days&#8221; shall be to calendar days unless otherwise indicated as a &#8220;Business Day&#8221; and (iii) all days, Business Days, times and time periods contemplated by this Agreement will be determined by reference to Eastern Time. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS812"><!--Anchor--></a>8.12&#8194;<u>Specific Performance</u>. The Parties acknowledge and agree that irreparable damage would occur and that the Parties would not have any adequate remedy at law if any provision of this Agreement were not performed in accordance with its specific terms or were otherwise breached, and that monetary damages, even if available, would not be an adequate remedy therefor. It is accordingly agreed that the Parties shall be entitled to an injunction or injunctions, specific performance and other equitable relief to prevent breaches of this Agreement and to enforce specifically the performance of the terms and provisions hereof, without proof of actual damages (and each Party hereby waives any requirement for the security or posting of any bond in connection with such remedy), this being in addition to any other remedy to which they are entitled at Law or in equity. The Parties further agree not to assert that a remedy of specific enforcement is unenforceable, invalid, contrary to applicable Law or inequitable for any reason, and not to assert that a remedy of monetary damages would provide an adequate remedy for any such breach or that the Company or Parent otherwise have an adequate remedy at law. Notwithstanding the foregoing, in no event shall the Company be entitled to both (a) specific performance to cause the other party to consummate the Closing and (b) the payment of the Parent Termination Fee. The Parties acknowledge that the agreements contained in this <u>Section&#160;8.12</u> are an integral part of the transactions contemplated by this Agreement, and that, without these agreements, the Parties would not enter into this Agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS813"><!--Anchor--></a>8.13&#8194;<u>Actions by Parent After the Closing</u>. Following the Closing and prior to the later of (x) the valid termination of the CVR Agreement and (y) the final determination of Parent Net Cash pursuant to <u>Section&#160;2.7</u> (such period, the &#8220;<font style="font-style: italic; font-weight: bold;">Post-Closing Period</font>&#8221;), any amendment of, or waiver under, this Agreement that would reasonably be expected to adversely impact the rights of the Legacy Parent Stockholders or adversely impact in any material respect the amount or timing of any payments to the Legacy Parent Stockholders (or the inputs into such payments) under this Agreement or the CVR Agreement, including any payments under the Illumina Agreement, shall require and be subject to the consent of the Legacy Parent Directors. If at any time during the Post-Closing Period, either Legacy Parent Director ceases to serve on the Parent Board for any reason, any decisions vested in the Legacy Parent Directors under this Agreement shall be vested solely in the remaining Legacy Parent Director. If the remaining Legacy Parent Director also ceases to serve on the Parent Board for any reason during the Post-Closing Period, (a) Parent shall appoint a nationally recognized securityholder representation firm, the fees and expenses of which shall constitute a &#8220;Permitted Deduction&#8221; under the CVR Agreement, to exercise the authority vested in the Legacy Parent Directors under this Agreement and (b) all references to &#8220;Legacy Parent Directors&#8221; in this Agreement shall thereafter be deemed to be references to such securityholder representation firm. To the extent the Legacy Parent Directors do not provide consent to the actions described in this <u>Section&#160;8.13</u> or elsewhere in this Agreement, all disputes between Parent or the Parent Board and the Legacy Parent Directors shall be resolved in accordance with <u>Section&#160;2.7(d)</u> to the extent related to the calculation of Parent Net Cash and otherwise pursuant to <u>Section&#160;8.6</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;"><a name="tANXAS814"><!--Anchor--></a>8.14&#8194;<u>Special Committee Approval</u>. For all purposes under this Agreement (other than <u>Section&#160;5.25</u>) and the other agreements contemplated hereby, Parent and the Parent Board, as applicable, shall act only as authorized and approved by, or in accordance with the recommendation of, as applicable, the Special Committee. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-style: italic; margin-top: 8.5pt; text-align: center;">[The remainder of this page is intentionally left blank.]<font style="font-style: normal;"> </font></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-60<br></div></div></div>
<!--End Page 445-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 446-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg66"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">IN WITNESS WHEREOF, this Agreement has been duly executed and delivered by the duly authorized officers of the Parties hereto as of date first set forth above. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_txtann" style="width: 528pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 264pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 252pt;" colspan="4"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr><td style="width: 264pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td colspan="4" style="width: 252pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">TREELINE BIOSCIENCES, INC.</div></td></tr><tr><td style="width: 264pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 12pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 228pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 264pt; padding-top: 0.67pt; padding-bottom: 1.75pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 12pt; padding-top: 0.67pt; padding-bottom: 1.75pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By: </div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 228pt; padding-top: 0.67pt; padding-bottom: 1.75pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ Joshua H. Bilenker </div></td></tr><tr><td style="width: 264pt; padding-top: 1.42pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 12pt; padding-top: 1.42pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name: </div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 228pt; padding-top: 1.42pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Joshua H. Bilenker </div></td></tr><tr><td style="width: 264pt; padding-top: 0.67pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 12pt; padding-top: 0.67pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Title: </div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 228pt; padding-top: 0.67pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chief Executive Officer</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 3pt; width: 264pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 12pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 228pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0.5pt; margin-left: 0pt; text-align: left;"> </div></div></div><div class="BRDSX_block-frill" style="width: 528pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-style: italic; margin-top: 10.73pt; text-align: center;">[Signature Page to Agreement and Plan of Merger]<br></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-61<br></div></div></div>
<!--End Page 446-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 447-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg67"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">IN WITNESS WHEREOF, this Agreement has been duly executed and delivered by the duly authorized officers of the Parties hereto as of the date first written above. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_txtann" style="width: 528pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 264pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 252pt;" colspan="4"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr><td style="width: 264pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td colspan="4" style="width: 252pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">STANDARD BIOTOOLS INC.<font style="font-weight: normal;"> </font></div></td></tr><tr><td style="width: 264pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 12pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 228pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 264pt; padding-top: 0.67pt; padding-bottom: 1.75pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 12pt; padding-top: 0.67pt; padding-bottom: 1.75pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By: </div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 228pt; padding-top: 0.67pt; padding-bottom: 1.75pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ Michael Egholm </div></td></tr><tr><td style="width: 264pt; padding-top: 1.42pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 12pt; padding-top: 1.42pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name: </div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 228pt; padding-top: 1.42pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Michael Egholm </div></td></tr><tr><td style="width: 264pt; padding-top: 0.67pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 12pt; padding-top: 0.67pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Title: </div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 228pt; padding-top: 0.67pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">President and Chief Executive Officer</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 3pt; width: 264pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 12pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 228pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 528pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-style: italic; margin-top: 10.73pt; text-align: center;">[Signature Page to Agreement and Plan of Merger]<br></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-62<br></div></div></div>
<!--End Page 447-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 448-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg68"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">IN WITNESS WHEREOF, this Agreement has been duly executed and delivered by the duly authorized officers of the Parties hereto as of the date first written above. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_txtann" style="width: 528pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 264pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 252pt;" colspan="4"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr><td style="width: 264pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td colspan="4" style="width: 252pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">SIRI MERGER SUB, INC.<font style="font-weight: normal;"> </font></div></td></tr><tr><td style="width: 264pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 12pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 228pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 264pt; padding-top: 0.67pt; padding-bottom: 1.75pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 12pt; padding-top: 0.67pt; padding-bottom: 1.75pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By: </div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 228pt; padding-top: 0.67pt; padding-bottom: 1.75pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ Sean Mackay </div></td></tr><tr><td style="width: 264pt; padding-top: 1.42pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 12pt; padding-top: 1.42pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name: </div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 228pt; padding-top: 1.42pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Sean Mackay </div></td></tr><tr><td style="width: 264pt; padding-top: 0.67pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 12pt; padding-top: 0.67pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Title: </div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 228pt; padding-top: 0.67pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 3pt; width: 264pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 12pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 228pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 528pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-style: italic; margin-top: 10.73pt; text-align: center;">[Signature Page to Agreement and Plan of Merger]<br></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-63<br></div></div></div>
<!--End Page 448-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 449-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg69"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;"><u>EXHIBIT&#160;A</u><br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195; <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;"><u>DEFINITIONS</u> </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 7.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;<font style="font-weight: bold;">Accounting Principles</font>&#8221; means the accounting principles, policies, procedures and methodologies set forth on <u>Schedule B</u> attached hereto.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Additional Filing Party</font>&#8221; means any stockholder of the Company that the Company reasonably determines is required to make any filings under the HSR Act in connection with the Merger. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">An &#8220;<font style="font-weight: bold;">Affiliate</font>&#8221; of any Person means another Person that directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with, such first Person. For purposes of this definition, &#8220;control,&#8221; when used with respect to any specified Person, means the power to direct or cause the direction of the management and policies of such Person, directly or indirectly, whether through ownership of voting securities or by Contract or otherwise, and the terms &#8220;controlling&#8221; and &#8220;controlled by&#8221; have correlative meanings to the foregoing. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Aggregate Company Exercise Price</font>&#8221; means the sum of the exercise prices of all In-the-Money Company Options that are unexpired, unexercised, and outstanding as of immediately prior to the Effective Time and that are included in the calculation of Company Outstanding Shares.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Aggregate Parent Exercise Price</font>&#8221; means the sum of the exercise prices of all In-the-Money Parent Options that are unexpired, unexercised, and outstanding as of immediately prior to the Effective Time and that are included in the calculation of Parent Outstanding Shares. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">AI</font>&#8221; means any machine learning, deep learning, automated decision making, and other artificial intelligence, including any and all (i)&#160;proprietary algorithms, software, generative AI tools or other IT assets that make use of, incorporate, or employ large language models, expert systems, natural language processing, computer vision, automated speech recognition, automated planning and scheduling, neural networks, statistical learning algorithms, transformers, trained models, or reinforcement learning, and (ii) proprietary embodied AI and related hardware or equipment. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Anti-Bribery Laws</font>&#8221; means the FCPA, as amended, any rules or regulations thereunder, or any other applicable United States or foreign anti-corruption, anti-bribery, or anti-money laundering laws or regulations. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Antitrust Laws</font>&#8221; means the Sherman Act, as amended, the Clayton Act, as amended, the HSR Act, the Federal Trade Commission Act, as amended, and all other federal, state or foreign statutes, rules, regulations, orders, decrees, administrative and judicial doctrines and other Laws, including without limitation any competition, antitrust, merger control or trade regulation Laws, that are designed or intended to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade or lessening competition through merger or acquisition. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;<font style="font-weight: bold;">Assumed Company Warrant</font>&#8221; means any Company Warrant that is not a Company Converting Warrant.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Business Day</font>&#8221; means any day other than a Saturday, Sunday or other day on which banks in New York, New York are authorized or obligated by Law to be closed. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;<font style="font-weight: bold;">CLIA</font>&#8221; means the Clinical Laboratory Improvement Amendments of 1988 (42 U.S.C. &#167;&#167; 263a et seq.), as amended. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Company Affiliate</font>&#8221; means any Person under common control with the Company or any of its Subsidiaries within the meaning of Section&#160;414(b), Section&#160;414(c), Section&#160;414(m) or Section&#160;414(o) of the Code, and the regulations issued thereunder. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Company Associate</font>&#8221; means any current or former officer, employee, independent contractor, consultant or director, of or to the Company or any of its Subsidiaries or any controlled Company Affiliate. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Company Benefit Plan</font>&#8221; means each (i) &#8220;employee benefit plan&#8221; (as such term is defined in Section&#160;3(3) of ERISA whether or not subject to ERISA) and (ii) other pension, retirement, supplemental retirement, deferred compensation, excess benefit, profit sharing, bonus, stock option, stock purchase, stock ownership, restricted stock, incentive, equity or equity-based, phantom equity, profits interest, employment, consulting, severance, change-of-control, retention, health, medical, life, disability, group insurance, paid-time off, holiday, welfare and fringe benefit plan, program, agreement, contract, or arrangement (whether written or unwritten, qualified or nonqualified, funded or unfunded and including any that have been frozen or terminated), in any case, sponsored, maintained, contributed to, or required to be contributed to, by the Company or any of its Subsidiaries for the benefit of any Company Associate or under which the Company or any of its Subsidiaries has any actual or contingent liability (including as to the result of it being treated as a single employer under Section&#160;414 of the Code with any other Person). </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;<font style="font-weight: bold;">Company Capital Stock</font>&#8221; means Company Common Stock, together with Company Preferred Stock. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Company Collaboration Agreement</font>&#8221; means any collaboration, co-development, co-promotion, license, option, research or similar Contract entered into by the Company or any of its Subsidiaries with any third-party for the research, development, manufacture, or commercialization of any drug candidate, product candidate or Company Product, which may include the grant of licenses or options to license Intellectual Property Rights, the transfer or sale of Company assets, co-funding arrangements, milestone or royalty payment obligations, or the sharing of development data and results with respect to any such drug candidate, product candidate or Company Product. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Company Contract</font>&#8221; means any Contract: (i) to which the Company or any of its Subsidiaries is a party; (ii) by which the Company or any of its Subsidiaries or any Company IP or any other asset of the Company or its Subsidiaries is or may become bound or under which the Company or any of its Subsidiaries has, or may become subject to, any obligation; or (iii) under which the Company or any of its Subsidiaries has or may acquire any right or interest. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">Exhibit A-1<br></div></div></div>
<!--End Page 449-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 450-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg70"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Company Converting Warrant</font>&#8221; means any Company Warrant that has been amended prior to the Effective Time to allow for the treatment of Company Converting Warrants pursuant to <u>Section&#160;2.3(c)</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Company ERISA Affiliate</font>&#8221; means any corporation or trade or business (whether or not incorporated) which is (or at any relevant time was) treated with the Company or any of its Subsidiaries as a single employer within the meaning of Section&#160;414 of the Code. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Company Intervening Event</font>&#8221; means any Effect that is material to the Company and its Subsidiaries taken as a whole, occurring or arising after the date of this Agreement that (i) was not known to, or reasonably foreseeable by, the Company Board (or if known, the magnitude or effect of which was not known to, or reasonably foreseeable) prior to the execution of this Agreement, which Effect (or the magnitude or effect thereof) becomes known to, or reasonably foreseeable by, the Company Board prior to the receipt of the Company Stockholder Approval and (ii) does not relate to (A) a Company Acquisition Proposal or (B) (1) any changes in the market price or trading volume of the Company, (2) the mere fact the Company or Parent meets or exceeds any internal or analysts&#8217; published projections, forecasts, estimates or predictions of revenue, earnings or other financial or operating metrics for any period ending on or after the date of this Agreement, or changes after the date of this Agreement in the market price or trading volume of the Company Common Stock or the credit rating of the Company (it being understood that, with respect to clause (2), the facts or occurrences giving rise or contributing to such change or event may be taken into account when determining a Company Intervening Event), (3) any events or developments relating to Parent or any of its Affiliates, (4) any event or development generally affecting the industries in which the Company or Parent operate or in the economy generally or other general business, financial, market or political conditions, including changes in interest rates in the United States or any other country or region in the world and changes in exchange rates for the currencies of any countries and any suspension of trading in securities (whether equity, debt, derivative or hybrid securities) generally on any securities exchange or over-the-counter market operating in the United States or any other country or region in the world, (5) any change in any applicable Law or other legal or regulatory conditions or changes in GAAP or other accounting standards, (6) any event or development to the extent directly resulting from the announcement or pendency of, or any actions required to be taken by the Company or Parent (or refrained to be taken by the Company or Parent) pursuant to the Agreement or the consummation of the Contemplated Transactions, including expiration or termination of waiting periods or the receipt of approvals, consents or clearances applicable to the Merger under the Antitrust Laws, (7) earthquakes, hurricanes, tsunamis, tornadoes, floods, mudslides, wildfires or other natural disasters, weather conditions and other force majeure events or (8) any Legal Proceedings made or brought by any of the current or former stockholders of the Company or Parent (on their own behalf or on behalf of the Company or Parent) against the Company or Parent, including Legal Proceedings arising out of the Contemplated Transactions. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;<font style="font-weight: bold;">Company IP</font>&#8221; means Company Owned IP and Company Licensed IP. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Company Licensed IP</font>&#8221; means all Intellectual Property Rights that are exclusively licensed (or sublicensed), or purported to be exclusively licensed (or sublicensed), by any third party to the Company or any of its Subsidiaries. For clarity, Company Licensed IP shall not include Intellectual Property Rights that have been denoted by a Governmental Entity as expired, lapsed or abandoned. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Company Material Adverse Effect</font>&#8221; means any Effect that, individually or in the aggregate with all other Effects, (1) materially adversely affects or would reasonably be expected to materially adversely affect the business, financial condition or results of operations of the Company and its Subsidiaries, taken as a whole, or (2) would reasonably be expected to prevent the consummation of the Contemplated Transactions, in each case, excluding any Effect to the extent that, either alone or in combination, it results from or arises out of (i) general business or economic conditions generally affecting the industry in which the Company and its Subsidiaries operate, (ii) political conditions, acts of war, the outbreak or escalation of armed hostilities, acts of terrorism, earthquakes, wildfires, hurricanes, tsunamis, floods, mudslides, weather conditions, other natural disasters, man-made disasters, health and other emergencies, calamities, epidemics, pandemics (including COVID-19 and any evolutions or mutations thereof), disease outbreaks, other acts of God or force majeure events, (iii) changes in financial, banking or securities markets, including changes in interest rates in the United States or any other country or region in the world and changes in exchange rates for the currencies of any countries and any suspension of trading in securities (whether equity, debt, derivative or hybrid securities) generally on any securities exchange or over-the-counter market operating in the United States or any other country or region in the world, (iv) any change in, or any compliance with or action taken for the purpose of complying with, any Law or GAAP (or interpretations of any Law or GAAP), (v) any change in the stock price or trading volume of Company Common Stock (it being understood, however, that any Effect causing or contributing to any change in stock price or trading volume of Company Common Stock may be taken into account in determining whether a Company Material Adverse Effect has occurred, unless such Effects are otherwise excepted from this definition), (vi) the failure of the Company to meet internal or analysts&#8217; expectations or projections or the results of operations of the Company (it being understood, however, that any Effect causing or contributing to the failure of the Company to meet internal or analysts&#8217; expectations or projections or the results of operations of the Company may be taken into account in determining whether a Company Material Adverse Effect has occurred, unless such Effects are otherwise excepted from this definition), (vii) the execution or announcement of this Agreement or the pendency of the Contemplated Transactions, including (A) the identity of Parent, (B) the loss or departure of officers or other employees of the Company or any of its Subsidiaries directly or indirectly resulting from, arising out of, attributable to, or related to the Contemplated Transactions and (C) any other negative development (or potential negative development) in the relationships of the Company or any of its Subsidiaries with business partners, whether as a direct or indirect result of the loss or departure of officers or employees of the Company or any of its Subsidiaries or otherwise, directly or indirectly resulting from, arising out of, attributable to, or related to the Contemplated Transactions, (viii) any actions taken or failure to take action, in each case, to which Parent has provided its prior written consent; or compliance with the terms of, or the taking of any action required or contemplated by, this Agreement; or the failure to take any action prohibited by this Agreement (excluding the requirement that the Company comply with the terms of <u>Section&#160;5.1(a)</u>, except to the extent Parent has unreasonably withheld its consent under <u>Section&#160;5.1(a)</u>), (ix) any fees or expenses incurred in connection with the Contemplated Transactions, (x) (A) any results, outcomes, data, adverse events or side effects arising from any clinical trials being conducted by or on behalf of the Company or any of its Subsidiaries or any competitor of the Company or any of its Subsidiaries (or the announcements thereof), (B) results of meetings with the FDA or other Governmental Entity (including any minutes of, or </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">Exhibit A-2<br></div></div></div>
<!--End Page 450-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 451-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg71"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">communications from, any Governmental Entity in connection with such meetings) with respect to the Company Products, (C) the determination by, or the delay of a determination by, the FDA or any other applicable Governmental Entity, or any panel or advisory body empowered or appointed thereby, with respect to a clinical hold, acceptance, filing, designation (including de-designation for the accelerated approval pathway), approval, clearance, non-acceptance, hold, refusal to file, refusal to designate, non-approval, disapproval or non-clearance, or requirement to conduct additional clinical studies or trials, with respect to the Company Products or (D) FDA approval (or other clinical or regulatory developments), market entry or pending market entry of any product competitive with or related to any of the Company Products, or any guidance, announcement or publication by the FDA or other applicable Governmental Entity relating to the Company Products, or (xi) any Legal Proceedings made or brought by any of the current or former stockholders of the Company (on their own behalf or on behalf of the Company) against the Company, Merger Sub, Parent or any of their directors or officers, including Legal Proceedings arising out of the Merger or in connection with any other Contemplated Transactions; except, in each case, with respect to clauses (i) through (iv), to the extent disproportionately affecting the Company and its Subsidiaries, taken as a whole, relative to other similarly situated companies in the industries in which the Company and its Subsidiaries operate. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Company Option</font>&#8221; means any option to purchase Company Common Stock (whether granted under the Company Equity Plan, assumed by the Company in connection with any merger, acquisition or similar transaction or otherwise issued or granted). </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Company Owned IP</font>&#8221; means all Intellectual Property Rights that are owned, or purported to be owned, by the Company or any of its Subsidiaries. For clarity, Company Owned IP shall not include Intellectual Property Rights that have been denoted by a Governmental Entity as expired, lapsed or abandoned. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Company Partner</font>&#8221; means any Person (other than the Company or any of its Subsidiaries) that is engaged by or on behalf of the Company or any of its Subsidiaries to perform any material activities relating to the research, development or manufacture of any Company Product, including any contract research organization, contract manufacturing organization, contract development and manufacturing organization, clinical trial site operator or other material service provider performing activities subject to regulation under applicable Law on behalf of the Company or any of its Subsidiaries; <u>provided that</u>, notwithstanding anything else in this Agreement, to the extent any representation relates to a Company Partner, that aspect of the representation is limited to the matters that have a direct effect on the activities subject to a Contract between the Company and the Company Partner and is limited to the Company&#8217;s Knowledge. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Company Product</font>&#8221; means all products and services currently marketed for sale or sold by the Company or any of its Subsidiaries, all products and services under development for sale by the Company or any of its Subsidiaries, and all modified, updated and/or next generation versions or derivatives of the foregoing. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Company Superior Proposal</font>&#8221; means any bona fide, written Company Acquisition Proposal on terms which the Company Board determines in its good faith judgment, after consultation with outside financial advisors and outside legal counsel, would reasonably be expected to be consummated in accordance with its terms, taking into account all legal, financial and regulatory aspects of the proposal and the Person or group of Persons making the proposal, and, if consummated, would result in a transaction more favorable to the Company&#8217;s stockholders from a financial point of view than the Merger (after taking into account any revisions to the terms of the Contemplated Transactions pursuant to <u>Section&#160;5.2(f)</u> of this Agreement and the time likely to be required to consummate such Company Acquisition Proposal); <u>provided</u> that for purposes of the definition of &#8220;Company Superior Proposal&#8221;, the references to &#8220;25%&#8221; in the definition of Company Acquisition Proposal shall be deemed to be references to &#8220;50%&#8221;. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;<font style="font-weight: bold;">Company Termination Fee</font>&#8221; means $16,100,000. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;<font style="font-weight: bold;">Company Warrant</font>&#8221; means any warrant to purchase Company Shares. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;<font style="font-weight: bold;">Confidentiality Agreement</font>&#8221; means the confidentiality agreement entered into between the Company and Parent dated March&#160;26, 2026. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;<font style="font-weight: bold;">Consent</font>&#8221; means consent, approval, ratification, permission, authorization, clearance, waiver, permit or order. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Contemplated Transactions</font>&#8221; means the Merger, the Parent Share Issuance, the Parent Charter Amendment, the Parent Reverse Stock Split and the other transactions and actions contemplated by this Agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Contract</font>&#8221; means any written, oral or other agreement, contract, subcontract, lease, instrument, note, option, warranty, purchase order, license, sublicense, insurance policy, benefit plan or legally binding commitment, understanding, arrangement or undertaking of any nature. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Data Protection Regulation</font>&#8221; means all Laws, Contracts, Company privacy policies or notices, and all binding regulatory guidance and standards issued by Governmental Entities or self-regulatory frameworks, concerning the privacy, protection, processing, cross-border transfer, and/or security of Personal Data, including HIPAA, the GDPR, state and foreign privacy Laws, Executive Order 14117 and rules and regulations issued thereunder (including 28 C.F.R. Part&#160;202), and, with respect to data obtained in connection with clinical trials or other clinical research, applicable requirements of 21 C.F.R. Parts 11, 50 and 56, ICH Guidelines for Good Clinical Practice and any comparable foreign Laws. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;<font style="font-weight: bold;">Effect</font>&#8221; means any effect, change, event or development. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Environmental Laws</font>&#8221; means any Law concerning environmental matters, Hazardous Materials, pollution or protection of the environment or natural resources, or protection of human health and safety as related to exposure to Hazardous Materials. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;<font style="font-weight: bold;">ERISA</font>&#8221; means the Employee Retirement Income Security Act of 1974, as amended. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;<font style="font-weight: bold;">Exchange Act</font>&#8221; means the Securities Exchange Act of 1934, as amended. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">Exhibit A-3<br></div></div></div>
<!--End Page 451-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 452-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg72"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Exchange Ratio</font>&#8221; means a ratio (rounded to four decimal places), subject to <u>Section&#160;2.1(c)</u>, equal to (x) the Company Value Per Share divided by (y) the Parent Value Per Share, in which: </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 40pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Company Outstanding Shares</font>&#8221; means the sum, without duplication, of the aggregate number of shares of Company Capital Stock that are issued and outstanding immediately prior to the Effective Time (on an as-converted to Company Common Stock basis) or issuable upon the exercise of any In-the-Money Company Options, Company Warrants or other &#8220;in-the-money&#8221; direct or indirect rights to acquire shares of Company Capital Stock, in each case that are issued and outstanding immediately prior to the Effective Time (whether or not then vested or exercisable). </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 40pt; text-align: left;">&#8220;<font style="font-weight: bold;">Company Valuation</font>&#8221; means (A) $2,500,000,000, plus (B) the Aggregate Company Exercise Price. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 40pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Company Value Per Share</font>&#8221; means the quotient of (A) the Company Valuation, divided by (B) the number of Company Outstanding&#160;Shares. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 40pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Parent Outstanding Shares</font>&#8221; means the sum, without duplication, of the aggregate number of shares of Parent Common Stock that are issued and outstanding immediately prior to the Effective Time<font style="font-weight: bold;"> </font>or issuable upon the settlement of any Parent RSUs or the exercise of any In-the-Money Parent Options, In-the-Money Parent Warrants or other &#8220;in-the-money&#8221; direct or indirect rights to acquire shares of Parent Common Stock (other than the 2014 Indenture, as defined in the Parent Disclosure Schedule), in each case that are issued and outstanding immediately prior to the Effective Time (whether or not then vested or exercisable). </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 40pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Parent Valuation</font>&#8221; means (A) $460,000,000, plus (B) the Parent Net Cash Surplus, if any, minus (C) the Parent Net Cash Shortfall, if any, plus (D) the Aggregate Parent Exercise Price. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 40pt; text-align: left;">&#8220;<font style="font-weight: bold;">Parent Value Per Share</font>&#8221; means the quotient of (A) the Parent Valuation, divided by (B) the number of Parent Outstanding Shares. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Ex-Im Laws</font>&#8221; means all applicable Laws relating to export, re-export, transfer, and import controls, including the U.S. Export Administration Regulations, the customs and import Laws administered by U.S. Customs and Border Protection, and the EU Dual Use Regulation. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;<font style="font-weight: bold;">FCPA</font>&#8221; means the Foreign Corrupt Practices Act of 1977, as amended. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;<font style="font-weight: bold;">FDA</font>&#8221; means the U.S. Food and Drug Administration and any successor agency thereto. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;<font style="font-weight: bold;">FDCA</font>&#8221; means the Federal Food, Drug, and Cosmetic Act (21 U.S.C. &#167;&#167; 301 et seq.), as amended. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Fraud</font>&#8221; means, with respect to a Party, an actual and intentional misrepresentation, deceit or concealment of fact made by such Party with respect to the making of the representations and warranties of such Party as expressly set forth in <u>Article&#160;III</u> or <u>Article&#160;IV</u>, as applicable, of this Agreement, with the intent to induce the other Party to rely on such misrepresentation, deceit or concealment of fact and act or fail to act to such other Party&#8217;s detriment, on which such other Party justifiably relies and subsequently justifiably acts or fails to act in a manner that results in actual material losses to such other Party. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;<font style="font-weight: bold;">GAAP</font>&#8221; means United States generally accepted accounting principles. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">GDPR</font>&#8221; means the EU General Data Protection Regulation 2016/679 including the UK implementation of this Regulation under section 3 of the UK European Union (Withdrawal) Act 2018. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Governmental Authorization</font>&#8221; means any: (i) permit, license, certificate, franchise, permission, variance, exception, exemption, approval, order, clearance, registration, qualification, accreditation, authorization, consents or listings issued, granted, given or otherwise made available by or under the authority of any Governmental Entity or pursuant to any Law; or (ii) right under any Contract with any Governmental Entity. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Governmental Entity</font>&#8221; means any (i) nation, state, commonwealth, province, territory, county, municipality, district or other jurisdiction of any nature; (ii) federal, state, local, municipal, foreign or other government; (iii) governmental or quasi-governmental authority of any nature (including any governmental division, department, agency, commission, bureau, instrumentality, official, ministry, fund, foundation, center, organization, unit, body or entity and any court or other tribunal, and for the avoidance of doubt, any taxing authority); or (iv) self-regulatory organization (including FINRA, Nasdaq and Payment Card Industry Security Standards Council) and independent third-party accrediting body and entities responsible for certifying an entity&#8217;s adherence to various International Organization for Standardization or Good Manufacturing Practice standards. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Hazardous Materials</font>&#8221; means any substance, material or waste that is listed, defined or otherwise characterized as &#8220;hazardous&#8221;, &#8220;toxic&#8221;, &#8220;radioactive,&#8221; a &#8220;biohazard&#8221; or a &#8220;pollutant&#8221;, or &#8220;contaminant&#8221; or terms of similar meaning or effect under any Environmental Law, including petroleum or its by-products, asbestos, polychlorinated biphenyls, perchlorate and per-and polyfluoroalkyl substances. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Health Care Laws</font>&#8221; means Laws, rules, policies, guidelines and regulations applicable to the business, products, and/or services of the Company or Parent, as applicable, including, but not limited to, Title XVIII of the Social Security Act, 42 U.S.C. &#167;&#167; 1395 et seq. (the Medicare statute); Title XIX of the Social Security Act, 42 U.S.C. &#167;&#167; 1396 et seq (the Medicaid statute); the Anti-Kickback Statute, 42 U.S.C. &#167; 1320a-7b(b); the civil False Claims Act, 31 U.S.C. &#167;&#167; 3729 et seq.; the criminal False Claims Act 42 U.S.C. &#167; 1320a-7b(a); the criminal laws relating to health care fraud and abuse, including 18 U.S.C. &#167;&#167; 286 and 287 and the health care fraud criminal provisions under HIPAA (as defined herein); the Civil Monetary Penalties Law, 42 U.S.C. &#167; 1320a-7a; the Physician Payments Sunshine Act, 42 U.S.C. &#167; 1320a-7h; the exclusion law, 42 U.S.C. &#167; 1320a-7; the Health Information Portability and Accountability Act, as amended by the Health Information Technology for Economic and Clinical Health Act, 42 U.S.C. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">Exhibit A-4<br></div></div></div>
<!--End Page 452-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 453-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg73"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#167;&#167; 17921 et seq., including all implementing regulations (collectively, &#8220;<font style="font-weight: bold;">HIPAA</font>&#8221;); the CLIA; the FDCA; the Public Health Service Act, 42 U.S.C. &#167;&#167; 201 et seq.; the regulations promulgated pursuant to such laws; ICH Guidelines for Good Clinical Practice; 21 C.F.R. Parts 11, 50, 54, 56, 312, 314, 812, 814 and 820; and any similar federal, state, local and foreign laws and regulations of any Governmental Entity, including the regulatory agencies applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution, marketing, storage, import, export or disposal of any of the products or services of the Company or Parent, as applicable. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;<font style="font-weight: bold;">HSR Act</font>&#8221; means the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;<font style="font-weight: bold;">Illumina Agreement</font>&#8221; means that certain Stock Purchase Agreement, dated June&#160;22, 2025, by and between Parent and Illumina, Inc. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Illumina TSA</font>&#8221; means that certain Transition Services Agreement, dated January&#160;30, 2026, by and among Parent, SomaLogic, Inc. and Illumina, Inc. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Indebtedness</font>&#8221; means, with respect to any Person, without duplication, (i) all obligations of such Person for borrowed money, or with respect to deposits or advances of any kind to such Person, including related prepayment fees, final fees or other similar fees, (ii) all obligations of such Person evidenced by bonds, debentures, notes or similar instruments, (iii) all capitalized lease obligations of such Person, (iv) all obligations of such Person pursuant to securitization or factoring programs or arrangements, (v) all guarantees and arrangements having the economic effect of a guarantee of such Person of any debt of any other Person (other than any guarantee by a Party with respect to debt of such Party or any wholly owned Subsidiary of such Party), (vi) net cash payment obligations of such Person under swaps, options, derivatives and other hedging agreements or arrangements that will be payable upon termination thereof (assuming they were terminated on the date of determination), (vii) letters of credit, bank guarantees, and other similar contractual obligations entered into by or on behalf of such Person, in each case, to the extent drawn upon or called, (viii) obligations in respect of banker&#8217;s acceptances, to the extent drawn upon or called, (ix) all unpaid or remaining lease costs for any operating leases of such Person (net of any payments to be made following the Closing by a sublessee to Parent in respect of such operating leases pursuant to a sublease in effect as of the Effective Time), and (x) obligations representing the balance deferred and unpaid of the purchase price of any property or services due more than one year after such property is acquired or such services are completed. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Intellectual Property Rights</font>&#8221; means all rights, title and interest in intellectual property, whether protected, created or arising under the Law of the United States or any other jurisdiction, including: (i) all patents, patent applications, provisional patent applications and similar instruments (including any and all substitutions, divisions, continuations, continuations-in-part, divisions, reissues, renewals, and extensions and any foreign equivalents of the foregoing (including certificates of invention and any applications therefor)) (collectively, &#8220;<font style="font-weight: bold;">Patents</font>&#8221;), (ii) all domestic and foreign copyrights, copyright registrations, copyright applications, original works of authorship fixed in any tangible medium of expression to the extent protectable by applicable copyright Law, including literary works, all forms and types of computer software, pictorial and graphic works that are so protectable (collectively, &#8220;<font style="font-weight: bold;">Copyrights</font>&#8221;), (iii) all trademarks, service marks, trade names, business marks, service names, brand names, trade dress rights, logos, corporate names, trade styles, and other source or business identifiers and other general intangibles of a like nature to the extent protectable by applicable trademark law, together with the goodwill associated with any of the foregoing, along with all applications, registrations, renewals and extensions thereof (collectively, &#8220;<font style="font-weight: bold;">Trademarks</font>&#8221;), (iv) all Internet domain names, (v) all trade secrets, technology, discoveries, improvements, know-how, proprietary rights, formulae, techniques, inventions (including conceptions and/or reductions to practice), designs, drawings, procedures, processes, models, formulations, manuals and systems, whether or not patentable or copyrightable, including all biological, chemical, biochemical, toxicological, pharmacological and metabolic material, in each case, which are not available in the public domain and have actual or potential commercial value that is derived, in whole or in part, from such non-availability (collectively, &#8220;<font style="font-weight: bold;">Trade Secrets</font>&#8221;) and (vi) all other intellectual property rights throughout the world, along with all rights to prosecute and perfect the same through administrative prosecution, registration, recordation or other administrative proceeding, and all causes of action and rights to sue or seek other remedies arising from or relating to the foregoing. For clarity, Intellectual Property Rights shall not include rights, title and interest in registrations of intellectual property rights or applications for such registrations to the extent such registrations or applications have been denoted by a Governmental Entity as expired, lapsed or abandoned. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">In-the-Money Company Option</font>&#8221; means a Company Option with a per-share exercise price of less than the implied per-share value of the Company Common Stock immediately prior to the Effective Time, determined in good faith by the Parties in connection with the calculation of the Exchange Ratio. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;<font style="font-weight: bold;">In-the-Money Parent Option</font>&#8221; means a Parent Option with a per-share exercise price that is less than the Parent Value Per Share. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;<font style="font-weight: bold;">In-the-Money Parent Warrant</font>&#8221; means a Parent Warrant with a per-share exercise price that is less than the Parent Value Per Share. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;<font style="font-weight: bold;">Judgment</font>&#8221; means any judgment, order, injunction, ruling, writ award or decree of any Governmental Entity. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Knowledge</font>&#8221; of any Person means, in the case of Parent, the actual knowledge of any of the Persons set forth on <u>Schedule 1</u> of the Parent Disclosure Schedule after reasonable inquiry of the individuals who as of the date hereof are officers or employees of Parent or any of its Subsidiaries and who have primary responsibility for the matter in question and, in the case of the Company, the actual knowledge of any of the Persons set forth on <u>Schedule 1</u> of the Company Disclosure Schedule after reasonable inquiry of the individuals who as of the date hereof are officers or employees of the Company or any of its Subsidiaries and who have primary responsibility for the matter in question. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Law</font>&#8221; means any federal, state, local, county, regional, foreign or transnational law, statute, regulation, code, ordinance, common law, ruling, writ, award, zoning law, building code or decree of any Governmental Entity. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">Exhibit A-5<br></div></div></div>
<!--End Page 453-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 454-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg74"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Legal Proceeding</font>&#8221; means any action, suit, litigation, arbitration, proceeding (including any civil, criminal, administrative, investigative or appellate proceeding), hearing, inquiry, audit, examination or investigation commenced, brought, conducted or heard by or before any court or other Governmental Entity or any arbitrator or arbitration panel, except for (i) examinations or administrative actions, hearings or proceedings by or before a Governmental Entity (e.g., appeals initiated by the applicant or patentee before the U.S. Patent Trial and Appeal Board) in the ordinary course of prosecution of Intellectual Property Rights, in connection with obtaining approval for conduct of clinical trials or in connection with obtaining approval for marketing or sale of products or services or (ii) audits by any Governmental Entity and that are not-for-cause and pursuant to which no materially adverse findings were issued (e.g., routine facility audits by U.S. Food and Drug Administration under which no warning letters or other material adverse findings were issued). </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;<font style="font-weight: bold;">Liens</font>&#8221; means pledges, liens, charges, mortgages, deeds of trust, encumbrances and security interests of any kind or nature whatsoever. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;<font style="font-weight: bold;">Nasdaq</font>&#8221; means the Nasdaq Stock Market LLC. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Ordinary Course of Business</font>&#8221; means, in the case of each of the Company and Parent, such actions taken in the ordinary course of its and its Subsidiaries&#8217; normal operations and consistent in all material respects with its and its Subsidiaries&#8217; past practices (in the case of Parent, (i) after giving effect to the transactions contemplated by the Illumina Agreement and (ii) except for any actions taken to dispose of or wind down the Parent Legacy Business). </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Organizational Documents</font>&#8221; means, with respect to any Person (other than an individual), (i) the certificate or articles of association or incorporation or organization or limited partnership or limited liability company, and any joint venture, limited liability company, operating or partnership agreement and other similar documents adopted or filed in connection with the creation, formation or organization of such Person and (ii)&#160;all bylaws and similar documents or agreements relating to the organization or governance of such Person, in each case, as amended or supplemented. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Parent Affiliate</font>&#8221; means any Person under common control with Parent or any of its Subsidiaries within the meaning of Section&#160;414(b), Section&#160;414(c), Section&#160;414(m) or Section&#160;414(o) of the Code, and the regulations issued thereunder. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Parent Associate</font>&#8221; means any current or former officer, employee, independent contractor, consultant or director, of or to Parent or any of its Subsidiaries or any controlled Parent Affiliate. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Parent</font> <font style="font-weight: bold;">Benefit Plan</font>&#8221; means each (i) &#8220;employee benefit plan&#8221; (as defined in Section&#160;3(3) of ERISA whether or not subject to ERISA) and (ii)&#160;other pension, retirement, supplemental retirement, deferred compensation, excess benefit, profit sharing, bonus, stock option, stock purchase, stock ownership, restricted stock, incentive, equity or equity-based, phantom equity, profits interest, employment, consulting, severance, change-of-control, retention, health, medical, life, disability, group insurance, paid-time off, holiday, welfare and fringe benefit plan, program, agreement, contract, or arrangement (whether written or unwritten, qualified or nonqualified, funded or unfunded and including any that have been frozen or terminated), in any case, sponsored, maintained, contributed to, or required to be contributed to, by Parent or any of its Subsidiaries for the benefit of any Parent Associate or under which Parent or any of its Subsidiaries has any actual or contingent liability (including as to the result of it being treated as a single employer under Section&#160;414 of the Code with any other Person). </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Parent Contract</font>&#8221; means any Contract: (i) to which Parent or any of its Subsidiaries is a party; (ii) by which Parent or any of its Subsidiaries or any Parent IP or any other asset of Parent or its Subsidiaries is or may become bound or under which Parent or any of its Subsidiaries has, or may become subject to, any obligation; or (iii) under which Parent or any of its Subsidiaries has or may acquire any right or interest. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;<font style="font-weight: bold;">Parent Equity Award</font>&#8221; means Parent Options and Parent RSUs. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Parent</font> <font style="font-weight: bold;">ERISA Affiliate</font>&#8221; means any corporation or trade or business (whether or not incorporated) which is (or at any relevant time was) treated with Parent or any of its Subsidiaries as a single employer within the meaning of Section&#160;414 of the Code. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;<font style="font-weight: bold;">Parent ESPP Option</font>&#8221; means an option to purchase capital stock of Parent pursuant to the Parent ESPP. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;<font style="font-weight: bold;">Parent IP</font>&#8221; means Parent Owned IP and Parent Licensed IP. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;<font style="font-weight: bold;">Parent Legacy Business</font>&#8221; means the mass cytometry business and the microfluidics business, in each case, of Parent and its Subsidiaries. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Parent Legacy Business NWC</font>&#8221; means the sum of (i) Parent&#8217;s accounts receivable minus its accounts payable and accrued expenses, in each case related to the Parent Legacy Business (which may be a negative number) and (ii) 20% of the book value of any inventory of the Parent Legacy Business, in each case as of the Closing and determined in accordance with GAAP. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Parent Licensed IP</font>&#8221; means all Intellectual Property Rights that are exclusively licensed (or sublicensed), or purported to be exclusively licensed (or sublicensed), by any third party to Parent or any of its Subsidiaries. For clarity, Parent Licensed IP shall not include Intellectual Property Rights that have been denoted by a Governmental Entity as expired, lapsed or abandoned. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Parent Material Adverse Effect</font>&#8221; means any Effect that, individually or in the aggregate with all other Effects, (1) materially adversely affects or would reasonably be expected to materially adversely affect the business, financial condition or results of operations of Parent and its Subsidiaries, taken as a whole, or (2) would reasonably be expected to prevent the consummation of the Contemplated Transactions by Parent, in each case, excluding any Effect to the extent that, either alone or in combination, it results from or arises out of (i) general business or economic conditions generally affecting the industry in which Parent and its Subsidiaries operate, (ii) political conditions, acts of war, the outbreak or escalation of armed hostilities, acts of terrorism, earthquakes, wildfires, hurricanes, tsunamis, floods, mudslides, weather conditions, other natural disasters, man-made </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">Exhibit A-6<br></div></div></div>
<!--End Page 454-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 455-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg75"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">disasters, health and other emergencies, calamities, epidemics, pandemics (including COVID-19 and any evolutions or mutations thereof), disease outbreaks, other acts of God or force majeure events, (iii) changes in financial, banking or securities markets, including changes in interest rates in the United States or any other country or region in the world and changes in exchange rates for the currencies of any countries and any suspension of trading in securities (whether equity, debt, derivative or hybrid securities) generally on any securities exchange or over-the-counter market operating in the United States or any other country or region in the world, (iv) any change in, or any compliance with or action taken for the purpose of complying with, any Law or GAAP (or interpretations of any Law or GAAP), (v) any change in the stock price or trading volume of Parent Common Stock (it being understood, however, that any Effect causing or contributing to any change in stock price or trading volume of Parent Common Stock may be taken into account in determining whether a Parent Material Adverse Effect has occurred, unless such Effects are otherwise excepted from this definition), (vi) the failure of Parent to meet internal or analysts&#8217; expectations or projections or the results of operations of Parent (it being understood, however, that any Effect causing or contributing to the failure of Parent to meet internal or analysts&#8217; expectations or projections or the results of operations of Parent may be taken into account in determining whether a Parent Material Adverse Effect has occurred, unless such Effects are otherwise excepted from this definition), (vii) the execution or announcement of this Agreement or the pendency of the Contemplated Transactions, including (A) the identity of the Company, (B) the loss or departure of officers or other employees of Parent or any of its Subsidiaries directly or indirectly resulting from, arising out of, attributable to, or related to the Contemplated Transactions and (C) any other negative development (or potential negative development) in the relationships of Parent or any of its Subsidiaries with business partners, whether as a direct or indirect result of the loss or departure of officers or employees of Parent or any of its Subsidiaries or otherwise, directly or indirectly resulting from, arising out of, attributable to, or related to the Contemplated Transactions, (viii) any actions taken or failure to take action, in each case, to which the Company has provided its prior written consent; or compliance with the terms of, or the taking of any action required or contemplated by, this Agreement; or the failure to take any action prohibited by this Agreement (excluding the requirement that Parent comply with the terms of <u>Section&#160;5.1(b)</u>), except to the extent the Company has unreasonably withheld its consent under <u>Section&#160;5.1(b)</u>, (ix) any fees or expenses incurred in connection with the Contemplated Transactions, or (x) any Legal Proceedings made or brought by any of the current or former stockholders of Parent (on their own behalf or on behalf of Parent) against Parent, Merger Sub, the Company or any of their directors or officers, including Legal Proceedings arising out of the Merger or in connection with any other Contemplated Transactions; except, in each case, with respect to clauses (i) through (iv), to the extent disproportionately affecting Parent and its Subsidiaries, taken as a whole, relative to other similarly situated companies in the industries in which Parent and its Subsidiaries operate. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Parent Net Cash</font>&#8221; means, as of 12:01 a.m. Eastern Time on the Closing Date and without duplication, (i) the sum of (A) the cash, cash equivalents and marketable securities of Parent and its Subsidiaries other than Restricted Cash, (B) any prepaid expenses or deposits paid or made by Parent or its Subsidiaries and (C) Parent Legacy Business NWC, <u>minus</u> (ii) the sum of, in each case to the extent unpaid as of 12:01 a.m. Eastern Time on the Closing Date, (A) any Transaction Expenses of Parent or its Subsidiaries, (B) any outstanding Indebtedness of Parent and its Subsidiaries, (C)&#160;any Parent Termination Costs (as defined in Section&#160;5.23(d) of the Parent Disclosure Schedule), (D) all premiums, underwriting costs, brokerage commissions, costs, expenses and other amounts in respect of the D&amp;O Tail Policy, (E) any out-of-pocket expenses incurred by Parent prior to the Closing (whether or not payable prior to the Closing) associated with the disposition of the Parent Legacy Business, (F) solely in the event the Wind-Down Activities with respect to any portion of the Parent Legacy Business have been commenced, or are required to be commenced, pursuant to <u>Section&#160;5.23</u>, any Wind-Down Costs as set forth in the Wind-Down Schedule with respect to such portion of the Parent Legacy Business, (G) actual costs incurred in connection with the matters set forth in <u>Section&#160;4.10</u> of the Parent Disclosure Schedule, (H) solely to the extent not provided for in the Wind-Down Schedule, any Specified Cash-Walk Items (it being understood that if Specified Cash-Walk Items are provided for in the Wind-Down Schedule, the treatment thereof in the Wind-Down Schedule shall govern to the extent conflicting with this paragraph) and (I) any unpaid Taxes incurred or to be incurred, in a Taxable period (or portion thereof) ending on or prior to the Closing Date or otherwise in connection with the Closing, by Parent and its Affiliates, including in connection with the foregoing clauses (A) through (H). Each component of Parent Net Cash, to the extent applicable, shall be determined in accordance with the Accounting Principles or as set forth in the Wind-Down Schedule. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;<font style="font-weight: bold;">Parent Net Cash Shortfall</font>&#8221; means the amount by which the Parent Net Cash is less than $449,000,000. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;<font style="font-weight: bold;">Parent Net Cash Surplus</font>&#8221; means the amount by which the Parent Net Cash exceeds $451,000,000. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Parent Option</font>&#8221; means any option to purchase capital stock of Parent (whether granted under any Parent Equity Plans, assumed by Parent in connection with any merger, acquisition or similar transaction or otherwise issued or granted). </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Parent Owned IP</font>&#8221; means all Intellectual Property Rights that are owned, or purported to be owned, by Parent or any of its Subsidiaries. For clarity, Parent Owned IP shall not include Intellectual Property Rights that have been denoted by a Governmental Entity as expired, lapsed or abandoned. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Parent Partner</font>&#8221; means any Person (other than Parent or any of its Subsidiaries) that is engaged by or on behalf of the Parent or any of its Subsidiaries to perform any material activities relating to the research, development or manufacture of any Parent Product, including any contract research organization, contract manufacturing organization, contract development and manufacturing organization, clinical trial site operator or other material service provider performing activities subject to regulation under applicable Law on behalf of the Parent or any of its Subsidiaries; <u>provided</u> that, notwithstanding anything else in this Agreement, to the extent any representation relates to a Parent Partner, that aspect of the representation is limited to the matters that have a direct effect on the activities subject to a Contract between the Parent and the Parent Partner and is limited to Parent&#8217;s Knowledge. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Parent Product</font>&#8221; means all products and services currently marketed for sale or sold by Parent or any of its Subsidiaries, all products and services under development for sale by Parent or any of its Subsidiaries, and all modified, updated and/or next generation versions or derivatives of the foregoing. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">Exhibit A-7<br></div></div></div>
<!--End Page 455-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 456-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg76"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Parent RSU</font>&#8221; means a restricted stock unit that entitles the holder to receive shares of Parent capital stock upon vesting or lapse of restrictions (whether granted under any Parent Equity Plans, assumed by Parent in connection with any merger, acquisition or similar transaction or otherwise issued or granted). </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;<font style="font-weight: bold;">Parent Termination Fee</font>&#8221; means $16,100,000. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;<font style="font-weight: bold;">Parent Warrant</font>&#8221; means any warrant to purchase capital stock of Parent. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Permitted Liens</font>&#8221; means any (i) Lien (A) for Taxes or other governmental assessments, charges or claims of payment (1) not yet due and payable or (2) the amount or validity of which is being contested in good faith in appropriate proceedings and for which adequate reserves have been established in accordance with GAAP, (B) which is a carriers&#8217;, warehousemen&#8217;s, mechanics&#8217;, materialmen&#8217;s, repairmen&#8217;s, or other similar lien arising in the ordinary course of business with respect to liabilities that are not yet due and payable or that are being contested in good faith by appropriate proceedings, (C) with respect to zoning, planning, and other limitations and restrictions, including all rights of any Governmental Entity (but not violations thereof) that are not presently violated and do not materially and adversely affect, impair or interfere with the use of any property affected thereby, (D) that restricts the transfer or assignment of a Contract that is included in the terms of such Contract, (E) with respect to this Agreement and Liens created by the execution and delivery of this Agreement, (F) which is disclosed on the most recent consolidated balance sheet of the Company or Parent, as applicable, or notes thereto which has been previously provided to Parent or the Company, as applicable, or (G) for which adequate reserves have been established, (ii) imperfections of title and (iii) non-exclusive license of Intellectual Property Rights granted in the Ordinary Course of Business. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Person</font>&#8221; means any natural person, firm, corporation, partnership, company, limited liability company, trust, joint venture, association, Governmental Entity, university, college, research institute or other educational, academic or not-for-profit institution, or other entity. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Personal Data</font>&#8221; means any information maintained by or on behalf of the Company or Parent, or any of their respective Subsidiaries, that includes (i) personal, personally identifiable, sensitive or regulated information or data that relates to an identified or identifiable natural person, (ii)&#160;protected health information as defined by HIPAA, (iii) any personal data of clinical trial subjects or participants in any clinical research study conducted by or on behalf of the Company or Parent, or any of their respective Subsidiaries, as applicable, including any data collected pursuant to an informed consent, or (iv) such other data defined as &#8220;personal data,&#8221; &#8220;personally identifiable information,&#8221; &#8220;consumer health data,&#8221; or other similar term in any applicable Data Protection Regulations. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Post-Closing Equity Incentive Plan</font>&#8221; means an equity incentive plan of Parent in form and substance as designated by the Company, reserving for issuance a number of shares of Parent Common Stock to be designated by the Company and containing an annual &#8220;evergreen&#8221; not to exceed five percent of outstanding shares of Parent Common Stock. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Post-Closing ESPP</font>&#8221; means an &#8220;employee stock purchase plan&#8221; of Parent in form and substance as designated by Company, reserving for issuance a number of shares of Parent Common Stock to be designated by the Company. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;<font style="font-weight: bold;">Reference Date</font>&#8221; means June&#160;3, 2026. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Restricted Cash</font>&#8221; means, without duplication, (i) cash of Parent that has been historically classified as restricted cash by Parent or that is otherwise required to be classified as restricted cash in accordance with the Accounting Principles, (ii) cash held outside of the United States that is subject to restrictions or penalties, or otherwise cannot be readily repatriated to the United States (by dividend or similar distribution if held by a Subsidiary), (iii) cash that is represented by real estate lease deposits, (iv) cash that is held in reserve accounts or third-party escrow accounts, and (v)&#160;cash collateralizing any obligation, but excluding restricted cash securing corporate credit card obligations; <u>provided</u> that if any cash would be treated as Restricted Cash pursuant to the foregoing clauses (i) through (v) on account of any of lease, escrow, obligation or other liability reflected as a deduct in the calculation of Parent Net Cash, then such cash shall not be deemed to be Restricted Cash. For purposes of determining the amount of cash to be considered Restricted Cash solely as a result of Taxes on repatriation, only the amount of any net Taxes payable to repatriate such cash to the United States shall be considered Restricted Cash. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Sanctions Laws</font>&#8221; means all applicable Laws pertaining to financial, trade and economic sanctions administered by the United States, United Nations, European Union or any member state thereof, or United Kingdom. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Sanctioned Country</font>&#8221; means any country, region or territory that is the subject of comprehensive Sanctions Laws, which currently comprise Cuba, Iran, North Korea, the Crimea region of Ukraine, the so-called Donetsk People&#8217;s Republic, the so-called Luhansk People&#8217;s Republic, as well as, for the purposes of this Agreement, Syria. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Sanctioned Person</font>&#8221; means any Person with whom dealings are restricted or prohibited under any Sanctions Laws, including the Sanctions Laws of the United States, the United Kingdom, the European Union or the United Nations, including any Person that is (i) organized under the laws of, ordinarily resident in, or located in a Sanctioned Country; (ii) 50% or more owned or controlled by the government of a Sanctioned Country; or (iii) (A) designated on a sanctioned parties list administered by the United States, European Union, United Nations or United Kingdom, including, without limitation, the U.S. Department of the Treasury&#8217;s Office of Foreign Assets Control&#8217;s Specially Designated Nationals and Blocked Persons List, Foreign Sanctions Evaders List, and Sectoral Sanctions Identification List, the Consolidated List of Persons, Groups, and Entities Subject to EU Financial Sanctions, and the UK&#8217;s Consolidated Sanctions List (collectively, &#8220;<font style="font-weight: bold;">Designated Parties</font>&#8221;); or (B) 50% or more owned or, where relevant under applicable Sanctions Laws, controlled, individually or in the aggregate, by one or more Designated Party, in each case only to the extent that dealings with such persons are prohibited pursuant to applicable Sanctions Laws. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">Exhibit A-8<br></div></div></div>
<!--End Page 456-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 457-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_300-annexa_pg77"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;<font style="font-weight: bold;">SEC</font>&#8221; means the Securities and Exchange Commission. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;<font style="font-weight: bold;">Securities Act</font>&#8221; means the Securities Act of 1933, as amended. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Security Incident</font>&#8221; means any unauthorized access, use, processing, transfer or disclosure, accidental or unlawful destruction, or any loss, theft or alteration, of data. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">SomaLogic Equity Plans</font>&#8221; means the SomaLogic 2009 Equity Incentive Plan, the SomaLogic 2017 Equity Incentive Plan, and the SomaLogic 2021 Omnibus Incentive Plan. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Standard IP Contracts</font>&#8221; of a Party means (a) shrink-wrap, click-wrap and off-the-shelf Contracts for commercially available software (including provision of software as a service) or services that are generally available on nondiscriminatory pricing terms; (b) non-disclosure agreements, employment agreements, clinical trial agreements, sponsored research agreements, consulting services agreements, material transfer agreements and other agreements entered into in the Ordinary Course of Business, in each case, that do not transfer ownership of material Intellectual Property Rights owned by the Party, or grant rights to use material Intellectual Property Rights owned by the Party for the supply, manufacturing, development or commercialization of products (other than on behalf of, or for the benefit of, the Party or its Subsidiaries); (c) Contracts granting to or granted by the Party or its Subsidiaries a license, ownership or other rights in and to incidental rights (e.g., rights in trademarks or feedback but, for the avoidance, of doubt, excluding rights to any Intellectual Property Rights that are material to the Party and its Subsidiaries, taken as a whole); (d)&#160;Contracts granting service providers a non-exclusive, royalty-free license to incidental rights in the Ordinary Course of Business for the provision of such service provider&#8217;s services to the Party or its Subsidiaries; and (e) employee invention assignment and consulting agreements that contain assignments of Intellectual Property Rights to the Party or its Subsidiaries. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Subsidiary</font>&#8221; means, with respect to any Person, another Person (i) of which such first Person owns or controls, directly or indirectly, securities or other ownership interests representing (A) more than 50% of the voting power of all outstanding stock or ownership interests of such second Person or (B) the right to receive more than 50% of the net assets available for distribution to the holders of outstanding stock or ownership interests upon a liquidation or dissolution, or (ii) of which such first Person is a general partner. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Tax Return</font>&#8221; means all Tax returns, declarations, statements, reports, claims for refund, schedules, forms and information returns, any amended Tax return and any other document filed or required to be filed with a Governmental Entity in connection with the administration or collection of any Taxes. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Taxes</font>&#8221; means any federal, state, local, foreign or other tax, including any income, capital gain, profits, franchise, gross receipts, environmental, customs duty, capital stock, severance, stamp, payroll, sales, employment, Medicare, unemployment, disability, use, property, withholding, excise, production, value added, occupancy and any other taxes, duties or assessments in the nature of a tax imposed by any Governmental Entity, together with all interest, penalties and additions imposed with respect to such amounts and any interest in respect of such penalties and additions. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Training Data</font>&#8221; means any data or databases, including any scraped data, processed or otherwise used to train, validate, test or otherwise improve an AI. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Transaction Expenses</font>&#8221; means with respect to each Party, all out-of-pocket fees and expenses incurred by such party at or prior to the Effective Time in connection with this Agreement and the Contemplated Transactions, including (i) any fees and expenses of legal counsel and accountants, financial advisors, investment bankers, brokers, consultants, and other advisors of such party; (ii) 50% of fees paid to the SEC in connection with filing the Registration Statement, the Proxy Statement/Prospectus, and any amendments and supplements thereto, with the SEC; (iii) 50% of fees and expenses in connection with the printing, mailing and distribution of the Registration Statement, including any amendments and supplements thereto, and (iv) with respect to Parent, any unpaid third party costs or expenses related to the Wind-Down Activities or any Parent Legacy Transaction incurred by Parent at or prior to the Effective Time, any unpaid employer portion of payroll or employment Taxes incurred in connection with the grant, exercise, conversion, settlement or cancellation of any equity compensation or other change in control or severance payments (including any bonuses payable) incurred in connection with the Contemplated Transactions by Parent at or prior to the Effective Time. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">Exhibit A-9<br></div></div></div>
<!--End Page 457-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 458-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_301-annexb_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: right;"><a name="tANB"><!--Anchor--></a>Annex B</div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 13.5pt; margin-left: 0pt; text-align: left;"><img style="height: 67px; width: 224px;" src="logo_centerviewpartnersv2.jpg"><br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><table cellspacing="0" cellpadding="0" class="BRDSX_txtann" style="margin-top: 0pt; width: 528pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 360pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 156pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr><td style="width: 360pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 156pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Centerview Partners LLC<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">31 West 52nd Street <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">New York, NY 10019 <br></div></td></tr><tr><td style="width: 360pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 156pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 360pt; padding-top: 0.67pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 156pt; padding-top: 0.67pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">June&#160;6, 2026</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 3pt; width: 360pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 156pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: -2pt; margin-left: 0pt; text-align: left;">CONFIDENTIAL <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195;<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The Board of Directors <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Standard BioTools Inc. <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">50 Milk Street, 10<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> Floor <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Boston, MA 02109 </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">The Board of Directors: </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">You have requested our opinion as to the fairness, from a financial point of view, to Standard BioTools Inc., a Delaware corporation (the &#8220;Parent&#8221;), of the Exchange Ratio (as defined below) provided for pursuant to the Agreement and Plan of Merger and Reorganization dated June&#160;6, 2026 (the &#8220;Agreement&#8221;) by and among the Parent, Treeline Biosciences, Inc. (the &#8220;Company&#8221;) and Siri Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Parent (&#8220;Merger Sub&#8221;). The Agreement provides for, among other things, a business combination through the merger of Merger Sub with and into the Company, with the Company being the surviving corporation (the &#8220;Merger&#8221; and, collectively with the other transactions contemplated by the Agreement, the &#8220;Transaction&#8221;), as a result of which the Company will become a wholly owned subsidiary of the Parent and each share of common stock, par value $0.00001 per share, of the Company and each share of preferred stock, par value $0.00001 per share, of the Company (collectively, &#8220;Company Shares&#8221;) issued and outstanding immediately prior to the effective time of the Merger (other than Company Shares held in treasury and Dissenting Shares (as defined in the Agreement)) will be automatically converted into the right to receive a number of shares of common stock, par value $0.001 per share, of the Parent (&#8220;Parent Shares&#8221;), rounded down to the nearest whole share, equal to the Exchange Ratio (as defined in the Agreement), which Exchange Ratio pursuant to the Agreement is based on an assumed valuation of the Parent of $460,000,000 and an assumed valuation of the Company of $2,500,000,000, in each case subject to certain adjustments (as to which we express no opinion) as set&#160;forth in the Agreement. The Agreement also provides that prior to the closing, the Parent may declare a dividend to holders of Parent Shares of one contingent value right (each, a &#8220;CVR&#8221;) for each Parent Share, each CVR representing the right to receive certain contingent payments upon the occurrence of certain events set forth in, and subject to and in accordance with the terms and conditions of, a Contingent Value Rights Agreement (the &#8220;CVR Agreement&#8221;) to be entered into by the Parent and the rights agent party thereto. The terms and conditions of the Transaction are more fully set forth in the Agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">We have acted as financial advisor to the Board of Directors of the Parent in connection with the Transaction. We will receive a fee for our services in connection with the Transaction, a portion of which is payable upon the rendering of this opinion and a substantial portion of which is contingent upon the consummation of the Transaction. In addition, the Parent has agreed to reimburse certain of our expenses arising, and indemnify us against certain liabilities that may arise, out of our engagement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">We are a securities firm engaged directly and through affiliates and related persons in a number of investment banking, financial advisory and merchant banking activities. In the past two years, we have been engaged to provide financial advisory services to the Parent, including in connection with the Parent&#8217;s sale of its SomaLogic business to Illumina, Inc. in 2025, and we have received compensation from the Parent for such services. In the past two years, we have been or are currently engaged to provide financial advisory services unrelated to the Parent to two companies in which affiliates of Casdin Capital, LLC (&#8220;Casdin Capital&#8221;), a significant minority stockholder of the Parent, hold a significant minority equity interest, and we have received compensation from one such company, and may receive compensation from the other such company in the future. In the past two years, we have been engaged to provide financial advisory services unrelated to the Parent to two companies in which affiliates of Viking Global Investors LP (&#8220;Viking Global&#8221;), a significant minority stockholder of the Parent, held a significant minority equity interest, and we have received compensation from such companies in connection with such engagements. In the past two years, we have not been engaged to provide financial advisory or other services to the Company, and we have not received any compensation from the Company during such period. We may provide financial advisory and other services to or with respect to the Parent, Company, Casdin Capital, Viking Global, or their respective affiliates, including portfolio companies of Casdin Capital and Viking Global in the future, for which we may receive compensation. Certain (i) of our and our affiliates&#8217; directors, officers, members and employees, or family members of such persons, (ii) of our affiliates or related investment funds and (iii) investment funds or other persons in which any of the foregoing may have financial interests or with which they may co-invest, may at any time acquire, hold, sell or trade, in debt, equity and other securities or financial instruments (including derivatives, bank loans or other obligations) of, or investments in, the Parent, the Company, Casdin Capital, or Viking Global, or any of their respective affiliates, including portfolio companies of Casdin Capital and Viking Global, or any other party that may be involved in the Transaction.</div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 14pt; text-align: center;"><img style="height: 39px; width: 485px;" src="logo_centerviewfooter.jpg"><br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201; <br></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">B-1<br></div></div></div>
<!--End Page 458-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 459-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_301-annexb_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Board of Directors <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Standard BioTools Inc. <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">June 6, 2026 <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Page 2</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">In connection with this opinion, we have reviewed, among other things: (i) the Agreement and a Form&#160;of CVR Agreement; (ii) the Annual Report on Form&#160;10-K of the Parent for the fiscal year ended December&#160;31, 2025; (iii) certain Quarterly Reports on Form&#160;10-Q of the Parent; (iv) audited consolidated balance sheets for the Company for the fiscal years ended December&#160;31, 2024 and December&#160;31, 2025 and related audited consolidated statements of income and cash flows for the fiscal years ended December&#160;31, 2023, 2024 and 2025, furnished to us by the Company; (v) unaudited consolidated balance sheets and related consolidated statements of income and cash flows for the Company for the fiscal quarters ended March&#160;31, 2025 and the fiscal years ended March&#160;31, 2026 furnished to us by the Company; (vi) certain internal information relating to the capitalization, business, operations, earnings, cash flow, assets, liabilities and prospects of the Company provided by management of Company and furnished to us by the Parent for purposes of our analysis (the &#8220;Company Internal Data&#8221;); (vii) certain financial forecasts, analyses and projections relating to the Company prepared by management of the Company as adjusted by management of the Parent and furnished to us by the Parent for purposes of our analysis (as so adjusted, the &#8220;Company Forecasts&#8221;); (viii) certain internal information relating to the business, operations, earnings, cash flow, assets, liabilities and prospects of the Parent provided by management of the Parent, including (a) certain financial forecasts, analyses and projections relating to the Parent prepared by management of the Parent and furnished to us by the Parent for purposes of our analysis (the &#8220;Parent Forecasts&#8221;) and (b)&#160;a liquidation analysis of the Parent prepared by the management of the Parent and furnished to us by the Parent for purposes of our analysis (the &#8220;Parent Liquidation Analysis&#8221;) (collectively, the &#8220;Parent Internal Data&#8221;) and (ix) certain cost savings projected by the management of the Parent to result from the Transaction furnished to us by the Parent for purposes of our analysis (the &#8220;Synergies&#8221;). We have participated in discussions with members of the senior management and representatives of the Parent regarding their assessment of the Company Internal Data, the Parent Internal Data and the Synergies, as appropriate. In addition, we conducted such other financial studies and analyses and took into account such other information as we deemed appropriate. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">We have assumed, without independent verification or any responsibility therefor, the accuracy and completeness of the financial, legal, regulatory, tax, accounting and other information supplied to, discussed with, or reviewed by us for purposes of this opinion and have, with your consent, relied upon such information as being complete and accurate. In that regard, we have assumed, at your direction, that the Company Internal Data and Parent Internal Data (including, without limitation, the Company Forecasts and Parent Forecasts) and the Synergies have been reasonably prepared on bases reflecting the best currently available estimates and judgments of the management of the Company or Parent, as applicable, as to the matters covered thereby and we have relied, at your direction, on the Company Internal Data, the Company Forecasts and Parent Internal Data (including, without limitation the Parent Liquidation Analysis, but excluding the Parent Forecasts) and the Synergies for purposes of our analysis and this opinion. Further, we have assumed, at your direction, that the Parent Liquidation Analysis has been reasonably prepared on bases reflecting the best currently available estimates and judgments of the management of the Parent as to the expected realizable value of the Parent assets, assuming an orderly liquidation of such assets and the remaining amounts estimated to be available upon completion of such liquidation for distribution to holders of Parent Shares and we have relied, at your direction, on the Parent Liquidation Analysis for purposes of our analysis and this opinion. We express no view or opinion as to the Company Internal Data, the Company Forecasts, the Parent Internal Data (including, without limitation, the Parent Forecasts and the Parent Liquidation Analysis) or the Synergies or the assumptions on which they are based. We have also assumed, at your direction, that there will be no Parent Net Cash Shortfall or Parent Net Cash Surplus (each, as defined in the Agreement) and that the adjustments to the valuation of the Parent for purposes of the Exchange Ratio in the Agreement will result in a valuation of the Parent of $465,700,000. In addition, at your direction, we have not made any independent evaluation or appraisal of any of the assets or liabilities (contingent, derivative, off-balance-sheet or otherwise) of the Parent or the Company, nor have we been furnished with any such evaluation or appraisal (other than the Parent Liquidation Analysis), and we have not been asked to conduct, and did not conduct, a physical inspection of the properties or assets of the Parent or the Company. We have assumed, at your direction, that (i) the final executed Agreement will not differ in any respect material to our analysis or this opinion from the Agreement reviewed by us, (ii) the representations and warranties made by the Parent and the Company in the Agreement and related agreements are and will be true and correct in all respects material to our analysis, and (iii) there will be no adjustments to the Consideration that would be material to our analysis or this opinion. We have also assumed, at your direction, that the Transaction will be consummated on the terms set forth in the Agreement and in accordance with all applicable laws and other relevant documents or requirements, without delay or the waiver, modification or amendment of any term, condition or agreement, the effect of which would be material to our analysis or this opinion and that, in the course of obtaining the necessary governmental, regulatory and other approvals, consents, releases and waivers for the Transaction, no delay, limitation, restriction, condition or other change, including any divestiture requirements or amendments or modifications, will be imposed, the effect of which would be material to our analysis or this opinion. We have further assumed, at your direction, that the Merger will qualify for U.S. federal income tax purposes as a reorganization within the meaning of Section&#160;368(a) of the Internal Revenue Code of 1986, as amended. We have not evaluated and do not express any opinion as to the solvency or fair value of the Parent, the Company or any other person, or the ability of the Parent or such other person to pay its respective obligations when they come due, or as to the impact of the Transaction on such matters, under any state, federal or other laws relating to bankruptcy, insolvency or similar matters. We are not legal, regulatory, tax or accounting advisors, and we express no opinion as to any legal, regulatory, tax or accounting matters.</div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">B-2<br></div></div></div>
<!--End Page 459-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 460-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_301-annexb_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Board of Directors <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Standard BioTools Inc. <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">June 6, 2026 <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Page 3 </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">We express no view as to, and our opinion does not address, the Parent&#8217;s underlying business decision to proceed with or effect the Transaction, or the relative merits of the Transaction as compared to any alternative business strategies or transactions that might be available to the Parent or in which the Parent might engage. This opinion is limited to and addresses only the fairness, from a financial point of view, as of the date hereof, to the Parent of the Exchange Ratio provided for pursuant to the Agreement. We have not been asked to, nor do we express any view on, and our opinion does not address, any other term or aspect of the Agreement or the Transaction, including, without limitation, the structure or form of the Transaction, the CVRs, the CVR Agreement, the form or terms of the CVR with respect to transferability, illiquidity or otherwise, or any other agreements or arrangements contemplated by the Agreement or entered into in connection with or otherwise contemplated by the Transaction, including, without limitation, the fairness of the Transaction or any other term or aspect of the Transaction to, or any consideration to be received in connection therewith by, or the impact of the Transaction on, the holders of any class of securities, creditors or other constituencies of the Parent or any other party. In addition, we express no view or opinion as to the fairness (financial or otherwise) of the amount, nature or any other aspect of any compensation to be paid or payable to any of the officers, directors or employees of the Parent, the Company or any party, or class of such persons in connection with the Transaction, whether relative to the Exchange Ratio provided for pursuant to the Agreement or otherwise. Our opinion is necessarily based on financial, economic, monetary, currency, market and other conditions and circumstances as in effect on, and the information made available to us as of, the date hereof, and we do not have any obligation or responsibility to update, revise or reaffirm this opinion based on circumstances, developments or events occurring after the date hereof. We also express no view or opinion as to any consequence that may result from the Transaction, including as to the price at which the Parent Shares will trade at any time, including following the announcement or consummation of the Transaction. Our opinion does not constitute a recommendation to any person as to how such person should vote or otherwise act with respect to the Transaction or any other matter. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Our financial advisory services and the opinion expressed herein are provided solely for the information and assistance of Board of Directors of the Parent (in their capacity as directors and not in any other capacity) in connection with and for purposes of its consideration of the Transaction. The issuance of this opinion was approved by the Centerview Partners LLC Fairness Opinion Committee. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Based upon and subject to the foregoing, including the various assumptions made, procedures followed, matters considered, and qualifications and limitations set forth herein, we are of the opinion, as of the date hereof, that the Exchange Ratio provided for pursuant to the Agreement is fair, from a financial point of view, to the Parent. </div><table cellspacing="0" cellpadding="0" class="BRDSX_txtann" style="margin-top: 4pt; width: 528pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 300pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 216pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr><td style="width: 300pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 216pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Very truly yours, </div></td></tr><tr><td style="width: 300pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 216pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 300pt; padding-top: 0.67pt; padding-bottom: 1.75pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 216pt; padding-top: 0.67pt; padding-bottom: 1.75pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ Centerview Partners LLC </div></td></tr><tr><td style="width: 300pt; padding-top: 1.42pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 216pt; padding-top: 1.42pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 300pt; padding-top: 0.67pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 216pt; padding-top: 0.67pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">CENTERVIEW PARTNERS LLC</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 3pt; width: 300pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 216pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0.5pt; margin-left: 0pt; text-align: left;"> </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">B-3<br></div></div></div>
<!--End Page 460-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 461-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_302-annexc_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: right;"><a name="tANC"><!--Anchor--></a>Annex C </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 13.5pt; margin-left: 0pt; text-align: left;"><img style="height: 43px; width: 116px;" src="logo_ubsv2.jpg"><br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">June&#160;5, 2026 </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">The Special Committee of the Board of Directors of Standard BioTools Inc.<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Standard BioTools Inc. <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">50 Milk Street, 10<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> Floor<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Boston, Massachusetts 02109 </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">Dear Members of the Special Committee of the Board of Directors of Standard BioTools Inc.: </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">We understand that Standard BioTools Inc., a Delaware corporation (&#8220;Parent&#8221;) intends to enter into an Agreement and Plan of Merger and Reorganization, draft dated as of June&#160;5, 2026 (the &#8220;Agreement&#8221;), among Parent, TreeLine Biosciences, Inc., a Delaware corporation (the &#8220;Company&#8221;), and Siri Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent (&#8220;Merger Sub&#8221;), pursuant to which, among other things, (i) Merger Sub will merge with and into the Company (the &#8220;Merger&#8221;); (ii) the Company will survive the Merger as a wholly owned subsidiary of Parent; (iii) each share of common stock, par value $0.00001 per share (&#8220;Company Common Stock&#8221;), of the Company and each share of preferred stock, par value $0.00001 per share (&#8220;Company Preferred Stock&#8221; and, together with Company Common Stock, &#8220;Company Capital Stock&#8221;), of the Company, in each case, issued and outstanding immediately prior to the effective time of the Merger (other than shares of Company Capital Stock held in treasury and the Dissenting Shares (as defined in the Agreement)) will be converted into the right to receive, for each share of Company Capital Stock, a number of shares of common stock, par value $0.001 per share (&#8220;Parent Common Stock&#8221;), of Parent equal to the Exchange Ratio (as defined in the Agreement), which Exchange Ratio, pursuant to the Agreement, is based on (a) a Parent Valuation (as defined in the Agreement) of (I) $460&#160;million plus (II) the Parent Net Cash Surplus (as defined in the Agreement), if any, minus (III) the Parent Net Cash Shortfall (as defined in the Agreement), if any, plus (IV) the Aggregate Parent Exercise Price (as defined in the Agreement), (and you have directed us to assume that the Parent Net Cash Shortfall and Parent Net Cash Surplus will each be zero, that the Aggregate Parent Exercise Price will be approximately $6&#160;million and that accordingly, the Parent Valuation will be equal to approximately $466&#160;million), (b) a Company Valuation of (i) $2.5 billion plus (ii) the Aggregate Company Exercise Price (as defined in the Agreement), (and you have directed us to assume that the Aggregate Company Exercise Price will be approximately $43&#160;million and that accordingly, the Company Valuation will be equal to approximately $2.543&#160;billion), (c) the number of fully diluted shares of Parent Common Stock, prior to the Reverse Stock Split (as defined below), issued and outstanding immediately prior to the effective time of the Merger and (d) the number of fully diluted shares of Company Common Stock issued and outstanding immediately prior to the effective time of the Merger, which Exchange Ratio is subject to adjustment pursuant to Section 2.7 of the Agreement as to which adjustment we express no view or opinion; (iv) Parent may declare a dividend (the &#8220;Closing Dividend&#8221;) to holders of Parent Common Stock of record of one contingent value right (each, a &#8220;CVR&#8221;) for each outstanding share of Parent Common Stock held by such stockholders as of the close of business on the last business day prior to the day on which the effective time of the Merger occurs, each representing the right to receive contingent payments upon the occurrence of certain events set forth in, and subject to and in accordance with the terms and conditions of, a Contingent Value Rights Agreement (the &#8220;CVR Agreement&#8221;) to be entered into by Parent and the rights agent party thereto; (v) Parent will effect a reverse split of the outstanding shares of Parent Common Stock (the &#8220;Reverse Stock Split&#8221;); and (vi) Parent may sell, license, transfer, dispose of, divest or otherwise monetize the Parent Legacy Business (as defined in the Agreement and any such transaction giving effect thereto, a &#8220;Parent Legacy Transaction&#8221;) or in lieu of pursuing a Parent Legacy Transaction with respect to all or any portion of the Parent Legacy Business, may commence the wind-down of the Parent Legacy Business. Any Closing Dividend or Parent Legacy Transaction together with the Reverse Stock Split are collectively referred to herein as the &#8220;Related Transactions&#8221; and the Related Transactions together with the Merger are collectively referred to herein as the &#8220;Transaction&#8221;. The terms and conditions of the Transaction are more fully set forth in the Agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">You have requested our opinion as to the fairness, from a financial point of view, to Parent of the Exchange Ratio provided for in the Merger. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">UBS Securities LLC (&#8220;UBS&#8221;) has acted as financial advisor to the Special Committee of the Board of Directors (&#8220;Board&#8221;) of Parent (the &#8220;Special Committee&#8221;) in connection with the Transaction and will receive a fee for its services, a portion of which is payable in connection with this opinion, a portion of which is payable upon execution of the Agreement and a significant portion of which is contingent upon consummation of the Transaction. In addition, Parent has agreed to reimburse certain of our expenses arising, and indemnify us against certain liabilities that may arise, out of our engagement. UBS Group AG (the indirect parent of UBS) and its subsidiaries, branches and affiliates provide a wide range of commercial banking, investment banking and other activities (including wealth and investment management, corporate finance, subscription lines, asset management, securities issuing, trading and brokerage activities, research and other investment and financial businesses and services). During the past two years, UBS or one of its affiliates acted as financial advisor to a special committee of the Board of Parent in connection with the sale of the SomaScan business for which UBS or its affiliates have received compensation. During the past two years, UBS and/or its affiliates have not provided services to Casdin Capital LLC, a significant shareholder of Parent (&#8220;Casdin&#8221;), and/or its affiliates or the Company and/or its affiliates and have not received compensation therefrom. In the future, UBS and/or its affiliates may provide services to Parent, Casdin and their respective affiliates and/or the Company and its affiliates for which UBS and/or its affiliates may receive compensation. In addition, in the ordinary course of business, UBS, its affiliates and their respective employees may currently own or trade or otherwise originate, hedge or enforce interests in loans, debt and/or equity securities of Parent (including its affiliates), Casdin (including its affiliates) and/or the Company (including its affiliates) for its own account or for the accounts of customers, and may at any time hold a long or short position in, or security interests over, such securities. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">C-1<br></div></div></div>
<!--End Page 461-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 462-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_302-annexc_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Special Committee of the Board of Directors of Standard BioTools Inc. <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">June 5, 2026 <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Page 2 </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Our opinion does not address the relative merits of the Transaction as compared to other business strategies or transactions that might be available to Parent, including without limitation winding down Parent, or Parent&#8217;s underlying business decision to effect the Transaction. Our opinion does not constitute a recommendation to any shareholder as to how such shareholder should vote or act with respect to the Transaction. At your direction, we have not been asked to, nor do we, offer any opinion as to the terms, other than the Exchange Ratio to the extent expressly specified herein, of the Agreement or any related documents or the form of the Transaction, including, but not limited to, any of the Related Transactions, the CVRs, the CVR Agreement, the Parent Voting Agreement (as defined in the Agreement) or the Lock-Up Agreements (as defined in the Agreement). In addition, we express no opinion as to the fairness of the amount or nature of any compensation to be received by any officers, directors or employees of any parties to the Transaction, or any class of such persons, relative to the Exchange Ratio. We express no opinion as to what the value of Parent Common Stock or CVRs will be when issued pursuant to the Transaction or the price at which Parent Common Stock will trade at any time. In rendering this opinion, we have assumed, with your consent, that (i) the final executed form of the Agreement will not differ in any material respect from the draft that we have reviewed, (ii) the parties to the Agreement will comply with all material terms of the Agreement and the CVR Agreement, as applicable, and (iii) the Transaction will be consummated in accordance with the terms of the Agreement and the CVR Agreement without any adverse waiver or amendment of any material term or condition thereof. We also have assumed that all governmental, regulatory or other consents and approvals necessary for the consummation of the Transaction will be obtained without any material adverse effect on Parent, the Company or the Transaction. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In arriving at our opinion, we have, among other things: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">i.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; text-align: left;">reviewed certain publicly available business and financial information relating to the Company and Parent; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">ii.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; text-align: justify;">reviewed certain internal financial information and other data relating to the business and financial prospects of the Company that were provided to us by the management of Parent that were not publicly available, including financial forecasts and estimates prepared by the management of the Company as adjusted by the management of Parent that you have directed us to utilize for purposes of our analysis (the &#8220;Company Projections&#8221;); </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">iii.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; text-align: justify;">reviewed certain internal financial information and other data relating to the business and financial prospects of Parent that were provided to us by the management of Parent that were not publicly available, including financial forecasts and estimates with respect to Parent on a standalone basis as a going concern prepared by the management of Parent (the &#8220;Going Concern Projections&#8221;) and a wind-down analysis of Parent prepared by the management of Parent (the &#8220;Parent Wind-Down Analysis&#8221;); </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">iv.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; text-align: justify;">reviewed certain estimates as to the amount of Parent Net Cash Surplus, if any, and the Parent Net Cash Shortfall, if any, in each case, prepared by the management of Parent and that you have directed us to utilize for purposes of our analysis (&#8220;Parent Net Cash Estimates&#8221;); </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">v.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; text-align: justify;">conducted discussions with members of the senior management of Parent concerning the businesses and financial prospects of Parent and the Company; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">vi.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; text-align: justify;">performed a discounted cash flow analysis of the Company in which we analyzed the future cash flows of the Company using the Company Projections; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">vii.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; text-align: left;">reviewed publicly available financial and stock market data with respect to certain other companies we believe to be generally relevant; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">viii.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; text-align: left;">reviewed the Agreement; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">ix.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; text-align: justify;">conducted such other financial studies, analyses and investigations, and considered such other information, as we deemed necessary or appropriate. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">In connection with our review, with your consent, we have assumed and relied upon, without independent verification, the accuracy and completeness in all material respects of the information provided to or reviewed by us for the purpose of this opinion. In addition, with your consent, we have not made any independent evaluation or appraisal of any of the assets or liabilities (contingent or otherwise) of Parent or the Company, nor have we been furnished with any such evaluation or appraisal (other than the Parent Wind-Down Analysis). With respect to the Company Projections and Parent Net Cash Estimates, we have assumed, at your direction, that they have been reasonably prepared on a basis reflecting the best currently available estimates and judgments of the Special Committee and the management of Parent as to the future financial performance or status of Parent and the Company and the other matters covered thereby. In addition, we have assumed with your approval that the Company Projections and Parent Net Cash Estimates will be achieved at the times and in the amounts projected. Further, we express no view or opinion with respect to the Company Projections, the Going Concern Projections, the Parent Wind-Down Analysis or Parent Net Cash Estimates or the assumptions on which they are based. We have relied on the assessments of the management of Parent as to, among other things, the product pipeline, future products, technology and intellectual property of the Company, including the viability of and risks associated with such product pipeline, future products, technology and intellectual property. You have advised us, and at your direction we have relied upon and assumed that (a) Parent&#8217;s assets and liabilities are comprised solely of cash and certain operating assets and related liabilities; and (b) (i) Parent has suffered significant recurring losses from operations, (ii)&#160;Parent&#8217;s management has prepared the Going Concern Projections and the Parent Wind-Down Analysis and (iii) the Board and the Special Committee have determined that the Parent Wind-Down Analysis reflects the best currently available estimates and judgments as to the future financial performance of Parent on a standalone basis and that the Going Concern Projections do not reflect the best currently available estimates and </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">C-2<br></div></div></div>
<!--End Page 462-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 463-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_302-annexc_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Special Committee of the Board of Directors of Standard BioTools Inc. <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">June 5, 2026 <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Page 3 </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">judgments as to the future financial performance of Parent on a standalone basis. We also have assumed, with your consent, that the Transaction will qualify for U.S. federal income tax purposes as a reorganization within the meaning of Section&#160;368(a) of the Internal Revenue Code of 1986, as amended. Our opinion is necessarily based on economic, monetary, market and other conditions as in effect on, and the information available to us as of, the date hereof. The issuance of this opinion was approved by an authorized committee of UBS. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Based upon and subject to the foregoing, it is our opinion that, as of the date hereof, the Exchange Ratio provided for in the Merger is fair, from a financial point of view, to Parent. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">This opinion is provided for the benefit of the Special Committee (in its capacity as such) in connection with, and for the purpose of, its evaluation of the Exchange Ratio in the Transaction. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; text-align: center;">Very truly yours, </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; text-align: center;">&#8195;&#8195;&#8195;UBS SECURITIES LLC </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_txtann" style="width: 528pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 228pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 254pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr><td style="width: 5pt; padding-bottom: 1.75pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By:</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 228pt; padding-bottom: 1.75pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ Kapil Gupta </div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5pt; padding-bottom: 1.75pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By:</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 254pt; padding-bottom: 1.75pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ James Chan</div></td></tr><tr><td style="width: 5pt; padding-top: 1.42pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 228pt; padding-top: 1.42pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name: Kapil Gupta</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5pt; padding-top: 1.42pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 254pt; padding-top: 1.42pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name: James Chan</div></td></tr><tr><td style="width: 5pt; padding-top: 0.67pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 228pt; padding-top: 0.67pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Title: Managing Director </div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5pt; padding-top: 0.67pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 254pt; padding-top: 0.67pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Title: Managing Director</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 3pt; width: 5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 228pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 254pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">C-3<br></div></div></div>
<!--End Page 463-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 464-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_303-annexd_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: right;"><a name="tAND"><!--Anchor--></a>Annex D</div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 13pt; text-align: center;">FORM OF VOTING AGREEMENT </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">This Voting Agreement (this &#8220;<font style="font-weight: bold;">Agreement</font>&#8221;), dated as of June&#160;6, 2026, is entered into by and among Treeline Biosciences, Inc., a Delaware corporation (the &#8220;<font style="font-weight: bold;">Company</font>&#8221;), Standard BioTools Inc., a Delaware corporation (&#8220;<font style="font-weight: bold;">Parent</font>&#8221;), Siri Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (&#8220;<font style="font-weight: bold;">Merger Sub</font>&#8221;), and the persons listed on the attached <u>Schedule A</u> who are signatories to this Agreement (each, a &#8220;<font style="font-weight: bold;">Stockholder</font>&#8221;, and collectively, the &#8220;<font style="font-weight: bold;">Stockholders</font>&#8221;). </div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 14.5pt; text-align: center;">RECITALS </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">WHEREAS, concurrently herewith, the Company, Parent and Merger Sub are entering into an Agreement and Plan of Merger and Reorganization (as amended, restated, supplemented or otherwise modified from time to time, the &#8220;<font style="font-weight: bold;">Merger Agreement</font>&#8221;); </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">WHEREAS, as of the date of this Agreement, each Stockholder is the record and/or &#8220;beneficial owner&#8221; (within the meaning of Rule&#160;13d-3 under the Exchange Act) of the number of shares of Parent Common Stock set forth on <u>Schedule A</u> opposite such Stockholder&#8217;s name (all of such shares of Parent Common Stock owned of record or beneficially by such Stockholder as of the date of this Agreement, the &#8220;<font style="font-weight: bold;">Owned Shares</font>&#8221; and, together with any additional shares of Parent Common Stock or other voting securities of Parent of which such Stockholder acquires record or beneficial ownership after the date of this Agreement, including by purchase, as a result of a stock dividend, stock split, recapitalization, combination, consolidation, reclassification, exchange or change of such shares, or other similar transaction, or upon exercise or conversion of any securities (including any Parent Warrants, Parent Options, Parent RSUs or Parent ESPP Options) and that such Stockholder is entitled to vote on the applicable matter, such Stockholder&#8217;s &#8220;<font style="font-weight: bold;">Covered Shares</font>&#8221;); </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">WHEREAS, in connection with the negotiation and execution of the Merger Agreement and related agreements and the transactions contemplated thereby, the board of directors of Parent established a special committee thereof consisting solely of &#8220;disinterested directors&#8221; (as defined in Section&#160;144(e)(4) of the DGCL) (the &#8220;<font style="font-weight: bold;">Parent Special Committee</font>&#8221;); </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">WHEREAS, as a condition and inducement to the willingness of the Company, Parent and Merger Sub to enter into the Merger Agreement and to proceed with the transactions contemplated thereby, including the Merger, the Parent Share Issuance, the Parent Reverse Stock Split, the Parent Charter Amendment and the adoption of the Post-Closing Equity Incentive Plan and Post-Closing ESPP, the Company, Parent, Merger Sub and the Stockholders are entering into this Agreement; and </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">WHEREAS, the Stockholders acknowledge that each of the Company, Parent and Merger Sub are entering into the Merger Agreement in reliance on the representations, warranties, covenants and other agreements of the Stockholders set forth in this Agreement and would not enter into the Merger Agreement if the Stockholders did not enter into this Agreement. </div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 14.5pt; text-align: center;">AGREEMENT </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">NOW, THEREFORE, in consideration of the foregoing and the respective representations, warranties, covenants and agreements set forth below and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, do hereby agree as follows: </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">1.&#8195;<font style="font-weight: bold;">Certain Definitions</font>. All capitalized terms that are used but not defined herein have the respective meanings ascribed to them in the Merger Agreement. For all purposes of and under this Agreement, the following terms have the following respective meanings: </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;&#8220;<font style="font-weight: bold;">Permitted Liens</font>&#8221; means (i) Liens that would not reasonably be expected to interfere adversely with the performance by the applicable Stockholder of its obligations hereunder, (ii) any bona fide pledge of the Covered Shares to any financial institution in connection with a bona fide financing transaction so long as such pledge does not prevent or otherwise restrict the Stockholders from voting the Covered Shares in accordance with this Agreement, (iii) Liens arising under applicable Law, including any statutory, judicial or administrative liens imposed without the willful action or omission of the applicable Stockholder, or (iv) any voting agreement or arrangement or grant of any proxy, power of attorney or other authorization either with respect to routine matters at an annual meeting of Parent stockholders, or that is not inconsistent with such Stockholder&#8217;s obligations pursuant to this Agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;&#8220;<font style="font-weight: bold;">Termination Time</font>&#8221; means the earliest to occur of (i) the date and time of the termination of the Merger Agreement in accordance with its terms, (ii) the date and time at which the Parent Stockholder Approval is obtained, (iii) the Effective Time, (iv) the written agreement of Parent, Merger Sub, the Company and the Stockholders to terminate this Agreement, and (v) with respect to any Stockholder, the date and time of any modification, waiver or amendment to any provision of the Merger Agreement without such Stockholder&#8217;s prior written consent which is adverse in any material respect to such Stockholder. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(c)&#8195;A Person will be deemed to have effected a &#8220;<font style="font-weight: bold;">Transfer</font>&#8221; of a security if such Person, whether voluntarily or involuntarily, directly or indirectly, (i) sells, pledges, encumbers, hypothecates, leases, assigns, gifts, grants an option with respect to, transfers, exchanges, tenders or disposes (by merger, by testamentary disposition, by operation of law or otherwise) of such security or any interest in such security, (ii) creates or permits any Liens, (iii) deposits such security into a voting trust or enters into a voting agreement or arrangement or grants any proxy, power of attorney or other authorization with respect thereto that is inconsistent with such Stockholder&#8217;s obligations under this Agreement or (iv) enters into an agreement to take any of the actions referred to in the foregoing clauses (i) through (iii); <u>provided</u>, <u>however</u>, that &#8220;<font style="font-weight: bold;">Transfer</font>&#8221; shall not include the creation, incurrence or existence of any Permitted Lien. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">D-1<br></div></div></div>
<!--End Page 464-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 465-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; position: relative; width: 528pt;"><a name="ny20077604x1_s4_303-annexd_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">2.&#8195;<font style="font-weight: bold;">Transfer Restrictions</font>. Except as expressly provided for in this Agreement or the Merger Agreement, from the date of this Agreement until the Termination Time, each Stockholder shall not Transfer (or cause or permit the Transfer of) any of such Stockholder&#8217;s Covered Shares except with the Company&#8217;s prior written consent. Notwithstanding anything to the contrary in this Agreement, this <u>Section 2</u> shall not prohibit a Transfer of Covered Shares by a Stockholder to (i) any of such Stockholder&#8217;s Affiliates or limited partners (including, for the avoidance of doubt, any distribution in kind to the limited partners), (ii) if such Stockholder is a natural person, any member of such Stockholder&#8217;s immediate family or to a trust for the benefit of such Stockholder or any member of such Stockholder&#8217;s immediate family, or (iii) any person or entity if and to the extent required by any non-consensual legal order, by divorce decree or by will, intestacy or other similar law; <u>provided</u> that in the case of clauses (i) and (ii), such a Transfer shall be permitted only if, as a precondition to such Transfer, the transferee agrees in writing (in form and substance reasonably satisfactory to the Company) to be bound by all of the obligations of such Stockholder under this Agreement with respect to such Covered Shares being Transferred. Any Transfer or attempted Transfer of any Covered Shares in violation of this <u>Section&#160;2</u> shall be null and void and of no effect whatsoever. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">3.&#8195;<font style="font-weight: bold;">Agreement to Vote</font>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;From the date of this Agreement until the Termination Time, at the Parent Stockholders Meeting and any other meeting of the stockholders of Parent (and at every adjournment or postponement thereof) to vote on any matter contemplated by this Agreement, however called, each Stockholder shall vote, or cause to be voted, all of such Stockholder&#8217;s Covered Shares owned at the record date of such meeting: </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(i)&#8195;in favor of the approval of the Parent Share Issuance, the Parent Charter Amendment, the Parent Reverse Stock Split and the adoption of the Post-Closing Equity Incentive Plan and the Post-Closing ESPP; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(ii)&#8195;in favor of the approval of any proposal to adjourn the meeting to a later date, if there is not a quorum or sufficient affirmative votes (in person or by proxy) to obtain the Parent Stockholder Approval on the date on which such meeting is held; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(iii)&#8195;against any action or agreement that would reasonably be expected to result in the conditions of the Contemplated Transactions not being fulfilled or a breach of a covenant, representation or warranty or any other material obligation or agreement of Parent contained in the Merger Agreement; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(iv)&#8195;against any action, proposal, transaction or agreement that would reasonably be expected to prevent or materially delay the consummation of the Contemplated Transactions or the fulfillment of Parent&#8217;s or Merger Sub&#8217;s conditions to Closing under the Merger Agreement; and </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 30pt; text-indent: 30pt; text-align: left;">(v)&#8195;against any action or proposal in favor of any Parent Acquisition Proposal. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;From the date of this Agreement until the Termination Time, each Stockholder shall appear, or shall cause to appear the applicable entity that is the record holder of any of such Stockholder&#8217;s Covered Shares, as applicable (in person, by proxy or by any other means permitted by the bylaws of Parent), at each meeting of the stockholders of Parent, adjournment or postponement thereof, to vote on any matter contemplated by this Agreement and shall cause all of such Stockholder&#8217;s Covered Shares to be counted as present thereat for purposes of calculating a quorum. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(c)&#8195;[In the event of a Parent Change in Recommendation by the Parent Special Committee, (i) 37.5% of Covered Shares entitled to vote on any applicable matter set forth in <u>Section&#160;3(a)</u> that is the subject of such Parent Change in Recommendation (an &#8220;<font style="font-weight: bold;">Applicable Matter</font>&#8221;) shall be released from the requirements set forth in <u>Section&#160;3(a)</u> and <u>Section&#160;3(b)</u> above (the &#8220;<font style="font-weight: bold;">Voting Requirements</font>&#8221;), and the Stockholders shall be free to vote such released shares in their full and absolute discretion, and (ii) if the Covered Shares of the Stockholders subject to the Voting Requirements, together with the &#8220;Covered Shares&#8221; of any other stockholders subject to similar voting requirements under voting agreements entered into with the Company in connection with the Merger Agreement and then in full force and effect, shall equal, in the aggregate, greater than 30% of the issued and outstanding shares of Parent&#8217;s capital stock entitled to vote on the Applicable Matter on the applicable record date, then a number of Covered Shares shall be released pro rata from the Voting Requirements (and the Stockholders shall be free to vote such released shares in their full and absolute discretion) such that the Covered Shares of the Stockholders subject to the Voting Requirements, together with the &#8220;Covered Shares&#8221; of any other stockholders subject to similar voting requirements under voting agreements entered into with the Company in connection with the Merger Agreement and then in full force and effect, shall equal, in the aggregate, 30% of the issued and outstanding shares of Parent&#8217;s capital stock entitled to vote on the Applicable Matter on the applicable record date (such reduction under this clause (ii) to apply on a <font style="font-style: italic;">pro rata</font> basis with any other stockholders who are subject to a corresponding reduction requirement) ((i) and (ii)&#160;collectively, the &#8220;<font style="font-weight: bold;">Voting Cut-Backs</font>&#8221;).]<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup> </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(d)&#8195;Nothing in this Agreement, including this <u>Section&#160;3</u>, limits or restricts any Stockholder, or any Affiliate or designee of any Stockholder, who serves as a member of or observer to the Parent Board or as an officer of Parent in acting or voting in his or her capacity as a director, board observer or officer of Parent and exercising his or her fiduciary duties and responsibilities or fulfilling his or her role as a director, board observer or officer, as applicable, in each case as such Person determines in his, her or its reasonable discretion (including with respect to the interpretation and discharge of such duties, responsibilities and role), it being understood that this Agreement applies to each Stockholder solely in such Stockholder&#8217;s capacity as a stockholder of Parent and does not apply to such Stockholder&#8217;s or any such Affiliate or designee&#8217;s actions, judgments or decisions as a director, board observer or officer of Parent, and such actions (or failures to act) (including, but not limited to, advocating for, voting for, or otherwise supporting a Parent Adverse Recommendation Change or Parent Superior Proposal or making any non-public statement to the Company, other members of the Parent Board, any committee thereof, or other directors or officers of Parent or Company in support of a Parent Adverse Recommendation Change or Parent Superior Proposal) shall not be deemed to constitute a breach of this Agreement. </div></div><div class="BRDSX_block-footnote" style="width: 528pt; margin-left: 0pt;"><div><div class="BRDSX_rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-top: 3pt; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt;"> </div></div></div><div class="BRDSX_block-footnote" style="width: 528pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 10pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt;"><font style="position: relative; top: -3.25pt;">1</font><br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; text-align: justify; font-size: 8pt;"><font style="font-size: 8pt;">Included in certain of the Voting Agreements such that the aggregate number of outstanding shares of common stock of Parent subject to the Voting Requirements is reduced to approximately 30% of the outstanding shares of common stock of Parent in the event of a Parent Change in Recommendation. </font></div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">D-2<br></div></div></div>
<!--End Page 465-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 466-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_303-annexd_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">4. &#8195;<font style="font-weight: bold;">No Inconsistent Agreements</font>. Each Stockholder hereby represents, covenants and agrees that, except as contemplated by this Agreement, such Stockholder (a) has not entered into, and shall not enter into at any time prior to the Termination Time, any voting agreement or voting trust with respect to any of such Stockholder&#8217;s Covered Shares and (b) except for Permitted Liens of the type described in clause (iv) of the definition thereof, has not granted, and shall not grant at any time prior to the Termination Time, a proxy or power of attorney with respect to any of such Stockholder&#8217;s Covered Shares, in either case, that is inconsistent with such Stockholder&#8217;s obligations pursuant to this Agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">5.&#8195;<font style="font-weight: bold;">Representations and Warranties of Each Stockholder</font>. Each Stockholder hereby represents and warrants to Parent, Merger Sub and the Company, solely as to itself and not as to any other Stockholder or other Person, as follows: </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a) &#8195;<u>Power; Organization; Binding Agreement</u>. Such Stockholder has the power and authority (in the case of each Stockholder that is not a natural person) or capacity (in the case of each Stockholder that is a natural person) to execute and deliver this Agreement, to perform such Stockholder&#8217;s obligations hereunder and to consummate the transactions contemplated hereby. With respect to each Stockholder that is not a natural person, (i) the execution, delivery and performance by such Stockholder of this Agreement, and the consummation by such Stockholder of the transactions contemplated hereby, have been duly authorized by all necessary corporate, limited liability company, limited liability partnership or similar equivalent action on the part of such Stockholder and (ii) such Stockholder is duly organized, validly existing and in good standing under the applicable Law of its jurisdiction of formation. This Agreement has been duly executed and delivered by such Stockholder, and, assuming due authorization, execution and delivery by Parent, Merger Sub and the Company, this Agreement is enforceable against such Stockholder in accordance with its terms, except that such enforceability may be limited by the Enforceability Exceptions. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;<u>No Conflicts</u>. None of the execution and delivery by such Stockholder of this Agreement, the performance by such Stockholder of such Stockholder&#8217;s obligations hereunder or the consummation by such Stockholder of the transactions contemplated hereby will (i) require any consent or approval under, or result in a violation or breach of, any agreement to which such Stockholder is a party or by which such Stockholder is bound, (ii) result in the creation of any Lien on any of the Covered Shares, (iii) violate any applicable Law or Judgment or (iv) with respect to a Stockholder that is not a natural person, violate the organizational documents of such Stockholder, in each case, except for such consents, approvals, breaches, Liens or violations that would not, individually or in the aggregate, prevent or materially delay such Stockholder from performing such Stockholder&#8217;s obligations under this Agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(c)&#8195;<u>Ownership of Covered Shares</u>. As of the date of this Agreement, such Stockholder is the beneficial owner of such Stockholder&#8217;s Covered Shares. As of the date of this Agreement, all such Stockholder&#8217;s Covered Shares are owned free and clear of any Liens other than Permitted Liens, and no Person has a right to acquire any of such Covered Shares. As of the date of this Agreement, except as set forth on <u>Schedule A</u>, other than such Stockholder&#8217;s Owned Shares, such Stockholder does not own beneficially or of record any (i) shares of capital stock or voting securities of Parent, (ii) securities of Parent convertible into or exchangeable for shares of capital stock or voting securities of Parent or (iii) options or other rights to acquire from Parent any capital stock, voting securities or securities convertible into or exchangeable for capital stock or voting securities of Parent. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(d)&#8195;<u>Voting Power</u>. Such Stockholder has the requisite voting power, power of disposition, power to issue instructions with respect to the matters set forth herein and power to agree to all of the matters set forth in this Agreement necessary to take all actions required under this Agreement, in each case with respect to all of the securities subject to this Agreement owned by such Stockholder, subject to applicable federal securities laws and those arising under the terms of this Agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(e)&#8195;<u>Reliance by the Company, Parent and Merger Sub</u>. Such Stockholder understands and acknowledges that each of the Company, Parent and Merger Sub is entering into the Merger Agreement in reliance upon such Stockholder&#8217;s execution and delivery of this Agreement (including the representations and warranties made by such Stockholder herein). </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(f)&#8195;<u>Consents and Approvals</u>. The execution and delivery of this Agreement by such Stockholder does not, and the performance by such Stockholder of such Stockholder&#8217;s obligations under this Agreement and the consummation of the transactions contemplated hereby will not, require such Stockholder to obtain any consent, approval, authorization or permit of, or to make any filing with or notification to, any Governmental Entity, except in each case for filings with the SEC or where the failure to obtain such consents, approvals, authorizations or permits, or to make such filings and notifications, would not, either individually or in the aggregate, prevent or materially delay the performance by such Stockholder of any of such Stockholder&#8217;s obligations hereunder. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(g)&#8195;<u>No Brokers</u>. Neither such Stockholder nor any of its Representatives or Affiliates has employed or made any agreement with any broker, finder or similar agent or any Person that will result in the obligation of such Stockholder, the Company, Parent or any of their respective Affiliates to pay any finder&#8217;s fee, brokerage fees or commission or similar payment in connection with the transactions contemplated hereby. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">6.&#8195;<font style="font-weight: bold;">Additional Covered Shares</font>. Prior to the Termination Time, in the event that a Stockholder acquires record or beneficial ownership of, or the power to vote or direct the voting of, any additional shares of Parent Common Stock or other voting interests with respect to Parent, such shares of Parent Common Stock or other voting interests will, without further action of the parties, be deemed Covered Shares held by such Stockholder and subject to the provisions of this Agreement, the number of shares of Parent Common Stock held by such Stockholder will be deemed amended accordingly, and such shares of Parent Common Stock or voting interests will automatically become subject to the terms of this Agreement as Covered Shares (subject in all events to the Voting Cut-Backs). In the event of any stock split, stock dividend, merger, reorganization, recapitalization, reclassification, combination, exchange of shares or the like of the capital stock of Parent affecting the Covered Shares, the terms of this Agreement shall apply to the resulting securities of Parent. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">D-3<br></div></div></div>
<!--End Page 466-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 467-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_303-annexd_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">7.&#8195;<font style="font-weight: bold;">Representations and Warranties of Parent, Merger Sub and the Company</font>. Each of Parent, Merger Sub and the Company hereby represents and warrants to each Stockholder, solely as to itself and not as to any other Person, as follows: </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;<u>Organization and Qualification</u>. Each of Parent, Merger Sub and the Company is duly formed, validly existing and in good standing under the laws of the State of Delaware. Each of Parent, Merger Sub and the Company have all requisite corporate power and authority to enter into the Merger Agreement and this Agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;<u>Authority; Binding Nature</u>. Each of Parent, Merger Sub and the Company have all requisite corporate power and authority to (i)&#160;execute and deliver this Agreement, (ii) perform its covenants and obligations hereunder and (iii) subject to the receipt of the Company Stockholder Approval, in the case of the Company, the Parent Stockholder Approval, in the case of Parent, and with respect to Merger Sub, the adoption of the Merger Agreement by Parent in its capacity as sole stockholder of Merger Sub, consummate the transactions contemplated hereby to be consummated by it and consummate the Contemplated Transactions. The execution and delivery of this Agreement by each of Parent, Merger Sub and the Company, the performance of each of their covenants and obligations hereunder and the consummation of the transactions contemplated hereby have been duly and validly authorized by all necessary action on the part of Parent, Merger Sub and the Company, as applicable, and no additional actions are necessary for (A) the execution and delivery of this Agreement by Parent, Merger Sub and the Company; (B) the performance by each of Parent, Merger Sub and the Company of its covenants and obligations hereunder; or (C) the consummation of the transactions contemplated hereby. This Agreement has been duly and validly executed and delivered by Parent, Merger Sub and the Company (assuming due authorization, execution and delivery by the Stockholders) constitutes a valid and binding obligation of Parent, Merger Sub and the Company, enforceable against Parent, Merger Sub and the Company in accordance with its terms, except that such enforceability may be limited by the Enforceability Exceptions. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(c)&#8195;<u>No Conflicts</u>. None of the execution and delivery by each of Parent, Merger Sub and the Company of this Agreement, the performance by each of Parent, Merger Sub and the Company of its obligations hereunder or the consummation by each of Parent, Merger Sub and the Company of the transactions contemplated hereby will (i) require any consent or approval under, or result in a violation or breach of, any agreement to which Parent, Merger Sub or the Company is a party or by which Parent, Merger Sub or the Company may be bound, including any voting agreement or voting trust, (ii) result in the creation of any Lien on any of the assets or properties of Parent, Merger Sub or the Company, (iii) violate any applicable Law or Judgment or (iv) violate the organizational documents of Parent, Merger Sub or the Company. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(d)&#8195;<u>No Litigation; Orders</u>. As of the date of this Agreement, there is no claim, complaint, suit, proceeding, hearing, enforcement audit, investigation, arbitration, or other adverse action pending or, to the knowledge of Parent, Merger Sub or the Company, threatened against Parent, Merger Sub or the Company, as applicable, at law or in equity before or by any Governmental Entity that questions the validity of this Agreement, the Merger Agreement or the performance by Parent, Merger Sub or the Company of its obligations under this Agreement or the Merger Agreement. As of the date of this Agreement, Parent, Merger Sub and the Company are not subject to any injunction, writ, judgment, decree, determination, ruling or other order of any kind or nature by any Governmental Entity that would reasonably be expected to impair in any material respect the ability of Parent, Merger Sub or the Company to perform its obligations hereunder or to consummate the transactions contemplated by this Agreement or the Merger Agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">8.&#8195;<font style="font-weight: bold;">Spousal Consent</font>. If a Stockholder is a married individual and any of its Owned Shares constitutes community property or otherwise needs spousal or other approval for this Agreement to be legal, valid and binding, such Stockholder shall deliver to Parent, Merger Sub and the Company, concurrently herewith, a duly executed consent of such Stockholder&#8217;s spouse, in the form attached hereto as <u>Schedule B</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">9.&#8195;<font style="font-weight: bold;">Waiver</font>. Each Stockholder agrees not to initiate, or join any stockholder class, in any action, suit, litigation, arbitration, or proceeding that (i)&#160;challenges the validity of or seeks to enjoin the operation of any provision of this Agreement, (ii) relates to the negotiation, execution or delivery of this Agreement, the Merger Agreement or the consummation of the transactions contemplated hereby or thereby or (iii) alleges that the execution and delivery of this Agreement by such Stockholder, or the approval of the Merger Agreement by the Parent Board, breaches any fiduciary duty of the Parent Board or any member thereof; <u>provided</u> that this <u>Section&#160;9</u> shall not be deemed a waiver of any rights of any Stockholder or such Stockholder&#8217;s Affiliates, successors, assigns and Representatives for any breach of this Agreement or the Merger Agreement by Parent, Merger Sub or the Company, and nothing in this <u>Section&#160;9</u> shall restrict or prohibit any Stockholder or any of its Affiliates or Representatives from asserting counterclaims or defenses in connection with any Legal Proceeding commenced or threatened against it by any Person, or from enforcing its rights under this Agreement, the Merger Agreement, or any of Parent&#8217;s, the Company&#8217;s or their respective subsidiaries&#8217; governing organizational or other governing documents. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">10.&#8195;<font style="font-weight: bold;">No Solicitation</font>. During the period from the date of this Agreement until the Termination Time, each Stockholder hereby covenants not to, and shall not authorize or permit its Affiliates or Representatives to, take, directly or indirectly, any action that Parent would then be prohibited from taking under Section&#160;5.3(a) of the Merger Agreement, it being understood that any action in compliance with Sections 5.3(a), 5.3(b), 5.3(f) or 5.3(g) of the Merger Agreement or otherwise permitted by this Agreement or the Merger Agreement shall not be deemed a breach by any Stockholder of this <u>Section&#160;10</u>. Notwithstanding anything to the contrary provided in this Agreement, each Stockholder and any of its Affiliates and Representatives shall not be prohibited from participating in any discussions or negotiations with respect to a possible tender and support, voting or similar agreement in connection with a Parent Acquisition Proposal in the event that Parent is permitted to take the actions set forth in <u>Section&#160;5.3(b)</u> of the Merger Agreement with respect to such Parent Acquisition Proposal. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">11.&#8195;<font style="font-weight: bold;">Termination</font>. This Agreement and all rights and obligations of the parties hereunder will terminate and have no further force or effect as of the Termination Time; <u>provided</u> that the representations and warranties contained in <u>Sections 5</u> and <u>7</u> of this Agreement will terminate at the Effective Time; <u>provided</u>, <u>further</u>, that <u>Section&#160;9</u>, this <u>Section&#160;11</u>, <u>Section&#160;12</u>, <u>Section&#160;14</u> and <u>Section&#160;16</u> shall survive the termination of this </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">D-4<br></div></div></div>
<!--End Page 467-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 468-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_303-annexd_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Agreement. Notwithstanding the foregoing, nothing set forth in this <u>Section&#160;11</u> or elsewhere in this Agreement relieves any party hereto from liability or damages, or otherwise limits the liability or damages of any party hereto, for any fraud or Willful Breach. For purposes of this Agreement, &#8220;fraud&#8221; means intentional and knowing common law fraud under Delaware law in the representations and warranties set forth in this Agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">12.&#8195;<font style="font-weight: bold;">Miscellaneous</font>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;<u>Severability</u>. Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions of this Agreement or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction. If a final judgment of a court of competent jurisdiction declares that any term or provision of this Agreement is invalid or unenforceable, the Parties agree that the court making such determination shall have the power to limit such term or provision, to delete specific words or phrases or to replace such term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this Agreement shall be valid and enforceable as so modified. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;<u>Assignment</u>. Except in connection with a Transfer of any Covered Shares in accordance with <u>Section&#160;2</u>, neither this Agreement nor any of the rights, interests or obligations hereunder shall be assigned, in whole or in part, by operation of Law or otherwise by any of the parties without the prior written consent of the other parties, and any purported assignment in violation hereof shall be null and void ab initio. Subject to the immediately preceding sentence, this Agreement shall be binding upon, inure to the benefit of and be enforceable by, the parties hereto and their respective successors and permitted assigns. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(c)&#8195;<u>Amendment and Modification; Waiver</u>. This Agreement may be amended or waived by any party only if such amendment or waiver is in writing and is signed, in the case of an amendment, by each party to this Agreement or, in the case of a waiver, by each party against whom the waiver is to be effective. Any failure of any of the parties to comply with any obligation, covenant, agreement or condition in this Agreement may be waived by any of the parties entitled to the benefit thereof only by a written instrument signed by each such party granting such waiver. No failure or delay by any party in exercising any right, power or privilege hereunder shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power or privilege. The rights and remedies herein provided shall be cumulative and not exclusive of any rights or remedies provided by applicable Law or in equity. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(d)&#8195;<u>Specific Performance</u>. The parties acknowledge and agree that irreparable damage would occur and that the parties would not have any adequate remedy at law if any provision of this Agreement were not performed in accordance with its specific terms or were otherwise breached, and that monetary damages, even if available, would not be an adequate remedy therefor. It is accordingly agreed that each of the Company and Parent shall be entitled to an injunction or injunctions, specific performance and other equitable relief to prevent breaches of this Agreement and to enforce specifically the performance of the terms and provisions hereof, without proof of actual damages (and each party hereby waives any requirement for the securing or posting of any bond in connection with such remedy), this being in addition to any other remedy to which they are entitled at Law or in equity. The parties further agree not to assert that a remedy of specific enforcement is unenforceable, invalid, contrary to applicable Law or inequitable for any reason, and not to assert that a remedy of monetary damages would provide an adequate remedy for any such breach or that the Company or Parent otherwise have an adequate remedy at law. The parties acknowledge that the agreements contained in this <u>Section&#160;12(d)</u> are an integral part of the transactions contemplated by this Agreement, and that, without these agreements, the parties would not enter into this Agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(e)&#8195;<u>Notices</u>. All notices, requests, claims, demands and other communications to be given or delivered under or by reason of the provisions of this Agreement shall be in writing and shall be deemed to have been given (a) when personally delivered, (b) when transmitted via email to the email address set forth below (to the extent that no &#8220;bounce back&#8221; or similar message indicating non-delivery is received with respect thereto) or (c) upon confirmed delivery if being sent by registered mail or by courier or express delivery service, in each case to the parties at the applicable address set forth below: </div><table cellspacing="0" cellpadding="0" class="BRDSX_txtann" style="margin-top: 4pt; width: 528pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 29pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 487pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr><td style="width: 29pt; padding-bottom: 0.5pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 487pt; padding-bottom: 0.5pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">if to Parent or Merger Sub: </div></td></tr><tr><td style="width: 29pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 487pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 29pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 487pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Standard BioTools Inc.<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">50 Milk Street, 10th Floor<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Boston, MA 02109 <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Attention: [***] <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Email: [***]<br></div></td></tr><tr><td style="width: 29pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 487pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 29pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 487pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">with copies to (which shall not constitute notice):</div></td></tr><tr><td style="width: 29pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 487pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 29pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 487pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Freshfields US LLP <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3 World Trade Center<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">175 Greenwich Street<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">New York, NY 10007<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Attention: Damien R. Zoubek; Jenny Hochenberg; Abigail G. Hathaway <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Email: damien.zoubek@freshfields.com; jenny.hochenberg@freshfields.com; abigail.hathaway@freshfields.com</div></td></tr><tr><td style="width: 29pt; padding-top: 0.17pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 487pt; padding-top: 0.17pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 29pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 487pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">D-5<br></div></div></div>
<!--End Page 468-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 469-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_303-annexd_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><table cellspacing="0" cellpadding="0" class="BRDSX_txtann" style="margin-top: 4pt; width: 528pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 29pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 487pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr><td style="width: 29pt; padding-bottom: 0.5pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 487pt; padding-bottom: 0.5pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">if to the Company:</div></td></tr><tr><td style="width: 29pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 487pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 29pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 487pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Treeline Biosciences, Inc.<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">[***]<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Attention: [***]<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Email: [***]</div></td></tr><tr><td style="width: 29pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 487pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 29pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 487pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">with copies to (which shall not constitute notice):</div></td></tr><tr><td style="width: 29pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 487pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 29pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 487pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Fenwick &amp; West LLP<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">401 Union St, 5th Floor<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Seattle, WA 98101<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Attention: Effie Toshav; David Michaels<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Email: EToshav@fenwick.com; DMichaels@fenwick.com</div></td></tr><tr><td style="width: 29pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 487pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 29pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 487pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">if to the Stockholders:</div></td></tr><tr><td style="width: 29pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 487pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 29pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 487pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">[&#8226;]<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">[&#8226;]<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Attention: [&#8226;]<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Email: [&#8226;]</div></td></tr><tr><td style="width: 29pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 487pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 29pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 487pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">with copies to (which shall not constitute notice):</div></td></tr><tr><td style="width: 29pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 487pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 29pt; padding-top: 0.17pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 487pt; padding-top: 0.17pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">[&#8226;]<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">[&#8226;]<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Attention: [&#8226;]<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Email: [&#8226;]</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 3pt; width: 29pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 487pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">or to such other persons or addresses as may be designated in writing by the party to receive such notice as provided above. Unless a different deadline for the delivery of notices, requests, claims, demands and other communications is expressly provided for in this Agreement, all such notices, requests instructions, demands and other communications will be deemed given on the day delivered pursuant to the means set forth above if delivered before 5:00 p.m. Eastern Time, and otherwise on the next following day. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(f)&#8195;<u>No Third-Party Beneficiaries</u>. Nothing in this Agreement, express or implied, will give to any Person (other than the parties hereto and their respective successors and permitted assigns hereunder) any benefit or any legal or equitable right, remedy or claim under this Agreement or under any covenant or provision herein contained, all such covenants and provisions being for the sole benefit of the parties hereto and their permitted successors and assigns. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(g) &#8195;<u>Governing Law</u>. This Agreement will be governed by, and construed in accordance with, the Laws of the State of Delaware (regardless of the Laws that might otherwise govern under applicable principles of conflicts of laws) and for all purposes shall be governed by and construed in accordance with the Laws of such State applicable to contracts to be made and performed entirely within such State. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(h)&#8195;<u>Jurisdiction</u>. In any action or proceeding between any of the parties hereto arising out of or relating to this Agreement or any of the transactions contemplated hereby, each of the parties hereto: (i) irrevocably and unconditionally consents and submits to the exclusive jurisdiction and venue of the Court of Chancery of the State of Delaware located in New Castle County or, to the extent such court does not have subject matter jurisdiction, the United States District Court for the District of Delaware or, to the extent that neither of the foregoing courts has jurisdiction, the Superior Court of the State of Delaware; (ii) agrees that all claims in respect of such action or proceeding shall be heard and determined exclusively in accordance with clause (i) of this <u>Section&#160;&#8206;12(h)</u>; (iii) waives any objection to laying venue in any such action or proceeding in such courts; (iv)&#160;waives any objection that such courts are an inconvenient forum or do not have jurisdiction over any party; and (v) agrees that service of process upon such party in any such action or proceeding shall be effective if notice is given in accordance with <u>Section&#160;&#8206;12(e)</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(i)&#8195;<u>Waiver of Jury Trial</u>. Each of the parties hereto hereby irrevocably waives any and all right to trial by jury in any legal proceeding arising out of or related to this Agreement or the transactions contemplated hereby. Each party certifies and acknowledges that (i) no representative, agent or attorney of any other party has represented, expressly or otherwise, that such other party would not, in the event of litigation, seek to enforce the foregoing waiver, (ii) each party understands and has considered the implication of this waiver, (iii) each party makes this waiver voluntarily, and (iv) each party has been induced to enter into this Agreement by, among other things, the mutual waivers and certifications in this <u>Section&#160;12(i)</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(j)&#8195;<u>Acknowledgements</u>. Each of the parties hereto acknowledges that such party has been represented by counsel of such party&#8217;s choice throughout all negotiations that have preceded the execution of this Agreement, and that such party has executed the same with the advice of such counsel. Each party and such party&#8217;s counsel cooperated and participated in the drafting and preparation of this Agreement and the documents referred to in this Agreement, and any and all drafts relating thereto exchanged among the parties shall be deemed the work product of all of the parties and may not be construed against any party by reason of such party&#8217;s drafting or preparation. Accordingly, any rule of law or any legal decision that would require interpretation of any ambiguities in this Agreement against any party that drafted or prepared it is of no application and is hereby expressly waived by each of the parties hereto. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">D-6<br></div></div></div>
<!--End Page 469-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 470-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_303-annexd_pg7"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(k)&#8195;<u>Entire Agreement</u>. This Agreement, taken together with the Schedules attached hereto and the Merger Agreement to the extent referenced herein, constitutes the entire agreement among the parties hereto with respect to the subject matter of this Agreement, notwithstanding the reference to any other agreement herein, and supersedes all prior agreements and understandings, both written and oral, among or between any of the parties hereto with respect to the subject matter of this Agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(l)&#8195;<u>Interpretation</u>. The rules of construction set forth in Section&#160;8.11 of the Merger Agreement shall apply to this Agreement, <font style="font-style: italic;">mutatis mutandis</font>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(m)&#8195;<u>Expenses</u>. Except as otherwise expressly provided in this Agreement or the Merger Agreement, all fees and expenses incurred in connection with this Agreement and the transactions contemplated hereby shall be paid by the party hereto incurring such fees or expenses. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(n)&#8195;<u>No Recourse</u>. This Agreement may only be enforced against, and any claims or causes of action that may be based upon, arise out of or relate to this Agreement, or the negotiation, execution or performance of this Agreement, may only be made against, the Persons that are expressly identified as parties hereto and no former, current or future equity holders, controlling persons, directors, officers, employees, agents or Affiliates of any party hereto or any former, current or future stockholder, controlling person, director, officer, employee, general or limited partner, member, manager, agent or Affiliate of any of the foregoing shall have any liability for any obligations or liabilities of the parties to this Agreement or for any claim (whether in tort, contract or otherwise) based on, in respect of, or by reason of, the transactions contemplated hereby or in respect of any representations made or alleged to be made in connection herewith. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">13.&#8195;<font style="font-weight: bold;">Counterparts</font>. This Agreement may be signed in any number of counterparts, each of which will be deemed an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. This Agreement or any counterpart may be executed and delivered by electronic communications by portable document format (.pdf), each of which shall be deemed an original. This Agreement will become effective when each party hereto will have received a counterpart hereof signed by the other parties hereto. Until and unless each party has received a counterpart hereof signed by the other party hereto, this Agreement will have no effect and no party will have any right or obligation hereunder (whether by virtue of any oral or written agreement or any other communication). </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">14.&#8195;<font style="font-weight: bold;">Stockholder Obligations Several and Not Joint</font>. The obligations of each Stockholder hereunder shall be several and not joint, and no Stockholder shall be liable for any breach of the terms of this Agreement by any other Stockholder. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">15.&#8195;<font style="font-weight: bold;">Action by Parent</font>. Actions taken under this Agreement on behalf of Parent will be taken only with the approval of the Parent Special Committee (if such committee is in existence at the time such action is to be taken). </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">16.&#8195;<font style="font-weight: bold;">No Ownership Interest</font>. Each Stockholder, solely as to itself and not as to any other Stockholder or other Person, has agreed to enter into this Agreement and act in the manner specified in this Agreement for consideration. Except as expressly set forth in this Agreement, all rights and all ownership and economic benefits of and relating to each Stockholder&#8217;s Covered Shares will remain vested in and belong to such Stockholder, and nothing herein will, or will be construed to, grant Parent, Merger Sub or the Company any power, sole or shared, to direct or control the voting or disposition of any of such Covered Shares. Nothing in this Agreement will be interpreted as creating or forming a &#8220;group&#8221; with any other Person, including other holders listed on <u>Schedule A</u>, for purposes of Rule&#160;13d-5(b)(1) of the Exchange Act or any other similar provision of applicable Law. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">17.&#8195;<font style="font-weight: bold;">Disclosure</font>. Each Stockholder hereby (a) authorizes Parent and the Company to publish and disclose in any announcement or disclosure required by the SEC or other applicable Law and in the Proxy Statement/Prospectus filed by Parent such Stockholder&#8217;s identity and ownership of the Covered Shares and the nature of such Stockholder&#8217;s obligations under this Agreement and (b) agrees to promptly give to Parent any information it may reasonably require for the preparation of any such announcement or disclosure; <u>provided</u>, <u>however</u>, that each of the Company and Parent hereby agree that any such announcement or disclosure, if relating to such Stockholder or any designee of any Stockholder, who serves as a member of or observer to the Parent Board or as an officer of Parent, or such Stockholder&#8217;s or any designee&#8217;s or observer&#8217;s involvement in or awareness of the transactions contemplated by this Agreement or the Merger Agreement, shall, to the extent practicable, be subject to such Stockholder&#8217;s advance review and reasonable approval before its public filing, issuance or dissemination (collectively, including the Proxy Statement/Prospectus, &#8220;<font style="font-weight: bold;">Public Disclosure</font>&#8221;). Drafts of any Public Disclosure shall be delivered to the Stockholders for review not less than three (3) Business Days (or, in the case of an exigent filing or release, twenty-four (24) hours) prior to the intended filing, issuance or dissemination. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">18.&#8195;<font style="font-weight: bold;">Further Assurances</font>. Each of the parties hereto shall execute and deliver, or cause to be executed and delivered, all further documents and instruments and use their respective reasonable best efforts to take, or cause to be taken, all actions and to do, or cause to be done, all things necessary under applicable Law to perform their respective obligations as expressly set forth under this Agreement. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; text-align: center;">[<font style="font-style: italic;">The remainder of this page is intentionally left blank; signature pages follow.</font>] </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">D-7<br></div></div></div>
<!--End Page 470-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 471-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_303-annexd_pg8"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first written above. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_txtann" style="width: 528pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 228pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 288pt;" colspan="4"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr><td style="width: 228pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td colspan="4" style="width: 288pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">TREELINE BIOSCIENCES, INC.<font style="font-weight: normal;"> </font></div></td></tr><tr><td style="width: 228pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 271pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 228pt; padding-top: 0.67pt; padding-bottom: 1.75pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5pt; padding-top: 0.67pt; padding-bottom: 1.75pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By:</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 271pt; padding-top: 0.67pt; padding-bottom: 1.75pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 228pt; padding-top: 1.42pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5pt; padding-top: 1.42pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name:</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 271pt; padding-top: 1.42pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 228pt; padding-top: 0.67pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5pt; padding-top: 0.67pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Title:</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 271pt; padding-top: 0.67pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 3pt; width: 228pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 271pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">D-8<br></div></div></div>
<!--End Page 471-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 472-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_303-annexd_pg9"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first written above. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_txtann" style="width: 528pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 228pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 288pt;" colspan="4"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr><td style="width: 228pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td colspan="4" style="width: 288pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">STANDARD BIOTOOLS INC.<font style="font-weight: normal;"> </font></div></td></tr><tr><td style="width: 228pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 271pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 228pt; padding-top: 0.67pt; padding-bottom: 1.75pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5pt; padding-top: 0.67pt; padding-bottom: 1.75pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By:</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 271pt; padding-top: 0.67pt; padding-bottom: 1.75pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 228pt; padding-top: 1.42pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5pt; padding-top: 1.42pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name: </div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 271pt; padding-top: 1.42pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 228pt; padding-top: 0.67pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5pt; padding-top: 0.67pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Title:</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 271pt; padding-top: 0.67pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 3pt; width: 228pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 271pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">D-9<br></div></div></div>
<!--End Page 472-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 473-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_303-annexd_pg10"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first written above. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_txtann" style="width: 528pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 228pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 288pt;" colspan="4"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr><td style="width: 228pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td colspan="4" style="width: 288pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">SIRI MERGER SUB, INC.<font style="font-weight: normal;"> </font></div></td></tr><tr><td style="width: 228pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 271pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 228pt; padding-top: 0.67pt; padding-bottom: 1.75pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5pt; padding-top: 0.67pt; padding-bottom: 1.75pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By:</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 271pt; padding-top: 0.67pt; padding-bottom: 1.75pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 228pt; padding-top: 1.42pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5pt; padding-top: 1.42pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name:</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 271pt; padding-top: 1.42pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 228pt; padding-top: 0.67pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5pt; padding-top: 0.67pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Title:</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 271pt; padding-top: 0.67pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 3pt; width: 228pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 271pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">D-10<br></div></div></div>
<!--End Page 473-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 474-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_303-annexd_pg11"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first written above. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_txtann" style="width: 528pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 228pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 288pt;" colspan="4"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr><td style="width: 228pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td colspan="4" style="width: 288pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">[STOCKHOLDER]<font style="font-weight: normal;"> </font></div></td></tr><tr><td style="width: 228pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 271pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 228pt; padding-top: 0.67pt; padding-bottom: 1.75pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td colspan="4" style="width: 288pt; padding-top: 0.67pt; padding-bottom: 1.75pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 228pt; padding-top: 1.42pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5pt; padding-top: 1.42pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name:</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 271pt; padding-top: 1.42pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 228pt; padding-top: 0.67pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5pt; padding-top: 0.67pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Title:</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 271pt; padding-top: 0.67pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 3pt; width: 228pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 271pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">D-11<br></div></div></div>
<!--End Page 474-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 475-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_304-annexe_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: right;"><a name="tANE"><!--Anchor--></a>Annex&#160;E </div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 19.5pt; text-align: center;">FORM OF LOCK-UP AGREEMENT<br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-weight: normal;">&#8195;</font><br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-weight: normal;">June&#160;6, 2026</font></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">Ladies and Gentlemen: </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The undersigned stockholder (the &#8220;<u>Undersigned</u>&#8221;) to this lock-up agreement (this &#8220;<u>Lock-Up Agreement</u>&#8221;) understands that Standard BioTools Inc., a Delaware corporation (&#8220;<u>Parent</u>&#8221;), has entered into an Agreement and Plan of Merger and Reorganization, dated as of June&#160;6, 2026 (as the same may be amended from time to time, the &#8220;<u>Merger Agreement</u>&#8221;) with Siri Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent, and Treeline Biosciences, Inc., a Delaware corporation (the &#8220;<u>Company</u>&#8221;). Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to such terms in the Merger Agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">As a condition and inducement to each of Parent and the Company to enter into the Merger Agreement and to consummate the transactions contemplated thereby, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Undersigned hereby irrevocably agrees that, subject to the exceptions set forth herein, without the prior written consent of Parent, the Undersigned will not, during the period commencing upon the Closing and ending on the date that is 180 days after the Closing Date (the &#8220;<u>Restricted Period</u>&#8221;): </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">(1)&#8195;offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Parent Common Stock or any securities convertible into or exercisable or exchangeable for shares of Parent Common Stock (including without limitation, shares of Parent Common Stock or such other securities of Parent which may be deemed to be beneficially owned by the Undersigned in accordance with the rules and regulations of the SEC and securities of Parent which may be issued upon exercise of an option to purchase shares of Parent Common Stock or a warrant to purchase shares of Parent Common Stock) that are currently or hereafter owned by the Undersigned, except as set forth below (collectively, the &#8220;<u>Undersigned&#8217;s </u><u>Shares</u>&#8221;); </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">(2)&#8195;enter into any swap, short sale, hedge or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Undersigned&#8217;s Shares regardless of whether any such transaction described in clause (1) above or this clause (2) is to be settled by delivery of shares of Parent Common Stock or other securities, in cash or otherwise; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">(3)&#8195;make any demand for, or exercise any right with respect to, the registration of any shares of Parent Common Stock or any security convertible into or exercisable or exchangeable for shares of Parent Common Stock (other than such rights set forth in the Merger Agreement); or </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">(4)&#8195;publicly disclose the intention to do any of the foregoing. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">The restrictions and obligations contemplated by this Lock-Up Agreement shall not apply to: </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-indent: 40pt; text-align: left;">(a)&#8195;transfers of the Undersigned&#8217;s Shares: </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(1)&#8195;(A) to any person related to the Undersigned (or to an ultimate beneficial owner of the Undersigned) by blood or adoption who is an immediate family member of the Undersigned, or by marriage or domestic partnership (a &#8220;<u>Family Member</u>&#8221;), or to a trust formed for the benefit of the Undersigned or any of the Undersigned&#8217;s Family Members, (B) to the Undersigned&#8217;s estate, following the death of the Undersigned, by will, other testamentary document, intestacy or other operation of Law, (C) as a bona fide gift or a charitable contribution, (D)&#160;by operation of Law such as pursuant to a qualified domestic order or in connection with a divorce settlement or (E)&#160;to any partnership, corporation, limited liability company, investment fund or other entity which is controlled by or under common control with the Undersigned and/or by any such Family Member(s); </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(2)&#8195;if the Undersigned is a corporation, partnership, limited liability company or other entity, (A) to another corporation, partnership, limited liability company, trust or other entity that is a direct or indirect affiliate (as defined under Rule&#160;12b-2 of the Exchange Act) of the Undersigned, including investment funds or other entities that control or manage, are under common control or management with, or are controlled or managed by, the Undersigned or affiliates of the Undersigned (including, for the avoidance of doubt, where the Undersigned is a partnership, to its general partner or a successor partnership or fund, or any other funds managed by such partnership), (B) as a distribution or dividend to equity holders, current or former general or limited partners, members, managers, beneficiaries or shareholders (or to the estates of any of the foregoing), as applicable, of the Undersigned (including upon the liquidation and dissolution of the Undersigned pursuant to a plan of liquidation approved by the Undersigned&#8217;s equity holders), (C) as a bona fide gift or a charitable contribution or otherwise to a trust or other entity for the direct or indirect benefit of an immediate family member of a beneficial owner (as defined in Rule&#160;13d-3 of the Exchange Act) of the Undersigned&#8217;s Shares, (D) transfers or dispositions not involving a change in beneficial ownership , (E) to a nominee or custodian of a person or entity to whom a transfer or distribution would be permissible under this clause (a) or, (F) with the prior written consent of Parent; or </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(3)&#8195;if the Undersigned is a trust, to any grantors or beneficiaries of the trust; <u>provided</u> that, in the case of any transfer or distribution pursuant to this clause (a), such transfer is not for value (other than transfers pursuant to clause (a)(1)(A), clause (a)(1)(E), clause (a)(2)(A) or clause (a)(2)(F)) and each donee, heir, beneficiary or other transferee or distributee shall sign and deliver to Parent a lock-up agreement substantially in the form of this Lock-Up Agreement with respect to the shares of Parent Common Stock or such other securities that have been so transferred or distributed; </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">E-1<br></div></div></div>
<!--End Page 475-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 476-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_304-annexe_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;the exercise of an option to purchase shares of Parent Common Stock (including net or cashless exercise of an option to purchase shares of Parent Common Stock) and any related transfer of shares of Parent Common Stock to Parent for the purpose of paying the exercise price of such options or for paying taxes (including estimated taxes) due as a result of the exercise of such options; <u>provided</u> that, for the avoidance of doubt, the underlying shares of Parent Common Stock shall continue to be subject to the restrictions on transfer set forth in this Lock-Up Agreement; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(c)&#8195;transfers of shares of Parent Common Stock sold in open market transactions during the Restricted Period to generate such amount of net proceeds to the Undersigned from such sales (after deducting any commissions) in an aggregate amount up to the total amount of taxes or estimated taxes (as applicable) that become due as a result of the vesting of Parent restricted stock units or the exercise of any Parent stock options during the Restricted Period; <u>provided</u> that, for the avoidance of doubt, the underlying shares of Parent Common Stock shall continue to be subject to the restrictions on transfer set forth in this Lock-Up Agreement; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(d)&#8195;transfers to Parent in connection with the net settlement of any other equity award that represents the right to receive in the future shares of Parent Common Stock, settled in shares of Parent Common Stock, to pay any tax withholding obligations; <u>provided</u> that, for the avoidance of doubt, the underlying shares of Parent Common Stock shall continue to be subject to the restrictions on transfer set forth in this Lock-Up Agreement; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(e)&#8195;(1) transfers of shares of Parent Common Stock pursuant to any contract, instruction or plan in effect on the date hereof that satisfies the requirements of Rule&#160;10b5-1 under the Exchange Act (a &#8220;<u>Rule&#160;10b5-1 Plan</u>&#8221;) and (2) the establishment, modification or amendment of a Rule&#160;10b5-1 Plan for the transfer of shares of Parent Common Stock; <u>provided</u> that such plan does not provide for any transfers of shares of Parent Common Stock during the Restricted Period; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(f)&#8195;pledges of the Undersigned&#8217;s Shares as collateral or security for any loan or similar financing activity with one or more banks, financial institutions, or lending institutions in effect as of the Closing Date; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(g)&#8195;transfers, distributions, sales or other transactions by the Undersigned of shares of Parent Common Stock purchased by the Undersigned on the open market or in a public offering by Parent following the Effective Time; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(h)&#8195;transfers by the Undersigned of shares of Parent Common Stock purchased by the Undersigned prior to the Effective Time that are unrelated to those shares of Parent Common Stock to be issued as consideration pursuant to the Merger Agreement; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(i)&#8195;transfers of the Undersigned&#8217;s Shares pursuant to a bona fide third party tender offer, merger, consolidation or other similar transaction made to all holders of Parent&#8217;s capital stock involving a change of control of Parent, and the Undersigned may enter into any lock-up, voting or similar agreement pursuant to which the Undersigned may agree to transfer, sell, tender or otherwise dispose of the Undersigned&#8217;s Shares in connection with such transaction; <u>provided</u> that in the event that such tender offer, merger, consolidation or other such transaction is not completed, the Undersigned&#8217;s Shares shall remain subject to the restrictions contained in this Lock-Up Agreement; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-indent: 40pt; text-align: left;">(j)&#8195;transfers of the Undersigned&#8217;s Shares pursuant to an order of a court or regulatory agency; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(k)&#8195;transfers of the Undersigned&#8217;s Shares to Parent pursuant to any agreement or arrangement under which Parent has the option to repurchase such Undersigned&#8217;s Shares or a right of first refusal with respect to transfers of such Undersigned&#8217;s Shares or there is a forfeiture of the Undersigned&#8217;s Shares, in each case upon termination of service of the Undersigned; or </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(l)&#8195;any shares of Parent Common Stock or other securities acquired after the Closing Date; <u>provided</u>, further, that, with respect to each of (a), (b), (c), (d) and (e) above, (x) other than with respect to clause (a), no filing by any party (including any donor, donee, transferor, transferee, distributor or distributee) under Section&#160;16 of the Exchange Act or other public announcement shall be made voluntarily reporting a reduction in beneficial ownership of shares of Parent Common Stock or any securities convertible into or exercisable or exchangeable for Parent Common Stock in connection with such transfer or disposition during the Restricted Period (other than any exit filings or a filing on a Form&#160;5 made after the expiration of the Restricted Period), and (y) if any filing under Section&#160;16(a) of the Exchange Act, or other public filing, report or announcement reporting a reduction in beneficial ownership of shares of Parent Common Stock in connection with such transfer or distribution, shall be legally required during the Restricted Period, such filing, report or announcement shall clearly indicate in the footnotes therein, in reasonable detail, a description of the circumstances of the transfer and that the shares remain subject to the lock-up agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">For purposes of this Lock-Up Agreement, &#8220;change of control&#8221; shall mean the transfer (whether by tender offer, merger, consolidation or other similar transaction), in one transaction or a series of related transactions, to a person or group of affiliated persons, of Parent&#8217;s voting securities if, after such transfer, Parent&#8217;s stockholders as of immediately prior to such transfer do not hold a majority of the outstanding voting securities of Parent (or the surviving entity). </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">In addition, in the event that, during the Restricted Period, any release or waiver of the foregoing restrictions is granted in respect of shares of Parent Common Stock held by an executive officer or director or other person who has executed a lock-up agreement in substantially the same form as this Lock-Up Agreement (a &#8220;<u>Discretionary Release</u>&#8221;), Parent agrees that the same percentage of shares of Parent Common Stock held by the Undersigned shall be released on the same terms from the lock-up restrictions set forth in this Lock-Up Agreement.<br></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The provisions of this paragraph will not apply if (1)(a) the Discretionary Release is effected solely to permit a transfer not for consideration and (b)&#160;the transferee has agreed in writing to be bound by the same terms described in this Lock-Up Agreement to the extent and for the duration that such terms remain in effect at the time of the transfer, or (2) the Discretionary Release is granted to any individual party or a collection of individual parties by Parent in an aggregate amount less than or equal to 1% of Parent&#8217;s total then outstanding shares of Parent Common Stock (calculated on an </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">E-2<br></div></div></div>
<!--End Page 476-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 477-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_304-annexe_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">as-converted, fully-diluted basis); <u>provided further</u> that if the Discretionary Release is granted to any stockholder in connection with any public offering that is wholly or partially a secondary follow-on public offering (a &#8220;<u>Follow-on Offering</u>&#8221;) of shares of Parent Common Stock pursuant to a registration statement that is filed with the SEC and the Undersigned has been given the opportunity to participate in such Follow-on Offering on a pro rata basis and otherwise on the same terms as any other equity holders participating in such Follow-on Offering, then the provisions of this paragraph shall only apply with respect to the Undersigned&#8217;s participation in such Follow-on Offering. The Company will notify the Undersigned of a Discretionary Release at least two business days prior to the Discretionary Release. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Any attempted transfer in violation of this Lock-Up Agreement will be of no effect and null and void, regardless of whether the purported transferee has any actual or constructive knowledge of the transfer restrictions set forth in this Lock-Up Agreement, and will not be recorded on the share register of Parent. In furtherance of the foregoing, the Undersigned agrees that Parent and any duly appointed transfer agent for the registration or transfer of the securities described herein are hereby authorized to decline to make any transfer of securities if such transfer would constitute a violation or breach of this Lock-Up Agreement. Parent may cause the legend set forth below, or a legend substantially equivalent thereto, to be placed upon any certificate(s) or other documents, ledgers or instruments evidencing the Undersigned&#8217;s ownership of Parent Common Stock: </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO AND MAY ONLY BE TRANSFERRED IN COMPLIANCE WITH A LOCK-UP AGREEMENT, A COPY OF WHICH IS ON FILE AT THE PRINCIPAL OFFICE OF THE COMPANY. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The Undersigned hereby represents and warrants that the Undersigned has full power and authority to enter into this Lock-Up Agreement. All authority herein conferred or agreed to be conferred and any obligations of the Undersigned shall be binding upon the successors, assigns, heirs or personal representatives of the Undersigned. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Upon the release of any of the Undersigned&#8217;s Shares from this Lock-Up Agreement, Parent will promptly cooperate with the Undersigned to facilitate the timely preparation and delivery of certificates or book-entry positions representing the Undersigned&#8217;s Shares without the restrictive legend above and the withdrawal of any stop transfer instructions imposed by virtue of this Lock-Up Agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The Undersigned understands that if the Merger Agreement is terminated for any reason, the Undersigned shall be released from all obligations under this Lock-Up Agreement. The Undersigned understands that Parent is proceeding with the transactions contemplated by the Merger Agreement in reliance upon this Lock-Up Agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Except as otherwise provided herein, any and all remedies herein expressly conferred upon a party will be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by law or equity upon such party, and the exercise by a party of any one remedy will not preclude the exercise of any other remedy. The parties agree that irreparable damage for which monetary damages, even if available, would not be an adequate remedy, would occur in the event that any of the provisions of this Lock-Up Agreement were not performed in accordance with their specific terms (including failing to take such actions as are required of it hereunder to consummate this Lock-Up Agreement) or were otherwise breached. It is accordingly agreed that the parties shall be entitled to an injunction or injunctions to prevent breaches of this Lock-Up Agreement and to enforce specifically the terms and provisions hereof in any court of the United States or any state having jurisdiction, this being in addition to any other remedy to which they are entitled at law or in equity, and each of the parties waives any bond, surety or other security that might be required of any other party with respect thereto. Each of the parties further agrees that it will not oppose the granting of an injunction, specific performance or other equitable relief on the basis that any other party has an adequate remedy at law or that any award of specific performance is not an appropriate remedy for any reason at law or in equity. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">This Lock-Up Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, regardless of the laws that might otherwise govern under applicable principles of conflicts of laws. In any action or proceeding between any of the parties arising out of or relating to this Lock-Up Agreement, each of the parties: (i) irrevocably and unconditionally consents and submits to the exclusive jurisdiction and venue of the Court of Chancery of the State of Delaware or, to the extent such court does not have subject matter jurisdiction, the Superior Court of the State of Delaware or the United States District Court for the District of Delaware, (ii) agrees that all claims in respect of such action or proceeding shall be heard and determined exclusively in accordance with the foregoing clause (i) of this paragraph, (iii) waives any objection to laying venue in any such action or proceeding in such courts, (iv) waives any objection that such courts are an inconvenient forum or do not have jurisdiction over any party and (v) irrevocably and unconditionally waives the right to trial by jury. This Lock-Up Agreement constitutes the entire agreement between the parties to this Lock-Up Agreement and supersedes all other prior agreements, arrangements and understandings, both written and oral, among the parties with respect to the subject matter hereof. This Lock-Up Agreement may be executed in several counterparts, each of which shall be deemed an original and all of which shall constitute one and the same instrument. The exchange of a fully executed Lock-Up Agreement (in counterparts or otherwise) by all parties by facsimile or electronic transmission in PDF format shall be sufficient to bind the parties to the terms and conditions of this Lock-Up Agreement. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-style: italic; margin-top: 8.5pt; text-align: center;">[SIGNATURE PAGE FOLLOWS]<font style="font-style: normal;"> </font></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">E-3<br></div></div></div>
<!--End Page 477-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 478-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_304-annexe_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_txtann" style="width: 528pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 156pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 108pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 240pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr><td style="width: 156pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 108pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 240pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Very truly yours, </div></td></tr><tr><td style="width: 156pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 108pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 240pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 156pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 108pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Print Name of Stockholder: </div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 240pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 156pt; padding-top: 0.67pt; padding-bottom: 1.75pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 108pt; padding-top: 0.67pt; padding-bottom: 1.75pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 240pt; padding-top: 0.67pt; padding-bottom: 1.75pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 156pt; padding-top: 1.42pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 108pt; padding-top: 1.42pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 240pt; padding-top: 1.42pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Signature (for individuals): </div></td></tr><tr><td style="width: 156pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 108pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 240pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 156pt; padding-top: 0.67pt; padding-bottom: 1.75pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 108pt; padding-top: 0.67pt; padding-bottom: 1.75pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 240pt; padding-top: 0.67pt; padding-bottom: 1.75pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 156pt; padding-top: 1.42pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 108pt; padding-top: 1.42pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 240pt; padding-top: 1.42pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Signature (for entities): </div></td></tr><tr><td style="width: 156pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 108pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 240pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By:</div></td></tr><tr><td style="width: 156pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 108pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 240pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name:</div></td></tr><tr><td style="width: 156pt; padding-top: 0.67pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 108pt; padding-top: 0.67pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 240pt; padding-top: 0.67pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Title:</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 3pt; width: 156pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 108pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 240pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 528pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-style: italic; margin-top: 10.73pt; text-align: center;">[Signature Page to Lock-Up Agreement]<br></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">E-4<br></div></div></div>
<!--End Page 478-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 479-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_304-annexe_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_txtann" style="width: 528pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 252pt;" colspan="4"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 264pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr><td colspan="4" style="width: 252pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Acknowledged and Agreed:</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 264pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 5pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 235pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 264pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td colspan="4" style="width: 252pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">STANDARD BIOTOOLS INC.</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 264pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 5pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 235pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 264pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 5pt; padding-top: 0.67pt; padding-bottom: 1.75pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By:</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 235pt; padding-top: 0.67pt; padding-bottom: 1.75pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 264pt; padding-top: 0.67pt; padding-bottom: 1.75pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 5pt; padding-top: 1.42pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name:</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 235pt; padding-top: 1.42pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 264pt; padding-top: 1.42pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 5pt; padding-top: 0.67pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Title:</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 235pt; padding-top: 0.67pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 264pt; padding-top: 0.67pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 3pt; width: 5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 235pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 264pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 528pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-style: italic; margin-top: 10.73pt; text-align: center;">[Signature Page to Lock-Up Agreement]<br></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">E-5<br></div></div></div>
<!--End Page 479-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 480-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_305-annexf_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: right;"><a name="tANF"><!--Anchor--></a>Annex&#160;F </div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 13pt; text-align: center;">FORM OF CONTINGENT VALUE RIGHTS AGREEMENT </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-variant: small-caps; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">This Contingent Value Rights Agreement<font style="font-variant: normal;"> </font><font style="font-variant: normal; font-weight: normal;">(this &#8220;</font><font style="font-variant: normal;">Agreement</font><font style="font-variant: normal; font-weight: normal;">&#8221;), dated as of [&#8226;] (the &#8220;</font><font style="font-variant: normal;">Effective Date</font><font style="font-variant: normal; font-weight: normal;">&#8221;), is entered into by and between Treeline Biosciences Holdings, Inc., a Delaware corporation (&#8220;</font><font style="font-variant: normal;">Parent</font><font style="font-variant: normal; font-weight: normal;">&#8221;), and [&#8226;], a [&#8226;], as Rights Agent (as defined herein). </font></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 13.5pt; text-align: center;">RECITALS </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">A.&#8195;Parent, Siri Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (&#8220;<font style="font-weight: bold;">Merger Sub</font>&#8221;), and Treeline Biosciences, Inc., a Delaware corporation (the &#8220;<font style="font-weight: bold;">Company</font>&#8221;), have entered into an Agreement and Plan of Merger and Reorganization, dated as of June&#160;6, 2026 (as it may be amended, supplemented or otherwise modified from time to time pursuant to the terms thereof, the &#8220;<font style="font-weight: bold;">Merger Agreement</font>&#8221;), pursuant to which Merger Sub will merge with and into the Company (the &#8220;<font style="font-weight: bold;">Merger</font>&#8221;), with the Company surviving the Merger as a wholly owned Subsidiary of Parent. Capitalized terms used but not otherwise defined herein have the meanings ascribed thereto in the Merger Agreement.&#8195;</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">B.&#8195;Pursuant to the Merger Agreement, and in accordance with the terms and conditions thereof, prior to the Effective Time, Parent may declare a dividend (the &#8220;<font style="font-weight: bold;">Closing Dividend</font>&#8221;) to its stockholders of record of one contingent value right for each outstanding share of Parent Common Stock held by such stockholder as of the close of business on the CVR Record Date, representing the right to receive contingent payments upon the occurrence of certain events set forth in, and subject to and in accordance with the terms and conditions of, this Agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">C.&#8195;Prior to the Effective Date, Parent has declared the Closing Dividend, with the payment of the Closing Dividend expressly conditioned upon the occurrence of the Effective Time. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">D.&#8195;The parties to this Agreement have done all things reasonably necessary to make the contingent value rights, when issued hereunder, the valid obligations of Parent and to make this Agreement a valid and binding agreement of Parent, in accordance with its terms. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-variant: small-caps; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Now, Therefore<font style="font-variant: normal; font-weight: normal;">, in consideration of the premises and the consummation of the transactions referred to above, it is mutually covenanted and agreed, for the proportionate benefit of all Holders, as follows: </font></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 13.5pt; text-align: center;">ARTICLE 1 <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">DEFINITIONS </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">1.1&#8195;Definitions<font style="font-weight: normal;">.</font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following terms have the meanings ascribed to them as follows:</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Acting Holders</font>&#8221; means, at any time, the registered Holders of more than 30% of the total number of CVRs outstanding at such time, as set forth on the CVR Register.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Affiliate</font>&#8221; of any Person means another Person that directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with, such first Person. For purposes of this definition, &#8220;control,&#8221; when used with respect to any specified Person, means the power to direct or cause the direction of the management and policies of such Person, directly or indirectly, whether through ownership of voting securities or by Contract or otherwise, and the terms &#8220;controlling&#8221; and &#8220;controlled by&#8221; have correlative meanings to the foregoing.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;<font style="font-weight: bold;">Assignee</font>&#8221; has the meaning set forth in <u>Section&#160;6.6</u>.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Business Day</font>&#8221; means any day other than a Saturday, Sunday or other day on which banks in New York, New York are authorized or obligated by Law to be closed.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;<font style="font-weight: bold;">CVR</font>&#8221; means a contingent contractual right of Holders to receive the CVR Payments pursuant to this Agreement.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">CVR Accounting Principles</font>&#8221; means GAAP applied in a manner consistent with the accounting principles, policies, procedures and methodologies used by Parent (to the extent in accordance with GAAP) in the preparation of its most recently publicly filed with the SEC annual audited financial statements of Parent.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">CVR Payment</font>&#8221; means, for any CVR Payment Period, a number of shares of Parent Common Stock equal to the quotient of (a) the aggregate Net Proceeds actually received by Parent and its Affiliates during such CVR Payment Period <font style="font-style: italic;">divided by</font> (b) the Reference Price, subject to <u>Section&#160;2.7</u>; <u>provided</u>, that in no event will the aggregate number of shares of Parent Common Stock distributed pursuant to this Agreement across all CVR Payment Periods exceed 76,000,000 shares (the &#8220;<font style="font-weight: bold;">Share Cap</font>&#8221;).</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">CVR Payment Period</font>&#8221; means each of the following consecutive periods occurring during the CVR Term: (i) the period commencing on the Effective Date and ending on the 12-month anniversary of the Effective Date and (ii) each successive 12-month period thereafter during the CVR Term.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">CVR</font> <font style="font-weight: bold;">Payment Statement</font>&#8221; means, for a given CVR Payment Period during the CVR Term, a written statement of Parent, signed on behalf of Parent, certifying to and setting forth in reasonable detail and with supporting calculations (i) the Gross Proceeds received by Parent and its Affiliates during such CVR Payment Period, (ii) the Permitted Deductions for such CVR Payment Period and the resulting calculation of Net Proceeds for such CVR Payment Period and (iii) the resulting aggregate CVR Payment payable to Holders, if any, in respect of such Net Proceeds for such CVR Payment Period.</div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-1<br></div></div></div>
<!--End Page 480-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 481-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_305-annexf_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;<font style="font-weight: bold;">CVR Register</font>&#8221; has the meaning set forth in <u>Section&#160;2.2(b)</u>.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;<font style="font-weight: bold;">CVR Term</font>&#8221; means the period beginning on the Effective Date and ending on the fifth anniversary of the Effective Date.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Disposition</font>&#8221; means the sale, license, transfer, disposition, divestiture or other monetization transaction (including any disposition providing for earnout payments, milestone payments, royalty payments, contingent payments or similar payments received pursuant to licensing or other arrangements) to a third party of any Legacy Asset by Parent or its Affiliates.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;<font style="font-weight: bold;">Disposition Agreement</font>&#8221; means any definitive agreement with respect to a Parent Legacy Transaction.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Existing Legal Proceeding</font>&#8221; means any Legal Proceeding pending, threatened or settled as of the Effective Time involving Parent or any of its current or former Subsidiaries or any current or former officer, employee, or director, of or to Parent or any of its current or former Subsidiaries or controlled Parent Affiliates (in his or her capacity as such), including any demands for disclosure or other remedies in connection with the Merger.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Gross Proceeds</font>&#8221; means, for any CVR Payment Period, without duplication, the sum of: (i) any proceeds actually received by Parent and its Affiliates during such CVR Payment Period (whether upfront or in the form of earnout, milestone, royalty, contingent or other similar payments) under a Disposition Agreement, (ii) any proceeds actually received by Parent and its Affiliates during such CVR Payment Period from the conversion, repayment, redemption or disposition of, or otherwise relating to or derived from, any convertible notes or other investments held by Parent or its Affiliates in another Person as of the Effective Date, (iii) any third-party earnout, milestone, royalties, contingent or other similar payments actually received by Parent and its Affiliates during such CVR Payment Period under Contracts of Parent or its Affiliates in effect as of the Effective Date (including any Illumina Payment Amounts), in each case that were not included in the calculation of Parent Net Cash pursuant to the Merger Agreement and (iv) any Final Parent Net Cash Surplus (which Final Parent Net Cash Surplus shall, for the avoidance of doubt, only be included in the calculation of Gross Proceeds for one CVR Payment Period); <u>provided</u> that, for the avoidance of doubt, Gross Proceeds shall not include any amounts that are Incidental Benefits. Non-cash proceeds shall only constitute Gross Proceeds to the extent they are either (A) equity securities listed and traded on a national stock exchange and without restrictions on transfer, in which case they shall have such value as quoted on such national securities exchange at the time of receipt of such equity securities by Parent or its applicable Affiliate, or (B) otherwise, disposed of by Parent in accordance with <u>Section&#160;&#8206;4.1</u> during the CVR Term, in which case such non-cash proceeds shall have such value, without duplication, as is received by Parent or its applicable Affiliate, either in cash or equity securities described in the preceding clause (A), in respect of any disposition thereof.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;<font style="font-weight: bold;">Holder</font>&#8221; means, at the relevant time, a Person in whose name one or more CVRs are registered in the CVR Register.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Holder Representative</font>&#8221; means the Legacy Parent Directors or any nationally recognized securityholder representation firm appointed by Parent pursuant to Section&#160;8.13 of the Merger Agreement.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;<font style="font-weight: bold;">Illumina Agreement</font>&#8221; means that certain Stock Purchase Agreement, dated June&#160;22, 2025, by and between Parent and Illumina, Inc.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Illumina Payment Amounts</font>&#8221; means the aggregate cash payment amounts received by Parent from Illumina, Inc. following the Effective Time pursuant to Sections 2.4, 2.5 and 2.7 of the Illumina Agreement.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;<font style="font-weight: bold;">Incidental Benefits</font>&#8221; means any amounts paid to, received or realized by Parent that are: </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;Tax attributes, Tax refunds, Tax credits, Tax deductions or other Tax benefits (including utilization of net operating losses, basis increases, amortization or depreciation deductions, or reductions in Tax liability), in each case generated as a result of any transaction or payment otherwise giving rise to Gross Proceeds, excluding, for the avoidance of doubt, the extent to which any Tax attributes (including net operating losses) that existed as of the Effective Time reduce the amount described in clause (a) of the definition of Permitted Deductions; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;reimbursements or payments for research, development, clinical, regulatory, manufacturing, commercialization, patent or other costs or services; and </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(c)&#8195; other ancillary, indirect or incidental benefits, rights or value received in connection with or arising out of the Disposition Agreement.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Law</font>&#8221; means any federal, state, local, county, regional, foreign or transnational law, statute, regulation, code, ordinance, common law, ruling, writ, award, zoning law, building code or decree of any Governmental Entity.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Legacy Assets</font>&#8221; means all of Parent&#8217;s rights, assets (other than cash and cash equivalents), technology and intellectual property used in or relating to the Parent Legacy Business. For clarity, the Legacy Assets shall not include any rights, assets, technology or intellectual property owned or controlled by the Company or its Subsidiaries prior to the Closing.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Liability</font>&#8221; means any liability, indebtedness, obligation, expense, claim, deficiency, guaranty or endorsement of any kind, whether accrued, absolute, contingent, matured, unmatured or otherwise.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;<font style="font-weight: bold;">Loss</font>&#8221; has the meaning set forth in <u>Section&#160;3.2(g)</u>.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Net Proceeds</font>&#8221; means, for any CVR Payment Period, (i) Gross Proceeds for such CVR Payment Period <u>minus</u> (ii) Permitted Deductions for such CVR Payment Period plus (iii) if any, any Reserve True-Up. For clarity, to the extent Permitted Deductions exceed Gross Proceeds for any CVR Payment Period, any excess Permitted Deductions shall be applied against Gross Proceeds in subsequent CVR Payment Periods.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;<font style="font-weight: bold;">Notice</font>&#8221; has the meaning set forth in <u>Section&#160;&#8206;6.1</u>.</div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-2<br></div></div></div>
<!--End Page 481-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 482-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_305-annexf_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Officer&#8217;s Certificate</font>&#8221; means a certificate signed by the chief executive officer and the chief financial officer of Parent, in their respective official capacities.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Permitted Deductions</font>&#8221; means, for any CVR Payment Period, the sum of, without duplication, in each case only to the extent not included in the calculation of Parent Net Cash and not included in the calculation of Permitted Deductions for any prior CVR Payment Period: </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;any applicable Tax (including any applicable value added or sales taxes) imposed on Gross Proceeds received during such CVR Payment Period or otherwise payable by Parent or any of its Affiliates, including, without duplication, any income or other similar Taxes payable by Parent or any of its Affiliates, in each case that would not have been incurred by Parent or any of its Affiliates but for such Gross Proceeds; <u>provided</u> that, for purposes of calculating income Taxes payable by Parent or any of its Affiliates in respect of the Gross Proceeds, such income Taxes shall be calculated taking into account any and all net operating losses or other Tax attributes generated by Parent or any of its Affiliates (excluding the Company and its Subsidiaries) in a taxable period (or portion thereof) ending on or before the Closing Date that are available under applicable Tax law to offset such income (on a &#8220;more likely than not&#8221; basis), after taking into account any limits on the usability of such Tax attributes, including under Section&#160;382 of the Code; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;any reasonable and documented out-of-pocket costs and expenses incurred in good faith and actually paid by Parent or any of its Affiliates during such CVR Payment Period in connection with the negotiation, entry into and closing of any Disposition Agreement or the Disposition of any Legacy Asset; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(c)&#8195; any reasonable and documented liabilities, costs and expenses incurred in good faith by Parent or any of its Affiliates during such CVR Payment Period in connection with the wind-down, termination or liquidation of all or any part of the Parent Legacy Business, including any such costs and expenses associated with the termination of any Parent Contracts that were in effect immediately prior to the Effective Time, and the costs of performing and servicing any such Contracts after Closing and prior to the termination thereof (including deferred revenues in accordance with the CVR Accounting Principles); </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(d)&#8195;(i) any amount, to the extent paid or reasonably reserved or reasonably accrued in accordance with the CVR Accounting Principles, in respect of such CVR Payment Period (and not previously reserved or paid) on Parent&#8217;s balance sheet, or that Parent determines, acting in good faith and in consultation with the Holder Representative and outside counsel advising the relevant parties on the matter in question, it could reasonably be expected to incur or pay (collectively, &#8220;<font style="font-weight: bold;">Reserved</font>&#8221; amounts and &#8220;<font style="font-weight: bold;">Reserve</font>&#8221; as applicable) with respect to any potential indemnification or warranty obligations under any Disposition Agreement (to the extent in excess of any escrow or holdback thereunder) and, to the extent not included in such amount, any Losses incurred or reasonably expected to be incurred by Parent or any of its Affiliates arising out of any third-party claims, demands, actions, or other proceedings relating to or in connection with any Disposition, including indemnification obligations as set forth in a claims notice received by Parent or any of its Affiliates pursuant to any Disposition Agreement plus (ii) the amount of any reasonable and documented out-of-pocket expenses incurred in good faith and actually paid by Parent or any of its Affiliates during such CVR Payment Period in connection with the matters set forth in clause (i) above solely to the extent such amounts were not included in a Reserved amount taken into account in the calculation of Permitted Deductions with respect to such CVR Payment Period pursuant to clause (i) above or any prior CVR Payment Period; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(e)&#8195;any amounts payable by Parent or any of its Affiliates pursuant to Contracts of Parent representing Legacy Assets during CVR Payment Period, including costs arising from the termination thereof, but determined net of any payments actually received by Parent and any of its Affiliates under the terms of any such Contract during such CVR Payment Period; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(f)&#8195;any amounts payable to the Rights Agent in connection with the distribution of any CVR Payments during such CVR Payment Period; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(g)&#8195;any liabilities that existed (including as contingent liabilities) as of the Closing and that were required to be included in the calculation of Parent Net Cash under the Merger Agreement, to the extent that such liabilities were not so included in such calculation and were not included in the calculation of any Permitted Deductions for any prior CVR Payment Period; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(h)&#8195;any reasonable and documented out-of-pocket costs incurred in good faith and actually paid by Parent or its Affiliates during such CVR Payment Period in enforcing the rights of Parent (or any Affiliate thereof) to receive any Illumina Payment Amounts or in defending any claims by Illumina pursuant to the Illumina Agreement, and any payments required to be made to Illumina or any of its Affiliates in connection with the Illumina Agreement or any such transactions (including with respect to any breach thereof); </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(i)&#8195;(i) any amount, to the extent Reserved or paid, in respect of such CVR Payment Period (and not previously Reserved or paid) with respect to Liabilities arising out of (A) the settlement of any Existing Legal Proceeding; <u>provided</u> that such settlement is entered into with the consent of the Holder Representative, (B) any order, writ, injunction, judgment or decree to which Parent or any of its Affiliates is a party or is otherwise bound relating to any Existing Legal Proceeding or (C) indemnification obligations owed by Parent or any of its Affiliates to any Person related to any Existing Legal Proceedings plus (ii) the amount of any reasonable and documented out-of-pocket expenses incurred in good faith and actually paid by Parent or any of its Affiliates during such CVR Payment Period in connection with the matters set forth in clause&#160;(i) above solely to the extent such amounts were not included in a Reserved amount taken into account in the calculation of Permitted Deductions with respect to such CVR Payment Period pursuant to clause (i) above or any prior CVR Payment Period; and </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(j)&#8195;any amounts payable by Parent or any of its Affiliates to employees described in clauses (ii) and (iii) of the definition of Retained Employee List as set forth in <u>Section&#160;5.23(d)</u> of the Parent Disclosure Schedule (including wages, salaries, bonuses, benefits, severance and the employer portion of any payroll or employment Taxes incurred in connection therewith) during such CVR Payment Period.</div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-3<br></div></div></div>
<!--End Page 482-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 483-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_305-annexf_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">To the extent any deductions set forth in the foregoing paragraphs (a) through (j) are modified by the Wind-Down Schedule, the Wind-Down Schedule shall govern with respect thereto.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Permitted Deductions shall not be available for, and may not include, any Liabilities to the extent reflected in Parent Net Cash.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">In the event that any matter with respect to which a Reserved amount was taken into account in the calculation of Permitted Deductions as provided in clauses <u>(d)(i)</u> and <u>(i)(i)</u> above and such matter is resolved and the amount of any reasonable and documented out-of-pocket expenses incurred in good faith and actually paid, or actually owing, by Parent or any of its Affiliates in respect of such matter is less than the applicable Reserved amount, the difference (a &#8220;<font style="font-weight: bold;">Reserve True-Up</font>&#8221;) (i) shall be credited to, and shall increase, Gross Proceeds for the immediately succeeding CVR Payment Period or (ii) in the event the CVR Term has expired, shall be distributed to the CVR Holders as if the CVR Term was still in effect. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Notwithstanding the foregoing, Permitted Deductions shall not include any Liabilities, costs, expenses or other amounts to the extent arising out of, in connection with, resulting from or otherwise relating to any breach or failure to perform by Parent or any of its Affiliates following the Closing of or with respect to any of their respective covenants, agreements and other obligations under any Disposition Agreement or any remaining liabilities under any Investor Agreements. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Permitted Transfer</font>&#8221; means a Transfer of one or more CVRs (i) upon death of a Holder by will or intestacy, (ii) pursuant to a court order, (iii)&#160;by operation of law (including by consolidation or merger) or without consideration in connection with the dissolution, liquidation or termination of any corporation, limited liability company, partnership or other entity, (iv) in the case of CVRs held in book-entry or other similar nominee form, from a nominee to a beneficial owner and, if applicable, through an intermediary, (v) to any trust, family partnership, family limited liability company or other estate planning vehicle for the benefit of the Holder or the Holder&#8217;s immediate family members or (vi) as provided in <u>Section&#160;&#8206;2.5</u>.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Person</font>&#8221; means any natural person, firm, corporation, partnership, company, limited liability company, trust, joint venture, association, Governmental Entity, university, college, research institute or other educational, academic or not-for-profit institution, or other entity.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Pro Rata Share</font>&#8221; means, with respect to any Holder, the quotient obtained by dividing (i) the aggregate number of CVRs held by such Holder by (ii) the aggregate number of outstanding CVRs held by all Holders, in each case, as reflected in the CVR Register.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Reference Price</font>&#8221; means for the calculation of the CVR Payment for any CVR Payment Period, an amount equal to the quotient of (i) the sum of the Parent Valuation <font style="font-style: italic;">plus</font> the Company Valuation, <font style="font-style: italic;">divided by</font> (ii) the sum, without duplication, of (A) the product of the Company Outstanding Shares <u>multiplied by</u> the Exchange Ratio and (B) the Parent Outstanding Shares.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Rights Agent</font>&#8221; means the Rights Agent named in the first paragraph of this Agreement, until a successor Rights Agent shall have been appointed pursuant to <u>&#8206;Article&#160;3</u> of this Agreement, and thereafter &#8220;<font style="font-weight: bold;">Rights Agent</font>&#8221; will mean such successor Rights Agent.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;<font style="font-weight: bold;">Securities Act</font>&#8221; means the Securities Act of 1933, as amended.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Transfer</font>&#8221; means transfer, pledge, hypothecation, encumbrance, assignment or other disposition (whether by sale, merger, consolidation, liquidation, dissolution, dividend, distribution or otherwise), the offer to make such a transfer or other disposition and each Contract, arrangement or understanding, whether or not in writing, to effect any of the foregoing.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">&#8220;<font style="font-weight: bold;">Subsidiary</font>&#8221; means, with respect to any Person, another Person (i) of which such first Person owns or controls, directly or indirectly, securities or other ownership interests representing (A) more than 50% of the voting power of all outstanding stock or ownership interests of such second Person or (B) the right to receive more than 50% of the net assets available for distribution to the holders of outstanding stock or ownership interests upon a liquidation or dissolution, or (ii) of which such first Person is a general partner. </div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 20pt; text-align: center;">ARTICLE 2<br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">CONTINGENT VALUE RIGHTS</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">2.1&#8195;<u>Holders of CVRs; Appointment of Rights Agent</u><font style="font-weight: normal;">. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;The CVRs represent the contractual rights of Holders to receive contingent payment of the aggregate CVR Payments from Parent pursuant to this Agreement. The initial Holders shall be the holders of Parent Common Stock as of the close of business on the last Business Day prior to the day on which the Effective Time occurs (the &#8220;<font style="font-weight: bold;">CVR Record Date</font><font style="font-style: italic;">&#8221;</font>). One CVR will be issued with respect to each share of Parent Common Stock that is outstanding as of the close of business on the CVR Record Date. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;Parent hereby appoints the Rights Agent to act as rights agent for Parent in accordance with the express terms and conditions set forth in this Agreement, and the Rights Agent hereby accepts such appointment. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">2.2&#8195;<u>No Certificate; Registration; Registration of Transfer; Change of Address</u><font style="font-weight: normal;">. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;Holders&#8217; rights and obligations in respect of the CVRs derive solely from this Agreement. The CVRs will not be evidenced by a certificate or other instrument. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;The Rights Agent will create and maintain a register (the &#8220;<font style="font-weight: bold;">CVR Register</font>&#8221;) for the purposes of (i) identifying the Holders of CVRs, (ii) determining the Holders&#8217; entitlement to CVRs and (iii) registering the CVRs and Permitted Transfers thereof. The CVR Register will be created, and CVRs will be distributed, pursuant to written instructions to the Rights Agent from Parent. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-4<br></div></div></div>
<!--End Page 483-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 484-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_305-annexf_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(c)&#8195;Subject to the restrictions on transferability set forth in <u>Section&#160;2.6</u>, every request made to Transfer CVRs must be in writing and accompanied by a written instrument of transfer reasonably acceptable to the Rights Agent, together with the signature guarantee of a guarantor institution which is a participant in a signature guarantee program approved by the Securities Transfer Association (a &#8220;signature guarantee&#8221;) and other requested documentation in a form reasonably satisfactory to the Rights Agent, duly executed and properly completed, as applicable, by the Holder or Holders thereof, or by the duly appointed legal representative, personal representative or survivor of such Holder or Holders, setting forth in reasonable detail the circumstances relating to the proposed Transfer. Upon receipt of such written notice, the Rights Agent will, subject to its reasonable determination in accordance with its own internal procedures, that the transfer instrument is in proper form and that the proposed Transfer would be a Permitted Transfer and otherwise complies on its face with the other terms and conditions of this Agreement (including the provisions in <u>Section&#160;&#8206;2.6</u>), register the Transfer of the applicable CVRs in the CVR Register. All Transfers of CVRs registered in the CVR Register will be the valid obligations of Parent, evidencing the same right, and entitling the transferee to the same benefits and rights under this Agreement, as those held by the transferor. Parent and the Rights Agent may require payment by the applicable Holder of a sum sufficient to cover any stamp or other Tax or governmental charge that is imposed in connection with any such registration of transfer (or evidence from the applicable Holder that such Taxes and charges are not applicable). No Transfer of CVRs shall be valid until registered in the CVR Register and unless such Transfer would not violate the Securities Act. Any putative Transfer not duly registered in the CVR Register or in violation of the Securities Act shall be null and void <font style="font-style: italic;">ab initio</font>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(d)&#8195;A Holder may make a written request to the Rights Agent to change such Holder&#8217;s address of record in the CVR Register. Such written request must be duly executed by such Holder. Upon receipt of such written notice, the Rights Agent shall promptly record the change of address in the CVR Register. The Acting Holders may, without duplication, make a written request to the Rights Agent for a list containing the names, addresses and number of CVRs of the Holders that are registered in the CVR Register. Upon receipt of such written request from the Acting Holders, the Rights Agent shall promptly deliver a copy of such list to the Acting Holders. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">2.3&#8195;<u>Payment Procedures</u><font style="font-weight: normal;">. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;No later than 60 days following the end of each CVR Payment Period during the CVR Term, Parent shall deliver to the Rights Agent a CVR Payment Statement for such CVR Payment Period. Concurrent with the delivery of each CVR Payment Statement, on the terms and conditions of this Agreement, Parent shall cause to be deposited with the Rights Agent, for further distribution to the Holders in accordance with the terms hereof, or as the Rights Agent directs, a number of shares of Parent Common Stock representing such CVR Payment (or applicable portion thereof); <u>provided</u> that in the event that the aggregate Net Proceeds on any CVR Payment Statement is less than $5,000,000, no CVR Payment shall be deposited with the Rights Agent for the applicable CVR Payment Period, and instead such Net Proceeds shall be added to the Net Proceeds for the subsequent CVR Payment Periods until (A) the aggregate Net Proceeds for a CVR Payment Period (after giving effect to all carry-over additions) are at least $5,000,000 or (B) the final CVR Payment Period.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;Upon receipt of (i) any deposit of shares of Parent Common Stock referred to in <u>Section&#160;&#8206;2.3(a)</u>, the Rights Agent will promptly (and in any event within 10 Business Days) deliver, or cause to be delivered, to each Holder the number of shares of Parent Common Stock equal to such Holder&#8217;s Pro Rata Share of the applicable CVR Payment or (ii) any wire transfer referred to in <u>Section&#160;&#8206;2.7</u>, the Rights Agent will promptly (and in any event within 10 Business Days) pay, by check mailed, first-class postage prepaid, to the address of each Holder set forth in the CVR Register at such time or by other method of delivery as specified by the applicable Holder in writing to the Rights Agent, an amount in cash equal to such Holder&#8217;s Pro Rata Share of the applicable Fractional Cash Payment. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(c)&#8195;For the avoidance of doubt, with respect to any Net Proceeds that are paid to Parent or its Affiliates, Parent shall have no further liability in respect of the respective CVR Payment upon delivery of such CVR Payment to the Rights Agent in accordance with <u>Section&#160;&#8206;2.3(a)</u> and the satisfaction of each of Parent&#8217;s obligations under this <u>Section&#160;&#8206;2.3</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(d)&#8195;Parent and the Rights Agent will be entitled to deduct and withhold, or cause to be deducted and withheld, from any amounts required to be paid or distributed under this Agreement (including any issuance of a CVR pursuant to this Agreement or any CVR Payment payable pursuant to this Agreement), such amounts as Parent or the Rights Agent reasonably determines it is required to deduct and withhold with respect to the making of such payment or distribution (including in respect of the distribution of CVRs) under any provision of applicable Law relating to Taxes. To the extent that amounts are so deducted and withheld pursuant to this paragraph (d), such deducted and withheld amounts will be treated for all purposes of this Agreement as having been paid or distributed to the Holder in respect of which such deduction and withholding were made. The Rights Agent will solicit from each Holder a properly completed IRS Form&#160;W-9 or the appropriate version of IRS Form&#160;W-8, as applicable, at or prior to any distribution or other payment to such Holder under this Agreement. If Parent or the Rights Agent fails to withhold any Tax required to be withheld pursuant to any issuance of a CVR or CVR Payment, Parent and the Rights Agent will be entitled to deduct and withhold, or cause to be deducted and withheld, such Taxes (including any interest and penalties) from subsequent payments with respect to the applicable CVR or, at Parent&#8217;s option, the Holder of such applicable CVR shall promptly pay such Tax to Parent upon request. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(e)&#8195;Any portion of a CVR Payment that remains undistributed to the Holders on the date that is twelve months after the Rights Agent&#8217;s receipt of the applicable CVR Payment will be delivered by the Rights Agent to Parent or a Person nominated in writing by Parent (with written notice thereof from Parent to the Rights Agent), and any Holder will thereafter look only to Parent for payment of such CVR Payment (which shall be without interest). </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(f)&#8195;If any CVR Payment (or portion thereof) remains unclaimed by a Holder on the date that is two years after the Rights Agent&#8217;s receipt of the applicable CVR Payment Statement or the CVR Payment (or immediately prior to such earlier date on which such CVR Payment would otherwise escheat to or become the property of any governmental authority), then: (i) such CVR Payment (or portion thereof) will, to the extent permitted by applicable Law, become the property of Parent and will be transferred to Parent or a Person nominated in writing by Parent (with written </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-5<br></div></div></div>
<!--End Page 484-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 485-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_305-annexf_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">notice thereof from Parent to the Rights Agent), free and clear of all claims or interest of any Person previously entitled thereto, and no consideration or compensation shall be payable therefor, and (ii) the CVRs to which such payment relate shall be deemed abandoned in accordance with <u>Section&#160;2.5</u> and shall no longer be deemed outstanding for any purpose (including for purposes of calculating each Holder&#8217;s Pro Rata Share). Neither Parent nor the Rights Agent will be liable to any Person in respect of a CVR Payment delivered to a public official pursuant to any applicable abandoned property, escheat or similar legal requirement under applicable Law. In addition to and not in limitation of any other indemnity obligation herein, Parent agrees to indemnify and hold harmless the Rights Agent with respect to any liability, penalty, cost or expense the Rights Agent may incur or be subject to in connection with transferring such property to Parent or a public official. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">2.4&#8195;<u>No Voting, Dividends or Interest; No Equity or Ownership Interest</u><font style="font-weight: normal;">. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 40pt; text-align: left;">(a)&#8195;CVRs will not have any voting or dividend rights, and interest will not accrue on any amounts payable in respect of CVRs. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;CVRs will not represent any equity or ownership interest in Parent or any of its Affiliates. The sole right of the Holders to receive property hereunder is the right to receive CVR Payments, if any, in accordance with the terms hereof. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(c)&#8195;The CVRs and the possibility of any payment hereunder with respect thereto are highly speculative and subject to numerous factors outside of Parent&#8217;s control, and there is no assurance that Holders will receive any payments under this Agreement or in connection with the CVRs. It is highly possible that there will not be any CVR Payments. Neither Parent nor its Affiliates owe, by virtue of their obligations under this Agreement, a fiduciary duty or any implied duties to the Holders and the parties hereto intend solely the express provisions of this Agreement to govern their contractual relationship with respect to the CVRs. This <u>Section&#160;2.4(c)</u> is an essential and material term of this Agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">2.5&#8195;<u>Ability to Abandon CVR</u><font style="font-weight: normal;">. A Holder may at any time, at such Holder&#8217;s option or upon the failure to claim payment under <u>Section&#160;&#8206;2.3(f)</u>, abandon all of such Holder&#8217;s remaining rights represented by CVRs by transferring such CVR to Parent or a Person nominated in writing by Parent (with written notice thereof from Parent to the Rights Agent) without consideration in compensation therefor, and such rights will be cancelled, with the Rights Agent being promptly notified in writing by Parent of such transfer and cancellation. No such notice to the Rights Agent shall be required in the case of abandonment due to the failure to claim payment under <u>Section&#160;&#8206;2.3(f)</u>. Nothing in this Agreement is intended to prohibit Parent or its Affiliates from offering to acquire or acquiring CVRs, in private transactions or otherwise, for consideration in its sole discretion. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">2.6&#8195;<u>Non-transferable</u><font style="font-weight: normal;">. The CVRs may not be sold, assigned, transferred, pledged, encumbered or in any other manner transferred or disposed of, in whole or in part, other than through a Permitted Transfer. The CVRs will not be listed on any quotation system or traded on any securities exchange. Any purported transfer of a CVR other than through a Permitted Transfer shall be null and void </font><font style="font-style: italic; font-weight: normal;">ab initio</font><font style="font-weight: normal;">. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">2.7&#8195;<u>No Fractional Shares</u><font style="font-weight: normal;">. No fractional shares of Parent Common Stock will be issued in connection with any CVR Payment and no certificates or scrip representing fractional shares of Parent Common Stock will be delivered. Each CVR Holder who would otherwise be entitled to receive, as a result of any CVR Payment, a fractional share of Parent Common Stock shall receive, in lieu thereof, cash (without interest) in an amount (rounded down to the nearest cent) determined by multiplying the fractional share interest to which such CVR Holder would otherwise be entitled by the Reference Price. The payment of cash in lieu of fractional shares of Parent Common Stock to such CVR Holders is not a separately bargained-for consideration and solely represents a mechanical rounding-off of the fractions in the exchange. </font></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 20.5pt; text-align: center;">ARTICLE 3<br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">THE RIGHTS AGENT </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">3.1&#8195;<u>Certain Duties and Responsibilities</u><font style="font-weight: normal;">. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;The Rights Agent will not have any liability for any actions taken or not taken in connection with this Agreement, except to the extent such liability arises as a result of the willful misconduct, bad faith, fraud or gross negligence of the Rights Agent (in each case as determined by a final non-appealable judgment of court of competent jurisdiction). Anything to the contrary notwithstanding, in no event will the Rights Agent be liable for special, punitive, indirect, incidental or consequential loss or damages of any kind whatsoever (including lost profits), even if the Rights Agent has been advised of the likelihood of such loss or damages, and regardless of the form of action. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;The Rights Agent will not have any duty or responsibility in the case of the receipt of any written demand from any Holder with respect to any action or default by any Person or entity, including, without limiting the generality of the foregoing, any duty or responsibility to initiate or attempt to initiate any proceedings at law or otherwise or to make any demand upon Parent. All rights of action under this Agreement may be enforced (but shall not be required to be enforced) by the Rights Agent, any claim, action, suit, audit, investigation or proceeding instituted by the Rights Agent will be brought in its name as the Rights Agent and any recovery in connection therewith will be for the proportionate benefit of all the Holders, as their respective rights or interests may appear on the CVR Register. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">3.2&#8195;<u>Certain Rights of Rights Agent</u><font style="font-weight: normal;">. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;The Rights Agent undertakes to perform such duties and only such duties as are specifically set forth in this Agreement, and no implied covenants or obligations will be read into this Agreement against the Rights Agent. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;The Rights Agent may rely and will be protected by Parent in acting or refraining from acting upon any resolution, certificate, statement, instrument, opinion, report, notice, request, direction, consent, order or other paper or document reasonably believed by it to be genuine and to have been signed or presented by or on behalf of Parent. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-6<br></div></div></div>
<!--End Page 485-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 486-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_305-annexf_pg7"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(c)&#8195;Whenever the Rights Agent deems it desirable that a matter be proved or established prior to taking or omitting any action hereunder, the Rights Agent may (i) rely upon an Officer&#8217;s Certificate and (ii) in the absence of bad faith, gross negligence, fraud or willful misconduct on its part, incur no liability and be held harmless by Parent for or in respect of any action taken or omitted to be taken by it under the provisions of this Agreement in reliance upon such Officer&#8217;s Certificate. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(d)&#8195;The Rights Agent may engage and consult with counsel of its selection, and the written advice or opinion of such counsel will, in the absence of bad faith, gross negligence, fraud or willful misconduct on the part of the Rights Agent, be full and complete authorization and protection in respect of any action taken or not taken by the Rights Agent in reliance thereon. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 40pt; text-align: left;">(e)&#8195;Any permissive rights of the Rights Agent hereunder will not be construed as a duty. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(f)&#8195;The Rights Agent will not be required to give any note or surety in respect of the execution of its powers or otherwise under this Agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(g)&#8195;Parent agrees to indemnify the Rights Agent for, and to hold the Rights Agent harmless from and against, any loss, liability, damage, judgment, fine, penalty, cost or expense (each, a &#8220;<font style="font-weight: bold;">Loss</font>&#8221;) suffered or incurred by the Rights Agent and arising out of or in connection with the Rights Agent&#8217;s performance of its obligations under this Agreement, including the reasonable and documented costs and expenses of defending the Rights Agent against any claims, charges, demands, actions or suits arising out of or in connection with the execution, acceptance, administration, exercise and performance of its duties under this Agreement, including the costs and expenses of defending against any claim of liability arising therefrom, directly or indirectly, or enforcing its rights hereunder, except to the extent such Loss has been determined by a final non-appealable decision of a court of competent jurisdiction to have resulted from the Rights Agent&#8217;s gross negligence, bad faith, fraud or willful misconduct; <u>provided</u> that this <u>Section&#160;3.2</u>(g) shall not apply to (i) income, receipt, franchise or similar Taxes, (ii) any Taxes imposed due to the Rights Agent&#8217;s connection with the jurisdiction imposing such Taxes (other than any connection caused solely by this Agreement or the Rights Agent performing, enforcing or receiving payments under this Agreement), or (iii) any Taxes imposed due to the failure of the Rights Agent to provide any form, document or certificate that would have reduced or eliminated the amount of withholding taxes (&#8220;<font style="font-weight: bold;">Excluded Taxes</font>&#8221;). </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(h)&#8195;In addition to the indemnification provided under <u>Section&#160;3.2</u>(g), Parent agrees (i) to pay the fees of the Rights Agent in connection with the Rights Agent&#8217;s performance of its obligations hereunder, as agreed upon in writing by the Rights Agent and Parent on or prior to the date of this Agreement, and (ii) to reimburse the Rights Agent for all reasonable and properly documented out-of-pocket expenses, including all stamp and transfer Taxes (excluding any Excluded Taxes) and governmental charges, incurred by the Rights Agent in the performance of its obligations under this Agreement, except that Parent will have no obligation to pay the fees of the Rights Agent or reimburse the Rights Agent in connection with any lawsuit initiated by the Rights Agent on behalf of itself or the Holders, except in the case of any suit enforcing the provisions of <u>Section&#160;2.3(a</u>) or <u>Section&#160;3.2</u>(g), if Parent is found by a court of competent jurisdiction to be liable to the Rights Agent or the Holders, as applicable in such suit. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(i)&#8195;No provision of this Agreement shall require the Rights Agent to expend or risk its own funds or otherwise incur any financial liability in the performance of any of its duties hereunder or in the exercise of any of its rights or powers if it believes that repayment of such funds or adequate indemnification against such risk or liability is not reasonably assured to it. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(j)&#8195;Subject to applicable Law, (i) the Rights Agent and any shareholder, affiliate, director, officer or employee of the Rights Agent may buy, sell or deal in any securities of Parent or become peculiarly interested in any transaction in which Parent may be interested, or contract with or lend money to Parent or otherwise act as fully and freely as though it were not the Rights Agent under this Agreement, and (ii) nothing herein will preclude the Rights Agent from acting in any other capacity for Parent or for any other Person. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(k)&#8195;The Rights Agent may execute and exercise any of the rights or powers hereby vested in it or perform any duty hereunder either itself or by or through its attorney or agents and the Rights Agent shall not be answerable or accountable for any act, default, neglect or misconduct of any such attorney or agents or for any loss to Parent resulting from any such act, default, neglect or misconduct, absent gross negligence, bad faith or willful misconduct (each as determined by a final non-appealable judgment of a court of competent jurisdiction) in the selection and continued employment thereof. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(l)&#8195;The Rights Agent shall not be liable for or by reason of any of the statements of fact or recitals contained in this Agreement (except its countersignature thereof) or be required to verify the same, and all such statements and recitals are and shall be deemed to have been made by Parent only. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(m)&#8195;The Rights Agent shall act hereunder solely as agent for Parent and shall not assume any obligations or relationship of agency or trust with any of the owners or holders of the CVRs. The Rights Agent shall not have any duty or responsibility in the case of the receipt of any written demand from any Holders with respect to any action or default by Parent, including, without limiting the generality of the foregoing, any duty or responsibility to initiate or attempt to initiate any proceedings at law or otherwise or to make any demand upon Parent. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(n)&#8195;The Rights Agent may rely on and be fully authorized and protected in acting or failing to act upon (a) any guaranty of signature by an &#8220;eligible guarantor institution&#8221; that is a member or participant in the Securities Transfer Agents Medallion Program or other comparable &#8220;signature guarantee program&#8221; or insurance program in addition to, or in substitution for, the foregoing; or (b) any law, act, regulation or any interpretation of the same even though such law, act, or regulation may thereafter have been altered, changed, amended or repealed. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(o)&#8195;The Rights Agent shall not be liable or responsible for any failure of Parent to comply with any of its obligations relating to any registration statement filed with the Securities and Exchange Commission or this Agreement, including obligations under applicable regulation or law. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-7<br></div></div></div>
<!--End Page 486-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 487-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_305-annexf_pg8"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(p)&#8195;The obligations of Parent under this <u>Section&#160;3.2</u> shall survive the expiration of the CVRs and the termination of this Agreement and the resignation, replacement or removal of the Rights Agent. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">3.3&#8195;<u>Resignation and Removal; Appointment of Successor</u><font style="font-weight: normal;">. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;The Rights Agent may resign at any time by written notice to Parent. Any such resignation notice shall specify the date on which such resignation will take effect (which shall be at least thirty (30) days following the date that such resignation notice is delivered), and such resignation will be effective on the earlier of (x) the date so specified and (y) the appointment of a successor Rights Agent. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;Parent will have the right to remove the Rights Agent at any time by written notice to the Rights Agent, specifying the date on which such removal will take effect. Such notice will be given at least thirty (30) days prior to the date so specified (or, if earlier, the appointment of the successor Rights Agent). </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(c)&#8195;If the Rights Agent resigns, is removed or becomes incapable of acting, Parent will promptly appoint a qualified successor Rights Agent. Notwithstanding the foregoing, if Parent fails to make such appointment within a period of thirty (30) days after giving notice of such removal or after it has been notified in writing of such resignation or incapacity by the resigning or incapacitated Rights Agent, then the incumbent Rights Agent may apply to any court of competent jurisdiction for the appointment of a new Rights Agent. The successor Rights Agent so appointed will, upon its acceptance of such appointment in accordance with this <u>Section&#160;3.3(c)</u> and <u>Section&#160;3.4</u>, become the Rights Agent for all purposes hereunder. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(d)&#8195;Parent will give notice to the Holders of each resignation or removal of the Rights Agent and each appointment of a successor Rights Agent in accordance with <u>Section&#160;6.2</u>. Each notice will include the name and address of the successor Rights Agent. If Parent fails to send such notice within ten (10) Business Days after acceptance of appointment by a successor Rights Agent, the successor Rights Agent will cause the notice to be mailed at the expense of Parent. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(e)&#8195;Notwithstanding anything to the contrary in this <u>Section&#160;3.3</u>, unless consented to in writing by the Acting Holders, Parent will not appoint as a successor Rights Agent any Person that is not a stock transfer agent of national reputation or the corporate trust department of a commercial bank. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(f)&#8195;The Rights Agent will reasonably cooperate with Parent and any successor Rights Agent in connection with the transition of the duties and responsibilities of the Rights Agent to the successor Rights Agent, including the transfer of all relevant data, including the CVR Register, to the successor Rights Agent; but such predecessor Rights Agent shall not be required to make any additional expenditure or assume any additional liability in connection with the foregoing. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">3.4&#8195;<u>Acceptance of Appointment by Successor</u><font style="font-weight: normal;">. Every successor Rights Agent appointed hereunder will, at or prior to such appointment, execute, acknowledge and deliver to Parent and to the resigning or removed Rights Agent an instrument accepting such appointment and a counterpart of this Agreement, and such successor Rights Agent, without any further act, deed or conveyance, will become vested with all the rights, powers, trusts and duties of the Rights Agent; <u>provided</u> that upon the request of Parent or the successor Rights Agent, such resigning or removed Rights Agent will execute and deliver an instrument transferring to such successor Rights Agent all the rights, powers and trusts of such resigning or removed Rights Agent. </font></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 20pt; text-align: center;">ARTICLE 4<br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">COVENANTS </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">4.1&#8195;<u>No Obligations of Parent</u><font style="font-weight: normal;">. Parent and its Affiliates shall have the power and right to control all aspects of their businesses and operations (and all of their assets and products), including with respect to the Parent Legacy Business, other than any matter that requires the consent of the Holder Representative or the Acting Holders pursuant to the Merger Agreement or this Agreement, and subject to its compliance with the terms of this Agreement, Parent and its Affiliates may exercise or refrain from exercising such power and right as they may deem appropriate and in the best overall interests of Parent and its Affiliates and its and their stockholders, rather than the interest of the Holders. None of Parent or any of its Affiliates (or any directors, officer, employee, or other representative of the foregoing) owes any fiduciary duty or other duty to any Holder in respect of the Legacy Assets, other than the covenant of good faith and fair dealing under Delaware Law. Following the Effective Time, with respect to any Legacy Assets for which a Disposition Agreement has not been entered into by Parent, Parent shall be permitted to take any action in respect of the Legacy Assets in order to satisfy any wind-down and termination Liabilities of the Legacy Assets and Parent and its Affiliates will not be required to undertake any level of efforts, or employ any level of resources, to dispose of, or otherwise with respect to, such Legacy Assets. Notwithstanding the foregoing, neither Parent nor any of its Affiliates may settle, compromise, consent to judgment on, or otherwise resolve any claim, action, proceeding, or dispute (whether by settlement, arbitration, mediation, or otherwise) that could affect the amount or timing of all or any portion of the Illumina Payment Amounts or any proceeds (whether upfront or in the form of earnout, milestone, royalty, contingent or other similar payments) under any Disposition Agreement entered into prior to Closing, in each case, without the consent, approval, or authorization of the Holder Representative.</font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">4.2&#8195;<u>List of Holders</u><font style="font-weight: normal;">. Parent will furnish or cause to be furnished to the Rights Agent, in such form as Parent receives from its transfer agent (or other agent performing similar services for Parent), the names and addresses of the Holders within thirty (30) days following the Closing Date. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">4.3&#8195;<u>Prohibited Actions</u><font style="font-weight: normal;">. Unless approved by the Holder Representative, Parent shall not grant any lien, security interest, pledge or similar interest in, or otherwise sell or Transfer, any Gross Proceeds or rights to receive any Gross Proceeds. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">4.4&#8195;<u>Audit Rights</u><font style="font-weight: normal;">. Until the Termination Date and for a period of one year thereafter, Parent shall keep, and shall require its Affiliates to keep, complete and accurate books and records that may be necessary for the purpose of calculating the CVR Payments payable under this Agreement. At </font></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-8<br></div></div></div>
<!--End Page 487-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 488-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_305-annexf_pg9"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">the request of the Acting Holders, the Holder Representative shall have the right to appoint an independent accounting firm reasonably acceptable to Parent to perform, on behalf of all Holders, an inspection of such books and records for the sole purpose of determining the CVR Payments payable hereunder, subject to the prior execution and delivery of a reasonable confidentiality agreement by such accounting firm. Upon at least 10 Business Days&#8217; prior written notice from the Holder Representative, such audit shall be conducted during regular business hours in such a manner as to not unnecessarily interfere with Parent&#8217;s normal business activities. Such audit shall not be performed more frequently than twice per calendar year. No accounting period of Parent shall be subject to audit more than twice, unless after an accounting period has been audited, Parent restates its financial results for such accounting period, in which event a second audit of such accounting period may be conducted in accordance with this <u>Section&#160;4.4</u>. If the audit reveals an overpayment, Parent shall be entitled to withhold such amount from future payments of CVR Payments. If the audit reveals an underpayment, Parent shall promptly (and in any event within thirty (30) days) remit such amount to the Rights Agent for distribution to the Holders. The Acting Holders requesting the audit shall bear the full cost and expense of such audit unless such audit identifies an underpayment by Parent of 10% or more of the CVR Payment due under this Agreement, in which case Parent shall bear the full cost and expense of such audit. The Rights Agent shall be entitled to rely on any audit report delivered by the independent accounting firm pursuant to this <u>Section 4.4</u>. </div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 20.5pt; text-align: center;">ARTICLE 5<br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">AMENDMENTS </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 7.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">5.1&#8195;<u>Amendments Without Consent of Holders or Rights Agent</u><font style="font-weight: normal;">. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;Parent, at any time and from time to time, may enter into one or more amendments to this Agreement for any of the following purposes, without the consent of any of the Holders or the Rights Agent (subject to <u>Section&#160;5.3</u>), <u>provided</u>, in each case, that if any such amendment(s) (individually or the aggregate) impairs or adversely affects the rights of the Holders hereunder, such amendment shall also require the prior written consent of the Holders in accordance with <u>Section&#160;5.2</u>: </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(i)&#8195;to evidence the appointment of another Person as a successor Rights Agent and the assumption by any successor Rights Agent of the covenants and obligations of the Rights Agent herein in accordance with the provisions hereof; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(ii)&#8195;to evidence the succession of another Person to Parent and the assumption of any such successor of the covenants of Parent outlined herein in a transaction contemplated by <u>Section&#160;6.6</u>; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(iii)&#8195;to add to the covenants of Parent such further covenants, restrictions, conditions or provisions for the protection and benefit of the Holders; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(iv)&#8195;as may be necessary to ensure that CVRs are not subject to registration under the Securities Act or the Securities Exchange Act of 1934, as amended, and the rules and regulations made thereunder, or any applicable state securities or &#8220;blue sky&#8221; laws; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(v)&#8195;as may be necessary to ensure that Parent is not required to produce a prospectus or an admission document in order to comply with applicable Law; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(vi)&#8195;to cancel CVRs (A) in the event that any Holder has abandoned its rights in accordance with <u>Section&#160;2.5</u> or (B) following a transfer of such CVRs to Parent or its Affiliates in accordance with <u>Section&#160;2.2</u> and <u>Section&#160;2.6</u>; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 30pt; text-indent: 30pt; text-align: left;">(vii)&#8195;as may be necessary to ensure that Parent complies with applicable Law; or </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 40pt; text-align: justify;">(viii)&#8195;to effect any other amendment to this Agreement that would provide any additional rights or benefits to the Holders or that does not adversely affect the legal rights under this Agreement of any such Holder. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;Promptly after the execution by Parent of any amendment pursuant to this <u>Section 5.1</u>, Parent will (or will cause the Rights Agent to) notify the Holders in general terms of the substance of such amendment in accordance with <u>Section&#160;6.2</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">5.2&#8195;<u>Amendments with Consent of Holders</u><font style="font-weight: normal;">. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;In addition to any amendments to this Agreement that may be made by Parent without the consent of any Holder or the Rights Agent pursuant to <u>Section&#160;5.1</u>, with the consent of the Acting Holders, Parent and the Rights Agent may enter into one or more amendments to this Agreement for the purpose of adding, eliminating or amending any provisions of this Agreement, even if such addition, elimination or amendment is adverse to the interests of the Holders. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;Promptly after the execution by Parent and the Rights Agent of any amendment pursuant to the provisions of this <u>Section&#160;5.2</u>, Parent will (or will cause the Rights Agent to) notify the Holders in general terms of the substance of such amendment in accordance with <u>Section&#160;6.2</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">5.3&#8195;<u>Effect of Amendments</u><font style="font-weight: normal;">. Upon the execution of any amendment under this <u>Article&#160;5</u>, this Agreement will be modified in accordance therewith, such amendment will form a part of this Agreement for all purposes and every Holder will be bound thereby. Upon the delivery of a certificate from an appropriate officer of Parent which states that the proposed supplement or amendment is in compliance with the terms of this <u>Article&#160;5</u>, the Rights Agent shall execute such supplement or amendment. Notwithstanding anything in this Agreement to the contrary, the Rights Agent shall not be required to execute any supplement or amendment to this Agreement that it has determined would adversely affect its own rights, duties, obligations or immunities under this Agreement. No supplement, amendment or other modification to this Agreement shall be effective unless duly executed by the Rights Agent. </font></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-9<br></div></div></div>
<!--End Page 488-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 489-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_305-annexf_pg10"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">ARTICLE 6<br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">MISCELLANEOUS </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">6.1&#8195;<u>Notices to Rights Agent and to Parent</u><font style="font-weight: normal;">. All notices, requests, instructions, demands and other communications under this Agreement shall be in writing and shall be deemed given (a) when delivered personally by hand (with written confirmation of receipt), (b) delivered by e-mail (provided that no &#8220;bounceback&#8221; or similar notification of non-delivery is received by the sender with respect thereto) or (c) when received by the addressee if sent by nationally recognized overnight delivery service or prepaid first class certified mail (with written confirmation of receipt), in each case, at the following addresses: </font></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_txtann" style="width: 528pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 24pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 492pt;" colspan="7"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr><td style="width: 24pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td colspan="7" style="width: 492pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">if to the Rights Agent, to: [&#8226;]</div></td></tr><tr><td style="width: 24pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 60pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 384pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 24pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 60pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">[&#8226;]</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 384pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 24pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 60pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">[&#8226;]</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 384pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 24pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 60pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Attention: [&#8226;]</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 384pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 24pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 60pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">E-mail: [&#8226;]</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 384pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 24pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 60pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 384pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 24pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td colspan="7" style="width: 492pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">if to Parent, to: [&#8226;]</div></td></tr><tr><td style="width: 24pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 60pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 384pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 24pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 60pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">[&#8226;]</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 384pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 24pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 60pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">[&#8226;]</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 384pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 24pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 60pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Attention: [&#8226;]</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 384pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 24pt; padding-top: 0.67pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 24pt; padding-top: 0.67pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 60pt; padding-top: 0.67pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">E-mail: [&#8226;]</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 384pt; padding-top: 0.67pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 3pt; width: 24pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 24pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 60pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 384pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">or to such other persons or addresses as may be designated in writing by the party to receive such notice as provided above. Unless a different deadline for the delivery of notices, requests, instructions, demands and other communications is expressly provided for in this Agreement, all such notices, requests instructions, demands and other communications will be deemed given on the day delivered pursuant to the means set forth above if delivered before 5:00 p.m. Eastern Time, and otherwise on the next following day. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">6.2&#8195;<u>Notice to Holders</u><font style="font-weight: normal;">. All Notices required to be given to the Holders will be given (unless otherwise herein expressly provided) in writing and mailed, first-class postage prepaid, to each Holder at such Holder&#8217;s address as set forth in the CVR Register, not later than the latest date, and not earlier than the earliest date, prescribed for the sending of such Notice, if any, and will be deemed given on the date of mailing. In any case where notice to the Holders is given by mail, neither the failure to mail such Notice, nor any defect in any Notice so mailed, to any particular Holder will affect the sufficiency of such Notice with respect to other Holders. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">6.3&#8195;<u>Entire Agreement</u><font style="font-weight: normal;">. As between Parent and the Rights Agent, this Agreement constitutes the entire agreement between the parties with respect to the subject matter of this Agreement, notwithstanding the reference to any other agreement herein, and supersedes all prior agreements and understandings, both written and oral, among or between any of the parties with respect to the subject matter of this Agreement. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">6.4&#8195;<u>Successor Substituted</u><font style="font-weight: normal;">. Upon any consolidation of or merger by Parent with or into any other Person, or any conveyance, transfer or lease of substantially all of the properties and assets of Parent to any Person, the surviving Person or acquiring Person (as applicable) shall succeed to, and be substituted for, and may exercise every right and power of, and shall assume all of the obligations of Parent under this Agreement with the same effect as if such Person had been named as Parent herein. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">6.5&#8195;<u>Merger or Consolidation or Change of Name of Rights Agent</u><font style="font-weight: normal;">. Any Person into which the Rights Agent or any successor Rights Agent may be merged or with which it may be consolidated, or Person resulting from any merger or consolidation to which the Rights Agent or any successor Rights Agent shall be a party, or any Person succeeding to the stock transfer or other shareholder services business of the Rights Agent or any successor Rights Agent, shall be the successor to the Rights Agent under this Agreement without the execution or filing of any paper or any further act on the part of any of the parties hereto, <u>provided</u>, that such Person would be eligible for appointment as a successor Rights Agent under the provisions of <u>Section&#160;3.3</u>. The purchase of all or substantially all of the Rights Agent&#8217;s assets employed in the performance of transfer agent activities shall be deemed a merger or consolidation for purposes of this <u>Section 6.5</u>. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">6.6&#8195;<u>Successors and Assigns</u><font style="font-weight: normal;">. This Agreement will be binding upon, and will be enforceable by and inure solely to the benefit of, the Holders, Parent and the Rights Agent and their respective successors and assigns. Except for assignments pursuant to <u>Section&#160;6.5</u>, the Rights Agent may not assign this Agreement without Parent&#8217;s prior written consent. Subject to <u>Section&#160;5.1(a</u>)<u> </u>(<u>ii</u>) and <u>Section&#160;6.4</u> hereof, Parent may assign, in its sole discretion and without the consent of any other party, any or all of its rights, interests and obligations hereunder to one or more of its Affiliates or to any Person with whom Parent is merged or consolidated, or any entity resulting from any merger or consolidation to which Parent shall be a party (each, an &#8220;</font>Assignee<font style="font-weight: normal;">&#8221;); <u>provided</u> that in connection with any assignment to an Assignee, Parent shall agree to remain liable for the performance by Parent of its obligations hereunder (to the extent Parent exists following such assignment). Parent or an Assignee may not otherwise assign this Agreement without the prior consent of the Acting Holders (such consent not to be unreasonably withheld, conditioned or delayed). Any attempted assignment of this Agreement in violation of this <u>Section&#160;6.6</u> will be void </font><font style="font-style: italic; font-weight: normal;">ab initio </font><font style="font-weight: normal;">and of no effect. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">6.7&#8195;<u>Benefits of Agreement; Action by Acting Holders</u><font style="font-weight: normal;">. Nothing in this Agreement, express or implied, will give to any Person (other than Parent, the Rights Agent, the Holder Representative, the Holders and their respective permitted successors and assigns hereunder) any benefit or any legal or equitable right, remedy or claim under this Agreement or under any covenant or provision herein contained, all such covenants and provisions </font></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-10<br></div></div></div>
<!--End Page 489-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 490-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_305-annexf_pg11"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">being for the sole benefit of Parent, the Rights Agent, the Holders and their permitted successors and assigns. The Holders are intended third-party beneficiaries under this Agreement, but will have no rights hereunder except as are expressly set forth herein. Except for the rights of the Rights Agent set forth herein, the Acting Holders will have the sole right, on behalf of all Holders, by virtue of or under any provision of this Agreement, to institute any action or proceeding at law or in equity with respect to the performance of this Agreement by Parent, and no individual Holder or other group of Holders will be entitled to exercise such rights. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">6.8&#8195;<u>Governing Law</u><font style="font-weight: normal;">. This Agreement and the CVRs will be governed by, and construed in accordance with, the Laws of the State of Delaware (without giving effect to any rule or principle that would result in application of the law of any other jurisdiction) and for all purposes shall be governed by and construed in accordance with the laws of such State applicable to contracts to be made and performed entirely within such State. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">6.9&#8195;<u>Jurisdiction</u><font style="font-weight: normal;">. In any action or proceeding between any of the parties hereto arising out of or relating to this Agreement or any of the transactions contemplated hereby, each of the parties hereto: (a) irrevocably and unconditionally consents and submits to the exclusive jurisdiction and venue of the Court of Chancery of the State of Delaware, or, if under applicable Law exclusive jurisdiction is vested in the Federal courts, the United States District Court for the District of Delaware (and appellate courts thereof); (b) agrees that all claims in respect of such action or proceeding shall be heard and determined exclusively in accordance with clause (a) of this <u>Section&#160;6.9</u>; (c) waives any objection to laying venue in any such action or proceeding in such courts; (d) waives any objection that such courts are an inconvenient forum or do not have jurisdiction over any party; and (e)&#160;agrees that service of process upon such party in any such action or proceeding shall be effective if notice is given in accordance with <u>Section&#160;6.1</u> or <u>Section&#160;6.2</u> of this Agreement. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">6.10&#8195;<u>Waiver of Jury Trial</u><font style="font-weight: normal;">. Each of the parties hereto hereby irrevocably waives any and all right to trial by jury in any legal proceeding arising out of or related to this Agreement or the transactions contemplated hereby. Each party certifies and acknowledges that (i) no representative, agent or attorney of any other party has represented, expressly or otherwise, that such other party would not, in the event of litigation, seek to enforce the foregoing waiver, (ii) each party understands and has considered the implication of this waiver, (iii) each party makes this waiver voluntarily, and (iv)&#160;each party has been induced to enter into this agreement by, among other things, the mutual waivers and certifications in this <u>Section&#160;6.10</u>. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">6.11&#8195;<u>Severability Clause</u><font style="font-weight: normal;">. In the event that any provision of this Agreement, or the application of any such provision to any Person or set of circumstances, is for any reason determined to be invalid, unlawful, void or unenforceable to any extent, the remainder of this Agreement, and the application of such provision to Persons or circumstances other than those as to which it is determined to be invalid, unlawful, void or unenforceable, will not be impaired or otherwise affected and will continue to be valid and enforceable to the fullest extent permitted by applicable Law. Upon such a determination, the parties hereto will negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible in a mutually acceptable manner in order that the transactions contemplated hereby be consummated as originally contemplated to the fullest extent possible; <u>provided</u> that if an excluded provision shall affect the rights, immunities, liabilities, duties or obligations of the Rights Agent, the Rights Agent shall be entitled to resign immediately upon written notice to Parent. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">6.12&#8195;<u>Counterparts; Effectiveness</u><font style="font-weight: normal;">. This Agreement may be signed in any number of counterparts, each of which will be deemed an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. This Agreement or any counterpart may be executed and delivered by electronic communications by portable document format (.pdf), each of which shall be deemed an original. This Agreement will become effective when each party hereto will have received a counterpart hereof signed by the other party hereto. Until and unless each party has received a counterpart hereof signed by the other party hereto, this Agreement will have no effect and no party will have any right or obligation hereunder (whether by virtue of any oral or written agreement or any other communication). </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">6.13&#8195;<u>Termination</u><font style="font-weight: normal;">. This Agreement will automatically terminate and be of no further force or effect and, except as provided in <u>Section&#160;3.2</u>, the parties hereto will have no further liability hereunder, and the CVRs will expire without any consideration or compensation therefor upon the expiration of the CVR Term (such date, the &#8220;</font>Termination Date<font style="font-weight: normal;">&#8221;). The termination of this Agreement will not affect or limit the (i) right of Holders to receive the CVR Payments under <u>Section&#160;2.3(a)</u> to the extent earned prior to the termination of this Agreement or (ii) in the event that Reserve True-Ups exceed $5,000,000 on the Termination Date, the right of Holders to receive CVR Payments in respect of any Reserve True-Up until all matters with respect to which a Reserved amount was included as a Permitted Deduction have been resolved and any Reserve True-Ups have been fully paid to the CVR Holders, and the provisions applicable thereto will survive the expiration or termination of this Agreement. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">6.14&#8195;<u>Funds</u><font style="font-weight: normal;">. All funds received by the Rights Agent under this Agreement that are to be distributed or applied by the Rights Agent in the performance of services hereunder (the &#8220;</font>Funds<font style="font-weight: normal;">&#8221;) shall be deposited in one or more bank accounts to be maintained by the Rights Agent in its name as agent for Parent. Until paid pursuant to the terms of this Agreement, the Rights Agent shall hold the Funds through such accounts in deposit accounts of commercial banks with Tier 1 capital exceeding $1&#160;billion or with an average rating above investment grade by S&amp;P (LT Local Issuer Credit Rating), Moody&#8217;s (Long Term Rating) and Fitch Ratings, Inc. (LT Issuer Default Rating) (each as reported by Bloomberg Finance L.P.). The Rights Agent shall, in the absence of bad faith, gross negligence, fraud or willful misconduct (each as determined by a final non-appealable judgment of a court of competent jurisdiction) on its part, have no responsibility or liability for any diminution of the Funds that may result from any deposit in accordance with this <u>Section&#160;6.14</u>, including any losses resulting from a default by any bank, financial institution or other third party. </font></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-11<br></div></div></div>
<!--End Page 490-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 491-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_305-annexf_pg12"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">6.15&#8195;<u>Construction</u><font style="font-weight: normal;">. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(a)&#8195;For purposes of this Agreement, whenever the context requires: singular terms will include the plural, and vice versa; the masculine gender will include the feminine and neuter genders; the feminine gender will include the masculine and neuter genders; and the neuter gender will include the masculine and feminine genders. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(b)&#8195;As used in this Agreement, the words &#8220;include&#8221; and &#8220;including,&#8221; and variations thereof, will not be deemed to be terms of limitation, but rather will be deemed to be followed by the words &#8220;without limitation.&#8221; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(c)&#8195;The headings contained in this Agreement are for convenience of reference only, will not be deemed to be a part of this Agreement and will not be referred to in connection with the construction or interpretation of this Agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(d)&#8195;Unless stated otherwise, &#8220;Article&#8221; and &#8220;Section&#8221; followed by a number or letter mean and refer to the specified Article&#160;or Section&#160;of this Agreement. The term &#8220;Agreement&#8221; and any reference in this Agreement to this Agreement or any other agreement or document includes, and is a reference to, this Agreement or such other agreement or document as it may have been, or may from time to time be, amended, restated, replaced, supplemented or novated and includes all schedules to it. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(e)&#8195;A period of time is to be computed as beginning on the day following the event that began the period and ending at 4:59 p.m. New York time on the last day of the period, if the last day of the period is a Business Day, or at 4:59 p.m. New York time on the next Business Day if the last day of the period is not a Business Day. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 40pt; text-align: justify;">(f)&#8195;Any reference in this Agreement to a date or time shall be deemed to be such date or time in New York City, United States, unless otherwise specified. The parties hereto have participated jointly in the negotiation and drafting of this Agreement. In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties and no presumption or burden of proof shall arise favoring or disfavoring any Person by virtue of the authorship of any provision of this Agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 40pt; text-align: left;">(g)&#8195;All references herein to &#8220;$&#8221; are to United States Dollars. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">6.16&#8195;<u>Adjustments</u><font style="font-weight: normal;">. In the event of the outstanding shares of Parent Common Stock shall be changed into, or exchanged for, a different number of shares or a different class or series of shares, by reason of any stock dividend, subdivision, reclassification, recapitalization, split, reverse split, combination or exchange of shares or other like change, the terms of this Agreement and the Share Cap shall, to the extent necessary, be equitably adjusted to reflect such change to the extent necessary to provide the CVR Holders with the same economic effect as contemplated by this Agreement prior to such stock dividend, subdivision, reclassification, recapitalization, split, reverse split, combination or exchange of shares or other like change. </font></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-style: italic; margin-top: 326.5pt; text-align: center;">[Signature Page Follows]<font style="font-style: normal;"> </font></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-12<br></div></div></div>
<!--End Page 491-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 492-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_305-annexf_pg13"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-variant: small-caps; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In Witness Whereof<font style="font-variant: normal; font-weight: normal;">, each of the parties has caused this Agreement to be executed as of the day and year first above written. </font></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_txtann" style="width: 528pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 240pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 276pt;" colspan="4"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr><td style="width: 240pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td colspan="4" style="width: 276pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-variant: small-caps; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Treeline Biosciences Holdings, Inc.<font style="font-variant: normal; font-weight: normal;"> </font></div></td></tr><tr><td style="width: 240pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 259pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 240pt; padding-top: 0.67pt; padding-bottom: 1.75pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5pt; padding-top: 0.67pt; padding-bottom: 1.75pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By:</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 259pt; padding-top: 0.67pt; padding-bottom: 1.75pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 240pt; padding-top: 1.42pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5pt; padding-top: 1.42pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name:</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 259pt; padding-top: 1.42pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 240pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Title:</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 259pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 240pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 259pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 240pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td colspan="4" style="width: 276pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-variant: small-caps; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">[Rights Agent]<font style="font-variant: normal; font-weight: normal;"> </font></div></td></tr><tr><td style="width: 240pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 259pt; padding-top: 0.67pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 240pt; padding-top: 0.67pt; padding-bottom: 1.75pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5pt; padding-top: 0.67pt; padding-bottom: 1.75pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By:</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 259pt; padding-top: 0.67pt; padding-bottom: 1.75pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 240pt; padding-top: 1.42pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5pt; padding-top: 1.42pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name:</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 259pt; padding-top: 1.42pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 240pt; padding-top: 0.67pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 5pt; padding-top: 0.67pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Title:</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 259pt; padding-top: 0.67pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 3pt; width: 240pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 259pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-13<br></div></div></div>
<!--End Page 492-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 493-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_306-annexg_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: right;"><a name="tANG"><!--Anchor--></a>Annex G </div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 19.5pt; text-align: center;">AMENDMENT TO CERTIFICATE OF INCORPORATION (REVERSE STOCK SPLIT) </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">G-1<br></div></div></div>
<!--End Page 493-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 494-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; position: relative; width: 528pt;"><a name="ny20077604x1_s4_306-annexg_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">THIRD CERTIFICATE OF AMENDMENT TO THE <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">EIGHTH AMENDED AND RESTATED <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">CERTIFICATE OF INCORPORATION OF <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">STANDARD BIOTOOLS INC.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup> </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Standard BioTools Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the &#8220;<font style="font-weight: bold;">Corporation</font>&#8221;), hereby certifies that:</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">1.&#8195;The name of the Corporation is Standard BioTools Inc. The Corporation&#8217;s original Certificate of Incorporation was filed with the Secretary of State of the State of Delaware on March&#160;29, 2007.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">2.&#8195;The Eighth Amended and Restated Certificate of Incorporation of the Corporation, as amended, is hereby amended by adding the following Article&#160;XII:</div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 20.5pt; text-align: center;">&#8220;<font style="font-weight: bold;">ARTICLE XII </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">As of &#8195;&#8195;&#8195;(Eastern Time) on &#8195;&#8195;&#8195; , 2026 (the &#8220;<u>Effective Time</u>&#8221;), each issued and outstanding share of the Corporation&#8217;s Common Stock (including each share of treasury stock, collectively, the &#8220;<u>Pre-Split Stock</u>&#8221;) shall automatically and without any action on the part of the holder thereof be reclassified as and reduced to &#8195;&#8195; of a share of Common Stock (such reduction of shares designated as the &#8220;<u>Reverse Stock Split</u>&#8221;). The par value of the Corporation&#8217;s Common Stock following the Reverse Stock Split shall remain $0.001 per share. Each holder of a certificate or certificates of Pre-Split Stock shall be entitled to receive, upon surrender of such certificates to the Corporation&#8217;s transfer agent for cancellation, a new certificate or certificates for a number of shares equal to such holder&#8217;s Pre-Split Stock divided by &#8195;&#8195;&#8195;, with any fraction resulting from such division rounded down to the nearest whole number (in each case, such fraction, if any, being a &#8220;<u>Fractional Share</u>&#8221;). No Fractional Shares will be issued for Pre-Split Stock in connection with the Reverse Stock Split. Each holder of Pre-Split Stock at the Effective Time who would otherwise be entitled to a Fractional Share shall, in lieu thereof, receive a cash payment equal to x) the Fractional Share multiplied by y) the closing price of the Company&#8217;s Common Stock as reported on The Nasdaq Global Select Market or other principal market of the Common Stock on the first business day immediately preceding the date of the Effective Time.&#8221;</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">3.&#8195;This Certificate of Amendment to the Corporation&#8217;s Eighth Amended and Restated Certificate of Incorporation, as amended, has been duly authorized and adopted by the Corporation&#8217;s Board of Directors in accordance with the provisions of Section&#160;242 of the Delaware General Corporation Law, and has been duly approved by the stockholders of the Corporation at a meeting of the stockholders on &#8195;&#8195;, 2026, in accordance with the provisions of Section&#160;242 of the General Corporation Law of the State of Delaware. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">IN WITNESS WHEREOF, Standard BioTools Inc. has caused this Certificate of Amendment to be signed by its Chief Executive Officer this &#8195;&#8195;&#8195; day of &#8195;&#8195;&#8195;, 2026. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_txtann" style="width: 528pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 264pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 17pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 223pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr><td style="width: 264pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 17pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 223pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 264pt; padding-top: 0.67pt; padding-bottom: 1.75pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td colspan="4" style="width: 252pt; padding-top: 0.67pt; padding-bottom: 1.75pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 264pt; padding-top: 1.42pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 17pt; padding-top: 1.42pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name: </div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 223pt; padding-top: 1.42pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Michael Egholm, Ph.D. </div></td></tr><tr><td style="width: 264pt; padding-top: 0.67pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 17pt; padding-top: 0.67pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Title: </div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 223pt; padding-top: 0.67pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chief Financial Officer</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 3pt; width: 264pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 17pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 223pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table></div><div class="BRDSX_block-footnote" style="width: 528pt; margin-left: 0pt;"><div><div class="BRDSX_rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-top: 3pt; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt;"> </div></div></div><div class="BRDSX_block-footnote" style="width: 528pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 10pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt;"><font style="position: relative; top: -3.25pt;">1</font><br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; text-align: justify; font-size: 8pt;"><font style="font-size: 8pt;">This amendment approves the combination of any whole number of shares of the Corporation&#8217;s Common Stock up to &#8195;&#8195; into one (1) share of the Corporation&#8217;s Common Stock. By this amendment, the Corporation&#8217;s stockholders would approve each of the alternate amendments proposed by the Corporation&#8217;s Board of Directors. If the reverse stock split is approved by the Corporation&#8217;s stockholders, the Certificate of Amendment filed with the Secretary of State of the State of Delaware will include only that reverse stock split ratio selected by the Corporation&#8217;s Board of Directors for filing. The other amendments will be abandoned pursuant to Section 242(c) of the General Corporation Law of the State of Delaware.</font></div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">G-2<br></div></div></div>
<!--End Page 494-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 495-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_307-annexh_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: right;"><a name="tANH"><!--Anchor--></a>Annex H </div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 19.5pt; text-align: center;">AMENDMENT TO CERTIFICATE OF INCORPORATION (NAME CHANGE) </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">H-1<br></div></div></div>
<!--End Page 495-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 496-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_307-annexh_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">FOURTH CERTIFICATE OF AMENDMENT TO THE <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">EIGHTH AMENDED AND RESTATED <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">CERTIFICATE OF INCORPORATION OF <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">STANDARD BIOTOOLS INC. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Standard BioTools Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the &#8220;<font style="font-weight: bold;">Corporation</font>&#8221;), hereby certifies that:</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">1.&#8195;The name of the Corporation is Standard BioTools Inc. The Corporation&#8217;s original Certificate of Incorporation was filed with the Secretary of State of the State of Delaware on March&#160;29, 2007.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">2.&#8195;Article&#160;I of the Eighth Amended and Restated Certificate of Incorporation of the Corporation, as amended, is hereby amended and restated to read in its entirety as follows:</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;The name of the Corporation is Treeline Biosciences Holdings, Inc. (the &#8220;<font style="font-weight: bold;">Corporation</font>&#8221;).&#8221;</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">3.&#8195;This Fourth Certificate of Amendment to the Corporation&#8217;s Eighth Amended and Restated Certificate of Incorporation, as amended, has been duly authorized and adopted by the Corporation&#8217;s Board of Directors in accordance with the provisions of Section&#160;242 of the Delaware General Corporation Law. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">IN WITNESS WHEREOF, Standard BioTools Inc. has caused this Fourth Certificate of Amendment to be signed by its Chief Executive Officer this &#8195;&#8195; day of &#8195;&#8195;&#8195;&#8195;, 2026. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_txtann" style="width: 528pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 228pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 288pt;" colspan="4"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr><td style="width: 228pt; padding-bottom: 1.75pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td colspan="4" style="width: 288pt; padding-bottom: 1.75pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 228pt; padding-top: 1.42pt; padding-bottom: 1pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 17pt; padding-top: 1.42pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name: </div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 259pt; padding-top: 1.42pt; padding-bottom: 1pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Michael Egholm, Ph.D. </div></td></tr><tr><td style="width: 228pt; padding-top: 0.67pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 17pt; padding-top: 0.67pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Title:</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 259pt; padding-top: 0.67pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chief Executive Officer</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 3pt; width: 228pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 17pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 259pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">H-2<br></div></div></div>
<!--End Page 496-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 497-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_308-annexi_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: right;"><a name="tANI"><!--Anchor--></a>Annex I </div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 19.5pt; text-align: center;">FORM OF POST-CLOSING EQUITY INCENTIVE PLAN </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">I-1<br></div></div></div>
<!--End Page 497-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 498-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_308-annexi_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">TREELINE BIOSCIENCES HOLDINGS, INC.<br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">POST-CLOSING EQUITY INCENTIVE PLAN</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">1.&#8195;<u>PURPOSE</u><font style="font-weight: normal;">. The purpose of this Plan is to provide incentives to attract, retain, and motivate eligible persons whose present and potential contributions are important to the success of the Company, and any Parents, Subsidiaries, and Affiliates that exist now or in the future, by offering them an opportunity to participate in the Company&#8217;s future performance through the grant of Awards. Capitalized terms not defined elsewhere in the text are defined in Section&#160;28. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">2.&#8195;<u>SHARES SUBJECT TO THE PLAN</u><font style="font-weight: normal;">. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">2.1.&#8195;<font style="font-weight: normal;"><u>Number of Shares Available</u>. Subject to Sections 2.6 and 21 and any other applicable provisions hereof, the total number of Shares reserved and available for grant and issuance pursuant to this Plan as of the Effective Date, is the sum of: (a) 200,000,000 Shares; (b) a number of Shares not issued or subject to outstanding awards granted under the Company&#8217;s 2026 Equity Incentive Plan (the &#8220;</font><font style="font-style: italic;">2026 Plan</font><font style="font-weight: normal;">&#8221;) on the Effective Date (as defined below); (c) a number of Shares not issued or subject to outstanding awards granted under the Treeline Biosciences, Inc. 2021 Equity Incentive Plan (the &#8220;</font><font style="font-style: italic;">Treeline Plan</font><font style="font-weight: normal;">&#8221;) on the Effective Date (calculated based on the number of Shares subject to the Treeline Plan pursuant to the exchange ratio described in the Merger Agreement); (d) Shares that are subject to awards granted under the 2026 Plan, the Company&#8217;s 2011 Equity Incentive Plan, and the Treeline Plan (collectively, with the 2026 Plan, the &#8220;</font><font style="font-style: italic;">Prior Plans</font><font style="font-weight: normal;">&#8221;) that cease to be subject to such awards by forfeiture, termination, or otherwise after the Effective Date; (e) Shares issued under the Prior Plans that are repurchased by the Company or are otherwise forfeited; and (f)&#160;Shares that are subject to awards under the Prior Plans that are used to pay the Exercise Price of a stock option or withheld to satisfy the withholding obligations for Tax-Related Items related to any award; provided, however, that any Shares reserved and available for grant and issuance pursuant to subparts (b)-(e) of this <u>Section&#160;2.1</u> shall be issuable as Common Stock of the Company regardless of their series or class. After the Effective Date, no further awards can be granted under the 2026 Plan.</font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">2.2.&#8195;<font style="font-weight: normal;"><u>Lapsed, Returned Awards</u>. Shares subject to Awards, and Shares issued under the Plan under any Award, will again be available for grant and issuance in connection with subsequent Awards under this Plan to the extent such Shares: (a) are subject to issuance upon exercise of an Option or SAR granted under this Plan but which cease to be subject to the Option or SAR for any reason other than exercise of the Option or SAR, (b) are subject to Awards granted under this Plan that are forfeited or are repurchased by the Company at the original purchase price, (c) are subject to Awards granted under this Plan that otherwise terminate without such Shares being issued or (d) are surrendered pursuant to an Exchange Program. To the extent an Award under the Plan is paid out in cash or other property rather than Shares, such cash payment will not result in reducing the number of Shares available for issuance under the Plan. Shares used to pay the Exercise Price of an Award or withheld to satisfy the tax withholding obligations related to an Award will become available for future grant or sale under the Plan. For the avoidance of doubt, Shares that otherwise become available for grant and issuance because of the provisions of this Section&#160;2.2 shall not include Shares subject to Awards that initially became available because of the substitution clause in Section&#160;21.2 hereof. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">2.3.&#8195;<font style="font-weight: normal;"><u>Minimum Share Reserve</u>. At all times the Company shall reserve and keep available a sufficient number of Shares as will be required to satisfy the requirements of all outstanding Awards granted under this Plan. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">2.4.&#8195;<font style="font-weight: normal;"><u>Automatic Share Reserve Increase</u>. The number of Shares available for grant and issuance under the Plan will be increased on January&#160;1<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">st</sup> of each of the first ten (10) calendar years during the term of the Plan by the lesser of (i) 5% of the sum of: (a) total number of Shares of all classes of the Company&#8217;s Common Stock; (b) the total number of Shares subject to Pre-Funded Warrants (if any); and (c) the total number of shares of the Company&#8217;s Common Stock issuable upon conversion of any preferred stock (if any), in each case outstanding on the immediately preceding December&#160;31st (rounded down to the next whole share) or (ii) such lesser number of Shares determined by the Board or the Compensation Committee. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 8pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">2.5.&#8195;<font style="font-weight: normal;"><u>ISO Limitation</u>. No more than 1,000,000,000 Shares will be issued pursuant to the exercise of ISOs granted under the Plan. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">2.6.&#8195;<font style="font-weight: normal;"><u>Adjustment of Shares</u>. If the number or class of outstanding Shares is changed by a stock dividend, extraordinary dividend or distribution (whether in cash, shares, or other property, other than a regular cash dividend), recapitalization, stock split, reverse stock split, subdivision, combination, consolidation, conversion, reclassification, spin-off, or similar change in the capital structure of the Company, without consideration, then (a) the number and class of Shares reserved for issuance and future grant under the Plan set forth in Section&#160;2.1 of this Plan, including Shares reserved under sub-clauses (a)-(d) of <u>Section&#160;2.1 </u>of this Plan, (b) the Exercise Prices of and number and class of Shares subject to outstanding Options and SARs, (c) the number and class of Shares subject to other outstanding Awards and (d) the maximum number and class of Shares that may be issued as ISOs set forth in Section&#160;2.5, will be proportionately adjusted, subject to any required action by the Board or the stockholders of the Company and in compliance with applicable securities or other laws, provided that fractions of a Share will not be issued. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">If, by reason of an adjustment pursuant to this Section&#160;2.6, a Participant&#8217;s Award Agreement or other agreement related to any Award, or the Shares subject to such Award, covers additional or different shares of stock or securities, then such additional or different shares, and the Award Agreement or such other agreement in respect thereof, will be subject to all of the terms, conditions, and restrictions which were applicable to the Award or the Shares subject to such Award prior to such adjustment. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">3.&#8195;<u>ELIGIBILITY</u><font style="font-weight: normal;">. ISOs may be granted only to Employees of the Company and its Parent and Subsidiaries. All other Awards may be granted to Employees, Consultants, Directors, and Non-Employee Directors, provided such Consultants, Directors, and Non-Employee Directors render bona fide Services not in connection with the offer and sale of securities in a capital-raising transaction. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">4.&#8195;<u>ADMINISTRATION</u><font style="font-weight: normal;">. </font></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">I-2<br></div></div></div>
<!--End Page 498-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 499-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_308-annexi_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">4.1.&#8195;<font style="font-weight: normal;"><u>Committee Composition; Authority</u>. This Plan will be administered by the Committee or by the Board acting as the Committee. Subject to the general purposes, terms, and conditions of this Plan, and to the direction of the Board, the Committee will have full power to implement and carry out this Plan, except, however, the Board shall establish the terms for the grant of an Award to Non-Employee Directors. The Committee will have the authority to: </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(a)&#8195;construe and interpret this Plan, any Award Agreement, and any other agreement or document executed pursuant to this Plan; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(b)&#8195;prescribe, amend, and rescind rules and regulations relating to this Plan or any Award; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(c)&#8195;select persons to receive Awards; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(d)&#8195;approve forms of Award Agreements for use under this Plan; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(e)&#8195;determine the form and terms and conditions, not inconsistent with the terms of the Plan, of any Award granted hereunder. Such terms and conditions include, but are not limited to, the Exercise Price, the time or times when Awards may vest and be exercised (which may be based on performance criteria) or settled, any vesting acceleration or waiver of forfeiture restrictions, the method to satisfy withholding obligations for Tax-Related Items or any other tax liability legally due, and any restriction or limitation regarding any Award or the Shares relating thereto, based in each case on such factors as the Committee will determine; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(f)&#8195;determine the number of Shares or other consideration subject to Awards; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(g)&#8195;determine the Fair Market Value in good faith and interpret the applicable provisions of this Plan and the definition of Fair Market Value in connection with circumstances that impact the Fair Market Value, if necessary; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(h)&#8195;determine whether Awards will be granted singly, in combination with, in tandem with, in replacement of, or as alternatives to, other Awards under this Plan or any other incentive or compensation plan of the Company or any Parent, Subsidiary, or Affiliate; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(i)&#8195;grant waivers of Plan or Award conditions or modify or amend any Awards; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(j)&#8195;determine the vesting, exercisability, settlement and payment of Awards; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(k)&#8195;correct any defect, supply any omission or reconcile any inconsistency in this Plan, any Award or any Award Agreement; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(l)&#8195;determine whether an Award has been vested and/or earned; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(m)&#8195;determine the terms and conditions of any, and to institute any Exchange Program; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(n)&#8195;reduce, waive or modify any criteria with respect to Performance Factors; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(o)&#8195;adjust Performance Factors; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(p)&#8195;adopt terms and conditions, rules, and/or procedures (including the adoption of any subplan under this Plan) relating to the operation and administration of the Plan to facilitate compliance with local law and procedures outside of the United States or to qualify Awards for special tax treatment under laws of jurisdictions other than the United States; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(q)&#8195;exercise discretion with respect to Performance Awards; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(r)&#8195;make all other determinations necessary or advisable for the administration of this Plan; and </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(s)&#8195;delegate any of the foregoing to a subcommittee or to one or more executive officers pursuant to a specific delegation as permitted by applicable law, including Section&#160;157(c) of the Delaware General Corporation Law. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">4.2.&#8195;<font style="font-weight: normal;"><u>Committee Interpretation and Discretion</u>. Any determination made by the Committee with respect to any Award shall be made in its sole discretion at the time of grant of the Award or, unless in contravention of any express term of the Plan or Award, at any later time, and such determination shall be final and binding on the Company and all persons having an interest in any Award under the Plan. Any dispute regarding the interpretation of the Plan or any Award Agreement shall be submitted by the Participant or Company to the Committee for review. The resolution of such a dispute by the Committee shall be final and binding on the Company and the Participant. The Committee may delegate to one or more executive officers the authority to review and resolve disputes with respect to Awards held by Participants who are not Insiders, and such resolution shall be final and binding on the Company and the Participant. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">4.3.&#8195;<font style="font-weight: normal;"><u>Section&#160;16 of the Exchange Act</u>. Awards granted to Participants who are subject to Section&#160;16 of the Exchange Act must be approved by two or more &#8220;non-employee directors&#8221; (as defined in the regulations promulgated under Section&#160;16 of the Exchange Act). </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">4.4.&#8195;<font style="font-weight: normal;"><u>Documentation</u>. The Award Agreement for a given Award, the Plan, and any other documents may be delivered to, and accepted by, a Participant or any other person in any manner (including electronic distribution or posting) that meets applicable legal requirements. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">4.5.&#8195;<font style="font-weight: normal;"><u>Award Recipients Outside of the U.S</u>. Notwithstanding any provision of the Plan to the contrary, to facilitate the administration of this Plan and compliance with the laws and practices in countries outside of the United States in which the Company and its Subsidiaries, and Affiliates operate or have Employees or other individuals eligible for Awards, the Committee, in its sole discretion, shall have the power and authority to: (a) determine which Subsidiaries and Affiliates shall be covered by the Plan; (b) determine which individuals outside the United States are eligible to participate in the Plan, which may include individuals who provide Services to the Company, Subsidiary or Affiliate under </font></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">I-3<br></div></div></div>
<!--End Page 499-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 500-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_308-annexi_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">an agreement with a nation or agency; (c) modify the terms and conditions of any Award granted to individuals outside the United States or non-U.S. nationals to comply with applicable local laws, policies, customs, and practices; (d) establish subplans and modify exercise procedures, vesting conditions, and other terms and procedures to the extent the Committee determines such actions to be necessary or advisable for legal or administrative reasons (and such subplans and/or modifications shall be attached to this Plan and/or to Award Agreements as appendices, if necessary); and (e) take any action, before or after an Award is made, that the Committee determines to be necessary or advisable to obtain approval or facilitate compliance with any local governmental regulatory exemptions or approvals, <u>provided</u>, however, that no action taken under this Section&#160;4.5 shall increase the Share limitations contained in Section&#160;2.1 hereof. Notwithstanding the foregoing, the Committee may not take any actions hereunder, and no Awards shall be granted or administered, that would violate the Exchange Act or any other applicable United States securities law, the Code, or any other applicable United States governing statute or law. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">5.&#8195;<u>OPTIONS</u><font style="font-weight: normal;">. An Option is the right but not the obligation to purchase a Share, subject to certain conditions, if applicable. The Committee may grant Options to eligible Employees, Consultants, and Directors and will determine whether such Options will be Incentive Stock Options within the meaning of the Code (&#8220;</font><font style="font-style: italic;">ISOs</font><font style="font-weight: normal;">&#8221;) or Nonqualified Stock Options (&#8220;</font><font style="font-style: italic;">NSOs</font><font style="font-weight: normal;">&#8221;), the number of Shares subject to the Option, the Exercise Price of the Option, the period during which the Option may vest and be exercised, and all other terms and conditions of the Option, subject to the following terms of this section. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">5.1.&#8195;<font style="font-weight: normal;"><u>Option Grant</u>. Each Option granted under this Plan will be evidenced by an Award Agreement and will identify the Option as an ISO or an NSO. An Option may be, but need not be, awarded upon satisfaction of such Performance Factors during any Performance Period as are set out in advance in the Participant&#8217;s individual Award Agreement. If the Option is being earned upon the satisfaction of Performance Factors, then the Committee will: (a) determine the nature, length, and starting date of any Performance Period for each Option; and (b) select from among the Performance Factors to be used to measure the performance, if any. Performance Periods may overlap, and Participants may participate simultaneously with respect to Options that are subject to different performance goals and other criteria. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">5.2.&#8195;<font style="font-weight: normal;"><u>Date of Grant</u>. The date of grant of an Option will be the date on which the Committee makes the determination to grant such Option, or a specified future date. The Award Agreement and a copy of this Plan will be delivered to the Participant within a reasonable time after the granting of the Option. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">5.3.&#8195;<font style="font-weight: normal;"><u>Exercise Period</u>. Options may be vested and exercisable within the times or upon the conditions as set forth in the Award Agreement governing such Option, <u>provided</u>, however, that no Option will be exercisable after the expiration of ten (10) years from the date the Option is granted and <u>provided </u>further that no ISO granted to a person who, at the time the ISO is granted, directly or by attribution owns more than ten percent (10%) of the total combined voting power of all classes of stock of the Company or of any Parent or Subsidiary of the Company (&#8220;</font><font style="font-style: italic;">Ten&#160;Percent Stockholder</font><font style="font-weight: normal;">&#8221;) will be exercisable after the expiration of five (5) years from the date the ISO is granted. The Committee also may provide for Options to become exercisable at one time or from time to time, periodically or otherwise, in such number of Shares or percentage of Shares as the Committee determines. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">5.4.&#8195;<font style="font-weight: normal;"><u>Exercise Price</u>. The Exercise Price of an Option will be determined by the Committee when the Option is granted, <u>provided</u> that: (a)&#160;the Exercise Price of an Option will be not less than one hundred percent (100%) of the Fair Market Value of the Shares on the date of grant, and (b) the Exercise Price of any ISO granted to a Ten Percent Stockholder will not be less than one hundred ten percent (110%) of the Fair Market Value of the Shares on the date of grant. Payment for the Shares purchased may be made in accordance with Section&#160;11 and the Award Agreement and in accordance with any procedures established by the Company. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">5.5.&#8195;<font style="font-weight: normal;"><u>Method of Exercise</u>. Any Option granted hereunder will be vested and exercisable according to the terms of the Plan and at such times and under such conditions as determined by the Committee and set forth in the Award Agreement. An Option may not be exercised for a fraction of a Share. An Option will be deemed exercised when the Company and/or an authorized third party administrator (the &#8220;</font><font style="font-style: italic;">Third Party Administrator</font><font style="font-weight: normal;">&#8221;) receives: (a) notice of exercise (in such form as the Committee may specify from time to time) from the person entitled to exercise the Option and/or via electronic execution through the authorized Third Party Administrator), and (b) full payment for the Shares with respect to which the Option is exercised (together with an amount sufficient to satisfy withholding obligations for any applicable Tax-Related Items). Full payment may consist of any consideration and method of payment authorized by the Committee and permitted by the Award Agreement and the Plan. Shares issued upon exercise of an Option will be issued in the name of the Participant. Until the Shares are issued (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company), no right to vote or receive dividends or any other rights as a stockholder will exist with respect to the Shares, notwithstanding the exercise of the Option. The Company will issue (or cause to be issued) such Shares promptly after the Option is exercised. No adjustment will be made for a dividend or other right for which the record date is prior to the date the Shares are issued, except as provided in Section 2.6 of the Plan. Exercising an Option in any manner will decrease the number of Shares thereafter available, both for purposes of the Plan and for sale under the Option, by the number of Shares as to which the Option is exercised. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">5.6.&#8195;<font style="font-weight: normal;"><u>Termination of Service</u>. Unless otherwise determined by the Committee or except as otherwise expressly provided in the Award Agreement or any other agreement between the Participant and the Company (or any Parent, Subsidiary or Affiliate, if applicable), if the Participant&#8217;s Service terminates for any reason except for Cause or the Participant&#8217;s death or Disability, then the Participant may exercise such Participant&#8217;s Options only to the extent that such Options would have been exercisable by the Participant on the date Participant&#8217;s Service terminates, except as otherwise determined by the Committee or required by applicable law. Such Options must be exercised by the Participant no later than three (3) months after the date Participant&#8217;s Service terminates (or such shorter or longer time period as may be determined by the Committee, including as necessary to give effect to any provision in any applicable agreement between the Participant and the Company (or any </font></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">I-4<br></div></div></div>
<!--End Page 500-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 501-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_308-annexi_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Parent, Subsidiary or Affiliate, if applicable), providing for acceleration of the Participant&#8217;s Options in connection with a Corporate Transaction, with any exercise of an Option beyond three (3) months after the date Participant&#8217;s employment terminates deemed to be the exercise of an NSO), but in any event no later than the expiration date of the Options. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(a)&#8195;<u>Death</u>. Unless otherwise determined by the Committee or except as otherwise expressly provided in the Award Agreement or any other agreement between the Participant and the Company (or any Parent, Subsidiary or Affiliate, if applicable), if the Participant&#8217;s Service terminates because of the Participant&#8217;s death (or the Participant dies within three (3) months after Participant&#8217;s Service terminates other than for Cause or because of the Participant&#8217;s Disability), then the Participant&#8217;s Options may be exercised only to the extent that such Options would have been exercisable by the Participant on the date Participant&#8217;s Service terminates and must be exercised by the Participant&#8217;s legal representative, or authorized assignee, no later than twelve (12) months after the date Participant&#8217;s Service terminates (or such shorter or longer time period as may be determined by the Committee), but in any event no later than the expiration date of the Options. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(b)&#8195;<u>Disability</u>. Unless otherwise determined by the Committee or except as otherwise expressly provided in the Award Agreement or any other agreement between the Participant and the Company (or any Parent, Subsidiary or Affiliate, if applicable), if the Participant&#8217;s Service terminates because of the Participant&#8217;s Disability, then the Participant&#8217;s Options may be exercised only to the extent that such Options would have been exercisable by the Participant on the date Participant&#8217;s Service terminates and must be exercised by the Participant (or the Participant&#8217;s legal representative or authorized assignee) no later than twelve (12) months after the date Participant&#8217;s Service terminates (or such shorter or longer time period as may be determined by the Committee, with any exercise beyond (a)&#160;three&#160;(3)&#160;months after the date Participant&#8217;s employment terminates when the termination of Service is for a Disability that is not a &#8220;permanent and total disability&#8221; as defined in Section&#160;22(e)(3) of the Code or (b) twelve (12) months after the date Participant&#8217;s employment terminates when the termination of Service is for a Disability that is a &#8220;permanent and total disability&#8221; as defined in Section&#160;22(e)(3) of the Code, deemed to be an exercise of an NSO), but in any event no later than the expiration date of the Options. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(c)&#8195;<u>Cause</u>. Unless otherwise determined by the Committee or expressly provided in the Award Agreement or any other agreement between the Participant and the Company (or any Parent, Subsidiary or Affiliate, if applicable), if the Participant&#8217;s Service terminates for Cause, or if the Committee has reasonably determined in good faith that such cessation of Service has resulted in connection with an act or failure to act constituting Cause (or such Participant&#8217;s Service could have been terminated for Cause (without regard to the lapsing of any required notice or cure periods in connection therewith) at the time such Participant terminated Service), then Participant&#8217;s Options (whether or not vested) shall expire effective as of such Participant&#8217;s date of termination of Service, or at such later time and on such conditions as are determined by the Committee, but in any event no later than the expiration date of the Options. Unless otherwise provided in the Award Agreement or other applicable agreement, Cause shall have the meaning set forth in the Plan. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">5.7.&#8195;<font style="font-weight: normal;"><u>Limitations on Exercise</u>. The Committee may specify a minimum number of Shares that may be purchased on any exercise of an Option, provided that such minimum number will not prevent any Participant from exercising the Option for the full number of Shares for which it is then exercisable. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">5.8.&#8195;<font style="font-weight: normal;"><u>Limitations on ISOs</u>. With respect to Awards granted as ISOs, to the extent that the aggregate Fair Market Value of the Shares with respect to which such ISOs are exercisable for the first time by the Participant during any calendar year (under all plans of the Company and any Parent or Subsidiary) exceeds one hundred thousand dollars ($100,000), such Options will be treated as NSOs. For purposes of this Section 5.8, ISOs will be taken into account in the order in which they were granted. The Fair Market Value of the Shares will be determined as of the time the Option with respect to such Shares is granted. In the event that the Code or the regulations promulgated thereunder are amended after the Effective Date to provide for a different limit on the Fair Market Value of Shares permitted to be subject to ISOs, such different limit will be automatically incorporated herein and will apply to any Options granted after the effective date of such amendment. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">5.9.&#8195;<font style="font-weight: normal;"><u>Modification, Extension or Renewal</u>. The Committee may modify, extend, or renew outstanding Options and authorize the grant of new Options in substitution therefor, <u>provided</u> that any such action may not, without the written consent of a Participant, impair any of such Participant&#8217;s rights under any Option previously granted, unless for the purpose of complying with applicable laws and regulations. Any outstanding ISO that is modified, extended, renewed, or otherwise altered will be treated in accordance with Section&#160;424(h) of the Code. Subject to Section&#160;18 of this Plan, by written notice to affected Participants, the Committee may reduce the Exercise Price of outstanding Options without the consent of such Participants, <u>provided</u>, however, that the Exercise Price may not be reduced below the Fair Market Value on the date the action is taken to reduce the Exercise Price. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">5.10.&#8195;<font style="font-weight: normal;"><u>No Disqualification</u>. Notwithstanding any other provision in this Plan, no term of this Plan relating to ISOs will be interpreted, amended, or altered, nor will any discretion or authority granted under this Plan be exercised, so as to disqualify this Plan under Section&#160;422 of the Code or, without the consent of the Participant affected, to disqualify any ISO under Section&#160;422 of the Code. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">6.&#8195;<u>RESTRICTED STOCK AWARDS</u><font style="font-weight: normal;">. A Restricted Stock Award is an offer by the Company to sell to an eligible Employee, Consultant, or Director, Shares that are subject to restrictions (&#8220;</font><font style="font-style: italic;">Restricted Stock</font><font style="font-weight: normal;">&#8221;). The Committee will determine to whom an offer will be made, the number of Shares the Participant may purchase, the Purchase Price, the restrictions under which the Shares will be subject, and all other terms and conditions of the Restricted Stock Award, subject to the Plan. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">6.1.&#8195;<font style="font-weight: normal;"><u>Restricted Stock Purchase Agreement</u>. All purchases under a Restricted Stock Award will be evidenced by an Award Agreement. Except as may otherwise be provided in an Award Agreement, a Participant accepts a Restricted Stock Award by signing and delivering to the </font></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">I-5<br></div></div></div>
<!--End Page 501-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 502-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_308-annexi_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Company an Award Agreement and/or via electronic acceptance through the Third-Party Administrator with full payment of the Purchase Price, within thirty (30) days from the date the Award Agreement was delivered to the Participant. If the Participant does not accept such Award within thirty (30) days, then the offer to purchase such Restricted Stock Award will terminate, unless the Committee determines otherwise. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">6.2.&#8195;<font style="font-weight: normal;"><u>Purchase Price</u>. The Purchase Price for Shares issued pursuant to a Restricted Stock Award will be determined by the Committee and may be less than the Fair Market Value on the date the Restricted Stock Award is granted. Payment of the Purchase Price must be made in accordance with Section&#160;11 and the Award Agreement, and any procedures established by the Company. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">6.3.&#8195;<font style="font-weight: normal;"><u>Terms of Restricted Stock Awards</u>. Restricted Stock Awards will be subject to such restrictions as the Committee may impose or are required by law. These restrictions may be based on completion of a specified period of Service or upon completion of Performance Factors, if any, during any Performance Period as set out in advance in the Participant&#8217;s Award Agreement. Prior to the grant of a Restricted Stock Award, the Committee shall: (a) determine the nature, length, and starting date of any Performance Period for the Restricted Stock Award; (b) select from among the Performance Factors to be used to measure performance goals, if any; and (c) determine the number of Shares that may be awarded to the Participant. Performance Periods may overlap and a Participant may participate simultaneously with respect to Restricted Stock Awards that are subject to different Performance Periods and having different performance goals and other criteria. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">6.4.&#8195;<font style="font-weight: normal;"><u>Termination of Service</u>. Except as may be set forth in the Participant&#8217;s Award Agreement or any other agreement between the Participant and the Company (or any Parent, Subsidiary or Affiliate, if applicable), vesting ceases on such date Participant&#8217;s Service terminates (unless determined otherwise by the Committee). </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">7.&#8195;<u>STOCK BONUS AWARDS</u><font style="font-weight: normal;">. A Stock Bonus Award is an Award to an eligible Employee, Consultant, or Director of Shares for Services to be rendered or for past Services already rendered to the Company or any Parent, Subsidiary or Affiliate. All Stock Bonus Awards will be made pursuant to an Award Agreement. No payment from the Participant shall be required for Shares awarded pursuant to a Stock Bonus Award. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">7.1.&#8195;<font style="font-weight: normal;"><u>Terms of Stock Bonus Awards</u>. The Committee will determine the number of Shares to be awarded to the Participant under a Stock Bonus Award and any restrictions thereon. These restrictions may be based upon completion of a specified period of Service or upon satisfaction of performance goals based on Performance Factors during any Performance Period as set out in advance in the Participant&#8217;s Stock Bonus Agreement. Prior to the grant of any Stock Bonus Award, the Committee shall: (a) determine the restrictions to which the Stock Bonus Award is subject, including the nature, length, and starting date of any Performance Period for the Stock Bonus Award; (b) select from among the Performance Factors, if any, to be used to measure performance goals; and (c) determine the number of Shares that may be awarded to the Participant. Performance Periods may overlap and a Participant may participate simultaneously with respect to Stock Bonus Awards that are subject to different Performance Periods and different performance goals and other criteria. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">7.2.&#8195;<font style="font-weight: normal;"><u>Form&#160;of Payment to Participant</u>. Payment may be made in the form of cash, whole Shares, or a combination thereof, or Services based on the Fair Market Value of the Shares earned under a Stock Bonus Award on the date of payment, as determined in the sole discretion of the Committee. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">7.3.&#8195;<font style="font-weight: normal;"><u>Termination of Service</u>. Except as may be set forth in the Participant&#8217;s Award Agreement or any other agreement between the Participant and the Company (or any Parent, Subsidiary or Affiliate, if applicable), vesting ceases on such date Participant&#8217;s Service terminates (unless determined otherwise by the Committee). </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">8.&#8195;<u>STOCK APPRECIATION RIGHTS</u><font style="font-weight: normal;">. A Stock Appreciation Right (&#8220;</font><font style="font-style: italic;">SAR</font><font style="font-weight: normal;">&#8221;) is an Award to an eligible Employee, Consultant, or Director that may be settled in cash, or Shares (which may consist of Restricted Stock or RSUs), having a value equal to (a) the difference between the Fair Market Value on the date of exercise less the Exercise Price multiplied by (b) the number of Shares with respect to which the SAR is being settled (subject to any maximum number of Shares that may be issuable as specified in an Award Agreement). All SARs will be made pursuant to an Award Agreement. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">8.1.&#8195;<font style="font-weight: normal;"><u>Terms of SARs</u>. The Committee will determine the terms of each SAR including, without limitation: (a) the number of Shares subject to the SAR; (b) the Exercise Price and the time or times during which the SAR may be exercised and settled; (c) the consideration to be distributed on exercise and settlement of the SAR; and (d) the effect of the Participant&#8217;s termination of Service on each SAR. The Exercise Price of the SAR will be determined by the Committee when the SAR is granted, and may not be less than the Fair Market Value of the Shares on the date of grant. A SAR may be awarded upon satisfaction of Performance Factors, if any, during any Performance Period as are set out in advance in the Participant&#8217;s individual Award Agreement. If the SAR is being earned upon the satisfaction of Performance Factors, then the Committee will: (x) determine the nature, length and starting date of any Performance Period for each SAR; and (y) select from among the Performance Factors to be used to measure the performance, if any. Performance Periods may overlap and Participants may participate simultaneously with respect to SARs that are subject to different Performance Factors and other criteria. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">8.2.&#8195;<font style="font-weight: normal;"><u>Exercise Period and Expiration Date</u>. A SAR will be exercisable within the times or upon the occurrence of events determined by the Committee and set forth in the Award Agreement governing such SAR. The SAR Agreement shall set forth the expiration date; provided that no SAR will be exercisable after the expiration of ten (10) years from the date the SAR is granted. The Committee may also provide for SARs to become exercisable at one time or from time to time, periodically or otherwise (including, without limitation, upon the attainment during a Performance Period of performance goals based on Performance Factors), in such number of Shares or percentage of the Shares subject to the SAR as the Committee determines. Except as may be set forth in the Participant&#8217;s Award Agreement, vesting ceases on the date Participant&#8217;s Service terminates (unless determined otherwise by the Committee). Notwithstanding the foregoing, the rules of <u>Section&#160;5.6</u> also will apply to SARs. </font></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">I-6<br></div></div></div>
<!--End Page 502-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 503-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_308-annexi_pg7"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">8.3.&#8195;<font style="font-weight: normal;"><u>Form&#160;of Settlement</u>. Upon exercise of a SAR, a Participant will be entitled to receive payment from the Company in an amount determined by multiplying (a) the difference between the Fair Market Value of a Share on the date of exercise less the Exercise Price; by (b) the number of Shares with respect to which the SAR is exercised. At the discretion of the Committee, the payment from the Company for the SAR exercise may be in cash, in Shares of equivalent value, or in some combination thereof. The portion of a SAR being settled may be paid currently or on a deferred basis with such interest, if any, as the Committee determines, provided that the terms of the SAR and any deferral satisfy the requirements of Section&#160;409A of the Code, to the extent applicable. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">8.4.&#8195;<font style="font-weight: normal;"><u>Termination of Service</u>. Except as may be set forth in the Participant&#8217;s Award Agreement or any other agreement between the Participant and the Company (or any Parent, Subsidiary or Affiliate, if applicable), vesting ceases on such date Participant&#8217;s Service terminates (unless determined otherwise by the Committee). </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">9.&#8195;<u>RESTRICTED STOCK UNITS</u><font style="font-weight: normal;">. A Restricted Stock Unit (&#8220;</font><font style="font-style: italic;">RSU</font><font style="font-weight: normal;">&#8221;) is an Award to an eligible Employee, Consultant, or Director covering a number of Shares that may be settled by issuance of those Shares (which may consist of Restricted Stock) or in cash. All RSUs shall be made pursuant to an Award Agreement. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">9.1.&#8195;<font style="font-weight: normal;"><u>Terms of RSUs</u>. The Committee will determine the terms of an RSU including, without limitation: (a) the number of Shares subject to the RSU, (b) the time or times during which the RSU may be settled, (c) the consideration to be distributed on settlement, and (d) the effect of the Participant&#8217;s termination of Service on each RSU, <u>provided</u> that no RSU will have a term longer than ten (10) years. An RSU may be awarded upon satisfaction of such performance goals based on Performance Factors during any Performance Period as are set out in advance in the Participant&#8217;s Award Agreement. If the RSU is being earned upon satisfaction of Performance Factors, then the Committee will: (i) determine the nature, length, and starting date of any Performance Period for the RSU; (ii) select from among the Performance Factors to be used to measure the performance, if any; and (iii) determine the number of Shares deemed subject to the RSU. Performance Periods may overlap, and Participants may participate simultaneously with respect to RSUs that are subject to different Performance Periods and different performance goals and other criteria. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">9.2.&#8195;<font style="font-weight: normal;"><u>Form&#160;and Timing of Settlement</u>. Payment of earned RSUs shall be made as soon as practicable after the date(s) determined by the Committee and set forth in the Award Agreement. The Committee, in its sole discretion, may settle earned RSUs in cash, Shares, or a combination of both. The Committee may also permit a Participant to defer payment under a RSU to a date or dates after the RSU is earned, <u>provided</u> that the terms of the RSU and any deferral satisfy the requirements of Section&#160;409A of the Code to the extent applicable. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">9.3.&#8195;<font style="font-weight: normal;"><u>Termination of Service</u>. Except as may be set forth in the Participant&#8217;s Award Agreement or any other agreement between the Participant and the Company (or any Parent, Subsidiary or Affiliate, if applicable), vesting ceases on such date Participant&#8217;s Service terminates (unless determined otherwise by the Committee). </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">10.&#8195;<u>PERFORMANCE AWARDS</u><font style="font-weight: normal;">. A Performance Award is an Award to an eligible Employee, Consultant, or Director that is based upon the attainment of performance goals, as established by the Committee, and other terms and conditions specified by the Committee, and may be settled in cash, Shares (which may consist of, without limitation, Restricted Stock), other property, or any combination thereof. Grants of Performance Awards shall be made pursuant to an Award Agreement. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(a)&#8195;<u>Performance Shares</u>. The Committee may grant Awards of Performance Shares, designate the Participants to whom Performance Shares are to be awarded, and determine the number of Performance Shares and the terms and conditions of each such Award. Performance Shares shall consist of a unit valued by reference to a designated number of Shares, the value of which may be paid to the Participant by delivery of Shares or, if set forth in the Award Agreement, of such property as the Committee shall determine, including, without limitation, cash, Shares, other property, or any combination thereof, upon the attainment of performance goals, as established by the Committee, and other terms and conditions specified by the Committee. The amount to be paid under an Award of Performance Shares may be adjusted on the basis of such further consideration as the Committee shall determine in its sole discretion. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(b)&#8195;<u>Performance Units</u>. The Committee may grant Awards of Performance Units, designate the Participants to whom Performance Units are to be awarded, and determine the number of Performance Units and the terms and conditions of each such Award. Performance Units shall consist of a unit valued by reference to a designated amount of property other than Shares, which value may be paid to the Participant by delivery of such property as the Committee shall determine, including, without limitation, cash, Shares, other property, or any combination thereof, upon the attainment of performance goals, as established by the Committee, and other terms and conditions specified by the Committee. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(c)&#8195;<u>Cash-Settled Performance Awards</u>. The Committee may also grant cash-settled Performance Awards to Participants under the terms of this Plan. Such Awards will be based on the attainment of performance goals using the Performance Factors within this Plan that are established by the Committee for the relevant performance period. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">10.2.&#8195;<font style="font-weight: normal;"><u>Terms of Performance Awards</u>. The Committee will determine, and each Award Agreement shall set forth, the terms of each Performance Award including, without limitation: (a) the amount of any cash bonus, (b) the number of Shares deemed subject to an Award of Performance Shares, (c) the Performance Factors and Performance Period that shall determine the time and extent to which each Award of Performance Shares shall be settled, (d) the consideration to be distributed on settlement, and (e) the effect of the Participant&#8217;s termination of Service on each Performance Award. In establishing Performance Factors and the Performance Period the Committee shall: (i) determine the nature, length, and starting date of any Performance Period; (ii) select from among the Performance Factors to be used; and (iii) determine the </font></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">I-7<br></div></div></div>
<!--End Page 503-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 504-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_308-annexi_pg8"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">number of Shares deemed subject to the Award of Performance Shares. Prior to settlement, the Committee shall determine the extent to which Performance Awards have been earned. Performance Periods may overlap and Participants may participate simultaneously with respect to Performance Awards that are subject to different Performance Periods and different performance goals and other criteria. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">10.3.&#8195;<font style="font-weight: normal;"><u>Termination of Service</u>. Except as may be set forth in the Participant&#8217;s Award Agreement or any other agreement between the Participant and the Company (or any Parent, Subsidiary or Affiliate, if applicable), vesting ceases on the date Participant&#8217;s Service terminates (unless determined otherwise by the Committee). </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">11.&#8195;<u>PAYMENT FOR SHARE PURCHASES</u><font style="font-weight: normal;">. Payment from a Participant for Shares purchased pursuant to this Plan may be made in cash or by cash equivalent or, where expressly approved for the Participant by the Committee and where permitted by law (and to the extent not otherwise set forth in the applicable Award Agreement): </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(a)&#8195;by cancellation of indebtedness of the Company to the Participant; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(b)&#8195;by surrender of shares of the Company held by the Participant that have a Fair Market Value on the date of surrender equal to the aggregate Exercise Price of the Shares as to which said Award will be exercised or settled; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(c)&#8195;by waiver of compensation due or accrued to the Participant for Services rendered or to be rendered to the Company or a Parent, Subsidiary or Affiliate; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(d)&#8195;by consideration received by the Company pursuant to a broker-assisted or other form of cashless exercise program implemented by the Company in connection with the Plan; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(e)&#8195;by any combination of the foregoing; or </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(f)&#8195;by any other method of payment as is permitted by applicable law. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The Committee may limit the availability of any method of payment, to the extent the Committee determines, in its discretion, such limitation is necessary or advisable to comply with applicable law or facilitate the administration of the Plan. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">12.&#8195;<u>GRANTS TO NON-EMPLOYEE DIRECTORS</u><font style="font-weight: normal;">. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">12.1.&#8195;<font style="font-weight: normal;"><u>General</u>. Awards pursuant to this Section&#160;12 shall be granted only to Non-Employee Directors, who are eligible to receive any type of Award offered under this Plan except ISOs. Awards pursuant to this Section&#160;12 may be automatically made pursuant to policy adopted by the Board or granted from time to time as determined in the discretion of the Board. A Non-Employee Director who is elected or re-elected as a member of the Board will be eligible to receive an Award under this <u>Section 12</u>. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">12.2.&#8195;<font style="font-weight: normal;"><u>Calendar Year Limitation</u>. A Non-Employee Director may not receive Awards under the Plan that, when combined with cash compensation received for service as a Non-Employee Director following the Effective Date, exceed Seven Hundred and Fifty Thousand Dollars ($750,000) in value (as described below) in any calendar year of his or her service as a Non-Employee Director, increased to One Million Dollars ($1,000,000) in value (as described below) in the calendar year of his or her initial Services as a Non-Employee Director. The value of Awards for purposes of complying with this maximum will be determined as follows: (a) for Options and SARs, grant date fair value will be calculated using the Company&#8217;s regular valuation methodology for determining the grant date fair value of Options or SARs for financial reporting purposes, and (b) for all other Awards other than Options and SARs, grant date fair value will be determined by either (i) calculating the product of the Fair Market Value per Share on the date of grant and the aggregate number of Shares subject to the Award, or (ii) calculating the product using an average of the Fair Market Value over a number of trading days and the aggregate number of Shares subject to the Award as determined by the Committee. Awards granted, or cash compensation paid, to an individual while he or she was serving in the capacity as an Employee or in consideration of Services as a Consultant but not a Non-Employee Director will not count for purposes of the limitations set forth in this section. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">12.3.&#8195;<font style="font-weight: normal;"><u>Vesting, Exercisability and Settlement</u>. Except as set forth in Section&#160;21, Awards will vest, become exercisable, and be settled as determined by the Board. With respect to Options and SARs, the Exercise Price granted to Non-Employee Directors shall not be less than the Fair Market Value of the Shares at the time that such Option or SAR is granted. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">12.4.&#8195;<font style="font-weight: normal;"><u>Election to Receive Awards in Lieu of Cash</u>. A Non-Employee Director may elect to receive his or her annual retainer payments and/or meeting fees from the Company in the form of cash or Awards or a combination thereof, if permitted, and as determined, by the Committee. Such Awards shall be issued under the Plan. An election under this section shall be filed with the Company on the form prescribed by the Company. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">13.&#8195;<u>WITHHOLDING TAXES</u><font style="font-weight: normal;">. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">13.1.&#8195;<font style="font-weight: normal;"><u>Withholding Generally</u>. In connection with any tax or tax withholding event related to Awards granted under this Plan, the Company may require the Participant to remit to the Company (or to the Third Party Administrator or to the Parent, Subsidiary or Affiliate, as applicable, employing the Participant or to which the Participant provides Services) an amount sufficient to satisfy applicable U.S. and non-U.S. federal, state and local income tax, social insurance, payroll tax, fringe benefits tax, payment on account or other tax-related items (the &#8220;</font><font style="font-style: italic;">Tax-Related Items</font><font style="font-weight: normal;">&#8221;) related to the Participant&#8217;s participation in the Plan and legally applicable to the Participant prior to the delivery of Shares, cash or other property pursuant to exercise or settlement of any Award or such other tax event. Whenever payments in satisfaction of Awards </font></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">I-8<br></div></div></div>
<!--End Page 504-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 505-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_308-annexi_pg9"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">granted under this Plan are to be made in cash, such payment will be net of an amount sufficient to satisfy applicable withholding obligations for Tax-Related Items. Unless otherwise determined by the Committee, the Fair Market Value of the Shares will be determined as of the date that the taxes are required to be withheld and such Shares will be valued based on the value of the actual trade or, if there is none, the Fair Market Value of the Shares as of the previous trading day. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">13.2.&#8195;<font style="font-weight: normal;"><u>Withholding</u>. The Committee, or its delegate(s), as permitted by applicable law, in its sole discretion and pursuant to such procedures as it may specify from time to time and to limitations of local law, may require or permit a Participant to satisfy such Tax-Related Items legally due from the Participant, in whole or in part, by (without limitation) (a) paying cash, (b) having the Company withhold otherwise deliverable cash or Shares having a Fair Market Value equal to the Tax-Related Items to be withheld, (c) delivering to the Company already-owned shares having a Fair Market Value equal to the Tax-Related Items to be withheld, or (d) withholding from the proceeds of the sale of otherwise deliverable Shares acquired pursuant to an Award either through a voluntary sale or through a mandatory sale arranged by the Company. The Company may withhold or account for these Tax-Related Items by considering applicable statutory withholding rates or other applicable withholding rates, including up to the maximum permissible statutory tax rate for the applicable tax jurisdiction, to the extent consistent with applicable laws. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">14.&#8195;<u>TRANSFERABILITY</u><font style="font-weight: normal;">. Unless determined otherwise by the Committee, an Award may not be sold, pledged, assigned, hypothecated, transferred, or disposed of in any manner other than by will or by the laws of descent or distribution. If the Committee makes an Award transferable, including, without limitation, by instrument to an inter vivos or testamentary trust in which the Awards are to be passed to beneficiaries upon the death of the trustor (settlor) or by gift or by domestic relations order to a Permitted Transferee, such Award will contain such additional terms and conditions as the Committee deems appropriate. All Awards shall be exercisable: (a) during the Participant&#8217;s lifetime only by (i) the Participant or (ii) the Participant&#8217;s guardian or legal representative; (b) after the Participant&#8217;s death, by the legal representative of the Participant&#8217;s heirs or legatees; and (c)&#160;in the case of all Awards except ISOs, by a Permitted Transferee. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">15.&#8195;<u>PRIVILEGES OF STOCK OWNERSHIP; RESTRICTIONS ON SHARES</u><font style="font-weight: normal;">. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">15.1.&#8195;<font style="font-weight: normal;"><u>Voting and Dividends</u>. No Participant will have any of the rights of a stockholder with respect to any Shares until the Shares are issued to the Participant, except for any Dividend Equivalent Rights permitted by an applicable Award Agreement. Any Dividend Equivalent Rights shall be subject to the same vesting or performance conditions as the underlying Award. In addition, the Committee may provide that any Dividend Equivalent Rights permitted by an applicable Award Agreement shall be deemed to have been reinvested in additional Shares or otherwise reinvested. After Shares are issued to the Participant, the Participant will be a stockholder and have all the rights of a stockholder with respect to such Shares, including the right to vote and receive all dividends or other distributions made or paid with respect to such Shares; <u>provided</u>, that if such Shares are Restricted Stock, then any new, additional or different securities the Participant may become entitled to receive with respect to such Shares by virtue of a stock dividend, stock split or any other change in the corporate or capital structure of the Company will be subject to the same restrictions as the Restricted Stock; <u>provided</u>, <u>further</u>, that the Participant will have no right to such stock dividends or stock distributions with respect to Unvested Shares, and any such dividends or stock distributions will be accrued and paid only at such time, if any, as such Unvested Shares become vested Shares. The Committee, in its discretion, may provide in the Award Agreement evidencing any Award that the Participant will be entitled to Dividend Equivalent Rights with respect to the payment of cash dividends on Shares underlying an Award during the period beginning on the date the Award is granted and ending, with respect to each Share subject to the Award, on the earlier of the date on which the Award is exercised or settled or the date on which it is forfeited; <u>provided</u>, that no Dividend Equivalent Right will be paid with respect to the Unvested Shares, and such dividends or stock distributions will be accrued and paid only at such time, if any, as such Unvested Shares become vested Shares. Such Dividend Equivalent Rights, if any, will be credited to the Participant in the form of additional whole Shares as of the date of payment of such cash dividends on Shares. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">15.2.&#8195;<font style="font-weight: normal;"><u>Restrictions on Shares</u>. At the discretion of the Committee, the Company may reserve to itself and/or its assignee(s) a right to repurchase (a &#8220;</font><font style="font-style: italic;">Right of Repurchase</font><font style="font-weight: normal;">&#8221;) a portion of any or all Unvested Shares held by a Participant following such Participant&#8217;s termination of Service at any time within ninety (90) days (or such longer or shorter time determined by the Committee) after the later of the date Participant&#8217;s Service terminates and the date the Participant purchases Shares under this Plan, for cash and/or cancellation of purchase money indebtedness, at the Participant&#8217;s Purchase Price or Exercise Price, as the case may be. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">16.&#8195;<u>CERTIFICATES</u><font style="font-weight: normal;">. All Shares or other securities whether or not certificated, delivered under this Plan will be subject to such stock transfer orders, legends, and other restrictions as the Committee may deem necessary or advisable, including restrictions under any applicable U.S. federal, state or foreign securities law, or any rules, regulations, and other requirements of the SEC or any stock exchange or automated quotation system upon which the Shares may be listed or quoted, and any non-U.S. exchange controls or securities law restrictions to which the Shares are subject. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">17.&#8195;<u>ESCROW; PLEDGE OF SHARES</u><font style="font-weight: normal;">. To enforce any restrictions on a Participant&#8217;s Shares, the Committee may require the Participant to deposit all certificates representing Shares, together with stock powers or other instruments of transfer approved by the Committee, appropriately endorsed in blank, with the Company or an agent designated by the Company to hold in escrow until such restrictions have lapsed or terminated. The Committee may cause a legend or legends referencing such restrictions to be placed on the certificates. Any Participant who is permitted to execute a promissory note as partial or full consideration for the purchase of Shares under this Plan will be required to pledge and deposit with the Company all or part of the Shares so purchased as collateral to secure the payment of the Participant&#8217;s obligation to the Company under the promissory note; <u>provided</u>, however, that the Committee may require or accept other or additional forms of collateral to secure the payment of such obligation and, in </font></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">I-9<br></div></div></div>
<!--End Page 505-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 506-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_308-annexi_pg10"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">any event, the Company will have full recourse against the Participant under the promissory note notwithstanding any pledge of the Participant&#8217;s Shares or other collateral. In connection with any pledge of the Shares, the Participant will be required to execute and deliver a written pledge agreement in such form as the Committee will from time to time approve. The Shares purchased with the promissory note may be released from the pledge on a pro rata basis as the promissory note is paid. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">18.&#8195;<u>REPRICING; EXCHANGE AND BUYOUT OF AWARDS</u><font style="font-weight: normal;">. Without prior stockholder approval the Committee may (a) reprice Options or SARs (and where such repricing is a reduction in the Exercise Price of outstanding Options or SARs, the consent of the affected Participants is not required provided written notice is provided to them, notwithstanding any adverse tax consequences to them arising from the repricing), and (b)&#160;with the consent of the respective Participants (unless not required pursuant to Section&#160;5.9 of the Plan), pay cash or issue new Awards in exchange for the surrender and cancellation of any, or all, outstanding Awards, including pursuant to an Exchange Program. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">19.&#8195;<u>SECURITIES LAW AND OTHER REGULATORY COMPLIANCE</u><font style="font-weight: normal;">. An Award will not be effective unless such Award is in compliance with all applicable U.S. and non-U.S. federal and state securities and exchange control and other laws, rules, and regulations of any governmental body, and the requirements of any stock exchange or automated quotation system upon which the Shares may then be listed or quoted, as they are in effect on the date of grant of the Award and also on the date of exercise or other issuance. Notwithstanding any other provision in this Plan, the Company will have no obligation to issue or deliver certificates for Shares under this Plan prior to: (a) obtaining any approvals from governmental agencies that the Company determines are necessary or advisable and/or (b) completion of any registration or other qualification of such Shares under any U.S. and non-U.S. federal or state law or ruling of any governmental body that the Company determines to be necessary or advisable. The Company will be under no obligation to register the Shares with the SEC or to effect compliance with the registration, qualification, or listing requirements of any state or non-U.S. securities laws, exchange control laws, stock exchange, or automated quotation system, and the Company will have no liability for any inability or failure to do so. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">20.&#8195;<u>NO OBLIGATION TO EMPLOY</u><font style="font-weight: normal;">. Nothing in this Plan or any Award granted under this Plan will confer or be deemed to confer on any Participant any right to continue in the employ of, or to continue any other Service with, the Company or any Parent, Subsidiary, or Affiliate or limit in any way the right of the Company or any Parent, Subsidiary, or Affiliate to terminate Participant&#8217;s Service at any time. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">21.&#8195;<u>CORPORATE TRANSACTIONS</u><font style="font-weight: normal;">. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">21.1.&#8195;<font style="font-weight: normal;"><u>Treatment of Awards in Corporate Transaction</u>. In the event that the Company is subject to a Corporate Transaction, outstanding Awards acquired under the Plan shall be subject to the agreement evidencing the Corporate Transaction, which need not treat all outstanding Awards in an identical manner. Such agreement, without the Participant&#8217;s consent, shall provide for one or more of the following with respect to all outstanding Awards as of the effective date of such Corporate Transaction: </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(a)&#8195;The continuation of an outstanding Award by the Company (if the Company is the successor entity). </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(b)&#8195;The assumption of outstanding Awards by the successor or acquiring entity (if any) in such Corporate Transaction (or by any of its Parents, if any), which assumption, will be binding on all Participants; <u>provided</u> that the Exercise Price and the number and nature of shares issuable upon exercise of any such Option or SAR, or upon the settlement of any Award that is subject to Section&#160;409A of the Code, will be adjusted appropriately pursuant to Section&#160;424(a) and Section&#160;409A of the Code. For the purposes of this Section&#160;21, an Award will be considered assumed if, following the Corporate Transaction, the Award confers the right to purchase or receive, for each Share subject to the Award immediately prior to the Corporate Transaction, the consideration (whether stock, cash, or other securities or property) received in the Corporate Transaction by holders of Shares for each Share held on the effective date of the transaction (and if holders were offered a choice of consideration, the type of consideration chosen by the holders of a majority of the outstanding Shares); <u>provided</u>, however, that if such consideration received in the Corporate Transaction is not solely common stock of the successor corporation or its Parent, the Committee may, with the consent of the successor corporation, provide for the consideration to be received upon the exercise of an Option or SAR or upon the settlement of an RSU, for each Share subject to such Award, to be solely common stock of the successor corporation or its Parent equal in fair market value to the per share consideration received by holders of Common Stock in the Corporate Transaction. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(c)&#8195;The substitution by the successor or acquiring entity in such Corporate Transaction (or by its parents, if any) of equivalent awards with substantially the same terms for such outstanding Awards (except that the exercise price and the number and nature of shares issuable upon exercise of any such option or stock appreciation right, or any award that is subject to Section&#160;409A of the Code, will be adjusted appropriately pursuant to Section&#160;424(a) of the Code and/or Section&#160;409A of the Code, as applicable). </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(d)&#8195;The full or partial acceleration of exercisability or vesting and accelerated expiration of an outstanding Award and lapse of the Company&#8217;s right to repurchase or re-acquire shares acquired under an Award or lapse of forfeiture rights with respect to shares acquired under an Award. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(e)&#8195;The settlement of the full value of such outstanding Award (whether or not then vested or exercisable) in cash, cash equivalents, or securities of the successor entity (or its parent, if any) with a fair market value equal to the required amount, followed by the cancellation of such Awards; <u>provided</u> however, that such Award may be cancelled if such Award has no value, as determined by the Committee, in its discretion. Subject to Section&#160;409A of the Code, such payment may be made in installments and may be deferred until the date or dates the </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">I-10<br></div></div></div>
<!--End Page 506-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 507-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_308-annexi_pg11"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 40pt; text-align: justify;">Award would have become exercisable or vested. Such payment may be subject to vesting based on the Participant&#8217;s continued Service, <u>provided</u> that the vesting schedule shall not be less favorable to the Participant than the schedule under which the Award would have become vested or exercisable. For purposes of this Section&#160;21.1(e), the fair market value of any security shall be determined without regard to any vesting conditions that may apply to such security. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(f)&#8195;Termination of any right to exercise any Option prior to vesting in the Shares subject to the Option (i.e., &#8220;early exercise&#8221;), such that following the closing of the transaction Options may only be exercised to the extent vested. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(g)&#8195;The cancellation of outstanding Awards in exchange for no consideration. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The Board shall have full power and authority to assign the Company&#8217;s right to repurchase or re-acquire or forfeiture rights to such successor or acquiring corporation. In addition, in the event such successor or acquiring corporation (if any) refuses to assume, convert, replace or substitute Awards, as provided above, pursuant to a Corporate Transaction, the Committee will notify the Participant in writing or electronically that such Participant&#8217;s Award will, if exercisable, be exercisable for a period of time determined by the Committee in its sole discretion, and such Award will terminate upon the expiration of such period. Awards need not be treated similarly in a Corporate Transaction and treatment may vary from Award to Award and/or from Participant to Participant. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">21.2.&#8195;<font style="font-weight: normal;"><u>Assumption of Awards by the Company</u>. The Company, from time to time, also may substitute or assume outstanding awards granted by another company, whether in connection with an acquisition of such other company or otherwise, by either: (a) granting an Award under this Plan in substitution of such other company&#8217;s award, or (b) assuming such award as if it had been granted under this Plan if the terms of such assumed award could be applied to an Award granted under this Plan. Such substitution or assumption will be permissible if the holder of the substituted or assumed award would have been eligible to be granted an Award under this Plan if the other company had applied the rules of this Plan to such grant. In the event the Company assumes an award granted by another company, the terms and conditions of such award will remain unchanged (<u>except</u> that the Purchase Price or the Exercise Price, as the case may be, and the number and nature of Shares issuable upon exercise or settlement of any such Award will be adjusted appropriately pursuant to Section&#160;424(a) of the Code). In the event the Company elects to grant a new Option in substitution rather than assuming an existing option, such new Option may be granted with a similarly adjusted Exercise Price. Substitute Awards will not reduce the number of Shares authorized for grant under the Plan or authorized for grant to a Participant in a calendar year.&#8195;</font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">21.3.&#8195;<font style="font-weight: normal;"><u>Non-Employee Directors&#8217; Awards</u>. Notwithstanding any provision to the contrary herein, and unless otherwise set forth in the applicable Award Agreement or any other agreement between the Participant and the Company (or any Parent, Subsidiary or Affiliate, if applicable), in the event of a Corporate Transaction, the vesting of all Awards granted to Non-Employee Directors will accelerate and such Awards will become exercisable (as applicable) in full prior to the consummation of the Corporate Transaction at such times and on such conditions as the Committee determines. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">22.&#8195;<u>ADOPTION AND STOCKHOLDER APPROVAL</u><font style="font-weight: normal;">. This Plan will be submitted for the approval of the Company&#8217;s stockholders, consistent with applicable laws, within twelve (12) months before or after the date this Plan is adopted by the Board. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">23.&#8195;<u>TERM OF PLAN/GOVERNING LAW</u><font style="font-weight: normal;">. Unless earlier terminated as provided herein, this Plan will become effective on the Effective Date and will terminate ten (10) years from the date this Plan is adopted by the Board. After this Plan is terminated or expires, no Awards may be granted but Awards previously granted shall remain outstanding in accordance with their applicable terms and conditions. This Plan and all Awards granted hereunder will be governed by and construed in accordance with the laws of the State of Delaware (excluding its conflict of laws rules). </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">24.&#8195;<u>AMENDMENT OR TERMINATION OF PLAN</u><font style="font-weight: normal;">. Subject to approval by the Company&#8217;s stockholders where required by applicable law, regulation or rule, the Board may at any time terminate or amend this Plan in any respect, including, without limitation, amendment of any form of Award Agreement or instrument to be executed pursuant to this Plan, <u>provided</u>, however, that the Board will not, without the approval of the stockholders of the Company, amend this Plan in any manner that requires such stockholder approval, <u>provided</u> further that a Participant&#8217;s Award shall be governed by the version of this Plan then in effect at the time such Award was granted. No termination or amendment of the Plan or any outstanding Award may adversely affect any then outstanding Award without the consent of the Participant, unless such termination or amendment is necessary to comply with applicable law, regulation or rule. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">25.&#8195;<u>NONEXCLUSIVITY OF THE PLAN</u><font style="font-weight: normal;">. Neither the adoption of this Plan by the Board, the submission of this Plan to the stockholders of the Company for approval, nor any provision of this Plan will be construed as creating any limitations on the power of the Board to adopt such additional compensation arrangements as it may deem desirable, including, without limitation, the granting of stock Awards and bonuses otherwise than under this Plan, and such arrangements may be either generally applicable or applicable only in specific cases. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">26.&#8195;<u>INSIDER TRADING POLICY</u><font style="font-weight: normal;">. Each Participant who receives an Award shall comply with any policy adopted by the Company from time to time covering transactions in the Company&#8217;s securities by Employees, officers, and/or Directors of the Company, as applicable, as well as with any applicable insider trading or market abuse laws to which the Participant may be subject. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">27.&#8195;<u>ALL AWARDS SUBJECT TO COMPANY CLAWBACK OR RECOUPMENT POLICY</u><font style="font-weight: normal;">. All Awards, subject to applicable law, shall be subject to clawback or recoupment pursuant to any compensation clawback or recoupment policy adopted by the Board or required by law during the term of Participant&#8217;s Service that is applicable to officers, Employees, Directors or other service providers, and in addition to any other remedies available under such policy and applicable law, may require the cancellation of outstanding Awards and the recoupment of any gains realized with respect to Awards. </font></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">I-11<br></div></div></div>
<!--End Page 507-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 508-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_308-annexi_pg12"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">28.&#8195;<u>DEFINITIONS</u><font style="font-weight: normal;">. As used in this Plan, and except as elsewhere defined herein, the following terms will have the following meanings: </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">28.1.&#8195;<font style="font-weight: normal;">&#8220;</font><font style="font-style: italic;">Affiliate</font><font style="font-weight: normal;">&#8221; means (a) any person or entity that, directly or indirectly, is controlled by, controls, or is under common control with, the Company, and (b) any person or entity in which the Company has a significant equity interest, in either case as determined by the Committee, whether now or hereafter existing. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">28.2.&#8195;<font style="font-weight: normal;">&#8220;</font><font style="font-style: italic;">Award</font><font style="font-weight: normal;">&#8221; means any award under the Plan, including any Option, Performance Award, Restricted Stock, Stock Bonus, Stock Appreciation Right, or Restricted Stock Unit. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">28.3.&#8195;<font style="font-weight: normal;">&#8220;</font><font style="font-style: italic;">Award Agreement</font><font style="font-weight: normal;">&#8221; means, with respect to each Award, the written or electronic agreement between the Company and the Participant setting forth the terms and conditions of the Award, and country-specific appendix thereto for grants to non-U.S. Participants, which shall be in substantially a form (which need not be the same for each Participant) that the Committee (or in the case of Award Agreements that are not used for Insiders, the Committee&#8217;s delegate(s)) has from time to time approved, and will comply with and be subject to the terms and conditions of this Plan. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 8.5pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">28.4.&#8195;<font style="font-weight: normal;">&#8220;</font><font style="font-style: italic;">Board</font><font style="font-weight: normal;">&#8221; means the Board of Directors of the Company. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">28.5.&#8195;<font style="font-weight: normal;">&#8220;</font><font style="font-style: italic;">Cause</font><font style="font-weight: normal;">&#8221; means the occurrence of any one or more of the following: (a) Participant&#8217;s commission of a felony or any crime involving fraud, dishonesty or moral turpitude; (b) Participant&#8217;s attempted commission of or participation in a fraud or act of dishonesty against the Company that results in (or might have reasonably resulted in) material harm to the business of the Company; (c) Participant&#8217;s intentional, material violation of any contract or agreement between Participant and the Company or any statutory duty Participant owes to the Company; (d) Participant&#8217;s conduct that constitutes gross insubordination, incompetence or habitual neglect of duties that results in (or might have reasonably resulted in) material harm to the business of the Company; (e) Participant&#8217;s willful failure substantially to perform his or her duties and responsibilities to the Company; (f) unauthorized use or disclosure by Participant of any proprietary information or trade secrets of the Company or any other party to whom the Participant owes an obligation of nondisclosure as a result of his or her relationship with the Company; (g) Participant&#8217;s failure to cooperate with the Company in any internal or external investigation or formal proceeding if the Company has requested Participant&#8217;s reasonable cooperation; (h) any misconduct by the Participant which is materially injurious to the financial condition or business reputation of, or is otherwise materially injurious to, the Company or a Parent, Subsidiary or Affiliate; provided, however, that the action or conduct described in clauses (c), (d), (e) and (g) above will constitute &#8220;Cause&#8221; only if such action or conduct continues after the Company has provided Participant with written notice thereof and thirty (30) days to cure the same. The determination as to whether a Participant is being terminated for Cause shall be made in good faith by the Company and shall be final and binding on the Participant. The foregoing definition does not in any way limit the Company&#8217;s ability to terminate a Participant&#8217;s employment or consulting relationship at any time as provided in Section&#160;20 above, and the term &#8220;Company&#8221; will be interpreted to include any Subsidiary or Parent, as appropriate.</font><font style="font-style: italic; font-weight: normal;"> </font><font style="font-weight: normal;">The foregoing definition of &#8220;Cause&#8221; may, in part or in whole, be modified or replaced in each individual employment agreement, Award Agreement or other applicable agreement with any Participant, provided that such document supersedes the definition provided in this Section&#160;28.5. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 8.5pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">28.6.&#8195;<font style="font-weight: normal;">&#8220;</font><font style="font-style: italic;">Code</font><font style="font-weight: normal;">&#8221; means the United States Internal Revenue Code of 1986, as amended, and the regulations promulgated thereunder. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">28.7.&#8195;<font style="font-weight: normal;">&#8220;</font><font style="font-style: italic;">Committee</font><font style="font-weight: normal;">&#8221; means the Compensation Committee of the Board or those persons to whom administration of the Plan, or part of the Plan, has been delegated as permitted by law. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 8.5pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">28.8.&#8195;<font style="font-weight: normal;">&#8220;</font><font style="font-style: italic;">Common Stock</font><font style="font-weight: normal;">&#8221; means the common stock of the Company. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 8.5pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">28.9.&#8195;<font style="font-weight: normal;">&#8220;</font><font style="font-style: italic;">Company</font><font style="font-weight: normal;">&#8221; means Standard BioTools Inc., a Delaware corporation, or any successor corporation. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">28.10.&#8195;<font style="font-weight: normal;">&#8220;</font><font style="font-style: italic;">Consultant</font><font style="font-weight: normal;">&#8221; means any natural person, including an advisor or independent contractor, who is engaged by the Company or a Parent, Subsidiary, or Affiliate to render bona fide Services to such entity, provided the Services (i) are not in connection with the offer or sale of securities in a capital-raising transaction, and (ii) do not directly promote or maintain a market for the Company&#8217;s securities, in each case, within the meaning of Form&#160;S-8 promulgated under the Securities Act. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">28.11.&#8195;<font style="font-weight: normal;">&#8220;</font><font style="font-style: italic;">Corporate Transaction</font><font style="font-weight: normal;">&#8221; means the occurrence of any of the following events: (a) any &#8220;Person&#8221; (as such term is used in Sections&#160;13(d) and 14(d) of the Exchange Act) acquires &#8220;beneficial ownership&#8221; (as defined in Rule&#160;13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing more than fifty percent (50%) of the total voting power represented by the Company&#8217;s then-outstanding voting securities, provided, however, that for purposes of this subclause (a) the acquisition of additional securities by any one Person who is considered to own more than fifty percent (50%) of the total voting power of the securities of the Company will not be considered a Corporate Transaction; (b) the consummation of the sale or disposition by the Company of all or substantially all of the Company&#8217;s assets; (c)&#160;the consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation; or (d)&#160;a change in the effective control of the Company that occurs on the date that a majority of members of the Board is replaced during any twelve&#160;(12)&#160;month period by members of the Board whose appointment or election is not endorsed by a majority of the members of the Board prior to the date of the appointment or election. For purpose of subclause (d), if any Person is considered to be in effective control of the Company, the acquisition of additional control of the Company by the same Person will not be considered a Corporate Transaction.</font></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">I-12<br></div></div></div>
<!--End Page 508-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 509-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_308-annexi_pg13"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">For purposes of this definition, Persons will be considered to be acting as a group if they are owners of a corporation that enters into a merger, consolidation, purchase, or acquisition of stock, or similar business transaction with the Company.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Notwithstanding the foregoing, to the extent that any amount constituting deferred compensation (as defined in Section&#160;409A of the Code) would become payable under this Plan by reason of a Corporate Transaction, such amount shall become payable only if the event constituting a Corporate Transaction would also qualify as a change in ownership or effective control of the Company or a change in the ownership of a substantial portion of the assets of the Company, each as defined within the meaning of Code Section 409A, as it has been and may be amended from time to time, and any proposed or final Treasury Regulations and IRS guidance that has been promulgated or may be promulgated thereunder from time to time. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 8.5pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">28.12.&#8195;<font style="font-weight: normal;">&#8220;</font><font style="font-style: italic;">Director</font><font style="font-weight: normal;">&#8221; means a member of the Board. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">28.13.&#8195;<font style="font-weight: normal;">&#8220;</font><font style="font-style: italic;">Disability</font><font style="font-weight: normal;">&#8221; means in the case of ISOs, total and permanent disability as defined in Section&#160;22(e)(3) of the Code and in the case of other Awards, that the Participant is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or can be expected to last for a continuous period of not less than twelve (12) months. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">28.14.&#8195;<font style="font-weight: normal;">&#8220;</font><font style="font-style: italic;">Dividend Equivalent Right</font><font style="font-weight: normal;">&#8221; means the right of a Participant, granted at the discretion of the Committee or as otherwise provided by the Plan, to receive a credit for the account of such Participant in an amount equal to the cash, stock, or other property dividends for each Share represented by an Award held by such Participant. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">28.15.&#8195;<font style="font-weight: normal;">&#8220;</font><font style="font-style: italic;">Effective Date</font><font style="font-weight: normal;">&#8221; means the later of (i) the date of the consummation of the merger of a wholly-owned subsidiary of the Company with and into Treeline Biosciences, Inc., as described in the Merger Agreement and (ii) the date this Plan was approved by the stockholders of the Company; provided that if the Merger Agreement is terminated prior to the consummation of the Merger, this Plan shall not become effective and shall be null and void. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">28.16.&#8195;<font style="font-weight: normal;">&#8220;</font><font style="font-style: italic;">Employee</font><font style="font-weight: normal;">&#8221; means any person, including officers and Directors, providing Services as an employee to the Company or any Parent, Subsidiary, or Affiliate. Neither service as a Director nor payment of a director&#8217;s fee by the Company will be sufficient to constitute &#8220;employment&#8221; by the Company. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 8.5pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">28.17.&#8195;<font style="font-weight: normal;">&#8220;</font><font style="font-style: italic;">Exchange Act</font><font style="font-weight: normal;">&#8221; means the United States Securities Exchange Act of 1934, as amended. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">28.18.&#8195;<font style="font-weight: normal;">&#8220;</font><font style="font-style: italic;">Exchange Program</font><font style="font-weight: normal;">&#8221; means a program pursuant to which (a) outstanding Awards are surrendered, cancelled, or exchanged for cash, the same type of Award, or a different Award (or combination thereof); or (b) the Exercise Price of an outstanding Award is increased or reduced. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">28.19.&#8195;<font style="font-weight: normal;">&#8220;</font><font style="font-style: italic;">Exercise Price</font><font style="font-weight: normal;">&#8221; means, with respect to an Option, the price at which a holder may purchase the Shares issuable upon exercise of an Option and with respect to a SAR, the price at which the SAR is granted to the holder thereof. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 8.5pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">28.20.&#8195;<font style="font-weight: normal;">&#8220;</font><font style="font-style: italic;">Fair Market Value</font><font style="font-weight: normal;">&#8221; means, as of any date, the value of a Share, determined as follows: </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(a)&#8195;if such Common Stock is publicly traded and is then listed on a national securities exchange, its closing price on the date of determination on the principal national securities exchange on which the Common Stock is listed or admitted to trading as reported in <font style="font-style: italic;">The Wall Street </font>Journal or such other source as the Committee may determine or, if there is no closing price on that date, then on the last preceding date on which such a closing price was reported; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(b)&#8195;if such Common Stock is publicly traded but is neither listed nor admitted to trading on a national securities exchange, the average of the closing bid and asked prices on the date of determination as reported in <font style="font-style: italic;">The Wall Street Journal</font> or such other source as the Committee deems reliable; or </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(c)&#8195;by the Board or the Committee in good faith. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">28.21.&#8195;<font style="font-weight: normal;">&#8220;</font><font style="font-style: italic;">Insider</font><font style="font-weight: normal;">&#8221; means an officer or Director of the Company or any other person whose transactions in the Company&#8217;s Common Stock are subject to Section&#160;16 of the Exchange Act. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 8pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">28.22.&#8195;<font style="font-weight: normal;">&#8220;</font><font style="font-style: italic;">IRS</font><font style="font-weight: normal;">&#8221; means the United States Internal Revenue Service. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">28.23.&#8195;<font style="font-weight: normal;">&#8220;</font><font style="font-style: italic;">Merger Agreement</font><font style="font-style: italic; font-weight: normal;">&#8221; </font><font style="font-weight: normal;">means the Agreement and Plan of Merger and Reorganization, dated as of June&#160;6, 2026, among the Company, Treeline Biosciences, Inc. and certain other parties thereto. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 8pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">28.24.&#8195;<font style="font-style: italic;">&#8220;Non-Employee Director</font><font style="font-weight: normal;">&#8221; means a Director who is not an Employee of the Company or any Parent, Subsidiary, or Affiliate. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 8pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">28.25.&#8195;<font style="font-weight: normal;">&#8220;</font><font style="font-style: italic;">Option</font><font style="font-weight: normal;">&#8221; means an Award of an option to purchase Shares pursuant to Section&#160;5 and granted under the Plan. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">28.26.&#8195;<font style="font-weight: normal;">&#8220;</font><font style="font-style: italic;">Parent</font><font style="font-weight: normal;">&#8221; means any corporation (other than the Company) in an unbroken chain of corporations ending with the Company if each of such corporations other than the Company owns stock possessing fifty percent (50%) or more of the total combined voting power of all classes of stock in one of the other corporations in such chain. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 8pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">28.27.&#8195;<font style="font-weight: normal;">&#8220;</font><font style="font-style: italic;">Participant</font><font style="font-weight: normal;">&#8221; means a person who holds an Award under this Plan. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 8pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">28.28.&#8195;<font style="font-weight: normal;">&#8220;</font><font style="font-style: italic;">Performance Award</font><font style="font-weight: normal;">&#8221; means an Award as defined in Section&#160;10 and granted under the Plan. </font></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">I-13<br></div></div></div>
<!--End Page 509-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 510-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_308-annexi_pg14"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">28.29.&#8195;<font style="font-weight: normal;">&#8220;</font><font style="font-style: italic;">Performance Factors</font><font style="font-weight: normal;">&#8221; means any of the factors selected by the Committee and specified in an Award Agreement, from among the following objective or subjective measures, either individually, alternatively or in any combination, applied to the Participant, the Company as a whole or any business unit thereof, or Parent, Subsidiary or Affiliate, either individually, alternatively, or in any combination, on a GAAP or non-GAAP basis, and measured, to the extent applicable on an absolute basis or relative to a pre-established target, to determine whether the performance goals established by the Committee with respect to applicable Awards have been satisfied: </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(a)&#8195;profit before tax; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(b)&#8195;billings; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(c)&#8195;revenue; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(d)&#8195;net revenue; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(e)&#8195;earnings (which may include earnings before interest and taxes, earnings before taxes, net earnings, stock-based compensation expenses, depreciation, and amortization); </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(f)&#8195;operating income; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(g)&#8195;operating margin; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(h)&#8195;operating profit; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(i)&#8195;controllable operating profit or net operating profit; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(j)&#8195;net profit; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(k)&#8195;gross margin; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(l)&#8195;operating expenses or operating expenses as a percentage of revenue; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(m)&#8195;net income; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(n)&#8195;earnings per share; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(o)&#8195;total stockholder return; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(p)&#8195;market share; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(q)&#8195;return on assets or net assets; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(r)&#8195;the Company&#8217;s stock price; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(s)&#8195;growth in stockholder value relative to a pre-determined index; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(t)&#8195;return on equity; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(u)&#8195;return on invested capital; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(v)&#8195;cash flow (including free cash flow or operating cash flows); </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(w)&#8195;cash conversion cycle; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(x)&#8195;economic value added;</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(y)&#8195;individual confidential business objectives; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(z)&#8195;contract awards or backlog; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(aa)&#8195;overhead or other expense reduction; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(bb)&#8195;credit rating; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(cc)&#8195;strategic plan development and implementation; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(dd)&#8195;succession plan development and implementation; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(ee)&#8195;improvement in workforce diversity; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(ff)&#8195;customer indicators and/or satisfaction; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(gg)&#8195;new product invention or innovation; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(hh)&#8195;attainment of research and development milestones; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(ii)&#8195;improvements in productivity; </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">I-14<br></div></div></div>
<!--End Page 510-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 511-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_308-annexi_pg15"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(jj)&#8195;bookings; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(kk)&#8195;attainment of objective operating goals and employee metrics; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(ll)&#8195;sales; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(mm)&#8195;expenses; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(nn)&#8195;balance of cash, cash equivalents, and marketable securities; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(oo)&#8195;completion of an identified special project; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(pp)&#8195;completion of a joint venture or other corporate transaction; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(qq)&#8195;employee satisfaction and/or retention; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(rr)&#8195;research and development expenses; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(ss)&#8195;working capital targets and changes in working capital; and </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(tt)&#8195;any other metric that is capable of measurement as determined by the Committee.&#8195;</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The Committee may provide for one or more equitable adjustments to the Performance Factors to preserve the Committee&#8217;s original intent regarding the Performance Factors at the time of the initial award grant, such as but not limited to, adjustments in recognition of unusual or non-recurring items such as acquisition-related activities or changes in applicable accounting rules. It is within the sole discretion of the Committee to make or not make any such equitable adjustments. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">28.30.&#8195;<font style="font-weight: normal;">&#8220;</font><font style="font-style: italic;">Performance Period</font><font style="font-weight: normal;">&#8221; means one or more periods of time, which may be of varying and overlapping durations, as the Committee may select, over which the attainment of one or more Performance Factors will be measured for the purpose of determining a Participant&#8217;s right to, and the payment of, a Performance Award. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 8pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">28.31.&#8195;<font style="font-weight: normal;">&#8220;</font><font style="font-style: italic;">Performance Share</font><font style="font-weight: normal;">&#8221; means an Award as defined in Section&#160;10 and granted under the Plan. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 8pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">28.32.&#8195;<font style="font-weight: normal;">&#8220;</font><font style="font-style: italic;">Performance Unit</font><font style="font-weight: normal;">&#8221; means an Award as defined in Section&#160;10 and granted under the Plan. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">28.33.&#8195;<font style="font-weight: normal;">&#8220;</font><font style="font-style: italic;">Permitted Transferee</font><font style="font-weight: normal;">&#8221; means any child, stepchild, grandchild, parent, stepparent, grandparent, spouse, former spouse, sibling, niece, nephew, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law (including adoptive relationships) of the Employee, any person sharing the Employee&#8217;s household (other than a tenant or employee), a trust in which these persons (or the Employee) have more than fifty percent (50%) of the beneficial interest, a foundation in which these persons (or the Employee) control the management of assets, and any other entity in which these persons (or the Employee) own more than fifty percent (50%) of the voting interests. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 8pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">28.34.&#8195;<font style="font-weight: normal;">&#8220;</font><font style="font-style: italic;">Plan</font><font style="font-weight: normal;">&#8221; means this Company Post-Closing Equity Incentive Plan. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 8pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">28.35.&#8195;<font style="font-weight: normal;">&#8220;</font><font style="font-style: italic;">Pre-Funded Warrant</font><font style="font-weight: normal;">&#8221; means any warrant to acquire shares of Common Stock for a nominal exercise price. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">28.36.&#8195;<font style="font-weight: normal;">&#8220;</font><font style="font-style: italic;">Purchase Price</font><font style="font-weight: normal;">&#8221; means the price to be paid for Shares acquired under the Plan, other than Shares acquired upon exercise of an Option or SAR. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">28.37.&#8195;<font style="font-weight: normal;">&#8220;</font><font style="font-style: italic;">Restricted Stock Award</font><font style="font-weight: normal;">&#8221; means an Award as defined in Section&#160;6 and granted under the Plan, or issued pursuant to the early exercise of an Option. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 8pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">28.38.&#8195;<font style="font-weight: normal;">&#8220;</font><font style="font-style: italic;">Restricted Stock Unit</font><font style="font-weight: normal;">&#8221; means an Award as defined in Section&#160;9 and granted under the Plan. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 8pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">28.39.&#8195;<font style="font-weight: normal;">&#8220;</font><font style="font-style: italic;">SEC</font><font style="font-weight: normal;">&#8221; means the United States Securities and Exchange Commission. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 8pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">28.40.&#8195;<font style="font-weight: normal;">&#8220;</font><font style="font-style: italic;">Securities Act</font><font style="font-weight: normal;">&#8221; means the United States Securities Act of 1933, as amended. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">28.41.&#8195;<font style="font-weight: normal;">&#8220;</font><font style="font-style: italic;">Service</font><font style="font-weight: normal;">&#8221; means service as an Employee, Consultant, Director, or Non-Employee Director, to the Company or a Parent, Subsidiary, or Affiliate, subject to such further limitations as may be set forth in the Plan or the applicable Award Agreement. Unless otherwise determined by the Committee, an Employee will not be deemed to have ceased to provide Service in the case of any leave of absence approved by the Company or a Parent, Subsidiary, or Affiliate, as applicable. In the case of any Employee on an approved leave of absence or a reduction in hours worked (for illustrative purposes only, a change in schedule from that of full-time to part-time), the Committee may make such provisions respecting suspension of or modification to vesting of the Award while on leave from the employ of the Company or a Parent, Subsidiary or Affiliate or during such change in working hours as it may deem appropriate, including suspension of or modification to vesting of the Award (including pursuant to a formal policy adopted from time to time by the Company or a Parent, Subsidiary, or Affiliate), except that in no event may an Award vest or be exercised after the expiration of the term set forth in the applicable Award Agreement. Unless the Committee provides otherwise (including pursuant to a formal policy adopted from time to time by the Company or a Parent, Subsidiary, or Affiliate), to the extent permitted under applicable law, vesting of Awards granted hereunder will continue during any leave of absence. A change in status between an Employee, Consultant, Director or Non-Employee Director shall not terminate the Participant&#8217;s Service, unless determined by the Committee in its discretion or to the extent set forth in the applicable Award Agreement. The Committee will have sole discretion to determine whether a Participant has ceased to provide Service and the effective date on which the Participant ceased to provide Service.</font></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">I-15<br></div></div></div>
<!--End Page 511-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 512-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_308-annexi_pg16"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">28.42.&#8195;<font style="font-weight: normal;">&#8220;</font><font style="font-style: italic;">Shares</font><font style="font-weight: normal;">&#8221; means shares of the Common Stock and shares of common stock of any successor entity of the Company. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 8.5pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">28.43.&#8195;<font style="font-weight: normal;">&#8220;</font><font style="font-style: italic;">Stock Appreciation Right</font><font style="font-weight: normal;">&#8221; means an Award granted pursuant to Section&#160;8 and granted under the Plan. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 8.5pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">28.44.&#8195;<font style="font-weight: normal;">&#8220;</font><font style="font-style: italic;">Stock Bonus</font><font style="font-weight: normal;">&#8221; means an Award granted pursuant to Section&#160;7 and granted under the Plan. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">28.45.&#8195;<font style="font-weight: normal;">&#8220;</font><font style="font-style: italic;">Subsidiary</font><font style="font-weight: normal;">&#8221; means any corporation (other than the Company) in an unbroken chain of corporations beginning with the Company if each of the corporations other than the last corporation in the unbroken chain owns stock possessing fifty percent (50%) or more of the total combined voting power of all classes of stock in one of the other corporations in such chain. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 8.5pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">28.46.&#8195;<font style="font-weight: normal;">&#8220;</font><font style="font-style: italic;">Treasury Regulations</font><font style="font-weight: normal;">&#8221; means regulations promulgated by the United States Treasury Department. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">28.47.&#8195;<font style="font-weight: normal;">&#8220;</font><font style="font-style: italic;">Unvested Shares</font><font style="font-weight: normal;">&#8221; means Shares that have not yet vested or are subject to a right of repurchase in favor of the Company (or any successor thereto). </font></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">I-16<br></div></div></div>
<!--End Page 512-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 513-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_309-annexj_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: right;"><a name="tANJ"><!--Anchor--></a>Annex J </div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 19.5pt; text-align: center;">FORM OF POST-CLOSING EMPLOYEE STOCK PURCHASE PLAN</div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">J-1<br></div></div></div>
<!--End Page 513-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 514-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_309-annexj_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">TREELINE BIOSCIENCES HOLDINGS, INC. <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">POST-CLOSING EMPLOYEE STOCK PURCHASE PLAN </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">1.&#8195;PURPOSE.<font style="font-weight: normal;"> The purpose of this Plan is to provide eligible employees of Standard BioTools Inc. (the &#8220;</font><font style="font-style: italic;">Company</font><font style="font-weight: normal;">&#8221;) and the Participating Corporations with a means of acquiring an equity interest in the Company, to enhance such employees&#8217; sense of participation in the affairs of the Company. Capitalized terms not defined elsewhere in the text are defined in <u>Section 28</u> of this Plan. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">2.&#8195;ESTABLISHMENT OF PLAN.<font style="font-weight: normal;"> The Company proposes to grant rights to purchase shares of Common Stock to eligible employees of the Company and its Participating Corporations pursuant to this Plan. The Company intends this Plan to qualify as an &#8220;employee stock purchase plan&#8221; under Section 423 of the Code (including any amendments to or replacements of such Section), and this Plan shall be so construed, although the Company makes no undertaking or representation to maintain such qualification. Any term not expressly defined in this Plan but defined for purposes of Section 423 of the Code shall have the same definition herein. In addition, this Plan authorizes the grant of options under a Non-Section&#160;423 Component that is not intended to meet Section 423 requirements, provided, to the extent necessary under Section 423 of the Code, the other terms and conditions of this Plan are met. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Subject to <u>Section 14</u> of this Plan, a total of 26,865,998 shares of Common Stock are reserved for issuance under this Plan. In addition, the number of shares of Common Stock available for grant and issuance under this Plan will be increased on January&#160;1<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">st</sup> of each of the first&#160;ten&#160;(10)&#160;calendar&#160;years during the term of this Plan by the lesser of (i) one percent (1%) of the sum of (a) the total number of shares of all classes of the Company&#8217;s Common Stock; (b) the total number of shares of the Company&#8217;s Common Stock subject to Pre-Funded Warrants (if any); and (c)&#160;the number of shares of the Company&#8217;s Common Stock issuable upon conversion of any preferred stock (if any), in each case, issued and outstanding on each December&#160;31<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">st</sup> immediately prior to the date of increase, rounded down to the next whole share, or (ii) such number of shares of Common Stock as may be determined by the Board or the Compensation Committee of the Board. Subject to <u>Section 14</u> of this Plan, no more than 270,000,000 shares of Common Stock may be issued over the term of this Plan. For the avoidance of any uncertainty, shares of Common Stock withheld to satisfy tax withholding obligations shall not reduce the number of shares of Common Stock available for grant pursuant to this Plan and shall again be made available for grant pursuant to this Plan. The number of shares initially reserved for issuance under this Plan and the maximum number of shares that may be issued under this Plan shall be subject to adjustments effected in accordance with <u>Section 14</u> of this Plan. Any or all such shares may be granted under the Section&#160;423 Component. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">3. &#8195;ADMINISTRATION.<font style="font-weight: normal;"> This Plan will be administered by the Committee. The Committee may delegate administrative tasks under this Plan to a subcommittee or to one or more officers to assist with the administration of this Plan pursuant to specific delegation as permitted by applicable law. Subject to the provisions of this Plan and the limitations of Section 423 of the Code or any successor provision in the Code, all questions of interpretation or application of this Plan shall be determined by the Committee and its decisions shall be final and binding upon all eligible employees and Participants. The Committee will have full and exclusive discretionary authority to construe, interpret and apply the terms of this Plan, to determine eligibility (including that the Committee may determine that an employee of a third party agency who is providing services to a Participating Corporation at the direction of the Participating Corporation is eligible to participate in an Offering Period under the Non-Section&#160;423 Component of this Plan), to designate the Participating Corporations, to determine whether Participating Corporations shall participate in the Section&#160;423 Component or Non-Section&#160;423 Component and to decide upon any and all claims filed under this Plan. Every finding, decision and determination made by the Committee will, to the full extent permitted by law, be final and binding upon all parties. Notwithstanding any provision to the contrary in this Plan, the Committee may adopt rules, sub-plans, and/or procedures relating to the operation and administration of this Plan designed to facilitate compliance with local laws, regulations or customs or to achieve tax, securities law or other objectives for eligible employees outside of the United States. Further, the Committee is specifically authorized to adopt rules and procedures regarding the application of the definition of Compensation (as defined below) to Participants on payrolls outside of the United States, handling of Contributions, taking / making of other Contributions to this Plan, establishment of bank or trust accounts to hold Contributions, payment of interest, establishment of the exchange rate applicable to Contributions made in a currency other than U.S. dollars, obligations to pay payroll tax, determination of beneficiary designation requirements, tax withholding procedures, and handling of stock certificates that vary with applicable local requirements. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The Committee will have the authority to determine the Fair Market Value of the Common Stock (which determination shall be final, binding and conclusive for all purposes) in accordance with <u>Section 8</u> and <u>Section&#160;28(k)</u> of this Plan and to interpret <u>Section 8</u> and <u>Section&#160;28(k)</u> of this Plan in connection with circumstances that impact the Fair Market Value. Members of the Committee shall receive no compensation for their services in connection with the administration of this Plan, other than standard fees as established from time to time by the Board for services rendered by Board members serving on Board committees. All expenses incurred in connection with the administration of this Plan shall be paid by the Company. For purposes of this Plan, the Committee may designate separate offerings under this Plan (the terms of which need not be identical) in which eligible employees of one or more Participating Corporations will participate, and the provisions of this Plan will separately apply to each such separate offering even if the dates of the applicable Offering Periods of each such offering are identical. To the extent permitted by Section 423 of the Code, the terms of each separate offering under this Plan need not be identical, provided that the rights and privileges established with respect to a particular offering are applied in an identical manner to all employees of every Participating Corporation whose employees are granted options under that particular offering. The Committee may establish rules to govern the terms of this Plan and the offering that will apply to Participants who transfer employment between the Company and Participating Corporations or between Participating Corporations, in accordance with requirements under Section&#160;423 of the Code to the extent applicable. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">J-2<br></div></div></div>
<!--End Page 514-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 515-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_309-annexj_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">4.&#8195;ELIGIBILITY. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;Any employee of the Company or the Participating Corporations is eligible to participate in an Offering Period under this Plan, except that one or more of the following categories of employees may be excluded from coverage under this Plan if determined by the Committee (other than where such exclusion is prohibited by applicable law): </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(i)&#8195;employees who do not meet eligibility requirements that the Committee may choose to impose (within the limits permitted by the Code); </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(ii)&#8195;employees who are not employed by the Company or a Participating Corporation prior to the beginning of such Offering Period or prior to such other time period as specified by the Committee; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(iii)&#8195;employees who have been employed less than two (2) years; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(iv)&#8195;employees who are customarily employed for twenty (20) or less hours per week; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(v)&#8195;employees who are customarily employed for five (5) months or less in a calendar year; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(vi)&#8195;(a) employees who are &#8220;highly compensated employees&#8221; of the Company or any Participating Corporation (within the meaning of Section&#160;414(q) of the Code), or (b) any employees who are &#8220;highly compensated employees&#8221; with compensation above a specified level, who is an officer and/or is subject to the disclosure requirements of Section&#160;16(a) of the Exchange Act; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(vii)&#8195;employees who are citizens or residents of a foreign jurisdiction (without regard to whether they are also a citizen of the United States or a resident alien (within the meaning of Section&#160;7701(b)(1)(A) of the Code)) if either (i) such employee&#8217;s participation is prohibited under the laws of the jurisdiction governing such employee, or (ii) compliance with the laws of the foreign jurisdiction would violate the requirements of Section&#160;423 of the Code; and </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(viii)&#8195;individuals who provide services to the Company or any of its Participating Corporations who are reclassified as common law employees for any reason except for federal income and employment tax purposes. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The foregoing notwithstanding, an individual shall not be eligible if his or her participation in this Plan is prohibited by the law of any country that has jurisdiction over him or her, if complying with the laws of the applicable country would cause this Plan to violate Section 423 of the Code, or if he or she is subject to a collective bargaining agreement that does not provide for participation in this Plan. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;No employee who, together with any other person whose stock would be attributed to such employee pursuant to Section 424(d) of the Code, owns stock or holds options to purchase stock possessing five percent (5%) or more of the total combined voting power or value of all classes of stock of the Company or its Parent or Subsidiary or who, as a result of being granted an option under this Plan with respect to such Offering Period, would own stock or hold options to purchase stock possessing five percent (5%) or more of the total combined voting power or value of all classes of stock of the Company or its Parent or Subsidiary shall be granted an option to purchase Common Stock under this Plan. Notwithstanding the foregoing, the rules of Section&#160;424(d) of the Code shall apply in determining share ownership and the extent to which shares held under outstanding equity awards are to be treated as owned by the employee. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">5.&#8195;OFFERING DATES.<font style="font-weight: normal;"> </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;Each Offering Period of this Plan may be of up to twenty-seven (27) months duration and shall commence and end at the times designated by the Committee. Each Offering Period shall consist of one or more Purchase Periods during which Contributions made by Participants are accumulated under this Plan. Offering Periods may be consecutive or overlapping. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;An Offering Period shall commence on such dates as are specified by the Committee, with each such Offering Period also consisting of a six (6)-month Purchase Period, except as otherwise provided by an applicable sub-plan, or on such other date determined by the Committee. The Committee may at any time establish a different duration for an Offering Period or Purchase Period to be effective after the next scheduled Purchase Date, up to a maximum duration of twenty-seven (27) months.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">6.&#8195;PARTICIPATION IN THIS PLAN.<font style="font-weight: normal;"> </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;<font style="font-weight: bold;">Enrollment in Offering Period.</font> An eligible employee determined in accordance with Section&#160;4 may elect to participate in this Plan by submitting an enrollment agreement prior to the commencement of the Offering Period (or such earlier date as the Committee may determine) to which such agreement relates to the Company and/or an authorized third party administrator (the &#8220;<font style="font-style: italic; font-weight: bold;">Third Party Administrator</font>&#8221;) (including electronically). </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;<font style="font-weight: bold;">Continued Enrollment in Offering Periods</font>. Once an employee becomes a Participant in an Offering Period, then such Participant will automatically participate in each subsequent Offering Period commencing immediately following the last day of the prior Offering Period unless the Participant withdraws or is deemed to withdraw from this Plan or terminates further participation in an Offering Period as set forth in <u>Section 11</u> of this Plan. A Participant who is continuing participation pursuant to the preceding sentence is not required to file or submit electronically any additional enrollment agreement in order to continue participation in this Plan, but participation in any subsequent Offering Period will be governed by this Plan and enrollment agreement and other terms in effect on the Offering Date for such relevant Offering Period. A Participant who has discontinued participation in this Plan will be required to submit an enrollment agreement to the Company and/or the Third Party Administrator (including electronically) prior to the commencement of the Offering Period (or such earlier date as the Committee may determine) in which such Participant wishes to resume participation. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">J-3<br></div></div></div>
<!--End Page 515-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 516-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_309-annexj_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">7.&#8195;GRANT OF OPTION ON ENROLLMENT.<font style="font-weight: normal;"> Becoming a Participant with respect to an Offering Period will constitute the grant (as of the Offering Date) by the Company to such Participant of an option to purchase on the Purchase Date up to that number of shares of Common Stock determined by a fraction, the numerator of which is the amount accumulated in such Participant&#8217;s Contribution account during such Purchase Period and the denominator of which is the lower of (i) eighty-five percent (85%) of the Fair Market Value of a share of Common Stock on the Offering Date (but in no event less than the par value of a share of the Common Stock), or (ii) eighty-five percent (85%) of the Fair Market Value of a share of the Common Stock on the Purchase Date; <u>provided</u>, <u>that</u>, the number of shares of Common Stock subject to any option granted pursuant to this Plan shall not exceed the lesser of (x) the maximum number of shares set by the Committee pursuant to <u>Section 10(b)</u> of this Plan with respect to the applicable Purchase Date, or (y) the maximum number of shares which may be purchased pursuant to <u>Section 10(a)</u> of this Plan with respect to the applicable Purchase Date. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">8.&#8195;PURCHASE PRICE.<font style="font-weight: normal;"> The Purchase Price per share at which a share of Common Stock will be sold in any Offering Period shall be eighty-five percent (85%) of the lesser of: </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(a)&#8195;The Fair Market Value on the Offering Date; or </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(b)&#8195;The Fair Market Value on the Purchase Date. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">9.&#8195;PAYMENT OF PURCHASE PRICE; CONTRIBUTION CHANGES; SHARE ISSUANCES.<font style="font-weight: normal;"> </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;The Purchase Price shall be accumulated by regular payroll deductions made during each Offering Period, unless the Committee determines that Contributions may be made in another form (including but not limited to with respect to categories of Participants outside the United States where Contributions must be made in another form due to local legal requirements). The Contributions are made as a percentage of the Participant&#8217;s Compensation in one percent (1%) increments not less than one percent (1%), nor greater than fifteen percent (15%) or such lower limit set by the Committee. &#8220;<font style="font-style: italic; font-weight: bold;">Compensation</font>&#8221; shall mean base salary or regular hourly wages or remuneration; however, the Committee shall have discretion to adopt a definition of Compensation from time to time that includes all cash compensation reported on the employee&#8217;s Form&#160;W-2 or corresponding local country tax return, including without limitation base salary or regular hourly wages, bonuses, commissions, overtime, shift premiums, pay during leaves of absence, and draws against commissions (or in foreign jurisdictions, equivalent cash compensation). For purposes of determining a Participant&#8217;s Compensation, any election by such Participant to reduce his or her regular cash remuneration under Sections 125 or 401(k) of the Code (or in foreign jurisdictions, equivalent deductions) shall be treated as if the Participant did not make such election. Contributions shall commence on the first payday that occurs on or following the Offering Date and shall continue to the end of the Offering Period unless sooner altered or terminated as provided in this Plan. Notwithstanding the foregoing, the terms of any sub-plan may permit matching shares without the payment of any purchase price. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;A Participant may decrease the rate of Contributions during an Offering Period by filing with the Company or the Third Party Administrator (including electronically) a new enrollment agreement, with the new rate to become effective as soon as practicable after the Company&#8217;s receipt of the authorization and continuing for the remainder of the Offering Period unless changed as described below. A decrease in the rate of Contributions may be made once during any Offering Period, or more frequently under rules determined by the Committee. A Participant may increase or decrease the rate of Contributions for any subsequent Offering Period by filing with the Company or the Third Party Administrator (including electronically) a new enrollment agreement prior to the beginning of such Offering Period, or such other time period as specified by the Committee. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;A Participant may reduce his or her Contribution percentage to zero during an Offering Period by filing with the Company or the Third Party Administrator (including electronically) a request for cessation of Contributions. Such reduction shall be effective beginning as soon as practicable after the Company&#8217;s receipt of the request and no further Contributions will be made for the duration of the Offering Period. Contributions credited to the Participant&#8217;s account prior to the effective date of the request shall be used to purchase shares of Common Stock in accordance with Subsection (e) below. A reduction of the Contribution percentage to zero shall be treated as such Participant&#8217;s withdrawal from such Offering Period and this Plan, effective as of the day after the Purchase Date following the date of such request with the Company. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(d)&#8195;All Contributions made for a Participant are credited to his or her book account under this Plan and are deposited with the general funds of the Company, except to the extent local legal restrictions outside the United States require segregation of such Contributions. No interest accrues on the Contributions, except to the extent required due to local legal requirements. All Contributions received or held by the Company may be used by the Company for any corporate purpose, and the Company shall not be obligated to segregate such Contributions, except to the extent necessary to comply with local legal requirements outside the United States. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(e)&#8195;On each Purchase Date, so long as this Plan remains in effect and provided that the Participant has not submitted a signed and completed withdrawal form (including electronically) before that date which notifies the Company that the Participant wishes to withdraw from that Offering Period under this Plan and have all Contributions accumulated in the account maintained on behalf of the Participant as of that date returned to the Participant, the Company shall apply the funds then in the Participant&#8217;s account to the purchase of whole shares of Common Stock reserved under the option granted to such Participant with respect to the Offering Period to the extent that such option is exercisable on the Purchase Date. The Purchase Price per share shall be as specified in <u>Section 8</u> of this Plan. Any fractional share, as calculated under this Subsection (e), shall be rounded down to the next lower whole share, unless the Committee determines with respect to all Participants that any fractional share shall be credited as a fractional share. Any amount remaining in a Participant&#8217;s account on a Purchase Date which is less than the amount necessary to purchase a full share of the Common Stock shall be carried forward without interest (except to the extent necessary to comply with local legal requirements outside the United States); however, the Committee may determine that such amounts should be refunded without interest (except to the extent necessary to comply with local legal requirements outside the United States) into the next Purchase Period or Offering Period, as the case may be. In the event that this Plan has been oversubscribed, all funds not used to purchase shares on the Purchase </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">J-4<br></div></div></div>
<!--End Page 516-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 517-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_309-annexj_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Date shall be returned to the Participant, without interest (except to the extent required due to local legal requirements outside the United States). No Common Stock shall be purchased on a Purchase Date on behalf of any employee whose participation in this Plan has terminated prior to such Purchase Date, except to the extent required due to local legal requirements outside the United States. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(f)&#8195;As promptly as practicable after the Purchase Date, the Company shall issue shares for the Participant&#8217;s benefit representing the shares purchased upon exercise of his or her option. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(g)&#8195;During a Participant&#8217;s lifetime, his or her option to purchase shares hereunder is exercisable only by him or her. The Participant will have no interest or voting right in shares covered by his or her option until such option has been exercised. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(h)&#8195;To the extent required by applicable U.S. or non-U.S. federal, state, or local law, a Participant shall make arrangements satisfactory to the Company and the Participating Corporation employing the Participant for the satisfaction of any withholding tax obligations that arise in connection with this Plan. The Company or any Subsidiary or Affiliate, as applicable, may withhold, by any method permissible under the applicable law, the amount necessary for the Company or Subsidiary or Affiliate, as applicable, to meet applicable withholding obligations, including any withholding required to make available to the Company or Subsidiary or Affiliate, as applicable, any tax deductions or benefits attributable to the sale or early disposition of shares of Common Stock by a Participant. The Company shall not be required to issue any shares of Common Stock under this Plan until such obligations are satisfied. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">10.&#8195;LIMITATIONS ON SHARES TO BE PURCHASED.<font style="font-weight: normal;"> </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;Any other provision of this Plan notwithstanding, no Participant shall purchase Common Stock with a Fair Market Value in excess of the following limit: </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(i)&#8195;In the case of Common Stock purchased during an Offering Period that commenced in the current calendar year, the limit shall be equal to (A) $25,000 minus (B) the Fair Market Value of the Common Stock that the Participant previously purchased in the current calendar year (under this Plan and all other employee stock purchase plans of the Company or any Parent or Subsidiary). </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(ii)&#8195;In the case of Common Stock purchased during an Offering Period that commenced in the immediately preceding calendar year, the limit shall be equal to (A) $50,000 minus (B) the Fair Market Value of the Common Stock that the Participant previously purchased (under this Plan and all other employee stock purchase plans of the Company or any Parent or Subsidiary) in the current calendar year and in the immediately preceding calendar year. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(iii)&#8195;In the case of Common Stock purchased during an Offering Period that commenced two calendar years prior, the limit shall be equal to (A) $75,000 minus (B) the Fair Market Value of the Common Stock that the Participant previously purchased (under this Plan and all other employee stock purchase plans of the Company or any Parent or Subsidiary) in the current calendar year and in the two&#160;immediately preceding calendar years. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">For purposes of this Subsection (a), the Fair Market Value of Common Stock shall be determined in each case as of the beginning of the Offering Period in which such Common Stock is purchased. Employee stock purchase plans not described in Section 423 of the Code shall be disregarded. If a Participant is precluded by this Subsection (a) from purchasing additional Common Stock under this Plan, then his or her Contributions may be discontinued and if, to the extent discontinued, shall automatically resume at the beginning of the earliest Purchase Period that will end in the next calendar year (if he or she then is an eligible employee), provided that when the Company automatically resumes such Contributions, the Company must apply the rate in effect immediately prior to such suspension. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;In no event shall a Participant be permitted to purchase more than Five Thousand (5,000) shares on any one Purchase Date or such higher or lower number as the Committee shall determine for a subsequent Purchase Period. If a lower limit is set under this Subsection (b), then all Participants will be notified of such limit prior to the commencement of the next Offering Period for which it is to be effective. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;If the number of shares to be purchased on a Purchase Date by all Participants exceeds the number of shares then available for issuance under this Plan, then the Company will make a pro rata allocation of the remaining shares in as uniform a manner as shall be reasonably practicable and as the Committee shall determine to be equitable. In such event, the Company will give notice of such reduction of the number of shares to be purchased under a Participant&#8217;s option to each Participant affected. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(d)&#8195;Any Contributions accumulated in a Participant&#8217;s account which are not used to purchase stock due to the limitations in this <u>Section&#160;10</u>, and not covered by <u>Section 9(e)</u> of this Plan, shall be returned to the Participant as soon as practicable after the end of the applicable Purchase Period, without interest (except to the extent required due to local legal requirements outside the United States). </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">11.&#8195;WITHDRAWAL.<font style="font-weight: normal;"> </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;Each Participant may withdraw from an Offering Period under this Plan pursuant to a method specified for such purpose by the Company (including electronically via the Third Party Administrator). Such withdrawal may be elected at least five (5) business days prior to the end of an Offering Period, or such other time period as specified by the Committee. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;Upon withdrawal from this Plan, the accumulated Contributions shall generally be returned to the withdrawn Participant, without interest (except to the extent required due to local legal requirements outside the United States), unless otherwise allowed in the enrollment agreement, and his or her interest in this Plan shall terminate. In the event a Participant voluntarily elects to withdraw from this Plan, he or she </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">J-5<br></div></div></div>
<!--End Page 517-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 518-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_309-annexj_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">may not resume his or her participation in this Plan during the same Offering Period, but he or she may participate in any Offering Period under this Plan which commences on a date subsequent to such withdrawal by submitting a new enrollment agreement with the Company and/or the Third Party Administrator (including electronically) in the same manner as set forth in <u>Section 6</u> of this Plan for initial participation in this Plan. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;To the extent there are multiple Purchase Periods within a single Offering Period, then (1) if the Fair Market Value on the Offering Date of an Offering Period in which a Participant is enrolled is higher than the Fair Market Value on the Purchase Date of any applicable Purchase Period within such Offering Period, the Company will automatically (i) withdraw such Participant from such Offering Period immediately after completion of the purchase on the Purchase Date of such Purchase Period as set forth in Subsection (2) below and (ii) enroll such Participant in the subsequent Offering Period and (2) any funds accumulated in a Participant&#8217;s account prior to such Purchase Date will be applied to the purchase of shares on the Purchase Date immediately prior to the first day of such subsequent Offering Period, if any. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">12.&#8195;TERMINATION OF EMPLOYMENT.<font style="font-weight: normal;"> Termination of a Participant&#8217;s employment with the Company or any Participating Corporation for any reason, including retirement, death, disability, or the failure of a Participant to remain an eligible employee of the Company or of a Participating Corporation, including Participant&#8217;s employer no longer being a Participating Corporation, immediately terminates his or her participation in this Plan (except as required due to local legal requirements outside the United States). In such event, accumulated Contributions credited to the Participant&#8217;s account will be returned to him or her or, in the case of his or her death, to his or her estate or legal representative (as determined by the Company), without interest (except to the extent required due to local legal requirements outside the United States). For purposes of this <u>Section 12</u>, an employee will not be deemed to have terminated employment or failed to remain in the continuous employ of the Company or of a Participating Corporation in the case of a transfer of employment between the Company and any Participating Corporation or any sick leave, military leave, or any other leave of absence approved by the Company; <u>provided</u> that such leave is for a period of not more than ninety (90) days or reemployment upon the expiration of such leave is guaranteed by contract or statute. The Company will have sole discretion to determine whether a Participant has terminated employment and the effective date on which the Participant terminated employment, regardless of any notice period or garden leave required under local law. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">13.&#8195;RETURN OF CONTRIBUTIONS.<font style="font-weight: normal;"> In the event a Participant&#8217;s interest in this Plan is terminated by withdrawal, termination of employment or otherwise, or in the event this Plan is terminated by the Board, the Company shall deliver to the Participant all accumulated Contributions credited to such Participant&#8217;s account. No interest shall accrue on the Contributions of a Participant in this Plan (except to the extent required due to local legal requirements outside the United States). </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">14.&#8195;CAPITAL CHANGES.<font style="font-weight: normal;"> If the number or class of outstanding shares is changed by a stock dividend, extraordinary dividend or distribution (whether in cash, shares or other property, other than a regular cash dividend), recapitalization, stock split, reverse stock split, subdivision, combination, consolidation, reclassification, spin-off or similar change in the capital structure of the Company, without consideration, then the Committee shall adjust the number and class of Shares of Common Stock that may be delivered under this Plan, the Purchase Price per share and the number and class of shares of Common Stock covered by each option under this Plan which has not yet been exercised, and the maximum number and class of shares under <u>Sections 2 and 10</u> of this Plan shall be proportionately adjusted, subject to any required action by the Board or the stockholders of the Company and in compliance with the applicable securities laws; provided that fractions of a share will not be issued. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">15.&#8195;NONASSIGNABILITY.<font style="font-weight: normal;"> Neither Contributions credited to a Participant&#8217;s account nor any rights with regard to the exercise of an option or to receive shares under this Plan may be assigned, transferred, pledged or otherwise disposed of in any way (other than by will, the laws of descent and distribution or as provided in <u>Section 22</u> of this Plan) by the Participant. Any such attempt at assignment, transfer, pledge or other disposition shall be void and without effect. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">16.&#8195;USE OF PARTICIPANT FUNDS AND REPORTS.<font style="font-weight: normal;"> The Company may use all Contributions received or held by it under this Plan for any corporate purpose, and the Company will not be required to segregate Participant Contributions (except to the extent required due to local legal requirements outside the United States). Until shares are issued, Participants will only have the rights of an unsecured creditor unless otherwise required under local law. Each Participant shall receive, or have access to, promptly after the end of each Purchase Period a report of his or her account setting forth the total Contributions accumulated, the number of shares purchased, the per share price thereof and the remaining cash balance, if any, carried forward to the next Purchase Period or Offering Period, as the case may be. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">17.&#8195;NOTICE OF DISPOSITION.<font style="font-weight: normal;"> Each U.S. taxpayer Participant shall notify the Company in writing if the Participant disposes of any of the shares purchased in any Offering Period pursuant to this Plan if such disposition occurs within two (2) years from the Offering Date or within one&#160;(1)&#160;year from the Purchase Date on which such shares were purchased (the &#8220;</font><font style="font-style: italic;">Notice Period</font><font style="font-weight: normal;">&#8221;). The Company may, at any time during the Notice Period, place a legend or legends on any certificate representing shares acquired pursuant to this Plan requesting the Company&#8217;s transfer agent to notify the Company of any transfer of the shares. The obligation of the Participant to provide such notice shall continue notwithstanding the placement of any such legend on the certificates. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">18.&#8195;NO RIGHTS TO CONTINUED EMPLOYMENT.<font style="font-weight: normal;"> Neither this Plan nor the grant of any option hereunder shall confer any right on any employee to remain in the employ of the Company or any Participating Corporation, or restrict the right of the Company or any Participating Corporation to terminate such employee&#8217;s employment. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">19.&#8195;EQUAL RIGHTS AND PRIVILEGES.<font style="font-weight: normal;"> All eligible employees granted an option under the Section&#160;423 Component of this Plan shall have equal rights and privileges with respect to this Plan or within any separate offering under this Plan so that this Plan qualifies as an &#8220;employee stock purchase plan&#8221; within the meaning of Section 423 or any successor provision of the Code and the related regulations. Any provision of this Plan </font></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">J-6<br></div></div></div>
<!--End Page 518-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 519-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_309-annexj_pg7"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">which is inconsistent with Section 423 or any successor provision of the Code, without further act or amendment by the Company, the Committee or the Board, shall be reformed to comply with the requirements of Section 423 (unless such provision applies exclusively to options granted under this Plan that are not intended to comply with Code Section&#160;423 requirements). This <u>Section 19</u> shall take precedence over all other provisions in this Plan. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">20.&#8195;NOTICES.<font style="font-weight: normal;"> All notices or other communications by a Participant to the Company under or in connection with this Plan shall be deemed to have been duly given when received in the form specified by the Company at the location, or by the person, designated by the Company for the receipt thereof. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">21.&#8195;TERM; STOCKHOLDER APPROVAL.<font style="font-weight: normal;"> This Plan will become effective on the Effective Date. This Plan shall be approved by the stockholders of the Company, in any manner permitted by applicable corporate law, within twelve (12) months before or after the date this Plan is adopted by the Board. No purchase of shares that are subject to such stockholder approval before becoming available under this Plan shall occur prior to stockholder approval of such shares and the Board or Committee may delay any Purchase Date and postpone the commencement of any Offering Period subsequent to such Purchase Date as deemed necessary or desirable to obtain such approval (provided that if a Purchase Date would occur more than six (6) months after commencement of the Offering Period to which it relates, then such Purchase Date shall not occur and instead such Offering Period shall terminate without the purchase of such shares and Participants in such Offering Period shall be refunded their Contributions without interest, unless the payment of interest is required under applicable local laws). This Plan shall continue until the earlier to occur of (a) termination of this Plan by the Board (which termination may be effected by the Board at any time pursuant to <u>Section 25</u> of this Plan), (b) issuance of all of the shares of Common Stock reserved for issuance under this Plan, or (c) the tenth anniversary of the Effective Date. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">22.&#8195;DESIGNATION OF BENEFICIARY.<font style="font-weight: normal;"> </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;If authorized by the Company, a Participant may file a written designation with the Company, or if permitted by the Company, with the Third Party Administrator (including electronically) of a beneficiary who is to receive any cash or shares, if any, from the Participant&#8217;s account under this Plan in the event of such Participant&#8217;s death prior to a Purchase Date. Such form shall be valid only if it was filed with the Company or a Third Party Administrator designated by the Company at the prescribed location before the Participant&#8217;s death. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;If authorized by the Company, such designation of beneficiary may be changed by the Participant at any time by written notice filed with the Company or if permitted by the Company, with the Third Party Administrator (including electronically) at the prescribed location before the Participant&#8217;s death. In the event of the death of a Participant and in the absence of a beneficiary validly designated under this Plan who is living at the time of such Participant&#8217;s death, the Company shall deliver such cash to the executor or administrator of the estate of the Participant or to the legal heirs of the Participant. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">23.&#8195;CONDITIONS UPON ISSUANCE OF SHARES; LIMITATION ON SALE OF SHARES.<font style="font-weight: normal;"> Shares shall not be issued with respect to an option unless the exercise of such option and the issuance and delivery of such shares pursuant thereto shall comply with all applicable provisions of U.S. or non-U.S. laws, including, without limitation, the Securities Act, the Exchange Act, the rules and regulations promulgated thereunder, and the requirements of any stock exchange or automated quotation system upon which the shares may then be listed, exchange control restrictions and/or securities law restrictions or other applicable laws outside the United States, and shall be further subject to the approval of counsel for the Company with respect to such compliance. Shares may be held in trust or subject to further restrictions as permitted by any subplan. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">24.&#8195;APPLICABLE LAW.<font style="font-weight: normal;"> This Plan shall be governed by the substantive laws (excluding the conflict of laws rules) of the State of Delaware. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">25.&#8195;AMENDMENT OR TERMINATION.<font style="font-weight: normal;"> The Committee, in its sole discretion, may amend, suspend, or terminate this Plan, or any part thereof, at any time and for any reason. Unless otherwise required by applicable law, if this Plan is terminated, the Committee, in its discretion, may elect to terminate all outstanding Offering Periods either immediately or upon completion of the purchase of shares of Common Stock on the next Purchase Date (which may be sooner than originally scheduled, if determined by the Committee in its discretion), or may elect to permit Offering Periods to expire in accordance with their terms (and subject to any adjustment pursuant to <u>Section 14</u> of this Plan). If an Offering Period is terminated prior to its previously-scheduled expiration, all amounts then credited to Participants&#8217; accounts for such Offering Period, which have not been used to purchase shares of Common Stock, shall be returned to those Participants (without interest thereon, except as otherwise required under local laws) as soon as administratively practicable. Further, the Committee will be entitled to change the Purchase Periods and Offering Periods, limit the frequency and/or number of changes in the amount contributed during a Purchase Period or an Offering Period, establish the exchange ratio applicable to amounts contributed in a currency other than U.S. dollars, permit payroll withholding in excess of the amount designated by a Participant in order to adjust for delays or mistakes in the administration of this Plan, establish reasonable waiting and adjustment periods and/or accounting and crediting procedures to ensure that amounts applied toward the purchase of Common Stock for each Participant properly correspond with amounts contributed from the Participant&#8217;s Compensation, and establish such other limitations or procedures as the Committee determines in its sole discretion advisable which are consistent with this Plan. Such actions will not require stockholder approval or the consent of any Participants. However, no amendment shall be made without approval of the stockholders of the Company (obtained in accordance with <u>Section 21</u> of this Plan) within twelve (12) months of the adoption of such amendment (or earlier if required by <u>Section 21</u> of this Plan) if such amendment would: (a)&#160;increase the number of shares that may be issued under this Plan; or (b) change the designation of the employees (or class of employees) eligible for participation in this Plan. In addition, in the event the Board or Committee determines that the ongoing operation of this Plan may result in unfavorable financial accounting consequences, the Board or Committee may, in its discretion and, to the extent necessary or desirable, modify, amend or terminate this Plan to reduce or eliminate such accounting consequences including, but not limited to: (i) amending the definition of Compensation, including with respect to an Offering Period underway at the time; (ii) altering the Purchase Price for any Offering Period including an Offering Period underway at the time of the change in Purchase Price; (iii) shortening any Offering Period by setting a Purchase Date, including an Offering Period underway at the time of the Committee&#8217;s action; (iv) reducing the maximum percentage of Compensation a participant may elect to set aside as Contributions; and (v) reducing the maximum number of shares a Participant may purchase during any Offering Period. Such modifications or amendments will not require approval of the stockholders of the Company or the consent of any Participants. </font></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">J-7<br></div></div></div>
<!--End Page 519-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 520-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_309-annexj_pg8"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">26.&#8195;CORPORATE TRANSACTIONS.<font style="font-weight: normal;"> In the event of a Corporate Transaction, the Offering Period for each outstanding option to purchase Common Stock will be shortened by setting a new Purchase Date and will end on the new Purchase Date. The new Purchase Date shall occur on or prior to the consummation of the Corporate Transaction, as determined by the Board or Committee, and this Plan shall terminate on the consummation of the Corporate Transaction. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">27.&#8195;CODE SECTION 409A; TAX QUALIFICATION.<font style="font-weight: normal;"> </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;Options granted under this Plan generally are exempt from the application of Section 409A of the Code. However, options granted to U.S.&#160;taxpayers which are not intended to meet the Code Section 423 requirements are intended to be exempt from the application of Section 409A of the Code under the short-term deferral exception and any ambiguities shall be construed and interpreted in accordance with such intent. Subject to Subsection (b), options granted to U.S. taxpayers outside of the Code Section 423 requirements shall be subject to such terms and conditions that will permit such options to satisfy the requirements of the short-term deferral exception available under Section 409A of the Code, including the requirement that the shares of Common Stock subject to an option be delivered within the short-term deferral period. Subject to Subsection (b), in the case of a Participant who would otherwise be subject to Section 409A of the Code, to the extent the Committee determines that an option or the exercise, payment, settlement or deferral thereof is subject to Section 409A of the Code, the option shall be granted, exercised, paid, settled or deferred in a manner that will comply with Section 409A of the Code, including Treasury regulations and other interpretive guidance issued thereunder, including without limitation any such regulations or other guidance that may be issued after the Effective Date. Notwithstanding the foregoing, the Company shall have no liability to a Participant or any other party if the option that is intended to be exempt from or compliant with Section 409A of the Code is not so exempt or compliant or for any action taken by the Committee with respect thereto. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;Although the Company may endeavor to (i) qualify an option for favorable tax treatment under the laws of the United States or jurisdictions outside of the United States or (ii) avoid adverse tax treatment (<font style="font-style: italic;">e.g.</font>, under Section 409A of the Code), the Company makes no representation to that effect and expressly disavows any covenant to maintain favorable or avoid unfavorable tax treatment, notwithstanding anything to the contrary in this Plan, including Subsection (a). The Company shall be unconstrained in its corporate activities without regard to the potential negative tax impact on Participants under this Plan. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">28.&#8195;DEFINITIONS.<font style="font-weight: normal;"> </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;&#8220;<font style="font-style: italic; font-weight: bold;">Affiliate</font>&#8221; means any entity, other than a Subsidiary or Parent, (i) that, directly or indirectly, is controlled by, controls or is under common control with, the Company and (ii) in which the Company has a significant equity interest, in either case as determined by the Committee, whether now or hereafter existing. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(b)&#8195;&#8220;<font style="font-style: italic; font-weight: bold;">Board</font>&#8221; shall mean the Board of Directors of the Company. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(c)&#8195;&#8220;<font style="font-style: italic; font-weight: bold;">Code</font>&#8221; shall mean the U.S. Internal Revenue Code of 1986, as amended. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(d)&#8195;&#8220;<font style="font-style: italic; font-weight: bold;">Committee</font>&#8221; means the Compensation Committee of the Board or those persons to whom administration of this Plan, or part of this Plan, has been delegated as permitted by law. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(e)&#8195;&#8220;<font style="font-style: italic; font-weight: bold;">Common Stock</font>&#8221; shall mean the common stock of the Company. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(f)&#8195;&#8220;<font style="font-style: italic; font-weight: bold;">Company</font>&#8221; shall mean Standard BioTools Inc., a Delaware corporation, or any successor corporation. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(g)&#8195;&#8220;<font style="font-style: italic; font-weight: bold;">Contributions</font>&#8221; means payroll deductions taken from a Participant&#8217;s Compensation and used to purchase shares of Common Stock under this Plan and, to the extent payroll deductions are not permitted by applicable laws (as determined by the Committee in its sole discretion), contributions by other means, provided, however, that allowing such other contributions does not jeopardize the qualification of this Plan as an &#8220;employee stock purchase plan&#8221; under Section&#160;423 of the Code. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(h)&#8195;&#8220;<font style="font-style: italic; font-weight: bold;">Corporate Transaction</font>&#8221; means the occurrence of any of the following events: (a) any &#8220;Person&#8221; (as such term is used in Sections&#160;13(d) and 14(d) of the Exchange Act) acquires &#8220;beneficial ownership&#8221; (as defined in Rule&#160;13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing more than fifty percent (50%) of the total voting power represented by the Company&#8217;s then-outstanding voting securities; provided, however, that for purposes of this subclause (a) the acquisition of additional securities by any one Person who is considered to own more than fifty percent (50%) of the total voting power of the securities of the Company will not be considered a Corporate Transaction; (b) the consummation of the sale or disposition by the Company of all or substantially all of the Company&#8217;s assets; (c)&#160;the consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation; or (d)&#160;a change in the effective control of the Company that occurs on the date that a majority of members of the Board is replaced during any twelve&#160;(12)&#160;month period by members of the Board whose appointment or election is not endorsed by a majority of the members of the Board prior to the date of the appointment or election. For purpose of this subclause (d), if any Person is considered to be in effective control of the Company, the acquisition of additional control of the Company by the same Person will not be considered a Corporate Transaction. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">For purposes of this definition, Persons will be considered to be acting as a group if they are owners of a corporation that enters into a merger, consolidation, purchase, or acquisition of stock, or similar business transaction with the Company. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">J-8<br></div></div></div>
<!--End Page 520-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 521-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_309-annexj_pg9"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(i)&#8195;&#8220;<font style="font-style: italic; font-weight: bold;">Effective Date</font>&#8221; means the later of (i) the date of the consummation of the merger of a wholly-owned subsidiary of the Company with and into Treeline Biosciences, Inc., as described in the Merger Agreement and (ii) the date this Plan was approved by the stockholders of the Company; provided that if the Merger Agreement is terminated prior to the consummation of the Merger, this Plan shall not become effective and shall be null and void. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(j)&#8195;&#8220;<font style="font-style: italic; font-weight: bold;">Exchange Act</font>&#8221; means the U.S. Securities Exchange Act of 1934, as amended. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(k)&#8195;&#8220;<font style="font-style: italic; font-weight: bold;">Fair Market Value</font>&#8221; shall mean, as of any date, the value of a share of Common Stock determined as follows: </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(1)&#8195;if such Common Stock is publicly traded and is then listed on a national securities exchange, its closing price on the date of determination on the principal national securities exchange on which the Common Stock is listed or admitted to trading as reported in <font style="font-style: italic;">The Wall Street Journal </font>or such other source as the Board or the Committee may determine or, if there is no closing price on that date, then on the last preceding date on which such a closing price was reported; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(2)&#8195;if such Common Stock is publicly traded but is neither listed nor admitted to trading on a national securities exchange, the average of the closing bid and asked prices on the date of determination as reported in <font style="font-style: italic;">The Wall Street Journal</font> or such other source as the Committee may determine; or </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(3)&#8195;by the Board or the Committee in good faith. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(l)&#8195;&#8220;<font style="font-style: italic; font-weight: bold;">Merger Agreement</font><font style="font-style: italic;">&#8221; </font>means the Agreement and Plan of Merger and Reorganization, dated as of June&#160;6, 2026, among the Company, Treeline Biosciences, Inc. and certain other parties thereto. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(m)&#8195;&#8220;<font style="font-style: italic; font-weight: bold;">Non-Section&#160;423 Component</font>&#8221; means the part of the Plan which is not intended to meet the requirements set forth in Section&#160;423 of the Code. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(n)&#8195;&#8220;<font style="font-style: italic; font-weight: bold;">Notice Period</font>&#8221; shall mean within two (2) years from the Offering Date or within one (1) year from the Purchase Date on which such shares were purchased. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(o)&#8195;&#8220;<font style="font-style: italic; font-weight: bold;">Offering Date</font>&#8221; shall mean the first Trading Day of each Offering Period.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(p)&#8195;&#8220;<font style="font-style: italic; font-weight: bold;">Offering Period</font>&#8221; shall mean a period with respect to which the option to purchase Common Stock may be granted under this Plan, as determined by the Committee pursuant to <u>Section 5(a)</u>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(q)&#8195;&#8220;<font style="font-style: italic; font-weight: bold;">Parent</font>&#8221; shall have the same meaning as &#8220;parent corporation&#8221; in Sections 424(e) and 424(f) of the Code. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(r)&#8195;&#8220;<font style="font-style: italic; font-weight: bold;">Participant</font>&#8221; shall mean an eligible employee who meets the eligibility requirements set forth in <u>Section 4</u> of this Plan and who elects to participate in this Plan pursuant to <u>Section 6</u> of this Plan. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(s)&#8195;&#8220;<font style="font-style: italic; font-weight: bold;">Participating Corporation</font>&#8221; shall mean any Parent, Subsidiary or Affiliate that the Committee designates from time to time as eligible to participate in this Plan. For purposes of the Section&#160;423 Component, only the Parent and Subsidiaries may be Participating Corporations, provided, however, that at any given time a Parent or Subsidiary that is a Participating Corporation under the Section&#160;423 Component shall not be a Participating Corporation under the Non-Section&#160;423 Component. The Committee may provide that any Participating Corporation shall only be eligible to participate in the Non-Section&#160;423 Component. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(t)&#8195;&#8220;<font style="font-style: italic; font-weight: bold;">Plan</font>&#8221; shall mean this Company Post-Closing Employee Stock Purchase Plan, as may be amended from time to time. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(u)&#8195;&#8220;<font style="font-style: italic; font-weight: bold;">Pre-Funded Warrant</font>&#8221; means any warrant to acquire shares of common stock for a nominal exercise price. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(v)&#8195;&#8220;<font style="font-style: italic; font-weight: bold;">Purchase Date</font>&#8221; shall mean the last Trading Day of each Purchase Period. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(w)&#8195;&#8220;<font style="font-style: italic; font-weight: bold;">Purchase Period</font>&#8221; shall mean a period during which Contributions may be made toward the purchase of Common Stock under this Plan, as determined by the Committee pursuant to <u>Section 5(b)</u> of this Plan. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(x)&#8195;&#8220;<font style="font-style: italic; font-weight: bold;">Purchase Price</font>&#8221; shall mean the price at which Participants may purchase shares of Common Stock under this Plan, as determined pursuant to <u>Section 8</u> of this Plan. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(y)&#8195;&#8220;<font style="font-style: italic; font-weight: bold;">SEC</font>&#8221; means the United States Securities and Exchange Commission. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(z)&#8195;&#8220;<font style="font-style: italic; font-weight: bold;">Section&#160;423 Component</font>&#8221; means the part of this Plan, which excludes the Non-Section&#160;423 Component, pursuant to which options to purchase shares of Common Stock under this Plan that satisfy the requirements for &#8220;employee stock purchase plans&#8221; set forth in Section&#160;423 of the Code may be granted to eligible employees. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(aa)&#8195;&#8220;<font style="font-style: italic; font-weight: bold;">Securities Act</font>&#8221; means the United States Securities Act of 1933, as amended. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(bb)&#8195;&#8220;<font style="font-style: italic; font-weight: bold;">Subsidiary</font>&#8221; shall have the same meaning as &#8220;subsidiary corporation&#8221; in Sections 424(e) and 424(f) of the Code. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 8.5pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(cc)&#8195;&#8220;<font style="font-style: italic; font-weight: bold;">Trading Day</font>&#8221; means a day on which the principal national stock exchange upon which the Common Stock is listed is open for trading. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">J-9<br></div></div></div>
<!--End Page 521-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 522-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a name="ny20077604x1_s4_310-annexk_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: right;"><a name="tANK"><!--Anchor--></a>Annex K </div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 19.5pt; text-align: center;">FORM OF PROXY CARD </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">K-1<br></div></div></div>
<!--End Page 522-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 523-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_400-cov01_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 456pt; margin-left: 6pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; text-align: center;"><div style="color: #FC0014; font-family: Arial, Helvetica, sans-serif; font-weight: bold; text-align: left; margin-bottom: 12pt;">Information contained herein is subject to completion or amendment. A registration statement relating to these securities has been filed with the United States Securities and Exchange Commission. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This prospectus shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.</div>[RESALE PROSPECTUS ALTERNATE PAGE] </div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; text-align: center;">PRELIMINARY&#8201;-&#8201;SUBJECT TO COMPLETION&#8201;-&#8201;DATED JULY 20, 2026</div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 14.25pt; text-align: center;"><img style="height: 127px; width: 177px;" src="logo_standardbiov2x1.jpg"><br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201; <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; text-align: center;">1,479,138,270 SHARES OF COMMON STOCK <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">OF <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">STANDARD BIOTOOLS INC.<br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-weight: normal;">(For Resale) </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This prospectus relates to the resale, from time to time, by the Selling Securityholders identified in the section entitled &#8220;<font style="font-style: italic;">Selling Securityholders</font>&#8221; (including their transferees, donees, pledgees and other successors-in-interest, the &#8220;Selling Securityholders&#8221;) of up to 1,479,138,270 shares of common stock, par value $0.001 per share, of Standard BioTools Inc. (&#8220;Standard BioTools Common Stock&#8221;) issued to such Selling Securityholders in connection with the merger of Siri Merger Sub, Inc., a wholly owned subsidiary of Standard BioTools, with and into Treeline Biosciences, Inc. (&#8220;Treeline&#8221;), with Treeline surviving as a wholly owned subsidiary of Standard BioTools (the &#8220;Merger&#8221;). Each of the Selling Securityholders may be deemed to be an &#8220;underwriter&#8221; within the meaning of Section&#160;2(a)(11) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), with respect to the shares of Standard BioTools Common Stock offered by this prospectus. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Selling Securityholders may sell all, some or none of the shares of Standard BioTools Common Stock covered by this prospectus. Standard BioTools will not receive any proceeds from the sale of shares by the Selling Securityholders. Standard BioTools will bear all costs, expenses and fees in connection with the registration of these shares. The Selling Securityholders will bear all commissions and discounts, if any, attributable to their respective sales of shares. We provide more information about how the Selling Securityholders may sell their shares in the section titled &#8220;<font style="font-style: italic;">Plan of Distribution</font>.&#8221; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The shares of Standard BioTools Common Stock covered by this prospectus represent approximately &#8195;&#8195;&#8195;% of the shares of Standard BioTools Common Stock expected to be outstanding immediately following completion of the Merger. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This prospectus is not a proxy statement, is not being provided in connection with any vote or approval of Standard BioTools stockholders or Treeline stockholders, and does not constitute a solicitation of any proxy. This prospectus should be read together with the accompanying proxy statement/prospectus, including the sections titled &#8220;<font style="font-style: italic;">Prospectus Summary &#8212; Lock-Up Agreements</font>&#8221; and &#8220;<font style="font-style: italic;">Risk Factors</font>,&#8221;<font style="font-style: italic;"> </font>each of which is incorporated by reference herein and forms a part of this prospectus. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Standard BioTools Common Stock is currently listed on the Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) under the symbol &#8220;LAB.&#8221; Following the completion of the Merger and the related change of Standard BioTools&#8217; name to &#8220;Treeline Biosciences Holdings, Inc.,&#8221; Standard BioTools Common Stock is expected to be listed on Nasdaq under the symbol &#8220;TRLN.&#8221; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Investing in Standard BioTools Common Stock involves a high degree of risk. See &#8220;<font style="font-style: italic;">Risk Factors</font>&#8221; beginning on page <a href="#tRF">33</a> of the accompanying proxy statement/prospectus. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Neither the United States Securities and Exchange Commission (the &#8220;SEC&#8221;) nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.<font style="font-weight: normal;"> </font></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 38.5pt; text-align: center;">The resale prospectus is dated &#8195;&#8195;&#8195;, 2026. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">Alt-1<br></div></div></div>
<!--End Page 523-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 524-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_401-selling_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; text-align: center;">[RESALE PROSPECTUS ALTERNATE PAGE] </div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; text-align: center;"><a name="tRESALE"><!--Anchor--></a>SELLING SECURITYHOLDERS </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This prospectus registers shares of Standard BioTools Common Stock for the possible resale by certain Treeline stockholders, who are referred to in this prospectus as the &#8220;Selling Securityholders.&#8221; The Selling Securityholders may offer and sell, from time to time, any or all of the shares of Standard BioTools Common Stock being offered for resale by this prospectus, which consists of up to 1,479,138,270 shares of Standard BioTools Common Stock issued in connection with the private placement made to Treeline stockholders who signed the Treeline Stockholder Consent approving the Merger Agreement following its execution on June&#160;6, 2026. The shares of Standard BioTools Common Stock covered by this prospectus represent approximately &#8195;&#8195;&#8195;% of the shares of Standard BioTools Common Stock expected to be outstanding immediately following the Closing. All of the shares held by the Selling Securityholders are subject to the lock-up agreements described under &#8220;<font style="font-style: italic;">Prospectus Summary &#8212; Lock-Up Agreements</font>&#8221; and may not be sold by the Selling Securityholders until the applicable lock-up period expires (subject to certain exceptions set forth in the applicable lock-up agreements), notwithstanding the registration of such shares for resale pursuant to this prospectus. The sale of a substantial number of these shares in the public market following expiration of the lock-up period, or the perception that such sales may occur, could cause the market price of the combined company&#8217;s common stock to decline. See &#8220;<font style="font-style: italic;">Risk Factors</font>.&#8221; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Selling Securityholders may from time to time offer and sell any or all of the shares of Standard BioTools Common Stock set forth below pursuant to this proxy statement/prospectus. In this proxy statement/prospectus, the term &#8220;Selling Securityholders&#8221; includes (i) the entities identified in the table below (as such table may be amended from time to time by means of an amendment to the registration statement on Form&#160;S-4 of which this proxy statement/prospectus forms a part or by a supplement to this proxy statement/prospectus) and (ii) any donees, pledgees, transferees or other successors-in-interest that acquire any of the securities covered by this proxy statement/prospectus from the named Selling Securityholders as a gift, pledge, partnership distribution or other non-sale related transfer. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following table provides, as of June&#160;1, 2026, information regarding the beneficial ownership of Standard BioTools Common Stock and other securities convertible or exercisable into shares of Standard BioTools Common Stock of each Selling Securityholder, the number of shares of Standard BioTools Common Stock that may be sold by each Selling Securityholder under this proxy statement/prospectus and the number of shares that each Selling Securityholder will beneficially own after this offering. The number of shares of Standard BioTools Common Stock of each Selling Securityholder that may be sold under this proxy statement/prospectus assumes an Exchange Ratio of 11.6997, which is based on the capitalization of each of Treeline and Standard BioTools as of June&#160;3, 2026 and May&#160;28, 2026, respectively, and taking into account Standard BioTools&#8217; estimate of Parent Net Cash as of the Closing and before giving effect to the proposed Reverse Stock Split. The Exchange Ratio is based on the relative capitalization of each of Treeline and Standard BioTools and assumes (i) an equity value for Treeline of $2.5&#160;billion and (ii) an equity value for Standard BioTools equal to $460&#160;million, reduced by the amount by which the Parent Net Cash is less than $449&#160;million at the Closing or increased by the amount by which Parent Net Cash is more than $451&#160;million at the Closing. As a result, the actual Exchange Ratio at the Closing will be adjusted based on the Parent Net Cash at Closing. See &#8220;<font style="font-style: italic;">The Merger Agreement&#8201;&#8212;&#8201;Exchange Ratio</font>&#8221; and &#8220;<font style="font-style: italic;">The Merger Agreement &#8212; Calculation of Parent Net Cash</font>.&#8221; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Because each Selling Securityholder may dispose of all, none or some portion of their securities, no estimate can be given as to the number of securities that will be beneficially owned by a Selling Securityholder upon termination of this offering. For purposes of the table below, however, we have assumed that after termination of this offering none of the securities covered by this proxy statement/prospectus will be beneficially owned by the Selling Securityholders and further assumed that the Selling Securityholders will not acquire beneficial ownership of any additional securities during the offering. In addition, the Selling Securityholders may have sold, transferred or otherwise disposed of, or may sell, transfer or otherwise dispose of, at any time and from time to time, Standard BioTools securities in transactions exempt from the registration requirements of the Securities Act after the date on which the information in the tables is presented. Beneficial ownership is determined in accordance with the rules and regulations of the SEC. In computing the number of shares beneficially owned by the Selling Securityholders and the percentage ownership of each Selling Securityholder, securities that are currently convertible or exercisable into shares of Standard BioTools Common Stock, or convertible or exercisable within 60 days following June&#160;1, 2026, are deemed beneficially owned by the Selling Securityholder. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">Alt-2<br></div></div></div>
<!--End Page 524-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 525-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_401-selling_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; text-align: center;">[RESALE PROSPECTUS ALTERNATE PAGE] <br></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Except as described herein or in the documents incorporated by reference, none of the Selling Securityholders or their respective affiliates has been an officer or director of Standard BioTools or any of Standard BioTools&#8217; predecessors or affiliates within the last three years, nor has any Selling Securityholder had a material relationship with Standard BioTools within the last three years. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 228pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.18pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.18pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 44.66pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.18pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.18pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 57.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.18pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.18pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 44.2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.18pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6.18pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 44.2pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 228pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name of Selling Securityholder</div></td><td style="width: 6.18pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.18pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 44.66pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Beneficially<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Owned Prior<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">to Offering</div></td><td style="width: 6.18pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.18pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 57.5pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Registered<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">for Sale<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Hereby</div></td><td style="width: 6.18pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.18pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 44.2pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Beneficially <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Owned After <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Offering</div></td><td style="width: 6.18pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.18pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 44.2pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Percentage<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Beneficially<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Owned After<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Offering </div></td></tr><tr><td style="width: 228pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Joshua H. Bilenker<font style="padding-left: 4.13pt;"></font></div></td><td style="width: 6.18pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.18pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 44.66pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.33pt; text-align: left;">&#8212;</div></td><td style="width: 6.18pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.18pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 57.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 7.5pt;">138,331,234</font></div></td><td style="width: 6.18pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.18pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 44.2pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.1pt; text-align: left;"><font style="padding-left: 3.75pt;">&#8212;</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div></td><td style="width: 6.18pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.18pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 44.2pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.1pt; text-align: left;">&#8212;% </div></td></tr><tr><td style="width: 228pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Entities Affiliated with Jeffrey Engelman <font style="padding-left: 3.4pt;"></font></div></td><td style="width: 6.18pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.18pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 44.66pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.33pt; text-align: left;">&#8212;</div></td><td style="width: 6.18pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.18pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 57.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt;">38,999,159</font></div></td><td style="width: 6.18pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.18pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 44.2pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.1pt; text-align: left;"><font style="padding-left: 3.75pt;">&#8212;</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup></div></td><td style="width: 6.18pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.18pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 44.2pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.1pt; text-align: left;">&#8212;% </div></td></tr><tr><td style="width: 228pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">OrbiMed Private Investments VIII, LP<font style="padding-left: 1.01pt;"></font></div></td><td style="width: 6.18pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.18pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 44.66pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.33pt; text-align: left;">&#8212;</div></td><td style="width: 6.18pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.18pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 57.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 7.5pt;">226,853,734</font></div></td><td style="width: 6.18pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.18pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 44.2pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.1pt; text-align: left;"><font style="padding-left: 3.75pt;">&#8212;</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup></div></td><td style="width: 6.18pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.18pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 44.2pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.1pt; text-align: left;">&#8212;% </div></td></tr><tr><td style="width: 228pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Entities Affiliated with ARCH Venture Partners<font style="padding-left: 0.62pt;"></font></div></td><td style="width: 6.18pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.18pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 44.66pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.33pt; text-align: left;">&#8212;</div></td><td style="width: 6.18pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.18pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 57.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 7.5pt;">226,853,722</font></div></td><td style="width: 6.18pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.18pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 44.2pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.1pt; text-align: left;"><font style="padding-left: 3.75pt;">&#8212;</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(4)</sup></div></td><td style="width: 6.18pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.18pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 44.2pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.1pt; text-align: left;">&#8212;% </div></td></tr><tr><td style="width: 228pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Entities Affiliated with GV<font style="padding-left: 2.09pt;"></font></div></td><td style="width: 6.18pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.18pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 44.66pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.33pt; text-align: left;">&#8212;</div></td><td style="width: 6.18pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.18pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 57.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 7.5pt;">222,790,891</font></div></td><td style="width: 6.18pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.18pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 44.2pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.1pt; text-align: left;"><font style="padding-left: 3.75pt;">&#8212;</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(5)</sup></div></td><td style="width: 6.18pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.18pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 44.2pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.1pt; text-align: left;">&#8212;% </div></td></tr><tr><td style="width: 228pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Aisling Capital V, LP<font style="padding-left: 4.76pt;"></font></div></td><td style="width: 6.18pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.18pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 44.66pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.33pt; text-align: left;">&#8212;</div></td><td style="width: 6.18pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.18pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 57.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.87pt;">28,193,119</font></div></td><td style="width: 6.18pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.18pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 44.2pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.1pt; text-align: left;"><font style="padding-left: 10pt;">&#8212;</font></div></td><td style="width: 6.18pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.18pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 44.2pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.1pt; text-align: left;">&#8212;% </div></td></tr><tr><td style="width: 228pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Entities Affiliated with KKR &amp; Co., Inc.<font style="padding-left: 3.21pt;"></font></div></td><td style="width: 6.18pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.18pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 44.66pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.33pt; text-align: left;">&#8212;</div></td><td style="width: 6.18pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.18pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 57.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 7.5pt;">234,894,480</font></div></td><td style="width: 6.18pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.18pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 44.2pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.1pt; text-align: left;"><font style="padding-left: 3.75pt;">&#8212;</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(6)</sup></div></td><td style="width: 6.18pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.18pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 44.2pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.1pt; text-align: left;">&#8212;% </div></td></tr><tr><td style="width: 228pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Entities Affiliated with Ajax Health<font style="padding-left: 3.48pt;"></font></div></td><td style="width: 6.18pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.18pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 44.66pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.33pt; text-align: left;">&#8212;</div></td><td style="width: 6.18pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.18pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 57.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 7.87pt;">115,887,699</font></div></td><td style="width: 6.18pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.18pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 44.2pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.1pt; text-align: left;"><font style="padding-left: 3.75pt;">&#8212;</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(7)</sup></div></td><td style="width: 6.18pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.18pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 44.2pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.1pt; text-align: left;">&#8212;% </div></td></tr><tr><td style="width: 228pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Ajax Zeus TL 2 LLC<font style="padding-left: 1.06pt;"></font></div></td><td style="width: 6.18pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.18pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 44.66pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.33pt; text-align: left;">&#8212;</div></td><td style="width: 6.18pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.18pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 57.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 17.5pt;">7,471,974</font></div></td><td style="width: 6.18pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.18pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 44.2pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.1pt; text-align: left;"><font style="padding-left: 10pt;">&#8212;</font></div></td><td style="width: 6.18pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.18pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 44.2pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.1pt; text-align: left;">&#8212;% </div></td></tr><tr><td style="width: 228pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Entities Affiliated with Access Industries<font style="padding-left: 1.84pt;"></font></div></td><td style="width: 6.18pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.18pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 44.66pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.33pt; text-align: left;">&#8212;</div></td><td style="width: 6.18pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.18pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 57.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 7.5pt;">281,561,409</font></div></td><td style="width: 6.18pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.18pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 44.2pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.1pt; text-align: left;"><font style="padding-left: 3.75pt;">&#8212;</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(8)</sup></div></td><td style="width: 6.18pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.18pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 44.2pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.1pt; text-align: left;">&#8212;% </div></td></tr><tr><td style="width: 228pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Entities Affiliated with Avi Naider<font style="padding-left: 3.11pt;"></font></div></td><td style="width: 6.18pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.18pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 44.66pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.33pt; text-align: left;">&#8212;</div></td><td style="width: 6.18pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.18pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 57.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt;">27,819,359</font></div></td><td style="width: 6.18pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.18pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 44.2pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.1pt; text-align: left;"><font style="padding-left: 3.75pt;">&#8212;</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(9)</sup></div></td><td style="width: 6.18pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.18pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 44.2pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.1pt; text-align: left;">&#8212;% </div></td></tr><tr><td style="width: 228pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total<font style="padding-left: 0.09pt;"></font></div></td><td style="width: 6.18pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.18pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 44.66pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.33pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">&#8212;</font></div></td><td style="width: 6.18pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.18pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 57.5pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">1,479,144,277</font></div></td><td style="width: 6.18pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.18pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 44.2pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.1pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">&#8212;<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(10</sup></font><font style="padding-bottom: 0.5pt;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">)</sup></font></div></td><td style="width: 6.18pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6.18pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 44.2pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.1pt; text-align: left;"><font style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">&#8212;</font><font style="padding-bottom: 0.5pt;">%</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 228pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.18pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.18pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 44.66pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.18pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.18pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 57.5pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.18pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.18pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 44.2pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.18pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6.18pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 44.2pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div><div class="BRDSX_rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 10.25pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Represents (i) &#8195;&#8195;&#8195;&#8195; shares of Standard BioTools Common Stock directly held by Dr.&#160;Bilenker, (ii) &#8195;&#8195;&#8195;&#8195; shares of Standard BioTools Common Stock Common Stock directly held by Dr.&#160;Bilenker&#8217;s spouse, and (iii) an aggregate &#8195;&#8195;&#8195;&#8195; shares convertible into Standard BioTools Common Stock held directly by trusts. Dr.&#160;Bilenker may be deemed to exercise voting and/or investment discretion over the securities held by each of the trusts noted in subclause (iii) of the preceding sentence. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(2)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Represents (i) &#8195;&#8195;&#8195;&#8195; shares of Standard BioTools Common Stock directly held by The Jeffrey A. Engelman Trust &#8211; 2023, (ii) &#8195;&#8195;&#8195;&#8195; shares of Standard BioTools Common Stock directly held by The Engelman Irrevocable Trust fbo Alexis, and (iii) &#8195;&#8195;&#8195;&#8195; shares of Standard BioTools Common Stock directly held by The Engelman Irrevocable Trust fbo Charles (together with The Jeffrey A. Engelman Trust &#8211; 2023 and The Engelman Irrevocable Trust fbo Alexis, the &#8220;Engelman Trusts&#8221;). Dr. Engelman serves as trustee of the Engelman Trusts and may be deemed to exercise voting and investment discretion in such capacity. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(3)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Represents &#8195;&#8195;&#8195;&#8195; shares of Standard BioTools Common Stock held by OPI VIII. GP VIII is the general partner of OPI VIII and OrbiMed Advisors is the managing member of GP VIII. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VIII. Dr.&#160;Bonita, a member of the Treeline Board, is a member of OrbiMed Advisors. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(4)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Represents (i) &#8195;&#8195;&#8195;&#8195; shares of Standard BioTools Common Stock directly held by ARCH Fund XI, and (ii)&#160;&#8195;&#8195;&#8195;&#8195; shares of Standard BioTools Common Stock directly held by ARCH Fund XII. AVP XI LP is the sole general partner of ARCH Fund XI, and AVP XI LLC is the sole general partner of AVP XI LP, and each of them may be deemed to beneficially own securities directly held of record by ARCH Fund XI. AVP XII LP is the sole general partner of ARCH Fund XII, and AVP XII LLC is the sole general partner of AVP XII LP, and each of them may be deemed to beneficially own securities directly held of record by ARCH Fund XII. Each of AVP XI LLC and AVP XII LLC exercises voting and investment power through an investment committee comprised of Kristina M. Burow, a member of the Treeline Board, Keith Crandell, Steven Gillis, and Robert Nelsen. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(5)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Represents &#8195;&#8195;&#8195;&#8195; shares of Standard BioTools Common Stock directly held by GV 2021, L.P. and &#8195;&#8195;&#8195;&#8195; shares of Standard BioTools Common Stock directly held by GV 2025 LP. GV 2021 GP is the general partner of GV 2021 LP and GV 2021 LLC is the general partner of GV 2021 GP. GV 2025 GP is the general partner of GV 2025 LP and GV 2025 LLC is the general partner of GV 2025 GP. Alphabet Holdings LLC is the sole member of GV 2021 LLC and GV 2025 LLC. XXVI is the sole member of Alphabet Holdings LLC. Alphabet Inc. is the controlling stockholder of XXVI. As such, GV 2021 GP and GV 2021 LLC may be deemed to indirectly beneficially own securities held by GV 2021 LP, and GV 2025 GP and GV 2025 LLC may be deemed to indirectly beneficially own securities held by GV 2025 LP. Further, Alphabet Holdings LLC, XXVI, and Alphabet Inc. may be deemed to indirectly beneficially own the securities directly held by the GV Funds. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(6)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Represents (i) &#8195;&#8195;&#8195;&#8195; shares of Standard BioTools Common Stock directly held by KKR Forest LLC, (ii)&#160;&#8195;&#8195;&#8195;&#8195; shares of Standard BioTools Common Stock directly held by KKR Forest Aggregator L.P., and (iii)&#160;&#8195;&#8195;&#8195;&#8195; shares of Standard BioTools Common Stock directly held by AZTL. </div></td></tr></table><div class="BRDSX_ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 3pt; margin-left: 20pt; text-align: left;">KKR Forest Aggregator L.P., as the managing member of KKR Forest LLC, KKR Forest Aggregator GP LLC, as the general partner of KKR Forest Aggregator L.P., KKR Health Care Strategic Growth Fund II SCSp, as the sole member of KKR Forest Aggregator GP LLC, KKR Associates HCSG II SCSp, as the general partner of KKR Health Care Strategic Growth Fund II SCSp, KKR HCSG II S.&#224; r.l., as the general partner of KKR Associates HCSG II SCSp, KKR HCSG II Holdings Limited, as the sole shareholder of KKR HCSG II S.&#224; r.l., KKR Group Partnership L.P., as the sole shareholder of KKR HCSG II Holdings Limited, KKR Group Holdings Corp., as the general partner of KKR Group Partnership L.P., KKR Group Co. Inc., as the sole shareholder of KKR Group Holdings Corp., KKR, as the sole shareholder of KKR Group Co. Inc., KKR Management LLP, as the Series&#160;I preferred stockholder of KKR, and Messrs. Henry R. Kravis and George R. Roberts, as the founding partners of KKR Management LLP, may be deemed to be the beneficial owners having shared voting and investment power with respect to the shares held by the KKR Entities.&#8195;</div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">Alt-3<br></div></div></div>
<!--End Page 525-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 526-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_401-selling_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; text-align: center;">[RESALE PROSPECTUS ALTERNATE PAGE] <br></div><div class="BRDSX_ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 8pt; margin-left: 20pt; text-align: left;">Neptune, as the managing member of AZTL, Zeus Health LLC, as a member of Neptune, KKR Zeus Aggregator LLC, as the managing member of Zeus Health LLC, KKR Health Care Strategic Growth Fund L.P., as the managing member of KKR Zeus Aggregator LLC, KKR Associates HCSG L.P., as the general partner of KKR Health Care Strategic Growth Fund L.P., KKR HCSG GP LLC, as the general partner of KKR Associates HCSG L.P., KKR Group Partnership L.P., as the sole member of KKR HCSG GP LLC, KKR Group Holdings Corp., as the general partner of KKR Group Partnership L.P., KKR Group Co. Inc., as the sole shareholder of KKR Group Holdings Corp., KKR, as the sole shareholder of KKR Group Co. Inc., KKR Management LLP, as the Series&#160;I preferred stockholder of KKR, and Messrs. Henry R. Kravis and George R. Roberts, as the founding partners of KKR Management LLP, may be deemed to be beneficial owners having shared voting and investment power with respect to the shares held by AZTL. </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(7)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Represents (i) &#8195;&#8195;&#8195;&#8195; shares of Standard BioTools Common Stock directly held by Ajax Health III LLC, (ii)&#160;&#8195;&#8195;&#8195;&#8195; shares of Standard BioTools Common Stock directly held by Ajax HQ Treeline 2022 SPV, LLC, and (iii)&#160;70,512,504 shares convertible into Standard BioTools Common Stock directly held by AZTL. </div></td></tr></table><div class="BRDSX_ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 3pt; margin-left: 20pt; text-align: left;">Ajax Health III LLC is governed by a board of managers comprised of five voting managers, a majority of which are appointed by HealthQuest Partners III, L.P. HealthQuest Venture Management III, L.L.C. is the general partner of HealthQuest Partners III, L.P. Garheng Kong is the managing member of HealthQuest Venture Management III, L.L.C. and has sole voting and investment power over the shares held by Ajax Health III LLC. </div><div class="BRDSX_ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 3pt; margin-left: 20pt; text-align: left;">Ajax HQ Treeline 2022 SPV, LLC is governed by a board of managers comprised of three voting managers, a majority of which are appointed by HealthQuest Ajax III-A SPV, L.P. HealthQuest Ajax III-A Management, L.L.C. is the general partner of HealthQuest Ajax III-A SPV, L.P. Garheng Kong is the managing member of HealthQuest Ajax III-A Management, L.L.C. and has sole voting and investment power over the shares held by Ajax HQ Treeline 2022 SPV, LLC. </div><div class="BRDSX_ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 3pt; margin-left: 20pt; text-align: left;">Dr.&#160;Kong, HealthQuest Partners III, L.P., HealthQuest Venture Management III, L.L.C., HealthQuest Ajax III-A SPV, L.P. and HealthQuest Ajax III-A Management, L.L.C. disclaim beneficial ownership over all of the shares owned by Ajax Health III LLC, Ajax HQ Treeline 2022 SPV, LLC and AZTL except to the extent of their pecuniary interest therein. </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(8)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Represents (i) &#8195;&#8195;&#8195;&#8195; shares of Standard BioTools Common Stock directly held by AI Life and (ii) &#8195;&#8195;&#8195;&#8195; shares of Standard BioTools Common Stock directly held by AI Treeline. Such securities may be deemed to be beneficially owned by AIH, AI, AIM, LSI Management and Len Blavatnik. AI Life controls a majority of the outstanding voting interests in AI Treeline, AIH controls a majority of the outstanding voting interests in AI Life, AI controls a majority of the outstanding voting interests in AIH, LSI Management is the management member of AI Life, AIM controls AI and AIH is the management of LSI Management. Len Blavatnik is the controlling person of AIM and controls a majority of the outstanding voting interests in AI and may be deemed to exercise voting and investment discretion over securities held directly or indirectly by each of the aforementioned entities. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(9)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Represents (i) &#8195;&#8195;&#8195;&#8195; shares of Standard BioTools Common Stock directly held by AZN TL LLC, (ii) &#8195;&#8195;&#8195;&#8195; shares of Standard BioTools Common Stock directly held by AZN TLII LLC (together with AZN TL LLC, the &#8220;Naider LLCs&#8221;), and (iii) &#8195;&#8195;&#8195;&#8195; shares of Treeline Common Stock directly held by the Debra Klein 2019 Irrevocable Trust (the &#8220;Klein Trust&#8221;). Mr. Naider serves as manager of the Naider LLCs and as trustee of the Klein Trust and may be deemed to exercise voting and investment discretion over the securities held by them in such capacities.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(10)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">The &#8195;&#8195;&#8195;&#8195; shares of Standard BioTools Common Stock directly held by AZTL are included in the aggregate number of shares convertible into Standard BioTools Common Stock for both the &#8220;Entities Affiliated with KKR &amp; Co., Inc.&#8221; and &#8220;Entities Affiliated with Ajax Health&#8221; rows of the table. The total amount only accounts for &#8195;&#8195;&#8195;&#8195; shares of Standard BioTools Common Stock directly held by AZTL once and does not double count these shares. </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">Alt-4<br></div></div></div>
<!--End Page 526-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 527-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_402-plan_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; text-align: center;">[RESALE PROSPECTUS ALTERNATE PAGE] </div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14pt; text-align: center;">PLAN OF DISTRIBUTION </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Standard BioTools is registering the shares of Standard BioTools Common Stock held by the Selling Securityholders to permit the resale of such shares of Standard BioTools Common Stock by the Selling Securityholders from time to time after the date of this proxy statement/prospectus, subject, in the case of shares held by Selling Securityholders that remain subject to a lock-up agreement, to expiration of the applicable lock-up period. See &#8220;<font style="font-style: italic;">Prospectus Summary &#8212; Lock-Up Agreements</font>&#8221; - of the accompanying proxy statement/prospectus. Standard BioTools will not receive any of the proceeds from the sale by the Selling Securityholders of the Standard BioTools Common Stock. See section titled &#8220;<font style="font-style: italic;">Use of Proceeds</font>&#8221; of the accompanying proxy statement/prospectus. Standard BioTools will bear all fees and expenses incident to its obligation to register the Standard BioTools Common Stock in this offering. Sales by the Selling Securityholders may not require the provision of a prospectus supplement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Standard BioTools Common Stock may be sold from time to time directly by the Selling Securityholders, including their donees, pledgees, transferees and other successors in interest, or, alternatively, through underwriters, broker-dealers or agents, or through any combination of the foregoing methods. If the Standard BioTools Common Stock is sold through underwriters, broker-dealers or agents, the Selling Securityholders will be responsible for underwriting discounts or commissions or agents&#8217; commissions, if any. The Standard BioTools Common Stock may be sold in one or more transactions at fixed prices, at prevailing market prices at the time of sale, at varying prices determined at the time of sale or at negotiated prices. We cannot currently determine the price or prices at which shares of Standard BioTools Common Stock may be sold by the Selling Securityholders under this prospectus. Such sales may be effected in transactions, which may involve block transactions: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">on any national securities exchange or quotation service on which the Standard BioTools Common Stock may be listed or quoted at the time of sale, including Nasdaq;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">in the over-the-counter market; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">otherwise than on such exchanges or services or in the over-the-counter market;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">through the writing of options;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">through trading plans entered into by the Selling Securityholder pursuant to Rule&#160;10b5-1 under the Exchange Act that are in place at the time of an offering pursuant to this proxy statement/prospectus and any applicable prospectus supplement hereto that provide for periodic sales of their Standard BioTools Common Stock on the basis of parameters described in such trading plans;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">through one or more underwritten offerings on a firm commitment or best efforts basis;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">pursuant to agreements with broker-dealers to sell a specified number of the shares of Standard BioTools Common Stock at a stipulated price per share;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">in &#8220;at the market&#8221; offerings, as defined in Rule&#160;415 under the Securities Act, at negotiated prices, at prices prevailing at the time of sale or at prices related to such prevailing market prices, including sales made directly on a national securities exchange or sales made through a market maker other than on an exchange or other similar offerings through sales agents;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">in privately negotiated transactions;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">in options or other hedging transactions, whether through an options exchange or otherwise;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">in distributions to members, limited partners or stockholders of the Selling Securityholders (to the extent a distributee is an affiliate of Standard BioTools, or as otherwise required by law, Standard BioTools may file a prospectus supplement to permit such distributee to use this proxy statement/prospectus to resell the shares of Standard BioTools Common Stock so distributed);</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any other method permitted by applicable law; or </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">through any combination of the foregoing. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Selling Securityholders may also sell all or a portion of the Standard BioTools Common Stock beneficially owned by them and offered hereby from time to time using other methods as permitted pursuant to applicable law. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">Alt-5<br></div></div></div>
<!--End Page 527-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 528-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_402-plan_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; text-align: center;">[RESALE PROSPECTUS ALTERNATE PAGE] <br></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, the Selling Securityholders may resell all or a portion of the Standard BioTools Common Stock in open market transactions in reliance upon Rule&#160;144 under the Securities Act, as permitted by that rule, or Section&#160;4(a)(1) under the Securities Act, if available, rather than under this proxy statement/prospectus, provided that they meet the criteria and conform to the requirements of those provisions. If Standard BioTools were classified as a &#8220;shell company&#8221; under SEC rules, Rule 144 would not be available for the resale of &#8220;restricted&#8221; or &#8220;control&#8221; securities of Standard BioTools until one year after the required Form 10 information has been filed with the SEC, and Selling Securityholders who were affiliates of Treeline at the time the Merger was submitted for the consent of Treeline&#8217;s stockholders and who publicly offer or sell shares received in the Merger may be deemed to be engaged in a distribution of such securities and therefore underwriters with respect to such resales. See &#8220;<font style="font-style: italic;">Risk Factors</font>&#8221; of the accompanying proxy statement/prospectus. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Broker-dealers engaged by the Selling Securityholders may arrange for other broker-dealers to participate in sales. If the Selling Securityholders effect such transactions by selling the Standard BioTools Common Stock to or through underwriters, broker-dealers or agents, such underwriters, broker-dealers or agents may receive commissions in the form of discounts, concessions or commissions from the Selling Securityholders or commissions from purchasers of the Standard BioTools Common Stock for whom they may act as agent or to whom they may sell as principal. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Such commissions will be in amounts to be negotiated, but, except as set forth in a supplement to this proxy statement/prospectus, in the case of an agency transaction will not be in excess of a customary brokerage commission in compliance with FINRA Rule&#160;2440, and in the case of a principal transaction a markup or markdown in compliance with FINRA IM-2440. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In connection with sales of the Standard BioTools Common Stock or otherwise, the Selling Securityholders may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the Standard BioTools Common Stock in the course of the positions they assume. The Selling Securityholders may also sell Standard BioTools Common Stock short and deliver Standard BioTools Common Stock covered by this proxy statement/prospectus to close out short positions and to return borrowed Standard BioTools Common Stock in connection with such short sales. The Selling Securityholders may also loan or pledge the Standard BioTools Common Stock to broker-dealers that in turn may sell such Standard BioTools Common Stock, to the extent permitted by applicable law. The Selling Securityholders may also enter into option or other transactions with broker-dealers or other financial institutions or the creation of one or more derivative securities which require the delivery to such broker-dealer or other financial institution of Standard BioTools Common Stock offered by this proxy statement/prospectus, which securities such broker-dealer or other financial institution may resell pursuant to this proxy statement/prospectus (as supplemented or amended to reflect such transaction). </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Selling Securityholders may, from time to time, pledge or grant a security interest in some or all of the Standard BioTools Common Stock owned by them and, if they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the Standard BioTools Common Stock from time to time pursuant to this proxy statement/prospectus or any amendment or supplement to this proxy statement/prospectus under any applicable provision of the Securities Act, amending, if necessary, the list of Selling Securityholders to include the pledgee, transferee or other successors in interest as Selling Securityholders under this proxy statement/prospectus. The Selling Securityholders also may transfer and donate the Standard BioTools Common Stock in other circumstances in which case the transferees, donees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this proxy statement/prospectus. If any shares of Standard BioTools Common Stock offered for sale pursuant to this proxy statement/prospectus are transferred other than pursuant to a sale under this proxy statement/prospectus, then subsequent holders could not use this proxy statement/prospectus until a post-effective amendment or prospectus supplement is filed, naming such holders as Selling Securityholders. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Selling Securityholders and any broker-dealer or agents participating in the distribution of the Standard BioTools Common Stock may be deemed to be an &#8220;underwriter&#8221; within the meaning of Section&#160;2(a)(11) of the Securities Act in connection with such sales. In such event, any commissions paid, or any discounts or concessions allowed to, any such broker-dealer or agent and any profit on the resale of the shares purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. Selling Securityholders who are </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">Alt-6<br></div></div></div>
<!--End Page 528-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 529-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_402-plan_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; text-align: center;">[RESALE PROSPECTUS ALTERNATE PAGE] <br></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">considered to be an &#8220;underwriter&#8221; within the meaning of Section&#160;2(a)(11) of the Securities Act will be subject to the applicable prospectus delivery requirements of the Securities Act and may be subject to certain statutory liabilities , including but not limited to, Sections 11, 12 and 17 of the Securities Act and Rule&#160;10b-5 under the Exchange Act. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Each Selling Securityholder has informed Standard BioTools that it is not a registered broker-dealer and does not have any written or oral agreement or understanding, directly or indirectly, with any person to distribute the Standard BioTools Common Stock. If required, the specific Standard BioTools Common Stock to be sold, the names of the Selling Securityholders, the respective purchase prices and public offering prices, the names of any agent, broker-dealer or underwriter and any applicable commissions or discounts with respect to a particular offer will be set forth in an accompanying prospectus supplement or, if appropriate, a post-effective amendment to the registration statement on Form&#160;S-4 of which this proxy statement/prospectus forms a part. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under the securities laws of some states, the Standard BioTools Common Stock may be sold in such states only through registered or licensed brokers or dealers. In addition, in some states the Standard BioTools Common Stock may not be sold unless such Standard BioTools Common Stock has been registered or qualified for sale in such state or an exemption from registration or qualification is available and is complied with. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">There can be no assurance that any Selling Securityholder will sell any or all of the Standard BioTools Common Stock registered pursuant to the registration statement, of which this proxy statement/prospectus is a part. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Each Selling Securityholder and any other person participating in such distribution will be subject to applicable provisions of the Exchange Act and the rules and regulations thereunder, including, without limitation, to the extent applicable, Regulation M of the Exchange Act, which may limit the timing of purchases and sales of any of the Standard BioTools Common Stock by the Selling Securityholder and any other participating person. To the extent applicable, Regulation M may also restrict the ability of any person engaged in the distribution of the Standard BioTools Common Stock to engage in market-making activities with respect to the Standard BioTools Common Stock. All of the foregoing may affect the marketability of the Standard BioTools Common Stock and the ability of any person or entity to engage in market-making activities with respect to the Standard BioTools Common Stock. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Standard BioTools will pay all expenses of the registration of the shares of Standard BioTools Common Stock held by the Selling Securityholders, including, without limitation, Securities and Exchange Commission filing fees and expenses of compliance with state securities or &#8220;blue sky&#8221; laws; provided, however, that each Selling Securityholder will pay all underwriting discounts and selling commissions, if any and any related legal expenses incurred by it. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Any FINRA member firm participating in the resale, on behalf of a Selling Securityholder, of the shares of Standard BioTools Common Stock offered hereby on a principal or agency basis shall satisfy the filing and disclosure requirements of FINRA Rule&#160;5110, and shall not receive compensation in excess of that allowable under FINRA rules, including FINRA Rule&#160;5110, in connection with such resale. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">Alt-7<br></div></div></div>
<!--End Page 529-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 530-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_403-use_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; text-align: center;">[RESALE PROSPECTUS ALTERNATE PAGE] </div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; text-align: center;">USE OF PROCEEDS </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">All of the shares of Standard BioTools Common Stock offered by the Selling Securityholders pursuant to this prospectus will be sold by the Selling Securityholders for their respective accounts. We will not receive any of the proceeds from these sales. The Selling Securityholders will pay any underwriting discounts and commissions and expenses incurred by the Selling Securityholders for brokerage, accounting, tax or legal services or any other expenses incurred by the Selling Securityholders in disposing of the shares. We will bear all other costs, fees and expenses incurred in effecting the registration of the shares covered by this prospectus, including, without limitation, all registration and filing fees, Nasdaq listing fees and fees and expenses of our counsel and our independent registered public accountants. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">Alt-8<br></div></div></div>
<!--End Page 530-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 531-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_404-part2_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">PART II <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">INFORMATION NOT REQUIRED IN PROSPECTUS </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 50pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item&#160;20.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Indemnification of Officers and Directors of Standard BioTools. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Standard BioTools is a Delaware corporation. Section&#160;102(b)(7) of the DGCL (&#8220;Section&#160;102(b)(7)&#8221;) allows a corporation to provide in its certificate of incorporation that a director or officer of the corporation will not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director or officer, except where the director breached the duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of the DGCL, or obtained an improper personal benefit. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Section&#160;145 of the DGCL (&#8220;Section&#160;145&#8221;), provides that a Delaware corporation may indemnify any person who was, is or is threatened to be made party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of such corporation), by reason of the fact that such person is or was an officer, director, employee or agent of such corporation or is or was serving at the request of such corporation as a director, officer, employee or agent of another corporation or enterprise. The indemnity may include expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding, provided such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the corporation&#8217;s best interests and, with respect to any criminal action or proceeding, had no reasonable cause to believe that his or her conduct was illegal. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">A Delaware corporation may indemnify any persons who are, were or are threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation by reason of the fact that such person is or was a director, officer, employee or agent of another corporation or enterprise. The indemnity may include expenses (including attorneys&#8217; fees) actually and reasonably incurred by such person in connection with the defense or settlement of such action or suit, provided such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the corporation&#8217;s best interests, provided that no indemnification is permitted without judicial approval if the officer, director, employee or agent is adjudged to be liable to the corporation. Where an officer or director is successful on the merits or otherwise in the defense of any action referred to above, the corporation must indemnify him or her against the expenses which such officer or director has actually and reasonably incurred. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Section&#160;145 further authorizes a corporation to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation or enterprise against any liability asserted against him or her and incurred by him or her in any such capacity, or arising out of his or her status as such, whether or not the corporation would otherwise have the power to indemnify him or her under Section&#160;145. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As permitted by Section&#160;102(b)(7), the Standard BioTools Charter contains a provision eliminating the personal liability of a director to Standard BioTools or its stockholders for monetary damages for breach of fiduciary duty as a director, subject to certain exceptions. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Standard BioTools Bylaws provide that Standard BioTools shall indemnify, to the fullest extent permitted by the DGCL (as currently in effect or as it may in the future be amended), any person (each, an &#8220;Indemnified Person&#8221;) who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (a &#8220;Proceeding&#8221;) (other than an action by or in the right of Standard BioTools) by reason of the fact that the Indemnified Person is or was a director of Standard BioTools or an officer of Standard BioTools, or while a director of Standard BioTools or officer of Standard BioTools is or was serving at the request of Standard BioTools as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the Indemnified Person in connection with such Proceeding if the Indemnified Person acted in good faith and in a manner the Indemnified Person reasonably believed to be in or not opposed to the best interests of Standard BioTools, and, with respect to any criminal action or proceeding, had no reasonable cause to believe the Indemnified Person&#8217;s conduct was unlawful. Expenses (including attorneys&#8217; fees) incurred by an Indemnified Person in defending any Proceeding shall be paid by Standard BioTools in advance of the final disposition of such Proceeding upon receipt of a written </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">II-1<br></div></div></div>
<!--End Page 531-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 532-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_404-part2_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">request therefor (together with documentation reasonably evidencing such expenses) and an undertaking by or on behalf of the Indemnified Person to repay such amounts if it shall ultimately be determined that the person is not entitled to be indemnified under the Standard BioTools Bylaws or the DGCL. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Standard BioTools has entered into indemnification agreements with its officers, directors and certain other employees. With certain exceptions, these agreements provide for indemnification for related expenses including, among others, attorneys&#8217; fees, judgments, fines and settlement amounts incurred by any of these individuals in any action or proceeding. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For a period of six years from the Effective Time of the Merger, Standard BioTools shall maintain in effect the exculpation, indemnification and advancement of expenses provisions as provided in the organizational documents of Treeline, and shall not amend, repeal, abrogate or otherwise modify in any manner that would adversely affect any Indemnified Person. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Standard BioTools shall indemnify and hold harmless each present (as of the Effective Time of the Merger) or former director or officer of Treeline, against all obligations to pay a judgment, damages, settlement, or fine or penalty, and reasonable expenses (including legal expenses) incurred in connection with any action or claim, whether civil, criminal, administrative, arbitrative or investigative, and whether formal or informal, by reason of the fact that such person is or was an officer, director, employee, fiduciary or agent of Treeline or its subsidiaries, or of another entity if such service was at the request of Treeline, whether asserted or claimed prior to, at, or after the Effective Time of the Merger, to the fullest extent provided for under existing arrangements disclosed to Standard BioTools prior to the date of the Merger Agreement. </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 50pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item&#160;21.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Exhibits and Financial Statements. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">(a)&#8194;&#8201;A list of the exhibits included as part of this registration statement is set forth on the index of exhibits immediately preceding such exhibits and is incorporated herein by reference. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">(b)&#8194;&#8201;All schedules for which provision is made in the applicable accounting regulations of the SEC have been omitted because they are not required, amounts which would otherwise be required to be shown with respect to any item are not material, are inapplicable or the required information has already been provided elsewhere in the registration statement. </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 50pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item&#160;22.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Undertakings. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">(a)&#8194;&#8201;The undersigned registrant hereby undertakes: </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(1)&#8195;To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(i)&#8195;to include any prospectus required by Section&#160;10(a)(3) of the Securities Act of 1933; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(ii)&#8195;to reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in the volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule&#160;424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective registration statement; and </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(iii)&#8195;to include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(2)&#8195;That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(3)&#8195;To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">II-2<br></div></div></div>
<!--End Page 532-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 533-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_404-part2_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(4)&#8195;That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser, each prospectus filed pursuant to Rule&#160;424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule&#160;430B or other than prospectuses filed in reliance on Rule&#160;430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(5)&#8195;That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities, that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser: </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(i)&#8195;any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule&#160;424; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(ii)&#8195;any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(iii)&#8195;the portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: left;">(iv)&#8195;any other communication that is an offer in the offering made by the undersigned registrant to the purchaser. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">(b)&#8194;&#8201;The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant&#8217;s annual report pursuant to Section&#160;13(a) or Section&#160;15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan&#8217;s annual report pursuant to Section&#160;15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">(c)&#8194;&#8201;(1)&#8195;The undersigned registrant hereby undertakes as follows: that prior to any public reoffering of the securities registered hereunder through use of a prospectus which is a part of this registration statement, by any person or party who is deemed to be an underwriter within the meaning of Rule&#160;145(c), the issuer undertakes that such reoffering prospectus will contain the information called for by the applicable registration form with respect to reofferings by persons who may be deemed underwriters, in addition to the information called for by the other items of the applicable form. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(2)&#8195;The registrant undertakes that every prospectus (i) that is filed pursuant to paragraph (1) immediately preceding or (ii) that purports to meet the requirements of section 10(a)(3) of the Securities Act of 1933 and is used in connection with an offering of securities subject to Rule&#160;415, will be filed as a part of an amendment to the registration statement and will not be used until such amendment is effective, and that, for purposes of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">(d)&#8194;&#8201;Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">II-3<br></div></div></div>
<!--End Page 533-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 534-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_404-part2_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act of 1933 and will be governed by the final adjudication of such issue. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">(e)&#8194;&#8201;The undersigned registrant hereby undertakes to respond to requests for information that is incorporated by reference into the prospectus pursuant to Items 4, 10(b), 11, or 13 of this Form, within one business day of receipt of such request, and to send the incorporated documents by first class mail or other equally prompt means. This includes information contained in documents filed subsequent to the effective date of the registration statement through the date of responding to the request. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">(f)&#8194;&#8201;The undersigned registrant hereby undertakes to supply by means of a post-effective amendment all information concerning a transaction, and the company being acquired involved therein, that was not the subject of and included in the registration statement when it became effective. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">II-4<br></div></div></div>
<!--End Page 534-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 535-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_404-part2_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">EXHIBIT INDEX </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 426pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 36pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exhibit</div></td><td style="width: 3pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Description </div></td></tr><tr><td style="width: 36pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1837412/000121390022041858/ea163386ex2-1_somalogic.htm">2.1&#8224;</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Agreement and Plan of Merger, dated as of July&#160;25, 2022, by and among SomaLogic, Inc., Panther Merger Subsidiary I, LLC, Panther Merger Subsidiary II, LLC, Palamedrix, Inc., and Securityholder Representative Services LLC (incorporated by reference to Exhibit&#160;2.1 to Standard BioTools&#8217; Current Report on Form&#160;8-K, filed on July&#160;27, 2022). </div></td></tr><tr><td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1162194/000110465923106606/tm2327474d1_ex2-1.htm">2.2&#8224;&#8224;</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Agreement and Plan of Merger, dated as of October&#160;4, 2023, by and among Standard BioTools Inc., SomaLogic, Inc., and Martis Merger Sub, Inc. (incorporated by reference to Exhibit&#160;2.1 to Standard BioTools&#8217; Current Report on Form&#160;8-K, filed on October&#160;4, 2023). </div></td></tr><tr><td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1162194/000110465925061438/tm2518613d1_ex2-1.htm">2.3&#8224;*</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Stock Purchase Agreement, dated as of June&#160;22, 2025, by and between Standard BioTools Inc., and Illumina, Inc. (incorporated by reference to Exhibit&#160;2.1 to Standard BioTools&#8217; Current Report on Form&#160;8-K, filed on June&#160;23, 2025). </div></td></tr><tr><td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANA">2.4*</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Agreement and Plan of Merger, dated as of June&#160;6, 2026, by and among Standard BioTools Inc., Treeline and Siri Merger Sub, Inc. (included as Annex&#160;A to the proxy statement/prospectus included in this registration statement). </div></td></tr><tr><td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1162194/000119312511078412/dex31.htm">3.1</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Eighth Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit&#160;3.1 to the Standard BioTools&#8217; Annual Report on Form&#160;10-K, filed on March&#160;28, 2011). </div></td></tr><tr><td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1162194/000119312522093794/d300506dex48.htm">3.2</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amended and Restated Bylaws (incorporated by reference to Exhibit&#160;4.8 to Standard BioTools&#8217; Registration Statement on Form&#160;S-8, filed on April&#160;1, 2022). </div></td></tr><tr><td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1162194/000119312522093794/d300506dex43.htm">3.3</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Certificate of Amendment to Eighth Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit&#160;4.3 to Standard BioTools&#8217; Registration Statement on Form&#160;S-8, filed on April&#160;1, 2022). </div></td></tr><tr><td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1162194/000110465924001640/tm2333984d3_ex3-1.htm">3.4</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Second Certificate of Amendment to the Eighth Amended and Restated Certificate of Incorporation of Standard BioTools Inc. (incorporated by reference to Exhibit&#160;3.1 to Standard BioTools&#8217; Current Report on Form&#160;8-K, filed on January&#160;5, 2024). </div></td></tr><tr><td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1162194/000119312522093794/d300506dex41.htm">4.1</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Specimen Stock Certificate of Standard BioTools Inc. (incorporated by reference to Exhibit&#160;4.1 to Standard BioTools&#8217; Registration Statement on Form&#160;S-8, filed on April&#160;1, 2022). </div></td></tr><tr><td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1162194/000095017025036608/lab-ex4_2.htm">4.2</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Description of Securities (incorporated by reference to Exhibit&#160;4.2 to Standard BioTools&#8217; Form&#160;10-K, filed on March&#160;11, 2025). </div></td></tr><tr><td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1837412/000121390021011765/ea136455ex10-1_cmlife2.htm">4.3</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Warrant Agreement, dated as of February&#160;22, 2021, by and between SomaLogic, Inc. (formerly CM Life Sciences II Inc.) and Continental Stock Transfer &amp; Trust Company (incorporated by reference to Exhibit&#160;10.1 to SomaLogic, Inc.&#8217;s Current Report on Form&#160;8-K, filed on February&#160;26, 2021). </div></td></tr><tr><td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1837412/000121390021018105/ea138502ex10-1_cmlife2.htm">4.4</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Form&#160;of SomaLogic, Inc. Subscription Agreement (incorporated by reference to Exhibit&#160;10.1 to SomaLogic, Inc.&#8217;s Current Report on Form&#160;8-K, filed on March&#160;29, 2021). </div></td></tr><tr><td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.1&#177;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Opinion of Freshfields US LLP as to the validity of the securities being registered. </div></td></tr><tr><td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="ny20077604x1_ex10-1.htm">10.1&#8224;*</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">License Agreement between CRT Pioneer Fund LP and Treeline Biosciences, Inc. dated May&#160;20, 2022. </div></td></tr><tr><td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="ny20077604x1_ex10-2.htm">10.2&#8224;*</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exclusive License Agreement by and between Treeline Biosciences, Inc. and Jiangsu Hengrui Pharmaceuticals Co., LTD. dated February&#160;9, 2023. </div></td></tr><tr><td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="ny20077604x1_ex10-3.htm">10.3</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amended and Restated Third Amendment to Lease, by and between Treeline Biosciences, Inc. and Are-500 Arsenal Street, LLC, dated May&#160;23, 2024. </div></td></tr><tr><td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">23.1&#177;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consent of Freshfields US LLP (included in Exhibit&#160;5.1 hereto). </div></td></tr><tr><td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="ny20077604x1_ex23-2.htm">23.2</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consent of PricewaterhouseCoopers LLP. </div></td></tr><tr><td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="ny20077604x1_ex23-3.htm">23.3</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consent of Ernst &amp; Young LLP. </div></td></tr><tr><td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tSIG">24.1</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Power of Attorney (included on the signature page to this registration statement). </div></td></tr><tr><td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="ny20077604x1_ex99-1.htm">99.1</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consent of Centerview. </div></td></tr><tr><td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="ny20077604x1_ex99-2.htm">99.2</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consent of UBS. </div></td></tr><tr><td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="ny20077604x1_ex99-3.htm">99.3</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consent of Joshua Bilenker. </div></td></tr><tr><td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="ny20077604x1_ex99-4.htm">99.4</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consent of Jeffrey Engelman. </div></td></tr><tr><td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="ny20077604x1_ex99-5.htm">99.5</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consent of Kristina Burow. </div></td></tr><tr><td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="ny20077604x1_ex99-6.htm">99.6</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consent of David Bonita. </div></td></tr><tr><td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="ny20077604x1_ex99-7.htm">99.7</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consent of David Schenkein. </div></td></tr><tr><td style="width: 36pt; padding-top: 1.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="ny20077604x1_ex99-8.htm">99.8</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consent of Aftab Kherani. </div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 426pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">II-5<br></div></div></div>
<!--End Page 535-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 536-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_404-part2_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="margin-top: 4pt; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 36pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 426pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 36pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exhibit</div></td><td style="width: 3pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Description </div></td></tr><tr><td style="width: 36pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="ny20077604x1_ex99-9.htm">99.9</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consent of Avi Naider. </div></td></tr><tr><td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="ny20077604x1_ex99-10.htm">99.10</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consent of Ali Satvat. </div></td></tr><tr><td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="ny20077604x1_ex99-11.htm">99.11</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consent of Susan Desmond-Hellmann. </div></td></tr><tr><td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="ny20077604x1_ex99-12.htm">99.12</a></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consent of Steven Elms.</div></td></tr><tr><td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tAND">99.13</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Form&#160;of Voting Agreement (included as Annex&#160;D to the proxy statement/prospectus included in this registration statement). </div></td></tr><tr><td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">99.14&#177;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Form&#160;of Proxy Card to be used by holders of capital stock of Standard BioTools Inc. </div></td></tr><tr><td style="width: 36pt; padding-top: 1.01pt; text-align: left; vertical-align: top; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="ny20077604x1_ex107.htm">107</a></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 426pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Filing Fee Tables.</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 36pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 426pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div><div class="BRDSX_rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 16pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#8224;<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Portions of this exhibit have been redacted in compliance with Regulation S-K Item&#160;601(b)(10)(iv) or pursuant to an order granted by the Securities and Exchange Commission for confidential treatment. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#8224;&#8224;<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">The schedules and exhibits to this exhibit have been omitted pursuant to Item&#160;601(b)(2) of Regulation S-K. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">*<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Certain schedules and attachments have been omitted pursuant to Item&#160;601(a)(5) of Regulation S-K. The Company agrees to provide, on a supplemental basis, a copy of any omitted schedules and attachments to the Securities and Exchange Commission or its staff upon request. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#177;<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">To be filed by amendment. </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">II-6<br></div></div></div>
<!--End Page 536-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 537-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20077604x1_s4_405-sig_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tSIG"><!--Anchor--></a>SIGNATURES </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Pursuant to the requirements of the Securities Act, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boston, State of Massachusetts, on July 20, 2026. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 2pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="margin-top: 0pt; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 192pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 264pt;" colspan="4"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr><td style="width: 192pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td colspan="4" style="width: 264pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">STANDARD BIOTOOLS INC.<font style="font-weight: normal;"> </font></div></td></tr><tr><td style="width: 192pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 12pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 192pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 12pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By:</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ Michael Egholm, Ph.D. </div></td></tr><tr><td style="width: 192pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 12pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 240pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Michael Egholm, Ph.D. </div></td></tr><tr><td style="width: 192pt; padding-top: 1.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 12pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 240pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">President and Chief Executive Officer</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 192pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 12pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 240pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We, the undersigned officers and directors of Standard BioTools Inc., hereby severally constitute and appoint Michael Egholm, Ph.D. and Alex Kim and each of them singly (with full power to each of them to act alone), our true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them for him or her and in his or her name, place and stead, and in any and all capacities, to sign any and all amendments (including, without limitation, post-effective amendments) to this registration statement (or any other registration statement for the same offering that is to be effective upon filing pursuant to Rule&#160;462(b) under the Securities Act of 1933), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his or her substitute or substitutes may lawfully do or cause to be done by virtue hereof. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Pursuant to the requirement of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 2pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="margin-top: 0pt; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 144pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 216pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 84pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 144pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Signatures</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 216pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Capacity</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 84pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Dates </div></td></tr><tr><td style="width: 144pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 216pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 84pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 144pt; height: 14pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">/s/ Michael Egholm, Ph.D.</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td rowspan="2" style="width: 216pt; height: 14pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: middle;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">President and Chief Executive Officer and Director <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">(Principal Executive Officer)</div></td><td style="width: 6pt;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td rowspan="2" style="width: 84pt; height: 14pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: middle;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">July 20, 2026 </div></td></tr><tr><td style="width: 144pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Michael Egholm, Ph.D.</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr><td style="width: 144pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 216pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: middle;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: middle;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 144pt; height: 14pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">/s/ Alex Kim</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td rowspan="2" style="width: 216pt; height: 14pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: middle;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Chief Financial Officer <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">(Principal Financial and Accounting Officer)</div></td><td style="width: 6pt;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td rowspan="2" style="width: 84pt; height: 14pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: middle;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">July 20, 2026 </div></td></tr><tr><td style="width: 144pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Alex Kim</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr><td style="width: 144pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 216pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: middle;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: middle;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 144pt; height: 14pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">/s/ Thomas Carey</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td rowspan="2" style="width: 216pt; height: 14pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: middle;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Chairman of the Board of Directors</div></td><td style="width: 6pt;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td rowspan="2" style="width: 84pt; height: 14pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: middle;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">July 20, 2026 </div></td></tr><tr><td style="width: 144pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Thomas Carey </div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr><td style="width: 144pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 216pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: middle;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: middle;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 144pt; height: 14pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8195;</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td rowspan="2" style="width: 216pt; height: 14pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: middle;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Director</div></td><td style="width: 6pt;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td rowspan="2" style="width: 84pt; height: 14pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: middle;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">July 20, 2026 </div></td></tr><tr><td style="width: 144pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Eli Casdin </div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr><td style="width: 144pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 216pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: middle;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: middle;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 144pt; height: 14pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">/s/ Kathy Hibbs</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td rowspan="2" style="width: 216pt; height: 14pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: middle;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Director</div></td><td style="width: 6pt;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td rowspan="2" style="width: 84pt; height: 14pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: middle;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">July 20, 2026 </div></td></tr><tr><td style="width: 144pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Kathy Hibbs </div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr><td style="width: 144pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 216pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: middle;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: middle;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 144pt; height: 14pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">/s/ Fenel M. Eloi</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td rowspan="2" style="width: 216pt; height: 14pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: middle;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Director</div></td><td style="width: 6pt;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td rowspan="2" style="width: 84pt; height: 14pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: middle;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">July 20, 2026 </div></td></tr><tr><td style="width: 144pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Fenel M. Eloi </div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr><td style="width: 144pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 216pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: middle;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: middle;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 144pt; height: 14pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">/s/ Troy Cox</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td rowspan="2" style="width: 216pt; height: 14pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: middle;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Director</div></td><td style="width: 6pt;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td rowspan="2" style="width: 84pt; height: 14pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: middle;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">July 20, 2026 </div></td></tr><tr><td style="width: 144pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Troy Cox </div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr><td style="width: 144pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 216pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: middle;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: middle;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 144pt; height: 14pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">/s/ Frank Witney, Ph.D.</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td rowspan="2" style="width: 216pt; height: 14pt; padding-top: 1.01pt; text-align: left; vertical-align: middle;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Director</div></td><td style="width: 6pt;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;" rowspan="2"><div style="font-size: 1pt;">&#8194;</div></td><td rowspan="2" style="width: 84pt; height: 14pt; padding-top: 1.01pt; text-align: left; vertical-align: middle;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">July 20, 2026 </div></td></tr><tr><td style="width: 144pt; padding-top: 1.76pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Frank Witney, Ph.D.</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 144pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 216pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 84pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">II-7<br></div></div></div>
<!--End Page 537-->
</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ny20077604x1_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 26.3.2.5342
         Copyright 1995 - 2026 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <!--PROfilePageNumberReset%Num%1%%%-->
  <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">
  <div>
    <div style="text-align: right; font-weight: bold;">Exhibit 10.1</div>
    <div>&#160;</div>
    <div style="text-align: center; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO TREELINE BIOSCIENCES, INC. IF
      PUBLICLY DISCLOSED.</div>
    <div><br>
    </div>
    <div style="text-align: center;"><font style="font-weight: bold;">DATED</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><font style="font-weight: bold;">20 May</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</font></div>
    <div style="text-align: center;">&#160;</div>
    <div style="text-align: center;"><font style="font-weight: bold; color: rgb(0, 0, 0);">(1)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">CRT PIONEER FUND LP</font></div>
    <div style="text-align: center;">&#160;</div>
    <div style="text-align: center; font-weight: bold;">AND</div>
    <div style="text-align: center;">&#160;</div>
    <div style="text-align: center;"><font style="font-weight: bold; color: rgb(0, 0, 0);">(2)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">TREELINE BIOSCIENCES, INC.</font></div>
    <div style="text-align: center;">&#160;</div>
    <div style="text-align: center; font-weight: bold;">LICENCE AGREEMENT</div>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">1</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="font-weight: bold;">THIS AGREEMENT is made the 20th day of May 2022</div>
    <div>&#160;</div>
    <div style="font-weight: bold;">BETWEEN:</div>
    <div>&#160;</div>
    <table id="zf4e533e087784c1783c3d91e47e370e6" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-weight: bold;">(1)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">CRT PIONEER FUND LP </font><font style="font-size: 10pt;">(&#8220;<font style="font-weight: bold;">CPF</font>&#8221;), a limited partnership established in England and Wales
                under number LP 14391 with registered office at 4 Claridge Court, Lower Kings Road, Berkhamsted, Hertfordshire, HP4 2AF, acting by its general partner, CRT Pioneer GP Limited, a company registered in England and Wales with registered number
                07933818 whose registered office is at 4 Claridge Court, Lower Kings Road, Berkhamsted, Hertfordshire, HP4 2AF (the &#8220;<font style="font-weight: bold;">General Partner</font>&#8221;); and</font></div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z0ef5507c40a944eda97520e8f78ee944" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">(2)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">TREELINE BIOSCIENCES, INC.</font><font style="font-size: 10pt;">, a company incorporated in the United States with an office at 677 Washington Blvd., Ste 525,
                Stamford, Connecticut 06901, United States (&#8220;<font style="font-weight: bold;">Treeline</font>&#8221;).</font></div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="font-weight: bold;">WHEREAS:</div>
    <div>&#160;</div>
    <table id="zef2999c9c7af4fc981e4b5126a7e8be3" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">(A)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>CPF is a limited liability partnership formed pursuant to a limited partnership agreement among the General Partner, the European Investment Fund (&#8220;<font style="font-weight: bold;">EIF</font>&#8221;), CRT (as defined below), Syncona Discovery
              Limited (&#8220;<font style="font-weight: bold;">Syncona</font>&#8221;), and CRT Pioneer CIP LP. The General Partner has the right to enter into legal agreements on behalf of CPF by which CPF is then bound.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z54b28723634841799e4474baf3a1f7d6" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">(B)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>CPF, CRT and the Institute of Cancer Research: Royal Cancer Hospital (&#8220;<font style="font-weight: bold;">ICR</font>&#8221;) entered into a licence and collaboration agreement relating to the development and commercialisation of BCL6 (B-cell
              lymphoma 6 protein) inhibitors, dated 6 July 2015, as amended by letter agreements dated 25 April 2017, 4 January 2018, 9 January 2019, 17 July 2019, 2 January 2020, 20 July 2021 and 23 November 2021 (together, the &#8220;<font style="font-weight: bold;">Head Licence</font>&#8221;).</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z966011cff03a4e10a980307ac0f4702a" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">(C)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>CPF and Treeline have agreed to enter into this sublicense agreement for the research, development, commercialisation and other exploitation of BCL6 modulators on the following terms and conditions.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="text-align: justify; font-size: 12pt;"><font style="font-size: 10pt;"></font></div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">2</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div>
      <div style="text-align: justify; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">NOW IT IS HEREBY AGREED</font><font style="font-size: 10pt;"> as follows:</font></div>
    </div>
    <div><br>
    </div>
    <div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" id="zec612732ca06468b9c5f525299c4f53f" class="DSPFListTable" cellpadding="0" cellspacing="0">

          <tr style="vertical-align: top;">
            <td style="text-align: right; vertical-align: top; width: 36pt;">
              <div style="text-align: left;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.</font></div>
            </td>
            <td style="text-align: left; vertical-align: top; width: auto;">
              <div><font style="font-weight: bold;">INTERPRETATION</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <table id="zb47f96bc26494ff5ad1e1bdb1c9fc041" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">1.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>In this Agreement except where the context requires otherwise, the following words and expressions shall have the following meanings:</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 72pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">&#8220;Affiliate&#8221;</font><font style="font-size: 10pt;"> of a person means any entity that Controls, is Controlled by or is under common
        Control with that person.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 72pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">&#8220;Affordable&#8221;</font><font style="font-size: 10pt;"> means in relation to a BCL6 Product: (i) [*]; and/or (ii) [*].</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 72pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">&#8220;Agreement&#8221; </font><font style="font-size: 10pt;">means this agreement and each of the Schedules as amended from time to time in
        accordance with Clause 18.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 72pt;">&#8220;<font style="font-weight: bold;">API</font>&#8221; means active pharmaceutical ingredient.</div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 72pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">&#8220;Arising Intellectual Property&#8221; </font><font style="font-size: 10pt;">means all Materials and Know How (other than that comprised
        in Licensed Intellectual Property) conceived, developed, reduced to practice or generated by or on behalf of Treeline, its Affiliates, BCL6 Licensees or their Affiliates, whether or not in the course of exercising the licence rights granted under
        Clause 2.1; and any and all Intellectual Property rights associated therewith or which claim any such Materials and/or inventions described or comprised in such Know How.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 72pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">&#8220;BCL6 Compound&#8221;</font><font style="font-size: 10pt;"> means a compound that is directed against and modulates the activity of BCL6
        [*].</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 72pt;">&#8220;<font style="font-weight: bold;">BCL6 Licensee</font>&#8221; means the Sub-Licensees and Treeline Licensees, taken together.</div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 72pt;">&#8220;<font style="font-weight: bold;">BCL6 Product</font>&#8221; means any product that contains a BCL6 Compound, whether or not covered by, claimed by or otherwise part of the Licensed Intellectual Property,
      as the sole API or in combination with one or more other APIs (&#8220;<font style="font-weight: bold;">Combination Product</font>&#8221;); provided that, (a) [*]; (b) [*]; and (c) [*].</div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 72pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">&#8220;Business Day&#8221; </font><font style="font-size: 10pt;">means a day other than a Saturday, Sunday or any public holiday in England or
        in New York City, New York, USA.</font></div>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">3</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">&#8220;<font style="font-weight: bold;">Change of Control</font>&#8221; means with respect to a Party (or in the case of a BCL6 Licensee): (a) the sale of all or substantially all of such Party&#8217;s assets or
      business relating to this Agreement; (b) a merger, reorganization or consolidation involving such Party in which the voting securities of such Party outstanding immediately prior thereto cease to represent at least fifty percent (50%) of the combined
      voting power of the surviving entity immediately after such merger, reorganization or consolidation; or (c) a person, or group of persons, acting in concert acquire more than fifty percent (50%) of the voting equity securities or management control
      of such Party.</div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 72pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">&#8220;Clinical Candidate&#8221; </font><font style="font-size: 10pt;">means a BCL6 Compound which has completed pre-clinical development and
        is ready to enter a Phase I Trial as reasonably determined by Treeline.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 72pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">&#8220;Commencement&#8221;</font><font style="font-size: 10pt;"> means, in relation to a clinical trial, the date upon which administration of a
        BCL6 Product to the first human subject has occurred, whether such subject is a healthy volunteer or a patient.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 72pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">&#8220;Commercially Reasonable Efforts&#8221;</font><font style="font-size: 10pt;"> means with respect to Treeline&#8217;s efforts, the efforts and
        resources commonly used by a [*], taking into consideration [*].</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 72pt;">&#8220;<font style="font-weight: bold;">Competent Authority&#8221; </font>means any local or national agency, court, authority, department, inspectorate, minister, ministry official or public or statutory
      person (whether autonomous or not) of, or of any government of, any country having jurisdiction over the Agreement or either of the Parties (such as the Financial Services Authority or any successor entity) or over the development or marketing of
      medicinal products (such as the FDA or the European Medicines Agency).</div>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">4</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify; margin-left: 72pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">&#8220;Confidential Information&#8221;</font><font style="font-size: 10pt;"> means any information, in tangible or non-tangible form (including
        oral disclosure) including Know How, research, development plans, reports, and information relating to the customers, suppliers, business partners, clients, finances, operation, business plans and products (in each case actual or prospective) of a
        Party, the existence and the terms of this Agreement, and any other technical or business information (whether or not marked as confidential), which is obtained by either Party from the other (or its representatives) pursuant to this Agreement.
        Licensed Know How shall be deemed the Confidential Information of each Party. In addition, all information disclosed by a Party or its Affiliates pursuant to the Confidential Disclosure Agreement between CPF and Treeline dated January 20, 2022 (the
        &#8220;<font style="font-weight: bold;">Confidentiality Agreement</font>&#8221;) shall be deemed to be Confidential Information of such Party disclosed hereunder.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 72pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">&#8220;Control&#8221;</font><font style="font-size: 10pt;"> means, as the context requires: (i) with respect to any item of Intellectual
        Property or right under any Intellectual Property, the possession (whether by ownership or license, other than pursuant to this Agreement) of the ability to grant access (by license or sublicense), without violating the terms of any agreement or
        other arrangement with any Third Party existing at the time; or otherwise (ii) the possession (directly or indirectly) of fifty percent (50%) or more of the voting stock or other equity interest of a subject entity with the power to vote, or the
        power in fact to control the management decisions of such entity through the ownership of securities or by contract or otherwise and &#8220;<font style="font-weight: bold;">Controlling</font>&#8221; and &#8220;<font style="font-weight: bold;">Controlled by</font>&#8221;
        shall be construed accordingly. For the avoidance of doubt, neither of Syncona or EIF Controls CPF.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 72pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">&#8220;CPF Indemnified Parties&#8221;</font><font style="font-size: 10pt;"> means CPF and its Affiliates, and its and their officers, employees
        and agents.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 72pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">&#8220;CRT/ICR Indemnified Parties&#8221;</font><font style="font-size: 10pt;"> means CRT, CRUK, ICR and their respective officers, employees
        and agents.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 72pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">&#8220;CRT/ICR Reviewers&#8221;</font><font style="font-size: 10pt;"> means:</font></div>
    <div>&#160;</div>
    <table id="z2cd5ba79b004470b93ee52205fd5b64e" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 108pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top;">i.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>independent individuals nominated by CRT, ICR or CRUK for the purpose of monitoring and reviewing work funded by CRUK and/or providing scientific advice (including any members of ICR&#8217;s or CRT&#8217;s Scientific Advisory Board from time to time);
              and</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">5</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <table id="z38cf6a3ea72f4fcfb69a2a0a8b891689" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 108pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top;">ii.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>as contemplated by Clause 16.2, any actual or potential royalty purchaser.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 72pt;">&#8220;<font style="font-weight: bold;">CRUK</font>&#8221; means Cancer Research UK, a company limited by guarantee (registered in England and Wales under number 4325234) and a charity (registered in England
      under number 1089464 and registered in Scotland under number SC041666 and in the Isle of Man under number 1103) of 2 Redman Place, London, E20 1JQ, United Kingdom.</div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 72pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">&#8220;Development Milestone Event&#8221; </font><font style="font-size: 10pt;">has the meaning given in Clause 4.2.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 72pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">&#8220;Development Milestone Payment&#8221; </font><font style="font-size: 10pt;">has the meaning given in Clause 4.2.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 72pt;">&#8220;<font style="font-weight: bold;">Effective</font>&#160;<font style="font-weight: bold;">Date&#8221; </font>means the date given at the top of this Agreement.</div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 72pt;">&#8220;<font style="font-weight: bold;">EMA</font>&#8221; means the European Medicines Agency or any successor entity.</div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 72pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">&#8220;Executive Officers&#8221;</font><font style="font-size: 10pt;"> means a managing partner of CPF, and the Chief Executive Officer of
        Treeline or, in each case such other authorised officer of a Party as may be substituted from time to time upon the giving of written notice to the other Party.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 72pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">&#8220;Existing Third Party Agreements&#8221;</font><font style="font-size: 10pt;"> means the Head Licence and the Third Party agreements as
        listed in Schedule 8.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 72pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">&#8220;FDA&#8221;</font><font style="font-size: 10pt;"> means the United States Food and Drug Administration or any successor to it.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 72pt;">&#8220;<font style="font-weight: bold;">Field&#8221; </font>means all uses and Indications.</div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 72pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">&#8220;First Commercial Sale&#8221; </font><font style="font-size: 10pt;">means, with respect to a BCL6 Product, the first transfer or
        disposition for value of such BCL6 Product to a Third Party by or on behalf of Treeline or a BCL6 Licensee or an Affiliate of either of them, after all relevant Regulatory Authorisations for the marketing and transfer or disposition of such BCL6
        Product have been obtained in respect of the relevant region or country.</font></div>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">6</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify; margin-left: 72pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">&#8220;Force Majeure&#8221;</font><font style="font-size: 10pt;"> means in relation to either Party any event or circumstance which is beyond
        the reasonable control of that Party, which event or circumstance that Party could not reasonably be expected to have taken into account at the Effective Date and which results in or causes the failure of that Party to perform any or all of its
        obligations under this Agreement including act of God, lightning, fire, storm, flood, earthquake, strike, lockout or other industrial disturbance, war, terrorist act, blockade, revolution, riot, insurrection, civil commotion, public demonstration,
        sabotage, act of vandalism, or explosion, provided that lack of funds shall not be interpreted as a cause beyond the reasonable control of that Party.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 72pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">&#8220;Generic Competition&#8221; </font><font style="font-size: 10pt;">means with respect to a BCL6 Product in any particular country in the
        Territory, the existence on the market of any Generic Product in competition with such BCL6 Product in such country.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 72pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">&#8220;Generic Product&#8221;</font><font style="font-size: 10pt;"> means any pharmaceutical product that (a) is sold by a Third Party other
        than pursuant to any rights granted by Treeline or a BCL6 Licensee or an Affiliate of either of them; and (b) contains the same API (or one which is substantially the same, such as a hydrate or salt of the API) as the BCL6 Product; and (c) was
        granted pursuant to an application for a marketing authorisation that relies on data held by a regulatory authority in relation to a BCL6 Product.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 72pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">&#8220;IND&#8221; </font><font style="font-size: 10pt;">means an investigational new drug application filed with the FDA, or the equivalent
        application or filing filed with any equivalent Competent Authority outside the United States of America (including any supranational agency such as the European Medicines Agency) necessary to commence human clinical trials in such jurisdiction.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 72pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">&#8220;Indication&#8221; </font><font style="font-size: 10pt;">means a disease classification as defined within the &#8216;International Statistical
        Classification of Diseases and Related Health Problems&#8217; as published from time to time by the World Health Organization (e.g. [*]).</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 72pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">&#8220;Intellectual Property&#8221;</font><font style="font-size: 10pt;"> means Materials, Patents and Know How.</font></div>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">7</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify; margin-left: 72pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">&#8220;Know How&#8221;</font><font style="font-size: 10pt;"> means technical and other information which is not in the public domain including,
        ideas, concepts, inventions, discoveries, data, formulae, algorithms, specifications, clinical data, technical information, know-how, methods, techniques, formulae, processes, information relating to Materials (including biological and chemical
        structures and functions as well as methods for synthesising chemical compounds), procedures for experiments and tests, results of experimentation and testing, results of research and development including laboratory records and data analyses.
        Information in a compilation or a compilation of information may be Know How notwithstanding that some or all of its individual elements are in the public domain.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 72pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">&#8220;Licensed Compound&#8221;</font><font style="font-size: 10pt;"> means any BCL6 Compound Controlled by CPF under or as a result of the
        Existing Third Party Agreements.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 72pt;">&#8220;<font style="font-weight: bold;">Licensed Intellectual Property</font>&#8221; means the Licensed Know How, Licensed Materials and Licensed Patents.</div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 72pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">&#8220;Licensed Know How&#8221;</font><font style="font-size: 10pt;"> means (a) the Know How described in Schedule 1, and (b) any and all Know
        How that (i) is (a) Controlled by CPF or its Affiliates as of the Effective Date or (b) becomes Controlled by CPF or any of its Affiliates during the Term, in each case ((a) and (b)) pursuant to the Existing Third Party Agreements, and (ii) relates
        to or is necessary or useful for the development, manufacture, or commercialization of, any BCL6 Compound or BCL6 Product.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 72pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">&#8220;Licensed Materials&#8221;</font><font style="font-size: 10pt;"> means (a) Licensed Compounds, (b) the other Materials described in
        Schedule 1, and (c) all proprietary materials that (i) are (x) Controlled by CPF or its Affiliates as of the Effective Date or (y) become Controlled by CPF or any of its Affiliates during the Term, in each case ((x) and (y)) pursuant to the
        Existing Third Party Agreements, and (ii) relate to or are necessary or useful for the development, manufacture, or commercialization of BCL6 Compounds or any BCL6 Products.</font></div>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">8</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">&#8220;<font style="font-weight: bold;">Licensed Patents&#8221; </font>means (a) the Patents listed in Schedule 1, (b) any and all Patents that (i) are (x) Controlled by CPF or any of its Affiliates as of the
      Effective Date or (y) become Controlled by CPF or any of its Affiliates during the Term, in each case ((x) and (y)) pursuant to the Existing Third Party Agreements, and (ii) cover, relate to or are necessary or useful for the Licensed Materials,
      Licensed Compound or any BCL6 Products or the use, research, development, manufacture, commercialization or other exploitation thereof; and (c) any Patents claiming priority from the Patents described in (a) and (b).</div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 72pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">&#8220;Major Markets&#8221; </font><font style="font-size: 10pt;">means the [*], the United States, [*], [*], [*], [*] and [*], and &#8220;<font style="font-weight: bold;">Major Market</font>&#8221; shall mean any one of them.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 72pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">&#8220;Material&#8221; </font><font style="font-size: 10pt;">means any chemical or biological material including any: organic or inorganic
        element or compound; nucleotide or nucleotide sequence including DNA and RNA sequences; gene; vector or construct including plasmids, bacterial vectors, bacteriophages and viruses; host organism including bacteria, fungi, algae, protozoa and
        hybridomas; eukaryotic or prokaryotic cell line or expression system or any development strain or product of that cell line or expression system; protein including any peptide or amino acid sequence, enzyme, antibody or protein conferring targeting
        properties and any fragment of a protein or a peptide enzyme or antibody; drug or pro-drug; assay or reagent; any other genetic or biological material or microorganism or any transgenic animal; and any physical property rights relating to any of
        the foregoing.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 72pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">&#8220;NDA&#8221; </font><font style="font-size: 10pt;">means an application for approval to market a product commercially such as the New Drug
        Application filed pursuant to the requirements of the FDA, as more fully defined in 21 CFR.&#167; 314.3 et seq, or a Biologics License Application filed pursuant to the requirements of the FDA, as more fully defined in 21 CFR &#167; 601, or a Marketing
        Authorisation application filed pursuant to the requirements of European Directive 2001/ 83/ EC, or any equivalent or similar application filed with any other Competent Authority in any country or region in the Territory, together, in each case,
        with all additions, deletions or supplements thereto.</font></div>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">9</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify; margin-left: 72pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">&#8220;Net Sales&#8221; </font><font style="font-size: 10pt;">means the gross amount invoiced by Treeline or any BCL6 Licensee or an Affiliate
        of any of them to Third Parties for sale of BCL6 Products in the Territory, less, to the extent deducted with respect to such sale consistent with U.S. generally accepted accounting principles (&#8220;<font style="font-weight: bold;">GAAP</font>&#8221;),
        consistently applied, the following items:</font></div>
    <div>&#160;</div>
    <table id="z543548c0efec486b8927511d0ef2ebd8" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 108pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top;">i.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>[*];</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z60aa6b26937e4d60aa2f4d4b8f61259c" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 108pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top;">ii.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>[*];</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z4ec8f2c0e95542f5af4ec220e5e7cee9" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 108pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top;">iii.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>[*];</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z5a089ba275824f0295cb53db8082f505" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 108pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top;">iv.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>[*];</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z32fa2bcda3dd4ac2b9135bf5e53b17ee" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 108pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top;">v.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>[*]; and</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z177ee1f668104ad097574e4ed2676027" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 108pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top;">vi.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>[*].</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 72pt;">[*].</div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 72pt;">[*].</div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 72pt;">[*].</div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 72pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">&#8220;Oncology Indication&#8221;</font><font style="font-size: 10pt;"> means an Indication in the range [*].</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 72pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">&#8220;Parties&#8221;</font><font style="font-size: 10pt;"> means CPF and Treeline and &#8220;<font style="font-weight: bold;">Party</font>&#8221; shall
        mean either of them.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 72pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">&#8220;Patent Costs&#8221; </font><font style="font-size: 10pt;">means<font style="font-weight: bold;">&#160;</font>any external out of pocket costs
        and expenses incurred in filing, prosecuting, maintaining, defending and enforcing the Licensed Patents, including official filing, prosecution, maintenance and renewal fees, patent attorney, translation, legal and other professional fees and
        expenses and costs and expenses associated with any opposition or interference action.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 72pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">&#8220;Patents&#8221;</font><font style="font-size: 10pt;"> means any patent applications, patents, author certificates, inventor certificates,
        utility models, and all foreign counterparts of them and includes all divisionals, renewals, continuations, continuations-in-part, extensions, reissues, substitutions, confirmations, registrations, revalidations and additions of or to them, as well
        as any Supplementary Protection Certificate, or any like form of protection.</font></div>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">10</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify; margin-left: 72pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">&#8220;Phase I Trial&#8221; </font><font style="font-size: 10pt;">means a clinical trial in which a BCL6 Product is administered to human
        subjects at multiple dose levels with the primary purpose of determining safety, metabolism, and pharmacokinetic and pharmacodynamic properties of the BCL6 Product, and consistent with 21 CFR &#167; 312.21(a) and any microdosing clinical trial conducted
        pursuant to the FDA&#8217;s 2006 Guidance on Exploratory Investigational New Drugs or any equivalent arrangements.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 72pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">&#8220;Pre-Clinical Candidate&#8221; </font><font style="font-size: 10pt;">means any BCL6 Compound selected by Treeline for pre-clinical
        development.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 72pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">&#8220;Price Approval&#8221;</font><font style="font-size: 10pt;"> means, in those countries in the Territory where a Competent Authority may
        approve or determine pricing and/or pricing reimbursement for pharmaceutical products, such approval or determination.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 72pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">&#8220;Progress Report&#8221;</font><font style="font-size: 10pt;"> means a reasonably detailed written report produced by Treeline in the form
        set out in Schedule 6.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 72pt;">&#8220;<font style="font-weight: bold;">Quarter&#8221; </font>means any of the three-monthly periods commencing on the first day of any of the months of January, April, July, and October in any Year and &#8220;<font style="font-weight: bold;">Quarterly&#8221; </font>has a corresponding meaning.</div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 72pt;">&#8220;<font style="font-weight: bold;">Regulatory Authorisations&#8221; </font>means all authorisations, approvals, clearances, and licences of a Competent Authority (including an NDA) that may be required in
      any country of the Territory prior to commercial sale of the relevant BCL6 Product in the Field, including any necessary variations thereto, but excluding any Price Approvals.</div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 72pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">&#8220;Sales Milestone Event&#8221; </font><font style="font-size: 10pt;">has the meaning given in Clause 4.3.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 72pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">&#8220;Sales Milestone Payment&#8221; </font><font style="font-size: 10pt;">has the meaning given in Clause 4.3.</font></div>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">11</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">&#8220;<font style="font-weight: bold;">Signature Fee&#8221; </font>means the non-refundable sum of two million U.S. Dollars (US$2,000,000).</div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 72pt;">&#8220;<font style="font-weight: bold;">Sub-Licensee&#8221; </font>means a person to whom a sub-licence is granted in accordance with Clause 2.6 in respect of the whole or any part of the rights granted under
      this Agreement. For clarity, a Sub-Licensee is not a Treeline Licensee.</div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 72pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">&#8220;Sub-Licence Provisions&#8221; </font><font style="font-size: 10pt;">means those provisions to be included in a sub-licence pursuant to
        Clause 2.6.3 and as set out in Schedule 5.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 72pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">&#8220;Supplementary Protection Certificate&#8221; </font><font style="font-size: 10pt;">means a right based on a patent pursuant to which the
        holder of the right is entitled to exclude third parties from using, making, having made, selling or otherwise disposing or offering to dispose of, importing or keeping the product to which the right relates, such as supplementary protection
        certificates in Europe, and any similar right anywhere in the world.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 72pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">&#8220;Target Patent Country&#8221; </font><font style="font-size: 10pt;">means any one of the countries listed in Schedule 3.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 72pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">&#8220;Term&#8221; </font><font style="font-size: 10pt;">means the term of this Agreement determined in accordance with Clause 13.1.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 72pt;">&#8220;<font style="font-weight: bold;">Territory&#8221; </font>means worldwide.</div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 72pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">&#8220;Third Party&#8221;</font><font style="font-size: 10pt;"> means a person other than a Party, or a BCL6 Licensee or an Affiliate of a
        Party.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 72pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">&#8220;Third Party Service Provider&#8221; </font><font style="font-size: 10pt;">means a Third Party who provides research, development,
        commercialization, manufacturing and/or other services to Treeline or a BCL6 Licensees or an Affiliates of either of them in connection with BCL6 Products, including contract research organisations, universities and hospitals. However, a Tobacco
        Party may not act as a Third Party Service Provider.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 72pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">&#8220;Tobacco Party&#8221; </font><font style="font-size: 10pt;">means: (i) any person who develops, sells or manufactures tobacco products;
        and/ or (ii) any person which makes the majority of its profits from the importation, marketing, sale or disposal of tobacco products. Furthermore, Tobacco Party shall include any person that is Controlled by or under common Control with any of the
        persons referred to in (i) and/or (ii).</font></div>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">12</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">&#8220;<font style="font-weight: bold;">Treeline Licensee</font>&#8221; means a person to whom Treeline grants a licence in respect of one or more BCL6 Compounds which licence does not include any Licensed
      Intellectual Property.</div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 72pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">&#8220;UK Pricing Authority&#8221;</font><font style="font-size: 10pt;"> means any supra-national, national or regional government department,
        authority, agency or entity (including a non-departmental public body or similar entity) with responsibility for evaluating the cost effectiveness of medicinal products in the United Kingdom (or one or more constituent countries thereof) or
        otherwise determining whether the NHS (or constituent parts thereof) should purchase medicinal products.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 72pt;">&#8220;<font style="font-weight: bold;">U.S.</font>&#8221;, &#8220;<font style="font-weight: bold;">United States</font>&#8221; or &#8220;<font style="font-weight: bold;">USA</font>&#8221; means the United States of America, including
      all possessions and territories thereof.</div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 72pt;">&#8220;<font style="font-weight: bold;">U.S. Dollar</font>&#8221; means a U.S. dollar, and &#8220;<font style="font-weight: bold;">US$</font>&#8221; shall be interpreted accordingly.</div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 72pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">&#8220;Valid Claim&#8221;</font><font style="font-size: 10pt;"> means either:</font></div>
    <div>&#160;</div>
    <table id="z6b1ec67c6679471bb070188d740d3db9" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 108pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top;">i.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>a claim of an issued and unexpired Licensed Patent (which include any Patent term extension or Supplementary Protection Certificate) in the relevant country in the Territory which covers the BCL6 Product and that: (i) has not been revoked
              or held unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed for appeal; or (ii) has not been abandoned, disclaimed, or admitted to be
              invalid or unenforceable through reissue or disclaimer or otherwise; or</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="zc064020adfd7473da966bbd70fff78ac" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 108pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top;">ii.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>a claim of a pending patent application, which claim has been filed in good faith, and [*], and has not been abandoned or finally disallowed without the possibility of appeal or re-filing of the application.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">13</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify; margin-left: 72pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">&#8220;Year&#8221;</font><font style="font-size: 10pt;"> means a calendar year.</font></div>
    <div>&#160;</div>
    <table id="z62681e7fde594667bce4cd822a7e0245" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">1.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>In this Agreement:</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z2de1c1e730374c5989ebdb528acbae30" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;">&#160;</td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">1.2.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>unless the context requires otherwise, all references to a particular Clause, paragraph or Schedule shall be references to that clause, paragraph or schedule, in or to this Agreement;</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="zc5dfa6bf349a444aae2f9cf9d45e998d" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">1.2.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>the table of contents and headings are inserted for convenience only and shall be ignored in construing this Agreement;</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="za5a9ad320ea741c0831714831f93a61d" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">1.2.3</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>unless the contrary intention appears, words importing the masculine gender shall include the feminine and vice versa and words in the singular include the plural and vice versa;</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="zf6fb538e13204260a45df0a16677dfdf" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">1.2.4</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>unless the contrary intention appears, words denoting persons shall include any individual, partnership, company, corporation, joint venture, trust association, organisation or other entity, in each case whether or not having separate
              legal personality; and</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z59ecd698c10741eba350146708e2cc9b" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">1.2.5</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>references to the words &#8220;include&#8221; or &#8220;including&#8221; shall be construed without limitation to the generality of the preceding words.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" id="z076936fecfb942eabac2632478a6a4b0" class="DSPFListTable" cellpadding="0" cellspacing="0">

          <tr style="vertical-align: top;">
            <td style="text-align: right; vertical-align: top; width: 36pt;">
              <div style="text-align: left;"><font style="font-weight: bold; color: rgb(0, 0, 0);">2.</font></div>
            </td>
            <td style="text-align: left; vertical-align: top; width: auto;">
              <div><font style="font-weight: bold;">LICENCE</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <table id="z6edf312b4e5442b4ba8f8b936fb93994" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">2.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Subject to the provisions of this Agreement, CPF hereby grants Treeline a licence under the Licensed Intellectual Property to research, develop, use, keep, make, have made, import, sell, offer for sale and otherwise dispose of BCL6
              Products in the Field in the Territory for the Term. Such licence shall be exclusive to the extent that CPF has exclusive rights in the relevant Licensed Intellectual Property under the Existing Third Party Agreements and, to the extent that
              CPF has non-exclusive rights to the relevant Licensed Intellectual Property under the Existing Third Party Agreements, CPF undertakes not to use or otherwise exploit such Licensed Intellectual Property on its own behalf or to grant any right
              to a Third Party or any of CPF&#8217;s Affiliates to do the same.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">14</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <table id="z80c10409b8f84cb79777e81f01843d5c" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">2.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>No licence to use any Intellectual Property is granted to Treeline, or implied, except the rights expressly granted in this Agreement. During the Term, neither CPF nor any of CPF&#8217;s Affiliates will, without the prior written consent of
              Treeline, use, develop, import, make, have made, register, promote, market, distribute, offer for sale, sell or otherwise exploit any product that contains any compound targeting BCL6 as its primary active component or that has the modulation
              of BCL6 activity as its primary mode of action.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="za653df298a9b458d9c7286a0fdc7cd36" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">2.3</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Treeline acknowledges that, subject to the [*], certain rights have been reserved and excepted by CRT and ICR pursuant to the Head Licence as further set out in Schedule 7 and the licences and other rights granted in this Agreement shall
              be subject to such reserved rights. For clarity, in no event shall any Arising Intellectual Property be subject to such reserved rights.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z3e6bfa47acac4d0f9f1d9f29ceb89d7d" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">2.4</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Promptly after the Effective Date and no later than [*] days thereafter, CPF shall, and shall use diligent efforts to procure that its Affiliates, ICR and CRT shall, without additional compensation, deliver, disclose and make available to
              Treeline or its designee(s), including any designated Third Party Service Provider(s), (i) all information relating to the Licensed Intellectual Property, including all non-clinical data, detailed summaries of data, results, research,
              analyses, and other information derived from the use of the Licensed Materials or any Licensed Know How and any other information claimed or covered by any Licensed Patent or otherwise relating to the Licensed Materials or any Licensed Know
              How or the research, development, manufacture, commercialization or other exploitation thereof, in each case that are in the possession of CPF, its Affiliates, ICR or CRT; and (ii) the Licensed Intellectual Property.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">15</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <table id="z85ea0fbd8e1444179960d97ee1ff9ea3" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">2.5</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Provided such request is received prior to the [*] anniversary of the Effective Date (the period of [*] months following the Effective Date, the &#8220;<font style="font-weight: bold;">Initial Technical Assistance Period</font>&#8221;), CPF shall, and
              shall use its diligent efforts to cause its Affiliates, ICR and CRT to, provide to Treeline (and/or its designee(s)) such reasonable assistance, consultation and cooperation, including technical consultation and assistance, as Treeline may
              reasonably request to effect the transfer of Licensed Intellectual Property pursuant to Clause 2.4 or as necessary or reasonably useful for the research and development of BCL6 Products (collectively, &#8220;<font style="font-weight: bold;">Technical




                Assistance</font>&#8221;), not to exceed [*] hours per month during months [*] of the Initial Technical Assistance Period and [*] hours per month during months [*] of the Initial Technical Assistance Period. The Parties will cooperate and
              reasonably agree upon formats and procedures to facilitate the orderly and efficient transfer of the Licensed Intellectual Property in accordance with Clause 2.4.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z6173d9154c344accb96b422e73b68a56" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">2.6</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Treeline shall not be entitled to grant sub-licences in respect of the rights granted under this Agreement without CPF&#8217;s prior written consent (which shall be in CPF&#8217;s absolute discretion) unless and until Treeline has filed an IND for a
              BCL6 Product. After Treeline has filed an IND for a BCL6 Product, Treeline shall have the right to grant sub-licenses, through multiple tiers, in respect of any and all of the rights granted under this Agreement without CPF&#8217;s prior written
              consent. With respect to any sub-licence granted to an entity:</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z6bc336879fd349d59dcf07f95c0492b0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">2.6.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>prior to grant Treeline shall inform CPF in writing of the terms of any sublicence proposed to be entered into, including the identity of the proposed Sub-Licensee;</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z98feefc871ba43aab4f3d790c3109701" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">2.6.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>any sub-licence granted by Treeline shall be expressed to terminate automatically on the termination of this Agreement for any reason. On such termination and provided the termination of this Agreement was not caused by a breach of the
              obligations under the relevant sub-licence, CPF shall immediately grant to the affected Sub-Licensee a sub-licence on materially the same terms to those contained in this Agreement. For the avoidance of doubt, expiry of this Agreement
              consequent upon the expiry of the term of this Agreement shall not result in the automatic termination of any sub-licence;</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">16</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <table id="zc25b09e1270a454dad33689c63630100" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">2.6.3</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Treeline shall ensure that there are included in the terms of any sub-licence substantially equivalent obligations and undertakings on the part of the SubLicensee to those applying to Treeline in this Agreement, including as set forth in
              Clause 2.3 (reservation of rights), Clause 2.6.5 (Tobacco Party), Clause 6.1 (maintenance and audit of accounts), Clause 7.2 (patent prosecution), Clause 7.4 (status of Licensed Patents), Clause 7.5 (filing strategy for Licensed Patents),
              Clause 7.6 (notification of infringement), Clause 7.7 (patent enforcement), Clause 7.12 (Supplementary Protection Certificate), Clause 9.1 (indemnity for CPF Indemnified Parties), Clause 9.2 (indemnity for CRT/ICR Indemnified Parties), Clause
              12 (confidentiality), and Clause 14.3 (effect of termination). Treeline shall additionally ensure that there are included in the terms of any sub-licence substantially equivalent obligations and undertakings to those set out in the
              Sub-Licence Provisions and shall use Commercially Reasonable Efforts to ensure that all Sub-Licensees duly comply with the same;</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z1f5541471a094c0dbc82c9ca2616fd66" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">2.6.4</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>within [*] Business Days of the grant of any sub-licence, Treeline shall provide CPF with a true copy of such sub-licence at Treeline&#8217;s expense;</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="zdf54eeea3fac4bb191cef42e0536b5b7" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">2.6.5</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>no sub-licence shall be granted to a Tobacco Party; and</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="zb803c8e1be6d4b87b2bf4d825157639a" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">2.6.6</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>the sub-licence shall be entered into on an arms-length basis.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">17</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <table id="zc89a5e1908be461a9a48d1ffed994503" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">2.7</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>The foregoing obligations shall not apply in relation to contracts Treeline or its Sub-Licensee or an Affiliate of either of them enters into with Third Party Service Providers, provided that: (a) such contracts relate to the provision of
              research, development, manufacturing, and/or commercialization services to Treeline or the applicable Sub-Licensee or Affiliate in connection with BCL6 Products; and (b) no rights under the Licensed Intellectual Property are granted to the
              Third Party to: (i) research, develop or manufacture its own products; or (ii) sell BCL6 Products (except in the case of a Third Party distributor engaged by Treeline or its Sub-Licensee to distribute or resell BCL6 Products). For clarity,
              neither the obligations in Section 2.6 nor the obligations applying to Sub-Licensees under this Agreement shall apply to any Treeline Licensee and in no event will any license granted by Treeline under the Arising Intellectual Property where
              no licence is granted under the Licensed Intellectual Property be deemed as a sub-license under this Agreement, nor will any person receiving a license grant under the Arising Intellectual Property where no licence is granted under the
              Licensed Intellectual Property be deemed as a Sub-Licensee.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z40edca3037cd486e9988aeaa2ebe8d1c" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">2.8</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>The grant of any sub-licence shall be without prejudice to Treeline&#8217;s obligations under this Agreement.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="zdc1bd897ee8548f4a14e571647b27b95" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">2.9</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>The right to grant sub-sub-licences shall be permitted only on terms materially equivalent to Clause 2.6 (including for the avoidance of doubt inclusion in each sub-sub-licence of an indemnity from the sub-licensee in favour of CPF
              Indemnified Parties) and Treeline shall procure that a copy of each sub-sub-licence is supplied to CPF within [*] days of its execution.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z0b11dcdf571b4cb6a6406072e5cb8e75" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">2.10</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Any act or omission of any Sub-Licensee which, if it were the act or omission of Treeline would be a breach of any of the provisions of this Agreement, will be deemed to be a breach of this Agreement by Treeline who will be liable to CPF
              accordingly.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" id="z1ce986c504854ce0b0d31f5a6ea192da" class="DSPFListTable" cellpadding="0" cellspacing="0">

          <tr style="vertical-align: top;">
            <td style="text-align: right; vertical-align: top; width: 36pt;">
              <div style="text-align: left;"><font style="font-weight: bold; color: rgb(0, 0, 0);">3.</font></div>
            </td>
            <td style="text-align: left; vertical-align: top; width: auto;">
              <div><font style="font-weight: bold;">PERFORMANCE</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <table id="ze8c660737fdb4c7e9ae9e05d3a2fdbce" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">3.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Treeline (directly or through one or more of its Affiliates or BCL6 Licensees) will use Commercially Reasonable Efforts to develop and commercialise at least one BCL6 Product in the United States, the United Kingdom, and at least one
              additional Major Market in an Oncology Indication.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">18</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <table id="z8617e253acf2436ea3e1f390957eb73b" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">3.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>If Treeline (directly or through one or more of its Affiliates or BCL6 Licensees) uses Commercially Reasonable Efforts and is unsuccessful in developing and commercialising a BCL6 Product in an Oncology Indication, Treeline (directly or
              through one or more of its Affiliates or BCL6 Licensees) shall use Commercially Reasonable Efforts to develop and commercialise in the United States, [*], and at least one additional Major Market a BCL6 Product with an application in any
              other Indication.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z19f0951889094abca78a939cc4b78a34" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">3.3</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Treeline (directly or through one or more of its Affiliates or BCL6 Licensees) shall use Commercially Reasonable Efforts to:</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z7cdf8b05f1c44c5e8a854ee908ed3dab" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">3.3.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>nominate a Pre-Clinical Candidate (if not already nominated);</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z1734ab4d574140a78a4f341480a81c5c" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">3.3.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>develop at least one BCL6 Product suitable for use in a human clinical trial;</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="ze25f917b64b54243b84a36da39b91676" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">3.3.3</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>pursue Regulatory Authorisation and (where applicable) Price Approvals in the United States, the United Kingdom, and at least one additional Major Market for those BCL6 Products in clinical development;</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z20273229fd9f419185c6b49e0df6bb72" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">3.3.4</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>make each BCL6 Product developed or commercialized by Treeline or a BCL6 Licensee or an Affiliate of either of them available for purchase in the United Kingdom after such BCL6 Product receives all necessary Regulatory Authorisation for
              launch in the United Kingdom;</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z17ea55cdc92e4d3693efe1fadcf84d0d" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;">&#160;</td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">3.3.5</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>without prejudice to the generality of the foregoing, develop and commercialise in the United States, the United Kingdom, and at least one additional Major Market at least one BCL6 Product. In the event that a BCL6 Product developed by
              Treeline or a BCL6 Licensee or an Affiliate of either of them is launched or ready to be launched in the United Kingdom which has received all necessary Regulatory Authorisation in respect of an Oncology Indication, [*];</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="zab549e55ff86475cabcc2d59b1751983" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">3.3.6</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>provide CPF with a Progress Report at least [*];</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z537505dd3b074b04ba15abd1f20cc584" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">3.3.7</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>promptly respond to any reasonable queries that CPF may have following receipt of a Progress Report; and</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">19</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <table id="z1f547a151d8a498d935a468ca81542e6" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">3.3.8</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>at CPF&#8217;s request, meet [*] per Year with CPF (either in person or by teleconference or videoconference, if a face-to-face meeting is not practical) to discuss the content of a particular Progress Report; and</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z08286bb833f34432956586a107952658" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">3.3.9</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>after nomination of a Pre-Clinical Candidate pursuant to Clause 3.3.1, provide CPF with a development plan in the form set out in Schedule 6, and update the development plan and provide a copy of the same to CPF at least [*] every [*]
              months.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z9ca33204c1684d3bb08d25f05ac706af" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">3.4</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>If at any time during the course of the development or commercialisation of a BCL6 Product, Treeline fails to meet one or more of its obligations under Clauses 3.1 or 3.3 in relation to a BCL6 Product for a period of [*] months or more,
              save where due to the acts or omissions of CPF, any of its Affiliates, ICR or CRT, then CPF shall have the right to give written notice to Treeline requesting detailed written justification for such failure and Treeline shall provide such
              detailed written justification to CPF within [*] days of the date of CPF&#8217;s request. Where remedy is possible Treeline shall use its Commercially Reasonable Efforts to take substantive steps to remedy such failure within [*] days of the date
              of CPF&#8217;s request. If Treeline fails to provide such justification to CPF within [*] days of the date of CPF&#8217;s request and/or use its Commercially Reasonable Efforts to take substantive steps to remedy such failure within [*] days of the date
              of CPF&#8217;s request, then, on written notice by CPF to Treeline (to be given in CPF&#8217;s sole discretion), this Agreement will terminate in respect of the relevant Licensed Intellectual Property. Any dispute between the Parties as to whether a
              diligence failure has arisen or whether Treeline has used its Commercially Reasonable Efforts to take substantive steps to remedy a diligence failure shall be resolved in accordance with Clause 27.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" id="z939fd10029e543d5adde045470513b82" class="DSPFListTable" cellpadding="0" cellspacing="0">

          <tr style="vertical-align: top;">
            <td style="text-align: right; vertical-align: top; width: 36pt;">
              <div style="text-align: left;"><font style="font-weight: bold; color: rgb(0, 0, 0);">4.</font></div>
            </td>
            <td style="text-align: left; vertical-align: top; width: auto;">
              <div><font style="font-weight: bold;">CONSIDERATION</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <table id="z1e8d43d631694183ba305c6aaf743af4" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">4.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Treeline shall pay the Signature Fee to CPF within [*] Business Days of the Effective Date.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">20</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <table id="z20eaaa82e4004068acadf038acf85cab" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">4.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Subject to Clause 4.5, Treeline shall pay the development milestone payments (each a &#8220;<font style="font-weight: bold;">Development</font>&#160;<font style="font-weight: bold;">Milestone Payment</font>&#8221;) to CPF upon the first achievement of each
              of the events (each a &#8220;<font style="font-weight: bold;">Development</font>&#160;<font style="font-weight: bold;">Milestone Event</font>&#8221;) in relation to a BCL6 Product developed or commercialized by Treeline or a BCL6 Licensee or an Affiliate of
              either of them as set out in Schedule 4. Each Development Milestone Payment shall be payable only one time under this Agreement regardless of the number of times the corresponding Development Milestone Event is achieved and whether such
              Development Milestone Event is achieved by one or more BCL6 Products. In no event shall the total aggregate amount payable under this Clause 4.2 exceed Twenty-Two Million and Five Hundred Thousand U.S. Dollars (US$22,500,000).</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z64da93b7104a49eea9e45f0796ef23ca" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">4.3</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Subject to Clause 4.5, Treeline shall pay the sales milestone payments (each a &#8220;<font style="font-weight: bold;">Sales Milestone Payment</font>&#8221;) to CPF upon the first achievement of each of the events (each a &#8220;<font style="font-weight: bold;">Sales</font>&#160;<font style="font-weight: bold;">Milestone Event</font>&#8221;) in relation to the total sales of all BCL6 Products developed or commercialized by Treeline or a BCL6 Licensee or an Affiliate of either of them as set out in
              Schedule 4. Each Sales Milestone Payment shall be payable only one time under this Agreement regardless of the number of times the corresponding Sales Milestone Event is achieved. In no event shall the total aggregate amount payable under
              this Clause 4.3 exceed Fifty-Three Million U.S. Dollars (US$53,000,000).</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z765c9549219f4fbcb5e9b10c06512b1d" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">4.4</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>During the Royalty Term (defined below), Treeline shall pay to CPF a royalty equal to [*] ([*]%) on Net Sales of any BCL6 Product developed by Treeline or a BCL6 Licensee or an Affiliate of either of them, that achieves marketing approval
              in any country. Such royalty shall be payable, on a BCL6 Product-by-BCL6 Product and country by-country basis, during the period beginning on the date of the First Commercial Sale of each such BCL6 Product, and ending, on a BCL6
              Product-by-BCL6 Product and country by-country basis, upon the commencement of Generic Competition in respect of such BCL6 Product in such country (the &#8220;<font style="font-weight: bold;">Royalty Term</font>&#8221;).</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">21</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <table id="za37c85cb769c485092ecbf77157cee45" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">4.5</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Notwithstanding anything to the contrary in this Agreement, no Development Milestone Payments, Sales Milestone Payments or royalty payments shall become due or payable by Treeline or any BCL6 Licensee or an Affiliate of either of them to
              CPF and neither Treeline nor any BCL6 Licensee or an Affiliate of either of them shall have any obligation to make any payment to CPF, for any BCL6 Product for which Treeline or a BCL6 Licensee, or an Affiliate of either of them, has not
              filed an IND within [*] years following the Effective Date.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" id="za6fa848bf30e4f5a84f88b31bc39d4b1" class="DSPFListTable" cellpadding="0" cellspacing="0">

          <tr style="vertical-align: top;">
            <td style="text-align: right; vertical-align: top; width: 36pt;">
              <div style="text-align: left;"><font style="font-weight: bold; color: rgb(0, 0, 0);">5.</font></div>
            </td>
            <td style="text-align: left; vertical-align: top; width: auto;">
              <div><font style="font-weight: bold;">PAYMENT AND STATEMENT</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <table id="z48dd9dddf0aa41418a63287acca46315" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">5.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>All payments due to CPF under this Agreement shall be made in U.S. Dollars in cleared funds to the following bank account:</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="margin-left: 72pt;">
      <table id="z666a202d455043cb93b88b2404b4c64b" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 15%;">
              <div>Account name:</div>
            </td>
            <td style="width: 50%;">
              <div>[*]</div>
            </td>
            <td style="width: 35%;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 15%;">
              <div>Account number:</div>
            </td>
            <td style="width: 50%;">
              <div>[*] <br>
              </div>
            </td>
            <td style="width: 35%;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 15%;">
              <div>Sort code:</div>
            </td>
            <td style="width: 50%;">
              <div>[*] <br>
              </div>
            </td>
            <td style="width: 35%;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 15%;">
              <div>IBAN:</div>
            </td>
            <td style="width: 50%;">
              <div>[*] <br>
              </div>
            </td>
            <td style="width: 35%;">
              <div>&#160;</div>
            </td>
          </tr>

      </table>
    </div>
    <div style="margin-left: 72pt;"> </div>
    <div style="margin-left: 72pt;"> <br>
    </div>
    <div style="margin-left: 72pt;">or such other account as CPF may notify Treeline from time to time.</div>
    <div style="margin-left: 72pt;"> <br>
    </div>
    <table id="za8cd505762454c4a9bd0a0b88da8fc1e" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">5.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Treeline shall pay to CPF:</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="zf24700ccf9cb4b5fbb24510b75109978" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">5.2.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>the Signature Fee in accordance with the date specified in Clause 4.1;</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z9eafa80e955847029aa18f8978e7e40d" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">5.2.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>the Development Milestone Payments due under Clause 4.2 within [*] days of the Development Milestone Event being achieved by Treeline or a BCL6 Licensee, or an Affiliate of either of them;</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z7a58b2d51f154588922fc12053e64258" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">5.2.3</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>the Sales Milestone Payments due under Clause 4.3 within [*] days following the end of the Quarter in which the Sales Milestone Event occurred;</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z3176a4f6fcc04ef498347d12a5b76ce2" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">5.2.4</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>the royalties due pursuant to Clause 4.4 Quarterly within [*] days following the end of each Quarter in which the relevant Net Sales is invoiced by Treeline or a BCL6 Licensee.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z7914a90bec3a460da78fd603a19b902e" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">5.3</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Where BCL6 Products are sold in a currency other than U.S. Dollars, the rate of exchange to be used for converting such other currency into U.S. Dollars shall be the relevant midspot rate quoted by the Financial Times on the Business Day
              on which the royalty is received in cleared funds by Treeline.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">22</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <table id="z363f985781a941f8816e3b9477e6671b" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">5.4</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>All costs of transmission and currency conversion shall be borne by Treeline.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="zce62e7bf2a134b028eca3f9031709e06" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">5.5</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>All payments to CPF under this Agreement are exclusive of value added tax howsoever arising, and Treeline shall pay to CPF in addition to those payments or, if earlier, on receipt of a tax invoice or invoices from CPF as applicable, all
              value added tax for which CPF is liable to account in relation to any supply made or deemed to be made for value added tax purposes pursuant to this Agreement.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z75577fa95d4a4785af82e86ddc067f91" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">5.6</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>If Treeline is required by law to make any such tax deduction or withholding, Treeline shall give reasonable assistance to CPF to claim exemption from or (if that is not possible) a credit for the deduction or withholding under any
              applicable double taxation or similar agreement from time to time in force, and shall promptly give CPF proper evidence as to the deduction or withholding and payment over of the tax deducted or withheld. Any and all expenses incurred by
              Treeline in providing such assistance shall be fully reimbursed by CPF. Any taxes required to be deducted or withheld by applicable tax law from any payment made by Treeline under this Agreement shall be treated as paid to CPF hereunder.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z0dea7ff6904649f5b2f5543485039049" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">5.7</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Within [*] days after the end of each Quarter, Treeline shall send to CPF a written statement detailing in respect of that Quarter (including a nil report if appropriate):</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="zaaf6429474f74813bc1ee909579ce10c" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">5.7.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>[*];</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z822237b2df3e4e9fa29c62710130f863" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">5.7.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>[*];</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="zdc4bb6ffb5a741778e6991e7080815e9" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">5.7.3</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>[*];</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="za1a0996168d24d27a2ccd50f5f0d3a20" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">5.7.4</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>[*];</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="zc8504ad8f18146639ffe468c03711802" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">5.7.5</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>[*];</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z1cc78cca17514a0087b8c4a39dd0fd12" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">5.7.6</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>[*];</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">23</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <table id="z7dc86323f4724f97b0ed2bd7eb71d325" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">5.7.7</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>[*]; and</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z85dc4c80b8e0472ab4136d8f2823a298" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">5.7.8</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>[*].</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="zb3b79a314c314f668735797c5c635330" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">5.8</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Treeline shall notify CPF in writing of the occurrence of any Development Milestone Event or Sales Milestone Event within [*] days of the same.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="zc1cbffbf4cfd49f6b5718cc720855234" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">5.9</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-size: 12pt;"><font style="font-size: 10pt;"><u>Interest.</u> Where the payee does not receive payment of any undisputed sums properly due and payable to it under this Agreement within the relevant period, interest shall accrue
                on the sum due and owing at the rate equivalent to an annual rate of [*] ([*]%) over the then-current base rate of the Bank of England, calculated on a daily basis, without prejudice to payee&#8217;s right to receive payment within the relevant
                period, provided always the provisions of this Clause shall not apply to the extent and for the period that a Force Majeure event prevents payment.</font></div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" id="z52d84666d2f84bd1a73caedc953b7d88" class="DSPFListTable" cellpadding="0" cellspacing="0">

          <tr style="vertical-align: top;">
            <td style="text-align: right; vertical-align: top; width: 36pt;">
              <div style="text-align: left;"><font style="font-weight: bold; color: rgb(0, 0, 0);">6.</font></div>
            </td>
            <td style="text-align: left; vertical-align: top; width: auto;">
              <div><font style="font-weight: bold;">ACCOUNTS</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <table id="z37341faa9968451989739c10df5f8da5" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">6.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Treeline shall:</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z6f7799c0aeaa4119b327f441ebadb297" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">6.1.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>keep, and notwithstanding the expiry or termination of this Agreement, maintain and shall use its Commercially Reasonable Efforts to procure that each BCL6 Licensee keeps and maintains, for at least [*] years, true and accurate accounts
              and records (including any underlying documents supporting such accounts and records) in sufficient detail to enable the amount of all sums payable under this Agreement to be determined; and</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z2cf2a1ccf83d4fb8aa4ffd61cf4e8b97" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">6.1.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>during the Term and thereafter until the period of [*] years relevant to the accounts and records has expired, no more frequently than [*] a Year, at the reasonable request of CPF and (subject to Clause 6.2) at the expense of CPF from time
              to time, permit or procure permission for a qualified accountant nominated by CPF, and reasonably acceptable to Treeline, to inspect and audit those accounts and records and, to the extent that they relate to the calculation of those sums, to
              take copies of them.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">24</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <table id="z1f18058303fd44c4882c14a070eefe9b" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">6.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>If, following any inspection pursuant to Clause 6.1.2, and in the absence of manifest error, CPF&#8217;s nominated accountant certifies that the payments in respect of any Quarter or Year fall short of the sums which were properly payable in
              respect of that Quarter or Year under this Agreement, CPF shall send a copy of the certificate to Treeline and Treeline shall (subject to Clause 6.3) within [*] days of the date of receipt of the certificate pay the shortfall to CPF and, if
              the shortfall exceeds [*] ([*]%) of the sum properly payable, Treeline shall also reimburse to CPF the reasonable costs and expenses of CPF in making the inspection.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z39debabe93914a778568fd76a4911642" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">6.3</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>If, within [*] of the date of receipt by Treeline of any certificate produced pursuant to Clause 6.2, Treeline notifies CPF in writing that it disputes the certificate, the dispute shall be referred for resolution in accordance with Clause
              27.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" id="z0801b59407eb45f39cc13e5d3880ce33" class="DSPFListTable" cellpadding="0" cellspacing="0">

          <tr style="vertical-align: top;">
            <td style="text-align: right; vertical-align: top; width: 36pt;">
              <div style="text-align: left;"><font style="font-weight: bold; color: rgb(0, 0, 0);">7.</font></div>
            </td>
            <td style="text-align: left; vertical-align: top; width: auto;">
              <div><font style="font-weight: bold;">INTELLECTUAL PROPERTY</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <table id="zf034efdec01a462c9d57653f0f3e5f78" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">7.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Inventorship of inventions shall be determined in accordance with the rules of inventorship under U.S. patent laws. The ownership of the Licensed Patents shall (as between the Parties) at all times remain vested in ICR and CRT. Treeline
              (or its Affiliate) shall solely and exclusively own all Arising Intellectual Property. For clarity, in no event will Treeline be obligated to notify or obtain consent from CPF, ICR, CRT or any Third Party, or pay CPF any amounts in addition
              to the amounts set forth in Clause 4 of this Agreement, in each case, in connection with Treeline&#8217;s ownership or the research, development, manufacture, commercialization or exploitation of any Arising Intellectual Property, and Treeline
              shall have the sole and exclusive rights to research, develop, manufacture, commercialize and/or otherwise exploit any Arising Intellectual Property in its sole discretion during and after the Term.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">25</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <table id="zcfac7352cd0541f9b28edb5d57e8ba90" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">7.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Subject to Clauses 7.3, 7.4, 7.5 and 7.7, and subject to Treeline receiving timely support from CPF, CRT and ICR, Treeline shall be responsible for filing, prosecuting and maintaining the Licensed Patents in ICR or CRT&#8217;s name (as
              applicable) and use Commercially Reasonable Efforts to enforce the Licensed Patents, and be responsible for the corresponding Patent Costs. Treeline will use its Commercially Reasonable Efforts to maximise the duration and scope thereof in
              the Target Patent Countries. Without limiting Clauses 2.3 and 2.4, within [*] days after the Effective Date, CPF will procure the transfer to Treeline or its designated representative the files of all Licensed Patents and all other documents
              related to the Licensed Patents as applicable. CPF shall cooperate with Treeline in the filing, prosecution, maintenance and enforcement of all Licensed Patents, including, executing all lawful papers and instruments, making all rightful
              oaths and declarations, delivering to Treeline (or its designee), all instruments and documents, including powers of attorney, needed to file, maintain, prosecute and/or enforce the Licensed Patents and providing any other assistance
              requested by Treeline.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="ze011e4ef5d7a44f3883d9437b7f4a582" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">7.3</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Treeline shall have the sole and exclusive right, but not the obligation, to prosecute and enforce any and all Patents claiming Arising Intellectual Property and/or any use thereof, including the right to elect whether to file or maintain
              a Patent claiming Arising Intellectual Property or any use thereof, in any country. For clarity, Treeline shall have the sole and exclusive control on the registration, prosecution or enforcement of any and all Arising Intellectual Property;
              and in no event will Treeline be obligated to notify or obtain consent from CPF, ICR, CRT or any Third Party, in connection with the registration, prosecution or enforcement of any Arising Intellectual Property (or lack or abandonment
              thereof).</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z890aa3bf16224f35b80fc3c54308da13" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">7.4</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Treeline shall keep CPF reasonably informed in writing as to the prosecution and/or maintenance status of the Licensed Patents and shall promptly provide CPF with a copy of all material submissions made to or material responses received
              from the relevant patent offices and all material correspondence to and material responses received from the relevant patent agent in relation to the Licensed Patents in each applicable country of the Territory. Treeline shall use
              Commercially Reasonable Efforts to notify CPF at least [*] months prior to any restriction of scope of any of the Licensed Patents.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">26</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <table id="z9b2502fb1a954bcf9b816cccd7de808f" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">7.5</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Treeline shall discuss the filing strategy for the Licensed Patents with CPF and shall take into consideration all comments received from CPF in respect thereof. If Treeline elects not to prosecute and/or maintain any part of the Licensed
              Patents in any Target Patent Country, Treeline shall notify CPF in writing at least [*] months prior to the expiration of any applicable time bars. During the aforementioned [*] month notice period, Treeline shall continue to prosecute and
              maintain the Licensed Patents in question. On the expiry of such notice period:</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z9e839e32b678460c801eaf0ce8b49006" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">7.5.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>the licence granted pursuant to Clause 2.1 shall terminate in respect of the Licensed Patents identified in such notice; and</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="ze36e8f7902644d9eaefcb90425443ed4" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">7.5.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Treeline shall, at CPF&#8217;s request, promptly transfer to CPF (or any other person nominated by CRT) any and all documents and information in Treeline&#8217;s control relating to such Licensed Patents; and</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z8f6ab60e43b845b5ba768c779ee0b86d" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">7.5.3</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>CPF shall be free to prosecute or abandon such Licensed Patents at its sole discretion and to grant rights thereunder to any person.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z76968dd7510d49edab6299de90ebd8a2" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">7.6</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Each Party will promptly notify the other Party in writing as soon as it becomes aware of any infringement or suspected infringement by a Third Party of any of the Licensed Patents or any unauthorised use of the Licensed Know How or the
              Licensed Materials.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z927ed55c9484421eb9a63796274b64fb" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">7.7</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Provided Treeline has a licence under this Agreement in relation to the relevant Licensed Patent and country (and where local law permits), within such country Treeline may:</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z056dcf72e89b4a569ee9dcef004b06c7" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">7.7.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>at its own cost and subject to Clauses 7.8 and 7.9, bring proceedings in its own name or, if required by law, jointly with CPF, for infringement of the Licensed Patents in the Field; and</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z64db1f52cd2d48b59491769851b9f00a" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">7.7.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>in any such proceedings settle any claim for infringement of the Licensed Patents in the Field, provided it obtains the prior written consent of CPF, where any such settlement would result in a restriction to the scope of such Licensed
              Patent.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">27</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <table id="z670b704e57b14221960f22afe551448f" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">7.8</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Prior to commencing any proceedings pursuant to Clause 7.7, Treeline shall (or shall procure that its Sub-Licensee shall) enter into a separate agreement with CPF pursuant to which Treeline (or the Sub-Licensee if applicable) shall [*].</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="zc60f0c05ac674a9aa2ae6cf1ff4201c4" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">7.9</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Any damages, profits, and awards of whatever nature recovered by Treeline for any infringement of the Licensed Intellectual Property shall be treated as Net Sales subject to a deduction for Treeline&#8217;s external legal expenses insofar as
              these are not recovered from a Third Party provided always, where damages are also awarded to CPF to the extent that this would otherwise result in a double receipt by CPF of royalties Treeline shall be entitled to deduct any such duplicated
              payment from any royalties payable to CPF. In any such proceedings, CPF shall, at Treeline&#8217;s cost, promptly provide Treeline with all documents and assistance as Treeline may reasonably require. Treeline shall promptly provide CPF with notice
              of such proceedings and keep CPF regularly and reasonably informed of progress and promptly provide CPF with such information as CPF may reasonably require including copies of all documents filed at court in the proceedings. If CPF is joined
              to proceedings pursuant to this Clause or otherwise, Treeline shall indemnify and hold harmless the CPF Indemnified Parties and the inventors named in any Licensed Patents (the &#8220;<font style="font-weight: bold;">Indemnitees</font>&#8221;) from and
              against [*]. If Treeline does not notify CPF whether Treeline will exercise its right to bring proceedings pursuant to Clause 7.7 within [*] days of written request to bring proceedings from CPF, then CPF or its nominee shall be entitled, but
              not obliged to bring such proceedings at its own cost. If necessary, including to recover damages, subject to Treeline&#8217;s consent (such consent not to be unreasonably withheld or delayed it being agreed that the lack of indemnity protection
              for Treeline would be reasonable grounds to refuse consent) CPF may require Treeline to join in such proceedings. If Treeline is joined to proceedings pursuant to this Clause or otherwise, CPF shall indemnify and hold harmless Treeline, its
              Affiliates and Sub-Licensees, and their respective directors, officers, employees and agents, from and against any and all claims, demands, losses, causes of action, damages and expenses (including without limitation, reasonable legal fees)
              arising from or in connection with such proceedings. Save as provided above, whichever Party brings the proceedings shall be entitled to all monies recovered in such proceedings (following deduction of reasonably incurred and unrecovered
              costs). In any such proceedings the Party not bringing the proceedings (<font style="font-weight: bold;">&#8220;Inactive Party&#8221;</font>) shall promptly provide the Party bringing proceedings (<font style="font-weight: bold;">&#8220;Active Party&#8221;</font>)
              with all documents and assistance as the Active Party may reasonably require and the Active Party shall promptly provide the Inactive Party with notice of such proceedings.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">28</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <table id="z1dd9a92cd6b8402a9405a4d79fc079ba" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">7.10</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>At Treeline&#8217;s sole discretion, CPF shall, at the request of Treeline and at the expense of Treeline but for no further consideration, enter into such confirmatory Patent licences relating to the Licensed Patents, substantially in the form
              set out in Schedule 2, as may be necessary or desirable in accordance with the relevant law and practice in each country in the Territory for registration at the relevant patent offices so that this Agreement need not be registered or
              recorded unless the Parties are required to do so by law. If there are any inconsistencies between the terms of any such confirmatory patent licence and the provisions of this Agreement, this Agreement shall prevail.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z20d4525ebb9a4d06ac7154a06abac305" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">7.11</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Treeline shall promptly inform CPF of any Pre-Clinical Candidates or Clinical Candidates it nominates during the term of this Agreement, provided that inclusion of information regarding such nomination in Progress Reports submitted to CPF
              in accordance with Clause 3.3.6 shall be deemed as notice to CPF meeting the requirements under this Clause 7.11.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z5fa50b00c18f4c929a74d683dcd0026e" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">7.12</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>With respect to each BCL6 Product developed or commercialized by Treeline or a BCL6 Licensee or an Affiliate of either of them, Treeline shall, at the time of receipt of the relevant Regulatory Approval, or such other time as appropriate,
              use Commercially Reasonable Efforts to apply for a Supplementary Protection Certificate, patent term extension and/or any other exclusivity in respect of such BCL6 Product. At Treeline&#8217;s reasonable request and sole cost, CPF will provide
              reasonable assistance to Treeline in connection with any such applications.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">29</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" id="zc39d409fed48406b814a8ee468f15707" class="DSPFListTable" cellpadding="0" cellspacing="0">

          <tr style="vertical-align: top;">
            <td style="text-align: right; vertical-align: top; width: 36pt;">
              <div style="text-align: left;"><font style="font-weight: bold; color: rgb(0, 0, 0);">8.</font></div>
            </td>
            <td style="text-align: left; vertical-align: top; width: auto;">
              <div><font style="font-weight: bold;">WARRANTIES AND COVENANTS</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <table id="zb4c1d0952beb497289f1dd6f22f28d1d" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">8.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Each Party acknowledges that, in entering into this Agreement, it does not do so in reliance on any warranty or other provision except as expressly provided in this Agreement, and all conditions, warranties, terms and undertakings implied
              by statute, common law or otherwise are excluded from this Agreement to the fullest extent permissible by law.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="za8fbebf9c0594558819a79ce52dcc620" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">8.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Each Party warrants to the others that it has the power and authority and the legal right to enter into this Agreement to which it is a Party and to perform its obligations hereunder and has taken all necessary action on its part required
              to authorise the execution and delivery of this Agreement to which it is a Party. This Agreement has been duly executed and delivered on behalf of such Party and in the case of CPF execution on its behalf by the General Partner constitutes a
              legal, valid and binding execution and is enforceable against it in accordance with its terms.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="zf6428f00c5304d3792ce1811e3b47285" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">8.3</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>CPF warrants to Treeline that CPF has the right, power and authority under the Existing Third Party Agreements to grant to Treeline the rights granted to Treeline hereunder. In particular, (i) the rights and obligations of Treeline set
              forth in this Agreement do not contravene nor are they inconsistent with or in conflict with the terms of the Existing Third Party Agreements in a manner that would limit the rights of Treeline hereunder; (ii) the Existing Third Party
              Agreements constitute all the agreements with any Third Party pursuant to which CPF has obtained any rights with respect to the Licensed Intellectual Property, (iii) CPF has provided to Treeline a true, complete and accurate copy of each of
              the Existing Third Party Agreements, as amended to date; (iv) each of the Existing Third Party Agreements is in full force and effect and CPF is not in breach or default in the performance of any of its obligations (including any of its
              payment obligations) under the Existing Third Party Agreements; and (v) CPF has not received any notice from any Third Party of any breach, default or non-compliance of CPF under the terms of the Existing Third Party Agreements.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">30</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <table id="z8743dd9e618340e8a3496879c92a5671" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">8.4</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>CPF warrants to Treeline that it has not challenged or sought to challenge the validity of any of the Licensed Patents.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z97d74d88c92d4474a75f358a0b2e1582" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">8.5</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>CPF warrants to Treeline that CPF owns or has an exclusive license (subject to the terms of the Existing Third Party Agreements, as applicable), with the right to sublicense, to the Licensed Patents listed in Schedule 1.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z59459e7c673243428fc0a58020904e1d" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">8.6</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>CPF shall fulfil all of its obligations, including but not limited to its payment obligations, under the Existing Third Party Agreements. In the event that CPF fails to fulfil any of its obligations, including any failure to make any
              payment when due under the Existing Third Party Agreements, Treeline shall have the right (but not the obligation) to perform such obligation (including to make any payment when due) on behalf of CPF. In such event, CPF shall promptly
              reimburse Treeline for its reasonable, documented direct out-of-pocket costs and expenses incurred in such performance (including any such amounts paid by Treeline) or, at Treeline&#8217;s election, Treeline may offset such amounts incurred or paid
              by Treeline against any amounts payable to CPF under this Agreement.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="zf37f362b0b244be49efaefb4a7f04567" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">8.7</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>CPF shall not amend, waive or modify any provision of the Existing Third Party Agreements, or take any action or omit to taking any action, that would materially alter any of CPF&#8217;s rights under the Existing Third Party Agreements in any
              manner that adversely affects, or would reasonably be expected to adversely affect, Treeline&#8217;s rights and benefits under this Agreement, or that could impair the value of the licenses to Treeline herein, or terminate or have terminated the
              Existing Third Party Agreements. CPF promptly shall provide Treeline with copies of notices received under the Existing Third Party Agreements and the Third Party Agreements which are relevant to this Agreement, BCL6 Product or the Licensed
              Intellectual Property under this Agreement. Without limiting this Section 8.7, CPF shall promptly notify Treeline in writing of any default under, termination or amendment of, the Existing Third Party Agreements.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">31</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <table id="z4342775588644607856c7271e63c71df" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">8.8</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Without limiting the scope of Clause 8.1 and except as expressly stated in this Agreement, CPF gives no warranty, representation or undertaking in relation to the Licensed Intellectual Property, including any warranty, representation or
              undertaking:</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z0b0cf8f834db4bc187d5a4201124a4ab" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">8.8.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>as to the efficacy, usefulness, completeness or accuracy of the Licensed Intellectual Property; or</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z368e6aa1695740ea9d2fec357a71a707" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">8.8.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>that any of the Licensed Patents is or will be valid or that any of the applications within the Licensed Patents will proceed to grant; or</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="zc69eb1d9e85f4bf981c7680ce186769f" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">8.8.3</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>that the use of any Licensed Intellectual Property, including without limitation any invention claimed in a Licensed Patent, or the exercise of any rights granted under this Agreement will not infringe the intellectual property or other
              rights of any other person.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" id="z007ddf5be416473c86dffa0ee29f30a0" class="DSPFListTable" cellpadding="0" cellspacing="0">

          <tr style="vertical-align: top;">
            <td style="text-align: right; vertical-align: top; width: 36pt;">
              <div style="text-align: left;"><font style="font-weight: bold; color: rgb(0, 0, 0);">9.</font></div>
            </td>
            <td style="text-align: left; vertical-align: top; width: auto;">
              <div><font style="font-weight: bold;">INDEMNITY</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <table id="z854e0eb01f1c47be807a95574f193029" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">9.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Treeline shall indemnify, defend and hold harmless CPF Indemnified Parties from and against any and all Third Party claims, demands, losses, damages, costs and expenses (including, without limitation, reasonable legal fees) (collectively,
              &#8220;<font style="font-weight: bold;">Claim</font>&#8221;) arising from the [*]; provided that Treeline will have no obligation under this Clause 9.1 to the extent any such Claim is based on the negligent acts or wilful misconduct of any CPF
              Indemnified Party.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z276e951d64e44ba9b0bb8cfcfd24f988" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">9.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Treeline shall indemnify, defend and hold harmless CRT/ICR Indemnified Parties from and against any and all Third Party Claims arising from [*]; provided that Treeline will have no obligation under this Clause 9.2 to the extent any such
              Claim is based on the negligent acts or wilful misconduct of any CRT/ICR Indemnified Party.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">32</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <table id="z5e4e4aedbc064541b62252d716b41e77" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">9.3</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Promptly after receipt by CPF of any claim or alleged claim or notice of the commencement of any action, administrative or legal proceeding, or investigation to which the indemnity provided for in this Clause 9 may apply, CPF shall give
              written notice to Treeline of such fact and Treeline shall have the option to assume the defence thereof by election in writing within [*] days of receipt of CPF&#8217;s notice. If Treeline fails to make such election, the CPF Indemnified Party or
              the CRT/ICR Indemnified Party (each the &#8220;<font style="font-weight: bold;">Indemnified Party</font>&#8221;) may assume such defence and Treeline will be liable for the legal and other expenses consequently incurred in connection with such defence.
              The Parties will cooperate in good faith in the conduct of any defence, will provide such reasonable assistance as may be required to enable any claim to be defended properly and the Party with conduct of the action shall promptly provide to
              the other Party copies of all correspondence and documents and notice in writing of the substance of all oral communications relating to such action.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z6d80f29eead849bbac509f43bb2ff59b" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">9.4</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Should Treeline assume conduct of the defence:</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z90344fe7bbcd468c83322e5a37d3498e" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">9.4.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>the Indemnified Party may retain separate legal advisers, at its sole cost and expense; and</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="zc0301be2821849c4b7bfc8f883a9c074" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">9.4.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Treeline will not, except with the written consent of the Indemnified Party (such consent not to be unreasonably withheld, delayed or conditioned) consent to the entry of any judgment or enter into any settlement provided always, that if
              the Indemnified Party shall not consent to such entry of judgment or settlement, and such judgment or settlement does not involve an admission of liability on the part of the Indemnified Party, then the amount which the Indemnified Party
              shall be entitled to recover from Treeline pursuant to this Clause 9 shall be limited [*].</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="ze78c578bbc0e4657ae2255c4ecef86f2" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">9.5</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>CPF shall not admit liability in respect of, or compromise or settle any such action without the prior written consent of Treeline, such consent not to be unreasonably withheld, conditioned or delayed.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">33</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" id="zb92dd225fe014efbb8881080b855712c" class="DSPFListTable" cellpadding="0" cellspacing="0">

          <tr style="vertical-align: top;">
            <td style="text-align: right; vertical-align: top; width: 36pt;">
              <div style="text-align: left;"><font style="font-weight: bold; color: rgb(0, 0, 0);">10.</font></div>
            </td>
            <td style="text-align: left; vertical-align: top; width: auto;">
              <div><font style="font-weight: bold;">INSURANCE</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <table id="zb4586a2f6a25421685d9a22c4f5e9754" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">10.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Reasonably prior to Commencement of any human being dosed with a BCL6 Product developed by Treeline, a BCL6 Licensee, or an Affiliate of either of them, Treeline shall put in place and thereafter maintain, at its own cost, comprehensive
              product liability insurance and general commercial liability insurance through a reputable insurance company. At CPF&#8217;s request, Treeline shall provide CPF with a certificate evidencing the coverage required hereby, and the amount thereof and
              the noting of CPF&#8217;s interest. Such insurance shall be maintained for not less than [*] years following the expiration or termination of this Agreement for any reason.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" id="z44b7981586704b44a2619b76ecf47678" class="DSPFListTable" cellpadding="0" cellspacing="0">

          <tr style="vertical-align: top;">
            <td style="text-align: right; vertical-align: top; width: 36pt;">
              <div style="text-align: left;"><font style="font-weight: bold; color: rgb(0, 0, 0);">11.</font></div>
            </td>
            <td style="text-align: left; vertical-align: top; width: auto;">
              <div><font style="font-weight: bold;">LIMITATION OF LIABILITY</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <table id="zba7cefddb2db4472b98b4c62c1fe0510" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">11.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Subject to Clause 11.4, no Party, nor CRUK, nor any CPF Indemnified Party, nor their respective directors, officers, employees and agents shall have any liability under or in connection with this Agreement whether under statute or in tort
              (including but not limited to negligence), contract or otherwise in respect of: (i) any consequential or indirect loss; and/or (ii) any loss of goodwill, opportunity, profit or contract, in either case even if advised in advance of the
              possibility of such losses.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="zb0357227e0594da79e3fee7f01195a3c" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">11.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Subject to this Clause 11.2 and Clause 11.4, as a result of the charitable aims of CRUK the liability of CPF under this Agreement shall not exceed [*]. The Parties agree that the sum of [*] may not adequately remedy Treeline for any losses
              incurred by it due to the acts or omissions CPF. Accordingly, the Parties agree that this Clause 11.2 shall in no instances be taken to limit, and shall accordingly be disregarded in respect of, Treeline&#8217;s right to seek any remedies other
              than damages, in particular equitable remedies (including specific performance or injunction) as a result of the acts or omission of CPF pursuant to this Agreement. For the avoidance of doubt, any liability of CPF for breach of its
              obligations under this Agreement shall be several and not joint.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="ze2da44e1bbf34e34aec6e4337ae5967f" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">11.3</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Treeline shall to the extent permitted lawfully by English law be able to offset any losses which would have been recoverable from CPF but for the operation of Clause 11.2 against any future payment obligations it has to CPF.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z76b1d603214c4b148cbb52f73ae129c3" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">11.4</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Nothing in this Agreement shall be construed as excluding or limiting the liability of any person for any liability which cannot be limited or excluded by law.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">34</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" id="z0e5022ccb40d458fa60a100f6e75ab4f" class="DSPFListTable" cellpadding="0" cellspacing="0">

          <tr style="vertical-align: top;">
            <td style="text-align: right; vertical-align: top; width: 36pt;">
              <div style="text-align: left;"><font style="font-weight: bold; color: rgb(0, 0, 0);">12.</font></div>
            </td>
            <td style="text-align: left; vertical-align: top; width: auto;">
              <div><font style="font-weight: bold;">CONFIDENTIALITY</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <table id="z5fabe711fc634aeebf9f695e32b3ef16" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">12.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Each Party (the &#8220;<font style="font-weight: bold;">Receiving Party</font>&#8221;) undertakes with each other Party (the &#8220;<font style="font-weight: bold;">Disclosing Party</font>&#8221;) that it shall keep, and it shall procure that its respective
              directors, partners, officers, employees and agents (collectively, &#8220;<font style="font-weight: bold;">Representatives</font>&#8221;) shall keep, secret and confidential all Confidential Information of the Disclosing Party, shall not use the same for
              any purpose other than as provided for in this Agreement (which includes the exercise of any rights or the performance of any obligations hereunder or thereunder), and shall not publish or disclose the same or any part of the same to any
              person whatsoever during the Term and for [*] years thereafter other than:</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z72ab224b4e6043a0bad5f7d397f42abc" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">12.1.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>in the case of Treeline to: (i) BCL6 Licensees and Third Party Service Providers, subject to compliance with Clause 16.3; (ii) investors in Treeline pursuant to its obligations under applicable laws and regulations (in particular but
              without limitation those of the Financial Services Authority); (iii) Competent Authorities in the Territory as necessary in communications relating to the BCL6 Products; (iv) potential BCL6 Licensees and potential Third Party Service
              Providers; and (v) legal, financial, scientific or business advisors or present or bona fide future collaboration partners, investors or acquirers, provided that any such persons have agreed to be bound by a customary legal obligation of
              confidentiality at least as restrictive as those under this Clause 12;</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="ze299960b4e90491a871d25be632976f9" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">12.1.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>in the case of each Party, to its Representatives directly or indirectly concerned in the exercise of the rights granted under this Agreement; and</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="zea42e7188f3144a3a83463190267c484" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">12.1.3</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>in the case of CPF, to any research institutions involved in the generation or development of the Licensed Intellectual Property pursuant to Clause 12.4, provided that any such persons have agreed to be bound by a legal obligation of
              confidentiality no less restrictive than that set forth in this Clause 12.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">35</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <table id="z99ea554be4c84e1b943ec260c8492fe4" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">12.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Each Party shall ensure that each of its Representatives to whom any Confidential Information is disclosed shall previously have been informed of the confidential nature of the Confidential Information and shall have agreed to be bound by
              a legal obligation of confidentiality no less restrictive than that set forth in this Clause 12.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z00fc2489923b411fb1c489cafde1de3d" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">12.3</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Where CPF is required to disclose any Licensed Know How to CRT/ICR Reviewers, CPF shall provide Treeline reasonable prior written notice and the opportunity to review and comment on any such Licensed Know How proposed to be disclosed to
              CRT/ICR Reviewers, and shall give due consideration to any comments received from Treeline; provided that such CRT/ICR Reviewers shall be bound by written confidentiality, nondisclosure and non-use obligations at least as restrictive as those
              under this Clause 12. CPF recognises the need to protect the confidentiality of the chemical structures of Licensed Compounds. Prior to disclosing the chemical structure of any Licensed Compounds (to the extent not already in the public
              domain), CPF shall limit the content of materials disclosed to CRT/ICR Reviewers solely to the extent necessary for the purpose of the review, being no more than (in the following order of priority): [*]. Notwithstanding the foregoing, CPF
              shall be permitted to disclose to any CRT/ICR Reviewers such Licensed Know How as it may determine in its reasonable discretion to disclose. CPF will however ensure that any such disclosure is made in accordance with the terms of this
              Agreement. For clarity, in no event shall any information disclosed under this Clause 12.3 include any Confidential Information of Treeline (including any Arising Intellectual Property), except for the Licensed Know How subject to this Clause
              12.3.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z8eb53288701a44d5acbd2338fcd1b12b" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">12.4</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Where CPF wishes to disclose any Confidential Information to any research institutions involved in the generation or development of the Licensed Intellectual Property, CPF shall:</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="zb5133ecc101d4d769ae2fba51ce132af" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 144pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">(a)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>be free to provide the Confidential Information only to the extent that the Confidential Information relates solely and directly to the revenues paid by Treeline to CPF (<font style="font-weight: bold;">&#8220;Revenue Information&#8221;</font>); or</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">36</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <table id="z3113d173bfa049c7ad449e5470516bb0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 144pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">(b)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>subject to Clause 12.3, only provide Confidential Information, which is not Revenue Information, having first obtained Treeline&#8217;s prior written consent to such disclosure.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z585b8a3557d74ceb9cf3f4967d1ad79d" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">12.5</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>The provisions of Clauses 12.1, 12.2 and 12.4 shall not apply to information which:</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="zd3210d9058aa43bf8b3bf959baff7c10" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">12.5.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>the Receiving Party can demonstrate by reference to written records to have been in its possession (other than under an obligation of confidence to the Disclosing Party or to a Third Party) at the date of receipt;</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z3cdb06c0665943178cb58b19e5cac06c" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">12.5.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>the Receiving Party can demonstrate by reference to written records that it received from a Third Party without obligation of confidence to the Disclosing Party after receipt from the Disclosing Party;</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z4d94b2bf8b0d44f98bd740cdd438b6f1" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">12.5.3</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>enters the public domain otherwise than through a breach of any obligation of confidentiality owed to the Disclosing Party; or</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z18fddf8358b44c978343917244b63588" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">12.5.4</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>the Receiving Party can prove it has independently developed without the use of any of the Disclosing Party&#8217;s Confidential Information.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z9248285fcfa740bc9fdfe692e3cc0ec8" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">12.6</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>The Receiving Party may disclose Confidential Information to the extent that such disclosure is:</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z3eaff6be633e450b9e69194e0dfa87a4" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">12.6.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>necessarily required of the Receiving Party by order of a Competent Authority or otherwise by applicable law; provided, that the Receiving Party shall, to the extent practicable in the time available and where legally permissible, first
              have given notice to the Disclosing Party and shall provide such reasonable assistance to the Disclosing Party as it may reasonably require in order for it to make an application to quash any such order or obtain a protective order requiring
              that the Confidential Information the subject of such order be held in confidence by such Competent Authority or, if disclosed, be used only for the purpose for which the order was issued; and provided further that if such order is not
              quashed or a protective order is not obtained, the Confidential Information disclosed in response to such order shall be limited to that information that is legally required to be disclosed in response to such order;</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">37</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <table id="z287d4f0ed123468bad0c62426cc336f8" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">12.6.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>reasonably necessary or useful (i) to a patent authority for the purposes of obtaining or enforcing a Licensed Patent (consistent with the terms and conditions of Clauses 7.2 and 7.7), (ii) to a regulatory authority to comply with the
              requirements of such regulatory authority with respect to obtaining and maintaining Regulatory Authorizations of BCL6 Products; or (iii) for the prosecution or defence of litigation; provided, however, that reasonable measures shall be taken
              to assure confidential treatment of such information, to the extent such protection is available; or</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="ze75bd6397df1437db1aaa2168a4fe19d" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">12.6.3</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>required with regard to the disclosure requirements of a national securities exchange or other stock market or of a related regulatory body on which the Receiving Party&#8217;s securities are or are proposed to be traded, provided it has used
              reasonable endeavours in the time available to provide notice to the Disclosing Party of the terms of any such disclosure beforehand.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="zd67a2d0d822743c7a876e2e658831172" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">12.7</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>The Receiving Party agrees that the disclosure of the Disclosing Party&#8217;s Confidential Information without the express written consent of the Disclosing Party may cause irreparable harm to the Disclosing Party, and that any breach or
              threatened breach of this Agreement by the Receiving Party may entitle the Disclosing Party to injunctive relief, in addition to any other legal remedies available to it, in any court of competent jurisdiction.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="za1d022badbf142c6a2e85941bba7b1b0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">12.8</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>The provisions of this Clause 12 shall remain in force for a period of [*] years from the expiry or termination of this Agreement.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" id="zc81fd7952f264f0599313064c9901c5c" class="DSPFListTable" cellpadding="0" cellspacing="0">

          <tr style="vertical-align: top;">
            <td style="text-align: right; vertical-align: top; width: 36pt;">
              <div style="text-align: left;"><font style="font-weight: bold; color: rgb(0, 0, 0);">13.</font></div>
            </td>
            <td style="text-align: left; vertical-align: top; width: auto;">
              <div><font style="font-weight: bold;">TERM AND TERMINATION</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <table id="z01b895fa0c4643d3988ba9392f066d10" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">13.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>This Agreement will become effective on the Effective Date. Subject to early termination pursuant to the provisions of this Clause 13 it will remain effective in each country of the Territory until the expiry of the Royalty Term in
              relation to that country pursuant to this Agreement.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">38</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <table id="zde9a2cde5d1d426fa34eab8b4d37b1fa" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">13.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Without prejudice to any other rights of the Parties, this Agreement may be terminated by notice in writing:</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z1b813f3aeab14f33bd4dd79ed3309500" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">13.2.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>subject to Clause 13.3, by either Party forthwith if the other Party is in material breach of any of its obligations under this Agreement and in the case of a remediable breach fails to remedy the breach within [*] Business Days of written
              notice containing full particulars of the breach and requiring it to be remedied;</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z58ef8baaf1414baebe8be6b7ca248bd1" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">13.2.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>by either Party forthwith if, in respect of the other Party, a voluntary arrangement is proposed or approved or an administration order is made, or a receiver or administrative receiver is appointed of any of the other Party&#8217;s assets or
              undertakings or a winding-up resolution or petition is passed (otherwise than for the purpose of solvent reconstruction or amalgamation, in particular with respect to any reorganisation of the structure of the relevant Party) or if any
              circumstances arise which entitle a court or a creditor to appoint a receiver, administrative receiver or administrator or make a winding-up order or similar or equivalent action is taken against or by the relevant Party by reason of its
              insolvency or in consequence of debt;</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="zfb89340eaf2448c6a9e9386f72e57979" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">13.2.3</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>by Treeline for any reason or no reason, in its entirety or on a country-by-country and/or BCL6 Product-by-BCL6 Product basis, on [*] days&#8217; prior written notice to CPF if such notice is given prior to the Commencement of the first clinical
              trial under this Agreement in respect of a BCL6 Product;</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z6f8694ece56c40ab9f07f8b18641c47e" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">13.2.4</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>by Treeline for any reason or no reason, in its entirety or on a country-by-country and/or BCL6 Product-by-BCL6 Product basis, on [*] days&#8217; prior written notice to CPF if such notice is given after the Commencement of the first clinical
              trial under this Agreement in respect of a BCL6 Product;</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">39</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <table id="zc4db90d5c33f4fa28b3e3182cccf9784" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">13.2.5</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>by CPF upon [*] days written notice to Treeline, if Treeline challenges or seeks to challenge the validity of any of the Licensed Patents and Treeline shall forthwith in writing notify to CPF any decision to challenge the Licensed Patents
              which it makes or of which it becomes aware;</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z91a8b6fa8f0441aebb0361aa318ead97" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">13.2.6</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>by CPF forthwith in the event of a Change of Control of Treeline where the new Controlling party is a Tobacco Party;</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z2323c3e8177b4ea3bc2e3050934517e6" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">13.2.7</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>by CPF forthwith in the event the Head Licence terminates for any reason (subject to Clause 14.1);</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z67370ddacc894de5ab8f7185a0c59f58" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">13.2.8</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>by CPF forthwith in the event of a Change of Control of Treeline which results in Treeline or the controlling party ceasing all activities regarding all BCL6 Products; or</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z74cf721b08b44ca782bc686300ef29d4" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">13.2.9</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>in accordance with Clause 3.4.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="za99d760acff94fcea33c73f0f8ade977" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">13.3</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>If the alleged breaching Party disputes in good faith the existence or materiality of a breach specified in a notice provided by the alleging Party, such alleged breaching Party shall provide the alleging Party with notice of such dispute
              within [*] Business Days of receiving the notice of breach provided by the other Party. Subject to this Clause 13.3 the alleging Party shall not have the right to terminate this Agreement under Clause 13.2.1 unless and until an arbitration
              panel, in accordance with Clause 27.3, has determined that the alleged breaching Party has materially breached the Agreement. Notwithstanding the foregoing, if the Parties have not convened an arbitration panel which has commenced the initial
              hearing of the dispute within [*] months of the date of the notice of dispute (and the delay was not caused by the alleging Party), the alleging Party shall have the right to terminate this Agreement immediately on written notice to the
              other. It is understood and agreed that during the pendency of such dispute, all of the terms and conditions of this Agreement shall remain in effect and the Parties shall continue to perform all of their respective obligations hereunder.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">40</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" id="z79d291e76480483295182000d9084acb" class="DSPFListTable" cellpadding="0" cellspacing="0">

          <tr style="vertical-align: top;">
            <td style="text-align: right; vertical-align: top; width: 36pt;">
              <div style="text-align: left;"><font style="font-weight: bold; color: rgb(0, 0, 0);">14.</font></div>
            </td>
            <td style="text-align: left; vertical-align: top; width: auto;">
              <div><font style="font-weight: bold;">EFFECTS OF TERMINATION</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <table id="z889b0acd1e244193b5f228f4f562db28" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">14.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>If CPF terminates this Agreement pursuant to Clause 13.2.7, CPF shall use reasonable efforts to procure that CRT and ICR shall comply with their obligations to immediately grant to Treeline a sub-licence on materially the same terms to
              those contained in this Agreement, save that this shall not result in CRT or ICR taking on any more onerous obligations or assuming any liability other than those under the Head Licence.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="zbfd21b8ec83544e899e4c23b6b1172f1" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">14.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>If Treeline terminates this Agreement pursuant to Clause 13.2.3 or Clause 13.2.4, or if CPF terminates this Agreement pursuant to Clause 13.2.1, Clause 13.2.2, Clause 13.2.5, Clause 13.2.6, Clause 13.2.7 (only in the event that CRT, ICR
              and Treeline enter into a licence on materially the same terms to those contained in this Agreement), Clause 13.2.8 or Clause 13.2.9, then notwithstanding any such termination, Treeline&#8217;s payment obligations pursuant to Clauses 4.2, 4.3 and
              4.4 shall continue in full force and effect in respect of any BCL6 Product developed or commercialized by Treeline, a BCL6 Licensee or an Affiliate of either of them, subject to Clause 4.5.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="ze101cf9688964b6fae874d39956a3fcf" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">14.3</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Upon the termination of this Agreement for any reason (except that, if such termination is limited to a specific country or BCL6 Product, then the following shall only apply to such country or BCL6 Product):</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z5800bd30f34541bb9b243642c9054cc3" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">14.3.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Treeline shall consent to the revocation of any confirmatory patent licence relating to the Licensed Patents granted pursuant to Clause 7.10 and the cancellation of the registration of any such licence in any register;</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z677f9eef006f4819957fcce387940d74" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">14.3.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Treeline shall promptly transfer to CPF (or any person nominated by CPF) any and all documents and information in Treeline&#8217;s control or possession relating to the Licensed Patents and CPF may assume responsibility for the prosecution and
              maintenance of the same;</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z562c91bb8a8546b69d88ac3428618d8e" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">14.3.3</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>the licences granted to Treeline pursuant to Clause 2 shall terminate forthwith;</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">41</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <table id="zde1d084be08d41c7b21bd0bdde8612bd" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">14.3.4</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Treeline shall, at the request and option of CPF, return or destroy the Licensed Know How and the Licensed Materials in its possession or control; and</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="zafd29700575745ccbdde5568a176a37e" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">14.3.5</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>If Treeline has terminated and intends to abandon all activities regarding all BCL6 Products, Treeline shall enter good faith negotiations with CPF as to the basis on which CPF might license rights to such BCL6 Products from Treeline.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="zc3c2831290de4c2daa2542aed472c0db" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">14.3.6</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>In the event that Treeline had signed a sub-licence, such sub-licence shall terminate and (in accordance with Clause 2.6.2) CPF shall immediately grant to the affected Sub-Licensee a sub-licence on materially the same terms to that
              contained in the terminated sub-licence, save that this shall not result in CPF taking on any more onerous obligations than it is under pursuant to this Agreement. CPF shall continue to pay to Treeline such sums as it would have received
              under the terminated sub-licence less the amount which Treeline would have had to pay CPF pursuant to this Agreement and less any Patent Costs or other costs which would have been borne by Treeline, but for the termination of this Agreement.
              The principles in Clauses 5.3 through 5.7, 5.9 and 6 shall apply to CPF as though they were substituting for Treeline in those Clauses and Treeline is the beneficiary of those Clauses.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="zbe576aca221e493386f04043bba54c43" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">14.4</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>The termination of this Agreement howsoever arising will be without prejudice to the rights and duties of either Party accrued prior to termination. The following Clauses will continue to be enforceable notwithstanding termination: Clauses
              2.6.2, 2.7, 6, 7.1, 7.9, 9, 10, 11, 12, 14, and 17 to 28 inclusive.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" id="z1ad8d43029274181b6fae728217a064d" class="DSPFListTable" cellpadding="0" cellspacing="0">

          <tr style="vertical-align: top;">
            <td style="text-align: right; vertical-align: top; width: 36pt;">
              <div style="text-align: left;"><font style="font-weight: bold; color: rgb(0, 0, 0);">15.</font></div>
            </td>
            <td style="text-align: left; vertical-align: top; width: auto;">
              <div><font style="font-weight: bold;">FORCE MAJEURE</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <table id="zb1d4a0c2f61f4ca7847d73b31d5bff68" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">15.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>If a Party is unable to carry out any of its obligations under this Agreement due to Force Majeure (the &#8220;<font style="font-weight: bold;">Non-Performing Party</font>&#8221;) this Agreement shall remain in effect but the NonPerforming Party&#8217;s
              relevant obligations under this Agreement and the relevant obligations of the other Party (&#8220;<font style="font-weight: bold;">the Innocent Party</font>&#8221;) under this Agreement shall be suspended for the duration of the circumstance of Force
              Majeure provided that:</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">42</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <table id="z335a5f580466408aad7f6b0e0580527f" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">15.1.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>the suspension of performance is of no greater scope than is required by the Force Majeure;</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="zad85f56fda07423396806945dd2bb355" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">15.1.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>the Non-Performing Party gives the Innocent Party prompt notice describing the circumstance of Force Majeure, including the nature of the occurrence and its expected duration, and continues to furnish regular reports during the period of
              Force Majeure;</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z87a08d8da28b4ad7ba1f11a6dffaa6d4" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">15.1.3</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>the Non-Performing Party uses all reasonable efforts to remedy its inability to perform and to mitigate the effects of the circumstance of Force Majeure; and</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="zd36f642060e44688826ef5be244d9a8c" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">15.1.4</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>as soon as practicable after the event which constitutes Force Majeure the Parties shall discuss how best to continue their operations as far as possible in accordance with this Agreement.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z54db6fb8ff0b483784a806ea657c4313" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">15.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>If the Force Majeure continues for [*] months or more, the Innocent Party may give [*] Business Days written notice to terminate this Agreement to the NonPerforming Party and termination shall occur if the Force Majeure is continuing at
              the end of that [*] Business Day notice period.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" id="z84bc39a7427648289dde762bdd8da893" class="DSPFListTable" cellpadding="0" cellspacing="0">

          <tr style="vertical-align: top;">
            <td style="text-align: right; vertical-align: top; width: 36pt;">
              <div style="text-align: left;"><font style="font-weight: bold; color: rgb(0, 0, 0);">16.</font></div>
            </td>
            <td style="text-align: left; vertical-align: top; width: auto;">
              <div><font style="font-weight: bold;">ASSIGNMENT AND SUB-CONTRACTING</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <table id="zdd524201f0194673bc3827ce4738eff7" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">16.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>This Agreement shall be binding upon and inure to the benefit of the Parties, their successors and assigns. This Agreement shall be assignable:</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z9d440f04471b4a089f5bb52d76cc0923" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">16.1.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>by a Party with the written consent of the other Parties; or</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z8fd6ff962fd243d1a81593bfe625bb43" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">16.1.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>by a Party without the consent of the other Parties, to any successor to all or substantially all the assets of its business to which this Agreement relates.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">43</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <table id="za459dec9521940ca8f2f77a45c25a956" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">16.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>CPF shall have the right to assign the right to receive income pursuant to this Agreement but shall not otherwise have the right to assign the benefit or burden of this Agreement.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z2d5635bf5b864a4fb665ca64d56b1213" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">16.3</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Treeline may not sub-contract its obligations under this Agreement to any person other than a Third Party Service Provider, its Affiliates or BCL6 Licensees.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" id="z47c0ce617c9e4ae4b38348ab65d4aebf" class="DSPFListTable" cellpadding="0" cellspacing="0">

          <tr style="vertical-align: top;">
            <td style="text-align: right; vertical-align: top; width: 36pt;">
              <div style="text-align: left;"><font style="font-weight: bold; color: rgb(0, 0, 0);">17.</font></div>
            </td>
            <td style="text-align: left; vertical-align: top; width: auto;">
              <div><font style="font-weight: bold;">NOTICES</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <table id="z5bb9327a769a4b99a689de9d12c5fbaa" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">17.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>All notices shall be in writing and sent by hand, email, or recorded delivery and shall be deemed to be properly served (i) if sent by hand, when delivered at the relevant address; (ii) if sent by recorded delivery, three (3) Business Days
              after posting; (iii) if sent by email, when transmitted, provided a confirmatory copy is sent by post within twenty four (24) hours of transmission, and shall be sent to the following addresses or email address as may be amended by the
              relevant Party in writing:</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 72pt;">Treeline:</div>
    <div>&#160;</div>
    <div style="margin-left: 108pt;">Treeline Biosciences, Inc.</div>
    <div style="margin-left: 108pt;">677 Washington Blvd.</div>
    <div style="margin-left: 108pt;">Ste 525</div>
    <div style="margin-left: 108pt;">Stamford</div>
    <div style="margin-left: 108pt;">Connecticut 06901</div>
    <div style="margin-left: 108pt;">United States</div>
    <div style="margin-left: 108pt;">Email: [*]</div>
    <div style="margin-left: 108pt;">Attention: [*]</div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 72pt;">CPF:</div>
    <div>&#160;</div>
    <div style="margin-left: 108pt;">C/O Sixth Element Capital</div>
    <div style="margin-left: 108pt;">[*]</div>
    <div style="margin-left: 108pt;">[*]</div>
    <div style="margin-left: 108pt;">[*]</div>
    <div>
      <div style="margin-left: 108pt;">[*]</div>
      <div style="margin-left: 108pt;">[*]</div>
      <div style="margin-left: 108pt;">[*]</div>
      <div style="margin-left: 108pt;">Email: [*] and [*]</div>
      <div style="margin-left: 108pt;">For the attention of: [*] and [*]</div>
      <div style="margin-left: 108pt;"> <br>
      </div>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">44</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" id="z7226f1eeb2e94a049578f3ecf7abb85a" class="DSPFListTable" cellpadding="0" cellspacing="0">

          <tr style="vertical-align: top;">
            <td style="text-align: right; vertical-align: top; width: 36pt;">
              <div style="text-align: left;"><font style="font-weight: bold; color: rgb(0, 0, 0);">18.</font></div>
            </td>
            <td style="text-align: left; vertical-align: top; width: auto;">
              <div><font style="font-weight: bold;">VARIATION</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <table id="z49f9cf6e87c345f2a0326f1f4a138c97" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">18.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>No variation, modification, amendment, extension or release from any provision of this Agreement shall be effective unless it is in writing, signed by each of the Parties.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" id="z87fb7f524c7f4160831a2aba10facfa1" class="DSPFListTable" cellpadding="0" cellspacing="0">

          <tr style="vertical-align: top;">
            <td style="text-align: right; vertical-align: top; width: 36pt;">
              <div style="text-align: left;"><font style="font-weight: bold; color: rgb(0, 0, 0);">19.</font></div>
            </td>
            <td style="text-align: left; vertical-align: top; width: auto;">
              <div><font style="font-weight: bold;">ENTIRE AGREEMENT</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <table id="zed368c6e662945eab849f022e6ac8971" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">19.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Each Party confirms that this Agreement (including all Schedules) represents the entire understanding, and constitutes the whole agreement, in relation to its subject matter and supersedes any previous agreement between the Parties with
              respect thereto.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="zd74108f866124333afd9c0b789c5dd54" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">19.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Each Party confirms that:</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z4ba114be0fbf4ce1b2c6acdd1e4b94c9" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">19.2.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>it has not relied on any representation or warranty or undertaking which is not contained in this Agreement; and</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z10d77159861f4b778c090e453d407f79" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">19.2.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>in any event, without prejudice to any liability for fraudulent misrepresentation or fraudulent misstatement, neither Party shall be under any liability or shall have any remedy in respect of misrepresentation or untrue statement unless
              and to the extent that a claim lies under this Agreement.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" id="zc844299c590e4c50b8f9deaaa9775bd4" class="DSPFListTable" cellpadding="0" cellspacing="0">

          <tr style="vertical-align: top;">
            <td style="text-align: right; vertical-align: top; width: 36pt;">
              <div style="text-align: left;"><font style="font-weight: bold; color: rgb(0, 0, 0);">20.</font></div>
            </td>
            <td style="text-align: left; vertical-align: top; width: auto;">
              <div><font style="font-weight: bold;">FURTHER ASSURANCE</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <table id="z12c20d4c48224e5d83062741dd1c9631" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">20.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Each Party hereby undertakes to do all such other acts and things, and execute and provide all such documents at the other Party&#8217;s request and cost as may be necessary or desirable to give effect to the purposes of this Agreement.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">45</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" id="zdd786bd881894a96bcee0c3a6d849a07" class="DSPFListTable" cellpadding="0" cellspacing="0">

          <tr style="vertical-align: top;">
            <td style="text-align: right; vertical-align: top; width: 36pt;">
              <div style="text-align: left;"><font style="font-weight: bold; color: rgb(0, 0, 0);">21.</font></div>
            </td>
            <td style="text-align: left; vertical-align: top; width: auto;">
              <div><font style="font-weight: bold;">NO PARTNERSHIP</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <table id="zbe270fdc0bfe4b0790e2e52bd25835c8" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">21.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Nothing in the Agreement and no action taken by the Parties pursuant to this Agreement shall constitute or be deemed to constitute a partnership association, joint venture or other co-operative entity between the Parties and none of the
              Parties shall have any authority to bind any of the others in any way except as provided in this Agreement.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" id="za1e3879eebd14f9cb03319098a308af2" class="DSPFListTable" cellpadding="0" cellspacing="0">

          <tr style="vertical-align: top;">
            <td style="text-align: right; vertical-align: top; width: 36pt;">
              <div style="text-align: left;"><font style="font-weight: bold; color: rgb(0, 0, 0);">22.</font></div>
            </td>
            <td style="text-align: left; vertical-align: top; width: auto;">
              <div><font style="font-weight: bold;">COSTS</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <table id="ze95167bf80cb49ecbb5a3677ad6ea126" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">22.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Each Party shall bear its own legal costs, legal fees and other expenses incurred in the negotiation, preparation, execution and implementation of this Agreement and the documentation referred to herein.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" id="z9ece8f70311449daa61d5bf29335a545" class="DSPFListTable" cellpadding="0" cellspacing="0">

          <tr style="vertical-align: top;">
            <td style="text-align: right; vertical-align: top; width: 36pt;">
              <div style="text-align: left;"><font style="font-weight: bold; color: rgb(0, 0, 0);">23.</font></div>
            </td>
            <td style="text-align: left; vertical-align: top; width: auto;">
              <div><font style="font-weight: bold;">WAIVER</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <table id="z32eae931a2d94e48bbfd2ada67e5db2e" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">23.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>No relaxation, forbearance, waiver or indulgence by either Party in enforcing any of the terms or conditions of this Agreement or the granting of time by either Party to the other shall prejudice, affect or restrict the rights and powers
              of such Party, unless contained in a writing signed by the Party charged with such waiver. The waiver of any breach of any term or any condition of this Agreement shall not be construed as a waiver of any subsequent breach of a term or
              condition of the same or of a different nature.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" id="z10f6ada38c33418594b7524dd3109ae9" class="DSPFListTable" cellpadding="0" cellspacing="0">

          <tr style="vertical-align: top;">
            <td style="text-align: right; vertical-align: top; width: 36pt;">
              <div style="text-align: left;"><font style="font-weight: bold; color: rgb(0, 0, 0);">24.</font></div>
            </td>
            <td style="text-align: left; vertical-align: top; width: auto;">
              <div><font style="font-weight: bold;">SEVERABILITY</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <table id="za15118e4653a462296976efc7a0141ac" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">24.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>If the whole or any part of this Agreement is or becomes or is declared illegal, invalid or unenforceable in any jurisdiction for any reason (including by reason of the provisions of any legislation and/or by reason of any court or
              Competent Authority):</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z23c624c89ba6426398196818ee99ac97" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">24.1.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>in the case of the illegality, invalidity or unenforceability of the whole of this Agreement it shall terminate only in relation to the jurisdiction in question; or</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">46</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <table id="zefadf9c89ff64a4fb131f32cfe30029b" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">24.1.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>in the case of the illegality, invalidity or unenforceability of a part of this Agreement that part shall be severed from this Agreement in the jurisdiction in question and that illegality, invalidity or unenforceability shall not in any
              way whatsoever prejudice or affect the remaining parts of this Agreement which shall continue in full force and effect and in no circumstances shall sums paid by Treeline to CPF under this Agreement be repayable.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="zc70abde5c3094dcea2801d3aaf57a4d2" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">24.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>If in the reasonable opinion of a Party any severance under this Clause 24 materially affects the commercial basis of this Agreement, the Parties shall negotiate in good faith to modify the Agreement to preserve (to the extent possible)
              their original intent.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" id="z3d42579feac2402faaa2ade6a08d74eb" class="DSPFListTable" cellpadding="0" cellspacing="0">

          <tr style="vertical-align: top;">
            <td style="text-align: right; vertical-align: top; width: 36pt;">
              <div style="text-align: left;"><font style="font-weight: bold; color: rgb(0, 0, 0);">25.</font></div>
            </td>
            <td style="text-align: left; vertical-align: top; width: auto;">
              <div><font style="font-weight: bold;">EXECUTION</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <table id="z3b78d7b36f5a4c948a39220726097117" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">25.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>This Agreement may be executed in any one or more number of counterpart agreements each of which, when executed, shall be deemed to form part of and together constitute this Agreement.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" id="z90320df2961f4db1b84bf5e336bfdbb4" class="DSPFListTable" cellpadding="0" cellspacing="0">

          <tr style="vertical-align: top;">
            <td style="text-align: right; vertical-align: top; width: 36pt;">
              <div style="text-align: left;"><font style="font-weight: bold; color: rgb(0, 0, 0);">26.</font></div>
            </td>
            <td style="text-align: left; vertical-align: top; width: auto;">
              <div><font style="font-weight: bold;">ANNOUNCEMENTS, PUBLICATIONS AND USE OF NAMES</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <table id="z5726cbf4b30440b9a04e2856fea4eed3" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">26.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Save as provided in Clause 26.2, neither Party shall make, or procure or permit the making of, any press release or other public announcement (including on any website or in any company publication) in relation to this Agreement without
              first obtaining the written approval of the other Party to any such release or announcement.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="ze921f10b0450430db8d7a2c03321a478" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">26.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>A Party may make an announcement with respect to this Agreement or any ancillary matter if required by any governmental agency, applicable law or the regulations of any stock exchange to which it is subject, provided that the Party
              required to make the public disclosure shall use reasonable endeavours in the time available to consult with and obtain consent from the other Party on the terms of any such announcement beforehand.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">47</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <table id="z2c8be3a7fc494a809439dcbfdb3658c2" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">26.3</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Treeline shall, and shall use its reasonable endeavours to procure that a Sub-Licensee agrees to, acknowledge ICR&#8217;s involvement in the research and development of any BCL6 Product which incorporates or relies upon the Licensed Intellectual
              Property (which, in the case of a sub-licensee is the subject of the Sub-Licence) in any publication relating to that BCL6 Product provided always that Treeline shall have no liability to CPF if, subject to Treeline having taken the steps set
              out in the remainder of this Clause 26.3, the Sub-Licensee does not agree to such a provision or subsequently breaches such a provision. In the event of a breach by a Sub-Licensee of the provisions of this Clause 26.3, and on receipt of
              written notice from CPF notifying Treeline of such breach (which may be delivered by email), Treeline hereby undertakes to notify the Sub-Licensee of such breach and to request future adherence to the terms of this Clause 26.3. CPF
              acknowledge that other considerations may take precedence over this clause when considering the merits of one potential Sub-Licensee over another.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z88e4bd6a8c5b4fcb835659af1a760c84" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">26.4</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>No Party shall use the name or marks of any other (including that of CRUK (or their successors)) other than as provided in Clause 26.1 and 26.2 without the prior written consent of that Party which shall be at that Party&#8217;s sole discretion.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="zf38b16410caf4e56b3684c2a1e7fe45f" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">26.5</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>The Parties shall comply with the terms of the [*], regarding any publication of Licensed Intellectual Property.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" id="ze0cb406b85b04c86949daddb00677ad8" class="DSPFListTable" cellpadding="0" cellspacing="0">

          <tr style="vertical-align: top;">
            <td style="text-align: right; vertical-align: top; width: 36pt;">
              <div style="text-align: left;"><font style="font-weight: bold; color: rgb(0, 0, 0);">27.</font></div>
            </td>
            <td style="text-align: left; vertical-align: top; width: auto;">
              <div><font style="font-weight: bold;">DISPUTE RESOLUTION AND GOVERNING LAW</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <table id="za325e1e9911342c3858bc405e2740a4d" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">27.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>It shall be a condition precedent to the commencement of any action in court or other tribunal (save an action for an interim injunction) in respect of any dispute relating to this Agreement that the Parties have sought to resolve the
              dispute by a Party notifying the other Party in writing for resolution to the Executive Officers who shall meet (whether in person or via teleconference) within [*] days of such notice to seek resolution in good faith. If the Executive
              Officers are unable to resolve the dispute at such meeting, any Party may pursue any remedy available to such Party at law or in equity, subject to the terms and conditions of this Agreement.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z3f65036eab1c4528942c21c6e6874f05" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">27.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>This Agreement shall be governed by and construed in accordance with the laws of England and Wales.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">48</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <table id="z4a1e097e9987490a8a14a1ea2ddea24c" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">27.3</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>All disputes arising out of or in connection with this Agreement, including any questions regarding its formation, existence, validity or termination, or the scope or applicability of this Agreement to arbitrate, shall be finally settled
              under the Arbitration Rules of the London Court of International Arbitration (LCIA) (the &#8220;<font style="font-weight: bold;">Rules</font>&#8221;) by a tribunal comprised of three (3) arbitrators. Each Party shall nominate one arbitrator and the two
              Party-nominated arbitrators shall nominate the third arbitrator, who shall serve as the presiding arbitrator, within [*] days after the second arbitrator&#8217;s appointment.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z7d6f7e5ec17a4c4e8c563c63fd0ee7c5" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">27.3.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>The seat, or legal place, of arbitration shall be London, UK. The language of the arbitration shall be English. The arbitral award shall be final and binding on the Parties, and the Parties undertake to carry out any award without delay.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z1631b1d1c0e741728222ad349f62ac8b" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">27.3.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Judgment on the award may be entered in any court of competent jurisdiction.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="z497cbe1276e54de58f7149034890af0c" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">27.3.3</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Each Party retains the right to apply to any court of competent jurisdiction for interim and/or conservatory measures, including pre-arbitral attachments or preliminary injunctions, and any such request shall not be deemed incompatible
              with, or a waiver of, this agreement to arbitrate.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table id="za0a1a56a29184125829c7814b7435668" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">27.3.4</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>The existence and content of the arbitral proceedings and any rulings or awards shall be kept confidential by the Parties and members of the arbitral tribunal except (i) to the extent that disclosure may be required of a Party to fulfil a
              legal duty, protect or pursue a legal right, or enforce or challenge an award in bona fide legal proceedings before a state court or other judicial authority, (ii) with the consent of all Parties, (iii) where needed for the preparation or
              presentation of a claim or defense in this arbitration, (iv) where such information is already in the public domain other than as a result of a breach of this clause, or (v) by order of the arbitral tribunal upon application of a Party.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">49</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" id="zf6acbb7eac8c40189a116e4137d49034" class="DSPFListTable" cellpadding="0" cellspacing="0">

          <tr style="vertical-align: top;">
            <td style="text-align: right; vertical-align: top; width: 36pt;">
              <div style="text-align: left;"><font style="font-weight: bold; color: rgb(0, 0, 0);">28.</font></div>
            </td>
            <td style="text-align: left; vertical-align: top; width: auto;">
              <div><font style="font-weight: bold;">CONTRACTS (RIGHTS OF THIRD PARTIES) ACT 1999</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <table id="z33a299a138bf425fb2e126f7cd7b4be6" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">28.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Save that CRUK may enforce Clauses 9.1, 11.1 and 26.4, and CRUK and ICR&#8217;s and CRT&#8217;s respective officers, employees and agents may enforce Clauses 9.1 and 11.1, no term of this Agreement is enforceable under the Contracts (Rights of Third
              Parties) Act 1999 by a person who is not a party to this Agreement. Notwithstanding the provisions of this Clause 28.1, the Parties shall be entitled to amend, suspend, cancel or terminate this Agreement or any part of it in accordance with
              Clause 18, without the consent of any Third Party including those referred to in this Clause 28.1.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">50</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify;">The Parties hereby execute this Agreement by their duly authorised representatives:</div>
    <div>&#160;</div>
    <div style="text-align: justify;">For <font style="font-weight: bold;">CRT PIONEER FUND LP acting by CRT Pioneer GP Limited its general partner</font></div>
    <div>&#160;</div>
    <table id="ze2ff14406f1c4d58a0427c57996cff76" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 7%; vertical-align: top;">
            <div>Signature:</div>
          </td>
          <td style="width: 28%; vertical-align: top; border-bottom: 2px solid black;">
            <div>/s/ Ian Miscampbell</div>
          </td>
          <td style="width: 65%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 28%; vertical-align: top;">&#160;</td>
          <td style="width: 65%; vertical-align: top;">&#160;</td>
        </tr>

    </table>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 5%; vertical-align: top;">
            <div>Name:</div>
          </td>
          <td style="width: 30%; vertical-align: top; border-bottom: 2px solid black;">
            <div>Ian Miscampbell</div>
          </td>
          <td style="width: 65%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;">&#160;</td>
          <td style="width: 30%; vertical-align: top;">&#160;</td>
          <td style="width: 65%; vertical-align: top;">&#160;</td>
        </tr>

    </table>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 4%; vertical-align: top;">
            <div>Title:</div>
          </td>
          <td style="width: 31%; vertical-align: top; border-bottom: 2px solid black;">
            <div>Director</div>
          </td>
          <td style="width: 65%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 4%; vertical-align: top;">&#160;</td>
          <td style="width: 31%; vertical-align: top;">&#160;</td>
          <td style="width: 65%; vertical-align: top;">&#160;</td>
        </tr>

    </table>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 58.74%; vertical-align: top;" rowspan="1">
            <div>For <font style="font-weight: bold;">TREELINE BIOSCIENCES, INC.</font></div>
          </td>
        </tr>

    </table>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 28%; vertical-align: top;">&#160;</td>
          <td style="width: 65%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top;">
            <div>Signature:</div>
          </td>
          <td style="width: 28%; vertical-align: top; border-bottom: 2px solid black;">
            <div>/s/ Joshua H. Bilenker</div>
          </td>
          <td style="width: 65%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 28%; vertical-align: top;">&#160;</td>
          <td style="width: 65%; vertical-align: top;">&#160;</td>
        </tr>

    </table>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 5%; vertical-align: top;">
            <div>Name:</div>
          </td>
          <td style="width: 30%; vertical-align: top; border-bottom: 2px solid black;">
            <div>Joshua H. Bilenker</div>
          </td>
          <td style="width: 65%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;">&#160;</td>
          <td style="width: 30%; vertical-align: top;">&#160;</td>
          <td style="width: 65%; vertical-align: top;">&#160;</td>
        </tr>

    </table>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 4%; vertical-align: top;">
            <div>Title:</div>
          </td>
          <td style="width: 31%; vertical-align: top; border-bottom: 2px solid black;">
            <div>CEO</div>
          </td>
          <td style="width: 65%; vertical-align: top;">&#160;</td>
        </tr>

    </table>
    <div><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">51</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: center; font-weight: bold;">SCHEDULE 1</div>
    <div style="text-align: center; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; font-weight: bold;">INTELLECTUAL PROPERTY</div>
    <div>&#160;</div>
    <div style="text-align: center;">[Intentionally omitted]</div>
    <div><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">52</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: center; font-weight: bold;">SCHEDULE 2</div>
    <div style="text-align: center; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; font-weight: bold;">CONFIRMATORY PATENT LICENCE</div>
    <div>&#160;</div>
    <div style="text-align: center;">[Intentionally Omitted]</div>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">53</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: center; font-weight: bold;">SCHEDULE 3</div>
    <div style="text-align: center; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; font-weight: bold;">TARGET PATENT COUNTRIES</div>
    <div>&#160;</div>
    <div style="text-align: center;">[Intentionally Omitted]</div>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">54</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: center; font-weight: bold;">SCHEDULE 4</div>
    <div>&#160;</div>
    <div style="text-align: center; font-weight: bold;">MILESTONE PAYMENTS</div>
    <div>&#160;</div>
    <div style="text-align: center;">[Intentionally omitted]</div>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">55</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: center; font-weight: bold;">SCHEDULE 5</div>
    <div>&#160;</div>
    <div style="text-align: center; font-weight: bold;">SUB-LICENCE PROVISIONS</div>
    <div>&#160;</div>
    <div style="text-align: center;">[Intentionally omitted]</div>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">56</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: center; font-weight: bold;">SCHEDULE 6</div>
    <div>&#160;</div>
    <div style="text-align: center; font-weight: bold;">PROGRESS REPORT</div>
    <div>&#160;</div>
    <div style="text-align: center;">[Intentionally omitted]</div>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">57</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: center; font-weight: bold;">SCHEDULE 7</div>
    <div>&#160;</div>
    <div style="text-align: center; font-weight: bold;">RESERVED RIGHTS</div>
    <div>&#160;</div>
    <div style="text-align: center;">[Intentionally omitted]</div>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">58</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: center; font-weight: bold;">SCHEDULE 8</div>
    <div>&#160;</div>
    <div style="text-align: center; font-weight: bold;">THIRD PARTY AGREEMENTS</div>
    <div>&#160;</div>
    <div style="text-align: center;">[Intentionally Omitted]</div>
    <div>&#160;</div>
    <div> <br>
    </div>
    <div style="text-align: center;"><font style="font-size: 8pt;">59</font><br>
    </div>
    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>ny20077604x1_ex10-2.htm
<DESCRIPTION>EXHIBIT 10.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 26.3.2.5342
         Copyright 1995 - 2026 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <!--PROfilePageNumberReset%Num%1%%%-->
  <div>
    <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">
    <div style="text-align: right;"> <font style="font-weight: bold;">Exhibit 10.2</font><br>
    </div>
    <div> <br>
    </div>
    <div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO TREELINE BIOSCIENCES, INC. IF
        PUBLICLY DISCLOSED.</div>
      <div><br>
      </div>
      <div style="text-align: center; margin-right: 3pt; font-weight: bold;">EXCLUSIVE LICENSE AGREEMENT</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">This EXCLUSIVE LICENSE AGREEMENT (this &#8220;<font style="font-weight: bold; font-style: italic;">Agreement</font>&#8221;) is entered into as of February 9, 2023 (the &#8220;<font style="font-weight: bold; font-style: italic;">Effective Date</font>&#8221;), by and between <font style="font-weight: bold;">TREELINE BIOSCIENCES, INC.</font>, a Delaware corporation with an office at 677 Washington Blvd., Ste 525, Stamford, Connecticut 06901, U.S.A. (&#8220;<font style="font-weight: bold; font-style: italic;">Treeline</font>&#8221;) and <font style="font-weight: bold;">JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.</font>, a Chinese corporation with offices at 7 Kunlunshan Road, Economy and Technology Development
        Zone, Lianyungang, Jiangsu, P.R.C. (&#8220;<font style="font-weight: bold; font-style: italic;">Hengrui</font>&#8221;). Treeline and Hengrui are referred to individually as a &#8220;<font style="font-weight: bold; font-style: italic;">Party</font>&#8221; and collectively
        as the &#8220;<font style="font-weight: bold; font-style: italic;">Parties</font>.&#8221;</div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">RECITALS</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">WHEREAS</font><font style="font-size: 10pt;">, Treeline is a pharmaceutical company in the business of developing and
          commercializing therapeutic products;</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">WHEREAS</font><font style="font-size: 10pt;">, Hengrui has developed and controls a program involving enhancer of zeste homolog 2
          (EZH2) as a drug target (&#8220;<font style="font-weight: bold; font-style: italic;">EZH2 Program</font>&#8221;) and certain candidate drug compounds directed to such target, including the compound designated as SHR2554; and</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">WHEREAS</font><font style="font-size: 10pt;">, Treeline wishes to obtain an exclusive license to Exploit the Licensed Product in
          the Territory (with each capitalized term as respectively defined below), and Hengrui wishes to grant to Treeline such license.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">NOW, THEREFORE</font><font style="font-size: 10pt;">, in consideration of the foregoing premises and the mutual covenants and
          agreements contained herein, the Parties hereby agree as follows:</font></div>
      <div>&#160;</div>
      <div style="text-align: center; font-size: 12pt; font-weight: bold;"><font style="font-size: 10pt; color: rgb(0, 0, 0);">ARTICLE 1</font><font style="font-size: 10pt;"><br>
          DEFINITIONS</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.1</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Accounting Standards</font>&#8221; means U.S. generally accepted
        accounting principles (&#8220;<font style="font-weight: bold; font-style: italic;">GAAP</font>&#8221;) or, to the extent that Hengrui adopts International Financial Reporting Standards (&#8220;<font style="font-weight: bold; font-style: italic;">IFRS</font>&#8221;), then
        &#8220;Accounting Standards&#8221; means IFRS, in either case consistently applied.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.2</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>[*].</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.3</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Acquiring Entity</font>&#8221; means a Third Party that acquires
        a Party (and is therefore deemed to be an Affiliate of such Party) through a Change of Control, together with any Affiliates of such Third Party. For purposes of clarity, an &#8220;Acquiring Entity&#8221; of a Party shall exclude the Party and all of its
        Affiliates existing immediately prior to the consummation of the Change of Control.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.4</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Acquiror Additional Product</font>&#8221; has the meaning set
        forth in Section 2.4.3.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <font style="font-weight: bold; color: rgb(0, 0, 0);"> </font>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.5</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">&#8220;<font style="font-weight: bold; font-style: italic;">Acquiror Program</font>&#8221; has the meaning set forth in Section 2.4.3.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.6</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Additional Product</font>&#8221; means any product or compound,
        other than a Licensed Compound or Licensed Product, that targets EZH2 [*].</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.7</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Adverse Event</font>&#8221; means any unwanted or harmful medical
        occurrence in a patient or subject who is administered any Licensed Product, whether or not considered related to any Licensed Product, including any undesirable sign (including abnormal laboratory findings of clinical concern).</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.8</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Affiliate</font>&#8221; means, with respect to a Person, any
        current or future Person that, directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with that Person.&#160; For purposes of this definition, &#8220;control&#8221; means: (a) the possession, directly or
        indirectly, of the power to direct the management or policies of a Person, whether through ownership of voting securities, by contract or otherwise, or (b) the ownership, directly or indirectly, of fifty percent (50%) or more of the total voting
        securities of, or other evidences of ownership interest in, such Person.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.9</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Alliance Manager</font>&#8221; has the meaning set forth in
        Section 3.1.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.10</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Anti-Corruption Laws</font>&#8221; has the meaning set forth in
        Section 10.6.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.11</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">API</font>&#8221; means active pharmaceutical ingredient.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.12</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">&#8220;<font style="font-weight: bold; font-style: italic;">Applicable Law</font>&#8221; means, with respect to any Party or other Person, any and all law (statutory, common or
        otherwise), constitution, treaty, convention, directive, ordinance, code, rule, regulation, executive order, injunction, judgment, decree, ruling or other similar requirement enacted, adopted, promulgated or applied by a Governmental Authority that
        is binding upon or applicable to such Party or Person.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.13</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Arising IP</font>&#8221; has the meaning set forth in Section
        8.1.1.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.14</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Background IP</font>&#8221; means all Know-How and Intellectual
        Property Controlled by a Party or its Affiliates (a) as of the Effective Date or (b) acquired or developed by such Party or its Affiliates outside of the scope of this Agreement during the Term.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.15</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Back-up Compound</font>&#8221; means any compound (if any) that
        targets EZH2 and is Controlled by Hengrui as of the Effective Date, including any compound having the chemical structure(s) and code number(s) set forth in Section II (Back-up Compounds) of <u>Exhibit A</u>.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.16</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">[*].</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.17</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>[*].</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.18</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>[*].</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.19</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>[*].</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">2</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.20</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>[*].</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.21</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>[*].</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.22</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>[*].</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.23</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Business Day</font>&#8221; means any day other than a Saturday, a
        Sunday or a day on which banks in New York, New York, U.S.A. or in Shanghai, P.R.C. are authorized or obligated by law or governmental order to close.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.24</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Calendar Quarter</font>&#8221; means each period of three (3)
        consecutive calendar months, ending March 31, June 30, September 30, and December 31.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.25</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Calendar Year</font>&#8221; means the period of time beginning on
        January 1 and ending December 31, except for (a) the first year which shall begin on the Effective Date and end on December 31 and (b) any year in which this Agreement is terminated or expires prior to December 31, in which case the Calendar Year
        shall be from January 1 of that year to the date of expiration or termination.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.26</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Change of Control</font>&#8221; means with respect to either
        Party: (a) the sale of all or substantially all of such Party&#8217;s assets or business relating to this Agreement (other than to an Affiliate of such Party); (b) a merger, reorganization or consolidation involving such Party in which the voting
        securities of such Party outstanding immediately prior thereto cease to represent at least fifty percent (50%) of the combined voting power of the surviving entity immediately after such merger, reorganization or consolidation; or (c) a Person, or
        group of Persons, acting in concert acquire more than fifty percent (50%) of the voting equity securities or management control of such Party.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.27</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">China Licensee</font>&#8221;<font style="font-weight: bold; font-style: italic;">&#160;</font>has the meaning set forth in Section 9.2.11.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.28</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Clinical Supply Agreement</font>&#8221;<font style="font-weight: bold; font-style: italic;">&#160;</font>has the meaning set forth in Section<font style="font-weight: bold; font-style: italic;">&#160;</font>5.1.1.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.29</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">CMC Information</font>&#8221; means Know-How related to the
        chemistry, manufacturing and controls of the Licensed Compounds and Licensed Products, as specified by the FDA or other applicable Regulatory Authorities.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.30</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">CMO</font>&#8221; has the meaning set forth in Section 2.2.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.31</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Combination Product</font>&#8221; means any product that contains
        or is comprised of (a) [*]; (b) [*]; or (c) [*].&#160; Any part of the Combination Product other than the Licensed Compound is referred to as &#8220;<font style="font-weight: bold; font-style: italic;">Other Product</font>&#8221;.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.32</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Commercialization</font>&#8221; means all activities undertaken
        before and after obtaining Regulatory Approvals relating specifically to the pre-launch, launch, promotion, detailing, medical education and medical liaison activities, marketing, pricing, reimbursement, sale, and distribution of pharmaceutical or
        biologic products, including strategic marketing, sales force detailing, advertising, marketing support, all customer support, product distribution and invoicing and sales activities; <font style="font-style: italic;">provided, however</font>, &#8220;<font style="font-weight: bold; font-style: italic;">Commercialization</font>&#8221; shall exclude any activities relating to the Manufacture of product.&#160; &#8220;<font style="font-weight: bold; font-style: italic;">Commercialize</font>&#8221; and &#8220;<font style="font-weight: bold; font-style: italic;">Commercializing</font>&#8221; shall have the correlative meanings.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">3</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.33</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">&#8220;<font style="font-weight: bold; font-style: italic;">Commercialization Plan</font>&#8221; has the meaning set forth in Section 4.3.2.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.34</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Commercialization Report</font>&#8221; has the meaning set forth
        in Section 4.3.2.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.35</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Commercialization Wind-Down Period</font>&#8221;<font style="font-weight: bold; font-style: italic;">&#160;</font>has the meaning set forth in Section 13.6.2.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.36</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Commercial</font><font style="font-style: italic;">&#160;</font><font style="font-weight: bold; font-style: italic;">Supply Agreement</font>&#8221; has the meaning set forth in Section 5.1.2.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.37</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Commercially Reasonable Efforts</font>&#8221; [*].</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.38</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Confidential Information</font>&#8221; of a Party means any and
        all information of such Party or its Affiliates that is disclosed to the other Party or its Affiliates in connection with this Agreement, which if disclosed in tangible form is marked &#8220;Confidential&#8221; or with other similar designation to indicate its
        confidential or proprietary nature or if disclosed orally is indicated orally to be confidential or proprietary by the Party disclosing such information at the time of such disclosure, provided that any information that is not marked or identified
        as &#8220;Confidential&#8221; will be considered as Confidential Information if the information would otherwise reasonably be understood to be confidential or proprietary in light of the nature of the information and the circumstances of its disclosure.&#160; For
        clarity, all Licensed Know-How provided by Hengrui are considered Confidential Information of Hengrui, whether or not marked or identified as &#8220;Confidential.&#8221;&#160; Each Party will be considered a disclosing Party and a receiving Party with regard to
        Joint Know-How and the terms of this Agreement. All reports, plans, summaries and other information provided by Treeline to Hengrui pursuant to this Agreement, including information provided under Sections 2.8 (Arising IP Update), 2.10 (Right of
        First Negotiation), 3.2.2(b) (Development Plan), 4.2.2 (Right of Reference), 4.3.2 (Commercialization Plan and Report) and under Article 7 (Accounting and Reporting), will each be the Confidential Information of Treeline.&#160; In addition, all
        information disclosed by a Party or its Affiliates pursuant to the Confidential Disclosure Agreement between Hengrui and Treeline dated June 16, 2021 (the &#8220;<font style="font-weight: bold; font-style: italic;">Confidentiality Agreement</font>&#8221;) or
        the Material Transfer Agreement between Hengrui and Treeline dated December 6, 2022 (the &#8220;<font style="font-weight: bold; font-style: italic;">MTA</font>&#8221;) shall be deemed to be Confidential Information of such Party disclosed hereunder; provided,
        however, that any use or disclosure of any such information that is authorized under Article 11 shall not be restricted by, or be deemed a violation of, the Confidentiality Agreement or the MTA.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.39</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">&#8220;<font style="font-weight: bold; font-style: italic;">Confidentiality Agreement</font>&#8221; has the meaning set forth in Section 1.38.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.40</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Control</font>&#8221; (and &#8220;<font style="font-weight: bold; font-style: italic;">Controls</font>&#8221; &#8220;<font style="font-weight: bold; font-style: italic;">Controlled</font>&#8221; or &#8220;<font style="font-weight: bold; font-style: italic;">Controlling</font>&#8221;) means with respect to any materials, Patents, Know-How or
        Intellectual Property, the ability or possession of rights (whether by ownership, license or otherwise, other than pursuant to this Agreement), whether directly or indirectly, to grant access to or a license, sublicense or other rights of, to or
        under, such materials, Patents, Know-How or Intellectual Property without breaching the terms of any agreement with any Third Party.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">4</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.41</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Cover</font>&#8221; (and &#8220;<font style="font-weight: bold; font-style: italic;">Covered</font>,&#8221; &#8220;<font style="font-weight: bold; font-style: italic;">Coverage</font>&#8221; or &#8220;<font style="font-weight: bold; font-style: italic;">Covering</font>&#8221;) means, as to a product, compound, formulation or process and
        certain Patent(s), that, in the absence of a license granted under, or ownership of, such Patent(s), the making, using, selling, offering for sale, importation or other Exploitation of such product, compound, formulation or process would infringe,
        violate or misappropriate such Patent(s) or, as to a pending claim in a patent application included in such Patent(s), the making, using, selling, offering for sale or importation of such product, compound, formulation or process would infringe
        such Patent(s) if such pending claim were to issue in an issued patent without modification. The determination of whether a product, compound, formulation or process is Covered by particular Patent(s) shall be made on a country-by-country basis.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.42</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">CRO(s)</font>&#8221; has the meaning set forth in Section 2.1.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.43</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Data</font>&#8221; means any and all data, including CMC
        Information, non-clinical data, preclinical data and clinical data, generated in connection with the Licensed Compounds, Licensed Products, or the Development and Manufacturing thereof.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.44</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Development</font>&#8221; means all internal and external
        research, development, and regulatory activities related to pharmaceutical or biologic products, including (a) research, nonclinical testing, toxicology, testing and studies, non-clinical and preclinical activities, and clinical trials, and (b)
        preparation, submission, review, and development of data or information for the purpose of submission to a Regulatory Authority to obtain authorization to conduct clinical trials and to obtain, support or maintain Regulatory Approval of a
        pharmaceutical or biologic product, but excluding activities that are directed to Manufacturing or Commercialization.&#160; Development will include development and regulatory activities for additional forms, formulations or indications for a
        pharmaceutical or biologic product after receipt of Regulatory Approval of such product (including label expansion), including clinical trials initiated following receipt of Regulatory Approval or any clinical trial to be conducted after receipt of
        Regulatory Approval that was mandated by the applicable Regulatory Authority as a condition of such Regulatory Approval with respect to an approved formulation or indication (such as post-marketing studies and observational studies, if required by
        any Regulatory Authority in any region in the Territory to support or maintain Regulatory Approval for a pharmaceutical or biologic product in such region).&#160; &#8220;<font style="font-weight: bold; font-style: italic;">Develop</font>,&#8221; &#8220;<font style="font-weight: bold; font-style: italic;">Developing</font>,&#8221; and &#8220;<font style="font-weight: bold; font-style: italic;">Developed</font>&#8221; will be construed accordingly.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.45</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Development Plan</font>&#8221; has the meaning set forth in
        Section 3.2.2(b).</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.46</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Distributor</font>&#8221; means any Third Party wholesaler or
        distributor or other subcontractor (including any Third Party subcontractor providing services such as logistics, storage, warehousing, dose preparation, shipping, or other distribution activities in connection with the Development or
        Commercialization of a Licensed Product) that is engaged by or on behalf of a Party, its Affiliate or their Sublicensee (in the case of Treeline) or China Licensee (in the case of Hengrui), as applicable, for the purpose of selling and distributing
        the Licensed Product to Third Party customers.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.47</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Dollars</font>&#8221;<font style="font-weight: bold;"> or </font>&#8220;<font style="font-weight: bold;">$</font>&#8221;<font style="font-weight: bold;">&#160;</font>means the legal tender of the U.S.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.48</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">&#8220;<font style="font-weight: bold; font-style: italic;">EMA</font>&#8221; means the European Medicines Agency or any successor entity.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">5</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.49</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">&#8220;<font style="font-weight: bold; font-style: italic;">Excluded Entity</font>&#8221; means a Third Party primarily engaged in the development and commercialization of pharmaceutical
        products that has generated more than [*] of its revenue from the sale of pharmaceutical products in the P.R.C. during the [*]-month period immediately preceding the grant of a Sublicense under Section 2.2 or the assignment of the Agreement under
        Section 14.4, as applicable.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.50</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Executive Officer</font>&#8221; means the Chief Executive Officer
        or head of business development of a Party.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.51</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Expert Determination</font>&#8221; has the meaning set forth in
        Section 1.96(g).</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.52</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Expert Determination Notice</font>&#8221; has the meaning set
        forth in Section 1.96(g).</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.53</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Exploit</font>&#8221; and &#8220;<font style="font-weight: bold; font-style: italic;">Exploitation</font>&#8221; mean to Manufacture, have Manufactured, Develop, and/or Commercialize.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.54</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">EZH2 Program</font>&#8221; has the meaning set forth in Recitals.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.55</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">FDA</font>&#8221; means the United States Food and Drug
        Administration or any successor entity.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.56</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Field</font>&#8221; means all uses and indications.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.57</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">First Commercial Sale</font>&#8221; means on a country-by-country
        basis, the first sale of a Licensed Product by a Selling Party following the receipt of all Regulatory Approval(s) required for the commercial sale of such Licensed Product in such country.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.58</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Fully Burdened Cost</font>&#8221; [*].</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.59</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Generic Product</font>&#8221; means a product (a) whose active
        pharmaceutical ingredient is rated as equivalent to the Licensed Product being sold in a country, (b) that obtained Regulatory Approval solely by means of establishing such equivalence to such Licensed Product, and (c) that is legally marketed in
        such country by an entity other than a Selling Party hereunder.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.60</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Generic Product Presence</font>&#8221; has the meaning set forth
        in Section 6.5.3.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.61</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Governmental Authority</font>&#8221; means any multi-national,
        transnational, national, federal, state, local, municipal, provincial or other governmental authority of any nature, including any governmental division, prefecture, subdivision, department, agency, bureau, branch, office, commission, council,
        court or other tribunal.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.62</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Greater China</font>&#8221; means mainland China, Taiwan, Hong
        Kong, and Macau.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.63</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Gross Selling Price</font>&#8221;<font style="font-weight: bold; font-style: italic;">&#160;</font>has the meaning set forth in Section 1.96(g).</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.64</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Hengrui Additional Product</font>&#8221;<font style="font-weight: bold; font-style: italic;">&#160;</font>has the meaning set forth in Section 2.4.1.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.65</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Hengrui Additional Product Option</font>&#8221;<font style="font-weight: bold; font-style: italic;">&#160;</font>has the meaning set forth in Section 2.4.1.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">6</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.66</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Hengrui Additional Product Option Period</font>&#8221;<font style="font-weight: bold; font-style: italic;">&#160;</font>has the meaning set forth in Section 2.4.1.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.67</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">&#8220;<font style="font-weight: bold; font-style: italic;">Hengrui Additional Product Option Exercise Notice</font>&#8221; has the meaning set forth in Section 2.4.1.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.68</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Hengrui Disclosed Documents</font>&#8221;<font style="font-weight: bold; font-style: italic;">&#160;</font>has the meaning set forth in Section 9.2.10.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.69</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Hengrui Partner Agreements</font>&#8221; has the meaning set
        forth in Section 9.2.11.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.70</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">IND</font>&#8221; means an Investigational New Drug application,
        or similar application to commence human clinical testing of a Licensed Product submitted to the FDA, or its foreign equivalent.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.71</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Indemnitee</font>&#8221; has the meaning set forth in Section
        12.1.3.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.72</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Indemnitor</font>&#8221; has the meaning set forth in Section
        12.1.3.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.73</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Indirect Taxes</font>&#8221; has the meaning set forth in Section
        6.6.1.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.74</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Infringement</font>&#8221; has the meaning set forth in Section
        8.3.1.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.75</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Insolvency Event</font>&#8221; has the meaning set forth in
        Section 13.3.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.76</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Intellectual Property</font>&#8221;<font style="font-weight: bold; font-style: italic;">&#160;</font>and<font style="font-weight: bold; font-style: italic;">&#160;</font>&#8220;<font style="font-weight: bold; font-style: italic;">IP</font>&#8221; each means any and all rights in Patents, Inventions, Know-How, trade secrets,
        priority rights, copyrights, design rights, Trademarks, and all other intellectual property rights (whether registered or unregistered) and all applications and rights to apply for any of them, anywhere in the world.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.77</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">&#8220;<font style="font-weight: bold; font-style: italic;">Invention</font>&#8221; means any invention, process, method, utility, formulation, formula, composition of matter, article of
        manufacture, material, creation, discovery or finding, or any improvement thereof, whether patentable or otherwise.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.78</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Joint Know-How</font>&#8221; means any Know-How within Arising IP
        generated jointly by both Parties and owned jointly by both Parties in accordance with Section 8.1.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.79</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Joint Patent</font>&#8221; means any Patent that Covers any
        Invention comprising Arising IP under Section 8.1 made or generated jointly by both Parties and owned jointly by both Parties in accordance with Section 8.1.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.80</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Joint Steering Committee</font>&#8221; or the &#8220;<font style="font-weight: bold; font-style: italic;">JSC</font>&#8221; has the meaning set forth in Section 3.2.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.81</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Joint Technology</font>&#8221; means the Joint Know-How and the
        Joint Patents.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.82</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Know-How</font>&#8221; means any and all Inventions, data,
        materials, improvements, protocols, commercial, technical, scientific and other know-how and information of any kind, trade secrets, works of authorship, knowledge, technology, methods, processes, practices, formulae, instructions, skills,
        techniques, procedures, experiences, ideas, technical assistance, designs, drawings, assembly procedures, computer programs, specifications, data and results (including biological, chemical, pharmacological, toxicological, pharmaceutical, physical
        and analytical, preclinical, clinical, safety, manufacturing and quality control data and know-how, including study designs and protocols), including preclinical, clinical, regulatory, manufacturing, marketing, financial and commercial information
        and data, in all cases whether or not patentable or copyrightable in written, electronic or any other form now known or hereafter developed; however &#8220;Know-How&#8221; excludes all information published in Patents and all claims included in Patents.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">7</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.83</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Knowledge</font>&#8221; means the actual knowledge of the
        following individuals of a Party after due inquiry of their direct reports: [*], and individuals with similar positions.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.84</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Late Payment Fee</font>&#8221; has the meaning set forth in
        Section 6.7.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.85</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">&#8220;<font style="font-weight: bold; font-style: italic;">Licensed Compound</font>&#8221; means any chemical compound that is (a) the chemical compound designated by Hengrui as
        &#8220;SHR2554,&#8221; having the chemical structure set forth in <u>Exhibit&#160;A</u>; (b) a Back-Up Compound; or (c) [*]; or (d) [*]. &#8220;<font style="font-weight: bold; font-style: italic;">Licensed Compounds</font>&#8221; means more than one Licensed Compound or all
        Licensed Compounds, as applicable.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.86</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Licensed Compound Arising IP</font>&#8221; has the meaning set
        forth in Section 2.7.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.87</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Licensed Know-How</font>&#8221; means any and all Know-How
        (including Data and Regulatory Materials) that (a) is Controlled in the Field in the Territory by Hengrui or any of its Affiliates as of the Effective Date or becomes Controlled by Hengrui or any of its Affiliates during the Term (excluding
        Know-How that is developed by the Acquiring Entity of Hengrui outside of the scope of this Agreement without using Hengrui&#8217;s Confidential Information or IP), and (b) is necessary or reasonably useful for the Development, Manufacture,
        Commercialization or other Exploitation of the Licensed Compounds or Licensed Products in the Field in the Territory.&#160; Licensed Know-How specifically includes the Know-How described in <u>Exhibit B</u> or the Manufacturing Technology Transfer
        Agreement, and Hengrui&#8217;s joint rights and interest in and to the Joint Know-How. For clarity, Licensed Know-How includes any Know-How that is necessary or reasonably useful for the Exploitation of any Combination Product, other than Know-How that
        is solely and directly relating to the Other Product.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.88</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Licensed Patents</font>&#8221; means any and all Patents that (a)
        are Controlled in the Field in the Territory by Hengrui or any of its Affiliates as of the Effective Date or become Controlled by Hengrui or any of its Affiliates during the Term (excluding Patents that are developed by an Acquiring Entity of
        Hengrui outside of the scope of this Agreement without using Hengrui&#8217;s Confidential Information or IP), and (b) Cover the composition of the Licensed Compounds or Licensed Products or the Development, Manufacture, Commercialization or other
        Exploitation of the Licensed Compounds or Licensed Products in the Field in the Territory. Licensed Patents specifically includes the Patents listed in <u>Exhibit C</u> and Hengrui&#8217;s joint rights and interest in and to the Joint Patents.&#160; For
        clarity, Licensed Patents include any Patents under the preceding subclauses (a) and (b) that are necessary or reasonably useful for the Exploitation of any Combination Product, other than any Patents that Cover solely and directly the Other
        Product.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.89</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Licensed Product</font>&#8221; means any product or component
        that contains or comprises a Licensed Compound.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">8</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.90</font></div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">&#8220;<font style="font-weight: bold; font-style: italic;">Licensed Technology</font>&#8221; means either or both of the Licensed Patents and the Licensed Know-How.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.91</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Major Market</font>&#8221; means any of the U.S., [*], [*], [*],
        [*], [*], [*], and [*].</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.92</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Manufacture</font>&#8221; means all activities and operations
        involved in the manufacturing, filling, finishing, processing, producing, quality control, quality assurance, testing (including inprocess, release, and stability testing), storage, releasing, labeling, post-marketing validation testing, inventory
        control and management, packaging and transporting of a drug product or drug substance, including oversight and management of vendors therefor.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.93</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Manufacturing Technology Transfer Agreement</font>&#8221;<font style="font-style: italic;">&#160;</font>has the meaning set forth in Section 5.2.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.94</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">MTA</font>&#8221; has the meaning set forth in Section 1.38.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.95</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">NDA</font>&#8221;<font style="font-weight: bold;">&#160;</font>means
        an application for approval to market a product commercially such as the New Drug Application filed pursuant to the requirements of the FDA, as more fully defined in 21 CFR.&#167; 314.3 et seq, or a marketing authorization application filed pursuant to
        the requirements of European Directive 2001/ 83/ EC, or any equivalent or similar application filed with any other Regulatory Authority, together, in each case, with all additions, deletions or supplements thereto.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.96</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Net Sales</font>&#8221; means the gross invoiced sales amount of
        Licensed Products billed by a Selling Party for the sale or other commercial disposition of Licensed Products in the Territory during the Term applicable to the country of sale, less the following items listed to the extent actually taken or
        incurred by the Selling Party with respect to such sale:</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;[*];</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;[*];</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;[*];</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;[*];</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">(e)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;[*];</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">(f)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;[*]; and</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">(g)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;[*].</div>
      <div>&#160;</div>
      <div style="text-align: justify;">[*].</div>
      <div>&#160;</div>
      <div style="text-align: justify;">[*].</div>
      <div>&#160;</div>
      <div style="text-align: justify;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;[*].</div>
      <div>&#160;</div>
      <div style="text-align: justify;">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; [*].</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">9</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify;">In the event that Hengrui disputes in good faith (A) the Gross Selling Price for the Licensed Product as determined by Treeline pursuant to the foregoing sub-clause (i) in one or more country(ies), or (B) the Gross
        Selling Price for the Licensed Product and/or the Other Product, as applicable, pursuant to the foregoing sub-clause (ii), then Hengrui shall within [*] days following receipt of the applicable Royalty Report provide written notice to Treeline (&#8220;<font style="font-weight: bold; font-style: italic;">Expert Determination Notice</font>&#8221;) requesting the matter (i.e., the determination of the Gross Selling Price for the Licensed Product and/or the Other Product, as applicable) (as applicable, the &#8220;<font style="font-weight: bold; font-style: italic;">Pricing Matter</font>&#8221;) to be submitted for determination (&#8220;<font style="font-weight: bold; font-style: italic;">Expert Determination</font>&#8221;) by a single expert who shall be an independent expert
        with at least fifteen (15) years of experience in the business of commercializing pharmaceutical products who is mutually acceptable to the Parties. If the Parties are unable to agree on an expert, the expert shall be an independent expert as
        described in the preceding sentence selected by the Arbitration Institute of the Stockholm Chamber of Commerce (&#8220;<font style="font-weight: bold; font-style: italic;">SCC</font>&#8221;). Each Party shall prepare and submit to the expert a written document
        setting forth its position with respect to the applicable Pricing Matter, together with any relevant information, within [*] days after the expert has been selected. The expert shall review each such document and information and shall have an
        opportunity to ask questions about the foregoing of each Party, provided that the expert shall complete and communicate to the Parties the Expert Determination within [*] days from submission to the expert of the documents and information described
        above. The Expert Determination shall be final and conclusive as to the applicable Pricing Matter and, provided that Treeline does not materially change A (except for commercially reasonable adjustments, e.g. inflation), or the allocation of Net
        Sales for the Licensed Product, then Hengrui may not request more than one (1) Expert Determination for any given Combination Product and country(ies). The Parties shall each bear their own costs with respect to the Expert Determination, and shall
        bear equally the cost of retaining the expert.</div>
      <div>&#160;</div>
      <div style="text-align: justify;">No later than [*] days prior to the First Commercial Sale of any Combination Product, Treeline will notify Hengrui of its proposed sale of the Combination Product, including the country where the sale is proposed to
        take place, the proposed Gross Selling Price of the Combination Product (as applicable) including, to the extent applicable and available, the Gross Selling Price of the Licensed Product and Other Product of the Combination Product in such country.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.97</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">&#8220;<font style="font-weight: bold; font-style: italic;">NMPA</font>&#8221; means the National Medical Products Administration of the P.R.C., formerly known as the China National Drug
        Administration, or any successor agency or authority thereto.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.98</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Patents</font>&#8221; means any and all (a) issued or granted
        patents; (b) all patents-of addition, extensions or restorations by existing or future extension or restoration mechanisms, including, supplemental protection certificates or the equivalent thereof, registrations, confirmations, reissues,
        reexaminations or renewals thereof; (c) pending patent applications, including all provisional applications, additions, divisions, continuations, continuations-in-part, substitutions, and renewals and all patents granted thereon; (d) inventor&#8217;s
        certificates; (e) any other form of government-issued right substantially similar to any of the foregoing; and (f) all U.S. counterparts and foreign equivalents of any of the foregoing.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.99</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Patent Term Extensions</font>&#8221;<font style="font-weight: bold; font-style: italic;">&#160;</font>has the meaning set forth in Section 8.4.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">10</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.100</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Person</font>&#8221; means an individual, corporation,
        partnership, limited partnership, limited liability partnership, limited liability company, trust, business trust, association, joint stock company, joint venture, pool, syndicate, sole proprietorship, unincorporated organization, Governmental
        Authority or any other form of private, public, or Governmental Authority not specifically listed herein.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.101</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Pharmacovigilance Agreement</font>&#8221; has the meaning set
        forth in Section 4.5.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.102</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">P.R.C.</font>&#8221; means People&#8217;s Republic of China.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.103</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Pricing Matter</font>&#8221; has the meaning set forth in Section
        1.96(g).</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.104</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Prosecute</font>&#8221; means to have primary responsibility for
        preparing, filing, prosecuting (including interference and opposition proceedings) and maintaining (including interferences, reissue, re-examination, post-grant reviews, inter-partes reviews, derivation proceedings and opposition proceedings)
        Patents.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.105</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Regulatory Approval</font>&#8221; means with respect to a
        country, extra-national territory, province, state, or other regulatory jurisdiction, any and all approvals, licenses, registrations or authorizations of any Regulatory Authority necessary in order to Exploit a product in such country, state,
        province, or some or all of such extra-national territory or regulatory jurisdiction, which shall include any Reimbursement Approvals.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.106</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">&#8220;<font style="font-weight: bold; font-style: italic;">Regulatory Authority</font>&#8221; means, with respect to a particular country, extra-national territory, province, state, or
        other regulatory jurisdiction, any applicable Governmental Authority involved in granting Regulatory Approval, including but not limited to the FDA and the NMPA, and in each case including any successor thereto.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.107</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Regulatory Materials</font>&#8221; means regulatory applications,
        submissions, dossiers, notifications, registrations, Regulatory Approvals and/or other filings made to or with, or other approvals granted by, a Regulatory Authority that are necessary or reasonably desirable in order to Exploit a Licensed Product
        in a particular country or regulatory jurisdiction, including INDs and NDAs.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.108</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Reimbursement Approval</font><font style="font-weight: bold;">&#8221;</font><font style="font-weight: bold; font-style: italic;">&#160;</font>means, with respect to a Licensed Product, the governmental approval, agreement, determination, or decision establishing the list price or level of reimbursement for such
        Licensed Product, in a given country in the Territory, prior to the sale of the Licensed Product in such country in the Territory.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.109</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Royalty Floor</font>&#8221; has the meaning set forth in Section
        6.5.5.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.110</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Royalty Report</font>&#8221; has the meaning set forth in Section
        7.1.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.111</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Royalty Term</font>&#8221; means, with respect to a given
        Licensed Product sold or commercially distributed in a given country in the Territory, on a country-by-country basis, the time period commencing on the date of the First Commercial Sale of the Licensed Product in such country and ending on the
        later of (i) ten (10) years from such First Commercial Sale, and (ii) the expiration of the last Valid Claim in such country Covering such Licensed Product or its use.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">11</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.112</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">SCC</font>&#8221; has the meaning set forth in Section 1.96(g).</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.113</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Selling Party</font>&#8221; means, as applicable, Treeline, its
        Affiliate, its Sublicensee, or an Affiliate of a Sublicensee, which sells any Licensed Product.&#160; &#8220;Selling Party&#8221; excludes any Distributor.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.114</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Sublicense</font>&#8221; has the meaning set forth in Section
        2.2.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.115</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Sublicensee</font>&#8221; has the meaning set forth in Section
        2.2.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.116</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">&#8220;<font style="font-weight: bold; font-style: italic;">Taxes</font>&#8221; has the meaning set forth in Section 1.96(b).</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.117</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">&#8220;<font style="font-weight: bold; font-style: italic;">Technical Assistance</font>&#8221; has the meaning set forth in Section 2.6.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.118</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Term</font>&#8221;<font style="font-weight: bold; font-style: italic;">&#160;</font>has the meaning set forth in Section 13.1.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.119</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Territory</font>&#8221; means worldwide, excluding the Greater
        China.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.120</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Third Party</font>&#8221; means a Person other than (a) Treeline
        or any of its Affiliates or (b) Hengrui or any of its Affiliates.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.121</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Third Party Agreements</font>&#8221; has the meaning set forth in
        Section 9.2.12(a).</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.122</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Third Party Commercial Supply Agreement</font>&#8221; has the
        meaning set forth in Section 5.1.3.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.123</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Third Party Infringement Claim</font>&#8221; has the meaning set
        forth in Section 8.3.5.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.124</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Trademark</font>&#8221; means any trademark, trade name, service
        mark, service name, brand, domain name, trade dress, logo, slogan or other indicia of origin or ownership, including the goodwill and activities associated with each of the foregoing</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.125</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Treeline Additional Product</font>&#8221;<font style="font-weight: bold; font-style: italic;">&#160;</font>has the meaning set forth in Section 2.4.2.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.126</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Upfront Payment</font>&#8221;<font style="font-weight: bold; font-style: italic;">&#160;</font>has the meaning set forth in Section 6.1.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.127</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">U.S.</font>&#8221; or &#8220;<font style="font-weight: bold; font-style: italic;">U.S.A.</font>&#8221; means the United States of America, including all possessions and territories thereof.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.128</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>&#8220;<font style="font-weight: bold; font-style: italic;">Valid Claim</font>&#8221; means (a) a claim of any pending patent
        application included in the Licensed Patents, which claim Covers the composition of matter or the method of use approved for labeling by the applicable Regulatory Authority for the applicable Licensed Compound or Licensed Product, and [*], and/or
        (b) a claim of an issued and unexpired patent included within the Licensed Patents, which claim Covers (i) the composition of matter or the method of use approved for labeling by the applicable Regulatory Authority for the applicable Licensed
        Compound or Licensed Product, or (ii) (solely if such claim is issued and unexpired as of the Effective Date) the manufacture of the applicable Licensed Compound or Licensed Product, in each case under (i) and (ii), that has not been held
        permanently revoked, unenforceable, or invalid by an unappealable (or unappealed within the time allowed for appeal) decision of a court or other Governmental Authority of competent jurisdiction, and which has not been dedicated to the public,
        abandoned, or admitted to be invalid or unenforceable through reissue or disclaimer or otherwise.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">12</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">1.129</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;">&#8220;<font style="font-weight: bold; font-style: italic;">Withholding Tax</font>&#8221;<font style="font-weight: bold; font-style: italic;">&#160;</font>has the meaning set forth in Section
        6.6.2.</div>
      <div>&#160;</div>
      <div style="text-align: center; font-size: 12pt; font-weight: bold;"><font style="font-size: 10pt; color: rgb(0, 0, 0);">ARTICLE 2</font><font style="font-size: 10pt;"><br>
          LICENSES</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">2.1</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">Licenses to Treeline</font>.&#160; Subject to the terms and conditions of this
        Agreement, Hengrui shall grant and hereby grants to Treeline and its Affiliates, under the Licensed Technology, effective as of the Effective Date, (a) an exclusive (without any reservation by Hengrui or its Affiliates), royalty-bearing license,
        with the right to sublicense (through multiple tiers) solely as contemplated in Section 2.2, to Develop, Manufacture, Commercialize and otherwise Exploit the Licensed Compounds and Licensed Products, including as part of a Combination Product, in
        the Field in the Territory, and (b) a non-exclusive and royalty-free license, with the right to sublicense (through multiple tiers) as contemplated in Section 2.2, to conduct preclinical studies in the Greater China with respect of the Licensed
        Compounds and Licensed Products through Third Party contract research organization(s) (&#8220;<font style="font-weight: bold; font-style: italic;">CRO(s)</font>&#8221;) located in the Greater China solely for the Exploitation of the Licensed Compounds and
        Licensed Products, including as part of a Combination Product, in the Field in the Territory; provided that Treeline shall, before engaging any such CRO(s) for pre-clinical studies in the Greater China, provide to Hengrui written notice identifying
        such CRO(s).&#160; Treeline shall remain responsible and liable for all actions and omissions of its Affiliates with respect to exercise of any rights under this Agreement, which if they were actions or omissions of Treeline would be a breach of this
        Agreement, and for all of its obligations under this Agreement that have been delegated to such Affiliates.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">2.2</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">Sublicensing by Treeline. </font> Treeline and its Affiliates shall have the right to grant sublicenses (through multiple tiers) (including
        any option to obtain a sublicense, each a &#8220;<font style="font-weight: bold; font-style: italic;">Sublicense</font>&#8221;) to any Third Party that is not an Excluded Entity at the time of the Sublicense grant (each such Third Party, a &#8220;<font style="font-weight: bold; font-style: italic;">Sublicensee</font>&#8221;), under the license set forth in Section 2.1.&#160; Neither Treeline nor any of its Affiliates shall have the right to grant any Sublicense to any Excluded Entity without Hengrui&#8217;s
        prior consent, not to be unreasonably withheld. Each Excluded Entity approved by Hengrui to receive a Sublicense shall be deemed a Sublicensee.&#160; Each Sublicensee shall be subject to a written agreement that is consistent with the terms and
        conditions of this Agreement, including but not limited to any restrictions regarding use of Licensed Technology, confidentiality obligations, license to Licensed Compound Arising IP (subject to Section 2.7). Treeline shall within [*] days
        following the execution of each Sublicense, provide Hengrui with written notice of the grant of such Sublicense and provide Hengrui with a copy of the Sublicense agreement (which may have financial information and other confidential information
        redacted).&#160; Treeline shall remain responsible and liable for all actions and omissions of any Sublicensee with respect to exercise of any rights under this Agreement that are sublicensed to such Sublicensee and all of its obligations under this
        Agreement that have been delegated to such Sublicensee.&#160; Any Sublicensee conduct, act, or omission that would have constituted a breach of this Agreement shall be imputed to Treeline and deemed a breach of this Agreement as if such conduct, act, or
        omission had been directly attributable to Treeline.&#160; Treeline shall not grant a Sublicense to any Sublicensee that has been debarred or disqualified by a Regulatory Authority. For clarity, and subject to Section 2.3, none of the following Third
        Parties will be deemed a Sublicensee: (a) any Distributor, (b) any CRO or contractor providing services to Develop Licensed Product, including for proof of concept studies and clinical trials, (c) any Third Party contract manufacturing
        organizations (&#8220;<font style="font-weight: bold; font-style: italic;">CMO</font>&#8221;) engaged to Manufacture a Licensed Compound and/or Licensed Product.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">13</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">2.3</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">Subcontractors.&#160; </font>Either Party may exercise its licensed rights in the
        Licensed Technology (in the case of Treeline as the licensee) or Licensed Compound Arising IP (in the case of Hengrui as the licensee) under this Agreement through one or more Distributors, CROs, CMOs or other Third Party contractors or consultants
        without meeting the requirements of Section 2.2 (in the case of Treeline as the licensee) or the third sentence in Section 2.7 (in the case of Hengrui as the licensee), provided that (a) each Party as the licensee remains responsible for any
        obligations that have been delegated or subcontracted to any such Distributors, CROs, CMOs, contractors or consultants, and the performance of such activities by such Distributors, CROs, CMOs, contractors and consultants in accordance with the
        terms of this Agreement, and (b) the Distributors, CRO, CMO, contractor or consultant undertakes in writing obligations of confidentiality and non-use regarding Confidential Information, Licensed Technology, or the Licensed Compound Arising IP (as
        applicable) that are substantially the same as those undertaken by the Parties under this Agreement, including pursuant to Article 11 hereof.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">2.4</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">Additional Product</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">2.4.1</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>If Hengrui or any of its Affiliates establishes an internal program for an Additional Product or otherwise
        obtains Control of an Additional Product (&#8220;<font style="font-weight: bold; font-style: italic;">Hengrui Additional Product</font>&#8221;) during the Term, Hengrui shall promptly provide Treeline written notice thereof; and Hengrui agrees to grant and
        hereby grants to Treeline and its Affiliates, an exclusive first option, exercisable in Treeline&#8217;s sole discretion at any time during the period of [*] years following the date of Treeline&#8217;s receipt of such notice (the &#8220;<font style="font-weight: bold; font-style: italic;">Hengrui Additional Product Option Period</font>&#8221;), to include such Hengrui Additional Product within the scope and meaning of the Licensed Compound or Licensed Product, as applicable, under the terms of this Agreement
        (the &#8220;<font style="font-weight: bold; font-style: italic;">Hengrui Additional Product Option</font>&#8221;). Hengrui shall promptly provide Treeline throughout the Term, any and all material data generated by or on behalf of Hengrui or such Affiliates
        with respect to the Hengrui Additional Product. In the event that Treeline elects to exercise the Hengrui Additional Product Option, it shall prior to the end of the applicable Hengrui Additional Product Option Period provide Hengrui notice in
        writing specifying that Treeline has elected to exercise the Hengrui Additional Product Option (&#8220;<font style="font-weight: bold; font-style: italic;">Hengrui Additional Product Option Exercise Notice</font>&#8221;).&#160; For the avoidance of doubt and
        without limiting Section 2.1, for each Hengrui Additional Product that Treeline has exercised the Hengrui Additional Product Option, such Hengrui Additional Product shall be deemed a Licensed Compound or Licensed Product, as applicable, under the
        terms of this Agreement, provided that Treeline&#8217;s right to grant a sublicense under Section 2.2 to a Sublicensee shall not extend to Hengrui Additional Product unless such Sublicensee agrees to grant a reciprocal license to IP related to the
        Sublicensee&#8217;s Additional Product under Section 2.4.2.&#160; If Treeline does not provide the Hengrui Additional Product Option Exercise Notice within the Hengrui Additional Product Option Period, Treeline shall promptly return to Hengrui (in any event
        within [*] Business Days following the expiration of the Hengrui Additional Product Option Period) any and all material information relating to the Hengrui Additional Product Program directly or indirectly disclosed by or on behalf of Hengrui to
        Treeline, and such Hengrui Additional Product shall not be deemed a Licensed Compound or Licensed Product.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">14</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">2.4.2</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>If Treeline or any of its Affiliates establishes an internal program to develop an Additional Product or
        otherwise obtains Control of an Additional Product (&#8220;<font style="font-weight: bold; font-style: italic;">Treeline Additional Product</font>&#8221;) during the Term, Treeline shall promptly provide Hengrui written notice thereof, and all IP in the
        Greater China pertaining to the Treeline Additional Product (excluding for clarity any IP relating to any other proprietary compounds Controlled by Treeline or its Affiliates, but including any IP pertaining to the combination of the Treeline
        Additional Product with other compounds not Controlled by Treeline or its Affiliates within the same class as Treeline&#8217;s or its Affiliates&#8217; proprietary compound(s)) that is Controlled by Treeline or its Affiliates during the Term will be
        automatically included within the scope and meaning of Licensed Compound Arising IP and subject to the license grant under Section 2.7. For the avoidance of doubt and without limiting Section 2.7, the Treeline Additional Product shall be deemed a
        Licensed Compound and Licensed Product, as applicable, but solely (a) for purposes of determining and triggering milestone payments and royalties under Sections 6.2, 6.3, 6.4, and 6.5, respectively, and (b) for purposes of Sections 2.7, 4.2, 4.6,
        8.2, 8.3, 9.3, 12.1 and Article 7.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">2.4.3</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">Notwithstanding the foregoing, in the event a Party enters into a transaction or series of transaction with a Third Party acquiror that constitutes a Change of Control of
        such Party, then Section 2.4.1 or 2.4.2, as applicable, shall not apply to any Additional Product Controlled by the Acquiring Entity immediately prior to the consummation of the Change of Control or thereafter (each such Additional Product, an &#8220;<font style="font-weight: bold; font-style: italic;">Acquiror Additional Product</font>&#8221;; each such program, an &#8220;<font style="font-weight: bold; font-style: italic;">Acquiror Program</font>&#8221;), provided that (a) all activities relating to the Acquiror
        Program or Acquiror Additional Product were, are, and shall be conducted by such Acquiring Entity independently of any and all activities of this Agreement and without use of any Licensed Technology, Joint Technology or Licensed Compound Arising
        IP, or any Confidential Information specifically relating to the Licensed Compound, as applicable, and (b) no Confidential Information specifically relating to the Licensed Compound, Licensed Technology, Joint Technology or Licensed Compound
        Arising IP, as applicable, were, are, and shall be provided to or shared with any personnel working on the Acquiror Program or Acquiror Additional Product.&#160; Such acquired Party and the Acquiring Entity shall put in place &#8220;firewall&#8221; safeguards
        reasonably designed to ensure compliance with clauses (a) and (b), including between individuals with access to any Confidential Information specifically relating to the Licensed Compound, Licensed Technology, Joint Technology or Licensed Compound
        Arising IP, as applicable, on the one hand, and the personnel involved with the Acquiror Program or the Development, Manufacture or Commercialization of the Acquiror Additional Product, on the other hand. For further clarity, in the event a Party
        enters into a collaboration with a Third Party with respect to the combination of a proprietary compound Controlled by such Party with an Additional Product Controlled by such Third Party or its Affiliates, in no event shall such Additional Product
        be deemed a Hengrui Additional Product or Treeline Additional Product, as applicable, provided that the applicable Party is not granted by such Third Party the right to sell such Additional Product.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">15</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">2.5</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">Transfer of Licensed Technology.&#160; </font>Promptly after the Effective Date and no later than [*] days thereafter, Hengrui shall without
        charge deliver (or have delivered), disclose and make available, and shall procure that its Affiliates deliver, disclose and make available, to Treeline (or its designee), including any designated Third Party subcontractor described under Section
        2.3, all existing Licensed Know-How (including Regulatory Materials), including (a) the clinical and non-clinical data, detailed summaries of data, results, research, analyses, materials, documentation and the items set forth in <u>Exhibit B</u>,
        (b) all technical data and information Controlled by Hengrui or any of its Affiliates that is necessary or reasonably useful for the Development or other Exploitation (except for Manufacturing) of Licensed Compounds and/or Licensed Products or as
        required by any Regulatory Authorities in the Territory to initiate an investigational new drug file or dossier (such as a clinical trial application, IND, IMPD, or the equivalent); and (c) copies (in original language and if already translated, in
        English) of all Regulatory Materials submitted by Hengrui to Regulatory Authority for the Licensed Compounds and/or Licensed Products, and all data, results and information supporting the submissions.&#160; Hengrui shall make such Licensed Know-How and
        Regulatory Materials available to Treeline in original language (and if already translated, in English) in such form as they exist within Hengrui&#8217;s control. If no English translation exists for certain materials within the Licensed Know-How,
        Hengrui shall use Commercially Reasonable Efforts to have such items translated into English, if requested by Treeline, at Treeline&#8217;s sole cost and expense, and provide the translation no later than [*] days after such request.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">2.5.1</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>From time to time during the Term or upon Treeline&#8217;s reasonable request, Hengrui shall promptly provide updates
        and transfer, and shall procure that its Affiliates promptly provide updates and transfer, without charge, throughout the Term to Treeline of any additional Licensed Know-How to the extent not previously delivered and any Licensed Know-How that
        Hengrui or its Affiliates comes to Control.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">2.5.2</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">Any Licensed Know-How or Regulatory Material that is required for submission to Regulatory Authorities in the Territory by Treeline and that was originally created in
        Chinese but if already translated to English will be delivered in both the original Chinese and translated English.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">2.6</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">Technical Assistance</font><font style="font-weight: bold; font-style: italic;">.</font>&#160;
        Hengrui shall, and shall cause its Affiliates to, provide to Treeline (and/or its designee(s)) such reasonable assistance, consultation and cooperation, as Treeline may reasonably request that is necessary to effect the transfer of Licensed
        Technology pursuant to Section 2.5 or as necessary or reasonably useful for the Exploitation of the Licensed Compounds or Licensed Products (collectively, &#8220;<font style="font-weight: bold; font-style: italic;">Technical Assistance</font>&#8221;).&#160; Without
        limiting the foregoing and as a part of the Technical Assistance, Hengrui shall make available to Treeline, including in person or by teleconference, those of Hengrui&#8217;s (or its Affiliate&#8217;s) personnel involved in the Development or Manufacture of
        the Licensed Compounds and/or Licensed Products, as Treeline may reasonably request for purposes of transferring the data, information, documentations and materials to Treeline as set forth in Section 2.5 or the Exploitation of the Licensed
        Compounds or Licensed Products.&#160; All Technical Assistance shall be provided at Hengrui&#8217;s sole cost and expense, [*].</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">16</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">2.7</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">License to Hengrui.&#160; </font>Subject to the terms and conditions of this Agreement, Treeline shall grant and hereby grants to Hengrui and its
        Affiliates, effective as of the Effective Date, (a) under the Licensed Compound Arising IP (as defined below), an exclusive (without any reservation by Treeline or its Affiliates), fully-paid, royalty-free, perpetual (subject to Treeline&#8217;s
        termination right under Section 13.2.1), non-transferable (except as permitted under Section 14.4) license, without the right to sublicense (except as contemplated in this Section) to Develop, Manufacture, Commercialize, and otherwise Exploit the
        Licensed Compounds and Licensed Products, including as part of Combination Products, in the Field in the Greater China; and (b) a non-exclusive and royalty-free license to conduct pre-clinical studies in the Territory with respect of the Licensed
        Compounds and Licensed Products through CRO(s) located in the Territory solely for the Exploitation of the Licensed Compounds and Licensed Products, including as part of a Combination Product, in the Field in the Greater China; provided that
        Hengrui shall, before engaging any such CRO(s) for pre-clinical studies in the Territory, provide to Treeline written notice identifying such CRO(s). Hengrui shall have the right to sublicense the rights granted under this Section solely to a China
        Licensee to whom Hengrui has granted a license to its Intellectual Property relating to the Licensed Compounds and Licensed Products.&#160; Hengrui shall within [*] days following the execution of such license with a China Licensee, provide Treeline
        with written notice of the grant of such license and a copy of the license agreement (which may have financial information and other confidential information redacted). Hengrui shall remain responsible and liable for all actions and omissions of
        its Affiliates and sublicensees with respect to exercise of any rights under this Section. &#8220;<font style="font-weight: bold; font-style: italic;">Licensed Compound Arising IP</font>&#8221; means any (i) [*] or (ii) [*], in each case of (i) or (ii), that
        is Controlled, in the Field in the Greater China, by Treeline or its Affiliates (whether solely or jointly with Hengrui) as of the Effective Date or becomes Controlled, in the Field in the Greater China, by Treeline or any of its Affiliates during
        the Term, and is solely relating to the Licensed Compounds or is necessary for the Exploitation of the Licensed Compounds or Licensed Products, in the Field in the Greater China, including any such Arising IP or Acquired IP that is necessary for
        the Exploitation of any Combination Product in the Field in the Greater China (excluding however, any IP relating to any proprietary compound(s) Controlled by Treeline or its Affiliates). For the avoidance of doubt and notwithstanding the
        foregoing, Licensed Compound Arising IP includes [*].&#160; For clarity, in no event shall Hengrui or its Affiliates have any license or other right under this Agreement to Exploit any proprietary compound(s) Controlled by Treeline or its Affiliates
        (other than the rights expressly set forth in Sections 2.4.2 and 2.10). Following the expiration of the Term, the license grant in this Section 2.7(a) shall become non-exclusive.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">2.8</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">Arising IP Update</font>. From time to time or upon Hengrui&#8217;s reasonable
        request, Treeline shall promptly provide updates and transfer, and shall procure that its Affiliates promptly provide updates and transfer, without charge, throughout the Term to Hengrui of any additional Licensed Compound Arising IP and Arising IP
        jointly owned with Hengrui or its Affiliates to the extent not previously delivered and all Licensed Compound Arising IP and any Arising IP jointly owned with Hengrui or its Affiliates that Treeline or its Affiliates or their Sublicensees come to
        Control.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">2.9</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">No Other Licenses</font>.&#160; Neither Party grants to the other Party any rights or licenses in or to any Intellectual Property, whether by
        implication, estoppel, or otherwise, other than the license rights that are expressly granted under this Agreement.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">2.10</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">Right of First Negotiation</font>.&#160; [*].</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">17</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: center; font-size: 12pt; font-weight: bold;"><font style="font-size: 10pt; color: rgb(0, 0, 0);">ARTICLE 3</font><font style="font-size: 10pt;"><br>
          GOVERNANCE</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">3.1</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">Alliance Managers.&#160; </font>Within [*] days following the Effective Date, each Party shall appoint (and notify the other Party in writing of
        the identity of) a representative having the appropriate qualifications to act as its alliance manager under this Agreement (the &#8220;<font style="font-weight: bold; font-style: italic;">Alliance Manager</font>&#8221;).&#160; The Alliance Managers shall serve as
        the primary contact points between the Parties regarding the activities contemplated by this Agreement.&#160; The Alliances Managers shall (a) promote communication and coordination between the Parties, providing a single point of communication for
        seeking consensus both internally within each Party&#8217;s respective organization, including facilitating review of external corporate communications, and raising cross-Party or cross-functional disputes in a timely manner; and (b) manage the JSC
        meetings by (i) calling meetings of the JSC; (ii) preparing and issuing minutes of each meeting within [*] Business Days thereafter; and (iii) preparing and circulating an agenda for the upcoming meeting, in each case at the direction of and in
        consultation with the then-current chairperson of the JSC.&#160; Each Party may replace its Alliance Manager by written notice to the other Party.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">3.2</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">Joint Steering Committee</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">3.2.1</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">Formation</font>.&#160; Within [*] days after the Effective Date, the Parties shall establish a joint steering committee (the &#8220;<font style="font-weight: bold; font-style: italic;">Joint Steering Committee</font>&#8221; or the &#8220;<font style="font-weight: bold; font-style: italic;">JSC</font>&#8221;) to coordinate the Exploitation of the Licensed Products worldwide.&#160; The JSC shall at all
        times consist of an equal number of representatives for each Party. Each Party shall appoint at least two (2) representatives to the JSC, each of whom shall be an officer or employee of such Party having sufficient experience and seniority within
        such Party to make decisions arising within the scope of the JSC&#8217;s responsibilities.&#160; Each Party may replace its JSC representatives upon written notice to the other Party.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">3.2.2</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">Role.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The JSC shall (i) provide a forum for the discussion of the Parties&#8217; activities under this Agreement; (ii) review and
        discuss the overall strategy for the Development of the Licensed Products worldwide; (iii) review, discuss and approve the Development Plan (as defined in Section 3.2.2(b)); (iv) establish subcommittees as necessary or advisable to further the
        purpose of this Agreement; (v) facilitate the exchange of information with respect to the Development, Manufacturing and Commercialization activities relating to the Licensed Products and conducted by or on behalf of each Party in such Party&#8217;s
        respective territory; and (vi) perform such other functions as expressly set forth in this Agreement or as the Parties may mutually agree in writing, except where in conflict with any provision of this Agreement.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In addition, each Party agrees to prepare and submit to the JSC a reasonably detailed development plan (including overall
        strategy, indications, study designs and timelines) for the Development of the Licensed Compound and Licensed Products in the Greater China (in the case of Hengrui) and in the Territory (in the case of Treeline) (&#8220;<font style="font-weight: bold; font-style: italic;">Development Plan</font>&#8221;), and all proposed updates or amendments thereto.&#160; Each Party, its Affiliates and licensees (in the case of Hengrui) or Sublicensees (in the case of Treeline) shall use Commercially Reasonable Efforts
        to conduct the Development of the Licensed Compound and Licensed Products in their respective territory in accordance with their respective Development Plan (or updates or amendments thereto) submitted to and approved by the JSC. In each case where
        a Party&#8217;s execution of any activity described in its Development Plan submitted to and approved by the JSC is postponed or cancelled despite the use of Commercially Reasonable Efforts, such Party shall, if requested by the other Party, provide the
        applicable reasons and/or discuss with the other Party in person or by telephone or video-conference regarding such postponement or cancellation and further explain such postponement or cancellation at the JSC Meeting.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">18</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">3.2.3</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">Limitation of Authority</font>.&#160; The JSC shall only have the powers expressly assigned to it by this Agreement and shall not have the
        authority to (i) modify or amend the terms and conditions of this Agreement; (ii) waive either Party&#8217;s compliance with the terms and conditions of this Agreement; or (iii) determine any such issue in a manner that would conflict with the express
        terms and conditions of this Agreement.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">3.2.4</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">Meetings</font>.&#160; The JSC shall hold meetings at such times as it elects to do so, but in no event shall such meetings be held less
        frequently than once every Calendar Year.&#160; Each Party may call additional <font style="font-style: italic;">ad hoc</font> JSC meetings as the need arises with mutual agreement by the Parties and reasonable advance notice (no less than [*] Business
        Days) to the other Party.&#160; Meetings of the JSC may be held in person, by audio or video conference or similar means.&#160; In person JSC meetings shall be held at locations mutually agreed by the Parties.&#160; Each Party shall be responsible for such
        Party&#8217;s expenses incurred in participating in the JSC meetings.&#160; No action taken at any JSC meeting shall be effective unless at least two (2) representatives of each Party are participating in such JSC meeting.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">3.2.5</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">Non-Member Attendance</font>.&#160; Each Party may from time to time invite a reasonable number of participants relevant to the items on the
        issued agenda, in addition to its representatives, to attend the JSC meetings in a non-voting capacity; <u>provided</u> that no Party may have any Third Party (including any consultant) attend such a meeting without the prior written consent of
        the other Party and if such other Party consents to such Third Party&#8217;s attendance, such Party shall ensure that such Third Party does not vote or otherwise participate in the decision making process of the JSC and is bound by confidentiality and
        non-use obligations consistent with the terms of this Agreement.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">3.2.6</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">Decision-Making</font>.&#160; All decisions of the JSC shall be made by unanimous
        vote, with each Party having one (1) vote.&#160; If after reasonable discussion and good faith consideration of each Party&#8217;s view on the Development Plan submitted to the JSC (or updates or amendments thereto), the JSC cannot agree upon the Development
        Plan (or update or amendment thereto) within [*] Business Days after such matter was brought to the JSC for resolution, Treeline will have final decision-making authority with respect to the approval of the Development Plan (or update or amendment
        thereto) in the Territory and Hengrui will have final decision making authority with respect to the approval of the Development Plan (or update or amendment thereto) in the Greater China.</div>
      <div>&#160;</div>
      <div style="text-align: center; font-size: 12pt; font-weight: bold;"><font style="font-size: 10pt; color: rgb(0, 0, 0);">ARTICLE 4</font><font style="font-size: 10pt;"><br>
          DEVELOPMENT AND COMMERCIALIZATION</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">4.1</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">Responsibility</font>.&#160; From and after the Effective Date, Treeline shall have
        the exclusive and sole right and responsibility for and operational control over all aspects of the Exploitation of the Licensed Compounds and Licensed Products in the Field in the Territory, including all non-clinical and clinical studies,
        regulatory filings, and all Development, Commercialization and Manufacturing activities, resourcing and decision making.&#160; Treeline shall bear all of the costs and expenses incurred by it in connection with its Development, Manufacturing, and
        Commercialization activities, except as otherwise expressly set forth herein.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">4.2</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">Regulatory Matters.</font></div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">19</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">4.2.1</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt; font-weight: bold;">Regulatory Filings.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;As between Treeline and Hengrui, Treeline will have sole right and responsibility for the conduct of all regulatory
        activities required to obtain and maintain Regulatory Approval of Licensed Products in the Field in the Territory, including (i) preparing and submitting all Regulatory Materials for Licensed Products in the Field in the Territory, and (ii)
        determining all regulatory plans and strategies for Licensed Products in the Field in the Territory. As between the Parties, Treeline will have the exclusive right to submit to and appear before Regulatory Authorities on any matter with respect to
        Licensed Products in the Field in the Territory.&#160; Treeline (or its Affiliates or Sublicensees, as applicable) will own all Regulatory Materials (including Regulatory Approvals) for Licensed Products in the Field in the Territory and all such
        Regulatory Materials shall be submitted in the name of Treeline (or its Affiliate or Sublicensee, as applicable) in the Field in the Territory.&#160; As between the Parties, Treeline shall have sole decision-making authority for all regulatory matters
        with respect to Licensed Products in the Field (including the decision to file and the content of any regulatory filing or dossier, pharmacovigilance reports, patient risk management strategies and plans, labeling, safety, recalls and withdrawals)
        in the Territory.&#160; For clarity, Hengrui has the sole right to engage in any and all of the regulatory activities described above with respect to Licensed Products in the Greater China.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; Without limiting Sections 2.5, 2.6, 4.1 and 4.2.1(a), Hengrui shall, and shall cause its Affiliates and China Licensees to,
        assist and support Treeline, as reasonably requested by Treeline and at Treeline&#8217;s expense, in obtaining Regulatory Approvals for Licensed Products in the Territory, including allowing reasonable and timely access, use and support of its existing
        technical documents and Regulatory Materials related to the Licensed Compounds or Licensed Products and necessary for Treeline&#8217;s completion and submission of any regulatory filing, and assisting Treeline&#8217;s completion and submission of an IND or NDA
        in the Territory. Each Party shall promptly notify the other Party in writing of any communication relating to the Licensed Compound or Licensed Products received from any Regulatory Authority that may be materially relevant to the other Party.
        Without limiting the foregoing, either Party shall promptly notify the other Party of any information it receives regarding any threatened or pending action or communication by or from any Regulatory Authority, which may adversely affect the
        Exploitation or regulatory status of any Licensed Product in the other Party&#8217;s territory.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;For clarity, during the Term of this Agreement, Hengrui or its Affiliates or licensees shall not, directly or indirectly,
        conduct any Development activities relating to the Licensed Products in the Territory, including any clinical trials or any regulatory activities (including any communication with Regulatory Authority) and Treeline or its Affiliates or Sublicensees
        shall not, directly or indirectly, conduct any Development activities relating to the Licensed Products in the Greater China, including any clinical trials or any regulatory activities (including any communication with Regulatory Authority), in
        each case, excluding any nonclinical activities conducted on a Party&#8217;s behalf by CRO(s) in the other Party&#8217;s territory under the license set forth in Section 2.1(b) or 2.7(b), as applicable.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">20</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">4.2.2</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">Right of Reference</font>.&#160; From and after the Effective Date, each Party
        hereby grants to the other Party a non-exclusive &#8220;Right of Reference or Use,&#8221; as that term is defined in 21 C.F.R. &#167; 314.3(b) (or equivalent Applicable Law within the Territory or Greater China) to all Regulatory Materials pertaining to the
        Licensed Products submitted by or on behalf of such Party. Treeline shall, and shall cause its Affiliates and their Sublicensees to, assist and support Hengrui, as reasonably requested by Hengrui and at Hengrui&#8217;s expense, in obtaining Regulatory
        Approvals for Licensed Products in the Greater China, including allowing reasonable and timely access, use and support of its existing technical documents and Regulatory Materials related to the Licensed Compounds or Licensed Products and necessary
        for Hengrui&#8217;s completion and submission of any regulatory filing, and assisting Hengrui&#8217;s completion and submission of an IND or NDA in the Greater China.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">4.2.3</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">Transfer of Regulatory Filings</font>.&#160; Without limiting Section 4.2.1(c), promptly after the Effective Date, Hengrui shall transfer into
        Treeline&#8217;s name, all Regulatory Materials and other filings pertaining to Licensed Products submitted by or on behalf of Hengrui or its Affiliate, if any, in the Territory and transfer any and all regulatory activities in the Territory to Treeline.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">4.3</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">Commercialization.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">4.3.1</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">Commercialization Activities</font>.&#160; Without limiting Section 4.1, upon
        receiving Regulatory Approval for one or more Licensed Product(s) in one or more countries of the Territory, Treeline will have the sole right and responsibility with respect to the Commercialization of such Licensed Product(s) in such countries.&#160;
        Without limiting the foregoing, Treeline will have the sole right and responsibility for the marketing and distribution of Licensed Products in the Field in the Territory.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">4.3.2</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">Commercialization Plan and Report</font>.&#160; Treeline shall keep Hengrui reasonably informed of its, its Affiliates&#8217; and Sublicensees&#8217;
        Commercialization activities with respect to the Licensed Products in the Territory, to the extent such information is available to Treeline and Treeline shall use Commercially Reasonable Efforts to obtain such information.&#160; Without limiting the
        foregoing, commencing no later than [*] months before the anticipated date of the receipt of the first Regulatory Approval to Commercialize the Licensed Product in the Territory and annually thereafter, Treeline will share with Hengrui an initial
        plan for engaging in Commercialization activities for such Licensed Product for Hengrui&#8217;s information (the &#8220;<font style="font-weight: bold; font-style: italic;">Commercialization Plan</font>&#8221;), which plan will summarize [*], provided that if
        Commercialization of the Licensed Product is conducted by a Sublicensee, Treeline will only share with Hengrui the Commercialization Plan to the extent such Commercialization Plan is available to Treeline and permitted to be shared with Hengrui,
        provided that Treeline shall use Commercially Reasonable Efforts to obtain such Commercialization Plan and permission to share with Hengrui. For each Calendar Year following first Regulatory Approval for sale and marketing of a Licensed Product,
        Treeline shall provide to Hengrui annually within [*] days after the end of such Calendar Year a report summarizing Treeline&#8217;s activities performed by and on behalf of Treeline with respect [*] under this Agreement (&#8220;<font style="font-weight: bold; font-style: italic;">Commercialization Report</font>&#8221;).&#160; The Commercialization Plan and Reports and the contents thereof shall be Confidential Information of Treeline.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">4.4</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">Diligence</font>.&#160; Treeline (whether on its own or through one or more of its Affiliates, Sublicensees or Development and/or
        Commercialization collaborators) shall use Commercially Reasonable Efforts to Develop (including obtaining Regulatory Approval for) and Commercialize at least one Licensed Product or a Combination Product in the Field in the U.S. and another five
        (5) Major Markets.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">21</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">4.5</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">Pharmacovigilance Agreement.</font>&#160; Within [*] months of the Effective Date,
        but in any event prior to commencement of any clinical trials with respect to the Licensed Product in the Territory, the Parties will in good faith negotiate and finalize a separate safety data exchange agreement (the &#8220;<font style="font-weight: bold; font-style: italic;">Pharmacovigilance Agreement</font>&#8221;), the terms of which shall set forth the obligations, procedures and timelines for either Party to report information (such as the occurrence of Adverse Events) observed in connection
        with the Licensed Product in order to enable the other Party to comply with its safety reporting obligations to the applicable Regulatory Authorities.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">4.6</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">No Diversion</font>.&#160; Each Party hereby covenants and agrees that it shall not, and shall ensure that its Affiliates, Sublicensees (in the
        case of Treeline) and licensees, will not, directly or indirectly, promote, market, distribute, import, sell or have sold the Licensed Products, including via internet or mail order, in the other Party&#8217;s territory.&#160; With respect to any country in
        the other Party&#8217;s territory, a Party shall not, and shall ensure that its Affiliates, Sublicensees (in the case of Treeline) and licensees will not: (a) establish or maintain any branch, warehouse or distribution facility for Licensed Products in
        such countries, (b) knowingly engage in any advertising or promotional activities relating to Licensed Products that are directed primarily to customers or other purchaser or users of Licensed Products located in such countries, (c) actively
        solicit orders for Licensed Products from any prospective purchaser located in such countries, or (d) knowingly sell or distribute Licensed Products to any person in such Party&#8217;s territory who intends to sell or has in the past sold Licensed
        Products in such countries.&#160; If either Party receives any order for any Licensed Product from a prospective purchaser reasonably believed to be located in a country in the other Party&#8217;s territory, such Party shall promptly refer that order to the
        other Party and such Party shall not accept any such orders.&#160; Each Party shall not deliver or tender (or cause to be delivered or tendered) Licensed Products into a country in the other Party&#8217;s territory.&#160; Each Party shall not, and shall ensure
        that its Affiliates, Sublicensees (in the case of Treeline) and licensees will not, knowingly restrict or impede in any manner the other Party&#8217;s exercise of its retained exclusive rights in the other Party&#8217;s territory.&#160; Each Party and its
        Affiliates will use Commercially Reasonable Efforts to monitor and prevent exports of Licensed Products from its own territory for Commercialization in the other Party&#8217;s territory, using methods permitted under Applicable Law that are commonly used
        in the industry for such purpose (if any), and shall promptly inform the other Party of any such exports of Licensed Products from its territory, and any actions taken to prevent such exports. Each Party agrees to take reasonable actions requested
        in writing by the other Party that are consistent with Applicable Law to prevent exports of Licensed Products from its territory for Commercialization in the other Party&#8217;s territory.</div>
      <div>&#160;</div>
      <div style="text-align: center; font-size: 12pt; font-weight: bold;"><font style="font-size: 10pt; color: rgb(0, 0, 0);">ARTICLE 5</font><font style="font-size: 10pt;"><br>
          MANUFACTURE AND SUPPLY</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">5.1</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">Manufacture and Supply.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">5.1.1</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">Clinical Supply</font>. Hengrui will, upon Treeline&#8217;s request, supply Treeline and/or its designee Licensed Compounds and Licensed Products
        for clinical studies under a separate agreement (&#8220;<font style="font-weight: bold; font-style: italic;">Clinical Supply Agreement</font>&#8221;) to be entered into between the Parties within [*] months following the Effective Date. The Clinical Supply
        Agreement shall contain customary and commercially reasonable terms as may be agreed upon in good faith by the Parties.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">22</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">5.1.2</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">Commercial Supply</font>. Upon Treeline&#8217;s written request, the Parties shall
        negotiate and enter into a separate agreement for the commercial supply of Licensed Compound and/or Licensed Products by Hengrui to Treeline and/or its designee in accordance with customary and commercially reasonable terms of forecasting and
        ordering procedures and other operational matters related to the supply of the Licensed Compounds and Licensed Products (the &#8220;<font style="font-weight: bold; font-style: italic;">Commercial</font><font style="font-style: italic;">&#160;</font><font style="font-weight: bold; font-style: italic;">Supply Agreement</font>&#8221;).&#160; The Parties agree that such Commercial Supply Agreement shall be entered into at least [*] months prior to the anticipated Regulatory Approval of the first Licensed
        Product in the Territory.&#160; For the avoidance of doubt, without limiting Section 2.1, Treeline shall have the right and option to purchase Licensed Compounds and/or Licensed Products from any other Third Parties in the Territory, at its sole
        discretion.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">5.1.3</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">Third Party Manufacture and Supply</font>. In the event that Treeline wishes to
        purchase Licensed Compounds and/or Licensed Products from any CMO that is engaged by Hengrui at the time Treeline wishes to purchase such Licensed Compounds and/or Licensed Products, Hengrui shall permit Treeline to negotiate and enter into with
        such CMO a separate agreement for the commercial supply of such Licensed Compounds and/or Licensed Products for Commercialization in the Territory (&#8220;<font style="font-weight: bold; font-style: italic;">Third Party Commercial Supply Agreement</font>&#8221;),



        and Hengrui shall facilitate the negotiations of such Third Party Commercial Supply Agreement, including, but not limited to, issuing permission letter to such CMO authorizing the CMOs to use the processes used for the Manufacturing services
        provided to Hengrui for Treeline&#8217;s Manufacturing requirement, and providing, at Treeline&#8217;s request, an introduction to such CMO.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">5.2</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">Manufacturing Technology Transfer.&#160; </font>Hengrui and Treeline agree that at
        Treeline&#8217;s sole cost, Treeline shall have the right to transfer and have transferred all methods and process chemistry and other technology relating to the Manufacturing of Licensed Compounds and/or Licensed Products to an alternative manufacturer
        of drug substance and drug product at any time; and Hengrui shall, and shall procure its Affiliates to, reasonably assist, cooperate, effect and support, such transfer at Treeline&#8217;s cost and expense.&#160; The Parties shall enter into a manufacturing
        technology transfer agreement (&#8220;<font style="font-weight: bold; font-style: italic;">Manufacturing Technology Transfer Agreement</font>&#8221;) within [*] days following Treeline&#8217;s request, under which Hengrui shall transfer to Treeline or its
        designee(s) such Data, documents and information in Hengrui&#8217;s or its Affiliate&#8217;s control or possession, and provide such technical assistance and support reasonably requested by Treeline, that are necessary or reasonably useful for Treeline to
        Manufacture or have Manufactured by a Third Party contractor engaged by Treeline, the applicable Licensed Compound or Licensed Product, to the extent Controlled by Hengrui as of such date.&#160; Treeline shall pay Hengrui&#8217;s reasonable costs and expenses
        incurred in connection with providing such information or assistance pursuant to this Section 5.2 and the Manufacturing Technology Transfer Agreement.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">5.3</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">Brand Security and Anti-Counterfeiting.&#160; </font>The Parties will establish
        contacts for communication regarding brand security issues, and each Party shall reasonably cooperate with the other Party with respect thereto.&#160; Practices around these incidents will comply with Treeline&#8217;s then-current standards, where such
        standards define product security features, warehouse/cargo protection requirements, and response and communication process for such incidents.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">23</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: center; font-size: 12pt; font-weight: bold;"><font style="font-size: 10pt; color: rgb(0, 0, 0);">ARTICLE 6</font><font style="font-size: 10pt;"><br>
          PAYMENTS</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">6.1</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">Upfront Payment.&#160; </font>Within [*] days following the Effective Date, Treeline
        will pay to Hengrui Eleven Million Dollars ($11,000,000) (the &#8220;<font style="font-weight: bold; font-style: italic;">Upfront Payment</font>&#8221;). The Upfront Payment is non-refundable and shall not be creditable against any other amount due hereunder.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">6.2</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">Development Milestone Payments.&#160; </font>Treeline shall pay to Hengrui the respective one-time only development milestone payments set forth
        in the table below for the first achievement of the applicable milestone event by a Licensed Product, whether such achievement is made by Treeline, its Affiliate or any of their Sublicensees.&#160; For clarity, each of the following milestone payments
        shall be payable only once under this Agreement regardless of the number of times the corresponding milestone event is achieved, and whether such milestone event is achieved by one or more Licensed Products (for clarity, including Treeline
        Additional Products, if applicable).</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z64f89ddee4504f0bb2b1b6b5e5ae13fc" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td colspan="1" style="width: 1%; vertical-align: middle; background-color: rgb(217, 217, 217); border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 59%; vertical-align: middle; background-color: rgb(217, 217, 217); border-bottom: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify; font-weight: bold;">Development Milestone Event</div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: middle; background-color: rgb(217, 217, 217); border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 39.42%; vertical-align: middle; background-color: rgb(217, 217, 217); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify; font-weight: bold;">Milestone Payment</div>
            </td>
          </tr>
          <tr>
            <td colspan="1" style="width: 1%; vertical-align: middle; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 59%; vertical-align: middle; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify;">[*]</div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 39.42%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify;">[*]</div>
            </td>
          </tr>
          <tr>
            <td colspan="1" style="width: 1%; vertical-align: middle; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 59%; vertical-align: middle; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify;">[*]</div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 39.42%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify;">[*]</div>
            </td>
          </tr>
          <tr>
            <td colspan="1" style="width: 1%; vertical-align: middle; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 59%; vertical-align: middle; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify;">[*]</div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 39.42%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify;">[*]</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">In no event shall the total aggregate amount payable under this Section 6.2 exceed forty-five Million Dollars ($45,000,000).&#160; The development milestone payments are non-refundable and shall not be
        creditable against any other amount due hereunder.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">6.3</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">Commercial Milestone Payments.&#160; </font>Treeline shall pay to Hengrui the
        respective one-time only commercial milestone payments set forth in the table below for the first achievement of the applicable milestone event by a Licensed Product, whether such achievement is made by Treeline, its Affiliate or its Sublicensee.&#160;
        For clarity, each of the following milestone payments shall be payable only once under this Agreement regardless of the number of times the corresponding milestone event is achieved, and whether such milestone event is achieved by one or more
        Licensed Products (for clarity, including Treeline Additional Products, if applicable).</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zcaee44c93e444b659f2ad7e6fab4c2c6" cellpadding="0" cellspacing="0">

          <tr>
            <td colspan="1" style="width: 1%; vertical-align: middle; background-color: rgb(217, 217, 217); border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 59%; vertical-align: middle; background-color: rgb(217, 217, 217); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify; font-weight: bold;">Commercial Milestone Event</div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: middle; background-color: rgb(217, 217, 217); border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 39.42%; vertical-align: middle; background-color: rgb(217, 217, 217); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify; font-weight: bold;">Milestone Payment</div>
            </td>
          </tr>
          <tr>
            <td colspan="1" style="width: 1%; vertical-align: middle; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 59%; vertical-align: middle; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify;">[*]</div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 39.42%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify;">[*]</div>
            </td>
          </tr>
          <tr>
            <td colspan="1" style="width: 1%; vertical-align: middle; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 59%; vertical-align: middle; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify;">[*]</div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 39.42%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify;">[*]</div>
            </td>
          </tr>
          <tr>
            <td colspan="1" style="width: 1%; vertical-align: middle; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 59%; vertical-align: middle; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify;">[*]</div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 39.42%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify;">[*]</div>
            </td>
          </tr>
          <tr>
            <td colspan="1" style="width: 1%; vertical-align: middle; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 59%; vertical-align: middle; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify;">[*]</div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 39.42%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify;">[*]</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">In no event shall the total aggregate amount payable under this Section 6.3 exceed six hundred and fifty Million Dollars ($650,000,000).&#160; The commercial milestone payments are non-refundable and
        shall not be creditable against any other amount due hereunder.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">6.4</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">Milestone Payment Terms.</font>&#160; Each milestone payment stated in the tables in
        Sections 6.2 and 6.3 shall be paid no more than once under this Agreement, regardless of whether or not similar achievement(s) are thereafter made for the same or one or more other Licensed Products.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">24</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">6.4.1</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">Payment Terms for Development Milestones</font>. Treeline shall notify Hengrui in writing within [*] following the achievement of each
        milestone event set forth in Section 6.2, and shall make the appropriate payment in Dollars by wire transfer to a bank designated in writing by Hengrui within [*] after the achievement of such milestone.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">6.4.2</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">Payment Terms for Commercial Milestones</font>. Within [*] following the end of
        the Calendar Quarter in which the commercial milestone event set forth in Section 6.3 occurred, Treeline shall notify Hengrui in writing the achievement of each milestone event set forth in Section 6.3, and shall make the appropriate payment in
        Dollars by wire transfer to a bank designated in writing by Hengrui within [*] after the end of the Calendar Quarter in which the commercial milestone event set forth in Section 6.3 occurred. Treeline shall make the appropriate payment in Dollars
        by wire transfer to a bank designated in writing by Hengrui.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">6.5</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">Royalty.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">6.5.1</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">Royalty Payments</font>.&#160; During the Royalty Term, in partial consideration of
        the licenses and rights granted hereunder, Treeline shall pay to Hengrui a royalty on Net Sales of all Licensed Products at the rates set forth in the table below, subject to the remainder of this Section 6.5.</div>
      <div>&#160;</div>
      <table style="border-collapse: collapse; width: 70%; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left;" id="zacdad0e012474938a18b79c6a36890cb" align="center" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td colspan="1" style="width: 1%; vertical-align: top; background-color: rgb(217, 217, 217); border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 34%; vertical-align: top; background-color: rgb(217, 217, 217); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify; font-weight: bold;">Portion of Aggregate Net Sales </div>
              <div style="text-align: justify; font-weight: bold;">during a Calendar Year</div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: top; background-color: rgb(217, 217, 217); border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 34%; vertical-align: top; background-color: rgb(217, 217, 217); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify; font-weight: bold;">Royalty Rate, as % of that</div>
              <div style="text-align: justify; font-weight: bold;">Portion of Net Sales</div>
            </td>
          </tr>
          <tr>
            <td colspan="1" style="width: 1%; vertical-align: middle; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 34%; vertical-align: middle; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify;">[*]</div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: middle; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 34%; vertical-align: middle; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify;">[*]</div>
            </td>
          </tr>
          <tr>
            <td colspan="1" style="width: 1%; vertical-align: middle; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 34%; vertical-align: middle; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify;">[*]</div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 34%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify;">[*]</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">6.5.2</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">Step-Down</font>. Subject to Section 6.5.5, the royalty rates under Section
        6.5.1 shall be reduced, on a country-by-country basis, to [*] of the rates otherwise stated in Section 6.5.1 with respect to any Net Sales made during any portion of the Royalty Term in the country of sale in which there is not at least one (1)
        Valid Claim under Licensed Patents in such country.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">6.5.3</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">Generic Competition</font>. On a Licensed Product-by-Licensed Product and country-by-country basis, if (a) a Licensed Product is sold in a
        country in the Territory and at any time one or more products that are Generic Products with respect to such Licensed Product are sold or marketed by a Third Party in such country, and (b) the total units of such Generic Product(s) sold in such
        country in any Calendar Year, as a percentage of the total aggregate units of Licensed Products and such Generic Product(s) sold in such country in such Calendar Year (&#8220;<font style="font-weight: bold; font-style: italic;">Generic Product Presence</font>&#8221;),



        is at least [*], then the royalties due to Hengrui pursuant to this Section 6.5 with respect to such Licensed Product in such country during such Calendar Year will be reduced by [*]. Units of Generic Products sold in a particular country for
        determining Generic Product Presence will be measured based on data provided by IMS International (or another Third Party data aggregating source reasonably selected by Hengrui).</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">25</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">6.5.4</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">Third Party License</font>. Subject to Section 6.5.5, to the extent a Third
        Party license is necessary to avoid infringement of a Third Party Patent with respect to use, Development, Manufacture, or Commercialization of a Licensed Compound or a Licensed Product (including as part of a Combination Product) that is directly
        pertaining to the Licensed Compound in a particular country, the royalties payable by Treeline to Hengrui shall be reduced by offsetting up to [*] of the royalties payable to such Third Party licensor(s) for such license with respect to Net Sales
        of the Licensed Product in such country against the royalties otherwise payable by Treeline to Hengrui with respect to Net Sales of the Licensed Product in such country.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">6.5.5</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">Royalty Floor.</font>&#160; The royalty reductions set forth in Sections 6.5.2,
        6.5.3 and 6.5.4 shall be applied on a cumulative basis; <font style="font-style: italic;">provided</font>, <font style="font-style: italic;">however</font>, under no circumstances will the royalties payable to Hengrui under Section 6.5.1 in any
        Calendar Quarter be reduced, on a country by-country basis, as a result of Sections 6.5.2, 6.5.3, or 6.5.4, to below a percentage (the &#8220;<font style="font-weight: bold; font-style: italic;">Royalty Floor</font>&#8221;) equal to [*] of the royalties
        otherwise payable under Section 6.5.1; provided that if the Generic Product Presence is equal to or more than [*], the Royalty Floor shall be equal to [*] of the royalties otherwise payable under Section 6.5.1.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">6.5.6</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">Payment Terms.&#160; </font>Royalties reportable in each Royalty Report provided
        for under Section 7.1 shall be due on the date such Royalty Report is due<font style="font-weight: bold;">. </font>Royalty payments will be made to Hengrui in Dollars by wire transfer to the following bank: [*], in accordance with the bank wire
        transfer details as set forth in the applicable invoice or otherwise provided by Hengrui in writing prior to the payment due date.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">6.6</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">Taxes.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">6.6.1</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">Indirect Taxes.</font> Amounts payable under this Agreement do not include any
        sales, use, excise, value added or other similar taxes, tariffs or duties as may be applicable.&#160; If any value added tax, sales, use, service, consumption, business or similar tax is imposed under applicable tax law with respect to the amount paid
        under this Agreement (<font style="font-weight: bold;">&#8220;</font><font style="font-weight: bold; font-style: italic;">Indirect Taxes</font><font style="font-weight: bold;">&#8221;</font>), then Treeline agrees to pay such Indirect Taxes and to indemnify
        and hold harmless Hengrui from and against the amount of such Indirect Taxes (and any penalties, interests, or additions to tax imposed with respect thereto), provided that if Hengrui becomes aware of a requirement of Indirect Taxes due or being
        imposed in any jurisdictions other than the U.S., Hengrui shall use commercially reasonable efforts to provide written notice to Treeline thereof, provided that failure to provide such notice does not excuse Treeline from its obligation to pay the
        Indirect Taxes. For avoidance of doubt, Hengrui will not be entitled to pass on to Treeline, and Treeline will not be obligated to pay or bear, any tax that is based on Hengrui&#8217;s real, personal or intangible property (whether owned or leased),
        corporate structure, franchise, continuing business operations, income, gross receipts, capital stock, net worth or imposed with respect to Hengrui&#8217;s engagement of employees or independent contractors. To the extent that any Indirect Tax is imposed
        under applicable PRC tax law by any tax authority in the P.R.C. on Hengrui, Hengrui will submit an invoice, or receipt, or such other evidence, to Treeline for the amount of such Indirect Tax, and Treeline shall directly pay to the applicable
        taxing authority (or reimburse and pay Hengrui for such Indirect Tax within [*] days after receipt of such invoice, or receipt, or such other evidence); provided that if Hengrui does not provide Treeline such an invoice, or receipt, or such other
        evidence, in a timely manner, Treeline will not be responsible for any interest, penalties or additions to tax directly resulting from such failure. The Parties will cooperate in good faith to minimize Indirect Taxes to the extent legally
        permissible (including using commercially reasonable efforts to obtain an exemption from P.R.C. VAT for the licenses granted under Article 2 of this Agreement).</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">26</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">6.6.2</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">Withholding Taxes.</font>&#160; Treeline will make all payments to Hengrui under
        this Agreement subject to deductions or withholdings for income taxes required by law in effect at the time of payment. Any such income tax required by law to be withheld on amounts payable under this Agreement to Hengrui (<font style="font-weight: normal;">&#8220;</font><font style="font-weight: bold; font-style: italic;">Withholding Tax</font><font style="font-weight: normal;">&#8221;</font>) will be deducted from amounts otherwise due to Hengrui under this Agreement and promptly paid over by
        Treeline to the appropriate Governmental Authority and Treeline will promptly furnish Hengrui with proof of payment of such Withholding Tax in a manner customarily provided for such tax payment. Any such Withholding Tax required to be withheld will
        be an expense of and borne by Hengrui and, to the extent withheld and timely paid over by Treeline to the appropriate Governmental Authority, will be treated as paid to Hengrui under this Agreement. If any such Withholding Tax is assessed against
        and paid by Treeline, then Hengrui will indemnify and hold harmless Treeline from and against such Withholding Tax (but not, for the avoidance of doubt, any penalties, interests, or additions to tax resulting from Treeline&#8217;s failure to timely or
        properly withhold such Withholding Tax). Treeline and Hengrui will cooperate with respect to all documentation required by any taxing authority or reasonably requested by Treeline to secure a reduction in the rate of applicable Withholding Taxes.
        Treeline agrees to use reasonable efforts to assist Hengrui in claiming exemptions from, or a refund of, any such deductions or withholdings. On the Effective Date, and otherwise upon Treeline&#8217;s reasonable request, Hengrui will provide Treeline
        with any tax forms it is legally entitled to provide that may be reasonably necessary in order for Treeline not to withhold tax or to withhold tax at a reduced rate under an applicable bilateral income Tax treaty, including IRS Form W-8BEN-E, Form
        W-8ECI, or other applicable IRS Form.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">6.7</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">Late Payment</font>.&#160; If Hengrui does not receive payment of any undisputed sums
        due to it on or before the due date set forth in this Agreement, then without prejudice to any other right or remedy available to Hengrui, Hengrui may charge interest on the amount outstanding, on a daily basis at the rate equal to the lesser of
        per annum rate of [*] over the then-current prime rate reported in The Wall Street Journal, and the maximum rate permitted by Applicable Law, until such payment is made in full (&#8220;<font style="font-weight: bold; font-style: italic;">Late Payment Fee</font>&#8221;).&#160;







        If Treeline disputes its payment obligation in good faith, Treeline will notify Hengrui of the dispute before the payment is due and the Parties will use the dispute resolution process described in Section 14.3.&#160; To the extent the payment dispute
        is resolved in favor of Hengrui, then Hengrui is entitled to charge the Late Payment Fee retroactive as of the date the original payment was due.</div>
      <div>&#160;</div>
      <div style="text-align: center; font-size: 12pt; font-weight: bold;"><font style="font-size: 10pt; color: rgb(0, 0, 0);">ARTICLE 7</font><font style="font-size: 10pt;"><br>
          ACCOUNTING AND REPORTING</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">7.1</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">Royalty Reports</font>.&#160; Within [*] days after the end of each Calendar Quarter during the Royalty Term, Treeline shall furnish to Hengrui a
        quarterly written report showing in reasonably specific detail (a) [*]; (b) [*]; (c) [*]; (d) [*]; and (e) [*] (a &#8220;<font style="font-weight: bold; font-style: italic;">Royalty Report</font>&#8221;).&#160; With respect to sales of Licensed Products invoiced in
        Dollars, the gross sales, Net Sales and royalties payable shall be expressed in Dollars.&#160; With respect to (i) Net Sales invoiced in a currency other than Dollars and (ii) cash consideration paid in a currency other than Dollars by Sublicensees
        hereunder, all such amounts shall be expressed both in the currency in which the distribution is invoiced and in the Dollar equivalent.&#160; The Dollar equivalent shall be calculated using the average of the exchange rate (local currency per US$1)
        published in The Wall Street Journal, Western Edition, under the heading &#8220;Currency Trading&#8221; on the last business day of each month during the applicable Calendar Quarter, or other newspaper agreed to by the Parties.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">27</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">7.2</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">Audits</font>.&#160; During the Royalty Term, upon the written request of Hengrui and
        not more than once in each Calendar Year (except to the extent an immediate prior audit has revealed an underpayment by Treeline by more than [*]), Treeline shall permit an independent certified public accounting firm of nationally recognized
        standing selected by Hengrui and reasonably acceptable to Treeline, at Hengrui&#8217;s expense, to have access during normal business hours to such of the financial records of Treeline as may be reasonably necessary to verify the accuracy of the payment
        reports hereunder for the [*] immediately prior to the date of such request (other than records for which Hengrui has already conducted an audit under this Section). Such audit shall be requested in writing at least [*] Business Days in advance.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">7.2.1</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>If such accounting firm concludes that additional amounts were owed during the audited period, Treeline shall
        pay such additional amounts within [*] days after the date Hengrui delivers to Treeline such accounting firm&#8217;s written report so concluding.&#160; The fees charged by such accounting firm shall be paid by Hengrui; provided, however, if the audit
        discloses that the royalties payable by Treeline for such period are more than [*] of the royalties actually paid for such period, then Treeline shall pay the reasonable fees and expenses charged by such accounting firm.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">7.2.2</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>Hengrui shall cause its accounting firm to maintain all information subject to review under this Section 7.2 or
        received by such accounting firm as a result of such audit in strict confidence; provided, however, that Treeline shall have the right to require that such accounting firm, prior to conducting such audit, enter into an appropriate non-disclosure
        agreement with Treeline regarding such information.&#160; All such information shall be deemed Confidential Information of Treeline.&#160; The accounting firm shall disclose to Hengrui only whether the reports are correct or not, the amount of any
        discrepancy, and the basis for the discrepancy.&#160; No other Confidential Information of Treeline shall be shared with Hengrui.&#160; Hengrui shall treat all such financial information as Treeline&#8217;s Confidential Information.</div>
      <div>&#160;</div>
      <div style="text-align: center; font-size: 12pt; font-weight: bold;"><font style="font-size: 10pt; color: rgb(0, 0, 0);">ARTICLE 8</font><font style="font-size: 10pt;"><br>
          INTELLECTUAL PROPERTY</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">8.1</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">Ownership.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">8.1.1</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">Ownership</font>.&#160; As between the Parties, each Party shall retain sole ownership of and rights in such Party&#8217;s Background IP and nothing in
        this Agreement shall vest in a Party any right, title or interest in or to the other Party&#8217;s Background IP, other than the license rights expressly granted hereunder.&#160; Subject to the foregoing and the provision of license grants under this
        Agreement, including Sections 2.1 and 2.7, and this Article 8 (Intellectual Property), ownership of and rights in any Invention and other Know-How (and in each case including all Intellectual Property rights therein), conceived, developed,
        generated, made, or reduced to practice by or on behalf of a Party or the Parties (solely or jointly) or their Affiliates in the course of exercising its (or their) rights or carrying out its (or their) obligations under this Agreement (the &#8220;<font style="font-weight: bold; font-style: italic;">Arising IP</font>&#8221;) shall be determined based on inventorship and authorship, as applicable, in accordance with the applicable intellectual property laws.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">28</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">8.1.2</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">Rights of Joint Owners</font>.&#160; Subject to the licenses and covenants in this
        Agreement, including Sections 2.1, 2.2 and 10.1, and this Article 8, each Party may exercise its ownership rights in and to any such Joint Technology, including the right to license and sublicense or otherwise to Exploit, transfer or encumber its
        ownership interest, without an accounting or obligation to, or consent required from, the other Party.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">8.1.3</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">Disclosure</font>.&#160; Each Party will promptly disclose to the other Party all
        Joint Know-How, including all invention disclosures or other similar documents submitted to such Party by its or its Affiliates&#8217; employees, agents, or independent contractors relating thereto.&#160; Each Party will also promptly respond to reasonable
        requests from the other Party for additional information relating thereto.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">8.1.4</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">Trademarks</font>.&#160; Treeline will, in its sole discretion, select and own all
        Trademarks used in connection with the Exploitation of Licensed Compounds and/or Licensed Products in the Territory.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">8.2</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">Patent Prosecution and Maintenance.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">8.2.1</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">Subject to Section 8.1 and the remainder of this Section 8.2, Treeline and Hengrui shall coordinate on global filing strategy for the Patent rights within the Licensed
        Technology and Licensed Compound Arising IP (for clarity, excluding Patent rights Covering any proprietary compound(s) Controlled by Treeline or its Affiliates other than Treeline Additional Product). The Parties will use reasonable efforts to
        consider and discuss the global filing strategy for such Patent rights in good faith.&#160; In the event a joint decision is not reached regarding the global filing strategy for such Patent rights, (a) Hengrui will have the final say on decisions
        related to the Greater China<u>, </u>and (b) Treeline will have the final say on decisions related to the Territory. Without limiting Sections 2.5 and 2.6, within [*] days after the Effective Date, Hengrui will transfer to Treeline or its
        designated representative the files of all Licensed Patents in the Territory to be Prosecuted by Treeline in the name of Hengrui.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">8.2.2</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>After receiving the files of all Licensed Patents in the Territory in accordance with Section 8.2.1, Treeline
        and its Affiliates shall use reasonable efforts to Prosecute all Licensed Patents in the Territory at its own cost and using prosecution counsel of its choice.&#160; Hengrui and its Affiliates shall cooperate with Treeline in the Prosecution of all
        Licensed Patents in the Territory, including executing all lawful papers and instruments, making all rightful oaths and declarations, delivering to Treeline (or its designee), all instruments and documents, including powers of attorney, needed to
        file, maintain, prosecute and/or enforce the Licensed Patents in the Territory (including authorization to opt out of the Unified Patent Court for European Patents) in the name of Hengrui and providing any other reasonable assistance requested by
        Treeline at Treeline&#8217;s expense. Treeline shall promptly provide to Hengrui copies of all material prosecution communications regarding any such Licensed Patents in the Territory, and will send Hengrui copies of drafts of such material prosecution
        submissions prior to filing.&#160; Treeline will consider all comments and suggestions provided by Hengrui on such material patent prosecution submissions in good faith and will use reasonable efforts to arrive at joint decisions on responses. In the
        event a joint decision is not reached, Treeline will have final say on such decisions.&#160; If Treeline decides to abandon or terminate any such Licensed Patent in the Territory, it shall provide written notice to Hengrui no less than [*] days prior to
        such termination and give Hengrui the opportunity to take over, at Hengrui&#8217;s expense, the Prosecution of such Licensed Patent in the Territory.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">29</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">8.2.3</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>In the event Treeline elects not to file any Patent application within the Licensed Compound Arising IP in the
        Greater China, Hengrui will have the right but not the obligation to file and Prosecute such Patent application in the Greater China in the name of Treeline at Hengrui&#8217;s expense, and Treeline will cooperate with Hengrui in the same manner as
        Hengrui is required to cooperate with Treeline under Section 8.2.2. Hengrui hereby consents and agrees to consent to the Prosecution of Patents by Treeline or its Affiliates using the Test Data (as defined in the MTA), subject to Section 8.2.1 and
        the first sentence of this Section 8.2.3.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">8.3</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">Enforcement of Patent Rights.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">8.3.1</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">Notice of Infringement</font>.&#160; Each Party shall promptly inform the other Party in writing of any suspected infringement of any of (i) the
        Licensed Patents or Licensed Compound Arising IP; or (ii) the infringement or misappropriation of Licensed Know-How or Licensed Compound Arising IP by a Third Party, to the extent such infringement involves Exploitation in the Field in the
        Territory (or in the Greater China in the case of Licensed Compound Arising IP) during the Term (&#8220;<font style="font-weight: bold; font-style: italic;">Infringement</font>&#8221;).&#160; For the avoidance of doubt, the term &#8220;Infringement&#8221; as used in this
        Agreement shall mean a Third Party&#8217;s infringement or misappropriation of applicable Licensed Technology or Licensed Compound Arising IP according to the Applicable Laws of the applicable country, including any claim alleging infringement or
        misappropriation and any counterclaims alleging that a Licensed Patent or Licensed Compound Arising IP is invalid or unenforceable or that a product or process does not infringe or misappropriate a Licensed Patent or Licensed Know-How or Licensed
        Compound Arising IP.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">8.3.2</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">First Right to Take Action</font>. Treeline (and/or its Affiliate or
        Sublicensee, as applicable) will have the first right, but not the obligation, to institute, prosecute and control any legal action to enforce any Licensed Patent or Licensed Know-How against any Infringement in the Territory as it reasonably
        determines appropriate. Hengrui (and/or its Affiliate or China Licensees, as applicable) will have the first right, but not the obligation, to institute, prosecute and control any legal action to enforce any Licensed Compound Arising IP against any
        Infringement in the Greater China as it reasonably determines appropriate. If a Party (hereby in Section 8.3.2 including its Affiliate, or Sublicensee (in the case of Treeline) or China Licensees (in the case of Hengrui), as applicable) requests
        that the other Party and/or any of its Affiliates join any such action in order to establish standing, the other Party shall, and shall cause its Affiliates to, do so and the other Party, on behalf of itself and its Affiliates, hereby agrees that
        counsel for such Party shall also represent the other Party in such action, unless there is conflict of interest. For clarity, should the other Party join in any such action brought by such Party, either at such Party&#8217;s request or otherwise, such
        Party shall retain control of the proceeding and shall have final say on all decisions related thereto.&#160; The other Party will provide reasonable cooperation to such Party in connection with such legal action (in the Territory at Treeline&#8217;s expense
        in the case of Treeline as such Party; or in the Greater China at Hengrui&#8217;s expense in the case of Hengrui as such Party), including by promptly supplying or executing all papers and instruments, or requiring its employees to supply or execute such
        papers and instruments, as may be necessary for purposes of initiating and pursuing such legal action. If such Party fails to commence an action or proceeding or otherwise take appropriate action to enforce or defend the Licensed Technology against
        an Infringement in the Territory in the case of Treeline (or the Licensed Compound Arising IP against an Infringement in the Greater China in the case of Hengrui) [*] days after written notice from the other Party requesting action (in any event,
        no later than [*] days before the end of any limitation period to bring such action under Applicable Law), then the other Party may, but will not be obligated to, bring and control any legal action in its name (in the Territory to enforce such
        Licensed Technology in the case of Treeline as such Party; or in the Greater China to enforce such Licensed Compound Arising IP in the case of Hengrui as such Party) against such Infringement, at its sole expense; and such Party shall have the
        right to be represented in any such action by counsel of its own choice and at such Party&#8217;s own expense.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">30</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">8.3.3</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">Allocation of Recoveries</font>. (a) If Treeline (and/or its Affiliate or Sublicensee) institutes suit against a Third Party with respect to
        an Infringement pursuant to Section 8.3.2, recoveries, if any, whether by judgment, award, decree or settlement, shall, after reimbursement of Treeline (and/or its Affiliate or Sublicensee) and Hengrui (and/or its Affiliate or China Licensee, if
        applicable) for the costs of such action, be treated as if they were Net Sales for purposes of calculating royalties under Section 6.5. (b) If Hengrui institutes suit against a Third Party with respect to an Infringement pursuant to Section 8.3.2,
        recoveries, if any, whether by judgment, award, decree or settlement, shall, after reimbursement of each Party for the costs of such action, be [*], provided that [*].</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">8.3.4</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">Abandonment of Actions</font>.&#160; Should either Hengrui or Treeline (and/or its Affiliate or Sublicensee) commence a suit under the provisions
        of this Section 8.3 and thereafter elect to abandon the same, it shall give timely notice to the other Party, who may, if it so desires or pursuant to the applicable provisions under this Section 8.3, be joined as a plaintiff in the suit (or
        continue as such if it is already one) and continue prosecution of such suit according to Section 8.3.2, provided, however, that the sharing of expenses and any recovery of such suit shall be as equitably agreed upon between Hengrui and Treeline.&#160;
        In all cases, any recovery amount paid to Treeline (and/or its Affiliate or Sublicensee) will be [*].</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">8.3.5</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">Third Party Claims.&#160; </font>If the Exploitation of a Licensed Compound or Licensed Product in the Territory (or a Treeline Additional
        Product in the Greater China) pursuant to this Agreement results in, or may result in, any claim, suit, or proceeding by a Third Party alleging patent infringement by Hengrui or Treeline (or any Selling Party) (&#8220;<font style="font-weight: bold; font-style: italic;">Third Party Infringement Claim</font>&#8221;), except as otherwise set forth under this Agreement (including under Section 12.1 (Indemnification)), Treeline shall have the right, but not the obligation, to defend and settle such
        Third Party Infringement Claim in the Territory and Hengrui shall have the right, but not the obligation, to defend and settle such Third Party Infringement Claim in the Greater China. If either Party becomes aware of any Third Party Infringement
        Claim, such Party shall promptly notify the other Party in writing of such claim or action.&#160; Each Party will, upon the other Party&#8217;s request and at the other Party&#8217;s expense (except as otherwise set forth under this Agreement, including under
        Section 12.1 (Indemnification)), fully cooperate with and assist the other Party in the other Party&#8217;s conduct of the defense against and control of any such Third Party Infringement Claim; provided that (and without limiting Section 12.1), if such
        Party elects to join the defense of such Third Party Infringement Claim, or is named as a defendant and found by the court to be at fault, such Party shall be responsible for its own costs and expenses associated with such Third Party Infringement
        Claim.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">31</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">8.3.6</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">Cooperation.</font> In any suit to enforce and/or defend the Licensed Patents
        or Licensed Know-How or Licensed Compound Arising IP pursuant to this Section 8.3, the Party not in control of such suit shall, at the request and expense of the controlling Party, reasonably cooperate and, to the extent possible, have its
        employees testify when requested and make available relevant records, papers, information, samples, specimens, and the like.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">8.4</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">Patent Term Extensions.&#160; </font>Treeline shall have the right to file any patent term restoration or supplemental protection certificates or
        the like or their equivalents in any country in the Territory (&#8220;<font style="font-weight: bold; font-style: italic;">Patent Term Extensions</font>&#8221;), where applicable to Licensed Patents or any other Patents Controlled by Treeline (or any of its
        Affiliates), as may be available under Applicable Law, in each case, in connection with any Licensed Product. Hengrui will assist and reasonably cooperate with Treeline in obtaining such Patent Term Extensions in any country in the Territory,
        making available all required regulatory data and information and executing any required authorizations to apply for such Patent Term Extension. All expenses incurred in connection with activities of Hengrui pursuant to this Section 8.4 shall be
        entirely borne by Treeline.</div>
      <div>&#160;</div>
      <div style="text-align: center; font-size: 12pt; font-weight: bold;"><font style="font-size: 10pt; color: rgb(0, 0, 0);">ARTICLE 9</font><font style="font-size: 10pt;"><br>
          REPRESENTATIONS AND WARRANTIES</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">9.1</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">Mutual Representations and Warranties</font>.&#160; Each Party hereby represents and warrants to the other Party that, as of the Effective Date:</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">9.1.1</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">It is a company or corporation duly organized, validly existing and in good standing under the laws of the jurisdiction in which it is incorporated.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">9.1.2</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>(a) It has the corporate power and authority and the legal right to enter into this Agreement and to perform its
        obligations hereunder, (b) it has taken all necessary corporate action on its part to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder, and (c) this Agreement has been duly executed and
        delivered on behalf of such Party, and constitutes a legal, valid, and binding obligation of such Party that is enforceable against such Party in accordance with its terms.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">9.1.3</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>Neither such Party nor any of its Affiliates is under any obligation to any Person, contractual or otherwise,
        that is in violation of the terms of this Agreement or that would impede the fulfillment of such Party&#8217;s obligations hereunder</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">9.1.4</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>All necessary consents, approvals and authorizations of all Governmental Authorities and other Persons required
        to be obtained by such Party in connection with this Agreement have been obtained.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">9.1.5</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>The execution and delivery of this Agreement and the performance of such Party&#8217;s obligations hereunder (a) do
        not conflict with or violate any requirement of Applicable Law, and (b) do not conflict with, or constitute a default under, any contractual obligation of such Party or any of its Affiliates.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">32</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">9.1.6</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">Neither it nor any of its Affiliates is, or has been, debarred or disqualified by any Regulatory Authority.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">9.2</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">Hengrui Additional Representations and Warranties.</font>&#160; Hengrui hereby
        represents and warrants as follows:</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">9.2.1</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">Title</font>. (a) Hengrui and its Affiliates solely and exclusively own the Licensed Technology or otherwise has sufficient legal and/or
        beneficial title or ownership or license with respect to the Licensed Technology, as necessary to grant the licenses to Treeline granted pursuant to this Agreement, and the Licensed Technology is free and clear from any mortgages, pledges, liens,
        security interests, conditional and installment sale agreement, encumbrances, charges or claim of any kind; and (b) as of the Effective Date, no Third Party has taken any action (including before the United States Patent and Trademark Office, or
        any counterpart thereof outside the United States) claiming legal and/or beneficial title to, or ownership of, or license to, any Licensed Technology.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">9.2.2</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">No Additional Back-up Compounds</font>.&#160; All Back-up Compounds that exist as of
        the Effective Date are scheduled in <u>Exhibit A,</u> the associated Patents directed to each Backup Compound as of the Effective Date are scheduled in <u>Exhibit C,</u> and such Back-up Compounds and related information (if any) have been
        disclosed and provided to Treeline. If no Back-up Compound is specified in <u>Exhibit A</u>, Hengrui hereby represents and warrants that there is no existing Back-up Compound as of the Effective Date.&#160; There is no other compound that is in
        development as a Back-up Compound by or on behalf of Hengrui as of the Effective Date.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">9.2.3</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">No Infringement. </font> To Hengrui&#8217;s Knowledge as of the Effective Date, no
        Third Party Patent or other Intellectual Property rights has been infringed, misappropriated or violated (as applicable) by (a) the practice or use of the Licensed Technology, including any process, method or other invention claimed in any Licensed
        Patent or comprising any Licensed Know-How, or (b)&#160; the Exploitation of any Licensed Compound, Licensed Product, any composition or methods claimed or disclosed in the Licensed Patents, or any Licensed Technology.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">9.2.4</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">Notice of Infringement or Misappropriation.&#160; </font>No claims have been
        asserted or, to Hengrui&#8217;s Knowledge as of the Effective Date, threatened by any Person, and there are no valid grounds for any claim, and there is no judgment or written settlement against or owed by Hengrui or any of its Affiliates or licensees,
        for any claim of any kind (a) challenging the validity, effectiveness, enforceability, or ownership of, or otherwise relating to, the Licensed Technology; and/or (b) regarding or disputing inventorship of any Licensed Patent; and/or (c) alleging
        that the conception, reduction to practice, use, reproduction, modification, manufacturing, distribution, licensing, sublicensing, sale, offer for sale, import or export of, or any other exercise of rights in, any of the Licensed Technology in the
        Territory infringes, misappropriates or otherwise conflicts with or has or will infringe, misappropriate or otherwise conflict with any intellectual property rights or other rights owned or controlled by any Third Party.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">9.2.5</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">Non-Infringement and Non-Assertion by Third Parties.&#160; </font>To Hengrui&#8217;s
        Knowledge as of the Effective Date, (a) there is no actual or threatened unauthorized use, infringement or misappropriation of any of the Licensed Technology by any Third Party; and (b) no Third Party has asserted in writing that the issued patents
        within the Licensed Patents are invalid or unenforceable.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">33</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">9.2.6</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">No Proceeding.&#160; </font>As of the Effective Date, there is no pending, and to
        Hengrui&#8217;s Knowledge as of the Effective Date, no threatened, adverse action, suit or proceeding against Hengrui involving any Licensed Technology or the safety (including any product liability claim) of any Licensed Compound or Licensed Product.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">9.2.7</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">Licensed Technology.&#160; </font>The Licensed Technology constitutes all
        Intellectual Property owned or Controlled by Hengrui or any of its Affiliates as of the Effective Date that are necessary, reasonably useful for (based on Hengrui&#8217;s good faith reasonable belief), or Cover the Development, Manufacture, or
        Commercialization of Licensed Compounds and/or Licensed Products in the Territory. To Hengrui&#8217;s Knowledge as of the Effective Date, there is no information which would lead it to believe that any issued patents included in the Licensed Patents are
        invalid or unenforceable.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">9.2.8</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">Prosecution of Licensed Patents.&#160; </font>All maintenance fees, annuity
        payments, and similar payments relating to the Licensed Patents have been made as of the Effective Date. Hengrui has not taken or failed to undertake any action in connection with Prosecuting the Licensed Patents in violation of any Applicable Law.
        Hengrui and its Affiliates have complied with all Applicable Laws in connection with the Prosecution of the Licensed Patents, including the duty of candor owed to any patent office pursuant to such Applicable Laws.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">9.2.9</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">No Conflicts</font>. Hengrui has not granted to any Third Party any option,
        license or other right or interest under the Licensed Patents to Exploit the Licensed Technology in the Field in the Territory and has not taken any action that would in any way prevent it from granting the rights and licenses granted to Treeline
        under this Agreement, or that would otherwise materially conflict with or adversely affect Treeline&#8217;s rights under this Agreement during the Term.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">9.2.10</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">True Information</font>. (a) Hengrui has disclosed and caused to be disclosed
        to Treeline all material information relating to the Licensed Compounds, Licensed Products and Licensed Technology in Hengrui&#8217;s or any of its Affiliates&#8217; possession or Control prior to the execution of this Agreement (for clarity, except for
        materials Hengrui is obligated to provide to Treeline (or its designee) under Sections 2.5, 2.6, and 8.2.1); (b) all tangible information and data provided by or on behalf of Hengrui to Treeline or its Affiliates (collectively, the &#8220;<font style="font-weight: bold; font-style: italic;">Hengrui Disclosed Documents</font>&#8221;) is true, accurate and complete in all material aspects; and (c) Hengrui has not failed to disclose, or cause to be disclosed, any information or data that would
        cause the Disclosed Documents to be misleading in any material respect.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">34</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">9.2.11</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">Hengrui Partner Agreements.</font>&#160;<u>Exhibit D</u> lists each and every
        agreement, whereby Hengrui or any of its Affiliates has, as of or prior to the Effective Date, granted or agreed to grant to a Third Party any option, negotiation right, license, or other similar right or interest in any of the Licensed Technology
        to Develop or Commercialize a Licensed Compound or Licensed Product in the Greater China, other than limited licenses in services agreements solely for the purpose to provide services to Hengrui or its Affiliate (collectively, the &#8220;<font style="font-weight: bold; font-style: italic;">Hengrui Partner Agreements</font>&#8221; and such entity &#8220;<font style="font-weight: bold; font-style: italic;">China Licensee</font>&#8221;), together with a summary of each such agreement including the name of
        the China Licensee and a description of the scope (territorial and as to field of application) and nature of rights or interests in all or specified portions of the Licensed Technology. Each of the Hengrui Partner Agreements (if any) provides that
        (i) Hengrui has the right to grant to Treeline cross-reference rights consistent with Section 4.2.2 with respect to Regulatory Materials and Regulatory Approvals generated, filed or obtained within the scope of the applicable Hengrui Partner
        Agreement; and (ii) Hengrui shall have the right to grant to Treeline a license consistent with Section 2.1 to any and all material scientific or technical information, results, materials, and data, whether or not patentable, and Patents within the
        scope of the applicable Hengrui Partner Agreement, provided that such China Licensee has reciprocal rights consistent with the license granted to Hengrui under Section 2.2 and 2.7 from Treeline and its Affiliates and their respective Sublicensees
        (if applicable) with respect to the Greater China. If no Hengrui Partner Agreement is specified in <u>Exhibit D</u>, Hengrui hereby represents, warrants and covenants that there is no existing Hengrui Partner Agreement as of the Effective Date.
        For clarity, and subject to Section 2.3, none of the following Third Parties will be deemed a China Licensee: (a) any Distributor, (b) any CRO or contractor providing services to Develop Licensed Product, including for proof of concept studies and
        clinical trials, (c) any CMO engaged to manufacture a Licensed Compound and/or Licensed Product.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">9.2.12</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">Third Party Agreements.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Listed on <u>Exhibit E</u> are all the agreements existing as of the Effective Date between Hengrui and Third Parties
        pursuant to which Hengrui has obtained any rights, license and/or obligations with respect to any Licensed Technology (&#8220;<font style="font-weight: bold; font-style: italic;">Third Party Agreements</font>&#8221;). Hengrui has the full right, power and
        authority under the Third Party Agreements (if any) to grant to Treeline the rights granted to Treeline hereunder, and to Hengrui&#8217;s Knowledge as of the Effective Date, such rights granted to Treeline constitute the full and complete Third Party
        Intellectual Property rights required for the Exploitation of Licensed Compounds or Licensed Products as contemplated under this Agreement.&#160; The grant of such rights requires no consent, waiver or other action by any party to the Third Party
        Agreements and the rights and obligations of Treeline set forth in this Agreement do not contravene nor are they inconsistent with or in conflict with the terms of the Third Party Agreements in a manner that would limit the rights of Treeline
        hereunder. If no Third Party Agreement is specified in <u>Exhibit E</u>, Hengrui hereby represents, warrants and covenants that there is no existing Third Party Agreement as of the Effective Date.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Prior to the Effective Date, Hengrui has provided to Treeline true, complete and correct copies of all Third Party
        Agreements and there have been no modifications, amendments or restatements other than as provided to Treeline prior to the Effective Date. Without the prior express written consent of Treeline, Hengrui shall not (and shall take no action or make
        no omission to) amend, modify or waive any provision of any Third Party Agreements or take any action or make any omission that could impair the value of the licenses to Treeline herein, terminate or have terminated any Third Party Agreement, or
        alter any of Hengrui&#8217;s rights under the Third Party Agreement in any manner that adversely affects, or would reasonably be expected to adversely affect, Treeline&#8217;s rights and benefits under this Agreement.&#160; All the Third Party Agreements are in
        full force and effect in accordance with their terms.&#160; There exist no breaches, defaults or events which would give rise to a right to terminate or modify any Third Party Agreements and Hengrui has not received any notice from any Third Party of
        any breach, default or non-compliance under the terms of any Third Party Agreements. Hengrui has not transferred or granted, and shall not transfer or grant, to any Third Party any license or other interest in the Third Party Agreements.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">35</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;As between Hengrui, on the one hand, and the Selling Parties, on the other hand, Hengrui shall be and remain solely liable
        for any payment obligations (including license fees, milestones or royalties) under any Third Party Agreements, including all amounts arising out of Hengrui&#8217;s provision of the Licensed Technology as contemplated by this Agreement.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">9.2.13</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>To Hengrui&#8217;s Knowledge, no employee of Hengrui has breached any non-use or confidentiality obligations under any
        agreement with his or her respective prior employers, or has otherwise misappropriated any trade secret or confidential information of such employers, in each case relating to the Licensed Technology.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">9.3</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">Disclaimer</font>.&#160; EXCEPT FOR THE EXPRESS WARRANTIES PROVIDED IN THIS AGREEMENT, EACH PARTY DISCLAIMS ALL OTHER WARRANTIES, EXPRESS OR
        IMPLIED, ARISING OUT OF OR RELATED TO THIS AGREEMENT, AND EACH PARTY EXPRESSLY DISCLAIMS ALL IMPLIED WARRANTIES OF TITLE, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND NONINFRINGEMENT OF THIRD PARTY RIGHTS.&#160; WITHOUT LIMITING THE GENERALITY
        OF THE FOREGOING, NEITHER PARTY REPRESENTS NOR WARRANTS AS TO THE SAFETY, EFFICACY, OR USEFULNESS OF THE LICENSED COMPOUNDS OR LICENSED PRODUCTS, THE PATENTABILITY, VALIDITY, OR ENFORCEABILITY OF ANY LICENSED TECHNOLOGY, LICENSED COMPOUND ARISING
        IP OR ARISING IP, OR THE USEFULNESS OF ANY LICENSED KNOW-HOW, LICENSED COMPOUND ARISING IP OR ARISING IP, OR THAT THE LICENSED COMPOUNDS OR LICENSED PRODUCTS WILL BE SUCCESSFULLY DEVELOPED OR COMMERCIALIZED.</div>
      <div>&#160;</div>
      <div style="text-align: center; font-size: 12pt; font-weight: bold;"><font style="font-size: 10pt; color: rgb(0, 0, 0);">ARTICLE 10</font><font style="font-size: 10pt;"><br>
          COVENANTS</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">10.1</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">Exclusivity.&#160; </font>During the Term, Hengrui and its Affiliates shall not
        grant or assign to any Third Party any option, license or other right in the Field in the Territory under the Licensed Technology or any portion or aspect thereof.&#160; During the Term, Treeline and its Affiliates shall not grant or assign to any Third
        Party any option, license or other right in the Field in the Greater China under the Licensed Compound Arising IP or any portion or aspect thereof.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">10.2</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">Additional Hengrui Partner Agreements</font>.&#160; If any time following the Effective Date, Hengrui enters into any Hengrui Partner Agreement,
        Hengrui shall so notify Treeline within [*] Business Days of doing so, together with a summary of such agreement including the name of the China Licensee and a description of the scope (territorial and as to field of application) and nature of
        rights or interests in all or specified portions of the Licensed Technology.&#160; Hengrui agrees that all such additional Hengrui Partner Agreements shall provide that (i) Hengrui shall have the right to grant to Treeline cross-reference rights
        consistent with Section 4.2.2 with respect to Regulatory Materials and Regulatory Approvals generated, filed or obtained within the scope of the applicable Hengrui Partner Agreement; and (ii) Hengrui shall have the right to grant to Treeline a
        license consistent with Section 2.1 to any and all material scientific or technical information, results, materials, and data, whether or not patentable, and Patent developed within the scope of the applicable Hengrui Partner Agreement, provided
        that such China Licensee has reciprocal rights consistent with the license granted to Hengrui under Section 2.2 and 2.7 from Treeline and its Affiliates and their respective Sublicensees (if applicable) with respect to the Greater China.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">36</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">10.3</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">Third Party Licenses.&#160; </font>Hengrui will keep in full force and effect throughout the Term all terms of all Third Party Agreements that
        are relevant to any rights sublicensed to Treeline under this Agreement. Hengrui shall timely perform in full all obligations required to be performed by Hengrui under all Third Party Agreements.&#160; Hengrui promptly shall provide Treeline with copies
        of all notices and other deliveries received under the Third Party Agreements.&#160; Without limiting this Section 10.3, Hengrui shall promptly notify Treeline of any default under, or termination or amendment of, the Third Party Agreements.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">10.4</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">Further Assurances; Consents.&#160; </font>Each Party shall use reasonable efforts
        to take such action as is reasonably necessary or appropriate in order to complete the transactions contemplated hereby on the terms and subject to the conditions set forth herein.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">10.5</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">Debarred Individuals</font>.&#160; Each Party will promptly inform the other Party in
        writing if it or any Person performing activities under this Agreement is debarred by the FDA or is the subject of a conviction described in 21 U.S.C. 335a or similar sanction, or if any action, suit, claim, investigation, or legal or
        administrative proceeding is pending or threatened relating to the debarment or conviction of such Party or any such Person performing activities in connection with this Agreement.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">10.6</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">Anti-Corruption Laws</font>.&#160; Neither Party nor any of its Affiliates will perform any actions in connection with this Agreement that are
        prohibited by local and other anti-corruption laws (collectively &#8220;<font style="font-weight: bold; font-style: italic;">Anti-Corruption Laws</font>&#8221;) that may be applicable to such Party.&#160; Without limiting the foregoing, neither Party nor any of its
        Affiliates will make any payments, or offer or transfer anything of value, to any government official or government employee, to any political party official or candidate for political office or to any other Third Party related to the transactions
        contemplated by this Agreement in a manner that would violate any Anti-Corruption Laws.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">10.7</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">Compliance with Laws</font>. Each Party and its Affiliates will comply with all
        Applicable Laws in the performance of its obligations and exercise of its rights under this Agreement.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">10.8</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">Diligence. </font>Treeline will use Commercially Reasonable Efforts to acquire the resources, expertise, and personnel reasonably necessary
        to Develop and Commercialize the Licensed Products in the Territory as required under Section 4.4.</div>
      <div>&#160;</div>
      <div style="text-align: center; font-size: 12pt; font-weight: bold;"><font style="font-size: 10pt; color: rgb(0, 0, 0);">ARTICLE 11</font><font style="font-size: 10pt;"><br>
          CONFIDENTIALITY</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">11.1</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">Confidentiality</font>.&#160; Each Party agrees that, during the Term and for a period of [*] years thereafter, it shall keep confidential and
        shall not publish or otherwise disclose and shall not use for any purpose other than as provided for in this Agreement (which includes the exercise of any rights or the performance of any obligations hereunder or thereunder) any Confidential
        Information of the other Party, except to the extent expressly agreed in writing by the Parties, provided that for any trade secrets included in a Party&#8217;s Confidential Information, such obligation will remain for as long as the information remains
        a trade secret under Applicable Law. The foregoing confidentiality and non-use obligations shall not apply to any information that the receiving Party can demonstrate by competent written proof:</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">37</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">11.1.1</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>was already known to the receiving Party or its Affiliate, other than under an obligation of confidentiality, at
        the time of disclosure by the other Party;</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">11.1.2</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>was generally available to the public or otherwise part of the public domain at the time of its disclosure to
        the receiving Party;</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">11.1.3</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>became generally available to the public or otherwise part of the public domain after its disclosure and other
        than through any act or omission of the receiving Party or its Affiliate in breach of this Agreement;</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">11.1.4</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>was disclosed to the receiving Party or its Affiliate without any confidentiality obligations by a Third Party
        who, to the Party&#8217;s knowledge, had a legal right to make such disclosure and who did not obtain such information directly or indirectly from the other Party; or</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">11.1.5</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>was independently discovered or developed by the receiving Party or its Affiliate without use of or reference to
        the other Party&#8217;s Confidential Information, as evidenced by a contemporaneous writing.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">11.2</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">Authorized Disclosure.&#160; </font>Notwithstanding the obligations set forth in
        Section 11.1, a Party may disclose the other Party&#8217;s Confidential Information and the terms of this Agreement to the extent:</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">11.2.1</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">such disclosure is reasonably necessary (i) for the filing or prosecuting of Patent rights as contemplated herein; (ii) to comply with the requirements of Regulatory
        Authorities with respect to obtaining and maintaining Regulatory Approval of Licensed Product; or (iii) for the prosecuting or defending litigation as contemplated herein;</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">11.2.2</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">such disclosure is reasonably necessary to its or its Affiliate&#8217;s employees, agents, consultants, contractors, licensees or Sublicensees, on a need-to-know basis for the
        sole purpose of performing its obligations or exercising its rights hereunder; provided that in each case, the disclosees are bound by written obligations of confidentiality consistent with those contained in this Agreement; or</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">11.2.3</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>such disclosure is reasonably necessary to comply with Applicable Laws, including regulations or rules
        promulgated by applicable securities commissions (or other securities regulatory authorities), security exchanges, court order, administrative subpoena or order; and</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">11.2.4</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>solely with respect to the terms of this Agreement and excluding disclosure of any other Confidential
        Information, such disclosure is reasonably necessary to any bona fide potential or actual investor, acquiror, merger partner, or other financial or commercial partner for the sole purpose of evaluating or carrying out an actual or potential
        investment, acquisition or other business relationship; provided that in connection with such disclosure, such Party shall inform each disclosee of the confidential nature of such Confidential Information and require each disclosee to treat such
        Confidential Information as confidential.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">38</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">11.2.5</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>Notwithstanding the foregoing, in the event a Party is required to make a disclosure of the other Party&#8217;s
        Confidential Information pursuant to Section 11.2.1 or 11.2.3, such Party shall (a) promptly notify the other Party of such required disclosure, to the extent that it is legally authorized or permitted to so, (b) use reasonable efforts to obtain,
        or to assist the other Party in obtaining, a protective order preventing or limiting the required disclosure, (c) assist and cooperate with the other Party in the exercise of its right to protect the confidentiality of the Confidential Information,
        and (d) disclose only the Confidential Information that is required by Applicable Law to be disclosed.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">11.3</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">No Publicity; Terms of Agreement.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">11.3.1</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>The Parties agree that the terms of this Agreement are the Confidential Information of both Parties, subject to
        Section 11.2 and this Section 11.3.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">11.3.2</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">Except as required by Applicable Law and subject to the requirements (a) through (d) under Section 11.2.5, neither Party shall make, or procure or permit the making of, any
        press release or other publicity or public announcement (including on any website or in any company publication) in relation to this Agreement without first obtaining the written approval of the other Party to any such release or announcement, such
        approval shall not be unreasonably withheld or delayed.</div>
      <div>&#160;</div>
      <div style="text-align: center; font-size: 12pt; font-weight: bold;"><font style="font-size: 10pt; color: rgb(0, 0, 0);">ARTICLE 12</font><font style="font-size: 10pt;"><br>
          LIABILITY AND INDEMNITY</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">12.1</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">Indemnification.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">12.1.1</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>Hengrui shall defend, indemnify, and hold Treeline and its Affiliates and Sublicensees harmless from all [*]
        arising out of (a) the [*] or the [*] by or on behalf of Hengrui, its Affiliates or China Licensees (other than Treeline), (b) [*] Hengrui or any of its Affiliates or China Licensees; (c) [*] Hengrui or any of its Affiliates or China Licensees; or
        (d) [*] Hengrui or any of its Affiliates or China Licensees; except in each case to the extent arising from (i) any breach of this Agreement (including any covenants, representations or warranties herein) by Treeline, its Affiliates or their
        respective Sublicensees or (ii) gross negligence or willful misconduct of Treeline, its Affiliates or their respective Sublicensees.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">12.1.2</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">Treeline shall defend, indemnify, and hold Hengrui and its Affiliates and China Licensees harmless from all [*] arising out of (a) the [*] or [*] by or on behalf of
        Treeline, its Affiliates or their Sublicensees (other than Hengrui); (b) [*] Treeline or any of its Affiliates or their Sublicensees; (c) [*] Treeline or any of its Affiliates or their Sublicensees; or (d) [*] Treeline or any of its Affiliates or
        their Sublicensees; except in each case to the extent arising from (i) the gross negligence or willful misconduct of Hengrui or any of its Affiliates or China Licensees, or (ii) any breach of this Agreement (including any covenants, representations
        or warranties herein) by Hengrui or any of its Affiliates or China Licensees.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">39</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">12.1.3</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">Indemnification Procedures.&#160; </font>The indemnified party (the &#8220;<font style="font-weight: bold; font-style: italic;">Indemnitee</font>&#8221;) promptly shall notify the indemnifying Party (&#8220;<font style="font-weight: bold; font-style: italic;">Indemnitor</font>&#8221;) of any liability or action in respect of which the
        Indemnitee intends to claim such indemnification, and the Indemnitor shall have the right to assume the defense thereof with counsel selected by the Indemnitor.&#160; The indemnification obligations in this Section 12.1 shall not apply to amounts paid
        in settlement of any loss, claim, damage, liability or action if such settlement is effected by the Indemnitee without the consent of the Indemnitor, which consent shall not be withheld unreasonably.&#160; The indemnitor shall not enter into any
        settlement of the indemnified claim that does not include a complete and unconditional release of the Indemnitee from all liabilities with respect thereto or that imposes any liability or obligation on the Indemnitee without the prior written
        consent of the Indemnitee, which consent shall not be withheld unreasonably.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">12.1.4</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>The failure to deliver notice to the Indemnitor within a reasonable time after the commencement of any such
        action, if prejudicial to its ability to defend such action, shall relieve the Indemnitor of any liability to the Indemnitee under this Section 12.1.&#160; The Indemnitee under this Section 12.1, its employees and agents, shall cooperate fully with the
        Indemnitor and its legal representatives in the investigation and defense of any action, claim or liability covered by this indemnification at Indemnitor&#8217;s expense.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">12.2</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">Limitation of Liability.</font>&#160; IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE
        OTHER FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, PUNITIVE, EXEMPLARY OR INDIRECT DAMAGES OF ANY KIND ARISING FROM OR RELATING TO ANY PERFORMANCE OR BREACH OF THIS AGREEMENT OR ANY CLAIMS ARISING HEREUNDER, HOWEVER CAUSED AND ON ANY THEORY OF
        LIABILITY (WHETHER IN CONTRACT, TORT (INCLUDING NEGLIGENCE), STRICT LIABILITY OR OTHERWISE), REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS SECTION 12.2 IS INTENDED TO OR WILL LIMIT OR
        RESTRICT (A) THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY PARTY UNDER SECTION 12.1, (B) DAMAGES AVAILABLE TO A PARTY FOR A BREACH BY THE OTHER PARTY OF THE CONFIDENTIALITY OBLIGATIONS UNDER ARTICLE 11, (C) [*], OR (D) [*]. For the avoidance of
        doubt, neither Party nor any of its Affiliates shall be responsible or liable for any losses, liabilities, damages or expenses arising out of the Exploitation of any Licensed Compound or Licensed Product or the practice of the Licensed Technology
        by or on behalf of the other Party or any Affiliate (or China Licensees in the case of Hengrui) of such other Party prior to the Effective Date.</div>
      <div>&#160;</div>
      <div style="text-align: center; font-size: 12pt; font-weight: bold;"><font style="font-size: 10pt; color: rgb(0, 0, 0);">ARTICLE 13</font><font style="font-size: 10pt;"><br>
          TERM AND TERMINATION</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">13.1</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">Term.</font>&#160; The term of this Agreement shall begin on the Effective Date and,
        unless earlier terminated in accordance with the terms of this Article 13, will continue until the end of the last-to-expire Royalty Term (the &#8220;<font style="font-weight: bold; font-style: italic;">Term</font>&#8221;). Upon expiration of the Term,
        Treeline and its Affiliates shall have, and Hengrui does hereby grant to Treeline, a non-exclusive, royalty-free, fully paidup, perpetual license, without the right to sublicense (except to Sublicensees) to use the Licensed Know-How to Exploit
        Licensed Products in the Field in the Territory.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">13.2</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">Termination for Breach.</font></div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">40</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">13.2.1</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>Subject to Section 13.2.2, each Party shall have the right to terminate this Agreement upon written notice to
        the other Party if such other Party materially breaches this Agreement and has not cured such breach to the reasonable satisfaction of the other Party within [*] days (and within [*] days in the case of a payment breach) after notice of such breach
        from the non-breaching Party; provided, however, that if the alleged breaching Party disputes in good faith the existence or materiality of a breach specified in such notice of breach and such alleged breaching Party provides the other Party notice
        of such dispute within [*] days after receiving such notice, then the Party that gave the notice of breach shall not have the right to terminate this Agreement under this Section 13.2 unless and until it is determined in accordance with Section
        14.3 that the alleged breaching Party has materially breached the Agreement as specified in the notice of breach, and then such breaching Party fails to cure such breach within [*] days following such determination (and within [*] days in the case
        of a payment breach).&#160; It is understood and agreed that during the pendency of such dispute, all of the terms and conditions of this Agreement shall remain in effect and the Parties shall continue to perform all of their respective obligations
        hereunder. For clarity, to the extent a material breach of this Agreement affects one or more specific countries only, the termination right under this Section 13.2.1 shall be limited to such specific country or countries, as applicable. In the
        event Hengrui materially breaches the license granted by Treeline to Hengrui under Section 2.7, Treeline shall have the right to terminate the license granted to Hengrui under Section 2.7, subject to the procedures and the right to cure provided in
        this Section 13.2 and the dispute resolution process provided in Section 14.3, without terminating this Agreement in its entirety (if the Agreement has not expired).</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">13.2.2</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>If Hengrui has the undisputed right to terminate this Agreement pursuant to Section 13.2.1, the Parties agree
        that such termination is a remedy to be invoked by Hengrui only if the breach cannot be adequately remedied through any of the following: (a) specific performance within a period of [*] days immediately following Hengrui obtaining such termination
        right, (b) payment of money damages, or (c) a combination of (a) and (b).</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">13.3</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">Termination for Insolvency.&#160; </font>Each Party shall have the right to
        terminate this Agreement upon written notice to the other Party if the other Party incurs an Insolvency Event; <font style="font-style: italic;">provided</font>, however, in the case of any involuntary bankruptcy proceeding, such right to
        terminate shall only become effective if the Party that incurs the Insolvency Event consents to the involuntary bankruptcy or if such proceeding is not dismissed or stayed within [*] days after the filing thereof.&#160; &#8220;<font style="font-weight: bold; font-style: italic;">Insolvency Event</font>&#8221; means circumstances under which a Party (i) has a receiver or similar officer appointed over all or a material part of its assets or business; (ii) passes a resolution for winding-up of all or a
        material part of its assets or business (other than a winding-up for the purpose of, or in connection with, any solvent amalgamation or reconstruction) or a court enters an order to that effect; (iii) has entered against it an order for relief
        recognizing it as a debtor under any insolvency or bankruptcy laws (or any equivalent order in any jurisdiction); or (iv) enters into any composition or arrangement with its creditors with respect to all or a material part of its assets or business
        (other than relating to a solvent restructuring). All rights and licenses granted under or pursuant to this Agreement by Treeline or Hengrui or their Affiliates are, and will otherwise be deemed to be, for purposes of Section 365(n) of the U.S.
        Bankruptcy Code, licenses of right to &#8220;intellectual property&#8221; as defined under Section 101 of the U.S. Bankruptcy Code.&#160; The Parties agree that the Parties and their respective Affiliates, Sublicensees and Third Party sublicensees, as licensees of
        such rights under this Agreement, will retain and may fully exercise all of their rights and elections under the U.S. Bankruptcy Code and any foreign counterparts thereto.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">41</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">13.4</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">Termination for Convenience</font>.&#160; Treeline shall have the right to terminate
        this Agreement at any time and for any reason upon [*] days&#8217; prior written notice to Hengrui.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">13.5</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">Termination for Patent Challenge.&#160; </font>Except to the extent the following is
        unenforceable under the laws of a particular jurisdiction, if Treeline or its Affiliate commences a legal action challenging the validity or enforceability of any Licensed Patent, Hengrui may terminate Treeline&#8217;s license to such Licensed Patent
        upon [*] days&#8217; written notice to Treeline, unless Treeline or its Affiliate withdraw such action within such [*]-day period. If a Sublicensee of Treeline or its Affiliates challenges the validity or enforceability of any Licensed Patent in a legal
        action, upon Hengrui&#8217;s request, Treeline will terminate the Sublicense granted to such Sublicensee to such Licensed Patent upon [*] days&#8217; written notice to the Sublicensee, provided such challenge is not dropped by such Sublicensee within such
        thirty (30)day period. Notwithstanding the foregoing, Hengrui may not terminate any part of this Agreement pursuant to this Section 13.5 if Treeline or its Affiliates, or its or their respective Sublicensee (as applicable) (a) challenges such
        Licensed Patent in defense of claims related to the Licensed Patents or this Agreement and raised by Hengrui or its Affiliates against Treeline or its Affiliate or such Sublicensee, as applicable; (b) acquires a Third Party that has an existing
        challenge, whether in a court or administrative proceeding, against one or more of the Licensed Patents and terminates such challenge in [*] days following the consummation of such acquisition; or (c) licenses a product for which there is an
        existing challenge, whether in a court or administrative proceeding, against one or more of the Licensed Patents and terminates such challenge in [*] days following the execution of such license.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">13.6</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">Effect of Expiration or Termination.</font>&#160; Upon expiration or termination of this Agreement for any reason and subject to Section 13.1:</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">13.6.1</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">The Parties shall not be relieved of any obligation accruing prior to such expiration or termination, and the provisions of Article 1 (Definitions), Article 6 (Payments)
        (with respect to any outstanding payment obligation), Article 11 (Confidentiality), Article 12 (Liability and Indemnity), and Article 14 (General Provisions) and Sections 2.7 (License to Hengrui) (except for termination for Hengrui&#8217;s material
        breach in accordance with Section 13.2.1), 2.9 (No Other Licenses), 8.1 (Ownership), 9.3 (Disclaimer), and 13.6 (Effect of Expiration or Termination) and the second sentence of Section 13.1 (Term) shall survive the expiration or termination of this
        Agreement. For clarity, all payment obligations with respect to Treeline Additional Products will terminate upon any expiration or termination of this Agreement except for payments already accrued as of the date of such expiration or termination.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">13.6.2</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>To the extent this Agreement is only partially terminated, the licenses granted to Treeline in Section 2.1 shall
        terminate solely with respect to the Licensed Compound(s), Licensed Product(s) and countr(ies) in which the termination becomes effective; provided, however, that Treeline and other Selling Parties, as applicable, shall be permitted to distribute
        and sell all Licensed Products that were in inventory or in production on an effective termination date for a period of [*] months following the effective termination date (&#8220;<font style="font-weight: bold; font-style: italic;">Commercialization
          WindDown Period</font>&#8221;), in accordance with the terms of this Agreement, including payment of the applicable royalties.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">42</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">13.6.3</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>Treeline will return to Hengrui or destroy (as directed by Hengrui) all tangible embodiments of the Licensed
        Technology (excluding Licensed Know-How in case of expiration) and other Confidential Information of Hengrui. Hengrui will return to Treeline or destroy (as directed by Treeline) all tangible embodiments of the Confidential Information of Treeline.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">13.6.4</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>Treeline will transfer back to Hengrui all rights to prosecute the Licensed Patents in the terminated country in
        the Territory.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">13.6.5</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font>Notwithstanding the foregoing, no termination of this Agreement shall be construed as a termination of any
        Sublicense of any Sublicensee hereunder, and thereafter, each such Sublicensee or any of its Sublicensees in any tier shall be considered a direct licensee of Hengrui having a direct license with the same scope as such Sublicense and on terms and
        conditions of this Agreement, provided that (i) such termination is not caused by such Sublicensee, and (ii) such Sublicensee agrees in writing to assume all applicable obligations of Treeline under this Agreement.</div>
      <div>&#160;</div>
      <div style="text-align: center; font-size: 12pt; font-weight: bold;"><font style="font-size: 10pt; color: rgb(0, 0, 0);">ARTICLE 14</font><font style="font-size: 10pt;"><br>
          GENERAL PROVISIONS</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">14.1</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">Force Majeure.</font>&#160; Neither Party shall be held liable to the other Party nor
        be deemed to have defaulted under or breached this Agreement for failure or delay in performing any obligation (other than payment) under this Agreement to the extent such failure or delay is caused by or results from causes beyond the reasonable
        control of the affected Party, potentially including, but not limited to, embargoes, war, acts of war (whether war has been declared or not), acts of terrorism, insurrections, riots, civil commotions, strikes, lockouts or other labor disturbances,
        fire, floods, or other acts of God, epidemics and pandemics (including the current COVID-19 pandemic), or acts, omissions or delays in acting by any governmental authority or the other Party.&#160; The affected Party shall notify the other Party of such
        force majeure circumstances as soon as reasonably practical and shall promptly undertake all reasonable efforts necessary to cure such force majeure circumstances.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">14.2</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">Governing Law.&#160; </font>This Agreement shall be governed by and construed in accordance with the laws and jurisdiction of New York, New York,
        U.S.A., without reference to its conflict of laws principles, and shall not be governed by the United Nations Convention of International Contracts on the Sale of Goods (the Vienna Convention).</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">14.3</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">Dispute Resolution.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">14.3.1</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">Disputes; Internal Resolution.</font>&#160; The Parties recognize that disputes as
        to certain matters may from time to time arise that relate to either Party&#8217;s rights and/or obligations hereunder.&#160; It is the objective of the Parties to establish procedures to facilitate the resolution of disputes arising under this Agreement in
        an expedient manner by mutual cooperation.&#160; To accomplish this objective, the Parties agree that if a dispute arises under or relates to this Agreement, including, without limitation, any alleged breach under this Agreement or any issue relating to
        the interpretation or application of this Agreement, and the Parties are unable to resolve such dispute within [*] days after such dispute is first identified by either Party in writing to the other, the Parties shall refer such dispute to the
        Executive Officer of each of Hengrui and Treeline for attempted resolution by good faith negotiations within [*] days after notice referring to the dispute is received.&#160; If the dispute is not resolved within such [*] days, then the dispute shall be
        resolved by arbitration in accordance with Section 14.3.2 and thereafter neither Party shall have any further obligation under this Section 14.3.1.&#160; Notwithstanding the foregoing, and without waiting for the expiration of any such [*]-day periods,
        each Party shall each have the right to apply to any court of competent jurisdiction for appropriate interim or provisional relief, as necessary to protect the rights or property of such Party.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">43</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">14.3.2</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">Arbitration.&#160; </font>All disputes arising out of or in connection with this
        Agreement, including any questions regarding its formation, existence, validity or termination, or the scope or applicability of this agreement to arbitrate, shall be finally settled under the [*] by a tribunal comprised of three (3) arbitrators.&#160;
        Each Party shall nominate one arbitrator and the two Party-nominated arbitrators shall nominate the third arbitrator, who shall serve as the presiding arbitrator, within [*] days after the second arbitrator&#8217;s appointment.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The seat, or legal place, of arbitration shall be [*]. The language of the arbitration shall be English.&#160; The arbitral
        award shall be final and binding on the Parties, and the Parties undertake to carry out any award without delay.&#160; Judgment on the award may be entered in any court of competent jurisdiction.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Each Party retains the right to apply to any court of competent jurisdiction for interim and/or conservatory measures,
        including pre-arbitral attachments or preliminary injunctions, and any such request shall not be deemed incompatible with, or a waiver of, this agreement to arbitrate.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The existence and content of the arbitral proceedings and any rulings or awards shall be kept confidential by the Parties
        and members of the arbitral tribunal except (i) to the extent that disclosure may be required of a Party to fulfill a legal duty, protect or pursue a legal right, or enforce or challenge an award in bona fide legal proceedings before a state court
        or other judicial authority, (ii) with the consent of all Parties, (iii) where needed for the preparation or presentation of a claim or defense in this arbitration, (iv) where such information is already in the public domain other than as a result
        of a breach of this clause, or (v) by order of the arbitral tribunal upon application of a Party.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">14.4</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">Assignment.</font>&#160; Neither Party may assign or transfer this Agreement or any
        rights or obligations hereunder without the prior written consent of the other Party, such consent not to be unreasonably withheld, except that a Party may assign or transfer this Agreement without such consent to its Affiliate or its successor in
        interest by way of merger, acquisition, or sale of all or substantially all of its assets or business pertaining to this Agreement, provided that Treeline may not assign to a successor in interest that is an Excluded Entity unless consented by
        Hengrui in writing, such consent not to be unreasonably withheld.&#160; For purposes of the foregoing, any change in control of the assigning Party will be deemed to be an assignment. Subject to the foregoing, any permitted assignment shall be binding
        on the permitted successors and assigns of the assigning Party.&#160; Any assignment in violation of this Section 14.4 shall be null and void.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">44</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">14.5</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">Publicity &#8211; Use of Name.&#160; </font>Neither Party shall be permitted to use the name, or any proprietary Trademarks of the other Party, or its
        Affiliates, or its Sublicensees, in any publicity, promotion, news release or public disclosure relating to this Agreement or its subject matter, without the prior express written permission of the other Party.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">14.6</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">Severability.&#160; </font>If any provision of this Agreement is held to be invalid
        or unenforceable by arbitrator(s) or any court of competent jurisdiction from which no appeal can be or is taken, the provision shall to that extent be considered severed from this Agreement, and the remainder of this Agreement will remain in full
        force and effect.&#160; The Parties shall make a good faith effort to replace any invalid or unenforceable provision with a valid and enforceable one such that the Parties&#8217; original goals and interests when entering this Agreement may be realized and
        protected.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">14.7</font></div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">Waiver.&#160; </font>Neither Party may waive or release any of its rights or interests in this Agreement except in writing.&#160; The failure of
        either Party to assert a right hereunder, or to insist upon compliance with any term or condition of this Agreement, shall not constitute a waiver of that right or excuse a similar subsequent failure to perform any such term or condition.&#160; Any
        waiver by a Party of a particular breach or default by the other Party shall not operate or be construed as a waiver of any subsequent breach or default by the other Party.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">14.8</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">Cumulative Remedies.</font>&#160; No remedy referred to in this Agreement is intended
        to be exclusive, but each shall be cumulative and in addition to any other remedy referred to in this Agreement or otherwise available under law.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">14.9</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">Waiver of Rule of Construction.</font>&#160; Each Party has had the opportunity to consult with counsel in connection with the review, drafting
        and negotiation of this Agreement.&#160; Accordingly, the rule of construction that any ambiguity in this Agreement shall be construed against the drafting Party shall not apply.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">14.10</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">Agency.&#160; </font>Neither Party is, nor will be deemed to be an employee, agent,
        or representative of the other Party for any purpose.&#160; Each Party is an independent contractor, not an employee or partner of the other Party.&#160; Neither Party shall have the authority to speak for, represent, or obligate the other Party in any way
        without prior written authority from the other Party.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">14.11</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">Exhibits.</font>&#160; All Exhibits to this Agreement shall form an integral part of
        this Agreement.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">14.12</font></div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">Entire Understanding.&#160; </font>This Agreement contains the entire understanding between the Parties hereto with respect to its subject matter
        and supersedes any and all prior agreements, understandings and arrangements, whether written or oral.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">14.13</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">Amendments.</font>&#160; No amendments of the terms and conditions of this Agreement
        shall be binding upon either Party hereto unless in writing and signed by both Parties.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">45</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">14.14</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">Interpretation</font>.&#160; Except where the context expressly requires otherwise,
        (a) the use of any gender herein will be deemed to encompass references to either or both genders, and the use of the singular will be deemed to include the plural (and vice versa), (b) the words &#8220;include,&#8221; &#8220;includes,&#8221; and &#8220;including&#8221; will be
        deemed to be followed by the phrase &#8220;without limitation,&#8221; (c) the word &#8220;will&#8221; will be construed to have the same meaning and effect as the word &#8220;shall,&#8221; (d) any definition of or reference to any agreement, instrument, or other document herein will
        be construed as referring to such agreement, instrument, or other document as from time to time amended, supplemented, or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein), (e) any
        reference herein to any person will be construed to include the person&#8217;s successors and assigns, (f) the words &#8220;herein,&#8221; &#8220;hereof,&#8221; and &#8220;hereunder&#8221; and words of similar import, will each be construed to refer to this Agreement in its entirety and
        not to any particular provision hereof, (g) all references herein to Articles, Sections, or Schedules will be construed to refer to Articles, Sections, or Schedules of this Agreement, and references to this Agreement include all Schedules hereto,
        (h) the word &#8220;notice&#8221; means notice in writing (whether or not specifically stated) and will include notices, consents, approvals and other written communications contemplated under this Agreement, (i) provisions that require that a Party, the
        Parties or any committee hereunder &#8220;agree,&#8221; &#8220;consent,&#8221; &#8220;approve,&#8221; or the like will require that such agreement, consent, or approval be specific and in writing, whether by written agreement, letter, approved minutes, or otherwise (but excluding
        e-mail and instant messaging), (j) references to any specific law, rule or regulation, or section or other division thereof, will be deemed to include the then-current amendments thereto or any replacement or successor law, rule or regulation
        thereof and (k) the term &#8220;or&#8221; will be interpreted in the inclusive sense commonly associated with the term &#8220;and/or.&#8221;.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">14.15</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">Counterparts.</font>&#160; This Agreement may be executed in one or more
        counterparts, each of which is an original, and all of which together constitute the one and the same agreement between the Parties. The signatures of all the Parties do not need to be on the same counterpart for it to be effective. Delivery of an
        executed counterpart&#8217;s signature page of this Agreement, by electronic mail in portable document format (.pdf) or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document, has the same effect as
        delivery of an executed original of this Agreement.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">14.16</font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);"></font><font style="font-weight: bold;">Notices.</font>&#160; Any consent, notice or report required or permitted to be given
        hereunder shall be in writing and may be delivered personally, sent by electronic mail (with reply confirming receipt), sent by nationally-recognized overnight courier or sent by registered or certified mail, postage prepaid, return receipt
        requested, at the postal addresses or email addresses specified below:</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z6b9164a1487e4430a63a99b445eabb47" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;">&#160;</td>
            <td style="width: 108pt; vertical-align: top;">If to Hengrui:</td>
            <td style="width: auto; vertical-align: top;">
              <div>Jiangsu Hengrui Pharmaceuticals Co., Ltd.</div>
            </td>
          </tr>

      </table>
      <div style="text-indent: 0pt; margin-left: 144pt;">1288 Haike Road</div>
      <div style="text-indent: 0pt; margin-left: 144pt;">Pudong New District, Shanghai,</div>
      <div style="text-indent: 0pt; margin-left: 144pt;">China</div>
      <div style="text-indent: 0pt; margin-left: 144pt;">Attn:&#160; [*]</div>
      <div style="text-indent: 0pt; margin-left: 144pt;">Email:&#160; [*]</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf40dd81333104deeabef1ac2bcf86d8c" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 108pt; vertical-align: top;">If to Treeline:</td>
            <td style="width: auto; vertical-align: top;">
              <div>Treeline Biosciences, Inc.</div>
            </td>
          </tr>

      </table>
      <div style="text-indent: 0pt; margin-left: 144pt;">677 Washington Blvd., Ste. 525</div>
      <div style="text-indent: 0pt; margin-left: 144pt;">Stamford, Connecticut 06901</div>
      <div style="text-indent: 0pt; margin-left: 144pt;">USA</div>
      <div style="text-indent: 0pt; margin-left: 144pt;">Attn:&#160; [*]</div>
      <div style="text-indent: 0pt; margin-left: 144pt;">Email:&#160; [*]</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">46</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-indent: 0pt; margin-left: 144pt;">With a copy to (which will not constitute notice):</div>
      <div style="text-indent: 0pt; margin-left: 144pt; font-weight: bold;">Treeline Biosciences, Inc.</div>
      <div style="text-indent: 0pt; margin-left: 144pt;">677 Washington Blvd., Ste. 525</div>
      <div style="text-indent: 0pt; margin-left: 144pt;">Stamford, Connecticut 06901</div>
      <div style="text-indent: 0pt; margin-left: 144pt;">USA</div>
      <div style="text-indent: 0pt; margin-left: 144pt;">Attn:&#160; [*].</div>
      <div style="text-indent: 0pt; margin-left: 144pt;">Email:&#160; [*]</div>
      <div>&#160;</div>
      <div style="text-align: justify;">or to such other address(es) as the Party to whom notice is to be given may have furnished to the other Party in writing in accordance herewith.&#160; Any such notice shall be deemed to have been given: (a) when delivered
        if personally delivered or sent by electronic mail on a business day (or if delivered or sent on a non-business day, then on the next business day); (b) on the business day after dispatch if sent by nationally-recognized overnight courier; or (c)
        on the fifth (5th) business day following the date of mailing, if sent by mail.</div>
      <div>&#160;</div>
      <div style="text-align: center;">[<font style="font-style: italic;">signature page follows</font>]</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">47</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">IN WITNESS WHEREOF, the Parties have executed this Agreement to take effect as of the Effective Date.</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z0681c671d6804490a8b29a0647e31ff4" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td colspan="3" style="vertical-align: top;">
              <div style="text-align: justify; font-weight: bold;">Treeline Biosciences, Inc.</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
            <td rowspan="1" colspan="3" style="vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td style="width: 3%; vertical-align: top; padding-bottom: 2px;">
              <div style="text-align: justify;">By:</div>
            </td>
            <td style="width: 32%; vertical-align: top; border-bottom: 2px solid black;">
              <div style="text-align: justify; margin-left: 9pt;">/s/ Joshua H. Bilenker</div>
            </td>
            <td style="width: 15%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          </tr>

      </table>
      <div><br>
      </div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z09337f1126a74a78a6d4302a2bfb3ffc" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
              <div style="text-align: justify;">Name:</div>
            </td>
            <td style="width: 30%; vertical-align: top; border-bottom: 2px solid black;">
              <div style="text-align: justify; margin-left: 9pt;">Joshua H. Bilenker</div>
            </td>
            <td style="width: 15%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 5%; vertical-align: top;">&#160;</td>
            <td colspan="2" rowspan="1" style="vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
              <div style="text-align: justify;">Title</div>
            </td>
            <td style="width: 30%; vertical-align: top; border-bottom: 2px solid black;">
              <div style="text-align: justify; margin-left: 9pt;">CEO</div>
            </td>
            <td style="width: 15%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          </tr>

      </table>
      <div><br>
      </div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z68f004ee7bd341789442747369cfb486" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td colspan="3" style="vertical-align: top;">
              <div style="text-align: justify; font-weight: bold;">Jiangsu Hengrui Pharmaceuticals Co., Ltd.</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
            <td rowspan="1" colspan="3" style="vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td style="width: 3%; vertical-align: top; padding-bottom: 2px;">
              <div style="text-align: justify;">By:</div>
            </td>
            <td style="width: 32%; vertical-align: top; border-bottom: 2px solid black;">
              <div style="text-align: justify; margin-left: 9pt;">s/ Frank Ningjun Jiang</div>
            </td>
            <td style="width: 15%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          </tr>

      </table>
      <div><br>
      </div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z08073e9b47934f12b9ecf45ae48004c1" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
              <div style="text-align: justify;">Name:</div>
            </td>
            <td style="width: 30%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify; margin-left: 9pt;">Frank Ningjun Jiang <br>
              </div>
            </td>
            <td style="width: 15%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 5%; vertical-align: top;">&#160;</td>
            <td colspan="2" rowspan="1" style="vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
              <div style="text-align: justify;">Title</div>
            </td>
            <td style="width: 30%; vertical-align: top; border-bottom: 2px solid black;">
              <div style="text-align: justify; margin-left: 9pt;">Chief Strategy Officer</div>
            </td>
            <td style="width: 15%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          </tr>

      </table>
      <div> <br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">48</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: center; font-weight: bold;"><u>EXHIBIT A</u></div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">Licensed Compound</div>
      <div>&#160;</div>
      <div style="text-align: center;">[Intentionally omitted]</div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">49</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: center; font-weight: bold;"><u>EXHIBIT B</u></div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">Licensed Know-How</div>
      <div>&#160;</div>
      <div style="text-align: center;">[Intentionally omitted]</div>
      <div> <br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">50</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: center; font-weight: bold;"><u>EXHIBIT C</u></div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">Licensed Patents</div>
      <div>&#160;</div>
      <div style="text-align: center;">[Intentionally omitted]</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">51</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: center; font-weight: bold;"><u>EXHIBIT D</u></div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">Hengrui Partner Agreements</div>
      <div>&#160;</div>
      <div style="text-align: center;">[Intentionally omitted]</div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">52</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: center; font-weight: bold;"><u>EXHIBIT E</u></div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">Third Party Agreements</div>
      <div>&#160;</div>
      <div style="text-align: center;">[Intentionally omitted]</div>
      <div><br>
      </div>
      <div>&#160;<br>
      </div>
    </div>
  </div>
  <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">53</font></div>
  <div class="BRPFPageNumberArea" style="text-align: center;">
    <hr style="height: 2px; color: #000000; background-color: #000000; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;"> </font></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>ny20077604x1_ex10-3.htm
<DESCRIPTION>EXHIBIT 10.3
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 26.3.2.5342
         Copyright 1995 - 2026 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div style="width: 100%;" class="BRPFPageHeader"></div>
  <div>
    <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">
    <div style="text-align: right;"><font style="font-weight: bold;"> Exhibit 10.3</font>
      <div><br>
      </div>
    </div>
    <div>
      <div style="text-align: center; text-indent: -0.5pt; margin-right: 23.7pt; margin-left: 15.1pt; color: rgb(0, 0, 0); font-weight: bold;">AMENDED AND RESTATED THIRD AMENDMENT TO LEASE</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; margin-right: 8.25pt; color: rgb(0, 0, 0); font-weight: bold;">THIS AMENDED AND RESTATED THIRD AMENDMENT TO LEASE AMENDS, RESTATES AND SUPERSEDES IN ITS ENTIRETY THAT CERTAIN THIRD AMENDMENT TO
        LEASE DATED MAY 10, 2024, BY AND BETWEEN LANDLORD AND TENANT.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; margin-right: 8.35pt; color: rgb(0, 0, 0);">THIS AMENDED AND RESTATED THIRD AMENDMENT TO LEASE (this &#8220;<font style="font-weight: bold;">Third Amendment</font>&#8221;) is made as of May 23, 2024, by and
        between <font style="font-weight: bold;">ARE-500 ARSENAL STREET, LLC</font>, a Delaware limited liability company (&#8220;<font style="font-weight: bold;">Landlord</font>&#8221;), and <font style="font-weight: bold;">TREELINE BIOSCIENCES, INC.</font>, a
        Delaware corporation (&#8220;<font style="font-weight: bold;">Tenant</font>&#8221;).</div>
      <div>&#160;</div>
      <div style="text-align: center; text-indent: -0.5pt; margin-right: 23.5pt; margin-left: 15.1pt; color: rgb(0, 0, 0); font-weight: bold;">RECITALS</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; margin-right: 8.35pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">A.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: rgb(0, 0, 0);">Landlord and Tenant are parties to that certain Lease Agreement
          dated as of May 6, 2021, as amended by that certain First Amendment to Lease dated as of May 8, 2022, and that certain Second Amendment to Lease dated as of February 5, 2024 (the &#8220;<font style="font-weight: bold;">Second Amendment</font>&#8221;) (as
          amended, the &#8220;<font style="font-weight: bold;">Lease</font>&#8221;).&#160; Pursuant to the Lease, Tenant leases certain premises containing approximately 45,000 rentable square feet (the &#8220;<font style="font-weight: bold;">Premises</font>&#8221;) in that certain
          building located at 500 Arsenal Street, Watertown,</font> Massachusetts (the &#8220;<font style="font-weight: bold;">Building</font>&#8221;), consisting of (i) approximately 22,362 rentable square feet located in Suite 201 on the second floor of the Building
        (the &#8220;<font style="font-weight: bold;">Existing Premises</font>&#8221;), and (ii) approximately 22,638 rentable square feet located in Suite 101 on the first floor of the Building (the &#8220;<font style="font-weight: bold;">Expansion Premises</font>&#8221;),
        consisting of (A) approximately 15,491 rentable square feet of mixed laboratory and office space (collectively, the &#8220;<font style="font-weight: bold;">Lab</font> <font style="font-weight: bold;">Expansion Premises</font>&#8221;), and (B) approximately
        7,147 rentable square feet of only office space (the &#8220;<font style="font-weight: bold;">Office Expansion Premises</font>&#8221;).&#160; The Premises are more particularly described in the Lease.&#160; Capitalized terms used herein without definition shall have the
        meanings defined for such terms in the Lease.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; margin-right: 8.35pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">B.</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <font style="color: rgb(0, 0, 0);">The Term of the Lease with respect to the Existing Premises is
          scheduled to expire on April</font> 30, 2027, and the Term of the Lease with respect to the Expansion Premises is scheduled to expire on February 28, 2025. </div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-right: 8.35pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">C.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="color: rgb(0, 0, 0);">Landlord and Tenant desire, subject to the terms and conditions
          set forth below, to amend the Lease to, among other things, extend the Term of the Lease with respect to both the Existing Premises and the Expansion Premises through December 31, 2027 (the &#8220;<font style="font-weight: bold;">Third Amendment
            Expiration Date</font>&#8221;).&#160; </font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; margin-right: 8.35pt; color: #000000;"><font style="font-weight: bold;">NOW, THEREFORE,</font> in consideration of the foregoing Recitals, which are incorporated herein by this reference, the mutual
        promises and conditions contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Landlord and Tenant hereby agree as follows:</div>
      <div>&#160;</div>
      <table id="zfe67ec764d304f81b6cab5ee0dd81d10" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">1.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;"><font style="font-weight: bold;"><u>Term</u></font>.&#160; The Term of the Lease with respect to each of the Existing Premises and the Expansion Premises is hereby extended through the Third Amendment Expiration Date.&#160;
                Tenant&#8217;s occupancy of the Premises through the Third Amendment Expiration Date shall be on an &#8220;as-is&#8221; basis, and, other than the Improvements Allowance (as defined in the Second Amendment), Landlord shall have no obligation to provide any
                tenant improvement allowance or to make any alterations to the Premises.&#160; For avoidance of doubt, nothing contained in this Third Amendment shall limit Landlord&#8217;s obligation to provide the Improvements Allowance in accordance with the
                Second Amendment.&#160; Tenant shall have no further right to extend the Term of the Lease with respect to either the Existing Premises or the Expansion Premises beyond the Third Amendment Expiration Date.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z7fbf0f19d953432885c329a1cdf9acfb" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">2.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;"><font style="font-weight: bold;"><u>Base Rent</u></font>.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="width: 100%;" class="BRPFPageFooter">
          <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 50%;">
                  <div>&#160;</div>
                </td>
                <td style="width: 50%; text-align: right; vertical-align: bottom;" rowspan="1">
                  <div><img src="ny20077604x1_ex10-3logo01.jpg"></div>
                </td>
              </tr>
              <tr>
                <td style="text-align: center; font-size: 8pt;" rowspan="1" colspan="2">&#160;<font class="BRPFPageNumber">1</font></td>
              </tr>

          </table>
        </div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
        <div style="width: 100%;" class="BRPFPageHeader"></div>
      </div>
      <div>
        <div style="text-align: justify; text-indent: -0.5pt; margin-right: 8.35pt; margin-left: 36.5pt; color: rgb(0, 0, 0);">a.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Existing Premises</font>.&#160; Tenant shall continue paying Base Rent with respect to
          the Existing Premises as provided for in the Lease through April 30, 2027.&#160; Commencing on May 1, 2027, Base Rent with respect to the Existing Premises will increase to $94.76 per rentable square foot of the Existing Premises per year.</div>
      </div>
      <div>&#160;</div>
      <div>
        <div style="text-align: justify; text-indent: -0.5pt; margin-right: 8.35pt; margin-left: 36.5pt; color: rgb(0, 0, 0);">b. &#160; &#160; &#160; &#160;&#160; <font style="font-weight: bold;">Expansion Premises</font>. Tenant shall continue paying Base Rent with respect to
          the Expansion Premises as provided for in the Lease through February 28, 2025.&#160; Commencing on March 1, 2025, (i) Base Rent with respect to the Lab Expansion Premises will increase to $91.00 per rentable square foot of the Lab Expansion Premises
          per year, and (ii) Base Rent with respect to the Office Expansion Premises will increase to $13.00 per rentable square foot of the Office Expansion Premises per year.&#160; On March 1, 2026, and on each March 1<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">st</sup> thereafter (each, an &#8220;<font style="font-weight: bold;">Expansion Premises Adjustment Date</font>&#8221;), Base Rent with respect to each of the Lab Expansion Premises and the Office Expansion Premises
          shall be increased by multiplying the Base Rent payable with respect to each of the Lab Expansion Premises and the Office Expansion Premises immediately before such Expansion Premises Adjustment Date by 3% and adding the resulting amount to the
          Base Rent payable with respect to each of the Lab Expansion Premises and the Office Expansion Premises, respectively, immediately prior to such Expansion Premises Adjustment Date.</div>
      </div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; margin-right: 8.35pt; margin-left: 36pt; color: rgb(0, 0, 0);">&#160;As set forth in <u>Section 6(b)</u> of the Second Amendment, so long as Tenant is not in default under the Lease beyond any
        applicable notice and cure periods, Base Rent with respect to the Expansion Premises shall be abated for the months of June 2025 and June 2026 (the &#8220;<font style="font-weight: bold;">Expansion Premises Additional Abatement Periods</font>&#8221;).&#160; For the
        avoidance of doubt, Tenant shall be required to pay Operating Expenses and all other amounts payable under the Lease during the Expansion Premises Additional Abatement Periods.</div>
      <div>&#160;</div>
      <table id="z84d1ab54fbe342a5a63e78925c1479f1" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">3.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;"><font style="font-weight: bold;"><u>Brokers</u></font>.&#160; Landlord and Tenant each represents and warrants that it has not dealt with any broker, agent or other person (collectively, &#8220;<font style="font-weight: bold;">Broker</font>&#8221;) in connection with the transaction reflected in this Third Amendment and that no Broker brought about this transaction, other than CBRE and Newmark.&#160; Landlord and Tenant each hereby agree to indemnify and hold the
                other harmless from and against any claims by any Broker, other than CBRE and Newmark, claiming a commission or other form of compensation by virtue of having dealt with Tenant or Landlord, as applicable, with regard to this leasing
                transaction.&#160; </div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z13717e8b857748d48cdbc334fddcd8c6" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">4.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;"><font style="font-weight: bold;"><u>OFAC</u></font>.&#160; Tenant and all beneficial owners of Tenant are currently (a) in compliance with and shall at all times during the Term of the Lease remain in compliance with
                the regulations of the Office of Foreign Assets Control (&#8220;<font style="font-weight: bold;">OFAC</font>&#8221;) of the U.S. Department of Treasury and any statute, executive order, or regulation relating thereto (collectively, the &#8220;<font style="font-weight: bold;">OFAC Rules</font>&#8221;), (b) not listed on, and shall not during the term of the Lease be listed on, the Specially Designated Nationals and Blocked Persons List, Foreign Sanctions Evaders List, or the Sectoral
                Sanctions Identification List, which are all maintained by OFAC and/or on any other similar list maintained by OFAC or other governmental authority pursuant to any authorizing statute, executive order, or regulation, and (c) not a person or
                entity with whom a U.S. person is prohibited from conducting business under the OFAC Rules.</div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; text-indent: -0.5pt; margin-right: 8.35pt; margin-left: 36.5pt; color: rgb(0, 0, 0);"></div>
      <div>&#160;</div>
      <table id="z0da0989686094f9ba3b3c1b754848c5b" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">5.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;"><font style="font-weight: bold;"><u>Miscellaneous</u></font>.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div>
        <div style="text-align: justify; text-indent: -0.5pt; margin-right: 8.35pt; margin-left: 36.5pt; color: rgb(0, 0, 0);"><font style="font-weight: bold;">a.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; This Third Amendment is the entire agreement between the parties with respect
          to the subject matter hereof and supersedes all prior and contemporaneous oral and written agreements and discussions.&#160; This Third Amendment may be amended only by an agreement in writing, signed by the parties hereto.</div>
        <div style="text-align: justify;"> </div>
      </div>
      <div>&#160;</div>
      <div>
        <div style="text-align: justify; text-indent: -0.5pt; margin-right: 8.35pt; margin-left: 36.5pt; color: rgb(0, 0, 0);"><font style="font-weight: bold;">b.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; This Third Amendment is binding upon and shall inure to the benefit of the
          parties hereto, their respective successors in interest and assigns.</div>
        <div style="text-align: justify;"> </div>
      </div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="width: 100%;" class="BRPFPageFooter">
          <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 50%;">
                  <div>&#160;</div>
                </td>
                <td style="width: 50%; text-align: right; vertical-align: bottom;" rowspan="1">
                  <div><img src="ny20077604x1_ex10-3logo01.jpg"></div>
                </td>
              </tr>
              <tr>
                <td style="text-align: center; font-size: 8pt;" rowspan="1" colspan="2">&#160;<font class="BRPFPageNumber">2</font></td>
              </tr>

          </table>
        </div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
        <div style="width: 100%;" class="BRPFPageHeader"></div>
      </div>
      <div>
        <div style="text-align: justify; text-indent: -0.5pt; margin-right: 8.35pt; margin-left: 36.5pt; color: rgb(0, 0, 0);"><font style="font-weight: bold;">c.</font>&#160;&#160;&#160;&#160;&#160; &#160; &#160; &#160; This Third Amendment may be executed in 2 or more counterparts, each of
          which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature process complying with the U.S.
          federal ESIGN Act of 2000) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.&#160; Electronic signatures shall be deemed original
          signatures for purposes of this Third Amendment and all matters related thereto, with such electronic signatures having the same legal effect as original signatures.</div>
        <div style="text-align: justify;"> </div>
      </div>
      <div>&#160;</div>
      <div>
        <div style="text-align: justify; text-indent: -0.5pt; margin-right: 8.35pt; margin-left: 36.5pt; color: rgb(0, 0, 0);"><font style="font-weight: bold;">d.</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; Except as amended and/or modified by this Third Amendment, the Lease is
          hereby ratified and confirmed and all other terms of the Lease shall remain in full force and effect, unaltered and unchanged by this Third Amendment.&#160; In the event of any conflict between the provisions of this Third Amendment and the provisions
          of the Lease, the provisions of this Third Amendment shall prevail.&#160; Whether or not specifically amended by this Third Amendment, all of the terms and provisions of the Lease are hereby amended to the extent necessary to give effect to the
          purpose and intent of this Third Amendment.</div>
        <div style="text-align: justify;"> </div>
      </div>
      <div>&#160;</div>
      <div>
        <div style="text-align: justify; text-indent: -0.5pt; margin-right: 8.35pt; margin-left: 36.5pt; color: rgb(0, 0, 0);"><font style="font-weight: bold;">e.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Landlord and Tenant each warrant to the other that the person or persons
          executing this Third Amendment on its behalf has or have authority to do so and that such execution has fully obligated and bound such party to all terms and provisions of this Third Amendment.</div>
        <div style="text-align: justify;"> </div>
      </div>
      <div>&#160;</div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">[Signatures are on the next page]</div>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" class="BRPFPageFooter">
          <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 50%;">
                  <div>&#160;</div>
                </td>
                <td style="width: 50%; text-align: right; vertical-align: bottom;" rowspan="1">
                  <div><img src="ny20077604x1_ex10-3logo01.jpg"></div>
                </td>
              </tr>
              <tr>
                <td style="text-align: center; font-size: 8pt;" rowspan="1" colspan="2">&#160;<font class="BRPFPageNumber">3</font></td>
              </tr>

          </table>
        </div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
        <div style="width: 100%;" class="BRPFPageHeader"></div>
      </div>
      <div style="text-align: justify; margin-right: 8.35pt; color: rgb(0, 0, 0); text-indent: 36pt;"><font style="font-weight: bold;">IN WITNESS WHEREOF</font>, the parties hereto have executed this Third Amendment as of the day and year first above
        written.</div>
      <div>&#160;</div>
      <table id="zc9f8d1c1fb2340cebba518c2d758390f" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="vertical-align: top;" colspan="2">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">LANDLORD:</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="vertical-align: top;" colspan="2" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="vertical-align: top;" colspan="2">
              <div style="color: rgb(0, 0, 0);"><font style="font-weight: bold;">ARE-500 ARSENAL STREET, LLC</font>,</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="vertical-align: top;" colspan="2">
              <div style="color: rgb(0, 0, 0);">a Delaware limited liability company</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="vertical-align: top;" colspan="2" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 3%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">By:</div>
            </td>
            <td style="width: 47%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">ALEXANDRIA REAL ESTATE EQUITIES, L.P.,</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 3%; vertical-align: top;">&#160;</td>
            <td style="width: 47%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">a Delaware limited partnership,&#160; </div>
              <div style="color: rgb(0, 0, 0);">managing member</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table id="z4a215999c80e4cc0b12ff5f0eb66118d" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 3%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">By:</div>
            </td>
            <td style="vertical-align: top;" colspan="2">
              <div style="color: rgb(0, 0, 0);">ARE-QRS Corp.,</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 3%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="vertical-align: top;" colspan="2">
              <div style="text-align: justify; margin-right: 47.75pt; color: rgb(0, 0, 0);">a Maryland corporation, general partner</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td style="width: 3%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td style="width: 3%; vertical-align: top; padding-bottom: 2px;">
              <div style="color: rgb(0, 0, 0);">By:</div>
            </td>
            <td style="width: 39%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="color: rgb(0, 0, 0);">/s/ Allison Grochola</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td style="width: 3%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td style="width: 3%; vertical-align: top; padding-bottom: 2px;">
              <div style="color: rgb(0, 0, 0);">Its:</div>
            </td>
            <td style="width: 39%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="color: rgb(0, 0, 0);">SVP - Real Estate Legal Affairs</div>
            </td>
          </tr>

      </table>
      <div><font style="color: rgb(0, 0, 0);"> </font><br>
      </div>
      <table id="zbe033a7e77ca4604b7dc792b34dd9ad1" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="vertical-align: top;" colspan="2">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">TENANT:</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="vertical-align: top;" colspan="2" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="vertical-align: top;" colspan="2">
              <div style="color: rgb(0, 0, 0);"><font style="font-weight: bold;">TREELINE BIOSCIENCES, INC.</font>, a Delaware corporation</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="vertical-align: top;" colspan="2" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td style="width: 3%; vertical-align: top; padding-bottom: 2px;">
              <div style="color: rgb(0, 0, 0);">By:</div>
            </td>
            <td style="width: 47%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="margin-right: 6.65pt; color: rgb(0, 0, 0);">/s/ Jennifer Burstein</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td style="width: 3%; vertical-align: top; padding-bottom: 2px;">
              <div style="color: rgb(0, 0, 0);">Its:</div>
            </td>
            <td style="width: 47%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="color: rgb(0, 0, 0);">SVP Finance Operations</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 3%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 47%; vertical-align: top;" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="vertical-align: top;" colspan="2">
              <div style="color: rgb(0, 0, 0);">X&#9633; I hereby certify that the signature, name, and title above are my signature, name and title.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div> <br>
      </div>
    </div>
  </div>
  <div style="width: 100%;" class="BRPFPageFooter">
    <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 50%;">
            <div>&#160;</div>
          </td>
          <td style="width: 50%; text-align: right; vertical-align: bottom;" rowspan="1">
            <div><img src="ny20077604x1_ex10-3logo01.jpg"></div>
          </td>
        </tr>
        <tr>
          <td style="text-align: center; font-size: 8pt;" rowspan="1" colspan="2">&#160;<font class="BRPFPageNumber">4</font></td>
        </tr>

    </table>
    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>5
<FILENAME>ny20077604x1_ex23-2.htm
<DESCRIPTION>EXHIBIT 23.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 26.3.2.5342
         Copyright 1995 - 2026 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <div style="text-align: right; color: #000000; font-weight: bold;">
      <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">Exhibit 23.2</div>
    <div><br>
    </div>
    <div style="text-align: center; color: #000000;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</div>
    <div><br>
    </div>
    <div><font style="color: #000000;">We hereby consent to the incorporation by reference in this Registration Statement on Form</font><font style="font-weight: bold; color: #FF0000;">&#160;</font>S-4 <font style="color: #000000;">of Standard BioTools, Inc.
        of our report dated March 16, 2026</font><sup style="color: #FF0000; vertical-align: text-top; line-height: 1; font-size: smaller;">&#160;</sup><font style="color: #000000;">relating to the financial statements and the effectiveness of internal control
        over financial reporting, which appears in Standard BioTools, Inc&#8217;s Annual Report on Form 10-K for the year ended December 31, 2025. We also consent to the reference to us under the heading</font><font style="font-weight: bold; color: #FF0000;">&#160;</font><font style="color: #000000;">&#8220;Experts&#8221;</font><sup style="color: #FF0000; font-weight: bold; vertical-align: text-top; line-height: 1; font-size: smaller;">&#160;</sup><font style="color: #000000;">in such Registration Statement.</font></div>
    <div><br>
    </div>
    <div style="color: #000000;">/s/ PricewaterhouseCoopers LLP</div>
    <div style="color: #000000;">Irvine, California</div>
    <div style="color: #000000;">July 20, 2026</div>
    <div><br>
    </div>
    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.3
<SEQUENCE>6
<FILENAME>ny20077604x1_ex23-3.htm
<DESCRIPTION>EXHIBIT 23.3
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 26.3.2.5342
         Copyright 1995 - 2026 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">
    <div>
      <div style="text-align: right; font-weight: bold;">Exhibit 23.3</div>
      <div><br>
      </div>
      <div style="text-align: center; font-weight: bold;">Consent of Independent Registered Public Accounting Firm</div>
      <div><br>
      </div>
      <div>We consent to the reference to our firm under the caption "Experts" and to the use of our report dated June 16, 2026, with respect to the consolidated financial statements of Treeline Biosciences, Inc. and subsidiary included in the Registration
        Statement (Form S-4) and related Prospectus of Standard BioTools Inc. for the registration of its common stock.</div>
      <div><br>
      </div>
      <div>/s/ Ernst &amp; Young LLP</div>
      <div><br>
      </div>
      <div>Iselin, New Jersey</div>
      <div><br>
      </div>
      <div>July 20, 2026</div>
      <div> <br>
      </div>
      <div>
        <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"> </div>
      <div><br>
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>7
<FILENAME>ny20077604x1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 26.3.2.5342
         Copyright 1995 - 2026 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div style="font-weight: bold; text-align: right;">
    <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">Exhibit 99.1</div>
  <div><br>
  </div>
  <div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zdcd8983d4f334aa0b2acf4df4dc9a73f" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: auto; vertical-align: top;">
            <div>
              <div><img src="ny20077604x1_ex99-1image1.jpg" width="229" height="72"></div>
            </div>
          </td>
          <td style="width: 3in; vertical-align: top;">
            <div>
              <div>Centerview Partners LLC</div>
              <div>31 West 52nd Street</div>
              <div>New York, NY 10019</div>
              <div>&#160;</div>
              <div>July 20, 2026</div>
            </div>
          </td>
        </tr>

    </table>
    <div>
      <div><br>
      </div>
      <div><br>
      </div>
      <div>The Board of Directors</div>
      <div>Standard BioTools Inc.</div>
      <div>50 Milk Street, 10<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> Floor</div>
      <div>Boston, MA 02109</div>
      <div><br>
      </div>
      <div>The Board of Directors:</div>
    </div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">We hereby consent to the inclusion of our opinion letter, dated June 6, 2026, to the Board of Directors of Standard BioTools Inc. (&#8220;<u>Standard BioTools</u>&#8221;) as Annex B to, and reference to such opinion letter under the
      headings &#8220;<font style="font-style: italic;">Prospectus Summary &#8211; Opinion of Standard BioTools&#8217; Financial Advisor</font>&#8221;<font style="font-style: italic;">, </font>&#8220;<font style="font-style: italic;">Risk Factors</font>&#8221;, &#8220;<font style="font-style: italic;">The Merger &#8211; Background of the Merger</font>&#8221;, &#8220;<font style="font-style: italic;">The Merger &#8211; Standard BioTools&#8217; Reasons for the Merger</font>&#8221;, &#8220;<font style="font-style: italic;">The Merger &#8211; Opinion of Standard BioTools&#8217; Financial
        Advisor</font>&#8221;, &#8220;<font style="font-style: italic;">The Merger &#8211; Summary of Centerview Financial Analysis</font>&#8221;, and &#8220;<font style="font-style: italic;">The Merger &#8211; Summary of Certain Unaudited Prospective Financial Information</font>&#8221; in, the
      proxy statement/prospectus relating to the proposed merger transaction involving Standard BioTools and Treeline Biosciences, Inc., which proxy statement/prospectus forms a part of the Registration Statement on Form S-4 of Standard BioTools (the &#8220;<u>Registration


        Statement</u>&#8221;).</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">In giving such consent, we do not admit that we come within the category of persons whose consent is required under Section 7 of the Securities Act of 1933, as amended (the &#8220;<u>Act</u>&#8221;), or the rules and regulations of
      the Securities and Exchange Commission (the &#8220;<u>SEC</u>&#8221;) promulgated thereunder, nor do we hereby admit that we are experts with respect to any part of the Registration Statement within the meaning of the term &#8220;experts&#8221; as used in the Act or the
      rules and regulations of the SEC promulgated thereunder.</div>
    <div>
      <div><br>
      </div>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z244ed6ddad914a3d865be01be5fbcf07" cellpadding="0" cellspacing="0">

        <tr>
          <td colspan="1" style="width: 50%; vertical-align: middle;">&#160;</td>
          <td style="width: 50%; vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td colspan="1" style="width: 50%; vertical-align: middle;">&#160;</td>
          <td style="width: 50%; vertical-align: middle;">
            <div>&#160;</div>
            <div>Very truly yours,</div>
          </td>
        </tr>
        <tr>
          <td colspan="1" style="width: 50%; vertical-align: middle;">&#160;</td>
          <td style="width: 50%; vertical-align: middle;">
            <div>&#160;</div>
          </td>
        </tr>
        <tr>
          <td colspan="1" style="width: 50%; vertical-align: middle; padding-bottom: 2px;">&#160;</td>
          <td style="width: 50%; vertical-align: middle; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>/s/ Centerview Partners LLC</div>
          </td>
        </tr>
        <tr>
          <td colspan="1" style="width: 50%; vertical-align: middle;">&#160;</td>
          <td style="width: 50%; vertical-align: middle;">
            <div>CENTERVIEW PARTNERS LLC</div>
          </td>
        </tr>
        <tr>
          <td colspan="1" style="width: 50%; vertical-align: middle;">&#160;</td>
          <td style="width: 50%; vertical-align: middle;">&#160;</td>
        </tr>

    </table>
    <div>
      <div><br>
      </div>
    </div>
    <div>
      <div><br>
      </div>
      <div><br>
      </div>
      <br>
    </div>
    <div>
      <div><br>
      </div>
    </div>
    <div>
      <div><br>
      </div>
      <div style="text-align: center; font-size: 8pt;">31 WEST 52ND STREET, 22ND FLOOR, NEW YORK, NY 10019</div>
      <div style="text-align: center; font-size: 8pt;">PHONE: (212) 380-2650&#160; &#160; FAX: (212) 380-2651&#160; &#160; WWW.CENTERVIEWPARTNERS.COM</div>
    </div>
    <div>
      <div><br>
      </div>
    </div>
    <div>
      <div style="text-align: center; font-size: 8pt;">NEW YORK &#8226; LONDON &#8226; PARIS &#8226; SAN FRANCISCO &#8226; PALO ALTO &#8226; LOS ANGELES</div>
      <div style="text-align: center; font-size: 8pt;">
        <hr style="height: 2px; color: #000000; background-color: #000000; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"> </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>8
<FILENAME>ny20077604x1_ex99-2.htm
<DESCRIPTION>EXHIBIT 99.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 26.3.2.5342
         Copyright 1995 - 2026 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">
    <div>
      <div style="text-align: right; font-family: 'Times New Roman',Times,serif; font-weight: bold;"> Exhibit 99.2<br>
      </div>
      <div style="text-align: center; font-weight: bold;"> <br>
      </div>
      <div style="text-align: center; font-weight: bold;">CONSENT OF UBS SECURITIES LLC</div>
      <div><br>
      </div>
      <div>We hereby consent to the use of our opinion letter dated June 5, 2026 to the Special Committee of the Board of Directors of Standard BioTools Inc. (the &#8220;Special Committee&#8221;) included as Annex C to the Proxy Statement/Prospectus which forms a part
        of the Registration Statement on Form S-4 of Standard BioTools Inc. relating to the proposed merger of TreeLine Biosciences, Inc. with Standard BioTools Inc., and references to such opinion under the captions &#8220;Prospectus Summary&#8212;The Special
        Committee,&#8221; &#8220;Prospectus Summary&#8212;Opinion of Standard BioTools Special Committee&#8217;s Financial Advisor,&#8221; &#8220;Risk Factors&#8212;The opinions of Standard BioTools&#8217; financial advisors do not reflect changes in circumstances that may have occurred or that may
        occur between the signing of the Merger Agreement and the consummation of the Merger,&#8221; &#8220;The Merger&#8212;The Special Committee,&#8221; &#8220;The Merger&#8212;Background of the Merger,&#8221; &#8220;The Merger&#8212;Standard BioTools&#8217; Reasons for the Merger,&#8221; &#8220;The Merger&#8212;Opinion of
        Standard BioTools Special Committee&#8217;s Financial Advisor&#8221; and &#8220;The Merger&#8212;Summary of Certain Unaudited Prospective Financial Information&#8221;&#160; in such Proxy Statement/Prospectus. In giving such consent, we do not admit that we come within the category
        of persons whose consent is required under Section 7 of the Securities Act of 1933, as amended, or the rules and regulations of the Securities and Exchange Commission thereunder, nor do we thereby admit that we are experts with respect to any part
        of such Registration Statement within the meaning of the term &#8220;Experts&#8221; as used in the Securities Act of 1933, as amended, or the rules and regulations of the Securities and Exchange Commission thereunder.</div>
      <div><br>
      </div>
      <div style="text-align: right;"><u>/s/ UBS SECURITIES LLC</u></div>
      <div style="text-align: right;">UBS SECURITIES LLC</div>
      <div><br>
      </div>
      <div style="text-align: right;">New York, New York</div>
      <div style="text-align: right;">July 20, 2026</div>
      <div style="text-align: right;"> <br>
      </div>
      <div style="text-align: right;"> <br>
      </div>
      <div style="text-align: right;">
        <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"> </div>
      <div><br>
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>9
<FILENAME>ny20077604x1_ex99-3.htm
<DESCRIPTION>EXHIBIT 99.3
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 26.3.2.5342
         Copyright 1995 - 2026 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div style="font-weight: bold; text-align: right;">
    <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">Exhibit 99.3</div>
  <div><br>
  </div>
  <div>
    <div>Treeline Biosciences, Inc.</div>
    <div>500 Arsenal Street</div>
    <div>Watertown, MA 02472</div>
    <div>&#160;</div>
    <div style="text-align: center; font-weight: bold;">Consent to Reference in Proxy Statement/Prospectus</div>
    <div>&#160;</div>
    <div>Standard BioTools Inc. (&#8220;Standard BioTools&#8221;) is filing a Registration Statement on Form S-4 (the &#8220;Registration Statement&#8221;) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). In
      connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendments and supplements thereto as a future member of the board of directors of the combined company
      following the consummation of the merger. I also consent to the filing of this consent as an exhibit to the Registration Statement and any amendments and supplements thereto.</div>
    <div>&#160;<br>
    </div>
    <table style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" id="ze590072c247c46fab44d056516890523" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-indent: -10pt; margin-left: 10pt;">Dated: July 20, 2026</div>
          </td>
          <td colspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: middle;">&#160;</td>
          <td colspan="1" style="width: 50%; vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">
            <div><br>
            </div>
          </td>
          <td colspan="1" style="width: 50%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>/s/ Joshua Bilenker</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-indent: -10pt; margin-left: 10pt;"><br>
            </div>
          </td>
          <td colspan="1" style="width: 50%; vertical-align: top;">
            <div style="text-indent: -10pt; margin-left: 10pt;">Name: Joshua Bilenker</div>
          </td>
        </tr>

    </table>
    <div>&#160;<br>
    </div>
    <div><br>
    </div>
    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"> </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.4
<SEQUENCE>10
<FILENAME>ny20077604x1_ex99-4.htm
<DESCRIPTION>EXHIBIT 99.4
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 26.3.2.5342
         Copyright 1995 - 2026 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div style="font-weight: bold; text-align: right;">
    <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">Exhibit 99.4</div>
  <div><br>
  </div>
  <div>
    <div>Treeline Biosciences, Inc.</div>
    <div>500 Arsenal Street</div>
    <div>Watertown, MA 02472</div>
    <div>&#160;</div>
    <div style="text-align: center; font-weight: bold;">Consent to Reference in Proxy Statement/Prospectus</div>
    <div>&#160;</div>
    <div>Standard BioTools Inc. (&#8220;Standard BioTools&#8221;) is filing a Registration Statement on Form S-4 (the &#8220;Registration Statement&#8221;) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). In
      connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendments and supplements thereto as a future member of the board of directors of the combined company
      following the consummation of the merger. I also consent to the filing of this consent as an exhibit to the Registration Statement and any amendments and supplements thereto.</div>
    <div>&#160;<br>
    </div>
    <table style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="width: 50%; vertical-align: middle;">Dated: July 20, 2026</div>
          </td>
          <td colspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: middle;">&#160;</td>
          <td colspan="1" style="width: 50%; vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">
            <div><br>
            </div>
          </td>
          <td colspan="1" style="width: 50%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>/s/ Jeffrey Engelman</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-indent: -10pt; margin-left: 10pt;"><br>
            </div>
          </td>
          <td colspan="1" style="width: 50%; vertical-align: top;">
            <div style="text-indent: -10pt; margin-left: 10pt;">Name: Jeffrey Engelman</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div> <br>
    </div>
    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"> </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.5
<SEQUENCE>11
<FILENAME>ny20077604x1_ex99-5.htm
<DESCRIPTION>EXHIBIT 99.5
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 26.3.2.5342
         Copyright 1995 - 2026 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div style="font-weight: bold; text-align: right;">
    <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">Exhibit 99.5</div>
  <div><br>
  </div>
  <div>
    <div>Treeline Biosciences, Inc.</div>
    <div>500 Arsenal Street</div>
    <div>Watertown, MA 02472</div>
    <div>&#160;</div>
    <div style="text-align: center; font-weight: bold;">Consent to Reference in Proxy Statement/Prospectus</div>
    <div>&#160;</div>
    <div>Standard BioTools Inc. (&#8220;Standard BioTools&#8221;) is filing a Registration Statement on Form S-4 (the &#8220;Registration Statement&#8221;) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). In
      connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendments and supplements thereto as a future member of the board of directors of the combined company
      following the consummation of the merger. I also consent to the filing of this consent as an exhibit to the Registration Statement and any amendments and supplements thereto.</div>
    <div>&#160;<br>
    </div>
    <table style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="width: 50%; vertical-align: middle;">Dated: July 20, 2026</div>
          </td>
          <td colspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: middle;">&#160;</td>
          <td colspan="1" style="width: 50%; vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">
            <div><br>
            </div>
          </td>
          <td colspan="1" style="width: 50%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>
              <div style="font-family: 'Times New Roman', Times, serif;">/s/ Kristina Burow</div>
            </div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-indent: -10pt; margin-left: 10pt;"><br>
            </div>
          </td>
          <td colspan="1" style="width: 50%; vertical-align: top;">
            <div style="text-indent: -10pt; margin-left: 10pt;">Name: Kristina Burow</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div><br>
    </div>
    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"> </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.6
<SEQUENCE>12
<FILENAME>ny20077604x1_ex99-6.htm
<DESCRIPTION>EXHIBIT 99.6
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 26.3.2.5342
         Copyright 1995 - 2026 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div style="font-weight: bold; text-align: right;">
    <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">Exhibit 99.6</div>
  <div><br>
  </div>
  <div>
    <div>Treeline Biosciences, Inc.</div>
    <div>500 Arsenal Street</div>
    <div>Watertown, MA 02472</div>
    <div>&#160;</div>
    <div style="text-align: center; font-weight: bold;">Consent to Reference in Proxy Statement/Prospectus</div>
    <div>&#160;</div>
    <div>Standard BioTools Inc. (&#8220;Standard BioTools&#8221;) is filing a Registration Statement on Form S-4 (the &#8220;Registration Statement&#8221;) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). In
      connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendments and supplements thereto as a future member of the board of directors of the combined company
      following the consummation of the merger. I also consent to the filing of this consent as an exhibit to the Registration Statement and any amendments and supplements thereto.</div>
    <div>&#160;<br>
    </div>
    <table style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-indent: -10pt; margin-left: 10pt;">Dated: July 20, 2026</div>
          </td>
          <td colspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: middle;">&#160;</td>
          <td colspan="1" style="width: 50%; vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">
            <div><br>
            </div>
          </td>
          <td colspan="1" style="width: 50%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>/s/ David Bonita</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-indent: -10pt; margin-left: 10pt;"><br>
            </div>
          </td>
          <td colspan="1" style="width: 50%; vertical-align: top;">
            <div style="text-indent: -10pt; margin-left: 10pt;">Name: David Bonita</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div><br>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"><br>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.7
<SEQUENCE>13
<FILENAME>ny20077604x1_ex99-7.htm
<DESCRIPTION>EXHIBIT 99.7
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 26.3.2.5342
         Copyright 1995 - 2026 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div style="font-weight: bold; text-align: right;">
    <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">Exhibit 99.7</div>
  <div><br>
  </div>
  <div>
    <div>Treeline Biosciences, Inc.</div>
    <div>500 Arsenal Street</div>
    <div>Watertown, MA 02472</div>
    <div>&#160;</div>
    <div style="text-align: center; font-weight: bold;">Consent to Reference in Proxy Statement/Prospectus</div>
    <div>&#160;</div>
    <div>Standard BioTools Inc. (&#8220;Standard BioTools&#8221;) is filing a Registration Statement on Form S-4 (the &#8220;Registration Statement&#8221;) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). In
      connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendments and supplements thereto as a future member of the board of directors of the combined company
      following the consummation of the merger. I also consent to the filing of this consent as an exhibit to the Registration Statement and any amendments and supplements thereto.</div>
    <div>&#160;<br>
    </div>
    <table style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-indent: -10pt; margin-left: 10pt;">Dated: July 20, 2026</div>
          </td>
          <td colspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: middle;">&#160;</td>
          <td colspan="1" style="width: 50%; vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">
            <div><br>
            </div>
          </td>
          <td colspan="1" style="width: 50%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>/s/ David Schenkein</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-indent: -10pt; margin-left: 10pt;"><br>
            </div>
          </td>
          <td colspan="1" style="width: 50%; vertical-align: top;">
            <div style="text-indent: -10pt; margin-left: 10pt;">Name: David Schenkein</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div><br>
    </div>
    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"> </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.8
<SEQUENCE>14
<FILENAME>ny20077604x1_ex99-8.htm
<DESCRIPTION>EXHIBIT 99.8
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 26.3.2.5342
         Copyright 1995 - 2026 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div style="font-weight: bold; text-align: right;">
    <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">Exhibit 99.8</div>
  <div><br>
  </div>
  <div>
    <div>Treeline Biosciences, Inc.</div>
    <div>500 Arsenal Street</div>
    <div>Watertown, MA 02472</div>
    <div>&#160;</div>
    <div style="text-align: center; font-weight: bold;">Consent to Reference in Proxy Statement/Prospectus</div>
    <div>&#160;</div>
    <div>Standard BioTools Inc. (&#8220;Standard BioTools&#8221;) is filing a Registration Statement on Form S-4 (the &#8220;Registration Statement&#8221;) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). In
      connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendments and supplements thereto as a future member of the board of directors of the combined company
      following the consummation of the merger. I also consent to the filing of this consent as an exhibit to the Registration Statement and any amendments and supplements thereto.</div>
    <br>
    <div>
      <table style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-indent: -10pt; margin-left: 10pt;">Dated: July 20, 2026</div>
            </td>
            <td colspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: middle;">&#160;</td>
            <td colspan="1" style="width: 50%; vertical-align: middle;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">
              <div><br>
              </div>
            </td>
            <td colspan="1" style="width: 50%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>
                <div>/s/ Aftab Kherani</div>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-indent: -10pt; margin-left: 10pt;"><br>
              </div>
            </td>
            <td colspan="1" style="width: 50%; vertical-align: top;">
              <div style="text-indent: -10pt; margin-left: 10pt;">Name: Aftab Kherani</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
    </div>
    <div><br>
    </div>
    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"> </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.9
<SEQUENCE>15
<FILENAME>ny20077604x1_ex99-9.htm
<DESCRIPTION>EXHIBIT 99.9
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 26.3.2.5342
         Copyright 1995 - 2026 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div style="font-weight: bold; text-align: right;">
    <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">Exhibit 99.9</div>
  <div><br>
  </div>
  <div>
    <div>Treeline Biosciences, Inc.</div>
    <div>500 Arsenal Street</div>
    <div>Watertown, MA 02472</div>
    <div>&#160;</div>
    <div style="text-align: center; font-weight: bold;">Consent to Reference in Proxy Statement/Prospectus</div>
    <div>&#160;</div>
    <div>Standard BioTools Inc. (&#8220;Standard BioTools&#8221;) is filing a Registration Statement on Form S-4 (the &#8220;Registration Statement&#8221;) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). In
      connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendments and supplements thereto as a future member of the board of directors of the combined company
      following the consummation of the merger. I also consent to the filing of this consent as an exhibit to the Registration Statement and any amendments and supplements thereto.</div>
    <br>
    <div>
      <table style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-indent: -10pt; margin-left: 10pt;">Dated: July 20, 2026</div>
            </td>
            <td colspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: middle;">&#160;</td>
            <td colspan="1" style="width: 50%; vertical-align: middle;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">
              <div><br>
              </div>
            </td>
            <td colspan="1" style="width: 50%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>
                <div>/s/ Avi Naider</div>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-indent: -10pt; margin-left: 10pt;"><br>
              </div>
            </td>
            <td colspan="1" style="width: 50%; vertical-align: top;">
              <div style="text-indent: -10pt; margin-left: 10pt;">Name: Avi Naider </div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
    </div>
    <div><br>
    </div>
    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"> </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.10
<SEQUENCE>16
<FILENAME>ny20077604x1_ex99-10.htm
<DESCRIPTION>EXHIBIT 99.10
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 26.3.2.5342
         Copyright 1995 - 2026 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div style="font-weight: bold; text-align: right;">
    <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">Exhibit 99.10</div>
  <div><br>
  </div>
  <div>Treeline Biosciences, Inc.
    <div>500 Arsenal Street</div>
    <div>Watertown, MA 02472</div>
    <div>&#160;</div>
    <div style="text-align: center; font-weight: bold;">Consent to Reference in Proxy Statement/Prospectus</div>
    <div>&#160;</div>
    Standard BioTools Inc. (&#8220;Standard BioTools&#8221;) is filing a Registration Statement on Form S-4 (the &#8220;Registration Statement&#8221;) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). In connection
    therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendments and supplements thereto as a future member of the board of directors of the combined company following the
    consummation of the merger. I also consent to the filing of this consent as an exhibit to the Registration Statement and any amendments and supplements thereto.
    <div>
      <div>&#160;<br>
      </div>
      <table style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-indent: -10pt; margin-left: 10pt;">Dated: July 20, 2026</div>
            </td>
            <td colspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: middle;">&#160;</td>
            <td colspan="1" style="width: 50%; vertical-align: middle;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">
              <div><br>
              </div>
            </td>
            <td colspan="1" style="width: 50%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>/s/ Ali Satvat</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-indent: -10pt; margin-left: 10pt;"><br>
              </div>
            </td>
            <td colspan="1" style="width: 50%; vertical-align: top;">
              <div style="text-indent: -10pt; margin-left: 10pt;">Name: Ali Satvat</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
    </div>
    <div> <br>
    </div>
    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"> </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.11
<SEQUENCE>17
<FILENAME>ny20077604x1_ex99-11.htm
<DESCRIPTION>EXHIBIT 99.11
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 26.3.2.5342
         Copyright 1995 - 2026 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div style="font-weight: bold; text-align: right;">
    <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">Exhibit 99.11</div>
  <div><br>
  </div>
  <div>Treeline Biosciences, Inc.
    <div>500 Arsenal Street</div>
    <div>Watertown, MA 02472</div>
    <div>&#160;</div>
    <div style="text-align: center; font-weight: bold;">Consent to Reference in Proxy Statement/Prospectus</div>
    <div>&#160;</div>
    <div>Standard BioTools Inc. (&#8220;Standard BioTools&#8221;) is filing a Registration Statement on Form S-4 (the &#8220;Registration Statement&#8221;) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). In
      connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendments and supplements thereto as a future member of the board of directors of the combined company
      following the consummation of the merger. I also consent to the filing of this consent as an exhibit to the Registration Statement and any amendments and supplements thereto.</div>
    <br>
    <div>
      <table style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-indent: -10pt; margin-left: 10pt;">Dated: July 20, 2026</div>
            </td>
            <td colspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: middle;">&#160;</td>
            <td colspan="1" style="width: 50%; vertical-align: middle;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">
              <div><br>
              </div>
            </td>
            <td colspan="1" style="width: 50%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>
                <div>/s/ Susan Desmond-Hellmann</div>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-indent: -10pt; margin-left: 10pt;"><br>
              </div>
            </td>
            <td colspan="1" style="width: 50%; vertical-align: top;">
              <div style="text-indent: -10pt; margin-left: 10pt;">Name: Susan Desmond-Hellmann</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
    </div>
    <div><br>
    </div>
    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"> </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.12
<SEQUENCE>18
<FILENAME>ny20077604x1_ex99-12.htm
<DESCRIPTION>EXHIBIT 99.12
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 26.3.2.5342
         Copyright 1995 - 2026 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div style="font-weight: bold; text-align: right;">
    <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">Exhibit 99.12</div>
  <div><br>
  </div>
  <div>Treeline Biosciences, Inc.
    <div>500 Arsenal Street</div>
    <div>Watertown, MA 02472</div>
    <div>&#160;</div>
    <div style="text-align: center; font-weight: bold;">Consent to Reference in Proxy Statement/Prospectus</div>
    <div>&#160;</div>
    <div>Standard BioTools Inc. (&#8220;Standard BioTools&#8221;) is filing a Registration Statement on Form S-4 (the &#8220;Registration Statement&#8221;) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). In
      connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendments and supplements thereto as a future member of the board of directors of the combined company
      following the consummation of the merger. I also consent to the filing of this consent as an exhibit to the Registration Statement and any amendments and supplements thereto.</div>
    <br>
    <div>
      <table style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-indent: -10pt; margin-left: 10pt;">Dated: July 20, 2026</div>
            </td>
            <td colspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: middle;">&#160;</td>
            <td colspan="1" style="width: 50%; vertical-align: middle;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">
              <div><br>
              </div>
            </td>
            <td colspan="1" style="width: 50%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>
                <div>/s/ Steven Elms</div>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-indent: -10pt; margin-left: 10pt;"><br>
              </div>
            </td>
            <td colspan="1" style="width: 50%; vertical-align: top;">
              <div style="text-indent: -10pt; margin-left: 10pt;">Name: Steven Elms</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
    </div>
    <div><br>
    </div>
    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"> </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>19
<FILENAME>ny20077604x1_ex107.htm
<DESCRIPTION>FILING FEE TABLE
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- Generated by Broadridge Transform (tm) - http://www.broadridge.com -->
<!-- Created: Fri Jul 17 13:40:11 UTC 2026 -->
<!-- Created by CompSci Resources, LLC on Mon Oct 13 19:35:23 UTC 2025 -->
<html xmlns:compsci="http://compsciresources.com" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:ffd="http://xbrl.sec.gov/ffd/2025" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml">
 <head>
  <title> </title>

<meta content="text/html" http-equiv="Content-Type"/>
</head>
 <body><div style="font-family: Times New Roman; font-size: 12pt;"><div>

  </div><hr style="border-top: 4px solid black; border-bottom: none; border-left: none; border-right: none; height: 2px; margin: 8px auto; width: 100%;"/><div style="text-align: right; margin-right: 0.75pt;">
   <span style="font-size: 10.0pt; color: #000000; font-weight: bold;">Exhibit 107</span>
  </div><div>
  </div><div style="margin-bottom: 10pt; margin-top: 10pt; text-align: center;">
   <span style="font-size: 10.0pt; font-weight: bold;">Calculation of Filing Fee Tables</span>
  </div><div>
  </div><div style="text-align: center;"> <span style="font-size: 10.0pt; color: #000000; font-weight: bold;">Form <ix:nonNumeric contextRef="c0" name="ffd:SubmissnTp" id="ixv-342"><ix:nonNumeric contextRef="c0" name="ffd:FormTp" id="ixv-343">S-4</ix:nonNumeric></ix:nonNumeric></span> </div><div>
  </div><div style="text-align: center;">
   <span style="font-size: 10.0pt; color: #000000;">(Form Type)</span>
  </div><div>
  </div><div style="text-align: center; font-size: 10pt;">&#160;
  </div><div>
  </div><div style="text-align: center;"> <ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName" id="ixv-24"><span style="font-size: 10.0pt; color: #000000; font-weight: bold;">STANDARD BIOTOOLS INC.</span></ix:nonNumeric> </div><div>
  </div><div style="text-align: center;">
   <span style="font-size: 10.0pt; color: #000000;">(Exact Name of Registrant as Specified in its Charter)</span>
  </div><div>
  </div><div style="text-align: center; margin-right: 0.75pt; font-size: 10pt;">&#160;
  </div><div>
  </div><div style="text-align: center;">
   <span style="font-size: 10.0pt; color: #000000; font-weight: bold; text-decoration: underline;">Table 1: Newly Registered and Carry Forward Securities</span>
  </div><div>


  </div><table style="border-spacing: 0px; border-collapse: collapse; margin-left: -0.25pt; width: 100%; font-size: 10pt; color: rgb(0, 0, 0);"> <tr style="height: 0px; font-size: 0px;"><td style="width: 9%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 12%;">&#160;</td><td style="width: 7%;">&#160;</td><td style="width: 7%;">&#160;</td><td style="width: 7%;">&#160;</td><td style="width: 7%;">&#160;</td><td style="width: 7%;">&#160;</td><td style="width: 7%;">&#160;</td><td style="width: 7%;">&#160;</td><td style="width: 7%;">&#160;</td><td style="width: 7%;">&#160;</td><td style="width: 7%;">&#160;</td></tr><tr style="vertical-align: top;"> <td style="padding: 0px 5.4pt; border-width: 1pt; border-style: solid; border-color: black; vertical-align: bottom;">&#160;</td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center;"> <span style="color: rgb(0, 0, 0); font-weight: bold;">Security Type</span> </td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 2pt 1px; vertical-align: bottom; text-align: center;"> <span style="color: rgb(0, 0, 0); font-weight: bold;">Security Class Title</span> </td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 2pt 1px; vertical-align: bottom; text-align: center;"> <span style="color: rgb(0, 0, 0); font-weight: bold;">Fee Calculation or Carry Forward Rule</span> </td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center;"> <span style="color: rgb(0, 0, 0); font-weight: bold;">Amount Registered</span> </td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center;"> <span style="color: rgb(0, 0, 0); font-weight: bold;">Proposed Maximum Offering Price Per Unit</span> </td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center;"> <span style="color: rgb(0, 0, 0); font-weight: bold;">Maximum Aggregate Offering Price</span> </td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; white-space: nowrap;"> <span style="color: rgb(0, 0, 0); font-weight: bold;">Fee Rate</span> </td> <td style="padding: 0px 5.4pt; border-width: 1pt; border-style: solid; border-color: black; vertical-align: bottom; text-align: center;"> <span style="color: rgb(0, 0, 0); font-weight: bold;">Amount of Registration Fee</span> </td> <td style="padding: 0px 5.4pt; border-width: 1pt; border-style: solid; border-color: black; vertical-align: bottom; text-align: center;"> <span style="color: rgb(0, 0, 0); font-weight: bold;">Carry Forward Form Type</span> </td> <td style="padding: 0px 5.4pt; border-width: 1pt; border-style: solid; border-color: black; vertical-align: bottom; text-align: center;"> <span style="color: rgb(0, 0, 0); font-weight: bold;">Carry Forward <br/>File Number</span> </td> <td style="padding: 0px 5.4pt; border-width: 1pt; border-style: solid; border-color: black; vertical-align: bottom; text-align: center;"> <span style="color: rgb(0, 0, 0); font-weight: bold;">Carry Forward Initial Effective Date</span> </td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.5pt 1.75pt 1px; vertical-align: bottom; text-align: center;"> <span style="color: rgb(0, 0, 0); font-weight: bold;">Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward</span> </td> </tr> <tr style="vertical-align: top;"> <td colspan="13" style="padding: 0px 5.4pt; border-width: 1pt; border-style: solid; border-color: black; text-align: center;"> <span style="color: rgb(0, 0, 0); font-weight: bold;">Newly Registered Securities</span> </td> </tr> <tr style="vertical-align: top; height: 11pt; background-color: rgb(204, 238, 255);"> <td style="padding: 2pt 1.25pt 1.75pt 5.4pt; border-width: 1pt; border-style: solid; border-color: black; vertical-align: bottom; height: 11pt;"> <div> <ix:nonNumeric contextRef="c1" format="ixt:fixed-false" name="ffd:PrevslyPdFlg" id="ixv-83"><span style="color: rgb(0, 0, 0);">Fees to Be Paid</span></ix:nonNumeric> </div> </td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> <ix:nonNumeric contextRef="c1" name="ffd:OfferingSctyTp" id="ixv-86"><span style="color: rgb(0, 0, 0);">Equity</span></ix:nonNumeric> </td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> <ix:nonNumeric contextRef="c1" name="ffd:OfferingSctyTitl" id="ixv-89"><span style="color: rgb(0, 0, 0);">Common Stock, $0.001 par value per share</span></ix:nonNumeric> </td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> <ix:nonNumeric contextRef="c1" format="ixt:fixed-true" name="ffd:FeesOthrRuleFlg" id="ixv-92"><span style="color: rgb(0, 0, 0);">Other</span></ix:nonNumeric> </td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> <span style="color: rgb(0, 0, 0);"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="ffd:AmtSctiesRegd" scale="0" unitRef="shares" id="ixv-344">2,760,078,538</ix:nonFraction><sup>(1)</sup></span> </td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> <span style="color: rgb(0, 0, 0);">&#8212;</span> </td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> <span style="color: rgb(0, 0, 0);">$<ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="ffd:MaxAggtOfferingPric" scale="0" unitRef="usd" id="ixv-345">572.20</ix:nonFraction><sup>(2)</sup></span> </td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> <span style="color: rgb(0, 0, 0);">$<ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="ffd:FeeRate" scale="0" unitRef="pure" id="ixv-346">0.00013810</ix:nonFraction></span> </td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> <span style="color: rgb(0, 0, 0);">$<ix:nonFraction contextRef="c1" decimals="2" format="ixt:num-dot-decimal" name="ffd:FeeAmt" scale="0" unitRef="usd" id="ixv-347">0.08</ix:nonFraction></span> </td> <td style="padding: 0px 5.4pt; border-width: 1pt; border-style: solid; border-color: black; vertical-align: bottom; text-align: center; height: 11pt;">&#160;</td> <td style="padding: 0px 5.4pt; border-width: 1pt; border-style: solid; border-color: black; vertical-align: bottom; text-align: center; height: 11pt;">&#160;</td> <td style="padding: 0px 5.4pt; border-width: 1pt; border-style: solid; border-color: black; vertical-align: bottom; text-align: center; height: 11pt;">&#160;</td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.5pt 1.75pt 1px; vertical-align: bottom; font-size: 0px; height: 11pt;">&#160;</td> </tr><tr style="vertical-align: top; height: 11pt;"> <td style="padding: 2pt 1.25pt 1.75pt 5.4pt; border-width: 1pt; border-style: solid; border-color: black; vertical-align: bottom; height: 11pt;"> <div> <ix:nonNumeric contextRef="c2" format="ixt:fixed-false" name="ffd:PrevslyPdFlg" id="ixv-113"><span style="color: rgb(0, 0, 0);">Fees to Be Paid</span></ix:nonNumeric> </div> </td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> <ix:nonNumeric contextRef="c2" name="ffd:OfferingSctyTp" id="ixv-116"><span style="color: rgb(0, 0, 0);">Equity</span></ix:nonNumeric> </td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> <ix:nonNumeric contextRef="c2" name="ffd:OfferingSctyTitl" id="ixv-119"><span style="color: rgb(0, 0, 0);">Common Stock, $0.001 par value per share</span></ix:nonNumeric> </td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> <ix:nonNumeric contextRef="c2" format="ixt:fixed-true" name="ffd:FeesOthrRuleFlg" id="ixv-122"><span style="color: rgb(0, 0, 0);">Other</span></ix:nonNumeric> </td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> <span style="color: rgb(0, 0, 0);"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="ffd:AmtSctiesRegd" scale="0" unitRef="shares" id="ixv-348">76,000,000</ix:nonFraction><sup>(3)</sup></span> </td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> <span style="color: rgb(0, 0, 0);">$<ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="ffd:MaxOfferingPricPerScty" scale="0" unitRef="usdPershares" id="ixv-349">0.8946</ix:nonFraction><sup>(4)</sup></span> </td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> <span style="color: rgb(0, 0, 0);">$<ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="ffd:MaxAggtOfferingPric" scale="0" unitRef="usd" id="ixv-350">67,989,600</ix:nonFraction><sup>(4)</sup></span> </td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> <span style="color: rgb(0, 0, 0);">$<ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="ffd:FeeRate" scale="0" unitRef="pure" id="ixv-351">0.00013810</ix:nonFraction></span> </td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> <span style="color: rgb(0, 0, 0);">$<ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="ffd:FeeAmt" scale="0" unitRef="usd" id="ixv-352">9,389.36</ix:nonFraction></span> </td> <td style="padding: 0px 5.4pt; border-width: 1pt; border-style: solid; border-color: black; vertical-align: bottom; text-align: center; height: 11pt;">&#160;</td> <td style="padding: 0px 5.4pt; border-width: 1pt; border-style: solid; border-color: black; vertical-align: bottom; text-align: center; height: 11pt;">&#160;</td> <td style="padding: 0px 5.4pt; border-width: 1pt; border-style: solid; border-color: black; vertical-align: bottom; text-align: center; height: 11pt;">&#160;</td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.5pt 1.75pt 1px; vertical-align: bottom; font-size: 0px; height: 11pt;">&#160;</td> </tr><tr style="vertical-align: top; height: 11pt; background-color: rgb(204, 238, 255);"> <td style="padding: 2pt 1.25pt 1.75pt 5.4pt; border-width: 1pt; border-style: solid; border-color: black; vertical-align: bottom; height: 11pt;"> <div> <ix:nonNumeric contextRef="c3" format="ixt:fixed-false" name="ffd:PrevslyPdFlg" id="ixv-144"><span style="color: rgb(0, 0, 0);">Fees to Be Paid</span></ix:nonNumeric> </div> </td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> <ix:nonNumeric contextRef="c3" name="ffd:OfferingSctyTp" id="ixv-147"><span style="color: rgb(0, 0, 0);">Equity</span></ix:nonNumeric> </td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> <ix:nonNumeric contextRef="c3" name="ffd:OfferingSctyTitl" id="ixv-150"><span style="color: rgb(0, 0, 0);">Common Stock, $0.001 par value per share</span></ix:nonNumeric> </td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> <ix:nonNumeric contextRef="c3" format="ixt:fixed-true" name="ffd:FeesOthrRuleFlg" id="ixv-153"><span style="color: rgb(0, 0, 0);">Other</span></ix:nonNumeric> </td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> <span style="color: rgb(0, 0, 0);"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="ffd:AmtSctiesRegd" scale="0" unitRef="shares" id="ixv-353">2,032,831,848</ix:nonFraction><sup>(5)</sup></span> </td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> <span style="color: rgb(0, 0, 0);">&#8212;</span> </td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> <span style="color: rgb(0, 0, 0);">$<ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="ffd:MaxAggtOfferingPric" scale="0" unitRef="usd" id="ixv-354">0.00</ix:nonFraction><sup>(5)</sup></span> </td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> <span style="color: rgb(0, 0, 0);">$<ix:nonFraction contextRef="c3" decimals="8" format="ixt:num-dot-decimal" name="ffd:FeeRate" scale="0" unitRef="pure" id="ixv-355">0.00013810</ix:nonFraction></span> </td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> <span style="color: rgb(0, 0, 0);">$<ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="ffd:FeeAmt" scale="0" unitRef="usd" id="ixv-356">0.00</ix:nonFraction></span> </td> <td style="padding: 0px 5.4pt; border-width: 1pt; border-style: solid; border-color: black; vertical-align: bottom; text-align: center; height: 11pt;">&#160;</td> <td style="padding: 0px 5.4pt; border-width: 1pt; border-style: solid; border-color: black; vertical-align: bottom; text-align: center; height: 11pt;">&#160;</td> <td style="padding: 0px 5.4pt; border-width: 1pt; border-style: solid; border-color: black; vertical-align: bottom; text-align: center; height: 11pt;">&#160;</td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.5pt 1.75pt 1px; vertical-align: bottom; font-size: 0px; height: 11pt;">&#160;</td> </tr> <tr style="vertical-align: top;"> <td style="padding: 2pt 1.25pt 1.75pt 5.4pt; border-width: 1pt; border-style: solid; border-color: black; vertical-align: bottom;"> <div> <span style="color: rgb(0, 0, 0);">Fees Previously Paid</span> </div> </td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> <span style="color: rgb(0, 0, 0);">&#8212;</span> </td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> <span style="color: rgb(0, 0, 0);">&#8212;</span> </td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> <span style="color: rgb(0, 0, 0);">&#8212;</span> </td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> <span style="color: rgb(0, 0, 0);">&#8212;</span> </td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> <span style="color: rgb(0, 0, 0);">&#8212;</span> </td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> <span style="color: rgb(0, 0, 0);">&#8212;</span> </td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; font-size: 0px;">&#160;</td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> <span style="color: rgb(0, 0, 0);">&#8212;</span> </td> <td style="padding: 0px 5.4pt; border-width: 1pt; border-style: solid; border-color: black; vertical-align: bottom; text-align: center;">&#160;</td> <td style="padding: 0px 5.4pt; border-width: 1pt; border-style: solid; border-color: black; vertical-align: bottom; text-align: center;">&#160;</td> <td style="padding: 0px 5.4pt; border-width: 1pt; border-style: solid; border-color: black; vertical-align: bottom; text-align: center;">&#160;</td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.5pt 1.75pt 1px; vertical-align: bottom; font-size: 0px;">&#160;</td> </tr> <tr style="vertical-align: top; background-color: rgb(204, 238, 255);"> <td colspan="13" style="padding: 0px 5.4pt; border-width: 1pt; border-style: solid; border-color: black; text-align: center;"> <span style="color: rgb(0, 0, 0); font-weight: bold;">Carry Forward Securities</span> </td> </tr> <tr style="vertical-align: top;"> <td style="padding: 2pt 1.25pt 1.75pt 5.4pt; border-width: 1pt; border-style: solid; border-color: black; vertical-align: bottom;"> <div> <span style="color: rgb(0, 0, 0);">Carry Forward Securities</span> </div> </td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> <span style="color: rgb(0, 0, 0);">&#8212;</span> </td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> <span style="color: rgb(0, 0, 0);">&#8212;</span> </td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> <span style="color: rgb(0, 0, 0);">&#8212;</span> </td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> <span style="color: rgb(0, 0, 0);">&#8212;</span> </td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center;">&#160;</td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> <span style="color: rgb(0, 0, 0);">&#8212;</span> </td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; font-size: 0px;">&#160;</td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> <span style="color: rgb(0, 0, 0);">&#8212;</span> </td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> <span style="color: rgb(0, 0, 0);">&#8212;</span> </td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> <span style="color: rgb(0, 0, 0);">&#8212;</span> </td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> <span style="color: rgb(0, 0, 0);">&#8212;</span> </td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.5pt 1.75pt 1px; vertical-align: bottom; text-align: center;"> <span style="color: rgb(0, 0, 0);">&#8212;</span> </td> </tr> <tr style="vertical-align: top; background-color: rgb(204, 238, 255);"> <td style="padding: 0px 5.4pt; border-width: 1pt; border-style: solid; border-color: black;">&#160;</td> <td colspan="4" style="padding: 2pt 5.4pt 1.75pt 5.4pt; border-width: 1pt; border-style: solid; border-color: black; text-align: right; vertical-align: bottom;"> <span style="color: rgb(0, 0, 0); font-weight: bold;">Total Offering Amounts</span> </td> <td style="padding: 0px 1.25pt 0px 1px; border-width: 1pt; border-style: solid; border-color: black; vertical-align: bottom; font-size: 0px;">&#160;</td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> <span style="color: rgb(0, 0, 0);">$<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="ffd:TtlOfferingAmt" scale="0" unitRef="usd" id="ixv-357">67,990,172.20</ix:nonFraction></span></td> <td style="padding: 0px 1.25pt 0px 1px; border-width: 1pt; border-style: solid; border-color: black; vertical-align: bottom; font-size: 0px;">&#160;</td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> <span style="color: rgb(0, 0, 0);">$<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="ffd:TtlFeeAmt" scale="0" unitRef="usd" id="ixv-358">9,389.44</ix:nonFraction></span> </td> <td style="padding: 0px 5.4pt; border-width: 1pt; border-style: solid; border-color: black; vertical-align: bottom; text-align: center;">&#160;</td> <td style="padding: 0px 5.4pt; border-width: 1pt; border-style: solid; border-color: black; vertical-align: bottom; text-align: center;">&#160;</td> <td style="padding: 0px 5.4pt; border-width: 1pt; border-style: solid; border-color: black; vertical-align: bottom; text-align: center;">&#160;</td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.5pt 1.75pt 1px; vertical-align: bottom; font-size: 0px;">&#160;</td> </tr> <tr style="vertical-align: top;"> <td style="padding: 0px 5.4pt; border-width: 1pt; border-style: solid; border-color: black;">&#160;</td> <td colspan="4" style="padding: 2pt 5.4pt 1.75pt 5.4pt; border-width: 1pt; border-style: solid; border-color: black; text-align: right; vertical-align: bottom;"> <span style="color: rgb(0, 0, 0); font-weight: bold;">Total Fees Previously Paid</span> </td> <td style="padding: 0px 1.25pt 0px 1px; border-width: 1pt; border-style: solid; border-color: black; vertical-align: bottom;">&#160;</td> <td style="padding: 0px 1.25pt 0px 1px; border-width: 1pt; border-style: solid; border-color: black; vertical-align: bottom;">&#160;</td> <td style="padding: 0px 1.25pt 0px 1px; border-width: 1pt; border-style: solid; border-color: black; vertical-align: bottom;">&#160;</td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> <span style="color: rgb(0, 0, 0);"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:fixed-zero" name="ffd:TtlPrevslyPdAmt" scale="0" unitRef="usd" id="ixv-359">&#8212;</ix:nonFraction></span> </td> <td style="padding: 0px 5.4pt; border-width: 1pt; border-style: solid; border-color: black; vertical-align: bottom; text-align: center;">&#160;</td> <td style="padding: 0px 5.4pt; border-width: 1pt; border-style: solid; border-color: black; vertical-align: bottom; text-align: center;">&#160;</td> <td style="padding: 0px 5.4pt; border-width: 1pt; border-style: solid; border-color: black; vertical-align: bottom; text-align: center;">&#160;</td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.5pt 1.75pt 1px; vertical-align: bottom; text-align: center;">&#160;</td> </tr> <tr style="vertical-align: top; height: 11pt; background-color: rgb(204, 238, 255);"> <td style="padding: 0px 5.4pt; border-width: 1pt; border-style: solid; border-color: black; height: 11pt;">&#160;</td> <td colspan="4" style="padding: 2pt 5.4pt 1.75pt 5.4pt; border-width: 1pt; border-style: solid; border-color: black; text-align: right; height: 11pt; vertical-align: bottom;"> <span style="color: rgb(0, 0, 0); font-weight: bold;">Total Fee Offsets</span> </td> <td style="padding: 0px 1.25pt 0px 1px; border-width: 1pt; border-style: solid; border-color: black; vertical-align: bottom; font-size: 0px; height: 11pt;">&#160;</td> <td style="padding: 0px 1.25pt 0px 1px; border-width: 1pt; border-style: solid; border-color: black; vertical-align: bottom; font-size: 0px; height: 11pt;">&#160;</td> <td style="padding: 0px 1.25pt 0px 1px; border-width: 1pt; border-style: solid; border-color: black; vertical-align: bottom; font-size: 0px; height: 11pt;">&#160;</td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> <span style="color: rgb(0, 0, 0);"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:fixed-zero" name="ffd:TtlOffsetAmt" scale="0" unitRef="usd" id="ixv-360">&#8212;</ix:nonFraction></span> </td> <td style="padding: 0px 5.4pt; border-width: 1pt; border-style: solid; border-color: black; vertical-align: bottom; text-align: center; height: 11pt;">&#160;</td> <td style="padding: 0px 5.4pt; border-width: 1pt; border-style: solid; border-color: black; vertical-align: bottom; text-align: center; height: 11pt;">&#160;</td> <td style="padding: 0px 5.4pt; border-width: 1pt; border-style: solid; border-color: black; vertical-align: bottom; text-align: center; height: 11pt;">&#160;</td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.5pt 1.75pt 1px; vertical-align: bottom; font-size: 0px; height: 11pt;">&#160;</td> </tr> <tr style="vertical-align: top; height: 11pt;"> <td style="padding: 0px 5.4pt; border-width: 1pt; border-style: solid; border-color: black; height: 11pt;">&#160;</td> <td colspan="4" style="padding: 2pt 5.4pt 1.75pt 5.4pt; border-width: 1pt; border-style: solid; border-color: black; text-align: right; height: 11pt; vertical-align: bottom;"> <span style="color: rgb(0, 0, 0); font-weight: bold;">Net Fee Due</span> </td> <td style="padding: 0px 1.25pt 0px 1px; border-width: 1pt; border-style: solid; border-color: black; vertical-align: bottom; font-size: 0px; height: 11pt;">&#160;</td> <td style="padding: 0px 1.25pt 0px 1px; border-width: 1pt; border-style: solid; border-color: black; vertical-align: bottom; font-size: 0px; height: 11pt;">&#160;</td> <td style="padding: 0px 1.25pt 0px 1px; border-width: 1pt; border-style: solid; border-color: black; vertical-align: bottom; font-size: 0px; height: 11pt;">&#160;</td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> <span style="color: rgb(0, 0, 0);">$<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="ffd:NetFeeAmt" scale="0" unitRef="usd" id="ixv-361">9,389.44</ix:nonFraction></span> </td> <td style="padding: 0px 5.4pt; border-width: 1pt; border-style: solid; border-color: black; vertical-align: bottom; text-align: center; height: 11pt;">&#160;</td> <td style="padding: 0px 5.4pt; border-width: 1pt; border-style: solid; border-color: black; vertical-align: bottom; text-align: center; height: 11pt;">&#160;</td> <td style="padding: 0px 5.4pt; border-width: 1pt; border-style: solid; border-color: black; vertical-align: bottom; text-align: center; height: 11pt;">&#160;</td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.5pt 2pt 1px; vertical-align: bottom; font-size: 0px; height: 11pt;">&#160;</td> </tr> </table><div>

  </div><ix:nonNumeric contextRef="c1" continuedAt="_OfferingNote-c1_cont_1" escape="true" name="ffd:OfferingNote" id="ixv-277"><table style="font-size: 12pt; border-spacing: 0px; border-collapse: collapse; width: 100%;"> <tr style="height: 0px; font-size: 0px;"><td style="width: 1%;">&#160;</td><td style="width: 99%;">&#160;</td></tr><tr style="vertical-align: top;"> <td style="padding: 0px 0pt;"> <div style="margin-bottom: 4pt;"> <span style="font-size: 10.0pt;">(1)</span> </div> </td> <td style="padding: 0px 5.4pt; text-align: left;"> <div style="margin-bottom: 4pt;"> <span style="font-size: 10.0pt;">Relates to common stock, $0.001 par value per share (&#8220;Standard BioTools Common Stock&#8221;), of Standard BioTools Inc., a Delaware corporation (&#8220;Standard BioTools&#8221;) issuable to holders of common stock, $0.00001 par value per share (&#8220;Treeline Common Stock&#8221;) of Treeline Biosciences, Inc., a Delaware corporation (&#8220;Treeline&#8221;), holders of preferred stock, par value $0.00001 per share of Treeline (&#8220;Treeline Preferred Stock&#8221; and together with the Treeline Common Stock, the &#8220;Treeline Capital Stock&#8221;), holders of warrants to purchase shares of Treeline Common Stock that have been amended to require net-exercise in connection with the Merger (as defined below) in the proposed merger (the &#8220;Merger&#8221;) of Siri Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Standard BioTools (&#8220;Merger Sub&#8221;), with and into Treeline, with Treeline surviving as a wholly owned subsidiary of Standard BioTools. The amount of Standard BioTools Common Stock to be registered includes the estimated maximum number of shares of Standard BioTools Common Stock that are expected to be issued pursuant to the Merger, without taking into account the effect of a reverse stock split of Standard BioTools Common Stock, assuming an estimated pre-split exchange ratio (which is subject to adjustment prior to the closing of the Merger) of approximately 16.07931 shares of Standard BioTools Common Stock for each share of Treeline Capital Stock. Such exchange ratio is only an estimate as the actual exchange ratio will be determined in connection with the closing of the Merger. In accordance with Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), this registration statement shall be deemed to cover any securities that may from time to time be offered or issued resulting from forward or reverse stock splits, stock dividends or similar transactions.</span> </div> </td> </tr> </table></ix:nonNumeric><div>











  </div><ix:continuation id="_OfferingNote-c1_cont_1"><table style="font-size: 12pt; border-spacing: 0px; border-collapse: collapse; width: 100%;">
   <tr style="height: 0px; font-size: 0px;"><td style="width: 1%;">&#160;</td><td style="width: 99%;">&#160;</td></tr><tr style="vertical-align: top;">
    <td style="padding: 0px 0pt;">
     <div style="margin-bottom: 4pt;">
      <span style="font-size: 10.0pt;">(2)</span>
     </div>
    </td>
    <td style="padding: 0px 5.4pt; text-align: left;">
     <div style="margin-bottom: 4pt;">
      <span style="font-size: 10.0pt;">Estimated solely for purposes of calculating the registration fee in accordance with Rule 457(f)(2) of the Securities Act. Treeline is a private company, no market exists for its securities, and Treeline has an accumulated capital deficit. Therefore, the proposed maximum aggregate offering price for the shares of Standard BioTools Common Stock expected to be issued pursuant to the Merger is one-third of the aggregate par value of the Treeline securities expected to be exchanged in the proposed Merger.</span>
     </div>
    </td>
   </tr>
  </table></ix:continuation><ix:nonNumeric contextRef="c2" continuedAt="_OfferingNote-c2_cont_1" escape="true" name="ffd:OfferingNote" id="ixv-302"><table style="font-size: 12pt; border-spacing: 0px; border-collapse: collapse; width: 100%;"> <tr style="height: 0px; font-size: 0px;"><td style="width: 1%;">&#160;</td><td style="width: 99%;">&#160;</td></tr><tr style="vertical-align: top;"> <td style="padding: 0px 0pt;"> <div style="margin-bottom: 4pt;"> <span style="font-size: 10.0pt;">(3)</span> </div> </td> <td style="padding: 0px 5.4pt; text-align: left;"> <div style="margin-bottom: 4pt;"> <span style="font-size: 10.0pt;">Relates to the maximum number of shares of Standard BioTools Common Stock issuable pursuant to the contingent value rights (&#8220;CVRs&#8221;) to be declared as a dividend to stockholders of record of Standard BioTools as of the close of business on the last business day prior to the day on which the effective time of the Merger occurs. Each holder of a CVR is entitled to a number of shares of the combined company&#8217;s common stock (with fractional shares settled in cash) equal to such holder&#8217;s pro rata portion of the aggregate net proceeds received by the combined company during such 12-month CVR payment period from the following sources, in each case less certain permitted deductions: (i) proceeds from any sale, disposition, or other monetization of Standard BioTools&#8217; legacy businesses; (ii) proceeds from convertible notes or other investments held by Standard BioTools as of the closing date of the Merger; (iii) earnout, milestone, royalty or other similar contingent payments due to Standard BioTools under contracts in effect as of the closing date of the Merger, including payments from Illumina, Inc. pursuant to the Stock Purchase Agreement dated June 22, 2025; and (iv) any surplus in Parent Net Cash (as defined in the Agreement and Plan of Merger and Reorganization dated June 6, 2026 (the &#8220;Merger Agreement&#8221;) by and among Standard BioTools, Treeline and Merger Sub and included as Annex A to this registration statement) delivered at closing of the Merger as finally determined under the Merger Agreement.</span> </div> </td> </tr> </table></ix:nonNumeric><ix:continuation id="_OfferingNote-c2_cont_1"><table style="font-size: 12pt; border-spacing: 0px; border-collapse: collapse; width: 100%;">
   <tr style="height: 0px; font-size: 0px;"><td style="width: 1%;">&#160;</td><td style="width: 99%;">&#160;</td></tr><tr style="vertical-align: top;">
    <td style="padding: 0px 0pt;">
     <div style="margin-bottom: 4pt;">
      <span style="font-size: 10.0pt;">(4)</span>
     </div>
    </td>
    <td style="padding: 0px 5.4pt; text-align: left;">
     <div style="margin-bottom: 4pt;">
      <span style="font-size: 10.0pt;">Estimated solely for purposes of calculating the registration fee in accordance with Rule 457(c) of the Securities Act based on the average of the high and low prices per share of Standard BioTools Common Stock on July 13, 2026.</span>
     </div>
    </td>
   </tr>
  </table></ix:continuation><ix:nonNumeric contextRef="c3" escape="true" name="ffd:OfferingNote" id="ixv-326"><table style="font-size: 12pt; border-spacing: 0px; border-collapse: collapse; width: 100%;"> <tr style="height: 0px; font-size: 0px;"><td style="width: 1%;">&#160;</td><td style="width: 99%;">&#160;</td></tr><tr style="vertical-align: top;"> <td style="padding: 0px 0pt;"> <div style="margin-bottom: 4pt;"> <span style="font-size: 10.0pt;">(5)</span> </div> </td> <td style="padding: 0px 5.4pt; text-align: left;"> <div style="margin-bottom: 4pt;"> <span style="font-size: 10.0pt;">Represents an aggregate of 2,032,831,848 Standard BioTools Common Stock issuable in accordance with (1) above to certain Treeline stockholders. Pursuant to Rule 457(f)(5) of the Securities Act, no additional filing fee is required to be paid for the registration of Standard BioTools Common Stock to be sold by the selling securityholders pursuant to the resale prospectus that are also being registered under this registration statement.</span> </div> </td> </tr> </table></ix:nonNumeric><div style="margin-right : 171.75pt; font-size : 8pt; width : 100%; ">&#160;
  </div><div>

 </div><hr style="border-top: 2px solid black; border-bottom: none; border-left: none; border-right: none; height: 2px; margin: 8px auto; width: 100%;"/><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="c0" name="ffd:CombinedProspectusTableNa" id="ixv-364">N/A</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey" id="ixv-365">0001162194</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="ffd:FeeExhibitTp" id="ixv-366">EX-FILING FEES</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="ffd:OffsetTableNa" id="ixv-367">N/A</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="https://xbrl.sec.gov/ffd/2025/ffd-2025.xsd" xlink:type="simple"/></ix:references>
<ix:resources xmlns="http://www.xbrl.org/2003/instance"><xbrli:context xmlns="" id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001162194</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2026-07-20</xbrli:startDate>
    <xbrli:endDate>2026-07-20</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001162194</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:typedMember dimension="ffd:OfferingAxis">
        <dei:lineNo>1</dei:lineNo>
      </xbrldi:typedMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2026-07-20</xbrli:startDate>
    <xbrli:endDate>2026-07-20</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001162194</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:typedMember dimension="ffd:OfferingAxis">
        <dei:lineNo>2</dei:lineNo>
      </xbrldi:typedMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2026-07-20</xbrli:startDate>
    <xbrli:endDate>2026-07-20</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001162194</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:typedMember dimension="ffd:OfferingAxis">
        <dei:lineNo>3</dei:lineNo>
      </xbrldi:typedMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2026-07-20</xbrli:startDate>
    <xbrli:endDate>2026-07-20</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:unit xmlns="" id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
<!-- [WMV7][fuOsgaMh7Vp6OyaBQ46kjwjyEz1Y+F+G90BP74m4qf6mswLrrdM/4If9DWqAAIO8NgPnKEgcEUV0bveym4lHjSKl0aScUB0e3XjJq+GvlNZvY01iQSDgP8lO68qfAftkOmwnvKpbVxAWhvdxlMY/G73Fzu3TUUJhFfe+zE9xPxH3VPzVkQ9sZuYb+5QehEfoJXL6lCp7ZRY7gsYhIMb6EfbskMh1OA40wbhU1UH/QGApE6fKSwfgV+yYrwAVr0mwzyz+tiG+Jov6T+vBjSms++xPq9Bj2lCpL5feQvjxfZg7v760hnqDk2TmaLLmHkPdUuGKgpHEBvO3f13MkoS+NkZKHvlOx9329Pp6bwrEc1at2fshlV8=] CSR-->
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit></ix:resources></ix:header>
</div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>logo_centerviewfooter.jpg
<TEXT>
begin 644 logo_centerviewfooter.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
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MWD<FIKJS:)>6,D/E6SP0,[SP_IC\&_%7C3QU\(?A5XW^)'@.;X6?$/QC\-_
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M1O?AQXATN[T/2I!%<5_/Q_P4K_;<_8@_:+^ O_!&_P 9?!'XZ?"2U^&^G?\
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MRQ^TQ_P4,_X)P_&CXG/\-OB]^V3^SEI7[/O[+WC;3?B3\5_!=U\2-&U#Q/\
M';XX_"G49_$W@GX8Z?X)TW4IO$?C'X?_  @\4Z/H7Q)U[2_#_AOQ(GQ8^+.G
M?#KP)X;N]0M/!7Q0\(>(P#UOQ]_P5/C_ &?O^"D&@_L*?M-?#;PY\/? 'Q5\
M$^"_$OP2_::T'QUK&L>$+SQ5\2?$'Q#\/_#KX7?%W2-<\#>'-*^&OC'QY??"
M'XGV?A0V?C7Q5::S>^&]-BM4=-;U-O"GUSJ?QP^-:_MCC]G#1_ 7POD^'K_
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MXZC\<VH.F>(8OBCX-O=!EO\ _A+-+T^\ /WY_;?_ &UO&W[)/Q(_8K\&:/\
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M6E:Q/J/@J\\8:[X9TK6_^$ \=6VC6/ GPZ_X*DVGCSQ9XY\4?#G]@/P[X_\
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M?V^/CR/&OB_]L7]GGX<_#'5_CGX9\0W6K:9KOQM_9^UOXS1:9+\,_CEID_\
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M?$OBS4]?\2-H7BWQ7I&G>+K70-1UMM.T74?[8N= TZTCU?5'G_9"O@/]F_\
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M_CCXDD^,'B_]BG6+C2?$/D>!-=U#Q!?>+'_:PT8QS^ +71K>WT/P7X,\,?\
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MU*#QEXY\'7MSN^)UUJ/AJYU_P[#8V&L6ECXCX;_:2^.VH_LR_LS>#_"'QO\
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MU+2=%TW3_#FJZM:0^'/!E]96GB3^P/$T\4VCW(!^:O@CX]_$_P#X)=_L]_\
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M1RQ08EF32VB0@O0!^,W[*W[0O@K]G/\ X*^_\%$_A)XW^)7Q3D_9R\7?!O\
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M7Q9^)WPCO?']WX6\6^*OVB/C-:?#2[UCQ)\7?&/QI\&^,-6\/K^QWJ.OK?>
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MI>$_C=K/Q4UO4O!G@OQ;H'C[6?"_P \+3?"'P9/=7/CG4_#>G>%Y/&7Q0O?
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M+Z+%X7'@^/4I8] ?6!HJV TM8F7^PAH<LO\ 9X^RL\NB2)(I,DL;SL93W]%
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M?#^CRP+*+.)5MC*]LBER(MVQD[K6]-EUC2=0TN'5M4T.2_M9;5=7T5[*/5K
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6">XEAM;9(O;:* LOU_K[@HHHH&?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>logo_centerviewpartnersv2.jpg
<TEXT>
begin 644 logo_centerviewpartnersv2.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MV3^RI\+O'FA- NM^"?B+^T-\(O!/B[1VNH([JV75?#?B7Q?IFLZ>UQ:RQ7,
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MPZ\4/I-\TJ66J+H'C#Q3H^K-IUV]O.EK?"T-M<-#*L4KF-PH!]*T5\A^#_\
M@H)^P5\0_$.G>$? '[;O[(?CGQ9K$PM])\,>#_VD_@SXF\0ZI.2 (-.T71?&
ME[J5[,20!';6TKDD +R*^N6DC2-I7D1(E0R-*S*L:QJNYI&<D*$"@L6)"A1D
MG'- #Z*^&=,_X*>_\$VM8%N-/_X* _L632W4Q@M[63]J#X*6M]--YIA6-+"[
M\:P7I:208A'V?]^I5X=Z.C-TM_\ \%#/V M*@DN=3_;D_8]TZVBCAFEN+_\
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MR221PRJUCXF^''PZ\-ZI;A9U= ]WIFK7=K%(H$T4DR2V[)<)$Z]=_P %C?\
M@D3IO[=?AC2/VA?V=]2?X0_\%!/@/%8^(_@C\6_#6JMX0U+Q?<^%;L:WHO@+
MQ7XCLI+2>SN(+^$W'P]\:/=VU]X&\1R0RM?Q>'+W6K64 _<T@$$$ @@@@C((
M/!!!X((X(/6OY;O^#9;P'IOC?_@EI^U!\/1?:CX4L_'?[67[27@VZUWPG_9^
MG^(-%M]?^%7PH\-C5]"GN["_T^#6=&LIXY=&FOM.O[.VGL[-9K*YM83;-]0?
M\$;/^"N][^V#9:U^R-^U_8'X1?\ !1GX$'5/#GQ-\ >(M&B\%S_%6#PI+):Z
MCXU\,: YBMK/Q;86T*3_ !'\&Z9!:VMG=&X\7>$=-M_!-ZVF^%X_^#=3PI'X
M6_8[_:(DMA90Z=XA_P""@O[6&K:5I]A;+:V^DZ?INM^&?!T.G)!&J01I$_A:
M6:".V1((;6>WA15,3"@#[]\!_P#!*[_@FK\-M!T/P[X5_8-_9+2U\/:;%I-A
MJGB#X"_#;QGXMGM(EV[M:\<^,O#NO>,_$=[*/^/G4_$&O:GJ-T<&YNI<#'\S
M'_!MM^S+^S=\7OBU_P %7[3XL?L^_!'XH6G@C]H;P1H_@NT^(GPI\">-;7PA
MI,WB7]H&*;3/"UMXET'4X/#^GS1:;IT4UGI"6=O-'I]A')&R6=L(O[8*_CO_
M .#6JYN'_:*_X+/V;2L;6#X\?""YA@)&R.XN_'/[7$5S*HQG=-'96J.<D$0)
M@#!R ?T._!__ ()M?LC_ +.W[45U^U5^SU\'_ OP.\8:[\%_%OP6\9>&?A?X
M3T7P=X,\4Z3XC\=^ /'EAKTOA[0K>QT?1]<T6_\ !-Q92W&C:;:'7[+6H5UE
M[@^'=%$'\UW@GP#X$\8_\'=7[4GA?Q=X*\)>*?#5U\&]%U*Y\.^(_#FCZYH5
MQJ-Q^R'\ K^?4)](U.SNM/EO9[Z[NKV:ZDMVGDN[FXN7D:::1V_M$K^):Y\"
M>-OB-_P=I?M2>&O 'QK\=_ #Q%+\'O"%Y%\1/ASX>^%/B?Q+;6EI^Q[^SX]U
MI46E?&;X>?$_P2]GJB,L5W//X5EU&%$5M/OK.0N[ ']/>F_\$T_V)_"7QX^"
MO[2/PJ_9W^$7P0^*_P $-;\<:KH_B#X,?#/P#\-F\667Q ^&OBOX::]H7CE/
M"WAO3O\ A(=/33_%)UC2[F9H]6TS5M+MH[/48M*U#7=-U7X8_P"#E'2-*U+_
M ((S_M:7NH:=97MWX?U']GS5]"N;JVBGGTC59OVE_A!H,VHZ;+(K/9WLNB:W
MK&DR7,!25M.U2_M&8P74R/\ 0/P-_99_X*!?#C]K[P=X\^.?_!0/QG^UA^SA
MIWPI^,-O!X'UGX0_"'X#3>$/B=J>N_"JR\"W'B&#X)VOANQ^,*:EX3E^)$EG
M<>)O#4&F>!;_ $1;O3K:/4_$]O+;>'_\'(?_ "A=_;,_[MW_ /6K?@90!'_P
M3\_X)^_L1_'[_@D]^Q[X7^*_[*GP%\4VOQ,_9*^$NH^,-9D^%W@[3O&.H>(_
M%GPM\/VNN>-+7QQI6D67B[2?'UT/+N4\=Z5K5GXLMK^WM;^WU>*[M8)H_P S
M_P#@W?T[XY_LT?MX?\%./^"==SXP\9>.?V9/V9_$5VWP^?QAJTNH_P#"'ZHO
MQ)UC2_!<^CV-L)-$T"Y^*W@*[OO$WBW3]*_LZTN-:\+P7<.EQW!U%H_;_P!G
M+]L__@I3^R?_ ,$D_P!EGXF>"/\ @G+\-OVCOA=X+_9*^%=_H7B'X9_M8ZR?
MB+IW@C2_AUH":/XT\:?!34?V=;;5-1=K62#5?$/AGX<^-?%=YH]E:ZL\NI+I
MUDVMGZT_X-^F_9Z\=?L7ZS^TI\+_ !G%\2_CY^T[\4O%?Q5_;8\=:CI5MHOB
MQ?VDM<OKC7O$W@&_T:&YO#H/A#P&GB,Q?#K2K>Y&DW_AW6F\;V-K977C34K=
M0#]U:_E0_P"";MU-;_\ !>+]OR*)@J7UM^T]:W(*JV^%/CU\/+U5!()0BXLX
M'W(0Q"%"=K,#_5?7\I'_  3D_P"4\_[>/T_:@_\ 5W^!J_3> DGD/B3=7_XQ
M)O7NL=0:?R>J\S\XXX;6>>'MM/\ C*4OD\)43^]-H^I/^#E7]B&S_:O_ ."=
M'C3XG>'?#MMJ/Q?_ &1IKGXW^$]2AM;3^V)?AU8VZ6_QN\-+J,Y6:#1'\#Q-
M\0KZPMBTVJ:S\-?#MM#&\I56^P/^"*W[8@_;=_X)O_LZ?%K5=5&J?$7PQX87
MX-_&!Y;T7VIGXE_"F.W\,:GK.N3+!;QQZKX]T&#PY\3I;6&,QVEMXWM+<.QC
M;'ZAZOI.EZ_I6IZ%K>GV>K:+K6GWNDZOI6HV\5WI^IZ7J5M+9ZAI]]:3J\-S
M9WMI--;7-O,CQ30R/'(K(Q!_CI_X(2ZCJ_\ P3F_X*F?M^_\$@_'>JW(\(Z]
MK=W\7OV=IM8U))#JJ^&["TUS1VLK:"V,-YXH^)'[/?BCPMXJ\4R)<B#2)OA!
MJ&E#?=12BOS(_1S])/\ @O\ >.O&7Q(^$7[.G_!,[X-WCV_QG_X*3?'/PW\,
M)+R&TOKP>#_@9\.]7T+QM\8?B!?#394N4TOPZR^$FU^S<!=5\"/X[$)D;3IH
MF_3WXD?!;X;_  9_8'^(WP"\">&K*Q^%GPU_91\<?#;PSX9O8HM2MQX5\-?"
MK5M$L;75#=QN-7NKFTM5EU:^ODEN-6OIKJ^OFFN;F:1_RY_89T=?VYO^"K_[
M:?\ P49U:%-4^$7[*\<W_!/7]D&XNK:RN+2\UCP;.^K?M%?$S0KA'F607'BC
M6M4T'PEXNTN5HM?\$^/M:T.ZD$FB/ G[-?M._P#)M?[0O_9#OBS_ .H%K] '
M\X7_  :$6EJG_!.+XZ7R6UNE[<_MM?$"TN+Q88UNI[6R^!/[.<UG;37 432V
M]I-?WTMM"[M'!)>W;Q*C7,Q?P#_@\9T+2)O@1^Q7XEEL87UW3?BW\4-"LM3.
M\7$&D:UX.T'4-4L1A@CPW=YH&D7#>8CO&]DODM&)9Q+]#_\ !H5_RC8^-W_9
M\7Q*_P#5"_LT5Y%_P=\:<-8^ O[$.DM*8%U3]H7Q9IQG""0PB]\&V=L91&60
M2&,2[PA= Q7;N7.0 ?T"_M ?\$MO^"?_ .TCX(\>>#_B!^R9^S_::GX[\+ZK
MX:?XE^%O@Y\,_#_Q8\*RZAI:Z99^(_!OQ M?"AU[0_$>A"&QN='O$N)K=)-.
ML[:^L[[3%EL)?9?VM_V;/#/[4O[)OQV_9=U:WTJ'1_BU\'_%GPZTBYU>R_M2
MQ\-:[>Z#/;^!_%2VLQ=Y;WP1XI@T+Q5I4VXW%OJ>B6=U%(+B)''YF?'G]A+_
M (*WZSX \=VOPU_X++_$37)[OPKJ$&G^!-0_9"_99\":]XHN&M)!=Z!IOQE^
M'>F> ?$GP[U'78O,T_1_&/A\:;JOA6^N(-5@U*.2V%S%^YE '\J/_!IK\:M6
MUG]CG]H+]E7QG)JEKX[_ &6/VA=3\WPSJL+6T_A'P=\5=.:[LM!>"3]Y#=0_
M$_P3\8;O4(6 ,-U>%&4,26] _P"#E/Q3\8/C+\#_  /_ ,$^?V<=.N/$/Q$^
M+7ACXL?M3_&33=/:XNCIW[.?[(WA.Y^(4VFZQ8Z;8:GJ<-W\2/BE%X.T7X;N
MEM':Z_X_\+V?A6:[M%U9[JW^=OV<;*X_8!_X.@/VA_@D8]2TSX5_\%'_ (7Z
M_P#%OP5:27D2:7?>-=9L]1^,&H>);R&-XH%^P_$3P!^T-X*\.P/$;F%?$MO;
M1*WVSS)?U?\ ^"=MO:?M1_M6_MU_\%'-12+6?"GBKQJ/V(OV4=5F%EJ-@_[-
M_P"S-JM[8_$3Q9X-UJR9K?5/!OQK_:(N_&GB$>9YIQX+TM%81IF4 [__ ((I
M?MF2?MR_\$X_V?OBWKNM?VW\3?"NAO\ !KXS7,]TUYJDOQ-^%T5KH5_K6NSL
MJ@ZSX\\-GPQ\2[R.,".)?&L4:+&%\I/B;]HWPA:?MV?\%]?V7?@Y>I9ZW\(/
M^"7OP*O_ -J3XC6TEM<RVR?M!?%O7-%'PN\(:A/"%@@UK3+/0_A/\7?#XO6E
MAN-+T#Q+:1Q1FXF:?X]_X(Z7 _X)O_\ !7S_ (*'?\$KO$-Y'H7PG^)EU/\
MM&_LQVVH7UY%I,.G:=9Q^*['0/#HNDC@U#5+SX+>*X;3Q?J^1 EW\ -1M1.K
MVC1-^GG_  1/T5OBKX+_ &MO^"BNLP7$NO?\%#OVJ?B+\0_ ^HZI;W%IX@MO
MV8_@]K.J_!_]G/PIKEI<%C!/H&BZ%XIO[%X6,%SI'B'3IH?W)B) /VXHHHH
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M^-FL16>G?$6Y\<:*D]TOA?7/#NHZ3#X.MO"B75^FAZ'X>TF$ZWXJGEN/%_B
M ]U\ ?\ !*G_ ()J_#3P[X=\-^&?V$/V398?#&EP:3I^M^)?@'\,?&?C*Z@A
MA,+7.N>./%OAG6?%WB'4KE&?[9J>M:S?7UT7833LFU1_._\ \&]_P/\ @KXJ
M_;6_X+L^$_%'P@^%WB3PKX._:D\)^'?"/AG7_A_X3UCP_P"%?#__  MG]LG3
M?["\-Z-J.DW.G:'H_P#9VEZ9I_\ 9FF6UK9?8M.L;7R/(M+>./\ L=K^3/\
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MQ_V7'QY_Z@4- '[K_M=_\$A?V#_VJ_@)XP^$%S^S)\"OA_X@N/!_B+2OA?\
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M2.&.2::1(HHD>2661U2..-%+/)([$*B(H+.[$*J@DD $U_!1!^W/^SY\'/\
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M]"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:K^'P[Q!63NNSI*RVDVD]-'^P]%%%?&GUH4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7QC\&_@
M_-X,_;,_;5^+)OH)[;XT>&OV60EDL\LES87/PY\)?$7PW<>; UC!#;P74%W9
M2V_EWM^\LBW+2BT BC<HKU<OJU*>$SV$).,:^54:59*WOTUGF35U%W3:2JT:
M4]+.\$KV;3\S'TJ=3%9+.<5*5#,ZM6DW?W*CR?-J+DK-7;I5JD-;JTV[72:^
MSJ***\H],**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
@* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>logo_standardbiov2.jpg
<TEXT>
begin 644 logo_standardbiov2.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
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MMKUI8GG:G1E[W*X-:>S?N*$K*-K,_IYHK\A/V!_V\/C!XJ^+_C7]@?\ ;O\
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ME-PJPG3G'>%2,H3776,DFM.Z/134E>+37=--?>@HHHJ!A1110 4444 %%%%
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MTXNK>ZT']GOX2:1<P7001BYBN-/\(V\T=QY8">>KB4H I?'%?#7_  6J^/\
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M71E4PV(A_>HU9I=6?,4L11KI^RFI-?%'6,X>4Z<DIQ?^**-FBBBO.-@HHHH
M**** "BBB@ HHHH ***^2?VQ_P!M_P#9R_81^%ES\5OVB/'-OX<L)H[^+PCX
M0TT0:G\0/B/K-A% \GA[P#X6-S;7&M:@)+RPBOK^>:P\.>'EU"TO_%.N:%I4
MAOTVP^&Q&+KTL-A:-3$8BM-0I4:,)5*E2;VC&$4VW:[>FB3;LDV3.<:<93G*
M,(15Y2DTHI=VWHCZCUO6]&\-:/JGB'Q'J^F:!H&AV%WJNM:YK=_::5H^D:78
M0/<WVI:IJ=]+!9:?865M%)<7=Y=SPV]M!&\LTB1HS#\ /BY_P5P^-7[57Q*U
M;]F7_@CE\*+7XZ^+]'U!M(^)?[7'Q TK4+#]FOX2VUU%-;+J.CZC<-9Q^)M1
MAGCU*]TK4]5CETW6_P#A'9W\"^"OB_INH"2U\1U;X,?M._\ !5NSD_:-_P""
MD_BG4_V$_P#@FIX/>W\4^"_V5X_%J^"_%_Q+T:TN[:ZT[QO^T%XLU6/3?[&T
MS4KW^S[?2X]6L;#6/LJM%X"\,>"KS5;7XD>+/D7]IG_@LCX.^#?@>U_96_X)
M6> /#_P)^"/A.TNM%3XHVOA>*Q\0:VS,MK=:EX&T+6HKBXTV35H87N]3^(?C
MZ#5OB5XDO;XZM<0^&=>LCJNH]N<9MPQP+1]KG%6AG6>.+]EE5":K9=A:BWCB
M)TIQ>95Z3LJE*E4HY?1GS0K8K$27L3[SPY\*^.O%S,W@.%,OE0RVC.,<QS[&
M^TPV78&$DG'V^)]E4]G.I%\U+#4*6)S"M!^TI86-*-2K#Z1^(?[%/['W[,>N
MZ9^TO_P6L_:[\1?MP_M,W-D=9\,?![4;J_N? NFN\RZJ-#^'WP4TB:SN=2\*
M1Z[9:G8VMWXEB^'WP1OQ>&TUKP'I%TY8_(/[3G_!>CXQ>+/#P^$_[''@#P_^
MRE\(])L3X>T*_P!(L=&N_B#'X;M8Y[&PLM"M[&PM_!?PQL6TQX532O"VE:KJ
M^@W4$3Z#XV@6(,WX1^)_%/B;QMX@U?Q9XR\1:[XM\4Z_>RZEKOB7Q-JU_KNO
MZUJ,Y!GO]6UC5+BZU#4;R8@&6YN[B::0@;G.!6%7X7Q3XH<3<33]G+%2P.!I
MIPP^%PO+2C1I/3DHQHPI4<+&WV<'2H76DY57[S_T8\,?HF^'/ L,/CL]P\>-
M.((\E2IB<UHI911K*S_V?*)3JT\2HO3VF:U<?S2BJM*EA6_9QZ?QCXW\9_$3
MQ#?^+OB!XN\3^.?%>JNLFJ>)O&&O:KXF\0:E(BA$>_UG6KN]U&[9$ 1&N+F0
MJH"K@ "N8HHK\YE*4I.4I.4I-N4I-N4FW=MMW;;>K;U;/ZBI4J5"G3HT*=.C
M1I0C3I4J4(TZ=.G!*,(4Z<$HPA&*48QBE&*2222"BBBD:&UX;\2>(/!WB#1/
M%GA/6]5\->)_#6JV&N>'O$.AW]SI>LZ)K.EW,=YINJ:7J5G)#=V-_8W<,5S:
MW5M+'-!-&DD;JR@U_9S_ ,$QO^"V?@?]H.S\+_ _]JK6-)\ ?'U_*T70OB#=
M)9:)\/\ XOWFY8]/2:2);;3/!/C_ %)2MO+HLJ6GACQ'JR >%KC3M0UG3/!5
MK_%96CH^D:IX@U;2]!T/3[S5M:UO4;+2-'TK3X)+J_U/5-2N8K+3]/L;6%7E
MN;R]NYH;:V@B5I)II$C12S 'V\CS['Y'B?:X27M*51Q5?"3<G2Q"3LM%K"JK
MM4ZL5S1;::E!RA+\M\5/";A/Q5R3ZAQ#2^JXW PK5,IX@PRIQQ^4591O-J<[
M1Q& J.,98S 5Y*A7C"-2,J&)IT,31_U%/B%J?P_\(>$_%7Q'^(D>@V?ACP'X
M5USQ5XG\1:U86MS#HGA;POIM[KNM:A<33032I9:;I]M?7TJID*JRNJEF.?\
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M?*%/@7C*>-=)47A8\,YU*JHQG*5W06 =12YDTVU:T6K)IL_B-UBR@_X)"_\
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M35+"X+"P<:<%O.I.4G*K7KU9-U*^)KSJ8C$592JUJE2I*4F4445SGLA1110
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MY]F'_$Q_@G_T7N7_ /AOSS_YU^?Y]F?S2T5_2U_Q#3_'#_HY?X4_^$EXO_\
MCM'_ !#3_'#_ *.7^%/_ (27B_\ ^.T?ZH<2?]"NM_X-PW_R[S_/LP_XF/\
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MO9"1/MSW(CA_*?\ X*4?L@?&OQE_P3$\->)O$OC'3?&/[;/[!EEI'[07PO\
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MC;Z1X;\)^$OVA/A)XC\2^(-6NW\NTTO1-"T?Q=>:IJNHW4A"6]E86MQ<S/\
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MOX76+3?&^D"S2[O9M/T^\U!4\2>&;:^G-]+X.U_PY?W*J]Z!7^?3_P $H/\
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MC3X'X9PV1Y-G&=<0XO+EFV'H5(16#=:FJU6DJLJ<72IU9*,4W[]11C;5O1G
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MJ0-?T"U^"7@2RA^&/_!Q?\;K"WNS9V7[2/\ P3P\*?$74]/,DEG#J_B_P/\
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M^$WCN]^&WAKP]X1T;5-,GUFW\8>$?%8^'GA.W8CQ=IVJ:-?Z1JFOV+:)8_\
M"+:KI]SJ5I=ZWIUK>_=<"5L_P/#^;XS"8#+\_P C>)E#'9'4E6>83K>SP\*M
M3#TEA,11J4ZF'JTI5H55552GAVH1C.$HU/-S..&JXJA3G4JX7$\EZ>)2C[+E
MO)Q4I.I"2:FI*+C:TI:MIJWR]\%_^#FCXP7<&B>$?VV/V9?@K^TMX'L;C3))
MM8T/2(?!_C.WOX%DL[OQ;<Z-K\7C+X>:YK<6G7=^MKINC>'OAY;RO=3VJZOI
MUI<R;?[ OV&OV@/V4_VHO@=I_P ;/V1K+PQIO@+Q)J=SIOB'1]%\):-X)\0>
M&_&6CP6QU+PMX]\.Z/$B:=XITFTOK&XV237UK>Z/J6EZUH>HZGX?U?2]2O/Y
M'_\ @OUK7_!([Q7\,O GB3]CK4OV?+_]J*Z^)NE'Q+>?LWQ62:#JOPONO#GC
M._\ $U[XU_X0)(/AC=Z[)XKNO"$D>KZ@EQ\099!)8I.^D0ZLEK]?_P#!IOI/
MBZ'X8_MHZ[>PWJ^ ]1\>?!K2?#=Q)]H_LV7Q=HOA_P ?7GC:&T+2FU^VP:-K
MWP_?4/)@CN/(N=,^TRS1FU2#IXGR3),9P?/B;+LKQO#N(I8BE"IEM=U*5'$>
MTQ-+#R<,-.7LU%>T5:C6H4Z*E&G44Z3=I0C!XC$4\>L'5K4\7%QDU6C9RA:F
MYJ\TK].649.6LDT^_P"_O_!3_P#Y1S?MQ_\ 9K'QO_\ 5?Z[7\3/_!M9_P I
M/?"W_9&OB[_Z:=/K^V;_ (*?_P#*.;]N/_LUCXW_ /JO]=K^)G_@VL_Y2>^%
MO^R-?%W_ --.GUCP9_R;[CC_ *]U_P#U 168_P#(SRW_ !0_].H_T4:_@4_X
M.>/VI3\5OVR/!/[-VB7XG\+_ +,/@9&UN&-5"M\4OBU;:/XI\0!IXG9+V#3_
M  /9?#FTMUE'F:7JLOB2U41O-<J_]U/Q;^)OA?X*_"OXD_&'QO<2VG@[X5^!
M/%OQ$\4W%O&)KF/P_P"#=!O_ !#JWV2 LIN+QK'3YDM+96#W-RT4$>7D4'_*
MNT_PM^T;_P %'/VLO&LWP\\%WOQ*^//Q]\;?$;XGW/AC2-0TW3H/M%[)K7CC
MQ!%;:GXGU33-(TG1-"TY+FUTN+4=5M((K6UT[1K#S+J6QLY<?";+*4\SQ^?8
MN5.EA,GPLHQKUI1ITJ>(Q,9J=5U9M0A&AA(5_:R;2@J\)2DEO6>5I*C2PT$Y
M3Q$TW&*;DXP::BDM6Y5'&VCNXM(_9[]N?_@F:/@[_P $2OV$?VA-,T2&/XA^
M#]0N/'GQON[#3DM[FZ\+?M:'3/$'A6_\3W4Q2[6[^'<VE_"WX;06.QXEU#Q'
MJDR^5\WF?K5_P:Z?M4O\1/V7_BC^RGXAU(2Z]^SOXR'BOP/;3S6<3M\+_BS=
M:EJ]UIVG6B!;V\3P[\2;'Q?JFLZC+YR6W_"?:!8%H4^S(_Y,_$[]E/\ X.4/
MC-\-]>^$'Q2\,_&7QO\ #'Q/86.EZ]X(USXF_L[S^']1L-,O;+4M-MI+*/QI
M$L2:=J&FZ?>Z>UN87LKJRM9[9HI((V7X?_X(F_M-WO[(/_!23X-WGB.:ZT3P
MK\3]8N_V=/BA9W:)9O:6'Q%U&QTG19=5^VF)=-MO#'Q-T_P7K^MSS!);32]%
MU.$[#(XK[+'9;4SS@W/L#5S;*<ZS#"XW%YWA)95C(XQ8=5*M3&QP\K*,H3J*
M>/PU"Z4/9U(QA90:7GTJRPV/PU6-"OAZ4Z=/#U%6INGSVC&FYKHTK4YRU;YD
MV]6?VP_\%V_^43W[7W_8N_#7_P!7=\,Z_C#_ ."4W[%UM^W7\)/^"A7P@T[3
M([_XF:!\#O!7Q/\ @E+F)+F'XK>"?%.K7.B:7;37%S:V=N/&VE76N?#R[NKZ
M1K2PL?%MSJ907%C;2Q?V>?\ !=O_ )1/?M??]B[\-?\ U=WPSK^>?_@U"_Y.
M#_:Q_P"R-^"?_4VFKYKA'&XC+O#;B+'X6?)B,'G=+$49:VYZ3R2:4DFN:$K<
MLX-VG!RB]&T=F/IQJYMA*4U>%2@XR7E)UT[=FMT^CLSQ_P#X-K_VX)O@#^U+
MX@_9%^(6JRZ;\._VF)8X?"UOJL[VMKX8^/?AJVFCT2$17MW;VVFR_$/0XKWP
M7?QQ6D^K:UXKTWX;Z2@2.!P/SO\ ^"4'_*6K]E;_ +.&N?\ T5XAKZG_ ."]
MW[)6O_L2_P#!0=?CK\+YM2\+>#_VA=7E_:!^''B'1I)]/N/"/Q?T?7K/4/B5
MIND:E'-YT6JZ/XVN=*^(MA-9I:0:19>.]$TRQ4MI3R5\?_\ !'Z\N-0_X*D_
ML<W]TXDNK[XVVEY<R!50/<7.FZW-,X1 J(&D=F"HJJN<*  !7Z#"C@<;E'$/
M%6 :C3XCX9C*O16\,5@L'F%.JY-))SBJL<-52T]IAI2N^=L\INK3Q&$P=75X
M3%M1EWA5J47&RZ)\KFO*:70_M_\ ^#@/_E$7^UK_ -T&_P#6FO@Q7\XW_!JI
M_P GM?'W_LUC6O\ U;7PHK^CG_@X#_Y1%_M:_P#=!O\ UIKX,5_+3_P;<?'[
MX(?L\?M=?&KQ7\=_BU\/?@_X9UG]G#5O#VDZ_P#$?Q9HOA#2-2UV7XF_#74H
M]'LK_6[NSMKG49-/TZ_O4LXI&G:VL[F8(8X9&7\]X6I5*WA;Q32HTYU:L\RQ
M*A3IPE4J3?U7)W:,(IRD[)NR3=D>KC6HYS@G)J*5*%VVDE[]?=O1']__ (Y\
M%^&?B1X*\7_#SQII5MKO@[QYX7U_P;XKT2]19+36/#?B?2KO1-<TNZC8%7M[
M_3+VZM9E((:.5@0:_P M[_@EYXDU[P+_ ,%*?V*+_P +WT[7TO[47PG\'37N
MD.X%UX=\;>--.\">*]C/;2.VFW_A3Q!K$5Z'AC9],GN%:2T+&>'^O[_@I/\
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MKXTM-2U>&9!#>V_BGXNZAX-T;6[=8MLMIXBO&\LQJRU_03_P=+_M5_\ "&?
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MP9\1?"'AOQUX1U>)2L>J>&?%NC66OZ#J**<E%O=+U"UN A^91)M/(-?YD?\
MP4:_9^_X*>^$=4\&_'#_ (*+^$OB VI^)+=/AIX4^(7C'7_ /BC[5'H/]J>(
M[3PM<:CX UK6+>QN(DU76=1TR#6A:W6H6Z:G_9SW=OI-TEE_7A_P;7?M5?\
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M.+C<5,T.-Q_4C_AXO_P3X_Z/L_8V_P#$GO@E_P#-Q1_P\7_X)\?]'V?L;?\
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M0NG_  6U74X8-9M)8;+5?!_@'2],\%65V+;^RK#Q%IC>(=,^T7%REW=^A?\
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MOK&^TCQ#)J\]QJ2^)_$OAJ!+62!Q'$UK/<S&8$/$B?/6$L@S:KPIQC"CE53
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M/?#S2K*W:[\5?%C6XHM ALQ/8^%9-8U"UU^_\)?J-\(/^"67_!/C_@D1\/\
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M16[ZRD^LIR=Y3D^LI-M]6%%%%<1H%%%% !1110 4444 %%%% !1110 4444
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M;?;K692S/J7D_P!L%<IXN\!^!_B!IK:-X\\&^%/&VCN&#Z5XN\.Z1XDTU@X
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@5M&,5&*]$DD@HHHK$H**** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>logo_standardbiov2x1.jpg
<TEXT>
begin 644 logo_standardbiov2x1.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
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M\\,>((W\'^!/".O:S:^.?$NG=7X^_P""'?[2/[!&CGX\_P#!*+]KKXT'QYX
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M&L*UO7X%?M"_M]?M?_M22WT?QH^._CGQ#H%^OE3>!]*U!?"/P]^SI,9X(9/
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M*M2KQYZ-2-2/>+O9]I+>+\I)/R"BBBN U"BBB@ HHHH **** "BBB@ HHHH
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M0;ZX\)V@\S-EX*\6V=EXU\$V#O-^\EEL?"?B/1K2:X/RW$L+SH DBBOZ"_\
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M:99+/L@A0HYE2HRQ.997AGRX?&8>*O5S'*Z+]^E.C)2^OY?K*C\=-+EE&?\
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M_P ':UJ,$$FIS_"CXI06EO;+KEK:W5O=Z6-'\2OH\_C+P)<>&],_BGK] /\
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MR_Z+*E_XC7"O_P Y3^3+_B&8\3?]'B:%_P"&/U#_ .>I1_Q#,>)O^CQ-"_\
M#'ZA_P#/4K^LVBC_ %(X9_Z%\O\ PLQW_P T!_Q-+XY?]%E2_P#$:X5_^<I_
M)E_Q#,>)O^CQ-"_\,?J'_P ]2C_B&8\3?]'B:%_X8_4/_GJ5_6;11_J1PS_T
M+Y?^%F._^: _XFE\<O\ HLJ7_B-<*_\ SE/Y,O\ B&8\3?\ 1XFA?^&/U#_Y
MZE'_ !#,>)O^CQ-"_P##'ZA_\]2OZS:*/]2.&?\ H7R_\+,=_P#- ?\ $TOC
ME_T65+_Q&N%?_G*?R9?\0S'B;_H\30O_  Q^H?\ SU*/^(9CQ-_T>)H7_AC]
M0_\ GJ5_6;11_J1PS_T+Y?\ A9CO_F@/^)I?'+_HLJ7_ (C7"O\ \Y3^3+_B
M&8\3?]'B:%_X8_4/_GJ4?\0S'B;_ */$T+_PQ^H?_/4K^LVBC_4CAG_H7R_\
M+,=_\T!_Q-+XY?\ 194O_$:X5_\ G*?R9?\ $,QXF_Z/$T+_ ,,?J'_SU*/^
M(9CQ-_T>)H7_ (8_4/\ YZE?UFT4?ZD<,_\ 0OE_X68[_P": _XFE\<O^BRI
M?^(UPK_\Y3^3+_B&8\3?]'B:%_X8_4/_ )ZE'_$,QXF_Z/$T+_PQ^H?_ #U*
M_K-HH_U(X9_Z%\O_  LQW_S0'_$TOCE_T65+_P 1KA7_ .<I\#?LS_L6ZE\-
M?V,+[]BW]HGX@:;^T7X%N/#WB[X=1:C)X:U#PG/)\)O%%B]K!X,OHKKQ-XFN
MWN?#GV[5;/P[K5CJ5@VCZ(OAW3=,L[*3P[;WEQ^2?_! 'QWXV^ 7CW]M#_@E
M/\8-:FO?%W[*/Q*UGQG\*?MJ7L,FL_#'7]>.F>*-3T&QG#1:7X/NM8O_  1\
M2-&MWD%U=S?&B\NV1LR^7_3+7\PG_!2".V_8L_X+5?\ !./]L_PRMOI6C_M2
M75S^S;\<81,]CI>JPQ7WAGX<'Q=XGN(RK7,NE>%OB=X-U2TAD<VV?@[H;& F
MWF-Q^I\)T:=;+LTX5@I.EB<N>*RN$YSJRI9CDM*>)H*$ZLI23Q&!ABL).<I.
M4HRIQD_=BX_S_P 1YKC<XSC$<29C.E/,,?F%?%9G5H87#8*E6J9C6YL356%P
M=*AAJ7-B9JNX4:-.FIN<E!<SO_0-X6^"G_"-?M&_&?X__P#"2_;?^%N_"OX"
M?#/_ (1+^QOLW_"/?\*0\0?'?7?[;_M[^U9_[6_X2?\ X79]E_LW^QM,_L7_
M (1GS_M^K?VSY.D_*GPT_P""<G@SP%X^_9 ^(=_X^U;7]5_96^"6E_"O4-+M
M]&;1?#OQ;\3>"/#OB+PI\(/B/XCT9_$&L6NF7OPHT3XJ?M KX:T@C6KC^TOB
MXNIKX@M)O"%@FI?I!17C0S/'4U54,1**KT*6&JI0IKVE"CA)X&G3E[FT<-.4
M$U:3ERU6W6A"I'G=&E+EO!/EDYQNWI*5156UKUG%/TO'X6T_&_V=/A)_PH']
MGSX$_ C_ (2#_A+/^%*?!KX8?"3_ (2K^RO[!_X2;_A6_@G0_!W_  D']A_V
MEK/]C?VS_8W]H_V5_;&J_P!G?:?L?]I7WD_:I2O9**Y:M6=:K4K59<U2K4G5
MJ2LH\TZDG*<K12BKR;=HI);)):&D8J,8QBK1BE%+5V25DKN[=DNNI_+A_P $
MF'?]I7_@LM_P5H_:_N;N#4M.\ :J/V?O"-[&J3VFH:#<>,CX2\,ZOIMQA%!C
M\%?LX:2I:*-I1:>(-DLP%P_VC^H^OY?_ /@V$L9-:^#G[;'Q9O+K3M1U3X@?
MM47%CJ&IVUI:17>H2:)X6M?$INI;JRBBMY=.GN/B#=7&FVENJVEG)-J$EM%%
M'>$-_4!7U/&[4>(L3A(Z4<NPN6Y=0BM%"GA,OPU-Q6B=O:^TEM]JVR.'+=<)
M"H[\U:=:M)O=NI5FTWY\M@K\F/\ @JW_ ,%7/AO_ ,$S/AQX;GE\/6WQ0^.7
MQ*;4(_AS\*UUT:+'#I6GQ/'J'C[QE?P66I76F>$-*U"2TL+6UBM8]2\7:K)/
MI.BW%K!IOB'6_#_ZSU_G6_\ !REXH\3:_P#\%/?%6DZ]87MGI?@CX-_"+POX
M+N+J&6*#5/#-WI&H>-+J_P!->2V@2YLH_&/B_P 6:9)-!+>1+J.G:A;M<I/!
M-9VG1P#D&$XBXAI8/'IRP=##5L;7HQFZ;KQHRI4X4>>+4U&52M!U.1J;IQFH
MRBWS169XFIA<+*I2TJ2G&G&32?*Y)MRL[IM*+2OI=IM/9_,_QD_X+>?\%._C
M1KNLZM?_ +4WC3X=Z9J=_<W5AX3^#<6G?##0O#=E-?&^M=%T:]\-6MOXNN;#
M3ALLK:\\2>*/$'B"ZL8Q!J^MZFTEQ)-Z3\"_^#@'_@IS\&/$.FZAK'QPMOC;
MX7M9=VH^!OC'X2\-Z]I^K1,WSA_%.BZ=X?\ B'83Q(TGV5[#Q?#:)*R/>6%_
M%$D%?L=_P;-?&S]A'P=\+_'G@/QCJ/PJ^'_[8VN?$75+>+7?B'>Z#I7BSXB_
M#;6-+\,1^&_#?P\\2>(+>P\VSMM9L]6AU;X<Z%J=[J=UJ%NGBB\M+JVOK6/2
MOM[_ (+1?\$7-)_:\\%>!/'/[''P?^$O@K]HW2OB&_\ PG6I6">'?A=I7COX
M>:WX?U=M7O\ Q9<:7I$4'B7Q=H_B;3/"2Z'J6HAM1BTG4?$-O)=3Q&UB@_5,
M;GG"6"SV?"^:\)8'+\!&3HTLRQ&&P=*A).FFL0HO#PE3H3:C&&*IXF=2[C*<
M824E'Q*>&QU3#+&T,=4JU;<SHPG4E+?6#?.[R6MX."5E973/TR_X)Q_\%$O@
M_P#\%(/@6/BS\.+:7PGXM\.:A'X>^*WPGU75(-4\0_#CQ+-'+<6$4U]%::<N
MN>&?$5E#)J'A3Q7;:=9V>LP0:C836NG>(-"\0Z+I/\4__!0/_@JG_P %#_AA
M^W)^UQ\.? '[67Q6\+>!_ _[1'Q:\+>$O#>EW^EIIV@^'M$\::QI^DZ38I+I
M<LB6EC900V\"O([+'&H+,1FOV_\ ^"&'_!+[]O#_ ()Z_M'?$[Q)\<])\#6?
MP=^*'PDG\-:K;^$_B'IOB&Y7QWH7BC0M9\%ZO=Z5#;6\LT%CI$GCC24FB+O;
MR>(@Y40F4C^D?5/@1\#];U&^UC6O@U\*=7U?5+N>_P!3U75/AYX1U#4=1OKJ
M1IKF\OKZ[T>6YN[NXE=Y9[BXEDFFD9GD=F8D_!0S+AKA#B3-'A,%A.)<HQ6'
MHO Q=;#XB&%<Y1J5*?M:U#$J4J4U.E%M>U=+V;J3E)R;]-TL9C\)1YZE3!UX
M3E[3W9P<[:*7+&4+)JTOY>:]DE:W^9U_P^._X*>_]'H_&3_P9:1_\IZ/^'QW
M_!3W_H]'XR?^#+2/_E/7[2?\'4?P]\ ^ ?%7[%$?@7P/X/\ !4>J>'_CV^IQ
M^$O#.B^'$U%[34?A&MH]\NCV5FMVULMQ<"W:X$AA$\PC*B5]W0?\&JGPZ^'W
MC_\ X;P_X3OP)X-\:_V3_P ,O_V5_P );X8T3Q)_9GV__AHC[=_9_P#;-C>_
M8OMOV*S^U_9O+^T?9+;SM_D1;/U&6:</1X-_UO\ ]5LL]G:+^H_5L#S^]F:R
MW_>/J?+I)^V_A;>YO[QXRH8IX_ZA]<J\U[>TYZEM*/MOAY[[+EWW2?D?&'_!
M+S_@J'_P4"^,7_!0+]E;X8?$_P#:I^*/C3P!XT^*-AHWBGPMK-_IDFEZWI<F
MF:I-)97L<.F0RM"TL,3D)*ARB_-7^A+7EVC? [X*^'=4LM;\/_!_X7:%K6FS
M"YT[5]&^'_A/3-4L+A0RK/9:A9:3!=VLP5F42P31N S -@FO'OVZ_P!I;3OV
M/OV0_C]^T;?26HO/AI\/=5OO"MM>Q/-::G\0=::#PU\-]&NHH_WC6FL>/-:\
M.Z;>N@/D6=U/<N/+A<C\1XBS;"\59KEZR?):652G"C@(82A[&V(Q-;$R5.;]
MA0H1YI.K"GK"4K17O6LE]%A*$\%0J^WQ#K)-U7.7-[L(P5U[TI.RY6][>2/X
MQ_\ @KS_ ,%DOVNM._;W^-GP[_9@_:$\:_"WX2?!;4[?X.V6D^#WL["WUKQ=
MX($]M\1]>U5+RUOS<ZDGQ N?$GARTO;>2*WNO#GAW0)%@24RO)]Z_P#!N[_P
M5%^/O[1'QX^,/[./[4_Q@\2?%36?$W@.R^(?PAUCQE=Z6;K3=0\#W[V/C?PG
MIK6UI9W5]<^(-#\1Z?XFAMB)HK&R\"ZY<KY1N)?,_DE^ 7P8^(_[7/[1'PZ^
M"O@Z:75OB-\;?B!9Z&FKZJ]S>+#=ZW>2WWB+Q;K\\8FO)=/T/3EU7Q1XANU6
M6X73M/O[D+)(N#V7[('Q\\4?L6_M??!;X[QVFK:?JWP5^*6GW?B_0HXH[;6;
MOPPEU<>&?B?X.:*^C*V=[K_@S4/$_A68S1K+9R:B[@QS1*R_O68\'9-6X<Q/
M#^$PF _M/#Y10='$1P]"&-E7IJ7U;$5*R@JR6+Q6$J0JSY_>BZL'>-XOYFEC
M\1'%PQ52=3V,Z\N:+E)TU%VYX*-VO<A-<JMI:+6JN?ZSM?._[7GBGQ#X&_9.
M_:@\;>$=6N]!\5^#OV=_C7XI\,:Y8,J7VB^(?#_PV\2ZMHNK6;NKHMWIVI6E
MM>6[.CJLT*%E8 @^YZ#KNC>*-#T;Q-X=U*SUKP_XBTG3M=T+6-.G2YT_5M&U
M>SAU#3-2L;F,F.XL[^RN(+JVG0E)8)4D4E6!KYM_;H_Y,E_;%_[-8_:#_P#5
M2^+J_F+ P3Q^#A.-T\9AX3A..C7MH*491:]5*+7=-'V-5_NJC3_Y=S::?]UM
M--?@S_.,_P"'QW_!3W_H]'XR?^#+2/\ Y3U_8/\ \&^?_!2+Q=^VG\!O'/PG
M^.WC6X\8?M$_ S7GU&]\1:U+:KKWC_X6^-+Z[OO#WB*Y$;0?VAJ/A/7O[6\'
M:U)8:=!9Z9HJ^ &O9IM2UR227^ 7X6_#S7/BY\3OAS\*/#$MA#XE^)WCOPA\
M//#TVJ326VF1:YXT\0:?X;TF74;B&&XEM["._P!2MWNYHK>>2*W$DB0RLH1O
MN'_@G#^U3XI_X)Q?MZ?#_P")GC&PU[P]I/A/Q7K/PE_:$\(7$%_::K%X$UC4
M/^$:^(6E:MHL7E7=YK'@;4[2V\8Z?X?N @G\7^"]'MKGR]C%?Z>XNX2RK-<E
MQV"R_ 8##9K0HK'8/ZKA</0KSG1<^6DW2A"4J>)2J8>S;A&I.$Y*\(GQV!QU
M:AB*52K5J3H2E[.ISSE**3M>5FVDX>[+:]DTMS^\K_@MQ\;/BM^SS_P3@^-O
MQ7^"GCG6_AS\1O#VN?"2VT7Q=X=E@AU;3H-<^+/@S1-6CMI+B"XB5;_2;^\L
M9]T3$P7$@4J2&'\U/_!$?_@I%^W/^T-_P4?^"7PH^-?[3'Q)^(WPY\0Z'\6[
MG6O"/B*]TZ;2=1GT/X3>,];TF2YCM].MY6:PU:PL[Z#;*H$]O&6# %3^^_\
MP<&:EIVL_P#!(WX[:QI%_9ZII.JZK\!=2TO4].N8;S3]1TZ^^,WP]NK*_L;R
MW>2WN[.[MI8KBVN8))(9X9$EB=D=6/\ )9_P;P_\I8?V>?\ L7?CA_ZI'Q_7
MY]PCE^!K>'/%.*KX'"5<70EG2I8BMAJ,\11=/*<+."IU9P=2FZ<VY1Y9+DFW
M)6;;/3Q]6I'-L%"%2:A)X:\8SDH24L1).\4[-25D[K5:/0_T#/VO/%/B'P-^
MR=^U!XV\(ZM=Z#XK\'?L[_&OQ3X8URP94OM%\0^'_AMXEU;1=6LW=71;O3M2
MM+:\MV='59H4+*P!!_S;?^'QW_!3W_H]'XR?^#+2/_E/7^CG^W1_R9+^V+_V
M:Q^T'_ZJ7Q=7^3_X1 ;Q9X8! (/B'1001D$'4K8$$'@@C@@]:ZO"3+\OQF7Y
MU/&X#!XR5+%890>*PU"O*$71J-Q@ZM.;BFTFTK)O5HG/*M6%;#JG4J4U*$K\
MDY1N^=6;46KV/T=TK_@M#_P5&T:_@U*S_;,^*DUQ;>;Y<>JQ>$M=L&\Z&2!_
MM&E:YX:U'2[K"2LT7VJSF\B81W,'EW$,,J?J#^R-_P '/O[5'PZUK3M%_:[\
M&^%OVB/ LTGE:GXM\+:/HWPQ^+>F>==6^[4K>+P]:6/PU\16UA9"Z$7AP^$O
M"=UJ-S);M)XQL(X9$G_MR\?_  '^!_Q6\.S>$/BA\'/A9\1O"EQ/%=3>&_'/
MP_\ "GBO0I+N!94M[MM*UW2;ZQ^UVZS3"WNA +B#S9##(A=B?XI?^"^/_!&_
MX<_LIZ%;_MB?LKZ'<^&OA%KOBZTT#XN?"FU>XO- ^&.M>(U6+P_XM\%/,)KG
M2? WB'7(I='U7P_?7LUIX9\3ZWX?L?"BP>&]5MM"\,:91Q%P/Q=BJ>39CPM@
M\KQ&+;I86M2AATI57\%&.,PM#!XFA5J._LH\KI5)I0E+FE",E7PF8X&#Q%+&
M5*T8:SBW/2.GO.G.52$HK[3O=+6UKM?VD?L]_M"_"']J;X2>$OCA\#/&-CXX
M^'/C2TDN-)UBT2>UN+>YM9GM=3T;6=+O(X-0T77M'O8I;'5=(U&W@N[.YB(9
M&B>*63VFOX+/^#8K]K_Q#\-OVKO$O[(NMZS<S?#G]HGPSKWB+PMH<\MS-:Z1
M\8?AWHDWB+^U-,C:8V6F+XD^'.D>*;#Q')';I<:W=>'?!,,MR1H]M!+_ 'IU
M^7\7\.RX8SNOEJG*KAY0AB<%6FDIU,+6<E#VG*E%U*=2%2C.45&,Y4W-1@I*
M*]G 8I8S#1K649IN%2*V4XVO;K9IQDD]4I6N[7?YD_\ !7_]KZ__ &*?V!_C
M1\5_"^L+HGQ.\0V=E\*?A!>JXCO;7XA?$%I]-M];TEGCEA.K^"O#,/B?X@:?
M'<Q2VLT_A-8;B*:*1HG_ ('4_P""R'_!3Y'5U_;0^,1*,K /?Z+(A*D$!HY-
M%9'7(^9'5D895E()!_8+_@Z7_:L'C3X\?!O]D/PYJOFZ+\%?#$OQ,^(UI:7;
M-!)\1_B1;Q1^%]*U>R*!4U'PI\/;*#6],N$<A]/^*5U&PR,+_.9J_P"S;\2]
M&_9C\%?M8W6F./A5XW^,OC?X(Z??F"YC>W\5^#?"?A+Q=%--+)&MM-8>([3Q
M!KMEHTEM)*S7_@/Q7!.(S:1[_P!J\/>'<KPG#>"Q6;8/ UL5G6)E7H/&X:A6
MFJ<X26$H4G6A*RJT*$\5%1MS>VL[M)+Y[-<56J8NI"A4J1AAX*,O9SE%74DY
MR?*U\,Y*#[<J?<_U-/V.?VBM%_:T_9;^!7[1NABRAA^+'P[T+Q)JVGZ?)++9
MZ'XN2%M+\=>&8)9B991X6\::?K_AQI7+-))I;N6;=N/TK7\F7_!K#^U8/%'P
MC^.'['7B/5?-UCX6Z_#\8OAK:7=VTES)X"\<2V^C>.-*TNTV!+;2/"GCBUTK
M6[IRY>;5?BE*<;5PO]9M?AO%&4/(L_S/+.5JE0Q,I8:]WS82NE7PKYOM-4:D
M(S:O:I&<79II?1X*O]9PM&M>\I02G_U\C[L].GO)M>336C/Y(?\ @XY_;@_:
MR_92^-7[-_A_]G7XZ^./A)HOBSX7>*]9\1Z=X3NK*WM]7U2R\6165I>W:W5E
M=,TT%HQ@0HR (<%2>:_G#_X?'?\ !3W_ */1^,G_ (,M(_\ E/7[)?\ !U[_
M ,G!_LG?]D;\;?\ J;0U[I_P:?Z-I&J^$_VX#JFE:;J1@\0_L_B$W]C:WAA$
MFF_& R"(W$4AC#E$+A,;MJ[L[1C]HRB>49-X<8'/L3D679G5H4H^TC6P^%C5
MKNOFTL(G+$U,-B)7IQJ*2YH2NH*"<4TU\_7C7Q&;5<-#$U:,92NG&4W&/+14
MW:"G%:N/1K774_"CP=_P7$_X*I>"+Z2^TS]K[QKJIG\D3VGC'PO\-_'-C)'"
MSL(X[7Q=X,UE+'S!(RS3::;*YD79NGS%"8_Z;?\ @D?_ ,' ES^U_P#%'PE^
MRW^U/X+\)^!OB]XKL+VT\!?%7PA>W6E^#/B+XETRT^UP>$]9\):I]N_X1+Q9
MK6FVE_=Z;J%GXEN-"\2ZZB^'])T'P_?W^B:9J'Z6?\%3_P!BS]DWXX?L=_M)
M^,/BI\*?A]8^+/AW\#/B/X\\+_%ZP\*:3IWC_P %:K\//!GB'Q1H-U:>*=+L
M[;Q!>:%::A:EM2\)RWTND:W:S7%G-9-<2P3P_P":K\%O&7BKX=?&/X3?$'P(
MBR^-_ GQ,\!^,O!L;"0K)XJ\,>*=*UOP\C"(-*5?5[&S4B-3(0?D!; IY=A>
M%_$/),RJ4.'\-DV/PG-2A6H4Z%*5+$3H.>'J+$X:EAUB:*E'EJTJ]*T8IM1B
MY0FE5GC<JQ%)2Q4\12G9N,G*2<%)*:Y)RER2_EE&5WWM='^OY7^9O\<O^"NO
M_!2GPY\:_C!X>T/]L/XO:;HNA?%+X@:-H^G6VHZ2MO8:7I?BW5['3[* -I+,
M(;6T@A@B#,S!(U!8GFO],BO\AS]HS_DX3X[_ /99?B?_ .IOKE?,^$6!P6.Q
M6>+&X/"XQ4Z&!=-8K#T<0H.53$J3@JL)J+DDE)QM>ROLCLSVI4IQPWLZDZ=Y
M5;\DY1O94[7Y6KVZ7V/LV'_@LG_P5 @FBG3]L_XP,\,B2HLUYH5Q"6C8.HEM
M[C1)8)XR0 \,\<D,JY21'1F4_<G[-_\ P<J_\%"/A+XAL7^-=]X&_:>\#FZC
M_M?0_%GA7PY\._%Z::JXDM_#'C;X:Z#H=EIM^\@5_P"T/%7@_P <QA&FB^PY
M>"6V_LT_8-^&WPZ\9_\ !.3]BO0_&'@'P5XKT7Q#^Q=^S5::_H_B7PMH6NZ7
MKEK>_!+P3]LMM8T_5+"ZM-3M[O<WVF&]AGCGW-YJODY_"C_@N#_P1#^!EO\
M WX@_MA?LA^ -*^$_C/X2: _B[XH?";P+I]AH?PW\6_#S08S+XK\5^'O"MK'
M:Z5X,\1^#- CE\1ZG!X>&G:!K?A_1-6D.B/XIF6^U+U\+Q1P3G&9SR+-.%,!
M@%4Q53 T<7"EA91=7VOL8.=:AA\)B<'[6:LJE*<U!N+G.,>:<<)X+,:%%8FA
MC:M2T(U94VYI\O*I.T92J0J<JW4DKI.R;LG^^?[!O_!03]GS_@H9\)/^%G?
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MV.A>(?#T5WH.@W&J7-_>7&D?GE_P5=_X)J>-?^";/[0LG@];G5_%/P-^(/\
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MG>6D96DKQ2M9JXR**."..&&-(8842***)%CCBCC4)'''&@"HB* J(H"JH
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MAXCT2YO%DLU,IGLXIX(S^[DD63Y:]B_X-\_^"??[5/[!OA_]J>P_:>^'^G^
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M4%.;:BFYOV;3;Y5\,8ZMZ;6_S:_^(>'_ (*P_P#1O/AW_P /A\$?_F_KZL^
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M,^)_C1>33F-O*C\.W$J[A%(!_3J[I&C22,J(BL[N[!41%!9F9F("JH!+,2
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M75A^UY^QAJ5KXRTBZ\/6UM-XG\8?#'0-2D\4W6E6%I-:SIXCUGX?ZXEQXO\
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M'_00_P#P51_^5^7Y]V?V)?\ $6IK'_1ANF_^)+77_P X>C_B+4UC_HPW3?\
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M:Q_T8;IO_B2UU_\ .'K^.VBC_B&W!7_0DC_X7YI_\W>7Y]V']KYA_P!!#_\
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M/[7S#_H(?_@JC_\ *_+\^[/[$O\ B+4UC_HPW3?_ !):Z_\ G#T?\1:FL?\
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M_P#$EKK_ .</1_Q%J:Q_T8;IO_B2UU_\X>OX[:*/^(;<%?\ 0DC_ .%^:?\
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M3_;_ /VO?'7_  6<_:9\.3>&O#=S8ZO\-OV'/A9J5Q?W1\'> +'^T?#D_C:
MRSI"UO;:9?>*-'M;@P'3?%/CGQE\3/&]CH>@6T'@^:;^F&OR'/IPRK X7AC#
MSA*IAZGU[/*M.2E&KF\X<D<(IQ;C.EE=!^P]V3A+%5,5*R:3/<PJ=>K/&S32
MFO98:+TY<.FFZENDJTUS:JZ@H:ZL****^2.\**** "BBB@#^53]L[X0?$?\
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M3_%'QA\1> ?BU\45U35;2RL?%&D?#SP'?^(O#?@[X7^#->U&.]7P];?$J_\
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M0_B9^R1\?_!W@BTL#J>J>)]6^&7BA=(\/Z>LIA:Z\475OI\Z>%8A* A/B/\
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MJF%HSI4I5/:U'4FIRE)))15M%%6B[WO[JT6M_P!+O^"./_*3W]B[_LLFF_\
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M_3[.YT>><12&*"]D<(V,'^Z[_@JG^P1'_P %KOV>?V7_ -H7]COXN_#VXO\
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M\,Z_IL]AXB\)Z]%;7%S:PZ]X9U;2=8BM+JZM4O5M[JXBD_GC\5?\$GOV_/\
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M>XBD@G@D>&:&9&BEAEB8I)%+&X5XY(W5D='4,C JP!!%1U](<@4444 %%%%
M!1110 4444 %%%% !1110 45] _!K]D_]I[]HAP/@5^SY\9/BW;"ZBL[C5/
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' HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>logo_ubsv2.jpg
<TEXT>
begin 644 logo_ubsv2.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^***^ _VD_P#@I_\
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MZ-8:DOC?X)?$-+22'P#\6[/2+;[/J&F:GIL5EXUT;3/M-YI/B?PY;^"O'6E
M'YY?\%(O^"5WBO\ X)P?LU_L$^*_C+I_B_PA^TS^T?\ \-2?\+R^&&L^*?AU
MXO\ "G@+_A3_ (]\"Z;\,_\ A#-9^'4FL:=<?\)3\/\ QSI?B'Q%]H\8^*/*
MU*YBM8?[%GMK[2XO]-+_ ()]?\F$_L1?]FA_LU_^J9\%U_$'_P '-'[;'[.G
M[>WP4_X)A?'?]FWQU;>+?"FJ)^UU;:[H=V(-/\;_  [\3?9_V6)]0\$_$7PR
MEU=7'AOQ3I32;98?/O-(U>T-OKWA;6-?\,:CI.N7_P"E_P"TM_P<%_"O]@']
M@+]CW]G[]F__ (1WXS_MC3?L@_LXZ?K%I)(VI?#GX!B3X(^"BM_\0I["XB?Q
M#X\=YX3HOPRTNZBELU2ZU;QSJ>@V\&B:!XS /VQ_X*B_\%=?V9_^"7GPW?4?
MB-J<7CKXZ^)]"NM2^$_[/7AS4K>+QCXO<RW-A8:_XDN?+NU\!_#E=5MKFVO_
M !GK%I,;O^S=:LO".D>*]>TJYT9?\W3XT_MQ^*O^"EG[:7@#XH?\%'/C%XYT
M'X+ZEXYL=*\0P?"?1$U2P^!GPEU/58'U?1_@]X#U&ZO+*PCM+*"TCU#6KFW\
M5>*]3^R#Q+KMG\1?$-G%I&K]5^WG^QM^VOX'^&7@O]NO]O7XBZ3;?&K]JWQU
M/<:?\(OBCXOE;]J;6/"G_"/2ZA:?%/7?AS)9H?"'PXT\6%KX.LM#FDTF[\%/
M)X:\.-X5T'3Y],LH?K?_ ()??\$G_&7QE^)/PJ\6^*/#GPF_:,_9F_:/^$/Q
M7^$OB/XD?![Q3:?%_6/V./C)\7?@O\0=*^$VM_&CX:Z:UAXM^&_C[P)X^B\-
M7<>L>*_#5Y\/=&?4[/7-.\5SZM;:3<VX!_=M_P $;/&_[+WCS]@_X=:C^QS\
M!OB/^SW\ M*\2>.?#W@SPI\4O#^H:5XH\5V^F>()ROQ0DUV^N=2B\=I\0;2X
ML]<O?%6EZWKVF6NO2:SX,@U::;PC<06_ZF5_+Q_P0:_X)0?MG?LQV?PU_:$_
M;:^/?Q6TG7/ GPX\:?##X&?L>6WC^?6_!/PJ^''CS7(M?U[_ (6)'::EJGAN
MXUG7M:M+#Q'IW@GPX\EMX:?2O"=[XBUVZU[2+3PCX(_J'H *\<\:_L[?L_?$
MK7)/$_Q&^!?P<\?^)9;:WLI?$/C7X8^"?%6N26=FI2TM)-6UW1+^_>VM49EM
MX&N#% K%8D4$BO8Z*RJT:->/)7HTJT+J7)5IPJ1YE>TN6:DKJ[L[75W8[LOS
M3,\HKO%95F..RS%.G*D\3E^+Q&"KNE-QE.DZV&J4JCIRE"#E#FY9.,6TW%6_
MRW?C996>G?&;XN:?I]I;6%A8?$[Q[96-C9016MG9V=KXJU:"VM+2V@2.&WMK
M>%$A@@A1(H8D2.-%10!_5]_P;Z? +X$_%3]C/XF>(?B?\%?A+\1]?L_VG/&>
MC6>N>//AQX.\7ZQ:Z/;_  J^"]];Z5;:GXAT;4;V#38+W4=0O(;&*=;6*ZOK
MRX2)9;F=W_E*^//_ "7+XS?]E7^(G_J7ZQ7]A_\ P;<?\F.?%7_LZ[QS_P"J
MA^!=?ROX84*-;CJ5*M1I5::P^:-4ZE.$X)Q?NODDG&\>FFG0_P"@CZ>F9YEE
MGT3,/CLNS''9?C?[7X!C]<P6+Q&$Q7+5C^\C]8H5*=6U3[:Y[3^U<_>_PWX9
M\.>#M#TSPQX0\/Z)X5\-:+;+9:/X>\-Z58:'H>DV:LSK::9I.F6]K86%LKN[
M+!:V\409V8("Q)YOQ_\ "CX6_%>ST_3_ (I?#7P!\2K#2;F6]TJQ\?\ @WP[
MXQL],O)XA!-=Z?;>(M.U&&RN9H0(99[9(Y9(@(W<IQ7?T5_5,J-*=/V,Z5.5
M'E4?92A&5/EC;EC[-IQY8V5E:RLK+1'_ #[4<RS'#8[^T\/C\;0S)5:E=9A1
MQ5>ECE7K<_MJWUN%2.(]K5]I4]I4]ISU.>?,WS2O_#'_ ,%8?AI\./ W_!5S
MP)X'\%?#_P $^#_!=U_PSS]I\(>%O"NA>'_"]Q_:NLVT>J>?X?TFPM-)E_M*
M-BE_YEHWVQ"5N/,4D5_:%X#^ 7P)^%>L7/B'X8?!7X2_#C7[S39M&N]<\!_#
MCP=X0UBZT>XNK.^N-*N=3\/:-IU[/IL][IVGWDUC+.UK+=6-G</$TMM Z?QY
M_P#!8K_E,)\/?^[:O_3Y:5_;-7Y9P'AL-_K+X@/ZO0OA\_IJ@_94[T%S8[2B
M^7]VM%I#E6B[(_O_ .EUGN=OP.^AQ!YQFKAF_@_C*F:P>88MPS.?L.%'SYA'
MVUL;.\I/FQ*JN\I.]VS\E/\ @J3^SC^SUI7[#G[6GQ#TSX#_  9T[Q^/ &M>
M(1XYL/A?X(L_& U^^UJQN;W7!XFM]#CUH:Q>7%S<3W6IB]^VW$T\TLT[O*[-
M_G]5_HU_\%6/^4=G[6O_ &2C4/\ TZ:77^<I7YSXTT*-#/\ *U1HTJ*GE*G-
M4J<*:E-XW%)RDH)<TFDDY.[LEJ?VS^R[S3,\T\(./IYGF./S&>'\1'A\//'X
MS$8R5##QX8R%QH498BI4=*C%MN-*#C!-MJ*;9_HW?L4? KX(^)/V'_V29?$7
MP<^%>ORZ_P#LJ? 6379-:^'OA'59-:DU7X1>%&U-]6>^TB=M1?4FGG:_:\,S
M7C32FX,AD?=^87_!7?\ X)"? W7?@1XS_:+_ &9?A]X<^$7Q(^#?AO4_%_B;
MP1\/]"TSP[X'^(O@/1$&H^)U/AG3FT[1_#WBCPKH<.J>(](U/P_8))K\%E>>
M&-2TK4[S4= U/P]^R/[!W_)CG[&7_9J/[.W_ *J'P?7I'[1OB/0O!_[/7QW\
M6^*+,ZAX:\+_  :^)_B'Q#IZS_96O]$T;P3K>HZK9+<AD-N]W8VT]NLP=#$T
M@<,I4$?M6,X?R?..%*>&Q^$PO++)J,HXGV,(UL+4C@X3AB:56,?:0G2FE-\K
M:FE*%2,Z<YPE_EOPUXP^)/AM](3%YWPEQ'GSK4?$_,:%?(UF6*JY;G^"K\2U
M\+B,DQ^75J_U/%8?'X:I/"0]K"-3"U)TL5@ZV%Q>'P^)H_YK_P"S_P#M"_%O
M]F'XG>'OBW\&/%^J>$?%N@7EI+)]CO+V'2?$FEP7UI?W7A;Q=IMI=6L7B'PI
MJ\EG!'J^AWSM;72)'(IANX+:YA_TB?V6?CYX?_:C_9X^$?Q^\-6XLM.^)O@Z
MPUVYTL3/<#0O$$+S:5XL\.?:GB@:[/AOQ3IVLZ$UX(8DO&TXW,:+'*HK_,,K
M_0N_X(R>"O$W@/\ X)K?LSZ3XLM+O3M1U71O&WC.QT^\ #P>&O'GQ+\9>,?"
M=U"!(X^RZYX:UO2O$=OQ&WEZP-\:R;R?R+P3S#'?VKFF5\]2>72RZ6.=-N4J
M='%TL5AJ,)0O[M.5:E7JJ:5G5]E!NZI77^C_ .U/X,X4?A_P#Q^\-@\/QK1X
MSI\+4\735*EC<SX=QV19WF>+HXKD2K8REE>/RK+Y82I5<Z> _M#$TH.$LPY:
MG4_\%2?VU+C]AC]E+Q#\3?#D$%W\3O%^M67PT^$\%W;P7>GV7C/7].U;4F\2
M:O:S%EGTSPKX?T36M;2"2VN;34=;MM$T*_6&UUB2YA_E7_X)/_L</_P4M_:H
M^)'Q(_:6U_Q!X_\  GP]MK+QK\6I=5UW53XC^)'B_P :W.JVGA#PYJ&OVM_:
M:QIVF7CZ+KVLZG?:==1W$=AX;A\/6"V*:K%?Z;^AO_!SCK&J)#^QGH"-<1:)
M<R?'K6)T$O\ HM_JEBOPALK5G@VC%QI-IJ-X(I2[9CUJ9 JX)?YW_P"#=C]J
M+X8_"#XR_&+X&?$/6M-\+ZI^T):?#M_AQK>K316.G:GXQ\!W/C"W7P-)?/!Y
M::OXIL_&KS^&8]0O;6TNM2T2;0M/^T:_XBTNQO?1XDQ^'SCQ5RO(LZJQ_L/+
M:F'A'"UY)82MC*^6_7J,JT)>Y-XC%UL-A&JBE&I3BJ5N2I-R^+\#^$,Y\-/V
M?''GBUX78*O_ ,17XYPF;8NOG^54'5XARSAK*>.%PIF5'+,50OB<+3R;A[+<
M]XBIU<+.G7P6-K5,PYGB,%AU2_KV\*?![X3>!?"J>!O!GPR\ ^%?!B6(TW_A
M%= \(Z!I6@/8"*& VL^E65A#97$,D5O DRSPR><(D,Q<J#7X9_\ !7G_ (),
M_!+XC?!#XC?M'? 3X?:1\.?C=\+O#-_XSU?1? FGZ?X>\*?$WPKH!_M7Q9#K
M/A?3K6+3E\8Z;X?BUC6=#US1+6UU?Q#?VRZ!KBZP;S2;K1/Z$JBN+>"Z@GM;
MF&.XMKF&2WN()D62&>"9&CEAEC<%9(Y(V9'1@596*D$$BOV/.N'LKSS+*^5X
MO"8=TJE"=*A-4::G@ZC@U2KX9J*=*=&34X\C479PDI0E*+_S-\,/&;C[PIX[
MRKCWAWB+.(YAA,UPV.S?#3S/%RPW$N#CB*=3,,KSRG.I.&/PN9T(SH5WB8U:
MM.4XXJA.EBJ-"M3_ )1_^#8J>%9_VV;9I%%Q-%^SC/%$?OO#;O\ ':.>11_=
MC>ZMU;G@RIUR<%?H1_P21_X)G_&+_@GUXM_:0O\ XE>+_ACXJ\/_ !37P+9>
M!V\!ZMXLOM5MK#P?J?CJ9Y?%%GXC\'^'+73KFYL?$FEF.#2]3U^-;F.^B>Z\
MN&"XNBO'\/<OQV5<(Y5E^8X:>$Q>&EF"JT*EN>*J9GC*U-OE<E:=.I&<6GK&
M2?4_3/IG<9<*^(/TD/$'C'@K.L+Q!PYG='@ZI@,UP3J?5L1+!<"<,Y9BX056
MG2J1EA\7@:^'K1G!.-:E4CLD?MK6/XB\/:'XM\/Z[X4\3:58Z[X;\3:/J?A[
MQ!HFIP)=:;K&AZU93Z;JVE:A:R QW-CJ%A<W%I=P2 I-!-)&X*L17R1^VW^W
M_P#LM?\ !/CX67?Q4_:8^).G>%K>6UOV\'^!=.DM=5^)OQ,U2Q2/=H?P]\&"
M[MK_ %V[,]Q9VU[J<SV'ACP\;ZUO/%.OZ%ICM?)_*[K_ /P>3Z+!XGNH_"W_
M  3ZU?5/ T-_<6]EJVO_ +2EIH/B?4; O']DO;K1-.^!_B/1]%OU@$LEQHT7
MB/7X7=HXXM;1%:9_M#^73]!?V</^#=;X<?LK?M\^/?B;\/[OX4?$']@;XQ_!
M?QWX)^(?[._QV\"0_%+Q[HVI^(-4T6^TGP/X'\3ZY:M':>#K+5+"T\26?CK4
M=5NO&=G8Z!#X*UC2?$VH:E;_ !(TC][/C+^SA^SA\7/V?]<_9[^,GPN^'NM?
ML[#P=;^';[P!JFFV.A>"_#'A+PUIJ6^D-H)TYM*7P(O@S3[*";PSKGAJZT._
M\&'3[2_T#4-)GL+:XA_FH_:F_P"#D3P3\7/^"=_Q!^,__!/;QSX ^&/[4O@G
M5O"J?$3X1?M*?V%I7Q+\&?#_ ,0WE_X;U'QG\%]"U2^G^'_QN\1Z=XGN?#,M
MEI^EZCXD_LKPW>7NJ>+O!-MJ,FE:!??BW\8_^"DG_!47_@X5\4?#7]B3]G#X
M<0?"SP)=>'/#,WQVT;P%K>M6?@;Q!K%O:6D7B_XE_&_X@W5J+GPO\%-,U6*^
MU+PC\*]VKSW5W+8:1(?B[\0T\$P68!^&?[?GPL_97^"W[5GQ5^&W[&?QPUC]
MH7X!^&=9:S\+_$?5])M+-9[Q6D_M;0-)\06#PZ=\1='\-W0_LFU^)FDZ)X:T
M'QM);W&K^&M)G\.2:3KNM?TZ_P#!K/\ L??\$Y_BSK.J_'3QYXYTWXL?MO\
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M ,%BO^4PGP]_[MJ_]/EI7]LU?E_ ?_)2>(W_ &4%/_TO'G][_2Y_Y,C]"?\
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MX7>+/^"9/[!_P3\#_$OXHW>NI^TEX-UOX4Z#\$M0\$V'AJ?PI>:-IYU;X/\
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M.GSN>8Y9C*F:*GA\7*<G-SKX?%J<KNNJ[:<?@C]@'_@GO\(/^"?WPUU+PEX
MNK_Q7XY\9'2;KXG_ !.UB)K+4O&E_HG]I_V/#:Z''>WNG^&_#^B#6=4CT;1K
M.>ZGC2]GFU75=7OY'O3][T45][@,!@\KP=# 9?AZ>%P>&A[.A0I)J$(W<F[M
MN4ISG*4ZE2<I5*E24JE24IRE)_R)Q=Q=Q+Q[Q)F_%_&&<XWB#B3/<5]<S7-L
M?.,\1BJRIPHTURTXTZ-##X;#TJ.%P>#PU*CA,%@Z%#"82A1PU"E2A_*U\?M!
M_P"#A3X^_#KXD?!CQE\ OAU>?#CX@V-_X=U6/3/$_P"S;I6J7&@RWJ3P?9K_
M /X7%]HM)W2WMV,IA$H^8,BL2!^2'_#D'_@J%_T;%_YFG]GK_P">S7^@I17Y
MWF7A5E&<5H5\TS[BG'UJ</94ZF*S# 5I4Z?-*?LX.>5MQ@I2E)16EVWU/[2X
M'_:#>)'AKEN(RC@+PD\ .$\NQF*6.QF$R+@[BW+J&,QRH4<,\9B:>%X^IPJX
MF5"A1I2JN-W"G&.B22_F(\ Z]_P<0?##X.> ?@KX(_95^"6C:#\-?A]X-^&W
MA7Q WBOX)ZEXJM]#\#Z#I?AS2+N[FU7]HN^\/7NK3Z;I4"ZA/-X<-G--+<2V
M]A:EH1#\U_%;_@G_ /\ !=7]NA+31OVGO&WASP]X9L+F*\L_#'C+XE_#_0?
M<=Y%)<I:W]QX/_9]TWQ1I&IZG81/(+36-6T>_P!8MK:\>&"^S-=Q#^PNBNZO
MX>83%T887&\2<78S!0IPI/ 5LVP\,'.E!)0A4HX? 4%.,5%*/,[JRLSY+*OI
MG\1\.YIB>(.%O _Z./#/%.)QE?,%Q9EGAWF^(XCPN.Q4I3Q.)P699SQ?FL\)
M4KSG.57V,(PG*4FXWE)O^:_]CK_@W=^&GPS\0:/X\_:S\?6/QKU32I+6^M?A
M7X0T^_T?X8KJ5N6<_P#"3:YJC0>)/'6EK,898=)72/!=C.UN8-<MM<TR\N=+
MK^D/3=-T[1].L-(TBPLM*TG2K*UTW3-,TVU@L=.TW3K&".ULK"PLK6.*VL[*
MSMHHK>UM;>*."W@CCBBC2-%47:*^ER/AO)N',/+#9/@:>%C4:=:K>57$5Y1O
M9UL15E.K44;MP@Y>SI\TO9P@FT?AOBQXW>)_C=G-'._$GBK&\05\'"I2RS ^
MSP^ R;**-5Q=2GE>3X"EA\OPDJJA2CB<3"@\;C%1HRQN)Q$Z<)+\I/\ @JA_
MP3/'_!13P;\-_P"Q?B:?AO\ $'X-GQY/X-.J:/\ VQX-\1CQW;^%?[3TKQ,+
M1X=;T@BZ\%Z)]AU_2CJ?]F6\VJBX\-ZY)<6AL?P1^%7_  3R_P""U/\ P3P\
M=:SXJ_9HL-&\5Z;>6MF_BQ/ASX_\%>(_A_XWL]-DEFM[+6?AW\3;CP?XAUJ^
MM$GO;?3M1L?!\/B32H=1U&+P]J]A)J%TTO\ :317B9UP#DN<YG_;:KYGE><7
MIMYCE6->'KRE1HQH4I-5(5Z<7&C"%)NE"E*<(\LI.[;_ %/PP^E_XH>&? ?_
M !"N>5\"<?>&EL;3CP5X@\+TLZRFE1S',:V;XZE">"Q658RM&KF>(Q&/IQQ^
M)QU+#8NJZM"E!0A"/\V%C^W#_P %[M2LXM'M_P#@GO\ #&+7KITMX-;O?"GB
MS2M-B7RI%>:YCU3X[6NFV]R6\N5+JZU.WTZ.1&1[*1)4B3Y%\6_\$N_^"LG_
M  46^,.G^//VU_$WAGX/>';&)X=-.K^(/#'BBP\&Z!>RPM<Z7\-?A9\-?$.L
M:;#?3>19R:B?$GB/PUJ&L+9P3:]XEU#4+2W1O[":*Y\3P#1S.%.CG?$?$F<8
M.G4C4>!Q&,PU#"5G!WBL1'"X2C5J6=VI*M"<7K&46KGLY)],#,N!L3C,T\*O
M!3P/\->(\7A,1@X<69/PSG6:\199#%1Y*[R?$<0\1YGE^!C4@E&I0EEN(PU:
M*<*U&I3DX'RA^QO^QO\ ![]B#X/V7PA^$%C>26\MXVM^+O%VN/;W'BGQSXGG
M@AMKC7-=NK:"WMT$=O;PV6EZ7900:?I.GPQP6\3W$EY>797U?17V^$PF&P.&
MH8/!T*>&PN&IQI4*%**C3ITXJRC%+[VW>4I-RDW)MO\ E;B'B'/.+,\S3B7B
M7-,9G6?9UC*V89KFN85I5\9C<77ES5*U:I+Y0ITXJ-*C2C"C1A"E"$(E%%%=
M!XP4UT21'CD19(Y%9)(W4.CHX*LCJP*LK*2&4@@@D$$&BB@#^:K_ (*M?\&X
M_P $?V[=?^&WCW]FB_\ @]^QMXY\/W?BB/XHR>%/@G VC?%^T\37WA273M9U
MBT\(>)O!^F:9XD\$Q:7XJN[>\7P[J%_XVNO%9M->UW2HM+M+P?L!^Q'^P-^S
M?^PA\)?!/P]^#/PN^&NA>+M&\!>%O"?Q!^+7AOP!H_ACQQ\6];T32[&#6O%?
MB_6A-K'B6[;Q%KEO=:^FAZGXHUNRT.2\&GZ?.;:UA:BB@#[7HHHH **** "B
IBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>ny20077604x1_ex10-3logo01.jpg
<TEXT>
begin 644 ny20077604x1_ex10-3logo01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1"  T 9$# 2(  A$! Q$!_\0
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MTN8W9X#"QQCHR,W0C[V1VP .3QSIZVR236E_;L]T+1$GC2,NY0LNUBVUL@8
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M5=N5D7_88A@&[[33]#\4Z?J=AITHN((KJ\MDN1;>8&==T8D*^Y"L#CKCG&*
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M6.'ZMD*0QZKG!IEKXFUE;NWT_P"VHMT\LN)+NV8^:5N2KQ (O41A2.GW@<D
MT =?I/AQ-/U6*^CGR0+DNNS&]IY5D9NO&"@ 'IUR3FJE[X3DNM0UVYCU.6W&
MLQ103>3'AXTC5E^1B2 2&/.#[5S(\3>(/[/MIVU*Q OWN(H)6LG$<,L<A6-&
MV[F.\8./E/RX!Y%6]#UF\U?QKIS7L<MO/ U_!+:B)@(E#((F)(_C5=P)X^;C
MH: -";X?Z?\ 8I+*!UAL@D"01A#FW\E&5&5]VX.-V=W'([\YF3P6$US3K_\
MM&1EL;Z:]CC:(99I8RC!F!Y^\3T]/2L8Z[K'_"3:EIRZE'!NUD6D1GM@PC@-
MEYJE>5SF08R2>:9!XVOQN\U'%LTT DG,!0VL;2SJ[,I'&/+C7G.#)N/H #23
MX>VYL);*:^EDM[B&XMI_W8!:.:<S,!SP<L1G!X]ZA7X<0HUP!J<_V>1;](XS
M&N8_MC*S\_Q8*C'MQ6'X$U[5(7L=*DE2UB61Y%:[@DW74;3S;RIVX&T!".<
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M%MITLTDSP(@(<R1E9 <GG+L90.@<]".!:?P4LEB]I-?,\4DHE<B+!;_1!:D
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=O; ^\WJ??@?E3@H'0"BB@ VCTI:** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>ny20077604x1_ex99-1image1.jpg
<TEXT>
begin 644 ny20077604x1_ex99-1image1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 0I!W@# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZ]OOUL?MW1117Y(?IP4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!MQBY*S:3:\PHHHI%!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\Q?MC
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MO_UQC_\ 0!5BJ]I_QZV__7&/_P! %6*_Q1EN_5_F?ZIQV7HOR"BBBD,****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)3FEMS2MZ79_JG2<G3@Y?$X1OZV04445)84444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M];]>Y_JK34E3@I.\E%)OSL%%%%26%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!1114E!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **8LB,2JG)%1W-Q%:PO/,P6.,%F8\   GG\J )Z*\#\5?M'_"_P=>"P
MUOQ%86EP?^6<LZH<Y(/!(_K7+?\ #7_P5_Z&S3/_  )2@#ZEHKY:_P"&P/@I
M_P!#;I?_ ($I_C1_PV!\%/\ H;=+_P# E/\ &@#ZEHKY<'[7OP5()_X2W3./
M^GE/\?YXKT[P5\8_ _CV/S?#NL6M^F[9F&56&[D <'VH ]5HH!R 1W&?SHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "OF+]L5L?L[?$X#[Q\,:F1[_
M .BR_P"?ZYKZ=Z5\M_MB$M^SU\3#G@>&-4/_ )*R<<=L=>G!)KU\@5\[RGRS
M'!O_ ,N*>AX^?5'3RC,.5<TG@\3:/5KV4D]+/O?Y'^9KK7G'QCXWZ[CX@U+&
M,_\ /S)S^6.O-?=__!(GS?\ ANGP)YF=_P!I3\M\?3\/QKX>UF5&\9^-),#:
MFOZEG(ZD7,G48]>,$^_3K]V?\$D)XY/V[O DB@%?M"C'H?,3Z_3_  %?[1>(
MS;\#LQE;7_5RLG%+;_9FM?SMUWZ'^7_ <9?\14I<T73C/.Z3YOY;5X_T]C_1
MGT[/V*VSU\F/_P! 7TJ[52Q8-9VQ'3R(O_0%_P GWJW7^)-3XYZ6]YZ6MU['
M^JE))4J:3NE"-GWT"BBBH- HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MPT+@3NI&TD<XQ]/? ^M;6B_$KXR^.?&/ACPE-XDU2XFU^_M[*%6G=B6N)!&
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJJ!ZGG%5M"\0:7XBM!?:5<QW5L20)(VW*2.M &W1110 4444 %%%% !1110
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MD%B;6$DG[%#G)V<UZR? /A(@C^P].Y_Z=(?_ (BN5^ _/P?^'I]?"VC]>O\
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MT0=]A6:8+@C<!R/4?A3I-VL^EK^O7[_7[[G5C(QBZ4E:\XW=N]E_P3_5@!!
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M#0!WV0>A!HK+TR=YED+9X/X=?\X[GFM2@ HHHH **** "BBD9@JEF. H))]
M.30 M%<%>?$KPC87$EK<ZM:QS1,5=&E *D=01C@UMZ'XIT;Q"'.EWD5T(_O>
M6X;'UZ4 =%156\O(+&WDN;EQ'%&"S,QP !ZFN,B^)7A*>[%G'JMLTY.T1B0;
ML_3&?T_&@#O:*@MKF&[B6:!P\;<AATJ>@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK)U;6].T2W>YU&XCMX8U
M9V=VV@*H)))^@H UJ*^?+C]ISX06LTEO-XMTM)8G*.IN%!#*<$$8/0U#_P -
M1_!S_H;]*_\  D?X4 ?1-%?.X_:B^#IZ>+]*/_;RO^%.;]J#X/+U\7:5]?M*
M_P"% 'T-17FO@KXL^"?'\LL/AG6K/4I(1F1;>4.5'N!_];\:* /2J\^^)OQ
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MU;M?,W[6/B9O"GPA\0ZJK^68K2?YLXZQ-QGC^= F[)OLC^4#P[_P4HO/!/\
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M$*QX91D=.OIGO7YN_P#!)K_@JO\ #Z[_ &5O#<OQ*\1VZ^)!+,MR+J]B,O!
M&3*=W8CD#]:^S/\ @OOA_P#@GK\64#+N_LN<@9&>(G[=?TYZ5_DSZ+^TQ\6/
M -O<Z!X>U_4+33[>\N!'##+(J+^]8< ,!VXQV&:(I.]W:RO^*_X<(I/FNTFH
MMJ[W=TDOQ_X)_L''_@J5^S\%#?\ "1Z=S_T^6W_Q1[^PIG_#TS]G[_H9-/\
M_ RU_P :_P B%?VS/CI-"$7Q1JNX*!GSILYXZC=['T[]>151_P!LOXZ@_P#(
MT:MQU_?3'GOG+<=/_KTDE9MNS5K+O=V+IT^=/6UGM]W_  ?G8_UZA_P5+_9^
MR!_PDFG<_P#3Y:G^3?US3F_X*E?L_*V/^$CTX''_ #^6P_FQ_G7^0U#^V5\=
M7(?_ (2C5<+U_?3#J?\ >X'YYR/05T\/[5?QXOK![]?%.J!(QR//E[9]7]#F
MIFU&_7:VN^B;?X_U<:I.510B[I]=/+SZ7^[\?];H_P#!4W]GT<'Q+IW_ (&6
MO^-*/^"IG[/QY'B33O\ P-M?_BJ_R,+O]J[X[P6?VP^*]4V]!^_D]?\ >_PP
M#^ R_P#AL;XZI&LG_"4ZJ0W<32D?GNYZ?6J2NX)Z<]G?LG;7\=+V0W1Y9-3;
MBKVBVMW<_P!>/_AZ9^S]_P!#)I__ (&6O^-'_#TS]G[_ *&33_\ P,M?\:_R
M'G_;$^.T:ASXHU;#X/\ KIOP_BR<\U$_[8_QVC&#XHU7GI^_FZ<9_B /KSV/
M>FE%V]Y*Z?WK;[_ZL-T$FDY:O5*W31_D[^3:1_KU#_@J5^S\4+?\)'IV!G_E
M\MO_ (K^E>K_  <_;O\ A#\9O%4'A/POK5G=ZC/]R**XAD8\@=$))Z]AZU_C
MDVW[9?QT>(Q_\)3JH)[^=,.<\#&[TY'^<?OU_P &Z7[2'Q2\=?MY^%M"\2^(
M+V]L9!\\$TTA4_O%ZJS'KD>O2E9M<RU5[7Z7,G3DE)M:1E:]MU9._P"/W'^I
M$#D CH0#^?-<%X[^(.B^ M-FU+6)TA@AA>9F=U4!47<22WH!^AKNH3F&(GO%
M&?S05\(?MS^!?%7C;X=:MIWA>2XCO)=)OHHS!G=YCP.%(QWR1CFD0>>:C_P5
M ^ 6G7US8S^(]/6:UF>&13>6P(=&*D8+'G(_I5,_\%3?V?1P?$FG?^!MK_C7
M^;W_ ,%!/!7[4'[-/Q UB75_$&N6]OJ6HWUS;K+)(@\IIY"H49&0%((Q7YI/
M^TM\?#ID^H+XJU3RX6P?](DQUQ@_-]..GIR:3=FEW_/I^I<8<T6T[M:\O6RW
M?RO^#/\ 6P_X>G?L^?\ 0RZ=_P"!EK_C1_P]._9\_P"AET[_ ,#+7_&O\[']
ME+]F3]KO]I/X8V'Q#T'7/$,]C>G"20O*R'N.?;/K^%?3W_#M[]M;&?[6\3?G
M+_\ J_6F0?W8?\/3OV?/^AET[_P,M?\ &E'_  5,_9]/3Q)IW'_3Y:_XU_!;
MXM_X)\_MH^&?#.M>(+C5_$JPZ5I]S>R,6E "00M(<\'LOKBOP&\6?M7_ ![\
M*>)-;\/7/B?5A/I-_<V<H:6;<&@E>-A][CE3_A512D[-V_KY_D5"*E*S=EKJ
M?ZJ?[1?_  46^'/Q!^&6N^&?AQKMM<^*;^W:+3XK:ZB:5I&X4*(B7SD_P@G]
M*^L_^"<E_P",M1^!>GW/C43_ -J232.?/+L^QB"N2^#S^6?I7^8M_P $@?VA
MOB?\4/VV/A3X4\6:[?:AHVHZY:Q7-K<2NT<BM,@(96)!!&<\'OSQ7^MM\.O#
M&E>%O"ND6&DVR6T'V&V<I& J[FB4DX&!DFI).ZJ&XF2WADFD.$C0NQ]@,U-6
M1K\4D^CZA%$2))+694(Z[C&P'Y'G\* 6ZZ'R!\8/VW?A3\'+V.R\3:Q9VLLK
M,JB6XAC.5)!'SD>A]>_M7BB_\%3/V?68 >)-..?^GRV_HP_G7X _\%=/V/?V
MCOBQXRT^[\ 7VM06R7$S,+0N%(+OC[HZ<CZ_4U_'U^V%<?M,_LH>/[+P9XE\
M2:W;W-U )E2XFE5B,KVRI[]OPZ5*;:3?^6E]_NU-)12FXQ=UI9]VTG;[W;].
MA_J!O_P5,_9]1B#XDTX'CC[9:_\ Q1_G3?\ AZ=^SY_T,NG?^!EK_C7^4=\-
MOC/^T+\2_%UIX>T[Q3JSS73*H6.>5B2<#@;B>^,5^R/P_P#V!OVSO&_ARRUV
MTUCQ*T-W&)$*-+@@@$$<=\_UIW7X7^1%I6NU:SL_*5KV^X_O@_X>G?L^?]#+
MIW_@9:_XU*G_  5*_9^8$CQ)IQ [_;+;^C"OX4O^':_[:_\ T%O$_P#WU+_A
M7YM_MLZ%^U%^QW=:58^)_$&NP2:LCF(3R2@G&X<8*Y_(GC\*9+OI;O\ <OZ_
M$_U!?AY_P44^"?Q%\4:=X5T37K&XU#49DA@B2ZMV9G<X  4YSGM@_P"/Z"PR
MK/%',ARLB*ZD=PPR*_QR/^">W[='Q2\"_M+^ /%?BWQ/?/H>G:O;37B7,\GE
M-$KAFW9?H0/7L">:_P!';]D7_@KC\-?V@_B!X:^&6D:G83:C?6L$02.;+EU1
M5/5_4^A/7WH&?N-134<2(KJ00RAA@Y'(!_K3J "BBB@ HHHH *^7/VQ6)_9Z
M^)@_A_X1C5,_06LO],GGUP>.OU$>0?H:^7OVP%S^SM\3P>2?#&J8SU&;63C_
M #Q7L</V_MK*G_U,<$OOQ-/_ (!XN?QE/*L?!-QC+!XEN2Z6I2:/\T'6DB_X
M37QGQE?[?U'=T_Y^9._^><>HK[M_X))"'_AN_P !A,;//3H!R?,3D]>W/_UZ
M^#-7C=?%WCB,YWMK^I[?J;F7''Z\#]2,_=/_  2+ADC_ &ZO J/DL;E",XSC
MS$_K_GM7^S_B-_R8[,4Y72X<K+FUU_V9O_@-=>A_F'P)"-/Q3P[B_:/^VJ?N
M[W_?1WZ;=?+1.Y_HYV./L=MCIY,?_H"USGCQKE?!_B)K//VI=*O#!MSGS! ^
MW&.<YQCWKH-.!6RM@>ODQ_\ H"^M3W,$=U!+;RJ&CE1D=3R"K#!!'T-?XEU-
M)S2=_>EK\S_5*CK2INW+>$7;MIL?P0_M<>.OVOM"_: 6ZT==97PY;>)YGF9)
M+P1"T6[<DG:NP+L_#OTYKZ\N/^"C]QX!T/3-+\1ZTT&I?8(%D26\*MYHB ?(
M<@YW=1@\U_2[\:_V4_AOXN\+^(KD>'[.35Y[.Z>"<0H9!.Z.5(.S()8YSGK^
M%?YLW_!:[P+\1_@+\:[?3[2YOK*RG,\L4:[D3R_,(7@;1@#H/2I5KJ[LKJ[[
M*^YO"#G)12;NU>W172;^5S^B:V_X*KZ2]L8SXA7S">,WR^O^\#TX_/%>+?M+
M_M]^.OB[\.K7PS\)-6N+WQ,UY$3%9W<CR[-Z@Y$.YNAQTK^)2S^*_P 1MXN/
M[8O/*'4>8V,]\\CT]>]?O%_P;S:S>_&K]MRV\)>.)6U;2!!O^S7),D88, /E
M;<,^O%*44JC:=TE9:[[._;^F.I[O-1WY:K;E;^5))?/<_M7_ ."2FI_%_4/#
M&C-\2%O!.VE0M)]J,Q/F%#G/F@'.>O>OW9KSOP1\-/"W@6V@AT#3X+-(X411
M$@4 !1QP!Q_@#7HE!DE96O<****!A1110!_+U_P<#ZW^T%I,'@,_!==18NT@
MO/L+7*\?-C=Y"D]1WZU^1/[*O[<7Q<^!WAR_TOXUZE>V&JW3!K5+ZZF1V7!Z
M"<*<?A]*_NA^)/P8\$?%,6P\6:3;:D+7/E?:(U?;G/0%3^=?YXO_  <_Z?#\
M!_COX&T7X>J-$L[RTS+%: 1*QR ,A=M-6;2;LFU=]EW'%<THQ[M+[W8_5)?^
M"K6D)8N&\1+YA("_Z:N><X[GV_\ K9KF/V@OCG\?_BI\'--\8?"^;4;N"]O;
M8QRVDMPX9/,7)#1*<C'Z8'U_BA^ TWQ:^.?Q6\/_  WT;4]0FN]6N(41(F=F
M;<Z9'&1WYXSU^H_U'?\ @ES^QY8>%?V0_!7A+XFZ2M[K-O;QR3M>QJTA8I&0
M3N7/4<9[]\4Y)*32=TMGW_(<XN$Y0?V7;U/L+_@GUJOBB?\ 9<^'MSXW,JZ^
MNB6\FH"X9_,$@CRQ;> W8YSTK:^+_P"VM\*_@[<+;>)]7M+21I'C EN(8SN4
MD'[[#T/;\..?H+2/"-IX9T"YT/18%M;."RDAMH8U"J@V,%  &.,XZ8[#'-?R
M/?\ !7W]DG]HCXG:S'?> ;[68((;NYF?[)OQL+2$9P.F#QGGT]:DD_>K_AZ=
M^SY_T,NG?^!EK_C1_P /3OV?/^AET[_P,M?\:_R]_P!JY_VF_P!FOQ)9:!K_
M (CUN":[^X)YI4).2/4?C_,5\?ZI^U+\>M/52WBK5/FVXS/+W( _B]_?U]Z!
M75[=?^ G^I_L%?#G_@H5\%_B3KL6@Z%KMC<7DN-J)=0.QR0. K>O'XU]WZ3J
M=OJ]C#?6SAXIE#H00<@@'M]?Y5_G(_\ !$/X)_M)?$[7O"WQ@U+5M:N_#UZ(
MVR[2-"1N1NIR.F,#)K_0W^%&G7NE^"M&L[\LUS#:QI*S_>+!0#GUZ'_/4&>D
MU'-*L,;2,>%!/Y5)67K"NUA<!#AC&P&/4C]/K0!XC\4?VAO!7PKTZZU'Q#?0
M6T%JA>1I940*!GKN(QCW]*^0&_X*F?L^JS*?$FG J2"/MEMU!QW-?'__  4V
M^"'Q5^)WPX\467@BYOXKN>RG$)M2VX-M;IM'/X5_FY_M3_$3]HW]GWXQ:W\-
MM9\3ZO#?6,TA:.6:57 +OCC(QTXH _U2_P#AZ;^S[C/_  DFG8_Z_+7_ !I/
M^'IW[/G_ $,NG?\ @9:_XU_EG_LN^*OVDOVC?&,_A/0_$NLS742!F6&:5B.<
M=,D9Z_\ ZLY_76P_X)S_ +:M[:072:OXF*S('',QX(]A_GZ8I1?,K[%3CR-)
M]8Q:_P"WDOPU1_=W_P /3OV?/^AET[_P,M?\:4?\%3?V?3T\2:=_X&6O^-?P
MH'_@FW^VN,?\3;Q./JTQ_D*_(O\ ;-US]IC]D[QY%X+\1>(M;ANY(O-"322J
MQ!Q[KS^'&/K0W97M?R""4I6;LN_W/\GN?ZB>K_\ !4WX +I>H,GB33MXM)RF
M+VVSN\MMO1L]<=*_#W_@F;^W/XE_: _X*C?%SPI;:I+>>#[<W4FGJMR\T.T2
MRA=JCY!D 8P>OTX_SZ[7]L'XZZA/%9GQ1J@^T.L&#-+SYK;<?>[Y_3'U_M@_
MX-HOV1OB!H7Q5/[1/BA+R:#Q7HZRB[G4[9&E#-D,02>HZGW^E07-&3EHTKI=
MW=;?C_F:NG%<WOWY8<R];K3\;>I_;G\;WU&+X4>.I-)W?VBGAS5#:;,[_/\
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MS"BBB@ HHHH *YSQ?_R*WB#_ +!%]_Z3O71USGB__D5O$/\ V"+_ /\ 2=Z
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ML^M]=/-65GIW/]>W_AZ9^S\1G_A)-._\#+7_ !H'_!4W]GT]/$FG'_M\M?\
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MTK^2[_@CQ_P4F.O_ +0'QP\!?$C7#YR^-]0TS2(;J[W':+YXD5%E(^@ '?\
M+^KS]I(9^!?Q/'KX/UO_ -()Z_R$O!_QU\4? S_@H%XHUW3]4FL-(M?BI>7.
MH(DC(CPQ:M(S[R&48PIX/% '^R3I$UO=V%M>VQ!BNX8YD*X(*R*'!XXZ$?\
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MFM4U= .HHHI@%%%% %2^NXK"SN;R8A8K:%YG). %12QY/ X'?BOP+_X*%?\
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MN45&,&I7<DVUV>G^9_F0?%?]K_\ ;2^#5G<ZEXINM<M+>V'SM+<WL8 Y/)9
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M%Y_P<?\ _!0)/!_AWQ5^S5%<[KG7M/:-+57!9O,7;P@)8_>]._TK\(?V%/\
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M_P!>H*3BFD[7/\<O4&B75M5L@B@Z7?7-F5VCK!*R8[9Z9_F.*]X_8H_9J?\
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M!'YUY GP3\$)XZ;Q^NEP#7VQF\V)YO!S][;N_P#'A_2@#UR$8AB!ZB.,'\%
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M7B+QC8^-M1TR";6[ @V]TR*9(RIR,,5R/P->N1HL:+&HPJ*% ]@,"@!]%%%
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MZ++Q[?A7KY [9UE*[YE@O_4BG^:/(SNGSY9CY-74<%BKQZ/]S+<_S,]79_\
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M**Z3,**** "BBB@ KXI_;VE$/[/WBIR,XM9?0_\ +-_6OM:OBK]O6)9OV?\
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M4K?\_(?^E*_X'\WFL6C;M(N<_*=1LACMQ,O7_.?2O]=C_@BB<_L!?!7V\-V
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MWQ-;P",C<'$EP1C'.<_3\.@K^OW_ (.Q_BS8Z.GPRL=/O8Y6E::*9(W#%?\
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M^&:Y97VY7:^GY]=65/\ @DE^VGJ?[(_[2%IXAU#5[B'2IW@LXX))V$(\R3:
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MZ3M#D7J^U^MOG;3[CJQGM.;WOAN^6W\MHVO_ %O^'[O44459Q!1110 4444
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MMDLT0Y'?@_C7^5!_P4%>0_M:ZF 3Y?\ PD=O@=O^/S'T_P C'%?ZN'_!(?\
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MVA_ANF?E-J!^.!S_ )]*_G1_8MCC_P"&DO!8XV_:[;/I]]3^'///3O7]%/\
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M/SA_X-V/@[XSO?V__"/CZ'3YF\/#5[IS=;'V8:Y#9!V;>F#G=_.O]6FV!%O
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M KX2_P""D_\ R9K\;<_]"=JW_I))_/I7W;7PG_P4G4M^QK\;0.O_  ANK?\
MI))C]:&[:L%NNI_C@W05O&_C96(VGQ+JV<C/_+W+Q^9-?LK_ ,&^$<<?_!3+
MP+Y?W2Z]!@??3_ZU?C-JJO'XQ\< </\ \)'JI'?/^ES9],=>O&*_9#_@WA+_
M /#RKP+O/.X?J\8_4_E^M<:3^L*2?-'EMS?./ZJWR9WUX\\*4OABJ5UV;T5K
M[>?WZZ'^LQ;_ /'O!_UQB_\ 0%J:H;?_ (]X/^N,7_H"U-78< 4444 %%%%
M'A_[27_)"_BA_P!B?K?_ *0SU_C]?#-F7_@JA:!,_P#):'SCL/[<?G^7%?[
MW[20S\"_B>!W\'ZW_P"D$]?Y 7PP41?\%3K3S,?-\9Y",]1_Q.W_ ,X[_K4M
MKFBKV>NG?_ABDTHR5M7:S[6:?Z6^;/\ 8>^#8#?"OP,".&\,Z2"#SULH:_F<
M_P"#B']AKPYXK_9[\=_&C3-.@F\50PL8I5A!FX21N'"DCIVR/IFOZ9/@U_R2
MWP+_ -BUI/\ Z1PU\Y_M[?"9?C+\ _$G@U[;[4+V!P(MH?)V..A!]?2J)/\
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M0[6U2S_M&WEN"L:!-QD=6R1C_:[>_/6O/?\ @WKDCM_^"COP_:=PH\Q<NY
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MU_DZ?\$H+7;^U;X?NER6\V(8QG^->/7'^>M?ZQG[+!9O@]X6+#!.GV_&,?\
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MU(?!LWM[UDWZ_P!,_P!1S^UM._Y_(/\ OXG^-']K:=_S^0?]_$_QK_..M?\
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M5RA.2?H[\N^[\NMC_7F_X)-ZYIVO?LP>&KS39EGMVAC ="".(DSR,C///?\
M "OU'K^?+_@W%\2ZGXH_8)\(:CJDKS7#<%G))X5 !DD]O?IVK^@VO0332:VZ
M'*VV[O5L****8@HHHH **** "BBB@ HHHH **** "OP-_P"#C,*?^"=7Q)W?
M\\"!]?+D^E?OE7X$_P#!QOG_ (=T?$G'7R#_ .@/4S5XR5[:;AL?Y4.@6K26
M[D A/.E(QVQ(><_B./R]*^W?V4_B3\8/!>MW_P#PK&UO[BY:()*MD7+;>F3M
M!X]_QKY#\(>4^G",C]X9),D#/\3>H]_7V]:_JF_X-N_V<_ WQM^+GBZP\8:;
M!?006@=%FBC< YP>'5O<_KD5S4:[E-PE'E44E%O[35E?]?.]_764H^RC'[7,
MY-K6Z:V?FK:GP'+\>_VSG=F.D>(<DDG G.>3R?EZU1D^.'[94DJ2G1_$&5]I
M\_\ H!QS[_7-?Z/?_#M']G[_ *%C3_\ P&@_^-4?\.T?V?O^A8T__P !H/\
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M\?GV@^%]3(0Y'[B?M_VS[?KZU6UC]C/XV:!HM[K6J>'=1@M-/A>::1H9P$1
M2224 X SG_"O]@+_ (=H_L_?]"QI_P#X#0?_ !JOE3]MC_@FS\&+?]FGXHMX
M?\-V2:J/#6H_9&CM8-XE^SOMQMC#$YQTP>V:T6B2['.?S[_\&O'[%/A/Q_\
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MC_MT^!&D^]]I0<^F^, _B.:^'=:,9\:>,V ^4:]J);D<XN9/?]<=>,>GW?\
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M)*B.-V\\@,K#\?\ #%?Z(G@[_@F_\ ;[PYI=R_AJP+26T+$FUMSG*@]?+_\
MU^O<X\S=6-.UN2*D]-[VW[:^6^K?::K;J3;ES7G))WOHMOE;^K'^1S??L+_'
ML-$R^%]3.%!/[FX] /[GX9YJN/V&OCZ1YA\+ZF2N<_N9_H/^67^2,U_K[/\
M\$U/V?WQGPSI_'K:V_\ /ROT_P#K5&?^":7[/^TC_A&=/P0?^7:W/_M*NJ+2
M;;5]&OO)BU%MM7T:7J^O]7/\=GQ-^S7\4/AU<:;K/B;1;VSMH=1M-\DT<B*/
MWR]V0=.OU''.37^N+_P0_)/_  3_ /@SGMX>LQ],01U^&'_!?3]B#X:?"/\
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MNGH _P Y'_@Z>^"WC'Q'^U=X=\;6.FSS:%IVDJ;JZ5&,2 >622P0K@ 9Y/\
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MPC\=_P!K;XT?M#^-]4\ V^M7MYI>N:C/"+=9II5>.2?:!M\P@@ G QZ8K_0
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M $!:FJ&W_P"/>#_KC%_Z M35UGGA1110 4444 >(?M(DCX&?$_'7_A#];_\
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M$A)&(CSSQN3^O^' K^S3_@[HT35[SXI_#&_LK"XN+>VB+RRQQ.Z( 6R695(
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M'!8JR>VM&7XG^9KK$++XO\<1'.Y]?U/!(.>;J7]?3.,''%?=O_!(>!H/V[/
MJ,<G[2I]^9$_EC%?!VMW1/C/QM)C)37]2P?I=2X[=<YST_K7WA_P2,NFG_;K
M\"RXP?M*CZ_O$]1_GI7^T/B1&4O W,K_ !OARK=7TN\*TOG;RZ,_S X"JS7B
MM0<_AIYY33[_ ,>+5N_;[M#_ $<;3_CUM_\ KC'_ .@"K%4[!M]G;-_TQC_]
M 6KE?XDS34I)[J37XG^J-.2E"$EM**:^:"BBBI+"FNJNK(PRK A@>X/44ZB@
M#^)G_@[8\">'="^!WA'6]*TRWMM1O-9W3W,48620EDSN8#).3^/I7\&?P_\
M&2^#K[2=4F?$MO+#-&Y(RI0AAM)P<@CK[?A7^D'_ ,'/?PJN_B5\ ?#<-K9R
M71LKU[AA'$9"H0*W10>F._\ ^K_-9\?>%YK*ZN=.*/')I[O$RXPRLA8=,#'N
M#["N>M&G.5.,G[[=X+76UF_+;U+IVN^;:SOMY=]#_30_X-K?C7>?%WX%:[<W
M5[)>"PFC@3>^_8$!4 =L#@?R[U_4+7\57_!I+KNFZ/\  7QG8:AJ$$5W)J96
M&":5$E<Y88568,03QP#UK^TJTF$T>\$$'D$=,8!S^((Z>E:PDFE;M?Y+2_S#
MD?*YKX4[7\].GS/Q>_X+@_&A_@I^RKJWB1+HVI+-%O#!<[DP1DD=OU_7_/?_
M &2/@?J/[?\ ^U*]WHJ/>7.G>(;;5IY(MS.5BNTD))0-Q\ISD'GWK^SO_@Z.
M\3Z8/V'M6TRVU* :BMT ;=)T\[ITV!M_Y#MZ5_.Q_P &CWAZ\G_:8\7W>JZ?
M));OI[M%+/$S(3N)!5F7'N,&J:O;R=Q1DXJ:7VU9^FFWW'^AU^S#X)G^'?P/
M^'W@^Y4K-H?A[3[&16R"&@MTC.0>>JGT^GK[]3(XTB18XU"(HPJC@ >P[4^F
M2%%%% !1110!_G/_ /!VT0W[0?PXC/5K5>?J1R?H:_G'_8OMF3]I#P9$/O-=
M6_'OYB$?7IWY/%?T7?\ !W!)Y7[0_P -7_NV@/\ 7^E?SF?L77ID_:-\&SD'
M*W=N!R>TB@?J:PE35W+JYQ_%QV^7ZG=AYNFFH[2I2F_\2Y4MWU\O3L?ZT7_!
M.*(Q?LW^%%)R1:Q<_P#;)#^/6OONO@/_ ()P3FX_9N\)R$8)M8O_ $5'7WY6
MZT278XG)S;D]Y:OYA1110(AN/^/>?_KC+_Z U?Y.'_!P4WV?_@I9\09G^[O;
MZ</+G'3_ #BO]8^X_P"/>?\ ZXR_^@-7^3+_ ,'"\GF?\%)_B#$,CYV/YR2^
MF,_3O].B;LKOH-1<FHQWDTEMN_4[G_@WX>2#]K'5+M6(26!,<\8+G/\ ^KV]
M\U_J5_#1S)X+T)SWL8?_ $ 5_EF?\&^LOG_M4ZC;'@1P1XYSSO/UX'/IZ8K_
M %,OADNSP5H2CH+&#'TV#I[>E8QY?;S:^)PBWZ:6\^WZ]#248QA%?;YIJ2[6
MLEZ77WZ?+O:***W,C\/?^"['PCE^+'[).J:#9V[2W$E_;.-@);"OGMSC\_UK
MZ2_X)->!KCX>_L:_#'PU<HT<MAI$$;*P(((1<CGGM_.OK7]H/X6P?%?P7+X=
MGA6=))$<JZAA\I]#QW_^M73?!OP-%\/? ^E>&HHQ$EC"L:HJA0 HQT''']?P
MH ]5HHHH ***"< GT&: /RU_X*H_L^GX^_ G4=$%K]J-C;75WLVEL>7$6S@
MX/RC_'C%?Y+O[1GAF3P5\<?B7X2="@TC6+^T$>#A#'*RXP3P< <=SUK_ &G?
MBB(KCP)XPBFC614T'4R-P!Y^RRC."/7^6?2O\;K]NR-)_P!LWX^QJ JQ^+M9
M*J!Z7,F../Y?I66(<J7+?X6DY=TG;7SW7?N=%&U*M!SV<;_*2TO\_O/ZZ/\
M@T9NET[P?\3(68*9[[@$\\MVSCU_K7]SMH#'"SDY^4O^&,]_I7^<]_P;/?&V
MW\ ZQK?AR>[2W;5M9AA2-Y ADWR*,!203GI[\5_HD6FIQOI%M<NX5)K!9-Y8
M8P\.<DGCOZD8_"M%6BHQ@OAJ7:?^'EO?3]?O(BY2C."2=VY_<UY7VW_(_C#_
M .#D_P#;ZT'_ (5_XP_9E-U"=2N72+R-R>82Y:/IG=U/;I7BO_!LE^P1KG@#
MQ;I?[0\]K,FG^(M++QRD/L82AGX)&WHW7/T&*_%/_@Y!^W:K_P %"];AT^>6
MZB:]M@(86+J3]H!/RJ2/7C'U[5_>W_P0GT6&P_8#^$4DMDD%X=$M-[&,+)GR
M4R"2 W?Z?K0G>_D[$2BXVNOB2DO1G[.*BKR  <<G\!_A]:?113)/SF_X*F_#
MRX^)_P"QY\4?"-JC23:EH=W"J)DL2T3=,#/IWZU_D7?M _"*^^"OQ(UGP9>Q
MR0RQWMS+L8$$;I7()# 'Z>XS7^U1\3_"L7C+P?JVA31K+'>6TD;(PR#E3U!R
M#]*_R@/^"[/@F'X=_MW>(O#MO$L,>';8BA5!9V.<  9Z\\9XS6<W).ZV2_&Z
M^[;KUMYG7AH49^[4OS.22]-/GOI8^Z_^#6_QOXFN/VSKSP_=:I<OI,&G,(K1
MY6,2X+=$)QUZ]?UK_354@JI!R,#D?2O\IK_@WC^(EM\-/VR+C5;NZCM(Y[=8
MEDE=8U.]F4 %B .P_/M7^IEX$\01>)/"NDZS#*LT=]:Q3*ZL&4JR@Y##(/'X
M=QW%2ZT8PYF]DK^KLNE[;F=6A*DW=:-M1\TFE^I_'+_P=)_'>_\ AOIOASPY
M;7\EJFN:=<V[QI)M$@>-EP1QG/X^M?@__P $ _V#?$/QE^.GA?\ :"M[:>:R
M\/>*DN9IP'91B<R$DJ,<X/)/\J_0?_@\4GD'BWX5K [$F.0[4)YX/8?Y_&OT
M;_X-)-,AE_95\37%Y9)YZZQE))8AO'+8(++GM[_G6J::36S5S _K/TK2)K9]
M,SD+;65O$03D I&B_AROY?A7>#@ >@% 51C ' P*6A*U_-W+E-S44_LQ45Z(
M****9 4444 %%%% !1110 5SGB__ )%;Q#_V"+__ -)WKHZYSQ?_ ,BMXA_[
M!%__ .D[T ?XVW_!2BW>;]O[X][3@+XOU5N/07!X_3BO,?V8\2_M4? Y$ZIX
MST4-@CG%[#GO]<^O3U->H_\ !2:Z-O\ M_?'S'\7B_5%[][D]@.V37EW[,0\
MC]JCX(.,9D\9Z*2.>-U[#[]_7US]:\Z/+];]YN]ER_-13Z^2_+>QTS4?9U&_
MCY::AV^S>]O+=?J?[+_P'X^#_P /1Z>%M'Z]?^/&#K7K=>2? @Y^$'P]/KX6
MT<_G8P5ZW7HG,%%%% !1110 4444 <[XMU==!\-:UK#G":=I]S=L3V6&)G)_
M)?\ /6O\R_\ X.$OVPM)_:F\<#P587,=Q-X*U6]LI51E8J89'C((4D_AU_.O
M])+X\ZC:6'PE\>-<W$=N6\,ZL$+NJ9/V.7IDCG_(K_&H_:\UJZD_:J^-:K/)
M="3QAK(@3<9 Q-W*%"#/?C& 2>V*YL2G./LHZSDU;Y2B_P OT*C925]KJY^Z
M_P#P0S_X*3>&_P!ACX<>)_#NM7L-M)J%V9569HU)^]T#$'GOG'K7[_K_ ,'%
M7P^:$R?VO9<?[<'?_@6,^GK^!K_-UU32/B)<2XL-,UF**0Y4PV]T%8')S\J8
M/7J..XS6/-X<^*L2F 6.O8/_ $QO.G//"^P_(8KHC"2Y8R2YTDOOV_,NK&*J
MRC#X;I1^:7ZG^DU_Q$8?#W:&_MBQS_OV_3_OKZ&O-?BG_P %_/A;X\\%Z]H-
M[?:==&^TR\MHE<V[8>:!T4C+\8+"O\Z6'PK\5))/+^PZ_P#]^;OCCH?DQ_/_
M !9'X7^*:7(W6&OE4<'!@NSGU&-GOQ_A3492;BTF[V^7GZ;"E#WE".KLD_\
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M7_H"U-7:<04444 %%%% 'B'[2(S\#/B>/^I/UOZ_\>$_3W]*_P @/X:GR/\
M@J?9;NK?&AR.@_YCC\^_X9K_ %_?VD3M^!GQ//IX/UO_ -()Z_Q]OA]*9?\
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M(V5E8$ Y!4D$<]J^1/V^#C]D_P",Q'_0EZU_Z0S5J8K=7VZG^3Y_P3HD"_\
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MM% [@J0IQR..X([U_E?OLM_$WB+1,@6UKJ][;?[.V*=T'Y8STR /0U_LK?\
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M\Z=10 4444 %?%/[>SLG[/WBIESD6DQP/^N;?X_3UK[6KXL_;R9%^ 'BHOC
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ME)-G\Y.L01>7H\V1YG]I68QW(\]>/Q_F!CI7^NA_P10.?V O@J3_ -"W8_\
MHA/Y5_D1ZP)_.T@Y/E?VC98'H?.3I_GZ<]/]=W_@BEC_ (8"^"N/^A;L,_7R
M$_R??-*&T%;["U^2T'6^.H[V7M)>[VVU_3Y'ZU44459B%%%% !1110!\!_\
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M]*:?^"!/P9+E_P"Q],R?^G<_A_RSK^DRBG=WO?7^OZL',[WN[[W/\SK_ (.
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M?[)7Q7T'XG_"'PC=Z)/'-'9:#IEO*8Y%<*Z6D0()7O\ +_\ KKZDII62796
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MRR>_^M3_ #[_ ("O]=#_ ((HC'[ 7P5'_4MV/X_N$_R?>O\ (JUBT&-(N?\
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M]$E?SO?\&U3[_P#@GOX)/'U'0_(@_I7]$-:PORQOO9&333:>Z"BBBJ$%%%%
M!1110 5_F<?\'7L@'[:WA),<G24Q^!C_ "_PK_3'K_,L_P"#L,[/VVO"+?\
M4)4\''0Q\?\ U_TXK.I%2C9]U^:_6QK1O[2#_EDI/IHFOZ]#\D/^"9DD<O[5
M/A.UP/,,T.#W_P!8G?\ /BO]9?\ 8WA,/P0\*KZ640]#_JT/3'%?Y,'_  3%
MCV_M6>$KP]IXL^OWXS[9P/UX]Z_UH?V.IA-\$O"S#O9Q'/TC05G"<I3M'X(+
MEEY235UO?;5?+N35:E4G);2DY+TV_0^J:***Z"#\W?\ @I;^S'H_[0G[.7Q
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M'UY(X_STK^<']BZVV?M)>"[7/WKJW].I=#G/X#GUZ5SWO4<'HW-2CYQC9O\
M-G13FXMN6B=&<8_]O6^?]6/]:C_@G)*DW[.'A1T&%^S1>F/]6GY5]\U\"?\
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M^"7S?5;'^LS;_P#'O!_UQB_] 6IJAM_^/>#_ *XQ?^@+4U=AYX4444 %%%%
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M3GD#!'(]*_KZ_P""'/Q377/V/_VJM/UG5=TEOX+U.&%+FXRS$63+A0[Y/3'
MZ_6LJ3DE*_PK9]=-_NM^3ZG1B]:Z:24G"F]%I=I-[:;G\^__  3L8_\ #U+P
M<,\'XJS\=N-5EY_K^?K7^QCX2_Y%C0?^P59?^B$K_'1_X)W1[?\ @JAX+<'*
MO\4YF4CD$'5)3D$=NF/J/I7^Q=X2_P"18T'_ +!5E_Z(2KAL_7]$1733BGOR
MZG0T4459@%?YMO\ P=JG_C*3X?CO]B7_ -D.?TQ^5?Z25?YNW_!VG &_:B\
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MU<K;1[V( !')( YS_G\JM5\O?M5_$]_A7\/)_$*.8RDJ)D,5Y9L=1]?TYX-
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ME>WTLL3PL)5V^>^3E,KT- ']^G[*/@VU\!? OP'X6LU5;?2M%L[:-5X 6.(
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M3V_3_'%<O-S>W;@[KW;=6HM6MY?A\CJ<H>QP]5Q]Y2Y9W^TU%7?3JM5O^O\
MJ(?#[CPEHP_Z<X?_ $ 5VE<5\/,GPCHI/4V4&?KY:UVM=<?ACI;W5IVTV.)Z
MMONV%%%%4(**** &O]UO]T_R-?Y@'_!TA,5_;QTU#T^P+_-<#WZ?GUXYK_3_
M '^XW^ZW\C7^7Q_P=*Y_X;PTW'7^SU_]"'ZXJ9_"_E^:-:/\2+_D:G;ORM-)
M'\X6L7;F31X.=HU*S(]/]<AZ?CZ $<')Z?Z[G_!%(8_8"^"OOX;L#_Y 3_\
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MI_H3_P#!MS^PQX8TGX*^!OVBX[2W&KZE;;WF" 2'>%<Y;;GJW S_ #K^P8#
M ] !^5?B+_P0)\(:EX*_8$^&^BZI$T5S!9QAD=2I'[N+'!Y'I^'XU^W=>@<[
MO=WWZA1110(**** "BBH+F=+:"2=SA8U+'/' &?Z4 ?YS?\ P=PN4_:%^&S+
MU%H.G]?_ *^/K7\XO[%TLK?M&^#)CD.+N  $#/$B8/\ /IS[&OZ(?^#KW7+/
MQ!^T/\/7M9%=+> +)@JW0@$<=_ZU_/M^QA#$W[2'@ITQY0NK?..GWX_Y=_H1
MR>F#E3<E+F7-S**UZ.UU:^E^C\^QTTI0F^66BC2FE_BTU6^KM_5S_6/_ .";
MTKR_LV^%'?.3:Q=?^N25]_5\$_\ !.<1K^SEX5$>-HMHNG_7-/\ /I7WM6YR
MK9>B_K0****!D-Q_Q[S_ /7&7_T!J_R8?^#A64O_ ,%*_B#&<X#MSQU$DOZ<
M_B:_UGKC_CWG_P"N,O\ Z U?Y+W_  <*1/)_P4M^((0'.X]..LLO^.:B:3MW
MOH^S_KY_B:4K*5Y*ZBFVO1H[?_@WQ1[K]JW4X"IV) N/3&\D?_6P1QTK_4T^
M&B>7X+T)/2Q@X]/W8XK_ "F?^"'7Q3\,?"3]I>;4?$=Q%;+>^1;(9'6/+O)M
M !;@9+#/4Y_3_5/^"^O6?B;X;^%]:L'62TOM,M9X64@@I)$K*003G@UE0BVY
M5%=1;E'E_O)J\OG]Q,W[[TM?5;[:6[?E^AZG111702%?/_QZ^*>C_##1["_U
M>^BLHKJZ2!'D<("S$ #DC.21U_QKZ K^?_\ X+T:S\0M'^$'@&3P"URMX_BO
M3Q<?9S("83<PA@?+YQC/!Z^W% TFW9:MG[J>"-=M_$GAK2]8M)5FM[VVCFCD
M4A@RNN001P<BNLKY._8AN-7NOV9_A9/KN_\ M23PSIS7?F%B_FFW0L6W?-G/
MKSZU]8T""BBB@!K'"G'^>:_+C_@I3^S7I'QY^"_C*[U:WCF/AWP[JU[ 9%5B
MK0V<SKMR..A_$=*_4DC((]:^?_VG8D7X!_%=NY\&:YG&,_\ (.N,?3/IWXJ)
MM)QUMN[=7;^K?/U+C)*,TU=R22?9II_I^?D?XN_Q+A_LWXN?$C1%&$TGQ-JM
MG$HX 6WO9D&/P  _ES5/P;I%_P",_%.F^%+2%[BXO[B&-(5!9F)= >.X_P ,
MYQ6[\: I_:&^+6W[O_";:[NQTV_VC<>X'7U.<>]?5O\ P32\(Z7XY_;Q^$/A
M?48TFL-0UJRCF1U#*P,J [E8 '/((]JRC.\E%K^(F[]G'E2]4^GW]S5U)<M%
MJ+4:?NMZVE=IOMNO\S_1^_X(&_#K4/AM^Q7X6T+4K1[.X15<Q2*5;YD0@XX]
M2/3&/2OW,KQGX%_#+0_A;X!T3P_H-O';V<=A;,J1HL:Y:)#PJ]/\_A[-6ZT2
M79(QFU*3:5DW=+L%%%%,D*R]<56TC4@P##[%<\$9_P"635J5GZK&TNF7\:\L
M]I.H'NT; 4 ?Y"W_  61AB;_ (*1_&%6"J%U6Z(Q@ 8ED[?C]<XYK\Z;/5[G
M3TU&*(LJ212(NTD9!5@!C.3].1C]?V4_X+K_ +./COP1^V5\2_BS?V5Q#X?U
M36+CR+EH9%C8/*V,.V%/![=C^?XU:2;;5;K2;"+:UQJEQ!;(!R6:9Q&!CJ3E
MAC'TSS6%>C&M!Q:UTL^JU5_O2M_5BE.5HQ<O=4KI=$VTOZ?3Y7/[;?\ @T,@
MF.E?%N6YB^_>EE9U!SE@<@GUS^/7IP/[HZ_DL_X-G?V<_$7P9\#^*=6UBQDM
M8?$,-O>6[21/&'25$<,"PY)!SD?SK^M.M()1BDE:RM\UH_R'4CR2:3OHG]ZO
M;Y!1115D!1110 4444 %%%% !1110 5SOB[_ )%?Q /^H3??^B'KHJYSQ?\
M\BMX@_[!%]_Z3O0!_C?_ /!2V1H/V^?CT8Q][Q=J8;')PUPV>_;O_C7BW[+#
M-'^U9\$V7J_C712W'K?19_#//_U^:]K_ ."CS)+^WY\?Q*>$\6ZJ<Y''^D-^
MG!X]<'->)_LGSQR_M8?!M2?N>-=&"_A>P_T)]_QKFI:3E&WO+64K;I[*^NUN
M_?YZKW:<KP;Y[<LK:*S5]>GZ^2W_ -G+X#_\D?\ AY_V*VC_ /I#!7K=>2?
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M['K_ % ?\&TKO+^P+X9F<$&:XEEY'7>5;/Z_XTQ']%U%%-=UC5G=@JJ"68G
M ')))H =7^9O_P '8$#/^VEX4=3P-)4]1U)3&/?\LCOTQ_I%>)?'GA[1]*OK
MIM6LU>VC=B#<1 @H"2,;O48^M?YDO_!S#\1[+QY^V!X?N;2ZBN4AL/*WQN'
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MZ?\ @[+\.7D_[1?@G4+6TE:W@L TDD<1*   \LJD>N>A[^U?DK_P0FL+R_\
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M03_2OXDO^#E#]MCPOXP^'7BG]G2VN[9]8L+@EH5<-(,;E/&3P".N/UK^J?\
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MY(UC.4I4(VTA-*_DY*]_Z?;0_E4\0Q.=)AD'W!+ #_WTO!Y[X/Z\>O\ JO\
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M!$JG(9LYXZ=OI0!_H1?:(/\ GM'_ -]C_&D:Z@56;SH_E4G[X[#/K7\&S?\
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M7=>H'Y>_\%#?V _#'[9VAZ/I6L6%M*FF2%U#HF.?3*__ *^F:_@A_P""VO\
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M5^EWP<^%>A_![P5IO@OP_!%;Z=IL0B@CBC6-0J@#A5X'05)FE;U=K]=E8]5
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MMT7P]KT$NHP[&\N&4$ Y/\+# '/&/J*_TFO^'.'[/?\ T+^F?^ %M_C4S?\
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M$Q4?,#W^O;CT_AY_X)H_LM>*?@!_P4;^*/ARWT*YM]#TW5IK>UF6$K"46X8
MJPPN,8QV/UXK_1PN85N+>:!P"LT3QL",@AU*GC\:^*/#O[$WPX\/_$_6?B;:
MZ=:IK.L3O/<3+;1!V9FW'+_>)SSD^U 'U/\ #Q'3PAHBR JXL8-P/4'RQ7;5
M3L+..PM(+2( )"BHH Q@*, <>E7* "BBB@ KR3XZZ]>^&/A/XXUW3E=KW3=
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MG)3>\4TOG:_Y(#^-C3O^"P/[5-K;V=H-(\2 0110 ^5<=$4+_>'&!BOZ.?\
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MTS^/TK^&W]OKXF_'_P#;$\<:3XNUKPUKES/IT>Q&EMY20!CNQZ9&??WQBO\
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M_O<].>/6O]</_ASC^SX>/^$?TS_P MO\:</^".?[/HP1H&F<=/\ B7VW^/\
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MM=_X)$? /7=7U'5[K0=->?4;J:ZE9K"V+%YG+L<DYSDFHE!.496]Z.S\GO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M0\ GT!KY?_; ?'[._P 3SSD>&-4X/4G[+)R/7K7U#7RW^V'_ ,F]_$P#E?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^'S@O%RA%2;_ .%RDX^:]O!7?W_F?Z.5I_QZV_\ UQC_ /0!5BJ]I_QZV_\
MUQC_ /0!5BO\3I;OU?YG^JL=EZ+\@HHHI#"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJLK/JUA&KK;9/[_-:?Y<^'G(_%O#R2L_[<IJ-]U'ZQ!OSMH?Z-%I_P >MO\
M]<8__0!5BJ]I_P >MO\ ]<8__0!5BO\ $^6[]7^9_JO'9>B_(****0PHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "OF/]L4$_LZ?$_&<_\ ",:GT_Z]9:^G*^9OVP6"?L[?$YCT
M_P"$8U/_ -)9:]7(E?.LI7?,<&OOQ%,\[-],JS%VO_L6)T[_ +F>A_F5:D)%
M\<>-?,SN/B#4L=?^?N3.,]OZ=AG%??\ _P $D"?^&[_ @/\ S\*0/3]XG?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *YGQBA?PYJBCJ;:3_ - ;_/6NFKF/&+E/
M#FJ,.HMI/_0&KKP%_KV#MO\ 6:%O7VD;?B<68V^H8R^WU:K?TY&?P ?\%P;<
MQ?&JPA)^9U8@]^9 1SV^F>_%?T4_\$#8&@_92TU&/_+QGG/H/_U#U-?SL?\
M!;^X,WQMTZ9N-B,,'N!(!Z8_Q]AS7]$__!!6=I/V4].?_IO^/08^G7/K^=?V
M+XL7?A;E$9?Q/;85RVW4?SO^%C^0O#U37'5>HU:E"%;E2U=O:1;]/+_@'[]I
M]T?C_,TZH8&W1@]R ?S_ /U5-7\8R5I->9_8U)J5*FUHG"-O2RL%%%%2:!11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6-X@M
M3>:1?6PY,L+J!]5([ GO6S5>X/R%?4?G_D UK0G*G6I3CI*%2$X^L9)K\CGQ
M:C+#5H2^&=.4'_V\FOU/X!_^"^6CMX8^..D)(I42PEQQQAG7U _SW-?T!?\
M! 8BY_9+TRX'07!_]!'?J<^_3IQFOPY_X./H0?CYX9084-9+G _VDSG'7KP?
M_P!=?N7_ ,$ (Q#^R-ID0Y G]NF%_P .G_ZJ_IWC7,:N.\(LEQ%76M5KX9MW
M^RE.-_P3U]#^;>#<!A\+Q_FN$M:%!U'3_P 7N26W5M_YG[[(<J/\^_\ 6GTU
M1@#WY_/_ .M3J_EYZM^K/Z7IIJ$$]U%+[D%%%%(L**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?Q^?\%J5TYOVLOA
M^E_"DL;+#N5UW C<A_+/-?O%_P $U(--C^!NFC3(8X;<I'\D8P"0HR>/I^OT
MK\6/^"R'P^O_ !)^TUX(O[:VEE2&.+YTC8@'<O\ $!QZD]NG/?\ ;'_@FSH\
M^B_ ZPM9T='4)PX()X[Y]O\ /%?I.<XQU.#,GH2DVZ<8**3V7,TV[==>NOWG
MP&7X2;XKS"O.-H^]&#TUBU!I;===->NA^B]%%%?FQ]^%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %(QP":6FO]T_A_,4UJUZHF7PO^NI\1_';]E;1?C%XNL/$M_;PR2V6
MT*9%4G@YXR./J.GX@#Z(^$OP[M?AQX=BT2U14CBZ!0 .V*]/@Z-]1_*IZZJV
M+KU*4,/.;=*EI"+V6ST.3#4*:M744JLU[TNKNE^2T[]V%%%%<AVA1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
B1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>ny20077604x1_figure01x1.jpg
<TEXT>
begin 644 ny20077604x1_figure01x1.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:AHNHVOCN]\,64GBO5/'7B#Q-.-$TCX4>#M-LO!=OHL=K?:+!8C4M0AU+4]
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MMXCTC2W@LX=*5Y?!>@)!K=R-0U>2TM_%NG&__LPVUE:_;?[8_P"QKXF_:?\
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MU%XVTKX-?"?6_A=^RE^TAJGPP\;:I=>)?$6C^)=>\%3>/!X#\-VWA[2EEU2
M>+A?>3=^(/$5[+'HD,.J6":7X4O#;ZG):>F_"K_@FW\1O 'Q"_9H\<:I^T=X
M6OM/_9B2\TKPIX0\-?L^:/X3T[6_#^L:?_9'B>76-3LO'TEW-XR\6:<676?%
MNH6VKS->QV^HBQFOA>W-_P!;X@_X)P_V[\*_VS_AG_PN3[+_ ,->?&F'XO\
M]M_\*\\__A7OE?$FP^(7_"/?V;_PG,/_  EF[[%_9']K?;_#6/-^W_V8=GV)
M_&JXKPXIYE1J1IY?7PDZ.44,5"&&S[V$&N(*U/-,51A*CAZU.HN'9TJL8Q=5
M*O!Q@\7BXNK7]&%'BV>#J1E+%4Z\9XZK1E*MEOM))Y72G@Z-1JI5IR@\UC4@
MV^1NG.\E0H-0IP?!/]N#XR^)_P!I[P+\#?C/\'_"_@'1/CM\*&^,7P8F\/\
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MQ.><%YA4Q*Q6,R^O&.>5\P]KC\NS*5?,(SR' 8>">+P66X?FH0S*&.A'$8S
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M>HZ[:Z58:IX#TG5-2U)K#2-)DUOPYHNHSZHGB$ZMXDO9X;0Z386]]<:9]N_
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M8/ 3R^G+!0FFZF(498.-#IE#BWV<E+^T'4YJKKRH5\DC&59?6OJCR^-:/[O
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MZ7"J?U/&6^K4^&H5/8^U6&4?:/B&=3"*3FZ*A3=?G5"<:K\E<.YTLX5?V/\
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MGB8XMSE3<LLIUG2^J46HU*\<1.A[)XQ5G"7LZK49.-7#RHJDE^Q:DE02I4D
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M5%'_  K#X9?]!3Q'_P!_8?\ Y44?\0GXF_Z"<B_\.M/_ .5A_KUDW_/C-?\
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M^_L/_P J*/\ A6'PR_Z"GB/_ +^P_P#RHI?\0GXF_P"@G(O_  ZT_P#Y6/\
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MLF_Y\9K_ .&^IY?WO/\ !]CYBHKZ=_X5A\,O^@IXC_[^P_\ RHH_X5A\,O\
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M=_X5A\,O^@IXC_[^P_\ RHH_X5A\,O\ H*>(_P#O[#_\J*/^(3\3?]!.1?\
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MC-?_  WU/+^]Y_@^Q\Q45]._\*P^&7_04\1_]_8?_E11_P *P^&7_04\1_\
M?V'_ .5%'_$)^)O^@G(O_#K3_P#E8?Z]9-_SXS7_ ,-]3R_O>?X/L?,5%?3O
M_"L/AE_T%/$?_?V'_P"5%'_"L/AE_P!!3Q'_ -_8?_E11_Q"?B;_ *"<B_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ML;9M0U[Q!?76I:C+:Z?:6MG ;F[F>"SMK>WC*P0QHOM'[7VK_'BV^!'BR?\
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M)'QH^"OPI\>_'KP+^V]^U1XM^//PZ\+Z_P#%.ZMOB+XZL-:^!GQ"U3PM9_\
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METE&\?\ P\^%>NMI=Q);>.?$$'V?2+>2SN_%6G^'[*_LKFXY[PQ_P4B&M_\
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MS7>_".U\0?#ZU^)?@#QEX9\01?'77;;PM\.-0L?BS%<:!X6T/3CKTY'C2_\
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M>W.FZMI&K:;\/_$-[IVJ:7J-E+!>:?J.GWD$-W97MI-#<VMS#%/!+'+&CC\
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MU"BBB@ HHHH **** "BBB@!5ZCZC^=)2KU'U'\Z2@ K\\?VMO^3L_P#@FO\
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M)M<TKXBZ]'X:M_$7C>5="\5ZCH&EW7B^75-2\'Z=<-9^%_[%2VMX(?MS5?\
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M-;X7>#[CP+H4_P 7?C]XO^"GPO\ B"?B?\/?V=O%WC#PU??"?PWXJM[Z;5=
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MP3X"T2'P7X,T,^(-,LO#?]JFXLK[2(5TK4[RTT >(O$=WX@M?WD^#'PB\$_
M3X5^!?@[\.;"73O!?P]\/VGA[0H+F5+B^FAM]\MUJ.IW,4-O'=ZOJ]_-=ZMJ
M]XEO MWJ=[=W*PQ"7RU^;?V;/V!O@]^RWXG\&^*_A_XD^)6L:CX(^ MW^SOI
M,/C'6/"^H65QX*O/B]XE^-,NJ:C'HG@WP]/+XI7Q3XIU"PCO;:YM-)&@0V=J
MVB-J,<^JW&=*OAZ=/&+E4I3J0EAO:4HS24%75Y1DI03M.%XM23U3ND7.E5G+
M#OF:482C6Y9RBVVZ+T<7&37NSU33U\SI?V&/C5X[^/W[-7@[X@_%"/P\OQ$C
M\0?$GP3XPG\)V5WIWAO4=7^''Q*\6> AJ^DV5]>7MW;Q:Q8^'K/4[N*22&--
M1NKU;2SLK(6UK%^='[7W[-OP#>+XB_LH_!3X8>'OC'^V5^USXZ\2?&/5?'/C
MO3M&UW7_ ("Z!XB\2Z;=>(OB]XK^(6FZ7IWB#X>^ ?!$!DTCX6>&[&YEO-4U
MN\@T+2]*\2KJ.JZ=JGZV? 7X'>$_V=_AY%\-/!6H>(M4T*'Q3XZ\6K=^*;O3
M;W5CJ7Q \9:YXXUF!I])TC1+,V-MJVOWEOID8L!/#IT5M%=7-[<I+=S?'OAG
M_@FQI/@GQ#\1?%'@O]L/]M+PGK/Q8\::E\0/'UWH?C?X+6\OB'Q1J9"RWEU+
M+\!9YQ:V< 6TTG3$F73M(M ;?3;6VCDE#NC6I4\37JPJNC#VG/0@HS4)6J.5
M-3]FFU3IZ2]G]NRC=:M*I3G.E2A*"G+D4:DFXN4;Q49N/-:+G+5<WV=6DW9'
M+CX8^!?C1_P4'\>>!/CMX<T?XK:5\%/V._A3I?P^T3XF:%IOBW2-5G^)'C#Q
MM#\3?B;:Z1J-I/H&D^)]:_X1KP[X2UC4+6PAU"[LK,VUI/!8)<6[^#_"+X>_
MLU:+^S;X8^,_[5,DEW\)_P!B'XR?MC_#_P"$'AWQSJ.F^.?!FK^$/^%O^)/
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M&C7OB'Q;\+=9\1?"2PU;08I=1\1VFF>(O&FD:AXPTG3++2='T?P]J%[<VG]
M-%:PQV(@VTXMM4XMM/54U.,>;EDN:ZG*ZE=-M224HQDLYX6E.U^9).3236G,
MXMVNG;X(V:L[7C?E;3^1?@Q\ _&/PZ_:E_;/^-^MZEX:NO"G[1>H_ "[\$Z?
MI5YJD_B'2X_A5\*%\"^(5\4VEWHUCIMB]YJX-QHPTG5M<6XT[]]?-IUS_H=>
M#_$G]G?]JWPSXP_:BL_V;KGX#3?#O]K2&VUS6[[XG:KXPT+Q-\(OB/J/@;2O
MAKXT\1Z+HOACP;XBTSX@Z/K7AGP[I6N:=IVJ:SX<N;?QK=73WSS:+'.NI?IE
M16:Q-13YVH2;ITJ3C*-XN-"-.-*ZNM8^R@[W]YIJ2<92B[=&+CRIRC:<YIQ=
MI*51S<[.ST?/);:)JUFDU^%L?_!,CXB^$_$'P"\8CX8?LD_M%2^%OV4_AQ^S
M_P#%WX>_'2[\0P>'X_&WPYMEM=%^)/PP\6M\)_&VHVUN+:5]*U6PO_"^COJ6
MBV:,VGOJMW;7.BLU+X53?L->*/V.?$D'Q!_9/^'_ ,<]0T'X\^&?'.C^+?#L
MO[/7[.7Q+TCQ9?\ @/Q7XA\/>&/B%X$\!:EIO@#Q-X"?0O"EAX*O?&?A2XUC
MXEZ?%J5Q<G^T;6YT=OW5K)UO0-"\3:?+I'B31=)\0:5.R/-IFMZ;9ZKI\SQ-
MNB>6ROX;BVD:-OF1GB)1N5(/-;K,*LG%5DIP2DI15HN<90J047S*<5&*J/X8
MQE)**YU*-.<,OJE.-W3;C*\6F]4FI4Y-Z<K;?LUO)I-RM&TI1E^"/PC^ _QI
M_:__ &.OV^_#MOK_ ,,;CQ7^T%^V9;>,/!_Q#TVY\36?P1\6Z3\._%WP0U'Q
M!JWP^\01Z!K&N^)/ MM-\//$GA#PIXNMM&O;7Q1J>C"Z>Z2":[OK?["_:A_9
M ^)?Q3_:0M_C+:?#_P" O[1O@F/X3Z9X)\+_  K_ &D_&WCC1/!?PL^(-EKG
MB"\N/']CX)\.^ ?''@SX@:+K.EZO!%K^F>*-*C\6MJ%A9+H7BC2M-MX;:W_3
M^**."..&&-(8842***)%CCBCC4)'''&@"HB* J(H"JH    %/I/'U>=RA&,(
MWFXPU]U5(4:<ESQ<)+W</35XN/VE;EDXC6%@H*,FY.T$Y.VKA*I--QES+XJD
MM^;H[\R3/QI^!W[#'[37[,WA7X"^(_A]?? /QA\7/@GJ_P"T+X+U_2-4U7Q3
MX-\#?%/X(?&_Q_;_ !)MFM-6TKX>:KJ/PU\<>&/$>E:4=+\-VF@>*_"EE:W6
MLQ)X@NX9(;9X=5_X)Y?'KXF_LT_M;> ?B[XK^"W_  N;X]_M%:;^T?X)O_#4
M?B76?A?X<\0:1IOP^-AX5\2:=XD\+07]_H"2>%M8\(W;S:1XA.H>';VVUZ]L
M[C4Y[G18/V<HI?7Z_/[3]VJG.JGM%!<UXUG72[<OM6Y<MM4^5^ZHI'U6E;E]
M]Q47#E<M+.FJ5]K\W)%*]]&N9>\VW^,6D_\ !//Q_KNB_&NYOO@O^Q-^S[K/
MBO\ 96^*?P5\!Z!\#/#2ZDM]\5_B9X1\2>$M2^)/BKXF:G\'O#/C?P9X0CT[
M5(]+L_!7A6+Q-,=*U/4;O6=0U>]LX+"[_4GX%>!M6^&/P1^#GPUU^XTZ[UWX
M>?"OX>^!M:N](FN;C2;K5O"?A'2- U&XTN>]M-/O)].GO-/FELIKNPLKF2V:
M)Y[2VE9X4]4HK*MB:M>*C-KE4N9)7T?+R_%)RDUU]Z3=WO:R6E.C"F[QO=II
MWMK=WV226RTBDO*]V%%%%<YJ%*>OX+_(4E*>OX+_ "% "5\:_P#!03]G?QK^
MU=^R)\6_@%\.]4\+:-XQ\>_\(%_8^I>-+W5M.\-6W_"+?$[P7XTU#^TKS0]$
M\1ZI#YVE^'+ZWL_LNC7GF:A+:Q3_ &>W>:Z@^RJ*NE4E1JTZL+<]*I"I"ZNN
M:$E*-UU5TKKJ3."J0G"7PSC*$K:.TDT]>FC/S:^*'P,_:U_:6\;?L]VWQ>T3
M]FOX7?#'X-?&_P '?'C6K_X=?$#XB_%;XEZ]X@^&]P=3\)>'?#,WBKX-_"K2
M/!^E:I?R7-IXKUF"_O\ 6I=,GBBTSR(HKZRU?Z$O_P!BS]EO4?B9K7QFN?@O
MX//Q7\0'7GU7Q\EO=#Q#<S>)M O?#&MW#3M=-;^=?Z%J-[ITK?9BOD3N H."
M/J&BM'B:MHQ@_90C&4%"DYQ3C-WFI-R<I\SM=2DU9)))*Q"I03;DN>3<9<TT
MI-.*M%I62BTNJ2=VVV?E!\$OV:_VZ? _P^^$/[,'BSXA?!:Q^ 'PMUS4=%\2
M_$CPEJ.O:S\5_BY\"+;3=>T[PW\(M1\$>+?AK)X6\'3WME?:?H_BKQ9H7C :
MQIFC65@OA&[BU2QNM2U7Y]^#'_!+KXA^"M,^&/PN\8?"3]AF\\-?#SXD6^J^
M(/VC;;P)9>*_CA\2?A/I6I:GJ6F>#K_P+XM^#K>%]'\<ZK&=*T?7?'W_  G%
M[-I6F1"ZTNTUG7(9M5OOWAHK;Z_77M.54H>T?-/DARWJ7J/VCL_>D_:2]V5Z
M?PI0M&-L_JM+W+N<N1<L>:7-:'N+E5UHO<CJK3>MY/FE?\C(/V!OC#'_ &9N
M\2?#4_8O^"N>N?M\RXUCQ1\WP>U/_A(?(\-QY\&C/Q*3^UK;SM';9X779/L\
M92;8_,^N?VL_@'XQ^/%S^RW-X0U+PUIR_!']KKX3?'SQ6/$EYJEFVH>#O >D
M^-;#5]-\/#3-&U@7?B6YF\1V+:;9ZD=)TN:.*[-UK-FR0I/]=45G+%UI3A4;
MCS4^?E]W1<ZL[KKIL6L/3C&4$G:7+?5_8::_+4_%33OAIX3^-/\ P5A\3:O\
M/?&ECXQ^#_PL\/\ @/X[_'3P_I$]EXA\*:3^V!X+TKX@? KX;Z3>WUM=R1:'
MXUT;P)>7/B35=(M5%S8:SX%M!K\0U&2.*T[CQG^P-\8?$7[*/[;'P*LO$GPU
MB\7?M(_ME^*_VB/ VHW6L>*$\.:5X*UWXV_#/XDVFE^*[N'P;/J=CXICT/P9
MJEI<V6D:1KNDIJT]A!%K<UG+<7]K^L&F:)HNB_VA_8VD:7I/]K:G=ZUJG]F6
M%I8?VEK%^RO?:MJ'V6*+[9J=ZZ*UW?W'F75RRJTTKD C3K1XZJI4G3T5&.&C
M!2M)WPS4X-M**=Y^5^11@Y/ENX6&A:?/JZDJSDXWBDJRY9)*[?P^?Q.4DE>Q
M^4?[<WP#\8OK_P"UC^U&-2\-#P!;?\$H_P!I/X!R:.;S5/\ A,3XQO;W5?B'
M%J2:>-&.BGPTNBZ?-:R7A\0+J@U1HH%T9[1GO4Y3]G3X,_M1_M#>#OV"O$W[
M0MU\&-)^#GP$\+?#KXV>'E\"ZUXM\3^/?BY\0+3X;?V3\*M9\5Z?KWA+PUH7
M@!/#6@^*;C6/$D.DZIXM>_\ &-I<1:3]FT?4;2YT7]?;ZQLM4LKS3=2L[74=
M.U&UN+'4-/OK>&[LKZRNX7M[JSO+6X22"YM;F"22&XMYXWAFA=XY$9&92ZSL
M[33[2UL+"UM[&QL;>"SLK*S@BMK2SM+:)8;:UM;:%4AM[>WA1(H((D2**)%C
MC544 "QLU1C248<\+J%1J\H0=-TVHKI)Q;7,[[II*45)-X>+J.?-)1?O2@GI
M*2G&:;\DXK16ZIZ-I_E+X&_82^+OAG]AS]E']F>_\1_#B;QW\"OCM\,_B?XN
MU:SU?Q-)X1U'0/!GQQU?XEZI9^'+^;PA;ZS=ZQ/H5_#:6%OJ>@Z192ZNLL%Q
MJ%K9JE^^'JO[)'[9FD_#CX]?LG?#[7_V?+#]F_XV^/\ XDWFB_$G5=3\;I\5
M?A?\)_C;XCUC7_BAX-3X>V/A#_A&/&6OPKXGU[3_  =J,_CO0[1;65AJUQ%]
MILTT3]?J*7UZMS3DU3DYUI8AJ4$TJTI\_.E?>,OA3O&S<9*46T'U:FE%)SCR
MTXTM)--TXQY>5O>S5KM6=TFFFDSXB\$_LLZSX"_;%T/XV>'[OPU:_"#PM^Q%
MX/\ V6?#_A[[9J/_  F-KK/A'XHWWBVQNWT]-#BT$>&H_#$EE8QWD6NKJ)U2
M.6#^PXK-4O&^6_#?_!/SXT:3^QE^P]^SI+XT^'^G>.OV:OVF_AU\9_&_B?1M
M6UZ?1Y?#7A+XC>/O%VH#P'<ZIX%DGU/Q9%IWBK3CH]EXF\-Z3H4^JVMS#J-]
M'8I'-=?L#14K&5U9WBVG2E=Q3;=&%6$&[[^[6GS=VTWL-X>F[Z-:36CM93E3
ME)+YTH6[)/N?S_:/_P $Q?C_ &/A_P"#ND#P%^R1;?$+X3?&7X=_%WQO^T;J
M7CCXH^,OC#^T-<^!_'&G:R-&O?$/BWX6ZSXB^$EAJV@Q2ZCXCM-,\1>--(U#
MQAI.F66DZ/H_A[4+VYM/</VROV%/C/\ M$?$#XH76G?#W]F3Q=!XIC\+WGP7
M^/'BWQ!XO^%7QT_9YU2P\/6ND:O;G4?A-\/FU/XMZ3I&L64OBSP#8^+/%T$&
MF:EJ<FEZW_:>C6\,$/[(T5K_ &CB/:1J>YS1YK/W[KGE"<K/GYDN:"]U24>5
MRI\OLWR*%@Z*C*'O<LN6ZO'7EBXJZY;-V>[3ES6G?G]X^8?@YK7QET[XJ_$;
MX0^-8+3Q!\,OA?\ #7X%Q^ ?BM<Z?XLC\8>//$NL:%XAT[X@Q^.-:U>&V\*Z
MUXGL]1\+V/B*\C\%K=6VG:9XPT-M:O1J^H3:?8>E?'7P-JWQ.^"/QC^&N@7&
MG6FN_$/X5_$+P-HMWJ\US;Z3:ZMXL\(ZOH&G7&J3V5IJ%Y!IT%YJ$,M[-:6%
M[<QVRRO!:7,JI"_JE%<CJ/VD:D8Q@X^S:26G-",4Y6VO.47-K:\FEH="@N5P
M;<D^9:O6TFW:_:*?*NMDNI\G>#/V5_!6L?LE_ []F?\ :#\*>$?B9I_PW^%/
MPA\'^)M+9M1O_"FH>*_AOX+T7P_-JFDS7-OHNI7%@NI:?=7&E3WMCI]U):R1
M275A:S,]O'X1\0OV./%GPH\?_LX?%']ASPU\(_"/_"D-+^*/@CQ-\(?&>K^)
MO"/@_P <_#;XJ:AIGB35M-T[Q+H'A[QIJ6BZ]I?C'3#XBTR6[TB[TU]0OGNK
MM9(;+^S=0_2BBKCB:T9-\S<92J2E2DY.DW5C*$VX72NXSDN96DKW3329#HTW
M%*UG%049JRFE3E&4?>M>RE%.SO%[---H_%[XL_L(_M-_%O7_ (+_ !Q^+;?L
MR_M#_%?P1XO^,(\:_!;XH:;/;?!$?![XB7=A<^#_ (:> ?%-M\*M0\12ZM\,
MIM+&I:)XX\7^#)O$.I:EK^IPZSJ-]HFFVFD:AN:+_P $\/B#9:#\&[VTT?\
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M** "BBB@!3U_!?Y"DI3U_!?Y"DH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ I3U_!?Y"DI3U_!?Y"@!**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** %/1?I_4TE*>B_3^II* "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** %7J/J/YTE*O4?4?SI* "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** +4'W#_O'^0HH@^X
M?]X_R%%;QV7HOR,9_$_E^2.B_P"$I_ZA.G_]\?\ V-'_  E/_4)T_P#[X_\
ML:Y.BNC^T\=_S_\ _*5'R_Z=^2,?J&$_Y]?^5*O_ ,F=9_PE/_4)T_\ [X_^
MQH_X2G_J$Z?_ -\?_8UR=%']IX[_ )__ /E*CY?]._)!]0PG_/K_ ,J5?_DS
MK/\ A*?^H3I__?'_ -C1_P )3_U"=/\ ^^/_ +&N3HH_M/'?\_\ _P I4?+_
M *=^2#ZAA/\ GU_Y4J__ "9UG_"4_P#4)T__ +X_^QH_X2G_ *A.G_\ ?'_V
M-<G11_:>._Y__P#E*CY?]._)!]0PG_/K_P J5?\ Y,ZS_A*?^H3I_P#WQ_\
M8T?\)3_U"=/_ .^/_L:Y.BC^T\=_S_\ _*5'R_Z=^2#ZAA/^?7_E2K_\F=9_
MPE/_ %"=/_[X_P#L:/\ A*?^H3I__?'_ -C7)T4?VGCO^?\ _P"4J/E_T[\D
M'U#"?\^O_*E7_P"3.L_X2G_J$Z?_ -\?_8T?\)3_ -0G3_\ OC_[&N3HH_M/
M'?\ /_\ \I4?+_IWY(/J&$_Y]?\ E2K_ /)G6?\ "4_]0G3_ /OC_P"QH_X2
MG_J$Z?\ ]\?_ &-<G11_:>._Y_\ _E*CY?\ 3OR0?4,)_P ^O_*E7_Y,ZS_A
M*?\ J$Z?_P!\?_8T?\)3_P!0G3_^^/\ [&N3HH_M/'?\_P#_ ,I4?+_IWY(/
MJ&$_Y]?^5*O_ ,F=9_PE/_4)T_\ [X_^QH_X2G_J$Z?_ -\?_8UR=%']IX[_
M )__ /E*CY?]._)!]0PG_/K_ ,J5?_DSK/\ A*?^H3I__?'_ -C1_P )3_U"
M=/\ ^^/_ +&N3HH_M/'?\_\ _P I4?+_ *=^2#ZAA/\ GU_Y4J__ "9UG_"4
M_P#4)T__ +X_^QH_X2G_ *A.G_\ ?'_V-<G11_:>._Y__P#E*CY?]._)!]0P
MG_/K_P J5?\ Y,ZS_A*?^H3I_P#WQ_\ 8T?\)3_U"=/_ .^/_L:Y.BC^T\=_
MS_\ _*5'R_Z=^2#ZAA/^?7_E2K_\F=:?%/\ U"=/Z#^#V'^S2?\ "4_]0G3_
M /OC_P"QKE#U_!?Y"DH_M/'?\_\ _P I4?+_ *=^2#ZAA/\ GU_Y4J__ "9U
MG_"4_P#4)T__ +X_^QH_X2G_ *A.G_\ ?'_V-<G11_:>._Y__P#E*CY?]._)
M!]0PG_/K_P J5?\ Y,ZS_A*?^H3I_P#WQ_\ 8T?\)3_U"=/_ .^/_L:Y.BC^
MT\=_S_\ _*5'R_Z=^2#ZAA/^?7_E2K_\F=9_PE/_ %"=/_[X_P#L:/\ A*?^
MH3I__?'_ -C7)T4?VGCO^?\ _P"4J/E_T[\D'U#"?\^O_*E7_P"3.L_X2G_J
M$Z?_ -\?_8T?\)3_ -0G3_\ OC_[&N3HH_M/'?\ /_\ \I4?+_IWY(/J&$_Y
M]?\ E2K_ /)G6?\ "4_]0G3_ /OC_P"QH_X2G_J$Z?\ ]\?_ &-<G11_:>._
MY_\ _E*CY?\ 3OR0?4,)_P ^O_*E7_Y,ZS_A*?\ J$Z?_P!\?_8T?\)3_P!0
MG3_^^/\ [&N3HH_M/'?\_P#_ ,I4?+_IWY(/J&$_Y]?^5*O_ ,F=9_PE/_4)
MT_\ [X_^QH_X2G_J$Z?_ -\?_8UR=%']IX[_ )__ /E*CY?]._)!]0PG_/K_
M ,J5?_DSK/\ A*?^H3I__?'_ -C1_P )3_U"=/\ ^^/_ +&N3HH_M/'?\_\
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M?7_E2K_\F=9_PE/_ %"=/_[X_P#L:/\ A*?^H3I__?'_ -C7)T4?VGCO^?\
M_P"4J/E_T[\D'U#"?\^O_*E7_P"3.L_X2G_J$Z?_ -\?_8T?\)3_ -0G3_\
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M_P#_ "E1\O\ IWY(/J&$_P"?7_E2K_\ )G6?\)3_ -0G3_\ OC_[&C_A*?\
MJ$Z?_P!\?_8UR=%']IX[_G__ .4J/E_T[\D'U#"?\^O_ "I5_P#DSK/^$I_Z
MA.G_ /?'_P!C1_PE/_4)T_\ [X_^QKDZ*/[3QW_/_P#\I4?+_IWY(/J&$_Y]
M?^5*O_R9UG_"4_\ 4)T__OC_ .QH_P"$I_ZA.G_]\?\ V-<G11_:>._Y_P#_
M )2H^7_3OR0?4,)_SZ_\J5?_ ),ZS_A*?^H3I_\ WQ_]C1_PE/\ U"=/_P"^
M/_L:Y.BC^T\=_P __P#RE1\O^G?D@^H83_GU_P"5*O\ \F=9_P )3_U"=/\
M^^/_ +&C_A*?^H3I_P#WQ_\ 8UR=%']IX[_G_P#^4J/E_P!._)!]0PG_ #Z_
M\J5?_DSK/^$I_P"H3I__ 'Q_]C1_PE/_ %"=/_[X_P#L:Y.BC^T\=_S_ /\
MRE1\O^G?D@^H83_GU_Y4J_\ R9UG_"4_]0G3_P#OC_[&C_A*?^H3I_\ WQ_]
MC7)T4?VGCO\ G_\ ^4J/E_T[\D'U#"?\^O\ RI5_^3.L_P"$I_ZA.G_]\?\
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M.=G+DGRIM.7*[)IV:;M9--I._5V%S1NES1N]E=7=]597OMJ>F4445)04444
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M4KJU[.S5^7YG/.CS5)348ZT903LK\[=T]NW6^ARW[#W_ "97^R!_V:[\ /\
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MX9TWQ1JOB:Y^(7CWX1^'['PS=WCWD>C:/?7:):Q697U#5O@KXO\ A_\ $_\
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MI:M\,-2^(-KX\TG7+/4)OB##>:<NK:?I-EI7A[P/;6EW'9W6DZE/IDMSK?Z
M?"7]@KP=\-?&'PM\6^)_C3\??CE'\"='U31_@AX:^,?BOPMJ_A[X;G5K)M)F
MURUM_"W@KPE?>)O$]EH,UYX=T?6O&-_K[:-H=W]DTZVMYK#2+K3MCP[^PE\(
MO#/[._P7_9GL/$?Q'F\"? KXC^$?B?X1U:\U?PS)XNU'7_!GQ$OOB7I=GXCO
MX?"%OHUWH\^NW\UI?V^F:#I%[+I"Q06^H6MXKW[RZ^$2LXTZDY3I*I-8:G",
MJ2^L\ZIPY5[.2C+#IR@HSE*+M)\KG,]EB'KS3BE&;C%UI2:F_8<KE)2?/&\:
MUHR<HI2M:TN6/VK7YA:KXW_;$^/GQB_:*B^ OQC^'?P2\!?LO^,K;X<Z-X4\
M5_"F'QW/\:?'L7@+PGX\UUOB/KNJZYHE]X)\!Q-XBM=!T.[\!3VNMS6US>>(
MKV]FCM++3KK["^"/P\^(7@/6_CQ?>./'.O\ C#2?'WQLUWQO\-=-\0>*[SQ7
M/X'\!:EX:\*6J>%+)[C1M$MM TF'Q;9>+-1T+PMID6H6>@^'=0T>SN-:U;5U
MU.[?P[XI_L&^%_B)\1?BE\1?#?QT_:$^"UQ\=/#^B>&_C/X:^$OBKPAI?AGQ
M]::#I,&@66J36OB;P)XIO_#WB>30+6TT&[\2>&=1TK49M&ADLE:+[=J,EYS4
M72ISJ*4Z;O3BJ=2=)5H1DY4Y33IR4E?DYX*5G:6S5U..]13G&#C&:]Y\\%/V
M<FK22]^+3MS<LFKJ\=T[<K_.CQ3\2OBG^UI\>/\ @CC\<O"'Q#D^#TWQ7\-?
MM :FOAQ? &E>);3PEXN\*?"_6)?BE?:>?$5S!=:YI'C_ $6"Z\$:#_:7R^'=
M&2U\8Z/-=:GJ$BMYM^Q#X_\ VI/@)^Q?^PA\7-.^*O@O6/@?XS^-/A[X'ZM\
M )_AA9VM[:^%OB=\</&GA&?QP/BJ/$%WXAOO&FGZY.VL6&EV^FZ-X8&G7-GI
M][8W,^EWESK?[+^,/V-_AEK=G^S=;^"-5\5?!RX_93O+E/A!J7P\GT*6_P!)
M\,ZMX/G\!>)?!U[)XWT'QBE_I'B;PM.+/5=0DC7Q*U[!;ZO!KD6IK)<R\_X=
M_82^$7AG]G?X+_LSV'B/XCS>!/@5\1_"/Q/\(ZM>:OX9D\7:CK_@SXB7WQ+T
MNS\1W\/A"WT:[T>?7;^:TO[?3-!TB]ETA8H+?4+6\5[]^UXW#.C"DH1]FJD$
MZ<Z,)RC157,)/WW%OF4,31491ESJ:J233E)SYOJU;VDJCDW/D;4XU)13J.&$
MC\-TN5RHU'*+CRN+@FG9*/YI>(/V_P#]J;Q:_P 5_BY\)O$JW%G\,OBE\1/
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M6WQL/QRN=7U'6+SXEWGB<>%CH-SX@O6U.YTZY'_"+1V7]E+:V]O:V]Q96EW
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M5\)GXB? [X>Z7XBTK1?A#^Q_XJ^-GQ*^)NIR>#;;Q+K&J?M!V6@>'_$'P^^
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M6]KY4,]]>2QO<R_C'^SA^T!^TCXJ^$'_  2Z^&'PC\9_#/X,W7[3G@W]LO\
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M%% !1110 4444 6H/N'_ 'C_ "%%$'W#_O'^0HK>.R]%^1C/XG\OR15HHHK
MV"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** %/7\%_D*2E/7\%_D*2@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "E/7\%_D*2E/7\%_D* $HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH 4]%^G]324IZ+]/ZFDH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH 5>H^H_G24J]1]1_.DH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M0?</^\?Y"BB#[A_WC
M_(45O'9>B_(QG\3^7Y(U/^$8US_GQ_\ )FS_ /DBC_A&-<_Y\?\ R9L__DBJ
M']JZI_T$K_\ \#+C_P".4?VKJG_02O\ _P #+C_XY71?*_\ GWC_ /P=A_\
MY08VS#^?!_\ @JO_ /+B_P#\(QKG_/C_ .3-G_\ )%'_  C&N?\ /C_Y,V?_
M ,D50_M75/\ H)7_ /X&7'_QRC^U=4_Z"5__ .!EQ_\ '*+Y7_S[Q_\ X.P_
M_P H"V8?SX/_ ,%5_P#Y<7_^$8US_GQ_\F;/_P"2*/\ A&-<_P"?'_R9L_\
MY(JA_:NJ?]!*_P#_  ,N/_CE']JZI_T$K_\ \#+C_P".47RO_GWC_P#P=A__
M )0%LP_GP?\ X*K_ /RXO_\ ",:Y_P ^/_DS9_\ R11_PC&N?\^/_DS9_P#R
M15#^U=4_Z"5__P"!EQ_\<H_M75/^@E?_ /@9<?\ QRB^5_\ /O'_ /@[#_\
MR@+9A_/@_P#P57_^7%__ (1C7/\ GQ_\F;/_ .2*/^$8US_GQ_\ )FS_ /DB
MJ']JZI_T$K__ ,#+C_XY1_:NJ?\ 02O_ /P,N/\ XY1?*_\ GWC_ /P=A_\
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ME?\ _@9<?_'*/[5U3_H)7_\ X&7'_P <HOE?_/O'_P#@[#__ "@+9A_/@_\
MP57_ /EQ?_X1C7/^?'_R9L__ )(H_P"$8US_ )\?_)FS_P#DBJ']JZI_T$K_
M /\  RX_^.4?VKJG_02O_P#P,N/_ (Y1?*_^?>/_ /!V'_\ E 6S#^?!_P#@
MJO\ _+B__P (QKG_ #X_^3-G_P#)%'_",:Y_SX_^3-G_ /)%4/[5U3_H)7__
M (&7'_QRC^U=4_Z"5_\ ^!EQ_P#'*+Y7_P ^\?\ ^#L/_P#* MF'\^#_ /!5
M?_Y<7_\ A&-<_P"?'_R9L_\ Y(H_X1C7/^?'_P F;/\ ^2*H?VKJG_02O_\
MP,N/_CE']JZI_P!!*_\ _ RX_P#CE%\K_P"?>/\ _!V'_P#E 6S#^?!_^"J_
M_P N- ^&=<_Y\NP_Y>;3L!_T\4G_  C&N?\ /C_Y,V?_ ,D51.JZGG_D)7_0
M?\OEQZ#_ *:4G]JZI_T$K_\ \#+C_P".47RO_GWC_P#P=A__ )0%LP_GP?\
MX*K_ /RXO_\ ",:Y_P ^/_DS9_\ R11_PC&N?\^/_DS9_P#R15#^U=4_Z"5_
M_P"!EQ_\<H_M75/^@E?_ /@9<?\ QRB^5_\ /O'_ /@[#_\ R@+9A_/@_P#P
M57_^7%__ (1C7/\ GQ_\F;/_ .2*/^$8US_GQ_\ )FS_ /DBJ']JZI_T$K__
M ,#+C_XY1_:NJ?\ 02O_ /P,N/\ XY1?*_\ GWC_ /P=A_\ Y0%LP_GP?_@J
MO_\ +B__ ,(QKG_/C_Y,V?\ \D4?\(QKG_/C_P"3-G_\D50_M75/^@E?_P#@
M9<?_ !RC^U=4_P"@E?\ _@9<?_'*+Y7_ ,^\?_X.P_\ \H"V8?SX/_P57_\
MEQ?_ .$8US_GQ_\ )FS_ /DBC_A&-<_Y\?\ R9L__DBJ']JZI_T$K_\ \#+C
M_P".4?VKJG_02O\ _P #+C_XY1?*_P#GWC__  =A_P#Y0%LP_GP?_@JO_P#+
MB_\ \(QKG_/C_P"3-G_\D4?\(QKG_/C_ .3-G_\ )%4/[5U3_H)7_P#X&7'_
M ,<H_M75/^@E?_\ @9<?_'*+Y7_S[Q__ (.P_P#\H"V8?SX/_P %5_\ Y<7_
M /A&-<_Y\?\ R9L__DBC_A&-<_Y\?_)FS_\ DBJ']JZI_P!!*_\ _ RX_P#C
ME']JZI_T$K__ ,#+C_XY1?*_^?>/_P#!V'_^4!;,/Y\'_P""J_\ \N+_ /PC
M&N?\^/\ Y,V?_P D4?\ ",:Y_P ^/_DS9_\ R15#^U=4_P"@E?\ _@9<?_'*
M/[5U3_H)7_\ X&7'_P <HOE?_/O'_P#@[#__ "@+9A_/@_\ P57_ /EQ?_X1
MC7/^?'_R9L__ )(H_P"$8US_ )\?_)FS_P#DBJ']JZI_T$K_ /\  RX_^.4?
MVKJG_02O_P#P,N/_ (Y1?*_^?>/_ /!V'_\ E 6S#^?!_P#@JO\ _+B__P (
MQKG_ #X_^3-G_P#)%*?#.N?\^78?\O-IV _Z>*S_ .U=4_Z"5_\ ^!EQ_P#'
M*4ZKJ>?^0E?]!_R^7'H/^FE%\K_Y]X__ ,'8?_Y0%LP_GP?_ (*K_P#RXO?\
M(QKG_/C_ .3-G_\ )%'_  C&N?\ /C_Y,V?_ ,D50_M75/\ H)7_ /X&7'_Q
MRC^U=4_Z"5__ .!EQ_\ '*+Y7_S[Q_\ X.P__P H"V8?SX/_ ,%5_P#Y<7_^
M$8US_GQ_\F;/_P"2*/\ A&-<_P"?'_R9L_\ Y(JA_:NJ?]!*_P#_  ,N/_CE
M']JZI_T$K_\ \#+C_P".47RO_GWC_P#P=A__ )0%LP_GP?\ X*K_ /RXO_\
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M?_\ @9<?_'*+Y7_S[Q__ (.P_P#\H"V8?SX/_P %5_\ Y<7_ /A&-<_Y\?\
MR9L__DBC_A&-<_Y\?_)FS_\ DBJ']JZI_P!!*_\ _ RX_P#CE']JZI_T$K__
M ,#+C_XY1?*_^?>/_P#!V'_^4!;,/Y\'_P""J_\ \N+_ /PC&N?\^/\ Y,V?
M_P D4?\ ",:Y_P ^/_DS9_\ R15#^U=4_P"@E?\ _@9<?_'*/[5U3_H)7_\
MX&7'_P <HOE?_/O'_P#@[#__ "@+9A_/@_\ P57_ /EQ?_X1C7/^?'_R9L__
M )(H_P"$8US_ )\?_)FS_P#DBJ']JZI_T$K_ /\  RX_^.4?VKJG_02O_P#P
M,N/_ (Y1?*_^?>/_ /!V'_\ E 6S#^?!_P#@JO\ _+B__P (QKG_ #X_^3-G
M_P#)%'_",:Y_SX_^3-G_ /)%4/[5U3_H)7__ (&7'_QRC^U=4_Z"5_\ ^!EQ
M_P#'*+Y7_P ^\?\ ^#L/_P#* MF'\^#_ /!5?_Y<7_\ A&-<_P"?'_R9L_\
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M^\?_ .#L/_\ * MF'\^#_P#!5?\ ^7%__A&-<_Y\?_)FS_\ DBC_ (1C7/\
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M_P#\'8?_ .4!;,/Y\'_X*K__ "XO_P#",:Y_SX_^3-G_ /)%'_",:Y_SX_\
MDS9__)%4/[5U3_H)7_\ X&7'_P <H_M75/\ H)7_ /X&7'_QRB^5_P#/O'_^
M#L/_ /* MF'\^#_\%5__ )<7_P#A&-<_Y\?_ "9L_P#Y(H_X1C7/^?'_ ,F;
M/_Y(JA_:NJ?]!*__ / RX_\ CE']JZI_T$K_ /\  RX_^.47RO\ Y]X__P '
M8?\ ^4!;,/Y\'_X*K_\ RXT#X9USC_0N@_Y^;3U/_3Q2?\(QKG_/C_Y,V?\
M\D51.JZGQ_Q,K_I_S^7'J?\ II2?VKJG_02O_P#P,N/_ (Y1?*_^?>/_ /!V
M'_\ E 6S#^?!_P#@JO\ _+B__P (QKG_ #X_^3-G_P#)%'_",:Y_SX_^3-G_
M /)%4/[5U3_H)7__ (&7'_QRC^U=4_Z"5_\ ^!EQ_P#'*+Y7_P ^\?\ ^#L/
M_P#* MF'\^#_ /!5?_Y<7_\ A&-<_P"?'_R9L_\ Y(H_X1C7/^?'_P F;/\
M^2*H?VKJG_02O_\ P,N/_CE']JZI_P!!*_\ _ RX_P#CE%\K_P"?>/\ _!V'
M_P#E 6S#^?!_^"J__P N+_\ PC&N?\^/_DS9_P#R11_PC&N?\^/_ ),V?_R1
M5#^U=4_Z"5__ .!EQ_\ '*/[5U3_ *"5_P#^!EQ_\<HOE?\ S[Q__@[#_P#R
M@+9A_/@__!5?_P"7%_\ X1C7/^?'_P F;/\ ^2*/^$8US_GQ_P#)FS_^2*H?
MVKJG_02O_P#P,N/_ (Y1_:NJ?]!*_P#_  ,N/_CE%\K_ .?>/_\ !V'_ /E
M6S#^?!_^"J__ ,N+_P#PC&N?\^/_ ),V?_R11_PC&N?\^/\ Y,V?_P D50_M
M75/^@E?_ /@9<?\ QRC^U=4_Z"5__P"!EQ_\<HOE?_/O'_\ @[#_ /R@+9A_
M/@__  57_P#EQ?\ ^$8US_GQ_P#)FS_^2*/^$8US_GQ_\F;/_P"2*H?VKJG_
M $$K_P#\#+C_ ..4?VKJG_02O_\ P,N/_CE%\K_Y]X__ ,'8?_Y0%LP_GP?_
M (*K_P#RXO\ _",:Y_SX_P#DS9__ "11_P (QKG_ #X_^3-G_P#)%4/[5U3_
M *"5_P#^!EQ_\<H_M75/^@E?_P#@9<?_ !RB^5_\^\?_ .#L/_\ * MF'\^#
M_P#!5?\ ^7%__A&-<_Y\?_)FS_\ DBC_ (1C7/\ GQ_\F;/_ .2*H?VKJG_0
M2O\ _P #+C_XY1_:NJ?]!*__ / RX_\ CE%\K_Y]X_\ \'8?_P"4!;,/Y\'_
M ."J_P#\N+__  C&N?\ /C_Y,V?_ ,D4?\(QKG_/C_Y,V?\ \D50_M75/^@E
M?_\ @9<?_'*/[5U3_H)7_P#X&7'_ ,<HOE?_ #[Q_P#X.P__ ,H"V8?SX/\
M\%5__EQH#PSK@(_T+N/^7FT_^2*3_A&-<_Y\?_)FS_\ DBJ(U74\C_B97_4?
M\OEQZ_\ 72D_M75/^@E?_P#@9<?_ !RB^5_\^\?_ .#L/_\ * MF'\^#_P#!
M5?\ ^7%__A&-<_Y\?_)FS_\ DBC_ (1C7/\ GQ_\F;/_ .2*H?VKJG_02O\
M_P #+C_XY1_:NJ?]!*__ / RX_\ CE%\K_Y]X_\ \'8?_P"4!;,/Y\'_ ."J
M_P#\N+__  C&N?\ /C_Y,V?_ ,D4?\(QKG_/C_Y,V?\ \D50_M75/^@E?_\
M@9<?_'*/[5U3_H)7_P#X&7'_ ,<HOE?_ #[Q_P#X.P__ ,H"V8?SX/\ \%5_
M_EQ?_P"$8US_ )\?_)FS_P#DBC_A&-<_Y\?_ "9L_P#Y(JA_:NJ?]!*__P#
MRX_^.4?VKJG_ $$K_P#\#+C_ ..47RO_ )]X_P#\'8?_ .4!;,/Y\'_X*K__
M "XO_P#",:Y_SX_^3-G_ /)%'_",:Y_SX_\ DS9__)%4/[5U3_H)7_\ X&7'
M_P <H_M75/\ H)7_ /X&7'_QRB^5_P#/O'_^#L/_ /* MF'\^#_\%5__ )<7
M_P#A&-<_Y\?_ "9L_P#Y(H_X1C7/^?'_ ,F;/_Y(JA_:NJ?]!*__ / RX_\
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M@E?_ /@9<?\ QRB^5_\ /O'_ /@[#_\ R@+9A_/@_P#P57_^7%__ (1C7/\
MGQ_\F;/_ .2*/^$8US_GQ_\ )FS_ /DBJ']JZI_T$K__ ,#+C_XY1_:NJ?\
M02O_ /P,N/\ XY1?*_\ GWC_ /P=A_\ Y0%LP_GP?_@JO_\ +B__ ,(QKG_/
MC_Y,V?\ \D4?\(QKG_/C_P"3-G_\D50_M75/^@E?_P#@9<?_ !RC^U=4_P"@
ME?\ _@9<?_'*+Y7_ ,^\?_X.P_\ \H"V8?SX/_P57_\ EQ?_ .$8US_GQ_\
M)FS_ /DBC_A&-<_Y\?\ R9L__DBJ']JZI_T$K_\ \#+C_P".4?VKJG_02O\
M_P #+C_XY1?*_P#GWC__  =A_P#Y0%LP_GP?_@JO_P#+B_\ \(QKG_/C_P"3
M-G_\D4?\(QKG_/C_ .3-G_\ )%4/[5U3_H)7_P#X&7'_ ,<H_M75/^@E?_\
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M5>+=-N]*/Q0\>+:0:/;>%?$?ARXM+U+O,D\]W/<PO!B-(D?+UZ]^V#^W;/\
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MA"QLO^$?'A_[%I/_ "$?,_M7^VO]$V?V;<[_ ,B[G3_^">:_LV_#Y]=^+/Q
M_:%\"Z?^V-X/^*'[1/[0GP]U^7P_C]H7QSHVO:=%\3?C5?64^D:EX&^%=W+J
M2:&EMX'OK1_"-O-X8C_M.YU W^LZEPWAWX<^./'?Q"_:F^"/_!,OQCHNJ_L@
MWVG_  >T#XK6NL_%_P 8Q^";3Q7KVI^*=9^,'A_]F/XK?V;\5H/#NI^*O 4&
MB^&/&&J:?HGB+3-$G\52WUI;0SZ'X/ACWEA:$J=11IN@U-N5:O"M&$(J=&#A
M"4JT5!^\YPA6HSJ2A-*52,E%F:KU(R@Y352\4E3I2IRG*3C.7-**IOFVM*5*
MI&"E%M1:NE^JO[+7[</@K]K+XN_M-?#[X=^'Y3X/_9[U+X=Z7I/Q,_MI;W3O
MBDWC1/',&HZOX>TJ/2H(;3PUI6J>!KVVT'7[;7==M/&.G7<&M6BZ;:F&.Y]O
M^//QC_X4]X=\)OI>C0>*?'/Q)^)'@OX4_#CPG<:A<Z5!KOBKQ?J>VZN;[4K3
M2]9GT_1/!_A*Q\3^/O$MXFG7,D7AWPIJB6\;WLMK%)^9_P"PK;_$_P /?M]_
MMR^%+SX0?"WX:>%M'\!?L=:#XB\->"_B;J_BK3_A]8>&?A)XNTSX8:-X&-Q\
M+/!47BC3-5T:*[_MPWUEX1;PDUG965A#XG2XEN[?Z0_:>MM3B_;C_P"":&LR
M).?"EOXO_:GT2]E$DR6=OXPUS]GK5)O"+W").L$MS-I6C^-+.R6:WF=3<SO#
M+;[9/.YZN'I1Q?)%<M)86&(Y?:*;DXX&.(E&4XR_Y>5$TW%JRE>FE'E-85:C
MH<S=YNM*ES<CA92Q+I)J,E]B+5KIW<;2;?,<#IG[<O[67Q#\<?''0/@1^P7I
MWQ6\(?!'XW^._@7J/C:[_:N\#_#Z35_$G@1]-FO+A?#'B7X=M?V*76F:UH^H
M!(KS5+2%KUK./4[J:UG*^W^)_CC^VMI?PZ^%WB/PS^PGI?BKXA>*?^$V_P"%
MF_#:3]JOX>:##\*O[$URWL?!?D>-;SP;<Z5X^_X3G1)+C7I?['L--_X19[<:
M3J'VRYF69?QD\!W_ .RM:_&?]N6/XX_M]?M#_LK^+#^W-\>7T[X??"7X_P#B
M'X5>'-8\.D^%UM/&5[X>TGP_JMM>:WJ&I+J^B7.LO<)/<6'A[3;%H5CTZ)Y/
MJ']I3]NSX3_#[X&? K]F_P#9^_:MN;G4?CGI&J:/+^US\3?%^J>)]6^''PDT
M37=7\.^-_B5J7BR>UTW6/%?Q.O\ 4M+U[P?X%MM-CL;^/6["ZU6;5= .DZ9?
MW/94PD?:4(4<)!\W(Y2G3QR@XNASSE.JL1RS2NZG+0C&;<%&*:O"6$*[Y9RJ
M8B2M=)1GA7)/VBC%1@Z5XM_!>I)I*3;:=I1]Z^"/_!1GXL?$^']K>^\7?LEP
M> =%_9(\!>-]8\4>)=&^/FB_$GPMX@^)_@S1'\0W/P?T_P 1Z'\.],T<ZW#I
MEM>R>)-5T2[\4+X-GBLK/7-*CN]6TV&X^O?^&D_^,*_^&P/^$+_YM=_X:3_X
M5Y_PD?\ U2?_ (6?_P (7_PEO]A?]P/_ (2/_A&?^HG_ &%_S#Z^)O#'Q,_8
M?L_V%_V@OV;OV/OB?X0\8V/PU_9.^-NKW6DZ+>W%_P"(;NT;P/K5MK?C3Q->
M2:=I\=_J^MZ_JT-SJ]['%!$;[44@L;*RTZ*UL[;SW_AGCPG_ ,.C?^$[_P"$
MX^/7]I_\.X_^$M_L?_AH?XU?\(5]O_X9F_MC^S/^$$_X3C_A$?\ A%OM'^B_
M\(E_8_\ PCG]D_\ $G_LS^S/]%K&=##RFFZ$\,GBZ5&--QJ\TJ;A&[DJM9RA
M[1WGI*3BGRQD[7=PJ5DK>TC6?L)U)-.G934K)1E"FE+D7NZJ*E9MI7LO=K7_
M (*'_$KQK#)>?!+]CKQQ\7=-\$_##X3_ !*^-NI6?Q/\%^$[;P8?BO\ #71O
MBG9>%/AU%XDL;>]^,7B+1/#.JR_VE;V%IX40W]I%IV8M1U*RLY/HZ/\ :X\)
MZGX-_9:^+N@:5+=_!G]I;7?#?A?_ (2K4KIK'6_A_KOQ$T"YO/AI;^(-$L;7
M6-/DCUGQG9I\+]=>/7HH]#\9Z]X=C@GU33I[V[M?QVU#]NGX/?$GX0?!/]B8
M_M ^%/@!\/O#_P"S[\$- _:E^+FLWZIXFUKP]J_PET)=;^#'P,M;>PUJVF\5
M:FAD\.?$3QGKT=C8^ +2>^M+"QU[7]FGU]N?MQ#X=ZQ_P2YN-$_9JFL-0\#Z
MBO[-/@WX"-X7N]2EM9#:?'CX4:#X"&BWMQ<PZM=/I]Y8VDJW-U>B_O'LI9+F
M[DN)I)G=3"4XU,-3GAI4/;5XTE-NJU[.HE!5*DYOV?.Y/VM*G!1Y:<;5>?F4
MF0KSE&K.-55/9TG-QM37OQ]YPA&*YN6RY)SDW><OW?*TTOUFHHHKR#O"BBB@
M HHHH **** %/7\%_D*2E/7\%_D*2@#P;]J#XW?\,W?L_P#Q4^.G_",?\)G_
M ,*S\+7'B7_A%O[:_P"$=_MOR+FUM_L7]M_V3KO]F[OM._[3_9%_MV;?(.[<
MO6:U\9?A9X2LOM7CKXC_  _\"S6_AS1/%>JVGBWQKX=T"31]"\0W<^F:3JNH
M?VQ?Z>UMI.H:Q:7NCZ=JES'!9W^I65U96TCW4$T,?RS_ ,%0/^4?_P"U1_V2
MZ_\ _3EIE?.FH?"_X;_%7_@JCH6D?$[P%X/^(FCZ/_P3/\%:YIFB^./#ND^*
MM%LM;7]H+Q=I$>L0Z1KEK?::NJ0Z7JVJZ?;Z@;4W=M9ZGJ-M;S1Q7UTLO;2H
M4ZE!5)N47%XF4G'64HTHX7EBE)J*UJS?-:^NM[)+FJ59QJN$;.\:2BI:)2G*
MJG)M)MZ16FVFEKMGV9\6_P!K#PQ\)?C9^S1\+M4L]!F\(_M"^'OCAXGN?BMJ
M'C?3]#\.>!=%^#7@SPYXQ74YTN-,N=,US2_$UMXA2%=2D\1Z#::1!;K?A]5C
MN1#%UGQ ^/5MHFC_  1\2?#.T\!_%?PQ\8?C'X.^&K>)+?XR^ O".B:9X;\2
MP>(GU#QIX2U/5[FZL?BGK.CW6A):67PV\'7$OBKQ(UQ>RZ4=FC7X'X+_ +/7
MPU\!>-_&?_!)OX:^,_"/A_Q=\/O#OQ%_X*NZ=IG@SQ3I5EXC\._V?X3\9R7?
MAFROM,UJ&^M]4@T.]@M+[31J*W3VUY86$Z/OLX-F[?\ AW1/!'C'2/ ?A+3+
M/P[X+\+?\' 'PGC\+^%=)MXK'0/#=IJ_P4EUF]TW0-*MUCLM&TDZA>7,]MI6
MG0VVG60D,=I;0Q_)78\!04J=-2DYPA5E4YHODJJ.+Q5",FE44H3Y:=/W8OE7
M+]IMM\_UJK:4FDHRG344FN:#E0P]5Q3<+2C><]9+FN]+))+]D?@%^V'X&^,^
MM?%3POKTGA/X:^*_ ?[2OQG_ &>/"OA;5_B%H]]XA^)9^#VHZ;87GB_P_HUY
M8>'M2)U,:BD]SX?TVTU[^Q BI+K=_P":'7D?C7^W-X=_9XT_]J3Q/\5?"6EV
M/@O]GR?X4Z?X3N?#/Q7^'GB7QW\6M:^)OAJ'63HK_#3^T=-U_P"&FI:-?RRQ
M6EGXNG>\\6>%M.U;QSX=M;K1M/DB;\4M:U#]BV7X4?\ !3[PCXW\(>"/$/[8
M/B_]LO\ :P\/?!K2+GP[IWB#XYZ]XO\ $/C+4-)^#>I?"5X=(F\667A_2O&G
MVQ+PZ#=FVL]6T_Q*^HW$!UJUM)M+]H3P)XM\1?##_@LEIGCS1;+Q9\4/"'@3
M_@G+XE\171M+35)=-\8^%?@/X+F^(/BG2;J9[UK2:RTM?%\L^J6=V]Q_8MQJ
M<(NY[>[G$^D<OP[K>\IQIMT8\DU*+M/$8*G*I2G[2\H..(E%RFI):N*4G%TY
M>*J^S7*XRGRU)<T6FKJCB)*-2/)I)2I)I1:O:ST3Y_Z.)?CC\%8/^$(\_P",
M'PNA_P"%F%A\./-^('A./_A8!22.%QX(WZL/^$K*32Q1-_8/V_;))'&<,Z@[
MOB_XD?#OX?+"WCWQ[X+\$+<Z;K&LV[>+_%.A^&EGTCP]_9_]OZK"=9OK(2Z;
MH?\ :VE_VQ?(6M=,_M+3_MLL'VRW\S\"M*\:?\$W/#_Q(_;>/[1^D_!77=/\
M36?A;7/V?KF;PEI%]X>\5_LT/\,_"^E>%/#'[-$UO97FD6^H:?\ $"U\4PW5
MI\.8].U.X\6J/$H-R=+GO='T]'^#6K^-/&/_  1 ^%O[6GA.U\;:Q#\'_P!K
M.3QKX)^(NA1ZC%.-(^%GP\U+P=H?C?P_KZ7OVS6/#&FP^&TU6VU>,W2^)-$^
MTWUO#=12VR<SP%--.4ZT(\DYRYZ<4YJ.$JXI^QO)<W)[.-*HW;EE.,M+\D=O
MK4G=*-.3YHQ7+-M1<J\*"]I[MX\W.ZD+7O&+6MN:7]!=A?V.JV-EJ>F7MIJ.
MFZC:6]_I^H6%Q#>6-_8WD*7%I>V5W;O);W5I=6\D<]O<0220SPR)+$[(RL;=
M5+"PL=+L;+3-,L[73]-TZTM[#3["R@BM;*QL;.%+>TL[2U@5(;:UMH(XX;>"
M%$BAB1(XU5% %NO+]#M]0HHHH **** "BBB@ I3U_!?Y"DI3U_!?Y"@!*^7?
MVT/VD_\ AD/]FGXD_M$?\(7_ ,+"_P"%>_\ "'?\4?\ \)'_ ,(G_:__  EG
MC[PMX'_Y&#^PO$O]G_V?_P )+_:G_($O?M7V+[%_HWVG[7!]15^7?_!9_P#Y
M1J?M)?\ ='?_ %?GPLKHPE.%7%X6E47-"IB*%.<;M<T)U8QDKQ::NFU=--;I
MIF5>4H4*TXNTH4JDHNR=I1A)IV::=FEHTUW1ZCI/[6WQ=\'?$'X7>"/VGOV9
MA\%=-^-/C _#GX=^.O!7QBT7XT^&'^(<VE7NMZ/X5\7I!X0\ ZWX:F\26&DZ
MPNA:A9Z5X@LIKS3WAU!]-MS+>0?>=?@#XG\0? ;3OVC_ -CS6/V4_P!JGQU^
MUQ\8;GXYZ5H6J?#;Q9\7M5_:<\*Z!\(-;L+C2/BS\2V-S>:C:?"#7_ WA6^G
MO-%\<V-Y9:G=17FKZ6VD>(M(EUI-/_4K4M$_;;_X6GKVH:9X^_9V_P"%*L/$
M3>'?#,GP_P#')^)D2R>'+^+PQ%?^)7\9KX8FN+;Q2VFW>JR+H<,%SI$=U:0)
M;W$L=S'OB,/"/LI14*'-2E)QFJT+RC-QM&%1U:B;5K-S<)-2LXV:,Z-63YT^
M:I:<8J473E92A%^]*"A%V;=TH\R5GJG<]\T_XF_#;5O&&I?#W2OB%X'U+Q]H
MT!NM7\#Z?XLT&\\8:5:ABIN=2\-6U_)K5C &!4S75E%&&!!;(Q5JV^('@.\\
M8ZA\/+3QMX1NO'^DZ=!K&J>!K;Q)HT_C'3=)N@AMM4U#PS%>MK5GIUP)8S!>
MW%E';3"1#'*V]<_SZ_LO>*_V,M:^#G[+'@RT^'$_B3_@H/!\4]8@UJ+1;?[!
M^T1X._:+T:V\67GCSXM_'CQ4FL^#_&>J?"#^T(VU+QU%KFM>)=,U_P /7=CH
M9\/>*M2\/7%AIORG^SYX?\(>)_AM^RMX3\/>-/@%X2_:J\.?M$>'+:?P[X-_
M9F\6:O\ MO>'OBMX9\6ZGJ7C76?C!XUUG]I+2GUWX:W=II]_<^/_ !+K?A]/
M!:^%9[;3K31=,U/2+71M(Z/[,A>KS5*U/V;4;SH.SNZJ]M[DIM8?]T_?<4O>
M=I2<4IXK&-\EHTYN:YDHU+6_A_N_>23J_O%[J;>FL5?3]NXO^"AOF_8/^+0;
M?MW_  4IU?\ X)Y?\C_GRO[+_MO_ (N__P B2-_G_P!C_P#(@?)Y7VC_ )':
M3R?WOTK^T?\ M#_\,^S_ +/D'_"(?\)=_P +W_:5^''[/&[_ (2#^P?^$5_X
M6#IOBK4/^$OV_P!B:U_;G]D?\(SY/_"/YT?[?]N\S^V[+[-LN/Q!M/\ F _]
MK*7BW_W=:_2G_@H]_P ?_P#P3Y_[24_LX?\ J.?%6E4PM"-?#P4+1J>VYUS3
MUY8)QU<KJS[-7ZW%"O5=*K)RO*+I<KY8Z<S2EI:SO?KMT/O!/B?\-9?!4_Q)
MC^(?@:3X=6J7LEUX^3Q;H#^"K:/3=2FT;47G\5+J!T*%+#5[:XTJ]:2_5;74
MH)K&<QW43Q+D)\;_ (+R:_IGA2/XO?"^3Q1K>L:KX>T;PVGC_P */K^KZ_H-
M[+IVN:'IFCKJQU&_UC1M0@GL-5TRTMI;W3KV&6UO((9XWC7\5O&_P^\3G]JK
MQ+_P3<AT74+CX*_'#]H[PG^W)?WLUN-5\.1?L_1)J?C?XR?##48(XH(/#VDZ
MO^TMX%\/:7H5C91O!'8>.2EY)']MC$WR[\7?@_\ #.^_8L_X*H?%ZZ\$^&9O
MBUI7_!3;XA:9X=^*$FAZ4_Q!\)Z='^T[\']+CL?"GB][-M=\/VJ6_B/Q$PAT
MV]@C>;7M6>176\D2E3R^E)P3K37M94?9\L8RM3Q,X4Z,I^]&THR=3VD5JN1)
M6YKJI8JI'FM3B^2-7GNVKSHQ<JD8Z?"X\O))Z/FOM'7^E[3OBK\+]7TSQ=K>
MD_$CP%JFC> 'U./QYJ^G>,/#U[IG@F31+:6\UF/Q=?VVHRVOAM](LX)KK4UU
MF6R:PMH99[L111NXL>&?B3\.O&NHZQH_@WQ]X*\6ZOX>^R_V_I?AGQ5H6O:C
MH?VV%+BR_MBQTJ_N[G3/M=O+%/:_;8H/M$,B2Q;T=6/X4_M,?"GX:?!/]HG]
MK+P3\(? GA7X:>$;W_@A]^T9?W_ASP5HEAX=TC4=4T?QU?:5I^LZG9:9#;PZ
MEKL6G7$UG-KM\MQJ]Y RI>WMP(X]F%\ M6_99\8:Y_P3%TW]A[0?!4'QT\-R
MZ#XE_: USP7X5L!XK\,_!?3?A1X@\-_&?2?V@M>T73]-DEUWQ-XXU+2;#2+C
MQ;>2F^\82V>O:';WD6IZ5+J"> @Z7M83JN,H.<9.DN6FE1=7]])3?*I.+C%J
M^Z=FURR?UJ2GR2C334N62YW>7OQA^[3CK;G3:=MK:7NOUB_9%_;+^'W[4WPE
M^%'CF>[\&_#SXB?%/0?$7B2R^"DOQ'T3Q+XTLM)\/^*?$?AN74+6T>R\-ZYK
M&G2Q>'9M2DU"+PO:6ULDDL#-(MJ]S)]'7?Q.^&VG^-]/^&=_\0O ]E\2-6T\
MZMI7P_N_%F@VWC?4]*7SMVIZ?X4FU!->O-/7[-<9O+:PDMAY$V9/W3[?YM_@
M3\'OA=X;_P"";O\ P3K^,V@^ ?">C_%V7]LKX+WUW\3],T#2['Q_J!U7]I;Q
M-X6OK'4_%UK:PZ[J>D3>'!;:(VCWU]<:8VGZ?ID#VK#3K0Q:7B_4OV3[?X!?
MML?#+XM^&?#^O_\ !1'5_CO\;=-\-V<OA.YO/V@/%WQ9\5>.?$,G[,_B3X.Z
MC]EO_%S^$K'2+KP:^BKX.O[;1]%TF*]L;FWMH]>B?6]:F7T95JRI.LH1Q-6@
MH1IJ<J?+6]GSMN=W0IQ<>:4I<S;BI27,Y+.&+J*G3<U3<G1A5<I2Y%.]-3Y5
M:-E4D^9I)<J2;2=K/^BKQC\7_A+\.YKJW^('Q1^'7@:XL=.T[6+V#QCXV\->
M&9K/2=8O[[2](U2ZBUK4[%[?3M4U/3-2T[3KV94MKZ_T^^L[:66XM+B.._:_
M$KX<WWB6R\&6/C_P5>>,-2T*#Q1IWA2U\5:%<>)=0\,W*J]MXBLM"AOWU2ZT
M*X1T>#5X+633Y596CN&# G\DH?@OX:^*O_!37P+X=_:4\%^"?BSKWAO_ ()8
M> +KQ'I_C'PSHGB;PU+\0F^.WB'1/$?B.UT76+?5=/BOFDO-?M;"ZC:62TL=
M7OX89W%P9*_/[X/_  Q^'_@[]@;_ ()8_&SP[\/M*N?C%XC_ &^/@G#KWCK2
M[#2X/B;XLTP_%'XH>%(?!K^,;N2QOWT1_#&BZ-X7TK0+[6+7P[96NG:86CMG
MM?MJ91P%&48_OI\\O8K2$73Y\13KU(6;E&7)'V$N9VNU.-DN5WTEB:BDU[./
M*N=ZRDI\M.5&,DTHM<S=962=ERO5W5OZ8%^+WPG?Q[_PJM/B?\.V^)_E-/\
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MN6.GZM:V]Y:3W%E'%=0/)+\._C'\-/BQ??$/3OAUXLL?%=U\*?'>H_#+Q_\
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MZDGP K]7_P!KO_DT[]I__LWCXU?^JV\2U>\8?LQ_ _Q[^S_:?LM^+/!']J_
MFQ\+>!_!=KX%_P"$E\7V/E>&OAO<^'[SP7IO_"3:;K]GXQ?^QKCPMH4GVR3Q
M"^H:C]AV:M=7T=U>+<>2^'/^">_[*?A6YU2ZTGP7X[D;6O#'BOP;JMMK?[0'
M[0_BC3;[PYXW\.:GX3\3:?/I/B?XJZOI;-J&@ZQJ%G#?"S&H:9-,FHZ3=V.I
MVUK>0=OUBA*,.9UHRIXS$8F*C3A*,XUEAN6+DZT'"2=!WM&:]Y--V:.94JL6
M[*FU+#T:+;G*+C*G[6[25.2DFJBM=Q>CO;<_%-KS5?V*?V%8K.?SY?V6/VYO
MV &:QDQ<7:_![]L3Q-^R:7N+,L1)=0^$_P!HF2T-W @?48;'XE1W;QP>&M%N
MKF;4/V"^'/QE\1_!O]CC]D/4_#GP*^+_ ,=9]9^!/P>L;G2?A#I_A?4-2T&*
MW^%OAFX34=83Q1XG\,6\=E<N?LT#6L]U,9P0\*)\]?1?B;]FOX(^,O@-9_LR
M>*/ 5EK?P.T_P?X6\!V/@:^U3Q!)':^&/!-OI5MX4LX/$"ZLOBN.]T./1-*D
MLM<77?[>6ZLHKV34Y+PR3OZAX0\*:!X#\)^%_ WA2P_LKPMX,\.Z)X4\-:7]
MJO;[^S= \.Z;;:1HUA]MU*YO-1O/L>G6=M;_ &J_N[J]N/+\ZZN9YWDE9U\9
M2KPCS4Y2J>WJ5*G,^6-6'*HTW)QDI*JHI1G:ZER1FY.4IA2P\Z3LII05*,8V
MUE"5TYJ/,FG!M-QOJN9Q248QM^67_!3WX<^#/C=^P;XW^-OC_P $>,=$\5^
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MEHCT.BBBN0Z HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^0U_PH_LGP]_T'?_ "&O^%']G5_Y\+_X5X;R_P"GGG_5U<^O4?Y,1_X35_\
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M7_\ D#DZ*ZS^R?#W_0=_\AK_ (4?V3X>_P"@[_Y#7_"C^SJ_\^%_\*\-Y?\
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MY?\ 3SS_ *NKGUZC_)B/_":O_P#(')T5UG]D^'O^@[_Y#7_"C^R?#W_0=_\
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MU_PH_LGP]_T'?_(:_P"%']G5_P"?"_\ A7AO+_IYY_U=7/KU'^3$?^$U?_Y
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M_P#":O\ _(')T5UG]D^'O^@[_P"0U_PH_LGP]_T'?_(:_P"%']G5_P"?"_\
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M?\*/[.K_ ,^%_P#"O#>7_3SS_JZN?7J/\F(_\)J__P @<G176?V3X>_Z#O\
MY#7_  H_LGP]_P!!W_R&O^%']G5_Y\+_ .%>&\O^GGG_ %=7/KU'^3$?^$U?
M_P"0.3HKK/[)\/?]!W_R&O\ A1_9/A[_ *#O_D-?\*/[.K_SX7_PKPWE_P!/
M//\ JZN?7J/\F(_\)J__ ,@<G176?V3X>_Z#O_D-?\*/[)\/?]!W_P AK_A1
M_9U?^?"_^%>&\O\ IYY_U=7/KU'^3$?^$U?_ .0.47J/J/YTE=:-)\/9'_$]
M[C_EFO\ A2?V3X>_Z#O_ )#7_"C^SJ_\^%_\*\-Y?]///^KJY]>H_P F(_\
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MY?\ 3SS_ *NKGUZC_)B/_":O_P#(')T5UG]D^'O^@[_Y#7_"C^R?#W_0=_\
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MU_PH_LGP]_T'?_(:_P"%']G5_P"?"_\ A7AO+_IYY_U=7/KU'^3$?^$U?_Y
MY.BNL_LGP]_T'?\ R&O^%']D^'O^@[_Y#7_"C^SJ_P#/A?\ PKPWE_T\\_ZN
MKGUZC_)B/_":O_\ (')T5UG]D^'O^@[_ .0U_P */[)\/?\ 0=_\AK_A1_9U
M?^?"_P#A7AO+_IYY_P!75SZ]1_DQ'_A-7_\ D#G8/N'_ 'C_ "%%=&--T5.(
MM7\Q3R6V*,'H1T] #^-%:+ UDDN?#[+;%4'T[JI8SEBZ3;:C6UMO0JKMTY//
M^M+\E1117F'H!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% "GK^"_R%)2GK^"_R%)0 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !2GK^"_P A24IZ_@O\A0 E%%% !1110 4444 %%%%
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M3:2>MH[W6ZL]'>UGH?1]%%%8F@4IZ_@O\A24IZ_@O\A0 E%%?-'[8WQ?\??
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MUJKK4J%6G-M0G&32NTGK;OYK57ML]'J=?1116184444 %%%% !1110 4444
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MDO;J_?E".BWUOV3/OJBOR(^"?Q<^-OP#_9D\+?MS_MA_M<^)OC/\(/%WP/\
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M]VUDOPSTOX;_ !P_:I_9#_X*@>$M$^&%G'\6/B+^W5HSQ?#BT\8>$[^PL)?
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M2JJ$GRMP3</=CI&S<FU*@IRG*4YOG2BX_N[**L^6+<'))M<S7-J][I)+X/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH 4]%^G]324IZ+]/ZFDH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 5>H^H_G24J]1]1_.
MDH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M0?</
M^\?Y"BB#[A_WC_(45O'9>B_(QG\3^7Y(]<_L?2O^@=9_^ \?_P 31_8^E?\
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MG_X#Q_\ Q-']CZ5_T#K/_P !X_\ XFBBCZOA_P#GQ1_\%0_^1#VU;_G[5_\
M!DO\_)?<']CZ5_T#K/\ \!X__B:/['TK_H'6?_@/'_\ $T44?5\/_P ^*/\
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M^ \?_P 3111]7P__ #XH_P#@J'_R(>VK?\_:O_@R7^?DON#^Q]*_Z!UG_P"
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M_P B'MJW_/VK_P"#)?Y^2^X/['TK_H'6?_@/'_\ $T?V/I7_ $#K/_P'C_\
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ML_\ P'C_ /B:**/J^'_Y\4?_  5#_P"1#VU;_G[5_P#!DO\ /R7W!_8^E?\
M0.L__ >/_P")H_L?2O\ H'6?_@/'_P#$T44?5\/_ ,^*/_@J'_R(>VK?\_:O
M_@R7^?DON#^Q]*_Z!UG_ . \?_Q-']CZ5_T#K/\ \!X__B:**/J^'_Y\4?\
MP5#_ .1#VU;_ )^U?_!DO\_)?<']CZ5_T#K/_P !X_\ XFC^Q]*_Z!UG_P"
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M  'C_P#B:/['TK_H'6?_ (#Q_P#Q-%%'U?#_ //BC_X*A_\ (A[:M_S]J_\
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MM7_P9+_/R7W!_8^E?] ZS_\  >/_ .)H_L?2O^@=9_\ @/'_ /$T44?5\/\
M\^*/_@J'_P B'MJW_/VK_P"#)?Y^2^X/['TK_H'6?_@/'_\ $T?V/I7_ $#K
M/_P'C_\ B:**/J^'_P"?%'_P5#_Y$/;5O^?M7_P9+_/R7W!_8^E?] ZS_P#
M>/\ ^)H_L?2O^@=9_P#@/'_\3111]7P__/BC_P""H?\ R(>VK?\ /VK_ .#)
M?Y^2^X/['TK_ *!UG_X#Q_\ Q-']CZ5_T#K/_P !X_\ XFBBCZOA_P#GQ1_\
M%0_^1#VU;_G[5_\ !DO\_)?<']CZ5_T#K/\ \!X__B:/['TK_H'6?_@/'_\
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M] ZS_P# >/\ ^)H_L?2O^@=9_P#@/'_\3111]7P__/BC_P""H?\ R(>VK?\
M/VK_ .#)?Y^2^X/['TK_ *!UG_X#Q_\ Q-']CZ5_T#K/_P !X_\ XFBBCZOA
M_P#GQ1_\%0_^1#VU;_G[5_\ !DO\_)?<(=&TS^&RMT'HD,0&?7E#S_@****A
>X>A?^!1W_P"?<.\/[OF_O*C6JZ?O:F_\\N\/,__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>ny20077604x1_figure02.jpg
<TEXT>
begin 644 ny20077604x1_figure02.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
M+0 R #< .P!  $4 2@!/ %0 60!> &, : !M '( =P!\ ($ A@"+ )  E0":
M )\ I "I *X L@"W +P P0#& ,L T #5 -L X #E .L \ #V /L! 0$' 0T!
M$P$9 1\!)0$K 3(!. $^ 44!3 %2 5D!8 %G 6X!=0%\ 8,!BP&2 9H!H0&I
M ;$!N0'! <D!T0'9 >$!Z0'R ?H" P(, A0"'0(F B\". )! DL"5 )= F<"
M<0)Z H0"C@*8 J("K *V L$"RP+5 N "ZP+U P #"P,6 R$#+0,X T,#3P-:
M V8#<@-^ XH#E@.B ZX#N@/' ],#X /L _D$!@03!" $+00[!$@$501C!'$$
M?@2,!)H$J 2V!,0$TP3A!/ $_@4-!1P%*P4Z!4D%6 5G!7<%A@66!:8%M07%
M!=4%Y07V!@8&%@8G!C<&2 99!FH&>P:,!IT&KP; !M$&XP;U!P<'&0<K!ST'
M3P=A!W0'A@>9!ZP'OP?2!^4'^ @+"!\(,@A&"%H(;@B"")8(J@B^"-((YPC[
M"1 ))0DZ"4\)9 EY"8\)I FZ"<\)Y0G["A$*)PH]"E0*:@J!"I@*K@K%"MP*
M\PL+"R(+.0M1"VD+@ N8"[ +R OA"_D,$@PJ#$,,7 QU#(X,IPS #-D,\PT-
M#28-0 U:#70-C@VI#<,-W@WX#A,.+@Y)#F0.?PZ;#K8.T@[N#PD/)0]!#UX/
M>@^6#[,/SP_L$ D0)A!#$&$0?A";$+D0UQ#U$1,1,1%/$6T1C!&J$<D1Z!('
M$B8211)D$H02HQ+#$N,3 Q,C$T,38Q.#$Z03Q1/E% 84)Q1)%&H4BQ2M%,X4
M\!42%3055A5X%9L5O17@%@,6)A9)%FP6CQ:R%M86^A<=%T$791>)%ZX7TA?W
M&!L80!AE&(H8KQC5&/H9(!E%&6L9D1FW&=T:!!HJ&E$:=QJ>&L4:[!L4&SL;
M8QN*&[(;VAP"'"H<4AQ['*,<S!SU'1X=1QUP'9D=PQWL'A8>0!YJ'I0>OA[I
M'Q,?/A]I'Y0?OQ_J(!4@02!L()@@Q"#P(1PA2"%U(:$ASB'[(B<B52*"(J\B
MW2,*(S@C9B.4(\(C\"0?)$TD?"2K)-HE"24X)6@EER7')?<F)R97)H<FMR;H
M)Q@G22=Z)ZLGW"@-*#\H<2BB*-0I!BDX*6LIG2G0*@(J-2IH*ILJSRL"*S8K
M:2N=*]$L!2PY+&XLHBS7+0PM02UV+:LMX2X6+DPN@BZW+NXO)"]:+Y$OQR_^
M,#4P;#"D,-LQ$C%*,8(QNC'R,BHR8S*;,M0S#3-&,W\SN#/Q-"LT932>--@U
M$S5--8<UPC7]-C<V<C:N-NDW)#=@-YPWUS@4.% XC#C(.04Y0CE_.;PY^3HV
M.G0ZLCKO.RT[:SNJ.^@\)SQE/*0\XSTB/6$]H3W@/B ^8#Z@/N _(3]A/Z(_
MXD C0&1 ID#G02E!:D&L0>Y",$)R0K5"]T,Z0WU#P$0#1$=$BD3.11)%546:
M1=Y&(D9G1JM&\$<U1WM'P$@%2$M(D4C721U)8TFI2?!*-TI]2L1+#$M32YI+
MXDPJ3'),NDT"34I-DTW<3B5.;DZW3P!/24^33]U0)U!Q4+M1!E%049M1YE(Q
M4GQ2QU,34U]3JE/V5$)4CU3;52A5=57"5@]67%:I5O=71%>25^!8+UA]6,M9
M&EEI6;A:!UI66J9:]5M%6Y5;Y5PU7(9<UETG77A=R5X:7FQ>O5\/7V%?LV %
M8%=@JF#\84]AHF'U8DEBG&+P8T-CEV/K9$!DE&3I93UEDF7G9CUFDF;H9SUG
MDV?I:#]HEFCL:4-IFFGQ:DAJGVKW:T]KIVO_;%=LKVT(;6!MN6X2;FMNQ&\>
M;WAOT7 K<(9PX'$Z<95Q\')+<J9S 7-=<[AT%'1P=,QU*'6%=>%V/G:;=OAW
M5G>S>!%X;GC,>2IYB7GG>D9ZI7L$>V-[PGPA?(%\X7U!?:%^ 7YB?L)_(W^$
M?^6 1X"H@0J!:X'-@C""DH+T@U>#NH0=A("$XX5'A:N&#H9RAM>'.X>?B 2(
M:8C.B3.)F8G^BF2*RHLPBY:+_(QCC,J-,8V8C?^.9H[.CS:/GI &D&Z0UI$_
MD:B2$9)ZDN.339.VE""4BI3TE5^5R98TEI^7"I=UE^"83)BXF229D)G\FFB:
MU9M"FZ^<')R)G/>=9)W2GD">KI\=GXN?^J!IH-BA1Z&VHB:BEJ,&HW:CYJ16
MI,>E.*6IIAJFBZ;]IVZGX*A2J,2I-ZFIJARJCZL"JW6KZ:Q<K-"M1*VXKBVN
MH:\6KXNP +!UL.JQ8+'6LDNRPK,XLZZT);2<M1.UBK8!MGFV\+=HM^"X6;C1
MN4JYPKH[NK6[+KNGO"&\F[T5O8^^"KZ$OO^_>K_UP'# [,%GP>/"7\+;PUC#
MU,11Q,[%2\7(QD;&P\=!Q[_(/<B\R3K)N<HXRK?+-LNVS#7,M<TUS;7.-LZV
MSS?/N- YT+K1/-&^TC_2P=-$T\;42=3+U4[5T=95UMC77-?@V&38Z-ELV?':
M=MK[VX#<!=R*W1#=EMX<WJ+?*=^OX#;@O>%$X<SB4^+;XV/CZ^1SY/SEA.8-
MYI;G'^>IZ#+HO.E&Z=#J6^KEZW#K^^R&[1'MG.XH[K3O0._,\%CPY?%R\?_R
MC/,9\Z?T-/3"]5#UWO9M]OOWBO@9^*CY./G'^E?ZY_MW_ ?\F/TI_;K^2_[<
M_VW__V1E<V,         +DE%0R V,3DV-BTR+3$@1&5F875L="!21T(@0V]L
M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
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M'_@L=^ROX4^*\/P+\1^"?VF]'^,EUJMCHEC\,KWX ^+8_&NI:EJC*-)@TK0
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M)X6ETJ_CD%K:^3_;Q'''#''%%&D442+'%%&JI''&BA4CC10%1$4!550%50
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MR^]]/Q?W>=C^B7X!?M6^$_VDY5U'X:_#;XXP?#VZT-=>T7XM^._AI?\ PW\
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M:D?BO1/'DZQZ/:W)F-_=:M=ZCN?\._OA%_PW[_P\!\QO^$__ .%5_P#"#_\
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MC6=+L=4>WD73[S4M'L]5T*[U6PMKLPSWFFVNN:-<7UNDEK!JNG2RK>0_DO\
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MT^%^F?$;X/\ A&3P%X0\(6?[*?B"7P2WA.ZL?'^GZC8ZS'<_M1/KM_>W]O\
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MTL]&\'26:6MI%&D%NEI)%$]LL4:"!XXVB",BD>S?\$H?^4<_[(__ &2?3_\
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MVB_Y]P^Y?Y'^>1_PU1_P=5?]"Q^VO_XASX-_^<?1_P -4?\ !U5_T+'[:_\
MXASX-_\ G'U_H;T4<K_FE]_]>?\ 2U/:+_GW#[E_D?YY'_#5'_!U5_T+'[:_
M_B'/@W_YQ]'_  U1_P '57_0L?MK_P#B'/@W_P"<?7^AO11RO^:7W_UY_P!+
M4]HO^?</N7^1_GD?\-4?\'57_0L?MK_^(<^#?_G'T?\ #5'_  =5?]"Q^VO_
M .(<^#?_ )Q]?Z&]%'*_YI??_7G_ $M3VB_Y]P^Y?Y'^>1_PU1_P=5?]"Q^V
MO_XASX-_^<?1_P -4?\ !U5_T+'[:_\ XASX-_\ G'U_H;T4<K_FE]_]>?\
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M10 4444 %%%% '\J?_!V[_R8I^SS_P!G::'_ .J=^+U?I#_P0!_Y1"?L9?\
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M!OACX2^*'[4H\*?\(5XM\>6W@+0?[!^)R>-[K_A*+KP]K_B&'S=-6-#:V_\
M9/A_5<WN2%D\N#'[^O[T_P#@WZCEC_X) _L:+-,9W.@?%>0.46,K%+\??BM+
M!#M3@BVA>.W#GYI!$)'^=FK\Y/\ @[=_Y,4_9Y_[.TT/_P!4[\7J_2'_ ((
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M_AW3?C[\9KW5M1F=-+\)? JP;P)J$RL7(LK2R^$6D:'K^K1JKLFV^N-2N)4
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M.^N[&WG:.2]@T_49+43+I]X8/ZT/V)="UGPO^QC^R-X9\1Z9>Z)XA\._LQ?
M/0M=T;4K>2UU'2=9TCX5>$]/U33+^UE"RVU[87MO/:W5O(JR0SQ21N RD5]$
M:OH6B>((+>UU[1]*UNUL]1T_5[2VU?3[34H+75M)NH[[2]3MX;R&:.#4=-O8
M8KS3[V)5N;.ZBCN+:6.5%<:M;6]YOO\ U^AY;E>,8V^&^O>[O\OQ"BBBF2%?
MP]_\'@O_ "-_[!'_ &+?[1W_ *=/@K7]PE?P]_\ !X+_ ,C?^P1_V+?[1W_I
MT^"M3/X7\OS1I2_B1^?_ *2S^M']@?\ Y,5_8L_[-,_9R_\ 5/>#:^LZ^3/V
M!_\ DQ7]BS_LTS]G+_U3W@VOK.G'9>B_(B6[]7^84444Q'\)_P#P=Z^&M>C^
M-?[&?BY]*NQX:U+X7_$SPU9:R(]UE/KVC^+-"U/4=*#J69+NWL->TFZ$<JIY
M\5WFW,I@N1#_ &.?L8^%_$/@?]CW]E#P5XNTB]\/^*_!_P"S5\"O"_B?0=2B
M\C4=$\0^'_A?X6TG6M(OX<GR;W3=2M+FSNHLGRYX9$R<9KW_ %;0=#U]+"/7
M=&TG6DTO5++7-,35M.L]133M:TR0RZ;K%@MY#,+/5-/E9I++4+<1W=I(Q>":
M-B36K2M[S??^OT+<[QC&WPWU[]O3^M@HHHID!1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 ?YX__  =I_P#*1KX+?]F3_#G_ -7K^TA7^AQ7^>/_
M ,':?_*1KX+?]F3_  Y_]7K^TA7^AQ4KXI?]N_D:S^"EZ2_0****HR"BBB@
MHHHH **** "BBB@ HHHH **** "BBN5\;>.O!'PT\+ZQXX^(_C'PK\/_  5X
M=M'O_$'C#QMXATCPKX7T*QC(#WNL>(-=O+#2=,M$) >XO;N"%20"XR* /Y??
M^#MW_DQ3]GG_ +.TT/\ ]4[\7J_2'_@@#_RB$_8R_P"Q:^)__J]?BC7XN?\
M!T%^UK^RI\?_ -C'X%>%O@/^TU^SY\;/$VD?M/:-K^K>'/A'\9_AQ\2-=TO0
MHOA5\4M.EUO4=(\&^)-9U"RTB/4-0L+&34KFWBLTO+ZSM6F$]S"C_M'_ ,$
M?^40G[&7_8M?$_\ ]7K\4:A?&_3_ "-7_!7^/]&?L71115F05_!Y_P %:O\
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M\5ZA/$B:_I=W8:M:Z;?07;0PW5E>_I510U?1C3:::T:V/\TG_@K?_P $)O\
MAUG\"?AY\:_^&IO^%Z_\)[\6K'X6_P#"-?\ "D/^%8_V5]M\'>+_ !9_;O\
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M:I;?8-2U'^H./1M(AOI-4ATK38M3EW>;J,=C:QWTN\ /YEVL0N'WA5#;I#N
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MECN5-YH7AOPOI/B#P=X7ANK,QL3!XNU?Q+XBN+2Y62-XG\#W,15X[HFO?O\
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M/+<HA45IU6H0H<Z:5FH4%5GB+.48XC%^RIU)JC-1_P!(_I3U\@^CI]&3P_\
MHD9?FV%SOC[-<PPW''B7B<#4<\+@%/%5\VCAJD924Z<L7FL\OPV3*5.E6K9+
MP]_:.-PF&J9GA95;GC+P!X#^(MA8:5\0?!/A'QUI>E:UIGB32]-\9>&]&\3V
M&F^(M$G^U:-K]A9ZW97UO9ZUI%S_ *3IFJV\<=]83_OK2>*3YJZVOYL/^#@W
M_@JY^TU_P3<D_99\/_LU0> +74?B]-\3]?\ %^N>-_#4GBISIWP[N?A[;Z;X
M>TRP;4+"TL[36'\6ZBVN7Q$FIF&VL8](N]*E6XN)OWJ_9S^)M]\:_P!GSX$_
M&34].M='U+XM?!KX8?$W4=)LGEDLM+OO'G@G0_%5WIUI).S326ME<:K);6[S
M,TK11(TC%R2?VFZNUU1_EHXM14NC;M\O\_T]#V6BBBF2%?P]_P#!X+_R-_[!
M'_8M_M'?^G3X*U_<)7\/?_!X+_R-_P"P1_V+?[1W_IT^"M3/X7\OS1I2_B1^
M?_I+/ZT?V!_^3%?V+/\ LTS]G+_U3W@VOK.ODS]@?_DQ7]BS_LTS]G+_ -4]
MX-KZSIQV7HOR(EN_5_F%%%%,1R/B[X?^ _B!#HMOX]\$^$?&\'AKQ!IOBSPY
M#XN\-Z-XEAT#Q3H[.^D>)=%CUFRO4TKQ!I3RR/INLV*P:C8M([6MS$78GKJ_
MF)_X. /^"OG[4'_!.+X@_LU_#W]FO3_AW;2^/_#OBOQ_XWUKQYX;N/%C:K9Z
M)KNDZ+HOA73[&/5-(CTC3I2-9N-?OX99=8OUNM+BTB_T Z=>2ZK_ $,_L_?$
M^7XW? 7X(_&B?2(_#\WQ=^$7PV^)\V@Q7;:A%HDOC[P;HOBN32([]X+5[V/3
M7U8V27;6UNURL(F:"$N8U5U=KKU_ IQ:BF]GMJ>NT444R0HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** /\\?_@[3_P"4C7P6_P"S)_AS_P"KU_:0
MK_0XK_/'_P"#M/\ Y2-?!;_LR?X<_P#J]?VD*_T.*E?%+_MW\C6?P4O27Z!1
M115&04444 %%%% !1110 4444 %%%?FI_P %"_V=OVU?VK(/A[\#?V>OVA?#
M'[,O[/?C"R\7VG[5/Q$TS1KW6/CSJ_AR:/2+30? GPB8JFDZ);^)K6X\1P>*
M_$,NJ>']7TJ--*FT[4-5L?[7\+ZX/[_0:5WO;S?0^SO@U\?/@Q^T/H7B/Q1\
M#_B3X4^*/AOPEXW\0?#CQ!K_ (.U*/5]&L?&OA9;)]>T%=2@!L[V>PCU*PF:
MYL)KJPN(+N">TNIX9%<^<?&W]M[]CW]FWQ%I?A#X^?M-_ _X0^+-9C@GL/#/
MC[XD^%O#OB![.Y8+!J=QH]_J46H6&D2L<)K%_;VVEL5?_2_D?;^*_P#P:TZ?
M#I/_  3O^*.EV[2O;Z;^V5\8]/@>9D:9X;/P/\(;>)IFC2-&E9(U,C)'&A<D
MJBC"CR#_ ((4_LT_!K]O3X-_M7?M\?MD_!WP!\?/C'^UA^TE\1=.DU3XN>%_
M#GQ"M/#'PR\/:+HECI7A;P#!XDAUR\\$:=I][KNO^%XX]+N=+N8O#/A;P7H]
MG'%I/AG1)I%=Z=VK_+2_YZ%N"3G=NT6EYMO\+:/\#^I+PYXC\/>,?#VA>+?"
M.O:+XI\*>*-'TWQ#X9\3^'-4L=<\/>(M UJSAU'1]<T+6M,GNM-U?1]6T^YM
M[_3=3T^YN+*_LYX;JUGE@E1VV:_FD_X(V_%C3/V3_%/_  6#_93^(OBJ+P7^
MRQ_P3X_:)N_&?PLU+QGXAU'6(_A=\%/B=??%K68O#/\ ;5_JNLW+^&]&T/X;
MZ3X@T_3XU;6+KQ'XH\27=Y%<Z[K<ME!]&3?\'(7_  2"BFEB7]I;Q!<+%+)&
ML\/P'^/7DS*CE1+%YOPWBE\J0 /'YL44FUAOC1LJ!-63>E^_EN)P=VDG)::I
M/JDUM?H^Y\1?\';O_)BG[//_ &=IH?\ ZIWXO5^D/_! '_E$)^QE_P!BU\3_
M /U>OQ1K^</_ (.%_P#@K!^PU^WO^RG\'OAA^R]\5]6\>^-/"7[0>E^/==TN
M_P#AM\2/!D5IX7MOAQ\1?#TU^FH>,O"VA:?<R+JOB#2K<65M<RWC+<-.L!@@
MFDC_ *.O^#?]E?\ X)!_L9E&5@/#GQ14E2& 9/CO\4D=202-R.K(PZJRE2 0
M14KXWZ?Y%R35))II\^S5NC/V-HHHJS$*\_\ BG\*_AW\;?A_XH^%GQ7\(Z/X
MY\ >,M.?2_$7AK7;?S[*]M_,CGMYXI$:.ZT_5--O8;;4]%UK3;BTU?0]7M++
M5]'OK+4[*UNX?0**BI3IUJ<Z56G"K2JPE3J4JD8SIU*<TXSA.$DXSA.+<91D
MG&2;333.G!8W&9;C,)F.78O$X#,,!B:&,P..P5>KA<9@\9AJL:V&Q6%Q-"<*
MV'Q.'K0A5H5Z,X5:56$:E.49137\3O\ P4!_X(4_&?X#7^M_$C]EBRUWXY?!
M@++J5SX1M8DO_B_X!A,Q62RDT2SCCF^(FBP+) UIJWA:SD\110M<KK/AB&RT
MJ;Q'J/B_['__  6Z_:\_99LM,\$>,I[/]H;X8Z4\-M#X:^)FI:G#XWT/3K82
M(=+\,?$J(7VK6,*_N8(+;Q9I/C;3]*M+:*RT?3=-@!6O[RJ^'_VF?^"<O['/
M[65IJLGQ9^"_AA?%^J--.WQ0\%V=OX*^)T.H/;26L.HW/B[0X+>Z\1O9K*9;
M;3?&4/B70//6.6XT>X:-,?D69>&>,R['5,WX%SBID6*FI.IE]6<Y8*H[\RA"
M:C5Y:+=VL-BJ&*HJ;3A*C3C&"_TEX'^G=PUQKPI@_#?Z7/AI@_%KA_#.G2P?
M&. P^%I\58&'(J,L7BL-*ME[J9FJ=H3SS(,WX?S*>&IN.(HYCBJU7$5/E3]G
M#_@N3^PI\=X]/TSQ7XSU']GSQG=1Q)/H?QAMHM+\-F[%NLMX=/\ B/IDM_X.
M73()=T-M>>*;[PA?WH"NNCPNQB7]5O OQ)^'7Q0T9/$?PS\?>"OB)X>D;9'K
MO@7Q3H7B[1G< ,435- O]0L6;:P.T3DX(.,$5_*I\=O^#;#QW83W6H_LU_M!
M^&O$EC)=3/;>%/C/H^H>%M4L-.5"T,(\:^#;/Q-I_B'4Y''EYE\%>$++D.TL
M:YQ^6GCG_@E!_P %*_@7J!UN/]GCXBWTNF323:;XB^#>L:3\0-0D%M,BQWNF
MVGPXUO5_%MH[R;);>*ZTBPU$JOF_94$;,O,N-/$/(E[/B#@V>9PIJTL;ECJ1
MC**Y?WM6I@Z>8X6+:;=N3#)MJ+A3E&1[D_HN_0K\7*CQW@U])["\"XC&.,Z/
M"W'JP=6M0KRY^; 8'!\28O@O/:L8M1ASK%Y[*/+.O#$8NC4I6_T*Z*_SO#^U
M[_P50_9SOHX_$OQD_:^\!W-FXD33/B[<_$+4+6#[.]E=E#H?Q6M-3L%@0"T:
M:W>R^SM;W+131M;ZA.EQVEO_ ,%L?^"G5K#'!%^T[.R1@A6N/A#\!+R8Y8L?
M,N;OX63W$IRQ ,LKE5PBD*J@;1\:,BIMPQV39[A:T=)4HT<'4<7V?ML9A9+Y
MP1YV(_9;>+F,C#$\*>)OA'G^655S4L=B,RXFP,:D>DH++>&L_P /-/36.+:\
M]-?] ^BO\_?_ (?<_P#!3[_HYO\ \PQ^SW_\Z>N&OO\ @HE_P4]^.=TNF:3^
MT/\ M#Z_?3.D<=E\)!?^%;Z22*/8(XX?A-I&@7)?;<*TJ(N97>&64/(L+J3\
M:N'9)1PN59[7JMVC3G0P---]$G3Q^(E=^5-DX;]ECXU492K9]XA^$659=3CS
M5L9ALUXLQLJ45\4I4L;PCD]!12UO/&07=K<_T+]8UK1_#VG76L:_JVF:'I%C
M"]Q?:IK%_:Z9IUG!$C223W5]>RP6UO#&BL[R32HB(K,S  D?G'\>/^"O7[ '
MP"M+D:M\>_#OQ*U^*WDFMO"?P1>'XIZI?212>5+9?VUX>N7\#:/?QMG=:>)O
M%^A2#:PP6&VOX[;#]@K_ (*A_M0:Y_;&N_ C]I7QMKGE01)XC^.4FM^%9IK:
M16> 6WB7XWZMX=BN;4*I(:WU"6"/<@9E,B!OT$^"'_!N1^T]XQ:SO_CG\5?A
MI\%M'N+;SIM*T"/4/BKXXL[H,#]AOM-L9/"_@R%)$R/M^G>/M:$+\_8IU #9
M/C[CC.;T^'.",104[QIXS,O;RHV;2YE.K#+L)":O?EEB:T4[.2E%-/T:?T//
MHH>&')CO&[Z5V2YK+#<E;%\,\"_V72S1.,>=T)8; 8OC;B'%8:JTE[:AD675
MJM-RA1E1JN-6-#]K3_@X1_:$^+%IK7@[]FSPGI_[/WA"_6:R'C2[ND\4_%VZ
MLF,L3S6&HM%!X8\%R7UK(!*FF:3KFN:5<*EQHWC"VGC6>ODG]C?_ ()9?M>?
MM^>)+7XEZ]%KO@KX5>*=6GU3Q/\ '_XI/?W^H>*#/,DVI:EX2TO5KV+Q/\2M
M5OGDG$>MI+#X6FU"WO;74_%UI?P/;/\ U6?LL_\ !&W]B#]F&.SU8_#N+XV>
M/[?9(WCKXUP:9XQ:UN5DM[E)/#_@Z2P@\#Z"UE=VZSZ5J<.@7/BBQ#-$WB6Y
M!+']4U5454151$4*B* JJJ@!550 %50       !BGA?#G.^(,51S'C[.ZF-5
M-\]/*,%4Y:%.[NZ<JM.-*A0BTN6K'!T54J*UL8G%2>?$'TW?"GP;R#,>"OH>
M>%."X5EBXO#8SQ'XIPBQ&;8Q4Z;IPQE# XO$8_-,UK1G)XC 5^)\T>$P<U*,
M^&IPKSIT_F7]DW]D;X+?L8?"BP^$GP5T&;3]+6==3\2>(M6FCOO%?C?Q&]O#
M;77B/Q3JL<%LEU?SQ01Q06EG;66D:7:HEEI&G6-H@AKZ<HHK]@PN%PV"P]'"
M82A3PV&P].-*C0HP4*=*G%648QBDDNKZMMMMMMG^:6?9_G7%.<YEQ%Q'FF.S
MO/<YQ=7'YIFV98BIB\=CL77ES5*^(Q%64ISF](Q5^6$(QITXQIPC%?Q#?\'@
MMA>_\)#^P1J?V2Y_L[^QOVCK#[>()#9B]^W?!6X%H;@+Y0N3!F98"XD:)6D5
M2J,1_6E^POI]_I'[$O['>E:I9W.G:GIG[+'[/FGZCI][#);7EC?V7PE\(VUW
M9W=O*JRP7-M<120SPR*LD4J.CJ&4@>P_$OX._"/XT:3IF@_&+X6?#GXL:'HF
MMV7B;1M&^)?@CPSX[TG2/$FFB0:=X@TS3O%.F:K9V&MV FF%EJMK#%?VHED$
M%Q&';/HH         &  .  !P !P .E:V]YRONK6^[_(\MRO",;?"WKWN[_J
M+1115$!7\/?_  >"_P#(W_L$?]BW^T=_Z=/@K7]PE?P]_P#!X+_R-_[!'_8M
M_M'?^G3X*U,_A?R_-&E+^)'Y_P#I+/ZT?V!_^3%?V+/^S3/V<O\ U3W@VOK.
MODS]@?\ Y,5_8L_[-,_9R_\ 5/>#:^LZ<=EZ+\B);OU?YA1113$?PA?\'>NE
M:G%\>?V-M;EL+R/1[_X1?$G2K+5'MY5T^[U/2?&6C7>J6%O=E!!->:?:ZUI%
MQ>6Z.TMM#J=C+*BI=0E_['?V(=%U?PW^Q=^R%X=\0:7J&AZ_H/[+_P  =%US
M1=6LY]/U72-7TOX4>$['4M+U.PNHXKJQU#3[V">TO+.YBCGMKF&2&:-)$91Z
MO\1_@U\(/C';^'[3XN_"GX;?%2U\):[;>*?"MM\1_ WACQQ;^&?$UD"+/Q%X
M?A\3Z7JD>C:[: D6VKZ<MMJ$ )$5P@->DTK>\WW_ *_0N4[QC&WPWN_R_P""
M%%%%,@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_/'_P"#M/\
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MEKX2UVV\4^%;;XC^!O#'CBW\,^)K($6?B+P_#XGTO5(]&UVT!(MM7TY;;4(
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MQ2_[=_(UG\%+TE^@44451D%%%% !1110 5_)Q_P4Q_:#_;__ &Y?^"E6M_\
M!(G]AKXN6G[-OA?X;?"[1O'/QZ^)2:[J/A+Q!XBL_$6@>"?&>I2CQ9X?@N_&
M:>'M%\/>._!F@:3X.\"C2+SQ1KFN^)8_&NJW/A$12^&_ZQZ_F;_X*]?\$L_V
MSO'/[4_P]_X*0?\ !,+QG9^$_P!J+PKX13P?X^\,'Q-X>\)ZQXPCTR#^PO#N
MO>&+KQI8M\/M:N[CPIJE_P"&/&_A_P"(NLZ7X>OO#GA[PU_9T-]J"WMK<S*]
ME:^ZO;>W]=BZ=N9WML^5RV4M+-_Y]#\$OV>?B+^WW\,O^"+7Q)_:A_9Q_: U
M;P?J?[+_ /P4[\=>-OC-XMO_ !KK,_C3Q98:A\'OV9/A1X.TJ/1M>TO7O#/Q
M'\*-XD\>7>H>+/!_CV[.DW$<>E7D.C:]>6WDVO\ =;^Q%^T%<_M6?LA?LW_M
M&:C9Z9INM_&'X/>!_&OB?3-%@U"VT72_&.I:):CQEI6C0ZM+<:BND:9XIBUB
MQTMKNZO99+"WMY#?7RN+N;^&GX ?\$4_^"YWQ)\!:K^QA\0EB_9F_9#\>_&&
M3XO?%P^*?'_P>USPYJ?C1HO"5CJGB*3P]\*/$7B/Q]X_U"'3_!WAR]\*^$KV
M^TSX;2^(M TR]_M?PQ>M/X@A_OB^!'P8\$_LZ?!?X6? ?X<6DUEX%^$/@/PQ
M\/O#$=VT4NH3:5X7TFUTJ'4-5N((;>.\UK5&MWU/6K\01-J&JW=Y>R())VI1
MOYI62U[KM\OQ*J\O1Q;;;O'MI9.WX=OS]8HHHJS(**** "O*?C3\"_@[^T9X
M U3X6?';X:^#OBO\/-9EMKF_\)>-]$L]<TE[VR=I+'4K:*[C>33]6T^1WDT_
M5M/DM=2L)'=[2ZA9F)]6HH _B/\ ^#E3_@G[^QC^R5^R!\$O'7[-W[._P^^$
M'B[Q#^TEI'A+6M?\(V=_;7^H^&Y_AA\3-8FTBX>ZO[M&M)-3TC3+UE6-7\ZS
MA._ (/[R_P#! '_E$)^QE_V+7Q/_ /5Z_%&OS>_X.W?^3%/V>?\ L[30_P#U
M3OQ>K](?^" /_*(3]C+_ +%KXG_^KU^*-0OC?I_D;-MT8W;?O]=>C/V+HHHJ
MS$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#^(+_@\&MKD>)OV!
M[PV\XLWT+]I"V6Z,4@MFN8]0^"4KVZS[?*,Z121R/$&,BQR(Y4*ZD_UI_L)V
M=YIW[$/[&^GZA:W-A?V'[*O[/-G?6-Y!+:WEG>6OPC\(07-K=VTZ)-;W-O,C
MPSP3(DL,J/'(BNI ]/\ B_\  'X%_M!:/H_A[X[_  ;^%WQGT'P_K4'B+0M&
M^*?@+POX^TO1]=MD:*+5M,L/%.EZI;6-_P#9Y);26YMHHY+BRGN+*=I;2XFA
MD]91$C1(XT6..-51$10J(B@*J(J@*JJH 50      *5O>;[_ -?H6Y7A&-OA
M;=_5O_,=1113("OX>_\ @\%_Y&_]@C_L6_VCO_3I\%:_N$K^'O\ X/!?^1O_
M &"/^Q;_ &CO_3I\%:F?POY?FC2E_$C\_P#TEG]:/[ __)BO[%G_ &:9^SE_
MZI[P;7UG7R9^P/\ \F*_L6?]FF?LY?\ JGO!M?6=..R]%^1$MWZO\PHHHIB/
MX/O^#O33[^/X_?L<:K)97<>F7GP>^(VGV>I/;3)87=_IGC32;G4K*VO&06\]
MWI]OJVE3WMM%(\UI#J>GRSI&EY;-)_8Y^PSIFI:+^Q/^QYHVLZ??:3J^D_LL
M_L^Z9JNE:G:3V&I:9J5A\)?"-K?:?J%C=1Q75E?65U%+;7=I<Q1SV\\<D,T:
M2(RCT3XN_L\_ 3]H"V\-V?QV^"OPI^,MIX.U8Z]X3MOBE\/_  KX]@\-ZRXA
M674M#B\4:5JB:7=W"6\$=U+9K";N*&**Y\V.-4'L-2E[S??3\O\ (N4[PC&W
MPWU_(****H@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_/'_X.
MT_\ E(U\%O\ LR?X<_\ J]?VD*_T.*_SQ_\ @[3_ .4C7P6_[,G^'/\ ZO7]
MI"O]#BI7Q2_[=_(UG\%+TE^@44451D%%%% !1110 5_,5_P4C_X)/_\ !5;]
MJ/\ :]^(_P :OV8?V_#\"O@QXHTSP':>&/AG_P +[_:.\#?V%=>'? OA[P]X
MAG_X1KX?:!?>%+'^V/$&FZEK&_3[J22\^V_;+X)>SW"+_3K7\M__  4PU_\
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MX?\ VD84G,;"%YHM1^"+RQ+*1L:6-)HGDC#%D66-F #J3_6G^PC:W5C^P_\
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M_KL?55%%%49!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?YX_\
MP=I_\I&O@M_V9/\ #G_U>O[2%?Z'%?YX_P#P=I_\I&O@M_V9/\.?_5Z_M(5_
MH<5*^*7_ &[^1K/X*7I+] HHHJC(**** "BBB@#\F_\ @K]J/_!333?@)\.9
MO^"6L=])\:G^+UA'X\%AI?P/U64?"X^#/&+7I>#X\6EYX8CC_P"$L7PJ#+I,
M:Z\&*I$XT][]6_G?_P"$J_X/"_\ GU\2?^$;_P $X_\ Y1U_<)7\;?\ P5"^
M.'_!3S]M3_@J9\4?^";_ .P=\;==^ &E?LT?![P]\3]4_P"$1^)_B7X0ZG\0
MM0O? /@;QYJ^JZEXY\"V+>,KJXE'Q<\+^"/#W@@7J^%Y+W3#X@U-;>666_L)
MDNMY:NR2?4UIN^G+"R3;E)7LOO/'_P#A*O\ @\+_ .?7Q)_X1O\ P3C_ /E'
M7]@/[)LWQRN/V8O@!/\ M-+*O[1$WPA\ R?&Y9X/"UK,/BB_AO3V\;"6V\#Q
MP^#8)!KYOM\7A>*/08VRNEHMH(@/\ZO3-*_X+(>//^">NK_\%$O!W_!0[]I'
MX@_ _P +>+-:\'?%?P5I7[7W[0LWQ)^&QTC7-*T5M5\2^&M5\06FBZKH\_\
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M 4444 %%%% !1110 4444 %%%% !1110 4444 ?YX_\ P=I_\I&O@M_V9/\
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M6N54;YFG+FM;79;+HM HHHJC,**** "BBB@#^5/_ (.W?^3%/V>?^SM-#_\
M5._%ZOTA_P"" /\ RB$_8R_[%KXG_P#J]?BC7YO?\';O_)BG[//_ &=IH?\
MZIWXO5^D/_! '_E$)^QE_P!BU\3_ /U>OQ1J%\<O3_(U?\&/^/\ 1G[%T445
M9D%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^"__!;;_@L/XR_X
M)7Q?LYZ5\//@_P"%_BGXD^-FI^,]4U6?QGK>K:5HNB>#_AS?>!X];TVP@T-4
MO9O$?B>'QA):Z3J]Q<-IOAF6P&H7NB>)DF_LQ?V:^"7Q-L?C7\&?A'\9-,TV
MXT?3?BU\,? /Q-T_2+R5+B[TJQ\>>%=)\56FFW4\2I'-<6,&JQVL\L:(DDL3
M.BJK #^,O_@\&1QXL_8'D*,(W\._M((DA4A&>/4O@DTB*V-K,BRQLZ@DJ)$+
M !US_6G^P;#-;_L-_L96]Q%)!/!^RA^SM#/!-&T4T,T7PA\'I+%+$X5XY(W5
MDDC=0R,"K $$5*;YVNB7^1HXI4X.VK<KOYO_ "/J^BBBJ,PK^'O_ (/!?^1O
M_8(_[%O]H[_TZ?!6O[A*_A[_ .#P7_D;_P!@C_L6_P!H[_TZ?!6IG\+^7YHT
MI?Q(_/\ ])9_6C^P/_R8K^Q9_P!FF?LY?^J>\&U]9U\F?L#_ /)BO[%G_9IG
M[.7_ *I[P;7UG3CLO1?D1+=^K_,****8C^??_@M;_P %IO%W_!+;Q=^SUX$^
M'7P8\,_%77_BE;:YXT\877C37=6T72M-\"^&]9TK2&T/PY_8:R77_"5>));G
M5A'K^I+<:3X533;&>3PYXM.K36VD_N#\'?B7I'QH^$?PL^,7A^RU#3= ^+'P
MX\#_ !+T/3M66!=5L-(\=^&=+\4Z;9:FMK-<6JZA:V6JP07BVUQ/ +F.00S2
MQA7;^'__ (.\X9E_:'_8]N&AE6WE^#'CZ&*<QN(9)K?QQ9R3PQRD;'EA2YMW
MFC5B\:7$+.%$L9;^QC]@V&:W_8;_ &,K>XBD@G@_90_9VAG@FC:*:&:+X0^#
MTEBEB<*\<D;JR21NH9&!5@""*E-\S72W^7^9I**4(-;N]_/_ (;H?5]%%%49
MA1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?YX__  =I_P#*1KX+
M?]F3_#G_ -7K^TA7^AQ7^>/_ ,':?_*1KX+?]F3_  Y_]7K^TA7^AQ4KXI?]
MN_D:S^"EZ2_0****HR"BBB@ HHHH _'O_@MU_P %%/&G_!-G]C1?BM\+-!T?
M6_BY\2?B/H?P?^'=WXCM9-0\.^$=2UG0/%'BK5O&NKZ2DMJNM_V-H/A'4;+1
MM)DO8;>3Q+JVB7VI6VJ:)I^K:5>?RB_\-^?\'$O[*'@GX;?\%#OCGK'CKQ%^
MS9\5M;\(_9=.^)VF_!^7X?\ C+2-=M-0U3P_9W/PN\(II_C?X1:1XOTFQN[C
M1O%NE>&O *ZJLNC7,.JZA'JVC0ZG^R7_  =N_P#)BG[//_9VFA_^J=^+U?F1
M_P %!/\ @O+^QG^UG_P2SUW]B3P+\,?VDM+^+UWX%_9[\/:-XD\:>#_AAIWP
M]LM<^%/C;X9ZYXFO9=6T+XR>(?$BVE_H/A/Q%8Z+(GA&>:YNM0L([ZUTV*6X
MN[+-O5ZM66B[NR^_T_X)O37NQM!2YI-2;5[*Z^[O\C^W;]FSXZ^%?VG?V?\
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M[KT\/C'7OA]+\0OAW:Z+XGTWQ%\-E\:>'(9M1T,:U?ZOH>KR+*;?2]9BT!]
MUF[M]+U6ZD _2XTKM*]O-]#\FO\ @[=_Y,4_9Y_[.TT/_P!4[\7J_2'_ ((
M_P#*(3]C+_L6OB?_ .KU^*-?PH_\%$_^";'_  4C_8P^$_@WXA_MF>,O^$C^
M'OB;XB6G@SPU:?\ "\-5^)_D^,KCPUXCURWN?[&O[B:*QQHFB:U%_::*)$\W
M[*#MNF!_NI_X-^TE3_@D#^QH)9?.8^'_ (K.'V+'B*3X^?%5X8MJY!\B%HX-
M_P!Z3R_,;#.16:UFW:VFWW&TTE2BDU+WKW7H]#]D****T, HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** /F_]I']D#]F7]K[1/"OAW]I?X+^"?C'
MH_@?Q'!XK\)VOBZPFFDT/6H6@:9[.\LKBROAIVJ):VUOX@T*6YDT+Q+9V\%C
MX@TW4[.)(%^A[.SL].L[73]/M;:PL+"V@L[&QLX(K6SL[.UB6"VM;6V@1(;>
MVMX42&""%$BAB18XT5% 'X4_\%K/^"Q7B;_@E8O[.^E^"?@QH'Q:\0?&VZ\>
MZEJ$OBGQ-J/A[2-!\-_#N;P5#?6EHFDV-W>7>M:_)XQ$=G>RR1V.BKIKSSV&
ML&[6W@_9'X)?$VQ^-?P9^$?QDTS3;C1]-^+7PQ\ _$W3](O)4N+O2K'QYX5T
MGQ5::;=3Q*D<UQ8P:K':SRQHB22Q,Z*JL %=7:Z]?Z^934N5-_"V[:_?IT_X
M'H>G4444R0K^'O\ X/!?^1O_ &"/^Q;_ &CO_3I\%:_N$K^'O_@\%_Y&_P#8
M(_[%O]H[_P!.GP5J9_"_E^:-*7\2/S_])9_6C^P/_P F*_L6?]FF?LY?^J>\
M&U]9U\F?L#_\F*_L6?\ 9IG[.7_JGO!M?6=..R]%^1$MWZO\PHHHIB/F?]I#
M]C;]ES]KVW\"6G[3'P/\!_&:#X9^(G\4>!E\9Z8]X^@:I<&R.HPPRV\]K-=Z
M%KHTS2U\3>%=1DO/"_BA-+TN/Q%H^IIIUDL'TLB)&B1QHL<<:JB(BA41% 54
M15 5550 J@      5^ G_!:+_@M3K_\ P2S\7_ /P+X)^!^B_%[7?BKI?B3Q
MCXEN?%'BK4/"^F:-X4\/:MI6CVVF:(VDZ;JES=:_KMS<ZLTFHWT:6'AZ'3;%
MQIGB)]6FBTG]MO@[\2](^-'PC^%GQB\/V6H:;H'Q8^''@?XEZ'IVK+ NJV&D
M>._#.E^*=-LM36UFN+5=0M;+58(+Q;:XG@%S'((9I8PKLKJ[77K_ %U*:DDF
M[\KO;MYZ=+_B>CT444R0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* /\\?\ X.T_^4C7P6_[,G^'/_J]?VD*_P!#BO\ /'_X.T_^4C7P6_[,G^'/
M_J]?VD*_T.*E?%+_ +=_(UG\%+TE^@44451D%%%% !1110!^4W_!5?\ :K_8
M:_9?\#?!.X_;]^ %A\<O@[\0?B==Z!HUWK_P9\"_&[PO\./&EAX<O;JT\4:U
MX9\;B8V?G:#<Z_9PZEX7L-7\4?9O[0M;'2+VUN+WRO(/@?\ \0]/[1NBV6M_
M!_X=_P#!+#Q*+ZT^W+H&H_!7]G#P9XZLK7S5@\[6/AUXX\%^&_'NA*9W2)?[
M9\.6&]W0)NWH6_8#XD?#+X=?&+P5KOPW^+'@7PC\2OA_XGMX[7Q#X+\=>'M*
M\4^&-9@@N(;RV74=$UJUO-/NFM+VWMKZSEE@:6SOK:VO;5X;JWAE3^/G]N;_
M ()._P#!O5X!^+7BKX?>(OVN=?\ V*?BSHUOI5WJOPPTOXA2>*?#>B'Q#I5G
MK^F7EUH'Q$\)^-/$JIJ>EZC9:C:VFG?$'3[""VNDCM[2WB$<,,N]^C[7T:VV
M?7:_<TARM6O-/O&[36VJ6JZ;?F?OU\0_V:?^"*_PCMTO/BO\ /\ @EW\,;22
M%;B.Z^(?PJ_9/\%V[P.ES(DZ3^)-!TV)H62SNW616*,EK<L&(@E*^1P_\%H/
M^"97@#XG?L__ +'7[-OC'1_BWXJ\>?$/X6_ KP!X!_9C\'0W?PM^'.C>*?$&
MD>$=-U23Q-IMKHGPTT[P)X)TNYDU"[TSP)J&OWNEZ3I;1IHEI9#[3#_+_P##
MC_@F#_P0!TF\GF^+'_!8G4/'=G]KDEL[+P'9^%_ABZ6>0;>TU"ZUWPI\56O)
M 05NKJSCTHSQL1;PV4@$H_J^_P""8?P?_P""2_PI\+W^E?\ !.#6?V>/&FN0
MZ+:R>.?&?@GQ_P"'?B?\;K_3+PV)W_$#Q%=:IJOC_1M)O;^&VNE\,7,>@>$]
M.U9Y%TKP[IDS/ !-Z:17E>[>BVMY?H.2BE=\\_5.*Z=7=]5IU[GZQ44451D%
M%%8EYXF\.:?<26=_X@T2QNX=GFVMYJMA;7$7F(LL?F037"2IOB=)$W*-R.KK
ME6!(!MT5GZ?JVEZLDDFE:EI^I1Q,$EDT^\MKQ(G(W!)&MI)%1BOS!6()'(&*
MT* /Y4_^#MW_ ),4_9Y_[.TT/_U3OQ>K](?^" /_ "B$_8R_[%KXG_\ J]?B
MC7YO?\';O_)BG[//_9VFA_\ JG?B]7Z0_P#! '_E$)^QE_V+7Q/_ /5Z_%&H
M7QR]/\C5_P &/^/]&?L71115F04444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% '\/G_!X*#_PEW[!#8.T^'/VCP#@X)&I_!0D ]"0&4D=0",]17]:7
M[!*LG["_[%R.K*Z_LF_LYJRL"K*R_!_P<&5E."&!!!! (((/-2?M5_L/?LI_
MMO:%X-\.?M3_  :\/_%W2OA]X@D\3^#5U;4?$FAW^@ZM<1V\5^+36?".M^']
M9?2=7CL[%->\.W-_/X>U]=/TX:UI=_\ V?9^1]0:;IVGZ/IUAI&DV-IIFE:7
M96NG:9IMA;PV=AI^GV,$=M96-E:6Z1P6MI:6T4=O;6\,:0P0QI%&BHJJ)2]Y
MONK?E_D6Y)PC&VL6[OU=U^9=HHHJB K^'O\ X/!?^1O_ &"/^Q;_ &CO_3I\
M%:_N$K^'O_@\%_Y&_P#8(_[%O]H[_P!.GP5J9_"_E^:-*7\2/S_])9_2]\#?
MB_>?!?\ X)J_L1Z_H>@6WBKQGXJ^ /[''PQ^'WAN_P!2DT72M7\=_$CP-\//
M"?AR+6M;BLM1;2-$L[K46U35[U;.>7^S["XM[2-[V>V1O5OAA\8/V@O#?Q@\
M-_!#]I_0?A$VN?$KP?XI\9_#/QQ\$+GQ=%X9O)? 7_"+1^-_!/B+P[XVEO\
M7;'5M)'BBSU32?$\5^NB^(-*81'3M(U>*73Z^<O!NJ?">'_@EA^QKX:^+%O\
M0]1@\;?LX?LH:)X#T;X.V^K7/QBU'XEZ7\+/!OC+P==?"W^QFCNK3QAX;O\
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MB@ HHHH _P \?_@[3_Y2-?!;_LR?X<_^KU_:0K_0XK_/'_X.T_\ E(U\%O\
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M(5_H<5_GC_\ !VG_ ,I&O@M_V9/\.?\ U>O[2%?Z'%2OBE_V[^1K/X*7I+]
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MAK3W\8)I=C<EI8M&'B9-5_L5R\D=QI7V.XAEEAECE?\ C\U__@E=_P '"/\
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M;(</4GA\++#U(T\+AI4ZF,S9:***^:/T8**** "BBB@ HHHH **** "BBB@
MHHHH **** /\\?\ X.T_^4C7P6_[,G^'/_J]?VD*_P!#BO\ /'_X.T_^4C7P
M6_[,G^'/_J]?VD*_T.*E?%+_ +=_(UG\%+TE^@44451D%%%% !1110!^3?\
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M4XH-,CBTE+"/1VGN[XB^M8S^NG@WQ+X#_:)^"OA+QE;Z4FO_  R^.7PP\/\
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M!.<FY2;>H4445S'HA1110 4444 %%%% !1110 4444 %%%% !1110!_GC_\
M!VG_ ,I&O@M_V9/\.?\ U>O[2%?Z'%?YX_\ P=I_\I&O@M_V9/\ #G_U>O[2
M%?Z'%2OBE_V[^1K/X*7I+] HHHJC(**** "BBB@ HHHH **** "BBB@ HHHH
M *^#/^"BO_!0KX-_\$U?@#!\?/C/HOC/Q1IVM>,]-^''@_PIX#L=,N]=\1>-
MM9T+Q)XATZQEN-9U/2-,T?1XM,\*ZQ>:MK5U=2M96UMMLM/U749[/3;K[SKR
M/XW? /X+?M)^ KWX7_'OX8>"_BW\/[^[MM1F\*^.="LM=TN/5+))XK+5[%+N
M-I=,UFQCNKI+'6--EM-3LUN;A;:ZB$T@8?EH-6NKZKK8_P ^;_@L[_P7'^%7
M_!4#]GOX:?!CP'\#/B#\+M3\"_&73_B?=ZUXN\1>'-8L+^PL_!'C7PHVEV]O
MHT:7$=V]QXIM[M9I281#:S(1O=*^H_\ @G!_P<B_!+]B']BKX&?LM>*OV;/B
MGXXU_P"$VE>+-/U'Q5X?\6>$M.T?5W\1?$+Q=XS@DLK/48FO8%MK7Q'!92B<
MDO/;2R)^[=*]B_X.5/\ @G[^QC^R5^R!\$O'7[-W[._P^^$'B[Q#^TEI'A+6
MM?\ "-G?VU_J/AN?X8?$S6)M(N'NK^[1K234](TR]95C5_.LX3OP"#]U_P#!
M&#_@EM_P3X^/W_!,O]EGXO?&7]E+X6?$+XE^,]!^(%SXH\8^(+#4YM8UN?3/
MB_\ $+0K"6]D@U2")FM=(TO3["+9"@$%I$I!8%CFK\SU5[*[MZ7_ *_+IT7I
M^S3Y7R\VU];ZW>_:_P#DNGZ^?\$W/^"D'P7_ ."FOP1UGXS_  =\/^-O!H\(
M^,)/ 'C;P=X^M='AUK1/%$&@:'XAD>PO-"U;5].UGPY>6FNPKI&L>9IU[=M:
M7BWVB:5-#Y!UO^"BO_!0KX-_\$U?@#!\?/C/HOC/Q1IVM>,]-^''@_PIX#L=
M,N]=\1>-M9T+Q)XATZQEN-9U/2-,T?1XM,\*ZQ>:MK5U=2M96UMMLM/U749[
M/3;KZ,^ _P"SK\"_V8/ O_"L_P!GKX4^"?@_X$;5KO7[CPUX%T.TT2PO]?OK
M6PL;W7M5-NGVC5M;N['2]+L;C5]3GN]1FLM-T^TDN6M[*VCBM_&[X!_!;]I/
MP%>_"_X]_##P7\6_A_?W=MJ,WA7QSH5EKNEQZI9)/%9:O8I=QM+IFLV,=U=)
M8ZQILMIJ=FMS<+;740FD#7K;?6V_G^!S^[S;/EOM?6W:Y_+/_P 1>/[.7_1H
M/QL_\+GP)_\ &:_>G_@FW_P4@^#/_!3;X(:S\9_A!X=\:^##X1\93?#_ ,;>
M#?'MOI$>LZ)XFM]"T3Q 9+"]T/5-5T_6?#U[9:Y!_96K;]/O+F2UOH[W1M-E
M@\I^&_X<J?\ !*K_ *,?^"?_ (*]8_\ ES7VU\!/V<?@3^RYX$_X5C^SS\*O
M!GP@\!OK-_XCN/#7@G1X-)L;_P 0ZG#9VM_KNJ.F^ZU76+JSTW3;"34]2N+J
M]_L[3--TY9ELM/L[> 7-U:?]+_@_UHJDZ;7NQDGYNZZ>?K_6B\*_X*#?M[?!
MW_@G%^SOJ'[1'QGT[Q5KVD/XFTGP)X3\)^"[&SN_$'B[QUX@L-9U+1]"MY]3
MO=.TG2;,:=H&LZMJVL:E>I%8:5I5Z]G:ZKJS:=HVH_SU?\1>/[.7_1H/QL_\
M+GP)_P#&:_JB^,WP1^$7[1'P]UKX4?'+X=>%/BG\.?$)LY-7\(>,M)MM8T>Z
MN-/NH[W3KU8+A2]KJ&G7D,5WI^HV<EO?V-S&LUI<0R -7P;_ ,.5/^"57_1C
M_P $_P#P5ZQ_\N:'S7T:MVMY_P##_P!:A%P2]Z+;\GZ>GG_6W1?\$T?^"G?P
M-_X*?_"GQ;\1_@_X>\;^"-5^'7B6Q\)^/_ OCZUTE=6T;4M4TF+5]+U+2]3T
M'4]5TO6O#FK1#4+73;]Y-,U5KO1M334-!TV(6,U]Z-_P4"_;V^#/_!.3]GN\
M_:'^-ECXMUO0Y/%.C^ _"_A?P/IUEJ'B3Q7XV\066L:EI6BV;:KJ.D:/IMLF
MF:!K>KZIJFJ:E;P6>EZ5>&TBU+57T_2-0]L^ '[-7P#_ &5_!$_PX_9U^$O@
MGX/>";S6[OQ+?^'_  /HT&DVNJ>(K^UL;"[UW5I4WW>K:O-I^F:9IQU'4KBZ
MNUT[3=/L$E6SL;6"+?\ C)\$_A'^T-\/M;^%/QQ^'7A+XI_#GQ%]F;6/!_C3
M1K36]&NI[&X2[T^]2WND9K34M.NXX[O3=4LGM]1TZ[CCN;*Z@G19 :VW5^]M
M/T$^7FND^732^OGJ?RN?\1>/[.7_ $:#\;/_  N? G_QFOW/_P""9O\ P4\^
M"/\ P5 ^$_B[XD?"3PYXT\"ZQ\.O%%KX2\?>!/'4.EMJFCWVI::NK:+JFF:K
MH=_J&F:SX?UJU6]@LKQFTW5([_2-6M[[1;.".PN]1P/^'*G_  2J_P"C'_@G
M_P""O6/_ )<U]I?L_P#[-'P"_95\#W'PW_9T^$W@KX/>"+S7;WQ/J'A_P3I$
M6EVNI^(]1M[.SO-<U:;,EYJVJRV&FZ;IPO\ 4;FZN8M,TW3=-ADCL-/L[>%+
MFZM?=Z?\'^MJDZ=O=C)/NWIT\_7^M%Y5^WA^V]\(_P#@GO\ LY>)_P!I+XS6
MGB;6/#>AZIH?AO1_#'@VRLK[Q/XL\5^);MK71]#TI=4O]*TFU'EPWNJZG?ZG
MJ=I!9:-I>I7$"W^H)9:7?_SI?\1>/[.7_1H/QL_\+GP)_P#&:_JK^+WP=^%G
MQ]^'?B3X2?&GP%X8^)OPU\7V]K;>)/!?C#2[?6-"U5+"_M=6TZ6>TN%81WFE
MZM86.K:5?V[0WVEZK8V>I:?<6U[:P3Q_ G_#E3_@E5_T8_\ !/\ \%>L?_+F
MF[]&ON\U^G]=4HN"^*+;OT?33S7G_6I9_P""8W_!53X$?\%1_ /Q \5?"/PS
MX[\!^)OA/J_A_1_B+X&\>6NE-=Z4?%MMK%WX7U;1M;T+4-1TO7-$UF/P_KEO
M%-(-+U>UO]&U"&^T6VM'TN_U/W?]NS]MWX/_ /!/C]G;Q'^TC\:[;Q3JGA;1
M=7T#PUIGAOP1IUAJ?BOQ3XG\37AM-*T71H-6U31-&A98(K[5]0N]5UC3[:UT
MC2M1FA:\OULM-O?2_P!GS]EW]GC]E'PC?>!/V<?@]X%^#GA35=7EU[5])\$:
M);Z6-9UJ:*.W;5-:O1YFHZQ?1VL,%E;7&IW=U):6,$%C:M#:010IV/Q<^#_P
MM^/?P]\1?"?XT> ?"WQ.^&WBV&T@\1^"O&6D6NMZ!JRZ=J%IJ^FRW%C=H\8N
MM+U>PL-6TN]B\N\TW5+*SU"QGM[RU@FC-;=+V^5Q/EYM$^6ZTOK;KJ?RI_\
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M$JO^C'_@G_X*]8_^7--WZ-?=YK]/ZZI1<%\46W?H^FGFO/\ K4\J_P""7_\
MP6R_9V_X*@^+/'OPS\ > ?B1\*_BE\/_  M_PGE[X6\;IH>IZ7K?@E=:TOP]
M=:UH'B7P_?W$<ESI.LZWHMIK&EZOIFCSQC6=.GTF768EU1M+_2S]I']H'X=_
MLJ_ GXI?M$_%BYU2W^'WPD\):AXN\2+H=BFIZY?06GEP66CZ'82W-E;76MZ[
MJEQ8Z+H\-[?Z=IS:E?VW]HZEIUB+B^M^*_9Q_8H_9._9$_X29OV:?@%\-_@Y
M<^,OL2^*=1\':%%::OKL&F>8=.LM1UFY>ZU:XTVPDGN)[/2VO/[.MKJYNKN&
MU2YN;B63Z!\6^$O"_CWPMXC\#^-_#VB^+O!OC#0M5\,>*_"OB/3;36/#_B3P
MYKMC/IFLZ'K>DW\4]CJ>E:KIUS<66H6%W#+;75K/+!-&\;LI%>VK5_3^OT$^
M7FT3Y=-+Z^>I_)I>?\'=_P"S.EW=)8?LD?'2YL4N)ULKF\\7^ +&[N+196%M
M/=64,VH0V=Q+"$DGM8K^^BMY6:*.\N403/\ JA_P2\_X+9_L]?\ !4+Q=\0?
MAGX$^'_Q%^%/Q0^'WAD>.[CPOXU.BZMINO>!5U;2/#]WKNB>(] NY8A>:1KV
MN:58ZOH^JZ=ILJ1:MI5YI5UK"/JT>C>M-_P16_X)5NS.?V'O@B"S%B%TG5D4
M%B20J)K"HBY/"HJJHX4  "OI_P#9Q_8F_9-_9#;Q/+^S3\ OAS\'+KQF+"/Q
M5J'@[1$M=5UVWTHSMIMEJ&KW4EWJ<VGV,ES<SVNG?:Q80W-S<7*6XN)Y9724
MM+M?=Z?\'^M%4G3M[L9)]V_3U\_ZV],^.WQG\$_LZ?!?XI_'CXCS:A!X$^$/
M@/Q-\0O%1TBT2_UB;1O"VDW.K7=GH]C+<6D5[J]^EM]BTJTFN[2"XU"XMX9K
MNVB=YX_Y;+[_ (.[OV98[V\CTW]DGX[7>G)=7"6%U?>+?A_I][<V2RNMK<7E
MA!<:G!8W4T CDN+.'4M0BMI6>&.^NT19Y/ZS_$OAKP[XS\.>(/!_B_0M(\4>
M$_%>B:KX:\3^&M?TZTU?0?$7AW7;"?2]:T+6])OXI['4](U;3;JYT_4M.O8)
MK2]L[B:VN(I(970_FPW_  16_P""5;LSG]A[X(@LQ8A=)U9%!8DD*B:PJ(N3
MPJ*JJ.%   IN_1I>OJO^#_6J47!7YDWVL_\ @K^OO7B/_!,+_@N-^SO_ ,%.
M_B+XT^#G@?X:_$[X4_%'P=X,OOB.=&\9_P#"/:OX?USP3INM^&O#=_?:5XDT
M'4GD36-/UGQ5I,5YHNHZ+8J;*ZAO=.U#4MFHP:;^K/QV^,_@G]G3X+_%/X\?
M$>;4(/ GPA\!^)OB%XJ.D6B7^L3:-X6TFYU:[L]'L9;BTBO=7OTMOL6E6DUW
M:07&H7%O#-=VT3O/'Y3^SG^PS^R#^R/?Z_JW[-G[/'PP^#^M>*;2/3O$&O>$
M?#L%OX@U72XIH+E-(NM?NVN]8.C+=VMO>_V.EZFF&]ACO3:FZ435])>)?#7A
MWQGX<\0>#_%^A:1XH\)^*]$U7PUXG\-:_IUIJ^@^(O#NNV$^EZUH6MZ3?Q3V
M.IZ1JVFW5SI^I:=>P36E[9W$UM<120RNA%>VKN_Z_KH2^6^B:6G6[\S^3'4/
M^#N[]F.._O8]*_9*^.]YID=W<IIMYJ'BOX?:9?W=@DSK9W-[IMM=:M;Z?=SV
MXCEN;*#5=3AM)G>"+4+Q(UN9/TX_X)@_\%Q_V>O^"GGQ&\;?!SP3\-/B;\*/
MBAX-\&WWQ&71O&3>']8T#7O VFZSX8\.:AJ&F>(]"U!I(M9T_7/%6F07FAZA
MH]HC6%S;W^G:GJ)&I6NE^Y3?\$6O^"5MQ--/)^P[\#E>:629UAT74K:%7D<N
MPBM[?5HK>WB!8B.&"*.&),1Q1HBJH^C_ -G/]A7]C_\ 9&U/Q#K?[-G[//PS
M^#^N>*[&#2_$.N^$=!2#7=4TJVN$NXM)GUJ\EO-3721>10WCZ7#=Q6$UY!;W
M<UO)<6\,B)<W5K[O3_@_Y=%;=.WNQDGTUTZ;ZOS_ *V]K^+_ ,4O"/P.^$_Q
M-^-'C^YN[/P-\)/ 'C#XE^,;JPM'U"_@\,>!_#^H>)==EL+"-DDOKU=,TRY-
MI9QLKW5QY<",K2 C^5[4_P#@[M_9AAU+4(M'_9,^/%_I,5]=QZ7?:CXJ^'^E
M:A>Z<D\BV5W?:7;W>KV^FWES;"*:ZL(-6U2&SG=[>+4;U(UN9?ZT]:T71_$F
MC:MX=\0Z5IVNZ!KVF7^BZYHFL65MJ6D:SH^J6LMCJ>E:IIUY'-9W^G:C93SV
ME]974,MM=6TTL$\<D4C*?S3F_P""+7_!*VXFFGD_8=^!RO-+),ZPZ+J5M"KR
M.7816]OJT5O;Q L1'#!%'#$F(XHT154-WZ-?=YK]/ZZI1<%?G3>UK/[^WY_=
MN?Y]7_!9?_@HUX*_X*=_M/\ @3X]^!/AQXI^%^D>$?@+X7^$-SH'BW5=)UC4
MKS4M ^(7Q1\9S:Q!<Z,J6L=C<6OC^SLHX)!YZSZ?<R,?+EBQ_JJ5_FF_\')G
M[+_[/_[)G[<OPI^'/[.'PK\+?"'P/K7[)_@;QKJOAKPE;W-OIM]XKU'XO_'7
M0K[7)TNKJ[D-]<Z1X;T.PD=9%0P:9; (&5F;_2RJ8WO*^^GY,NI;EIV5E9V3
M^044459B%%%% !1110 4444 %%%% !1110 4444 %%%% '\J?_!V[_R8I^SS
M_P!G::'_ .J=^+U?I#_P0!_Y1"?L9?\ 8M?$_P#]7K\4:_-[_@[=_P"3%/V>
M?^SM-#_]4[\7J_2'_@@#_P HA/V,O^Q:^)__ *O7XHU"^.7I_D:O^#'_ !_H
MS]BZ***LR"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y8\?_ ++L?B?X
MB>)OB=X"^,_Q=^!OB;Q[X>T?PW\1!\,)_ 3:;XU@\/0W-EH>N:C9>./ GC(:
M?XPTK2;D:)8^*M#ETS58='M+"R$A6RA9?9_A7\,O"?P;^'OA3X9>![2>T\,^
M$-,73M/%Y<&\U&]FEGFOM3UC6+YDC;4-<U[5KN^UO7-1=$?4-7U"]O716G*C
MT"BN_$9IC\5AJ6#KXB53#T?8\D.2G%R^K4I8?#>VJ0A&KB/JN'G*AA?;SJ?5
MJ,I4J'LZ<G%^%@>&<CRW,L5F^"P$*&88SZW[6LJV)J0A_:.*IX[,OJF&JUIX
M7 ?VECJ5+&YE]1HX?^T,92IXK&^WQ$(U%_#W_P '@O\ R-_[!'_8M_M'?^G3
MX*U_6C^P/_R8K^Q9_P!FF?LY?^J>\&UR?[:__!.K]DK_ (*$:-\/M$_:F^&\
M_CF'X7:]>Z[X+O\ 2_%/B;P?K.E+K3Z2/%&B#5O"VJ:7?2Z#XMMM#TJSUZQ:
M7S'2PLKW3;G3=6L;'4;;[(\/Z!HOA30=$\+>&M+LM$\.^&M(TW0- T738$M=
M.TC1='LH=.TK2["VC CM[+3[&V@M+6",!(8(8XU 50*\Y+WF^ZM^7^1] Y)P
MC'6\6V^VK=K?>>"?'3]D']FW]I*,O\9/A)X6\5ZO]GM+2+Q9';S:%XWMK.PN
M&NK.QM_&OA^?2_%$>G03R3.NF_VJVGL+BY5[5DN)E?\ (U_V"->^$'B7XY>"
M-/\ @K\??C/X6^(?C[6_%GPKT;P[\9O#6E_LW^,;:YM3K?@O3OVGM'\1>.]&
M^(]W=?"SQ-.LD^JW$^NV/CB/1-+GBTV]U2?4X-4_H$HKZ[)>-,]R6A4P='%U
ML3@)Q@H8'$XO'+#X:I2JTZU.MA%AL5AYX:JI4HQE*C.'-!MKEK0H5J/Y3QCX
M.\#\98ZAF^*RK!Y;GM*I6=;.\NRK))9AF&&Q.&KX7$8+-)9AEF/HYEAITL14
MG3AC*-;V=9)/VF%K8S"8O\'-"_X),:O\-?!K^'-0^+WPG@\"7/A")?''C_QS
MX7\9ZWXR^&L^J>%X=/\ BK/\+AJGQ'TCX/:/;ZY=MXCDT+Q_XC^'<?C?PAHO
MB1XQJEY>Z!I][/\ BG_P7;^%'[,M[\6O^"?.G_LJ#X2GX>Z38?''Q5XWE^#6
MJ^$]<L/$^J?#._\ @O'X=L_$>H:#?W-EKWB..XUTZ8+KQ!?OJ%I9^(M9O)+E
M/METT_[A_M8Z_P#M*_&+X&?%#]HC1/%G@?7O@_\ !;XWZXFJ?LCZSX)TN;1O
M$O@[]G7XK:]HNO:E\:/$FH:I;>)=4UB]OO#.G>/+WX=6DND>'H/"UM96CZ9X
MDUJ6UFF_"O\ X+#_ !(^%GQ_UWX)?%G]F'X 'PIJDGPQG.C^+-<\$'P+X4\5
M>)=2U.V\,>*]$6."+1K7QEIOP]TO6KW2M>UW3XK_ $N_U71XK&=[BVT#PN;_
M /6,LPG$/$.)RW%YWFF+S>G@\TQ-7-,%E$.3#4:^5T\'F%?*LTI4Z&'Q..Q^
M+HQJ1P-/"4L7@IUJ%58:M/ZQF&,PW\K\1YIP#P!EO$.5\%\,Y3PGB,WX;R[#
M<+YSQ96=?,,9@N)ZV:9#@N*.&L56QF.R[)LBRK$U:%3.J^9XO+,XH83&8:68
M82@\OR'*,P^<?%'Q8\9>+?#7@'PUKWB+Q;K>G_#?1I-)\%0Z[XM\3ZM8^$K6
M8Z%(?^$3TO4];U2V\,R1-HL&E3)HLUIH-[IMGIDMOX=TK6+2;4+CWSX3^)?$
MUUKNO>.+:WUGXQ^(_B]<^*?A]XM\'W_CNTU[XS>*?"^F^%+#QQXQ\=6ES-X+
M\3ZUX+U?PSK^D^'?''A'XF:C?XLM3\.S:0FC_$31-$\?FT^,5)VC#!MZC.W^
M(9!Z<XR0"!].37VW\/O &E>&_!?AKXG^ /C7+HWQ?O\ 5H? WC_X5^"_#=KX
MCN?#7P;^(/P^.D^)/B/%XTTSXEZG97RZYI/BS3?"FM>%-27P-XBTGXF>*;SP
M58-X7UK1;)5_HK-J.!PN!5!4Z=+VWMZ="'L<3.E*K6E]9M5E@H3K8.C/%QI5
M:N+@H4Z53E4*M'$5</(_S[X5Q6=9GG,L:Z];$+!_4<3C:DL9EU'$QPN#C'+[
MX6GG-2GA,WQE'*JF)PF&RNM*O6Q.'E-U</BL!AL= _<7_@G_ /L[^&/B3\8'
M^,WQC02?$;P9HG@?XT>#? 6E>$O#WA_X4^(M-^,&F:W/\//VBK2+0KFW\/\
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M+K8"OE=7^9+_ (.D_C%X$^.'Q>_8_P#&7@'4+RXLH/A+\1=!U[1M:TN_\/\
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MA&,(16T8Q2C%+R222"BBBD4%%%% !1110 4444 %%%% !1110 4444 %%%%
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MJF^%FM>.--TC48-$T?Q#X9\3C38[.S\:-K*^$4\17.OZP=(6^D?0?S5_R?\
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M;_LR?X<_^KU_:0K_ $.*E?%+_MW\C6?P4O27Z!1115&04444 %%%% !1110
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M^Q:^)_\ ZO7XHU*^.7I_D:/^#'_'^C/V+HHHJS(**** "BBB@ HHHH ****
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M ,':?_*1KX+?]F3_  Y_]7K^TA7^AQ4KXI?]N_D:S^"EZ2_0****HR"BBB@
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M[:7\L/N?^?DON/\ . _X<G?\'!'_ $#_ (C_ /B9O@3_ .?!1_PY._X."/\
MH'_$?_Q,WP)_\^"O]'^BCD7>7W_\#R7W![:7\L/N?^?DON/\X#_AR=_P<$?]
M _XC_P#B9O@3_P"?!1_PY._X."/^@?\ $?\ \3-\"?\ SX*_T?Z*.1=Y??\
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M_-)\7_\ ! +_ (+@?$&33I?'WPMOO',FD"X&E/XR_:?^$OB@Z:MXT#7B6/\
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MEZ\FG&SD\2:0J)J+6KW7VEC:B403F/\ TOZ_A[_X/!?^1O\ V"/^Q;_:._\
M3I\%:]%^,/B.DVN)'\\HR%]E_P!"L^?A]$?Z/,YI/P[BKWVXKXY6R;Z<36_
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MC_\ B9O@3_Y\%?Z/]%'(N\OO_P"!Y+[@]M+^6'W/_/R7W'^<!_PY._X."/\
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MZ"::;3W^_?7<****8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M']N']@?]E_QI^V/^SG_P54_:V\<_&C]G7P5/XX\9_#SXMZOX;U7]FGQI\/\
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M1NK2[U'2M/O=6U_7?$NN#3-!L-5L/#.A_IS0E9*_G^+N*;3EH[JR5^]DE?\
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MJ$.L^+_"[1>%O%'QFO\ 5$O(I]<O]8O_  5JD%E<-X,LK^X\/Z-IUU<??_\
MP10_:W_:)_:G_9N^+FB_M9:CHGB+]H/]F#]I[XJ_LS?$'QGH%EHNG67C>[\!
MP>'=4B\02V?AG3-%\,PW5M<^(K_PP'T#2K&QU'3_  YI^MR0"^U6\9OC'X-?
MLE_\%T_V&/A0_P"QI^RAX^_88^*WP"T:X\;6/P.^.?QM_P"%FZ1\6/A%X7\1
MZKJFN6]MXJ\.Z+97?A_5=4TO5-;OKWPM!;Z'\2](T^ZC6WU87/AA-.\*Z?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "OY)O^"V'_  7X^/?["'[7%C^S)^RQH?P6\2/X-^'7AS7?B_J/
MQ+\,^*O$E_I?CKQF;C7M&\*V$>A>-/"-O90V'@&?PIXDGFD74'O&\7PP[K4Z
M>RS?U._%3XD^$_@U\,OB)\7?'M^=*\#_  M\#^*_B'XPU)8VF>Q\,>#-"O\
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M]\3>"O$WB/3CIY\&ZI9ZGJNE^--0UK2K"UT?0_MVE7&K?;7_  ;NZ/X=TO\
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M_;'^)/@V\T6PF>\U+Q%\*_ L>D_&'1H-0M$9YHX-1^)G[0/A;3?#4;@+<O\
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M^'R5OPL2YM\^EN=I^EG?0_@3_8T^*O\ P4-_X-ZO'G[1WP$^('[!GQ!_:B\
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M_LQ_"?XH_L[:!X'\ ^"?@'XPU'4O#?PI^!O[0,'Q"\1^+?B'X/\ AYX$CG\
M7FJW/B[7]0TBTO\ PGH]E>^'+*TC\-S^*[;2;K7K[[$_X.,/@S^T'X._X*,_
ML-?MU?#7X"?$CXU^ OA/X2^%,&KP^!?#_B36=.C\4_!/]H#Q/\4;?PKXDUCP
M[X9\1CP6_C"U\;6&GZ)J^IVUXM_+'J!T[3+N;1KJ"X_M(HHL[-7U;3OYZ?Y#
M]IJGRJR35KO5/SWOYZG\(/\ P7,T7]M+_@I7\#_^";_Q]\(_\$__ -J;PGXR
MO= _:J3XA_!;0/A#\7/B3XE^$WE_$GP/X?\ !:>+KNP^&/A[4K1?'?AGPM#X
MR\.76J>%]#AU;3+]Y-+2\M[.2Y;]'/\ @XP_X)J_M"_'S6O@;^W?^R)HNO\
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MF:!Y>F0S:C)_:UU:;+"*6\;%O&T@_KTHIVW\VG]UO\@51IQ:2]U->MS^2O\
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M[\#>;K7P_P#B-\+X%/A[3?%/B6PE\/W]A>ZY>:1::G9ZS?6FG>?_ +76H_\
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MPEK<^KZ??Z#+CH^K=NRV?3M_P!QG[T;6A%7[M:[WN[O[]#^8_P#X+(?ME?\
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M/Z.J*^.?#?[?/[*GB/\ 9>'[8G_"T+/0_@1";BUU7Q%K^EZO::SH>N6FL_\
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M<6US%"6?9A9]F?;=%?FM\-?^"K7[+'Q(^*?@KX6FS^-'P\D^+.J/HWP,\?\
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M>!M3U&.WAU#4O!^L:G8W6H>&;^_AM+2*\O-%N+*XNH[6WCGD=8(@O+W7[/\
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M=;OO$WP<_9^^"_PL\2:E:W6GWWB'X?\ PR\&^$M=N-,O)[6YNM)?5]#T:QU
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M]%?C7_P2VO+NZ_:"_P""KL=S=7-Q':?MS>,8+5)YY9DMH%N=>VPVZR,RPQ#
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9HHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>ny20077604x1_figure03x2.jpg
<TEXT>
begin 644 ny20077604x1_figure03x2.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
M                                                          !8
M65H@        ]M8  0    #3+71E>'0     0V]P>7)I9VAT($AE=VQE='0@
M4&%C:V%R9"P@,C P- !S9C,R       !#$0   7?___S)@  !Y0  /V/___[
MH?___:(   /;  # =?_; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! ?_  !$( 8 $T@,!(@ "$0$#$0'_Q  ?   !!0$!
M 0$! 0           0(#! 4&!P@)"@O_Q "U$  " 0,# @0#!04$!    7T!
M @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F
M)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
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M-NC,L*("095KZ[?U_73U)5KZ[?U_73U/Q(_XB6?V/_\ HB/[2?\ X*?A?_\
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M@-<)<6UX+.WNXU@DF_5.OX5_^"C?Q4TKX&_\%W?$_P 9-<TK5==T?X7?%?\
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M'A6W\-^%M<MK_0!JFKZ1INF>)+OQ+>:=-KML^IG2M-N[&QBNEU#YA_X+Q_\
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M*_[*E/B'Q!XCO8FTC4[?P1I9T W7AW6+;5KCQ=I4DNG6.J?GUX:_X+Q?MK?
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M]YN?*^SQX\PM:->J&M&O5'L__!.;_DP?]C?_ +-L^#O_ *@VC5_+O_P<L_\
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M%3^1L_X27P+J_@O^S/\ A/\ _A9<V[[%_:O]I?;?^$*7[3Y'V/[)!YOVJ/\
M9VG)IVMTBE\QR:=K=(I?,_F;_P"#F>V\3O\  ']FF\M'<>#(/C!XEMM?C N/
M+?Q/=^"YI?"+N5F6T#QZ59>-EC$]O+<%993:S01"\2X_3;]BWQC\#A_P2?\
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M2.T22!9[7]HO^#9.TM$^"W[45^EM;I?7/Q0\#VEQ>+#&MW/:67A349K.VFN
MHFEM[2:_OY;:%W:."2]NWB5&N9B_Z&? /_@DE\)OV=?V-OCW^R_X%\:ZC<>-
M_P!I#X?Z[X.^)GQTUKPW;7.HWE]J?AO5_#VDW6G^"[76K.*S\+^%O[<U2^T;
MPFWBF:Z,^I:D;WQ/=3WGVJ+LO^"97_!.;_AW/X%^)W@O_A<?_"XO^%C^+-'\
M4?VE_P *]_X5[_8W]E:.^D_8?L?_  G'CC^T?M&_[1]I^U6/E8\K[/)GS W)
M6:OU5K];6U_ ;DK-7ZJU^MK:_@?S[?\ !/;PMH]]_P ' ?[0#S6Y"^"_C;^V
M[J^@Q H\=O=KXI\?>%XR_GI-(RQ:5KU^L;))',)O*<S,JR1R[W_!=.&*+_@J
M[^R.\<:(]Q\*OV?YIV10K32K^T5\6;<22$#+N(((80S9(CBC3.U !^R?[.G_
M  26_P"% _M__%7]N?\ X7__ ,)9_P +-\6_&_Q1_P *N_X55_8/]B?\+D\3
M:EXB^P_\)M_PLC6?[2_X1S^T/L?VK_A$;#^V/)^T?9]+\SR$/VZ_^"2W_#:O
M[5OP@_:=_P"%_P#_  K3_A5/A+P!X7_X0C_A57_"9?V]_P (-\2/%_Q!^W?\
M)+_PLCPK_9?]J?\ "5_V1]E_L#4?L/V#[?\ :+O[5]BMB,DG=O3E2Z^7_!",
MDG=O3E2Z^7_!/PA_;,\3> _!G_!P_;^*OB;+I]MX'T+XZ?LGZCKNH:O<16FD
MZ,L'P;^"YT_7]6N9RL%OI?A_538ZWJ,UP1;QV=A,]P1"'-?M)_P<)ZGX(M/^
M">&J6?B=8)=?UCXO_#.V^&P=())8_%MO<:KJ&I75N9 TD6WP!:^-;:2XM]KA
M+S[.[^5=.DF5^U!_P0T\"?M9?MH_$#]J7XE_';6+;P7\1;/1K75_A%X?\ +8
M:Y82Z!\'-&^&&D:CI/Q0D\=W%M'J&G:WH.G>.;47WPYU#3)9;=?#FJ:9J>G2
M75S<_*>J?\&[?Q'\>^,?"EK\9?V^_'7Q*^%'@J.QL- TW5?".OWWB_3/#!N-
M^J>%/"S>*/B3XH\.>"(FM+:RM[+5+&SUBP\\F[N/"GEV,-E=EXOEUM9+H[?U
MW^07B^76UDNCM_7?Y'XP_M.6^N0?\$I/^"8AU=D-G<>/?VTKCPY&L<\<D6AM
M\2?#:2+,9I9$D>37H]<N8Y+=((#;3P#RFF6:XG[;_@K+;07GQ&_X)PV=S&);
M:Z_X)I?L@6UQ$2RB2"?7?B/%+&60JZAXW92596&<J0<&OZ9?V\/^"0WA']L#
MX3_LQ?!GP#\6%^ /@K]F#1-=\-^%[)?ATWQ)?5M$U/1O!FBV$%Q(_CWP-+:W
MEA!X/6XOM2N)=5NM;O-2GN[HPW"RRW7BW[5W_!#G_AIWQ/\ LV>)/^&G_P#A
M"/\ AGK]FSX._L]?8O\ A2G_  DO_"7_ /"IM0\1W_\ PE_VC_A;6@?V!_;_
M /;_ )7]@>1K?]E?9/,_MO4O/V0M26E]/B[]6F-26E]/B[]6F?1/_!;ZQL;3
M_@EA^TG:6MG:VUIIL?P/ATZUM[>&&WL(8/V@/A-:0164,:+':QPVK-;11P+&
ML=NS0H!&2M?B7^S'_P %"=)_8,_X)!?#'['\/O#OQ-^)?QB^-/QTT7P%X;\;
M6SWG@6TM/#4_AU_%7B+Q98P26]YK%AIT7B/1M.CT&QO=,N-4EUGYM5LK6VN/
M-_IO_;C_ &7_ /AL[]EOXH?LU_\ "<?\*W_X61_PA7_%:?\ ",_\)A_8W_"'
M_$3PEX]_Y%S_ (2#PM_:/]H_\(M_9/\ R'K'[)]N^W?Z5]E^QW'Y@Z]_P0M\
M(>(OV$O!O[(.J_'5[SQI\-?BIXJ^*7@3XVP_"^+3S8OXPA6VU[PAJ7@E_'FJ
M2W&@ZM;16+7L]IXPL[HZIH^AZFL3PZ=/I>H2FK)/^:[]+?UYDIJR3_FN_2W]
M>9^7W[5GA/\ X*O_ !>_X)TZY^TA^T5^T)\*/"'[+^H> /A;XXT+X > M#T7
MPWJFO>&/%_B3P39^ -.U*V\+>!M,M+32A%X@T+7;'0M4\?:\;*;3K*TFT*RU
M*%!;:?[!G_* #_@H=_V5GXD_^JT_9TK["\*?\$%OC9XK^'<7PI_:._X*$_%/
MQC\+O"_AG5-*^&7PG\,0^*[OX?\ A'Q%!IU[9^!?$4^D>+/'$^DW>C^#[FY2
MY'A+3?#VBW5Y8J=#TSQAX?L@9)/MS]DC_@E!;?LY_LD?M(?L;^._CBGQ@^&7
M[0-QK>I1WVF_"X?#CQ!X*USQ-X0T_P (ZWJ\%U)\0_'D&O21Q^&_!FKZ!;3P
M:9;Z3J>@W;7:ZQ;:R\%E7-%+=;IZ*VS7^7<KFBENMT]%;9K_ "[GYK?\$>F4
M_P#!%K_@H(@92ZZY^U6S("-RJ_[*/PT",5SD*Q1PI(PQ1@"2IQ^)/P/LO%]U
M_P $O_V\I_#5Q<0Z+IOQT_8YO?B%'#YGEW?A"2?XPZ=96]WY:.IMU\?7_@BZ
M7SFBC^U6UL0YF\J.3]^_V?\ _@@=\8_@AXG\5VUK^W+<K\,M9\-_$?0/^$0T
MGX;>)H=*\4W/Q(^$OC'X47.O^*?!X^+-EX=M=6\/:;XSN[K39A=>(YKI+..T
M^U:;'<L\'VC^PO\ \$?/ _[)?PD_:9^"OQ*^)UK^T5X$_:;TWPMH_B;2[OX:
M_P#"O$TG3O#ECXLLV^SLOCWQS-<:E)-XGBU+2-7M9M(OO#NJZ/9ZCI\CWJV]
MQ:-R6NO5/9]+?Y#<EKKU3V?2W^1A?\$ -5^'%[_P3F\#Z;X+?2AXLT;XA?%"
M'XO064:17X\<WOBZ^OM%NM9 1)+BYG^&$OP^M[2]?S4?3[*ULHYB=/DA@_%[
MX-7OA[Q5_P '&]_JWP,:S;P]_P +Y^+=SJ%]:0EM-N+G3_A#XQL_C)J,,UA)
M!#+!K?B2+QJ;#4A+)::C<ZG:73?;XKSRKGZU\0_\&Y_C_P &^)O$8_9N_;=\
M4>!/A]XT0Z'XAT37_#VMV7B63P;/*K7.A^(=8\">*] T7XBQKAI_L5_X=\)Z
M7=R%8I+:W*&Y?]/_ /@FS_P2A^%/_!/*+Q+XJM_%U]\6?C3XRTL^'M:^(VH:
M#!X7L-*\*G4+?4SX8\)>&H]3UZ;2K.]O;+3+K7KZ^U[5+O6KS2=.GC32K6!-
M.66TKM.]TU:VU_/^OU);2NT[W35K;7\_Z_4_GV_X-KM,T^[_ &S?B]J-S9V]
MQ?:5^S9X@.F7,T:R2V#WOQ*^&5M=2VA<$03SVVZV>>,+-]FEN+<2"&YN$D]%
M_P""ZD<:?\%7/V162-$:;X4_L_R3,JJK2R#]HSXM0B20@ NXBBBB#,2PCCC0
M':B@?KK_ ,$TO^"/G_#N_P",'C?XK_\ #1'_  N#_A,OAK=_#S^P/^%2?\*_
M_LW[5XH\,^)/[7_M3_A9OC;[9Y?_  CGV+^S_P"SK7=]L^T_;5^S^1/N_MU_
M\$EO^&U?VK?A!^T[_P +_P#^%:?\*I\)> /"_P#PA'_"JO\ A,O[>_X0;XD>
M+_B#]N_X27_A9'A7^R_[4_X2O^R/LO\ 8&H_8?L'V_[1=_:OL5LU)<[=]&O/
MR&I+G;OHUY^1^QU?QC?\'&'_ "?/^S=_V0KPC_ZN#XB5_9S7XQ_\%&/^"1/_
M  W]\=/AM\:?^&@_^%3?\*]\":1X*_X1K_A4_P#PGG]K_P!E>,/$7BO^T_[9
M_P"%E>#?L'G_ -O_ &#[%_95[Y7V3[5]KD\_[-#,6D]>W^1,6D]>W^1^&W[7
M^F:?K/\ P<8^'=-U6SM]0T^Z_:3_ &+Q=65W&LUK<I'\-?@1,L5S X,<\#/&
MGFP2J\,Z;HIHY(G=&_4__@Y2CC/[#GPFE,:&5/VKO!,:2E5,B1R_"'XY-+&K
MD;E21H86D4$*[11E@2BD>U_%;_@CY_PL[_@H_I?_  4$_P"&B/[#_LWXE?!G
MXA_\*D_X5)_:7G_\*C\+^!?#?]D?\)[_ ,+-T_R_^$A_X0O[;_:'_"%R?V3_
M &E]G^Q:E]C\^Z^HO^"E'[!W_#PWX%^%/@M_PM7_ (5#_P (Q\6="^*'_"2_
M\(-_PG_V[^Q?!_COPI_8?]C?\)AX*^S?:?\ A-OM_P#:?]JW'D_V9]E_L^7[
M;]IM&VO<UVM?\!MKW-=K7_ 3_@E#_P HY_V1_P#LD^G_ /IUU6OSG_X.0O@Y
MJGC3]DGX8?%K1M%O=4E^#'Q:CB\1WMHJO#X>\$_$71+G1;[5]04QEULY?&>D
M^ =&$R3*([O5K59()4E,UK^SO[*'P&_X9@_9S^$?P _X2K_A./\ A5GA.W\+
M_P#"6_V'_P (U_;OD75W<_;O[!_MCQ!_9>_[5L^S?VSJ.W9N^T'=M7UKQWX'
M\*?$SP5XL^'7CO1+7Q)X*\<^'=9\)^*] O6GCM=8\/Z_83Z9JVG32VDUO=P"
MZLKF:);FSN+>\MG99[2X@N(XI4E.S3[,E.S3[,_)/_@A[^U7X%^.G[$7PP^&
M2>)M+_X6O\!M,N_AQXN\&W&JVO\ PD,?A_0KZ4^"?$UCI$U]-J\_A>]\)7NB
M:5'JYM8=-C\0Z5KNBVFR/2T6OE7_ (.,?VHO!OA?]G'PK^RWH_B#3[_XD?%3
MQQHGBCQ1X=L-2MI[WP]\.O _F:O%?>(K"TOOMNF/XA\7R>&U\,1ZI9&RUF#0
M_$]S9N;G0@R>8?&3_@VG\,7GBS5_%'[.G[3>K_#W27ODU#PWX(\>^"IO%%QX
M?GXG-O;?$?0_%6A:FUG9W8(TEKGPA>ZM:V0@CO\ 5]5O[>74;SL_V;?^#;OX
M1^!?&6E^,?VD_C7JGQSTVP2*]D^&GAOPG<_#SPW?ZTLJN\?B3Q2?%NO^)/$6
M@;3*6L=*MO!-]=7(@ENM1:R%UIEY7NWO?SM;\+[;E>[>]_.UOPOMN>7^'OV-
M_&4'_!NIXE\.P^"M3;XF^)1_PU2/#\GV?^T5TJR^).AZU'K<%NJ^8\EY^SYX
M>CURVTT-)JDQNTL5C^V.NG+[3_P;@_M">"M?_9L^('[.-YXAL;;XE?#WXF:U
MXUTSPS=W%A:7VJ_#[QGI6BM%JFAV[/%?:RFD>)])\0P^(W@@NAH:ZGX=^VW,
M,6LZ; O]'T=O;Q6Z6D4$,=K'"MO';1Q(EO';H@B2!(541K"L8$:Q*H14 0*%
M&*_FU_:?_P"#<SX5?$+Q]JOQ"_9D^,=S^S];ZAOU1/AGJOA*[\9^%-.\2!WG
M67PGXCM_%FB:_P"#]#EG6&9=*FL?%ATFYDN'T6:STN/3]"LBZ::>EW>^K_#T
M"Z::>EW>^K_#T/M7_@I7_P %;_A[_P $]M?^''@BS\$6GQH^(_BV2YUGQ3X'
MLO&\?A&]\%^!HX'AT_7=2OU\-^*5BU'7]5?9H.E7-A#]NL-*UBYFN+.,V$]Q
M\+?\%Y/B1=?&'_@EU^R_\5KSP;KWP]F^(OQ^^$WC-?!?BB2RD\0^'K;Q%\#_
M (WZI96.KFPEEMX[T6=S;S2V[>3=VWFBVU"SL;^*YLK?4_96_P"#=+X;_"_X
ME^&_B=^T;\:I/CLGAR_T_P 11?#+2_ L7ASP=JWB2SGBO=GC75M<\0>)]0\:
M^&?M@=KC0ET?PR-9,,/]LW%UI=UJ&A7'ZC?\%*/V#1_P4+^!?A/X*CXJ#X0#
MPO\ %C0OB>/$@\#?\)\+T:)X/\=^$QH0T8>,/!(M1<CQK]O&I?VK<>1_9GV3
M^SY?MGVFT7NIQL[V>KU[]O(7NIQL[V>KU[]O(\G_ ."'/_*+C]F#_NM?_K1'
MQ:K\8_CW^S)_P<!ZS\=/C3K'PL\2?M"0_#'5?BS\1M2^',.E?M;_  XT'2XO
M =]XPUFZ\(1Z;H=W\9].N]&L$\/RZ>MGI5SI]C<:=;B.SFL[62%H$_I-_8<_
M9?\ ^&,?V6_A?^S7_P )Q_PLC_A6_P#PFO\ Q6G_  C/_"'_ -L_\)A\1/%O
MCW_D7/\ A(/%/]G?V=_PE/\ 9/\ R'K[[7]A^W?Z+]J^QV_UC1>S;5G=O?UN
M%[-M6=V]_6Y_+3_P5F\/?&SPI_P1?_9D\._M'7&N77QQTGXO?#2T^)=QXD\3
M6'C/79?$B^$_C \SZGXHTO5M=T_6[DV[VP:]M=7OXF4*@G)0JOZ+?\$(O^49
M'P)_[#WQB_\ 5P>-Z^AO^"CO[#G_  \"^ >D_ __ (6A_P *D_LOXE>'OB'_
M ,)/_P (5_PGOG_V#H?BG1?[(_L7_A+?!GE?:_\ A)OM/]H?VM)Y'V+R?L4W
MVGS;?\-?^(7W_J^'_P UH_\ R@*%;ELW;6^S?0%;ELW;6^S?0_J;\<^#/#GQ
M'\%>,/AYXPT]-6\)>._"^O\ @WQ1I<C,D>I>'O$^E7>BZS8.Z$.BW>G7MS 7
M0AD$FY2& -?PK?LO_M+^-?\ @DK\4/\ @HW^SOXHU+4[37[CX=>-/ WP\U&U
MTRXAFNOC9X2UF70_@UX^L+6[;_0?#NJ>%?&VM>.S+(N[4-(BT/,C!8"/VF_9
M%_X(R>"O^";WQU\,_MA_$3]M3PM?>#/A;IGBFWUN/QI\,=)^$?AB&+QQX;U/
MP':7.J_$#7/C1KNE:%'#J'B6T-O]KTZ5=1O#;Z7')!/>12I^-7_!:G6_@Q^T
MW_P4-\'6G[)NO>&_BUXJ^(/@GX6>!/$VM?#K6M*\3^&/&'Q9U36]1\/^&+'1
M_$>C75]I>M:JGA2[\"^']1N-.O+BQLY+*TTJ1X]3T[588JBEJKW35]K:IK^F
M5%+57NFK[6U37],_8+_@W#_9I?P+^SK\1_VFM>L#'KGQW\6'PSX.N)TMI6'P
MY^&=U?Z9=:A8W"LUU;#7OB#=^*--U6RF$8F_X0G1KP"1'A8=9_P<H_\ )C'P
MI_[.Q\"_^J?^.U?MS\!?A!X>^ 'P5^%?P3\*A6T'X7> _#/@JRNA!%;2ZFVA
M:7;65[K=Y%"!'_:.NW\=UK.IR 9GU"^NIV)>1B?E#_@I1^P=_P /#?@7X4^"
MW_"U?^%0_P#",?%G0OBA_P )+_P@W_"?_;O[%\'^._"G]A_V-_PF'@K[-]I_
MX3;[?_:?]JW'D_V9]E_L^7[;]IM)O>5WW3^1-[RN^Z?R.$_X(N_\HR/V5_\
ML _$'_U<'Q#K]0R0 22  "22<  <DDG@ #J:^7OV+OV;/^&0?V9/A7^SE_PF
MG_"P_P#A6=AX@L?^$Q_X1S_A$O[;_MWQAXA\6>;_ ,(]_;OB;^S?LO\ ;WV#
M9_;E_P"?]D^U;X?/^S0W?VNO@K\1_P!HGX">-_@O\,_C,GP%U7X@V:^'M?\
MB)%X'F\>:O:^#;U9(_$FB>'].B\:^!DTK4_$=F5T>?7Y=1OWL-%N]7BT_3H=
M7N].UO1D]6_-O\Q/5OS;_,_@K_X*G>-/@7\8/VYOCWXS_9>\-R?\(%#J/G^+
MO$6A31ZGX9\8^-["X33_ !]\3M"BTVR2TTCPKXB\274,<=_]MU*S\2ZJ9_&D
M6I1KXPM]+L?W(M_C#\'OB;_P;O?%?P_^S7HT/A+7_A9X+\ >#/C%X(M;F[N/
M$&F^+O\ A:G@*\^(_B[6;BVC@O=3T_XCZ%)KOC*SU?;)HPTV^O?#4[PQ^%]8
MTG3/TL_8$_X)!?!3]BSX>_&3PIXNUK3OV@O$WQSTG4/!'C?Q?KG@=/"%O+\)
M]0T^.UN?AM8Z ?%/C"2RTS4[U[W5/$5];:Y%+X@N!H2W5M$?#.E2)X-^R7_P
M1$O?V2?B[XZ\2^&OVJY_&WP*^*GA[QA\.?BI^S]XO^#!:P^(GPE\4V^I64'A
M3Q%XOTWXMVD7_"2:)9WR?8O'&F>#]/N!<'58[?1K/1O$&K:+<6Y+_P !M;?6
MWR+<E_X#:V^MOD?E]_P1IT+_ (*6>(OV;O'L'[$?Q9_9&\'^ ].^,NM2>+_#
MGQFL_%MUX_7QA?>#?!(_METT'X>^*H4\,:EHEGI5EHDTFH1B;4-'U^%+='M9
MV?Z(_P""5/[+'CGP'_P4&\8?M"W?[7?[!/Q?U#Q_IWQC_P"%H?#W]GGXSZAK
M_CF*?QMJZ>*[VXT/X>W?PZT4VGA[3/&MCI1E3^T=-MM-TR-A;75W]E&GWG>Z
M[_P0!^*OPM\3^,-6_8N_;R^(_P $O"_C:X%IJ?@Z=/%^@:@/#BBX:+2-<\;_
M  \\;:+_ ,)O;V,MW=QZ?:ZOX/T\0VT[>?>7-TT]U<?H3_P34_X)0?#+_@GB
MGBKQ8GC.]^+/QF\;:7_PCFK^/[O0H_"NF:1X0%_9ZJWA;PQX:CU;7I;."^U/
M3].O=<U._P!:O[G5KC2=+:WM](M[9[69-IW=][:6UZ=?EL)M.[OO;2VO3K\M
MC^?O_@VNTS3[O]LWXO:C<V=O<7VE?LV>(#IES-&LDM@][\2OAE;74MH7!$$\
M]MNMGGC"S?9I;BW$@AN;A)/1?^"ZD<:?\%7/V162-$:;X4_L_P DS*JJTL@_
M:,^+4(DD( +N(HHH@S$L(XXT!VHH'ZZ_\$TO^"/G_#N_XP>-_BO_ ,-$?\+@
M_P"$R^&MW\//[ _X5)_PK_\ LW[5XH\,^)/[7_M3_A9OC;[9Y?\ PCGV+^S_
M .SK7=]L^T_;5^S^1/N_MU_\$EO^&U?VK?A!^T[_ ,+_ /\ A6G_  JGPEX
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M#/%)=SZ?=Z>_]$/_  3B_8<_X=^_ /5O@?\ \+0_X6W_ &I\2O$/Q#_X2?\
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M0:V32Q&L;+D_\%+?V ?^'B'P?\$?"C_A;/\ PI__ (0WXE6GQ#_M_P#X0/\
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M_:-_VC[3]JL?*QY7V>3/F!IKE:ZM_P"0TURM=6_\C^;[]EO3/%5U_P %B/\
M@H7HWPV>73_&]PO_  4>TSP#)8*Z36/BJ76O'5KX6>R6WCDD26VU=K!K=8(G
M=71!'&S!5/LW_!LKJOPXM?C!^U%I.KOI4?Q7U;X>_#Z;P&;F-!J\_@;3=?\
M$C_$VUTNX=-WV9M9NOA?=:G91RA[@V=C=&&6/3GDM_V#_9T_X)+?\*!_;_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=C<:??6UR!,/U9HIW?=CN^["BBBD(**** "BBB@ HHHH **** "BBB@#Y_\
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M-O$$.E:;I<GP_P##EEKGA\>%=%T"[\2QKK7B*ZT.UU74?$+7EC#\F_LL^._
MS_\ !6K_ (*;Z/8^,O";W^O^$OV21::7:^(=':\UK4_!/POUVQ\4BWLH;PS:
ME?\ A'SDL_$ BBFN- \U;?4?LGF!#^3D?Q-B\.>#?CM\;?#&K:3X]^&GP$_X
M. OB5^T7\:O"_AJYMO$=W-\#KRX\.:5H'Q<M['2-0-SJWAO1=;+7?AN]MH+_
M $F[\1MI6MAWM_#T\L;MZ[1^]V_S8[>NT?O=O\V?U _!W]I'X+?'NX\4:?\
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M;[!+H?AW5-3A%EHNI:GI^D_;9+RVM MWJ]MKFGQ6ZW,<NB7<D\4UM^87@O\
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MFH<U_;2ORWO:ROM=;G]^]%?XF]%8_P!L_P#4-_Y6_P#N1T?ZM_\ 4;_Y;?\
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M?$/PNT];3Q;\-?A_%;7UKJOA'Q$UQJ_B?4_$MC+X4\"^.+/1-1U+2_HS1?\
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MZ2.W"5<54K359-4[5=)4YPY>6I&-%QDZ,(2]I3YIRM4J-NS2I:TU\&U]^?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?L0?\$C/B9\</C9X)^('BCQ5_P %/?B9<?L[_#W2/A?\5/#'P8^)%O\ LO?
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MHFI^(]1BBU'Q'J>CZ+;&VT71]2OF:^U*U61;5H86DN)(89/):_8S_@W_ /\
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M'6+M4\8ZQF^U"[)EM&)L;3^PBOY2?VX?&OQ'_:;_ &Z/VB/@E_P3]_X)+_\
M!/3]JOQ_^S;'X$D_:I_:+_:P^%'P8\4W_BCQMXO\&6>L>#/!&AZCK_B/X>:U
M<WFFZ/X>OO ]_J>L^(_$MX-2TNYTJ6T\":+X;T_Q!K[ELNNJZ-_EY:_AU)I[
MO5K35IJ-M5NW=6O^-CZ,_P"#:S2_ &E?LD?M+6/PN\0^./'_ ,/](_;@^,GA
MGP7\7O&9O+%?C'X-\.^&OAY:^#_B%HGA;5+.VU7P9;:IX8ETJVU+P[>7&IF'
M6K._NVN["]N[[PWH']%5?E[_ ,$D_P!JW0/VHOV8]:L;7]G7P]^R;XZ_9O\
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MRXT^\?2/$GAR^U+1M22TU"TNK&Y:SO9A!>6UQ;2E)H9$4"S[>7S['#?M+?\
M)N7Q_P#^R)_%7_U!->K\N_\ @W5_Y0X?L>?]W!?^M2_&ZOU$_:6_Y-R^/_\
MV1/XJ_\ J":]7Y=_\&ZO_*'#]CS_ +N"_P#6I?C=2ZKT?YQ+_P"7;_QK_P!)
MD?MA7\@GPU_8@L?^"F__  5'_P""O6E_&S]J+]L3X;Z5^SI\6/@9HGP\TGX!
M_&33_ VE+I7C/POX_P!+N['5-,\0^#/&UB8-*L?AEX>AT<:-;Z*4,^JS:FVJ
M3W<,MK_7W7\\?_!)O_E*K_P7S_[+9^RW_P"F?]H.A]/7\DW^:"+:YFM&HK_T
MJ)U__!MG\0/'/Q%_X)<> M4\?>+O$7C35=+^+'QBT2QU;Q1J][KFJQ:5'XH_
MM2*Q?4]2FN+ZX@AOM6U":$7-Q*81<&&)D@CBBC_>VO\ .6_X)<?$/]LOXLW'
M[!?_  3\_9M_:[\4_L>^%?BAX?\ VIOBGKOCSP5X1@\9ZC>^(-*\0>.M1:'6
M_#]YXE\,0:O91:=\*['3-$2WUC2)=)GU_7-0N9-722VL(/Z7_P#@B[\4_P!J
MB7]I/_@J#^R?^TU^TEXD_:E?]DCXD? GP_X+^)OBS0(?#.KWR>.-)^++>(=F
MAVVLZ[;Z3ILY\&Z)-:Z:-4U*:"Z^WS2ZE<I<PP6BB]$K/9*^EKVOWOMY%5(6
ME)W2^URZWLVE?:V_2Y_051115&04444 %%%% !1110 4444 %%%% !7PS_P4
M>_Y-%^(__82\"?\ J=>'J^YJ^&?^"CW_ ":+\1_^PEX$_P#4Z\/5]-P7_P E
M?PO_ -E!E'_J?0/"XH_Y)O/_ /L39G_ZAUCSG]KK_DLO_!/G_LK$?_I=\-Z^
ML/\ AJC]FO\ Z+Q\)_\ PNO#O_R?7PU_P4$_Y&#]CC_L8_$W_I#X&KYZ_P"%
M5_#7_AUA_P +._X0/PG_ ,+%_P"AW_L+3O\ A*?^3B_^$?\ ^0W]G_M#_D!_
M\2C_ %__ "#O]$_U'R5^AX;AW*\XX8X'JYGB<?1^LYI_J[A8X&.'?+7SGB'/
MY+$XAXB]Z5)81)QIKG]YOWME\97SO'Y9GW%=/ T,'4]A@/[;KO%RK+FI99DN
M2Q="BJ-K5*BQ+:E-N/NK:SO^\U%?ERW[7?[3=XOQ;O?AQ^S]X3\6?#WX)>)_
M&/A'7O%-[XXT[1[J&+P!%)-J-W/I.H:S8ZC<R#288]0*:78W:R^;]GMA)<JT
M"_<OP ^*A^-GP=\!_%%],&C3^+-)FN;S3%?S(K/4=/U&]T?4H[:0O(\ED;_3
MKE[&25A.]F\#SQQ3&2)/SG-N%LVR;"1QN,6#>'EB*.%E]6S#!8NMA\1B,-/%
MT*.+P^&KU:V$JU</"=6,*\(2<8ORO]KEW$&79GB'A<,\4JRHU,1'V^"Q6&IU
MJ-&M##U:N'K5Z5.EB*<*TXTY2HRFKM=#V&BBBOG#VPHHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9=_T$Q_\ J^7]SS1_(717]>G_$(?^T7_ -'A? __ ,(GQS_\>H_XA#_VB_\
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M^2\U]X?VMEW_ $$Q_P# *OE_<\T?R%T5_7I_Q"'_ +1?_1X7P/\ _")\<_\
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M,L%5I4HTZ\9-8G#3:4:B]R%6$I/6"VCK9:]DV?YNE?2G['_[4WQ!_8I_:/\
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MZMXE\:^+_BKX]\:^(O$GBWQQXQC\)Z&FI:_XH;[3<MIUA96RZCJ5]<ZE]?\
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M1?B#\0_$'BKQ5I7AZS;PSX8NY]4M;/PUX:N[K0])L+>SE*U_0E_Q"'_M%_\
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MTW4]-OX)+6^T_4+&ZCEM;VQO;666VN[2YBD@N())(9HWC=E/D%W^S3^SI?\
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M*Z:W=^&(_"^JOK]MH[7'P(M+==4GTI;N+3VGNK:%;MX3+<0H&D7ZV_X-U?\
ME#A^QY_W<%_ZU+\;J_43]I;_ )-R^/\ _P!D3^*O_J":]7Y=_P#!NK_RAP_8
M\_[N"_\ 6I?C=1:S6K>CW?;E_I@W>F]$O?6RM]EG[85_/'_P2;_Y2J_\%\_^
MRV?LM_\ IG_:#K^AROYX_P#@DW_RE5_X+Y_]EL_9;_\ 3/\ M!TWO'U_1DQV
MG_A7_I<3^<'_ ((+_P#*1#_@E[_V1/\ ;!_]&?M'5_1]_P $F_\ E*K_ ,%\
M_P#LMG[+?_IG_:#K^<'_ ((+_P#*1#_@E[_V1/\ ;!_]&?M'5_1]_P $F_\
ME*K_ ,%\_P#LMG[+?_IG_:#J8]/5?^D&U7XI?]>U_P"G$?T.44459SA1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MK\G/T,_(K]B;_E)=_P %?O\ L._L6_\ JH?'=<-_P0"_Y1X>&_\ LJWQ0_\
M3G8UW/[$W_*2[_@K]_V'?V+?_50^.ZX;_@@%_P H\/#?_95OBA_Z<[&OS3)/
M^1SD'_7WQ2_]:_"']V>*7_)KO&'_ +%O[/O_ -AKXA/VNHHHK]+/X3"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!DG^KD_W&_P#037E5>JR
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M[[XI_;O!?A_^VO%>F7VDQ^)A92P^';:[$@_M&WM["\_:;^S=0_Y\[G_OR_\
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M_P#B:/95?^?=3_P"7^7FOO#VM+_GY3_\#C_GYK[RE15W^S=0_P"?.Y_[\O\
M_$T?V;J'_/G<_P#?E_\ XFCV57_GW4_\ E_EYK[P]K2_Y^4__ X_Y^:^\I45
M=_LW4/\ GSN?^_+_ /Q-']FZA_SYW/\ WY?_ .)H]E5_Y]U/_ )?Y>:^\/:T
MO^?E/_P./^?FOO*5%7?[-U#_ )\[G_OR_P#\31_9NH?\^=S_ -^7_P#B:/95
M?^?=3_P"7^7FOO#VM+_GY3_\#C_GYK[RE15W^S=0_P"?.Y_[\O\ _$T?V;J'
M_/G<_P#?E_\ XFCV57_GW4_\ E_EYK[P]K2_Y^4__ X_Y^:^\I45=_LW4/\
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MU?#UTKQDKMTW9;;NZMZG-B:E-PA:<'^^H/247HJD6WOLEJWV.4HJ[_9NH?\
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M[0=?T.5_/'_P2;_Y2J_\%\_^RV?LM_\ IG_:#H>\?7]&*.T_\*_]+B?S@_\
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M%7ZWE/\ R27AM_V<'(O_ %?\6'YSF7_)1\<_]D=F_P#ZI^'#UCX%_P#)#/\
M@HC_ -E8_:8_]0]Z^COV!/\ DT7X-?\ 8-\3_P#J=>**^<?@7_R0S_@HC_V5
MC]IC_P!0]Z^COV!/^31?@U_V#?$__J=>**^6XP_Y$^?_ /97<._^LKC3Z#AO
M_D99+_V36<_^K_!GV%1117Y.?H9^17[$W_*2[_@K]_V'?V+?_50^.Z_FA_X)
MX_L_^&OVP/C5^S/^SG\3?%GQ#T/X;-\ _B[XZ2V^'_B*V\.ZG#XBMOBU\1HI
M;N*ZO=*UFUVWT&CZ5;WJR6$CR0Z?;+%)"59G_I>_8F_Y27?\%?O^P[^Q;_ZJ
M'QW7X,?\$1O^3X?V9/\ LU/XT?\ JW?BQ7X-FU"CB\;P5A,1357#8GBCC>AB
M*,K\E:C/CK"<U.HDUS0E973TT78_U\\-\WS+A[A7Z4O$.2XNKEV=Y#]'_P"B
M?FV39GA^18K+<RPGT2N(I8;&X2I.,O98BBY2Y*D5=*4H[2:?ZX?\$??A_:?
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MAJ$+Z+XGTRSOS&CB:?\ 7E>U_0'%J_5)O739/EO:][7T]=#] J***9(4444
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M?:UJDWCC5_#>A^$=%U/QA=^(VL(Y+:"/]EO]KOQ9\;/B)\7/@?\ &7X"Z_\
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MS;5V^>T=4[\S5K.]A^QPWO?N*7NNS_<QO>R=DN6[T:M:][Z'LG]N:I_S]?\
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M&B#H941)'C#*9$CE:18W9,[E21HI51B KM%(%)*-C+ZUB?\ H(K_ /@ZI_\
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MK6)_Z"*__@ZI_P#)%_5\/_SXH_\ @J'_ ,B:W]N:I_S]?^0+?_XS1_;FJ?\
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M;R;<DHQ3NN9M+1ZZ Z.&5[T:.C2_A0;N]DDHMM^2NSZK_MS5/^?K_P @6_\
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M?3UTWO?U372_^8J=KO5JR=W=6M=6NG&77R['ZC_\$,O!_P"Q[X!_8\U[PO\
MLA?M%ZA^U9;CXQ>*?$/QY^..K>&?&?A#4/&OQW\2:!X3OO$-[)H'CBSAU;3K
M9/"R>#X;2!-0UY7CC:]O]<U'7;S5KA_V:K\Q_P#@EA^S+^U3^RU\$_'O@K]K
M6_\ V5-0\=:]\4[WQ3X>E_9(^&GAGX7>!$\)3^$O"FDP1^(=%\+?!CX(V-_X
MM&L:3J[3ZI/X;U2Z?1VT>T;6Y(;2&PL?TXIK9:6TV)G\3UOKOW_!?DO0*_(?
M_@M#9?MA^)?V8_AE\.OV*=/^.DWQ'^)O[3GPD\(^.-;_ &=_%-U\/OB3X3^$
M"6_BGQ%XPURP^)::GH^F_#NSGU+0?#>@7OBCQ'J5MX:AAULV6O>9I=Y=1M^O
M%?(/[9_[%WPU_;=^'7A+P+X_\3_$?X>ZQ\./B;X1^,GPO^)_PA\0V'A?XC_#
MSXD^!YKBX\.>(O#^K:IHOB'3'6WFN6DN-/U+1[ZTFGALM0@2UUC2](U.P'>V
M@HNS3TT?577W:'\KWAC]J7XC^(?@%^S]^QWX&_:#_P""COPF^+'QP_X*R>'?
MV4/VPM=_:%_:?T?XP?M._!'3M%TWPW:>)O 'P.^.V@^#O"\FB^#_ !'(=/U#
M2/$$7A?2+F/Q9H7Q TU]+\0^#]5FDU[](/V#/VL/VP/A1^R=^WOX=T#P/\9?
M^"DOQ'_8O_X*.?'+]ESX7:1XS^*>E:7\9?&7PC\)Z[X:L=/U/QK\2=;\/ZY>
M^)=6\/SZCK&L7MX=%UK59[748=)L+/3O#NAVRZ=]I#_@C;^S6?V=+GX&/\0/
MCRWCBZ_:F/[;TG[4J^,_#T?[1<?[6!U>+4V^,5IKJ>#1X&M-0-G%_P (TNAP
M> ET)-#>2^6S'C9SXQKZQ_8K_8O^%_[#/PGUSX7?#77_ (@>-KOQK\2O&GQE
M^)WQ+^*WB"U\3_$?XG?%3X@7-I+XF\:>+]6T[2M"TF74KFTTS1])A73-$TV)
MM/T>SN-0&HZ[<:MK6II)K?M;?;2/3;H_U-)2BUM?6]K;[==[65M[GXJ_&?\
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MHHHK4]P**** "BBB@ KX9_X*/?\ )HOQ'_["7@3_ -3KP]7W-7PS_P %'O\
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M/HVGVOCZVTOXQ^(_'=O9?$Z1-4N?%^O6.OZM'>W>F#3!7Q%X"\.76L?LK_\
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MQHTC(B(TKB25E55:601I$'D( +N(HHXPS981QHF=J* R6W@G:%IH(9FMY1-
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M_!+W_LB?[8/_ *,_:.KT;X__ /*57]IK_M.I_P $LO\ TS_M7UYS_P $%_\
ME(A_P2]_[(G^V#_Z,_:.KT;X_P#_ "E5_::_[3J?\$LO_3/^U?4=(_XH_P#I
M*.B?\1_]>U_Z6C]UOVE_^5F7_@G5_P!F3_%W_P!-?[3]?T?5_.#^TO\ \K,O
M_!.K_LR?XN_^FO\ :?K^CZK6\O7]$83VA_@7YR"ORC_X+#QQS?LQ>"(9462*
M7X_> 8Y(W 9)(W\/>.%='4Y#*RDJP/!!(-?JY7Y3?\%@O^39O O_ &<#\/\
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M[*Q^TQ_ZA[U]'?L"?\FB_!K_ +!OB?\ ]3KQ17SC\"_^2&?\%$?^RL?M,?\
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MTJ30=#CNKB]@T62RMQ)J=K&EQ<1/+((E<CU3_@IS_P FL:M_V.O@[_TLN*_
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MO_$>KW_YV%'_  TY_P $C_\ GE^S]_XCU>__ #L*^[?^&:?V<O\ H@'P3_\
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MQ5I2E6=Y5Y12M#FD5^)__!!;_DS?XI?]GL?M<_\ JT[VOVPKQ/X"_LZ_!O\
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MV\L'TK[6;^%K-9R,[QE\ /A)\0/B_P#!;X\^+O"7]K_%C]GFV^)EG\'O%?\
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M?*X6Y9SAOS7OR2C?;KMK8Z/^V-._Z UM_P!\P?\ R/1_;&G?] :V_P"^8/\
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M='NX%DGZ[B?YH?\ @BAT_P"X72WX>0_JE#M/_P '5?+^_P!?U]+=;_;&G?\
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MR7W#^IT.U3_P=6_^3_J[\K='_;&G?] :V_[Y@_\ D>C^V-._Z UM_P!\P?\
MR/7SMXI^/GPV\'?&/X7? ;7=0UJV^)7QBL_%VI> ]-7PKXD?1=6T[P+H=QK_
M (KNO^$N.EIX3671K.*T2]TJ/6I=<@EU?1I)=+2SU&&[K"^*W[4?P8^"OBK3
M/!/C[6?%\7BG5O">L^.[71_"'PE^+OQ-GA\'>'IC;ZWXDU27X9^!?%]KH>E:
M;,-ES=:U/IZ+E6&Y64FUBL8W%))N47**6&HMN*;3DDJ6J3BTVM$XOL3]6PRN
MVY)1:C)NO523LG9_O-&TUI_>]#ZF_MC3O^@-;?\ ?,'_ ,CT?VQIW_0&MO\
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MI_\ @BA_\J\E]P?4Z':I_P"#JW_R?]7?E;H_[8T[_H#6W_?,'_R/1_;&G?\
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M_P ,_P#K4WB6O)_C-_RD/^/?_:73_@GM_P"FS]HNO6/^"[/_ ">'XL_[1O\
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MIN<7447;5.2BCJ?^%:_\%+?^CB/@K_X2-K_\["C_ (5K_P %+?\ HXCX*_\
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M/Q1\>: _@GQ%\)/%%E<>*O']\=8\-^'?$=K:6&C>#?&_C1O[7\/W'V]^RW\
M/BW\.?\ @H/_ ,%2OCAXS\)?V-\+OVC=<_8TO/@SXH_M[PSJ/_"96WPH_9TC
M\">/I/[%TK6;[Q%X>_L'Q6ITK9XJTG0Y-4Q]NT5=1TW%Y7Y ?";]A_\ ;E_9
MN_9U_P""(_C*V_9BUCXH?%7]@WQG^U:GQP^ OAGXI_!;2O$UGHO[0$GC72]
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M_#?_ ()@?M(Z!^S9HW[!_C[]A[X@_%+Q/HOQ#M? ]Y^TOX^_;[^. _84\2_
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MN_GN+DPMJ6J7$>GV?F_8](TN*QT72X+32=.L;.W\5T3]E7X/Z)XCT[Q,UO\
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M!H,:VOA/P,\HO/%/@/Q)X8T^1EF^)4""VAO]8MIKUP[2Q6:3R0PW$RQV\O\
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MM\1U==ZL!'L1]S9!VCFO</V5/^"W_P"RE\#OCYX"^*/BWX=_M%7_ (?\,?\
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M?V3B\APOL/8_\1"?/]8_MIU/:^UA[+ZMR^SJ^VYJ7]*'_$6;_P $Y.,_!O\
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M3BM3<PV;SGZ*_8X_;I_9[_;G\'^*_$WP/USQ#!KGPX\2-X*^+?PM^(7A?4_
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M16E[H5OX!\3?^"Q?[&_PM^+7CSX8:LWQM\2>'_@WXC;P3\?_ (^> ?@=X_\
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MWW0\O[OE^/K?IO[,T3_H*?\ D6'_ .(H_LS1/^@I_P"18?\ XBN9HH^M4?\
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M3_Y(/J]7_H+K?=#R_N^7X^M^F_LS1/\ H*?^18?_ (BC^S-$_P"@I_Y%A_\
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M6'_XBM2VM-/33[N&*\WV\C9FFWQGRSA!C<%"C@ \@]:X6NCL/^0'J?\ O_\
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MY_W<%_ZU+\;J],_X*"?\%0OV"_V<M ^-_P"SA\9OVBO#?@WXVZG\%_%D%MX
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M_P#R ?V?_P#LA>F_^K)^)U?U)?\ !M/_ ,D/_:7_ .RK>$O_ %$):_1?#/\
MY+[+?^P'$?\ JG9_$GT[?^4.>-?^RIR7_P!>32/Z6J***_JX_P"=P**** "O
ME6__ &&?V--:\3^,O&GB/]EKX"^+_%OQ \2W?B_Q=XB\<?"[P?XXU;5?$-_;
MVEM?7RWOB[2M:FTZ.\^QQW5S8:4UCIL^IS7^KR6;:KJFI7EW]55^2'QD_P""
MH4_PQ^*?CSX>:7\'HM?M/!7B34/#7]L:AXR?1[G4+O2)/L6HS_V=;>'=6B@M
M_P"T8KI+(_;I99[);>XGBM9YI+2#ULGX.S#C*O4PF795A\UJX*G]:E#$RP4(
MT(2DJ'M(2QU2G34Y.IR6A+G<7+3E4BO^(@8SP_A4Q>$XGSGAE9HHX&O5R;'9
MK@ZF-ITIQQ4,/B5E4HU*U"G5HPKQA64J4*T*<U:HH,^P_P#AA#]A[_HS7]E/
M_P 1X^$7_P Q]'_#"'[#W_1FO[*?_B/'PB_^8^OSQ_X>]ZQ_T0;3?_#BW7_S
M%T?\/>]8_P"B#:;_ .'%NO\ YBZ^C_X@;Q5_T2.6?^%'#_\ \U'/_P 3&YC_
M -'1XU_\/'%O_P GY+[C]1_A]^S!^S3\)-?'BKX4_L\? SX9>*!:3V \2?#[
MX2^ ?!FOBQN@%NK(:QX<\/Z;J/V2Y55$]O\ :/)F  D1@!7N=?F/^S%_P42D
M_:!^+FD?"W4_A:GA)M=TO7+K3M7L?%3:\JWVBZ=+J[6][:7&B:,8;2?3[._"
MW4$UU,MXMI ;0P3S75K^G%?-9OPOF'".*CE>99=1RRO.C#&1P]"6%G3E2JSJ
M4XU5+!SJ46Y3HSB_>YTX>\EH7#C"IQOS9S6SS,>(*D9?4I8_-,1C\3BH^PC&
MI'#NIF+>)5.G&LI0C?V:]HW#=G*>._ OA#XG^"?%WPX^('A[3?%G@7QYX;UK
MPAXP\,:Q#]HTKQ!X9\1:=<:3K>CZA"&5GM-0TZ[N+68(Z2!)"T<B2!77\]OA
M/_P1_P#V _@YX[^%GQ'\-_"/Q3XA\2_ IE;X(1?%#XW_ !S^+GACX0&.>YO+
M<_#[P1\2OB-XG\&^'Y+&_N?[5TF>'07N=%UNWM-=T>:PUFW2_KW?]K'X/_M;
M?%JT\#P_LJ_MD:;^R)=Z%<>()/&UYJ/[-W@?]H@>/+?4(M'70+:*V\:>*_"Z
M>%#X=DL]7E>?3GO6UD:RL=TL TV R_E'_P $J?$/_!33]JS2;7]H+XO?\%#]
M!UGX:> /VA?BQ\*O&/P-MOV-OA!I$_Q#T?X4^)+SPO)<1?%'0O$.DZOX/;Q%
M*D.I^78>&]3GT@1FR6^U)7:YKRKZVM\]/+SOV-DG9M32[J\O3HK:^OJ?I9\3
MO^":_P"R#\7/BQ\2/CAXN\&?$VQ^)_Q@TGPSH/Q0\1_#O]IO]J+X/0>.]&\'
M>'T\+>&=,\2>'?A%\9O _A?4K+2- 1M.MX)M%*.EQ?3SB:ZU"^GN/8/V8?V1
M_P!G3]C/X>7/PL_9H^&&D_"_P5J'B'4?%FK6-GJ?B+Q%JVO>)M66"*^U[Q)X
ML\8ZSXB\7>)-5EMK2TLHKW7M=U&>UT^SL].M'@L;2WMXOFS_ ()(_M"_%?\
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MT+3_ +1=7?V'1M$L(-,TNS^UWT]U?77V6QM8(/M%Y<W%U-L\RXGEF9Y&\O\
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M;WT>D^)](N]'O9["X:.5;>_MX+M[BQN&BD$%W'#,8WV;3\A?LW^"?VP?V?\
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M'V^*LNB^'O%=MK7B>_MO%L.B_P#"*Z#_ &9J'BB+5]5T]-.6.UOXHY[I9_V
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MLEU>W-Q=W#AIKB>69WD;=TW_ )"%E_U\P_\ H:UC2_BTO^OD/_2D:5/X<_\
M!+_TEGI=%%%?:'R1^9/_  5__9ST#]J/]@SXL?"W6_C;\.OV>+T:KX!\7>#_
M (L?%S7X/#7PRT#QSX0\:Z)K/A?3O&NJW=_965MHWBK4(%\*&ZN;?7&TN\UJ
MTUJQ\,^(M4TRPTB[_FW^ 'P9^,_Q._:*\,^(_P!N+_@HS_P2]\,? G0_VZO#
M7[?OQ$TOX0?M+_#75O&/Q9^.GPV\(>&/"?A#^R;>?4+.PT#P'J]IX>$&HV5S
MJ.@7]A'K7B:^CT.:['A>#1OWD_X+_P#A?Q3XM_X)6_M%:?X:\"WOQ!M+"_\
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M_$+XC_ #X)_$#Q]I?P/^(<.F>./&WPJ\"^*_&&G0Z-X.\17ND16/B77=!O\
M6K2/2KR66[TV.WO8UL;F22>U$4KLY^)_^#=7_E#A^QY_W<%_ZU+\;J_43]I;
M_DW+X_\ _9$_BK_Z@FO5^7?_  ;J_P#*'#]CS_NX+_UJ7XW4NJ]'_P"VE_\
M+M_XU_Z3(_;"BBBF0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MNEZ1:LT4$S^;?ZA:0 (0TH8J#\K=7W5]K7[V_P CZ)*5G:+:=M;.VES\\_\
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M_'I\9=/_ &@?A1XZ_:AU#]D+X0?\%#O@5^U)XN_:[U76Y_V,M3^$FH_M@_\
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M)^)_B5<ZLPM?@C<?#NXAFUCP]J$EQJ%YX1CN=1M=+_(;X<_LT_&>Z_8*T/\
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MW_Q='V^^_P"?V[_\"9O_ (NCFP'_ #ZQ/_@VGY?W/7^MCEQO_/S#_P#@N?\
M\E_5WY6T/^$?U+^Y%_W]6C_A']2_N1?]_5K/^WWW_/[=_P#@3-_\71]OOO\
MG]N__ F;_P"+HYL!_P ^L3_X-I^7]SU_K8Y<;_S\P_\ X+G_ /)?U=^5M#_A
M']2_N1?]_5H_X1_4O[D7_?U:S_M]]_S^W?\ X$S?_%T?;[[_ )_;O_P)F_\
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M;_S\P_\ X+G_ /)?U=^5M#_A']2_N1?]_5H_X1_4O[D7_?U:S_M]]_S^W?\
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M_5H_X1_4O[D7_?U:S_M]]_S^W?\ X$S?_%T?;[[_ )_;O_P)F_\ BZ.; ?\
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M\\)6UMX>U)_"OC+P5XQTS3]:M%;3M>^Y?V%_^"F(^(_[/_[07C?]O#7/V?\
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MEM<RW%K/''2USX8_#?Q-XW\#?$OQ'X \&:_\1?AC#XGM_AOX\UGPSHVI^,/
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MV^D>,8O!GB2]LIM8\,)XJTFUM]+\0KHMY9#6=.A2RU#[1;#RJ/Z_S#3SZ_\
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MIUWXG\7W&F65M+XBUZ[LK.VM[K5M6:ZOKA(QYT[LSLP&GGM^.E_EO^!GZ?\
M&KX-ZM\+YOC?I?Q:^&>I?!:WT75O$EQ\7M/\>>%KSX7P>'= EO+?7=>F\?V^
MJR>$XM%T6?3M0AU;5'U9;'3I;&\CO)X7M9U33U[XG_#7PKH'AWQ7XH^(?@;P
MWX7\7ZKX8T+PGXDU[Q;H&CZ!XHUSQM<6]IX,T;P[K&H:A;Z=K>J^+KJ[M;;P
MQIVFW-S=Z_<7-O#I4-W)-&K<UIO[/WP)T;X/3?L]Z/\ !KX7:3\![C1M8\.S
M_!G2_ ?AC3_A=+H7B&]OM2U[2&\"6>F0^&38:SJ6IZCJ6J6W]F^5?:C?7E_<
MK)=W$TSZ?B;X+_!_QGX5\)^!?%WPK^'?B;P5X"U;PEKO@;PAKO@OP[JGAGP9
MK7@)HF\$:IX5T*]TZ;3/#U_X2$$47ARYTFUM)='MU^S6#06[-$QZAIY[_A_G
MN;NK^/\ P'H'BSPAX"UWQMX1T7QU\08O$5QX"\%ZOXDT;3?%GC>#PA96NH^+
M)O"'AR\O8=8\2Q>%]/O;*_\ $4FC6=ZFB65W:W6I-;07$4CNM_'O@6[\;:E\
M-+7QIX3N?B-HWAW3O%^K^ +?Q'H\WC;2O">L7U[I>D>*-2\*QWC:[8^'=4U/
M3=1T[3M;NK"+3;Z^L+VTMKF6XM9XXZ6N?#'X;^)O&_@;XE^(_ '@S7_B+\,8
M?$]O\-_'FL^&=&U/QAX @\:Z?;Z1XQB\&>)+VRFUCPPGBK2;6WTOQ"NBWED-
M9TZ%++4/M%L/*HM/AA\-['XB:M\7K+P#X-M/BMKWA?3O!.M_$JV\-:/#X[U;
MP=I%_/JFF>%=1\5QV:ZY=^'K'4KF6_MM(GOGL([LI.L'F10LA_2#3SV_&_Y6
M_$N^&O'O@7QG?>+-,\'^-/"?BS4O 7B*3PAXYT[PUXCT?7;[P7XLAL+'59O"
M_BRTTN\NKCPYXBBTS4]-U*31-8CL]2CL-0L;QK86]W;R2<]8?&OX-:K\,[[X
MU:7\6_AEJ7P;TS3_ !!JVI?%JP\>^%;SX9Z?I7A.]U#3?%6IWWCRWU63PM::
M?X:U'2-5L/$%Y/JL=MHU[IFH6NHR6T]E<QQ:G@_X8?#?X>ZGXVUGP'X!\&^"
M]7^)7BB;QM\0]3\*^&M'T"_\<^,;FSM;"Y\5>++K2K.UF\0>(;FSL[:"XU?5
M'NK^=8@99W9G9N8TW]GOX#:+\(K_ . &C?!?X6:/\"]3T_Q!I.H?!S2O /A?
M3?AA=Z9XKU&_U?Q+I\_@6RTN#PR]GKVJZIJ6IZK;G3?*O=0OKJ\G5[B:21C^
MOZ_$-//I_P '_@?B=/KWQ/\ AKX5T#P[XK\4?$/P-X;\+^+]5\,:%X3\2:]X
MMT#1] \4:YXVN+>T\&:-X=UC4-0M].UO5?%UU=VMMX8T[3;FYN]?N+FWATJ&
M[DFC5K>M>/\ P'X;\3^#?!'B+QMX1T'QG\1I=>M_A[X1UKQ)HVE^)_'<_A;2
MCKGB>'P;H%]>P:KXHE\.:(#K&O1Z):7SZ1I0.H:@MO:#SJPO$WP7^#_C/PKX
M3\"^+OA7\._$W@KP%JWA+7? WA#7?!?AW5/#/@S6O 31-X(U3PKH5[ITVF>'
MK_PD((HO#ESI-K:2Z/;K]FL&@MV:)M+Q!\,?AOXM\8> OB%XI\ >#/$?CWX5
MS>([CX9>-==\,Z-JOBSX>3^,-)30O%LO@GQ#?64^K>%W\3Z+'%I/B!M$N[(Z
MQIT4-GJ'VB"*-%/Z_P PT\^O_ _'<NV_CWP+=^-M2^&EKXT\)W/Q&T;P[IWB
M_5_ %OXCT>;QMI7A/6+Z]TO2/%&I>%8[QM=L?#NJ:GINHZ=IVMW5A%IM]?6%
M[:6US+<6L\<9X:\>^!?&=]XLTSP?XT\)^+-2\!>(I/"'CG3O#7B/1]=OO!?B
MR&PL=5F\+^++32[RZN/#GB*+3-3TW4I-$UB.SU*.PU"QO&MA;W=O))2M/AA\
M-['XB:M\7K+P#X-M/BMKWA?3O!.M_$JV\-:/#X[U;P=I%_/JFF>%=1\5QV:Z
MY=^'K'4KF6_MM(GOGL([LI.L'F10LAX/^&'PW^'NI^-M9\!^ ?!O@O5_B5XH
MF\;?$/4_"OAK1] O_'/C&YL[6PN?%7BRZTJSM9O$'B&YL[.V@N-7U1[J_G6(
M&6=V9V8#3SV_'2_RW_ HZ3\8_A%K_P -[WXR:%\5/AQK7PATW3/$NM:C\5=)
M\<>&-2^&]AH_@RXU.T\8:M>^.;/5)O#%KIGA2[T36;7Q+?SZI':Z%<:1J<.J
M2VLEA=+%/JGQ9^%>A^%_"GCC6OB9\/\ 1_!7CN^\):9X'\7ZIXS\.:?X7\9:
MEX^DM8? NG^%/$%WJ4.D^(K[QK+?647A*TTB[O+CQ')>6J:/'>-<1!\?0_@-
M\$/#'PHO_@/X:^#_ ,,?#WP1U32O%&A:C\(-$\"^&=*^&5]HGC:YU2\\8Z/=
M>!;'3(/#,^E^*;K6]8N/$%A)IC6NKS:IJ$E]%.UW.7EUOX&_!;Q+X+\%?#CQ
M#\)/AKK?P^^&U]X,U/X=^!M5\#^&K[PCX#U#X=+;Q^ ;WP=X=N=-DTCPS<^#
M(;6WMO#$NC6EDVAVD8M-.-O;%HB:]?Z?4-//?\/\]SI=:\?^ _#?B?P;X(\1
M>-O".@^,_B-+KUO\/?".M>)-&TOQ/X[G\+:4=<\3P^#= OKV#5?%$OAS1 =8
MUZ/1+2^?2-*!U#4%M[0>=0OC_P !OX[E^%J>-O"+?$V#PG#X]F^'2^)-&;QW
M#X%N-7F\/P>-)?"(O3X@C\)SZ_;SZ)#XC?3QH\NKP3::EXU[&\*U/$'PQ^&_
MBWQAX"^(7BGP!X,\1^/?A7-XCN/AEXUUWPSHVJ^+/AY/XPTE-"\6R^"?$-]9
M3ZMX7?Q/HL<6D^(&T2[LCK&G10V>H?:((HT43X8_#>/XDS?&1/ '@Q/BY<>"
MHOAO/\4%\,Z,/B#+\/8=;?Q+%X%D\8BR_P"$@;P@GB)VUU?#AU Z1_;&-2^R
M?;%68&O]=K?Y_@&GGM^-_P K?B7?#7CWP+XSOO%FF>#_ !IX3\6:EX"\12>$
M/'.G>&O$>CZ[?>"_%D-A8ZK-X7\66FEWEU<>'/$46F:GINI2:)K$=GJ4=AJ%
MC>-;"WN[>23$TGXQ_"+7_AO>_&30OBI\.-:^$.FZ9XEUK4?BKI/CCPQJ7PWL
M-'\&7&IVGC#5KWQS9ZI-X8M=,\*7>B:S:^);^?5([70KC2-3AU26UDL+I8KW
M@_X8?#?X>ZGXVUGP'X!\&^"]7^)7BB;QM\0]3\*^&M'T"_\ '/C&YL[6PN?%
M7BRZTJSM9O$'B&YL[.V@N-7U1[J_G6(&6=V9V; T/X#?!#PQ\*+_ . _AKX/
M_#'P]\$=4TKQ1H6H_"#1/ OAG2OAE?:)XVN=4O/&.CW7@6QTR#PS/I?BFZUO
M6+CQ!82:8UKJ\VJ:A)?13M=SES7^N_0-//I_P?\ @?B;&J?%GX5Z'X7\*>.-
M:^)GP_T?P5X[OO"6F>!_%^J>,_#FG^%_&6I>/I+6'P+I_A3Q!=ZE#I/B*^\:
MRWUE%X2M-(N[RX\1R7EJFCQWC7$0?2UKQ_X#\-^)_!O@CQ%XV\(Z#XS^(TNO
M6_P]\(ZUXDT;2_$_CN?PMI1USQ/#X-T"^O8-5\42^'-$!UC7H]$M+Y](TH'4
M-06WM!YU<UK?P-^"WB7P7X*^''B'X2?#76_A]\-K[P9J?P[\#:KX'\-7WA'P
M'J'PZ6WC\ WO@[P[<Z;)I'AFY\&0VMO;>&)=&M+)M#M(Q::<;>V+1':\0?#'
MX;^+?&'@+XA>*? '@SQ'X]^%<WB.X^&7C77?#.C:KXL^'D_C#24T+Q;+X)\0
MWUE/JWA=_$^BQQ:3X@;1+NR.L:=%#9ZA]H@BC13^O\PT\^O_  /QW+:^/_ ;
M^.Y?A:GC;PBWQ-@\)P^/9OATOB31F\=P^!;C5YO#\'C27PB+T^((_"<^OV\^
MB0^(WT\:/+J\$VFI>->QO"KM!\>^!?%6N>,/#'ACQIX3\2>)?A[J=AHOC_P]
MH/B/1]8USP/K&JZ5;:[I>D^,-)T^\N+_ ,,ZGJ6B7MGK%A8:U;V5U>:5=VVH
M6\4EI/%,])/AC\-X_B3-\9$\ >#$^+EQX*B^&\_Q07PSHP^(,OP]AUM_$L7@
M63QB++_A(&\()XB=M=7PX=0.D?VQC4OLGVQ5F!X7^&'PW\$^(_'?C'P=X!\&
M^%?%OQ1U;3M=^)/B?P[X:T?1M?\ 'VLZ/ID>C:3JGC'6-/L[?4/$E]IFE1+8
M6%SJ]Q=RVEL98[=HQ--O T\]OQTO\M_P*.D_&/X1:_\ #>]^,FA?%3X<:U\(
M=-TSQ+K6H_%72?''AC4OAO8:/X,N-3M/&&K7OCFSU2;PQ:Z9X4N]$UFU\2W\
M^J1VNA7&D:G#JDMK)872Q3ZS\6?A7X=\$Z1\2_$'Q,^'^A?#CQ OA9M!^(&L
M^,_#FF>"=;7QS=:=8^"FTCQ7>ZE!H6I+XPO=7TFS\+&ROYAX@NM4TZWTG[7+
M>VR2X^A_ ;X(>&/A1?\ P'\-?!_X8^'O@CJFE>*-"U'X0:)X%\,Z5\,K[1/&
MUSJEYXQT>Z\"V.F0>&9]+\4W6MZQ<>(+"33&M=7FU34)+Z*=KN<O+XA^!OP6
M\6_#K0?A!XH^$GPU\1?"CPM'X1A\-?#/6O _AK4_ 'A^#P!+I\W@>VT7P?>:
M;-X?TRU\(OI6FCPY;66GPV^CQV-K#81P10H@->O]/J&GGO\ A_GN=+K7C_P'
MX;\3^#?!'B+QMX1T'QG\1I=>M_A[X1UKQ)HVE^)_'<_A;2CKGB>'P;H%]>P:
MKXHE\.:(#K&O1Z):7SZ1I0.H:@MO:#SJ%\?^ W\=R_"U/&WA%OB;!X3A\>S?
M#I?$FC-X[A\"W&KS>'X/&DOA$7I\01^$Y]?MY]$A\1OIXT>75X)M-2\:]C>%
M:GB#X8_#?Q;XP\!?$+Q3X \&>(_'OPKF\1W'PR\:Z[X9T;5?%GP\G\8:2FA>
M+9?!/B&^LI]6\+OXGT6.+2?$#:)=V1UC3HH;/4/M$$4:*)\,?AO'\29OC(G@
M#P8GQ<N/!47PWG^*"^&=&'Q!E^'L.MOXEB\"R>,19?\ "0-X03Q$[:ZOAPZ@
M=(_MC&I?9/MBK,#7^NUO\_P#3SV_&_Y6_$NZ#X]\"^*M<\8>&/#'C3PGXD\2
M_#W4[#1?'_A[0?$>CZQKG@?6-5TJVUW2])\8:3I]Y<7_ (9U/4M$O;/6+"PU
MJWLKJ\TJ[MM0MXI+2>*9\32?C'\(M?\ AO>_&30OBI\.-:^$.FZ9XEUK4?BK
MI/CCPQJ7PWL-'\&7&IVGC#5KWQS9ZI-X8M=,\*7>B:S:^);^?5([70KC2-3A
MU26UDL+I8KWA?X8?#?P3XC\=^,?!W@'P;X5\6_%'5M.UWXD^)_#OAK1]&U_Q
M]K.CZ9'HVDZIXQUC3[.WU#Q)?:9I42V%A<ZO<7<MI;&6.W:,33;\#0_@-\$/
M#'PHO_@/X:^#_P ,?#WP1U32O%&A:C\(-$\"^&=*^&5]HGC:YU2\\8Z/=>!;
M'3(/#,^E^*;K6]8N/$%A)IC6NKS:IJ$E]%.UW.7-?Z[] T\^G_!_X'XFQK/Q
M9^%?AWP3I'Q+\0?$SX?Z%\./$"^%FT'X@:SXS\.:9X)UM?'-UIUCX*;2/%=[
MJ4&A:DOC"]U?2;/PL;*_F'B"ZU33K?2?M<M[;)+YO^T]+X>\2_"+Q[\#I?''
M@7PM\1OVA?AK\6/A;\(]#\9>*M,\/77C3QEK'PX\1K_9N@65U*VK:]+I5B\N
MM:U;^']-U:_T[0[.]U22R:VMI&KM?$/P-^"WBWX=:#\(/%'PD^&OB+X4>%H_
M",/AKX9ZUX'\-:GX \/P> )=/F\#VVB^#[S39O#^F6OA%]*TT>'+:RT^&WT>
M.QM8;"."*%$&UXH^&'PW\;>(_ GC'QCX!\&^*O%OPNU;4==^&WB?Q%X:T?6=
M?\ ZSK&F2:-JVJ>#M8U"SN-0\-WVIZ5*UA?W.D7%I+=VPCCN&D$,.S*M2C7H
MU:$[\E:G.E.SL^2I%PE9ZV?*W9VT=CMRS,*^4YEE^:X3D6+RS'87,,,ZD>>F
ML1@J]/$T/:0NN>'M:<>>-US1NKJ]S^ :#_@D%_P4 G^('_"J?^%/^#HOB6GA
M>V\=7/@!_P!HK]F=_&UGX#NM9E\.P^.;GP?;_&"?Q,G@]]=@N-&3Q$FDR:9+
MJMO/ID%Q+?QM;5\U_MJV<NG?MD_M:Z?.T;S6/[37QYLYFB+-$TMK\4_%<$C1
MLZHYC+H2A9$8J0653D#_ $C4^&/PWC^),WQD3P!X,3XN7'@J+X;S_%!?#.C#
MX@R_#V'6W\2Q>!9/&(LO^$@;P@GB)VUU?#AU Z1_;&-2^R?;%68?YPG[=_\
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M]+>5DM+6UMWOJ?SB_P#!,W]D7]E_QY^QU_P4N_9,^)W@VSB_96\&_P#!5?\
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M^(_@N^\0Z%-X<\6Z L_B_P *>-/#VL^!_'.CO:V'CGP?J^@7>E^*+/3;"TU
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MU^U!\(? O@KQU\%+SX(?$WX3_$3XOK++\,_%GB+QI-HGPP\0? GP_>Z;H7Q
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M !9\)_#3XRZ1\.O%'[!^A?#Q/&_BC]GWXP_#WP[/\0K#XPZOXUDT36=9\7>
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M4^#+OPM/XEEOO"]Y:?#^\^(%WHVN^*K#X?R7T=QX2T^^M[;7;#0-6GN](M.
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M6>,]2;Q/X*\0+I5S;^)[;6K>Q\::%XABN1X4\)7F@WL&I4O^"@WP5\4_'/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *_P TO]N__D^']LK_ +.L_:'_ /5N^,*_
MTM*_S2_V[_\ D^']LK_LZS]H?_U;OC"OP_QP_P"15D?_ &,,3_ZC(_UA_9/_
M /)P_%G_ +(S)?\ U>2.'^,__(!_9_\ ^R%Z;_ZLGXG5_4E_P;3_ /)#_P!I
M?_LJWA+_ -1"6OY;?C/_ ,@']G__ +(7IO\ ZLGXG5_4E_P;3_\ )#_VE_\
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MMSG**Z/_ (26\_YX6WY2_P#QVC_A);S_ )X6WY2__':\CV6$_P"@JI_X3/\
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M_':/983_ *"JG_A,_P#Y=_5GY7/:8K_H%A_X4+_Y7_5GY7YRBNC_ .$EO/\
MGA;?E+_\=H_X26\_YX6WY2__ !VCV6$_Z"JG_A,__EW]6?E<]IBO^@6'_A0O
M_E?]6?E?G**Z/_A);S_GA;?E+_\ ':/^$EO/^>%M^4O_ ,=H]EA/^@JI_P"$
MS_\ EW]6?E<]IBO^@6'_ (4+_P"5_P!6?E?G**Z/_A);S_GA;?E+_P#':/\
MA);S_GA;?E+_ /':/983_H*J?^$S_P#EW]6?E<]IBO\ H%A_X4+_ .5_U9^5
M^<HKH_\ A);S_GA;?E+_ /':/^$EO/\ GA;?E+_\=H]EA/\ H*J?^$S_ /EW
M]6?E<]IBO^@6'_A0O_E?]6?E?G**Z/\ X26\_P">%M^4O_QVC_A);S_GA;?E
M+_\ ':/983_H*J?^$S_^7?U9^5SVF*_Z!8?^%"_^5_U9^5^<HKH_^$EO/^>%
MM^4O_P =H_X26\_YX6WY2_\ QVCV6$_Z"JG_ (3/_P"7?U9^5SVF*_Z!8?\
MA0O_ )7_ %9^5^<HKH_^$EO/^>%M^4O_ ,=H_P"$EO/^>%M^4O\ \=H]EA/^
M@JI_X3/_ .7?U9^5SVF*_P"@6'_A0O\ Y7_5GY7YRBNC_P"$EO/^>%M^4O\
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MVM^+[8::WB74-1B2734&E17=W^J--:)>B%+XGZ^G]6V"BBBF2%%%% 'Y,?\
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M[2__ &5;PE_ZB$M?RV_&?_D _L__ /9"]-_]63\3J_J2_P"#:?\ Y(?^TO\
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M#6*]Z7(HW2:N].9V3EU)*G&?+9MTT[VLE.48N6DGI%2;WZ:V6I]DZ7^T^O\
MPL/X:_#'QS\#?C?\*/$OQ9U[7M#\%3^-M-^'FK>&]1;PYX$\7_$#4Y[CQ;\,
M/B-\1?#.DWD>C^#[J&#PSK>JZ9XNU&:Z^VZ3H&HZ'H_B/5]&\]US]N&VTO\
M:)\3?LP:5^S+^TEXO^)GA?P</B1,WAQ?V>H_#NJ?#:77#X=M/'.D:KXE_:#\
M.SS:5>ZJ#;6VD7MA8>,/,'E3^&8+@&&OL+6+CPT-8\)VFLV]G=ZW)JM_>>$5
MFTQM2O-/U.U\/ZO;:EK%E-':W+:$L6@:CJFC76O2R6%J(]>3P])?&X\1VFGZ
MA^:V@_\ *9SQ[_VCK\+?^M 34Z<:<_:-TU[E"4TG*?*YJ:5U:2ERV=FN9ZIN
M_1*;E%12G>]2$;VC?EE:Z>EKWNTTEHTK=3[8^"7[17PT^/EMXGB\&7FK:7XL
M\!ZJFA?$7X:>-='N?"?Q,^'>LSQ-/96?C#P=J6W4=-AU6U1KS0M8A^UZ!XAL
MTDNM"U;48(9I(_-M-_;?^!=WX#^/OQ-U:X\9>#_!/[.7C6+P#X^U/QGX)U[P
M]JL_B&ZT7PAJ]A;:)X/N[;_A-)9=3G\<>']!TW3=7\/:-KMWK]PUDND+$UM=
M7'RI\,[A/B%_P6$^.OCOX:K%??#_ .%7[(/A/X(_&CQ'IS12:/<_'34/B8/&
M>A>&WN/-B35/$6B^!(C:ZM<::NI1^&FTF;P[K<NFZI=16=<]K/[/\O[55I_P
M4O\ A)X>\;Q>"?%W_#7GPJ\8>#_%(@&L6.B>,O /P(_9K\3>'I->T5)TCU/1
M;C6/#TNEZC:7*3K ?/O(;6XU#3(81:HT5.TW*,'3H56[W=.-2=-3C*T;OW9N
M479-1L^638N>;7N\KDI5()6LIN*;BU=K2ZLU>S=_>21^@?PM_:.\,_$?QWXF
M^$FL^$?&_P )/C%X5\.:7XXO_A9\3(O"2^)KWX>Z[J%UI&C>/M"U/P%XN\>>
M"_$'AJZUFPOM#OGT?Q7>:GX>UNT;3?$FFZ1-=Z8;_P!L\1^(] \'Z!K7BOQ7
MK6E^&_#/AO2[[6_$'B#6[ZVTS1]%T?3+:2\U'5-4U&\DAM;&PL;6&6XNKJXE
MCA@AC>21U52:_+/]FW2OBM\8O^"@'Q(_:)\<Z;X,@T;X+_LV:3^R?=^*/AK>
MZU?_  \\:_%BY\>VGQ$^)5IX-UK7/L>J^(=)^'FIVK^&];%YI5G#X?\ %=Y?
M>$YI-4USPKJ>J/U'_!8_PYXT\4?\$\?CO8^"]/NM7-A_P@GB/Q9H^GP2RZCJ
M'@7PM\0?#/B+Q2;2:%]]BFE6&F?V]JM[Y-VL6A:3JJ/;.LI>.'1BZ]&ES<BJ
M>Q4W?F4'4Y;V;>J2:DDWI>S>C8U4E[*I.SDX*;C=6<U%.S:6UVK:+6UTM4CV
M7Q1^V[H/A7X;ZK\:[WX#_M$7/P0LO!TGCC3?BO9^$_!DNCZWH#Z.VLZ;J2^"
M/^%@#XR^'-)U6W:W"Z_XS^&'AO0M#@G;6?%NH^'?#EM<ZS']KLRHK.[*B(I9
MW8A555!+,S$@*J@$DD@  DG%>8:=XZ^%?CWX067CVPO]"\5_!_QGX+M]2LYX
M=._MS1/$GA#Q#IR10:9'H$5G=S:N-7M+M=(7PO'IMS?W]W<#05TR:^E%BWCG
M[8FNZ_>?#.P^"G@20'XC_M)ZXGP>\.JNI/HUQI/A75M.O=4^+_C/^UH;:_N]
M!_X0_P"$NF>,+_2->CTO4EL_&T_@_35L;R_UBPL;K/E4Y1@H.F^:2DVVTHJU
MW*]K."YG-Z*WV8V*NXIR<E-<L7%))-MWT5KJTG91W?FSI?V?_P!J/X:?M/\
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M_ ^K?!G]EGPS?7VFIKWBW1O$OF?$#Q[\59-*D0:Q:WOC31O"5JG@KPV5CO\
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MXZ?#_P#9OF\8:#X/T"+XM?%?QK?_  Y^&.EOJ'Q*\%PKX3^('C;2Y8M1\/\
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M'\1RR6/AW3M1U:!-O\-K7ZI7T?9]"U&-M7?WDM':ZLWI=)[JU_N\_P!DHO\
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MNV^+>A:=X:\?)=>&]*UJR\,>)?[:T;2K&UB;Q5HVM'2)(%O=&_L^_ N@:;\
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MAWEIH^N:UJ.B^&TL_#^GVMBUMX9T_2+:[6*)KR*X-M:?9^&\&?L;_L\?#_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:9_SQ?\ [_2__%5/]D8K^>C_ .!ST_\ *?F_Q^;_ +4P_P#+5_\  8>7]_\
MJWI?Y N_V3?V6-0@\06U_P#LT?L_WMMXLU"WU?Q5;W?P:^'5S!XEU6TEEGM=
M3\013>''CUG4+:>:::WO=16YN89999(Y5>1B=_X<?L\_ #X.:EJ&L_"+X&_!
M[X5ZQJUB-,U35?AQ\,_!?@?4M2TU;B.Z73]0OO#&B:7=7EBMU##<BTN)9+<7
M$4<PC\Q%8?4']@:9_P \7_[_ $O_ ,51_8&F?\\7_P"_TO\ \55/+,:TXNM3
M:=KIU:K3M:UUR6=M/N]!+,L*FFJ=1-;/DIW7_D_]6?E?YVU+X,_!_6?'FF_%
M/6/A1\-=5^)^CQPQ:1\1]2\"^%[[QYI45NFRWCTWQ?=:7+XAL8X$^2%+748E
MB3Y4"CBO2J[_ /L#3/\ GB__ '^E_P#BJ/[ TS_GB_\ W^E_^*J7E.*=KU*+
MLK*\ZCLNR_=Z+T[/RNUF>&5[0JJ[N[0@KMVU=IZOS\O2_ 5S?B[P=X1^('AS
M5?!_CSPMX<\:^$M<@6VUKPOXMT33?$?AW5[9)HKB.#4]%UBVO--OX4N(89TC
MNK:5$GBBE4"2-&'L?]@:9_SQ?_O]+_\ %4?V!IG_ #Q?_O\ 2_\ Q5"RC%)I
MJ=%-:I\\[IZ:_P /I^GI<_M/#O>%77O&'_R?]6?E?YK^&OP-^#WP=BDB^%_P
MV\'^!S+9_P!FR7.@:)9V=^VDKJ%WJL&B#41&U^N@V.H7][<Z9H2W(TC2GN9E
MTVRM4<I7/>(?V7/V9?%WB74O&?BO]G7X$^)_&&LB9=7\5^(?A'\/]:\2ZJMP
MI6<:EKNI>'KG5+X3JS+,+JZE$BL0^X$BOK7^P-,_YXO_ -_I?_BJ/[ TS_GB
M_P#W^E_^*JO[+QMW+VU.[T;]I4NUIHWR7?\ P/2Z_M'"V2]G4LME[.G9;=.?
M^K>E_%?!?@3P/\-] MO"GP[\&^%/ 7A>SEGFM/#?@OP[I'A;0+6:ZD,UU-;:
M/H=G8Z=!+<RDRSR16RO-(2\A9B37%Z-^SY\!O#DOBJX\-_!;X4^&KGQT?^*W
MNO#GP^\*:!=>,E-RMV\7BRYTC2K.?Q'!-<J);F#6)+V&Y)87$<JNZM]/?V!I
MG_/%_P#O]+_\51_8&F?\\7_[_2__ !5+^RL9J_:TDY6O^\J:ZIZ_N];/7U7I
M<_M+"Z?NZFFB]R&BTT7OZ?+MZ7\G\/>'?#_A+1--\->%-"T;PQX<T:U2QT?0
M/#VEV6BZ)I5E&28[/3=*TV"VL;&UC+,4M[6"*)"3M09-;) (((!!&"#R"#U!
M'<&N_P#[ TS_ )XO_P!_I?\ XJC^P-,_YXO_ -_I?_BJ7]D8I[SHZ]YS_P#E
M?]6?E=_VGA_Y*J_[=AIM_?\ ZMZ7^2/"?[+G[.'@3Q+-XO\ !?P-^%OA7Q!+
MJ<&N+?:!X*T'2H[37[=-0B3Q'IFGV=E#IND^))(=5U&"Z\1:99VFM7MO>3P7
ME_/"^P=YKWPL^&/BGQ;X:\?>)_ASX#\1^.O!@9?!_C37O"'A_5_%OA17E,[C
MPUXCU#3KC6-"#SDS,-+O+4-*3(<N=U>]_P!@:9_SQ?\ [_2__%4?V!IG_/%_
M^_TO_P 53>58QN[JTF[6NZE1NVBM?V>UM+>7I=+,L*E94ZB5[VY(6O=.]N?=
M/6_=>A\T^.O@-\#?BAKFD^)OB7\&?A1\1/$F@0M;:%X@\=?#OPAXMUS1;=I?
M.:WTG5M?T?4+_3H6F_>M%9W$,9E_>%=W-/\ !GP*^"/PXL-?TKX>?!SX5^ ]
M+\5B\7Q3IO@SX>^$?"]AXE7484MM077[/0](L;?6!?6\<<%X-1CN1=0HD4^]
M%51])_V!IG_/%_\ O]+_ /%4?V!IG_/%_P#O]+_\51_96,MR^UI<O;VE2RUO
MM[.VCU]4WVN?VEA;W]G4OWY(7Z+?GOMI\O2_A/@#X9?#?X4:&?#'PM^'W@CX
M:^&VNY+]O#W@#PIH/@[0VOIHXHIKPZ3X=L-.L#=RQ00QR7!M_.>.&)&<K&@#
MO'OPV^'7Q5T%_"OQ0\ ^"OB1X7DN(+N3PWX]\*Z%XPT&2[M6WVUT^C^(;#4=
M/>XMW^>"9K<R1-\T;*>:]T_L#3/^>+_]_I?_ (JC^P-,_P">+_\ ?Z7_ .*H
M_LK%\W-[2ES7OS<]3FOWO[.]_/R?E=_VGAK6Y*MMK<D+6TTMSV_X;TOY'X8\
M+>&?!.@Z7X5\&^'-"\)>%]$MA9Z-X;\,:1I^@Z#I%H'>46NEZ/I5O::=86PD
MDDD$%I;Q1;W=]NYF)X'XE? +X&?&:\T'4?B[\&_A=\4+_P +M,WAR]^(/@/P
MOXPNM$%PR27,6F7&OZ7J$MG;W,L4,US;0LEO//;VT\T3S6T#Q_37]@:9_P \
M7_[_ $O_ ,51_8&F?\\7_P"_TO\ \50LJQ:?,JM)2_F52HGKOJJ=];N_?7RN
M?VGAFK.%6VFCA"VEK:<]M/TTZ'A_CGX=^ ?B=X7O?!'Q'\$^$_'O@W4A;B_\
M*^,?#VD^)/#UV;21)K-Y]'UBTO+!Y;.>..>SE,'FVD\<<]N\<L:.M7P+\+OA
MK\,/"47@'X;_  _\%^ O!$/VPIX1\'^&-&\.>&R^HY_M&631=)LK33Y9]2+,
M^HW$MN\U_([R7<DTCLQ]Z_L#3/\ GB__ '^E_P#BJ/[ TS_GB_\ W^E_^*H_
MLK%VY?:4E&][<]2U]-;>SM?SWT]+G]IX:]^2K>UK\D+VWM?GO:^MO)^5_D2'
M]E+]EVW-H;?]FWX!VYT_5;G7;!H/@]\/(6L=<O?.^V:S9-'X=5K75KHW$YN-
M2@,=Y,9I3),QD?/5?#[X'_!KX3&)OAA\*_A]\/W@TM]#MY/!_A'0O#TMMH<E
MZNI2Z+:RZ98VTEMH\VIK_:DVEP-'8S:HTFI26[7TLD[_ $C_ &!IG_/%_P#O
M]+_\51_8&F?\\7_[_2__ !5-Y7C&K.K3:[.I4:^[V?\ 5GY72S+"IW5.HGW4
M*=^G]_\ JWH<!17?_P!@:9_SQ?\ [_2__%4?V!IG_/%_^_TO_P 54?V1B?YZ
M'_@4_P#Y7_5GY7K^U,/_ "UO_ 8?_)_U9^5^ HKO_P"P-,_YXO\ ]_I?_BJ/
M[ TS_GB__?Z7_P"*H_LC$_ST/_ I_P#RO^K/RN?VIA_Y:W_@,/\ Y/\ JS\K
M\!71V'_(#U/_ '__ &2*MS^P-,_YXO\ ]_I?_BJM1Z9:16\MJB,(9SF13(Y)
M. .&)W#A1T(KHPV6UZ4Y2E*DU*E5@K2FW><'%7O!:)O7T=D]+XULPH5(QC&-
M5-5:4W>,;6A.,GM-ZV32\_+4\VHKO_[ TS_GB_\ W^E_^*H_L#3/^>+_ /?Z
M7_XJN?\ LC$_ST/_  *?_P K_JS\K[?VIA_Y:W_@,/\ Y/\ JS\K\!17?_V!
MIG_/%_\ O]+_ /%4?V!IG_/%_P#O]+_\51_9&)_GH?\ @4__ )7_ %9^5S^U
M,/\ RUO_  &'_P G_5GY7X"BN_\ [ TS_GB__?Z7_P"*H_L#3/\ GB__ '^E
M_P#BJ/[(Q/\ /0_\"G_\K_JS\KG]J8?^6M_X##_Y/^K/ROP%%=__ &!IG_/%
M_P#O]+_\51_8&F?\\7_[_2__ !5']D8G^>A_X%/_ .5_U9^5S^U,/_+6_P#
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M;]WO_EZ"GF>'E"45&K>46E>,-VK?S^?X/ROJT445]">$%%%% !1110 4444
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M\PYGVC_X!#_Y$_ ?_AWS_P %J_\ I.'_ .:1?!S_ .7%'_#OG_@M7_TG#_\
M-(O@Y_\ +BOWXHHLO/[W_F',^T?_  "'_P B?@/_ ,.^?^"U?_2</_S2+X.?
M_+BC_AWS_P %J_\ I.'_ .:1?!S_ .7%?OQ119>?WO\ S#F?:/\ X!#_ .1/
MP'_X=\_\%J_^DX?_ )I%\'/_ )<4?\.^?^"U?_2</_S2+X.?_+BOWXHHLO/[
MW_F',^T?_ (?_(GX#_\ #OG_ (+5_P#2</\ \TB^#G_RXH_X=\_\%J_^DX?_
M )I%\'/_ )<5^_%%%EY_>_\ ,.9]H_\ @$/_ )$_ ?\ X=\_\%J_^DX?_FD7
MP<_^7%'_  [Y_P""U?\ TG#_ /-(O@Y_\N*_?BBBR\_O?^8<S[1_\ A_\B?@
M/_P[Y_X+5_\ 2</_ ,TB^#G_ ,N*/^'?/_!:O_I.'_YI%\'/_EQ7[\4467G]
M[_S#F?:/_@$/_D3\!_\ AWS_ ,%J_P#I.'_YI%\'/_EQ1_P[Y_X+5_\ 2</_
M ,TB^#G_ ,N*_?BBBR\_O?\ F',^T?\ P"'_ ,B?@/\ \.^?^"U?_2</_P T
MB^#G_P N*/\ AWS_ ,%J_P#I.'_YI%\'/_EQ7[\4467G][_S#F?:/_@$/_D3
M\!_^'?/_  6K_P"DX?\ YI%\'/\ Y<4?\.^?^"U?_2</_P TB^#G_P N*_?B
MBBR\_O?^8<S[1_\  (?_ ")^ _\ P[Y_X+5_])P__-(O@Y_\N*/^'?/_  6K
M_P"DX?\ YI%\'/\ Y<5^_%%%EY_>_P#,.9]H_P#@$/\ Y$_ ?_AWS_P6K_Z3
MA_\ FD7P<_\ EQ1_P[Y_X+5_])P__-(O@Y_\N*_?BBBR\_O?^8<S[1_\ A_\
MB?@/_P .^?\ @M7_ -)P_P#S2+X.?_+BC_AWS_P6K_Z3A_\ FD7P<_\ EQ7[
M\4467G][_P PYGVC_P" 0_\ D3\!_P#AWS_P6K_Z3A_^:1?!S_Y<4?\ #OG_
M (+5_P#2</\ \TB^#G_RXK]^**++S^]_YAS/M'_P"'_R)^ __#OG_@M7_P!)
MP_\ S2+X.?\ RXH_X=\_\%J_^DX?_FD7P<_^7%?OQ119>?WO_,.9]H_^ 0_^
M1/P'_P"'?/\ P6K_ .DX?_FD7P<_^7%'_#OG_@M7_P!)P_\ S2+X.?\ RXK]
M^**++S^]_P"8<S[1_P# (?\ R)^ _P#P[Y_X+5_])P__ #2+X.?_ "XH_P"'
M?/\ P6K_ .DX?_FD7P<_^7%?OQ119>?WO_,.9]H_^ 0_^1/P'_X=\_\ !:O_
M *3A_P#FD7P<_P#EQ1_P[Y_X+5_])P__ #2+X.?_ "XK]^**++S^]_YAS/M'
M_P  A_\ (GX#_P##OG_@M7_TG#_\TB^#G_RXH_X=\_\ !:O_ *3A_P#FD7P<
M_P#EQ7[\4467G][_ ,PYGVC_ . 0_P#D3\!_^'?/_!:O_I.'_P":1?!S_P"7
M%'_#OG_@M7_TG#_\TB^#G_RXK]^**++S^]_YAS/M'_P"'_R)^ __  [Y_P""
MU?\ TG#_ /-(O@Y_\N*/^'?/_!:O_I.'_P":1?!S_P"7%?OQ119>?WO_ ##F
M?:/_ (!#_P"1/P'_ .'?/_!:O_I.'_YI%\'/_EQ1_P .^?\ @M7_ -)P_P#S
M2+X.?_+BOWXHHLO/[W_F',^T?_ (?_(GX#_\.^?^"U?_ $G#_P#-(O@Y_P#+
MBOT(_8>^ G[:/P+L/B-:_M@?MNI^V7-XCN_"\WP^F'P)\#_!A_AW%ID6OIXH
MC>X\(7=U<>*1XK>_T!DBU8K'H'_".,VG;CK=^%^\**+>OWO_ #!R;5O=^48I
M_>DF%%%%,D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HK\)OB!\8OVZ;;]OCP5X+T*'XC1^ [F_P#C7IT,
M$'PW\.B]OO@E8_&_]GNUE\9:?\,I_CQ;^!/$FF>%3J</@70OV@M=O;7X@V_@
MSQ_XKUR;]G^VCT2+7-9X_P *WV@0?M$?\%/O ?Q9_: _;%T_P'\#_$GP!T_X
M.KX#_:,_:$O/%O@:/XE_#ZXUO7;?P\$\8ZEHNK27?B6[T]+6\^)MGKNAZ%9J
M);Z[T_2+?4+Q';\K]^J7?S';\K]^J7?S/Z":*^+KCXU7/[.WAWX;_ 5O#WQH
M_:W^,O@#X(>$M;^(UU\.8? =[X]NO#GA^TL_!DWQ8\:VWQ(^)W@QKK4_B/XE
MT;Q!=Z-H&A:MXL\9^)=5TSQ(-.TO4(])OKY.'\=?\%*/@7X9;]G1O!'A/XR?
M'6U_:E\.>.O$WP@N_@SX"_X2'^WH/A]X:U;Q%KNB-8ZYJWAK58/%<#:4^D7W
MAY[#[9X7OY&D\;'PQ8V]Q=HA'Z$T5\%_MN?M;^+/V</V&/'/[4G@SX7^);OQ
M3;^!?#.J:/X3\9Q:-X>U+X=:O\0#I6E:1J7Q.T6]UD3G_A"-:U_3X/$_A/PW
M-K6L7VLQ#0X9;+2Y=1\4Z-D:E_P41\*Z#X<_:CUCQ+^SM^T;X=UO]C[2? WB
M/XT>!+U?V?+_ ,4V'A?QYX6U?QK8^(_#][X?_:"UGP1X@L-(\+Z/-JNN6=KX
MQ378UN+:STO2-6U$7=G:M)O;^MO\T-)O;^MO\T?H717P)XI_X*$> =#^(UE\
M)O#OP5_:,^)7Q U;]G"T_:>T7P]\/_ GAW4I]:\ 7>H^'M/%AIUWJWC;1=.D
M\06IUYVN?.O(/#T]_I-YX6T?Q!JWC:]T'PQK%+X8_P#!2;X(?%?6?V<(/#_@
MOXTZ;X+_ &J;35+?X3?%OQ+X+TC1_AG>>-]#TC5=6UCX7:SJY\57&LZ;X[LV
MT+6M)M8UT"Z\+^(-9TJ_M/"GB?7XK.YN859]OZ_I/[A6?;^OZ3^X_0BBOBKQ
M1^W5\+O"&N:O/K'A#XDCX,^&OB2?@]XN_:;LK/P1?_ _PC\3%U6P\,W'AOQ%
M-:^.Y?B=86.F^.-2L_A]KGC7_A6<G@#0?&DDND:OXJLXM.UB\TWS3PU_P4W^
M$7B/4/C"_P#PJ']I/1O!/P$\2_&GPQ\6OBIJWPNMX_AYX&O?@9X"MO'_ (G/
MB+5+3Q)>:E8W.M6,LVD^%M"&D3>)KK7$L;'6M%T'^VM'>\=G_7]>:'9_U_7F
MC](**\!^$'QXE^*OBOQUX.U+X2?$WX5:SX'T+P%XG_XN!+\-K_3O%7AWXC3^
M-(/#VM>$M:^&/Q$^(VAZI9*W@?5$U$3:G9W5G<R0V[6SC,I_/CXR?MD?%GQ=
MXT_X*<? /1OAC\2/ VA_LS?LTZ;K/AOXO>%O%7P^T[4/#'C'7/A+\9_B3:^.
MM:O[+XAV7C33=+\;1Z#X,TGX<:9X'\.>+]=TB30]8U;X@R^ Y->@TS2BS?\
M7>W^86;_ *[V_P S]A:*_,S]B/\ :ZTO7/A[^Q;\#?'VA?%Z'XB_$S]B[X9?
M$_PW\5/'.GVMWX8^+U_X1^'?@"'XHM8Z_/XDU'QS<>*-*U77H=4U2_\ &GAC
M0[;Q/:W:^)- UC7])UG0]4UKU'X4?MY_#?XP>(O"GAOP[\.?C!I-Q\4OA3XH
M^,WP&OO%&E> ='T[X^>"?"-SI]MJLGP^=?B+=76BZNXUC1+ZSTCXK6GPVN9M
M(UFPUB3R--6^N;)"/N*BOA/_ ()Y?M5^./VQ/V?K'XR>-?A3KWPW.M^*_B4F
M@7MUJ7@C4O"^O^'],^+GQ&\,Z'I7AJ;P]XNU?Q7<7_@70?#FC^&/&>K^-?!W
MP_3Q!XH@O=9\)Z;J>@7<=W#YKXD_;/\ @Y^SIX+_ &UOCSKVE_M/>)=&^$WQ
MO\->&OB)X5UU[7Q*/#WB#5_AC\+;G1X?A-H.K>*X-.\#?#'5-.\3>'-8O8-?
MO_#UPGC+Q!KBMIL4UYI&EL[.]NH[.]NI^FU%?"&D?\%#?@I-=_%K3O&7A7XS
M?";5OA59_#76(?#_ ,3_ (;7_A[Q=\2?#OQC\5W'@+X7Z]\./!5K>:IXOU"#
MQAXX@B\)P:1XDT/POXFT+6KZRL_%VA^'9#>K987Q&_X*._#3X1?"[X]?$7XE
M_!_X_P#@[5OV<;[P+:?$KX:7_A7P9JGBVSM/B= ;CP#K^F^(?"OQ \1?"G5_
M#FNH&@N-4T[XCW)T/5(Y- UJWLO$+6VE7)9]OZ=O\U]X6?;^G;_-?>?H917Q
M9#^VSX;GL8[<?!#]H6P^(6JZGX^C\'?!_P 4^$/"'P_^(?CKPC\-O^$)'B;X
MG:!_PL/Q_P"$_!>G^ 4F^(7A:QTZ\\8>,?"_B#5M7O9]$TWPY=:Q97-BGE _
MX*H?LYZOX#'Q-^'WAGXQ_%/P-I/PJ/QK^(FN^#O!VB6'_"I_AK#X\\9?#;4-
M>\;Z7X]\6^"M9NKG2O%?PZ\>07N@>!M.\9^(7TOPIJFO:?I=]H\NEWFHEG_7
M]?\ #A9_U_7_  Y^E5%?'7Q;_;0\%?#.7Q##X<^'WQ+^-<G@WX1^&_CMXU_X
M50OP]G;PM\*_&,_BZV\+>+;BT\<_$#P1JGB"TU63P-XFN)K3P1IWBK4M'TS3
MAJ&M66GQZGH2:MF?'']O7X)_ *X\;W7C#3_'6J>"OA)XA\.^%OC?\1_"VDZ'
MJ?A?X.:YXLTWPMK'A^Q\3Z5>>)=,^(/BF2\TSQOX0OKT_"?P1\1E\/VVOV3^
M)6T9A.D)9_U\O\U;N%G_ %\O\U;N?;%%?F)^W=^U)I<7P"_;)\$_"+_A<FK^
M/O@K\!_$OB?Q=\1/@M>V>@0?!?Q9K?@"X\6?#%M8\47'BCPUX@O+BZM9]/\
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M=$UC5OA]=?$GP7X$T_QUI^FR/X:N[^XO]#M]6RO@A^WIX+^/WQ4\3_"_P/\
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M%^R[XM\)^.O%WB;XEW.G?$7QIX1U6Z^$'Q,T;Q3XWU#Q!XNTR\EUOP$GP_\
M%^C+X@C\,:\OCJ#Q=-I<?BG1[B[UWVK]H[]IS0_V:#\)[CQ1\-/BEXTT/XL?
M%#PO\(;;Q1\/[7P#=:#X'\8>.-8TS0?!A^(<WC#X@^#+[1-!\1ZIJ,EI:^(]
M.T_6M&TZYL)++7KO2+_5?#5KKJ$?2]%? L'_  4!\)OHO[1FH7?P%_:!TO7_
M -F7QWX ^&_C;X?7T?P*;Q[XC\6_$V\\/6O@JP\!:+8?'6^M=<C\1)XL\-W/
MARZU#4M%@\8'5X-,\$OXEU^"]T>UW/''[>/PS^'GC36?"OB;P!\6[;1/!GC[
MX3?"OXI?$N'2?!$OP_\ A/\ $3XU:/X6UOP+X8\873>/X_$VHM+:^-O"46MZ
M]X"\+^-/"N@W7B'3$U+7889)Y[=V?;^M/\U]X[/M_6G^:^\^WJ*^2O"_[77A
MOQE\2O#7@?PY\,OBCJ/A/Q7\3/BI\'])^-$,?P]E^&9^(?P9M/B#)X[\/7]M
M;?$&Y^)6BRVNH_#3Q/H^C7NN_#S2]-\17%F-0T>\NM"NM-U74/0/BU\>]"^%
MFO>#_ MEX2\;?%#XJ?$'3O%.M>"?A9\.[;PU_P )-KF@^!_[#'C'Q!/K7COQ
M/X&^'WAS1?#S^)?#\%S>>*_&NA/J-[J]EI?A^#6=6F6PI"/=:*^'Y?V\_AKJ
M'@OX0>+/ ?PX^-GQ-U;XU^$_BAXW\)_#KPQX1T#0/']AX=^"M]I>D?%.Y\3V
M/Q.\8?#_ $#0[SPCKVM:7X?DTJ7Q'-J6NZQ?6UOX7M=;@E6ZKSGXB?'#3?BO
MXJ_X)D_%_P"#OCSQ=%\-_CC\:-8$VGZ?K.L:!I'BWP?JW[,GQQ\7VVD^-?#%
MO<PVFIW>D>(O#FD7#Z=K45XNCZYHY:W5+F#SB ?I-17Q)XA_;K^'^D:[!9:)
M\,OC3X\\)WWQ6UKX Z3\3?!_A[P@_@;6?C[HM[K.BO\ ">Q;Q)X[\.>*8+R[
M\5:#J'@N'XCZOX7TOX(6OBOR-,U3XI:?&;FZM>9\&?\ !13X7>./#7[*/C33
M/A=\;+/P?^U]XWUKX;_#[Q%J>F_"^*U\*^-]$U/QEITN@?$/3[3XK7NNZ=)>
MQ> _$6J6.H>%M)\7Z0;"W@2\U"SU*X33@ ?H#17YE_#CX]P_!36/^"A?B_XF
M>(?B1XV\*?#K]K7X<^"O!>@"_P!2\:Z_;7'Q.^#_ .S9I_ACP#X&T[6-3@L=
M*L]>^)OQ'$.FZ7'>:+X<TV]UZXOKV?3[3[9>)A?M*_\ !1]OAU^R3^U7\8?A
MW\)O&]E\8/V;]=LOAKXR^&?Q&D\!6&H_#/QEXPMM _X0_P ;>+)/#?CGQ1X=
M\5>!#;^+_#^OV$7@'Q%XDU#Q,L\.C,NA1?VYK/AUV?Y?C;_-#L_R_&W^:/U1
MHK\__'G_  45^%/PKT#Q%XI^)OPW^,7@KP_\-==T7PS\>M1O+3X6^(1^S_KW
MB:'P]?>&M,\>6O@;XJ^*[[Q=<:OHOC'P9K\K? RV^+\'AW2O%>E#QA-X=U*/
M4M-L.$_;N_:DTN+X!?MD^"?A%_PN35_'WP5^ _B7Q/XN^(GP6O;/0(/@OXLU
MOP!<>+/ABVL>*+CQ1X:\07EQ=6L^G^--;M_AS9>*Y_#G@>TNM4\7/H46I:';
M:V)-_P!>G^:^\$F_Z]/\U]Y^G=%?-&G?%NP^%'[(OA[XU^-X/%?B?3?!/P&\
M+^//%:Z#9OXC\6ZK:Z=X)TS5=:O((;N\M1?7K(+B^O;W4M1M+6&-;G4-4U"V
MM8;FZC\:^''_  4+^'GQ&\"^&_'4/P=_:$\)VWQ#M_ATOP;TKQOX'\/^%[KX
MY:Q\1?ASXD^*-OHOPNU?5?&5OX5O1X8\+>$?$-WXL\3>+?$'@_P1ID5G:7\'
MBB]TK5])O[Q"/ORBOR=^.'[6'ASX[?L^:;XZ^#/B?XE?#[Q/\,/VX_V:O@A\
M4O"SZC=>#_%'A?Q9)^T5\)/#7Q"^''BZ?PIK6H^'?%NBWOAGQ9+8WD_AGQ/X
MK\!>([+49$M-7U5(9T@^CM*_;I^%VJ?%/P]\.'\'?%'2M$\8_&/XC?L^>#_B
M_J^C>%;;X7^)OC3\*CX@B\7^ +!HO&=Q\0;2]BO?"GB?3-'UO6/A_IGA37]3
MT#4K/2=?NI!:_:G;2_\ 73_,=M+_ -=/\S[4HK\<;+]NO6/BS\&_^"B^H_%S
MX-_M$?##X8_ #XB_&CX5Q^./@QXH^&5M\0/"VA?#3X>^ ?\ A(;#2_$>B_%.
M/7--^,%IJ>H^*OB-:ZY!H9^%ND:+?:'X4M?B#XJ\06,ECJWVE9_M5:#I/[1?
M@?\ 91NOA1\;;?7O%WPLU#XD>"?BCKO_  KA_AGXQ\+^%=(T5_$$>F^)K_XH
MCQGKGC'1M4UK2-!\0>'CX-?Q+:W^H0>*;^RC\!7<7C.4L_Z^7^:"S_KY?YH^
MO**^)-$_;D\'^(O O@/Q7I7PB^,<WB?XJ:-XO\7_  P^%$K_  9@\=>.OAUX
M(N?"]GKGQ.TK67^,?_"I]/\  \L_C+PU_8-[XC^)NAZOXJAU?3[CPQHNL07]
MA)=>S?!+]HCX=_M&_!'1OCW\%GUOQMX/\1:=XAN=$TU--C\.>*+_ %;POJ6J
M:'J_A5]-\7W?A^RTW7X?$.C7VAHVL:IIVA2W217RZW_85Q#J[H1[K17Y/_LI
M_P#!2+Q%\:_@?X \<^)_V=OBA>_$SXN^+/C9+\+?AOX#UGX'7EUXY\#_  [^
M)OC_ $G4]1\-7OB;XR^%([72O@_X>TSP;X-^(_BGXE6_PS'B+Q[K6FGP!HOB
M2U\1:<H^_P#X'?'+P)^T%X)D\;>!)-6METOQ#KO@GQCX5\3:8^A^,_A[\0O"
M5Y_9OC#X?>-]#>6<:3XJ\+ZD#9ZE!;75_IEVC6VJZ'JFKZ%J&F:K>-JPVK'L
M-%? F@?\% O"NM^$?V@?$EU\ /VB/#.N?LX_$KP7\)/&?PT\36?P0L?B/K_C
MGQ[J'A_3O#.F^!]&M?CC?Z5K=IK+^+?"D_AO6+W7-(TCQY#XATY?AQ>^,;K[
M7;6NI\6_^"@/P<^"5GXEUKQYX:^)-KX5^&6I>$="^//BS2]-\'ZSI?P#\2>-
MM$\):_HOASQSI^G^-YO$_B[5(K#QWX3;69?@?X?^+>DZ%_;-M+JNJ6MMNG!9
M_E^.WYA9_E^.WYGW/17XJ:;^UGJGP!_:^_X*F^*/&</QW^,GPF^$7A+]CGQM
M8^%_!MU!XMTSX5^!];^&GQ!\3?$;Q=H>F^+_ !9X8\*Z'H,-Q>6>L:QH_AJ]
ME\6:]86<FJZ?X?UW3O#&NZAHGV#X^_:)^"7ACXZ> O%GBKQ=\8?#NC:5^RM\
M:OC=#KD&H:E8?L_:K\*_#D_PGUOQ5XG\4^$$O#K7B3Q[X7T[7]!F\(7%EX3N
MWLM.U[Q7I1GGUO[+IUH-;>=OR3_4&MO.WY)_J?=5%?'6@?M-:#\7-6\;_""X
M\ _&_P"#WC"Y^#5Y\6_"5WXQTS1] D\6_#*_NW\/VWC3PEXD\#^+O%G_  C.
MJ6VL36<=SX1\8S^#/BCH,=]I]_J7A'3%F\R'Q?\ 9G_:BC\)_L;_ +%Y\60_
M$/XU?&[XH_LR>$OB!;>%]&U3P]J'Q"\;V?AOPOX%7Q_XTU?Q;\4_&?@KPC&;
M'5?&OAU=0O?%GCK3]6U[4]=M[;1+?7-3>>W1"/TMHKQG]G[X^_#/]IWX2^%/
MC9\(=7O-:\">,%U5--N=2TG4-"U2UOM UK4/#FO:5JFD:I!;WEEJ&D:[I.HZ
M=<*R26MPUL+S3KJ^TVYL[VX_-[P__P %4+SPUX%_;8^,7QJ_9U^,.A_##]F7
M]HWQ3\'=-U#PB/A1XI>U7PKI/PL\/GPIXE:R^*D6IIXTU'Q?XDUKQ;?:PFBC
MX8:1X>U[0O">F?$3Q-XJLDM=4=F]/ZWM^8[-Z?UO;\S]AZ*^+(?VV?#<]C';
MCX(?M"V'Q"U74_'T?@[X/^*?"'A#X?\ Q#\=>$?AM_PA(\3?$[0/^%A^/_"?
M@O3_  "DWQ"\+6.G7GC#QCX7\0:MJ][/HFF^'+K6+*YL4Y_3O^"A_P %_&/@
M'X1^._@]X4^+'QP/QJ\-_%CQ;X.\(> /#.@Z5XNBT#X&:EIFB?%B[UZW^*'B
MSX=:%H\_A+7]9TK01ITVOR:CXBU/4+-?"=KKMG<Q7C*W^7]?U^0K?Y?U_7Y'
MWG17Y=>"O^"B5Q\6?VM?@Q\*/A1\*?%WC#X(?$[]DF7]H\?$>TU#X;:==KIO
MB7XC^ ?"&D>+=3TGQ3\0?#6I:#X*^&,<GC+0_B#IMM;Z[\2-6\5ZG:1^&OA_
M?:#X:D\0:U[5X,_;Y^"'C/XE?";X=0V7CC0K;]H31-<\0_L\?$#7M*T)/ _Q
MITKPUX=3Q=KEQX>&C^)=8\9>#?LOAB6#6[&/XP>#_AK)X@LIX6\-IJ[RQ)([
M/\+_ "_K\-1V?X7^7]?AJ?;=%?CS\<?VJ/\ A;'Q!_X)_>+?@O+\<]%^%GQ#
M_;&TKP?9?$>RU&+PQ\'_ (V^ [3P#\2[K6[2?0K#Q4/%6IZ9>^*]#TNX\(GX
M@^#-"L_$EGX5\1>(/#,.H^'O[+UK6/I[]NK]JCQM^RWH'P!G\"_"[6OB3JOQ
MH_:>^"GP1D.E:CX,L_[,L?&/C"PDUG2;&U\7>*O"MM?^,/&WAK3]>\+^!WO=
M3T7PCHNN78\0>,_%N@6&E6EEKRW%N?=%%?GUK7_!0SPCX;T/]J?4_$/[/_[0
M^DZQ^QWI7@7Q%\9O!LL?P$O/$=KX6\>>%=6\;6/B7PW=Z5\>]0\(:_I^C^&-
M'GU37+.+Q5;Z]&)[>STK1M6U 75I;6O%/_!0CP#H?Q&LOA-X=^"O[1GQ*^(&
MK?LX6G[3VB^'OA_X$\.ZE/K7@"[U'P]IXL-.N]6\;:+ITGB"U.O.USYUY!X>
MGO\ 2;SPMH_B#5O&U[H/AC6'9_UZ)_DQV?\ 7HG^3/ONBOSU^&G_  4H^!WQ
M3U?]G*/0O!OQGTKP1^U-9ZM#\*?B]XH\&Z/HOPPN?&N@Z/JNKZS\,-;UAO%<
M^L:7XYLCH6MZ5;H- N?"VOZQI.H6OA7Q1KT5G=7,/;>%OVY_AAXD\3_#NQN_
M!WQ+\*?#GXU^([OP=\"/CWXBL?!,OP=^,WBR*75/[)T+PGJ?AGQUXC\8:%<>
M,K'1-8U;X?77Q)\%^!-/\=:?ILC^&KN_N+_0[?5E;^OP%;^OP/M2BOS?\-?\
M%-_A%XCU#XPO_P *A_:3T;P3\!/$OQI\,?%KXJ:M\+K>/X>>!KWX&> K;Q_X
MG/B+5+3Q)>:E8W.M6,LVD^%M"&D3>)KK7$L;'6M%T'^VM'>\^HOA!\>)?BKX
MK\=>#M2^$GQ-^%6L^!]"\!>)_P#BX$OPVO\ 3O%7AWXC3^-(/#VM>$M:^&/Q
M$^(VAZI9*W@?5$U$3:G9W5G<R0V[6SC,I+?U_7J@M_7]>J/?J*^*_B-^W3\+
MOAC\0?$G@O7O!WQ1NO#O@+XD?"WX1_$SXN:9HWA4_#+X;^/_ (R:9X9U;P#H
MOB6;5/&>E^-[VWU"R\:>$&U/6_"/@CQ/H7AZ3Q+I46N:E8,]T;3F/V,?VM_B
M!^TUXW_:JT7Q/\%/%OP_\.?!?]HSQY\(/#7B&^U;X::EH]K'\/O#/PSL[_P?
MXBD\/_$#5?%%W\0]0U_6O$?C:>XTGPA=_#C3/#.JZ5X<L?B'K^N:3<&[=G_7
MR_S0[/\ KY?YH^^Z*_.SX]_%E/@O^V3\//&/BKQMXPTOX1^'_P!BO]KCXJ?$
M7PW:ZMKE]X5^S?"/Q/\  /4X_%">";*9M/U#Q'HV@ZUXIALKZ.PGUAX-1N+"
MVF$4YA;O/#O[=OPJO;3XT2>/O"/Q/^"VJ? KX/Z9^T!XP\._$S2/"DFMZA\&
M=8TG7M6T_P >>&HOAYXT\?V.IVCCPUK&EW>A7%_8>+-+URV32M3T"TN+FU\]
M6?;^OZ:%9]OZ_IH^UZ*_*[]JS_@H?XP^#/[-W[37Q)\-_LX_%'P]X_\ @SX)
M^&^MZ+#\1=0^$,WA6XL_C;K7BGPEX&^)$.J^ OBIXYT[Q1X0\/:UX=>77=#T
M6]D\2W^H3Z=HBV.G:;=:GXHT3[,^)/QQ\0?#K]FKXA?M :A\%O'=KKG@'X>>
M,?'MW\&=>U_X8V?C18_"5IJ5[+9ZKXA\,>.O&GP[M+>73]..NW5YHGB[Q-=6
MV@NWV+2M4\3HGA:9V>GGHOP_S0[/3ST7X?YH^A:*_+?X4_M-W'QD\"?\$Y?&
M7QD\(?M!_#'XA_&C4/"^L:$_@_7?!VA?"SXA^*=7_9H\4^/K_4O&=CX0^)OB
MDZI\'/%%A;^)_$7@GP?X@AA\?Z3X@\/>&9_&7A/PO;2!=4LZM_P5;^"&A:1X
M]\6ZI\(OVE;3X=_"?]H>;]F[XL_$=_AMHW_"*_#/Q<D_A2PMM?\ %2'QF/$)
M\,WFL>+K+2?)T'0M<\7:5>0Q0^(O"NBS^(O!<'B=6_I:BM_2U/T_HKX;TG]O
MWX/OXD^,G@WQUX2^+?P@\7?!N;X8?:?#/Q,\(Z;I^M?$'3_C1XG'@CX7:U\,
MK/PWXC\4'Q'I?BWQI+9^%$DO'T>YT#7;^"Q\6VOA^2WU3^SO2?@1^U7\/_CS
MXO\ BK\--,T3QAX$^*WP3N/"R?$OX:^.K?PS+K?A^P\=:?>:OX*UFV\0^ /%
M/CSX=>)-+\2:587-Y!+X5\;:W<:44%EXAMM'U"2*T=V?]?+_ #7WCL_Z^7^:
M^\^FZ*_-WXK?\%-OA7\*/%7QY\)7'P._:G\:WG[,]QX7F^,^J> _A-9:SH/@
M_P +^*-)O?$$7CRZU.\\6Z7YG@_3O#UC)KMYJ"P"ZN-(:75=*L=1TO2?$5]H
MOM'B?]L?P/;1>$A\)_ ?Q,_:1U#Q=\)M$^/$.B?!*V\"7.L:1\&_%!A'A+Q[
MJMC\2?'WPV>:V\9,;^/PAX<T(ZUXS\13:)KJZ?X;DCTB^E@5OZ^[_-"M_7W?
MYH^NJ*^!O&O[3/P0\>W/[&?Q"\)^)/C=XG\*_%;QQXBUSX6:U\&[C5-*\'>,
M=0TOX/\ Q7UV[\&_%KP]=7NCZUXCLQIGA7Q--;^ 1H.H>(-+^(_AS0+36K#2
M=MS!=\G\#O\ @I_\%_CMJ7P5AT7X8?M ^#O#'Q[\4^.? 7@'XD_$'P!I?A[X
M<W7Q#\$77C,2> I/$L?BJ^74/$.NZ7X'U;4]&N?#-IXA\,2W;_\ "*7'B.#Q
MKI7B7P[H19]@L^Q^DM%?E_\  S]OKXA_$+3OVV/%?B7]EKXWWGA_]FKX[^/?
MAIX9T3X;67PS^('BW7(_AYH'PLTR_P#A_;>'= ^)LOBGQ)\5=0U_Q!XD\>SI
MH_AR;X>:;X0O['P_IOQ#\1^(-&FCO_T3UWQ+JFE^#;KQ3I/@;Q;XNU6'28-3
MM/ &A2^$--\9:G/.D,G]BVLOC7Q9X2\&VFK0B5EG&M>,-)TV-X)D_M)F\H2G
M]?>']?>=;17X0?L+?M"^)_%_P5^$G[9GQ9N_VIV^(GQ>\2^./!FC_"JP^)_@
M+Q/\*OVHO&GQ ^(GCAO"OA_X,?#/QE\6M4M/AH/@IX8\'7EO]HOX_P!G?2;?
M0](U_P 0Z_/XOTF'4==/VQX]_P""D'P<^&?P/^,_QC\:>!/C%HFM?L\Z]H'A
MCXT_!*X\->&Y_BU\/-8\7"UG\'SZW%I_C"]\ 7'A?Q;INH:;K'ASQOH?CW5_
M"6KV-_#:6&KW'B"*[T.W=G>W7;I_74=G>W7;I_74_0>BO$_A=\9KGXI^"_%W
MC"S^#WQI\%3>&-?\1:#IO@_XF^$]*\!^,?'*Z'IMCJ5AK?A#3M<\20:>= \5
M"_BL?#VH^*-6\,!=3@OK77XM"6QN98_SX_9H_P""G6J?$/X,_ #XG?&#]G?X
MM>%+']I/]HSQ)\#/ 7C/PY>?!;7/AY9:SK_QA^(_A;X>:/?A/C%:_$YK?PYX
M=\*+X?\ &'BB[^%VEQZGXD\.ZWJVC:/+I&JZ!)J!9O\ KO\ F%F_Z[_F?KG1
M7YK^)_\ @I_\(?!7BC7?!?B[X0?M$:'XG\.?M)_#;]E[4]+3P?X(\4./'?Q6
MTZPUWP;JUG-X#^(_BV#4/#^J^'M1MM9L[*SDF\<:A&9;#3?!MYJUI?6%IGZO
M_P %2_A;X?\ #WQMUG7OV?\ ]JS2]6_9K\4Z7H?Q^\%O\.?!M]XH^%'AS7=-
MM-:T'XF>(#I7Q*O_  [J?@#6-&N9-7M+WPCX@\2:\-&L-0\03^'H?#4,>M3E
MGV_K3_-?>%GV_K3_ #7WGZ<45\N_$C]JGPYX-UK3?"_@/X=?$O\ :%\5W?P^
MMOBUJ7AGX(+\.]3U?P]\,-1OCIVA>--3C\>_$3X?6U_:>*[V#5+;P?HGABY\
M0>*_%$NA:XVD:!<6^E7EQ%\[WO\ P5(^!M_XU\,>"?A3\-OVA?V@+OQG\%+;
MX]>%M0^"_P ,4\0VFN>!9_&>D>!KI[.SUS7_  UK5OJ&@ZUJ-];>*(]6TO3+
M/0-4T+5?"UY>_P#"91)X=9"/TJHKY*\+_M=>&_&7Q*\->!_#GPR^*.H^$_%?
MQ,^*GP?TGXT0Q_#V7X9GXA_!FT^(,GCOP]?VUM\0;GXE:++:ZC\-/$^CZ->Z
M[\/-+TWQ%<68U#1[RZT*ZTW5=0\Y_:B_:W^('P0_:5_8Z^!G@OX*>+?B7:?M
M Z[\6KG7[[PUJWPTM-4OM'^&GPK\3>()_"OA*T\??$#P)IT&O6.M7/ACQEXB
MUOQ)K6@Z3!X/T:^T3PQ_PE_BK73I>B"5P2N??=%?B%^S%^V3-\$E_;(NOC2/
MCS\3/!ND_P#!4GXF_ ^V^(TLG_":>'O@QX6\0P?"'P9\,]-UZ^\4>*-.U:W\
M&CQ)J,M@FC_#?1_%3^%[C48KO6M#T5?$_A]]?^Z?B-^W3\+OAC\0?$G@O7O!
MWQ1NO#O@+XD?"WX1_$SXN:9HWA4_#+X;^/\ XR:9X9U;P#HOB6;5/&>E^-[V
MWU"R\:>$&U/6_"/@CQ/H7AZ3Q+I46N:E8,]T;1V?Y?C;_-#L_P OQM_FC[4H
MKX$^$G[6_P 0/B/^W'^U#^S-<_!3Q;IO@/X#Z%\$[:#Q['JWPTN;&QUCQYH'
MQ*\877BKQ="?B!;^*(]!\?:;I_A31OAWHGA'POXTU;2Y=$U;5_B-_P (.VNP
MZ5I?WW2_K[Q?U]X4444 %%%% !1110 5^=/[-G[,?QC\ _M.?MR_%WXO:5\&
M]1^'_P"UGJGPQOM)T#PQXP\4^+=3TFP^'/@J^\"RZ)XKT/Q/\+/"VB:C:^(M
M-OC=WLUMK%S# Z2V#:==V]S]HA^OOC%\;_AE\ O"UKXT^*_B*7PQX;O?$&@>
M%;748]"\1:\LFO\ BG5K30O#]A+!X<TG5[BT75-9O['38KZ^BMM-ANKNW2[O
M;=958^L4^_GI^3_R'W\]/R?^1\"^+_@3\>/"'[;.J?M4?!I?A[XM\(_$']G&
MQ^#/Q%^&?C?QSXF\ W'_  G/@KQ;K/BGX;_$"PUG2? /Q$M+O2HK/7-2\):]
M9'3;._T73[^ZU[2;/Q+>S2:0WSU\//\ @GQ\5O@_XW_X)PW/A+7?AKXH\)_L
M@7_[3OB?XJZMK.M>(/!NN^+?%G[4&C^)H/$@^'W@W1? 'B30;'P_X8UWQ1>7
MVB66J>*=*>?1X+3191:SPR:M/^O]%%W_ %Z6_)A=_P!>EOR9\=?\% /V=_%7
M[5_['OQP_9^\#ZMH>B>+OB'X?T:W\/:CXEEO;?08]3\/^+O#WBVVM]4N=.LM
M2O;6TOVT'^SWN[?3[V2U-T+C[-,L91OB;XJ_L@_ME>+I_P!N"XT73/V=YKC]
MO']G_P %^$?&,]]\2OB!I\'P@\?>!_!'C[X?0:#X9T^/X3ZC+\2/#VK^&-;\
M)PMXPU75?A[=6>NVWB/7SX.DT_\ LOPK/^SU%";6W];?Y($VMOZV_P D?EU\
M+?V8?VF?!_[5'PS_ &A_$&D_ J73? _[ ]K^R;?^'-'^+'C^XOKWQIIOQ"T7
MQU:>([.\O?@38P)X7NU\/VVE7#S(-6LVOY[Z+3;T6,=G?>(_!W]@;]J'X;_
M'_@G;\'-3;X"7^H_L<?M!:C\5_&^M6'Q/^(8LO%/AZZE^)ZPV7A6VN/@9%/_
M &U]G^)<DLMOJ[:?8I-H20)J,B:JUQIG[9TR65(8I)I6VQQ1O+(V"VU(U+.V
M%!8X4$X4$GH 3Q1=_E^&B"[_ "_#1'XZ3?L#_'B_^"W[4G['>J:]\-[G]GW]
MH']I#Q/\4?"_Q#_X277[KQU\-/@_\0O'ND_$KQG\/+7X=:GX"OM&U/QI8>(-
M-U33O"FO'Q[!IB-XNN_'EY<6VL>&K3PAX@]3^!W[*W[0/PL^$G[?7A/4]/\
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MO#6B: /AMJNCW.K:3=>.[[4[CQ/9ZU:Z3I9\+_8?$7V[\/\ X%?$37?VJ/\
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M\7ZAHDVI6^HLT&H1^'-56)K<JULYD6OECXZ_L=_M5>)=:_;C7X>I\#==T_\
M;H_9T^&_@CQ?X@\4^-?&OA"?X<_$[X?_  S\8_#C58?#'@_3OA]XR7Q/X/\
M%MGJ^B76E7^K^.-"U/PM/_:US?6?B1+.STW5/V%K@O"'Q-\&^.M?^(OACPS?
MW]WK7PI\4VG@SQS;7GA[Q%HT6E>(K[PUH?C"UL[.^UK2M/L-?AF\.^)-%U$:
MCX>NM5TT)?11-=K.'B5IM;=-?R_5(:;6W37\OU2/R-\)?L*_M7V'AO\ X*!V
M.OP?L\P:M^V#^RI\&OV?O",>C_%CXDZAIWA77?AA\!_%_P $KW7O$=W>_ +2
M[F32=4'BUO$UK#IEC=WD)TT:-+'B].JV?K?@_P#8\^.]O\0_V$]8\8V7P<;P
M;^S1^RQXY_9W^)T.B_$OQU>ZYXANO&O@KP%X.GUCP;:7'P=T2VN-/MXO B71
MCU;6M O7&MRQ1F)])CFU/]5*@:ZMDN8K)[B!;RX@N+J"T:6-;F:VM)+6*[N(
MH"PED@M9;VRCN)41HX9+NU21E:XB#C=_Z\DOT0-W_KR2_1'Y"_"+]A?]H&V^
M!_[)7[,7QI\0?#74O W[)/Q\\-?%BR^*?AGQ%KNL>+?B+X6^$/B+7/$7P3\(
M6W@K6O 6E6W@6\']K:1HWCC5(/&NJG1_#_A!=#\.GQ)'XTOM3\*?37[$O[/W
MQ9^ 5W^U?/\ %!?AVR?'K]K?XI?M'>%AX"\7>)?$[Z5HOQ&TOPCIL7AO7QXA
M^'W@80ZII/\ PBHFDO-.;4;2\_M QJMM]D$EU]ST47?W_P!?H@N_O_K]$?B]
M^UK?ZMXC_;WTG0_AE<_ B/X@^'OV2]0^'WB?P[\0_P!H'7?V<?B#\3O!OQU\
M>ZE?7/A3P[JUC\+_ (D:EXV\/>&++X57VKQW/@9?"WB#P%K/B>]U6'Q=;:Q=
M:3!9ZO[&GPS^)WCS]H?X5_M=:5\+?A1\'_@;X-_8^\3_ +$NB_#CP_\ %S5?
M'NIV;?#KXY17=EXN\!:EIWPZ@\->*?AG./ S:/X4U2[\4V&J:[HTUKXG6.6T
MGM?[1_33XB? 7X&?%^]TG4OBS\&/A/\ %#4=!"KH=_\ $3X=>$/&U[HRI*\Z
MC2;KQ+H^ISZ<%GDDF46<D($LCR##LS'U&UM;6QM;:RLK:"SLK."&UM+2UACM
M[6UM;>-8;>VMK>%4B@@@B1(H88D6.*-51%55 !_3_#]5V^;#^G^'ZKM\V?CQ
M-^P/\>+_ ."W[4G['>J:]\-[G]GW]H']I#Q/\4?"_P 0_P#A)=?NO'7PT^#_
M ,0O'ND_$KQG\/+7X=:GX"OM&U/QI8>(--U33O"FO'Q[!IB-XNN_'EY<6VL>
M&K3PAX@^F/CW^Q99_&;]I+X/_%X:CI%IX#L?AUX@^$G[17@C4(;VYD^,'PXT
MCQ9X9^*?PB\*'839IIGAGXIZ!<W_ (EAOM\?B/P?X@\2^#[Z.ZT?Q#JEK-][
M447?]>87?]>9^+NJ?\$R?B,/^"=_[1?[)UO\3M.\7?%+XDRV/ACX>>-O&]S=
MMI^@_![X.>,]&3]G;X8ZAJNGZ(^HVFCZ+\/_  K;W>IP6ND7MMHGCOQWXWN=
M/74[6;[;?>_Z#\!_VII?VW=&_:Z\5Z)\ ELH?V.-=_9[U#PAH/Q0^(27MOXN
MU7XM6?Q8T^YMKF^^#%Q;7?A_3%T^S\'7VMR3VFH:L_VKQC;>%](26'P;#^D=
M>:Z'\7OA]XD^)OC?X/:-KDMU\1/ASH'A3Q1XPT%]%UZS32M"\;W/B"S\+W\.
ML7VF6VAZO'J=UX5\00%-%U+49;*73)H]1CM'>!92[_KY?Y(+O^OE_DCPC]A?
MX*_$W]F[]D?X1? OXDKX$O\ QQ\+/"T_A<WG@?Q-X@UGPIKD=K>7EUIE^-3U
M[P3X5U?37NQ=+%?6O_"/7ZV)C,MO<Z@'$2?"][^Q%^UUJ_PD^!?@?4;7]G"#
M7_A3_P %(G_;:U:>R^+/Q-?2-3\&O\8/&_QA;P9IUQ/\ EO5\3/?^/+[P^MW
M<V,6E0V>DVFIF6>;4)K"Q_:FBEL+8_%']I+]A3]J[XW>%O\ @I'X2TA?V>M)
MM/VT?%/P#U;P!J&I?%'XD"X\)6'P>\/_  ^\+ZD_C"SM?@7=1/>:W8?#NQU"
MRL]%NKZ&SO-7N[*?4)H;&&\N^^_:E_9)_:J^-WC[]H[Q7X0TS]GW2[#X\?L*
M:3^R7;0>)/BW\1X[OPYXC/C/Q_XIUKQ3.FE_ .^AU#1+:V^(=_IVEP1SVM_?
M3Z-:7UW#IT>I366G_KA13YG_ %\O\D/F?]?+_)'YRW/P,_:5T#]IWP-^T[X>
M\-_!?Q)JR_L:C]F_Q?X(O_BGXR\.:=H?CFS\=GXAZ=XDT3Q*OP=URY\2>";K
M488=$U-[K0/#OB/2[*=M6LM%UV>'^RI?.O"/[#OQ=^#?@O\ X)__  ^^%\_P
MF\1Z3^S%\5_%OQA^,6N>*O$?B+P-=^)_%'Q(\+_%'1O&\/PZ\-^%?AEXETF#
M28M8^,7BC5O#&GZOJ&BIINDZ'X;\,RN\;7.JV_VI\3OVL?@%\'/%T/@GXC>.
M)_#^L[?![:K=KX0\<:QX4\)+\0=;O?#7@3_A/_'>A>&M3\$?#M_&6O:=>Z7X
M8B\<>(?#\VN7%M.VG1W$$,LR?1=+_AON%_PWW'XYWW[%7[4NG?"?_@I7\%O"
MMQ\"+[P[^V/\5?C?\2OAWXA\2>,O'NDZKILWQ[\.>"_"^IVGBRSTGX<:];Z)
M!X#TSP[J\UK'I9\4R^--3U73U>Y\(6>CW#ZYMZ%^R7^UCX3UG]LFSTA_@==^
M$OVTOASX&M[S3[_QYXTO;#X(_%V'X46_P?\ BAX@M-(U#X4S1_%'PIKNDPV?
MBW1K.ZE\%W>L:CH&F^!=7L_#6C7LOC#3OUQHIW?]?+_)#N_Z^7^2/RV^&_[&
M?Q?^!W[4?PP^)WPZ7X8^)/A-\&?^">FB?L6^$;7Q=\0/%NA?$#7]=\,>*O#O
MC#2O%OB#3]*^$WB#P_I>D7MQX;MM%U%=/U[4KR".]N-<M;&0P1>'Y/=_V)?V
M>_'7P0_8T^&?[-7QOC\"ZGKG@KP9JWP^UNY^'GB#Q#KWAC7_  _=W.II!=Q7
MGB+PGX+U>SO+S2]1-OJ%D=+DBMKB-Y+74)XY56#Z=^(_Q$\'?"3P)XK^)?Q!
MU<Z!X(\#Z%J/B7Q3K8T[5M6&DZ%I%M)>ZEJ,FG:'8ZGJUS#96D,MS.ME8W,J
MPQR2>651B+W@CQCX>^(O@OPC\0?"-Z^I>%/'7A?0/&/AC49+6[L'U#P]XGTJ
MTUO1;U[&_@MKZS>ZTV^MIVM;VVM[NW,AAN8(ID>-4(^*_P#@FWX3\1_!_P#9
M;\,_LU>/+W3[KXI_LT:OXL^%GC&WLV,=E<6$?B;6?$GPR\2:;*+:)KGP]XS^
M%VN>#O$.FWZ0236\UYJ6@ZN(O%?A_P 1Z;8ZG[(?P-^-GP<^(/[67B+XH6/P
MLBT/X_?'S6?C5X7;P%X\\6^*-5T:#4?"O@[PC#X=UZQ\0_"[P-9B5+7PK_:4
MNIZ?J=X@N+O["EBT<?VX_;/]EZ9_:?\ ;7]G6/\ ; L3I8U;[);_ -IC3#<"
M[.G?;_+^U?83= 7)M/-^SFX F\OS!NJ]3OOY_P"=_P!!WW\_\[_H?FY\(?V;
M_C-^Q[\7/C_K?P7T[PK\7/V?/VBOBMJWQVUGX<:GXE;P)\4/A7\5/%Z65KXY
MG\%7E_HVI^#?B%X4\2KI^GWD6E^(O$?PXN_"T.G6FG:?/KFRXN+WY?\ '_\
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M?&'1]4U'QKXE\-W]AX7\06VJZ7+I]AX+_7+QA\3?!O@/7?AWX;\3W]_9:O\
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M6TGPS-K7@;QEX>USP_XF_M,:=K^H-;VMIV_@_P"-/[6]O^T7\//V+?BQ\7O
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M+D>4>*/^"?G[*?C30?C1X7\4^!O&.M>'OVA_%6C^-?C-I%W\=/C[]A\=>)=
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MO4_+*Y^.'[7OP!_:!_:%^ WQ2_:!^#_Q)T:Z_8H\=?M5?"SXT_$/P+H7P?\
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M!T?2M!T'3XO$G[2W[4_A_P#9G_:,\>6W[1OC&\\8?L_?\%,I?V=-$UR]\!?
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M:E/=V^@Z)%8?-E__ ,$]?V3]3\$_$KX<WW@7QG<>"_C!\5%^-OQ*T1OCO^T
MD?BWXJ+?V&J_\)EJ-['\44U*/4GU/2-%U&:&RO+73Y[_ $/0KR:SDN-$TJ2S
M::OJNW1;W5_EH[?\.--7U7;HM[J_RT=O^'/M2BO,?"/PA\%^"/&_CKXAZ$/%
M#>*/B/IG@71_%-SKGCOQMXIL)[+X<Z3>Z+X7&EZ-XF\0:OI&@7$=EJ%Y)K-[
MH=EI]YXFU*XFUGQ%/JFKS37TGIU22%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
9110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>ny20077604x1_figure04x2.jpg
<TEXT>
begin 644 ny20077604x1_figure04x2.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
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M[XQ?^K@\;U^P%)Z-KLV)Z-KLV%%%?S,_\$E/V[/VK_VB_P#@H7^TG\&?C/\
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M6K@WDULEG&UJD$DZSW%O'+V'P$^._P ,?VF?A-X4^-WP;UVX\3?#?QM_;O\
MPCFMW6C:QX?GO?\ A&_$NL^$=7WZ1K]CINK6GV;7M!U2T7[790^>ENMS!YEM
M-#+)_/?_ ,%V/CG\-_VD_P#@E[^SE\;/A+KL?B#P)X\_::\ ZKI-WB*.^LIE
M^$7QYMM3T/6K2*:X&G>(- U.&[T?7=-::5K'5+*ZMQ+*B)*_S5^QI_P6P^!7
M[#W[ O[-OP0LOA_XL^,WQ=T"W^*-YXRT+2]1A\%>&?"$7B#XY?$CQ#I-EJ/B
MK5=*U>;4=9OO#FKZ;KD%KH.@:KIL=K?6UM?:S8ZC]IL[8Y;KK>]K!RW76][6
M/ZW?&_C+P_\ #KP7XO\ B#XMO'T[PKX%\+Z_XR\3:A':W5])8>'_  QI-WK>
MLWD=E8PW%[>/:Z;8W,ZVMG;SW5PR"&WAEF=$;Y?_ &4_V^?V7?VU;OQO9?LZ
M>/=0\:W/P[M] NO%B7O@SQEX3&G0>)Y-7AT9XW\5Z%HR7QNI-"U,.MBUPUOY
M"FX$0FA+_)OPG_X*;_LG?MY?LJ?M-7>DVGBRPU'P1\!?BGK7Q?\ @=K-Q9:)
M\0&\ IX+UB#7+[PKKEI+?:+JFE:I;R3Z/8^(+&=KG1-3N]./B'2-'>_TN._^
M#_\ @C[\<?V)?"'@C]N/XH_LO_ OXR^ (_A-\*/#?Q"^(VG_ !#^)&E^,Y_%
MVE>%-(^*?B+2=+\-O#:6\.CWJ+I&MP3W%T)(IWU"R)"K;/N+:/1W_#I\[ZA;
M1Z._X=/G?4_IJHK^>;PU_P '&?[*FJ?#/Q]XX\1?#;XB>&?$_AG4O#ND^#OA
MDE_H>M>)OB)/K<>J2ZA?V5[;?9='\.Z%X733[9];U36[I'E_M*VM]&L]5OP;
M)O2/V)O^"\'[//[67Q.T'X,>,O 'B?X"_$/QIJD>B^ AJ^N6?C;P;XIUJ[G$
M&E^'1XGL-)T"]T?Q'K#,D>EVFI^'(M(N[S&EPZ\^IW.FVFH+E=KV%RNU['[H
MT5^(O[;W_!=#]F_]D'XC^(O@OX<\&>*OCO\ %+P?<6UEXNMO#.L:'X=\!>&]
M6=9'U#PSJ/C:Y_MR^F\5Z*/L\>L:7I/A+4['2[R:?1]2UBRU_3-5TFRY']C+
M_@O;\"_VG/BUH/P3^)GPM\0?L[>-O&.HP:#X-O=8\6V7C3P=J_BFZEM[6P\*
M7^NCP]X/U+0M<UF_F:PT-;WP\^FW]ZD-C-J5EJ-]8V-P<KM>V@<KM>VA^[6J
M:IIFB:;J&LZUJ-CI&CZ3976I:KJNJ7=O8:;IFG6,#W-[?ZA?7<D5K965G;12
M7%U=7,L<%O!&\LLB1HS#YD^-W[:O[-?[/?P6\+?M#_$KXC6]M\'/&^J:%I'A
M+QOX9T;7O&VF^(+CQ-I6J:WH-SI:>$=-UFYN]+U32M&O[ZSU>*!M,FMTAD2Z
M9;JV,O\ -Y_P<8_M?S:IXD\*_L::';^,="?PG/HOQ'\;:C:^(6MO"'CC2_$6
MD&;P_H^HZ!9S1'49_#VIVO\ :5N^K17-O;7>RYLEBN%WUY$/^"D7[(GQM_X)
MV_#']G']H/\ 9Z^,?BCPQ^S/:? /PYJ,_@WX@Z#X6N?$/B[3?!7C+PK8ZUIU
MU]FGGM])2#3=:DEL+M3+(;ZS8L&MW!:B[)VT;\MM+;]QJ+LG;1ORVTMOW/ZX
M?V?OV@?A7^U#\*_#_P :?@MX@N/%'P[\47&MVNBZU=:)K7AZ>ZG\/:U?^'M6
M1])\0V&F:K;BWU73+RW5KBSB6=8A/ 9()(Y&]HK\I_\ @G%\9/V5OA[_ ,$V
M_!?QA\%6^K? 7]FOPO-\2]2D'Q=\7VFO:EX;2'XG^)-/U634_$,$42:C/K?B
MB66/P_IEE;2ZC>7&IZ9H6GVMYJ4]O!-^??Q#_P"#E_X Z)XNATKX:?L[_$_Q
M_P"#XKV6VU+Q=XB\4>'?A_?R6\,DD?\ :/A[PO%8>,I-3MKD*D]G%KFL>%+U
MH)%^VVEA<*]NJLVW9/3O^OF*S;=D]._Z^9_2Y17Q7^Q?^WY^SE^W;X-O/$WP
M2\372Z_H,5L?&WPU\56L6C^/_!4MX\B6K:MI<5S>V.H:7>F)C8^(?#NI:SH5
MPY:R?4(-6MK[3;/\Q_ W_!Q-^RMK<WQ.'CWX=?$+X;P_#[PUJ.JZ-%/?:)XE
MU?XB^([36['1K/P5X4TO3C:I%JVHI=7.I?VCK5]IVA:;8:==2ZGJ-J#$7+/7
M1Z;A9ZZ/3<_H,HK^>#]GK_@XM_9K^*_Q,LO /Q4^%GC+X$:-X@UF+1_#/Q U
M#Q%IOC;PU$]W*L&GS^.(M.TC1-1\(P7<[QV\MW86_BK3-,DE2YU74K+2HKO4
MK7^A^AIK= TUNCY'_:L_;D_9J_8JM/!%[^T7XYOO!5M\1+C7[7PF]EX0\7>+
M#J,_AB+2)M961/"FB:R]B+6/7=,*M?"W6X\]A;F4PS"/Z ^&?Q&\(_%_X>>"
M?BGX!U&35_!/Q#\+Z)XR\)ZK-8WVERZCX?\ $-A!J>E7DFG:G;VFHV+W%G<P
MRM:WUK;W4!8QSPQR*RC\.O\ @NWXM_9"\*Z%^S._[6'PC^*OQ6M+W5_BNO@>
M+X8>/K'P++HEQ;V?P^/B"369+VUN1J4>H13:.MBD80VC6=VS;OM"XJ>*/^"O
M?[/O["_PF_8N^&.B_ SXDZCX&^(W[+/PD^(7@%9O&/AU[SP?X(U9+SPYHFA^
M)]3U")/[4U;2;70?-U+5(!%;7 ?S%5"&P6NE9.[OZ?+]6PM=*R=W?T^7ZMG]
M!%%?SF_&7_@Y _9K\ _%&X\&_#3X1>.?C-X%TG4GT_6/BAI_B'3?!]E?I$J>
M??\ @?PWK&D7FH>([%)C);PSZ]>>"Q=M ]Q:B6QEMKN?]I_V6/VI_@]^V-\'
M]&^-?P2UN[U?PGJ=W=:1J%EJU@^E>(?"WB;3H;2;5O"OB73&DGCL]:TR.^LY
M9?LEU?Z;>VEW9ZEI.HZCI=[9WLXTUNMP::W6Y]%U\O\ [2O[9_[,7[(.E:7J
MW[0_Q=\/?#PZZ)VT#1IX-6U_Q5KL=MD3W&D^$?"^G:UXEO+""79;W.JQZ7_9
M5I<S007=]!)/$K]K^TC\9M,_9V^ 7QB^.>KVB:C:?"KX=>*_&L>DO.]J-<U'
M1-(N;K1M 6Z2*<VLFOZNMCHT5R8G2WDODFD'EHQ'\5/_  3I_9#\8_\ !8#]
MK#XO_&G]IKQWKU_X+\(WVD>,OBU?:;.+?6_%NN>,-0U3_A$/AIX9EEE9/"/A
M-=/T#7!-/I$%S_PC/AO0]/\ #.B6FEW&M:9K>C-*]V]E^/H-*]V]E^/H?TM>
M!?\ @N#_ ,$U/'6MPZ GQ^F\(WU[KD>B:9<>.OA[\0_#>B7YGN$MK;5IO$LW
MAF?PYX>T.9G6634?%VJ^'DT^WWW&JI811RLGZN6%_8:K866J:7>VFI:9J5I;
M7^G:C87,-Y87]A>0I<6E[97=N\EO=6EU;R1SVUS!))#/#(DL3LC*Q_"#]J7_
M (( _L:_$#X0:]IO[-/@ZZ^!?QDTNSN-2\&>(SXZ^(GB_P .>(-4L[6Y>U\*
M^-M-\<^*?%2V^@:W.ZV\VO\ A^.RU[0;DVFK*-<TZPN?#&K_ )Y_\&\'[7/C
MOPS\7?'W[#7Q*UK4Y?#>IZ)K_BWX7Z'X@O)I;GP5X]\&7B_\)SX+T*UGBDGL
M['Q'H4NI^);_ $L746FZ3JG@O4+ZPT^/4/$NNW5T633<;Z;I[V[JW]?J633<
M;Z;I[V[JW]?K_5E\5OBW\,_@;X#U_P")WQ>\;^'OA]X"\,VK7>L^)?$M_'8V
M, PWD6=JAWW6J:OJ$H%II&AZ5;WNLZUJ$D&G:387M_<06TGYER_\%UO^"8T6
MLMI7_"_]6DM%C#-X@B^#WQF?1O,W!6@5!X"_MIY$R29(]':U=5)BN) 4W?SR
M?MC^)?BO_P %5O\ @K:W[)UCXUN?#'P[\*_%?Q;\&?!&F75])?>'?"?AWX1V
MWB"Z^+'Q$LM&A>RT_6O%?B"V\(>,?$6FM/\ 9K[5+;_A%_!EQKL>F:;9WMO^
M[/C#_@W_ /\ @GUK/P=NOA[X3\)>,O!WQ#CT%+/2/CDWCSQ=X@\8+XCMK:)8
M?$/B#PO?ZU#\.=7MM0N[>)]?T'2O"?AJRFLY[^W\-2^%+VX@U.S+15KMW>NG
M1!:*M=N[UTZ(_8CX??$3P)\6/!VA?$+X9^+_  ]X[\$>)K3[=H/BGPMJMIK.
MBZG;K+)!*;:^LI983-:W,4UG?6KLEU87UO<6-[#!=V\T,?R#X:_X*5?L>^+O
MVF+G]D/0?B5J=Y\>[3QAXL\!S^$7\!>/+6S3Q/X(M-9OO$E@/$]UX<A\,M'8
MVV@:HZ7BZL;.[-NJ6D\[S0B3\VO^",7_  3_ /VZ/V&O&GQ-7XT:Q\-[+X'^
M/]&E2Y^'^E>.=1\0^([?XAZ)J%A'X<\>:/867ANY\,VMAJ'AXZWHVN)_PDNF
M:QJ,,WAV74;&<^';*VA_)_\ 9U_Y6+O$'_9V/[47_J+_ !<HLKM7O9-W7R]0
MLKM7O9-W7R]3^W6BBBI)/B+X-_\ !1S]C+]H#XQZC\ ?A%\9/^$M^+>E?\)-
M]O\ "?\ PKSXJZ#]G_X0Z=[;Q'_Q/O$W@;1?#,O]G31NG[G69/M>-UA]J0AC
M]NU_$3_P1N_Y3%_$+_NY?_T]W=?V[4WI]R_%)C>GW+\4F%%?C?XF_P""QOPW
M\ _MTQ?L,_$7X+^._"'B>Y^*/A_X96GQ GU_P]>^&9G\<1:=/\/O$CV*+!?0
MZ1XI@U[PW/)OE,FC0ZM(UV9383JWV]^VQ^UWX&_8@_9^\1_'SQYI=_XCL='U
M?PUX>T?PEI%[96&M>*M=\2ZQ;V$6F:3<:B1:">PTO^UO$EX),L-(T+4GB5Y4
M1&+/33?;SN%GIIOMYW/K*OB?XN_\%#_V2/@;\>_!_P"S+\1?B>VF?&CQS<^#
M++0O".F>%?%WB()>_$#6CH7A.RUC6= T34=$T"]U2\,,XL]9U"RN;72[S3]8
MNXH-+U&RNY_RX^,W_!9;XV>)/V2?A3\;/V5OV7=;;QO\?OC%XU^#OPRT'QI!
MJ/C_ %C4T\&Z#8WFH^+_  MX/\ I;WGBAY-;GUGPYIUC)?1+;:OX8U.YOM/U
M*P5;6X_G.@^&_P"TA\.O^"EO[,\G[6<VI2_'7XA_'O\ 9U^*7C%-=U6VU;Q'
M;_\ "9?$[P_<:9;^(7L-VFZ9J::?:V[+X>TV5K/PWISV&A+!IDUA-H^G5&-]
M_NZW5O\ ,J,;[_=UNK?YG^BA1114$'PO^S5_P4@_9#_:Z^)7B'X2? ;XCZEX
MN\=^%O"^K>,M;TF\\">.O#,-KX?T/7]!\,ZE>)J?B;P]I.FW#P:SXET>V6UM
M[J6ZF6Y:XBA>WM[B2/[HK^ O_@DC^UQ\'?V*?VK/VBOC5\:]3U*T\/1?L_\
MQ)\.:!I&AZ<^J>(?&'C#4/C!\)=3TKPIH%J7M[,:GJ%EHNJW8N=5OM,TFSL]
M/N[J_P!0MH82Q_=W]GC_ (.*?V8_BU\3[;P#\4_AOXN^ 6@ZYJ9TSPS\1M<U
M^P\8>&5EF.S3CXWBTC2-.O\ P='J$YCLS>VL7B?1=+GGCN=;U?3=&BO=6M*<
M6F[)M%.+3=DVC^A>BOR)^,W_  5U^'7P:_;M\+_L)ZG\(?&NM>+/%'Q ^"_P
M_@\>6.NZ%;^';6\^,_\ PB7]F:A-IMPAU)[;1?\ A+;?[?$C>;<?8Y_LY'F1
MU]:?MR_M@^&_V&_@+J'QZ\5^#M<\=:1I_B?PWX8?0/#U_8:;J,D_B2XFMX+I
M;G4E:V$-LT):5"-[A@$Y!I6>FF^WG<5GIIOMYW/L*BOQO\9_\%C_ (:>#?V$
MOA+^W9<_!KQS>^$_BS\6]2^$NG^ X->T"/Q%I&HZ;_PLS?J][J4B'39[*7_A
M6E]L@@43C^T[3)_<S9^7OBA_P<>_LV^#_"_@"^\!?"+QM\3/&7BCPYIOB'Q=
MX7C\2:9X8T?X=2ZC-+_Q3&I^+IM'UE=>\56EBD.H7EKH6A7&BV@O;?3KK7X-
M8@U33]-%%O9>7_#]@46]EY?\/V/Z,:*_#*Y_X+__ +$\/[.,'QMA7Q?-\0+O
M7+WPO;?L[-'I2_$P:Q8)83W&I7EU;WMWH&G^!GL]2@O;'QC=WD<.IB*^TK3M
M-NO$FEZIH5EVW[ O_!:CX _MQ?$"W^#=SX+\2_!3XO:EIVIZGX=\/^)=;T3Q
M#X7\7+I2"YN]'\+^*[5=&U"^\30Z8EWK,FC7WA33%?3-/U">QO;Y[2:)#E>]
MG_7]?U8.5[V?]?U_5C]EZ*_$7]M[_@NA^S?^R#\1_$7P7\.>#/%7QW^*7@^X
MMK+Q=;>&=8T/P[X"\-ZLZR/J'AG4?&US_;E]-XKT4?9X]8TO2?"6IV.EWDT^
MCZEK%EK^F:KI-ER/[&7_  7M^!?[3GQ:T'X)_$SX6^(/V=O&WC'48-!\&WNL
M>+;+QIX.U?Q3=2V]K8>%+_71X>\'ZEH6N:S?S-8:&M[X>?3;^]2&QFU*RU&^
ML;&X.5VO;0.5VO;0_>BBOS6_X**_\%*/!'_!.O3OA/J/C/X:>*OB,GQ8O?&=
MEI\?AC5](TI])?P;!X9GN7O3JJ.)UO1XF@6 08,9M93)D.E?GW\:?^#CG]F[
MX?S>#;#X8_"?QA\9-1U?PUX5U_QK+;>)].\'Z!X*U#7],M]1U;PA::U=:)KD
M_BWQ+X4><Z?JSV.DV'AJ>^C:&P\1W!CN?LPHM[(%%O9'[J_''XV_#C]G+X5^
M+OC3\7-;G\.?#OP-;Z==>)=:MM(U;79[&#5M:TWP_8M'I.A66H:K>&;5=6L+
M<K:6<[1+,9Y0D$4LB>?_ ++G[7OP$_;+\%Z]\0?V>_%]YXR\*^&O%$W@W6-0
MO?#'B;PK);>(+?2=*UN6S6R\4Z3I%[<(NFZUITXNK>"2U9IFA68RQ2HGYG_%
MO_@H3^QA^VW_ ,$T/VD?BCJ'A[XA>*OAUX+M? .F?&SX,VNH6?@KXHZ#>:M\
M0_"__"-01:VDFIZ*VGZAJEM#JNF:YIEW?66J:?I>IZ=*+'5[;4=-L/CK]C__
M (*&_L<?L2?L$^+/CC\"/V>/C/I_PWU[]KRW^%&L>#/$WQ%T+Q'XFF\;ZQ\&
M8?%Y\3V^LW%K#9P:$F@^$;32CI@C-S_:#M=AS$[*';39WO9=NF_5;CMIL[WL
MNW3?JMS^HVBOYD_^(FGX&?\ 1L?Q8_\ "O\ !_\ \9K]'OV'?^"K/P?_ &T/
M 'Q^^)TGA#6_@GX+_9UT_0=9\<:YX\US2+^Q31-8TOQ9J]UJHFTF/-O;:/9>
M$KR2Z5TDFG,\*6T;R#8RY6M6OZT_S_JS%RM:M?UI_G_5F?J=17\V7Q-_X.5/
MV=O#/C^7P]\-?@3\1_B?X$L=1O;&]^(5WXATGP)+J-O:SR0P:QX4\(ZCI&L:
MEJ.F:BJ+<V:>*+[P5JR6\J?;]*LKD26R?M#^R%^V;\"?VW/AA%\3O@?XDDU"
MWM)+6Q\7>$=9ACT[QIX"URY@-PNB^*M'2>Y2WEE1)FT_5-/NM0T+68[>YETC
M5+U;:Y\D<6M6OZ\^WS!Q:U:_KS[?,^K*^9_VH_VO?@)^QIX+T'X@_M">+[SP
M;X5\2^*(?!NCZA9>&/$WBJ2Y\07&DZKK<5FUEX6TG5[VW1M-T749S=7$$=JK
M0K"TPEEB1_A/]O?_ (+._LX_L/>*KGX5PZ)KOQJ^->G)#+X@\!>%;Z#0-(\&
M)>:?8:IID7C+QGJ5C?VMC?ZO8:C!=V6EZ#I/B;4;>W5IM;M]'2XTPZA^#_\
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MWVAVJ6]S<:Q$(79ZZ;;CL]=-MS]3Z*_FR^)O_!RI^SMX9\?R^'OAK\"?B/\
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M.KRQ1(G>XLQI?AF[^T(NG^)KLQW'E?J1^R]^VQ\ _P!K/X!R_M&?#KQ.NA^
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MWPQXF\*R6WB"WTG2M;ELULO%.DZ1>W"+INM:=.+JW@DM6:9H5F,L4J)\0?\
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M@7QOXFU*WWZ;H^I7/VN[LX+%?LWDM<BXF@BEI?#+Y?F4OAE\OS/UW_X*O?\
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MEC9ZA/!%K>C_  ^FT[7=0\%>";V^OD6[UM_$7PIEU@1Z?'X@MU33]+%M\R?
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M/_!1WPUH'A'_ (+N_ V?POI-GH$FN?%?]CSQ-JG]DQ?8DN=?D\7>$["75A%
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M_M3]Y9)]BU'[)^O'[$7[/?Q?^$'_  2_\(?L[?$3PA_PCWQCTOX3?&7PS?\
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M%%[##+%"1&>;_;,_X)G?MP?LX_MUZI^W#_P3P\-V_BRT\1^)/$OQ%&C:7?\
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M6JK#80/?B.'CO@Q\*/\ @O-^P#X%\6_LV_!GX2:-XT^'OB#Q-K(\(>+-+O/
MOCZQ\-:GK$L%I?>*O &H7GB[1M5\'Z3K36L6IBR^)GAFTTK3[JXO=:E\/:1J
MVH:I=7'ZU?\ !(']CW]L;]G[PCXH\??MF?&CXJ^(?%OBBPM/#G@CX&^)?C!X
MB^(WA7X:>&+*:&YN-:U*W?Q-KW@\>,M<N+>VM+&#P^;F/PUX=LVADU:XOO$6
MHZ1H VK2VUMU;;VMITZ_EZC:M+;6W5MO:VG3K^7K^ ?PO^%/@_XU?\'!'BWX
M?>/=%L/$7A2[_:]_:(\3ZGH6JQ)<Z7JLGP[M/B5\1=-LM3LY8IK?4-.GU;PI
M8K?:9=PRV.J6OFZ??1M9W,X/Z'_\'+O@GPAIWPH_97\2Z=X;T?3M=L/'/C;P
MM::EI]C!8SQ>';CPSI%ZVC$6B0QRV$5SI-A+9P2I(M@8I5L?LZ75VL^G^S[_
M ,$[?VQO!'_!:_7OVN/%'P?_ ++_ &>KWXW?M,^+[;X@_P#"P/A;>^;X=^(/
M@3XKZ-X0U'_A%-.\;W?C=/[7U+Q+HEM]DD\-)?6'VWSM4MK*WMKN6#ZP_P""
MY_[''[1_[8WPI^!7AK]G#X<_\+&UOP;\0O$>N>)++_A+_ GA'^S=+O\ PW'8
M6EU]I\=^*/#%I>>;=J8O(L)[JXCQYDL*18>E?6&NR77;O_P17UAKLEUV[_\
M!/YC_P!IF]U+XT_'+_@GK\'_ (BZM?Z!\/\ 3_V6_P!AKX7:9JS7?F0Z=X-\
M;^&O#.I^)?$]G!)'Y%O<65[XKUBP>219Y)(?#=A%)*UI:6EK:_V6?M@?L:?L
MLZO^PU\6?A5<?"/X;>$_ OPS^#/Q'U[X>7.G^%=+LW^%NNZ!X0U?6;+QIX>O
MK>"+4K+5K74;*/5==ODO?M7BA?M\'B2;5(-3U%+G\B/VQO\ @C#\8?V@/V2?
MV._$O@#3-$\/_M7? 7]FWX<_"#XE?#C7_$^DVUCXOTOPGX?:Z@T/1O$^FW.I
M^#U\9^&O%%[K%C9ZC=:S:^&]>TO566Z\4VD&A:0MU\Y^/]#_ .#B+X^_"C4O
MV6/&WPYUX^$]2TFW\,^-?$<[_!#PKJ_C#PQ)':!M(U_XECQ+:66K6$MO;I%K
MTGABZBUGQ!;2ZAI?B2YUJ+4=0L;IZ-1LTK;W[Z:^8]&HV:5M[]]-?,_+#X%?
M%CXK:3_P3:_;M^%NACQ#??#75/BC^RMJ7B)[?4+>+0?"#Z]K/C]M5N);.:47
M+77CO4/ /@'2KLZ?!FZM_"]HFH7"6MLMM=_TY?\ ! 'X+_!H_L!CQDO@[PCK
MWC#XH^./B-I/Q1U35?#-C?ZE?Z?I&J_V%I/@G5;_ %2WN7U3PS!X>M['5X=%
MC;^PH[OQ%JDALO[2NM4GN-3X<_\ !*KX$_LU_P#!,OXP_LW?'CXJ?#WP9XG^
M.5IH^H_%[X^ZYJEEH7@K0OB9::W8S?"*TT?4/%-]X5DO/"O@7Q0FC66BZ;JE
M_HE]XTU34?$$JV^AOXO_ +$T[\E/V3_V5?\ @M+^SK9>-/ /[$GQ)^%7B;X,
M^+O$\DVI?$+X=_%G]G7XC?"^769+;3M-/C/2(?%]SJ_B[P_J5UH=M8)>MI_A
M2TU>[T^RLA=Z==W.G:,T(VI)V=KN^NB=DE_P?T!M23L[7=]=$[)+_@_H>7>"
M_AO\.?A%_P ' >A?#OX36NG:=X!\._M10KHFCZ1;_8])\/3:GX9;6M;\,:99
M@F.ST[POX@U'5?#UE:0!+6VMM-B@M8H;:.*).$_X((? 7X6?'O\ ;CU2Q^+7
M@_0?'FA?#?X'>-OB5H_ACQ5I&G^(/#-]XFMO%7P_\#V%QK.A:M;W>F:I'IEE
MXZU/4].CO;6=+/6[/2]4@5+RPMIHIOV5/@-XK^#O_!;SX4_!C7O'Z?%CQSX,
M^,RZOX\\?2)J< \1^+D^&M[\0_B1=>?K4MQJVI26&M3^(;!-8U%HKWQ%+8KJ
M\]M8R:D;6#].O^"(7_!./]LS]D']J[X@_$K]HGX-_P#"O/!6N?L]>*_ VEZU
M_P +#^%7BW[5XIU+XD?";7[+2_[.\#>./$VK0>?I/AG6[O[;<6$.G1_8O(FN
MX[FYM(;@D]'KO&/J]7_3"3T>N\8^KU?],^L_^"JEY_P2M_9>^%'@/PQ\>_V8
M?!?CC7)G\9:E\&_@C\+;.[^%EVK:]>Z9-XW\1_VU\/[GPS9>"M$U'5+;2?[6
MUB0SZGJE]"O]C:1K$VGZC]B_(O\ ;B_:?_;'_:&_8?\ $%C9?\$XO _[,'[$
MWAE/AS?:7XF\0Z+/;^+/"T<WBOPQ:^$=3^%]_KS?#:.YL/$MW>:5H-WJ7@[X
M6ZR;WPUJ^IK+JL.F2W][%^D7_!<__@F;\<OVM==^&?[0'[.^E/X]\8^"O"+?
M#7Q=\-/[7TK2;^Z\,P:[K/B;1?$WA=]=O],TJZO;+4/$&MV7B#3FO8]2O;23
M1)-,@NS8W,(^4?BO\&?^"ZG[?_[/-I\%OB_\,_!?PQ^'O@3PQ;Z_<PW^K>'_
M  5XX_:"\7>!X9+?PSH'B6UD\;ZW_P 3S5-36'5XQK&G_#;X:?VG9VWB>]N5
MO+#P_$!6LM5H^K:MZ+^O\A6LM5H^K:MZ+^O\NT_X)^Z5=2_\$!?VQ+K7(;6^
M@71OVK+WPHUQ'!<R:;IJ_#31K>=;<O&7LY&U^TUBYPK>83*LV_:Z*N=_P;1^
M&/#7BGP9^V;I_B?P]H?B.PEUKX'12V.O:38:O9R1/8_%-WBDMM0M[B%XV>.-
MV1D*LT:,02BD?3_[$?[''[7_ ,,O^"4/[8?[)'Q3^#6I^&/BYXPT[XSI\)]$
MN/B+\*-?TOQ;!\1_AIIFD:5I.F:QX>\>:OI'AJ>#Q7IVIC48_$UYH>FJ=8M-
M2AOYUGU/^SNG_P""$G[$W[3O[&FA?M+V7[27PS_X5Q<_$'5_A3=>$(_^$S^'
MWC#^UX/#5G\08M;??X"\5^*([#[%)KFEKMU-[)[G[5FT6=8+@PC:M+5;]/E_
M3\[@VK2U6_3Y?T_.Y^3?_!%SP9X/\3_\%5/VB_#_ (E\*>&O$.@V7@CX_P M
MGHFN:%I>K:1:2V?QB\$6UI);:;?VMQ9P26MO++;VSQ0HT$,DD416-V4_VM6]
MO!:006MK!#;6MM#';VUM;QI#!;P0HL<,$$,:K'%#%&JQQQQJJ1HJJJA0!7\9
MFI?L&_\ !5K]C+]N_P",/Q:_8W^$X\2:?\0?$WQ;L/A_XX@U;X:Z_P"'+[X=
M^/\ 69O$=A:^)[?QEKVDIX<UW0<:)+(WBFTTJQN/%7A_98R>(="FVZI_8!\,
M)O&]Q\-/AY<?$RSCT[XCS^!O"4WQ T^&YTV\AL/&\N@:>_BNSBN]&5-'NH[7
M7FOX$N=*5=-G5!+8JMJT0$RZ.Z=TNNNB6Y,NCNG=+KKHEN?Q5_MZ^ O#WQ2_
MX.!!\.?%VG6VL>$O&OQ^_8Y\.>*M'O/-^RZQX9U3X9? FVU_2)S"\<JQ:II+
MWE@[1NCJ+C<'4C(^^?\ @Y6\$^$-#^"_[)U]HGAG0]%N=#\=^.?#&D-I&FVN
MF1:=X>O/"^C74^C6EO8Q06T.G&XT;3)(K98A';FT06ZQ*\HDT_V@O^"=O[8W
MC?\ X+7Z#^UQX7^#_P#:G[/5E\;OV9O%]S\0?^%@?"VR\KP[\/O GPHT;Q?J
M/_"*:CXWM/&[_P!D:EX:UNV^R1^&GOK_ .Q>=I=M>V]S:2S_ %A_P7/_ &./
MVC_VQOA3\"O#7[.'PY_X6-K?@WXA>(]<\267_"7^!/"/]FZ7?^&X["TNOM/C
MOQ1X8M+SS;M3%Y%A/=7$>/,EA2+#U3:]S7:U]=MMRFU[FNUKZ[;;G)?"3]F[
MX5^#O^"!?B^Q3P;X8N;[Q?\ L3_$SX\>(-8DT+2I]4U?QYJ/P[\2?$_P]KNI
M7US8R7%WJOA6[_L73=#OY6>[T>QT/3K?2[FV6RM98_YK?@%XX\5>$/\ @F!^
MWSIGAL72V?CWXT?LB^"O%=U:W#6[V'AB<_&'Q1<NS*AD:WU/5_"FAZ%>P1R0
M?:K35);>X>6T>>UN/[,-%^ GQ9M/^"3$W[,UQX4\OXWO^P9K_P %U\$_V[X:
M?/Q+O?@;J7@ZU\-?\)(FLMX1'F^([B+3O[8.OC0$W_;)-52P5KI?R6_X)L_\
M$DOC9I_[+?[<G[-W[9?PZN/A1I_[0,?PC/@;5K+QC\/O&=]9:[X"E\::UI_B
M>T'@/Q?XC2W;PQXGN/#%[<:=JESIBZ_8R7>DAYK*XU Q$6N5W?VD_/=?,(M<
MKN_M)^>Z^9[Q_P &_7[./P/M?V*&^,<OA#PEXJ^)GQ5\7_$/0/&OB'6]!TO5
MM8TKPSHVIQ>';3X<Q75];3R6_AN]L-,MO%&I:7'LAU:[\0*^IB[BLM,CL_R'
M_:6\%>&OV0O^"[?PPTW]F?2D\*:?)\;/V<]1@^'O@)(=%MM+D^*:>$])\=?#
MW1K7[1:V-AI?CK2=>U=#I"2V.C6FE>-'T:VBL=(AAAA]:^#?[-W_  7._P""
M:DWC7X8?L\^!M+^('PV\6>(FU)+WPN/ 'Q"\$:EXEO=)MM*3QIHUAXDO-$\<
M>%;Y+#3;&RU!_$&CZ)I%Q)I6GKJUCJ5M!IT\OV#_ ,$WO^"5?[3FK?M6:S^W
MC_P4:\B;XF67B"?Q7X.\%ZEK?A?Q'XAUGXBM#9KI7Q"\2GP5<:CX,\/>'?!E
M@%MO 7@_1KJ*[TW6=/TR8:7X4T;PCI&G^(BZ3D[IIK:^KVMI^'Z!=)R=TTUM
M?5[6T_#]#\VO^"5/AKPK^T1_P6!^(/B/X_:'IGB+7TUCX_\ Q3L_#7BVPMO%
M%A<?$Z'Q0[0Q7,#12:--=>%H-7UO7-'O+BU>PL=3\/Z?=:5%;:A;Z3/;?=__
M  <J?!+X5Z5X!^ 7QQTC0?#^@?%/4OB#K7@'6K_2=&L=/U7QKX6N?"LNL0W7
MB'4+6*&XU4^#KW0+*RT<WWVB2TM_%%[##+%"1&>;_;,_X)G?MP?LX_MUZI^W
M#_P3P\-V_BRT\1^)/$OQ%&C:7?\ A>[\0>!O%7B[2+RV^)>C:KX3\<7ME;>*
M/"WCBXUSQ-=Z)!X974KW2K;5IM&AL=#NM'\/:IJ'CO[7?["7_!:+]OSPKX?^
M,GQW\#>%)/%'A3Q+!X6^'7[.7ASQ/\,/"7_".>#_ !'H=WJ_B_XCFYU7QZ-
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M\$^*?'_P9U2XM?#D.MVUH9M)7QJGB[5KF.UB98=6UR^FED+7JJGVI_P;3?\
M)G_QN_[.3U;_ -5?\,Z^@?BK^PW^TW;_ /!(SXG?LMW?Q"\;_M3?M1^.]*\+
M:QK.J^-?B7=ZNMYXF;XB^!=?U3PIX2\5?%CQ'90:;X.\(:!H4]II+:IJFCQZ
MU<6-]K::7IFHZ^-$M[?_  0\_9+_ &@OV/OV;_BEX!_:+\ ?\*[\6>(_C=J/
MB_1M)_X2KP3XM^V>'9_ ?@;18M1^W>!?$GB;3;??J6CZE;?9+N\@OE^S><UL
M+>:"657O&6UV^GRUMN*]XRVNWT^6MMS]I:***@@**** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\=>';AF2WU[P=XATCQ/HL[H<.L.J:)>7UC*RGAE2=BIX(%?C7\//"7A74/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC7Q]X;US7+O2C'J&MZM#9Z:(18VUM;6%S?7]X\%G^G]%.[_"WRM;]?Z0[O\
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MZAJ^H6%Y+J$5KY%;?\$V/AUX9\>>._&/PC_:!_:V^ VA?$KQ9XB\<^,OA/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MH<[7_P!:[\*U/V8_]N_FC1_%/_"_R1^ZE%%%49A1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MYFM.UG>+>JUM%KT]ZUOE\]$?V_\ ['WQ>\1?M _LG?LR_';Q=I5GHGBKXS?
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M-&BO+RYU&[CTK0-"M+#2M.CNM0O+N^N$L[2%9[RZN;J4-//*[?S(_P#!*?\
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MM3]F/_;OYHT?Q3_PO\D?NI1115&84444 %%%% !1110 4444 %%%% !1110
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MOP>_^>Y1_P 1</["O_1N_P"UG_X)?@]_\]RO\^BBC^U,7_-#_P  B']A9?\
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M_HW?]K/_ ,$OP>_^>Y1_Q%P_L*_]&[_M9_\ @E^#W_SW*_SZ**/[4Q?\T/\
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MT_5M1O-(\*C0_'NMQ3:]/%H\Z6T>KRZ5IYDDA$M_&I=D^&O^(N']A7_HW?\
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M9QBE=RE6DDEW;;22]3^[+_B+A_85_P"C=_VL_P#P2_![_P">Y1_Q%P_L*_\
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MNHG4YKGQ58RVZ/IZ6I@M[HRW4<BPQR_Y>M?TR_\ !J-_RDP\:_\ 9IGQ1_\
M5B?!NM\-F.)JXBE3G*#C.:C*T$G9^?0Y<;D^"H83$5J<)J=.G*46ZDFKKNGH
MS^^O]J>:"W_9B_:-GNOAQJ7QCMH/@/\ %^:Y^$6C_:?[7^*D$?P^\0O-\.-*
M^QV]Y=_VEXXC5O#%C]EM+JY^U:I%Y%O/+MB;^5#_ ()M>"_^#AN^_8I_9^U?
M]G#X]_L47O[/^I^ -,D^#^B_%=QKWC'PCX(M9[RSTKPQJFJ>$OA?J,;7&D)
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M5]_ZD0^-;;O?3H_N?;LS\O?V-_B!^R)^U#_P6;_8]^(G_!)G]F[Q5\'O@O\
M _X._%+1OVN?'F@>"'^&'PW\1^'_ !%\._$FF_#[0?$WA32'N-,N==M?$YL8
M9/$/B%V\0_$#Q3-I>J/#>0_#F#Q2W]H5?@/^Q!_P4I_;)^)_QJ^%7[/WC/\
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MMGIFKK-X:UC4].\4QC1&-3_X*W?L':3^U);_ +(-Y\8;I?BS<?$2/X,'48?
MWCBX^&5O\;YIM.@@^#%Q\4H= ?P2/B,\NIV]K<:1'JTMGIFKK-X:UC4].\4Q
MC1&_DAUNSU>V\/\ CS_@FBVMZ[9_MV^(?^#BJW^-&@Z'/H&M7'B5?A9K'@2Q
M72?VBC?ZEIMY#+X.2WA?QN=8O'O)6\-ZI;^)9[6XT*YOKZ(UNSU>V\/^//\
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MF^&M>\<ZMX(T'Q%J-_HMOHVIWJ^(-!DU)_PB_P""2G[3WQ4^%_CCXP:QXG^
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MOAG\6?!5O\-?':>)_#G@7Q=X9D\?6%M9:OX?O=6U#7M0\-^)8[OPQ<7=C?\
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M\N)YY$DT_+M=OM;?T94Y*225[JVK27>^BOOIIMI?=L[>BBBJ,RO]DM/M8O\
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MB+QCXO\ '>L:9=KXNUCPGXPTT7$NI>'+#1;?3[^PTRPD&KS:C=Z_I\>F"VU
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%% PHHHH **** "BBB@ HHHH **** /Z0?\ @@/_ ,D?_P""RO\ VC<^*_\
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M3X-U_,U7],O_  :C?\I,/&O_ &:9\4?_ %8GP;JL%_O>'_Z^+]2<S_W#%_\
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MHYT/0?$&KWOQ]\->'M%FDCNXO&'C7P-HJZ1X0\4W^T1SR?$7Q'\:-=M[A_\
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M]9O+"SDFNK;2M1FB2SF_DN_;7\>?\%9?%'Q4_P""7%A^W=\#OV3?AE\'XO\
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M ,)L1_\ *O-?>?Q#45_;S_Q"$^ ?^D@NM_\ B.FE?_/MH_XA"? /_2076_\
MQ'32O_GVT?4J_:E_X/H?_+/ZL_*Y_:V"_P"?E7_PFQ'_ ,J\U]Y_$-17]O/_
M !"$^ ?^D@NM_P#B.FE?_/MH_P"(0GP#_P!)!=;_ /$=-*_^?;1]2K]J7_@^
MA_\ +/ZL_*Y_:V"_Y^5?_";$?_*O-?>?Q#45_;S_ ,0A/@'_ *2"ZW_XCII7
M_P ^VC_B$)\ _P#2076__$=-*_\ GVT?4J_:E_X/H?\ RS^K/RN?VM@O^?E7
M_P )L1_\J\U]Y_$-17]O/_$(3X!_Z2"ZW_XCII7_ ,^VC_B$)\ _])!=;_\
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M+<7O%M/5/5.SU5T_5-I]"TTTFM4TFGY/5!1112&%%%% !1110 4444 %%%%
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MB+Q%>W6@_%GQ]XK^(?@F+4M5GF\.^'/@]I\%AX-^&-YX;%[<M;:-H'C7X?\
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M8:U7]IK1OVH=6_9(^(_@>#QQKJZUH=LL=O\ "#1_CMK?C6?Q%I?P,>=IDMO
MD/AO^SM)TIY$M;:7QA=W7CQN1U#_ ((<7=W\?K_5(/VI;BW_ &+M7_;PL?\
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MP'7\O'P<_P"3>O\ @FQ_VL?^)_\ U-OB97]0_P#P33_Y1R_L _\ 9D_[*O\
MZHKP'7\O'P<_Y-Z_X)L?]K'_ (G_ /4V^)E+I'T7YP".\_7]6?NI_P %_O\
ME$)^V;_V+7PP_P#5Z_"ZOB?_ ()?_P#*7O\ ;._[,"_X)]?^J*^$E?;'_!?[
M_E$)^V;_ -BU\,/_ %>OPNKXG_X)?_\ *7O]L[_LP+_@GU_ZHKX24W\2^7Y3
M$OX;_P"WO_2J1]9_MR_\IC_^"%7_ 'DZ_P#66O"-?MA7XG_MR_\ *8__ ((5
M?]Y.O_66O"-?MA36\O7]$3+:'^%_^ER"BBBF2%%<+<_%'X9V5S<6=Y\1? MI
M>6D\MM=6MSXN\/P7-M<P2-%/;W$$NH)+#/#*CQRQ2*LD<BLCJK*0-K0O%OA3
MQ3]J_P"$8\3>'O$?V'R/MW]A:UINK_8_M7G?9OM7]GW-Q]G^T?9[CR/.V>;Y
M$WE[O*?;*E%NRE%OLFF_NN<E/'X&K55&EC,)4K-R2I4\11G5;BFY)4XS<FXJ
M,G)):)-NR3.@HHHJCK"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KY=_;A^'7C#XO_L5
M_M??"7X>Z3_;WC[XH_LN_'_X=>!]"^VV&F_VUXP\;?"?Q;X:\-:3_:.JW5EI
M=A_:.M:G96?VW4KRTL+7SO/O+J"WCDE3ZBHH!:-/L?S*?LPM_P '$7P"_9R^
M!?P1\,?LF_L%'P[\*/A/X#\ Z(/'7Q,\7OXU32_"_AO3M)LHO%K^&_B6/#[>
M(X8+9(M:.AYTDZ@EQ_9[/:^4[>Z?\+?_ .#C_P#Z-,_X)P?^')^)/_SS*_?>
MBE:W5_?Z?Y?B^Y?/_=A]S_S_ *N_*WX$?\+?_P"#C_\ Z-,_X)P?^')^)/\
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M9?RR^Y_UU7WAS1_FC]Z_KJOO(J*E\B?_ )XR_P#?M_\ "CR)_P#GC+_W[?\
MPHY9?RR^Y_UU7WAS1_FC]Z_KJOO(J*E\B?\ YXR_]^W_ ,*/(G_YXR_]^W_P
MHY9?RR^Y_P!=5]X<T?YH_>OZZK[R*BI?(G_YXR_]^W_PH\B?_GC+_P!^W_PH
MY9?RR^Y_UU7WAS1_FC]Z_KJOO(J*E\B?_GC+_P!^W_PH\B?_ )XR_P#?M_\
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M(;YX3>^(;K4IHX;V"2:7=&DT(DW+])_\$N/^2/\ QM_[.L^,7_I/X3KX]_;
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MB3J5S8:O).NI:5+>G]#/V:?@[_PSO^SE\ /V?_\ A(O^$P_X49\$_A5\'?\
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M@'P9X=MK#79938WWBV&&#P]K&C>/.,^(_P ;O^"O/P+\ _L;?M%_$?\ :9^
M7C'P1^UI^TI^Q_X'^(GP;\$?L^Z5X5?X!>&?C=XJT1[[0/AYX^U_Q'XIU3XA
M:)K.C7-QX5\3WWBW3!XMTG5]4LM:\(:S:V-A=R-]Q?M,_P#!/;PHGQ5_:@_:
MG\(ZIXXD\ _M#_LF_$WX4?MI?LH?#/P39>(_$'[5L6E^ _$-A\/O%?PPU.\\
M;^$M/\#_ +0OAVROKSPWX?UC4-,\4:=XIM+R+1([?PKJNK:QXJOOP#\+:YXO
M_:\U'_@EO^SK\'_^"@'Q-_;/T[X1_M0_LP?%?5?V=]1_9#TKX+^/OV</@O\
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M)!J7]^+_ +]+6)11]<Q7_016_P# Y?Y^7Y]V'U7#?\^*7_@"_P O+\^[-O\
MX2#4O[\7_?I:/^$@U+^_%_WZ6L2BCZYBO^@BM_X'+_/R_/NP^JX;_GQ2_P#
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MU_P4F_[5O_C=_P"KUM*_2'_@CS_R4/\ X*\_]I9_VDO_ $Q?#^OS>_X*=?\
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M12C3E%I-Z.3IM):?"E!ZNSVT[>KT445B:!1110 4444 %%%% !1110 4444
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MB6WBG0(-3N+R:"SUJ*\,-IJNOZ-'(NA>)_$NF:OZGJ7@OPWJLG@QKG3Q'%X
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M4M5\&:?I1^**?&+3$3PO:>(])TVTL]0FT*VUFVO[+7;B;PLMW;>-M-'AZ?\
MN3HI-7_K=73_ $*C)QO9=K>36S/S8_:@_P""2G[#W[8OQ3NOC-\>_A]XZ\4>
M/[S1M(T";4-)^./QI\'Z6NF:' UMIT%IX;\)^/-'\.Z=LB8FX;3M,M/MMPTE
M[>">^N+FYF_"O_@J3_P1I_8#^!%K_P $^K3X9?#3QOHL?QX_X*>_LH_LY?$D
MZE\;/C#XJ_M3X4_%"/X@Q>,-&L(O%GC76[;1=2OET>P^R^(=*@M=<TWRI%L;
MZ".XN4E_K[K\3_\ @M1_SB8_[38?L'_^]4I-+LMUT\T5"4KI<TK=KNVQP?\
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MF$HD 4++_P 0U7_!)O\ Z(_\2/\ P^GQ2_\ FBK][**++LON0<\_YI?^!/\
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M-%M/A]\-?$$$#6.C:S:6LDJZGXDU:9KEXS,R31PLYC@B5?Y\O$W_ ",6M_\
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MJR[$7;>[O?OUV/C2?_@BQ_P3GU#P_?>"=<^"_B[Q)\-)[[Q=JFC_  A\0?M
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M/6]2^(_[=/PS_:=\1/\ LO\ A_PU/X^TG7=6^,GP7_8JU7XN^,]>TCXI^.?
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MXE\'Z)X9N?#?A?Q1K^C^(O&/]HV&I:!IFHIK=@;A*U]'>]]=.ZTNMWJM[O\
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M?]^V_P#C%<_11]9C_P! F%_\!J__ "X/J\_^@G$??3\O^G?E^/K?H/L>@_\
M02F_[]M_\8H^QZ#_ -!*;_OVW_QBN?HH^LQ_Z!,+_P" U?\ Y<'U>?\ T$XC
M[Z?E_P!._+\?6_0?8]!_Z"4W_?MO_C%'V/0?^@E-_P!^V_\ C%<_11]9C_T"
M87_P&K_\N#ZO/_H)Q'WT_+_IWY?CZWZ#['H/_02F_P"_;?\ QBC['H/_ $$I
MO^_;?_&*Y^BCZS'_ *!,+_X#5_\ EP?5Y_\ 03B/OI^7_3OR_'UOT'V/0?\
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MAV:RBT^Z3Q0^HR7,<^DVL4R?3U7YHN"U6J6^FMWH]K)K[VC^M2BBBF0%%%%
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MF>*P_9\_Y22_\%"_^Q-_9,_]5YK58W[2W_*3+_@FC_V!OVNO_5-R5L_L^?\
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M>'I=7_8?_@H3^Q]9_M\?L@?%W]DW4/'US\,+3XK_ /" ^;XYL_#D7BVYT/\
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MK:Y^#W[5_P .? &E_P#!9;_@B_HNG^"?"MMI7AOX2?ML:/H%@F@Z8;?2-+\
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M\+P>)+O0]'UG@OCM^R_\?OC+\-_@_P"+[_Q=\/&_:=^"W[2'A7]HOPM9I?\
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M_P!L\0Z1X>U _P!D#COA_P#MU^&/'7Q/^!_PYU;X6?$;X?V7[3GA_P")6N?
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MRLK72U2:O)T%.*Y97LH[-)<LN:5TM%=6L[N^NS:=EU%%%%<IN%%%% !1110
M4444 %%%% !1110 4444 %%%% &[HO\ J]4_Z\)?_06K"K=T7_5ZI_UX2_\
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M:_BKBYT,5A*]+$X:O3_XF9XL2J4,10G4HUJ;:?+4ISE"6\9-!^SY_P I)?\
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M_P#RLJ?8+[_GRN__  &F_P#B*/L%]_SY7?\ X#3?_$5;_MS5/^?K_P @6_\
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MO"45CXB3QR?&'F3:G=2: OAK; VJ5P]SXP_:0C^$OQ/\16OP3\!3_&+0M?\
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M^_R[6Z7U/GRV\8?M(2?"7X8>(KKX)^ H/C%KNO\ P_M/BM\-D^,4TOAGX?\
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M_P"4DO\ P4+_ .Q-_9,_]5YK58W[2W_*3+_@FC_V!OVNO_5-R5Y<_P#D2O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4HW?+*ZN[&T)<T5*UGJFKWLXMQ=GU5T[/2ZL[*X4445!04444 ;NB_ZO5/\
MKPE_]!:L*MW1?]7JG_7A+_Z"U85=-7_=\+Z5O_3ASTOX^)_Q4O\ TU$****Y
MCH"BBB@ HHHH **** .;\8>+O#G@'PKXA\:^+M4AT7PQX6TB^US7=4GCGF2S
MTW3K=[FYE6WM8I[R[G*(4MK&RM[B^OKEXK2RMKBZFAA?Q/\ 9(_:,TS]K/X
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M6?"/QPM?VH_#OPXU/POXUUOQ1J#:?IMB][\1O@I\4=-FLM7T:YF\/-X<&H6
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MP+J%[9:I>:9XBT_0- ^'7BV\6RO-/;^S?#R2>/\ 0V>?4M!@U'4/&.G>$?\
MA*O"\_BV#5X"25M5M;Y;;V_&WR%!OFLG;FNGU3W_ )NO:_5Z[LP_^"7/[,GP
M+\:_'GPQ\<OV?_\ @MI^T[^VK:?!R\UN]\6_ WQI\4_$U]H^K6>L:!KGA&VN
MO&?@#Q3X@AU[_A'[74=8BU31=:N?#DNCW>LZ98O8WLDB)(O]-M?Q>_L;_$#]
MD3]J'_@LW^Q[\1/^"3/[-WBKX/?!?X'_  =^*6C?M<^/- \$/\,/AOXC\/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KRE_OM_O-_,U
MZM7'-X:N"2?M,/))^Z_<UY.:8>M7]A[*#GR>UYK-*W-[.V[6]GMV/2RZO2HN
MK[6:AS*'+=-WLY7V3VNCF*\I\%_ ?X'?#?7]7\5_#OX,_"CP%XH\02-+KWB3
MP7\._"'A;7];E9KAVDU?6-#T>QU'4I&>[NW9[RYF8M=7#$DSREO?/^$9N/\
MGYA_[Y>C_A&;C_GYA_[Y>O*6!QJ32HS2>Z4HI.VUUS:V\ST_KN$=FZL6ULW&
M6E[;>[IT_I,^9/$O[+O[,WC/Q'>^,?&'[.WP*\5^+M2#C4?%/B7X1^ -=\1W
MXDE:=Q>ZYJGA^ZU.Z#S.\SB>ZDW2NTAR[$E8_P!E_P#9HBT$>%HOV=_@7'X8
M'B#_ (2P>'(_A)X 301XJ\C2[7_A)AI"^'QIX\0?9M#T2W_MD6_]H^1H^EP_
M:?+T^T6'Z:_X1FX_Y^8?^^7H_P"$9N/^?F'_ +Y>G]3Q^G[NKIM[ZTMM;WQ?
M6\%O[2%WN^26M[;^[Z7]/+3SC5/"/A76_#I\(:QX:T'5/"GV>PM!X:O](L+O
M05MM*FMKC2H$TF>W>QCBTNXLK.XTU$@46$]I:S6@AEMX73H:Z;_A&;C_ )^8
M?^^7H_X1FX_Y^8?^^7J?J&,_Y\R[_%#=[OXNH_KN$_Y_1_\  9__ "/G^?9G
MA_CCX,?![XG:CHFK_$GX4?#7XA:MX:N(+KPYJGCCP+X7\6:CH%U:S27%K<Z)
M>Z]I5_<Z5<6UQ++/!-8RP20S222QLKNS'@?%'[(7[)OC?7]4\5^-/V7_ -G?
MQ=XHUNX^UZSXD\4?!3X:Z_K^KW?EI#]JU36-5\,W>HW]QY44<7G7=S+)Y<:)
MNVHH'U=_PC-Q_P _,/\ WR]'_",W'_/S#_WR]4L'CXVY:=565E::5D]TK3V=
MD)XS!O>I!WMO"3VM;>/3\/DSR^3P+X(E\'V_P\E\'>%9/ %IHVG^';7P-)X>
MTA_!]MX?TF"WMM+T*W\,M9G18=&TVVM+2WT_2X[);*S@M;>*V@CCAC5:G@+X
M;?#KX5:"GA7X7^ ?!7PW\+QW$]W'X;\!>%="\'Z#'=W3;[FZ31_#UAIVGI<7
M#_//,MN))6^:1F/->M_\(S<?\_,/_?+T?\(S<?\ /S#_ -\O2^HXVS7L9V;N
MUS1LWW:YM7Y[C^NX2]_:QO:R?+*]G;3X=MM/+RTYFBNF_P"$9N/^?F'_ +Y>
MC_A&;C_GYA_[Y>E_9^,_Y\2^^'_R0_KV%_Y_1_\  9__ "/G^?9GSIJ?[.7[
M/6M>+[CX@ZS\"/@SJWCV[6=+KQOJ?PO\$7_B^Y2Y:5KE+CQ+=:'+K,RW#3S-
M.LEZPE::4R!C(Y/QW^U=^PKI'Q)\$?!7X:_ 3X0_LY^#? 'A3]JOX9_M#?%C
MP??Z=%\./"_CO2O!?VFS\2Z%-X=\#?"_Q-I7B'6?&NAW$>BZAJ/B"&UB_L^R
MM[2\-_;;(K?]3_\ A&;C_GYA_P"^7H_X1FX_Y^8?^^7K2&%S"$HR5*;<=DYI
MK1-+3G6U].S,Y8K!233J0L^T))[I_P G6ROWMKMIXMX'^%GPZ\ :7J^G^$/A
MYX*\'1^*[@ZIXPL_#.B:;:P>(M8N+**RN[S7;R'3K&X\2W'V2*/34U'687NI
M--M[>U,<%M%':Q8WPS^ 'P*^"]UK5]\(/@U\+?A=>^(V4Z]>?#[P%X7\'W6L
M+'(TT4.HW&@:782W5K!*SRVUI,[6UM(\CP11M(Y;Z"_X1FX_Y^8?^^7H_P"$
M9N/^?F'_ +Y>I^I8ZS7LJEI6YESQM*VUUSZVZ7V*^N8/1^UA=;/EEI>U[>[I
M?K^.S/ M(^!'P3\/^,)_B!H7PC^&VC>.+G7=:\53^+=+\%>';#Q"_BGQ+92Z
M;XD\4?VK;:=%>+XD\1:=/-I^OZ^DJZMK5C+)9ZG>75NQC-C3?@C\&-&\9^(O
MB-H_PB^&&E?$+Q?#=6WBSQYIO@'PI8^,_%%O>HD=[;^(O%%KI,6MZW#=QQQQ
MW46I7US'<)&BRJZJH'NO_",W'_/S#_WR]'_",W'_ #\P_P#?+T?4L=_SZJ;<
MOQQ^%:I?'M?6VP?7,'_S]AO?X9;NVOP[^?\ DSY\T?\ 9_\ @/X=\+>,/ _A
M[X*?";P_X,^(37;^/?"6A?#KPAH_AOQM)?0M;WLOBS1-.T>VTWQ%+=P,T-Q+
MJ]M=R31L4=F4XKFY?V3OV79[GPG>3_LZ? ^>Z\!Z!_PBO@NXG^%G@F:;PMX:
M^V7^HKH6A22:(S:;I4>HZKJVHQ65J8X(=0U;5KZ)$NM3OI;CZG_X1FX_Y^8?
M^^7H_P"$9N/^?F'_ +Y>CZGC]?W=77?WUKI;7W^VGIIL'US!Z?O(:;>Y+35/
M^736S]=>C/G&W_9O_9YM8_ <<'P)^#R#X6V<VG_#1V^&O@V2;X?V5S-)<75M
MX+GET9Y_#,5W<S37-VNC26?VNZFFN;CS9Y9)&JR_LP_LU7&E^)=#G_9Y^!LV
MB>,]577?&&CR_"7P#)I?BO6TE$Z:QXET]_#[6FNZJLRK,NH:I#=7:RJ)!,'
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M<W%[=R10*]S>7$]U.TD\TDC=+73?\(S<?\_,/_?+T?\ ",W'_/S#_P!\O4O
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M>C^S\9_SXE]\/_D@^O87_G]'_P !G_\ (^?Y]F<S173?\(S<?\_,/_?+T?\
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M_DS/%?\ V<7QX_\ 7K\;'W)_P5Z_Y/P^/_\ V477/_2'0Z]G_P""/O\ Q_\
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M?.[OIY?YBE:RM)RMW5DO):O\D=?7\_&O_P#!1#]LK6O^"S?[*'[*J_!_Q=\
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MR;"Z\J&;X>> +BU\$V-QX&\'3V7PUO;#4OAS9S>&=%EM? &HZ5HM[X;TN_\
M!-N]DT/A6]TWP[J.H:#876A)83V>BW][I=O)'8W4\$E^S\)>%-.\2ZWXST_P
MQX>L?&'B;3]%TCQ)XKL]%TVU\2^(-*\-OJ3^'=,UO78+9-4U;3] ?6M8?1;*
M_NKBVTI]6U)K&* W]T907](X+_AH/X"?\*L_X7G_ ,+O^$/_  I/[7]@_P"%
MQ?\ "RO!G_"K/MW_  EW_"O_ +%_PL'^VO\ A$OM?_">?\43]F_M?SO^$N_X
MIO9_;/\ H5=IJ'COP/I/B_PY\/\ 5?&7A33/'OC#3-?UKPCX(U#Q#I%GXO\
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M#\>?$6+Q+<?#[P3K'B71=,\7>.H/!EE9ZEXPF\&^&[V]@UGQ/%X4T[4=/O\
MQ+)HEE?)H5E?6=UJC6L%S#(\%G\2_AQJ-[X^TW3_ (@>";_4?A3/!:_%&PL_
M%>A75[\-KFZT"V\56UOX^M8+]Y_!T]QX7O;/Q)!%XACTZ2;0+NVUB-6TZ>*X
M?1U+P9X/UGQ)X9\9:QX4\-:KXO\ !46NP>#?%6I:%I=]XD\)0>*+:ULO$T/A
MG7+JUEU/08O$5G86-IKL>E75HFKVUG:P:@+B*WA1([3P-X)L+OQA?V/@_P +
M65]\0KB&[\?WMIX?TFVN_'%W;:):>&K>Y\87,-HDWB:XM_#EA8Z!#-K3WLD6
MB65II4;+8VT,"'](-//;\;_E;\3FIOC9\&;?PO\ #SQQ/\6_AC!X*^+NL>$/
M#WPG\7S>/?"L?A?XGZ_\04$G@+0_AYX@?5ETGQKK'C>,A_"&F>&[O4[WQ*A#
M:-!>J<UOK\0? +>/I/A4OC?P@WQ0A\(0_$&;X;KXET4^/HO -SK5QX<M_&\G
M@\7O_"0IX0G\0VMUH,/B5M.&BRZU;7&EI>M?0R0+1?X5?"^7P]X*\(R?#?P%
M)X4^&NH>&-7^'/AA_!_AY_#W@#5?!"+'X,U/P5HK:<=-\*ZAX11$3PQ>Z%;6
M%SH"(JZ5+:!0!L#P9X/7QA)\0E\*>&E\?S>&H?!DOC@:%I8\82^#[?5)]<M_
M"DGB86O]M/X:@UJZN=7AT)KTZ7%JEQ/J"6JW<TDS :>=_P#AO^#^!RT/QL^#
M-QX7^(?CB#XM_#&?P5\(M8\7^'OBQXOA\>^%9/"_PPU_X?(9/'NA_$/Q FK-
MI/@K6/!$8+^+],\27>F7OAI 6UF"R49K8O/B7\.-.O? .FZA\0/!-AJ/Q6GG
MM?A=87GBO0K6]^)-S:Z!<^*KFW\ VL]^D_C&>W\+V5YXDGB\/1ZC)#H%I<ZQ
M(JZ=!+<) GPJ^%\7A[QKX1C^&_@*/PI\2M0\3ZO\1O#">#_#R>'O'^J^-T:/
MQGJ?C715TX:;XJU#Q<CNGB>]UVVO[G7T=EU66[#$'4N_ W@F_N_!]_?>#_"U
M[??#VXGN_ %[=^'])N;OP/=W.B7?AJXN?!]S-:/-X9N+CPY?WV@3S:*]E)+H
ME[=Z5(S6-S- X&GGU_+3\=_(AT?X@^ ?$/B[QEX T#QOX0USQY\.HO#5Q\0?
M!.C^)=%U/Q=X%@\9V5YJ7@^;QEX;LKV?6?#$7BO3M.U"_P##4FMV5BFNV5C>
M76EM=06TTB<I:_'SX%7WPUT?XS67QI^$MY\'_$-[IFF:!\5[7XC>#KCX:ZYJ
M6M>)8O!>C:?H_CJ+67\+ZG>ZMXQFA\)Z9:66J3SW_B66+0K6.75)%M3VNF^#
M/!^C>)/$WC+1_"GAK2O%_C6+0H/&7BK3="TNQ\2>+8/"]M=V7AF'Q-KEK:Q:
MGKT7AVSO[ZTT*/5;J[32+:\NX-/%O%<3(_/V_P '_A):>!=+^%]I\+?AU:_#
M31+O3+_1?AW;^"/#,/@72+_1=?A\5Z/>Z7X2CTQ= L+O2?%-M;^)=,N;33XI
MK#7X(=9M7BU&)+E3^OZ_$-//I_P?^!^)MS^._ ]KXUT[X;7/C+PI;_$76/#F
MI^,=)\ S^(=(A\:ZIX1T74-.TC6?%6G>%9+Q==O?#FDZKJ^DZ9J>N6UA+IEA
MJ&J:=975U%<WMM%+@6WQF^#]YH'Q)\66GQ6^&UUX6^#6J^*M"^+_ (EMO'7A
M>?0/A3K?@32H-=\;Z-\2=9BU1M.\#:KX-T.ZMM9\5:?XHN=+N_#VE7,&HZO#
M9V<T<S=1-X2\*7'BFQ\<S^&/#T_C;2]"U'POIOC";1=-D\4Z=X:UB^T[4]7\
M.V/B![9M6M-"U34M'TG4-1TFWNX["^OM+TZ[N;>6XLK:2+'A^%_PTM]&\=>'
M;?X=^!8/#_Q0U#Q#JWQ,T*'PEH$6C?$35?%NFPZ-XKU/QUIB:>MEXNU#Q-H]
MM;Z5XAO-?@U"YUK3;>&QU*2YM8HXE 5NM_EZ_P"5_F0S_%CX66MC\.]4N?B7
MX MM,^+]]I6E_";49_&7AV&Q^*&IZ[H5YXHT/3OAW=R:DMOXVOM9\,Z??^(M
M*M/#4FIW&HZ%8WFKV<<VGVTUPFKI_COP/JWB_P 1_#_2O&7A34_'O@_3- UK
MQ=X(T_Q#I%YXO\+:-XK.IKX7U;Q'X:MKR36=$TSQ(=%U@:!?ZG96MKK!TG4Q
MITMR;"Z\J&;X>> +BU\$V-QX&\'3V7PUO;#4OAS9S>&=%EM? &HZ5HM[X;TN
M_P#!-N]DT/A6]TWP[J.H:#876A)83V>BW][I=O)'8W4\$E^S\)>%-.\2ZWXS
MT_PQX>L?&'B;3]%TCQ)XKL]%TVU\2^(-*\-OJ3^'=,UO78+9-4U;3] ?6M8?
M1;*_NKBVTI]6U)K&* W]T907](X+_AH/X"?\*L_X7G_PN_X0_P#"D_M?V#_A
M<7_"RO!G_"K/MW_"7?\ "O\ [%_PL'^VO^$2^U_\)Y_Q1/V;^U_._P"$N_XI
MO9_;/^A5VFH>._ ^D^+_  Y\/]5\9>%-,\>^,-,U_6O"/@C4/$.D6?B_Q3HW
MA0Z8OBC5O#GAJYO(]9UO3/#9UK1QK]_IEE=6NCG5M,&HRVQO[7S<#_A3/P?_
M .%?_P#"I_\ A5/PV_X59]J^W?\ "M/^$%\+_P#"O_MO_"3?\)I]L_X0W^R_
M^$<^U?\ "8_\59]H_LWSO^$F_P")]O\ [4_TJNHO/"7A34?$NB>,]0\,>'K[
MQAX9T_6M(\-^*[S1=-NO$OA_2O$CZ:_B+3-$UV>V?5-)T_7WT71WUJRL+JWM
MM5?2=-:^BG-A:F(U^?7]1Z>?7_@?\'\#\5]-_;0_9C_9P_X*-?MW7WQA^*VF
M>&K3Q)HW[.?AW29]+T/Q9XW237O!GP_N8O%.C7O_  @6@>)VTC4]#EU:PAO[
M+5Q8W$<TYA$;2PW"18?BO]M3]E_]H;_@H_\ \$]-9^$WQ:TG7M*\)O\ M"^&
M-=U#6M&\5> [2U\1_$?X8SZ!X#T*WF^(.@^%DU/5O%NO*FA:%I^EF]NK_6KJ
MPTJ&)K_4;"WN?VH/PJ^%[)XPB/PW\!&/XAWE[J/C^,^#_#Q3QSJ&HZ1::!J%
M_P",$.G;?$UY?Z#I]AHE[=:T+V>ZTBRM--G>2SMH84K_ /"G_A)_9_@O2?\
MA5OPY_LKX;ZAH6K?#O3/^$(\,_V?X"U7PO8RZ7X9U/P79?V9]F\+:AX=TR>?
M3M"O-#BL;G2+&:6TT^2WMY'C/R;R+,V_JW]I8!9;_;L<Z]E_9>(>.O'.XYW]
M7^M_VJJ&M:/L?:_4=*6O(YZG]#TO%S@.FGG;X&XNEQN_":MX7?V@N/<F7"O+
M5\*I^%*SG_5S_B'KS>\<KFLS>!_ULL\>N7ZTL._9+;@\=^![KQKJ/PVMO&7A
M2X^(NC^'-,\8ZMX!@\0Z1-XUTOPCK6H:CI&C>*M1\*QWC:[9>'-6U72-6TS3
M-<N;"+3+_4-+U&RM;J6YLKF*+C[KX^? JQ^&NL?&:]^-/PEL_@_X>O=3TS7_
M (KW7Q&\'6_PUT/4M%\2R^"]9T_6/'4NLIX7TR]TGQC#-X3U.TO=4@GL/$L4
MNA74<6J1M:CN8?"7A2W\4WWCF#PQX>@\;:IH6G>%]2\80Z+IL?BG4?#6CWVH
MZGI'AV^\0);+JUWH6EZEK&K:AIVDW%W)86-]JFHW=M;Q7%[<R2\W<?!_X27?
M@75/A?=_"WX=77PTUN[U._UKX=W'@CPS-X%U>_UK7YO%>L7NJ>$I-,;0+^[U
M;Q3<W'B74[F[T^6:_P!?GFUFZ>7497N6^L/YXT\^G_!_X'XFMK'Q!\ ^'O%W
M@WP!K_C?PAH?CSXBQ>);CX?>"=8\2Z+IGB[QU!X,LK/4O&$W@WPW>WL&L^)X
MO"FG:CI]_P")9-$LKY-"LKZSNM4:U@N89'@L_B7\.-1O?'VFZ?\ $#P3?ZC\
M*9X+7XHV%GXKT*ZO?AM<W6@6WBJVM_'UK!?O/X.GN/"][9^)((O$,>G23:!=
MVVL1JVG3Q7#Z.I>#/!^L^)/#/C+6/"GAK5?%_@J+78/!OBK4M"TN^\2>$H/%
M%M:V7B:'PSKEU:RZGH,7B*SL+&TUV/2KJT35[:SM8-0%Q%;PHD=IX&\$V%WX
MPO['P?X6LK[XA7$-WX_O;3P_I-M=^.+NVT2T\-6]SXPN8;1)O$UQ;^'+"QT"
M&;6GO9(M$LK32HV6QMH8$/Z0:>>WXW_*WXGYE_\ !6/XD_#KQ#_P33^)/B70
M/'W@K7/#GQ3'P:;X8:_H_BK0M3T3XCKJ/Q.\#>,=/;P'JME?SV/B\7WA'1=9
M\569\/3ZB+KPWI.IZY!OTRPNKJ+^#BW\#^*8]0@G?2\1)>12LWVW3CB-9U=F
MVB[+'"@G !8] ,\5_IR7'PF^%=UX:\&^"[KX:?#^Y\'?#J]\-ZE\/O"=QX-\
M.3>&O NH^#(A!X/O_!NA2::VE^&+WPI"JP^&[K1+6QGT*)1'I<EJ@ JP/AE\
M-E\42>.%^'W@<>-)= B\*2^+QX3T$>*)/"\&HS:O!X;DU\6']K/H$.K7%QJD
M6CM=G3H]1GFO4MA<RO*WYEQKX=+C#,\+F+S;ZA]6P-/!^Q6#^L\SAB,17=3G
M^LT;7]OR\O)IR7YGS6C_ 'A]%GZ;4_HT<"9]P73\.H<7O/.*\7Q++,9\3O)?
MJZQ.3Y+E*P4<+'(\S]HX?V3*N\0\1%3^L*FJ$?9.=7^(W]M"2#Q9_P $]_\
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MD6UY=P:>+>*XF1_U0_SXT\]OQO\ E;\3I:***!!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M.>7?\%_D?A7_ ,.)?"'_ $D]_P""QG_B:FE__.AH_P"'$OA#_I)[_P %C/\
MQ-32_P#YT-?NI119=OZT_P D'/+O^"_R/#/V;/@7;_LV?!?P;\%K7XJ?&GXU
MV_@Q=<2'XE?M"^._^%E?%SQ#'K?B/5_$21>*/&(TK1(]3AT-=6'A[P]##I5G
M%I?AG2M'TI4E^Q&XE]SHHI[$[A1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% 'E_Q?\ C1\,/@+X*U'X@?%GQEHO@OPS80ZF
MT-QJMW''>ZYJ&E^']9\42^'O"VE!CJ7BGQ7>:)X>UF\TCPKH%KJ&OZS_ &?<
M1:7I]U,A2O)]0_;5_9KL-9^&6@0_$#4/$&I?&*^\1Z/\._\ A!_A[\3?B'IV
MO^(O!]MJ-YXN\(R:WX#\&^(]$T3QMX6M](U23Q%X*\0:CI?BO1?L%RNHZ/;O
M$RUL?M6?LT^%_P!K'X/:Y\(/%WB'Q1X<TW4?MFH65YX<U?4K&T/B!/#^NZ7X
M=N/%NAV&H:;;>//"V@ZUJ]EXMG\!:_<MX:\0ZSX>T1-<M[JRMGMY/S2^-'P]
M^$/[+/QU_P""2_P"\+?$*ZT;1_!?Q>^-MUH\?COQ];ZYXFTG0-:^"GCS2])\
MN7Q5<7)LO#?]N7UOX3\,62VL6EQ.+;1=-6340SN]+=;ZZ>5M_P"OP'I;K?73
MRMO_ %^!^MOPK^,7@7XS:;XCU3P+/XH*>$?%-QX*\3:;XS^'?Q$^%WB31/$U
MMHFA>)'T[4/"7Q/\*^#O%$"S:!XGT#5[*^;1_P"SM1T_5;6YL+RYC9F7U"OS
M+^-MS\0O@?X1_95\'?%7XLWW_"!_$+]HW7_!W[3_ ,<M!UO4?AEXCUG2_$W@
MWXKZC\*#>>*="DT_5/AEI7B/QWIWPO\ "&K:QX;\5^'[GPO%;Z#\/O#>NMX?
MU*,CX!T/XA_$/XL?M%? []FKQ=^U-\<? /PTUWXC_M]_#CP!XP\'_%QO!7Q#
M^+OPQ^%M]\'X_@)XL?Q7<Q7NH>+]0T_Q3JOQ5\ >&?B 1J%[\48OAQ=7]]J/
MB"ZG\1_;EZ?UW_KL+T_KO_78_HCU'5M+TB.VEU;4M/TN*]U"QTFSEU&\M[*.
M[U35+F.RTS3;9[F2)9]0U&\EBM+&SB+W%W<RQP6\<DKJAOU^67_!3K3?"*R_
ML':SXV\1>)?"_A33OVZ/AYHGB'6]'^(WCOP!;Z=HGB'X5_&* 7=]K'@_Q)H%
MS9:B=>L/#UEI'B<W46O:-+?7EAHVK6%OXCUN#4_AMOVBO^$*U?X7^"O%O[3O
MC#PIXG\'_P#!7?XY_!CQ'HWB_P#:"\56GB&P_9=U?3OBM?>"].\=VGBSQA+=
MZYX1BL](^%L_@[Q5XZAU:XL9[F.+2-9BN?$.O0ZF ?T8T5_,M^S_ /%:[\6Z
MG_P3<B\5?MM_&3Q!:_M/_#+]IO0OVD!=_M)7FE*D/PYTV+Q-\/[K3CHNIZ1+
M\*_$MCXGL&TQ/&/A9_#GC3Q!I@N_#.L^(-7TRXNK*7V3]E_]HWQ-\:OA+^PA
MH7[0/Q\\1Z%\+OB3\&?VF= \1_%'PY\7=8^&OB[Q3^T!\(OB/X5T/X9Z3XY^
M*GAG4]!U[3M=/P83Q7XWM=,?Q9:Q_$O6HM1UGQ)H>KV6D6D-P[:7_KK_ )/\
M/D[:7_KK_D_P^7] M%?SYZ)\4/BQ\?-9_P""9OPU^,_[17QB^"?B'X^?!?\
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M=0^%'B/QCK7B;0_&_@?7[>W\,6&B9\/[6FH:;\=/@3J%[^TSXRO?$>F_M(?
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MO;J]\.OXBTS3%\4>&I(]4MXK#Q9X?.H^&]3N8;ZWT[4[J2QNA%^;_P#P2?\
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MVD0?">X>Y^(>@ZCHMZG@CQ?IWAVYT*WM+/Q#XBTK55_7]?UU%_7]?UU/U/\
M'GC?P_\ #;P=XC\>>*WU:+PUX4TNXUG7)]#\->)/%^J6VF6@#W=U;^'/"&DZ
MYXCU)+6(M<72Z9I5X]M:13WDZQVEO/-'6^&GQ!\-_%KX<?#_ .*O@V:ZN?"'
MQ,\$^%/B#X5N+ZTDL+V?PWXST*P\1Z'->6,W[VRNI=,U*U>XM)?WEO*SPO\
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M6Q87=Y;POUU?ACJL'C'XZ_%+_@HS\#/@#^TS\4CXA\ ? ;]C_P ;_LS1:/\
MM!^.9;G0O&MEX2^,6H7>G_VH?%C:MJOAWX@[O ^B_%'4_$5UK-_K,'B/0?$^
MNZE/XHL_"6M6%WQS^TCXHU#]BOQ-^W7X9UGXJ_"KP)\5?&W[.'A[5;;Q'XI^
M)OB34OA/^SQ8>.?AY\-?C-XQTSP%<:[>2:9XRU74Y?B!9WOBCP)<^$?$^L>
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M?B-\1],T1_BAX/L_VA_'O@?P7X$_8@\+_';]C+Q'X7^.WCCQ)>>//B79:O\
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M=Q:UX4\6ZI<ZUX+U6Y&A\)?VD]-\9?MH?#SPQ:?'KQE=>$OC)K_[<7PU\?\
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MB?2;;X8^&O#.D_#+5='TKQ]K,OQ2TK1;O5]#\/WGA6Y/A_6+VXH?&/\ ;_\
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M,T:/2;6Z\0+KOH;QI( LB)(H>.0*ZA@'B=98G 8$!XY$22-NJ.JNI#*"'44
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M+6MLT/V@W7E&"(Q?:C<F\-SY979]H-V3=&;'F&Y)GW>:2U6:* "FHB1@A$5
MS,[!%"AG=BSN0 ,L[$LS'EF))))IU% $4%O!:QB&V@AMX0TCB*"-(HP\LCS2
ML$C55#2RN\LC 9>1W=B68DRT44 1+;P)-+<)!"EQ<+$D\ZQHLTR0;_)664*'
MD6'S)/*5V81^8^P#>V2:W@N!&MQ!#.(IHKB(31I*(YX'$D,\8=6"30N \4BX
M>-P&1@0#4M% !4<<44*E(8XXD,DLI6-%C4RSRO//(54 &2::22:5R-TDLCR.
M2[,3)10!!]EM?,N)?LT'FW4<<5U)Y,?F7,40D6*.X?;NFCC6641I(65!)(%
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M$JC32E0#(Y:2B@".&&&WBC@MXHX((46.&&&-8HHHT 5(XXT"HB(H 5%4*H
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MPMRS:Y+J<P$H** ,.X_80_9CN[F\O+OPCXWNKO4/@=)^S9>7-Q\=OCY///\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
?!1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>ny20077604x1_figure05.jpg
<TEXT>
begin 644 ny20077604x1_figure05.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
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M:<;G3]"7,]=&W=V6BM:U[OYZ"<-G=1CRQ;>KNW?I:]WV6B1_<]17\2'[.?\
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M0KE4XIQCROF46KMIWV>NJMUZ6U/[DZ*_AO\ "'['/_!<GX@?L:'_ (*C0_\
M!4/XLZ;\2M3\ 7/[4/A?]G9/&_Q%;PKKWPILO##?$72D30M)U1OA'9Z]XGT.
MU6^\/_!I/A'??#V_BU#2;#7M?TJ:^U2PTSR;]I+_ (+T_MU?&O\ X)?? KQK
MX$UJX^#7C74_CO\ $O\ 9X_:S^.WPHT)++Q%&=$\$^!_%WPLO_!$HO%C^&6I
M_%3POXN\;7EW/H>I>'_$5SXP^#>O7'@/7?!_AR:]TF(YNZ:ZK;5?Y^0>R;M:
M47KRNW1[]=_D?WTT5_"I^R'K'[1>H?''X5ZU_P $\O\ @X0\%_M5^)=3U:6+
MXC_ O_@H!J_[0/P;L?%,TTNCZC_87A+X;?%:[^,&H?$K4_%<=KKEGK.K_#N+
M0?&/@Z*TM)-'\5ZC!K%]?Z3N?M;_ +?/[17_  4'_P""F/QK_8^\+_\ !1CP
M9_P2X_9:_9BUKQUX7N?B;JGQ6_X4]?>.?$OPY\0Z)\._&J?\)+;>/OA[=_%'
MQ'KOC>77M2\#>#V\8^#O#-M\-=%N-:O+0>([6\FUDYO+6]K76_K?;;7S%[/7
MXE:UWI)-=O=:OKTL?W'T5_)=_P $4?\ @HC\>]'_ &VOBI_P2Z_:+_:B\"_M
MNZ#X=\,:QXM^ G[5'@[X@6_Q3/BNZT[2]#\;ZIX7_P"%G'4+^]^(.F3^%?$.
ML7T\FLZIX@\2> _%'A'7O!1U;4="M;2+P[_6C33NOS]?U)E%Q=GKHFGW3ZG\
MCGC?_@Y7_:"@_:8^//[-OP6_X)I^(_CYX@^"/Q'^*/@ZY'PY^)7C;Q/XBU'P
M[\-?']WX"F\:7_A7PG\#O$E[HNF7EZNE?:GDFNK'3K[6;'36U&>:XMGG]>^"
M_P#P75_;]^)GQB^$_P ./%/_  1D_:!^'OAGX@?$OP)X(\1^/M5_X73_ &7X
M'T+Q7XITK0=7\8:E_:/[.FD:?]@\,Z??W&M7GV[5=,L_L]E)]JU"R@WW,7\[
M'[.'[27[9/[+?_!87_@H;\0/V'OV<?\ AI[XL:QX_P#VM/!WB'P#_P (3X^\
M>_V1\/-0_:AT/6M6\7_V/\.M7T76[;[!XD\/>$M%_M*ZNI-*A_X2#[+/;O=W
MEC)%_15^QY_P4]_X+:?&#]ISX,?#+]H3_@F9_P *B^"OC/QE;:-\1OB7_P *
M)_:'\-_\(=X=EM+R6;6/[=\4^,[_ ,/:9Y=Q#;Q?:=6L[BT7SMK1EF4B(R;W
M;W[*VZ\O/^NNK@DM(QM9.[FT]KO2Y_4%17\7W_!1#XS_ +=G_!$W_@HKX2_:
MFM/BW^T=^TW^P-\<KOQ9%9?!GXJ?'/XC>,?!'A?6];L);SQ)\(HK[QA?>,M+
M\&:[X8U-+7QS\&_$(T>#5[_P;8:EX-2[UVS\/?$"YO?I/_@B'X?_ &]OVKI?
MC/\ \%/OVO\ ]HSX[IX"\?#XDC]G']GC3?BW\3-$^"8ENH=7TKQ!X\L?A'#X
MKD\)VW@?P<4NO!/PIT76+/59IM7L-;\=ZC'+KVC>$/%VIUS7=K._GT\^OR[F
M;A[O-=<MM'U;_EMW77I;4_JNHK_/U_X),Z;_ ,%@?^"IOPE^,WPP\+?\%(?C
M#\%_A7\)_%]KXI\0_&'Q3XW^+GC[XS>,_'GCCPL-.\+_  QT+QS+XSLO$NE?
M#?PU9^"KW6_$&EZ+XS\/VVCZEXY36;SPWX]N=2T^'PW],?L&_MR_\%=O%%S^
MW5_P2@L?B]\-O&W[7_[/ND^,YOAG^TW\9?&NJ:A)X0T_X7?%W1O OQFBD\::
M]X*\5:A\4KO4[#Q+;:Q\)=4^).B:)>^&+--9O/%>KW%KIOA[P=IZY]M'KMMO
MI_G_ %K:G3M=<T;JU]]$^KT_#M]Q_;E17^<)^U3\4?VF?V&_!OPX^+7@K_@X
M!\:?M&_M:#Q)X0U+XC?LU^ _BE\2_BMX(\'7MO#?:AK>G7_CA/B7\3/@S\1;
M#P3XEAAT'5/!'CSP;X6TG7-,O=2$.B36MNVB:E^QO_!;/]MW]HV[_P"".W_!
M.S]J/X8_%OXC? ;XH_'GQ#\#?%/Q!U?X&^.O&?PKFN[SQI^SCXW\6>*/#]O>
M^%/$=KJ\OA ^*XQ>Z;H^I:K?((['2I[OS+VU21#GWNK:)VWT?_#[,3IN\;-/
MF;5[-;>NK/Z[J*_A1_;<\+?\%@/A'^Q?\)_^"O>O?\%+?BI8^)?';?!GQOJG
M[,OPNC\<^$_@_P#"?P5\4[#3KKX?V::8OC75_ ?C$Z>MSX.TKQOH_COX<26>
MO:SJU['KOBWQOJ<*ZCXI7_@I#_P54_;4\5_"'_@E5IMQ^T#\1?V1?@-^U7^S
M;\-_'?[0/[4/PA\%7UOX[U'XLV/B]_"GQAO]&D\#ZWX8UR/0OA_#H^A>/A\/
MOACXG\&ZGK>D?$-],UN/4+*XT'0[%\R[/9-;;.R[Z:L%3O:TD[MI[Z-*[6UV
M?W6U^.G[$/\ P4W^+W[5W[:_[3_[*OC7]D3Q)\%O!GP"/Q-_X1GXRZIKGB?4
M-,^)?_"!?%G2_ASIOV'3]6^'?AG2K3_A)-*U"7Q5!_9_B76_)M[9H(/MMLS7
M\?XT_P#!,&[_ &FA^U?\/)?V._\ @MW\)_V^OV<-1;2)?C+\%_VLO%?QG\#_
M !RG\/6>L7T7C.U^%/P1^*%E\1O&]A?:'X>O[3Q%X?\ 'WA[Q#X*\.ZQXHD7
M0_&VF3:+I<3ZY\W_ +*7_!3W]H#]GK]M3_@M?\4?BU\;?C#\8?AY^S5X%_::
MU/X2?"#XF?%;XA^+?AEHWC@_M>^"/A?\(]&TGPIJOB*[TOPQI$>L^*-%\)^=
MX=M-/NM(\+7]_8Z8]O;GR2G+;=7?DUTZ]NEU^@_9_$M).RMNFG=+9K?R9_=C
M17\.O[*7[,?_  6Q_P""LGP4\2?M]P?\%-_'G[/EQXVUOQ+%\!?A/X2\;_%3
MP+\.O$*^#_$>K^&-:@O-'^&'B/1] ^&7A.QUW1[WPUIFH_\ ")_$SQ5XG.D7
M]UXMMG46VJZUPUO_ ,%E?VOOVB/^"/?[>?A;XF?$3Q7\-OVP?V3/&W[-]C:_
M&CX8:U>_"'XA^)?!WCGXV:)X2U>'4CX"O=#FTOQ7X;U'P_K?AWQEJ7AQ-"T;
M6]#\5:#I]QI ODUJ]U=\WDU=-KSM_7_!%[-]))V:C*U]&W;JM=3^\.BOX.W^
M'O\ P5T_:#_X)1Z/_P %/;W_ (*9_&KP!#\'OA))/X"^ GPUUOXJZ)>^,_AI
M\&->N? /B?XD?%7XDZ!\1K74_$GQ3\4RZ#XN\=:]K'B_PWXZ&J:?Y"7_ (E\
M.Z%J']B>$/U%_9[\9_\ !07_ (*X?\$0/A[?_!_]I"7X4_MEGXLZKH'BGXZR
M^,O%GP(&NZ-\/?'^NNZ+KOP%\-W^L6DNI>"-1\,:3J%O8^&]/LM:U73;^XU*
M)/-%W<BE?H]KKS7]?Y]0=.WVD[2Y96O[K\]%IW\]#^G^ODS]L;]KC0/V+/A-
MJGQO\<_"+XU_$KX;>%[*_P!4\>ZY\&=$\#>);GX?:-8O81C6_$VA^)_B%X*U
MV?2+AKZ1WO\ PQIOB.#2+;3M0O\ Q&VBV$=O=7/:_LJ> ?BE\*_V:/@+\-?C
MAXT_X6/\8_ ?PE\!^$_BAX__ .$C\1>,/^$S\=Z%X<T_3O$_B7_A*O%UGIWB
MGQ%_;.KV]U?_ -L^(;"SUC4?/^U:A;0W,DB+X#_P56_Y1H_MZ?\ 9I?QX_\
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MTW3+.[U&_DM;*5;.PM;F\N#';P2R+^"_["7_  41_P""IG["_P"Q#\)/V/?
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MZ)J*$K6UV37Y?Y YW4M+.33;\UY>=VWYL****9 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
M_$W_ ,%RO@_^UM8?\%E?V4/VM/@;^QS^T9^TMX.^ 7@W]F3XAW(^%'PH^)GB
M3PSX@UWX2?'CQW\0;WP%/X\\(>!?&>E^']7O[2VTZWNI9+#5;S1;;6++4Y=%
MO8I(+>Y_MDHI-7_#\'<J,N5WM?1JWJ?Q-?MN?MH_\%F/^"H_PHUW]C3X;_\
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M0TOPQX%:WM?B'K/A#P#K^G_"R2.SU;PW':_$'PTVNZO8W6IGPMJ-I>_V1?\
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M6CP7B6Z,?[OZ*GD6E^]]++MT^13JRZ);63=V]T[W>^W4_AN_8J_;Q_X*A_\
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M(=+T2#5;:%?Z\:*7+^GSU3N_/3^NM>T_N[-O?NK6\DELEL?SK?%S2O'>J_\
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MK;1[#5)6(3WG]DC]M?X%_MMZ)\5O$OP%U#Q3JF@?"'XJW/P=\2WOBWP9XD\
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M^/7^,W_"\_!R6WC/7K>]\7:KX)T#PE\+M:\-ZA8:!(=.N?'MEJVC^((O(?\
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M]D#Q+\*OC'J/C3]J3Q5>^&? 7Q!@T#1=-^$J/HNG:5J7B5E\2ZGKT&LZW?\
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M#PMX?L;33/#^D+I^@6E_<Z]X@CTQ?$/BGQ/JNKWKT,U;JF_).WW^7]:'SO\
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M71K?1_#)U:\\0VC;U2[W_(E*]_)+K:UVE^I^TU%?RJ? _P#X*@?\%:_VD?\
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M.]1^)7P^\/6MM!900_"'6XYKV2W_ $"_:M_;5\9?#[]JW]E[]A'X"Z-X'O\
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M"\9?^_IU_3'0KZWUL_T0227+96O&[WWNU^@45^(7[.G[;/[:3_\ !4GXG_\
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ME2@U)J.JNTM=597U^6OH?M!17XK?%+]N']I_]@_]JC]F?X2?MDW_ ,'/C;\
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MV?M8_;<^'O\ P3H_X+'1?LW? C]J7X7_ +4_Q*_;D^/?[1_P)TSQO^S?\7_
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M9N- ^*'QC_;F_;)_X*C_  R^$WBA/!G[-O\ P3Q\1_LW?LCKX^^&?BO3;_\
M:7^+EHGC+XT:OXX\)?#[7++PU\1[WP3HVK:M%\)]-O8=$L;7XIKKEQ+X \1Z
ME8VE\$]RN?V.?VUI/^"MEA_P4)MK;]F*V^%\'P)?]EO4/ATWQ8^*4_CK4/AB
MWCJ]\7)\04U1OV?TT*R\:I=S66K'P,AFT5Q9/X5/CX1W;^+HOVBHM=N_>_W)
M6?\ 7^:!M*W7W4M_.[5OPU[]T?Q_/\ /A]#^U!^P_P#M4?\ !*?X6?M!_LC_
M +5OQ,^,WP]\.?MH_LMW'P6^,'PV^#GA+X$:I8MXI^.NK?&/PKXT\*^'/ GA
MCPGX?N[+2/#6C6GA7Q#9>"OB%K+Z;JOP<TZ7XD:!#XAMO7/ WQS^/?\ P1J_
M;A_;A^'OQ*_9-_:G_:/_ &1/VQ?V@]8_:F^!'Q)_9K^&<7Q'U31OB;\79&N_
M&W@:_P!,;5M/LKR_DN8[#PC_ &=K7C'1O%MM!\.-.\4:;X5US2?'T-_8_P!4
MM%'+U3L_+;975K];>OGH'/T:NK6U>N]UKOILO+0_EF_;Z\,_\%!/'>K?L!?\
M%5]"^!'Q,N+C]F+]I/QYXUO?V,_#?A^'5?VA_ _[)WQ4T_X4^%I+36=!T.6_
M35_B3XIT'X<^,]<^)>B6#ZEJO@$?&CPYX2N[>XTGX5>*O$(Y/]MW]J8_M5?M
M]_\ !&'XX? []F7]M'Q?\-?@[\1OC7XE\7ZY-^R[\3?#UR\7C*R^"EMJ-GHN
MC^(],TK5=6B\ 0Z4M_XU\46]H/ *6M]&GA;Q=XHO=,\0V>B_UBT46\^J;]5;
M[KVV^X%.UM%=)I=-'^=KNWKK<I0L=2TV)[JSO-/:_LHVN+"YFABU"Q-U #-9
MSW&EWES!'>6QD:&6;3K^XA2=&>TO)4$<S?S3?\$J]?U3_@DEHW[1G[!/[5/@
M?]H*'P_X8_:(\6^.?V7/C'X2_9]^-GQ@\#_'/X7^-M!TU])T?PO?_!GP1\1+
M'3?']HOA&X\0:]X&N9;._@UCQ9<:/9Q7VI:;J#O_ $S44VM4T[6O^/W"3LFK
M73MY.ZV_4_CC^-G['/QM\$_\$6/V]8+GX!?&;4?VG?\ @I?^U7:?M/>&O@#\
M._A!\3OBE\0/AQX1UG]H/X3?$CP]\-OB0OP^\(:Y9^$]?\(^ _#OB?Q-KD_B
MF+PO;6NM:U<^"U63Q-IYTU_ZC/V/_$<GB?\ 9=^ -]=>%O'G@C5+3X0_#C1]
M=\(?$SP)XN^''C3PWK^D>#=$L=:T/6_"WC71M#UFVNM*U&&XL);J.TFTN]EM
MY)]+O[ZS:.Y?Z0HH2M]UON_X=_A:U@<KJSWNW?U25K=K)!1113)"BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *_-S_@J_\ L#Z?_P %'/V,/'W[/D.H:?H?Q"LM0TWXD?!;Q'K$UY#H
MNA_%CPE::I;:$=<>QANIX]"\1:-K7B'P7K=XFGZI/I&D^)[S6['2[_4M-LK=
M_P!(Z*&KZ,:;336Z=S\4_P!CG_@I%J/@'X)> O@__P % /@Q^T_\ /VFOA;I
MVF?"/Q??:M^S5\>/B7\/_C9XD\'6;:%%X]^$GQ/^$?P_\?>$/',7CF#2H]5^
MQ6>I6][?^([S4['PG:^(]'@L=9O?JGQ'8>/_ -O3X1_M+_#K4?#GBOX(_LX_
M&7X!^.?@E\/]6^('@K7?"7QE\9ZS\3O"NJZ#XB^+&H?#OQ-+H/BSX=>"_!]M
MJ$&B^$O!?C[0O#WC3QOJ3>*-9\0:+H?A.'P==>)_T#HI?/\ S^;_ *_S&U>Z
M5GOOHO1?YMG\TO\ P3U_:A\:_L8?\$^[[]B7]I?]GC]IO_AK?]G#0?CAX!\"
M_#/PM^S]\<_B+I'[1^F6VM^(M>^'UU\(OB=X&^'?C'X>ZCX8U%/%>C>!CKE_
MKUII?AZWTU_$.KQ:=X847$7Q)^U/^PK\9OV4/^"3/_!-/]DOP_\ !KXS?''X
M[_#+]MGX;_M3?'+1OV?O@E\5/BU9Z1ILEO\ '#5_&"S^)?!7A?6_!XU#P7_P
MF'A#X?P6MSX@L+[Q')IT6O:5I[Z/-->6_P#9K12Y?/:R6G9I_-Z+R\BU.SNE
MO+F:OHWK]RNV[:G\WG_!6RV\:_%G]LS_ ((S_$+X9?!3]I7QYX*^"7[2<_Q6
M^+GB+PM^R[^T3K-E\// VI^*?@I=VFI^*4L_AA+=:9?FV\,Z]/=>');?_A)M
M.CTV5M2T>T\VV$_=?M+S>+=<_P""Y7_!/#XLZ#\&/VD-=^$_PK^"_P =_!GQ
M'^*6D?LT?'R^^'?@[Q#\2/!/C>V\'VFJ^,(?AT=$EBU"^N].L+Z]TV\O[+0+
MK4K;_A(9]*@CO9K3^@FBG;?S:?W6_P A*=DE;:,H_P#@77Y7/YL_^"<?Q57]
M@?XB?\%'/A5^T[\)_P!H_P (>./B]^WW^T#^T#\%--\*?LU?'+XLZ;\:OASX
MQAT>XT.Z^&/B?X3^!/&GA7Q'K$L.F*]YHIUNTO=,^W6ZZBMLUGK:Z1D0?LM_
M%SX _P#!*3_@IOXJ^('PC^(VL_M/?\%*/&'[4'QID^ WP>^&_BKXR>-?AYKW
M[1EAJ6G?#SX1ZH_PUT/79]2/@^"_EUGQ?XGN+;2O#6@:AK>MZ5;M*^GPW>M_
MTQT4)6MY*R]-/\A<W6V[3?R[=OQ_._\ (I^VYX=^*WQ&_P""4W_!&[X,^#/V
M;_VM->^*'P-^*G[#VO\ Q?\ !5C^R9^T=-KGP]T?X#? ?Q/\//B5?>)+1/AD
MS6J:7XFU2SM]-BC,USX@M)&U#1(;ZTBDE7Z]_P""H+^-?&W_  45_P"",GQ2
M^'_P-_:9^(7@#X%?%'XL^)OC#XH\$_LR?'O7])^'7AWXKVOP+LO"NJ^);NU^
M'GDVGDII.MWOB+28WF\0>&K;1=3AUG2+34H8["7^BZBDE96OU3^ZW^17/MIM
MS=?YM'TZ=#^4[_A(?C5XP_:@_P""D7AC]KK]A3]JG]IKXY:IX[\=^$O^">>O
MP? ^/Q9^SQ\.O@C=>'_%6D?#C7/AEX[\?_\ "/?"#X)Z]/;R:)K7Q2^*7_"1
M6'B[Q1J,MMH9^U>+]"N/#%YYAX:^#'[1OQ4_X->?'7[+^F_LR_'OPS\9_ .A
M:+:6W@'QM\.M7\.>-_'LOAK]K_2OC=K]QX!\!W2MXTUS3;7P'%'<:9=2Z%97
M'B35Q?Z3X?L=0GT]GF_L HHY?/HUKYVU??;[K=M5S[:+1QEUWCV[)]O7Y?RT
M_P#!2#QM\5OVG_\ @AOIWPG^'W[(O[81^)_C#3/V;? OACX<O^S=\6M4\=W=
M[\++SX9>*OB'XEUOPOH?A/4M2\%^!]+N=#UGPWX;\0>,X]!N/'6IZ;+J?A?2
M;[PM>Z+X@U7VG]MKP5\1_A[_ ,%(/V _^"NGPU^&7QX^)/P2LOAGK_[-_P"T
MGX \+_";XCS?%CX;> _$:_$&;PI\0]3^#4NC1_%*XT?2=<^)&J:OXST>'P8T
MVC+X"T>XM[*]U#Q58SC^BVBG;SZ+[T[I_P":_(%.VB6GO=>DDDUWV2U[^6A^
M"?BGP_IG_!07_@I9^QQ^U1X \'_$E/V8?V"/A-\5OB1K/Q0\<?!OXP_#V/XL
M_%#XR:;-H?@[X<_"OPGX_P# 7A+QCXSU#X<0^$[;XB>)==\+Z5X@TB"]O=&\
M%!4\37KV5>??\$>I/%_PF^+W_!77QQ\4_@G^TQ\.O#WQ?_;B^*GQZ^&,WC']
MES]H?1+SQS\,/$OC7Q9/H^M^%].NOAFM]K>HW4.MZ=.?"VFP7/BJ&VEEO)]%
MCLK2[N(/Z+:*$M;WOO\ C;\K!SZ.-M+);[)2YG\VS^.__@G*WCK]GW_@DK\-
M_@#^TW^P/^T#X^\)Z[^VYJ?@+]ISX(?$?]D7XTZWXB_X4'\1?"OB;Q;:_&+P
M3X2F\(Q:CK]I\/\ QGHGA'6[K6?#UAK&NZ+=>']0L-)TVS\4:CX/U*7Z]_X)
M>_L[S_LX_P#!0_XS>&/V%O$7QKNO^"7'BKX"6?Q%\5^%OBSX:^).F^ / ?[4
MWB3Q=#::9X!^#U_\4]'\->*-0\3:'\/]*M;SQQ?1P^(=1T;2KNU\$?%S5+WQ
MIHG@]]$_I3HI6VN]K6Z-6W^3!SOS:6YM]=.FMNZMH]#S#XU>+[7P)\)_B%XK
MO-"\:>)HM(\):[,GA[X=^"/%7Q&\:ZU</IUQ#:Z9X=\&^"]*UKQ%K>I7MS)%
M;V]O9:?(D;2>?=S6MG'/<Q?R(#X>_&X_\&OQ_8S_ .&8OVMA^TZ-=_L ?!X_
MLH_M#?\ "5M/_P -U#X[?VB(1\-S;?V%_P *W)U;^VVN1IWVX'1//_M;%H?[
M/J*;5_N:^^W^0HRY>E_>C+?K&]NGF[G\N_\ P5QTOXD?%#_@G[_P32\+_"O]
MG_\ :B^)GC3X:?M'?LI_%GQQX'\&?LO?'W4_%WAGP;\*_A1\2_"_C2XU_1IO
MAY:3>'M4T_Q!?6&FVVA^('TK5M1%]9ZC8VD^CW$>HG^FRW\0V%SX<C\51V^N
M+IDNC_VXMK<>&/$MIXD%E]D-]Y$G@ZZTF'Q=%K'DC9_PCLNAIX@^V8T_^S/M
MY%L=RBBV_G_E8&[I*VB;?WV_R/YD_P!B_P#X3&V_X+A_\%(OB/XU_9M_:>TC
MX"_M/>!_A]X)^'/Q0\=?LH_'_1/AGXLU?P3HGPV\'ZWH>KZCXB^&-OIND:'K
M36WB2XM?$'BTZ1X2N]'T2YGN-3$&I::+OH_V;?!7QN_X(Y_MH?$']G'0_A!\
M??C'_P $N_VD;O7/C!\&?%/PA^$?Q5^/]_\ LA_$F4)_PE/P[\5:3\,/"7C/
MQQ:>"]:G2ST_2%N=.U;[99_\(IXBTZZO-=A^,E^/Z2:*+>?5OY/=>=_P'S;Z
M:-)-7_E5D[]&ONWTLS\\_P!E2&]^+W[37[7O[5VJZ+K^F:)-J?P__90^!T?B
MWP?KG@W6V^%_P,TJ^\7_ !!\21Z/XHL-+\0:<?%?[0?Q6^)7A;4HK_3;"XO+
M+X1^%7NH UG D/Y/>/\ 6_' _P"#ASX2?M'V/[.W[6FJ?L^:3^R-=_ CQ)\8
M[']DK]I.;P5H/CJ];XD^)[2.2\B^%<EUJ.DR2ZQX>T*?7--M+G1['5-8)O;^
MWL]+U6YM/Z;:*&K_ 'I_<[B4M7INN7MI9+[]/FS^<7QK\'OC=_P2D_X*+W/[
M1/[-'P:^+7QF_8*_;M\0^7^U3\&?@C\/?%_Q7\1_L^_&U9+J^'QS\+> / ^A
MZ]XJMO"&K"\U+5M6M]"LK[3Y$O/%OA::QM[RW^"FCP?T)>"_%^D^/?"VC>,-
M#M/%%CI.NVIO+&T\:>"/&GPW\4P1+-+ 4UGP/\1- \+>-?#EUOA=A8^(?#^E
MWK0F*Y6W-O/!+)U%%"5MO^&]!-WM?=:7[I;7\UM?MOKJ?RU_M-^(/'%K_P '
M"O[*W[5=E^SA^V#XD_9S^#7[+>O?!GXB_%CP=^QQ^U+XO\/Z-XQU:P_:7NK=
M--M_#OPAU+5_%VG1W/Q*\'65QJG@S3_$&FH^I3O'=RG3-3BM/U7^+7[=/B#Q
MO=_#?X0_LL_!7]L6Y^(?Q;^)?@3P;JGQ7\8_L1?M(?";X:_ GX=W7BO1YOBG
M\3?%OBC]H_X0_#_PB=4T+X:P^+)OA_IAL_%-EJWQ!'AK3=:TB?3+J>WN/T]H
MHMOKN[_E_E_75N2=KKX59:Z=7JK=WW/P4_X+L_"3QEX4^&_P&_X*/? %].T_
M]IW]@CXO>#]?\*P7,LMJ/BG\.?BKXL\/_#CQ;\&+Y;*ZTR^UQ?%VK^(-!LK3
M18M3CO\ 4-#U/QQX6\-1-K_C:!9?8OB9\ ?$?[-__!%WXU?L[3Z5X_\ BM\;
MO&/[(?[0/AKQ;_PKSP5X_P#C%XO^*/[4_P"T%\/?B#KWQ!UF#3_ WAGQ!XDN
M;3QK\:_&VOSVVNZIIUMI&B:;J&G1ZQJ>GV-LDJ;7@[]BK]LWXH_M"WWC#]NK
M]J+P!\9/V;OA;^T/??'C]F3X"_#CX8V/@B>RUSP[>Z@WP5O/BUXLMM/TG4=;
MT[X3P:I/KFF^!IIO%XU;XAZ;X6\8ZSX^U&#PU%H-]^M]"6K=K?UKLVNWW#;L
MHJZ=G>Z^32O:^FOS;/Y/?&WAGXK>(?\ @V@LOV9;']G7]J=/VB+?X8_#_P"&
M#_!:Y_9>^/B?$,^*/#'QX\-^(M0==!A^'LTIT"3PQI-SXBM?$Q==">Q:&RFO
M[?76DTB/?_X*2:%\3/B'_P $1/V/_@;\/?V?OVH_'/QET;0_V/[;6OACX9_9
M:_:$O_&&@W7P=\):'9_$"W\1Z8_PV@'AEM(OM-N;.TE\13:5;Z[+Y<FA3:E:
MR+<5_5'12Y?/[/+\@Y]M-IN:U]-/30_F(^)O[2/@7X3_ /!Q%X'^)OBG0/BL
M_@/QE_P2\T[P]?ZWI'P?^)>IZC\.K35OCAX@U6R\6_%#P3;^&#\0? _@U-1T
M2S\,ZOKVL>%(H/#.L^)= N/$Z:-H$FI:UIOU+\*?#ES\;/\ @J)\:_\ @IQJ
MGP[^)?A[]G3X#?LD^%OV3_@CKNH?![XC7/C3X\^(M5\;:I\3OB%\5/AS\+X?
M"<GQ?O\ PKX.A\2W'PYTG5]/\!75E\0H]3NM6\%ZMJ^B:3JZQ]A<_L<_MK2?
M\%;+#_@H3;6W[,5M\+X/@2_[+>H?#IOBQ\4I_'6H?#%O'5[XN3X@IJC?L_IH
M5EXU2[FLM6/@9#-HKBR?PJ?'PCNW\71?M%1:[=^]_N2L_P"O\T#:276\4M]N
M^G?IKWVNC^2__@G5X!^+GPN_X-]OVO/V=_B#^S_^TUX3^.>O_#G]L+P?H'PJ
MU?\ 9D^/UOXV\0:]\8/AGXHTGX>V^@:)_P *X:ZURTUO49(K2XU?2EN](T&:
M:WC\17VDM<VXE\KO?V9_VE(_V /^",/[6/P_^ G[1%Q\:/\ @EY\2L?&C]F'
M6/A5XZ\#_&+Q)\-=9\<^'I_B+<^#/!?BK3]%UOQ1?-I_@/0X-(M_#.GZG#X@
M\,>-]1O[Z8'PQ?:3%_9)11RZ)7V5E^&OWH?M-6[*[E??NK-?-/<_GX_:Y'A[
M_@K1\6?V OA?\$?!7Q7N_A3\$OVF]-_:K_:*^)_Q.^!GQK^#OA+P;X<^"L+:
M3#\%&F^+'P]\$1^(_B7\4M<\476AIX>\+ZEJ.H^$M,\/:OXEUZR72/L5S+R_
M[)LOC/0?^"['_!2;XR:Y\#OVFM#^#7QS^$_P+T'X8?%S7/V8?C]H7P]\2Z_\
M*_AC\)?#GBW1XO$&L?#JQBM9TU71M?AT>^O(H-&UY="NWTG4[L7NB#5OZ+Z*
M=M;WZW_"VU^WX^EB>;1JVEK+7:[3;VWNE\D?S>?\$DK;QK\)_P!LG_@LO\1?
MB;\%/VE? 7@KXW?M+)\4_A'K_BO]EW]HG1K7XA>!M(\5?&JYN]6\+QWGPPCN
MM3O'MO$^@W%CX=B@_P"$FU.'48VT[1KKRKD0?+/[*$/[<WPB_P""1'_!331/
MV>?@C^TG\,OVM=5_:N^,'Q2^$6B>,/V?_BOX#\<Z_P#"WXD>(/@_:ZKXO^%E
MAXV\%Z2VO>+_ /A (/'S>'-'T?SO&^D^)-'BN;31$U)-$%__ %TT4E&R2OLF
MOOMJ/GNVVEKRZ=/=MH^][:G\8GQ;LX]<_P"'3_Q0_9Q_X)F?MN>';#X'?M;?
M!3X@?M2?$#Q'^S;=VOQL^)OCBST32;_7M1\5W^K3V'Q<^./B2VGTGQ9>^)_C
M7XNTFR^',>IRV^G6_C6._P!5.CZ;ZA^W)\-_@5^USH/[3_Q1^)O[.W[2'[)_
M_!4#]GSXG_%W_AE3XM? WX&?';2/%G[1-S\,];NX/V<(?#/C/P!X8\0>"OBU
MKFI+!X0\"ZAXETO7T\=>&Y?"LWCOPGK?AGX7P*Q_KKHHM]SW5M-K:=5LK=OR
M.>S32M;9W=^F][W[-=OQ^>/V2$^.L?[+W[/J_M.SVUQ^T,/@_P##\_&:6V@T
M^V)^(I\-:<WB=+V/1YI]$.L1:F9XM<GT%H_#]SK*7]SH-K9:1+96<'T/115$
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <
MEXZ\2ZIX/\)ZUXET7P+XM^)>IZ3!%/;>!_ LW@ZW\6:_ONK>":'1I/'_ (M\
M"^$O/M+>:74)8]6\5Z3YUK9W$-@UYJ<EGI]W^//P^_X+F?!7XK3?%*'X<?L:
M_P#!1GQP?@CXDO\ P?\ %T^$/V;=!\4R?#[Q/I-_)INKZ#K]GX=^*>J:A_;6
ME3P74E]H^GV=_JL5I97MZMD]K:7$L?[9U_&W_P $Y_\ @H)\$/V /$'_  6<
M^(_QO\-_'#5O#=I_P4-^*FI3ZE\,?@MX[\;>'+$W'COQ;H.E:;K_ ,1H=,L?
MA3X/UG7]>U"PT?0M)\9>//#]_J5W>V\D$!LV-TJ;LUK9:_A;^OZNK@DU+2[5
MK)-J]VD?U,?LP_M:_L[?MD_#:U^*_P"S=\4O#GQ-\(RRBSU/^RII;3Q#X4U@
M*S2>'O&_A+4XK+Q-X,\01(OG?V/XDTK3;RXLGM]3LX[G2[RSO;CZ,K^>W_@A
M%^Q[\:?A-??MI?MK_&;0/#'PU;_@H=\5-)^-OPX^#7@[QCX?\=Z3X*^&FHZ_
M\3?B+X8U*;Q3X,O+SP?JT.NV?Q>CM_#4>DR.]AX<T>VO+L6-UKUSHNE>B?$G
M_@IGX@^*/Q7_ &G_ (7?L[_M/_L'_LNP_LK>.M9^$(\0?MB^((]6U?X]?&_P
MQIFE7_BOPIH_@^V^+OP=UOX4?"KP/K\UUX!\2_$]].^*U_XKUR35)O!N@:<G
M@Z[&OI/1-[OIW_K_ (&X./O-1U2M=[VO;JM[-VT]=C]HO'OCKPA\+_!'B_XD
M?$'Q!IWA/P+X"\-:WXP\8^)]7E,&E^'_  SX<TZXU;6]8OY55W6UT_3K2XNI
MO+CDE9(RL4<DC*C?G9X4_P""H?A#7/BI^RY\/_$?[+_[5?P_\)?MHZ3::M^S
MC\9M>\*?#3Q'\./%:7WA75?'.G6WBIOAI\5/'7B;X=WNL^#;&S\3Z5IGBKP_
M::S::'J$VH^,-+\(6_A[Q0^C?BM^V#_P4"^-?_!0S_@@Q\?/C]X7T_P%\#;G
MP;)+\'/VN/AAKG@_Q9XMUOQ!XDC^(7P3CT6_^ WC^W^(/A;3O"?@[7M%\7+K
M.L2^+_!'Q/-U;:Q?>!M)U5;SPK<>-_$'V+^T#^TQ_P %"?\ @GM_P2AT_P#:
M-T*;]BKXD:1\-OA)^SE:^%[&S^&'QF^&$G@+P;XHN/AW\,M$TH^#A\6OB-I?
MQ0USS_&NB3'4K?QA\%M"\*VGAN^EB\+^-%U^VTGP\7^223O:][O[]D_Q[*[4
M+*S^)R<;-VLTEUVW:?9K;5G]$=%?SS:Y^V3_ ,%KO"'PI3X\6W['?P-^+W@C
MXN?"GX10_ +X=?"\_$#Q5\8O!/Q*^).LZ(EKXW_:)T[2M2L],'@O2?"-UK7B
M/XB:/\/X?[(\-ZE?^"-$M_'FFZ-IOCSQC'[9\/\ ]M[]HWX2?\%.?AI_P3J_
M:%\?_ 3]H6P^-7P5\:?$SPO\3O@Y\.M1^#WC;X<>.O"Y\2>)K[P+\2OA]J/Q
MQ^,$$?A:7P7X<GG\*:NCZ5KM_+J>DI=_VREEK&KL[^OS36^BW_KN3RNU]'HW
MH^B2;^Z_SZ7/VMJM>7EGIUG=ZAJ%U;6%A86T]Y?7UY/%:V=G9VL3SW-U=W,[
MI#;VUO"CS3SS.D4,2/)(ZHI(_)ZU_:B_:?\ VPOC/^UA\*OV)_%/P9^$/@K]
MCGQU;?"+Q%\8?B]\,_%WQD3XS_'RTT>TUWQ;\,O#>AZ)\0?A/:_#3PM\,-1C
M/@WXC>*+Y_B/KVNW6NPW7A#2/#T.E0:IK?YN_P#!1S]IG]N[XJ?\$&_C=\9_
MBG\/[_\ 8A^,.C:AI'PL_:!^&>H^$-3N]3^*'@_Q+\6/ /PDUBX^%/B"X\>6
MNI?#?P'XXA\:7DNH2>)M#\>ZAKWARRUWPGI-W)H6M:9\0]2&]].EUYV_K_*X
M*+;2NE=I>G-MI_EMUL?T_P"F:GINM:;I^LZ-J%CJVD:M8VFIZ5JNF7<%_INI
MZ;?P1W5CJ&GWUK)+:WMC>VLL5S:7=M+)!<021S0R/&ZL;M?B#KG[9/QM_8V_
M9G_8,^&VOW?P9^/'[17[8_C/X(_ K]G71O#O@;QI\#O!G@;POX@\!>%8=1\=
M?%*QU/XJ_'3Q!X\TWX5S7NFWOC"_\(ZAX%D\31>(-(TW2] \,O'<:K)J_%+]
MN']I_P#8/_:H_9G^$G[9-_\ !SXV_ +]LKQG!\*?AM\:_@G\-/%?P7\7?"/X
MUW^M:;86?A?XB?#SQ5\5OB_I7B'X;ZW_ ,)+H,?ASQ1HOC&S\1Z-:V/B:?Q/
M9:JVD65UKQ=?=OY7MI^/3YARORU3:\[;VOV_'I<_:FBOYLKS_@H#_P %;_B9
M^W;^VQ^PU\#?A%^QK;_$#]GKX<>!/%_AC5_$'B+XFZG\.O#]CXX\)>%/'%M_
MPD/C"ZMO#7B3Q_\ $#5+/QIH7AKPEIUGX!^&W@FSU&#Q'K/BFXFTS1;)-<]N
M_9%_;G_;XU7_ (*.^*/V"OVZXOV3/AOKVD? 7P[\=/ 5O\'OAA\5H'^..E:U
MI=O!XCLO ?C[QS^T'K%CIL_PW\5S:KIFIVS_  X\377BZU\#>.[K3QX=T_1U
MUERZ\_N:ZVZV_KSL'*U?5:).U[NS2?3U_7;4_=^BOSK_ &4_CO\ M+?'+]IW
M]M'2=?USX$ZG^RE^SU\7)?@;\,-8\&_"_P ?>'OB?XR^(UAX8\*>+?B!IWB'
MQ3KGQL\4^%Y=/^"UWXD7X7Z]J6C_  \L8OB#XXM==U'3E\"6_A6Y\/:O\X?\
M%^_VHO%7[+?_  30^+^I?#^\OM-^(7QLU?PY^SMX/U73/M/]H:9+\3/[1;Q;
M<Z<]FOVJWU:3X<:%XULM#OK6>TN],UV[TW4K.<W=I!;SEU:_3^OZ7<%%N2CU
M=OE>WY7U['OGQ-_X*<_"[P'\-_B;\=O"?P4_:,^./[.?P<;Q9:_$+X]?"/PC
MX(E\"6NH>!M4N-*\8OX.M/B)\1?AWXN^*?A/PE<V&IQ^(_B;\,?#?BWX8VES
M8W=EIWB_5KK1_%4?AOP7PS_P7*_9FU7X?>#/C9XS^ 7[;WP@_9R\<SVT6F?M
M+?$G]G*Z'P.TZ&_O+73=+U/7_%?@7Q7XYOM(T/5]5O;;2M+UZ?1#H]YJ+R6T
M5Z6M;LV_JG[<_P )O"WP%_X(V?M/?!'P1;-:>$/A%^P-\1?AMX;ADD\Z?^QO
M!?P8O_#UA+=W!2-[N^N+?3TN+Z]E03WMY+/=SDS32,?P;\&_M\^!X/\ @BY^
MS3_P3L\"?![XL_$']J/]L;]FKQ#^S=\$M#\:_#_4_@W\(_$OBKQH=0\,ZMK_
M (?^,WQMA\"_#[Q>O@J+Q5I^H:#=^!-4\466K^/)O"?AFVU.PN-5;5-.3OWM
MI?:^J:^;OTZZ^EJC%26D6_>M>]K*UVWTOU[>I_89X.\9^#_B)X6T+QQX \5>
M'/''@OQ1IUOK'AKQ=X0UO3/$GACQ#I-VN^UU/1->T:YO-+U73[A?F@O+&ZGM
MY0"4D;!KY5_: _;'MO@?\4]#^%&@_!'XM?'KQ(_P:\?_ !Y\<Z5\&CX#O/$G
M@'X=>#/$/A3PII6J7>@>.O&?@:/Q#>>-]>\0:S:^&-#\/ZM=^(M2B\#>+IM.
MT?46TQX:X3_@E5^R1XQ_89_8'_9]_9E^(>O:?XA\=^ M&\5:GXON]&N+BZT*
MP\0_$#Q]XJ^(NI>']$GN0K7&G>&KCQ6V@I?QPVT.L3Z?<:U':6HU$P1\U^S"
M9/BQXO\ V]OVM+IIY]-^(GQ UW]F_P"$5Q+<6US;CX)?L<VWB[X:W%QIKP!@
MMGXA_:5UK]I?Q1:7"R,FI:#JWARY!DBC@D+[7T?]7)LDY=4M%TOK9?AKH?-_
MPY_X+R_LW?%#X77?QY\,_LP_M^S_ +/VCZE=V'BKXZVW[-MMXC^&G@ZWTI)I
M?$&M^(M1\$^/O%.L)H/A:WMY;CQ/J6EZ'JD>AQ"(7R12W-M'-^HG@W]HWX;?
M%_X(1?'W]G35K']I#P5J&DMK'AV+X2Z]X8OM1\4?9C"^H^']+D\0ZUX>T?3?
M&=A"\UO<^%O%VK>&+_3];@.@Z^VAWPG%O_(G_P $F?\ @I]\%OV$O^"/VBZ)
MX\^&WQ9\<^,_&7QB^+O@SX>:7)\,/$OA[X(>-/B%XTD<>$_ _B']H3QUIF@_
M!'3+&_%G=W?C3[/XNUS4_"GA:SUC5-3T&62T73[G]N_^"#'[ ?QB_P"">?[$
M=[\-/CW-I]G\4_B;\6_$?QD\1>#-)U>TUVP^'B:UX4\$>#M.\)7&L:5>7V@Z
MOKL5CX(AU77=2T&YN=*^UZHFDVE_JEOH\.IWB3;MUTN_)Z?GKIO\BYQ4;O:T
MK*[OS=7INK:7>SO;1GZN?"'XT?#'X\>$/^$X^%/BNT\5:#!K&K>&M706>IZ+
MK_A7Q;X?N/L?B/P3XY\(^(;'2?%G@/QWX9O?]!\3>"/&6B:'XK\.WO\ HFLZ
M/8W'[NJOQL^*6H?!KP!JOQ L/A-\4?C+%H8EN=5\)_!^U\#ZCXTM]'M;"^O[
M[6[72/'7CKP!:ZU;V2V26S:3X?U+5O%5[=7UG'I/A[4(Q=RVGX\>"_B+#^S=
M_P %^_BU^SU:7HL_ O[?/['_ ($_:.30$2X%A;_'_P"$>J>+_AY=W^D6D?E:
M9IMWXI^%?PZ\1ZOXUO8K>2_\0:CH_AJYU&]DDM88E_;WQE_R*'BK_L6]<_\
M37=4U^6C_KS6I#5FNJ:37SZ=-G=76Y^1'P,_X+9_!O\ :/\ !,OQ0^#O['O_
M  43\=?"ZWO[W2[CXA^%/V9;7QEX>&I:?%=O=V-C;^"/B%XF\1:]=VL]J+*^
M@\-Z%K,FEW=W8KJRV$-W#,WVM^RE^W[^R)^VS;^(1^S=\:= \<Z_X.GN+;QG
MX!U#3]?\$?$_P?-9S6MI>R>(_AIX[TGPWXXT_3+74KN/2&\0'0I/#=SJ\=SI
MMCK%W=VMQ%'^5'_!L!_RBJ\)?]EL^,G_ *>-.KY3_P""KNCK^R+_ ,%MO^"3
MW[4_P1:/PUXY_:I^(5K\!OC?HGA^ (?B#X6A^(/PN^'6L7WB+2;26W37=8U_
MP7\81HVF7.I+,B:M\/\ PAJ<*-J/ARUFB5W9/>]K_.RT^9;C'FE%735^5WO>
MRO9KTOJFK=F?JWXR_P""OOPR\#_M;:3^P[JW[*G[9MU^TIXEL+K7/"/@;2_!
M7P1N[+Q=X5MK+7]2_P"$QT'Q:_Q_@\)R>%I=.\+Z]='5K_6=/2S?2[[3M4CL
M-8M+G3HOUBT^YFO+"RO+G3[O2;BZM+:YGTO4'L)+_39IX4EET^]DTN]U+3)+
MNS=FMKE].U'4+!YHW:SO;JW,<\G\T_[1O_*TK^P/_P!F!>,O_?TZ_ICIJ^M]
M;/\ 1$227+96O&[WWNU^A^1?BO\ X+ ?#SP;^T];?L;ZO^Q]^W)/^T;?^'E\
M8:9\.]"^'?P6\1OJO@U_MFWQ?I_B30OV@-0\)3^& VGWT,^M'74L;*\M+G3[
M^6UU"WFM8_7?A+_P5#_9E^)'QHT[]F[QG:?%S]F;]H/7H3-X2^$7[4WPPUOX
M.>(?'BK<_9'B^'NNZC)J/@'QW=&Y*1V5EX4\8ZM>:RK//H,&J6UI?S6OY4?'
M#Q5=^#?^#F3X0ZW9>#?%_CR>+_@G->P_\(_X(M]#NM>E2;Q?\5P]U#!X@U[P
MYI[V]L%W3C^TA<$,H@@G8[1\K_\ !1']I/PC^W[_ ,%/O^"7_P"SA?\ AGXE
M?L6V7P0^,$'QHO/B'^V#X$US]GSQ/\39+GQE\.+_ $GP9\!+O4-.U/5H]9UV
M3X?:SX>\,ZGK=WX:T'Q3\2'TG1K.6;6/#^C1:TKM=5>Z23ZWM^.N_P"&UK44
M[65O=<FT[VM?IYVMKKV/ZOOCA\=?A!^S9\,/%7QF^.WQ!\.?#'X9>"["34/$
M/BSQ-=M;V=NBJWV>PT^TMX[C4]=U[5)@MEH7AK0;'4_$7B'5)K;2="TO4=3N
MK:TE^-/#W_!2+3?$GAO4_B;:_L8_MXV/P'TNW74V^-VK?!#PWI^F7_AQU:X3
MQ?HWP:F^)7_#4VN^%)].,6K6VJ:'\ M2EDTJ1K^6RM[5%ED_)O\ X*::U=_M
M)?\ !=?_ ()2?L*>,;JY7X)^#-)O_P!K36?#<TMQ'H'C3X@^&H/C!XJT*W\1
MZ3=1SZ-XCM-.LO@%#X>TUKBRN/*L?'WCC0XKJW36M30?U#T]7?6UO\D_NUVW
M\R&DE&^KDK[[*]E\]'U:\C\A_'O_  6@_9F\$?LG^'OVX]/^&?[1GQ'_ &5_
M$7BSQKX1C^+?P\\$>"KO3M&O/"GQ7\0_"32M0\2>&_%OQ)\'>.-#T?Q[K&A0
M:QX0U"\\+K"-+\0:!IWB8^'/%UY-X9MONK]EW]HVV_:F^%F@?&+1/A#\8?A3
MX,\8Z/H'B;P+)\9--\!:)K'C3PKXFT>VUS1_$VDZ)X-^(7CO4--TJZT^\M9(
MX_%</AS4Y?/1X-.F@W3+^/O_  7"^!W@/X!_\$5?V\/#/PXMK[3/#7B[XF_#
MSXK2>'YI[9](\/>(OB;^V'\&/%?B^P\+6=K9V<>D>'K_ ,4WVK^(H=)_TA;3
M4M;U0P3K:RV]K;?J[^P/_P F*_L6?]FF?LY?^J>\&TDW>S_EN_7;^O4;2Y;I
M?::5][))KROKJ?6=%%%40?E-JG_!6'P7I'[4B_L7W?[(W[9)_:1F\&2_$6P^
M'L.@?LYR1ZOX$A^TAO%6D>+?^&E5\%:EI1:RO(<VOB)[I+NSO+"6VCU"SNK6
M'N_!'_!2;PEXI_:.T3]E?Q5^R]^V%\%_BQXM\->/?$G@1/C)\-O 'A;P5\1#
M\.-$@\0>)-"^'_Q"TSXL>(/!WB_7(=/N;9_+T76+K3+'STFUO5-)LQ)=)^37
M[1'CG6/AW_P<L?"'Q)H7PN^(?Q@OXO\ @G9/9KX,^%__  @G_"53Q7?C'XKI
M+J$7_"Q?'/P\\-?8; *)+SS?$D5YL=?LEG=ON1?UC_9'_:@N/VR_C'^T/;>.
M_P!FWQI\%I/V2?B5X+T'X9:+\>/!>D:)\8M*\0>+_A?KL'BWQU$NF>(/%NAZ
M?I7B/1?$NJ:!X3U;PEKU]::_X'OI]0DU.XM_$+Z?83KKKL^W2R?W_P#!T[:-
M)*]E;E3WU3>BTN^O2VW4\R^&/_!7WX9?%O\ :F\:?L8^$?V5/VS?^&A?AI"E
M_P#$OP;K'@KX(Z/:> M":Z\.V[>)O$'B:\^/Z>&V\/F/Q9X>O[*^T?5-6;6]
M.U2TO/#T.KQS1;_UMK^9S]DO_E9Y_P""I/\ V:9\&/\ U77[&E?TQT1;=[]&
MU]UB9I*UEO&+Z[M7"BOGO]J[XN>/_@/^SG\7?B]\+/@WXM_:#^(O@3PA=ZQX
M-^#?@:VNKSQ/X[UXSVUE9:986FGVM_JES!:O=_VKJL&C:=JFN2Z/I]_'H>E:
MIJS66GW/Y ZG^W[^VI^R_P#M ?\ !.;X>_M5Z]^SK\0;+]OW6M"\,>//A#X"
M^%^N_"7XS_LK^._&7A[PC#X:T:T&M?M _$G_ (6!X%TGQKX@OM#\5^)-;\*Z
M3?O/X=U>73;FVGU+2/#EDV[='^FKL"BWM;K;75V5W^'>R/Z J*_GG\%_MW_\
M%0OBM^W_ /MQ_L0>!OAQ^QOI'C']GKX>?"WQ%X(UCQ%XC^*>I_"/PHGQ"T[P
MAXXCU/QYXBLM(T;XG_%/Q-<^%_&=AX>T[0?"O@7X5>%X=0L-:UC5-<LAI6DZ
M?XV]"_9$_P""M>OS?LA?MS?%K]NC1/ _AOXL?\$XOC+\4O@I\<E^"2:W)X/^
M(VK^!+^+0_"UY\/;3Q?.DEEJ_CWQ>USX!TG3]2UM+*[UNUL?$5XWA+2?$<6A
MZ$77Y^6UK[^H<DO)[:)W^*UOOND??O[>W[='P_\ ^"?'P*U7]H#XH?#CXQ?$
M'P7HUS8V>K'X2>%M)UT^'Y-6UC1_#>C7GBK5/$/B+POH7A[2M3\1^(=%T6UN
M;K4Y;VZN[[;IVF:@\$\:?57P]\7VWQ!\ ^!_'UG9SZ=:>-_"'AKQ?:Z?<R1R
MW-C;>)=%LM:@L[B6("*2>VBO5@EDC C>1&9 %(K^67_@LOXO_P""@'Q7_P""
M.7Q'^/GQ!U']G'PQ\$OC/H_[/WB[Q;^SOI'@#XA+\4_@[\/?%WQB^&GC#X93
M#XWZG\0GT?X@_$^P\1W'@3PQ\4-&?X-^!_":6>H^(+CPK<1W/AR"Y\5?TN_L
MT_\ )N7P _[(G\*O_4$T&B^K]$_ON#5DGUO)/Y*.GXL^$_VFO^"M'PS_ &3_
M ([^!?V=?B=^R_\ MD:G\1/BWJ>L:=\%T^'GP]^%GCS2?C$FBWT5E=WO@.XT
M/XU2ZA*%%U8WL^C^(=,\/>*-*L-1L+G7M TG[2B5Z!\!?^"HG[,OQS^(NM_
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M3^%/BAXT^)_Q8L/,OYO$'B6_^-^D_%GP?X:\,S^'8/#/C"QL&@^#.IP:M?\
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M:*+:-7TLUZ7_ ,M?O\@YM5*RNK-^=K?=>VMC^5']K#P-^T+\=/@1_P $KO\
M@H'\&OV:OVD+?Q;_ ,$XOB+\-Y?&_P"SWXC\!:WX5^-'Q,^%^I>&_A!_PN?5
M_ OPUU,V?BV\71-;\ )X%T.%]&MK_P ?:1J7B;Q?::=<^!M)\/:IXC^I_P!K
MD>'O^"M'Q9_8"^%_P1\%?%>[^%/P2_:;TW]JO]HKXG_$[X&?&OX.^$O!OASX
M*PMI,/P4:;XL?#WP1'XC^)?Q2USQ1=:&GA[POJ6HZCX2TSP]J_B77K)=(^Q7
M,O\ 0/11R^>]K^JZKM?0.?:RMRWY==K_ )VU:>F_R/YT/V0'\<6/_!>/_@HY
M\6=5^!?[2_A_X-_'WX7_  /\+?"[XP^*OV9_CSX0^&WB'Q-\*?AW\(O"/BG2
M&\4^*/AYI&GZ7&VKZ1XB&CZYJSV/AO6[30+N]TO6+JUOM%EU/T3_ (+L_"3Q
MEX4^&_P&_P""CWP!?3M/_:=_8(^+W@_7_"L%S++:CXI_#GXJ^+/#_P ./%OP
M8OELKK3+[7%\7:OX@T&RM-%BU.._U#0]3\<>%O#43:_XV@67]ZZ_)#P=^Q5^
MV;\4?VA;[QA^W5^U%X ^,G[-WPM_:'OOCQ^S)\!?AQ\,;'P1/9:YX=O=0;X*
MWGQ:\66VGZ3J.MZ=\)X-4GUS3? TTWB\:M\0]-\+>,=9\?:C!X:BT&^&G:V]
M[Z[6>_>^^NG3\127,I:+E236_,DN6VUM5H]ENS[$_8B^ &I?LQ_LM?"#X0>)
M=4?Q#\0]*\/W'B?XQ>*Y;Z75)O&7QR^(NK:C\0_C7XP?4[B**ZOHO$GQ1\3^
M*]5L)+E/.ATRXLK/B.VC5?RW_P"#DWX!>+_C=_P3&\7>(_ ]M>W^N_LV_%'P
M+^T?+8:;:S75_+X?\):=XJ\%^+M2A$4T2P6_A+PK\0M9\;ZM=W$=U!;:+X9U
M*4P"18[B#]\ZSM8T?2?$.D:IH&OZ9I^MZ%KFG7VCZUHVK6=OJ.E:OI.IVTME
MJ.F:GI]W'-:WVGW]G/-:WEG<Q2V]S;2R031O&[*6TFK=+6_R)4FI*75.Y^9W
M_!17XD6?Q5_X)@?'>Z^&/A+XF_%34OVE_P!D_P 86WPBT'X._"GXF?%[5/$U
MY\5?AY%'X15;?X>>$=?ETNQOSXITNX&JZ]%H]B-/%[?M(L.GWWV?\W?@'^PM
M'^WM_P $1_@5^RG\2O /Q@_9O_:?_9Y\*PW_ ,-==^+'PM^*WP;\5_"/XZ^#
MO$'BX>"?$FE:IXK\(Z!+K_A+Q5ID=N/$TO@R3Q%_9GA[Q';W'_$M\<Z1H,VF
M_M=^RC^SGXB_9/\ #$_P-\.^,D\9?LX^%EO'^!NG>*9=8N?BA\)]#O\ 6+S4
M_P#A4FH^)+FZU&P^('P[\++J,FF?##5+B+PQXB\#>#-*T/P'JL'C>.Q@\4VW
MUM1:^_9IKUM^5AJ5M%TES)]5Y-6MZ_Y;_@K\!/\ @HO^UC;_ +"7Q)TK]I']
ME[]I'P)_P4%^#WA#Q9\,=%MM9_9H^,$GPH^._P 8;+R/ GPH\>^&OBIH/@.7
MX*R:/\0_'VK^'(=;@LO&%CI<]Z=<UOP?9S^"[K0YG_2CPKX(\)_L7_L8>"?A
M+9V'CKQAI'P@^"^F_#V%OA]\-/'7Q+\:>,M<T/P9/#JGB$^#_AQX>\4^)+[7
M/&FMVFI:YJ=X-.>.[\0ZTZW-W]MU&$3?85%/^K]0;3Z6UNTOT[+>V^Y_*A_P
M1V_8ZM/V@/\ @D3\5/\ @G9^V=^S_P#M ?!G7-3\>_$C56@^*OP.^*GPRO=-
M@U>?PMX@\!?%/X?>+/&_@S1O"EWXA\->*9B]EH4&L7NIW$OAS4X-?T&Z\(ZE
M=17_ -Q_\$K/CS^U;\(-%U7]@7]O#X0?'V?XE_L]>*;/X4_![]J'1/@/\9O&
MOP/_ &@_A3#$T?@;7[GXR>%? NL^!M!U#P[H,>FZ?JGB#Q]KWAPSZ3-H\7BV
M_/Q$TSQU'%^YE<GX[7QR_@[Q'%\,Y?"EOX_FTNYM_"5YXYAU>Z\(:=K5PHAM
M-5\0Z=H,MIK.L:9I+2'4KC0=.U+0[K7Q:C18_$?AO[>=>TY6M;796]?ZZ=AN
M7,W=*TG??9[7OV[K]4F?@IXK^'6H_'K_ (.2OAWX_P##DJ7OA/\ 86_8-LS\
M1KZ.(S6OA_XE?&G4_C;HGA3P?>74-L_V3Q#XE\ _% >+M-T^]GB2?P_X=U6]
MMG#[H;C]P_C7XVTWP!\,O&'B#4]&\<Z_#'H&N6\&D?#KX=>._BEXJO[M]%U&
M>"UT_P )?#GP[XG\27<ER;=K>&2/3/LQO);6T>XCGN[9)?./V6?V9])_9J\%
MZ_97GBW5_BK\7/B;XKU#XD_'KXY>*;"PTWQ9\8/B9K$4%M=:]>Z7I>=+\,>&
M- TBSTSPA\.? &B-_8'@#P)H6A>&M,-T]I>:IJ/TW0EOYN_IMI^ F[V[))?=
MO^+=M-C^8#_@A+\7=8_8R_8!TSX'?M$?LS_MU>!OBIHWQ0^(?B-?"D7[!?[8
M'B)=5TKQ/J6GSZ3/8>(_#OP8U3PC;ET607":UX@TC[+Y4C3E(MLC>A_#?]E+
M]H__ (*-_P#!37X??\%"/VKO@QXH_9V_99_9.TJ&U_9 ^ OQ1N+;2OC-XO\
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MGAT2;Q9I_AN3Q#HGB3WNA7U_#[OZZ+[K"=K*RL];Z].B^7^1_,QX[UGQF?\
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M+'XGWO@NYTG6(-%T?3]3L;K1$TNUU:P\,7]T/ZVZ*+:M]VG]PU.R2MLI+?\
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M?$M?C1K'AG]HZ#P'XET[P1\./#NA>*?C1XL\43?#S4]1.G^*?%OBCXI6>O\
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M4[7P9KUA9:S>Z[X'7X;:1I][>1^$K6:]FB\,VEV,[]E/_@EKHOPA_;X^.O\
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M9O\ @K/X,\>?%O\ X+&?\$Q[7XK> OB-I7[$W[/-L_Q?UKXQ:?\ #'QGXM\
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MC^LO_@DW^SS^P=\#/V3O#&M_\$^;^3Q=\'/B[*?&=Y\4=7UB_P!<\9?$/7;
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M,PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*-I2:;YHQ2Y^UN_B!XBN)"T$T%C'T$<%M#)QS]Y[I)V+8(R5V#(!"KR*H_\
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M/_Y'KEZ*/[8S?_H:YE_X78K_ .6^2^X/[.R__H!P?_A-0_\ D#J/^$T\3_\
M05D_\![/_P"1Z/\ A-/$_P#T%9/_  'L_P#Y'KEZ*/[8S?\ Z&N9?^%V*_\
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M3Q/_ -!63_P'L_\ Y'KEZ*/[8S?_ *&N9?\ A=BO_EODON#^SLO_ .@'!_\
MA-0_^0.H_P"$T\3_ /05D_\  >S_ /D>C_A-/$__ $%9/_ >S_\ D>N7HH_M
MC-_^AKF7_A=BO_EODON#^SLO_P"@'!_^$U#_ .0.H_X33Q/_ -!63_P'L_\
MY'H_X33Q/_T%9/\ P'L__D>N7HH_MC-_^AKF7_A=BO\ Y;Y+[@_L[+_^@'!_
M^$U#_P"0.H_X33Q/_P!!63_P'L__ )'H_P"$T\3_ /05D_\  >S_ /D>N7HH
M_MC-_P#H:YE_X78K_P"6^2^X/[.R_P#Z <'_ .$U#_Y ZC_A-/$__05D_P#
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M6^2^X/[.R_\ Z <'_P"$U#_Y ZC_ (33Q/\ ]!63_P ![/\ ^1Z/^$T\3_\
M05D_\![/_P"1ZY>BC^V,W_Z&N9?^%V*_^6^2^X/[.R__ * <'_X34/\ Y ZC
M_A-/$_\ T%9/_ >S_P#D>C_A-/$__05D_P# >S_^1ZY>BC^V,W_Z&N9?^%V*
M_P#EODON#^SLO_Z <'_X34/_ ) ZC_A-/$__ $%9/_ >S_\ D>C_ (33Q/\
M]!63_P ![/\ ^1ZY>BC^V,W_ .AKF7_A=BO_ );Y+[@_L[+_ /H!P?\ X34/
M_D#J/^$T\3_]!63_ ,![/_Y'H_X33Q/_ -!63_P'L_\ Y'KEZ*/[8S?_ *&N
M9?\ A=BO_EODON#^SLO_ .@'!_\ A-0_^0.H_P"$T\3_ /05D_\  >S_ /D>
MC_A-/$__ $%9/_ >S_\ D>N7HH_MC-_^AKF7_A=BO_EODON#^SLO_P"@'!_^
M$U#_ .0.H_X33Q/_ -!63_P'L_\ Y'H_X33Q/_T%9/\ P'L__D>N7HH_MC-_
M^AKF7_A=BO\ Y;Y+[@_L[+_^@'!_^$U#_P"0.H_X33Q/_P!!63_P'L__ )'K
MO/!T_B?69/M]_J4RZ7$Q54\FU1KV52,HC+;AA;H<B:5&4EP88FWB5HN)\*>&
M)M>NO-F#QZ9;N/M,V"OG,,-]EA;C,C@@R.I_<QD,2'>)7]^AABMXHX((UBAA
M18HHT&%2- %55'8*  *^]X2P&;X^4<RS#,<R^I0E?#T)XS$VQ<XM>_-.I9X>
M#5K6M5FN7X(24OEL_P 5E^%C+!X3"8/ZS)6JU8X:C?#Q:VBU#2M)/1[TXOFT
MDXM24A(4%F("@$DD@  #)))X  Y)/ %+7D'C?Q;YYET73)/W"DQW]RC$&9@2
M'M(F!'[E3Q.XSYQS$/W0<S?;9OFV&R;!SQ6(=W\-"BFE4KU6KJ$;WLEO.;34
M(IMIOEC+YK+\!6S'$1H459?%5J->[2IWUD^[Z1C>\I66BO)0^)?'=X]Z;?0K
MGR+2W+*URL<4ANY.-S+YT;A84(*Q[0#)\TA)4H%YS_A-/$__ $%9/_ >S_\
MD>N7HK\4Q7$&<8K$5<0\PQE'VDW)4L/B:]&C36BC"G3A448QBDE?64FN:<I3
M;D_TFAE.74*5.DL)AZG)%)U*M&E4JS?64YR@VY-W?9:1BE%)+J/^$T\3_P#0
M5D_\![/_ .1Z/^$T\3_]!63_ ,![/_Y'KEZ*Y_[8S?\ Z&N9?^%V*_\ EODO
MN-?[.R__ * <'_X34/\ Y ZC_A-/$_\ T%9/_ >S_P#D>C_A-/$__05D_P#
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MIXG_ .@K)_X#V?\ \CUR]%+^V,W_ .AKF7_A=BO_ );Y+[@_L[+_ /H!P?\
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M/_Y'KEZ*/[8S?_H:YE_X78K_ .6^2^X/[.R__H!P?_A-0_\ D#J/^$T\3_\
M05D_\![/_P"1Z/\ A-/$_P#T%9/_  'L_P#Y'KEZ*/[8S?\ Z&N9?^%V*_\
MEODON#^SLO\ ^@'!_P#A-0_^0.H_X33Q/_T%9/\ P'L__D>C_A-/$_\ T%9/
M_ >S_P#D>N7HH_MC-_\ H:YE_P"%V*_^6^2^X/[.R_\ Z <'_P"$U#_Y ZC_
M (33Q/\ ]!63_P ![/\ ^1Z/^$T\3_\ 05D_\![/_P"1ZY>BC^V,W_Z&N9?^
M%V*_^6^2^X/[.R__ * <'_X34/\ Y ZC_A-/$_\ T%9/_ >S_P#D>C_A-/$_
M_05D_P# >S_^1ZY>BC^V,W_Z&N9?^%V*_P#EODON#^SLO_Z <'_X34/_ ) Z
MC_A-/$__ $%9/_ >S_\ D>C_ (33Q/\ ]!63_P ![/\ ^1ZY>BC^V,W_ .AK
MF7_A=BO_ );Y+[@_L[+_ /H!P?\ X34/_D#J/^$T\3_]!63_ ,![/_Y'H_X3
M3Q/_ -!63_P'L_\ Y'KEZ*/[8S?_ *&N9?\ A=BO_EODON#^SLO_ .@'!_\
MA-0_^0.H_P"$T\3_ /05D_\  >S_ /D>C_A-/$__ $%9/_ >S_\ D>N7HH_M
MC-_^AKF7_A=BO_EODON#^SLO_P"@'!_^$U#_ .0.H_X33Q/_ -!63_P'L_\
MY'H_X33Q/_T%9/\ P'L__D>N7HH_MC-_^AKF7_A=BO\ Y;Y+[@_L[+_^@'!_
M^$U#_P"0.H_X33Q/_P!!63_P'L__ )'H_P"$T\3_ /05D_\  >S_ /D>N7HH
M_MC-_P#H:YE_X78K_P"6^2^X/[.R_P#Z <'_ .$U#_Y ZC_A-/$__05D_P#
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M6^2^X/[.R_\ Z <'_P"$U#_Y ZC_ (33Q/\ ]!63_P ![/\ ^1Z/^$T\3_\
M05D_\![/_P"1ZY>BC^V,W_Z&N9?^%V*_^6^2^X/[.R__ * <'_X34/\ Y ZC
M_A-/$_\ T%9/_ >S_P#D>C_A-/$__05D_P# >S_^1ZY>BC^V,W_Z&N9?^%V*
M_P#EODON#^SLO_Z <'_X34/_ ) ZC_A-/$__ $%9/_ >S_\ D>C_ (33Q/\
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M\![/_P"1Z<OC;Q.IR-48^S6MDP_)K8CMU&#Z'FN5HIK.<W6JS7,M/^H[%?\
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MC^GY=E]'+L/&A25Y.TJM5JTJM2VLGVBMH1O:,>\G*3****\D[PHHHH ****
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MI4TWMSSC>SML[?LE17\X'_$0SX>_Z-4UG_P\5C_\[6C_ (B&?#W_ $:IK/\
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MA1+_ ,+,N_\ FL_H_HK^<#_B(9\/?]&J:S_X>*Q_^=K1_P 1#/A[_HU36?\
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M_1JFL_\ AXK'_P"=K1]?PG_/Y?\ @%3_ .0\_P ^S#_4'BW_ *%$O_"S+O\
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M^$_Y_+_P"I_\AY_GV8?Z@\6_]"B7_A9EW_S6?T?T5_.!_P 1#/A[_HU36?\
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M\-Q7MU;1VXGN);+]M:]MVCNIXAYDTEHX: I*S- P:(A#E:^LOA-\#OAS:?\
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M^G_&WP_XN_LO5;CX?:=XU\)>"M#C^,?B6R@WZ/\ #GX>7T/Q'U"PA^('C6Z
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M*K&M.E)>[&-?V3]FI:QNN8^'J*_J _X+N_\ !-_P5\-?#WAC]K']G+X=^$?
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M-1/.=?\ ^0[K7_86U'_TLFK)K6U__D.ZU_V%M1_]+)JR:_%,;_OF+_[":_\
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M,DR>.74O:U4I8RK%<\MU2@[/V,'ZI.I):2DDDW&*;****^3/>"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *VO#G_(?T;_L)6?_ */2L6MKPY_R
M']&_["5G_P"CTKKP'^_8+_L+PW_IZ!ABO]VQ'_7BM_Z;D?2U%%%?T:?CP444
M4 %<#\1_^0!%_P!A*W_]$75=]7 _$?\ Y $7_82M_P#T1=5XG$G_ "(LT_[!
M*GZ'I9/_ ,C3 _\ 81#\SPVBBBOP(_5@HHHH _E<_P"#@O\ Y+%^SW_V33Q1
M_P"I3'7\^5?T&_\ !P7_ ,EB_9[_ .R:>*/_ %*8Z_GRKYK'?[W6]8_^D1/Z
M=X'_ .24R;_KQ5_]2JY^@/\ P2L_Y2'_ +)G_95]._\ 3;J=>K_\%N?^4GW[
M3?\ W1?_ -9[^$]?G/\ "KXI>._@E\1/"7Q7^&.N_P#",^/_  -JT>N>%M?_
M +,T;6O[+U2&*6&.Z_LOQ!I^K:+>[8YI5\C4=.N[<[LM"652-;XW?&[XH?M&
M_%#Q/\9OC-XG_P"$R^)/C+^Q?^$D\2?V+X>\/?VC_P (]X>TGPKH_P#Q)_"N
MDZ'H-G]CT'0]+L/] TNU^T?9?M5UY][/<7$WH+,J"X;GD_)6^LRSRGF2J<L/
M8>PA@*N%<'+VGM/;>TJ*2C[+DY$VZBE:+J61XM\;4N)%4P_U&'"U?(W2YZOU
MMXNKFV&Q\:BI^Q]C]75&C*,INNJJJN,51<6YK^B/XF_"KXH?&#_@W^_8U\*_
M"3X;^/?BCXGM_C%<ZS/X<^'7@_Q#XVUZ#1[3Q=^T3:W6JS:/X9T[4]0CTVVN
M;ZRM[B^>W6UAGO+6&259+B%7^!/^"<_[*/[4GPN_;I_9:\:?$S]FSX^_#OP=
MI?Q;T*+4_%GCKX._$3PCX9TZ748;W3]/COM>U_PYI^EVDE]?W-M8V:7%U&US
M>7$%M 'FEC1O"O@S_P %5/V]?V?/AGX6^#WPA^.__"(_#GP7!J%MX9\._P#"
MK_@UK_\ 9L&JZQJ.O7Z?VOXG^'>M:[>>?JVJW]WNU#4[IXO/\B%H[:*&&/LO
M$'_!9/\ X*1^*+?3[77?VCOMT&E:[H?B:PC_ .%0? :U\C6_#>IV^L:+>[K/
MX7V[R_8M1M+>X^S3-):7/E^3=V\\#O$WOU,WX;Q%?)\?6EGD,;E>"RB@Z-+"
MX"6%J5<LA23:J3QT:OLZDH/5TXRY6GRQ=T?(4>'.-\'A>)<HPL.%:N69]FO$
M.,CB,1F&;PQU'#Y[6KRLZ-/*9X?VU&E53Y56E#VB:]I*-I/^@&[_ &L/">D?
M\%:?VT?V!OV@$M=<_9\_:T@^$_AK2M-UB<P:=HWQ,\0?LS?"?P^VE)=13VMW
M96_Q1TI+/PS%/9S2:A:>,]-\$RZ-_9LMWJVH'Y2_X.$_ -C\*?@5_P $\OA=
MI=_=ZIIOPV\/?$'P#IVIWZ0QWVHV/@[P?\&?#MI?WL=NJ6Z7=W;Z='<7*0(L
M*S2.(E5 H'\YGQE^._Q8_:!^+&O_ !R^+7BZ?Q/\5?$\^@7.M>+K;2M"\+W-
MS<^%]"T?PUH%Q;Z=X0TO0-%TV?3=%T#2+2*73--LY))+-;V=I;^6>YE]3_:4
M_;@_:C_:^L/!.F_M%_%*3XCV?PZ?69/!Z3>#_ 'AF;2I/$$.D6^L22W?@SPK
MX<N]6DOHM"TL/)K,^HO&UL9(&BEN+IYML=QAAL=E?$67UJ&(E4Q^.K5<IQ,H
M4O:4<#7S6.8RPF,E[9RC&DX.5%4_K$8SJSIIPIQ4I<V5>&V-RG/^#,XP^+P<
M*&4Y5AL/Q%@H5,1[+$YKA.'IY)#,<MB\,HSEB(SC#$NM]3E.E0IUI1J5IRA#
M[Q_8^\0_\$7K#X!>$+7]L'P+\5=;^/T=YXH/B_4?"]Y\48M%GLW\3ZL_A=;:
M/PUXQTC1P\/AAM)BN/LUA"QN$D-PTMP997^2/V8Y_ T__!2S]GE_A=#?6GPO
M?]NCX43?#>RU%[U[VS\"S?'WP\WA."\_M&>ZOC>Q^'AID5V][<W%X\T;&ZGF
MF#2'X6KJ_ ?C?Q1\,_''@SXD>"-3_L3QI\/O%?AWQOX0UG[%IVI?V1XH\*:O
M9Z]H&I_V=J]I?Z3?_8-6L+2[^Q:G8WNG77E>1>VES;22PO\ ,+-U-Y7">!P%
M"&75</.5;!82%'&8J-%TN9XFKS_[14DJ?->7(G5E*3:YFU]V^')4O[>JTLVS
MC%U<ZP^,IPPN:9E5Q.6X">)C6<8X'#>S:P=&$JO(HTU-QH1C!*7*D_U>_P""
MV6AZQXF_X*E?%SPWX>TR]UK7_$-O\#]#T/1]-MY+O4=6UC5OA7X#L-,TRPM8
M5:6YO;^]N(+6UMXE:2:>6.-%+,!7Z_?"?]EG7O\ @C_^S2OQ&^'_ .SK\1?V
MLO\ @H%\8-%NM'M+CX>_"[QO\1_!'P@BEMK6XO\ 3-1UGP?H^HQZ-X4T"6YM
M#JGE7VG^*/BYKT":=I$FE^%-/OM6\*_S#^+_ -K?]H+Q]^T1I?[5WB_QY!K?
MQ\T;7?!_B73/'=QX-\!0QVNN^ ;72[/PAJ2^$K3PO;^"))]#AT72VMA-X:DB
MDN;**]NHY[S?.WV3_P /N?\ @I]_T<W_ .88_9[_ /G3U]'@,_R&CFN>YOB*
M>9PQN.QF*JY5B*.%P5>67TL36J5)5W2KXRG36-Y)J$)+VL*+3E&4W*Q\5FW"
M'%N)X?X3X<PE;(JN695EN P_$&#Q6/S/"0SC$8'#4*-/"JOA,LK5WE?M*3JU
M8/ZO5Q*<83C244S\_P#XX#XSK\6O']U^T%I?CK0OC-KVNS>)?B)IWQ&T#5?"
MGC)M:\5)!XG6\USP[J]AI5[I@U2TU2RU?3;5M.M+3^R[O3YM-@33WM*_<C_@
MKS_RCZ_X(X?]FWZ3_P"J3_9ZK\-?C=\;OBA^T;\4/$_QF^,WB?\ X3+XD^,O
M[%_X23Q)_8OA[P]_:/\ PCWA[2?"NC_\2?PKI.AZ#9_8]!T/2[#_ $#2[7[1
M]E^U77GWL]Q<3=E\7OVKOC]\>?A]\&_A7\5_'O\ PE?@/]G_ ,-Q>$?A'H7_
M  BW@O0_^$2\/0:)X>\.1:?_ &IX;\.:/K.O;-&\*:!9_:_$VHZS?-]@^T-<
MFZNKV>Y\*AF6%P^%XCPJ>+K+-(4*6#K58T_:.-',J6+]IC;5I<E2I1IOG]DZ
MZ]M)J[C^\/K,7D>88S'\$X^2R[#/A^IBZ^9X;#3K^P4\5D=?+O8Y6GAHNI0H
MXFLE3^L1PK6%@I<JJ)4CYWHHHKP#Z\**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ K]=_P#@B'_R?;H'_9-/B-_Z;K.O
MR(K]=_\ @B'_ ,GVZ!_V33XC?^FZSK?"_P"\T/\ K[#_ -*1X'%7_)-YY_V+
M,7_Z9D?V<T445]2?RL%%%% 'KGPP_P!5K/\ UTL?_0;JBCX8?ZK6?^NEC_Z#
M=45^Z<(_\D[EO^'$_P#J9B#\PX@_Y'&,]:'_ *C43SG7_P#D.ZU_V%M1_P#2
MR:LFM;7_ /D.ZU_V%M1_]+)JR:_%,;_OF+_[":__ *=F?I&%_P!VP_\ UXH_
M^FXA1117,;A7XL_MQ_\ !#K]FW]O/X\ZA^T%\3OBE\</"?BK4?#'AOPM-H_@
M/4O =MX?2R\,V\UM9W$<7B#P)K^HBZG2=FN6;46B9P#%%$,@_M-175A,;BL!
M5=?!UIT*K@Z;G"UW"3BW'WDU9N,6].AC7P]'$P]G7IQJ0YE+EE>W,KI/1K57
M?WG^=C_P1;_X)A_!K_@I/K/[0VF_%_QS\3O!,/PATSX97V@O\-KSPK:2:C)X
MVN_'4&HIJY\3^%O$RR):KX6LC9"R6S96GNO/:<-$(OKK_@X*_9H\'?L>?L\?
M\$O_ -F[P!K?B7Q'X0^&-E^V#8Z-K7C";2[CQ)?1Z]XJ^"'BVZ?4YM%TO1M,
M=XK_ %^ZM[<VNF6JBTAMUD628232>V?\&I/_ "-7[;W_ &+_ .S_ /\ IQ^,
M%=!_P=?_ /-A'_=TO_ON=?I-3&XJIQO1P,ZTY82A.56E0?+R0J2R6JW):<UV
MZM1ZMKWGIL?)1P]&/#M3$1IQ5>HE"=37FE%8^"2>MK+DCTZ>I_817\'?_!Q]
MJOB[P]_P4Y^%_B?P%>:[IGC+PC^S?\+_ !EX<UGPRUY%KWA_4_!_Q!^+GB:#
MQ)IES8#[787'AO\ LIM=_M.$H=,CT]]0>6&.V>5/[I/^$L\*_P#0S>'_ /P<
MZ=_\DU_*3^WO%I>N_P#!Q=^P5;SQV&L:/JOPR^%EK<P2I;ZAIFI6%WXE^.MO
M<VT\3B:UO+.YA>2&>&19(9HG>.161F4_*\)U'A\RKUY4^=4<MQM5PEHIJG3C
M-P;::M)*ST>CO9GN9U#VN$ITE+E=3%X:"DM7'GGR\R5U>UT]UTU1[)^T5^W/
MH?[?_P#P;[_M _&+?IUE\2]&\._#?P+\;/#-@&ABT+XF:%\7OA8=4O+*SDW/
M;^'_ !=97%CXP\.1I-?16.FZTNA3:C=ZKHNJ&/[._P"#?7_E%5^S[_V,'QL_
M]77X]K^6C_@I=\!OBA_P2F^,O[3O[/\ \.H;M_V1OVZ/!.FWWA"SO3JDFDP:
M1X3^(>B>.M+T""_GEG2X\<?!3Q+:7'A>WFO;S5;ZZ^''C6UU+5#;:EXPBFL/
MZE_^#?7_ )15?L^_]C!\;/\ U=?CVO3SC"8?#<-RJ8.2E@L=G=+&X3O3I5L#
M*+HS5WRRHU:=2DXMMI07,^:]N/+Z]6MFO)B(N.(PV6RP]>^TYPQ5-JI%Z7C4
MA*,[V2O)V5K-_M)7X*?\%:/VV/VT?"OQ%T_]@_\ 81^!GB3Q5\7OBI\&--^(
MWB7XYZ1+-/!\*/ WBGQ-\0?!5Q]F,EE:>'?!.L,_@:^N(?B3XQ\466EZ%'=Q
MV^C:5<>))M.U32OG#]I/5O\ @Y5B_:"^-,7[.GAC0[GX"Q_$WQFGP<N)[C]B
M99IOALNO7H\'RRKXR\0V_BP.^A_8V8>)((=:!)_M*-+KS5']!O@!_B3)^SAX
M*D^,L20?%]_@EX<?XJPQ'13'#\26\"63>.8HSX:DF\.%(_$YU1$.@2RZ*5 .
ME2/8^0Q\"GAZ655,+C*M3*LU557IX6CC)5G1JN,9PGBZ4(P=H-V=*4N6<TXR
M=EKZ3JSQRK8>$<;@G%VE6G05/GAS.,E0G)R5Y):32O%-22OM_.+_ ,&K7_)
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M^(/!-O\ $&TTZYO]*T>:WTWPWXAEN_\ BVEO8Z6;*70-;\*VMLYMI([AN/\
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MUZ-94\14E1KUU24FO]HH4H.$I1A5BW--2NIFO^K^*Q,,P6.JPP7#&;\15_\
MA5JYC"G2PF)PSKX.C#$X3"SQ$H*_U3%8BI&I"$JE&48TY*4?P#HK[[F_:_\
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M]#ENM,M[+7ETF8Z0_M?PR_:8\?? O_@D!\-_C1X"\/?"*V^)/A+_ (*"Z5X
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M@WX5^&X/"WA[4_&%YI>H>)KS3[>XN;E)M9O=%T?P_I5Q>&2ZD#26.BZ= 4"
M6ZL&9O;:**Y*DYU9SJ5).4ZDY3G)[RG-N4I/S;;;]3>,8PC&$4E&,5&*6RC%
M627DDK!1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MPFO_ .G9GZ1A?]VP_P#UXH_^FXA1117,;A1110 4444 %%%% !1110 4444
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M[-T4?ZV<1_\ 0UQ'_@-'_P"5A_Q#?@;_ *)O ?\ E?\ ^7'XR?\ #E#X(?\
M1?/VE?\ PK/"/_S%4?\ #E#X(?\ 1?/VE?\ PK/"/_S%5^S=%'^MG$?_ $-<
M1_X#1_\ E8?\0WX&_P"B;P'_ )7_ /EQ^,G_  Y0^"'_ $7S]I7_ ,*SPC_\
MQ5'_  Y0^"'_ $7S]I7_ ,*SPC_\Q5?LW11_K9Q'_P!#7$?^ T?_ )6'_$-^
M!O\ HF\!_P"5_P#Y<?C)_P .4/@A_P!%\_:5_P#"L\(__,51_P .4/@A_P!%
M\_:5_P#"L\(__,57[-T4?ZV<1_\ 0UQ'_@-'_P"5A_Q#?@;_ *)O ?\ E?\
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M7EA)5:E:G0K4*T:4G0G6G.K&G5C.,G2E.:A.,G3<82C3A^T%%%%:'YH%%%%
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M^%5X3_\ F-H_X<O?!7_HO7[2/_A5>$__ )C:_8^BC_B9#QP_Z.-GG_@&7_\
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M'.+^ZE_\J\OS[L_"3_AP%^RY_P!%=^/O_@S^'?\ \[ZC_AP%^RY_T5WX^_\
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M%^RY_P!%=^/O_@S^'?\ \[ZC_AP%^RY_T5WX^_\ @S^'?_SOJ_=NBCZEA?\
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M_P!=+'_T&ZHH^&'^JUG_ *Z6/_H-U17[IPC_ ,D[EO\ AQ/_ *F8@_,.(/\
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M5JX=-8*I"M^C-%? '_"Q/CG_ ,-->?\ \* ?^T/^%$^5_8/_  MKPEY?V/\
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M=;$Y1D>'I1:4JM?!8&E3BY-**<ZE.,4Y-I)-ZMI+4^Y/^'RG_!0C_HLFC?\
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M(Z=2NY1HTYX+ QG6E!<THTH2IJ51QC[TE!-Q6KLC[O\ ^'RG_!0C_HLFC?\
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MW_YD*_+JBCZSB/\ G_6_\&3_ ,_+\^[#_5KAW_H191_X;L)_\J/U%_X?*?\
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MO_!D_P#/R_/NP_U:X=_Z$64?^&["?_*C]1?^'RG_  4(_P"BR:-_X:SX6_\
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M_KI8_P#H-U11\,/]5K/_ %TL?_0;JBOW3A'_ ))W+?\ #B?_ %,Q!^8<0?\
M(XQGK0_]1J)YSK__ "'=:_["VH_^EDU9-:VO_P#(=UK_ +"VH_\ I9-637XI
MC?\ ?,7_ -A-?_T[,_2,+_NV'_Z\4?\ TW$****YC<**** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@#^5__@HI_P I]?V0O^S);_\ ]/O[5U?=%?#'
M_!1@&+_@OE^QU+*K1Q7?[%FJ6MK(ZE8[BYM]6_:MN9[>%R LLT-NR3RQ(2\<
M3I(ZA74G[GKYWC'_ 'O*O^Q+AO\ U+QQ_3W@E_R2N9?]E%C/_5=E(4445\B?
ML1\B^'OV2E\(?$+XN?$_PG^T#\=/#_BOXVW_ (=U'QU/:VOP#O[.>Y\):8^B
M^'3IEGK?P)U6/3DTW2)9+!5C+F[C<W%^;N^5+I=&S_9"^'&C_ _XA_ GP[X@
M\?:!HOQ<N/&-_P#%3QK;:QHFL?$;X@:Q\0]-FTGQQKOB+7O%?AOQ#ISZOXEL
MI5CO+O3M#T\6H@@72H]/C5HW^J:*[I9EC9.+==IQ>'=XTZ4.9X2"IX53Y(1]
MHL/",8T8U.:--)*"5CR89%E4%.*PJ:G'&1M.MB*G(LQJ2K8]T?:59>PEC:LY
M3Q4Z/LYUY2;J2E<^6=$_9BNM"\$> _AO!^T)\=;KP3\/K7PCIVEZ)=Q_ Y3J
M>E>!)M+G\*Z5K^K6/P2LM=U&PT]M$TN.]BCU2U?Q':6TMAXHDUNPU'5+:^Z+
MPK\ I--UWP+XB\>_%GXE_&+4/AG'JC^!X_'B^ K.RTG6=5T^_P!"F\7WD'@;
MP/X0EU_QE%X8U74_"UMK.N7%];VND:AJ$UKIMOKFIZKK-_\ 0E%3+'XJ2FG.
M"]HZCG*-"A";=6,HU6IPI1G%U8R<*KC).I"T)N44DM(91@*;I.-*JU15&-.%
M3%XRK3C'#RISP\72JUYTI1P]2G"I0C.$E1JIU::C4E*4N<\7>$?#WCKP]J'A
M7Q5I_P#:N@ZK]D^WV'VN^L?/^PWUMJ-K_I6G7-G>Q>5>V=O-^YN(]_E^7)OB
M>2-NCHHKDYI.*@Y-QBY24;OE4I**E)+9.2A!2:5VHQ3ORJWH*$%.510BJDXP
MA*HHI3E"FYRIPE*W,XPE4J.$6VHNI-I)SE<HHHI%'A7[47_)LW[17_9"OBY_
MZ@'B"OH?_@WR_P"45'[/G_8P?&W_ -79X^KYX_:B_P"39OVBO^R%?%S_ -0#
MQ!7T7_P;ZPRQ_P#!*;]G9Y(I(TN-<^-TT#NC(L\2_''XAP&6%F $D8G@FA+H
M642PRQD[XW4??\,_\B+,/^QKA/\ U$Q)_-OCC_R.,@_[%N-_]2J!^T5%%%>B
M?B(4444 %%%% !1110 H!8A5!+$@  $DDG   Y))X ')->X^#/"8TB,:C?Q@
MZG,F(XVPPL87 RHXXN9 2)G!.Q#Y*$ RF3.\$^$OLXBUG4XO](8!["UD4@VX
M.<7,RG'[YAS"A!\E2)#^^91!Z?7ZIPAPQ]75/-LPIVKR2G@\/-?P8M7CB*D7
MM6DM:479TH^]+]Y)*E\-Q!G7M7/ 82?[I-QQ-:+_ (DD]:4&MZ:>DY+^([Q7
MN)N96=JNJ6FCV4M]>/MCC&%12OF3RD'9#"K$;Y'P<#("J&=RJ(S"Q>7EMI]K
M->7<JPV\";Y)&S@#(55 &69W8JD:*"SNRHH+, ?GGQ'XAN?$%Z9GW16D.Y;.
MU)!$2'&YWQPTTNT-(W.,+&I*(M?0<2<04LDPUH<M3'UXM8:B]5%;.O52U5*#
MNHK1U9KDCHJDH>3D^4U,SK7E>&%I->VJ+1R>C]E3?6<EJWJH1?,]7",JNM:S
M=ZY?/>W1 XV00J<QV\()*Q)P-Q&27<@-(Y+$ 85<BBBOQ"O7K8FM4KUZDJM:
MK-SJ5)N\I2ENV_P25DDDDDDD?IE*E3HTX4J4%"G3BHPA%648K1)?JW=MW;;;
M;"BBBLBPHHHH **** "BBB@ HHHH _B8_P""+O\ R17X]?\ 9R/BK_U$_!M?
ML?7X\?\ !&FTN]/^$'[0EA?VMQ97UE^TSXQM+VRNX9+:[M+NV\,>#X;BUNK>
M94FM[BWF1XIH9422*1&CD564@?L/7^3OTD/^3X>(W_8\A_ZK\$?W?X5?\F\X
M5_[%S_\ 4G$!7F/QC^%VG_&GX;>+?A=K/B/Q-X8T'QMH]_X>\07WA)O#L>M7
M.AZK:3V.IZ;#/XG\.^*-/M8[ZUN'CDNH--74("%>SO+:0%F].HK\;P.-Q.6X
MS"9A@JOL,9@<11Q>%K*%.HZ.(P]2-6C5C"K&=.4J=2,9QYX22E%.VA]WB,/1
MQ5"MAL1#VE#$4JE&M3YI14Z56+A4@Y0<9)2@W%\LD[-ZGQY??L:>%O$?@'P=
M\)/'WQ8^,?Q#^$/@VT\*V$/PQ\0W7PPTCPUXBT_P0ELGA?3O%M]X"^%O@SQ;
MKVFZ6]AIMP=.G\2QV&H7>FV-WJMO?7,/F-U_Q*_9JTWXD_%GX8_&.3XI?%+P
M=XH^#\'BJV\!V/A _#(>'M,@\;Z18Z%XLCN=/\5?#/Q3<:FNM:9I]O#(-0OK
MC[ ZBXTC^S[B."2'Z4HKZ)<<\4K$0Q,<S49TZ6=TH4H8'+88-1XDPWU+B&?U
M".#6!=?.\%;!9KB98=XG'X*,,)B:M3#PA3CY?^KV3NE*D\)>,IY?.4Y8C%2K
MMY556(RR/UEUWB%3R_$?[1@Z*JJEAZ[E6I0C5E*3^>[KX%>(9X_%5[%^T'\:
M8?%GB3_A$X+/QB8/@\NI^%=(\(ZMJFM6WA_P]I%G\)+'PH-)UJ^U>Y/BB35_
M#^JZUK]I#I^G7VL-INGVEI%V/@+X5:?X)U_Q=XRO?$?B3QQXY\<+HUIKWBWQ
M6VAI?1Z#X;&HMX<\)Z+IWAK1/#VAZ-X8T&XUK7+VQL[;3&U"YO\ 6M3U'7-5
MUC4KE[RO4Z*\_$<1YOB<-B,)4KX>%#%QIT\1'"Y=EN"G6H45@?982=;!X.A6
M^I4Y9;@:L,"JBPBKX:GB%0]NG4?52RK!4:M*O&G5E4HN4Z3K8K%XB,*DWB.>
MLJ=>O4I_6)+%8B#Q'+[=TZLZ7M/9OD7._P#")^'_ /A+?^$Z_L__ (JK_A'/
M^$3_ +4^U7O_ "+_ /:?]L?V?]A^T_V=_P A'_2/M7V/[;_RQ^T^1^ZKHJ**
M\>I6K5O9^VJU:OLJ4*-+VE253V=&G?DI4^9ODI0N^2G&T8W=DKL[84X4^;DA
M"'/-U)\D5'GG*W-.5DN:<K*\G=NRN] HHHK,L_+'_@J/_P @K]CG_L]+X0_^
MDWB"O[)J_C;_ ."GR/>K^Q5HEDCWFLZK^VI\(TTS2K5'N-1U%U&JVA2QLH0]
MQ=/]JU"QM@D$;N9[RVB ,DT:M_9)7^JWT8$UX(<,W35\ZXJDKJUX_P!I0C==
MUS1E&ZTO%K=,_B?QK:?B%F-FG;+\J3\G]53L^SLT_1I]0HHHK]Z/R<*VO#G_
M "']&_["5G_Z/2L6MKPY_P A_1O^PE9_^CTKKP'^_8+_ +"\-_Z>@88K_=L1
M_P!>*W_IN1]+4445_1I^/!1110 5P/Q'_P"0!%_V$K?_ -$75=]7 _$?_D 1
M?]A*W_\ 1%U7B<2?\B+-/^P2I^AZ63_\C3 _]A$/S/#:***_ C]6"BBB@#^5
MS_@X+_Y+%^SW_P!DT\4?^I3'7\^5?T&_\'!?_)8OV>_^R:>*/_4ICK^?*OFL
M=_O=;UC_ .D1/Z=X'_Y)3)O^O%7_ -2JY^['_!*S_@HI^V./VA_V3/V41\8?
M^+!?\)9IW@C_ (0+_A7WPM_Y%<V^J7ATS_A*?^$(_P"$T_X^3YGVW_A(_P"T
M?X/M?E_)7J__  6&_P""BG[8_P /OVMOVI_V4?"'QA_LCX!7_A3PGX(N_ 7_
M  K[X6W_ )OA?XF_ 7P3>>-],_X2G4_!%[XTC_MNY\5Z_)]MB\1IJ.F_;]FD
M7=A':V26WYH_\$K/^4A_[)G_ &5?3O\ TVZG7J__  6Y_P"4GW[3?_=%_P#U
MGOX3U]C#-LT7!$YK,LP4X\1T,%&:QF)4HX/^R*[^J1DJEUAKQB_8)JE>*?)=
M(^0J</9!+Q3HTY9'D[ISX+Q>:3IO+,$X3S-<1X.*S&470Y98Y1G.*Q;3Q"4I
M+VEI._W)^TE_RKP?L7_]ET/_ *D_[2=?F)_P2L_Y2'_LF?\ 95]._P#3;J=?
MOEX!_8S^*'[='_!#K]D#X-_"37O 7AWQ/IGC[6?'D]_\1=4\0Z1H+Z/HGCSX
MZZ/=6T-UX9\+>+M0;4I+GQ%926\+Z7':O!%=-)>12)#%/X+^RW_P1<_:D_8]
M_:>_9W^/WQ,\>_ +7/!WA#XQ>"K+4]-\"^*?B)J?B:>7Q1J/_",:>UC9Z_\
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M1\,/]5K/_72Q_P#0;JBOW3A'_DG<M_PXG_U,Q!^8<0?\CC&>M#_U&HGG.O\
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M95?^?=3_ , E_EYK[Q77=?>CV*BO'?\ AHC]G_\ Z+G\'?\ PYO@K_Y=T?\
M#1'[/_\ T7/X._\ AS?!7_R[H]E5_P"?=3_P"7^7FOO"Z[K[T>Q45X[_ ,-$
M?L__ /1<_@[_ .'-\%?_ "[H_P"&B/V?_P#HN?P=_P##F^"O_EW1[*K_ ,^Z
MG_@$O\O-?>%UW7WH_E1_:]^%/Q@_X)*?MA?&W]HGPY\-?&_Q:_82_:DU^;XC
M^.+_ ,(6%M<S_!'XC:YXCU#4-8LKU$)M-,MK34-:U$>&7UAO"OAWQ-H?B/0O
M#9\0S^(/!SR2<_'_ ,%E?V*GC1VU?XD1,Z*S12> ;HR1,R@F-S%?RQ%T)VL8
MY)(RP.QW7#'^LT_M#_L_$$'XY_!P@@@@_$WP400>""#K>"".HKRB]OOV#-2O
M+G4-1O/V1=0O[V>2YO+Z]N/@U=7EW<S.9)KBYN9WDFGGE=B\DLKO)(Y+,Q))
MK\GXZ\!_#;Q(SI\1\2Y3G>'SRMA\/A\=CLAS.. 69K"4:6&PM;'8?$X''498
MJCA:5+#_ %B@J,JM*G2C64W",E^A<,^*7%O">6QRC+,3@*^7TJE2IAZ&8X66
M(>%]K.56K3P]2E7P\U2J59SJ.G4=11G.;AR\S3_F,_X?)_L4_P#0;^(O_A 7
MW_R91_P^3_8I_P"@W\1?_" OO_DROZ:?^-?_ /U9W_YA6C_C7_\ ]6=_^85K
MXO\ XE(\&O\ H'X[_P##_@?+_J0^?Y=]/HO^(\<=]N'O_#=B?_GA_5WY6_F6
M_P"'R?[%/_0;^(O_ (0%]_\ )E'_  ^3_8I_Z#?Q%_\ " OO_DROZB?#7A+]
MBGQIJ?\ 8O@[PS^RWXLU@V\MV-)\-:-\)M=U,VL!03W/V#2[:ZNOL\)DC$LW
ME>7&70.R[ESZ%_PSO^S_ /\ 1#/@[_X;+P5_\I*E_1,\%XNTJ7',7H[/B'+T
M[/K9Y"O.W?YZ"\=^/'M'A]_]T[$^7_4P_J_I;^33_A\G^Q3_ -!OXB_^$!??
M_)E'_#Y/]BG_ *#?Q%_\("^_^3*_K+_X9W_9_P#^B&?!W_PV7@K_ .4E'_#.
M_P"S_P#]$,^#O_ALO!7_ ,I*G_B4WP5_DXX_\2++_P#YQ>O]/1_\1WX]_EX?
M_P##;B?_ )X?U=^5OY-/^'R?[%/_ $&_B+_X0%]_\F4?\/D_V*?^@W\1?_"
MOO\ Y,K^LO\ X9W_ &?_ /HAGP=_\-EX*_\ E)1_PSO^S_\ ]$,^#O\ X;+P
M5_\ *2C_ (E-\%?Y../_ !(LO_\ G%Z_T]#_ (COQ[_+P_\ ^&W$_P#SP_J[
M\K?R:?\ #Y/]BG_H-_$7_P ("^_^3*9)_P %E?V*DC=UU?XD2LB,RQ1^ ;H2
M2LJDB-#+?Q1!W(VJ9)(XPQ&]T7+#^L[_ (9W_9__ .B&?!W_ ,-EX*_^4E6K
M+X"_ S3;RVU#3O@O\)]/O[*>.YL[ZR^'7@^UO+2YA<20W%M<P:/'-!/$ZAXY
M8G22-P&5@0#3_P")3O!5:^SXW?D^(LO2>VC:R*]M]M?T7_$=N/?Y<@7G_9N)
MOZ_\C"W_  _I;^6']AWX+_&;_@J5^V;\&OVP_'_PW\7?"']BG]E?5AXX^"MM
MXML4M=6^,GQ(T[6;#5= U33'+6RW&FKK6C^']=\4:MI1\2^$]/A\&1> -.U#
M4-6US7-<T[^O:BBOWO)LGRCAS)LKX=X?R^GE61Y+A7A,MP%.I4K>RIRJU,17
MJU:]5RJXC%8K$UJV)Q6)JMU*]>K.I+5V/RO-,TQ^=9CC,VS3$RQ>88ZK[;$U
MY1C#FDH1IPC"$$H4Z5*E"G2HTH)1ITX1A%604445Z)P!6UX<_P"0_HW_ &$K
M/_T>E8M;7AS_ )#^C?\ 82L__1Z5UX#_ '[!?]A>&_\ 3T##%?[MB/\ KQ6_
M]-R/I:BBBOZ-/QX**** "N!^(_\ R (O^PE;_P#HBZKOJX'XC_\ ( B_["5O
M_P"B+JO$XD_Y$6:?]@E3]#TLG_Y&F!_["(?F>&T445^!'ZL%%%% '\KG_!P7
M_P EB_9[_P"R:>*/_4ICK^?*OZ#?^#@O_DL7[/?_ &33Q1_ZE,=?SY5\UCO]
M[K>L?_2(G].\#_\ )*9-_P!>*O\ ZE5PHHK]$?VE_P!FKX*?#?\ 8O\ V(OV
MB_A==_$:X\0?M'W7QR@\;P^/-2\/W%M97GPG\3Z/X)6'PWIF@:391Z9I5UJU
MOKFIVZ:AJ6N:DUK?6L5S?[H/*14,)5Q-'&5J;ARX&A#$UU*7+/V4\30PBE"-
MO?:K8FDI*ZLI7Z6/<Q>8X?!8G+,+657VF;8NI@<+*$.:FL12P.+S!QJRNO9J
M6&P6(E!VES2ARZ7N?G=17M6N77[/;_ KP/:>'-)^+,/[2,7C'Q!+\1=7U?4?
M"TGP?NO CQS?\(U;^$M/M(5\60^)4D-H-5;5'&GQ>3?2P3WPU&TMM%\5K&I3
M]FXI5*=3FITZEZ<G)1]I!3]G)N,;5*=^6I%749II2=KG31K.LIMT:U'DK5J-
MJT8P<U2J."K0492O1JVYZ4FU*4&I.,6[!11169L%%%% !1110 4444 %%%%
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M^OL/_2D>!Q5_R3>>?]BS%_\ IF1_9S1117U)_*P4444 >N?##_5:S_UTL?\
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MOB;_ /-91_PZ&_8)_P"B0ZO_ .'.^)O_ ,UE?I?11_K#GW_0YS3_ ,+\3_\
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MKX@MK:*2&[LH(O%?B/2[/0]?U[QKK$=W;V%I^^7_  7Q=T_X),?M8,C,A*_
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M;2KZW\'>'%\#-I'C.UFT[1?!,?XJ^.?VS/&'CW]D_P"&/['VH_"_X0:;\/\
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M\?\ _P $^?\ DO?_  4\_P"SZ/BU_P"IGXRK^P"OX_\ _@GS_P E[_X*>?\
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M+PW_ *>@88K_ ';$?]>*W_IN1]+4445_1I^/!1110 5P/Q'_ .0!%_V$K?\
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M_/\ J*_T ?\ AA']BW_HU7X!?^&L\'?_ "IH_P"&$?V+?^C5?@%_X:SP=_\
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M\'?_ "IH_LJK_P _:?W2_P O7^GH?\17RS_H5X__ ,&8?_Y+U_IZ?Y_U%?Z
M/_#"/[%O_1JOP"_\-9X._P#E31_PPC^Q;_T:K\ O_#6>#O\ Y4T?V55_Y^T_
MNE_EZ_T]#_B*^6?]"O'_ /@S#_\ R7K_ $]/\_ZBO] '_AA']BW_ *-5^ 7_
M (:SP=_\J:/^&$?V+?\ HU7X!?\ AK/!W_RIH_LJK_S]I_=+_+U_IZ'_ !%?
M+/\ H5X__P &8?\ ^2]?Z>G\ EO;W%W<06MK!-<W5S-%;VUM;Q/-<7%Q,ZQP
MP00QJTDLTLC+'%%&K/([*B*6(!_K?_X(T?L'^+OV>/#/BCX_?&+0=3\*?%+X
MEZ0/"OAOP;J\,EEJ_A/X<&]TS6[J;Q%I\I2XT_Q!XKUO3--N9M$O[>.^T'3=
M!TX7?D:AJVI:;IWZO> /V:OV=_A5J*:S\-/@5\(O >M(&":WX3^'7A+0M;57
M!#(-8T[2;?4_+(9E$?VK8%9E50"0?;:ZL+EZH352I-3DOA2348O^:[U;W2T2
M6^KM;Y7BCQ"J9W@9Y;@<'/!8:LX_6:M6K&I7K0C)35&,814:5-RBG4?-.51)
M0]R+FIE%%%>D?FP4444 >N?##_5:S_UTL?\ T&ZHH^&'^JUG_KI8_P#H-U17
M[IPC_P D[EO^'$_^IF(/S#B#_D<8SUH?^HU$\YU__D.ZU_V%M1_]+)JR:UM?
M_P"0[K7_ &%M1_\ 2R:LFOQ3&_[YB_\ L)K_ /IV9^D87_=L/_UXH_\ IN(4
M445S&X4444 %%%% !1110 4444 %?Q__ /!/G_DO?_!3S_L^CXM?^IGXRK^P
M"OX\/^">NIV,G[2'_!4C1$G4ZII_[;/Q)U.\M"&$D-CJWCSXCVEA.V0%VW%Q
MHNIQ  EE:U;>%#)NQS)-\/YS9-V67M^2^O4U=]E=I>K2ZGZ'X522X[R=-I.5
M#-(Q3=G)_P!G8B5EW?+&4K+HF]DS]5Z***_-3^O0KQ7XL_L]?"OXWWWA#4?B
M3I/B75KOP#KEGXG\'2:+\2/B7X)30/$NGF<Z?XCL8/ OB_PW;C7[$7-Q'9:S
M+%+J5K#-)#!<QPL4KVJBM*5:K0FJM"K4HU8W4:E*<J<XJ2<9)3@U)7BW%V>J
M;3T9AB,-AL92EA\7AZ&*H3<7.CB*5.O2DX24X.5.K&4).,XQE%N+Y9)25FDS
MQ?PM^SY\*/"'C<_$JPT'6-9^(":7+H=EXR\>>.?'WQ-\1:+HMQ+/-=:3X:U7
MXC^)_%5WX7TV\DN9VO;+PY)I=M>B1ENXYEPHY:P_9-^"ND^,?'/Q TBS^).C
M>,OB6-,'CSQ!HWQ[^/>D7WB@Z'9-INAOJG]F_$RUADET/3WDL=$FCBCETBTF
MGM].>VBGF1_I&BMECL:G.2QF*4JE.-*<EB*J<Z4)*<*4WSWE3A.,9Q@[QC)*
M22:3.9Y3E;C3B\MR]QHUIXFE%X/#.-+$5:<J53$4U[.T*U2E*5.=6*52=.4H
M2DXMI_*DG[%GP!>^@U2+3OBG8ZG;Z?=Z8-1TK]H[]H_1[^>TU#7M3\4ZG]OO
M-*^+%G<ZE<ZMXFUK5_$.KW^H275_JVMZE>ZKJ-S=7UQ).WO7@#P!X5^&'A33
MO!/@K3[G3/#NESZM=VUO>ZQK?B&_EO=>UG4/$6MZCJ.O>)-1U?7]8U/5]=U;
M4M5U+4M7U.^O[R^O;B>XN)'<FNQHI5L9C,1!4\1BL37@I*:A6KU:L%-*24E&
M<Y)22G-*5KI2DD_>=ZPV69;@ZCK8/+\#A:K@Z;JX;"8>A4=.3A*5-SI4X2<)
M.G3;BWRMTX-J\8V****YCN"OQ;_X+J_\FD?#O_LXSPC_ .JS^+M?M)7XP?\
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M"BBB@ HHHH **** "BBB@ K:\.?\A_1O^PE9_P#H]*Q:VO#G_(?T;_L)6?\
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MQ_\ S>?Z2]%?YM'_  D?B'_H.ZS_ .#2^_\ C]'_  D?B'_H.ZS_ .#2^_\
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MCX8?ZK6?^NEC_P"@W5%?NG"/_).Y;_AQ/_J9B#\PX@_Y'&,]:'_J-1/.=?\
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M1;*L>MZ%%\*9;R/3+[&Z2U2ZU6Y\.ZC.JJ599+O0],F8-EK5!@F3_AZKHO\
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M6_\ #06G_P T=?V(@@@$$$$ @@Y!!Y!!'!!'0TM<W]E</?\ 0JK_ /ARK?\
MRKU_I:W_ ,1;XX_Z#L!_X;,/_GZ_TM?X[?\ AZKHO_1F_P"VM_X:"T_^:.C_
M (>JZ+_T9O\ MK?^&@M/_FCK^Q*BC^RN'O\ H55__#E6_P#E7K_2U/\ B+?'
M'_0=@/\ PV8?_/U_I:_QV_\ #U71?^C-_P!M;_PT%I_\T='_  ]5T7_HS?\
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M1]*_Z,Y_;2_\-%;?_-!1_P /1]*_Z,Y_;2_\-%;?_-!7] /_  ^"_P""9?\
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M>:@KQ:5JFO2>&8-;:;2X[E)9;^/4=8\'62V5M<S2^(["**:YM_V/_P""0?\
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MR^'G_@)J/_RQH_X=X_L4?]&Y?#S_ ,!-1_\ EC7V;17'_P 1*\1?^B^XU_\
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MZ+[C7_Q*L]_^;P_U4X6_Z)K(/_#/EW_S,?&7_#O']BC_ *-R^'G_ (":C_\
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M3E2P698K#SKXW"TI5_K+C!SJNA*4*NM&K.A*K13ER33::\3'^'F58[&X^O\
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MHH **** "BBB@ HHHH *_7?_ ((A_P#)]N@?]DT^(W_INLZ_(BOUW_X(A_\
M)]N@?]DT^(W_ *;K.M\+_O-#_K[#_P!*1X'%7_)-YY_V+,7_ .F9']G-%%%?
M4G\K!1110!ZY\,/]5K/_ %TL?_0;JBCX8?ZK6?\ KI8_^@W5%?NG"/\ R3N6
M_P"'$_\ J9B#\PX@_P"1QC/6A_ZC43SG7_\ D.ZU_P!A;4?_ $LFK)K6U_\
MY#NM?]A;4?\ TLFK)K\4QO\ OF+_ .PFO_Z=F?I&%_W;#_\ 7BC_ .FXA111
M7,;A7Y,_\%SO^45'[7'_ &+_ ,-O_5V?#6OUFK\F?^"YW_**C]KC_L7_ (;?
M^KL^&M=> _W[!?\ 87AO_3T"*G\.I_@E_P"DL^"OV(O^3//V8?\ LA7PQ_\
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MD,,US-%;V\,MQ<7$L<,$$,;RS332N(XH8HHPSR2R.RI'&BL[NP5020*_I/\
MV5-5\9>'?VH?^"5UA^T;XAU7PUX_G^!_P]T;]GSX._!#3X_#'A:'X%^(YO&3
M^&OB7\?O%]_K6M:?JWB_XBVZZM<:]X%\$>&3<:]8:;I4WCC7?!7B7^T=/OOS
MU^&?BO1O@?\ \%9?&WCZ/X4OX_\ !WP?_:+_ &E_&NH_#WPS9Z-9W.G?#_X<
MR_%/7?$?B#PAI]_>:+H\6J?"WPCH>I^._"MA%?Z4%U7PAIUGIUW970MI8NNO
MD5&E3R^H\35I+%9A2P&)56BI5,/[2AA*[KNC1E.<'%8F2^JR<J]J<92<9U?9
M0\_"<68FO7SFBL#0KO 9-7SC!/#XAPHXM4<5F&$6$CBL1"%*HJD\%"2S"$88
M52K3A&,X4/;U?@OQ[\"/CA\*K&+4_BA\&OBM\-]-GN=.LX=0\>_#OQ?X/L9K
MS5[74K[2;6*[\0Z/IUO)<ZI8Z-J]YIT"2&6]M=*U*XMDEAL;IXJ/@;X-_%[X
MGZ?XAU;X:?"KXD?$/2O"-O%=^+-3\#>!O$_BW3_#%K.LSP7/B&]T#2]0MM%M
MYDMYVBFU*2VCD6"9D8B-ROZF?M??!;0O#?[&EK\0_P!DG]HV[_:!_8;\1?M!
M>'M7O?"WCZRU*P^,WP%^-">"O&&F-H?B"V>WT_39M*\0Z-K+G7-831M&_M+4
M8/!TVDV=[IDS^(]>]+_:7\47'[%\7_!,+XK_  [T/XB'P%I_[,OP0^,?P]/A
M#XE0>"_AGKOQ=<P^*OC+'XM\,KX'UV_USQ+XPU+4]+?XBW5UKUI>:MX-U[1O
M!"&STCP[:V-BYY%1HU<1/$5:M+!X6A@Z]:I3E2Q?-3QM?V-.OAZ^&4Z-;"I>
M_&LHIU)N&'E"C.<I4II<5XG$X?!T\%0P]?,L?B\RPN'HUZ>(R_V=7+,+'%5L
M)C,)C94\3A<?)MTYX>524:5)5,93J8JE3IPQ'X045]X_$_\ X5_\:_VX?'VJ
M_M,3V/[&GASQ_K=_XN^(L/@GPWJGQ=C^'?BW6/!L/B.ZTYO"^BZBFKG6_$7C
M&?;XKT">XM=3\!^(=:UG1-<T[3;[P_?:9:^<_M-_#/\ 96^'7_"$_P##,W[3
M>N_M&_VQ_P ))_PFW]M?!?Q/\(/^$._L_P#L#_A&_LW_  D>H7__  D/_"0_
M;M?\[['Y7]D_V'%]H\S^TX-GD5<!.G#%5H5L-.CA<14H?O,1A\/BZO)4C352
M&75JL,>XRYXR=J#]FE44VO95>7Z/#YQ2K5,OPU3#8VGBL?@J6,7LL%C,9EU#
MVE&=:5&KG6%P]3*5.'LYPCS8N#K-T72C)8B@JGEUK\ ?CM?>"8/B79?!7XMW
MGPXNK'5]3MOB!:_#CQC<>";C3?#]I>ZAK^H0>*XM&?0I;'0[#3=1O=7NX[]H
M--M+"]N;V2"&UG>/BO#W@SQAXNCUR;PGX4\2^)XO#&B7_B;Q++X>T+5-:C\/
M>&]*@DNM4\0:X^FVMRNDZ)IMM%+<7^K7YM["S@CDFN+B.-&8?T;_ !,\*>&/
MVAKG]IOXG_LE_$?6?@K^U;X*_9S\9_"/]K[]@7XHV B\-/X%^''PMMO@[XWT
M[X*:IX7N)-%U&R\#GPM!/X,TV&]UR$^(K?0=0U1?!&G7]MX=U?YP_P""2OQ2
M^(?A+]GC_@IK8Z#XOURTTCPA^R=XL^(WAGP_/>R:AX8T;Q[!8WUK'XPL_"^H
MF[\/KXA-MIFF6TVIOIKW-U;:;I]M=//;V=O%'[DN'J$<PPF$EB:OU?$TL?4A
MC*4:->G66!H5*K=."J4Y4:C=*4,1A<1RXC"5&J=13TJ2^4CQGBY9-F&91P.'
M^MX&OE%&IEN(GBL)6PTLUQ-"@HUJDJ%>&)HQ6(A4PF88+VF"S*BG6HRIOFHT
M_P :_&GPO^)?PW30I/B)\._'/@*/Q3IQUCPP_C3PEK_A9/$>D!D0ZIH3:YI]
MB-7TX-)&IOM/-Q;!I$'FY909?A[\*?BC\7-5O-"^%/PV\??$[7-/TZ;5]0T;
MX>^#_$/C35;'2;=XX[C5+S3O#>G:E=VVG022Q1S7LT*6T3R1J\JLZ@_LW:_M
M ?$;]I[_ ((\?M63?M/^*=3^)>O_  4^/?P2F_9_^(WCS5EU/QA+XI\::Y:6
MWC+PC;:S>3#5M>;0_ L_BG58X[^34KV'2O$MU$LG]DZ%IT.D>??$/P];_";_
M ()F?L#_ !:\&V/Q+MO#'C;QU\=-6^*/B#X3?$:W^&TA^-WA_P"(U]I?P^U+
MQS=2>"_%E[JNL:7X)\,W6E_#I_-T^U\,6V@^)-2TN**\\87UYJ.$\EPO,J]'
M$UZF!63T\XESTHT\7&E+,(Y94HRA3=>,7#$.5558QG#ZMRU'%7TZZ?%&.Y7@
M\1@L+1S5\2U>&H.GB)5LOG6CD\L]HXJ%2JL)4G&I@N7#O#2E2J?7N>C&;Y5?
M\<K^POM*OKW3-3LKO3M2TZ[N+#4-/O[>:SOK"^LYGM[NRO;2X2.XM;NUN(Y(
M+BWGCCF@FC>*5%=64=EXA^%?Q/\ "/AS0O&'BOX<>/?#'A'Q2@D\,^*?$/@_
MQ#HOASQ'&REQ)H6MZEIUMIFKH45F#Z?=7"E5+ X!-?N+\ _&MG^V[_P5]_9C
M^)GQX^"/@+X=ZA\3_ ,OCN3P?_:/]OZ3XY\0>$OA9\1-7^%GC_QEI$LT-QI-
M_K2^&/!VN:?H.J6.F0^)_#^C^%?$%OIE]H'C/3KK5?SFTWXV?M<Z-X>_;1_9
M\\1F\\5O\28[?5_VF_\ A9HF\3:]X2U;X&^,HYI?$2:]K&J/9>'_ !%#XG-G
MX*-]-]MDUC4;_P .^'M&1M?_ .$7DML:N4X:C2G7^L8BMAZN,S'!X*K2PDHR
ME/!87#XJC/$4*DHSI+%+%T:?L[\U&*KU^:K&BH5>JAQ!CL1B*6#6"P6&QE#+
M<ES+,Z%?,:<Z<*6:9AC,!B:>"Q5",Z5=Y?\ 4,36=5QY<3.6$PG)0J8B=3#^
M1_!/4/#EKX!_:"M-8_9FO_CKJE_\.HAX?^(5EK7CC38_V=+JWOV%Q\2-0L?"
MEG=:1J]A(+BVM6@\6S:;I<5W;68:_>SGU/2]3]F_X)R_L;:K^VG^T]\.OAKJ
M6D^,8?A(-<EO/BUXW\.:'?WFG>&_#^E>']?\4QZ+J'B".%M+\-:IXZ;PW-X3
M\/7VH3-)!J&I#4+73]4_LZ:RD^NO^">WBGQ/>?\ !/3_ (*P^#[SQ'KUUX1T
M+X/_  TUO1/"USJ^H3^'-'UG7M>\66VN:OI6B2W#:9I^IZS;Z/I%OJU_:6L-
MUJ,.E:=%>2S1V-LL7-_\$)]=UNR_X*-?![0K/6=5M-$UO1OBG+K.CVNHW=OI
M6KR:;\)?',^G2:II\4R6E^^GSN\UD]W#*UK*[20&-V)/=EV7X:IC>$*>);Q&
M&S*M!5:*H4*#2>;U\+*C4JT[U,33G*FW*I6DZJHR]E3]G&,(Q\G.LXQU'*O$
MBM@$L'CLCH5?88F6*Q6*BY1X<P>80Q-&A5:HX.M"G748T</35!XFFJ]?V\JE
M64_ _BYXA^#FB^'?A[X)\5_\$]M;^!7[06B?%O0/%$VAQZ_\==!T3XH? .YN
M-=/_  @FM^&/B=XI\1>,X_$6KZX+;1+7QUX:>VN;VRLKQ;.:SN;.+3J^6_VB
MKG2;OXV?$.YT+X'7_P"S9I$VMH]C\#=4U#Q-JNH_#N'^S[(?V/>ZAXQLM-\1
MW5Q<.'U65]0TW3U5M0,=E86>GI:6\?L/['7Q3^)Q_;6_9>\3GXC>/#XEN/C?
M\)/"EQXA/B_Q!_;D_A;7/'VC:5K?AJ;5O[1^WRZ!K&F:IJ>G:KHSW#:=J%AJ
M-]9W=M-;W=Q')^KOAKP'X(^)/_!PYXL\*^/]+T;7-%D^,WQ,UNPT;Q#;?:]#
MO_%7A3X/^(/%/@[^T[4R1QW4%AXGT?2M6CLIV:WU&YT^#3IX;B*[>WEBEA'G
M%"@Z52C1>*SS+LIIP^H8&AR*O1K1I5ZE;#4Z4Y-7:JTH1IPJM0J352K&$H:5
M\R7#6,Q<<11Q.*C@.$\YXBK5%FV:8MU)87%8:6(PE'#8^O7IPA*REAZ]6I6J
MT%*=&DZ%"52-7\%?$/PK^)_A'PYH7C#Q7\./'OACPCXI02>&?%/B'P?XAT7P
MYXCC92XDT+6]2TZVTS5T**S!]/NKA2JE@< FN"K[ITWXV?M<Z-X>_;1_9\\1
MF\\5O\28[?5_VF_^%FB;Q-KWA+5O@;XRCFE\1)KVL:H]EX?\10^)S9^"C?3?
M;9-8U&_\.^'M&1M?_P"$7DMOA:O!Q5*C2]DZ#Q%I0FJL<325*5.M3K5*<H1<
M9-5$X1IU).T72G4E0?.Z7M:GU^7XC%5UB%BE@KPJ4WAZF"Q$J\*^&K8:A6C5
MG&4(RHR56I6HP7--5Z5&GBX^R6(]A2Z'PKX1\5^.M=L/"_@CPQXA\8^)M4D,
M6F>'?"NBZEXAUW4954NT5AI&D6UYJ%Y($!8I;V\C!06(P":A\1^&?$G@[6K_
M ,-^+O#^N>%?$6E3&WU/0/$>DW^AZUIMP &,%_I>IV]K?6<P4AC%<01O@@[<
M$5^IO@;P5J>E?\$;_BG\6_A?%=V/BR\_;7T;P+\>?$V@W-S8:Z?@C;?":R3P
MOX4URZ@NX7E\ 7?Q)\:Z9<7VFI"UMK?B/5=(_M!+I- @^Q?(G[1'QB^-7QZT
M#]G+Q3\;+?1[;2_"?PET_P""WPV\5V^D"U\0^+/A]\,=<O\ 34\1^(II;VZU
MCQ1+8:GJ>I^'T\1,+;3-3U30-=LK.-]?T[Q1<2]>(R^EAL+2G4J5GB:^#P^/
MIJ%)/#.AB*TJ/+*HY*4)4VH\U5IP=9RP_*G!5)^=@\YK8['XBG1I898+"9EC
M,HKRJ8B4<;'%X3"T\2IPH*#A4C6C.?+04E5CAXPQG/*-1T:7B?A_X2_%7Q;X
M7USQOX5^&?Q!\3>"_# +>)?%_A_P9XCUGPOX>4*7+:YK^FZ;<Z5I(" L3?W=
MN H+= 37O/[!WA+X8?$/]KGX"_#;XP> O^%C^!?B5\2?"/P^U3PZWBCQ!X2B
MC_X2_P 0:;HG]K2ZGX6N;#7)O[+@N[BY@T^RU32OM-V+<W%[]FBFM;G])?V[
M_$GQ)_98_P""GWP0TKX!WFI^'/AU\,O"/[-6D?LPZ%X1UV;3M"\2?"34-/T*
M75M(COK:>2R\0:)\1OB)-\0K7Q;?:G_:5MXMEU#4I-?;5$FF\S-^(GA'X;^!
M/^"^WAGPO\)M.TC1_!.G?MC? N:WTG05MX](TOQ%JD_@#5_'>G6%K:2RVNGP
M67CN_P#$MM_95L(+?2'B;3(+*PBM$L;?UHY-2P6.IIU%6G@.(<'E.,HUZ$)4
M<1*K*K-5J,9J4:F&FL-7A*%6+;IRH5;VKNG3^>EQ-7S3*ZS5%X:GF_!V9<19
M;B<)BJM/$X.&'AAZ<L+BITG"='&TWCL+5A6P]2*56&+H*-\(J]?\[/VM_@AK
MG@[]H+]K.]\!_##Q/I?P/^&G[3OQE^'6F:_I/AG7I_ 'A*TT?XF>(M&\->%)
M?%!M9])LKFVTV"PLK"QOM3^W31B  2NX9OE+3=,U+6;^STK1]/O=5U34+B*T
ML--TVTGOK^^NIF"0VUG9VL<MQ<W$KD)%##&\DC$*BDG%?TW_  ^^//QB^,'[
M7_\ P6G^#OQ+^(?B3Q?\)/"?[-/[?$?A;X7ZI>@_#WPY/\./B?IOASPAJFA>
M#;=(/#VDZ]IVG7M]-=^(K#3K?7=<UF^OO$FO:CJ?B&[N-4D_.G]@7PA'-^Q[
M_P %/OBEX'C@E^/GP_\ @I\-](\%W4+'^W_#GPE\;>+M7MOVB==T*,R[H3-\
M-]'GTO5M<LH5OM$TJXN;,7MM;>(9X;M8O)*%;&TWA*]3V6*EGE6<9T(4YT_[
M(^L5ZU/#TJ=6<9^UHTE##P<HOVC496CJC+>*<7A\JK+,<+0>(P$.%,-3J4L7
M5K4JW^L2P.$P]?%UZV'I3I_5\1B)5<;55.:]@G*"E--2_,WQU\-_B)\+]87P
M[\2_ 7C3X=^('MHKU-#\=>%M<\):PUG-GR;M=,U^QT^]:VFP?*G$!BDP=CG%
M7O"WPC^*_CFRL-2\%?#'XA^,-.U7Q+;^#-+U#PMX+\2>(++4O&%WIFIZU:>%
M+"ZTG3;N"\\2W6C:)K.K6^A6\DFJ3:9I&IW\=JUK874L7ZA?#GQ$/B9_P1V_
M:@T_XN22>(9?@%\>/@J_[,WB+Q)JW]H:KX:USXB:C8:=\1/ '@Z6]G_M+3O#
M@\%:5J7B2\\+V4LVAW%]J%SKJZ1'?Z;-J</L7AW]IG]H/X;_ /!%3P#XS\$_
M&3XB:#XM\._\%"+/X<>&O$EOXHU2XUOPQ\/]&^ 6IZ[IW@GPQJ5[<75UX=\*
M07VGQQMX?T:2QTJXTNZU;0[FUFT76]9T^^PI9-@I356IBL1'"SR66<05.C3G
MB(JGB:F%JX:HIU:4.95:-1TZJ]VI2=*HX0YG%=>(XES.%.5"C@,%/'T>)Z7#
M565;$UZ6"G*O@J&/HXZC[.A7J\DJ&)HQJX>3<J&(5:C[:M[-5)_G/^S+^PW\
M</VE]6^-MEX>\&>,M.L_@)\,?BMXU\<S#P=K5]J-OXR\!^%-<O\ PS\)+?2#
M%:W,WQ"\<>,M/L/"MMX81CXALK.37-;AT?4CX?GTZX^8I?AW\0(/&P^&D_@7
MQC#\1FU:'0%\ 2^&-;C\;'7;AD6WT4>%7L1KIU:=I8UATX6'VR5I$"0L77/Z
MT_\ !,;QEXL\6Q_\%3_%7B3Q%K.M>)/$O_!.G]K'QEKVL7]_<3W^K>+-:72-
M1U7Q%>3%]TNLZA?W$UU<WY_TB2:1G+Y-?.'_  3P\?\ @3X>?%OXN^*?CCX+
M\;^*_A%JO[.?Q%\#_%KQCX&.F2?$7X/^#?C'?^#_ (4K\6_"G]N7$32ZE;ZO
MX[T'PA/-9+J%^F@^.-3NX])URSBNM)O9678&K0R3DG5H2Q];'?6<56DG3IT:
M%;DC*5.$)*E&%.+G.HY3C3O4G4;IQ7);SK-J&+XI]I3H8N&48;*E@L!AJ;A6
MK8K%X55IQA6JU4Z\ZM>I[*E14(3J\M"E1C&M.7M?CCX@?"#XL_":>TM?BI\+
M_B)\-+F_N=0L[&W^('@GQ+X-GO;S28=,N-5M;2'Q'IFFR7-SIEOK6C3ZA!"K
MRV4.K:9+<I&E_:M+YW7ZL?\ !0;X,:]\,/@U^R]?^ /C[I/[37[&^KZC\7[[
M]FOXC_8=6TSQOX8&N3^"9_&?PS\>:7J)6/2I-!U'189]'M$M=.OCJDGC)]2T
M7P\RVV@:9^4]>9F>#> QE3#<LXJ-/#S7/.E5NJV'I5N:G6H.5&O1DZC="O2?
M+6H\E1*+DXKW<BS-9OEE''<]*;J5<73E[*GB*'*\-BZ^&Y*N&Q<(8G"8F"I)
M8K"5X^TPV)56@Y35-3D4445P'KA1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %?KO_P1#_Y/MT#_ +)I\1O_ $W6=?D17Z[_
M /!$/_D^W0/^R:?$;_TW6=;X7_>:'_7V'_I2/ XJ_P"2;SS_ +%F+_\ 3,C^
MSFBBBOJ3^5@HHHH ]<^&'^JUG_KI8_\ H-U11\,/]5K/_72Q_P#0;JBOW3A'
M_DG<M_PXG_U,Q!^8<0?\CC&>M#_U&HGG.O\ _(=UK_L+:C_Z635DUK:__P A
MW6O^PMJ/_I9-637XIC?]\Q?_ &$U_P#T[,_2,+_NV'_Z\4?_ $W$****YC<*
M_)G_ (+G?\HJ/VN/^Q?^&W_J[/AK7ZS5^7O_  6D\)ZWXT_X)>?MA:/X?M'O
M;^S^'>D>++B&..>5DT3P%X\\(^.O$UV5MX9Y FG^&_#FK7\LC(L$,=L\MU-;
MVR37$75@6ECL&V[)8K#MM[)*M!MOT(J?PY_X)?DS\YOV(O\ DSS]F'_LA7PQ
M_P#41TJOJ.OC_P#X)_\ B/2O%/[%G[-.IZ//Y]I:_"?PSX<F?,9*ZKX/MV\)
M:Y!^ZDE4?9]:T2_@ +"0",":.&7?$GV!7YGFD7',\QC)-2CCL7&2>C36(J)I
MKNFK,_NW(9QJ9%DLX24H3RG+IPE%WC*,L'1<9)K=---/JF%%%%<)ZQY7XL^!
M7P1\>Z]#XJ\=?!SX5^-/$]M''#;^(_%GP]\(^(]>@AA4)#%#K&L:1>:A%'$@
M"1QI<*J* J@  5M>%/A=\,_ >D:IX?\  _PZ\">#=!UMYI-:T3PIX1\/^'=(
MU>2X@-K<2:IIND:?9V6H//:DVTS7<,K2P$PN6C.VNZHK9XC$.FJ3KUG2BDHT
MW5FZ:47>*4'+E2B]59:/5'-'!8.-66(CA,-&O-R<ZT:%)59N:M-RJ*"G)S6D
MFY/F6CNCP@?LM?LQK'J<*_LY_ @0ZU(9M8B'PA^'PCU:8R/*9=30>'MM_(99
M))#)="5C([OG<S$]IXG^$?PH\;Z)HGAKQG\,?AYXN\.>&1;+X;\/^)_!?AO7
M]$\/K9P16MFNB:5JNFW=AI(M;6""VMA806X@@ABABVQQHH]#HIO%8J4HREB:
M\I0=X2=:HY0;CRMQ;E>+Y4HW5GRJVQ$<OP$(3IPP.#A"K%1J0CAJ,85(J3FH
MSBH)3BIMS2DFE)N2UU(+6UM;&UMK*RMH+.SLX(;6TM+6&.WM;6UMXUA@MK:W
MA5(H(((D2*&&)%CBC541550!/116&^YV)))))))626B26R2Z)!1110!^:7PU
M_P"5AK]E?_LVKQS_ .H#^T!7]<M?R/? .)_'G_!PQ\+G\.*;Q?@O^S-XHE\>
MD L-+35/ _C>WM&S;B<1AYOBQX,0F]-D-VH;5+,]H+O^N&OU5)K+LD35FLFP
MCL][2G6G%_\ ;T91DNZ:9_$W&THSXQXGE"2DEG.*C=.ZYJ?)3G'UC.,HR724
M6GJ@HHHK(^8"BBB@ HHHH ***LV=G<W]S#9VD337$[A(XU')/4LQ/"HB@L[L
M0J(&9B%!(J$)U)QITXRG.<E"$()RE.4G:,8Q2;E*3:223;;LA2E&,92E)1C%
M.4I2:48Q2NY2;LDDDVVW9+5EC2]+N]8O8K&S3=+*269LB.&)<;YIF .R- 1D
MX)9BL:!I'1&^B=%T:TT.QCLK49(^:>=E42W$Q^]))CM_#&F2(XPJ D@L:?AO
MP];^'[(0IMENY@K7ER 1YKC.U$SRL,6XK&, MEI& 9R!T5?M'"W#<<GH_6L5
M&,LQKP]_:2PM.5G["#5TYO1UJB=FTH0;A%RJ?G&>9S+,*CH4&XX.E+W=TZ\U
MI[6:T:BM?9P>J7O22DU&!7$^+_%2:)!]DM&5]4N$R@/S+:1-D?:)!T,A((@C
M/!8&20%%"2WO%'B2#P_9DKMEU"X5A:6Y((!P1]HG (801MV&&F<>4A4;Y(_G
MZYN9[R>:ZN96FGG=I)97QN=V.2<  *!T55 5% 55"@ <O%O$RRZG++\#4_V^
MK&U6K%W^J4Y+H_\ G_4B_<6].+]H[2=.^^09*\9)8S%1_P!EA+]W!Z?6)Q?5
M?\^HOXGM.2Y%=*=HG=Y'>21VDDD9GDD=B[N[DLSNS$LS,Q)9B222222:;117
MX^VVVVVVW=MZMM[MOJV?H*22LE9+1);)=@HHHH **** "BBB@ HHHH *_F>_
MX+7_ /*0#_@DE_V,OQR_]#^%U?TPU_,5_P %T=7M?"O[<7_!)/Q/K*SVV@KX
M]^+6ARZH8PME!?ZUK'P=TBU6>ZE:*WA2&?5+:XNV>4-#9"6X".(]I\CB2E4K
M\*\84:,)5*M;@[BVE2IP3E.I4J<.YE"$(16LI3DU&*6K;21Z_#\X4^(,@J5)
M*$*>>Y-.<Y.T8PCF6&E*4GT44FV^B1].T445_B,?Z,A1110!X?<_LQ_LV7EY
MJ6HW?[/?P/NM0UES+J]]<_"?P%/>:K(T@E:34KJ70&GOG:4"0O=/*QD <G<,
MUW.H_#+X;ZQX1M_A_J_P^\$:IX#LX(K6T\$ZCX3T&^\(VMM!')%!;V_ANYL)
M=&@@ABFEBBBBLECCCED1%"NP/;T5ZU;/L\Q#P\L1G.;5Y82I"MA'6S'&57A:
MM.*A3JX=SK2=&I3@E"$Z?+*,4HQ:22.*GEN74E55+ 8*FJ\90K*GA:$%6A)\
MTH5>6FO:1E+649W3>K39X[I'[.W[/WA^]T+4M!^!?P<T34?"UXNH^&;_ $CX
M9>"M-O?#NH(YD2^T*ZLM$AGTB\60F1;K3Y+>=7)<.&.:Z6P^%?PPTKQE??$7
M2_AQX"TWX@ZHDL>I^.K#P?X>L_&6HQSKLG2^\3V^G1ZW=I,GR2K<7TBR+\K@
MCBN]HJ:V>9WB75EB,XS6O*M0J86LZV88NJZV%JU/;5<-5<ZTG4H5*O[VI1G>
MG.I[\HN6HZ>79?24%2P.#IJG4C6@J>&H04*T(\D*L%&"Y:D(>Y&:M*,?=32T
M"BBBO+.P***SM8U?2_#^DZIKVMW]II6BZ)IU[J^KZI?S);6.FZ7IMM+>:A?W
MEQ(5C@M+.TAEN+B:1E2*&-W<A5)JH0G4G"G3A*I4J2C"G3A%SG.<VHQA",4Y
M2E*32C%)MMI)-L4I1C&4I248Q3E*4FE&,4KN4F[)))-MMV2U9X__ ,&N7_)@
M'Q?_ .SP_B!_ZI7]GVOZ2:_G,_X-A-#U/2?^">GQ O[^UEM[7Q/^U;\1M<T6
M62.5$OM,M_AG\%_#4MU TD:)-$FL^'M6LC) TL0FLYH3()HIHH_Z,Z_W@SC_
M )&>-_Z_/\$K_<?YF4OX4/\ "@HHHKS30**** "BBB@ HHHH **** "BBB@
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M_A"\T*?P7!;WNE^*=<1-/C\/+IUM<WTEY!:)= 2UC_\ #*7[4?\ T;9\??\
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MO+^^N)[JZF<EY9Y7=B2QK)KWW_AE+]J/_HVSX^_^&=^(G_S.4?\ #*7[4?\
MT;9\??\ PSOQ$_\ F<KB<:DFY2C.4I-MMJ3;;=VVVKMMN[;U;?F>I'&X",8Q
MCB\'&,4HQC&O148Q22C&*4TDDK))*R5DCU?XB?\ !0#]I/XGW'Q$UKQ'K?@B
MQ\=?%S0+SP;\3OBAX/\ A;\// OQ+\<> [XV'VKP+KOBWPAX=T:]E\.W<&EZ
M=INJ&V6VUK7M LK;POXAUC5O#,*:.OW5_P $C?$G_"O?A=^W_P")AXS^$'A3
MQ#XM_9I\0>"/A=IWQ4\;?"33K7QI\0ULM7U"Q\*CP7\2]7CLO$=AJ:206-Y%
MK>B77A*\%\NFZO<B*YDC/Y??\,I?M1_]&V?'W_PSOQ$_^9RC_AE+]J/_ *-L
M^/O_ (9WXB?_ #.5[&"S;'8?,*.88AXK&5:,<3&'M*]134L32JTIU%5E&I)3
MO6E5<DN:=6TY-MN_SF9Y-D.-R?$9-@ZV599A\34P,JBH4L+*FX8'$8:O2HNA
M"K1A*GRX>GAXP<N2G0?LX12Y4K/Q<_:-^*/Q,\,Z7\*]8'@_P;\,?"'BS7O%
MFD_"SX7>%/#?@KP#:^-M9C33]:\5W-GX:MU?Q3K\UG;KI>GZ]X@U77[C2-""
MZ'X;NM-\/&/3Z]1_9E_X*%_M7?LC^%?$O@+X+_$2UT[P%XLN[O5-7\$^*/"?
MA7QMX9_MV[T^+36U^QT_Q1I&IG3=36"VLGF6REAT[59-.T\:Y8:K#9P0IY+_
M ,,I?M1_]&V?'W_PSOQ$_P#F<H_X92_:C_Z-L^/O_AG?B)_\SE<=/'9E2Q*Q
ME'$XREB5#V<:].K5A5C2Y5!4E.#BU35.T%35H*%HJ*C9'HU<)PWB,$\NQ-')
ML1@9U/;3PE:.#JX>==S]J\1*E4<XRKRJOVKK2YJKJ2]HYN;<GA^)OV@/C-XP
M^-=Q^T9XA^(6OWGQNN?%FG>.6^(L,MOINNV_BG1Y+232-4T\:7;V5AI8TD:?
M8P:78Z;9VFFZ=96=K86=G!9016Z_0G[1'_!1S]K;]J3P7_P@7Q>^(.DZCX?O
MIM%NO%@\->!/!'@C4OB%?>&YKF?P[<^/M4\):#H][XC@T*6Z,VE:+/+%X<L[
MRWL]5CT;^U[.WU"/Q?\ X92_:C_Z-L^/O_AG?B)_\SE'_#*7[4?_ $;9\??_
M  SOQ$_^9RE'&YE"&)I1Q6-C3QLG/%P5:MRXJ<K\TZZYK59SYY*4I\TI*<E)
MM2:;GA.&JM7 UZF'R2=;+(0IY=5E3P+G@:<.3V=/"2M?#TX.%-TX4G&$)0IR
MBE*$&M/X-_M;?'GX ^!_B;\-_A3XI\/>'O!OQETHZ%\3])U'X8?"KQC+XQT3
M[#J&G+H^J:MXV\$^(]:72X;75M2%O86FHVUK;3WUS>6\45Y*TYR/V?/VF?C-
M^RSXS/Q$^!?B31?!WCA;2YL;7Q1>_#[X<^-M7TRUO;:>ROH]%NO'_A+Q2VA-
M?V5U<65_+HPL9KVSFDM;J2:!C'4G_#*7[4?_ $;9\??_  SOQ$_^9RC_ (92
M_:C_ .C;/C[_ .&=^(G_ ,SE3#%9A!X9PQ.,@\'S?4W"M7B\+S3YY?5FI)T.
M:;YY>RY+S?,[MW-*E'AZK''1JTLFJ1S/E_M*-2&!G',.2G&C#Z\I)K%\M)1I
M1]NJG+348*T4D<QH7QI\>^&/BGH/QF\.OX-T3Q_X7URQ\2>'[S2_A?\ #"R\
M-Z5KNEW0OM-U.T\ 0>#T^'RW.GWJQW=D6\+LEK=06T\")+:V[1=/\0_VH?CI
M\4OCA;?M)>,/'3/\<+35/#NN0?$/PUX;\(^ M737/":VB>'];-MX#T#PUI,F
MLZ?'86,0U673GU"YBL[:*\N+B.")5/\ AE+]J/\ Z-L^/O\ X9WXB?\ S.4?
M\,I?M1_]&V?'W_PSOQ$_^9RI5?&JFZ2K8I4I5XXETU4K*F\3!<L,0X<W*Z\8
MR<8U6O:)2LI),MQR)U8UW'*77CA9X&-9K!NK'!5)1E/!QJ/WUA9R493PZE[*
M4E%N#:1[1^T1_P %'/VMOVI/!?\ P@7Q>^(.DZCX?OIM%NO%@\->!/!'@C4O
MB%?>&YKF?P[<^/M4\):#H][XC@T*6Z,VE:+/+%X<L[RWL]5CT;^U[.WU"/X:
MKWW_ (92_:C_ .C;/C[_ .&=^(G_ ,SE'_#*7[4?_1MGQ]_\,[\1/_F<IXK$
M8['5?;XRMB<56Y5#VN(G4JU.5:J/--R=KR;M?64G)ZR;:P$,ARNA]5RQ95E^
M&YY5/88-X3#4>>2C%S]G1<(<SC&$$[:0C""M&,4NL_9?_;2_:)_8]U/Q->_
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MB^KV=]NN[6]AN&:0]3_PRE^U'_T;9\??_#._$3_YG*/^&4OVH_\ HVSX^_\
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M,I?M1_\ 1MGQ]_\ #._$3_YG*/9S_DG_ . O_+S7WA]?P/\ T&83_P **/\
M\GYK[SP*BO??^&4OVH_^C;/C[_X9WXB?_,Y1_P ,I?M1_P#1MGQ]_P##._$3
M_P"9RCV<_P"2?_@+_P O-?>'U_ _]!F$_P#"BC_\GYK[SP*BO??^&4OVH_\
MHVSX^_\ AG?B)_\ ,Y1_PRE^U'_T;9\??_#._$3_ .9RCV<_Y)_^ O\ R\U]
MX?7\#_T&83_PHH__ "?FOO/ J*]]_P"&4OVH_P#HVSX^_P#AG?B)_P#,Y1_P
MRE^U'_T;9\??_#._$3_YG*/9S_DG_P" O_+S7WA]?P/_ $&83_PHH_\ R?FO
MO/ J*]]_X92_:C_Z-L^/O_AG?B)_\SE'_#*7[4?_ $;9\??_  SOQ$_^9RCV
M<_Y)_P#@+_R\U]X?7\#_ -!F$_\ "BC_ /)^:^\\"HKWW_AE+]J/_HVSX^_^
M&=^(G_S.4?\ #*7[4?\ T;9\??\ PSOQ$_\ F<H]G/\ DG_X"_\ +S7WA]?P
M/_09A/\ PHH__)^:^\\"HKWW_AE+]J/_ *-L^/O_ (9WXB?_ #.4?\,I?M1_
M]&V?'W_PSOQ$_P#F<H]G/^2?_@+_ ,O-?>'U_ _]!F$_\**/_P GYK[SP*BO
M??\ AE+]J/\ Z-L^/O\ X9WXB?\ S.4?\,I?M1_]&V?'W_PSOQ$_^9RCV<_Y
M)_\ @+_R\U]X?7\#_P!!F$_\**/_ ,GYK[SP*BO??^&4OVH_^C;/C[_X9WXB
M?_,Y1_PRE^U'_P!&V?'W_P ,[\1/_F<H]G/^2?\ X"_\O-?>'U_ _P#09A/_
M  HH_P#R?FOO/ J_7?\ X(A_\GVZ!_V33XC?^FZSKX%_X92_:C_Z-L^/O_AG
M?B)_\SE?OQ_P18_83^,'PK\?^,?VC?C;X'U_X<8\(77@7X>>$_&6BOH_BB_N
M-<U.SNO$?BB\T;46M]<\-1:59Z'#HNG0ZIIEM/KD7B+4;F Q6=A$^H].$I5)
M8BDU"5HSC.3<6DE%J3;;LNR7=M6W1\UQ?FN74>',VC+&8:4\1@ZN&HTX5J<Z
ME2K7C[.$80A)RE;FYY63481E.348MK^CNBBBOI3^9@HHHH ]<^&'^JUG_KI8
M_P#H-U11\,/]5K/_ %TL?_0;JBOW3A'_ ))W+?\ #B?_ %,Q!^8<0?\ (XQG
MK0_]1J)YSK__ "'=:_["VH_^EDU9-:VO_P#(=UK_ +"VH_\ I9-637XIC?\
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M;DW_ ,[O+\^[/Y)/^%Z_\%4?^D2GQ+_\.3;?_,A1_P +U_X*H_\ 2)3XE_\
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M_1P__F)?CG_\[*C_ (? _P#!.K_HX?\ \Q+\<_\ YV5'UC#_ //^C_X-A_\
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M1]8P_P#S_H_^#8?_ "0?ZN<0_P#0BSG_ ,->._\ E!^EE%?FG_P^!_X)U?\
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M?6,/_P _Z/\ X-A_\D'^KG$/_0BSG_PUX[_Y0?I917YI_P##X'_@G5_T</\
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M/_H-U17[IPC_ ,D[EO\ AQ/_ *F8@_,.(/\ D<8SUH?^HU$\YU__ )#NM?\
M86U'_P!+)JR:UM?_ .0[K7_86U'_ -+)JR:_%,;_ +YB_P#L)K_^G9GZ1A?]
MVP__ %XH_P#IN(4445S&X4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %>P>"?"7V<1ZSJD7[\X>PM9%.8!U6ZE4_\MFZP(R_N1B4_
MO2GDYG@GPE]J,>LZG%_HJD/8VS@$7+ D?:)D(/\ HZ$#RD(_?N-[8A51/['7
MZ9P?PQ_"S?,:?:I@</-;]8XJK%_)X>+_ .OS7\-GQG$.=VY\OPD]=8XJM%_)
MT(27W56O^O=_C055O;VVTZUFO+R58;>!"\CL?P55'5Y'8A(T7+.Y"J"2!4TT
MT5O%)//(L4,*-++(YPJ1H"S,Q[!0"37@'BOQ/+K]UY<):/3+9V^S0\CSF&Y?
MM4RX!\QU)$:$?N8V*CYWE9_K>(,^H9'A>=\M3%UE*.%P[?QR5DZE2VL:-.Z<
MGHY.T(M-N4?G\IRNKF=?E5X8>FTZ]6VR>T(7T=2=FENHJ\I)I)2I^(_$%SX@
MO3/)NCM82R6=MD$0QDC+/CAII=H:5N>@13L1:YZBBOPW%8FOC,15Q6)J2JUZ
MTW.I.6[;T226D8Q2481BE&,4HQ2BDC].HT:6'I0H48*G2IQ481CLEOZMMMN4
MG=RDW)MMMA1116!J%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%?RV_M=_P#!5?\ ;H_:$_;0\9_L ?\ !*[PEX=M_%'PQU_5-+\<?&N^
MM?#?B.]DE\('3=)^(%XUM\1-'E\!^!O!'@GQ;J5UX3U75=2TOQ;JWBC6;#2S
MX1NK:;6-/T?5_G#XB_MM?\%J_P#@DW\5OA;<?ML>(/!O[47P2^*.LZCIEO;Z
M'9>&-4@U2XMK_1M3\36/A#Q?X=\&^ ?''AGQW8Z?J8B\+Z5XUTN^\&WUM+J$
M.BZ!J4&CS76B_14N&L;4A23Q& I8O$4?;X?+ZN)Y<;5I<CFFJ?(X0E*"<HPJ
M5(RLI\RBX2MY<\WP\)3?LL3.A2J>RJXJ%*^'A/F46G+F4FE)I-QA)7<;<W,C
M^R&BN)TGXB>$-5^'>D?%:36(=!\":OX/TSQVNN>+5?PE%I?AC5=(M]=@U#Q%
M%XA73IO#AMM-N8YM3@UI+*?2W6:&_CMY8943SCX6?M6_LO?'+7;SPO\ !;]H
M[X$_%SQ-I]G-J-[X=^&GQ:\!>.==M=-MY88)]3FTCPSK^IZ@FF13W$$+:D;?
M[$)9HX_/+NH/@JC5<9R5*HXTG:I)0DXTW>UIR2M'73WFCT74@G%.<4YZP3DD
MY?X4W=_(]]HKR;4/CY\"M)^)MG\%-5^-/PFTSXRZAIT^KV'PDU#XC>#[/XFW
MVDVNCZAXAN=4L_ 5SK,?BJYTZWT#2=4UR>]ATI[:+1]-U#4Y)5LK.XGCQ/AA
M^U#^S5\;==UCPO\ !K]H3X(_%GQ+X?LY=1USP_\ #7XJ>!O'.M:5IL$UG:SZ
ME?Z9X9UW4[VVTV"[U"SL9]0EA6SAO[B.QDG6[)A#]A6Y7/V-7D4(U'+V<^50
MDVHS<K64)--1E>S::3=@]I3OR\\.9R<4N:-W**3<;7OS)--K=)IM:GNE%>+?
M##]I+]G?XVZIK&A_!GX\_!GXM:SX>C:77M)^&?Q/\$^.]2T:%)88'GU.Q\+Z
MWJES90)<7$%L\]Q%'$ES(MLSB?,8_!?_ ()N_P#!1'XQ>-OVV_\ @I;X5_:O
M_:)T"P_9]_9U\7^,K'P9=?$-OAK\//!WPZTRT^/&O>!-#CO_ !C_ &3X:(B-
M@FDZ!:S>)=<NVN[J2U0R3:A<AY>NAEF*KTL954>1X*G1JU*52-2-6:KU8TH*
ME!0;E)RDG:3BFMFWH85,71I3H0;YOK$YPA.#@X1=.#G)SDY*R23U2EKNDM3^
ME&BO)O!'QD^%OQK\ ZOXW^!WQ6^'/Q.\.0QZIIT/C#X?^-/#7C'PWI^NVNF1
M7K6-_K.A7^IZ997^GQ7MA>7]A>RI<V=O<P2W=ND<J;OQR_X)6?M)_'C2OAW^
MTCX__P""@O[>'[)WQ9\)>$M7^%%MX<\>^#/CW^SGK/@WX;IX@?Q?IU_9>-?$
MWPZ3P[H7AJZ\7:L?#MIX<@\579GUBZLKBVT3,L=U')%+ 5JM#%5N:,)X65"#
MPTU46(JSQ%3V<8TJ:IM-P>LU.4'9KE4F[%3Q,(5*,+.2KQJRC5BX.E"-**FW
M.3DFE)/W7%25T[V6I^\U%?.?BC]L+]DGP1%X,N/&?[47[.WA*W^(V@Z=XJ^'
M]QXE^-7PWT.#QQX6UCS1I'B;PE-J?B6VB\1>'=5:&2/3=<TA[O2[^5?*M;J6
M4JA]OUOQ3X9\->'=0\7^(_$6A>'_  EI&F2ZUJOBC6]7T_2O#NF:-##]IFU;
M4-;O[BWTRRTR*W_?RW]S<Q6L</[UI0GS5S2I58\O-2J1YVU#FA)<[3Y6HW7O
M-/1I7:>CU-E.$FU&<6XV<DI)N*:NF[/2ZU5^FINT5\V?#G]LO]D/XP>*K7P)
M\)_VI?V>/B7XWOWO4T[P?X#^,_PZ\6>*-4_LW3Y=5U"72= T/Q%?:KJMM9:;
M!<WUU=:?:7-M!:VMW-)*J6ER8OR8_;B_X+.Z/\ ?VZ_V<_V/?AOK7P1F\&>(
M_'/PS_X:5^.NM_$;0]6T_P"$VCWOQ3U_PC\0OAEK-A;7MEH/PX\9>'-(\,1:
MMXIUOQQKMQ<Z#H?B1%D\*Z1>+8>(DZ\-E>.Q=>6'I8>HJL:4Z\HU(NGRTH)M
MS?.DVG9J*BG*<M(IN]L*N,P]&FJLZL7!SC33@U.\Y-)1O%M*U[R;:45JVD?O
MU17X/_M)?'7]J#5?^"C7[(T'[/G[;?[,.@_LD_$'2O@3KGB'X2WWQK_9[B\<
M_&#1?$OQ!\1+KFL?#?P]K=KJ7C_QGI?COPJNE:7X4U#P/JS6FO7MI/;^'9OM
M\=Q*W[ ?%K]H3X"_ 2UTN]^./QK^$_P=M=<EF@T.?XH?$/PEX#36IK8(US#H
M_P#PE&KZ6=4EMDD22XCL1.\$;"24(GS5-; 5J*PMI0K3Q=)U8TJ*J3JT[-Q=
M.K!TXM5$T[J'.DOM7NDZ>)IS=:Z=.-&:A*=1PC"5TFI0DI/W7S))RY7?H>P4
M5YEI'QK^#6O_  UN_C/H7Q;^&6M_!ZPTO5=<OOBOI'CWPKJ7PULM%T(3G7-7
MN_'5GJLWA>WTO1A:W1U74)M42TTX6TYNYH?)DV^>:M^V1^R)H/@OPM\2-;_:
MG_9RTCX=^.+O5[#P5X\U+XV_#2R\&^+[WP_>KINOVGA?Q/<>)H]%U^XT'4&%
MGKD6E7MV^D7.8M1%LZL!SQH5Y-QC1JRDI^S:C3FVJEF^1I*_/:+?+\5DW:R9
MJZE-*[J02Y>>[G%+DNES7;^&[2YMKM*^J/I"BL;P]XB\/^+M"TGQ1X4UW1O$
M_AG7]/M=6T+Q%X>U.RUK0M:TN]B6>RU+2=7TV>YT_4M/NX'2:UO+.XFMKB)E
MDBD=&!/G_P .?CW\"_C#JOBK0OA)\:?A-\4M<\"W$-IXWT;X<_$;P?XWU7P=
M=W-S?V=O:^*M.\,ZSJ=WX>N+B[TK5+6&'5X;.26YTV_@C5I;.X6.53FU-J$V
MJ=O:-1;4+OE7.[6C=Z+FM=Z;E<T;Q7-&\K\JNKRLKOE[V6KM?34]9HHHJ!A1
M110 5M>'/^0_HW_82L__ $>E8M;7AS_D/Z-_V$K/_P!'I77@/]^P7_87AO\
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MR:'XDO\ PWKU_K.LM+965]=17&CZS+H'AVSNUUSQ5_9EVND6KPVM]=67LO\
MP5I_8:^%7[!/QR^'/PO^$OB3X@^)]%\5_"+3O'FK7_Q%U/PYJ>J1ZW<^+_%_
MAZ>'3G\->%O"EI;:4;3P_:316US:WUW'<2W)?4)8VBCBY/[%S)9;B,VGAITL
M#AZ\,-.K5_=N=:<W3<*49)2J>SFN6K*/NPD^5OF4DO1_UHR1YW@^'Z>-IU\T
MQN#JXZG0H-553PM.G"M&IB)P;C1]O3FIX>,O>JP3FDH.,I?E=117TU>?L?\
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MBBBH- HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K]LO\
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MGU\!/@G:?$7X0W?[1/[/GQ7^-/B^PL]-\5>,#\+?%G@?XQ'PM=ZEI]MK6M>
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M %XJ_P#J57/VM_X(!_\ *1#PU_V2KXH?^FJSKX:_;(_Y2"_M4_\ 9Y'QQ_\
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M6<=KIOC?0-)'Q%\,2?V8UAIWC3P]XR\":#!#:W>HZL/PP_X+G_\ *2_XZ?\
M8#^#_P#ZJ#P17SC_ ,$_OVZ?'?[ OQQ'Q7\,:*_C;PQK6@:CX7^(/PUFU]O#
M>G^--'GC:YTDG6#HWB*/1]7\/:]%8ZMIFLQZ'?7<5LFJZ*GEZ?K^IB7D_P!N
M?]JG_AM+]I?QU^T3_P ()_PK7_A-;'P?9?\ "'_\)1_PF/\ 9G_"*>#]$\*>
M;_PD'_".^%?MGV_^QOM^S^Q+3[+]I^R[[GR?M,OCYOQ#@<VX7HT:DG'/I9EA
M*F81]G4MC(8/!8G"T\>ZBA['VDZ4Z%*M%U%4E4IN<:2IVD_I.'.#<UX>X\Q.
M(HP4^$J>29C2R:7M:%\MJYGFF!QU?*%0=18GV%*O1Q6(PTU1E1A1K1IRKNK>
M"_2'XP_\$8_ /PK^!?Q"^,EE^WO\'O&5_P"!OAQKWCZV\!:7X;T6#6/$5SHN
MA3ZS'X:LKB+XLZE-%?W\D(L(98])O)$F<,ME,P\DP?\ !&O]J+X_^+?VUOV+
M/V=M;^*/B:3X(?#R'XZQ>&?AE87$&C>%0]_\'?C+XKFN]>L-'M[$>+M0@U[4
M;N^TS4/%CZU>:.93!I$]C;@15^%=?5G[$?[3G_#&_P"T_P##+]I#_A"/^%C?
M\*Y_X33_ (HS_A)?^$0_MG_A+_A[XL\!_P#(Q?V!XH_L[^SO^$H_M7_D!7WV
MO[#]A_T;[3]LM_,P6<8"AG>4XO!X2>1X.CB\"\Q5+&XS&1KX>ECJ&(JRJJ:=
M24(QI*;H0C-2E"+C!S44>YF?#>;XKA;B++\SS&GQ7F6)R[-5DLL3E>5Y;+"8
MS$95BL'AX4)4N2A3JSG7E!8NI.E*G"M.,JD:;DSM/V[Y-?C_ ."AG[5O_"*O
MK">))/VH/BK!H7_"/M>KKDFJW'C_ %:"QATG^SB+]M0GN9(X;2.SS<RSND<(
M:1E!_<C]G?X<>"O^"+OP3\0_MG_M:ZS<^+/VU/CMX4UKPW\,?@C_ &W]OUBW
MCU:ZTGQ!J-AK]XTUS-/J']J6>@ZG\5/'D\EQ8^$K'R?"VA/K/B77(+/Q1^+'
MP_\ VV_#GA3_ (*#ZQ^W7XF^!\/C>VO?BO\ $/XNZ7\'[KQW!I]II?B/Q@VO
M7'AYYO&<W@36/MTW@;5=9MM=TN^A\(Z=/<ZSHNFWD::=L,=?J%\1_P#@NQ^S
MC\8M=M_%'Q<_X)2?!+XI^);33(-$M/$7Q'\>^!/'&NVNC6MS>7MMI%OJ_B;]
MF75-0ATRWO-0O[N"PCN%M8;F^O)XXEEN9G?U\EQF18?$9KFE;-J.&S26.Q+R
M>.)P68XC#8:%63?]I2IX?#5(U,1R5)0PU*JX^QG!U*L)-TU'YWB?+>+,9@^'
MN'\-P]B<=D,,JP*XDE@<SR;!XW&U,/"$?[#A7QN.HSH83VE&%3'5Z$:GUFG.
M-&A6@E5D_P 9=*_;9_:@\-GX]GP=\7/$?@9_VF?&<GCSXS77@LVOAO5O%6OR
MZIXDUB41>(=.MXO$FAZ7<7GBW7A?:1H6KZ=I^JVEZ;+5H+ZTCCA7]=_^#DC_
M ).\^"O_ &;?I'_JSOB97X/_ !:\8:'\0_BI\3/'_ACP5I/PV\->.?B#XS\8
M>'OAUH)LVT/P#H?B;Q'J6M:3X*T9M/TK0;!M)\+6%[;Z%IQL=#T:S-G80FVT
MK3H=EG#]H?\ !23]O?\ X>$_%[P5\5?^%4?\*B_X0_X;V?P^_L'_ (3K_A/O
M[1^R^)_$WB/^U_[4_P"$.\%?9/,_X2+[']@_LZZV?8_M'VUOM'D0>-1S2"R+
M/LNQ&.JUZM?%97++X5/K$X5*5#$X^MBYTN>+AAU*6(C6E";I2J3JMJ,I\]OI
ML1D-5\5\)9S@\JH83#X7 9]'.*E+ZG3J4:^+P.3X;+Z5?V<XU,9*%/!SPU.I
M2C7A2IT(Q<X4G3YO OV2-?\ V:/#/QX\(ZS^UYX)\3_$/X"6UIXF3Q?X3\'7
M>J67B#4;NX\,ZM;^&)+.YT;Q=X&U%$L?$\FDWMT(/$MB'M;>9)8[R%GM)_ZY
MM;^(7_!+F/\ X)2^#_%^I? KXJ3_ +"\_P 1[JU\/_"R+5_%@\>6?C ?$/Q3
M;3:C<ZBOQCAU]K-O%L.MZ@J2?$>Z@%G=0(+%852QMOXAJ^@KK]JGX^WO[/FF
M_LK77Q$O)?@#I&MR>(M.^'9T7PPMG;:U+K5_XADOEUI-$7Q/([:QJE_>^5+K
M<EN&N&B$0MTBB33A[B.GDN'S&A5P.#Q*Q6"Q5.C4J8'#8BL\16^KJ%'%5:LH
MRGEMJ,I5<,N>+J24O9MMM8<9<%5N)\9DN+H9MF6"> S3 5\50HYMC<)AHX/#
M?7)5<3@,/AX3ITL[YL1"%#'/V<XT8RINM%))S?M7:Y^SIXD^/WCW6OV3/!OB
M3X?_ +/U[_PBW_" >$?%UUJ=[XATC[-X+\.6GBK^T+G6/%7C;49?M_C6#Q)J
M=I]I\3ZGLL;VVCA^Q0)%I]I^Z_\ P2-T/P-^SQ_P3Z_; _X*&Z=X#\*>/OCW
M\,-=\7^%/A_<>++)M0L_"-KX:\">#-1M?LCPK;:GIG]M:G\0YY_%YT/4M.U#
M6?#6F6&CP:SI8N+N5/YH*_3;_@GQ_P %+/%G[#EE\2OA_KGPS\/_ !W^ GQ?
MM98O'?PD\4:F-)L[B]N=*FT"_O\ 3[RZT;Q/I!M]>T"<:+XNT35_#6J6/B?2
M['3+*:2P%F)GCAW,\)A<]EC\=[+"1K0QWLJ]'"\U#+L7B:=3ZOB*.$I1ERTL
M-4DE3ITH2=*%N2/N(WXSR+,<=PG3RC*OK&8SPU7*5B,+BL>Z>*SK+\#7H_7,
M'B<QKSAS5\=0IMUJ]>I%5ZG-[6:]HS]T_P!@[]JWQM_P5"_9^_:>7]ISPQ\(
M[GXD?LG2>"_BU\$?B\GA%;"?P3XVOU\?^,_"GB":U2YF%C!X*\0?"[2%U,Z'
M<:8OB_P=-<^&_%-OJ<4NHW6J_:/Q%_:Z^,EKK/\ P2$T6*^T 6/[8L&@ZW\:
M5;0K=I+Z^T_P)\+/'ULWAZ3S<Z!&/$.MWTKQVXE#VK1VI.R,$_SN?M"?\%:?
MA_?_ +.WCC]EO]B?]E;P[^RA\/?BC-*/B1XGT[7H+SQ9XGTK4XH!K^C0VFC:
M/I:63:O!&_AK4-5UC7_%)N?!4USX?L-,T2&>$V?L_@#_ (+=?"?1O@_^S!H/
MQ,_8PM_B=\8OV4=%\+^'/AOXY;XGVOAZPLX_#OA_P_X<O/%&F.W@+7+O0=9\
M1Z7X=L;35M(73]6L0R&[M-4@)AM+;[W!\59=1I0P5?/_ &F+I87"O%YS[#'*
MGCZE'-H8F>&M'#/$U94LMC4P<:]6DEB%5<7+EN?D68^'^<XG$3S/"\(>QRZO
MF&8++^&?K>4RK911Q/#M3!4L<Y3QL<%0AB,[E2S*>%P^(D\)*A&<8<]C],?'
M7_!0KXQ^ _\ @M-9?L?^$=#^'VE_!_Q/XA^'GAWXAV\7A#3X?%'C?Q/XO^#/
MA#Q';^/]7\76[1ZU<^(O#FE2^'O".D)-.^ECPSH%OIEUIUP\5C>67T!X(_9\
M^&?[.GB[_@IW^T#\%M/_ &?/AM\8H/BGI'ACP7\0/C/>V7A#X3?"6UU?]G?X
M&?$2_EU77;;2=1N_!>B:KXU^+GB+Q'XGL=(2TM/%K0^$M)OEM+6TLKFS_E<\
M9_\ !1#_ (2[_@I-9_\ !0O_ (4__9_V3Q9X#\3_ /"H?^%@?:_,_P"$(^&G
MAWX=_8?^$_\ ^$)MMG]I_P!@?VQ]I_X0IOL7VO\ L_[/=^1]NF^R?"__  7+
MU&W^./[5/BOQY^S9H_CG]GO]J^V\*OXL^ .L?$-[Y_#>L>'_ (3>$?A!K.H6
M'BV;P3!I6N:=XX\->%+>/Q3HU_X(LIITM_#T-CK-F-"O'U_/"<7934KXV688
M^562XCS.ME%:IA\3/ZCEV(P.+HX;$TFJ#G1I>VE13I12Q$)S]LZ-XSDMLQ\.
M.(:.%RN&3Y1"A&7!6187B+"T<;@::S7.<%FV6XC&X+$1EBXTL56>&IXEQQ%2
M7U*I3I?5HXGEG3IR^MO^"AWB?X2?';_@FY>:I^T3^TK^PQ\9?VY_@SK/A^\\
M%>+?V:_C#X#\1:SXW\.7OCG2-%U32AI2:=X?\3O'<>$?$>N:WXA\)>']$3PZ
M-?\ #6F>*K46=NEQ8V/NNH?MG>./V%?^"+?[%GQB^&?A7P=XE\>>()/!WPRT
M.;QQ8ZAJ.BZ##KVG_$;Q3JVJ/9:3J>B:C=RS:=X(FTJ&"#5[&-;C48+VY^U0
MV1LKC\3?VSO^"COPL^,W[._@O]DC]EW]F;2?V<_@9X4\11^)=0:]UR#Q9XN\
M23PM-?VVFM>3Z<UYIEJ->OKS6-:U.]\1>)-=\275KHOF7^DV=G?Z=JGGOQV_
MX*(?\+K_ &!_V?/V'O\ A3__  C7_"B/%GASQ/\ \+/_ .%@?VS_ ,)5_P (
M_P"&_B)X>^P_\(5_PA.E?V']K_X3W[9]I_X2W6/L_P#9/V?[/-]N\^S\VOQ/
MA,/C<UQ6%S"'UR7#6'R_#XZA1Q;>*S&GB*4Y2=;$4G5JU84DZ?U[$4\/[7V,
M964N5R]K"\"9EC,KX>P..R>K_9L..,9G&,RK&8K+XQP&2UL%6I0@L-@\0L/A
MZ%7$?OGE6"K8OV'UF=-RE#GC#P?X;27G[9/[<7P]/Q>O_P#2OVF/VG/!]O\
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M3^';LW.;.XDTNVF-_HL-WHUQ_-U_P4+_ ."E/_#>6I?L]ZC_ ,*7_P"%5?\
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MG:?YTC/]H6Y,44H_),'](+(,5PEF7',^#^.\+POEV%IXF.:U\NR54,PG4SW
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MXFEMX+QH)5M9KBW6-YX(K@J(9)H4FB:6)'9XUEC9U4.I-:OT&^,WP_\ VN/
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M8K3=H\W-Z52OE^(I48.I4G[+EA'=VKTI.WI%-OR1^XOA+_D5?#/_ &+^C?\
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M_A7_ /PKK[+_ ,)UX2\4;_L'V7QUY_\ 9?V';]MA^W?:MUG]G_DK_8B^'_\
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MTS^T_P"S?^%/7^?M_P!A\[_A.+?&?M'D>9L_X1;I_%LW^V[O7VY\=?CKX.^
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M(^EJ***_HT_'@HHHH *X'XC_ /( B_["5O\ ^B+JN^K@?B/_ ,@"+_L)6_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_.XK^P>BC^S<-VJ?^!_\#^KORL?\1,XF_FP'_A)_]T_J[\K?Q\?\.'/VTO\
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MVTO^AF^ 7_A<>,?_ )W%'_#AS]M+_H9O@%_X7'C'_P"=Q7]@]%']FX;M4_\
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M.)OYL!_X2?\ W3^KORM_'Q_PX<_;2_Z&;X!?^%QXQ_\ G<4?\.'/VTO^AF^
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M-\ O_"X\8_\ SN*/^'#G[:7_ $,WP"_\+CQC_P#.XK^P>BC^S<-VJ?\ @?\
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M7?E8_P"(F<3?S8#_ ,)/_NG]7?E;^/C_ (<.?MI?]#-\ O\ PN/&/_SN*/\
MAPY^VE_T,WP"_P#"X\8__.XK^P>BC^S<-VJ?^!_\#^KORL?\1,XF_FP'_A)_
M]T_J[\K?Q\?\.'/VTO\ H9O@%_X7'C'_ .=Q1_PX<_;2_P"AF^ 7_A<>,?\
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M7IO?_M[1Z[/5/1ZF+16U_P (YK__ $!M2_\  .?_ .(H_P"$<U__ * VI?\
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MOO,6BMK_ (1S7_\ H#:E_P" <_\ \11_PCFO_P#0&U+_ , Y_P#XBCZACO\
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M<U__ * VI?\ @'/_ /$4?\(YK_\ T!M2_P# .?\ ^(H^H8[_ * L7_X35O\
MY /K6%_Z"</_ .#J?_R7FOO,6BMK_A'-?_Z VI?^ <__ ,11_P (YK__ $!M
M2_\  .?_ .(H^H8[_H"Q?_A-6_\ D ^M87_H)P__ (.I_P#R7FOO,6BMK_A'
M-?\ ^@-J7_@'/_\ $4?\(YK_ /T!M2_\ Y__ (BCZACO^@+%_P#A-6_^0#ZU
MA?\ H)P__@ZG_P#)>:^\Q:*VO^$<U_\ Z VI?^ <_P#\11_PCFO_ /0&U+_P
M#G_^(H^H8[_H"Q?_ (35O_D ^M87_H)P_P#X.I__ "7FOO,6BMK_ (1S7_\
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M_P#B*/\ A'-?_P"@-J7_ (!S_P#Q%+ZACO\ H"Q?_A-6_P#D!_6L+_T$X?\
M\'4__DO-?>8M%;7_  CFO_\ 0&U+_P  Y_\ XBC_ (1S7_\ H#:E_P" <_\
M\11]0QW_ $!8O_PFK?\ R ?6L+_T$X?_ ,'4_P#Y+S7WF+16U_PCFO\ _0&U
M+_P#G_\ B*/^$<U__H#:E_X!S_\ Q%'U#'?] 6+_ /":M_\ (!]:PO\ T$X?
M_P '4_\ Y+S7WF+16U_PCFO_ /0&U+_P#G_^(H_X1S7_ /H#:E_X!S__ !%'
MU#'?] 6+_P#":M_\@'UK"_\ 03A__!U/_P"2\U]YBT5M?\(YK_\ T!M2_P#
M.?\ ^(H_X1S7_P#H#:E_X!S_ /Q%'U#'?] 6+_\ ":M_\@'UK"_]!.'_ /!U
M/_Y+S7WF+16U_P (YK__ $!M2_\  .?_ .(H_P"$<U__ * VI?\ @'/_ /$4
M?4,=_P! 6+_\)JW_ ,@'UK"_]!.'_P#!U/\ ^2\U]YBT5M?\(YK_ /T!M2_\
M Y__ (BC_A'-?_Z VI?^ <__ ,11]0QW_0%B_P#PFK?_ " ?6L+_ -!.'_\
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M $!8O_PFK?\ R ?6L+_T$X?_ ,'4_P#Y+S7WF+16U_PCFO\ _0&U+_P#G_\
MB*/^$<U__H#:E_X!S_\ Q%'U#'?] 6+_ /":M_\ (!]:PO\ T$X?_P '4_\
MY+S7WF+16U_PCFO_ /0&U+_P#G_^(H_X1S7_ /H#:E_X!S__ !%'U#'?] 6+
M_P#":M_\@'UK"_\ 03A__!U/_P"2\U]YBT5M?\(YK_\ T!M2_P# .?\ ^(H_
MX1S7_P#H#:E_X!S_ /Q%'U#'?] 6+_\ ":M_\@'UK"_]!.'_ /!U/_Y+S7WF
M+16U_P (YK__ $!M2_\  .?_ .(H_P"$<U__ * VI?\ @'/_ /$4?4,=_P!
M6+_\)JW_ ,@'UK"_]!.'_P#!U/\ ^2\U]YBT5M?\(YK_ /T!M2_\ Y__ (BC
M_A'-?_Z VI?^ <__ ,11]0QW_0%B_P#PFK?_ " ?6L+_ -!.'_\ !U/_ .2\
MU]YBT5M?\(YK_P#T!M2_\ Y__B*/^$<U_P#Z VI?^ <__P 11]0QW_0%B_\
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M ,@'UK"_]!.'_P#!U/\ ^2\U]YBT5M?\(YK_ /T!M2_\ Y__ (BC_A'-?_Z
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&1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>ny20077604x1_figure06.jpg
<TEXT>
begin 644 ny20077604x1_figure06.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
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M _"+_P"=]7YAT4?V]GG_ $.<V_\ #CC/_EWDON#_ %.X1_Z);AS_ ,,>6?\
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M1_P^8_X*7_\ 1TFO?^$#\(O_ )WU?F'11_;V>?\ 0YS;_P ..,_^7>2^X/\
M4[A'_HEN'/\ PQY9_P#,I^GG_#YC_@I?_P!'2:]_X0/PB_\ G?4?\/F/^"E_
M_1TFO?\ A _"+_YWU?F'11_;V>?]#G-O_#CC/_EWDON#_4[A'_HEN'/_  QY
M9_\ ,I^GG_#YC_@I?_T=)KW_ (0/PB_^=]1_P^8_X*7_ /1TFO?^$#\(O_G?
M5^8=%']O9Y_T.<V_\..,_P#EWDON#_4[A'_HEN'/_#'EG_S*?IY_P^8_X*7_
M /1TFO?^$#\(O_G?4?\ #YC_ (*7_P#1TFO?^$#\(O\ YWU?F'11_;V>?]#G
M-O\ PXXS_P"7>2^X/]3N$?\ HEN'/_#'EG_S*?IY_P /F/\ @I?_ -'2:]_X
M0/PB_P#G?4?\/F/^"E__ $=)KW_A _"+_P"=]7YAT4?V]GG_ $.<V_\ #CC/
M_EWDON#_ %.X1_Z);AS_ ,,>6?\ S*?IY_P^8_X*7_\ 1TFO?^$#\(O_ )WU
M'_#YC_@I?_T=)KW_ (0/PB_^=]7YAT4?V]GG_0YS;_PXXS_Y=Y+[@_U.X1_Z
M);AS_P ,>6?_ #*?IY_P^8_X*7_]'2:]_P"$#\(O_G?4?\/F/^"E_P#T=)KW
M_A _"+_YWU?F'11_;V>?]#G-O_#CC/\ Y=Y+[@_U.X1_Z);AS_PQY9_\RGZ>
M?\/F/^"E_P#T=)KW_A _"+_YWU'_  ^8_P""E_\ T=)KW_A _"+_ .=]7YAT
M4?V]GG_0YS;_ ,..,_\ EWDON#_4[A'_ *);AS_PQY9_\RGZ>?\ #YC_ (*7
M_P#1TFO?^$#\(O\ YWU'_#YC_@I?_P!'2:]_X0/PB_\ G?5^8=%']O9Y_P!#
MG-O_  XXS_Y=Y+[@_P!3N$?^B6X<_P##'EG_ ,RGZ>?\/F/^"E__ $=)KW_A
M _"+_P"=]1_P^8_X*7_]'2:]_P"$#\(O_G?5^8=%']O9Y_T.<V_\..,_^7>2
M^X/]3N$?^B6X<_\ #'EG_P RGZ>?\/F/^"E__1TFO?\ A _"+_YWU'_#YC_@
MI?\ ]'2:]_X0/PB_^=]7YAT4?V]GG_0YS;_PXXS_ .7>2^X/]3N$?^B6X<_\
M,>6?_,I^GG_#YC_@I?\ ]'2:]_X0/PB_^=]1_P /F/\ @I?_ -'2:]_X0/PB
M_P#G?5^8=%']O9Y_T.<V_P##CC/_ )=Y+[@_U.X1_P"B6X<_\,>6?_,I^GG_
M  ^8_P""E_\ T=)KW_A _"+_ .=]1_P^8_X*7_\ 1TFO?^$#\(O_ )WU?F'1
M1_;V>?\ 0YS;_P ..,_^7>2^X/\ 4[A'_HEN'/\ PQY9_P#,I^GG_#YC_@I?
M_P!'2:]_X0/PB_\ G?4?\/F/^"E__1TFO?\ A _"+_YWU?F'11_;V>?]#G-O
M_#CC/_EWDON#_4[A'_HEN'/_  QY9_\ ,I^GG_#YC_@I?_T=)KW_ (0/PB_^
M=]1_P^8_X*7_ /1TFO?^$#\(O_G?5^8=%']O9Y_T.<V_\..,_P#EWDON#_4[
MA'_HEN'/_#'EG_S*?IY_P^8_X*7_ /1TFO?^$#\(O_G?4?\ #YC_ (*7_P#1
MTFO?^$#\(O\ YWU?F'11_;V>?]#G-O\ PXXS_P"7>2^X/]3N$?\ HEN'/_#'
MEG_S*?IY_P /F/\ @I?_ -'2:]_X0/PB_P#G?4?\/F/^"E__ $=)KW_A _"+
M_P"=]7YAT4?V]GG_ $.<V_\ #CC/_EWDON#_ %.X1_Z);AS_ ,,>6?\ S*?I
MY_P^8_X*7_\ 1TFO?^$#\(O_ )WU'_#YC_@I?_T=)KW_ (0/PB_^=]7YAT4?
MV]GG_0YS;_PXXS_Y=Y+[@_U.X1_Z);AS_P ,>6?_ #*?IY_P^8_X*7_]'2:]
M_P"$#\(O_G?4?\/F/^"E_P#T=)KW_A _"+_YWU?F'11_;V>?]#G-O_#CC/\
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M_P M*\UHH_M/,O\ H8X[_P *\1_\L#^P,B_Z$N4_^&[!_P#RD]*_X7/\8?\
MHJ_Q*_\ "Z\4?_+2C_A<_P 8?^BK_$K_ ,+KQ1_\M*\UHH_M/,O^ACCO_"O$
M?_+ _L#(O^A+E/\ X;L'_P#*3TK_ (7/\8?^BK_$K_PNO%'_ ,M*/^%S_&'_
M **O\2O_  NO%'_RTKS6BC^T\R_Z&.._\*\1_P#+ _L#(O\ H2Y3_P"&[!__
M "D]*_X7/\8?^BK_ !*_\+KQ1_\ +2C_ (7/\8?^BK_$K_PNO%'_ ,M*\UHH
M_M/,O^ACCO\ PKQ'_P L#^P,B_Z$N4_^&[!__*3TK_A<_P 8?^BK_$K_ ,+K
MQ1_\M*/^%S_&'_HJ_P 2O_"Z\4?_ "TKS6BC^T\R_P"ACCO_  KQ'_RP/[ R
M+_H2Y3_X;L'_ /*3TK_A<_QA_P"BK_$K_P +KQ1_\M*/^%S_ !A_Z*O\2O\
MPNO%'_RTKS6BC^T\R_Z&.._\*\1_\L#^P,B_Z$N4_P#ANP?_ ,I/2O\ A<_Q
MA_Z*O\2O_"Z\4?\ RTH_X7/\8?\ HJ_Q*_\ "Z\4?_+2O-:*/[3S+_H8X[_P
MKQ'_ ,L#^P,B_P"A+E/_ (;L'_\ *3TK_A<_QA_Z*O\ $K_PNO%'_P M*/\
MA<_QA_Z*O\2O_"Z\4?\ RTKS6BC^T\R_Z&.._P#"O$?_ "P/[ R+_H2Y3_X;
ML'_\I/2O^%S_ !A_Z*O\2O\ PNO%'_RTH_X7/\8?^BK_ !*_\+KQ1_\ +2O-
M:*/[3S+_ *&.._\ "O$?_+ _L#(O^A+E/_ANP?\ \I/2O^%S_&'_ **O\2O_
M  NO%'_RTH_X7/\ &'_HJ_Q*_P#"Z\4?_+2O-:*/[3S+_H8X[_PKQ'_RP/[
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M^BK_ !*_\+KQ1_\ +2O-:*/[3S+_ *&.._\ "O$?_+ _L#(O^A+E/_ANP?\
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M.9TH8R<JCU<I4XU:>'BV[JG1IQ5E%)%%%%?-GW04444 %%%% !1110 4444
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M5K^:>TEYQ;7F?AC^V+_R<=\1?^Y1_P#4$\,5\RU]-?MB_P#)QWQ%_P"Y1_\
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MMHKW3M2\1>+M/O[.==\%W97GBKX66]U;3(>'BG@DDBD7^)'8=Z\5^'NI7O\
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MXM?\G'XO_P"QM4_],T3^+K_@LQ_RDP_:D_[#W@#_ -5%\/J_,.OT\_X+,?\
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M/WD2[M+F MT\R%P,@9/S#7\:<4IKB;B*Z:_X7,V>NFCQ^(:?HTTT^J::T/\
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M\]S=316UO!&I:2:>>18H8HU'+/)(RHJCDL0*_L/MOV<?V%O^",'[+'@WXO\
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M ,CZ_P!+7['_ (F<XA_Z)K)?_"C'?_)^O]+7^>[_ (43\:/^B6>/?_"7U?\
M^1:/^%$_&C_HEGCW_P )?5__ )%K^A&BC_B#64_]#C,?_!6&_P#D?7^EJ?\
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M_1-9+_X48[_Y/U_I:_SW?\*)^-'_ $2SQ[_X2^K_ /R+1_PHGXT?]$L\>_\
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M;_Y'U_I:G_$SG$/_ $362_\ A1CO_D_7^EK_ #W?\*)^-'_1+/'O_A+ZO_\
M(M'_  HGXT?]$L\>_P#A+ZO_ /(M?T(T4?\ $&LI_P"AQF/_ (*PW_R/K_2U
M/^)G.(?^B:R7_P *,=_\GZ_TM?Y[O^%$_&C_ *)9X]_\)?5__D6C_A1/QH_Z
M)9X]_P#"7U?_ .1:_H1HH_X@UE/_ $.,Q_\ !6&_^1]?Z6I_Q,YQ#_T362_^
M%&._^3]?Z6O\]W_"B?C1_P!$L\>_^$OJ_P#\BT?\*)^-'_1+/'O_ (2^K_\
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M\!__ "^H_P"&F?V;_P#HX'X(_P#AUO ?_P OJ7-'^:/WK^NJ^\?LY_R3_P#
M7_EYK[SVZBO$?^&F?V;_ /HX'X(_^'6\!_\ R^H_X:9_9O\ ^C@?@C_X=;P'
M_P#+ZCFC_-'[U_75?>'LY_R3_P# 7_EYK[S\2_\ @Z%_Y14>+/\ LMWP:_\
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MD_%+Q4223:Y))Y)/6OF?_A#/&'_0I^)?_!%JG_R+7^U717]4O*DVW[=ZMO\
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MEMSWNO:6Y;+X[#6&J+EE[-<ZQ_M7*\.;V%V[WO>W7DO?^Z?@3^R'^S]\(_\
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M:\1?$'Q&/#.K6#: ==N-7\(Z/INEZE::7;7GA&T@U"QTL:;:Z[Y+>F_\$E_
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MW3[#2=/NM9OK:PCN]4FT[2M+T^2]FG:QTVPM##:0_P D_P#P13_Y3_?\%?\
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MPUCZCTKX3:U_P55_X)>?L?6OAH_:OC;^R?\ 'CPM^S3XNU4QNT^E?"3QC?\
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M:XE:"1&=B<,+E^1SJ9'@ZV5RE/.,GKXS$8JGC<5"IAZE.68NG+"4Y3G14_\
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M5J>$I5*&"S?(:V#Q&6T)83#X=5,+1P]2=9SQ/ML55C1;K8BK.-.W\^-%%%?
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MM_PMSX?_ /0='_@#J/\ \BT?\+<^'_\ T'1_X ZC_P#(M'^MO"W_ $4F0_\
MAVP'_P O\_S[,/\ 5_/?^A+FO_AOQ?\ \J/2:*\V_P"%N?#_ /Z#H_\  '4?
M_D6C_A;GP_\ ^@Z/_ '4?_D6C_6WA;_HI,A_\.V _P#E_G^?9A_J_GO_ $)<
MU_\ #?B__E1Z317FW_"W/A__ -!T?^ .H_\ R+1_PMSX?_\ 0='_ ( ZC_\
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M_P"'; ?_ "_S_/LP_P!7\]_Z$N:_^&_%_P#RH])HKS;_ (6Y\/\ _H.C_P
M=1_^1:/^%N?#_P#Z#H_\ =1_^1:/];>%O^BDR'_P[8#_ .7^?Y]F'^K^>_\
M0ES7_P -^+_^5'I-%>;?\+<^'_\ T'1_X ZC_P#(M'_"W/A__P!!T?\ @#J/
M_P BT?ZV\+?]%)D/_AVP'_R_S_/LP_U?SW_H2YK_ .&_%_\ RH])HKS;_A;G
MP_\ ^@Z/_ '4?_D6C_A;GP__ .@Z/_ '4?\ Y%H_UMX6_P"BDR'_ ,.V _\
ME_G^?9A_J_GO_0ES7_PWXO\ ^5'I-%>;?\+<^'__ $'1_P" .H__ "+1_P +
M<^'_ /T'1_X ZC_\BT?ZV\+?]%)D/_AVP'_R_P _S[,/]7\]_P"A+FO_ (;\
M7_\ *CTFBO-O^%N?#_\ Z#H_\ =1_P#D6C_A;GP__P"@Z/\ P!U'_P"1:/\
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M0_\ AVP'_P O\_S[,/\ 5_/?^A+FO_AOQ?\ \J/2:*\V_P"%N?#_ /Z#H_\
M '4?_D6NNTGQ)H&N@?V1K&G:A)Y*SO!:W<$MS#$Q4!I[97,\'S,J$2QH0YVG
MYN*Z\)G^1YA55# YSE6,K/:CA<PPM>J^NE.E5E-[/9='V9AB,IS3"0]KBLMQ
M^&I_\_*^$Q%*"VWG4IQBMUUZFW1117K'GG^>G_P68_Y28?M2?]A[P!_ZJ+X?
M5^8=?IY_P68_Y28?M2?]A[P!_P"JB^'U?F'7\J9[_P CS.?^QKF/_J76/]#>
M#O\ DD>%O^R<R/\ ]5F%"BBBO*/HPHHHH **** "BBB@ HHHH **** /LK_A
MMOXE?\,4_P###'_",^!O^%9_\+'_ .%E_P#"4_8]?_X3O^U?MGV_[!]K_P"$
M@_X1_P#L_P"T_P#4O_:?(_=^=YG[^OC6BBMZ^)KXGV/MZLJOU>A3PU'FM^[H
M4K^SI1LE[L.9VO=ZZLY,)@,'@?K/U2A"A]<Q=;'XKDO^^QF(Y?;5YW;]^IR1
MYK67NJR1[U^S#^T+XN_93^._P]_: \!Z3X;UWQ7\.;[5;W2=)\76^IW7AZ].
MM>'=8\,7L>HP:-JNBZDP73M;NY;5K;4[?RKV.VEE6X@26UFY3XU_%77/CI\7
M_B=\9O$UAI.E^(OBGXZ\3^/M;TW0H[R+1;#4_%.KW>L7EGI<6H7FH7R6%O/=
MO%;+=WUW<")5\V>1\L?,**/K-=X98/VLOJL:\L2J.G(J\J<:4JNU^9TX1@];
M62T!8#!K'RS-4(+'SPD,!+%:^T>#IUIXB%!Z\O)&M4J5%[M^:3UMH?H/^QK_
M ,%,/VE/V)](\1>#/A_-X.\>_"KQ8]Q<:Y\(OBSHE]XH\"/J%ZD%O?ZOI=KI
M^L:%JND:C?64/V._CM-4&BZJABEUO1M4FL[)[;WWXO\ _!9+XO>,_AIX_P#A
M+\&?@%^S5^R]X4^*FB:IX>^(6H_!_P"'-M8^,/$FC^(;&ZTWQ+ITVL3RQZ/!
M;Z]97MW!<WT?AD^([02B?3-?LKQ!<G\>Z*[Z.?9Q0PJP=+,,1##QA.G""E%R
MI4ZB:G3HU91=6C":;YH4IPB[O34\;$\(<,XO,)9IB,FP=7'3JTZ]6JX24:]:
MBXNE6Q-",XX?$U:;A%PJ8BE4G&RM(_4#]EC_ (*P_'W]E#X&M^SSX9^&7[.W
MQ/\ AROB_5O&=K:?&?P!XF\67EEJ&LQV'VBSA&B>/?"NE3V$%W92ZC9/?Z3>
MZK;W>HWJ#5&L5L+.QY3]K#_@I-\1_P!KOX:Z=\,/%WP&_97^&FF:;XOTSQE%
MXA^"_P +=<\'>+IKW2M+US28M,N-6U3QUXF@?1+F'7KB>\LX["*>:ZM+"1;N
M..&6*?\ .JBD\[S66$6 EC:LL(J*PZH2Y)15&/PTTW%S48K1)2T6BLBX\*<.
MPS*6;PRK#0S*6)EC)8N#JQG+%3UE7E&-14W4D]9-P?,]7=EJQO;O3;VSU&PN
M)+2^L+JWO;*ZA;9-;7=K*D]M<1-_#)#-&DB-V90>U?N__P %D]3T[]IGX7?L
M,_\ !0GPN%GL?C1\'IOA3\1[?3;:Y71_"/Q-^'^I7VLZAX?:>Y_>BZDU_7OB
M)H]@LX5KS2_ Z:C;/<VLZ3'\%JUY?$&O3Z+:^&Y];U>;P[8WLVHV.@2ZE>R:
M+9ZA<(8[B_M=*>9K&WO9XV9)KJ&!)Y48J\C D5&$S#ZO@<SP$Z;J4LPAAI1:
MERNABL)752E75U)27L9XBC.&C:K*2DG!)Z9CDWUW-\ASBE75#$9-5QT9IT_:
M1Q6 S'".AB<*[2@Z<OK%+!8JG5O)1EAG!PDJK:_5'PE_P5R^)5M\&/AK\'_C
M#^SA^RM^TR?@AHD.@_!KQI\>/AI=>,/$'@_3H(;/3HK74(?[;M=/URV@T+3=
M*TF)+:WT*YO3HFA:GXAN]>U+2XKA_!/VO/\ @H=\?/VV_!GPA\)_')?"6I7W
MP@U#XAZEI_B[1-&GT;7O$<_Q#U/2[ZYAUVUM[X^'8++P_::-IVC>'[;0M#T<
M0:;;*+]]0NLW)^$J*JMG>:U\//"UL=6J4*E*E0JTY<O[ZG0E3E15:2BIUI4G
M2IJG4JRG4A&/)&2@Y1>>&X4X=P>-IYAA<IPM'&4<1B,5AZT54;PU?%PK4\5+
M"PE-T\-#$QQ%9UZ5"%.C5J3]K.G*K&$X_7W[2G[9_P 1_P!J#X<?LQ_##QMX
M<\$Z'H7[*WPMM/A1X%O/"UGKMOJVNZ+::'X/\/C4?%DVK:_J]G<ZH]CX)TB0
MMH]CHUHMU/J4GV8PSVMO9>__ +,?_!4CXD_L\_ =OV:?$OP2^ '[17P>L/$V
MH^-?"OACXZ>#K[Q9%X5\47LXOX9]/@.KQZ/-I5IK3WNMQV<NC+JB:AJNJO::
M[9QWC1K^85%13S?,J6+GCJ>+J+%5*,:%2JU"3J48TZ=*-*I"473G35.E3CRR
M@U[D7:Z3-:W#>1XC+J64ULNH2R^AB9XRAATZL%1Q<Z];$3Q%&I"I&M2K2K8B
MO-SA4C+][4C?EDXGZ"?LX?\ !2/X\?LS>._C=XI\)>'_ (5>*?!_[1.K:KJ_
MQ9^"WCOP5_;7PDUZ?5+_ %R]$5CX>M-2TW4-&M--A\1ZQI=EI]EK TJ[TJXM
M['Q!I^N0:=IJ6GK'Q*_X*F/X@\%?$CP1\'OV*?V,/V=X_BQX'USX?^,?&'PX
M^$T5M\0!X>\4:;>Z-XCL_#VOVUYI.G:';ZKI-_<V,D(T&]:%)Y9XIA=?9Y[;
M\HZ*TIYWFM*A]6AC*BHKVO+&4:4W3]LY2JJC4G"52@JDISE)49P3E*4K7;;R
MK<)\/8C&?7ZN5T7BFL.IU(3KTHU_JL:<,.\31I584,5*C"E2A3EB:=64:=.$
M$^2*2^R/AY^VU\3/AK^Q_P#&G]B_1/#?@:[^'/QR\7Z7XR\4>)-4LM>E\;:9
M?:7/X+N$M-!N[7Q#::#!9S/X$TA9/[0T#49UCN=3"3!YK22R^-Z**X:V)KXB
M-"%:K*I'"T5A\.I6M2HJ=2JJ<;)>ZJE6I+6[O)ZVL>MA<!A,%/&5,+0A1GC\
M5+&XR4+WQ&*E2HT)5YW;]]T:%&GI9<M..E[M^^?LW_'Z^_9M^(W_  L:P^%G
MP4^,,QT'5- ;P?\ 'OP$OQ%\"-%JDEG*VIKH0U31IH-;L7LD&GZG;:C!+;Q3
MWENXEM[N>)_OK_A[UXE_Z, _X)@_^(JW_P#\\NOR)HKJPN;9C@J7L<+B94J7
M,Y\BITI+FE9-WG3D];+2]O+<\_,.',ES7$?6L?@8XBO[.-+VCK8BF^2#DXQY
M:5:G%V<GKRWULW9*WUO\3OVN=1^)_P"T%X _:$F^ '[,'@>^\ 2>$)8_A1\.
M_A1)X=^"/B\^#_$%WK\8\<^ YO$>I2:\/$'VO^QO$[+K-E)J6A6ME8PO9R6R
MW)^]=$_X+C?&SPSX7\1^!_#?[('_  3W\/\ @KQAL_X2[P?HG[/_ (MTGPOX
MI\I%CC_X2/P_8?%JWTG6_+C543^T[2ZV(JJN%  _%.BM*&=YKA:E>KA\9.E4
MQ,Y3K2A"DG4E*+A)N]-I*46XRC&T6FTTS'&<)\/8^CA,/C,LI8BC@:<:6%IU
M*F(<:,(352"5JR<I0J)3C.;E.,DFI)I'OO[2/Q^N_P!I+XBK\1KWX3_!'X-S
MCP_IGA\^$?@#X"/PZ\#2KI<U[*NL3Z$^KZW+/K]Z+WR-0U.:_=[BUL]/MUCB
MBM(UKT']E']L;Q5^RF/B3I-C\+/@I\:? GQ<TOP]I?CSX=?'7P5-XV\)ZD/"
MM]?W^@:I9V=MJ^CR66M:5)JNJ)97DDMY;1"_DG-B]Y;V-S:_(-%<L,=BX8MX
MZ%:4<4Y3FZRC"[=2,H5+QY>1QG"4H2BX\LHR<6FFT>A4RG+JV7+*:N%A/+XP
MI4XX:4ZEHQH5(5:/+4Y_:J=*K3IU*=15%4A.$9QDI),_1O\ :2_X*3?$;XZ?
M""7]G/P'\)/@E^S!^S]=^*T\::[\,_@#X3N/"5MXWUV 6+V=UX_U#^T9(?$@
ML+K3--OK>&#2](MYKS2="N-1AOYO#F@2:9^DG_!#+QSXK_9K^"'[?O[6_B.\
M2V^!?P_^'N@6IT&^BBMX/'WQ@\.P:SK/A?1])UN0EK#4+"#Q!9>&+JR5534;
MSXI>&I7,C:=$(OYP*[&U^(GQ L?!.I?#2Q\=>,;/X<ZSJ\>OZQX M?$VMV_@
MG5=>B6P2+6]2\*PWR:%?:O&FE:6D>I75A+>(NFV"K,!9VXC]3 9_BL-FM+-\
M5.KB<3A</7I85*4:4*<Y8>M1P\>2$5"&&I3K.I*A2A",_>BU:<[_ #V<<'8#
M'<.XCAO+Z6'P&!Q^-P=?,'*%3$5*]&GC<-BL9/VM2I*K4QV(IX:-&GBZ]2I4
MI>Y-2O2I\OJ'PJ_:8^)_PE_:*TO]J'2[C1_%/Q1LO%_B3QKJDOCG3I->T/Q9
MJOC.'6;;QA!XITZ*[T^XU"Q\36GB'6K;55MK^QNV34)I+2\M;E8IX_O6_P#^
M"O?C[P_X8\7V'[/G[+7[)'[+'CWXB>%M5\)>-/C!\"_AC=^%OB)_9>L7J7EY
M#X-U9-<8>$HYGAMY")4UV:UU&ULM:TJXTS5=,TFZT_\ (FBN'#9OF6#IU*>&
MQ=2E&I.I4DTH.:J58QA5JTZLHRJTJE2$(QG4I3A.2BDY:'K8_AK(\SK4:^.R
MVAB)T*5*A!2=2-*5"A4G5H4*U"%2%#$4*52<YTZ.(IU:4)2DXQ3;/J']D+]K
MKXM?L4?&:P^-WP>DT.X\10Z)J_AG5]#\56FHZAX7\4>&];-K-?:+K]GI6JZ)
MJ4]HNHZ?I6LVK6>K64UOJ^D:;=^9(D#P2^K_ !^_;\\8?%WXK_"3XO?#7X/?
M!#]EWQ-\%]>N_&/A*7X#>!K#PY)?^-]1U?1]?O\ Q5XN:[2\L_%5Y)JVC0-#
M9ZKITNGFPN+[3M2M]4AO[Y[GX'HJ*>98^EA/J-/%5887VRKJDFK0K*5.:J4Y
MV]I2ESTJ<G[.<%*4(RDFTF;5LBRC$9C_ &M6P%"IF'U:6#EB)*3]KAI0K4G1
MKTN;V.(BJ>(KTX^VIU'&%6I"+49-/]H?$?\ P62OOB$X\5_%K]@G]@[XI?&)
M)--D;XJ^+/@[-?:GJDNEP6EM:W7B*UN=8NM3UB[6&U&P)XDL-,MF\I++2[6V
MMTMC\?Z#^WQ\7-%_;7T_]NIO#/PVN?BCINIB^M/"5OX?U/1_AG:6<'PZ;X6Z
M9HEAH&D:[::K9:3HWA$6UIIL::\]R+BRM[B]N;TM<)<?#U%=%?/<VQ,Z-2MC
M)RG0Q%+%TYJ%&$OK-%R=+$3E"G%U:L.:7+4JN<O>E=ZLXL)PCPY@J>)I8;*Z
M5.EB\%7RZO3=7$U:;P&*C".(P=*%6M..'P]6-.FI4L.J4/<@TDXJWMOCKX\>
M+?B!^T/XE_:4UC3?#UMXV\4?%J]^,5]I&G6VHQ>%H/$=[XI;Q8^G6EI<:I=:
MLNAQWY^S1P3:S-J'V(!'U%[@FXKI?VM_VGO&O[8OQX\7_M _$+0_"WASQ5XR
MM?#5G?Z1X-M]6MO#]K#X6\,Z3X6L3:1:WJ^N:B))[+1[>>[:;495>ZDF:%((
M2D*?-M%<4L9B9TZ]&=:<J6)Q$<77@[6J8B"JQC5EI?F2KU5HTO?=UM;U:>6X
M"E7PN)IX:G"O@L%4R["5%S<U#!598:=3#PO*WLY2PF&;NG+]U&TDKW^ROVO/
MVV_B7^V8/@S_ ,+&\->!O#A^"?PWL_AIX>/@JSU^T&J:7:?9<ZAK0UWQ#K^^
M_D^QP\6)LK=,R?N7W+LE_;*_;D^*O[;/Q&\ _$WXA:)X-\&>(/AQX T3X?>'
ME^'-OXBTJ 6.A:UK&OVNKSRZWXC\07ZZU_:.MW)6XLKRS@AAM[,0VRW$4MS/
M\845K5S+'U_K7ML34G]=EAY8J]OWTL*G'#N=DM:2;4;6\[G/ALARC"?V>\-@
M*%+^RH8VGE_*I/ZK#,91GC8T^:3TQ$HQ=3FYMK1LKH_;A_\ @N)\7/$VG>%]
M6^,?[*W[''QS^,7@33]'LO!OQJ^)'PD;4/%FGW&DRR7/]KWD-IJUK%;ZE<7T
MLNJ+'X)NO ND6.ISW%UI^E6PD2*+\F?C9\8_'G[0?Q8\=_&CXFZHFK^.OB)K
M]SX@U^\AB:WLXYI4BM[/3M-M6DF-GI&C:=;V>D:-8^=+]BTJQL[02R"$.?+:
M*TQN<9GF,(4\;C*N(A"2FE/DO*HHN"J591C&5:JH-Q52JYS46US6;,,JX9R'
M)*U6OE668?!5:M-TG*E[1J%&4XU94*$)SG##8>52,:CH8>-*BYQC)PO%-?4'
M[(/[7/Q9_8G^,UA\;?@Z^A3^(8-$U?PQJVA^*K34+_POXG\-:W]EEO=$U^ST
MG5=$U*>T34-/TK6;0V>JV4MOJ^D:;=^9(D#P2^O?'3]OG5?B_P#&7X)?&'PQ
M^SQ^SO\  ^Z^!GC.U^(6B>&?A/X'?PUI'C#Q>OBCP]XPU#5?B#/I]]9W_B$W
M^L>'+9%\F;3KJST^YO8(KQ[NYEOV^ :*SIYGCZ6$^HT\34CA?;*NJ-HRC&M&
M5.:G!RBY4VYTJ<I*$HQG*$7)-HVK9#E&(S'^UJV!I3S!X:6#EB;U(SJ8:5.M
M2=*K&$XTZJ5/$5X0E4A.=.-6<:<HJ3/I']K7]IWQO^V)\>/&/[0/Q$T7PMX>
M\5>,[?PW:7VD>#+;5K3P]:0>%_#6D^%M/%G#K>KZ[J7FS6&CV\][)/J4RRWL
MMP\$=M;M%;1>_P#[)/\ P4E^+W[*?PZ\4? ^7P#\'OCS\ ?&>OIXEU[X/?'3
MP6GB_P ,Q:RXTQ+[4=&9+NS>VGOX]&TLO9:S#X@\/VMY9KJMEH5OJMS?7MW^
M=]%%+,\?1QM3,*>*JPQE:5:=:NFG*JZ[;K*K%IPJ1JN3<X3BX2>\=%8KY#D^
M)RRADU?+Z%3+,+##4\+A&I*.&C@U&.%=":DJM&I04(JE5IU(U8I.T]7?])_C
M]_P4>O\ XN?"?QS\#_AQ^RI^RC^S7\//B-?>'KSQA+\&OAG_ &)XXUV+PSKF
MD^)]-TO4/%8U"*T?2D\0:)IVH?9;7P]9R*MK%:QW"0-=+=>@^$O^"N7Q*MO@
MQ\-?@_\ &']G#]E;]ID_!#1(=!^#7C3X\?#2Z\8>(/!^G00V>G16NH0_VW:Z
M?KEM!H6FZ5I,26UOH5S>G1-"U/Q#=Z]J6EQ7#_DO170L]S95IUUC)J=2@L--
M*G15)T(U76A3^K^S]@HPK2E5IVIIPJ-S@XR;9Q/A#AR6&I82664Y4J&*EC:4
MI5L4\1'%3H0PM2M]<==XN4ZN&A##U>:NXU:,(TJBE!*)]V_M>?\ !0[X^?MM
M^#/A#X3^.2^$M2OOA!J'Q#U+3_%VB:-/HVO>(Y_B'J>EWUS#KMK;WQ\.P67A
M^TT;3M&\/VVA:'HX@TVV47[ZA=9N3ZI^S/\ \%3?B=^S[\!(_P!F;Q1\%?@%
M^T9\&](\1:EXO\'>%OCKX/OO%D/A#Q'?7DFKQ2:; =7CT>72+7Q!=:GKZ64N
MCKJBZEK.KO::]9QWK1K^7U%1'.LTAC)X]8VL\95HQP]6O-QJ3K48PITU3K*I
M&4:L>2E3352,N9PC*5YKF-9\+\/U,LHY.\JPL<LP^)GC,-@Z49T:>&Q4ZU:O
M*OAG1G3GAY^TQ%=IT9P48U9TXI4WR'W=8?\ !0+XK:;^SA^TM^S)9>"_A=:>
M!OVHOBK=?%KQIJ%CH6MZ?J_AG6+S7/"NO2Z)X%MK'Q';^'=&\-PW/@_2K2PT
M^]T/5)+'3I+RUBN"6M);+A/V8OVPOB%^RKH/Q_\ #_@7P]X,UVT_:)^$6N?!
MSQ;-XLM-<N;C1]!UZTO[*XU/PZVCZ[HT4.KPPZE<F%]3BU.R\U8&DM'1)(Y?
MDRBLO[3Q_M</7^M5/:X2C.AAY^[>E1J.LYTX>[;ED\16;NG_ !)6>UNC^P<G
M^KXW"?4*'U;,,33QF-H^_P N(Q5%8:-*M4]Z_/!8/"I6:7[F&F]_JG]C;]K?
MQ[^Q/\;=.^.GPW\/^$/$WB33_#_B#PVND^-[;6;K0Y;'Q%:I;74ICT'6M!OU
MNX/*B>WD%\81AUD@DWJT>!\)_P!J7XO? _\ :'A_:=^%^KV'ACXF0^*/$WB8
M[-.CU'P[<KXP?4E\2>'[[1M4DO!>^']3LM6OM.:WN+A]0M(G@OM/U*TUJRL=
M4MOG6BHACL92IX:E3Q%6G#"8B6+PRA+D=#$S]ES5J<HVE&H_8TK-2T<$U9WO
MM5RC+*];&XBM@L/6JYE@H9=CY58>TCB\#3]OR86M3G>G.BOK-=.+C[RJR4KJ
MR7[/:Q_P6*75M5A\?/\ \$]?^"?S?&AM4NM:U'XFWOP7N;ZXOM8NY)YI=:-B
M==@UE]=:XE2Y.KZGXLU:[,ZR2[@\JM%\G_LT_P#!0?XS?LQ_M.?$G]K#PSH'
MP_\ %WQ,^*MK\08_%-IXQTG6O^$7:\^)'BW3O&NOZA8:9X8\0>&[JSE37--B
M^Q6Z:@UG!8S7%KY!8P3P?"-%==3/<VJUJ%>>,G[;#5?;T9PIT:3A6LH^V:I4
MX1G5LK<]12EOKJ[^91X1X<P^&QF#IY93>&Q^'^J8JE5K8K$*IA5)S6&3KUZD
MJ5!2=U2HRITTTK1T5O6?A#\8/$/P;^-GP]^.N@:?H^J>*/AS\1/#_P 2=*TS
M6HKV30K[6/#VNV^OV]GJ,-A>V-^VG7%U;K%.EKJ%M<^0S".Y1P'KT/XX?M8?
M$[XX?M1:U^UQ?+HW@CXJZIXP\'^.=/?P1%J-GI7AOQ%X$T_P]8>&K_1(]7U'
M6-0BFL6\,Z7?;[K4+IFOUEE4QQ,D,?S'17"L7B8T/JT:TXT/K$<7[.+LEB80
ME3A632YE.,)2BFFK7O:^IZ\\MP-3%_7YX6E/%_4JF6^VE'FD\#5JPK5<*XMN
M#I3JTX3E%Q=W%*]KI_J-^UG_ ,%2O'/[87PYU;PGX^_9Q_9B\._$'Q6/#-KX
MR^.7@WX>WEK\5=:TKP?J5GJ>@:/8^)-7UK6-4TFQ$]G'!J,!U#4(;JR9K&RA
MTRS+0/\ 5?\ P50\0VG[.W[&O[ __!.339HH_$O@/P-9?'WXXZ2^^XN_#_Q"
M\8VVO7-CHPO1+B'_ (J3QQ\7+R\TJYA2Y33F\):@(K>WNK99/P.!((()!!R"
M."".A![$5K:YK^N^)]4N=;\2ZUJWB'6KT0B\U?7-1O-6U2[%M;Q6EN+F_OYK
MB[G$%K!#;0^;*_E6\,4*;8XT4>J\^Q=6CF?UF4L1C<QP^'P3QDG"$J>#AB'B
ML13<84X^TGB:L*/-4D[N*J\_/*<7'YZ/!V6X?%9"L!3IX+*\DQN-S2.6P56I
M"OF=7!QP&"KJ=6M/V5+ X>IBO9T8Q<5-X=4_9PI2C/)HHHKPCZX**** "BBB
M@ HHHH **** "BBB@ HHHH _U:****_L _S/"BBB@ HHHH _G=_X.A?^45'B
MS_LMWP:_].^I5^ G_!HW_P GV_M#_P#9I6N?^KB^$-?OW_P="_\ **CQ9_V6
M[X-?^G?4J_ 3_@T;_P"3[?VA_P#LTK7/_5Q?"&O(K_\ (SH>D/\ VX^APO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MB%EN"Q^)P.)QU.M1J.B\+6="IB*N&O"JL.II2E*G[64*;<Y0M%G]&E%>"_M
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MI7R^A# 8F.E[<N(PU6-M[+5+8****\$^O"BBB@ HHHH **** "BBB@ HHHH
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MW5UO1=._8.\5P:AJ^EV,Y_:/^($@AO+^TMI3&W@CX7A9!'/*CE&*L VW:2K
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MF?BM_P"$CX0_^.U_2]11_J1PM_T**/\ X.Q?_P T!_Q%;Q!_Z*7%?^$N7?\
MS'Y?GW9_-#_Q#2? _P#Z.9^*W_A(^$/_ ([1_P 0TGP/_P"CF?BM_P"$CX0_
M^.U_2]11_J1PM_T**/\ X.Q?_P T!_Q%;Q!_Z*7%?^$N7?\ S'Y?GW9_-#_Q
M#2? _P#Z.9^*W_A(^$/_ ([1_P 0TGP/_P"CF?BM_P"$CX0_^.U_2]11_J1P
MM_T**/\ X.Q?_P T!_Q%;Q!_Z*7%?^$N7?\ S'Y?GW9_-#_Q#2? _P#Z.9^*
MW_A(^$/_ ([1_P 0TGP/_P"CF?BM_P"$CX0_^.U_2]11_J1PM_T**/\ X.Q?
M_P T!_Q%;Q!_Z*7%?^$N7?\ S'Y?GW9_-#_Q#2? _P#Z.9^*W_A(^$/_ ([1
M_P 0TGP/_P"CF?BM_P"$CX0_^.U_2]11_J1PM_T**/\ X.Q?_P T!_Q%;Q!_
MZ*7%?^$N7?\ S'Y?GW9_-#_Q#2? _P#Z.9^*W_A(^$/_ ([1_P 0TGP/_P"C
MF?BM_P"$CX0_^.U_2]11_J1PM_T**/\ X.Q?_P T!_Q%;Q!_Z*7%?^$N7?\
MS'Y?GW9_-#_Q#2? _P#Z.9^*W_A(^$/_ ([1_P 0TGP/_P"CF?BM_P"$CX0_
M^.U_2]11_J1PM_T**/\ X.Q?_P T!_Q%;Q!_Z*7%?^$N7?\ S'Y?GW9_-#_Q
M#2? _P#Z.9^*W_A(^$/_ ([1_P 0TGP/_P"CF?BM_P"$CX0_^.U_2]11_J1P
MM_T**/\ X.Q?_P T!_Q%;Q!_Z*7%?^$N7?\ S'Y?GW9_-#_Q#2? _P#Z.9^*
MW_A(^$/_ ([1_P 0TGP/_P"CF?BM_P"$CX0_^.U_2]11_J1PM_T**/\ X.Q?
M_P T!_Q%;Q!_Z*7%?^$N7?\ S'Y?GW9_-#_Q#2? _P#Z.9^*W_A(^$/_ ([1
M_P 0TGP/_P"CF?BM_P"$CX0_^.U_2]11_J1PM_T**/\ X.Q?_P T!_Q%;Q!_
MZ*7%?^$N7?\ S'Y?GW9_-#_Q#2? _P#Z.9^*W_A(^$/_ ([1_P 0TGP/_P"C
MF?BM_P"$CX0_^.U_2]11_J1PM_T**/\ X.Q?_P T!_Q%;Q!_Z*7%?^$N7?\
MS'Y?GW9_-#_Q#2? _P#Z.9^*W_A(^$/_ ([1_P 0TGP/_P"CF?BM_P"$CX0_
M^.U_2]11_J1PM_T**/\ X.Q?_P T!_Q%;Q!_Z*7%?^$N7?\ S'Y?GW9_-#_Q
M#2? _P#Z.9^*W_A(^$/_ ([1_P 0TGP/_P"CF?BM_P"$CX0_^.U_2]11_J1P
MM_T**/\ X.Q?_P T!_Q%;Q!_Z*7%?^$N7?\ S'Y?GW9_-#_Q#2? _P#Z.9^*
MW_A(^$/_ ([1_P 0TGP/_P"CF?BM_P"$CX0_^.U_2]11_J1PM_T**/\ X.Q?
M_P T!_Q%;Q!_Z*7%?^$N7?\ S'Y?GW9_-#_Q#2? _P#Z.9^*W_A(^$/_ ([1
M_P 0TGP/_P"CF?BM_P"$CX0_^.U_2]11_J1PM_T**/\ X.Q?_P T!_Q%;Q!_
MZ*7%?^$N7?\ S'Y?GW9_-#_Q#2? _P#Z.9^*W_A(^$/_ ([1_P 0TGP/_P"C
MF?BM_P"$CX0_^.U_2]11_J1PM_T**/\ X.Q?_P T!_Q%;Q!_Z*7%?^$N7?\
MS'Y?GW9_-#_Q#2? _P#Z.9^*W_A(^$/_ ([1_P 0TGP/_P"CF?BM_P"$CX0_
M^.U_2]11_J1PM_T**/\ X.Q?_P T!_Q%;Q!_Z*7%?^$N7?\ S'Y?GW9_-#_Q
M#2? _P#Z.9^*W_A(^$/_ ([1_P 0TGP/_P"CF?BM_P"$CX0_^.U_2]11_J1P
MM_T**/\ X.Q?_P T!_Q%;Q!_Z*7%?^$N7?\ S'Y?GW9_-#_Q#2? _P#Z.9^*
MW_A(^$/_ ([1_P 0TGP/_P"CF?BM_P"$CX0_^.U_2]11_J1PM_T**/\ X.Q?
M_P T!_Q%;Q!_Z*7%?^$N7?\ S'Y?GW9_-#_Q#2? _P#Z.9^*W_A(^$/_ ([1
M_P 0TGP/_P"CF?BM_P"$CX0_^.U_2]11_J1PM_T**/\ X.Q?_P T!_Q%;Q!_
MZ*7%?^$N7?\ S'Y?GW9_-#_Q#2? _P#Z.9^*W_A(^$/_ ([1_P 0TGP/_P"C
MF?BM_P"$CX0_^.U_2]11_J1PM_T**/\ X.Q?_P T!_Q%;Q!_Z*7%?^$N7?\
MS'Y?GW9_-#_Q#2? _P#Z.9^*W_A(^$/_ ([1_P 0TGP/_P"CF?BM_P"$CX0_
M^.U_2]11_J1PM_T**/\ X.Q?_P T!_Q%;Q!_Z*7%?^$N7?\ S'Y?GW9_-#_Q
M#2? _P#Z.9^*W_A(^$/_ ([1_P 0TGP/_P"CF?BM_P"$CX0_^.U_2]11_J1P
MM_T**/\ X.Q?_P T!_Q%;Q!_Z*7%?^$N7?\ S'Y?GW9_-#_Q#2? _P#Z.9^*
MW_A(^$/_ ([1_P 0TGP/_P"CF?BM_P"$CX0_^.U_2]11_J1PM_T**/\ X.Q?
M_P T!_Q%;Q!_Z*7%?^$N7?\ S'Y?GW9_-#_Q#2? _P#Z.9^*W_A(^$/_ ([1
M_P 0TGP/_P"CF?BM_P"$CX0_^.U_2]11_J1PM_T**/\ X.Q?_P T!_Q%;Q!_
MZ*7%?^$N7?\ S'Y?GW9_-#_Q#2? _P#Z.9^*W_A(^$/_ ([1_P 0TGP/_P"C
MF?BM_P"$CX0_^.U_2]11_J1PM_T**/\ X.Q?_P T!_Q%;Q!_Z*7%?^$N7?\
MS'Y?GW9_-#_Q#2? _P#Z.9^*W_A(^$/_ ([1_P 0TGP/_P"CF?BM_P"$CX0_
M^.U_2]11_J1PM_T**/\ X.Q?_P T!_Q%;Q!_Z*7%?^$N7?\ S'Y?GW9_-#_Q
M#2? _P#Z.9^*W_A(^$/_ ([1_P 0TGP/_P"CF?BM_P"$CX0_^.U_2]11_J1P
MM_T**/\ X.Q?_P T!_Q%;Q!_Z*7%?^$N7?\ S'Y?GW9_-#_Q#2? _P#Z.9^*
MW_A(^$/_ ([1_P 0TGP/_P"CF?BM_P"$CX0_^.U_2]11_J1PM_T**/\ X.Q?
M_P T!_Q%;Q!_Z*7%?^$N7?\ S'Y?GW9_-#_Q#2? _P#Z.9^*W_A(^$/_ ([1
M_P 0TGP/_P"CF?BM_P"$CX0_^.U_2]11_J1PM_T**/\ X.Q?_P T!_Q%;Q!_
MZ*7%?^$N7?\ S'Y?GW9_-#_Q#2? _P#Z.9^*W_A(^$/_ ([1_P 0TGP/_P"C
MF?BM_P"$CX0_^.U_2]11_J1PM_T**/\ X.Q?_P T!_Q%;Q!_Z*7%?^$N7?\
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MQ_KYQ7_T-7_X28#_ .93YL_X9['_ $-!_P#!4/\ Y.H_X9['_0T'_P %0_\
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M_P"3J^DZ*/\ B%7 ?_0BC_X<,T_^;?ZN_*Q_KYQ7_P!#5_\ A)@/_F4^;/\
MAGL?]#0?_!4/_DZC_AGL?]#0?_!4/_DZOI.BC_B%7 ?_ $(H_P#APS3_ .;?
MZN_*Q_KYQ7_T-7_X28#_ .93YL_X9['_ $-!_P#!4/\ Y.H_X9['_0T'_P %
M0_\ DZOI.BC_ (A5P'_T(H_^'#-/_FW^KORL?Z^<5_\ 0U?_ (28#_YE/FS_
M (9['_0T'_P5#_Y.H_X9['_0T'_P5#_Y.KZ3HH_XA5P'_P!"*/\ X<,T_P#F
MW^KORL?Z^<5_]#5_^$F _P#F4^;/^&>Q_P!#0?\ P5#_ .3J/^&>Q_T-!_\
M!4/_ ).KZ3HH_P"(5<!_]"*/_APS3_YM_J[\K'^OG%?_ $-7_P"$F _^93YL
M_P"&>Q_T-!_\%0_^3J/^&>Q_T-!_\%0_^3J^DZ*/^(5<!_\ 0BC_ .'#-/\
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MV.+Q%:DVFD[N#[;:&&)XSXFQ5*5&KFU=0DFI>QIT,-)J2LU[3#TJ52S7:0@
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M11_KOQ3_ -#>M_X)PG_S.'_$*?#[_HFL+_X59C_\V>7Y]V?TN_\ $2W\<O\
MHV?X4?\ A6^+_P#XW1_Q$M_'+_HV?X4?^%;XO_\ C=?S144?Z[\4_P#0WK?^
M"<)_\SA_Q"GP^_Z)K"_^%68__-GE^?=G]+O_ !$M_'+_ *-G^%'_ (5OB_\
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MV>7Y]V?TN_\ $2W\<O\ HV?X4?\ A6^+_P#XW1_Q$M_'+_HV?X4?^%;XO_\
MC=?S144?Z[\4_P#0WK?^"<)_\SA_Q"GP^_Z)K"_^%68__-GE^?=G]+O_ !$M
M_'+_ *-G^%'_ (5OB_\ ^-T?\1+?QR_Z-G^%'_A6^+__ (W7\T5%'^N_%/\
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M -#>M_X)PG_S.'_$*?#[_HFL+_X59C_\V>7Y]V?TN_\ $2W\<O\ HV?X4?\
MA6^+_P#XW1_Q$M_'+_HV?X4?^%;XO_\ C=?S144?Z[\4_P#0WK?^"<)_\SA_
MQ"GP^_Z)K"_^%68__-GE^?=G]+O_ !$M_'+_ *-G^%'_ (5OB_\ ^-T?\1+?
MQR_Z-G^%'_A6^+__ (W7\T5%'^N_%/\ T-ZW_@G"?_,X?\0I\/O^B:PO_A5F
M/_S9Y?GW9_2[_P 1+?QR_P"C9_A1_P"%;XO_ /C='_$2W\<O^C9_A1_X5OB_
M_P"-U_-%11_KOQ3_ -#>M_X)PG_S.'_$*?#[_HFL+_X59C_\V>7Y]V?TN_\
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ML-22279+1!1117(>B%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%?NU^Q;_P0]^('Q\^%&G_ +0W[1/Q9T3]FCX,
M:UH^D^*_"T]_9:7KGB7Q/X-U*"WOH?%.HSW_ (BT'P]X \.ZII]U!-H.J:W>
M:MJEX&-U=>&+33)=-OM3]#+<JS#-Z[P^7X:6(J1@ZE1J4*=.E3CO4JUJLH4J
M4%LG.:YG[L;R:3\7/>(<FX;PD<;G6-IX.A4JQH44X5:U?$5Y_#1PV&P\*N(K
MU'NXTJ<N2-YS<8)R7X2T5^\G[9O_  2(^"WPG_9S^(7[4W[*?[7_ (2^/WP_
M^%U]H-OXR\.1WWA'Q1?6MKXA\1Z;X;MWL/'/P[UK4-#N-8L[O7-+EGT+5/#^
MAB?38]2U"#51<PVFD7?X-T9EE>-RFO##XVG"$ZE*->E*G6I5Z56C*<X1J4ZM
M&<X2BYTYQM=23BU**T%D/$.5<282IC<IK5*M*CB)83$0KX;$82OA\3"G2JRH
M5J&*I4JD9JE6I3NHN$HSBXSEK8HHK^@_]A/]@[]F#XS_ /!*;]L']IKXD> +
MWQ#\:?AIIO[1-WX"\6KXS\::1%X:E^&GP3T3QIX8$'AW0]?TWPSJJ1^(+NXN
MKT>(='U@W<4IM69+=(XTK*LJQ&;XBIAL-.C"I2PN(Q<G7E.,/9X:'/-)PIU&
MYM:03BHM_%**U)X@XAP7#>"H8['T\34HXC'X/+H1PL*=2HJ^.J^RI2DJM:A%
M4HN\JDE-S44^2$Y6B_Y\****\T]T**** "BBOT&\5?\ !-3]H3P=^Q3H'[>&
MKZI\-#\(/$,>AW4'AZT\2:W-\1K+3?$GBG_A$=%U2_T=O"T7AH6MYJ<EG+Y%
MEXNO=2M[._MY;JP@EBOH+/IP^#Q6+CB)8:A4K1PE">*Q+@KJCAZ;2G5GVA%R
M5WO;6UDVN'&YGE^72P4,=BZ.%GF.,I9?@8U9<KQ.,K\SI8>DM>:I/E?*M%>R
MO=I/\^:**_9?_@G=_P $HM$_;#^$'BW]HWXM_M$>&?@1\%_"'B_4?!-S<SV=
MG/K-QJ^D:=X?U34;O5-8\2ZIX>\*^%M$%MXETZ&POY;S7+N\O5NX)],L(HK>
MXO-<NRW&9KB5A,#256LX3J-2J4Z4(TZ:O.I.I5G"G&,5JVY+LDVTCGSO/,LX
M>P,LRS;$/#86-2G14HT:^(J5*]:7+2HTJ.'IU:U2I4EI&,8/JY-13:_&BBOZ
M2_VX/^"">G?!GX$^*OV@OV8?C'J_Q-T#P#X7OO'OBCPEXWC\/-J.J> M*TJ#
M5=:\2^#O%WAR/3-$U271],@U3Q$^D7.EVQU;0XVAT74KS6K6ST[Q!_-I6V;9
M-F.28B&'S&A[&=2FJM*49PJTJM-MKFIU*<I1=FK2BVI1TO%*46^7ASBC).*\
M'4QV28OZS2HUGA\1"=*K0KX>LHJ7LZU"M&$X\T6I0FE*G/WE"<G":B45_0'_
M ,$<_P!A[]G_ .*7P?\ VHOVO_VM?"%KXW^#'PA\.^(O#NC^';S4-5L;5;[P
MOX4B^(7Q)\4S'1M0T?45U'P_X5F\/Z?X:ECU'[,9_$&NW#0QZEIFEWEM\^?\
M$N?^";'A?_@I!XH^/>H:[\1+_P"#WA;X3OX*N8= \*:"/$=W>R_$JZ\=2Z7I
M]CJGB+6FDL=,\-6_@JXMW?4(]:U+5%O+4R7D,L%Q/<=='AO,L1')U0C1J5\[
M6+G@\+[54ZRHX--SK5G54*5.G.,:DJ7[QRG&FVHW<4_.Q/'.18*?$SQ<\30P
MG"DLMI9IC_8.MAGB<S<8TL-AE0=7$5JU*I4HT\0O81A2G5BG.RFX_C_17Z$?
M\%&?^"?7CC_@GO\ &#1_ FM^)%^('@/QOH/_  D7PY^)$.@S>&TU^&Q:WM/$
MVA:EHSZCK,&F^(O"NIW%O'?6MGK6JP7.BZKX;UPRV,NMR:-IGMG[6O\ P3-\
M.?LT_L"?LM_MC6'Q8UKQ9X@^/K_"DZWX*N_"UCI6C:%'\6?A-XD^*UD-+U2'
M6+R]F?PU#H*>'[IKNW===ENGU>)=#2$:5)S2R/-(5,SI5,,Z=3)Z?M<PA.I2
M3HP<XP4H^_:LI<RE!T7.,X-3BW%Q;[J?%N05J.0XBCCU6H<2UG0R:I3HXB4<
M35C3G4E"?[J^&E#V<H5(XE4I4ZJ=*<8SC)1_(NBBBO)/HPHK]P?^"?G_  1'
M^-G[7&BZ)\6?BQJTGP.^ _B#26U;POJTEM;ZG\0O'UK>0.='U3PQX9E=;;2_
M"]P^V\/B#Q+<64NI6)M)O#NCZQIVIKK-C^?_ .WQ^S1HG['O[6?Q8_9S\.^)
M]4\9:-\.SX&^Q>)-:LK33M3U%?%WPV\'>.IA=6=B\EK$;*Y\3S:?$T38F@M(
MIG5))&1?6Q.1YIA,MH9MBL).A@L36C0H5*KC"I4E.E.M"2HM^U5.=.G.4*C@
MH223BVI1<OG,#Q;P_F6>8OAW+\QI8S-,!A:F+Q=+#QJ5*-&G2KT</5A+%1B\
M.Z]*MB*4*E"%652G*3C.*E"<8_'U%?LM^P=_P2+U;]J'X0:A^T]\=/C5X8_9
MH_9IL9KU=,\;:^NC75[XHBT373X?UZ_-WK?B'P[X=\%>&[/5K>_T./Q)XAU"
M[N)M>LWM;?PW=63IJ![7]N'_ ((ZV'P0^!,G[6'[)_QWTG]I_P" %E<W4_B:
MZTI_#5_JGA;PVNI1:+!XGTOQ5X2US4O#GQ%TG3];^U:3XO?1M-T'4/"\L4.H
M2:5J&DQ>([WPQT1X9SN67O,XX)O"_5_K:7M:/UB6#6^+CA?:?698=73=54N7
MD:J*].\UQSX\X5IYRLAGFD5C_KBRYOZMBW@H9D_ARZ>8*A]1AC9:Q5!XA251
M.A*U=JF_PTHK^@'PE^QI^S_^T9_P16UC]H/X0_#33]%_::_9Y\2>*M2^*GB;
M2]4UR:]\5:?X'OEU/QA::I'K>N:AI\5A'\&O$/A_X@&TTVSL4@U_09K70[>S
M@U34+>^_G^KCS#+*^6K SJSIU*>88&CC\/5HN;@Z=:Z=.3G"#5:C.+A6A9\L
MK:M23?IY+G^$SR6;4L/3KT*^2YMBLHQM#$QIQJJMAN5QKP5.I54L-B:<XU<-
M5;3G'F3BI1DD4445YI[@4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 ?Z<_P"R7XPU?XA_LK?LS^/_ !!<2W6O
M>.?V?O@SXPUNZGE:::YU?Q-\.?#>M:E<33/\\LLU[>S222M\TCL7;DFOH&OE
M+]@__DQW]C/_ +-2_9W_ /50^#Z^K:_K7 2E/ X.<FY2EA,/*4GJW*5&#;;[
MMMMG^<&;PA3S;-*=.*A"GF.-A"$5:,80Q-6,8I=%%))+L@HHHKK/."BBB@ H
MHHH **** "BBB@ HHHH @N;FVLX);J[N(;6VA1I)KBXE2&&*-02SR2R,J(B@
M$LS,% !)( KRO4?C7X'L61;:YO=5)9UD^PV4R+$5P!E[X6:2*QSM:!I5.,YV
MD$^2_'+Q)<WOB"/P[%*Z6&D00RSP!G43:C=1^=YDJ[MCB&TD@%OE"T?G7!#D
M2[4\,K^?.-O%_,LLSC&Y/D&%P:AE]:6%Q&.QD*E>I4Q-)Q5:-"C&I2ITH4:J
MJ4).JJ[J.+E%4K*_Z[PSX>8/'9=ALQS:OB7+%TXUZ.%P\H480H5$W2E6J2A4
MJ5)5(.%6*INDH)J,G4U/KK_A?/A'_GQUS_P&M/\ Y-H_X7SX1_Y\=<_\!K3_
M .3:^1:*^(_XC-QK_P _<L_\((__ "S^KORM]-_Q#?AK_GWC?_"M_P#R!]=?
M\+Y\(_\ /CKG_@-:?_)M'_"^?"/_ #XZY_X#6G_R;7R+11_Q&;C7_G[EG_A!
M'_Y9_5WY6/\ B&_#7_/O&_\ A6__ ) ^NO\ A?/A'_GQUS_P&M/_ )-H_P"%
M\^$?^?'7/_ :T_\ DVOD6BC_ (C-QK_S]RS_ ,((_P#RS^KORL?\0WX:_P"?
M>-_\*W_\@?77_"^?"/\ SXZY_P" UI_\FT?\+Y\(_P#/CKG_ (#6G_R;7R+1
M1_Q&;C7_ )^Y9_X01_\ EG]7?E8_XAOPU_S[QO\ X5O_ .0/KK_A?/A'_GQU
MS_P&M/\ Y-H_X7SX1_Y\=<_\!K3_ .3:^1:*/^(S<:_\_<L_\((__+/ZN_*Q
M_P 0WX:_Y]XW_P *W_\ ('UU_P +Y\(_\^.N?^ UI_\ )M'_  OGPC_SXZY_
MX#6G_P FU\BT4?\ $9N-?^?N6?\ A!'_ .6?U=^5C_B&_#7_ #[QO_A6_P#Y
M ^NO^%\^$?\ GQUS_P !K3_Y-H_X7SX1_P"?'7/_  &M/_DVOD6BC_B,W&O_
M #]RS_P@C_\ +/ZN_*Q_Q#?AK_GWC?\ PK?_ ,@?77_"^?"/_/CKG_@-:?\
MR;1_POGPC_SXZY_X#6G_ ,FU\BT4?\1FXU_Y^Y9_X01_^6?U=^5C_B&_#7_/
MO&_^%;_^0/KK_A?/A'_GQUS_ ,!K3_Y-H_X7SX1_Y\=<_P# :T_^3:^1:*/^
M(S<:_P#/W+/_  @C_P#+/ZN_*Q_Q#?AK_GWC?_"M_P#R!]=?\+Y\(_\ /CKG
M_@-:?_)M'_"^?"/_ #XZY_X#6G_R;7R+11_Q&;C7_G[EG_A!'_Y9_5WY6/\
MB&_#7_/O&_\ A6__ ) ^NO\ A?/A'_GQUS_P&M/_ )-H_P"%\^$?^?'7/_ :
MT_\ DVOD6BC_ (C-QK_S]RS_ ,((_P#RS^KORL?\0WX:_P"?>-_\*W_\@?77
M_"^?"/\ SXZY_P" UI_\FT?\+Y\(_P#/CKG_ (#6G_R;7R+11_Q&;C7_ )^Y
M9_X01_\ EG]7?E8_XAOPU_S[QO\ X5O_ .0/KK_A?/A'_GQUS_P&M/\ Y-H_
MX7SX1_Y\=<_\!K3_ .3:^1:*/^(S<:_\_<L_\((__+/ZN_*Q_P 0WX:_Y]XW
M_P *W_\ ('UU_P +Y\(_\^.N?^ UI_\ )M'_  OGPC_SXZY_X#6G_P FU\BT
M4?\ $9N-?^?N6?\ A!'_ .6?U=^5C_B&_#7_ #[QO_A6_P#Y ^NO^%\^$?\
MGQUS_P !K3_Y-H_X7SX1_P"?'7/_  &M/_DVOD6BC_B,W&O_ #]RS_P@C_\
M+/ZN_*Q_Q#?AK_GWC?\ PK?_ ,@?77_"^?"/_/CKG_@-:?\ R;1_POGPC_SX
MZY_X#6G_ ,FU\BT4?\1FXU_Y^Y9_X01_^6?U=^5C_B&_#7_/O&_^%;_^0/KK
M_A?/A'_GQUS_ ,!K3_Y-H_X7SX1_Y\=<_P# :T_^3:^1:*/^(S<:_P#/W+/_
M  @C_P#+/ZN_*Q_Q#?AK_GWC?_"M_P#R!]=?\+Y\(_\ /CKG_@-:?_)M'_"^
M?"/_ #XZY_X#6G_R;7R+11_Q&;C7_G[EG_A!'_Y9_5WY6/\ B&_#7_/O&_\
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M6G_R;7R+11_Q&;C7_G[EG_A!'_Y9_5WY6/\ B&_#7_/O&_\ A6__ ) ^NO\
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MG&'I4J4:3Q2AS06)I4>6E[6I3TK0C9N'(M*;IGQF-E4QG!V;4<+C,QJ\-?\
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M]NO;2***UL'FT_XZ>"+^*ZM[*U6'1=,\7:_8P&74I? [[_"?^"J@(_X(>?\
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M*WP_6XY15C7Y;:<W.I>V^US\O-:Z,FBBBOC#]0"BBB@ HHHH **** "BBB@
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M@ HHHH **** "BF221PQR2RR)%%$C22RR,J1QQHI9Y)'8A41%!9F8A54$D@
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M222<UT7ASQEXO\'375QX1\5^)/"L]] +:]G\.:[JFAS7EL&#BWNI-,NK5[B
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M<TQ.+P.7X"M[.5++/K,<+449*NJ>)G"I.E4J<S4Z=.<+T5R)TU*45)Q:2\3
MY!@,OS7.<WPOMHU\]>"GCZ#G&6$=; TIT:>(I4?9J5*O5ISY<1)5'&JX0FX*
M:<I%6[F_OKR.WBN[V[NHK1#':Q7-S-/';1E44QVZ2NRPH5BC4K&%4K&@QA%
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MB_\ !'I_T^\_R[Z?[0U%?XO/_%X?^JE?^711_P 7A_ZJ5_Y=%']J_P#4._\
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MA7XGZ]X-UJ*SB\'VO@J?3&T9?"G@+P4]O)._B2^%\;Y]1658K06Z6ICF,_\
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M-7N(;K[/H/B*.[-AIUK/KNO7NCZ%;7FHVOP5_P %8?A#<_LY?#G_ ()-^$_
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MS%8C#0KXB>+GBL;AJ]'#SFZE&B\%37LW2E*52JTZ9L_$;_E/Y\ _^T?&L_\
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M-11\ _\ D3]2_P"QEO/_ $UZ-17]N^'G_)$\.?\ 8NA_Z<J'\Q\8?\E-G/\
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M;"]5K/SQ8?:##]K5K7S OGJ8MXK]IO\ @XK_ +>_X;R\+?VN;<Z<?V<_A_\
M\(L(%G$@T/\ X33XFBZ%X96,;77_  DO_"0$-;!8?L1LU93<+.S9X;&2JX'-
M\[Q6&P&*QF G@,!@8O+\#3PU#ZY4Q<ZF)K83#X>CA\14A"@X4)8BG5C&=3F:
ME[."71CLLAALWX;X5R_'9O@,KSBEG&;YM.&<YK7Q^,65T<MI4<!A\SQN,Q.-
MP5"K4Q4:N+A@:]"<Z5+DC*G[:I-^#_M$_&W_ ()??M&_ [XC>*O 7[-?B[]C
MS]JK1)-'U7P/X<\$>);OQA\'OB-'=^)?#^GZSH-XD6EV.D>'I].\.W_B77K>
M*Q\$_#ZT231[%4\3:S-/%X6N.N_;0_9W^"OPZ_X)C_\ !/#XP^"?A]HOA[XF
M_%$^(3\0?&5D^H-J_BLM87E\O]K-<WL\$HAN8D:U6."-;.)?L]J(;8F(_C#7
M] W_  4%_P"4/O\ P2S_ .X__P"F2_K+"8E9GA.(L3B<+@8UZ&2T>6IA\'0P
MRE5_M7"7Q#IT81I0Q$H5'3G4HTZ7/324DY.4I;YE@99!F7!6!P.89M/"8OBG
M$\]'&YGB\:X8?_5_,>7 JMB:E3$5<%"I1C7IT,56Q'LZLI.$E!4X0_GYKT/X
M1?#?6?C%\5OAI\)/#C)'K_Q/\?>$/A_HTLJEH8-2\8:_I_A^SN;@!DQ;6T^H
M)/<LSHJ01R.\B*I8>>5^GO\ P1FT;3==_P""F'[+=CJH@-K!KOQ UF(7"JT?
M]I>'/A#\0?$.C%0SH!.NKZ78M:L&++<B%D21PL;?/Y9AHXW,LOP<G:.+QN$P
MTFG9J->O3I-WZ64V[GV>>X^659'G.9P2E/+<JS''PBU=2E@\)6Q$4UU3=-*W
M4]K_ ."X7CSP]8?M'_#O]DCX<V4VC?";]B_X0>#?AAX5T1W6:./6_$GAW0?$
M^N:LEV0)[RYO/#;> ]'U6[N]US>:QX=O[^=Y9KN21_SQTK]BS]L+7?"=MX[T
M7]EC]H?5_!U[8KJEEXETSX-?$*^TB]TEH/M2ZO9WEKX>EBN]'-MF<:M;F33C
M$K2?:=J,1[U^UWXX^(UI_P %3OCEXV\#:1<:U\3_  I^V;XCE^'>AIX>_P"$
MAN-9\3> ?BFVG> --A\,6UM*WB(ZG<:#HD$&DK;7$VN)/';NES-=L9/V>^$?
MAS_@L3X?_:;^"WQ/_:H_; ^'7P5M_$WQ&\$)J?P2^+/[1/P\\-V_C_PCJOBC
M3[#5_!WA#X*>$3J_@C4/$/B+1(;_ $OP_;V%E8>)$U24"UU33?$(EN(OJ)8*
MCGF<YM6K4LTE!9D\-3> PE&6&PF&C4>'P_MZ]:K3A3]E1ITZ5'#J*=2-.3C4
MCRJ+_/Z>:XGA/A;AS#87$</PJ/(HXZLLXS'%4\;F6/G0CC,;]3PF&P]:M6^L
M8JO6KXC&RJ3C1J5HJ5&?.YK^8/P%\-/B/\5/$L?@SX8?#_QM\1_&$UO>7</A
M3P%X4UWQAXEEM=/3S;^YCT+P]8:CJDEO8Q_O+R9;4QVR?/,R+S7]5G_!1SQ+
M^U)^R=I_AK]AO]B/]EE_$7[,NJ?LN?\ ")^/]2\,_L\^*/'<GB7Q-XV7QMX-
MU^_U'Q5X9M);-O%FGZ3::=XL6_N@VM7/BW7M0UOQ.VN6U[:0+^7'_!4CQMXU
M_9-_X*N?M">-_P!GCQ3JOPH\47W_  B?B!M7\(M!IURFH?$;X7>$=8\<2,!#
M)!<'Q+KNH:GK>J/<0R/<:GJ$]VY-R%FK[0_X+M_M8_M.?!']L_PUX/\ @]\?
M_B]\,/"MQ\!?!&N3^'? OC_Q+X8T:;6;WQ?\1;2[U273M(U&UM7O[FVT^QMY
M[IHC-+#:6T;N4AC"]6!I8?)<OXII3Q&-IXO!9GA,LK8K!TZ$9O#^UQ]/EH2J
M5.:,,5+#R>*A)I<D:,4YWFEP9O7QW%6<^'U>G@LKJY=FF0YEGV%R_,ZV+G3A
MC5ALGK>TQ4:%+DG5P$,9".7UH1<E4J8J;5)JDW\0?M;?\$G_ (D?!WX.?L@^
M/_@C\+?VF/BIXG^,?P3M/'WQXT&W^&>O>*8?A'XTE\,^!M;N?#MW:^$O!D.H
M>$8(;SQ%X@L#IGC*2;5HSX=N?,N3+;7J1?E=\._A;\3?B]K[>%/A/\.O'7Q/
M\4+8SZF_AOX>^$M?\::\FFVTL$%SJ+Z1X<T_4M02PMIKJVBN+QK<6\,EQ DD
MBM+&&_I#_P""G7[8W[4?PJ_9._X)?ZA\//CI\1/"FJ?&K]D?3];^*NL:7KLR
MZWXYUN[^&WP6GN=:UW6IUFU6?6)KCQ%K=U)JL=Y%?M=ZE<W9N/M++*O:?#CX
M$?%#X+?\$NOV9M-_9<^/W[/'[*GQ0_:>?4OBM\;?C1\4_BYI?PD\>>,]#DB%
MUX0\$^ _%[Z;K>JVUCX?TC5]!36+;P[J&B7OA^\L'E3[)=>-O%D%\L=P_EV*
MS?%4,OCC*-# 9=A,9C:4*="4I.MALO5"E@E*LDZM>IB74Q$Z\X0I?O9P4U&,
M)UE/&6=X#AO+\7G$\LQ.+S?.\PRS*\15KXN$*:PN/SB6,Q&:.GA925#!T,"J
M.#I8.G4JXA?5X594I3J5:?\ ,G\2O@[\6_@SJUKH'Q?^%WQ#^%>N7ULUY8Z1
M\1?!?B/P5J5]9I)Y37EE9>)--TVXO+,2$)]JMHY;<L0!(<C-[2/@7\;?$&A^
M#/%&A?![XHZQX8^(_B@>"/A]XETSP!XKOO#WCGQF9KVW'A+PAK=MI,FF>)/$
MHGTW48CH>CW5YJ:R6%ZC6P:TN!'_ $8_&C^U]2_X)>?M%_##]M?]L;]EC]H[
MXJ_#_7/"/CW]F3Q9X(^.GA[XO_%>RO!K6CV6N^&+BYDM=%\5:R^H0/?Z9%J5
MV?$>HII'BO67U.[32?#>C066O\-/VHO'7[(W_!!/X*?%#X56^F6OQ/USXN_$
M#X;>#?&=_8:;J=S\/)O%/Q'^*^HZUXIT>PU73]0LKK5G\/\ AS4] LTGCCA@
MEUI=0G^UP64FFWW(N&L%'%5HU\;B:.$IY'4SF5Z-&IC:+HXN&&JX2M1A6=-U
M6^>5&:J0A.,Z,Y<D744?1EQWFD\OPL\)E6!Q695^+*'"\6L5BJ&5XI8K+JN/
MHYEAL36PD:\:$$J<,32E0JU:4Z6)IP]K)4G/^:7XF_"3XI?!;Q+_ ,(;\7OA
MUXV^&/BPZ?;:LGASQ[X8UCPIK,NDWLEQ%9ZI!I^MV=E<W&FW4UI=P07T,<EK
M+/:74"2M+;3(GVQ^QO\ L)^$?VT_ 'BG3/!/[2GPU^'W[46D>+9;+P=\!_B>
M\V@6?Q2\(OHNE7UMJ/A/Q8AFF?Q'%J">);270--T/Q),T5E97>J_\(UID@U6
MZ^1?C9\?OC'^T;XJT[QQ\;_'VM?$?Q=I7AK3?"%EX@U\63:FGA[2+G4+S3]/
MFN+.TM#>&"ZU74+AKR\%Q?W$MU(]S=3';MD^"'[/WQN_:,\96G@;X%?#3Q?\
M2?%4KPNUKX8TV6:UTB)YXH$U+Q!KLS6VA^%M)CN)H(YM;\0ZGI6DVLDL0GO8
MC(F?GL.\(LPY:6!KYEA:DI4Z6%J2G2QE2,U:#A+".?+B8.SARPK4VU:=*I%N
M)]GCEF+R55,3FV#R',*,*=?$YA1A2Q.649TG>K&I#,51<\%4C>-3FJ86O&+O
M3Q%*<5,W/V@/V5_VAOV6?$B>%?C[\)_%OPVU*YEN(M+O-8LH[GPWX@-H(S=2
M>&/%VE3:AX6\316PFA-S)H.L:@MJ98TN3%(P2O8/V,/%?["_@.?XD^,_VS?A
MQ\3OC-J&CV/AN+X._"CP3J[>&_"WB;5[MO$$GB74/B!XBL]7T'6=-LM%:S\+
MII::?J%W#<IJFL&^\/:\D$-O#_0A\/?BG;?\$^_@EXC^%_\ P5=_:L\'?M2_
M\)'H-L-(_8@A\.:3^T1\0/#%Q(VF:II\WB+Q[XKN8)M-DAM93%8:+XSO++P1
MI_V%+WP%XJU&>-(G_E!\?:KX>\4?$+QKKG@?PNWA'PIXB\9>(]5\(>"XKF34
MF\,>'M7UN\O/#_A>*[*B6_;1=-N+324N2@DNC;"4J&DQ7JYE@</D>(P>)PTZ
M=6M/VDIY1FE+#8K$X&2BX16-IT9U,+5NY>TI0K0H5>:,?;8.*3B_G<BS?&\7
M8/,L!C:5?#X:E["-+B7(*^/R_ 9O#VD:E1Y56Q5*ACZ&E-T,14PM3%X?DG46
M%S.<G&<?Z+?A7X$_X)X_\%5_A)^T!X7^#G[*4/[('[3WP=^&NI^// <WA?QF
M;[P=XCTK1+!=/T4ZYJ"6&@Z%/;WFN1Z7I?C@:QX+M]9L;?5[77](\6ZO>S:V
M+3^:"OZ#O#VG2?\ !)?]@7XGMX_N/[+_ &WOV^?!MKX:\*?#8N8O$GP3^!4E
MIJFGWOBKQ5;(ECJ_A7Q-J,>N:^([::[:9/%EMX3L(=/%_P"!O'D5C_/C1Q')
M.GE*Q-##4,X^J5*N:1PV'HX5)5JSG@88BAAX4Z4,6L-:I6M"$E"K1A.*G!E<
M$4Y1K<12P.+QN*X968T*&03QV-Q682D\-AHTLVJX+%XRI6Q%7+98^]'#.5:I
M3E5P^)J49RIU(L[?PM\,OB1XYT;QAXB\$_#[QOXQ\/\ P]TE=>\?:[X6\*:]
MXAT;P/H;I=R)K/C#4])L+NR\,Z2\=A?.NHZU/96;)97;"8K;3%/1=4_95_:=
MT3X?P?%C6/V=_C?IGPPN-)37X_B'??"OQO;>"UT&9(I;?6YO$LNAKH]MH]W%
M/%-9:G<W<5E>PR+-:3S1?/7[=_\ !!?Q</A]\+?^"E_Q!.AZ1XF;P#\"?"7C
MF'P[K\ N=$UNY\'Z'\:?$=KI>JPX8R6%[<:;%!=!1Y@B=FC(D"D<A_P3=_X*
M8_MC?&+_ (*"?#GPQ\8OBKXA^*7@+X]:MK/@?QO\,M8CL_\ A K32]1\-:N]
MC=>&?!]M9#0?#(T*YL[.ZOGTK3K>36])@U.SUVXNVU&ZOETP>2974PV23Q>-
MQM+$9Y5K4*,*&&I5:.&G3QL\'"M6G.K"<Z;E[.]*G%U/XDN=<L(5,,RXKX@H
MX_BRCEV5977P7"5'"XK$U<7CL10Q..I5LIHYI4PV%ITL-5ITJ\(.NHUZ]14;
MJA#V4N>K4H_A?X ^&/Q*^+&M7'AOX6?#WQQ\2_$5II5WKEWH'@#PGK_C+6K7
M1-/>WBO]8N-+\.Z?J5]#I5E)=VL=WJ$D"VEL]S;I-,C31ANFN_V?OCK8?"RU
M^.-[\'/B=:?!F]EBAM/BK<>!O$D/P^N'GU)M&MS'XN?35T-H[C6%.DV\WVWR
M9]4']G12/>$0G^C3_@F'\,?"OPJ_X+:_ME?"_P *6NEQ>"_#?A3]H+2= T?3
MG2XTO2O#US\4OAY=6'AJ-?+1530;"\CT&XM&5C;2V$MI)),T32O^0O[8?_!2
M;]J/]IS6/BKX&\1>.KKP_P# CQ)XAM['1/@9HUCH,'@SPMX6\%^(CJ'@?1+-
MK;1;.\FO-%:RT^2^UN-[2[UJZM8_M,<6FP6&E6.-?)\#@<L^MXW%8KZY4QF:
M8"AAL/1ISI2KY?[%>UJ5JE2#A0YZD8SC&$ZLE.,J:2IRC+IP?$^;YOG_ /9N
M59?@/[-HY;D&<8O'8[$UZ>(C@\YC7G]7H8:C1JJIBW2HSG2E.I3H0=&<*LFZ
MU.4,?_@H?X@\+>(?B9\.;CPG^Q!KG["]G!\(?"\-UX#\1:%XB\/:CXYO$N=2
MBF\=VUGKFA^&XK_1I3#_ &%I_B&#29-3\1S:1?ZOX@U:\U&Z^P:3\^>!/V4O
MVH?BEX8C\;?#3]G'X[?$+P;.ER]MXK\$_"3Q[XI\.7@LKZ33+U;'6]$T"^TV
M^DL[^&XM;N*TN9I;:6TO!.D8L[HP_P!(7_!2OX*Z#^T3_P %7O\ @G3\'/%4
M27/A3QC\&?AROBNQDN1:#5/"N@^._B;XG\2:,+K[1:R02:SHFBW^E126TZWB
MR7B&Q26\\B)_B+_@I3_P4U_:Q\+_ +87Q!^%'P-^)WB?X!_"?]G'Q>_PV^'_
M (!^'(M?">D2+X'BM=&O=1\0V.GVT-KXFTO4]2L)YM%\/ZO;W/A;3?#7]EZ?
M9Z*&^WWFI>CFN3X3#XK-<;F>*Q#P]+,:>7T8X'"86E5Q&(EA:>)JS=./L,+A
MZ5&C*-U"#E5J3BK1]^;\7AWB;,L=EW#>5Y!E^#6,Q.1ULYQ<\WS/,,10P6"A
MCZN!H4HUYQQ688W$XK$QJ<LZU2,,/1HS;=3]W27X7:QH^K^'M6U30-?TO4=#
MUW1-0O=(UK1=8L;G3-6TC5=.N)+/4-,U33KV*"\L-0L+N&:UO;*[ABN;6XBD
M@GBCE1E'NNE_LC_M4ZUXR?X=:9^S;\=KKQ]'X6MO'$G@L?"?QU%XI3P9>W;Z
M?9>+'T*;0H]37PW?7\<EC9:V;8:;>7J/:6US+<*8Q^M__!6?4]$_:,_9*_X)
M^_MWW7A7P[X<^+7QC\-^+_ _QAU/0[%M,/C#7/!XL-+LM2FM!#B2VL-5\.^+
MVTJ6YN9KVRT;6=,T;[9JFGZ;836GW3_P6M_;X^/_ .S!XJ^ OP@_9Y\2GX4W
MOBKX4>&_BAX[^(&@6>CS>*_%26NLZEX?\)>%);S4-)NYK+0] E\.ZQJ%Y%%/
M*NN#7AIUS%;Z;;ZA;:S@^'LOPW]K5L9C\3+!Y?#*,1AZF%PT'6QN'S>E.M07
MLZM2,*-50=/G<JDH0:JV]HU!2Z5QKG6.?#F$RO)\#',\ZJ<283'4LPQU6.%R
MO&<-8BCAL8_;8>A.KBJ$ZCK>Q5.C"K44L.Y*BG5E#^3+5](U;P_JVJ:#KVEZ
MCHFNZ)J-[I&M:+J]E<Z;JVD:MIMS+9:CI>J:=>Q0WFGZCI]Y#-:7ME=PQ7-K
M<PRP3Q1RQN@[3X9_!_XL?&C79?"_P?\ AEX^^*7B.WM/[0NM#^'OA#7_ !CJ
MEGIPN(;5]2OK+P_8:A/9:;%<7-O#-J%VD-E#)-&LLZ%USS'BKQ1KWC?Q1XD\
M:>*M2EUCQ/XOU[6/%'B/5[A((I]5U[7]1N-5UC4IH[:*"VCEOM0N[BZD2WAA
M@1Y66**.,*@_H7_X)O>+;+XO_P#!/7XJ?L;?L\?M#>$/V6OVRO$'QIM_&%OJ
M_B3Q9?> -1^,/A&\L]%MK;0O#WC33+:[\1Q7D=OIMWIDVD^#K>[U>Q32X9KB
MQ32?%FLW3>1E&74,SQT\-*M.G!4<15HTX^R6)Q<Z4>:EA*/M:D**Q%;IS3:7
M++EC4ERPE]1Q+G6+R'**6/AA:5:K+$X+#8JK)XB6!RZEB)J&(S'%.A1J8F6"
MPKUER4XR?-!U)48<]2'XDZI^RA^U'HNM>(_#>K?LW_'C3]?\'^&I/&?BO1[K
MX1^/HM1\.>#8I+N-_&&MVC:!YVF>$P]C>A?$EVL6BO\ 9+EDOF6&0KXCI&D:
MMX@U;2]!T'2]1UO7=;U&RTC1=%TBRN=2U;5]6U*YBLM.TO2].LHIKS4-1U"\
MFAM+*RM(9;FZN9HH((I)9$0_TC?LI?'_ /;Q_9&_X*)_L\_!7_@H!K/CO4/"
MWB/1O$G[/'A_4?'CV?BK2M6\/?$W4?#EQH&M^'/B)"6B\=62?$31?A[:ZKK.
MN:[K^H^$]!O-9T6^@T6\DO=-CY3]D7]@O1OA#_P6)^+^@>-8+/2_@A^Q3=>+
M?VDCJNJ3:A-I5CX(@LK7Q5\#I+C6S'&#K/AV+Q/X:\5W[7$C0RS^ /$ULSW/
MV28-ZO\ JW#$2P7U.6,INMF[RK'4,PHPH8C 5'1I8B%2K",FO9^P^MS<I<K<
M<+*?)%R=.'SO^O-3!0S1YG3RRNL-PW'B+*L5DV*JXS!9Q2CB*^"JT,/4J4X/
MVWUMY?3C3A[11EF$*;J34(UJOX*ZS\)/BMX<^(8^$?B'X8_$+0OBNU_I.EK\
M,=9\%^)-+^(;:GK]G9:AH6G#P7?:;!XD-_K5AJ6G7VDV8TW[1J-G?V5S9QS0
MW4#R=Q\0?V5OVF_A-::'?_%#]GGXV_#RQ\2ZC9:/X?O?&GPN\:^&[36-;U+>
M;#0=/N=7T6TAN=?NA&_DZ'&YU9MO_'GR,_L9_P $ZOVW_AGXI_X*&_M6_&SX
MW>-M,^$/B_\ :=\(?$O1?@S\7O'-Q976E_!S6]=UJQG\':'J&IZNW]@Z79:-
MX2TW2-#T[5]8E@TU(?"ECX=FNXK379DF\B_;3^'O_!5S]EGX<ZGHWQD^-GC?
MXS_LY?$7Q+X6\;1?%KPQXXU'XN_#F[\3:+K6E^(/"5_;^+/$EA)XM^&]^-9A
MT>]TR)4\+Z-XCO8$AT:Y\11V%P8<7DV!>75\QHU<?C*,<1C*:EA*-"HL%2H5
M%'"3S&$JL:E-8R,E+VD8PI4D[IUIWI+I7$^;+/<)D>*P^3Y9B)X/*ZTHYCBL
M71EFM?%4G+,:625(4)T*SRVI&=-4)U*N(Q$TE*.'I-5WE?$7_@DG\5?#?["'
MP!_: \*?"3]I_P 0_M)?$+XA^*O#?Q/^!2?"KQ'J%_X$\+:7K7Q)L=#\0S>"
MM-\%KX]T&/4=/\*^%;TW_B&673KP>*+>:S$4%[IH?\H='^&OQ&\1>.?^%7^'
M_ 'C;7?B7_:VI:#_ ,*\T?PKKNI^.?[<T8W8UC1O^$2LK"?7_P"UM*-A?#4M
M._L_[98FSNQ=0Q?9YMG]+?QU_;=_:P\-_P#!&/\ 8I^/NA_'3QQIGQD^(/QT
M^(GASQI\0K:[LU\0>(M#TKQ;^T)8Z?IFHS-9- ]M:6GA?P_!$L<$;"/2K4%B
M58M2_83^&/Q%\._\$U?B?^U!\+/B_P#!?X4?M8?M4?&S7/#.H?M,?M!_$+2_
M"=]X=\!Z=JM[_P )#H_AWQEK]AXE-EX[\7^(=(\5:G>L+2PUO6(M77Q))<M?
M^#_">I6GJXK(<LQN.P6'RU8VC&&18/-,;>E0E.>'>!P]2,J$/;*,L=BJM6$:
MJJ5*>'IU:CG&<H1L_G,NXPS_ "S*<VQN>/*\54GQ?F7#V5\N(Q4*='&+-<70
MG#$U/JCG'*<OH4*E2A*E1K8VO0H*G.G&M--?SL?$[]G_ .._P4CTV;XR?!7X
ML?">'6G>/1Y_B3\._%W@>#5I8HQ++%IDWB72-,BOY88SNGBM7EDAPPE5"K <
MYIOPO^)FL^!=;^*&D?#OQUJOPT\-:M9Z!XC^(FF^$=?OO N@:[J,EA%I^BZW
MXMM=/ET#2M6OI=4TR.STZ_U""\N9-1L$@A=KRW$G]1OPIL_'=I^R]^V#\%?V
M_OV^OV2/VC/AGXN^"WBC7?A=<C]IG1/C+\3?!'Q:\/:9J.H:)JF@2Z_:Z5XI
MU5?M*V.J:;I*:YJDL&M^']-T_0-+MDU[7!?>+_\ !-CXMZE\!?\ @C=^V[\9
M=!\/^&_$/BKX>?'G3M:\%Q>*M*L=:TK0_&EUI/P0T3PIXSCTW4;6\L[C5_ N
MN:M9>,-!\Z JFMZ)8.)(2!-'RKAG#/$T8RQ>(PV'K97F./G&M2HSQF$GEU.<
MZD*M*C6E"K3J1C&K2E&=*52,G!J$X29Z#X]S". Q-2&78+&XW#9_D>3T9X7$
M8NCEF8T\[JTJ=*KA\1BL+3K4*U&<YT,13J4JT:%2"J\U6E4BG^!OQ'_9J_:)
M^#OAS1_%_P 6O@3\7_ACX6U^\_L[1O$'C_X<^+O!^DZCJ#02W4=C;WOB#2-/
M@:\N+2">\M+8NL]W9P37=JDUM%)*JZ_^S/\ M&>%?AU9?%_Q-\!?C'X?^%.H
MV6FZE9_$K6?AIXQTWP)/IVM3VMMHE^/%=WHT.AI9:W/>V<6BW4E\D&KO=VPT
MZ2Y\Z/=_1=_P2^_;G^,W[1WPB_X* :#^UK=:9^U%X6^&WP5N/CYHGA+XL:+X
M=U3P_<:IX.M_$6NWOA>^L(]#6UF\-:WJ>B^&;N#2I;:?2_#]QH[W&BZ=;2:A
M>^?@_P#!(O\ X* _M5?M:?MG>*_A%^T1\1H_BE\*?BS\,/B%<>)/ASXB\->&
MV\(V/]FVEN]I:^'=*M-+MDTC36TZZO\ 0M0TE'FTO7-*OY3KMGJ>IV^G:E97
M0R#),3/*E2S',8K//:4,#&>#P[GAL31KSPTY8UQQ*A*A.JJ;IQP[E4Y)S<W%
MTXJK&+XRXKP%/B*6)R7(YOA)4,5FU2CF>,5+&X+$X6CCJ=/*XSP+JPQ=/#RK
MQK3QBA156G25*-2-:;H?CE_P3LUSPSH'QXUF[\5_L9>(OVY].G^%WC*QA^#_
M (8T#5?$VJ:/?W,^BK:^/AI.D^'/%,AM])VR>'I]2GTP#0AXI77;"<:WINE6
M]Q\71Z9J?BCQ2FC>&_#-X^L^(=?&FZ#X.\/V>K:K?MJ6JZA]FTSPUHMA(^HZ
MYJ-V;F>#2].M))+_ %6[E\F%WNKN0L_[_P#_  0>\.VG@_\ X*<?&KPEI[R2
MV'A?X3?&OP[922Y\V2TT3XJ?#[3+9Y,LY\QX;5&?+L=Q.6;J8?\ @F@=/_9P
M_9/_ ."CO_!0'2-%TO5_C!\,F3X4?"'5-1M+35#X)U7Q+?64&I:[#I5S<202
MI=:QXO\ !=W>S7FGJ9=+\,ZAI-G>26>J>(+.3##9-+&8#*85<3&C1>)X@J8J
M<<-1E/#4,LP^$Q&)J*I!4ZV)E."<:5*K5Y(345!PC.;75CN*899F_$E3#X&>
M*Q,<'P90P%*>/Q,*>.QF?XS'X/!494:CK87 0I5)1J8BOA\/[6K2YW456=.E
M$_%?XD_LR?M'?!O1K'Q'\7/@)\8_AAH&I.(K+6?'_P -?&/A'3)YF946V%[K
MVCV%NETS.FVUED2X8.C+$5=2?%[*RO-2O+33M.M+K4-0U"ZM[*PL+*WENKR]
MO+J5(+6TM+6!))[FZN9Y$AM[>%'EFE=(XT9V /WEJG_!3S]MKQ1\-/C!\(OB
M%\;-;^*'@/XV:=>V/BS2/B+;6?B2;2Y;[4;'4I+SP9J4L,&H^$4@:Q^S6>@Z
M/=0>$;.VN9S;^'([J.RN;/X1TS4M0T;4M/UC2;RXT[5-*OK34M-U"TE:&[L=
M0L9X[JSO+:9"'AN+:XBCFAE0AHY$5U((%?/8R.7*I2> J8R=&4$ZL<72HTZU
M.:G)-0=&K4A4C*"C.,FJ;C)N#B^7GE]KED\[E0KK.:&64L5"HUAYY;B,36PU
M:DZ<91E4CB</1K4)QJN=.<$ZRE&"JQE'G]G#]A_B+_P23^*OAO\ 80^ /[0'
MA3X2?M/^(?VDOB%\0_%7AOXG_ I/A5XCU"_\">%M+UKXDV.A^(9O!6F^"U\>
MZ#'J.G^%?"MZ;_Q#++IUX/%%O-9B*"]TT/\ EIIGP:^+^MK\1'T;X4_$G5T^
M$,-Y<?%EM,\#>*+]?A?;Z=+J,&H3_$1K32Y1X*AL)M(U:&\E\2G3$M9=,U&.
M=D>RN1%_21\=?VW?VL/#?_!&/]BGX^Z'\=/'&F?&3X@_'3XB>'/&GQ"MKNS7
MQ!XBT/2O%O[0ECI^F:C,UDT#VUI:>%_#\$2QP1L(]*M06)5BW!?\$*/B7=Z'
MX3_X*>?&?QI9-\2=3\/_  H\-?%CQ+8^)KUKN7QSJVAVGQL\::G%KNI7T&HO
M/<>(=0LY3J&H7=M?2-/=2W4T-R^Y'^NQ.2Y+B\WR?+\'4Q>$CB\IPV*KU:E*
ME*,8O)_KL*_)"I.4J]64.;%05H*4I*BW=6_-<#Q5Q3EO#?%&=9G1R[,ZF6\2
MXW+L'AJ.(Q$)SJ?ZRPRJIA%4JT*=.GA,/"LH8"K+FJRA"#Q2B^9'X$^./V?O
MCK\,_!_A;XA?$7X.?$[P+X$\;BT/@_QEXM\#>)/#_ACQ+_:&GOJVGKHNN:II
MMKINH2:AI,<FJ6$=O</)>Z;%+?VJRVL;RKN>!_V5_P!I[XG>%8_'7PW_ &<_
MCM\0/!,OVSR/%_@KX2>/O%/ABX.GW$EIJ"VVO:'H%]I=RUA<PSP7R074C6DL
M$ZW C,,NS[[^#W[0?[1G_!4']KKX ? ']J/XIZGXZ^%?C7X]:;XXUGP(8='\
M.^'=/LM#T?5;O7-'\,MI4&EZAH=K=^"[36?#=A!9:J;D2ZG)J*"_\1W#7=S^
MLG[6>F?MS3?M-^([KX%?\%%_V,?V9_A5\*==C\(_"7X#Z;^T_P"'OAOI/@CP
MYX06#2[31_'?PHM?![>&]0UF6ZLKB\UKP]XPL/$5II$MU+X:M$30M.LK&'AP
MF0X+&T:^/P\LTKY?3Q-+!4H0H82.-J5_9*MB*TXSQ*H4J%.#AR052I5G.K&+
M<(PG4/6S+B_-\KQ.#RC&T^'\+G-;!5\TQ-6KB\RGE=#"+$/#8/#4I4L#+&5\
M7B*JJJI4E1I8>C3PU2HE4E5IT5_)==VEU875S8WUM<65[97$UI>6=W#);75I
M=6TC0W%M<V\RI-!<03(\4T,J))%(C(ZJRD#Z2TK]BS]L+7?"=MX[T7]EC]H?
M5_!U[8KJEEXETSX-?$*^TB]TEH/M2ZO9WEKX>EBN]'-MF<:M;F33C$K2?:=J
M,1^J'_!6'Q1X5C_;?_95^.7[-^N_"3XC_M":[X-^$?B[QYH7P+NM,^*_A/5?
MVB/"'C0KHSP1Z')?KXJOO$>I6>EZ#:^'[JP@UC6-)T'29;_3WN-<'F?9'PC\
M.?\ !8GP_P#M-_!;XG_M4?M@?#KX*V_B;XC>"$U/X)?%G]HGX>>&[?Q_X1U7
MQ1I]AJ_@[PA\%/")U?P1J'B'Q%HD-_I?A^WL+*P\2)JDH%KJFF^(1+<1/#\.
M4'F&-P56698N.&Q5*@L5EV%HSPT*59*4*^*KU:ZA2J.,DOJJO)SC4BJUX69C
M.-L9')<JS6A#(LMJ8_+\1C)8#.\PQ5/'5<1A7*%7"8#"8;!NMB**G"3>8-*$
M:<Z,GA6JMX_SU_LB_LU>,?VHOC[\,_A;HO@WXCZ]X5UCXC_#S0OBKK_P]\+:
MIX@O/AS\/_$WC32/#OB3QIK5U::1JVG>&K#0].O;V].M^(X(]$LY;4R7Y:".
M5#[I^WY^P%\2/V1OC7\7-&\+?#7XZ:Q^SKX$U;PS8^'OCCXP^'VO)X2U:'Q#
MH'AVZ NO'VG>&M+\#7,Z>)=8NO#D#6,T"S7]JMAY7V\215^FWQR\;>-?V</^
M"_#^&?@IXIU7X>>'/CC^T/\ LH:=\4-#\.-!8Z=XPTGXEWGPFUCQWIVLVPA>
M*ZB\3:WK&NZOJ5QM2\EO-:U&3[0'N9GD^;O^"U'[4?[0NJ?M@_M)?LVWWQ<\
M93? G2?$GP\GL/A>-1$/A6-X?A[X(\2PK+9P1127<,7B"[FUJ.VO)I[=-4$%
MZL0N+6UDATQ65Y7@,FS2&)^LU,QP.?5<MCB*5.DJ<ZE*CC/91M.JY1PM7V,:
MM71UH348PYHWD88#B'B'-^*.'YX+ZA1R3-^#Z&>SP.(K8AU:=&OBLJ^L5.:G
M0Y9YAA_K,Z&%7-'#5*,ISJ\D[(_*FT_9X^/]_=_#RPL?@9\8;V_^+NFW>M?"
MBRM/AEXUN+OXGZ/864.I7^K?#RVAT1YO&NFV6G7-O?W=_P"&TU.UMK*XANII
M4@E21H?&7P#^./P\\>Z/\+/'7P?^)OA+XE>(O[,_X1WP#X@\#^)-,\8>(?[:
MN6LM'_L'P[=:;'JNM?VI?1RV%A_9EK=?:[^*:R@WW4,L2?TE?MF?M;?%G]E'
M_@FK_P $QYO@7>:9X(^(?Q2_9^T?P[??%JTT?1[SQYX>\#^'O /PTU#6/!WA
M?5=4TV_ET6P\7ZQJN@ZIK5W826UV+CPAH[0,)ECN+6WXA_;[^,\/_!'OX-?M
M;:M#X7\5_M6^&OC+XI^ '@KX^>*_"WA?6_&O@2R\01>*9=:\9^%S?:'/8V7B
MS5? 6@6?@'5-06W6;5K:2XUK6)M1OY;E;JY\.Y1"IBL-/,L=#$8/+,-F]9K!
MTJE%8:I0PE:MAJ;]O"=3%<N)YJ,Y*E0^&G4E%\U194>-N):^'R['TLBRJI@<
MSS['<-X6+S3$4L4\;1Q>8X7#XZLG@ZE*CEZJ8%T\33C*MB_CK4*<TZ=%_P U
M'Q4^ OQP^!ESI-G\:?@_\3OA-<:^EY+H,?Q&\"^)O!@UV/3OLG]HR:))XATS
M3X]633S?V27[Z>]RME)=V\=R8I)D5L'X=_"WXF_%[7V\*?"?X=>.OB?XH6QG
MU-_#?P]\):_XTUY--MI8(+G47TCPYI^I:@EA;375M%<7C6XMX9+B!))%:6,-
M_1!\*/CA\5_VVO\ @CC^WDG[3'BZ3XJ:Y\$/$WA;Q-\./&'B33-,G\6Z%<6]
MQH?B+R%UFWMK6>Y(DCUC3+?4;D2ZQ!HGB;6="DU"XT$V&E67J_PX^!'Q0^"W
M_!+K]F;3?V7/C]^SQ^RI\4/VGGU+XK?&WXT?%/XN:7\)/'GC/0Y(A=>$/!/@
M/Q>^FZWJMM8^'](U?04UBV\.ZAHE[X?O+!Y4^R77C;Q9!?1#ABAB*M*OA:^+
MJY;4RE9K9T**QZ_VR6 ^J1A[;ZNZDL3'F5:52%.-!RFX2G!0GM5X]Q>"P]?"
M9AA,MH9Y0XC_ -76X8K%2RAWRRGG']I2J?57C(T(8&?)+"QHU*T\6H4U5A3J
MNK2_F3^)7P=^+?P9U:UT#XO_  N^(?PKUR^MFO+'2/B+X+\1^"M2OK-)/*:\
MLK+Q)INFW%Y9B0A/M5M'+;EB )#D9FLO@M\8]1\-^$/&>G_";XF7_@_X@^)T
M\$^ O%=EX#\4W7AOQOXSDN+NTC\(^$-=@TJ32_$OB=[NPOK5- T:ZO=5:XLK
MN%;0R6TRI_1S\:/[7U+_ ()>?M%_##]M?]L;]EC]H[XJ_#_7/"/CW]F3Q9X(
M^.GA[XO_ !7LKP:UH]EKOABXN9+71?%6LOJ$#W^F1:E=GQ'J*:1XKUE]3NTT
MGPWHT%E)X%_:0\;?LJ_\$&?V?OBK\+K'P]!\4;CXW_$#P/X'\<ZSHFD:[J?P
MQNO%7C;XSMKGB_PC;ZUI^HV5OXEN?#&EZQX2ANVA7R=-\3:DS&:,/:7!_JU@
MXXFNJN,Q%'"T\CJ9RTZ-&IC:#HXNGAJN$K4(5W3E5=YRHS56G"HI492=*+J<
MA_KUF<\!A)8;*\%B<PK\64.%TXXK%4<KQ2Q.75<?0S'#8FMA%7C0C:G3Q-*6
M'K5:,Z>)IP5>:I>T_G,^*/P(^-WP0FT:W^,_P>^*/PEF\10W5QX?B^)7@'Q5
MX'?7(;%;-M0?2!XFTK3/[2&G?VA8IJ(L_.;3Y;NWAO!!-*J']'/V+?\ @F%X
MI_:7_9I_:O\ C;XK\&?'W0M;^&OPRT3QC^S18^'? NHKH7QYUV]TWXD7.I:3
MX>_M+PI?W?C^*UU'PIX<TL0> +[[9;W/B!(IY))[JPB/WK^S=\=_B;^WI_P2
MK_X*,^#_ -J#Q)-\5=9_9^T'3/BG\._'/BBTLKOQ3I%_#H7B3Q=86,.I6D-A
M<YL-2\ W]O;ZG+--J!TCQ=K.@W4UYX>$.CK5_P""3W[37Q\'[ W_  4QMO\
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M?_Y*)XA_[A/_ *8],KS6O2OB_P#\E$\0_P#<)_\ 3'IE>:U_"W%__)6\4?\
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M0=,MM&TE9=*\'>/_  ]HBR6FEV=K9B>+38[B:*",W$LKKNKU#]GG]AS]DO\
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MXCM]+CL9O#>GV>AWL^D6&E:M=Z="D$VIG:K+](^!_P!F'X ?#CX(']FWP?\
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MM)N8+ZVETS1+OQ.+;4()+^VBO;FQ\2G7K">=0&MA"!"/U4HJ\'G><Y=0JX7
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M(83"X7&X#$9I_;.$CC(8F,\)C*D+MQ5&OAU45+VDJ,J5>-;#U'1A-1E"_/\
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M!=G_ /*^C_A0W@__ )_=>_\  NS_ /E?1_Q!CC3_ )]Y7_X7K_Y3_5GY7/\
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MPU_/CO\ PD?_ ,L_JS\K_(=%?7G_  H;P?\ \_NO?^!=G_\ *^C_ (4-X/\
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MR_Z.8^%'_A)>+_\ XY1_J1Q3_P!"BM_X.PG_ ,T!_P 16\/O^BEPO_A+F/\
M\Q^?Y]F?S145_2[_ ,0TGQR_Z.8^%'_A)>+_ /XY1_Q#2?'+_HYCX4?^$EXO
M_P#CE'^I'%/_ $**W_@["?\ S0'_ !%;P^_Z*7"_^$N8_P#S'Y_GV9_-%17]
M+O\ Q#2?'+_HYCX4?^$EXO\ _CE'_$-)\<O^CF/A1_X27B__ ..4?ZD<4_\
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MR_Z.8^%'_A)>+_\ XY1_J1Q3_P!"BM_X.PG_ ,T!_P 16\/O^BEPO_A+F/\
M\Q^?Y]F?S145_2[_ ,0TGQR_Z.8^%'_A)>+_ /XY1_Q#2?'+_HYCX4?^$EXO
M_P#CE'^I'%/_ $**W_@["?\ S0'_ !%;P^_Z*7"_^$N8_P#S'Y_GV9_-%17]
M+O\ Q#2?'+_HYCX4?^$EXO\ _CE'_$-)\<O^CF/A1_X27B__ ..4?ZD<4_\
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MR_Z.8^%'_A)>+_\ XY1_J1Q3_P!"BM_X.PG_ ,T!_P 16\/O^BEPO_A+F/\
M\Q^?Y]F?S145_2[_ ,0TGQR_Z.8^%'_A)>+_ /XY1_Q#2?'+_HYCX4?^$EXO
M_P#CE'^I'%/_ $**W_@["?\ S0'_ !%;P^_Z*7"_^$N8_P#S'Y_GV9_-%17]
M+O\ Q#2?'+_HYCX4?^$EXO\ _CE'_$-)\<O^CF/A1_X27B__ ..4?ZD<4_\
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MR_Z.8^%'_A)>+_\ XY1_J1Q3_P!"BM_X.PG_ ,T!_P 16\/O^BEPO_A+F/\
M\Q^?Y]F?S145_2[_ ,0TGQR_Z.8^%'_A)>+_ /XY1_Q#2?'+_HYCX4?^$EXO
M_P#CE'^I'%/_ $**W_@["?\ S0'_ !%;P^_Z*7"_^$N8_P#S'Y_GV9_-%17]
M+O\ Q#2?'+_HYCX4?^$EXO\ _CE'_$-)\<O^CF/A1_X27B__ ..4?ZD<4_\
M0HK?^#L)_P#- ?\ $5O#[_HI<+_X2YC_ /,?G^?9G\T5%?TN_P#$-)\<O^CF
M/A1_X27B_P#^.4?\0TGQR_Z.8^%'_A)>+_\ XY1_J1Q3_P!"BM_X.PG_ ,T!
M_P 16\/O^BEPO_A+F/\ \Q^?Y]F?S145_2[_ ,0TGQR_Z.8^%'_A)>+_ /XY
M1_Q#2?'+_HYCX4?^$EXO_P#CE'^I'%/_ $**W_@["?\ S0'_ !%;P^_Z*7"_
M^$N8_P#S'Y_GV9_-%17]+O\ Q#2?'+_HYCX4?^$EXO\ _CE'_$-)\<O^CF/A
M1_X27B__ ..4?ZD<4_\ 0HK?^#L)_P#- ?\ $5O#[_HI<+_X2YC_ /,?G^?9
MG\T5%?TN_P#$-)\<O^CF/A1_X27B_P#^.4?\0TGQR_Z.8^%'_A)>+_\ XY1_
MJ1Q3_P!"BM_X.PG_ ,T!_P 16\/O^BEPO_A+F/\ \Q^?Y]F?S145_2[_ ,0T
MGQR_Z.8^%'_A)>+_ /XY1_Q#2?'+_HYCX4?^$EXO_P#CE'^I'%/_ $**W_@[
M"?\ S0'_ !%;P^_Z*7"_^$N8_P#S'Y_GV9_-%17]+O\ Q#2?'+_HYCX4?^$E
MXO\ _CE'_$-)\<O^CF/A1_X27B__ ..4?ZD<4_\ 0HK?^#L)_P#- ?\ $5O#
M[_HI<+_X2YC_ /,?G^?9G\T5%?TN_P#$-)\<O^CF/A1_X27B_P#^.4?\0TGQ
MR_Z.8^%'_A)>+_\ XY1_J1Q3_P!"BM_X.PG_ ,T!_P 16\/O^BEPO_A+F/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
)HH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>ny20077604x1_figure07x1.jpg
<TEXT>
begin 644 ny20077604x1_figure07x1.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
M                                                          !8
M65H@        ]M8  0    #3+71E>'0     0V]P>7)I9VAT($AE=VQE='0@
M4&%C:V%R9"P@,C P- !S9C,R       !#$0   7?___S)@  !Y0  /V/___[
MH?___:(   /;  # =?_; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! ?_  !$( :($R@,!(@ "$0$#$0'_Q  ?   !!0$!
M 0$! 0           0(#! 4&!P@)"@O_Q "U$  " 0,# @0#!04$!    7T!
M @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F
M)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
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M\R:)T'OE !1110 445X'X(_:H_9K^)?Q$\??"/X>_'CX3>-OBC\*_P#A(/\
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M,25KVSTW6KSP[X@M-)OKB".UU&YT+68+.6:72[U(-.@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^V'XL8Q7%O*LT,@5_C<R,4D16"NK(<892"0<NK^'XG\6^_Y?\$#[A_X*-_\
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M<NDVT_D2)%X?U=H)9$GN1!/-)7UOHG]]O\P/Z'_AQ_P<GZIIWC;X.2_MB?\
M!/?XQ_L@_L]?'2=9? _[17B3Q-XN\4^&)=#NM/WZ=XBM-)O_ (&^!4\7:"]X
M]E?:KJ/A/7+^\TWPOJUMKMEHVM6\=HVL?H'_ ,%$O^"M!_X)X?M&_LD_"KQS
M\!;3Q3\%_P!J+5[#1KG]H)_C!%X6@^&\]EXW\/\ AWQ]=7W@1OAOXACU[3_!
M7AGQ?X5\9K=/XW\/+KL.H7^E1KIW]E/J5S_.[_P4.T.#XP?L[_ /1OVT?^"_
M_P '/BQ\"_B!XHT[Q]\*M#^''[#?PRUK4M%U+P[X4\2Z'%XHU33_ -G?6K;Q
M]H&DZ#9ZWK'@G4].OD-I:^)=1&C:AHYU+1[E]'_3K_@MG^QO=_$#_@A]\)6T
MS5[[XC^./V+_  !\ /'UOXUN/!NL^&?$WCCPKX;\!:1\,OB7K5WX;\2._B;P
M3:ZCX>UU_BGXG\/Z]++JNC_\(9'I^L^9J.G-(K4I6?DD];>5_E^/S ]M_P""
MJ'_!>GPS_P $S/VD? G[/,G[.<_QNG\1_#;P]\2?%?B>R^+\/@*3P;9>(O%?
MBCP];:1'X?/PS\;'6]4CT[PO/KY2;6="62VU'3( %2X-VOKO_!0C_@L/;?L9
M?M(_LG?LL?"OX!VW[3'Q4_:M@\/WFA6:?%__ (59IWAZP\?^.=/^'WPOU 7X
M^&/Q'@UZR\9Z\OB@23J^DKHEKX:^TR_;HM31K/\ C1T3X>?%'_@KEX5_X*8?
MMQ^-H9-0\;?LQ?L<?LYW\33WQ2&3QG\/-)^&^G>._%-O&L*Q>3X@^%?P&^/G
MB=]&A"+:Z[XSLQYDK(&G^[O^"&Q\>_\ !1?_ (*E?"?]H'XEVMU?^#_V#OV0
M/A;X,T?^U(?[9TY-<\ ?"[2/@EX'LY[R4 6NL^)?%^L?$CXXZ;+(KRP:SHVH
MF-S/;I/1S-OR;5GV5]>]_P! /IG_ (*N?\K*?_!-?Z?L=_\ K17Q&K]G/"?_
M  6*NV_X*OZY_P $MOBQ^S4?A?JSWOB*W^'GQI@^,2^*M)\=6D/@.3XH>!;Z
M7P?<?"_PK%H0\;>"89DE@M?&OB)M!\:H/!2OK5V)K^'\8_\ @JY_RLI_\$U_
MI^QW_P"M%?$:O9_^#EOX.>*/@;\4?V)O^"JOPDLH/^$S^!/Q,\'^ O&A<W)A
MNI_"_B6Z^*_P:O=2MK6(1_V(-7T[Q_X6\4WMW/NOH?$7A31 LD++$"[2DUTF
M[KNM/(#]-?VS_P#@L1>?LR_\% ?V?O\ @GO\,/V;(OV@/B/\<;7X;O?^(U^,
MC^ =/^'=]\2/&FM>&[2TUW1M/^%'Q)U"Y@\/^'-&/Q"\1WKSZ8+#PI?6EZMO
M+"9+A/VNO+RTTZTNM0U"ZMK&PL;:>\O;Z\GBM;2SM+6)I[FZNKF=DAM[:WA1
MYIYYG2**)&DD944D?QP?\$:-,/\ P4<_X+$_MO?\%2M:TZYF^'/PTU&_\+_
MZ;5=.N=)OA>^,=(D^&/PUN#;C[5IS:MX8_9V\'ZC9^-=,2]>>QU_QWHFHJSK
M<+(_]47[77@CQ?\ $S]D_P#:>^&_P]=X_'WQ!_9Y^-7@CP/)&RI)'XO\5_#;
MQ+H/AIT=_D1UUJ_LF5G^56 +< U46W=]&]/0#^?#7_\ @Y5N_'/Q=\<Z!^QG
M_P $^/C[^UQ\"_A/);77Q'^,W@N;Q1!J5AX;\V]74/%L7@7P_P#"WQG%X<\-
MM:Z3JNH>&=0\>>*_#5SXBM+*<ZEIOA1K6[,/Y_\ _!!+XL>$_C?_ ,%>O^"H
M_P <_"]AJ[^!?B]\/OVG?BQX=TO7HHM(UYO"?C_]ISPCXPTBPUJ&QNM2ATO5
MVT?5K>WU&*SO=0BLKPS+;W5TD22R>O\ _!L#^U[^RA\!?V7/VG?AC\</C#\*
M?@=\2]'^.I^(FJ2_%KQSX6^',^O> M5^'_A3PUI4.COXMU+2)-;/A'Q)X.\6
MKKEGIQNYM!G\3Z.M_#:R:_IXO/"?^"!/CGP1\3_^"KG_  4_^)?PSLQIWPW^
M(?PG_:8\<_#[3ULGTQ;'P1XM_:0\'Z_X4LUTV2.*33Q:Z#J%A +*2*)[0)Y#
M1HT941=MQ;=]=NVJ _2'_@W3^/W[&7B_X>_MK>+?V>_V3)/V*_"?P_E^$VM?
M%2^\0_M+^-?CYI_B33;?1/BMJ=KKEUJ/CGPOX7'@RQ\':;I6O37ILA=PZG!J
MAGO'M_[+A$O)^)/^#E7XH>.I/B9XR_8]_P""7WQ^_:)_9Y^%E[JD7B'X]-JO
MC+2]#M+#0]-CU;5]2\3Z;X-^#'Q!T3P#;6NE2+X@V>(?'$FHV_AF6'6=:TO1
M%^TV]K\5_P#!L)\5H?@1^RQ_P5>^.%SH5WXHM_@UX'^'GQ6G\-6$YM;[Q%#\
M//AU^T#XOET*SNA:WQMKO5TT=M/MYQ97AAFN$D%K<%?*?S_X?_M<_M<?\%&_
MV5_VL?VCOC1_P5,^!?\ P3_^#OA36/'EIJO[-WP<\(>#?!?Q$^(?B"W^&%IK
MNF6":H?%/A?XN:W:_$ZTC_X0OP^)O&GQ!UKQSJ7AKQ!X?TSP_-)I:62%VHQL
M[;]NC\P/Z=?V(_\ @K=^S_\ M@_L1?$/]M[5])UGX'>#/@A<>*=+^..@^++Z
MT\0GP;K/@SP?X?\ &VMCPWJ^CV]M=^-M$O-)\3:9!X7O4\.:#KWB/5FFT>#P
MM;:FL5I-^4OAC_@YQU#QEJGB7XG>%_\ @FI^TQKO[$W@OQ1!X?\ &W[36CW]
M[K-SX'LRFG3W6H^,/#^B?#S4_ACH6N6T&LZ5(_@^\^.4;""_TZZ'B-VU2SLS
M^+O_  3A\%^+OB;_ ,$(/^"QW@OX=0MJOC"P\2?!GQS>Z/8O9RZDO@OP+J_A
M?Q]XSNS9W$T;F%_!'@CQD\&P-=7ATZ\@TF*[U*&.V;]5_P#@CW_P4C_X)_?!
M#_@C#JOPP^-?Q.^%VA>._A=H/[1-O\2O@GKNJ:1H7Q ^,H\9^*O&?B/0]/\
M"WAZ^EMM1^(MWXM\*>*- \#0W>E1:C_9R:;]@U>33]+T5[B%J3=M4M+WLM=;
M=0/U2_X)-?\ !8+_ (>A^$?VCO%7_#/'_"C?^&?CX''V#_A;?_"S/^$M_P"$
MRTSQSJ7_ !]?\*R^'_\ 8/\ 9O\ PAGD_P#'OK7VS^TO,_T7['Y=U^;_ ,)?
M^#GOQ)\??!^NZ9\$?^":WQF^+?[1=IJT\^E?!'X2^.O$GQ2MX?AQI^FVTFL_
M$GQ3XH\,_ B/5](AM==U+3M#TKPYI7@G7AJLHO'U;Q%X5>30H==^=?\ @TU_
MY)%_P4<^OP0_]1CXXUO?\&@D$"^%_P!O:Y$,0N9-?_9P@DN!&@GD@AT[XVR0
MPO*!YC1127$[Q1LQ2-YI60!I'+--OEUWO?1= /V=_P""37_!8SX>?\%/=(^*
M.BW'POUGX$_&'X,PZ9J?C?P/JWB"'Q3X>N?#>LWNJV%IKWA[Q4VD^&[UVTV[
MTI[3Q/I6M^&]'FT6YO=-%I=:S!/<SV7P7\8?^#EK2+KXU^,_A5^PI^Q'\5?V
MZ/#OPZL+C5/%?Q)\$>(?$VA6%QIVDW@M=>UW0/#/AKX/_$[6G\!VCRVUK;^/
M_$+^'[&YNY6E@T:XTN33M1U/\EO^"<WPY\4>.?V_/^"_?PD^$FDQMXU\8_LO
M?\%%OAS\,M"L)+72XF\4>(/C3'X9\&:3933-!9:=&=6N]-L[:25X;6T78SM'
M%&2/KO\ X-@?VL?V4?@!^SS^U)\(OCI\3?A7\ OC%I?QRC\<:W??&3QEX/\
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M*/PEXBU'2;2\UOPQ'X@CL-*CUU-!U.:YTI=8CTO34U-;07JV%FLXMX_XZ?\
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M:GJ5TR(%4W%]J%W=7MU*1OGNKB:>0M)(S'^HG_@I."?^"=7[?0 ))_8K_:G
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M./V<_B1^S1\'/VBOV1OBK\.?!7@SXO:G\1M#N?%-SX@A^$VJ^'=+^*_A;2?
MMWJB>$!JW_")WG@[Q-X%NO%<FJZ8OB&6\\VSU*'2))K7\RO^"H'[.?\ P;Q7
M7[&WCWX_?LH_%7X8^%?CK>:/8Z]\*/!?P)^,M_XE\2>+/$VM7]@ECX<\9_ #
MQCXJU34/ 7AR.#49;KQ*O_"-_#W6/!]C:37 M[N\T^/PMJH]+[7LDT_1;/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\P/VB?^",W_!-C]J_
MXQ>,/C]\?OV;_P#A/?BWX]_X1_\ X2SQ9_PN#X]>%O[6_P"$6\+:)X+T'_B0
M^"_BCX<\,V/V'PSX<T;3?^);HUG]J^Q_;+S[1J%Q=74_BG_$.[_P1U_Z,_\
M_-@/VH__ )]M?M512LNR^Y ?$?QW_P""<G[%O[3'P3^&O[/GQK^!7A[QM\,_
M@UX=TCPK\);6[U;Q39>+/ASH6B:-HN@65AX5^(VFZ[:?$*PAGTGPYX?M-<1O
M$\R^*ET73'\4KK4EI"R_*W[-?_!!_P#X)F_LM_$+PM\6O ?P,U'Q+\2_ OB"
MT\4>"?%OQ*\?^,_&;^%M=TV2*XTK5-,\-7.KVG@E]3T:_AAU71-6U'PQ?ZOH
MNKPV^J:7?VE[:6DT'["T4679?<!^7?[7_P#P1P_8$_;E^+>F_'#]H+X3ZOK/
MQ'M='TOP]JVM^%_'GB_P4OBW1-$6Z31['Q39^'-5L;>_GTZ*[:VM]:M4L/$+
M:?;Z?I=QJ\VEZ7IUE:^X_'K_ ()X?L>?M.? WX6?LV_''X0MXX^"WP5;PLWP
MS\&M\0?BEX=;PVW@OPA>> _#3-XD\)>-]!\6ZVVG>%+^[THGQ#KVK&^,WV_4
M?M>II'>I]IT466NBUW _/[XL?\$M?V$?CA>?L^W_ ,4?@7_PD]W^RQX2\*^!
MO@/+_P +-^,>B_\ "">%O!,NE3>&-+\OP[\0M)B\3_V9+HFF-]M\9)XAU&]^
MS;=0N[M9K@2]9^V#_P $[OV.OV]_^%=_\-9?!_\ X6O_ ,*H_P"$M_X0#_BX
M'Q2\"_V!_P )U_PC/_"5?\DU\;>#O[4_M3_A#O#?_(:_M'[#_9W_ !+OL?VR
M_P#M7VK119=E]W;8#Y%_:Z_80_93_;N\.>$/"?[5GPK_ .%J>'_ >MWWB+PI
MI_\ PG'Q'\#_ -E:SJ5BNFWMY]J^''C#PA>WWG62K!]GU*YO+6/'F101S$R5
MPO[:G_!-+]D']O[PMX%\+_M(_#J]\0-\,1?Q_#WQ+X=\3Z]X5\5^%+75HM+@
MU?3[/5]+O474=-U6'1=+6\T_7K75[0RV4%[!#!J$:78^]**++LON _'./_@@
M'_P207PKX;\(R?LBZ5):>%M5U;6]/UJ'XK?'/2_&5WJFMVVAVU]/K?C70_B;
MI?BG7;.(>'M/GT70]5U6Z\/>%KR;6+OPKI.B7'B'7I-2^O?VT_V ?V7_ /@H
M!\/?#OPW_:9\"WGBS2?!NMR^(O!NLZ1XBUKPSXK\+:Q<Z?)I=[<:7K^DW<-U
M-;:E8ND>J:3JRZEHVI36NG7U]I\^H:5IEU9_9]%%EM9?UW[@?&G[/?\ P3__
M &3_ -F']G7Q7^RE\*OA9;Q? GQ[<>*+OQWX'\8Z]XD^(-EXQN/&NB:?X<\4
MG6Y/&>K:U*;76=$TK3["XTJP-AH\:P-/:Z?!=W-W<3_ NG_\&YO_  22T[QK
M%XP3]G/6[JTMVBGM_!&H_&3XOWW@I+V&]-[%=RV5QXT?6KY0=EK+I6I:]>:#
M<V2"WN])G$DYE_<6BBR[+3] .*U?X;?#S7_A]>_"76_ WA'5/A;J7A1_ E]\
M.;WP[I,_@>Z\%/I@T1O"4OA9[0Z(?#8T<#2TT460TZ/3U2TCMU@14'Y+_#W_
M (-^_P#@E1\-O&OB+QMHO[-TVJ7&N:5K>BV6@^*OB9\3O$?AOPG8>)-"OO#N
MLMX6LM1\627EIJDUAJ5W-I?B#4=1U7Q#X5U4VVM>#]5\/ZMI^GWEK^SM%#2>
MZ3]0/FC]E3]C[]G3]B/X:WWP@_9A^'?_  K+X=:CXLU3QS>>'?\ A+?'7C3S
MO%.LZ=HVDZEJG]K?$+Q-XLUV/[3I_A_2+?[%%J::=#]D\VWM(I[BZDFSOVM?
MV)_V8_VZ/ OA[X:?M3_#/_A:/@GPKXM@\<Z#HO\ PF?Q!\$_8/%-MH^KZ!!J
MG]I?#KQ7X1U:ZV:3KVK6GV*]O[C3F^U^>]HUS!;30_5%%.RVMIV ^8/BE^QG
M^S9\:?V:-/\ V/?B9\-_^$E_9STKPW\/_"-A\._^$P\>Z-Y'A[X62Z%/X#T_
M_A+M \4Z5XZE_L*7PUHC?:YO$\E]J?V+;K-SJ"W-V)\&U_8*_9'MOV3H/V'&
M^#&C:A^RQ:Z7>:1:_"C7->\8^(;6UM;WQ3>>-GFMO%6O>(]1\=V^JVOBR_N-
M>TG7(?%":WHFH?9Y=&U"P%G9K!]>T4K+LNVW3L!^+?PJ_P"#?;_@E5\(?B3I
MOQ0T']G:\\0:UX?UG2_$'A?1?'OQ)^(GC3P;X>U32&26VF3PMK7B.?2_$MN]
MRBW<^G^.X_%FGM<*K1VL4:1QI^O'CWP-X4^)_@;QG\-?'FBV_B/P-\0_"?B+
MP-XS\/7<ES#::]X4\6Z/>:!XBT6ZFLI[6\BM]4T?4+RQFDM+FWN4CG9H)XI0
MDB]910DELK ?%7[-7_!.S]C3]D'X<_$[X3?L\_!+3? ?P_\ C-YZ_$_0+KQ9
M\0?''_"807.A7/AJ6RU+5?B%XM\5ZW'IIT2]OK*/2['4K33H?M]_<PVL=W?7
M<\UK]D'_ ()\_L@?L%V7CRP_9.^#UO\ "BW^)UUX=O/'3+XT^(WC>[\03>$H
MM9A\.+-?_$?QAXOO[2WTE/$.N&UL].N;.T\S5+N:2"2:4R5]ET4679:;>0'Q
M5\5_^"=W['7QP_:5^&O[7_Q0^#__  D_[1/P@_X0[_A7?Q#_ .%@?%'1?^$>
M_P"$ \1ZEXL\)?\ %)>'O&VD^!M6_LGQ!J^H:A_Q//#.I_;_ +1]EU/[;910
M6T7\^/\ P<!_\%&_%?B;2OCQ_P $G_A]^R%\5/'_ ,0OB#)\&X]%^)-C87?B
M31->TN63P)\8Q??#[P=X?T+5-?\ $'B&QU;3F\%I")[5;'4[#5]75[C[!;Z=
M>?UQT4-75EI??3?^NX'Y2?\ !%W]AW4_V!OV"?AE\*/&-DEC\6_&]YJ/QC^,
M]JGEDZ9X_P#'-KIB)X8E:+>CW?@GP?I'A3P9JDL5S=V=UK>@:IJ&GW!L;RW1
M/U;HHIK1)=@/R#^-/_!"3_@F%\>_C;J/Q[\??L[JGC/Q'K5YXD\;Z7X2\<^.
M?!7@OQWXAOC%)=:WXB\*>%]?TS3;;4KRZCDU+5Y_# \._P#"2:O>:CJ_BA=:
MU+4KZZG^F?@5_P $VOV)?V9OBU\3/CC\"?@7IGPW^)/Q?\/ZQX3\>ZMHGB_X
MBS:-J7AK7M8TO7=1T+2/!&J>,-0\"^#],_M+1=+>PM/!OAO0(='M+*+3=(6Q
MTS?9M]QT4K+LON ^+OV1_P#@GG^QY^PIIOQ#T?\ 98^#L7PQTSXK2:!+\0+*
M?QS\2_'\'B)O#%OK=KHBS+\3?&?C,V,5I;^(]:BD@TLV,-\EZ1?QW7D6QA^+
M/"W_  ;Y?\$G_"OQ0G^*<'[,T6MW@URT\1:5X)\3^/OB!KOPQT/4[6\^WE+;
MP)>>(SHVLZ)=7'RW7A3Q>GB7PFUH!IT6APZ:/LE?M)119=D!^8_@[]@+X/?\
M$^/@)^U-JW_!,_X">'_"OQL\??#F]UK0_!7BSQW\4O'_ (.^)7Q"^'NA>++[
MX<>%M7T[XD?%2XL='L]7U+Q!JGAZ:XTG7/",#Q:Y&^L:HEGIUK+9_P ?OPG_
M &L_V7O@WXD\=>/OVE/^"'^I> /^"A-KK^M:K\$=,^%'PY^-/@'X-6&NW>CQ
M/HVJ:M\!/BO\2?$>F>$?$7A7Q5-=Z]IEYX+\!:Q';P'1&T"R\+ZKHMOJ]S_H
M=44G&]K65K]$]P/YFO\ @V9_8C^*W[-O[)'QN\;?'SX;^*OACXH_:-^(NF_V
M5X,\;Z9J7AOQ3/\ ##P+X9FTO0M<U70+ZYM]6\/#7-?\6>.8M.L]3TC1=9N=
M*LK+7D:]T;6-!N5_9G]D#_@GU^R%^P79^/;#]D_X1_\ "J;3XG7/AR\\<1?\
M)[\3O'/]MW'A*+6H?#\GF?$GQIXQETW^SXO$.L+LTA]/CNOMFZ]6Y:WM3!]F
M44TDDO+^G]X'Q5\"/^"=W['7[,WQT^*O[2OP1^#_ /PA/QK^-O\ PE7_  L_
MQI_PL#XH^)/^$F_X37QA:>/O$_\ Q3GB[QMKWA/1?[3\66-KJW_%/:#I/V+R
MOL.G_9-->2S?Y@_:7_X(9_\ !-7]JWXK:M\;/B=\"KG3_B-XHUR'7_'&L_#[
MQSXQ\!VGCS4 S/?W'B;0= U>WT!K_7I6:Y\1>(-%TS1O%.MWSRZE?Z[-J,\]
MW)^NE%%EV7W ?/G[-7[*?[.W['OPYM_A/^S3\)O"WPE\"PW<NHW.F>'XKRZU
M+6]5F58WUGQ7XHUN\U7Q7XQUO[-'!8IK?BO6]9U6/3;2RTR.\33[&SMH/S2^
M+'_!O5_P2H^+?CZ;XAW_ .SS=>!]0U#4I=4U[P[\+?'OC+P%X&URXF>!GA_X
M0[1]671/"]EMA>-;'P#;>$+4"YN9?*^TM'/%^V%%#2>Z6@'SK^S5^R5^SI^Q
M_P#"H?!+]G'X5Z!\,OAD^J:GKE]X<L)]7UN37-;UFVM+'5-9\3:YXIU+7/$7
MBC5;W3M/T[2Y=0\0ZMJ=T-(TW3=)CE33=.LK6#\S/%7_  ;K?\$EO%GC=_&L
M_P"SCJFAI=:AJ.I:KX.\*_%GXJ^'?!&IW.HN)7C31=.\717'A[3[28R2:?I/
M@W4/#6E6*RFT@LUL8;6U@_;VBBR[(#SWX;?"?X;?![X;^%_@_P###P3X>\$_
M#'P9H,7AGPUX)T/3X;;0=,T2))%>S%HPD^U->O-<76J7E\]S?:Q?W=[J.JW-
MY?WMU<S?EE8_\$"_^"5FG?&Z+XZ6?[,FG1:Q;ZXGBFU\ CQ?XS;X/6OB:/5F
MUE-3@^&;:X?#J::EV5AB\#F%OAO;Z?'%IEMX-AL$%O7['T4679?<!\>?LF_L
M"_LE_L-_\+'_ .&6OA/_ ,*O_P"%MZEH>K_$+_BN_B7XV_X2#4?#G]N?V+<?
M\7$\9>+?[*^Q_P#"2:U^ZT3^S8+C[;_I<4_V:T\CX2_X.&O"_B;QE_P2@_:'
M\/\ A#P[KOBK7KSQ#\$'L]$\-Z1J&N:O=):_&[P!=73VVFZ9;W5[.MM;0RW,
M[10L(8(I)I"L:,P_;"BAI-6V _DU_P""9G_!"[]@K]IK]@C]DWXO_M+_ +/?
MBW3/C9=:!XS7XAQV_C'XE?#6]\6KI7Q6^(&F:)!XT\,V&L:4+6XCT"VTJ)-3
MTBT\/Z[?V,-B]WJEU$L+5_2EX?\ V8/V?_"O[/*_LG^'/A1X2T?]G4> ]7^&
M;_"BQLI8O#5QX,\0VM];>(=-O,3G4;Z]\0MJFIZCK_B"\OY_$>MZ[J6H>(M4
MU:ZUZ^NM2E]XHH44NBVL_,#\4OAW_P &]'_!)OX=ZGXAU2/]FB3QI+K]EXDT
MF*U^(7Q+^)GBG3?#VC^*=%O=!U"Q\/:=-XJM[2VO+.QU"XF\/>*KZ+4?&_A;
M6$L_$/ASQ/I>O:=I^I6OV'\-/^":?[$WP?\ V9_BC^Q[\/?@G!H_[.7QEOM=
MU7XA_#;4O'?Q.\7VFLZKXCT;0="U/4[/7O&OC3Q'XI\/7PLO"_A^?3I_#>N:
M2VC:OI-KKVD?8M<$FH/]U44679?<!^;G[$W_  2<_8F_X)]>,/%?Q!_9K^'W
MB7P_XW\9^';GP?K?B/Q)\1?&OBR:3PG<ZWIWB%M M]*U;69/#L%O%J>CZ5+#
MJ/\ 8SZ\L5DL#:L\5U?K=^G? C_@G=^QU^S-\=/BK^TK\$?@_P#\(3\:_C;_
M ,)5_P +/\:?\+ ^*/B3_A)O^$U\86GC[Q/_ ,4YXN\;:]X3T7^T_%EC:ZM_
MQ3V@Z3]B\K[#I_V337DLW^U:*++LM /QR^//_!!/_@F!^T1\3]>^,'C?X!7V
MC^./&'B>?Q?XXN_ 7Q&\?^#-(\8ZU?S3W6L7&J^&]*\0+H&G2:]>3O?ZW=^%
MM.\/:EJ&HM-J4M]]OO+^YNOT2^ '[+WP#_9:^$&G? 7X _#30_AI\*M-74S'
MX8T:;5+F6^NM:&W5M5USQ#J^H:CXG\1:[J$8C@NM?U_6=2UJ2VMK*U-^+:QL
MXH/>Z*$DMDD!\9_L@?\ !/K]D+]@NS\>V'[)_P (_P#A5-I\3KGPY>>.(O\
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M9%DU#6=<UW7+W5/$?B;7;WRX(KK7/$6K:IJTUM:V5F]X;2RM((/<J*:26R2
M_'+XF?\ !!+_ ()>?%[XX^*_C[X]_9^OM3\5>.M;U3Q7XP\/Z?\ $SXD^'/
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MOL9?)MX/%UGK6IP22()+BS\1ZYK=G<;GAFMWM6,%?N?119=E]P&!X4\)^%O
MGAK0?!?@CPWH/@[P?X6TFQT'PSX4\+:1I_A_PWX=T/3+=+33='T/0])M[33-
M)TO3[6*.VLM/L+:"TM8(TB@B2-54;]%%, HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BH&NK5&*/<P(RG#*TT:L#Z$%@0?J*;]ML_^
M?NV_[_Q?_%U#J4T[.I!-:-.<;W[;^:*Y)O:$G?;W7K>UNGFOO19HJM]ML_\
MG[MO^_\ %_\ %T?;;/\ Y^[;_O\ Q?\ Q=+VM+_GY3_\#C_GYK[Q^SG_ "3_
M / 7_EYK[RS15;[;9_\ /W;?]_XO_BZ/MMG_ ,_=M_W_ (O_ (NCVM+_ )^4
M_P#P./\ GYK[P]G/^2?_ ("_\O-?>6:*K?;;/_G[MO\ O_%_\71]ML_^?NV_
M[_Q?_%T>UI?\_*?_ (''_/S7WA[.?\D__ 7_ )>:^\LT56^VV?\ S]VW_?\
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M7WA[.?\ )/\ \!?^7FOO+-%5OMMG_P _=M_W_B_^+H^VV?\ S]VW_?\ B_\
MBZ/:TO\ GY3_ / X_P"?FOO#V<_Y)_\ @+_R\U]Y9HJM]ML_^?NV_P"_\7_Q
M='VVS_Y^[;_O_%_\71[6E_S\I_\ @<?\_-?>'LY_R3_\!?\ EYK[RS15;[;9
M_P#/W;?]_P"+_P"+H^VV?_/W;?\ ?^+_ .+H]K2_Y^4__ X_Y^:^\/9S_DG_
M . O_+S7WEFBJWVVS_Y^[;_O_%_\71]ML_\ G[MO^_\ %_\ %T>UI?\ /RG_
M .!Q_P _-?>'LY_R3_\  7_EYK[RS15;[;9_\_=M_P!_XO\ XNC[;9_\_=M_
MW_B_^+H]K2_Y^4__  ./^?FOO#V<_P"2?_@+_P O-?>6:*K?;;/_ )^[;_O_
M !?_ !='VVS_ .?NV_[_ ,7_ ,71[6E_S\I_^!Q_S\U]X>SG_)/_ ,!?^7FO
MO+-%5OMMG_S]VW_?^+_XNC[;9_\ /W;?]_XO_BZ/:TO^?E/_ ,#C_GYK[P]G
M/^2?_@+_ ,O-?>6:*K?;;/\ Y^[;_O\ Q?\ Q='VVS_Y^[;_ +_Q?_%T>UI?
M\_*?_@<?\_-?>'LY_P D_P#P%_Y>:^\LT56^VV?_ #]VW_?^+_XNC[;9_P#/
MW;?]_P"+_P"+H]K2_P"?E/\ \#C_ )^:^\/9S_DG_P" O_+S7WEFBJWVVS_Y
M^[;_ +_Q?_%T?;;/_G[MO^_\7_Q='M:7_/RG_P"!Q_S\U]X>SG_)/_P%_P"7
MFOO+-%5OMMG_ ,_=M_W_ (O_ (NC[;9_\_=M_P!_XO\ XNCVM+_GY3_\#C_G
MYK[P]G/^2?\ X"_\O-?>6:*K?;;/_G[MO^_\7_Q='VVS_P"?NV_[_P 7_P 7
M1[6E_P _*?\ X''_ #\U]X>SG_)/_P !?^7FOO+-%5OMMG_S]VW_ '_B_P#B
MZ/MMG_S]VW_?^+_XNCVM+_GY3_\  X_Y^:^\/9S_ ))_^ O_ "\U]Y9HJM]M
ML_\ G[MO^_\ %_\ %T?;;/\ Y^[;_O\ Q?\ Q='M:7_/RG_X''_/S7WA[.?\
MD_\ P%_Y>:^\LT56^VV?_/W;?]_XO_BZ/MMG_P _=M_W_B_^+H]K2_Y^4_\
MP./^?FOO#V<_Y)_^ O\ R\U]Y9HJM]ML_P#G[MO^_P#%_P#%T?;;/_G[MO\
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M;?\ ?^+_ .+H^VV?_/W;?]_XO_BZ/:TO^?E/_P #C_GYK[P]G/\ DG_X"_\
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M)_\ @+_R\U]Y9HJM]ML_^?NV_P"_\7_Q='VVS_Y^[;_O_%_\71[6E_S\I_\
M@<?\_-?>'LY_R3_\!?\ EYK[RS15;[;9_P#/W;?]_P"+_P"+H^VV?_/W;?\
M?^+_ .+H]K2_Y^4__ X_Y^:^\/9S_DG_ . O_+S7WEFBJWVVS_Y^[;_O_%_\
M71]ML_\ G[MO^_\ %_\ %T>UI?\ /RG_ .!Q_P _-?>'LY_R3_\  7_EYK[R
MS15;[;9_\_=M_P!_XO\ XNC[;9_\_=M_W_B_^+H]K2_Y^4__  ./^?FOO#V<
M_P"2?_@+_P O-?>6:*K?;;/_ )^[;_O_ !?_ !='VVS_ .?NV_[_ ,7_ ,71
M[6E_S\I_^!Q_S\U]X>SG_)/_ ,!?^7FOO+-%5OMMG_S]VW_?^+_XNC[;9_\
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M_P !?^7FOO+-%5OMMG_S]VW_ '_B_P#BZ/MMG_S]VW_?^+_XNCVM+_GY3_\
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MU]Y9HJM]ML_^?NV_[_Q?_%T?;;/_ )^[;_O_ !?_ !='M:7_ #\I_P#@<?\
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M'_/S7WA[.?\ )/\ \!?^7FOO+-%5OMMG_P _=M_W_B_^+H^VV?\ S]VW_?\
MB_\ BZ/:TO\ GY3_ / X_P"?FOO#V<_Y)_\ @+_R\U]Y9HJM]ML_^?NV_P"_
M\7_Q='VVS_Y^[;_O_%_\71[6E_S\I_\ @<?\_-?>'LY_R3_\!?\ EYK[RS15
M;[;9_P#/W;?]_P"+_P"+H^VV?_/W;?\ ?^+_ .+H]K2_Y^4__ X_Y^:^\/9S
M_DG_ . O_+S7WEFBJWVVS_Y^[;_O_%_\71]ML_\ G[MO^_\ %_\ %T>UI?\
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M:A_X*A_D'UG$?\_ZW_@R?^?E^?=F3_8FG?\ /%O^_P!+_P#%T?V)IW_/%O\
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M_P [ROP^HHY(?RQ_\!7^0>SI_P#/N'_@,?\ (_<'_B(O_P""M_\ T<=X>_\
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M%;_^CCO#W_AB_@7_ /.\K\/J*.2'\L?_  %?Y![.G_S[A_X#'_(_<'_B(O\
M^"M__1QWA[_PQ?P+_P#G>4?\1%__  5O_P"CCO#W_AB_@7_\[ROP^HHY(?RQ
M_P# 5_D'LZ?_ #[A_P" Q_R/W!_XB+_^"M__ $<=X>_\,7\"_P#YWE?M;\8O
M^"M7[=OA+_@A?^RE^VMH/Q<TJS_:,^*'[6?B/X6^-/&S_#3X:7-EJG@G3Q^T
MF;72HO"=SX3F\)Z=+'_PKOPGG4=.T6UU%_[.DWW3?;K[[1_$C7])?[0W_*L'
M^PE_V?KXO_\ 0?VR:B48IPM&.LTGHM59Z;$5*<%R6A!7J13M%:K73;8^=?\
MB(O_ ."M_P#T<=X>_P##%_ O_P"=Y1_Q$7_\%;_^CCO#W_AB_@7_ /.\K\/J
M*ODA_+'_ ,!7^1?LZ?\ S[A_X#'_ "/W!_XB+_\ @K?_ -''>'O_  Q?P+_^
M=Y1_Q$7_ /!6_P#Z..\/?^&+^!?_ ,[ROP^HHY(?RQ_\!7^0>SI_\^X?^ Q_
MR/W!_P"(B_\ X*W_ /1QWA[_ ,,7\"__ )WE'_$1?_P5O_Z..\/?^&+^!?\
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MKX?L/%WBSP5I>O0W'AS3_"5KX<UMKNRUG4(DEUO2[^6V,RR6SQ211,GXV?\
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M ,[RC_B(O_X*W_\ 1QWA[_PQ?P+_ /G>5^'U%')#^6/_ ("O\@]G3_Y]P_\
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M /HX[P]_X8OX%_\ SO*/^(B__@K?_P!''>'O_#%_ O\ ^=Y7X?44<D/Y8_\
M@*_R#V=/_GW#_P !C_D?N#_Q$7_\%;_^CCO#W_AB_@7_ /.\H_XB+_\ @K?_
M -''>'O_  Q?P+_^=Y7X?44<D/Y8_P#@*_R#V=/_ )]P_P# 8_Y'[@_\1%__
M  5O_P"CCO#W_AB_@7_\[RC_ (B+_P#@K?\ ]''>'O\ PQ?P+_\ G>5^'U%'
M)#^6/_@*_P @]G3_ .?</_ 8_P"1^X/_ !$7_P#!6_\ Z..\/?\ AB_@7_\
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M*W_]''>'O_#%_ O_ .=Y7X?44<D/Y8_^ K_(/9T_^?</_ 8_Y'[@_P#$1?\
M\%;_ /HX[P]_X8OX%_\ SO*/^(B__@K?_P!''>'O_#%_ O\ ^=Y7X?44<D/Y
M8_\ @*_R#V=/_GW#_P !C_D?N#_Q$7_\%;_^CCO#W_AB_@7_ /.\H_XB+_\
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M!?\ \[RC_B(O_P""M_\ T<=X>_\ #%_ O_YWE?A]11R0_EC_ . K_(/9T_\
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MEH+.UAB:>YFEGF*F2:1Y&9CYI_P;H?\ *6_]G'_L7OCI_P"J+^(=?E+^T?\
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M_P#X*W_]''>'O_#%_ O_ .=Y1_Q$7_\ !6__ *..\/?^&+^!?_SO*]8^$O\
MP;7_ +;_ ,2/AE\//%WBKXF_LQ_ [XE_&'0-0\3_  H_9V^+_P 2-:T7XR^+
M=(TO3Y]:O%DT/1?".OV%CJPT$Z9KLVBVNH:O?^';#58HO'\?@K5++4M-M/E?
M]C+_ ((N?M??MI>/?VJ/A)X57P3\*_BY^R2FBVOQ#^''QAO]>\.Z[J7B/7Y/
M%]OIGAG0;K1_#^OZ+]LN+OP=<Q1ZIJ^IZ7X>FM]3TG4[75[C2KA[V*?JE2\%
M[#6I?D7*KNRYFO)\NMG9VZ%+$8%JI)5*#5*W.THVBG+D3O:SCS^[S1O%/1L]
M0_XB+_\ @K?_ -''>'O_  Q?P+_^=Y1_Q$7_ /!6_P#Z..\/?^&+^!?_ ,[R
MOD;_ (*)?\$Z_B#_ ,$W?B/X ^%OQ.^+OP2^*7BGQYX"/C]8O@OK?B_7K3P[
MID?B+6/"#QZU>^)O!?A.V)N?$WAKQ1IFFC3I;V\?_A'M0DUG3]"E:TMKG^CS
M_@AM^SCX ;_@E_\ &/\ :I_94_99^"7[9/\ P45T;XL:QX*7P=^T')X;M-,\
M'V5O<>$SI&C>#9?%FJ6>A:=IX\#:W/XZFU@:M\/]5\8ZK=>)/!TGC"6#PUI&
MGLZ>$YZKI2C&$HQ<I+D4I623M&,;N4FGI%:[]B:V(P]*A&O&G"I"<HP@[0A%
MN;:4ISFDH05G><E9:=S\?/\ B(O_ ."M_P#T<=X>_P##%_ O_P"=Y1_Q$7_\
M%;_^CCO#W_AB_@7_ /.\K['_ ."P7Q_^#/Q4_9DM?"7[7G_!.+Q=^P]_P5.T
M/QG8:K:^.O ?P=\.^%_@U\8M"L=8@T;Q?.OQ,&O_ -K>./".HZ%?ZAJNDB _
M$M=!\7^'-,L=,\?3Z7JVM23_ !O^Q)_P03_:]_;,^"=C^T==^,?@O^S?\&/$
MUU#IOPZ\4_'WQ/K'AZ\^)6H:E>SZ'H4_A;1M%\/ZW)%H6K^*4M?#]EJFOW6C
M7>L3WUO=>#](\5PL@D<L)^\=.E%56HJ3M#E<5U4XR2Y&GHTWI=:ZA&OAU1]M
M7ITZ"Y^1<W)-3?1TY0352,OLN*N[.Z5F+_Q$7_\ !6__ *..\/?^&+^!?_SO
M*/\ B(O_ ."M_P#T<=X>_P##%_ O_P"=Y7J?[,/_  35^/?[ _\ P6=_8@^
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MR?\ GY?GW9D_V)IW_/%O^_TO_P 71_8FG?\ /%O^_P!+_P#%UK44?4\)_P!
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M]*1_,C1115F@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MKDP/^[0_QU__ $_5.G%_QY?X*/\ Z9IA11176<P4444 %%%% !1110 4444
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M<6GCG3OAUX;U;XBZW?WCS7=SIMQK3J70VK_0?[0O[1W_  4TTO\ X.,?@O\
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MV5[;(\3HHHKF.\_<'_@W0_Y2W_LX_P#8O?'3_P!47\0Z_*7]H_\ Y.'^//\
MV6?XH_\ J<:[7ZM?\&Z'_*6_]G'_ +%[XZ?^J+^(=?E+^T?_ ,G#_'G_ ++/
M\4?_ %.-=J/^7C_P+_TJ1FOXLO\ KW'_ -*F>,44459H%%%% 'TK^Q__ ,,Q
M?\-'_#+_ (;+_P"$R_X9H^W:]_PM'_A7WVO_ (3#[!_PB>O_ -@?V+]A_P!*
M\W_A+O\ A'_M7E<_8/M6_P#=[J_K/^'O[ '_  ;L?$_]B[XQ?M[^%=._:QF_
M9[^!GCF/X=^/=1O?%'B6S\56_B20_#<+%I?AAX&N=2L\_%7PEF[CG11YU_\
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M3_"[PWGAS3?Z3_\ G:A_[LK_ /=.I<S=NGO1VNM&!_4!1116@!1110!6O?\
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M*Y_JKC?^?E+\/_DO7^GI] T5\_?\)9JG_3+_ +ZN/_C]'_"6:I_TR_[ZN/\
MX_1_KYE7_/JO]TO_ )#^K/RN?ZJXW_GY2_#_ .2]?Z>GT#17S]_PEFJ?],O^
M^KC_ ./T?\)9JG_3+_OJX_\ C]'^OF5?\^J_W2_^0_JS\KG^JN-_Y^4OP_\
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M)X<\.>$]*T+P]H=A!>W][?2+IVF6\]_J-W=ZIJ4][J5U<W<O^J)_PI+X!_\
M1OOP,_\ #5>#/_E11_PI+X!_]&^_ S_PU7@S_P"5%#XKP#@J;JXAP6J@XU'%
M;;*UM+NW:SMN-9?5C4=586BJLE:512IJ;7G)1YG?2^NME?9'^>KX9_X.(_\
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M=NA_D/45_KP_\*2^ ?\ T;[\#/\ PU7@S_Y44?\ "DO@'_T;[\#/_#5>#/\
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M^2+A%/V348MM\L5RV2NV[+2[;ZN_^6G??MT?M3ZE^R5HW["][\4O._97\/\
MB67Q?I'PM_X0GX=1_9/$4WB/5?%LNH_\)O%X1C^(MQN\0ZWJFH?9+KQ=-8K]
MJ^R+;"QAM[:+L;G]O3XY?%+X7?LU_LJ_M(^.]8^(7[&G[/OQ#\&^(]*^$/AW
MPO\ #?PIX@L/#6CW.H:?K]CH?C[1O"6E>-+O6+WPEXC\5:7IESXF\3:M:V][
MJD%[/&TME:2V_P#I]_\ "DO@'_T;[\#/_#5>#/\ Y44?\*2^ ?\ T;[\#/\
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M%R\O+S?W>8?5<5_SZC_X-C_D?Y#U?TW?\&WG_.3+_LRW7?\ W8:_MS_X4E\
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M?8Q]Z-^66D%[T>:7*]U=V:NS_+3^)O[='[4_QC_9N^$G[(OQ'^*7_"1_L\_
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MUVRM]2C]<_;,_P""Q7_!0']O'P):?"S]H#XTK>?"Z&[TS4K_ .'O@CPKX:\
M^&_$FK:0\4]CJ7BU/#>G6FI^*/LU_!;ZM::3K>I7GAW3=9MK35M*T:PU"TMK
MB'_2C_X4E\ _^C??@9_X:KP9_P#*BC_A27P#_P"C??@9_P"&J\&?_*BC_6S
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M:EX<T*SUB_1=0MK*]FT&QU#3?",UYI^G7C>'?M5A:S1?Z0W_  I+X!_]&^_
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MO^?4?_!L?\C_ #W_ /@W0_Y2W_LX_P#8O?'3_P!47\0Z_*7]H_\ Y.'^//\
MV6?XH_\ J<:[7^M+X*^&'PD\->(['6/"OP@^%?A/6[9+M+77?#'@'PSH6LVB
M7%G/!<I:ZGIVG6]W MS;22VUPL<JB:WEEAD#1NRGGKWX,_ NZO+NYN_@+\$[
MNZN+JXGN;NZ^%_@^>YNKB65Y)KBXGETEI)IYI&:2:61F>21F=V+$DV^(<O4(
MXANI[.I*5&/[N5^>FH3G=6O9*K&SZZV,EA\0Z\HJG'F5*#:]I&R3E.SO;JT]
M.EC_ "%**_UX?^%)? /_ *-]^!G_ (:KP9_\J*/^%)? /_HWWX&?^&J\&?\
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M/OHE::;A6^$7P^^,/[:W_!5GX7?L%KX0U#X._$G_ ()L:SX.^-FE_#*]T?\
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M=7ELQ;>8_P#!.G]J#X5?LC_\$I/BO\*/BU\1/ /A#XP_L2:M^U=\-/'GP_\
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M**8%:]_X\[O_ *]I_P#T4]><5Z/>_P#'G=_]>T__ **>O.*^<SS^)A_\$_\
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MN;_X_1_PDM]_SRM/^_<W_P ?H]AEW_0PK?\ A __ )I_JS\KGM<7_P! M/\
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MJS\K\]170_\ "2WW_/*T_P"_<W_Q^C_A);[_ )Y6G_?N;_X_1[#+O^AA6_\
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MM2)O6\9I:KXI-PS2'5RS-G[*_P"$EOO^>5I_W[F_^/T?\)+??\\K3_OW-_\
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M:+90:;HVAZ'HVFP6VG:3H^DZ=;6UAIFF6%M;V5A96\%K:P1011QKA>"/AO\
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M (26^_YY6G_?N;_X_1[#+O\ H85O_"!__-/]6?E<]KB_^@6G_P"%*_\ E/\
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MGJ*Z'_A);[_GE:?]^YO_ (_1_P )+??\\K3_ +]S?_'Z/89=_P!#"M_X0/\
M^:?ZL_*Y[7%_] M/_P *5_\ *?ZL_*_/5T&@_P#,0_Z\W_K2_P#"2WW_ #RM
M/^_<W_Q^M33-8N;W[5YJ0+Y%NTJ>6L@RPSPVZ5\KQT&#[UVY=1P,<91=/&U:
MDU[2T'@W!.]*:=Y>WE:R;?PN]K=4SFQ=3$O#U%/#PA&].\E74FOWD&ER^R5[
MNRW5M7TUXJBNA_X26^_YY6G_ '[F_P#C]'_"2WW_ #RM/^_<W_Q^N+V&7?\
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M<W_Q^C_A);[_ )Y6G_?N;_X_1[#+O^AA6_\ "!__ #3_ %9^5SVN+_Z!:?\
MX4K_ .4_U9^5^>KX9_X*<?\ *.S]M_\ [-;^-O\ ZK_7:_0?_A);[_GE:?\
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M#3[BYN[30[O6);8:AJOAF*ZO+NY;PMJUQ?>')9[JXFFTN22:1F^BO^$=LO\
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M)NPES'9:YK U2PCT56N?RG^ ?P[^ O[,G_!6+X<_L\_\$\M=&H_ +XS?L_\
MQ&\6_ME?"WP?XWU+XI?#CP _AZP\06WPM\;#Q3?>(/%VI>%_%NM>*;S3_#-U
MH=UK-@NG:-K>CR6D(MO%.G0)C@Z+G@,31KX:%-+!8K$8>H\)3?M9T*LY5JM?
M'.4J]&O15*5"AAH*G2JRY85%!U7.MKB:BCBJ-2E7G.^*H4JT/K%3W(UJ<%3I
MTL*E&C5I5.=5:M:3G."YY1<O9J-+J?AG\7OV^/VU_P!G;XV?\%#/@S^TW??
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M0ABL33J0]M&FN?ZO%QHS2G-U9J4:BG1C-N473E!_T%$@ DD  $DDX  Y))/
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M*E:+J.22Y]2BBBO&/2"BBB@ HHHH *Z#0?\ F(?]>;_UKGZZ#0?^8A_UYO\
MUKT,J_W^A_W%_P#3-0Y,=_NM3UI?^G8'/T445YYUA1110 4444 %%%<A\0;G
MQK9^ O&]W\-M/T;5OB+:^$/$MSX!TKQ'/-:^'M3\:P:->R^%=/UZZMYK>>VT
M:]UU;"VU2>">&:&QEGDCFC=5=7%<TE&Z5VE>32BKNUVWHDNK>B6HF[)NS=DW
M9*[=NB2U;[+J?@G_ ,%NO^"@_P :/@S\._'WPB_8_P!8O-%\??"O1?AW\1OV
MEOB_HLL#M\&/"'CSQMHWA3X9?#W3[I[:\L[;XG?%36=27Q!_9=Z]OJ-A\+]
MUG5;>QN[?Q!;:AIG]#=?QG_MQ_#7]N3X _\ !+#X_P#@/X\_LW_#6#_A9GQ1
M\(_%7]HG]J"V_:*T[QC\0OB)\5/$WQB\):G'K\_PZTOX:Z#IMGI;7,&A>"]
M\.:1K=KI'@_PI96K6T=[<P7LVH_U'?"7XY:[9>'?@SX,_:RN_A!\&_VIOBW_
M ,)U_9/P9\-?$*TUR+Q#_P (AK&K7#?\(!-J<EKJWBO['X&70/$'B/[%:2_V
M/<ZA=03;88$=OHLSP=*EEN 6%6'J^RQ>84IU\/6HUZN*4,/@*LJ\O92E)4H/
MVSC"23PU"5'VRC4JN4_'P.)G4QN+=9UH<^'P52-*K3J4Z=!RJXJFJ4?:1C'V
MD[TDY*_MJJJ>S;C!1C^0/_!9[_@H)^UE\'OAY\:OAW^R?\(OBAX*L/@Y#\,]
M6^-O[8FIZ?I^D>"/"FF>.M8\$V^@^"O@]>:DT]OXP\;:YJOCGPII/BFZ@274
M?".C3ZXL/AV47,/B[P[^B/\ P4S_ &J?B)^RM^S[X:N_@OI&F:K\=?CY\9_A
MW^S)\#YM?6&3PUH/Q+^*[:Q_97B7Q%'/NAFL-$TS0-8N[6"XBN+*?6ETF'4[
M:XTM[V)_#O\ @O9_RB<_:M_[H7_ZTG\':H_\%I;*;P[\&?V5/VAYK5Y/"_[)
MG[??[+GQ^^)-]&AN7TGX<:%XGU+PUK.H+8+=6LE]Y>N^)_#"R0VY:Y6%I9 U
MO;+=7,-X2&%Q%+(HO"48WS#'T*BO*4L94IX;*ZE-5I2=Y*I7JN$:4>6$83Y(
MQ<I3G-8B6(HU,T:Q%25L)@ZL/ABL/"=?'0J.FDK)PI4U*525Y2E'FDU&,8QY
M#Q#\4?VI/^"?'[4'[(7@;XW_ +37B+]K7X#_ +9'CJ7X&ZI=^./AQ\._!OC?
MX3_'#4O[/7P5K_A'4? %AX?AU/P5XXUW6[?1]2\*:[;7Z^#]*TR>_P!)U*\N
MI$L[IOAGQU^V!_P4#^//[9,'P0_:>\0?L@?![]DCXL:O^S7\-5\*?#KX:?$#
M4_B/\<? L-ZOQ*\8?$^U\>Z/J\]SX-T75;C1+/P]X7T:[TFSUW1;];JYN+/5
M["YEN<7]OSXC^"_VHOVKO^"5?P(^!'C#P7\7=3T7]JKPW^UWXUG^'GB31_&%
MMX-^%WP/L[/6+7Q=XBU?P[JU_9:#H'B;_A(+JU\-7.I0"V\5ZI:PZ=I%^MR4
MMM0D_P""=_Q5^%7[*_Q=_P""J/P$^-WQ%\ _"?Q!X;_;D^*?[3UI;>//%V@>
M&([GX.?'?PSX0\2>$O$]A>ZWK4*ZKIVGZ)I%@-=FMD=M!NM2TZWUB6&]U6VM
M(M?9_P"PK&+"4'F;P<9.G]4HM>S_ +3=!8EX+V/L5.4%'#N7L;2A+G?[R;F\
MU+_:GAW7J_45B7%3^L54^?ZC"M['ZS[3VKCS.=;E56ZDG'X%RK[(_P""8_[8
M'BC]LW]FA_&OQ'T33O#_ ,8_A=\2O&WP'^-=AH431>&Y/B5\.Y--DO\ 5/#B
MO<W4J:9K>@:[X=UB6V=PFGZK?:EIEJ;BQLK6\N?T-K\;?^"(&B>)[C]EOXP?
M&OQ'H%[X=M?VK_VP?C_^TWX0L]1LKG3+J[\%?$&\\-Z3H.KC2KR:XNM/L=67
MPI<7ND)+<W2WNCRZ?JMK>7MEJ%M=S_LE7B9K2I4<QQE*C&-.G"O.*IQ=XTY:
M<].+U?+3GS0BFVTDD]4>G@)U*F"PU2K)RG.C!N35G-->[-KO.-I/HVVUH%%%
M%>>=84444 %%%% &OH7_ "%+;Z3?^B):S9_]?-_UUD_]#:M+0O\ D*6WTF_]
M$2UFS_Z^;_KK)_Z&U=T_^1;AO^PS%_\ IG"'+'_?*O\ V#T?_3E8BHHHKA.H
M**** "BBB@ K^=_]LW_@H)^UE=_M7_LK_#'X._"+XH?!#]F;2O\ @HQ\#?V;
M?BW\=_&NGZ?H3_'_ ,2ZW\0;S2=3^'?PRTR\:XN-2^$EQHGA7QO<>(/&>E&]
MEUN\AT32[F;P>;>73O%/]$%?C_\ \%>?^<8'_:8#]BK_ -Z77K9,Z/UV,*V'
MIXAU(580]JVX4G[*HW4]FK1J325H<]XPE[_*Y1BUP9DJGU9RIUITN2=*4O9V
M4IKVL%R.;NXQ=_>Y;2DO=YDF[_L!7XZ?$;XI_M(?M9_M[_&7]CGX&?&WQ%^R
M[\*_V2?AG\/?%'QA^)7@OPOX$\4?$/Q]\5_C%I>F^+?AWX3TJ/Q[H_B#3-)\
M!Z5X.DO-4U:\L+"/4M0UJQO=%OW?3[ZPFM/U*\?_ !9^&/PJ_P"$2_X67X_\
M(> O^$]\7Z3X \$_\);K^FZ#_P )7XXU[SO[%\)>'_[2N+?^U?$.J_9Y_P"S
M])L_.O;KR9/)A?8V/R%^"_C'P5^S5_P6$_X*(>&_BQXK\+?#NU_:K^$G[*OQ
MR^$M_P"+_$&D:#I_B?1OA+X-\3_#/QQ;Z?JFL:M;6[ZO9^)I->OWT((VHG1=
M-OM7B@@T?39+B=9;3:CC:RHJI6I8&=7"*I256$JJQ>$HU9QISC*%65+#U:\[
M.,E!Q]HTG!,,;.[PM/VCA3J8J-/$.%1TY*#P^(J4XN<91E!5*T*46U*+DI<B
MNI-'GWA/_@J3\4_@;^RU_P %%4_:'@TKXJ_M&?\ !-_QMHOPYOO%^C^'[3P?
MX=^-EG\5/$">#O@'\0]>\-:-?&S\+7GB'7WFNO'_ (?\.M!8:7H]HDVBR+=W
M<EI997Q?^+'[=?\ P3M^%O[/O[9/[0/[4.H_'[P/XP\9_#7PW^UW\!M7^&?P
MRT7P]\/+'XHV22ZCXB^!GBCP=IGA_7[>?X6:G$V@Z=HVLWVIZ9X]6[BU35FT
MJ0-+!\+?&+X<>)?VL_V9_P#@O[^TI\.=+B\0^ OBI\5O@I_PJ7Q9I<H_L+Q_
MX0_8:UB*Z^('C/PA<_;Y[/Q+X=D\)V>L2Z9X@TJ[N]-\1:A%?0Z3 M]8G2[;
M[@_X*I_M%?#']LW]A+X&? _X >-O!GQ0^(_[<7Q3^ &A>$/ GA+7M*UKQ;::
M*NM67Q"\6ZYJ^A:3K5YJGA/2_ DOAE-+\=ZIJ]O=6O@VZDN-.U[[%<I+>67T
M2PV'CB<-".$P[I8K'0I9K%T:<EAJ3RS+:]>$).#^IQI5Z^8U$Z?LG"5!1NE0
M2CX[KUW1K2EB*JG0PLJF :JSC[>:QV,I4I32DOK+G2I8.#53VBDJS;NZKO\
M1_Q&^*?[2'[6?[>_QE_8Y^!GQM\1?LN_"O\ 9)^&?P]\4?&'XE>"_"_@3Q1\
M0_'WQ7^,6EZ;XM^'?A/2H_'NC^(-,TGP'I7@Z2\U35KRPL(]2U#6K&]T6_=]
M/OK":T]+_P"";_[4_P 5_B[JW[4W[,W[0^KZ9XO^/W[%7Q:MOAMXM^)FA>';
M#PEI/Q:\#^)H=9NOAI\2;GPOIES/I?ACQ/XDL_#6O2>(O#FCHFBZ:8-.EL&#
M7ES9V7@GP7\8^"OV:O\ @L)_P40\-_%CQ7X6^'=K^U7\)/V5?CE\);_Q?X@T
MC0=/\3Z-\)?!OB?X9^.+?3]4UC5K:W?5[/Q-)KU^^A!&U$Z+IM]J\4$&CZ;)
M<3W_ /@EI<S?%C]J3_@JA^UOH4<%_P#";XW_ +07PZ^''PJ\:Z>=_A_X@Z/^
MS;X7\3^!-2\5^$[M;F]M=>\,WMQK-JMCXITN[GTC6[Q=12S^S26%S86?FXBC
M36!Q$?84HT*.691B,)75*$:D\;B7A'BDZZBJE9S]KCE*E*I*,/J\5&*]CIVT
M:E1XJC+VLY5:F-S"CB*3J2E".&H_6/8-4G+DI\O)A6IJ$92]M)MOVKO^UE%%
M%?-'M!1110 4444 %?#/_!3C_E'9^V__ -FM_&W_ -5_KM?<U?#/_!3C_E'9
M^V__ -FM_&W_ -5_KM=&$_WO"_\ 811_].1)G\$O\,OR8G_!OY_RB _8P_[%
MKXH?^KW^*5?L?7XX?\&_G_*(#]C#_L6OBA_ZO?XI5^Q]?T5A_P#=Z'_7FE_Z
M1$_(<7_O>*_["*W_ *<D%%%(Q(5BHW, 2%R!N(' R>!D\9/ ZUL<Y_-E\<KW
M_@K/\/O@!^T!^W[\?/VW_!7[$^N?#5OB7XO^$?[%-UX ^!GQ&^%4O@;P9J&K
M:GX/^%WQ$^)J:MJ&H>._B-\:].T/2]%T;4O!NK/XFT:YUR >'K:QUS6[KP=X
M:]C_ &@?V[OVIOBOX9_X)2? 7]GJZ\*?LW?'7_@J'\,[_P")GC#XK^(_#P\?
M-^SOX4\&?!;PA\8?'5KX$\&ZU<V6C>)O%VI0>(;_ $WPLWB^Y>*VM]';3=4T
M73];\0V>M^&/$OVF_B1_P2D_X*F?LH>/OV@OVF=4?X#_ !H_9BT3X[>&]+\*
M^./C'%X(_:4_9K\<>#==\26-FL_PBT'XCV>C:IXV\3ZOX+TC5-!\*ZOH^NR>
M)=5AL?"EC<WFI:9$]MX9XM\7Z#\>OV"?^".'Q0_;\^+7QC_94_;"\2^*?%6I
M_L^_MSZ5X1\,2^$/A1XTBGO9? LWQ\?QE>Z%HL?AW]HKX8Z#X!\5):2V5O9^
M*]4\/2ZQJVO:/X-L?$3:KG>U[.ZLGOKNEJ^C^[3T _0[X3_&K]IS]CK_ (*&
M?!+]@S]HG]H;4/VOOAK^UK\)O&_BGX"_$KQ7X+^'W@?XN_"SQQ\$?#VL>)/'
M'A+QW'X LM+M/&_A#Q5X7TJ?6-$\;ZWI]OKW]O[/#L8OHM)U?5;S]-_VL?$O
M[0GA']G/XMZ_^RC\.=*^*_[1=IX5EM_A'X&US7_#_AG1M2\6ZG>V>E6VI:KJ
MOBK6/#V@G3_"UM>W7BR\TJ_U[1AX@@T.30+;4[&\U.WN8_YU?@_\#_%?C/\
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MJNE?$-+N+5M8?2)0TUM^?OQM^&'BK]L?]E;_ (.-/VI/AEI,7B3X=_%WXO\
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M453FPT(\L/:T&Y1M7ES24K)1=DTV^965^?$2Q;>'YJ-%6Q$'&U63O+EG9/\
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M"L7_ .$E/R_ZB?7^MZY\;_SXH?\ @Z7_ ,J,GR)_^>,O_?M_\*/(G_YXR_\
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M5*4E:TI4UBN5R5M&TVK*VRO#6)<U5>%PKJ).*J.H^=1>Z4_8\R3ZI.S/D_\
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M^EKB]GEG_05B_P#PDI^7_43Z_P!;]//C?^?%#_P=+_Y49/D3_P#/&7_OV_\
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MHVLW%I//X?U[XDW%SX:\0ZWXG\6Z?>:S]M3Q'#8V6H:7I%K9^$_#W[4? O\
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M_94G"K)MX2A+-K5+N%66-P<<0ZS4OW=3V/U]2^%JG!](1M]J?#Z]\<_L(?\
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MAK?ASPYIOB6*WM;:T%KIFMZ=:W-CIU]#=:?:_LO5+9>B ****8%:]_X\[O\
MZ]I__13UYQ7H][_QYW?_ %[3_P#HIZ\XKYS//XF'_P $_P#TJ)[>5?PZO^./
M_I)ZA1117T9XAXAXPM[B?46,,$TP6>]#&*)Y I,XP&V*<9P<9ZX-<C]@OO\
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M*[_\!IO_ (BC[!??\^5W_P" TW_Q%6_[<U3_ )^O_(%O_P#&:/[<U3_GZ_\
M(%O_ /&:7+E/_/S,?_!&&_\ FCU_I:N^._DPG_@RM_\ *O7^EK4^P7W_ #Y7
M?_@--_\ $5@V/@;1M+UG5O$>F>#],T[Q#KRVZ:[KMCX?M;36=:2T#"U35M4M
M[2.^U%;8,PMUO)YA"&81A<FNI_MS5/\ GZ_\@6__ ,9H_MS5/^?K_P @6_\
M\9II94KI5<Q2:LTJ.&5U=.S_ -HU5U?7K;MJO]M=KPPCL[K]Y5T?=?NM'O\
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MSY7?_@--_P#$4?8+[_GRN_\ P&F_^(JW_;FJ?\_7_D"W_P#C-']N:I_S]?\
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MI)*&$26B2J5DDM-%^ZTZ_AVUJ?8+[_GRN_\ P&F_^(H^P7W_ #Y7?_@--_\
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M?_XS7%RY3_S\S'_P1AO_ )H]?Z6O1?'?R83_ ,&5O_E7K_2UJ?8+[_GRN_\
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M )H]?Z6I?'?R83_P96_^5>O]+6I]@OO^?*[_ / :;_XBC[!??\^5W_X#3?\
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M9C_X(PW_ ,T>O]+7IOCOY,)_X,K?_*O7^EK4^P7W_/E=_P#@--_\11]@OO\
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M>K;HX9MOJVWB/7^EJ)XU))0PB2T252LDEIHOW6G7\.VM3[!??\^5W_X#3?\
MQ%'V"^_Y\KO_ ,!IO_B*M_VYJG_/U_Y M_\ XS1_;FJ?\_7_ ) M_P#XS2Y<
MI_Y^9C_X(PW_ ,T>O]+5WQW\F$_\&5O_ )5Z_P!+6I]@OO\ GRN__ :;_P"(
MH^P7W_/E=_\ @--_\15O^W-4_P"?K_R!;_\ QFC^W-4_Y^O_ "!;_P#QFCER
MG_GYF/\ X(PW_P T>O\ 2U+X[^3"?^#*W_RKU_I:U/L%]_SY7?\ X#3?_$4?
M8+[_ )\KO_P&F_\ B*M_VYJG_/U_Y M__C-']N:I_P _7_D"W_\ C-'+E/\
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M[_\  :;_ .(JW_;FJ?\ /U_Y M__ (S1_;FJ?\_7_D"W_P#C-'+E/_/S,?\
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M+?\ ^,T?VYJG_/U_Y M__C-'+E/_ #\S'_P1AO\ YH]?Z6I?'?R83_P96_\
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MS[?^1KC_ ..T?V+IG_/M_P"1KC_X[1?,/Y,'_P"#:_\ \I"V#_FQ/_@NE_\
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M/_CM']BZ9_S[?^1KC_X[1?,/Y,'_ .#:_P#\I"V#_FQ/_@NE_P#+#&\/>'?
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MYOCI-IJ.H^$KK0O#GA+4+:9=,\(^(K#2K"6Y_0_X8_'7_@HQ^R__ ,$[]/\
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M^1?@+_@IO^S?^TE^W!K/[8W_  4PT7XG^,?"_P /6MX?V8_V9OAUX:T7QO\
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M^R#X0T/P59_ 'X1?LU_%'7OAMK_C'Q-/HTT_C_QC\=]3L-!M[^\O=&\4& ^
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M<TM-/\1V_B>Z\-ZI\ ? ']HU?V9_VA/VMO\ AC_X]_$[]L/]@_X'?L-?$/\
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M*CSJG)-ITXXCV\8V;2LXJR22****\D] **** "BBB@ HHHH W+/_ ) NJ?\
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MH?\ <7_TS4.3'?[K4]:7_IV!S]%%%>>=84444 %%%% !1110!_-?^WY\6/\
M@H!KW[5_[%][XG\(V/[/'['?AW_@J1^SE\%/".G:7X[DOOB1^TOJ>I?$'5IK
M;XB^*+71!"NC_"I?#O@C7$TKP-K:Z5)>W/BNUU._@\:VT.C:IX;_ *4*_'__
M (*\_P#.,#_M,!^Q5_[TNOT'\?\ [2_P<^&/QG^"7[/_ (S\37.E_%/]H?\
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MV=K_ (<\.:9XI_LSQ!KT<,NG_P#"5:3JB6DZVEU;Z5*GYN_MC?ML_P#!//\
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M 'T/\*/^$K_J8?\ EL'^W?\ 4)_Y6\O^#^'F']E:C_SYS?\ ?(_QH_LK4?\
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M !H_M74?^?R;_OH?X4?VKJ/_ #^3?]]#_"C_ (2O^IA_Y;!_MW_4)_Y6\O\
M@_AYF!J'P^T?5M:T?Q)JG@[1=2\1>'A<#P_KVH:)IMYK6AB\0QW8T?5+FWDO
MM,%U&2EP+*>#ST)67<O%;<VB7EQ%+!/I[3P3QO#-#-$DD4T4BE)(I8WW))'(
MC%'1U*NI*L""15&^\70:8\<>I>(;/3WE4O$E]J%K:/(BG:6C6XDC+J#P64$
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MF_[Y'^-']JZC_P _DW_?0_PH_M74?^?R;_OH?X4?\)7_ %,/_+8/]N_ZA/\
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M7>%FBD570JP!K9BT6]ACCAAL'BAB1(HHHHUCCBCC4*D<:+A41% 5$4!54
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M_P#/G-_WR/\ &MK1K&[@^V^=!)'YEJR)N &YCG"CGK6+_:NH_P#/Y-_WT/\
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M_?(_QH_M74?^?R;_ +Z'^%']JZC_ ,_DW_?0_P */^$K_J8?^6P?[=_U"?\
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M&:2";[-JL^B>#;GPM9ZE;^1J6B3>)DUW1KRRUC3+&\@_=#QK_P A'_MO??\
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MU&"YT>YTJ&&[ET.776<2>SS^+)?^"F/[:7[!_P &/CE8:?JOP!B_X)L^!_\
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MQY(>WC&K[9J+4??]F\/&H[7YHVD^:+2****\(]0**** "BBB@ HHHH W+/\
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MOH^FQR06?B?4K'YTT;]A[XW_ +7?[&W_  5;^*WBKP;XN^&_Q+_X*$^.=/\
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M]=^Q>+[/XD>+;[2-5U0R1WM[HTK2Q^&;G2+(&>V]2_9A_9N^$/\ P4T^-/\
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MW\;?_5?Z[71A/][PO_811_\ 3D29_!+_  R_)B?\&_G_ "B _8P_[%KXH?\
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M=J^NN]JF$=G9VA5=GIH_WNC\GY=]+?\ 8>J?\^O_ )'M_P#X]1_8>J?\^O\
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M_P#QZJGV^^_Y_;O_ ,"9O_BZ/M]]_P _MW_X$S?_ !='-E/_ #[S'_P?AO\
MYG]?Z>A;'?SX3_P76_\ EOK_ $]+?]AZI_SZ_P#D>W_^/4?V'JG_ #Z_^1[?
M_P"/54^WWW_/[=_^!,W_ ,71]OOO^?V[_P# F;_XNCFRG_GWF/\ X/PW_P S
M^O\ 3T+8[^?"?^"ZW_RWU_IZ6_[#U3_GU_\ (]O_ /'J/[#U3_GU_P#(]O\
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MZ.;*?^?>8_\ @_#?_,_K_3T+8[^?"?\ @NM_\M]?Z>EO^P]4_P"?7_R/;_\
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MNM_\M]?Z>EO^P]4_Y]?_ "/;_P#QZC^P]4_Y]?\ R/;_ /QZJGV^^_Y_;O\
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M_P 71S93_P ^\Q_\'X;_ .9_7^GH6QW\^$_\%UO_ );Z_P!/2W_8>J?\^O\
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M9_7^GH6QW\^$_P#!=;_Y;Z_T]+?]AZI_SZ_^1[?_ ./4?V'JG_/K_P"1[?\
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MB]EF-W:R]MAM;VM;_9];].^G?0MC?Y\)IO\ NZVG?_E[Z_T]-;^P]4_Y]?\
MR/;_ /QZC^P]4_Y]?_(]O_\ 'JSK?6)[N"&ZM-4ENK6YB2>WN;>]>:">&50\
M<T,T<K1RQ2(0Z2(S(ZD,I((-5+3Q/;ZA=:A8V'B&&]OM)E2#5;.TU9+FZTR>
M5/,CAU"WAN'FLY9(_P!XD=RD;NGS*I7FB^5:_NLQTW_?8;35+7_9]-=->MN^
MA;&Z>_A-=OW=;7KI^]UTN_E]VY_8>J?\^O\ Y'M__CU']AZI_P ^O_D>W_\
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M3-_\71]OOO\ G]N__ F;_P"+HYLI_P"?>8_^#\-_\S^O]/0MCOY\)_X+K?\
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MEF-W:R]MAKN]K6_V?6_3OIWT5L;_ #X3_P %UNF__+WIK]WW:W]AZI_SZ_\
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M_B36=*US1/$OCG3/!>K74-]KUSJ'BW2]>AD\7:5>731>*9/"=]X;T+4]%O\
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MZ)XF\<Z#XET+7_"_A?PG>C4=:UC3["SUI?$L%R(HUT36=,T3Q!IGY1_\$O\
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M)4\M>"<XMUH0C67M%&33Y)0CS/%*\9.FU[;W6K_T!4445\,?4!1110 4444
M%%%% !70:#_S$/\ KS?^M<_70:#_ ,Q#_KS?^M>AE7^_T/\ N+_Z9J')CO\
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MIB_==JE.:R;W7^[J?6\0T\.N6U/WGAJD;<MJ"@U:G%M?TL4445\$?5A1110
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MG_A1.D_M/_!/5/C#_:U]X>_X5UIWQ/\ "U[XH_X233+BXM-2\+_V=;:K*_\
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MQ_\ &CVF6?\ 0+B__"NGY?\ 4-Z_UL<F-_Y_T/\ P3+_ .6FM_PC^I?W(O\
MOZM'_"/ZE_<B_P"_JUD^?/\ \]I?^_C_ .-'GS_\]I?^_C_XT>TRS_H%Q?\
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MQ_\ &CVF6?\ 0+B__"NGY?\ 4-Z_UL<F-_Y_T/\ P3+_ .6FM_PC^I?W(O\
MOZM'_"/ZE_<B_P"_JUD^?/\ \]I?^_C_ .-'GS_\]I?^_C_XT>TRS_H%Q?\
MX5T_+_J&]?ZV.3&_\_Z'_@F7_P M-;_A']2_N1?]_5H_X1_4O[D7_?U:R?/G
M_P">TO\ W\?_ !H\^?\ Y[2_]_'_ ,:/:99_T"XO_P *Z?E_U#>O];')C?\
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M-Z_UM7)C?^?]#_P3+_Y::W_"/ZE_<B_[^K1_PC^I?W(O^_JUD^?/_P ]I?\
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M>?/_ ,]I?^_C_P"-<?M,L_Z!<7_X5T_+_J&]?ZVWY,;_ ,_Z'_@F7_RTUO\
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M_P!_'_QH\^?_ )[2_P#?Q_\ &CVF6?\ 0+B__"NGY?\ 4-Z_UL<F-_Y_T/\
MP3+_ .6FM_PC^I?W(O\ OZM:VE:5=VGVOSE0>=;M&FUPV6.<9QT'O7)^?/\
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M_P ]I?\ OX_^-'GS_P#/:7_OX_\ C1[3+/\ H%Q?_A73\O\ J&]?ZV.3&_\
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M_+36_P"$?U+^Y%_W]6C_ (1_4O[D7_?U:R?/G_Y[2_\ ?Q_\://G_P">TO\
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MB_[^K1_PC^I?W(O^_JUD^?/_ ,]I?^_C_P"-'GS_ //:7_OX_P#C7)[3+/\
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M (1_4O[D7_?U:/\ A']2_N1?]_5K)\^?_GM+_P!_'_QH\^?_ )[2_P#?Q_\
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M5O%4VE+VD+-I8=-I/5I-76EU=64H8SEE>M0MRN_[F6UO^OIZA_P2<^!/C_\
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MMO\ T;'6'6Y9_P#(%U3_ *Z6W_HV.L.N_&_P<N_[ O\ W:Q)S8?X\5_V$O\
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M_:K\0?';]F#]FKQ;^U/\ OC!^S5\#_@[\1_!W@[QKX/T?XJ>"_B%^SAH-O\
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MYO!J*AR^\Y7M9WO:Q"K-S5-9GA'-RY5!0I.;E=+EY5B+\S>EK7N[6O8^]/\
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MEW_0OK?^%[_^9OZN_*Q[+%_]!5/_ ,)E_P#+OZN_*W0_\(U??\];3_OY-_\
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M_P#&*YZBN+V^7?\ 0OK?^%[_ /F;^KORMT^RQ?\ T%4__"9?_+OZN_*W0_\
M"-7W_/6T_P"_DW_QBC_A&K[_ )ZVG_?R;_XQ7/44>WR[_H7UO_"]_P#S-_5W
MY6/98O\ Z"J?_A,O_EW]7?E;H?\ A&K[_GK:?]_)O_C%'_"-7W_/6T_[^3?_
M !BN>HH]OEW_ $+ZW_A>_P#YF_J[\K'LL7_T%4__  F7_P N_J[\K=#_ ,(U
M??\ /6T_[^3?_&*/^$:OO^>MI_W\F_\ C%<]11[?+O\ H7UO_"]__,W]7?E8
M]EB_^@JG_P"$R_\ EW]7?E;H?^$:OO\ GK:?]_)O_C%'_"-7W_/6T_[^3?\
MQBN>HH]OEW_0OK?^%[_^9OZN_*Q[+%_]!5/_ ,)E_P#+OZN_*W0_\(U??\];
M3_OY-_\ &*/^$:OO^>MI_P!_)O\ XQ7F7CGQYX(^&/A/6_'GQ'\7^&O 7@GP
MW:"^\0>+O&&MZ;X<\.:+:&6.W2XU/6=7N;33[*.2XFAMH3/<)YUS-#;Q!YI8
MT;C/@U^T#\#?VB/#]YXJ^!/Q<^'GQ=\/Z;>KINJZG\/O%FB^*(='U)X5N8]-
MUI-)N[F?1M1DMG2ZCL=4BM+N2UDCN4A:"1)&T4\$Z;JK*\2Z49*,JBQDW3C)
MVM&4UA>52?1-IN^G0CEQ"FJ;QM'G:YE!T(\[BMY*/MKM:.[2MO\ +Z _X1J^
M_P">MI_W\F_^,4?\(U??\];3_OY-_P#&*YZBL_;Y=_T+ZW_A>_\ YF_J[\K7
M[+%_]!5/_P )E_\ +OZN_*W0_P#"-7W_ #UM/^_DW_QBC_A&K[_GK:?]_)O_
M (Q7/44>WR[_ *%];_PO?_S-_5WY6/98O_H*I_\ A,O_ )=_5WY6Z'_A&K[_
M )ZVG_?R;_XQ1_PC5]_SUM/^_DW_ ,8KGJ*/;Y=_T+ZW_A>__F;^KORL>RQ?
M_053_P#"9?\ R[^KORMT/_"-7W_/6T_[^3?_ !BC_A&K[_GK:?\ ?R;_ .,5
MSU%'M\N_Z%];_P +W_\ ,W]7?E8]EB_^@JG_ .$R_P#EW]7?E;H?^$:OO^>M
MI_W\F_\ C%'_  C5]_SUM/\ OY-_\8KGJ*/;Y=_T+ZW_ (7O_P"9OZN_*Q[+
M%_\ 053_ /"9?_+OZN_*W7Z;HEW9WD5Q+);LD8DR(WD+G?&Z# :)1U89RPXS
MU/%5)/#E\\DCB6UP[NPR\V<,Q(SB C.#SR:I:%_R%+;Z3?\ HB6LV?\ U\W_
M %UD_P#0VKLG6P'U&@W@:K@\5B%&'UQIQDJ6&<I.?L-5-.*Y>5<O*VF^:RYH
MT\3]:J+ZS#F5"DW+ZNK.//4LN7VNC33;=]>:UE9,W/\ A&K[_GK:?]_)O_C%
M'_"-7W_/6T_[^3?_ !BN>HKC]OEW_0OK?^%[_P#F;^KORMT^RQ?_ $%4_P#P
MF7_R[^KORMT/_"-7W_/6T_[^3?\ QBC_ (1J^_YZVG_?R;_XQ7/44>WR[_H7
MUO\ PO?_ ,S?U=^5CV6+_P"@JG_X3+_Y=_5WY6Z'_A&K[_GK:?\ ?R;_ .,4
M?\(U??\ /6T_[^3?_&*YZBCV^7?]"^M_X7O_ .9OZN_*Q[+%_P#053_\)E_\
MN_J[\K=#_P (U??\];3_ +^3?_&*/^$:OO\ GK:?]_)O_C%<%XG\3>'?!7AK
MQ#XR\7ZWI?AGPGX2T/5O$WB?Q'KE[;Z;HOA_P[H-A<:KK6MZQJ-W)%:Z?I>E
M:;:7-_J%[<RQV]K:6\T\TB1QLP^._P#AYA_P3S_Z/9_9?_\ #U^ ?_EY6U)8
M6LFZ.48NLHM*3I8JI42;M9-PPKLWV??3I;*;K4FE4Q^'IMJZ4Z,(-JZ5TI5U
M=7TTZOTM^@/_  C5]_SUM/\ OY-_\8H_X1J^_P">MI_W\F_^,5P7ACQ-X=\:
M^&O#WC+PAK>E^)O"?BW0])\3>&/$>AWMOJ6B^(/#NO6%OJNBZWH^HVDDMKJ&
MEZKIMW;7^GWMM+);W5I<0SPR/'(K&AXZ\=>#_AEX-\3?$+X@^)-)\(>"/!NB
MW_B+Q3XGUV[CL=)T31=,@>YOK^^N92%2*&)"0BAY9I"D$$<L\D<;9JK@')06
M6UW-RY5#Z[+F<KI<O+]6OS-Z6M>[M:]K7R8E1YGC*7*ES<SP\>7EM?FO[:UK
M:WO:S;[6],_X1J^_YZVG_?R;_P",4?\ "-7W_/6T_P"_DW_QBO*=$^(_@/Q%
M\.]'^+FD>+-"N/AEKW@O3OB+I?CJ>_AL/#4_@75=$A\2V'BN74]0:UM[/1)M
M N(M7:^O6MH;>Q8SW)A1'*^=?!C]J;]FS]HN?7K3X#_'?X3_ !>O?"^QO$6G
M_#WQWX=\4ZCHL$T\EM;7VHZ?I.H7-[:Z9>W$,T6GZK) NG:@\4HLKJX\M\7S
M8/EJ2_LK%.-)J-67UNIRTY-V2J/ZK:#;35I-.]TM=E:O>$?KU'FJ*\%["-YI
M)-N"]M>2MJW&ZL[]CZ;_ .$:OO\ GK:?]_)O_C%'_"-7W_/6T_[^3?\ QBOE
MSXP_M8_LQ?L^:UX?\.?'/]H#X0?"+7O%,)NM!T?XB?$'PSX2U#4+ 32VQU5+
M76M2M)8-&6Y@FM6UFZ6#2ENHGMFO!.IC'O-E>V>I6=IJ.G7=M?Z??VT%[8WU
ME/%=6=[9W423VMW:74#R07-M<P2)-!/"[Q31.DD;LC E2G@H0A4EE>)C"I?V
M<Y8R<83Y6D^23PJ4K/1\K=F^FEA1Q$I2C'&T92A;GBJ$7*-]5S)5KQNM5=*]
MW;I;JO\ A&K[_GK:?]_)O_C%'_"-7W_/6T_[^3?_ !BN>HK/V^7?]"^M_P"%
M[_\ F;^KORM?LL7_ -!5/_PF7_R[^KORMT/_  C5]_SUM/\ OY-_\8H_X1J^
M_P">MI_W\F_^,5SU%'M\N_Z%];_PO?\ \S?U=^5CV6+_ .@JG_X3+_Y=_5WY
M6Z'_ (1J^_YZVG_?R;_XQ1_PC5]_SUM/^_DW_P 8KGJ*/;Y=_P!"^M_X7O\
M^9OZN_*Q[+%_]!5/_P )E_\ +OZN_*W0_P#"-7W_ #UM/^_DW_QBOF_]L/\
M9Z\:?M!_LI_M%_ SP9J?A?3/%OQ=^#'Q$^'7AO4?$][JUEX=L=;\7>%]2T33
M;K7+O2M$UK4[;2H+J\BDOI[#2-3NX[=9'@L;F0+$WM]?#/\ P4X_Y1V?MO\
M_9K?QM_]5_KM;X:OE[Q.'4<!5C)UZ2C)XUR49>TC:3C]77,D]6KJ^JNM&IE2
MQ?+*^*A\+_YAEV_Z^_U?T/=_^"7O[//C3]B?]A#]G[]E_P"*FI^%]?\ '_PH
MTCQEI_B+5_A_>ZMJO@^]F\0_$KQGXRLFT74/$>B>%-:N(HM,\164%TU]X?TY
MTOXKJ*))[=(;J?[Y_P"$BLO^>5U_WQ%_\?K\CO\ @W\_Y1 ?L8?]BU\4/_5[
M_%*OV/K]PH4L6Z-%QQ=.,72IM)X5-I<BLF_;*]EI>ROO9'YGB9X=8G$*5"<I
M*O54I*NXJ4E4E>2C[-\J;N[7=KVN]S!_X2*R_P">5U_WQ%_\?H_X2*R_YY77
M_?$7_P ?K>HK7V6-_P"@RG_X2+_Y<8>TPO\ T#3_ /"A_P#RHP?^$BLO^>5U
M_P!\1?\ Q^C_ (2*R_YY77_?$7_Q^MZOEZU_;<_8\O?C+??L\6W[4'P&?XYZ
M?J]OX=N/A2_Q3\&P^.&\37-S/:+X5L] FU>.^U'Q9%<VTD5YX6T^.Z\0:>QA
M-]IUNMS;F4]EC/\ H,I_^$J_^7A[3"_] T__  H?_P J/9(+;P7;>*-3\;VW
MAC38/&6M:#HGA;6/%D.CZ9%XDU3PUX:U#7]5\.^'M1UM-NI7FB:%JGBOQ/J.
MCZ7<7,EEIM]XAUNZM((9]4O7FW_^$BLO^>5U_P!\1?\ Q^MZOEWXY?MM_L@_
MLS^(-$\)?M ?M*?!?X0>*?$44=SI/AOQY\0/#N@:[/83&=(M7GTF\ODO]/T.
M66VG@CUW48+31WN8GMEOC<#RJ/98S_H,I_\ A*O_ )>'M,+_ - T_P#PH?\
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MX&_ WPI_PF_Q2\;_ /"J/^$7\+_V[X:\-?VI_P (U\;OAMXOUO\ XG?B_6=
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M:Z18WFM^(M5T72M-TBWNITU#7+E]02]71K._&DVVH:LUCI]U_,+XI_X+.?\
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MQXBU:;X=^)_&<4WB59]#TJ]UW7_#MIXAFTB#3=>O)/?4\(?M5_\ !0K]K/\
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MK$7ZZ?&K]I/QC\*_VG_V0?@-I7POL?%/A3]IS5?B]HNN?$&3QO8:1J7P_O\
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MUMIB)IEM+#*\#RPN)I@^(1@D'-'^HV3+=5/_  95\O\ I[Z_AVU/]:\5_P!
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M[9W_ (3TO_S-T?\ $0S>_P#2-+]L[_PGI?\ YFZ_KNHK/_4;)^U7_P &5?\
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ME::/H'AW0-'M);[5-8UC5+Z6&SL-.L+.&6YNKJYECBABC9F8 4?ZC9-VJ?\
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M_P#@RK_\M]?Z6I_K7BO^@>'_ (&O_E1_(C_Q$,WO_2-+]L[_ ,)Z7_YFZ/\
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M9T.X\&>(-)\76=BSGPSKUC/H.I/'JUK?6EH?ZC9-VJ?^#*OE?_E[Z_AVU/\
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M^6__ (B8_P#K%_\ ML?^"7_\&J/^(F/_ *Q?_ML?^"7_ /!JOZD*0D $D@
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M]Q':Q1L9I9DB5G Z>(5KXK_RA#R\_7[_ "#V^"_Z /\ RZJ__(GP'_Q$Q_\
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MLOAR[.E#PC?7%KK.EP:OIUC.!)[6=_==]+65NOR>@'['44458!1110 4444
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M^VO+E/#\_B*/2XM;EL!:7EH4;4H]%TI+GS#(&%C#M"X;=^6_P[_X(?\ [/\
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M'?''Q#USXC_M8:I\)= U.T\!:-<Z)XDT"TLO#OA[7=8DT^_^+T.LP:/>:EJ
MFU7P3/IOV>SL(OZ'ZJ.[=K7MIZ( HHHJ@"BBB@ HHHH R=;_ .0;-_O0_P#H
MU*T8/]1#_P!<H_\ T!:SM;_Y!LW^]#_Z-2M&#_40_P#7*/\ ] 6N2'^_5O\
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M3INC^'?"D7B3Q!;>'=/MK6?5(;'4S9ZQKNMK8Z<]I_4G7YZ_M&_LF_$;XO\
M[>W_  3>_:E\-:UX*L?A_P#L>_\ #8/_  LS1]<U'7;;QCKG_#07P9T/X=^#
M/^$%T^P\-ZGHFI_V9K>F3W7B?^W_ !#X8^Q:6\,^E?VU=L]C'L_'_P"-WQ^\
M$?MI_L*?!;X:67P]U7X2_',_M#7?QUM]6T3Q;J?Q&\/>&_A7\/-/\0:#XU\-
MZEI,T'A;PWX2M/&6L>%_!/B/4_$PNYKSQ)X^\$:'I-GYFJ7-]9):7TTNK?-)
M?F!\W?\ !9O]HOXF?#+]GOP!^S;^SOJL>G?M0_MY_%?P]^RW\(;R*]>UU+PE
MH_C&2.W^)WQ-C^SP3WUMIGA'PS=P:+?^([!K:Z\%7_C31?%T=U$^CJ'^/_\
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M=/U*P?6_"U]>PV.K3:-9^(9]<M-&U:^TRUL)TU?F[Z)7[*S_ !=_^ !\%?\
M!8FQ?P[^TW_P1=^*OA35AHOQ)TC_ (*,_#SX36<FG2BUUV^^%OQC%AI/Q=T^
M.6*[@N)?#UWX<T2WT3Q!;?9KFVDL_$'V:>6W2\:WU#0_X(Q:59^)?B%_P5^^
M*WB:&.]^)'BS_@JA^T7\+/$]UJ=R-5UA/A]\(+?0;/X:^#[R[DE=;GP_X1M/
M&/B;1/#UNMK#:P6:W5O TD")#;:7@G]E3]O?]K+]K/\ 9P^.W_!1/P[^SC\-
MOAK^Q;<>+O%WPI^&O[/?C/QOXLD^*?Q\URV\/Z5IWQ0\5OXJTU8-*\!>%K33
MKS7/ 6A?;K3QCI/B 1V^N_VII=[>EJOBK]F'_@H[^R7^T?\ M6?$7_@GQI'[
M+GQ'^$'[9WC71?BMK'@?X\^*?B%X4U7X%_'N]T"'0?'OQ'M$T&"^L?&G@KQG
M>6D/BOQ-IEI?6WB:74&T[1=#TK3]-T![CQ =5*SM=^NJ2O;U6OWH#+_X-]K>
MY\._LT?M:?"^QUM]:^'?P6_X*/?M5_"SX.&*Y-QHVG_#+16\!ZQ86GAI1>7\
M-OH=YXEU_P 4Z[##;74T#WVL7]T)KB2YDN9OWBKX7_X)R_L9V?["?[*O@GX'
MW/B%O&OQ NK_ %KXC?&KQ\9IYU\=?&?QY<1ZMX]\06DMS9Z?<R:/%?"#0O#D
MEY86FI2^&]%TB;5XFU>2_FE^Z*I:)>B ****8!1110 5\ _\%6?^49_[>_\
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MDDM$MD8/]K7O_0&NOSE_^1:/[6O?^@-=?G+_ /(M;U%5[#%?]!U3_P $8?\
M^5D^VH?] D/_  ;6_P#DS!_M:]_Z UU^<O\ \BT?VM>_] :Z_.7_ .1:WJ*/
M88K_ *#JG_@C#_\ RL/;4/\ H$A_X-K?_)F#_:U[_P! :Z_.7_Y%H_M:]_Z
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M_!&'_P#E9/MJ'_0)#_P;6_\ DS!_M:]_Z UU^<O_ ,BT?VM>_P#0&NOSE_\
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MO_0&NOSE_P#D6C^UKW_H#77YR_\ R+6]11[#%?\ 0=4_\$8?_P"5A[:A_P!
MD/\ P;6_^3,'^UKW_H#77YR__(M']K7O_0&NOSE_^1:WJ*/88K_H.J?^",/_
M /*P]M0_Z!(?^#:W_P F8/\ :U[_ - :Z_.7_P"1:/[6O?\ H#77YR__ "+6
M]11[#%?]!U3_ ,$8?_Y6'MJ'_0)#_P &UO\ Y,P?[6O?^@-=?G+_ /(M']K7
MO_0&NOSE_P#D6MZBCV&*_P"@ZI_X(P__ ,K#VU#_ *!(?^#:W_R9@_VM>_\
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M:]_Z UU^<O\ \BT?VM>_] :Z_.7_ .1:WJ*/88K_ *#JG_@C#_\ RL/;4/\
MH$A_X-K?_)F#_:U[_P! :Z_.7_Y%H_M:]_Z UU^<O_R+6]11[#%?]!U3_P $
M8?\ ^5A[:A_T"0_\&UO_ ),P?[6O?^@-=?G+_P#(M']K7O\ T!KK\Y?_ )%K
M>HH]ABO^@ZI_X(P__P K#VU#_H$A_P"#:W_R9@_VM>_] :Z_.7_Y%H_M:]_Z
M UU^<O\ \BUO44>PQ7_0=4_\$8?_ .5A[:A_T"0_\&UO_DS!_M:]_P"@-=?G
M+_\ (M']K7O_ $!KK\Y?_D6MZBCV&*_Z#JG_ ((P_P#\K#VU#_H$A_X-K?\
MR9RDUU>RWEM=_P!EW2_9U<>7ME._>&&=_P!G&W&[^ZV<=JN_VM>_] :Z_.7_
M .1:WJ*B.$KP<Y1QM1.I+GF_8T'>7+&-]8.WNQBK*RTO:[;*EB*4E%2PL&H1
MY8_O:JM&[E;22OJV[N[UWL8/]K7O_0&NOSE_^1:/[6O?^@-=?G+_ /(M;U%7
M[#%?]!U3_P $8?\ ^5D^VH?] D/_  ;6_P#DS!_M:]_Z UU^<O\ \BT?VM>_
M] :Z_.7_ .1:WJ*/88K_ *#JG_@C#_\ RL/;4/\ H$A_X-K?_)F#_:U[_P!
M:Z_.7_Y%H_M:]_Z UU^<O_R+6]11[#%?]!U3_P $8?\ ^5A[:A_T"0_\&UO_
M ),P?[6O?^@-=?G+_P#(M']K7O\ T!KK\Y?_ )%K>HH]ABO^@ZI_X(P__P K
M#VU#_H$A_P"#:W_R9@-JEVZLCZ+<NC*596$K*RL,,K*;4@J02""""#@\4O\
M:U[_ - :Z_.7_P"1:WJ*/88K_H.J?^",/_\ *P]M0_Z!(?\ @VM_\F8/]K7O
M_0&NOSE_^1:/[6O?^@-=?G+_ /(M;U%'L,5_T'5/_!&'_P#E8>VH?] D/_!M
M;_Y,P?[6O?\ H#77YR__ "+1_:U[_P! :Z_.7_Y%K>HH]ABO^@ZI_P"",/\
M_*P]M0_Z!(?^#:W_ ,F8/]K7O_0&NOSE_P#D6C^UKW_H#77YR_\ R+6]11[#
M%?\ 0=4_\$8?_P"5A[:A_P! D/\ P;6_^3,'^UKW_H#77YR__(M']K7O_0&N
MOSE_^1:WJ*/88K_H.J?^",/_ /*P]M0_Z!(?^#:W_P F8/\ :U[_ - :Z_.7
M_P"1:/[6O?\ H#77YR__ "+6]11[#%?]!U3_ ,$8?_Y6'MJ'_0)#_P &UO\
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M[6O?^@-=?G+_ /(M;U%'L,5_T'5/_!&'_P#E8>VH?] D/_!M;_Y,P?[6O?\
MH#77YR__ "+1_:U[_P! :Z_.7_Y%K>HH]ABO^@ZI_P"",/\ _*P]M0_Z!(?^
M#:W_ ,F8/]K7O_0&NOSE_P#D6C^UKW_H#77YR_\ R+6]11[#%?\ 0=4_\$8?
M_P"5A[:A_P! D/\ P;6_^3,'^UKW_H#77YR__(M']K7O_0&NOSE_^1:WJ*/8
M8K_H.J?^",/_ /*P]M0_Z!(?^#:W_P F8/\ :U[_ - :Z_.7_P"1:/[6O?\
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M_P#)F#_:U[_T!KK\Y?\ Y%H_M:]_Z UU^<O_ ,BUO44>PQ7_ $'5/_!&'_\
ME8>VH?\ 0)#_ ,&UO_DS!_M:]_Z UU^<O_R+2?VI=E@YT6Y+JK*K8EW!6*EE
M#?9<A6*(6 ."44G)48WZ*/88K_H.J?\ @C#_ /RL/;4/^@2'_@VM_P#)F#_:
MU[_T!KK\Y?\ Y%H_M:]_Z UU^<O_ ,BUO44>PQ7_ $'5/_!&'_\ E8>VH?\
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M>_\ 0&NOSE_^1:WJ*KV&*_Z#JG_@C#__ "LGVU#_ *!(?^#:W_R9@_VM>_\
M0&NOSE_^1:/[6O?^@-=?G+_\BUO44>PQ7_0=4_\ !&'_ /E8>VH?] D/_!M;
M_P"3,'^UKW_H#77YR_\ R+1_:U[_ - :Z_.7_P"1:WJ*/88K_H.J?^",/_\
M*P]M0_Z!(?\ @VM_\F8"ZI=J,+HMRH+,Q"B4 L[%W; M0-SNS,QZLQ+'))-+
M_:U[_P! :Z_.7_Y%K>HH]ABO^@ZI_P"",/\ _*P]M0_Z!(?^#:W_ ,F8/]K7
MO_0&NOSE_P#D6C^UKW_H#77YR_\ R+6]11[#%?\ 0=4_\$8?_P"5A[:A_P!
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
A110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>ny20077604x1_figure08x2.jpg
<TEXT>
begin 644 ny20077604x1_figure08x2.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
M                                                          !8
M65H@        ]M8  0    #3+71E>'0     0V]P>7)I9VAT($AE=VQE='0@
M4&%C:V%R9"P@,C P- !S9C,R       !#$0   7?___S)@  !Y0  /V/___[
MH?___:(   /;  # =?_; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! ?_  !$( DH$U ,!(@ "$0$#$0'_Q  ?   !!0$!
M 0$! 0           0(#! 4&!P@)"@O_Q "U$  " 0,# @0#!04$!    7T!
M @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F
M)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
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M"7^DV/[07_!;+Q=\<O@'X47P[\"_!_C7]H3XF?\ $ETUM!TC2/AWXM\/^-_
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M7P>\9ZC\6]]N]EJ*>)OCOX;O5U*TU6-A*8]7\'>&]6T/P5)-'&2!X4MY51I
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MA.;:<(8G_!3_ (-IO^3/_C=_V<GJW_JK_AG7[/?MF?\ )G_[5O\ V;9\=/\
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MN%;FWU3Q++!HNGRPV3W<B7EY-&;<J);5A>+;U_+A_P %,O\ @GW\3?V*-"^
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MPQ_T9KKW_A\]/_\ G4U_0G^V9_R9_P#M6_\ 9MGQT_\ 57^*:_E:_P"#>O\
M:;_9]_9MLOVRM0^//QA\!?"F#Q%%\ )O#L?C+Q!9Z3>^(D\/_P#"[/[;'A[3
M97.HZY+I7]M:1]N@TJUNY[?^TK+S(Q]HBW"2Y6VKN]MWY?Y@DN5MJ[O;=^7^
M9^E'[,G_  <0_LT?&CX@Z%\/?B[\-_%'[.[^)]3CTG1_&^L^*M$\8?#K3[N>
M-OL9\9>(%L/"NI>%K2]O!%IZ:J= U/1=/FN8;W7]3T;1HK[4[+[+_P""E_\
MP4OTS_@G)IGP>U+4O@]??%H?%J^\;V4,-EXWM_!9T(^"[?PM.\DCS^%O$XU
M:@/$ZJJ*MG]F^QL2T_G@1?RF_P#!8OXL?L7_ +0W[1GP[UK]AO1-*U>^U3PK
M)I_Q*UKP!X#UCP9I'CCQUJ_B2=] M[3PK>>&/#FHZUXR6&YF36?$=OIUW)XA
M_M30],6YN;S19E'WO_P7\T?QCX>_9B_X)E^'_B(&7X@Z'X#\6Z/XZ#S6ERX\
M8Z9\/O@A9>)PUQ8%K&=AK<%\&FLB;24Y>W)A9#3Y5>.C5[W3\E]X^57CHU>]
MT_)?>>MK_P '//A;<-W[&VOA<C<5^.6G,P7/)"GX5J&('(!903P6'6OV9_8/
M_P""E_[.G[?VBZNGPQO-6\)_$CPO:+?^*_A)XV&GVOB_3]),EI:GQ-HSZ=>7
MNG^)O"7]HWD&G/K&G3+=:;>3V,'B'2M#EU;1X[_M/V.O!/@WXA_\$]OV/_"/
MC_PEX9\<>%-7_9(_9UM]5\,^+]"TOQ)X?U.!O@]X05H;_1]9M;W3KR,JS I<
M6\BX)XY-?R<?%GPQIW_!.?\ X+C^$;+X+&X\ _#:3XR?!_4+;2H\S:=;_##X
MUVOAFT^)WA6VMQ#.K^';<>(?&>C^'[9K:YN-%M[#2);0RZGI%K>4DE*]E9I7
M6M[_ 'B24KV5FE=:WO\ >?OU^WQ_P5ZU'_@G]\<] ^&'Q&_98\2>*? /B[2M
M,\0^$?BQH'Q+L;2#Q%H@DM;/Q=%9^&[WP0UM'XF\(:E)/;W7AR?Q6C7-G<>'
M=5N-0TNS\26C0?HQ\0?VK/@C\._V9]6_:WU/QA9ZG\%+'P!:?$33/$>D,COX
MGTG6+:VD\,:;H-O?26)EU_Q3J%_IN@Z-I-\]A.==U&VTZ_-C*)_)\*_X*5?L
M/^'?V[OV9O$_PT>WTZT^*'AN.Z\7_!3Q5>Y@.A>/K"TD%OI5[?1@RP>&?&5L
M&\->)4>.\MK:WN[3Q"FG7FK>'=',/\(FA?$']JCXP>$OA-_P3>L]<O;OPWIW
MQ]O;?P3\-]1NX+2&Q^)_C/58/"JZ5J.K2S26]KH&AZ_>^(M3M+5&CT[3=6\6
M^+]:N&NY+V![,45)*VC3UWU7?U!14DK:-/7?5=_4_M*_X)O?\%0_$?\ P43\
M3>/;?0OV8=5^%WP]^'6E6<FO_$?5?BC:>)K.7Q1J\X&B>#]+T:+P)X?FU#4;
MS3X-4U?4+J&_^S:)8V-M_:(2?6M&AO/USKY8_8P_91\!_L7?L\> _@-X#CAN
M5\/V?]H^,?$XM$M+WQUX_P!5B@D\5>,=24&2;S-2O(4M=*M;FXO)=&\-Z?H?
MAZ*[FM-'MFKZGJ7:^BLB7:^BLC\T_P#@H=_P4-A_8F/P2\%>"?AHGQT^/'Q]
M\>6GA'P%\([7Q2?"U]=:=-+%I;ZY+J$.A>(WBDN_%.J^&_#6A:?<V-HFM7>I
M:G<6M_L\.ZC"?N?QG\2_"WPD^&>J?$[XT>)/#'P]\-^$O#]MK'CK7[W59/\
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M]X?\4Z7I#S/#_I=M%XHU#QL]F)KBXEM+&6WTM([;3K'3XBFDUS);.S73_/\
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ME231P:3I]EI5K!I:_57[%?\ P2$_9%_8>\9-\3O -EXT^(/Q4BM+ZPT7Q_\
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MO"/_ *F$E?V):A91:C87NGSM(D-_:7-E,T1595BNH7@D:-G21!($D)0LCJ&
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M75[;5;::_*Q@PG5-+U^]FOG=S;)>-&9%6V6./^PT#  ))( &3C)]S@ 9/4X
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M?O)MO\SSS]CC]L;]DGP#^P_^RA9^-/VGOV?_  SJ/A+]EKX"Z;XETC6/C!X
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M\1/#V@QQ'P@OP_30O%OA'PGH7A:]N-3\[QJ=6M=,UG7[FS&GZ<;^+21<6O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MWXD_%/X>^+/C!\9_C?\ %?3+?0?%_P 9_CSXITOQ;XX;PY!=VM^_A[2[G2=
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M.E6^N6.N6UY!+I-WHMW:)?VNJP7Z2&UDTZ>QD2\BO%E,#VSK,)#&0U?P^?\
M!RK\!/V[;OP;XL_:*_: _:$\/W7[+&A_M*^%_A_^R_\ LT>$+:94L]/\1^"O
M'-Y<?$SXC36>GZ'IDGB^QA\-ZAIF@S:E/X\UJ/2O%>M6UIJ?@VR:]TC6_OO_
M (+V_'7Q]\&O^"(W[/7ASP#KNJ>'O^%]W/[._P &/'%[I+W%G<WOP[O?@EXI
M\=>(O#YU2V59+6T\27?@31]%UJQ2Y@.O^&;S7M#O([S1;[5[.:>;XM-K?.YH
MH7Y-5[[:]+6]+O77IYG]$_PD_:C_ &9_C]J>O:)\"OVAO@?\9]9\+1K-XETG
MX4_%;P+\0M2T"!YEMDN=8L?"6NZM<Z=:O<NMJES=Q10/=;K99#.K1A?B]^U%
M^S3^S[J7AK1OCQ^T)\$O@MJWC(73>$],^*_Q3\#_  ]O_$D=D\45[/HEIXLU
MS29]2M;2>>VMKJZM4EMK>[N[.TEE2YO+:*7^/+]@S2_V O"7[</[!]CKO[(G
M[:__  32^(JZ#:Z3^RE\8->\<1>&_"G[="&ZM)B_[07A_7_!=S>Z=XA^)DNK
MG3E\.^"O%FI:)JUKX[TOP%>:^=$7X9V]M3^%/[,_PF_X*A_MG?\ !P#\5/VL
M='UCX@ZG^S5+XP^&OP'FN?$WB/0[GX96WAS4_C[X9\"ZQH&FZ1>Z=9_;/#.E
M_!/1+B+2]7M[_09-2U'6I-;T769];U*:5*3TVNWYVLM?5?T]A^S5WJ^6R>RN
M[OETUMYOJMK7/[@)=3TV#39-9GU&QAT>&Q?4YM6EN[>/38M-CMS=R:C)?/(+
M6.QCM0;E[MI1;K;@S-((P6KQOX-_M._LW?M%?VZ/@!\?_@M\;V\+O;IXE3X2
M?%#P3\1'\/F\EN8;%]9C\):WJ[Z9#J#V=U_9T]XL,&HI;RRV4D\2%Z_@@\6_
MMD?&BZ_X-D?A]X!D\7>(BD_[<%S^R7>:K)JM[<ZAJ'P/T'P!KGQQL/!USJLH
M:[M]&L-6.@^$M.T);O[*O@C1(?#<&WP[ VCI]^_&#]F?X4?\$GO^"T'_  25
MTC]D/1-6^'FG?'+PWX;^$/QKT2T\9>)]6T;XB)XI\6)\-/$>OZXFN7^I&\EU
M1=:TOQ-<Z/&EKX:_X2;P?X8\0:7HNCZW9G4B^:_3M?\ [>M:WH'L]TWK[UM-
M/=M>[WUOI9']JE?@1^RI_P K!'_!4W_LV[]D[_U!/ 5?8'[2G_!4/P5^S1\7
M?$'P>U3]D3_@H'\7M1\.6>A7=WXW^ G[+.O_ !'^&5Z^OZ+9:Y#9Z+XS77=(
ML]9NM.M=0@M=8_L^">VT[54N]*EN3?V-[!!^97_!,/X\Z;^TM_P6J_X*5?&+
M2/AO\8?A+8>)?V=_V;+6+P+\>? =Q\-/B?I+:!H/A/099M>\'75]J,VF6^I2
M:<^I:-*]W(+_ $>ZL;]1&MR$4;5TNMW^3_S1*349-K1Q7_I43^FRBBBJ("BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@*F]X^OZ,4=I_P"%?^EQ/WWHHHIDA1110 4444 %%%% !1110 4444 %%%%
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M_'/B71-4\4>,/B?XJTWQ'X7\265K\/-;U2]U._\ !?BOQKX[\-:#9RV_A6$
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M9R2!DU^URL'564Y5@&4^H(R#SSR#WH272WRM^-OUZ^:%?^K+^NG]78M%%%,
MHHHH **** "BBB@ J"YM;6]A>VO+:WN[=RI>"YACGA<HP="\4JNC%7567*G:
MP##! -3T4 ?CA_P2Q@@M?V@/^"Q-O;0Q6\$7_!2;6UB@@C2*&-?^&<?@$=L<
M<:JB+DDX50.>E?L?7XZ_\$N/^3AO^"QO_:2C6_\ UG'X U^Q5);+T0!1113
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M_#/@S2'BN]4D@N=3AN]1F:>VL]+TFWOM5U"ZM[&RN)D_GY_X)A_'G3?VEO\
M@M5_P4J^,6D?#?XP_"6P\2_L[_LV6L7@7X\^ [CX:?$_26T#0?">@RS:]X.N
MK[49M,M]2DTY]2T:5[N07^CW5C?J(UN0BI[Q]7^3_P RXI\LWTY4OGS1/Z;*
M***9 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %>,^-OV@OA/\.M5U+1O&/B+4=)OM(M8[W4S'X.\;ZI865I+9I?BXFU;1_#
MFH:2L:6;K/.PO3]F3=]H\IE8+[-7YR_MU_M:^&/A=X?\4?!"ST*Y\3>,/B!\
M/]<TO4IH]1M[#2_">D>+]*UC0H+Z[D6&^NKW6%#-?0:']GL4DL7M[N;4[=+B
MWCN&E=I??Z";LMTO57/LCP-\:/AU\2-2N-)\'ZOJ>HWUK8-J<T=YX1\8Z!"+
M))[>V:5+SQ#H&E64S>==0*L$-Q)<,KF18C''(Z?./[3G[;G@;X%?:?"'AB*W
M\?\ Q:F MK;PO8S/+IOA^\N,):OXKN[,M*EQN=98O#=BW]LWJ^4D[Z/;WMKJ
M)^+[C]M#]H']IRV\/?!O]GGP+/X'\2ZAI3Q>+_$MEKG]HW>G:9!LL)]0LM>D
MTW3(?!^C10RQ3W>LM'-KHU"\L]+T"YBU**VDUK[2_9D_8D\#? G[/XN\32P>
M/_BS.OVFZ\47\+R:;X?O+@&2[B\*VEWOD2;S':*7Q)?K_;5\BR2P)HUO>W6F
M%VMO\E??NV^B_'[KDW;V^^UE\D[W9\T_"[]CWXJ?M$^*8?C1^V+K.K&WN4@E
MT+X9K-)I=^NGEO.@T_4K6S,*>"M"2/83H.F&'Q'>W$]S=:U=Z3JB7,FI?K#H
MNBZ/X<TJPT+P_I>GZ)HNE6T=EIFDZ5:06&G6%I"-L5M:6=LD4%O"@^['%&J@
MDG&22=.BDVWO\ET1227ZM[L****0PHHHH **** "BBB@ HHHH **** "BBB@
M K^??_@YE3X<C_@E_KE]X\AUG5=7TCX^? G5?A3X-TO2&URP^(WQ1M/%,W]D
M_#_Q5I\=Q:2MX4\2^')/%5OJTUO<)>6YCMIK&&^ODM].N_Z"*_)K_@MM\%7^
M._\ P3O^+7@^#XI?!'X'7ND^(?AKXXT[XS?'[6)?#?@7X7W_ (-\=:)K-OXN
MM?$UO'+=>'_%5J839^&K^W1VGO[X:7-%<6NHW%O,FKIKR&M_Z_73UON?@UX'
M_;$\12Q^$X+[_@UGU6PNI#HL4^L:;\(_#D6G63.]NG]I6GVWX+RWT=M;*1<Q
MFYNGN51 9)S)EZ_M'C.40[-F44[.FS('R8P,;>G0=.@K^#7PC_P4+_X*'6M]
MX;T:;_@X&_X)E:Y;0WNDZ?-'/H;WNKZM +F""2)[Z7X*J]S?WJ;H_M,DJM)/
M()&<9W#^\J,DQQDL')1267[K$J,LO X)Y' X/04D[];_ /@/_MOIU_S;'LO\
M[]%_7X=!]%%%4(**** /R'_X*I?\%36_X)[2?L[_  N^&OP2US]HW]J#]K+Q
MQ=^!O@;\)M*U:'0-.O[K3+SP]I^H:CKVM217$ENDFI^*="TO2;"&&(WT]U>W
M<]_8VFD7+2^??\$Z_P#@K3X\_:=_:<^.?["O[6W[,NH_LE?M@? OP=9?$C5/
M!8\6Z;XV\(>(_ ER_A^.[U32O$5@[VR36*^+?"U_;R6M[K&E:UI&LF^LM1B_
ML^XAD_./_@XHOYOBO^V-_P $H?V5O@+8MX/_ &Y_$/Q@N?B%\#_VBKS7;C1]
M"^"VA+X@T*VOYM1TJ#3=07Q?_:VK>$UUC["X672$\)F.T@OIO$1M7^7OV-K#
MXQ_LP_\ !83_ (*$? #]M76X/VB_VY?V@?V(_%/B#X5?M3^$]0N;/3G\#Z'\
M.(]9@\ 6GP]&E64'AF34K+PGIX2\CDBFL+[P+;:9:V]Y8Z^FIR1?WM]+I=+7
M:>FU[W\^MA_YVN^FS_X/HUIU/I'XC_\ !SKX[M-?^,/QA^!O[ GC_P",/_!/
M_P" 'Q2L?A;\2?VG;?Q!/I4MQ?76JV>E)K&CV3:5-H^F6NIS7UG+HECJ]U)-
M)!J_AS^V;G1;G78+2']0?^"@/_!:'X.?L>_LH_LX?M"?##P9K?[1'C#]M"3P
MM;?LK?"_0)6TG4/'?_"5:/H^MQZIJ\H@OKO3K/1[?Q#H&FWNEV5G>ZS=>)==
MTG08((?/O-1T_P#F1_8"N=!B_P"#3'_@H^DLMG'=Q?%OXF0:PDY"S+K=RW[.
MD6C)<"7!^U2[]*CL\?>F\I$_?JX'E*P^(+"#_@T1N?&7]HV_AL>-TD676WF&
MF+!+^UC\,KO3VS<L80C>$KCP_)9YX&D/8+#BW$8!=]]TGMLV[:??U%V>FO+H
MW_-;_/IV9_4E_P $S_\ @L7XJ_:[_:-^+?[$G[5?[,OB#]D#]L'X5>%[;Q__
M ,*ZUG59=5TOQ3X+F31I+FXTZ6]MK2^L]6T^U\1:%JR6Q-_::QH6IMJEA=HF
MG7<=?NM7\B/C(P7/_!X#\)QH WR:?^QSJ0\;_8U?]S._P7^);6AU4J-O-O?>
M$1&S_)^]TU0?,V"OV"_:B^'O_!:?7OC?XPU3]D/]H']A[P-^S]<Q>&QX'\,?
M&/X>?$37?B+ITT/A?1H/%+:]JF@Z)>Z5<I>^+XM>OM)%K<.8-&N=/MYPMQ%*
MH:>]^DFMOSM_P$-*_9>OJ8/_  2X_P"3AO\ @L;_ -I*-;_]9Q^ -?L57X+_
M /!#W3OC;I/B3_@J=IO[1_B'P+XL^.5G_P %"]7B^)7B/X9:;J6D> M6\1#]
MGKX%-)=>&--U>&WU*TTTVC6J+%>012^<DS;%5E%?O13CLO1?D(****8!1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !114-Q<6]I;SW=W/#:VMK#+<7-S<2I#;V]O"C233SS2,L<4,,:M)++(RI
M&BL[L%!( )6945G=@JJ"S,Q"JJJ,EF)P   222  ,FO@[Q3XZ\8_M8>(=8^%
MGP1US4/"OP1T2^FT?XM?'K2'\F^\37$#>7J?PZ^#MZ5:.>Y<%[3Q'XYA6:QT
MN,R0:8UQ,\)O:6K>(?%7[:>KW_A#X?ZEJWA#]EC2+Z?3/'7Q,TZ2?3M>^.5Q
M:3-!J/@KX<7:B.:Q\ B2.6R\3>,H27UP&72=&/V47DT_W!X6\+>'?!/A[2/"
M?A+1M/\ #WAO0+&'3M'T;2[:.UL;"S@7"10PQ@#)):261MTL\SR3S/)-([L
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MC?M^?$B>U<1W4/@+X,>$_&$MM(4\T1SQ^'OB/J+PN8_W@6158I\X&WFON_\
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M_P#!+C_DX;_@L;_VDHUO_P!9Q^ -?L51'9>B_( HHHI@%%%% !1110 4444
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MW+?V19;A^_GQZA_P0Z_:&N/V@OA5^UM(_P &?V?/@GI_PI_;-^)GPET/P_\
ML[?"VP^%'AS6-%\+>'/!C:?K_BG1].O[ZVU?QC/!>+97^N(+07%C8Z=:I9PQ
MVB9_%KP=^SW_ ,''O@7]NKXL?\%"](_9-_9ED^.?QD^$VF?!CQ7I6H?$3X;S
M?#JW\*:8?AHMK/HN@Q?M"6VMVFMN?A7X9$EW=>)[^U<W&K!+!/M5L+/]E/\
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M154 "Q2;OILNR_7O\P44G?=]W_6@4444B@HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ K\7?VU/^"+'PM_:A^,_B#]J#X/_M'?M*?L6_M0
M>*;/1K3Q/\5_V??B'KFE6'C!?#VE6&A:.?&/@O\ M73[/5H[31=,L=->#3=6
MT**[@M8FNQ-*UQ)<?M%7YQ?\%4OVZ-5_X)\?LDZU\;O"/@6#XE?$_P 2>.O
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MQ;;Z?%HTMUX8OYY+V*_FGAMF@'V9Y'*+^E?PQ_8O_P""8/\ P3:_X*T?L/\
MP/\ @Q^SW\5[/]H/XY^ _P!H#QG\.OBA/\6-9UKP1X+L?"'PK\>6WBNR\0^&
M=:U*6;5KO7O#$>N:9ILD%L\=C=WEI=LP:'='_-C9^'?^"F]K_P $M?@9_P $
MW#_P2G_:9>;X-_M.Z?\ M%O\71:ZH(O$"V7C#QEXI/A-/!1\';]-:1/%@LQK
M)\3WH5[$S?V81<^7!^WOP3^+7[<G[>O_  6S_P"">?[3'QA_X)M_'+]CWX;_
M +//PW_:9\%>(_$'C:^OO%?AZ=_'GP8^)46C7UYKDO@OP;#HYGUN]L-#MK62
MWO/M=Y?VP2>-G$92_P .ONZ\OWWTL+IL]HO9]>6Z]%=_A?H?U^T4458!1110
M 4444 %<9\0/B-\/_A/X5U#QU\4/&_A/X=>"M(DLHM5\6^-_$.E>%O#>FRZE
M?6^F:='?:WK5U9:=:O?:C=VMA9K/<HUS>7,%M"'FE1&[.N$^)/PO^''QC\'Z
MG\/OBQX%\*?$CP+K,EA-JWA#QKH6G>)/#FI2Z5?VVJZ;)>Z1JMO=6-R]AJ5G
M:7]HTL+&"[MH9XRLD:L #\C/^"1/C+PE\0?C!_P5U\:> _$^@>,_"'B+_@H[
MK.H:!XI\+:O8:_X>UJQ;]G3X"1+>:5K&EW%UI^H6IDCDC$]K<2Q%XW7=N5@/
MVNK\3/\ @D%X'\&_#7XM_P#!7'P)\/?"V@^"?!?AG_@HWK.F^'?"OA?2K/1/
M#^B:>G[.OP%E6RTO2M/A@LK&V$LLD@AMX8TWR.VW<Q)_;.E'9>B_( HHHI@%
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !12$
M@ DD  $DDX  Y))/  '4U\D^.OVMO"-OK6H?#SX+Z%KO[0'Q4A1[>?P[\-3:
MW/A_PQ<OOBCG\=?$&Y8^$O"=O%,K),EQ=WNI1S((7TS>ZT ?(\/Q&\"_#S_@
MIE^T'XQ\:>*M%\/^&_#_ .S;HK:KJ=]?0)%!+:3^ Y);&.-&>>YU-AB.#2[:
M*;4+F=XX+>VDFEC1O>O#O@KQ=^UYKND_$CXQZ+J/A3]G_1;^#6?A9\#]7C-O
MJ7CZYMG$NF_$/XOV).TV+86[\,> [A7MX8Y([S6!/G9?_AG\*_V3_P!H'5OV
MUM)^&_BVQMAX^\+>+-"^*7Q UK4M4TW7;&/PY%KVDZ[>^)Y;B2::/73JAO;=
M+>Q,3W5W>WR6]];6T8NW@_K!Z=* V_K;T&HB1HD<:+''&JHB(H5$10%5$50%
M554 *H      %.HHH **** "BBB@ HHHH **** "OXV_V[(_BA\;O^"I'[6'
MPD_:6_X*\>/O^"8WPP^%W@SX)^(OV6_"]CXGU;P3\/OBI\//&7A5D\6^(=&U
M>S^*GPDT6^\0Z)X\TO5K7Q#+K8\1>)=3U'4;_2-(U"+PSX"BL[;^R2OX&_VX
M_BS_ ,$L/@K_ ,%BO^"@+_\ !1/]GSXX?M:6_B2\^!NH>!M1\'ZU?Z)?_"O7
M8?A#I2^*?"$FAV7QI^%>D^-?#=[HU]X%_P"$;US5-2%SX=M-)?1K?0S/;RZQ
MJ$RZ>JZM=^J-*>[M?X>B3>ZV3T^_I<_H0_X(V_"'P'\+M8_: E\&?\%;=3_X
M*=/K6F?#6/4-,U'Q_)XV'P;2PNO&[6U_%&_Q@^*?]G'QT;N>W=Q%HGVH>%%!
MDO\ R MGS?\ P<1_%WXR_#K]DGX'> /A'\7+[X#VG[2_[6OPQ_9W^)GQ5TZ:
M^T^X\.?#SQMX:\>7^KQSZWI;1ZQI&D33Z#:ZAXC;1)[75-5\.:3JVA"=],U/
M5+2[YC_@A9\;_P#@E/\ %_7/VE8?^":_[+WQ=_9TU+0=)^%,OQ>N?BA)YD7B
MRQU&\^(">"8-%_XOK\9<2:-/9>*9+_\ <^'\KJ=I^]U/&RQ_8K]K7]D;X#_M
MN_!/Q#\ /VB_!J>,OA]KUWIVKQ);WUUH^O\ AKQ+HLKS:)XK\)^(-/>+4-!\
M0Z6\MQ EW;.UOJ&EWVJ^'];M-4\.:UK&D7YO%6MTZNV_??\ RV!NU2[3T:O=
M)/9=%IZ=^I_(]XM_9ATC_@I7_P %%/A__P $ES^T#\3K[]C7_@F1^QSX>\*>
M,_&_P^U_0+:;XB?&3PGH'A/P[JWC1A=:1XL\*VGB]?&'C3PSX1UG1=<M]>NM
M)L/AE\0-/T'4M,U#5-3U9?UQ_P"#<SXO?$SXB?L??&OX?^//C!>?'SPU^S;^
MUG\3/@'\&_BM>,]TOB+X2^%?#'@+5?#26&KW$;:IJVB>=KU_K/AQ];O]4U/2
M/#FO:1X<@NH- T;0M/LO</!W_!"K]AGX<_L;_'7]BSX?VGQ-\+^"_P!I&^\!
MWGQ>^*-OXKT>_P#C5XDC^'/C#1/&/A:Q3Q1J7A:Y\.6.F:5>Z1<6]EI%OX/&
MB01Z_P"(;EM+FOM6O+B7]!_V4OV3O@3^Q3\%?#?P#_9W\%6W@KX?>'9;K4)(
MS/+J.N^)O$>I^4=9\7>,->NBU_XB\3ZPUO;I=:C>/LM;"STW0M(M]-\/:/H^
MDV HM.[\_ELDO.R7W_>.4DXV5W:UM$MM92[IR;>GW^7YA_\ !P3^QW^T;^V]
M^PYX7^#W[+_PZ_X6=\1M._:&\!^.;SP[_P )=X$\%^3X6T7P9\2])U/5/[7^
M(7B?PGH4GV;4/$&D6_V&+4WU&;[7YMO:2P6]U)#M?\%(_A__ ,%%;O\ X)G_
M  U_9\_8.^'^I:E^T!XK\,?"_P"%WQ5U'1_B)\,_ NM_#CX<:3\/9(?B#-X<
M\6^,?'WA32?^$AU?7=+T?P3%?>'+_5KJ'0=:\1ZGI-Q87L&E:Q!^V%%.V^^N
MY"DURZ)\K;5_.V^OD?R#?\$B/@!_P6'_ & M4^&WP0@_X)C?L\?#[X-^/OB9
MX*?]IW]H&Z^,GP^\6?&+6O"R:HMCK'BV]?2/VHM8CN)/!WAN^U1_"OA/POX(
MDT33Y9+VYL?"U]K>N:Y=ZP[]HO\ 9(_X*3?L,_MF?\%$O&O[#/[,S_M-_!K_
M (*=> =:@;7[+Q5X1T+4/@M\:/B+J/BB;6=9UVPU?4+:[N[?PGK/BSQ_KMDV
MHV.D>!]1TOQOX6;5O&@U+PQKVE7/]>]%+E5K7>FSTNM+=OZ>NY3J-MNT=59K
M6SUNKZ[JVEC^5GQ5_P $*_B!<?\ !"#0/V)],DTNZ_:P\+^+!^UK_94-]HEG
MHFM?'^:QUFUO_A>=>FOVT)IX?AOKMS\)=,\6W&O6OAV\\4:;IOB2[U73/"<\
M\5KS/[-7[+'_  47_;R_X**?L@?M1_M\?LTQ_LR?#3]@;X2:3X=L[74/$'A7
MQ#=_&;XX^$UEDA\4:)8:;J3ZCHUAK7C#5=.\>I=6^GZQX1T72_ UOX8TCQ)J
MVLZM)K47]9E%'*M-^GSMM?07M):[7=]=;KFWMK_PW0*_ C]E3_E8(_X*F_\
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MU33-7\'G3+G3[_3[ZUU*#]A/^"NW_!*A?^"D'A3X,>,?AK\6+SX ?M5_LO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MAGPGHFAZQ?+KTWQL\&Z1:6FKZCI=WXBO97TC3E.IZS/"!=7#">X_H"K\.?\
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M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X]\?OA_\
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MY$&EMD6421,\;>ST4 ?A9_P18^#_ ,-?@#XZ_P""KGP<^#WA+3O ?PR^'_\
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M/3+*VL+42R8\R06]K%%$)'P-[[-S8&XG K0HHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_DZ^/7[._P#P6F_9
MU_X*@_ME?M;_ + 7P&^!^M_"C]H>'X7Z3>3?$OQO\-8]$\81>$OA]X5TE=;O
M-(U[XL>$?&7A_6[?Q>?$$.VSO=#T_4Y9%FETJ\AFMI'_ *Q:_C0_:9^"'PI_
MX*=?\%C/VP_V;?\ @H/^UOX[^ GPE_9A\)_#+_AF'X%Z7X^\&> +/Q9:^)O
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M5/VF/CO<V&G2RV]\WA'2[J7Q$;:93MFA31;!]#\!>'[L1C"7NB1:W%N(+Q2
M8/U]\,_V%_V;?ADMO/!X$@\::S A5M;^(4B>*9I6W!UD&CW$,/A:VFB8 P7-
MGH%O=1X'^D,P#4[1ZMOT7^87D]E9=W_DG_7D?@-^T'\8=4^.OQ7\4?$74%O+
M6RU6Z%OX<TJ[F\TZ+X;L%%II.G($)MXY!#$;G4/LH$,VJW-_<Y>2=W;]$O\
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M9Q\)?L,?L>_%;X#?M,?&[XHVVO>$[?\ :/D\56VO0_"WP#X;\*:O;VT4VG^
MO%.O7?BVVN8+5+RZ5+RYURXA&G>';.;XI\=^ O\ @XO_ &8]<N;G]KOXS?\
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MTTW=M;]KIK[M;]-D]U^X7Q?_ .#ES_@E[\%_C_XD^ /B+Q=\6M>N/!/C'_A
MO'/Q9\%_#7_A(O@UX1\3Q7L^G7UEJ?BB/7[;7+^'3;RTO8;J_P##?A77;&1K
M"^:PN+U;:5E_1?\ ;+_X*.?LG_L)?L\:)^T[\=OB"5^&7C"70[;X=GP39#Q;
MK_Q,O/$NDR:_H=MX%TRUN;>#5TO]"BDU@:G<7]CHMKIH6[OM3M8986D_BZ_8
M2\ >#-<_X-2?^"DOBO6-$TS5/$NN_&;QUXEU36[RUM)]4;7/"%S\ +KPU/\
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MOBUO#OAZ+6+JVU#3I-1BN'\/R/JED'M;BW2[CMQ"[R?V/@      8 '  '0
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M&)5CBBC4!4C1555 "@ 8J:BI&DEL%%%% PHHHH **** "BBB@ HHHH ****
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M(_94_P"5@C_@J;_V;=^R=_Z@G@*D]X^OZ,J.T_\ "O\ TN)^^]%%%,D****
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M."VM;:"..&WMX8TBAB1(XT5%51:J6V]W<I)+9(****0PHHHH **** "BBB@
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M#PEH,>DZ1>Z%IUCIVB^$+B"3P7H-K)HOAVPOKSH/A3^S/\)O^"H?[9W_  <
M_%3]K'1]8^(.I_LU2^,/AK\!YKGQ-XCT.Y^&5MX<U/X^^&? NL:!IND7NG6?
MVSPSI?P3T2XBTO5[>_T&34M1UJ36]%UF?6]2FEA2;TM9M[/LDF[_ *:?\'3V
M:ON[*,7=+?F:2MMIJ?W 2ZGIL&FR:S/J-C#H\-B^IS:M+=V\>FQ:;';F[DU&
M2^>06L=C':@W+W;2BW6W!F:01@M7C?P;_:=_9N_:*_MT? #X_P#P6^-[>%WM
MT\2I\)/BAX)^(C^'S>2W,-B^LQ^$M;U=],AU![.Z_LZ>\6&#44MY9;*2>)"]
M?P0>+?VR/C1=?\&R/P^\ R>+O$12?]N"Y_9+O-5DU6]N=0U#X'Z#X USXXV'
M@ZYU64-=V^C6&K'0?"6G:$MW]E7P1HD/AN#;X=@;1T^_?C!^S/\ "C_@D]_P
M6@_X)*Z1^R'HFK?#S3OCEX;\-_"'XUZ):>,O$^K:-\1$\4^+$^&GB/7]<37+
M_4C>2ZHNM:7XFN='C2U\-?\ "3>#_#'B#2]%T?6[,ZD7S7Z=K_\ ;UK6] ]G
MNF]?>MII[MKW>^M]+(_M4K\"/V5/^5@C_@J;_P!FW?LG?^H)X"K[ _:4_P""
MH?@K]FCXN^(/@]JG[(G_  4#^+VH^'+/0KN[\;_ 3]EG7_B/\,KU]?T6RUR&
MST7QFNNZ19ZS=:=:ZA!:ZQ_9\$]MIVJI=Z5+<F_L;V"#\RO^"8?QYTW]I;_@
MM5_P4J^,6D?#?XP_"6P\2_L[_LV6L7@7X\^ [CX:?$_26T#0?">@RS:]X.NK
M[49M,M]2DTY]2T:5[N07^CW5C?J(UN0BC:NEUN_R?^:)2:C)M:.*_P#2HG]-
ME%%%40%%%% !1110 4444 %%%-=E16=V5$12SNY"JJJ"69F) 55 )))  !).
M* '45^*'[5__  4$^)&C?$[5O _P-UW1M$\.>#[DZ;>^*;?3M$\37'BG5EA@
M;43"^LV&I:9::5IEV9M-MA8P//=S6]S?2:@\%Q;6EI4\"_MA?MK_ +0>DP>!
MOA#X-\/MXBTJQL;?Q7\0].TFVC>WDF,RV^I7MSX@O!X+\.W&J06=Y(]H-/N)
M[ZXM[V3P[9VGDI9P5R.U]%ZNUO7^KD\ZO;5^G7T/V.\9>//!?P[TA]?\=>*M
M!\):.C-&M_K^IVFFPSSB-Y1:V@N94>]O7CC=H;*S2>[GVD0PNW%?GA\1O^"E
M/A8ZE_PB7[/W@+Q%\6O%-Y(UKIM_-I^IZ?HUQ<-$'ADTO0K>UE\7>("DF^*>
MQDL/#;ML,EO>RQX+8/@S_@G)K?C'6$\9_M1?%S7_ !]X@E*F;1M#U74;N,Q1
M3"6&SN_%_B")M2DT\QM) ^EZ1H^BK9;MNG:H(U4U^B?PY^$/PR^$FF'2?AQX
M)T'PE:R11174VFV8.J:BD#.T)U?6[IKC6=9DB,C^5+JM_>2QABJN%XH]U=Y/
M[E_F'O/M'\7_ )??J?F)_P *%_;C_:F)F^.'C^/X1> +YGD/@ZR5(Y9;.Y59
MXH#X,\/WD"W\,3J(=OCWQ*=9T]LL+:?YE;Z_^$7[#'[/?PD-I?P^%/\ A./$
MML?,'B/QZT.NS1S91U>RT4P0>&[!K>5=]E=1:0VJ6^0&U*9U$E?85%)R?HNR
MT7]>H**6N[[O40 * J@*J@!5    &  !P !P . *6BBD4%%%% !1110 4444
M %%%% !1110 45RGBGQWX'\#VC7_ (U\9>%/!]BB&1[WQ3XBTCP_:(BQRRL[
M7.K7EI"J+%!/(6+@".&5R=L;D?./BS]OC]BSP7;S7&M_M/\ P6F%OY@FM_#G
MCK1?&>H1M"ES))$=+\'7.O:D9E%K*A@6T,QG,%N$,]U:QS<F(Q^!PE_K6-PF
M&LKOZQB*-&R[OVDXV7F?19/PAQ9Q"X+(.&.(L\=27)!9/DN99FYS>BA#ZEAJ
M_-*^G*KOR/KFBOXLOCS_ ,%2OVMI?C?\8)/A'^TCXC'PJ?XG>.F^&HLM \-0
MV8\!GQ/J?_"(BUBUCPI'JT=O_8/V#R5U1%U$1[?MH%SYE>]_LA_M_P#_  5-
M^*R^/O!OPB\/R_M&^)M0/AQ?^$J\8>'=+31OA3"\'B15?^UK.Z\#^#M*O_%$
M@$]D_C?5;RTN#X7FBT_2KO%_M^ H>*&28C'/ 4<!G%:I[2M2IRPV&HXM5I4E
M-KV%/#8BK6JJLX6IN-.UI*<W""E*/]B9M] 7Q6R;A*/%^8\6^&V6X*."RS'X
MNAG>>9GP_+*Z.85,)"HLUQN=Y+@<MR^>7+%.6-AB,9&?/1J8?#1Q&*E1H5?Z
MT))$B1Y972..-&DDDD8(D:("SN[L0JHJ@LS,0% )) %?!_QQ_P""E_[&'P#%
M[:>)_C+H?BOQ+9I<C_A#OA@1\0=?>\M)/*GTRZFT&2;PYH&I+("GV7Q5K^@'
M*MEA@U^=\/\ P3,_;D_:EEAU3]N7]L35+/P[=RZ?>W7PK^'<LFJZ>RQ*3):W
M&E6-OX0^%_AK6[3)1-5TKPSXWBE8;WN)R2U??'P/_P""6W[%'P*6TNM*^$.G
M?$'Q):QJC>+/B])'\0=3FDCE$T-VFBZE;0^"-+O[>15,%_H/A+2;N,JI$Q*@
MCVO[1XKS.ZR[)L-DV'E\.+SZO[3$N#TO#*\#*<J=1+51Q.+@K[II)3_+WP1]
M'C@5I\:^*&=^)V<46E6X<\(,I6"R*%>*Y_9XCC[BVE0HXS!5'[E2MDO#^(JJ
M&E.I"I.4L/\ "T__  5%_;!_:9N9M(_81_8U\0:CHTUW=6-M\4?B;#->:* D
M)R)YH+_PQ\.?"VM6TA\R.WU?XB>);>;8%:PERR5G#_@FU^WS^U2ZWW[;G[85
MYHGA:\-C/=?"[X=R2:M8SQ0RLSV5_H.C0^"?AAHNJVZG_1M:M-)\=.QVM.TS
M!L?T 0PQ6\45O;Q1P001I###"BQ10Q1*$CBBC0*D<<:*J(B*%10%4  "I*'P
MG+'6EQ#G69YS?XL)"HLKRM[63P. =.51+:]?$UN9:2NW-R2^D32X37LO!KPN
MX$\,)4U%4.),1@O]?N/Z<D[SJ1XKXMIXNAA'5LIRCE>2Y=&E4]ZA[/V>'5'\
MZ/@?_P $J/V)O@<+2[L_A/:_$SQ':HRGQ1\8YXO'UW,=XDCE_P"$<N[2T\ V
M=U;NH-M?:9X/L;^(@'[4S ,/T0MK:VLK>"SL[>"TM+6&.WMK6VBC@M[>"%!'
M%!!!$J10PQ1JJ1QQJJ(BA54  5/17T6!RW+\LI>QR_!87!4K*\<-0ITN:RLG
M-PBI5)=YS<I-ZMMNY^*<6<<\9<=X]YGQGQ3GW%&.3FZ>(SS-,9F+H*HTY4\+
M#$U:E+!T-$HT,+"C0A&,8PIQC%)%%%%=Q\J%%%% !1110 4444 %?E]^UU^P
MYXG_ &AO$7Q,U30/ '['HN?''@^3PUI_Q#^(GP[\<ZM\8=)OY?"2>'K?74\3
MZ+K]MI,.I>'K@)+X7N1HUY_9UO8:;]HANV@:$_J#17!F66X3-<,\)C8.I1<N
M=Q3L^;DG"Z=FT^6<E=6:OHT?7\$\<<0^'V=QX@X8Q<<'F<:'U=5IQE4A[+ZS
MA<7RRIJ<(U(NMA*$I0J<].2BU.$KJWP7^RE^RIK/P%\8:IXAU/X<_LF>$DO?
M!TGAS^VO@/\ #OQGX2\9:A*^IZ+>FVUK4O$?B76;*XT*X_LPW=W:06T5Q)JE
MOILZRK%!(C?>E%%:8' X?+L/'#86')1C*4E'3>3N]DE^%^YR<5\5YUQIG%7/
M<_Q/UK,:U&C0J5ESJ]/#PY*:M4J5)*T>G-9=$EH%%%%=9\V%%%% !65KFA:)
MXGTC4/#_ (DT;2O$.@ZO:R66JZ)KFGVFK:1J=E,,36FH:;?PW%G>VLHXDM[F
M&6)QPR$5JT4FE).,DI1DFI1:3335FFGHTUHT]&BZ=2I1J4ZM*I.E5I3C4I5:
M<I0J4ZD)*4*E.<6I0G"24HRBU*,DFFFDSP3_ (94_9>W;O\ AF[X";L;=W_"
MGOAYNVYSMS_PCN<9).,XSS7LNA:#H7A?1]/\/>&=%TGP[H&DVR6>E:'H6G6>
MD:/IEI'DQVNGZ9I\-O965LA)*06T$42Y.U1DUK45C2PN&H-RH8>A1DU9NE2I
MTVU=.S<(IM72=GI=(]+'Y[G>:TX4<TSG-<RHTI^TI4L?F.+QE.G4Y7'VD(8B
MM4C"?+)QYHI2Y6U>S:"BBBMSR@HHHH **** "BBB@ K^/KQ=_P %?+?]@#_@
MLM_P5,\*?&#P)^U=^T!X#U[3_P!DVT^&G@OX)^'V^(FC?#*?3/@Y;ZKXIN)M
M$U7Q)H]AX7B\577B&SGBDTV-FU:[T^_DN5#VZN_]@M? WP*_80T+X(_MM?MK
M_MH0?$&_\3:K^V;8? JQU3P#>^&K.QT[P OP0\(7WA*TET[7DU6\N=>;Q%'>
MF]N5N-,TL:>\2P1F[5O-"=^G]?UL'],_);3/^#GK]G#5-2T_38OV'/\ @HM#
M+J-]:6,<UQ\!]!CMXI+N>.W26=QX\8I#&T@>5PI*H&.#C%?TP(P=$< @.JL
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M6U+2/M0:PEOHK])+5/OFF!^.O_!+C_DX;_@L;_VDHUO_ -9Q^ -?L57XZ_\
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M-X*^$_P_\.7$>,7^G>%='357P" 9M7DM)-4G(!(!FNY" 3@C)H_+^NGW]?\
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M*O %T?."6?C+X@^%/#=]*T !FC@LM7U:TN[B6,,NZ&"&24%E79E@#\4^._\
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M*4?\%%O&SI#\+/\ @FGXY\/-."+>\\?Z+\4-8TLLDCF0MJ,OA7X7Z<RB.">
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MP*'[T,4WAC21J;1-R"+J^N7*G:SLN16EIO[#'[-EO(+KQ#X,U3XAZAD-+?\
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MCQ&'PGUBNXI^SI?6<5AZ+F]%.M!/>YZ'1117:<H4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !114:S0O)+"DL;S0B,S1+(K21"4,8C+&"6C$@5C
M&6 #A6*Y .$VE9-I-NR3=KNS=EW=DW9=$WLF-)N[2;25W9;*Z5WV5VE=]6EN
MR2BBBF(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF]Z-"C"3LN2"NP:XJP[7+/(<UC9+EG#'Y'45DVY.K">?0J.3LN54*"6LN9_
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M?C#)N$:.$KYQ+$QIXVI4I47AL.\0^>E",Y\Z4H\JY9IQNWS:V6AX/%_'/#W
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MZ'YW)\,OV^[1%MX?C-X,GCA&Q)7GM[AY .=S3WOP\-W(>?O3DN>_&*IOX?\
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M0EK>.K+EXJTJBM5\,?"B2:<6Z?"V+P\N5JSM+#9S2M+JIV<XMZ-'YU3?%?\
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M@0:7K&]-HV/]NW(,A" S [JAQ5A4E2QV3YO!7?+CL+B<IQ#[*6+P4\?AW?\
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M[;1OC'?2Z#XTTJVD@N=3\+:NMCK5A:2K<W5G%&4W]L?^"V-N+I+,_P#!)_\
MX+4BZ>"2Y6V/["J"Z:WCDCB>=+?_ (6KYC0))*D<DP&Q)'C0DM(,',N^_P#P
M/\U_5PY)=OQ7^9^V]%?B3'_P6P@EEN((_P#@D]_P6JDFM6C6>*/]A1'E@,L2
MRQBXC7XJ[H&D1A)&KCYXBLBDAN.)^'W_  7X^&_Q9\#Z9\3/A9_P3:_X*Z?$
MOX=:VFK2Z'X_^'W['^@^,_ ^LPZ)JFH:+JTNF>+?#OQAU'0KY-+U;2M2TK5F
ML[V==-U33]0TZY9;FRG13F3Z_P!:?YH.27;\5_F?O917XBS?\%L[:&".X?\
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M (*H^%3'#I?CS]K6 /#&8X]*\7_%:6V(MBR00SC0_$6IV\<<8.V.*<9",X2
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M7E@T=Y!K&ERO$R/]JM[N7BX?CK[XN_\ !/Z6);N?_@A!_P %G8H9GM$6:/\
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MX)[N3RK.R@+[KC4-2O9 4LM+TZ"[U&\97%M:R['V^MU_(A_P<?"#XT_MS_\
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M\.OC9+ R0ND<G^D1_#-H P>15"-('<A]BL(I-AS1[K[T%GV?W'[%45^/*_\
M!?C_ ()#NTJK^V=X6S"X23/PW^-ZC<8TE&PM\,0)5V2+\\1= ^Z,MYB.JUX?
M^#@/_@C]<0)<6_[:GA*:)Y$AS%\./C?(R2NRIY4T2_#$RP2(SJ)DF2-K?DSB
M,*Q!S1[K[T%GV?W,_8ZBOQZ/_!?C_@D.)1#_ ,-G>%=[1M(/^+;_ !O*;495
M;,H^&7E!LNN(RX=AEE4JK$0Q_P#!?_\ X) R_:1'^VEX3<V<C0W*K\./C>7C
MD6-)2FS_ (5EO<F.1&78K!PP"%CQ1S1_F7WH+/L_N9^Q=%?CN?\ @OW_ ,$A
M0D+G]L[POMG:-8_^+:_'$MF493S$'PPWPC'WFE5!&>)"IXI%_P""_O\ P2":
MYDM%_;2\)-<111SR1#X=?&TF.*5G2-G8?#/8I=HWVJ6#L%+!=HS1S1[K[T%G
MV?W,_8FBOQW_ .'_ '_P2%\N:7_AL[POL@,HD_XMK\<=^8<^9Y<?_"L/,FZ'
M88D<2\>5OR,L;_@O_P#\$@5EB@/[:?A+SYE5T@'PY^-K3>6P<B62)?AD7BAR
MC(9I52(28B+B1E4G-'NOO06?9_<S]BZ*_'D?\%^/^"0YE:$?MG>%=Z(DC9^&
M_P ;PFV1G5<2'X9"-FS&VY%<N@VLZJKH6KO_ ,' ?_!'Z,'?^VIX21\7++"W
MPX^-XN95M&9+AH+4_#'[3<+&5.&@BD5U*O&71T9CFCW7WH+/L_N9^QU%?CR_
M_!?C_@D.C1(W[9WA;,SE$V_#?XWN-PC>4[V7X9,L0V1MAI2BEL("795:-O\
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M)+=U\,O^SPMOI2ZA+H\EE9>(=*T!+D7=K<[[]'$Q?]Y8?^"]O_!+J6>ZM_\
MA=_Q34VC0HTC?L<?MJ,LIEA68%$B_9ZDGB"AMK"ZAMV9@6B62$K*WY?X9<(<
M3991SF.9YCGW#[K8G#U*-.C_ &!7AC%;$.=>I]>PN>2A73<75C3E0C>HE*IB
MFN:E^)^"7A]QCPU@>(Z.?9GQ5E%3&9I3Q&%AB%PQ7>*I<F(4L5*^)XK]GB*G
M-"IBJ:K891JR45/&I.M'ZK?]H']KB$QK)^PAKTQ:,,[6?[0?PHFC5^04!F2W
M8\C() ^4@GG($"?M(_M4 1FX_8#^(H+.!(+3XV_!&Y*1YY=?/\0V0=@O(0E
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M@JZ<WA6[\-:W\2-+^),'B)I#;#58=;L+^UU+39(A=R6-Y9ZA:R"*UGTYS?\
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M6$QL)_WB _8%,333LTT^ST84444""BBB@ HHHH **** "BBB@ HHHH ****
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MAB662=8HUFE2..68(HEDCA,AB220#>Z1&:4QJQ*H99"H!=LR44?J!\D?MO\
M[)NC?MJ?LN_$3]F+4_%MW\.M)^(.J?#K5+CQ3HVBVFM7>F2?#[XL^"OBLB0Z
M1<7NF6UP=9OO!J:7<RO=Q- FI3WX6>:$0R_6;PQ.\4KQ1O) 6:&1T5GA9T,;
MM$Y!:,O&S(Q0@LA*G*DBI**/Z_K[P_K^ON/S+_X+)>&=9\4?\$MOV\="\*>'
M]3\1>)M>_9U\;V.G:-X>TFZU?7=9N_L:"WL[+3M-M[C4-1N=N\0V\$,TN-P1
M,9KZ7_8OT6?2OV-/V3M!UC29M-OM,_9J^!-AJFC:E8/9W6GZE9?#'PK'>V=_
MIUU%'-:7UI?12)=6]Q#'<6]W&ZRHDR,!YA\;/^"G7_!/K]G#XCZY\(/CO^UW
M\#_A5\3_  S#I%QK_@;QEXSLM)\1:1#KVD6.OZ-)?:?*#) NI:+J5AJ=H6_U
MMG=P3#Y9!7<?LY?MX?L;_M=ZUXD\._LR?M(?"GXWZ[X/TNTUKQ/I7P]\46FO
M7NAZ3?W;6-GJ&H008>"UN+Q&MHY2"IF 0D$C*TOOK:UK]K_UY:@?0'Q%\%6G
MQ$\!^-? ]W<G3T\9>#?%7@YM6BMHKFZTNW\5:)>:+<WEK'*T8DDACNQ.(#+$
MD[0HDCA>1Y7^R5^SUI?[*'[,WP)_9NTCQ!/XOLO@C\*O WPOA\7WNE6^BZAX
MIA\$>'K#P]!K=_IEM<WT5E<7T%A'*UHE]>+:J5MTN94C#'Z(HIA_P?QM?\D5
M_LEKY$=K]FM_LT)A,5OY,?D1&W=)+<QQ;?+0P21QR0[5'E.B,FUE4CY0_8:_
M9-T;]B3]ESX3_LRZ/XMN_B#9_"FV\9VMCXUU71;30M3U2+QG\0/$WC^[633;
M6]U**Q2WN?$8T_RX;Z9;F/3K>YEVR-Y<?UO11_7]?<']?U]Y&L,*-,R11HUP
MXDG9456GD$4<(DF( ,CB&**(,Y9A%'''G:B@?#O["7[$'A[]ASP#\9/ .B^-
M[WXAV?Q>_:@^,?[34MWJOAVQT ^'-3^+>JZ7JC>%+&TM-0U.*ZL_#3Z5#'8Z
MLSVMQ=%O--E:%$2ON:BC^OZ^X=WJN^_R(S%$91.8HS.L;1+,47S5B=E=XA)C
M>(V=$=D!VLR*Q!*@CY,_9S_9.TC]GGXF?M??$BR\87WBJ;]K?XZVWQPU?1K_
M $:UTZV\&W=O\-?!7PX/ARQN(;V[;6[26#P:FJ-?W4%C()-0>S-JR6XN)OK>
MB@1";:W*0QF"$QV[1M;QF)"D#0C;$T*E=L31+Q&4"E!PI KY0\!?LH:3X$_;
M(_:&_;!@\8W^HZQ^T!\*?@;\+;[P3-H]M;Z?X9MO@E=>/[FUU>SUM+V6ZU&;
MQ%_PG;I=64UA:QV!TN-X[BZ^U%;?ZUHH_0"#[+;>7-#]G@\FY,S7$7DQ^7.U
MQGSVFCV[93/N/G%PQDR=^[)KY._X9,T0_MU#]N!O%ET^M1_LGVW[*]O\/6T2
MT.E6VG6WQ=N_BPOC6'7C>&[CU(S7DF@#2DTU8%LRUT+_ 'NUM7UQ11_7W!^I
M&(HA*TXCC$SQI$\P11*T4;2/'&TF-[1QO+*R(255I)&4 NQ/X<_M6^!/$FJ?
M\%R/^"4_BC3_  ;K>H^"-!^ O[=5IXI\16?AZ_N_"NC7FO\ @;2X[*U\0:O!
M9R:1IUSK=U(Z6L.HW$,NI7$C+$LTC$']:_CS\??@[^S#\*?%?QP^/GC[1/AE
M\*O!$%C<>*/&6O\ VQ]/TQ-3U*ST?3HQ;:;:WVI7UU?ZI?V=C9V6G6-W>7-Q
M<(D,#\D=3\-?B-X*^,'P]\$_%;X;:_;^*OA]\1_"VA>-O!7B6T@O;6UU_P +
M>)=-M]7T/5[>VU*VLM0@AU#3KNWNHX;VTM;J-90D\$4H9%3UT]']SO\ H.^_
MFK?K^AV3PQ2-$[Q1N\#M) [HK-"[1O"SQ,03&[1221,R$$QNZ$[68'Y*_:%_
M9+T7X_\ QC_9"^,-[XNO/#&H_LE_&/7OB[I^E66BVFH1^.I];^%_C3X9KH&J
M:A->VD^D6MC#XSN-8@O((=0=IK4V8MHTNWN(N_\ %O[4?[.O@/XV> /V;_&/
MQF^'OAWX]?%33;C6/AY\(]3\1V-OX[\7:5:KJKS:CH_A\R&^GLMNAZUY5RT<
M<5PVDZBENTK6=PL?O5/?^OF+8K_9+3R&M?LMO]E<R%[;R8_(<RR-+*6AV^6Q
MDE9I)"5.^1F=LL23\S?M+_LM>&/VF]3_ &9=3\2^)=>\.2?LQ?M0^ _VI?#4
M6AQ:?*GB3Q/X!\(_$+PAI_AK7#?P3M#H-[;?$._N[R6P\G4!/I]HD$\<;S;O
MJ&BC^ON *^7/VR/V6/"_[9OP&UKX!>,?$VO^$=!UOQK\(_&L^N>&8M.FU>&\
M^$/Q9\%?%O2K**/5+>YLOLVK:IX)L]*U!WA:6.PO;F2V*7"1,/J.BC<-@KY?
M_;1_9;\,?MK?LN?&;]ECQGXEU[P?X8^-'A:/PMK'B;PQ%I\^O:/;1ZOIFLI=
M:;#JL%SI\D_GZ7%$R74$D9BDDP%?:R_4%%&X;'(?#[P=9_#SP%X(^'^G7=U?
MZ?X&\(>&O!UA?7HB%[>6?AG1;+1;6[NQ D< NKB"R2:X$,<<0E=Q&BIA1E_%
MSX=:=\7_ (4?$[X2ZO?WNE:3\4?AYXT^'6J:IIJP/J.FZ=XV\-ZEX:O;^P6Z
MCEMFO;.VU.6XM5N(I(#/'&)HWC+*?0Z* V/(/V>_@[I'[/'P#^"'P \/ZMJ6
MOZ#\#OA%\-_A!HNNZQ':Q:OK6D_#7P=HW@W3M6U2*RCBLX]1U&ST6&\O4M(H
MK9+F:58(TB"*/6;B%;BWGMV)59X9869<;E65&0E<@C(#$C((SU%344; ?,?[
M&7[+_AG]BW]E_P"#7[+?@WQ)KOB_PQ\&/"K>%=(\2^)HM/@U[6+9M5U+5FNM
M2ATJ"VT^.?S]2EC5+6".,11QY#/N9OIRLCQ!X@T'PEH.M>*?%.M:3X;\,^&]
M*U#7?$/B'7M0M-)T30M$TFTEO]4UC6-5OY;>QTW3--L8)[R_O[R>&UM+6&6>
M>6.*-F'Y:?"O_@N7_P $H_C5\8=(^!'PY_;+^'>M?$CQ%KD?AGPU8WNC^._#
M?A[Q-XAGN19V>C>'_'/B?PGH_@C5;_4[UH[/1(;3Q!)_PD%W/;VVA-J4US D
MBT6FB[:_EW \N_X('?##XE?"7]B?QYX8^*OP\\<_#/Q+=_M@_M3^([7P]\0?
M"6O^#-<N?#VO?$BYO-#UVWTGQ'I^FW\VC:S9D76E:I';M8ZC;$3V<\T1WU^V
M=<!\5OBG\/O@A\-?'/Q?^*WBG3/!/PW^&WAC5_&/C7Q7K#R)I^A^'M"LY;[4
M;Z988YKFX=(8BEM96<%Q?W]T\%C86US>7$$$G&?LV_M(?!K]KGX+>"_VA?V?
MO&"^/?A%\0DUZ3PCXL71M>\/KJR^&?$VM>#M:(TCQ/IFC:Y:?8_$7A_5]/\
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MF?V.=;_X1[P5X<UCQ5KG]B^'/VH?A7KOB'5_[)T*SO[_ /LO0=$L+[6-9O\
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M0!_ %_P6"_8&\<?LL?M3_L.?'CXS?M.?$3]ICXS?M)_M6Z\NHZAXL\^#PO\
M#GX=>#?B!\*]7\!?#GP59ZGJ6N:L++P^?'.MPSW2:AI.AS1&SCTGP?H4D-_<
MZK_1=_P6S_;_ /%/[.GPY\#?LA_LWZS86_[9_P"VC<R?#[X:ZA/XDL_#%O\
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M 5_,A_P=I?$SQ3\/_P#@E"N@>'-1NM.LOB_^TK\)?AGXO%I.T!O_  M%X?\
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M(T(_V<4H]=&M5OOLOOUZ]1]_-M]5TCTZ:I_\-9A1115 %%%% !1110 4444
M%%%% !1110!^!7_!9+]E'_@E;\+?@E^TE_P4<_:U_9-^'WQ@^*NA^#]%@MM0
M\0^(/'6F:G\1O'L.F:/\.OA+X/DAT+Q?I%JD%Q>1>'-)O[C3K$7-CX=L=1UB
M1)S8SR-S?_!NM_P35T']BW]D:R_: \8^%=,T;]I']LC2])^*_CJWLK0VEG\.
MOAQX@:?Q+\,_A)X>LI)9Y='T_1]$U>WUSQ!9.XO1X@U$Z/J+W$?AC3&BV?\
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MTAM(Y[R8*@FNIDA62XE"())6=PJ@X"C=7NK:]7>^BO\ UY^0=]+:WWO]F/\
ME^G0U****H HHHH **** "BBB@ HHHH ^<OVM_V8? 7[9O[.GQ1_9B^*&M>-
MM ^'WQ=T:Q\/^*]2^'>MV?AWQ>NDV>NZ5KTMGIFKZAI.NV5O#JCZ3'IFK17.
MDWD=[HUYJ%B43[2)8_XLO^"L_P"RO^Q=XDUS]AW_ ((H?\$Q_@[X4\5_M?\
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MW[IW?W6%;5/R:_%67Y_CW/U/HHHIC"BBB@ HHHH **** "BBB@ K\I?VZO\
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M*-<-GX8UMX]<@TW6+F[\,>)+?2?UOIW3V=P::W37JFOS"BBB@04444 %%%%
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M"5I8IH=O=Z1=WNH_N7J&CZ3JPB75=+T[4U@+F :A8VUZ(3(%$AB%S%((RX1
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M'7QO_P"";7_"Y?\ @IG^RM_P46_X7/\ \(Y_PS-\-];^'W_"G?\ A77]L?\
M";?VQ:?%>U_M?_A8/_"=:7_PC?V;_A9^_P"P?\(1K_G?V'M^VQ?VGNT_].[6
MTM+&!+6QM;>SMHRYCM[6&.W@C,LCRRE(852-3)+(\KE5!>1W=LLQ)&KMWVNG
MYZ)+>^GW7'SI)65WR<K=]%[U[6MJ]-T^OD?YWFO?M9?L6:I_P0[TG_@F[I?P
M,U6'_@I'!\3],^'P^$-O\!O$4_Q-M?C%8?'NPU36_B$GBH^&S?'Q;K_@FQF^
M&DV@6NJO\1SJ]X?AJ_A4>";;ST^Q/^"B_P ./!/P%\7_ /!*>Q^._P ?OVJO
MV$/VT/AA^Q+\)O@[%^W!X:\+6GQ _9RM/^$&^'_BNT\5?#W5]9^'_C&S^+-S
MXUL/&?B'5O!OB;7=)L[[3I?"7CZSUKQ;H&L^&M:EU:W_ +>(]*TN*^EU2+3;
M"+4[A/+GU&.SMTOIH\1CRY;M8Q<2)B*(;7D9<11C&$7#K[3=.U2$6VIV%EJ-
MN)%E%O?6L%W")5#*L@BN(Y$$BJ[JKA=P#, 0&.5R^?1):=$T^]^G</:>3W;?
MO7U:2TNMO)IG\.'[,OQ?^.?[2G_!)W_@ME:>,_!WP=^)WA?P/I%]>^$?VN?A
M3\!-&^#.L_M,Z]INH^-/$OQ%\8^+UTOP=X"F\<ZCH'ANTTKQW_PDWBCP?HWQ
M)TZ/Q]J\WCR[UG6]=D.G_P!"O_!##]I3X%_'[_@G;^S]X;^#_B&WU3Q+\ _A
M9\+_ (/?&G1ET+5-#OO#GQ)\.>!-%M[ZWNFU'3;"'78-0M8(KZQ\0Z/-JNE7
MD3268U$ZGIVIV-C^P"6UM%;)9QV\$=I' MM':I%&ELELD8B2W2!5$2P+$!&L
M2J(UC 0*%&*AL-,TW2H6M]+T^QTVW>5IG@L+2"SA>9E1&E:*WCC1I62.-&D*
MEBL:*3A5 :5K:WLK;>?Z$RGS)JUO>NM?)+MY=+>EC^23]JSQWXJ_X)$?\%R/
M''_!07XK> /&?B;]BK]M'X0Z%\-?&?Q(\&>&M2U^#X6^*;+PQX TMM*O]EU%
M;2^*8_%'P4T?Q/'I]Y<68U3X?>-O$)\)VNNZYX3O].M_RLMM/_9=_:-_X+#_
M +(_C[_@F!KG[;?[04.H_MP>%OV@_P!K/Q%X^\/@_"?P=X;U3]H#P#X__M3P
M%I^D^#O"/BWPIX"\.V9^(Y\43_%;38X8]-@\)V.DZGJ5Z-6,W^AT0""" 000
M01D$'@@@\$$<$'K5#3])TO24DCTK3=/TV.5@\L>GV=M9I*X&T/(MM'&KL%^4
M,P) X!Q1RZ]+7OMJGI>SOUL-5+=->7EO?1K975M6O5'\G?\ P22^$O@OXB?\
M%9/^"[FMZSH.AS^-_#7QQU'1_ 'C74=#TO7-7\ W7BGXM_&N[N]:\-QZQ:WE
MG::G#J_A7POJT5S]G,JW6A62K(L1F27\L/V=/VDOV0_V'?\ @FS_ ,%(/^">
M_P"VY\'%\/?M]7OB/XQ^$[3PKXA^%5WXUUWXG>+?%?@.UT'X2>*[/XDII6IZ
M/IUC\.?%,\OC3P[X@N?$>E6"Z#>:=\1/A5=^(]:\4RM/_H1U0DTK2Y;Z+5)=
M-L)=3MT\N#49+.W>^ACQ(/+BNVC-Q&F)91M215Q+(,8=LG+9))ZJ^MM[^0>T
MU;:=GRZ)V?N;:VV>[5O1G\#_ .T7\)OC1^R!_P $^/\ @WP^*'[2'A#QMHOA
M[]F[]I7QC\0OC MWI5S=:_\ "[PIX_\ CGX/^,WP[\*Z_H]P8=;L=?N/AQX<
MU,Q>'M3MK6Z\/:Q82>![Y=.OK*QL9/M#P'^UC\(_VS_^#E[]D?XT? >Y\3:]
M\(I/V5?'_A3P7X_U[P9XL\$:5\2H/#W@+]I)==\4^"=/\:Z-X?U_4?"NF>*[
MO7O 4NKSZ3:P3>+/!?BFRMO.BL!/)_8Q<VUM>02VMW;P75M.I2:WN8HYX)D/
M)26&56CD4D#*NI!QTI\,,-M#%;V\44%O!%'#!!#&L4,,,2A(HHHD"I'%&BJD
M<:*JHJA5   HY7WTTZ=K>?6P>TNG>.K4U=.R7.VWI9[7[[?>?YT'_!/W]N+]
MAK]G3_@FQ_P4_P#@?\??"T2?M!?'#5/CCI/PBU*_^%.I>*K;XJ-X@^%VE>&/
M!/@:S\<6F@:II'AZ3X5?$//CS5D\4:IH<.B6WC'3O$/AL:MK8:TC]D\5_"GX
ME_!C]E__ (-@_!'Q9T74_#/BU_VO/'WC&+PUK,44.J:+X7^(W[4_P@^('@R*
M_A2626VN-2\*>)=(UZ33[X0:GHYU;^QM3L[&^T^>S@_JS_X)9?\ !,^T_P""
M:OPA^*7PJN_B[;_'8?$CXZZO\;K?7;CX:1_#T>&[O4_#/A;P[!HT.ER>./B!
M]NN+!O#1OHM>34=-D8WQ@33H#;^?<?J90HNRN]K:6\TWZ[6N5*HN9V5TW>]]
M_=<5;2ZWOK?Y'\K/PI\*^'?$?_!UM^T_J.NZ/9:I>^"_V1?#7BKPK<7D7FOH
M?B)_AA^SKX6;6+#)VQWH\/\ B?7]+65E;9;ZI<E LOER)_.E\8/@?XZ\6_ 7
M_@KUIWPH\(:SXE^'_P"SA_P5@^'GQ \5> M 6^N;30OAII\_[:WPWGUR"RMG
MN+Y+/2+G6_".D:K=V5O//9Z'.^LZE-'IV@37,'^FG7QE^W;^R5KW[97P/3X7
M>#_VC/C-^ROXXT3QAI'CWP3\8O@?XAU/0/$VB>(M'TO7=%BM-;BT;5_#FJ>(
M/"=YI_B/4&U'0+'Q/X:N+C4;?2+^/6(#IWDW"<+WUZM[=_GY?\,*-2S5UI:$
M=[V46M=NOX>>S_E$_:^_;D_9=_;K_P""I/\ P1,\<_LJ^"?%47@KP-\>?"'@
MJ]^+.M?#'5/AWH7B><?$WX/:O:_"+PU)JUC82:NWP1%]=W&MVNFQRZ#HMY\3
M81HUU>6FI"\N/[B*_!?X1_\ !'+XU:M^UC\ /VK_ -O3]OCQ'^VGKG[*EA-:
M_ ?P;_PHGP=\'-(TG5;==VB^*?&&J:!XE\07OBO5M/U,6OBJ2:XMH/$>H>+-
M$\.WNN>,];T?3I]"O?WHJE?6_5_HEW?YDS<7RJ.JBK=7UONTG^"\@HHHID!1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% '\?'[?W[2GP._9+_X.?/V3/C=^T5\0])^%OPK\
M/?\ !/'4--UGQCK=KJ]YI]C?>(M=_:CT71;:2WT/3M5U*1[_ %2\MK2(PV4J
MH\H>9HXE>1<O4OCE\./^"N?_  <"_L._%3]B?4]:^*7P!_80^%/B7Q+\:_CC
M9^&?$>@^"K?7-8/CBXTCPIIEQXGTS0[NZNM5U._\.Z+8-):P_P!K277B"\TZ
M*ZT7P]?ZH/ZO_'G[/_P&^*>L0>(OB=\$OA%\1_$%KIT.D6VN^//AMX-\7ZQ;
MZ3;W%U=V^F0:GXAT74;V'3H+J^O;F&RCG6VBN+RZF2)9+B5GZ[P5\/O 7PUT
M4>'/ASX(\(> /#RW$MV-!\%>&M&\*Z*+N8(LUR-+T*RL+$7$JQQK+,(/,D"(
M'8A5Q-G??2Z?GHE;Y:?UT%I?S=^UM5+OW_ _S1_VI/VS;C]IG]B#]O>3QU\=
MO@C^QUXFO/VCK[2]+_X)5_ 3]D'X>^#/&/Q#UGP_XI\'7UY\4/C)\5H_#R^/
MIIO#FGV>O7_BKQ!<RVD=QXG\$36VJ7>ERZQI&BU^Q/[9]W?_ +$7PI_X((?\
M%IO!6E7WB"P^"?[.'[.W[-W[2UEH;1W&H^*/@[\1_@/8MI)<2-':3RZ9+JWQ
M'TZWN]0ND5?$^N>#X_,5K>)XO[#+_P"!WP5U75O%FOZI\'_A=J6N^/=+DT3Q
MSK5_\/\ PG>:MXST646ZRZ1XLU*XTB2\\1:7(MG:+)8:Q->6CBUMPT1$$6W\
MG/\ @II_P2Y^//\ P4!TGP3^S?X0_:G\)?LW?L PZ1\/8OB?\ ?!7P.T2\\7
M^)M5\ ^,-6\0V\7A?QG;ZOHMEX8\,2V">#[?3/#B:3-IFC:UX7BUE[35(IAI
MJ+E:6CN[)+Y._5O_ "\AONM[):KM\]>M_)6[)?@'X(_96^%%]_P;[_M$?M6_
MMW7/QN\->*O^"@O[1UO^V-X^^*/P4^'[_$OQYX!75/'=\WP8\1>)/"6H:[X7
ML-<^&I>ZUOQ/?-J.MZ3:)8?%:WEMM2L;]=-O[2S_ ,$X_P!J_P"-ND_\%2_V
M-O@LW[1/['/_  5I\(>.?A]XKTO1/VB/ _[/VBZ/^TQ^RQ\+M*\+:M=P3^)_
MB6OP\T/Q3X'DF-[-8ZUX5U[QAXTN+G3[_5]$U>?0=2U+2A>?V[^#? /A'P!X
M!\*_"_PIHEEIG@3P5X1T/P)X<\.+&)]/L/"?AW1K70-(T413^8)K2UTBSM[+
M9-YGFQ)B7?N;.3X#^#OPC^%DNJS_  Q^%GPY^',^NF)M;F\!^"/#/A"76&@:
M5X&U63P_IFGOJ!A>:9XC=F8QM+*R8,CDG+MLM%??5I_*]_,/ZZ]UYV[^>KMO
M=?B/_P '._\ RAI_:6_[&3X'?^KG\$5^$/[6GQU_9._:Z^%__!!+]FW_ ()\
M'0[K]L;X9_&GX!74_A;P3X,OM&\<?L^^&_!7A32(?BG8_$9!IVGW.A"P\;:5
M9^,-<6]DN(M4L/"&L^,I;M]+N8-3U3^L?_@JM^P]KG_!1?\ 8C^*7[)GASX@
M:3\,-7^(6I^ M0MO&>MZ%>>)-.TQ?!OCC0?%LT4^D6&H:7<W!OH='>RB:.\C
M$,LZ3.'1"A^F_@A^S[X ^#7A?P+%9^$? LGQ)\.?"_P+\-O$WQ0TCP=HND>*
M_%]MX-\,Z)X?WZEKL5JVO7.GW#:);7%OIVH:I>1VT<5K%N<VT;"FK^7RU^78
M7]+U36_E^?WG\HO[(OQ__91_8,_X*@_\%M+/_@J'JGA7X;_$'XV?%.[^(/P<
M\:_&GPC<:YIGQ-_98U+5_B'>:?X-\ ZA/H>L1ZKIMQX6U'P+I<W@K3I;AO$C
M:+;>'X;#4+_P;=6MG^77PT^"/P\L_P#@CKH/Q$_:;\:?M'?LC?"/Q9_P5,\0
M_&W]@SXM>$/A#?\ Q%\/_!31-1T#2M&\.>+_ (E^#)/$&A7&C?"S6[RQU>]T
M;4],OI]7_M?PI=:SX7T_7XM2_L[Q1_H=>.OA/\+/B@-+7XE_#3P!\1!H<\EU
MH@\=>#?#OBT:/<R^7YMQI8U_3=0&GSR>3#YDUIY,C^5'N8[%QU.JZ#H>NZ->
M^'-;T72=8\/:C8R:9J&@ZKIUGJ&C7^FS1>1+IU[I=W#-8W5C+ 3#):3P26[Q
M'RVC*<4N7I=6UMIW:>OW6TMW'MKU_KK?T?JEN?QP_P#!'3]IOXS^/?\ @J'\
M0OV=/B9XY_8L_P""DGA_7?V9-1U3QG^WI\"/@5X5T'QWX=\,65WIMIX<^&GQ
M3^)ND_#;P<OBS3-<^Q:5I6K^"]8?Q-$^HW'A^[7Q7?7N@ZUIB>T_\&I?Q#^"
MMG^S]^TI\!_[:\(67[3/AO\ :H^.GB[Q)X >TM[3XE:7\+(X_A3X>M-4U&)[
M2/48O"L7BXS:5##)/]ECUN.ZA2!;F"XV?U(^ _A?\,_A9IUWI'PQ^'?@7X<:
M3?W7VZ^TSP'X2T#PAIU[>[!']LN[+P_I^G6UQ=>6!']HFB>78 F_: *70OAA
M\-?"_BCQ!XW\,_#SP-X=\:>+=W_"5>+]"\):!I'BCQ-NF2X;_A(-?T_3[?5M
M:W3Q1SM_:5W<YFC20Y=%8"3TN[M7W5][=;^6_F%[*WEZ]5_EY_Y?RZ_\%B=5
MU+]AG_@L=_P36_X*M_$3PYKVK_LI^$O WBK]FSXQ>+=!T>]UQ?A5J/BNR^*N
MA67B76[>QM+JXM;.XTSXPRZSIR6BM?:T/!FOZ-9)-?7-G97OYJ?\%E/V[?!7
MB'XT_#[XE_\ !-;_ (*Z_M5?%KXN_'_XQ?##3S^R?\!/B'XZ?X.^ _AVGA*'
M0]2ET*Q\+V-A)8^+/$'B;2M!FE\%S7<VN3WOB#Q+=7VBVYCB8_WJ>(O#?AWQ
MAH>J>&/%N@Z+XH\-:Y9S:=K?A[Q%I=CK>AZQI]PNV>QU32=3@NK#4+.=?EFM
M;NWF@D7AT8<5XA\*_P!D+]E#X&:]/XJ^"O[,OP ^$GBBZBEMY_$GPU^#WP^\
M$:]);3@B:U;6/#7A[3=0%K*&8/:BX%NP)!C()H:;OKN[[/>R71KL+^G^&W:_
MX/7R/YHOAQ^S]\%_C]_P=1_MU67QQ^&'@?XM:1X&_8?^&?BKP]X;^(WA?1?&
M7ANR\4W?A7]E_P +'7I- \0V6H:7<ZG:Z#K^O:=9S7-K+]E35KJ:)5N5@FB\
MA_8B_:3_ &4O^"='[>?_  6P\+?\%0M4T+X:_%'XS_&W7_B3X'\4_%3P/J/B
M"S^-_P"S1K^J>/=0TOPMX%N(_#^KP^(-)OM(U?0(V\&6[M%X@$UMI*6%W=>$
M]2M],_L3L_AW\/\ 3O&FK?$G3_ W@ZQ^(NO:7#H>N>/K/PSHMMXTUG1;;[#]
MGTC5O%,%DFN:CI=O_9FF^3I]Y?S6D7]GV/EPK]D@\N'QC\,OAO\ $-]*D\?_
M  ^\$>.9-"G>ZT23QCX3T'Q,^C7,AC:2XTIM:L+UM/G=H86>:T,,C&*,EB8U
MP<OFKW;V[]-Q^5W;]?2Y_F[>+_A!\8_AC_P0#^ 'Q5\=^!_&?A;X0O\ \%DK
M#]H[X?:3K6E7L=UX&_9IUWX::OX6\/:]/I($]UI'AW7/'%MJ\NCO)&EOJLVO
MZ?J-@UU;>(--NK[]GO$G[8G[.G[:'_!SA_P2]\?_ +,7Q)T_XN?#_P *?LT_
M'CP9J?CGP_IVN6_AB7Q8?@U^T_XJOM TW4M8TS38]4U'1M%\3>'Y]<CL5G72
M;G58=-OG@U*&[M+?^PW6="T3Q%I%_P"'_$&CZ5KN@ZI:26&IZ)K.GVFJ:1J-
MC*NR6RO]-O89[*\M)4^62WN(9(77Y60CBN.T?X/?"/P]>^%]2T#X6_#G0]1\
M#VNI6/@K4-'\$>&=,O?!]EK*7,>KV?A>ZLM,@G\/VNJI>7::E;Z3):17R75R
MMTDHGE#%GIJK>[T[/U]?ZU%NGJ^GX-/]$O\ AK/^!/\ X)H?MG?L$?LV_LT_
M\%P_AO\ M5ZAX<\/>/OB]\5OV@[/PI8>)/"&HZI<?&W0Y- \5^'M$^&?@[5+
M;2[VUU+Q#X;\9ZR-0N-#GO;"30U\<:7XI>6#3HM1U32Y_"OPX^*?PL_9-_X-
M5/#'Q=T_6-%\0W7[?_B?Q9HN@:_:W-GJ^B^!?&W[1O@+Q7X(ANK>\"W$<6I^
M'M7LO$6FQR(A@TK6K&W6-%A5!_4Y_P $SO\ @DWH7[#/A7]I#PS\5O$GP\_:
M*3XV?M5>+/VE?"\FK?#"SMH/ ,_B'3M.L+33K>V\1ZCXH$FN:?\ 87?^WM/;
M3G*R!(H4P2?UE\1>!/ _B^]\.ZGXL\&^%/%&H^$-336O"6H>(O#VD:U>^%]9
MC>"2/5O#MWJ5G<SZ)J:26MLZ7^F26UTKV\#"4-%&52B[+;2W3S3?Y?,=^G3_
M #M_D?RC?\$K/!'@_P 4?\%J_P#@X+U'Q'X9T37;ZTUK1_"]M=:KIMK?RP>'
M?&&K^.O^$IT:)KF.0)I_B :#HZZK; >7>IIUJDP9(PI_GY^&'AS4M,_X(Y?L
M&?&+Q=X=UCQA^R5^SM_P68\3^*_VH_"VGZ?=:]9I\-V;X61V]_K6F)Y@ET3^
MRK7QEX6,EV!:2:OXTT^QEE6YU6$2_P"EWH_P_P# ?AW7?$GBCP_X)\(Z%XE\
M920R^,/$6C^&]&TS7?%<MMYOV>3Q)JUE907^NR0?:)_)?5+BZ:+SI=A7S'W?
M#W[:7[#/B7X]?L]Q_!S]E3X\:I^PEXAT_P 7'Q;;:_\ "+P'X9OO WBF.\TV
M^TKQ#X2^)WPL1_#^@>./"GB6VO(IM2L[NY@D:_T[3Y[@W]I'<Z==OELDENN;
M7JV[6_*S\F'5OOS?+FDI=^GROOY'\T?QB_:L_9"_:[_X.1?^"4/Q!_9%\2^'
M?B)H6A^!/&?A7QO\3?!_A[4-)\-:]KL'P_\ BUJ^C>&8=5O]+TK^WM7\&^'-
M7T]-5$,,_P#8,6M:=H-S/%=V,^GV/]M=?@;^RW_P1X^,_A/]LSX._MJ?MC_M
M8>"/CMXM_9L^'_BSP#^S_P##+X+?LU>"?V<?AIX-7QI:ZU9:]XAU;3/"^IZA
M#K%]<Q>)?$%\MK;:9IDBZU>VE\VJ/9:;#I4O[Y4U?6^[?Z+S8GNWWM^$4OT"
MBBBF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 445\T_M4?M$?\,S_#[1_'?_
M  A__":_VMXRT_PE_97_  D'_"-_9_M^B>(=9_M#[=_8FO>;Y7]@_9OLGV./
MS/M?G?:4\CRIC<3:6K/I:BOPB^+G_!3WQUXY\%W_ (8^'_@9OA7K.IR1PW7B
M^W\9?\))JEKI+1S+>6NBQ'PIH TG4[MF@2/7$N+BZT^W%R=/AMM2EL]4T_XN
M^$?[1'Q2^#OC>P\:^'O%&L7KQWD<FNZ+JFIW=[I7B?3WEMSJ&G:M!=O<HQO8
M+=(4U%(_[0L)%ANK*>*X@B86H/T_KR)<UTU[]#^JZBOR(\.?\%5/[?\ $.A:
M#_PHC[)_;>LZ7I'VK_A:'G_9O[2OH+/[1Y'_  KN'SO)\[S/*\Z+S-NSS8]V
MX?KO4M-;HI-/9A7S?XG_ &M/@3X-^./A?]F_Q'XE\36'QG\;O!_PA_@^/X5_
M%K4$\3VLMI%?76K:%XFTWP->>$=4\/Z):2O/XJ\26FORZ!X/2RU8>*M2T=M&
MU867TA7YG?\ !3[P=KVC?"GX?_M??#S2I=2^*7[#'Q#L?CUIUI9,EMJ/B7X2
MQPC1?V@? ']IOO&F:/XG^&4]_JNLW"6]Q,\?A2U@BCS*30M7;OHO7I\BEJ[=
M]%Z]/D?9?B3X_P#PM\)?%WP7\"==U?Q!;_%#XAZ1J&O^#M M/A]\1-7T_6=&
MT>=+?6]23Q;H_A2_\&V5KH$L]D/$,FH^(+/^P$U319=8%E%K>D/>V/BQ\=_A
M9\$)OAM;?$WQ,WAVX^+OQ-\)?![X>0KHVO:NWB'XB>.-1CTSPWX?5]%TS48M
M,-[<2%I-2UB33]*M;>&>>ZO8DB8U^?.J?M(VLOPF_;%_X*4_#[3+3Q_X:\#_
M  EUGP!^S#)+97]WI'B/PC\+K74=;\:>-I+>&>QUC3]!\8?'34]5\.^-A9SZ
M>^I>"/@9X2U^"XCVVURGQ'^VQ8_M;Q^-_P!A&[USX\^#OB7\#OB7^V;^QIXI
M\!ZUXQTKP!<^/- ^,3>.K]K/6_ N@?";PU\.]%U_]GZ;PKKMA?W&F>)O$/B'
MQM!JW]B6A\=&#5+G4KX2O;I=V_X;3S6_W@E>W2[M_P -IYK?[S]_OB9\4O!?
MPA\/67BGQY?:IIVB7_BGPEX,MKG2?#'BCQ9.WB+QSXAT_P *^%[.73O"6C:Y
MJ5O#J>OZKI^FC4;BTBTVUN+N 7EW;B5"W?RRI#%)-*VV.*-Y9&P6VI&I9VPH
M+'"@G"@D] ">*_ GXI_M5?M3?">T_;:^%D/QTUKQ5X@_9=_:2_8>T'PQ\4]?
M\#_"6#Q;XG^'O[4C?#J?Q-X,\1Z7X<^'_A_P1$NB+K6N1Z9KNB^$],UU8K^"
M/^T ]A!.?I7X(?&#]H_]H^VU+X\^%OCYX7^'7A[P?^VMXB^"?BOX$^,?"GA>
MP\$Z?\&/!7Q&?X>7?AG4M4N_"=W\3H_VE/&T-YX=US1+R/XC6W@==<UW1O#5
MIX3L!=7JSEM/Z\G^O]=2VG]>3_7^NOZ%_!SXX?#'X_>&=6\8?"?Q')XG\.:)
MXP\3^ M1U&31-?T!H/%7@W4#I7B33/L/B32](U%O[,U%9+1KI;,V=R\;R6=Q
M<0;96]9K^:_]CGX@_M$?$?Q7^V[^S?\  'XG_P#"HO%GPU^,'[1'QB\%3VVF
M?#NZN/'OC?Q]^T7\</#MNOC9OB/X0\?O<?!WPI>^ _"5EXA@^'VA^'_&$M]X
MMOT?Q="L6F:;<?T$?![6/&VO_"SX?ZO\2I/ TWQ#O?"FC2>.)_AEJ=YK'P]N
M?%:6<<.OW7@O4-11-0G\-7.IQW-QI"7S37=M9R16MS=WDT+W<R_K]1?U^IXA
MK?[<W[-7A_XK>)/@AJ7BSQJ?BMX0LSJOB7P9IOP.^.^MZCI&@"YBM!XKN9]$
M^&FH:<?!<DUQ 8?&L5[)X3GAGANH=9DMI$F;L]1_:K_9_L?@S<?M"VGQ&L/%
M?P8L;:YO-4\??#G1_$OQ1TG1++3[&?4=8OO$$'PXT7Q3J?AZQ\/6=M/+XHO-
M;L;"U\+&-HO$,NF38C/YP^+V^*B_\%AOBNWP9B^'\WQ '_!-3PG_ &'%\3I_
M$=KX.>?_ (:*ER-5G\*VUWK<<03<0;.VE<L%4@ EE^=O@/=7.F_L"_\ !:CP
M/X[2TL_VA-.\1_MP^/?VA-(\+1V[_"K2_&_Q+^#&M7NGQ?"34+35-5DOO!KZ
M)H5M\GB62S\?V&K1ZA9^,]-M+N.S$E6U2_P_C;[M_P BK:I?X?QM]V_Y'Z=:
M'_P4N_8X\37MQIOAWX@^/-;U&T\$V'Q+N=/TO]G7]I2^OH?AMJT=G-I/Q$DM
M+?X0R7 \!:M#J.GSZ5XR\O\ X1O4H+^RFL=3GBNX'D^JOA1\7OAE\<_ ^D_$
MGX0^-] ^('@?6S<)I_B+PY>K>6;7%G*8+ZPNHR([K3=4T^X5K?4=)U*WM-3T
MZX5K>]M()E*#\,_^"=7_ ">A^SA_V@H_9(_]2CPI7K?A#0-3U;_@K7^V7X!_
M9W\=^)OAAX4\0?LF_#;Q#\?/%O@/3_"^KV7@C]J>Y\::8/ VJ0:!XV\-^,?
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MC2"TD&I0WT=BNL06Q-C"I;?R2?WV_P PMOY)/[[?YGZT4444A!1110 4444
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M#]IG]F_X@^(M.\(> ?V@O@CXW\6:O]K_ +)\+^$/BOX#\2^(M4^P6-SJE_\
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M75A?6_FQR1^=:W$L>]'3=N5@-N@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M8+K6I]%LI],TS4+^X\.:9K7B;3-$LO$NKC_1?D#_ $7Y'Y$^ I?$VA_M<_\
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M>,_%OC/P+XMDN]:OO%>AVFI7<VD6.C6ODG^RK:SMM'M-,L+!W6GK'\$K_P#
MMY^0[K3UC^"5_P#@6\_(\9TGP]H%]_P6I^*^EWNAZ/>:9KW_  37\*)KFG76
MF65Q8ZRA^/::85U6TF@>WU%3IME9Z>5O(Y@;&TMK0CR((HTX'X7V7C+X(_\
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MO\O5M7?W(=][_+U;5W]R/PY^)GQ%\;:O^Q1^WA_P4$-U_9W[2/PQ_;(UZS^
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MA#K?B&ZD^U-]P5/]?UW_ *Z$_P!?UW_KH%%%% !1110 4444 %%%% !1110
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MH<+:>=6_4CP(WC&3P=X;E^(,NBS>-9M)M)O$K>'='O/#^C)JDT8EG@L=&O\
MQ'XON]/CMMZV\D$OB;6_WT4KQW\L3I@M;^O)/]0M;^O)/]3&^(7Q@^$GPDAT
MNX^*WQ1^'7PR@UR2[AT6?XA>-O#/@R'6)K!8'OHM+D\1ZGIJ:A)9)=6KW:6C
M3-;K<P-,$$T9:UX#^*7PR^*=A<:I\,?B+X$^(VF6;QQW>H^ _%WA_P 7V%J\
MKW$<27%WX?U#4+>!Y9+.[CC6612[VMPB@M!*%_,[_@M[:6MS_P $\?B5-<6=
MM=S6'Q"^!-W8-/#%(]K=O\9?!5@\]K)*C&VGELKV\L7GB*.;2\NK=F,,\J/Y
M-\4=6\30_P#!5K]B[Q/\0_@Q;?LO^&-,M/CQX \,_%ZV\0:/XGA_:LU;Q/X(
MM]+\%?"'6Y_ VF_8_!\?AV5-2\:>%-(^*UZT^J7WVFT\%6UAK<4TMP6TOZ_@
ME_G^O0+:7]?P2_S_ %Z'Z=3_ +8/[)-K/<VMS^U)^SI;W-E))#>6\_QN^&D,
M]I-#+]GFBN89/$ZR0213_N9(Y51DE_=L _RUUW@3]H'X"_%'5I=!^&7QN^$7
MQ%UV"U>^GT7P)\2?!OB[5H;*-E62\ET[P_K6H7D=K&S*KW#PB)690S@D"OP@
M^,NGV%W\3?\ @Y%CNK&SN8X_V=/V6;N..XMH9DCN[;]DWQOJ=M<HLB,JW%OJ
M5K:ZA!,H$D5];07<;+/#'(OT#\>?A;\.K[_@DC\-OCS<26'P]^-?P%_8N^$?
MQ)^#OQUT&.RT/XE>#/&OA+X5>%]4\.Z#H7C**%=6ATSQYJ44'@35M :YDT[6
M;+Q)+:O:&[-G/ [;>=E^$7^K';;SLOPB_P!6?MW7)>-O'_@/X::!<>*_B/XV
M\(_#_P +6<D45WXD\;>)-&\*:!:RSML@CN-8UV]L-.@DF?Y(DEN5:1OE0,>*
M_&CXN_MV_MB? OX._L>_'?Q%I/P-OOAE^TM\)?!WA_5HO$WA#7?#GC#X;_M-
M_$7X$+K_ ,,H?&_B6[^-7A_PD/A)XC^+"3WGC?78O"GAR]\!^!;+4-*NU75V
ML]='W]\5?@_\'-:\#^'_ (J_MP>'?A+\6]8^%O@+Q!I.J2WOPVNM5^&5E>>-
M-0T,Z_)X ^%'BO4OB5JUQXL\3W.C>&?"/AY4O_$OC;6)MOAWPI':S^+]1T/4
M9_(G\CZ[L+^PU6PLM4TN]M-2TS4K2VO].U&PN8;RPO["\A2XM+VRN[=Y+>ZM
M+JWDCGMKF"22&>&1)8G9&5C0TOQ)X=UR\UW3M%U[1=8U#POJ2:+XFL-+U2QU
M"\\.ZQ+I]EJT6DZ[:VD\T^D:E)I6HZ?J:6&H);W3Z??V5XL1MKJ"23Y$_P""
M>_P#UK]FO]E3P!\+]>L[O0[U-4\=>,8/ ]SJ\NN+\,=(^(7CGQ!XVT+X80ZG
M+=7PO)? >C:[8^'M8N[>^OK*_P#$5GK.I6-[=V=Y#/)XC_P3?\,^&_!OCK_@
MHGX7\(>']#\*>&=$_;C\366C>'?#>DV&A:%I-FGP>^$+K::9I&EV]KI]A;*[
MNRP6MO%$&=F" L27;?R_S2_4=M_+_-+]3[=\6_M'?L\^ /$DW@SQW\>/@SX*
M\86PLC<>%/%OQ1\$>&_$EN-2@BN=.,VA:SKEEJD0O[:X@N+(R6J_:H)HI8/,
MCD1F]9TW4M.UC3[+5M(O[+5=+U*VAO=.U+3;J"^T^_L[F-9;>[LKRUDEM[JV
MGB99(9X))(I8V5T=E()_'+]ME;>Q_P""FW_!.C5(OAM>_%&]NOA1^VIIU[X*
MT*'P.-<\9Z=%\,=+$7AX3?$+Q%X0\(W%JO\ :>I/':>)/$NFZ6BWM_B0/=2)
M-\F?&;P5^TG^Q7_P21_:_O\ 4_MWPAUGXO?M'^)/%GAWP%X9U_3-<A_96^!7
MQP^*W@_PY+\/M#U/P_J>JZ'##%I,^J6SV_@?4I=,TJ\\>276DRPZQ'J.JR%M
MO/\ 5V_2[?\ 3+;>?ZNWZ7;_ *?[]Z%\<O@GXH\::E\-_#/QA^%OB+XB:-=:
MI8ZOX"T+X@^$M7\::5>Z)))%K5GJ7A;3]7N-<L;K2)8I8]4M[JQBEL)(I$NT
MB9& ]2K\W_V\_@G\.?"G_!.KXN>'?!.FVWP_M?V</@MJ_P 0?@7K/AJXFT;7
M_AEXN^#?AR?Q%X)U;P7XEM#_ &WH>NSSZ.NAW>K6%[!J6MV&MZOINI7LUMK6
MH^?]6_LO^-/%/Q)_9I_9X^(GCAUD\:^/O@9\)/&GC!T@MK97\4^*? /A_7/$
M#K;644%G;JVK7UV5@M((;:($1P11Q*B MI?S:^ZW^86TOYM?=;_,]SHHHI""
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@#Y^^/GP%M_CUIV@:-JGC#5_#FCZ'>76I-I^EV=I<QZEJ4T"VMM>7
MC73C#Z=;/>0V:Q*H4:C>&0R;HQ'\SQ?\$Z?!\$D<T/Q,\5PS0NDL4L6F:7')
M%)&P>.2.1) R.C ,CJ0RL 000#7Z$ZMJVEZ#I>I:YKFI6&C:+HUA=ZKJ^KZK
M=V^GZ9I>F:?;R7=_J.HW]W)%:V5C96L4MS=W=S+'!;P1R2RR)&C,/CO]FG]O
M?]G[]JGQEX^\#?#77;R+7_!FI7*Z79^(+9=)N?'?A>U2WBD\:^%;29_M,^C?
M;WN('LKN.VURQL_[.U#5M,TT:G';0_B'&O@KX(\7<4T\YXVX9RW,^*<\]E1H
M5\;G&=4,5BXY=AJ=&E3PN'P^:4*-.&'H4J:4</1I0=1N34J]:<I_5Y=XX\2\
M$4\FX0P'&M#(UF57&1R7)Y4LH5;'5;SQ6,=&.(P=2OB)7FW*=2<]94Z$'K3I
MGV/IMO=6FG6%K?7SZG>VUE:V]YJ4D$5L^H74,$<=Q?/;0?N;=[N57G:"']U$
M9#''\BBKM%%?ME.G&E3ITH.;C3A&G%U*E2K-QA%13G5JRG5J3LES5*DYU)N\
MIRE)MOY:<G.<IRY5*<I2:C"-.-Y-M\L(1C"$;O2$(QC%648I)(*\ _:=_9Y\
M/?M4?!?QA\"O&'C'QYX+\'^/+6WT[Q1??#JY\)V/B+4-(@O+>^ETA;_Q=X0\
M9V5G9WLUK"EY)9Z9!?R0!X(KV&*:99/?Z*O8G8^?/B)^SY:?$W]GK7_V<_$?
MQ1^*$?A[Q9X&UGX<>*?&VG/\.8?B%K_A#Q!HNH^'=7TR\O+KX<WOA*VEO=$U
M%["34=+\':?J06W@N$NUO'N[FZ\X\+?L=OX8\#?"'X7-^TM^T7KWPS^#H^'=
MMIG@G6#\ K:R\7Z-\*M4T+5/!/ASQUKWAOX">'_&NJ:'9'PUHNGZO:Z3XHT*
M?Q;I-K<:=XNNM=M]4U=;_P"RJ*/Z_K[@_K^ON/#OA1\#K?X4^*/B]XLB^(_Q
M$\<7OQI\:V?C_P 5V7C;_A7YTVR\1V'@3P1\-;6;0(O!_@#P?<V=K'X-^'GA
M723:7MWJ43_8'O)-U[<SW#XW[.?[+GPF_97T_P"*NA?!K2)?#7A;XK_&#7_C
M5?\ A.)K<:!X7\2^)_#'@WPWK6E>#[."V@.D>%YG\'0:Q9:&TES;Z-=ZK?Z=
MHYL?#]OI&CZ;]%44 >,?$?X7^-/&OB3P_P"(/"OQ^^*OPD@T?1M=T2_\.^"-
M+^$FK:!X@77#:NFMZC:?$CX9>.IX_$N@RV=O-X>O[:ZCTZS(N+>^T?4[#4=6
ML[_8^#GPD\*_ [X>Z-\./!\NLWFF:9=:]J]_K?B;4WUKQ3XJ\4^+O$&J>+O&
M?C'Q3K#16XU+Q)XN\6:YK/B+6[J&VL[(ZAJ4\6G6&GZ=':6-OZ?10!Y/\+?A
M%H?PKO/BGJFFZKKFO:S\7_BIK_Q9\7:OX@GLY[Q]7U;2= \,:1HUC]BL[**W
MT#PCX+\)>%?"'AZU>.:ZCTG0K:6_N[W4)[N[G^5;;]@7[-XB^)WB#_AK_P#:
M[D'QGUZ36?BAIJZS^S[9?\)78O9C2(_"?_"4Z7^SM8?$/PWX3TW0#+X?\.Z;
MX.\9^';GPCIUS=3^$;_0M6N9=3;] J* /G3XK^!OBIXC^*W[/FM_#KQ[XQ\$
M^%?!/B#Q+?\ Q0TC39_!A^'WC+P;=:/;11>'O$FAZII.H^+M6\32ZK:Z?:>#
MIO#MWX<T?P[IE_XP\1:QK5QJNE^&?#/B+I/B/\+_ !IXU\2>'_$'A7X_?%7X
M20:/HVNZ)?\ AWP1I?PDU;0/$"ZX;5TUO4;3XD?#+QU/'XET&6SMYO#U_;74
M>G69%Q;WVCZG8:CJUG?^ST4 >-_#GX$?#SX;?"+_ (4G8Z?=^*?!=]:>+XO%
MI\=7*>*-5^(.H?$35=:U[XC:[X[N[J".WU[5O'VO>(_$&K^)\V5MIMS<:Q=V
MMEIMCI:VVGV_EWPM_8Z^'WPR\7?#/Q?-XH\<_$&Z^!GPVU7X1_ ?3_']QX6U
M*Q^$'@?7)M-CUB'PQ/I'A71-6O\ Q'J/A_0O#'@:[\8>)M3USQ#/X(\+:5I,
MEZVH:GXSUGQ;]:T4 >>?%SX<:=\8?A=\0OA/K.M:_P"'=%^)/@[Q#X&US6/"
MSZ+'XAL]$\4:9<Z-K)TB7Q%HGB/1H+R?3+RZM8[B]T34%M_.,T,27"0S1_*7
MAS]@3P/X9UO]D77K+XR?'*XOOV*? /B?X:_!H7US\'IH)O"_BWPQH_@G5H/&
M"1?!R"36[H>$/#N@^'[2ZLY=(:VMM+AO55M8N=0U*\^\** /R>^-_P"REJ?P
M!_8T_:)^'/PAU3]H_P"-5K\;_B[%X[^(VDZ+>?#*_P#BMI/AOXL?$WP]>_M
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M10%55 55     I]% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MAZM;R7.@^ M#T']F?P7#<'?:2I)IFG?$_P",WB'1+N%ABU\4ZWXM\"?#OQ!
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 445\F?MD>/OCG\.?ACH6M_L_^&-4\5^,KKQYI
MFE:GIVD^#=1\;W,/AF?P_P"*+N\O7TG3+>YGMX(]5L=&@;4700Q27,=LSA[N
M,-WY7E]7-<PPN74*N'HUL755&G5Q=7V&&A)IOFK5>67LX*VLN5ZVT.3'XVGE
M^#Q&-JTZU6GAJ;J3IX>FZM>:32M3IIKGEKM=:7/;/B?\7/AS\&?#]OXI^)OB
MBT\*:%=ZI;Z+:WUU;:C>?:-4N;>[NX;."UTJSO[V61K6QNYV*6YCCBMY'D=
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M-KJ5Y8(1^A%%?"_QU_;\^&'P,U7XU:;)X ^+7Q1A_9L\+>"_%_[06J?"[3O
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M$=)U77+M?&WC'5K*35Y= \%:1J?C']'** /S9^+?[)'Q8DU[]L]/@IJ/@-=
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
H* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>ny20077604x1_figure09x1.jpg
<TEXT>
begin 644 ny20077604x1_figure09x1.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
M                                                          !8
M65H@        ]M8  0    #3+71E>'0     0V]P>7)I9VAT($AE=VQE='0@
M4&%C:V%R9"P@,C P- !S9C,R       !#$0   7?___S)@  !Y0  /V/___[
MH?___:(   /;  # =?_; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! ?_  !$( C@$U ,!(@ "$0$#$0'_Q  ?   !!0$!
M 0$! 0           0(#! 4&!P@)"@O_Q "U$  " 0,# @0#!04$!    7T!
M @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F
M)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
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MGF2#5?%/Q"\-^"]4G@67;!,VAZ7H'CFVA>:+]X\)UU_)<B(2RC,@_:+]B/\
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M1@TS2M/A+I#"C3SL#/>7ES)#9Z=I]JD]_J=_/;V&GVUS>W$$$GX _P#!M]\
M[;PC^S/\4?VB-6T]U\3_ !K^(T_AK1=2N1',TWP^^&MNMI#/8SNAN+<ZCX[U
MGQI:ZO&LGEWK>'='EFWO:1>5^4G_  4L^+WQB_X*3_\ !3*T_8Y^'FMRP>!/
M GQ8F^!?P\T"=;FWT+3O$VAW']D_%SXG^)[>VEN'U5M+U32O$]TNHV\320>
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M3:LEW>1>;+# ))H_.?V1OVQ/@M^VW\-];^*WP*OO$-_X1\/^-]2^'NHS>)=
MG\.WZ^(]*T'PUXCNXHK*XEF>6T73/%FD-'=!@KS//"%!@8G^,K]L_P#:3_X*
M&?\ !2'X*^._VCO&/@B[^&7[&/P2'A^^BT/1!K/A_P"'.N:YXH^(&D> =%F@
MU+6I3>_&3QY8:IK]I;ZC?6:?\(WX*TW3[Z>WTSPEJ>NM;>)OW(_X-KO^3&/B
MM_V=CXZ_]4_\":;C:+;W73[M_/4;C:+;W73[M_/4_H3KX2_;"_X*/?LL?L-Z
MKX-\/_'CQ=JUGXE\=:?J.LZ+X:\)Z%-XIUV#0].N8[)M<UC3[.>.32-)O[]K
MBPT>\O3&FL7FF:S!IPN&T;5/LOOO[2'[0?PZ_9:^"OCWXZ_%/4CI_A'P%HLV
MHS6]N83JFOZK*5MM#\+:!!/+#%=:_P")=6FM-'TF"6:&V%U=I/?7-I8075W!
M_G-_M=?%+X\?M-^/;W]L#XSZ9=VFG_'7Q5XOTKP'<;C%H%MI?PWC\.6=SX1\
M&VD\@NSX:\$6'B30-$CU1H/)U?6/[8GNK_4?$T7B66-1C=Z[?KV_448W>NWZ
M]OU/]*;X?^-M"^)G@/P3\1_"\ES+X9^('A'PWXV\.RWMLUG>2:%XKT:RUW2)
M+NT=F>UN7T^_MVGMF9F@E+Q,Q*DU\"_$W_@KY_P3K^#OQ!\8?"SXB_M%0Z#X
M[\ Z_J'A?Q;HD'PL^-FOII&OZ3,UMJ6FMJ_AOX;ZQH=[-97*/;7#Z=J5Y#'<
M1RP-+YL4B+]'?L>7,%G^QM^RU>74J06MK^S+\$;FYGD.V.&"#X6>&)9I9&/"
MI'&K.Y/15)K^#[]FNW_9+_:L_:]_:"^)O[=/Q0U?X*_";Q9'\5?C5+J?A[5Q
M;^(+_P >^+_B7H^H:=X4TF#_ (13QMJNNRFQ\4^(=1FLM,\/W%]+!HKW+7$2
M1O'.15[WO9=OZ815[WO9=OZ9_9W\*/\ @KC_ ,$]?CA\1O"/PF^%W[07_"3_
M ! \=ZM'H7A30/\ A5'QNT7^U=5FBEFCM?[5\0_#;2=$L=T4$K>?J6I6=L-N
MUI@S*#1^(W_!8/\ X)T?"7Q]XR^&'Q!_:(_X1_QS\/\ Q+K'A#Q=H?\ PJ3X
MZ:K_ &1XBT"^FTW5]._M/1/AEJ6CW_V2]MYH?M>F:A>V,^SS+:YFB99&^#?^
M"?O_  3D_P""5'B+XC^%/VD/V/?C_P#$_P"+'B+X+^*++6DT^]\<: 1I.J26
MUW%I_P#PEG@S4/A=X4\7V>FZA$UW]@N+B+3+?49+2Z6QO)FL[I(_=/C'_P $
M&?V+/CC\6/B/\9/&/B;X_6WBOXH>-/$?COQ';Z%XX\'V6BPZUXGU2YU?48M*
ML[OX<:A=6U@EU=2+:P7%]>310A$DN9F!=CW;[NUOG?[@]V^[M;YW^X]*_P"'
MXW_!+C_HY_\ \PK^T1_\Z6OT"^!'Q[^$W[3/PQT+XR?!'Q7_ ,)M\-_$UQK-
MKHGB/^PO$OAO[;/X?UB^T#5T_LCQ=HV@Z];?9-6TV]M-UWI=ND_D^?;--;21
M32?PL?M9_L2_L_W?[=O@?]A']@>?XB^-?&R^(9?!/Q)\6_$7Q9HGB#0[#QHI
M-]XCL=/B\.^#_#\MEHOPE\/:;K.I_$#5)'U2[DOK;6-'L]+MKGPR[:U_;Y^R
M;^S3X)_9"_9]^''[/G@"ZO\ 4=!\ Z3/#/K6J/(;_P 0^(=8U"[UWQ3XBN('
MN+I-/.N>(M2U+4XM)M9WLM)@N8M-LV:WM8V8DDDK7UUU[!)))6OKKKV/HNOQ
M@\3?\%Z_^"?/A+Q)X@\*:QXB^*B:OX9US5O#VJ);_#+4IX$U'1;^XTV^6"=;
MX+-"MS;2B.50!(@5P #BOV?K_/O_ &$_@)\)OVF?^"KE_P#!OXW>%/\ A-OA
MOXF^(7[1]UK?AS^W?$OAO[;/H&C?$+7](?\ M?PCK.@Z];?9-6TVRN]MIJEN
MD_D^1<K-;22PR$4G>]]$WH$4G>]]$WH?U)>#_P#@NO\ \$T_%ES86=U\;=<\
M&W>HWL=C#'XP^%_Q&L[:"6:>.WMY;_5M(\-ZWHNG64KR!Y+^^U*WL[*!9+C4
MI[*"-Y!^I$GQ%\&/\.Y_BMI7B#3/$O@!/!]QX\LO$_A:^L_$.DZWX4@TB378
M]9T#4-,GGL=9LK[2X_M>G7-C<RV]]%)$]O,Z2*Y_FE_X*P?\$>_V)O@?^Q]\
M0_V@O@3X;U;X*>+OA)%H5_\ 8AX[\<^+_"WCJ+Q-XT\*>%!HVN6_CW5_&FJV
M.J1#5G7PO=>'-0T2U;5;O[/XABO;*6&\TC@_^"#'Q1\<^(OV+_\ @H#\)];U
M&[OO WPS\*KXD\#P7<TEP-(O_B3X ^*4?B[2M.,I9K32VF\#Z+JZZ= R6<>J
MZOJ^HI MYJE]-<#2M=7T=G?Y=O4&E:ZOH[._R[>I^B/_ !$&?\$Z/^AD^+/_
M (:W4_\ Y.KV+X6?\%K_ /@F_P#%;6M%\-V?Q]B\$:]KUP]K96GQ.\'^,/ ^
ME03H;I@-5\::IHI\ :)'+%;"6&XU?Q796TK75I:+-_:,QLT_EU_X(>?LE_L^
M_M@_M(?%+P#^T7X _P"%B>$_#GP1U'Q?HVD_\)5XV\)?8_$4'CSP-HL6H_;O
M OB3PSJ5QLTW6-2MOLEW>3V+?:?.:V-Q#!+%^MO_  4G_P""&'[+_A;]G3XF
M_'#]E70_$?PK\:?!SP%JWC>\\"GQEXD\8>"?&GA[PGY_B#QA-=/XZOO%?B[3
M_%-OX4M]2ET(Z1XBAT6]N],L=+N-!6XU*;6;=M13M[WX6U&U%.WO?A;4_IS#
MJT8ECQ*K)OC\MD82J5W+Y;%@A#C&UBX0Y!+ <U^57@;_ (++_L2^-_CGHW[.
MIUWXC>#?BAK/CR;X8#2O'OP\U3PS::7X^BU*XT-/#&MWLT]P-+U*X\10+X=A
M6XB$2ZQ<6]O<2P1-)/'\#?\ !N7^U=XZ^*7PF^+7[-OC_7)M?@^!#^$-<^%U
M[JEZ+K6+/P)XP;7K+4O!Z&0"YFT#P=K.AV=SHCS/>2:?;^+6T*.:ST;2M T^
M#YJ_X.$OV!'\.ZU9?MY_"G29(-.UJ\T7PU^T#9:8MPHTKQ&?LNC^"/B@J0QO
M#96VM^58>#?$URLUC$OB)/"%Y%;7FJ^)M;OU7*N9Q;]'_F+E7,XM^C_S/ZH/
MB[\6/ 7P*^&7C;XO_%#7[7PQX"^'V@7OB/Q+K-T<B"RM%58K6SMP?-U#5M4O
M)+;2M$TFU62_UC6;VQTK3X9[Z\MX9/B[]DS_ (*B_LO?MK_$/4OAG\!3\2];
MU[0_#=WXLUZ^UKP'=:!X?T31+6[L]/2;4=7O+XPI<WVH:A:66G6$"3WUY(\T
M\=O]CL=0NK7^//\ :_\ ^"IWQZ_;<_9Z_9R_9GU6TU47WA*RL8OBQ?Z4TUYJ
M?QV^)&G:C<Z%X#U">QMOM6H7)@T!=-U74--640:_\2==U74H]%@AT3PH;?\
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M3Q)9C4;73=UT?78&HVNF[KH^NQ^\[LJ*SNRHB*6=W(55502S,Q("JH!))(
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MG<Z_HF@^';75+W4="M- T+0?AUK^OZ:\^GLW@#0-;>WM8=<GDB]R\=_M;_\
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M4M3%[<"2X6_OTOKU+N[603W$=W<QRNR3R*W\;_\ P<H_\GS_  I_[-.\"_\
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M[#7[:'[-7PC^$WP1^%_QS\ >-O@+KFC0_#&Z\9^#/AYI_A;3OAXOAQ/"NO\
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M=M;32I\R?\&_'PC^*_P8_8U^)GA?XP_#'XA?"CQ-?_M-^,M?L?#OQ*\%^)/
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M_+J$FI*^S6ZOT_I^74_J8K^+K]I!XO&O_!Q[X0L=9OUL[#0?V@?V8DTO^T!
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%>9_%GXU?!OX!^$7\?_'7XM?#/X+>
M XM1LM(D\;?%GQYX6^'/A&/5M2,HT[2W\2>,-5T;1DU'4#!,+*R:]%S=&&40
M12>6^ #TRBLW1M9TCQ%I&E>(/#^JZ;KN@Z[IMCK.B:WHU]:ZGI&LZ1J=K%>Z
M;JNE:E92SV6H:;J%E/#=V-]:336MW:S17%O+)%(CG2H **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **YKQ7XT\'> ]*_MWQSXL\->#-#-U;V(UGQ7KNE^'=*-]=EA:V?]
MHZQ=6=I]JN2CBWM_.\Z8HPC1BIQTBLK*&4AE8!E92"K*1D$$<$$<@C@CD4 +
M1110 444UW2-'DD=8XXU9W=V"HB*"S.[,0JJJ@EF)  !)( H =17D6E?M _
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#\U/^"K?_ ":M'_V5/X?_ /I1J-?I
M%9?\>=I_U[0?^BDK\W?^"K?_ ":M'_V5/X?_ /I1J-?I%9?\>=I_U[0?^BDH
M!_9_[>_]L+-%%% &-K.JP6,<5C'J.DV>NZPE]:^&;/5;R*W_ +5U:VT^ZOUM
MK:W,B7-]Y$%M+>WD-DDL\5A;W-P56.)W7^4+4_\ @EG\1?\ @I#\9-2\$_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MP9XDTO5O"::HNN0:3X>M=5\.:]IFD:M80Z/;WCV%VG)_MD_MP_\ !3C]NO\
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MYMF(YBG>Q_9?O;-I$Z,;:[N(B?NRL.:_J._9I\*?%OP)^SW\%/!?Q[\8:?\
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MLNI\;](_^DH****H@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'+_A-O\ A2GQ@_X5I]N_X6/_ ,*M^('_  K_ /LP0-J7_";?\(GJ_P#PBO\
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M110 5_,]_P '97_*)+6O^SA_@M_Z-\35_3#7\-W_  =4?\%+/"OB+P)\5O\
M@FE%\$/BU9^*O GQ'^!7C^X^-]S::</A-JMM>>"[+QRNDZ==+-_:1U".W\90
M:2_F1"/^U--OHQ\@1C,_A?R_,'M+_#+\4U^;/[ _V.O^31?V6/\ LW'X'_\
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MO<-&P99!!,4E*,K!@NT@@XK^3?X[_M8?\%8?V6],M_AM_P %*O\ @EQ\&O\
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MA&_\$B\\1Z[IUNMWI<>DV2ZE.FF+;VGX5?!#]IGXS_%:X.D^//\ @O;^U_\
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MT[X5M\/O^"B_AIA\+[CX[?$";PUX>O/%/COX@SWOA"[AU;X>ZEXS@;QSX?\
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M%O/M-%T>QO)M4CTJTN1\O?LV_L3_  B^)?\ P;H_MJ?M3>,/AYX,\3_M'O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ML77E\-^GQ?TEIY(ERTNFK\J>_6RTWZ-;;_=I_H7_ +*GBWPIX^_9>_9N\=^
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M *K+PQ7T=3CLO1?D.6[]7^84444Q!1110 4444 %%%% !1110 4444 %%%%
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MVWP+\+]/E-[\._A*SX,=Q:6\A:V\2^-8HPJ7/BJ\CE%M,&&C+"B0W ^O:**
M"BBB@#\U/^"K?_)JT?\ V5/X?_\ I1J-?I%9?\>=I_U[0?\ HI*_-W_@JW_R
M:M'_ -E3^'__ *4:C7Z167_'G:?]>T'_ **2@']G_M[_ -L+-%%% !117XB_
M\%V_VT/CI^R)^S)\*M$_9J\4:#\._C)^TO\ M >"_@1H7Q6\5164'A_X8:/K
M=CJ^JZWXIN-;U_2]4\(Z%<M)INF:/+J?B*WF_LGP[JGB3Q+I-L=0\/1W^FIN
MRN^@TG)I+=NQ^W5%?P9/<_\ !53]F_X:_P#!7CPS#_P4*^('C3XW_L#?$?\
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MVIC=INE^&="TRZU37M1U ;),V-CI5K=W-V/+DS!%(-C_ '3^,?\ P34_;/\
M^"KG[17QU\5^"?VZ/V M!_96^$FE_";7?%/A[XA:6_BIKC6/B+8^+_ FDZ1X
M-<:YK^J6GDZCX:UOQ;K;&.W2YW^'H]DRQ><DGZA_M6_"+4OV@/V7OVC_ ($:
M+J5MHVL_&CX$?%OX4Z1J]Z919:9JGQ!\ Z_X3T^_OO(228V5I=ZM#/>+%&\C
M6R2JB,Q"EQV6M^VEM.V@=?N_+T_1^5S\(?V.?^"SOP2_:C\#?MO?M/\ B/\
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MM!FETFQ6 6]A(UM'&3,;=+?*]^G=_P!>NA=1NRNI+UM;9+9)*_\ 6VWYD_\
M!7GX[?\ !)K]EL?#WXK_ /!0+]G;X?\ Q_\ BAXOTZ;P5\./#R?!SX=_%3XN
MWW@SPS>:AK5\UE+X\O\ 0-.T?P/X>UKQ/<2.^I>)=/@?6O$TZZ39W]U+J9M_
MSU_X*0?M(?\ !"S_ ()T^+O"'PMUW_@FY\!/C+\8/$_A/2_'.J^!O OP0^#F
MFVW@#PUKB0S: _CKQ)K&E-;:?KOB&U:ZO]'\.Z38ZUJ*Z99IJNN+H>F:UX8O
M-<\T_P""P>L_!'X&_P#!=[]@?]H;]M[P?9>)OV-;O]FW5?!^J:AXP^'4WQ!\
M 6?BO0[[X_P^7?\ A2/1/$$?C&7P3XH^(WPS\::K:6^DZCK&CP:UHVK6VGW,
MNEZ7#<^$?\$N_C#\*?C?_P %(/\ @I=_P6M_:'O+3P9^RO\ !^UU#PAX$^('
MCCPUJS+X>_X6/JWAWX5?"^.STW1=/UJ:[\3Z/\"/#MEX'\4:#HL6J7UI+\3]
M'LA;S0ZU:R2#>MM+W73I9-M_AVVT\G&/NJ7O-<MVDW9MOEC%6VL]^NI^_P!_
MP1\^.W_!-?\ :8^%OQ"^+/\ P3^^ O@?]GG5$UK1O"/QL^'^F_#?P#\-_B'I
MM[IT.I:AX.F\6V7@.\U.PUKPSJ<%_KUWX(U^/4[RQO'3Q'8JMAKFE>(=)T_]
MAZ_D:_X-MO[.^(W[6'_!6[]HWX+^&=0\"?LI?$SXTZ-#\*O#[>%$\/:%>I>>
M/?C#XS\-:9I$5FJ:/H5[\/? OB32QJO@C2#/;>&K/XB:#9*T=E#ISW7]<M.+
MNE_7D1-6DUKTWU>J3M\M@HHHJB HHHH *_+']N+_ (*R?";]A#XI>'?A/XZ_
M9Q_;*^,.L>(_ MAX_@\0_L\_!G0_'W@RPT[4==\0^'X=(U+7M<^(/@T1^(XK
MGPW=W=WIEG:7JVNG7>F7$URCWJ0K^IU% U9/577:]C^5G_@W(^)&F_&3]I+_
M (+2?%[1M"\4^%](^*G[76C_ !(TKPSXXTR#1/&OAW3?''CS]I'Q/8Z%XPT:
MUOM4M=(\4Z1:ZI%I_B#3+;4]1@L-6M[NTAOKN.);B3^J:OYG/^"$W_)]7_!?
M3_L_W7O_ %</[4E?TQU,/A7S_-E5/C?I'_TE!1115$!1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !117CGQ\\9_$+X?_"OQ+XK^%O@IOB!XUTT::NE>&DL]3U-[A;S4[2RNKI=
M(T4IJVK"PMKB2[DL-/GMIWABDF^T1QPR9%JTNX'L=%?A[K/_  4*_;$\.^(=
M*\)>(/@GX-T+Q7KOV'^Q/#.L_#?XHZ9XAUC^T[Z73--_LK1;WQK!J6H?VAJ4
M$VGV/V2VF^UWT,MI;^9/&\8^[_V4/C5^T;\5K_Q;:_''X,GX;V.CV=A<:-K!
M\,>+_!BZC>74\D<FFQZ3XPO-1NM3*01R74NH:?=1P6.R*WN8&DO;=UIQ:5W;
M[]]MOO\ ZTO*DGHK_=Z?U_2/M.BJM[?66FVL]_J-Y:Z?8VL;2W-Y>W$-K:V\
M2#+2SW$[QPPQJ.6>1U4#DD5\S^-OVT/V9/ 9:+5/BUX<U:[\N1X[/P<;OQK)
M(\><V[W7A>VU33;.X)!4)J-]9 -P[)4V;V5QMI;M+U/J*BOSWA_;F\2^.Q;?
M\*(_9A^,'Q&MKN62V37M<MH?!_AF.895'_MNUM_$^E&+.&9;_4=(;;D,T9!*
MH8/^"C/Q(5#)=_!S]G[3A<LLD5ND?BWQ.UD^06)=?'6@W,T:DE3!=:#(S ',
M1&:=GULO5Z_<KO\  7,GM=^B?ZV/T)) !). .23T ]37AWCC]I;X!_#G[0GB
M_P"+/@O3[NTD,5UI5GJ\6O:];R#.5F\/^'QJNN1X((RVG@;@5SN&*^9T_8/O
MO&2EOCO^T?\ &/XJ!KD70T>TU0^&O#*%\F:W.C7USXIC6)BS('TR31R(\"..
M$85?;_!?[&_[,_@38^C_  C\+ZA<H%S>>*XKGQG<&5=O[]%\57&KVUK-N4.&
ML;>U6-LF)(\D4>[W;VV7W[_/H@][LEZN_;M\^OW'C-W_ ,%!_ VO75WI7P8^
M%?Q?^-.K6V=G_",^%+FTTAQDA7GNF6_URRB8E&:2Y\-*L<3[WP5*54?Q]_P4
M$^)AV>$?A#\-_@?HM_;[[;6/B#KW_"0:[9-P1NM[*2XF@D8'!@U'X?DJ5);9
MT/Z!VEG::?;065A:V]E9VT:PVUI:016UM;Q(,)%!!"J111J.%2-%51P *L47
M71+YMO\ R_(=GU?R6G^;]=3\]H?V1_CUX\:.Y^-_[7'Q O8+J%X]5\+?"^W3
MP9I+^8NQHH[VV>TTN[@*Y5ENO!$98%B1EVK\\/VVOV.=*_9X@\/>-?!>OWNI
M>"M?O;3PY/8>)+P7GBBW\3M8ZGJ$U[]IL]*L=.NM*O;/37FD9C;W5MJ$CQ1V
M\UI*C6W] 'B*37(O#^N2^&(-/NO$L>CZG)X>M=6EEATNYUQ+*=M)@U*:#]_#
MI\U^+>.\EA_>QVS2/'\X6OPX^,WPY_X*+_'?2[?P_P#$?P -1T/3M>;Q!IVE
MZ=-\+M,@L-0%O?642P7ECK:ZA<6UO::A<V\*7E_>&1"DLTL\ZB8U%N^Z2ZK1
M7OZ==")15M$VWUU?;<^\?V!?V>U^"_PI_P"$KU'5(-4\3?%W3_#'BF^%EYG]
MG:5H"Z=<7WAC2H6N+>"XFU".WUV\NM9N"J6_VNY2QM4F@TY-1U#[NK\QOV6V
M_;V\/^,_!/A#XI^%=-M_@[H^AC0;V74SX#AN=$TG1=">UT)M-N_#&H/K-[J(
MNK73;';>6^IQ7-O+</=?96+:I:?IS4RWU:=^VQ4=EHU;N%%%%(H**** "BBB
M@ HHHH **** "BBB@ HHHH **** $(!!! (((((R"#P00>""."#UK^+'X)?\
M$]/^#CS]E+6/BWI_[,G[2G[*_P -OAM\3OBEXM^*%Q\-K?2OAIJ/@G2?$OBF
M]674M6\+>'M<^'>I)X+_ +5BM[:74-$\-3Z9X?:ZWRII,;K&8_[3Z_C;\2?\
M&_\ ^R9JOB+7]4N?^"UWQUTVYU+6M5O[C3A\?/AK&NGSWE]/<2V0CD\2I(@M
M9)&@".J.HCVLJL"!,EL]=.SMO9=NHUUT;VV3?WV:^[9^J37ZQ?\ !-/P3_P6
MY\-_';Q7??\ !2;X[? KXG_ N7X3:]:>%= ^&/A_P!I.OVGQ7D\8>!)M"U>[
MN?"O@[P]J#Z1;^$(/'5G<0S7LEDUY?V#R6KSQV\L/[A5_%[_ ,$:_A1\./V*
M/^"VGQS_ &6+#]M3X@?MA'Q!^QQ>:W\+?%,'CA/&7@#3H-3\=^ _$/C#PIXZ
ML[;4]=L-.^*?ARW\&6FH:-K.BZH=%N/"OB"\LK^VT_6KRWLV_M"HCM\^KO\
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MSC^QU_R:+^RQ_P!FX_ __P!5EX8KZ.IQV7HOR'+=^K_,****8@HHHH ****
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MDVJV\>H2ZB]UF4_+_P#P4F_X*U?LY?\ !+?_ (4Q_P - >"OC9XP_P"%Y_\
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MDGM?[CKZ*QM=\1^'O"VGRZMXFUW1O#FE0?Z[4]=U2QTC3X?^NM[J$]O;1_\
M Y!7REXX_;T_9D\$M/;)X\;QIJD+*J:5X"TN\\1M=,QPJV>LA;3PM.Q)  &O
M@DD  YH2;V0-I;M+U/L:BOST?]J[]HOXB>=#\#?V2_%YM)8XY]-\5_%B]C\)
M:5/!)@B8:9=OHUE>Q[3N']F^,[AV .U&. 1_A)^W;\3O._X3_P#: \(?![1K
MV..3^P_A/H,VH:K9N<%[<ZO,-%U>SD RIFM/&FJ1 X91(."6[M+\7]R_KO87
M,NB;^7IWMW_4^\M=\1^'O"VGRZMXFUW1O#FE0?Z[4]=U2QTC3X?^NM[J$]O;
M1_\  Y!7R;X^_;U_9I\#I>V]IXY7QQKENC"VT;P/I]]KJ7UPP(AB@UZ."+PR
MRR2;49TUJ1U#;EBD("GF-$_X)Y_!5]0.N_$S7/B1\9=?FCC%W?\ COQCJ/E2
MSI@F:(:*VF:MY;,,BWU#6]33!*NSC.?2_B-X5T_]G?X4^(_%7[.7P)\(ZIXZ
MTR#3+;3=&T'PF9M6U"&ZU*SL;FYNUT""/Q1XD^P6T\EW-:1ZBMW-%%),]TD<
M,A+5KK=N_HOU?X+Y!>79+[WV[?U\M3^;7QOXY\8?$'Q9JWC+QKKFHZWXHU6]
MDNKW4+Z9_.BD\UGCM;2(;(M.L;'/D:?IME';V6FV\<=K9V\$$4<:_L!^S[X>
M_;9^/GPD\+:S/^T3!\/O -W:7VDZ9J$/A^#7?B)K%KI&HWNF/JM_JDMKIVIF
M4W%M-96]^GBVWO;N*T6\NHI)F6ZNO@_XD^#OVA_B?\2/^%F:U^R7XBTG4+N\
ML]0\0^'O#/PA^+.D^%_%E_!?RWU_?:[:&]N=52\\0+(+77KG0]8T6:]16OXW
MM];N;W5;G]??V.?BG\>?&\.N>&/BK\";3X0^&/"&C:/:^$I;#PCXJ\!:>8T+
M6<.@V&@>*[J^EO(+6RMS*+S3+B&VTY(H;6XMV>]MW6Y/1:+\';;1??\ =\B(
M[N_-KZZ[;V]?QWV,G3?^">_PUU6\M=8^,7Q!^+/QNUN&+RYY/&/C&_@TR3G(
M-M%9R-XAM%QQY?\ PE,Z8Z $9KZ3\$_L[? OX=?97\'?"GP3I-Y9/YEKJSZ'
M::GKT+\X9?$.KI?ZX2,G:6U [02%P*]GHK-MOK\NGW;&BBET04444AA1110
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M_P#%WCC2KGQU>+XBU^ZFG3[1/?W^CV%[J=C;1VNDWDT4B26 M[BX@E_=, *
MJ@*J@!5    &  !P !P . *_,?XG_P#*5+]G#_LW[QC_ .A?$VOTYH$%%%%
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MDZ8B:Z^B>&_&<5U]ITS0='NI+74X]*UOPYJ;ZIIUY/JUHUDVG_N5_P %:?\
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M_9]1LDO \&HZ)JUN&=;?6?#VKVVH:#K$$<DL,.J:==QPS3PJDK_@I_P=E?\
M*)+6O^SA_@M_Z-\342^%_+\T+I+_  R_])9^Z?['7_)HO[+'_9N/P/\ _59>
M&*^CJ^<?V.O^31?V6/\ LW'X'_\ JLO#%?1U..R]%^0Y;OU?YA1113$%%%%
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M_6%E;S@7*>,-@\+F2:,ECJX5'TW=^U]?S8_\&_G[27[-7[2NH_M2>(?V7_\
M@G3H?[$?@KPW%\+-"UOQGX?\8:QXWL_BOXB?_A,]0?PW<ZG<>"?"FBZ;J/P_
MLKF#4)M'LK[6M1^Q^-+#4+]=.@O+*.X_I.JELMODK(B:M)IWOI\33>RW:T?E
MY!1113)"BBB@ HHHH _F<_X(3?\ )]7_  7T_P"S_=>_]7#^U)7],=?S.?\
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M?V.7ER+.SN[LPS7 M;:>Y,%M&TUQ,((GE,-O$N6EFDV;(HU^9Y&51R:_-/\
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M#^ ;)-1\<>,/#/A"QD++#=>)=<TW18;AT +16S:C<V_VF;D 0P>9*Q955"S
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M;46RVTFA:_HVJ+MNFD^R:C;R%!N8+,_A?R_-!TE_AE^3/Z8?V.O^31?V6/\
MLW'X'_\ JLO#%?1U?./['7_)HO[+'_9N/P/_ /59>&*^CJ<=EZ+\ARW?J_S"
MBBBF(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KSCXL_%/PO\
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M;:IHFIV&KZ;<?VUJ[^1?Z;=17MG-L>Z*OY5Q#')M8%6VX8$$U]NT44 %%%%
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MBN-MMMMMMMMMN[;>K;;U;;W9PMMMMMMMW;;NV^[;U;/C/]N[_DA7_<\>$?\
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M7ZMJFH:IJMM:V'A?3->NH(M0U**PTJ^3V>MO/MJ5#XE=75]K7O\ )GB.D?\
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MKQ)8_M?:+;3Z7X5T^\ETGPOH6EZ5I6B:1;27^H1Z?)XAU_Q-K6M?HC_P4_\
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MUX4TXQ)#%!"8GLV1HHS&0(7\I2?X2_\ !0SPW-&OA?\ :>^&OCBRB7 @\>^
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MLE'K^A2ND46MZ1))(ZQQQQZE9N\CN0J(B+,69V8A5502Q( !)K6K^:_X8_\
M)2?A[_V/'A/_ -/VGU_2A73X%>-%;QER_B'&UN':?#SR/&8'"JG3S269K$K&
M4*]9S<I8# >Q=-T.514:G,I7O'EUP\7/"VGX88S)<+3SN>=+-\-B\0YSR^.
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MYF\/_$C]DGP1@>%E\*Z;,%VFZT+P%KU_J,P4$?O=1L?#=YJ%T<*0&EN)6.0
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MWRBOU5\$YG/E]KXC\>U.5ZJ-7A+#J:LU:7U7A&@U>][P<)72::Z_$_6Z:O;
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MI4U"527M,-7YE&/LY3T****_7SX **** "BBB@#Q'Q3^SA\$O&NO:CXH\4^
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MLD@HHHIDA1110 4444 %%-=TC1Y)'6..-6=W=@J(B@LSNS$*JJH)9B0  22
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M^U)7],=3#X5\_P V74^-^D?_ $E!1115$!1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *AN;:"\MY[2ZACN+6ZAEMKFWF19(9X)T:*:&6-@5>.6-
MF1T8%65BI!!J:BC;8$VG=.S6J:W3[GS?I_['?[*.DW]CJNE_LX_!;3]2TR\M
MM0TZ_L_AQX5M[NQOK*9+FTO+6XBTQ98+FVN(XYH)HV62*5%=&#*"/I"BBMJN
M(KUW%UZ]:LXW475J3J.*=KJ//*5KV5[6O97V.O%X_'8]PECL;B\;*FFJ<L7B
M:V(=-2:<E!UIS<5)I-J-DVE?8****Q.0**** /QK\:?\$F?%GC+XRR?':7]N
MG]HC3OB'9G7++PIXBMV$FN^"O"^M7^L7A\(>'-<;Q$FH6&@6D6NZE9Q65L\%
MNT%W<@PK]HE4_L+I-E+IVEZ;I\][<ZE/8:?9V4VHWC%KO4);6WC@DO;IBS%K
MFZ>,SSL68F61B6.<F_17H8W-,=F,:$,96C5CAHN%!1H8>C[.#UY$Z-*FW&]V
MHR;2;DTDY2;^@SOBG/>(J67T,XQD,72RJC+#9?&."P&%^K8>3BW1C+!X7#RG
M24H\T8593C"<JDX*,JM1S****\\^?"BBB@"E?:9INJ1>1J6GV.HPX8>3?6D%
MW%AAAAY=Q'(F&'##'(X->">-/V1_V8?B'+)<^,O@+\*]=O9#(W]I7'@W18=6
MA>4 /+:ZM:6MOJ-I,P !FM;J&4=G%?1%%;4L3B,.[T*]:B^]*K.F_OA*+.O"
MX_'8&:JX'&XO!U5M4PN(K8>:])T9PDOO/Y4/^"G/["WP)\%?M'_L?Z+\-/&&
MK^!]#^-GQ6TKX7^+_#/_  EU]XCM?APEQXA\&VTOB[P[_P )'K6HW_AUI[+Q
M#)<SZ;/<P:2EQIEK=6BVT;S1K^UFF_L'Z*VDZ:GAS]L7]N.UTF*TAAL)-&_:
M1N+RP>TBC6*+[*;KP[J5KY(V90V^%!RBGRQL%CXM_P#!,G]CGXX?$3Q/\5?B
M1\,YM<\;>,+JUO=?U5?$.LV8O+BSTZSTJW<6UM=1P1!+&PM8=L:*#Y>XY9F)
M^OOA?\-/!_P<^'_A7X8> --;1_!O@S3$T?P]IC7$UVUEI\<LLZ0FYN&>>;$D
MTAW2.S8.,X KZK,N(IXC+,IP]#,,=6Q6"IU(8AXK#4.6HZTG4<E6=6O4J2H^
MY0@YQ3J0C[63C-N+_5N(_$JOF'"_!^68'/\ /L5FF18;%4,REFN6Y>Z&)GC:
MTL5*I#%RQV/Q&(E@_P!U@*4L10A+$T*2Q4Y4:LY4#Y0'[%?B^S!_LC]N']M"
MW8$.IUCX@> _$(#_ '7++??#1 \;(,+$3L1\RC+'%0+^R/\ '6V9VT_]OS]H
MZ/(81C4= ^#^KA!G,6Y;OP%M=D.-[!4,HRIVJ<5]YT5X2S?'+[>'E_CP.!J=
MO^?F&EV/@O\ 6S.F[SJ9=5=K7KY%D5=V[-ULMFVO7S[L^#IOV;/VOH@RZ7_P
M43^(=NA96"ZI^SS^SMK+ [0K@RMX/LY=K8!1$=%0Y.'+-D7X"_MP62?Z-^WO
M'J[B,C_B>?LQ?">W4R*<HS'1+BQSYGW9BJ* .8HU;I]XT4O[5Q3WI9<_7)\I
MN_62P2ET[_FQ_P"M>:-)/"\-M+OP=PCS/UFLC4W\Y'\RW_!9'X9_MH:+^S]X
M-UGXD_M!>$OB3\+[3XFZ/::GX=\/_#VQ^'FH_P#"3:C97<?A75;N2TN=3.JV
MNGR0ZM$ELMW:1VLU['=RPWDBPM9_O;^R]X?^,7A?X!_#+0OCYXMTOQQ\5M/\
M,V</BGQ%I%B+*VNI2&>QMYF4K'J&H6&G-:V6HZO';V::K>P3WPM8S,6?YD_;
M"_X)S>#OVR_%5GKWCKXT_&KPOH5GI&CZ<OP^\)>)HX/ <NH:+>:I=VGB27PW
M?P7>G-XA_P")K);G5! +E8(+>-)%"'/T]^SC\#!^SQ\-XOAT/B5\2/BLL.LZ
MGJZ^*_BIXBN/$_BDKJ(ME73#J=RS2#3;%;8+8VP(2 22!0-QKVLSS3"8OA[+
M<%&MAOKF&Q5?$5:-'*XX3E6(C!<D*U-1I_NW&7M7"*5?]RW_  5?[/B7BK*L
MV\.N%\BIXO+?[8RO-<SS#&87!\+T,J<89C3P\:<*>.PM*C0<J,J558SV5."Q
MR^H.:D\#!GO-%%%?)GY.%%%% !1110 4444 %%%% !1110!\>_\ !0W4]9T7
M]@']N36?#EU>V/B'2?V/?VF=3T&]TTNNHV>LV'P6\;76EW5@T0,BWMO?1036
MIC!<3I&4!; K^/S]C_0_A_+_ ,&JW[=GVW4)D^W_ !E\2:YXDQIY?[-\0-(\
M8_LY?\(5IZ?\2R3[3#>_V)X \W4/]+%E_:$N=3T_[ ?[,_NPUW0](\3Z)K/A
MOQ!I]MJV@^(=*U'0];TJ]C\VSU/2-6M)K#4M/NXLCS+:]L[B:VGCR-\4CKD9
MK^*S6_\ @A5_P5D^'WP[^.O_  3R^ OQI^! _P"">7QU^.=K\4)_$'C+6YYO
M'VE^']&UK1;K0K?Q-#;> +;7E\23:;X(^'UWXJT?PE'/X<UGQ#X2TP:9KFA:
M1JOB2*[F7I>Z:^^V_EIN:TVK6;2]Z,KOLGJO7L?I1_P2W^(/[9OA[_@@1^RG
MXJ_9&^%_@;X[_M#V9^(VB>'O!GQ>\8R>#=!?P78?M+_%O0(;N*^GO] M]2?P
MYX5LM(BTG1;SQ7X3MI]$MWN;/6;J[L;#0M;=_P -+_\ !S+_ -(ZOV)__#NZ
M7_\ 1/U^['[.WP+\$?LQ_ KX3?L^?#>*[C\$?!_P'X=\!>'YM1:WDU74;70-
M/ALYM;UJ6TM[2UN-=U^\2YUO7+FVM+6WN=6U"]N(;:WCD6)/9J+:+5JR2T_X
M;^OO)YU>3Y8N\F_>3OKTT:/X(O\ @EY\9?\ @LCX8_:9_P""I6J_LN_LD?LZ
M_$GXL>+/VHK[6?VMO#'CWQS8:'H/PM^+TWC_ .-]S?>$_ %ZWQN\.0:UH-OX
MDO?'>GK=VVN>-(A9Z+I,JZ]<)=I>:A^Q]K^T[_P<YR7NHQ7'_!.']BJ*TA:V
M%C.WQ8T%$N5>)C/LDA_:TO;B7RI %8W6GZ45+!8DNUW3+E?\$)O^3ZO^"^G_
M &?[KW_JX?VI*_ICI16BU:^[OZ>7Y]V5.24K<D7I'5IW^%>9_,!X\_;9_P"#
MDSX7>$/B1\2?'O\ P3P_8NT;X??#+P9KOCWQ%KD?Q,TV_:V\->$] OO$?B>^
MM[32OVK=3UG4Y-.TW3KJ46,6A6EW/)%]GL(]1DDC8^<_LR_\%+_^#A7]KSX3
M^$?C_P# C]@7]C/Q9\%OB!::_)X.\5WGCD>%Y=3NO"GC#7O WB&*32O$G[4N
MG>)K1K3Q#X;UBRCCU#PMI\,\=G]MM;ZZM;FU:3^GGXT_#+3?C7\'/BS\&M9U
M*^T;2/BW\,_'GPRU75],2"34M*TWQ[X6U7PK?:EI\=TDEK)?6-KJLMU:)<H\
M#SQ1K,C1E@?GC_@GA^Q_!^P1^QQ\%_V38/'<OQ,_X5/9>,EN?'$V@)X6_M[4
M?''Q%\7_ !(U22#0$U77/[,LK+4O&%WIEA#)J]_.]C96\UQ<-/+(%=G?=V]5
MY6Z?U\W=<\>7X(<UUI9VM9W>_>W7Y'Y!G]IW_@YS_M5;<?\ !.']BK^SC9&5
MKO\ X6QH)C%WYQ40><?VM%O _E#>8QHKVY!#?VBL@, \)_:<_P""E_\ P<+?
MLA?";Q3^T!\=?V!/V,_"GP7\ P:&WC3Q59>.1XHFTF;Q5XLT'P1X<5=*\._M
M2WWB6Z^V^)/$FCV#II?A?5DA6[^V7ES8V5M=3Q_UBU\3?\%%OV/3^WQ^QI\9
MOV3%\?#X7R?%>#P+Y'CIO#?_  EZ:%<^!?B;X+^)5L9?#HUSPVVHP:E<>#H]
M(G":U926L.H/>QF=[9;68:=M&[]-5_EY?GW8*:NKP@E=7T>W7J?C9X?_ &P?
M^#EOQ?HW@SQ7X6_X)U?L6ZCX5\8Z'8^)+'4S\4=)M]VC:SI5MJNBW,T-_P#M
M8:=J-B]Y;W<+^0-)U"XC8M#=PV+*9*W+W]IW_@YTCNM.CM/^"</[%4UO-/(M
M_*OQ7T&1;>$(-C.\_P"UMI\T.YSP]M9ZLY",K6T65D/]$7P^\(6OP^\!>"/
M5C=W&H67@CPAX:\(6=_=)''=7MKX:T:RT:WN[F.$")+BYBLDFF2("-9'94 4
M"NNHM_>E^'^7E^?=BYU_)#[G_P#)'\CWQ\_X*K_\%\/V;_B-^SI\*OBM^P[^
MQ=X8\;_M2?$!_AO\&])C\7:KXEC\6^*(+[PUIUQI4NIZ!^TI/IOA?%WXNT%5
MU7Q)<VFG!+F5U,BV]P8?I'5/VG?^#G6""%M._P""</[%5U,UW!'*B?%?09RE
MLQ)GE9;O]K;1D554 >9'<7$J,RLEE<@,J_IW^VA^P!9?M?\ Q\_8,^.-S\3+
MKP-)^Q+\<;[XPKX=@\,PZZGQ#ANI?".J1Z VI2:SIC>&Y8]:\"Z&KZD+/65?
M2[W58ULENULYD_16BSUU?EJNR\N_]:N[<XV5H0OK?1Z:Z=>WJ?S8ZI^T[_P<
MYV]E)+IW_!.']BJ[NU:()!'\6-!F=U,J"3;'>?M::+;G;&6;+ZA$5 W*DS 0
MO\[ZG_P5'_X. X/VEI_V.-/_ &"_V-;K]I!?@['\>8? T?C:6:U?X8MXK3P<
M^O#Q-=_M/Z/X.>=-;9[9M%D\4VVLB-3=I92PA1)_6M7P-_PP]'_P\O\ ^'A_
M_"QWV_\ #'__  RW_P *G_X1==WV_P#X6E_PL'_A//\ A-?[=Q]C_L__ (D?
M_"*_\(MYWVS_ (G'_"2^1_Q**+/HWTZKNK].R_J[N*:UO"&VFCW^\_*V^_:;
M_P"#G&.PGEL_^"<G[%,UZL!:"%?BQHDK/-@87RI_VL-.@?!)RCZG;(0"!<C@
MD;]IS_@YP&G&=?\ @G%^Q4;X61E%K_PMK0C*;OR-XM_+/[6"6GF>=^[V'5EM
M]WR_V@(_](K^DNBBW]Z7X?Y>7Y]V+G7\D/N?_P D?R1?L_?\%4?^"_/[3>K_
M !T\*_"']A']C3Q)XL_9K^)NN?!;XRZ9=>,[KPZ/#'Q0\-76HZ=K?AZVEUS]
MIJVTW78[/4=)O[8:IX>UG5]"N#"'M=;GMY8KE_I'3?VG/^#G&:PMY=0_X)Q_
ML4VUZR'SX7^+&APLCAV49BM?VL=7@0,H5U6/4KK"L-TBON1/U%_8?_8/MOV-
M/B!^VYX]C^)4_P 0+C]L;]JKQY^TFU@_AB/PW#X"M/&FHZAK,7@Q9%UO6W\0
MW&E:CK>K12>(C_9$>H62:=MT.PGCN6N/T'H2=E=N_75>7EY?U=C<XWTA"VFZ
M?;7KWN?S >,/VV?^#DOX9_#+QI\5/B/_ ,$\/V+M \+_  Z\(>*_'GC*\'Q,
MTZ[N-+\+>#M*U'7]:OTTO0_VK?$=Q?26NBZ;<726FG7%]>WC((H+87,JVJ\#
M^R]_P4H_X.$?VNO@AX._:%^"7["'[%?C+X6>/YO$P\(^)I?&]UX/?5(?"OBS
M7/!6L%O#WBC]IR#7[(V/B/PYK.EE]1L[(WK6)O[.W.GW-G//_3C\:?AEIOQK
M^#GQ9^#6LZE?:-I'Q;^&?CSX9:KJ^F)!)J6E:;X]\+:KX5OM2T^.Z22UDOK&
MUU66ZM$N4>!YXHUF1HRP/SQ_P3P_8_@_8(_8X^"_[)L'CN7XF?\ "I[+QDMS
MXXFT!/"W]O:CXX^(OB_XD:I)!H":KKG]F65EJ7C"[TRPADU>_G>QLK>:XN&G
MED"EG?=V]5Y6Z?U\W<YX\OP0YKK2SM:SN]^]NOR/R#T[]IW_ (.<YENS??\
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M_"WA33+G7?$>JC2;+]J>VOM2&F:+8WU\UCI[R:C=+;F'3[6^O7@LY^#^ ?\
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ML[L)-2ML*I*&60+#)_2;11;^]+\/\O+\^[%SK^2'W/\ ^2/Y(OC;_P %4?\
M@OU\ _B=^S_\$/B'^PE^QGHWQ8_:FU;Q?X=^!?AVW\9W>O0^+->\#VWARY\1
M65UJ6F?M-+H/A\6:>+-",<OB77]"M+PW;K:WTGV:Y:+Z2;]IS_@YP&G&=?\
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MS?\ @"RN%N;(7=L9E: +B:,JS YKW;_A[5_P7*_Z0&^,/_#^6_\ \Q=?OO\
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MO9^);Y'\ +8KI]Q-XK\.(GE7LD^=6M"80K.4]Y_X>U?\%RO^D!OC#_P_EO\
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M4:L/$&DZL("NZU$#DL?I&BTOYOP7SZ>H6\Y?^2^7]WU_#>VO\>7Q@_X.(?\
M@IS\ ?B-\%_A)\8_^"-<WP_^)'[1/B(^$O@GX1UW]H"9-5^(OB-=6\/Z&=(T
M%;7X?7,#77]K^*?#U@/MD]I&9]5M@)"OF,GT7_P]J_X+E?\ 2 WQA_X?RW_^
M8NOW>^./[%7[,'[27Q2^ OQJ^-OPIT[QW\3_ -F'Q0?&GP)\5WFO^+])N?A_
MXG;6O#7B$ZK9V'A[Q#I&D:Q)_;/@_P .7WV?Q)I^LV8?3(XA;B">[BN/J2BS
M_F[=%Y7_ %M\GY!;S?\ Y+\_L^O_  ;:_P @GQC_ .#@G_@J9^S[XD^#WA#X
MS_\ !%^[^'OB7X_^/M.^%WP:T?7OC_*EW\0?B!JU_I6F:=X7T(6O@"Y1M1NK
M_7-)M8_M;VUN);^ /.H9BOO/_#VK_@N5_P!(#?&'_A_+?_YBZ_?3XZ_LC_L[
M?M+^*O@;XV^./PTL/'WBG]FOXDZ9\7O@CJUYK7BC29? ?Q&T;4=&U;3?$MG!
MX>US2+/5IK74?#^CW(L/$-OJ^DRM8QI/82123))]'46E_-^"^?3U"WG+_P E
M_P#D?Z\[:_QW?M%?\'$__!33]DJT\"W_ .T?_P $;I/A%9_$SQ0O@OP'/XJ_
M: FC3Q-XH:*.8:-IWV'X?7I-UY4L3DSB&%0Z[I03BOH__A[5_P %RO\ I ;X
MP_\ #^6__P Q=?NS^U%^Q)^RY^VE9?#O3OVG?A-IOQ6LOA/XN7QY\/H-1U_Q
MAH(\.>+%BB@&KP/X1\1>'Y+U_*AB0VNJ/?6#! 6M2V2?JFBTOYM-.B^?3[AV
M\Y?^2_G;]-/,_CO_ &C_ /@XD_X*;?LAZ)X2\2?M*_\ !&R7X/Z'X\\4Q>"O
M"&I>*_V@)X[?7O%4]I/?1:+9&P^'U\YNWM+>:?,J10A(SNE!(!^CO^'M7_!<
MH]/^"!WC#_P_EO\ _,77[M_M4?L3_LO?MM>'_!7A7]J+X3Z;\6= ^'7C"'Q[
MX,T[4M?\7Z FA^+;>RN-/AUB*;P?XA\.W-U(MG=3P&UU">[L'$FY[5I%1U^I
MP   .@&!]!1:7\VFG1?/I]P6\Y?^2_G;]-/,_C__ &D?^#A#_@J/^R#\/8/B
MM^TM_P $8KKX/_#NY\1Z;X1@\6>*_C_-'IDOB36+74;[3-'0V'P_OK@W=Y::
M1J4\0\C9Y=G,6=< '^M+X?\ B=_&W@/P3XSDLUTZ3Q=X1\-^)Y-/2<W*6+Z]
MHUEJK6:7+10-<+:M=F!9S#"90@D,49;8/R$_X+S?\$^/CG_P4M_8CT;]G?\
M9[U/X>:3X\T_X[> _B3/=?$W7]9\.>'6\/\ AKPWX\TC4(8]0T/PUXJO&U-[
MKQ-I[6ULVF)!)"ET[W<3QQQS?KC\,?#E_P"#OAM\/?".JO;2:IX6\#^$_#FI
M264DDUG)?Z'H-AIEX]I++%!++;-<6LC02200R/$49XHV)11<UW=W5M]-].WS
M%UZVLM[;ZWV2\O\ ,[BBBBJ&%%%% !1110 4444 %%%% !1110 4444 %%%?
MS[?\'#W_  43^*?[#G[,?PY\!?L]>(;CPA^T!^U%XUU/P=X3\8V<-@^J^$/
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M[[;=;W*BKOXN5Z6WO>^EK=3^LY$2-$CC18XXU5$1%"HB* JHBJ JJJ@!5
M    IU?S<_\ !N)H/[?GBSX"_$7]IW]M#XY?%GXE>#?CL?!Z?L]>%?BYXZ\2
M^,]<L?"?A.;Q0NO?$BSM]>U2_7P[HOCV^UBRL-#@,-KJ>O:=X53Q&\)\.ZCX
M7U#5?Z1J$[I/:XI+E;5[VTNOZZ;!1113$%%%% !1110 4444 %%%% !1110
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M8L5MC]E2/_A'#<+8BV B:R3$9,<<8']F=.+NDP"BBBF 4444 %%%% !1110
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M.["BBBF,**** "BBB@ HHHH ****  D $DX Y)/0#U-?@[\5/^"]O[.'A?\
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MJ+^JZ6-)HY(9 3'*CQN%9D8HZE6 =&5T)!.&1E93RK @&OY9/VY?VB?V.?\
M@ECX-\??\$YO^"6W[,7ASQQ^W#^V##J&GM\!?A+8:IXLA\,77BWPO-X:B\;_
M !0.I7^M?99+70!+>:#X(GN[&Q2S6\\4Z]#H^@SS7FMIWMH[?*_:UOQ_K87]
M65_P1^WG[ ?_  4 ^ __  45_9ITK]IWX)7NI:=X2?5-9\.>+M"\6I:Z=KW@
M'Q9X=MK*^USP_P")?)N)]/22STW4M-U:*_MKN:PNM*U&SO4F59'2/X*^'O\
MP7@_9W^-G_!4CPS_ ,$V_@1X</Q6L=2TKQ<FO?M#:!XML6\$:?XP\%>$?%/B
M[7/#GA_38M,NO^$LL+2'0+72W\26.LV^G3:E>78L5O+.PCNKWR[_ ()[_P#!
M$8?!O_@C[XW_ ."?'Q[\<:SX?\8?M-^(Y/B;\>]9^&NHVQO/"NN:Q>_#R2?P
M;X6U>2.2RN5L?"_PXT+PQJFJ"":QN[NYUFXM8;JQ>W67\;O@E^R9\#?V(_\
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MTUKI6HVJZA#L\,^)YKPVB:<AN/FK]I;_ (+E?!OX-?''XO?LV_!7]FC]JO\
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MTVO=Z6\S]O:*_G,^-7_!?'X(_$;_ ()D?&?]JK]D>#XK2_%O1X9_A5+X2M_
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MM-+S/T HHHIDA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,?!VA:Z+6QO1HM]K;7*V::L]KJ>G31::DCWDRWUJ(H7::,-_ 3\,?V\O'O\
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MAIX;_;9_9]U3QO/J,&DPZ''X\T^!IM1N98X+>UBO[OR-+D>:66..-DOC&S.
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MU>PU.]N9K:'14\1'5KV2WM2MP[;:2Z-M)OHN[UZ!V]5^+7K\OQ.^^,'[9?\
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M-7U'P)X@M=7_ +)NYT>2WAU.T4I?:>;J..5K1[NUACNA#-]G:3R9=GG&N?\
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M'?B+2_#^H^'(]%L=4U<QM<P::EWH\]PEHK1YC6::1U!(+' KZ,_8'_X-[O\
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M?&+QN-?\$^&[K3;F&\TI9=#AL8%U:VTVZM;*Y@L+F:/39YK.%;ZQN[;?;/\
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MNZQJGB(:9:WT$%Q=:/I^GZO'&;'4[*23^HRBBFE9)=@[>22^X****8!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@?!3XQ_LR?M[_LS>%_AQ^U7^T[\<O /QL\._'CQ)^T;X!_:"^(5I\4]/\/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'Q[K_[>7[,7AC7=;\-
M:SX\O[76/#VKZEH>JVR^#?&-PMOJ6DWDUA?0+<6^ARP3K%=6\L8F@DDAE"AX
MG=&5C^<W[27_  4<\>>(_$EUH/P#UAO"7@?3SY">*3I%J_B7Q4[P*+BY$6N6
M5R?#^F13LZZ=%;6UMK4BQ+>WEY;FY_LNS^^_$G_!/;]G+Q7XBU_Q1J^F>+7U
M7Q)K6JZ_J;P>*KJ"!M0UB^GU&]:&%8"L,37-S*8X@2(T(0$@9K\T/VG/V!OB
M-\.?%E[JGP>\)>)/'OPUODMY].BTE?\ A(/%&@W4D6V[TG4-*LD&LZC"EQ'+
M/8ZG9:;<0K936]M?3B]B:6YN/+?6][=;6O\ UW_,SESV_P#D;W_K^O7W']F+
M_@I%>P2WWAO]I35X;C3XK&6ZT;Q]I_A^8ZJ]ZES"JZ-K>C^&;#[+<0R6LLC6
M6J66F6DT+6?E:E]NDO1>6_WO\/\ ]M#]GCXH>,-%\">"_&=[JGB?Q!+=0Z58
M2^%/%6GQW$EG876I7 :\U#1[:S@V6=E<2@S3QAR@C0M(Z*WYK_LK_P#!/#7_
M !;=:AXC_:&\.ZSX6\+-I6SP]X<74XM+\3ZCJD]Q 1J&I6T N;O2-/LK6.ZB
M-AJ"6.I7-W<02F".UMV^U?H=\-?V&_@+\*/&^@_$'PAI_B>'Q'X<EO)M,EO_
M !)<WUHCWVG7FESF:U>%5F!M+Z<*"PVR%7Y*@$ERW=K_ "M;;^KCBYZ;6\][
M:?UK_D?8-%%%06?DS_P5P\!?%&Q^ 8_:5^#/Q!^-_AGQ-^SSKOA3QU\1/!/P
MR^-7Q>^'NA_%#X%:!K,]S\3/#.J:#X%\=^&-$M+ZRT;4I_%5]XX@M8/%EMX<
M\-7^DVVL",Z:EEZS^T/JFA_M*?"G]ESP/\&OB;\4/#*_M$^+OAYXX\'_ !%^
M%?Q0^(GP[\9Z/\#_  QHD'Q&^(OB_4]7\,:[IFO:EIVN> A:_"Y4\6_VOIVF
M?$?XK> ]5U>P?6[*PN+?[]U?2-+U_2=3T+7-.LM7T76].O=(UC2=2MH;W3M4
MTO4K:6SU#3K^SN$DM[NRO;2::VNK:>-X9X)9(I49'93^6G_!-K]CCXI_LOWO
MQ7T'XJZ[=>(?"/PH\6>-/@Y^R%'J%Q9ZA>:-^SAXE\3V_P 6[[69M4M5BFN-
M8\;Z_K/AS0/$]I?6\!TNZ^$.F:=ID*:/:V,D[Z>:=UYWM^5OZL/IYIW7G>WY
M6_JQZ+\0_P!NKX#?!WPQK^F:MX=^.NK_  !^&'BNV_9U^*/[2FFWT^J^#_AE
MXYM[JR\#76C>+/''B+XD67[0'B75M%U:\L-&\4_%;PAX=\;QZ9XQO4AU3QO)
MXP@UK^S?D#]B#]M_P;\#OV=/A9H'Q8T_XZ^++;QO^U1\:?A/J?QLU#3=6\7>
M"?!7B/Q9^T5\0=%\ VWQ/^*?COQ+!K&HMJ=LEI#<:OI<GC6XT2".WF\8W.CM
MJ&E-J/->%OV??C?\%/'_ ,?/@9>_\$\_AI^TYX7^)7QO^)?Q0^"G[3WC%_@O
MX@TKPQX,^*'B"#Q5=:7\6M)^($Z>-?$FK?"[7M:U*]M;&ZU_3=6^)<D,NDZ/
M<:!8V_\ PD\-+3_V<_VLI?\ @G3;?LX7O[+7CC3_ (I#]JVV^)RZ8OQ%_9SN
MM'M/!3_M40_'F;5I-:A^,\=HLEMX7DN="&G6J3:C+KT211V@TJ=M1A++37JK
MZ]';\M;]@LM->JOKT=ORUOV/L;PE^U5^RYX!^/O[9NHZ;;_',?%&+Q_^SY\.
M_&/A?7[7Q+J?_"Q_BGXB^'GB9OA=X"^ 'PXU?56GTS4M7\+>'KV_UR^N=(\&
MZ!=1?\53K^L6_A#0[CQ!IGS9_P %'?VE]!^,_P"PS^UC9^&[;XT_!/XT?LX>
M.OV?_#?Q&^'6N^(W\(>)?#\?Q;^)GPST^VM/$DOPG\?^)_AU\0_!OCKX>>*-
M96TLSXG\6:+(CO<7-E9:C;VD@\D^,7[,/[;=Y^UU\=/VR_A;\ O%<&H^'OVC
M?V3_ (V?#;X?:[\3_@WI%S\8O ?PO^!6J? WXR^"/M>@?$7Q=9>%/%>JZ;XB
MOKCP[J'B#3YK0>&3XBCM'FUV\T[P_K'U'^V9HO[7G[9'[$WQ@\):#^S%XD\&
MZQ\1M7^ =K\-_A'XC\:?":T^(MA;>#/BEX4^*'Q!\?\ Q%UF]^(-CX,T+2;^
MPT*T\+^$?!.FZQJ?C"RO=(N=8\26]L?$XT7P:]+K_MWKZ7O_ %^0]+K_ +=Z
M^E[_ -?D?2_Q._X*(?!CX52>*-?USPI\5=4^#'P[^)B?!SXK?M$:%X?\.3?"
M7X8?$L:W:>&[WP[XC35/%^D_$C6+30_$%_8Z#XC\4^!/AYXO\(:)K]Y%H%YK
MHUFUU>QTO[3\6>&=.\:^&M8\+ZI>>(;'3==LGL;J]\(^+/$_@;Q';PRE6\[1
MO%_@O5]!\4Z#>*54QW^B:Q87B+N19_+DD1OPD^''[/\ \<?A9X\^,OP/UW_@
MG=\./CEX8^+GQO\ 'WQ0^$/[3/Q0D^"?BC3?AQX,^+?B&T\4ZEI?QRTK6+OQ
M#XQ\5:M\&M=U[5;^2QTKQ'=:K\3WL[G2?"MS86<$7B8?J9^S]^T'\0/BQ\*/
M&WBKQ-^S9XX^%WQ#^'/C76_A_?\ P:D\5> ]?U#5;W1]+\.ZO87?A7QH=4\,
M^!=2TR[TOQ+8P7LTNI:;#H6O:9XC\,W!EU/0Y(IE_7WK3];B_K[UI^MS^>_]
MG7]J#X<:7_P2^L/C-\0_VYOC58?MPSV/QDF^'=G+^U5\7?B5XV\1?$WPOXJU
MU/A;X4U+]GOQ)X\\8^!=9T?7$B\$Z7J&F^(?AQ%IE_H6LK?W-]:-JTNK2_HG
M^W?XL^/MO_P1Z/QL\=>)OB9\&?VH_"?PB^"GBGQ#JGPT^(/C?X5:YHOQ \0>
M*/AQH_C.'6]-\#:IX4L99=1MM3U:VU7PGK&G:AIGAB^U"^LM(2*[T^UU0>4?
MLR_ O]I+X3?\$O;C]C7XH_L ^+OBE\25T;XM:?8:+XB\<?LG:Q\(+CQ!XT\4
M>+/$O@S7=6U:?]HNW\26NF^';K6=*N[^_P!$\/Q^*],U&SDF\,I]I@M-53NO
MB]^Q]^U!HG_!&K2OV']%\,ZG\>_C_=^!_#/AB[O='\:>"-+\/:&VG_%_0_'H
MTJZ\2_$SQ3X)DGT/PGX2B?PGX;.FV5_+<1^'+&T>VT^SF@NA6EUM\7EMIVZ>
MNW3J5I=;?%Y;:=NGKMTZG.VGPQN+K_@J1\/OV<KCXV?M;2?!S4O^">6E_&W5
M/"2?MG?M6VS:C\3X_BUJ7@AO$]QKUI\8K?Q)$\^@VENEQI=GJ]KHLMXC7S:;
M]HEF>3U"[^(GQ>_8,_;?^"7P$U7XG?$K]H3]F[]L'1/BU)\,/#7Q0\46_C+X
MO_"KXL_#?2M-\0-X6T+XG^,[ZPU/Q;X.\5Q:MX?\*^'-/^(GBMYM-U/68+W4
M?$]LNE:MJ?B.#3O!G[45M_P49\ _M87W['WQ;'PYTC]A;3/V<]6L--^(O[+-
MYXELOB&OQ.U#QW>3K8WO[0FDVEUX9M[*Z^PQZI!?-?7%UY+C2(HI)C:^XVOP
M)^,WQS_;'\!_M?\ QK\#S?#OP%^S%X"\?:)^S=\"1XE\'>)/B?X@\??$;3O[
M+\<?$/Q]J?A[6;[X;:"-0\-0V?ACPIX-L/'_ (EM%U*TL/$^J^)_#IM)K&^3
M_#E7WV2^^^_DA/\ #E7WV2^^^_DC?^'W_!23X;?$^[.@>$/@G^T3=_$*W^,6
MJ?!+5OA+J/A[X7:'\4?#?B;0_"R^+]9\0^*?"6L_%RQN?#?P\TS2GAAN/'FL
M36?AY]5NK#2K:[N+W4M/BNN\_:>_96\1_M$ZI/?ZU^UC^T1\ /A_X9\+V+^'
M]'_9W\?V?PCN;?Q3;7FN:AXD\;_$#Q<-)U+4_$]@FG_\(Q::#X=EN]*T'PXN
MBZWK$XO]3UNTN] ^+(?@K^U-X-_:>^'O_!0+PI\ ?$EY\3OC%K?CGX4?M2_L
M\V'B;]GZROO#/[.ELFDZ;\(=<TWQI=_$[3/"VO\ Q'\,2^ /"OBW79[7Q+XE
MO/%!\4:MX,CU7PAX:\,:':+]:_M.>)?C?XNO]'^%VD_LB_&7XE?!77-(L-7^
M*FJ>$/B-^S7X?NO%\$R"6;X+76E^.OCIX.U&'PYJ,CI;_$S5X&N]/U_1+74/
M FE0:OH?BO4/$>F+JK/\M&M][?+OZW%U5G^6C6^]OEW];F=^PGXG_:6^(?\
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M$\%M;0S7<LTD5O"C+&OHM(04444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45BZCXE\.:1.+
M75M?T33+EHUF6WU'5;&RG:%V94E$-S/%(8V9'57"[69& )*D# U;XF_#[1-*
MU+6;_P 9>&DL=*L;O4;MH=:TZYF%M9P27$WDVT%S)/<3&.-A#;P(\T\A6*)'
MD=5/F8K.\FP2KRQF;99A%A8SGB7B<=A:'U>%*+G4E6]I5C[*-."<IN?*HQ3;
MLD=M#+,QQ+I+#X#&UW7E"-'V.%KU/:RFU&"I\D'SN<FE%1O=M)'<T5\M?L]_
MM,>'/B]X5U;4O$%_H?A;Q!I/B#4K2XTF\U2TM,Z/=W,UYX=NH#=S1M.JZ;(N
MEW<ZX,VI:7>W/DV\-S!$/?/^$Y\$_P#0X>%O_"@TG_Y+KPN&./N$.+\@RKB7
M(L^R_$Y3G&%CB\'5J8FEAJW(Y2IU*5?#UYPJT,10K0J4,11J14J5:G4@[\MW
MZ>=<*\09!FN.R;,\KQ=''9?7=#$0A1J5J?,DIPG2JTXRIU:56G*%6E4@VITY
MQDK7L=312 A@&4@J0"""""",@@C@@CD$<$4M?8;['SX45XM\=/C1;_ [PMHG
MB(_#GXF?%?4_$OC/0/ OA_P-\)-)\.ZSXRU76O$/VR2":&V\5^*?!FA6VDZ;
M::?>ZEKNJZCK]E::/I5K=:G>.EE:W,T/RC;?\%$8-1\9_'[X=:+^Q[^UWXA\
M=_LQ:=X!U7XR>$_#UI^S+K6M:!:?$SPG>^-O!ZZ+:6'[3<Q\;WVI>'=/NKK^
MR_!#>(=3CN$73S9F_FAMG=OZ^[_,=OZ^[_,_1>BO@?XC?M_^%?AY\3/V=/A7
M_P *$_:"\9>(/VJO#UWXA^"M]X2B^!2:)XCBT;PQI'C#Q9IM_=>+_CKX2O?#
M^I>#]"US3KG6AK6GV6GWCS&'PSJ'B"2-@/H7]H7XXQ_L[_"KQ-\7M3^&'Q.^
M)?AWP7HVH^)/%NE_"VV\#:CXET+PWH]F^H:QKDNE^,O'G@B'4K/2K&*XN[R#
M0KW5=26WMKB:&PFCCW%6V\]A6V\]CW.BO OAM^T7X)^-GP!T#]HGX(Z=KWQ;
M\*>*O#(\1>&_#GA*;PG9^,-5N8I6M-2\*^7XP\5>%O"NE^+-#U."^TC6M-US
MQ9I=K8ZKIU[9MJ#O'$9M?]G[XSV?[0OPB\$?&;2? OCKX?\ AOXBZ!I'BWPC
MI7Q$_P"$)3Q'JGA'Q'I-AKGAOQ*]MX#\:^/-*L;'7=*U&VN[2QO]8MM>M5+1
MZMH^FS!8V /9JR+30-#L=7U;7[+1],M==UZ/3H-;UFWL;:+5=7@TB*:'2;?4
M=02-;N\M],CN;I=/@N)9(;/[5=&W2-KF<R>4_&KXVVGP=TNT>R^'GQ*^+WB_
M5+/5]2T3X;?"/0]+UWQIJNE: MB-;UE(M>UWPSH5CI&E7&JZ-975WJ6N6DDU
M_K&F:=IEOJ.HWD%H^?\ LX_M)?#;]J'X/:+\:_AV^N:9X:U*?7--U;1?&NFQ
M^'/%O@KQ#X6U&ZTGQ1X6\:Z.;R]@T;7?#VH6=Q!J$4>H7MB\0BOK&_O=.N;6
M\F /?:*_*B3_ (*P>#6\'#XEZ;^QM^WEJOPLO?$/A_P_X:^)@^#WP[T'PGXU
M/C+Q%HWA;P)K/@\>,?C+X:U_6- \=ZQXC\/V_A+4O["MQJKZQ9PB*&[6YMK?
MZ+_:6_;3\,_LX:Q!X8M?@C^TI^T%XMBT#3_%_B7PU^S?\)KKXD7O@;P=JVHZ
MQIFD>(_&5]<:IH&B:1#KMYX;\30>'],35+K6]4?P[J]RNG0:587>IP.S^]V^
M>G^8[/[W;YZ?YGV917COP!^/'PT_::^$7@OXX_"#6YO$'P^\=V5Y=Z)J%UI]
MYI-\DVEZK?Z#K.FZCIM_%#<V>HZ/KFEZEI5[&5>!KFSDFLKF\L9;:[G]A9E5
M69F"JH+,S$!54#)9B<   $DDX Y-(0M%?#>G_M[_  SG^.7PV^"VM?#GXU^#
MK#XU_P!K6_P3^,_BSP9I6G?!GXKZII.G2ZR=)\+^((/$]YXBM;S6M%B;5?"S
M>)O"F@6_B.S"R:?,WVW1_P"U/=_C5\=_"WP3M_!5IJ6D>(_&OC?XG>+8? _P
MQ^&'@=?#TWCCQ]XD_LZ^UW4[?14\5^(?"?AFPTWP[X;TK5O$GB7Q!XF\2Z#X
M?T;2M/<7.I_VE?:1IVH@'MM%>)? WX]>#?CUHWB^]\-V/B'PYXA^'/CWQ%\+
M_B7X"\8VFG67B[P#X]\,M;R:AH.M+HFJZ_X=U"*ZTV_TO7=%U[PMXA\0^&M<
MT35K"^TO6;G?/%;^VT %%%% !117E7C_ .)\7@KQ?\'?!%KHTFO:[\7?&VJ^
M&;:&*_6R7P]H'ASP-XI\<>)/&NH@6E[+-I.EIX>TWPVB)%#'/XF\8>%].FO;
M)-1$Z@'JM%?-=W^TEIUG^U=H7[*5QX"\6VNM:]\(/%'QDT_X@7EYX5'@[4]#
M\,Z_X3\-W6F:/::?K^I>*GU.+5/%'DW_ /PD&@>&;:#[#YFERZW;W7GV_P!*
M4 %%%% !17Q1\=?VV=%^ _QV^#W[/>I? ?X[^/?&OQ\7Q0/A+J7@(_ P>%_%
MEUX&T>SU[QO8#4/'GQP\":CH=UX6TG4+*[OF\2:1H]IJ(N4A\/76M3B2).K^
M'7[7?@3Q]\3?%7P(U#P;\3/AK^T%X2\#2?$RY^"7Q%T7P[8^*M;\ "]M-'MO
M%OA7Q5X8\5^*_A'XET:]\17B^&X[C2OB5.UIK4%W#JL>G6UK+=J ?5E%?D[X
MB_X*X_#+PK\/_C_\4];_ &8OVL;3P'^S#\4F^#7QIU_^S?V<9(_"WQ!C\0Z7
MX6DTBUL(_P!I-M4\1V\>N:]H%H=6\-V.JZ4T6M6%]'>/8&YN;?UWQ3_P40\#
M_"F7P7?_ +17P(_:-_9J\ ^/+FUL-'^+OQ1T#X5:_P#"O3=2U%(&TG3_ !GX
MH^"7Q?\ B\_P_GU>2YAAT^7QQI_A^RD;[5++=PVNFZI<6+L_Z^7^:'9_U\O\
MT?H+13(Y(YHXY8I$EBE19(I8V5XY(W4,DD;J2KHZD,K*2K*002"#7G?Q:^*7
MA?X,> =<^(OB^/7;K2-&?2K.'2?"N@:IXK\6>(]>\1:SI_AKPMX4\*>&-%M[
MK5=?\3^*O$NKZ3X>T#2;*!I+S5-2M8G>"$RSQ(1Z/17PQ^S5^WS\-OVCOB;X
MK^"-Q\,/C[\ ?C5X4\+MX^D^%G[17PU?X?>*M<^'?]L6N@+XZ\._8M7\1:/J
M6@+K%]9Z5*YU6"[;4'N5L;:_L;*YOT];^.7[3WP^^ /B#X/>&/&6E^-[[5?C
M?\7?A]\&/!LV@^%-0NM B\5_$:[UF#2'UCQ7?#3_  S:P65KX=UK4M3TVUU:
M^\306-K#<1:#-#?6<LP!]&45SOBW6]0\-^&]9UW2?"7B+QWJ.EV4EW:>#_"4
MWA>W\2>()8RH&GZ/-XT\2>#_  LE[(I9XSK?B;1K,A&4WBR&-'_-'X>_\%</
M@'XV^&_PY^./B#X5_M!_"3]GWXH>.)?ASX<^//Q+\/?"Y?AS9>+$N=>TV*T\
M4IX!^+OCWQKX2TNYUWP]>>'T\3^(/!UAX7MM3FM7U#6;+3'GU&W+!8_5"BO&
MOC?\>OAQ^SYX7TOQ-\1-1U%)/$WB;2O W@;POX=T?4/$GC/XA^/_ !!YZ^'?
M W@GPWI4,U[K/B/7);:9+6,_9M.LH8I]2UK4=+TBTO=1MO(X_P!L'2_#?B_P
M%X1^.?P9^+O[.*_%?7['P?\ #+Q7\3I?A1K?@OQ3X]U9!+HOPUN?$/PB^*/Q
M-M_"GC_6H([^71=*\6QZ-HVO-IEY8^'?$6LZL@TXE@L?8-%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M$=U\1C\(;/5I-/B^)LGQ6L/!5]\3@/!MIXOU'X:6FE-=E-<N'MO!]Q9>);L
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MHZ;J=E>:9JFE:G96>I:9J-I=6-_:6]U;RQ)Z/0 4444 %%%% !1110 4444
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M""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MA5#LJJS@#<RH7**6QDJI=RH)PI=R "QS^3O_  0[57_X);_LOAU5@&^-# ,
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MB&V\/W&G>(O$6J:U8ZMXI'AO7O#?VW\=OCU\=]4_X)K_ ++/QP\.W7B9]?\
MBO8_L7:K^T%JGPQ@GM/B8WPZ^,K> [?XI)\(;+04CU>W\>^)-3\46GASPTGA
M"!/$VFKKT]WX2-AK=EIU]9_7I_8:_9I,_P"T%<OX1\92W'[5&F#1?C]+/\;?
MCI</\1=)2RN=*BT^_,WQ)D_LBU@T2\N_#MM%X;_L9;;PQ=7/ABW$>@3RZ:WS
ME^V7^S"5_9V_9Z^!7PE_9_\ $7QI^!GPO^*7@*3Q7\+O#GQ?U7P[\7/#_P -
MO OASQ!#X/NOA1\1OB%X_P!'O;?4/"7B1?"UN]K=^.+;4V\'Q7OA[0+G2%N5
MUO0G=::=5?;LOU3W[CNM-.JOMV7ZI[]QO[&W@[XJG]IK]JSQ+<>-_P!H>Z_9
M6\+:A\+_  [^S-H/Q?\ $?Q1N+?4[O4/AW%JWQHO(D^,T5U\0_%_AO2/&6H6
M%EX7\3:SJLUC8ZA;Z]H.AS7>FZ,OD?2W['H/B?X<^(_CQ< O=_M/?$+Q!\<;
M"<C:)_ASJMGI'@WX#R+"<O92S_ #P7\+K_5;$G]UXCO=<F95FN9L_'O[./[*
M&N6?CGQ+_P (QX/_ &M_V;?V?O$7P8^(WP[\7_#WXW?M+P?$K6O&'BOQY/X;
MMM&\7> O#.B?%WXZ:9\.-5\&Z59>*_.\:S>+-'\1W=_J>C6NF^'I=*.JWTOZ
MO:)HND^&]%TCP[H.GVNDZ%H&EV&BZ+I5C$L%EIFDZ5:16.G:?9PK\L-K96<$
M-M;Q+\L<4:(. *3_ $7Y?U_P!/\ 1?E_7_ /YUO"_P 1-0NOVHOVF_V8]4\6
M_$;X ^!OVA/^"BGC"V;]I7P'XBO/#6HOXY\*_"/X)ZKX<_9W\,>(=(U.U;P=
MXU^+EJNH/:>(_%UM?:/J6E:1>^#?"'ASQ+XR\11ZU\/_ +<_:/U#7/"W[5'[
M./P,\7:W^T'8?LI:I\ /B]KT&I_"'QU\>=5^)=Y\9/!.N^$+.SU7XG^.OAOK
M>I_&_4/"?A[PKXDM[?09]4UN[T/7/B'XLT6#7H]8U.S\/Q67ONL_\$WOV._$
M7ASXM>$?$'PT\3:YX=^.?C*P^(?Q4TO6/C=\>M3B\5^.M,U.VU>R\6/+>_$Z
M:YT?7H;NSMHVU+P_-I5S-IT*:/.\ND9L3\??M1_LKMXA_:/\)WWB[]E/X_\
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MM]^VVW4J^O\ X#ZZ6^_;;;J?B_X%_P"1_P#^#:[_ +(5\=O_ %F;X4U]:?\
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MV.F>']*63QH5\":)9VFOZW!'I?P^'A6Q*:I>[X',[D\]K?[%OP!\1?##P/\
M!S5M.^*4WP^^&^KZ9KG@K2;;]HS]HW3=3T34="BMH?#SKXLTSXKV?C"_M?#0
ML[63PQINJ:]>Z;X:N8([O0K33[H>=1IIO?KZ??TZ;:=@TTWOU]/OZ=-M.QSW
M[-GPT31_B5\;OVAO&MFOA/XM_M7WOAC7H/AWJ3V-KX@\)?![X,:'9^"?AWI6
MJZ?'<3W-WXKBM/$@\5_$JXA>>S\,^)OB#8> EN;RT\-:3K&L_@_X>?QCX$UG
MP;^U[X:@U/XE_P#!)7QE^W%XA^(6D_!?_A)8K#5O@_XRO?C$/A[H_P ?K_1]
M*\&66I:G\++#XR6^N>-/!'P-CU"ZT[0[B;P7?Z_II\5O>:Q9_P!"_P '?V1?
M@-\"/&OB;XD?#OPYXK7Q]XPT'3_"_B#QAX[^+GQA^+OB*\\.Z7=F^LM&@U7X
MN>/?'%WIEA'=^7/);Z5)9)<O;VGVH3+9VHAQ=%_8F_9U\/7\DVD>%/$MMH3_
M !/7XT+\/G^)_P 4+KX60?%./Q&?%\/C&T^&-WXPG\#VEQ;^*RGB>UT2VT.+
MPM:^);>S\1VV@Q:[86.HVY====O^&\O)KMMJ%UUUV_X;R\FNVVI]75^*WQ(A
M\;3_ /!<3P[%\/\ 4/"VE^(W_P""7.H+:WOC'1]6UW1+=W_:)\81VDUQIFB:
MYX=O[M;;5&T^ZN+6/5[(WMA!>6$=W87%U!J-G^U-?,=W^QW^S_??M!6'[4]U
MX7\52_'C2]*_L#3_ !U_PMWXQH+;PV;V[U%O"\?A>/Q\G@T^%7O;^\G?PP_A
MUM D:YE5].:-MM"Z^:_5/] 77S7ZI_H?$&H_L0>*/V9?^";W[;GPK\"^.M;^
M+WQK^-?AC]HOXM>-/&@\,2:/J7CSXB_$'PA/!K&F>&?"6GZ]JMWI+:KHNDVV
MA:-8#Q#K4YUZ\GU5OM7VUM)'U#_P3:UWPWXB_8"_8ZU#PK=VE[I=O^SO\+-"
MNIK*YCNH4\2>%_"FG>&?&5H\L<LRI=Z?XOTC7+"_MBXDL[ZVN;.6*"6!X(_M
MJOCN\_87^ QT_P 1>&?#G_"SOAU\./&=QK%UXR^$GPO^,/Q)^'GPNUZ3Q 9&
MUN.T\(^%?$FFVO@>RUJ2>[FU[3/AG-X)TSQ)<7]_<>([/5I[VXDD+W_K\/\
M+L%[_P!?A_EV/CS_ ((\VNI77A;]M[QOI3,WP<^)'_!0+]H_Q=\#[A;>3^S=
M<\%2ZU8::_B?PSJJW<]CJWA?4+O3UTBSFTR,V46K^']= OKV:25+3]AZY;P1
MX'\'_#7PEX?\!> /#6C>#_!GA33+?1O#GAGP]86^F:-H^F6J[8;2QLK9$BB0
M$M)(^TRSSR2W$[R3RR2/U-#=_P /PT!N_P"'X:!1112$%%%% !1110 4444
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M^#V@2^-X76[>_P#$VF75GX/N=)O3!8:;=>(;6:XUBRU_!O[57BCQ9^U3\?\
M]E-_A;H6F^)O@]\-?#OQ,\,>*1\2;^]T'QQIOC*[N[3POI^MV_\ PK>UU'P1
M>.]O&=?>QA\<1:1YDHTX^(!#&UR6=K]/^&_S06=K]/\ AO\ -'VC63=Z]H=A
MJND:%?:SI-EKFOIJ,F@Z-=ZC9V^JZW'H\4-QJTFD:=-,EYJ2:7!<V\VHO9PS
M+913PR7)B25&;\Q/A9_P4+^*WQ2^)/B'X!6O[+NC>&/VD/!'Q/N_"?Q#^#_B
M3XZ722^!_A=:^$M,\30_'[5?%NE?!G4]#OOAYK5YKF@^&_#5MH@U+7M<U37-
M-EMK!;$WEQ9;7[7?[0O@_P"#O[57[,FGZS^RW+\5/B _P\_:@\9_"[XL/XA\
M)Z/J?A"S\!_"ZWUWXCZ)X.34Y991<>(-)DT?3/$E[JUSH36.B2W;Z'9>*+N=
M=,N2SO;Y_A?\@L[V^?X7_(_3>BOR"T7_ (*A?$%M/_9#\<>+OV./%^@?"3]L
M"/0?#?@7Q1IGQ<\#:YXQ_P"%K^*_"5QXB\(>#+#P-=6&A:9/X;\9:C"FA^%_
M'7BSQUX%5X5O?$'BGPYX2TJUMCJ/U1^RE^UIX@^/OCK]HSX-_$OX02?!+XU?
MLS>+?!VC>.?!]MX\TWXF>'[[PW\2_#MQXK^&_BO0_&.FZ)X;6X3Q)H=E>WEQ
MI-QHEM=:1&MFMW+]MN;JPTU6_P _Z["M_G_78^U:S)M;T6WU>Q\/W&KZ7!KV
MJ6.H:GIFB37]I%J^HZ;I,MA!JNH6.FO*M[=V.F3ZIID.H7=O#)!92ZC81W,D
M3W=N)/S=\ ?\%"?$FO\ QG_9N^&GQ#_9_G^%&C?M7CXJ_P#"K!X@^(5T?C3X
M9'PQT_6M7@F^-7P,U?X<^&KSX>VOCC2]$GN?#-QHGC3QW%"\]K!K3Z;))-]G
M^7?VA];\<?"K_@K[I?C/X"_L^P_&WXJ:Y_P3LURY;P-HOBKP-\*G\6:E'\>[
M'3FUSQ=X\\5O!9Q1Z9H6E6VFV]V]GX@UB9H-$T:WLH=,\[4-*:7Y7_%+?^NP
MTORO^*6_]=C]UZ*^2_V-_P!K/0?VO_AGXC\967@?Q3\+_&/PY^(_B?X-?%SX
M9>,6L[C6O /Q6\$0:5+XL\,C4K!A;:W86#ZQ:)9ZREKILEX/-CNM+TR^M[JQ
MM_HOQSX:N/&7@OQ9X1M/$FO^#KGQ1X<UGP]%XL\*7,5CXH\--K.GW&G_ -N^
M&[Z>&YAL-?TL7!O='OI+>X2RU&&VNC!-Y7ELA'3+)&[2*DB.T+B.5596:*0Q
MQRB.0 DHYBEBE"L QCDC<#:ZDN9E4%F8*HZEB !DX&2< 9/'UK\7O#O[$'PL
M_9W_ ."B/[.&I?L>:/XI^'-F/ OQD\:?MB:18_$'XA^)_#OBOP+JV@3>%O@Q
M<_$!?&OBKQ"+WQ/X@^*=QXAU/PG'+,;_ %UO!_COQ/*+B[\)W%V.Y\?ZEX?_
M &C/^"J=E^S+\3- \.?$/X)_ W]C74/C))\-_&?A^UUWPK>?''QS\4?#_A:Q
M\5:OX?UNRN]!\3S>&_AK,]EX:O+ZVNO^$:OO$^OOI307M[J#1NWY7]-;?G^&
MH[?E?TUM^?X:GZTT5^8/_!*SQYXIUOX3_M!_!_Q+J6H:W:?LG?MC_M ?LP^!
MM9U6]U76-4N_AQ\.M9TJ]\&V.I:[JLDLVJ7'AS3O$3>%[ EHY+3PWHWA^WFM
MXR$DF^AOVPOVH[_]E+P;X \76?PF\1?%=/''Q=^'?PI>Q\/^(/#^A3Z3<_$'
MQ-IOARRN8EUF<W&L:O,]]*^AZ-;VMMINHW=H]IK?B;PK;S6^H2EM;>EOGL%M
M;>EOGL?7%%?EG:_M\?M!7?Q:^-'[.2?L1ZB?VAO GPZT'XQ?#7P)#^T!X$E\
M-?$'X6ZQ?ZCIEUKWB?Q]<^';'3? >MZ;K%K8>%!X:T73_B,U_P",]7AM(M5A
M\%:=J_Q!L?5?"O\ P4(^$NN_L!VO_!075-$\2:-\.%\!:EXLU7PG +35?$MK
MKVB^)KWP'J7@W3;@OIUAJ5U+X^L)_#>D:O=-I%C>Q2VFK:A'H]M+<16A9_UY
MZK[PL_Z\]5]Y][UFZEK6CZ,=.75]6TS2FU?4[?1=)74K^UL3JFL7:32VFDZ<
M+J6(WNIW4=O<26]A;>;=3)!,\<3+$Y7X(\#?MD_%C4OVHO#/[)_Q#_9VT/PS
MX[\1?!BT_:$E\0^"OC7'XY\'Z/\ "ZY\4Q^"KE[F]U[X:?#K4=0\8:+XFECL
M=3\/:/IU]9S6,MMK.G:W=VUQ)!:>L>+_ /BX?[77PI\'I^_T3]GOX?>(OCMX
MDC/R"T^(/Q237_@Q\&)58?\ 'S')X)M/VFOMUL25M+A?#]Y)'YDME+&OZ^\7
M]?>?42:KIDFISZ+'J-@^LVMC:ZG=:2EY;MJ=MIM]/=VMEJ$]@LANH;&[N;"^
MM[6[DB6"XGL[N**1Y+>94OU^*D'Q%\-?LY?M^?\ !0[Q+X5\$:1KOCCQ5\)O
MV1W\#?"GPW]G\.^)?C=\6M=MOC1??V#HPTG0]7N]0\4ZW;V%YJ^O>([C1[^U
MT+P_I&L>,O&FHZ1X0\.Z]X@TK[C^*?[4?BGX$_ [P3\0?B]\*M)T+XK_ !-^
M(7P_^$?@3X/>&_B6OB?3;KXF?%36(-&\&>&_$7Q-N/!.@:=HEI:327-YXWUW
M3O#?B+3=!T_2M4F\.MXUG73;;5';\;?BK_TQV_&WXJ_],^R**^%_@+^UMX^^
M*W[17QN_9I\8_ _3_!7B[]G>S\!W/Q+\5^'/BC%XT\$R+\4?#5WXK\ R^$9-
M8\#^ ?$^O6VK:5974.K27'AO2V\/:M;SZ?.M[$L%]<_=%+^OO%_7WA17X:?%
M7]G#X ?$?_@M%X<T'Q[\%OA?XPT3Q3_P3\\5^,O$FD>(?!'AW5-,UWQDOQOF
M\.IXQU:QNM/DMK_Q='H=_<Z5'XGN8I-=BLOL\$=^JV=F((?^":>K_#K]B'1/
MVYOV/_B);Z9X<N_V0/&?BKXR2>+CI.D)K7Q*_9F\7Z'-XT\&>.=9GTJTMM0\
M8^(_#FAP3Z1XG)@O4T&34/#GA&RN"8(K"V;7GK9-Z='\_-#:\];)O3H_GYH_
M=&BOBS]A?]F#P9^S=\'UN].^%W@[X9?$WXQ:G?\ Q6^,>F^%=#TC2AI?BGQG
MK.M>+[7X:P3Z3%'#+X1^#5OXHN/AWX'TZT,6DV.DZ5/J%E96][K>K3WGY!>#
M_!?[(W@#_@I;_P %4K7XH?LOZ9\1_"?AG0/V6M>\)^$O O[*.M_&W_A'+WQ'
M\)--U[QS?:'IO@;X>>*+'P+JGBCQ!JL/B'5-2NKCPR^NZA;ZAK[WMR^AZG>V
M!:][7T\M=TMK^86O>U]/+7=+:_F?TH45^-?_  23OH/CE^SA\?QXKU:P^)G[
M/GBS]H[XF6WP.^%7Q*\5:7\7O$?PY^ JKHL/@WX7_$73M3\0>+QX:@TJTM(G
MT?X9^)D75/#MEB^F:^L-9TN=/Q]\)?LJ> 9_^"-WPJ_:M\!_!OX=:[\7?V9O
MVC/$_P >?$4U]X)T;4]7^*?PY^&_QT\6^'?%'@'QQK$\']H:QX&L?"$.FZ_K
M.G:K/J%H=$\"FRBM<W,A=\NMK]4MK[]]>G7<?+K:_5+:^_?7IUW/[%J*_G0^
M)'C3]GO0/^"IW[%/[5'PT^'/A^X\!?&[X=_#SP)\1_B3#X=\/'2XO'7[5^E?
M$'7/V9=8MK(6;W>D?%34U\"ZE;^+O%$4L6JVW@;6]"L;^^CM+](=2_0/X&?#
M[P_-XK_:\_;0^$OP*^&WB;XL^._B?XO\#_"Z*6YT7X?ZAXP\)? V8?#'Q*TO
MCNW\+^($TC5_B7\6?#WQ7\1IXHDTV2#QEH5Q\-[?Q/JB:5I5EK6FJWY7_K\]
M?U%;\K_U^>OZGZ64TN@=8RZAW#,B%@'=4V[RJDY8)N7<0"%W+G&1G\T?V7?V
M^_&_[4_B#0_"_A/]G_2_#WB#PWJ_CC1OVG-!U_XMZE%K7[,>K>$O&MQX0TGP
MQXGM1\(HK3Q=XV\=Q:9XAUSPKH.@:A!IZV'A^^.O^(-$BEL[JX_*?]KGXA^$
M/AK^TA^UU^S/\:?!G@'7OC+^TMX\\#:[^RK^V?\ $"_\&:?8_LY^'/B+X.T_
M1=*TOQ1\15U"3QE\%9/@'J'A3Q-XG^#V@Z$MEJ/C;6FNM?O+71K3Q7/XEU4M
MTZ_?U\OO]-=@MTZ_?U\OO]-=C^HBBL_2;.YT_2M,L+W4KK6;RQT^RL[O6+Z.
MTAO=6N;:VCAGU*\AL+>TL8KJ^E1[JXCLK6VM$EE=;>WAA"1KH4A!1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110!YKXN^#/P?\ B!JD>N>//A1\-?&V
MM16<6G1:OXN\"^%_$FJ1Z?!+/-!8QZAK.EWMVEG#-<W,L5LLPACEN)Y$17ED
M+?DY_P %#?\ @EGX2^*_AF;XG?LT^$/#O@GXI>&=/<ZAX!\,:7IGAOPS\1]*
MM5>4V]EIUA#9:5I7C6V7?_9U\D5O;:\N-,U=UF^PZC9_M;17S^><,9)Q#@<5
M@<QP-"<<4FWB*=*G3Q=*LO@Q%'$*#G&M3=FI-RC-7IU8SI2G"7Q_%? ?"_&6
M58_*LZRK"U(8^+E+&T*%&CF.'Q*UI8S#XR--U88FC.TE*3G"I'FHUX5:%2I2
MG_)E_P $ZO\ @F7XC_:"\1K\3/CIH>M>%/@GX4UJZL6\/ZC!?:'XB^)GB'0[
MZ2SU+PY;1RK:ZEI'A?2-2M9].\6ZX@M[V:]M[KPOH$D6K1:SJWA?^EB+]ES]
MF:&..&+]G;X%QQ1(L<<:?"3P J)&BA41%'A\!550 H P  !7NM%>5PKP'D7"
MV7+!T</1QV)J253&9AB\/2G7Q-57Y;1DJBH4*:;5&A"3C!.4I2J59U*D_G^
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M,TR/PM\*?B)':1:Q'X@1W\0W4DCV+QLJZ'=+&&N/T;"JI<JJJ78,Y  +L%5
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M10%554 *JJ  JJ        ,4G_E^7S_KML)_Y?E\_P"NVQ^<>N?L\?M'WO\
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M_3?#S? _P]-+K-MK;>%_%0O[R/4H=.L5TK[%;EX+V:[^U#[(895Z=?O7D_\
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M@D M@9.!U.!R<=!UKY^_9+\!>(?A7^RQ^S9\,O%RRQ>*OAY\!?A%X)\2P3-
M[VFO>%_ .@:+JUD'MOW+QV-_93VD+J\I:*%&>XN)"T\GY^?'SX+_  X^+/\
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M^&=!M?&]]KVLI!K9TRQT[XOS^,OAPSZ?X<NY].3P1?:J+76FOH+6/\]OV.O
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M3P/X!\/>%/#7AVUTG0I;C2]%N-1FUJ;Q%KFHWFD6]_<ZPUW=:I+?FEO/7O\
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M?YDL],U#X*_MY?L3>%?V=OBGXZ\6_ 7]H+X(?&K4OB=X U7XI^*_BG\.]/\
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M3;ML-.W]>FW;8^FOAG^QCX?\)?L?:C^RSK^E_#;5M'\0ZAXPUNZ\*ZCX3O\
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MP;;7NI:L;"S\,:?8:1:/<%%._P#7W?Y;[OJ._P#7W?Y;[OJ?9-%%%(04444
#?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>ny20077604x1_figure10x1.jpg
<TEXT>
begin 644 ny20077604x1_figure10x1.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
M                                                          !8
M65H@        ]M8  0    #3+71E>'0     0V]P>7)I9VAT($AE=VQE='0@
M4&%C:V%R9"P@,C P- !S9C,R       !#$0   7?___S)@  !Y0  /V/___[
MH?___:(   /;  # =?_; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! ?_  !$( AH$X ,!(@ "$0$#$0'_Q  ?   !!0$!
M 0$! 0           0(#! 4&!P@)"@O_Q "U$  " 0,# @0#!04$!    7T!
M @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F
M)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
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M,\+V?B2".SG;6+V]2U\2:1%XC\)M=W?AW1Y9]8GBL8K<?KK\0?AW_P $C_\
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M(M7O[B&TBT*X\96OAWPO)X:U6XN9U&GRZ_H5EH%W'')'-KUGJ,ECIM[]0_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJ5V]KM)=_P#@?UZG*E=O:[27?_@?UZ^O?&[_ (+ZZE^S5\6H/@[\<OV+=?\
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M_A8/"EEH/@CX.?%+2[_PO+X1^-'ASX<:)>>(-#TG0[B.RN_#6J6FE7?A2_\
M$WA6?PS/J5AI_AJZ\1V.F:9JW]D:O;!&TI8)OAW]JS]C73_V$_\ @B7^TY\"
M-)^*/C#XJZ=;7'ACQ3%JWBNTT[3+?1[C7_BW\+#J6C>$]$T\W)T+PU+J5G=Z
M^NF76K:U<#7-<UN];4'%Z(HCW6U;2[2:\O4/=;5M+M)KR]3YP_XB>?#'_1FN
MO?\ A\]/_P#G4U]P?LN?\%\/V0/VB_B'X;^%GB+0O'WP,\4^++MM.T/6/B&_
MA63X>W.K2--_9^D7'C#3M?,^EW^J[(+>P?5]!T_39M2N8]-&I">2U-U\_?\
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M\26OAS7+JQ@GU70K?Q##8Z9#KL.DWTD]A'J\.G6,6HK;B\BM($F6)?Y+/^"
MO["6I?$[QQK?_!0/XWV]]KMKHOB'7;+X,MXF%UJ5WXP^(]S-=1^./BU?WFIE
MVU4>&[NZN]&T/5'?46O/'%SXBU-[BPUOP7:37/\ 7E1)):+IN^[_ . $DEHN
MF[[O_@#7945G=E1$4L[N0JJJ@EF9B0%50"220  23BORY_82_P""CUQ^W?\
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M+;AVBK)IM]==K]%W_KY.T59--OKKM?HN_P#7R]/_ &1/VT?@%^V]\.;CXD_
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M#'_1FNO?^'ST_P#^=31_Q$\^&/\ HS77O_#YZ?\ _.IK]5/^"I'P;^$.@?\
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M5W@[]L;]IK]G*P^!WA#XQOX3^)?QJ^#G[/G@SP#X5\4Q>,M<\<^%?B=<^%?
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M3_M-^!/VC?\ AJ3_ (69_P (58>,;'_A#O\ A2/_  AG]I_\);X/USPGYO\
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MM4MX[O3-:T'6[&?3-7TG4;24-%=6&I:?=7%G>6\BF.:WFDC<%6(K^9GXZ?\
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M,$$MV\4)E=Y#&JEV9LD_UX_M4^'?B?XN_9J^//A;X*7NJZ;\7_$/PF\=Z/\
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MDUGQ'+I&@>%=(NYH;+3IO$.K^;K>J>)-=2:U&N?V;8RFE=[R?2VW=_\ #?\
M#2FE=[R?2VW=_P##?\-_.3_P0S_;@U[]EKX]>)OV$OV@'U'POX5^(7CJ^T#P
MS9>)$%I<?"[]H+3[P^'-0\)ZE%<&.XT^T\?7=A#X9O+5FN$T_P <Z9X?%O96
M<>O>)=4']G]?AG_P4(_X(A^ ?VW?C?:?'SPA\99_@!XUU+1K/3OB$MI\-T\?
MV'C;5=$2VL_#OBF-$\>^!+C0=?L]'MXM%U2=)]4M]6L]-T*:*VTR^L=1N]:_
M83X/^%_'G@KX8>!_"'Q.^(5O\6/'GAKP]8Z)XD^)5OX5?P4WC:\TY#:P^(;[
MPRWB/Q8NFZQJ%G';2ZZUOKEQ9WVLF_U&QM-)L[N#2+ E9ZKKNNWZ?U]Q*SU7
M7==OT_K[OP/_ .#EO3]6E_9)^!FJPW(70[+]HNQL-2L_L\3M/JFI?#3X@SZ-
M="Z+B>!+2UTO7(6@CC:&Y:^229XWM;=9/TA_X)LZ1X7\:?\ !,O]F3PW:1SO
MX?\ $7[/EAX8UB.ZD61Y+R]L=1T3Q>H:TNMPMY-;;6/LL:7,%S#:M#%(+2Y1
MXHF?\%8?V;[O]J']A'XX^ ]"TYM2\;>&M%@^*?P_MH+*74-0N?%/PXF/B%M(
MTBS@_?3:QXJ\.0>(?!NG+'EA<^(D.V108W^5O^#??XR6GQ(_X)^Z)X"::V&M
M? CXB^.O -Y:BXB>_DTCQ#JC?$S0]6N+56\Z"SN#XVU/0["=T6.X?PW>QQ,[
MVL^TM[M^S_!V_5!;W;]G^#M^J/P6_P""1_Q@L?\ @G7_ ,%&?B!\(/VF;E/A
MW9>(M)\6? /Q=KFO7W]C^&?"/C/2_$VC:YX6\4:Y>7IBLSX4U=_#]QI&E^(Y
M NFQ6'C/3?$K:E;>&_M]ZW]"'_!2K_@E_P# C]M7QAX:_:&^+_[1=_\ !/P_
MX ^&5KX0FU93X.M_!XT.VU[Q%XI37]2\1^)[ZSLK)'_X2&9#*UREG]EMHIA)
M\[FNM_X*&?\ !'[X!_MZ:G_PL4ZUJ?P<^.\6G6FEO\3/#NEV^NZ;XGL-/C@M
MM,M?'_@^YO=*C\0OI-A";#2=6TS6_#NN6UJ;6SO]1U72M+TS2[7\?;3_ (-F
M/BE<:@-*U;]L'PE!X0M);B?3KFT^%WB+4M02:Z:T2XF'AFY\;Z;IEE+<PPYN
M'@\0S-*UI:1.SJWF6SNF[W<7UT;O_P  =TW>[B^NC=_^ ?$?_!'/P_X8\)?\
M%A/!WA7P3XDC\9>#/#.N_M(^'_"/B^)K=XO%?AC1OA_\1].T#Q)&]H6M6CUW
M2K:TU1&MF-NRW0,),94U^L/[5W_!47]K3XX?MR6W_!/_ /X)ZQ>"_A_XR\.>
M/_%?@76/BSX]T_P]K5WJ?BKP-HNO3^/?L=MXJT/Q)H'AGP?X/MM(\2-?S0^&
MO$WB[Q)<:%&-#2WBN3H.M_H-^P)_P1\_9P_80UZ/XE:9J?B+XM_'!=,O-)A^
M)7B^*VTNQ\-VFIPRVFKQ>!/!NF23V/AYM8L)%L=0U'5]3\4^(%M&O;#3M;T_
M2M6U33KOY,_;._X(;Z]\:_VH/$7[5W[-O[2,O[/_ (X\6:O8>*-3TJ#P_K=I
M/HOC5+&"PUOQAX2\<>$O$VE:YI%YXA,4FL:C9G3)+AM>O=6NX];2TU..RT\O
M%N[V2ZKKYI?\,%XMW>R75=?-+_AC\%?^"O'P0_:E^"OC+X,P_M??M:V_[2/Q
M;\:Z!XT\3R>%-+O=8E\-_"C0AJ^C:78W/AO3]2CT.RT[3?'EU97ZN-&\!^#[
M*2\\&W$!75FLQ-:_N/\ \%<OV9?V0_BU\&?V>/#7Q+_:V^$?[/'[0?P>^&6A
MVO@V3Q]J$-Q<^./A_J&BV^E&R\0>#-#O+OQIINC7?B7P[]LT#Q?IVDZ[::7<
MVOBO2XM*UB6\GGTKCO'O_!N;=_%/2+'Q!\1/V[?B9XT^.5WJ]W<>,/BAXZ\
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M/T_5]3O_ (=^'DU&PMK?4(B]M9SOJ]W)IEH:_:3_ ()Q?L.?\._?@'JWP/\
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MA&/L[_@IK_P2*T/_ (**>.OAC\1+?XT_\*7\2^ O">K^"]6N_P#A6G_"Q/\
MA*M#GUA-<\/6^/\ A8'@4Z/_ ,([?WWB>3/_ !-?[1_X2#_EQ^PG[9]R?L3_
M ++FE?L8_LR_#/\ 9RTGQ._C:/P!!XB>]\8RZ&GAN;Q)JOB?Q9KOBW4M1DT1
M-5UW^ST6ZUQ[*TMGUG4G@L;.UA-W((Q@<ERI+>R3^0.2Y4EO9)_(\?\ ^"KW
M_*.?]KC_ +)/J'_IUTJOR=_X-EO^2&?M.?\ 96/"'_J'S5^\_P"U?\!O^&G_
M -G/XN? #_A*O^$'_P"%I^$[CPO_ ,);_8?_  DO]A>?=6ES]N_L'^V/#_\
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M-M_P3BUZVMH8K>WM_BI\*8+>W@C2*&"&+4;V.*&&*,+'%%%&JI'&BJB(H50
M *_E[_:D_P"49'_!*C_L/?M\_P#JX/AM7]L__!0;]C;_ (;M_9TU+X _\+'_
M .%6?VAXM\+>*/\ A+/^$0_X3CR?^$:NI[G[#_8/_"4>$/,^V^?L^U?VRGV;
M;N^SS[MH_E8_X+)_LH_\,3_LR?\ !./]G+_A/?\ A9G_  A5_P#MD7W_  F/
M_"+?\(9_:?\ PEOC#X-^+/*_X1[_ (2/Q7]B_L_^V?L&_P#MR[^U_9OM6RV\
M[[-$0:T77F;^7*P@UHNO,W\N5G]2'[#'Q'^$M]_P3A_9N\=KK/ANV^%GA?\
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M[7I=,NM5\1:C+K$O]IR1PSHDTG>]NFUM=?\ @?\ #3HDTG>]NFUM=?\ @?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]KB%IX@TO2;XB06IB?\ JY_9E$J_LW?L^K/=WE_.OP0^% FOM1N9;W4+V4>
M] $EW?7DQ::[O+E]TUU<RLTL\[O+(2SDU2;NTU;1/?O_ )6(:22:=[MK:VUO
M\SV^BBBF2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%>3>/OCO\ !WX6ZC:Z/\0/B-X7\+:O>6HOK?2M2U%!
MJ1LFD>*.\DL+=9[JWM)Y8YH[:YN(HH;F2"Y2W>5K><1\);?MA_LQ74L<,7QH
M\%J\LXMU-S>7%G$)&D$0:2>[M8((8-QR;F61+98\S-*(@7HL^W]?TT*Z[K[S
MZ4HJO9WEIJ%I:W]A=6]]8WUO!>65[9SQ7-I>6ES$LUM=6MS"SPW%O<0NDL$\
M3O%+$ZR1LR,";% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **\%_:0
M_:A^ '[(?PROOC%^TE\4_"_PE^'=E?0Z1'KOB6XN&GUC7;FRU#4K3PWX7T+3
M+:_\1>+O%%YINDZMJ-GX9\+Z3J^NW6G:3JE_!I[V>FWL\'X*:Y_P<0>.OB9/
M++^PM_P2L_;4_:P\*-+=6UE\0Y/"WB;P=X5OA'=/96^LZ>W@CX>?&7SM"N)@
MLT<FMWWAB]$++#?VVEW1ECMTVE_6O;;U*492U2T[Z)?>[(_IEHK^:_P!_P '
M%.G>"?$^B^'_ /@HC^P%^U1_P3\T;Q)?MI6B_$CQUX4\=^,? 1O8[>2X=M5&
MJ_"OX:>,$@D2&0Q+X0\*>.KE0T<LT26(N+^#^A;X9_$_X=?&?P)X;^)_PE\<
M>%OB1\._&%B^H^&/&O@S6[#Q#X;UNTBNKBPN7L-5TV>XM)I+'4;2\TS4;;S!
M<Z=JEE>Z;?0V]]:7-O$)I[,'&4=U;SW7WK0[JBBBF2%>>?%OXJ>!_@;\+_B#
M\9/B9J\GA_X>?"WP=XA\>^-M;BTW4]8ETGPOX6TRYUC6K^/2M%L]0U?49+6P
MM)Y4LM-L;N]N&416\$DC*I]#K"\4>%O#/C?PYKG@_P :>'="\7^$?$^EWNA^
M)/"WBC2-/U_PYXAT34K=[74='US1-6M[O3-6TO4+662VO=/O[6XM+JWD>&>&
M2-V4@>I_)=^QG_P6\_:)_;K_ ."T7PW^$/@"_P!:^&_["WC/PI\3#X/^%WB7
MP'X(C\1_$'3?!/PP^(.LZ9\4-<\77OAN^\9Z;>:]XOT-;N'1/"OC"#PYI>G:
M-8^'[E-4U"W\1:AJ_P"BG_!7#_@I;\=OV;/BQ^S!^P]^Q7X:\%>(/VP?VN=;
MM;/1-?\ B+8ZEJ?A#X7>#-:UF?P9I'BVYTVPDB2ZU"Z\1IJVJ)J>H0Z[H7AK
M0/ OB6]UWPMKJ7NGVZ_ /BRSL]._X.Q/@EI^GVMM86%A^S+>V=C8V<$5K9V=
MG:_LV_%&"VM;6V@1(;>VMX42&""%$BAB18XT5% 'SW_P7J^".C^*?^"U/_!.
M:_\ B_XF\9^ O@#\?_A_\/?@)XA\>^']<'AJ:"VB^,?Q T3XE>%-/\3BYLU\
M/Z3?>&/C#X6L?%]_<R/;Z;H7C;4]1N4O;626QJ-4FKW=TK[;V];;F_+%SAHD
MO9J5N[LWKM=]]KVU/V$_8I_:2_X*A?!/4/VIO"O_  5,^'OA#QI\)/V=OA1X
MH^-.D?MK_""+0-.\(^-]-\*:)8>)-:\%Z7X4T_3_  A/XEN5\.KXAU&UU:Q\
M"^$IM!U7PMJGA[Q);74NL>'[^OQ.?_@L-_P6FE^#EY_P5HM-#^"0_P""?]O\
M>V^&J_LR7&@Z3_;*>#&O(_#$/B%_&P\+1>/)[ >(9X?!\GCRW^(&X_%LO=CX
M2+\/4?04YOP1\)7^ O[=7_!8+_@FG^PUXH\<>,?V8/$__!.']H/61\*K3X@7
MGC;1/!_QGO/@AX"M4N;!DNM4FU7Q0_C+78?A1J\4<3>)WTWQ2WAK7O[0E\*V
M<MOY5IG[1?P=?_@U(\1?!YO%_AS_ (63%\>H/A6GA._O;./Q%_PES?M.:)^T
M'_Q)=,:5[^>(_"]I-2EU-((K46RZQ9^<98'CD5W;=W7-UZJWWK7KZ DKI\J?
M,X+;:,E=NUVDW;?9=#]L_P#@H?\ \%9OV@_$6K?\$_OV8_\ @F;9Z+H_[0?_
M  40^'7P_P#CEX9^('Q/T+3]23X5?![X@6B:KX8O;K0KNS\5>&TUB:WTSQ;?
M>/;_ %#2/&4/A#PQX,UV#2/#>NZ[KFCZGH?=_P#!([_@HS^UC\3/VG/VF?\
M@FQ_P4%TWPMJ?[5O[,VFZAXQL_BGX#TK3=&\/?$;P+9:_P"&],U"YU:PTJUT
M+1H[QHOB!X$U_P "ZEH7A3PR/$'@?6V'B/PSH/B3P[?W/B'\:=+TVX_9E_X*
M:?\ !NK\3?C,U_X0\&ZS_P $Z_V>/A4=5U^.YLK#0_B!J/@?XN^$)O"MS+J4
M-C;Z4^BZS\8OA]_PDT$T^=%NO$-U>WH2WD@DG^UOV$=>T7XS?\'.?_!1_P"*
M7PXN],\0?#[PW^S\_@_4_%/AV0WGAX^)?#EA^R[\-]2TV+5;&.2QDUBY\3^#
M/%K2+]H07DV@^(+FWFG-HY<N[K5W;2:\K)O3IY]A.*46DE;D<N:VO,I6M?M9
M;>O4_K4J,S0B9;<RQBX>-YD@,BB9X8FC2258L[VCC>:)'D"E4:6-6(+J#^"M
M]_P0E:]O;R]?_@JS_P %;-]W=7%TWF_M7O<2[KB5Y6\VXD\)^9/)ESOFD^>5
MLN_S,:^ _P!FS]F&_P#V.O\ @XE^%OPCB_:+_:/_ &A+;4_V#/%GB>X\9_M%
M?$FY\?>-OL6K^(_&L8\&'5H[/2XI?!>FZEX=M_$6FZ#-:R6]MXBN;K5P6NS"
M\57>FG5)Z[7M^KM\B.5.]I;*]K/4_KJHHHJB HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M#@_BGX\A^%?PQ^(WQ/N/"_C#QO;_  X\!^+_ !Y/X+^'FC+XC\?^+H?"'A_4
M?$,OA?P-X>>[L$U[QAKZ:<VE>&=&>^LEU36KNRL6N[83F9/Y^?&'QF_X.(_V
MN+V:\_9M_9S^ G_!//X3ZE':3>%->_:6\2Z+XW^-5W9RM+G4O$F@V>D>/X/"
M4TT2PS7/A'6_@I:ZSH4TDMF=7U]56\' _M@>,O\ @H]\5/\ @K+\4?V<_@7^
MUOXJ_9@U7X;_ +/G@OXW?L/_  N7X9GQ1\$/VG5@T)(_C$GQS\3PK=6&B6UI
MXQ3Q!X+T^X\8Z3K>EZ?Y.BWV@6VC^)8M._X2KB?V5/AW^T7^R+_P5(_8M_9V
ML?VO?VP?VDOB7\4_V?O'OQ7_ ."F7P_^-?BKQ%\0_@O\/9KGX7I)X!\8?#[Q
M#J>AVFDV5C=?&"SN_!V@ZEIFI^)]5C72=*\,ZAXDL+36;_1S+=WU2O;2VNJ7
MJM_+374U225_=;MS:W=E:]K;>5]5?W=#N+?X/?\ !TK\$I'\<0?M0?L8_M<0
M:<C:C<?!K4M#\->&9_$UY(1/=:5I^KK\"?@"+*)I"\&GO+\5O#-C%'M)@L(P
ML0_73]@+]M#XK?M8:-\1O#_Q[_9!^,O['GQL^#EWX9T_QQX0^(]I]L\$^*5\
M4OXGATSQ%\(O'#VVE2>-_#KR>$=3.I7D&BII6ESW5A8Z9X@\4H9M23]"J*:5
MNK^>O_!_3?0ARNM8Q3Z-*WX+1_=<****9(5^/OQ _P"""/\ P2>^*?COQK\3
M?B!^RQ=>)O'GQ%\6>(_'7C7Q'>_'_P#:=BO-?\6>+=8O-?\ $6M745G\:+:S
MBN-4U>_O+V:*TMK>UCDG9+>"&%4C7]@J*32>Z3]1IM;-KT;7Y'RI^R1^Q)^S
M#^PIX$\0_#3]E;X9?\*L\$^*_%L_CK7]$_X3/XA>-_M_BJYT?1] GU3^TOB-
MXL\7ZO:[](T'2;3[#97]MIR_9//2S6YGN9ICX[?L2?LP_M,?%+X!?&KXV_#+
M_A-?B9^R_P"+8/'7P+\2_P#"9_$+PW_P@_BJV\1>%O%D&J?V-X2\6:#X?\3;
M/$'@KPS?_8?&&E>(-.;^S/LKV;65YJ%M=_5=%,+N][N_>^OWGY\_MR_\$O/V
M-/\ @HDG@^Z_::^&U]KWB?P!::AIO@[QSX5\4Z_X,\7:-I&K7MC?ZGHLM]HE
MY#8:[I%Q<V"2VUCXFTS6HM%EN]4N?#PTF\UC5+B[]F_9N_8R_9H_9*^!DG[-
M_P "?A5H?A/X.WLOB*ZU_P ):A/J7BY/%U]XNMTLO%%]XSU+Q=>ZWJGBNXUS
M3XH-)O!KEY>VZ:%:6'AZT@MM!TW3]-M?J"BBRWMKW"[M:[MVOI]Q^/?P'_X(
M/_\ !,G]G#X[:'^T-\,?@/J-OX[\':[:>*/A[9>)/B1\0/%WA3X?>(K&.1;/
M6_#N@>(O$.H17NHV5Q)_:6E7/BVX\3/H6L0V6KZ!_9>I:=I]S:_L)1119+96
M!MO=M^KN?B?_ ,'%7_*'#]L/_NWW_P!:E^"-?J)^S3_R;E\ /^R)_"K_ -03
M0:_DX_X++?\ !4GXO?M!?L!_M,_ C7?^"7W[?'P!\(>)[_X8VLOQU^-WPEU_
MPI\.?#-OX5^//PW\3:?<^*-5.A3:#IY\47>@6OAC1Q;^)[VSN=?U[2K6RO\
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MH;FUNK:97AN+>XA=XIX)4>*6)VCD5E8@@'\F@_;T_P""H'[>'A_]F/P9IO\
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MDA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% ##'&SI(R(9(PZQR%5+HLFWS%1R-RA]B;PI
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM8W4T.B7NROI?OY:KSU_RT,W*\E;6WSWW^X_I)HHHK,T"BBB@ HHHH ****
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MZG),DFL0QK:2I*\D/[STUMU^=K_A^NI,K7TY>GPWM^.H4444R0HHHH ****
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MI]I=:E):M>7%M8V<$TSQ6L")+OIM:Z]=T7'EM+?FY7U5K:=+7_$_J-HHHJB
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M-JS6\5Z?#OAVUFET:&9?/=:K6UFGM_7HRX63O>-]5RRNDTU9Z[==F<]\%_\
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MOAOX_P#"FI6L^BC4X/%.CZAXH6/6K'QGKL-C<:5'H5IX*@UZ^\0_TC_\$Z?
M/C+X5?L%?L<_#3XB>'M0\)^// ?[-OP=\)^,/#&JI''J?A_Q'H7@;1=.UC2+
M](I)8TN]/OK>:VN%2615EC8*[ 9K\L/^#G__ )15>+?^RV?!O_T\:C5._+NT
MTKOOHC.%O:+1-.5EV5WOYV6R/KKQ5^V;J?[)7_!&CP+^V=XP-_\ $?QCX,_8
MO^ 'BSS/%>JZAJE[XW^*7C_P/\//#/AFY\8:Y=7O]LZBGB#XB^+M(G\5ZJU]
M)K5W;76I7D<T^I2(7_GK_9;^)'_!5[XRWO[-'[3?P]_X*U_L_P#CS]K3XZZY
M#KGB#_@FY\9?B%X$\#^&=,^#=[;:Y?>']7_X5CX:\17,MQ<:]X'TO3_&EQIO
M@KX4>'/']AX4UZU\5V'B'5]2TV]FN/UC_;.^"7BG]H#_ (-Q-)\!>"-,EUCQ
M5I_["W[*/Q*TO3H'F%U>6WP?\._"'XI^(K:QMX5=]1U*Y\*>$-=MM+TM89I=
M1U&:UM+2/[;+;2)_*#\5IO\ @GK+_P $;/V*)/V?K#P?9?\ !3"3X_BW\4P^
M";^^N_VBA=Z?XB^(\%UJ'B%M'@_M*/PYJLC_  SOOAK9N+=H+B[T6U\*W-WJ
MVD^+0TMO3>W*GUU=U?7O]]BX15G;=S<=D[*S:]%WM;9:Z']$W[>WQL_;=_;N
M_P""L47_  2K_9._:7\5?L8^!O@=\([7XL_&GXJ?#Z?4H_&6L>(]5\$^'_&%
MB[:AX:\1>#O$^I>&;&W^(WP\\*6'A/3_ !/X;LI=1USQ)XO\11^(UT?POI^E
M>7?L7_\ !93]J'X2_L _\%.M-_:BN-+^+7[2O_!,C5_#OPW\/_$34KJ&]C^(
M&M?$+Q[XA^!O@F#QH;2WT:Y\5IX ^)OAL7.O^+7N+#Q#X^\)ZMID>I2#Q7#J
M?B/6>8B^)&D_\$^_^#C?QA\9?VR=:T3X8^"_VJOV0/"T,'Q1U.Z;3?AS9>,;
M3X2_"*R\97C:S=>:L>G7/Q*^!GB_PY96DHM;NUO/$?AE9;6&SOK*6Z_/3X+_
M  @\>_MI?L9?\'&W[2OPQ\*>(M:\&_'#XX^"?BG\)[\:-<VTWBR+X=?M&^/?
MVD?B/;:=8/-#<2:OX;^%WB#1KF\T1(+JZ%QXFLK:WAFU&"*TF+N[MO[WW65M
M/NUZC25HWBN6U-IVZN24M>[5[KLCU*[_ &FO^"LG_!/+X/\ [$?_  5<^,G[
M9?C+]I+X8?M?^*_/^+'[+WC/4;A_">D>$O&D5YX^\+:5X/L;B]U'P?X7U'QC
M\/\ 1-5U[3-9^'G@WX?1_"K7(-*\*KIOBOPK?:QIEW_<_P"*/BK\,/ ]OH]U
MXV^(O@;P9;^(8);K09?%OBS0O#*ZS;VZ6DEQ-IG]MW]B;Y+9+^R:Y-L)/LXO
M+;SMGGQ;OX!?VV_VO_A5^V/_ ,$>O^"2G[#/P!UA?'7[3:_$#X8>$]:^#6AH
MVI>+=#\0_"?P#XT^ >DPZW%#&JZ5)X_UWQOIFL>#;6<[M6T.\FO5<QZ9=./[
M"?VK?^"1G["O[<'BKP/X^_:@^%.I_$3QSX!^'>D?"_1?$.G_ !$^)/@<#PGH
MVHZMK5I8RZ5X-\7:/IDI36-?UN^2XN(+B^']H-;27DUO!;)$XWUM_=^^VNNO
MW="9I>[S+EUDGRQ5[)KETNE:VB?;N?%G_!P/\</@KXP_X)$_M;>'/"7Q?^%W
MBGQ#J/\ PH7^S]"\.?$#PGK>LWWV3]IOX,7UW]CTO3-6NKZZ^RV-K<WEQY$#
M^3:V\]Q)MABD=?V5_9I_Y-R^ '_9$_A5_P"H)H-?RN?\%E/^")?_  3B_9%_
MX)N?M'?M#? 7X)ZWX1^+'P]_X5!_PBGB&\^+7Q9\36^G_P#"6?'GX7^!]=\S
M0_$WC/5M$OOM?AOQ+K%BGVW3[C[-)<K>6WE7=O;SQ_U.?LOVMO8_LT?L[V5K
M$L-K9_ OX26MM"I8K%;V_@#P_%#$I8LQ6.-%4%F+$#DD\TU>[O;9=;]7Y(B5
MN6-FVN:6Z2UM#LV>YT4451 4444 %%%% !1110 4444 %%%% !1110 4444
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MQK^%WAVYF,]GXE\0Z[HWAVR\6QZ9ILMGK]YHWAB-M1U:Z3]Z_P!LG]I_P?\
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MXAAURZ\37/P^\%:?I4-U/XPMM)ALKFWE+7,",MV[W<=O']A_$G_@N_\ M<_
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M10 4444 %%%% !7\W_CG_E:"^#?_ &C?U3_U+OBK7](%?S?^.?\ E:"^#?\
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M\;75_P"+=+\,>*[?3[7PCJ^M:S)H6K?V?+::1:>H_MJ?\$5OC;\8O@O^QO\
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M<W.H:E=>0;G4+^YN+V]EGNIY97]"HH"[M:[MVZ?<?&OPQ_X)W?L*?!;XH/\
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MIL7%NTEI;E;V5^G6U_Q/Z0****H@**** "BBB@ HHHH **** "BBB@ HHHH
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M^,-8:7P'H.L*(A>V^DLPT<:A<V]K>:=JR6C7^H:M:Q7:)-X<U*TC2]O/SO\
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M#]L/_NWW_P!:E^"-?J)^S3_R;E\ /^R)_"K_ -030:_!G_@O)^W#^Q7\8/\
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M+Z>A_4;1113("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF^F'5GO#J-N\:2I9^3<1N3%+][T4W*ZM9?);>@E&SO=_?OZZ!1114E!1110
M4444 %%%% !1110 4444 %%%% !1110!YI\:/$'CSPG\'?BQXJ^%GAJ#QG\3
MO#7PT\=^(/ASX/NHKB>U\6>/-&\+ZKJ/A#PU<P6EYIUU-!KOB"VT[2YHK;4+
M"XDCNF2&\M9"LZ?R?>+_ -M__@O?\0;FSO?'W_!%']GOQO>:? ]K87?B_P"$
M'BCQ+<V-M+)YLMO9SZU\9;V6V@DE_>/%"Z1O)\[*6YK^PROYMO\ @M!\<OVJ
MOB!^UW^P[_P3!_9B^/-W^RHG[5]IXM\2_$SXYZ>VI:1KB:!HSZ@-/\,^&/$U
ME=Z#>Q:@EGX5\42MX6\,>*-$U_QKXAU?P/X5O-;\/:/K$C:VGWN_E;6[7?\
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M2TM5TZ.V6WB"?/G_  [3_P""<O\ T8#^Q/\ ^(J_ K_Y@Z3B_=U6G>^_??\
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MH **** "BBB@ HHHH **** "BBB@ K^57]H?]HC_ (*C?\%*OV[/VL/V*?\
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M$I/V0OVE/CSHO[2_[5W_  43D_9*MM1T32/!G@;PYXU\<_#'P5X.@U'1-/\
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M2.-%"(B( J(BJ JJJ@*JJ %    %.HHI%!1110 4444 %%%% !1110 4444
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MM0,GA;43K(TS3=32=FN-4T_4;<P(ELTM2VM%U;7YIEQ3M)].5_H?U[44451
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M]O;/2KS4+'4M/L;Z\A@MK^]TK5K6REN)M+U!;?\ A?\ C?\ MD:9_P %*_\
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M%55 55     IJ]W>VRV^?ZW_  (E;EC:]N:6]M[0['M]%%%40%%%% !1110
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MDTC6=+TVPUY/;3R_/I?KV+A;F5_.UVTKVTNUJE??\=+GY5?L]?&+]H3]A?\
M;+_9S^!__!4W_@F5^Q+HOA?]H?XN:?X/^!O[2OP4^ /[/^BZSX1^(=UXFTRS
M\':OI>L?#^UN]#ET3P_XHUGPM;S6>L:?X"^)OAO0KAO':7OB2ZT8:3K']H]?
MR,>"OV??^"K?_!4']KG]E3QI_P %/? OP*_9O_9H_93\;6_Q>TOX<_#+QOX,
MU*'XO?$+3-3T>YT?1+_PEI_QG^,VMWMY?ZEHEC87^H^)[C0],TGP+?>*=.\*
M+)K/B:YENOZYZ4>N]KZ7WV7](=1IVVO9WY6W&]]+:M;6V/XZO^"C/_!!+3/#
MWQP^-W[=G@G]NK]FKX1ZO\5OB+XN^(%SX0_;C^&?PLN?@KIVN>.=<GU[6;"3
MQO\ $./QSX5>UM9KN5='BU#X.ZSJD,*I"VHL\LUPWXDZ3_P4?^%G[,?Q%N/A
M9\<_^">/_!(K]MG1/"A^PZA\2O@)\)="\'-XSN0S*+[2OB#I_@^[\"W$38'.
ME?!FPMVRI0#=BOT$_;6_X('?\%*?CM^W7^TK^T3H?@+X)_$_X??$7XU_$7Q;
MX%TWXF_&?5[-9?!6L^)]1OO"5I?V6A:OH&O:7%IND36D%MHD&MPV=A&HLC \
M$8C'TE\#/V%O^"[W[,\FGW?P%_9>_P""6GPMUK3+-;"V\6>%OAM\)[7QU):J
M,>7J'CZ;3KCQIJS-SOFU77KR>0DF21B23-G?1<O?KNUTZ6WZ;>1JFK)2G&6G
M=1MM975WI=_CU1_4_P#L:>,_#'Q&_9+_ &;/'_@KX6V7P0\'^-/@C\-?%'A?
MX/::EO'IWPQT'7/">EZCI7@>P2TTCP_:BS\-V5Q#I5M]FT/2(##;(8M.M$*P
MI]+5Y#^S_P#\+C_X4=\(_P#AH?\ X1__ (7O_P *[\)?\+@_X13R/^$9_P"%
MC_V)9_\ "7_V#]F_T?\ LG^W/MOV#R/W7V?R_+^7%>O5:V7IZ'.]WZ^H5SVG
M^$/">DZYK/B?2O#'AW3/$OB)+:/Q!XAT_1=-LM<UU+,$6::SJUM;1W^II:AF
M%LM[<3B ,1$$!-=#13$8'B;PGX6\:Z1-H'C+PUX?\6Z%<2P37&B>)M&T[7M(
MGFM95FMI9M-U6VN[.66WF598)'A9HI562,JP!&Q;6UM96\%G9V\%I:6L4<%M
M:VT4<%O;P1*$BA@@B5(HHHT4)''&JHB@*J@ "IZ* .9T[P5X-T?7]9\5Z1X2
M\,Z7XH\1"$>(/$FG:#I5CK^NBV4);C6=8MK2+4=4$"*$A%[<S^4H"IM  KIJ
M** /Q/\ ^#BK_E#A^V'_ -V^_P#K4OP1K]1/V:?^3<O@!_V1/X5?^H)H-?R"
M_P#!8'X._P#!=_P[^PM^TGXJ_:]_:O\ V//B!^RC;ZC\.)O''PX^$_A6\TCQ
MKJ-A??'/X>6G@*W\/R:C^SUX>O[-=(\<77A'5=2AO/BA)<C1].U"WFU;Q Y-
MKJ?]>'[+BWB?LR_LZ)J,MO<:@GP)^$2WT]K"]O:S7B_#_P /"YEMK>2:XD@M
MY)@[PPR3S/%&RH\TC*7:4[MZ-:+?Y_Y_@RY*T8ZI^]+:_:/=+^F>[44451 4
M444 %%%% !1110 4444 %%%% !17.^*/%_A3P1I4FN>,O$N@^%=&B<1OJGB'
M5K'1[$2LK,D"W.H3V\3SR!&\J!&::4@K&C-Q7Q+XM_;Y\#:E>7GA/X ^#/'G
MQW\:/:M]E'A/0-1LO#]G*\CV[3WVH7UA+JPBLVVW!N8/#ESI%Q&%!U:&-FE1
MI-[)B;2W/I;7OVB/@;X7\6Q^!?$/Q4\%Z3XJ>3R)-)O-:MHVL[DR+$+34[L,
M;#2;UI'4+9:G=6ETP(=82GS5>^)7QT^$7P@M?M/Q&\?^'O#4C0)<P:9/=_;-
M?O+=V9$GL/#FFI>:[?0%U*&XM-.F@1A^\D0<U_*[XLT+Q5H?BO7-"\8:?JEG
MXPM-8N[;7;'4UD?5#K#W#&Z\\DR-=3W-PYE6XC>9+SS5GAEFCE21OWM_91_8
MK^&'A7X<>"_%GQ0^'&GZ]\5=6TQ]6UM?&*SZW;:0=0NI[G2].7PUJ9?1K+4-
M.TE].BO&N=,FU.SU6.[474914CIQ22=WKZ:^:_I]"5)RV27G_6[W[$4G[8_Q
M5^+DLNG_ +*OP!\1>+;,R2P)\2/B(H\.>"(I;:X6&Z:"(7UE;:@JQNLZ6[^*
M=.UE5)#Z%(ZM#31^R-\;/C&WVO\ :C_:"UO4M)F):3X9?"O9X?\ "@19DN+6
M*]O9;"TM-1$.9+>47/A>YU%5"M!XC=QYI_1&...*-(HD2**)%CCCC54CCC10
MJ(B* J(B@*JJ JJ   !3ZF_9)?B_O?Z6';N[_@OFEO\ ,\<^&'[/WP;^#D*)
M\._A_H&@7BQO$^N&W;4_$MQ'+M\V.?Q)JLE[K<D$C+O-I]N6SC8D0V\284>Q
MT44BK);*P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 5_(]\:Y/VZO^"0'_!3;]K7]ISX'?L8?$']N3]F?]NVW
M\,^-]8@^&]MXRU/Q7X$\<Z+<WTEUHNM>*?#W@+XEZOX-&CZ]KWBR?3-&O/#C
M^#O%'A/Q+X0M-*UFWUKPG>Z1H7]<-?R>_&GXW?\ !<#]MW_@H;^V/^SA^PO\
M9_A!^R5\,OV-M9\$^$]0TSXDZ?X334_$]MXUTC4]:\*^/M3OKCX7?&SQGJTO
MCZRT^_UO1$T?2_#WA32O"4OA:UO["/Q-)JVH:C,NF][Z6M?K??R^XN'VOAM;
MWN9M*UU;;6][:GJ__!*[X/\ [8/[4W_!1G]H/_@K+^UO\ /$W[(NFZO\+;/X
M!?!GX#^*M(UOPOXSNK.%/"B:CKWB6#6M"\&>*?$NDZ/I_AJ41:]XU\+6\7B;
M7/%,#^&(;'1/A_HUE9_K7_P5+M?VE[_]@;]HJQ_8]?QTG[1]YX?\*VOPT?X9
MWAT[QVEU<?$7P?#XC?PWJ"SVLMA>KX.?Q"7O+>YM[JUM1<3VD\-RD4B_(O\
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MUC2FADT'5M5\.Z%8^+=.;1KFSTGP_P"-;75_$^A0P:UK=U+?3S:OMKZZ)/\
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M\/Z]+E^L<6\ T+VOR\6Y?CN2ZUYO[+^OWY;23Y.>[C[O-S4^?[%HKXM'@?\
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M"ZMX*T_XI>%?#T5SKGA+P^-1O/&%[X@7P_;:!X7UW5M5T;2]2_MZK^1[0/\
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MXZ8E>S7B5P6H0BU"&'XRXFR:G*/N^XX8/#JG!.[C_P O6EJHM*4%]UZ7>_\
M!/'1T5+3Q=^RQ,%6)0=4^('PZUQR(5*(6?6M?U!W8@DRN[,\[8>=I' 8>Q:/
MK7[+FDK%<:!JWP"TU7%M/#/H]_\ #NS5A#F2TFBELI8PPBWE[:1&(3<6B(W9
M/Y/1>%/^"*,DBH_@BU@5LYFEM?VB6C3 )!807TTIR0%&R)SDC("Y(KM\+_\
M@AZ[,QT)068L0NH_M<HH).3M1+]45<GA54*HX4  "OI,%X3^(&5<BP'A!PI@
M_9_PO[/R;.<$J6]^1X?A":5]=(\C5];W/GJ_BEXK8[G_ +0XC\.<Q]I926)\
M3N)=;6?O_6.'\7[1:*UU&W*G=[1[K]K_ .$7P2\$^&_CA^TOX1^-.@:D\LK>
M,]2\ MKVAZ^VK^+;F/1-#;1_#VNP:[]KTFRO8QI)L=%DTC6VTR>9X;&2'1YM
M-TW3.-_8J^#GPT_:*\!_"WXU^(OBI8>&+G_A+U\07'PNTS4M,@\36NI_#GQD
M]]I%N_B5M8M=2M;>]OO#^G:K>O;^%[/4&T6YEATR^L+B:TURW_)G]O;PK^QA
MX<\3^&[3]CE[VZTV>QO]6\;2ZAK_ (A?3]%F,L-EI'AK0M+\>W,'C.6\5;;4
M-8UJ:_MK^+[-?Z&FF7[@:E!#Q_[#GA/]E7Q;\2+[2?VM=0N]%\%7&DQ7_AO5
M]-\27=@TOB'3M4M8W\+ZOI.@QW?B*2Q\2Z?<W7E7]E#:W5I/IL4-M.G]I+=V
MO\TX[PGX6GXTTUC/#7!RXAG-8^O2AGO&U'*'Q3#&T\?'-IQ63QK0A0QD:>3U
MLMADT\F>/G*%>HZ<I3A\/'Z8WC)@,^?A!2Q/"?\ J/7R',>$L7DE'&93/AO$
M_P!LRJ5,;CGQ?6X+GG-/#U,-C,1E52*BZ5+$XF=26(IU:472_LRD^+GPIADD
MBE^)WP]BEB=HY8I/&GAM)(Y$8J\<B-J09'1@596 96!! ((IG_"X/A+_ -%1
M^'7_ (6WAK_Y9U^-J_!?_@B.JJ#I.G.0 "[>+/VH@S$#!9@FNJH+=3M55R>%
M P!G'X6?\$/ 2/["Z<<:I^UT1^8U'!^HXK^M%PQXRROR\!X5VWM4XJ=K[7MP
MD?2/B_C1;KPCC?92\1,UO_ZQRO;K8_7<_M._LUJ2K?M"_ X,"00?BSX"!!!P
M00=?R"#P0>0::?VG_P!FD D_M#_ P  DD_%KP"  .223X@P !U-?E"/!'_!$
MD  >'-(P !S9?M.$\>I*DD^I))/4G-.'@K_@B4""/#>C9!!&;#]IIAD'/*LA
M4CU!!!'!!%'^J?C5_P!$1A/_  1Q8_\ WW5Y]O\ /+_6WCG_ *"_![_Q-<X_
M^</K_3T_47_AK_\ 9+_Z.B_9U_\ #V?#3_YIJ1OVP?V2E5F/[47[.Q"@L0OQ
MK^&SL0!D[43Q*S,>.%4%F/ !) K\YR/^",6#_P 4?\.C[#X9_&#)]N?#('YD
M#WJA'J/_  1MBDCE7X:^"2T;K(HD^&?Q%FC+(P8"2*73'BE0D -'*CQNN5=6
M4D&X\'^-$MN#\(K6O? <4Q[;<V51OUV\KVN6^*N,E:^;>$>O;B/-I=KZ+">M
MDVKZ:[GP%^WQ)_P3DT_X827_ .RMJ6CZI\4;_P"(FG+J-GH6O>-[W2H_#-Q8
M^(;S6&M+#6[MM(L]-AU6'2([9M/A3R@8+>Q*V4KY^SOV+O%/_!+7X>6'P5\?
M0^.O"'A7X\Z9\-O#TVOZEXO\9>+[&QTGQKJ7@>"R\;[H]>U%?!]E>_:+O6[&
M*-E2VB>X:+25$_V0K^-7[>GC[X >/_CC?7/[,WA?P)X6^$V@:+I&DZ.O@SPK
M?^$Y/$^ISP'4O$7B+5;"]T72O*EM]7O9?#=G;H[6O]G:)9W]C$%U"YD?ZL_X
M)G_$/]A[1=#\=>$/VL_"7PHU77VU33-6^'FO^)OAKXF\;ZWJ%EJ-C<CQ/X<O
M#9>%-:TN"'P[-H^EZAIDTBI>2MKVLPP7=S9VZ1P?S?D6$RNOXGXG Y9PQP=]
M<JPP>#R.G0>#K8"GGF'Q$7A\7E&%PU.5>698W&Q]C2C@J2QTJJI7495*;I_S
M)P]QPZOB]C<)A\/X4X93=/+L#FE3"RP_#4<9E%:MB88W*L3#$NM2QF/K*5'#
M8KGDJ]2GA/8P4JU-S_HI_P"&V_V/O^CG/@9_X<WPE_\ +2KEK^V9^R+>!S#^
MT_\  !/+*AOM7Q=\!V).[.-@O==MS*!M.XQAPG&[;N7/Q%'XQ_X(^2R+&O@/
MX$AG.T&3]G?Q!#&"?[TLWPW2)!_M.ZJ.YJMJLG_!'?6# UWX.^"4)MQ((_[*
M^%OBS0@PD*%O/71/"VGK<D;%\LW(E,0+B(H))-W]'RX1\8H;\+89O3W991Q3
M2NM+^]]2J-6UM[COHM+MK^H/]9>,;7AGGA-4::]W^V,TI)ZJ_P"\4JUFEJE[
M.5W9:7NOO'_AK_\ 9+_Z.B_9U_\ #V?#3_YIJ/\ AK_]DO\ Z.B_9U_\/9\-
M/_FFKX7A\"_\$?)X8IT\._ E4FC25%FMO$-O,%D4.HEM[CRKB"0 @20SQ1S1
M-E)41U91L6'PI_X)$ZDDDEOH?[.,:Q,$87^LMI3DD9!CCU34[.25<=7B5T4_
M*6#<5RRX?\6J:;J<-99!)I-RPW$L4G=*S<LL5G=M)/JT:1S[CV;2AC/"J3>J
M4<^SF3:T=U;!.^E_P\S[0_X:_P#V2_\ HZ+]G7_P]GPT_P#FFH_X:_\ V2_^
MCHOV=?\ P]GPT_\ FFKY#A^"/_!)2>18DTG]EU6;.#-XTT>WC&U2QW37'B.*
M). 0-[KN;"KEF4&[_P *!_X)-_\ 0,_90_\ #C^%?_FMK%Y1XI1:4LBR9/1V
M=/B).VFJOEOK;Y&JS?Q$>U?PO?IG>>/^7_J!\_QCW/K:W_:V_93NY5@M/VF_
MV>[J=PQ2&W^,_P .)I6"J68K''XD9V"J"S84X4$G !-:/_#3W[-7_1PWP-_\
M.UX!_P#F@KX]OOV7/^"56J6;6TWAS]FU;>;RW\W3OB5IVEW!"LLJ&*_TKQE9
MWD:L5&[R;A%EC)CD#QNRFK8?L*_\$M]4A:XTSP5\)=1MTD:%Y[#XS>)[R%)E
M5':)I;?XC2(LBI)&[1E@P5T8C#*3SSP/B935Y9)P]RZ7E.OQ!12;MI9Y/47H
M^:[NO=5M7_:GB:Y*-*EX85VU>_\ K#Q!2E?2Z5..28BZ2L^;G5[I<JW=C]JS
MXU?L&^);OX=:O\1_$7A;XJ:YX<F\3-X4N_AO\2?#]S<^'(=4M-.M-<35I]*\
M::9:?9]5B6R6UMM02^D,ME+-9I;&.>23\<?@/^T)\#;W]I'XUZ=\5X=:U3X*
M6MQXT/PKTJTU;0M)O+&VB\;V<7AL76MIJFDMJ;6?A=Y[1F;7=4^W,POLW1C:
M\3[O_;)_9D_X)S_!7]GGXD>*_ O@'X0'XFMX>GL/AY87GQD\0K=RZ]J5W8Z.
M-8T[3;SQW>KK,OA6+5/^$A;3FL+NTNFL(;341!974L\?\Z7PD30+7XI^#)/%
MVC>'?%/A73_%FC'Q1X>U_P 2Q>&M#\1:$-5M[?5]+/B9+JV&FI?63SK!J]K<
M9L05U)"T5NQK\+\1LHRK$<5<)5N*?"S@O.\ZH8_VV:8R-#%8Z6=T'AY4L-E6
M;U,5DM/$>SP>%Y<53H4X8RI##PIU522JTK_C?&_CIXV>&W%&19-DW%=#AFCC
M\PAGN89?P-Q+Q/0RG&U\5A:.3>UXA6'PV6RQN)^JX##U+_5L7BHX/!8&"C[*
MGAJ<O[-/@/\ 'S]C+PG\)/!7AWX;_%3X4?#_ ,%Z7I]W!HOA#Q)\3/"6G:]H
MX?5;^?4$U>VU;Q3>Z@U]>:K+?:C/=W%Y='4'NSJ$=S/#=1RM[[8?''X*ZK:Q
MWVE_&#X7:E92EQ%>6'Q \)WEK(8W:.01W%OJTD3F.16C<*Y*NK*V&! ^//#_
M /P3;_X)W>+-&T[Q'X6^#'A#Q)X>U>W6[TG7= ^(GC[6-'U.T9F5;G3]3T_Q
MU<65Y;LR,HFMYY(RRLN[*D">X_X)2_L!W4K32? &!78*"MO\2OC#:1#:H4;8
M+3X@PP(2 "Q2-2S99LL23^R49\7TJ5.&7Y1P70RZ%.$,!A<+G.;0P^'P<8Q6
M%HT)PR&5-T*-!0ITN2G&+@HN/+%6?[+@:GBKA\)A:5+)_#2KAZ6&H4J*PG$/
M$6#H>SA2A&G*A&GPIB*5.AR)*E2IPY(P<5"2C%)_9'_"X/A+_P!%1^'7_A;>
M&O\ Y9T?\+@^$O\ T5'X=?\ A;>&O_EG7QA_PZ=_8 _Z('_YE/XU?_/&H_X=
M._L ?]$#_P#,I_&K_P">-6OM^.O^A7PG_P"'_./_ *&SL^M^*W_0@\/?_$OX
MD_\ H'/L_P#X7!\)?^BH_#K_ ,+;PU_\LZZ2Q\7^$]3M8K[3?$_AW4+*X#&"
M\L=:TV[M9@CM&YBN(+F2&0+(CQL4=@KHRG#*0/@S_AT[^P!_T0/_ ,RG\:O_
M )XU9L__  2/_8*EE>2/X-ZE;(Q&V"#XG?%-HH\* 0AN?&5Q.02"Q\R9SN8X
M(7"AK$\;QUGD_"U1;)4^(LU@T^[<^&9)KI9*]VGW*CC?%.+O4X;X"JK91H\:
M<04I)W^)RJ<"SBXI75DD[M-.R:?A?_!0?0/V6-=^)&GZS\0_A[X@\4^-1X C
M$GB3PY\0H_".E3:5;7FK_P!DPW$45GK,&J7VGSK?K<7+6UC-':/9VDUQ>PPV
MT=C^//[&NE?LY^,]*\4K\6?AMXL\4W&F>(M)-I_PC7CVX\.?8M)O8)!/YVG_
M -GWDFHSW9LW,0&J:> T#VZ30DFZ/Z$_\%"O^">W[-OP3^ USK?P*^$VF6'C
MZ^U:V#>(O%OQV;P_9^&/#.EJ^IZYJ6G:;\2?B/I=GXLUK4&AL?#FFZ!I=AK6
MH3/K<D]M:#4(=.CN/C/_ ((]>,_B+X(_:4_XIY=%O/ 'C&TM?!?Q(T?4O'W@
M;PSJGEZ@]W=>&/$OA[POXK\7^'=5\7WOAK6+1CJ!\+Z3XEU/3_#^J:Q:06(O
M=;T^*Z_.,VAPK4\1^#H\2>$>6XBBXYLN*JF6YAFN883BC%9AA:,,)CL96ED6
M7TJ-3AZJ\/CL4J5'&PC1Q?/7JTZDFW_,G%N*SG_B,W#&4<1<.Y)@?[4JUY8B
MIDV63XDP]59M1A1A5K5L;D&2U<PGEU2C2Q./JPC7AAJ&)G5E5C5ISI+^L7PK
M:Z79>&/#EEH>E2:%HEIH.CVNCZ)+;-92Z/I=OI]O%I^E26;EGM)-/M$AM'MG
M8M T)B8DH36]117[BHPBE&E"-.G%<M.G&RC3@M(0BDDE&$4HJR2LMD?VS"*A
M"$$HI0C&*48J$4HI)*,5I&.FD5HEHM@HHHIE!1110 4444 %%%% !1110 44
M44 %%%% !7\S7[77_!=+Q+^SE^TK\8O@=:?\$KOBS\9[;X:>+[GPW#\4M$U:
M_ATGQLD%I:7 UJQBB^!7B2.."4W!A"IKFI@-"W^DM]U?3O\ @Y@^-7QD^ __
M  3V\(>-/@=\6OB9\&?&-S^T[\.= N?%GPH\>>*?AWXFN-"OO ?Q8O+W19]>
M\(:KH^JRZ3>7>G:?=76FR736=Q<V%E/-"\MK T<7_$3_ /\ !*K_ *&WXV?^
M&;UC_P"6-2VKM7LU;M^II&+LI<O.G=63:M9K5M=[O\^A\P_\$?OBI\>/VJ/^
M"I'[37[6'@S]CSQ5^Q)^RYXU_9Y\.^&/C!X*URTUB+PW\3_CYHOB33;CP;XR
MMFN_#/P\TN]^)*:!?>*CJFH:%X9O[32/#2WDGB:2/Q'\1+'4[W^KJORB_8F_
MX+.?L1_\% ?B]J7P0_9VUWXC:EX\TKP/K/Q#N[?Q9\/M0\+Z8/#F@ZMX?T74
M)8]2NKN>-[M;[Q-I:Q6H0-+$T\@8"$@_J[36V]_NW^6Q,[WUCRZ+37:VF^O]
M6Z!1113)"BBB@ HHHH **** "BBB@"M>7MGI]O)>7]W;6-I#L\VZO)XK:WB\
MR18H_,GF=(DWRND:;F&Z1U1<LP!_FC^.WB[0/AY_P< :%^TIJ>H0:O\ #[X7
M_L&^"?!?B&V\-S6^J^(+C5OBEXU^/-MH,FEVS36VD3VE@WAB]?6VO-:L;JUB
MN;%[*TU RS+;_M3^VO\ L0? ?]O_ .#]E\#OVB=.\4:GX#T_QKHOQ M(/"7B
MG4?"6I)XCT#3=<TG3Y9K[3]WVNR6R\1:HDNGWD-Q://);W@C6\LK2>'^7S6O
MV#/@I^Q3^W[\4_V4?V4-%\6WJ^.?V=_V??BGI/@;5/$%UXX\=:[J<?B[]HW2
M?&&JZ-9^2NKWNBZ'INE^&FU5K2SFL]&-Y#/>SP"_B+88FWL*[EB/J<52J2>+
MO23PRC!R]O\ [1"I0_=6YW[:,J=E[\7&Z-Z%_:T^6C]:FZD(K#6J-5[SBO97
MHSA6_>7Y%[*49W?NR3LS^A;QY_P4J^&MO;Z;I?PA\-ZQ\0?%NLVMBR)K3P>#
M_#/AZ\U!,-9Z_K.H2,);K2IW1=1:Q'_".R(LK0^+4A0W(^:]:\37OQHN7F_:
ML_:@MO#GAAPMP?@K\#M/UK5-/F@DE,@T[5_$FD:;J?A2XGL[JWAE@>_U3Q[)
MY#,;;5].D="?JWX+?L$?!2V^'/A"[\<Z)XPU?Q#K?A3PWJGB+2]8U_5?"KZ-
MX@O=%LY]9T^W@\)1>$-9M%M-1DN8!;ZQ=WVHPB,17=S-+&S'W[1OV/\ ]F71
M;+^S_P#A3'@OQ!:Y5MGCRSN/B1("N=I%Q\0;KQ-<#:267$HVL=PPW-?FE;$^
M+V8\D\CAX>93EM2C1EA<PSFIQ'GV:8FC."DL9B,JPF%X8P>!KUH.-7ZG''8J
M.'DW3E6J:J/T[7!6"]HL7@N*<UQM.5>-; TL=D_#F"HXBG/ECA:..6'XQK8O
M"J491^O3H8>M.%I?4XRO?X=\.?MC?L5_LWZ9-H_PR\ 2Z'J+0FV;4M:G\+Z)
MJOB']]NC74?$^K^(-5\57D$MSO>&UGLI(;60B*RT^!-L,=FZ_P""C/Q,\5VQ
MF^$_[./C?Q&IW>3>Z-X"^+/Q.TRY4K T31:AX2\':)I"HRS1R^<^L"V,4\,@
MG$6)9/U \*^ _ W@2R73O!'@SPGX-T]-VRP\*^'='\/62[@@;;:Z19V<"[A'
M&&Q&,B- <[5P>/%\8-X(\8+\/7TJ/QZWA?7AX*DUU7;14\6'2[K_ (1YM66/
M+G31JWV0WNT,1;^8=CXVGR\3P7XGXVE5JYOXP9A0I1HSG4P/!_!G#^5U*C@G
M-0P^+S26>Y@IRY?9P5/$T93;2<E=LX\3Q-@\)3J5\FX%X5HRIPE4A3S^MQ5Q
M9BH*--MPIRP'$/!N78JM*2O2=?)8TW-I2HN+L?S@^+-;UOQ-XI\2^)/$ND7.
M@>(_$&OZSK?B#0KW3[K2;S1=;U;4;F_U72+O2KZ6:]TRYTV_N)[.?3[R:6ZL
MI87MKB626-W/9^$;[]N"U\.S)^SA\-O&GC+X=G69YM6U+PE\4O#'@=H?&*6=
MA'J%A+I=_.FN3M'HLOA^X-ZL;:9=+<)%$'N=,NC#XOXN_8 _X*3>,/$VI^*]
M7TK79M7\1^(M2U_Q#+9_&;P?IL%U>:W?S:GJES#9:?XVLK&RC:ZFF,%A86UO
M:0+,(;:*V@B1!^H__!-OX*?M@? I_'7A3XZV^G6/PSOT/B#0K34/$VD>+O%$
MOCJ];1M.GN;/5M)U35YH-!70-',6H6&JW2HNH'3;C1H$,NM/+_'7AKX#Y\_$
M2&-XEPW'N"R?-:F<J6883 YID.949UY3KT*N;9G#V=&C3Q%FL3"+J4Z]6<8J
MFTTE])Q%]+C/N/\ AS!\#9)X>\>>'.:0GE48\98C(N%LWRRDL!A^>O".5<5<
M.Y]E>&H8GD=*$YX:KBL)-PIX>OS.4Y?#=_XZ_;CM'DM?'?[(_P"V5XHB VRQ
MZ%\>K_4(9/+E"Q8FMOA)XSMI%CN(Y)E"^8&C:*6,H@$\OENH?'^3P?.LWC[_
M ()Y?'N20LNY_'/QRUO2FE\Q9P/WEM\!?#[N)9(YYU*2KYDL,A5O*61*_J-H
MK^P8?1^\-G.C/&8;.,TE2=V\WGPSG/-JFDEG/"F8JW,FVJGM4[[73;_+J_$/
MCJH3AEOT@.,\KC-OF6%X:\/<)H[;?V5PKE4HO3>$H]+6MK_,#;?MV_ '2S%*
MO_!/?Q)<.DD)#7/QS\1ZIODB)=3+;2^'+B QL0?.0VZV\HQ'*C*52O8/#?\
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M5Z:IQCS_ *X?\+P^"O\ T5_X7?\ AP/"?_RVH_X7A\%?^BO_  N_\.!X3_\
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M_#S_ ,*S1?\ Y+K$_P"&H?V?_P#HJGA?_O\ W7_R+7YG7_Q3^-7AM#_PD_\
MP1SAG\NV>YDG\'^.O _BXN//:...*Q\/_#S5G\W:IWP)>3W1"K.ML(9D*Z]M
M^UG\/M/W#QI_P2I_:+\/A)EC$FE_LR^'M?MGB5 T[QW=[IOAV"62+DJD3R1R
M*-SSQ'*B9\9>(K:C+&\!8"2^)8_ACQ(IWOMKB:&7QARV=W>HI-JSC;WG#Q/\
M (2<,75\5,+.T;QS+AO&9(Z=[W4GF/#:C*]FKJ48Q:WES*WZ-?\ #4/[/_\
MT53PO_W_ +K_ .1:JW?[5O[/-E&LLWQ1T%U9Q&!:0:OJ$@8JS M#8:;<S*F$
M(,K1B-6*H7#.@;\US_P45_X)]:?*(?&'[,GCCX>-]F^TG_A-/V;_  /8[4:<
MV\"LFEZKJ\N;IE=K>18VMV$;QO/'./)/H.C_ +?_ /P2FN61EU#X>Z)<2B)
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M;E)!P>02#P:NT45RN4I.\FY/:[;;MVU.A)+9)>BM^05QOQ ^'O@OXJ>$-:\
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M/AMH]/OOM6KW,DCPZ1)>67V$2NEU>E84>)_Z0?VAO /QM\>V/AJU^#OQ"L_
MOV&YU*7Q"MQJ6K:)-J@E2S&EO#JVB:5JE^JV)COEEL@+:VN?MB33/*]K J?"
M/A?]B7]K;PMXN\4>+]/^-'A2SU7Q)-=R7.I:?XS\=VFJ78U*_P#[4U :E=P^
M#8YKEIKY8YF,DTQFDC$\I$IP/=RCAO@;/,'G>;\7K@O->(LXI1=#'<39;4S3
M.L+BL/".74ZN(QN(I3J58QP%*E]6INI6C2A3H./*X3IK\;XS\..%\UXAPF,7
MAY3Q7L*E)9CBL%@\!AZ.94(T8RIPM#D<JE)J.'G5G&%1TX>ROR0HRC[OH_\
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M%UA,-"GPUE>"IQPU&$,)# 86@\-35.*CAW'#QY(RH1M3]R4HQY;0DXV9^?\
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MV G=>ZM'=75[7;NI<+9'+_F$K1TY5[/,,RI67E[/%PL_[RL]M=$?SQ_MT?\
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M3I6@/JCWC3>'&UO23<7R'O=UJ^VVGKY?B"<-?=>BOK/?5*WPKS?W_+Y.O/\
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M5:-HV7:49""I0J2I4@J5.",4+FLM4OD_\P;@G\+?_;ZU_P#)>OZ^EOYV8?\
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MQW>"2WEG?4E^#UV+*"6.2-$LY8WUU=1-Q.LC2Q-#836@CAD$]U#*88Y8I_\
M@Z*_X)917UG:1ZQ\>[FWNEG:?4X?@_*MCIQB3=&EY'<>(K?4G:Y;]W =/TZ^
M17.;EK>/+U_1,8(#.ET88C<QQ201W!C0SQP3/%)-"DI7S%BED@@>2-6"2/#$
MS*6C0C^<+QTB-_P=!_!DLJL8_P#@G#JCH64$HY\5_%="R$C*L4=T+#!VNRYP
MQ!3YEU6ZZ=VEW&N1W]UZ*_Q;VM_=-RY_X.A_^"6$$EHD6O?'>\6YN!!-+;?!
MZ[6.PB\J23[9=B[UVUE>W#HL!6QCO;OS9HR+4PB::(O/^#H?_@EA;1QO#KWQ
MWU!GN+>!HK/X/7:20Q32K')>2&_UVQB-O:(QGN%ADENVB1A:VMS,4A;^B&2"
M"9H7FABE>VE\^W:2-)&MY_*E@\Z%F4F*7R9YH?,C*OY4TL>[9(X.1XETD:[H
M&L:0([626_TZ\M[4WB;[>*]D@D%E</\ NIFC-M=&*=)HXGEA>,2Q*9$6GKW7
MW?\ !%>'\C_\#_\ M3^>^?\ X.B_^"6<5@]Y'J_Q\NKA5#+I4'P?D6_D)D";
M$DN?$=OI88*3,3)J2)Y8(#F7$1L77_!T+_P2OM[6>XA\0_'2^EAADECL;7X.
MWR75TZ*66W@>]UNSLEFE("(US>6UN&(,L\:9<?8O_!%?]ESXP_LE_P#!-OX(
M_L_?M&^#+/P=\4?#6J_%N]\4^#&UWPOXPBTNW\3?%_QOXCT..YUCPEJOB'PM
M?O?Z%J.F:L$TS6-12VBOH;6]>VU."]L;7]6YH8;F&6WN(HI[>>*2&>":-989
MH95*2Q2Q.&22*1&9)(W5E=6*L""127-9:K;L_P#,'R)M<K=G:_.M;=?AZV_'
MTM_.[+_P=#_\$L(X(YDU[X[SR/Y>ZUB^#UVL\.]=S>8T^NPVI\H_))Y5S+EN
M8O,3YJ=:_P#!T+_P2ON+6"XF\0_'2QEFA262QNO@[?/=6KNH9K>=[+6[RR::
M(DI(UM>7-N6!,4\B8<_0_P#P6?\ V-OCO^V7X$_8O\+? 7PQIOB.[^&?[='P
M:^)WQ$DU+Q'X?\-VOA'X8:-HWC+3O$?C:X_M[4=.?6+#P[+J>GM>Z%X9CUKQ
M??1W2?V%X<U8Q72V_P"S,,,-M#%;V\44%O!%'#!!#&L4,,,2A(HHHD"I'%&B
MJD<:*JHJA5   H]Z[U6GD]?QZ>OKT'^[LGRMMWNN;:UO[O77I^A_.[8_\'0_
M_!+"[M8;B?7OCOIDTJL7L;[X/7<EU;D.RA9GTW7=0LF9@HD7[/>3KL=0S*X=
M%BL?^#HK_@EE=_:?M&L?'O3/(N98(OMWP?ED^V11NRI>6W]F^(M0V6TZ@21+
M>?9+L(RB:UAD#(O]$MO;V]I#';VL$-M;Q+MB@MXDAAC7).V.*-51%R2<*H&2
M3U-?C;^P5^QA\<OV?_\ @HW_ ,%7?V@/B%X>TC3/A1^TYXT^">N_!7Q#IWB#
M1-2E\7VFE:/XTU3Q;+-H=A>2ZYX=E\-ZIXDM-#U%?$^FZ1)JFJI>7F@C6-&6
M+5ISWM-5VV\MWKY>6XDX6?NO1)KW]]4K?#ZO[_E\X6O_  =#_P#!+"X-T)M>
M^.]B+>ZDMXFNO@]=.+Z%%0K?6OV+7KQDM9BS+&EZMG>AHW,MG$IC:1B_\'1/
M_!+)I=0C.L_'I$LQ&;>=O@_,8M6+P>:RZ>$\0O/&89/]&D_M2'35,_S1&6V_
MTBOZ)(K>W@,Q@@AA-Q,UQ.8HDC,]PZHCSS%%4R3,D:*TK[G9412Q"@#Y(_;W
M^$7C#XW?L2_M??"+X7Z'::U\2OBO^SM\7/!7@_1WO=+T0^)/%VN^ M:TCPYH
M\VM:O<6&DV4NHWTUII=MJ&N:C8Z59-/%)J.H6&GQSW4+U[K[G_F"<+KW7_X&
MO+^[_5WY6_).+_@Z)_X)8R736[ZW\>8(EM(+@7TOP>N#:O-,TBR6"I!X@FO1
M=VH17G=[-+%EEC%M>7#B5(G'_@Z'_P""6 OEM/[>^.YMS:M<'4Q\'KK["LRR
MK&+%HSKPU(W3H3.KKI[60B5@]XLY6%OUJ_8$^$?C'X%_L3_LE_"7XE:)::!\
M3?AK^S?\&_ /CS2H+W2]7DT;Q+X7\$:38ZSX??6]&N+[2M571-7_ +0LS=:3
MJ.HZ-/<+<W.E7U[9SQ7D_P!;_9[<W NC!";I86MUN?*3[0+=G61H!-M\P0M(
MB2-$&V%T5RI900O>:6J6W1_=N#<$_A;_ .WUK_Y+U_7TM_.W-_P=%?\ !+**
M^LK2/6?CU<V]VETT^J0_!^9;'3#;HC11WL=QXBM]2D>]9FCM3ING:@B/&YO7
MM(S'(\D__!T/_P $L(9[.*/7OCO=1W,KQS7,'P>NU@T]$A>59[Q;K7;:Y>*5
MT6W1;"WOIQ-*C20QVXEGC^B_VKOV-_CS\4_^"O7_  38_:Q\&>&M,U'X&_ #
MP1\>-(^+7BF;Q+H-A?>%-2U_P;XIL/"ML/#=_?VWB#71XGU+Q+:V-A-X:T[6
M8=/>QU&?Q$^BVBV$]_\ LM)!!*\$LL,4DMK(TMM))&CO;RO#);O) [*6BD>"
M::%GC*LT,LD9)1V4GO:ZK?MY+S_K\FW35K1;NKOWMG=JS]W?3RWVV/YE/'W_
M  <3_P#!&+QU?Z?J_B[1_BUXQU2(6^D)>R?!2[6\LM->>6;S+FXN?$.FM-IU
MC+--.8(GO+N-KB9K&RE>:56X&V_X+O\ _!"G1K6233?AU\3V9M2W-86_P6O&
MFE:6Z2&34#]N\6QV36BQ 7;027(N/L<9ACL6N=EDW]5$UO;W C%Q!#.(9H[B
M(31)*(KB%M\,\8=6"31. T<JX>-OF5@>:_%?_@AE^PW\<_V%?V7?CE\(_P!H
MW0/#NF^)_%W[8WQ8^*?AJWT77])\5Z=J?@:Z\,_"WPEX5\3BYTZ6XBLCKU[\
M/[[Q%I.FZ@MKK^FZ7=Z0VN:9HNN?;-)L/2HYSG.'I1P]#-LQH4(QM&C1QN*I
MT8I.Z4:<*T8)7;:225VW8X*F5Y17G.O6RS U:TFG*I5PV&J59MV3<JDJ+DW[
MJNVVW\E;P2X_X.@?^"5>GV#M9:Y\<KS[);A;;3-.^#=U!-*L2A8[6T%]K>GZ
M?$0H"QK/=VL"* #(@ J:;_@Z$_X)710B5/$?QSN')B'V>'X.WZS 2.JLQ:XU
MF"WQ"K&27$Y8HC"$2R%$?^AZ>""ZAEMKF&*XMYXWBG@GC2:&:*12KQRQ2*R2
M1NI*NCJ592000:_GH_X.?_\ E%5XM_[+9\&__3QJ-><W+5MI[O9Z_B=T>1N,
M>5J[2^):;+;E7]/TM^\GPR^(OA/XP?#?P!\6? 5]=:IX&^)W@OPQ\0/!NIWN
ME:KH5WJ7A7QCHMEXA\/ZA<:-KEGIVLZ5+>Z3J-I<O8:I86=_:F7R;JVAF1XU
M[BBBF0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 ?R2_\ !8C1[?\ ;5_X+1_\$W/^";GQ-UW6I/V;+KP8_P ;/'W@
MK1[_ %318?%'B6YE^,5_J=CJEYIUW8W3S7G@OX0VGA72M;L)H=7\*:=XX\63
M>'M3L=0U6]*9W_!)/PG-^PO_ ,%R/^"A_P#P3K^%NM>);?\ 9>@^%L?QF\+_
M  [U?49O$,?ASQ)/:? GQ;X3N]/OKR;4-4=](\%?%S7?!<]XUU-KWBK2].\)
MR^,+G5M7\/64]M[-_P %H_A#\?/@)_P4#_8,_P""L_P7^$/CCX\>%?@/8I\)
M/CCX&^&OA?4_%?B_0_ EMJ/Q"UFZ\0QZ7IL%\;?3M:\'?$SXD:,GBB^MK+1/
M#'B73_"T6M:F@U[35BQ/^".?PL^/W[2__!3G]N'_ (*T?%CX(^/?V?/AK\5_
M""?"?X,^"OBGH6N>'/%_B;3KQOA;%IGBBRM-4MK$WVF:#X$^$^AV.M:K;177
MAF^\2^,;K3?"^HZF?#&IR6,->]MKS)_*ROKM_7F;7]S=<O)9K3X^9;K>]NI]
M):G_ ,'.7_!*K3=2U#3AXV^,UZ+"^N[(7EM\%?$]O;W8M9Y(/M,$&JR:;JD$
M,_E^;%#J6G6%_$CJEY96MPLD$?XQ^)O^"U?[#NK?\%N_A[^W9::W\2O^% >&
M/V.[WX)ZGJ4OP]O4\3GQQ<:[XXU..*V\,B^:[ETO[/XAT]&U!I8P)A.OE%(Q
M(_\ =57\WWCE5/\ P=!_!HD E?\ @G!JC*2 2K?\)9\5ERI/0[69<CG:Q'0F
MF[]UNNGFO,F+AK[K^%_:WV_NHVI?^#H?_@EA'=VELFO?'>>&X6X::_B^#UT+
M2P,*HT:7:3Z]#?.UV6*6YL;*]17C<W36R%'=9_\ @Z'_ ."6$,]G%'KWQWNH
M[F5XYKF#X/7:P:>B0O*L]XMUKMM<O%*Z+;HMA;WTXFE1I(8[<2SQ_P!$#V]O
M)-#<200O<6ZRK;SO$C30+.$$RPRE2\2S"-!*$91($0/D*,9/B/21K6BZI8)'
M:F\N-,U2UT^>Z3*6EW?Z;=Z>LZRB*66 &.ZDBFD@1I3;R31A75V1G:7=?=_P
M17A_(_\ P/\ ^U_J_H?SWR?\'1?_  2S2&UE75OCY-)<7,,$UM'\'W$]C%*[
M*][=--XDBMWMK=0))DL;B\O&1E%O:3R!HUFO?^#H?_@EA:P>;!KWQWU&3S8(
M_LUE\'KN.<)-,D4D^[4-=L+;RK5':XG47'GM#$ZVT-Q<&."3['_X(K?LN?&'
M]DC_ ()P? GX"_M%^#+/P9\5_"&N?%;5]?\ "1UWPOXO_L)O$'Q@\;^)?#LK
M:YX2U7Q!X9N;JYT/4=,U>)](UF_-DE]%;74MKJ<%[96OZM3007*>5<0Q7$0D
MAE$<T:2IYMO,EQ!)L=67S()XHYH7QNBFC21"KHK!+FLM5MV?^8/D3:Y6[.U^
M=:VZ_#UM^/I;^=K4?^#HK_@EE96LEQ;:S\>M8F0C;8Z=\'YHKJ7.<E'U;Q#I
M=B ,<^;>1GD8!YQ8E_X.@_\ @E;'!),GB7XY3R)"\BVL7P<U$3S.J%A;QM-K
M$-J)I& C1I;F* .09)TCS(/H3_@M%^QI\=OVT/ 7[&7A3X%>%],\3W/PX_;G
M^#GQ,^)#ZKXB\/>'K/PK\+])T;QGIOB;QK=CQ!J&GMK>G^'Y-4L#?Z#X;BUO
MQ=?Q7:_V'X<U<Q72P?LXZ)(CQR(LD<BLCHZAD=&!5D=6!5E920RD$$$@@@T>
M]=[:>3U_$?[NR=FV[W7,M+6M]GKK^/E;^=Z#_@Z$_P""5TUK#<2>(OCI:RR0
M)*]E/\';YKJWD= [6TSVVM7-FT\3$Q.T%W/;%U)CN)(\2&O8?\'17_!+*\A$
MMQK'Q[TIRD3FWU#X/RR3*TB;GB+:7XBU*#? W[N4K.T9?F"2:/\ >5_1/%%%
M!%'!!''###&D4,,2+'%%%&H2...- $2-$ 5$4!54!5   K\8_P!@7]C#XY?L
M]_\ !1W_ (*M?'3Q[X4TG1O@Y^TCXH^!.L? WQ+IGB#P[?Q>++#1M%\;7?B>
MUC\.:9J$WB'PP_@Z[US3]!U&+Q1HV@Q:A?LT_A9M>T:-]30][35=MO+=Z^7E
MN).%G[KT2:]_?5*WP^K^_P"7SS9?\'0__!+"Z@\V?7OCOITGFSQ_9KWX/7<D
MY2&9XHY]VGZ[?VWE72(MQ IN//6&5%N8;>X$D$<<'_!T3_P2RFBNY)-9^/5J
M]M/<PPP3_!^9I;^.#_575HUMXAN($@O?^79;Z:RN4_Y?+>TK^B6&""V3RK>&
M*WB,DTICAC2)/-N)GN)Y-B*J^9//+)-,^-TLTCR.6=V8_(_[>GPB\8?&K]A_
M]KOX-?"S0[35_B'\4_V>OC)X0\&:#]MTO0H_$/C/Q1X'UNPT;3)-5U6XT_1K
M"ZUO5KBVLAJ>M7]AID%Q<I<:KJ5E9)<7D+M+NON_X()P;^%K7^?T_N_U=^5O
MR3M/^#HG_@EC<27*3:W\>;!8'B6*6[^#UP\=ZLD$<SR6PL?$%Y*B02.UK*+R
M.TD,\,C01S6QBN)71?\ !T/_ ,$L)+N[MGU[X[P0VZV[0W\OP>NC:7YF5VD2
MT2#7IKY&M"H2X-]962,\B&U:Y0.Z?K5^P#\(_&/P'_8D_9.^$'Q'T2T\._$C
MX=_L\?!WP;\0M&M;W2]5_LOQCX:\ :!HNN:5/K&B7%[I&L7&CWEE)I,FI:7J
M&I:7<_8@^EZC?:=]EN9?K=+>WCFFN(X(4N+A8EN)TB19IU@#B%9I0H>581(X
MB#LPC#N$P&.4N:RU6W9_Y@W!/X6_^WUK_P"2]?U]+?SM'_@Z*_X)9#4EL1K'
MQ[:U:U-P=9'P?E_LU)A(4%BT3>(EU<W14"4.FE/8^6P!O!+NB663_@Z'_P""
M6"7EO;+KWQWEAFBGDDU"/X/78L[1X3$(X+A)==COVENA(Y@:TL;J!1!+]JFM
MB81-]$_M6_L:?'?XI?\ !7S_ ()M?M:^"_#&E:C\$/@%X&^.VB_%SQ7+XCT#
M3]0\+7^N>#O%ECX2M#X=O[ZV\1:\GB74_%,-EITOAO3]9@TV2TU2X\0OHEK]
MBN-0_9AH('FBN6AB:XACFBAG:-&FBBN&B:>.*4J7CCG:W@:9$8+(T,1<,8TV
MGO:ZK?MY+S_K\F_9JWNMW5W[VSO:WP^5_GVL?SNS?\'0_P#P2PBN;."/7OCO
M<Q7+3K/>0_!ZZ6VTX11&2-[Q+C7K>\=;E_W$(T^TOG64@W"V\.9A#)_P=&?\
M$LT\C;JOQ]E\V_\ L<GE_"!A]FM\R?\ $UG\WQ+'NL/D4^7;?:-4Q+'_ ,2W
M(E$?]$\EO;RRP3RP0R36S2-;321(\MNTL9BE:"1E+Q-)$S1R&,J7C8HV5)%?
MB=_P0K_8@^._[#'[,WQX^$W[2'A70]#\5:]^VA\6?BAX-?2O$/A_Q9IVN>!-
M1\#_  J\'^'/&FGW>C7EZVE1Z_<^#M;O-/TS6HM(\4V&F2VW]N:+I%Y<26,9
M[U]U]WIIOUU_'Y"]G9NSNK67,M;[_9Z6_'TMXA>?\'0__!+"VCC>'7OCOJ#/
M<6\#16?P>NTDABFE6.2\D-_KMC$;>T1C/<+#)+=M$C"UM;F8I"T6I?\ !T5_
MP2RL;.2YM=8^/>LS(T873]-^#\L5Y,'D5&:-]8\1:3IX6%6,TGG7T3&-&$*R
MRE(G_HFF@@N%5+B&*=$EAG19HTE5)[>5)[>95=6"RP31QS0R !XI421&5U!'
M\XO_  =" ']@#X/ @$']M?X) @C((/@[XM @@\$$=10VTF[K3R?^81Y)24>6
M2N[7YO\ [5=OQ?E;;NO^#H7_ ()7V]K/<0^(?CI?2PPR2QV-K\';Y+JZ=%++
M;P/>ZW9V2S2D!$:YO+:W#$&6>-,N'_\ $4'_ ,$K?(\W_A)?CCYGE>9]E_X4
MYJ/G[]F[R-W]K_9O-W?N]WVCR-_/G>7\]?T.S0PW,,MO<113V\\4D,\$T:RP
MS0RJ4EBEB<,DD4B,R21NK*ZL58$$BG[5V[-J[-NW;@;=N,;=O3;CC&,8XZ4]
M>Z^Y_P"8KP_EE_X'_P#:_P!7?E;^=>R_X.B?^"6-TB//K7QYTYGMK>=HKWX/
MSR212S!C)9N=/\07\1N;0J%N&BDDM&+K]DNKI0[(ZQ_X.A_^"6%W;)//KWQW
MTR5VE5K.^^#UU)<QB.5XT=WTW7M0LRLZ*L\0CNY'$4B"989A)#'[S^SQ^PY\
M=/AQ_P %M?V[/VV]>T'P]IG[/'QF_9Y^#GP\^%^JV>OZ3/JVL>(=&\)?!#P_
MKVE_\(M92OJFAV_A>X^#FJ&\N-6M=/L+NT\0^&3X>GU=_P"WH=!_:B"WM[6)
M8+:"&VA5G988(DAB5I9&ED98XU5 TDKO(Y R\CL[99B2ES=6M+K;?SW_ *^X
M;]FK6BWHG\6S:3M\/3;[_E_.[:_\'1'_  2QN(II)==^/%B\<]S"D%U\'KEY
M;B."1DBNH39:_>0+!>*HFMEGF@N5C=1=V]K,'B1EA_P=%?\ !+*\6<W&L?'O
M2C%*(XUO_@_+(UTAABE-Q =+\1ZDJQ*\CVY6Y:WG\Z"5EA: PSS?LE^V/\*/
M$?QG_8\_:P^"GP^M--_X33XP_LX?'KX;>$;:\N(=*TRY\8_$?X:>*_#6C'4;
MYD\FSM[O7=:MWU#4)581K+-=3;R&)^=O^"1/[.7Q0_9-_P""=?[-/P$^-7AR
MP\)?%CP1X=\5OXY\/Z?J^B>($TO5/$?Q$\7^*+.RN==\.7FHZ'JM_9:)K.E6
M5]<Z7J6I6"7%N]K9ZA>6MO#.Y[UUJMGT]//^OR/W=K\KO=+EYUM:]_AO;2WS
MWV/SZA_X.A_^"6$MS>02:]\=[:*V:%8+R;X/736VHB6(22/9I;Z]<7B+;/\
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M+W[*]Q'\'Y!#!!]G,W]I2K-XCBG-D) +3RX()M1^T,&%@;3=<K+=_P#!T/\
M\$L+86YAU[X[WYFNH+>1;3X/72&UAE8B2^N/M^O62M:VP&Z=+5KF]92!;6=P
MV5'O/_!+?]AOXY_LN_M0_P#!5[XM?&;0/#NF^%OVI?VR-9^*OP.FL-?TGQ!J
M&L>"+CQ/\6_%UOXHNK73I;F3PVTUG\5[7PZ-.U<V'B!-4T7Q*LNFIH<FBZMK
MG[436]O<",7$$,XAFCN(A-$DHBN(6WPSQAU8)-$X#1RKAXV^96!YI+F>]EY6
MV_'YC?LT[*+>BU4UK=)_RO;;[_E_.WJ7_!T3_P $LK&SENK76?CUK$\9B":=
MIOP?FBO)Q)*D;&)]7\0Z5IX$*.T\OGWT),43B$2SF.&22\_X.AO^"6%M:3W$
M&O\ QVU&:*(R1V%G\'KQ+NY8=(8'U#7+&Q65N@-S>V\.?O2J.:^TO^"U7[,/
MQF_;"_X)Q?'7X"_L_P#ABV\:?%CQ1J'PKU/PQX4N?$'A[PN-<7PI\6?!7B;6
M;6#7?%>J:)X;L;F+0]*U*]A.KZOIUM<-:_98[C[3/!%)^A'PC\&WO@[X.?##
MX?\ B6*PN]1\*?#3P5X/UZ* _;=,N+_0?"^F:-J:0-/#%]JL9+FTF$3S6\9F
M@*L\*%B@?O7W73H_/S_JXO<LGRO=JW.NG+K\/77\?E^%,O\ P=!_\$K8X))D
M\2_'*>1(7D6UB^#FHB>9U0L+>-IM8AM1-(P$:-+<Q0!R#).D>9!#;_\ !T1_
MP2QF6 R:Y\>+0S6B7,BW'P>N6:UF;;NT^<VFOW2M=Q[CO>V:XL#L;R[V3*;_
M .B9T21'CD19(Y%9'1U#(Z,"K(ZL"K*RDAE((()!!!K\CHOV4/C5!_P6YC_;
M @\(V,/[.,/_  3F3X&0^-8O$'AJ-HOBG'\<AXBC\$1^$$U,>+DD3PL!KJ:T
MOA\>$5L@+!=?&M@:32?-W7W/JUKOT!<CO[K5E?XUKMI\/7]7Y6^3+'_@Z'_X
M)87=K#<3Z]\=],FE5B]C??!Z[DNK<AV4+,^FZ[J%DS,%$B_9[R==CJ&97#HI
M9?\ !T/_ ,$L+J#S9]>^.^G2>;/']FO?@]=R3E(9GBCGW:?KM_;>5=(BW$"F
MX\]8946YAM[@201_T06]O;VD,=O:P0VUO$NV*"WB2&&-<D[8XHU5$7))PJ@9
M)/4USGBR""V\&^*XK>&*WB/A_P 12F.&-(D,MQ8WMQ/)L157S)YY9)IGQNEF
MD>1RSNS%VEW7W?\ !"\/Y'_X'_\ :G\_MA_P=%?\$LKQ;AKC6/CWI1@NIK>)
M+_X/RR-=PQ[=E];G2_$6I(MK<;CY27;VMZNQO/LX<INE@_X.A_\ @EA-/>12
M:]\=[6.VE2.&YG^#UVT&H(\*2M/9K:Z[<W*11.[6[K?V]C.9HG:.&2W,4\EC
M_@U_1%_X)5^%2JJID^-WQD=RJ@%W&K:8@9R!EF"(B!CD[45<X4 ?T,QP01//
M+%#%'+=2++<R1QHCW$J0QVZ23NJAI9$@AAA5Y"S+#%'&"$15"5VD[K5+I_P1
MRY(R<>63L[7YK7V_N_U=^5OYV#_P=%_\$LQ>/:C5_CXT"?9=NHCX/R?8Y?M'
MG^;L1O$:Z@/L7E1_:O,L8]_VF#[%]KVW/V>4?\'0_P#P2P-\UI_;WQW%N+5;
M@:F?@]=?86F:5HS8K&->.I"Z1 )V=M/6R,3*$O&G#0K]9?\ !6#]D[XT?M/S
M?L 7/P2\'Z?XHN/@O_P42_9S^-'Q6GGU_P ->')O#OPC\#MXK;Q)XOEE\1:E
MI3Z]:>&FU*%G\/Z VL>*KMM2)T'P]J9^V^1^M_V>W%P;H00BZ:%;=KGRD^T&
MW5VD6 S;?,,*R.\BQ%M@=V<*&8DGO:ZK?L^R\Q>Y9/E>O3G6EK?W>OZORM_.
M_)_P=#_\$L$O+>V77OCO+#-%/))J$?P>NQ9VCPF(1P7"2Z['?M+="1S UI8W
M4"B"7[5-;$PB:&7_ (.B_P#@EG'>0VR:O\?)X991&^H1?!^06=LI@EF\Z9)O
M$<-^T0DC2U(M[&>;SYXF$1M1/<P_T3M! \T5RT,37$,<T4,[1HTT45PT33QQ
M2E2\<<[6\#3(C!9&AB+AC&FW\C_V0_V3OC1\+/\ @I__ ,%3/VD?'_@_3]-^
M$?[0\G[*,OP.\6C7_#6JW'BR7P'\*-9\/>.Y8-#T[4KSQ)X8D\-:I>#0[U_%
M&E: VJM=M+X=.MZ0;B^0][NM7VVT]?+\1IPU]UZ+^?=W2_EWU;T\].WR;=?\
M'0__  2PMS:B'7OCO?"XNH[>5K7X/72"QA=7+7UU]MUZS9[6$JJR)9+>7I:1
M#%9RJ)&C;J'_  =$_P#!+&SM7N+;6_CSJTJO$HLM/^#T\=TZR2I&\B/JOB#3
M+() C&>4/=I(8HW$"33%(7_HCEM[><PF>"&8V\RW$!EB20P7"*Z)/"75C',J
M2.JRIM=5=U# ,0?A_P#X*8_ GQ_^TU^P/^U7\"OA7IECK?Q(^(OPCU_2?!&A
MZCJ.GZ1;Z[XELWM=9TK1$U75IK72-,O=8NM,CTW3;_6+W3M'M-1NK6XU74],
MT^.YO[9^]KJON?Z/_,2<&TG%I75WS;;:_#_5WY6_+V[_ .#HC_@EC;64EU#K
MGQXOYT1'73;3X/7"7LK,RAHHY+[Q!9:<'C#%G,M_'&51A')(Q17EN/\ @Z$_
MX)706T\\7B/XYWDL4,DL=G;_  =OUN;ET0LMO UWK-K:+-*P$<;7-U;VX=@9
M9XH]TB_K7^PI\'O%GP2_8A_90^!_Q1TJPM/''PR_9V^$7@/QWH<=W8:W8:=X
MH\->!]$TS7M)6_LI+O2]433=4MKBS-[83W6G7;VYN+&YN+5X9W^M)8HIXI()
MXXYH9HWBFAE19(I8I%*21R1N"CQNA*NC JRDJP()%"YK+5+Y/_,&X)_"W_V^
MM?\ R7K^OI;^=O\ XBB/^"6/EV[_ -N?'C=-;O-)#_PIZX\RTD6)9%M+@_\
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MOP)N=#T2^EO)/+,-['!XTU34+^73XH3<1P76EVMDD]Q;7-O?33V\D"?93?\
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MX 5_0Y7FJ^M^C_1/S[G=-)-6O9QB]7?=7[+^ON"BBBF2%%%% !1110 4444
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MNP\:75A<>//"6J>)/ _AS1]'U&UT?1+3P[>>&/&:#5;S7?$;V-UJ.A:5X?\
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M[0?QO^"?[1WQ?^%W_"7?&;]G34K#5_@WXR_X3;XBZ!_PAVH:7X@MO%-C<?\
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M:GK%C?\ ]O>#;#P]XFE\C4KG[+/K,ME+Y,UM)!%_,#^VIH_CO_@J[_P77?\
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M^ -(\13V_A32?$/BGPV^F^)_&%K>Z+<ZYX5D> KJ?\%U_P!JK]FCX@?LF_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&;]C;G_1QFG=?A?Y?TQ<DNUO>Y=?YGT[_/8_>6BOYE/C[_P7L^*OP/\ B/\
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M,ZY\1?C1^V\-5\.?!#]GFWUJYN7@\?\ A'5D\&_$VRU/Q1IWA_[7XAT3X?\
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MO?#7[9'[5?CC_@B7\.O^":?@K_@GQ^T_XM^*7Q=\):;X3^&'QH\(_#*7Q/\
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MN+7?"NEMK":=K7B*WNWGU?4/#GA3^IG_ (*6?\$Q?@;_ ,%/?A5X1^'/Q?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MP4_9F^(/QO\ V9)? >H>*_A'H=]XW\2>#?'O@[4O$]EXJ\&:3)9S^*)=.O\
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M-<T?4].M=9US4+:;3=#T3P]>Z/JFD7VFZW?ZM(&M=/ /T3HKQ/X;?M)_L_\
MQB\1ZUX0^%7QF^&OQ"\4>'M/@UC5M \(^,-$US5K?0KG[$MOXAALK&\FGO\
MPW-+J%E:Q^(M/2ZT1KZX2P%_]LW0#YI_X*<_M!_%_P#90_9!^(7[1GP9O_!2
M>(OAC?\ @F2^T'QWX3U+Q1H_B73/&/C[PKX >TBDTGQ7X4O-$OM.G\4Q:S#J
M FU2"XBL)M-ETY6O8M0L7;5+O;\1VU2[V_$_0*BOSK^)'[3?Q?\ V<?VF_V7
MO@M\34\#?%CP)^U7K'B?P1X>\1>"O#FK>!?B)\//&OA73UUB;5=:\-7?BSQM
MIGCCP'J=KJ6D6=Y>Z6/"-WX'6WU/6=7O->AN-.TUN<\5?&[]IN__ ."C6J?L
M?>#_ (@?"_PWX G_ &0+C]I_2-?UGX1:MXG\5:;JK?%.3X3VG@Z\G@^*/A[3
M-4TB+4_)\2W6HQZ9INH7.EB;PW"+.]DC\4PEORO^-@M^5_QL?IO17XS?LD_M
M$?\ !1/]I7]BSP3^USX2U;]EWQAXH\81^-=3M?V?M0^$WQ!\#2:S9^ OB+XI
M\#W?AS0?C/'\=]?T_1O$7B*U\*7FHZ1J7B#X8:AH4>JZAIFC:D=+T^WO_$DO
MUI^SO_P4(_9S^/?PC^ ?Q(O/''A?X8>(OV@["9/"'PQ\:^*=)M/%EWXJTOQ-
MJO@GQ!X7T*&9K&?Q/)I_B[0M5TVPO+&PMYM5L8[+5&TW3UOTMHQJWY?/^OOU
ML#5OR^?]??K8^Y:*^=]?^,]]X]^%FO>*/V2[GX=?&WQ='XGMO VD33^+XH?A
MYHGB!->L-)\5:AXSUW1!?WPL?A_IMQJ&MZ[H&B07'B/4[G3$\,V,=IJ6HI=6
MGS;^RU\<?VLY?VE?C5^RU^U;H7PHU[6/!?P^\)?&CP-\6_@?8^(-%\(:AX)\
M<^*/$OA?2_"_BKPYXHUC6M5T/Q4-0\+ZW)I5L+ZY$NFZ%JKW%WJ*+8:QJBM_
M7W?YBM_7W?YGZ-45\5^/OCS\3O"W[;O[//[/L5CX,B^&7Q;^'OQO\8WE\D&K
MWWC:6]^%NE^!S8J]_+=66BZ/IUYJ?C2]2XTFWTC6+V2/0=-U%?$MNFK7V@6/
MHG[7_CSX@?"C]F'X[?%OX8:KX=TOQG\)/A5X]^*6F#Q9X<N_%.@:LGP]\*ZO
MXLNO#^H:98>(/#%[&NN6^DR:;#J=MJ\<FDW%Q%J#6>I16\FG70M6EW!:M+N?
M2%%?C+X)_;I_:+^'7Q*_X)_>&_C]_P *D^)O@C_@H)X"M]6\+ZA\*? 'C'X>
M>/?A+XYG\)^#/%3V6NZ/J_Q%^)NC^._ </\ PFNC:7<>(+$^#M1TR.35O$&I
MVR66CV^G:Q]4:C^T'\3/C-^TU\7OV8/V?-4\%>";7]G;P[\-]4^.GQ<\9>&M
M5\>:A;>)?BQI^M:WX5^'/PZ\$VOB#P9I)U:'PMI2>(]8^(.N:_XET71+JXA\
M,S^ -3O6GO+1V_*_XV_/3_@#M^5_QM^>G_ /O*BOA+X3_M.>-=-_:H\2?L3?
M'V/P??\ Q5M?A'IWQX^&WQ)^'FE:MX8\)_$[X:7?BC4_"&J6^J>!M<\0>,+_
M ,">-_"NN::]K=6$7C7Q3IOBG3TN?$E@/#4"+H2?=M+^OO%_7WA1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/4?$.KZ?HMB]W*DLL5JEWJ5Q;6[7,D<$TD<"R&5TAE=5*QN1Q?\ PO#X*_\
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MAK\4=.^$?@/]FKX__M">)I?"T/BSQ#J7PFTCP3!X,\%VM]=ZA;:1I'BGQO\
M$+QMX'\+:?XGU>+2K[4K/PVNJ2ZN=*%CJ$EJMOJVF/=?+O[0=K\3_"/[='[%
MGQZ\$_$SPW\7_ GQ:\2:Y^SYHWP1UKPWX<OY/A[X7\6^#=4^(7Q*^.WPC\:Z
M#=66H2SZ?HWPNTRV\47NLVNNM#H>IS:%;ZLNG>(H+&R^ROVP?BGK_P &_P!F
MSXK^-O!EO/>?$1]!M?!?PJL;:))YK_XO?$[6=,^&OPFLA [(LD5S\1?%GAF.
MZ!8!+,W$I^6-C1VMKY:[_G_6C[':VOEKO^?]:/MY;X9_;N\(^)O@#X)^.EG\
M'_C3>7_Q+\>>+_AO\.O@YX=T/PMXR^*7C'Q/X)U?QCI.MG3$\+^+M2\#VWAV
MW'@+Q3JTGC+5_&FG>$8="T^#59M;2#5='^W]=^R/^V-X#_:ZT#QQ/H'A/Q_\
M,/'_ ,*O%(\%_%;X0_%;0D\-_$+P#K\UL;S3TU?3([F\A?3=9M8[B?1]0CF7
M[6+.]CEM[:>UEB'7>&--^'7['W[.?P[\'WMZB^&?@[\//"/PZ\/K##:+X@\8
MZIH>A66AZ7HWA[3I;B!]:\;^.M2L433M&MIWO]>U_4%B#2SS-+7(?LR>%-"\
M*ZY\5]=\1ZWX2OOVB/CIXBM/C9\8]#\,:[:>(E\(:-+I]M\//A9X02^M(+>:
M;0/!O@KP59>#=.\07]IIL/CSQ7X>^('BO1=/L+>YO]%T-?TOPW_$7]+\-_Q/
MKJOB#XA_MP^'?A?\5/AWX'\8_!3XY:3\//B=\5K+X&^%OC_<>'O# ^&-Y\5-
M7U4Z!H.A/ID?BZ3XF:?H>L^(8-0T/3?&NN^ =&\+:S<6T&K^&=1\0>$;^W\2
MU]A^'/$_AKQAI,.O>$O$.A^*="N9KRWM]:\.:M8:WI-Q<:=>3Z?J$$.HZ9<7
M5G+-8W]K<V-Y%',SVUY;SVTZI-%(B_EY_P %%[;XG:3>?L\?M*?";XF^&O&%
MC\%/V@/A[X=L_P!F'Q)X<\.>(_"GQ8^)?Q$\:0?!.VN=$U^QNM/\2Z3\4? =
MEX\\0:GHEM/=ZS9:#J&C2Z]%IFF7VBWKWS6K&M6?;GQX_:)\.? VZ^&7AM_#
M7B7XA_$OXT>,9O _PL^&'@E_#Z^*/%.IZ?HU]XC\2:S)+XFUSP_I&D>#_!?A
M[3KC6O&7B:_U!;71;)[.,17>H:CIUC=[GP/^.W@?X^^&_$&O>#?[4L-0\$^.
M/$OPO^(W@_Q#;V=MXH^'GQ,\&3P6_BKP-XECTN_U?1)M5T>2ZM)1J'AW7->\
M-ZO87EEJN@:YJVE7MK>R_$/[2MKK&D_\%-/^"</B_6K%[GP!>^%OVK?AQHFL
M2PO!IGA7XH^(_AYI?B.TBN=4S);?VMXW\+>#]2T?0=*N!9R7IT?56LI[VXC-
MI'H?\$\]#U ?$?\ X**>.H6NT\'>-?VYOB'9>%(Y-/DL]-U&[\!^%_"7A#QM
MXAT:YD2--4MI_&=AK'A>_OK426IUKP=J=N+B6Z@NTB+:?*_KK:V_S^\+:?*_
MKK:V_P _O/TUHK\O_P#@JA%K:?#/]G*\\.?$?XC?#?5+W]LW]FSP9<7GP]\=
MZ[X0DUW0/&_C^QTC7-$UC3=/O4T7Q- D*0:UI]MK^DZQ'IVH:/%<V\*VLFIP
M7GPKXR^&=Q<_$'_@L#\+W^,_[2R_#_\ 9>^#'PK^-'P,\*O^TK\:;N?P;\3_
M !A\ /'WCO4/%_\ PENH^-+SXA>($TOQ=X/T_6M+\+>)/%VL>!(=2U6_O=0\
M+ZA?1Z%<:,)7^^WXI?J"5_OM^*7ZG]%5%?C;\;/BQ\8==_X)K_L1?$^#QY+;
M^(/B3<_L):U\<XK'QI%\-_B#\8?!OCNU\$ZI\4/ 7PV\6P>(_!T^C^./'%U?
M&ZN$TG7M+O;OPE;>+=.M)H5N6>/VO]C+X5:]X \=_M3_ !D\3^,_C!:_!W5?
M&B:?\ ?!WQ:^-?Q(\7:7X$^$>E^"O"&M>+]9/@OQ%\3/$OA+PAINI^.HM=D\
M)6>O^%-#^)7@SPAIDUAJ-U9:/XC?1XCY_P!:?Y_@'S_K3_/\#[&T_P"+$VL?
M$#XP^"M"\(:GX@M_@_X;\&7-_JFD:II"W7B#X@>*]+\0^)KGX6Z79:U<:+I-
MCXBT;P?#\/O$<NH:YXETW2)K?XH^&UN;C3;:VO;\<_\ LN_'ZP_:>^"GAWXT
MZ9X2UOP+9>(_$/Q+T"/PKXDN]+O=>TN3X<?%#QG\,[G^U9]$N;W1UO+VZ\'S
M:C+;:;J&IV=D;O[%!JFIQVXO[FK^RYHNH0_"R/Q]X@L-0TWQA\<_$6N?'/Q5
M8ZU9FP\0:1)\0Y8+WP;X.\0VQ"E=9^&7PPM? ?PKN25#,G@>'=ELD_AG^P7X
M[L?&_B_]G7X$?'.^\<_#KX;-K_[7'CC]EG4?A[\1_%'AGP7^TGX_7]JKXV7/
MQ-\+_%G6/"VI^'KH:O\ #JP@T+5? /PLCEOM!\1Z3>:QXG\4ZYJJZ]X=\$VR
M_K^OZZ>HOZ_K^NGJ?TKT5^$G[6Z_&'Q]^T1^VU\-=(\8?$C6_%5K^S;\&[G]
MCB#X&?''4_AI/\$?BCJL'CT:NOQ+L](^)'A/3O#_ (A\9^(TT_Q3>^-O&.FQ
M6%Y\(M,M/"6GZK]OU/3]'UW]=OA?I.A_!?P+\*?A'XE^(DFM^,)M%?2K*_\
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MJ<OA;QK;^%]1$=YIEG$)M6UK1].OO4?V^&5/V%_VT"[*H/[*'[1*@L0H+/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZ/96WB1&\/W&IZYXCTS38];CN-*^UM?6=[!;?=VBZUH_B/1]*\0^'M6TS7M
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M#QA>:)H-A#)=:GKUYHOAC3]5UDZ-I%I#+>ZQJ$%C-;Z5I\4^HW[6]A;7-S"
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MAWXWTGP_XU\,+J]M!/>:!>ZOH=KIWB33HFU7P]>:II;)>/Z_0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\.?\%
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M;]K'Q?X#^(6C0RR07.DZPW[ ?[5WC;2FMKSR_P#0_$&B1:MX4\6:)J%MY_\
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M]YI-_J[ZM;.ZTTZKM\_OTW\_F[K33JNWS^_3?S^?H?[&+_'_ %?XF_M-:_\
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M_P"3&/VT/^S3OVB__5/^,:]"^*W[.GPF^->O_#_Q/\1M(\2ZMK/PL\0P^+?
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M"GAO3]'^(NE:Y>:?>7D'A&^\6>$&@O+BSTKQ/K*::NK:F6?]?+_-!9_U\O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[]QW_KY6_K[]SY!^+/[&OPW^*'[37[.W[6*NWASXM_ &]\16+ZK8V44R^/?
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144 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>ny20077604x1_figure11.jpg
<TEXT>
begin 644 ny20077604x1_figure11.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
M+0 R #< .P!  $4 2@!/ %0 60!> &, : !M '( =P!\ ($ A@"+ )  E0":
M )\ I "I *X L@"W +P P0#& ,L T #5 -L X #E .L \ #V /L! 0$' 0T!
M$P$9 1\!)0$K 3(!. $^ 44!3 %2 5D!8 %G 6X!=0%\ 8,!BP&2 9H!H0&I
M ;$!N0'! <D!T0'9 >$!Z0'R ?H" P(, A0"'0(F B\". )! DL"5 )= F<"
M<0)Z H0"C@*8 J("K *V L$"RP+5 N "ZP+U P #"P,6 R$#+0,X T,#3P-:
M V8#<@-^ XH#E@.B ZX#N@/' ],#X /L _D$!@03!" $+00[!$@$501C!'$$
M?@2,!)H$J 2V!,0$TP3A!/ $_@4-!1P%*P4Z!4D%6 5G!7<%A@66!:8%M07%
M!=4%Y07V!@8&%@8G!C<&2 99!FH&>P:,!IT&KP; !M$&XP;U!P<'&0<K!ST'
M3P=A!W0'A@>9!ZP'OP?2!^4'^ @+"!\(,@A&"%H(;@B"")8(J@B^"-((YPC[
M"1 ))0DZ"4\)9 EY"8\)I FZ"<\)Y0G["A$*)PH]"E0*:@J!"I@*K@K%"MP*
M\PL+"R(+.0M1"VD+@ N8"[ +R OA"_D,$@PJ#$,,7 QU#(X,IPS #-D,\PT-
M#28-0 U:#70-C@VI#<,-W@WX#A,.+@Y)#F0.?PZ;#K8.T@[N#PD/)0]!#UX/
M>@^6#[,/SP_L$ D0)A!#$&$0?A";$+D0UQ#U$1,1,1%/$6T1C!&J$<D1Z!('
M$B8211)D$H02HQ+#$N,3 Q,C$T,38Q.#$Z03Q1/E% 84)Q1)%&H4BQ2M%,X4
M\!42%3055A5X%9L5O17@%@,6)A9)%FP6CQ:R%M86^A<=%T$791>)%ZX7TA?W
M&!L80!AE&(H8KQC5&/H9(!E%&6L9D1FW&=T:!!HJ&E$:=QJ>&L4:[!L4&SL;
M8QN*&[(;VAP"'"H<4AQ['*,<S!SU'1X=1QUP'9D=PQWL'A8>0!YJ'I0>OA[I
M'Q,?/A]I'Y0?OQ_J(!4@02!L()@@Q"#P(1PA2"%U(:$ASB'[(B<B52*"(J\B
MW2,*(S@C9B.4(\(C\"0?)$TD?"2K)-HE"24X)6@EER7')?<F)R97)H<FMR;H
M)Q@G22=Z)ZLGW"@-*#\H<2BB*-0I!BDX*6LIG2G0*@(J-2IH*ILJSRL"*S8K
M:2N=*]$L!2PY+&XLHBS7+0PM02UV+:LMX2X6+DPN@BZW+NXO)"]:+Y$OQR_^
M,#4P;#"D,-LQ$C%*,8(QNC'R,BHR8S*;,M0S#3-&,W\SN#/Q-"LT932>--@U
M$S5--8<UPC7]-C<V<C:N-NDW)#=@-YPWUS@4.% XC#C(.04Y0CE_.;PY^3HV
M.G0ZLCKO.RT[:SNJ.^@\)SQE/*0\XSTB/6$]H3W@/B ^8#Z@/N _(3]A/Z(_
MXD C0&1 ID#G02E!:D&L0>Y",$)R0K5"]T,Z0WU#P$0#1$=$BD3.11)%546:
M1=Y&(D9G1JM&\$<U1WM'P$@%2$M(D4C721U)8TFI2?!*-TI]2L1+#$M32YI+
MXDPJ3'),NDT"34I-DTW<3B5.;DZW3P!/24^33]U0)U!Q4+M1!E%049M1YE(Q
M4GQ2QU,34U]3JE/V5$)4CU3;52A5=57"5@]67%:I5O=71%>25^!8+UA]6,M9
M&EEI6;A:!UI66J9:]5M%6Y5;Y5PU7(9<UETG77A=R5X:7FQ>O5\/7V%?LV %
M8%=@JF#\84]AHF'U8DEBG&+P8T-CEV/K9$!DE&3I93UEDF7G9CUFDF;H9SUG
MDV?I:#]HEFCL:4-IFFGQ:DAJGVKW:T]KIVO_;%=LKVT(;6!MN6X2;FMNQ&\>
M;WAOT7 K<(9PX'$Z<95Q\')+<J9S 7-=<[AT%'1P=,QU*'6%=>%V/G:;=OAW
M5G>S>!%X;GC,>2IYB7GG>D9ZI7L$>V-[PGPA?(%\X7U!?:%^ 7YB?L)_(W^$
M?^6 1X"H@0J!:X'-@C""DH+T@U>#NH0=A("$XX5'A:N&#H9RAM>'.X>?B 2(
M:8C.B3.)F8G^BF2*RHLPBY:+_(QCC,J-,8V8C?^.9H[.CS:/GI &D&Z0UI$_
MD:B2$9)ZDN.339.VE""4BI3TE5^5R98TEI^7"I=UE^"83)BXF229D)G\FFB:
MU9M"FZ^<')R)G/>=9)W2GD">KI\=GXN?^J!IH-BA1Z&VHB:BEJ,&HW:CYJ16
MI,>E.*6IIAJFBZ;]IVZGX*A2J,2I-ZFIJARJCZL"JW6KZ:Q<K-"M1*VXKBVN
MH:\6KXNP +!UL.JQ8+'6LDNRPK,XLZZT);2<M1.UBK8!MGFV\+=HM^"X6;C1
MN4JYPKH[NK6[+KNGO"&\F[T5O8^^"KZ$OO^_>K_UP'# [,%GP>/"7\+;PUC#
MU,11Q,[%2\7(QD;&P\=!Q[_(/<B\R3K)N<HXRK?+-LNVS#7,M<TUS;7.-LZV
MSS?/N- YT+K1/-&^TC_2P=-$T\;42=3+U4[5T=95UMC77-?@V&38Z-ELV?':
M=MK[VX#<!=R*W1#=EMX<WJ+?*=^OX#;@O>%$X<SB4^+;XV/CZ^1SY/SEA.8-
MYI;G'^>IZ#+HO.E&Z=#J6^KEZW#K^^R&[1'MG.XH[K3O0._,\%CPY?%R\?_R
MC/,9\Z?T-/3"]5#UWO9M]OOWBO@9^*CY./G'^E?ZY_MW_ ?\F/TI_;K^2_[<
M_VW__V1E<V,         +DE%0R V,3DV-BTR+3$@1&5F875L="!21T(@0V]L
M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
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MK]'_ %TI0T5[:QD^UFG;7^OO/ZI:*_&C]AG]M_\ :0\3_MV_M=_\$Z/VMO\
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MG>^)?&-WX?L)Y,FWTRY\5:_-;( DFIW39D/44R HHHH **** "BBB@ HHHH
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MTF2/(4QZBTART*X_.3]FG]O_ .(7["'_  ;)_!KX^Z'J%IJ/Q;OM?^(7P9^
MUQXOC;6;&#6=9_:$^*>F:?<&VN&E748/ '@KP[XQUCP_I%^)=+8^$=-T*YMV
MT.,VH5VFTW>RO?;RM_7_  S<5*,915FY<C6K3TNG=[:;_?Z_V T5_#AX)_X)
MQ?\ !7;XT?L46G_!3*3_ (*F?'71/CYXH^%=]^T3X/\ @JWC/XB:'HE[\-[G
M36\<:9I5OXWT'XD6?A;PW>>.?!5AH^O:-X*M/AA:> [6XGTCPQXAN]/T^:]U
M;0OE#]H+_@O#^WG\<_\ @F'\)H=#\>ZE\/OB39?';QK\'/VI/CQ\-+:Q\*>-
MO$6AR>$-#\9?!%](E\-6>A6/PXNOB)87'Q2L_$*>#O[#U#4[[X)K<Z/K&CZ'
MXD\1>' ^9+=-:76VJT\]]=NP>R;^&2?O<KW5G\]UZ;O8_P!#ZBO\^?\ 9:E\
M;ZS\9/A%K7_!-S_@O@_B#XF^(?$G]H>/_@Q^WU<?&OX+:?KOB#5FTX_8(_#W
MB"?XO?#7XXZUXTG@N],O] TF^/B73+B'1Y='\57^H7D6IZ'[)^U3^V;\=_\
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MM=2BL-7\+:'J4%W;6_Z3U_*G\/)/VJ)_^"_/_!5?PS^R_'\)-.\:Z_\ "?\
M9%A\7?%3XQ6FNZMX)^'?ANP^!'P6EO=3TSX;>%]:TCQ+X]\6Z]J$EO8>'/#I
M\5>&?#NFVBZOK'B#Q8LNFZ3H/B?]"_\ @GI_P4F\=_%;PC^W]X8_;&M? VA_
M$S_@FW\4/'OA#XR?$#X3Z)XAL_A_XS^'W@VT\9W=O\0-$\-:KJGB'7['59[7
MX<^,+O4M#AN)1);IH\UG9V5U?SZ/8)/H[WN]>]G_ )?+YCE'JMK1;2N[<R7?
MNWWZH_:&BOYD_B'_ ,%2?VU!^RQH7[>/PO\ &'[*NLIK*^!?'&C_ /!.C3/
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M/X[^)<'AF;7/ USX>^&EMX4\-KJVB:=XAU'Q':W]WKNB?)7[0G_!;CXVZ_\
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M^U9XM&\*:Y>Z/J]]HIK]V:*=M]=VG]UM/G;\0YOAT7NW_&[^5KZ=M.Q_+/\
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M?"+4?BU<K9W%KI6M6?COXJW'Q"D-WI_B_P +W2_MQ^W7X'_;D\>?";PSIW[
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M/^"9?P+_ &I_@=_P6 _X+(_'W6OV;?C5H/A7Q)IG[:OB+X->+/&?PA^(NB^
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MHW)GL_M'YQ?M6?"OX??M2? WPM^V)\*OV?\ ]J#]CC_@MWHVM^'#I'A7X,?
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MXH_"SQE!H5OX8T?P_K>@6/C"S\5:+J?C'1Y-4T6UCBN4K"_X(O?![PA\%/\
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MT'[MD[/=IJ^Z5M;]'KVMVV9XA^PU_P %#/ G_!0/X&^)_P!H3X(_!?XX:5X
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M8:OX<^!'CG]H+PM\5#::GHQDU*RT;Q%HWAWX@322Z?I,/@676;JYL;#\BO\
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MT7X5>$O%4&^*>,GPGXB\;:9XFD22)HGBTITE*QLS+^%_PR\7_L9?LR_M+_\
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M^/'[>_[0^G?M5_$ ?MC_ +(UIJNH?#[]E;X,>.OV/_V0_BOI&@ZMX$?]I/\
M;7_X* WMK^S9:^&/@[J'B#1M*D\9^ _V<O!EYJ/C<ZS8&/3U\<+<Q:!#>Z,L
M^KWWV?\ M3?LO_#OPMX(_P""6'_!'/X4:%8Q^#/%7Q3\*_$_XU26&@V=OI6M
M_ 3]CS2--^('Q9U_QY;Z48C:>)OCI\5M1\#V<6OW]K<VVL>+=:UJ2[EDNU5@
M7?2S\[=VDNO>_?;TNN6.EU)7W5U>-KN5_=UTLUHMVGLS^@\D $D@  DDG  '
M)))X  Y)/2OYZOV,/^"YW[+OQ!\2_%&3]HW]JKP%X9;XN?M3^-O"7[)O@N'P
MQJQT/PC\ M(U2#X>?"Z\^*7C[PSX,N_#OP\\7_%+Q'X8\;>.9K7XS>-])NH?
M#E[HVKZ8FG^$;G3;FZ^OO^"UG[4-W^RG_P $Y?C]XI\-7EW!\3OBCH]O^S[\
M'K32I;^'Q#?_ !"^,GG^%4F\+2:8CWB^)O"_A&7Q;X[T98-DLMWX46&!C<20
MH_Y::E#^R;^V%^R]^R!_P2-_X)X'P7\5_A3X@D_9^^(O[9'Q.\$^&&MO"GPK
M^!?PTO/"WQ \4ZS\0?%%C8VEGIO[3?QW\:>&=/T.S\+7@U+QFM_+XS'CRQ\-
MVGD7Y;>J5TM.O5O1;._?ND$8JUVG9NUUIRI6N]4UU7;LF?OW^T5^VQ^S#^RG
M>^%M#^-WQ2L] \9>.9X(/!7PU\,^'/&'Q.^+7BX7,]Q9P7OAWX3?"[P]XR^(
MVJ:,VH6SZ5)XAMO##Z!;:M):Z7=:G!?WEI;S>7:+_P %1/V"-?\ V9Y?VOM/
M_:1\'#X P^*+WP))XKO=-\6Z=KQ\?Z=&ES>?#ZW^&M]X=M_B??>/4T^2/6H/
M!FG^#KKQ)?>')(_$UAIMUX=EBU1_Y\OB=_P5(C\?^)OVO/VG/!?[2?P7_8D\
M>_#&^^+GP=\)? [X>?LN:)\;_P#@HA\>/#/[.NF>*=1TN7XQZ_\ $?0-7L_A
M#X*N=;@O_$<=A>_"S5?"/PQTU-97QQXT(\*:KJEQX#\-O^%(^#?A9^QCX,^+
MO[:/C#_@GS_P4&\._#OXC_\ !5'3?VN?'/@CX6^(?@;\7/$7[<[7-MXJL)_!
MGB'Q';VOC?XAQ_#K3=,\"G2UT'1(+!_#?BFP\/Z9XBGO'TN%<VNEGM;[TN_G
MUL-4U;6]_*_:[^R]-M4Y6O>SV/ZS_P!F?]NG]E+]K[0/B'XB^ /Q>TOQ9;_"
M/4H])^*NDZ[H7BWX;^+?AM>36E[?6[^-_!7Q-\/^#_%WAS3;N#2]9_L_7=3T
M6#0M3FT#Q#;Z=J5W/H&L1V7DWPO_ ."K_P#P3T^-'QNLOV>/A=^T[X,\8_$_
M6-5UC0?#=OIFD>-$\$^,=>T"(7&JZ%X%^+%YX8M?A1XYUB"V>*YMM.\)>-=9
MNM4MIHIM)BOHRS+_ #U_M"_$OX[_ !#_ ."3O@CXD_M/V'A#X,1_MS?MU?!7
MX(?M3?ME?#;X'1?"GQ]\4OV$-'NM6T3P)^T5\:_#L=II'B73$\36WAO3]-T&
MUUB&TT.7X2:YHVD:9I,6C>.(-'UKT[Q_X<3]H+PQ-)^SY^U]\6OVV?#O_!,_
MP5XA_:M^"K_!']E_]FGP'^S#X6_:'^"7PY\2W'P!^$FF^.OA]I'A.]\?ZG=Z
M@+>[/P^^$>C^/M!@T33UTOQ%)HFI7^C6\IS.ZM;I?OK;I?HG>^J#D6KUMJEK
M>S5E=OEL[M[/E>W5V/W ^.W_  5E_P"">?[-7Q4O_@I\9OVE_"WA3XEZ,^FQ
M>(]!M_#OCSQ/8>#[K68&N-)L?'7B[PGX4USP7X"U#4(=DMO8^-/$6@W7DSV]
MQ+%';SQS-O?\$T/BQ\<_V@?V0?A[^T1^T!<-!XK_ &@=5\:_&/P=X2&E^'].
MMOAW\%O&_BS5M1^!_@JRN= TW36UZWM?A6/"NMR>(==%]XBU*\UVZ.I:C<B&
M 1_SJZE^T;^Q_P#%S_@E1^Q[_P $LOV7_B-IGQ$_:4_;HMOV9O"7Q93PUI=S
MX^UGX=>,?B3XZ\.?$_\ :D^+OQQUF\6_L-*\9:7JV@?$?4I-$U;6[WQQ8LMC
MKF@Z8WA+0(=<L/Z?OVC+_P 0?L^?L7?''4?V?/"@_P"$G^"G[,OQ&N?@IX+T
M+31?1P:U\._A?J[_  [\/Z5HRAVOH+2\TC2+*TTF".>XO(84LK6"XN)8H9&F
MWK=6MT[OH]=UZ+<4HI)))IN5KR[+2ZTTNWMJ]-^_AO[0?_!67_@GI^RU\5U^
M"'QP_:6\+>$OB9 VDCQ!X>T_P_XZ\:0^!%UUK9-(?XE:[X&\+>)/#OPV-^;_
M $N:*'QQJN@W*:=JVF:U/!%H=TFICUS]H;]O']D/]E*#X:7G[07QU\(?#?3_
M (Q:/XWU_P"&>K:A%KFK:+XOT;X=^%K/QCXIO],UKPWI.LZ4L,6AZGH_]B?:
M[RV?Q=K.N^'O"_A%-<\3^(-&T>^_GE^&O[07[*GCG_@DY\*?^">G[$5[X8^.
M_P"V1^VI^S]X2\&_$[PUH&B:QXSU?P;\0?C;8Z?IO[3/[17[5'B^ST[6V\&S
M_#'6O$/C/Q0;_P 9:O=^)$U:R\(67A*UNO#B6&K:?]T?L??!CP)XF_;Q\>:[
M>RQ^*O@E_P $B?V8/@A^P'\!/%_BYM'U71O^%NP> =)\:_M"?%*UNKA6C\+_
M !&\(>!X_AK\,?%6HVCV[P6=UKEHTR0O*&+M]M;6WTOK9][+7=>FJ!Q2WNK7
MNFTFTM$TK.VKMUZZZ,_3[]E/]M[]EO\ ;<\/^,/$G[,?Q8L/B39?#_Q#%X6\
M;Z?+X=\9>!_%7A36;FU-Y81Z]X)^(GASPEXRTRRU6".Z_L;5[K0H](UB?3=9
ML]-OKJ]T/6+>QZK]I#]JO]G;]D/P$?B9^TE\7/"/PE\'R7::=IUYXCNYY=5\
M0ZJ^TC1_"/A;2+;4O%?C+6EB8W4FC>%-$UG5(K&*XU"6T2RM;FXB_/O_ ((\
M>'KCQ]\/?VDOV\];TV]T[6O^"A'[27CKXT^$+;6=/ET[Q'I/[.W@^\G^&G[.
MOA_7H99)EDND\&:!>^++6XMIWL9]/\9VLEHL<1P?S$_:9^*_@]/^"Q?[5/CK
M]HO]N*R_8;UG]DWX)? WPM^R!+XO^%'PY^)<?C/X=_%7P?<^+OC3XN^$^@?$
MC0_%EGJ?Q"F\?LOA"ZU/X>Z#-\1]3\/K)X-AN+W3M+UK1M.+Z)Z:_=KKKKV\
M]P44Y-*]DM5N[W2:TCW>_+LMC]RO#G_!3[]A3Q7^SA\2OVLM%^/NDS_ OX.:
MO9^'OBKXDN?!_P 1].\2^ -?U+6M)\.Z7HGB;X8:AX.M?BGI^J:OK6NZ38:+
M9-X+:;6I+V.725O;8/,GF>E?\%I/^"7FM:W\3- L?VP?AY]L^$OAK5O%WBR\
MO=(\>:7X?U#0-&URV\-7-W\._%6J>$K/PS\7Y[S7+RTT[0-.^$NK>-M3\53W
M,1\,6>L1DNOXIZ-^R[8?'W]H?X#?#7Q3K?QT^(VJ_P#!1GXV>'?VY?VS(?V@
M/AU\+?A7K>L?LJ?L&>%[CPK\$]&\8_ _X;7UWI/A[P!^T-\0_'WA.".S\0VV
MA>+V72X4\4^%M#UJQO8)OLWX;7?P=\:_\%)/^"AO_!07Q]X?T/\ X4;_ ,$J
MO@7H'[)OP1U?2-'M3H?AO5/AQX%\6?%S]IZ[T'2EAB@TOQO\-'\1W?POTX:3
M%"G_  C/B*?28 $DA55=^7S7E?OII;OKY:ARQU^)Z-Z-=TDMM6Y<RVVM*W0_
M6SX&_MW?LC?M&_!/Q7^T9\*?CEX0U'X+> =8U_0?'_COQ8-6^&&G_#_5_#$5
MI<:[9^/++XGZ9X.U?P8]A:7]A?M)XET_2X)M.O[+4+:6:SNH)WX']FS_ (*=
M_L*_M=_$+4_A5^SY\?\ 1?'7CW3=%O?$L.@7/A7X@^"W\1^'=-O7T[4]=\#W
M_C[PEX7TOQ_I.F7L4T.HWO@F^U^&Q6)[FZ:*S*7#_P L?BGP?JUM^S?_ ,$O
M]/\ VK?BO:?LW_"[_@I9^UC^TW_P47_:W^,VN>'O#7BGX66?QCUS0-&^(_[*
MO@[QMI?C19_!3> O$OAZ;PS<W_@;XA6>H>#+O4M/>YU;3+JT\.7UUI'L_P"U
M1XON?B'X4UK]K3X??M4_'3]KOXD?"S3?$G[#?["OQ)G^"7P9^ 7P7^(O[0G[
M<NFQ_ _Q7HWP7U_P#9>&/&?Q-UKX6^ [S7/&5GX@'A(_#1-:T."+PWXSU6YL
MM4T^0YG:^G3SOLW;;9._7S\Z]G'N]6[/HK/E5W:SNT^L;)7/Z(_@;_P52_8%
M_:5^(>B_"OX%?M"Z3\2O&^M^#?&7Q!&FZ!X*^)PT_0/!O@'6M1T#Q/K_ (Z\
M2:AX)LO#/PYL;74--W:<?'VL>&Y?$&FZQX2UOP]'JFB^./!E_KWG6D_\%K/^
M"8.O^)M2\'Z#^U;X=USQ%8ZMHN@Z?IVC> OB[JI\;:UXA\=:/\-]*TKX5W-A
M\/KBT^,%]/XNU[3;*:#X63^,&LM->]\27OV?PUI&L:O8?!__  4M^%O@7]AK
M_@F=^Q%^R;86MSHG[*:_M*?LL? ']K[QUX<T"^1[3]G2?6-0\=_'KQGX@E\/
M1R:GX>M?BEXU\*6^I>/M:MP\.HR^)]5T:X@U&Z\16>EWW@?[67[<7[-O[3'[
M5/P@^)/PCTQ?&/[*W_!)/]G_ ..?[<WB7QA>>#M8\&_##XI?%.QT^U^&/[,7
MPV^$6MZQHFB?:X;7XI:)/=^&/$>BJ_@CQCJ&B7>G^&;O5E\,2W4;N^\;Z7W\
MO/9+6_Y6)Y$]4I<NMGII;:[M:\MDM+=WK;]@K/\ ;5\">#?$?[<?[37Q3_:D
M\&M^Q?\ LT>,/"?[/-UX;T/X4>/(]4^$GQP\'7NEZ/\ &:+QGKP\$W?BCXE^
M(M5\:_$#P+X3\.V?PQ_X2+PAI\*_V9Y,OBF+6I8N^^!W_!4']@O]I+XW7_[.
MOP2_:-\*^._BY:6/B/4K'P_9Z'XVTK2/%MEX2NY;/Q'<?#GQQX@\,:3X"^)Z
M:4;:\O)O^%=>)O%!ETC3=7URU$^CZ-JU]9?COH/[-NI:E\-O^"1W_!,'XEVE
MYXJ\1_%;Q+XK_P""C7_!0FTUQ-+U&^UBQ\&7=Q\7?$7@[XO:)/&]OXD\+_$3
M]IOXL>%?AQ-/>QSK>6GP]%LX9+;RQX__ ,%</%WQ)\<?%/\ ;_\ CE\#=(UQ
MM+_X)M_L;>!/V4_"VH>&] GU&ZT7XN_MJ^-?![_M >-/AY)H\ZK'+\)_V3]:
MM_#VMO9'3-3\%ZUX@36[FZLM.T5[FW7,[7]+Z.^NKMKT3_#H-1C)VOOLU:UD
MU"+:MK>5[[.SOZ_M)XY_X+-?\$Q_AO\ $'QM\,/&7[6O@C2O%GP[B\8'Q=Y/
MAWXB:OX8L-2\!Z-=:[XG\+V7CW1?!NH^!/$'CJRLK*YMK7P!X<\2:MXVUC7%
MB\,:+H&H>)+JTTF?](_#VO:;XIT#0_$^CM>/I'B/1],U[2GU'2]4T/4'TW5[
M*#4+%K[1-<LM.UO1[QK6XB-UI>L:?8:II\Y>TU"RM;N&:"/^7?XT_%K]C;]N
M_4/^";G_  2E_8CC?XD?L\Z3\6/ /Q.^+7C/2O GB:#X1Z9^S]^RIX)'BO7?
MAK)XKUCP[I%OKOC7QS=ZUX.\/^*=7\/7-U+X7\2Z_:Z+XWO+7Q%XHETL?J[_
M ,%I/B3\3?A-_P $O_VOO&?PC374\81_#S3/#DVJ>&K-[[6O#?@KQQXU\+^"
MOB=XLL8X)H+NUG\+?#7Q!XLUV+5[26*;09;%-=:ZT^WTZ?4K-I[O1I=O2[]?
M73KH2XJ\4DTY/[79NR>RM=WTUTMJ>>_M.?\ !</_ ()\? '3/CMX9TW]H'PG
MXQ^-_P )/"'Q)ETKP%I^B>/;GPQXE^*7@CPOJ6KV/PKC^*MEX3F^%P\5ZGK-
MK:Z%-HD/C.35K6]GDLWM!?Q&VKH?#/\ P46^$7[)OP+^!O@S]OK]H-=5_:\F
M^"&A?$7X\>$?!/PQ\1?$#QUX0UB?PC;^._&]WXQ^'?[.W@'Q&OPX\(>$+&\U
M"VTWQ#XGT+PQI6L>&_"]]KL=YJ$MGK-W'^8/[4'Q[_8)_:?O/V!?^";_ .QU
M=Z3\;/@I\!/B!X<_:@^,-G\(O!E[\2O!_A[]GC]C_P"$7B#Q['\-(-8CLS'X
MF^(OQ<U'4?"_@2[L?#-WJ_BF'6=>O=#\=3:1K?BF&QU7X7^*W_!4GQIXC_95
M^.'[77P4_:U^ G[/'QF_: MY_$9_8K_9#_9K\(_$_P"+OVS6O%GAWX0^%_$_
M[7_[2GCWPYXB.D^(-'T6_L;&]UR[\#?#&RU.6]T;2/ &IGQ!XET*V57W=UIV
MU72_57M=:W770M034=)*[ZO7M':+:3LWL^EWU/Z!?VY?^"OGP-_9Y_8C\&_M
M2? +Q)X=^-WB+]H@6.B_LDZ3'X;^)FJ^%/BAXKG\6:%X;UVUUN7PKX9EU?PY
M/X'M-2UC5=<\(>(I/"GBW5-5\,:IX$TN"/Q@'T^W]L\>?\%1OV*?@7X:\ I\
M6/CW)J'C#Q)\*M'^*%WX=\)_!WXQ>(OB-9^#)?!=CXTNOB!\0/@SX+\#^*?B
M%\$-!O?#<UQXK6U^*VB>%7T_2;;54>25M!U4VOXR^)_#GPM_9=_:G_X([_\
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M&UB"^FTV.Y:'19+E-:D_L\?VL44FK_<U]]O\BHRY>E_>C+?K&]NGF[G\JO\
MP6#TGXF?M#?\$I_V)_AI\(_V>/VJO%_Q.TKXC?LS^+/$_P .=._96_:$E\8>
M#-)\"_"OQGX?\8_\)?IL7PXDBT*[T#7;RVTN:UNKKS-2DGAO-"_M72IH;^3^
MI'P]KMCXGT33/$&FP:S;6&KVD5[:V_B'PYXA\(ZW%#*"434_#/BO2]%\2:)=
MC'[VPUG2K"_A/$UM&2!6S10E9M][?@@<KI*UDFW]]ORL?RZ_'T>+/&W_  <,
M?LO?M#K^SC^U1K/[-7PW_90\0_ GQ]\4)?V/OVD]6\ /XM\4:-^TA<1:5(T?
MPFNFU30;AOBKX7T34]8CL;KPY:W-W?IJ=_!96&HSVWFOQI^#G[1W_!%/]M+2
M/BK_ ,$V_@?\>?VC_P!D?]IZXO/$GQ^_8I^&WP:^,GCGPY\,=5M+FW@/BOX=
M>,O"G@KQ#X2\$:G>0R7*^&M U/4(M;TJULV\.ZOH>J>"I?"MSX3_ *U**5O/
M6]T^JV5ON7^=Q\^RM=<O*TWHUJUZ--W36JZ=;_SM_P#!83XWW_[8_P#P2=^-
M_P -/@?^SA^VUJ_Q<^+!^!D.D?"77?V(/VK_  ]XWT:^T7XS?#KXC^(M/UP7
MOPA/AE6\.Z'X.UR'4M7TOQ)J?A>;4(;:TTC7]3DU31QJ,'Q>_8$U3]NC_@F3
M^QGKGPMTSXB? G]OC]BKX,_!+5_@%XK\??#WQM\&?&_A7XQ?#3X>^"?^$D^%
MNOV'Q/\ #/AB^E\-:]XB\.6]G9^)(8+CP]I/C#2-#\2V.KZIX>M?$&DZ_P#T
M5T4<NMWKI9].M[Z;:@I6225K2YM[[JS6RTLOS/R&^!'_  4W\<^(/V0O^%G?
M'/\ 8P_;2\%_M2^#_ >J2^,_V>]$_8Q_:MO1XT^(FAQ7-C86GPU\76OP@U;P
M=)H/Q$U2VM;W2&O?$]TW@JQU9HO%-Z]GI$NN7V/_ ,$[_P!C']F_Q_\ LJ>
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MQ"VDZ?-;VEVL-X7@F\J;]@?Q^WP]_P""9O[,U]XQ^&WQV\/Z_P# ;]D_X/\
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MCX6_#:RTGP%K/CO48]/LO'_C72+W5?#\4UIJ@BL,'_@J?'XNT_XF_P#!&?\
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M65M)%:PB37XM^;;^_3_+Y$FFMM59+_"E;7S>_P!_D?B1_P %G?V$/VA_B/\
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M/X3^+?C9\7[_ ,0Z5\//!&G3ZKXEU3PUX&\;?$&_TW3[:":YN;^XT+P#X?\
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MS:'\1O"_A'Q");&SU[2I)+E=*:Q=[IH(;J2XMKJ*#\+_ -DO_E9Y_P""I/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH ^#/^"GOQ\^-O[+W[!G[2?QZ_9V\)P>,/B[\./ \&
ML>&K&ZTYM8M-#L;CQ%HNE>+/'EWI"LJZG;_#?P=?Z_X_ELIUFL)U\-[=5MY]
M*^VQM_*9^U7\?/V0/%-__P $=?VF?!W[0'Q8_:6U[P'^W/\ L\^+_P!J_P#:
MK^*VF?$W6(O!4UWXC\->/-6^'MP]QHD/PR^%#:;!X7\6Z]8?L_?!G3[+^S=
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M>1=0M6BNU=V83!F)/4TTK.]_7I=][7M^ .5TE9Z/1MW:5MEHM/6]OS****9
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MPL?7_P#GEIO_ (#S_P#R57 T4?ZR9[_T-,7_ .#/^ ']C97_ - .'_\  /\
M@^7Y]V=]_P +'U__ )Y:;_X#S_\ R51_PL?7_P#GEIO_ (#S_P#R57 T4?ZR
M9[_T-,7_ .#/^ ']C97_ - .'_\  /\ @^7Y]V=]_P +'U__ )Y:;_X#S_\
MR51_PL?7_P#GEIO_ (#S_P#R57 T4?ZR9[_T-,7_ .#/^ ']C97_ - .'_\
M /\ @^7Y]V=]_P +'U__ )Y:;_X#S_\ R51_PL?7_P#GEIO_ (#S_P#R57 T
M4?ZR9[_T-,7_ .#/^ ']C97_ - .'_\  /\ @^7Y]V=]_P +'U__ )Y:;_X#
MS_\ R51_PL?7_P#GEIO_ (#S_P#R57 T4?ZR9[_T-,7_ .#/^ ']C97_ - .
M'_\  /\ @^7Y]V=]_P +'U__ )Y:;_X#S_\ R51_PL?7_P#GEIO_ (#S_P#R
M57 T4?ZR9[_T-,7_ .#/^ ']C97_ - .'_\  /\ @^7Y]V=]_P +'U__ )Y:
M;_X#S_\ R51_PL?7_P#GEIO_ (#S_P#R57 T4?ZR9[_T-,7_ .#/^ ']C97_
M - .'_\  /\ @^7Y]V=]_P +'U__ )Y:;_X#S_\ R51_PL?7_P#GEIO_ (#S
M_P#R57 T4?ZR9[_T-,7_ .#/^ ']C97_ - .'_\  /\ @^7Y]V=]_P +'U__
M )Y:;_X#S_\ R51_PL?7_P#GEIO_ (#S_P#R57 T4?ZR9[_T-,7_ .#/^ ']
MC97_ - .'_\  /\ @^7Y]V=]_P +'U__ )Y:;_X#S_\ R51_PL?7_P#GEIO_
M (#S_P#R57 T4?ZR9[_T-,7_ .#/^ ']C97_ - .'_\  /\ @^7Y]V=]_P +
M'U__ )Y:;_X#S_\ R51_PL?7_P#GEIO_ (#S_P#R57 T4?ZR9[_T-,7_ .#/
M^ ']C97_ - .'_\  /\ @^7Y]V=]_P +'U__ )Y:;_X#S_\ R51_PL?7_P#G
MEIO_ (#S_P#R57 T4?ZR9[_T-,7_ .#/^ ']C97_ - .'_\  /\ @^7Y]V=]
M_P +'U__ )Y:;_X#S_\ R51_PL?7_P#GEIO_ (#S_P#R57 T4?ZR9[_T-,7_
M .#/^ ']C97_ - .'_\  /\ @^7Y]V=]_P +'U__ )Y:;_X#S_\ R51_PL?7
M_P#GEIO_ (#S_P#R57 T4?ZR9[_T-,7_ .#/^ ']C97_ - .'_\  /\ @^7Y
M]V=]_P +'U__ )Y:;_X#S_\ R51_PL?7_P#GEIO_ (#S_P#R57 T4?ZR9[_T
M-,7_ .#/^ ']C97_ - .'_\  /\ @^7Y]V=]_P +'U__ )Y:;_X#S_\ R51_
MPL?7_P#GEIO_ (#S_P#R57 T4?ZR9[_T-,7_ .#/^ ']C97_ - .'_\  /\
M@^7Y]V=]_P +'U__ )Y:;_X#S_\ R51_PL?7_P#GEIO_ (#S_P#R57 T4?ZR
M9[_T-,7_ .#/^ ']C97_ - .'_\  /\ @^7Y]V=]_P +'U__ )Y:;_X#S_\
MR51_PL?7_P#GEIO_ (#S_P#R57 T4?ZR9[_T-,7_ .#/^ ']C97_ - .'_\
M /\ @^7Y]V=]_P +'U__ )Y:;_X#S_\ R51_PL?7_P#GEIO_ (#S_P#R57 T
M4?ZR9[_T-,7_ .#/^ ']C97_ - .'_\  /\ @^7Y]V=]_P +'U__ )Y:;_X#
MS_\ R51_PL?7_P#GEIO_ (#S_P#R57 T4?ZR9[_T-,7_ .#/^ ']C97_ - .
M'_\  /\ @^7Y]V=]_P +'U__ )Y:;_X#S_\ R51_PL?7_P#GEIO_ (#S_P#R
M57 T4?ZR9[_T-,7_ .#/^ ']C97_ - .'_\  /\ @^7Y]V=]_P +'U__ )Y:
M;_X#S_\ R51_PL?7_P#GEIO_ (#S_P#R57 T4?ZR9[_T-,7_ .#/^ ']C97_
M - .'_\  /\ @^7Y]V=]_P +'U__ )Y:;_X#S_\ R51_PL?7_P#GEIO_ (#S
M_P#R57 T4?ZR9[_T-,7_ .#/^ ']C97_ - .'_\  /\ @^7Y]V=]_P +'U__
M )Y:;_X#S_\ R51_PL?7_P#GEIO_ (#S_P#R57 T4?ZR9[_T-,7_ .#/^ ']
MC97_ - .'_\  /\ @^7Y]V=]_P +'U__ )Y:;_X#S_\ R51_PL?7_P#GEIO_
M (#S_P#R57 T4?ZR9[_T-,7_ .#/^ ']C97_ - .'_\  /\ @^7Y]V=]_P +
M'U__ )Y:;_X#S_\ R51_PL?7_P#GEIO_ (#S_P#R57 T4?ZR9[_T-,7_ .#/
M^ ']C97_ - .'_\  /\ @^7Y]V=]_P +'U__ )Y:;_X#S_\ R56C8_$R[60#
M4M/MY8B5!>R:2"6-<_.VR>2=)FQRJ>9 ">"X'(\PHK2EQ1GU*<9K,J\G%WY:
MO)5@^ZE"<))I[;)K=-.S43R3*IQ<7@J44UO#FA)>:E&2::MWL^J:;O\ 3^F:
MM8:Q;BZT^X6:/.UUP4EB?^Y-$P#QMP<9&UQ\T;,A#'1KYATK5+O1[V&^LW*O
M&WSQDGRYXCP\,J]&1UR.1E&VR(5D1&'TG8WD.H6=M>VYS#=0I,F<;E#C)1\$
M@/&V4< G#JP[5^H\-<1QSRC4IU:<:..P\8NM"#?LZL):*M24FY17-[LZ;<N1
MN'OR4U;XC.LG>65(2IS=3#5G)4Y27OPDM73J-)1;Y7>,DH\R4O=7+=VZ***^
MH/#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **S+O6M(L&
M*7FI6<$@QF)[B/S@"< ^2&,N,]]F.IZ UE?\)IX8_P"@K'_X#WG_ ,CUQ5<R
MRZA)PKX_!49IV<*N*H4Y)[6<9U$T[Z;'33P>,JQYJ6%Q-2/\U.A5G'7;6,&O
MQ.HHKE_^$T\,?]!6/_P'O/\ Y'H_X33PQ_T%8_\ P'O/_D>LO[8RC_H:Y;_X
M787_ .6^:^\O^SLP_P"@'&?^$U?_ .0.HHKE_P#A-/#'_05C_P# >\_^1Z/^
M$T\,?]!6/_P'O/\ Y'H_MC*/^AKEO_A=A?\ Y;YK[P_L[,/^@'&?^$U?_P"0
M.HHKE_\ A-/#'_05C_\  >\_^1Z/^$T\,?\ 05C_ / >\_\ D>C^V,H_Z&N6
M_P#A=A?_ );YK[P_L[,/^@'&?^$U?_Y ZBBN7_X33PQ_T%8__ >\_P#D>C_A
M-/#'_05C_P# >\_^1Z/[8RC_ *&N6_\ A=A?_EOFOO#^SLP_Z <9_P"$U?\
M^0.HHKE_^$T\,?\ 05C_ / >\_\ D>C_ (33PQ_T%8__  'O/_D>C^V,H_Z&
MN6_^%V%_^6^:^\/[.S#_ * <9_X35_\ Y ZBBN7_ .$T\,?]!6/_ ,![S_Y'
MH_X33PQ_T%8__ >\_P#D>C^V,H_Z&N6_^%V%_P#EOFOO#^SLP_Z <9_X35__
M ) ZBBN7_P"$T\,?]!6/_P ![S_Y'H_X33PQ_P!!6/\ \![S_P"1Z/[8RC_H
M:Y;_ .%V%_\ EOFOO#^SLP_Z <9_X35__D#J**Y?_A-/#'_05C_\![S_ .1Z
M/^$T\,?]!6/_ ,![S_Y'H_MC*/\ H:Y;_P"%V%_^6^:^\/[.S#_H!QG_ (35
M_P#Y ZBBL"#Q3X=N2!'J]F">@FD-MGH,?Z2L7)SP._;.#6ZCI(JNC*Z,,JR,
M&5@>A5@2"#Z@XKKH8K"XI.6&Q-#$15KNA6IU4K[7=.4DK]#"K0K47:M1JT6]
ME5ISIM_*:3'4445N9!1110 55OIS:V5Y<CK;VMQ.. >887D'!(!Y7H2 >F15
MJLW6?^0/JO\ V#;[_P!)9:QQ,I0P]><7:4*-647VE&$FG\FC6A%2K48R5U*K
M3BUW3FDU\TSYB)))))))R2>22>I)[DTE%%?S:?L84444 !( ))  &23P !U)
M/8"OAKXD?\%*_P!A?X3ZU-X=\8_M&^"SK%K))!>6GA&S\4?$A;&Y@FFM[BRU
M"Z^'&@>*[/3[^UGMY8;NPO+B"\M9%"7$$1= WXF?\%DO^"A'C34_B!XE_9%^
M$/B&Z\/>!_"]H-'^,FLZ-=11WGCC7M4L[6[O?!7VZW4W5IX:\/6<ZZ7XALK>
MZMVUS6+C6=%UFWDTW2TCOOYYZ\K$YC[.<J=&,9.+M*4KN-UNDDXMV=TW?=:)
MK5_J_#7AO',<#1S#.,57PT,53C6P^%PGLXUE1G'FIU:U6M3JPBZD6IQI1I2<
M8.+G-3E*G#^X3_A\#_P3J_Z.'_\ ,2_'/_YV5'_#X'_@G5_T</\ ^8E^.?\
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M=%']J8C^2C_X#/\ ^6!_Q"OA[_H,SG_PHP/_ ,[C^X3_ (? _P#!.K_HX?\
M\Q+\<_\ YV5'_#X'_@G5_P!'#_\ F)?CG_\ .RK^'NBC^U,1_)1_\!G_ /+
M_P"(5\/?]!F<_P#A1@?_ )W']PG_  ^!_P""=7_1P_\ YB7XY_\ SLJ/^'P/
M_!.K_HX?_P Q+\<__G95_#W11_:F(_DH_P#@,_\ Y8'_ !"OA[_H,SG_ ,*,
M#_\ .X_N$_X? _\ !.K_ *.'_P#,2_'/_P"=E1_P^!_X)U?]'#_^8E^.?_SL
MJ_A[HH_M3$?R4?\ P&?_ ,L#_B%?#W_09G/_ (48'_YW']PG_#X'_@G5_P!'
M#_\ F)?CG_\ .RH_X? _\$ZO^CA__,2_'/\ ^=E7\/=%']J8C^2C_P" S_\
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M ,Q+\<__ )V5?P]T4?VIB/Y*/_@,_P#Y8'_$*^'O^@S.?_"C _\ SN/[A/\
MA\#_ ,$ZO^CA_P#S$OQS_P#G94?\/@?^"=7_ $</_P"8E^.?_P [*OX>Z*/[
M4Q'\E'_P&?\ \L#_ (A7P]_T&9S_ .%&!_\ G<?W"?\ #X'_ ()U?]'#_P#F
M)?CG_P#.RH_X? _\$ZO^CA__ #$OQS_^=E7\/=%']J8C^2C_ . S_P#E@?\
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M/?\ 09G/_A1@?_G<?W"?\/@?^"=7_1P__F)?CG_\[*C_ (? _P#!.K_HX?\
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M_P !G_\ + _XA7P]_P!!F<_^%&!_^=Q_<)_P^!_X)U?]'#_^8E^.?_SLJ/\
MA\#_ ,$ZO^CA_P#S$OQS_P#G95_#W11_:F(_DH_^ S_^6!_Q"OA[_H,SG_PH
MP/\ \[C^X3_A\#_P3J_Z.'_\Q+\<_P#YV5'_  ^!_P""=7_1P_\ YB7XY_\
MSLJ_A[HH_M3$?R4?_ 9__+ _XA7P]_T&9S_X48'_ .=Q_<)_P^!_X)U?]'#_
M /F)?CG_ /.RH_X? _\ !.K_ *.'_P#,2_'/_P"=E7\/=%']J8C^2C_X#/\
M^6!_Q"OA[_H,SG_PHP/_ ,[C^X3_ (? _P#!.K_HX?\ \Q+\<_\ YV5'_#X'
M_@G5_P!'#_\ F)?CG_\ .RK^'NBC^U,1_)1_\!G_ /+ _P"(5\/?]!F<_P#A
M1@?_ )W']PG_  ^!_P""=7_1P_\ YB7XY_\ SLJ/^'P/_!.K_HX?_P Q+\<_
M_G95_#W11_:F(_DH_P#@,_\ Y8'_ !"OA[_H,SG_ ,*,#_\ .X_N$_X? _\
M!.K_ *.'_P#,2_'/_P"=E1_P^!_X)U?]'#_^8E^.?_SLJ_A[HH_M3$?R4?\
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MI8:CA\SP=:K7CA^;V\J-.G6E.I&DH3E-P348PG)^[&37Q_17ZC:I_P $8_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:.)JQBO1))+R1^MY8DLNP%M/]BPK^;HP;^]NX4445Y9VA1110 5^&'_!0O\
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MW_)T?[2?_9??C%_ZL3Q'7@5?(S^.7^*7YL_KW ?[C@O^P3#?^F8']$'[*_\
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M9^$?%$,%KI,8U.:"^\8^)'M$\.:A<ZO<?SQ3_M,?M'7?Q(T?XQWOQ]^,]_\
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M45\6?J 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,3V]C<:QI<-S)%)J%HLWP?\ LX^%_B9\!?CKK'[-C?$S7/C'\"[+X)Z+\0?
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MC5*]'KSCXQ_\DB^*G_9./''_ *C&J5KA_P#>*'_7ZE_Z7$Y\;_N>+_[!J_\
MZ:F?;7_!'W_E&7^QK_V1[3O_ $[ZO7Z2U^;7_!'W_E&7^QK_ -D>T[_T[ZO7
MZ2U^IXW_ 'S%_P#837_].S/X%I_PZ?\ @C_Z2@KZ>T;_ ) ^E?\ 8-L?_26*
MOF&OI[1O^0/I7_8-L?\ TEBK[OP\_P![S+_L'H?^G)GR?%W\#!?]?:O_ *1
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MUJ6N2Z;=V'ACPMX9T/Q!XM\37\,\6BZ'>0V6HW%E]8?\%EO^4EW[4?\ V'O
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M^#_P@_X)U?LF_M":=^RM^SWXN^*EY^T!\2_!VJ:AX^\.^*/%.@>*;'PAH6G
M:CXWT>]\7"^\47VI%G)T.;7;3X=:5)?:I>:5X"MM4_L#4/#OT[^U%^R?\'?@
MA\5/^"D_[4'@SX6_#JY\-?LZ^'/V6D^$?P1U?0]/UWX:>'?''[2^A> +/Q)X
MMU_P3/=K::AH7@\:QKNI^#?#VJZ5-X/OO%&NVJ/I,^F^$9=.;N7#E65'VT,7
M0FH4<+BL1&,*R=#"XK+,7FOM;SA%5)4L/@<1&5.#O*I[*,6^=\GDRXUPU/%?
M5JN78NDZN)Q^!P<YU<*XXK'X'/<LX?\ J]J=6I*C&MC<WP<H5IIQC1]O.<5[
M**J?D3\9/V4X/A-^S+^S-^T?:?%+0_'=G^T??_$ZRM_#V@^&_$.EV_@R3X9W
M?A[3-2L;[6O$L6D7NLZL-6UB_P!,U&*S\-VNBVEQH[SZ+KWB;3;^VU ?(-?K
MY^V-XHN?&7_!,G_@FEXBOM+\.Z3J.H>.?VSWU&#PIX<T+P?H,UV/B=H >ZL/
M"WA?3](\-:"DL?EA]/T#2M-TM)$:6WLH/-9*\ _X)\_!+P3\6O%W[17B_P =
MZ!#XRTW]FO\ 9%^./[26B^!;V=UT7QEXQ^'NGZ19>$]*\4VMK>Z?JE]X3L=6
M\0P^(M;L=/NX1J:Z);:+?FXL-5N-/OLL9EM.IFF%P6!4:<<3@,IKIR=1QC/$
MY3A<9B:LE*5:HESSJU'3C*IR_P .E=**.G+,\K4<@Q^:9K.=:>"S?B#!M4XT
M5.5/!<0X_+,#0@Z=/#492]G2P]!5IPI*;_>UG%N;7P%7Z"?LB_L$ZO\ M&?M
M$Z[^SE\1_B/IW[/_ (Y\/>&+_P 2S>'/$7A?6?$OC'63IOAJ7Q;>:+I.D:?+
MI^@66IZ?HB176N6OB;Q9H6JZ4MSLMM%UB\T[6K#3?L;]DZ7P)^T%\!/'/Q^\
M3?#'X*>%/CM^QM\=OV7_ .P/%/A3X0?#GPOX1^*W@O\ :$^*#?#JZ\%_$7X4
M:%X5L_ACK>K>%$MK_6O"WBRW\)0>((+VVTN74KMI+:^UBZ^PO!/CF^\2?\%_
M_&&@ZGHOA"TT_P %:E^TC86=SX:\%^$_"GB#6;6\^ GB.6X?Q9XET+1+36?%
M^HH+98[+5/%5SK-YIZ23I:ND=Q<1R^IEF081RRG%8JJ\5ALQS/+,/1H*,Z4:
MF%QE7&X:NZ\J=:-:C7HU\%7@HTY2A>DI*=6G63AX&>\7YC&GQ%@,#067XW)<
MBSW&XG%.I2Q$Z&/RS#95CL(L+3K8:IAL5A<3A,TPM24ZT*=5+$2@Z5"KAI1J
M?RYT5^NWQ,M/A9\=/^"9EC\=[#X!_!3X+?$7X;_MB>'OV?O#NL_";1=:\,IJ
M?PSU/X17'B?[)\1-1UOQ#XCU'QSKL.K_ &6XN/&_B6\O/$<J62M)??Z3J?V_
MZ%^*EE^QI^S#^TS\5/V&OBW\!?$OCWX:Z3X1\.?#+PK;_#K]GKX=:Q^TG<_$
MWQ)X7\)Z]X9^+GA?XY3_ !6T'XA>(/$'B[Q'K)UN+P-<PMX(CT[5K/P'IG@A
M='LVM;OS8Y!)I5'CL-#"SA@G3Q,U4A!U<?#%RH0J1G&,X1O@L1&<XQJ325.4
M:4U*:I^V^+X)RHQRK'5,?1JYHJ^ I2H5:L:&45<NIXRK1G3G.E5GRYK@YTJ<
MYT:<FZT)UZ;ITW6_ 2BOVZ^'WQ ^$'PB_P""8_PI_:'3]CG]E?XA?$FP_;"U
M?X,ZIJ'Q-\$^*?%\'BGPW8?!:?Q!<:OXA>^\;_VI<Z]?:CJ#SK86NJ6GP_TV
MYCBOM+\!VM_:Z;<Z?^=/[(,7P*UG]J3X8_\ #1]I]@^!UYXBUJZ\;P:9:ZY>
MZ;HMD/#^NW>BW-_:Z=-=Z]-X/T'Q"FC7OB=8[F>['A*QU5KBZ8++/7+6RN-&
MKEM%8W#RJ9A##5&Y1JTJ6%IXM4_93KU:D%'D7//VK@GR1IN3NI(]#"Y]/$4,
M[Q+RO&0H9-5QU%*$L/B,3CZV7^V=>EA<-0J3E[22ITU0C.2=6=:,%RN+/ENB
MOV9^-?[)/CC4OB?^Q5\&/B-X?^!USX/^.?[1-YX<\._M?_LM:!\+="^&WQ<^
M'/Q0USX-^"-'T?35^'WA?PWX;B\5_#$^'O&6K6NEZOIWVFZO?&4ZP0ZK+_:&
MK:OZG\&/!7P7^./_  4$^-?_  3E\9_ WX5>$/@S?>+_ (__  N^%/BKPSX'
M\.Z#\9/@QJ7P.T[QSJGASQJWQ=MK5_'/Q"O=6LO <C^+]+^)OBGQ;H&JW>H&
M33UTS3T>RO.N/#V(>(CAIU/8SK8O#9?AE7I3@ZN,Q>'A7I4ZBBYQI4O?A3^L
M1G5I3E4IU*3J8=SK0\Z?&>#A@I8Z%#ZS2P^78[.,<\)B:=6-#+,OQ<\+B*U%
MRC3E7KI4ZM?ZG.GAZ].%&M1Q"H8Q4\-5_-[XW_LEV/P?_9B_9;_:1T_XLZ+\
M0K3]I>X^*$,6@:%X:US2;7P3+\,=2T/1-3TZ]U;Q"VG:EJ^K#6]1U33K]$\,
MZ9ID+:5'>:-JGB'2M2L]2?P?XT^#_AWX"^(^N^%OA3\6+3XW^!-.MO#\NC_$
MRR\'Z_X#MM?GU+PYI.J:U;IX5\3.^M:;_8&NWNI^'&DO'/\ :)TDZG L4%Y%
M#'^C_P ?-1L_#_\ P3/_ ."6VJ7>BZ'XPL=(^)_[9-W/H.N-KJ>'?$5O9_%;
MP[(UAJ9T/5/#7B)=*U!$\NX_L[5M&U/[/(PBNK2;YD^O_C;^R-\$I_\ @HA^
MV9K7AWX7^"=*^#_[(/['5A^TQH/P-TZPM-+\+>,O$WAKX'>!]7\->'?$6C:3
M>Z3J5_X3NO$^J/XF^(U_:327.MQV4VEZM=FX\5">3KKY)'$.V"IX>ES4^&^9
M2GBIU*4\PR*KF&*JP;J3IO#RE1KUJT91JUHNG2AAN2#G"IYN$XIG@US9I6QF
M(Y*O&_LY0I8"G1Q%/)N+,-DV P]6,:-*M'&0IXK"8;#SA+#X6:K8BKC?:U%3
MJ4/R,;]E. ?L2S?MD6WQ2T/5$@^.ND? V[^&.F>&_$*ZGH>J:CX4USQ;-?Z_
MXGUB+1]+^TQZ=INEW%II_AFS\4:9<V>NPO<^(]/U2POM%C^5M"T+6?%&N:-X
M:\.Z9>ZWX@\1:KIVA:%HVF6\EWJ6KZSJUY#8:9IFGVD*M-=7M_>W$%K:6\2M
M)//+'$BEF /[ >)OB'?_ !+_ ."./C_Q%JWAWP)X=U)_^"CWAF*2W^'?@3PG
M\-_#YM/^&?;AK*WC\*^"-(T+P[#)8QE[<:A'IPU/4(O+DU>\O[R-KN7P?_@D
MGKUQH?\ P4+_ &:(H-.\/:BNO>.[?0;G_A(/#FB>(FL+>ZMYKPZCH1UNQOCH
M'B&VEL(1I_B/2/L>MZ:DEREA?6XN9M_'6R["5,?DF$HRE2I9AA\O56LHSE)U
M,3B)T95O95*TU&32BW3C45--/ELGKZ6%SK,:.4<59CBH0Q&(R;&YPZ&&E4IP
MIQHX'!T<33PJKT</3<Z<6YJ-:=%UI1:]I>6WY[Z]HFJ>&=<UGPWK=K]BUKP_
MJNHZ)J]EYUO<_9-4TJ\FL+^U^T6DMQ:7'V>[MY8O.M9YK>79YD,LD;*[95?N
M3X/U70?CCX0_X*T2_$/X5_ R]U+X2^ ]>\2_#KQ!H?P-^%/A'Q1X6\01_%BZ
MT"?6++Q/X5\):/KT^H:AIK1I?7&H:A>/+<Q&]C,-Y=ZC/>^C? _P=\%]<^'/
M_!&7Q%XV_9X^!OC35?CE\;OC-\'OB3<WO@.S\-_\)1HVB_%;P+X'\*:[XB@\
M"3>%+/Q?XC\,Z"9;>WF\;6OB72]8FOM4U+Q'I6KZW?R:LFM/A[V\X^PQD53J
MTG7IRK49Q:IK.:62M5%3E4M-5JT*JY5)2I*5^25HO&KQD\)2D\5EDYUJ.)6$
MK0PN)ISBZSX8K\3J=%UXT$Z<L-AZF':J2C*%=PM[2#<U_/A17]"MK%^S=X[L
MO^"I_@_5_P!CCX Z7I7[(GB;Q-\2?A5J/A*Q\5^&O%>H:GX8^-&I>&;GPWXU
M\4VGB235;OP!XF@M;.#5_!/@R3P)H>CZ)+JVD>!;?P=<W&BZQX>\Q^*_PF^&
M/[5OPW_X)*^.+;X6?"GX ^+_ -JKXT?$CX$_%BX^ W@[3?A]X;U+1]$^,_@;
MP!X?\2V?AE[B[TN+Q1INA:KJ5Q)/,;J76]9O760&U&FZ59JIPY45.4Z.-P^(
MJ*BJU.E&G7INI&.;4\FJKFJTX0BX8JK3E#F?OTG*3Y)14).CQK1E6IPQ.58S
M!T98EX:KB*E;"58T9SX=J\34)>SH5JE2I&>7T*T*G+%.EB%"G'VL)NI#\.**
M_>SX,>"O@O\ ''_@H)\:_P#@G+XS^!OPJ\(?!F^\7_'_ .%WPI\5>&? _AW0
M?C)\&-2^!VG>.=4\.>-6^+MM:OXY^(5[JUEX#D?Q?I?Q-\4^+= U6[U R:>N
MF:>CV5YR'@/Q[\'O@[_P3,^%W[04/['W[*?Q)^(^F?MBZU\%=2U?XC^"/%WB
MZS\7^&M-^#%QK\^N:ZVJ>,XM9N-:U+4+]KJ+3XK_ $_P)IDR0WVG^ ++4;33
MI].F'#_-&I5ECZ$,/1^OPK594<0Y1K9;4PD,53C2C"4Y1Y<=AZM&HW'VD)N,
MH4ZD9TXW4XPY9T</#*,75QF)_LBIAJ$,1A%3GAL]I9A4R^M/$3J1A3FZF5XS
M#XFC&-3V-6ES0J5J$Z=:?XA45^ZVE_!3PAXR_9LT/XF_LK> ?@-\8M"T']EC
MQJG[3G[/VH>$_"<_[4OPW^-/B[X=>,=$/QW\+ZAXS\/:K\3K_P"%_@[Q!XL\
M(^,O!-OX3\4-H2:/X9LYK#3+W7Y+[Q#8?A37G9AEM3+UAW.:J1Q-/VE.I"+]
MC.'+3ES4:R;A5BI3=.:3C4I5:=2%6E3:CS>UD^=4LX>-C3I2HRP5?V%:E5G%
M8FE4YZL?9XG#-1J8>;A3C6IMJI0KT*U*KAZ]:+ER%%%%><>T%%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5_9S_ ,$0_P#D
MQ+0/^RE_$;_TXV=?QC5_9S_P1#_Y,2T#_LI?Q&_].-G7HY9_O,O^O4O_ $J!
M^=^)W_)-0_[&6%_]-8D_7>BBBO?/Y["O:OAI_P @>^_["3_^DMM7BM>U?#3_
M ) ]]_V$G_\ 26VKZ[@C_D?T?^P?$_\ IL\#B7_D55?^OM#_ -.(]&HHHK]J
M/S8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HKB]?\;:=HS/:P+]OOTRK0QL%A@;N)Y\, XYS%&KN"
M"LAB)!KSNY^(/B*=B89+6S7D!8+9),#G!+71N"6'&2 JDC.T#BOFLQXMR;+:
MLJ%2M/$5H-J=/"055PDG9QE.4Z=)23NI0]HY1::DD]#VL'D&8XR$:L*<*-*:
M3A/$2<%)/52C&,9U'%IIJ7)RR6L6SWBBOGO_ (3CQ3_T%/\ R2T[_P"1*/\
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MXE;_ !1_])"BBBO$-@K^9VW_ .4M'_!6+_NQ/_UFIJ_IBK^9NY=-(_X*[_\
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MQ=_ P7_7VK_Z1 TJ***_5#X8*S=9_P"0/JO_ &#;[_TEEK2K-UG_ ) ^J_\
M8-OO_266N?%_[IBO^P>M_P"FY&V'_P!XH?\ 7ZE_Z7$^8:***_F\_8@HHHH
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M)IUU=6E[<6>A7GC*TLKR_P!+TWQG::/?W>G2]1\)OBC\)_#?['?[1?PW\?\
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M=KHV@(=(L;+5M!U>*YM99I=9_M6]E:[/O7CC_@I_\2/B3\-M&T+QU\$_V?\
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MQ=:GB,53Q=1U7/'4L37HTJM>EC)5Z56=*G*<).$;?7GC#]K_ %KQS\ _@/\
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MU?7<$?\ (_H_]@^)_P#39X'$O_(JJ_\ 7VA_Z<1Z-1117[4?FP4444 %%%%
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M:9;_ .%</\@_U&XQ_P"B;S;_ ,)__MOZL_*_YI_\'!__ "E4_85_[)[\&?\
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M?PL=2N[S4=$U>PM]2O?"M]JFL:CIVD76IW=E>Z7\/_\ #:?_  68_P"B5_\
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M7/V5_P#P_P!J'_RNK^DBBH^IY5_T)\!]^-\O^HSR_%]S#_B(W''_ $4>,_\
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MRO\ ^'^U#_Y75_2111]3RK_H3X#[\;Y?]1GE^+[A_P 1&XX_Z*/&?^$^7_\
MS'_5WY6_FW_X5/\ \%D?^C7/V5__  _VH?\ RNKHO"W_  36_;)_:V\1>&[#
M]OO6?A1\)_V:?#FNVVO>)/V>?@-XF\5:_P"+OCA>Z0T%UI6A_$SXAS#3K+1/
MA['JD<.H2Z7X5FDU?4TAG@G32-:@\-^+- _HFHK2C2P6&J1K87+L%AZ\-:=>
M$:\ZE.5K<]/V]>M"-2.\*BASTY>_"49)-<>/XWXMS/"5L#CL^QM?"8B/)7H*
M.&HQK4W;FIU)8?#T:DJ<TK5*?/R5(MPJ1E!N)7M+2TL+6VL+"VM[*QLK>&TL
M[.TACMK6TM+:-8;>VMK>%4A@MX(42*&&)$CBC141550!8HHIGRP5]/:-_P @
M?2O^P;8_^DL5?,-?3VB\Z/I)_P"H;8?^DL5?HGAY_O>9?]@]#_TY,^0XN_@8
M/_K[5_\ 2(_Y&E1117ZH?#!6;K/_ "!]5_[!M]_Z2RUI5FZS_P @?5?^P;??
M^DLM<^+_ -TQ7_8/6_\ 3<C;#_[Q0_Z_4O\ TN)\PT445_-Y^Q!1110!^77_
M  4;_P"";/AG]MS1],\7^&-9L?!'QX\(:0=%\.^)M5%Y+X:\2^'XKF^U&W\)
M>+HK*.ZN[*SM]3U"]O-+\0:78WM_I4E]?I/IFL6]Q#!:_P PGQ _X)D_MU?#
MG5)]-U3]G+QYXA2.X:&WU/X?VMI\0M+OHM\XAO()_!]UK$]M;W"6[3+'JEMI
M][;I+!'?VEG<3QP-_>!17%7P-&O+G?-";W<+6EYM--7MU5O.Y]MD/'F<Y%AH
MX*$</C<'3;]E2Q2J<]!-MN%&K3G%JFVV^2I&HH[0Y%=/_/\ O^&$?VTO^C5?
MC[_X:SQC_P#*FC_AA']M+_HU7X^_^&L\8_\ RIK_ $ :*Y_[*I?\_:GW1_R]
M?Z6OT'_$5\S_ .A7@/\ P9B/_DO7^EK_ )_W_#"/[:7_ $:K\??_  UGC'_Y
M4T?\,(_MI?\ 1JOQ]_\ #6>,?_E37^@#11_95+_G[4^Z/^7K_2U/^(KYG_T*
M\!_X,Q'_ ,EZ_P!+7_/^_P"&$?VTO^C5?C[_ .&L\8__ "IH_P"&$?VTO^C5
M?C[_ .&L\8__ "IK_0!HH_LJE_S]J?='_+U_I:G_ !%?,_\ H5X#_P &8C_Y
M+U_I:_Y_W_#"/[:7_1JOQ]_\-9XQ_P#E31_PPC^VE_T:K\??_#6>,?\ Y4U_
MH T4?V52_P"?M3[H_P"7K_2U/^(KYG_T*\!_X,Q'_P EZ_TM?\_[_AA']M+_
M *-5^/O_ (:SQC_\J:/^&$?VTO\ HU7X^_\ AK/&/_RIK_0!HH_LJE_S]J?=
M'_+U_I:G_$5\S_Z%> _\&8C_ .2]?Z6O^?\ ?\,(_MI?]&J_'W_PUGC'_P"5
M-'_#"/[:7_1JOQ]_\-9XQ_\ E37^@#11_95+_G[4^Z/^7K_2U/\ B*^9_P#0
MKP'_ (,Q'_R7K_2U_P _[_AA']M+_HU7X^_^&L\8_P#RIH_X81_;2_Z-5^/O
M_AK/&/\ \J:_T :*/[*I?\_:GW1_R]?Z6I_Q%?,_^A7@/_!F(_\ DO7^EK_G
M_?\ #"/[:7_1JOQ]_P##6>,?_E31_P ,(_MI?]&J_'W_ ,-9XQ_^5-?Z -%'
M]E4O^?M3[H_Y>O\ 2U/^(KYG_P!"O ?^#,1_\EZ_TM?\_P"_X81_;2_Z-5^/
MO_AK/&/_ ,J:/^&$?VTO^C5?C[_X:SQC_P#*FO\ 0!HH_LJE_P _:GW1_P O
M7^EJ?\17S/\ Z%> _P#!F(_^2]?Z6O\ G_?\,(_MI?\ 1JOQ]_\ #6>,?_E3
M1_PPC^VE_P!&J_'W_P -9XQ_^5-?Z -%']E4O^?M3[H_Y>O]+4_XBOF?_0KP
M'_@S$?\ R7K_ $M?\_[_ (81_;2_Z-5^/O\ X:SQC_\ *FC_ (81_;2_Z-5^
M/O\ X:SQC_\ *FO] &BC^RJ7_/VI]T?\O7^EJ?\ $5\S_P"A7@/_  9B/_DO
M7^EK_G_?\,(_MI?]&J_'W_PUGC'_ .5-'_#"/[:7_1JOQ]_\-9XQ_P#E37^@
M#11_95+_ )^U/NC_ )>O]+4_XBOF?_0KP'_@S$?_ "7K_2U_S_O^&$?VTO\
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M&/\ \J:_T :*/[*I?\_:GW1_R]?Z6I_Q%?,_^A7@/_!F(_\ DO7^EK_G_?\
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M$?\ R7K_ $M?\_[_ (81_;2_Z-5^/O\ X:SQC_\ *FC_ (81_;2_Z-5^/O\
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M3_GY/_P*7^8?V=E__0!@O_"6A_\ *_)?<?2W_#:'[8G_ $=A^TM_X?;XH_\
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M_P"&T/VQ/^CL/VEO_#[?%'_YJ:^::*/:5/\ GY/_ ,"E_F']G9?_ - &"_\
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MH *^G-#_ .0+H_\ V"]/_P#22&OF.OIS0_\ D"Z/_P!@O3__ $DAK]#\//\
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M8:UK.G7-_H-_HU]<>)?\$]/ W_!.CQ?<>.IOVZOC)\2/A7KNF:YX$_X5%:>
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M/@'_ ,$E?B+^Q_\ \%#?V"--^._C3X8>--(^(_Q%^(?BG0(? FH^)Y?L6N_
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M107?A73[.*^ECCU#4O%^E6T+J5E-?J5_P24U2']L3]AS]M[_ ()R^)[V"_\
M$USX;O?BY\&8M6U:Y65=8U"6PEAE#$@66@>#_B_X?^'OB'4BDVV^N?'FJK=)
MY=Q,9LK]MZ67]B;_ ()#?LE_L:PPMHWQ._:7O/\ A<_QIL7M(K+58=)MKO3O
M'UWH'B>PD(O;+6=,\1ZU\-/"=M=R*BW5O\,=8L<2>5,(]7DF4SPT>((X>5/)
MO[!Q&(GAE7K-1SRE667QP?M93==0GBJU'$P3GS.C=.\;<_/'BGB"ECZG!U3&
MPJ\2_P"MN$P=+&O"86,I\*UL+_;$\S>'A2CA76A@,/BL%4<:2@L2X\JC4O[+
MYW^$_P#P1GU+X@?LZ_";]I+QI^U[^S_\$O!_Q=TFVU#0H/BG<S^&EAO;HZBT
M>B?VQJNI:;I=]JAMM+O+P6UG*\K6T$\RQF."5E^;OVO_ -@7PA^RQ\--#^(.
M@?MD?LW_ +0UYK'CG3/!LO@OX/>*],UWQ-I=MJ&@>)M;?Q1?6EEK>I2QZ%92
M^'H=)N;EH$C34-;TR(RJTR))^Z?C'4OV--,_X(Y_L"S?MLZ!\7/$7PZ>ZT*+
MPO:?!V:P@U^'QJ= ^(SV]QJ3:AK>A0G1QH2:W%(J7,LGVV2S(@*AI(_R$\2Z
MK_P2UUKXZ_LAVO[+G@KX^:/8']I'X9K\:T^-K:-J&B:E\-9?&'AR/4++3;6S
M\1>(Q-<20F^%Y#<6:PS6C&-O-#&(Z9KD^387"X:E0HY93Q.)R[+*OM*V;8Y8
M^-?&TL/*I5C@>26'E!2J2FHNJDZ:<DERI&/#W$O$V88_'8C%8C/*V!P6<Y[A
M_8X7A[*WE,\+EE?%1I8>>:^TCC(590HQI.<:$I>V<8MR4N8]$^!?_!$;XI>+
MOA3I/QB_:=^.GPN_8T\+>+VT>/P#IWQ4DL9_$^O2:Y:_;M,76M/U#Q/X0TOP
MK<:I:R1OI6A76N7WC&26*_AU?POHC6L)O/EC]NS_ ()G_'O]@R3POKGCJZ\-
M^/OA;XXG6Q\*_%;P')J%QX;FUIK2?4$\-Z[!J%G:W.@^(+K3;6ZU;2K=FO=-
MUS2;:[NM&U:^FTK7+32?T2_X+::+<^.?^"H_PD\#?';Q?)\.O@9K/@SX1:-H
MOC9"]U9^%OAOKGB75[?QYXP:SF#V2ZKIOB8^*3>@1F2?3=(T/[5OA2V"W_VZ
M_P!DO0O O_!-_P *_%;X1_M\?&;]I+]GWPQXT\->#_A]X!U6]CC^%42Q^(?$
M6C7-Q9Z=;W$0DO/"^HG5].TU[FSE;3X<Z;920:?;6L$1C\CRM4L^P>"RNLJV
M0QJ)YC/-:7UJO+#<DJ]>OEE9PB\).$OW<\)3YH-TTY5'.R>4<59Z\1PEF6:9
M]A987BZ=)PR6GP_B'@,)#&J<<)A,)GN&5:7]I4JD$ZU/,:O)42KM0HQI1;\S
MO/\ @AK<^&O"/P^\6?$K]N7]F+X31_$GPMIOBKPYIWQ(U*3PA=WMI>Z9IFI7
M4-B=?UC35U-]*75[&#4); 2Q02W$'F%!<0AOS+_;"_9AT+]E7Q_X<\$>'_C_
M /"/]HBUU_P?;^*IO%GP=URSU[0-&N)]:UK2#X>U*YLM1U*.'6(H](CU)X&F
M1Q9:E9R&(*ZN_P#3M_P4BTC_ ()Z:I\)_P!A8_MR>*?CQX<OX?@I,/ANOP8M
M]+GAN[23PW\,#XI;Q#_:/AS7BLL$R: -,\EK4%);[>)L(8_Y4/VF;/\ 9UL/
MC+XGM?V4]5\?ZW\#H[;P^?"FH_$Z.TB\9SW3^'],?Q(NIQV6FZ1;B*'Q(VJP
MZ?LL(2;!+8N96)E?GXLRS*LJ53#X+"X&%2,L(HU(YMB*^81]KA:>(G*ME\Y2
MA3IR;E%3N[1E2DDN='9X>Y[Q#Q Z.,S/'YK5I2AF4ITI\/8/"9-4^KX^I@Z,
M<+G%*,:E:M&,8SE245><,1"5U29X)7UM\(_V,/BU\:/V>/CK^TUX2U#P5;_#
MS]GK[)_PG5GK>L:I9^*+K[;;174/_".Z;:Z#?V%_B.9 _P!MU;3-KA@-P 8_
M-G@[5-)T/Q=X5UO7M*CU[0]'\1Z'JFM:'*D,D6LZ3I^IVMWJ.E21W*O;R1ZC
M9PS6;I.C0LLQ6560L#_:+^S/^V9^Q%X]_8?_ &P?BW\/?V)O#?P^^#OPQ_LW
M_A:OP?M-!\ 6VG_%/[186TUM]NLM,TR'0[O[/#)' /[8MI]HC 3Y<"O,X8R;
M 9O7Q,,=CZ>&]CA<55IT&J_M*CI86M55=3ITJD%2PTJ<:E:$FIU(7C34I.Q[
MO'?$N;\.87 5<JRBOCWB<PR^A6Q,)87V-&-;,,)AWA)4Z]:E4>(Q\*TZ&%JP
M4J=&LU.M*,%<_B7HKZR_;3^,WP1^/'QQO_B!^S[\$]-_9_\ AS<^'/#VEVOP
M[TJPT#3;2VU;3+>6+5=5%MX:MK32Q)JDKI*[I")G* S,Q K]?_V>[#X._L#_
M /!*WX=_MXC]GSX9_M!?'W]H#XNZQX$T;4_BOIH\3>&_AMI%AJOQ)TO25M=*
M#7%O#:VTGPFOK_4)='D\.>)M1UCQ='I.J>(UL=%T[3H.+!9/#&XW'4(9A0C@
MLNP]?&8C,52KSIO"T*E.E[6C0Y(UJDJE2M2C"G)4Y6DY2<5%GIYIQ)5RS+,I
MQ53*,5+,\ZQF#R[!Y-+$86E6CF&+HUL1]7Q.+=26&I0H4L/7E5K0=6/-!0IQ
MFYQ/R)_8A_9$\2?MN_'?3_@3X5\7Z)X'U?4/#7B/Q*FO>(+&_P!0TZ.#PY;1
M7,]LUMIQ%R9;E90L3@[$()?BOFGQIX:G\&>,?%G@^ZN8KVY\)^)==\-7%Y;H
M\<%W/H6J76ES7,,<G[Q(IY+5I8T?YU1U5OF!K^IS]@/]H7]F;]H__@H[^SWX
MS^!_[+O_  S-XYA_9V^)L'Q<L?#^D^&_"WPZ\7ZM=Z#X?U"UU'PEX:\.6MM!
M+'8ZI<^(8XO%EY!8ZMXDT.ZT0ZM9+/81"'H_V2_'O[,W[=OQ"_;@_8N\7?L@
M?!3PA\/_  %I?Q-\5_#?QQX4\.O;_%AXM)^($V@:IXH\6>.]6N]:UNY^(FHZ
MMJOA_P 16NMZ5=:?:VPM[_P_J%GK.BF&&OHJ/"N Q>#P5+#9IAGC<5F.887#
M8KV>,=''*C@L'BJ%'V<H+ZK[-U*L*M2<&U5E",55C:2^+Q/B!F^6YEF=?'9#
MC8Y9@,ER7'XW >WRU8K*OK>9YC@<5B'6A5FL=[6-'#U</0I5%&5"$ZDI8>HW
M3E_(W17]G?PT_9@\-?LA?LC_ ++$7P9_9P_8Z^*WQ,^,W@W0?&_[0GC3]JCQ
MMX-T^^U.UUWPYX3UGQ%X:\$7GB9)?[1TJ5]<FT70X=&N8O"6@6>A6>KZWX<\
M1:UXIO=1N.-^#'[''[(7A'_@LAXG\)?#CPE\)/B/\$/B%^Q_KOQ<M? -S:>%
MOB9X#\"^.I?B7X=\*ZUINAV.JS>);73Q_P 2=_$=A;N+==#A\87FAZ#;V'A^
MULK&&7P)C8O PGC*,*N)KX&A7IRHUXK#2Q])U:,J=2:C#&*DDH8GV+7L:DXQ
M]]7E'1>+65RCFM6&68J>'P.%S3%82K#$X6<L;'*,1##XF-:C3E4J9;*NY.K@
M7B4UB:%.I/\ =R482_CVHK^O3]G'5_V.OVN/A]_P4'\!?$G]B?X!Z!\&_P!A
M+6T\0_#B3X<>'=1\&?$'Q-X)\,GXG7D*>*_'5C>R>,9?%.MZ7\%[*#Q7KEAJ
M]I)XFMM<N++5[*YEM!=W?F.@_"GX$?\ !3;_ ()U^%OBO<_L^? []FKXK>'O
MVO/@[\#/^$A^ 7P_T#X?V/\ 8'CSXQ?"7X:7=O&/],O=0TV#PO\ &=-2@TC6
M+Z^B;Q=H,%SIMK#'=&TGP7!TZM*-3"9KA<5.M@L;C,+25#$TI8B.65Y8?'0<
MJD%"ER5(M4)3D_K"4GRTTDY=3\2Z=#$3I9AP_F&!IX;,\JRW'XB6*P5>GA)9
M[A*>-RJHH4:DJM=U*-2/URG3@OJ<I02G7<I*'\K-?47P0_8\^./Q_P#AM\:O
MC%X#T'3E^%_P \'Z_P"+_B1XRUK6;+3K'3UT/P[J/B6+P_IE@K7&N:SX@UFR
MTR:+3X=/TN;3;6>2W?7-3T>UGBN6_HT^)'QS_9#_ &6OVXO ?_!-3PS_ ,$[
M_@1XK^&NIZS\&/@[XT^(7B?0M%U7XD^*M1^+^F^!/[$\6+JU]X,U/4M=E\+6
MWC&X.J1:IJ6I:OXGUI)1I.N^#Y+8_:/N/PEH_@?]BOX$?\%-_A;\,OA'\);[
MX=_LXZ'JOC[P=X=\0Z9)XH/CO2?'_P )KOXL3>#/C7-=:I<:IXLTGPYJNK:C
MX*\/6FMW::R_PUM="BU"^OY;K^T[GOP/!6$GB<1'$YM3KT<!/&X3,(X6AB83
MP^887"5\3&BI5J25;#KZO7]I6I\KDZ+I4[.K"HO(S?Q0S"C@<'/!<.UL)B<V
MI97F.43Q^+P56EC,FQV8X3!3Q$H8;$.6%QDOKN%5'#U7.--8E5ZKDL/5H/\
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MA14\6ZTE-->VG*M/#PNZ=&4>5N7[M&#\3\1EF"GB.),LQ4J%3'<54,+C\-/
MN-2KD>+Q+IY<L-"=.2?U6$,/3QE1Q5;$PFIPY'[>7\1%%?U]?M)?!3X9?M%?
MLH?M4WGQZ^#_ .Q%^S]\0OA%X1UCQY^RCK?[./Q*\!:CXLN=/\):'K_B'_A
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MBYX2\'>"?#.F>"=(M_A5'8?$:QTKQMI>BVEOHDNH_$&_\7:=\(O$MJ;4S%=
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M $XV=?QC5_9S_P $0_\ DQ+0/^RE_$;_ -.-G7HY9_O,O^O4O_2H'YWXG?\
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M8GJ3?W1)[<DRYZ<4G]LZQ_T%=2_\#KK_ ..U\U_Q$/"?]"W$?^#Z?_R)[/\
MJC7_ .@RC_X*GY?WO7\.^GT]17S#_;.L?]!74O\ P.NO_CM']LZQ_P!!74O_
M  .NO_CM'_$0\)_T+<1_X/I__(#_ -4:_P#T&4?_  5/_P"2]?Z>GT]17S#_
M &SK'_05U+_P.NO_ ([1_;.L?]!74O\ P.NO_CM'_$0\)_T+<1_X/I__ " ?
MZHU_^@RC_P""I_\ R7K_ $]/IZBOF'^V=8_Z"NI?^!UU_P#':/[9UC_H*ZE_
MX'77_P =H_XB'A/^A;B/_!]/_P"0#_5&O_T&4?\ P5/_ .2]?Z>GT]7RU?\
M_']>_P#7W<_^CGJ?^V=8_P"@KJ7_ ('77_QVLYF9F+,2S,2S,Q)9F)R22>22
M>23R3R:^8XEXDHY]3PD*6%J8?ZM.M)NI4C/F]K&FDERI6MR.]^Y[>2Y/4RN6
M(E.M"K[:--)0C*/+R.;=[MWOS?AYZ)7\:?\ P6K_ .4ZG_!.#_L7_P!C_P#]
M;"^*M?V65_&G_P %J_\ E.I_P3@_[%_]C_\ ];"^*M>7D7^^U/\ L$Q7_IMG
MLUO@7^.'_I2/[+****\8U"BBB@#^93PQ_P I.?\ @JS_ -CO^RU_ZH>*OK.O
M"/V^_@_\3OV0?VP_%/[=?P^\ >/_ (K_ +.G[1?A'PUX?_:K\-_#O0QXH\3_
M  H\>?#+1[+P_P"!OC!:>'+.2/5+[P9>^$8&TSQ,-.MFAT6YM?$.OZW?3W>K
M^&]./SA!_P %4?V"9HED/Q_L;=B65X+SP%\5+.ZA=':.2.>VN? T<T3HZLI#
MH V R%D96;Y_B#*LRQF8?7,'@L5C,/7PN!BIX2A5Q'LZF'P=#"5:594H2=*H
MJE"4HQG;GIRA.-U+3^GO#'BSAW#\)8'+<;G&79=C<OJXZE6H9AC,-@Y35?'X
MC%TJM#ZQ5I^VI2I8F$7*%^2K&<)6:3?Z#45^?W_#TS]@G_HX32/_  B_B;_\
MQ5'_  ],_8)_Z.$TC_PB_B;_ /,57A_V'G?_ $)\U_\ #?B__E/FOO/T+_6W
MA3_HIN'O_#UEO_S3YK[S] :*_/[_ (>F?L$_]'":1_X1?Q-_^8JC_AZ9^P3_
M -'":1_X1?Q-_P#F*H_L/._^A/FO_AOQ?_RGS7WA_K;PI_T4W#W_ (>LM_\
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M +:_X1/P;Y7VK_A)/LWV#^R9/(^Q>=]MF^T>5!A?L _MA?\ ##/[1&F?'O\
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M_A"_"7_"/^1_PA_F_8O/UOS?[1V?:X_LF^Z^8OV5OCK_ ,,S?M#_  F^/?\
MPBW_  FW_"KO%EMXG_X13^V_^$;_ +<^SVUU;_8?[=_LC7_[,W_:=_VG^Q]0
MV[-OV=MVY?G^BG7S3'8G,(YI6K\^.C4P]6-?V5&-JF%C2A0E[*%.-%^SC1IJ
MSIVERWFI-R;G"9#E6!RB60X7"^RRF='&4)83V^)G>ECZE>KBX>WJ5IXE>UJ8
MFM+F592I\]J3@HP4?Z&=7_X+8_LVZE\4-7^.Q_X)9_"/4/CGJFHZ%KD?Q/\
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MS+-\REB99=2K/+*%".98[%T<+3HXRK3Q56=*G&I-8:E2BU%MQ^U/V$/VZ?\
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M.BL4CGUJR\0:+?WZZGKLVF6EYXTNK#QA#H?BB^>:YN/"EO#_ *')\\_MN_\
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MKQQ6.C@L*L6J.7_6\1"%6O+ PP\I2C9.,7*+_3K]F;_@H[_PSIX8_;T\.?\
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M$[XE_P!D?\+&^(WCSQ__ ,(_9_V?H/\ PFWB_P 0>*O[$L#LS8Z1_;NH7_\
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M48I+1'[#A:,,-AZ-"FDHTJ4(*W6R5Y/NY.\I/=R;;U84445RFX4444 %</\
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M7044KON_O8'/_P#")^%?^A9\/_\ @FT[_P"1J/\ A$_"O_0L^'__  3:=_\
M(U=!11=]W][ Y_\ X1/PK_T+/A__ ,$VG?\ R-1_PB?A7_H6?#__ ()M._\
MD:N@HHN^[^]@<_\ \(GX5_Z%GP__ .";3O\ Y&H_X1/PK_T+/A__ ,$VG?\
MR-70447?=_>P(X88K>**""*."""-(88846.*&*-0D<44:!4CCC10B(BA44!5
M   J2BBD 4444 %%%% !1110 4444 %%%% !1110 5].:'_R!='_ .P7I_\
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ML/'$86FZ^ KN>'IO%5JM>G2E*G36(E7J06)BG":JR^E/^"T_B/Q#K'_!1_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?^DD-?H?AY_OF8_]@U'_ -.L^1XN_P!WP?\ U^J?^D(U:***_53X4*S=9_Y
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5_:1_P
M1/TR]L/V"O!=U=0F*#6_'GQ*U/37W*WVBRB\2S:-), I)0+J.D7]OM<*Q,!<
M#8Z,W\E'[/'[/'Q/_:>^*/A[X4_"O0+O5M9UF]M%U35OLEY+H/@W0I;N"VU#
MQ;XMO[2WN!I/A[2$G$MU<NCSW4I@TW3+>^U:]L;"Y_OD^ WP<\,?L^_!SX=?
M!CP?O?0?AYX8L- M[R6)8+C5[Z,/<ZUX@O(4>2.&_P#$6MW.HZ[J$4+F".]U
M&X2 +"$5?5RNE+VDZMFH*#@GWDW%V7>R6O:Z/RGQ2S/#0R["93&<98NMBX8N
M=---TL/1IUH*4TG>+JU*L53O\485&OA/6Z***]L_#0KVKX:?\@>^_P"PD_\
MZ2VU>*U[5\-/^0/??]A)_P#TEMJ^NX(_Y']'_L'Q/_IL\#B7_D55?^OM#_TX
MCT:BBBOVH_-@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /E.;_6
MR_\ 71__ $(U'4DW^ME_ZZ/_ .A&HZ_FB6[]7^9^SQV7HOR/XEO^"W7PW\,_
M&3_@M_\ L7_"'QK%>3^#?BKH7[)OPW\6P:==OI^H3>&?'/[1'C?PQKT5C?QJ
M\EE>2:5JEVEK=HC/;3E)E5F0 _L#_P 0WW_!,S_H5_C%_P"':U7_ .5]?EW_
M ,%9O^5@_P#X)S_]C!^P[_ZU3XGK^RROH<;C,5AL'E,</7JT8RP=Y*G-Q4FI
MV3:6[MIZ:&,80E.JY13:FEJK_91^"_\ Q#??\$S/^A7^,7_AVM5_^5]'_$-]
M_P $S/\ H5_C%_X=K5?_ )7U^]%%>9_:N9?]!N)_\&R_S\OS[LOV5+^2/W'\
MGOPD_P"#8'X:_P#"]?B+XP^-_P 5-07X!V_Q%\1W/PB^#7PXU"^G\5:G\.X]
M::?PE!\3?B;K^EVDVG7LFD(+'Q#H?A+0KN^N$F%WIWQ!TF]1HTXW]@3X>>#?
MA)\=O^"D?PM^'>B1^&_ 7PZ_:^\4^"O!OA^&[U"_CT;PSX9N-9T?1-,6_P!6
MN[_5;[['I]I;P->ZG?7NH7;(;B]N[FYDEF?^O2OY/_V2_P#D[;_@JS_V?1\1
M_P#T]>(JY,]Q^+QN1YI]9K2J*G# J$=%&/\ MM!-\JM>3MK.5Y/O;0_1?":G
M"''65<JM?#YI=]7_ +!7_#R6A^A%%%%?E9_7X5\Y?M<^&?&/CG]FKXU> O /
MA/4?&?B_Q[\.O%O@O0M&T[4O#.D'^T/$>A7^FVMY>ZAXLU[P[I5OIUK//&UV
MZWTMV$8&WL[C#[/HVBML/6EAZ]'$1C&<J%6G6C&?,X2E3FIQ4U"4).+:5U&4
M7;9K<YL9AH8W"8K!U)U*=/%8>MAISI."JPA7IRISE3=2%2"FHR?*YTYQ3LW%
M['YG?%GX:?&_]HSX$?#/]EVX^#_BKX5^$-5/PJT[XY^.O&_BOX4RK:^!? <^
MC:SKVA> K;X<_$7X@:S?>+->U7P[I]GIUWJFDZ?H,&GS3?;KH_:95M.ZCT3X
MM>%_VUOB!\6+/X">.M>^&FJ? #PG\,=&USP_XF^"EN]UX@\'^+O%7B5OL^A:
M_P#%7P_JEMI&IV6LVUCI=S=VMG+'?*L>H65A9&2]@^]Z*]#^UZJISH+#814)
MPQ,712Q/+SXNIAZE:MS?6?:NK+ZIAX*]1TXTZ22IW<I/QO\ 5O#^VI8IX[,'
MBJ53 2CB6\"ZCI9;1QE'"85P^H>P6'@\PQM:2C2C6E6Q$Y.MRJ$(_'GB[4O$
M7Q-\%MX;^.'[&_B/Q]H'BV_\5WUGX",_P*\4CPC8Z%=3:9X.M?&=[KWQ<M]$
M7QUXIM8;CQ+8ZWX*N+S0_!JZ[8:!<^(QJ&CW_B"]]!_94^%.N_!#]GGX5?"W
MQ-JESJVO>$_#?V?4Y+G4Y-:&F7&HZC?:T?#-EJ\L5O+J>C^#TU)/"FAWTEO;
M/=:-HMA,UM;ES"GT%17-5QLZF&>$C3IT:#KQQ#ITY5Y152$:L(.*K5JJA:G5
ME"3C:=51A*M*I.*D=U#*J5'&QS&I6K8G&0P<\$J]:&%C4="K/#5:JJ2PV&P[
MJ.=;"PJQ4[TZ$IU8X>G1I3<$4445Q'J!7SG^V%_R:1^U+_V;G\;O_59^)Z^C
M*^<_VPO^32/VI?\ LW/XW?\ JL_$]=> _P!^P7_87AO_ $] \[./^13FG_8N
MQO\ ZC53]@?^">'_ "8!^PU_V9Y^S-_ZI7P37V'7QY_P3P_Y, _8:_[,\_9F
M_P#5*^":^PZ_2\1_O%?_ *_5?_2Y'\'0^"/^&/Y(****Q*"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KZ;T+_D!Z-_V"M._])(:
M^9*^F]"_Y >C?]@K3O\ TDAK]#\//]\S'_L&H_\ IUGR/%W^[X/_ *_5/_2$
M:M%%%?JI\*%9NL_\@?5?^P;??^DLM:59NL_\@?5?^P;??^DLM<^+_P!TQ7_8
M/6_]-R-L/_O%#_K]2_\ 2XGS#1117\WG[$%%%%  0""" 01@@\@@]01W!KXM
M^('_  3J_8B^)VJ3ZUXM_9M^'+:I=7#7=Y>^&K+4/ DM]=R//)-=W_\ P@NH
M>&TOKJYEN9IKNYNUFFO)BDUT\TL,+Q_3/Q)^)G@'X/>"M=^(OQ.\5Z/X*\$^
M&K3[9K/B#7+G[/9VR,ZQ001(BR7-_J-]</%9Z9I6GP76J:K?SV^GZ;9W5[<0
M02?B5\3/^"_7P"\/:K<Z=\+O@]\1OB5:6EY/:G7=<U/1OAWI6I0PS3QKJ.C0
MO!XLUR6RNHT@GM4UO1M U'RYV6\T^SFA,3X5ZF'@DJ[IZZJ,TI/M=1LW\[?D
M?09'EO$>-G4J9#2QZ<6H5:^$KRPE--+F5.>)=6A3YDGS<CJ<R33M9IO[;_X=
M.?\ !/?_ *-QT;_PN/BE_P#-S1_PZ<_X)[_]&XZ-_P"%Q\4O_FYK\T_^(AGP
M]_T:IK/_ (>*Q_\ G:T?\1#/A[_HU36?_#Q6/_SM:Y?;Y;VH_P#@A^7_ $[]
M/N\M/I_[!\2_^?F<_P#A^I__ #R/TL_X=.?\$]_^C<=&_P#"X^*7_P W-'_#
MIS_@GO\ ]&XZ-_X7'Q2_^;FOS3_XB&?#W_1JFL_^'BL?_G:T?\1#/A[_ *-4
MUG_P\5C_ /.UH]OEO:C_ ."'Y?\ 3OT^[RT/[!\2_P#GYG/_ (?J?_SR/TL_
MX=.?\$]_^C<=&_\ "X^*7_S<T?\ #IS_ ()[_P#1N.C?^%Q\4O\ YN:_-/\
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M1#/A[_HU36?_  \5C_\ .UH]OEO:C_X(?E_T[]/N\M#^P?$O_GYG/_A^I_\
MSR/TL_X=.?\ !/?_ *-QT;_PN/BE_P#-S1_PZ<_X)[_]&XZ-_P"%Q\4O_FYK
M\T_^(AGP]_T:IK/_ (>*Q_\ G:T?\1#/A[_HU36?_#Q6/_SM:/;Y;VH_^"'Y
M?]._3[O+0_L'Q+_Y^9S_ .'ZG_\ /(_2S_ATY_P3W_Z-QT;_ ,+CXI?_ #<T
M?\.G/^">_P#T;CHW_A<?%+_YN:_-/_B(9\/?]&J:S_X>*Q_^=K1_Q$,^'O\
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M-/\ XB&?#W_1JFL_^'BL?_G:T?\ $0SX>_Z-4UG_ ,/%8_\ SM:/;Y;VH_\
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M(?E_T[]/N\M#^P?$O_GYG/\ X?J?_P \C]+/^'3G_!/?_HW'1O\ PN/BE_\
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M*7_S<T?\.G/^">__ $;CHW_A<?%+_P";FOS3_P"(AGP]_P!&J:S_ .'BL?\
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M?_SR/TL_X=.?\$]_^C<=&_\ "X^*7_S<T?\ #IS_ ()[_P#1N.C?^%Q\4O\
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MQ$,^'O\ HU36?_#Q6/\ \[6CV^6]J/\ X(?E_P!._3[O+0_L'Q+_ .?F<_\
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MV[_\"9O_ (NC[???\_MW_P"!,W_Q=5**/;U_^?U7_P &3_S#V=/_ )]P_P#
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MK31)QT6FR_5B_P"(?<%K;AO+%_W!?_R?DCX5_P"&'M2_Z/D_X*,?^):>*_\
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M'G^^9C_V#4?_ $ZSY'B[_=\'_P!?JG_I"-6BBBOU4^%"LW6?^0/JO_8-OO\
MTEEK2K-UG_D#ZK_V#;[_ -)9:Y\7_NF*_P"P>M_Z;D;8?_>*'_7ZE_Z7$^8:
M***_F\_8@HHHH _SS/VKO^3H_P!I/_LOOQB_]6)XCKE_@C\:OB+^SO\ %+PG
M\9?A-K</AWXA>"+C4;KPWK5QI.DZY#8SZKHVHZ!?,^E:Y9:AI5V)M*U6^MPM
MW9SK&TPGB"3Q12)U'[5W_)T?[2?_ &7WXQ?^K$\1UX%7RD:E2C75:E.=*K2J
MJI2J4Y.%2G4A/FA.$XM2C.$DI1E%IQ:3331_7&&H4<3E5##8BE3KX?$9?2H5
MZ%:$:E*M1JX:-.K2JTYIPJ4ZD)2A.$DXRBW&2:;1_8#\!/\ @HQ^UOXY_P""
M/W[6G[6/B7XC:=??'3X6?&F'P=X)\6)X%\#6=II7A]S^SV&LY?#5GX>@\-ZB
MY_X3WQ1_I6HZ5=70^WQXF_T*S\CFO^"'O[4?QK_:Z_:S_:+^*/QZ\4VOB_QK
M8_ +P%X/MM4M/#OAWPQ%'H&D^/M9U*QLSIWAG2])TYWBO-;U*4W3VK74HG6.
M29XX853\_P#]FSXO?";0O^"&7[;'PDUOXH?#O1OBMXK^/UOK/A?X8ZKXU\-:
M=\0O$FCJW[,.=5T#P7=ZG#XDUC31_8&NYOM.TVYM1_8FKYE_XEMYY/9?\&^7
MQH^#OP7^,G[0FJ?&+XL?#3X3Z9K7PS\,6&C:C\2_'?A;P)8ZM?6_BE[B>RTR
M[\4ZKI5O?W<%N1/-;6LDLT<)\UT5/FK]6P&<XFMGG!,,1FE:IAY95&OC(UL9
M*5)XM/-8>UQ*G4</K')[.//4_><O(KVL?@N;\,X'#\*^*53!9!AJ.,AQ!+"Y
M9/#993IXB.7.'#U1X? NE1518-U/;3=.A^Y<_:RM?F9_/C7]W'[9G[+_ ,/?
MVXOV,_AS^SWI]_HUM^T_X$_9U\"_';X%V]X;.WU>]CL?#^E^'=<T>VN+F:UE
ME\,>*YXK'PIXG=+I--T'7=7\ ^)=8ANGTW2K6;\([_\ X)'_ +)-I8WEW%_P
M6%_8YO);6TN+B*TAUCX:&:ZDAA>1+:(+\?Y&,L[*(HPL;L7881CA3[5^WW^W
M5H_P=^/'_!.'X\?LV_%/P!\1]:^#W[/VC:/XZT;P/X[\/^)].N+2X&D6GBKX
M;>.&\.WNKC1I->TC[=8RVNI6ZZEI-V+?6;&WBU32K.>#S<BP_P#J_E^>+/J%
M"6$Q\,MPU2C3QF#Q-6>&GB9TL16HK"UZ[C6PL:\,12YDFYPCRV:<H^WQ7C/]
M<LYX5?"6+QD,QR>IG6.H8FOEF9X'#TL;3P-'$8+#XF688/"QGAL?+"U<'7Y'
M)*G5DJB:DH3QOVN],U'1?^" /[#&CZQ87NE:MI/[3NIZ9JFEZE:SV6HZ;J-A
M<_M<6M]87]E<I%<VE[9W,4MO=6MQ''/;SQR12HDB,H_GCL]'U?4(FFL-*U*^
MA60Q-+9V-U<Q+*JJ[1M)#$Z"0(Z,4)#!75B,,"?ZIO\ @M9^U3^RS^T'_P $
M_O@A_P *#^*/PNUG5?$7[0W@WXJZC\,/#WBSP;)\1O#%OXL^&GQJUOQ/J'C?
MP!H>KWFM>'M8C\5^+%C\87&H6:JGBO6'6\O)[S48I;G\BOV)_P#@K1^T;^P=
M\*]?^$/PA\%_!/Q'X:\1_$'5?B1?7WQ(\.>.M7UR+7-8\.>%/#%S:6ESX8^)
M'@^P324L/!^F3003:9/>+>3WTDE]+#+;V]KY_$F'RMYYA,+B,SY,%ALDRS#K
M'X3#K&^TEA\)"G!JC"O2LJG+S/\ >7A>S3/7X'QF?1X5S+,,'D7M,TQO%.>X
MV649AC)97[&&-S"=>HI8FIA*[;H\_+']Q:K9M2B?4W_!,K]KC]HRP\#^&_V%
MOV&_@_X \!_M&^,OB#JWQ#^(7[0OQ UJ#5M/U[PQX8@U34;S0/$?A&\\ WLV
M@:=INBV^D>'+6]37=;FMMVM_V!HVG>)?&"ZGIGK_ /P5Z_:/;]E;_@ISX ^,
MO[.7A[2O"OQI\$?!J*T\?^)-7^'MYIGAWQ;XI\6CQMHTVJ'2]8TO3+?QE=Q>
M"=9L[23QOI^IZ_8W*G3- &KO?>#[RU@\B^&'P _9F_X*2_"CQW\:+?\ :)\!
M?LZ_\%"?%_QW\6>-_B/X=^(WCZV\(_#+5M"UWQ#K7B:ZD^%GABXNKWQA!X=@
MT'6=+N(]2FU?Q=JUAXH\(:IINK2:=H^MV&L0U?\ @MI^T+\&?BCJ'[)/P ^$
MWQ0L?CSK/[-GPRU/PQX_^.=OK&G:Q9>,O$.OV'@+0XH+KQ79WCZ3K6MC_A [
MCQ1XJU&UN;[1;/4/%B6MMJJZA;^(;2U]*I7QF&X4JNICZ;6'K91B,BQ-.OA_
M>A0KS4,-A,%15*K@,RPZE/%9AB)_6*M6RI59WM5EXU#"9;C?$+#JEE%6,L9A
M>(L'Q9@*V$QGN5<5A*,ZN-Q^9XEUJ&;Y)C)0IX#*,'!83#T'.5?#TU'GP\/T
MN\#?\%0/VL?A?_P3<\8?MK_M(W/@W7/&'Q>\8P_#/]DKP3I?@^R\-V9U""W\
M20:E\0O%QL[N:]U#0DNM%UZ_M=(>'3_M=MX+M((M02W\=Z=J6G?D[^RQ_P %
M*_'OP6_9G\(_LR?L9?!6;1?VP_B'\7!>>+_B_9Z'X9\=ZE\5K;6-9UZ\TW1[
M+PQJ&@S2VVJV\-]X>\+:?8746IZ+I6C:?KVM6+Z?JVNS3V76?\%K?B_\(M1M
M_P!B[]F;X ?%+P'\5/A7^SK\ K;3XM?^''C/0?&VB/K=T=,\#0V>LZOX8U75
M-+?Q#9:%\-+#4GL[J8:I9P>)9+V91#K<<DWV7_P1Q\)?L<_ ']GK4_V@O%'[
M3O[)O@K]L/XFV/BG3O!A^,7Q0^'CS?!#PS#?7F@:9:WW@:?Q_P"&]=CU7Q/]
MBF\3:\R:GH&K:AX<U'1?#4=UH]O_ &U+JO7+%YKCN(J&4X?._9T\JRKZMB<U
MJUZ-6M*5>&&K9G7P>(K2]W%UL2X83#.G6A*G1I1BJD:7MF_.AEW#^4\&8KB'
M%\+^WK9_G\<;@>'Z&%Q-#"QAA*N-PN0X7,<'AJ;4\NPV"C4S''1KX6I&MB<1
M.4J,\0\,H^!?\'"\'@6'XC_LL->6_@^#]IBY^$6JW/[1)\(PK!#,7/A-/!4M
MXB/,Q0ZU'\2TT9[^YN=7.@)ID=S-)81Z6[?E1^R+^P?^TC^V=<^);WX$^ K'
MQKH_P\U7PK;^.FO?&7A'PJ;"'Q-)JDU@D:>)==T:XOOM5KH6K%VTT3M;^0HD
M:*2: /[!_P %*_@EH7P\\?>&?BB/V\OAA^W7X_\ C?J7C75?B%XG^'^I>%M1
MO_"5WX6@\&VFB+X@7POX^\:VNGV.MV.LS:9X4TM+?0-+TG2O!\NE:%9MIU@E
MKIWQO\'_ -H/XV? N^N'^$_QC^+7PLTW6M2T:\\5V7PR^(?BWP1%XDBT::<V
MBZS;>&]:TB#6)+.WO=1BL1J1E6W6^NXXFB2ZGW_)YUB,-7XHQF(S;"5J.&G5
MA*KAL%B<'.OR?5*<</4>)A]9PDJM5*E7Q;CSIU)UH74]5^A<,8/'87@'+,'P
M]F.&Q..I8><</C<TP.94\)[3^T*LL92C@JSP&8T\/A[XC"9<JBHN-&EAJCC*
MEI+]R?\ @J]_P2'\6?#GQOK_ ,6_V2/@9H_A;]F#X>?!*#Q5X]O(?B/8SRV&
MO^';WQ=JGC'48])\=>,[_P 97SP^&XM!=8-+M[BUN#%Y6GP/>?:E;\)/@3_R
M6_X-_P#95?AY_P"I=H]?IC_P4W_X*A^(?VM_BT^H_L[_ !(_:3^&GP)U?X3:
M7X#\6_"GQ%XPOO!N@^)=7.J>*Y/$ESK'@;P/\0/$G@[6=-UO1-8TG3+R;4Y)
M;K4H+)[*_L_LEM;&7\P_@Q?V.E?&'X3ZGJ=[::=ING?$KP+?ZAJ%_<0V=C86
M-GXHTJXN[V]N[AX[>UM+6WCDGN+B>2.&"&-Y975%9@L_JY-4S^53)H2IX7ZW
M%SE>BL)*7M8M2P=.E2I*CAE':$^:2:;YK:*^#:'$]#A&G2XGJPJXY8"4:47'
M%2S"G#V$U*&9UL1B,0\3C.?>K2Y(.+2Y6U<_NB_;GT+_ (*Z:E\9=-N/V&/&
M?PV\/_!I? >B1:E8^+;7X:3:H_CM=7\0MK=PC^+_  IK>J"SDTA_#R1+'>+9
MB2*8Q0)*9WD_'_X0?LT_M$_M:_\ !6GPM\/_ /@IG>>#_B+XI^!?[/\ #\1M
M6\/:+8>$HO"_B7P1HOB@3>!_"VJP>$M+T#2=3L%\;?% ZWKMI=:?>OK&F6T_
MA_55N-(N'6#Z*_X**_L\_LH?MT?'G2OC+H/_  5>_92^$=EIOPX\/^ V\+GX
MG?#;Q)Y]QHFM^*-7DUC^T++XU>&X4^UIXBCMOLQT]WC^Q>8US()5CB_.OX0:
MW\'_ /@DY^W?\"?B)I?[6OPX_:Z^&?CSPMXB\*?%_P 7?"74+#6%\!>%_$-]
M:Z49M3A\)>-/B/<:E<:!J%KH_C4Z*5^WZIIFBW%AI6GOJ-Q97D'W^=UU+.*5
M;'+%SR6&=82I7JU^),)C<KGA_;0C&:R:"]K2HQG.$W&3J*G34U.+C)N/X]PM
MA90X:Q&%RIY?2XHJ\+YC0PM#"\$YEEF?4\7]7<ZE.?$]67U>OB)T85:<905&
M56M4I.G-3A&,OIS1/^"M/_!0;XN_M9>*? G[%WP>\'>./@A\&M3UG3=&^!W@
M_P ":?"NO?!WPEXKA\*Z5K^KZ[=7$>M^&M3N],GTBST^/PK/I'AS0'O-.MCX
M5U2.RN#>\EKTFK>(O^"T?[(7Q-UK]CWQ3^QWJ?Q&\:66IZOX<\2ZYI>IR?$G
M7+"X\1P7WQ)&F:/I=AIV@:OJEM<:=8>(K:RGOH-3U2P;6KB:;6-0U;4-2]NM
M?V+OA=H_[0OQ1_:Q_9$_X*V? O\ 9Z^%/Q>N]>U[Q1>Z+KG@>37O!FF>,_$%
MAXLO/ Y-_P#$#1M)BTEM>A>:TAU[_A%]4\.+::?H]SHVH3V=S*^1^U5^VK^S
M%\6_^"L7[!7B#P-\9?"^N^!/@/=S:%\2/BSJFI6>@?#BTU.ZU#5+B6>'QIK<
MVG:)J-C!%%#->>(+*=_#,SW]LFF:O?M]H6WYZJQL</3GG>:3G6CQ'EE;!TJN
M*RG$X+$4GF$(^VRU0E6QV%H4L(^>K&,L/2Y6HM2Y:T5W89Y7+&U:/"^04Z6&
MGP5GN%S+$4,!Q#@LSP>(63RJ?5L\=6GALKQ^*Q&/_=T)SIXO$<T7-2@Y8>3^
MT?VN_P#A^G_PT7\2_P#ADS_A$_\ AGK[=H7_  K?^T/^&;?MGV+_ (130?[;
M\_\ X3G_ (JK=_PE/]N;?[7_ 'FS;]F_T+[-7R__ ,$B?'_[1OQ'_9<_X*=_
M$OP1>_VK^U3XR\=>(_%?AK4+/3?!UO\ ;OC-J_@G7+_3[BVTG5K6/P)$)O%$
MT;QV>H6:>'%!$<\ L0RU^/7_  5*_:2\1^)/V]?VA=;^#GQ[UK7OAK?:QX-?
MPOJ_PS^*5]JG@>\@A^&G@NWOVT&_\+:[/H%Q#%J\.H07C:=*Z)J,5Y%,1<I.
MH^KO^":?QV^&GPR_X)N?\%)?#/B+XR>!OA]\4/%WA?Q+)\.?#^M?$/0/"?CW
MQ/J[?"S6;.QD\$Z5?:Q8>(=:U%M6DAM;1]"M[FY.HO%!"?M+(IQI9[0K\5XA
M+&9M['"?ZQN3Q>;PK8=36'Q$*,LJ7L*<<'M.-"\J[4948Q;Y'S]%;A7%87P\
MP<Y99P[]:S*'!*A'+^':N%QLJ<L=@*N)AG\GBZT\S>M.6+M#"*4J>)G.,?:I
M4OV)_8_UW]O:;X;?M(S?\%D-"^'$O[-.E>!8]4:[^)>B_!9KV^EMI?M.K:<=
M$^$__$AOO#UGI]I]J4:_H?\ PD=UXIO-!M_"-[?3Q7MI9?P_I;27MXUMIEM=
MW)EDF^R6R1M<WCPIOD4,EO'F21(%+S-'&%&UW"J@X_H\_8*_:Y^"/[:7[-/Q
M'_8._P""C7Q'\':4OAKPW+KW[/\ ^T!\7?$?AW2-5\*ND9TB&TM?'/C'4M+V
M^-O!%[?V.H>%!/JLUUXN\'7/B3PAK3OX>T<6&I_C+\%OC)X[_8+_ &KK/XG_
M  ZN_A7\1_&WP1\2?$'PYHVK"_O/'/PD\7+J?A[Q3\.;[7M(U3PEKWARZ\0>
M'M1T?7KW5_#6I:=K5@)RVFW=S&\(N-/E\+B3$X;,<'PQ4CC<36R^V)I8C,,;
M6CC\YHU:N(I/%4<9!1H.<,)"/-@8J2C7@YM5(N5U]9P1@L=DN9<=4)Y9@L+G
M-\%7PF3Y7A9Y1PQBJ&'P5:.7XG+:LI8N-*IF%6?)FLW!SPE54XRI5%#7WW_@
ME=\$_A7\5/VW_@_X/_:!GM-'\+2WTNKZ#X1\7>!K[Q/H7Q9\6Z7=Z=_9WPUU
M*PEC6RMK'5[.ZU#5+O4-6ANM'2/1AI]_;3+J4:']0_VY/V!?V7OC;^WO\:KH
M_MN?"GX%:7X4\'Z?XG^,?@G7_!L.DZK\++;P?\-?!%MX0\(?#?PU=^)/"\'Q
M,MM3\":%K/B?4[CP:6@\!V5CI>E76E7UWJVG6LGS5X7_ ."MWQ*_:N_;2_85
M\6_M.Z5\&/AUX,^"'QI:Z7Q#X%TWQ-X5TW3;3XBOH/A[5M9\9:GXX^(7BNPM
M=!T'^S=.U&ZU!)-*ATO3H]5O+V6YC2-8/V''PB_9"N/VWOVK?CUX@^-'[%7Q
M,^.7QX\#:#XP_8ULOB'XXT;QOX-\"7_@KX;>'_#NH:UXYT"/4(M%^W:WXMD\
M(ZSH,^ESZGXGO? VA^(=7\"7UM)8^,8K+U<FP&58S*9Y?A8X/,J$>(*$ZN*Q
MWM\MKRH?V9.<92I4L:ZG,\4YX"A2C4<*SJO6C4J+$4?GN)LVXBRWB&EG&.GF
M>28N?!V+I4,ORKZGGF$IXMY]0I3IPKXC+%1<5@%#-\77J4HU<*L,M,30HO!X
MG\*OVK/^"9OPJ\!_LH6'[;?[)7[2T?[0/P&M=:MO#/BP^)O!FK> _$^G:I=>
M);7PG!?:/::C;VEU>P#7KZVL-2T;6-$T#4-,A-OJUE=Z]8WSC3?K?XE?\$*?
M@_\ ":+PS9^-OVZ-(T7Q;\6M!MK+X"^!K_X<Z+IWB_XG_%#8UQ=>"]&TK5/B
M?8V=[%</J'A'P]HUU'K%J+GQ+XML;/4)=,?^R;;Q#]1?MN?M!:1XT_X)2?&S
MX0_%G]L_]ECX\_M2:;XQ\'7VN>'_ (1>./AYH^EPZ;8?%/P5XCL_"/PTT:W3
MPM?^/+#PCX/,4EYJVF:#<WWV^UUS0[J:]U70+O=X+_P5-_:O^%;?ME_\$W_B
MW\(?B!X,^.NF_!7_ (0SQ+K^A_"/QOX:\>W#:AHOQ)\,:Q>^%<>&K_6X--\2
M>(=.TPZ?9VUS$E]+(ULZ0N88]M8O+.&,&\9B9X+#U8_4>'ZBP[Q6(I1P^(QN
M-QF$S)PHX?,,544Z-*G3JRPLL7BG0JQBG-Q;C+/+,]X\S1Y;@:>:8S#R6:<8
MTI8Q8#!UIXS!Y5EF4YAD<:N*QF38"C*GB<1B*^'CCHY=@(XO#RFU252,9P\G
MU/\ X(H?!?0OB#\./V;]<_X*#?#'3?VN/$<GAK4O%7PC?P7J+Z3;Z#J5QH%Q
MXDL?"OB)M:BN+GQ7I?AF]UCQ#X'T3Q/IGAW5/B=';Z:J:-X,TF74M?T["@_X
M(F:5X=^+O[4G_"VOVG=&^&G[*O[*E_X)T3Q3\<]=\)1V^O>*O$_BOX9?#;XE
MW7A_2/!Z>(KJRTI=(LOB/H^DOJ5QKVJ7^I:OJ?AK3O#WAK7[[6+^VT/](_%G
MP?\ V(?C;_P4V^"7[=GAC]MWX6>(#XT\6?"*ZM/V??#]]::O\7]8^+&DZ/X:
M\!_#:V'AFSU>/Q9X.\.Q#3M!\0^.T\7^$;&]\,KX>U2RU2**VUR:]\.?4_Q&
M_:L\!:M\7?\ @H1^QYIGQ6^!'P?_ &@D\>?"CQO\)M3_ &A-/T"?X2>/$U#X
M$_L\)/HNM+K<4FGZWK^G:WX:U#1[NR,=]XETRQU#0M?\.:/KT?A75;*P]*/#
M?#C5>I7P."P\:6;5L+EOL,TJXJ.9X:GEF,KX+ZQ_PH<D*F,J4X5)0C6PDZDZ
M4:,?9*<I5O'GQMQFG@Z.$S;-<7.OP]AL?GBQ>08; 5,CQM;/,KPF:/!_\(W/
M6H9;0KU*,:L\-F-.A2Q$\34^L2IPIX?^?#Q;_P $Q_A1\+_BK^R)\3K;]I'1
MOB5^PG^TEX]70-)^.=OX#UYK[2/$&FQZI?:?X \8>"X)!.9?&VIZ'=^$].O[
M2^M[VVN;#Q9+X@\/^'?^$?CBU/\ 3;_@H_\ \$S?AY^U%^V3\%O@[^SU\1O!
M'PN\<Z-\(?#4'BCX+:=\-KK1/!_PG_9UT#Q'X\N;[XO:7>Z"MEH.JWE_XT\0
M6'@[2/AYIMOIUY?Z_J]KJ.J:QH^C2ZEK5A\N?\%)?VDIO W@3]D7X'^-/VDO
M@E\:_%G@OXM>&_C/\7_A[^S;\/?!EI\,_ACJ?A#5]9$47AWQ;X?NK*XM]5OH
M?$>O6?\ PC.HZ3!K&JNFH>*-<M_"EKJNAZ;JWZ_^,/VB_P!FCX3_ +>7A?\
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M%_\ 36)/UWHHHKWS^>PKVKX:?\@>^_["3_\ I+;5XK7M7PT_Y ]]_P!A)_\
MTEMJ^NX(_P"1_1_[!\3_ .FSP.)?^155_P"OM#_TXCT:BBBOVH_-@HHHH **
M** .>\6?\BYJ_P#UZ-_Z&E?.%?1_BS_D7-7_ .O1O_0TKYPK\E\0?^1E@O\
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M****DT"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]>8%M9?@VHN36#P[48\JE)JA!J,7*48W>RYI1C=ZR2NS^H;]LGQ;^S_\!_\
M@JQ\._VGOC3\;9]!M_A#\)OA1XGLOA!X"\'>/=;^*OC75K#P5?VFD:3::O)H
M.D_"[2M U>>^C?4I]5^(4=S>:9;:GHMYIEBE_!J _+CP?<_"W]I#5?VG_P!H
MC_A0.E_%?XN^./VB/$7C[6/!'Q1\9:_\*/V;/@7\#?'&IZSXINO%OBGXS>&O
MB9\&;.#XC:QXOU.T\!>#M+\2^)X-)OXK/5+^#PUXIU_4M/L;/Q3]OW]L'PI^
MVW\8;/XS:3\(=;^$6N+X2\-^#]2T>Z^*%I\1=%N;#PM;7%EID^G ?#7P-J.G
M7+6LL*79NK_5XYG@:2-(3,0EWX3?M<_"GPU^R/JG[*7Q@_9]U/XK:5;?'Y_V
MB?"6OZ'\6I_AI$GBH^ ]/\ Q^&O&NG:;X&UW5/$GA$V%M>W5_P#V3XD\,>);
MB&_DTS1_$/AN6*UUBV^SQN<8+&9KCZ?ML%'+'BLPQ^'K3PN*J+%8K$4J=*G.
MK'$4,5*E/V<%&#>!E1IOF;H<\HUH?G&5\-9IEO#^3UOJV:3SV&79+D^,PU/'
MX"C+ 9?@J\Z]>EAYX+%X"GB*3K3<ZB6;0Q5:#C%8KV4)X:K^C/Q+_83_ &-O
MA?\ &G_@J7X U;P-\3-7T?\ 96^&W@7XI?#*XTWXF&T;2-*\?^&OAWXE7PG9
M6=UH$]Q-J^F7WBC5=%T_QIXOUKQKI]GHTNG7FI^ ?$VJZ3=/K_SG\4/V4/@;
M\:_ O_!,KQK^SM\/KWX ZA^V7\1O'_P3\<^']5\?>(?BCI6CZ[X-^)_@_P"'
MNG>/++4?$26.H2_;;36=6\0:WI%J-,LXF2STG2+$O;R:A?\ 6_%+_@JY\'_B
M=XF_:[\67W[(?B&R\0?MA_#+PK\//'>N6'[1AMKW1E\+^%_#/ARQNM(L;KX-
M:KH[6&GMX/T+4-,L'L8K\WD_B-M8UG5K/5](T[PO\K:A^W)I-I\ ?V0OA5X#
M^%OB+PG\1?V-?B9X@^*WP[^*VH?$_2/$NFZEXF\2^.].^(&H#5_AZ?A3HT9L
MK76-&TI=(@'BV9K:*UD&H2:K'<R1#;'8OAIRQ=.B\!/#3CBJE*-#+ZU'$<RX
MCIXG#4J=>>"I5:<WDCK8=/VL:.U*K/FC2:PRK+^-XT\NK8F.;TL?2J8"EB98
MO.,+B,'R/@JK@L=B*V$IYI7H5Z:XICA\7)/#SQ"UQ&'I*,\1&6E\7[?]A_09
M_P!J7X,S?"SXC?"CQ[\&=8OO"/[/_CVRUWQ%XS\5?$OQ5X&\6WGA7Q9:?M"Z
M-XCUK2_!VA'Q1:6(UK3E^&_@SP,/ ]T^IVE[_P )@UAI^F:M]!_%SP)^PC\)
M_P!DO]D7XFV7[*?Q$\6>./VJ?A=^T!965_J?[2>MV=[X,\<^#?%NF>"/"GC*
M\&G>"+#PYXMN+35I7U"UT.U\->"M ALIKBTUNS\3S26MUIWFW[1G[=O[-WQ6
M_P"%G?%#X7_L@GX6?M0?'?1-<T/XF?$C4?BA?^,O!OAP>,8+O2OB;K?PV\#7
MFA6=I:^)_BMX>U+5M#UW6M49'\,Z?JVJ-X?MY==U*[\1OX+^T5^U9X&^-7[/
M_P"RS\"_"WP@\2?#X?LOZ'XUT+3/$VJ?%>P\<)XOC^(6M67B?Q->ZAHD/PN\
M'2:5>2>(K1KO3?LFN7-I86%S+I[VMVR0WD?#6Q66T%FGLZV48FI+!J.7RI92
MU&4I9K0K03CB<#[*GBH9<\53JR=*G",)4:?MZ]>-Z/J8;+\[QG]@^VPW$>!I
M0S*53.:>(XB3E&G#A_$X>HXSP.:NO6P%3.8X"K0IK$5JDZD,76^JX3"U+8C[
MC\9?L[_\$]_@9\7?BM^R%^T7XCT?P'J'@3P':Z3;?M,6=Q^TIK'Q:M?C=)X=
MT'Q,-3U/X9:#X$U[X/:A\)=6U/4[K2]%T#2]''B>/P*--U"Z^(%QXFO)=1M>
MH_8?_8Z_9R_:+\0?LX?#)O@J^M^ ?C#\,_',7Q%_:5^(GCWQ5\+OB?:_'[2O
M GCCQ'JWA3]FCP GQ4T;PG\5O GPGO=%\+V6NZM!\*/B'/\ :[S7=4\7ZMHF
ME+I^CQ^$_%K_ (*,?!;XU66B_&?QQ^RDUQ^W?HWA+1_#9_:'TWXIZGI/@_5?
M%?ASP[!H?A;XU:M\+;'0H=)N/'_A!].TS4/#^BQRP^'QJ=M:W.I75]HVC:1X
M8@[?X8?\%4_A-X#^)G[(WQRU7]DS5?$'QD_9;^ WAO\ 9VM]?A^.LVB^#]9\
M'>&_!/B;P:/$FC^!;#X9I'HOC/58/%NL^<VHZ[K_ (7L-.O;^UB\.W>M3:/X
MD\.^C1Q/#BS&G*K4R?\ L^&(ISIQAEN+5:675<;AYRPV,E4PM>G/%X?#1JPG
M*GA_:U.::CFG*X<OC8G <:RR:M##T>)/[8JX&K3KSJ9[ESPT<ZH99BZ,<=EL
M*688.M3R_&8Z="K3C7QBH47"G.>0J4:BJ9O[//B#X:^'_P#@DU^T_P"(=8^
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M?L+"#PRGT%KG_!2B+3?BO^Q1\9?A!\(=<\ >,?V,?A?X/^#6DIXG^*FF>/\
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M^G&SKT<L_P!YE_UZE_Z5 _._$[_DFH?]C+"_^FL2?KO1117OG\]A7M7PT_Y
M]]_V$G_]);:O%:]J^&G_ "![[_L)/_Z2VU?7<$?\C^C_ -@^)_\ 39X'$O\
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MK1JPC.-.<H1BZL*OLU[1OV?-%I+^?"BOW"_X<$_MB?\ 12?V:?\ PL?BC_\
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M[E_F'^N/#'_0ZP7_ (%/_P"0\_S[,_#VBOW"_P"'!/[8G_12?V:?_"Q^*/\
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M ,O7^EJ?\0GP/_0XQ?\ X34?_EGK_2U_T,_^&K?V7/\ HY/X!?\ AXOAW_\
M-'1_PU;^RY_T<G\ O_#Q?#O_ .:.O\\RBC^U9_\ /F'_ ($_\O7^EJ?\0GP/
M_0XQ?_A-1_\ EGK_ $M?]#/_ (:M_9<_Z.3^ 7_AXOAW_P#-'1_PU;^RY_T<
MG\ O_#Q?#O\ ^:.O\\RBC^U9_P#/F'_@3_R]?Z6I_P 0GP/_ $.,7_X34?\
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M@%_X>+X=_P#S1T?\-6_LN?\ 1R?P"_\ #Q?#O_YHZ_SS**/[5G_SYA_X$_\
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M$U'_ .6>O]+7_0S_ .&K?V7/^CD_@%_X>+X=_P#S1T?\-6_LN?\ 1R?P"_\
M#Q?#O_YHZ_SS**/[5G_SYA_X$_\ +U_I:G_$)\#_ -#C%_\ A-1_^6>O]+7_
M $,_^&K?V7/^CD_@%_X>+X=__-'1_P -6_LN?]')_ +_ ,/%\.__ )HZ_P \
MRBC^U9_\^8?^!/\ R]?Z6I_Q"? _]#C%_P#A-1_^6>O]+7_0S_X:M_9<_P"C
MD_@%_P"'B^'?_P T='_#5O[+G_1R?P"_\/%\._\ YHZ_SS**/[5G_P ^8?\
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M*_\ L8X+_P!2:1XO$G_).Y__ -B7-?\ U!KG]%/[._\ R;_\#/\ LCOPR_\
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M9ALWR^<YX/%1JN#JTIT:L)4*U3#UZ56E-*4*E"O1JT:D=4ITY<KE&TG4HK[
M_;:_8Q^(?["OQ?T_X,_$SQ+X,\5>(=2\#Z-X\AU/P+<:Y<Z,FEZWJNOZ1;6D
MLFOZ)H%\+^*X\.W<DZ)9/;B&:V,=Q([2I%\?UCB<-7P>(JX7$TI4<10FZ=6E
M.W-":WC*S:NO)LZ<#CL)F6#P^/P%>&)P>*IQK8>O3OR5:4OAG'F496=NJ3\@
MHKZC\/?L1?MA>+OA]8_%7PI^S)\<?$OP^U2WBO=*\3:!\-?%6KV>JZ;/%/-'
MK&EP6&FW%]J.AF*VED;7+*UGTB-!&TEZ@FA\S[B\(?L(>!OB!_P2RT7]I/P-
MX-\?>,/VFO$?[0T7PKT#1?#5SJFM1:SILVLM91Z=IO@O3[.XFO-3:V5V,T&^
M15229U5$=E[L+DV8XKVJAAZE)TL#6S"*KTZM-U\/0=-2^K7IOVTY>UAR*/NR
MNO>5U?S,?Q-DV7K#NIC*-=5\UPN3R>%K8>LL)C,7[7V?UUJLOJU."H5'5E/W
MH*+?([.WX]45Z]\8/@#\;/V?_$5CX3^-?PM\;?#'Q#JME_:6DZ9XPT"^TB75
M]/\ M,EF;[2)+B(6^JVBW<4EL]QI\US$EPC0NRR?+7:?$7]CK]JOX1> [3XG
M?%#]GKXN^ ? %X]O$/%/BOP-KVC:7927D\=M8QZQ)>V<4F@OJ-Q+%#IJ:W%I
M[:C)(BV0G+KGC>#QB==/"XE/"KFQ*="K?#Q>J==<G[I-:WJ<J/169Y:UA)+,
M,$XX^3C@6L70:QDDTG'"/VEL1)-I-4>=IM*Q\VT5[[X-_95_:7^(OASPKXP\
M _ +XO>-/"OCG6;_ ,.^#?$7A;X?>*-=T;Q/KNE0:W=:II6AZAINFW-MJ5]I
MMMX;\0W%_!:R2/9P:)JLUP(X[&Y:/3_X8[_:M/Q.U#X+Q_LY?&BX^*VE:-_P
MDFH^ K3X<^*;SQ':>&#=C3X_%,MA:Z;,W_"+3W[)8VOB52VAW=[)%:VU_+/+
M'&S6!QLHPG'!XJ4*DH1IR6'JN-252//",)*%I2G#WX*+;E'WE=:DRS7+(3JT
MY9C@(U*,:DZU.6,PZG1A2G[*K*K%U%*G&E4_=U)324)^Y)J6A\WT5Z))\(?B
MS%\17^$$OPP^(<?Q92_.E/\ "]_!7B1?B(NIBS_M$Z<W@HZ:/$@OAI_^GFT.
MF^?]B_TKR_(_>5Z5X]_8_P#VJ?A;)X-B^(W[/'QB\%2_$/6=-\-^"4\1_#_Q
M+I;>)/$NL21PZ7X9TP7.GIYOB6_EECCMO#S;-9D<E18Y5@LQPF*G&I..&Q$H
M49^SJSC1J.-*=U'DJ246H3YFERR:=VE:[1I+,,!"=&G/'8.%3$T_;8>G+$T8
MSKTN5S]K1BYJ56GRIRYX*4>5-WLFSYQHK^B"\_X(I?\ "J/B?^P7H?CN/XG?
M$OPC\<M>O(_VD]>T?PU>^$O"_P *CJUKX/3P=X*;484U2[T#69M8UG6=(DU?
M7M3@E\0WUG#%I^@Z-);7%O/\(?M8?\$\_C'X-^.G[2T'[/?P$^,7BK]GWX-^
M/-<\/V?C&R\.:]XGT^QTS0=+MM0U4W&O167_ !-SHL;7$VM75FDZ:5&%&HM;
M93=Z^+X8SG!49U:^$FI0KT\/.A34JU:,JF#AC54Y:49PE1C2GRU*D9RC"K&=
M-ZQ;/F\NXZX9S3$4Z&$S&FX5L)6Q=/%5I4\-AI1HYE/*W1<L14IU(XFIB(<]
M&A.E&53#SIUHZ3BG^9U%>U_!?]F_X]_M%:CJNE_ SX1>/OBG=Z%%;3:ZW@WP
MYJ&KV6A1WJW;6!UO4X8?[,TAM1%C>KIR:C=VSZA):7$5DL\D,BKE0_ KXTW'
MQ4/P,A^%/Q"?XS"^N-,/PK_X1'7!X_\ M]KIDNM3VG_"*-9#6C-'HT,NK%!9
M\Z:AOES:XE/CK"XETZ558>NZ5>I[*C45&HZ=:K>WLZ4^7EJ5+Z<D&Y7TM<^D
M>/P*JU\.\;A%7PM'ZQBJ+Q-%5<-0LI>WKTW/GHT>5J7M*D8PLT^:S/*:*^H;
MS]B/]L:PTRSUBY_9:^/XT_4/$VH>#;*:'X3>-[I[GQ3I=_<:3?:'';6NBS71
MOXM5M+W3$B,(^T:C8W]C;--=6-W%#1^+W['7[4_P#\+Z3XV^,WP"^*/PX\(Z
MU<0V5EXC\4>$]2T_2(]0N(O.M=+U.],3PZ)JUW$LKV>E:TVGZC=BUO?LUK*;
M&\$&DLOQ\(3J3P6+C3IQC.I4EAJT84X2MRSG)P481E=<LI-)W5GJ8PSC**E6
ME1IYIEU2M7G*E1I0QV&E5K5(?'3I4XU7*I.%GS0@G*-M4CYLHKZ-T+]C_P#:
MJ\3GP /#O[.GQHUM?BKHMQXD^'$NF?#GQ5>V_C3PW9Q:1<7OB/P_<P:8]O?^
M'[&WU_1)[[6XI3I=G!JVGS7-U%'=P,\EI^QU^U??^*/&G@FQ_9Q^-5[XP^'5
MAI6J^._"]K\-_%=QKWA/2]=M;J]T74M=TJ'3'O=/L-7M+&\N--O)X5M[V*VF
M>VDD"-@6 QSY6L%BVIR48M8>M[TG3]LHQ]S63I?O4E=NG[Z7+J-YME2<T\SR
M].G%SJ)XW#)P@JWU=SFG4]V*Q'[ARE9*M^Z;Y_=/FZBO4_AK\#_C)\98O$\_
MPF^%WCSXCP>"M.BU?QA<>"_"VL>(K?POI<ZW;P:AK\^EVES#I-G,FGW[Q7%\
M\$<B65XZ,5MIBGEE<\J=2,(5)4YQIU>;V4Y0DH5.1\L^232C/DE[LN5OE>CL
MSLC6HSJ5:,*M*=6AR>WI1J1E4H^TCST_:P3<J?M(>]#G2YX^]&ZU"BBBH- H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_M7_P""+GB&]UO]@7X<
MV-WRGA7Q;\2O#UBY8N[V3^,M3\1+O+#(\JX\07,$:Y8)!%$JD* B_P 5%?V<
M_P#!$/\ Y,2T#_LI?Q&_].-G7HY9_O$O.E+_ -*@?G7B?&,N&Z3:3<,SPLHO
MLW1Q46U_V[)KYGZ[T445[Y_/@5[5\-/^0/??]A)__26VKQ6O:OAI_P @>^_[
M"3_^DMM7UW!'_(_H_P#8/B?_ $V>!Q+_ ,BJK_U]H?\ IQ'E>O\ _(=UK_L+
M:C_Z635DUK:__P AW6O^PMJ/_I9-637S6-_WS%_]A-?_ -.S/8PO^[8?_KQ1
M_P#3<0K^5S]AXC^T_P!N=<C='_P4:_:T21<C<C_\)3I#;''56VLK;6 .UE.,
M$$_U1U_+[^U%X/\ %G_!,_\ :G^._P 9M:\)^._%?["W[5WC)OC3XB^('A/P
MY+XH7]G;]H+Q5J*67Q$_X3NQT>:;68/ WCFX-GKMMXF.F.D=W-HGA'1K&_U3
M3[^?5>'&X:KCLLQV$PT?:8F;P]:C17QU_85&YTJ2^U5<)N<*:]ZIR2C!.;C&
M7Z%X;YQ@,CXMP6,S*M'#82KA\7@YXFHU&CAYXB$72J5Y-VA1<Z:ISJ/W:;FI
MU'&G&<X_95%?$MK_ ,%'OV'KNV@NHOVC_ *17$4<T:W3:U97*I(H=5GL[W2+
M>[M90"!);W,$,\3926-'!43_ /#Q;]B+_HY'X=?^!FH__*ZOA7E&;)V>5YBF
MM&G@L3>_;^%YH_JI<2\.-)KB#)&G9IK-< TT[6:_?ZWNK>J[GVG17Q9_P\6_
M8B_Z.1^'7_@9J/\ \KJ/^'BW[$7_ $<C\.O_  ,U'_Y74O[(S;_H69C_ .$6
M)_\ E7FOO'_K+PY_T/\ )/\ PZX'_P"7^:^\^TZ*^+/^'BW[$7_1R/PZ_P#
MS4?_ )74?\/%OV(O^CD?AU_X&:C_ /*ZC^R,V_Z%F8_^$6)_^5>:^\/]9>'/
M^A_DG_AUP/\ \O\ -?>?:=%?%G_#Q;]B+_HY'X=?^!FH_P#RNH_X>+?L1?\
M1R/PZ_\  S4?_E=1_9&;?]"S,?\ PBQ/_P J\U]X?ZR\.?\ 0_R3_P .N!_^
M7^:^\^TZ*^+/^'BW[$7_ $<C\.O_  ,U'_Y74?\ #Q;]B+_HY'X=?^!FH_\
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MJ5DEV5@HHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %?3>A?\ (#T;_L%:=_Z20U\R5]-Z%_R ]&_[!6G?^DD-?H?AY_OF8_\
M8-1_].L^1XN_W?!_]?JG_I"-6BBBOU4^%"LW6?\ D#ZK_P!@V^_])9:TJS=9
M_P"0/JO_ &#;[_TEEKGQ?^Z8K_L'K?\ IN1MA_\ >*'_ %^I?^EQ/F&BBBOY
MO/V(**** /\ /,_:N_Y.C_:3_P"R^_&+_P!6)XCKP*O??VKO^3H_VD_^R^_&
M+_U8GB.O J^1G\<O\4OS9_7N _W'!?\ 8)AO_3,#^B#]E?\ Y5\/V]O^SD+;
M_P!"_9+KN?\ @VG_ .2Y?M+_ /9*/"?_ *E[U^%WA7]J[X_>"?V>_'W[*WAC
MQ[_9GP%^)_B1?%WCGP)_PBW@N]_MSQ"A\)%=0_X2C4/#EWXSTS!\"^%?]$T?
MQ%I]B?[+YMC]NU'[9>_9I_;!_:+_ &/]=\3>)?V=/B)_PKO6O&&DVFA^([W_
M (1+P+XM_M'2[&\-_:VOV;QSX9\36EIY5V3+Y]C!:W#_ .KDF>+Y*^RP7$>!
MPV:\+XZI2Q;HY)EBP6+C"%%U*E52Q[YL.I5XQG3MBJ>M2=*7NS]S2/-^=YKP
M5FN.X?X]RFCB,OCB.*<\>9Y?.I5Q*HT:#IY/'DQDHX2=2G6OE];W:%/$0M*E
M^\]Z:A4D_8^_:VACDEE_9;_:+BBB1I)99/@E\2TCCC12SR2.WAD*B(H+,S$*
MJ@DD $U_6U\;OVW=,_90^//[!W@/XJS6=Y^S3^T1^R/X>^'GQATG7(K2[\/:
M-)?+INF^'_'.HVU\C0MI6D_VKJ&C>,('D6TNO!FN:S=W=GJE[HVC6T?\]5U_
MP6O_ ."F][:W-E=?M,>;;7=O-:W$?_"FOV?D\R"XC:*5-\?PI21-\;LNY'5U
MSE65@"/B_P"/'[4OQW_:9_X0#_A=_CK_ (3;_A5WA.'P/X%_XICP=X;_ +"\
M+V_D>3I?_%(^'M _M/9]FA_TW6/[0U%MGS7;;GW5@<]RK(</C/[$JYK5Q>)J
M8"<98_"8.A12PF)=2I2J>PQU>4Z6(H5*M&I'EU4N712<HQFG"?$'%N,R[_6K
M#\/4,NP5'-Z,H93F&98K%2EF6"C1HXBE]<RO"0IU\%BJ.'Q%&?M/=E'GLW!0
ME_3%_P %I?@'X9_9@_X):? +X'>"[VYOO!_@K]K\R>%6O#(]W9>'?%6A?M.>
M,]&T6XN);BYEOYO#^G>(K?0I-5FE$NKMIQU.6&VDNVMHOQQ_8;^''_!*+Q?\
M)O$.I_MU?'WXM?"OXMP?$35K'P[X>\!Z-XOU'1[SX<Q>&O"5QI&LW,_A_P""
MOQ'LUU*X\37/BZQFBEURUN5M=.LW?2H(GAN[[Y9^+'[<'[4OQS^"O@#]GCXK
M_%:[\9?"'X7W?AJ^\$>%[[PMX&M+O1[OPAX9U;P?X=GG\6:5X8L/&>M-IWAS
M7-4TT#7O$.IK=+<K<WJW-[;VMS#\HUS9OQ!@,5G-+,<%E="IA*67X7!4\!FE
M)U*-/V%%4DHQPV)@Y1I)*-&;J1;BKSIIOE7;PWP=FV X9KY+FN?XNCF.(SG'
MYI6S?(<1&CBJWUO$.NY3GC<#4C"==RE+$TU0G%2?+3K22YG^QWP_^$7Q;_8Y
M\6S_ /!1O]EWX5>%_P!H']E'2_BSX]\ ? ?Q!\18]1\6:EJ/AR]\2>*O 6@>
M-/%/@3P]+X/\8>'=1!TB;2;#4O%&A>'6M?$>LZ%<IH'F:EI!;Z!_X+Y_#K3U
M\4?LG_M':NGC'PK\6/VAOA+>77Q+^$/B[Q??^*H_A;=>%-*\!:E:>'O#L%\9
MQX<L+/6O'/BK2]6TO3);'P[=Z_I=]K.D:3!?ZCXAGF_-7]E+_@HW^UO^QAHN
MK>%/@5\1[;2?!.NZO<^(=5\$^(?#'AWQ3X=G\07.G6VER:U;+J^G3:KI-\UI
M96"SG1M4TZWU Z?9#5+>^2VB1?"_CY^TC\:_VG_B1+\6?CMX[O\ XA>.&L;+
M2;;4=3LM)M=/TS1=-N+J[L-"T?P_IEA8^'])T2VN[Z^N_P"RM/TRWLI[V_U"
M^NXKB]U"]N+AULXRE</XK+L/3QOM\=4PF(EA:M+#+!8#&TJO/BL7@\1&;Q,Z
M>(H\N&H8:K!.A2YU4K5I*$Y+#<-<02XPP&=XVKEGU3*J&88.GF%"OC99KF^5
MXF@J> R_,L)4I+!4JN#Q//CL5C:%5K%8A4W1PV&A.K3C^T7_  5"TZ#]D+]@
M3]@_]A+P_9QZ)KOBK1)OV@_C["A:/5+[QZ^F641M]2NX(K9-8TQO%WBGQC86
MD=^DL]EI_P /O!UN#LTRV\ORO_@E+_P32T;]H73];_:Q_:/L==7]EWX57][)
M!X3T+0_$.N^)_C5XB\/)#<WVAZ1HGAFQO_$>H^$M,GD@L=8/AZRNM6\2ZLTG
MA+00MW!K=YI'YB?M(_M5?'S]KKQIH_Q"_:&\?2?$+Q=H'A>U\&Z1JA\-^#_"
MD5EX<L]5UC6[>P32O!'A_P -Z/)(NIZ]JEQ)J$^GRZE<+/%;7%Y+:V=C!;?0
MOP9_X*I?MY?L]_#3PO\ ![X._'*#P7\./!D%_;^&_#=O\)_@GJR:>FJZM?Z[
MJ3/J>O\ PXU;6K^>^UC5-0U"YNM2U*\N9;BZD9IBNU5T6<9#7XA^OX_"XVIE
M&$PN'P^6X*-##U)+ZI0HT,-'%498NE3=!2C5Q%:G#$2]K5DH2O3G-+&7#?%V
M$X-_LC*,?E=#B/,<PQ>,SS-)XK&482_M'%8G%8ZIE^)CE^(KQQ3C/#X/#UJN
M$@Z%"#J0M6I4F_1O^"L'[1_Q\_::^..B>,_B=\%/BC\ ?A+H>F:EX3_9]^'W
MQ*\%ZYX/N(?#FEMI3^)=7(U/3-.T[4/$NL7EQH][XCAT,WEGX>T^3POX:^VZ
MC!I5IK&I\Y_P3T_;4^$/[)MQXZTGXG_L>_#?]J.[^(^N>!/[ U7QYJ/ABQN/
MA]_83Z[;7G]CKXA^%OQ%DF_MJ37;.YN?L5SHFU]%M1+]K9XI+3Y__:<_;<_:
M?_;(_P"$(_X:0^)O_"QO^%<_\)+_ ,(9_P 47\/?"']C?\)?_8'_  D7_(A^
M$_"_]H_VC_PB^A?\A7[=]D^P_P"@_9OM-Y]H^4Z\K%9S5CGE;.,#BL17JSJ.
MI#$YAA<&ZTG4H*G553"MXO"0C'FG2H1CSQITHTG!4Y148>_E_#6'GPIA>&\U
MP.$PM"G15&K@\GS#,EAH*ABG7P\Z68)9=F-2I4Y*5?%U)JE.MB)UXU'5ISE*
MI_7M_P %N_VU/A#\*?&7C/\ 9J\3_L>_#?XG_$+XD?LXK_PCW[1&O:CX8@\9
M?#S_ (3"\\=>'M)_L:SU#X6^(=;F_P"$2O\ 3KC7].^P^.=#\R\U"9;;^S)@
M][/_ #"_LIZ5X%UW]J#]G+1/B@-//PWU?XZ_";3/'J:NT*:/)X/O_'F@VOB.
M'69;B>WA@T>;29;N+5;F24+;:>]S<;9#&(G\#HJ\YX@Q&<YLLRKT:2ITZRJ4
M,(XT6H4E453V%6M2H4)XF[34JM:,JCB[7LDC/AG@["<,</RR3"8FO*M6PTJ6
M*S%3Q2E5Q$J,J*Q5##5\7BJ>"<4U*-##5(4E**E;F;9_7;^V7\<_^"IOAG_@
MJ_\ \*O_ &7Y->UOPK?> ;:]^#GPV\16:6?P6\2^'&^%6GW?CO7?$T\]SX>T
M&\U/0O'MMKQTS7=;\007.CZW%H&@Q7D>GZO_ &-JG'^,_C!^TA^S_P#\$??C
MYXFFU.'X1?M#:A^VK\1/"WQ U#X97^D:/+X*\3ZS\3DN_'=EX+U7P-J5UI.B
M3?;K*_T)Y_#VI2BSLKS4;6VN8[G]]%^2WAG_ (+4_P#!1OPK\/;?X=V7QY_M
M"VL=-M='TWQ9XA\$^"/$'CVQTVTLQ8QQ2>*]6T&ZO=9OGB"R3^(/$BZUXEGN
MA]KEUEKDM(?C2[_:P_:!U#X!77[,%_\ $.XO?@A>^-)OB'>^#[OP_P"$KF[N
M_&=S>MJ5QKMUXQFT!_'5Q<7%\[W,T$OB5[.61V,ELP8@_3XKBW >TS+$8?&<
M05JV8X?-_94\1*A&AEM;,(894*6'4<1.IRT94JD7B*=2E[.BJ,*>%E/FG'X7
M ^'>;>QR/!XW+>#\/A\EQG#GUBM@H8J>+SS#9-4Q<\3B,;*>#I4?:8B-:E)8
M.K1K^UQ4L35K8^%/V=.7]A?[+GB:V_:5^ '_  1]^*W[0NHV?C'XBQ?%?XFO
MI/B/Q+8V6IZKXA\5>!_A9^T-I/AV:_U:^_TH:PP\"Z!XSGU)9);S5O&GA/1=
M2N1/J(AN89M"^.O@:[_:<_;C\%>/?B%^V5^T?X=M?"GCCPE\7?V9[_X'0R_"
MGX8>"+_5!IME<>$WT_4+)KS3;[P<^I:3IE]ID9U7XD>'M2N?%]VNJS6!O[7^
M0.3]LS]II_A1\'_@E!\5]6TSX<? +QE'\0O@_I6A:/X6\/:SX%\:0WNOZC!X
MATOQKH6A:=XYN+ZWOO$^N7-M_:?B2^AMY;U3!#&+2R%M],?%O_@L%^WY\;/A
M1K'P<\<_&6V;PKXITF[T#QG>^'/ _@KPGXD\8:%?%1=Z-K&M^'M#T^:STV\@
M$ECJ-KX<BT)-7TRZOM*UC^T--O[RTG[L/QUE\<-2C4IXWZS0IX2I.I*C"M_:
M&)I931P%:%=K'TE&+KTG.-:O3Q<9X>I44L+3K6;\K%^$^<SQV(G1KY6\!C*V
M8T*="&)J8;^Q\#B.(L1G&&JX-/)\1.5186NJ4\-A*V73I8RE0E#'U<,FH_J]
MX:^,OQ!^!7_!O)X1\3_"+QCXB\%>*=4^*NO^%-.\;>%]4OO#7BG2-+O_ -H;
MQ;?7MUI&J:9<1W^E7>I6.DMI=RUI=QS)8ZE>0K<?-EO2?^"A_P"V1^T3\*_V
M0O\ @D[XW\"_$SQ+X>\=?&;P3\+?B%\4O%^DZC/I6L^/=2\.?#+X8:PVD^++
MK3&LY]9\-:WK/Q%\0ZGKGAZ>8:1J%S,KW%E(RQM%_-C=_M;_ +0E]^SAI?[)
M%U\0/-_9[T;79/$VF_#_ /X13P0GV;6Y=<U'Q')>_P#"5Q^&T\;S;M:U;4+S
M[-<>)9;0?:/LZVXM(H8(SXJ_M;_M"?&SP/\ !/X;_$[X@?\ "3>"_P!G70K3
MPU\&]&_X13P1HW_"':)8Z1X<T&ULO[1\/^&M)U;Q#Y6D^$O#]I]I\4WVN7;_
M -G^?).]S=WLUSX]3B^"P$L+AJF8T9KA_)<KH<KA"G2QF7XJ%7%UH\F(;C3J
MT.>G3JQBZT^90J4X0U7T='PWJO-Z>88VCDN*I2XQXHS_ !2J1J5:U?+LXP,Z
M&78::J8)1G6P^*]E7K8>4UAJ3A[6C5JU$D_[B?B-X*TW2?VPOVSOB-\)/#6@
MW/[6%I_P3P^&&L?!VXGTG2;K5;OQ??\ B7]JS0HKVT.H1SQW<M_K'@?X1>'-
M7-U;BW.FZ=HFG7+W-E<RV\7Y:?L)_'S]K/XN_L2?\%)O$W[;/C+X@R>"/A_X
M)U+5_AIXW\=>&[+P_P")O"'Q=T2S^)/B36W\!WDND^';N;Q-X"\?Z1\.+[PQ
MH+ZA##X&\96/AC1O"5IHLTDUK#^#&K_\%*OVW=<^/?AS]IV_^/&K)\;O"O@;
M_A6FE>,=,\)_#S0[:7P#_:NM:X?"NM^$M#\(Z=X)\3Z2=:U_4=6,'B7PYJS?
MVD-.O=_VG1-%ET_=_:7_ ."H?[:W[6?@4_#'XP?%K[5\.[E](N-9\'^%O#'A
MGP=I/B6^T6>&]L;SQ-)H&EV>I:VD>IVUIK*Z/>W[^';?6;*PU2RT:UO-/L9;
M?U<3QME=6K4Q5!9MAY4GG*IY?&-&&"S-YI&I[*MF/L\7[E3#SJ/VB5/$N4:5
M"5.<9)Q7S^#\+L^H8>E@,4^'<7'$+AAULXJ3Q57-,CCD$Z'UC#9*JV7M5:.,
MIT%[)RK8&,)8C%PK4IPE&3_J"_:0^(_Q9E_:8_X(SZ#8>,?'$O@GXB63>)/B
MIIEIJVKR>'/%^J:3H_PGOM"UKQK!#*UAJUU8:_JZW.FWVK"5X-4U))+>1;F[
M0R>$?!K]K_\ :$UW_@O+\2_@1J7Q*\27/P7N9?B#X&M?A=-J=Y+X&T>R\%_"
MT^*=-UC1O#LLSZ;IOB:[U_P\-0U37[:!-3OO[6U>TEN#8W0M8_P<T/\ X*Z_
MMZ^&_A-X!^#6B_&#2[7PI\,O^$)@\&7<WPS^&>I^(-+TWX<'1'\#Z2^IZMX3
MOTOK7P_+X?TV2.\O[6XUK4Q'-;Z[JNJV=S/;/\XZ!^V5^TCX7_:/U#]KC0OB
M/]A_:$U2_P!<U._^(/\ PB'@.Y\^^\2:'<^&]:G_ .$4O/"]QX(B^VZ+=W%E
MY</AJ.&V\S[3:1P7:).N>*XVP<L5@\1AJF;12SG+,RQM-PI4TL+A<#2P>)P5
M)QQLO;QJ2I2K1C4C1I3E6GSJ+BISVR_PMS*& S+!XZAP]*?^K.?Y'E=:-2O6
M<L=F.:ULRP.:8B,\LA]4E1A6AAISHRQ.(I0PU+V;G&;IT_ZW_'^I?"GX _\
M!/#7]2\,?&+XL_LW>#-:_; _: 7XA?$W]FKX?:7JWC.PUF;X^?&/26\/:K'8
MR6TWA#0[.70/"W@RT\4V,]A>KI?AOPAX966WL->6RE\[\<>,/"?CK_@I%_P2
M)UG_ (1?XN6?Q/L?AY\4M$\4_$3XO?#G_A M>^+'A&#X+W=_X2\0210WUQ8I
M?0ZYJ'CC6M7T&&VM+OP_J/C&XM+ZVM"T%NO\Y7P#_P""H7[:O[-^N?$+6?AU
M\65>V^*WC76_B/X^\,^)?"WA?7O">M>.O$ES=7>N>)K+0Y]*B@\*ZAJMS=&3
M4E\&OX=L]12UTRUU"UNK/2-+M[/S_P 1_M\_M:>*OVD?#_[6VN?%R^OOCSX1
MM&T[PAXNN/#G@ZYT[PKI+:3J^B?V/H/@N\\/W/@BQTL6&O:T6LU\.O'/J6JZ
MAKUSY^O7MSJ<M5N-<LG0P*A0Q4'1KY(JV%5"#A2HY3CJ>*J5L/5ECW3=2O"D
ME3I1PN'G&=2M&MBJM-Q;6&\+\]I8G-75Q>7U5B,+Q0\-CWBZD:U?$\1935R^
MEAL90AE$:ZH82I6E*M7GF&,ISI4L+/"Y?0JPE&/](-I\=/V_OVD/^"N7Q]_9
M]^#?[1/AWX3?##X'ROK\NE^)_AYX4^(6DZ#X2\(V7ACPC?S^%O#6H:.FM:KX
MQ\4ZQXXNCJ5['XJ\-SQ:5K>KVH\10VFGZ%H5QZ9X6\>_#KXH_P#!,?\ X*.R
M>!OC+^UA^T?H&@>"?BW8ZA\3/VKK6S-CJ7C'3_AW-JU]!\(+&YL++7-!\*Z'
M=C3+Z3PWK]G9WOAC6Y+=K&SL5D05_+-X%_;G_:?^'?[2FM?M;^&_B3)!\<_%
M,^IR>,/$K^'O#,>E>+K76HK2'6-)U_PC9:/9>%;C2+];"QF-C;:1:)9:A8:?
MK&EM8:SI]CJ%M[S\0_\ @K__ ,%!?B=9^/\ 1/$WQQM7\(?$OPKJ'@CQ5X%A
M^&?PJG\(3^%-5M]8M-3TJRTK5O!>J/82ZC:Z]J5MJ.MV]TOB/48&LHK_ %BY
M32=)%CGA^,LO4,?4Q=3-ZU;%8C.U&%2^)IK"YC3<,'"E"IF5+#8..'O:O2IX
M:LYVA[.M&$.5WC?#+.95,IHY?1X<PV%P&#X7YZM&V!K2Q^3UH5,RJ5YT,CKX
MW,9XQQYL)B*V.PL:5ZKK8:=6JZD?W&_:P^+7[4?P:_X(Z?\ !/WQ7^S'K?B_
MPM=S^%/@'I/C[Q-X!LKJ[\4:=H<_PR-WH-E)/:Z9?R:7X:UCQ58Z59:Q>>?8
MB_U$^'_#$[WMEXBO--N_L'Q)^TQK'P7^)/\ P2'\7_'UY-'^-/[1WPOU3X)_
M&R.\TFST75)-1\?>#_A%K'VCQ%H=K9Z5'HNI:+\=T\(V\EM]CM-*\(VOB7Q_
M9V-I;17,P'Y6_&?_ (*D7?P)_8<_X)Y:5^R#\?\ PZOQ@\ ?#WPMX5^,W@2V
ML++Q':V^GV/P[\/6]QHOB_0=?TN?3BUMKNG/:0ZAITD&M:=)]LCTO5+-+RZ,
M_P";/PG\4S?\%*OVJY_%7[=G[:EC\$+O0_!-KJ6A?$OQ)H?AG2](>W\*^)](
M:Q^&GA%;;6_ GACP%?36FO>(/$FD:M':Z@K:K8ZGJ%[INK:QJ,LUSZF(XCIX
M7%T</EV*Q&,QV(PG#E*CAJN(PU+)\.\''#8NM4CB:F*4(U:L8RPM2$J5)PG.
MLY59N4:9X.!X*KX[+L3CLZP&#RS*<%F'&N(Q6-HX+'U^),;#,WC,NPU*>!HX
M!U9X?#RG#'T:T*^(]K3IX54Z%-0G6/V._:E^$FC?\$H_V OVTM$\.'1M.\=?
MMN?M&>+?AY\.5T;;-<Z'^S_J<FL#0_#.II=%Y)X]"^& ^(%BU];8;2]:^(NE
M_O%N$3?_ "95^S?_  6N_;G\'?MB?M#>%?#OPC\0_P#"3_!?X&^&KS0?#7B&
M*WFAL?%7C3Q3<65_X[\3:6UW:V=_+I+0Z5X7\,V3W4'DW$_AB_UC3'ET[68)
MYOQDKXCB_&8.OFSPF6N']F973^I8+V4E*E+]Y.OBJL''W)>TQ5:M:<;QG3A3
MDGR\J7ZKX<9;F6$X>CF.>*I_;N?5O[4S-UH2A7@O8TL)@,/553]Y!T,OPV&Y
MJ52TJ-:I6A)<_,V4445\L??!1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 5_9S_P1#_Y,2T#_ +*7\1O_ $XV=?QC5_9S_P $0_\ DQ+0/^RE_$;_
M -.-G7HY9_O,O^O4O_2H'YWXG?\ )-0_[&6%_P#36)/UWHHHKWS^>PKVKX:?
M\@>^_P"PD_\ Z2VU>*U[5\-/^0/??]A)_P#TEMJ^NX(_Y']'_L'Q/_IL\#B7
M_D55?^OM#_TXCRO7_P#D.ZU_V%M1_P#2R:LFM;7_ /D.ZU_V%M1_]+)JR:^:
MQO\ OF+_ .PFO_Z=F>QA?]VP_P#UXH_^FXA2$ @@@$$$$$9!!X((/!!'44M%
M<QN>2WGP"^!6H7=U?W_P5^$M]?7MQ/>7M[>?#CP=<W=W=W,K37-U=7,VC/-<
M7%Q,[RSSRN\LLKM)(S,Q)K_\,[_L_P#_ $0SX._^&R\%?_*2O8J*OVM3_GY/
M_P #EY>?DON0K+LON1X[_P ,[_L__P#1#/@[_P"&R\%?_*2C_AG?]G__ *(9
M\'?_  V7@K_Y25[%11[6K_S\J?\ @<O\_)?<%EV7W(\=_P"&=_V?_P#HAGP=
M_P##9>"O_E)1_P ,[_L__P#1#/@[_P"&R\%?_*2O8J*/:U?^?E3_ ,#E_GY+
M[@LNR^Y'CO\ PSO^S_\ ]$,^#O\ X;+P5_\ *2C_ (9W_9__ .B&?!W_ ,-E
MX*_^4E>Q44>UJ_\ /RI_X'+_ #\E]P679?<CQW_AG?\ 9_\ ^B&?!W_PV7@K
M_P"4E'_#._[/_P#T0SX._P#ALO!7_P I*]BHH]K5_P"?E3_P.7^?DON"R[+[
MD>._\,[_ +/_ /T0SX._^&R\%?\ RDKUNUM;6QMX;2RMH+.TMT$5O:VL,=O;
MP1K]V.&&)4CB1>R(JJ.PJ>BE*<Y6YI2E;;FDW;TN_)?<.R6R2"BBBI ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OIO0O\
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ML75PT,+3=7*E+&TE4K0=2C3JN"E*E4C#X"HK[\\9_L7>!]&\._M 1>#OVG/
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M:9^T7^T%\(-;^-'PZ\!^'/ .E^._AOH_A^V\,>*_%7AGP[\5?BKIWQ0TS5_
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M,=_T!XO_ ,)ZW_R'FOO#ZUAO^@BA_P"#J?\ \D8U%;/_  CNO?\ 0&U/_P
MKC_XW1_PCNO?] ;4_P#P"N/_ (W1]0QW_0'B_P#PGK?_ "'FOO#ZUAO^@BA_
MX.I__)&-16S_ ,([KP_Y@VI_^ -R?Y1TW_A']=_Z NJ_^"^[_P#C5'U''?\
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M^0\T+ZUAO^@BA_X-I_\ R1C45L_\([KW_0&U/_P"N/\ XW1_PCNO?] ;4_\
MP"N/_C='U#'?] >+_P#">M_\AYK[P^M8;_H(H?\ @ZG_ /)&-16S_P ([KW_
M $!M3_\  *X_^-T?\([KW_0&U/\ \ KC_P"-T?4,=_T!XO\ \)ZW_P AYK[P
M^M8;_H(H?^#J?_R1C45L_P#".Z]_T!M3_P# *X_^-T?\([KW_0&U/_P"N/\
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MRJ5YTI8FO4E*5:K*,:4*11117$>J%%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_J(_\I?_ '0^B_XBW_U3_P#YE?\ \&G^:?17^EA11_9/_41_Y2_^Z!_Q%O\
MZI__ ,RO_P"#3_-/HK_2PHH_LG_J(_\ *7_W0/\ B+?_ %3_ /YE?_P:?YI]
M%?Z6%%']D_\ 41_Y2_\ N@?\1;_ZI_\ \RO_ .#3_-/HK_2PHH_LG_J(_P#*
M7_W0/^(M_P#5/_\ F5__  :?YI]%?Z6%%']D_P#41_Y2_P#N@?\ $6_^J?\
M_,K_ /@T_P T^BO]+"BC^R?^HC_RE_\ = _XBW_U3_\ YE?_ ,&G^:?17^EA
M11_9/_41_P"4O_N@?\1;_P"J?_\ ,K_^#3_-/HK_ $L**/[)_P"HC_RE_P#=
M _XBW_U3_P#YE?\ \&G^:?17^EA11_9/_41_Y2_^Z!_Q%O\ ZI__ ,RO_P"#
M3_-/HK_2PHH_LG_J(_\ *7_W0/\ B+?_ %3_ /YE?_P:?YI]%?Z6%%']D_\
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@\SK^UK6A&*<:5&+;A3B][-_%*32<YM)R:2245&*__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>ny20077604x1_figure12x1.jpg
<TEXT>
begin 644 ny20077604x1_figure12x1.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
M                                                          !8
M65H@        ]M8  0    #3+71E>'0     0V]P>7)I9VAT($AE=VQE='0@
M4&%C:V%R9"P@,C P- !S9C,R       !#$0   7?___S)@  !Y0  /V/___[
MH?___:(   /;  # =?_; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! ?_  !$( ;X$T@,!(@ "$0$#$0'_Q  ?   !!0$!
M 0$! 0           0(#! 4&!P@)"@O_Q "U$  " 0,# @0#!04$!    7T!
M @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F
M)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
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M$KPKI.C6.DQ>'A;:9%XWT>73+R/Q'?I:>(+..Y\37,MN\E]4_;!_:!TGX_\
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M'Q/KURTD*)9Z>C16<<IU#5KG3M)M[S4+;\]?^"2?_!2+XE_\%$8?VBM4\?>
M_ W@/3?A9X@\"6O@^R\('7YKV?2?&:>.+AHO$M]K6KZA!J.HV$'AO3HA>:78
M:);3S2WLQL(TE@AM_L#]I?\ 8)_9O_:]^(/PA\?_ +0'AC5/'?\ PI:W\41>
M%O!D^M3:?X(U.X\57GAJ^NKSQ7IFG16VIZ_]AG\+6"VFES:S#X>N[>XO[77M
M&UJVN$BA_#__ (-JHHH(OVZ8((XX88?''P@BAAB18XHHHU^+J1QQQH D<<:
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MN/B3\*?&_P ,->^"'[3OP=\/:WKGC;X9ZX+M])U"#PSJA\/>(I-%N-0MM/\
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M:QW-F=0CT/Q-I>D:M/I3W=M!JT%G+IMQ-';W<K#\N_V@/VC/B9X)_8B\8?\
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M^R/%!8:L]P+A#&;?[W_X*O?\HY_VN/\ LD^H?^G72J_D3_9'\;:5^PM\1/\
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MO@Q^R=X'^!_[0/["W[5W[1/B#]LJWO/#/_"\?"WB'P%XSL?AWJEMJOAFYO\
MQC'ILVL_#OP]9Z]X<TWQ38Z7H$OA_P 5:QXJ_P"$BTN\AUN"6PO-'B+OEO\
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M1T0>)M3\0:W'_P 3:]M466XO?8?V]/\ @EA\5_BA^T?X6_;?_8;^,&@_ ?\
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M_M2>(OAEXG\)_M8+X1@T:Y^%NK^)]<O?#$GAB3QKJ&G>(;I/&'@?PA;VVO\
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M7T:[_H%%%%(04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MA^'8=,:'4M/U#_BUWPNS<W&I%;F+_0-4Q$#_ *7#_J3]ZT44A!1110 4444
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MOC_@FO\ '3]J;]@_]D[]E[X?>*_A-H_C_P"!/_"J?^$NU?QEKOC#3_!^H_\
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M9'['OQ*_9]^&.K^#]"\9^,=3\!7NF:GX\U#6M,\,01>%O'GAWQ1J"W][X?\
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MKND:]HXT?4/#EAHLEK>Z9?6%P^H_N)13YG^?SONGY#YG^?SONGY'X!?L[_\
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MC:=X(U2*0Z_J^AI+?W%B)+QHY[JYM?UVHHI7>B[;?,5WHNVWS"BBBD(****
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M\3^'/#_BWPI\)M<^)D.@R> ]%^(/BOP[XIT"^\.^'=2\06USJ=UK&D:%"?\
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M@6__ ,9KR#X0_%KP)\=/AUX:^*OPTU:?6_!?BR'4)-(O[O2M5T.]\W2-6O\
M0-7L;_1];L]/U;3=0TK6]*U+2M0L[ZS@F@O+*>,JRA7;TFH>)Q2;3KXA--II
MU:B::T::<KIIZ-/8M8?#-)JA0::NFJ=-II[-/EU3/6****^P/E0HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *3<HZD?F*6OR<_X+(_&C]I3]
MFG]B?QW^T;^S-\4/#OPU\5?!OQ'X0\1>)K;Q+\--+^)%KX]\':YX@T_P->^#
M;4:OJNG6WA*\DU3Q5I/B)/%$=IK=Q%!H$VB)IP766OK >B;[ E=I=VEKY_>?
MK&"#R#D>HHJ&W7;!"IYQ&HSQS@=> !SUX '/'%34;@%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9>M?\@RY_[8_^
ME$5:E9>M?\@RY_[8_P#I1%7/B_\ =,5_V#UO_3<C;#_[Q0_Z_4O_ $N)P=?F
MKJW_  3^OM3\7?&'1Y/B;HLG[/7QN_:W^%7[8_BOX<7G@?6+[Q_I?Q"^&X^&
M6O:IX7T#XE7WQ!N]-MO!OCSXC?!WP/XIU.%/ MM>^'_#]WXY\%:'(L?B;2M>
M\*?I517Q,9RA=Q=KVZ)[-235T[--)IJS7>S9]1*$9VYE>U[?---/NFFTT]'V
MT1^<?BC]@23QIXV^.)\2?$G3;WX0_'G]J?X$?M4^+/!4?@5T\5IK7P(\+_";
M3=)^'D7BVX\57FDOX6\1>+/@EX#\2ZSK">$;;65\/R>*?!%O")M<LO%^A[_@
M_P#8CNO#7[7NK_M;-\2?[+\2:]J_C+_A+=*\ Z)JO@>T^+/@74O#[:!\-? W
MQOT>V\5ZAX)^(VI?!YY[S5O"OQ2;PAHOQ#NH(O"_A.^U,>'?".S7_OVBJ]M4
MLUS:./(URQ^'EC&VW50BF]WRIMW29/LJ=T^752YD[N][MI[]&W9;*[25FSX;
M_9K_ &4?'O[/7B?Q!I"_%;P=XA^!-GX^^+7Q ^%G@:P^$MSX>^)GA2;XN>-/
M$?C.Y\&>+?BQ-\1==L?&W@'P1<^,/$ECX/TN#X?>&M;^SR>&QJGB&YMO"L%C
MJ6IX)_8ZT>T_9]_:(_9Q^+'B73OB7X%_:%^)/[4OC'6#I7A&;P7=:1X:_:B^
M(GC;XCZUX8 OO%7C=+_6O".J>/=7M=#\8VQT8R)9:+>KX>L=1L9;F[^T**'5
MFVW?5N+;2BG>-VG=*Z=VVVMV];C5."5DM$G%)MM<KLFK-[6226RMI8_&KXU?
M\$MOB1\7/@9X4^"-]^T]9Z_HZ?LU?%?X3?$D?%GX57GQ'T3Q7\<OBOKNC>,-
M7_:H\-Z!:?$CPC%X:^*EAXH@\11>%[CQ#=>.K?X?>&]>;2O *>'YFUJ\U[[C
M\9? /XD^)OCS^RU\=[/XH>$;#6/@C\/OB]\-OB9I-W\,]3OK3XE:-\9;GX):
MUXCU#P=)!\1]/;X;ZG::]\$M/_LQ=57XB6D&D^)+Z"9+F[TNWN;[ZRKQ+XZ_
M$[Q!\*O"^DZ_X?\ #=EXFFO_ !3X?\/7-I>ZB=-2WCU[4(M.BNDE"/YC1SS)
ME. %)8\#DE6J-*[3Y5.WNP_Y>*T^B^)::O3=6W$J-.[LFN9T[^]+_EVTX;-O
MW6D]-]4[WL?GA\//^"97C_X)_M _%[]I7X3?M!>$$\?_ !E\;?M9ZKXDTOQU
M\&/$.O\ A*+P/^TKKWPO\9>&?#*Z/I_QLTJWN?$'PB\:?#3^U&\6"&SC^(N@
M^)]8\+ZCH?AA;?3-7L_7F_X)\6GA[1/V<O!OPS^)UOX8\$?L[_L<_'O]D/3=
M-\3> Y_&&O\ B;3?C9X;^$6DQ^/K[7M.\=>#;'3]8T#6O@YH6O:GH\/AVZLO
M$L>L^(-,M+OPN9M-U#3/T6M9)Y((6N8EAG:&)YHE;>L<KH#)&K\;U1\J' &X
M ''-6*IUZK>LE=)J_+&]K2C9Z:V4I)-ZI-V:T$J-)*RCHW?>6]XRNKNZNX1;
MM:]E>YXM^S=\(I?V?OV>/@3\!I?$<?C!_@G\'?AI\)!XLCT5O#B^)8OAQX-T
M;P=#KQT!M7U\Z/)JT.C1WTNFC6]46TEG>%+ZX1%D/O>D?\A*U_WG_P#14E9M
M:6D?\A*U_P!Y_P#T5)589N6*H-[O$4F]EJZD6]%HM>V@JR2P]5+1*C-)>2@T
MCOJ***^X/E0HHHH **** "BBB@ HHKQS]H'P9\6/B%\&O'_@OX&?%]?@)\6?
M$&C+9>"?B\W@G1/B,O@C5!?6=Q+J1\&>(Y8-&UO[3I\-YI?EWDJ_8S?_ -HV
MX:ZLX%8#\/Z\CV.BOP0_X-U/CO\ 'K]H7]B+XH^-/VB?B]XP^-7CG3/VN/B]
MX6L?%?C6^?4-4L_#]AX6^&6IQ:%9RNS?9M%MM=UG7]1TG2H=ECHEMJ@T;2X+
M72K"RM8?WOH6J3[CDN5M=G8****!!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %,D_U<G^XW_H)I],D_P!7)_N-_P"@F@<=
MUZK\SRJOECXJ_ 'Q;XD^-7A;X\_#'QWX=\'>,])^#_Q$^"7B'3_&?@W6/'GA
MKQ'X4\::SX9\4Z#?QZ78>.O!\.EZOX,\5>&O[0W^5?KXGT?5]4\/7TNG+_9^
MIV'U/17Q,9.+O%ZV:U2:::LTTTT]'U6^JU29]=**DK/:Z>[3NFFG=--6:_38
M^&=/_8UG\ 3?L]-\'?']CX;@_9^_9S^(/[..DP^,_"$OC%]7TGQQ;?#=K;QM
M=OIWB7PG"-?T?6?AM8ZKJ.DFU;2?$::OJ5C%)X=5+:X7B?%__!/30-5\)_ G
MP#X.\>WO@G0OV=OAWX?\&_"GQEI6F76G?&CP-XETN\LH]9^(/AWXD^&M<\.A
MIO&7AVUGT?QGX!US0-8\ >)]2NM.\0ZAHX?PW::7J'Z.45:KU4T^=W3;O:-[
MMR;;=KOXY[WTE);-HATJ;T<=+)6N^G+:VNEN2.W6*>Y\B^+OV<?&-Y\?M;^,
M7@+XC>%_"N@_$?P;X#\%_%WPEXA^&MQXPUC4XOA[J_BJZTGQ5\./%L?CGP[#
MX"\97F@>+;[PK>:AJ/ASQAI(MM/T#5FT2YOM'CBG]#^'GP9N_!GQ#_:0\8:M
MXCTGQ/H?[0'C?PMXS7PLWA.73Y/#)T'X1>!/A#J&CZCJMSXEUFS\66.L:7X
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K+UK_D&7/\
MVQ_]*(JU*R]:_P"09<_]L?\ THBKGQ?^Z8K_ +!ZW_IN1MA_]XH?]?J7_I<3
M@Z***^'/J@HHHH **** "OF+]K#_ ))QHG_93?AG_P"I=IU?3M?,7[6'_).-
M$_[*;\,__4NTZIG\+^7YH<=UZK\SZ=HHHJA!6EI'_(2M?]Y__14E9M:6D?\
M(2M?]Y__ $5)6^%_WG#_ /7^C_Z<B95_X%;_ *]5/_2)'?4445]R?*!1110
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M9 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MI^-UU;1O!D_BG4=$O6M?5I?V2/CQ^VWKW[</QG^"?[3'[3O[ ^@_'_\ :'^
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M:)W!I-Z+_+[V]%\S])J*_#[1_P#@H%_P54\ RC7/VC?^",?CR+X;V[R7^O\
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M+G_MC_Z415J5EZU_R#+G_MC_ .E$5<^+_P!TQ7_8/6_]-R-L/_O%#_K]2_\
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MA1113("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[*D[3^;"(Y#+'Y>Z/8^\#:V-BOY!_P#@FC\+?^"</AG]LCX 7OP8_P""2/\
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M>+;3Q[XJ\6^$;?X8SQ_#;1!?Z'K-YXBUV/2AHS:3J/SM_P %1OVAO#_[4O\
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M%J'B?2]+U35_"D7B3X?>'[34;.TB%Q>V<^J:1%?JZ_/\-_S'9]NWX[:;Z_\
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MN!8VT&@32W'C[Q )IXDMH[G7+-1<:8]RZ1^7IGAA+6XS<7&GW>JZS:RA3M?
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M!_&SX4_ OXO_ ++/CS]G'QS\6KC]H_PYX=?5?&7A_P ?Z%:?%']ESQ7?:/\
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M_4.^$M?T?41V7HOR"I\<O4****9 4444 %%%% !1110 4444 %%%% !1110
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M^R)_P6<_9>_:Y^)OA7X,6'@OX[_!+XI^._%OQF\#>#_!7QR^'<?AG4M2\6_
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MW7Q/^)^H_P#"Q?CCXCW7FL^*=4)NX=&EN?FEL-"6?<8%C!\LW:A'(411"*$
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MKT:CZZ*P44451 4444 ?B?\ MR_\IC_^"%7_ 'DZ_P#66O"-?MA7XG_MR_\
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M4 %%%% !1110 4444 %%%% #))%C7<V<9P3QQP3DY(&./J3@ $FF13I-G8&
M&>6VX.#CC#$D>^,>^>*KZE$\UG-#&R))*CQ([AV1&DC=%=DCDB=U1F#%%EC+
M ;0Z$AA\H_L8_P#"3W'POU>_\5ZS9:UJ$WQ*^*&G03V5KK-HD-EX:\;ZMX4A
MA9=:\1>)+A@[:%)<P+%=P16UG/;6317%Q;3ZC>\=2MB8XW#4*>'HSPM6CBJF
M(Q$L3*%:C.C+#QH4Z6&6&G'$1K>UJNI4EB:'L%2C:%9U4H=$*5&6&KU9UJD:
M].I0A1HQH1E3JPJ*JZLZE=UX2I.E[./)"-"K[5U'>5)0O+Z\HHHKL.<****
M/E@_\G?0_P#9N5W_ .K0M:^D]:_Y!ES_ -L?_2B*OE&X\2:#;?MCI93:SI<=
M[%^SM>1264FH6D=W&X^(EOJ15[9YEF4C3T:^(* BT4W) @#2#R+]HC_@H_\
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MKL7P,^"W_!(OX5_\%)/V:/&GP_\ #&O?$&_^+G[1G[/?P^\'MX]L/'.N7Z>
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MGG[$?Q(_X)G_ /!/']N#]AWX7?"+X=?M ^%_^"@_BC]H^Q^)7AOP-XR_M;P
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M=$TN*^@O[>;2[Z6YO+G4;2XU1[AK"ZTNWM/ONOE+]B'_ )-=^%O_ %R\7_\
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M /\ R<7\?O\ L#_"O_U'[RO"XO\ ^1UX:_\ 9<XC_P!8'CD];AO_ )%?'/\
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M'%\1^%=1U7PQXLT66TU72-=\,>+-!OI+#Q%X9UK2-4^S:;=7%SIEE^3GA/\
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M]"_L'Q)J_P /O%CZ;KNAWEWI^K7NK:)/IM_;66SDC_P3H^-L6M0?M'VWQO\
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M.2J*"?7 ZU)2+T'T'\J6G'9>B_(D****8!1110 4444 %%%% !1110 4444
M%%%% $4TR01/-(0J1C+,2% &0,DL0 !GDD@"L#P[XO\ #7BVWDO/#&NZ-X@L
MH9VM9;W1-5L-5M8[E(XY6MWGL)[B)9UCECD:(N) CJY4*RD[EW&LMM-&ZJR.
MA#*PW*5[@CN,=N,],CK7R;^QIX<\/^'/AGXGM_#^B:5HEO)\;_V@(F@TJPMM
M/A:+3/C%XST;38VBM8XD*V&D:;I^F6@(*V]A96MI"L<$$:+E)U/:TU&4%3:G
M[2+A)U&TERN$U4C&"3OS)TYN5U9PL[Z15/V=1R4O:)P<&I)02;:DI1<6Y-WC
MRM2CRV=U*^GUU1116IF07'W!_OK_ %KY?_8__P"22WW_ &5?X[_^KI\=5]07
M'W!_OK_6OE_]C_\ Y)+??]E7^.__ *NGQU7//_>J'_7G$_\ I>&-H_P*O_7R
MC_Z36/J>BL?7->TCPYI\VJZWJ-CI>G6RE[F]U&\M[&U@C'+22W%U)%#&BCJ6
M<=@,DU\&_&/]OSP%X1TW4W\!6$GBQ]+7_3O$]_*^C^"=,9V*1-/?SHEUJ)DE
M0K;P6\5M#J)*1V.H2R2*!\YQ-QOPOPA"C_;N:T<-BL6^3 970A6QV=9G4;:C
M2RS)\#3Q&98Z<I+E_P!FPU2$'_$E!)M>YD/"F?\ $LZO]D9=5KX?#KFQF859
M4L)E>!@K.53'9GBYT,#A(QB^;]_B(2DE[D9/0^_[V^M=/@DNKV>*VMH4>2:X
MGD2&&&*,;GDEEE98XT0<LSLJ@=37YY_'_P#X*-_!GX67">&/!(O_ (N?$:ZE
M^Q:5X6\'.9K2?4;DB*TAN=7@CN0^^7 CBTVVOYIVS%&H<@C\YK+Q/^V+_P %
M ];FTWP3>ZAX?^%]M>F'5?'6IPWF@>"--4/^^@T/34_>:YJ4$07R8D34]6BE
M>(7UWH\#B\7]7OV9OV&_A!^S7;1:KI-HWC'XC7$6=6^(_B>!+C6Y995/VB/1
M86>>#P]8R,S#R;-I+V>,^7J&HWY <<^3YCQ-Q#RXVOE-7A/)YM2H87,_8UN*
M,93TE&IB<)2G6P&0TYKE?U>M5S/,9PG.%>GE&)I<IOFF R')>;"T\QI\1YG&
M\:U? >UI9!A9[2A0Q52-+%YQ4CJO;4J>!P4)J$Z4\QH3N?A5I_[)O[3WQU_:
M?ME^*'A_5O"&J?$DM\3O%]W?Z[8I>Z%\.-3UPZ?J442)>W5W#<6EO)_8&FZ'
M/;_:(F%I#=VD-FLSP_O_ /"W]DGX"_ '1G_X5W\/=$LM5BCMT?Q3JD7]M^*[
MAA-$'D?7-3$]W:B0@,]MIS6=EN *6R  #.VK_P -JQ#:N!^S,Y P, CXJ)@X
MQV[5]2ZU_P @RY_[8_\ I1%7TE6,OJN-E*;E:E7IQ3LE&-.$^7S<O>]Z3;;L
MK)=?%]U8C!J*MSO#59-N[<JOLY271*":O&*^&[U>EN!V(. B@ 8 VCIG..G3
M))QZ\TX  8 P!P .@'I117QQ]"?+>@?\G=^-O^R*Z!_ZD]?4E?+>@?\ )W?C
M;_LBN@?^I/7U)26\O7]$;5MZ?_7FE_Z0@KYD_:@_:K^%_P"RKX#D\9>/]2:7
M4[P2VOA+P5IIBF\3^,M8"J8M.TFR+CRX$+1G4-5N3'8:9#-%+/*TLMO;7'GW
M[77[:?@[]FC2++0M,L9O'OQH\6[;'P!\+]#+7>L:IJ%TWD6=YJ45J)9[#2EN
M"JM(T1N+L[H;.*1O,>/Y^_9A_8K\:>+/'<?[5O[:%Y!XY^-VI"&]\'^!KG$_
MA/X3:>"UQIEI::86FLVU?3BY>V@7S+?2K@G4)9=0UUVOX/%QF95JF(EEF4JG
M5QZ2^LXBHN;"99"3MSXAK^)B&N9T<)'WI-<]1QIQE?\ 6^$> <GP62X?Q"\3
MZV+RS@N<ZJR#(<%.-#B;Q$QN':Y\#D:J1D\NR*C4M#.>*<13EAL+!O"Y=3QN
M93C3H\%\%/V7?BS^V/X_TG]J+]MZT;3_  O82)?_  8_9M=K@:'X=TJ603V6
MJ>+;&?8UQ<7*);W%S:W\:ZEKTZQOK266BVMEX>;[@_;!N=*T3X5^&+=Y+'3+
M5/BA\+HK2$M;V=O'#9^*M.D:.",F*-8[>UB9MD:[8H4/"HO'UR !T &>N !G
M\J^6OVO$1_ACH.]%;'Q4^%^-RAL9\7Z<#C(.,@D'U!(Z&NO 9;# TYQP]3VN
M+KSC5Q..Q475K8JLK)SK<DZ;Y5%.-*E"<84DTHW?,Y?/<8^(&:\<YKE]3'4,
M-E>09+2^H<,\)Y+%X3(^&LK4N:&#RS#S]KS5JLE&MF.98KV^89KBN?$X[$5*
MDH^S^H89H[B))H6#Q2HLD<BD,KHXW(ZLI(964@JP."#D&I:0 * % 4#H   /
MH!Q2UZ':]KV5[:*_5V;=K]KL_/\ ^OZV"M+2/^0E:_[S_P#HJ2LVM+2/^0E:
M_P"\_P#Z*DK?"_[SA_\ K_1_].1,J_\  K?]>JG_ *1([ZBBBON3Y0_GA_X+
M*?!/]B73/B-X?_:V^*7_  5&^)G_  3)_:I\*?!O2_ /@CQA\+OB[!::EXV^
M'/ASQQXK\5Z/:>(?V;]((^(7QN\.Z;XJ\6^+!<Z3X/N=/AU(7D^G:W)?V=DE
MK%\3?\$<?^"K_P#P4Y_:5_:KT;X#>)_!NH?MN?L12ZOXVTE?^"CDO[,_B_\
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MZ_\ 66O"-?MA7XG_ +<O_*8__@A5_P!Y.O\ UEKPC7[84EO+U_1%2VA_A?\
MZ7(****9(4444 %%%% !1110 4444 %%>:?&&^\4:=\-O%5YX,\7>#? GB6*
MRMUTSQ=X_9$\)Z&\U_:03WFIR2DP1/\ 999XM.DNH;NT75)+(W5C>V_F6LOX
MIZ[^V=^T3H7C#5O#+_M0?#;5;#2=*NKG_A*M"^'4>I^&]1U>UD9?^$?TF:'X
M:K?7M]<[<6NJBV3PK*"KC7$C;SC,9TYU)T8U*;K4X0JSI<Z=2%*K*I"E4E!7
ME&%25&K&G-I1G*E446W"5G*,XPC5E3FJ4YSIPJ<K]G*I34)5(1F_=<X1JTI3
MBFW&-2#:2G&_[[UXQ\7OV@OA)\#=.-[\1?%^GZ5>2P-/I_AVU8ZCXHU9<2B,
MZ?H-IYE\T$TT+6PU*Z2UTB"<JEYJ-L#N'XF>,?\ @I%\?_$7@O2_"FD76C>&
M=6CL9+3Q#X[TK3(H?$FORM)<HMQ96LCW&D>%VDL9;>*[;2[:6\_M*WDU/2;_
M $6&>/3+7Y,TOPIK?C?5+CQ#XV\375DNHW3WFJZ[K3WOB+Q3JTK2P"[EM["6
MX%YJ&IO%,;B";Q!J>A:;?>5)&-;248KRL]XAX?X6P,\SXESK+,BR^%T\5FF-
MP^"I2FE=4Z4J\X>VK2T5.A252M4DU&$)2:3]#*,FSGB#%QP&195C\VQD[-8?
M 86MBJD8MVYZBHPE[*E'[=6HX4H).4YJ*;7W-\<_^"F'Q'\:?;="^#VF_P#"
MM?#LOFP?\)!=_9M2\=7]NWFQ[XY,3:1X9\Z"1=\6GIJ>IV=Q$L]CXCB/RCPW
MP1^R5\:_BEIVN?%KXE7=]X!\"6UC?>*O$WQ&^(JZMJ&OZIIUK;?VA?:EI'AY
MVD\4>*;Z>S_TFPEN/L-CK1Q!8ZO-=,D+=)X*\8^"OA&D,_PP^'VD7/BZ!<K\
M3?B/#;^+/$MK=H\4D.H^%?#C)'X0\'2PR1E[<-9>)]6@662&7Q%>1E0.\LO"
M?[2W[2=['J,EMXV\;VLEQ--!JVMW4EAX1L9'<+<_V9<:E+8>&[(1ALR6&BJD
MJI\L5FQ*H?YKS[Z6?"CQW]B^&W#'$GB3G4WRT:>68+%8#!5;24).G.I@\7FU
M;DE):QR94)JW+B%&2FOW3*/HY<0K"?VKQUG^1\#97%7J3Q^*P^+Q5/3F2J1A
MBL/EM+GBFK2S-U8N_-0;BXOY"\4S? ?3?&7A2/P5I_COQ+X*T>>W'C"Y\4:I
M8Z-JGC58;F&6\?2K72M*E/@^RO8Q<6EK"UUKU_!:FWN9KA;T2H?NJY_;M\:Z
MCX8L?"_P>T#P_P#"?P9H=K;:+H]EIEJVM:SI]C96T<2V0U368?L$BF)D<W<&
MAV^H&1FFDO7N6:4\UXQ_93^)G@CQO\/O 6K7GA6XU?XDS36^A76G:I?S:;;3
MVLENE['JDUSI-I=0&S2Z@FE:UL[R.6-BMH]Q*K1C];O@U^S=\./A%HFBI;^'
M]&UGQG96\<FI>-;_ $Z*ZU:XU1U;[5/I<UX+B31;,&1K:UM=.:W_ -$CB^UO
M<W;3W,W@4,\\8?&JIG/"V!PG$_@_/A_%4*&?9WBN)L!C*M.KCI/,Z>64<NRS
M@_(<TKXY95F6&EAY8;/\KPM++J."J8ZKB,95C5Q/LU<I\,_"N&5\0XO$9!XE
MPSFA5JY/E6'R'%X:$Z>$4<!/'U,;C^)LWR^EA'F& K*LJ^3X_$5,;5Q4,)"A
MA:;IT/R3T#X(?M)?'J^@UV\TKQ7K$-P(E7Q7X_U2[L[%+2<[TFLKK7YOMM_I
MZ9R$T&TU!(A\J0@+M'TY9_L0> /AEX9O?'GQ[^(UV^B:+#:3:I8>$=/NH;&"
M:YO[:QM[=M2DM-0UG58+RYNH+14LM$T>Y2282?:(HT>0?JG3)(TE1HY422-Q
MADD4.C#T96!4CV((KZ7A_P"B?X?Y12Q..S:OC>->)ZU&M.EFG%D\1BLIAF<J
M<HT,7B,CR_&Y?4S#"QJ\D\1@L?FV)G7IJ=.&+H3E"K2\+./I%<99E4H83+J.
M%X6R"E5I0J9?PY&CA\RG@(U(NKAJ.;XS"XVG@L1*GS0HXK!Y;0C1FXSEAJT5
M.G4_%"UF_8ZL_CO;W\9U"3X.6W@Z*\CL[FW\:W43^.XM2"):SV]Q#)K]SIQT
M]1=R0SO)ITUQF&61X&:S/[%>"_&'ASQ]X8TGQ=X1OQJ7AW689I--O!:W5EYB
M6MU/87"-:WL%M<P/;W=K<6SI+"F'B8INC*.VQ_9&E;_,_LS3_,V[/,^Q6V_9
MG=LW>5NV[N=N<9YQFKL<:1(L<2)'&@PJ1J$11Z*J@*![  5^B>%_AIF'AWB<
M_OB^#)Y?GV-KYE6PW#?!-?AG$TL94J4OJU".*EQ+F])Y-@*#Q=/!97]33PU3
M%SJ4L9&+JTJWQ/'_ !W@^-:&3VPW%$,9D^%HX&G7SWBJEGU"IAH0G[>M+#K(
M\NJ+,\95^KSQ6/6)M7AAXPJ8:4O9U*3Z***_83\T"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *_,__ (*ZZQ^S_H'[ '[1>K?M._#WQ#\6OA!;
M:!X3AU;X7>%?$FL^#]<^(?B;4/'WA;3?AWX/L_$N@WNG:EHT>O?$.\\,:??W
M\-R\,&FSWDEY:7MFD]E<?IA7YI_\%=-0_9ST[_@GS^TO-^U?I_C_ %/X(3^$
MO#VG:_:?"BW2Z^)\GB74_'7AC3_AK+\/(I7CM?\ A,[/XF7/A&]\.R7[C2K?
M4[>WN=6#:9#=(QO?T?RTW>^BZ^0UNO5?FOZ7G8_$'_@F#^S7X1_9 _;\^!/@
M7]H#_@GM:_LE?%SXL_#KXM>*/V5?'/PX_:\^+GQ]\"SKX2\**GQ-^%/CKPIX
ML\37NBZ5XRT;X?\ B6;5;754LIM%N3%,VC0Q74"36W]=5?R0_P#!*/0OVC?$
MG[<_PO\ B!^V#\,_^"IOQ0\4>#?AM\1/ OP(^+/[6WPE\!_#+X/? 7P]K_A\
M:AXHO-3C\)>(M7N]>^(/Q$L/#FE>#!XJU$I<7SW4=K>6,TDEI>6'];U3&UG9
M6UZ[[+?^MK=;CE?2_P#*NUODELKW_30****HD*_$?_@X3^(O@GP=_P $L/VA
M_#WBSQ/HGAW5_B/=_#?P9X#L=7U&WLKGQ;XJC^)OA#Q0WA_089V1]2U?_A'?
M#NOZT+&V$DYT[1M1N0OEVSD?MQ7XR?\ !?[P]HNJ_P#!*3]J74=5TG3-3O/#
M]I\-=7T&ZU"PMKRYT75'^+G@/2GU+29[B.273=0;3-0O].-[9M#<&QOKRT+^
M1=3QR*6S]&..Z]4?LQ&V^-&QC<H./3C_ #SWZT^F1+LC1<YVJ!GIG ZX[?2G
MT+9>B\_QZB"BBBF 4444 %%%% !1110 445YU\3?BEX1^$7AMO%OC:?5+/08
M[VPTZ2[TKP_X@\2317>IW M;%)+#PWI>K:@D=Q<LELERUJ+<74]M;/*LUU K
M@6OM_7IW/1:*IV%[%J-G;7T"RK!=P0W$(GAFMI_*GB29/.MKF.&XMI0K@203
MQ1S1."DJ(X91<H **** (I_]3+_N-_*OF3]DW_DG'B3_ ++E^T;_ .KT^(%?
M3<_^IE_W&_E7R[^RM/':_#'Q1<2LJQQ?'#]HUG9V"(JCXZ>/]S.Y!"*HRS,V
M%4 EB!DC.32G%MI)1FVWHDDE=M]$BXIN,TDVWR62U;]^.B75^1]3T5\L_$#]
MKWX/^"9FTJUU:;QKXD\P0P:#X+1=;FDNLE5MVOX9(]-202CRY84NY;I1N M7
M;"-X/XC^)W[2'CFP?5IG\'_LR?#V3.[Q5\0M6T^QUS[-M<EX_P"V/LQMIECR
MP#Z=I&UN8]09-I'YOF?BQPKAL95RG(GC^-\^I/EJ9-P9A'G=7#3U7+F68TYT
M\DR=*7NS>:YG@W!Z<K:L?<8#P[XAKX:GF.;+!\*Y157-3S3B?$?V53KPLGS8
M'!3A/-<S;B^:"R_ 8E32^)+4^P_B[\6_"_PG\(ZMXD\0W%NSV$#R66C_ &RV
M@U'6;K<(X+.PAF8/(\DKIYLB1R);PB2:0;4(/YA_LT_M.?$?Q!X%U#X??"#X
M:V^N>+&\=_$WQ!-J]YJZ3:)HNG^*/B'KVNK-?1^58#=:R:LMO&9;^*.X189X
MXY6F-N/*OBC\7_V,/AEX>\2:OJ/Q*NOVI/C(=/N8M-T^ZN]?OO"MSJDP:W3[
M7J^GDZ6-/C,C3SQMK^J7311&.T2%YHI!\L_L5:7\:/V@4\5? SX1ZEX7^!WA
M"5[OQ1\6/'GA;3=4B\6:MH.JZDT.F>%H+^6^GE6"U26;3]+T^TO-$6;2[61]
M7O\ 43;K%<_.XC+?%_B[&X>OBL?@O#?(JE3#TJ^79/C<#GO$\<O]EF,L?*>9
M5\FJY9@\RQM:64T\.\!5Q=/+Z.'Q5:&)JUIQ4_?PV-\+N',!BJ5/"8[C;/H)
MU,'B\RP.*RKAR>*=7!*A?"4<WHYE6P6$HQS"I-8JA2GCZU:A3G0HTH-Q^IOC
M7\2].L_%-KX1\9>)_$7[5'Q^N[HV^D?!GX<7%VO@3POJ1+((?$6J:3$K%[0G
M==:;H=I8Z@JPR#5;VRC<W@]B^#'_  3[\4?$S4M*^('[7>I64UK8.M_X9^ 7
M@QO[)\!^&!(5=(=873)A%>W10JE\EM-<WM^T:KK7B'5E5H!]Z?L[?LI_!_\
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M_<\9_AQ?_IMG=_S$8'_KW@OR@<'15'4-2L-*MGO-2O+2PM(^9;F]N8;2WC4
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M$C5558XHXXHU  2-$10%50/Z0Z4=EZ+\BZGQR]0HHHID!1110 4444 %%%%
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M%%?H9\4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQI!:^!]7NI;_ %357TQ/%4-]X1MXF\62)?7YU&>XT<P:E),?M"R?U!5_*?\
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M;>#9-"FT&.69HET&[T^YL5^QW44LO!7\-\KSNC.EQ[CJ_&F,Q56E-/$_\(V
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ML[!F;]#?AU\#?A+\([!=,^&/PZ\$^ [-5"%/"GA?2-$EF3 4BZN;&VBN;QV
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M_M'_ !V^+&H.,W=K=>)VT31YRP4N?(LE.HH7(*MG4F 5B!R :^A? G_!./\
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MR2/?**IV*S+;1"Y\HW(BC%P85983.$ F\D.[OY/F;C%YC-)L(#DMDFY7:_\
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M?M(_#;]EGPG^S)J/C+0+K09C-\/=)\ ^$+7X[Z;J7P.3Q;X2O?%O@WXX>(]
M\12>!XO%GB+4/"=]&+*33C^OR_.^@U%O;NEYZ]E\M3^H^BOYV_C3\>_VN_V4
M?C-??L.Q_M1?$CXN^)_CWX?_ &--9\ _M2?$#X6_!YO$OP(\2_'W]KBW_9V^
M,$<>D>%O!WAGX:ZEHU]X=CN_$_P3\*^)O"FK76A>+9)M U'5?$^AP0FR]:T3
M_@I#\/\ ]@/6/VLOA1^WE^T#X\\6>!?V>/C9\$?AU\*?C_XS^&=UKGCSX@0_
M'_X%S?&G3/ ?C"+X'^ ;3PWJ_BKP&OAWQJ+GQ5:>#O"-C<^%V\*PZM ?$%W#
M-K"O;?3UM]V__ \RN1VTL]+V5[M:=+=VEWWZ:GA?_!KY_P F _&'_L]CXW?^
MH=\):_H^K^;'_@UIU6QUC_@GO\7KS3YC/;R?MJ?&217,4L1VWG@'X-ZC;Y69
M$;+V=[;2D8.SS/+?;*DB+_2=1'9>B_(*GQR]0HHHID!1110 4444 %%%% !1
M110 4444 %%?G3_P44\5>,O!?@WX<:]X,^+NI_#:[?Q9=:)>Z1HNJW6EZCXD
MM-6@LG;5B]EJ=E<36'A)+"5[M#;7,(;7+</<64C1"YL^)_V_?@7\(/"^B>%T
M\8:I\</&V@:#I>C:KJGA&T_XEFLZUINE6UO=:U?^)-4NAI;6^L7<4EU+/HEY
MXHF@EG9)%G9'<\5&MC*F.Q5">$I0PE&-)X?%1Q-2=:O.<(2J1JX66$I4Z$82
ME*,)T\7B7/D;J1H-QC+IJT\+#"X>K#$5)8FI*HJV'E0A"G2C&<HP=.O'$U*E
M5RBHRG&>&H*',E"55*4E^AM<EXQ\>^"/A[IAUGQUXM\/>$=+^<)>>(=7L=*B
MN)(T,C6]F+R:)[VZ90?+M+1)[J9B$BA=V53^.5U^UQ^VE^TI<S:3\ OAU=>$
M] N)IK3^U?#NFKJ4UO\ N"TMIJWQ&\4Q6?A;2[@)^\@EM+;P]?J^U8)GD*YN
MZ+_P3S\6:]>#QO\ M4_'>UTF:[$$M]&-?.N^(;B'R))9;6_\9^+YX=-TZ[L]
MC+BULO$MB4CE:&X$:!CUU:E'#TYUL36I4*--<U2K5J1IPA'36<YM1BM=V[?(
MYZ<*M><:5"E4K5)NT(4X2G.3[1A%.4GY)7*W[9G[<W@GQTG@SPG\'XE\36GA
M/QOX>^(-[XKU:PU33M+N=5\+SRW&E:/I^F72Z9JUS:23S2-JU[<1V ,<<<&F
MF;SFO8,WPE\%/VH?V[[O3/B%\8/&+^#_ (3SW$E[H-I%$([&2U6YO(F7P7X)
MM[H1AD'FV \5>*;DZC/9O;RI>^)(;<P#SC]LKPW\ /@QX<^&7AK]GC3/A3XW
MU2?6]0UKQIKOB#Q-XD\7:[=2:!9VI\-:7<:AH$LGAV#PYK][<:C;^-=.L+O1
M]42"#2Y=%T>5I+N]T_Z>TS]KOXV?%'0_"G@'X!_#'3_#&HV_AG0+._;PU8C5
MK72&BT^QM7AT&'4K&QT+PCX3LYQ)8:=-K]K*\5@MDS3Z5<*T"_F/%GB[P7P;
MA:&+KRS+-Z^;8JK@LDPO#>68C/,3Q%F&%A2C7P64U<(I8"MB<.Y>PK1K8S#Q
MA6HUJ#E[:E.FOTC(O"KBOB.G"=.MDV H8;#QQ6:?VQF^%RRIP_@JM;$0HXO.
M<'B&L?A:&)]@Z]"4,+7E4P]?"XE)4<32G+[#\(?#C]FC]C?PRM[$=$\+W-Q
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MX)_9>^$W[27[3'_!1/\ 8L^._BW_ ()N_"#_ ()H^ /V(/#7QW\->(IO"'Q
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M#X9\[26\%?\ "&P?$.Z^)":R+5M*.LCQ&=8NGM&G_M@Z>=.1(QIXGS.3^O\
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M]Q(JG][/AC^R5^SK\'E@?P!\)_".D7]N$\O7+O35UWQ&&7DN/$6O/J>M1EW
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MX%5(U78J(JHBJ,8554!548. !W/7C%JBBOJ3\2W;;U;;;?5MZMOS;U84444
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M[+T7Y%5/CEZA1113("BBN%_X6C\,_P#A*O\ A!?^%B^!?^$W^T?8_P#A#O\
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M ,1_$+5KZU4MF27P!\/M,T6\@G*[25MO%^H11$-EY01CF2?^"ZW[5.2!XA^
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M4ZN5XS3$X?"QS:IC%ELJT+TIULN6%K^QE.BJBISE%E%%%>P?D@4444 %%%%
M'K%%%%?<'QX4444 %%%% !1110 5^6__  69\*?#GQM_P3R^-'AKXK_M!:1^
MRWX'OM;^$D^I?&_6OAUK7Q3MO!M[I7Q<\$ZOH36_A'PX!KTNI:KKMAIND:9J
MVD2V][H-]?0:PEQ"EF[5^I%?F]^W!\;]/\4>#?B]^S-\!?@_\$OVU?VM?"_A
MCX?_ !(NOV,OBWJ7@^PT36_ %_X_\*6,_C+Q')\1I]+\%16?A^#44U_1FOM5
M6XDUFQT^.RB>]:!"GLRH_$O)IW[:[ZZ+U>G<_&K_ ()Y_M?>)/B/^V)\$_ U
M[_P7ZT3]L.SUO4?%,$O[.%M^PUJ'PINOB<MEX \5:@EDGQ%N/"E@OAYM!>S3
MQ:]Q)?1-J"Z VEEI'OPC_P!6U?R\_LD_LE_MX>.?^"A'[+7[1/Q4_P"":?[)
MO_!.'X<_L\:-\:AXXU[X&^)_@_J6O?&JP^(O@&Y\+>'O VHZ'\(_$NN6]^GA
M_P 2S6?B73[[Q-I=HFBQ)J]WI.MP7\D>DZQ_4-2C>VO?S[+OJ.=KJUMM;<NC
MN]/=23TMW]0HHHJB HHHH _!/_@K)KVJ^#?VR/\ @GMX_P##5RFF>,O 7PE_
M;A\1>#O$"VMG<WWA[69O$_[%?AV[OM/-[;W,,;ZAX<U[7O#FJ1/$]OJGA[7-
M:T+48KK2=5U"SN/SV^(/Q0\:?$76I/$'Q"\7:[XNUIO-$<^L7\UZ;.&:9[EK
M/3;5G%GI&GB:5Y(=.T^&SL(-Q%O;QK@#](O^"EOANU^)'_!1[_@DY\$KZXN-
M-L/C?X._X*"^#;[7[3RY;OP_9^%/!_[.7QHN+RTLID\F^N=3C^%3>&(5FG@B
MTY]?&N2+J*Z4=&U/]%/#O[!7[)WAV*-?^%0:+XAN/[/BL+N[\87^M>*O[0*-
M;R27]SINM:E=:'#J$\]LD[7&G:58K;EYK>QCM+*5K8^QDL\BABN?/X9E5P<(
MN2H97]6A7JU>:'+3J5L5)1HT90YG.5.%6J[*,?9M^TCYV9T\TGA^7*JF#HXB
M;7[W&QK5*4(>\I3C1HN+J5$TE%3G&"U<E)+E?\PJZQ-',DL<,!$;JXCG0S(^
MTD[9%)561N-R[><8W$9S[-HG[7GQM^'GA^;P_P"&_B)IG@72)]/FM+F70O"W
MP^\+ZE<6BQLKSW/B'3O#=CKD]U;1R$PZI-J;W]EA'M[N$QQLO]#&I_L!_L1Z
MT6.L_LI? 35BTHG8ZG\,O"M^6G"L@F8W6FRYE".Z"0Y<*S*&PQ!Q;;_@FY_P
M3YM!<+%^Q'^RHXN8FAD-U\!OAG>LJ,""T#WOANX:UFY.+BU,,ZG!60$ C]6P
MO&'A%A:N%Q4?#7#5\?@H2IX3,,=EF39CF.'A4LJL:.98Z6(QM)54KU(TZL8U
M';F3Z?#5>%^.L11KX>KX@YE0PN*E&>)P."GC<)@:\H:P=7"87&8;#5'3?\.4
MZ$G!?#:[/YCXM0OHKV/5(;VZCU&.Y6]BU".XE6]2[603)=I=JXG6X$H$JSK(
M)!)APV[FOTG\"_\ !5#]H'PY'86?B[1/ OQ LK942[O+S3;[P_XCOD3 )_M'
M1;Z/1()G7[TI\,39;#E"=V^W\9O^#>/X%>,_"_C70?A1^TW^U)\+K/6+._7P
M9X'U?QOIGQ ^$_A!KF]>:V\/S>']2T33/&NN^!]/TQAHEAHU_P#$-M5@@C@O
M;W7=6FCN(+S^4WX^?!K]OO\ X):_%C2O#GQ4AUZTT."]NXO!NN3W&H^.?@%\
M4-(MW>.]B\/S:I$FE2-/92"2]TF6U\-?$3PM!?6>I-:>&]0GTN_K]KR[,/#G
MQ27U",\'C\QPM.<\+EN;86> Q_LZE.,JGU*NIN3^!+$1P5:K[-THU*B]FJ51
M_'T.#>*^&?:5\#G7U3VM1*<J"J2PU54V_9RQ,6ZD>9.3Y54P\TE.2C-MRB?V
MO>#/^"M?POU%0GC[X8>-O"MPTB(DGAK4=&\96"JQP\]S+?-X/O843[QCMK"_
MDQE5WL!N^M?!G[<O[*WCCRTT_P"+_A[1KIE0R6GC*/4/!9MW<9\I[WQ-9Z;I
M,SKT=K/4;J$'CS37\V'[!O[27_!.O]O!M&^&?C^;Q'^Q_P#M,7Z6>F:9X8A\
M:#5?@_\ $;7)T6UC;X>^(/']OKFK6VIZA?[&M_AUXG\26FOR37]CI/ACQ#XW
MN$OKFV_2;QC_ ,$C_B#9*9/ /Q9\(>(^2WV?Q7HNL>$) @4G9'/I4GC**>;(
M"*9([.)R=SM"O _+<_X.\,<%F%3+,TGQ#P3F2]ZEA\="K5PE6#T56CBIT\TP
MN)P]TTJM+,U#GYH.?-"4(_08?-/$K"4XU?JF4\18=:3JX=TX5E:VGLZ=3 U8
MS=UH\%.R5W%73?[677C[P;:^#M7^(*^(]+U#P9H6B:GXBU+Q!HEP/$%C'HVC
MV,VI:C>V[:&-0DOQ!902SB&PCN;B8*$@AED=$;XD/_!3K]EC<!_:GC8@@DL/
M!UUA<8P#FZ#9;)QM4CY3N*\9_(G6OV+_ -L?X2W9UW2_A[XO$]C-_HFM_#/7
M+;7=3+*6V3V5KX2U2?Q/$IVEE9]-MY%#+N5&;%?+OB#Q=X\U3Q'%K7BGQ/XM
MU'Q;HDT-M#JOB#6=8N_$6DW&E7+R001WVHW,FI6,VG7@D>.)98GM+KS&58Y=
MQKJR#PAX3QWUF<>(X\18?25&ME6-PN'EAM)<M&O2I0S*-24W\59UJ#CRVCAF
M[L\K./$GB+">PA+))9+6U52EF&%Q%>.(UC>K1J5)X%P4%M25*LI<UW76EOZQ
MO@M\;_A]\?O"$WC;X;ZA?W^BVNLWOA^]_M+2KW2;NSU>QM[*\FM)(;R)4F!L
M=2T^\2XLIKJV,=VD+3)=PW5M;^N5_,%HO_!0C]K#0=)T_1K+XDV\EIIEI!96
M\E]X.\&7]]+%;QK$DM[?W6@R7>H7CJH:YO[V:>]O9B]S>7$]S++,_:)_P4X_
M:H1$5M9\&2,JJID?P;8!Y"  7<1S1QAG(W,(XT0$G:BK@#YO'^"'$SQ5>>7U
M,HIX.56;P]&MF>)Q%>E1O[D:M?\ LC"0J2MUC1CIHTVN:7MX/Q5R+ZO2CC89
ME+$QIP5>K3P%"C2J5+>\Z=)9EB90C?I*I+NFD^5?T8Z_XAT#PKI%[X@\4:YH
M_AO0=-2.34=;U_4[+1](L(YIHK:)[W4M1GMK.U26XFAMXVGFC5YI8HE)DD53
MY;_PTG^SI_T7WX*_^'3\#?\ R]K\'_%__!2/XV>/_#>H^$/&G@GX,>)?#6KI
M;QZGH^J^$?$,]G>BTN[>_M6FC'C)/GM[VUMKN%XRC17$,<L95D4CX<3Q+.OB
M-?$ATGPX\HNQ<G1GT#3O^$<=!A39MHB0I:"T:,>6P14N.3.MPMU^_KT<E\#L
M96H5WGV,E@L3";=!8"I0Q-&K3Y(<L92J0C.%3G]JIMQY%'V3CSMS4>+-/%?"
MTJM'^R,-'%4)12K/&4ZU"K2GS/FDE"3C.'(X\J3YG-3YN5*#E_8KH'B'0/%6
MD67B#POKFC^)-!U)))-.UO0-3LM8TB_CAFEMI7LM2TZ>YL[I(KB&:WD:":14
MFBEB8B2-E&Q7X!?#?_@J%JWPY\-:1X0TOX!?#_3O#FC6US%9:/X3US6O#EA;
MSW=[-?W,UM#>VWB-HH[B[NKNYN(Y9;B>:YN'G>[+%@_K5I_P5^A("WW[/\L9
M$:[I+3XGI*'E&T-B&;P!#Y4;?,R@W$S+\J$ORX^/QGA'QQ2KUUA,FE7PJJU/
MJ\Y9EE$:LJ'._9.K!XZ-JKARNI&"E%2NHMI)GTF&\2.%*E&D\3F:HXATZ?MH
M1P.92IQJN"=14Y+"2O34^90<K2<4FTF?M'17Y-Z9_P %;OA/*K'6?A;\1+!P
MD11=,N_#6K*TA#><K-=:CHI1(SM$4@1VE!8O'"5 ;LK3_@JU^S=<MMF\-_%^
MP&]%WW?AGPJZX<D-)BQ\<WK[(QRXV;R"/+20Y \BKX;\<46U/AO'NW_/KV%=
M=-G0K5$]ULWU[.WIPXWX3J)..>8-7_G]K2?S56G!KYV[['Z945^/'C'_ (*W
M^&M/\4-9^!_A%J?B3PC;2^7)K>O>*(O#6KZFOE[7ELM&MM$UZ&P@CGS);/>Z
MA/<7UML6XL](G=UB^K="_P""B'[).M:997]Q\39= N[FSM;F[T76_"/C*+4M
M*N+B%9)-.O);#0-0TFYN[-RUO<RZ1J>IV!E0M;7MQ"\4KY8WP]XUP%'#UZ_#
MF93IXF+E!82BL?5IZ)VQ-# RQ%;"2:E&T<33I-MN"]^$XQO"\9\+8NK6HTL[
MP,9T':;Q%5X2G/=7H5<4J-+$)-.[H3J))<S]V492^VJ*^;[#]K_]F#4GD2W^
M.7P[C:)0[&_U^WTI""< 1R:I]CCE;/5(F=U'S,H7FNJM?VCOV>[W;]E^.OP=
MG9HA-Y:?$SP89ECP"6DA.M"6+;N <2(K1L=KA6XKPJF1YW1TJY/FM)K=5,OQ
M<-[-?%16Z:?S1Z\,VRNIK3S++ZB>SAC,/*^MOLU'UT]3V:BOBJ+_ (*#_LK3
M>-QX)3XA.&>Y2Q3Q9)HVI1>"7OGD,/D?V_)"JQVZRX5]8FMH] ",+D:L;0-<
M#[-MKNUO8A/9W-O=P-PLUM-'/$255@!)$SH?E96X/W64]"*C,,FS;*?8/-,M
MQV7K$T_:X=XS"UL.JT-+NG[6$>9QYH\T5[T.:/,E=7K!9GEV8^U^H8["8SV$
M_9UOJV(I5O9SULI^SE*U[/E?PRL^5NS+%%%%>:=P445!)=6L,UO;S7,$5Q=F
M06L$DT:37)A3S)A;Q,P>8Q1_/((U8HGS-A>::3>R;T;TUT2NWZ))M]DKB;2W
M:6J6NFK=DO5MI+NW8GHHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "OQT_X+EW#>)?^"?7Q2^"]M!>QZY\<M?\#^ ?#6KIIE_>:#HN
MJ:5XJTKXBRWGBN_LH9QH>EW&E^"-2TVTU"Y3R+C7+W2--4B?4(0?V+K\4O\
M@L3\,/'GB+P9\/?B+I.K*_@7P7?ZIIOB/P_/?V]@(M6\1SZ7;Z/K=G;321G6
MIWCM;FQFA07%WI=NSW5K"ME/JUQ!E7ER4IRYX4K)?O*EO9P3:3E.\H+E2;TY
MHW=E=;G5@Z<:N)IPE2J5[MM4*-_:UI)-QI4VHR:E.5ES<LK*[49-*+_2SQC^
MTQ\(OAIX'\/^-/B;XST+P"NOZ#INNP>'];U&TN?$JQ:A817QLX-#T>?4=0U2
MZM3*MM<-I,-];B=6\N:2+$M?F%\6_P#@KD^K/>>'?V;OA9J'BB]R\*>+O&D-
MU:Z7 X#)Y\/AO2KD7=Q;LI\R&?5=;T5D;:)]/8 JWR#H?_!(;]IGQ_X-\*^+
M]%^.WPD\$W'B/0+#5H].USX;^(/B?=Z1%=/I;Z5':^(M.^(NE^%=6M)M N+W
M4"8] O;.UO;/3-,L[J_L=2N-6TK$NO\ @AI^W+J-[:3+_P %*M1\-Q1W-JP;
MP+\+-2\""RMI-5O;>]EL;'PCXQ\.PQ36_A^+3-1M;,SQ)<:S=:AI+W%G;64'
MB#4W_9&89I04<+Q1PGD?-3C>OG-/BVM5A*2BU*."R/AS'QQE)*_-&&>Y/63?
MN59P]\^@P.(X:RV<JN.P698ZM&<G'#T*&#Q#IN#TA-X_&X'"X6HI/ED\3@>(
ML-/EM/#15^;Y8US2_C=\1/C4_BW6+B_C^)GC/Q"OBW^V]*N@EW8ZE+?0B"?2
M/[,NC/:2Z1++9V.D6-BXEM8XK*ULG9$C>/\ 0:S_ &/OVZO']NL5[\3?C4EM
M.B*S>)O&&H:;9-$V!^\T^\\6P79C8;OO6S[EQ@!AAOS<U?\ X)M?MM^&?C?;
M?LU?\-PZ+JWQQ\4:YH/Q7\,_$;7/&/BV?6K?1-(AL]7U2WU&XU+Q!=^-(]8E
MU7P[JVJZ5H5MX?U:QUBS\(QWTLZVFHZ[+X,_22'QM_P<2_LS!AXD^%_[,_[<
M?A:SB#7.M>$KO3_"OC![.,&1!965K<?!ZYDO2'2&2.#X?^))G:-C''(2]T_G
MT/"#B[/JBY_&KAG*'@JDL'1P/#F4T.$:W$&&BH5L-FZQW'V7<02ITL53Q/U>
MG@:&-H>QKX;$5/KF-EB8K"_0YCQEPUE2HO <,U^(GCZ=+,ZTN*<SQ6;X;)\7
M7HTX8C+J>7</XC)L'5JT94'*IB:^#E&K1EA*-/#48T.6>E8?\$</B[XC*W'C
M'XXZ1I$K%F>:WT/4O$U^@9N%8ZCJ%M \B_Q%;C86 8%L'/;VW_!#[0)$0ZO^
MTQ\1IR(R)4TCP/X5TH!CD'RIGFO9,;N3OWMM&"1P:\8D_P"#@7QI\*=8AT+]
ML'_@G[\>OV:KAYK6W;5M2M=<UK1]S:Y9PWMSG7O"?@:[FLD\.#5;ZPET>/73
M?:O!86";-,NKG6;+[?\ @M_P6,_9$^.9TVW\+_M!?L[Z'JM[]@$VA_$3QKXS
M^%NJ13S2:JE]9VD?Q'\ >%[75;V$_P#"/)9Q:;>74=[+=:WLE6#3+*XU3V*W
M@GQ+DV'57-,%QEGM!J[S*6=8[-<#*-H^^ZO#F(AE$8/5\T*,(N[4;)*)C@_&
M;/L'4B\EP? .237\..&\.>!/KD'=6Y<7F_#V-S;F322<L5)IW=[W9XK%_P $
M-_ <&\0?M,_'B$."&6$Z)"F#U^2*!$Y^F/05\Z?M4?\ !)6\^#'@&R^)WP]^
M.7CCQHOA2X\GQ1H/Q.ORT$UAX@GL= LKKPX^EV>R&ZMM8O;":]L[Y)H[BUC2
MXAO89]/2"\_H TKQE\2-?T>'5_#UG\(]=M+S3?M6GW^D>/M=U+1[V>7PO'=6
MKP:E9>#IXIM.F\6L;#[5"LLO_",%-=2W?4MV@#Q7]I_X9?&7XZ_#'4OAYIEE
MX&TM-0UFWNS>)\3O'7A9OL.E:EHM]IL=\^B?#S69K];V--86_P!+D$5K9W<&
MA:C;75[*C+:_#8G@'AB-66*HY-"GFE*<9T<4\1BX8NE6IU(--5JU6I*&JY9I
MQ?-%R@UJS[[ _28\8;?V?F7&%.OD.+P^*P.99;/AGAB>"Q& QV%JX/%4IX;"
M95A)2;HUY>QE"M2G1J\E:G)2@?GI\,/V&?\ @I)^SOX%T30?@A^V'X+U6UT^
MS:[F^''CGPC<7/A33M3OYI+W5K'1M?O=,\4ZE)82ZC<74JRBST)Y))7G6SMV
M<A?1X?VE/^"JGP;WQ?%7]C#P9\:-'M6_TCQ#\%O%36E]/$F2\L>DF_\ $FI2
MLR*SJJ^&;-=Q(8J[)#7Z9>%G^+FG:;I%A>:'X*F6S@T>SU">7QSXKUS4###J
MUQ::A.-0OO!%C<:M>IX:CL=0BGO%M7U#Q!->V-XUC9Q+JL^G%J/QD:WB^T>&
M?ATEP8;0W*P^+/%$L*SMH^L27\=N[^"HGDBAUZ/0;2SFDCC:YTBZUC4)H;6^
ML+'2]3Z*7"D,)3IQRO.<]RODA",*$<>\?A*;C"*L\-F-+$T^6ZU5+V2DUI96
M1CC/'C$\08O%8CCKPV\*>.)XS$5JV*S#$<)QX1SNNZM1SE/^V. \=PQBY5M6
MXUL:\=4YFY5G6GS-_F?I'_!9'X,Z->V^C_'CX.?'G]GS6I6$<T7C7P'>W>G0
M2@#S%6:V:UUN=$SN61?#B,Z#<\4.:ROVKO\ @HC^R%\0O@;/I?@;XO:/XOUG
MQ'XH\ /I^@:/INMKKD4'A7QUX>\:ZU=ZII&J:=IMYI=M;:)X?U#RI[Z.&&ZO
M&M[2V>:6=<?I/K.F_$?7M/N].UCP'\+-;M+BTNHFT_6M=UR_TVXF;2=->VAN
M+>Z\!W$1M)-=?5[6[D:WE>'2;?3-1BAN+ZZNM,L/R6_;V_X)^>!]>\-V_P 5
M_"/@'X6?!GQ!X6URUTFYO? 5A="U\6V/CSXA^%/!MA/XD\-Z?H?A*TN-5LM$
MU:\U<:G%K#O9:@L^B"/5K/48]:TKGQ\.+<NPF(JQS3*LSPU*#J8B>)RZI@\9
M3PL6GB9TY8?%/"59T\/[27*Z$.=IJG%SM"?I\-8CZ/W&&=9?@:_!O'O F;XZ
MI+#93')>,\!Q)PWB,[K4IPR7#XS#9SP[2SW 8+$YM+"8>O6AG&82HX>I.=5Q
MCSUJ7UQK'_!5?]AGPMX=T_69_CAH^J-J>GVVIVFB^'-!\3Z_KB1W5O',MMJ%
MCINDS1Z1?(I"3V>K7%E<03AXGCRC$>'M_P %<G\?2?9?V:_V0/VBOC=+,S1V
MFK?\(U-X=\-NQ#".:74].MO%K00,X !NXK/*GYGB8%1[=^SG^P]X"_9^\'^%
M-"T'X&_ _P 0^(-'ALTUKXC>(HGUCQQK%]-J>MW&KWYU>]^'LMTD=O:?\(])
MH>FB[AM[?[1J&EM-'#I%EJ>L?8EL_P 7+:V7R?"OPYAF2U_=VT7BOQ,MFM\O
MAN281JP\#"1+)O%ZPZ=]H$ F'AMY=9^S_P!J1IH$O13PG&&+ITY8W.<MRN4J
M<'4HY7E;Q56,W%<\7B<?B:U'FC)M-PP\X.SY/=M)^9C<_P#H\</XS%TN&_#S
MC7CRE3Q->.$S#CGCBED>7UZ$*LEAZJR/A'),NS)4ZM)0FXU>(Z597Y9PIR<H
M0_,63XE?\%A_C&^_PI\"?@=^S?I%QM$&H?$'Q WB?7K>%E4AWMK"]UK-RK;L
M177A*'!"I/"@^8Q?\,$_MQ?%+=)^T!_P4$\>V=G<'-SX:^"N@/X0L5C<CS(H
MM4L;KPY$^0657N/#]PP7[QD3,8_5";4?C !-Y'AOX>N5-^(/-\4^)HQ+M.@C
M2S*(_!LIA\[S?$QU )Y_V;[%H/V4WHU/43HSTU+XM-<JK>&_ :VANU0R#Q/X
MC-P++_A()HI)1$WA!8OM/_"*""^2$SB(^(FET@SC3%37)+_U4PM;7,\TSW-5
MHY4L5F5:AAI-V;MA<N6"HI-[IQ;MI*3L<O\ Q'?.LL]W@O@;PKX#<=*6*R7@
M?*\ZS>G"-E'ESWCF7%F;PJ+1NM1QE&HY:IK9?FQI?_!&3]D*UTS4+CQ@?BG\
M3?$U[93VK>)_&WQ U.34K:6Y1X/M]M#H4.BVS75N9/M5O]N@OHTN(T=HBA>-
MK7_!+C]DKPA\"_#GQ!^("7!USQYKOCGX@?"NYUZ2*2W$'A;X->.M<^'$=I:V
MC22QP+KFM>$;GQ'=.K&61+G3;68EM.W/^B9U/XO?9XFN_#GP[A_=V;7I3Q9X
MF,<+FPUA[]8))?!41E2+58_#T%F\B0&YL+[6;J5+6YTNSL]5^2_V-_$OQ(U+
MX3^+)_#VF_##5ROQY_:L97M_&^O7-JM[<_'+XA:I81RS6/@ZY*VEUK-]<A;@
M+YK^%7TG7K>VGNM0?28*H9%D>7YIE\<'EF"PTEA\=B(2A0BJKKT)82E2JNI)
M.I.5*EC,3&,I2ER*M+9\K1F?BEXG<8<"<6U>)..>*<ZH/-N&,FJ8;&9MBJN7
M4LKS.GGN8XS 4\$IK!83"XK'\.Y+7G0H4:,)U,OHI1<5.,OT+HKS*34?BYOE
M\GPYX!,9FN1;-+XG\2K(;9=;TR*U>XC7P>ZQSR>'7UB]GB61HXM:MM,TR*:>
MQOKO5M.$U'XN>9!YOASP"L)DLQ<F/Q/XEDE2)M6UE+]X%;P?&LCQ:#'X?NK.
M.1HA<:Q=ZS87$EI9:?8:GJOU"U=O3=-+7S:Z=3\-L_+[U_F=_J,4<UK)%,JO
M%("CQN 4D1T9&C=3PRNK$,IX8'!XKY$_8=T'0M!^#^L0Z'IUCIT<OQE_:"26
M*RAA@5TTWXV^.=#TW>L2J"+71=)TO3[<L"5L[.UB4[$6O:Y[GXP7]@\%WX6^
M'@DEL@)H4\6^*# US)X=O#<P"5O!*NUJ?$QL["*9H/.D\/S7>K/:Q:E;0Z-<
M\!\-OAAK'P8T74O#WPG^%WPJ\'Z)?ZAK.MOI.G>)?$]K97.MWUOX>$>H72+X
M.G:.;4+J+7(]4F3S&CBL-&O(DNY=6OHM*Y*E*M+&86M"450I4,73K1E*:FYU
MIX25*4(*E*%115"HI.52#@I^XI79[^$QN74N&\ZRVO"L\SQF:Y!C<OJPP^&J
M4(8;+\/GM''T:^*GBJ>(PTJTLSP=2E"AA<3"M+#-5Y47"G)_3M%>9-J7Q9%T
MX7PYX$-F+QUCD/B7Q(+DZ>OB3R4E:$>$3&+R3PA_Q,3;B8PQ^)<:+]H?2R=>
M6./4OC 5M_.\-?#Y9&%B;KRO%7B:1$WP:TVI"W+>#8C)Y%Q%X=CLC)Y)N8;W
M6I)UM9--L8=5Z^J\_7\=/ZZ7/ MZ?>O\SU&BO*WU/XR"!V3PQ\.VN/LSF*-O
M%GB@1?;!X:M)HXI)1X*9A;-XP>]TYIUB:1?#4=KK"P/JLUQH%K-)J7Q<#3^5
MX:\ M&LMT(#)XH\21O) -2TI+%I57P?((YI-)?7;B[CC:9(-0M=(M89;BUU"
M\O=-.E_PL[_=8+/R^]?YGC]PRG]LFS 8$_\ #-6IC&1G)^*6G$#'N 3] 3VK
MZ:UK_D&7/_;'_P!*(J^;(_A%KLGQ>M?C1<^&=(3QJFB6OA"74H?BU\4GTJ/P
MC)X@U"74;*+P,^F1^"9;E-&CT?6[6271X[J;Q3->VLVH6T6G6>M7O>ZKJWQB
M30[F6Z\)> I+E+"WFDM+#Q;X@8RWZZ+?3S6=K/>^$+.$Q'Q5'I&GVUU<FV\W
M0KG4=5GAM;^SMM)OO'IX:KAL)F_M?9_OZ^-Q%+V<YS_<U*,%#GYJ5/EJ>Z^:
M$>>$;:5)7T^HSC,<#F-;AI8*6)D\!DF59=C?K5"CA^7'8>M6=>.&]EB\5[?"
MI5*?L<14^K5JK<N?"4>5<VU17FLVN_$E7F\CP9HDL:M?BW9O$K1M*L3:5_9S
M.O\ 9K>5]K2XU8SC+&W.GVZCS/MG[D_M[XD>:ZCP7HOEBX=$<^)7!:W&K- D
MQ']F85VT;9J!CR=MTYLMQ"^>?ES?:WG\_OMM\SB-+\#>/+/]H'Q'\2;B7PLW
M@O5O ]AX4M;2&35#XCCN+#4'U%;J8/$-.,4DKM$RHY9$ ;EB17T #D ^H!KS
M7^WOB7P#X*T,-LC)QXG=E\QHKII%##3.526.TC!QEEN)7P/(VR1R>(/B:L>Y
M/!&AO)Y<QV'Q.Z@RK:VTD";O[,.%ENWNX'?GRX[>.;#>=L3&C0A0510YK5:U
M6O+FES>_5:E-1T5HWUC'I>UWH=^89GB,SEA)XE44\'E^"RVBJ%)4D\-@:4:%
M"51)OGJ\B7M*KUFTFU>[?I]%>;MKGQ'#2[?!FC-&L[I$W_"2,K/ -7LK=)2A
MT[Y7.C2WNI/'N.VYMH; ,WGF>-8-<^([SP)<>#=%AMWFL%N)D\2-*\,$NM:E
M:ZC*L?\ 9Z^8]KHD.EZG!'O3[1=7MQ8EHQ:BXEV. ]'HKS"#Q!\3GBMC/X(T
M.&=XK!KF,>*&D2&6;2K^XOXXY/[+4RK::M#8:?"Y5/M-O=S7N(_LODRN;7OB
M9LDV>"=#,BQN8U;Q.X1Y%TVUG12_]F?*KZF]Y8[L,5@MXKO:3/Y* ?\ #_U]
MYZ;17FS:]\1Q( /!>BF+S'4N?$KAO+%W#'&^W^S#DM9M-<E<C;+$D&3YGF*U
M=>^)7[O?X*T1=SQ+(5\3LWEHQO/,<#^S%+E!'9;5^7<;J7E1;YD O?\ K^OO
M/2ZTM(_Y"5K_ +S_ /HJ2O'SKWQ.\N1O^$(T/S1;/)&G_"4,%:Y&AM=1P,_]
MF?*CZ\!I9E"L%LS_ &AM)'V<]5X2U;QK<^)=/@U7PSIFGZ6TNKK/?6^MM=W$
M:P6>EOI+I:?8HM_V^:XUF*Y!E'V)=.M7S-]NVP[X7_></_U_H_\ IR)E7_@U
MO^O53\8M*_S9[I1117W)\H%%%% !1110 4444 %>1?'KXS>'OV>?@]\0/C5X
ML\/^._%/AWX=:#+X@U7P]\,_"6H^.O'6JVT=Q;VHM?#OA;2\76I71EN8WG>2
M6UT_3K)+K5-6OM/TJRO;VW]=HH _FQ_X-:=2AU7_ ()[?%R\@ANH$E_;3^,D
MPCO+=[>91=^ ?@W?(I5LJS1Q7213&-Y$CN4G@+F2%P/Z3J_BX_9$^+_Q3^ ?
M[*>AVWP2M_BGHG@76=#\/^+_ (BK\$/ACXN\36D'C74?#5@^J>)/$NH_#_PK
MJ[^%_$>OVMDKZAK6HWNC7WB2VTA);N[U"+1 ]G\^_$S_ (*C>&=7GN=*\9^/
M?BUXMU'3)Y(YM-\?WWB_-K+L4,/LNLMJU];2,@C'E2:;#+Y>P%  JGJP66YQ
MF&&6)R[),[S6BE%2GDN2YQG?)/W>:G-95@,6XU$I+W'>3DTK6:;^EPO#&99C
MC986C5RC!3YY*-3B+B+AOA/#5(*4H*M2Q7$^<93AYX=RA)>W57V22;E--.*_
MM_\ $WQF^$7@R=[7Q9\4?A]X;O(T1VL=:\8>'].U#8^=C+87.H1WCAP"5V0,
M2JLP^56(^=_$O_!03]E?P['<B'X@W7B2[M@_^@>&O"_B2\DN&1MFRVU"^TS3
MM#E+D,4?^U5A95W^8%:,O_$!J'_!1;P?<.JZ0^AZ8C%5:35-.\9:MY>YL&0F
MST?2FVHI!(6&5OE)"/D)7I7P_P#BSXR^,[-+X._:$_9U\/I)/%"EEXW^+7PA
M^$$YDN$#Q1VMI\9-3\*ZQ<\'8! +AQ.PMSFY*15Y^94.*LNI3K2\-?%"O3AI
M[7_4/B+!4+O;FJYE@<'RQ;T;Y6^T6?J^0> =7.'#^T_&GZ./"O-'GE3S?QJX
M0S.O%*24H*/"6*XDI2J6?-&+KQ@TG>K$_JQ\4?\ !5KX:6:X\&_"[QOXAD#N
MK?\ "1ZGH?A*$J%^5XY-.D\8RL'?C$EM$RQX<C?F(?FQXK_:L^*'B;XYZI\;
MO"\6@^#_ !?JEFWA[14L?#7A;6)M(T>7%O:0K>ZQH$WV_7TMRMI)XLN+>+6W
MM"VFPW-GH@BTN'YR\'_\$X_^"A'CJPA\5_#[XE?"_P 6Z-?QQSVNN>"/CCX;
MUK0[F*12D4MG=^'UN-+>*01/M>V;9(RR,"S;R?&-0^ OQZU7X[/^P_J$OP_N
MOCSJ.M^=)X^U#XXW#^&AJSZ0UQ]KO=1MH[_7;>YB\.I]D?P;#I,WB!(5%Q:^
M!YE>".3\YQ/&N>4JU>CB^$,5DLOJ]6CE=;-:^9.>+SV:4<'EM3+L+E<(N-6?
M/*4ZV/H12I\KE1<U4A^H8+Z*G#>.AAZF1^/' ?&\,'5I9EQE1X+JY-BI\*<%
M81J>?\7XK$YYQ'D\Z^!R>G.DIX;+\)B\RQ,J\'A\!74*D%]9?$#4O%VN:K8Z
MY\>OB>+#4-2ADFTN[^)GC&UTZ6XM=^^2#1[CQ9J>GZ=':J3F.VTF26WC48BM
MU1<#QZZ_: _9T\"K+=6OC4:]K6EW2K]C\.Z/KNKZNTL;9$^E:M<Z?I7@Z<QG
M#1W%IXE@B?@I.2#CM_!__!#']LG3]2N7^(.D_LS>,M),@^RQ>#_VOOBG\-M2
MV<[FN;G6_P#@GK\5[8R.<$".VQ'@@M+G(^Z/AQ_P3*\4_#DZ;=?\.\OV*/'F
MKZ:$_P")O\2/^"DW[3'B@7[H03)J7AK_ (=R6/@>[+D O&?"J6Y&56%49E/Y
MCF_ASXJ<=MKBKC'-<OP%3XLERG,J7#N4.G*,;TZE#(*&(S3&)3O4IT\SSS%0
M@N6,TY4^8^YRW//H2>%JC++<5QEXGYKA[*&995PMA\%&MB(.34IU^-Z]&.#H
MRBHT:E;)L#1K.7/6HN=*IR+\H=8_;?\ #VH:H-,\!?#;QKXSOM258M/EUC4+
M'0M4DU.0C;$/#^C6GCF;5E;YMJP:U97#D#"#FO#?#OB7]K#Q5^TUH]MX1\&:
MQ:?''6!:>']!^'FI^#+&-8=#ENTU^ST34/#WCRQ:R_L ,%U*ZOO$^;:2V+W=
M_?"T9F']7W@?2?VSOAC9OIWPV_81_P""=OP^L)55);+P1^VC\5O"EI*J'*K)
M;Z%_P3$L(I IY&]&P>>O-?*'_#/?_!5/_AMO_AL;_A#OV$/LO_"$_P#"L/\
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M_P#I<='_  G/_!0S_HU[]C+_ ,3Q^-__ -+CH]G+O#_P93_^2#F7:7_@$_\
MY$_26BL3PU<>([KPYX?NO&.E:)H7BZYT32KCQ5H?AKQ!?^+/#FC>(YK""37-
M*\/^*M4\,^"]3\2Z)IVIM=6>E>(-1\'>$[_6;"&#4;SPSH5Q<R:7:[=?:GR(
M4444 %%%% !1110 5_)[^T1\(?VY/BE_P7I_:%M?V'/VC/#_ .RSXYM?V'OA
M?>>)?B%XP^%OAKXG:)XB\'Q>*?"5M=>$+/3_ !?X3\6:5::C)KESHFL?;[6T
M@OH[?29[87*P7,\4O]85%)J_WK\-?D5&7+?1.ZMKMNGMUVV/Q?\ V7_V9?\
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M>3:CKFIQ^#GT@WNH.%9[Z?2M'TJSTJ]O+Z<--J5S-#%-=W$DU[=O>74\SO\
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MBZDT+Q%<1AHS+)Y27#*X$CM&NUF)1- _X*$Z.J/:V7[7EJ-@MT&FR?%UG6(
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M$,I3Q,Z-)I]U96^E7)B:1)+S4[*2V::S6\N;4;QQXH5"P^%WBYF$3.(Q=^%
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MS&2WPY_;I_:'^#K$Q+.JEF^$7_!.CP.S%A<2&4L29W6&2?S'MK9HO@_XB_\
M!O)<^,KN2\\)?LS?"3X2@I"L6E^#?^"HGQ?US1D:,$2/(GQ)_P""4?CG7)3.
M"6<+K\2I*L;1!(A)#+]!?%/_ (.)/''P/\)S>//C+_P21_;^^$?@FWO[#3)_
M&/Q3\#:O\/?"<&H:E*8K*PF\1^*O!NFZ3'?WI25;"S>Z6>]EC,4*_>9/1O\
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M/^"F_P 1_P!HI].M?@U9?\$P_&FLZLJMI_A2+_@IE\8-$\=7 9%<8\ ^)/\
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M\/G_ -WMD6NW_41?_AWY%_VA'_H!S'S_ -@Q.FWEY_AZ7_J#_P"$\_X*-?\
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MP6F\5_"RP\3^&/V0O%7[8/A76=3U670OC1IG['7QYU6QU1;&]ETG4M'L];^
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M _S8_P#\->8?_,1^Q7_"<_\ !0S_ *->_8R_\3Q^-_\ ]+CH_P"$Y_X*&?\
M1KW[&7_B>/QO_P#I<=?B9\.O^"\O[9_Q@\&Z/\1?A+_P2'_:$^*/P^\1?VA_
MPC_COX=:1\>O&W@W7?[(U6^T+5?['\3^&?V;=3T34_[,UO3-2T?4/L5]/]BU
M73[[3[GRKNTN(8_G[P-_P6__ ."H]]^T[\2_"%W^P)\1?'EOX9TJPU+7/V5?
M#?[/_P >=/\ BK\)]!UFW^U>#_$'B#6;3P#KOC.REUVVO=,NKS5_%G@E/#_B
M:!DE\+:-X9BOH6BZ:'AIG=:&(E4S3@3"RHT75I4Z_'W"LIXN:E%+#8=X;.L1
M"-:2ESJ6*GAL/RQ=ZZDXQE$L\P<7%*.93YI<LG'+,8E37\\^?"P;C?2T%.=V
MO=MJ?T:?\)S_ ,%#/^C7OV,O_$\?C?\ _2XZ/^$Y_P""AG_1KW[&7_B>/QO_
M /I<=?B'X]_X+X_MA_"O_A%/^%G_ /!)+X]_#C_A//%NE> ? _\ PGNG_'7P
M?_PF?CO7?._L/P5X4_X2']G#3O\ A(O%NL_9Y_[*\.:1]LUC4?(F^QV<WEOM
M[+4_^"UG_!0/1=-U#6=9_P""+'[5NDZ1I-C=ZGJNJZGX(_:0L--TS3;""2ZO
MM0U"^NOV8HK6RL;*UBEN;N[N98X+>".2::1(T9AS?\0[X@_Z".#/_%@<%?\
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M6EU9:IX3C\-VMTEI>6_#K.887&XJMF/!-%8/#3Q,:"XXX9Q6*QKIV<L-@:&
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MWAW23X]B^'<^N)XGE\#1^+#:_P!MKX3?Q&BZZV@"]_LS^UMVH"V%TS2MWE%
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MI>A:-;6>G67]H:OJ.H:K?-!;HUWJ-]>7UP9+FYFE=-*^%WPVT+Q_XL^*VB^
M?!VD_$WQYI/A_0O&WQ!T[PYI-EXR\6Z-X42YC\-:7XC\26]I'JVLV.A17EQ%
MI5M?W<\5E"XB@5(XXE3NZ* //OB!\)OA?\5_^$-_X6=\//!GQ!_X5WXYT'XG
M> O^$Q\-Z3XC_P"$-^(OA;[5_P (WXY\,_VK:W7]B^*]"^VWG]DZ[I_D:E8?
M:9_LUQ'YKY[B\L[/4;.[T_4+6VO["_MI[.^L;R"*ZL[RSNHG@N;6[MIT>&XM
MKB%WAG@F1XIHG>.1&1B#9HH XWX>_#KP#\)?!GA_X<_"[P7X7^'G@'PI9'3O
M#/@SP7H>F^&_#&@V+7$UW):Z3HFDV]II]C%+=W-Q=S+;VZ>==7$]S*7GFED:
MEH_PI^&/A[X@^,?BSH/P]\%Z+\4/B'IOA[1_'OQ#TOPSH]AXT\9Z5X3MY;3P
MQI_BCQ+:V<6L:[:Z!:3-::3#J5W<I8VBPVUN$@MX(X^_HH X'QW\*OAE\47\
M&2?$GX?^#?'S_#GQQH?Q-\ -XP\-Z1XC/@OXB^&5NT\.>.O"YU:TN_[#\6Z"
M+^\_L?Q!IWV?5--:YF>SN86<M7P3^T;^V;\+U\<>+/V6_BK^S]\<]7^!?C_Q
MMX3_ &//BE\>TM_".@_">#XC?M.>$_#]AX,^'.AQS>/M+^+WC&/Q!8?$/3=
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M<H""]O=VD\UO,H(+1R,,C.:^ _\ @G1\0/B)XA\)?M+_  G^)'Q \5_%B_\
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M9&G?H_NZ63N_+5+U8K>:_K^NFQ^LE%%%,04444 %%%% !1110 4444 %%%%
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M_'.F7VA:H^EJMM>71==U_P .'+)='W^5KW^X_0*BBBF2%%%% !1110 4444
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MX65NW0****8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MEBBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQ2C9^2_/O;TT'*IS1:ZMV[M15M+Z7O)7VT^9Z11115F04444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>(XO@G\:OC#XS^'$GBSQ%+;Z/I6M?$KPCX1\*QW]W:V^I>(-/DG1:K?M#_\
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M-M/SW[,))).VEI67]Y6>O;31Z:>\O*_Z>4444R HHHH **** "BBB@ HHHH
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M?Q>\2P?#QOA[\=+CP1H6M^+=5C\&0^%_B+XG\?Z$]]X-\,>*?%^@Q?$WP+X
MN-8T#PSK=U;0^=;V]M=>2?L#?$/]G#XE>.OVH?B;\,_BO\'?C1^T1\7O$'@'
MXH?M%W?P%\:Z/\4?!7P^T2W\)R?#CX ?!^W^)?A^27PIK-SX3\"> =2CO!'J
MT5QK/CRZ^(WC8:-X8T+Q1I&CV7X[?\$W/#,'A_\ :J_9!^,'P[UGP#XI^&_Q
MXU?]KC1]3_8CU#QSXZ\5^-/^"5WC<Q?$;Q/XSNOA+X>\2ZI!;>&O#FJW?A'P
M]\%_CI>Z]X.\*1V7Q"\912?"&3_A!?BK!X917?NVUOU\KI??9V?F_(.5>]NK
M):;ZM-M7]5I?1KSL?T;_ +5G[1ND?LE_ CQ]^T)XF^'/Q*^)G@[X8:->>*/&
MVC_"B'P%=>+-'\'Z39W.H:_XK%A\0_'_ ,.=)U#2_#]E:O=:E9Z9KEYX@DA8
M/IFB:B([CR?(O@'^WU\,/CE\6;'X$:E\/?B_\#OC'K_P5T?]HOP3X#^,>D>!
M/M'C_P"">LZP- B\=^$O%'PF^(?Q7\!W$5CJLVGV^J^&-6\6:1XWL$U.VN9O
M#'V6#4YM/XW_ (*Y^)_#?A?_ ()G?MP2>)=?T7P_'KG[,_QC\,:*^M:G9:8N
MK^)-<\ Z_:Z+H&EF]FA^WZUJUSF'3M,M?-O;R0,L$,A5L<9^Q'^RY\.M?U7]
MG_\ ;SG^-/B_XU^-Y_V+/A[\ ?AY"]]\.9/A)X#\ 2VOA+Q#XG?P9IG@WPCI
M]]/XUU7Q9H%S;>)_%.L^*=9OQ$]_X7BMM,TNRM-+L*]/ZU^_O;IW$DN5M]VD
M]=]/EUUZ]CWOQ-^VMX=B\8?$[P5\'/@G\>/VG]1^"-_+H/QCU+X$Z1\-)?#G
M@#QC!HVE>([CX>OX@^+'Q2^%.F>./B-8^'];TS5=9\#?"V?QWXC\.K>6FE>(
MK#2?$6H:7HM][Q\$/CA\,/VC/AIX?^+GP?\ $R>*_ OB1]5MK'46T[5=$U"S
MU3P_J]]X>\1:#KOA_7['3-?\.^(O#NOZ9J6B:]H.N:;8:KI6IV-S:7EK%)'@
M_D3_ ,$U_B5X*_9$_P"&Z/V?/VL_B!X#^#7QC\-?MF?M"?M$ZCK/Q0\3^%_
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M+H_B5TT%_P!1/G;/\+_)GTE%%%!%'!!''###&D4,,2+'%%%&H2...- $2-$
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MPS2NOZ^7^:'9O6W];OY)+5['W=5>*TM(9[FZAM;>*YO3";RXBACCGNS;Q^5
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M<;P5)K&NVD^O_%KQQX.N=8\.?"WPMI<%]J'AJ^E?XA^,;(:9H.E>&_''D/\
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M6O'?PXU'PN]MX4\8V^GVNA>,/$GC]Y^T)X4^%'@'XR?#S6_C;?:[^P_\/?\
M@LC\1/A9\7-9\1^._BM^T"GPV_9]\4_LP^'/$/P<T+Q9)X?^)-A\2M0_9UO/
MVG[J^'B2>7XBV>G7.O6/_"/ZR/&6C7_B[P9K_P#79%%%!%'!!''###&D4,,2
M+'%%%&H2...- $2-$ 5$4!54!5   HFAAN89;>XBBGMYXI(9X)HUEAFAE4I+
M%+$X9)(I$9DDC=65U8JP()%+EMLTMNCV5M-]M-1\_==^J6[O?:UUWMYV/Y79
M?^%%V_[7W_!)KQ)XJ^/LO[3?P8O?CE_P49\-?"SXW?$.4:[X4\06-Y\*?!NK
M>"?AA\)/%^H>,OB#XG^)'A'P=\8+OQ%\+OA+?^*_$>M>//$OBCP[!X&T*[\8
M6NE^#-7U[9U'Q]X_^('A?XG>*]"^('BC2?\ @J1\)O\ @K)=_"#PEX'L_B5X
MLTR]\3?"K4/VAO"5QIWPQNOA]!+H2Z[^R>/V08;WX@-)JGA/5_#$NF^#?%OQ
M::[M_$=[XJU&/^H06=F$M(Q:VPCL&1K%!!$$LFC@DM8VM%V;;=DMI9;=#"$*
MP221 B-V4K]DM/M9O_LMO]N-N+0WODQ_:S:"0S"U-QM\XVXF9I1#O\L2$R!=
MQ)HMY_U9+K?5-75[_J'.M+J]M-[77,W9V2WO9]]]S^>']D'XS? ?XE?&WQ3%
M\6_CA\2_#?\ P49^&_[>O[1^G?$CX8^"?B//IU_XA^%'A'Q1\0O#7A3P?KGA
M'QM'%X=E_8F\%?L_?\(9\0+J>WMO#T=YXV\"V'B[0]9U+XO:_8Z3XN_._P"#
MWQ_^&,7[(?PQ^#<OQ,TS3-;\92_\%<+W1+3Q3\:+[X>_!N]\76_[3]AJO@:?
M1='\'VK>+/C+^UQH.HZ_X-U[]G3X8>&_%O@?5]/T'QGXG\=V7B*TU6[\$IJ_
M]F"V]NL\ETL$*W4T44,MRL2">6&%I'ABDF"B1XH7FF:*-F*QM+(R %V));>W
MG>%YH(9GMW>2W>6))'@DDAEMY)(6=28G>WFF@=D*LT,LL3$I(RDL]-5=>6^V
M^N^FX<RO>SZ6UVM?3;;71=/,_EU^.FL3_M(_\$]_^";WQK^"GQB@\4_\%&O#
M?[,GPR^,_AD2^.?#D@^,^B_"?X/66L_M/Z'\8]-\4WD_A[Q5HMMX@7Q3H=AK
M&JZ)K=QX6_:#OM+TN6Y\.Z=/\1-7T?\ 7K]B_P#:N_83U'X'_LA>!?@!\8/"
M]OH?QL\!ZO%\"?!OBCQ@NJ?$OQ7J'PZT/0=8^)OA_P 2W>HW^H:EJ_Q;\)GQ
M%:7_ ,1[+5M1N?$EYJ=UJ6L?\3"U2YO4_1&"""UABMK:&*WMX(TB@@@C2&&&
M*-0J1Q11JJ1QHH"HB*%50   *X+Q5\,O#'C3Q?\ #KQCXC6]O[SX5ZQJWB;P
M;IOGPV^DV7BO5O#FK^$3XDO$M[:/4=3N[#PUXB\0Z;I^EW^I3^&8[C5D\07&
M@W/BC0/">N>'Q)KKVO?K:VOK:_X=A.2:M:UFVK/OTM;H]NVO?3X%_P""CGPQ
M_P""=_QF7X4^ OVWOBWX?^"_CNVT_P")GBW]G+X@7?QVU+X ^-O!>MZ19>&(
M/&?CKX9^*3XCT'PQ?>+?",5WX7U.*S\1VGB6"W@#7#Z!>Z0VMQR?GE\#-?\
MC1\-/C/_ ,$@_CE^VUXLU?78?$/[._[;GP+G^-/Q1TJU^']KX?U_Q!XO\(_$
M+]GGQA\4+G4-MOX,^)WQT_9S^']A97OA?QCK47B%O%6F^(=+U.,>,8-6@O/Z
M0)[.TN9+::YM;:XELY3-:2SP12R6LQ4H9;9Y%9H)2A*F2(JQ4E<X.*?<6]O=
MPR6]U!#<V\J[98+B))H9%R#MDBD5D=<@'#*1D ]13:UOZ=-[-/7[G]X*5E;?
M?MI=-.VEU?2_>Q^27_!*+PA>V?[%GQ3\;>.K[Q-X6^&?[1?[0W[6O[1'PX@U
MC5=2^'.K>#?V>/C/\2?$OB/P-JNG:GH]UX?UWX>VGB#PI-)\4-)U2PUJSU?1
M(_%\>NV&KZ;-]F6P_%/]C-OA#J_P@_X)%^.]9_:<^)\'Q;_:$_:!_:M^#OQ_
MN1^V3\6[#5_%GPD&C_M5>(=0\+ZKH@^*4=MX6MW\<:=\+-2F\2>'=/\ #WBP
M^+O%>G^)X_$0\9^+;;7;O^Q^BER[>5OS7^7XAS;Z;N_II)?JGZH_DVM/VH+#
MX5_L-76B^&/VC++4?A'\$O\ @M)XZ^ .N^%_$'Q]D'B'QG^QCX9^+_Q)NO#?
MP&TSXV>-?&EG9Z+I%_\ #+P_9^(_#^I?%CXJ^#_!WCWX?^#-7\ 77C2^MO%-
MEX=USZN_8L\%^#_'/A5_A]X,_:,T+X^:#^TE^W'XF^/?_"+^%?VE;OX[VW[.
MG[&'[./B_3?BQ\*_@G-';^//'O@+39]'\>?\*:^&'Q/\/>#I8;&?PW\:SX3N
MO$7Q T'P/H.NWWZQ_M6?LS^,?V@U^%6O?#G]H;QW^SW\1/@IXMUWQOX%USP_
MX7\"_$'P1JFO>(?!>O?#V\7XD?#;QWHU[8^,]-M?"GBKQ-8:3!8ZYX7U'2;G
M7+S4['58=1AL+FSZ#X _LTZ/\%-9^(7C[5_$TGQ&^+_Q9F\/#Q[\1;OP9X"\
M#--HGA&UO;?PEX(\.^'O 'AW0K/3?!?A>XUCQ%J6D0^(+OQ;XOFU'Q+K$VO>
M--<C&F0Z:)-/?1))>>U^OE;\5U*<E;HG>]NM]+=+6Z[WOH]#^9G]I7XU_#;0
MO^"GG[?VC?&7Q5I"_L3:O\:O^"?>B?M:^)/A]\0Y?#GQ9\ ZIH/P9FTGX5ZC
M<7V@W"Z[8? VW^++-X _:2OO!FI>'_B+X>/B#PEIEGK-MHEYXST/6.Y_;5^*
MGA/Q_P#M(?M7?LN6'[87PL^"YO-#_80MOV)/BW!^U/H'P.\'_LG^%X]+\/>(
M?C7HL'AVY^)7@'Q'XKO/B=\.-1N-6T/Q+\'?"_Q#\._$'1?&7A#X8>+_ (A>
M"W\+ ^#/ZQ:_-KQ+^P5\1]5^)'QPUK0_VR?B=H_PF_:,\1ZEXR^)'PPUWX4_
M ?XAZ]H'B?4/#/A#P,)/A%\2?&W@+59_!7AVU\"^"M'\*VGACQ3X4^(]G86B
M2:EI%QIFN37&ISEGT?6_WWNMUI]W5K6P*:OJK6BEOIIRZVMN^77NK)Z+7ZQ^
M$GQ:^!&O:WXI^ OPJ^)V@^+_ !;^S[H?P[T7QMX17QMJ/C7QKX3T3Q1X-TS7
MOAYJ7BK6/$.IZQXG\0KXJ\)RV>J6GC+5]6UNY\23_;;C4-;OM:CU-E_$#XR?
M%?X/K_P5\_:ET[5/V\_#7[']RG_!.[X-^"G^(NF^/OV;])N])\8Z'\=/BEKN
MMZ-=-\>/"GC;0%UKPUH\]O)KFCVEOI>M:9H?B*YO)+G2M3;0=;TC]R?A;^S]
M\,/@WJ$^H> M$;267X?_  V^$NB62RHNF>%/A9\(M.U/3_A[X"\.:=;0VUK:
MZ3H(US6KA]3O8[_Q3K!OK6PUSQ#J>B^&O!^E^'?:JHE-*^[35NGD^S70_C9@
M^(OAGPC_ ,$(+WPYXDG\->'/!W@G]OOP3HOPH^+NIR>)/#5]^UY\+_!G[:WP
MH\8ZQ^UT-#^(GB7Q+XODO/B+<:QXB\1^+8H=9U32-'ETZZ.AV^A>%(]'T/2_
MU!T?]J[]ESP?_P %G?V@?%/BW]I'X"^%?"]S_P $]/@+H=KXD\2_%_X?:%H%
MUK6E?&KXN:]JFDVNLZKXAM--N=2TW1-6TO5]0LH+F2XLM-U"RO;F.*WN8I'_
M 'EHI)-65UI;I_P?^&\QN5TTUNV]^_+W3_E_'I8_E]TKPK\(/VAO$_\ P6;_
M &K/BQJGC#X7_LC?M/>*?V8OA3^S'\3+2\F^&7C[XB_%_P"!WPAUKX61_%KX
M"7?B#4/#,6J3>)?'GB?3/"_PG\16FM6WA+XG68U72_$T@T2SU^"V]E_8!_:_
M^ '[(/[//[22?MF_%+P7X2_;%_9[^(]M\./VLK*Y\9^%%G\9ZWX>TO1?!GP)
MU#X-:1-?^'M$M? /Q!\ 6WA.YT^"WLO">EZ=\0K_ .(WB+XCCP_J3^+->']#
MM%%O/OT[N[Z][?UJAROHT[:=5T26]NJ6O2]G;2S_ )N_C%\4OV1_'?[&_P#P
M4N^)FEZO\!OVKOBQ\<?^%,>,/VL(?A/\0-1^(GPE^!W@S7-6\*_!OX%OKWQ3
M^$L6HW^L:/\ LM^ O".H_&7Q'%X%OH/&?B#Q?X-^)GC#0K3P!8>+-$.@_2/_
M  28\%>(OA)\5?VT_A-JGQ9\,?M<:)I5_P# ;QGX4_;>M/%VH^/OB=\6/#OB
MGPUXWTGP]\&_CKXMN]>\0Z->>/O@)X8\(Z%)I-KX+U!= NO!GQ(T+QMJ&C>'
M_$/CK48+[]LZKVEI:6%O':6-K;V=K"&$-M:0QV]O$&9G81PPJD:!G9G8*H!9
MF8\DDJVJ;W7E;O?[[_?Z@Y:-6T?=WM;E2MIT2MYIJ^J3/P[_ &R_%OAO5/\
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M7'PW\-?$9O&ENTNE-#_;0\'ZSKWA3X<>(_&>DZ.MW8_;]9'@'0A;27<27%E
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M3>%2_IYZ^:\M]?ZN')?J^EM.Z3Z-V5]+_P##'Z\Z5_P4'\:7?[1?[,'PPO\
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M_F2U9+2S;>GEI9ZZZN_W??+1113)"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ KY]^+O[4WP*^!6M6/ASXI>-V\-:YJ>CKKVGZ>GAGQ?K3W>F/=W
MEC'.MSH&@ZI8PM)>6%U L-S=03 QB1T2%XY&^@J^1_VA/V+_ (4?M)^)=+\6
M>/-4\;:?J^C^'4\-6!\,ZMI-C:+91W^HZE'--;ZCH&K-+=+=:G/EO.2%HDB0
MPY5W?VL@IY#4S*G#B2MF.'RMTZOM*F5JE+%JJH_N5%5J5:'LW+^)^[<N7X6F
M>7G$\WA@9RR.E@JV8*=/V=/'NHL.Z;E^];=*I2ESJ.L/?2ONGL?,/@__ (*O
M?";6_'%QHGBKP-XD\$^"))+J/3/'4U^OB"Z CE_T2?7_  EH^DO>:9!<VP=I
MO[%U+Q1<6MV8;=;>YMWEOK?]!_A-\9OAK\<O#E[XL^%OB3_A*/#^G:W<^';S
M4/['U[1/)UFTL=-U*XL_LOB+2](O9/+LM7T^?[1%;/:O]H\M)VFBGCB_([P7
M_P $E/$,7CDCXA?$W0[OX;VLTSI)X1@U&T\::W"I*VT$UIJ^FW&B^&VERLMS
M/%J/B8Q!'M88G:5;Z#]4/@#^S_X'_9P\':EX'\ W7B&[T?5?$UYXKN9/$M_9
M:C?+J=]I>C:1,D4]CIFE0K:"UT.S:.)K=Y%F:=S,RNB1_;\<83PRH8:#X2QF
M85<Q<,-:E3G6JY8Z;<O;5*\\=1^M1QCARR=.E6C1@VHNE"2E!?*<*8CCNM7D
MN(\-@Z>"YZ]ZDX4J>/4TH^RA2AA:JP\L*I<R4YTI596;]I*/+)_!'[0W_!0#
M]IGX#Z[\+%N/V./ -QX0^.W[<.F?L2?"#5/&O[3GBSP'XRUK5]<OO'6G:!\7
M?%/@BR_97\;67ACX;>()OAYKNI:&VG^,/%.NZKX8OO#7B2STV6QUR-;?"^)G
M_!0;]LGX3^)?@;X)\8_L'?#;1O%/QK_:FF_93TXZE^V!XEMO"R>(KKP4?B5X
M:^)?A?Q';_LC7LOC3X3ZYX*@U3[5K$.C:+XIT'QIH6N>!]0\('4],N;E'_\
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M/C/3/#FJ:WX_T7XB6VHQ0>([*[M9R^K_ ,_3_/\ JXG&R3WOKMY7W-7]L_\
M:\^,W[,OQ%_9=\$?#KX"?#?XMZ=^T_\ %JU^!VC^(?&?[07B3X0R^$?B'?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)N]2\&ZG#KNK>&=6,NC6Q?\ KT_K^K!RO\NJ6^V[V=UKMUV/TWHKQ_\ 9_\
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MN]2TB>6&>2VBU[PIJFBZ_I^^6WB,C:?J=L9X@]K<^=9SW%O+X_\ !/\ 8_\
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M5BL^S.WHHHH$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M$AL)[J'2IK,VVL2V%S+#"_RK\<O@[^U9^UY^T-^W?^U[\"OA]\4?@MHN@?\
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M7AK2Y-0N[@:-X5\/>'?"ND+9>'?#^C:98]13MMY=O1KS[B3Y7HKW2W\FI/\
M%6]#\K?V=_ WB+XI_P#!23]IS]M"/PIX[\'_  IM/V;_ ('_ +*WPUO/'?AO
MQ?X!OOB?JVEZWK_QI^(OC#3O OC+3/#>OVGA_P (WGC7PS\/K/6=;\/J]UXK
MTOQ[IFCW4<>EZO%/E_\ !;SX::C\6O\ @F_\;/!WAKX4^*_C#X]GUOX3ZC\/
MO"O@/X:>)?BCXVMO$&E?%3PA>:KK?AC1_".@^(->T?4+'P/'XO@N/$-E!8M;
MZ5>ZCI;:@@U<6MW^LU%%KJSZAS:I_P O+IZ6_.U_F?R[?M+_ +(_P'U7Q1_P
M58L/AC^POXA7PKXD_P""</PYMO@!I/AW]B'XI:?X6UG]JRS\,?M.1:?KGPOT
M:#X16^BR?&;0H?&'P=T]O%^@V:>*O#<UQ-87&K:?)I?BN*SYS]K:\U+Q;X\^
M'/ASQAX,^,/B?PM\4O\ @CK%^SW\1M*\??LH_M2_$(_LX^+OC'XJUC0K'XU:
M7X:^&OP8^)OC6V^+2ZKX \1Q^,O 7Q TKX%2^)=.^'WP_P!1\+_%J]NTNAX;
M_JLKXJ^)/["OPR^(/QNU/]H+2?B7^T?\(OB+XLT/0/"WQ+D^#'QW\<>!O#OQ
M4\*^%-,UO2O"FA>,/#"WFI:-9#PO#XDUVY\/:_X&M?!OB_1]2U;4=3L/$<%_
M?WD\XUV26JOTV=_Z_J]*?>^VG7HEU]/T?<\(^#/@'X->)OV?_P!@#]G[]FN\
MB\9?LV^#M0T7X@:_XRM/!5]X5T[Q%8?LB:K97<,GB-+/1/#MGX2^-.M_MA1_
M#7QOXS\+>(=)TOQ!KVH^$OC0-1TD:II.OR6?R;_P6(\"_M.>/?VD_P!@UOV5
M-)^(]AX_\%>$?VSKNX^)&B?!WXI^-?AQX;F\;_"GPQHOA_P+XX^(?@?09]/^
M&DGQJ&A>(OA=8^-+;Q%I7BKX;R^(K?XA:7+IUYI.CWTG[G^ ? ?A3X8>#/#G
M@#P1I;:/X5\*Z9#I6CV,VHZIK-[Y$1:2:\U77==O=3U_Q#KFIW4D^I:]XD\0
MZIJGB'Q%K-W?:WKVJ:CJ]_>7L_7T6TMZ?A;;MM\B5*SOO\6C\TUJMGOK]VQ_
M.?\ M$^+/"[_ /!//]@?4?@+^R[\:/V;M-\&?M?_ +.VL/\ L5^)/V9_C193
MZC)\--,\=?$+QY\*OB?X*\-_#3Q'\3M?\$BR\+:YX[@^,'@WX2?&"YUKQ[X:
M\&^+]9\.R_:_$>N^&?K'_@D=X/\ V;O!^A_M3WGPAO+:#XL?%K]HKQC^T'\;
MO ^H?!?Q]\$?%/PEL/C!KOB/5?A=\*K?0/BQ\._AG\2-:^&/@^PTSQ7:^!/%
M&J^&=,\.Z_XBF^(^L>$]#\)V>H7GA31OM[]IC]DKX<?M26_@*Y\6^)?BW\/O
M&WPGUK6O$GPJ^*'P4^*/BKX7^/OA_K_B+0;GPMKNIZ/>Z)>-H.K-JOAJ^U#P
M_>V/B_P]XETF;1]3U73SI_V;4[^.X[[X/? [P?\ !:T\1?V#J7C?Q5XD\9ZI
M;ZUXU\>_$OQMXB^('CCQ5J-G8Q:=8+>:WXBO;I-'T+2[6-UT/P5X3L_#O@7P
M[+>ZK<^'_#.EW.LZO-?)+6[>RLOPU[+T0^9<K6MVWII;=/5[O\[[Z6/E7]LS
M]B?P_P#'JRLO$^D:C^T/=^-[WXU_LJZUK&B>$/VR?VG_ (7^ [/P/X"_:$^#
M^K_$+7-'^&GA;X[>#?A1H.M^'_ACX=\3>)M/UCPWX6T_QI'XLTVV\5^$KI_B
M@NBZHWUY\)?A!X3^"OAR]\*^#M6^*.LZ9J&MW/B">Z^+7QP^-7Q]\1QW]U8:
M;ITMO9>,?CM\0/B/XNTW1%M]*M9+;PSIVN6OARSOY=2U2STJ#4]9UB\OO4:*
MJRWMKW)N[6N[>OI_D?EQ_P %,?@OXSDTOX&?MK_ 7X=WOQ"_:6_8>^)^F_$7
MP]X0\-:?9W7C#XM? WQ4C^"?VBO@II+7HE@-]XE^&VNZKXE\+3&RU/4]/\7^
M%=*_X1VU&HZE*ES\9_M0_"7Q1^S_ /$#]BO5OBQ\)OB9\8?@#KG@7]IC2/VD
MY_V9OV>M"^/=M\./VL?VB_%_P_\ B#XS^.FM?"OQ#\-_BWJ%_P##OQE-<_%C
MP#H6H:+X'N?&7@+PIK5UX4TO79M/\7:AX5\4_P!"=%*R_)_=;_)7]!J35E;:
M_P".WW-MKU=]#^3%?V._A6GQZUFTUC]BOXZ^)?@[8?\ !'OQGX#^']W\7_V;
MOBY\:_$P^)MS\6/$]_\  [0/%'BP?""8GX^>'/V?KGPEHMGX>?[=XQ^"NGQV
M_P &X_$$VH>$G>XK:'X-U>U\-?L[>!OVT/V</VUO'/P/^*G_  2B_90^ NC7
MWPM_9-USX@^,_@Y\8/A+X5\7:7\>O@MXST3Q+\(O&GQ<^%/C_P"(_B>?P?KW
MACXG>#H?AY+K.J>&O"5]>>)-0T_P#H'B[P3_ %KT4N5+;YZ+7;_+\2O:/M\[
MZZ=NVOKV>Y_--^UQ\'OVC;?]I?QA8?#3X9?&9/BA\0_^"%7C#X!_#?XD:)HO
MBCXH06/[2FD>/Y-6N/!_B#]HNRTCPOX<TGXDOX8@NGT_XH^*M3\%3ZAJ$FG:
MII-I)XEUGPSX1UGE/B]\#OB[\9?"GA_XM_L,_![XB_LU_$72?^"1?Q]^%/QZ
MTN3X+^.?A'XC\2>/]7\%_#O2?@-^SCH]GXFTSPOJVM_%WP)K_A#XH6FE>(=+
MO_$M]\.+./PM+)K%O:^,/"$NO?U"44<NK^7RM;;[M?EV$IM6TVV[?-=?\_N/
MYDOVB/#_ ,._CK_P3P_:RUC]E[]@/]H_X._$[Q-^Q-\-/V>]8\&WOP ^/GPZ
M\17^K>$_$]QJG@/X)> O@;_PB/\ 9?Q';X:R:E\0SXI^,&CZ)%%X?MK_ ,*^
M&+?Q5XKMM7U6Q\"X?_!5:P^(OQ0\-?M$^"_ /[/'QI3Q-XN_X)]_ 6Y^'GCC
M1?V9?CM\3/%'Q:UGP)\0?B1\18? GA_Q#_9<_P -_P!E;7/@EJ1FU_Q?8^.?
M"VD?'+XC:QXT\)Z1X2N/#VL>&O!0\0?U$T4[:6OZZ=]_U?KY:,4[-:;-M7??
MEW[KW?Z:3/YQ?VK? NFZO^V/\.?V^OA;^RS\>_%OP[\$^*/@A\.OVO\ X3I^
MSU\>['Q5^TKHFN7LWC3X3_&3P]\'_P#A74,WC_6_V,/%]KX%^(%YK4^F:U>Z
MK<&[\%ZC<>$/$/PJT:S\0?MWX _:2^'_ ,1_BA\5OA!H>D_$G3/&OPBT'X?^
M*=<MO&/PP\<>"-.\0>&OB7X<_P"$A\-ZSX)U3Q5HNDV?B:&&6'4O#/B&QM7C
MUCPOXOT75_#VO:;87=HOF^_UR^E>"_#&B^)/$WC'3](@C\5>,(-$L_$?B&>6
MYOM7U'2_#0U,^'-!%_?3W-Q9^&M N-<\0ZCHOAFP>UT#2M8\3^*M:L=-@U;Q
M1X@O=1+6^>_K_7K^HF[I7Z*RU]-_Q_!;(_%3X+? SX&>//VZOV9_VK/V)O@-
M\4OV7--TKP'\9+/]L.RU3]GSXH?LG>!?B+X0U7PO=:#\,OAMXO\ AUXR\ >"
M?#GC_P"+^C_%W5H_'-EXA\&6^JP:1X:\!Z])XY\37(U+X/0:CY+^T/\ #'XX
M>$;;_@M#^SMH/P4^)?CK5OV\M1^&VK?LN^*=&\*^)=>\-^,M0^/OP<\%?LZ_
M$*V\4_$G3M/UGPI\/=#^ /B?PW>^+/$>E>/-6\-3:-\,8G\2:5;S:)>6S0?T
M6T4)6VTUOHM.VVO_  _EH'-K=J]DEJ]=))ZO2_;R7H>=_"'P$GPJ^$WPO^%\
M6H3ZM'\-_AWX*\!1ZK=2W5Q<ZFG@_P -:9X>34+B>^GNKV:>]73A<RRWES<W
M4DDC/<3S2L\C?RM6_P"R;X"M/A?^TM?G]B#XE6/Q-D_X+=>#_&_P=U[1_P!B
MWXR6/C+1OV7!^T#\&?$FH^(/A]K^C?"B#6?"_P '(OACI?Q4>Y/A^]TSP[;"
MZOK!X(]8U_38-0_KIHH:3>NN_P"-O\@C)QOOJT[WML[_ (G\_P!\-_!>B?!5
M_P#@NQX?\ _#7XN_LP?!/5?!MIX_^#FO?#C]G3QK\+_#.FV>F?L1^'O#?Q,\
M<_ #3-9T'X9_#[7?'&C?$[1]>U*/2]"\1:)/X@\4V5OJDFIPZ?=#7HO(O^"9
M/A3X'7'[4_[/WQ-^+_A6T^#G[4W@W]ASX?\ [(7PX^%>K_LR?'_X5:3XU\2?
M#;3_ !'XO^(GQK\,^.OC[^SS\%;*3XIZGX &I^'I/ _@3^V=:\._#JW\>M?^
M-?'7A;58$\-?T&?&SX,?#O\ :'^%'CKX)_%G1[SQ!\./B1H4WASQ?HMAX@\0
M^%KO4M(GEAGDMHM>\*:IHNOZ?OEMXC(VGZG;&>(/:W/G6<]Q;R^/_!/]C_P7
M\&M<TCQ5?_%#]H7XY>+/#&FZ]HG@[Q'^T-\:/%?Q0NO!VB^(KW[5J-OH>EWD
MFG^&FUMK8+H8^(.L:%JWQ/E\,^?X;N_&UUHM_J=E>EM5M9+]5T^6@^9-/=-Z
M:=?=2NV^]KOKVZDW[,NEW&A?#;Q_\:O%6DZUI_B3X^_$#QE^T+XDTX^&?$L?
MBNW\+W^F:3X6^#VAZEX%^Q7?BFS\<^'/V=? 7PC\*>)_"5KIDNL-XWT76K6V
MTL7]R+(?SZ?\$=?"/Q;^#'BK]FG2_P!K#]EOXZ^);'4OAU\6=#_9B^(GB3]E
MOXVZ1J/[#_B:Y^,/B[4OBK\+_B+I.J>"SI?A&U^/5CJ?A/XD>%/VA[NQT?5-
M1T^]U7X3:SK\WA+PM9QZ3_5O11;;7;\=5O\ =]^O02E9-6O>WRLFE;MO]VFS
M/Y%O%6@? [QY\??BSX>_:]B\2:7\$?A[_P %;OB/^UC;_M"_$O\ 94^/7B.T
M\6^&_AS8:I\)]2_9O\;?$!?@CXJ_9UT_]GW2?%^DOX8A^(^N_'K6=*F^$G@[
M2_#/BCX8_#[Q'+#<^#?ZZ:_/OP-_P39^!'P]U34[70O''[2-S\)M1\7'Q\O[
M.6N_M#_$S7/@19>,+CQ7JWCK6=13PQJ&LS>(=4T3Q5XPUO4?$7C#X>>(_%NM
M_"_Q7J=S+-KO@F^$TZS?H)0E:]]6_P"K:ZNP2:=DKZ=[6V6UO37\- HHHIDA
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !7Y_?M<_\$POV-_VXO&&C?$#]HOX=:SXK\9>'/!R^!=!UW2?'_CCPI)I?
MA^/5-8UJWBBT[P[KNGZ-=7-MJNNZC>1W.I:;>N[2I!<">UBC@'Z T5W9=FF9
M9/BHXW*L?C,MQD(SA#%8'$5<+B(PJ*TX*K1G":C->[./-:2TDFM#.I2I5H.G
M5IPJP=FX3BI1;3NG:2:NGJGT/Y1O@]_P:[?#CPO\:QXA^,?[0]_\4O@5I5[<
M7EA\.M'\'7O@;Q?XIMY!<_8='\4^,;#Q;=KI%II[-9_VE?>&+.*_\0K'<"Q;
MPBTL;1?T._LH_L>_ #]B;X=ZS\*_V<O!]YX)\$>(/&FH_$'5=*O?%'B?Q;+<
M>*M5T/PYX<OM074?%FKZSJ,$<ND>%-#MA90W4=E&UH\\=ND]S<R2_3E%?1<1
M<?<7\5TXT<]SW&8S#1A2C]3C[/"8*<J+<H5JN"P=.AAJN(4I2E]8J4I5M5%3
M4(PC'GPV7X/"-O#T(0DV_?=YU$I6O%3FY34=%[J:76UVV_Q^_P""M&D>+/$>
ML?\ !->/P=\.?BS\03\./^"GO[,OQF\?2?#3X1_$SXDVW@[X7>$= ^+.E>)O
M&?B.[\"^%/$%KI6E:+>Z_I"7JW<T=ZL5['<Q6LEN'E6#_@IUK.L-\4?^":'B
M#P_\+OCU\0-(^&O[:?A#XQ_$*\^%?[/?QM^*@\%?#>/X5_%;PE=>(_$<7P^\
M!>(Y]-ELM9\4:1'=^'I8O^$JCMYGN%T-XXR3^Q%%?'6_-/[K?Y'<I6Y=-K_.
MY^4G[;GQ]F^+_P"RS^V7\,/AI\$OVEO$CP_L_P#C?PDFH3_LO_M,:!J_B?XE
M^.=,UK1O!O@OX8^$->^#=AK'Q.L'MM*U[4O&?COPP\W@[P29_ ]A<:GJESXS
M;^P?G']J?]DOXO?#3]HCX7?M)?L9^&[V^^!7[6O[5?[%^K?MW? AO#VN:1<:
M-K_A+]I[X/>.= _;%\&^#+^TTW6?"7C*T3PY'X;_ &BK0:3"FK>&KY_B)XT\
M-_VOH?B?Q]X;_>FBG_7]?EZ I6V6GGUV\NZNCXFUCX1?MS2_%[Q=XOT/]L[X
M8V7P?U"Q\;IX,^#&H_LCVE[J_AO4=6\$ZUI/@.;5_BU!\<;6_P#$5IX.\=76
MB>,=7@3P5I,OBS2=(NO"?G:&-5_MRR_/?X<?LN?MJ?!O]N?]B>Q/BOX,^*_A
MU\//V=OVH]-\>?%#1?V</C);V>L_\)]\8?V</&GQ-C\=^,[_ /:"U_28?VB?
MCQXEM]?^(6D>-M5N3976MV/Q(UR^^'7C$73MH'[PT4FD_P"O-/\ 1"YGY?<N
MUNW_  _6^I^"O[>/[%7C_P"*GC[X\?##]D7XF?'_ ,">)_\ @H ?"7AG]KF"
MY\,^%M5_9#\!?#WPOX2\/^"/'?Q8O=1\9?";5-07XR^*_A+96/PVTCX=?!_X
MI^&O%7CWQ#K'ACQIXQ_LGPOX#U7Q%9_6W[;_ ,$/#VF_\*/^-GPGF_:.\,?M
M"?LW^'/&W@O]GSPI^RMHOAB_OO'^@?$*Q\(^'-1^#?Q$M?'WPQ^)WPLT?X4Z
MM>^'/!AG\:?$S3]'\+_"J]T^U\=1Z]IMUI2O)^FE%%EKOK^'I\]?4?,]+VT_
M%62L_DK'Y<?L9:./V!OA7^R]^RG^T%K6K^./VC?VE?%WQ\^(OCOXL^ ?AAXB
MF^%/B'X_>,?%6N?&_P"(&E^(_%NB:)!X?\)7-S;>++[0?AY<^(;+PM!XST;X
M?7LMAI6A3V\.@Q>5_M_^ ?%7C[_@HE_P2KGTOP1\7M4\"^$(_P!N;2/BC\1_
M 7PQ^)?B7PS\,;/XW?LS:E\+? NH^(O''A+PY?Z#X6NM5\5RO96DU]K5A/I#
MBWU?5)-+TN6#46_7/5?!?AC7?$7A?Q7K.D0:IKO@F?4[SPC=7\MS<V_AS5-8
MTJ]T#4->TC3)9VTNR\2R^'=4UKPW%XFALEU^T\-^(?$WAZSU*#1?$NO6.H]1
M1;IT35O16"^M^K4K]-9)K2WDS^:_]GKX*_''XF?#;_@C5^R]XU^"_P 1OAGX
MS_8-^*FM?$C]I/7M3\*^*O"O@;PA;_LN^%?%_P )OA]IFA>-YK&Q\)_$ZZ^/
M^M>,_#'B3PS<^ ?$OB+2O$'@ZQ\<Z]J,<NEV&I62^L?M+_L\?";QS_P5;^(_
MCSXN_LE:W\6/A->_\$R=:T+6/%DW[)WCWXM>!?$'QRTKXJRWVFZ?%K.B?#7Q
M-HGB;XKVGPD\K2?#4MG<ZCXJM])1/"6ASQ7J)I%?OQ11RJUO-/[K6_!:_/8?
M-KMT>SM:[N[/7Y?U?^9C]BCX*GX1_%[_ ((N>+--_9F^+OP^\=0_L0_&?X8_
MM<^/A^S%\8?#>J0>/;WP'^SQIGPV\-_M!>/KGX>6F7TW7O!_CRP\*CQWK3Z9
MX6M;%$L)-)T2ZT9I_GWQ5H'P.\>?'WXL^'OVO8O$FE_!'X>_\%;OB/\ M8V_
M[0OQ+_94^/7B.T\6^&_AS8:I\)]2_9O\;?$!?@CXJ_9UT_\ 9]TGQ?I+^&(?
MB/KOQZUG2IOA)X.TOPSXH^&/P^\1RPW/@W^NFOS[\#?\$V?@1\/=4U.UT+QQ
M^TC<_";4?%Q\?+^SEKO[0_Q,USX$67C"X\5ZMXZUG44\,:AK,WB'5-$\5>,-
M;U'Q%XP^'GB/Q;K?PO\ %>IW,LVN^";X33K-/+LKZ7N_.UNFVMKC4E=MW7:U
MK[MZ-K3?TT]#V7P]X;O_ !C^UAX\^)VK:;>6VB_!CX9:7\"OAU<:AI>IZ7+<
M>(/B;=^&_B]\<]8TFXNU2P\2^%-7T?0_V;="TO6M,$L.G>+? _Q$\/RW+7ME
M?6UI_/=^T+X2^,5I_P %)_VR_BUXD_9@^.O[0?[%]U\8_P!B)OC%\![3]F/X
MU:]:_'S3/!'PI_X1#2?BY\+]4LO!XT;XSV7[+GQ>CT[7_$_P@4>)/!7Q)T+6
M;SQ3-;7,O@'P_K%E_5A1563^^_Z:_+3\R5*U]-TE^*=UV=U?R;ON?S7?\%,[
MFT\5_M6:QH,WA3XA>,?A;\7O^"7WB_X&ZY8ZM^RW^TG\3/#_ .SM/\>/B5XH
MM?!_QM\*>'?@_P#!OXH>)]/^)HC\%:M%XN^&7CW2?@'=ZCIWP]\ #0_B?_;%
MEJ5GX4_:3]AO1O@7X9_9(^ OA/\ 9LU[3O%/P:\&^ K'P5X7\36'AZ+PG<>(
M=2\&W5YX8\;:WXF\-IH_AZ;1?'VJ^/=)\3WWQ)L-1T/2M:A^($_B4:[90:R;
M]!R_Q)_85^&7Q!^-VI_M!:3\2_VC_A%\1?%FAZ!X6^)<GP8^._CCP-X=^*GA
M7PIIFMZ5X4T+QAX86\U+1K(>%X?$FNW/A[7_  -:^#?%^CZEJVHZG8>(X+^_
MO)Y_J;P#X#\*?##P9X<\ >"-+;1_"OA73(=*T>QFU'5-9O?(B+237FJZ[KM[
MJ>O^(=<U.ZDGU+7O$GB'5-4\0^(M9N[[6]>U34=7O[R]G$M6]-_T2_34<FFD
ME?1+M;;[_P#@>9^=?B7_ ()S^ M0_:8^%GC"T\0?M>S?#S3?@I^T/HOBWQ#_
M ,/%/VYH]7TGQQXI\?\ [,NJ> M#TB_E_:@3QKI6B:]H?A7XEWVKZ/X3>V\%
MZA=>&O#\WC*UDU;1?AZ;7[(^+?[-_P -/C3^S=XT_98\=6NM:]\,/&WPLNOA
M-J3^)/$.M^-_%PT9]"71--\07?C3QUJ'B7Q3XA\<Z++!8^(;/QQXIU?6_%-Q
MXKL+;Q/J>K7VN>;?R>]T466OG_DE^A+;=M=C\9/"?['W[7'Q%_X)I_M'_"#X
M_>,]./[9_P :/@+XG^  \96>KP7FFW6B?"GP9K/PJ^$MMJ7BF2+4+G4?"_QB
MO[7Q+\;?&\^I60UC3-2_:)^(.D-86)L;33K+XJ_:)_9N_:T_:N_9)^.(;_@F
M_P"+_A5^U1XU^$7P@^"WBF?QK^TO\.?B[X@^($VA?M%^!?BKJFF?#WXB>-?V
ME-7TO2?@/\/M)\">)]?N-/\ &L-KXGUKQ?\ $S0M-\"6<^G:'X[U[Q'_ $X4
M46TM=VM;IVMV&I-.]E=--;]+:63M;1?=N?SM_M)_LL?ME?$GXO?M[_%7X1_L
M]>+/#UYXX7_@F/\ %3X)Z-XD^*OP:\%Z1\:O%G[$/Q+\6>//''PD\3ZY\/?B
M[K7BWP)-KUAKVBVW@SQ:[^'+>S\2^&[&]3Q=X>MM,T_4;B+XK?LZ_M ?$?0O
M@Y^T#X _8#\<_"[QWHO_  4%_8A^//Q@^%GB/XV_#CXA?M$?$;PU\!?#OC?2
M/'GQ%U3XC^*?CWJ_P\\0Z9H=GXST'X?_  MT'6?%'A/QM<Z5X+U/6O%4>C^&
M-6\-Z=X1_HIHHMYOOT[W[?F/G>FBTMWV22UU[)?/Y6_!3XN?LM?M0ZY<?\%<
M/@W<_ ^7XB>%O^"AGAOX?ZI\%/B=_P )?\,KGPOX"\;>(O@/X5^!7C/2OB?<
M:KJGA+QWIV@_ +7/#6A_$3P;<Z5X1\2MXA\'Z3)%X5LK[XAR7F@:MI_"OX!_
MM0_ SXQ?M1?L_>(_V5[?]K'X(?M"?$G]GGXC>!/VI/BSXA^!_BKPCH.I> _@
MS\#/AMK>I_';X8^)O&/A_P"(OB"+X.^)_A%IOCKX9^'O!V@7^IZ[JEK:P:/X
M@\*7LUWXUT7]V**+=FU\_7O?O^0N9]ELEUZ)*^CW]W[[^5OP!D^ W[9/@_P+
M_P %)+OPY^S-J6IZU\:?^"B'PJ_:&^&EEJ>K_LT>,/$^O?!G3M4^ =GXF\??
M"/0/&7C_ ,2?#6S^._PVB^&6L^//AGI7QOA\/>'+/Q/I_A36?(\0ZE9MX6GY
MKX;?LA?';QS\&_VZ?V5OC9^RI\5#X _;7_;4N_B3<?%#XC?$C]GSQIKWPZ^%
MWQ ^$GP0MK_XGZI%HOQ=NIY_C'\-O$?PPU-=)MO VE^(O"GA#XFWGA&_\&Z;
MXX^'/AS4;,?T1T46\WZ:6]-@4VMDMT^O2UNO2Q^0W[-?QA_:4_9(_9-^ OPY
M_:-_9-\:'7O 'QH^&W[)NJ^-O!/B_P" BZ/XO\!^*O$]W\./AI^TY%X=TGXN
M:[J,=SXQUVY^'UM\1/A].]OX[/CCQ[J.I>'M+U^VAFMU_0_XV_$;QO\ #?2/
M"M]X-^ /C_\ :#M_$'B^U\+^+= ^&^M_"_2M?\)>&=1TC69I/&MS8_%CQQ\/
M/#_B#1+/5K32M%U;2K#Q&NMQV^N?VI::=J-MIUY!7K5YI&DZA=:7?7^F:=?7
MVAW<U_HEY>65M<W6CWUQ8W6EW%YI=Q-$\VGW<^FWU[ITUQ:/#-+8WEU:.[6]
MQ-&^A1;2UW^'^0F[ZV76^^OXG\_.B?\ !.WXI_!SPG\&_C+\#/@_I?A#Q-X
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827:WY>KO^GS-FBBBF2%%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Submission<br></strong></div></th>
<th class="th"><div>Jul. 20, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_SubmissionLineItems', window );"><strong>Submission [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Central Index Key</a></td>
<td class="text">0001162194<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Registrant Name</a></td>
<td class="text">STANDARD BIOTOOLS INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FormTp', window );">Form Type</a></td>
<td class="text">S-4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_SubmissnTp', window );">Submission Type</a></td>
<td class="text">S-4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeExhibitTp', window );">Fee Exhibit Type</a></td>
<td class="text">EX-FILING FEES<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OffsetTableNa', window );">Offset Table N/A</a></td>
<td class="text">N/A<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_CombinedProspectusTableNa', window );">Combined Prospectus Table N/A</a></td>
<td class="text">N/A<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_CombinedProspectusTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_CombinedProspectusTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeExhibitTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeExhibitTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:feeExhibitTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FormTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FormTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OffsetTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OffsetTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_SubmissionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_SubmissionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_SubmissnTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_SubmissnTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Offerings<br></strong></div></th>
<th class="th">
<div>Jul. 20, 2026 </div>
<div>USD ($) </div>
<div>shares </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingAxis=1', window );">Offering: 1</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_PrevslyPdFlg', window );">Fee Previously Paid</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeesOthrRuleFlg', window );">Other Rule</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_AmtSctiesRegd', window );">Amount Registered | shares</a></td>
<td class="nump">2,760,078,538<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxAggtOfferingPric', window );">Maximum Aggregate Offering Price</a></td>
<td class="nump">$ 572.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="nump">0.01381%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeAmt', window );">Amount of Registration Fee</a></td>
<td class="nump">$ 0.08<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingNote', window );">Offering Note</a></td>
<td class="text"><table style="font-size: 12pt; border-spacing: 0px; border-collapse: collapse; width: 100%;"> <tr style="height: 0px; font-size: 0px;"><td style="width: 1%;">&#160;</td><td style="width: 99%;">&#160;</td></tr><tr style="vertical-align: top;"> <td style="padding: 0px 0pt;"> <div style="margin-bottom: 4pt;"> <span style="font-size: 10.0pt;">(1)</span> </div> </td> <td style="padding: 0px 5.4pt; text-align: left;"> <div style="margin-bottom: 4pt;"> <span style="font-size: 10.0pt;">Relates to common stock, $0.001 par value per share (&#8220;Standard BioTools Common Stock&#8221;), of Standard BioTools Inc., a Delaware corporation (&#8220;Standard BioTools&#8221;) issuable to holders of common stock, $0.00001 par value per share (&#8220;Treeline Common Stock&#8221;) of Treeline Biosciences, Inc., a Delaware corporation (&#8220;Treeline&#8221;), holders of preferred stock, par value $0.00001 per share of Treeline (&#8220;Treeline Preferred Stock&#8221; and together with the Treeline Common Stock, the &#8220;Treeline Capital Stock&#8221;), holders of warrants to purchase shares of Treeline Common Stock that have been amended to require net-exercise in connection with the Merger (as defined below) in the proposed merger (the &#8220;Merger&#8221;) of Siri Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Standard BioTools (&#8220;Merger Sub&#8221;), with and into Treeline, with Treeline surviving as a wholly owned subsidiary of Standard BioTools. The amount of Standard BioTools Common Stock to be registered includes the estimated maximum number of shares of Standard BioTools Common Stock that are expected to be issued pursuant to the Merger, without taking into account the effect of a reverse stock split of Standard BioTools Common Stock, assuming an estimated pre-split exchange ratio (which is subject to adjustment prior to the closing of the Merger) of approximately 16.07931 shares of Standard BioTools Common Stock for each share of Treeline Capital Stock. Such exchange ratio is only an estimate as the actual exchange ratio will be determined in connection with the closing of the Merger. In accordance with Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), this registration statement shall be deemed to cover any securities that may from time to time be offered or issued resulting from forward or reverse stock splits, stock dividends or similar transactions.</span> </div> </td> </tr> </table><table style="font-size: 12pt; border-spacing: 0px; border-collapse: collapse; width: 100%;">
   <tr style="height: 0px; font-size: 0px;"><td style="width: 1%;">&#160;</td><td style="width: 99%;">&#160;</td></tr><tr style="vertical-align: top;">
    <td style="padding: 0px 0pt;">
     <div style="margin-bottom: 4pt;">
      <span style="font-size: 10.0pt;">(2)</span>
     </div>
    </td>
    <td style="padding: 0px 5.4pt; text-align: left;">
     <div style="margin-bottom: 4pt;">
      <span style="font-size: 10.0pt;">Estimated solely for purposes of calculating the registration fee in accordance with Rule 457(f)(2) of the Securities Act. Treeline is a private company, no market exists for its securities, and Treeline has an accumulated capital deficit. Therefore, the proposed maximum aggregate offering price for the shares of Standard BioTools Common Stock expected to be issued pursuant to the Merger is one-third of the aggregate par value of the Treeline securities expected to be exchanged in the proposed Merger.</span>
     </div>
    </td>
   </tr>
  </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingAxis=2', window );">Offering: 2</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_PrevslyPdFlg', window );">Fee Previously Paid</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeesOthrRuleFlg', window );">Other Rule</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_AmtSctiesRegd', window );">Amount Registered | shares</a></td>
<td class="nump">76,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxOfferingPricPerScty', window );">Proposed Maximum Offering Price per Unit | $ / shares</a></td>
<td class="nump">0.8946<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxAggtOfferingPric', window );">Maximum Aggregate Offering Price</a></td>
<td class="nump">$ 67,989,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="nump">0.01381%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeAmt', window );">Amount of Registration Fee</a></td>
<td class="nump">$ 9,389.36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingNote', window );">Offering Note</a></td>
<td class="text"><table style="font-size: 12pt; border-spacing: 0px; border-collapse: collapse; width: 100%;"> <tr style="height: 0px; font-size: 0px;"><td style="width: 1%;">&#160;</td><td style="width: 99%;">&#160;</td></tr><tr style="vertical-align: top;"> <td style="padding: 0px 0pt;"> <div style="margin-bottom: 4pt;"> <span style="font-size: 10.0pt;">(3)</span> </div> </td> <td style="padding: 0px 5.4pt; text-align: left;"> <div style="margin-bottom: 4pt;"> <span style="font-size: 10.0pt;">Relates to the maximum number of shares of Standard BioTools Common Stock issuable pursuant to the contingent value rights (&#8220;CVRs&#8221;) to be declared as a dividend to stockholders of record of Standard BioTools as of the close of business on the last business day prior to the day on which the effective time of the Merger occurs. Each holder of a CVR is entitled to a number of shares of the combined company&#8217;s common stock (with fractional shares settled in cash) equal to such holder&#8217;s pro rata portion of the aggregate net proceeds received by the combined company during such 12-month CVR payment period from the following sources, in each case less certain permitted deductions: (i) proceeds from any sale, disposition, or other monetization of Standard BioTools&#8217; legacy businesses; (ii) proceeds from convertible notes or other investments held by Standard BioTools as of the closing date of the Merger; (iii) earnout, milestone, royalty or other similar contingent payments due to Standard BioTools under contracts in effect as of the closing date of the Merger, including payments from Illumina, Inc. pursuant to the Stock Purchase Agreement dated June 22, 2025; and (iv) any surplus in Parent Net Cash (as defined in the Agreement and Plan of Merger and Reorganization dated June 6, 2026 (the &#8220;Merger Agreement&#8221;) by and among Standard BioTools, Treeline and Merger Sub and included as Annex A to this registration statement) delivered at closing of the Merger as finally determined under the Merger Agreement.</span> </div> </td> </tr> </table><table style="font-size: 12pt; border-spacing: 0px; border-collapse: collapse; width: 100%;">
   <tr style="height: 0px; font-size: 0px;"><td style="width: 1%;">&#160;</td><td style="width: 99%;">&#160;</td></tr><tr style="vertical-align: top;">
    <td style="padding: 0px 0pt;">
     <div style="margin-bottom: 4pt;">
      <span style="font-size: 10.0pt;">(4)</span>
     </div>
    </td>
    <td style="padding: 0px 5.4pt; text-align: left;">
     <div style="margin-bottom: 4pt;">
      <span style="font-size: 10.0pt;">Estimated solely for purposes of calculating the registration fee in accordance with Rule 457(c) of the Securities Act based on the average of the high and low prices per share of Standard BioTools Common Stock on July 13, 2026.</span>
     </div>
    </td>
   </tr>
  </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingAxis=3', window );">Offering: 3</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_PrevslyPdFlg', window );">Fee Previously Paid</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeesOthrRuleFlg', window );">Other Rule</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_AmtSctiesRegd', window );">Amount Registered | shares</a></td>
<td class="nump">2,032,831,848<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxAggtOfferingPric', window );">Maximum Aggregate Offering Price</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="nump">0.01381%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeAmt', window );">Amount of Registration Fee</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingNote', window );">Offering Note</a></td>
<td class="text"><table style="font-size: 12pt; border-spacing: 0px; border-collapse: collapse; width: 100%;"> <tr style="height: 0px; font-size: 0px;"><td style="width: 1%;">&#160;</td><td style="width: 99%;">&#160;</td></tr><tr style="vertical-align: top;"> <td style="padding: 0px 0pt;"> <div style="margin-bottom: 4pt;"> <span style="font-size: 10.0pt;">(5)</span> </div> </td> <td style="padding: 0px 5.4pt; text-align: left;"> <div style="margin-bottom: 4pt;"> <span style="font-size: 10.0pt;">Represents an aggregate of 2,032,831,848 Standard BioTools Common Stock issuable in accordance with (1) above to certain Treeline stockholders. Pursuant to Rule 457(f)(5) of the Securities Act, no additional filing fee is required to be paid for the registration of Standard BioTools Common Stock to be sold by the selling securityholders pursuant to the resale prospectus that are also being registered under this registration statement.</span> </div> </td> </tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_AmtSctiesRegd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of securities being registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_AmtSctiesRegd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegativeDecimal2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total amount of registration fee (amount due after offsets).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The rate per dollar of fees that public companies and other issuers pay to register their securities with the Commission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeesOthrRuleFlg">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Checkbox indicating whether filer is using a rule other than 457(a), 457(o), or 457(f) to calculate the registration fee due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeesOthrRuleFlg</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_MaxAggtOfferingPric">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum aggregate offering price for the offering that is being registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_MaxAggtOfferingPric</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative100TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_MaxOfferingPricPerScty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum offering price per share/unit being registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_MaxOfferingPricPerScty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegativeDecimal4lItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingSctyTitl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The title of the class of securities being registered (for each class being registered).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingSctyTitl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingSctyTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Type of securities: "Asset-backed Securities", "ADRs/ADSs", "Debt", "Debt Convertible into Equity", "Equity", "Face Amount Certificates", "Limited Partnership Interests", "Mortgage Backed Securities", "Non-Convertible Debt", "Unallocated (Universal) Shelf", "Exchange Traded Vehicle Securities", "Other"</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingSctyTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:securityTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_PrevslyPdFlg">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_PrevslyPdFlg</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fees Summary<br></strong></div></th>
<th class="th">
<div>Jul. 20, 2026 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeesSummaryLineItems', window );"><strong>Fees Summary [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlOfferingAmt', window );">Total Offering</a></td>
<td class="nump">$ 67,990,172.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlPrevslyPdAmt', window );">Previously Paid Amount</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlFeeAmt', window );">Total Fee Amount</a></td>
<td class="nump">9,389.44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlOffsetAmt', window );">Total Offset Amount</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_NetFeeAmt', window );">Net Fee</a></td>
<td class="nump">$ 9,389.44<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeesSummaryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeesSummaryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_NetFeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_NetFeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlFeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlFeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlOfferingAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlOfferingAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlOffsetAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlOffsetAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlPrevslyPdAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlPrevslyPdAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>4</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>1</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="ny20077604x1_ex107.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995210 - Document - Submission</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/submissionTable</Role>
      <ShortName>Submission</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ny20077604x1_ex107.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995211 - Document - Offerings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/feesOfferingTable</Role>
      <ShortName>Offerings</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ny20077604x1_ex107.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995215 - Document - Fees Summary</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/feesSummaryTable</Role>
      <ShortName>Fees Summary</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="EX-FILING FEES" original="ny20077604x1_ex107.htm">ny20077604x1_ex107.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="2">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/ffd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>48
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ny20077604x1_ex107.htm": {
   "dts": {
    "inline": {
     "local": [
      "ny20077604x1_ex107.htm"
     ]
    },
    "schema": {
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/arcrole/deprecated-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ffd/2025/ffd-2025.xsd"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 1,
   "memberCustom": 0,
   "hidden": {
    "total": 4,
    "http://xbrl.sec.gov/dei/2025": 1,
    "http://xbrl.sec.gov/ffd/2025": 3
   },
   "contextCount": 4,
   "entityCount": 1,
   "segmentCount": 1,
   "elementCount": 107,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/ffd/2025": 38,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "report": {
    "R1": {
     "role": "http://xbrl.sec.gov/ffd/role/document/submissionTable",
     "longName": "995210 - Document - Submission",
     "shortName": "Submission",
     "isDefault": "true",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077604x1_ex107.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077604x1_ex107.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
     "longName": "995211 - Document - Offerings",
     "shortName": "Offerings",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "ffd:PrevslyPdFlg",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077604x1_ex107.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c1",
      "name": "ffd:PrevslyPdFlg",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077604x1_ex107.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable",
     "longName": "995215 - Document - Fees Summary",
     "shortName": "Fees Summary",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ffd:TtlOfferingAmt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077604x1_ex107.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ffd:TtlOfferingAmt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077604x1_ex107.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "ffd_AggtRedRpPricFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AggtRedRpPricFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Redeemed or Repurchased Price, Fiscal Year",
        "terseLabel": "Aggregate Redeemed or Repurchased, FY"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AggtRedRpPricPrrFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AggtRedRpPricPrrFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Redeemed or Repurchased Price, Prior Fiscal Year",
        "terseLabel": "Aggregate Redeemed or Repurchased, Prior FY"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AggtSalesPricFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AggtSalesPricFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Sales Price, Fiscal Year",
        "terseLabel": "Aggregate Sales Price"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AmtRedCdts": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AmtRedCdts",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Redemption Credits",
        "terseLabel": "Redemption Credits"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AmtSctiesRcvd": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AmtSctiesRcvd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Securities Received",
        "terseLabel": "Amount of Securities Received",
        "documentation": "Amount of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form)"
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ffd_AmtSctiesRegd": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AmtSctiesRegd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Securities Registered",
        "terseLabel": "Amount Registered",
        "documentation": "The amount of securities being registered."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CeasedOprsDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CeasedOprsDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ceased Operations Date",
        "terseLabel": "Ceased Operations Date"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_CfwdFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Form Type",
        "terseLabel": "Carry Forward Form Type",
        "documentation": "The Form Type of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6). This should be an EDGAR submission type (S-3, S-3/A, S-3ASR, etc.), which means there is a fixed set of possible responses. Note that while the XBRL response should be an EDGAR submission type, the human-readable Ex. 107 could include a simpler label (e.g., \"Form S-3\" in the human-readable and \"S-3ASR\" in the XBRL)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CfwdPrevslyPdFee": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdPrevslyPdFee",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Previously Paid Fee",
        "terseLabel": "Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward",
        "documentation": "The fee previously paid in connection with the securities being brought forward from the prior shelf registration statement on which unsold securities are carried forward under 415(a)(6)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CfwdPrrFctvDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdPrrFctvDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Prior Effective Date",
        "terseLabel": "Carry Forward Initial Effective Date",
        "documentation": "The initial effective date of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CfwdPrrFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdPrrFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward File Number",
        "terseLabel": "Carry Forward File Number",
        "documentation": "The EDGAR File Number of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6). If the prior registration statement has a Securities Act File Number and an Investment Company Act File Number, the Securities Act File Number should be used."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CmbndPrspctsItemAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CmbndPrspctsItemAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus Item [Axis]",
        "terseLabel": "Combined Prospectus",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different references to earlier prospectuses on a single fee bearing submission."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CmbndPrspctsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CmbndPrspctsLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus [Line Items]",
        "terseLabel": "Combined Prospectus:"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CmbndPrspctsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CmbndPrspctsTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus [Table]",
        "terseLabel": "Combined Prospectus Table"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CombinedProspectusTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CombinedProspectusTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus Table [N/A]",
        "terseLabel": "Combined Prospectus Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_CshPdByRegistrantInTx": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CshPdByRegistrantInTx",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Paid by Registrant in Transaction",
        "terseLabel": "Cash Consideration Paid",
        "documentation": "Amount of cash consideration paid by registrant in connection with the exchange or other transaction being registered (in a 457(f) calculation)."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "ffd_CshRcvdByRegistrantInTx": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CshRcvdByRegistrantInTx",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Received by Registrant in Transaction",
        "terseLabel": "Cash Consideration Received",
        "documentation": "Amount of cash consideration received by registrant in connection with the exchange or other transaction being registered (in a 457(f) calculation)."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "ffd_FeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Amount",
        "terseLabel": "Amount of Registration Fee",
        "documentation": "Total amount of registration fee (amount due after offsets)."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeExhibitTp": {
     "xbrltype": "feeExhibitTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeExhibitTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Exhibit Type",
        "terseLabel": "Fee Exhibit Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_FeeIntrstAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeIntrstAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Interest Amount",
        "terseLabel": "Interest Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Note",
        "terseLabel": "Fee Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeNoteMaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeNoteMaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Note Maximum Aggregate Offering Price",
        "terseLabel": "Fee Note MAOP"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeRate",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Rate",
        "terseLabel": "Fee Rate",
        "documentation": "The rate per dollar of fees that public companies and other issuers pay to register their securities with the Commission."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeesOthrRuleFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeesOthrRuleFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fees, Other Rule [Flag]",
        "terseLabel": "Other Rule",
        "documentation": "Checkbox indicating whether filer is using a rule other than 457(a), 457(o), or 457(f) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeesSummaryLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeesSummaryLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fees Summary [Line Items]",
        "terseLabel": "Fees Summary:"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FnlPrspctsFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FnlPrspctsFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Final Prospectus [Flag]",
        "terseLabel": "Final Prospectus"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FormTp": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Form Type",
        "terseLabel": "Form Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_GnlInstrIIhiFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "GnlInstrIIhiFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General Instruction II.H,I [Flag]",
        "terseLabel": "General Instruction II.H,I"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrCity": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrCity",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, City",
        "terseLabel": "City"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStatOrCtryCd": {
     "xbrltype": "stateOrCountryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrStatOrCtryCd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, State or Country Code",
        "terseLabel": "State or Country Code"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStrt1": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrStrt1",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Street 1",
        "terseLabel": "Street 1"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStrt2": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrStrt2",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Street 2",
        "terseLabel": "Street 2"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrZipCd": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrZipCd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Zip Code",
        "terseLabel": "Zip Code"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrNm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrNm",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Name",
        "terseLabel": "Issuer Name"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_MaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "MaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Aggregate Offering Price",
        "terseLabel": "Maximum Aggregate Offering Price",
        "documentation": "The maximum aggregate offering price for the offering that is being registered."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_MaxOfferingPricPerScty": {
     "xbrltype": "nonNegativeDecimal4lItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "MaxOfferingPricPerScty",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Offering Price per Security",
        "terseLabel": "Proposed Maximum Offering Price per Unit",
        "documentation": "The maximum offering price per share/unit being registered."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NetFeeAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NetFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Fee Amount",
        "terseLabel": "Net Fee"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NetSalesAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NetSalesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Sales Amount",
        "terseLabel": "Net Sales"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NrrtvDsclsr": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NrrtvDsclsr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure",
        "terseLabel": "Narrative Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NrrtvMaxAggtAmt": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NrrtvMaxAggtAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure, Maximum Aggregate Offering Amount",
        "terseLabel": "Narrative - Max Aggregate Offering Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NrrtvMaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NrrtvMaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure, Maximum Aggregate Offering Price",
        "terseLabel": "Narrative - Max Aggregate Offering Price"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Axis]",
        "terseLabel": "Offering",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different security offerings on a single fee bearing submission."
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Line Items]",
        "terseLabel": "Offering:"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Note",
        "terseLabel": "Offering Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingSctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingSctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Security Title",
        "terseLabel": "Security Class Title",
        "documentation": "The title of the class of securities being registered (for each class being registered)."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingSctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingSctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Security Type",
        "terseLabel": "Security Type",
        "documentation": "Type of securities: \"Asset-backed Securities\", \"ADRs/ADSs\", \"Debt\", \"Debt Convertible into Equity\", \"Equity\", \"Face Amount Certificates\", \"Limited Partnership Interests\", \"Mortgage Backed Securities\", \"Non-Convertible Debt\", \"Unallocated (Universal) Shelf\", \"Exchange Traded Vehicle Securities\", \"Other\""
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Table]",
        "terseLabel": "Offering:"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Table [N/A]",
        "terseLabel": "Offering Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OffsetAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset [Axis]",
        "terseLabel": "Offset",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different offsets as applied to a fee bearing submission."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetClmInitlFilgDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetClmInitlFilgDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claim Initial Filing Date",
        "terseLabel": "Initial Filing Date",
        "documentation": "The initial filing date of the earlier registration statement with which the earlier (offsetting) fee was paid for a claimed offset. If the offset fee was paid with an amendment, do not provide the amendment date under this element; instead, provide the date of the initial filing (i.e. the \"parent\" filing) ."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetClmdAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetClmdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claimed Amount",
        "terseLabel": "Fee Offset Claimed",
        "documentation": "The amount of offsetting fees being claimed."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetClmdInd": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetClmdInd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claimed Indicator",
        "terseLabel": "Offset Claimed"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetExpltnForClmdAmt": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetExpltnForClmdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Explanation for Claimed Amount",
        "terseLabel": "Explanation for Claimed Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetLineItems",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offset:",
        "label": "Offset [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Note",
        "terseLabel": "Offset Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetPrrFeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Fee Amount",
        "terseLabel": "Fee Paid with Fee Offset Source",
        "documentation": "The fee previously paid from which an offset is being derived."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior File Number",
        "terseLabel": "File Number",
        "documentation": "The EDGAR File Number of the earlier registration statement with which the earlier (offsetting) fee was paid. If the offset filing for the offset has a Securities Act File Number and an Investment Company Act File Number, the Securities Act File Number should be used."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrFilerNm": {
     "xbrltype": "filerNameItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFilerNm",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Filer Name",
        "terseLabel": "Registrant or Filer Name",
        "documentation": "The name of the registrant that filed the earlier registration statement with which the earlier (offsetting) fee was paid."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Form Type",
        "terseLabel": "Form or Filing Type",
        "documentation": "The Form Type of the offset filing."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrNbOfUnsoldScties": {
     "xbrltype": "nonNegativeIntegerItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrNbOfUnsoldScties",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Unsold Number of Securities",
        "terseLabel": "Unsold Securities Associated with Fee Offset Claimed",
        "documentation": "The number of unsold securities registered on the prior registration statement that are associated with the claimed offset."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrSctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrSctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Security Title",
        "terseLabel": "Security Title Associated with Fee Offset Claimed",
        "documentation": "The title of the class of securities from which offset fees were derived."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrSctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrSctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Security Type",
        "terseLabel": "Security Type Associated with Fee Offset Claimed",
        "documentation": "Type of securities: \"Asset-backed Securities\", \"ADRs/ADSs\", \"Debt\", \"Debt Convertible into Equity\", \"Equity\", \"Face Amount Certificates\", \"Limited Partnership Interests\", \"Mortgage Backed Securities\", \"Non-Convertible Debt\", \"Unallocated (Universal) Shelf\", \"Exchange Traded Vehicle Securities\", \"Other\""
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrUnsoldOfferingAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrUnsoldOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Unsold Offering Amount",
        "terseLabel": "Unsold Aggregate Offering Amount Associated with Fee Offset Claimed",
        "documentation": "The aggregate offering amount of unsold securities registered on the prior registration statement that are associated with the claimed offset."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetSrcFilgDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetSrcFilgDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Source Filing Date",
        "terseLabel": "Filing Date",
        "documentation": "The filing date of the earlier registration statement with which the earlier (offsetting) fee was paid in an offset."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offset Payment:",
        "label": "Offset [Table]"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Table [N/A]",
        "terseLabel": "Offset Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_PrevslyPdFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "PrevslyPdFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Previously Paid [Flag]",
        "terseLabel": "Fee Previously Paid"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_RegnFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "RegnFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration File Number",
        "terseLabel": "Registration File Number"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_RptgFsclYrEndDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "RptgFsclYrEndDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reporting Fiscal Year End Date",
        "terseLabel": "Reporting FY End Date"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule011Flg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule011Flg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 0-11 [Flag]",
        "terseLabel": "Rule 0-11"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule011a2OffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule011a2OffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 0-11(a)(2) Offset",
        "label": "Rule 0-11(a)(2) Offset [Flag]"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule415a6Flg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule415a6Flg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 415(a)(6) [Flag]",
        "terseLabel": "Rule 415(a)(6)",
        "documentation": "Checkbox indicating whether filer is claiming a 415(a)(6) carryforward."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_Rule429AggtOfferingAmt": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429AggtOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Aggregate Offering Amount",
        "terseLabel": "Maximum Aggregate Offering Price of Securities Previously Registered",
        "documentation": "The maximum aggregate offering amount of unsold securities registered on the prior registration statement that are carried forward under Rule 429. Only applicable if 457(o) was used in the fee calculation for the prior registration statement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429CmbndPrspctsFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429CmbndPrspctsFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Combined Prospectus [Flag]",
        "terseLabel": "Rule 429",
        "documentation": "Checkbox indicating whether filer is using a combined prospectus under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429EarlierFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429EarlierFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Earlier File Number",
        "terseLabel": "File Number",
        "documentation": "The Securities Act File Number of the earlier effective registration statement(s) from which securities may be offered and sold using the combined prospectus pursuant to Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429EarlierFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429EarlierFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Earlier Form Type",
        "terseLabel": "Form Type",
        "documentation": "The Form Type of the earlier registration statement from which unsold securities are carried forward under Rule 429. This should be an EDGAR submission type (S-3, S-3/A, S-3ASR, etc.), which means there is a fixed set of possible responses. Note that while the XBRL response should be an EDGAR submission type, the human-readable Ex. 107 could include a simpler label (e.g., \"Form S-3\" in the human-readable and \"S-3ASR\" in the XBRL)."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429InitlFctvDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429InitlFctvDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Initial Effective Date",
        "terseLabel": "Initial Effective Date",
        "documentation": "The filing date of the earlier registration statement from which unsold securities are carried forward under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429NbOfUnsoldScties": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429NbOfUnsoldScties",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Number Of Unsold Securities",
        "terseLabel": "Amount of Securities Previously Registered",
        "documentation": "The number of securities registered on the prior registration statement that are carried forward under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429PrspctsNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429PrspctsNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Prospectus Note",
        "terseLabel": "Combined Prospectus Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Rule429SctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429SctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Security Title",
        "terseLabel": "Security Class Title"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Rule429SctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429SctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Security Type",
        "terseLabel": "Security Type"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Rule457aFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457aFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(a) [Flag]",
        "terseLabel": "Rule 457(a)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(a) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ffd_Rule457bOffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457bOffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(b) Offset [Flag]",
        "terseLabel": "Rule 457(b) Offset",
        "documentation": "Checkbox indicating whether filer is claiming an offset under Rule 457(b) or 0-11(a)(2)."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ffd_Rule457fFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457fFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(f) [Flag]",
        "terseLabel": "Rule 457(f)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(f) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ffd_Rule457oFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457oFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(o) [Flag]",
        "terseLabel": "Rule 457(o)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(o) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "ffd_Rule457pOffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457pOffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(p) Offset [Flag]",
        "terseLabel": "Rule 457(p) Offset",
        "documentation": "Checkbox indicating whether filer is claiming an offset under Rule 457(p)."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "ffd_Rule457rFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457rFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(r) [Flag]",
        "terseLabel": "Rule 457(r)"
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "ffd_Rule457sFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457sFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(s) Flag",
        "terseLabel": "Rule 457(s)"
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "ffd_Rule457uFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457uFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(u) [Flag]",
        "terseLabel": "Rule 457(u)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(u) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "ffd_Scties424iAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Scties424iAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Axis]",
        "terseLabel": "Securities, 424I"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Scties424iLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Scties424iLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Line Items]",
        "terseLabel": "Securities, 424I:"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Scties424iTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Scties424iTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Table]",
        "terseLabel": "Securities, 424I Table"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Securities424iTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Securities424iNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities 424I [N/A]",
        "terseLabel": "Securities 424I N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_SubmissionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "SubmissionLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Submission [Line Items]",
        "terseLabel": "Items"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_SubmissnTp": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "SubmissnTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Submission Type",
        "terseLabel": "Submission Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_TermntnCmpltnWdrwl": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TermntnCmpltnWdrwl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination / Completion / Withdrawal Statement",
        "terseLabel": "Termination / Withdrawal Statement"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_TtlFeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Fee Amount",
        "terseLabel": "Total Fee Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlFeeAndIntrstAmt": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlFeeAndIntrstAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Fee and Interest Amount",
        "terseLabel": "Total Fee and Interest Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlOfferingAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Offering Amount",
        "terseLabel": "Total Offering"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlOffsetAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlOffsetAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Offset Amount",
        "terseLabel": "Total Offset Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlPrevslyPdAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlPrevslyPdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Previously Paid Amount",
        "terseLabel": "Previously Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlTxValtn": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlTxValtn",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Transaction Valuation",
        "terseLabel": "Total Transaction Valuation"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TxValtn": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TxValtn",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction Valuation",
        "terseLabel": "Transaction Valuation"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_ValSctiesRcvd": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "ValSctiesRcvd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of Securities Received",
        "terseLabel": "Value of Securities Received",
        "documentation": "Value of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form)"
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ffd_ValSctiesRcvdPerShr": {
     "xbrltype": "nonNegativeDecimal4lItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "ValSctiesRcvdPerShr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of Securities Received, Per Share",
        "terseLabel": "Value of Securities Received, Per Share",
        "documentation": "Value per share of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form). This is included in the explanation of 457(f) fee calculation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "415",
   "Subsection": "a"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "429"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "f"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "o"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "p"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "r"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "s"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "u"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Subsection": "f",
   "Section": "457"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>49
<FILENAME>0001140361-26-028868-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001140361-26-028868-xbrl.zip
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MS>;_ 5!+ 0(4 Q0    ( )A5]%SOS,%'%14  -ZI   6              "
M 0    !N>3(P,#<W-C T>#%?97@Q,#<N:'1M4$L%!@     !  $ 1    $D5
$      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>ny20077604x1_ex107_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ffd="http://xbrl.sec.gov/ffd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef
      xlink:href="https://xbrl.sec.gov/ffd/2025/ffd-2025.xsd"
      xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001162194</identifier>
        </entity>
        <period>
            <startDate>2026-07-20</startDate>
            <endDate>2026-07-20</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001162194</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>1</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-20</startDate>
            <endDate>2026-07-20</endDate>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001162194</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>2</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-20</startDate>
            <endDate>2026-07-20</endDate>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001162194</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>3</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-20</startDate>
            <endDate>2026-07-20</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <ffd:SubmissnTp contextRef="c0" id="ixv-342">S-4</ffd:SubmissnTp>
    <ffd:FormTp contextRef="c0" id="ixv-343">S-4</ffd:FormTp>
    <dei:EntityRegistrantName contextRef="c0" id="ixv-24">STANDARD BIOTOOLS INC.</dei:EntityRegistrantName>
    <ffd:PrevslyPdFlg contextRef="c1" id="ixv-83">false</ffd:PrevslyPdFlg>
    <ffd:OfferingSctyTp contextRef="c1" id="ixv-86">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="c1" id="ixv-89">Common Stock, $0.001 par value per share</ffd:OfferingSctyTitl>
    <ffd:FeesOthrRuleFlg contextRef="c1" id="ixv-92">true</ffd:FeesOthrRuleFlg>
    <ffd:AmtSctiesRegd
      contextRef="c1"
      decimals="INF"
      id="ixv-344"
      unitRef="shares">2760078538</ffd:AmtSctiesRegd>
    <ffd:MaxAggtOfferingPric contextRef="c1" decimals="INF" id="ixv-345" unitRef="usd">572.2</ffd:MaxAggtOfferingPric>
    <ffd:FeeRate contextRef="c1" decimals="INF" id="ixv-346" unitRef="pure">0.0001381</ffd:FeeRate>
    <ffd:FeeAmt contextRef="c1" decimals="2" id="ixv-347" unitRef="usd">0.08</ffd:FeeAmt>
    <ffd:PrevslyPdFlg contextRef="c2" id="ixv-113">false</ffd:PrevslyPdFlg>
    <ffd:OfferingSctyTp contextRef="c2" id="ixv-116">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="c2" id="ixv-119">Common Stock, $0.001 par value per share</ffd:OfferingSctyTitl>
    <ffd:FeesOthrRuleFlg contextRef="c2" id="ixv-122">true</ffd:FeesOthrRuleFlg>
    <ffd:AmtSctiesRegd
      contextRef="c2"
      decimals="INF"
      id="ixv-348"
      unitRef="shares">76000000</ffd:AmtSctiesRegd>
    <ffd:MaxOfferingPricPerScty
      contextRef="c2"
      decimals="INF"
      id="ixv-349"
      unitRef="usdPershares">0.8946</ffd:MaxOfferingPricPerScty>
    <ffd:MaxAggtOfferingPric contextRef="c2" decimals="INF" id="ixv-350" unitRef="usd">67989600</ffd:MaxAggtOfferingPric>
    <ffd:FeeRate contextRef="c2" decimals="INF" id="ixv-351" unitRef="pure">0.0001381</ffd:FeeRate>
    <ffd:FeeAmt contextRef="c2" decimals="2" id="ixv-352" unitRef="usd">9389.36</ffd:FeeAmt>
    <ffd:PrevslyPdFlg contextRef="c3" id="ixv-144">false</ffd:PrevslyPdFlg>
    <ffd:OfferingSctyTp contextRef="c3" id="ixv-147">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="c3" id="ixv-150">Common Stock, $0.001 par value per share</ffd:OfferingSctyTitl>
    <ffd:FeesOthrRuleFlg contextRef="c3" id="ixv-153">true</ffd:FeesOthrRuleFlg>
    <ffd:AmtSctiesRegd
      contextRef="c3"
      decimals="INF"
      id="ixv-353"
      unitRef="shares">2032831848</ffd:AmtSctiesRegd>
    <ffd:MaxAggtOfferingPric contextRef="c3" decimals="INF" id="ixv-354" unitRef="usd">0</ffd:MaxAggtOfferingPric>
    <ffd:FeeRate contextRef="c3" decimals="8" id="ixv-355" unitRef="pure">0.0001381</ffd:FeeRate>
    <ffd:FeeAmt contextRef="c3" decimals="2" id="ixv-356" unitRef="usd">0</ffd:FeeAmt>
    <ffd:TtlOfferingAmt contextRef="c0" decimals="INF" id="ixv-357" unitRef="usd">67990172.2</ffd:TtlOfferingAmt>
    <ffd:TtlFeeAmt contextRef="c0" decimals="2" id="ixv-358" unitRef="usd">9389.44</ffd:TtlFeeAmt>
    <ffd:TtlPrevslyPdAmt contextRef="c0" decimals="0" id="ixv-359" unitRef="usd">0</ffd:TtlPrevslyPdAmt>
    <ffd:TtlOffsetAmt contextRef="c0" decimals="0" id="ixv-360" unitRef="usd">0</ffd:TtlOffsetAmt>
    <ffd:NetFeeAmt contextRef="c0" decimals="2" id="ixv-361" unitRef="usd">9389.44</ffd:NetFeeAmt>
    <ffd:OfferingNote contextRef="c1" id="ixv-277">&lt;table style="font-size: 12pt; border-spacing: 0px; border-collapse: collapse; width: 100%;"&gt; &lt;tr style="height: 0px; font-size: 0px;"&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 99%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt; &lt;td style="padding: 0px 0pt;"&gt; &lt;div style="margin-bottom: 4pt;"&gt; &lt;span style="font-size: 10.0pt;"&gt;(1)&lt;/span&gt; &lt;/div&gt; &lt;/td&gt; &lt;td style="padding: 0px 5.4pt; text-align: left;"&gt; &lt;div style="margin-bottom: 4pt;"&gt; &lt;span style="font-size: 10.0pt;"&gt;Relates to common stock, $0.001 par value per share (&#x201c;Standard BioTools Common Stock&#x201d;), of Standard BioTools Inc., a Delaware corporation (&#x201c;Standard BioTools&#x201d;) issuable to holders of common stock, $0.00001 par value per share (&#x201c;Treeline Common Stock&#x201d;) of Treeline Biosciences, Inc., a Delaware corporation (&#x201c;Treeline&#x201d;), holders of preferred stock, par value $0.00001 per share of Treeline (&#x201c;Treeline Preferred Stock&#x201d; and together with the Treeline Common Stock, the &#x201c;Treeline Capital Stock&#x201d;), holders of warrants to purchase shares of Treeline Common Stock that have been amended to require net-exercise in connection with the Merger (as defined below) in the proposed merger (the &#x201c;Merger&#x201d;) of Siri Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Standard BioTools (&#x201c;Merger Sub&#x201d;), with and into Treeline, with Treeline surviving as a wholly owned subsidiary of Standard BioTools. The amount of Standard BioTools Common Stock to be registered includes the estimated maximum number of shares of Standard BioTools Common Stock that are expected to be issued pursuant to the Merger, without taking into account the effect of a reverse stock split of Standard BioTools Common Stock, assuming an estimated pre-split exchange ratio (which is subject to adjustment prior to the closing of the Merger) of approximately 16.07931 shares of Standard BioTools Common Stock for each share of Treeline Capital Stock. Such exchange ratio is only an estimate as the actual exchange ratio will be determined in connection with the closing of the Merger. In accordance with Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), this registration statement shall be deemed to cover any securities that may from time to time be offered or issued resulting from forward or reverse stock splits, stock dividends or similar transactions.&lt;/span&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;table style="font-size: 12pt; border-spacing: 0px; border-collapse: collapse; width: 100%;"&gt;
   &lt;tr style="height: 0px; font-size: 0px;"&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 99%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;
    &lt;td style="padding: 0px 0pt;"&gt;
     &lt;div style="margin-bottom: 4pt;"&gt;
      &lt;span style="font-size: 10.0pt;"&gt;(2)&lt;/span&gt;
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="padding: 0px 5.4pt; text-align: left;"&gt;
     &lt;div style="margin-bottom: 4pt;"&gt;
      &lt;span style="font-size: 10.0pt;"&gt;Estimated solely for purposes of calculating the registration fee in accordance with Rule 457(f)(2) of the Securities Act. Treeline is a private company, no market exists for its securities, and Treeline has an accumulated capital deficit. Therefore, the proposed maximum aggregate offering price for the shares of Standard BioTools Common Stock expected to be issued pursuant to the Merger is one-third of the aggregate par value of the Treeline securities expected to be exchanged in the proposed Merger.&lt;/span&gt;
     &lt;/div&gt;
    &lt;/td&gt;
   &lt;/tr&gt;
  &lt;/table&gt;</ffd:OfferingNote>
    <ffd:OfferingNote contextRef="c2" id="ixv-302">&lt;table style="font-size: 12pt; border-spacing: 0px; border-collapse: collapse; width: 100%;"&gt; &lt;tr style="height: 0px; font-size: 0px;"&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 99%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt; &lt;td style="padding: 0px 0pt;"&gt; &lt;div style="margin-bottom: 4pt;"&gt; &lt;span style="font-size: 10.0pt;"&gt;(3)&lt;/span&gt; &lt;/div&gt; &lt;/td&gt; &lt;td style="padding: 0px 5.4pt; text-align: left;"&gt; &lt;div style="margin-bottom: 4pt;"&gt; &lt;span style="font-size: 10.0pt;"&gt;Relates to the maximum number of shares of Standard BioTools Common Stock issuable pursuant to the contingent value rights (&#x201c;CVRs&#x201d;) to be declared as a dividend to stockholders of record of Standard BioTools as of the close of business on the last business day prior to the day on which the effective time of the Merger occurs. Each holder of a CVR is entitled to a number of shares of the combined company&#x2019;s common stock (with fractional shares settled in cash) equal to such holder&#x2019;s pro rata portion of the aggregate net proceeds received by the combined company during such 12-month CVR payment period from the following sources, in each case less certain permitted deductions: (i) proceeds from any sale, disposition, or other monetization of Standard BioTools&#x2019; legacy businesses; (ii) proceeds from convertible notes or other investments held by Standard BioTools as of the closing date of the Merger; (iii) earnout, milestone, royalty or other similar contingent payments due to Standard BioTools under contracts in effect as of the closing date of the Merger, including payments from Illumina, Inc. pursuant to the Stock Purchase Agreement dated June 22, 2025; and (iv) any surplus in Parent Net Cash (as defined in the Agreement and Plan of Merger and Reorganization dated June 6, 2026 (the &#x201c;Merger Agreement&#x201d;) by and among Standard BioTools, Treeline and Merger Sub and included as Annex A to this registration statement) delivered at closing of the Merger as finally determined under the Merger Agreement.&lt;/span&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;table style="font-size: 12pt; border-spacing: 0px; border-collapse: collapse; width: 100%;"&gt;
   &lt;tr style="height: 0px; font-size: 0px;"&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 99%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;
    &lt;td style="padding: 0px 0pt;"&gt;
     &lt;div style="margin-bottom: 4pt;"&gt;
      &lt;span style="font-size: 10.0pt;"&gt;(4)&lt;/span&gt;
     &lt;/div&gt;
    &lt;/td&gt;
    &lt;td style="padding: 0px 5.4pt; text-align: left;"&gt;
     &lt;div style="margin-bottom: 4pt;"&gt;
      &lt;span style="font-size: 10.0pt;"&gt;Estimated solely for purposes of calculating the registration fee in accordance with Rule 457(c) of the Securities Act based on the average of the high and low prices per share of Standard BioTools Common Stock on July 13, 2026.&lt;/span&gt;
     &lt;/div&gt;
    &lt;/td&gt;
   &lt;/tr&gt;
  &lt;/table&gt;</ffd:OfferingNote>
    <ffd:OfferingNote contextRef="c3" id="ixv-326">&lt;table style="font-size: 12pt; border-spacing: 0px; border-collapse: collapse; width: 100%;"&gt; &lt;tr style="height: 0px; font-size: 0px;"&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 99%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt; &lt;td style="padding: 0px 0pt;"&gt; &lt;div style="margin-bottom: 4pt;"&gt; &lt;span style="font-size: 10.0pt;"&gt;(5)&lt;/span&gt; &lt;/div&gt; &lt;/td&gt; &lt;td style="padding: 0px 5.4pt; text-align: left;"&gt; &lt;div style="margin-bottom: 4pt;"&gt; &lt;span style="font-size: 10.0pt;"&gt;Represents an aggregate of 2,032,831,848 Standard BioTools Common Stock issuable in accordance with (1) above to certain Treeline stockholders. Pursuant to Rule 457(f)(5) of the Securities Act, no additional filing fee is required to be paid for the registration of Standard BioTools Common Stock to be sold by the selling securityholders pursuant to the resale prospectus that are also being registered under this registration statement.&lt;/span&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;</ffd:OfferingNote>
    <ffd:CombinedProspectusTableNa contextRef="c0" id="ixv-364">N/A</ffd:CombinedProspectusTableNa>
    <dei:EntityCentralIndexKey contextRef="c0" id="ixv-365">0001162194</dei:EntityCentralIndexKey>
    <ffd:FeeExhibitTp contextRef="c0" id="ixv-366">EX-FILING FEES</ffd:FeeExhibitTp>
    <ffd:OffsetTableNa contextRef="c0" id="ixv-367">N/A</ffd:OffsetTableNa>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
